P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|0 19|Pharmacologic aspects
P00008171T0000|22 47|neonatal hyperbilirubinemia
P00008997A0472|4 6|CSF
P00008997A0472|34 40|CSF PCO2
P00008997A0472|50 63|K-depleted rats
P00012653T0045|4 17|blocking agents
P00013683A0210|40 52|CO2 production
P00015731A0090|0 24|Intravenous administration
P00015731A0090|36 62|carbonic anhydrase inhibitors
P00015731A0090|36 52|carbonic anhydrase
P00015731A0090|64 76|acetazolamide
P00015731A0090|109 117|sulthiame
P00015731A0090|198 200|CO2
P00015731A0090|214 215|pH
P00015731A0090|218 230|arterial blood
P00022143T0000|36 38|rat
P00022143T0000|42 47|rabbit
P00023348A0601|0 15|Colorectal polyps
P00024600A0522|14 26|dosage regimen
P00024600A0522|86 98|dosage regimen
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|45 56|liver disease
P00027739T0000|59 64|cattle
P00027967A0207|20 31|HI antibodies
P00027967A0207|80 87|patients
P00029555A0861|18 42|virus assay and quantitation
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00029953T0045|17 22|lipase
P00030183T0000|0 16|Takayasu's disease
P00030183T0000|33 38|HLA-B5
P00030183T0000|33 38|HLA-B5
P00030937A0119|0 3|SGPT
P00030937A0119|0 3|SGPT
P00030937A0119|5 8|SGOT
P00030937A0119|5 8|SGOT
P00030937A0119|13 31|alkaline phosphatase
P00030937A0119|13 31|alkaline phosphatase
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|28 40|GGTP) activity
P00033873T0001|28 31|GGTP
P00033873T0001|46 57|seminal fluid
P00034935A0545|0 7|Patients
P00034935A0545|12 29|Parkinson's disease
P00034935A0545|77 89|drug treatment
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|89 94|FLA 136
P00039271T0000|0 17|Anti-anxiety action
P00039271T0000|33 48|intra-amygdaloid
P00039271T0000|65 67|rat
P00041512T0067|0 8|Abstracts
P00048373A0377|70 87|squamous epithelium
P00050628A0202|2 24|IgG monoclonal gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|40 44|serum
P00050628A0202|48 55|patients
P00050628A0202|59 81|Bence-Joanes proteinuria
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|9 23|immunoglobulin E
P00054900A0226|0 17|Peroxydase reaction
P00054900A0226|0 9|Peroxydase
P00054900A0226|37 57|chloroacetate esterase
P00054900A0226|37 57|chloroacetate esterase
P00055040A0000|64 87|direct immunofluorescence
P00055040A0000|89 90|IF
P00055040A0000|89 90|IF
P00055040A0000|116 125|fibrinogen
P00055040A0000|116 125|fibrinogen
P00055040A0000|127 132|fibrin
P00055040A0000|127 132|fibrin
P00055040A0000|158 167|FR-antigen
P00055040A0000|158 167|FR-antigen
P00055040A0000|192 195|skin
P00055040A0000|209 236|heparin-precipitable fraction
P00055040A0000|238 241|HPF)
P00055040A0000|238 240|HPF
P00055040A0000|243 254|cryoglobulin
P00055040A0000|263 278|plasma fibrinogen
P00055040A0000|269 278|fibrinogen
P00055040A0000|284 288|blood
P00056837A0000|36 45|1966 to 1973
P00056837A0000|88 105|pulmonary carcinoma
P00056901A0308|10 21|human albumin
P00056901A0308|10 21|human albumin
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|68 75|dilution
P00060529A0695|12 23|control group
P00060529A0695|49 59|symptomatic
P00060529A0695|75 85|0acteriuria
P00060529A0695|128 132|women
P00060529A0695|180 200|transient, symptomatic
P00061478T0000|0 16|Late complications
P00061478T0000|37 56|intravenous nutrition
P00063680T0000|0 16|Prenatal diagnosis
P00063680T0000|19 31|galactosaemia
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|0 47|False positive amniotic fluid alpha fetoprotein levels
P00066874T0000|26 41|alpha fetoprotein
P00066874T0000|61 73|contamination
P00066874T0000|78 87|fetal blood
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|27 42|haemochromatosis
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|41 51|lymphocytes
P00074758T0000|16 29|hypothyroidism
P00083846T0000|0 6|Albumin
P00083846T0000|0 6|Albumin
P00083846T0000|10 18|cyclic AMP
P00083846T0000|27 42|peritoneal fluids
P00084275T0063|0 6|Preface
P00086313A0000|20 47|Legionnaires' disease bacteria
P00086313A0000|79 87|serologic
P00086313A0000|132 142|fluorescent
P00088391A0181|14 21|factor IX
P00088391A0181|14 21|factor IX
P00088391A0181|64 71|factor IX
P00088391A0181|64 69|factor
P00088391A0181|70 78|IX antigen
P00089778A0000|18 56|alpha 2-macroglobulin, alpha 1-antitrypsin
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|58 68|plasminogen
P00089778A0000|58 68|plasminogen
P00089778A0000|70 82|C3-complement
P00089778A0000|70 82|C3-complement
P00089778A0000|84 93|fibrinogen
P00089778A0000|84 93|fibrinogen
P00089778A0000|114 116|FDP
P00089778A0000|114 116|FDP
P00089778A0000|121 140|fibrinolytic activity
P00089778A0000|158 178|aqueous humour and serum
P00089778A0000|187 194|patients
P00089778A0000|199 224|Fuchs' endothelial dystrophy
P00089778A0000|228 235|patients
P00089778A0000|240 266|uncomplicated senile cataract
P00089778A0000|275 290|secondary aqueous
P00089778A0000|298 313|cataract patients
P00092689A0352|12 19|patients
P00094639A0313|0 7|Prazosin
P00094639A0313|43 50|patients
P00096241A0087|0 1|T4
P00096241A0087|5 8|FT4I
P00096241A0087|107 122|premature infants
P00096241A0087|136 138|EGA
P00096241A0087|149 155|infants
P00097989A0106|42 49|patients
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100540T0000|81 87|aspirin
P00100791A0425|34 40|monkeys
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|135 144|norcocaine
P00101300A0257|9 35|surgically resectable cancers
P00101300A0257|37 38|T1
P00101300A0257|40 41|T2
P00101300A0257|40 41|T2
P00101300A0257|43 44|T3
P00101300A0257|43 44|T3
P00101300A0257|46 47|N0
P00101300A0257|46 47|N0
P00101300A0257|49 50|N1
P00101300A0257|49 50|N1
P00105401A0635|11 13|CBZ
P00105401A0635|17 19|DPH
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|52 65|thyroid hormone
P00105401A0635|75 77|TBG
P00105401A0635|75 77|TBG
P00105401A0635|113 134|metabolic clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|204 206|FT4
P00105401A0635|210 212|FT3
P00105903A0288|67 69|PEG
P00105903A0288|70 72|400
P00105903A0288|93 97|toxic
P00112627A0542|0 19|Pentobarbital (1, 3, 10
P00112627A0542|86 98|normeperidine
P00112627A0542|111 121|anileridine
P00112627A0542|132 143|alphaprodine
P00112627A0542|157 164|fentanyl
P00113657A0628|0 5|Pb foil
P00114144A0189|2 11|anatomical
P00114144A0189|136 143|glycogen
P00114144A0189|159 175|Andersen's disease
P00114144A0189|220 231|enzyme defect
P00115974A0576|22 38|Hebb-Williams maze
P00117748T0000|0 35|Erythromycin and clindamycin resistance
P00117748T0000|38 63|Corynebacterium diphtheriae
P00117748T0000|68 78|skin lesions
P00118044A0000|0 41|Imposed angular displacements of monkey's wrist
P00118044A0000|75 84|terms M1, M2
P00118044A0000|89 90|M3
P00118044A0000|115 125|EMG activity
P00118810T0001|0 15|Hemolytic disease
P00118810T0001|18 31|African newborn
P00119339A0400|59 66|virulent
P00119339A0400|112 128|severe myocarditis
P00119339A0400|134 153|myofibre degeneration
P00119339A0400|170 179|oesophagus
P00122718A0500|13 20|MRF units
P00129659T0000|0 10|Variability
P00129659T0000|17 30|Down's syndrome
P00129659T0000|32 42|trisomy-21)
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|7 17|demographic
P00131739T0001|27 45|isolated populations
P00131739T0001|48 57|Uzbekistan
P00133214T0064|0 0|2
P00133214T0064|20 26|nervous
P00133214T0064|40 43|USSR
P00136175A1137|25 50|myocardial capillary density
P00136175A1137|153 155|ECA
P00137671A0896|50 59|VIII-ratio
P00137671A0896|87 110|intravascular coagulation
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|48 65|serum ceruloplasmin
P00139624A0318|89 98|female rats
P00139624A0318|108 115|male rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|32 43|progesterone
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|68 70|DHA
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|92 98|estriol
P00139827A0000|103 110|cortisol
P00139827A0000|142 152|fetal plasma
P00139827A0000|193 200|delivery
P00142718A0156|9 16|patients
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|115 130|chest radiographs
P00146327A0147|13 18|tumors
P00146327A0147|32 44|nasal cavities
P00146327A0147|110 120|stem bronchi
P00149899T0001|0 9|Prediction
P00149899T0001|22 39|sandfly development
P00150066A0100|6 20|human fibrinogen
P00150066A0100|11 20|fibrinogen
P00150066A0100|33 43|coagulation
P00150066A0100|52 59|thrombin
P00150066A0100|52 59|thrombin
P00154430A0906|3 19|Southern technique
P00154430A0906|89 114|1.8 kb HindIII-EcoRI fragment
P00154430A0906|94 114|HindIII-EcoRI fragment
P00155973A0387|34 48|maximized errors
P00155973A0387|172 183|gas flow rates
P00155973A0387|213 229|minute ventilation
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00159600A0871|71 83|hypertrophied
P00159600A0871|84 86|SHR
P00159600A0871|87 99|left ventricle
P00159600A0871|116 129|rightward shift
P00159600A0871|135 153|Frank-Starling curve
P00163384A0000|3 9|carcass
P00163384A0000|24 26|owl
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|103 110|necropsy
P00167544A0067|3 11|inner ears
P00167544A0067|104 128|light or electron microscopy
P00167544A0067|157 180|surface specimen technique
P00168176A0000|0 6|Patulin
P00168176A0000|22 39|apple butter samples
P00168176A0000|44 55|ethyl acetate
P00168176A0000|83 97|silica gel column
P00168176A0000|104 123|benzene-ethyl acetate
P00168176A0000|136 141|eluant
P00168431T0000|7 18|glucuronides
P00168431T0000|21 33|amniotic fluid
P00172199A0270|63 83|homogeneous appearance
P00172199A0270|131 139|fibrillar
P00173860A0475|0 9|Riboflavin
P00173860A0475|37 60|aflatoxin-treated animals
P00173860A0475|37 45|aflatoxin
P00173860A0475|65 96|abnormal urinary excretion patterns
P00173860A0475|156 164|kynurenic
P00173860A0475|168 183|xanthurenic acids
P00176742T0000|14 29|suture absorption
P00176742T0000|42 56|cellular enzymes
P00183063A0300|14 26|DNCB reactions
P00183063A0300|42 70|Stage I and II cancers (37 patinets
P00183063A0300|85 108|resectable Stage III cancer
P00183063A0300|112 119|patients
P00183063A0300|136 143|patients
P00183063A0300|148 185|unresectable or inoperable Stage III cancer
P00188387A0975|9 20|lipoproteins
P00188387A0975|44 51|children
P00188387A0975|75 76|FH
P00188387A0975|79 103|early coronary heart disease
P00193088A0196|12 25|normal subjects
P00193088A0196|34 43|Metyrapone
P00193587T0000|0 12|EEG theta waves
P00196255A0000|0 14|REM dream content
P00196255A0000|75 88|left hemisphere
P00196255A0000|133 147|right hemisphere
P00196255A0000|154 158|music
P00196255A0000|160 174|spatial salience
P00196255A0000|176 186|bizarreness
P00198510T0000|0 10|Innervation
P00198510T0000|16 42|ventral diaphragm of the locust
P00198510T0000|44 60|Locusta migratoria
P00199012T0000|0 18|Ectopic ACTH syndrome
P00199012T0000|22 30|medullary
P00199012T0000|31 46|thyroid carcinoma
P00201881A0487|63 68|PI ACTH
P00201881A0487|65 68|ACTH
P00201881A0487|72 74|MSH
P00201881A0487|72 74|MSH
P00205074A0000|7 22|hypophosphatemia
P00205074A0000|55 61|rickets
P00209664A0836|28 34|serum LH
P00209664A0836|33 34|LH
P00210220X0000|0 22|Molecular neurochemistry
P00210220X0000|25 38|addictive drugs
P00211881A0602|52 64|kidney lesions
P00211881A0602|126 128|PBB
P00216939T0001|32 70|tricarboxylic acid dehydrogenase reactions
P00216939T0001|32 61|tricarboxylic acid dehydrogenase
P00216939T0001|76 80|brain
P00216939T0001|83 86|rats
P00216939T0001|99 114|mercuric chloride
P00219533T0001|0 11|Distribution
P00219533T0001|34 42|uric-acid
P00219533T0001|48 69|French adult populations
P00219533T0001|77 92|men and 6,861 women
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|40 50|transfusion
P00219674A0000|0 55|Technetium-99m stannous pyrophosphate myocardial scintigrams
P00219674A0000|73 82|clinically
P00219674A0000|131 155|acute myocardial infarction
P00221136A0984|39 44|humans
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|43 52|peroxidase
P00221725A0523|43 52|peroxidase
P00221725A0523|61 65|lipid
P00221725A0523|75 95|peripheral neutrophils
P00221725A0523|123 140|phagocytic activity
P00222102A0227|11 19|2 patients
P00222102A0227|24 52|pseudohypoparathyroidism type I
P00222102A0227|57 76|vitamin-D-3 and 1 alpha
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|71 99|1 alpha-Hydroxycholecalciferol
P00222102A0227|124 141|nonuniform response
P00222102A0227|172 184|serum-calcium
P00222827A0000|0 6|Workers
P00222827A0000|26 44|toluene diisocyanate
P00222827A0000|46 48|TDI
P00222827A0000|98 121|bronchial hyperreactivity
P00224013A0661|5 7|VO2
P00224013A0661|38 50|severe hypoxia
P00224013A0661|58 60|VO2
P00224013A0661|167 173|hypoxia
P00224013A0661|292 309|O2 extraction ratios
P00224013A0661|318 333|venous O2 pressure
P00224013A0661|335 359|beta-Vasodilator receptors
P00224013A0661|335 350|beta-Vasodilator
P00224013A0661|416 428|severe hypoxia
P00225352T0000|0 31|Phenobarbital-induced alterations
P00225352T0000|37 46|metabolism
P00225352T0000|49 61|[3H]vitamin D3
P00225352T0000|83 90|rat liver
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|63 90|cytochrome P-450 monooxygenase
P00227393T0000|63 77|cytochrome P-450
P00227610A1593|11 18|respects
P00227610A1593|31 37|DBP mRNA
P00227610A1593|31 37|DBP mRNA
P00227610A1593|66 69|SV40
P00227610A1593|73 79|polyoma
P00231555T0001|8 45|corticosteroid-containing antirheumatic
P00231555T0001|74 77|ACTH
P00231555T0001|74 77|ACTH
P00231555T0001|81 98|cortisol production
P00232354A0286|0 8|Serum ACTH
P00232354A0286|5 8|ACTH
P00232354A0286|24 43|insulin and metyrapone
P00232354A0286|24 30|insulin
P00232456T0000|0 6|Anatomy
P00232456T0000|12 21|RNA and gene
P00232456T0000|12 14|RNA
P00232456T0000|32 35|MC29
P00232456T0000|39 41|MH2
P00232456T0000|55 71|avian tumor viruses
P00232456T0000|79 103|acute leukemia and carcinoma
P00232456T0000|127 143|transforming genes
P00232456T0000|127 143|transforming genes
P00234206T0000|0 7|Bertioga
P00234206T0000|23 45|Anhembi (Bunyamwera group
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|0 26|Gamma glutamyl transpeptidase
P00234264A0164|84 91|children
P00234626T0036|0 2|XXI
P00239014A0000|1 3|gas
P00239014A0000|53 77|p-chlorophenoxyisobutyric
P00239014A0000|79 87|CPIB) acid
P00239014A0000|90 100|blood plasma
P00239169T0000|0 15|Dopamine receptor
P00239169T0000|0 7|Dopamine
P00240016T0033|0 0|V
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00254537T0000|54 59|boards
P00261981A0434|18 34|serum somatomedin A
P00261981A0434|23 34|somatomedin A
P00261981A0434|60 63|rats
P00264240A1843|34 39|oocyte
P00264240A1843|50 56|5S genes
P00264240A1843|50 56|5S genes
P00264240A1843|83 92|14 residues
P00264240A1843|152 170|X. laevis oocyte 5S DNA
P00264240A1843|152 159|X. laevis
P00264240A1843|160 170|oocyte 5S DNA
P00265964A0562|34 58|grain boundary precipitates
P00294502T0001|0 8|Diagnosis
P00294502T0001|31 47|Class II, division 2
P00300314A0132|9 25|serious infections
P00300314A0132|116 124|drug death
P00300314A0132|136 143|patients
P00300314A0132|145 165|oral calcium leucovorin
P00300314A0132|178 183|orally
P00300314A0132|203 214|methotrexate
P00303189A0247|45 58|serum chemistry
P00303189A0247|110 128|inflammatory process
P00304240A0369|53 72|retrocochlear disease
P00304310A0000|33 64|proliferative diabetic retinopathy
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|12 24|serum alpha1AT
P00304806A0760|38 51|newborn infants
P00313766A0666|2 9|patients
P00313766A0666|74 75|67
P00313766A0666|83 89|control
P00316723A0558|9 18|body weight
P00316723A0558|22 38|agonistic behavior
P00321261A0104|3 17|uterine response
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|36 39|PGE2
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|93 104|intrauterine
P00321261A0104|150 163|menstrual cycle
P00321261A0104|191 195|women
P00330364A0132|10 19|BCG strains
P00330364A0132|74 76|BCG
P00330364A0132|125 132|children
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|168 177|fatal cases
P00330364A0132|183 197|BCG-vaccination
P00331128A0000|0 9|High levels
P00331128A0000|17 26|calcitonin
P00331128A0000|17 26|calcitonin
P00331128A0000|38 45|patients
P00331128A0000|50 68|chronic renal failure
P00331936T0000|11 35|anti-lymphocyte antibodies
P00331936T0000|11 35|anti-lymphocyte antibodies
P00331936T0000|44 59|immunoperoxidase
P00331936T0000|60 78|antiglobulin technic
P00331936T0000|60 71|antiglobulin
P00336354A0543|18 19|GH
P00336354A0543|18 19|GH
P00336354A0543|22 37|arginine infusion
P00336354A0543|59 85|insulin-induced hypoglycemia
P00336354A0543|59 65|insulin
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|99 117|congenitally athymic
P00336547A0000|119 127|nude) mice
P00336547A0000|130 132|ICR
P00336547A0000|136 148|C3H/eB origins
P00336547A0000|190 198|white mice
P00336547A0000|207 224|inbred mouse strains
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|243 257|New Zealand Black
P00336547A0000|259 282|BALB/c, CBA/LAC, and C3H/eB
P00336547A0000|264 264|c
P00336547A0000|266 268|CBA
P00336547A0000|270 272|LAC
P00337102T0058|0 7|Williams
P00339289T0049|5 23|radioactive isotopes
P00342623A0228|0 16|Disrupted vaccines
P00342623A0228|20 60|whole-virus vaccines containing type B antigen
P00342623A0228|49 60|type B antigen
P00346829X0000|0 5|255-61
P00350465T0000|20 42|haematological disorders
P00350465T0000|46 50|1978'
P00352569A0000|0 18|Hepatic oxygen supply
P00352569A0000|59 73|fasted male rates
P00354315T0000|0 17|Gonadal dysfunction
P00354315T0000|20 27|patients
P00354315T0000|32 51|ataxia telangiectasia
P00358945A0225|3 15|maximum period
P00358945A0225|33 36|oral
P00358945A0225|39 40|73
P00358945A0225|60 61|75
P00358945A0225|63 68|dermal
P00361059T0000|69 88|clobetasol propionate
P00361340A0529|20 42|azotaemic osteodystrophy
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|150 168|primary significance
P00361340A0529|178 205|secondary hyperparathyroidism
P00361340A0529|208 219|renal failure
P00369397A0280|5 18|FSH and LH levels
P00369397A0280|5 7|FSH
P00369397A0280|11 12|LH
P00369397A0280|43 49|addicts
P00369397A0280|56 59|GnRH
P00369397A0280|56 59|GnRH
P00369397A0280|82 95|FSH and LH values
P00369397A0280|82 84|FSH
P00369397A0280|88 89|LH
P00369397A0280|134 141|controls
P00369683T0000|0 9|Adriamycin
P00369683T0000|73 84|breast cancer
P00377466A0188|19 36|luteinizing hormone
P00377466A0188|19 36|luteinizing hormone
P00377466A0188|38 39|LH
P00377466A0188|38 39|LH
P00377466A0188|42 71|follicle stimulating hormone (FSH
P00377466A0188|42 67|follicle stimulating hormone
P00377466A0188|69 71|FSH
P00377466A0188|74 82|prolactin
P00377466A0188|74 82|prolactin
P00377466A0188|84 87|HPRL
P00377466A0188|84 87|HPRL
P00377466A0188|90 99|oestradiol
P00377466A0188|101 102|E2
P00377466A0188|101 102|E2
P00377466A0188|105 116|progesterone
P00377466A0188|118 119|P)
P00377466A0188|123 134|testosterone
P00377466A0188|143 166|catabolic and healing phase
P00377466A0188|169 179|burn disease
P00378492A0475|25 44|hypertensive patients
P00378492A0475|98 116|plasma renin activity
P00378492A0475|98 108|plasma renin
P00378492A0475|122 138|plasma aldosterone
P00378492A0475|200 213|artery stenosis
P00378735A0000|35 47|adult patients
P00378735A0000|82 102|blood and marrow culture
P00378735A0000|128 141|dosage schedule
P00378735A0000|154 159|orally
P00378735A0000|215 244|clinical and temperature response
P00381505X0000|0 4|202-8
P00381783T0000|0 9|Bone marrow
P00383169A0000|46 61|dopamine receptor
P00383169A0000|46 53|dopamine
P00383169A0000|80 90|apomorphine
P00383169A0000|119 138|rye-ergot derivatives
P00383169A0000|169 207|biochemical and pharmacological properties
P00384744T0000|3 34|unilateral vestibular hypofunction
P00385457A0187|20 25|pepsin
P00385457A0187|20 25|pepsin
P00385457A0187|28 44|human gastric juice
P00385457A0187|93 105|duodenal ulcer
P00386251A0899|83 102|sulphonamide residues
P00390932T0001|0 15|Capsular antigens
P00390932T0001|18 37|Staphylococcus aureus
P00393598A0198|47 49|ALS
P00401521A0138|0 10|Seventy-one
P00401521A0138|20 27|patients
P00401521A0138|39 49|ticarcillin
P00401676A0414|35 42|patients
P00401676A0414|71 82|radiotherapy
P00406585T0001|0 17|Inherent hematology
P00409927A0570|0 7|Neomycin
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00409927A0570|104 136|gram-negative intestinal organisms.
P00411465A0142|27 33|section
P00411465A0142|86 93|cavities
P00411465A0417|0 0|2
P00413854A0958|9 18|tissue PCO2
P00413854A0958|80 90|venous blood
P00414575T0000|22 33|renal calculi
P00415543A0320|76 95|anteroposterior films
P00415543A0320|107 114|patients
P00415543A0320|119 143|acute or chronic lung disease
P00417166T0000|0 21|Pharmacokinetic profile
P00417166T0000|36 48|rhesus monkeys
P00417301T0001|0 20|Immunologic mechanisms
P00417301T0001|23 40|chronic brucellosis
P00417301T0001|43 48|humans
P00418341T0000|0 9|Intestinal
P00420460A0291|2 9|patients
P00420460A0291|34 46|drug treatment
P00420460A0291|65 69|renin
P00420460A0291|89 105|mean blood pressure
P00420460A0291|111 117|SQ 20881
P00423649A0259|33 38|people
P00425547A0000|2 9|patients
P00425547A0000|14 33|chronic osteomyelitis
P00425547A0000|57 90|bactericidal beta-lactam-antibiotic
P00427715A0000|10 17|patients
P00427715A0000|22 37|Hodgkin's disease
P00427715A0000|55 76|diaphragm (Stages I and II
P00427715A0000|78 82|A and B
P00427715A0000|78 78|A
P00427715A0000|82 82|B
P00427715A0000|99 114|radiation therapy
P00429893A0000|41 60|cochlear implantation
P00429893A0000|88 96|inserting
P00429893A0000|109 120|scala tympani
P00429893A0000|157 174|bipolar stimulation
P00429949A0000|2 11|authorized
P00429949A0000|61 85|Biological Standardization
P00429949A0000|103 116|human prolactin
P00429949A0000|103 116|human prolactin
P00429949A0000|132 137|75/504
P00429949A0000|161 173|International
P00429949A0000|195 197|IRP
P00429949A0000|195 197|IRP
P00429949A0000|201 228|human prolactin for immunoassay
P00429949A0000|201 214|human prolactin
P00430889T0001|0 22|Biliary-enteric fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|18 28|venous blood
P00431832T0001|42 53|beta receptor
P00431832T0001|42 53|beta receptor
P00432615A0541|85 103|bovine gammaglobulin
P00432615A0541|85 103|bovine gammaglobulin
P00432615A0541|151 164|Sephadex system
P00432615A0541|167 170|RIST
P00437749A0242|87 107|severe intractable pain
P00439618T0001|6 71|Tachmalcor (4-(3'-diethylamino-2'-hydroxypropyl)-ajmaline) poisoning
P00439618T0001|74 82|childhood
P00439716T0001|51 73|arteriocavernous fistula
P00445259T0000|5 25|ferritin concentration
P00445259T0000|5 12|ferritin
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|3 30|systolic pressure gradient (SPG
P00445720A0263|42 54|left ventricle
P00445720A0263|56 57|LV
P00445720A0263|62 71|left atrium
P00445720A0263|73 74|LA
P00445720A0263|91 122|high-fidelity pressure transducers
P00450367T0000|1 11|prospective
P00450367T0000|39 50|hysterectomy
P00450367T0000|55 67|vaginal radium
P00450367T0000|72 84|uterine radium
P00450367T0000|103 108|stage I
P00450367T0000|109 128|endometrial carcinoma
P00450559A0269|33 51|inaccurate Clinitemp
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 34|Raynaud's syndrome
P00451192A0248|22 35|semi-automatic
P00451192A0248|66 85|averaged-volume curve
P00451192A0248|100 107|LV region
P00453780A0430|3 30|preferential serum IgA response
P00453780A0430|20 22|IgA
P00453780A0430|44 60|patient population
P00453780A0430|73 105|bronchial associated lymphoid tissue
P00453780A0430|111 122|diseased lung
P00453780A0430|155 157|IgA
P00453780A0430|155 157|IgA
P00454780A0340|60 73|titanium alloys
P00454780A0340|81 84|Ta 6 V
P00454780A0340|81 84|Ta 6 V
P00454780A0340|101 112|fatigue limit
P00456424A0000|12 25|intracisternal
P00456424A0000|45 53|clonidine
P00456424A0000|72 84|blood pressure
P00456424A0000|88 96|heart rate
P00456424A0000|154 166|cisterna magna
P00463973A0000|0 13|Platelet number
P00463973A0000|59 67|pregnancy
P00463973A0000|72 76|women
P00463973A0000|105 130|gestational age (SGA) infants
P00463973A0000|138 142|women
P00463973A0000|147 153|infants
P00464387A1185|20 32|total serum IgE
P00464387A1185|30 32|IgE
P00464387A1185|58 72|disease activity
P00464387A1185|75 78|ABPA
P00465223A0373|6 13|patients
P00465223A0373|58 64|delta PU
P00465223A0373|68 74|delta PM
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|7 16|hemoglobin
P00465681A0000|58 62|total
P00465681A0000|63 66|iron
P00465681A0000|72 81|blood serum
P00465681A0000|84 92|white mice
P00465681A0000|106 119|oxygen pressure
P00465681A0000|136 153|preconvulsive state
P00465681A0000|158 161|6 atm
P00465681A0000|163 177|convulsive state
P00465829T0000|20 72|equations and stationary state membrane electric potentials
P00473229T0000|9 25|methylene chloride
P00473229T0000|113 119|embryos
P00473249T0000|8 37|intraventricular administration
P00473249T0000|40 52|streptolysin O
P00473249T0000|40 52|streptolysin O
P00473249T0000|80 86|rabbits
P00474064A0205|80 84|kg-1 I
P00474064A0205|115 128|phenoperidine 4
P00474064A0205|138 167|fentanyl 4, sufentanil 4 and R 34 995
P00474064A0205|173 177|kg-1 I
P00476020T0000|17 29|amniotic fluid
P00476020T0000|38 48|fetal growth
P00476572A0139|0 19|Roentgenographically
P00476572A0139|24 29|lesion
P00476572A0139|87 91|lytic
P00476572A0139|106 124|central radiodensity
P00477794T0000|9 35|chronic descending tractotomy
P00477794T0000|71 106|trigeminal nuclei principalis and oralis
P00478714T0000|0 7|Efficacy
P00478714T0000|11 22|three- versus
P00478714T0000|33 55|alcohol treatment program
P00479222A0682|15 23|simulated
P00479222A0682|24 45|physiologic environment
P00479222A0682|76 95|mechanical properties
P00479222A0682|117 146|pseudo-extracellular fluid (PECF
P00479246T0000|28 40|osteomyelitis
P00481612A1121|17 31|opiate receptors
P00481612A1121|50 66|cerebral ventricle
P00481612A1121|110 117|fentanyl
P00483716A0366|41 47|carotid
P00483716A0366|51 69|common carotid artery
P00484177A0242|50 59|expiration
P00484177A0242|76 77|CT
P00484177A0242|97 98|VT
P00485615A0935|42 56|abdominal crisis
P00485615A0935|153 169|acute pancreatitis
P00485615A0935|176 186|performance
P00485615A0935|221 227|surgery
P00488534A0308|31 48|X Strain interaction
P00488534A0308|113 114|MR
P00488534A0308|147 148|MR
P00490336A0181|49 54|group C
P00493818A0422|58 70|mechanical fit
P00493818A0422|120 128|insertion
P00494659A0391|8 25|urinary metabolites
P00494659A0391|33 80|3-carboxyphenyl)-5-hydroxymethyl-2-oxazolidinone
P00494659A0391|98 107|toloxatone
P00495097A0663|52 76|collagenous fiber synthesis
P00495097A0663|94 106|osteoid tissue
P00497494A0112|32 36|PACO2
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|41 47|glucose
P00499588T0000|49 55|insulin
P00499588T0000|49 55|insulin
P00499588T0000|60 71|sperm studies
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|34 37|CIEC
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|121 125|serum
P00503336A0285|162 170|diagnosis
P00506559A0000|32 39|furfural
P00506559A0000|52 71|Syrian golden hamsters
P00506649T0000|19 40|serum protein components
P00506649T0000|50 63|surgical stress
P00509703A0581|54 62|textbooks
P00510341T0036|11 19|E.O.R.T.C
P00512215A0000|38 56|difference tone level
P00512215A0000|58 58|L
P00512215A0000|60 64|f2-f1
P00512215A0000|60 61|f2
P00512215A0000|63 64|f1
P00512215A0000|96 103|two-tone
P00512215A0000|110 111|f1
P00512215A0000|110 111|f1
P00512215A0000|113 117|f2/f1
P00512215A0000|113 114|f2
P00512215A0000|116 117|f1
P00512215A0000|119 120|f2
P00512215A0000|132 133|f1
P00512215A0000|132 133|f1
P00512215A0000|136 137|L1
P00512215A0000|136 137|L1
P00512215A0000|139 140|L2
P00512215A0000|139 140|L2
P00512215A0000|145 146|L1
P00512215A0000|148 149|L2
P00513284A0000|26 36|doxycycline
P00513284A0000|38 41|DOTC
P00513284A0000|43 60|Vibramycin 'Pfizer'
P00513284A0000|76 87|tetracycline
P00513284A0000|146 160|pediatrics field
P00513284A0000|191 194|DOTC
P00513284A0000|224 230|glucose
P00513284A0000|231 242|solution and 2
P00513284A1255|0 0|5
P00513284A1255|23 34|DOTC infusion
P00513284A1255|54 58|liver
P00513284A1255|62 75|renal functions
P00513284A1255|79 83|blood
P00516545T0001|0 24|Structural characteristics
P00516545T0001|30 70|erythrocyte membrane, peroxidation processes
P00516545T0001|95 102|children
P00516545T0001|114 131|glomerulonephritis
P00517890A0468|35 46|transmission
P00517890A0468|50 59|hepatitis A
P00517890A0468|79 93|hepatitis A virus
P00517890A0468|124 131|jaundice
P00519173A0126|5 12|patients
P00519173A0126|39 50|oesophagitis
P00521732T0000|0 15|Urinary excretion
P00521732T0000|38 43|17 beta
P00521732T0000|47 67|oestriol in pregnancies
P00521732T0000|81 107|steroid sulphatase deficiency
P00521732T0000|81 97|steroid sulphatase
P00524451A0136|11 38|spontaneous locomotor activity
P00524451A0136|41 44|mice
P00524451A0136|72 97|amphetamine induced toxicity
P00524451A0136|154 167|catecholamines
P00524451A0136|190 192|rat
P00528144T0000|11 21|transferrin
P00528144T0000|11 21|transferrin
P00528144T0000|44 53|tumor cells
P00534613A0000|0 10|Irradiation
P00534613A0000|13 31|human blood platelets
P00534613A0000|36 39|UV-A
P00534613A0000|95 102|collagen
P00534613A0000|95 102|collagen
P00540707A0255|58 70|complications
P00540707A0255|126 139|pouch haematoma
P00540707A0255|257 269|vena cephalica
P00541752A1032|36 44|12 samples
P00550399A0615|6 14|commonest
P00553858A0000|8 23|Grice's operation
P00553858A0000|111 129|publications dealing
P00555492A1034|1 1|5
P00555492A1034|29 46|gastric venous blood
P00555492A1034|85 94|cimetidine
P00555492A1034|122 125|flow
P00555492A1034|144 164|systemic blood pressure
P00555495T0000|7 33|re-establishment of ovulation
P00555495T0000|88 111|re-appearance of ovulation
P00555495T0000|117 124|abortion
P00555495T0000|128 144|premature delivery
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|33 35|man
P00557559A0170|21 78|alpha-(3-methyl-2-quinoxalinyl)-N-methylnitrone 1,4-dioxide
P00557559A0170|21 37|alpha-(3-methyl-2
P00557559A0170|119 131|gram-negative
P00557559A0170|138 141|gram
P00564032A0724|7 20|in ionic content
P00564032A0724|83 105|excretory duct of the gland
P00564943A0444|0 16|Calves fed MCT-milk
P00564943A0444|38 53|blood cholesterol
P00564943A0444|71 78|SBO-milk
P00565136T0000|18 21|mice
P00565136T0000|55 58|CH2O
P00565136T0000|60 65|SO2Cl2
P00565136T0000|70 72|Br2
P00565314A0293|0 9|Guinea pigs
P00565314A0293|34 36|350
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|28 47|flow pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|105 110|dPn/dt
P00574222T0000|0 15|Sensory kindling:
P00574222T0000|44 60|sensory prostheses
P00574956A0304|58 81|striatal dopaminergic tone
P00574956A0304|131 169|striatal cholinergic-dopaminergic systems
P00574956A0304|195 202|dopamine
P00575231A0422|9 23|cystometrograms
P00575231A0422|49 60|contractions
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|26 47|subacute administration
P00580106T0000|11 24|Graves' disease
P00580151A0706|43 72|orally administered testosterone
P00580151A0706|98 107|normal male
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|107 122|psoriatic lesions
P00583004A0445|160 163|skin
P00583522T0001|0 15|Etiopathogenetic
P00583522T0001|40 63|acute orbital inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|9 16|patients
P00587791T0054|21 41|gynecological diseases
P00589073A0000|10 43|basal plasma prolactin concentrations
P00589073A0000|21 29|prolactin
P00589073A0000|45 53|in samples
P00589073A0000|76 90|follicular phase
P00589073A0000|96 115|normal (control) women
P00589073A0000|138 145|patients
P00589073A0000|173 183|infertility
P00590594T0000|7 25|allotransplantation
P00592887T0000|0 15|Allergic reaction
P00592887T0000|40 51|lymphography
P00593119T0001|11 24|asthma patients
P00593119T0001|42 44|IgE
P00593119T0001|42 44|IgE
P00593119T0001|75 102|allergospecific IgE antibodies
P00593119T0001|90 102|IgE antibodies
P00594466T0001|14 21|seizures
P00594466T0001|25 34|Papio papio
P00594466T0001|45 56|allylglycine
P00594617A0192|89 91|FDP
P00594617A0192|89 91|FDP
P00594617A0192|110 120|nephropathy
P00594617A0192|124 141|renal insufficiency
P00594617A0192|171 184|fibrin monomers
P00594617A0192|171 184|fibrin monomers
P00594617A0192|186 216|Godal's ethanol-gelification test
P00594617A0192|243 256|primary disease
P00594617A0192|275 277|ESR
P00597715A0256|14 16|men
P00597715A0256|21 31|azoospermia
P00597715A0256|39 50|sperm density
P00597715A0256|79 90|FSH elevation
P00597715A0256|79 81|FSH
P00597715A0256|97 106|experience
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|7 15|prolactin
P00598012A0174|28 33|stage 2
P00598012A0174|52 59|menarche
P00598012A0174|84 98|prolactin levels
P00598012A0174|84 92|prolactin
P00599601A0260|29 46|surgical procedures
P00599601A0260|90 114|pineal-induced alterations
P00599601A0260|166 168|rat
P00600943T0001|8 31|toxic lymphomononucleosis
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|6 15|hemoglobin
P00601401A0181|57 62|oxygen
P00601401A0181|104 119|Po2/delta pH ratio
P00602622A0362|9 20|ulcer therapy
P00602622A0362|25 32|atropine
P00602622A0362|36 42|Vikalin
P00602622A0362|44 48|Roter
P00602702A0309|16 29|severe diarrhea
P00602702A0309|33 39|estriol
P00602702A0309|74 91|intestinal function
P00602702A0309|108 114|estriol
P00603783A0647|0 10|Serum levels
P00603783A0647|13 21|IgG and IgM
P00603783A0647|13 15|IgG
P00603783A0647|19 21|IgM
P00603783A0647|68 85|observers IgA levels
P00603783A0647|77 79|IgA
P00606849T0000|12 31|ischemic heart disease
P00606849T0000|41 53|thromboxane A2
P00606849T0000|41 53|thromboxane A2
P00606849T0000|56 62|rabbits
P00614915T0001|0 9|Vitrectomy
P00614915T0001|12 29|ocular traumatology
P00616575A0000|27 38|central brain
P00616575A0000|86 103|decimeter waves (EMF
P00616575A0000|106 107|DW
P00616575A0000|132 149|single unit activity
P00617815A0215|12 14|L-R
P00618078A0367|14 21|lysozyme
P00618078A0367|14 21|lysozyme
P00618078A0367|70 88|bacterial meningitis
P00619782A0058|0 7|Deep tans
P00619782A0058|33 42|volunteers
P00619782A0058|73 92|ultraviolet radiation
P00619782A0058|94 95|UV
P00619948A0000|46 62|Motival (one tablet
P00619948A0000|127 143|negative variation
P00619948A0000|145 147|CNV
P00619948A0000|163 171|heart rate
P00619948A0000|173 185|blood pressure
P00619948A0000|189 205|self-rating scales
P00619948A0000|219 225|anxiety
P00619948A0000|248 257|depression
P00619948A0000|281 288|diazepam
P00619948A0000|314 324|propranolol
P00621626T0000|0 12|Stress effects
P00621626T0000|42 49|subjects
P00621626T0000|67 96|A coronary-prone behavior pattern
P00622556A0111|16 23|collagen
P00622556A0111|16 23|collagen
P00622556A0111|64 69|tendon
P00623361A0221|0 6|Smoking
P00623361A0221|42 61|pulmonary dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|14 26|nevoid lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|57 63|workers
P00627129A0944|99 120|antihypertensive effect
P00627129A0944|123 131|labetalol
P00627129A0944|165 191|alpha-and beta-adrenoceptors
P00627129A0944|165 191|alpha-and beta-adrenoceptors
P00627202T0000|0 8|Diuretics
P00628990A0000|5 12|patients
P00628990A0000|51 76|single-stage reconstruction
P00628990A0000|108 138|ipsilateral ureteroneocystostomy
P00628990A0000|161 181|cutaneous ureterostomy
P00630713T0000|15 23|Du Pont aca
P00633909A0000|0 9|Internally
P00633909A0000|18 25|patients
P00633909A0000|60 78|Locus of Control Scale
P00633909A0000|117 126|externally
P00633909A0000|171 177|control
P00635143T0001|0 5|Action
P00635143T0001|33 46|Cyprinus carpio
P00635194A0093|5 12|XV-2 film
P00635194A0093|29 58|cylindrical water-filled phantom
P00636526T0033|0 8|Diagnosis
P00637637T0000|3 17|multiple factors
P00637637T0000|27 45|plasma renin activity
P00637637T0000|27 37|plasma renin
P00637637T0000|48 68|essential hypertension
P00639410T0000|0 26|Cortisone induced bone changes
P00639410T0000|43 61|lipid clearing agents
P00641395A0441|4 15|blood samples
P00641395A0441|18 25|patients
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|80 82|ZPP
P00641395A0441|150 165|extraction method
P00644314T0000|25 27|man
P00644314T0000|38 60|systemic anticoagulation
P00644539A0783|12 16|seven
P00644539A0783|53 61|FEV1 falls
P00646023T0058|21 34|virus excretion
P00646023T0058|38 62|non-arthropod transmission
P00646193T0000|0 6|Potency
P00646193T0000|39 60|halothane and isoflurane
P00656008T0000|0 9|Prevention
P00656008T0000|12 32|acute paraquat toxicity
P00656008T0000|35 38|rats
P00656008T0000|41 59|superoxide dismutase
P00656008T0000|41 59|superoxide dismutase
P00657551T0000|13 31|magnesium absorption
P00657551T0000|48 51|26Mg
P00659962T0000|9 34|urinary riboflavin excretion
P00663166A0000|0 22|Radionuclide angiography
P00663166A0000|32 47|whole body imaging
P00663166A0000|61 94|technetium-99m-labeled particulates
P00663166A0000|138 145|patients
P00663166A0000|150 171|patent ductus arteriosus
P00663166A0000|173 175|PDA
P00663166A0000|181 201|Eisenmenger physiology
P00664320T0000|0 15|Looming detectors
P00665053A0276|0 10|Escherichia
P00665053A0276|14 50|single sero-anzymatic type (06a6b: K13: H1
P00665053A0276|49 50|H1
P00665214A0374|60 64|nasal
P00665336A0908|43 57|EEG-information
P00668122A0414|10 20|liver biopsy
P00668122A0414|34 41|patients
P00668122A0414|46 54|hepatitis
P00668122A0414|81 95|mean iron content
P00668122A0414|101 122|liver ferritin molecules
P00668122A0414|106 113|ferritin
P00669800A0579|0 9|Female mice
P00669800A0579|42 50|infection
P00669800A0579|55 59|males
P00676790T0000|0 10|Angiotensin
P00676790T0000|0 10|Angiotensin
P00676790T0000|22 32|human kidney
P00681550A0000|7 15|yellow dye
P00681550A0000|51 64|auditory fibers
P00681550A0000|132 137|fibers
P00681550A0000|146 162|site of termination
P00681550A0000|168 181|saccular macula
P00681571T0028|23 31|epidermis
P00681571T0028|54 65|eccrine sweat
P00682762T0001|0 8|Silicosis
P00685922A0451|47 69|intrahepatic biliary tree
P00685922A0451|71 73|IHB
P00686836A0000|0 15|Pentane and ethane
P00686836A0000|33 49|lipid peroxidation
P00686836A0000|71 87|gas chromatography
P00686836A0000|90 102|breath samples
P00686836A0000|105 108|rats
P00686836A0000|122 143|vitamin E-deficient diet
P00686836A0000|174 188|vitamin E acetate
P00693987T0001|0 36|Thromboplastic and fibrynolytic activity
P00693987T0001|68 77|intralipid
P00693987T0001|80 82|men
P00693987T0001|96 115|myocardial infarction
P00696680A0000|57 66|adult women
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00696858A0000|22 36|porcine secretin
P00696858A0000|22 36|porcine secretin
P00696858A0000|39 58|endocrine and exocrine
P00696858A0000|59 77|pancreatic secretion
P00696858A0000|123 130|pancreas
P00701144T0000|0 16|Biometric analysis
P00701144T0000|76 86|450 implants
P00701462A0722|0 14|Urine antibodies
P00702773A0327|0 9|Althoug RBF
P00702773A0327|84 86|RBF
P00702773A0327|88 90|GFR
P00702773A0327|94 106|cardiac output
P00703350A0418|0 11|99mTc phytate
P00703350A0418|13 24|198Au colloid
P00703350A0418|29 33|99mTc
P00703932A0000|3 10|patients
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|106 112|therapy
P00704675A0199|3 6|mass
P00704675A0199|9 11|UO2
P00704675A0199|17 37|extrapulmonary bronchi
P00710217T0001|0 12|Synovial cysts
P00710217T0001|18 25|hip joint
P00710372A0302|10 32|hypothalamic dysfunction
P00710372A0302|45 69|impaired pituitary function
P00710372A0302|82 93|GH deficiency
P00710372A0302|82 83|GH
P00710372A0302|109 132|endocrinological features
P00712117A0521|16 25|influenza A
P00712117A0521|39 42|base
P00712117A0521|71 92|A/Texas/1/77-like virus
P00712117A0521|107 130|A/Victoria/3/75 prototpye
P00713525A0268|38 47|stutterers
P00715180T0074|53 79|plutonium-239 dioxide aerosol
P00715180T0074|82 84|rat
P00715753A0241|10 14|CK-MB
P00715753A0241|10 14|CK-MB
P00715753A0241|30 42|myocardial CPK
P00715753A0241|53 61|total-CPK
P00715753A0241|59 61|CPK
P00715753A0241|115 119|CK-MB
P00715753A0241|115 119|CK-MB
P00716366T0001|0 4|Value
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|77 119|obstructive jaundice and biliary liver cirrhosis
P00722298A0619|1 15|one-way analysis
P00722298A0619|49 59|men and women
P00722298A0619|87 98|phobic groups
P00722298A0619|157 163|females
P00722298A0619|219 224|female
P00722298A0619|256 260|males
P00722652A0118|7 33|free 2nd-generation schizonts
P00722652A0118|115 119|cecum
P00725257A0452|13 21|pD2 values
P00725257A0452|32 32|E
P00725257A0452|40 42|DHE
P00725257A0452|52 53|M.
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725336T0000|45 49|local
P00725534A0888|40 47|M. leprae
P00725534A0888|40 47|M. leprae
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|66 68|IgA
P00725534A0888|85 104|intestinal epithelium
P00725534A0888|139 151|IgA deficiency
P00725534A0888|139 141|IgA
P00725534A0888|165 179|subtotal atrophy
P00725534A0888|185 199|intestinal villi
P00725534A0888|205 212|patients
P00725534A0888|217 234|lepromatous leprosy
P00725752T0001|44 74|adrenergic beta receptor blockader
P00725752T0001|44 65|adrenergic beta receptor
P00726581T0122|0 5|Orthop
P00728718T0000|0 6|Thyroid
P00728718T0000|17 25|pregnancy
P00729003A1182|0 7|Residues
P00733067A0188|42 55|technical steps
P00733067A0188|85 97|fluted section
P00733067A0188|103 114|jejunal stump
P00733067A0188|149 159|anastomosis
P00733067A0188|201 217|double valve system
P00733067A0188|269 274|mucosa
P00733067A0188|327 336|ileal lumen
P00736376A0371|38 50|acute ischemia
P00737422A0832|0 8|Pathogens
P00737422A0832|10 29|Staphylococcus aureus
P00737422A0832|32 51|Gram-negative bacilli
P00737422A0832|144 151|patients
P00740409A0000|3 16|histochemistry
P00741476A0000|74 81|abortion
P00745775A0170|12 19|patients
P00745775A0170|67 100|transient neurological complications
P00745775A0170|121 132|Urografin 310
P00745775A0170|133 134|M.
P00747722A0486|16 34|three-phase reaction
P00747722A0486|40 41|B1
P00747722A0486|52 57|Phase 1
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|0 11|Serum relaxin
P00748978T0000|20 34|prostaglandin E2
P00748978T0000|42 50|abortions
P00753237A0000|57 67|plantar arcs
P00753237A0000|69 86|diffuses body weight
P00753237A0000|90 93|PAIN
P00753237A0000|108 116|outsentry
P00753237A0000|118 120|fig
P00753237A0000|130 130|B
P00753237A0000|133 160|Plantar perforating ulceration
P00753237A0000|162 164|PPU
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|219 219|C
P00753237A0000|254 263|traumatism
P00753237A0000|396 406|plantar arcs
P00753237A0000|430 451|easier blood circulation
P00753237A0000|481 483|PPU
P00753237A0000|485 487|fig
P00755245A0000|41 53|vasomotor loci
P00755245A0000|70 95|chloralose anesthetized cats
P00755245A0000|115 126|central sites
P00755671A0485|14 20|heparin
P00755671A0485|89 109|subcutaneous hematomas
P00755869A0216|0 21|Contingency contracting
P00755869A0216|44 61|parents/caregivers
P00755869A0216|121 133|caloric intake
P00755869A0216|135 144|weight loss
P00756511T0036|0 8|Dietetics
P00756511T0036|11 39|childhood- and juvenile diabetes
P00759049A0185|3 13|micromethod
P00759049A0185|93 96|ICSH
P00759400T0000|0 7|Platelet
P00759400T0000|8 21|serotonin (5-HT
P00759400T0000|18 22|5-HT)
P00759400T0000|26 44|5-HT releasing factor
P00759400T0000|26 44|5-HT releasing factor
P00759400T0000|55 72|migrainous patients
P00762763A0253|21 24|SIDS
P00764737X0000|3 15|vigilance task
P00764737X0000|35 53|attentional deficits
P00767161A0837|26 45|serum E2 concentration
P00767161A0837|31 32|E2
P00768220X0000|3 17|motor unit viewed
P00771729X0000|5 22|reproductive system
P00771729X0000|52 59|hormones
P00775582T0000|0 19|Biological properties
P00775582T0000|22 30|sumithion
P00779272T0001|0 17|Serological studies
P00779272T0001|32 48|Epstein-Barr virus
P00779272T0001|32 48|Epstein-Barr virus
P00779272T0001|51 73|infectious mononucleosis
P00780639X0000|0 58|Carcinoembryonic antigen (CEA) procedures and clinical evaluation
P00780639X0000|0 22|Carcinoembryonic antigen
P00780639X0000|24 26|CEA
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|44 46|ALG
P00792847A0000|44 46|ALG
P00792847A0000|57 78|immunosuppressive agent
P00792847A0000|81 86|humans
P00799988A0554|13 18|global
P00799988A0554|29 36|patients
P00799988A0554|96 102|placebo
P00800141X0000|0 4|39-47
P00803867A0315|0 7|Patients
P00803867A0315|48 69|primary untreated cancer
P00803867A0315|75 89|recurrent cancer
P00803867A0315|105 112|patients
P00806295A0193|23 24|65
P00806295A0193|75 82|pregnant
P00806295A0193|86 105|non-pregnant subjects
P00807356T0001|0 37|Bacteriostatic and bacteriacidal activity
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|25 41|gynecologic cancer
P00808266T0000|44 59|radiation therapy
P00808898A0000|3 26|clinico-pathological data
P00808898A0000|32 38|patient
P00808898A0000|55 77|post-partum renal failure
P00808898A0000|79 82|IPRF
P00811852T0001|0 19|Personal satisfaction
P00811852T0001|61 68|patients
P00812183T0000|0 23|Dialyzable transfer factor
P00812183T0000|10 23|transfer factor
P00815369X0000|0 4|19-32
P00818380A0239|0 42|Rheumatoid factor and antinuclear antibody tests
P00818380A0239|0 15|Rheumatoid factor
P00818380A0239|80 83|gold
P00818380A0239|84 90|therapy
P00818380A0239|118 138|rheumatoid populations
P00819176T0001|11 29|hydrostatic pressure
P00819176T0001|58 79|hyponeustonic crustacea
P00819176T0001|81 100|Anomalocera patersoni
P00819176T0001|102 121|Pontella mediterranea
P00819176T0001|123 142|Labidocera wollastoni
P00821833A0000|33 47|vocal repertoire
P00821833A0000|50 62|howler monkeys
P00821833A0000|64 79|Alouatta palliata
P00821833A0000|108 125|southwestern Panama
P00822611A0467|18 25|patients
P00822611A0467|58 64|persons
P00822611A0467|77 89|binephrectomy
P00823087A0608|0 7|Deflunia
P00823087A0608|28 35|patients
P00827364A0000|51 68|biological material
P00830568A0000|0 28|Pancreatic and biliary secretion
P00830568A0000|32 38|gastric
P00830568A0000|55 68|liquid test meal
P00830568A0000|70 72|LTM
P00830568A0000|90 102|normal persons
P00830568A0000|106 113|patients
P00830568A0000|118 136|subtotal gastrectomy
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|160 165|STG-BI
P00830568A0000|160 165|STG-BI
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|191 197|STG-BII
P00830568A0000|191 197|STG-BII
P00830568A0000|205 212|patients
P00830568A0000|217 231|truncal vagotomy
P00830568A0000|235 246|pyloroplasty
P00830568A0000|250 251|P)
P00832096T0000|0 24|Abnormal calcium metabolism
P00832096T0000|41 51|sarcoidosis
P00833472A0907|16 22|patient
P00833472A0907|35 44|gallstones
P00833472A0907|67 76|colestipol
P00833472A0907|90 104|gallbladder bile
P00833472A0907|109 119|cholesterol
P00836637A0000|1 20|five-phase experiment
P00836637A0000|65 79|music-listening
P00836637A0000|137 144|children
P00837262A0000|19 30|visual cortex
P00837262A0000|32 33|VC
P00837262A0000|57 58|SC
P00837262A0000|94 116|conditioning "ON" or "OFF"
P00837262A0000|134 139|rabbit
P00837811A0675|12 13|MS
P00837811A0675|34 48|neurologic signs
P00837811A0675|61 73|gamma globulin
P00837811A0675|61 73|gamma globulin
P00837811A0675|88 100|abnormalities
P00838152A0863|14 32|mean temperature rise
P00838152A0863|125 147|passable' qualifications
P00838152A0863|153 165|triplet groups
P00839378A0649|11 15|Viso V
P00839378A0649|21 28|RDS group
P00839378A0649|49 69|small airway resistance
P00842406A0771|3 20|psychological tests
P00842406A0771|33 47|free-recall task
P00842406A0771|83 97|recognition task
P00842522T0000|9 27|bronchial intubation
P00842522T0000|45 84|unilateral pulmonary interstitial emphysema
P00843232A0100|70 75|lesion
P00843232A0100|81 90|epithelium
P00843232A0100|117 128|inflammatory
P00843232A0100|133 145|posttraumatic
P00843670T0000|3 7|sense
P00843670T0000|10 13|self
P00846559A0000|15 26|Fusarium poae
P00846559A0000|55 66|U.S.S.R. and 7
P00846559A0000|55 55|U
P00846559A0000|187 194|T-2 toxin
P00846559A0000|187 194|T-2 toxin
P00847967T0000|0 16|Current diagnostic
P00847967T0000|23 44|computerized tomography
P00851041A0000|19 26|patients
P00851041A0000|31 46|Ebstein's anomaly
P00851286A0375|25 44|copper concentrations
P00857024A0888|0 9|Recurrence
P00857024A0888|12 24|bladder tumors
P00857024A0888|76 84|properdin
P00857024A0888|107 112|median
P00863184T0043|0 9|Adaptation
P00863184T0043|12 32|taurocholate transport
P00863184T0043|51 63|secretory load
P00863184T0043|69 71|rat
P00863773T0000|0 6|Dangers
P00863773T0000|14 23|live-virus
P00863773T0000|24 31|vaccines
P00866577A0579|13 19|heparin
P00866577A0579|21 41|plasminogen activators
P00866577A0579|21 41|plasminogen activators
P00866577A0579|45 66|fibrinogenolytic agents
P00866577A0579|91 103|renal function
P00866577A0579|131 162|long term oral anticoagulant therapy
P00868301A0043|2 13|diethyl ether
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868903A0000|0 7|Amikacin
P00868903A0000|40 62|gram-negative infections
P00870859A0121|71 83|recirculation
P00871237A0601|37 42|angina
P00872442T0000|0 9|Estimation
P00872442T0000|12 20|L-alanine
P00872442T0000|30 35|plasma
P00872442T0000|44 66|LKB reaction rate analyser
P00872922A0204|65 89|anti-inflammatory activity
P00874942T0000|0 21|Unrecognized amnionitis
P00875778T0000|18 38|Gravigard IUCD inserter
P00876722T0000|0 18|Bacterial meningitis
P00876722T0000|42 52|nasal septum
P00877857A0763|5 11|amylase
P00877857A0763|5 11|amylase
P00877857A0763|58 65|serum FFA
P00879329A0176|56 86|isogravimetric capillary pressure
P00879329A0176|88 90|Pci
P00879329A0176|141 150|plasma (IIp
P00879829A0564|0 6|Infants
P00879829A0564|35 38|'IVH
P00879829A0564|122 127|apnoea
P00881630A0000|3 22|morphological effects
P00881630A0000|28 38|snake venoms
P00881630A0000|49 60|A. piscivorus
P00881630A0000|70 86|Direct Lytic Factor
P00881630A0000|76 86|Lytic Factor
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|129 142|naja crude venom
P00881630A0000|162 165|lung
P00881630A0000|169 184|cremaster vessels
P00881630A0000|187 190|rats
P00885562A0281|27 41|cartilage matrix
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|121 123|GAG
P00890028A0507|104 119|Taylor microscale
P00890028A0507|140 155|Kolmogoroff scale
P00891370A0000|0 26|Well-visualised arteriograms
P00891370A0000|94 108|contrast-medium
P00891370A0000|141 148|patients
P00892353A0686|2 12|hypotension
P00892353A0686|23 30|patients
P00892353A0686|35 41|toxemia
P00898500A0246|3 6|sera
P00898500A0246|15 24|secretions
P00898500A0246|27 29|142
P00898500A0246|30 37|patients
P00898500A0246|56 57|HD
P00898500A0246|60 72|mites skin test
P00898500A0246|90 112|radioallergosorbent test
P00898500A0246|114 117|RAST
P00898500A0246|143 161|IgE antibody activity
P00898500A0246|143 153|IgE antibody
P00903772A0359|20 42|conditioning stimulation
P00903772A0359|92 94|leg
P00909114A0000|0 21|Diallylnitrosamine (DAN
P00909114A0000|19 21|DAN
P00909114A0000|35 46|nitrosamines
P00909114A0000|77 85|neoplasms
P00909114A0000|88 91|rats
P00909114A0000|115 136|respiratory tract tumors
P00909114A0000|139 167|Syrian golden hamsters treated sc
P00910823A0196|0 7|Near term
P00910823A0196|14 35|experimental conditions
P00910823A0196|48 62|fetal blood gases
P00910823A0196|67 95|uterine and umbilical blood flows
P00911590T0000|0 20|Haemodynamic responses
P00911590T0000|23 32|antagonism
P00911590T0000|54 73|atropine-neostigmine
P00911590T0000|83 90|children
P00913623A0242|43 72|diphosphonate 99mTc-labeled EHDP
P00913623A0242|75 100|99mTc-labeled pyrophosphate
P00913623A0242|126 129|bone
P00915090A0536|39 44|Tc-99m
P00915090A0536|67 72|testis
P00915090A0536|85 89|sperm
P00915090A0536|110 116|control
P00916099A0000|42 60|psychiatric disorder
P00916099A0000|84 100|surgical treatment
P00917572T0001|0 10|Possibility
P00917572T0001|14 16|TSH
P00917572T0001|14 16|TSH
P00917572T0001|47 60|hypothyroidism
P00917572T0001|66 72|newborn
P00917721A0484|93 104|dream content
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|40 44|HBsAg
P00918556A0000|40 44|HBsAg
P00918556A0000|49 56|anti-HBs
P00918556A0000|49 56|anti-HBs
P00918556A0000|97 122|radio-immunoassay technique
P00918556A0000|134 141|patients
P00918556A0000|146 165|chronic liver diseases
P00918965A0728|18 25|patients
P00918965A0728|30 52|acute respiratory failure
P00918965A0728|107 120|pulmonary shunt
P00918965A0728|171 174|PAO2
P00920381T0000|16 23|glycogen
P00920381T0000|54 100|hyperglycemic, hyperinsulinemic anaesthetized rats
P00921032T0000|0 19|Biological evaluation
P00921032T0000|37 48|female Beagle
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00921911A0159|56 72|spontaneous labour
P00921911A0159|77 84|cervical
P00921911A0159|129 134|labour
P00926272A0000|43 52|spinal cord
P00926604A0504|0 10|Propranolol
P00926604A0504|53 76|beta-adrenergic apparatus
P00926604A0504|82 86|heart
P00926604A0504|157 169|strophanthin K
P00926604A0504|184 208|left ventricular myocardium
P00926751A0000|25 33|rat larynx
P00927633T0001|0 26|Scanning electron microscopic
P00927633T0001|57 71|Reissner's fiber
P00927633T0001|74 85|Rattus rattus
P00928529T0001|0 14|Feeding behavior
P00928529T0001|16 35|circannual body weight
P00928529T0001|39 56|hibernation rhythms
P00928529T0001|59 82|European hamsters lesioned
P00929418T0001|9 26|infectious-disease
P00929418T0001|74 93|communicable diseases
P00930947A0629|13 28|drug interactions
P00930947A0629|78 80|PZA
P00930947A0629|173 176|drug
P00931089T0001|0 16|Circulatory arrest
P00932738A0116|3 23|systolic blood pressure
P00932738A0116|25 26|BP
P00932738A0116|25 26|BP
P00932738A0116|37 53|C02 responsiveness
P00932738A0116|99 100|BP
P00932817A0499|0 9|Iodine-123
P00932817A0499|44 46|MEC
P00932817A0499|50 67|pinhole collimators
P00932817A0499|124 128|99mTc
P00933251T0000|0 18|Petrous meningioma en
P00933251T0000|38 56|right middle ear tumor
P00935526A0000|39 40|PG
P00935526A0000|44 67|gas-liquid chromatography
P00935526A0000|107 123|gas-chromatograph
P00935526A0000|174 186|packed columns
P00938594A0149|51 74|radiologic manifestations
P00938594A0149|77 104|hypertrophic osteoarthropathy
P00938594A0149|106 108|HOA
P00938594A0149|149 167|rheumatoid arthritis
P00938594A0149|169 170|RA
P00941050T0000|11 14|food
P00941050T0000|17 38|procainamide absorption
P00947327A0000|34 53|antibiotic resistance
P00947327A0000|88 94|1973/74
P00947327A0000|138 153|SMZ) trimethoprim
P00947327A0000|155 157|TMP
P00947327A0000|189 199|antibiotics
P00947327A0000|203 224|chemotherapeutic agents
P00947327A0000|266 267|N1
P00947327A0000|266 267|N1
P00947327A0000|270 273|4,5-
P00947327A0000|274 387|dimethyl-2-oxazolyl)-sulfanilamide) (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim
P00947327A0000|403 404|CN
P00947327A0000|416 424|Supristol
P00947327A0000|455 461|TMP/SMZ
P00947834X0000|13 21|IgE levels
P00947834X0000|13 15|IgE
P00951909X0001|4 23|afferent loop syndrome
P00951909X0001|72 91|adducent loop syndrome
P00951909X0001|116 123|patients
P00951909X0001|135 156|Billroth-II gastrectomy
P00952734T0000|0 5|Letter
P00952734T0000|17 21|solar
P00952734T0000|49 76|post-inflammatory elastolysis
P00952734T0000|80 88|cutis laxa
P00952734T0000|90 95|PECL)'
P00954819A1041|48 66|respiratory function
P00954819A1041|88 92|Soman
P00954819A1041|128 139|AChE activity
P00954819A1041|128 131|AChE
P00956364A0138|15 22|S. mutans
P00956554A0414|14 18|serum
P00956554A0414|45 64|solid-phase allergens
P00956554A0414|95 107|IgE antibodies
P00956554A0414|95 107|IgE antibodies
P00958550T0001|0 5|Crisis
P00959656A0250|0 12|Pregnant women
P00959656A0250|39 53|antithrombin III
P00959656A0250|39 53|antithrombin III
P00961711T0000|28 36|band or seg
P00962222A0633|67 92|erythrocyte characteristics
P00962222A0633|102 118|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|42 59|gelatine derivative
P00964758T0001|14 25|plasmacytoma
P00964758T0001|31 42|parotid gland
P00967223T0059|0 0|I
P00968181A0264|31 38|immunity
P00968181A0264|41 65|homologous severe challenge
P00970320A0000|3 13|performance
P00970320A0000|64 66|SO2
P00970320A0000|83 99|working conditions
P00970320A0000|103 115|copper smelter
P00970488A0105|3 29|neuroleptic-induced increase
P00970488A0105|39 48|DA turnover
P00970488A0105|75 92|DA receptor blocking
P00970488A0105|75 84|DA receptor
P00970488A0105|152 163|neuroleptics
P00970839A0118|0 11|Rainbow trout
P00970839A0118|29 47|commercial trout farm
P00970839A0118|62 76|water and feeding
P00970839A0118|79 97|experimental pellets
P00974901A0080|13 30|macrophage function
P00975314T0001|0 17|Primary amenorrhoea
P00975314T0001|35 50|female individual
P00975314T0001|56 69|karyotype 46, xy
P00975314T0001|73 95|bilateral gonadoblastoma
P00975540T0000|75 95|high-accuracy analyses
P00980255T0000|16 24|2-deoxy-D
P00980255T0000|16 23|2-deoxy-
P00980255T0000|24 32|D-glucose
P00980255T0000|54 71|cerebral metabolism
P00980255T0000|75 83|blood flow
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|5 11|gastrin
P00984209A0614|62 87|serum gastrin concentrations
P00984209A0614|67 73|gastrin
P00984209A0614|115 117|V&P
P00984209A0614|118 125|patients
P00985110T0001|0 18|Efferent projections
P00985110T0001|24 37|ventral portion
P00985110T0001|94 96|cat
P00985110T0001|97 110|cerebral cortex
P00985276A0000|0 8|Preflight
P00985276A0000|10 17|inflight
P00985276A0000|22 52|postflight exercise response tests
P00985276A0000|92 104|Skylab mission
P00985276A0000|106 112|Skylab 3
P00985276A0000|161 183|long-term weightlessness
P00985279A0493|4 38|corpuscular hemoglobin concentrations
P00985279A0493|15 24|hemoglobin
P00985279A0493|91 93|CO2
P00986800A0325|3 4|Cu
P00986800A0325|26 31|organs
P00986800A0325|76 77|Cu
P00986800A0325|118 119|Cu
P00986800A0325|158 165|delivery
P00986925A0002|11 20|calcitonin
P00986925A0002|11 20|calcitonin
P00986925A0002|36 42|calcium
P00986925A0002|48 53|orally
P00986925A0002|70 77|glucagon
P00986925A0002|80 89|plasma 47Ca
P00986925A0002|133 136|47Ca
P00987649T0001|0 4|State
P00987649T0001|16 24|disorders
P00987649T0001|27 53|diurnal physiological rhythms
P00988572A0000|0 12|Oxygen tension
P00988572A0000|18 34|small lymph vessels
P00988572A0000|36 39|PLO2
P00988572A0000|46 59|rabbit hind limb
P00988572A0000|92 103|micro chamber
P00988572A0000|108 147|polarographic catheter-tip oxygen electrode
P00988572A0000|185 190|oxygen
P00988572A0000|196 200|lymph
P00989973A0000|22 31|fibrinogen
P00989973A0000|66 75|turpentine
P00989973A0000|106 114|endotoxin
P00989973A0000|128 140|normal rabbits
P00989973A0000|196 203|busulfan
P00992316A0178|0 28|Constantly rectilinear pressure
P00992316A0178|42 58|uterine activities
P00992316A0178|120 135|ectopic gravidity
P00993176A0066|5 13|myoglobin
P00993176A0066|5 13|myoglobin
P00993176A0066|35 44|hemoglobin
P00993176A0066|35 44|hemoglobin
P00993176A0066|50 61|heme pigments
P00993176A0066|116 125|hemoglobin
P00993176A0066|116 125|hemoglobin
P00999494A0000|3 10|patients
P00999494A0000|29 38|acute mania
P00999494A0000|68 82|beta-adrenergic
P00999494A0000|96 106|propranolol
P01000378T0000|16 29|plasma glucagon
P01000378T0000|22 29|glucagon
P01000378T0000|33 53|insulin concentrations
P01000378T0000|33 39|insulin
P01000378T0000|56 60|sheep
P01003819A0498|66 81|corneal curvature
P01004298A0744|34 44|CA component
P01004298A0744|85 90|scores
P01009451A0728|23 24|UB
P01009451A0728|23 24|UB
P01009451A0728|28 34|OCS rats
P01009451A0728|103 110|drinking
P01009739T0001|8 19|indomethacin
P01009739T0001|22 40|coronary circulation
P01009739T0001|50 59|ECG tracing
P01009841T0001|4 14|innervation
P01009841T0001|17 26|fast fibers
P01009841T0001|43 55|lamprey larvae
P01010638A0161|3 6|feed
P01012640T0001|36 43|patients
P01012640T0001|48 63|pheochromocytoma
P01012640T0001|73 88|Sipple's syndrome
P01012904A0333|53 69|normal populations
P01019207A0232|73 77|betaI
P01019207A0232|87 89|lgC
P01019207A0232|106 125|0.5--10 mug ruscogenin
P01021091T0000|14 29|adrenergic nerves
P01021091T0000|45 56|blood vessels
P01021091T0000|62 70|rabbit ear
P01021091T0000|73 108|2--phenylalanine-8-lysine vasopressin
P01021091T0000|76 88|phenylalanine
P01021091T0000|90 108|8-lysine vasopressin
P01021091T0000|110 120|Octapressin
P01021091T0000|110 120|Octapressin
P01027644T0001|0 13|Potscoital test
P01030985T0090|0 0|I
P01036714A0072|9 42|biochemical and morphological changes
P01036714A0072|51 73|normal and treated animals
P01036714A0072|83 92|chrysotile
P01036714A0072|115 136|lung free cell population
P01036714A0072|140 158|pulmonary surfactant
P01044338A0240|0 19|Infrared measurements
P01044338A0240|77 81|mical
P01047417T0000|0 6|Who says
P01047417T0000|8 33|National Health Dis-service'
P01047895T0001|2 10|criticism
P01047895T0001|13 19|patient
P01047895T0001|72 80|criticism
P01048020T0000|0 7|Critique
P01048020T0000|113 129|Course Information
P01048968A0152|44 56|staphylococci
P01048968A0152|72 82|penicillin G
P01048968A0152|108 121|beta-lactamase
P01048968A0152|108 121|beta-lactamase
P01050144A0297|66 76|antibiotics
P01050144A0297|78 95|multiple-resistant
P01050144A0297|114 123|83A complex
P01050400T0000|83 89|infants
P01057137A0192|17 37|clinical acceptability
P01064124A0560|20 47|radiolucent caries-like lesion
P01067493A0119|3 22|contraceptive pattern
P01067493A0119|28 32|women
P01067493A0119|67 84|inefficient methods
P01071715A0903|0 24|Plethysmographic technique
P01071715A0903|28 58|indirect blood pressure recordings
P01075075T0038|0 0|I
P01078982A0227|52 90|cyclophosphamide + antilymphocyte globulin
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|92 94|ALG
P01078982A0227|92 94|ALG
P01078982A0227|109 111|ALG
P01078982A0227|150 165|cyclophosphamide
P01080374A0709|23 54|Leber's military aneurysm retinitis
P01080374A0709|92 104|Coats' disease
P01081904A0198|0 13|Fibrin cloaking
P01081904A0198|0 5|Fibrin
P01081904A0198|22 29|catheter
P01081904A0198|42 49|patients
P01081904A0198|59 79|pull-out arteriography
P01082726A0248|44 49|DC-ERG
P01082726A0248|44 45|DC
P01082726A0248|47 49|ERG
P01082833A0000|17 38|anti-inflammatory agent
P01082833A0000|83 94|indomethacin
P01082833A0000|96 97|IM
P01082833A0000|102 121|inflammatory response
P01082833A0000|128 146|ultraviolet erythema
P01082833A0000|149 158|guinea pigs
P01082833A0000|171 175|edema
P01082833A0000|177 216|evans blue and carrageenin-induced pleuritis
P01082833A0000|220 248|acetic acid-induced peritonitis
P01082833A0000|251 254|rats
P01083321X0000|47 58|subalpine fir
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|27 44|childhood cirrhosis
P01083784T0000|0 23|Lymphocyte subpopulations
P01083784T0000|25 32|serum IgE
P01083784T0000|30 32|IgE
P01083784T0000|41 56|eosinophil counts
P01083784T0000|59 66|patients
P01083784T0000|71 85|bronchial asthma
P01084413A0271|8 36|normal ventricular measurements
P01087288T0000|61 68|patients
P01087288T0000|80 85|iodine
P01087288T0000|93 108|thyroid carcinoma
P01088654T0001|0 8|Technique
P01088654T0001|45 48|mass
P01090210A0417|4 20|total lung capacity
P01090210A0417|52 65|residual volume
P01090210A0417|99 111|closing volume
P01090210A0417|116 119|lung
P01090210A0417|152 158|phase IV
P01090210A0417|209 230|positive airway pressure
P01090210A0417|248 250|H20
P01092248T0000|0 12|Current status
P01092248T0000|48 59|neurological
P01092248T0000|78 101|musculoskeletal disorders
P01093055T0000|0 29|Calcium and phosphorus metabolism
P01093055T0000|39 44|uremia
P01093845A0208|0 12|Modern studies
P01093845A0208|27 37|Delta-9-THC
P01093845A0208|41 58|healthy voluntaries
P01093845A0208|140 144|sleep
P01093845A0208|148 152|dream
P01093847A0000|3 18|correcting action
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|52 72|extrapyramidal effects
P01093847A0000|82 93|neuroleptics
P01093847A0000|112 131|acute psychotic states
P01096741X0000|0 15|Epididymal growth
P01096741X0000|29 35|animals
P01096741X0000|54 66|chickpea haulm
P01097100A0217|3 10|patients
P01098179A0167|18 55|chloramphenicol-containing preparations
P01098179A0167|96 110|cup-plate assays
P01098179A0167|126 140|chloramphenicol
P01098179A0167|184 189|creams
P01098179A0167|198 216|ophthalmic ointments
P01098592A0567|0 8|IgG levels
P01098592A0567|0 2|IgG
P01098592A0567|42 51|ten samples
P01099693T0000|0 5|Letter
P01099693T0000|21 45|bone marrow transplantation
P01101272T0000|0 9|Assessment
P01101272T0000|32 55|non-nutritive sweetners II
P01101272T0000|70 84|cyclohexylamine
P01103390A0149|38 41|mice
P01103390A0149|69 75|animals
P01103390A0149|114 124|parasitemia
P01107226A0808|0 20|Residual amphotericin B
P01107226A0808|47 50|mice
P01113908A0475|30 41|transferrin 2
P01113908A0475|30 40|transferrin
P01116254A0000|38 60|myocardial concentration
P01116254A0000|82 90|potassium
P01116254A0000|125 128|mice
P01116254A0000|211 219|potassium
P01116466A0185|0 13|Thromboplastin
P01116466A0185|26 39|thromboplastin
P01116466A0185|45 52|thrombin
P01116466A0185|45 52|thrombin
P01116466A0185|58 77|heat-dependent fibrin
P01116466A0185|72 77|fibrin
P01116466A0185|97 115|clotting factors II, V
P01116466A0185|97 113|clotting factors II
P01116466A0185|115 120|V, VIII
P01116466A0185|117 123|VIII, IX
P01116466A0185|122 123|IX
P01116466A0185|125 125|X
P01116466A0185|133 145|platelet count
P01118293A0150|40 45|images
P01118293A0150|52 67|binocular rivalry
P01119586A0337|49 65|creatine phosphate
P01119586A0337|67 80|ATP, and lactate
P01119586A0337|101 106|hearts
P01119586A0337|122 125|flow
P01119658A0000|65 85|squamous cell carcinoma
P01119658A0000|91 100|oral cavity
P01119658A0000|102 111|oropharynx
P01119658A0000|134 144|hypopharynx
P01119658A0000|169 185|cervical lymph node
P01119658A0000|186 203|metastases staged N1
P01119658A0000|205 207|N2A
P01119658A0000|211 213|N2B
P01119658A0000|230 233|neck
P01119658A0000|262 277|radiation therapy
P01123658A0000|32 56|transverse axial tomography
P01123658A0000|62 66|spine
P01123658A0000|116 132|normal lumbar spine
P01123658A0000|137 139|L-4
P01123658A0000|137 139|L-4
P01124944A0830|0 4|Owing
P01124944A0830|7 22|parental attitude
P01124944A0830|25 38|low protein diet
P01128985A0000|17 32|diagnostic method
P01128985A0000|101 108|patients
P01130186A0568|8 27|hypoglycaemic patient
P01130186A0568|47 60|insulin release
P01130186A0568|47 53|insulin
P01130186A0568|73 83|tolbutamide
P01130531A0224|0 15|Nerve stimulation
P01130531A0224|71 73|CBF
P01131946T0001|19 28|Norbiogest
P01131946T0001|38 52|quiescent period
P01131946T0001|58 70|genital organs
P01138215T0001|31 39|fractures
P01138330A0204|0 12|Bulbar pouches
P01138330A0204|29 37|solutions
P01138330A0204|44 47|Na C1
P01138330A0204|52 55|N HC1
P01138330A0204|60 66|glucose
P01138330A0204|71 74|NaC1
P01138330A0204|110 130|acetylcholine chloride
P01140184A0342|5 14|microsomes
P01140184A0342|20 23|shag
P01140184A0342|48 69|epoxide hydrase activity
P01140184A0342|48 61|epoxide hydrase
P01140184A0342|92 129|hydroxylating capacity of liver microsomes
P01140184A0342|137 139|rat
P01141114A0188|0 13|Prolonged heavy
P01141114A0188|42 52|plus or minus
P01141114A0188|62 70|in vivo P50
P01141114A0188|76 79|PH-v
P01141114A0188|97 104|45 Pv-CO2
P01141114A0188|149 165|venous temperature
P01141114A0188|169 172|[H+]
P01145884T0028|10 20|serological
P01147436T0000|11 33|Burkitt Lymphoma Registry
P01147502T0000|0 9|Vitrectomy
P01147502T0000|16 42|alternative instrument system
P01148868A0284|3 24|metabolic clearance rate
P01148868A0284|27 38|progesterone
P01150658A0683|39 61|human luteinizing hormone
P01150658A0683|44 61|luteinizing hormone
P01150658A0683|63 68|Sairam
P01156631A0658|3 31|mean plasma sodium concentration
P01156631A0658|69 85|diuretic treatment
P01156814T0000|0 8|Editorial
P01156814T0000|18 24|heparin
P01156814T0000|43 69|venous thromboembolic disease
P01157191A0536|28 42|sodium saccharin
P01157191A0536|46 60|sodium cyclamate
P01157191A0536|69 87|solitary carcinogens
P01157191A0536|97 109|4/253 and 3/228
P01157191A0536|110 123|bladder tumours
P01157191A0536|155 161|tumours
P01157614T0000|75 82|children
P01158512T0000|0 31|Glucose-6-phosphate dehydrogenase
P01158512T0000|0 31|Glucose-6-phosphate dehydrogenase
P01158512T0000|33 35|G-6
P01158512T0000|33 35|G-6
P01158512T0000|37 38|PD
P01158512T0000|37 38|PD
P01158512T0000|55 61|newborn
P01158838A0438|3 9|eluting
P01158838A0438|20 38|methanol-chloroform
P01158838A0438|49 56|flow rate
P01159822A0353|3 20|bronchial epithelia
P01159822A0353|26 45|smoke-exposed animals
P01159822A0353|50 61|hyperplastic
P01159822A0353|111 121|nuclear axes
P01159822A0353|153 186|lysosomes and multivesiculated bodies
P01159822A0353|209 242|enlarged intramitochondrial granules
P01168607A0672|3 23|routine administration
P01168607A0672|26 28|fat
P01168607A0672|86 96|prothrombin
P01168607A0672|104 117|serum vitamins A
P01168607A0672|121 121|E
P01168908A0000|0 13|Prostaglandins
P01168908A0000|16 18|PGF
P01168908A0000|34 44|uterine vein
P01168908A0000|46 79|ovarian artery, and jugular vein plasma
P01168908A0000|88 105|endometrial tissues
P01168908A0000|181 192|progesterone
P01168956A0552|38 52|fetal weight gain
P01168956A0552|80 87|placenta
P01170143A0247|26 35|saline mice
P01170143A0247|58 62|light
P01170143A0247|66 79|dark conditions
P01170143A0247|92 107|covered cylinders
P01171020A0711|26 32|nucleus
P01171935A0313|15 41|dyskinetic movement disorders
P01171935A0313|44 49|humans
P01171935A0313|74 81|levodopa
P01171935A0313|84 94|amphetamine
P01171935A0313|134 164|dopamine receptor site sensitivity
P01171935A0313|134 153|dopamine receptor site
P01171935A0313|174 181|striatum
P01172734T0035|15 22|HL-A W-27
P01172734T0035|19 22|W-27
P01172917T0000|0 5|Letter
P01172917T0000|7 27|Lactose tolerance tests
P01172917T0000|42 54|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01176905A0094|4 18|pineal melatonin
P01176905A0094|20 33|serum melatonin
P01176905A0094|43 50|mid-dark
P01176905A0094|59 67|mid-light
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|23 52|ultrasonic Doppler-cardiography
P01185956A0722|97 108|stroke volume
P01186344A0303|3 12|attainment
P01186344A0303|47 67|sexual characteristics
P01186344A0303|100 103|male
P01186344A0303|119 131|female pattern
P01186344A0303|145 147|ova
P01186344A0303|166 185|developmental process
P01190120A0832|39 52|thromboplastin
P01190251A0335|0 6|Caution
P01190251A0335|46 56|lymphograms
P01191955A0077|22 47|short saphenous incompetence
P01191955A0077|71 81|varices stem
P01191955A0077|87 108|saphenopopliteal reflux
P01191964A0000|13 20|patients
P01191964A0000|44 56|thyroidectomy
P01191964A0000|60 74|Graves's disease
P01191964A0000|76 98|toxic multinodular goitre
P01191964A0000|162 185|serum thyroxine (T-4) level
P01191964A0000|177 179|T-4
P01191964A0000|247 282|raised serum thyrotrophin concentration
P01191964A0000|258 269|thyrotrophin
P01193458T0001|0 24|Routine isotope cystography
P01193458T0001|30 40|99M Tc sulfur
P01193458T0001|74 94|vesico-ureteral reflux
P01193770T0000|0 11|Air ion action
P01193770T0000|14 21|bacteria
P01194673A0652|18 46|positive or negative chemography
P01201977T0000|19 45|antibiotic disc sensitivities
P01202616A0466|9 21|retransfusion
P01206772T0000|8 18|chromosomes
P01206772T0000|21 31|lymphocytes
P01206772T0000|36 43|patients
P01206772T0000|55 64|hycanthone
P01206896T0001|0 14|Characteristics
P01206896T0001|45 64|emergency lung surgery
P01208811T0001|10 30|physico-chemical state
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 75|citrate solution-blood system
P01209618A0409|107 120|d-tubocurarine
P01211754A0192|74 81|patients
P01215067A0000|3 30|specific electrical resistance
P01215067A0000|36 53|cerebrospinal fluid
P01215067A0000|98 116|meningitis purulenta
P01215067A0000|127 142|meningitis serosa
P01215067A0000|153 164|encephalitis
P01215067A0000|172 186|control subjects
P01217450A0295|0 18|2 - Chemical occlusion
P01217450A0295|21 23|vas
P01217450A0295|75 78|dogs
P01224116A0576|18 25|patients
P01224116A0576|35 54|serum immunoglobulins
P01224116A0576|35 54|serum immunoglobulins
P01224116A0576|63 65|IgG
P01224116A0576|63 65|IgG
P01224116A0576|115 135|French-Canadian family
P01228258A0000|0 23|Streptococcal preparation
P01228258A0000|25 30|OK-432
P01228258A0000|43 58|anti-cancer agent
P01228258A0000|73 80|patients
P01228258A0000|85 98|advanced cancer
P01228258A0000|116 131|Mitomycin-C, 5-FU
P01228258A0000|135 153|Cytosine arabinoside
P01228882A0437|0 8|Generally
P01228882A0437|63 80|CSF immunoglobulins
P01228882A0437|63 65|CSF
P01228882A0437|92 120|meningeal inflammatory response
P01228882A0437|152 171|neurological diseases
P01233561T0001|0 16|Maternal lactation
P01235347T0001|12 25|cardiotoxicity
P01236224T0001|0 16|Muscular pathology
P01237206A0199|42 44|6th
P01237206A0199|69 86|microscopic methods
P01237206A0199|88 92|Stamp
P01237206A0199|96 111|auramine staining
P01237206A0199|113 140|fluorescent antibody technique
P01237206A0199|146 160|Coxiella content
P01237206A0199|176 184|titration
P01237206A0199|187 206|embryonated hen's eggs
P01241437A0152|3 10|patients
P01241437A0152|42 46|NLA II
P01241437A0152|60 69|nalorphine
P01241437A0152|71 78|morphine
P01241437A0152|81 87|Micoren
P01241588A1470|16 19|5-HT
P01241588A1470|23 34|5-HIAA levels
P01241588A1470|56 60|brain
P01241588A1470|102 105|IDPN
P01241588A1470|137 159|5-HT-containing neurones
P01241866A0682|1 1|5
P01241866A0682|15 30|leukocyte-counts
P01241866A0682|60 64|serum
P01241866A0682|77 82|rabbit
P01242636A0678|81 98|beryllium retention
P01243628A0286|44 65|blood carboxyhemoglobin
P01243628A0286|49 65|carboxyhemoglobin
P01243628A0286|67 70|COHb
P01243628A0286|67 70|COHb
P01244236A1122|61 87|pulmonary vascular resistance
P01244236A1122|146 152|vessels
P01244236A1122|165 183|vasomotor reactivity
P01244236A1122|223 234|smooth muscle
P01244236A1122|254 259|muscle
P01244236A1122|272 278|vessels
P01245162A0262|109 126|transaminase levels
P01246210A0648|3 14|calcium ratio
P01246210A0648|49 52|TBCa
P01246210A0648|56 58|men
P01246210A0648|79 83|women
P01247475A0000|16 29|retinoblastoma
P01247475A0000|100 106|outlook
P01248124A0281|5 15|cholesterol
P01248124A0281|29 42|amniotic fluids
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|67 75|pregnancy
P01249198A1097|80 90|GTD patients
P01249198A1097|98 120|clinical hyperthyroidism
P01253191T0000|10 29|phase-plane technique
P01253191T0000|46 68|cardiac action potentials
P01256410T0001|0 10|3 activities
P01256410T0001|16 31|factor II molecule
P01256410T0001|16 31|factor II molecule
P01256410T0001|44 49|infant
P01261005A0711|19 37|lot-to-lot variation
P01261005A0711|54 64|performance
P01264640T0028|15 20|Saigon
P01265443A0159|0 16|Hypertonic glucose
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|93 125|pentagastrin-induced acid secretion
P01265443A0159|133 137|pouch
P01265443A0159|148 154|stomach
P01265443A0159|163 178|hypertonic saline
P01265887T0001|0 26|Acquired factor VIII inhibitor
P01265887T0001|8 17|factor VIII
P01265887T0001|29 50|non-hemophilic patients
P01267446A0210|0 15|Biohydrogenation
P01267446A0210|18 29|linoleic acid
P01267446A0210|34 49|octadecenoic acid
P01272816A0000|10 26|calcium metabolism
P01272816A0000|32 64|thalassaemic children comperatively
P01272816A0000|82 99|oral administration
P01272816A0000|102 105|47Ca
P01272816A0000|124 143|intestinal absorption
P01275335A0158|0 15|Chlamydial agents
P01275335A0158|55 70|chlamydemic phase
P01275541A0405|21 31|CPK activity
P01275541A0405|21 23|CPK
P01275541A0405|45 52|newborns
P01275541A0405|66 95|Duchenne-type muscular dystrophy
P01275541A0405|130 137|delivery
P01276105A0313|14 28|insulin response
P01276105A0313|14 20|insulin
P01276105A0313|45 56|non-pregnant
P01276105A0313|81 90|puerperium
P01278251A0000|66 81|plastic materials
P01278251A0000|83 94|polyethylene
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01279197T0000|0 17|Mutational analysis
P01279197T0000|23 41|major homology region
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|84 94|mutagenesis
P01279352A0297|3 6|site
P01279352A0297|8 10|PAL
P01279352A0297|8 10|PAL
P01279352A0297|27 38|10 bp sequence
P01279352A0297|39 48|GGGGAGGAGG
P01279352A0473|0 14|Nuclear extracts
P01279352A0473|31 36|neural
P01279352A0473|44 58|neural cell lines
P01279352A0473|60 83|mouse brain, and mouse liver
P01279352A0473|124 142|PROX and PAL sequences
P01279352A1197|16 28|NF(H) promoter
P01279352A1197|16 28|NF(H) promoter
P01279352A1197|46 65|tissue specific manner
P01279352A1197|83 96|transgenic mice
P01279352A1197|110 123|promoter region
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279374A0396|30 34|genes
P01279374A0396|90 105|carboxy-terminal
P01279374A0396|118 123|PET122
P01279374A0396|118 123|PET122
P01280413T0001|22 38|smears and sections
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|80 103|ThrRS/CGU operator complex
P01280807A0575|80 96|ThrRS/CGU operator
P01281322A0604|71 82|smooth muscle
P01281322A0604|115 122|flow rate
P01281472T0000|0 5|Rabbit
P01281771T0000|21 50|human gene encoding cytokeratin 17
P01281771T0000|21 29|human gene
P01282014A0275|19 23|DSP-4
P01282014A0275|51 55|motor
P01282014A0275|79 89|saline group
P01282638A0934|36 43|patients
P01282638A0934|75 86|chemotherapy
P01282638A0934|188 195|patients
P01282638A0934|223 241|therapeutic schedule
P01282638A0934|298 304|patient
P01284032A0213|0 1|AP
P01284032A0213|14 32|intraductal infusion
P01284032A0213|63 82|glycodeoxycholic acid
P01284032A0213|84 87|GDOC
P01284595A0102|3 11|isolation
P01284595A0102|54 58|Y-231
P01284595A0102|59 64|cosmid
P01284595A0102|77 92|CpG rich sequences
P01284595A0102|110 120|human insert
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|6 25|plasminogen activator
P01284828T0001|73 77|blood
P01284828T0001|80 87|patients
P01284828T0001|119 126|prostate
P01285009A0000|0 3|Gene
P01285009A0000|26 43|human growth hormone
P01285009A0000|26 43|human growth hormone
P01285009A0000|45 52|hGH) gene
P01285009A0000|45 47|hGH
P01285009A0000|61 87|promoter/regulatory sequence
P01285009A0000|90 113|mouse metallothionein (mMT
P01285009A0000|90 109|mouse metallothionein
P01285009A0000|111 113|mMT
P01285009A0000|116 139|viral thymidine kinase (vTK
P01285009A0000|116 135|viral thymidine kinase
P01285009A0000|137 139|vTK
P01285009A0000|142 159|rat cholecystokinin
P01285009A0000|142 144|rat
P01285009A0000|145 164|cholecystokinin (rCCK
P01285009A0000|161 164|rCCK
P01285009A0000|169 185|chicken beta-actin
P01285009A0000|169 185|chicken beta-actin
P01285009A0000|187 194|cBA) gene
P01285009A0000|187 189|cBA
P01285009A0000|214 222|cytoplasm
P01285009A0000|225 244|fertilized medaka eggs
P01285009A0000|251 259|micropyle
P01285358A0396|0 11|Serum gastrin
P01285358A0396|5 11|gastrin
P01285358A0396|15 23|AFP levels
P01285358A0396|15 17|AFP
P01285358A0396|34 42|evolution
P01285554T0000|0 8|Prospects
P01285807A0365|3 6|mean
P01285807A0365|99 103|PaCO2
P01286732A0572|6 17|hepatomegaly
P01286732A0572|36 42|enzymes
P01286732A0572|82 89|patients
P01286732A0572|104 108|liver
P01286732A0572|123 131|hepatitis
P01286732A0572|134 150|liver cell necrosis
P01286732A0572|186 197|P. falciparum
P01286732A0572|198 204|malaria
P01287197A0761|37 51|plasma potassium
P01287197A0761|62 71|salbutamol
P01287197A0761|148 156|decrement
P01287197A0761|213 214|po
P01292230A0283|28 48|early diastolic filling
P01294345A0591|60 68|Bromergon
P01294345A0591|122 142|normal prolactin levels
P01294345A0591|128 136|prolactin
P01294345A0591|165 169|edema
P01294345A0591|171 180|weight gain
P01294345A0591|184 199|breast tenderness
P01295373A0651|17 29|early response
P01295373A0651|44 44|A
P01295373A0651|91 95|B(119
P01295373A0651|105 105|C
P01295500A0366|9 16|patients
P01295500A0366|30 53|Transient Ischemic Attacks
P01296815A0059|11 24|third human gene
P01296815A0059|16 24|human gene
P01296815A0059|31 34|LD78
P01296815A0059|31 34|LD78
P01296815A0059|42 50|LD78 gamma
P01296815A0059|42 50|LD78 gamma
P01296815A0059|88 109|5'-truncated pseudogene
P01296815A0059|88 109|5'-truncated pseudogene
P01297332A0983|44 47|SCBs
P01297332A0983|68 71|SWI4
P01297332A0983|68 71|SWI4
P01297332A0983|73 88|6-dependent genes
P01297332A0983|111 134|revised consensus sequence
P01297332T0000|0 17|Mutational analysis
P01297332T0000|21 31|DNA sequence
P01297332T0000|49 62|gene expression
P01297332T0000|68 76|cell cycle
P01298173A0153|32 53|locoregional efficiency
P01298173A0153|98 109|chemotherapy
P01298173A0153|128 132|death
P01298398A0461|67 88|mobile phase composition
P01299489A0788|101 108|athletes
P01299489A0788|121 131|dietary RDIs
P01300914A1066|14 33|histological criteria
P01300914A1066|113 132|endomyocardial biopsy
P01300914A1066|146 175|thin and fragile ventricular walls
P01300914A1066|191 194|ACRV
P01300914A1066|264 285|ventricular arrhythmias
P01300914A1066|320 321|VT
P01300914A1066|379 399|adrenergic stimulation
P01300914A1066|425 438|late potentials
P01300914A1066|444 463|high amplification ECG
P01300914A1066|611 625|RV abnormalities
P01300914A1066|666 691|dyskinetic parietal vaulting
P01301171A0979|15 22|enhancer
P01301171A0979|35 55|c-myc bearing sequences
P01301171A0979|35 39|c-myc
P01301171A0979|58 68|chromosome 8
P01302765A0999|54 56|R2s
P01302765A0999|102 114|EEG components
P01304515A0178|34 45|control group
P01304515A0178|49 64|female volunteers
P01309244A0798|64 74|orientation
P01309244A0798|125 144|heterologous promoter
P01309587A0715|0 25|Synergistic transactivation
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|49 49|Z
P01309587A0715|51 55|c-myb
P01309587A0715|101 108|Z protein
P01309587A0715|101 108|Z protein
P01309587A0715|118 129|c-myb protein
P01309587A0715|118 129|c-myb protein
P01309593A0095|3 17|UCR core sequence
P01309593A0095|19 27|CGCCATTTT
P01309593A0095|35 57|ubiquitous nuclear factor
P01309593A0095|89 108|MuLV promoter activity
P01309593A1092|20 24|UCRBP
P01309593A1092|20 24|UCRBP
P01309593A1092|39 50|target motifs
P01309593A1092|73 80|UCR motif
P01309593A1092|73 80|UCR motif
P01309593A1092|85 126|adeno-associated virus P5 promoter and elements
P01309593A1092|85 115|adeno-associated virus P5 promoter
P01309593A1092|132 170|immunoglobulin light- and heavy-chain genes
P01309593A1092|132 170|immunoglobulin light- and heavy-chain genes
P01309593A1092|190 210|ribosomal protein genes
P01309593A1092|190 210|ribosomal protein genes
P01309815A0972|0 7|Possibly
P01309815A0972|12 25|scr1-1 mutation
P01309815A0972|12 25|scr1-1 mutation
P01309815A0972|58 76|translational arrest
P01309815A0972|109 127|translational arrest
P01309815A0972|130 141|AEP synthesis
P01309815A0972|130 132|AEP
P01309860A0559|3 19|cellular sequences
P01309860A0559|103 109|mouse L1
P01309860A0559|108 109|L1
P01309860A0559|134 152|repetitive sequences
P01309894A0807|4 8|Rep78
P01309894A0807|4 8|Rep78
P01309894A0807|12 16|Rep68
P01309894A0807|12 16|Rep68
P01309894A0807|31 33|AAV
P01309894A0807|56 68|nucleotide 124
P01309910A0428|0 17|Nucleotide sequence
P01309910A0428|38 55|TAR-binding protein
P01309910A0428|38 55|TAR-binding protein
P01309910A0428|74 85|CREB2 protein
P01309910A0428|74 85|CREB2 protein
P01310154A0879|28 51|N- and C-terminal mutations
P01310154A0879|28 42|N- and C-terminal
P01310154A0879|89 98|FBR protein
P01310154A0879|89 98|FBR protein
P01310154A0879|187 200|gene regulation
P01310154A0879|203 212|FBR protein
P01310154A0879|203 212|FBR protein
P01310178A0876|3 14|JS78 mutation
P01310178A0876|30 34|gp0.7
P01310178A0876|39 48|amber codon
P01310178A0876|91 120|30-kDa gp0.7-related polypeptide
P01310178A0876|97 99|gp0
P01310178A0876|138 159|11-kDa C-terminal domain
P01310178A0876|144 159|C-terminal domain
P01310879A0000|1 7|patient
P01310879A0000|21 58|heparin-associated thrombocytopenia (HAT
P01310879A0000|56 58|HAT
P01310879A0000|91 107|acute renal failure
P01310879A0000|134 140|heparin
P01310899A0339|38 69|cysteine-rich extracellular domain
P01310899A0339|78 107|hydrophobic transmembrane domain
P01310899A0339|122 160|cytoplasmic serine/threonine kinase domain
P01310899A0339|122 154|cytoplasmic serine/threonine kinase
P01310935T0000|0 14|Drosophila UbcD1
P01310935T0000|0 14|Drosophila UbcD1
P01310935T0000|38 64|ubiquitin-conjugating enzyme
P01310935T0000|38 58|ubiquitin-conjugating
P01310935T0000|75 101|selective protein degradation
P01312005A0600|19 33|16.7-kb mt genome
P01312005A0600|49 52|MDP1
P01312005A0600|49 52|MDP1
P01312005A0600|71 80|chick mtDNA
P01312005A0600|103 138|L-strand sequence-specific target sites
P01312005A0600|103 118|L-strand sequence
P01312005A0600|158 177|A + T-rich genomic tract
P01312005A0600|270 300|H-strand origin (OH) of replication
P01313715A0461|84 91|rp47phox
P01313715A0461|84 91|rp47phox
P01313715A0461|97 100|HL60
P01313715A0461|104 134|U937 human hematopoietic cell lines
P01313715A0461|143 190|Epstein-Barr virus transformed B-lymphocyte cell line
P01313715A0461|143 159|Epstein-Barr virus
P01313715A0461|192 198|EBV-BCL
P01313715A0461|212 238|p47phox-deficient CGD patient
P01313715A0461|212 218|p47phox
P01313846A0850|42 48|Tactile
P01313846A0850|42 48|Tactile
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|109 125|Drosophila amalgam
P01313846A0850|109 125|Drosophila amalgam
P01313846A0850|130 145|melanoma Ag MUC-18
P01313846A0850|130 145|melanoma Ag MUC-18
P01313846A0850|159 182|carcinoembryonic Ag family
P01313846A0850|159 182|carcinoembryonic Ag family
P01313846A0850|187 204|poliovirus receptor
P01313846A0850|187 204|poliovirus receptor
P01313846A0850|212 237|neural cell adhesion molecule
P01313894A1179|54 72|LMP2B mRNA expression
P01313894A1179|54 62|LMP2B mRNA
P01313894A1179|119 124|tumors
P01313909A0526|3 12|phenotypes
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|18 21|ICP0
P01313909A0526|70 83|wild-type virus
P01313909A0526|70 83|wild-type virus
P01313909A0526|104 122|ICP0-coding sequence
P01313909A0526|104 107|ICP0
P01313909A0526|140 153|nonsense mutant
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|49 70|herpesvirus saimiri (HVS
P01314457T0000|99 117|genetic organization
P01314457T0000|125 127|HVS
P01314457T0000|131 147|Epstein-Barr virus
P01314457T0000|131 147|Epstein-Barr virus
P01314841A0724|13 18|MK-801
P01314841A0724|27 42|burst suppression
P01314841A0724|48 50|EEG
P01314841A0724|93 108|arterial pressure
P01314953A1266|11 37|gel mobility shift experiments
P01314953A1266|60 63|HAP2
P01314953A1266|60 63|HAP2
P01314953A1266|66 69|HAP3
P01314953A1266|66 69|HAP3
P01314953A1266|77 83|domain 1
P01314953A1266|90 93|hap3
P01315706A0000|0 22|Myogenic differentiation
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|67 85|rat L6 muscle cell line
P01316125A0176|37 39|1O2
P01316125A0176|48 59|free radicals
P01316125A0176|66 67|OH
P01316125A0176|71 76|YHPD-.
P01316125A0176|99 102|YHPD
P01316125A0176|136 138|1O2
P01316125A0176|140 143|YHPD
P01316125A0176|152 155|BHPD
P01316125A0176|183 184|OH
P01316125A0176|186 189|YHPD
P01316125A0176|201 204|BHPD
P01316125A0382|31 51|photosensitized damage
P01316125A0382|54 57|YHPD
P01316125A0382|81 83|1O2
P01316125A0382|92 103|free radicals
P01316125A0382|110 111|OH
P01316125A0382|115 120|YHPD-.
P01316125A0382|141 161|photosensitized damage
P01316125A0382|164 167|YHPD
P01316125A0382|188 191|BHPD
P01316125A0382|199 219|photosensitized damage
P01316125A0382|254 256|1O2
P01316125A0382|296 297|OH
P01316461A1083|4 31|in vitro-synthesized S2 protein
P01316461A1083|35 51|synthetic peptides
P01316461A1083|67 68|S2
P01316461A1083|67 68|S2
P01316461A1083|98 101|sera
P01316461A1083|114 132|EIAV-infected horses
P01316461A1083|192 206|infected animals
P01316476A0842|4 25|canonical TATA sequences
P01316476A0842|53 80|VZV transcriptional start sites
P01316476A1428|3 10|ORF 4 gene
P01316476A1428|3 10|ORF 4 gene
P01316476A1428|40 48|ORF 62 gene
P01316476A1428|40 48|ORF 62 gene
P01316680A0643|17 22|IR5 ORF
P01316680A0643|17 19|IR5
P01316680A0643|20 22|ORF
P01316680A0643|25 29|EHV-1
P01316680A0643|25 29|EHV-1
P01316680A0643|50 61|13 amino acids
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|101 124|consensus zinc finger motif
P01316680A0643|110 124|zinc finger motif
P01316680A0643|126 152|C-X2-4-C-X2-15-C/H-X2-4-C/H
P01316680A0643|126 141|C-X2-4-C-X2-15-C
P01316680A0643|143 150|H-X2-4-C
P01316680A0643|152 152|H
P01316900A0000|3 13|DNA sequence
P01316900A0000|19 40|sulfate activation locus
P01316900A0000|45 63|Escherichia coli K-12
P01316900A0000|45 59|Escherichia coli
P01316900A0000|60 63|K-12
P01316903A0296|3 22|unphosphorylated form
P01316903A0296|25 39|RNA polymerase II
P01316903A0296|25 39|RNA polymerase II
P01316903A0296|52 54|IIA
P01316903A0296|52 54|IIA
P01316903A0296|66 83|phosphorylated form
P01316903A0296|96 98|IIO
P01316903A0296|96 98|IIO
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|30 61|transcriptionally active complexes
P01316903A1040|97 112|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|0 11|Fructokinase
P01317376A0981|45 45|Z
P01317376A0981|81 87|glucose
P01317376A0981|119 131|frk mRNA levels
P01317376A0981|119 125|frk mRNA
P01318310A0000|6 14|membranes
P01318310A0000|17 29|cultured cells
P01318310A0000|61 82|high density lipoprotein
P01318310A0000|61 82|high density lipoprotein
P01318310A0000|84 86|HDL
P01318310A0000|84 86|HDL
P01318310A0000|135 145|cholesterol
P01318739A0410|15 22|patients
P01318739A0410|47 56|teniposide
P01318739A0410|58 62|VM-26
P01320255A0795|34 45|short element
P01320255A0795|74 83|L1 sequence
P01320255A0795|74 83|L1 sequence
P01320255A0795|90 109|nuclear factor binding
P01320255A0795|90 102|nuclear factor
P01320255A0795|158 164|human L1
P01320255A0795|158 164|human L1
P01320640A0336|0 9|Tumor cells
P01320640A0336|38 59|neuron-specific enolase
P01320640A0336|38 59|neuron-specific enolase
P01320640A0336|61 67|insulin
P01320640A0336|61 67|insulin
P01320640A0336|69 76|glucagon
P01320640A0336|69 76|glucagon
P01320640A0336|80 82|VIP
P01320640A0336|80 82|VIP
P01321277A0342|17 21|5' end
P01321277A0342|26 28|src
P01321277A0342|26 28|src
P01321277A0342|33 37|3' end
P01321277A0342|42 44|ros
P01321277A0342|52 54|SRC
P01321277A0342|52 54|SRC
P01321277A0342|56 58|ROS
P01321277A0342|56 58|ROS
P01321277A0342|78 94|embryo fibroblasts
P01321277A0342|96 98|CEF
P01321277A0342|103 124|spindle shape morphology
P01321277A0342|141 143|UR2
P01321277A0342|141 143|UR2
P01321277A0664|0 2|ROS
P01321277A0664|0 2|ROS
P01321277A0664|4 6|SRC
P01321277A0664|4 6|SRC
P01321277A0664|8 8|R
P01321277A0664|8 8|R
P01321277A0664|22 39|amino-acid deletion
P01321277A0664|55 60|3' half
P01321277A0664|66 84|transmembrane domain
P01321277A0664|87 89|ros
P01321280A0494|31 32|E6
P01321280A0494|31 32|E6
P01321280A0494|36 49|E7 gene products
P01321280A0494|36 49|E7 gene products
P01321280A0494|61 82|BPV-1-transformed cells
P01321280A0494|61 65|BPV-1
P01321280A0494|95 124|immunoprecipitation experiments
P01321280A0494|129 136|antisera
P01321280A0494|145 155|bacterially
P01321280A0494|165 171|BPV-1 E6
P01321280A0494|165 169|BPV-1
P01321280A0494|170 171|E6
P01321280A0494|175 190|E7 fusion proteins
P01321280A0494|175 176|E7
P01321332A0970|0 26|Transient transfection assays
P01321332A0970|69 100|RXR alpha-mediated transactivation
P01321332A0970|69 76|RXR alpha
P01321332A0970|106 127|apoAI gene basal promoter
P01321332A0970|106 127|apoAI gene basal promoter
P01321332A0970|130 152|human hepatoma HepG2 cells
P01321332A0970|168 169|RA
P01321332A0970|181 195|transactivation
P01321332A0970|228 245|cotransfected ARP-1
P01321332A0970|241 245|ARP-1
P01321336A0000|3 16|enhancer region
P01321336A0000|19 40|Akv murine leukemia virus
P01321336A0000|65 72|ACAGATGG
P01321336A0731|3 16|splice variants
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|53 66|72-bp insertion
P01321336A0731|77 92|putative proteins
P01321336A0731|101 113|706 amino acids
P01321337A0318|101 106|45Ca2+
P01321337A0318|134 153|regulatory (B) subunit
P01321337A0318|156 175|mammalian calcineurin
P01321337A0318|165 175|calcineurin
P01321337A0318|218 234|bovine calcineurin
P01321337A0318|224 234|calcineurin
P01321337A1161|26 37|MATa cna1 cna2
P01321337A1161|26 29|MATa
P01321337A1161|30 33|cna1
P01321337A1161|34 37|cna2
P01321337A1161|38 50|double mutants
P01321337A1161|52 59|MATa cnb1
P01321337A1161|52 55|MATa
P01321337A1161|56 66|cnb1 mutants
P01321337A1161|107 138|alpha-factor-induced growth arrest
P01321337A1161|107 118|alpha-factor
P01324172A0880|0 9|Antibodies
P01324172A0880|44 47|RIM1
P01324172A0880|44 47|RIM1
P01324172A0880|50 61|mitochondria
P01324385A0329|8 20|IgG antibodies
P01324385A0329|8 20|IgG antibodies
P01324385A0329|23 27|HHV-6
P01324385A0329|23 27|HHV-6
P01324385A0329|29 38|anti-HHV-6
P01324385A0329|34 42|HHV-6-IgG
P01324385A0329|40 42|IgG
P01324385A0329|60 85|indirect immunofluorescence
P01324385A0329|98 126|seronegative and 71 seropositive
P01324385A0329|130 134|HIV-1
P01324385A0329|130 134|HIV-1
P01324385A0329|150 156|stage II
P01324385A0329|164 168|IV-C1
P01324385A0329|171 173|CDC
P01324385A0329|171 173|CDC
P01324385A0329|188 202|healthy subjects
P01324404A0813|1 30|position-independent activation
P01324404A0813|51 74|conserved regions II and III
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A0813|114 129|HNF-3 beta protein
P01324404A1208|0 31|HNF-3 beta amino-terminal sequences
P01324404A1208|0 4|HNF-3
P01324404A1208|9 31|amino-terminal sequences
P01324404A1208|75 89|transactivation
P01324404A1208|139 156|region II-III domain
P01324406A1250|15 18|RAD5
P01324406A1250|19 52|putative ATPase/DNA helicase activity
P01324406A1250|27 44|ATPase/DNA helicase
P01324406A1250|55 63|DNA repair
P01324406A1250|114 138|simple repetitive sequences
P01324639T0000|0 15|Susceptibilities
P01324639T0000|30 49|gram-negative bacilli
P01324639T0000|64 83|amoxicillin-BRL 42715
P01324639T0000|85 107|amoxicillin-clavulanate
P01325221A0870|0 15|Nocodazole arrest
P01325221A0870|18 27|DU249 cells
P01325221A0870|59 84|M-phase-activated MBP kinase
P01325221A0870|59 84|M-phase-activated MBP kinase
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|118 123|phenyl
P01325221A0870|125 146|Superose chromatography
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|3 8|hit1-1
P01325386A0766|44 64|74-kD heat shock protein
P01325386A0766|44 64|74-kD heat shock protein
P01326329A0703|3 19|319 base pair region
P01326329A0703|44 50|CAP site
P01326329A0703|44 50|CAP site
P01326329A0703|86 92|TATA box
P01326329A0703|127 133|GC boxes
P01326329A0703|135 139|CACCC
P01326329A0703|146 155|CCAAT boxes
P01326329A0703|146 155|CCAAT boxes
P01326329A0703|157 173|activator protein 2
P01326329A0703|157 173|activator protein 2
P01326329A0703|175 184|Ap-2) sites
P01326329A0703|175 184|Ap-2) sites
P01326329A0703|193 222|glucocorticoid response elements
P01326329A0703|193 222|glucocorticoid response elements
P01326329A0703|224 227|GREs
P01326329A0703|224 227|GREs
P01326329A0703|240 264|cyclic AMP response elements
P01326329A0703|240 264|cyclic AMP response elements
P01326329A0703|266 269|CREs
P01326329A0703|266 269|CREs
P01326557T0000|63 91|aggregating chondroitin sulfate
P01326557T0000|106 110|brain
P01327280A0000|2 5|rats
P01327280A0000|47 61|extracellular pH
P01327280A0000|69 88|spinal cord dorsal horn
P01327280A0000|105 106|pH
P01327280A0000|110 134|K+ ion-selective electrodes
P01327758A0000|13 34|bovine papillomavirus-1
P01327758A0000|13 34|bovine papillomavirus-1
P01327758A0000|36 40|BPV-1
P01327758A0000|36 40|BPV-1
P01327758A0000|56 72|viral gene products
P01327758A0000|56 72|viral gene products
P01327758A0000|77 85|E1 protein
P01327758A0000|77 85|E1 protein
P01327758A0000|92 111|full-length E2 protein
P01327758A0000|103 111|E2 protein
P01327967A0668|0 22|Insertional inactivation
P01327967A0668|25 27|sms
P01327967A0668|58 72|alkylating agent
P01327967A0668|73 94|methylmethane sulfonate
P01327967A0668|119 124|serine
P01327967A0668|132 142|metabolites
P01328197A0985|27 54|MAP kinase activator/MAP kinase
P01328197A0985|27 44|MAP kinase activator
P01328197A0985|46 54|MAP kinase
P01328197A0985|91 119|ras signal transduction pathways
P01328197A0985|91 93|ras
P01328219A1397|0 5|NSCL-1
P01328219A1397|0 5|NSCL-1
P01328219A1397|39 47|cell lines
P01328681A0149|6 24|LTR-binding proteins
P01328681A0149|6 24|LTR-binding proteins
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|47 51|c-myc
P01328681A0149|77 101|LTR-enhanced transcription
P01328681A0149|120 138|LTR-binding proteins
P01328681A0149|120 138|LTR-binding proteins
P01328681A0149|180 195|protein synthesis
P01328681A0348|0 6|Ruddell
P01328854T0000|7 15|MEF-2 site
P01328854T0000|7 15|MEF-2 site
P01328854T0000|24 48|positive regulatory element
P01328854T0000|78 83|muscle
P01328854T0000|105 135|human phosphoglycerate mutase gene
P01328854T0000|105 135|human phosphoglycerate mutase gene
P01328854T0000|138 166|skeletal and cardiac muscle cells
P01328884T0000|40 58|MHC class II molecules
P01328884T0000|40 58|MHC class II molecules
P01329039A0239|11 24|E-box consensus
P01329039A0239|11 15|E-box
P01329039A0239|45 50|CANNTG
P01329039A0239|63 73|nucleotides
P01329039A0239|86 92|E-boxes
P01329039A0239|86 92|E-boxes
P01329039A0239|126 137|bHLH proteins
P01329039A0239|126 137|bHLH proteins
P01329039A0951|0 17|Intermediate levels
P01329039A0951|20 31|gene activity
P01329039A0951|47 58|TnI enhancers
P01329039A0951|47 58|TnI enhancers
P01329039A0951|69 75|E-boxes
P01329039A0951|90 105|MCK left E-box site
P01329039A0951|90 105|MCK left E-box site
P01329039A0951|115 128|Ig kappa E2 E-box
P01329039A0951|115 128|Ig kappa E2 E-box
P01330077A0000|0 44|T-cell receptor beta (TCR beta) gene rearrangements
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|19 30|TCR beta) gene
P01330077A0000|60 97|early B-cell acute lymphoblastic leukemias
P01330077A0000|99 102|ALLs
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|30 33|MyoD
P01330309A1134|30 33|MyoD
P01330309A1134|37 58|myogenin fusion proteins
P01330309A1134|37 58|myogenin fusion proteins
P01330309A1134|86 100|nuclear extracts
P01330309A1134|105 120|cultured myotubes
P01330975T0000|0 23|Peripheral polyneuropathy
P01330975T0000|38 52|multiple myeloma
P01331057A0000|24 28|COX12
P01331057A0000|24 28|COX12
P01331057A0000|33 56|nuclear gene for subunit VIb
P01331057A0000|33 43|nuclear gene
P01331057A0000|59 99|Saccharomyces cerevisiae cytochrome c oxidase
P01331057A0000|59 81|Saccharomyces cerevisiae
P01331057A0000|82 99|cytochrome c oxidase
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|63 85|genomic and cDNA sequences
P01331086T0000|3 23|basal promoter elements
P01331086T0000|26 62|murine cytochrome c oxidase subunit IV gene
P01331086T0000|32 49|cytochrome c oxidase
P01331086T0000|90 98|ets motifs
P01331086T0000|90 98|ets motifs
P01331086T0000|109 140|GABP-related transcription factors
P01331086T0000|109 140|GABP-related transcription factors
P01331292A1425|39 43|short
P01331292A1425|44 58|oligonucleotide
P01331292A1425|59 71|direct repeats
P01331292A1425|109 121|vaccinia virus
P01331501A0397|14 35|short synthetic peptides
P01331501A0397|49 68|pRB-binding sequences
P01331501A0397|49 68|pRB-binding sequences
P01331501A0397|71 73|E1A
P01331501A0397|71 73|E1A
P01331501A0397|105 108|p107
P01331501A0397|105 108|p107
P01331501A0397|110 116|cyclin A
P01331501A0397|110 116|cyclin A
P01331501A0397|121 124|p130
P01331501A0397|121 124|p130
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01331516A0103|75 88|wild-type virus
P01331516A0103|75 88|wild-type virus
P01331516A0103|115 125|C2 myoblasts
P01332589A0666|3 6|MICs
P01332589A0666|57 85|methicillin-resistant S. aureus
P01332964A0247|3 17|minimal promoter
P01332964A0247|23 33|RII beta gene
P01332964A0247|23 29|RII beta
P01332964A0247|58 75|functional elements
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|10 28|cAMP receptor protein
P01333035T0000|45 56|alpha subunit
P01333035T0000|45 56|alpha subunit
P01333035T0000|59 86|Escherichia coli RNA polymerase
P01333035T0000|59 73|Escherichia coli
P01333035T0000|74 86|RNA polymerase
P01333047A0404|14 34|epidermal growth factor
P01333047A0404|14 34|epidermal growth factor
P01333047A0404|37 64|platelet-derived growth factor
P01333047A0404|37 64|platelet-derived growth factor
P01333047A0404|78 101|intact human or murine cells
P01333047A0404|109 123|phosphorylation
P01333047A0404|126 135|Nck protein
P01333047A0404|126 135|Nck protein
P01333047A0404|138 145|tyrosine
P01333047A0404|147 152|serine
P01333047A0404|157 173|threonine residues
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|22 43|steroid hydroxylase gene
P01333053A0110|73 85|adrenal cortex
P01333053A0110|97 119|pituitary peptide hormone
P01333053A0110|97 119|pituitary peptide hormone
P01333053A0110|121 124|ACTH
P01333053A0110|121 124|ACTH
P01333053A0110|138 141|cAMP
P01333125A0000|25 40|sequence analysis
P01333125A0000|44 63|thermodynamic methods
P01333125A0000|88 112|tertiary structure elements
P01333125A0000|118 137|5' untranslated region
P01333125A0000|139 141|UTR
P01333125A0000|145 162|human enteroviruses
P01333125A0000|166 177|rhinoviruses
P01333317A1008|3 15|-64/-37 region
P01333317A1008|38 40|Sp1
P01333317A1008|38 40|Sp1
P01333317A1008|46 64|unidentified protein
P01333317A1008|66 92|s), proximal regulatory factor
P01333317A1008|69 92|proximal regulatory factor
P01333317A1008|94 96|s) I
P01333317A1008|98 102|PRF-I
P01333317A1008|98 102|PRF-I
P01334428A1102|0 1|Km
P01334428A1102|26 43|src-related peptide
P01334428A1102|26 43|src-related peptide
P01334428A1102|47 50|poly
P01334428A1102|52 54|Glu
P01334428A1102|56 58|Tyr
P01334493A0289|4 14|soluble form
P01334493A0289|20 29|HGFr (sHGFr
P01334493A0289|20 23|HGFr
P01334493A0289|25 29|sHGFr
P01334493A0289|36 38|HGF
P01334493A0289|36 38|HGF
P01334493A0289|45 52|affinity
P01334493A0289|81 107|membrane-associated receptor
P01334518T0000|0 9|Strategies
P01334518T0000|33 47|hepatitis C virus
P01334518T0000|57 82|human immunodeficiency virus
P01337142A2043|8 45|human glycoprotein alpha-subunit promoter
P01337142A2043|8 45|human glycoprotein alpha-subunit promoter
P01337142A2043|65 67|FSK
P01337142A2043|65 67|FSK
P01337142A2043|70 89|GH4 rat pituitary cells
P01338867A0503|40 55|chronic treatment
P01338867A0503|103 117|chronic blockade
P01339125A0153|0 16|Laboratory studies
P01339125A0153|22 37|Ca45 labeled teeth
P01339125A0153|114 124|bleach teeth
P01339373T0000|33 51|Arabidopsis thaliana
P01339373T0000|77 93|SNF1 protein kinase
P01339373T0000|77 93|SNF1 protein kinase
P01339391A0000|56 60|HRAS1
P01339468A0272|3 6|ORF1
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|79 101|ORF2, -3, -5 and -6 proteins
P01339468A0272|79 82|ORF2
P01339468A0272|84 93|-3, -5 and -6
P01339468A0272|127 164|potex- and/or carlavirus-encoded proteins
P01339773A0000|11 18|patients
P01339773A0000|118 134|blood-gas analysis
P01339773A0778|49 51|CO2
P01339815A1545|31 33|VO2
P01339815A1545|56 61|3 tests
P01340470A0000|2 23|RNA-binding protein gene
P01340470A0000|2 23|RNA-binding protein gene
P01340470A0000|25 28|rbp1
P01340470A0000|25 28|rbp1
P01340470A0000|34 55|Drosophila melanogaster
P01340470A0000|67 85|RNA recognition motif
P01340470A0000|67 85|RNA recognition motif
P01340470A0000|91 111|Arg-Ser rich (RS) domain
P01340470A0000|103 111|RS) domain
P01341119A0450|40 45|tumors
P01341119A0450|70 81|H2 inhibitors
P01341119A0450|70 71|H2
P01346262A0377|44 53|wild-type S
P01346262A0377|44 52|wild-type
P01346262A0377|53 65|S. entomophila
P01346262A0377|66 68|UC9
P01346262A0377|72 81|mutant UC21
P01346262A0377|97 102|mutant
P01346534T0000|21 27|regulon
P01346534T0000|43 77|leucine-responsive regulatory protein
P01346534T0000|43 77|leucine-responsive regulatory protein
P01346534T0000|80 94|Escherichia coli
P01347476T0000|12 60|mouse ornithine decarboxylase-related sequence family
P01347476T0000|12 54|mouse ornithine decarboxylase-related sequence
P01347664A1026|4 11|mutation
P01347664A1026|50 56|CAD mRNA
P01347664A1026|50 56|CAD mRNA
P01347908T0000|25 47|dopaminergic stimulation
P01347908T0000|50 57|patients
P01347908T0000|62 79|Parkinson's disease
P01347944A0964|0 16|Mutational studies
P01347944A0964|37 68|homeodomain binding site II sequence
P01347944A0964|37 68|homeodomain binding site II sequence
P01348504A0757|8 30|pol alpha-primase complex
P01348504A0757|8 30|pol alpha-primase complex
P01348508A0313|17 25|positions
P01348508A0313|33 39|introns
P01348508A0313|91 121|transglutaminase-like activities
P01348508A0313|153 160|TGM1 gene
P01348508A0313|153 160|TGM1 gene
P01348508A0313|208 214|introns
P01348590A0000|45 61|malignant lymphoma
P01348590A0000|79 98|HIV-infected patients
P01348590A0000|110 120|HIV-disease
P01348590A0000|125 133|CD4 counts
P01348590A0000|125 127|CD4
P01348590A0000|166 185|antineoplastic agents
P01348590A0000|188 199|radiotherapy
P01348684A0000|0 0|1
P01349705T0000|9 15|dioxins
P01349705T0000|18 32|thyroid function
P01349705T0000|35 47|newborn babies
P01349837T0000|0 9|cDNA clones
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|40 91|Zea mays mitochondrial chaperonin HSP60 and gene expression
P01349837T0000|40 69|Zea mays mitochondrial chaperonin
P01349837T0000|70 81|HSP60 and gene
P01349837T0000|98 112|seed germination
P01349837T0000|116 124|heat shock
P01350780A0184|72 107|Escherichia coli gamma-glutamyl kinases
P01350780A0184|72 107|Escherichia coli gamma-glutamyl kinases
P01350932A1123|15 27|glycosylation
P01350932A1123|44 53|C-terminus
P01350932A1123|44 53|C-terminus
P01350932A1123|59 84|N-glycosylation sequon -Asn-
P01350932A1123|85 88|Cys-
P01350932A1123|89 92|Ser-
P01350932A1123|100 102|Cys
P01350932A1123|115 130|disulphide bridge
P01352113A0002|3 22|pulmonary toxic events
P01352113A0002|32 51|acute nitrogen dioxide
P01352113A0002|53 54|NO
P01352113A0002|81 83|rat
P01352113A0002|123 141|therapeutic measures
P01352113A0231|3 18|pulmonary effects
P01352113A0231|62 78|NO2 concentrations
P01352113A0231|88 90|125
P01353478T0000|13 17|H-2Eb
P01353478T0000|13 17|H-2Eb
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|47 66|A20/2J B cell lymphoma.
P01354506T0000|0 31|Gestational trophoblastic diseases
P01354506T0000|67 93|cytogenetics, histopathology
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|67 85|mutant glycoproteins
P01357190A0726|67 85|mutant glycoproteins
P01357190A0726|119 134|CD4-bearing cells
P01357190A0726|119 121|CD4
P01357528A0084|19 23|curli
P01357528A0084|48 60|amino terminus
P01357528A0084|63 68|SEF-17
P01357528A0084|63 68|SEF-17
P01357528A0084|89 92|thin
P01357528A0084|115 135|Salmonella enteritidis
P01357528A0084|147 148|3b
P01357528A0084|192 208|surface organelles
P01357528A0084|211 224|enterobacteria
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|33 41|H-2E beta k
P01358190A0654|33 41|H-2E beta k
P01358190A0654|62 95|recognition; alpha chain substitution
P01358592A0752|4 28|negative regulatory pathway
P01358592A0752|80 93|inducible state
P01358592A0752|99 119|ventroposterior region
P01358592A0752|125 130|embryo
P01358758A0000|3 15|distal portion
P01358758A0000|21 49|rat insulin I gene 5'-flanking DNA
P01358758A0000|21 23|rat
P01358758A0000|24 35|insulin I gene
P01358758A0000|36 49|5'-flanking DNA
P01358758A0000|61 76|sequence elements
P01358758A0000|81 98|Far and FLAT elements
P01358758A0000|149 189|beta-cell-specific transcriptional enhancer
P01358758A0000|149 189|beta-cell-specific transcriptional enhancer
P01358880A0251|10 26|amino acid sequence
P01358880A0251|52 88|human cellular transglutaminase sequence
P01358880A0251|57 88|cellular transglutaminase sequence
P01359588A0375|4 14|computation
P01359588A0375|46 52|locally
P01359588A0375|62 80|neuron-like elements
P01360180A0513|24 47|recombinant baculoviruses
P01360180A0513|59 73|wild-type kinase
P01360180A0513|59 73|wild-type kinase
P01360180A0513|88 99|recombinants
P01360180A0513|111 129|nonfunctional kinase
P01360180A0513|135 149|catalytic domain
P01360180A1568|27 42|P68 amino terminus
P01360180A1568|27 29|P68
P01360180A1568|82 86|dsRNA
P01360180A1568|109 131|dsRNA-binding properties
P01360294A0000|30 49|pregnant Chinese women
P01360294A0000|104 125|antithrombin III (AT III)
P01360294A0000|104 118|antithrombin III
P01360294A0000|120 124|AT III
P01363080A0710|0 11|Visual acuity
P01363080A0710|46 60|refractive error
P01363080A0710|69 80|sulfonamides
P01363080A0710|85 112|antifungal agent metronidazole
P01363080A0710|122 151|diuretics, and carbonic anhydrase
P01363080A0710|135 151|carbonic anhydrase
P01363166T0001|17 37|H2 receptor antagonists
P01363166T0001|17 26|H2 receptor
P01363166T0001|54 59|ulcers
P01364100A0377|12 17|21-mer
P01364100A0377|18 35|subrepeat structure
P01370281A0461|51 63|39-kDa protein
P01370446A0818|26 54|keratan sulfate attachment sites
P01371181A0688|13 20|plasmids
P01371181A0688|26 35|pLS1 family
P01371181A0688|37 41|pE194
P01371181A0688|43 49|pADB201
P01371181A0688|54 57|pLB4
P01371272A1167|0 11|Perturbation
P01371272A1167|14 22|dNTP pools
P01371272A1167|38 55|frameshift fidelity
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371272A1167|77 94|DNA polymerase alpha
P01371275T0000|0 21|Differential expression
P01371275T0000|27 28|"B
P01371275T0000|42 60|vacuolar H(+)-ATPase
P01371275T0000|42 60|vacuolar H(+)-ATPase
P01371275T0000|63 75|bovine tissues
P01371413A0742|14 23|hGCSFR gene
P01371413A0742|14 23|hGCSFR gene
P01371413A0742|51 70|Southern blot analysis
P01371413A0742|116 125|hybrid DNAs
P01371413A0742|134 145|radiolabeled
P01371413A0742|146 154|cDNA probe
P01371863A0000|31 64|differentially-regulated gene family
P01371863A0000|70 86|protozoan parasite
P01371863A0000|87 96|Leishmania
P01371863A0000|97 101|major
P01372365A1202|34 50|Cl- concentrations
P01372456A0426|0 7|Necrosis
P01372456A0426|22 31|TA infusion
P01372802A1481|23 24|C3
P01372802A1481|38 54|amino acid residues
P01372802A1481|107 108|C3
P01372802A1481|107 108|C3
P01372802A1481|109 119|(D) epitopes
P01372802A1481|110 110|D
P01372802A1481|138 154|erythrocyte-bound
P01372802A1481|155 165|C3 fragments
P01372802A1481|155 165|C3 fragments
P01372802A1481|272 273|C3
P01372802A1481|272 273|C3
P01372802A1481|274 284|(D) epitopes
P01372802A1481|275 275|D
P01372802A1481|321 322|C3
P01372802A1481|321 322|C3
P01372802A1481|343 364|physiological fragments
P01372900A0448|5 9|exons
P01372900A0448|30 35|exons 9
P01372900A0448|65 81|amino acid residues
P01372900A0448|91 112|alpha s1-casein variant A
P01372900A0448|91 97|alpha s1
P01372900A0448|105 112|variant A
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|101 134|polymerase chain reaction experiments
P01373374A0735|0 9|Homodimers
P01373374A0735|52 61|G-box motif
P01373374A0735|52 61|G-box motif
P01373374A0735|67 70|GBF1
P01373374A0735|67 70|GBF1
P01373374A0735|74 77|GBF3
P01373374A0735|74 77|GBF3
P01373374A0735|104 122|palindromic sequence
P01374331A0636|62 79|nuclease S1 analysis
P01374392A0341|3 20|hydrophobicity plot
P01374392A0341|23 27|NHE-3
P01374392A0341|23 27|NHE-3
P01374392A0341|49 53|NHE-1
P01374392A0341|49 53|NHE-1
P01374392A0341|57 61|NHE-2
P01374392A0341|57 61|NHE-2
P01374398A0951|40 43|cDNA
P01374398A0951|79 98|amino acid composition
P01374398A0951|103 114|glutamic acid
P01374398A0951|133 137|total
P01374398A0951|138 154|amino acid residues
P01374688A0471|64 69|plasma
P01375224A0152|41 45|v-Crk
P01375224A0152|41 45|v-Crk
P01375224A0152|71 77|chicken
P01375224A0152|78 94|embryo fibroblasts
P01375224A0152|121 136|cellular proteins
P01375224A0152|147 162|growth regulation
P01375913A0484|23 50|synthetic DNA oligonucleotides
P01375913A0484|53 64|U14 snRNA gene
P01375913A0484|53 64|U14 snRNA gene
P01375913A0484|94 120|T7 RNA polymerase promoter site
P01375913A0484|94 120|T7 RNA polymerase promoter site
P01375913A0484|141 147|plasmid
P01376319T0000|0 3|Gene
P01376319T0000|22 68|mouse cation-dependent mannose 6-phosphate receptor
P01376319T0000|22 42|mouse cation-dependent
P01376319T0000|43 49|mannose
P01376319T0000|50 60|6-phosphate
P01377696A0000|3 52|chick axon-associated surface glycoprotein neurofascin
P01377696A0000|42 52|neurofascin
P01377696A0000|107 137|antibody perturbation experiments
P01377764A0309|3 11|carcinoma
P01377764A0309|34 43|epithelium
P01377764A0309|53 64|mucosal layer
P01377764A0309|78 92|submucosal layer
P01377818A0468|11 19|C/EBP beta
P01377818A0468|11 19|C/EBP beta
P01377818A0468|23 32|C/EBP gamma
P01377818A0468|23 32|C/EBP gamma
P01377818A0468|79 88|C/EBP alpha
P01377818A0468|79 88|C/EBP alpha
P01377962A1012|11 21|tobacco GS-2
P01377962A1012|11 21|tobacco GS-2
P01378052A0594|7 10|acoR
P01378052A0594|7 10|acoR
P01378052A0594|14 20|acoXABC
P01378052A0594|14 20|acoXABC
P01378052A0594|77 84|CAC-(N11
P01378052A0594|87 94|N18)-GTG
P01378052A0594|98 105|TGT-(N10
P01378052A0594|108 115|N14)-ACA
P01378052A0594|153 156|NtrC
P01378052A0594|153 156|NtrC
P01378052A0594|160 189|NifA upstream activator sequences
P01378052A0594|160 189|NifA upstream activator sequences
P01378127A0841|23 39|calcium supplement
P01378127A0841|42 58|calcium antagonist
P01378127A0841|120 130|predictable
P01378431A0202|0 0|C
P01378431A0202|20 34|Vallejo-Ramirez
P01378506A0884|16 34|full-deletion mutant
P01378506A0884|16 34|full-deletion mutant
P01378506A0884|55 66|virus release
P01378506A0884|82 83|NC
P01378506A0884|82 83|NC
P01378506A0884|96 108|virus assembly
P01378526A0535|29 45|FK506 plasma levels
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379032A0495|94 101|steroids
P01379032A0495|112 121|prednisone
P01379150A0996|63 84|pharmacokinetic profile
P01379150A0996|113 123|class I drugs
P01379150A0996|126 133|patients
P01379150A0996|161 171|arrhythmias
P01380062A0097|0 7|T antigen
P01380062A0097|0 7|T antigen
P01380062A0097|20 79|H-2Db-restricted cytotoxic T lymphocyte (CTL) recognition epitopes
P01380062A0097|97 108|CTL clones Y-1
P01380062A0097|110 123|Y-2, Y-3, and Y-5
P01380062A0097|110 112|Y-2
P01380062A0097|114 116|Y-3
P01380076A0165|18 37|reversed-phase column
P01380076A0165|42 60|paired-ion technique
P01380076A0165|71 84|docusate sodium
P01380454A0451|24 37|protein product
P01380454A0451|43 51|ref-1 gene
P01380454A0451|43 51|ref-1 gene
P01380454A0451|65 82|DNA binding activity
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|85 91|Fos-Jun
P01380454A0451|105 121|Jun-Jun homodimers
P01380454A0451|105 121|Jun-Jun homodimers
P01380454A0451|125 144|Hela cell AP-1 proteins
P01380454A0451|125 128|Hela
P01380454A0451|133 144|AP-1 proteins
P01380454A0451|171 190|transcription factors
P01380454A0451|200 208|NF-kappa B
P01380454A0451|200 208|NF-kappa B
P01380454A0451|210 212|Myb
P01380454A0451|210 212|Myb
P01380454A0451|228 241|ATF/CREB family
P01380454A0451|228 230|ATF
P01380454A0451|232 235|CREB
P01380716A0174|3 15|pulpal tissues
P01380716A0174|30 45|mandibular molars
P01380716A0174|77 90|calcium hydrate
P01380825A0622|0 19|Northern blot analyses
P01380825A0622|35 56|3.9- and 5-kilobase mRNAs
P01380825A0622|75 78|cDNA
P01380825A0622|92 101|all tissues
P01380825A0622|153 164|housekeeping
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|3 5|ARG
P01383690A1023|6 14|SH2 domain
P01383690A1023|49 51|BCR
P01383690A1023|49 51|BCR
P01383690A1023|105 116|ABL SH2 domain
P01383690A1023|105 116|ABL SH2 domain
P01383695A0100|12 25|EBV B-cell clone
P01383695A0100|12 25|EBV B-cell clone
P01383695A0100|27 31|E29.1
P01383695A0100|27 31|E29.1
P01383695A0100|48 61|week-old embryo
P01383695A0100|79 98|IgM kappa and IgM lambda
P01383695A0100|79 98|IgM kappa and IgM lambda
P01384040A1043|18 27|activation
P01384040A1043|110 123|wild-type pCF10
P01384165A0000|2 5|rats
P01384165A0000|70 76|trachea
P01384165A0000|99 115|mucosal epithelium
P01384165A0000|140 159|free tracheal grafting
P01384229A0175|36 53|putative chicken ICS
P01384229A0175|44 53|chicken ICS
P01384229A0175|57 71|oligonucleotide
P01384229A0175|83 99|upstream sequences
P01384229A0175|105 113|BF-IV gene
P01384229A0175|105 113|BF-IV gene
P01384229A0175|115 123|-174/-194
P01384229A0175|167 182|herpes TK promoter
P01384229A0175|167 172|herpes
P01384229A0175|173 174|TK
P01384229A0175|197 237|chloramphenicol acetyl transferase (CAT) gene
P01384229A0175|197 228|chloramphenicol acetyl transferase
P01384229A0175|230 237|CAT) gene
P01384229A0175|239 245|pBLCAT2
P01384229A0175|239 245|pBLCAT2
P01385462A0151|43 61|chromatographic runs
P01385462A0151|85 119|gamma-aminobutyric acid determination
P01385462A0151|150 159|monoamines
P01386210A0293|26 49|electroconvulsive therapy
P01386210A0293|64 79|severe depression
P01386210A0293|88 90|man
P01386210A0293|95 102|adult GM2
P01386897A0000|0 4|Entry
P01386897A0000|7 16|yeast cells
P01386897A0000|24 39|mitotic cell cycle
P01386897A0000|41 45|Start
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|94 111|G1-specific cyclins
P01386897A0000|94 111|G1-specific cyclins
P01386897A0000|121 124|CLN1
P01386897A0000|121 124|CLN1
P01386897A0000|128 131|CLN2
P01386897A0000|128 131|CLN2
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|36 58|backcross and cogenic mice
P01387105A0933|60 83|recombinant inbred strains
P01387105A0933|88 105|somatic cell hybrids
P01387105A0933|135 159|cyclin B1-related sequences
P01387105A0933|135 159|cyclin B1-related sequences
P01387105A0933|171 183|loci Cycb1-rs1
P01387105A0933|175 194|Cycb1-rs1 to Cycb1-rs9
P01387105A0933|186 194|Cycb1-rs9
P01387105A0933|208 224|mouse chromosomes 5
P01387105A0933|228 231|17, 4
P01387105A0933|233 237|14, 13
P01387105A0933|241 241|X
P01388160A1102|5 11|residue
P01388160A1102|12 14|Glu
P01388160A1102|21 24|beta
P01388160A1102|68 81|epsilon peptide
P01388160A1102|106 120|peptide sequence
P01388160A1102|148 150|Ser
P01388160A1102|156 162|Ser-107
P01388160A1102|166 168|Ser
P01389362T0000|0 8|Porcelain
P01389362T0000|17 28|bond strength
P01389362T0000|34 47|dentin adhesive
P01389573A1071|0 3|TBPf
P01389573A1071|79 91|P1 - P2)/(A1 - A2
P01389573A1071|79 83|P1 - P2
P01389573A1071|87 91|A1 - A2
P01389585A0825|18 28|Scotchbond 2
P01389585A0825|32 51|Prisma Universal Bond 2
P01391001A0583|26 38|yeasts species
P01391001A0583|67 75|ATB method
P01391001A0583|87 105|conventional methods
P01392012A0228|3 29|neurohypophysial vasopressin
P01392012A0228|19 29|vasopressin
P01392012A0228|33 40|oxytocin
P01392012A0228|33 40|oxytocin
P01392012A0228|63 75|pressor effect
P01392012A0228|85 115|Dekanski or milk-ejection activity
P01392277A0000|0 7|Comments
P01392277A0000|57 61|water
P01392277A0000|64 76|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|141 153|Federal German
P01392277A0000|163 165|DIN
P01392358A0389|39 48|home visits
P01394200A0592|27 48|in vivo T-cell activation
P01394200A0592|124 136|subset markers
P01394200A0592|137 140|CD25
P01394200A0592|137 140|CD25
P01394200A0592|142 162|interleukin 2 receptor)
P01394200A0592|142 161|interleukin 2 receptor
P01394200A0592|166 185|CD45RO (T-memory cells
P01394200A0592|166 171|CD45RO
P01394200A0592|173 173|T
P01394655A0615b|0 13|Urease activity
P01394655A0615b|0 5|Urease
P01394655A0615b|34 50|ammonia production
P01394655A0615b|55 58|urea
P01394655A0615b|101 118|Jack bean meal urease
P01394655A0615b|101 118|Jack bean meal urease
P01395755A1023|84 95|oxygen uptake
P01395755A1023|97 99|213
P01395755A1023|113 115|193
P01395755A1023|137 150|oxygen delivery
P01395755A1023|197 209|cardiac output
P01396432A0388|20 37|cognitive functions
P01396444A0934|72 73|AM
P01396444A0934|82 110|physiological activation states
P01396444A0934|118 135|phagocytic activity
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|81 85|pUC19
P01396572A0320|87 88|CG
P01396572A0320|107 111|dG-dC
P01396572A0320|126 131|Z-form
P01396572A0320|126 131|Z-form
P01396583A0204|1 11|cDNA library
P01396583A0204|14 24|tumour cells
P01396583A0204|42 71|interleukin 2 gene-specific probe
P01396583A0204|42 57|interleukin 2 gene
P01396592A1113|28 34|SCL gene
P01396592A1113|28 34|SCL gene
P01396592A1113|53 80|erythroid transcription factor
P01396592A1113|81 86|GATA-1
P01396592A1113|81 86|GATA-1
P01396592A1113|97 110|SCL gene product
P01396592A1113|97 110|SCL gene product
P01396592A1113|139 162|erythroid differentiation
P01396601A0986|14 27|lumenal domains
P01396601A0986|30 35|Sec12p
P01396601A0986|30 35|Sec12p
P01396601A0986|37 41|Stl1p
P01396601A0986|37 41|Stl1p
P01396601A0986|45 49|Stl2p
P01396601A0986|45 49|Stl2p
P01398068A0948|19 27|wild-type
P01398068A0948|37 56|his175 or his273 mutant
P01398068A0948|37 42|his175
P01398068A0948|45 59|his273 mutant p53
P01398068A0948|57 67|p53 proteins
P01398068A0948|98 111|RGC DNA sequence
P01398068A0948|98 111|RGC DNA sequence
P01398071A0526|5 40|temperature- and cold-sensitive strains
P01398071A0526|77 88|BRF1 activity
P01398071A0526|77 80|BRF1
P01398071A0526|105 127|transcriptional activity
P01398071A0526|130 154|RNA polymerases I, II, and III
P01398071A0526|130 144|RNA polymerases I
P01398073A0986|42 65|multisubunit TFIID protein
P01398073A0986|42 53|multisubunit
P01398073A0986|54 65|TFIID protein
P01398073A0986|74 99|transcriptional stimulation
P01398073A0986|134 150|TATA-less promoter
P01398074A0697|30 46|340-nucleotide RNA
P01398074A0697|54 58|yeast
P01398074A0697|59 61|RNA
P01398074A0697|75 100|RNase MRP enzyme preparations
P01398074A0697|75 88|RNase MRP enzyme
P01398074A1081|3 17|RNase MRP RNA gene
P01398074A1081|3 7|RNase
P01398074A1081|11 17|RNA gene
P01398074A1081|76 92|cellular viability
P01398074A1081|127 134|RNase MRP
P01398074A1081|127 134|RNase MRP
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398098A0770|28 31|mRNA
P01398098A0770|67 83|38-kDa polypeptide
P01398104A0834|17 21|CBF-A
P01398104A0834|17 21|CBF-A
P01398104A0834|30 36|CArG box
P01398104A0834|39 65|ssDNA- and RNA-binding protein
P01398104A0834|48 65|RNA-binding protein
P01398104A0834|86 106|transcriptional factor
P01398106A0754|13 32|intron-encoded enzyme
P01398106A0754|34 39|I-CreI
P01398106A0754|34 39|I-CreI
P01398106A0754|47 57|5 bp and 1 bp 3'
P01398106A0754|63 81|intron insertion site
P01398106A0754|88 94|3'-exon
P01398106A0754|101 125|top (/) and bottom (,) strands
P01398106A0754|183 194|3'-OH termini
P01398140A0488|16 28|Xenopus U7 gene
P01398140A0488|16 22|Xenopus
P01398140A0488|48 68|octamer-binding motifs
P01398140A0488|80 96|12 and 24 bp upstream
P01398140A0488|104 106|PSE
P01398140A0488|104 106|PSE
P01398140A0488|139 155|150-200 bp upstream
P01399206A0375|35 55|collagenase inhibitors
P01399206A0375|35 45|collagenase
P01399206A0375|78 93|blister formation
P01399206A0375|105 134|dystrophic epidermolysis bullosa
P01400217T0000|0 17|Mutational analysis
P01400217T0000|29 44|IncP alpha plasmid
P01400217T0000|58 68|traF and traG
P01400217T0000|58 61|traF
P01400217T0000|65 68|traG
P01400217T0000|85 88|traF
P01400217T0000|85 88|traF
P01400217T0000|91 106|phage sensitivity
P01400396A1265|3 10|promoter
P01400396A1265|35 47|phorbol esters
P01400396A1265|109 126|protein kinase C beta
P01400396A1265|109 126|protein kinase C beta
P01400401A0065|2 7|humans
P01400401A0065|9 15|four AMP
P01400401A0065|13 32|AMP deaminase variants
P01400401A0065|40 48|M (muscle)
P01400401A0065|40 47|M (muscle
P01400401A0065|50 57|L (liver)
P01400401A0065|52 56|liver
P01400401A0065|59 60|E1
P01400401A0065|59 60|E1
P01400401A0065|65 66|E2
P01400401A0065|68 78|erythrocyte
P01400401A0065|110 144|biochemical and immunological criteria
P01400401A0854|0 18|Western blot analyses
P01400401A0854|25 55|anti-E-specific immunoreactivity
P01400401A0854|25 30|anti-E
P01400401A0854|97 115|bacterial expression
P01400401A0854|119 136|truncated AMPD3 cDNA
P01400401A0854|119 136|truncated AMPD3 cDNA
P01400775A0435|27 49|endogenous N-methylation
P01400775A0435|95 99|brain
P01402647A0114|0 11|DR1 molecules
P01402647A0114|0 2|DR1
P01402647A0114|24 51|human lymphoblastoid cell lines
P01402647A0114|110 121|phage surface
P01403222A0391|65 85|maternal blood donation
P01403222A0391|89 111|intrauterine transfusion
P01403391T0000|0 16|Chronic hepatitis B
P01403391T0000|34 41|children
P01404401A0740|0 21|Behind the ATPase cluster
P01404401A0740|9 21|ATPase cluster
P01404401A0740|26 42|open reading frames
P01404401A0740|85 99|chloroplast gene
P01404401A0740|85 99|chloroplast gene
P01404612A0303|21 28|human Ads
P01404612A0303|53 55|HIV
P01404612A0303|63 79|microbial proteins
P01404612A0303|93 99|vaccine
P01406630A0545|92 121|homodimeric Rel-related proteins
P01406630A0545|103 121|Rel-related proteins
P01406630A0545|126 151|DNA-protein binding analysis
P01406630A0545|126 136|DNA-protein
P01406630A0545|157 176|selected DNA sequences
P01406630A0965|12 40|p50- or p65-selected kappa B motif
P01406630A0965|12 14|p50
P01406630A0965|18 40|p65-selected kappa B motif
P01406630A0965|139 167|heterodimeric NF-kappa B complex
P01406630A0965|139 160|heterodimeric NF-kappa B
P01406656A1075|9 19|cosmid clone
P01406656A1075|39 56|mouse alpha 1(I) gene
P01406656A1075|39 49|mouse alpha 1
P01406656A1075|51 56|I) gene
P01406656A1075|74 98|5'- and 4 kb of 3'-flanking DNA
P01406656A1075|129 139|fibroblasts
P01406656A1075|154 165|oncogenic ras
P01406656A1075|154 165|oncogenic ras
P01406677A0000|8 37|transcriptional control elements
P01406677A0000|52 76|muscle-specific expression
P01406677A0000|82 99|human myoglobin gene
P01406677A0000|82 99|human myoglobin gene
P01406677A0000|132 148|upstream sequences
P01406677A0000|150 176|nucleotide positions -373 to +7
P01406677A0000|190 213|transcriptional start site
P01406677A0000|224 244|firefly luciferase gene
P01406677A0000|224 244|firefly luciferase gene
P01406688A0898|34 44|rap1t allele
P01406688A0898|34 44|rap1t allele
P01406688A0898|54 69|nonsense mutation
P01406688A0898|98 116|amino acids 663 and 684
P01406703A1435|12 28|Y1 cell cDNA library
P01406703A1435|36 52|DNA-binding region
P01406703A1435|36 52|DNA-binding region
P01406703A1435|58 91|H-2RIIBP nuclear hormone receptor cDNA
P01406703A1435|58 91|H-2RIIBP nuclear hormone receptor cDNA
P01406703A1435|104 107|cDNA
P01406703A1435|136 153|steroidogenic cells
P01407286A0427|0 6|Autopsy
P01407286A0427|36 52|transplanted cells
P01407286A0427|79 83|brain
P01407286A0427|117 142|immunocytochemical reaction
P01407286A0427|146 164|tyrosine hydroxylase
P01407286A0427|146 164|tyrosine hydroxylase
P01408090A0572|17 19|TEE
P01408090A0572|46 61|coronary arteries
P01408137A0974|32 41|G+C content
P01408137A0974|102 105|mRNA
P01408137A0974|106 110|start
P01408137A0974|115 117|G+C
P01408219A0670|10 17|patients
P01408219A0670|43 62|lymph-adenopathy (PGL
P01408219A0670|67 75|nontender
P01408219A0670|77 93|nonenlarging nodes
P01408219A0670|95 112|pathologic analysis
P01408219A0670|121 139|lymphoid hyperplasia
P01408474A0531|0 12|PaO2 threshold
P01409581A0206|18 38|E26 virus-encoded v-ets
P01409581A0206|18 38|E26 virus-encoded v-ets
P01409581A0206|45 77|myeloid/B-cell-specific factor PU.1
P01409581A0206|45 73|myeloid/B-cell-specific factor
P01409581A0206|74 77|PU.1
P01409643A0618|7 16|lambda gt11
P01409643A0618|38 53|oligonucleotides
P01409643A0618|72 109|human immunodeficiency virus 1 TATA element
P01409643A0618|72 109|human immunodeficiency virus 1 TATA element
P01409643A0618|139 153|cellular protein
P01409643A0618|169 181|molecular mass
P01409643A0618|184 189|123 kDa
P01409643A0618|205 231|TATA element modulatory factor
P01409643A0618|205 215|TATA element
P01409643A0618|216 235|modulatory factor (TMF
P01409643A0618|233 235|TMF
P01410071T0000|13 21|melatonin
P01410071T0000|23 31|serotonin
P01410071T0000|33 40|cortisol
P01410071T0000|45 53|prolactin
P01410071T0000|45 53|prolactin
P01410071T0000|69 83|circadian rhythm
P01410071T0000|86 108|platelet serotonin uptake
P01413984A0737|2 7|couldn
P01413984A0737|27 27|n
P01413984A0737|30 46|FA supplementation
P01413984A0737|54 64|cholesterol
P01413984A0737|66 79|HDL cholesterol
P01413984A0737|66 79|HDL cholesterol
P01413984A0737|81 94|LDL cholesterol
P01413984A0737|81 83|LDL
P01413984A0737|84 94|cholesterol
P01413984A0737|96 100|apo A1
P01413984A0737|102 103|Lp
P01413984A0737|102 103|Lp
P01413984A0737|105 105|a
P01413984A0737|108 112|HbA1C
P01413984A0737|108 112|HbA1C
P01413984A0737|114 120|glucose
P01413984A0737|122 138|fibrinogen, factor
P01413984A0737|122 131|fibrinogen
P01413984A0737|133 142|factor VIII
P01413984A0737|139 142|VIII
P01413984A0737|144 158|antithrombin III
P01413984A0737|144 158|antithrombin III
P01413984A0737|160 188|plasminogen activator inhibitor
P01413984A0737|160 179|plasminogen activator
P01413984A0737|190 215|tissue plasminogen activator
P01413984A0737|196 215|plasminogen activator
P01413984A0737|219 250|von Willebrand factor concentration
P01413984A0737|219 237|von Willebrand factor
P01413984A0737|270 301|systolic or diastolic blood pressure
P01414219A0319|3 19|healthy volunteers
P01414219A0319|63 82|plasma concentrations
P01414219A0319|112 114|OXC
P01414219A0319|149 151|ERY
P01418272A1072|16 21|cutoff
P01418272A1072|39 41|CEA
P01418272A1072|39 41|CEA
P01418494T0000|0 13|Rolandic spikes
P01418494T0000|17 33|cognitive function
P01418542A0000|11 36|sodium 18 beta-glycyrrhetate
P01418542A0000|38 40|SGA
P01418542A0000|44 65|experimental arrhythmia
P01418834A0987|5 29|chronic hematocrit decrease
P01418834A0987|39 39|H
P01418834A0987|39 39|H
P01418834A0987|42 42|P
P01418834A0987|42 42|P
P01418834A0987|71 83|blood pressure
P01418860A0797|12 20|diltiazem
P01418860A0797|69 82|d-cis diltiazem
P01418860A0797|133 146|l-cis diltiazem
P01418860A0797|165 186|calcium channel blockade
P01419945A1386|0 11|Localization
P01419945A1386|38 42|nerve
P01419945A1386|108 115|axillary
P01420177A1065|20 24|Val33
P01420177A1065|28 30|Gly
P01420177A1065|34 38|Gly28
P01420177A1065|42 44|Ser
P01420177A1065|68 75|residues
P01420177A1065|81 94|protein kinases
P01420177A1065|81 94|protein kinases
P01420223T0000|32 52|latissimus dorsi muscle
P01420223T0000|56 66|fiber typing
P01420363A0818|3 14|TIMP(-59/ -53
P01420363A0818|3 6|TIMP
P01420363A0818|16 22|AP1 site
P01420363A0818|16 22|AP1 site
P01420363A0818|51 61|c-Fos/c-Jun
P01420363A0818|51 55|c-Fos
P01420363A0818|57 64|c-Jun AP1
P01420363A0818|62 64|AP1
P01420363A0818|120 136|nuclear AP1 factors
P01420363A0818|120 136|nuclear AP1 factors
P01420363A0818|142 153|consensus TRE
P01420363A0818|207 218|consensus TRE
P01420363T0000|13 15|AP1
P01420363T0000|13 15|AP1
P01420363T0000|19 34|PEA3 binding sites
P01420363T0000|19 22|PEA3
P01420363T0000|52 94|murine tissue inhibitor of metalloproteinases-1
P01420363T0000|52 94|murine tissue inhibitor of metalloproteinases-1
P01420363T0000|96 101|TIMP-1
P01420363T0000|96 101|TIMP-1
P01420579A0292|5 33|serum neutralizing (SN) antibody
P01420579A0292|5 21|serum neutralizing
P01420579A0292|23 24|SN
P01420579A0292|84 85|SN
P01420579A0292|105 114|intranasal
P01420579A0292|118 141|intramuscular vaccination
P01421145A1190|0 12|Fractionation
P01421145A1190|15 34|crude nuclear extracts
P01421145A1190|37 43|heparin
P01421145A1190|45 65|agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|79 84|PCAT-1
P01421145A1190|135 144|leaf tissue
P01421390T0000|18 79|recombinant human granulocyte-macrophage colony-stimulating factor
P01421390T0000|18 79|recombinant human granulocyte-macrophage colony-stimulating factor
P01421390T0000|85 104|total body irradiation
P01421390T0000|115 126|chemotherapy
P01421390T0000|131 165|autologous bone marrow transplantation
P01421390T0000|169 194|acute lymphoblastic leukemia
P01421390T0000|197 213|malignant lymphoma
P01421609A1067|24 27|DMVA
P01421609A1067|44 59|myocardial trauma
P01421609A1067|64 66|CPB
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|3 5|IgG
P01422265A0263|32 45|coeliac disease
P01422265A0263|69 83|healthy controls
P01422265A0263|85 88|IgG1
P01422265A0263|102 105|IgG2
P01422265A0263|102 105|IgG2
P01422265A0263|107 110|IgG3
P01422265A0263|107 110|IgG3
P01422265A0263|112 115|IgG4
P01422265A0263|112 115|IgG4
P01422265A0263|186 200|coeliac patients
P01423454A0309|13 16|ANCA
P01423454A0309|13 16|ANCA
P01423454A0309|81 95|renal vasculitis
P01423454A0309|167 192|immunosuppressive treatment
P01423738A0639|121 127|rhythms
P01424674A0000|0 20|Cicatricial pemphigoid
P01424674A0000|35 49|systemic disease
P01424674A0000|65 96|chronic conjunctival cicatrization
P01425653T0000|48 76|postexercise oxygen consumption
P01425653T0000|79 92|untrained women
P01425921A1286|38 53|amino acid changes
P01425921A1286|71 76|lysine
P01425921A1286|96 119|primate consensus sequence
P01425921A1286|161 164|V1J1
P01425921A1286|161 164|V1J1
P01426635A0496|3 15|in vivo profile
P01426635A0496|18 22|ZFH-2
P01426635A0496|18 22|ZFH-2
P01426635A0496|63 65|DDC
P01426635A0496|76 84|serotonin
P01426635A0496|88 95|dopamine
P01427034A0440|9 15|introns
P01427034A0440|33 53|ribosomal protein genes
P01427034A0440|33 53|ribosomal protein genes
P01427034A0440|90 97|S13 genes
P01427034A0440|90 97|S13 genes
P01427034A0440|162 168|introns
P01427457A0000|3 13|prospective
P01427457A0000|61 90|subcutaneously (SC) administered
P01427457A0000|107 113|heparin
P01427457A0000|116 126|intravenous
P01427457A0000|137 143|heparin
P01427457A0000|177 190|thrombosis (DVT
P01428490A0671|33 39|allergy
P01428490A0671|41 52|chronic cough
P01428490A0671|70 78|shortness
P01428490A0671|119 124|asthma
P01428490A0671|135 142|children
P01428490A0671|149 152|pets
P01428513A0440|45 51|persons
P01429596A1669|55 67|hemagglutinin
P01429596A1669|55 67|hemagglutinin
P01429596A1669|81 121|Limulus 18K agglutination-aggregation factor
P01429596A1669|81 87|Limulus
P01429596A1669|88 129|18K agglutination-aggregation factor (18K-LAF
P01429596A1669|123 129|18K-LAF
P01429624A0328|13 36|nonpermissive temperature
P01429624A0328|61 94|guanyl nucleotide-dependent activity
P01429624A0328|97 111|adenylylcyclase
P01429714A0730|0 3|Clin
P01429724A0664|22 43|minimal catalytic domain
P01429724A0664|46 50|Nmt1p
P01429724A0664|46 50|Nmt1p
P01429724A0664|67 71|Ile59
P01429724A0664|75 79|Phe96
P01429724A0664|83 88|Gly451
P01429724A0664|92 97|Leu455
P01429740A1065|26 49|mitochondrial presequence
P01429740A1065|92 97|exons I
P01429740A1065|105 106|IV
P01429740A1065|112 127|functional E2 gene
P01429740A1065|122 127|E2 gene
P01429768T0000|0 22|Human neutrophil response
P01429836A0457|12 23|microtubules
P01429836A0457|59 66|vacuolar
P01429836A0457|96 100|Vps1p
P01429836A0457|96 100|Vps1p
P01429836A0457|125 136|microtubules
P01429836A1205|13 17|Vps1p
P01429836A1205|13 17|Vps1p
P01429836A1205|34 50|GTP-binding domain
P01429836A1205|34 50|GTP-binding domain
P01429836A1205|65 72|vacuolar
P01429836A1205|89 102|wild-type cells
P01431380A0244|31 39|tick fauna
P01431380A0244|140 162|anti-SF group rickettsiae
P01431380A0244|140 146|anti-SF
P01431380A0244|164 167|SFGR
P01431380A0244|164 167|SFGR
P01431380A0244|179 182|mice
P01431380A0244|201 213|tick emulsions
P01431380A0244|225 243|rickettsiae reactive
P01431380A0244|253 256|sera
P01431380A0244|296 299|JSFR
P01431380A0244|296 299|JSFR
P01431380A0244|334 341|electron
P01431380A0244|369 372|SFGR
P01431380A0244|369 372|SFGR
P01431380A0244|423 427|ticks
P01431602A0229|3 14|second method
P01431602A0229|20 30|macro" assay
P01431602A0229|104 108|HClO4
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|21 43|transcriptional analysis
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 104|Spodoptera exigua nuclear polyhedrosis virus
P01432453T0000|0 9|Validation
P01432453T0000|12 27|automated systems
P01433391A0594|16 26|dark rearing
P01433391A0594|49 63|cortical neurons
P01433391A0594|113 120|normally
P01433502A1163|32 53|class I enhancer activity
P01433502A1163|32 45|class I enhancer
P01433502A1163|56 76|Ad12-transformed cells
P01433502A1163|119 143|an enhancer-specific factor
P01433502A1163|121 143|enhancer-specific factor
P01433524A0788|1 12|second domain
P01433524A0788|26 48|C-terminal 437 amino acids
P01433524A0788|51 53|IE1
P01433524A0788|51 53|IE1
P01433524A0788|81 101|DNA-binding activities
P01435698A0000|57 65|graft (AVG
P01435698A0000|77 88|prostacyclin
P01435698A0000|90 93|PGI2
P01435698A0000|114 123|harvesting
P01435698A0000|127 146|arterial implantation
P01436261A0145|0 25|Subcutaneous administration
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|31 42|somatostatin
P01436261A0145|52 61|octreotide
P01436261A0145|148 165|faecal incontinence
P01436261A0145|181 196|calcitonin levels
P01436261A0145|181 190|calcitonin
P01437562A0462|0 17|Anti-CRK antibodies
P01437562A0462|0 17|Anti-CRK antibodies
P01437562A0462|25 36|53kDa protein
P01437562A0462|49 61|C.fasciculata
P01437562A0462|100 117|nucleotide sequence
P01437562A0462|123 132|cloned gene
P01438287T0000|14 27|vaccinia vector
P01438287T0000|48 63|recombinant genes
P01438287T0000|48 63|recombinant genes
P01441818T0001|0 14|Interferon type I
P01441818T0001|0 14|Interferon type I
P01441818T0001|27 39|body reactions
P01443047A0773|79 84|Id-SCL
P01443047A0773|79 80|Id
P01443047A0773|82 94|SCL expression
P01443745T0000|0 21|Respiratory interaction
P01443745T0000|27 42|spinal anesthesia
P01443745T0000|58 66|midazolam
P01443748A1190|22 30|121 atm abs
P01443748A1190|107 112|reflex
P01443748A1190|117 136|involuntary movements
P01446132A0328|37 74|filter- or retrieval-related complication
P01446828A1088|3 10|5' region
P01446828A1088|13 16|ADH5
P01446828A1088|13 16|ADH5
P01446828A1088|25 45|consensus binding sites
P01446828A1088|52 84|transcriptional regulatory proteins
P01446828A1088|52 84|transcriptional regulatory proteins
P01446828A1088|86 88|Sp1
P01446828A1088|86 88|Sp1
P01446828A1088|90 92|AP2
P01446828A1088|90 92|AP2
P01446828A1088|94 98|LF-A1
P01446828A1088|94 98|LF-A1
P01446828A1088|100 103|NF-1
P01446828A1088|100 103|NF-1
P01446828A1088|105 109|NF-A2
P01446828A1088|105 109|NF-A2
P01446828A1088|114 118|NF-E1
P01446828A1088|114 118|NF-E1
P01447139A0208|0 0|V
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|33 46|serine protease
P01447189A1546|33 46|serine protease
P01447189A1546|85 92|granules
P01447189A1546|95 118|large granular lymphocytes
P01447189T0000|30 43|serine protease
P01447189T0000|30 43|serine protease
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|62 69|granules
P01447189T0000|73 100|rat natural killer cell leukemia
P01448107A0361|16 36|dominant GCN2 mutations
P01448107A0361|24 27|GCN2
P01448107A0361|61 74|GCN4 expression
P01448107A0361|61 64|GCN4
P01448107A0361|89 107|amino acid starvation
P01448806A0135|16 28|growth hormone
P01448806A0135|62 75|bone maturation
P01448917A0775|0 10|Comparisons
P01448917A0775|27 42|amino acid residue
P01448917A0775|47 65|sequence information
P01448917A0775|81 96|CPMV RNA 1 sequence
P01448917A0775|81 96|CPMV RNA 1 sequence
P01448917A0775|120 143|red clover mottle virus RNA 1
P01448917A0775|120 143|red clover mottle virus RNA 1
P01448917A0775|155 163|CPSMV RNA 1
P01448917A0775|155 163|CPSMV RNA 1
P01448917A0775|208 228|32K proteinase cofactor
P01448917A0775|208 210|32K
P01448917A0775|211 228|proteinase cofactor
P01448917A0775|230 248|58K presumed helicase
P01448917A0775|230 232|58K
P01448917A0775|250 268|VPg 5'-linked protein
P01448917A0775|250 268|VPg 5'-linked protein
P01448917A0775|274 288|genomic RNAs, 24K
P01448917A0775|286 298|24K proteinase
P01448917A0775|289 298|proteinase
P01448917A0775|303 323|87K presumed polymerase
P01448917A0775|303 305|87K
P01448917A0775|336 339|four
P01448917A0775|340 352|cleavage sites
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01448932T0000|0 8|Rice dwarf
P01448932T0000|29 41|S12 transcript
P01449183A0795|23 43|beta 2 transferrin assay
P01449183A0795|23 38|beta 2 transferrin
P01449183A0795|60 85|cerebrospinal fluid otorrhea
P01449301A0710|0 15|Cold cardioplegia
P01450815A0337|29 32|IPRK
P01450815A0337|69 71|RPF
P01450815A0337|75 77|GFR
P01451771A0619|114 116|PCA
P01451771A0619|121 151|multidimensional scaling analysis
P01451771A0619|153 155|MDS
P01451771A0619|203 207|wives
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|66 70|GAPDH
P01452037A0000|66 70|GAPDH
P01452037A0000|73 100|3-phosphoglycerate kinase (PGK
P01452037A0000|73 96|3-phosphoglycerate kinase
P01452037A0000|98 100|PGK
P01452037A0000|108 121|N-terminal part
P01452037A0000|124 147|triosephosphate isomerase
P01452037A0000|124 147|triosephosphate isomerase
P01452037A0000|149 151|TIM
P01452037A0000|149 151|TIM
P01452037A0000|157 184|mesophilic Bacillus megaterium
P01452037A0000|185 190|DSM319
P01452037A0000|208 218|gene cluster
P01452037A0000|208 218|gene cluster
P01452037A0000|220 228|gap operon
P01452037A0000|220 228|gap operon
P01452037A0000|251 280|Escherichia coli gap amber mutant.
P01452584T0000|0 29|Pseudomonas aeruginosa exotoxin A
P01452584T0000|0 20|Pseudomonas aeruginosa
P01452584T0000|53 64|wound healing
P01452703A0782|0 16|Laboratory studies
P01452703A0782|36 59|fluorescent-antibody kits
P01452703A0782|120 135|elementary bodies
P01452703A0782|151 159|ELISA kits
P01452703A0782|175 177|130
P01452703A0782|184 199|elementary bodies
P01454518A0336|97 118|Drosophila melanogaster
P01454518A0336|132 158|low stringency hybridizations
P01454518A0336|186 199|human ERCC3 cDNA
P01454518A0336|186 199|human ERCC3 cDNA
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|61 95|NAD:arginine ADP-ribosyltransferases
P01454819A0000|61 63|NAD
P01454819A0000|73 95|ADP-ribosyltransferases
P01454819A0000|97 106|EC 2.4.2.31
P01454819A0000|97 98|EC
P01454819A0000|111 139|ADP-ribosylarginine hydrolases
P01454819A0000|111 139|ADP-ribosylarginine hydrolases
P01454819A0000|141 150|EC 3.2.2.19
P01454819A0000|141 142|EC
P01454819A0000|165 181|opposing reactions
P01454819A0000|186 206|ADP-ribosylation cycle
P01456888A0074|58 92|HIV-1 group specific core antigen p55 gag
P01456888A0074|58 86|HIV-1 group specific core antigen
P01456888A0074|87 92|p55 gag
P01456888A0074|161 168|bacteria
P01456888A0074|170 194|vaccinia- and baculoviruses
P01456888A0074|227 240|core protein p55
P01456888A0074|227 240|core protein p55
P01456888A0074|281 308|myristylation consensus signal
P01457380A0000|3 11|tramtrack
P01457380A0000|3 11|tramtrack
P01457380A0000|13 20|ttk) gene
P01457380A0000|13 15|ttk
P01457380A0000|23 32|Drosophila
P01457380A0000|40 62|69-kDa and 88-kDa proteins
P01457380A0000|70 88|alternative splicing
P01457380A0000|94 113|primary ttk transcript
P01457380A0000|101 113|ttk transcript
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|9 27|beta 2-microglobulin
P01458170A0155|0 9|Adapromine
P01458170A0155|74 95|dominant theta-activity
P01458170A0155|115 117|EEG
P01458170A0155|123 128|cortex
P01458170A0155|132 140|hippocamp
P01458170A0155|158 174|rapid wave activity
P01458170A0155|180 189|beta 2 range
P01458170A0155|195 205|right cortex
P01458170A0155|209 217|hippocamp
P01459447A0484|36 51|full-length genes
P01459447A0484|36 51|full-length genes
P01459447A0484|57 75|yeast genomic library
P01459451A0478|0 8|GAL4-VP16
P01459451A0478|0 3|GAL4
P01459451A0478|5 8|VP16
P01459451A0478|42 56|auxiliary factor
P01459451A0478|114 130|Drosophila embryos
P01459885A0705|13 23|haloperidol
P01459885A0705|63 67|delta
P01459885A0705|93 98|alpha 1
P01459885A0705|93 98|alpha 1
P01459885A0705|114 121|fast beta
P01459921A0000|4 12|ruminally
P01459921A0000|16 51|duodenally cannulated Hampshire wethers
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|127 142|calcium linoleate
P01459921A0000|170 190|unsaturated fatty acids
P01459921A0000|196 203|2 + cis C18
P01460054A0478|9 13|ICSBP
P01460054A0478|9 13|ICSBP
P01460054A0478|31 54|amino-terminal amino acids
P01460054A0478|71 73|ICS
P01460054A0478|71 73|ICS
P01460054A0478|105 120|DNA binding domain
P01460054A0478|105 120|DNA binding domain
P01460054A0478|152 164|amino terminus
P01460054A0968|10 14|ICSBP
P01460054A0968|10 14|ICSBP
P01460054A0968|41 73|submaximal transcriptional activity
P01460054A0968|76 93|IFN-inducible genes
P01460054A0968|76 93|IFN-inducible genes
P01460054A0968|96 113|hematopoietic cells
P01460772T0001|7 23|chronic hepatitis C
P01460772T0001|28 48|primary hypothyroidism
P01460772T0001|65 83|interferon treatment
P01462786T0000|22 33|human control
P01462786T0000|36 49|complex systems
P01464329T0000|61 79|prophase chromosomes
P01464606A0344|19 37|alpha 5 beta 1 integrin
P01464606A0344|19 37|alpha 5 beta 1 integrin
P01464606A0344|66 79|chromatography
P01464606A0344|82 98|detergent extracts
P01464606A0344|102 146|fibronectin cell-binding fragment affinity column
P01464606A0344|102 132|fibronectin cell-binding fragment
P01464606A0344|161 164|EDTA
P01467088T0075|0 8|Abstracts
P01467828A0542|42 57|endogenous opioid
P01467828A0542|71 84|cardiac effects
P01467828A0542|90 122|myocardial ischaemia and reperfusion
P01467828A0542|134 148|opiate receptors
P01467828A0542|162 171|antagonism
P01468625A0282|8 14|library
P01468625A0282|16 19|LEU2
P01468625A0282|16 19|LEU2
P01468625A0282|23 31|HIS3 cDNAs
P01468625A0282|23 31|HIS3 cDNAs
P01468625A0282|112 136|galactose-dependent manner
P01468625A1080|11 14|ACT1
P01468625A1080|11 14|ACT1
P01468625A1080|39 42|NSR1
P01468625A1080|39 42|NSR1
P01469042A0355|5 14|CENP-B gene
P01469042A0355|5 14|CENP-B gene
P01469042A0355|28 43|mammalian species
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|96 98|DNA
P01469042A0355|100 113|minor satellite
P01469042A0355|137 158|DNA-protein interaction
P01469042A0355|137 147|DNA-protein
P01469047A1606|27 36|tail domain
P01469047A1606|41 51|1,094-1,830
P01469047A1606|62 78|amino acid sequence
P01469047A1606|92 104|723-aa protein
P01469047A1606|109 118|mouse brain
P01469047A1606|132 156|glutamic acid decarboxylase
P01469047A1606|132 156|glutamic acid decarboxylase
P01470243A0871|248 254|albumin
P01470243A0871|248 254|albumin
P01470243A0871|285 302|normovolaemic group
P01470741T0062|0 11|Distribution
P01471602A0362|30 49|bile acid sequestrants
P01471602A0362|51 63|nicotinic acid
P01471602A0362|65 75|fibric acids
P01471602A0362|77 139|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
P01471602A0362|77 111|3-hydroxy-3-methylglutaryl coenzyme A
P01471602A0362|113 129|HMG-CoA) reductase
P01471602A0362|144 151|probucol
P01473196A1016|46 59|renal clearance
P01473207A0582|33 40|placenta
P01473207A0582|61 70|hypoplasia
P01473234A1001|0 10|Green pepper
P01473234A1001|33 68|N-nitrosothiazolidine-carboxylic acid
P01473234A1001|88 99|ascorbic acid
P01474990A0000|14 18|pTt21
P01474990A0000|68 98|Trypanosoma cruzi trypomastigotes
P01474990A0000|137 150|genomic library
P01474990A0000|155 187|trypomastigote and epimastigote cDNA
P01476376T0000|0 4|Assay
P01476376T0000|7 10|urea
P01476376T0000|24 29|urease
P01476376T0000|40 59|differential pH-meter
P01477021A0394|13 20|AGA group
P01477021A0394|26 46|fetal and maternal serum
P01477021A0394|47 55|prolactin
P01477021A0394|47 55|prolactin
P01478672A0795|3 12|phage clone
P01478672A0795|37 53|alpha satellite DNA
P01478672A0795|63 86|low-copy repeated sequence
P01480183A0000|3 19|5'-flanking region
P01480183A0000|25 44|human lactoferrin gene
P01480183A0000|25 44|human lactoferrin gene
P01480183A0000|61 88|human placental genomic library
P01480183A1689|37 44|estrogen
P01480183A1689|64 78|lactoferrin gene
P01480183A1689|64 74|lactoferrin
P01480183A1689|102 106|mouse
P01480183A1689|110 114|human
P01480470A0323|0 5|BiP670
P01480470A0323|21 39|Ca2+ ionophore A23187
P01482912A0617|3 5|CEM
P01482912A0617|38 47|HL7 message
P01482912A0617|88 96|interface
P01482912A0617|102 119|relational database
P01483755A0000|0 47|Magnetic resonance spectroscopy (MRS) and imaging (MRI
P01483755A0000|130 135|muscle
P01483771A1335|22 23|NA
P01483771A1335|46 70|plasma epinephrine response
P01485648A0000|38 48|in vitro test
P01485648A0000|50 67|Pharmacia CAP System
P01485648A0000|69 90|Pharmacia Diagnostics AB
P01485648A0000|100 105|Sweden
P01485648A0000|139 168|allergen-specific IgE antibodies
P01485648A0000|156 168|IgE antibodies
P01485648A0000|185 188|RAST
P01485648A0000|200 207|patients
P01485648A0000|226 231|atopic
P01486836A0774|0 7|Patients
P01486836A0774|17 19|VPA
P01486836A0774|112 113|T1
P01486836A0774|140 141|T2
P01486836A0774|160 161|T3
P01486836A0774|197 198|T4
P01487144A0505|38 46|mu m poly(A
P01487144A0505|38 40|mu m
P01487144A0505|41 47|poly(A)
P01487144A0505|72 97|downstream flanking sequence
P01487144A0505|136 147|myeloma cells
P01487144A0505|151 166|L cell fibroblasts
P01490493A0416|39 54|serum cholesterol
P01490493A0416|39 43|serum
P01490493A0416|44 54|cholesterol
P01490493A0416|61 86|lipid and triglyceride levels
P01492463T0001|0 4|Alena
P01492463T0001|62 66|ocean
P01493864A0619|0 7|Dopamine
P01493864A0619|37 42|6-OHDA
P01493864A0619|75 83|GBR-12909
P01495069A0392|0 3|DIBA
P01495069A0392|92 95|DFAT
P01496348A0000|0 5|Caries
P01496348A0000|57 63|mankind
P01496784A0939|65 75|sudden death
P01497582A0593|19 27|disorders
P01497582A0593|30 38|pregnancy
P01497582A0593|58 67|infections
P01497582A0593|73 78|mother
P01497582A0593|116 121|embryo
P01497582A0593|127 134|placenta
P01498607A0000|4 38|short nucleotide sequences (boxes I to IV
P01498607A0000|79 109|parsley chalcone synthase promoter
P01498607A0000|79 109|parsley chalcone synthase promoter
P01499213A0185|36 38|man
P01499213A0185|141 145|L2-L3
P01499213A0185|150 154|space
P01499616A0136|3 15|mean blood flow
P01499616A0136|21 34|penile foreskin
P01499616A0136|107 116|anesthesia
P01499616A0136|159 180|parameatal foreskin flap
P01502157A0000|0 4|ME1a1
P01502157A0000|0 4|ME1a1
P01502157A0000|7 42|16-base-pair nuclear factor binding site
P01502157A0000|7 42|16-base-pair nuclear factor binding site
P01502157A0000|61 67|c-MYC P1
P01502157A0000|61 67|c-MYC P1
P01502157A0000|71 100|P2 transcription initiation sites
P01502157A0000|71 100|P2 transcription initiation sites
P01502157A0000|115 116|P2
P01502157A0000|115 116|P2
P01504178T0000|20 29|prevention
P01504178T0000|46 62|visionary, complex
P01504853A0299|9 12|LHRH
P01504853A0299|9 12|LHRH
P01504853A0299|36 49|mating behavior
P01505488A0231|22 29|patients
P01505488A0231|41 43|EVL
P01505516A0928|12 23|aspartic acid
P01505516A0928|29 34|lysine
P01505516A0928|47 53|alanine
P01505516A0928|56 61|valine
P01505516A0928|87 108|disulfide-linked dimers
P01506705A0282|6 8|V-A
P01506746A0476|0 13|Greater rupture
P01506746A0476|35 43|adult pigs
P01506746A0476|53 61|young pigs
P01509798A0520|6 8|AFF
P01509798A0520|33 34|UT
P01509798A0520|52 53|AT
P01509798A0520|62 64|UEA
P01511231A0085|98 111|placebo patches
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|78 93|isolated antibody
P01511950T0000|96 119|hepatitis B surface antigen
P01511950T0000|96 119|hepatitis B surface antigen
P01512259A0867|61 68|cysteine
P01512259A0867|104 110|Dfurin2
P01512259A0867|104 110|Dfurin2
P01512259A0867|132 145|mammalian furin
P01512259A0867|132 145|mammalian furin
P01512654A0503|22 44|phosphate buffered saline
P01512654A0503|61 62|ES
P01512654A0503|73 85|KLH challenges
P01512654A0503|91 92|ES
P01512654A0503|146 152|latency
P01512941A0000|29 56|fluoroquinolone, levofloxacin
P01512941A0000|58 61|LVFX
P01512941A0000|63 69|DR-3355
P01512941A0000|116 128|ciprofloxacin
P01512941A0000|130 133|CPFX
P01512941A0000|136 144|ofloxacin
P01512941A0000|146 149|OFLX
P01512941A0000|154 164|norfloxacin
P01512941A0000|166 169|NFLX
P01513213A0231|0 15|Model predictions
P01513213A0231|64 68|women
P01513213A0231|105 109|women
P01513213A0231|128 134|HIP data
P01516427T0000|0 32|High-resolution computed tomography
P01516427T0000|49 67|miliary tuberculosis
P01516829A0113|23 26|SNF2
P01516829A0113|23 26|SNF2
P01516829A0113|28 31|SNF5
P01516829A0113|28 31|SNF5
P01516829A0113|36 39|SNF6
P01516829A0113|36 39|SNF6
P01516829A0113|66 90|transcriptional activation
P01516829A0113|108 125|heteromeric complex
P01516829A0460|10 18|LexA-GAL4
P01516829A0460|10 13|LexA
P01516829A0460|15 18|GAL4
P01516829A0460|22 46|LexA-Bicoid fusion proteins
P01516829A0460|22 25|LexA
P01516829A0460|27 46|Bicoid fusion proteins
P01516829A0460|65 68|SNF2
P01516829A0460|65 68|SNF2
P01516829A0460|70 73|SNF5
P01516829A0460|70 73|SNF5
P01516829A0460|78 81|SNF6
P01516829A0460|78 81|SNF6
P01516829A0460|97 107|target genes
P01516829A0460|131 143|lexA operators
P01516829A0460|131 143|lexA operators
P01518833A0397|1 21|lambda gt10 cDNA library
P01518833A0397|40 50|poly(A)+ RNA
P01518833A0397|53 62|young green
P01518833A0397|71 77|spinach
P01518849A0165|0 1|NE
P01518849A0165|0 1|NE
P01518849A0165|5 7|PR3
P01518849A0165|5 7|PR3
P01518849A0165|32 43|phagocytosed
P01518849A0165|44 57|microorganisms
P01518849A0165|88 107|tissue protein elastin
P01518849A0165|120 140|chemotactic activities
P01518849A0165|143 184|forming alpha 1-proteinase inhibitor complexes
P01518849A0165|150 166|alpha 1-proteinase
P01518849A0165|188 202|elastin peptides
P01518849A0165|188 202|elastin peptides
P01518926T0000|8 13|topics
P01518926T0000|16 39|pediatric ultrasonography
P01522699A0092|29 34|recall
P01522699A0092|36 46|menu weights
P01522699A0092|51 64|recipe analysis
P01523111A0769|86 93|body mass
P01524549A0241|4 15|GH deficiency
P01524549A0241|4 5|GH
P01524549A0241|27 38|spinal growth
P01524549A0241|85 96|early puberty
P01524549A0241|114 125|GH deficiency
P01524549A0241|114 115|GH
P01524549A0241|152 160|GH therapy
P01524549A0241|152 153|GH
P01525153A0359|11 19|d(T2AG3T)
P01525153A0359|11 11|d
P01525153A0359|13 29|T2AG3T) and d(T2G4T
P01525153A0359|23 30|d(T2G4T)
P01525153A0359|42 70|G-quadruplex monomer structures
P01525153A0359|84 90|K cation
P01525966T0000|0 14|Differentiating
P01525966T0000|20 30|renal stones
P01526658A0454|0 8|IFI 16 mRNA
P01526658A0454|0 8|IFI 16 mRNA
P01526658A0454|46 58|lymphoid cells
P01526658A0454|82 94|T and B lineages
P01526690T0000|0 23|Mitochondria-lytic action
P01526690T0000|26 33|warfarin
P01526690T0000|36 46|lymphocytes
P01527020A0511|25 41|human and rat AdoMet
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01527020A0511|94 103|exons 6 and 7
P01527020A0511|109 117|human gene
P01527020A0511|109 117|human gene
P01527020A0511|131 134|exon
P01527020A0511|140 146|rat gene
P01527020A0511|140 146|rat gene
P01529530T0000|0 37|Interferon-alpha-induced gene expression
P01529530T0000|0 27|Interferon-alpha-induced gene
P01529530T0000|68 74|ouabain
P01529530T0000|92 116|ISGF3 transcription complex
P01529530T0000|92 116|ISGF3 transcription complex
P01531086A0127|3 6|cDNA
P01531086A0127|12 27|open reading frame
P01531086A0127|30 42|900 amino acids
P01531086A0127|61 73|97-kDa protein
P01531214A0885|9 12|LD50
P01531214A0885|21 26|RP-170
P01531214A0885|21 26|RP-170
P01531214A0885|39 40|v.
P01531214A0885|65 82|oral administration
P01531632A0000|24 42|eukaryotic nucleolus
P01531632A0000|82 90|nucleolin
P01531632A0000|82 90|nucleolin
P01531632A0000|92 102|fibrillarin
P01531632A0000|104 107|SSB1
P01531632A0000|104 107|SSB1
P01531632A0000|111 114|NSR1
P01531632A0000|111 114|NSR1
P01531632A0000|130 144|structural motif
P01531632A0000|149 157|GAR domain
P01531632A0000|149 157|GAR domain
P01531632A0000|172 197|glycine and arginine residues
P01532229A1264|41 56|ubiquitous factor
P01532229A1264|58 62|HF-1a
P01532229A1264|58 62|HF-1a
P01532229A1264|67 79|a muscle factor
P01532229A1264|68 79|muscle factor
P01532229A1264|81 91|HF-1b/MEF-2
P01532229A1264|81 85|HF-1b
P01532229A1264|87 91|MEF-2
P01532229A1264|107 130|E-box-independent pathway
P01532229A1264|107 111|E-box
P01532229A1264|134 158|muscle-specific expression
P01532229A1264|161 189|ventricular cardiac muscle cells
P01532796A0107|0 8|Mutations
P01532796A0107|57 58|F1
P01532796A0107|57 58|F1
P01532796A0107|70 89|alpha and beta subunits
P01532796A0107|70 89|alpha and beta subunits
P01532796A0107|104 115|mitochondria
P01532796A0107|118 135|inactive aggregates
P01532796A0107|137 144|Ackerman
P01532914A0067|21 38|hepatitis B vaccines
P01532914A0067|43 73|low-dose intradermal immunization
P01532914A0067|93 111|cost-saving strategy
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|35 46|breast cancer
P01533760T0000|60 72|meta-analyses
P01535242A0557|9 23|FDC-P1/MAC cells
P01535242A0557|28 33|growth
P01535242A0557|36 40|M-CSF
P01535242A0557|36 40|M-CSF
P01535242A0557|43 48|GM-CSF
P01535242A0557|43 48|GM-CSF
P01535242A0557|80 88|c-fms mRNA
P01535242A0557|80 88|c-fms mRNA
P01535242A0557|102 116|factor switching
P01536153A0574|56 81|chronic respiratory symptoms
P01536153A0574|89 94|animal
P01536153A0574|99 105|workers
P01536153A0574|121 137|negative skin tests
P01536153A0574|140 148|house dust
P01536153A0574|153 161|fish flour
P01536153A0574|195 197|IgE
P01536153A0574|195 197|IgE
P01536575A1213|43 52|-403 to -385
P01536575A1213|64 86|dioxin responsive element
P01536575A1213|152 172|cytochrome P450IA1 gene
P01536575A1213|152 161|cytochrome
P01536575A1213|162 168|P450IA1
P01536575A1213|174 179|CYPIA1
P01536575A1213|174 179|CYPIA1
P01536575A1213|204 228|detoxification/activation
P01536575A1213|241 260|aromatic hydrocarbons
P01537334A0507|15 19|TRP-2
P01537334A0507|15 19|TRP-2
P01537334A0507|26 42|mouse chromosome 14
P01537334A0507|60 82|coat colour mutation slaty
P01537334A0507|60 77|coat colour mutation
P01537845A0571|5 10|bovine
P01537845A0571|14 30|murine c-myb clones
P01537845A0571|14 24|murine c-myb
P01537845A0571|51 59|c-myb gene
P01537845A0571|51 59|c-myb gene
P01537845A0571|75 87|mRNA stability
P01537845A0571|108 116|cell cycle
P01538401A1244|1 26|13 base-pair oligonucleotide
P01538401A1244|35 53|nucleotides +80 to +92
P01538401A1244|59 67|5 S RNA gene
P01538401A1244|59 67|5 S RNA gene
P01538401A1244|87 106|high-affinity binding
P01538401A1244|158 169|DNA fragments
P01538403A1058|28 31|eUSF
P01538403A1058|28 31|eUSF
P01538403A1058|35 39|TFIID
P01538403A1058|35 39|TFIID
P01538403A1058|49 70|transcription complexes
P01538403A1058|121 125|TFIID
P01538403A1058|121 125|TFIID
P01538403A1058|133 136|eUSF
P01538403A1058|162 177|complex formation
P01538403A1058|184 202|H5 promoter mutations
P01538403A1058|184 202|H5 promoter mutations
P01538403A1058|213 220|TATA-box
P01538403A1058|213 220|TATA-box
P01539996A0588|16 32|amino acid sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|71 91|Escherichia coli enzyme
P01539996A0588|71 91|Escherichia coli enzyme
P01539996A0588|147 156|Ser residue
P01539996A0588|193 204|E. coli enzyme
P01539996A0588|193 204|E. coli enzyme
P01539996A0588|255 257|141
P01539996A0588|258 270|extra residues
P01539996A0588|276 284|C terminus
P01539996A0588|290 309|T. thermophilus enzyme
P01541556A1040|13 21|palmitate
P01541556A1040|47 60|mutated protein
P01541556A1040|47 60|mutated protein
P01541556A1040|73 89|lipid modification
P01541556A1040|101 113|Cys-22 residue
P01541577A0000|2 16|volunteer deaf Ss
P01541577A0000|35 43|volunteer
P01541577A0000|82 91|Scale (SHCS
P01541577A0000|95 100|Morgan
P01542565A0220|6 12|tobacco
P01542565A0220|13 22|L12 protein
P01542565A0220|29 45|amino acid identity
P01542565A0220|50 71|ribosomal protein L7/L12
P01542565A0220|50 65|ribosomal protein
P01542565A0220|66 67|L7
P01542565A0220|69 71|L12
P01542565A0220|74 88|Escherichia coli
P01542565T0000|0 44|Nuclear-encoded chloroplast ribosomal protein L12
P01542565T0000|0 41|Nuclear-encoded chloroplast ribosomal protein
P01542565T0000|42 44|L12
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|128 137|cDNA clones
P01542565T0000|149 168|cytoplasmic precursor
P01542667A0125|15 23|IFN-gamma
P01542667A0125|15 23|IFN-gamma
P01542667A0125|53 75|intronic enhancer element
P01542667A0125|156 177|IFN-gamma-encoding gene
P01542667A0125|156 177|IFN-gamma-encoding gene
P01542686A0000|0 15|Molecular cloning
P01542686A0000|46 84|Rel-related human p75 nucleoprotein complex
P01542686A0000|46 64|Rel-related human p75
P01542686A0000|65 84|nucleoprotein complex
P01542686A0000|114 131|65-kDa (p65) subunit
P01542686A0000|121 123|p65
P01542686A0000|134 142|NF-kappa B
P01542686A0000|134 142|NF-kappa B
P01542730A1982|7 20|single-chamber
P01542730A1982|55 61|patient
P01542730A1982|80 96|future development
P01542730A1982|99 100|AV
P01542730A1982|109 117|DDD pacing
P01542730A1982|185 201|dual-chamber (DDDR
P01542730A1982|247 254|patients
P01543909A0787|30 38|K562 cells
P01543909A0787|44 57|Lg genomic clone
P01543909A0787|60 78|actively transcribed
P01543909A0787|201 215|ferritin subunit
P01543909A0787|201 208|ferritin
P01544854A0699|10 27|orally administered
P01544854A0699|29 37|WR-168643
P01544854A0699|62 64|DMF
P01544918A1240|39 63|8-azido-cAMP photoaffinity
P01544918A1240|103 140|phosphorylation-dependent mobility shift
P01544918A1240|143 195|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P01544918A1240|197 204|SDS-PAGE
P01544918A1240|230 236|RII beta
P01544918A1240|230 236|RII beta
P01544918A1240|255 275|RII alpha dephosphoform
P01544918A1240|255 262|RII alpha
P01544918A1240|294 300|RI alpha
P01544918A1240|296 300|alpha
P01544928A1252|15 32|genomic DNA sequence
P01544928A1252|130 143|murine pre-mRNA
P01545523A0000|33 57|immunoserological testings
P01545523A0000|69 84|C reactive protein
P01545523A0000|69 84|C reactive protein
P01545523A0000|86 101|rheumatoid factor
P01545523A0000|105 121|antistreptolysin O
P01545523A0000|105 121|antistreptolysin O
P01545787A0345|9 21|human enhancer
P01545787A0345|9 21|human enhancer
P01545787A0345|72 87|DNase I footprints
P01545787A0345|72 77|DNase I
P01545787A0345|89 104|NFAT-1 and NFIL-2B
P01545787A0345|89 94|NFAT-1
P01545787A0345|98 104|NFIL-2B
P01545792A0000|3 27|cardiac myosin light chain-2
P01545792A0000|10 27|myosin light chain-2
P01545792A0000|29 46|MLC-2) gene promoter
P01545792A0000|29 46|MLC-2) gene promoter
P01545792A0000|62 99|positive and negative cis-acting sequences
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|87 108|MLC-2 gene transcription
P01545792A0492|87 95|MLC-2 gene
P01545797A0587|43 50|SLK1 gene
P01545797A0587|43 50|SLK1 gene
P01545797A0587|52 59|slk1 null
P01545797A0587|52 55|slk1
P01545806T0000|0 8|Molecular
P01545806T0000|32 72|yeast early meiotic recombination genes REC102
P01545806T0000|67 72|REC102
P01545806T0000|76 86|REC107/MER2
P01545806T0000|76 81|REC107
P01545806T0000|83 86|MER2
P01545818A0696|3 6|p130
P01545818A0696|3 6|p130
P01545818A0696|10 43|p62 tyrosine-phosphorylated proteins
P01545818A0696|10 43|p62 tyrosine-phosphorylated proteins
P01545818A0696|57 64|v-Src SH2
P01545818A0696|57 61|v-Src
P01545818A0696|62 64|SH2
P01545818A0696|90 94|v-Src
P01545818A0696|90 94|v-Src
P01545818A0696|97 101|v-src
P01545818A0696|97 101|v-src
P01545818A0696|114 123|Rat-2 cells
P01545818A0696|159 172|v-Src SH2 domain
P01545818A0696|159 172|v-Src SH2 domain
P01546522A0000|19 47|multifocal leukoencephalopathy
P01546522A0000|49 51|PML
P01546522A0000|49 51|PML
P01546522A0000|95 118|magnetic resonance imaging
P01546522A0000|133 135|man
P01546522A0000|161 181|non-Hodgkin's lymphoma
P01547775A1024|52 61|frameshift
P01547775A1024|122 144|RNA template-binding site
P01547775A1024|150 162|PLRV replicase
P01547775A1024|150 162|PLRV replicase
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547787A0548|0 19|Proprotein processing
P01547942A0120|1 14|32P-labeled LAP
P01547942A0120|15 53|DNA-binding and dimerization domain "zipper
P01547942A0120|97 119|C/EBP-homologous protein
P01547942A0120|97 119|C/EBP-homologous protein
P01547942A0120|121 127|CHOP-10
P01547942A0120|121 124|CHOP
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|41 45|oligo
P01547957A1083|57 76|N-terminal aa sequence
P01547957A1083|57 66|N-terminal
P01547957A1083|92 96|oligo
P01547957A1083|143 146|CYP1
P01547957A1083|143 146|CYP1
P01547957A1083|150 153|CYP2
P01547957A1083|150 153|CYP2
P01547957A1083|185 208|CYP3-specific DNA fragment
P01547957A1083|185 208|CYP3-specific DNA fragment
P01547957A1083|226 248|polymerase chain reaction
P01547957A1083|250 252|PCR
P01547957A1083|259 272|GL81 genomic DNA
P01548756A1102|0 21|Stringent hybridization
P01548756A1102|24 28|EHS-1
P01548756A1102|24 28|EHS-1
P01548756A1102|42 51|genomic DNA
P01548756A1102|72 80|EHS-1 loci
P01548756A1102|72 80|EHS-1 loci
P01548756A1102|109 119|band pattern
P01548756A1102|122 131|chimpanzee
P01548756A1102|132 134|DNA
P01548756A1102|140 150|single locus
P01548756A1102|153 164|rhesus monkey
P01548756A1102|165 167|DNA
P01548891A0635|10 44|carboxyl-terminal parathyroid hormone
P01548891A0635|50 57|patients
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|100 107|patients
P01548891A0635|115 130|thyroid carcinoma
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|53 92|sex-, stage-, and tissue-specific regulation
P01549118A0000|121 147|adult hermaphrodite intestine
P01549123A0480|3 10|MET4 gene
P01549123A0480|3 6|MET4
P01549123A0480|86 114|bZIP transcriptional activators
P01549123A0480|86 114|bZIP transcriptional activators
P01549125A0140|35 41|insulin
P01549125A0140|35 41|insulin
P01549125A0140|43 46|IAPP
P01549125A0140|43 46|IAPP
P01549125A0140|51 65|beta GK promoters
P01549125A0140|51 65|beta GK promoters
P01549125A0140|84 102|transient expression
P01549125A0140|106 121|DNA binding assays
P01549129A0356|60 74|protein-protein
P01549129A0356|121 123|Src
P01549129A0356|121 123|Src
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|24 45|transcription activator
P01549346A0000|69 71|DNA
P01549465A0122|8 33|transactivation experiments
P01549465A0122|83 85|Gly
P01549465A0122|87 89|Ser
P01549465A0122|93 95|Val
P01551176A0000|0 7|GR63178A
P01551176A0000|34 44|mitoquidone
P01551176A0000|47 71|pentacyclic pyrroloquinone
P01551568A1476|0 19|Marker rescue analysis
P01551568A1476|32 34|ts8
P01551568A1476|32 34|ts8
P01551568A1476|44 58|internal segment
P01551568A1476|61 64|rpoB
P01551568A1476|61 64|rpoB
P01551568A1476|79 87|Rif domain
P01551568A1476|79 87|Rif domain
P01551898A1084|28 32|yeast
P01551898A1084|33 55|Saccharomyces cerevisiae
P01551898A1084|116 125|LAPP/liter
P01551898A1084|128 140|culture medium
P01551910A0313|0 18|Competition analysis
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|69 90|DNA-protein interaction
P01551910A0313|69 79|DNA-protein
P01551910A0313|117 136|transcription factors
P01551910A0978|28 50|protein-binding sequence
P01551910A0978|28 50|protein-binding sequence
P01552052A0139|86 93|patients
P01552052A0139|98 106|psoriasis
P01552052A0139|128 139|cyclosporine
P01552457T0000|0 22|Intrapocket chemotherapy
P01552457T0000|30 42|periodontitis
P01552457T0000|70 94|insert containing ofloxacin
P01552457T0000|96 100|PT-01
P01552662A0398|0 23|Electromagnetic blood flow
P01552662A0398|25 32|BF) probe
P01552662A0398|48 51|left
P01552662A0398|52 59|anterior
P01552662A0398|60 79|descending artery (LAD
P01552853A1377|5 15|temperature
P01552853A1377|19 22|virF
P01552853A1377|19 22|virF
P01552853A1377|58 67|yop regulon
P01552853A1377|58 67|yop regulon
P01553407T0000|37 52|quantitative risk
P01554334A0000|20 57|gamma-interferon (IFN-gamma) assay system
P01554334A0000|20 35|gamma-interferon
P01554334A0000|37 45|IFN-gamma
P01554334A0000|81 92|tuberculosis
P01554334A0000|95 100|cattle
P01554334A0000|161 169|Australia
P01555556A0565|7 13|Tmuscle
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|13 25|aerogenes gene
P01556068A0000|26 29|maoA
P01556068A0000|62 77|monoamine oxidase
P01556068A0000|62 77|monoamine oxidase
P01556068A0000|91 98|tyramine
P01556068A0000|146 166|ammonium ion repression
P01556111A0241|25 31|plasmid
P01557217A0272|9 18|infectious
P01557217A0272|21 39|inflammatory lesions
P01557411A1282|8 19|human D1A gene
P01557411A1282|8 19|human D1A gene
P01557411A1282|42 71|tissue-specific, regulated genes
P01557411A1282|80 105|housekeeping-type promoters
P01559209T0000|0 12|Preceptorship
P01559209T0000|15 25|CNS students
P01559209T0000|29 44|exploratory study
P01560021A0379|53 59|cardiac
P01560021A0379|63 78|brain AE3 variants
P01560021A0379|63 67|brain
P01560021A0379|109 115|rat gene
P01560021A0379|109 115|rat gene
P01560774A0885|8 21|cloned fragment
P01560774A0885|60 67|fliA gene
P01560774A0885|60 67|fliA gene
P01562659A0676|0 10|Institution
P01562659A0676|17 27|intravenous
P01562659A0676|31 58|intracisternal administration
P01562659A0676|61 73|amphotericin B
P01562659A0676|123 135|dexamethasone
P01562659A0676|185 193|C. immitis
P01562659A0676|201 224|vasculitis or encephalitis
P01562659A0676|255 274|cultural confirmation
P01562659A0676|277 285|C. immitis
P01562659A0676|286 294|infection
P01562659A0676|307 309|CNS
P01563343A0548|0 11|Lac operators
P01563343A0548|55 88|CAB promoter and operator-free plasmid
P01563343A0548|55 65|CAB promoter
P01563635T0000|48 71|M.HinfI methyltransferase
P01563635T0000|50 71|HinfI methyltransferase
P01563635T0000|78 91|deletion mutant
P01564653A0307|33 36|lens
P01565093A0179|37 43|persons
P01565093A0179|85 88|BLLs
P01565093A0179|195 211|Public Health (ADPH
P01565882A0737|23 38|perfusion defects
P01565882A0737|46 47|Ex
P01565882A0737|49 62|RD and ReI images
P01565882A0737|93 97|Type I
P01565882A0737|119 125|RD image
P01565882A0737|140 147|ReI image
P01565882A0737|153 157|Type I
P01565882A0737|206 207|Ex
P01565882A0737|239 240|Ib
P01565882A0737|251 257|RD image
P01566576A0605|0 3|Keck
P01567649A0139|18 24|infants
P01567649A0139|32 56|periventricular hemorrhage
P01567649A0139|77 83|spastic
P01567649A0139|84 96|cerebral palsy
P01568960A1129|24 47|elevated alveolar pressure
P01568960A1129|95 107|corner vessels
P01568960A1129|126 136|VA/Q regions
P01569015A0120|15 28|FRAME" analysis
P01569015A0120|49 65|open reading frames
P01569015A0120|67 70|ORFs
P01569015A0120|83 91|direction
P01569102A0708|0 7|Domain II
P01569102A0708|31 41|LDL receptor
P01569102A0708|31 41|LDL receptor
P01569102A0708|104 112|cysteines
P01569344A0404|13 21|HTLV-I/II
P01569344A0404|68 81|New Orleans age-
P01569344A0404|97 105|HTLV-I/II
P01569581A0482|38 50|mRNA sequences
P01569581A0482|92 101|start codon
P01569581A0482|132 161|21K translation initiation region
P01569581A0482|183 212|translation initiation frequency
P01569584A0672|29 33|6F6.2
P01569584A0672|29 33|6F6.2
P01569584A0672|73 85|m6F6 cDNA clone
P01569584A0672|73 80|m6F6 cDNA
P01569584A0672|93 97|6F6.1
P01569584A0672|93 97|6F6.1
P01569584A0672|101 105|6F6.3
P01569584A0672|101 105|6F6.3
P01569584A0672|113 117|6F6.2
P01569584A0672|113 117|6F6.2
P01569584A0672|132 146|alpha-type genes
P01569584A0672|132 146|alpha-type genes
P01569945A0529|3 10|SEN1 gene
P01569945A0529|3 10|SEN1 gene
P01569945A0529|33 48|open reading frame
P01569945A0529|59 81|2,112-amino-acid protein
P01572549A0000|0 21|Protein tyrosine kinases
P01572549A0000|7 21|tyrosine kinases
P01572549A0000|23 26|PTKs
P01572549A0000|23 26|PTKs
P01572549A0000|55 64|cell growth
P01572549A0000|110 128|retroviral oncogenes
P01572549A0000|110 128|retroviral oncogenes
P01572549A0000|132 161|intracellular signal transducers
P01572549A0000|168 188|growth factor receptors
P01572549A0000|168 188|growth factor receptors
P01573270A0000|3 8|IA4 mAb
P01573270A0000|3 8|IA4 mAb
P01573270A0000|54 63|BALB/c mice
P01573270A0000|89 107|HLA class I-deficient
P01573270A0000|89 97|HLA class I
P01573270A0000|109 138|lymphokine-activated killer (LAK
P01573270A0000|152 170|EBV-B lymphocyte line
P01577056A0178|90 99|omeprazole
P01577740A1111|0 14|Primer extension
P01577740A1111|18 38|mung bean and S1 nuclease
P01577740A1111|18 25|mung bean
P01577740A1111|29 30|S1
P01577740A1111|31 45|nuclease mapping
P01577740A1111|63 90|transcription initiation sites
P01577740A1111|112 127|Northern analyses
P01577819A0709|10 29|PRP-precursor alleles
P01577819A0709|10 22|PRP-precursor
P01577819A0709|23 29|alleles
P01579472A1018|16 30|enhancer element
P01579537A0000|37 50|botulinum toxin
P01579537A0000|37 50|botulinum toxin
P01579537A0000|53 68|potent neurotoxin
P01580738T0001|0 18|Allagille's syndrome
P01580738T0001|33 48|antenatal ascites
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|69 84|DPC AlaSTAT System
P01581409A0398|113 125|skin prick test
P01581577A1186|0 4|PSI-G
P01581577A1186|0 4|PSI-G
P01581577A1186|8 12|PSI-K
P01581577A1186|8 10|PSI
P01581577A1186|56 68|ancestral gene
P01581965A0388|5 14|C-terminus
P01581965A0388|120 129|n-chimerin
P01581965A0388|120 129|n-chimerin
P01581965A0388|134 139|rho GAP
P01581965A0388|134 139|rho GAP
P01581965A0388|173 192|intrinsic GAP activity
P01581965A0388|182 184|GAP
P01581965A0388|195 206|small GTPases
P01581965A0388|195 206|small GTPases
P01582413A0192|0 23|Site-directed mutagenesis
P01582413A0192|49 63|basic amino acids
P01582413A0192|80 90|basic region
P01582413A0192|97 114|amphipathic helices
P01582413A0192|124 140|adjacent HLH domain
P01582413A0192|156 182|sequence-specific DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|14 18|Myf-5
P01582413A0759|14 18|Myf-5
P01582413A0759|26 57|ubiquitously expressed bHLH protein
P01582413A0759|47 57|bHLH protein
P01582413A0759|58 60|E12
P01582413A0759|58 60|E12
P01582413A0759|111 125|transactivation
P01582413A0759|141 150|DNA binding
P01582500A0178|25 29|sleep
P01583819A0377|0 2|SEA
P01583819A0377|18 37|bidirectional filters
P01583819A0377|64 75|Simson method
P01584812T0000|0 24|Neural-specific expression
P01584812T0000|26 41|genomic structure
P01584812T0000|46 68|chromosomal localization
P01584812T0000|89 124|zinc-finger transcription factor NGFI-C
P01584812T0000|89 118|zinc-finger transcription factor
P01584812T0000|119 124|NGFI-C
P01585014A0000|45 73|gonadotrophin releasing hormone
P01585014A0000|45 73|gonadotrophin releasing hormone
P01585014A0000|88 91|GnRH
P01585014A0000|134 139|season
P01585014A0000|158 165|v. spring
P01585014A0000|179 198|supplementary feeding
P01585014A0000|203 212|lupin grain
P01585014A0000|283 291|ovulation
P01585014A0000|344 347|400 I
P01585014A0000|363 380|serum gonadotrophin
P01585014A0000|368 380|gonadotrophin
P01585014A0000|382 385|PMSG
P01585014A0000|382 385|PMSG
P01585014A0000|390 419|12 mg follicle stimulating hormone
P01585014A0000|394 419|follicle stimulating hormone
P01585014A0000|421 426|FSH-P)
P01585014A0000|421 423|FSH
P01585014A0000|425 425|P
P01586901A0000|0 20|Drug-drug interactions
P01586901A0000|106 122|therapeutic window
P01587267A1144|52 81|X-ray crystallographic structure
P01587267A1144|87 92|enzyme
P01587267A1144|124 138|clostridial gene
P01587267A1144|153 176|site-directed mutagenesis
P01587763A0402|5 19|body irradiation
P01588270A1029|12 24|blood pressure
P01588270A1029|124 126|DBP
P01588315A0356|0 5|AgMNPV
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|33 38|OpMNPV
P01588315A0356|59 75|promoter structure
P01588315A0356|79 103|polyhedrin primary sequence
P01588315A0356|79 103|polyhedrin primary sequence
P01588315A0356|111 124|polyhedrin gene
P01588315A0356|111 124|polyhedrin gene
P01588315A0356|156 178|anti-clockwise direction
P01588913A0000|0 4|A gene
P01588913A0000|20 42|Escherichia coli dnaA gene
P01588913A0000|20 42|Escherichia coli dnaA gene
P01588913A0000|58 74|Pseudomonas putida
P01588913A0000|81 93|transcription
P01588913A0000|111 116|E. coli
P01588913A0000|127 134|P. putida
P01588961A0000|0 3|STP1
P01588961A0000|0 3|STP1
P01588961A0000|8 27|unessential yeast gene
P01588961A0000|50 69|intervening sequences
P01588961A0000|99 109|intervening
P01588961A0000|129 137|pre-tRNAs
P01588963A1153|10 19|antibodies
P01588963A1153|77 88|Cdc25 protein
P01588963A1153|77 88|Cdc25 protein
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|0 7|GCR1 gene
P01588965A0000|39 62|glycolytic gene expression
P01588965A0000|65 87|Saccharomyces cerevisiae
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|66 96|exponentially decaying components
P01589576A0170|129 130|T2
P01589576A0170|144 145|T3
P01592545A0726|5 11|tilting
P01592545A0726|13 33|systolic blood pressure
P01592545A0726|54 61|patients
P01592545A0726|124 131|patients
P01594554A0845|41 43|CCK
P01594554A0845|41 43|CCK
P01594554A0845|47 63|trypsin inhibitors
P01594554A0845|47 53|trypsin
P01594554A0845|111 128|pancreatic exocrine
P01596007A0908|4 15|apneic events
P01596007A0908|30 41|Stages I and II
P01596007A0908|46 48|REM
P01596007A0908|83 94|gamma OH study
P01596007A0908|162 167|apneas
P01596007A0908|187 189|SWS
P01596007A0908|194 200|gamma OH
P01597170A0000|5 11|rabbits
P01597170A0000|45 49|CoCl2
P01597170A0000|73 74|Cr
P01597170A0000|73 74|Cr
P01597170A0000|76 80|NO3)3
P01597170A0000|76 78|NO3
P01597170A0000|90 91|Cr
P01597170A0000|113 118|m3 Co2+
P01597272A0077|2 6|women
P01597462A0457|26 30|CDC14
P01597462A0457|26 30|CDC14
P01597462A0457|35 47|essential gene
P01600531A0483|8 11|flow
P01600531A0483|32 46|phosphocreatine
P01600531A0483|60 71|control group
P01601181A0842|3 16|60A transcripts
P01601181A0842|3 16|60A transcripts
P01601181A0842|55 66|gastrulation
P01601181A0842|82 89|mesoderm
P01601181A0842|104 111|germ band
P01601869A1389|1 13|724-bp segment
P01601869A1389|19 35|5'-flanking region
P01601869A1389|59 63|E-box
P01601869A1389|82 111|mammalian-specific 352-bp region
P01601869A1389|82 111|mammalian-specific 352-bp region
P01601869A1389|135 159|transcriptional activation
P01601869A1389|162 188|postconfluent BC3H1 myoblasts
P01603088A1121|45 46|TR
P01603088A1121|45 46|TR
P01603088A1121|55 79|transcriptional activation
P01603088A1121|83 92|repression
P01603088A1121|96 118|promoter-specific manner
P01605038T0001|11 26|neural regulation
P01605038T0001|29 50|anti-arrhythmic effects
P01605038T0001|53 56|GABA
P01605038T0001|59 62|rats
P01607223A0000|42 60|dye release technique
P01607223A0000|76 85|laser light
P01607223A0000|106 119|fluorescent dye
P01607223A0000|124 144|temperature-sensitive
P01607223A0000|177 187|vasculature
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|49 53|fresh
P01611699A0000|54 61|stem bark
P01611699A0000|64 82|Albizzia julibrissin
P01611699A0000|83 90|DURAZZ..
P01612085A0624|3 21|serum erythropoietin
P01612085A0624|8 21|erythropoietin
P01612085A0624|23 25|EPO
P01612085A0624|23 25|EPO
P01612085A0624|45 59|male triathletes
P01612085A0624|107 125|male distance runners
P01613640A0158|3 18|coating materials
P01613640A0158|37 85|poloxamine 908, poloxamine 1508, poloxamer 338, and Brij
P01615049A0000|3 8|eating
P01615049A0000|30 47|pygmy goats fed ad lib
P01615182A0206|39 57|in sputum amoxycillin
P01615182A0206|59 63|amoxy
P01615493A0408|3 14|HC II activity
P01615493A0408|3 6|HC II
P01615493A0408|18 30|antigen levels
P01615493A0975|0 9|Argatroban
P01615493A0975|33 49|low HC II conditions
P01615493A0975|80 95|thrombin activity
P01615493A0975|80 87|thrombin
P01615493A0975|105 122|vascular wall damage
P01616475A0756|42 45|NFPD
P01616475A0756|48 49|CP
P01616475A0756|54 61|patients
P01616475A0756|74 81|patients
P01616475A0756|101 113|panic disorder
P01616475A0756|123 130|patients
P01617242T0000|17 29|growth factors
P01617776A0343|10 32|adrenergic nervous system
P01617776A0343|64 83|myocardial infarction
P01617776A0343|101 122|sympathetic innervation
P01617776A0343|128 132|heart
P01617776A0343|160 183|sympathetic nervous system
P01617801A0088|7 22|Serum aldosterone
P01617801A0088|26 44|plasma renin activity
P01617801A0088|26 36|plasma renin
P01617801A0088|94 97|oral
P01617801A0088|98 106|captopril
P01618027A1108|54 73|developmental profile
P01618027A1108|95 114|wild-type E10 fragment
P01618027A1108|95 114|wild-type E10 fragment
P01618027A1108|162 173|cloned region
P01618243T0000|0 27|Intravenous amine pressor tests
P01618243T0000|30 46|healthy volunteers
P01618256A0521|14 38|steady-state concentration
P01618256A0521|47 57|oral regimen
P01618256A0521|72 74|l-1
P01618256A0521|129 131|l-1
P01619114A0383|35 38|SMSP
P01619114A0383|67 85|Mini Speech Processor
P01619114A0383|87 89|MSP
P01619114A0383|87 89|MSP
P01619642A0131|4 10|parents
P01620118A0470|5 18|mutant proteins
P01620118A0470|59 98|kappa B-mediated transcriptional activation
P01620118A0470|59 64|kappa B
P01620118A0470|104 147|human immunodeficiency virus long terminal repeat
P01620118A0470|104 147|human immunodeficiency virus long terminal repeat
P01620118A0470|179 198|chicken lymphoid cells
P01620129A0417|3 30|sequence-specific interaction
P01620129A0417|33 51|nuclear factor HiNF-D
P01620129A0417|33 45|nuclear factor
P01620129A0417|46 51|HiNF-D
P01620129A0417|63 85|proximal promoter element
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|125 142|normal diploid cells
P01620129A0417|144 145|J.
P01620610A1070|31 54|TI region-based expression
P01620610A1070|92 106|versatile vector
P01620610A1070|141 167|periShine-Dalgarno sequences
P01620610A1070|179 196|coding MTI subregion
P01620781A0611|89 90|A1
P01620781A0611|95 102|B2----A3
P01620781A0611|95 102|B2----A3
P01620781A0611|107 114|B4----A5
P01620781A0611|113 114|A5
P01621584A0183|0 5|UF-021
P01621584A0183|69 75|rabbits
P01621584A0183|83 108|dose-dependent IOP reduction
P01621584A0183|140 146|IOP rise
P01623900A0670|5 17|blood pressure
P01623900A0670|21 41|noradrenergic activity
P01623900A0670|65 76|plasma levels
P01623900A0670|80 95|urinary excretion
P01623900A0670|98 111|norepinephrine
P01623900A0670|136 142|Pl group
P01623900A0670|182 195|diastolic blood
P01623900A0670|219 231|resting venous
P01623900A0670|232 245|norepinephrine
P01623900A0670|263 285|norepinephrine excretion
P01623900A0670|314 329|dF administration
P01624425A0907|0 15|Wild-type protein
P01624425A0907|9 15|protein
P01624425A0907|21 29|azido-ATP
P01624425A0907|67 85|consensus amino acids
P01624425A0907|102 107|azido-
P01624425A0907|108 110|ATP
P01625131A0452|28 36|stoma site
P01625131A0452|58 71|early rejection
P01625527A0000|0 24|Whole blood serotonin levels
P01625527A0000|44 55|control group
P01625527A0000|75 93|chronic renal failure
P01625527A0000|94 101|patients
P01625527A0000|138 158|conservative treatment
P01625527A0000|204 223|renal transplantation
P01626372T0000|35 43|thymidine
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626430A1112|20 24|RAD16
P01626430A1112|20 24|RAD16
P01626430A1112|26 30|RAD54
P01626430A1112|26 30|RAD54
P01626430A1112|34 37|SNF2
P01626430A1112|34 37|SNF2
P01626430A1112|87 109|yeast and Drosophila genes
P01626430A1112|95 109|Drosophila genes
P01626440A0449|28 50|instrument disinfectants
P01626631A0557|5 16|Rett syndrome
P01626631A0557|62 66|brain
P01626631A0557|67 70|stem
P01626631A0557|159 172|conscious level
P01627106A0320|21 59|simultaneous nitrofurazone administration
P01627106A0320|65 84|enteritidis challenge
P01627106A0320|121 133|S. enteritidis
P01627828A0475|19 34|southern blotting
P01627828A0475|37 44|mouse DNA
P01627828A0475|49 57|SmN probes
P01627828A0475|49 51|SmN
P01627828A0475|102 111|pseudogene
P01627828A0475|139 162|intron-containing SmN gene
P01627828A0475|156 162|SmN gene
P01627830A0000|3 7|cDNAs
P01627830A0000|16 29|casein kinase-1
P01627830A0000|16 29|casein kinase-1
P01627830A0000|51 66|yeast cDNA library
P01627830A0000|76 79|CKI1
P01627830A0000|76 79|CKI1
P01627830A0000|83 86|CKI2
P01627830A0000|83 86|CKI2
P01628201A0824|27 61|122/100,000/year and 190/100,000/year
P01628201A0824|92 102|raw datasets
P01628806A1347|11 27|sequence variation
P01628806A1347|44 46|ORF
P01628806A1347|76 78|ORF
P01628806A1347|99 112|helicase region
P01628904A0386|41 59|2 kilobase (kb) insert
P01629768A0131|36 45|kainic acid
P01629768A0131|53 55|SOC
P01629768A0131|53 55|SOC
P01629768A0131|89 105|glass micropipette
P01630454A0635|6 15|poly(dA-dT
P01630454A0635|55 74|Act1 promoter activity
P01630454A0635|55 66|Act1 promoter
P01630455A0448|27 37|NFIL-1 beta A
P01630455A0448|27 37|NFIL-1 beta A
P01630455A0448|39 45|NF beta A
P01630455A0448|39 45|NF beta A
P01630455A0448|75 90|12-bp DNA sequence
P01630455A0448|92 94|-49
P01630455A0448|121 132|TATA box motif
P01630455A0448|121 132|TATA box motif
P01630455A0448|142 168|human and murine IL-1 beta genes
P01630455A0448|156 168|IL-1 beta genes
P01630569A0605|7 19|amphotericin B
P01630569A0605|21 23|AmB
P01630569A0605|29 37|remission
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|3 21|DRF-2 nuclear protein
P01633435A0743|3 21|DRF-2 nuclear protein
P01633435A0743|59 89|muscle-specific regulatory factor
P01633435A0743|59 89|muscle-specific regulatory factor
P01633435A0743|91 95|MEF-2
P01633435A0743|91 95|MEF-2
P01633435A0743|97 102|Buskin
P01633816A0667|12 34|clone a 4-kb EcoRI fragment
P01633816A0667|18 34|4-kb EcoRI fragment
P01633816A0667|56 60|exons
P01633816A0667|74 89|5' flanking region
P01633816A0667|95 101|opn gene
P01633816A0667|95 101|opn gene
P01633816A0667|157 179|primer extension analysis
P01633816A0667|183 192|S1 nuclease
P01633816A0667|183 184|S1
P01633816A0667|185 199|nuclease mapping
P01634308A0191|0 24|Cardiovascular risk factors
P01634308A0191|39 60|standardized techniques
P01634400A1101|23 26|feed
P01634400A1101|28 35|non-feed
P01634464A0163|9 15|patient
P01634464A0163|26 43|factor VII inhibitor
P01634464A0163|26 34|factor VII
P01634464A0163|65 88|penicillin administration
P01634464A0163|102 117|fatal haemorrhage
P01634861A1336|73 101|oxygen debt and lactate clearance
P01636339A0200|0 6|Account
P01636339A0200|17 27|noncellular
P01636339A0200|31 46|nonhuman elements
P01636339A0200|71 75|mucus
P01636339A0200|77 98|Charcot-Layden crystals
P01636339A0200|100 111|pollen grains
P01636339A0200|113 136|vegetal fragments and fungi
P01636714A0845|48 50|MBF
P01636714A0845|56 60|liver
P01636714A0845|62 72|renal cortex
P01636714A0845|84 104|small intestinal serosa
P01636714A0845|110 112|MBF
P01636714A0845|143 145|CLP
P01637758A0532|30 34|women
P01637758A0532|40 52|sweeping group
P01637758A0532|57 64|cervical
P01637758A0532|77 79|4 cm
P01637758A0532|96 113|vaginal examination
P01637758A0532|119 134|labour ward (16/33
P01639092A0776|0 4|Lewis
P01639724A0452|19 23|women
P01639724A0452|41 58|oral contraceptives
P01639724A0452|102 110|pill cycle
P01640778A0485|34 41|MLPA test
P01640778A0485|65 84|large-scale screening
P01641628A0869|21 35|reference values
P01641628A0869|156 170|reference values
P01642060A0471|27 57|antibody-targeted Phthalocyanine
P01642060A0471|73 80|patients
P01642060A0471|96 119|advanced ovarian carcinoma
P01642060A0471|121 128|FIGO III)
P01643943A0300|11 20|lung cancer
P01643943A0300|55 57|TFR
P01643943A0300|55 57|TFR
P01644751A0590|4 19|open reading frame
P01644751A0590|88 114|overproduced msgB gene product
P01644751A0590|100 114|msgB gene product
P01644796A0374|41 56|recombinant furin
P01644796A0374|41 56|recombinant furin
P01644814A0068|3 7|virus
P01644814A0068|16 28|40-kDa protein
P01644814A0068|16 28|40-kDa protein
P01644814A0068|30 32|tax
P01644814A0068|30 32|tax
P01644814A0068|72 77|T cells
P01644821A1259|8 15|butyrate
P01644821A1259|58 68|CAT activity
P01644821A1259|58 60|CAT
P01644821A1259|71 81|fusion genes
P01644821A1259|92 108|upstream sequences
P01644821A1259|110 119|-834 to -576
P01644821A1259|140 156|proximal sequences
P01644821A1259|158 167|-456 to -172
P01644821A1259|195 204|PSG1-I gene
P01644821A1259|195 204|PSG1-I gene
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|55 60|NGFI-B
P01644831A0824|55 60|NGFI-B
P01644831A0824|118 133|nuclear receptors
P01644831A0824|118 133|nuclear receptors
P01644831A0824|135 141|mutants
P01644831A0824|162 177|carboxyl terminus
P01645902A1462|37 45|Syn 5 locus
P01645902A1462|37 45|Syn 5 locus
P01645902A1462|77 78|gH
P01645902A1462|77 78|gH
P01645902A1462|114 115|TK
P01645902A1462|114 115|TK
P01645902A1462|119 127|UL 24 genes
P01645902A1462|119 127|UL 24 genes
P01645902A1462|139 149|syn mutation
P01645902A1462|188 189|TK
P01645902A1462|188 189|TK
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|42 54|vaccinia virus
P01645905A0341|58 61|TGEV
P01645905A0341|118 128|degradation
P01645905A0341|134 143|C-terminus
P01645905A0341|134 143|C-terminus
P01645905A0341|152 176|discrete breakdown products
P01646157A0414|18 52|full-length alpha-GalNAc cDNA sequence
P01646157A0414|18 52|full-length alpha-GalNAc cDNA sequence
P01646157A0414|110 126|amino acid homology
P01646157A0414|161 185|human alpha-galactosidase A
P01646157A0414|161 185|human alpha-galactosidase A
P01646157A0414|187 196|alpha-Gal A
P01646157A0414|187 196|alpha-Gal A
P01646487A0874|0 7|Patients
P01646487A0874|73 75|IgA
P01646487A0874|73 75|IgA
P01646487A0874|77 79|IgG
P01646487A0874|77 79|IgG
P01646487A0874|81 83|IgM
P01646487A0874|81 83|IgM
P01646487A0874|85 100|T and B lymphocytes
P01646487A0874|85 85|T
P01646487A0874|107 124|phagocytic activity
P01646487A0874|150 157|patients
P01646487A0874|173 189|enzymatic activity
P01646753A0336|13 24|nitrous oxide
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|76 96|one-electron reduction
P01646753A0336|167 168|EO
P01646753A0336|170 176|N2O/N2O
P01647070A0232|3 20|mutant JCV T antigens
P01647070A0232|3 20|mutant JCV T antigens
P01647070A0232|28 37|JCV and SV40
P01647070A0232|47 60|DNA replication
P01647656A0000|18 50|myocardial beta-adrenergic receptor
P01647656A0000|18 50|myocardial beta-adrenergic receptor
P01647656A0000|54 68|left ventricular
P01647656A0000|70 80|LV) function
P01647656A0000|95 102|patients
P01647656A0000|135 142|LV volume
P01647656A0000|162 187|chronic mitral regurgitation
P01647813A0512|101 132|differentiation-dependent control
P01647813A0512|135 144|expression
P01648142A1170|2 9|patients
P01648142A1170|21 27|disease
P01648142A1170|45 55|alternating
P01648142A1170|101 106|CAV arm
P01648142A1170|133 137|PE arm
P01648530A0000|27 48|muscle-specific Xenopus
P01648530A0000|42 72|Xenopus cardiac actin gene promoter
P01648530A0000|56 72|actin gene promoter
P01648530A0000|78 86|282 to -348
P01648530A0000|104 122|embryonic expression
P01648530A0000|126 161|cardiac actin-beta-globin reporter gene
P01648530A0000|133 161|actin-beta-globin reporter gene
P01648530A0000|174 187|fertilized eggs
P01649173A0160|51 61|attenuator 1
P01649173A0160|72 92|nucleotides downstream
P01649173A0160|100 130|major late transcription start site
P01649173A0160|150 160|attenuator 2
P01649173A0160|162 192|situated 55 nucleotides downstream
P01649318A0734|0 5|EBNA-2
P01649318A0734|0 5|EBNA-2
P01649318A0734|12 32|cis-acting CD23 element
P01649318A0734|22 32|CD23 element
P01649318A0734|42 43|TK
P01649318A0734|42 43|TK
P01649318A0734|53 56|mRNA
P01649318A0734|74 101|herpes simplex virus TK promoter
P01649318A0734|74 91|herpes simplex virus
P01649318A0734|92 93|TK
P01649318A0734|102 123|transcription start site
P01649318A1222|26 64|186-bp, EBNA-2-responsive cell DNA fragment
P01649318A1222|33 64|EBNA-2-responsive cell DNA fragment
P01649318A1222|91 96|EBNA-2
P01649318A1222|91 96|EBNA-2
P01649318A1222|126 134|cell genes
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|20 25|lipids
P01649539T0000|29 49|myeloperoxidase levels
P01649539T0000|29 43|myeloperoxidase
P01649539T0000|56 68|spinal surgery
P01649835A0822|27 37|PBR/IBP cDNA
P01649835A0822|27 29|PBR
P01649835A0822|31 33|IBP
P01649835A0822|42 51|COS-7 cells
P01649835A0822|105 110|[3H]PK
P01649835A0822|154 161|Ro5-4864
P01650524A0837|26 45|vascular permeability
P01650524A0837|51 66|peritoneal cavity
P01650524A0837|70 83|LTB4 production
P01650524A0837|116 119|5-LO
P01650524A0837|130 138|phenidone
P01650524A0837|140 144|BW A4C
P01650524A0837|146 158|A63162, and ICI
P01650524A0837|162 164|968
P01650524A0837|173 185|dexamethasone
P01650557T0000|0 16|Discrepant results
P01650557T0000|22 43|latex agglutination test
P01650557T0000|61 75|cytomegalovirus
P01650557T0000|92 114|cardiac transplant donors
P01651232A0152|26 48|internal uridine residues
P01651232A0152|85 87|UTP
P01651232A0152|91 98|thio-UTP
P01651918A0000|40 52|cDNA fragments
P01651918A0000|80 96|amino acid sequence
P01651918A0000|99 136|rat testis fructose-6-phosphate,2-kinase
P01651918A0000|99 116|rat testis fructose-
P01651918A0000|117 127|6-phosphate
P01651918A0000|129 164|2-kinase:fructose-2,6-bisphosphatase
P01652372A0153|16 19|SWI5
P01652372A0153|16 19|SWI5
P01652372A0153|22 46|nuclear localization signal
P01652372A0153|48 50|NLS
P01652372A0153|74 104|cell cycle-dependent nuclear entry
P01652372A0153|108 126|heterologous protein
P01652515A0379|65 103|haloperidol intrastriatal microinjections
P01652515A0379|121 133|synaptic level
P01652515A0379|136 153|rostral neostriatum
P01652755A1492|9 40|transient transfection experiments
P01652755A1492|43 51|HeLa cells
P01652755A1492|79 117|retinoblastoma susceptibility gene product
P01652755A1492|79 117|retinoblastoma susceptibility gene product
P01652755A1492|119 120|RB
P01652755A1492|119 120|RB
P01652755A1492|155 163|IL-6 (-225
P01652755A1492|155 158|IL-6
P01652755A1492|171 175|c-fos
P01652755A1492|171 175|c-fos
P01652755A1492|178 185|711 to +42
P01652755A1492|191 222|beta-actin (-3400 to +912) promoters
P01652755A1492|191 200|beta-actin
P01652755A1492|232 246|PRV-induced IL-6
P01652755A1492|243 246|IL-6
P01652755A1492|248 256|-110 to +13
P01652755A1492|263 283|serum-induced MHC (-528
P01652755A1492|276 278|MHC
P01652755A1492|290 298|promoters
P01653173A0619|4 13|repression
P01653173A0619|44 60|E2 DNA-binding site
P01653173A0619|44 45|E2
P01653173A0619|85 103|P105 promoter TATA box
P01653173A0619|85 88|P105
P01653173A0619|143 160|HPV-18 P105 promoter
P01653173A0619|143 148|HPV-18
P01653173A0619|149 152|P105
P01653173A0619|215 234|preinitiation complex
P01653236A0895|14 16|p50
P01653236A0895|14 16|p50
P01653236A0895|34 61|native glucocorticoid receptor
P01653236A0895|40 61|glucocorticoid receptor
P01653236A0895|64 69|L cells
P01653236A0895|92 113|glucocorticoid receptor
P01653236A0895|92 113|glucocorticoid receptor
P01653236A0895|116 139|Chinese hamster ovary cells
P01653238A1062|3 47|putative 12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|49 51|TPA
P01653238A1062|104 122|transcription factor
P01653238A1062|123 126|AP-1
P01653238A1062|123 126|AP-1
P01653238A1062|151 179|transforming growth factor beta 1
P01653238A1062|151 179|transforming growth factor beta 1
P01653238A1062|181 189|TGF-beta 1
P01653238A1062|181 189|TGF-beta 1
P01653238A1062|222 235|promoter region
P01653238A1715|0 2|TPA
P01653238A1715|0 2|TPA
P01653238A1715|6 14|TGF-beta 1
P01653238A1715|6 14|TGF-beta 1
P01653238A1715|53 64|72-kDa enzyme
P01653918A0286|100 111|human corneal
P01654349A0327|0 9|Feed intake
P01654349A0327|33 35|KCl
P01654349A0327|38 58|NaHCO3 supplementation
P01654349A0327|101 101|K
P01654349A0327|124 136|dietary NaHCO3
P01655126T0000|0 18|Extraction procedure
P01655126T0000|38 54|butyltin compounds
P01655126T0000|87 89|HBr
P01655713A0294|86 97|388 exs1::Tn1
P01655713A0294|89 92|exs1
P01655713A0294|95 97|Tn1
P01655713A0294|100 132|chromosomal Tn1 insertional mutation
P01655713A0294|100 113|chromosomal Tn1
P01655713A0294|125 132|mutation
P01656220T0000|0 2|axl
P01656220T0000|33 64|primary human myeloid leukemia cells
P01656220T0000|74 100|novel receptor tyrosine kinase
P01656220T0000|79 100|receptor tyrosine kinase
P01656221A1319|14 31|amino acid sequences
P01656221A1319|43 49|Tyr-766
P01656221A1319|81 85|FGFRs
P01656221A1319|81 85|FGFRs
P01656221A1319|103 118|tyrosine residues
P01656221A1319|141 150|FGFR family
P01656221A1319|141 150|FGFR family
P01656235A0946|22 28|element
P01656235A0946|32 54|linker-scanning analysis
P01656235A0946|59 69|10-bp region
P01656235A0946|83 92|CCAAT motif
P01656675A0236|21 31|HVS patients
P01656675A0236|35 49|non-HVS patients
P01656675A0236|83 97|healthy controls
P01657246A0325|3 29|transcription initiation site
P01657246A0325|77 79|Met
P01657249A1019|3 19|anti-I and anti-i CA
P01657249A1019|3 8|anti-I
P01657249A1019|12 19|anti-i CA
P01657249A1019|38 51|VH4 heavy chains
P01657249A1019|38 51|VH4 heavy chains
P01657249A1019|62 63|CA
P01657249A1019|93 95|VH4
P01657249A1019|102 131|hypervariable region determinant
P01657249A1019|139 146|VH4-HV2a
P01657249A1019|139 146|VH4-HV2a
P01657415A0837|6 13|K1 cox1.2
P01657415A0837|6 13|K1 cox1.2
P01657415A0837|26 37|S. cerevisiae
P01657594A0472|71 75|cgs1+
P01657594A0472|71 75|cgs1+
P01657594A0472|79 83|cgs2+
P01657594A0472|79 83|cgs2+
P01657969A1420|21 33|electrostatic
P01657969A1420|77 98|amino acid substitutions
P01657969A1420|109 128|conformational change
P01657969A1420|157 166|calmodulin
P01657969A1420|157 166|calmodulin
P01658356A1369|19 30|coexpression
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|87 92|FeLV-C
P01658356A1369|111 129|feline 3201B cell line
P01658356A1369|179 196|FeLV-specific mRNAs
P01658356T0000|0 12|Recombination
P01658356T0000|20 47|feline leukemia virus subgroup B
P01658356T0000|50 50|C
P01658356T0000|64 74|env elements
P01658356T0000|64 74|env elements
P01658356T0000|116 122|viruses
P01658375A0854|27 37|5' and 3' ends
P01658375A0854|45 51|introns
P01658375A0854|78 88|transcripts
P01658375A0854|93 123|eukaryotic protein-encoding genes
P01658375A0854|93 123|eukaryotic protein-encoding genes
P01658375A0854|162 166|5' end
P01658375A0854|172 180|LAT intron
P01658375A0854|197 213|consensus sequence
P01658468A0123|4 4|5
P01658468A0123|39 49|C. kutscheri
P01658468A0123|57 66|oral cavity
P01658468A0123|68 75|hamsters
P01658468A0123|114 131|culture C. kutscheri
P01658741A1047|47 64|nucleotide sequence
P01658741A1047|70 101|Saccharomyces cerevisiae ADE 1 locus
P01658741A1047|70 92|Saccharomyces cerevisiae
P01658741A1047|93 101|ADE 1 locus
P01659685T0000|14 22|promoters
P01659685T0000|31 51|5' untranslated regions
P01659685T0000|60 64|Dd ras
P01659685T0000|62 74|ras expression
P01659685T0000|77 89|Dictyostelium
P01660486A1756|49 62|gene cotransfer
P01660486A1756|68 91|aminoglycoside resistance
P01660486A1756|139 163|cellular control mechanisms
P01660486A1756|173 182|PKC pathway
P01660486A1756|173 175|PKC
P01660486A1756|204 217|gene expression
P01660925T0000|8 15|RNA genes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|98 111|consensus boxes
P01660925T0000|119 141|5' and 3'-flanking regions
P01661369A0825|13 28|strD and strE genes
P01661369A0825|13 16|strD
P01661369A0825|20 28|strE genes
P01661369A0825|81 92|biosynthetic
P01661369A0825|106 124|deoxyhexose moieties
P01662609A0398|18 29|polypeptides
P01662609A0398|32 44|420 amino acids
P01662609A0398|46 53|M.HgiCI)
P01662609A0398|60 69|amino acids
P01662609A0398|71 78|R.HgiCI)
P01662794A0640|15 21|wt1 gene
P01662794A0640|15 21|wt1 gene
P01662794A0640|25 45|transient transfection
P01662794A0640|48 57|COS-1 cells
P01662794A0640|67 78|52 kDa protein
P01662794A0640|114 137|N-terminal- and C-terminal
P01662794A0640|114 128|N-terminal- and C
P01662794A0640|147 154|antisera
P01662807A1182|24 36|TR promoter co-
P01662807A1182|24 33|TR promoter
P01662807A1182|51 54|SV40
P01662807A1182|55 65|chromosomes
P01662807A1182|81 89|infection
P01662884A1029|35 40|orally
P01662884A1029|89 115|chronic bacterial prostatitis
P01664192A1577|3 22|neuromuscular effects
P01664192A1577|42 45|ED90
P01664192A1577|52 61|vecuronium
P01669611A0142|3 9|patient
P01669611A0142|95 106|real diseases
P01671675A0483|17 21|pKB11
P01671675A0483|17 21|pKB11
P01671675A0483|32 58|1369-base pair (bp) cDNA insert
P01671675A0483|60 77|overlapping pCAD142
P01671675A0483|71 77|pCAD142
P01671675A0483|80 84|781 bp
P01671675A0483|101 120|hybridization methods
P01671675A0483|124 139|sequence analysis
P01671675A0483|166 177|cDNA sequence
P01671675A0483|184 191|amino end
P01671675A0483|197 210|CAD polypeptide
P01671675A0483|197 210|CAD polypeptide
P01671675A0905|28 51|Northern blotting analysis
P01671675A0905|57 73|5'-flanking region
P01671675A0905|76 82|CAD gene
P01671675A0905|76 82|CAD gene
P01673220A0578|22 41|genomic and cDNA clones
P01673220A0578|47 65|light-independent Sn
P01673220A0578|64 76|Sn: bol3 allele
P01673220A0578|67 76|bol3 allele
P01674177T0001|0 10|Histamine-2
P01674177T0001|21 29|psoriasis
P01674242A0358|92 105|troleandomycin
P01674242A0358|107 127|triacetyloleandomycin
P01674242A0358|153 165|ciprofloxacin
P01674242A0358|200 220|fluoroquinolone T-3262
P01674242A0358|222 234|pipemidic acid
P01674242A0358|236 245|cimetidine
P01674242A0358|258 268|propranolol
P01674242A0358|301 310|furosemide
P01674242A0358|312 320|frusemide
P01674242A0358|423 450|influenza- and BCG-vaccination
P01674242A0358|452 461|interferon
P01674242A0358|452 461|interferon
P01674242A0358|466 473|caffeine
P01674369A0417|75 81|cloning
P01674662A0000|10 12|253
P01674662A0000|13 45|HIV-antibody positive heroin addicts
P01674662A0000|53 70|HIV-related disease
P01674662A0000|93 118|generalized lymphadenopathy
P01674662A0000|129 144|prospective study
P01674662A0000|176 197|AIDS related complex (ARC
P01674662A0000|195 197|ARC
P01674662A0000|201 204|AIDS
P01674817A0862|25 29|RNA14
P01674817A0862|25 29|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|33 37|RNA15
P01674817A0862|47 51|RNA14
P01674817A0862|47 51|RNA14
P01674817T0000|0 8|Mutations
P01674817T0000|14 23|yeast RNA14
P01674817T0000|14 23|yeast RNA14
P01674817T0000|27 36|RNA15 genes
P01674817T0000|27 36|RNA15 genes
P01674817T0000|94 110|RNA-binding domain
P01674817T0000|94 110|RNA-binding domain
P01674817T0000|116 127|RNA15 protein
P01674817T0000|116 127|RNA15 protein
P01675154T0000|0 19|Myocardial infarction
P01675154T0000|22 29|patients
P01675154T0000|48 54|surgery
P01675424A0991|30 52|birch NAD(P)H-NR sequence
P01675424A0991|35 44|NAD(P)H-NR
P01675424A0991|67 82|NADH-NR sequences
P01675424A0991|67 82|NADH-NR sequences
P01675424A0991|104 132|pyridine nucleotide binding site
P01675637T0033|1 25|single amino acid difference
P01675637T0033|31 46|C-terminal region
P01675637T0033|57 80|dominant negative activity
P01675637T0033|84 105|receptor dimer formation
P01675763A1389|25 32|children
P01675763A1389|37 46|CD4+ counts
P01675763A1389|37 40|CD4+
P01678287A1308|10 37|human Antp TATAA binding protein
P01678287A1308|15 37|Antp TATAA binding protein
P01678287A1308|55 82|lymphoid and non-lymphoid cells
P01678287A1308|101 112|homeobox gene
P01678287A1308|101 112|homeobox gene
P01678287A1308|135 167|transcriptional regulatory function
P01678287A1308|176 190|eukaryotic cells
P01678392A0648|99 107|cmH2O l-1 s
P01679068A0000|8 14|infants
P01679068A0000|138 152|Escherichia coli
P01679068A0000|166 180|Enterobacter spp
P01679124A1368|0 17|Biochemical studies
P01679124A1368|43 54|ChAT activity
P01679124A1368|43 46|ChAT
P01679124A1368|60 85|dorsal and ventral hippocampi
P01679124A1368|88 102|lesioned animals
P01679124A1368|128 141|norepinephrine
P01679124A1368|143 144|NE
P01679124A1368|151 156|dorsal
P01679124A1368|170 175|MS/HSI
P01679124A1368|176 182|animals
P01679749A1171|3 14|localization
P01679749A1171|43 53|human genome
P01679749A1171|77 81|RFLPs
P01679749A1171|100 112|future studies
P01679749A1171|115 127|human diseases
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01681075A0429|11 29|dobutamine injection
P01681075A0429|45 63|pimobendan injection
P01681075A0429|131 141|metabolites
P01681075A0429|144 149|energy
P01681075A0429|153 174|carbohydrate metabolism
P01682484A0680|6 21|coronary stenosis
P01682484A0680|106 126|myocardial dysfunction
P01682484A0680|150 167|global hemodynamics
P01682484A0680|171 194|cardiac lactate metabolism
P01682509A0539|25 39|major IE proteins
P01682509A0539|25 39|major IE proteins
P01682509A0539|40 43|IE86
P01682509A0539|40 43|IE86
P01682509A0539|45 48|IE72
P01682509A0539|45 48|IE72
P01682509A0539|53 56|IE55
P01682509A0539|53 56|IE55
P01682509A0539|88 93|HIV LTR
P01682509A0539|88 93|HIV LTR
P01682509A0539|97 106|T-cell line
P01682509A0539|108 113|HUT-78
P01682542A0690|95 128|unknowingly seropositive individuals
P01684791A0000|3 19|cis-acting element
P01684791A0000|29 54|glucocorticoid inducibility
P01684791A0000|60 89|chicken glutamine synthetase gene
P01684791A0000|60 66|chicken
P01684791A0000|67 85|glutamine synthetase
P01686909A0299|21 36|biliary excretion
P01686909A0299|79 87|bretylium
P01686909A0299|91 108|hexylsalicylic acid
P01686909A0299|115 120|kidney
P01687050T0000|0 14|Diagnostic value
P01687050T0000|35 53|immunoglobulin G (IgG
P01687050T0000|35 49|immunoglobulin G
P01687050T0000|51 53|IgG
P01687050T0000|57 85|pediatric neurological diseases
P01688841A0430|12 19|six genes
P01688841A0430|15 19|genes
P01688841A0430|21 24|ipaB
P01688841A0430|21 24|ipaB
P01688841A0430|26 29|ipaC
P01688841A0430|26 29|ipaC
P01688841A0430|31 34|invE
P01688841A0430|31 34|invE
P01688841A0430|36 39|invG
P01688841A0430|36 39|invG
P01688841A0430|41 44|invJ
P01688841A0430|41 44|invJ
P01688841A0430|49 52|invK
P01688841A0430|49 52|invK
P01688841A0430|81 97|positive regulator
P01688841A0430|98 101|virF
P01688841A0430|98 101|virF
P01688972A0803|9 10|VT
P01688972A0803|37 43|patient
P01690703A0285|0 9|Venkatesan
P01690728A1166|29 49|mature mRNA transcripts
P01690728A1166|55 70|3.5 kilobase pairs
P01690728A1166|77 92|human fibroblasts
P01690728A1166|103 127|Northern blot hybridization
P01690728A1166|129 138|S1 nuclease
P01690728A1166|129 130|S1
P01690728A1166|131 153|nuclease protection assay
P01690728A1166|161 183|polymerase chain reaction
P01690812A0000|21 37|ribosomal DNA (rDNA
P01690812A0000|21 32|ribosomal DNA
P01690812A0000|34 37|rDNA
P01690812A0000|46 67|Drosophila melanogaster
P01690812A0000|96 114|28 S RNA ribosomal gene
P01690812A0000|96 114|28 S RNA ribosomal gene
P01690812A0000|126 139|type I and type II
P01690812A0000|126 130|type I
P01690812A0000|134 139|type II
P01691184A0995|0 4|Gap b3
P01691184A0995|3 4|b3
P01691184A0995|18 34|polypeptide chains
P01691184A0995|108 121|disulfide bonds
P01691184A0995|127 142|precursor protein
P01692135A0783|11 34|rtFc gamma R alpha cDNA clone
P01692135A0783|11 29|rtFc gamma R alpha cDNA
P01692135A0783|77 81|mRNAs
P01692135A0783|93 104|CRNK-16 cells
P01692135A0783|120 133|single Fc gamma R
P01692135A0783|126 145|Fc gamma R-related mRNA
P01692135A0783|142 152|mRNA species
P01692135A0783|164 194|human and mouse natural killer cells
P01692837A0390|31 37|introns
P01692837A0390|52 76|long 3'-untranslated region
P01692837A0390|78 93|3.2 kilobase pairs
P01692837A0390|128 139|4.1 kilobases
P01692962A0980|21 37|chimeric alpha i(54
P01692962A0980|21 34|chimeric alpha i
P01692962A0980|54 82|Chinese hamster ovary (CHO) cells
P01692962A0980|110 122|cAMP synthesis
P01692962A0980|126 160|cAMP-dependent protein kinase activity
P01692962A0980|126 152|cAMP-dependent protein kinase
P01694009A0112|4 7|exon
P01694009A0112|18 22|exon 0
P01694009A0112|42 61|5' untranslated region
P01694009A0112|68 91|N-terminal signal sequence
P01694009A0112|68 91|N-terminal signal sequence
P01694014A0716|11 31|human myeloid cell lines
P01694014A0716|32 36|HL-60
P01694014A0716|40 43|U937
P01694014A0716|48 76|phorbol 12-myristate 13-acetate
P01694014A0716|78 80|PMA
P01694014A0716|118 120|RNA
P01694014A0716|121 142|hybridizable to LD78 cDNA
P01694014A0716|135 142|LD78 cDNA
P01694280A0000|13 37|fiberoptic ventriculoscope
P01694280A0000|57 66|ventricles
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|13 22|N isomerase
P01694525A0000|24 32|epimerase
P01694525A0000|24 32|epimerase
P01694525A0000|53 76|Streptomyces clavuligerus
P01694525A0000|84 100|amino acid sequence
P01694525A0000|106 115|N-terminus
P01694525A0000|106 115|N-terminus
P01695098A1116|0 7|Serum IgG
P01695098A1116|5 7|IgG
P01695098A1116|31 38|patients
P01695116A0078|45 47|CR1
P01695116A0078|53 76|conventional chemotherapy
P01695314A0762|14 15|NS
P01695314A0762|18 30|glucose levels
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|22 37|metabolic control
P01695314T0000|54 70|calcium antagonist
P01695314T0000|82 103|type II diabetes mellitus
P01695322A0000|0 8|Wnt-1 (int
P01695322A0000|0 4|Wnt-1
P01695322A0000|6 10|int-1
P01695322A0000|15 30|cellular oncogene
P01695322A0000|58 68|proviral DNA
P01695322A0000|74 95|mouse mammary tumor virus
P01695378A1406|11 30|Jurkat leukemic T cells
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|98 105|FKBP mRNA
P01695378A1406|98 105|FKBP mRNA
P01695905A0480|0 8|GLUT5 mRNA
P01695905A0480|0 8|GLUT5 mRNA
P01695905A0480|37 50|small intestine
P01695905A0480|73 78|kidney
P01695905A0480|80 110|skeletal muscle, and adipose tissue
P01697611A0738|48 67|hamartomatous growths
P01697683T0000|38 45|promoter
P01697683T0000|52 65|cytotactin gene
P01697683T0000|52 65|cytotactin gene
P01697928A1214|57 61|Ly-6E
P01697928A1214|57 61|Ly-6E
P01697928A1214|94 129|interferon-stimulated response element
P01697928A1214|94 129|interferon-stimulated response element
P01697928A1214|197 235|alpha/beta interferon-inducible promoters
P01697928A1214|197 235|alpha/beta interferon-inducible promoters
P01698761A1059|0 31|Relatively large DNA rearrangements
P01698761A1059|59 71|direct repeats
P01698761A1059|83 121|carboxy-terminal histone H1-like structure
P01698761A1059|83 98|carboxy-terminal
P01698761A1059|99 107|histone H1
P01698761A1059|124 127|AlgP
P01698761A1059|124 127|AlgP
P01698761A1059|188 205|nonmucoid phenotype
P01699944A1538|59 80|CArG box binding proteins
P01699944A1538|59 65|CArG box
P01699944A1538|117 131|promoter element
P01699944A1538|137 173|VLC1, cardiac alpha-actin, and c-fos genes
P01699944A1538|137 140|VLC1
P01699944A1538|142 159|cardiac alpha-actin
P01699944A1538|164 173|c-fos genes
P01700272A0838|0 14|Polyadenylation
P01700272A0838|17 21|B4 RNA
P01700272A0838|17 21|B4 RNA
P01700272A0838|117 136|polysomal recruitment
P01701088A1335|19 36|regulatory elements
P01701088A1335|64 74|AP-2 element
P01701088A1335|64 74|AP-2 element
P01701088A1335|77 84|CCAAT box
P01701088A1335|77 84|CCAAT box
P01702361A0621|35 42|collagen
P01702361A0621|86 107|angiogenesis inhibitors
P01702426A0196|8 24|5'-flanking region
P01702426A0196|53 70|hormonal regulation
P01702426A0196|128 153|avian fatty acid synthase gene
P01702426A0196|128 153|avian fatty acid synthase gene
P01702426A1006|9 18|cDNA clones
P01702426A1006|61 70|lambda-ZAP
P01702426A1006|71 91|goose liver cDNA library
P01702426A1006|100 129|5'-most exon-containing fragment
P01702426A1006|135 141|5'-most
P01702426A1006|142 156|genomic DNA clone
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|52 56|genes
P01702432A1296|95 106|pollen tissue
P01702972A0613|7 23|cDNA hybridization
P01702972A0613|26 35|genomic DNA
P01702972A0613|67 76|G0S19 genes
P01702972A0613|67 76|G0S19 genes
P01702972A0613|116 120|cDNAs
P01702972A0613|131 139|G0S30 cDNA
P01702972A0613|131 139|G0S30 cDNA
P01702972A0613|155 170|single-copy genes
P01703335T0000|0 27|Lymphoproliferative disorders
P01703335T0000|40 56|immunosuppression
P01703335T0000|61 65|FK 506
P01703335T0000|94 113|transplant population
P01703632T0000|3 33|Drosophila suppressor of sable gene
P01703632T0000|3 33|Drosophila suppressor of sable gene
P01703632T0000|80 98|RNA-binding proteins
P01703632T0000|80 98|RNA-binding proteins
P01705541A0273|2 8|121-133
P01707659A0458|54 58|' gene
P01707659A0458|60 66|HLA-5.4
P01707659A0458|60 66|HLA-5.4
P01707659A0458|76 89|chimpanzee gene
P01707659A0458|91 94|Ch28
P01707659A0458|91 94|Ch28
P01707800A0354|11 17|N13-N20
P01707800A0354|61 73|parallel shift
P01707800A0354|127 135|latencies
P01707800A0354|138 140|N11
P01707800A0354|144 146|N20
P01708098A0922|5 40|avidin-biotin complex DNA binding assays
P01708098A0922|5 10|avidin
P01708098A0922|12 17|biotin
P01708098A0922|51 86|overlapping alpha promoter DNA sequences
P01708098A0922|62 74|alpha promoter
P01708098A0922|141 142|GR
P01708098A0922|141 142|GR
P01708098A0922|159 161|GRE
P01708098A0922|168 180|bound receptor
P01708771A1215|0 20|Sequence determination
P01708771A1215|23 30|isolated
P01708771A1215|52 57|Asn120
P01708771A1215|60 71|glycosylated
P01708771A1215|73 77|Asn65
P01708771A1215|81 86|Asn109
P01708771A1215|87 98|glycosylated
P01708771A1215|132 136|Asn72
P01708771A1215|140 151|glycosylated
P01708774A0203|3 35|DNA sequence conferring AP-1 activity
P01708774A0203|24 27|AP-1
P01708774A0203|51 72|proximal promoter region
P01709486A0000|3 37|murine mutation dominant white spotting
P01709486A0000|48 61|proto-oncogene
P01709486A0000|48 61|proto-oncogene
P01709486A0000|63 67|c-kit
P01709486A0000|63 67|c-kit
P01709933T0000|33 50|rat chromosomal gene
P01709933T0000|33 50|rat chromosomal gene
P01709933T0000|54 65|a polypeptide
P01709933T0000|67 69|pS1
P01709933T0000|67 69|pS1
P01710766A0349|42 44|21-
P01710766A0349|45 62|amino-acid sequence
P01710766A0349|72 90|amino acids C terminal
P01710768A1172|93 117|tissue-specific expression
P01710768A1172|123 132|HLA-B7 gene
P01710768A1172|123 132|HLA-B7 gene
P01710768A1172|167 181|gamma interferon
P01710768A1172|167 181|gamma interferon
P01710979T0000|3 18|SH2 and SH3 domains
P01710979T0000|3 5|SH2
P01710979T0000|9 11|SH3
P01710979T0000|21 27|pp60src
P01710979T0000|21 27|pp60src
P01710979T0000|55 84|tyrosine phosphorylated proteins
P01710979T0000|85 88|p130
P01710979T0000|85 88|p130
P01710979T0000|92 95|p110
P01710979T0000|92 95|p110
P01711041A0348|36 49|structural gene
P01711041A0348|69 81|C5 alpha-chain
P01711041A0348|69 81|C5 alpha-chain
P01711041A0348|93 102|beta-chain
P01711041A0348|93 102|beta-chain
P01711041A0962|3 15|C5 alpha-chain
P01711041A0962|3 15|C5 alpha-chain
P01711041A0962|51 55|exons
P01711041A0962|60 69|beta-chain
P01711041A0962|60 69|beta-chain
P01711041A0962|103 109|16 exons
P01711048T0000|0 19|Heterozygous mutation
P01711048T0000|25 35|G+5 position
P01711048T0000|38 45|intron 33
P01711048T0000|51 67|pro-alpha 2(I) gene
P01711048T0000|51 60|pro-alpha 2
P01711048T0000|62 67|I) gene
P01711048T0000|69 74|COL1A2
P01711048T0000|69 74|COL1A2
P01711048T0000|86 104|aberrant RNA splicing
P01711048T0000|108 135|lethal osteogenesis imperfecta
P01713213A0000|37 60|human pim-1 proto-oncogene
P01713213A0000|37 46|human pim-1
P01713213A0000|47 60|proto-oncogene
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|133 148|human Pim-1 enzyme
P01713213A0000|133 148|human Pim-1 enzyme
P01713213A0000|183 211|protein tyrosine kinase activity
P01713213A0000|183 203|protein tyrosine kinase
P01713213A0488|12 25|human pim-1 cDNA
P01713213A0488|12 21|human pim-1
P01713213A0488|22 25|cDNA
P01713213A0488|45 66|bacterial vector pGEX-2T
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|73 77|Pim-1
P01713213A0488|97 109|fusion product
P01713213A0488|114 146|bacterial glutathione S-transferase
P01713213A0488|123 150|glutathione S-transferase (GST
P01713213A0488|148 150|GST
P01714322A0969|42 50|18 kDa hsps
P01714322A0969|47 50|hsps
P01714322A0969|90 94|genes
P01714358A0990|3 18|10 kDa polypeptide
P01714358A0990|55 77|wheat etioplast membranes
P01714358A0990|82 91|[gamma 32P]
P01714358A0990|92 94|ATP
P01714452A0559|15 26|human protein
P01714452A0559|15 26|human protein
P01714452A0559|41 58|tandem repeat domain
P01714452A0559|87 93|serines
P01714452A0559|116 152|sites of O-linked carbohydrate attachment
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|39 50|Ti alpha-beta
P01714902A0221|51 70|CD3 gamma delta epsilon
P01714902A0221|71 82|TCR complexes
P01714902A0221|88 98|cell surface
P01714902A0221|100 106|CD3 zeta
P01714902A0221|100 106|CD3 zeta
P01714902A0221|130 152|interleukin-2 production
P01714902A0221|130 142|interleukin-2
P01714902A0221|158 171|TCR stimulation
P01714902A0221|158 160|TCR
P01714902A0221|176 213|antigen/major histocompatibility complex
P01714902A0221|176 213|antigen/major histocompatibility complex
P01715593A0838|4 14|desipramine
P01715593A0838|56 66|brain levels
P01715593A0838|69 79|desipramine
P01715975A0885|17 20|CYP1
P01715975A0885|17 20|CYP1
P01716292A0000|1 17|segmental analysis
P01716292A0000|35 41|HLA-DR1
P01716292A0000|35 41|HLA-DR1
P01716292A0000|53 72|T cell allorecognition
P01716292A0000|101 120|transfected cell lines
P01716292A0000|155 163|DRB/H-2Eb
P01716292A0000|155 157|DRB
P01716292A0000|159 163|H-2Eb
P01716292A0000|170 175|paired
P01716292A0000|186 203|DR alpha or H-2E alpha
P01716292A0000|186 192|DR alpha
P01716292A0000|195 203|H-2E alpha
P01716629A0000|15 24|cDNA clones
P01716629A0000|39 69|extracellular matrix glycoprotein
P01716629A0000|39 69|extracellular matrix glycoprotein
P01716629A0000|70 76|undulin
P01717718A1255|31 39|Gag-Pol PR
P01717718A1255|31 33|Gag
P01717718A1255|35 45|Pol PR domain
P01717718A1255|67 68|RT
P01717718A1255|79 89|wild-type PR
P01717718A1255|88 89|PR
P01717718A1255|132 139|PR domain
P01717718A1255|132 133|PR
P01717718A1255|142 144|Gag
P01717718A1255|142 144|Gag
P01717718A1255|146 148|Pol
P01717718A1255|146 148|Pol
P01717718A1255|178 179|RT
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|41 43|CRE
P01717833A1223|72 85|granulosa cells
P01717833A1223|102 112|CREB protein
P01717833A1223|102 105|CREB
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|33 49|cyclic adenosine 3'
P01717833T0000|33 47|cyclic adenosine
P01717833T0000|48 50|3',
P01717833T0000|51 66|5'-monophosphate
P01717833T0000|88 104|rat granulosa cells
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|52 60|bovine DNA
P01717925A0477|104 115|bp downstream
P01717925A0477|123 134|coding region
P01717994T0000|10 18|human cDNA
P01717994T0000|10 18|human cDNA
P01717994T0000|28 45|CDC2-related kinase
P01717994T0000|28 45|CDC2-related kinase
P01717994T0000|73 90|yeast cdc28 mutation
P01717994T0000|78 82|cdc28
P01718043A0384|2 9|patients
P01718043A0384|14 26|osteomyelitis
P01718043A0384|48 58|PMN elastase
P01718043A0384|48 58|PMN elastase
P01718043A0384|132 148|sedimentation rate
P01718983A1640|0 0|E
P01718983A1640|55 63|Chi-Rosso
P01719684A0494|36 60|alpha-adrenergic receptors
P01719684A0494|36 60|alpha-adrenergic receptors
P01719684A0494|69 76|prostate
P01719684A0494|141 164|urinary sphincter function
P01720555A1087|15 36|2-kilobase B2 transcript
P01720843A1506|27 36|sulfhydryl
P01720843A1506|51 87|angiotensin converting enzyme inhibitors
P01720843A1506|51 77|angiotensin converting enzyme
P01720843A1506|127 146|nitrovasodilator EDRF
P01720843A1506|143 146|EDRF
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|18 22|FK 506
P01721261T0000|25 42|transplant patients
P01721884A0962|37 48|E. coli region
P01721884A0962|37 48|E. coli region
P01721884A0962|62 84|retroviral ribonuclease H
P01721884A0962|72 84|ribonuclease H
P01721884A0962|86 98|RNase H) domain
P01721884A0962|86 98|RNase H) domain
P01721884A0962|180 191|E. coli RNase H
P01721884A0962|180 191|E. coli RNase H
P01721884A0962|207 218|Pol I helices O
P01721884A0962|207 217|Pol I helices
P01721884A0962|218 218|O
P01721884A0962|222 222|P
P01721884A0962|238 245|helices A
P01721884A0962|255 276|RNase H crystal structure
P01721884A0962|255 260|RNase H
P01722319A0849|20 36|amino acid sequence
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|73 95|bilayer-spanning domains
P01722319A0849|118 166|N-glycosylation sites, and intracellular N and C termini
P01722479A0302|30 32|HCG
P01722479A0302|30 32|HCG
P01723619A0766|3 13|reduced rate
P01723619A0766|16 26|F absorption
P01723619A0766|42 61|plasma F concentration
P01723619A0766|48 48|F
P01723619A0766|81 87|gastric
P01723619A0766|117 117|F
P01723619A0766|125 138|small intestine
P01723619A0766|144 154|major factor
P01723619A0766|144 154|major factor
P01723619A0766|157 172|rapid F absorption
P01723962A0165|13 23|serum lipase
P01723962A0165|13 23|serum lipase
P01723962A0165|27 33|amylase
P01723962A0165|27 33|amylase
P01723962A0165|99 103|Na-Tc
P01724982A0237|18 25|anti-HCV
P01724982A0237|27 37|anti-C100-3
P01724982A0237|27 37|anti-C100-3
P01724982A0237|49 51|kit
P01724982A0237|53 61|Abbott Lab
P01724982A0237|77 79|IL)
P01725547A0354|0 8|Diltiazem
P01725547A0354|78 90|coronary blood
P01725547A0354|96 98|CBF
P01725622A0292|8 18|transfusion
P01725622A0292|49 53|32 Gpt
P01725622A0292|57 61|CCI 11
P01726211A0502|45 62|vessel wall-related
P01726211A0502|80 90|focal action
P01726211A0502|92 106|systemic factors
P01726631T0001|0 11|Epidemiology
P01726631T0001|27 44|hospital infections
P01726631T0001|67 73|Sassari
P01726631T0001|84 102|bacterial resistance
P01726631T0001|106 124|antimicrobial agents
P01727488A1146|0 21|PRDII-BF1-derived cDNAs
P01727488A1146|0 4|PRDII
P01727488A1146|6 21|BF1-derived cDNAs
P01727488A1146|62 95|tat-induced activated gene expression
P01727488A1146|62 85|tat-induced activated gene
P01727494A0000|0 12|Vaccinia virus
P01727494A0000|14 15|VV
P01727494A0000|50 59|VV proteins
P01727494A0000|88 101|immune response
P01730412T0000|0 2|Max
P01730412T0000|0 2|Max
P01730412T0000|39 43|c-Myc
P01730412T0000|39 43|c-Myc
P01730747A0205|15 24|G1 to S phase
P01731107A0928|44 52|ICR2 motif
P01731107A0928|44 52|ICR2 motif
P01731107A0928|68 82|pRNA replication
P01731107A0928|132 133|5'
P01731107A0928|134 151|stem-loop structure
P01731107A0928|176 186|viral genome
P01731933T0000a|0 4|Zn(II
P01731933T0000a|0 4|Zn(II
P01731933T0000a|33 47|T4 gene 32 protein
P01731933T0000a|33 34|T4
P01731933T0000b|0 4|Zn(II
P01731933T0000b|0 4|Zn(II
P01731933T0000b|33 47|T4 gene 32 protein
P01731933T0000b|33 34|T4
P01731979A1408|3 19|tissue specificity
P01731979A1408|22 35|gene expression
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01732033A0000|3 17|pathophysiology
P01732033A0000|41 56|acute brain injury
P01732033A0000|69 77|childhood
P01732033A0000|95 119|acute traumatic brain injury
P01732736A1076|22 35|POU-domain gene
P01732736A1076|22 31|POU-domain
P01732736A1076|37 42|Oct-25
P01732736A1076|37 42|Oct-25
P01732736A1076|68 74|oocytes
P01732736A1076|78 89|early embryos
P01732736A1076|126 142|early gastrulation
P01732752A0156|6 16|early B cells
P01732752A0156|20 45|Abelson murine leukemia virus
P01732752A0156|58 72|pre-B-cell lines
P01732752A0156|74 79|LT mRNA
P01732752A0156|74 75|LT
P01732752A0156|76 79|mRNA
P01733105A0127|11 22|Thogoto virus
P01733105A0127|45 59|single-stranded
P01733105A0127|61 76|negative sense RNA
P01733358A0240|5 10|tumors
P01733358A0240|46 61|I, cystadenoma; II
P01733358A0240|89 102|adenocarcinoma
P01733358A0240|107 121|mucin production
P01733358A0240|107 111|mucin
P01733358A0240|136 139|cyst
P01734020A1318|0 13|Immunostaining
P01734020A1318|70 82|myristoylated
P01734020A1318|124 129|nuclei
P01734020A1318|138 154|wild-type PKC alpha
P01734020A1318|147 154|PKC alpha
P01734283A0817|27 38|RAP74 protein
P01734283A0817|27 31|RAP74
P01734283A0817|43 59|purified HeLa cells
P01734283A0817|70 85|complementary DNA
P01734283A0817|101 118|translation product
P01734283A0817|134 138|RAP30
P01734283A0817|134 138|RAP30
P01734570T0000|9 39|thromboxane synthetase inhibition
P01734570T0000|9 29|thromboxane synthetase
P01734570T0000|60 77|vascular resistance
P01734570T0000|90 111|bacterial translocation
P01734570T0000|115 133|chronic porcine model
P01735347A0482|10 19|pancreatic
P01735347A0482|84 95|plasma lipase
P01735347A0482|84 95|plasma lipase
P01735347A0482|115 121|ascites
P01735347A0482|141 158|pancreatic necrosis
P01735447A0271|12 25|mutant molecule
P01735447A0271|53 72|cytoplasmic precursor
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|84 90|pro-PrB
P01735447A0271|105 116|sec61 mutants
P01735447A0271|105 116|sec61 mutants
P01735447A0271|142 161|endoplasmic reticulum
P01735447A0833|8 26|active-site mutation
P01735447A0833|8 18|active-site
P01735447A0833|62 75|N-glycosylated
P01735447A0833|76 90|73-kDa precursor
P01735447A0833|93 95|PrB
P01735447A0833|93 95|PrB
P01735447A0833|101 114|41.5 kDa pro-PrB
P01735447A0833|108 114|pro-PrB
P01735447A0833|120 139|endoplasmic reticulum
P01735721A0185|3 28|predicted amino acid sequence
P01735721A0185|57 87|Bacillus stearothermophilus TyrTS
P01735721A0185|57 82|Bacillus stearothermophilus
P01735721A0185|83 87|TyrTS
P01735721A0185|110 120|E. coli TyrTS
P01735721A0185|110 115|E. coli
P01735721A0185|116 120|TyrTS
P01735721A0185|144 151|cryptic B
P01735721A0185|151 169|B. subtilis TyrTS gene
P01735721A0185|153 169|subtilis TyrTS gene
P01735721A0185|181 184|tyrZ
P01735721A0185|181 184|tyrZ
P01736093A0731|14 24|CAT activity
P01736093A0731|14 16|CAT
P01736093A0731|68 81|native promoter
P01736093A0731|97 106|CCAAT boxes
P01736093A0731|117 119|HSE
P01736093A0731|136 148|constructions
P01736651A0104|0 6|SETTING
P01736844T0000|0 28|Testosterone, free testosterone
P01736844T0000|30 59|non-sex hormone-binding globulin
P01736844T0000|34 59|sex hormone-binding globulin
P01736844T0000|66 77|testosterone
P01736844T0000|82 98|free androgen index
P01736844T0000|105 127|testosterone measurement
P01736844T0000|159 172|sexual function
P01736844T0000|175 177|men
P01736844T0000|182 189|epilepsy
P01737741A0000|29 54|monoamine oxidase inhibitors
P01737741A0000|29 44|monoamine oxidase
P01737741A0000|56 60|MAOIs
P01737741A0000|64 72|tricyclic
P01737789A0800|3 31|upstream delta-alpha breakpoint
P01737789A0800|46 58|direct repeats
P01737789A0800|72 81|splice site
P01737789A0800|104 124|alpha-delta breakpoint
P01737789A0800|147 152|intron
P01738470A0441|0 7|Patients
P01738470A0441|20 24|PDDAT
P01738470A0441|42 56|serial positions
P01738470A0441|79 102|spatial recognition memory
P01738653T0014|0 11|Bone and bones
P01738936A0292|3 10|patients
P01738936A0292|20 28|C-peptide
P01739439A0257|7 26|repetitive discharges
P01739439A0257|50 56|mdx mice
P01739439A0257|132 148|normal control mice
P01739956A0638|0 9|Management
P01739956A0638|31 44|calcium channel
P01739956A0638|60 65|type IC
P01740121A0136|41 45|Kex2p
P01740121A0136|41 45|Kex2p
P01740121A0136|54 91|baculovirus/insect cell expression system
P01740437A0851|14 24|core protein
P01740437A0851|35 49|HSPG preparation
P01740437A0851|111 127|cytoplasmic domain
P01740437A0851|130 140|fibroglycan
P01740448A1735|14 33|transmembrane regions
P01740448A1735|61 89|hydrophobic amino acid stretches
P01740448A1735|126 136|Pro II region
P01740448A1735|126 136|Pro II region
P01740448A1735|189 197|membranes
P01740682A0703|34 39|emesis
P01740682A0703|49 56|patients
P01740682A0703|75 84|leukopenia
P01740682A0703|92 113|Health Organization (WHO
P01740682A0703|133 140|patients
P01740682A0703|162 177|thrombocytopenia
P01740682A0703|187 194|patients
P01742341A0499|100 109|Beagle dogs
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|26 29|cDNA
P01742606A0000|50 76|lambda Gt11 expression library
P01742606A0000|84 91|antibody
P01742606A0000|121 146|235 kDa spectrin beta-subunit
P01742606A0000|121 146|235 kDa spectrin beta-subunit
P01742879A0471|8 16|Plasma AVP
P01742879A0471|28 45|osmotic stimulation
P01742879A0471|73 80|drinking
P01742879A0471|94 101|patients
P01742879A0471|106 128|compulsive water drinking
P01744039A0511|39 61|polymerase chain reaction
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|101 137|single-strand conformation polymorphism
P01744042A1355|3 12|csbA fusion
P01744042A1355|3 12|csbA fusion
P01744042A1355|74 83|Luria broth
P01744042A1355|96 102|glucose
P01744042A1355|110 118|glutamine
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|111 138|oligoribonucleotide synthesis
P01744119A0757|144 161|63-kDa gene 4 protein
P01744119A0757|144 161|63-kDa gene 4 protein
P01747972T0000|0 18|Thrombolytic therapy
P01747972T0000|21 39|spontaneous coronary
P01748067A0000|35 52|unselected patients
P01748067A0000|56 84|men, mean age 67.5 years, 115 women
P01748067A0000|118 125|total hip
P01748067A0000|165 185|inflammatory arthritis
P01748067A0000|201 214|neck of the femur
P01748194A0767|118 138|spinal cord transection
P01748287T0000|5 23|SRF-related proteins
P01748287T0000|5 23|SRF-related proteins
P01748287T0000|25 45|DNA-binding properties
P01748292A0000|14 18|cDNAs
P01748292A0000|37 56|G protein alpha subunit
P01748292A0000|37 56|G protein alpha subunit
P01748292A0000|61 92|tomato (Lycopersicon esculentum, cv
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|59 63|c-Myc
P01748630A0125|59 63|c-Myc
P01748630A0125|97 101|Ser62
P01748630A0125|109 126|proline-rich region
P01748630A0125|165 173|Myc family
P01748630A0125|165 173|Myc family
P01748630A0125|175 181|Alvarez
P01751163A0000|34 56|thrombotic complications
P01751163A0000|83 93|ventricular
P01751163A0000|100 105|device
P01751163A0000|107 118|Sarns/3M-VAD
P01751163A0000|126 131|calves
P01751255A0529|0 15|Cardiac output (CO
P01751255A0529|61 69|MBBF group
P01751970A0209|5 23|acid residues 147-167
P01751970A0209|68 78|new residues
P01752441A0000|0 24|Transcriptional activation
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|95 107|trinucleotide
P01752441A0000|118 123|TAR RNA
P01752441A0000|124 141|stem-loop structure
P01752441A0000|152 172|5'-untranslated leader
P01752441A0000|178 193|viral transcripts
P01752792A0000|69 72|ITDs
P01752792A0000|76 87|click stimuli
P01752792A0000|110 123|auditory cortex
P01752792A0000|126 147|anesthetized albino rats
P01753317A0879|31 37|locally
P01753317A0879|46 48|TTC
P01753317A0879|66 69|FDBA
P01753317A0879|81 93|bone formation
P01753317A0879|96 126|experimental alveolar bone defects
P01754381A0000|43 56|replicative DNA
P01754381A0000|134 173|Trypanosoma (Trypanozoon) brucei brucei gene
P01754381A0000|188 205|DNA polymerase alpha
P01754381A0000|188 205|DNA polymerase alpha
P01754381A0000|220 227|pol alpha
P01754381A0000|220 227|pol alpha
P01756539A0354|9 20|hypertension
P01756539A0354|35 42|coronary
P01756539A0354|89 112|isolated atrial infarction
P01757341A0591|18 19|Vv
P01757341A0591|35 36|Na
P01757341A0591|43 53|capillaries
P01757341A0591|66 76|nonperfused
P01757341A0591|92 96|brain
P01757341A0591|127 145|alkaline phosphatase
P01757341A0591|127 145|alkaline phosphatase
P01758750A0000|0 23|Airway pressure and air flow
P01758750A0000|61 68|children
P01758750A0000|81 91|ventilators
P01759052A0786|0 3|Appl
P01759282A0000|0 5|Issues
P01759282A0000|37 54|traumatizing object
P01760166A0963|21 24|SpO2
P01760166A0963|30 40|nasal septum
P01760166A0963|92 110|hypothermic patients
P01761736A0158|0 8|Diltiazem
P01761736A0158|26 38|body clearance
P01761736A0158|137 140|14.3
P01761736A0158|168 177|antipyrine
P01762053A0557|49 57|void space
P01762914A1218|9 19|uPA promoter
P01762914A1218|9 19|uPA promoter
P01762914A1218|40 57|cis-acting elements
P01762914A1218|85 104|translation start site
P01762917A0615|13 15|Ser
P01762917A0615|19 23|Gly69
P01762917A0615|27 35|Glu for Lys
P01762917A0615|52 67|TGEK tetrapeptide
P01762917A0615|52 55|TGEK
P01762917A0615|70 77|finger II
P01762917A0615|80 85|TFIIIA
P01762917A0615|80 85|TFIIIA
P01762917A0615|105 114|DNA binding
P01763065A0913|0 0|P
P01763106A0070|6 24|exploratory behavior
P01763106A0070|36 44|hole pokes
P01764899A0399|40 56|water fluoridation
P01764899A0399|114 124|cavity level
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|85 89|mRNAs
P01765095A0680|102 119|myogenic regulators
P01765095A0680|120 123|CMD1
P01765095A0680|120 123|CMD1
P01765095A0680|127 134|myogenin
P01765095A0680|127 134|myogenin
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|34 73|elongation factor 1-alpha variant EF-1 alpha O
P01765266A0000|34 56|elongation factor 1-alpha
P01765266A0000|64 73|EF-1 alpha O
P01765266A0000|90 95|oocyte
P01765266A0000|120 131|early embryos
P01765269A0308|5 11|introns
P01765269A0308|30 44|nuclear pre-mRNA
P01765269A0308|45 51|introns
P01765269A0308|69 95|5'- and 3'-consensus sequences
P01765375A0290|23 38|human and rat cells
P01765375A0290|46 63|human clathrin clone
P01765375A0290|46 58|human clathrin
P01765375A0290|163 180|clathrin heavy chain
P01765375A0290|163 180|clathrin heavy chain
P01765386A0305|62 63|5'
P01765386A0305|78 82|4 kb of
P01765386A0305|83 89|exon and
P01765386A0305|90 100|exon-intron
P01765386A0305|114 120|583 bp 3'
P01765407A0866|19 25|DMEA/m3
P01765407A0866|40 70|postexposure plasma concentration
P01765407A0866|77 104|postexposure urinary excretion
P01766666A0788|20 23|rE12
P01766666A0788|20 23|rE12
P01766666A0788|27 33|rNFIL-6
P01766666A0788|27 33|rNFIL-6
P01766666A0788|41 62|nucleoprotein complexes
P01766666A0788|72 87|DNA-binding sites
P01766666A0788|72 87|DNA-binding sites
P01766876A0000|30 43|targeted events
P01766876A0000|49 64|mu heavy chain gene
P01766876A0000|49 64|mu heavy chain gene
P01766876A0000|94 104|co-exchange
P01766876A0000|155 171|replacement vector
P01766999A0000|0 17|Allergenic activity
P01766999A0000|51 52|AE
P01766999A0000|65 81|fifteen volunteers
P01767060A0000|35 39|c-DDP
P01767060A0000|71 82|radiotherapy
P01767060A0000|156 163|patients
P01767060A0000|199 216|squamous carcinomas
P01767060A0000|222 225|head
P01767060A0000|229 232|neck
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|66 83|non-coding 5' region
P01767592A0682|66 83|non-coding 5' region
P01767592A0682|86 122|HAP2/HAP3 consensus recognition sequence
P01767592A0682|86 89|HAP2
P01767592A0682|91 94|HAP3
P01767592A0682|125 138|nucleotide-154
P01767592A0682|143 174|BAF1 consensus recognition sequence
P01767592A0682|143 174|BAF1 consensus recognition sequence
P01767592A0682|177 190|nucleotide-136
P01767899A0136|0 21|Marked thrombocytopenia
P01767899A0136|34 48|serum fibrinogen
P01767899A0136|39 48|fibrinogen
P01767899A0136|61 71|prothrombin
P01767899A0136|91 104|thromboplastin
P01767899A0136|150 172|intravenous envenomation
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|52 87|dimerization and DNA-contacting domains
P01768648A0853|90 93|cRel
P01768648A0853|90 93|cRel
P01769189A0000|0 32|Plasma lipid and lipoprotein profiles
P01769189A0000|47 66|elderly female runners
P01769189A0000|68 69|RU
P01769189A0000|92 98|body fat
P01769189A0000|139 144|VO2max
P01769189A0000|187 200|untrained women
P01769189A0000|202 203|UT
P01769189A0000|222 228|body fat
P01769919A0393|0 22|Auditory threshold shifts
P01769919A0393|39 69|auditory evoked brainstem response
P01769919A0393|102 106|24 kHz
P01770651T0001|0 31|Fundamental and clinical evaluation
P01770651T0001|55 76|radioimmunoassay system
P01770651T0001|93 110|serum free thyroxine
P01771593A1152|14 15|TA
P01771593A1152|41 43|AGD
P01771593A1152|46 47|GD
P01771593A1152|74 78|PCD 23
P01771593A1232|14 19|adults
P01771593A1232|54 55|TA
P01771959A0442|5 8|PTCA
P01771959A0442|141 144|PTCA
P01771959A0442|161 164|PTCA
P01771959A0442|220 223|PTCA
P01771959A0442|238 241|PTCA
P01771959A0442|243 244|19
P01772201T0001|3 18|alcoholic patient
P01772341A0852|45 74|thromboxane synthetase inhibitor
P01772341A0852|45 65|thromboxane synthetase
P01772341A0852|79 107|thromboxane receptor antagonist
P01772341A0852|79 97|thromboxane receptor
P01772341A0852|140 158|digoxin intoxication
P01774062A0257|7 9|YAC
P01774062A0257|11 16|A148A7
P01774062A0257|32 44|HLA-DQA1 locus
P01774062A0257|32 39|HLA-DQA1
P01774062A0257|55 62|Y3/Ring 4
P01774062A0257|55 56|Y3
P01774062A0257|58 67|Ring 4 locus
P01774062A0257|86 90|130 kb
P01774062A0257|104 106|YAC
P01774062A0257|107 111|B1D12
P01774063A0161|0 29|Interspecific backcross analysis
P01774063A0161|63 70|C57BL/6J
P01774063A0161|72 85|Mus spretus) F1 x
P01774063A0161|86 97|C57BL/6J mice
P01774063A0161|114 131|thrombospondin gene
P01774063A0161|114 127|thrombospondin
P01774063A0161|152 155|Fshb
P01774063A0161|157 161|Actcl
P01774063A0161|163 165|Ltk
P01774063A0161|170 176|B2M loci
P01774063A0161|170 176|B2M loci
P01774063A0161|179 195|murine chromosome 2
P01774093T0000|30 32|IgM
P01774093T0000|41 60|Chlamydia trachomatis
P01774093T0000|61 69|infection
P01774093T0000|72 80|pregnancy
P01774822A0289|7 22|image-processing
P01774822A0289|81 92|cardiac cycle
P01776306A0572|19 20|VT
P01776715A0489|81 83|CO2
P01776715A0489|114 116|gas
P01777841A0744|44 62|post-tetanic effects
P01777841A0744|67 93|muscle and cutaneous afferents
P01777841A0744|96 112|adults and neonates
P01779299A0000|36 49|brown cockroach
P01779299A0000|51 68|Periplaneta brunnea
P01779299A0000|101 124|Moniliformis moniliformis
P01779433A0694|28 42|Alu family repeat
P01779433A0694|28 30|Alu
P01779433A0694|79 79|I
P01779433A0694|102 126|alpha 2 gene-containing unit
P01779433A0694|102 111|alpha 2 gene
P01779433A0694|129 141|rhesus macaque
P01779433A0694|157 163|dimeric
P01779433A0694|164 178|Alu family repeat
P01779433A0694|164 166|Alu
P01779433A0694|180 183|Alu 3
P01779433A0694|180 183|Alu 3
P01779433A0694|251 265|Alu family repeat
P01779433A0694|251 253|Alu
P01779433A0694|273 277|3' end
P01779433A0694|298 312|Alu family repeat
P01779433A0694|298 300|Alu
P01779769A0000|16 29|repressor locus
P01779769A0000|16 24|repressor
P01779769A0000|31 31|c
P01779769A0000|38 70|Streptomyces temperate phage, phi C31
P01779769A0000|101 116|open reading frame
P01779769A0000|126 137|74 kDa protein
P01780235A0094|3 11|EPO levels
P01780235A0094|3 5|EPO
P01780235A0094|41 51|transfusion
P01780235A0094|91 101|transfusion
P01781923A0744|29 30|DB
P01781923A0744|65 66|DB
P01781923A0744|84 91|righting
P01781923A0744|94 95|LS
P01781923A0744|150 166|brain distribution
P01782424A0278|93 101|sentinels
P01782669A0496|57 62|A23187
P01782982A0155|0 9|Felodipine
P01782982A0155|32 35|FEV1
P01782982A0155|83 123|histamine and AMP induced bronchoconstriction
P01783088A1136|10 17|patients
P01783088A1136|43 51|mast cells
P01783088A1136|77 86|hyaluronan
P01783088A1136|120 122|l-1
P01783088A1136|126 136|fibronectin
P01783088A1136|196 203|patients
P01783088A1136|216 232|regressive disease
P01783375A1066|94 102|neoplasia
P01784589A0000|41 61|5-HT2 receptor activity
P01784589A0000|41 53|5-HT2 receptor
P01784589A0000|68 70|rat
P01784589A0000|71 84|sexual behavior
P01785749A0695|44 56|obese children
P01787085A0331|39 49|control rats
P01787085A0331|51 69|99mTc-sulfur colloid
P01788002T0001|0 13|Magnetotherapy
P01788002T0001|16 29|hepatitis A and B
P01788002T0001|16 25|hepatitis A
P01788002T0001|29 29|B
P01788002T0001|32 39|children
P01791363A0208|35 42|patients
P01791363A0208|47 75|conventional end-to-end sutures
P01791754T0000|0 17|Mutational analysis
P01791754T0000|65 89|C-terminal secretion signal
P01791754T0000|92 116|Escherichia coli haemolysin
P01791754T0000|92 116|Escherichia coli haemolysin
P01792580A0198|5 15|blood donors
P01792580A0198|31 36|Serbia
P01792580A0198|59 72|blood donations
P01792580A0198|89 100|female donors
P01792580A0198|146 160|male blood donors
P01792914T0000|23 39|childhood leukemia
P01797459A0103|0 19|Mycoplasma pneumoniae
P01797459A0103|38 49|pleural fluid
P01797459A0103|56 62|patient
P01797467A0000|0 13|RU486 and ONO 802
P01797467A0000|55 70|early termination
P01797467A0000|73 81|pregnancy
P01798407A1011|13 30|local abnormalities
P01798407A1011|37 44|patients
P01798407A1011|75 80|cortex
P01798407A1011|97 104|temporal
P01798407A1011|105 116|anterior lobe
P01798407A1011|144 159|laughing seizures
P01804671A1001|27 31|QS/QC
P01804671A1001|86 102|occluded air spaces
P01804671A1001|108 111|lung
P01804671A1001|190 196|gas data
P01804671A1001|201 206|CDCSF6
P01804671A1001|226 231|mmHg-1
P01806314A0322|24 46|endothelial-cell markers
P01806314A0322|67 84|monoclonal antibody
P01806314A0322|98 102|actin
P01808049A0262|0 1|CT
P01808049A0262|26 31|babies
P01808049A0262|40 49|hemorrhage
P01808049A0262|88 98|hypodensity
P01808049A0262|167 181|cerebral atrophy
P01808136T0000|12 24|contrast media
P01808136T0000|27 46|coagulation factor XII
P01808136T0000|27 43|coagulation factor
P01808136T0000|44 46|XII
P01808186A0984|0 3|Pigs
P01808186A0984|35 47|finishing diet
P01808602A0000|2 16|sixteen patients
P01808602A0000|89 118|serum uric acid and renal excretion
P01808602A0000|121 128|uric acid
P01808829A0510|0 3|TPTA
P01808829A0510|12 26|brain congestion
P01808829A0510|31 58|hepatic and pulmonary petechial
P01808829A0510|62 83|generalized hemorrhages
P01809854A0106|0 7|Examples
P01809854A0106|55 64|developing
P01809854A0106|65 83|consensus statements
P01809854A0106|91 103|meta-analysis
P01810108A0000|1 23|two phase slug flow tubular
P01810108A0000|24 36|heat exchanger
P01810108A0000|50 68|thermal inactivation
P01810108A0000|71 91|Listeria monocytogenes
P01810108A0000|94 112|natural infected milk
P01810108A0000|122 125|cows
P01810154A0491|7 14|children
P01811243A0000|8 24|cerebral blood flow
P01811243A0000|26 42|rCBF) measurements
P01811243A0000|46 63|psychiatric ratings
P01811243A0000|84 96|schizophrenic
P01811243A0000|97 104|patients
P01811243A0000|182 199|psychiatric ratings
P01811243A0000|214 226|rCBF technique
P01811948A0289|37 65|positive cis-regulatory element
P01811948A0289|68 79|-70 bp to -75 bp
P01811948A0289|85 100|LpS1 beta promoter
P01811948A0289|85 100|LpS1 beta promoter
P01811948A0289|117 119|G)6
P01811948A0289|142 152|cis-element
P01811948A0289|155 168|-721 bp to -726 bp
P01812102A0101|70 75|VEP-P)
P01812102A0101|95 107|pregnant women
P01812102A0101|120 126|latency
P01812102A0101|129 138|NPN complex
P01812102A0101|174 184|non pregnant
P01812690A0475|8 10|SMF
P01812690A0475|32 45|tumorous growth
P01814182A0000|16 34|15-methyl-PGF2 alpha
P01814182A0000|63 72|luteolysis
P01814182A0000|123 135|oestrous cycle
P01816655T0000|40 50|dermoid cyst
P01817497A0715|12 33|thermographic asymmetry
P01817497A0715|50 55|Delta T
P01817497A0715|94 117|post-treatment population
P01822581A0533|25 40|alcohol responses
P01822581A0533|120 137|10min post-exposure
P01822995T0000|0 16|Maize rbcS promoter
P01822995T0000|5 24|rbcS promoter activity
P01822995T0000|60 77|dicot rbcS promoters
P01822995T0000|60 77|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|25 61|commercial haematofluorometer Buchler ZF
P01823524A0238|84 99|combined exposure
P01823524A0238|209 219|xenobiotics
P01824713A0964|3 15|12S E1A product
P01824713A0964|3 15|12S E1A product
P01824713A0964|32 42|TRE sequence
P01824713A0964|65 80|c-jun circumvents
P01824713A0964|65 69|c-jun
P01824944A0988|18 28|tunicamycin
P01824944A0988|33 45|transfectants
P01824944A0988|68 85|18-kDa polypeptides
P01824944A0988|104 106|IgE
P01824944A0988|104 106|IgE
P01825027T0000|0 3|PAS1
P01825027T0000|0 3|PAS1
P01825027T0000|6 14|yeast gene
P01825027T0000|6 14|yeast gene
P01825027T0000|77 91|putative ATPases
P01825027T0000|85 91|ATPases
P01826003A0694|14 30|base pairs (bp) long
P01826003A0694|57 65|SIG family
P01826003A0694|57 65|SIG family
P01826003A0694|70 79|beta TG gene
P01826003A0694|70 75|beta TG
P01826003A0694|94 98|exons
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01826043A0431|3 23|pp90rsk-protein kinase
P01826043A0431|45 54|rsk-kinase
P01826043A0431|45 54|rsk-kinase
P01826043A0431|74 122|cofactor-dependent signal transducing protein kinases
P01826043A0431|132 164|cyclic AMP-dependent protein kinases
P01826043A0431|132 164|cyclic AMP-dependent protein kinases
P01826043A0431|178 197|protein kinase C family
P01826043A0431|178 197|protein kinase C family
P01826043A0431|206 235|Ca2(+)-dependent protein kinases
P01826043A0431|206 235|Ca2(+)-dependent protein kinases
P01827068T0000|0 10|Human GATA-3
P01827068T0000|5 10|GATA-3
P01827068T0000|13 49|lineage-restricted transcription factor
P01827068T0000|81 102|T cell receptor alpha gene
P01827068T0000|81 102|T cell receptor alpha gene
P01827203A0136|8 37|eukaryotic transcription factors
P01827203A0136|8 37|eukaryotic transcription factors
P01827203A0136|58 60|DNA
P01828248A0189|15 25|UvrA protein
P01828248A0189|15 25|UvrA protein
P01828248A0189|42 52|UvrB protein
P01828248A0189|42 52|UvrB protein
P01828248A0189|123 134|UvrAB complex
P01828248A0189|123 134|UvrAB complex
P01828248A0189|145 152|helicase
P01829060A0649|3 12|ED30 values
P01829060A0649|64 73|nifedipine
P01829060A0649|75 76|ED
P01829460A0329|0 23|Southwestern blot analysis
P01829460A0329|44 57|phosphoprotein
P01829460A0329|68 80|kappa B element
P01829460A0329|68 80|kappa B element
P01830114A1587|24 26|NS1
P01830114A1587|24 26|NS1
P01830114A1587|52 64|P4 transcripts
P01830114A1587|52 64|P4 transcripts
P01830114A1587|92 105|gene copy number
P01830114A1587|126 140|terminal repeats
P01830928A0361|3 37|minus-end-directed microtubule motors
P01830928A0361|42 48|dyneins
P01832019A0265|39 43|empty
P01832152A0000|3 17|incompatibility
P01832152A0000|31 33|pSa
P01832152A0000|44 67|Agrobacterium tumefaciens
P01832152A0902|47 57|ORF1 and ORF2
P01832197T0001|0 10|Imaging of D2
P01832197T0001|9 26|D2 dopamine receptor
P01832197T0001|11 26|dopamine receptor
P01833185A0547|3 19|Thr161Val mutation
P01833185A0547|27 41|lethal phenotype
P01833185A0547|54 58|yeast
P01833185A0547|59 82|Schizosaccharomyces pombe
P01833185A0547|102 107|Thr161
P01833185A0547|112 123|glutamic acid
P01833185A0547|167 180|uncoordination
P01833185A0547|183 189|mitosis
P01833185A0547|193 211|multiple cytokinesis
P01833637A0531|63 80|cdc68-1 mutant cells
P01833637A0531|63 75|cdc68-1 mutant
P01833637A0531|155 163|HSP82 gene
P01833637A0531|155 163|HSP82 gene
P01833716A0990|44 66|malignant transformation
P01833716A0990|81 86|HTLV-1
P01837787T0000|3 18|murine Mov-34 gene
P01837787T0000|3 18|murine Mov-34 gene
P01837787T0000|20 34|full-length cDNA
P01837787T0000|31 34|cDNA
P01837787T0000|38 56|genomic organization
P01837842A1410|0 3|CREB
P01837842A1410|0 3|CREB
P01837842A1410|58 74|gel shift complexes
P01837842A1410|95 97|CRE
P01839414T0000|36 53|malignant neoplasms
P01840513A1019|19 37|Drosophila SL-2 cells
P01840513A1019|39 49|pCAT plasmid
P01840513A1019|60 66|2,090 bp
P01840513A1019|69 85|5'-flanking region
P01840513A1019|116 155|chloramphenicol acetyltransferase activity
P01840513A1019|116 147|chloramphenicol acetyltransferase
P01840513A1019|174 185|retinoic acid
P01840513A1019|192 203|8-bromo-cAMP
P01840607A0294|23 28|5' UTRs
P01840607A0294|40 53|type I and type II
P01840607A0294|40 44|type I
P01840607A0294|48 53|type II
P01840607A0294|57 67|222 and 115 bp
P01840607A0294|105 107|PFP
P01840607A0294|105 107|PFP
P01840608A0823|3 12|N-terminus
P01840608A0823|22 37|open reading frame
P01840608A0823|52 55|nifA
P01840608A0823|52 55|nifA
P01840608A0823|82 85|nifB
P01840608A0823|82 85|nifB
P01840711A0000|3 11|RNA genome
P01840711A0000|14 19|rabbit
P01840711A0000|20 42|hemorrhagic disease virus
P01840711A0000|44 47|RHDV
P01840902A1089|39 54|nuclear targeting
P01840902A1089|57 62|plants
P01840902A1089|88 112|nuclear transport machinery
P01840902A1089|124 140|monocots and dicots
P01842498A0000|1 14|novel cDNA clone
P01842498A0000|21 22|R2
P01842498A0000|36 59|subtractive hybridization
P01842498A0000|63 73|cDNA library
P01842498A0000|76 144|phytohemagglutinin (PHA)/phorbol myristate acetate-stimulated Jurkat cells
P01842498A0000|76 93|phytohemagglutinin
P01842498A0000|95 97|PHA
P01842498A0000|162 172|cDNA library
P01842498A0000|175 214|PHA-stimulated peripheral blood lymphocytes
P01842498A0000|175 177|PHA
P01842867A0696|57 72|mechanical injury
P01842867A0696|78 88|nasal mucosa
P01844017A0410|48 89|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|48 81|glucose-6-phosphatase dehydrogenase
P01844017A0410|95 107|vitamin E level
P01844017A0410|148 160|sodium nitrite
P01844878A0000|1 6|vector
P01844878A0000|43 74|neomycin phosphotransferase II gene
P01844878A0000|43 74|neomycin phosphotransferase II gene
P01844878A0000|118 142|random genomic DNA fragments
P01844982A0324|0 13|Chagas' disease
P01844982A0324|37 54|anti-nuclear factor
P01844982A0324|37 54|anti-nuclear factor
P01844982A0324|72 87|rheumatoid factor
P01844982A0324|97 104|controls
P01845829A0158|21 33|98-bp sequence
P01845829A0158|54 75|protein-binding domains
P01845829A0158|95 108|nuclear factors
P01845829A0158|118 132|human brain cells
P01845885A1003|9 27|transcriptional unit
P01845885A1003|39 44|UL26.5
P01845885A1003|39 44|UL26.5
P01845885A1003|74 86|329 amino acids
P01845885A1003|98 103|family
P01845885A1003|134 137|mRNA
P01845885A1003|187 217|UL26 transcription initiation site
P01845885A1003|187 217|UL26 transcription initiation site
P01845885A1003|240 264|methionine initiation codon
P01845885A1003|274 286|position +1099
P01845885A1003|292 314|UL26 transcriptional unit
P01845885A1003|292 314|UL26 transcriptional unit
P01845899A0000|3 35|adeno-associated virus (AAV) rep gene
P01845899A0000|3 23|adeno-associated virus
P01845899A0000|25 27|AAV
P01845899A0000|56 60|Rep78
P01845899A0000|56 60|Rep78
P01845899A0000|62 66|Rep68
P01845899A0000|62 66|Rep68
P01845899A0000|68 72|Rep52
P01845899A0000|68 72|Rep52
P01845899A0000|77 81|Rep40
P01845899A0000|77 81|Rep40
P01845899A0000|94 110|AAV DNA replication
P01845899A0000|114 120|AAV gene
P01845899A0000|114 116|AAV
P01845899A0000|117 130|gene regulation
P01846206A0665|23 56|human CMV dbp also mediated replication
P01846206A0665|23 33|human CMV dbp
P01846206A0665|59 73|transient assays
P01846489A1119|15 47|picornaviral 3C-like protease domain
P01846489A1119|15 47|picornaviral 3C-like protease domain
P01846489A1119|54 79|papain-like protease domains
P01846489A1119|54 72|papain-like protease
P01846491A0459|33 39|VV genes
P01846491A0459|41 58|genus Orthopoxvirus
P01846491A0459|99 102|ORFs
P01846491A0459|105 107|SFV
P01846491A0459|109 127|genus Leporipoxvirus
P01846491A0459|240 247|ancestor
P01846803A0688|22 36|phosphorylation
P01846803A0688|39 41|Thr
P01846803A0688|50 54|Tyr 15
P01846803A0688|63 83|p34cdc2 kinase activity
P01846803A0688|63 75|p34cdc2 kinase
P01846803A0688|113 120|residues
P01846803A0688|138 151|ATP binding site
P01846803A0688|138 140|ATP
P01846803A0688|157 162|kinase
P01847464A0856|29 43|pFRTK-CAT target
P01847464A0856|29 33|pFRTK
P01847464A0856|35 37|CAT
P01847464A0856|54 72|EBNA-1-binding sites
P01847464A0856|54 72|EBNA-1-binding sites
P01847464A0856|80 88|EBV origin
P01847464A0856|91 108|plasmid replication
P01847464A0856|110 114|ori-P
P01847464A0856|136 188|carboxy-terminal EBNA-1 construction (amino acids 450 to 641
P01847464A0856|136 157|carboxy-terminal EBNA-1
P01847464A0856|206 210|c-myc
P01847464A0856|206 210|c-myc
P01847665A1079|55 67|PDGF receptors
P01847665A1079|55 67|PDGF receptors
P01847665A1079|70 80|glioma cells
P01847665A1079|150 169|developmental program
P01847665A1079|178 193|glia cell lineages
P01848300A0910|33 36|cstA
P01848300A0910|33 36|cstA
P01848871A0392|32 37|sodium
P01848871A0392|79 91|late potential
P01848871A0392|134 158|signal-averaged QRS complex
P01848871A0392|183 195|late potential
P01848871A0392|223 244|ventricular tachycardia
P01849509T0000|17 34|nucleotide sequence
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|105 115|transposase
P01849509T0000|105 115|transposase
P01849509T0000|125 129|ISRm3
P01849509T0000|125 129|ISRm3
P01849509T0000|147 171|Staphylococcus aureus IS256
P01849509T0000|147 171|Staphylococcus aureus IS256
P01849509T0000|175 202|Thiobacillus ferrooxidans IST2
P01849509T0000|175 202|Thiobacillus ferrooxidans IST2
P01849675A0167|52 62|DNA sequence
P01849675A0167|65 66|KV
P01849734A1063|8 25|PR55 beta transcript
P01849734A1063|8 15|PR55 beta
P01849734A1063|66 93|neuroblastoma derived cell line
P01849734A1063|94 99|LA-N-1
P01849734A1063|94 99|LA-N-1
P01849734A1063|114 117|mRNA
P01849734A1063|138 151|human cell lines
P01850096A0662|0 11|Heterodimers
P01850096A0662|14 21|myogenin
P01850096A0662|14 21|myogenin
P01850096A0662|25 27|E12
P01850096A0662|25 27|E12
P01850096A0662|31 34|MyoD
P01850096A0662|31 34|MyoD
P01850096A0662|38 40|E12
P01850096A0662|38 40|E12
P01850096A0662|60 78|restriction fragment
P01850096A0662|92 101|-200 to -103
P01850096A0662|122 152|cardiac alpha-actin transcription
P01850096A0662|122 139|cardiac alpha-actin
P01850105A1093|12 16|c-myc
P01850105A1093|12 16|c-myc
P01850105A1093|50 54|c-myc
P01850105A1093|50 54|c-myc
P01850105A1093|65 79|differentiation
P01850105A1093|95 96|Id
P01850105A1093|95 96|Id
P01850105A1093|118 138|muscle differentiation
P01850127A0000|19 25|U2 snRNP
P01850127A0000|19 25|U2 snRNP
P01850127A0000|33 51|branchpoint sequence
P01850127A0000|54 71|mammalian pre-mRNAs
P01850127A0000|63 71|pre-mRNAs
P01850127A0000|90 105|non-snRNP protein
P01850127A0000|90 105|non-snRNP protein
P01850127A0000|111 129|polypyrimidine tract
P01850893A0286|9 26|acquired antibodies
P01850893A0286|62 76|commercial farms
P01851386T0092|30 36|FONICAP
P01851527T0000|3 18|promoter activity
P01851527T0000|24 72|gene encoding Alzheimer beta-amyloid precursor protein
P01851527T0000|36 72|Alzheimer beta-amyloid precursor protein
P01851527T0000|74 76|APP
P01851527T0000|74 76|APP
P01851527T0000|102 118|upstream sequences
P01851862A0273|0 18|Nucleotide sequences
P01851862A0273|29 35|env gene
P01851862A0273|29 35|env gene
P01851862A0273|42 51|LTR of SFV-1
P01851862A0273|42 44|LTR
P01851862A0273|47 51|SFV-1
P01851876A0129|28 51|EMBL3 mouse genomic library
P01852438A0928|3 11|MVV-value
P01852438A0928|47 51|67-76
P01852603A0000|3 25|rad9.192 DNA repair mutant
P01852603A0000|3 6|rad9
P01852603A0000|11 25|DNA repair mutant
P01852603A0000|40 44|yeast
P01852603A0000|46 69|Schizosaccharomyces pombe
P01852603A0000|88 89|UV
P01852603A0000|93 109|ionising radiation
P01853796T0000|22 37|glucose tolerance
P01853796T0000|55 71|insulin resistance
P01853796T0000|55 61|insulin
P01854339A0221|3 10|5' region
P01854339A0221|42 74|Escherichia coli consensus promoters
P01854339A0221|42 74|Escherichia coli consensus promoters
P01854339A0221|78 102|ribosome-binding sequences
P01854339A0221|78 102|ribosome-binding sequences
P01854339A0221|136 141|E. coli
P01855255T0000|0 18|Premature initiation
P01855255T0000|30 34|yeast
P01855255T0000|42 45|RCC1
P01855255T0000|42 45|RCC1
P01855255T0000|48 66|an interacting GTPase
P01855255T0000|61 66|GTPase
P01856021A0577|111 130|occupational exposure
P01856021A0577|133 139|toluene
P01856021A0577|146 151|xylene
P01857143A0351|14 28|78-year-old male
P01857143A0351|35 45|skin lesions
P01857143A0351|68 80|myelofibrosis
P01857326A0160|57 62|IBM-AT
P01857326A0160|76 84|computers
P01860846A0663|3 11|human cDNA
P01860846A0663|3 11|human cDNA
P01860846A0663|36 60|tumor necrosis factor-alpha
P01860846A0663|36 60|tumor necrosis factor-alpha
P01860846A0663|82 104|MARCKS gene transcription
P01860846A0663|82 91|MARCKS gene
P01860846A0663|110 143|human promyelocytic leukemia cell line
P01860846A0663|144 147|HL60
P01861034A0798|19 34|proximal fragment
P01861034A0798|81 102|distal scaphoid fragment
P01861188A0000|0 10|Plate luting
P01861188A0000|53 56|PMMA
P01861188A0000|89 92|bone
P01861188A0000|112 121|screw heads
P01861188A0000|232 262|mid-diaphyseal osteotomies plated
P01861188A0000|280 300|ASIF compression plates
P01862027A0212|53 76|Rothmund-Thomson syndrome
P01862455T0000|0 6|Thyroid
P01862455T0000|7 14|lymphoma
P01863768A0649|19 24|ORF113
P01863768A0649|19 24|ORF113
P01863768A0649|34 52|transmembrane domain
P01863887A0174|76 111|tissue plasminogen activating substance
P01863887A0174|76 81|tissue
P01863887A0174|82 111|plasminogen activating substance
P01863887A0174|113 120|hormones
P01863887A0174|127 133|thyroid
P01863887A0174|135 141|insulin
P01863887A0174|135 141|insulin
P01863887A0174|143 155|growth hormone
P01863887A0174|143 155|growth hormone
P01863887A0174|157 170|erythropoietin
P01863887A0174|157 170|erythropoietin
P01863887A0174|173 187|clotting factors
P01863887A0174|192 204|blood products
P01864510A0946|0 7|Dd PK1 RNA
P01864510A0946|2 16|PK1 RNA decreases
P01864821A0000|17 33|sickle cell disease
P01864821A0000|59 77|abnormal globin chain
P01864821A0000|67 77|globin chain
P01864821A0000|111 117|hypoxia
P01864821A0000|141 153|red blood cells
P01864821A0000|170 181|blood vessels
P01864837A1029|72 86|mouse contrapsin
P01864837A1029|72 86|mouse contrapsin
P01864837A1029|124 150|rat alpha 1-protease inhibitor
P01864837A1029|124 141|rat alpha 1-protease
P01865010A0000|21 55|underlying cross-modality integration
P01865010A0000|69 77|injecting
P01865010A0000|94 110|retrograde tracers
P01865010A0000|112 122|Fluoro-Gold
P01865010A0000|135 140|yellow
P01865010A0000|232 245|cerebral cortex
P01865010A0000|251 253|rat
P01867069A0000|5 12|CD-1 mice
P01867069A0000|36 50|nicotine sulfate
P01867069A0000|88 100|untreated pups
P01869565A1254|0 2|USF
P01869565A1254|0 2|USF
P01869565A1254|18 37|in vitro transcription
P01869565A1254|41 57|translation system
P01869565A1254|72 82|ADH promoter
P01869565A1254|72 82|ADH promoter
P01869565A1254|96 98|MLP
P01869907A2146|3 21|across-fiber pattern
P01869907A2146|38 59|hypotonic NaCl solutions
P01869907A2146|103 105|H2O
P01869968A0000|0 27|Arterial radioactivity content
P01869968A0000|63 67|HMPAO
P01869968A0000|75 87|human subjects
P01869968A0673|6 23|regression analysis
P01869968A0673|79 83|HMPAO
P01869968A0673|105 120|high significance
P01870194A0302|0 30|Human immunodeficiency virus type 1
P01870194A0302|0 30|Human immunodeficiency virus type 1
P01870194A0302|32 36|HIV-1
P01870194A0302|32 36|HIV-1
P01870194A0302|38 39|IN
P01870194A0302|52 66|Escherichia coli
P01870194A0302|85 95|homogeneity
P01870428A0677|0 9|Thigh girth
P01870428A0677|34 36|HDL
P01870428A0677|34 36|HDL
P01870428A0677|40 45|HDL2-C
P01870428A0677|40 45|HDL2-C
P01870428A0677|61 63|LDL
P01870428A0677|61 63|LDL
P01870428A0677|81 85|women
P01870500A0276|0 12|Contributions
P01870500A0276|119 129|healthy host
P01870500A0276|178 188|healthy host
P01871033A0434|0 4|Tests
P01871033A0434|71 90|laboratory simulation
P01871135A0295|3 6|cDNA
P01871135A0295|18 33|open reading frame
P01871135A0295|36 41|1392 bp
P01871135A0295|65 77|464 amino acids
P01871135A0295|97 101|52 kDa
P01871135A0295|130 148|rat liver glucokinase
P01871135A0295|130 148|rat liver glucokinase
P01871971A0836|10 21|viral mutants
P01871971A0836|10 21|viral mutants
P01871971A0836|47 68|NFIII/OCT-1 binding site
P01871971A0836|47 51|NFIII
P01871971A0836|53 68|OCT-1 binding site
P01871971A0836|82 89|ATF motif
P01871971A0836|82 89|ATF motif
P01871971A0836|115 125|viral growth
P01872856A0277|0 7|Recovery
P01872856A0277|23 24|BA
P01872856A0277|32 36|urine
P01872856A0277|45 50|faeces
P01872856A0277|107 111|liver
P01872856A0277|115 120|testis
P01872856A0277|148 163|scorbutic animals
P01873999A0000|0 22|Saccharomyces cerevisiae
P01873999A0000|0 22|Saccharomyces cerevisiae
P01873999A0000|115 128|gene expression
P01873999A0000|180 199|heterologous proteins
P01874195A0139|25 34|GH receptor
P01874195A0139|25 34|GH receptor
P01874195A0139|45 49|liver
P01874195A0139|98 125|signal transduction mechanisms
P01874195A0139|151 188|ligand-activated tyrosine kinase activity
P01874195A0139|167 180|tyrosine kinase
P01874752A0948|51 58|cdc2/p58
P01874752A0948|51 54|cdc2
P01874752A0948|56 58|p58
P01874752A0948|62 69|cdc2/p62
P01874752A0948|62 65|cdc2
P01874752A0948|67 69|p62
P01875922A0770|47 66|5' untranslated region
P01876836T0000|16 43|Ets- and notch-related subunits
P01876836T0000|23 35|notch-related
P01876836T0000|46 61|GA binding protein
P01876836T0000|46 61|GA binding protein
P01878489A0959|3 19|enzymatic response
P01878489A0959|22 32|neutrophils
P01878489A0959|36 44|monocytes
P01878489A0959|80 99|NADPH oxidase activity
P01878489A0959|80 91|NADPH oxidase
P01878489A0959|124 134|neutrophils
P01878489A0959|141 149|monocytes
P01878755A0496|5 9|ileum
P01878755A0496|115 125|chloroquine
P01881595A0476|0 7|Formalin
P01881595A0476|21 25|SNO NS
P01881595A0476|29 39|NnS neurones
P01881595A0476|63 72|NS neurones
P01881595A0476|116 126|NnS neurones
P01881671T0001|0 5|Uptake
P01881671T0001|19 33|Escherichia coli
P01882240A0526|84 103|AIDS related behaviors
P01882240A0526|106 121|Black communities
P01882386A0000|18 57|alpha-mercapto-beta-(2-furyl)acrylic acid
P01882386A0000|33 39|beta-(2
P01882386A0000|59 61|MFA
P01882386A0000|66 101|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|103 105|NaB
P01882386A0000|157 160|lead
P01882386A0000|178 181|rats
P01883992A0922|23 28|beta-1
P01883992A0922|23 28|beta-1
P01883992A0922|38 74|tissue-specific, trans-acting regulator
P01883992A0922|95 107|beta-zein gene
P01883992A0922|95 107|beta-zein gene
P01883992A0922|120 133|maize endosperm
P01884435A0088|29 39|hypovolemia
P01884435A0088|45 80|extracellular ptO2 and ptH distributions
P01884435A0088|83 101|multiple tissue sites
P01884435A0088|125 148|multipoint microelectrode
P01884435A0088|188 191|ptO2
P01884435A0088|195 197|ptH
P01884998A1135|36 54|in vivo transcription
P01884998A1135|59 67|promoters
P01884998A1135|80 96|C/EBP-binding site
P01884998A1135|80 96|C/EBP-binding site
P01885006A0995|20 34|superactivation
P01885006A0995|77 97|synergistic activation
P01885613A1298|0 10|Information
P01885613A1298|13 39|conserved noncoding sequences
P01885613A1298|77 101|pro alpha 1(II) collagen gene
P01885613A1298|77 88|pro alpha 1(II
P01885752A0198|0 19|Chlamydia trachomatis
P01885752A0198|23 39|Chlamydia psittaci
P01885915A0000|8 22|human infections
P01885915A0000|27 37|bacteraemia
P01885915A0000|43 62|Pasteurella multocida
P01885915A0000|104 116|P. haemolytica
P01886043A0380|3 5|SMX
P01886043A0380|44 47|HPCD
P01886043A0380|96 98|SMX
P01886043A0380|170 173|HPCD
P01886368A0000|0 14|PO2 measurements
P01886368A0000|21 60|double barrelled recess type microelectrodes
P01886368A0000|83 91|nerve head
P01886368A0000|94 106|miniature pigs
P01886368A0000|120 128|hyperoxia
P01886774A0000|0 30|POU-specific and POU-homeo domains
P01886774A0000|0 2|POU
P01886774A0000|15 30|POU-homeo domains
P01886774A0000|33 36|Oct3
P01886774A0000|33 36|Oct3
P01886774A0000|51 64|Echerichia coli
P01886774A0000|101 115|octamer sequence
P01888896A0505|20 35|5' flanking region
P01888896A0505|58 67|-1329 to -74
P01888896A0505|81 109|transcriptional initiation site
P01888896A0505|142 148|tobacco
P01889753A0441|3 25|nucleotide (nt) sequences
P01889753A0441|31 35|exons
P01889753A0441|37 57|exon/intron boundaries
P01889753A0441|61 88|5'- and 3'-untranslated regions
P01890362A0305|7 14|patients
P01890362A0305|38 53|eye complications
P01890362A0305|59 76|leprosy, 37 patients
P01890989A1392|21 38|regulatory elements
P01890989A1392|55 71|estrogen induction
P01890989A1392|88 108|chickens and amphibians
P01892680A0907|44 51|sedation
P01893195A0000|16 27|green monkeys
P01893195A0000|29 42|Syrian hamsters
P01893195A0000|46 54|white mice
P01893927A0704|86 88|NMA
P01893927A0704|92 94|NNA
P01893927A0704|122 134|cardiac output
P01895358A0000|0 5|Limits
P01895358A0000|75 79|upper
P01895358A0000|108 124|training programme
P01895370A0199|24 27|flow
P01895384A0746|3 16|IE0 gene product
P01895384A0746|3 16|IE0 gene product
P01895384A0746|38 48|IE1 promoter
P01895384A0746|38 48|IE1 promoter
P01895384A0746|84 91|promoter
P01895393A0745|9 17|promoters
P01895393A0745|29 35|TATA box
P01895393A0745|50 57|Sp1 sites
P01895393A0745|50 57|Sp1 sites
P01895393A0745|60 67|Sp1 sites
P01895393A0745|60 67|Sp1 sites
P01895393A0745|83 89|TATA box
P01895393A0745|125 148|RNA polymerase III promoter
P01895393A0745|125 140|RNA polymerase III
P01895555T0001|12 26|left ventricular
P01895555T0001|45 67|planar myocardial imaging
P01895555T0001|72 82|Tc-99m-MIBI
P01896777T0000|0 15|Ivermectin uptake
P01896777T0000|36 50|plasma and tissue
P01896777T0000|53 78|Sudanese and Mexican patients
P01896777T0000|91 108|Onchocerca volvulus
P01897515A0348|0 9|Bone marrow
P01897515A0348|25 40|Hodgkin's disease
P01897515A0348|114 127|aplastic anemia
P01898113A0265|3 19|smaller uptake rate
P01898113A0265|60 62|BCF
P01898113A0265|66 77|SWA killifish
P01898164A0839|72 78|infants
P01898164A0839|83 102|transverse aortic arch
P01898928A0260|0 23|DNA hybridization analysis
P01898928A0260|52 68|nonpigmented cells
P01898928A0260|87 94|DNA locus
P01898928A0260|110 131|Escherichia coli fur gene
P01898928A0260|110 131|Escherichia coli fur gene
P01899209A0883|14 26|perfusate PCO2
P01899209A0883|38 48|perfusate H+
P01899209A0883|88 110|myocardial contractility
P01899209A0883|114 130|oxygen consumption
P01899287A0726|37 51|steady-state RNA
P01899287A0726|100 121|growth-stimulated cells
P01899409T0000a|0 11|Determinants
P01899409T0000a|23 31|ischaemia
P01899409T0000a|35 61|revascularisation procedures
P01899409T0000a|83 119|recombinant tissue plasminogen activator
P01899409T0000a|83 99|recombinant tissue
P01899409T0000a|100 119|plasminogen activator
P01899409T0000a|129 145|coronary occlusion
P01899846A0862|13 26|rbcL-rbcS locus
P01899846A0862|13 26|rbcL-rbcS locus
P01899846A0862|77 98|photoautotrophic growth
P01900194T0000|19 55|mitochondrial NADH-ubiquinone reductase
P01900194T0000|19 55|mitochondrial NADH-ubiquinone reductase
P01900194T0000|60 91|bacterial NAD-reducing hydrogenase
P01900194T0000|69 91|NAD-reducing hydrogenase
P01901405A0694|10 23|mRNA expression
P01901405A0694|33 47|AT-BP1 and AT-BP2
P01901405A0694|33 38|AT-BP1
P01901405A0694|42 47|AT-BP2
P01901405A0694|68 74|tissues
P01901443A0297|11 18|patients
P01901443A0297|65 79|acute hepatitis C
P01901443A0297|95 121|chronic persistent hepatitis C
P01901443A0297|127 159|incidental microvesicular steatosis
P01901443A0297|174 187|oil-red O stains
P01901859A0000|0 59|UDP-Gal:Gal beta 1----4GlcNAc alpha 1----3-galactosyltransferase
P01901859A0000|0 6|UDP-Gal
P01901859A0000|8 15|Gal beta 1
P01901859A0000|20 32|4GlcNAc alpha 1
P01901859A0000|37 59|3-galactosyltransferase
P01901859A0000|63 89|terminal glycosyltransferase
P01901859A0000|123 138|mammalian species
P01901859A0000|165 191|man, apes, and Old World monkeys
P01901946A0243|1 24|synthetic oligonucleotide
P01901946A0243|38 48|SRE sequence
P01901946A0243|38 48|SRE sequence
P01901946A0243|56 77|mouse c-fos gene promoter
P01901946A0243|56 69|mouse c-fos gene
P01901946A0243|79 88|-299 to -322
P01901946A0243|132 149|mobility shift assay
P01901946A0243|153 185|Southwestern (DNA-protein) blotting
P01901946A0243|166 176|DNA-protein
P01901946A0243|201 239|sequence-specific affinity chromatography
P01901950T0000|0 19|Sequence requirements
P01901950T0000|23 50|premature transcription arrest
P01901950T0000|60 70|first intron
P01901950T0000|76 89|mouse c-fos gene
P01901950T0000|76 89|mouse c-fos gene
P01903404A0688|85 105|infarct-related artery
P01903404A0688|164 169|global
P01903404A0688|191 206|ejection fraction
P01903404A0688|232 246|perfusion status
P01903841A0125|8 21|lysine residues
P01903841A0125|97 102|eIF-5A
P01903841A0125|97 102|eIF-5A
P01903841A1449|3 25|plasmid shuffle technique
P01903841A1449|45 57|wild-type gene
P01903841A1449|45 57|wild-type gene
P01903841A1449|99 108|yeast cells
P01904154A0164|69 74|Ig loci
P01904154A0164|69 74|Ig loci
P01904154A0164|112 135|gene rearrangement process
P01904437A0000|0 12|Transcription
P01904437A0000|18 25|metH gene
P01904437A0000|18 25|metH gene
P01904437A0000|28 48|Salmonella typhimurium
P01904437A0000|52 66|Escherichia coli
P01904437A0000|93 107|metR gene product
P01904437A0000|93 107|metR gene product
P01904437A0000|110 126|DNA binding protein
P01904437A0000|110 126|DNA binding protein
P01904546A0671|15 33|chromosomal AAR1 gene
P01904546A0671|26 33|AAR1 gene
P01904546A0671|36 55|alpha and a/alpha cells
P01904546A0671|68 85|nonmating phenotype
P01904546A0671|95 107|alpha diploids
P01905199A0210|11 18|ICRF-187
P01905199A0210|66 68|ADR
P01905199A0210|72 74|WBH
P01905199A0210|125 140|therapeutic index
P01905199A0210|155 182|therapeutic modality treatment
P01905517A1076|3 5|ORF
P01906111A1295|85 96|purged marrow
P01906111A1295|104 128|acceptable toxicity profile
P01906166A0119|0 10|Mitomycin-C
P01906166A0119|19 32|severe necrosis
P01906166A0119|79 96|skin and soft tissues
P01906166A0119|106 125|IV drug administration
P01906509A0072|27 43|5'-flanking region
P01906509A0072|49 64|human nidogen gene
P01906509A0072|49 64|human nidogen gene
P01906692A0321|0 12|INTERVENTIONS
P01906692A0321|30 34|rt-PA
P01906692A0321|33 34|PA
P01906692A0321|36 42|heparin
P01906692A0321|47 53|aspirin
P01907265A0670|48 60|endonucleases
P01907265A0670|66 81|crude cell extract
P01907265A0670|109 127|DNA cleavage activity
P01907941A0275|13 23|I kappa B beta
P01907941A0275|13 23|I kappa B beta
P01907941A0275|31 42|I kappa B alpha
P01907941A0275|31 42|I kappa B alpha
P01907941A0275|69 71|Rel
P01907941A0275|69 71|Rel
P01907941A0275|77 86|kappa B site
P01907941A0275|77 86|kappa B site
P01909027A0922|0 15|Sequence analysis
P01909027A0922|30 45|DNA binding domain
P01909027A0922|30 45|DNA binding domain
P01909027A0922|48 50|ILF
P01909027A0922|48 50|ILF
P01909027A0922|90 97|fork head
P01909027A0922|124 156|Drosophila homeotic protein fork head
P01909027A0922|124 133|Drosophila
P01909027A0922|134 148|homeotic protein
P01909027A0922|149 156|fork head
P01909027A0922|169 192|hepatocyte nuclear factors
P01909027A0922|169 192|hepatocyte nuclear factors
P01909027A0922|194 198|HNF-3
P01909027A0922|194 198|HNF-3
P01909621A0119|0 6|Lengthy
P01909621A0119|59 72|nontoxic ranges
P01909960A0134|1 7|single i
P01909960A0134|52 80|noradrenaline (NA) biosynthesis
P01909960A0134|123 142|normetanephrine (NMN)
P01909960A0134|160 167|NA levels
P01910505A0000|0 21|Fufang wuzi yanzong pills
P01910505A0000|50 65|cyclophosphamide
P01910505A0000|73 82|leukopenia
P01910505A0000|85 88|mice
P01911767T0000|0 8|Mutations
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|82 90|catalysis
P01913955A0177|22 33|intra-acinar
P01913955A0177|122 135|precursor cells
P01913955A0177|137 145|pericytes
P01913955A0177|149 165|intermediate cells
P01913955A0177|211 222|arterial wall
P01913955A0177|225 240|smooth muscle cell
P01913955A0177|250 268|medial wall thickened
P01913955A0177|274 298|hypertrophy and hyperplasia
P01913955A0177|301 317|smooth muscle cells
P01913955A0177|354 361|collagen
P01913955A0177|354 361|collagen
P01913955A0177|376 388|type 1 collagen
P01913955A0177|376 388|type 1 collagen
P01915580A0889|23 28|NZ-107
P01915580A0889|62 76|bronchial asthma
P01915580A0889|87 111|late-phase airway responses
P01915580A0889|115 135|airway hyperreactivity
P01916168A0969|45 60|ISO2 measurements
P01916168A0969|74 84|ulcer margin
P01916168A0969|101 112|normal mucosa
P01916168A0969|117 125|delta ISO2
P01916405A0242|0 23|Bronchial mucosa tattooing
P01916405A0242|26 32|persons
P01916405A0242|93 94|PC
P01916405A0242|96 97|DB
P01916632A0431|0 17|Anti-HBc production
P01916632A0431|0 7|Anti-HBc
P01916632A0431|20 23|PBMC
P01917943A0621a|0 15|Sequence analysis
P01917943A0621a|21 49|sMtCK genomic upstream sequences
P01917943A0621a|21 49|sMtCK genomic upstream sequences
P01917943A0621a|65 72|TATAA box
P01917943A0621a|82 83|80
P01917943A0621a|84 92|base pairs
P01917943A0621a|94 95|bp
P01917943A0621a|162 177|chimeric plasmids
P01917943A0621a|185 224|chloramphenicol acetyltransferase reporter
P01917943A0621a|185 216|chloramphenicol acetyltransferase
P01917943A0621b|0 15|Sequence analysis
P01917943A0621b|21 49|sMtCK genomic upstream sequences
P01917943A0621b|21 49|sMtCK genomic upstream sequences
P01917943A0621b|65 72|TATAA box
P01917943A0621b|82 83|80
P01917943A0621b|84 92|base pairs
P01917943A0621b|94 95|bp
P01917943A0621b|162 177|chimeric plasmids
P01917943A0621b|185 224|chloramphenicol acetyltransferase reporter
P01917943A0621b|185 216|chloramphenicol acetyltransferase
P01917962A0152|3 13|cDNA segment
P01917962A0152|28 45|immunoglobulin gene
P01917962A0152|28 45|immunoglobulin gene
P01917962A0152|83 93|cDNA segment
P01917962A0152|109 124|human IL-2R L chain
P01917962A0152|109 124|human IL-2R L chain
P01917962A0152|168 179|SV40 promoter
P01917962A0152|168 179|SV40 promoter
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|18 20|LPL
P01918010A0000|18 20|LPL
P01918010A0000|35 61|normal lipoprotein metabolism
P01918010A0000|96 120|tissue-specific expression
P01918010A1730|0 7|Deletion
P01918010A1730|21 39|octanucleotide motif
P01918010A1730|47 53|plasmid
P01918010A1730|67 78|-461 fragment
P01918010A1730|84 94|LPL promoter
P01918010A1730|84 94|LPL promoter
P01918010A1730|158 173|3T3-L1 adipocytes
P01918010A1730|177 192|HepG2 hepatocytes
P01918070A0281|30 44|T3 receptor alpha
P01918070A0281|30 44|T3 receptor alpha
P01918070A0281|46 53|T3R alpha
P01918070A0281|46 53|T3R alpha
P01918070A0281|71 85|Escherichia coli
P01918070A0281|124 130|rGH T3RE
P01918070A0281|124 126|rGH
P01918070A0281|127 130|T3RE
P01918070A0281|148 169|transcriptional potency
P01918070A0281|193 195|T3R
P01918070A0281|193 195|T3R
P01918073A0150|15 18|cDNA
P01918073A0150|29 61|avian TnIcardiac amino acid sequences
P01918073A0150|34 61|TnIcardiac amino acid sequences
P01918073A0150|71 82|TnI sequences
P01918073A0150|71 82|TnI sequences
P01918073A0150|113 139|N-terminal extension sequence
P01918073A0150|149 181|dual protein kinase A phosphorylation
P01918073A0150|153 166|protein kinase A
P01918073A0150|205 223|proline-rich segment
P01918073A0150|260 262|TnI
P01918073A0150|260 262|TnI
P01918073A0150|338 355|N-terminal troponin
P01918073A0150|348 356|troponin C
P01918073A0150|358 373|TnC)-binding site
P01918073A0150|358 360|TnC
P01918073A0150|417 419|TnI
P01918073A0150|417 419|TnI
P01918073A0150|423 425|TnC
P01918073A0150|423 425|TnC
P01918073A0150|439 507|avian TnIcardiac internal actin/TnC-binding, actomyosin-inhibitory, domain
P01918073A0150|439 453|avian TnIcardiac
P01918073A0150|454 461|internal
P01918073A0150|462 478|actin/TnC-binding
P01918073A0150|546 573|mammalian TnIcardiac sequences
P01918073A0150|546 573|mammalian TnIcardiac sequences
P01918073A0150|597 620|protein kinase C target site
P01918073A0150|597 610|protein kinase C
P01918073A0150|629 635|cardiac
P01918073A0150|654 656|TnI
P01918073A0150|654 656|TnI
P01918073A0150|659 665|mammals
P01921463T0000|2 17|ASSEMBLER routine
P01921463T0000|21 41|on-line graphic display
P01921463T0000|71 91|personal microcomputer
P01922082A0149|15 30|mouse TSH beta gene
P01922082A0149|15 30|mouse TSH beta gene
P01922082A0149|61 65|mRNAs
P01922082A0149|82 102|5'-untranslated region
P01922734T0000|0 10|Habituation
P01922734T0000|56 76|electrical stimulation
P01922739A0336|17 20|ROSP
P01922739A0336|206 209|ROSP
P01922739A0336|272 280|dura mater
P01922739A0336|285 298|positive values
P01922739A0336|335 342|pia mater
P01923167A0000|40 63|pulsed Doppler examination
P01923167A0000|69 88|fetal internal carotid
P01923167A0000|92 97|middle
P01923167A0000|98 113|cerebral arteries
P01923628T0001|0 19|Quantitative analysis
P01923628T0001|30 42|flow cytometry
P01923628T0001|46 71|immunocytochemical findings
P01923628T0001|83 96|cardiac myxomas
P01923766A0485|0 15|Sequence analysis
P01923766A0485|70 80|mRNA species
P01923766A0485|96 114|alternative splicing
P01923766A0485|140 141|92
P01923766A0485|147 170|170, 174 and 263 nucleotides
P01923766A0485|193 197|exon 1
P01923803A0609|14 23|isoleucine
P01923803A0609|29 57|complete SsoL12 protein sequence
P01923803A0609|37 57|SsoL12 protein sequence
P01923803A0609|68 75|AUA codon
P01923985A0111|0 7|Symptoms
P01923985A0111|24 41|mastocyte mediators
P01924315A0158|5 9|yeast
P01924315A0158|10 32|Saccharomyces cerevisiae
P01924315A0158|34 45|copper levels
P01924315A0158|76 89|SOD1 expression
P01924315A0158|76 79|SOD1
P01924920A0115|18 29|Mobiluncus SP
P01924920A0115|57 68|Gram staining
P01924920A0115|117 119|RLK
P01924920A0115|123 141|anaerobic atmosphere
P01925092A0000|87 105|solid fibrin meshwork
P01925092A0000|92 97|fibrin
P01925092A0304|25 31|animals
P01925092A0304|86 111|tissue plasminogen activator
P01925092A0304|92 111|plasminogen activator
P01925092A0304|130 146|physiologic saline
P01927421A0181|0 27|Neuro-otological examinations
P01927421A0181|36 63|spontaneous downbeat nystagmus
P01927421A0181|65 86|bilateral gaze nystagmus
P01927845A0107|23 29|lesions
P01927845A0107|49 66|cutaneous disorders
P01927845A0107|68 81|Bowen's disease
P01928923A0000|0 11|Equine amnion
P01928923A0000|19 37|yeast cell derivative
P01928923A0000|54 71|biological dressing
P01928923A0000|85 99|wound medicament
P01928923A0000|129 145|granulating wounds
P01928923A0000|151 163|distal portion
P01928923A0000|176 181|horses
P01930470A0337|44 46|PTH
P01930470A0337|44 46|PTH
P01930470A0337|90 93|AABB
P01930470A0337|121 134|PTH-associated
P01930470A0337|121 123|PTH
P01930470A0337|136 145|surrogate"
P01930470A0337|172 176|blood
P01930660T0000|0 24|Insulin-like growth factor 1
P01930660T0000|7 24|-like growth factor 1
P01930660T0000|26 30|IGF-1
P01930660T0000|26 30|IGF-1
P01930660T0000|34 45|burn patients
P01931966A0490|8 16|ubiquitin
P01931966A0490|8 16|ubiquitin
P01931966A0490|19 24|pADPRP
P01931966A0490|19 24|pADPRP
P01931966A0490|44 49|pADPRP
P01931966A0490|44 49|pADPRP
P01932650A0435|2 9|group III
P01932650A0435|11 18|patients
P01932650A0435|39 62|mediastinal drainage blood
P01932650A0435|97 109|concentration
P01932650A0435|123 126|MBRS
P01932695A1155|36 59|transient expression assay
P01932695A1155|71 94|isolated barley endosperms
P01933614A0406|11 36|salmon calcitonin nasal spray
P01933614A0406|11 26|salmon calcitonin
P01933614A0406|39 43|women
P01933614A0406|59 70|osteoporosis
P01934378A1219|8 36|muscle metaboreceptor responses
P01934378T0000|8 44|muscle metaboreceptor exercise responses
P01936213T0000|37 52|membrane fluidity
P01936348A0155|3 14|examinations
P01936348A0155|49 63|AmF/SnF2)-, resp
P01936997A0795|0 16|RNA gel retardation
P01936997A0795|20 38|competition analyses
P01936997A0795|51 64|TRP-185 binding
P01936997A0795|51 57|TRP-185
P01936997A0795|89 107|TAR RNA loop sequences
P01936997A0795|89 107|TAR RNA loop sequences
P01937790A0292|3 9|vaccine
P01937790A0292|40 61|older children and adults
P01937989A0383|23 39|hypnotic induction
P01937989A0383|66 67|R2
P01938178T0000|0 11|Applications
P01938178T0000|14 38|three-dimensional analysis
P01938178T0000|44 55|auditory P300
P01939131A0871|29 41|BW2001 (xth-11
P01939131A0871|43 59|nfo-2) strain cells
P01939131A0871|62 76|Escherichia coli
P01939199A0588|11 20|human TFIID
P01939199A0588|16 20|TFIID
P01939199A0588|34 51|basal transcription
P01939199A0588|54 65|heat-treated
P01939199A0588|106 110|TFIID
P01939199A0588|106 110|TFIID
P01939199A0588|123 131|HeLa cells
P01939199A0588|146 172|maximal level of transcription
P01939827A0150|42 58|oxide surface layer
P01939827A0150|113 121|solutions
P01939827A0150|139 143|CaCl2
P01939827A0150|152 157|KH2PO4
P01939827A0150|167 171|Hepes
P01939827A0150|173 177|pH 7.2
P01939827A0150|207 225|metastable solutions
P01939827A0150|245 249|CaCl2
P01939827A0150|260 265|KH2PO4
P01939827A0150|275 279|Hepes
P01939827A0150|281 285|pH 7.2
P01939878A0765|14 27|solidification
P01939878A0765|58 63|casein
P01939878A0765|58 63|casein
P01939878A0765|82 86|feeds
P01939878A0765|107 114|patients
P01939878A0765|128 141|gastric acidity
P01939906A0233|4 17|generalization
P01939906A0233|20 22|MFP
P01939906A0233|52 78|high-resolution cost function
P01939906A0233|96 106|search space
P01939906A0233|133 153|constructing solutions
P01939906A0233|247 252|global
P01939906A0233|265 276|cost function
P01942033T0000|0 12|Determination
P01942033T0000|17 28|RNA structure
P01942033T0000|60 74|muscle-specific
P01942033T0000|75 78|exon
P01943184A1050|0 15|Endothelial cells
P01943184A1050|38 54|Wisconsin solution
P01943184A1050|63 72|trypan blue
P01945430A0660|55 67|inner ear fluid
P01945430A0660|71 89|diagnostic procedure
P01945430A0660|123 145|acoustic neuroma suspects
P01947449A1082|1 1|2
P01947449A1082|153 169|homogeneous models
P01948783A0000|3 24|antihypertensive effect
P01948783A0000|27 33|Estulic
P01948783A0000|70 92|101 hypertensive patients
P01954355A0997|10 17|patients
P01954355A0997|22 34|acute leukemia
P01954355A0997|38 41|IL-1
P01954355A0997|38 41|IL-1
P01954355A0997|45 53|TNF levels
P01954355A0997|45 47|TNF
P01954355A0997|83 89|disease
P01954835A0000|0 21|Echinococcus granulosus
P01954835A0000|36 64|fine-needle aspiration cytology
P01954835A0000|68 75|lung cyst
P01954835A0000|87 97|white female
P01954835A0000|100 114|central Missouri
P01956285A0000|26 40|6493 nucleotides
P01956285A0000|56 63|bet genes
P01956285A0000|66 80|Escherichia coli
P01956285A0000|95 123|osmoregulatory choline-glycine
P01956491A0095|17 29|amphotericin B
P01956491A0095|69 92|glomerular filtration rate
P01956491A0095|94 96|GFR
P01956491A0095|94 96|GFR
P01956491A0095|221 224|rats
P01958368A0556|0 8|Evolution
P01958821T0000|0 29|Confocal fluorescence microscopy
P01958821T0000|32 48|modern cell biology
P01960974A0000|0 6|Toluene
P01960974A0000|57 72|volatile solvents
P01961213A0150|11 32|DDT-, HCH- and HCB-levels
P01961747A0000|1 29|herpesvirus proteinase activity
P01961747A0000|82 93|cloned enzyme
P01961747A0000|113 139|transient transfection assays
P01961996A0522|13 13|R
P01963419A0501|13 25|liquid chamber
P01963419A0501|45 56|17 MeV protons
P01963419A0501|59 63|water
P01963419A0501|94 96|13N
P01963419A0501|102 104|16O
P01963419A0501|108 124|alpha)13N reaction
P01963419A0501|127 142|[18F]fluoride ion
P01963419A0501|148 150|18O
P01963419A0501|154 154|n
P01963419A0501|156 166|18F reaction
P01963438T0000|0 28|Heterogeneous electron transfer
P01963438T0000|31 41|cytochrome c
P01963438T0000|31 41|cytochrome c
P01963438T0000|55 114|polypyrrole and methylene blue polypyrrole film modified electrodes
P01963858T0001|21 39|adrenaline secretion
P01963858T0001|45 54|rat adrenal
P01964989A0145|0 4|Urine
P01964989A0145|30 52|phencyclidine (PCP) or 11-
P01964989A0145|57 100|delta 9-tetrahydrocannabinol-9-carboxylic acid
P01964989A0145|102 111|9-THC-COOH
P01964989A0145|132 145|sodium chloride
P01964989A0145|162 179|potassium hydroxide
P01964989A0145|181 190|liquid soap
P01964989A0145|192 201|2-propanol
P01967130A0645|3 23|1489-base pair EFIA cDNA
P01967130A0645|16 23|EFIA cDNA
P01967130A0645|32 51|322-amino acid protein
P01967130A0645|98 120|human DNA binding proteins
P01967130A0645|98 120|human DNA binding proteins
P01968043A0908|12 29|positive cDNA clones
P01968043A0908|49 61|largest insert
P01968043A0908|63 68|pASB-1
P01968043A0908|63 68|pASB-1
P01968156T0000|4 34|standardisation of botulinum toxin
P01968156T0000|21 34|botulinum toxin
P01968224A0119|21 52|260-amino-acid residue polypeptide
P01968224A0119|76 86|short intron
P01968224A0119|89 99|60 base pairs
P01968224A0119|101 102|bp
P01968224A0119|128 144|amino acid sequence
P01968224A0119|150 163|Drosophila PCNA
P01968224A0119|150 163|Drosophila PCNA
P01968224A0119|181 195|rat and human PCNA
P01968224A0119|192 207|PCNA polypeptides
P01968224A0119|196 207|polypeptides
P01968224A0119|237 243|leucine
P01968224A0119|249 264|C-terminal region
P01968224A0119|249 264|C-terminal region
P01970560A1024|25 45|aroF regulatory regions
P01970560A1024|25 45|aroF regulatory regions
P01970560A1024|48 51|lacZ
P01970560A1024|48 51|lacZ
P01970560A1024|103 137|E. coli chromosome. beta-Galactosidase
P01970560A1024|103 118|E. coli chromosome
P01970560A1024|120 137|beta-Galactosidase
P01970560A1024|147 169|tyrR-mediated regulation
P01970560A1024|172 190|aroF-lacZ expression
P01970560A1024|172 175|aroF
P01970560A1024|177 180|lacZ
P01970560A1024|206 224|E. coli TyrR repressor
P01970560A1024|206 211|E. coli
P01970560A1024|212 224|TyrR repressor
P01970801A0925|39 42|Ly-1
P01970801A0925|39 42|Ly-1
P01970801A0925|46 49|CD20
P01970801A0925|46 49|CD20
P01970801A0925|51 54|OSBP
P01970801A0925|66 87|conserved syntenic group
P01970801A0925|93 99|long arm
P01970801A0925|102 113|chromosome 11
P01970801A0925|119 154|human and the proximal end of chromosome 19
P01970801A0925|160 164|mouse
P01970926A0000|30 46|contracting muscle
P01970926A0000|50 70|plasma K+ concentration
P01970984A0668|19 38|serum estradiol levels
P01970984A0668|51 63|groups E + T and E
P01970984A0668|70 75|group C
P01971191A1271|17 38|beta-adrenergic agonist
P01971191A1271|40 52|isoproterenol
P01971191A1271|95 105|liver volume
P01971191A1271|122 145|hepatic outflow resistance
P01971191A1271|170 178|histamine
P01972379T0042|0 10|DNA sequence
P01972379T0042|28 36|CPS domain
P01972379T0042|28 36|CPS domain
P01972379T0042|42 76|Syrian hamster multifunctional protein
P01972379T0042|77 79|CAD
P01973384A0206|19 39|synthetic binding sites
P01973384A0206|123 129|embryos
P01974550A0362|5 16|base-line CBF
P01974550A0362|32 51|hexamethonium bromide
P01974550A0362|63 80|ipratropium bromide
P01974550A0362|101 112|indomethacin
P01974550A0362|126 136|intravenous
P01974876A1051|1 51|high-frequency restriction fragment length polymorphism
P01974876A1051|104 109|enzyme
P01974876A1051|110 114|BglII
P01974876A1051|110 114|BglII
P01975157A0836|3 23|antilog transformation
P01975157A0836|26 27|pH
P01975428A0151|36 60|exonucleolytic degradation
P01975428A0151|79 87|linear DNA
P01975428A0151|121 132|cell division
P01976638A1135|24 44|5'-untranslated region
P01976638A1135|58 76|regulatory sequences
P01977585A0222|27 36|protease-B
P01977585A0222|36 67|B-deficient URA2-transformed cells
P01977585A0222|47 50|URA2
P01977585A0222|98 114|catalytic subunits
P01977585A0222|121 147|cAMP-dependent protein kinase
P01977585A0222|121 147|cAMP-dependent protein kinase
P01977856A1036|21 25|BSPMs
P01977856A1036|52 54|AMI
P01977856A1036|93 109|myocardial infarct
P01978834A0076|7 35|abomasum lambda gt11 cDNA library
P01978834A0076|52 69|monoclonal antibody
P01978834A0076|86 92|rabbit H
P01978834A0076|86 92|rabbit H
P01978834A0076|94 112|K-ATPase beta subunit
P01978834A0076|94 112|K-ATPase beta subunit
P01978857A0504|53 65|CD4 cell counts
P01978857A0504|53 55|CD4
P01982061A0615|9 15|TATA box
P01982061A0615|50 76|transcription initiation site
P01982061T0000|21 25|5' end
P01982061T0000|60 66|CAD gene
P01982190T0001|0 13|Early cirrhosis
P01982190T0001|51 59|hepatitis
P01982997A1104|13 46|immediate-early transcription factor
P01982997A1104|13 46|immediate-early transcription factor
P01982997A1104|66 75|MDI regimen
P01982997A1104|88 89|RA
P01982997A1104|130 134|c-Jun
P01982997A1104|130 134|c-Jun
P01982997A1104|152 171|diminished expression
P01982997A1104|174 186|c-Fos and Jun-B
P01982997A1104|174 178|c-Fos
P01982997A1104|182 191|Jun-B mRNAs
P01982997A1104|187 191|mRNAs
P01983026A0483|8 16|heart rate
P01983026A0483|73 84|free and total
P01983026A0483|85 100|CA concentrations
P01984665T0000|42 96|carboxy terminally truncated dengue-2 virus envelope proteins
P01984665T0000|42 75|carboxy terminally truncated dengue-2
P01984665T0000|76 96|virus envelope proteins
P01984665T0000|108 118|insect cells
P01984665T0000|121 144|recombinant baculoviruses
P01985301T0000|8 14|therapy
P01985301T0000|19 24|MK-801
P01985301T0000|53 71|ischemic brain damage
P01985920A0156|7 15|screening
P01985920A0156|19 26|rat liver
P01985920A0156|27 37|cDNA library
P01985920A0156|44 63|oligonucleotide probe
P01985920A0156|78 99|rat SCP2 protein sequence
P01985920A0156|78 80|rat
P01985920A0156|81 99|SCP2 protein sequence
P01985920A0156|110 130|825-base pair cDNA clone
P01985920A0156|151 169|SCP2 protein sequence
P01985920A0156|151 154|SCP2
P01985920T0000|22 39|nucleotide sequence
P01985920T0000|42 75|rat liver sterol carrier protein 2 cDNAs
P01985920T0000|42 49|rat liver
P01985920T0000|50 69|sterol carrier protein
P01985920T0000|71 75|cDNAs
P01985924A0554|36 41|fourth
P01985924A0554|80 94|pol II holoenzyme
P01985924A0554|80 84|pol II
P01985924A0554|97 122|ion-exchange chromatography
P01985924A0554|138 141|urea
P01985924A0554|151 185|promoter-directed initiation activity
P01985924A0554|188 200|pol II delta 4/7
P01985924A0554|188 200|pol II delta 4/7
P01986225A0250|31 33|HSF
P01986225A0250|31 33|HSF
P01986225A0250|46 50|yeast
P01986225A0250|51 74|Schizosaccharomyces pombe
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|48 60|specific sites
P01986241A0117|66 79|promoter region
P01986241A0117|85 92|CUP1 gene
P01986241A0117|85 88|CUP1
P01986254A0452|0 21|Gel mobility shift assays
P01986254A0452|28 43|synthetic E6 motif
P01986254A0452|53 74|B-cell-specific complex
P01986254A0452|53 74|B-cell-specific complex
P01986254A0452|113 118|T cells
P01986254A0452|122 130|HeLa cells
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|79 114|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|123 125|32P
P01986360A0000|126 136|end-labeled
P01986360A0000|154 193|mouse (2'-5')oligoadenylate synthetase gene
P01986360A0000|154 165|mouse (2'-5')
P01986360A0000|166 189|oligoadenylate synthetase
P01986360A0000|194 218|interferon response element
P01986360A0000|194 218|interferon response element
P01988041A0281|48 61|3018-bp BAL cDNA
P01988041A0281|48 61|3018-bp BAL cDNA
P01989561A0100|133 137|heart
P01989561A0100|158 179|left ventricular venting
P01989999A0000|0 29|Adenylosuccinate synthetase (IMP
P01989999A0000|0 25|Adenylosuccinate synthetase
P01989999A0000|27 29|IMP
P01989999A0000|31 47|L-aspartate ligase
P01989999A0000|31 31|L
P01989999A0000|32 47|-aspartate ligase
P01989999A0000|49 51|GDP
P01989999A0000|49 51|GDP
P01989999A0000|54 62|EC 6.3.4.4
P01989999A0000|54 55|EC
P01989999A0000|86 103|purine biosynthesis
P01989999A0000|117 129|GTP-dependent
P01989999A0000|142 149|IMP to AMP
P01990254A0791|0 16|Immunophenotyping
P01990254A0791|45 61|B, non-T cell origin
P01990254A0791|72 86|pre-B cell origin
P01990266A0678|0 32|DNA-protein UV cross-linking studies
P01990266A0678|46 50|UHF-1
P01990266A0678|46 50|UHF-1
P01990266A0678|81 115|sodium dodecyl sulfate-acrylamide gels
P01990266A0678|131 135|85 kDa
P01990266A0678|185 192|promoter
P01990266A0678|204 207|site
P01991521A0481|77 85|G4 content
P01991521A0481|77 78|G4
P01992459A0000|37 53|structural element
P01992459A0000|59 88|human immunodeficiency virus mRNA
P01992459A0000|59 88|human immunodeficiency virus mRNA
P01992459A0000|90 92|RRE
P01992459A0000|90 92|RRE
P01992459A0000|97 115|Rev response element)
P01992459A0000|97 114|Rev response element
P01992459A0000|122 144|virus-encoded protein Rev
P01992459A0000|122 141|virus-encoded protein
P01992459A0000|142 144|Rev
P01992459A0000|190 198|unspliced
P01992459A0000|214 217|mRNA
P01992459A0000|225 231|nucleus
P01992459A0000|237 245|cytoplasm
P01992742A0000|25 32|patients
P01992742A0000|37 49|optic neuritis
P01992953A0247|0 12|Cut-off levels
P01992953A0247|103 117|healthy patients
P01992953T0000|0 22|Alanine aminotransferase
P01992953T0000|7 22|aminotransferase
P01993181T0000|0 17|Nucleotide sequence
P01993181T0000|31 76|Pseudomonas putida PpG7 salicylate hydroxylase gene
P01993181T0000|31 47|Pseudomonas putida
P01993181T0000|48 76|PpG7 salicylate hydroxylase gene
P01993181T0000|78 81|nahG
P01993181T0000|78 81|nahG
P01993181T0000|89 105|3'-flanking region
P01993656A1860|6 13|ARF cDNAs
P01993656A1860|6 13|ARF cDNAs
P01993656A1860|69 101|guanine nucleotide-binding proteins
P01993656A1860|69 101|guanine nucleotide-binding proteins
P01995951A0000|3 20|long terminal repeat
P01995951A0000|22 24|LTR
P01995951A0000|31 61|human immunodeficiency virus (HIV)
P01995951A0000|31 56|human immunodeficiency virus
P01995951A0000|58 60|HIV
P01995951A0000|75 86|binding sites
P01995951A0000|93 113|transcriptional factor
P01995951A0000|114 116|Sp1
P01995951A0000|114 116|Sp1
P01996312A0454|0 2|DNA
P01996312A0454|7 9|PCR
P01996312A0454|36 62|several lambda gt11 cDNA clones
P01996312A0454|76 89|full-length one
P01996312A0454|91 100|Dd kinase-2
P01996312A0454|91 100|Dd kinase-2
P01997465A0276|0 23|Radiation-induced changes
P01997465A0276|58 65|collagen
P01997465A0276|93 103|irradiation
P01999035A0383|80 92|Speedwell; 251
P01999035A0383|98 106|IHD events
P01999999T0001|0 16|Perilunar luxation
P02000093A0794|0 13|Landsberg (La-O
P02001033A1907|12 39|equianesthetic concentrations
P02001033A1907|41 50|desflurane
P02001033A1907|79 96|hemodynamic effects
P02001033A1907|136 152|autonomic reflexes
P02001033A1907|171 195|negative inotropic activity
P02001033A1907|221 236|arterial pressure
P02002051A0276|27 46|full-length cDNA clone
P02002051A0276|27 41|full-length cDNA
P02002051A0276|89 103|bovine C-subunit
P02002051A0276|95 103|C-subunit
P02002051T0000|0 12|Isoform C beta 2
P02002051T0000|7 12|C beta 2
P02002051T0000|38 53|catalytic subunit
P02002051T0000|56 82|cAMP-dependent protein kinase
P02002051T0000|56 82|cAMP-dependent protein kinase
P02002511A0637|0 18|Salient applications
P02002511A0637|21 25|PB-PK
P02002511A0637|21 22|PB
P02002511A0637|24 25|PK
P02004521A0266|0 7|Patients
P02004521A0266|27 28|CT
P02004521A0266|60 74|epidural disease
P02004705A0686|3 14|cdr1 sequence
P02004705A0686|3 14|cdr1 sequence
P02004705A0686|38 47|amino acids
P02004705A0686|53 70|contiguous fragment
P02005547A0121|0 4|Armed
P02005547A0121|103 132|unconjugated hyperbilirubinemia
P02006558A0000|24 38|peripheral sites
P02006558A0000|50 60|human vision
P02007045A0092|53 61|brain cyst
P02007045A0092|89 107|respiratory distress
P02008982A0463|0 4|ELISA
P02008982A0463|48 59|tuberculosis
P02010912A0366|73 88|MalT binding sites
P02010912A0366|73 88|MalT binding sites
P02010912A0366|121 142|pulAp and pulCp promoters
P02010912A0366|121 125|pulAp
P02010912A0366|129 142|pulCp promoters
P02011924A0729|23 30|patients
P02011924A0729|82 90|alpha-IFN
P02011924A0729|82 90|alpha-IFN
P02011924A0729|115 122|patients
P02011924A0729|127 143|hairy cell leukemia
P02012097T0000|0 21|Paroxysmal fluctuations
P02012097T0000|32 42|parasitemia
P02012097T0000|45 64|Plasmodium falciparum
P02012097T0000|65 71|malaria
P02014928T0000|0 17|Occupational asthma
P02014928T0000|67 84|bovine serum albumin
P02014928T0000|78 84|albumin
P02015921A0523|21 31|Category pN1
P02015921A0523|36 39|pN1a
P02015921A0523|41 50|metastasis
P02015921A0523|53 62|single node
P02015921A0523|67 70|pN1b
P02016053A0752|0 16|Amino acid sequence
P02016053A0752|33 43|E74A protein
P02016053A0752|33 43|E74A protein
P02016053A0752|66 81|C-terminal region
P02016053A0752|94 115|basic amino acid residues
P02016053A0752|148 182|sequence-specific DNA binding activity
P02016769A0720|36 44|promoters
P02017159A0646|0 5|Grasso
P02017271A0502|56 80|carnitine-treated patients
P02017271A0502|93 100|controls
P02017414A0307|5 7|POI
P02017414A0307|11 19|asymptote
P02017414A0307|40 47|Line RBC2
P02019572A0000|59 80|rat liver pyruvate kinase
P02019572A0000|59 66|rat liver
P02019572A0000|67 91|pyruvate kinase (L-PK) genes
P02019572A0000|82 91|L-PK) genes
P02019572A0000|122 166|chloramphenicol acetyltransferase reporter genes
P02019572A0000|122 166|chloramphenicol acetyltransferase reporter genes
P02019572A0000|205 229|3200 base pairs (bp) upstream
P02019572A0000|235 249|L-PK gene cap site
P02019572A0000|235 249|L-PK gene cap site
P02019572A0000|268 286|transient expression
P02019572A0000|308 325|hepatoma HepG2 cells
P02019572A0000|327 340|rat hepatocytes
P02019572A0000|358 376|fibroblast LTK- cells
P02019572A0000|386 395|C2C12 cells
P02019572A0000|400 407|CHO cells
P02020082A0356|3 13|disturbance
P02020082A0356|25 35|gas exchange
P02020082A0356|63 67|AaDO2
P02020082A0356|83 108|left ventricular dysfunction
P02020082A0356|113 117|AaDO2
P02020082A0356|158 178|hemodynamic parameters
P02020082A0356|208 235|plasma colloid osmotic pressure
P02020082A0356|239 241|PCW
P02020314A1290|29 34|GM-CSF
P02020314A1290|29 34|GM-CSF
P02020314A1290|55 65|neutropenia
P02020314A1290|69 84|thrombocytopenia
P02020314A1290|90 129|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|158 169|chemotherapy
P02020314A1290|173 185|ovarian cancer
P02020314A1290|191 196|future
P02021630A1104|31 46|hydrogen-bonding
P02021630A1104|92 105|guanine N7 sites
P02021630A1104|99 105|N7 sites
P02021630A1104|111 121|major groove
P02021630A1104|144 172|DNA phosphodiester conformation
P02021630A1104|182 195|protein binding
P02022188A0112|0 18|Biochemical analysis
P02022188A0112|38 47|BJ1 protein
P02022188A0112|38 47|BJ1 protein
P02022188A0112|64 74|nucleosomes
P02022188A0112|92 100|chromatin
P02022188A0112|156 180|high mobility group proteins
P02022188A0112|156 180|high mobility group proteins
P02022188A0112|182 185|HMGs
P02022188A0112|182 185|HMGs
P02022188A1463|113 126|a regulated gene
P02022188A1463|123 136|gene expression
P02022920A0334|3 15|C4BP alpha gene
P02022920A0334|3 15|C4BP alpha gene
P02022920A0334|65 78|198 nucleotides
P02022920A0334|84 88|5' UTR
P02023097A0000|3 33|human immunodeficiency virus type 1
P02023097A0000|3 33|human immunodeficiency virus type 1
P02023097A0000|35 50|HIV-1) Rev protein
P02023097A0000|35 39|HIV-1
P02023097A0000|41 50|Rev protein
P02023097A0000|54 89|positive posttranscriptional regulator
P02023097A0000|92 120|viral structural gene expression
P02023097A0000|92 110|viral structural gene
P02023097A0000|136 151|virus replication
P02023421A0343|22 32|fibroblasts
P02023421A0343|36 43|collagen
P02023421A0343|36 43|collagen
P02023421A0343|73 90|mechanical strength
P02023421A0343|110 121|wound healing
P02023421A0343|152 173|chemotherapeutic agents
P02023904A0120|3 10|CDC7 gene
P02023904A0120|3 10|CDC7 gene
P02023904A0120|25 33|AUG codons
P02023904A0120|44 64|translation start sites
P02023904A0120|89 102|56-kDa proteins
P02023904A0120|89 102|56-kDa proteins
P02024252A0000|32 38|persons
P02024252A0000|70 92|municipality of Nordreisa
P02024252A0000|95 108|northern Norway
P02024488A0506|0 21|HeLa and Jurkat cell lines
P02024488A0506|33 39|nef gene
P02024488A0506|51 61|CMV promoter
P02024488A0506|51 61|CMV promoter
P02024488A0506|67 74|HIV-1 LTR
P02024488A0506|67 74|HIV-1 LTR
P02024488A0506|103 120|neomycin resistance
P02024625A0202|103 121|microscopic features
P02024791A0582|83 98|FEV1 measurements
P02024791A0582|119 132|metaproterenol
P02024816A0521|7 11|ELISA
P02024816A0521|24 46|surfactant protein A (SP-A
P02024816A0521|24 41|surfactant protein A
P02024816A0521|43 46|SP-A
P02024816A0521|72 88|pneumonia patients
P02026144A0741|0 14|Temporal control
P02026144A0741|17 29|GUS expression
P02026144A0741|17 19|GUS
P02026144A0741|50 76|negative regulatory sequences
P02026144A0741|78 81|NRS1
P02026144A0741|89 111|-295) and NRS2 (-518 to -418
P02026144A0741|139 142|UAS1
P02026147A0000|11 25|Ca2+/calmodulin
P02026147A0000|11 14|Ca2+
P02026147A0000|16 25|calmodulin
P02026147A0000|27 53|CaM)-dependent protein kinase
P02026147A0000|27 53|CaM)-dependent protein kinase
P02026147A0000|55 63|CaM kinase
P02026147A0000|55 63|CaM kinase
P02026147A0000|72 76|yeast
P02026147A0000|77 99|Saccharomyces cerevisiae
P02026147A0000|123 147|mammalian type II CaM kinases
P02026147A0000|138 147|CaM kinases
P02026461A0760|12 25|DR4-homozygous
P02026461A0760|27 43|DRB1-heterozygous
P02026461A0760|27 30|DRB1
P02026491A0399|3 10|patients
P02026491A0399|41 43|NMF
P02026491A0399|93 105|abdominal pain
P02027839A0250|17 29|ischemic group
P02027839A0250|74 89|capillary density
P02027839A0250|93 113|capillary to fiber ratio
P02027839A0250|174 184|normal group
P02028125A0101|51 62|AIDS patients
P02028125A0101|89 102|tumour response
P02028125A0101|112 124|cancer therapy
P02029468A0296|5 21|TNF concentrations
P02029468A0296|5 7|TNF
P02030910A0000|28 40|human ETS1 gene
P02030910A0000|33 36|ETS1
P02030910A0000|75 95|molecular organization
P02030910A1070|0 30|Polymerase chain reaction analysis
P02030910A1070|33 40|ETS1 cDNA
P02030910A1070|33 36|ETS1
P02030910A1070|58 74|amplified products
P02030910A1070|86 104|alternative splicing
P02033038A0309|18 36|human E3 polypeptides
P02033038A0309|23 24|E3
P02033038A0309|25 36|polypeptides
P02033038A0309|62 76|insoluble pellet
P02033038A0309|102 109|mature E3
P02033038A0309|108 109|E3
P02033038A0309|123 137|soluble fraction
P02033062A1169|23 35|chimeric genes
P02033062A1169|23 35|chimeric genes
P02033062A1169|69 80|chicken IGF-I
P02033062A1169|69 80|chicken IGF-I
P02033062A1169|81 94|5'-flanking DNA
P02033062A1169|98 124|promoterless reporter plasmid
P02034655A1224|3 28|alpha 4 gene 5' flanking region
P02034655A1224|3 28|alpha 4 gene 5' flanking region
P02034655A1224|37 44|promoter
P02034655A1224|47 64|transfection assays
P02034655T0000|21 46|alpha 4 integrin gene promoter
P02034655T0000|21 38|alpha 4 integrin gene
P02034669A0293|36 47|adult tissues
P02034669A0293|102 121|central nervous system
P02034676A0267|18 30|rhombotin gene
P02034676A0267|18 30|rhombotin gene
P02035805T0000|0 18|Angina haemorrhagica
P02036066A0000|57 90|hemoglobin polyoxyethylene conjugate
P02036066A0000|57 66|hemoglobin
P02036066A0000|92 94|PHP
P02036066A0000|106 120|cardiac function
P02036066A0000|131 139|rat hearts
P02038293A0919|0 9|Conclusion
P02038293A0919|11 46|inlet type VSD and perimembranous type TOF
P02038293A0919|51 66|anatomic features
P02038293A0919|85 93|His bundle
P02038293A0919|127 136|VSD closure
P02038326A0538|3 18|gcd2-503 mutation
P02038326A0538|3 10|gcd2-503
P02038326A0538|69 87|80S ribosomal couples
P02038326A0538|69 80|80S ribosomal
P02038326A0538|134 168|general translation initiation factor 2
P02038326A0538|141 161|translation initiation
P02038326A0538|170 179|eIF-2 alpha
P02038326A0538|170 179|eIF-2 alpha
P02038326A0538|183 198|43S-48S particles
P02038326A0538|183 185|43S
P02038326A0538|187 189|48S
P02038784A0317|5 12|patients
P02038784A0317|17 19|ARC
P02038784A0317|17 19|ARC
P02038784A0317|23 34|renal failure
P02041088A1053|30 33|DR60
P02041088A1053|30 33|DR60
P02041088A1053|36 50|reporter plasmid
P02041088A1053|78 81|DR60
P02041088A1053|78 81|DR60
P02041088A1053|101 144|reporter chloramphenicol acetyltransferase gene
P02041088A1053|109 144|chloramphenicol acetyltransferase gene
P02041088A1053|165 188|delayed-early 39K promoter
P02044785A0000|15 28|adenocarcinoma
P02044785A0000|40 70|retroperitoneal enterogenous cyst
P02044785A0000|91 103|left renal cyst
P02044950A0258|8 30|polymerase chain reaction
P02044950A0258|45 54|U6 RNA genes
P02044950A0258|45 54|U6 RNA genes
P02044975A0380|4 13|tear volume
P02044975A0380|138 147|tear volume
P02045366A1149|0 21|Hydrophobicity analysis
P02045366A1149|38 41|KlaA
P02045366A1149|38 41|KlaA
P02045366A1149|45 60|KlaB polypeptides
P02045366A1149|45 60|KlaB polypeptides
P02045366A1149|92 106|KlaC polypeptide
P02045366A1149|92 106|KlaC polypeptide
P02045366A1149|138 161|membrane-spanning domains
P02045524A0000|41 57|therapeutic agents
P02045524A0000|88 90|FDA
P02045524A0000|97 105|mid-1970s
P02045524A0000|166 197|holding end-of-phase II conferences
P02045524A0000|202 213|drug sponsors
P02045809A0331|27 44|sphaericus products
P02045809A0331|46 68|ABG-6184 technical powder
P02045809A0331|72 76|BSP-2
P02046202A0625|3 11|remainder
P02046202A0625|26 39|IgA nephropathy
P02046202A0625|26 28|IgA
P02047597A0149|0 6|Grossly
P02047597A0149|11 30|experimental vulvitis
P02047597A0149|66 73|bacteria
P02049617A0504|0 0|3
P02052544A0641|15 36|DNA polymerase II complex
P02052544A0641|15 36|DNA polymerase II complex
P02052544A0641|61 77|dpb2-1 mutant cells
P02052544A0641|61 72|dpb2-1 mutant
P02052544A0641|100 121|DNA polymerase II complex
P02052544A0641|100 114|DNA polymerase II
P02052544A0641|130 133|DPB2
P02052544A0641|130 133|DPB2
P02052544A0641|151 172|chromosomal replication
P02052592A0000|74 85|bone turnover
P02052592A0000|118 143|postmenopausal osteoporosis
P02052592A0000|168 179|oophorectomy
P02052592A0000|193 211|estrogen replacement
P02052592A0000|239 250|interleukin 1
P02052592A0000|239 250|interleukin 1
P02052592A0000|252 255|IL-1
P02052592A0000|252 255|IL-1
P02052592A0000|260 283|tumor necrosis factor alpha
P02052592A0000|260 283|tumor necrosis factor alpha
P02052592A0000|285 293|TNF-alpha
P02052592A0000|285 293|TNF-alpha
P02052592A0000|303 338|phytohemagglutinin A-induced secretion
P02052592A0000|303 320|phytohemagglutinin
P02052592A0000|341 386|granulocyte-macrophage colony-stimulating factor
P02052592A0000|341 386|granulocyte-macrophage colony-stimulating factor
P02052592A0000|388 393|GM-CSF
P02052592A0000|388 393|GM-CSF
P02052592A0000|399 429|peripheral blood mononuclear cells
P02053289A0701|38 45|virulent
P02054754A0919|3 20|standard principles
P02054754A0919|23 30|surgical
P02054754A0919|83 90|patients
P02055484A0538|9 19|PCR products
P02055484A0538|40 43|ATG1
P02055484A0538|40 43|ATG1
P02055484A0538|50 53|ATG2
P02056553T0000|0 15|Hemorrhagic shock
P02056553T0000|19 40|bacterial translocation
P02056553T0000|44 53|swine model
P02060052A0954|31 36|oxygen
P02060052A0954|37 48|free radicals
P02060052A0954|64 74|hepatocytes
P02060052A0954|78 89|mitochondria
P02061282A0447|16 27|pMxL1 plasmid
P02061282A0447|41 56|invertible region
P02061282A0447|73 84|tandem repeat
P02061282A0447|120 128|pilin gene
P02061282A0447|134 139|middle
P02061282A0447|145 169|recombination junction site
P02061333A0784|26 32|introns
P02061333A0784|42 49|acvA gene
P02061333A0784|42 49|acvA gene
P02061333A1359|45 89|putative 4'-phosphopantetheine-attachment sites
P02061333A1359|94 117|putative thioesterase site
P02061333A1359|102 117|thioesterase site
P02061333A1359|189 201|ACV tripeptide
P02061333A1359|189 201|ACV tripeptide
P02062116A0688|0 8|Pargyline
P02062116A0688|11 35|monoamine oxidase inhibitor
P02062116A0688|11 26|monoamine oxidase
P02062116A0688|61 63|max
P02062933A0738|34 39|female
P02062933A0738|44 61|sexually active male
P02062933A0738|67 69|AOF
P02062933A0738|71 79|flutamide
P02062933A0738|80 86|females
P02062933A0738|117 127|male partner
P02064119A1172|7 26|ventilatory responses
P02064119A1172|99 113|control subjects
P02065022A0747|4 17|small deletions
P02065022A0747|27 41|conserved region
P02065022A0747|83 85|dbl
P02065022A0747|83 85|dbl
P02066246A0258|4 15|computerized
P02066246A0258|34 45|central files
P02066246A0258|51 85|Massachusetts Cancer Registry and cases
P02068085A1273|25 49|negative regulatory element
P02068085A1273|55 70|5' flanking region
P02068085A1273|76 105|Mlu I upstream activation sequence
P02068085A1273|76 105|Mlu I upstream activation sequence
P02069738A0000|39 45|ethanol
P02069873X0000|26 41|vav protooncogene
P02069873X0000|26 41|vav protooncogene
P02069873X0000|43 45|vav
P02069873X0000|43 45|vav
P02069873X0000|49 58|human locus
P02069873X0000|49 58|human locus
P02069873X0000|104 122|hematopoietic origin
P02070227T0000|0 21|Endothelial cell seeding
P02072238T0000|0 15|Menetrier disease
P02072798A0330|5 28|hemodynamic stabilization
P02072798A0330|39 45|therapy
P02073222A0269|11 18|patients
P02073222A0269|73 80|protocol
P02073222A0269|104 124|double blind conditions
P02075876A0408|23 25|EER
P02075876A0408|60 68|amplitude
P02075876T0001|10 35|electrically evoked response
P02075876T0001|37 39|EER
P02075876T0001|81 85|cat (1
P02075876T0001|81 83|cat
P02076620A0548|18 33|fibrinogen levels
P02076620A0548|18 27|fibrinogen
P02076620A0548|85 95|gemfibrozil
P02076620T0000|0 10|Gemfibrozil
P02076620T0000|13 35|hyperlipidaemic patients
P02076620T0000|50 57|arterial
P02076620T0000|70 88|undiscovered actions
P02076816T0000|2 24|RME1-independent pathway
P02076816T0000|2 5|RME1
P02076816T0000|28 45|sporulation control
P02076816T0000|48 70|Saccharomyces cerevisiae
P02076816T0000|48 70|Saccharomyces cerevisiae
P02076816T0000|82 107|IME1 transcript accumulation
P02076816T0000|82 95|IME1 transcript
P02077560T0000|9 32|pharmacological profiling
P02078570A0287|11 30|high-level expression
P02078570A0287|36 58|truncated avian integrins
P02078570A0287|45 58|avian integrins
P02079811A0407|39 44|EMB AZS
P02079811A0407|47 60|recurrent ulcer
P02079811A0407|80 86|stomach
P02079811A0407|107 110|acid
P02079811A0407|124 133|ulcerative
P02080902A0183|16 19|rats
P02080902A0183|83 90|controls
P02081463A0110|28 43|Spec gene activity
P02081463A0110|28 35|Spec gene
P02081463A0110|63 96|Spec1 transcriptional initiation site
P02081463A0110|63 96|Spec1 transcriptional initiation site
P02081463A0110|118 139|protein-DNA interaction
P02081463A0110|118 128|protein-DNA
P02083199A1175|0 20|Phosphopeptide mapping
P02083199A1175|36 59|autophosphorylation sites
P02083199A1175|70 76|EGFR-IC
P02083199A1175|70 73|EGFR
P02083199A1175|75 76|IC
P02083199A1175|96 108|wild-type EGFR
P02083199A1175|105 108|EGFR
P02083230A0938|62 75|hydrophilic 707
P02083230A0938|76 91|amino acid residue
P02083230A0938|102 117|8 N-glycosylation
P02083230A0938|125 143|transmembrane domain
P02083230A0938|149 164|C-terminal domain
P02083230A0938|149 164|C-terminal domain
P02083230A0938|167 178|52 amino acids
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|42 65|TCR alpha enhancer activity
P02083253A1512|42 57|TCR alpha enhancer
P02083253A1512|68 98|transcriptionally active extracts
P02083253A1512|103 108|Jurkat
P02083253A1512|115 123|HeLa cells
P02083253A1512|139 148|TCF-1 alpha
P02083253A1512|139 148|TCF-1 alpha
P02083253A1512|152 185|T-cell-specific transcription factor
P02083253A1512|152 185|T-cell-specific transcription factor
P02083546A0000|4 23|semi-automatic method
P02083546A0000|46 59|cerebral uptake
P02083546A0000|62 104|99m technetium-hexamethylpropylene amine oxime
P02083546A0000|106 116|99mTc-HMPAO
P02083546A0000|167 180|normal subjects
P02083546A0000|184 191|patients
P02083546A0000|196 213|Alzheimer's disease
P02083546A0000|217 224|patients
P02083546A0000|229 236|dementia
P02083546A0000|258 265|patients
P02083546A0000|270 277|dementia
P02083546A0000|287 300|neurone disease
P02088781A0653|20 22|fog
P02088781A0653|91 108|diagnostic accuracy
P02089054A0121|0 6|IdB 1031
P02089054A0121|26 46|liquid-solid partition
P02089054A0121|53 60|extracts
P02089054A0121|89 108|reversed-phase column
P02089054A0121|165 174|UV detector
P02091890A0614|39 53|anti-aggressive
P02091890A0614|55 69|serenic) profile
P02091890A0614|96 112|social interaction
P02091890A0614|180 187|sedation
P02092131T0000|16 30|in vitro transfer
P02092131T0000|33 55|delayed hypersensitivity
P02093033T0001|36 68|plutonium-239, hexachlorobutadiene
P02093033T0001|72 88|tributyl phosphate
P02093033T0001|94 104|thymus gland
P02093033T0001|107 110|rats
P02093741A0211|26 38|query language
P02093741A0211|112 118|MAXITAB
P02093741A0211|142 165|tabular analysis technique
P02093888A0293|0 4|ARPIA
P02093888A0293|31 44|relational DBMS
P02093888A0293|74 90|personal computers
P02094221A0247|0 7|Diuresis
P02094221A0247|20 36|scheduled drinking
P02094221A0247|39 41|tea
P02094257T0000|0 14|Diagnostic value
P02094257T0000|17 34|adenosine deaminase
P02094257T0000|17 34|adenosine deaminase
P02094257T0000|45 64|tuberculous effusions
P02095150T0000|0 12|Femoral strain
P02095150T0000|28 46|total hip replacement
P02095150T0000|98 104|canines
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|26 33|antisera
P02099622A1046|41 59|Campylobacter jejuni
P02099622A1046|99 113|epithelial cells
P02099622A1046|178 193|Campylobacter spp
P02102823A0492|0 17|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|57 84|neomycin phosphotransferase II
P02102823A0492|57 84|neomycin phosphotransferase II
P02102831A1282|3 11|5' regions
P02102831A1282|22 38|soybean actin genes
P02102831A1282|22 38|soybean actin genes
P02102831A1282|74 84|(CT) repeats
P02102831A1282|103 120|pyrimidine-rich DNA
P02103140A1088|10 17|patients
P02103140A1088|22 44|fulminant hepatic failure
P02103140A1088|56 61|grafts
P02103140A1088|92 113|ABO-incompatible grafts
P02103403A0149|2 8|patient
P02103403A0149|28 40|alcohol intake
P02103403A0149|61 76|hepatotoxic drugs
P02103403A0149|80 87|steroids
P02103403A0149|106 117|malnourished
P02105497A1092|26 43|amino acid sequences
P02105497A1092|48 60|HSP70 proteins
P02105497A1092|48 52|HSP70
P02105497A1092|86 93|BiP genes
P02105497A1092|86 88|BiP
P02105497A1092|137 146|HSP70 genes
P02105497A1092|137 146|HSP70 genes
P02105497A1092|162 171|eukaryotes
P02106287A0478|0 11|Spore inocula
P02107073A0584|31 34|STE4
P02107073A0584|31 34|STE4
P02107073A0584|38 50|STE18 proteins
P02107073A0584|38 50|STE18 proteins
P02107073A0584|111 114|STE4
P02107073A0584|111 114|STE4
P02107073A0584|130 138|wild-type
P02107073A0584|147 151|STE18
P02107073A0584|147 151|STE18
P02107548A0727|0 23|Reverse transcription-PCR
P02107548A0727|46 56|human poly(A
P02107548A0727|51 61|poly(A)+ RNA
P02107548A0727|65 68|cDNA
P02107548A0727|105 111|psi ARF 4
P02107548A0727|105 111|psi ARF 4
P02107548A0727|125 133|human ARF 4
P02107548A0727|125 133|human ARF 4
P02109544A0000|30 43|screening tests
P02109544A0000|47 66|Chlamydia trachomatis
P02109544A0000|69 83|adolescent males
P02109544A0000|132 165|leukocyte esterase urine dipstick test
P02109544A0000|194 216|fluorescent antibody (DFA
P02110145T0000|22 62|imipenem-cefoxitin-hydrolyzing enzyme (CfiA
P02110145T0000|59 62|CfiA
P02110145T0000|68 86|Bacteroides fragilis
P02110145T0000|87 93|TAL2480
P02110145T0000|124 127|CfiA
P02110145T0000|124 127|CfiA
P02110145T0000|131 160|Bacillus cereus beta-lactamase II
P02110145T0000|131 160|Bacillus cereus beta-lactamase II
P02110148A0423|9 23|HindIII fragment
P02110148A0423|9 23|HindIII fragment
P02110148A0423|40 58|DNA sequence analysis
P02110148A0423|70 83|N-terminal half
P02110148A0423|89 108|B. subtilis IF2 protein
P02110148A0423|89 89|B
P02110148A0423|91 142|subtilis IF2 protein and 0.2 kb of upstream flanking sequence
P02110148A0423|193 222|2.76-kb ClaI chromosomal fragment
P02110148A0423|193 222|2.76-kb ClaI chromosomal fragment
P02110148A0423|236 258|entire IF2 structural gene
P02110148A0423|242 258|IF2 structural gene
P02111015A0574|3 25|N-terminal 115 amino acids
P02111015A0574|47 63|DNA-binding domain
P02111015A0574|47 63|DNA-binding domain
P02111015A0574|109 132|cloned IFN response factors
P02111015A0574|115 132|IFN response factors
P02111015A0574|134 138|IRF-1
P02111015A0574|134 138|IRF-1
P02111015A0574|142 146|IRF-2
P02111015A0574|142 146|IRF-2
P02113015A0295|0 15|Maternal seizures
P02113174A0064|26 36|zinc fingers
P02113174A0064|56 74|transcription factor
P02113174A0064|75 77|Sp1
P02113174A0064|75 77|Sp1
P02113174A0957|0 6|Krox-24
P02113174A0957|0 6|Krox-24
P02113174A0957|19 59|sequence-specific transcriptional activator
P02113699A0372|3 10|patients
P02113699A0372|43 50|patients
P02113699A0372|63 70|hot spots
P02113699A0372|88 89|IM
P02113699A0372|98 105|patients
P02113699A0372|116 123|hot spots
P02113699A0372|145 148|N+ IS
P02113699A0372|175 182|hot spots
P02113699A0372|204 207|N- IS
P02113699A0372|204 207|N- IS
P02113901A0000|0 10|Inspired CO2
P02113901A0000|96 99|PaO2
P02113901A0000|112 128|alveolar-arterial
P02115111T0000|11 28|nucleotide sequence
P02115111T0000|55 71|open reading frames
P02115111T0000|77 115|nif gene region of Anabaena sp. strain PCC7120
P02115111T0000|77 89|nif gene region
P02115111T0000|92 108|Anabaena sp. strain
P02115111T0000|109 115|PCC7120
P02115115A1053|66 72|CAR1 URS
P02115115A1053|66 69|CAR1
P02115115A1053|70 72|URS
P02115115A1053|91 108|5'-flanking regions
P02115115A1053|128 137|yeast genes
P02115116A1137|42 50|enhancers
P02115116A1137|61 76|promoter elements
P02115118A0565|4 5|Mr
P02115118A0565|27 44|purified smg p25A GDI
P02115118A0565|35 44|smg p25A GDI
P02115118A0565|56 108|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P02115118A0565|112 152|sucrose density gradient ultracentrifugation
P02115121A0000|25 47|pet complementation group
P02115121A0000|48 51|G104
P02115121A0000|67 106|alpha-ketoglutarate dehydrogenase activity
P02115121A0000|67 98|alpha-ketoglutarate dehydrogenase
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115121A0000|162 164|KE2
P02115121A0000|162 164|KE2
P02115121A0000|180 186|complex
P02115122A0562|27 36|repression
P02115122A0562|56 77|C-terminal 27 amino acids
P02115122A0562|80 84|c-Fos
P02115122A0562|80 84|c-Fos
P02115122A0562|91 95|v-Fos
P02115122A0562|91 95|v-Fos
P02115122A0562|99 119|C-terminal truncations
P02115122A0562|99 99|C
P02115122A0562|122 126|c-Fos
P02115122A0562|122 126|c-Fos
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|41 63|psi V lambda 1, 3 kb upstream
P02115572A1323|41 51|psi V lambda 1
P02115572A1323|69 82|U266 lambda gene
P02115572A1323|69 82|U266 lambda gene
P02115889A0436|40 48|human gene
P02115889A0436|40 48|human gene
P02115889A0436|52 58|Gx alpha
P02115889A0436|52 58|Gx alpha
P02116071A0000|48 55|children
P02116071A0000|83 119|immediate type hypersensitivity reaction
P02116071A0000|132 142|mite antigen
P02116071A0000|160 174|mite specific IgE
P02116071A0000|172 174|IgE
P02116071A0000|182 185|sera
P02116071A0000|205 220|asthmatic attacks
P02116071A0000|255 265|mite antigen
P02116071A0000|310 324|mite specific IgG
P02116071A0000|310 324|mite specific IgG
P02116537A1237|58 60|AMK
P02117799T0000a|0 3|Uses
P02117799T0000a|16 19|OKT3
P02117799T0000a|16 19|OKT3
P02117799T0000a|79 99|kidney transplantation
P02117799T0000b|0 3|Uses
P02117799T0000b|16 19|OKT3
P02117799T0000b|16 19|OKT3
P02117799T0000b|79 99|kidney transplantation
P02118519A0516|32 46|consensus motifs
P02118519A0516|79 87|positions
P02118519A0516|104 128|nerve growth factor receptor
P02118519A0516|104 128|nerve growth factor receptor
P02118519A0516|135 160|68-kDa neurofilament protein
P02118519A0516|135 160|68-kDa neurofilament protein
P02118525A0737|14 30|-119 to -81 fragment
P02118525A0737|36 46|CCK promoter
P02118525A0737|36 38|CCK
P02118525A0737|56 78|transcriptional enhancer
P02118525A0737|117 157|herpes simplex virus thymidine kinase promoter
P02118525A0737|117 134|herpes simplex virus
P02118525A0737|135 157|thymidine kinase promoter
P02118525A0737|161 201|position- and orientation-independent manner
P02118612A0629|39 57|DOPAC concentrations
P02118612A0629|85 88|rats
P02118612A0629|109 113|ether
P02118612A0629|133 137|ether
P02119530T0000|11 20|metoprolol
P02119530T0000|32 57|sympatho-adrenal activation
P02119530T0000|60 71|fibrinolysis
P02119626A0471|41 56|linear dimensions
P02119946T0000|0 16|Managing dysphagia
P02120707A0594|0 23|Gel-mobility-shift assays
P02120707A0594|40 43|Raji
P02120707A0594|44 58|nuclear proteins
P02120707A0594|70 82|W and V elements
P02120707A0594|103 129|HLA-DRA X-box oligonucleotide
P02120707A0594|103 110|HLA-DRA X
P02120833A0000|23 57|transfusion-associated hepatitis NANB
P02120833A0000|59 66|TAH-NANB
P02121371T0000|3 10|NF1 locus
P02121371T0000|3 5|NF1
P02121371T0000|47 58|mammalian GAP
P02121371T0000|47 58|mammalian GAP
P02121371T0000|62 77|yeast IRA proteins
P02121371T0000|62 77|yeast IRA proteins
P02122454A1042|22 27|Phe-62
P02122454A1042|32 34|Ser
P02122454A1042|71 87|lambda I light chain
P02122454A1042|71 87|lambda I light chain
P02122454A1042|109 130|intracellular transport
P02123029A0478|1 13|second isotype
P02123029A0478|16 48|Raja immunoglobulin heavy chain genes
P02123029A0478|16 48|Raja immunoglobulin heavy chain genes
P02123029A0478|76 92|spleen cDNA library
P02123029A0478|107 119|Raja VH- and CH1
P02123029A0478|111 112|VH
P02123029A0478|117 119|CH1
P02123029A0478|173 186|mu-like isotype
P02123029A0478|173 174|mu
P02123029A0478|180 186|isotype
P02123293A0227|0 4|Petko
P02123295A0645|12 15|ARF2
P02123295A0645|12 15|ARF2
P02123300T0000|5 53|recombinant DNA-derived antihemophilic factor (factor
P02123300T0000|27 57|antihemophilic factor (factor VIII
P02123300T0000|54 57|VIII
P02123300T0000|75 85|hemophilia A
P02123300T0000|87 107|recombinant Factor VIII
P02123300T0000|87 107|recombinant Factor VIII
P02123466A0272|32 43|AP-4 HLH motif
P02123466A0272|32 43|AP-4 HLH motif
P02123466A0272|58 68|basic domain
P02123466A0272|102 124|site-specific DNA binding
P02123467A0811|27 34|promoter
P02123467A0811|46 72|Drosophila melanogaster cells
P02123467A0811|81 85|MyoD1
P02123467A0811|81 85|MyoD1
P02123467A0811|89 91|Sp1
P02123467A0811|89 91|Sp1
P02123467A0811|178 180|Sp1
P02123467A0811|178 180|Sp1
P02123467A0811|184 188|MyoD1
P02123467A0811|184 188|MyoD1
P02123820A0000|19 38|monoamine oxidase (MAO
P02123820A0000|19 34|monoamine oxidase
P02123820A0000|36 42|MAO)--A
P02123820A0000|53 62|clorgyline
P02123820A0000|74 87|MAO-B inhibitor
P02123820A0000|74 78|MAO-B
P02123820A0000|89 96|deprenyl
P02123820A0000|115 126|MAO inhibitor
P02123820A0000|115 117|MAO
P02123820A0000|128 136|nialamide
P02123820A0000|156 182|footshock-induced aggression
P02123820A0000|184 186|FIA
P02123820A0000|184 186|FIA
P02123820A0000|196 199|rats
P02123875A0223|49 56|c-region
P02123875A0223|49 56|c-region
P02123875A0223|73 93|fidelity and efficiency
P02123875A0223|127 155|co-translational translocation
P02123875A0223|172 193|amino acid substitutions
P02123875A0223|201 212|COOH terminus
P02123875A0223|218 228|hydrophobic
P02123875A0223|259 269|NH2 terminus
P02123875A0223|291 300|+1 position
P02123875A0223|310 355|eukaryotic preprotein-human pre(delta pro)apoA-II
P02123875A0223|320 355|preprotein-human pre(delta pro)apoA-II
P02123877A1452|21 25|c-fos
P02123877A1452|21 25|c-fos
P02123877A1452|29 38|egr-1 mRNAs
P02123877A1452|29 38|egr-1 mRNAs
P02123877A1452|69 88|stimulated liver cells
P02123877A1452|90 94|fos-B
P02123877A1452|90 94|fos-B
P02123877A1452|96 100|fra-1
P02123877A1452|96 100|fra-1
P02123877A1452|105 109|egr-2
P02123877A1452|105 109|egr-2
P02123877A1452|156 174|serum response factor
P02123877A1452|156 174|serum response factor
P02123877A1452|203 221|immediate-early gene
P02123877A1452|203 221|immediate-early gene
P02124433A0235|5 12|patients
P02124433A0235|95 102|MMC + 5-FU
P02124433A0235|104 115|chemotherapy
P02124433A0235|117 119|253
P02124433A0235|141 155|MMC + 5-FU + OK-432
P02124433A0235|158 160|PSK
P02124433A0235|187 200|group C (surgery
P02124710A0193|3 17|nuclear proteins
P02124710A0193|30 34|c-fos
P02124710A0193|30 34|c-fos
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|99 108|osteoblast
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|59 66|AP-1 site
P02124710A1624|59 66|AP-1 site
P02124710A1624|72 97|type alpha I collagen promoter
P02124710A1624|72 97|type alpha I collagen promoter
P02124710A1624|140 143|VDRE
P02125016A0145|0 3|PBSX
P02125016A0145|0 3|PBSX
P02125016A0145|35 45|SOS response
P02125016A0145|35 37|SOS
P02125153A0410|69 70|R3
P02125153A0410|78 81|97 R5
P02125153A0410|93 95|115
P02125153A0410|98 105|patients
P02125153A0410|130 141|streptomycin
P02126417A0408|31 42|right-handed
P02126417A0408|55 80|left-handed control subjects
P02126417A0408|88 95|right VHF
P02126417A0408|102 115|left hemisphere
P02126504A0602|10 22|Rh-antibodies
P02126504A0602|10 22|Rh-antibodies
P02126504A0602|78 86|Rh-system
P02129338A0568|10 26|amino acid sequence
P02129338A0568|59 97|green alga Scenedemus obliquus plastocyanin
P02129338A0568|59 97|green alga Scenedemus obliquus plastocyanin
P02131652A0883|6 37|fasting serum gastrin concentration
P02131652A0883|18 24|gastrin
P02131652A0883|66 68|l-1
P02131652A0883|81 106|postprandial gastrin release
P02131652A0883|93 99|gastrin
P02131652A0883|108 115|AUC0-120
P02131652A0883|146 151|l-1 min
P02131652A0883|170 172|VTP
P02131652A0883|185 191|VTP-Cas
P02131666A0483|42 50|class II/2
P02131902A0000|44 75|transesophageal echocardiographic
P02131902A0000|77 90|TEE) transducer
P02131902A0000|126 138|left ventricle
P02131902A0000|140 143|S-LV
P02132636A0188|0 7|Subjects
P02132636A0188|14 38|male chronic schizophrenics
P02132636A0188|52 54|DST
P02132636A0188|70 83|nonsuppressors
P02133731A1572|4 5|S3
P02133731A1572|7 9|CBF
P02133731A1572|20 21|S5
P02133731A1572|20 21|S5
P02133731A1572|23 25|CBF
P02133731A1572|23 25|CBF
P02133731A1572|35 37|WTh
P02133731A1572|39 49|1/TPC and 1/T
P02135343A0131|46 60|normal occlusion
P02135343A0131|145 155|dental archs
P02135536A0621|21 33|brush abrasion
P02135536A0621|57 74|transverse strength
P02135536A0621|156 182|thermal expansion coefficient
P02137458A1129|0 0|9
P02137704A0000|28 47|hypertensive patients
P02137704A0000|101 125|blood pressure measurements
P02137704A0000|156 168|blood pressure
P02137704A0000|205 217|blood pressure
P02137704A0000|245 257|blood pressure
P02137704A0000|287 299|blood pressure
P02137704A0000|349 355|cardiac
P02137704A0000|374 383|left atrial
P02137704A0000|393 396|left
P02137704A0000|429 450|posterior wall thickness
P02137704A0000|496 499|left
P02137704A0000|500 514|ventricular mass
P02137704A0000|518 526|mass index
P02137704A0000|553 567|left ventricular
P02138707A0198|39 65|lambda gt11 expression library
P02138707A0198|67 83|murine protein mXBP
P02138707A0198|67 83|murine protein mXBP
P02138707A0198|122 126|3' end
P02138707A0198|132 184|murine class II major histocompatibility complex A alpha gene
P02138707A0198|132 174|murine class II major histocompatibility complex
P02138707A0198|176 188|alpha gene X box
P02138707A0198|185 188|X box
P02138707A0198|200 219|transcription element
P02138707A0198|238 249|class II genes
P02138707A0198|238 249|class II genes
P02138915A1060|3 9|p36 gene
P02138915A1060|3 9|p36 gene
P02138992A0911|4 25|multimodality treatment
P02138992A0911|44 60|gynecologic tumors
P02139473A1603|43 57|Fur-binding site
P02139473A1603|43 57|Fur-binding site
P02139473A1603|60 63|entC
P02139473A1603|60 63|entC
P02139473A1603|84 86|Fur
P02139473A1603|114 133|protected region to +49
P02139473A1603|161 182|Shine-Dalgarno sequence
P02139891A0532|3 15|major promoter
P02139891A0532|34 61|virus-encoded trans activators
P02139891A0532|62 64|EIA
P02139891A0532|68 70|EIV
P02139891A0532|68 70|EIV
P02139891A0532|86 93|elements
P02139891A0532|96 104|TAGA motif
P02139891A0532|119 125|TATA box
P02139891A0532|119 125|TATA box
P02139891A0532|130 138|EIIF sites
P02139891A0532|130 138|EIIF sites
P02139891A0532|175 186|ATF/CREB site
P02139891A0532|175 177|ATF
P02139891A0532|179 182|CREB
P02141425A0175|15 44|fingertip-to-floor (MFTF) method
P02141425A0175|46 53|patients
P02141425A0175|111 118|patients
P02141425A0175|170 174|floor
P02142240A0506|79 95|estrogen receptors
P02142240A0506|79 95|estrogen receptors
P02142240A0506|108 127|progesteron receptors
P02142240A0506|108 127|progesteron receptors
P02142240A0506|141 148|patients
P02142486A0367|0 10|Teicoplanin
P02142486A0367|61 84|Gram-positive bacteraemia
P02142921T0000|0 40|Luteinizing hormone-releasing hormone analog
P02142921T0000|0 34|Luteinizing hormone-releasing hormone
P02142921T0000|50 63|uterine fibroid
P02142921T0000|115 164|intranasally and goserelin administered subcutaneously
P02142921T0000|168 179|monthly depot
P02142955A0248|19 25|infants
P02142955A0248|31 36|adults
P02142955A0248|82 99|physical appearance
P02142993A0176|23 29|disease
P02142993A0176|59 93|anthropogenic cutaneous leishmaniasis
P02142993A0176|102 110|L. tropica
P02142993A0176|102 110|L. tropica
P02142993A0176|123 139|cutaneous patterns
P02142993A0176|148 157|L. infantum
P02142993A0176|196 202|France.
P02143023A0729|18 32|octamer elements
P02143023A0729|38 53|adenovirus genome
P02143023A0729|82 94|transcription
P02143023A0729|104 118|octamer elements
P02143023A0729|124 151|viral terminal repeat sequences
P02143186A0867|19 27|16 introns
P02143186A0867|38 41|AHA3
P02143186A0867|38 41|AHA3
P02143186A0867|43 46|AHA2
P02143186A0867|43 46|AHA2
P02143186A0867|59 64|intron
P02143186A0867|70 90|5'-untranslated region
P02143186A0867|95 106|second intron
P02143186A0867|112 133|C-terminal coding region
P02143186A0867|112 133|C-terminal coding region
P02143186A1306|0 19|Northern blot analysis
P02143186A1306|33 40|AHA2 mRNA
P02143186A1306|33 36|AHA2
P02143186A1306|56 66|cellular RNA
P02143186A1306|107 116|root tissue
P02143186A1306|131 141|shoot tissue
P02143768T0000|0 8|Impaction
P02143768T0000|31 43|abdominal wall
P02143961A0400|72 75|pCPA
P02143961A0400|93 101|analgesia
P02144558A1022|0 0|A
P02144610A1306|0 28|TCR alpha and beta gene expression
P02144610A1306|0 7|TCR alpha
P02144610A1306|11 18|beta gene
P02144610A1306|57 77|T-cell nuclear proteins
P02144610A1306|57 77|T-cell nuclear proteins
P02144610A1306|87 99|T beta 2 element
P02144610A1306|87 99|T beta 2 element
P02144610A1306|113 152|cyclic AMP response element-binding proteins
P02144610A1306|113 152|cyclic AMP response element-binding proteins
P02144610A1306|174 187|T alpha 1 element
P02144610A1306|174 187|T alpha 1 element
P02144610A1306|193 213|human TCR alpha enhancer
P02144610A1306|193 213|human TCR alpha enhancer
P02144610A1306|220 233|decamer element
P02144610A1306|257 286|human and murine TCR beta promoters
P02144610A1306|271 286|TCR beta promoters
P02145195A0253|3 13|3' stem-loop
P02145195A0253|85 95|binding site
P02145195A0253|99 108|Sm proteins
P02145195A0253|99 108|Sm proteins
P02145268A0746|10 27|nucleotide sequence
P02145268A0746|87 104|type I collagen genes
P02145268A0746|87 99|type I collagen
P02145268A0746|143 152|COL3A1 gene
P02145268A0746|143 152|COL3A1 gene
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|52 66|cyanogen bromide
P02145268A1454|70 98|mammalian collagenase digestion
P02145268A1454|70 89|mammalian collagenase
P02146266A0000|4 33|-kilobase BamHI-HindIII fragment
P02146266A0000|13 33|BamHI-HindIII fragment
P02146266A0000|51 89|Neurospora crassa CuZn superoxide dismutase
P02146266A0000|51 66|Neurospora crassa
P02146266A0000|67 89|CuZn superoxide dismutase
P02146266A0000|111 115|sod-1
P02146266A0000|111 115|sod-1
P02146266A0000|133 146|genomic library
P02146266A0000|155 187|60-base deoxyoligonucleotide probes
P02146266A0000|217 239|crassa amino acid sequence
P02146495A0706|8 15|peptides
P02146495A0706|51 61|basic region
P02146495A0706|51 61|basic region
P02146495A0706|85 103|leucine zipper domain
P02146495A0706|139 141|CRE
P02147223A1047|14 16|CRE
P02147223A1047|22 39|human c-fos promoter
P02147223A1047|22 39|human c-fos promoter
P02147223A1047|49 51|-60
P02147223A1047|70 73|cAMP
P02147223A1047|77 79|E1a
P02147223A1047|77 79|E1a
P02147223A1047|86 89|HeLa
P02147223A1047|93 101|PC12 cells
P02147422A0000|44 66|human U1-70K snRNP protein
P02147422A0000|49 66|U1-70K snRNP protein
P02148219A0508|106 111|flexor
P02148291A0173|16 43|synthetic HSE oligonucleotides
P02148291A0173|76 92|HSE binding domains
P02148291A0173|110 142|tomato lambda gt11 expression library
P02148291A0173|145 163|DNA-ligand screening
P02148508A0374|0 9|Fluid (AVLF
P02148508A1478|44 46|TCM
P02148508A1478|56 63|patients
P02148508A1478|80 105|pathophysiological patterns
P02148799A0000|3 9|nmr gene
P02148799A0000|3 9|nmr gene
P02148799A0000|15 41|major negative regulatory gene
P02148799A0000|20 41|negative regulatory gene
P02148799A0000|47 54|nitrogen
P02148799A0000|71 86|Neurospora crassa
P02148799A0000|71 86|Neurospora crassa
P02148799A0000|106 128|positive regulatory genes
P02148799A0000|188 194|circuit
P02149487A0348|8 35|dexamethasone suppression test
P02149487A0348|66 96|dehydroepiandrosterone-sulphate
P02149487A0348|128 139|testosterone
P02149487A0348|143 163|androstenedione levels
P02149566A0478|14 18|NMR-S
P02149566A0478|26 44|inorganic phosphates
P02149566A0478|51 65|phosphocreatine
P02149566A0478|67 70|PCr]
P02149566A0478|102 104|LVH
P02149566A0478|105 111|baboons
P02149570T0000|0 16|Cutaneous necrosis
P02149570T0000|31 48|protein S deficiency
P02149570T0000|31 38|protein S
P02151229A0000|8 24|cerebral blood flow
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|77 115|single-photon emission computed tomography
P02151229A0000|117 118|CT
P02151229A0000|124 135|aged patients
P02151229A0000|140 175|noninsulin-dependent diabetes mellitus
P02151229A0000|177 181|NIDDM
P02151229A0000|217 229|plasma glucose
P02151229A0000|246 264|nondiabetic subjects
P02151229A0921|4 15|ROI-A/B ratio
P02151229A0921|35 47|diabetic group
P02151229A0921|90 105|nondiabetic group
P02153243A0965|47 55|int-2 gene
P02153243A0965|47 55|int-2 gene
P02153243A0965|76 103|fibroblast growth factor family
P02153243A0965|86 103|growth factor family
P02153243A0965|108 125|contributory factor
P02153243A0965|142 154|mammary tumors
P02153683A1579|31 39|complexes
P02153683A1579|55 61|ankyrin
P02153683A1579|55 61|ankyrin
P02153683A1579|65 70|fodrin
P02153683A1579|81 105|uvomorulin or Na+,K+-ATPase
P02153683A1579|81 90|uvomorulin
P02153683A1579|93 95|Na+
P02153683A1579|97 105|K+-ATPase
P02153977A0364|71 75|mRNAs
P02154467A0709|3 12|PC2 protein
P02154467A0709|52 71|NH2-terminal sequence
P02154467A0709|77 97|human furin gene product
P02154467A0709|77 97|human furin gene product
P02154467A0709|100 145|putative membrane-inserted receptor-like molecule
P02154474A1504|39 56|cAMP responsiveness
P02154474A1504|77 84|P-450scc
P02154474A1504|77 84|P-450scc
P02154474A1504|96 118|steroidogenic P-450 genes
P02154474A1504|109 113|P-450
P02154599A0382|18 29|footprinting
P02154599A0382|33 60|gel mobility retardation assays
P02154599A0382|73 83|bacterially
P02154599A0382|95 111|Zta fusion proteins
P02154599A0382|95 111|Zta fusion proteins
P02154599A0382|130 147|TGTGCAA-like motifs
P02154599A0382|154 156|DSL
P02154599T0000|3 19|zta transactivator
P02154599T0000|3 19|zta transactivator
P02154599T0000|41 64|lytic cycle gene expression
P02154599T0000|67 103|Epstein-Barr virus-infected lymphocytes
P02154599T0000|67 83|Epstein-Barr virus
P02154599T0000|115 118|AP-1
P02154599T0000|115 118|AP-1
P02154599T0000|122 129|ZRE sites
P02154599T0000|122 129|ZRE sites
P02154599T0000|132 163|target promoter and enhancer regions
P02154602A0092|7 18|human homolog
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|60 73|influenza virus
P02154686A0185|22 45|21-base-pair repeat region
P02154686A0185|60 72|simian virus 40
P02154686A0185|97 123|beta-galactosidase synthesis
P02154686A0185|97 114|beta-galactosidase
P02154686A0185|149 174|polyomavirus enhancer region
P02154686A0185|149 174|polyomavirus enhancer region
P02154885A0153|19 29|mutagenesis
P02154885A0153|31 43|residues 60, 61
P02154885A0153|76 95|helical loop structure
P02154885A0153|116 135|substrate recognition
P02154885A0153|141 146|enzyme
P02155017A1106|21 23|LMW
P02155017A1106|24 30|heparin
P02155017A1106|72 91|hypertriglyceridemia
P02155017A1106|143 159|observation period
P02155017A1106|180 203|hemorrhagic complications
P02155017A1106|206 220|routine dialyses
P02156828A0164|10 26|amino acid sequence
P02156828A0164|29 35|destrin
P02156828A0164|91 97|cofilin
P02156828A0164|91 97|cofilin
P02156828A0164|118 152|pH-sensitive actin-modulating protein
P02156828A0164|130 152|actin-modulating protein
P02157067A0610|0 6|Summers
P02157141A0923|16 23|T antigen
P02157141A0923|16 23|T antigen
P02157141A0923|39 52|topoisomerase I
P02157141A0923|39 52|topoisomerase I
P02157141A0923|73 94|ori-auxiliary sequences
P02157141A0923|114 135|T-antigen-dependent DNA
P02157141A0923|186 196|50 base pairs
P02157764A1115|1 15|rabbit antiserum
P02157764A1115|33 48|synthetic peptide
P02157764A1115|65 82|hydrophilic portion
P02157764A1115|98 115|murine cDNA sequence
P02157882T0000|0 11|Conservation
P02157882T0000|24 48|Drosophila melanogaster abl
P02157882T0000|24 48|Drosophila melanogaster abl
P02157882T0000|52 70|murine v-abl proteins
P02157882T0000|58 70|v-abl proteins
P02157882T0000|89 102|mammalian cells
P02158099A0487|2 30|transient cotransfection assays
P02158099A0487|36 50|Chang liver cells
P02158099A0487|52 56|CCL 13
P02158099A0487|83 104|trans-activating effect
P02158099A0487|125 146|pSV2CAT reporter plasmid
P02158927A0000|19 40|nucleotide (nt) sequence
P02158927A0000|52 61|COR segment
P02158927A0000|87 94|six genes
P02158927A0000|87 94|six genes
P02158927A0000|96 104|CYC1, UTR1
P02158927A0000|96 99|CYC1
P02158927A0000|101 104|UTR1
P02158927A0000|106 109|UTR3
P02158927A0000|106 109|UTR3
P02158927A0000|111 114|OSM1
P02158927A0000|111 114|OSM1
P02158927A0000|116 124|tRNA(Gly)
P02158927A0000|116 123|tRNA(Gly
P02158927A0000|128 131|RAD7
P02158927A0000|128 131|RAD7
P02158927A0000|142 152|chromosome X
P02158927A0000|158 162|yeast
P02158927A0000|163 185|Saccharomyces cerevisiae
P02159470A1432|20 33|protein factors
P02159470A1432|63 73|Mt sequences
P02159470A1432|63 73|Mt sequences
P02159470A1432|142 153|nuclear genes
P02159470A1432|142 153|nuclear genes
P02159470A1432|184 220|mitochondrial oxidative phosphorylation
P02159559A0779|37 63|HSV-induced DNA amplification
P02160502A0471|2 29|recombination signal sequences
P02160502A0471|58 75|recombination point
P02160622A0000|3 27|antinociceptive properties
P02160622A0000|44 53|tail-flick
P02160622A0000|57 70|hot-plate tests
P02160622A0000|177 184|morphine
P02160622A0000|199 202|rats
P02160955A0899|27 32|AATAAA
P02160955A0899|39 51|GT-rich region
P02160955A0899|39 51|GT-rich region
P02160955A0899|97 100|43 bp
P02162049A0291|22 35|gene for factor Y
P02162049A0291|29 35|factor Y
P02162049A0291|66 76|DNA sequence
P02162103A0000|23 27|cDNAs
P02162103A0000|35 41|genomic
P02162103A0000|42 47|RNA and
P02162103A0000|48 51|mRNA
P02162103A0000|55 68|phosphoprotein
P02162103A0000|70 71|P)
P02162103A0000|74 101|human parainfluenza type 2 virus
P02162103A0000|103 107|PIV-2
P02162103A0000|103 107|PIV-2
P02162103A0000|110 118|cDNA clone
P02162103A0000|123 129|genomic
P02162103A0000|130 132|RNA
P02162103A0000|168 177|poly(A) and
P02162103A0000|195 216|small open reading frames
P02162103A0000|241 253|249 amino acids
P02162467A0311|10 13|cytR
P02162467A0311|10 13|cytR
P02162467A0311|51 61|CytR protein
P02162467A0311|51 61|CytR protein
P02162467A0311|88 102|cAMP/CAP complex
P02162467A0311|88 102|cAMP/CAP complex
P02162754A0339|31 47|amino acid sequence
P02162754A0339|53 58|3T3-L1
P02162754A0339|59 82|adipocyte insulin receptor
P02162754A0339|88 92|mouse
P02162754A0801|0 2|PAO
P02162754A0801|22 36|phosphoryl group
P02162754A0801|39 42|pp15
P02162754A0801|39 42|pp15
P02162754A0801|95 112|signal transmission
P02162754A0801|133 155|glucose-transport system
P02162835A0989|80 95|heme binding sites
P02162835A0989|102 118|copper binding site
P02162835A0989|126 132|enzymes
P02163347A0472|3 14|cDNA sequence
P02163347A0472|20 41|813-bp open reading frame
P02163347A0472|43 45|ORF
P02163347A0472|61 77|amino acid sequence
P02163347A0472|99 127|272 carboxy-terminal amino acids
P02163347A0472|133 149|human ets-1 protein
P02163347A0472|133 149|human ets-1 protein
P02163382A0169|17 28|O7-LPS region
P02163382A0169|17 28|O7-LPS region
P02163382A0169|44 57|cosmids pJHCV31
P02163382A0169|61 67|pJHCV32
P02163382A0169|85 105|transposon mutagenesis
P02163382A0169|110 117|Tn3HoHo1
P02163382A0169|110 117|Tn3HoHo1
P02163382A0169|132 143|promoterless
P02163382A0169|144 152|lac operon
P02163382A0169|144 152|lac operon
P02163382A0169|176 201|lacZ transcriptional fusions
P02163382A0169|176 179|lacZ
P02163382A0169|206 223|target DNA sequences
P02163394T0000|3 10|sacT gene
P02163394T0000|3 10|sacT gene
P02163394T0000|24 34|sacPA operon
P02163394T0000|24 34|sacPA operon
P02163394T0000|37 52|Bacillus subtilis
P02163394T0000|37 52|Bacillus subtilis
P02163394T0000|77 106|transcriptional antiterminators
P02164585A0416|3 23|TraD protein (83,899 Da)
P02164585A0416|3 13|TraD protein
P02164585A0416|37 54|hydrophobic regions
P02164585A0416|83 102|amino-terminal region
P02164585A0814|19 22|orfD
P02164585A0814|19 22|orfD
P02164585A0814|43 49|tra gene
P02164585A0814|43 49|tra gene
P02164585A0814|56 59|traX
P02164585A0814|56 59|traX
P02164585A0814|73 93|hydrophobic amino acids
P02164585A0814|111 117|alanine
P02164585A0814|121 127|leucine
P02164588A0266|7 19|mutant HN genes
P02164588A0266|13 19|HN genes
P02164588A0266|53 60|residues
P02164588A0266|72 90|signal-anchor domain
P02164588A0266|72 90|signal-anchor domain
P02164588A0266|104 118|cytoplasmic tail
P02164588A0266|133 154|intracellular transport
P02164588A0266|160 173|HN glycoprotein
P02164588A0266|160 173|HN glycoprotein
P02164604A0399|43 63|E2 transactivation gene
P02164604A0399|43 44|E2
P02164604A0399|87 95|promoters
P02164604A1574|25 34|E2 proteins
P02164604A1574|25 26|E2
P02164604A1574|77 88|BPV-1 mutants
P02164604A1574|77 88|BPV-1 mutants
P02164604A1574|147 148|E2
P02164604A1574|147 148|E2
P02164637A0515|15 22|IRA2 gene
P02164637A0515|15 22|IRA2 gene
P02164637A0515|58 66|heat shock
P02164637A0515|70 87|nitrogen starvation
P02164637A0515|93 110|sporulation defects
P02164637A0515|150 160|cdc25 mutant
P02164637A0515|150 160|cdc25 mutant
P02165181A0299|12 19|patients
P02165589A0000|7 28|Drosophila melanogaster
P02165589A0000|52 56|2C1-3
P02165589A0000|62 74|distal portion
P02165589A0000|80 91|X-chromosome
P02165589A0000|111 151|steroid/thyroid hormone receptor superfamily
P02165589A0000|111 151|steroid/thyroid hormone receptor superfamily
P02165589A0888|10 17|Region II
P02165589A0888|40 60|human c-jun oncoprotein
P02165589A0888|40 60|human c-jun oncoprotein
P02165589A0888|63 75|leucine zipper
P02165589A0888|115 132|heterodimerization
P02165589A0888|147 167|jun and fos oncoproteins
P02165589A0888|147 149|jun
P02165589A0888|153 167|fos oncoproteins
P02166040A0385|18 25|vanadate
P02166040A0385|38 59|PEPCK gene transcription
P02166040A0385|38 46|PEPCK gene
P02166040A0385|70 82|chimeric genes
P02166040A0385|70 82|chimeric genes
P02166040A0385|114 149|P-enolypyruvate carboxykinase promoter
P02166040A0385|114 141|P-enolypyruvate carboxykinase
P02166040A0385|205 238|amino-3-glycosyl phosphotransferase
P02166040A0385|205 238|amino-3-glycosyl phosphotransferase
P02166040A0385|240 242|neo
P02166040A0385|240 242|neo
P02166040A0385|246 277|chloramphenicol acetyltransferase
P02166040A0385|246 277|chloramphenicol acetyltransferase
P02166040A0385|295 307|hepatoma cells
P02166040A0385|343 384|Moloney murine leukemia virus-based retrovirus
P02166040A0385|422 434|neo expression
P02166040A0385|462 494|chloroamphenicol acetyltransferase
P02166040A0385|462 494|chloroamphenicol acetyltransferase
P02166416A0419|14 32|miliary tuberculosis
P02166416A0419|67 70|ARDS
P02166825A0198|24 41|functional elements
P02166825A0198|47 54|promoter
P02166825A0198|113 129|promoter mutations
P02166825A0198|161 184|linker-scanning mutations
P02166825A0198|200 213|promoter region
P02167321T0000|21 42|cAMP-responsive element
P02167321T0000|21 42|cAMP-responsive element
P02167321T0000|48 52|exon-
P02167321T0000|60 88|activator protein-2 binding site
P02167321T0000|69 88|protein-2 binding site
P02167321T0000|94 141|human tissue-type plasminogen activator gene promoter
P02167321T0000|110 129|plasminogen activator
P02167321T0000|153 167|basal expression
P02167321T0000|171 186|convey activation
P02167321T0000|189 200|phorbol ester
P02167321T0000|204 207|cAMP
P02167467T0000|3 32|26S rRNA binding ribosomal protein
P02167467T0000|3 5|26S
P02167467T0000|6 32|rRNA binding ribosomal protein
P02167467T0000|45 63|bacterial protein L11
P02167467T0000|45 60|bacterial protein
P02167467T0000|61 63|L11
P02167467T0000|101 123|Saccharomyces cerevisiae
P02167784A0109|4 22|healthy male subjects
P02167784A0109|106 140|steady-state end-tidal CO2 measurement
P02168640A0268|51 54|SSEP
P02168640A0268|67 68|AS
P02168640A0268|140 159|psychogenic disorders
P02169887A0360|85 92|EMCV-RNA
P02169887A0360|103 107|mRNAs
P02170687A0000|3 15|E6/E7 promoter
P02170687A0000|3 4|E6
P02170687A0000|6 7|E7
P02170687A0000|21 27|genital
P02170687A0000|28 48|human papillomaviruses
P02170687A0000|80 101|viral transforming genes
P02172672T0001|7 27|Goodpasture's syndrome
P02173399A0333|63 79|tissue radiographs
P02173399A0333|81 84|STRs
P02173405A0270|2 23|symptomatic abnormality
P02173405A0270|41 54|neonatal period
P02173405A0270|61 89|periventricular calcifications
P02174105A1232|0 26|Immunohistochemical analysis
P02174105A1232|36 44|rat organs
P02174105A1232|65 79|epithelial cells
P02174427A1574|94 137|wild-type ubiquinol-cytochrome c oxidoreductase
P02174427A1574|94 123|wild-type ubiquinol-cytochrome c
P02174861A0736|12 15|irgA
P02174861A0736|12 15|irgA
P02174861A0736|45 64|transcriptional level
P02174861A0736|93 109|symmetric sequence
P02174861A0736|128 135|promoter
P02174861A0736|154 168|Fur binding sites
P02174861A0736|154 168|Fur binding sites
P02174861A0736|171 176|E. coli
P02174861A0736|171 176|E. coli
P02174974A0000|0 12|Transcription
P02174974A0000|18 28|first operon
P02174974A0000|38 62|m-xylene-degrading enzymes
P02174974A0000|68 77|TOL plasmid
P02174974A0000|80 96|Pseudomonas putida
P02174974A0000|113 127|xylR gene product
P02174974A0000|113 127|xylR gene product
P02175433A0575|25 46|normal beta A-globin gene
P02175433A0575|31 46|beta A-globin gene
P02175433A0575|51 60|mutant gene
P02175433A0575|51 60|mutant gene
P02175433A0575|64 81|Ylp vector sequences
P02175908A0805|48 61|Ulysses element
P02175908A0805|48 61|Ulysses element
P02175908A0805|67 77|mutant locus
P02175908A0805|67 77|mutant locus
P02175908A0805|144 151|mutation
P02176021T0000|0 12|Determination
P02176021T0000|44 76|electron spin resonance spectroscopy
P02176152A0896|14 15|RA
P02176152A0896|14 15|RA
P02176152A0896|53 65|a reporter gene
P02176152A0896|54 65|reporter gene
P02176152A0896|77 79|TPA
P02176152A0896|90 103|AP1 binding site
P02176152A0896|90 103|AP1 binding site
P02176152A0896|114 126|HSV tk promoter
P02176152A0896|114 126|HSV tk promoter
P02176209A0954|21 23|EFI
P02176209A0954|21 23|EFI
P02176209A0954|25 28|NF-Y
P02176209A0954|25 28|NF-Y
P02176209A0954|32 34|CBF
P02176209A0954|58 79|gel retardation patterns
P02176232T0001|32 41|metastasis
P02176232T0001|44 53|lung cancer
P02176232T0001|65 66|II
P02176232T0001|69 72|IIIA
P02176822A0000|0 32|Multifunctional protein kinase (MFPK
P02176822A0000|0 27|Multifunctional protein kinase
P02176822A0000|29 32|MFPK
P02176822A0000|48 63|ATP-citrate lyase
P02176822A0000|48 63|ATP-citrate lyase
P02176822A0000|66 73|peptide B
P02176822A0000|85 86|BT
P02176822A0000|85 86|BT
P02176822A0000|90 91|BS
P02176822A0000|90 91|BS
P02176822A0000|95 103|threonine
P02176822A0000|107 112|serine
P02176822A0000|140 154|threonyl residue
P02176822A0000|159 174|glycogen synthase
P02176822A0000|159 174|glycogen synthase
P02179052A1044|16 33|Y' repeated sequence
P02179052A1044|84 103|sequence interactions
P02179052A1044|117 125|evolution
P02179188A1223|3 36|electrically induced motile responses
P02179188A1223|69 81|dinitrophenol
P02179188A1223|84 96|cytochalasin B
P02179815A0582|6 13|p59v-rel
P02179815A0582|6 9|p59v
P02179815A0582|11 13|rel
P02179815A0582|23 36|nuclear protein
P02179815A0582|39 41|CEF
P02179815A0582|43 68|indirect immunofluorescence
P02179815A0582|79 86|p68c-rel
P02179815A0582|79 82|p68c
P02179815A0582|84 86|rel
P02179815A0582|89 98|JD214c-rel
P02179815A0582|107 109|CEF
P02179815A0582|135 143|cytoplasm
P02179815A0582|180 187|p68c-rel
P02179815A0582|180 183|p68c
P02179815A0582|185 187|rel
P02179815A0582|209 233|nuclear localizing sequence
P02179815A0582|273 280|p59v-rel
P02179815A0582|273 276|p59v
P02179815A0582|278 280|rel
P02180935A0535|0 17|Kinetic experiments
P02180935A0535|57 72|precursor protein
P02180935A0535|87 96|HL-60 cells
P02180935A0535|118 124|150,000
P02180935A0535|125 142|chondroitin sulfate
P02181760A0311|5 8|flow
P02181760A0311|34 50|Doppler ultrasound
P02181760A0311|76 83|diastole
P02181760A0311|118 136|cotyledon resistance
P02182240A0355|11 18|patients
P02182240A0355|27 38|anistreplase
P02182240A0355|42 44|119
P02182240A0355|53 59|heparin
P02182240A0355|79 81|188
P02182323A0121|8 25|primary transcripts
P02182323A0121|29 39|variant tRNA
P02182323A0121|36 53|tRNA(Val)(UAC) gene
P02182323A0121|41 43|Val
P02182323A0121|46 53|UAC) gene
P02182323A0121|89 104|growth conditions
P02182323A0121|139 154|5' flanking region
P02182618A0168|3 18|promoter activity
P02182618A0168|55 95|chloramphenicol acetyltransferase (CAT) gene
P02182618A0168|55 86|chloramphenicol acetyltransferase
P02182618A0168|88 90|CAT
P02182618A0168|116 133|5'-deletion mutants
P02182618A0168|139 155|5'-flanking region
P02183467A0668|15 18|ORFs
P02183467A0668|24 36|central region
P02183467A0668|39 41|BIV
P02183467A0668|98 126|nonstructural/regulatory genes
P02183467A0668|128 130|vif
P02183467A0668|128 130|vif
P02183467A0668|132 134|tat
P02183467A0668|132 134|tat
P02183467A0668|139 141|rev
P02183467A0668|150 161|lentiviruses
P02183467A0668|188 191|ORFs
P02183467A0668|199 203|W and Y
P02183467A0668|199 199|W
P02183467A0668|203 203|Y
P02183467A0668|220 224|exons
P02183467A0668|228 237|novel genes
P02185140A0000|3 33|Saccharomyces cerevisiae 14DM gene
P02185140A0000|3 25|Saccharomyces cerevisiae
P02185140A0000|26 33|14DM gene
P02185140A0000|43 90|cytochrome P450 lanosterol 14 alpha-demethylase (14DM
P02185140A0000|43 85|cytochrome P450 lanosterol 14 alpha-demethylase
P02185140A0000|87 90|14DM
P02185140A0000|118 136|S. cerevisiae strains
P02185140A0000|165 203|heterologous yeast transcription promoters
P02185140A0000|177 203|yeast transcription promoters
P02185140A0000|205 209|pADC1
P02185140A0000|205 209|pADC1
P02185140A0000|211 214|pGPD
P02185140A0000|211 214|pGPD
P02185140A0000|216 220|pPHO5
P02185140A0000|216 220|pPHO5
P02185140A0000|248 255|promoter
P02185250A0726|21 37|78 and 64 amino acids
P02185250A0726|63 90|endoplasmic reticulum membrane
P02185250A0726|147 159|SRP-dependent
P02185250A0726|147 149|SRP
P02187091A0721|9 26|vascular resistance
P02187091A0721|77 102|isovolumic relaxation period
P02187091A0721|117 119|119
P02187871T0000|3 11|ANB1 locus
P02187871T0000|3 11|ANB1 locus
P02187871T0000|14 36|Saccharomyces cerevisiae
P02187871T0000|14 36|Saccharomyces cerevisiae
P02187871T0000|79 84|eIF-4D
P02187871T0000|79 84|eIF-4D
P02188096A0955|19 43|alternative splicing events
P02188096A0955|46 60|c-myb expression
P02188096A0955|46 50|c-myb
P02188096A0955|70 74|c-myb
P02188096A0955|70 74|c-myb
P02188168A0000|0 23|Serum beta 2-microglobulin
P02188168A0000|0 23|Serum beta 2-microglobulin
P02188168A0000|31 38|beta-2-M
P02188168A0000|31 38|beta-2-M
P02188168A0000|60 66|addicts
P02188168A0000|76 95|asymptomatic carriers
P02188168A0000|98 116|anti HIV-1 antibodies
P02188168A0000|102 116|HIV-1 antibodies
P02188168A0000|120 138|symptomatic carriers
P02188168A0000|153 178|generalized lymphadenopathy
P02188168A0000|205 212|patients
P02190122A0633|4 15|emancipation
P02190122A0633|107 112|mating
P02190134A0572|2 8|therapy
P02190134A0572|77 106|laser photocoagulation treatment
P02190134A0572|182 202|subretinal hemorrhages
P02193033A0195|0 0|R
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|45 65|Haemophilus influenzae
P02194273A0913|69 91|Streptococcus pneumoniae
P02194972T0000|20 28|cefpirome
P02194972T0000|30 34|HR 810
P02194972T0000|38 64|experimental mixed infections
P02194972T0000|69 88|Enterococcus faecalis
P02194972T0000|92 106|Escherichia coli
P02194972T0000|109 112|mice
P02195025T0000|12 20|yeast LEU2
P02195025T0000|12 20|yeast LEU2
P02195715A0143|53 60|newborns
P02195715A0143|92 102|individuals
P02195715A0143|124 139|venous thrombosis
P02195715A0143|143 159|pulmonary embolism
P02195715T0000|0 13|Ischemic stroke
P02195715T0000|19 36|protein C deficiency
P02195715T0000|19 26|protein C
P02196176A0749|0 4|TREB7
P02196176A0749|0 4|TREB7
P02196176A0749|8 13|TREB36
P02196176A0749|8 13|TREB36
P02196176A0749|43 46|21 bp
P02196176A0749|51 55|TREB5
P02196176A0749|51 55|TREB5
P02196176A0749|72 83|second repeat
P02196311A1034|23 29|5 KE X 3/W
P02196311A1034|64 80|antitumor immunity
P02196311A1034|83 85|RNL
P02196450A0870|17 31|deletion mutants
P02196450A0870|80 82|QBP
P02196450A0870|80 82|QBP
P02196450A0870|169 171|QBP
P02196450A0870|169 171|QBP
P02196450A0870|202 225|TATA-independent promoter
P02196565A0606|5 28|general regulatory factor I
P02196565A0606|5 28|general regulatory factor I
P02196565A0606|30 109|GRFI)/repressor/activator site binding protein 1 (RAP1)/translation upstream factor (TUF
P02196565A0606|30 33|GRFI
P02196565A0606|36 73|repressor/activator site binding protein 1
P02196565A0606|75 105|RAP1)/translation upstream factor
P02196565A0606|107 109|TUF
P02196565A0606|138 155|MAT alpha expression
P02196565A0606|138 145|MAT alpha
P02196565A0606|174 177|PYK1
P02196565A0606|174 177|PYK1
P02196565A0606|206 218|GRFI/RAP1/TUF
P02196565A0606|206 209|GRFI
P02196565A0606|211 214|RAP1
P02196565A0606|216 218|TUF
P02196565A0606|239 251|gal11 mutation
P02196565A0606|239 251|gal11 mutation
P02196565T0000|0 16|Yeast Gal11 protein
P02196565T0000|5 16|Gal11 protein
P02196565T0000|73 90|transacting factors
P02196565T0000|92 95|Gal4
P02196565T0000|92 95|Gal4
P02196565T0000|99 160|general regulatory factor I/repressor/activator site binding protein
P02196565T0000|99 132|general regulatory factor I/repressor
P02196565T0000|134 187|activator site binding protein 1/translation upstream factor
P02196565T0000|174 187|upstream factor
P02198259A0685|21 38|N- or C-terminal ends
P02198259A0685|21 25|N- or C
P02198259A0685|41 47|repA (28
P02198259A0685|41 44|repA
P02198259A0685|51 58|69 codons
P02198259A0685|81 105|286-codon open reading frame
P02198259A0685|136 153|inhibitory activity
P02198289A0436|12 19|peptides
P02198289A0436|34 48|amino acids 1-228
P02198289A0436|70 79|amino acids
P02198289A0436|82 85|-228
P02198289A0436|135 139|dimer
P02199311A0620|2 27|vitro transcription extracts
P02199311A0620|32 42|ret1-1 cells
P02199311A0620|32 37|ret1-1
P02199311A0620|73 103|transcription termination signals
P02199311A0620|117 125|RET1 cells
P02199311A0620|117 120|RET1
P02199311A0620|142 154|tRNA templates
P02200150A1381|0 14|Guiding patients
P02200150A1381|74 91|surgical oncologist
P02200150A1381|134 147|plastic surgeon
P02200315A0278|0 2|IgG
P02200315A0278|0 2|IgG
P02200315A0278|6 16|IgM antibody
P02200315A0278|6 16|IgM antibody
P02200315A0278|85 94|A60 antigen
P02200315A0278|85 94|A60 antigen
P02200736A1003|64 67|AP-4
P02200736A1003|64 67|AP-4
P02200736A1003|71 74|MLTF
P02200736A1003|71 74|MLTF
P02200736A1003|89 101|CACCTGTC motif
P02201770A0188|59 72|Anomiopsyllini
P02201901A0229|59 69|SSN6 protein
P02201901A0229|59 69|SSN6 protein
P02201905A1004|31 41|ABFI protein
P02201905A1004|31 41|ABFI protein
P02201905A1004|50 60|RAP1 protein
P02201905A1004|50 60|RAP1 protein
P02201905A1004|123 136|gene expression
P02202496T0000|0 16|Clinical nutrition
P02202496T0000|19 29|adult horses
P02204029A0184|0 20|RNase protection assays
P02204029A0184|0 4|RNase
P02204029A0184|40 42|unr
P02204029A0184|77 81|N-ras
P02204029A0184|77 81|N-ras
P02204029A0184|92 96|3' end
P02204029A0184|113 121|base pairs
P02204029A0184|145 149|N-ras
P02204029A0184|145 149|N-ras
P02204621T0000|12 38|temperature-sensitive mutant
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|93 130|gene encoding tRNA nucleotidyltransferase
P02204621T0000|136 140|yeast
P02204621T0000|141 163|Saccharomyces cerevisiae
P02204623A0000|27 57|insulin receptor (IR) beta-subunit
P02204623A0000|27 41|insulin receptor
P02204623A0000|43 57|IR) beta-subunit
P02204623A0000|68 97|unphosphorylated tyrosyl residue
P02204623A0000|99 104|Tyr960
P02204623A0000|124 163|insulin-stimulated tyrosyl phosphorylation
P02204623A0000|124 130|insulin
P02204623A0000|170 189|endogenous substrates
P02204623A0000|200 218|biological responses
P02204625A1130|23 27|genes
P02204625A1130|73 79|insulin
P02204625A1130|73 79|insulin
P02204625A1130|88 95|mitogens
P02204810A1080|3 10|3' region
P02204810A1080|12 14|GA2
P02204810A1080|12 14|GA2
P02204810A1080|30 46|maximal expression
P02205970A0684|0 0|1
P02206430A0197|17 32|novel environment
P02206430A0197|42 48|mothers
P02206430A0197|79 80|DA
P02206789A0002|28 61|percutaneous anaesthetic preparation
P02206858A0000|0 31|Homozygous protein C (PC) deficiency
P02206858A0000|17 17|C
P02206858A0000|19 20|PC
P02206858A0000|47 54|siblings
P02206858A0000|63 65|boy
P02206858A0000|109 121|7 4/12 and 1 3/12
P02208762A0228|3 13|grandfather
P02208762A0228|51 63|meatal atresia
P02208762A0228|126 144|auricular appendages
P02209237A0239|8 29|intrapulmonary shunting
P02209237A0239|31 33|IPS
P02209237A0239|60 89|whole-body radionuclide scanning
P02209237A0239|94 102|99mTc-MAA
P02209237A0239|132 139|cyanosis
P02209237A0239|142 155|liver cirrhosis
P02209243A0237|3 16|urinary protein
P02209243A0237|18 29|serum albumin
P02209243A0237|18 29|serum albumin
P02209243A0237|31 33|BUN
P02209243A0237|37 39|SCr
P02209540A1362|14 17|Ets1
P02209540A1362|14 17|Ets1
P02209540A1362|21 24|Ets2
P02209540A1362|21 24|Ets2
P02209540A1362|53 65|cellular genes
P02209605A0510|21 28|MSAS gene
P02209605A0510|21 28|MSAS gene
P02209605A0510|45 72|5322-bp-long open reading frame
P02209605A0510|118 130|molecular mass
P02209811T0000|0 20|Horseradish peroxidase
P02209811T0000|0 20|Horseradish peroxidase
P02209811T0000|24 41|permeability marker
P02209811T0000|44 59|injured rat caudal
P02209811T0000|63 75|iliac arteries
P02212540A0473|0 31|Standardized gastric wall specimens
P02212540A0473|45 63|grossly healed ulcers
P02212540A0473|101 115|light microscopy
P02212540A0473|121 150|transmission electron microscopy
P02213128A0209|0 0|2
P02213566A0000|12 22|coenzyme Q10
P02213566A0000|24 26|CoQ
P02213566A0000|31 39|captopril
P02213566A0000|42 59|functional capacity
P02213566A0000|100 103|rats
P02213566A0000|122 153|experimental myocardial infarction
P02217307T0000|12 33|therapeutic alterations
P02217307T0000|37 51|circadian rhythm
P02217307T0000|55 77|gastric emptying response
P02217741T0001|3 15|interrelation
P02217741T0001|29 43|glucocorticoids
P02217741T0001|47 53|insulin
P02217741T0001|47 53|insulin
P02217741T0001|59 63|blood
P02218094A0395|33 35|Ft'
P02218094A0395|40 52|mitochondrial
P02218094A0395|67 69|Fm'
P02219751A0517|0 16|Foveating saccades
P02219751A0517|55 58|FEMs
P02219751A0517|71 75|speed
P02220102A0271|33 43|oral hygiene
P02220102A0271|47 64|periodontal disease
P02220304A0501|26 30|Alcoy
P02220304A0501|93 99|MS areas
P02220304A0501|129 142|MS distribution
P02223652A0939|26 27|CY
P02223652A0939|28 30|216
P02223652A0939|34 38|CY 222
P02223652A0939|70 71|UH
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223773A0000|10 38|actin depolymerizing factor (ADF
P02223773A0000|36 38|ADF
P02223773A0000|66 79|actin filaments
P02223773A0000|66 79|actin filaments
P02223773A0000|88 100|actin monomers
P02223773A0000|88 100|actin monomers
P02223928T0069|22 37|serotonin agonist
P02225687A0546|22 28|patient
P02225687A0546|39 52|human teratogen
P02225687A0546|79 106|prenatal diagnostic procedures
P02227438A0492|0 22|Primer extension analysis
P02227438A0492|26 38|RNA sequencing
P02227438A0492|83 92|rat ODC mRNA
P02227438A0492|83 85|rat
P02227438A0492|86 92|ODC mRNA
P02227438A0492|102 114|303 nt upstream
P02227438A0492|135 144|start codon
P02228615A0974|3 6|85Sr
P02228615A0974|69 89|desorption experiments
P02228615A0974|131 149|metal-oxyhydroxides
P02229068A0156|0 3|Gene
P02229068A0156|35 37|tat
P02229068A0156|35 37|tat
P02229068A0156|39 41|rev
P02229068A0156|39 41|rev
P02229068A0156|43 50|tat+ rev+
P02229068A0156|43 49|tat+ rev
P02229068A0156|55 62|env genes
P02229068A0156|55 62|env genes
P02229068A0156|89 98|COS-1 cells
P02229068A0156|101 114|precursor SU-TM
P02229068A0156|110 114|SU-TM
P02229068A0156|116 120|gp160
P02229068A0156|116 120|gp160
P02229068A0156|123 127|SU.TM
P02229068A0156|123 124|SU
P02229068A0156|126 127|TM
P02229068A0156|129 133|gp120
P02229068A0156|129 133|gp120
P02229068A0156|135 150|41), and nucleolar
P02229068A0156|135 136|41
P02229068A0156|142 160|nucleolar rev protein
P02229072A1012|4 15|growth arrest
P02229072A1012|36 48|minimal medium
P02229072A1012|99 121|mitochondrial metabolism
P02229282A0454|0 7|Patients
P02229282A0454|22 29|serum TNF
P02229282A0454|27 29|TNF
P02229282A0454|57 77|serum T3 concentrations
P02229282A0454|62 63|T3
P02229541T0000|0 23|Giant pilomatrix carcinoma
P02231162T0000|16 25|mandibular
P02231479A0585|67 79|conversations
P02231479A0585|95 112|social conversation
P02231479A0585|117 126|structured
P02231479A0585|128 139|task activity
P02233626T0000|0 39|Droperidol-induced extrapyramidal symptoms
P02233626T0000|44 53|adolescent
P02233626T0000|63 79|strabismus surgery
P02233680A1115|27 48|cis-regulatory elements
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233715A0914|14 30|pseudorabies virus
P02233715A0914|35 47|IL-6 construct
P02233715A0914|35 47|IL-6 construct
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|78 89|RNA start site
P02233715A0914|92 113|initiator" or Inr element
P02233715A0914|124 132|MRE region
P02233715A0914|151 153|Dex
P02233715A0914|169 179|wild-type GR
P02233715A0914|169 179|wild-type GR
P02233729A1065|4 12|mutations
P02233729A1065|21 24|Dhfr
P02233729A1065|90 104|Dhfr transcripts
P02233729A1065|90 104|Dhfr transcripts
P02233729A1065|148 162|Dhfr transcripts
P02233729A1065|148 162|Dhfr transcripts
P02234345A0215|3 15|glial cyst wall
P02234345A0215|43 60|cuboidal epithelium
P02234731A0503|14 34|class I cytologic smears
P02234731A0503|55 66|inflammation
P02234731A0503|96 106|condylomata
P02234731A0503|110 126|cervical dysplasia
P02236002A0958|4 10|mammals
P02236002A0958|73 80|variable
P02236002A0958|112 130|chicken TCR beta cDNAs
P02236002A0958|119 130|TCR beta cDNAs
P02236022A0000|3 20|protooncogene c-myb
P02236022A0000|16 20|c-myb
P02236022A0000|29 54|nuclear transcription factor
P02236022A0000|29 54|nuclear transcription factor
P02236022A0000|66 68|DNA
P02236022A0000|72 94|sequence-specific manner
P02236022A0000|134 154|viral and cellular genes
P02236060A1671|0 11|Modification
P02236060A1671|61 101|membrane-associated N-myristoylated protein
P02236064A1178|0 7|S6 kinase
P02236064A1178|0 7|S6 kinase
P02236064A1178|99 121|multiple phosphorylation
P02236276T0000|0 3|Rats
P02236276T0000|11 19|olfactory
P02236276T0000|37 60|contralateral naris closed
P02237431A0000|15 46|human T cell receptor (TCR) alpha gene
P02237431A0000|15 32|human T cell receptor
P02237431A0000|34 46|TCR) alpha gene
P02237431A0000|61 97|T cell-specific transcriptional enhancer
P02237431A0000|61 97|T cell-specific transcriptional enhancer
P02237431A0000|111 128|4.5 kilobases (kb) 3'
P02237431A0000|134 150|C alpha gene segment
P02237431A0000|134 150|C alpha gene segment
P02237431A0833|3 18|Ets-1 binding site
P02237431A0833|3 18|Ets-1 binding site
P02237431A0833|34 54|17-base pair (bp) region
P02237431A0833|62 66|3' end
P02237431A0833|69 75|T alpha 2
P02237431A0833|69 75|T alpha 2
P02241742A0766|8 24|flow and resistance
P02241742A0766|50 51|HD
P02241892A0681|0 10|Utilization
P02241892A0681|77 92|sialophorin mRNAs
P02241892A0681|77 92|sialophorin mRNAs
P02241892A0681|136 156|3' untranslated regions
P02243093A0000|0 28|Human T-cell leukemia virus type I
P02243093A0000|0 28|Human T-cell leukemia virus type I
P02243093A0000|30 36|HTLV-I)
P02243093A0000|30 35|HTLV-I
P02243093A0000|45 64|40-kDa nuclear protein
P02243093A0000|45 64|40-kDa nuclear protein
P02243093A0000|66 68|Tax
P02243093A0000|66 68|Tax
P02243093A0000|107 128|21-base pair (bp) repeats
P02243093A0000|134 141|U3 region
P02243386A0113|27 32|serial
P02243386A0113|52 54|MHV
P02243386A0113|57 66|small DI RNA
P02243386A0113|62 66|DI RNA
P02243386A0113|68 72|DIssF
P02243386A0113|68 72|DIssF
P02243386A0113|104 110|virions
P02246362T0000|3 23|Jenkins Activity Survey
P02246362T0000|30 40|CPI-revised
P02246362T0000|59 66|adaptive
P02246362T0000|70 91|maladaptive type A traits
P02246447A0460|93 102|food groups
P02246447A0460|112 119|r2 values
P02246803A0692|25 45|non-invasive TTD method
P02246803A0692|101 113|cardiac output
P02247069A0261|3 10|TUP1 gene
P02247069A0261|3 10|TUP1 gene
P02247069A0261|51 60|mating type
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|80 88|positions
P02247072A0794|104 123|E. coli S5 ram mutations
P02247072A0794|104 109|E. coli
P02247072A0794|110 123|S5 ram mutations
P02247081A0223|29 38|VPS34 locus
P02247081A0223|29 38|VPS34 locus
P02247081A0223|50 76|temperature-sensitive growth
P02247081A0223|101 109|VPS34 gene
P02247081A0223|101 109|VPS34 gene
P02247924A0078|47 73|amphotericin B and nephrectomy
P02248732A1113|36 46|haloperidol
P02248732A1113|93 99|LC cells
P02248732A1113|152 153|NA
P02248732A1113|167 178|DOPAC changes
P02249872A1051|55 67|charge density
P02249872A1051|83 85|800
P02249872A1051|103 116|charge per phase
P02250919A0404|0 10|Perceptions
P02250919A0404|64 74|muscle cramp
P02250919A0404|78 93|headache symptoms
P02250919A0404|152 163|muscle cramps
P02250919A0404|166 174|headaches
P02251119A0319|49 74|U14 snRNA-homologous regions
P02251119A0319|49 57|U14 snRNA-
P02251119A0319|91 98|introns 5
P02251119A0319|116 140|cognate hsc70 heat shock gene
P02251119A0319|123 127|hsc70
P02251119A0319|128 140|heat shock gene
P02252891T0000|0 19|65-kilodalton protein
P02252891T0000|0 19|65-kilodalton protein
P02252891T0000|36 47|interleukin 2
P02252891T0000|36 47|interleukin 2
P02252891T0000|75 92|actin-binding sites
P02252891T0000|75 92|actin-binding sites
P02252891T0000|99 118|calcium-binding sites
P02252953A0300|3 23|highly restrained girls
P02252953A0300|47 54|EAT score
P02252953A0300|62 80|low-restrained girls
P02253274A0000|18 44|Varkud mitochondrial plasmids
P02253274A0000|63 81|closed-circular DNAs
P02253274A0000|133 162|mtDNA introns and retroid elements
P02253663A0687|3 17|circadian rhythm
P02253663A0687|82 88|maximum
P02254282T0000|0 7|Sequence
P02254282T0000|33 59|Zymomonas mobilis gene cluster
P02254282T0000|78 84|enzymes
P02254282T0000|87 103|glucose metabolism
P02254418A0641|18 30|S. lugdunensis
P02254418A0641|88 90|CNS
P02254749A0133|8 12|cDNAs
P02254749A0133|26 32|60K, 87K
P02254749A0133|34 37|110K
P02254749A0133|41 66|170K protein coding sequences
P02254749A0133|89 101|ATG start codon
P02254749A0133|125 141|60K coding sequence
P02254749A0133|147 158|TAA stop codon
P02254749A0133|185 198|coding sequence
P02256678A1224|47 60|upstream region
P02256678A1224|89 97|HSC82 gene
P02256678A1224|89 97|HSC82 gene
P02256678A1224|131 146|protein complexes
P02257251T0000|0 14|Pathophysiology
P02257251T0000|17 24|bone loss
P02257251T0000|27 42|castrated animals
P02257899T0000|0 25|Auditory-visual interaction
P02258918A0242|40 55|primary disectors
P02259334A0205|3 18|upstream promoter
P02259334A0205|37 50|coding sequence
P02259795A0570|34 37|skin
P02259795A0570|116 129|total cutaneous
P02259795A0570|154 157|skin
P02261254A0168|38 57|pulmonary circulation
P02261254A0168|75 99|extracorporeal circulation
P02261254A0168|128 135|ischemia
P02261254A0168|141 166|respiratory pulmonary tissue
P02262439A0508|0 10|MCh infusion
P02262439A0508|18 66|concentration-dependent increase in airway resistance
P02262439A0508|77 79|QBA
P02264601A0000|0 19|Taste reactivity tests
P02264601A0000|60 76|alcohol preferring
P02264601A0000|78 106|P) rats and alcohol nonpreferring
P02264601A0000|108 109|NP
P02264601A0000|111 114|rats
P02264601A0000|127 133|alcohol
P02265055A0417|0 19|Plasma concentrations
P02265055A0417|22 31|atracurium
P02265055A0417|71 72|-1
P02265055A0417|131 141|laudanosine
P02265055A0417|147 150|-440
P02266679A0740|6 7|Al
P02268461A0224|3 10|survival
P02268461A0224|27 34|patients
P02269426A0428|0 2|IST
P02269426A0428|0 2|IST
P02269426A0428|11 19|RNA target
P02269426A0428|11 19|RNA target
P02269426A0428|21 23|TAR
P02269426A0428|21 23|TAR
P02269426A0428|28 46|Tat trans-activation
P02269426A0428|28 30|Tat
P02269426A0428|108 110|IST
P02269426A0428|108 110|IST
P02269426A0428|149 167|Tat trans-activation
P02269426A0428|149 151|Tat
P02269426A0428|190 209|full-length viral mRNA
P02269426A0428|201 219|viral mRNA expression
P02270096T0000|0 16|Genotoxic activity
P02270096T0000|20 46|tobacco-specific nitrosamine
P02270587A0000|3 21|endodontal treatment
P02270834A0123|0 0|1
P02270834A0123|21 23|HML
P02272095A0832|35 71|peripheral enkephalins in pain modulation
P02272095A0832|74 81|patients
P02273690T0001|20 49|upper-gastrointestinal motility
P02273690T0001|53 69|digestive hormones
P02274343A0064|6 20|foot pathologies
P02274343A0064|60 67|clawtoes
P02274343A0064|77 89|hallux rigidus
P02274343A0064|99 106|calluses
P02274343A0064|108 132|nail pathologies, arthritis
P02274509A0623|5 15|dysfunction
P02274509A0623|89 98|blood serum
P02274509A0623|110 121|liver enzymes
P02274509A0623|136 158|protein-forming function
P02276891T0000|0 10|Coenzyme Q10
P02276891T0000|12 22|blood levels
P02276891T0000|26 40|metabolic demand
P02277005A0227|3 4|CT
P02277319A0211|0 12|Unfortunately
P02277319A0211|52 72|microbiological assays
P02277319A0211|106 120|bioburden levels
P02277452A0116|16 29|angina pectoris
P02277452A0116|43 46|LVEF
P02277452A0116|48 52|LVESV
P02277452A0116|56 64|PSP/LVESV
P02277452A0116|115 122|ischemia
P02277452A0116|142 150|chest pain
P02277452A0116|166 168|ECG
P02278217A0372|41 47|therapy
P02278217A0372|79 93|cesarean section
P02278217A0372|100 107|delivery
P02278474A0000|5 33|Fibrin Degradation Products (FDP
P02278474A0000|5 29|Fibrin Degradation Products
P02278474A0000|31 33|FDP
P02278474A0000|53 70|oral cancer patients
P02278474A0000|76 92|normal individuals
P02280777T0000|3 21|uteroglobin promoter
P02280777T0000|3 21|uteroglobin promoter
P02280777T0000|43 67|estrogen responsive element
P02280777T0000|43 67|estrogen responsive element
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281118A1191|61 64|bone
P02281330A0556|3 19|inspiratory oxygen
P02281330A0556|40 43|FiO2
P02281330A0556|115 117|1st
P02281330A0556|126 131|trauma
P02281948A0245|3 28|corn and mineral oil emulsions
P02281948A0245|76 82|sucrose
P02282815T0000|14 27|thin glomerular
P02282815T0000|56 63|children
P02283148T0000|14 31|cytokine production
P02283148T0000|35 51|adhesion molecules
P02283148T0000|54 61|malarial
P02283148T0000|62 76|immunopathology
P02283378A0385|72 84|labour-saving
P02283378A0385|97 111|ultrafiltration
P02283378T0000|33 52|cephalosporin DQ-2556
P02283378T0000|89 108|liquid chromatography
P02283873A0308|15 25|adolescents
P02283873A0308|63 74|parents smoke
P02283873A0308|128 135|enhancer
P02284573A0943|0 7|Staining
P02284573A0943|12 17|IF MoAB
P02284573A0943|25 32|BAL fluid
P02284573A0943|95 97|BAL
P02284573A0943|99 101|TBB
P02287860T0001|40 61|myeloid parenchyma cells
P02287860T0001|64 67|mice
P02287860T0001|81 93|X-ray exposure
P02289102A0114|7 23|audiotape cassette
P02289639A0989|3 12|mean change
P02289639A0989|15 18|HbA1
P02289639A0989|15 18|HbA1
P02289639A0989|85 96|control group
P02290216T0001|8 25|biliary obstruction
P02290216T0001|42 57|serum SPan-1 level
P02290216T0001|42 52|serum SPan-1
P02291144A0493|60 62|H*2
P02291144A0493|75 103|machine and the reference methods
P02291144A0493|114 118|MCHCH
P02291144A0493|122 134|basophil count
P02291628A0264|71 73|NMR
P02291628A0264|151 163|endocrinology
P02292272T0000|27 43|fictive locomotion
P02292272T0000|57 59|cat
P02293019A0000|0 22|Antileukoproteinase (ALP
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|20 22|ALP
P02293019A0000|30 34|mol wt
P02293019A0000|66 77|human tissues
P02293019A0000|105 111|neutral
P02293019A0000|112 145|serine lysosomal proteinases elastase
P02293019A0000|112 137|serine lysosomal proteinases
P02293019A0000|138 145|elastase
P02293019A0000|149 159|cathepsin-G
P02293019A0000|149 159|cathepsin-G
P02293664A0946|22 30|deletions
P02293664A0946|36 51|vimentin promoter
P02293664A0946|36 43|vimentin
P02293664A0946|86 96|30 base pairs
P02293664A0946|121 137|base pairs upstream
P02293664A0946|143 153|mRNA cap site
P02294048A0881|68 89|hsp70 of Escherichia coli
P02294048A0881|68 72|hsp70
P02294048A0881|75 89|Escherichia coli
P02294048A0881|93 110|Bacillus megaterium
P02294048A0881|93 110|Bacillus megaterium
P02295521A0922|65 81|trapezius activity
P02295521A0922|211 236|musculo-skeletal complaints
P02296509A0997|0 4|All 89
P02296509A0997|18 33|household members
P02296509A0997|38 57|anti-HIV seronegative
P02296509A0997|86 103|p24 antigen negative
P02296509A0997|86 88|p24
P02298741A0809|22 43|anti-peptide antibodies
P02298741A0809|55 75|alpha, beta, or gamma PKC
P02298741A0809|55 64|alpha, beta
P02298741A0809|68 75|gamma PKC
P02298741A0809|104 106|PKC
P02298741A0809|104 106|PKC
P02298741A0809|121 127|JK cells
P02298741A0809|137 145|JKPE cells
P02298741A0809|174 203|immunoreactive cytosolic protein
P02298741A0809|218 238|anti-PKC alpha antibody
P02298741A0809|218 238|anti-PKC alpha antibody
P02300541A0000|51 69|surface active agents
P02300541A0000|80 98|metered dose inhalers
P02300541A0000|100 103|MDIs
P02300541A0000|180 187|rat lungs
P02300577A0852|3 11|beta chain
P02300577A0852|33 58|N-linked glycosylation sites
P02300577A0852|63 77|endoglycosidase
P02300577A0852|63 77|endoglycosidase
P02300577A0852|103 111|beta chain
P02300577A0852|121 135|multiple complex
P02300577A0852|136 157|carbohydrate side chains
P02300759A0000|3 22|therapeutic protocole
P02300759A0000|81 98|uterine cervix rests
P02300759A0000|116 129|T1B-T2 proximal
P02300759A0000|134 150|combined radiology
P02300759A0000|154 160|surgery
P02303158T0000|0 28|Thyrotropin-induced expression
P02303158T0000|0 10|Thyrotropin
P02303158T0000|40 55|ribosomal protein
P02303158T0000|68 78|trk oncogene
P02303158T0000|68 78|trk oncogene
P02303470A0242|3 9|introns
P02303874A1643|7 28|initial titration period
P02305014A0226|30 51|Sprague-Dawley male rats
P02305014A0226|81 93|guide cannulas
P02305014A0226|104 119|lateral ventricle
P02306539T0000|5 28|Selenastrum capricornutum
P02306539T0000|51 62|Daphnia pulex
P02307067A1348|175 199|low-water-content habitats
P02307371A0263|86 90|c-myc
P02307371A0263|86 90|c-myc
P02307371A0263|105 121|Burkitt's lymphoma
P02307371A0263|178 206|Burkitt's lymphoma c-myc alleles
P02307371A0263|195 206|c-myc alleles
P02307371A0263|211 221|murine cells
P02307371A0263|225 237|Xenopus oocyte
P02307613A0783|11 37|protoporphyrin concentration
P02307613A0783|95 103|basal diet
P02307613A0783|163 175|dietary groups
P02307848A0347|3 17|coding sequences
P02307848A0347|23 30|Crry gene
P02307848A0347|23 30|Crry gene
P02307848A0347|44 52|25 kb of DNA
P02307848A0347|64 79|Crry-ps sequences
P02307848A0347|64 79|Crry-ps sequences
P02307848A0347|104 123|5.6-kb Eco-R1 fragment
P02307848A0347|104 123|5.6-kb Eco-R1 fragment
P02307848T0042|43 61|Crry and Crry-ps genes
P02307848T0042|43 46|Crry
P02307848T0042|50 53|Crry
P02307848T0042|55 56|ps
P02307850A0000|6 11|RNK-16
P02307850A0000|6 8|RNK
P02307850A0000|12 29|lambda-gt11 library
P02307850A0000|67 84|rat NK cell protease 1
P02307850A0000|70 84|NK cell protease 1
P02307850A0000|86 91|RNKP-1
P02307850A0000|86 91|RNKP-1
P02307850A0000|123 137|serine proteases
P02307850A1197|14 29|RNKP-1 expression
P02307850A1197|14 19|RNKP-1
P02307850A1197|35 58|Con A-cultured spleen cells
P02307850A1197|35 38|Con A
P02307850A1197|89 90|NK
P02307850A1197|89 90|NK
P02307850A1197|94 139|lymphokine-activated killer lymphocyte activities
P02308496A0000|55 58|ACTH
P02308496A0000|55 58|ACTH
P02308496A0000|60 62|STH
P02308496A0000|60 62|STH
P02308496A0000|64 66|TSH
P02308496A0000|64 66|TSH
P02308496A0000|68 75|cortisol
P02308496A0000|77 78|T3
P02308496A0000|77 78|T3
P02308496A0000|80 86|insulin
P02308496A0000|80 86|insulin
P02308496A0000|88 96|C-peptide
P02308496A0000|88 96|C-peptide
P02308496A0000|122 132|respiration
P02308496A0000|167 172|oxygen
P02308496A0000|174 179|GHM-10
P02308496A0000|174 179|GHM-10
P02310261A0115|3 9|abscess
P02310261A0115|61 81|autologous pericardium
P02310300A0298|38 47|CT negative
P02310350A0221|65 79|spectral content
P02310350A0221|82 85|ABRs
P02310350A0221|90 111|normal-hearing subjects
P02310496X0000|7 23|memory impairments
P02310496X0000|31 59|medial septal-vertical diagonal
P02310496X0000|66 70|Broca
P02310496X0000|167 197|non-specific subcortical cell loss
P02310496X0000|212 218|nucleus
P02310496X0000|227 228|NB
P02310496X0000|233 261|medial septal-vertical diagonal
P02310496X0000|268 272|Broca
P02310496X0000|274 280|MS-VDBB
P02310496X0000|322 327|memory
P02311544A0086|47 54|MSMR cyst
P02311544A0086|58 69|certain signs
P02311544A0086|82 88|disease
P02312470A0774|3 31|BAL-to-plasma specific activity
P02312470A0774|34 37|urea
P02312470A0774|57 59|Na+
P02312470A0774|57 59|Na+
P02312470A0774|75 86|urea diffused
P02312470A0774|94 96|ELF
P02312470A0774|112 114|Na+
P02312470A0774|155 169|radioactive urea
P02312470A0774|173 175|Na+
P02312470A0774|220 225|lavage
P02312689A0360|3 18|kappa coefficient
P02312689A0360|40 49|Patho Dx Kit
P02315151T0020|0 12|Senior systems
P02315151T0020|18 23|Mental
P02315472A0583|68 71|RASE
P02315472A0583|78 80|C/A
P02317413A0364|0 7|Patients
P02317413A0364|12 36|acute myocardial infarction
P02317413A0364|46 65|plasma concentrations
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|92 108|non-peroxide diene
P02317413A0364|127 138|linoleic acid
P02317413A0364|143 158|normal volunteers
P02317413A0364|161 168|patients
P02317413A0364|179 199|ischaemic heart disease
P02317554T0000|0 12|Determination
P02317554T0000|15 48|three-dimensional imaging properties
P02317554T0000|52 72|light microscope system
P02318208A0817|3 19|cis-acting element
P02318208A0817|33 43|CACGTGACCCG
P02318208A0817|73 99|transcription initiation site
P02318208A0817|115 126|core sequence
P02318208A0817|132 155|upstream promoter sequence
P02318208A0817|158 163|Ad2MLP
P02318208A0817|158 163|Ad2MLP
P02319610A1527|99 103|P.HCl
P02320008A0651|0 5|TMBr-1
P02320008A0651|0 5|TMBr-1
P02320008A0651|19 49|striated muscle alpha-tropomyosin
P02320008A0651|92 110|COOH-terminal region
P02320999A0606|60 65|carpet
P02320999A0606|82 90|wallpaper
P02320999A0606|106 124|polyurethane lacquer
P02320999A0606|137 163|steady-state emission factors
P02320999A0606|167 172|m-2 h-1
P02322535A0658|39 50|introns 2 and 3
P02323517A0557|20 28|secretory
P02323517A0557|38 44|stomach
P02323517A0557|58 88|mucosal prostaglandin E2 synthesis
P02323517A0557|107 144|ex vivo prostaglandin generation technique
P02324102A1157|12 45|transmembrane and cytoplasmic domains
P02324102A1157|79 82|48K5
P02324102A1157|79 82|48K5
P02324102A1157|87 106|human lung fibroblasts
P02324104A0151|26 65|cAMP-dependent phosphotransferase activity
P02324104A0151|26 57|cAMP-dependent phosphotransferase
P02324104A0151|79 111|particulate fractions of homogenates
P02324104A0151|149 157|C. elegans
P02324104A0516|0 9|High levels
P02324104A0516|12 20|C subunits
P02324104A0516|12 20|C subunits
P02324104A0929|13 20|C subunit
P02324104A0929|13 20|C subunit
P02324104A0929|22 32|CeCAT alpha'
P02324104A0929|22 26|CeCAT
P02324104A0929|27 44|alpha', 374 residues
P02324104A0929|66 88|carboxyl-terminal region
P02324104A0929|133 141|C pre-mRNA
P02324104A0929|133 141|C pre-mRNA
P02324104A1195|36 51|carboxyl terminus
P02324104A1195|59 73|translation stop
P02324104A1195|132 156|carboxyl-terminal residues
P02324104A1195|159 168|CeCAT alpha
P02324104A1195|159 168|CeCAT alpha
P02324104A1195|173 198|3'-untranslated nucleotides
P02325208A0209|0 5|French
P02325895T0000b|0 33|Slowly adapting type I mechanoreceptor
P02325895T0000b|95 106|glabrous skin
P02325895T0000b|109 115|raccoon
P02325895T0000b|119 132|squirrel monkey
P02326716A0139|51 56|T7-T12
P02326716A0139|75 99|concave rib-vertebra angles
P02326716A0139|101 104|RVAs
P02326716A0139|136 140|RVADs
P02326716A0139|143 159|vertebral rotation
P02326716A0139|161 179|tilt and displacement
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|15 40|cholesterol acyltransferase
P02326946T0000|42 54|LCAT) activity
P02326946T0000|42 45|LCAT
P02326946T0000|90 107|allograft viability
P02326946T0000|110 137|clinical liver transplantation
P02327159T0001|0 3|Lars
P02327159T0001|7 10|AIDS
P02328328A0419|8 18|nodal status
P02328328A0419|20 51|tumour progesterone receptor status
P02328328A0419|56 61|season
P02328328A0419|64 78|tumour detection
P02328328A0419|116 120|older
P02328328A0419|142 148|younger
P02328328A0419|160 171|yrs) patients
P02329840A0383|78 84|retinal
P02329840A0383|86 89|K+]o
P02330041A0335|74 83|cloned hUBF
P02330041A0335|80 83|hUBF
P02330041A0335|92 106|nucleolar factor
P02330041A0335|133 154|upstream control element
P02330041A0335|167 182|rRNA gene promoter
P02330041A0335|209 235|binding site-dependent manner
P02330333A0325|0 12|Accumulations
P02330333A0325|15 18|Tl+1
P02330333A0325|15 18|Tl+1
P02330333A0325|49 50|Ga
P02330333A0325|49 50|Ga
P02330333A0325|53 54|In
P02330333A0325|60 64|brain
P02330333A0325|88 93|plasma
P02331361A0268|29 35|myocyte
P02331361A0268|72 87|autopsy specimens
P02332018A0538|35 40|asthma
P02332018A0538|42 44|EIA
P02332018A0538|42 44|EIA
P02332018A0538|60 64|WH air
P02332018A0538|66 82|asthmatic patients
P02332018A0538|114 125|GH increments
P02332018A0538|130 143|normal subjects
P02332798A0725|3 17|afferents' phase
P02332798A0725|53 66|EVS stimulation
P02333545A0313|22 37|fibrinogen levels
P02333545A0313|22 31|fibrinogen
P02333749A0411|19 36|regression analysis
P02333749A0411|39 41|SPT
P02333749A0411|39 41|SPT
P02333749A0411|45 48|RAST
P02333749A0411|69 86|serum IgE antibodies
P02333749A0411|69 86|serum IgE antibodies
P02333749A0411|89 100|P. orbiculare
P02333749A0411|89 100|P. orbiculare
P02334972A0145|54 59|drusen
P02334972A0145|123 135|complications
P02335034A0584|23 42|whole-body heat stress
P02335034A0584|44 62|water-perfused suits
P02335034A0584|81 84|LBNP
P02335521T0000|2 40|NF1-related vitellogenin activator element
P02335521T0000|2 40|NF1-related vitellogenin activator element
P02335521T0000|69 86|estrogen-regulated
P02335521T0000|87 119|Xenopus laevis vitellogenin promoter
P02335521T0000|87 99|Xenopus laevis
P02335521T0000|100 119|vitellogenin promoter
P02335713A0905|38 40|PbB
P02335713A0905|38 40|PbB
P02335713A0905|44 47|ALAD
P02335713A0905|44 47|ALAD
P02335713A0905|69 75|workers
P02335815A0530|5 20|carboxyl terminus
P02335815A0530|37 46|residue 388
P02335815A0530|59 68|in vitro TRF
P02335815A0530|88 111|trans-activating activity
P02336338A0931|12 24|mean luminance
P02339005T0000|8 20|hyperglycemia
P02339005T0000|38 53|alloxan-diabetic
P02339005T0000|54 57|rats
P02339447A0162|17 32|[7,7-2H2]-19-OHA
P02339447A0162|37 56|high deuterium content
P02339447A0162|73 82|[7,7-2H2]A
P02339447A0162|86 86|[
P02339447A0162|87 94|9,11-2H2
P02339447A0162|96 102|estrone
P02339447A0162|104 105|E1
P02339447A0162|104 105|E1
P02339447A0162|122 138|quantitative assay
P02339447A0162|141 150|serum level
P02339447A0162|151 158|19-OHA, A
P02339447A0162|163 164|E1
P02339447A0162|173 232|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|270 278|pregnancy
P02340595A0124|0 15|Sequence analysis
P02340595A0124|93 101|tRNA genes
P02340595A0124|93 101|tRNA genes
P02340595A0124|111 122|mitochondria
P02341669A0000|31 64|brain-stem auditory-evoked responses
P02341669A0000|66 70|BAERs
P02341669A0000|143 166|MLS) and Legendre sequences
P02341669A0000|143 145|MLS
P02341669A0000|168 170|LGS
P02342477A1292|8 11|UfAP
P02342477A1292|8 11|UfAP
P02342477A1292|15 18|UTMP
P02342477A1292|15 18|UTMP
P02342477A1292|28 39|biosynthetic
P02342477A1292|95 105|endometrium
P02342477A1292|107 108|P4
P02342477A1292|141 184|mannose 6-phosphate lysosomal recognition marker
P02342477A1292|141 148|mannose 6
P02342477A1292|223 226|UfAP
P02342477A1292|223 226|UfAP
P02342477A1292|233 236|UTMP
P02342477A1292|233 236|UTMP
P02343033A0000|7 11|light
P02343033A0000|15 26|dates infants
P02343033A0000|35 43|placentae
P02343033A0000|70 76|infants
P02343033A0000|85 93|placentae
P02344529T0000|0 19|Treating renal anaemia
P02344529T0000|24 53|recombinant human erythropoietin
P02344529T0000|24 53|recombinant human erythropoietin
P02347102A0000|3 24|pseudolymphoma syndrome
P02347102A0000|38 54|reactive condition
P02347102A0000|67 87|fever, lymphadenopathy
P02347102A0000|91 105|generalized rash
P02347407A0217|49 57|SE-sector
P02347655A0193|15 18|lung
P02347655A0193|36 39|lung
P02347655A0193|43 59|peripheral tissues
P02347655A0193|61 63|gas
P02347655A0193|99 118|blood inlet conditions
P02347655A0193|120 132|blood flow rate
P02347655A0193|162 164|gas
P02347655A0193|191 210|blood tissue perfusion
P02347655A0193|226 228|etc
P02348225A0192|42 45|2.06
P02348225A0192|186 193|patients
P02348225A0192|198 205|jaundice
P02348225A0192|222 229|controls
P02348408A0126|0 8|Attitudes
P02348728A1153|14 22|DNA ploidy
P02348728A1153|84 103|endometrial carcinoma
P02349827A0193|14 26|digital system
P02349827A0193|28 37|Videoplan 2
P02349942A0287|42 53|older cohorts
P02349942A0287|83 88|recall
P02349998A0297|0 11|Dopamine SERS
P02349998A0297|65 82|uncoated electrodes
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|50 57|surgical
P02351239A0693|81 86|mucosa
P02351239A0693|92 94|rat
P02351239A0693|123 140|mucosal HDC activity
P02351239A0693|123 132|mucosal HDC
P02351239A0693|142 163|histamine concentration
P02351239A0693|167 180|ECL cell density
P02351239A0693|268 284|antisecretagogues
P02351297A0000|8 27|experimental toxicity
P02351297A0000|79 97|corrosion inhibitors
P02353453A1249|13 25|helicase motif
P02353453A1249|13 25|helicase motif
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|55 63|RUB genome
P02353453A1249|90 105|alphavirus genome
P02353453A1249|161 169|evolution
P02353875A0800|35 45|eosinophils
P02353875A0800|49 59|neutrophils
P02353875A0800|89 94|type Ib
P02353875A0800|97 107|atopic cases
P02353875A0800|116 126|eosinophils
P02354381A0207|67 73|cage (S)
P02354381A0207|125 125|H
P02354381A0207|139 150|surround (H/S
P02354381A0207|148 148|H
P02354381A0207|150 150|S
P02354381A0207|158 160|box
P02354381A0207|199 204|hollow
P02354381A0207|206 206|N
P02355293A0749|34 49|tensile responses
P02355293A0749|99 117|nonirradiated grafts
P02355293A0749|151 170|nonirradiated tissues
P02355765A0220|24 43|benzathine penicillin
P02355920A0681|1 20|consensus binding site
P02355920A0681|27 48|transcription factor SP1
P02355920A0681|27 45|transcription factor
P02355920A0681|46 48|SP1
P02355920A0681|87 120|proenkephalin germ cell cap site region
P02355920A0681|87 114|proenkephalin germ cell cap site
P02357537A0451|12 26|reflex latencies
P02357537A0451|35 39|paCO2
P02357537A0451|42 44|pHa
P02357537A0451|58 65|naloxone
P02357537A0451|94 110|morphine-tolerant
P02358975A0709|92 103|gluten intake
P02358975A0709|92 97|gluten
P02358975A0709|120 132|IgA deficiency
P02358975A0709|120 122|IgA
P02360336A0574|0 20|Drug and personnel costs
P02360336A0574|63 76|multidose vials
P02360336A0574|92 116|extemporaneous compounding
P02360336A0574|121 134|unit-dose vials
P02361575T0000|0 13|Dermal toxicity
P02361575T0000|34 63|4-vinyl-1-cyclohexene diepoxide
P02361575T0000|66 89|Fischer rats and B6C3F1 mice
P02361812A1110|0 2|Per
P02361812A1110|50 56|EX group
P02361812A1110|68 89|non-exercising subjects
P02361812A1110|132 139|D + DE 15.8
P02362161T0000|0 5|MK-927
P02362161T0000|23 65|ocular hypotensive carbonic anhydrase inhibitor
P02362161T0000|40 56|carbonic anhydrase
P02362803A0608|0 19|PCR-derived fragments
P02362803A0608|56 67|U3 snRNA genes
P02362803A0608|56 67|U3 snRNA genes
P02362803A0608|73 86|genomic library
P02362803A0608|89 99|Arabidopsis
P02368931A0587|10 17|serum IgE
P02368931A0587|15 17|IgE
P02368931A0587|18 31|concentrations
P02370571A0663|31 46|iodine deficiency
P02370571A0663|71 76|goiter
P02370571A0663|148 158|men and women
P02370571A0663|170 186|goitrogenic factor
P02371273A0144|3 21|transcriptional unit
P02371273A0144|28 44|chromosomal region
P02371273A0144|52 66|55 kilobase pairs
P02371273A0144|68 70|kbp
P02371517A0747|8 15|patients
P02372496A0782|0 16|Co-administration
P02372496A0782|19 21|5FU
P02372496A0782|23 35|angiotensin II
P02372496A0782|23 35|angiotensin II
P02372496A0782|57 69|hepatic artery
P02372496A0782|79 90|drug exposure
P02372496A0782|96 114|systemic compartment
P02372496A0782|159 175|5FU administration
P02372496A0782|182 194|hepatic artery
P02372712A0002|12 14|tap
P02372712A0002|12 14|tap
P02372712A0002|16 17|TW
P02372712A0002|16 17|TW
P02372712A0002|21 30|carbonated
P02372712A0002|32 39|CW) water
P02372712A0002|42 49|arterial
P02372712A0002|84 87|PCO2
P02372712A0002|92 104|plasma lactate
P02373686T0000|0 18|Transient expression
P02373686T0000|21 56|human and chicken progesterone receptors
P02373686T0000|29 56|chicken progesterone receptors
P02373686T0000|71 104|alternative translational initiation
P02373686T0000|110 119|single mRNA
P02373810A1118|11 15|2,397
P02373810A1118|17 18|74
P02374886A0305|75 86|productivity
P02376023A0307|51 54|IgG1
P02376023A0307|51 54|IgG1
P02376023A0307|56 56|P
P02376023A0307|75 78|IgG4
P02376023A0307|75 78|IgG4
P02376023A0307|80 80|P
P02376023A0307|105 111|infants
P02376023A0307|126 128|IgE
P02376023A0307|126 128|IgE
P02378615A0807|40 65|N-linked glycosylation sites
P02378615A0807|70 96|threonine/serine-rich region
P02378615A0807|133 152|O-linked carbohydrate
P02378945A0487|94 102|vagal tone
P02383693A0301|37 60|chemiluminescent solution
P02383693A0301|71 79|lucigenin
P02383693A0301|71 79|lucigenin
P02383693A0301|83 93|Triton X-100
P02383693A0301|103 113|KOH solution
P02383693A0301|136 160|chemiluminescence detector
P02383771A0544|26 43|cuboidal epithelium
P02383771A0544|49 62|mucous membrane
P02383771A0544|86 103|columnar epithelium
P02383771A0544|129 142|enlarged nuclei
P02383771A0544|148 166|vacuolized cytoplasm
P02384265A0947|46 51|cancer
P02384265A0947|57 69|polyp patients
P02384265A0947|127 142|subsequent cancer
P02384389A0854|42 43|YG
P02384389A0854|88 94|seam fat
P02384389A0854|97 105|fed cattle
P02386485A0554|3 20|nucleotide sequence
P02386485A0554|37 58|5'-end non-coding region
P02386485A0554|68 79|coding region
P02386485A0554|90 111|3'-end non-coding region
P02386485A0554|126 136|poly(A) tail
P02386895A0496|19 33|nausea/vomiting
P02386895A0496|40 47|headache
P02386895A0496|54 59|chills
P02386895A0496|72 81|tumor sites
P02386895A0496|88 98|hypotension
P02386895A0496|108 119|hypertension
P02388685A0577|32 57|oyster shell supplementation
P02388685A0577|67 102|increased alkaline phosphatase activity
P02388685A0577|76 94|alkaline phosphatase
P02388685A0577|104 121|bone mineralization
P02388685A0577|187 188|CV
P02388685A0577|218 224|calcium
P02388685A0577|228 244|phosphorus content
P02390538A0000|7 13|infants
P02390538A0000|94 100|airways
P02390538A0000|147 158|Olympus PF18 S
P02390633T0000|0 16|Fatal encephalitis
P02390633T0000|20 26|patient
P02390633T0000|31 61|chronic graft-versus-host disease
P02390989A0745|29 35|GPB gene
P02390989A0745|29 35|GPB gene
P02390989A0745|37 41|exon 3
P02390989A0745|47 53|GPE gene
P02390989A0745|47 53|GPE gene
P02390989A0745|69 82|point mutations
P02390989A0745|106 114|stop codon
P02391344T0000|0 15|Molecular cloning
P02391344T0000|19 22|cDNA
P02391344T0000|31 59|rat NADH-cytochrome b5 reductase
P02391344T0000|31 33|rat
P02391344T0000|34 38|NADH-
P02391344T0000|39 59|cytochrome b5 reductase
P02392032A0657|86 98|distance scale
P02392032A0657|124 132|pore space
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02392511T0000|0 21|Serotonin 5-HT2 receptor
P02392511T0000|31 44|blood platelets
P02392511T0000|70 91|major affective disorder
P02393001A0324|9 10|BF
P02393001A0324|34 37|BMIs
P02393001A0324|46 49|0.82
P02393001A0324|96 99|BMIs
P02393001A0324|103 104|BF
P02393001A0324|107 118|densitometry
P02393895A0918|3 10|RF values
P02393895A0918|77 95|aortal insufficiency
P02393895A0918|168 182|differentiation
P02393895A0918|201 220|severe regurgitations
P02394707A0789|0 15|Promoter elements
P02394707A0789|33 39|TATA box
P02394707A0789|41 44|GTTA
P02394707A0789|50 57|CCAAT box
P02394707A0789|76 89|initiation site
P02394707A0789|116 126|CCAAT (ATTGG
P02394707A0789|135 168|pyrimidine-rich nucleotide stretches
P02394718A0130|3 13|cloned genes
P02394718A0130|30 45|genetic libraries
P02394718A0130|48 69|hybridization screening
P02394718A0130|79 104|deoxyoligonucleotide probes
P02394718A0130|134 150|amino acid sequence
P02394718A0130|156 169|purified enzyme
P02395868A0322|13 30|catalytic zinc sites
P02395868A0322|93 114|main-chain hydrogen bond
P02396415T0001|46 53|patients
P02396415T0001|66 77|hypertension
P02398897A0000|10 29|transcription factors
P02398897A0000|43 57|RNA polymerase II
P02398897A0000|43 57|RNA polymerase II
P02399053A0153|14 24|newborn rats
P02399053A0153|63 64|RA
P02399053A0153|99 100|RA
P02399053A1032|34 54|elastic recoil pressure
P02400070T0000|56 79|electroconvulsive therapy
P02400457A0469|2 13|Experiment II
P02400457A0469|83 96|LBNP conditions
P02400457A0469|100 113|sedentary women
P02400457A0469|215 225|Experiment I
P02402678A0463|44 60|lambdacyhalothrin
P02402678A0463|83 87|water
P02402678A0463|98 118|aerosol space-spraying
P02402678A0463|125 139|diesel/kerosene
P02402678A0463|143 156|thermal fogging
P02402678A0463|230 244|housefly control
P02403035A0621|55 75|mitochondrial fumarase
P02403035A0621|55 75|mitochondrial fumarase
P02403634A0788|0 15|Sequence analysis
P02403634A0788|43 53|ATA and GC box
P02403634A0788|124 143|muscle-specific genes
P02403634A0788|146 152|CArG box
P02403634A0788|155 159|-91 bp
P02403634A0788|161 217|myocyte-specific enhancer-binding nuclear factor 1 binding site
P02403634A0788|161 206|myocyte-specific enhancer-binding nuclear factor 1
P02403634A0788|230 232|-58
P02403634A0788|242 247|-583 bp
P02403634A0788|253 259|muscle-
P02403634A0788|260 280|CAAT consensus sequence
P02403634A0788|283 288|-394 bp
P02403634A0788|302 308|cap site
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|33 69|human breast carcinoma cell line MDA-MB 231
P02403926A0000|72 94|genomic DNA-transfection
P02403926A0000|99 109|NIH3T3 cells
P02403926A0000|124 160|trk proto-oncogene receptor kinase domain
P02403926A0000|124 160|trk proto-oncogene receptor kinase domain
P02403926A0000|169 207|N-terminal 41 amino acid activating sequence
P02403926A0000|169 207|N-terminal 41 amino acid activating sequence
P02403926A0307|0 9|Antibodies
P02403926A0307|24 80|bacterially produced beta gal-trk receptor kinase fusion protein
P02403926A0307|43 49|beta gal
P02403926A0307|51 67|trk receptor kinase
P02403926A0307|96 109|phosphoprotein
P02403926A0307|126 131|serine
P02403926A0307|133 152|threonine and tyrosine
P02403926A0307|165 192|trk-2h transformed NIH3T3 cells
P02403926A0307|165 170|trk-2h
P02404451A1532|90 96|Cys-118
P02404451A1532|104 110|Cys-118
P02404451A1532|125 139|maximal activity
P02404451A1532|158 164|Cys-118
P02404451A1532|192 204|glycosylation
P02404451A1532|208 230|maximal biologic activity
P02404451A1532|233 238|GM-CSF
P02404451A1532|233 238|GM-CSF
P02405393T0000|0 8|Molecular
P02405393T0000|43 50|promoter
P02405393T0000|53 56|ETS2
P02405393T0000|53 56|ETS2
P02405393T0000|61 76|human c-ets-2 gene
P02405393T0000|61 76|human c-ets-2 gene
P02405589A0000|16 42|immunologic drug interactions
P02405818A0550|0 14|Branch occlusion
P02405818A0550|17 31|Heubner's artery
P02405818A0550|61 68|anterior
P02405818A0550|71 76|middle
P02405818A0550|77 92|cerebral arteries
P02405818A0550|100 127|posited mechanism of infarction
P02406570A0466|3 19|ABFI-binding sites
P02406570A0466|3 19|ABFI-binding sites
P02406570A0466|52 62|UAS function
P02406570A0898|50 53|ARS1
P02406570A0898|54 57|left
P02406570A0898|80 83|ABFI
P02406570A0898|80 83|ABFI
P02406570A0898|107 120|DNA replication
P02406570A0898|123 126|ARS1
P02406570A0898|129 153|transcriptional activation
P02406992A0192|0 20|Nonvascular ophthalmic
P02406992A0192|24 42|neurologic disorders
P02406992A0192|64 77|amaurosis fugax
P02406992A0192|93 101|algorithm
P02406992A0192|129 149|ophthalmic examination
P02406992A0192|172 195|noninvasive carotid artery
P02408248A0414|43 68|converting enzyme inhibitors
P02409297A0984|0 9|Polyclonal
P02409297A0984|73 85|46-kilodalton
P02409297A0984|86 97|polypeptides
P02409297A0984|102 115|virus particles
P02409297A0984|121 132|polypeptides
P02409297A0984|155 159|HBsAg
P02409297A0984|155 159|HBsAg
P02411513A0667|22 28|N22/P22
P02411513A0667|114 129|dorsal negativity
P02411513A0667|134 163|simultaneous anterior positivity
P02417023T0001|6 24|superoxide dismutase
P02417023T0001|6 24|superoxide dismutase
P02417023T0001|27 52|cellular oxidative processes
P02417669A0218|48 69|gamma-aminobutyric acid
P02417669A0218|73 79|taurine
P02417669A0218|100 110|asparagine (
P02417669A0218|126 153|excitatory amino acid aspartate
P02417669A0218|177 183|animals
P02418701A0000|48 70|carcinoembryonic antigen
P02418701A0000|48 70|carcinoembryonic antigen
P02418701A0000|88 118|carcinoembryonic antigen staining
P02418701A0000|88 110|carcinoembryonic antigen
P02418701A0000|132 146|villous adenomas
P02418701A0000|148 175|mixed polypoid villous adenomas
P02418701A0000|177 192|polypoid adenomas
P02418701A0000|219 252|peroxidase-antiperoxidase technique
P02418701A0000|219 228|peroxidase
P02418701A0000|230 243|antiperoxidase
P02419327A0998|3 17|priming activity
P02419327A0998|43 59|Drosophila enzymes
P02419327A0998|43 59|Drosophila enzymes
P02419327A0998|110 129|E. coli endonuclease IV
P02419327A0998|110 115|E. coli
P02419327A0998|116 129|endonuclease IV
P02419327A0998|181 192|apurinic site
P02420432A1060|81 97|severely depressed
P02420432A1060|106 121|serum PAPP-A level
P02420432A1060|111 116|PAPP-A
P02420432A1060|144 164|extrauterine pregnancy
P02423533A1314|15 48|MAP1-specific and MAP2-specific mRNAs
P02423533A1314|15 48|MAP1-specific and MAP2-specific mRNAs
P02423533A1314|96 112|MAP1-specific mRNA
P02423533A1314|96 112|MAP1-specific mRNA
P02423533A1314|136 138|rat
P02423533A1314|139 147|PC12 cells
P02423533A1314|162 178|nerve growth factor
P02423533A1314|162 178|nerve growth factor
P02423533A1790|3 7|cDNAs
P02423533A1790|27 42|genomic sequences
P02423533A1790|45 47|rat
P02423533A1790|58 67|chicken DNA
P02423533A1790|91 100|Drosophila
P02423533A1790|104 112|sea urchin
P02423773T0001|0 17|Colorimetric method
P02423773T0001|44 48|blood
P02423850A0292|0 15|Deletion analysis
P02423850A0292|45 61|5'-flanking region
P02423850A0292|82 95|upstream region
P02423850A0292|101 113|yeast CYC1 gene
P02423850A0292|106 113|CYC1 gene
P02424743A0280|3 4|N1
P02424743A0280|3 4|N1
P02424743A0280|8 9|P2
P02424743A0280|8 9|P2
P02424743A0280|26 34|amplitude
P02427024X0000|23 30|anorexia
P02427024X0000|38 44|fiction
P02427024X0000|111 118|anorexia
P02427797A0199|11 14|left
P02427797A0199|15 23|limb (tail
P02427797A0199|30 37|pancreas
P02427797A0199|51 54|left
P02427797A0199|60 74|abdominal cavity
P02427797A0199|91 99|blood flow
P02427797A0199|109 120|warm ischemia
P02427797A0199|127 128|60
P02427797A0199|184 202|cold Ringers' lactate
P02427797A0199|223 234|iliac vessels
P02427812A0865|42 47|6-OHDA
P02427812A0865|55 62|alpha-MD
P02427812A0865|75 88|pressor actions
P02427812A0865|94 96|rat
P02427812A0865|112 133|antihypertensive action
P02427869A0939|12 40|beta 2-adrenoceptor sensitivity
P02427869A0939|12 29|beta 2-adrenoceptor
P02427869A0939|63 65|BHT
P02431314A0834|14 19|Hansel
P02431314A0834|92 104|Wright's stain
P02436005A0707|51 60|nicorandil
P02436005A0707|83 90|Ca influx
P02436005A0707|94 118|intracellular mobilization
P02436005A0707|121 122|Ca
P02437625A0197|35 62|ocular histoplasmosis syndrome
P02437625A0197|64 67|POHS
P02437625A0197|72 101|age-related macular degeneration
P02437625A0197|103 105|AMD
P02437792T0000|12 21|elastase-1
P02437792T0000|12 21|elastase-1
P02437792T0000|26 39|amylase, lipase
P02437792T0000|26 32|amylase
P02437792T0000|34 39|lipase
P02437792T0000|44 71|trypsin-like immunoreactivity
P02437792T0000|44 50|trypsin
P02437792T0000|88 104|acute pancreatitis
P02437895A0000|0 30|A probe evoked potentials procedure
P02437895A0000|73 91|cerebral hemispheres
P02437895A0000|137 149|dextral adults
P02437895A0000|151 164|left hemisphere
P02437895A0000|166 169|LH)-
P02437895A0000|166 167|LH
P02437895A0000|170 194|damaged aphasics recovering
P02437895A0000|218 232|right hemisphere
P02437895A0000|234 262|RH)-damaged nonaphasic patients
P02437895A0000|267 287|normal control subjects
P02438637T0000|0 18|Mucolipidosis type IV
P02442837A0060|51 71|calcium channel blocker
P02442837A0060|108 128|calcium channel blocker
P02443028A0695|2 7|reflow
P02443028A0695|45 66|muscle microvasculature
P02443028A0695|71 81|reperfusion
P02443924A0083|0 5|Rarely
P02443924A0083|7 14|patients
P02443924A0083|54 78|metastatic prostatic cancer
P02444507A0240|0 15|Lysozyme activity
P02444507A0240|0 7|Lysozyme
P02444507A0240|65 68|sera
P02444507A0240|83 90|patients
P02445751A0925|52 56|mRNAs
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|93 103|beta subunit
P02445751A0925|93 103|beta subunit
P02445751A0925|106 113|F1 ATPase
P02445751A0925|106 113|F1 ATPase
P02445751A0925|116 123|wild type
P02445751A0925|130 139|hem2 mutant
P02445751A0925|130 139|hem2 mutant
P02446871A1021|4 18|S-like structure
P02446871A1021|37 53|5'-terminal region
P02446871A1021|64 90|fungal mitochondrial LSU rRNAs
P02446871A1021|70 90|mitochondrial LSU rRNAs
P02446871A1021|108 122|S-like structure
P02446871A1021|137 141|3' end
P02449431A1121|0 8|ATP gamma S
P02449431A1121|3 18|gamma S inhibition
P02449431A1121|54 56|ATP
P02449431A1121|58 61|dATP
P02449431A1121|63 68|araATP
P02449431A1121|72 76|ddATP
P02452313A0114|0 7|ASL-8123
P02452313A0114|35 53|beta-adrenoreceptor
P02452313A0114|35 53|beta-adrenoreceptor
P02452313A0114|80 88|guinea pig
P02452313A0114|89 98|right atria
P02452313A0114|104 106|pA2
P02452313A0114|123 142|agonist-like activity
P02452313A0114|184 191|ASL-8123
P02454390T0000|0 7|Enhancer
P02454390T0000|49 72|glucocorticoid repression
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02454390T0000|102 112|hepatocytes
P02454976A0944|94 96|cat
P02455821A0099|25 46|1.8-kilobase AccI-EcoRI
P02455821A0099|37 40|AccI
P02455821A0099|42 65|EcoRI restriction fragment
P02455821A0099|47 72|restriction fragment mapping
P02455821A0099|106 113|UL region
P02455821A0099|106 113|UL region
P02455821A0099|119 129|EHV-1 genome
P02455821A0099|150 154|right
P02455821A0099|157 160|left
P02456827A0899|5 6|AP
P02456827A0899|45 59|sensory activity
P02456827A0899|84 86|TEA
P02456827A0899|89 92|Ba2+
P02457922A0991|0 12|Hybridization
P02457922A0991|37 56|electrophoretic blots
P02457922A0991|59 62|RNAs
P02457922A0991|76 87|human tissues
P02457922A0991|106 117|2.8-kilobase
P02458080T0000|0 8|Prognosis
P02458080T0000|23 37|multiple myeloma
P02458234T0000|16 35|quantitative analysis
P02458234T0000|38 50|sleep spindles
P02458234T0000|67 88|overnight EEG recordings
P02459309T0000|0 9|Endogenous
P02459309T0000|27 63|serotonin and 5-hydroxyindoleacetic acid
P02459309T0000|89 91|rat
P02459309T0000|104 124|intracerebral dialysis
P02459309T0000|150 169|liquid chromatography
P02461368A0162|66 78|type X collagen
P02461368A0162|66 78|type X collagen
P02461368A0162|109 112|cDNA
P02461368A0162|116 125|genomic DNA
P02462047A0208|0 14|Viable flap areas
P02462047A0208|39 61|vascular pedicle ligation
P02462047A0208|67 73|vessels
P02462047A0208|80 91|artery or vein
P02462047A0208|112 127|flap replantation
P02462305A1071|28 57|glycosylation or phosphorylation
P02462305A1071|60 63|Ag35
P02462305A1071|60 63|Ag35
P02462305A1071|81 100|proline-rich sequence
P02462523A0394|7 23|KpnI-SalI fragment
P02462523A0394|7 10|KpnI
P02462523A0394|12 23|SalI fragment
P02462523A0394|60 74|su(Hw) mutations
P02462523A0394|60 74|su(Hw) mutations
P02462523A0394|104 115|su(Hw) mutant
P02462523A0394|104 115|su(Hw) mutant
P02462523A0394|130 138|P-element
P02462523A0394|130 138|P-element
P02462523A0394|148 170|germ-line transformation
P02463050A0514|3 34|corticosterone synthesis inhibitor
P02463050A0514|35 44|metyrapone
P02463050A0514|86 99|corticosterone
P02463050A0514|117 129|stressed males
P02464097T0000|12 15|L655
P02464097T0000|31 41|thromboxane
P02464097T0000|45 79|prostaglandin endoperoxide antagonist
P02464097T0000|83 105|ischemia- and reperfusion
P02464097T0000|114 131|cardiac arrhythmias
P02466414A0000|0 24|In 10 pentobarbitalized dogs
P02466414A0000|26 40|plasma viscosity
P02466414A0000|42 43|Ep
P02466414A0000|42 43|Ep
P02466414A0000|75 88|blood viscosity
P02466414A0000|90 91|Ea
P02466414A0000|134 144|transfusion
P02466414A0000|154 159|plasma
P02466414A0000|164 179|plasma containing
P02466414A0000|180 205|high molecular weight dextran
P02466414A0000|207 218|mol wt 500,000
P02466665A0202|3 25|small IGF-binding protein
P02466665A0202|8 25|IGF-binding protein
P02466665A0202|38 55|human amniotic fluid
P02468795A1086|0 28|Serum prostatic acid phosphatase
P02468795A1086|5 28|prostatic acid phosphatase
P02468795A1086|76 87|cancer volume
P02469451A0239|88 101|MAO-B inhibitor
P02469451A0239|88 92|MAO-B
P02470955A0101|47 59|CSF AP activity
P02470955A0101|47 51|CSF AP
P02470955A0101|62 69|purulent
P02473156A0000|1 4|cDNA
P02473156A0000|17 50|human lymphocyte cell surface molecule
P02473156A0000|126 141|adhesion proteins
P02473198A0613|0 7|Dopamine
P02473198A0613|49 59|86Rb+ efflux
P02473198A0613|64 76|control glands
P02473198A0613|99 114|denervated glands
P02473619A0202|11 23|sensitization
P02473619A0202|64 77|control animals
P02473619A0202|112 135|spontaneous sensitization
P02473619A0202|138 145|patients
P02473619A0202|150 171|anaphylactoid reactions
P02473619A0202|220 232|IgE antibodies
P02473619A0202|220 232|IgE antibodies
P02473693A0174|35 46|fetal protein
P02473693A0174|48 51|HGB F
P02473693A0174|48 51|HGB F
P02473718A0000|54 71|urinary metabolites
P02473718A0000|74 82|serotonin
P02473718A0000|86 98|catecholamine
P02473718A0000|100 105|5-HIAA
P02473718A0000|109 111|VMA
P02473718A0000|114 120|T-cells
P02473718A0000|122 126|OKT3+
P02473718A0000|122 125|OKT3
P02473718A0000|129 142|T-helper (OKT4+
P02473718A0000|138 142|OKT4+
P02473718A0000|145 156|T-suppressor
P02473718A0000|145 156|T-suppressor
P02473718A0000|158 173|OKT8+) and B-cells
P02473718A0000|158 162|OKT8+
P02473718A0000|175 197|EAC-rosette forming cells
P02473718A0000|210 225|subjects, 1 female
P02473718A0000|228 231|male
P02473718A0000|280 287|subjects
P02473718A0000|290 295|female
P02473718A0000|299 306|male, age
P02473907A1338|3 10|84.1C mAb
P02473907A1338|3 10|84.1C mAb
P02473907A1338|28 30|IgE
P02473907A1338|28 30|IgE
P02473907A1338|63 83|Fc epsilon R binding site
P02473907A1338|63 83|Fc epsilon R binding site
P02473907A1338|109 111|IgE
P02473907A1338|109 111|IgE
P02473907A1338|147 167|Fc epsilon R binding site
P02473907A1338|147 167|Fc epsilon R binding site
P02473942A1207|5 20|hydropathic plots
P02473942A1207|54 72|hydrophobic segments
P02473942A1207|86 119|alpha-helical transmembrane segments
P02474093T0000|0 26|Angiotensin converting enzyme
P02474093T0000|0 26|Angiotensin converting enzyme
P02474093T0000|47 62|antihypertensive
P02474093T0000|73 81|diuretics
P02474093T0000|99 121|adverse metabolic effects
P02474110A1039|37 49|blood pressure
P02474110A1039|54 80|angiotensin converting enzyme
P02474110A1039|54 80|angiotensin converting enzyme
P02474110A1039|82 94|ACE) inhibitor
P02474110A1039|82 84|ACE
P02474110A1039|95 102|ramipril
P02474110A1039|143 168|left ventricular hypertrophy
P02474110A1039|183 225|magnetic resonance imaging and echocardiography
P02474204A0105|0 8|Endocrine
P02474204A0105|34 57|Grimelius' silver staining
P02474204A0105|61 74|immunostaining
P02474204A0105|78 89|chromogranin
P02474204A0105|78 89|chromogranin
P02474204A0105|107 120|endocrine cells
P02474356A0559|25 30|tumour
P02474356A0559|43 54|normal tissue
P02474356A0559|58 58|N
P02474356A0559|159 164|animal
P02475506A0878|3 6|mRNA
P02475506A0878|42 73|polymerase chain reaction technique
P02475717A0565|0 13|Tissue necrosis
P02475717A0565|31 58|triphenyltetrazolium staining
P02475717A0565|102 112|infarct size
P02475717A0565|114 125|anatomic risk
P02475717A0565|137 158|coronary collateral flow
P02476030A0000|29 36|human eye
P02476030A0000|48 55|diseased
P02476030A0000|68 90|laser scanning tomography
P02476664A0563|49 56|human K14
P02476664A0563|49 56|human K14
P02476664A0563|58 58|D
P02477373A0930|10 16|TATA box
P02477373A0930|28 44|base pairs upstream
P02477373A0930|55 81|transcription initiation site
P02479635A0659|0 13|Cotransfection
P02479635A0659|35 42|plasmids
P02479635A0659|51 58|PKI(1-31
P02479635A0659|51 53|PKI
P02479635A0659|68 82|cAMP-stimulated
P02479635A0659|97 129|phorbol ester-stimulated expression
P02479823A0727|0 15|Sequence analysis
P02479823A0727|21 36|5' flanking region
P02479823A0727|52 58|GC boxes
P02479823A0727|64 82|identifiable TATA box
P02480419A0735|3 21|underlying cirrhosis
P02480419A0735|71 80|hepatitis B
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|44 54|LH/hCG surge
P02480959A0470|44 45|LH
P02480959A0470|47 49|hCG
P02480959A0470|148 160|gonadotropins
P02480959A0470|148 160|gonadotropins
P02480959A0470|189 197|prolactin
P02480959A0470|189 197|prolactin
P02480959A0470|222 225|cAMP
P02481230A1258|11 22|human but not a
P02481230A1258|23 42|bovine alpha transgene
P02481230A1258|29 42|alpha transgene
P02481230A1258|57 64|placenta
P02481230A1258|67 80|transgenic mice
P02481429T0000|1 22|rapid staining technique
P02481429T0000|26 35|Leishmania
P02481429T0000|36 44|parasites
P02481429T0000|47 67|splenic aspirate smears
P02481779A0213|0 6|NIK-244
P02481779A0213|17 64|coronary ligation- and digitalis-induced arrhythmias
P02481779A0213|88 107|plasma concentrations
P02481779A0213|142 157|coronary ligation
P02481779A0213|196 197|v.
P02481779A0213|222 223|v.
P02481779A0213|253 254|v.
P02482293A1518|2 14|TNF-resistant
P02482293A1518|2 4|TNF
P02482293A1518|18 33|bladder carcinoma
P02482293A1518|40 42|TNF
P02482293A1518|40 42|TNF
P02482293A1518|56 89|EGF-R tyrosine protein kinase activity
P02482293A1518|56 81|EGF-R tyrosine protein kinase
P02482293A1518|102 104|EGF
P02482293A1518|102 104|EGF
P02482293A1518|108 119|phorbol ester
P02482293A1518|142 158|enzymatic activity
P02482293A1518|164 171|receptor
P02482511A0860|5 31|phosphodiesterase inhibitors
P02482511A0860|45 74|opiate quasi-withdrawal syndrome
P02482511A0860|85 104|interoceptive stimuli
P02482511A0860|108 117|weight loss
P02482511A0860|179 200|morphine-dependent rats
P02483210A0000|20 29|blood serum
P02483210A0000|40 53|amylase, lipase
P02483210A0000|40 46|amylase
P02483210A0000|48 53|lipase
P02483210A0000|58 64|trypsin
P02483210A0000|58 64|trypsin
P02483210A0000|82 109|chronic relapsing pancreatitis
P02483438A0498|44 54|inodilators
P02483438A0498|75 101|phosphodiesterase inhibitors
P02483438A0498|75 101|phosphodiesterase inhibitors
P02483438A0498|108 125|dopaminergic agents
P02484714T0000|0 21|Structural organization
P02484714T0000|40 60|mouse estrogen receptor
P02484714T0000|45 60|estrogen receptor
P02484994T0001|0 24|Intravenous gamma globulins
P02484994T0001|11 24|gamma globulins
P02485188A0415|9 24|chondroitinase AC
P02485188A0415|28 39|ABC digestion
P02485188A0415|28 30|ABC
P02485188A0415|89 103|dermatan sulfate
P02485188A0415|160 167|diabetic
P02485188A0415|228 246|chondroitin sulfates
P02486634A0632|0 18|Myocardial perfusion
P02486634A0632|129 149|collateral development
P02487898A0315|4 6|NGF
P02487898A0315|4 6|NGF
P02487898A0315|80 82|NGF
P02487898A0315|80 82|NGF
P02489032A0000|0 23|Immunoglobulin light chain
P02489032A0000|0 13|Immunoglobulin
P02489032A0000|14 27|light chain (IgL
P02489032A0000|25 27|IgL
P02489032A0000|54 60|chicken
P02489032A0000|92 139|functional variable (VL) and joining (JL) gene segments
P02489032A0000|111 112|VL
P02489032A0000|125 126|JL
P02489032A0000|153 174|somatic diversification
P02489032A0000|180 197|rearranged VL region
P02489753A0581|41 51|EMG activity
P02489753A0581|54 55|FB
P02489753A0581|117 118|CG
P02489753A0581|122 128|GF group
P02489895T0001|0 20|Muscle action potential
P02489895T0001|24 40|masticatory rhythm
P02489895T0001|43 50|anterior
P02489895T0001|51 58|temporal
P02489895T0001|79 95|children and adults
P02492111A0670|19 26|children
P02492111A0670|52 55|LXRF
P02492111A0670|95 128|normal and industrially exposed adults
P02493644A0588|2 16|resting 3T3 cells
P02493644A0588|18 22|jun-D
P02493644A0588|18 20|jun
P02493644A0588|22 22|D
P02493644A0588|58 62|c-jun
P02493644A0588|58 62|c-jun
P02493644A0588|66 70|jun-B
P02493644A0588|66 70|jun-B
P02493644A0588|78 90|transcription
P02493644A0588|117 134|serum growth factors
P02493644A0588|117 134|serum growth factors
P02495745T0000|3 21|thrombolytic effects
P02495745T0000|30 60|tissue-type plasminogen activator
P02495745T0000|41 60|plasminogen activator
P02495745T0000|62 67|AK-124
P02495745T0000|62 67|AK-124
P02495745T0000|71 106|experimental canine coronary thrombosis
P02496090A0252|5 7|CO2
P02496100T0000|0 30|Enzyme-linked immunosorbent assay
P02496100T0000|43 53|aflatoxin B1
P02496100T0000|52 53|B1
P02496100T0000|87 104|collaborative study
P02496109A0754|23 24|S1
P02496109A0754|23 24|S1
P02496109A0754|72 82|alpha region
P02496109A0754|72 82|alpha region
P02496109A0754|88 98|single-copy
P02496109A0754|99 125|transcriptional fusion vector
P02496109A0754|189 205|logarithmic growth
P02496109A0754|214 226|major promoter
P02496109A0754|233 254|alpha operon lay upstream
P02496109A0754|233 243|alpha operon
P02496109A0754|295 302|IF1 to L17
P02496109A0754|295 297|IF1
P02497340A0989|20 32|antibody genes
P02497340A0989|49 50|JH
P02497340A0989|49 50|JH
P02497340A0989|54 65|VH heavy chain
P02497340A0989|54 65|VH heavy chain
P02497340A0989|79 80|Jk
P02497340A0989|79 80|Jk
P02497340A0989|84 101|Vk light chain probes
P02497340A0989|84 95|Vk light chain
P02498322A0226|11 30|DNA-protein complexes
P02498322A0226|11 30|DNA-protein complexes
P02498322A0226|47 66|gel retardation assays
P02498322A0226|72 94|HeLa cell nuclear extracts
P02498322A0226|100 119|oligonucleotide probe
P02498322A0226|131 147|footprinted region
P02498652A0460|5 16|transfection
P02498652A0460|26 48|TSH beta promoter activity
P02498652A0460|26 40|TSH beta promoter
P02498652A0460|65 129|TRH-responsive pituitary-derived GH3 and primary pituitary cell cultures
P02498652A0460|65 67|TRH
P02500432A1416|13 18|E. coli
P02500432A1416|32 44|CAT expression
P02500432A1416|32 34|CAT
P02500432A1416|71 86|0.3 kilobase of DNA
P02500432A1416|94 98|3' end
P02500432A1416|104 122|1.6-kilobase segment
P02500432A1416|168 174|CAT gene
P02500432A1416|168 174|CAT gene
P02502096A0462|0 7|Lowering
P02502096A0462|13 22|renal blood
P02502096A0462|36 73|glomerular and tubular excretion processes
P02502602A0323|0 8|Tonometry
P02502602A0323|11 22|blood samples
P02502602A0323|27 34|patients
P02502602A0323|90 114|hemoglobin-oxygen affinity
P02502602A0323|90 99|hemoglobin
P02502602A0323|119 122|p50.
P02502602A0323|119 121|p50
P02502960A0762|0 2|100
P02504603T0000|11 25|Weeksella virosa
P02504603T0000|27 45|formerly CDC group IIf
P02505087A1037|15 37|dimerization specificity
P02505087A1037|40 42|Fos
P02505087A1037|40 42|Fos
P02505087A1037|66 78|leucine zipper
P02505087A1037|91 95|GCN4.
P02505087A1037|91 94|GCN4
P02506390T0001|0 5|Growth
P02506740A0742|74 87|chronic hypoxia
P02506740A0742|90 106|cerebral blood flow
P02507523A0791|3 6|ORF1
P02507523A0791|28 37|competence
P02507523A0791|44 47|ORF2
P02507523A0791|74 77|ORF1
P02507523A0791|98 119|protein of 126 amino acids
P02507815A0000|0 7|Kindling
P02507815A0000|26 31|cortex
P02507815A0000|33 34|VC
P02507815A0000|70 73|cats
P02508306A0528|8 19|infiltration
P02508306A0528|22 32|lymphocytes
P02508306A0528|36 46|plasma cells
P02508306A0528|75 83|carcinoma
P02508306A0528|106 122|lymphoid follicles
P02508726A0498|42 46|LiCO3
P02508726A0498|106 125|affective instability
P02508726A0498|131 141|brain injury
P02508726A0498|178 190|neurotoxicity
P02508726A0498|245 261|neuroleptic agents
P02509123A0371|18 20|IFN
P02509123A0371|18 20|IFN
P02509123A0371|25 31|latency
P02509123A0371|37 49|P100 component
P02509123A0371|55 57|VEP
P02509123A0371|82 99|baseline conditions
P02510242A0313|15 39|post-transfusion hepatitis
P02510242A0313|54 68|hepatitis B virus
P02510242A0313|96 100|HBs Ag
P02510242A0313|96 100|HBs Ag
P02510242A0313|162 177|serological tests
P02510242A0313|209 211|CMV
P02511069A0532|9 23|lethal mutations
P02511069A0532|87 95|Df(3L)RR2
P02511069A0532|87 91|Df(3L
P02511069A0532|111 119|DRE region
P02511069A0532|144 158|chromosome bands
P02511150T0025|0 12|Current status
P02511207A0282|0 0|K
P02511430A0000|1 23|215-base-pair (bp) region
P02511430A0000|29 81|mouse MOPC 41 kappa light-chain immunoglobulin gene enhancer
P02511430A0000|34 37|MOPC
P02511430A0000|38 81|41 kappa light-chain immunoglobulin gene enhancer
P02511430A0000|117 138|lymphoid and nonlymphoid
P02511430A0000|139 152|nuclear factors
P02511898A0000|46 58|Chagas disease
P02512010A0801|3 19|PETCO2 measurement
P02512010A0801|94 115|spontaneous circulation
P02514498A0000|39 75|simultaneous inhibition of acid secretion
P02514498A0000|78 83|intra-
P02514498A0000|87 117|extragastric pCO2/pH measurements
P02514498A0000|122 128|persons
P02514498A0000|182 185|pCO2
P02515953A0459|30 37|patients
P02517008A0481|8 15|patients
P02517008A0481|55 65|monotherapy
P02518645T0001|8 20|Chagas disease
P02518691A0251|5 28|mutated IL2R alpha promoter
P02518691A0251|12 28|IL2R alpha promoter
P02518691A0251|41 61|transient transfection
P02518691A0251|65 80|DNA binding assays
P02518691A0251|155 168|kappa B enhancer
P02518691A0251|155 168|kappa B enhancer
P02518691A0251|200 222|IL2R alpha gene expression
P02518691A0251|200 212|IL2R alpha gene
P02519327T0001|0 20|Palindromic rheumatism
P02519679T0000|0 9|Inefficacy
P02519679T0000|12 30|phosphine fumigation
P02519679T0000|38 42|ticks
P02520622A0200|5 12|patients
P02520622A0200|14 20|divided
P02520622A0200|49 64|gastrointestinal
P02520622A0200|114 131|cimetropium bromide
P02520622A0200|172 183|double-blind
P02520622A0200|185 203|parallel group design
P02521217A1035|2 30|immunologically related protein
P02521217A1035|74 85|mitochondria
P02521217A1035|90 112|Saccharomyces cerevisiae
P02521674T0000|9 12|RNA-
P02521674T0000|13 40|temperature-sensitive mutants
P02521674T0000|34 54|mutants of Sindbis virus
P02521674T0000|43 54|Sindbis virus
P02521674T0000|97 101|nsP4.
P02521674T0000|97 100|nsP4
P02522297A0000|14 66|thromboxane A2 (TXA2)/prostaglandin endoperoxide receptor
P02522297A0000|14 26|thromboxane A2
P02522297A0000|28 31|TXA2
P02522297A0000|34 76|prostaglandin endoperoxide receptor antagonist
P02522297A0000|78 85|SQ 29,548
P02522297A0000|88 109|pacing-induced ischemia
P02523800A1178|36 43|CHS1 gene
P02523800A1178|36 43|CHS1 gene
P02523800A1178|79 102|TGAAACA consensus sequence
P02523800A1178|128 161|alpha-factor-inducible BAR1 promoter
P02523800A1178|128 139|alpha-factor
P02523800A1178|150 161|BAR1 promoter
P02525044A1026|17 23|T25-T75
P02525044A1026|60 67|patients
P02526165X0000|9 21|Leser-Trelat:
P02526165X0000|43 54|Leser-Trelat
P02526165X0000|83 97|cutaneous marker
P02526165X0000|108 117|malignancy
P02527365T0000|0 13|Xenopus homolog
P02527365T0000|0 6|Xenopus
P02527365T0000|19 34|mos protooncogene
P02527365T0000|19 34|mos protooncogene
P02527365T0000|45 64|mammalian fibroblasts
P02527365T0000|87 100|Xenopus oocytes
P02527745A0865|0 19|Southern blot analyses
P02527745A0865|42 58|single, copy number
P02527745A0865|104 114|vertebrates
P02528329A0000|35 60|Escherichia coli F1F0-ATPase
P02528329A0000|35 49|Escherichia coli
P02528329A0000|50 60|F1F0-ATPase
P02528329A0000|94 106|hydroxylamine
P02528329A0000|121 127|plasmid
P02528329A0000|139 156|uncB (subunit a) gene
P02528329A0000|139 156|uncB (subunit a) gene
P02528730A1073|9 15|exons 2a
P02528730A1073|19 20|2b
P02528730A1073|33 42|5' sequence
P02528730A1073|102 106|171 bp
P02529378A0536|0 9|S1 nuclease
P02529378A0536|0 1|S1
P02529378A0536|2 17|nuclease analysis
P02529378A0536|55 67|HIV constructs
P02529378A0536|72 80|HeLa cells
P02529378A0536|93 111|wild-type adenovirus
P02529378A0536|128 135|enhancer
P02529378A0536|137 139|SP1
P02529378A0536|137 139|SP1
P02529378A0536|141 144|TATA
P02529378A0536|162 194|transactivation-responsive element
P02529378A0536|222 247|E1A/E1B-mediated activation
P02529378A0536|222 224|E1A
P02529378A0536|226 228|E1B
P02529378A0536|253 258|HIV LTR
P02529378A0536|253 258|HIV LTR
P02530413A0195|17 31|plasma ANP levels
P02530413A0195|23 25|ANP
P02530470A0604|22 31|HBV markers
P02530470A0604|46 57|staff members
P02530470A0604|67 77|blood donors
P02531203A0241|0 22|Quantitative predictions
P02531203A0241|41 57|positive responses
P02531203A0241|98 106|SSTS model
P02532032A0385|0 19|Plasma concentrations
P02532032A0385|22 24|ANF
P02532032A0385|22 24|ANF
P02532032A0385|26 29|pANF
P02532032A0385|26 29|pANF
P02532032A0385|32 42|aldosterone
P02532032A0385|44 46|PAC
P02532032A0385|51 59|renin (PRC
P02532032A0385|51 55|renin
P02532032A0385|57 59|PRC
P02532032A0385|85 105|hemodynamic parameters
P02532210A0000|3 19|adenovirus E1A gene
P02532210A0000|3 19|adenovirus E1A gene
P02532210A0000|65 79|viral early genes
P02532210A0000|65 79|viral early genes
P02534067A0316|16 28|dexamethasone
P02534067A0316|70 112|17 alpha OH progesterone, 11 beta-desoxycortisol
P02534067A0316|114 117|DHEA
P02534067A0316|145 156|testosterone
P02534067A0316|179 194|urinary excretion
P02534067A0316|197 229|androsterone, 11 beta OH androsterone
P02534067A0316|247 250|DHEA
P02534067A0316|264 267|DHEA
P02535460A1443|0 13|RNA transcripts
P02535460A1443|0 13|RNA transcripts
P02536096A0327|2 10|HeLa cells
P02536096A0327|43 88|herpes simplex virus type 1 thymidine kinase promoter
P02536096A0327|43 65|herpes simplex virus type 1
P02536096A0327|66 88|thymidine kinase promoter
P02536096A0327|100 135|chloramphenicol acetyltransferase gene
P02536096A0327|100 135|chloramphenicol acetyltransferase gene
P02536096A0327|181 203|thymidine kinase promoter
P02536096A0327|181 203|thymidine kinase promoter
P02536096A0327|221 256|chloramphenicol acetyltransferase gene
P02536096A0327|221 256|chloramphenicol acetyltransferase gene
P02536160A0518|32 54|Ren1d 5' flanking sequence
P02536160A0518|32 54|Ren1d 5' flanking sequence
P02536160A0518|60 75|sense orientation
P02536160A0518|85 102|basal CAT expression
P02536160A0518|90 92|CAT
P02536160A0518|110 119|TK promoter
P02536160A0518|110 111|TK
P02536160A0518|122 128|pUTKAT1
P02536160A0518|157 176|antisense orientation
P02537441A0231|22 35|clinical duties
P02537441A0231|46 75|varicella-zoster immune globulin
P02537441A0231|46 75|varicella-zoster immune globulin
P02537441A0231|88 94|disease
P02538450A0000|14 23|cDNA clones
P02538450A0000|28 48|rat brain and human liver
P02538450A0000|58 72|putative isoform
P02538450A0000|78 79|Na
P02538450A0000|78 79|Na
P02538450A0000|81 99|K-ATPase beta subunit
P02538450A0000|81 99|K-ATPase beta subunit
P02538656A0172|27 35|E1 mutants
P02538656A0172|27 28|E1
P02538656A0172|52 63|M and R regions
P02538656A0172|52 52|M
P02538656A0172|56 63|R regions
P02538656A0172|85 108|upstream regulatory region
P02538656A0172|142 155|mouse C127 cells
P02538656A0172|163 177|wild-type genome
P02538720A0582|0 3|UbiA
P02538720A0582|0 3|UbiA
P02538720A0582|26 43|polyubiquitin genes
P02538720A0582|26 43|polyubiquitin genes
P02538720A0582|60 77|cis-spliced introns
P02538720A0582|87 100|coding sequence
P02541251A1327|9 14|T2 gene
P02541251A1327|9 14|T2 gene
P02541251A1327|58 88|mammalian transcription factor SP1
P02541251A1327|58 85|mammalian transcription factor
P02541251A1327|86 88|SP1
P02541251A1327|95 114|TATA or CCAAT sequences
P02541251A1327|101 114|CCAAT sequences
P02541251A1327|134 138|5' end
P02541251A1327|187 197|human T1 gene
P02541251A1327|192 197|T1 gene
P02541882A0251|0 15|Radiation therapy
P02541882A0251|30 61|controlling symptomatic metastasis
P02541882A0251|72 79|patients
P02542194A1496|24 31|patients
P02542194A1496|55 65|irradiation
P02542194A1496|69 94|low grade spinal astrocytomas
P02542270A0000|3 13|methylation
P02542270A0000|16 40|nuclear and chloroplast DNAs
P02542270A0000|26 40|chloroplast DNAs
P02542270A0000|100 120|C4 photosynthesis genes
P02542270A0000|126 137|bundle sheath
P02542270A0000|141 154|mesophyll cells
P02542270A0000|157 174|etiolated, greening
P02542612A0530|0 9|S1 nuclease
P02542612A0530|0 1|S1
P02542612A0530|2 17|nuclease analysis
P02542612A0530|20 22|RNA
P02542612A0530|44 53|B95-8 cells
P02542612A0530|61 69|Vero cells
P02542612A0530|87 108|NotI repeat promoter-CAT
P02542612A0530|87 104|NotI repeat promoter
P02542612A0530|106 108|CAT
P02542612A0530|112 112|Z
P02542612A0530|112 112|Z
P02542612A0530|123 123|Z
P02542612A0530|123 123|Z
P02542612A0530|183 196|RNA transcripts
P02543226A1559|32 49|detecting carcinoma
P02543226A1559|52 70|atypical hyperplasia
P02543226A1559|118 129|benign breast
P02543226A1559|205 216|benign breast
P02543226A1559|274 290|fibrous parenchyma
P02543226A1559|354 362|carcinoma
P02543226A1559|365 383|atypical hyperplasia
P02543621A0788|29 36|sporadic
P02543621A0788|48 58|Wilms' tumor
P02543679A1291|35 41|lambda O
P02543679A1291|35 41|lambda O
P02543679A1291|45 55|P initiators
P02543679A1291|62 71|E. coli DnaJ
P02543679A1291|62 67|E. coli
P02543679A1291|68 71|DnaJ
P02543679A1291|75 95|DnaK heat shock proteins
P02543679A1291|75 78|DnaK
P02543679A1291|79 95|heat shock proteins
P02543734A0414|9 24|oligonucleotides
P02543734A0414|40 53|19 bp repeat unit
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|134 152|transient expression
P02544059A0377|9 16|nitrogen
P02544059A0377|35 40|helium
P02544059A0377|42 47|PHe: 13
P02544059A0377|51 55|14 MPa
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545357A0000|3 24|mustard chloroplast gene
P02545357A0000|25 29|rps16
P02545357A0000|41 65|887 bp group II (or III) intron
P02545903A0639|0 9|Antibodies
P02545903A0639|30 32|NS3
P02545903A0639|30 32|NS3
P02545903A0639|49 52|mice
P02545903A0639|65 67|NS3
P02545903A0639|65 67|NS3
P02545903A0639|71 74|NS3A
P02545903A0639|71 74|NS3A
P02545903A0639|77 99|BTV-10-infected BHK cells
P02545903A0639|116 135|BTV-10 virus particles
P02546234A1382|46 65|resuscitative efforts
P02547079A0910|3 24|negative calcium balance
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|72 89|oral administration
P02547079A0910|92 93|Cd
P02547079A0910|118 133|urinary excretion
P02547079A0910|136 142|calcium
P02547611A0318|0 6|Clone 4c
P02547611A0318|48 55|clone 22c
P02547611A0318|78 83|intron
P02547706A0928|16 18|ISH
P02547706A0928|16 18|ISH
P02547706A0928|22 24|IHC
P02547706A0928|22 24|IHC
P02547706A0928|100 105|CMV-IP
P02547706A0928|109 111|IIP
P02547706T0001|0 7|Validity
P02547706T0001|10 24|immunohistology
P02547706T0001|28 46|in situ hybridization
P02547706T0001|75 89|cytomegalovirus
P02547706T0001|112 132|interstitial pneumonia
P02547706T0001|138 171|allogenic bone marrow transplantation
P02547778A0786|34 67|ANT1 transcriptional control elements
P02547778A0786|34 37|ANT1
P02548683T0001|41 55|viral hepatitis A
P02549036A0000|3 38|Bacillus subtilis phage phi 105 repressor
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549036A0000|41 92|lambda repressor-like transcriptional regulatory protein
P02549036A0000|47 92|repressor-like transcriptional regulatory protein
P02549036A0000|111 125|Escherichia coli
P02549036A0000|143 153|homogeneity
P02549036A0000|173 200|in vitro DNA-binding properties
P02549343A1008|17 19|gpI
P02549343A1008|17 19|gpI
P02549343A1008|48 51|mO74
P02549343A1008|98 100|gpI
P02549343A1008|98 100|gpI
P02549343A1008|105 108|VZV-
P02549343A1008|141 166|immunoprecipitation pattern
P02549343A1008|264 279|recombinant virus
P02549343A1008|340 349|complement
P02549417A0000|29 36|malarial
P02549417A0000|37 45|parasites
P02549417A0000|62 73|mitochondria
P02550118A0610|8 45|bilateral diffuse pulmonary infiltrations
P02550682A0411|0 6|Grossly
P02550682A0411|27 38|IIc carcinoma
P02550682A0411|57 67|IIc + III type
P02551886A0332|0 14|Restriction maps
P02551886A0332|20 33|cloned plasmids
P02551886A0332|80 99|overlapping fragments
P02552143A0748|0 2|VP5
P02552143A0748|0 2|VP5
P02552143A0748|19 36|major capsid protein
P02552143A0748|24 36|capsid protein
P02552143A0748|52 87|chloramphenicol acetyltransferase gene
P02552143A0748|52 87|chloramphenicol acetyltransferase gene
P02552316A0526|5 35|initially seronegative caretakers
P02554310A0419|37 54|38-base-pair region
P02555177A0488|7 17|pet54::LEU2
P02555177A0488|7 11|pet54
P02555177A0488|14 17|LEU2
P02555177A0488|40 64|short' mitochondrial genome
P02555177A0488|78 106|COX1 introns aI5 alpha and aI5 beta
P02555177A0488|78 88|COX1 introns
P02555177A0488|89 96|aI5 alpha
P02555177A0488|100 106|aI5 beta
P02555177A0488|124 141|COX3 gene expression
P02555177A0488|124 131|COX3 gene
P02555177A0488|150 165|COX1 mRNA splicing
P02555177A0488|150 157|COX1 mRNA
P02555418A0973|0 6|Insert2
P02555418A0973|25 47|non-Ig-related sequences
P02555418A0973|25 47|non-Ig-related sequences
P02555418A0973|52 74|small Ig-related sequence
P02555418A0973|52 74|small Ig-related sequence
P02555519A0798|38 52|primary sequence
P02555519A0798|58 94|CDR3 (complementarity determining region
P02555519A0798|58 61|CDR3
P02555519A0798|112 119|H-chains
P02555519A0798|112 119|H-chains
P02555519A0798|148 155|D-region
P02555519A0798|203 215|hapten binding
P02555703T0000|0 7|Tyrosine
P02555703T0000|31 53|interleukin-3 dependence
P02555703T0000|31 43|interleukin-3
P02555703T0000|56 73|murine myeloid cells
P02555703T0000|107 111|c-myc
P02555703T0000|107 111|c-myc
P02555703T0000|136 153|c-myc transcription
P02555703T0000|136 140|c-myc
P02555703T0000|156 182|temperature-sensitive v-abl.
P02555703T0000|177 181|v-abl
P02556264A0278|4 16|TC-II enhanson
P02556264A0278|4 8|TC-II
P02556264A0278|9 16|enhanson
P02556264A0278|39 49|kappa B motif
P02556264A0278|39 49|kappa B motif
P02556264A0278|57 74|kappa chain enhancer
P02556264A0278|57 74|kappa chain enhancer
P02556264A0278|91 118|lymphoid and non-lymphoid cells
P02556264A0278|187 197|kappa B motif
P02556264A0278|187 197|kappa B motif
P02556269A0187|16 45|tandemly repeated, 13mer sequence
P02556269A0187|105 134|single-strand-specific nuclease
P02556269A0187|105 134|single-strand-specific nuclease
P02556269A0187|159 165|plasmid
P02556269A0187|190 201|DNA unwinding
P02556269A0187|211 243|two-dimensional gel electrophoresis
P02556269A0187|246 256|topoisomers
P02556603A0606|52 70|periampullary cancer
P02556603A0606|72 88|gallbladder cancer
P02556603A0606|92 117|extrahepatic bile duct cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|15 18|ACTH
P02557217A0000|15 18|ACTH
P02557217A0000|22 38|cortisol secretion
P02557217A0000|59 75|healthy adult males
P02557217A0000|81 90|nasal spray
P02557217A0000|110 125|salmon calcitonin
P02557217A0000|116 125|calcitonin
P02557217A0398|19 28|calcitonin
P02557217A0398|19 28|calcitonin
P02557217A0398|37 50|beta-endorphin
P02557217A0398|72 109|enhanced corticotrophin-cortisol release
P02557217A0398|80 93|corticotrophin
P02557350A0632|33 39|SRP54sc
P02557350A0632|33 39|SRP54sc
P02557350A0632|43 49|SRP54sp
P02557350A0632|43 49|SRP54sp
P02557350A0632|77 84|SRP54mam
P02557350A0632|77 84|SRP54mam
P02559630A0270|50 63|thromboplastin
P02559630A0270|70 80|prothrombin
P02559630A0270|87 94|thrombin
P02559630A0270|87 94|thrombin
P02559630A0270|101 110|fibrinogen
P02559630A0270|101 110|fibrinogen
P02559630A0270|112 125|platelet counts
P02559630A0270|130 146|fibrin/fibrinogen
P02559630A0270|130 135|fibrin
P02559630A0270|137 146|fibrinogen
P02560415T0012|0 18|Rare neurogenic tumor
P02560415T0012|23 32|metastasis
P02562787A0637|27 38|cellular NBP"
P02562787A0637|35 43|NBP" (CNBP
P02562787A0637|40 43|CNBP
P02562825A0413|16 35|beta-2 agonist therapy
P02562825A0413|16 21|beta-2
P02565405T0000|9 21|trauma victims
P02565683A0841|1 17|critical heart rate
P02565683A0841|35 50|sympathetic state
P02565683A0841|82 118|reentrant or automatic atrial tachycardia
P02565683A0841|122 150|atypical junctional tachycardia
P02565807A1198|14 30|neu proto-oncogene
P02565807A1198|14 16|neu
P02565807A1198|17 30|proto-oncogene
P02565807A1198|57 78|transforming properties
P02565807A1198|109 119|NIH 3T3 cells
P02566613A0831|8 15|sequence
P02566613A0831|27 58|octameric cAMP-responsive enhancer
P02566613A0831|60 62|CRE
P02566613A0831|64 83|TGACGTCA (nucleotides
P02566613T0000|0 25|Somatostatin gene expression
P02566613T0000|0 15|Somatostatin gene
P02566613T0000|28 47|pancreatic islet cells
P02566613T0000|60 90|cell-specific DNA control elements
P02566613T0000|94 112|DNA-binding proteins
P02566613T0000|94 112|DNA-binding proteins
P02566680A0820|14 19|full mu
P02566680A0820|53 63|I-methadone
P02567030A0482|5 16|overtraining
P02568930T0000|31 34|cDNA
P02568930T0000|44 59|putative cytokine
P02568930T0000|93 104|CD2 structure
P02568930T0000|93 95|CD2
P02568930T0000|107 123|human T lymphocytes
P02569411A0151|31 37|animals
P02569411A0151|66 72|nucleus
P02571924A0000|0 11|Haploid cells
P02571924A0000|14 24|mating type A
P02571924A0000|45 49|yeast
P02571924A0000|50 73|Rhodosporidium toruloides
P02571924A0000|82 96|mating pheromone
P02571924A0000|98 111|rhodotorucine A
P02571924A0000|98 111|rhodotorucine A
P02571924A0000|122 134|undecapeptide
P02571924A0000|145 162|S-farnesyl cysteine
P02571924A0000|168 182|carboxy terminus
P02572777T0000|0 54|Tumour necrosis factor and adult respiratory distress syndrome
P02572777T0000|0 19|Tumour necrosis factor
P02572928T0000|12 30|rheumatoid arthritis
P02573303A0000|13 27|left ventricular
P02573303A0000|29 43|LV) stroke volume
P02573303A0000|50 84|positive end-expiratory pressure (PEEP
P02573303A0000|112 120|LV filling
P02573303A0000|134 149|contractile state
P02573336A0000|32 34|ROF
P02573336A0000|53 81|snake- or spider-phobic subjects
P02573336A0000|178 180|ROF
P02573829T0000|0 23|Evolutionary conservation
P02573829T0000|26 49|homeodomain-binding sites
P02573829T0000|26 49|homeodomain-binding sites
P02573829T0000|87 108|major transcription unit
P02573829T0000|114 148|Drosophila segmentation gene engrailed
P02573829T0000|114 139|Drosophila segmentation gene
P02573836A0244|38 40|NBS
P02573836A0244|53 75|drug resistance phenotype
P02573836A0244|87 90|mdr1
P02573836A0244|87 90|mdr1
P02573836A0244|104 125|amino acid substitutions
P02573836A0244|131 151|core consensus sequence
P02573836A0244|155 171|nucleotide binding
P02573836A0244|173 178|GXGKST
P02574016A0428|20 22|TOF
P02574016A0428|105 110|adults
P02574016A0428|129 146|infants and children
P02574052A0910|62 86|beta-adrenoceptor blockade
P02574052A0910|62 78|beta-adrenoceptor
P02574193A0663|14 15|22
P02574193A0663|80 85|CIWA-B
P02574193A0663|226 232|placebo
P02574193A0663|246 261|low-dose subjects
P02574193A0663|268 284|contingency tables
P02574193A0663|296 313|regression analysis
P02574551T0000|0 13|Antihistamines
P02574551T0000|16 21|asthma
P02575174A0229|60 93|orally active selective alpha 1 blocker
P02575174A0229|81 86|alpha 1
P02575174A0229|97 104|patients
P02575174A0229|109 128|systemic hypertension
P02575490A1021|0 19|Northern blot analysis
P02575490A1021|36 52|oIGF-I transcripts
P02575490A1021|36 52|oIGF-I transcripts
P02575490A1021|67 86|800-1,100 nucleotides
P02575490A1021|131 135|liver
P02575567T0001|0 22|Materials science studies
P02575959A0643|3 9|latency
P02575959A0643|20 39|lactate concentration
P02575959A0643|50 58|top values
P02575959A0643|71 85|aerobic training
P02575959A0643|87 88|T2
P02576405A0223|2 9|patients
P02576405A0223|21 23|VAD
P02576405A0223|25 42|high-dose therapies
P02576405A0223|47 66|intravenous melphalan
P02576405A0223|69 82|CBV combination
P02576405A0223|84 99|cyclophosphamide
P02576405A0223|101 110|BCNU-VP-16
P02576405A0223|116 141|EDAP regimen (VP-16 -platinum
P02576405A0223|128 132|VP-16
P02576405A0223|172 179|patients
P02577458A0412|48 84|angiotensin converting enzyme inhibitors
P02577458A0412|48 74|angiotensin converting enzyme
P02577458A0412|86 117|alpha-adrenergic receptor blockers
P02577458A0412|86 109|alpha-adrenergic receptor
P02577458A0412|122 139|calcium antagonists
P02577867T0000|8 22|cellular homolog
P02577867T0000|28 38|oncogene jun
P02577867T0000|28 38|oncogene jun
P02580830A1131|1 14|736-bp sequence
P02580830A1131|20 35|5' flanking region
P02580830A1131|49 55|cap site
P02580830A1131|61 72|human AFP gene
P02580830A1131|61 72|human AFP gene
P02580830A1131|123 134|mouse AFP gene
P02580830A1131|123 134|mouse AFP gene
P02582240A1009|0 16|High ATP/GTP ratios
P02582240A1009|40 54|primer synthesis
P02582240A1009|57 69|3'-dCTTT sites
P02582240A1009|78 93|low ATP/GTP ratios
P02582240A1009|114 125|3'-dCCC sites
P02582918A0000|5 33|hepatitis B vaccine immunization
P02582918A0000|35 55|serum antibody response
P02582918A0000|61 71|primary type
P02582918A0000|85 92|anti-HBs
P02582918A0000|85 92|anti-HBs
P02582918A0000|101 119|2.1 S/N (S/N Ratio Unit
P02582918A0000|123 124|T0
P02582918A0000|129 148|anti-HBs positive rate
P02582918A0000|129 136|anti-HBs
P02582918A0000|179 180|T1
P02582918A0000|182 183|T2
P02582918A0000|185 186|T0
P02582918A0000|190 192|T12
P02584969A0119|42 56|regression model
P02584969A0119|82 101|proportional end point
P02585492A1005|13 32|complementation tests
P02585492A1005|46 55|P7 proteins
P02585492A1005|46 47|P7
P02585492A1005|77 78|P1
P02585492A1005|77 78|P1
P02585492A1005|79 82|parA
P02585492A1005|79 82|parA
P02585492A1005|85 95|parB mutants
P02585492A1005|85 95|parB mutants
P02585492A1005|103 112|P1 proteins
P02585492A1005|103 104|P1
P02585492A1005|132 133|P7
P02585492A1005|132 133|P7
P02586485A0511|0 4|GN101
P02586485A0511|6 12|YC819-9
P02586485A0511|17 19|SB3
P02586513A0622|13 38|inferred 1,859-residue ama-1
P02586513A0622|21 45|1,859-residue ama-1 product
P02586513A0622|95 100|RNAP II
P02586513A0622|95 100|RNAP II
P02586513A0622|143 157|zinc finger motif
P02586513A0622|143 157|zinc finger motif
P02586513A0622|165 177|amino terminus
P02586513A0622|183 205|carboxyl-terminal domain
P02586513A0622|208 209|42
P02586513A0622|218 227|reiterated
P02586513A0622|253 255|Tyr
P02586513A0622|256 270|Ser Pro Thr Ser Pro
P02586513A0622|271 273|Ser
P02590097A0093|23 30|left lung
P02590097A0093|51 56|mucosa
P02590097A0093|62 65|left
P02590097A0093|71 82|lobe bronchus
P02590097A0093|108 127|monoclonal gammopathy
P02590097A0093|129 142|IgA--Type Kappa
P02590097A0093|129 131|IgA
P02590097A0093|138 142|Kappa
P02590278A0540|0 0|5
P02590391A0442|43 49|neutral
P02590391A0442|62 74|phospholipids
P02590391A0442|76 94|phosphatidylcholine
P02590391A0442|96 119|phosphatidylethanolamine
P02590391A0442|144 168|sphingomyelin and fatty acid
P02590391A0442|186 202|phospholipid class
P02590391A0442|242 248|lesions
P02590540A0741|5 9|women
P02590540A0741|14 35|non-malignant diagnoses
P02590615A0636|98 113|pharmacokinetics
P02590615A0636|116 125|nifedipine
P02590615A0636|139 154|biphasic' tablets
P02590869A0743|3 19|GALT-primed calves
P02590869A0743|32 39|serum IgG
P02590869A0743|37 39|IgG
P02590869A0743|41 49|lavage IgG
P02590869A0743|47 49|IgG
P02590869A0743|53 55|IgA
P02590869A0743|53 55|IgA
P02590869A0743|68 76|LNA titers
P02590869A0743|83 94|lavage fluids
P02590869A0743|98 102|serum
P02590869A0743|129 136|bacteria
P02591078A0000|33 41|Grenz rays
P02591078A0000|56 88|allergic contact dermatitis reaction
P02591078A0000|106 120|Langerhans cells
P02591078A0000|134 147|OKT6 antibodies
P02591078A0000|134 147|OKT6 antibodies
P02591078A0000|151 168|electron microscopy
P02591078A0000|186 194|epidermis
P02591969A0961|3 10|elements
P02591969A0961|25 49|glucocorticoid stimulation
P02591969A0961|52 71|ADH gene transcription
P02591969A0961|52 58|ADH gene
P02591993A0000|0 0|1
P02592543A0106|27 52|biochemical characteristics
P02592543A0106|54 79|Kanagawa hemolysin reactions
P02592543A0106|62 70|hemolysin
P02592543A0106|84 98|plasmid profiles
P02592543A0106|103 109|patient
P02592640A0466|0 9|High values
P02592640A0466|16 38|retinol and beta-carotene
P02592640A0466|54 63|fat cheeses
P02592640A0466|67 79|whipping cream
P02592640A0466|98 106|Edam-type
P02592640A0466|131 143|whipping cream
P02592640A0466|164 172|Edam-type
P02592640A0466|197 209|whipping cream
P02592640A0466|214 229|all-trans retinol
P02592640A0466|233 250|total beta-carotene
P02595451A1136|18 29|aniridia gene
P02595451A1136|18 29|aniridia gene
P02595451A1136|31 33|AN2
P02595451A1136|31 33|AN2
P02595451A1136|48 61|T-cell leukemia
P02595451A1136|73 76|TCL2
P02595451A1136|73 76|TCL2
P02595451A1136|115 118|MIC1
P02595451A1136|115 118|MIC1
P02595451T0000|1 22|fine-structure deletion
P02595451T0000|28 45|human chromosome 11p
P02595451T0000|57 71|J1 series hybrids
P02597484A0624|35 43|platelets
P02597484A0624|54 78|surface reactivity constant
P02597484A0624|80 80|K
P02597549A0964|10 23|recent patients
P02597549A0964|50 65|oral dipyridamole
P02597549A0964|81 87|aspirin
P02597549A0964|106 124|early recovery period
P02597549A0964|157 167|prothrombin
P02597549A0964|157 167|prothrombin
P02597549A0964|178 191|thromboplastin
P02598034A0000|0 37|Middle-latency auditory evoked potentials
P02598034A0000|39 43|MAEPs
P02598034A0000|59 66|controls
P02598034A0000|70 77|patients
P02598034A0000|82 93|focal lesions
P02598034A0000|96 123|dorsolateral prefrontal cortex
P02598745A0251|24 37|Sylvius fissure
P02599995A1031|0 20|Intracellular activity
P02599995A1031|52 54|MBC
P02599995A1031|102 114|intracellular
P02599995A1031|115 127|staphylococci
P02599995A1031|137 144|survival
P02600306A0140|59 80|envelope phase disparity
P02600306A0140|115 127|single channel
P02600306A0140|138 144|AM tones
P02601707A0986|0 19|Gel retardation assays
P02601707A0986|32 49|DNase I footprinting
P02601707A0986|32 37|DNase I
P02601707A0986|53 72|diethyl pyrocarbonate
P02601707A0986|96 108|nuclear factor
P02601707A0986|127 136|C2 myotubes
P02601707A0986|173 188|A + T-rich sequence
P02602150A0993|14 19|plants
P02602150A0993|62 77|sequence elements
P02602150A0993|161 177|gene amplification
P02602150A0993|180 185|plants
P02602150A0993|195 214|minimal virus replicon
P02603374A0383|0 15|Ventral rhinotomy
P02603374A0383|37 51|dorsal rhinotomy
P02603374A0383|84 109|postoperative complications
P02603923A0220|18 30|skin incisions
P02603923A0220|52 61|female pigs
P02603923A0220|100 120|epidermal growth factor
P02603923A0220|100 120|epidermal growth factor
P02603923A0220|138 160|Ringer's lactate solution
P02604420A0234|16 23|rebiopsy
P02604420A0234|35 53|reticulin antibodies
P02605160A0000|11 14|iron
P02605160A0000|23 36|59Fe absorption
P02605160A0000|47 55|pregnancy
P02605160A0000|62 85|maternal and fetal Fe status
P02605160A0000|128 131|rats
P02605182A0936|10 24|protein sequence
P02605182A0936|43 87|putative 16-residue amino-terminal signal peptide
P02605182A0936|114 135|239-residue polypeptide
P02605679A0306|42 61|isomerization rate k12
P02605679A0306|116 126|delta 3 ester
P02605679A0306|127 130|kdeg
P02605679A0306|167 180|delta 2 ester k24
P02607766A0000|1 8|protocol
P02607766A0000|67 81|control material
P02607766A0000|83 85|QCM
P02607766A0000|121 127|cadmium
P02607766A0000|129 130|Cd
P02607766A0000|156 157|Pb
P02607766A0000|182 192|bovine blood
P02607766A0000|206 208|QCM
P02607766A0000|219 220|Cd
P02607766A0000|247 248|Hg
P02607766A0000|272 273|Pb
P02607766A0000|297 307|bovine blood
P02607766A0000|318 341|aqueous spiking-solutions
P02607766A0000|354 358|salts
P02607766A0000|361 362|Cd
P02607766A0000|370 371|Pb
P02609112A0000|0 12|Reagent strips
P02609112A0000|81 92|professional
P02614668A0971|48 52|serum
P02615078A0283|0 22|Precipitating antibodies
P02615078A0283|26 50|Thermophilic actinomycetes
P02615078A0283|56 56|f
P02617623A0740|0 5|LON-72
P02617623A0740|7 16|34 isolates
P02617623A0740|19 24|LON-73
P02617623A0740|41 46|LON-10
P02620085A0656|6 40|experimental and clinical applications
P02620085A0656|59 64|spinal
P02621983T0001|14 37|delta-aminolevulinic acid
P02621983T0001|48 60|clinical tests
P02623038A0632|25 31|FR-task
P02623038A0632|25 26|FR
P02627159A0899|3 30|antigen-specific IgG4 antibody
P02627159A0899|3 30|antigen-specific IgG4 antibody
P02627159A0899|59 82|immunotherapy objectively
P02629109A0000|32 46|black population
P02629109A0000|136 150|black population
P02629109A0000|183 188|1940's
P02630543A0210|35 50|anti-T antibodies
P02630543A0210|35 50|anti-T antibodies
P02630543A0210|55 74|glandular tissue cells
P02630543A0210|91 104|T-, T+, T++, and T
P02630543A0210|191 205|glandular tissue
P02631505A0382|0 13|Ampicillin (AMP
P02631505A0382|43 45|AMI
P02631505A0382|64 64|9
P02631566A0151|0 43|Alkoxymetgyl-3,4-dimethylpyridinium chlorides
P02631566A0151|69 115|3,4-dimethylpyridine with chloromethyl alkyl ethers
P02631566A0151|122 175|1-ethyloxymethyl-3-alkylthiomethylimidazolium chlorides
P02631566A0151|229 253|chloromethyl alkyl sulfides
P02631743A0275|28 52|congenital color deficiency
P02631743A0275|75 103|H-R-R pseudoisochromatic plates
P02631743A0275|75 77|H-R
P02631887A0000|0 13|Eighty patients
P02631887A0000|26 29|HGGM
P02631887A0000|34 55|non-Hodgkin's lymphomas
P02632904A0619|18 31|VE/VO2 and Q/VO2
P02634490A0186|81 82|CT
P02634490A0186|108 125|modern ATB treatment
P02634490A0186|157 171|surgical therapy
P02634872A0000|0 16|Retrograde filling
P02634872A0000|79 94|surgical approach
P02636920T0001|20 70|Japanese Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|0 17|Serological studies
P02637597A0362|68 75|serum ANA
P02637597A0362|68 75|serum ANA
P02637597A0362|77 79|IgA
P02637597A0362|77 79|IgA
P02637597A0362|83 90|IgM level
P02637597A0362|83 85|IgM
P02637597A0362|95 103|normal IgG
P02637597A0362|101 103|IgG
P02637597A0362|117 118|C3
P02637597A0362|117 118|C3
P02637597A0362|122 123|C4
P02637597A0362|122 123|C4
P02638964A0372|3 15|maximum stress
P02638964A0372|24 45|hygroscopic examination
P02638964A0372|51 59|composite
P02638964A0372|91 103|water absorbed
P02638964A0372|109 117|composite
P02641762T0001|0 19|Ischemic heart disease
P02641762T0001|57 78|myocardial scintigraphy
P02641762T0001|93 97|SPECT
P02641762T0001|101 109|bull's eye
P02642466T0000|0 15|Sequence analysis
P02642466T0000|21 54|47-kilodalton major integral membrane
P02642466T0000|66 83|Treponema pallidum.
P02642976A1474|9 26|consensus sequences
P02642976A1474|30 34|early
P02642976A1474|42 59|regulatory elements
P02644735A0427|2 9|FP mutant
P02644735A0427|2 3|FP
P02644735A0427|11 19|AcFP875-2
P02644735A0427|11 19|AcFP875-2
P02644735A0427|43 54|S. frugiperda
P02644735A0427|65 69|5' end
P02644735A0427|95 104|S1 analysis
P02645276T0088|15 32|RIP1 deletion strain
P02645276T0088|15 18|RIP1
P02645276T0088|47 74|temperature-sensitive mutants
P02645431A1562|36 60|type I renal tubular acidosis
P02645431A1562|80 101|proximal tubule function
P02646007T0000|11 36|chronic lymphocytic leukemia
P02646007T0000|38 57|acute myeloid leukemia
P02646007T0000|62 71|thrombosis
P02646007T0000|76 93|protein C deficiency
P02646007T0000|76 83|protein C
P02647403A0000|32 51|other psychopathology
P02647918A0423|21 44|GH and somatomedin-C levels
P02647918A0423|21 22|GH
P02647918A0423|26 38|somatomedin-C
P02647918A0423|75 79|error
P02647918A0588|32 35|cure
P02647918A0588|50 57|patients
P02647918A0588|71 72|GH
P02647918A0588|71 72|GH
P02647918A0588|93 100|patients
P02647918A0588|115 133|somatomedin-C values
P02647918A0588|115 127|somatomedin-C
P02647918A0588|137 144|patients
P02647918A0588|161 173|GH suppression
P02647918A0588|161 162|GH
P02647918A0588|196 199|OGTT
P02647918A0588|206 213|patients
P02647918A0588|281 282|GH
P02647918A0588|281 282|GH
P02647918A0588|293 300|TRH/GnRH
P02647918A0588|293 295|TRH
P02647918A0588|297 300|GnRH
P02647937A0191|21 28|surgical
P02648396A0565|2 12|Rat-1a cells
P02648396A0565|28 41|human c-jun mRNA
P02648396A0565|28 41|human c-jun mRNA
P02648396A0565|82 88|agarose
P02648396A0565|96 101|tumors
P02648396A0565|104 111|nude mice
P02648396A1033|29 43|transformed RECs
P02648396A1033|49 57|c-jun/ras
P02648396A1033|49 53|c-jun
P02648396A1033|55 57|ras
P02648396A1033|92 138|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|64 77|airway response
P02648646A0216|96 116|partial expiratory flow
P02648646A0216|138 141|Vp30
P02648646A0932|39 62|baseline PC40 methacholine
P02648646A0932|82 85|Vp30
P02648646A0932|150 173|platelet activating factor
P02648646A0932|150 173|platelet activating factor
P02649445A0412|4 5|BG
P02649445A0412|4 5|BG
P02649445A0412|9 25|IRI concentrations
P02649445A0412|9 11|IRI
P02649445A0412|35 38|OGTT
P02649445A0412|54 65|body builders
P02649445A0412|99 106|obese men
P02649811T0000|0 22|Postcoital contraception
P02650663A0178|1 9|0.5 rating
P02650663A0178|77 90|senile dementia
P02650663A0178|96 108|Alzheimer type
P02650663A0178|176 183|dementia
P02651448A0000|2 8|implant
P02651448A0000|71 94|polymeric implant material
P02651448A0000|102 117|depolymerization
P02651448A0000|129 138|bioerosion
P02651448A0000|165 169|Type B
P02651487A0000|25 46|calcium channel blockers
P02651487A0000|72 91|vascular smooth muscle
P02651487A0000|126 154|excitation contraction coupling
P02651487A0000|160 174|endocrine glands
P02651487A0000|196 220|insulin and glucagon release
P02651487A0000|196 202|insulin
P02651487A0000|206 213|glucagon
P02655381A0000|49 62|organic factors
P02655381A0000|65 81|erectile impotence
P02655381A0000|209 222|sexual arteries
P02655381A0000|224 241|venous incompetence
P02655381A0000|243 265|subclinical neuropathies
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|74 85|a recombinase
P02656257A0000|75 85|recombinase
P02656257A0000|98 115|crossing-over sites
P02656257A0000|120 142|recombinational enhancer
P02657388A1011|63 76|RNA polymerase I
P02657388A1011|63 76|RNA polymerase I
P02657883A0000|0 9|US-Doppler
P02657883A0000|106 108|FAV
P02657883T0001|0 10|Doppler echo
P02664229A0138|0 15|Improved cosmesis
P02664229A0138|103 131|distal urethrocutaneous fistula
P02664229A0138|155 167|Arap procedure
P02666034A1520|12 19|patients
P02666034A1520|67 83|calcium antagonist
P02666034A1520|88 120|beta-adrenergic reflex vasodilation
P02666034A1520|187 193|therapy
P02666404A0220|3 22|galactose transporter
P02666404A0220|79 95|sugar transporters
P02666404A0220|112 133|human HepG2-erythrocyte
P02666404A0220|137 147|fetal muscle
P02666404A0220|148 166|glucose transporters
P02666404A0220|171 205|rat brain and liver glucose transporters
P02666404A0220|171 186|rat brain and liver
P02666404A0220|187 205|glucose transporters
P02666404A0220|210 251|Escherichia coli xylose and arabinose permeases
P02666404A0220|210 230|Escherichia coli xylose
P02666404A0220|234 251|arabinose permeases
P02666404A0220|259 310|S. cerevisiae glucose, maltose, and galactose transporters
P02666404A0220|259 270|S. cerevisiae
P02666404A0220|271 277|glucose
P02666404A0220|279 285|maltose
P02666404A0220|290 310|galactose transporters
P02666568A0000|24 31|patients
P02666568A0000|55 71|protocol TCL821, 96
P02667259A0331|25 40|adverse reactions
P02667259A0331|42 45|ADRs
P02667259A0331|64 69|nausea
P02667259A0331|92 104|menstrual flow
P02668691A0570|23 26|nagB
P02668691A0570|23 26|nagB
P02668691A0570|30 33|nagA
P02668691A0570|30 33|nagA
P02668691A0570|70 80|distal genes
P02668691A0570|82 92|nagC and nagD
P02668691A0570|82 85|nagC
P02668691A0570|89 92|nagD
P02669199A0000|0 22|Tumor necrosis factor (TNF
P02669199A0000|0 18|Tumor necrosis factor
P02669199A0000|20 22|TNF
P02669199A0000|42 54|shock syndrome
P02669199A0000|78 86|endotoxin
P02669199A0000|88 90|LPS
P02670457T0000|3 9|calcium
P02670457T0000|24 34|hypothermic
P02670457T0000|47 60|cardiac explant
P02674141A1202|3 17|seventh cysteine
P02674141A1202|27 30|CTSE
P02674141A1202|27 30|CTSE
P02674141A1202|49 71|activation peptide region
P02674141A1202|77 85|proenzyme
P02674327A0493|3 11|p34.8 gene
P02674327A0493|3 11|p34.8 gene
P02674327A0493|22 26|codon
P02674327A0493|75 88|polyhedrin gene
P02674327A0493|75 88|polyhedrin gene
P02674671A0601|23 35|transformants
P02674671A0601|76 87|met2 mutation
P02674671A0601|76 87|met2 mutation
P02674671A0601|102 116|wild-type allele
P02674671A0601|102 116|wild-type allele
P02674674A1308|41 57|OBF1-binding sites
P02674674A1308|41 57|OBF1-binding sites
P02674674A1308|64 74|OBF1 protein
P02674674A1308|64 74|OBF1 protein
P02674674A1308|96 106|ARS function
P02674679A1237|12 21|S1 nuclease
P02674679A1237|12 13|S1
P02674679A1237|14 39|nuclease protection analysis
P02674679A1237|42 44|RNA
P02674679A1237|68 79|mouse tissues
P02674679A1237|85 88|dhfr
P02674679A1237|92 105|divergent genes
P02675492A0806|11 18|patients
P02675492A0806|55 77|Ritchie-Index, pain score
P02675492A0806|79 81|ESR
P02675492A0806|79 81|ESR
P02675492A0806|85 87|CRP
P02675492A0806|85 87|CRP
P02677002A0205|8 16|wild-type
P02677002A0205|23 35|mutant enzymes
P02677002A0205|53 60|[14C]Asp
P02677002A0205|74 95|N-carbamyl-L-aspartate
P02677002A0205|85 102|L-aspartate (C-Asp)
P02677002A0205|97 101|C-Asp
P02677002A0205|109 121|[32P]carbamyl
P02677002A0205|132 135|C-P)
P02677002A0205|132 134|C-P
P02677429A0366|0 12|Survival rates
P02677429A0366|93 108|delayed treatment
P02677429A0366|219 222|AIDS
P02677429A0366|270 288|AIDS-related complex
P02677666A0356|88 103|ag alpha 1 mutation
P02677666A0356|88 95|ag alpha 1
P02679804A2000|18 22|ura10
P02679804A2000|26 29|ura3
P02679804A2000|26 29|ura3
P02679804A2000|71 92|orotidine monophosphate
P02680843A0724|21 24|RS 86
P02680843A0724|21 24|RS 86
P02680843A0724|26 35|REM latency
P02684159A0870|0 20|Hybridization analysis
P02684159A0870|43 46|mRNA
P02684159A0870|54 65|1.4 kilobases
P02684585T0001|0 23|Agranulocytosis treatment
P02684585T0001|28 35|rhGM-CSF
P02684585T0001|28 35|rhGM-CSF
P02685331A0523|3 24|R. meliloti nifH promoter
P02685331A0523|13 24|nifH promoter
P02685331A0523|34 57|K. pneumoniae nifH promoter
P02685331A0523|34 45|K. pneumoniae
P02685331A0523|46 57|nifH promoter
P02685331A0523|81 101|methylation protection
P02685331A0523|104 118|guanine residues
P02685331A0523|151 161|nucleotides
P02685331A0523|178 203|sigma 54-dependent promoters
P02685331A0523|178 182|sigma
P02685461A0380|57 64|patients
P02685565A0165|37 53|c-myb-encoded mRNA
P02685565A0165|37 53|c-myb-encoded mRNA
P02685565A0165|118 127|c-myb genes
P02685565A0165|118 127|c-myb genes
P02686588A0592|7 22|clinical analysis
P02686588A0592|49 58|hemoglobin
P02686588A0592|71 73|BUN
P02686588A0592|77 95|alkaline phosphatase
P02686588A0592|77 95|alkaline phosphatase
P02686588A0592|101 112|treated group
P02686749A0000|34 50|early renal changes
P02686749A0000|73 79|cadmium
P02686749A0000|83 89|workers
P02686749A0000|143 158|urinary excretion
P02686749A0000|161 179|beta 2-microglobulin
P02686749A0000|161 179|beta 2-microglobulin
P02686749A0000|182 202|retinol binding protein
P02686749A0000|182 202|retinol binding protein
P02686980A0000|57 75|eukaryotic nucleolus
P02686980A0000|114 122|nucleolar
P02686980A0000|138 142|yeast
P02686980A0000|143 165|Saccharomyces cerevisiae
P02686985A0811|1 33|transcription factor exclusion assay
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|92 104|transcription
P02688772T0000|0 9|Psychiatry
P02688772T0000|16 19|skin
P02689136A1851|5 18|adverse effects
P02689439A0000|3 36|cytosolic glutathione S-transferases
P02689439A0000|12 41|glutathione S-transferases (GSTs
P02689439A0000|38 41|GSTs
P02689439A0000|43 52|EC 2.5.1.18
P02689439A0000|43 44|EC
P02689439A0000|71 87|dimeric isoenzymes
P02689439A0000|117 139|electrophilic substrates
P02689439A0000|144 154|glutathione
P02689439A0402|15 36|3'-untranslated regions
P02689439A0402|39 44|pmGT10
P02689439A0402|80 87|3' region
P02689439A0402|93 102|rat Yb1 gene
P02689439A0402|93 102|rat Yb1 gene
P02689439A0402|121 125|pmGT2
P02689439A0402|121 125|pmGT2
P02689439A0402|177 186|rat Yb2 gene
P02689439A0402|177 186|rat Yb2 gene
P02689544A0456|0 6|Model IV
P02689544A0456|8 23|primary abutments
P02689544A0456|31 44|lateral incisor
P02689544A0456|64 81|secondary abutments
P02691557A0273|14 36|fetal breathing movements
P02691557A0273|122 130|plasma PGE
P02691811A0355|79 91|blood acidosis
P02691811A0355|118 141|bicarbonate concentration
P02691998A0672|128 131|ET-1
P02691998A0672|128 131|ET-1
P02692881A0354|16 34|normal pregnant women
P02692881A0354|44 60|non-pregnant women
P02692881A0354|71 73|PIH
P02692881A0354|123 147|peripheral sympathetic tone
P02692881A0354|174 186|renal function
P02692881A0354|209 221|serum uric acid
P02692881A0354|236 250|sodium excretion
P02692881A0354|272 287|calcium excretion
P02692881A0354|305 319|sodium excretion
P02693208A0166|26 48|recombination- and repair
P02693208A0166|69 72|rad1
P02693208A0166|69 72|rad1
P02693208A0166|76 80|rad52
P02693208A0166|76 80|rad52
P02693208A0166|111 133|transcriptionally active
P02694731A0241|43 60|Parkinson's disease
P02695914T0000|3 19|stereoselectivity
P02700977A0444|0 10|Scotchbond 2
P02700977A0444|69 95|XR bond/Silus Plus combination
P02702566A0000|14 22|cisplatin
P02702566A0000|26 39|5-fluorouracil
P02702566A0000|106 109|head
P02702566A0000|113 116|neck
P02702849A0418|9 28|plasma concentrations
P02702849A0418|55 62|patients
P02702849A0418|125 144|plasma concentrations
P02703121T0000|0 8|Diagnosis
P02703121T0000|11 38|primary sclerosing cholangitis
P02703121T0000|42 51|blood donor
P02703121T0000|64 91|serum alanine aminotransferase
P02703121T0000|64 91|serum alanine aminotransferase
P02703925A0359|65 89|sedimentation coefficients
P02703925A0359|157 179|proteoglycan aggregation
P02703925A0359|183 197|sedimentability
P02703925A0359|227 252|cartilage matrix degradation
P02703925A0359|263 269|S values
P02703925A0359|291 303|high weight (HW
P02703925A0359|345 356|low weight (LW
P02703925A0359|392 413|normal cartilage samples
P02703925A0359|455 460|matrix
P02703925A0359|490 498|HW regions
P02703925A0359|521 535|LW-bearing areas
P02703925A0359|574 591|cartilage thickness
P02703925A0359|661 676|articular surface
P02703925A0359|687 707|deepest cartilage layer
P02703925A0359|806 815|middle zone
P02703925A0359|821 833|normal samples
P02704579A1078|40 48|evolution
P02704579A1078|68 73|CRS/BW
P02704579A1078|77 97|gas exchange parameters
P02704579A1078|99 102|FIO2
P02704579A1078|136 146|gas exchange
P02704579A1078|166 178|lung mechanics
P02705072A0464|42 61|myocardial infarction
P02705072A0464|63 69|MI) rate
P02705296A0231|32 42|polyprotein
P02705296A0231|52 55|ORF1
P02705296A0231|58 74|33 kilodaltons (kDa
P02705556A1049|22 31|RC O2 supply
P02705556A1049|52 62|flow reserve
P02707909A0209|2 18|alternative method
P02707909A0209|21 23|UKM
P02707909A0209|100 107|dialyses
P02708288A0139|0 19|Liquid chromatography
P02708288A0139|46 47|LC
P02708288A0139|49 50|AD
P02708288A0139|49 50|AD
P02708288A0139|125 139|fluazifop-butyl
P02708288A0139|142 162|soybeans and soybean oil
P02708288A0621|3 17|dichloromethane
P02708288A0621|81 85|PRP-1
P02708288A0621|81 83|PRP
P02708288A0621|92 112|chromatographic column
P02708288A0621|114 126|fluazifop acid
P02708288A0621|200 200|V
P02708353A1080|0 25|Primer extension experiments
P02708353A1080|42 68|transcription initiation site
P02708353A1080|149 158|P-450e gene
P02708353A1080|149 158|P-450e gene
P02708353A1452|17 39|polymerase chain reaction
P02708353A1452|63 79|gene IV transcripts
P02708353A1452|98 121|hepatic polysome fractions
P02709081T0000|0 9|Validation
P02709081T0000|54 58|type A
P02709819A0495|32 44|ciprofloxacin
P02711145T0000|0 16|HIV infectiousness
P02711145T0000|23 34|AIDS epidemic
P02711167A0818|14 20|turnout
P02711167A0818|25 33|PFB-group
P02711167A0818|55 75|serum pepsinogen levels
P02711167A0818|60 69|pepsinogen
P02711167A0818|104 117|abomasal damage
P02711601A0601|16 50|inhibition of acid phosphatase activity
P02711601A0601|28 42|acid phosphatase
P02711601A0601|53 82|control male and female guinea pigs
P02712246T0042|3 43|clinical and histopathologic characteristics
P02712450A0989|0 10|Normocapnic
P02712450A0989|83 90|subjects
P02713310T0000|0 12|Fundus changes
P02713310T0000|15 57|(type II) mesangiocapillary glomerulonephritis
P02713310T0000|16 21|type II
P02713520T0000|0 17|Chronic dose effects
P02713520T0000|20 34|methyl parathion
P02713520T0000|48 61|cholinesterase
P02713520T0000|65 79|ptilochronology
P02713994A0482|10 31|anti HSV type 1 and anti HSV
P02713994A0482|10 21|anti HSV type 1
P02713994A0482|25 46|anti HSV type 2 antibodies
P02713994A0482|32 46|type 2 antibodies
P02713994A0482|52 58|mothers
P02713994A0482|63 71|cord blood
P02714525A0529|0 11|Kidney weight
P02714525A0529|15 39|kidney-to-body weight ratio
P02714852T0000|0 15|Allelic variation
P02714852T0000|18 22|HLA-B
P02714852T0000|18 22|HLA-B
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|60 71|HLA-B alleles
P02714852T0000|60 71|HLA-B alleles
P02717133T0001|58 74|oxygen consumption
P02717349A0311|0 2|Men
P02717349A0311|48 52|women
P02718683A0142|0 18|Handgrip dynamometry
P02718683A0142|46 53|patients
P02720966A0455|2 19|cerebrospinal fluid
P02720966A0455|23 25|ADA
P02720966A0455|57 58|mu
P02720966A0455|103 110|patients
P02721169A0171|51 65|tree-like manner
P02723503T0000|0 8|Swim-over
P02723503T0000|32 58|harvesting motile spermatozoa
P02724227T0000|28 48|microvascular free flap
P02724227T0000|60 67|ischemia
P02725495A0929|26 30|U2 RNA
P02725495A0929|26 30|U2 RNA
P02725495A0929|56 85|pre-mRNA branchpoint recognition
P02725495A0929|88 92|yeast
P02725495A0929|115 128|metazoan U2 RNAs
P02725495A0929|123 128|U2 RNAs
P02725495A0929|151 162|trypanosomes
P02725513A0617|71 74|rule
P02725513A0617|79 109|metazoan RNA polymerase I promoters
P02725513A0617|79 100|metazoan RNA polymerase I
P02725513A0617|118 118|G
P02725513A0617|119 125|residue
P02725513A0617|128 138|position -16
P02727909A0383|1 15|raised amplitude
P02727909A0383|34 39|plates
P02727909A0383|86 88|ADP
P02727909A0383|109 115|persons
P02727909A0383|125 127|IIa
P02727909A0383|131 136|IIb HLP
P02727909A0383|142 144|CHD
P02727909A0383|152 154|HLP
P02729666A0267|61 86|dentoskeletal and soft tissue
P02731611A0134|3 8|author
P02731611A0134|77 91|surgical hiccups
P02731611A0134|145 167|Mental Research Institute
P02731671A0000|3 18|relative toxicity
P02731671A0000|21 31|nickel oxide
P02731671A0000|33 35|NiO
P02731671A0000|38 61|nickel sulfate hexahydrate
P02731671A0000|63 67|NiSO4
P02731671A0000|69 72|6H2O
P02731671A0000|95 99|Ni3S2
P02731671A0000|113 135|F344/N rats and B6C3F1 mice
P02732341A0000|0 17|Light microscopical
P02732341A0000|28 53|immunohistochemical studies
P02732341A0000|57 64|cervical
P02732341A0000|109 127|histiocytic lymphoma
P02732341A0000|156 176|chloroacetate esterase
P02732341A0000|156 176|chloroacetate esterase
P02733116T0000|27 32|Health
P02733690T0000|0 15|Molecular cloning
P02733690T0000|43 57|homologous genes
P02733690T0000|67 82|nitrate reductase
P02733690T0000|67 82|nitrate reductase
P02733690T0000|85 91|tobacco
P02735364A1330|32 41|peritoneal
P02735364A1330|69 88|progesterone receptor
P02735364A1330|170 189|disease-free survival
P02736482A0550|26 41|radiation therapy
P02736482A0550|43 57|brain metastases
P02736482A0550|64 68|fatal
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|37 62|steroid receptor superfamily
P02739739T0000|37 62|steroid receptor superfamily
P02740196A0704|2 12|Experiment 2
P02740196A0704|90 102|target numbers
P02740196A0704|107 112|21, ...
P02740347A0644|0 11|Cosmid clones
P02740347A0644|26 38|VNTR sequences
P02740347A0644|57 74|restriction mapping
P02740347A0644|97 100|15 kb
P02740627A0137|3 14|oxygen uptake
P02740627A0137|16 18|VO2
P02740627A0137|41 44|VCO2
P02740627A0137|47 61|respiratory rate
P02740627A0137|63 64|fR
P02740627A0137|63 64|fR
P02740627A0137|67 83|minute ventilation
P02740627A0137|85 107|VE), alveolar ventilation
P02740627A0137|109 110|VA
P02740627A0137|121 134|oxygen pressure
P02740627A0137|136 139|PAO2
P02740627A0137|145 155|VE/VO2 ratio
P02740627A0137|184 194|tidal volume
P02740627A0137|196 197|VT
P02740627A0137|215 223|dead space
P02740627A0137|225 226|VD
P02740627A0137|243 248|horses
P02740874A0957|0 15|Epithelial damage
P02740874A0957|70 72|SO2
P02740955A0333|58 73|unbooked patients
P02743842A0000|64 76|gastric mucosa
P02743842A0000|84 117|hemorrhage-induced stress ulceration
P02743842A0000|149 171|dimethyl prostaglandin E2
P02743842A0000|173 184|16,16-dm PGE2
P02743842A0000|196 221|microscopic lesion formation
P02743842A0000|223 242|intramucosal tissue pH
P02743842A0000|264 279|mucosal blood flow
P02743842A0000|282 297|rat gastric mucosa
P02743842A0000|307 317|luminal acid
P02743842A0000|324 326|HCl
P02743842A0000|334 349|hemorrhagic shock
P02743981A0347|55 58|L11e
P02743981A0347|55 58|L11e
P02743981A0347|62 86|tricistronic L1e-L10e-L12e
P02743981A0347|74 76|L1e
P02743981A0347|78 81|L10e
P02743981A0347|83 86|L12e
P02743981A0347|126 133|NAB-L11e
P02743981A0347|126 128|NAB
P02743981A0347|130 133|L11e
P02743981A0347|137 163|monocistronic NAB transcripts
P02743981A0347|150 163|NAB transcripts
P02743981A0347|181 206|ORF monocistronic transcript
P02743981A0347|181 206|ORF monocistronic transcript
P02744123A0237|55 66|rhesus monkey
P02744123A0237|70 72|man
P02744123A0237|88 103|scotopic branches
P02744490A0894|35 44|cDNA clones
P02744490A0894|54 63|S1 nuclease
P02744490A0894|54 63|S1 nuclease
P02744490A0894|67 88|primer extension studies
P02744490A0894|117 125|PTHrP gene
P02744490A0894|117 125|PTHrP gene
P02744490A0894|144 147|mRNA
P02745280A0276|49 75|arterial and venous blood gases
P02745280A0276|77 102|venous lactate concentration
P02745280A0276|143 160|inorganic phosphate
P02745280A0276|162 176|phosphocreatine
P02745280A0276|196 227|31P magnetic resonance spectroscopy
P02745444A0391|3 29|transcription initiation site
P02745444A0391|45 54|S1 nuclease
P02745444A0391|47 61|nuclease mapping
P02745666A0000|0 18|Endometrial biopsies
P02745666A0000|22 37|plasma oestradiol
P02745666A0000|39 40|E2
P02745666A0000|39 40|E2
P02745666A0000|45 56|progesterone
P02745666A0000|58 59|P4
P02745666A0000|58 59|P4
P02745666A0000|71 78|patients
P02745666A0000|98 117|26 replacement therapy
P02745666A0000|127 149|premature ovarian failure
P02746099A0000|3 10|mobility
P02746099A0000|16 20|upper
P02746099A0000|100 113|occlusal facets
P02747653A0910|1 25|larval albumin-like protein
P02747653A0910|1 25|larval albumin-like protein
P02747653A0910|44 57|silver staining
P02747653A0910|67 74|tadpoles
P02748188A0091|0 11|Behaviorally
P02748188A0091|118 128|Ss) averaged
P02748188A0091|154 169|cold-pressor test
P02748595A0492|17 36|baboon liver class I ADH
P02748595A0492|23 36|liver class I ADH
P02748595A0492|69 81|human ADH-beta
P02748595A0492|69 81|human ADH-beta
P02749215A0000|8 18|proteinuria
P02749215A0000|31 39|hematuria
P02751080A0176|76 77|dB
P02752303A0000|16 30|circadian rhythm
P02752303A0000|33 45|wheel-running
P02752303A0000|64 83|plasma concentrations
P02752303A0000|85 88|0.59
P02752303A0000|110 124|toxic weight loss
P02752629A0163|0 26|Dynamic and static scintigrams
P02752629A0163|33 67|99mtechnetium methylene diphosphonate
P02752629A0163|107 114|fracture
P02752651A0480|67 84|spastic paraparesis
P02752651A0480|136 160|Th 10 and urinary disturbance
P02756731T0001|0 13|Prostaglandins
P02756878A0075|82 89|patients
P02756878A0075|104 114|symptomatic
P02756878A0075|125 126|AF
P02757033A0905|60 66|long arm
P02758382A0478|0 6|Obesity
P02758382A0478|48 73|nonprotein-bound and albumin
P02758382A0478|67 73|albumin
P02758382A0478|80 88|estradiol
P02758382A0478|116 140|sex hormone binding globulin
P02758382A0478|116 140|sex hormone binding globulin
P02758382A0478|142 145|SHBG
P02758382A0478|142 145|SHBG
P02758382A0478|171 174|SHBG
P02758382A0478|171 174|SHBG
P02758382A0478|181 189|estradiol
P02760922A0000|0 56|Heterogeneous nuclear ribonucleoprotein (hnRNP) core protein A1
P02760922A0000|0 12|Heterogeneous
P02760922A0000|13 36|nuclear ribonucleoprotein
P02760922A0000|38 54|hnRNP) core protein
P02760922A0000|55 56|A1
P02760922A0000|76 101|mammalian hnRNP 40 S particles
P02760922A0000|85 89|hnRNP
P02760922A0000|92 101|S particles
P02761008X0000|0 26|Brain cholinesterase activity
P02761008X0000|0 18|Brain cholinesterase
P02761008X0000|37 59|great egrets, snowy egrets
P02761008X0000|63 87|black-crowned night-herons
P02761008X0000|101 119|brain cholinesterase
P02761008X0000|101 119|brain cholinesterase
P02761008X0000|121 132|ChE) activity
P02761008X0000|121 123|ChE
P02761008X0000|198 216|carbamate pesticides
P02761150A0000|11 24|zinc deficiency
P02761150A0000|27 37|trace metals
P02761150A0000|43 47|liver
P02761150A0000|49 54|spleen
P02761150A0000|56 61|kidney
P02761150A0000|63 81|pancreas and duodenum
P02761150A0000|126 129|rats
P02761150A0000|149 157|pregnancy
P02761492A0124|54 71|cardiac involvement
P02761492A0124|74 87|uremic patients
P02761537A0168|0 11|Heating cells
P02761537A0168|60 63|rRNA
P02761537A0168|127 150|transcription termination
P02761537A0168|194 198|3' end
P02761537A0168|201 207|28S rRNA
P02761537A0168|201 207|28S rRNA
P02761537A0168|245 261|transcription unit
P02761540A0873|0 15|Deletion analysis
P02761540A0873|29 34|NF-4FA
P02761540A0873|29 34|NF-4FA
P02761540A0873|36 41|NF-4FB
P02761540A0873|36 41|NF-4FB
P02761540A0873|46 58|AP-1 sequences
P02761540A0873|46 58|AP-1 sequences
P02761540A0873|78 89|full enhancer
P02761540A0873|82 97|enhancer activity
P02762006A0071|4 11|swelling
P02762006A0071|26 33|patients
P02762006A0071|46 60|complete lesions
P02762198T0001|0 13|Reye's syndrome
P02763467A0903|4 58|two-dimensional polyacrylamide gel electrophoretic patterns
P02763467A0903|61 75|[35S]methionine
P02763467A0903|132 149|recombinant viruses
P02763467A0903|202 215|molecular weigh
P02763467A0903|259 264|N1L ORF
P02763467A0903|259 261|N1L
P02763467A0903|262 264|ORF
P02764797A0182|0 4|PULSE
P02764797A0182|20 45|NMR spectroscopic parameters
P02764797A0182|95 101|rf phase
P02764797A0182|124 140|imaging parameters
P02764797A0182|145 174|pulse shape and gradient waveforms
P02765001A0105|8 11|JPsA
P02765001A0105|15 22|patients
P02765001A0105|96 108|psoriatic rash
P02765001A0105|112 120|arthritis
P02765001A0105|173 190|psoriasis-like rash
P02765001A0105|209 217|psoriasis
P02765214A0486|12 24|Kurti's demand
P02766330A0779|90 107|calcium antagonists
P02766508A0421|88 95|IQRST map
P02766745T0000|1 19|hospital-based study
P02766745T0000|52 59|placenta
P02766745T0000|73 81|dairy cows
P02767166A0368|17 33|lipid peroxidation
P02767166A0368|65 78|senile cataract
P02767166A0368|105 117|retinal damage
P02767166A0368|142 149|cataract
P02767166A0368|165 176|severe myopia
P02767733A0690|3 21|histological grading
P02767733A0690|46 47|G1
P02767733A0690|56 57|G3
P02772495A0641|0 5|Asthma
P02772495A0641|45 52|ASA group
P02772495A0641|54 55|91
P02773507A0750|25 25|V
P02773507A0750|75 76|CL
P02773507A0750|167 171|CLunb
P02773930T0000|3 16|solitary kidney
P02773930T0000|26 47|chronic hyperfiltration
P02773930T0000|50 55|humans
P02774271A0000|0 8|Halothane
P02774271A0000|26 41|oxidative pathway
P02774271A0000|74 92|trifluoroacetic acid
P02774271A0000|94 108|TFAA) and bromide
P02774271A0000|120 136|reductive pathways
P02774271A0000|145 161|inorganic fluoride
P02774808A0194|51 56|summer
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|41 75|irregular nocturnal breathing patterns
P02775136A1151|128 130|AMS
P02775136A1151|174 198|abnormal breathing patterns
P02775136A1151|220 222|AMS
P02775333A1137|0 9|Buflomedil
P02775333A1137|13 14|v.
P02775333A1137|48 54|cardiac
P02775333A1137|78 92|biphasic changes
P02776471A0235|80 100|humoral immune response
P02776742A0000|0 8|Heart rate
P02776742A0000|10 11|HR
P02776742A0000|14 30|rectal temperature
P02776742A0000|32 34|Tre
P02776742A0000|37 61|blood pressure, temperature
P02776742A0000|118 136|professional firemen
P02776742A0000|158 160|VO2
P02776742A0000|184 211|wearing fire fighter's uniforms
P02776742A0000|213 214|SU
P02776742A0000|213 214|SU
P02776742A0000|218 227|aluminized
P02776742A0000|229 242|fire resistant,
P02776742A0000|266 269|self
P02776742A0000|279 299|breathing apparatus (FE
P02776823A0000|3 19|clinical tolerance
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|41 48|FCE 22101
P02776823A0000|50 58|sodium (5R
P02776823A0000|60 69|6S)-6-[(1R
P02776823A0000|60 66|6S)-6-[
P02776823A0000|68 127|1R)-hydroxyethyl]-2-carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|134 148|penem antibiotic
P02776823A0000|185 186|v.
P02776823A0000|206 226|healthy male volunteers
P02777797A0720|0 19|DNA blot hybridization
P02777797A0720|35 43|rat genome
P02777797A0720|77 97|PtdIns transfer protein
P02777797A0720|77 82|PtdIns
P02778237A0585|12 37|corticosteroid-dependent IA
P02778237A0585|66 74|chronic IA
P02778237A0585|95 104|prednisone
P02778873A0761|16 19|CRL3
P02778873A0761|16 19|CRL3
P02778873A0761|27 30|-184
P02778873A0761|47 62|enhancer function
P02778873A0761|73 95|tandem repeated sequences
P02778873A0761|97 101|DR-A1
P02778873A0761|97 101|DR-A1
P02778873A0761|105 109|DR-A2
P02778873A0761|105 109|DR-A2
P02779752A0000|0 23|1-(1-Naphthyl)piperazine
P02779752A0000|0 3|1-(1
P02779752A0000|27 28|NP
P02779752A0000|51 69|serotonin antagonist
P02779752A0000|85 96|5-HT2 subtype
P02779752A0000|85 96|5-HT2 subtype
P02779752A0000|99 106|receptor
P02779752A0000|161 169|5-HT1 site
P02779752A0000|161 169|5-HT1 site
P02779752A0776|0 27|1-(m-Chlorophenyl)piperazine
P02779752A0776|29 32|mCPP
P02779752A0776|50 86|1-(m-trifluoromethylphenyl)piperazine
P02779752A0776|88 92|TFMPP
P02779752A0776|135 144|5-HT1 sites
P02779752A0776|194 205|methysergide
P02779752A0776|211 214|1-NP
P02779752A0776|224 233|ketanserin
P02780157A0576|26 30|liver
P02780157A0576|34 39|spleen
P02780157A0576|40 41|MP
P02780157A0576|52 59|patients
P02780157A0576|64 66|VHA
P02780157A0576|81 85|HBsAg
P02780157A0576|81 85|HBsAg
P02780157A0576|120 139|compensatory reaction
P02780157A0576|157 158|MP
P02780157A0576|232 239|MP system
P02780157A0576|254 273|antigenic stimulation
P02780157A0576|276 280|HBsAg
P02780157A0576|276 280|HBsAg
P02781495T0001|9 23|xanthine oxidase
P02781495T0001|9 23|xanthine oxidase
P02781495T0001|34 41|patients
P02781495T0001|46 63|circulatory failure
P02781567A0544|1 4|soap
P02781567A0544|8 12|water
P02781567A0544|18 20|v/v
P02783181A0000|3 16|cytoprotective
P02783181A0000|20 38|antiulcer activities
P02783181A0000|44 69|antacid magaldrate (ES Riopan
P02783181A0000|91 97|gastric
P02783181A0000|98 131|mucosal blood flow and mucus secretions
P02783181A0000|152 154|rat
P02784507A0000|3 33|human immunodeficiency virus type 1
P02784507A0000|3 33|human immunodeficiency virus type 1
P02784507A0000|35 39|HIV-1
P02784507A0000|35 39|HIV-1
P02784507A0000|62 77|CD4+ T lymphocytes
P02784507A0000|62 65|CD4+
P02784507A0000|92 105|latent provirus
P02787430A0124|0 22|Histiocytic panniculitis
P02787430A0124|36 41|biopsy
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|17 45|human 4F2 heavy chain (4F2HC) gene
P02789062A0000|17 34|human 4F2 heavy chain
P02789062A0000|36 40|4F2HC
P02789062A0000|135 148|gene expression
P02789062A0000|161 181|human T-cell activation
P02789062A1420|1 4|cDNA
P02789062A1420|16 43|NF-4FB enhancer binding protein
P02789062A1420|16 43|NF-4FB enhancer binding protein
P02789062A1420|69 89|lambda gt11 cDNA library
P02789062A1420|95 122|rabiolabelled oligonucleotide
P02789062A1420|141 165|NF-4FB recognition sequence
P02789062A1420|141 165|NF-4FB recognition sequence
P02789180A0407|20 46|right ventricular hypertrophy
P02789180A0407|88 95|patients
P02789217A1323|6 19|IL6 mRNA species
P02789217A1323|6 12|IL6 mRNA
P02789217A1323|79 86|distance
P02789217A1323|89 100|1.2 kilobases
P02790009A0375|33 55|0.54- and 0.4-kb fragments
P02790009A0375|77 90|150 nucleotides
P02790009A0375|103 110|5' region
P02790009A0375|116 129|0.4-kb fragment
P02790009A1052|29 65|cysteine-rich, highly hydrophilic region
P02790009A1052|81 103|ovomucoid serine protease
P02790009A1052|90 113|serine protease inhibitors
P02792270A1220|61 88|superficial peroneal responses
P02792270A1220|91 107|flexor motoneurons
P02792270A1220|131 139|amplitude
P02792270A1220|149 160|flexion phase
P02792430A0000|15 23|white rats
P02792430A0000|29 38|guinea pigs
P02792430A0000|65 76|indomethacin
P02792430A0000|97 119|prostaglandins synthesis
P02792430A0000|142 156|pulmonary oedema
P02792430A0000|166 182|heterologous serum
P02792430A0000|185 188|rats
P02792430A0000|204 213|guinea pigs
P02793216A0876|38 63|membrane attachment sequence
P02793216A0876|64 98|arginine-glycine-aspartic acid argues
P02793216A0876|131 133|CgA
P02793216A0876|131 133|CgA
P02793620A0214|9 24|later-parity cows
P02793620A0214|67 90|Charolais and Red Poll bulls
P02793620A0214|93 113|multiple-sire pastures
P02793753A0354|18 29|PA dispersion
P02793753A0354|46 48|CFV
P02793753A0354|77 78|PA
P02793753A0354|107 126|intralobar dispersion
P02794828A0214|91 111|parasystolic pacemaker
P02795923A0000|31 37|basic CT
P02795923A0000|51 71|interstitial pneumonia
P02795923A0000|73 82|radiologic
P02795923A0000|143 147|lungs
P02795923A0000|152 158|autopsy
P02795923A0000|162 168|surgery
P02796216A0063|3 9|disease
P02796216A0063|15 28|atypical course
P02796216A0063|39 54|jaundice syndrome
P02796216A0063|62 74|enterorrhagia
P02796216A0063|94 100|roseola
P02796988A0735|3 21|transcription factor
P02796988A0735|22 24|Sp1
P02796988A0735|22 24|Sp1
P02796988A0735|59 76|footprinting assays
P02796988A0735|80 95|gel shift analysis
P02796988A0735|108 110|Sp1
P02796988A0735|108 110|Sp1
P02797877A0475|30 32|PEF
P02797877A0475|63 79|secondary regrowth
P02797877A0475|102 112|antibiotics
P02798953A0307|13 19|mothers
P02798953A0307|22 35|healthy infants
P02798953A0307|59 75|revised instrument
P02798953A0307|77 81|WPL-R
P02798953A0307|77 81|WPL-R
P02799892A0154|31 38|red cells
P02799892A0154|40 44|WRBCs
P02799892A0154|86 96|transfusion
P02799892A0154|99 106|patients
P02799892A0154|111 113|PNH
P02800417A0332|12 21|asthmatics
P02800417A0332|72 75|PC20
P02800417A0332|76 84|PGF2 alpha
P02800417A0332|88 102|histamine values
P02800435A0000|0 15|Acute experiments
P02800435A0000|18 42|nembutal-anesthetized cats
P02800435A0000|90 115|pulsating magnetic field (PMF
P02800435A0000|119 137|neuromuscular system
P02800435A0000|143 145|leg
P02802280A0495|43 44|TS
P02802280A0495|51 53|PTS
P02805945A0000|118 143|Scripsiella trochoidea Stein
P02805945A0000|268 275|lighting
P02805945A0000|279 292|microEin m-2 s-1
P02806916A0000|1 15|genomic DNA clone
P02806916A0000|24 36|oryzacystatin
P02806916A0000|24 36|oryzacystatin
P02806916A0000|38 39|Oc
P02806916A0000|38 39|Oc
P02806916A0000|43 69|cysteine proteinase inhibitor
P02806916A0000|51 69|proteinase inhibitor
P02806916A0000|71 78|cystatin
P02806916A0000|71 78|cystatin
P02806916A0000|103 125|lambda EMBL3 phage library
P02806916A0000|141 146|Sau3AI
P02806916A0000|163 181|rice chromosomal DNA,
P02806916A0000|199 204|oc cDNA
P02806916A0000|199 204|oc cDNA
P02807780A0143|31 43|methylene blue
P02807780A0143|55 58|NaCl
P02807780A0143|88 104|premalignant areas
P02807780A0143|108 110|CIS
P02809116A0237|74 92|husbands' retirement
P02809116A0237|127 131|wives
P02809651A0492|37 49|meta-analysis
P02809651A0492|59 83|clinicians and policy makers
P02809722A0926|5 22|acromegalic patient
P02809722A0926|67 77|GH secretion
P02809722A0926|67 68|GH
P02809831A0799|14 21|PPSF + DBP
P02809831A0799|46 58|bone formation
P02810911A0372|3 12|accuracies
P02810911A0372|34 46|neuroblastoma
P02810911A0372|66 81|131I-MIBG imaging
P02810911A0372|92 103|tumor markers
P02811378A0250|3 17|congenital forms
P02811378A0250|39 51|female infants
P02811378A0250|66 71|mucosa
P02811378A0250|90 102|anterior ridge
P02811378A0379|0 25|Immunohistochemical studies
P02811378A0379|53 63|S100 protein
P02811378A0379|53 63|S100 protein
P02811378A0379|72 89|granular cell tumors
P02811378A0379|114 143|congenital granular cell epulides
P02813369A0390|22 26|males
P02813369A0390|118 134|familiar neighbors
P02813404T0000|0 19|Male-enhanced antigen
P02813404T0000|13 23|antigen gene
P02813404T0000|77 91|spermatogenesis
P02814182A1211|2 5|rats
P02814182A1211|13 42|Walker-256-carcinosarcoma 4-EPI
P02814820A0967|107 118|Billroth dogs
P02814820A0967|215 220|solids
P02815229A0139|96 109|[14C]diltiazem
P02816251A0397|3 35|subepicardial lymphatic capillaries
P02817724A0075|25 26|T1
P02817724A0075|30 40|T2 sequences
P02817724A0075|56 61|planes
P02818122A0000|99 118|neuronal distribution
P02818122A0000|142 155|cerebral cortex
P02818122A0000|164 169|nuclei
P02820128A1333|61 80|hexanucleotide ATTGTT
P02820128A1333|89 103|flanking regions
P02820128A1333|106 117|dyad symmetry
P02820128A1333|136 141|ORF T3C
P02820128A1333|136 141|ORF T3C
P02820128A1670|22 39|palindromic domains
P02820128A1670|46 48|ORF
P02820128A1670|94 103|palindrome
P02820128A1670|166 171|B chain
P02820128A1670|174 180|insulin
P02820128A1670|174 180|insulin
P02820128A1670|196 206|palindromes
P02820128A1670|219 227|T2 protein
P02820128A1670|219 220|T2
P02820128A1670|239 253|functional units
P02821340A0434|26 28|DCR
P02821340A0434|34 35|UT
P02821340A0434|54 65|resting value
P02821340A0434|81 83|Hg X
P02821340A0434|109 121|Hg X ml-1 X min-1
P02821340A0434|142 146|speed
P02822081A1034|0 0|7
P02824334A0972|23 41|G-protein gene family
P02824334A0972|23 41|G-protein gene family
P02825139A0661|16 18|DNA
P02825139A0661|59 78|nucleic acid sequences
P02825750A0260|13 20|patients
P02826127A0709|50 65|SV40 octamer motif
P02826127A0709|72 105|lymphoid cell-specific protein oct-B2
P02826127A0709|72 99|lymphoid cell-specific protein
P02826127A0709|100 105|oct-B2
P02826127A0709|152 166|nuclear extracts
P02826127A0709|178 194|lymphoid cell lines
P02826717A0179|41 53|water deprived
P02826717A0179|56 61|oxygen
P02826717A0179|76 84|water flow
P02826729A0790|0 5|Growth
P02826729A0790|9 10|PA
P02826729A0790|14 16|14C
P02826729A0790|42 43|WB
P02826729A0790|57 65|B-6 intake
P02826729A0790|73 76|rats
P02828926A1870|13 27|myogenic factors
P02828926A1870|88 124|different and complex modulatory programs
P02828926A1870|127 145|actin gene expression
P02828926A1870|127 135|actin gene
P02828926A1870|166 186|muscle differentiation
P02829183A0117|0 18|DNA sequence analysis
P02829183A0117|66 76|translocase
P02829183A0117|66 76|translocase
P02830214A0000|11 23|acetazolamide
P02830214A0000|25 27|ACZ
P02830214A0000|31 51|HCO3- and Cl- activities
P02830214A0000|54 66|inner ear fluid
P02830214A0000|84 117|ion-selective microelectrode methods
P02830265A0341|0 5|RPA190
P02830265A0341|0 5|RPA190
P02830265A0341|32 45|186,270 daltons
P02830265A0341|54 78|uninterrupted reading frame
P02830282A0155|13 21|A1 protein
P02830282A0155|13 21|A1 protein
P02830282A0155|51 60|UP1 protein
P02830282A0155|51 60|UP1 protein
P02830282A0155|76 106|Staphylococcus aureus V-8 protease
P02830282A0155|76 106|Staphylococcus aureus V-8 protease
P02830282A0155|119 130|polypeptides
P02830282A0155|133 144|92 amino acids
P02831398A0346|0 6|Irmiere
P02831556A0173|19 27|alpha-MSH
P02831556A0173|19 27|alpha-MSH
P02831556A0173|35 41|mothers
P02831556A0173|109 116|morphine
P02831796A0000|0 26|Simian immunodeficiency virus
P02831796A0000|28 30|SIV
P02831796A0000|49 61|morphological
P02831796A0000|88 113|human immunodeficiency virus
P02831796A0000|134 165|acquired immunodeficiency syndrome
P02831796A0000|167 170|AIDS
P02831796A0000|174 179|humans
P02832149A1009|30 47|two spliced products
P02832149A1009|81 96|5'-rearranged myb
P02832149A1009|81 96|5'-rearranged myb
P02832149A1009|140 152|121 amino acids
P02832149A1009|158 177|larger myb transcripts
P02832149A1009|164 177|myb transcripts
P02832149A1009|197 220|tumor-specific activation
P02832149A1009|226 241|mouse myb oncogene
P02832149A1009|226 241|mouse myb oncogene
P02832293T0000|8 13|CRF-41
P02832293T0000|8 10|CRF
P02832293T0000|42 58|Cushing's syndrome
P02832744A0403|10 23|mos transcripts
P02832744A0403|26 46|Northern (RNA) analyses
P02832744A0403|64 70|chicken
P02832744A0403|74 85|quail ovaries
P02832744A0403|89 94|testes
P02833012A0428|3 11|predicted
P02833012A0428|12 16|L mRNA
P02833012A0428|12 16|L mRNA
P02833012A0428|20 34|6398 nucleotides
P02833012A0428|58 73|open reading frame
P02833012A0428|91 98|L protein
P02833012A0428|91 98|L protein
P02833012A0428|130 131|MW
P02833021A1185|58 68|72-bp repeat
P02833021A1185|80 105|transcriptional enhancement
P02833021A1185|111 123|early promoter
P02833021A1185|111 123|early promoter
P02833021A1185|154 173|late promoter function
P02833021A1185|154 165|late promoter
P02833049A0630|0 9|Variations
P02833049A0630|23 24|U3
P02833049A0630|23 24|U3
P02833049A1041|26 34|RNA levels
P02833049A1041|37 55|T-lymphoid cell lines
P02833049A1041|87 115|incomplete proviral transcripts
P02833049A1041|167 176|RD-114 mRNA
P02833049A1041|167 176|RD-114 mRNA
P02833049A1041|220 231|proviral loci
P02833049A1041|286 300|feline cell types
P02833101T0000|0 34|Aplastic crisis in sickle cell disorders
P02833101T0000|36 53|bone marrow necrosis
P02833101T0000|57 80|human parvovirus infection
P02833517A0467|88 94|diffuse
P02834478A0000|3 17|molecular weight
P02834478A0000|97 104|Xa factor
P02834478A0000|97 104|Xa factor
P02834843A0000|3 14|bactericidal
P02834843A0000|31 50|rifamycin derivatives
P02834843A0000|63 65|RBU
P02834843A0000|68 75|FCE 22250
P02834843A0000|77 79|F22
P02834843A0000|82 92|rifapentine
P02834843A0000|94 96|RPE
P02834843A0000|99 106|CGP 29861
P02834843A0000|108 110|C29
P02834843A0000|113 119|CGP 7040
P02834843A0000|121 123|C70
P02834843A0000|128 135|CGP 27557
P02834843A0000|137 139|C27
P02834843A0000|144 158|rifampicin (RMP)
P02834843A0000|211 229|sterilising activity
P02834843A0000|263 287|Mycobacterium tuberculosis
P02834843A0000|289 293|H37Rv
P02836623A1094|0 10|Mo + SV M-MuLV
P02836623A1094|84 94|Mo + SV M-MuLV
P02837575A0979|0 20|Sodium dodecyl sulphate
P02837575A0979|39 62|eukaryotic topoisomerase I
P02837575A0979|49 62|topoisomerase I
P02837575A0979|106 113|3' cut end
P02837763A0259|0 16|Amino acid sequence
P02837763A0259|22 36|human liver clone
P02837763A0259|22 36|human liver clone
P02837763A0259|38 42|HL-14
P02837763A0259|38 42|HL-14
P02837763A0259|61 97|rabbit skeletal muscle phosphatase 2A cDNA
P02837763A0259|61 66|rabbit
P02837763A0259|81 93|phosphatase 2A
P02837763A0259|94 97|cDNA
P02837763A0259|106 123|nucleotide identity
P02838246A0225|0 19|Herpes virus infection
P02838246A0225|52 56|T4/T8
P02838246A0225|110 122|proliferation
P02838246A0225|128 142|T8 subpopulation
P02838246A0225|176 183|patients
P02838246A0225|188 202|rejection crises
P02838319A0527|0 3|RVEF
P02838710A0299|11 16|NPY-ir
P02838710A0299|11 13|NPY
P02838710A0299|22 35|rat vas deferens
P02838710A0299|59 66|surgical
P02838710A0299|69 92|pharmacological treatment
P02839488A1314|0 17|Quantitative assays
P02839488A1314|41 57|synthetic alpha s-1
P02839488A1314|41 57|synthetic alpha s-1
P02839488A1314|91 114|human erythrocyte type-1 Gs
P02839488A1314|91 112|human erythrocyte type-1
P02839488A1314|113 114|Gs
P02839488A1314|177 181|error
P02839716A0673|13 22|E2 proteins
P02839716A0673|13 14|E2
P02839716A0673|86 99|HPV-11 enhancer
P02839716A0673|86 91|HPV-11
P02839716A0673|92 112|enhancer-SV40 promoter
P02839716A0673|101 112|SV40 promoter
P02839716A1907|19 22|E2-C
P02839716A1907|19 22|E2-C
P02839716A1907|32 59|E2-dependent enhancer activity
P02839716A1907|32 51|E2-dependent enhancer
P02839716A1907|93 94|E2
P02839716A1907|114 142|transcriptional regulatory site
P02840034A1266|41 62|unresectable lung cancer
P02840034A1266|88 104|prognostic factors
P02840376A0461|1 8|anti-IIa
P02840376A0461|6 8|IIa
P02843495A0544|14 18|v-fms
P02843495A0544|14 18|v-fms
P02843495A0544|24 61|CSF-1 dependent murine macrophage cell line
P02843495A0544|24 28|CSF-1
P02843495A0544|90 103|tumorigenicity
P02843495A0544|107 127|nonautocrine mechanism
P02843694T0001|0 23|Chronic E-B virus infection
P02843694T0001|36 52|malignant lymphoma
P02844767A0191|42 51|petCA genes
P02844767A0191|42 51|petCA genes
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|74 95|nuclear encoded in plants
P02844767A0191|74 80|nuclear
P02844767A0191|90 95|plants
P02844767A0191|100 121|apocytochrome f proteins
P02844767A0191|100 121|apocytochrome f proteins
P02844767A0596|9 18|petBD genes
P02844767A0596|9 18|petBD genes
P02844767A0596|43 50|psbB gene
P02844767A0596|43 50|psbB gene
P02844767A0596|63 92|51-kDa photosystem II polypeptide
P02844767A0596|63 92|51-kDa photosystem II polypeptide
P02844767A0596|109 115|introns
P02844767A0596|137 152|chloroplast genes
P02844767A1022|0 20|RNA blot hybridizations
P02844767A1022|33 38|1.8-kb
P02844767A1022|39 42|mRNA
P02844767A1022|51 62|cytochrome b6
P02844767A1022|51 62|cytochrome b6
P02844797A1225|10 22|muscle isoform
P02844797A1225|33 45|997 amino acids
P02844797A1225|66 73|sequence
P02844797A1225|74 85|Ala-Ile-Leu-
P02844797A1225|86 88|Glu
P02844797A1225|176 195|50-amino acid sequence
P02844797A1225|218 236|transmembrane domain
P02844797A1225|270 294|N-linked glycosylation site
P02845654A0510|15 30|threonine residue
P02845654A0510|35 48|alanine residue
P02845654A0510|59 63|-2 (P2
P02845654A0510|123 137|tyrosine residue
P02845654A0510|141 160|phenylalanine residue
P02845654A0510|180 184|-1 (P1
P02845654A0510|183 184|P1
P02845654A0510|191 202|cleavage site
P02846640A0643|8 31|indigo-producing bacteria
P02846640A0643|37 54|indoxyl phosphatase
P02846640A0643|37 54|indoxyl phosphatase
P02846852A1459|11 21|polymerases
P02846852A1459|40 54|E strand promoter
P02846852A1459|40 54|E strand promoter
P02846852A1459|78 88|polymerases
P02846852A1459|94 108|L strand promoter
P02846852A1459|94 108|L strand promoter
P02848842A0643|9 20|RNA molecules
P02848842A0643|26 41|2.0-2.2-kilobase
P02849100A0441|7 17|hydrophobic
P02849100A0441|40 65|carboxyl-terminal extremity
P02849100A0441|103 108|anchor
P02849100A0441|114 127|plasma membrane
P02849759A0865|3 14|SV40 enhancer
P02850472A0112|42 55|DNA replication
P02850967T0000|11 27|proto-oncogene fos
P02850967T0000|11 27|proto-oncogene fos
P02850967T0000|51 66|adenylate cyclase
P02850967T0000|51 66|adenylate cyclase
P02850967T0000|94 115|cAMP-responsive element
P02850967T0000|94 115|cAMP-responsive element
P02850971A0180|1 26|17-mer oligodeoxynucleotide
P02850971A0180|55 75|VtHb amino acid sequence
P02850971A0180|55 75|VtHb amino acid sequence
P02850971A0180|113 138|Vitreoscilla genomic library
P02850971A0180|168 179|cosmid vector
P02850971A0180|180 185|pVK102
P02852805A0216|1 18|total soluble solids
P02852894T0000|0 5|Causes
P02852894T0000|60 71|Thai villages
P02853799T0001|16 52|non-A, non-B hepatitis to chronic diseases
P02853799T0001|16 20|non-A
P02853799T0001|76 98|hepatocellular carcinoma
P02853922A0596|24 31|patients
P02856622T0001|10 22|thyroglobulin
P02856622T0001|10 22|thyroglobulin
P02856622T0001|52 75|differentiated carcinomas
P02856622T0001|81 87|thyroid
P02859434T0000|0 11|Poor response
P02859434T0000|45 49|serum
P02859434T0000|50 56|lithium
P02861067A0000|45 64|nebulized ipratropium
P02861067A0000|67 74|patients
P02861067A0000|79 89|acute asthma
P02861067A0000|151 161|beta agonist
P02861144A0242|21 31|DNA fragment
P02861144A0242|46 50|genes
P02861144A0242|87 97|21 and 89 kDal
P02861238T0000|0 11|Hantaan virus
P02862656T0000|9 35|dopamine receptor sensitivity
P02862656T0000|38 43|humans
P02862656T0000|49 66|heavy alcohol intake
P02863492A0544|102 128|platelet-associated IgG index
P02863492A0544|102 123|platelet-associated IgG
P02863492A0544|193 202|responders
P02863747T0000|18 29|histone genes
P02863747T0000|18 29|histone genes
P02863747T0000|37 56|intervening sequences
P02865502T0000|40 70|tissue-type plasminogen activator
P02865502T0000|51 70|plasminogen activator
P02865502T0000|86 110|acute myocardial infarction
P02868446A0184|3 19|C-terminal domains
P02868446A0184|3 19|C-terminal domains
P02868446A0184|21 24|CTDs
P02868446A0184|21 24|CTDs
P02868446A0184|31 46|RPase beta subunit
P02868446A0184|31 46|RPase beta subunit
P02868446A0184|50 59|DNA primase
P02868446A0184|50 59|DNA primase
P02868446A0184|61 71|dnaG protein
P02868446A0184|61 71|dnaG protein
P02868446A0184|147 156|RPase alpha
P02868446A0184|147 156|RPase alpha
P02868446A0184|174 196|alpha subunit-like enzyme
P02868446A0184|174 196|alpha subunit-like enzyme
P02868446A0184|228 245|core enzyme subunits
P02868446A0184|249 255|primase
P02868446A0184|249 255|primase
P02868848A0167|21 30|fosfomycin
P02868848A0167|62 73|bactericidal
P02868848A0167|114 114|G
P02868848A0167|154 164|gas gangrene
P02869125A0120|0 7|Fentanyl
P02869125A0120|20 43|mu-opiate receptor agonist
P02869125A0120|20 36|mu-opiate receptor
P02869125A0120|118 137|locomotor stimulation
P02869125A0120|146 156|tachycardia
P02869125A0120|171 188|behavioural arousal
P02870249T0000|0 23|Intravesical chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870720A0188|33 59|beta-adrenoceptor antagonist
P02870720A0188|33 49|beta-adrenoceptor
P02870720A0188|64 72|pA2 values
P02870720A0188|104 117|guinea pig atria
P02870851A0349|0 5|Output
P02870851A0349|8 15|99mTcO-4
P02870851A0349|62 82|parotid saliva flow rate
P02872786A0147|3 26|Hagen-Poiseuille equation
P02872786A0147|61 69|parasites
P02872786A0147|84 93|Leishmania
P02872786A0147|114 122|blood flow
P02873593A0581|33 38|T-maze
P02873593A0581|68 90|delayed-but-large reward
P02873593A0581|92 94|BZP
P02873593A0581|141 153|delayed reward
P02873593A0581|168 171|5-HT
P02874078A0252|13 33|luteal phase deficiency
P02874078A0252|64 71|patients
P02874635T0000|0 15|Prenatal exposure
P02874635T0000|21 36|fungicide dinocap
P02874635T0000|43 63|behavioral torticollis
P02874635T0000|91 94|mice
P02874635T0000|108 115|hamsters
P02875224A1059|0 10|Reperfusion
P02875224A1059|15 25|normal blood
P02875224A1059|39 51|working hearts
P02875224A1059|58 82|extensive structural damage
P02875224A1059|91 96|reflow
P02875967A0377|67 76|guinea pigs
P02875967A0377|97 109|fertility rate
P02876820A0841|2 18|metabolic acidosis
P02876899A0568|2 6|Days 1
P02876899A0568|17 39|young and elderly subjects
P02876899A0568|73 102|bevantolol plasma concentrations
P02876899A0568|118 122|phase
P02877124A0000|12 16|B6AF1
P02877124A0000|20 29|B6D2F1 mice
P02877124A0000|39 55|acidified tap water
P02877124A0000|58 72|promethazine HCl
P02877124A0000|92 101|H1 receptor
P02877124A0000|92 93|H1
P02877124A0000|120 135|chlorpheniramine
P02877124A0000|139 147|H1 blocker
P02877124A0000|139 140|H1
P02877124A0000|151 165|trifluoperazine
P02877124A0000|187 204|H1 blocking activity
P02877124A0000|187 188|H1
P02877124A0000|213 225|drinking water
P02877124A0000|255 272|bone mineral content
P02877124A0000|317 334|whole body retention
P02877124A0000|337 363|Tc 99m methylene diphosphonate
P02877124A0000|365 369|Tc 99m
P02877124A0000|370 372|MDP
P02877124A0000|387 400|bone metabolism
P02877124A0000|464 469|sacrum
P02878100A0674|52 73|ganglionic transmission
P02878100A0674|128 146|sympathetic activity
P02878100A0674|163 190|normal ganglionic transmission
P02879906A0000|52 57|rabbit
P02879906A0000|93 127|beta adrenoceptor subtype distribution
P02879906A0000|93 108|beta adrenoceptor
P02879906A0000|129 149|intrinsic myogenic tone
P02879906A0000|164 179|nerve innervation
P02879951T0000|13 33|antihypertensive agent
P02879951T0000|35 42|SGB-1534
P02879951T0000|46 67|rat platelet aggregation
P02880841A0313|19 21|TF1
P02880841A0313|19 21|TF1
P02880841A0313|73 75|TF1
P02880841A0313|73 75|TF1
P02880841A0313|104 114|beta subunit
P02880841A0313|104 114|beta subunit
P02880841A0313|132 149|nucleotide sequence
P02880841A0313|190 193|beta
P02880841A0313|220 223|F1's
P02880841A0313|220 223|F1's
P02880841A0313|246 257|chloroplasts
P02880841A0313|262 273|mitochondria
P02882893A0301|0 14|Body temperature
P02882893A0301|88 99|nominative sp
P02883327A0413|48 54|early (E
P02883327A0413|54 61|E) region
P02883327A0413|67 74|viral DNA
P02883871A1075|9 11|ISA
P02883871A1075|26 39|" beta receptors
P02883871A1075|26 39|" beta receptors
P02883871A1075|95 114|drug hypersensitivity
P02883871A1075|140 142|ISA
P02883963A0000|3 10|patients
P02883963A0000|15 47|human T-cell lymphotropic virus type I
P02883963A0000|15 47|human T-cell lymphotropic virus type I
P02883963A0000|49 80|HTLV-I)-associated myelopathy (HAM
P02883963A0000|49 54|HTLV-I
P02883963A0000|95 119|electrophysiologic methods
P02884860A0329|0 8|Terazosin
P02884860A0329|29 36|prazosin
P02884860A0329|50 68|alpha 1 adrenoceptors
P02884860A0329|50 68|alpha 1 adrenoceptors
P02884860A0329|104 110|therapy
P02885517T0000|7 17|blood donors
P02885517T0000|21 25|non-A
P02885517T0000|27 40|non-B hepatitis
P02889352A0000|4 11|patients
P02889352A0000|16 32|high blood pressure
P02889352A0000|34 35|BP
P02889352A0000|34 35|BP
P02889352A0000|82 127|diuretic, beta blocker, converting enzyme inhibitor
P02889352A0000|130 146|calcium antagonist
P02890200T0001|0 30|Somatostatin-producing endocrine
P02890200T0001|31 45|pancreatic tumor
P02890200T0001|48 80|Recklinghausen's neurofibromatosis
P02892762A0296|9 22|inverted repeat
P02892762A0296|48 60|22 nucleotides
P02892762A0296|73 84|promoter site
P02894689A0000|51 64|chromatin loops
P02894689A0000|79 102|novel extraction procedure
P02894689A0000|110 119|lithium-3'
P02894689A0000|121 139|5'-diiodosalicylate
P02894741A0000|0 10|Seventy-one
P02894741A0000|31 40|vecuronium
P02894741A0000|52 67|muscle relaxation
P02894741A0000|75 88|22-h-long NLA II
P02894789A0954|58 59|T1
P02894789A0954|61 62|T0
P02894789A0954|66 67|T4
P02894789A0954|66 67|T4
P02894789A0954|69 70|T1
P02895472A0178|11 27|bacterial colonies
P02895472A0178|43 61|recombinant plasmids
P02895472A0178|72 75|cDNA
P02895472A0178|85 87|BiP
P02895472A0178|85 87|BiP
P02895566A0187|0 2|DPA
P02895566A0187|43 75|ischemic and pressure pain components
P02895566A0187|90 97|ischemia
P02895754A0000|0 7|Topical 1
P02895754A0000|15 27|isoproterenol
P02895754A0000|46 71|phosphodiesterase inhibitor
P02895754A0000|72 83|theophylline
P02895754A0000|126 141|aqueous humor flow
P02895754A0000|152 166|anterior chamber
P02895754A0000|217 224|human eye
P02895754A0000|226 241|Horner's syndrome
P02897651A0000|0 14|Hyperthyroidism
P02897651A0000|41 51|infertility
P02897651A0000|55 71|recurrent abortion
P02898752A0683|43 58|CFU-GM transfused
P02898752A0683|71 82|granulocytes
P02898752A0683|86 94|platelets
P02899177A0605|97 109|antipsychotic
P02899177A0605|112 129|antiepileptic drugs
P02899177A0605|152 164|limbic regions
P02899792T0000|0 23|Oestrogen implant overdose
P02900760A0073|64 87|transcription termination
P02900760A0073|90 108|RNA polymerase I (pol I
P02900760A0073|90 103|RNA polymerase I
P02900760A0073|105 108|pol I
P02900760A0073|124 151|cell-free transcription system
P02900760A0073|180 201|rDNA minigene constructs
P02900760A0073|206 213|3T6 cells
P02901498A0354|37 50|mutant proteins
P02901498A0354|37 50|mutant proteins
P02901498A0354|74 93|wild-type erbB protein
P02901498A0354|74 93|wild-type erbB protein
P02901498A0354|142 158|embryo fibroblasts
P02901763A0977|12 24|C. reinhardtii
P02901763A0977|25 36|mitochondria
P02901763A0977|88 106|protein-coding genes
P02901763A0977|88 106|protein-coding genes
P02901763A0977|126 130|codon
P02901763A0977|162 174|C. reinhardtii
P02901763A0977|175 179|mtDNA
P02901763A0977|210 214|tRNAs
P02901763A0977|230 258|mitochondrial protein synthesis
P02902615A0000|33 64|HBV-related polyarteritis inspired
P02902615A0000|91 113|chronic active hepatitis B
P02902615A0000|126 133|patients
P02902656A0481|4 16|scrotal testes
P02902656A0481|18 34|undescended testes
P02902656A0481|52 54|fat
P02902656A0481|91 92|TR
P02902656A0481|91 92|TR
P02902656A0481|101 107|time (TE
P02902656A0481|149 151|fat
P02902656A0481|154 171|long TR/TE sequences
P02902844A1219|48 65|hydrophobic protein
P02902844A1219|99 108|atp operons
P02902844A1219|111 116|E. coli
P02902844A1219|118 145|bacterium PS3 and cyanobacteria
P02902927A0145|29 40|bovine and rat
P02902927A0145|38 49|rat GHF-1 cDNA
P02902927A0145|41 45|GHF-1
P02902927A0145|46 55|cDNA clones
P02903500A0278|53 55|neu
P02903500A0278|53 55|neu
P02903500A0278|67 76|fusion gene
P02903500A0278|89 105|cytoplasmic domain
P02903500A0278|108 110|neu
P02903500A0278|108 110|neu
P02903500A0278|116 135|extracellular portion
P02903500A0278|140 163|immunoglobulin heavy chain
P02903500A0278|140 163|immunoglobulin heavy chain
P02904322A0002|3 28|East African dik-dik antelope
P02906027A0553|54 70|5'-terminal region
P02906027A0553|54 70|5'-terminal region
P02906027A0553|92 100|CpG island
P02906027A0553|128 143|CpG dinucleotides
P02906027A1156|42 67|G + C-rich conserved sequences
P02906027A1156|80 90|first intron
P02906249A1195|100 105|Oxy-Hb
P02906249A1195|100 102|Oxy
P02906249A1195|104 105|Hb
P02906249A1195|108 116|PGF2 alpha
P02906673T0000|0 7|Efficacy
P02906673T0000|28 58|Bacillus thuringiensis (H-14) and B
P02906673T0000|50 53|H-14
P02906673T0000|77 96|floodwater mosquitoes
P02907308T0001|8 24|type II tyrosinosis
P02907308T0001|26 48|Richner-Hanhart syndrome
P02907533A0362|4 7|loss
P02907533A0362|24 40|drug concentration
P02907533A0362|90 114|free diazepam concentration
P02907533T0000|44 58|diazepam binding
P02907533T0000|61 72|human albumin
P02907533T0000|61 72|human albumin
P02909528A1081|1 22|second promoter activity
P02909528A1081|60 89|major transcriptional start sites
P02910496A0583|1 15|decamer sequence
P02910496A0583|17 33|5'-CGA-CCCCUCC-3'
P02910496A0583|51 67|conserved sequence
P02910496A0583|107 131|mitochondrial RNA substrate
P02910496A0583|147 158|RNAase MRP RNA
P02910496A0583|147 158|RNAase MRP RNA
P02910989T0000|9 40|aging and beta-adrenergic-blockade
P02910989T0000|59 71|QT/QS2 changes
P02911540A0478|1 7|patient
P02911540A0478|47 51|hands
P02911540A0478|65 72|perineum
P02913368A1037|0 18|Pharmacology studies
P02913368A1037|23 39|potassium chloride
P02913368A1037|67 73|raveron
P02913368A1037|81 97|calcium antagonist
P02913368A1037|132 138|calcium
P02914422A0409|24 39|digital averaging
P02914422A0409|51 66|digital filtering
P02914422A0409|152 156|slurs
P02914492A0183|16 22|ICU, 117
P02914492A0183|23 30|patients
P02914492A0183|60 64|serum
P02914492A0183|88 95|patients
P02914492A0183|148 155|patients
P02916764A0253|29 31|sex
P02916764A0253|33 44|hypertension
P02916764A0253|46 61|diabetes mellitus
P02916764A0253|63 82|hypercholesterolemia
P02916764A0253|84 99|cigarette smoking
P02918474A0817|7 15|verapamil
P02918474A0817|46 64|myocardial blood flow
P02918474A0817|126 138|subepicardium
P02919483A0091|20 24|girls
P02919530A0000|0 9|Controlled
P02919530A0000|16 38|uncontrolled reperfusion
P02919530A0000|41 58|ischemic myocardium
P02919530A0000|64 98|experimental coronary artery occlusion
P02919530A0000|139 153|ventricular wall
P02919832A0144|0 13|Cardiac disease
P02919832A0144|32 37|M-mode
P02919832A0144|63 96|pulsed-wave Doppler echocardiography
P02920591A0251|92 99|dopamine
P02923687A0218|71 78|patients
P02923687A0218|83 103|unilateral cleft palate
P02925013A1112|59 74|intestinal tissue
P02925568A0460|35 51|routine conditions
P02925568A0460|147 169|maternal psychopathology
P02926499A0340|62 66|brain
P02926499A0340|107 109|CBF
P02926499A0340|107 109|CBF
P02926499A0340|125 127|CBF
P02926499A0340|129 139|Cb/(tau rho c
P02926499A0340|154 160|thermal
P02926499A0340|192 196|blood
P02926499A0340|201 201|c
P02927391A0238|49 69|founder SWR/J-RF/J mice
P02927391A0238|159 174|viral integration
P02927391A0238|218 232|somatic lineages
P02928112T0000|0 15|Molecular cloning
P02928112T0000|21 24|cDNA
P02928112T0000|31 60|human U2 snRNA-specific A' protein
P02928112T0000|36 60|U2 snRNA-specific A' protein
P02928376A0312|28 36|saturated
P02928376A0312|56 57|H2
P02928376A0312|56 57|H2
P02928376A0312|80 89|heat defect
P02929056T0000|73 90|anastomotic failure
P02930623A0404|6 20|flexion whiplash
P02934778A0702|29 54|5-HT2 serotonergic receptors
P02934778A0702|29 54|5-HT2 serotonergic receptors
P02934778A0702|60 74|bronchial artery
P02934889A0558|0 10|Oxfendazole
P02934889A0558|50 51|65
P02934889A0558|71 77|grazing
P02934891A0845|20 35|DNA-footprinting
P02934891A0845|41 54|impure extracts
P02934891A0845|57 77|ner overproducing cells
P02934891A0845|107 122|ner-binding sites
P02934891A0845|107 122|ner-binding sites
P02934891A0845|140 161|nucleotides 1026 and 1058
P02934891A0845|169 177|Mu left end
P02935638A0000|49 57|Spec1 gene
P02935638A0000|49 57|Spec1 gene
P02935638A0000|63 99|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 15|Platelet function
P02936163T0000|19 55|platelet-polymorphonuclear-neutrophil
P02936163T0000|69 76|patients
P02936163T0000|90 117|platelet lipoxygenase activity
P02936163T0000|90 109|platelet lipoxygenase
P02936284A0357|11 21|degradation
P02936284A0357|36 41|plasma
P02936284A0357|72 74|man
P02938185A0223|0 19|Transformed cell lines
P02938185A0223|36 53|E1a or E1a and E1b gene
P02938185A0223|36 38|E1a
P02938185A0223|41 43|E1a
P02938185A0223|47 53|E1b gene
P02938185A0223|100 126|anchorage-independent growth
P02938185A0223|166 189|cytoskeletal architecture
P02938185A0223|213 224|fibroblastic
P02938185A0223|225 233|CREF cells
P02939260A1553|7 41|N-terminal amino acid sequence analysis
P02939260A1553|55 72|43K and 42K T antigens
P02939260A1553|55 57|43K
P02939260A1553|61 63|42K
P02939260A1553|64 72|T antigens
P02939260A1553|80 89|methionine
P02939260A1553|92 99|residues
P02939260A1553|104 104|5
P02939260A1553|124 134|DNA sequence
P02939260A1553|145 154|methionine
P02939260A1553|173 183|39K T antigen
P02939260A1553|173 183|39K T antigen
P02940334A0141|38 61|hepatitis B immune globulin
P02940334A0141|38 61|hepatitis B immune globulin
P02940334A0141|63 66|HBIG
P02940334A0141|63 66|HBIG
P02941237A0160|32 43|serum calcium
P02941237A0160|47 74|phosphorous ion concentrations
P02941237A0160|76 83|tissue pH
P02941237A0160|85 95|blood supply
P02941237A0160|97 104|hormones
P02941237A0160|111 127|vitamin D, vitamin A
P02941237A0160|139 145|enzymes
P02941237A0160|152 188|alkaline phosphatase and pyrophosphatase
P02941237A0160|152 170|alkaline phosphatase
P02941237A0160|174 188|pyrophosphatase
P02941237A0160|212 220|ancillary
P02943562T0000|0 22|Penicillinase production
P02943562T0000|0 12|Penicillinase
P02943562T0000|25 51|Staphylococcus aureus strains
P02947866A1416|91 109|myocardial perfusion
P02947866A1416|115 133|coronary angioplasty
P02949170A0184|56 71|ethinyl estradiol
P02949170A0184|78 95|cyproterone acetate
P02949170A0184|98 110|gonadotropins
P02949170A0184|98 110|gonadotropins
P02949170A0184|112 120|prolactin
P02949170A0184|112 120|prolactin
P02949170A0184|122 133|testosterone
P02949170A0184|135 159|sex hormone binding globulin
P02949170A0184|135 159|sex hormone binding globulin
P02949170A0184|161 164|SHBG
P02949170A0184|161 164|SHBG
P02949170A0184|196 216|free testosterone index
P02950216A0084|10 13|flow
P02950216A0084|31 51|laser Doppler flowmetry
P02950216A0084|53 55|LDF
P02950216A0084|69 80|output signal
P02950216A0084|82 98|blood cell flux (BCF
P02950216A0084|121 125|volts
P02957125A0601|6 13|patients
P02957125A0601|18 49|renal failure routine haemodialysis
P02957125A0601|87 108|plasma ANP concentration
P02957125A0601|93 95|ANP
P02958204A0175|25 36|isotretinoin
P02958204A0175|39 41|HDL
P02958204A0175|39 41|HDL
P02958204A0175|53 57|HDL-C
P02958204A0175|53 55|HDL
P02958204A0175|59 74|HDL phospholipids
P02958204A0175|59 61|HDL
P02958204A0175|76 81|HDL-PL
P02958204A0175|76 81|HDL-PL
P02958204A0175|84 95|apoprotein A1
P02958204A0175|97 102|apo A-1
P02958204A0175|97 102|apo A-1
P02958204A0175|108 124|HDL-C subfractions
P02958204A0175|108 112|HDL-C
P02958204A0175|126 131|HDL2-C
P02958204A0175|126 131|HDL2-C
P02958204A0175|135 140|HDL3-C
P02958204A0175|135 140|HDL3-C
P02958204A0175|146 165|healthy, male patients
P02958204A0175|191 202|isotretinoin
P02958204A0175|237 248|acne vulgaris
P02958233A0123|60 80|serum sickness reaction
P02958660A1094|63 71|LDF signal
P02959089T0000|0 15|Preventive effect
P02959089T0000|18 25|ONO-3708
P02959089T0000|28 37|thrombosis
P02960012A0838|14 24|PPNG strains
P02962859A0276|0 21|Monospecific antibodies
P02962859A0276|36 66|beta-galactosidase fusion protein
P02962859A0276|36 53|beta-galactosidase
P02962859A0276|75 79|clone
P02962859A0276|94 117|U1 snRNP-specific A antigen
P02962859A0276|94 117|U1 snRNP-specific A antigen
P02963517A0453|0 19|Quantitative analysis
P02963517A0453|25 40|coronary stenosis
P02963517A0453|66 69|PTCA
P02963517A0453|77 86|dilatation
P02964329A0000|24 40|Joint Mobility (LJM
P02964329A0000|44 51|diabetes
P02964329A0000|125 139|microangiopathy
P02966671A0151|104 112|stem cells
P02966671A0151|118 131|duodenal crypts
P02966671A0551|0 8|Schedule 2
P02966671A0551|25 29|c-DDP
P02966671A0551|62 66|X-ray
P02966671A0551|124 138|radiation effect
P02966671A0551|255 266|fractionated
P02966671A0551|272 283|radiotherapy
P02967496A0182|3 25|cpc-1-encoded transcript
P02967496A0182|3 25|cpc-1-encoded transcript
P02967496A0182|39 55|open reading frames
P02967496A0182|82 108|720-nucleotide leader segment
P02967496A0182|121 125|cpc-1
P02967496A0182|121 125|cpc-1
P02967915A0000|22 44|1,25-dihydroxyvitamin D3
P02967915A0000|76 96|calcium binding protein
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|129 141|target tissues
P02967915A0968|14 35|calbindin-D28K promoter
P02967915A0968|14 35|calbindin-D28K promoter
P02967915A0968|58 80|simple repeated sequences
P02968055A0984|3 5|HOI
P02968055A0984|38 40|ANF
P02968055A0984|38 40|ANF
P02968055A0984|46 52|elderly
P02969316A0002|46 65|plasma concentrations
P02969316A0002|68 91|atrial natriuretic peptide
P02969316A0002|68 91|atrial natriuretic peptide
P02969316A0002|93 95|ANP
P02969316A0002|93 95|ANP
P02969316A0002|118 140|plasma ANP concentrations
P02969316A0002|124 126|ANP
P02969316A0002|159 186|chloralose-anaesthetized dogs
P02969819A0814|0 19|Ig D-JH recombinations
P02969819A0814|0 2|Ig D
P02969819A0814|4 5|JH
P02969819A0814|30 49|TcR gene recombination
P02969819A0814|30 36|TcR gene
P02969819A0814|57 71|early T cell lines
P02969819A0814|96 116|sterile Cmu transcripts
P02969819A0814|103 116|Cmu transcripts
P02970061A0271|3 11|RAD18 gene
P02970061A0271|3 11|RAD18 gene
P02970061A0271|12 27|open reading frame
P02970061A0271|45 57|487 amino acids
P02970061A0271|74 88|molecular weight
P02970640A0341|0 15|Atomic absorption
P02970640A0341|42 52|bacterially
P02970640A0341|62 72|E1A proteins
P02970640A0341|62 72|E1A proteins
P02970640A0341|88 107|289-amino acid protein
P02970640A0341|88 107|289-amino acid protein
P02970640A0341|116 122|zinc ion
P02970640A0341|134 153|243-amino acid protein
P02970640A0341|134 153|243-amino acid protein
P02970640A0341|161 164|zinc
P02971603A0883|53 56|v 200
P02971603A0883|76 78|104
P02971710A0734|0 4|Plots
P02971710A0734|7 8|RV
P02971710A0734|10 13|LV + S
P02971710A0734|17 18|2A
P02971710A0734|134 147|CO cardiomegaly
P02971957A0287|3 27|absorbable perisplenic mesh
P02973304A0000|20 38|Budd-Chiari syndrome
P02973304A0000|53 62|thrombosis
P02973304A0000|68 77|portal vein
P02973304A0000|103 113|male patient
P02973304A0000|127 156|postmyocarditic cardiosclerosis
P02975680A0000|32 44|EEG recordings
P02975680A0000|91 109|drug-free inpatients
P02975680A0000|131 145|anxiety disorder
P02975680A0000|147 149|GAD
P02975680A0000|197 212|sex-matched group
P02975680A0000|215 222|patients
P02975680A0000|227 229|GAD
P02975680A0000|248 270|major depressive disorder
P02975680A0000|272 274|MDD
P02975680A0000|276 283|patients
P02975753A1333|0 14|Oligonucleotide
P02975753A1333|33 46|binding domains
P02975753A1333|76 100|transcriptional regulation
P02975753A1333|106 115|E3 promoter
P02975753A1333|106 115|E3 promoter
P02975753A1333|118 127|yeast cells
P02976332A1277|18 21|PGI2
P02979426T0000|0 19|Organ transplantation
P02979426T0000|22 28|Denmark
P02979834T0000|26 32|maltose
P02979834T0000|47 59|immunotherapy
P02979834T0000|61 76|cyclophosphamide
P02979834T0000|77 88|chemotherapy
P02979834T0000|92 103|radiotherapy
P02979834T0000|106 110|ethyl
P02979834T0000|131 147|primary lung cancer
P02979834T0000|150 152|A/J
P02979834T0000|153 156|mice
P02981840A0907|45 72|purine-pyrimidine nucleotides
P02981840A0907|90 90|d
P02981840A0907|92 101|AC) repeats
P02981840A0907|92 93|AC
P02982332T0001|14 18|VP-16
P02982332T0001|14 18|VP-16
P02982332T0001|20 26|capsule
P02982332T0001|30 40|solid tumors
P02983316A0310|7 20|coding segments
P02983316A0310|62 80|-determining regions
P02983316A0310|100 119|murine probe sequences
P02983316A0310|133 146|metric analysis
P02983316A0310|224 240|mammalian sequence
P02983316A0310|224 240|mammalian sequence
P02983316A0310|281 298|nucleotide sequence
P02983331T0000|18 56|endogenous corticotropin-releasing factor
P02983331T0000|28 56|corticotropin-releasing factor
P02983331T0000|59 83|cold, ether, immobilization
P02983331T0000|88 102|traumatic stress
P02985812A0984|23 38|replicative genes
P02985812A0984|48 58|smaller mRNA
P02985812A0984|72 91|long open reading frame
P02985812A0984|97 106|larger mRNA
P02985820A1287|57 65|c-myc gene
P02985820A1287|57 65|c-myc gene
P02985820A1287|97 121|oncogenic retroviruses CMII
P02985820A1287|123 126|MC29
P02985820A1287|130 132|MH2
P02986279A0000|53 60|delivery
P02986279A0000|91 105|cytomegalovirus
P02986279A0000|107 109|CMV
P02987220A0472|31 52|8.5-kilobase (kb) insert
P02987220A0472|72 82|DNA fragment
P02987220A0472|110 117|FBP+ gene
P02987220A0472|110 117|FBP+ gene
P02987220A0472|124 139|regulatory region
P02987777A0000|12 42|primary signet-ring cell carcinoma
P02988457A0650|56 72|Bestatin treatment
P02988457A0650|88 97|malignancy
P02989637A0671|44 50|adrenal
P02989637A0671|51 65|zona glomerulosa
P02989637A0671|66 79|corticosteroid
P02989637A0671|83 101|renal renin secretion
P02989637A0671|83 92|renal renin
P02989637A0671|112 119|patients
P02989637A0671|128 149|spinal cord transections
P02989637A0671|171 184|neural pathways
P02989637A0671|192 211|central nervous system
P02989637A0671|227 251|metoclopramide stimulation
P02989637A0671|254 264|aldosterone
P02989637A0671|268 281|renin secretion
P02989637A0671|268 272|renin
P02989637A0671|284 286|men
P02989786A0328|14 30|enhancer sequences
P02989786A0328|35 51|adenovirus E1A gene
P02989786A0328|35 51|adenovirus E1A gene
P02989786A0328|67 81|CATase synthesis
P02989786A0328|67 72|CATase
P02991060A0465|5 17|IgG antibodies
P02991060A0465|5 17|IgG antibodies
P02991060A0465|23 28|babies
P02991060A0465|51 58|delivery
P02991060A0465|118 123|babies
P02993630A1190|17 31|nucleotide level
P02993630A1190|66 75|nuclease S1
P02993630A1190|66 75|nuclease S1
P02993630A1190|118 125|sequence
P02993630A1190|127 132|G-A)12
P02993630A1190|127 129|G-A
P02993630A1190|145 163|complementary strand
P02994253A0482|25 39|mean NTE activity
P02994253A0482|29 31|NTE
P02994253A0482|42 51|spinal cord
P02994253A0482|78 82|brain
P02994253A0482|157 166|spinal cord
P02994253A0482|230 241|dosed animals
P02994336A0864|0 1|FK
P02994336A0864|10 30|methionine-enkephalin
P02994336A0864|50 59|plasma ACTH
P02994336A0864|56 59|ACTH
P02994336A0864|67 76|basal level
P02994336A0864|83 102|bromocriptine (CB-154
P02995967T0000|0 27|A v-erbB-related protooncogene
P02995967T0000|1 27|v-erbB-related protooncogene
P02995967T0000|29 36|c-erbB-2
P02995967T0000|29 36|c-erbB-2
P02995967T0000|55 93|c-erbB-1/epidermal growth factor-receptor
P02995967T0000|55 62|c-erbB-1
P02995967T0000|64 97|epidermal growth factor-receptor gene
P02995967T0000|133 146|adenocarcinoma
P02995999A0000|3 18|sequence analysis
P02995999A0000|45 53|phi 80 site
P02995999A0000|50 81|site-specific recombination events
P02995999A0000|115 133|secondary attachment
P02995999A0000|135 142|att) site
P02995999A0000|241 257|base-pair deletion
P02995999A0000|269 287|recombination events
P02995999A0000|310 337|single base-pair substitutions
P02997622A0916|4 16|L-myc sequence
P02997622A0916|4 16|L-myc sequence
P02997622A0916|44 59|SCLC cell line DNAs
P02997622A0916|72 85|tumour specimen
P02997622A0916|104 110|patient
P02997777A0609|33 55|synchronously grown cells
P02997777A0609|59 92|delta top1 top2 temperature-sensitive
P02997777A0609|59 67|delta top1
P02997777A0609|68 95|top2 temperature-sensitive (ts
P02997777A0609|94 108|ts) double mutant
P02997777A0609|123 134|top2 ts strain
P02997777A0609|123 128|top2 ts
P02997777A0609|186 197|top2 ts mutant
P02997777A0609|186 197|top2 ts mutant
P02997777A0609|269 277|cell death
P02997777A0609|283 291|delta top1
P02997777A0609|283 291|delta top1
P02997777A0609|292 309|top2 ts double mutant
P02997777A0609|292 309|top2 ts double mutant
P02998016A0527|13 17|v-mil
P02998016A0527|13 17|v-mil
P02998016A0527|33 46|coding sequence
P02998016A0527|49 60|exon 1 and ends
P02998016A0527|70 89|3' untranslated region
P02998016A0527|92 97|exon 11
P02998016A0527|129 141|nonsense codon
P02998016A0527|190 202|c-mil and v-mil
P02998016A0527|190 194|c-mil
P02998016A0527|198 202|v-mil
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|78 97|hydrophobic sequences
P02998043A1199|108 119|19-amino acid
P02998043A1199|121 136|carboxy-proximal
P02998043A1199|138 154|hydrophobic region
P02999267A0606|8 10|FAP
P02999267A0606|15 32|primary amyloidosis
P02999267A0606|41 74|diffusely positive myocardial uptakes
P02999267A0606|111 117|sternum
P02999267A0885|14 29|myocardial uptake
P02999267A0885|32 41|Tc-99m-PYP
P02999267A0885|44 51|patients
P02999267A0885|73 98|left ventricular hypertrophy
P02999267A0885|105 136|highly refractile myocardial echoes
P02999267A0885|147 177|granular sparkling appearance (GS)
P02999267A0885|206 213|patients
P02999267A0885|225 245|myocardial hypertrophy
P02999267A0885|249 250|GS
P03000457A1554|72 77|125 kDa
P03000457A1554|79 100|alpha') and 83 kDa (beta')
P03000457A1554|79 85|alpha')
P03000457A1554|89 99|83 kDa (beta'
P03000489A0822|0 18|Alveolar lymphocytes
P03000489A0822|50 57|patients
P03000489A0822|62 65|AIDS
P03000489A0822|98 100|CGL
P03000489A0822|172 187|blood lymphopenia
P03001054A0703|59 69|mutant sites
P03001084A0406|28 51|4024-base pair (bp) segment
P03001084A0406|72 73|5'
P03001084A0406|79 85|cap site
P03001084A0406|88 102|alpha 1 to 207 bp 3'
P03001084A0406|88 93|alpha 1
P03001084A0406|105 112|psi alpha
P03001084A0406|105 112|psi alpha
P03001086A0587|3 28|predicted amino acid sequence
P03001086A0587|60 74|Drosophila hsp70
P03001086A0587|60 69|Drosophila
P03001086A0587|70 74|hsp70
P03001086A0587|76 85|trout hsp70
P03001086A0587|81 85|hsp70
P03001086A0587|87 98|Xenopus hsp70
P03001086A0587|87 93|Xenopus
P03001086A0587|94 98|hsp70
P03001086A0587|100 109|yeast hsp70
P03001086A0587|105 109|hsp70
P03001086A0587|131 159|heat-inducible dnaK gene product
P03001086A0587|131 152|heat-inducible dnaK gene
P03001086A0587|162 176|Escherichia coli
P03001110A0546|4 18|phosphorylation
P03001110A0546|21 46|exogenous peptide substrates
P03001110A0546|71 98|receptor self-phosphorylation
P03001110A0546|100 121|tyrosine kinase activity
P03001110A0546|100 113|tyrosine kinase
P03001110A0546|166 174|phosphate
P03001353A0146|42 49|6m2 cells
P03001353A0146|57 62|P58gag
P03001353A0146|57 62|P58gag
P03001353A0146|78 93|4.0-kilobase (kb)
P03001353A0146|94 107|viral RNA genome
P03001353A0146|111 130|P85gag-mos translated
P03001353A0146|111 116|P85gag
P03001353A0146|118 120|mos
P03001353A0146|149 152|mRNA
P03001645A0785|3 7|pet56
P03001645A0785|3 7|pet56
P03001645A0785|11 19|his3 genes
P03001645A0785|11 19|his3 genes
P03001705T0000|0 22|Multistep transformation
P03001705T0000|43 68|herpes simplex virus type 2 DNA
P03001705T0000|43 65|herpes simplex virus type 2
P03001952A0958|19 26|patients
P03001952A0958|43 55|genital herpes
P03001952A0958|66 68|HSV
P03001952A0958|139 147|acyclovir
P03002501A1327|23 27|ovine
P03002501A1327|31 36|bovine
P03002501A1327|38 40|rat
P03002501A1327|44 72|guinea-pig alpha s1-casein mRNAs
P03002501A1327|44 53|guinea-pig
P03002501A1327|68 72|mRNAs
P03002501A1327|120 137|5' non coding regions
P03003695A0395|32 45|c-sis cDNA clone
P03003695A0395|32 40|c-sis cDNA
P03003695A0395|70 76|748-750
P03003695A0395|105 113|DNA region
P03003695A0395|129 139|5' c-sis exon
P03003695A0395|149 154|1050 bp
P03004364A0775|47 50|5-FU
P03004364A0775|52 54|ADM
P03004364A0775|58 60|MMC
P03004364A0775|63 68|FAMLIP
P03004364A0775|81 85|FULIP
P03004364A0775|87 92|ADRLIP
P03004364A0775|96 101|MMCLIP
P03004739A0753|18 29|transversion
P03004739A0753|52 69|CAT pentanucleotide
P03004739A0753|52 69|CAT pentanucleotide
P03004739A0753|108 116|promoters
P03004739A0753|148 164|CAT binding protein
P03004739A0753|148 164|CAT binding protein
P03004982A0199|3 20|nucleotide sequence
P03004982A0199|31 63|cloned R. sphaeroides chromosomal DNA
P03004982A0199|82 100|structural genes fbcF
P03004982A0199|97 100|fbcF
P03004982A0199|102 105|fbcB
P03004982A0199|102 105|fbcB
P03004982A0199|109 112|fbcC
P03004982A0199|109 112|fbcC
P03004982A1094|3 20|N-terminal sequence
P03004982A1094|26 43|hydrophilic peptide
P03004982A1094|49 58|FeS protein
P03004982A1094|49 58|FeS protein
P03004982A1094|91 106|fbcF reading frame
P03004982A1094|91 94|fbcF
P03005231A0649|3 30|5' and 3' untranslated sequences
P03005231A0649|174 196|overlapping -10 sequences
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|6 12|P135gag
P03006066A0653|14 20|myb-ets
P03006066A0653|55 59|c-myb
P03006066A0653|55 59|c-myb
P03006066A0653|61 68|P75c-myb
P03006066A0653|61 68|P75c-myb
P03006066A0653|79 93|nuclear proteins
P03006066A0653|95 102|P54c-ets
P03006066A0653|95 102|P54c-ets
P03007281A0905|3 13|Dox-A2 locus
P03007281A0905|3 8|Dox-A2
P03007281A0905|37 56|Df(2L)OD15 breakpoint
P03007281A0905|37 56|Df(2L)OD15 breakpoint
P03007281A0905|74 82|vital loci
P03008094A0697|3 15|C-terminal end
P03008405A0532|7 15|outbreaks
P03008405A0532|18 30|ocular disease
P03008405A0532|39 51|red deer calves
P03008405A0532|60 64|HVC-1
P03008405A0532|60 64|HVC-1
P03009366A0438|7 21|ultrastructural
P03009366A0438|59 75|Type II pneumocytes
P03009366A0438|94 102|radiation
P03009366A0438|118 127|surfactant
P03009826A0201|47 55|dimer unit
P03009826A0201|61 66|repeat
P03010281A0220|14 18|72-bp
P03010281A0220|54 67|gene expression
P03011793A0582|3 19|open reading frames
P03011793A0582|22 25|rbsD
P03011793A0582|22 25|rbsD
P03011793A0582|27 30|rbsA
P03011793A0582|27 30|rbsA
P03011793A0582|35 38|rbsC
P03011793A0582|35 38|rbsC
P03011793A0582|69 85|amino acid residues
P03013477A0000|28 31|iron
P03013477A0000|45 85|polymorphonuclear leucocyte (PMN) metabolism
P03013477A0000|88 95|patients
P03013477A0000|98 116|chronic hemodialysis
P03013477A0000|130 144|superoxide anion
P03013477A0000|152 154|PMN
P03013477A0000|191 210|hemodialyzed patients
P03013477A0000|239 249|individuals
P03013477A0000|254 258|serum
P03013477A0000|259 266|ferritin
P03013477A0000|259 266|ferritin
P03013477A0000|306 316|individuals
P03013477A0000|321 325|serum
P03013477A0000|326 333|ferritin
P03013477A0000|326 333|ferritin
P03013841A0207|0 7|Cattaneo
P03014515T0000|0 24|Human alpha-galactosidase A
P03014515T0000|0 24|Human alpha-galactosidase A
P03014515T0000|26 43|nucleotide sequence
P03014515T0000|47 55|cDNA clone
P03014593A0681|0 7|Diazepam
P03014593A0681|29 37|Ro 11-6896
P03014593A0681|67 74|Ro 5-4864
P03015611A0331|3 19|amino acid sequence
P03015611A0331|60 75|lysine residue 721
P03015611A0331|94 108|ATP-binding site
P03015611A0331|94 108|ATP-binding site
P03015628A1078|0 35|Osteocalcin (and urinary hydroxyproline
P03015628A1078|0 10|Osteocalcin
P03015628A1078|54 81|isolated hyperphosphatasaemia
P03015628A1078|125 136|bone turnover
P03015628A1078|169 200|serum alkaline phosphatase activity
P03015628A1078|169 192|serum alkaline phosphatase
P03015953T0000|10 47|glucocorticoid unresponsive cell variants
P03015953T0000|59 101|glucocorticoid receptor complementary DNA clone
P03016301A0605|8 18|v-myc codons
P03016301A0605|8 12|v-myc
P03016301A0605|55 64|5' terminus
P03016301A0605|76 97|c-myc exon, and 412 codons
P03016301A0605|76 80|c-myc
P03016301A0605|113 129|c-myc coding region
P03016301A0605|113 117|c-myc
P03016506A0611|1 17|recombinant vector
P03016506A0611|19 23|p410+
P03016506A0611|54 68|BamHI-K fragment
P03016506A0611|54 68|BamHI-K fragment
P03016506A0611|70 86|nucleotides 107565
P03016506A0611|100 110|B95-8 strain
P03016506A0611|123 156|EBV-associated nuclear antigen EBNA-1
P03016506A0611|123 156|EBV-associated nuclear antigen EBNA-1
P03016506A0611|162 179|cis-acting sequence
P03016506A0611|187 201|BamHI-C fragment
P03016506A0611|187 201|BamHI-C fragment
P03016506A0611|243 247|G-418
P03016883A0000|2 4|men
P03016883A0000|19 73|recurrent genital herpes simplex virus type 2 (HSV-2) infection
P03016883A0000|35 57|herpes simplex virus type 2
P03016883A0000|59 63|HSV-2
P03017225A0706|9 27|carcinoma presenting
P03017225A0706|29 41|leather bottle
P03017225A0706|43 61|linitis plastica type
P03017225A0706|68 74|stomach
P03017225A0706|87 94|c portion
P03017225A0706|100 106|stomach
P03017225A0706|118 129|fundic glands
P03017225A0706|131 155|undifferentiated carcinoma
P03017996A0731|31 48|mutant polypeptides
P03017996A0731|53 65|signal peptide
P03017996A0731|106 119|nascent protein
P03017996A0731|140 146|X2 and X3
P03018491A0840|3 16|hexanucleotide
P03018491A0840|17 28|5'-TGTCCT-3'
P03018491A0840|53 63|GRE activity
P03018491A0840|102 118|5'-flanking region
P03018491A0840|147 151|3' end
P03019505A0390|4 11|patients
P03019505A0390|21 36|metastatic spread
P03020001A0781|16 30|mini-Mu elements
P03020001A0781|37 52|7.9 kilobase pairs
P03020001A0781|96 112|31.1 kilobase pairs
P03020001A0781|135 151|21.7 kilobase pairs
P03020001A0781|197 213|17.3 kilobase pairs
P03020513T0000|3 12|52-protein
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|57 68|gyrA-protein
P03020513T0000|57 68|gyrA-protein
P03020513T0000|71 76|gyrase
P03021050A0501|32 43|quantitation
P03021050A0501|46 54|sulbactam
P03021088A0135|55 71|anastomotic ulcers
P03021088A0135|78 96|subtotal gastrectomy
P03021088A0135|101 116|Billroth's type II
P03022129A0842|3 13|nucleosomal
P03022129A0842|30 38|MPE X Fe(II
P03022129A0842|30 38|MPE X Fe(II
P03023067A0779|0 10|Translation
P03023067A0779|21 33|cellular genes
P03023067A0779|41 73|chimeric viral-cellular transcripts
P03023067A0779|41 73|chimeric viral-cellular transcripts
P03023679A0624|3 17|molecular weight
P03023679A0624|70 95|in vitro-translated proteins
P03023679A0624|112 140|posttranslational modification
P03023682A0271|11 13|4 bp
P03023682A0271|21 37|SV40 early promoter
P03023682A0271|21 37|SV40 early promoter
P03023682A0271|48 94|chloramphenicol acetyltransferase (CAT) expression
P03023682A0271|48 79|chloramphenicol acetyltransferase
P03023682A0271|81 83|CAT
P03023859A0000|14 58|Ph1-positive chronic myelocytic leukemia patients
P03023859A0000|86 97|chromosome 22
P03023859A0000|102 114|Ph1 chromosome
P03023859A0000|150 176|bcr (breakpoint cluster region
P03023859A0000|150 152|bcr
P03023887A0470|0 19|Nuclease footprinting
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|116 144|tandemly repeated sequence motif
P03023887A0470|156 157|Sa
P03023970A0922|5 13|-bp insert
P03023970A0922|55 74|premature termination
P03023970A0922|113 115|p53
P03023970A0922|113 115|p53
P03023970A0922|124 133|amino acids
P03024343A0372|3 8|tumors
P03024343A0372|33 46|neuroendocrine
P03024703A1036|17 31|2385 nucleotides
P03024703A1036|64 76|795 amino acids
P03024703A1036|114 126|hsp108 protein
P03024703A1036|114 126|hsp108 protein
P03025606T0000|0 28|Transcriptional control signals
P03025606T0000|32 70|herpes simplex virus type 1 late (gamma 2) gene
P03025606T0000|32 54|herpes simplex virus type 1
P03025606T0000|60 70|gamma 2) gene
P03025606T0000|85 93|-34 to +124
P03025606T0000|107 116|5' terminus
P03025606T0000|122 125|mRNA
P03025655T0000|33 66|cytoplasmic protein-tyrosine kinases
P03025655T0000|33 66|cytoplasmic protein-tyrosine kinases
P03025655T0000|78 91|kinase function
P03025655T0000|117 143|Fujinami sarcoma virus P130gag
P03025655T0000|117 136|Fujinami sarcoma virus
P03025655T0000|137 147|P130gag-fps
P03025655T0000|145 147|fps
P03025661A0260|0 6|Gluzman
P03025862A0860|7 10|exon
P03025862A0860|21 49|carboxyl-terminal 26 amino acids
P03025862A0860|55 62|ssd chain
P03025862A0860|55 62|ssd chain
P03025862A0860|69 88|3' untranslated region
P03025862A0860|94 97|mRNA
P03025862A0860|110 117|poly(A)-
P03026915A1024|3 27|5'-nontranslated sequences
P03026915A1024|41 55|coding sequences
P03026915A1024|65 74|yeast genes
P03026915A1024|107 123|lacZ fusion vectors
P03026915A1024|107 110|lacZ
P03027661A0000|0 12|Two activities
P03027661A0000|18 25|D protein
P03027661A0000|31 42|miniF plasmid
P03027779A0000|0 15|SPECT examination
P03027779A0000|21 23|TMJ
P03027779A0000|29 34|99m Tc-
P03027779A0000|35 37|MDP
P03027779A0000|54 61|patients
P03027779A0000|89 116|anterior dislocation of the disc
P03027779A0000|124 130|normals
P03027905A0632|0 18|Plasma renin activity
P03027905A0632|0 10|Plasma renin
P03027905A0632|29 50|plasma aldosterone level
P03029111A0155|40 62|pet complementation group
P03031602A1001|16 33|homologous elements
P03031602A1001|48 61|upstream region
P03032143A0218|13 24|S. cerevisiae
P03032143A0218|44 46|DNA
P03032143A0218|61 65|150 bp
P03032143A0218|147 166|specific conformation
P03032143A0218|172 180|chromatin
P03032143A0218|185 200|yeast kinetochore
P03032964T0000|0 19|Constitutive function
P03033283A0837|11 25|NF1-binding loci
P03033283A0837|11 25|NF1-binding loci
P03033283A0837|54 61|IE68 gene
P03033283A0837|54 61|IE68 gene
P03033283A0837|64 67|HCMV
P03033283A0837|69 73|Towne
P03033283A0837|95 143|DNA sequence and competition filter binding experiments
P03033283A0837|177 197|consensus binding sites
P03033283A0837|213 235|promoter-enhancer region
P03033283A1415|32 74|13- to 18-base-pair interspersed repeat elements
P03033283A1415|179 210|tandemly repeated NF1-binding sites
P03033283A1415|195 210|NF1-binding sites
P03033283A1415|284 291|SCMV IE94
P03033283A1415|284 291|SCMV IE94
P03033283A1415|304 311|HCMV IE68
P03033283A1415|304 311|HCMV IE68
P03034570A0943|44 84|bacterial chloramphenicol acetyltransferase
P03034570A0943|89 101|bacterial gene
P03034570A0943|129 138|hygromycin
P03034570A0943|146 150|ORF E7
P03034570A0943|146 148|ORF
P03034570A0943|149 150|E7
P03034570A0943|156 180|human papillomavirus type 18
P03034570A0943|156 180|human papillomavirus type 18
P03034956A0666|16 41|basal adrenal androgen levels
P03034956A0666|85 98|normal subjects
P03034956A0666|125 134|prednisone
P03035056T0000|6 11|lambda
P03035056T0000|15 44|kappa antibody gene rearrangement
P03035056T0000|15 31|kappa antibody gene
P03035056T0000|47 72|Abelson murine leukemia virus
P03035056T0000|85 98|pre-B cell lines
P03035218T0000|16 49|p40x-responsive regulatory sequences
P03035218T0000|16 49|p40x-responsive regulatory sequences
P03035218T0000|59 105|human T-cell leukemia virus type I long terminal repeat
P03035218T0000|59 87|human T-cell leukemia virus type I
P03035218T0000|88 105|long terminal repeat
P03035658A0355|6 28|pentobarbital anesthesia
P03035658A0355|38 40|VO2
P03035658A0355|74 84|epinephrine
P03035658A0355|109 128|plasma concentrations
P03036415T0000|11 35|cyclo-oxygenase inhibition
P03036415T0000|11 25|cyclo-oxygenase
P03036415T0000|41 59|leukotriene receptor
P03036415T0000|41 51|leukotriene
P03036415T0000|70 94|pulmonary vascular pressure
P03036415T0000|137 147|hypoxic dogs
P03036817A0213|0 34|Oligonucleotide-directed mutagenesis
P03036817A0213|52 70|NdeI restriction site
P03036817A0213|52 70|NdeI restriction site
P03036817A0213|83 85|ATG
P03036817A0213|91 96|yeast R
P03036933A0774|0 10|ACTH release
P03036933A0774|0 3|ACTH
P03036933A0774|40 47|children
P03036933A0774|53 65|exogenous ACTH
P03036933A0774|62 65|ACTH
P03037334A0932|25 47|upstream promoter element
P03037334A0932|53 66|yeast RP39A gene
P03037334A0932|53 62|yeast RP39A
P03037334A0932|82 104|identical sequence motifs
P03038643A1374|20 42|mammalian erythroid alpha
P03038643A1374|29 51|erythroid alpha-spectrin
P03038643A1374|96 125|ancestral alpha-fodrin-like gene
P03038643A1374|105 125|alpha-fodrin-like gene
P03038891A0935|0 15|Northern analyses
P03038891A0935|18 21|RNAs
P03038891A0935|26 37|mouse tissues
P03038891A0935|63 75|p11 mRNA levels
P03038891A0935|63 69|p11 mRNA
P03039177A0503|13 22|cDNA clones
P03039177A0503|38 64|2.9-kilobase early transcript
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|135 144|enzyme SmaI
P03039177A0503|141 144|SmaI
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|50 52|BCG
P03039387A0920|136 147|methotrexate
P03039387A0920|152 154|BCG
P03039387A0920|158 173|cyclophosphamide
P03039387A0920|178 187|levamisole
P03040023A0113|0 7|Morphine
P03040023A0113|17 41|dose-dependent bradycardia
P03040023A0113|52 62|tachycardia
P03040403A0155|3 9|PSS gene
P03040403A0155|3 9|PSS gene
P03040403A0155|27 40|1.1-kb fragment
P03040403A0155|46 53|yeast DNA
P03040403A0155|59 69|YEp13 vector
P03041046A0127|7 12|A-MuLV
P03041046A0127|32 38|viruses
P03041046A0127|49 59|Moloney MuLV
P03041046A0127|102 107|A-MuLV
P03041046A0127|128 134|viruses
P03041046A0127|145 150|BALB/c
P03041046A0127|161 172|N-tropic MuLV
P03041046A0127|198 217|lymphogenic potential
P03041802A0975|13 41|circulating platelet aggregates
P03041802A0975|61 75|fibrinopeptide A
P03041802A0975|61 75|fibrinopeptide A
P03041802A0975|95 100|fibrin
P03041802A0975|95 100|fibrin
P03041802A0975|114 131|platelet activation
P03041802A0975|135 150|fibrin deposition
P03041802A0975|135 140|fibrin
P03042778A0643|21 41|yeast vegetative growth
P03045117A0936|73 93|epidermal growth factor
P03045117A0936|73 93|epidermal growth factor
P03045117A0936|133 144|Glu24----Gly
P03045117A0936|156 167|Asp27----Gly
P03045117A0936|191 193|Thr
P03045117A0936|205 216|Tyr29----Gly
P03045117A0936|237 239|His
P03045725A0872|38 52|prolactin levels
P03045725A0872|38 46|prolactin
P03045725A0872|76 95|breast cancer patients
P03045725A0872|139 150|chemotherapy
P03046655A0000|50 60|affected eye
P03046655A0000|66 81|selected patients
P03046655A0000|86 93|herpetic
P03046931A0247|13 38|eIF-4A intronless retroposon
P03046931A0247|13 18|eIF-4A
P03046931A0247|62 65|cDNA
P03046931A0247|82 101|nucleotide difference
P03048024A0418|0 19|Bacteriologic culture
P03048024A0418|22 37|pancreatic tissue
P03048024A0418|54 55|IB
P03048024A0418|63 69|NIB rats
P03049570A1242|33 42|E2 proteins
P03049570A1242|33 34|E2
P03050147A0896|5 13|infection
P03050147A0896|16 23|293 cells
P03050147A0896|50 65|E1a-E1b functions
P03050147A0896|50 52|E1a
P03050147A0896|54 56|E1b
P03050147A0896|101 103|P/C
P03050147A0896|101 101|P
P03050147A0896|103 116|C-specific mRNA
P03050147A0896|113 129|mRNA transcription
P03050147A1520|4 14|observation
P03050147A1520|53 71|ribosomal initiation
P03050147A1520|120 127|internal
P03050147A1520|128 135|mRNA site
P03050147A1520|156 163|AUG codon
P03050147A1520|170 177|C protein
P03050147A1520|170 177|C protein
P03052327A1474|33 62|pancreas-kidney transplantation
P03052327A1474|97 109|Type I diabetic
P03052327A1474|110 117|patients
P03053713A0752|0 12|DNA sequencing
P03053713A0752|18 25|DPM1 gene
P03053713A0752|18 25|DPM1 gene
P03053713A0752|36 51|open reading frame
P03053713A0752|54 61|801 bases
P03057259A0514|29 45|malignant lymphoma
P03057259A0514|51 78|thyroid and chronic thyroiditis
P03059171A1232|36 42|heparin
P03059171A1232|44 58|prostaglandin E1
P03059171A1232|93 111|alleviating symptoms
P03060846T0000|0 17|Mutational analysis
P03060846T0000|23 35|L1 binding site
P03060846T0000|23 35|L1 binding site
P03060846T0000|38 44|23S rRNA
P03060846T0000|38 44|23S rRNA
P03060846T0000|47 61|Escherichia coli
P03060953A0481|23 37|oral vaccination
P03061301A0624|0 20|Prostacyclin formation
P03061301A0624|70 75|6-keto
P03061301A0624|77 96|prostaglandin F1 alpha
P03061301A0624|118 133|radioimmunoassay
P03061301A0624|171 188|smoking-free period
P03061301A0624|232 254|high-nicotine cigarettes
P03061301A1409|19 24|6-keto
P03061301A1409|26 45|prostaglandin F1 alpha
P03061301A1409|68 74|smokers
P03061301A1409|82 99|oral contraceptives
P03061383A0000|3 17|in vitro activity
P03061383A0000|20 29|mecillinam
P03061383A0000|33 58|amoxicillin/clavulanic acid
P03061383A0000|66 87|Escherichia coli strains
P03061383A0000|97 111|beta-lactamases
P03061383A0000|117 121|TEM-1
P03061383A0000|117 121|TEM-1
P03061383A0000|123 127|Oxa-1
P03061383A0000|123 127|Oxa-1
P03061383A0000|131 145|chromosomal type
P03061383A0000|177 193|dilution technique
P03062370A0000|0 3|GCN4
P03062370A0000|0 3|GCN4
P03062370A0000|12 35|transcriptional activator
P03062370A0000|38 58|amino acid biosynthetic
P03062370A0000|66 88|Saccharomyces cerevisiae
P03062370A0384|24 34|GCN3 product
P03062370A0384|24 34|GCN3 product
P03062370A0384|75 78|GCN4
P03062370A0384|75 78|GCN4
P03062370A0384|100 120|amino acid availability
P03064524A0160|18 39|immunosuppressive drugs
P03064811A0485|3 19|amino acid sequence
P03064811A0485|25 32|S. aureus
P03064811A0485|33 39|peptide
P03064811A0485|51 65|phosphoryl group
P03064811A0485|78 108|Gln-Val-Val-Ser-Thr-Phe-Met-Gly
P03064811A0485|78 81|Gln-
P03064811A0485|82 85|Val-
P03064811A0485|86 89|Val-
P03064811A0485|90 93|Ser-
P03064811A0485|94 121|Thr-Phe-Met-Gly-Asn-Gly-Leu-
P03064811A0485|122 152|Ala-Ile-Pro-His-Gly-Thr-Asp- Asp
P03065140A0273|5 13|mutations
P03065140A0273|31 41|GAL4 protein
P03065140A0273|31 41|GAL4 protein
P03065140A0273|46 61|DNA binding domain
P03065140A0273|46 61|DNA binding domain
P03065140A0273|69 97|transcription activation domain
P03065141A0448|23 30|two genes
P03065141A0448|32 35|citA
P03065141A0448|32 35|citA
P03065141A0448|39 42|citB
P03065141A0448|39 42|citB
P03065141A0448|56 64|promoters
P03065141A0448|85 92|promoter
P03065141A0448|99 106|citB gene
P03065141A0448|99 106|citB gene
P03065141A0448|112 135|Tn3411 nucleotide sequence
P03065141A0448|112 117|Tn3411
P03065141A0448|158 164|pMS185.
P03065610A0375|3 9|rci gene
P03065610A0375|3 9|rci gene
P03065610A0375|22 25|lacZ
P03065610A0375|22 25|lacZ
P03065610A0375|58 76|Western blot analysis
P03065621T0000|25 35|nuclear gene
P03065621T0000|25 35|nuclear gene
P03065621T0000|38 60|Saccharomyces cerevisiae
P03065621T0000|74 78|MRP13
P03065621T0000|74 78|MRP13
P03065621T0000|110 122|mitochondrial
P03066131A0000|17 26|anatomical
P03066131A0000|90 108|stereotactic lesions
P03066131A0000|128 142|posterior medial
P03066131A0000|219 257|conservatively untreatable aggressiveness
P03066208A0310|0 22|Histological examination
P03066208A0310|43 51|renal cyst
P03066208A0310|66 83|renal cell carcinoma
P03066625A0756|80 98|specific risk factors
P03067505A0688|5 16|prostacyclin
P03067505A0688|28 49|autoregulative property
P03067505A0688|55 69|inner ear vessels
P03069980T0000|21 32|bond strength
P03069980T0000|40 57|glass polyalkenoate
P03069980T0000|59 73|ionomer) cements
P03069980T0000|77 83|dentine
P03072021A0696|3 20|amino acid sequences
P03072021A0696|26 30|yeast
P03072021A0696|34 55|mammalian mitochondrial
P03072021A0696|111 122|polypeptides
P03072580A0455|0 9|Van der Ende
P03073091A0338|6 20|insulin infusion
P03073091A0338|45 51|infused
P03073091A0449|0 6|Amounts
P03073091A0449|9 15|glucose
P03073091A0449|52 66|insulin infusion
P03073091A0449|52 58|insulin
P03073091A0449|156 169|spironolactone
P03073091A0449|210 222|indomethacine
P03073091A0449|258 270|stopping drugs
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03073192T0000|55 86|acquired immunodeficiency syndrome
P03075154T0000|0 9|Recurrence
P03075154T0000|12 28|oxalate deposition
P03075154T0000|32 46|renal transplant
P03075154T0000|53 64|ciclosporin A
P03076124A0496|3 22|bile acid sequestrants
P03076124A0496|24 37|cholestyramine
P03076124A0496|41 50|colestipol
P03076124A0496|53 65|nicotinic acid
P03076124A0496|67 77|fenofibrate
P03076124A0496|93 139|hydroxymethylglutaryl coenzyme A (HMG CoA) reductase
P03076124A0496|93 122|hydroxymethylglutaryl coenzyme A
P03076124A0496|124 139|HMG CoA) reductase
P03076124A0496|145 154|lovastatin
P03076124A0496|157 167|simvastatin
P03076124A0496|201 208|patients
P03076124A0496|213 240|primary hypercholesterolaemia
P03076124A0496|259 278|plasma concentrations
P03076124A0496|289 303|LDL-cholesterol
P03076124A0496|289 303|LDL-cholesterol
P03078268A0529|11 35|pathophysiological aspects
P03078268A0529|38 57|urinary acidification
P03078268A0529|81 106|renal tubular acidosis models
P03078268A0529|117 123|maleate
P03078268A0529|127 148|amphotericin B treatment
P03078268A0529|158 175|cellular mechanisms
P03078268A0529|194 208|adrenal steroids
P03078268A0529|211 230|urinary acidification
P03079276T0029|19 26|patients
P03079276T0029|64 80|malarial flare-ups
P03080793T0000|0 8|Statement
P03080793T0000|55 70|AIDS transmission
P03080793T0000|76 84|workplace
P03083441T0000|46 59|diseased people
P03088643A0000|0 18|Cocaine-treated rats
P03088643A0000|41 75|cocaine-associated contextual stimuli
P03088643A0000|77 78|CS
P03088643A0000|90 115|saline-injected control rats
P03090372A0607|0 31|Intravenous glucose tolerance tests
P03090372A0607|75 77|CyA
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|28 37|dimensions
P03091849A0000|57 73|microvascular beds
P03091849A0000|76 87|rat mesentery
P03091849A0000|148 161|intra-arterial
P03091849A0000|211 240|exteriorized mesenteric membrane
P03097509A0654|30 51|3'-untranslated regions
P03097509A0654|61 83|375, 655, and 945 base pairs
P03097643A1357|8 13|BALB/c
P03097643A1357|13 17|c gene
P03097643A1357|33 44|substitution
P03097643A1357|57 71|octamer sequence
P03097643A1357|95 113|nucleotides upstream
P03097643A1357|119 130|coding region
P03098018A0139|72 84|P2-A2 pilosity
P03098018A0139|88 97|micropenis
P03102289A0786|48 64|hCG administration
P03102289A0786|48 50|hCG
P03102289A0786|148 149|13
P03102289A0786|159 161|hCG
P03102289A0786|159 161|hCG
P03102289A0786|166 172|serum E2
P03102289A0786|171 172|E2
P03102289A0786|184 193|1100 to 1200
P03102289A0786|203 210|follicle
P03104245A0402|4 11|patients
P03104245A0402|21 32|Ir192 implant
P03104245A0402|53 61|radiation
P03104248A0322|6 24|Stage IA, 141 patients
P03104248A0322|52 53|G1
P03104248A0322|56 57|20
P03104248A0322|95 96|G2
P03104248A0322|104 111|patients
P03104248A0322|136 137|G3
P03104914T0000|14 45|t(14;18) chromosomal translocation
P03104914T0000|71 82|derivative 14
P03104914T0000|88 105|reciprocal partners
P03104982A0690|15 30|hemoglobin levels
P03104982A0690|15 24|hemoglobin
P03104982A0690|34 36|men
P03104982A0690|67 71|women
P03104982A0690|86 98|sex difference
P03108171A0088|0 9|Ritanserin
P03108171A0088|62 72|S2 receptors
P03108171A0088|76 79|5-HT
P03108171A0088|85 104|central nervous system
P03109147A0000|0 13|Ethylene glycol
P03109147A0000|17 32|diethylene glycol
P03109147A0000|90 103|female NMRI mice
P03109147T0127|0 7|Research
P03109147T0127|10 23|ethylene glycol
P03109954A0945|67 95|ethinyl estradiol-containing OC
P03109954A0945|118 125|coronary
P03109954A0945|132 146|atherosclerosis
P03109954A0945|165 189|progestin-induced lowering
P03109954A0945|198 211|HDL cholesterol
P03109954A0945|198 200|HDL
P03109954A0945|201 211|cholesterol
P03109954A0945|241 255|hormonal balance
P03109954A0945|303 314|plasma lipids
P03109954A0945|318 330|atherogenesis
P03110119A0267|87 95|side ports
P03110119A0267|104 111|catheter
P03110119A0267|149 154|carina
P03110678A0702|12 30|beta 2-microglobulin
P03110678A0702|12 30|beta 2-microglobulin
P03110678A0702|50 69|polysulphone membrane
P03110678A0702|73 85|haemodialysis
P03110678A0702|113 131|beta 2-microglobulin
P03110678A0702|113 131|beta 2-microglobulin
P03110678A0702|230 242|urea clearance
P03110692A0156|47 52|beta 2m
P03110692A0156|47 52|beta 2m
P03110692A0156|80 87|patients
P03110692A0156|92 100|bone cysts
P03110692A0156|151 158|dialysis
P03110692A0156|198 205|patients
P03110692A0156|210 218|bone cysts
P03110692A0156|234 239|beta 2m
P03110692A0156|234 239|beta 2m
P03110692A0156|250 257|patients
P03110746A0146|19 30|linoleic acid
P03110746A0146|36 48|triglycerides
P03110746A0146|54 85|subcutaneous adipose tissue (PLASAT
P03110801A0532|20 42|plasma prolactin response
P03110801A0532|20 34|plasma prolactin
P03110801A0532|45 48|12.5
P03110801A0532|61 62|v.
P03111946A0309|18 33|grooming behavior
P03112028A0404|15 22|patients
P03112028A0404|61 77|seminal parameters
P03112412A0985|12 26|wild-type strain
P03112412A0985|38 89|temperature-sensitive threonyl-tRNA synthetase mutation
P03112412A0985|38 81|temperature-sensitive threonyl-tRNA synthetase
P03112412A0985|105 123|thr operon expression
P03112412A0985|105 113|thr operon
P03112412A0985|129 153|non-permissive temperature
P03112412A0985|171 177|mutants
P03114188A0907|68 75|patients
P03114188A0907|89 104|chest wall sarcoma
P03114188A0907|116 123|patients
P03114188A0907|148 174|breast and regional nodal areas
P03114829T0000|0 7|Clinical
P03114829T0000|33 43|panic states
P03114995T0000|18 36|parenteral nutrition
P03114995T0000|39 52|gastrin release
P03114995T0000|39 45|gastrin
P03114995T0000|55 58|dogs
P03115087A0515|3 12|mean weight
P03115787A0633|3 10|patients
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|39 56|hexamethylmelamine
P03115787A0633|71 79|cisplatin
P03115787A0633|81 86|CHAP-5
P03115787A0633|81 86|CHAP-5
P03115787A0633|103 109|disease
P03117046T0000|31 42|vinculin cDNA
P03117046T0000|31 38|vinculin
P03117046T0000|53 69|embryo fibroblasts
P03117147A1059|69 72|EMGd
P03117147A1059|91 101|surface EMGd
P03118631A0140|64 85|intravascular perfusion
P03118631A0140|89 101|cochleas fixed
P03118631A0140|104 129|intralabyrinthine perfusion
P03119227A0079|3 13|DNA sequence
P03119227A0079|70 100|human c-abl proto-oncogene product
P03119227A0079|70 100|human c-abl proto-oncogene product
P03119227A0079|116 128|amino terminus
P03119227A0079|141 153|656 amino acids
P03119227A0079|182 203|tyrosine kinase activity
P03119227A0079|182 195|tyrosine kinase
P03119485A0476|34 43|fatty acids
P03119485A0476|46 53|patients
P03119485A0476|63 81|parenteral nutrition
P03119485A0476|92 97|injury
P03119485A0476|158 162|shock
P03119485A0476|164 169|sepsis
P03119485A0476|172 203|adult respiratory distress syndrome
P03120334A0893|51 67|right marginal vein
P03120334A0893|85 92|anterior
P03120334A0893|93 104|cardiac veins
P03123310A0000|3 32|Drosophila melanogaster Gart gene
P03123310A0000|3 32|Drosophila melanogaster Gart gene
P03123310A0000|45 63|enzymatic activities
P03123310A0000|79 84|purine
P03125422A0202|50 75|upstream activator sequences
P03125422A0202|77 79|UAS
P03125422A0202|106 114|galactose
P03126531T0000|23 51|apomorphine-induced stereotypy
P03126531T0000|67 86|REM sleep deprived rats
P03126531T0000|89 116|dopamine agonist pretreatments
P03127034A0591|3 11|heart rate
P03127034A0591|13 27|respiratory rate
P03127034A0591|50 67|vascular resistance
P03127463A1017|0 9|Human rIL-3
P03127463A1017|5 9|rIL-3
P03127463A1017|21 29|COS7 cells
P03127463A1017|47 57|CSF activity
P03127463A1017|47 49|CSF
P03127463A1017|79 93|bone marrow cells
P03127463A1017|134 161|My-10+ marrow or cord blood cells
P03132498A0730|4 11|patients
P03132498A0730|17 21|PaCO2
P03132498A0730|47 50|torr
P03132498A0730|63 89|torr) and clinical asthma score
P03132498A0730|104 108|PaCO2
P03133250A0000|1 10|randomized
P03133250A0000|49 66|ovarian stimulation
P03133250A0000|71 97|human menopausal gonadotropin
P03133250A0000|86 97|gonadotropin
P03133250A0000|99 101|hMG
P03133250A0000|99 101|hMG
P03133250A0000|106 142|human follicle-stimulating hormone (hFSH
P03133250A0000|106 137|human follicle-stimulating hormone
P03133250A0000|139 142|hFSH
P03133250A0000|148 167|in vitro fertilization
P03133250A0000|171 176|embryo
P03133250A0000|186 199|IVF-ET) program
P03133360A1215|25 34|mtr product
P03133360A1215|25 34|mtr product
P03133360A1215|84 94|translation
P03133360A1215|97 104|trpE mRNA
P03133360A1215|97 104|trpE mRNA
P03134872T0029|0 6|Apropos
P03137105A0146|1 21|prostaglandin analogue
P03137105A0146|46 71|human chorionic gonadotropin
P03137105A0146|60 71|gonadotropin
P03137105A0146|99 113|follicular phase
P03137105A0146|163 178|oocyte collection
P03137105A0146|207 237|oocyte donors and embryo recipients
P03137346A0319|3 15|nucleolin gene
P03137346A0319|3 11|nucleolin
P03137346A0319|27 40|9000 base-pairs
P03137346A0319|75 94|706 amino acid residues
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|38 41|DOPS
P03137601A0212|56 69|norepinephrine
P03137601A0212|71 82|NE) precursor
P03137601A0212|114 117|mice
P03137601A0212|185 200|NE neurotoxin DSP4
P03138190A0347|20 38|liposomal ampicillin
P03138190A0347|64 75|Kupffer cells
P03138190A0347|93 107|L. monocytogenes
P03138449A0759|17 22|delta 6
P03138449A0759|26 31|delta 5
P03138449A0759|88 90|C18
P03138449A0759|92 100|2w6 supply
P03139750A0000|40 49|VH allotype
P03139750A0000|40 49|VH allotype
P03139750A0000|55 60|rabbit
P03142875A0366|23 44|6-kilobase cDNA sequence
P03142875A0366|88 103|genomic structure
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|36 52|apolipoprotein A-I
P03143048A1091|50 52|A-I
P03143485A0366|3 36|Euglena ribosomal protein gene cluster
P03143485A0366|10 36|ribosomal protein gene cluster
P03143485A0366|49 74|S-10 ribosomal protein operon
P03143485A0366|49 74|S-10 ribosomal protein operon
P03143485A0366|77 91|Escherichia coli
P03143485A0366|94 109|gene organization
P03143485A0366|163 169|tobacco
P03143485A0366|173 199|liverwort chloroplast genomes
P03144705A0859|27 51|recombinational resolution
P03144705A0859|143 155|X recombinants
P03144705A0859|173 179|3' third
P03144705A0859|185 185|X
P03144705A0859|208 223|Alu family repeats
P03144705A0859|208 210|Alu
P03146017A0983|3 20|nucleotide sequence
P03146017A0983|44 58|M. voltae ORFtrpA
P03146017A0983|44 51|M. voltae
P03146017A0983|52 58|ORFtrpA
P03146017A0983|98 100|ORF
P03146017A0983|103 117|1227 nucleotides
P03146017A0983|119 125|ORFtrpB
P03146017A0983|119 125|ORFtrpB
P03146017A0983|136 158|409 amino acid polypeptide
P03146017A0983|161 163|mol
P03146150T0000|0 11|Potentiation
P03146150T0000|39 59|single-chain urokinase
P03146150T0000|39 59|single-chain urokinase
P03146150T0000|61 73|Pro-urokinase
P03146150T0000|61 73|Pro-urokinase
P03146150T0000|77 83|heparin
P03146784A0158|25 29|phase
P03146784A0158|154 162|receptors
P03146784A0158|164 166|PSR
P03146784A0158|183 223|intrapulmonary CO2-sensitive chemoreceptors
P03146784A0158|225 227|IPC
P03147912A0422|0 26|Symptomatic hyperventilators
P03147912A0422|108 117|expiratory
P03147912A0422|126 131|PETCO2
P03149774A0173|5 10|IA task
P03149774A0173|52 61|picrotoxin
P03149774A0173|65 75|bicuculline
P03149774A0173|84 108|dose-dependent enhancement
P03149774A0173|178 198|bicuculline methiodide
P03149774A0173|201 222|GABA receptor antagonist
P03149774A0173|201 212|GABA receptor
P03149774A0173|249 266|blood-brain barrier
P03150015T0001|0 15|Clinical research
P03150015T0001|18 22|non-A
P03150015T0001|18 22|non-A
P03150015T0001|24 53|non-B post-transfusion hepatitis
P03150296A0594|67 90|glomerular filtration rate
P03150296A0594|92 94|GFR
P03150296A0594|92 94|GFR
P03150296A0594|163 179|simpler techniques
P03154072A0862|3 17|protein mixtures
P03154072A0862|20 45|sesame flour and soybean flour
P03159903A0352|3 7|5' end
P03159903A0352|13 24|coding region
P03159903A0352|65 81|amino acid sequence
P03159903A0352|93 119|N-terminal amino acid sequence
P03159903A0352|122 124|IHF
P03159903A0352|122 124|IHF
P03166458A1356|1 16|protein footprint
P03166458A1356|38 49|GC box element
P03166458A1356|52 70|nucleotides -59 to -45
P03167060A0000|0 25|Insulin-like growth factor II
P03167060A0000|7 25|-like growth factor II
P03167060A0000|27 31|IGFII
P03167060A0000|27 31|IGFII
P03167060A0000|36 55|mitogenic polypeptide
P03167060A0000|60 64|mRNAs
P03167060A0000|120 129|single gene
P03168709A0000|37 51|106 glaucoma eyes
P03168709A0000|86 107|suprathreshold strategy
P03171221A0531|35 53|alternative splicing
P03171221A0531|56 60|exons
P03171221A0531|68 92|primary elastin transcripts
P03171221A0531|75 92|elastin transcripts
P03171279A0158|29 44|metatarsal artery
P03171279A0158|63 75|MP joint grafts
P03171279A0158|85 94|unilateral
P03171279A0158|101 107|digital
P03171279A0158|130 143|PIP joint grafts
P03171279A0158|170 188|dorsal cutaneous vein
P03172863T0000|15 28|undernutrition
P03172863T0000|47 56|cold stress
P03172863T0000|59 79|young adult and aged rats
P03178097A0000|74 87|choanal atresia
P03178161A0000|0 34|Esophageal brush cytological screening
P03178161A0000|51 69|blood concentrations
P03178161A0000|72 85|micronutrients
P03178161A0000|87 94|vitamin A
P03178161A0000|98 100|B12
P03178161A0000|102 110|folic acid
P03178161A0000|114 123|methionine
P03178161A0000|154 172|esophageal carcinoma
P03178161A0000|174 175|EC
P03178626A0137|0 7|Aviators
P03178626A0137|15 29|Light Attack Wing
P03179496T0000|12 25|human and bovine
P03179496T0000|35 44|hemoglobin
P03179496T0000|55 60|oxygen
P03179496T0000|78 99|blood volume replacement
P03180595A1040|45 60|ejection fraction
P03180595A1040|100 113|biliary disease
P03181276A0422|12 14|PAF
P03181276A0422|17 23|placebo
P03181276A0422|42 52|nasal cavity
P03181276A0422|72 88|allergen challenge
P03183103A0000|10 23|MR examinations
P03183103A0000|29 58|nasal cavity and paranasal sinuses
P03183103A0000|95 110|normal volunteers
P03183127A0068|26 49|neuroradiological imaging
P03183127A0068|69 70|CT
P03183127A0068|84 107|CT ventriculography, and CT
P03184267A0000|3 6|feed
P03184267A0000|26 33|chickens
P03184267A0000|65 82|Salmonella kedougou
P03184267A0000|85 92|serotype
P03184267A0000|111 131|subclinical infections
P03184267A0000|134 145|commercially
P03184267A0000|152 159|chickens
P03184267A0000|178 183|humans
P03185322A1305|39 46|atypical
P03185322A1305|48 71|inflammatory) cytological
P03185322A1305|79 84|class 2
P03185322A1305|79 84|class 2
P03185322A1305|90 116|benign histological diagnosis
P03185322A1305|123 135|class-2 smears
P03185322A1305|149 173|histologically as dysplasia
P03185540T0000|17 37|specific transcription
P03185540T0000|40 63|mammalian RNA polymerase II
P03185540T0000|40 63|mammalian RNA polymerase II
P03185540T0000|78 95|genetic specificity
P03185540T0000|100 115|TATA box-promoter
P03185540T0000|100 115|TATA box-promoter
P03185540T0000|130 134|TFIID
P03185540T0000|130 134|TFIID
P03186091T0000|0 5|Change
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|35 45|oxytocinase
P03186091T0000|35 45|oxytocinase
P03186091T0000|88 116|pregnancy-induced hypertension
P03186270T0001|0 2|You
P03190481A0292|10 46|alpha-naphthyl esterase and quantitation
P03190481A0292|10 31|alpha-naphthyl esterase
P03190481A0292|49 59|macrophages
P03190481A0292|170 180|macrophages
P03190481A0292|197 203|capsule
P03190914A0149|0 9|Determined
P03190914A0149|35 74|chemotactic and chemokinetic responsiveness
P03190914A0149|96 111|neutropenic group
P03192537A0370|3 28|deduced 96-residue amino acid
P03192537A0370|48 65|murine HMG-I(Y) cDNA
P03192537A0370|48 58|murine HMG-I
P03192537A0370|60 65|Y) cDNA
P03192537A0370|111 120|human HMG-I
P03192537A0370|116 120|HMG-I
P03192537A0370|141 158|internal amino acids
P03192537A0370|172 183|human protein
P03192724A0000|0 28|Interpersonal style differences
P03192724A0000|34 44|drug abusers
P03192724A0000|62 67|Ryan's
P03192724A0000|93 98|FIRO-B
P03192799T0000|0 8|Statement
P03192799T0000|31 46|Implant Dentistry
P03192950A0566|0 3|Sera
P03192950A0566|8 46|euthyroid post-menopausal or pregnant women
P03192950A0566|54 62|TSH levels
P03192950A0566|54 56|TSH
P03194410A0771|2 11|UOxase mRNA
P03194410A0771|2 11|UOxase mRNA
P03194410A0771|27 43|nonhepatic tissues
P03194410A0771|46 48|rat
P03194410A0771|95 104|UOxase gene
P03194410A0771|95 104|UOxase gene
P03195167A0104|3 22|platelet adhesion rate
P03195167A0104|96 121|basic-polymers polyurethane
P03195167A0104|123 125|PUR
P03195167A0104|128 144|polyvinylchloride
P03195167A0104|146 148|PVC
P03195167A0104|154 164|polystyrene
P03198436T0000|0 20|Conservative treatment
P03198436T0000|23 38|bladder carcinoma
P03198436T0000|73 82|iridium 192
P03198525A0164|21 30|105 heifers
P03198525A0164|51 70|medium and heavy weight
P03198525A0164|101 103|MGA
P03198525A0164|110 117|hd-1.d-1
P03198525A0164|110 113|hd-1
P03198525A0164|130 132|MGA
P03198525A0164|136 143|DEPO-MGA
P03198525A0164|170 171|60
P03198525A0164|178 183|MGA/hd
P03199043A0248|0 8|Existence
P03199043A0248|24 32|solutions
P03199043A0248|96 141|small permeability coefficients and transport rates
P03199043A0248|174 188|small resistance
P03199043A0248|191 203|flow constants
P03199436A1060|29 52|photosynthesis components
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|62 65|psbB
P03199436A1060|67 70|psbH
P03199436A1060|72 75|petB
P03199436A1060|77 80|petD
P03199436A1060|87 95|psbE-psbF
P03200488A0439|30 32|TIQ
P03200488A0439|131 134|mice
P03200844A1211|3 17|partial sequence
P03200844A1211|23 51|62-kDa nuclear pore glycoprotein
P03200844A1211|23 28|62-kDa
P03200844A1211|29 51|nuclear pore glycoprotein
P03200844A1211|154 177|nuclear pore glycoproteins
P03200844A1211|154 177|nuclear pore glycoproteins
P03207975A0709|37 45|vitamin K1
P03207975A0709|47 66|plasma concentrations
P03207975A0709|72 78|vitamin
P03208493A0849|3 26|glomerular filtration rate
P03208493A0849|42 48|lithium
P03209019A0662|46 53|CD-1 mice
P03209019A0662|93 96|DMBA
P03209019A0662|109 115|acetone
P03209019A0662|163 174|test material
P03212551T0001|17 38|Dupuytren's contracture
P03212929A0000|2 15|ELISA procedure
P03212929A0000|52 62|IgE response
P03212929A0000|52 54|IgE
P03212929A0000|71 97|Dirofilaria immitis infection
P03214709A0559|42 67|plasma corticosterone levels
P03214709A0559|97 107|biting group
P03214709A0559|128 142|non-biting group
P03216131A0559|16 34|Aeromonas hydrophila
P03216131A0559|43 62|cytotoxic enterotoxin
P03218714A0000|14 17|girl
P03218714A0000|31 54|Dandy-Walker malformation
P03218714A0000|56 58|DWM
P03218714A0000|85 94|Fallot (TOF
P03219107A0212|14 37|early neonatal convulsions
P03219107A0212|47 52|babies
P03219107A0212|64 73|live births
P03220077A0274|3 16|median survival
P03223123T0001|56 68|fetal maturity
P03223123T0001|71 83|amniotic fluid
P03227288A0542|7 13|infants
P03227568T0001|0 6|Variety
P03227568T0001|39 62|dermatoglyphics (patterns
P03228518A0339|90 119|Community/Vocational dimensions
P03228785A1047|0 7|Recovery
P03229917A0099|16 34|pancreatic resection
P03229917A0099|47 72|pancreatic remnant infection
P03232410A1467|40 49|lung cancer
P03233862T0000|0 18|Neuromyelitis optica
P03233862T0000|20 34|Devic's syndrome
P03233862T0000|46 62|multiple sclerosis
P03234790T0001|20 42|cutaneous administration
P03234790T0001|45 64|methyl isobutyl ketone
P03235487A0404|0 12|Incorporation
P03235487A0404|24 39|sodium dihydrogen
P03235487A0404|54 67|sugar solutions
P03235487A0404|104 112|diltiazem
P03239106A0856|35 38|diet
P03239106A0856|64 70|calcium
P03239106A0856|74 82|magnesium
P03243027T0000|32 61|ribosomal protein gene expression
P03243027T0000|32 51|ribosomal protein gene
P03243027T0000|81 103|Dictyostelium discoideum
P03243920A0591|14 45|static plasma concentration-effect
P03246999A0483|13 33|amplitudes of the b-wave
P03246999A0483|77 96|lead-exposed subjects
P03246999A0483|103 110|controls
P03249792A0241|34 56|psychotic symptomatology
P03249792A0241|63 77|group activities
P03249792A0241|111 123|stress factors
P03249792A0241|167 187|bipolar manifestations
P03249840A0411|0 19|Baseline measurements
P03249840A0411|22 43|forced expiratory volume
P03249840A0411|49 52|FEV1
P03249840A0411|55 79|specific airway conductance
P03249840A0411|81 84|SGaw
P03249840A0411|140 143|SGaw
P03249840A0411|145 148|PD35
P03249840A0411|169 172|FEV1
P03249840A0411|174 177|PD20
P03251210A0981|4 11|children
P03251210A0981|16 18|BGC
P03251210A0981|103 123|neurologic dysfunction
P03253219T0000|18 32|right precordial
P03253219T0000|40 66|anthracycline cardiomyopathy
P03256150A1866|25 43|pooling requirements
P03257146A1037|24 28|CSFHU
P03257146A1037|24 28|CSFHU
P03257146A1037|40 55|neutrophil counts
P03257146A1037|80 87|maturity
P03257146A1037|93 118|marrow neutrophil precursors
P03257146A1037|132 158|childhood chronic neutropenia
P03258069A0000|98 102|nerve
P03258069A0000|144 159|experimental pain
P03259437A0140|5 20|infected neonates
P03259437A0140|26 43|alpha-amylase value
P03259437A0140|26 38|alpha-amylase
P03259437A0140|62 77|blue starch method
P03259437A0140|95 109|healthy controls
P03259437A0140|144 158|healthy neonates
P03259437A0140|233 248|infected neonates
P03261005A0216|0 6|Records
P03261005A0216|11 18|children
P03261005A0216|23 26|AIDS
P03261005A0216|29 47|AIDS-related complex
P03261005A0216|90 112|acute respiratory failure
P03261223A0644|8 15|patients
P03261223A0644|25 41|multifocal disease
P03261223A0644|64 68|SPECT
P03261223A0644|76 78|TCT
P03261331A0563|0 4|SPECT
P03261331A0563|37 55|AIDS dementia complex
P03261331A0563|93 120|pathophysiological mechanisms
P03263357A0112|51 65|circadian rhythm
P03263357A0112|68 82|body temperature
P03263357A0112|102 121|plasma concentrations
P03263357A0112|124 127|iron
P03263357A0112|129 132|zinc
P03263357A0112|134 159|circulating leukocyte counts
P03263357A0112|164 181|plasma interleukin 1
P03263357A0112|170 181|interleukin 1
P03263357A0112|183 186|IL-1
P03263357A0112|183 186|IL-1
P03263465T0000|3 22|murine MHC class I genes
P03263465T0000|9 22|MHC class I genes
P03263465T0000|24 28|H-2Dq
P03263465T0000|32 36|H-2Lq
P03263465T0000|32 36|H-2Lq
P03263465T0000|73 77|H-2Ld
P03263465T0000|106 127|tumor-specific antigens
P03264073A0224|3 19|active derivatives
P03264073A0224|60 76|analgesic activity
P03264073A0224|84 108|aconitine-induced writhing
P03264073A0224|111 120|albino mice
P03264073A0224|124 142|ulcerogenic activity
P03264073A0224|145 154|albino rats
P03264299A0679|2 14|untreated mice
P03264299A0679|16 27|bactericidal
P03264299A0679|38 58|peritoneal macrophages
P03264299A0679|109 123|L. monocytogenes
P03264886A0000|50 65|medium sized towns
P03264886A0000|69 103|rural areas in south-western Germany 552
P03264886A0000|118 122|croup
P03264886A0000|174 183|physicians
P03267732A0788|15 32|Ga-fbg scintigraphy
P03267732A0788|91 112|left ventricular thrombi
P03267732A0788|140 159|anticoagulant therapy
P03268555T0000|40 54|dental materials
P03268555T0000|60 80|millipore filter method
P03270085A0382|0 13|Hypomagnesemia
P03270085A0382|43 48|kidney
P03274204A0642|0 11|Dentalplaque
P03274204A0642|30 46|oral higienic index
P03274204A0642|97 109|alkaline fuxin
P03275867A0187|0 3|GRFI
P03275867A0187|25 50|negative regulatory elements
P03275867A0187|52 60|silencers
P03275867A0187|67 97|silent mating type loci HML E and HMR E
P03275867A0187|67 86|silent mating type loci
P03275867A0187|87 90|HML E
P03275867A0187|94 97|HMR E
P03275867A0187|106 131|upstream activating sequence
P03275867A0187|133 135|UAS
P03275867A0187|166 178|MAT alpha genes
P03275867A0187|166 178|MAT alpha genes
P03275873A0379|17 25|mutations
P03275873A0379|28 42|RNA polymerase II
P03275873A0379|28 42|RNA polymerase II
P03275873A0379|85 95|mutant genes
P03275873A0379|85 95|mutant genes
P03275873A0379|104 127|alpha-amanitin resistance
P03275873A0379|104 117|alpha-amanitin
P03275873A0379|158 168|rodent cells
P03276246A0037|35 41|albumin
P03276246A0037|49 62|white blood cell
P03276246A0037|64 70|TAC-WBC
P03276924A0090|29 41|rearrangement
P03276924A0090|75 88|MoMuLV provirus
P03278829A0082|45 53|secondary
P03278829A0082|80 88|tip grafts
P03280021A1615|3 13|SSB-poly(dT
P03280021A1615|3 10|SSB-poly
P03280021A1615|12 13|dT
P03280021A1615|66 69|NaCl
P03280021A1615|89 92|NaBr
P03280021A1615|111 121|Kobsd/alpha
P03280021A1615|126 129|NaBr
P03280021A1615|160 167|omega T/O
P03280807A0000|0 8|Mutations
P03280807A0000|14 23|suf12 locus
P03280807A0000|14 23|suf12 locus
P03280807A0000|38 60|Saccharomyces cerevisiae
P03280807A0000|88 106|frameshift mutations
P03280807A0000|109 115|glycine
P03280807A0000|117 119|GGX
P03280807A0000|124 130|proline
P03280807A0000|132 141|CCX) codons
P03280807A0000|151 153|UGA
P03280807A0000|157 159|UAG
P03280807A0000|160 176|nonsense mutations
P03280807A1447|13 42|suf12-null/SUF12+ heterozygotes
P03280807A1447|13 29|suf12-null/SUF12+
P03280807A1447|30 42|heterozygotes
P03280807A1447|56 60|suf12
P03280807A1447|56 60|suf12
P03280807A1447|100 130|suf12 allele-specific suppression
P03280807A1447|100 110|suf12 allele
P03280807A1447|164 177|mutant proteins
P03280807A1447|207 221|wild-type SUF12+
P03280807A1447|216 229|SUF12+ activity
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|3 18|putative immunity
P03280946A0375|45 59|[35S]methionine
P03280946A0375|104 106|cni
P03280946A0375|118 128|lac promoter
P03280946A0375|118 128|lac promoter
P03280946A0375|167 183|expression vectors
P03280946A0375|202 224|bacteriophage T7 promoter
P03282232A0743|0 9|Antibodies
P03282232A0743|21 33|fusion protein
P03282232A0743|47 55|DP1A clone
P03282232A0743|47 50|DP1A
P03282232A0743|79 88|DP-I and -II
P03282232A0743|79 88|DP-I and -II
P03282232A0743|91 101|immunoblots
P03282813A0794|27 46|QO2, oxygen extraction
P03282813A0794|59 66|patients
P03282813A0794|71 74|ARDS
P03282813A0794|85 92|patients
P03282813A0794|97 122|non-ARDS respiratory failure
P03283881A0216|6 13|patients
P03283881A0216|62 73|inflammation
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|41 65|infraclinical neuropathies
P03285764A0675|67 82|arterial stenoses
P03285764A0675|132 155|organic starter or cofactor
P03285764A0675|160 177|sexual consequences
P03285764A0675|199 218|psychological factors
P03286611A1198|0 3|Yang
P03287597T0000|0 16|Secretory function
P03287597T0000|22 34|prostate gland
P03292076A0820|0 17|Chronic endotoxemia
P03292076A0820|62 86|microvascular permeability
P03292076A0820|106 128|hyperdynamic circulation
P03292076A0820|208 229|eicosanoid biosynthesis
P03292082A0486|47 54|patients
P03292082A0486|59 64|tumors
P03292082A0486|70 89|central nervous system
P03292082A0486|103 112|meningioma
P03292082A0486|119 130|glioblastoma
P03292082A0486|132 135|9/23
P03292082A0486|141 153|neurinoma (5/5
P03293844T0000|0 18|Diet and atopic eczema
P03296019T0000|21 31|tensile bond
P03296019T0000|54 63|Silicoater
P03296212A0603|3 8|future
P03296212A0603|23 32|interferon
P03296212A0603|23 32|interferon
P03296212A0603|172 187|fullest potential
P03296212A0603|190 192|IFN
P03296212A0603|256 263|adjuvant
P03296212A0603|269 282|tumor debulking
P03296212A0603|379 394|fullest potential
P03296212A0603|400 413|biologic agents
P03296254A0556|72 82|prothrombin
P03296254A0556|112 121|depression
P03296254A0556|124 143|factor II and factor VII
P03296254A0556|124 143|factor II and factor VII
P03297181A0127|3 21|healthy male subjects
P03297181A0127|62 80|RR) quinidine sulfate
P03297181A0127|99 100|SR
P03297181A0127|99 100|SR
P03297181A0127|139 147|SR product
P03297181A0127|139 147|SR product
P03297181A0127|152 155|food
P03297181A0127|157 160|SR-F
P03297181A0127|157 160|SR-F
P03298134A0000|35 76|interferon alfa-2b (Intron A; Schering-Plough)
P03298134A0000|35 51|interferon alfa-2b
P03298134A0000|61 75|Schering-Plough
P03298134A0000|93 109|hairy cell leukemia
P03298134A0000|111 113|HCL
P03300118A0392|6 13|delivery
P03300118A0392|56 59|pigs
P03304015T0000|0 16|Clinical chemistry
P03304866T0001|0 16|Revascularization
P03304866T0001|22 29|anterior
P03304866T0001|30 60|maxillary and mandibular osteotomy
P03305875T0000|0 13|Static orthoses
P03305875T0000|32 42|microstomia
P03306340A0537|3 23|intrapancreatic spread
P03306340A0537|29 37|carcinoma
P03306340A0537|52 76|portal invasion of carcinoma
P03306340A0537|91 94|body
P03306340A0537|120 133|pancreatic duct
P03306340A0537|137 160|irregular pancreaticogram
P03308909A0485|0 15|Lysosomal enzymes
P03309892A0637|37 43|S. pombe
P03309892A0637|72 76|yeast
P03309892A0637|81 101|heterologous actin gene
P03309892A0637|93 111|actin gene transcript
P03309892A0637|125 143|nucleotides upstream
P03309892A0637|149 167|initiation start site
P03309892A0637|177 186|homologous
P03309892A0637|187 191|yeast
P03311954A0000|1 16|multicentre study
P03311954A0000|27 45|Italian institutions
P03311954A0000|150 167|reflux oesophagitis
P03312033A0501|0 10|Monotherapy
P03312033A0501|15 25|ceftazidime
P03312033A0501|95 103|cefazolin
P03312033A0501|107 116|tobramycin
P03312514A0756|3 8|N3 wave
P03312514A0756|14 17|SSEP
P03312514A0756|127 148|insulin-treated animals
P03312514A0756|127 133|insulin
P03312514A0756|174 184|fasted group
P03315359A0732|0 10|Proctoscopy
P03315359A0732|82 89|patients
P03315359A0732|104 122|perianal suppuration
P03315359A0732|133 144|anal fissures
P03317796A0853|48 61|osteoarthritis
P03319621A0707|16 19|mRNA
P03319621A0707|26 47|alpha and beta actin mRNAs
P03319621A0707|26 47|alpha and beta actin mRNAs
P03319621A0707|68 76|myoblasts
P03319621A0707|80 87|myotubes
P03319646T0000|0 18|Plasma renin activity
P03319646T0000|0 10|Plasma renin
P03319646T0000|36 51|antihypertensive
P03319646T0000|62 75|chlorthalidone
P03319912A0000|67 80|female patients
P03319912A0000|190 196|dysuria
P03320875A2090|89 97|infection
P03322829A0952|108 115|patients
P03322829A0952|198 214|their prescription
P03325081A0524|0 17|Bullous keratopathy
P03325081A0524|62 91|pseudophakic bullous keratopathy
P03325081A0524|93 95|PBK
P03325081A0524|120 137|bullous keratopathy
P03326381A0423|3 25|ultrastructural findings
P03326381A0423|38 62|urinary C-peptide excretion
P03326381A0423|80 94|glycemic effects
P03326381A0423|154 170|endocrine pancreas
P03329716A0187|16 34|EGF receptor promoter
P03329716A0187|16 34|EGF receptor promoter
P03329716A0187|51 74|E1A protein and receptor RNA
P03329716A0187|51 60|E1A protein
P03329716A0187|72 80|RNA levels
P03329716A0187|107 118|phorbol ester
P03329716A0187|121 134|fetal calf serum
P03330711T0000|2 26|vitro antimalarial activity
P03330711T0000|29 32|neem
P03330711T0000|34 51|Azadirachta indica A
P03331525T0001|16 29|dentin adhesion
P03331525T0001|82 91|isocyanate
P03332022A1094|36 51|N-terminal region
P03332022A1094|36 51|N-terminal region
P03332022A1094|57 64|c-raf(-1
P03332022A1094|57 64|c-raf(-1
P03332022A1094|87 104|nucleotide sequence
P03332022A1094|182 197|N-terminal region
P03332022A1094|182 197|N-terminal region
P03332022A1094|200 213|protein kinase C
P03332022A1094|200 213|protein kinase C
P03332848A0000|25 37|Doppler probes
P03332848A0000|55 70|spectral analysis
P03332848A0000|87 114|predict carotid artery stenosis
P03334950A0000|53 82|Cooperative Ewing's Sarcoma Study
P03334950A0000|84 87|CESS
P03334950A0000|119 130|chemotherapy
P03334950A0000|164 170|surgery
P03334950A0000|177 185|radiation
P03335127A0176|27 38|generic BASIC
P03335398A0568|17 31|immunoglobulin G
P03335398A0568|17 31|immunoglobulin G
P03335398A0568|70 72|NVS
P03335444A0000|21 29|human male
P03335444A0000|53 57|241Am
P03335444A0000|61 62|Pu
P03335651A0000|2 15|analytic method
P03335651A0000|50 77|magnetic resonance (MR) imaging
P03335651A0000|185 186|T1
P03335651A0000|185 186|T1
P03335651A0000|188 189|T2
P03335651A0000|188 189|T2
P03335651A0000|194 210|hydrogen weighting
P03335923A0257|10 17|patients
P03335923A0257|81 102|asymptomatic volunteers
P03335923A0257|106 113|patients
P03335923A0257|118 150|duodenal-gastric reflux gastropathy
P03335923A0257|152 154|DRG
P03335923A0257|159 166|patients
P03335923A0257|191 202|duodenal bulb
P03335923A0257|204 206|RUD
P03335923A0257|214 221|patients
P03335923A0257|226 242|Moynihan's disease
P03337024A0000|53 75|intravenous procainamide
P03338154T0000|0 17|High concentrations
P03338154T0000|20 42|tumor-associated trypsin
P03338154T0000|36 51|trypsin inhibitor
P03338154T0000|54 73|hemodialyzed patients
P03340548A1018|12 16|liver
P03340548A1018|26 38|chicken MT mRNA
P03340548A1018|26 34|chicken MT
P03340548A1018|35 38|mRNA
P03340548A1018|59 64|metals
P03340548A1018|66 69|Cd2+
P03340548A1018|71 79|Zn2+, Cu2+
P03340548A1018|82 96|glucocorticoids
P03340548A1018|100 117|lipopolysaccharide
P03340726A1103|4 12|histology
P03340726A1103|16 24|Evans blue
P03340726A1103|36 53|blood-brain barrier
P03340726A1103|99 102|50 Gy
P03340774A0328|93 102|whole-body
P03343730A0486|54 62|urinary pH
P03343730A0486|82 87|female
P03343730A0486|95 99|stone
P03343730A0486|100 107|patients
P03344586T0000|3 14|technologies
P03344586T0000|45 54|malignancy
P03344812A0924|33 34|BP
P03344812A0924|33 34|BP
P03344812A0924|38 51|HR measurements
P03344812A0924|176 177|BP
P03344812A0924|181 188|HR values
P03344812A0924|219 224|animal
P03344812A0924|293 294|BP
P03344812A0924|293 294|BP
P03344812A0924|298 305|HR levels
P03344812A0924|298 299|HR
P03345706A0561|21 25|PaCO2
P03345706A0561|29 33|PtcO2
P03345706A0561|36 38|RDS
P03346157A0000|34 66|ABCC/RERF radiological examinations
P03346157A0000|71 99|Adult Health Study (AHS) subjects
P03346157A0000|144 156|medical x-rays
P03346157A0000|195 198|RERF
P03346157A0000|228 239|examinations
P03346210A0000|3 36|epidermal growth factor (EGF) receptor
P03346210A0000|3 23|epidermal growth factor
P03346210A0000|25 36|EGF) receptor
P03346210A0000|51 88|intrinsic protein tyrosine kinase activity
P03346210A0000|60 80|protein tyrosine kinase
P03346210A0000|157 169|EGF activation
P03346210A0000|157 159|EGF
P03348382A0785|3 12|millimolar
P03348382A0785|13 19|ouabain
P03351478A0371|19 26|long runs
P03351478A0371|36 36|C
P03351478A0371|42 50|G residues
P03352439T0000|0 31|Vocal cord abduction rehabilitation
P03352439T0000|34 40|nervous
P03352439T0000|50 60|anastomosis
P03352727T0000|0 16|UK's biotechnology
P03352727T0000|24 34|specialists
P03352947T0001|7 33|AIDS-related complex (ARC/LAS
P03352947T0001|27 29|ARC
P03352947T0001|31 33|LAS
P03354295A0157|0 12|Distant spread
P03354295A0157|23 24|46
P03354295A0157|25 32|patients
P03354341A0177|3 26|glomerular filtration rate
P03354341A0177|39 53|renal plasma flow
P03354341A0177|71 93|standard clearance method
P03354341A0177|124 129|inulin
P03354341A0177|124 129|inulin
P03354341A0177|133 154|para-aminohippuric acid
P03355122A0238|8 27|meal containing potato
P03355122A0238|29 47|plasma glucose levels
P03359860A0000|32 68|emotional and behavioral characteristics
P03359860A0000|75 84|aggression
P03359860A0000|86 92|anxiety
P03359860A0000|184 207|New York Longitudinal Study
P03360667A0000|21 28|altitude
P03360667A0000|31 60|adolescent growth and development
P03360667A0000|75 82|healthy,
P03360667A0000|133 146|ethnic grouping
P03360667A0000|159 161|sea
P03360667A0000|184 195|mid-altitude
P03360948A0477|42 56|abusive behavior
P03360948A0477|103 105|CAP
P03360948A0477|103 105|CAP
P03360948A0477|121 152|Behavioral/Emotional Control scale
P03361653A0459|26 51|nuclear contour digitization
P03366720A1335|30 36|mammary
P03366720A1335|70 78|fatty acid
P03366720A1335|91 100|metabolism
P03366720A1335|103 109|glucose
P03366720A1335|113 122|glycolysis
P03366864A0099|3 10|skin site
P03366864A0099|12 54|6-cm-distal and -proximal subcutaneous segments
P03366864A0099|69 85|exudates, and blood
P03368701A0113|84 107|medical imaging techniques
P03370815T0000|0 13|Rapid detection
P03370815T0000|16 53|radioisotopically contaminated test serum
P03370815T0000|72 81|vitamin B12
P03371139A0829|31 43|fecal material
P03371806A0000|25 44|EDP) latex immunoassay
P03371806A0000|50 81|anti-human seminal acid phosphatase
P03371806A0000|50 81|anti-human seminal acid phosphatase
P03371806A0000|83 103|anti-HSAP) immune serum
P03371806A0000|83 91|anti-HSAP
P03371894A0355|0 17|Vimentin positivity
P03371894A0355|0 7|Vimentin
P03371894A0355|31 46|undifferentiated
P03371894A0355|50 71|fibroblastic components
P03372422A0558|33 34|Ar
P03372422A0558|38 39|N2
P03372422A0558|44 69|extrapolated phase III slopes
P03372422A0558|127 143|gas concentrations
P03372422A0558|153 157|lungs
P03373755T0001|53 63|peptic ulcer
P03373755T0001|94 118|gastrin receptor blockaders
P03373755T0001|94 108|gastrin receptor
P03375184A0000|3 23|spermicide nonoxynol-9
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|78 95|polyethoxyethanols
P03375184A0000|99 145|general formula C9H19-C6H6-O-(CH2CH2O)n-1 CH2CH2OH
P03377864A0000|6 19|magnetic fields
P03377864A0000|61 69|solutions
P03377864A0000|95 107|Maxwell stress
P03377891A0652|0 23|Psychological disturbance
P03377891A0652|97 115|global severity index
P03377891A0652|121 139|Symptom Checklist-90
P03377891A0652|155 166|somatization
P03377891A0652|168 186|obsessive compulsive
P03377891A0652|213 222|depression
P03377891A0652|224 254|anxiety and psychoticism subscales
P03378994T0000|0 20|Chronic administration
P03378994T0000|23 35|sodium cyanate
P03378994T0000|45 61|O2 extraction ratio
P03379058A0188|0 9|Nucleotide
P03379058A0188|37 52|E1 alpha cDNA clone
P03379058A0188|37 47|E1 alpha cDNA
P03379058A0188|55 67|1821 base pairs
P03379058A0188|69 70|bp
P03379058A0188|86 101|open reading frame
P03379058A0188|104 109|1365 bp
P03379058A0188|114 134|3'-untranslated region
P03380547A0169|0 2|SPA
P03380547A0169|7 14|PAG sites
P03380547A0169|32 39|aversion
P03381039A0364|14 16|MAN
P03381039A0364|14 16|MAN
P03381039A0364|33 50|skewed distribution
P03382310A0903|0 36|Abnormal technetium Tc 99m medronate scans
P03382310A0903|39 46|patients
P03382310A0903|96 118|inflammatory arthropathy
P03382772A0319|47 71|pharmacokinetic parameters
P03382772A0319|109 120|phase I trials
P03382855A0368|3 12|artery cuff
P03382855A0368|37 43|fat wrap
P03382855A0368|65 78|fewer adhesions
P03383897A0189|0 22|Lithium-carbonate action
P03383897A0189|29 44|radiation therapy
P03383897A0189|86 97|leukopoiesis
P03383897A0189|143 150|patients
P03384272A0145|91 96|lesion
P03387665A0000|31 68|Trypanosoma congolense, T vivax and T brucei
P03387665A0000|74 77|skin
P03387665A0000|80 84|goats
P03387665A0000|104 110|animals
P03387665A0000|131 156|Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03390074A0000|29 49|non-invasive technique
P03395009A1750|33 41|secondary
P03395009A1750|42 62|spinal cord compression
P03395009A1750|77 83|group-1
P03395009A1750|159 186|transverse spinal cord sections
P03395009A1750|207 209|T12
P03395009A1750|212 213|L1
P03395009A1750|212 213|L1
P03395009A1750|224 226|T11
P03395009A1750|228 233|T11-12
P03395009A1750|235 238|L1-2
P03395009A1750|235 238|L1-2
P03395009A1750|243 244|L2
P03395009A1750|243 244|L2
P03395009A1750|257 264|surgical
P03395164A0000|43 102|WEB 1881 FU (4-amino-methyl-1-benzyl-pyrrolidine-2-one-fumarate
P03395164A0000|53 68|4-amino-methyl-1
P03395249A1044|0 27|Histopathological examination
P03395249A1044|63 79|type II pneumocytes
P03395249A1044|104 120|interstitial cells
P03395249A1044|124 157|delayed septal/capillary development
P03395249A1044|160 167|neonates
P03396437A0321|19 26|multiply
P03396628A0207|9 25|observation period
P03396628A0207|40 56|cardiac white spots
P03396628A0207|62 75|right ventricle
P03396628A0207|78 87|BALB/c mice
P03396628A0207|123 126|mice
P03396628A0207|157 173|cardiac white spots
P03396628A0207|203 206|mice
P03398433T0001|13 17|liver
P03398433T0001|38 59|meningococcal infection
P03398714A0594|13 14|RH
P03398823A0459|20 37|oral administration
P03398823A0459|98 122|inhaled p-xylene dissipated
P03400694A0245|31 52|myocardial scintigraphy
P03400694A0245|132 139|patients
P03400694A0245|144 154|sarcoidosis
P03401060A0000|0 12|Thin melanomas
P03402183A0171|3 4|TA
P03402183A0171|5 10|muscle
P03402183A0171|52 63|contractions
P03402183A0171|84 99|contractions (MVC
P03402183A0171|105 107|MVC
P03402183A0171|153 164|contractions
P03402183A0171|227 238|contractions
P03403313A0298|78 93|subtotal excision
P03403313A0298|104 119|subtotal excision
P03403313A0298|137 152|radiation therapy
P03403412A0000|12 27|anabolic implants
P03403412A0000|49 67|energetic efficiency
P03403412A0000|124 135|grain content
P03403480A0299|49 70|geometric configuration
P03403480A0299|162 173|cortical area
P03403480A0299|175 189|density, mineral
P03403480A0299|194 201|collagen
P03403480A0299|194 201|collagen
P03403480A0299|202 215|concentrations
P03403826T0000|0 24|Which cineangiographically
P03403826T0000|33 48|anatomic variable
P03403826T0000|67 88|functional measurements
P03403826T0000|91 106|stenosis severity
P03403826T0000|121 140|quantitative analysis
P03403826T0000|146 166|coronary cineangiogram
P03403826T0000|179 223|coronary flow reserve and exercise/redistribution
P03404334T0000|0 11|Water content
P03404334T0000|26 39|water partition
P03404334T0000|42 58|immature cartilage
P03404495A0172|0 6|Thyroid
P03404495A0172|56 66|707 untested
P03406054A0351|28 30|LSF
P03406054A0351|51 55|image
P03406054A0351|135 152|polystyrene phantom
P03407676A0585|0 15|Primary infection
P03407843T0000|0 5|Papers
P03407843T0000|29 43|Vascular Surgery
P03413681A0659|0 19|Ischemic heart disease
P03413681A0659|106 120|cardiac function
P03413890T0001|0 8|Prognosis
P03413890T0001|11 24|Bowen's disease
P03413890T0001|39 55|ano-genital region
P03417104A0536|95 101|animals
P03417588T0000|6 26|chromatographic method
P03417588T0000|60 70|corn and rice
P03417668A1233|25 43|autophosphorylation
P03417668A1233|46 64|Thr286 (alpha subunit
P03417668A1233|53 64|alpha subunit
P03417668A1233|69 74|Thr287
P03417668A1233|76 86|beta subunit
P03417668A1233|76 86|beta subunit
P03417668A1233|116 127|CaM-kinase II
P03417668A1233|116 127|CaM-kinase II
P03417668A1233|133 152|Ca2+-independent form
P03418727A0992|21 31|penetration
P03418727A0992|59 70|chemotherapy
P03418727A0992|93 102|myelopathy
P03420266A0000|16 24|radiation
P03420266A0000|28 39|hyperthermia
P03420266A0000|69 104|Dunning R3327G prostatic adenocarcinoma
P03420266A0000|109 118|preeminent
P03420266A0000|133 152|human prostatic cancer
P03420324A0178|0 11|Pregnant rats
P03420324A0178|53 54|N2
P03420324A0178|87 91|11, 14
P03420324A0178|99 107|pregnancy
P03420324A0178|119 120|N2
P03420466A0000|33 45|young children
P03421425A0878|5 12|patients
P03421425A0878|34 47|hypothyroidism
P03423732A0341|22 27|De-Nol
P03423732A0341|50 69|gastric HCO3 secretion
P03423732A0341|133 150|16,16-dimethyl PGE2
P03423732A0341|152 157|dmPGE2
P03427474A0853|15 40|control rats operated animals
P03427474A0853|87 104|saccharin solutions
P03427613A0659|2 15|Salmo gairdneri
P03427613A0659|38 50|portal vessels
P03427613A0659|75 85|pineal organ
P03427613A0659|107 111|brain
P03428084A0430|35 52|scalp distributions
P03428084A0430|74 77|P100
P03428084A0430|96 97|C1
P03428274A0000|0 21|Nuclear factor III (NFIII
P03428274A0000|0 15|Nuclear factor III
P03428274A0000|17 21|NFIII
P03428274A0000|37 45|HeLa cells
P03428274A0000|75 108|adenovirus type 2 (Ad2) DNA replication
P03428274A0000|75 89|adenovirus type 2
P03428274A0000|91 93|Ad2
P03428274A0000|129 146|nucleotide sequence
P03428274A0000|172 200|nuclear factor I recognition site
P03428274A0000|172 200|nuclear factor I recognition site
P03429306T0000|0 10|A Golgi study
P03429306T0000|31 44|cerebral cortex
P03429371A1051|36 43|S. aureus
P03429371A1051|65 74|phagocytes
P03429371A1051|100 125|phagocyte-inaccessible site
P03430221A1236|54 74|cortical-bar detectors
P03434347A0358|4 7|rCBF
P03434347A0358|56 70|ipsilateral side
P03436119A0000|0 29|Quantitative computed tomography
P03436119A0000|42 68|vertebral bone mineral content
P03436119A0000|75 89|high sensitivity
P03436529A1066|17 24|enhancer
P03436529A1066|40 48|inserting
P03436529A1066|56 68|complementary
P03436529A1066|69 98|synthetic oligodeoxynucleotides
P03436529A1066|131 152|nt positions -235 and -215
P03436529A1066|189 196|enhancer
P03436877A0950|0 1|Kf
P03436877A0950|3 8|c and CT
P03436877A0950|32 39|lung mass
P03436877A0950|140 146|delta CT
P03436877A0950|173 176|0.82
P03439248A0000|0 22|Two scintigraphic methods
P03439248A0000|24 42|resting dipyridamole
P03439248A0000|66 91|myocardial perfusion imaging
P03439248A0000|112 119|coronary
P03439248A0000|120 133|artery stenosis
P03439248A0000|150 157|patients
P03439248A0000|171 191|coronary artery disease
P03440780A0779|34 37|EDLF
P03440780A0779|87 96|adrenergic
P03440780A0779|99 120|calcium entry mechanisms
P03440780A0779|176 180|EDLFs
P03440780A0779|203 214|vascular beds
P03441587A0000|0 7|Research
P03441587A0000|26 42|rheumatoid factors
P03441587A0000|26 42|rheumatoid factors
P03441587A0000|48 52|serum
P03441587A0000|58 65|patients
P03441587A0000|92 102|polystyrene
P03441587A0000|113 124|erythrocytes
P03443144A0409|1 26|low aspirin esterase activity
P03443144A0409|4 18|aspirin esterase
P03443144A0409|33 50|contributory factor
P03443144A0409|71 77|aspirin
P03443566A0675|30 53|gain and gain-to-feed ratio
P03443566A0675|68 69|TR
P03443566A0675|68 69|TR
P03443566A0675|73 74|CR
P03443566A0675|73 74|CR
P03443573A0329|28 35|uncooked
P03443573A0329|39 61|cooked longissimus muscle
P03443573A0329|65 79|subcutaneous fat
P03443609A0000|9 44|supercritical fluid chromatography (SFC
P03443609A0000|129 154|capillary column methodology
P03446332A0831|42 43|LH
P03446332A0831|42 43|LH
P03446332A0831|53 56|LHRH
P03446332A0831|53 56|LHRH
P03448035T0000|7 12|tumors
P03449358T0001|22 34|polyarteritis
P03450438A0446|0 5|X2 test
P03450438A0446|42 52|statistical
P03451761A0215|20 30|WPW syndrome
P03451761A0215|34 42|simulated
P03451761A0215|86 104|base of the ventricles
P03451761A0215|109 111|RNV
P03452920T0001|0 2|Man
P03452920T0001|6 11|insect
P03457330A0271|3 10|patients
P03457330A0271|17 21|CA 125
P03459385T0000|0 27|Allergy and Tourette's syndrome
P03459736A0184|3 11|criterion
P03459736A0184|67 82|pills and capsules
P03463537T0001|0 13|Clinical method
P03463537T0001|31 45|Class II occlusal
P03463543A1613|0 7|Enoxacin
P03463543A1613|57 59|UTI
P03465957A1008|4 18|fluorosis scores
P03466730A0210|0 20|Autonomic dysfunctions
P03466730A0210|37 47|tonic pupils
P03473253A0000|75 94|workers (2,460 exposed
P03473253A0000|98 112|3,692 nonexposed
P03473253A0000|123 150|chloromethyl ether manufacture
P03473379A0183|14 24|amyloidosis
P03473379A0183|43 61|labial salivary gland
P03476002A0148|0 18|Hair and blood samples
P03476002A0148|34 41|vitamin C
P03476002A0148|44 65|placebo supplementation
P03478354A0436|65 84|prostaglandin F2 alpha
P03479897A0961|33 35|ANB
P03479897A0961|89 96|Class III
P03484075T0001|0 17|Emergency treatment
P03484075T0001|20 25|facial
P03484075T0001|29 37|maxillary
P03484894A0782|47 55|biotype II
P03484894A0782|65 74|biotype III
P03484894A0782|103 103|V
P03485064A0135|8 23|117 EVS treatments
P03485064A0135|41 48|patients
P03486405A0341|9 25|prepeptide portion
P03486405A0341|31 50|precursor polypeptide
P03486405A0341|98 106|IL-1 alpha
P03486405A0341|98 106|IL-1 alpha
P03487348A0000|1 10|stochastic
P03487348A0000|20 28|Kernell's
P03487348A0000|49 80|cumulative afterhyperpolarization
P03487348A0000|82 84|AHP
P03487348A0000|89 97|simulated
P03488532A0235|53 67|dermatomal signs
P03488532A0235|83 91|acyclovir
P03491190A0233|3 15|detectability
P03491190A0233|30 32|RCA
P03491190A0233|35 43|LAD region
P03491190A0233|74 86|stress studies
P03493240T0000|0 22|Pharmacologic properties
P03493240T0000|25 42|serotonergic agents
P03493240T0000|46 64|antidepressant drugs
P03494649A0472|9 28|hypercapnic challenge
P03494649A0472|52 54|CBF
P03494649A0472|80 83|MABP
P03499608A1054|46 57|heterozygote
P03499608A1054|70 86|prenatal diagnosis
P03499608A1054|89 106|11 beta-hydroxylase
P03499608A1054|91 116|beta-hydroxylase deficiency
P03499608A1054|146 173|congenital adrenal hyperplasia
P03499657A0000|0 10|Osteocalcin
P03499657A0000|0 10|Osteocalcin
P03499657A0000|12 31|serum bone-Gla protein
P03499657A0000|33 36|sBGP
P03499657A0000|33 36|sBGP
P03499657A0000|39 62|serum alkaline phosphatase
P03499657A0000|39 62|serum alkaline phosphatase
P03499657A0000|64 66|sAP
P03499657A0000|64 66|sAP
P03499657A0000|78 107|hydroxyproline/creatinine ratio
P03499657A0000|109 127|uOH-Prol/creatinine
P03499657A0000|149 156|patients
P03499657A0000|161 186|primary hyperparathyroidism
P03499657A0000|188 191|PHPT
P03499657A0000|202 209|patients
P03499657A0000|214 227|hypercalcaemia
P03499657A0000|241 242|HM
P03499822A0182|51 64|seropositivity
P03499822A0182|105 114|hepatitis B
P03504971A0000|0 5|Hexsyn
P03504971A0000|11 47|Goodyear Tire and Rubber Company tradename
P03504971A0000|127 145|residual double bonds
P03504971A0000|149 161|vulcanization
P03507689A0000|0 7|Chimeric
P03507689A0000|8 37|phage-plasmid expression vectors
P03507689A0000|102 106|ssDNA
P03507689A0000|131 145|bacteriophage f1
P03507689A0000|149 157|inserting
P03507689A0000|159 181|bacteriophage T7 promoter
P03507689A0000|159 181|bacteriophage T7 promoter
P03507689A0000|191 212|beta-galactosidase gene
P03507689A0000|191 212|beta-galactosidase gene
P03508698A0535|30 76|flexors, jaw, crossed adductors, and triceps reflexes
P03513989A0580|7 13|ethanol
P03513989A0580|17 24|estrogen
P03513989A0580|44 58|UROD-deficiency
P03513989A0580|44 47|UROD
P03513989A0580|61 67|animals
P03513989A1149|70 88|porphyrin metabolism
P03515840A0000|60 69|granuloma'
P03515840A0000|86 107|malignant histiocytosis
P03515840A0000|109 126|histiocytic sarcoma
P03516189A0406|47 48|v.
P03517388A0763|23 27|CK-MB
P03517388A0763|23 27|CK-MB
P03517388A0763|45 49|BC (BC
P03517388A0763|58 58|U
P03517388A0763|60 60|L
P03517388A0763|62 63|CC
P03517388A0763|65 72|56 +/- 13 U
P03517388A0763|65 66|56
P03517388A0763|74 74|L
P03520729A0381|29 38|body weight
P03520729A0381|57 69|renin activity
P03520729A0381|57 61|renin
P03520729A0381|73 83|aldosterone
P03522105A1011|10 31|serum TOB concentrations
P03522105A1011|50 54|death
P03526279T0000|0 13|State-approved
P03526279T0000|23 30|nursing R
P03531317A0930|92 97|Fisher
P03534581A0976|20 37|malignant neoplasms
P03534581A0976|73 86|5-fluorouracil
P03534581A0976|88 98|doxorubicin
P03534581A0976|103 118|cyclophosphamide
P03534581A0976|128 149|historical control group
P03536682A0572|0 8|Ovulation
P03536682A0572|29 36|patients
P03537686A0099|3 11|small size
P03537686A0099|29 45|mutagenesis marker
P03537686A0099|50 71|supF suppressor tRNA gene
P03537686A0099|50 67|supF suppressor tRNA
P03537686A0099|76 90|Escherichia coli
P03537686A0099|196 209|mammalian cells
P03537686A0099|214 223|plasmid DNA
P03537686A0099|231 249|UV-induced mutations
P03537686A0099|278 298|spontaneous background
P03537721A0491|0 13|Tetrad analysis
P03537721A0491|17 47|mitotic recombination experiments
P03537721A0491|60 67|PEP4 gene
P03537721A0491|60 67|PEP4 gene
P03537721A0491|78 81|GAL4
P03537721A0491|78 81|GAL4
P03537721A0491|84 96|chromosome XVI
P03537721A0876|86 93|PEP4 gene
P03537721A0876|86 93|PEP4 gene
P03537721A0876|116 127|yeast vacuole
P03537721A0876|156 173|vacuolar hydrolases
P03537721A0876|156 173|vacuolar hydrolases
P03537727A0243|3 9|poly(A)
P03537727A0243|22 24|RNA
P03537727A0243|56 85|72,000-molecular-weight protein
P03537727A0243|87 96|72K protein
P03540591A0330|20 22|RNA
P03540591A0330|41 51|cloned cDNAs
P03540591A0330|64 76|P0 transcripts
P03540591A0330|64 65|P0
P03540591A0330|100 114|12.5-kilodalton
P03540591A0330|145 160|open reading frame
P03540853A0652|3 29|N-terminal amino acid sequence
P03540853A0652|32 34|Mop
P03540853A0652|32 34|Mop
P03540853A0652|58 75|DNA binding proteins
P03540853A0652|58 75|DNA binding proteins
P03541263A0368|7 19|new techniques
P03541263A0368|54 61|diabetes
P03542945T0000|0 12|Ciprofloxacin
P03543485A0069|62 79|space flight effects
P03543936A0000|3 10|rho genes
P03543936A0000|78 88|ras oncogene
P03543936A0000|78 88|ras oncogene
P03544858A0374|49 55|insulin
P03544858A0374|49 55|insulin
P03544858A0374|59 61|VO2
P03544858A0374|84 98|basal metabolism
P03544858A0374|102 116|HDL-cholesterol
P03544858A0374|102 116|HDL-cholesterol
P03544858A0374|120 126|females
P03544858A0374|130 134|males
P03545955A0751|3 14|glucose areas
P03545955A0751|58 68|glucose 11.7
P03545955A0751|96 114|glucose + fructose 6.3
P03545955A0751|146 152|glucose
P03545955A0751|215 225|glucose 12.6
P03545955A0751|227 237|ice cream 8.1
P03545955A0751|250 264|lactose 4.1 mmol X
P03545955A1378|3 22|serum insulin response
P03545955A1378|8 14|insulin
P03549045A0878|0 2|SCL
P03549045A0878|25 33|verapamil
P03549045A0878|38 48|sinus arrest
P03549045A0878|91 97|animals
P03550444T0000|32 52|mutational specificity
P03552363A0568|11 28|serum insulin levels
P03552363A0568|11 22|serum insulin
P03552363A0568|64 101|systolic or diastolic blood pressure levels
P03552363A0568|104 106|men
P03552363A0568|113 149|female diabetic and non-diabetic subjects
P03552363A0568|198 223|systolic blood pressure level
P03553149A0299|6 40|oligonucleotide-directed mutagenesis
P03553149A0299|55 58|MucA
P03553149A0299|55 58|MucA
P03553149A0299|74 80|Ala-Gly
P03553149A0299|95 98|LexA
P03553149A0299|95 98|LexA
P03553439A0404|38 53|solid tumor tissue
P03553439A0404|90 99|tumor cells
P03553439A0404|108 123|solid tumor tissue
P03553439A0404|156 165|tumor cells
P03553439A0404|167 173|Type III
P03553439A0404|183 192|tumor cells
P03555318T0000|17 25|carnitine
P03556834T0000|0 22|Acute inhalation toxicity
P03556834T0000|25 36|T-2 mycotoxin
P03556834T0000|39 42|mice
P03559193A0000|66 85|Framingham Type A scale
P03559193A0000|87 90|FTAS
P03559193A0000|129 141|psychological
P03559232T0000|19 35|pyogenic arthritis
P03559287T0000|0 9|Legionella
P03559287T0000|11 26|microbial ecology
P03559287T0000|31 54|inconspicuous consumption
P03561036T0000|0 9|Lymphatics
P03561036T0000|22 25|rats
P03561036T0000|38 66|soy-bean oil extract (lipofundin
P03561622A0659|80 96|DiaTAP button graft
P03561622A0659|116 140|Staphylococcus epidermidis
P03561622A0659|144 168|intermittent positive blood
P03561622A0659|182 206|long term vancomycin therapy
P03563399A0534|3 8|signal
P03563399A0534|42 51|SoNo and S pi
P03563399A0534|87 109|masking-level difference
P03563604A1075|3 12|spleen rate
P03563604A1075|34 36|RK I
P03563604A1075|59 70|parasite rate
P03567017A0000|68 88|anti-inflammatory drug
P03567017A0000|123 138|drug accumulation
P03567017A0000|146 160|elderly subjects
P03568311A0273|4 11|patients
P03568311A0273|24 39|cardiac tamponade
P03568311A0273|41 66|pulmonary wedge pressure (PWP
P03568311A0273|64 66|PWP
P03568311A0273|69 71|RAP
P03568311A0273|69 71|RAP
P03568311A0273|76 78|IPP
P03568311A0273|109 124|systolic function
P03568311A1361|0 20|Encompassing tamponade
P03568311A1361|47 61|left ventricular
P03568311A1361|106 110|TMFP1
P03568311A1361|121 125|TMFP2
P03568311A1361|143 147|TMFP3
P03570455A0433|16 35|profound hypocalcemia
P03570455A0433|103 108|TSST-1
P03570455A0433|103 108|TSST-1
P03571135T0000|0 10|Reward value
P03571135T0000|42 49|autistic
P03571135T0000|77 84|children
P03572706A0329|155 155|F
P03572706A0329|155 155|F
P03572706A0329|159 161|F-K
P03572706A0329|159 159|F
P03572706A0329|179 189|MMPI profile
P03575656A0120|38 41|90Sr
P03575656A0120|68 71|lung
P03577670A0102|17 34|generalized atrophy
P03577670A0102|45 53|symmetric
P03577670A0236|14 40|metachromatic leukodystrophy
P03577670A0236|42 44|MLD
P03577670A0236|72 88|low arylsulfatase A
P03577670A0236|75 88|arylsulfatase A
P03577670A0236|90 92|ASA
P03577670A0236|90 92|ASA
P03577670A0236|102 120|cultured fibroblasts
P03578948A0448|0 20|Artificial ventilation
P03578948A0448|39 49|tidal volume
P03578948A0448|56 60|X kg-1
P03581160A0583|18 36|heart rate reactivity
P03581160A0583|67 70|left
P03581160A0583|71 84|temporal artery
P03581160A0583|119 141|non-medicated TH subjects
P03581160A0583|148 155|controls
P03582149T0001|25 45|rheumatic valve disease
P03582149T0001|49 57|rheumatic
P03582149T0001|65 97|primary and secondary school students
P03582184A0448|26 41|phase II reactions
P03582184A0448|61 76|dosage adjustment
P03582982A0000|8 17|human genes
P03582982A0000|8 17|human genes
P03582982A0000|27 43|U4 small nuclear RNA
P03582982A0000|27 43|U4 small nuclear RNA
P03583001A0111|16 27|gas procedure
P03583001A0111|39 50|gas injection
P03583001A0111|100 108|giant tear
P03583001A0111|131 157|subretinal fluid or vitrectomy
P03584426A0706|50 62|stool isolates
P03584426A0706|84 93|42 isolates
P03584426A0706|131 142|suckling mice
P03584426A0706|152 177|cytotoxin-producing strains
P03584426A0706|192 206|LT-like material
P03586925T0001|14 63|provisional information-retrieval descriptor language
P03586925T0001|112 126|Medinform system
P03590911T0001|10 31|acantholytic dermatosis
P03591464A0840a|37 51|disease activity
P03591464A0840a|68 84|calcium antagonist
P03591464A0840b|37 51|disease activity
P03591464A0840b|68 84|calcium antagonist
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0138|33 56|oxygen-sensing electrodes
P03592297A0138|61 79|surface temperatures
P03592297A0138|124 142|sympathetic activity
P03592297A0138|155 167|vasomotor tone
P03592297A0138|171 175|TcpO2
P03592297A0138|178 181|skin
P03592297A0138|213 234|submaximal vasodilation
P03592297A0679|41 55|sympathetic tone
P03592297A0679|67 84|cervical cord trauma
P03592297A0679|86 90|TcpO2
P03592297A0679|118 122|index
P03595418A0688|27 49|human and murine ornithine
P03595418A0688|35 67|murine ornithine decarboxylase mRNAs
P03595418A0688|50 62|decarboxylase
P03595418A0688|63 67|mRNAs
P03595418A0688|98 116|3'-noncoding regions
P03597218A0901|27 49|alpha 2-plasmin inhibitor
P03597218A0901|27 40|alpha 2-plasmin
P03597218A0901|51 70|alpha 2-macroglobulin
P03597218A0901|51 70|alpha 2-macroglobulin
P03597218A0901|75 89|antithrombin III
P03597218A0901|75 89|antithrombin III
P03597218A0901|168 178|acute shifts
P03597218A0901|181 191|plasma water
P03597269A0409|64 75|+ b[exp(cVO2)
P03600633A1069|0 3|Cell
P03600705T0000|0 5|Timing
P03600705T0000|19 33|oocyst excretion
P03600705T0000|36 57|human cryptosporidiosis
P03601275A0601|5 20|dopamine infusion
P03601275A0601|23 27|women
P03601275A0601|32 54|polycystic ovary syndrome
P03601275A0601|110 123|norepinephrine
P03601275A0601|138 146|dopamine/
P03601275A0601|147 160|norepinephrine
P03601533T0001|60 67|children
P03601533T0001|72 92|autoimmune thyroiditis
P03602261A0238|18 29|unstimulated
P03602261A0238|102 122|systolic blood pressure
P03602261A0238|126 133|dopamine
P03602261A0238|143 156|norepinephrine
P03602261A0238|168 178|epinephrine
P03602261A0238|230 238|melatonin
P03602261A0238|242 249|dopamine
P03602261A0238|260 273|norepinephrine
P03602261A0238|286 298|growth hormone
P03605895A0888|4 11|patients
P03605895A0888|16 38|carboxyhemoglobin levels
P03605895A0888|16 32|carboxyhemoglobin
P03607109A0370|92 99|controls
P03607961T0001|0 17|Hypoglycemic action
P03607961T0001|58 73|diabetes mellitus
P03608916A0790|17 19|HPT
P03608916A0790|30 40|1,25-(OH)2D
P03608989A0668|12 23|60 amino acids
P03608989A0668|93 109|filament formation
P03608989A0668|115 123|rod region
P03610663A0201|143 153|nutritional
P03610663A0201|157 171|metabolic states
P03610674T0000|18 31|zinc deficiency
P03610674T0000|37 46|mossy fiber
P03610674T0000|63 65|rat
P03610674T0000|66 76|hippocampus
P03612316A0102|0 9|Weaned rats
P03612316A0102|18 27|normal diet
P03612316A0102|31 41|low-protein
P03612316A0102|43 56|low-energy diet
P03612316A0102|73 89|saline or thyroxine
P03612316A0102|107 108|BW
P03612648A0085|22 39|lupus anticoagulant
P03612648A0085|68 81|thromboplastin
P03615550A0000|19 32|opioid agonists
P03615550A0000|39 62|opioid antagonist naloxone
P03615550A0000|77 80|rats
P03615550A0000|122 133|FCN) schedule
P03615550A1094|27 34|morphine
P03615550A1094|38 43|U50488
P03615550A1094|90 97|naloxone
P03615763A0170|8 13|119 men
P03615763A0170|34 41|coronary
P03615763A0170|189 200|hypertension
P03615763A0170|202 217|serum cholesterol
P03615763A0170|202 217|serum cholesterol
P03615763A0170|234 241|diabetes
P03615763A0170|258 269|heart disease
P03615763A0170|271 290|Type A behavior pattern
P03616174A1069|2 17|intralobar change
P03616174A1069|69 87|lobar bronchial blood
P03616174A1069|127 139|nearby tissues
P03616174A1069|171 190|bronchial circulation
P03616237T0001|0 15|Convulsive status
P03618039A0126|52 64|noradrenaline
P03618039A0126|103 132|catecholamine biotransformation
P03619249A0428|37 41|serum
P03619249A0428|43 46|skin
P03619249A0428|50 54|liver
P03619249A0428|60 67|patients
P03619249A0428|72 87|chronic hepatitis
P03619249A0428|89 91|HBV
P03619249A0428|93 97|HBs Ag
P03619249A0428|93 97|HBs Ag
P03619249A0428|101 105|HBe Ag
P03619249A0428|101 105|HBe Ag
P03619249A0428|107 114|anti-HBs
P03619249A0428|107 114|anti-HBs
P03619249A0428|116 123|anti-HBe
P03619249A0428|116 123|anti-HBe
P03619249A0428|127 134|anti-HBc
P03619249A0428|127 134|anti-HBc
P03619249A0428|140 148|serum, HBs
P03619249A0428|140 144|serum
P03619249A0428|146 148|HBs
P03619249A0428|152 156|HBc Ag
P03619249A0428|152 156|HBc Ag
P03619249A0428|162 166|liver
P03619249A0428|169 178|non-A non-B
P03619249A0428|178 184|B (non-A
P03619249A0428|180 184|non-A
P03619249A0428|186 203|non-B Ag and antibody
P03619249A0428|186 203|non-B Ag and antibody
P03619249A0428|205 219|anti non-A non-Bc
P03619249A0428|225 235|serum, non-A
P03619249A0428|225 229|serum
P03619249A0428|237 244|non-Bc Ag
P03619249A0428|243 244|Ag
P03619249A0428|250 254|liver
P03622423A0000|8 20|male and female
P03622423A0000|31 34|rats
P03622423A0000|36 45|B6C3F1 mice
P03622423A0000|57 66|guinea pigs
P03622423A0000|144 159|methyl isocyanate
P03622423A0000|161 169|MIC) vapor
P03622571A0208|0 16|Radionuclide study
P03622571A0208|20 39|endomyocardial biopsy
P03622571A0208|72 81|myocardium
P03625688A0372|39 47|cuff sling
P03625762A0308|29 37|phenytoin
P03625762A0308|114 122|phenytoin
P03625762A0308|191 200|vitamin B12
P03626129T0001|20 28|laser beam
P03626129T0001|44 53|newt embryo
P03627720A0196|0 6|Typical
P03627720A0196|10 33|atypical clinical features
P03627720A0196|40 54|lacrimal sac cyst
P03628596A0000|0 6|Samples
P03628596A0000|27 34|patients
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628596A0000|98 121|lumbar cerebrospinal fluid
P03628713A0961|27 29|AIB
P03628713A0961|33 44|86RbCl uptake
P03628713A0961|47 57|36B-10 cells
P03628713A0961|87 97|irradiation
P03628713A0961|150 159|tumor cells
P03628713A0961|166 168|AIB
P03628713A0961|171 172|Rb
P03628794A0648|3 10|patients
P03628794A0648|26 42|metastatic disease
P03628794A0648|67 82|MIBG scintigraphy
P03629974A1468|15 31|amino acid sequence
P03629974A1468|37 63|M RNA product of Uukuniemi virus
P03629974A1468|37 40|M RNA
P03629974A1468|50 63|Uukuniemi virus
P03629974A1468|74 82|Punta Toro
P03629974A1468|185 200|COOH-terminal end
P03629974A1468|206 214|precursor
P03632739T0000|0 11|Cyclosporine
P03632739T0000|24 46|intractable polymyositis
P03635597A0377|16 36|Cohler's maternal scale
P03635597A0377|44 50|mothers
P03635597A0377|71 77|infants
P03635597A0377|115 121|mothers
P03637037T0000|1 27|preoperative teaching booklet
P03637037T0000|40 47|patients
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|69 79|splice sites
P03649340A1119|90 102|exon sequences
P03651330T0000|0 28|UVA-induced melanocytic lesions
P03651840A0266|0 18|Ex vivo MAO inhibition
P03651840A0266|55 59|MAO-B
P03651840A0266|55 59|MAO-B
P03651840A0266|103 128|tranylcypromine or pargyline
P03652083A0720|21 38|vessel pyridinoline
P03652083A0720|79 86|collagen
P03652083A0720|79 86|collagen
P03653226A0833|1 7|careful
P03653226A0833|82 94|metabolic fate
P03658866A0081|0 25|Systemic lupus erythematosus
P03659603A0797|50 52|CO2
P03659603A0797|78 91|CO2 sensitivity
P03659805A0404|3 25|statistical significance
P03659805A0404|59 86|uni- and multivariative methods
P03659805A0404|109 111|Cox
P03659805A0404|128 130|IMB
P03659805A0404|131 138|computer
P03659994A0150|42 57|focal abnormality
P03659994A0150|90 104|signal intensity
P03659994A0150|107 108|T1
P03659994A0150|143 157|signal intensity
P03659994A0150|160 161|T2
P03663789A0568|53 56|RHAL
P03663789A0568|63 77|neuroleptic test
P03663789A0568|117 120|RHAL
P03663789A0568|123 125|HAL
P03664038A0000|61 93|Gudjonsson Suggestibility Scale (GSS
P03664038A0000|138 164|interrogative suggestibility
P03666957A0219|0 8|Organisms
P03666957A0219|29 39|conjunctiva
P03666957A0219|59 75|persistent genital
P03666957A0219|79 94|gastrointestinal
P03666957A0219|123 137|ocular infection
P03666957A0219|144 147|cats
P03668003T0000|2 30|vivo epiluminescence microscopy
P03668003T0000|33 52|pigmented skin lesions
P03668396A0171|5 24|equilibrium solutions
P03668736A0177|25 35|X-ray counts
P03668736A0177|113 127|variable element
P03672532A1111|68 82|maternally toxic
P03673640A0533|3 13|MAO subjects
P03673640A0533|79 95|KSP Somatic Anxiety
P03673640A0533|99 110|Irritability
P03673640A0533|180 222|alcoholics, psychopaths, and suicide attempters
P03673640A0533|243 261|platelet MAO activity
P03673640A0533|243 253|platelet MAO
P03673881A0000|46 47|CW
P03673881A0000|56 84|pulse repetition frequency (HPRF
P03673881A0000|96 141|estimating aortic transvalvular pressure gradients
P03673881A0000|143 161|Doppler examinations
P03673881A0000|204 211|patients
P03673881A0000|216 233|aortic valve disease
P03676054A0865|2 7|group I
P03676054A0865|13 18|delta V
P03676054A0865|20 23|PaO2
P03676054A0865|25 28|Vinj
P03676054A0865|32 33|VT
P03676054A0865|63 79|operating pressure
P03676054A0865|83 83|E
P03676054A0865|134 148|injector cannula
P03676174A0730|96 98|1st
P03678269A0633|31 53|plasma cholesterol levels
P03678269A0633|31 47|plasma cholesterol
P03678269A0633|106 114|childhood
P03678372A0170|11 15|fecal
P03679407A0556|23 40|N-nitroso compounds
P03679407A0556|63 70|infected
P03679407A0556|71 77|bladder
P03679407A0556|117 139|urinary-tract infections
P03679407A0556|159 171|bladder cancer
P03679756A0830|0 26|Epithelial nerve fiber defects
P03679756A0830|94 98|intra
P03680791A0230|3 17|histologic grade
P03680791A0230|28 35|anatomic
P03680791A0230|51 56|hearts
P03680791A0230|74 86|anatomic sites
P03682805A0375|0 10|Serum levels
P03682805A0375|13 28|albumin, globulin
P03682805A0375|13 19|albumin
P03682805A0375|21 28|globulin
P03682805A0375|33 58|coagulation protein activity
P03682805A0375|33 50|coagulation protein
P03682805A0375|111 121|lymph levels
P03682805A0375|136 139|Day 3
P03684378A0653|49 57|vitamin K1
P03684378A0653|60 70|cholesterol
P03684378A0653|92 110|lipid or phospholipid
P03684378A0653|129 139|cholesterol
P03684378A0653|156 164|vitamin K1
P03684378A0653|169 181|colostral milk
P03684517A0462|0 16|Endurance training
P03684517A0462|39 47|stiffness
P03684517A0462|73 84|type II fibers
P03685073A0200|22 34|physostigmine
P03685073A0200|38 66|acetylcholinesterase inhibitor
P03685073A0200|38 57|acetylcholinesterase
P03687078T0001|0 9|References
P03687078T0001|34 44|adolescents
P03687078T0001|62 77|respiratory tract
P03687078T0001|81 85|lungs
P03687148T0187|0 7|Salzburg
P03687148T0187|9 21|9-12 September
P03687313A0000|6 26|glucosidase inhibitors
P03687313A0000|6 16|glucosidase
P03687313A0000|28 35|BAY m 1099
P03687313A0000|39 46|BAY o 1248
P03687313A0000|61 70|volunteers
P03688202A0377|57 59|PBB
P03688202A0377|63 64|CN
P03688301A0129|24 36|mucosal spread
P03688301A0129|44 58|stromal invasion
P03688301A0129|60 64|type A
P03688301A0129|114 118|type B
P03688301A0129|124 148|muscle-invasive carcinomas
P03688301A0129|154 160|bladder
P03688676A0487|77 85|infection
P03690262A0428|3 35|maximum amplitude of evoked responses
P03690262A0428|41 48|cervical
P03690262A0428|83 84|T2
P03690262A0428|159 160|T1
P03690262A0428|159 160|T1
P03690262A0428|162 163|T3
P03690262A0428|162 163|T3
P03690262A0428|165 166|T4
P03690262A0428|165 166|T4
P03690262A0428|170 180|T5 white rami
P03691316A0560|33 36|K-CG
P03691316A0560|33 33|K
P03691316A0560|35 36|CG
P03692331A0000|12 38|beta-adrenoceptor antagonist
P03692331A0000|12 28|beta-adrenoceptor
P03692331A0000|40 47|pindolol
P03692331A0000|51 57|uterine
P03692331A0000|58 69|smooth muscle
P03692331A0000|76 88|pregnant women
P03692331A0000|130 134|women
P03693543A0405|13 45|mycolic acid-containing Rhodococcus
P03693543A0405|134 151|Nocardia asteroides
P03696899T0001|5 28|serum erythropoietin level
P03696899T0001|10 23|erythropoietin
P03696899T0001|37 49|hematological
P03696899T0001|85 98|newborn infants
P03697587T0000|3 24|XXXXY chromosome anomaly
P03697587T0000|44 64|Klinefelter's syndrome
P03697798T0001|0 10|Contraction
P03697798T0001|16 29|tracheal muscle
P03697798T0001|46 61|stretch receptors
P03697971A0311|3 15|selenium level
P03697971A0311|19 39|glutathione peroxidase
P03697971A0311|19 39|glutathione peroxidase
P03697971A0311|53 63|blood, liver
P03697971A0311|68 80|stomach mucosa
P03697971A0311|109 130|high-selenium diet group
P03697971A0311|144 155|selenium diet
P03698251T0000|6 13|delivery
P03698251T0000|17 33|consumption and P50
P03698251T0000|36 43|patients
P03698251T0000|48 72|acute myocardial infarction
P03700952A0273|0 6|Infants
P03700952A0273|31 32|PL
P03700952A0273|74 81|McDonald
P03701640A1178|47 59|pentobarbital
P03701640A1178|81 99|FR30 FI600 responding
P03703493A0654|11 29|crystalline deposits
P03703493A0654|67 93|RPE-choriocapillaris complex
P03704087A0394|5 12|subjects
P03704087A0394|84 90|anxiety
P03704087A0394|92 135|Spielberger's State-Trait Personality Inventory
P03704087A0394|167 189|State Anger Reaction Scale
P03709191A0125|30 35|cortex
P03709191A0125|41 43|rat
P03709191A0125|77 85|asymmetry
P03709627A0247|37 50|acetaminophen i
P03709627A0247|52 70|v. and concentrations
P03709627A0247|73 78|plasma
P03709627A0247|152 162|metabolites
P03710973A0817|4 26|weighted skin temperature
P03710973A0817|28 30|Tsk
P03710973A0817|89 99|acclimation
P03710973A0817|132 149|Tre-to-Tsk gradient
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712050T0000|28 35|patients
P03712050T0000|40 58|rheumatoid arthritis
P03712106A0000|11 22|L-methionine
P03712106A0000|75 77|SPI
P03712106A0000|93 124|short-term nitrogen balance studies
P03712106A0000|127 136|young women
P03712153T0000|0 47|Primary invasive Haemophilus influenzae type b disease
P03713187A0691|120 133|skeletal muscle
P03713187A0691|201 206|deeply
P03713187A0691|207 225|infiltrating lesions
P03713187A0691|244 261|superficial lesions
P03714348A0833|49 51|CIC
P03714348A0833|85 97|CIC population
P03714348A0833|135 159|low peak expiratory flow rate
P03714348A0833|172 184|total serum IgG
P03714348A0833|182 184|IgG
P03714473A0496|42 50|heat shock
P03717475A0208|0 2|New
P03717475A0208|53 65|immunotherapy
P03717475A0208|89 125|immunologically conditioned infertility
P03717936A0252|0 7|Amikacin
P03720615A0434|72 85|preterm infants
P03720966A1043|9 19|nucleic acid
P03720966A1043|20 30|N absorption
P03720966A1043|39 45|N intake
P03721594A0000|9 20|phagocytosis
P03721594A0000|22 32|chemotactic
P03721594A0000|36 50|random migration
P03721594A0000|52 83|nitroblue tetrazolium dye reduction
P03721594A0000|86 113|peritoneal exudate neutrophils
P03721594A0000|117 127|macrophages
P03721594A0000|129 138|fibrinogen
P03721594A0000|162 167|fibrin
P03721594A0000|162 167|fibrin
P03721594A0000|171 204|serial dilution protamine sulfate test
P03721594A0000|223 240|115 New Zealand white
P03721666A0000|0 5|Nickel
P03721666A0000|28 52|allergic contact dermatitis
P03721666A0000|95 104|patch tests
P03722016A0797|3 11|FFA levels
P03728230A0104|23 26|left
P03728230A0104|35 43|renal cyst
P03732252A0556|54 58|VO2 AT
P03732252A0556|92 97|VO2max
P03732252A0556|262 271|delta VO2 AT
P03732252A0556|275 285|delta 5,000 m
P03733563A0716|12 33|herd X period interaction
P03733563A0716|44 50|liver TG
P03733563A0716|54 65|serum dextran
P03733563A0716|78 102|cholesterol concentrations
P03733563A0820|5 6|TG
P03733563A0820|10 32|serum NEFA concentrations
P03734641A0203|18 22|nerve
P03736081A0465|7 19|coronary sinus
P03736081A0465|72 83|cardiac index
P03736081A0465|132 148|coronary blood flow
P03736081A0465|206 228|left ventricular pressure
P03736081A0465|285 315|coronary arteriovenous difference
P03738919A0000|0 13|Calcifications
P03738919A0000|47 77|11th and the 12th thoracic vertebrae
P03738919A0000|83 85|men
P03738919A0000|92 96|women
P03738919A0000|113 130|computed tomography
P03743683A0000|11 33|402 consecutive autopsies
P03743683A0000|35 56|parietal pleural plaques
P03743683A0000|58 59|PP
P03743683A0000|58 59|PP
P03743702A0158|18 27|cell bodies
P03743702A0158|30 43|primary neurons
P03743702A0158|58 62|intra
P03743702A0158|94 109|inferior alveolar
P03743702A0158|119 124|mental
P03743702A0158|129 140|buccal nerves
P03743702A0158|258 265|2, and 444
P03744168T0001|0 20|Pharmacological action
P03744168T0001|23 32|eptazocine
P03744168T0001|34 39|l-1,4-
P03744168T0001|40 109|dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benz azonine
P03745833A0258|58 73|arterial pressure
P03745833A0258|93 96|flow
P03745833A0258|117 121|brain
P03745833A0258|157 174|reticular formation
P03745833A0258|203 212|cerebellum
P03746053A0670|10 27|positive potentials
P03746053A0670|38 39|N1
P03746053A0670|61 67|ventral
P03746053A0670|88 107|ventro-lateral column
P03746053A0670|111 112|N2
P03746053A0670|123 134|dorsal column
P03746107A0192|34 47|primary tumours
P03746508A0390|0 7|Failures
P03746601A0299|26 39|extravasation 2
P03746601A0299|61 69|hematoma 2
P03746896A0890|126 140|coronary effects
P03746896A0890|143 155|Type A behavior
P03746906A0000|44 75|student Jenkins Activity Survey (JAS
P03746906A0000|100 112|Type A behavior
P03747493A0000|0 21|Splenectomized patients
P03747493A0000|64 82|bacterial infections
P03749226A0506|4 16|phencyclidine
P03750700T0001|0 12|Possibilities
P03750700T0001|26 49|wrist joint endoprosthesis
P03751308T0001|31 46|sensomotor cortex
P03751308T0001|50 60|hippocampus
P03751308T0001|67 90|14C)2-deoxyglucose method
P03753022A0000|0 16|Malignant lymphoma
P03753022A0000|48 65|biological behavior
P03755623A1233|61 83|physiological properties
P03755623A1233|86 89|DLIS
P03755673A0054|21 40|benign and 34 malignant
P03757294A0414|14 16|PLD
P03757294A0414|14 16|PLD
P03757294A0414|34 43|renal cysts
P03757294A0414|64 67|APCD
P03758250A0000|4 34|goal-directed voluntary movements
P03758250A0000|45 58|upper extremity
P03758250A0000|106 116|EMG activity
P03759330A0713|16 17|F1
P03759330A0713|16 17|F1
P03759330A0713|21 22|F2
P03759330A0713|21 22|F2
P03759330A0713|49 51|CHD
P03759330A0713|69 70|G1
P03759330A0713|122 130|abdominal
P03759731A0992|0 4|Renal
P03759731A0992|46 51|group I
P03761122T0000|19 31|type A behavior
P03761122T0000|83 84|IQ
P03761122T0000|87 94|children
P03761523A0000|3 6|rats
P03761523A0000|40 45|sepsis
P03761523A0000|73 75|fat
P03763241A0446|16 23|weakness
P03763241A0446|29 44|upper extremities
P03763836T0001|9 23|electron therapy
P03763836T0001|26 31|tumors
P03765552A0582|68 92|reticuloendothelial system
P03765552A0582|94 107|RES) Fc receptor
P03765552A0582|98 107|Fc receptor
P03765552A0582|132 160|antiplatelet antibody synthesis
P03765731A0918|0 9|Incidences
P03765731A0918|12 25|nonfatal stroke
P03765731A0918|27 46|myocardial infarction
P03765731A0918|65 90|left ventricular hypertrophy
P03766370A0546|0 16|High radial r values
P03766370A0546|64 65|LV
P03766370A0546|90 98|MI regions
P03766370A0546|135 161|homogeneous radial shortening
P03768208A0879|58 75|bone formation rates
P03768208A0879|104 115|skeletal mass
P03769224A0000|20 27|patients
P03769224A0000|32 57|Systemic Lupus Erythematosus
P03769224A0000|59 61|SLE
P03770143A1209|17 34|hereditary disorder
P03770143A1209|65 78|fibre structure
P03770143A1209|108 125|spontaneous lesions
P03771670T0058|0 9|Prevention
P03771670T0058|13 35|heparin-antithrombin III
P03771670T0058|21 35|antithrombin III
P03771703A0000|0 36|N-Substituted trimethylsilylcarbamates
P03771703A0000|49 68|derivatizing reagents
P03771703A0000|72 97|gas chromatographic analysis
P03771749A0465|0 3|MICs
P03771749A0465|10 25|antifungal agents
P03771749A0465|27 42|5-fluorocytosine
P03771749A0465|55 66|ketoconazole
P03771749A0465|71 83|amphotericin B
P03771749A0465|115 128|Candida species
P03771749A0465|166 206|dilution and microtiter broth dilution systems
P03772471A1054|11 18|patients
P03772471A1054|23 38|Group II(a) tumors
P03772471A1054|48 58|tumor biopsy
P03772471A1054|118 124|surgery
P03774111T0000|12 26|opiate addiction
P03774111T0000|37 50|immune response
P03776080A0400|15 36|post-mortem examination
P03776080A0400|42 60|seropositive animals
P03776080A0400|93 99|animals
P03776080A0400|104 106|E/S
P03776080A0400|104 104|E
P03776080A0400|106 120|S and CWE antigens
P03776080A0400|110 120|CWE antigens
P03776438A0000|0 32|Glucocorticoid induced hypertension
P03776438A0000|63 68|sodium
P03776438A0000|70 71|Na
P03776438A0000|86 121|mineralocorticoid induced hypertension
P03776438A0000|130 143|Na+-dependent.
P03776779A0238|42 49|steroids
P03777398A0156|0 7|Examples
P03779182A0370|66 75|hepatitis B
P03779182A0370|81 98|drug-related deaths
P03779205A0459|9 16|patients
P03779205A0459|32 48|metastatic disease
P03779205A0459|99 106|patients
P03780248A0274|38 44|infants
P03780248A0274|98 117|mandatory ventilation
P03780248A0274|119 121|IMV
P03780248A0274|158 164|infants
P03780248A0274|198 209|acceptable pH
P03780248A0274|213 222|PCO2 values
P03780371A0792|43 49|introns
P03780371A0792|55 77|cytochrome P-450PBc2 gene
P03780371A0792|55 73|cytochrome P-450PBc2
P03780371A0792|97 113|5'-flanking region
P03780704A0573|16 27|serum ketones
P03780704A0573|69 87|respiratory quotient
P03780704A0573|111 113|fat
P03780704A0573|126 127|WW
P03780704A0573|141 142|CW
P03781000A0101|46 62|metabolic activity
P03781000A0101|68 88|endometriotic implants
P03781948T0000|0 36|Respiratory adaptation to chronic hypoxia
P03781948T0000|39 49|newborn rats
P03783160A0285|0 8|Compound 1
P03783160A0285|17 29|21-O-angeloyl
P03783160A0285|36 55|tigloyl R1-barrigenol
P03783160A0285|59 70|21-O-tigloyl
P03783160A0285|77 97|angeloyl R1-barrigenol
P03785212A0091|0 4|Human
P03785212A0091|22 40|S14 protein sequences
P03785212A0091|55 59|cDNAs
P03785212A1128|0 12|RPS14 introns 3
P03785212A1128|0 4|RPS14
P03785212A1128|28 39|Alu sequences
P03785212A1128|28 30|Alu
P03788231A0802|63 68|animal
P03788231A0802|159 166|anatomic
P03789052A0527|2 26|exaggerated tissue response
P03789052A0527|40 56|cyanoacrylate site
P03789052A0527|91 105|thermal reaction
P03789052A0527|119 132|tissue adhesive
P03789052A0527|167 179|ocular effects
P03791645A1124|71 73|MAL
P03791645A1124|71 73|MAL
P03791645A1124|89 91|OSA
P03795488A0487|50 51|CR
P03795488A0487|73 74|PR
P03799323A0501|49 54|oxygen
P03799323A0501|101 111|sickle cells
P03799323A0501|119 129|normal cells
P03799790A0146|47 68|indirect ophthalmoscopy
P03799790A0146|98 107|fiberoptic
P03799790A0146|145 160|episcleral plaque
P03802195A0481|5 18|fusion proteins
P03802195A0481|50 94|transcriptional activation and DNA binding domains
P03802195A0481|100 110|ToxR protein
P03802195A0481|100 110|ToxR protein
P03802195A0481|138 154|N-terminal portion
P03805090A0645|29 36|patients
P03805090A0645|67 89|secondary chondrosarcoma
P03805090A0645|92 99|patients
P03805090A0645|107 119|Ollier disease
P03805090A0645|146 155|forty years
P03805090A0645|164 184|malignant degeneration
P03805090A0645|205 212|patients
P03805090A0645|220 235|Maffucci syndrome
P03806696A0000|3 16|lethal toxicity
P03806696A0000|19 27|inorganic
P03806696A0000|29 44|HgCl2) and organic
P03806696A0000|46 68|CH3HgCl) mercury chloride
P03806696A0000|83 90|Coturnix
P03806696A0000|92 104|Japanese quail
P03806696A0000|106 121|Coturnix japonica
P03806696A0000|154 162|adulthood
P03806696A0000|165 184|single-dose acute oral
P03810361A0576|18 52|13h00-16h00 plasma cortisol estimation
P03810361A0576|83 117|13h00-16h00 plasma cortisol estimation
P03810361A0576|159 175|Cushing's syndrome
P03810867A0305|9 16|patients
P03810867A0305|35 41|lesions
P03810867A0305|43 48|63 T3-4
P03810867A0305|70 85|adopted TNM system
P03810867A0305|87 103|Lederman-Gadeberg
P03810867A0305|105 116|Sisson-Jesse
P03811852A0109|15 27|complications
P03811852A0109|95 110|magnesium sulfate
P03811852A0109|114 135|beta-adrenergic agonist
P03811852A0109|148 169|adrenocortico-steroids
P03811852A0109|178 199|fetal pulmonary maturity
P03814493T0000|0 11|Chlorambucil
P03814493T0000|15 24|interferon
P03814493T0000|15 24|interferon
P03814493T0000|28 56|low grade non-Hodgkin's lymphoma
P03818467A0180|0 13|Selenium (.1 ppm
P03818467A0180|18 18|E
P03818467A0180|48 51|diet
P03818467A0180|69 84|plasma tocopherol
P03818467A0180|128 148|glutathione peroxidase
P03818467A0180|128 148|glutathione peroxidase
P03818467A0180|150 164|GSH-Px) activity
P03818467A0180|150 155|GSH-Px
P03818866A0116|10 22|Type A behavior
P03818866A0116|50 71|diastolic blood pressure
P03818866A0116|102 106|women
P03820222A0203|3 29|in vitro antibacterial potency
P03820222A0203|47 79|1-substituent is 2,4-difluorophenyl
P03820222A0203|86 98|7-substituent
P03820222A0203|102 110|3-amino-1
P03824908A0116|3 15|M reading frame
P03824908A0116|82 93|conservative
P03824908A0116|94 99|lysine
P03824908A0116|102 118|arginine amino acid
P03824908A0116|138 153|carboxy-terminus
P03824908A0116|171 179|M proteins
P03824908A0116|171 179|M proteins
P03826871A0000|5 25|chromatographic method
P03826871A0000|46 48|ion
P03826871A0000|54 58|urine
P03826871A0000|61 70|Greyhounds
P03827071T0040|0 1|II
P03828209T0000|0 20|Laryngographic changes
P03828209T0000|30 51|endotracheal intubation
P03828209T0000|54 59|adults
P03828500T0001|0 14|Intensification
P03828500T0001|17 50|human myocardial contractile activity
P03828500T0001|63 72|blood serum
P03829848T0001|0 18|Autotransplantation
P03829848T0001|58 73|deep vein valvular
P03830147A0000|25 69|descriptors of lactate increase: lactate threshold
P03830147A0000|78 80|VO2
P03830147A0000|88 112|blood lactate concentration
P03830147A0000|182 184|LT1
P03830147A0000|189 191|VO2
P03830147A0000|199 210|blood lactate
P03830147A0000|231 242|resting level
P03830147A0000|245 247|LT2
P03830147A0000|252 254|VO2
P03830147A0000|262 286|blood lactate concentration
P03830147A0000|319 342|blood lactate accumulation
P03830147A0000|344 347|OBLA
P03830147A0000|362 373|blood lactate
P03830147A0000|434 439|VO2max
P03830147A0000|469 493|19 untrained female students
P03835413A0616|51 62|space flights
P03835413A0616|128 147|duration space flights
P03836777T0001|31 52|viral hepatitis B markers
P03836777T0001|56 68|hepatic biopsy
P03836777T0001|71 75|HBs Ag
P03836777T0001|92 112|chronic hepatitis stage
P03836853A0204|5 7|2, 3
P03836853A0204|16 28|survival rates
P03836854T0000|31 46|gastric secretion
P03836854T0000|54 55|RP
P03836854T0000|72 96|gastric antisecretory agent
P03837609T0000|27 51|peripheral white blood cells
P03837609T0000|54 76|infectious mononucleosis
P03838797A0903|0 15|Northern blotting
P03838797A0903|27 47|17-mer oligonucleotide
P03838797A0903|75 88|mutant sequence
P03838797A0903|110 120|cDNA library
P03838797A0903|136 145|mutant cDNA
P03838797A0903|136 145|mutant cDNA
P03840480T0000|46 61|peptide sequences
P03841627T0001|0 11|Chemotherapy
P03841627T0001|27 38|breast cancer
P03843496A0919|24 42|physiological models
P03843496A0919|84 103|nonvolatile chemicals
P03843676A0381|0 18|Linear extrapolation
P03843676A0381|79 94|carcinogenic risk
P03848527T0020|27 47|psychiatric counsellor
P03857577A0413|37 56|upstream DNA sequences
P03857577A0413|91 113|basal level transcription
P03857577A0413|116 124|HeLa cells
P03857577A0413|138 161|EIA-induced transcription
P03857577A0413|138 140|EIA
P03860162A0000|0 12|Incorporation
P03860162A0000|18 47|polyene antibiotic amphotericin B
P03860162A0000|49 51|AMB
P03860162A0000|55 63|liposomes
P03860162A0000|91 102|drug toxicity
P03860162A0000|115 131|antifungal potency
P03861687A0000|14 30|normotensive males
P03861687A0000|108 129|hemodynamic alterations
P03861687A0000|151 174|sympathetic nervous system
P03862898A0563|0 7|Serum IgM
P03862898A0563|5 7|IgM
P03862898A0563|11 13|IgE
P03862898A0563|11 13|IgE
P03862898A0563|14 27|concentrations
P03862898A0563|29 48|allergen-specific IgE
P03862898A0563|46 48|IgE
P03862898A0563|49 54|scores
P03862898A0563|62 75|tumor E2R status
P03862898A0563|100 114|three-level risk
P03863231A0530|3 12|M-3 subtype
P03863231A0530|3 12|M-3 subtype
P03863231A0530|25 40|prognostic factor
P03863561A0405|9 25|Strep. mutans group
P03863561A0405|70 96|Strep. mutans/Strep. cricetus
P03863561A0405|125 137|mean clump size
P03865743A0859|24 25|T.
P03865743A0859|29 33|LDL-C
P03865743A0859|29 33|LDL-C
P03865743A0859|36 40|HDL-C
P03865743A0859|36 38|HDL
P03865743A0859|43 48|HDL2-C
P03865743A0859|43 48|HDL2-C
P03865743A0859|51 54|apo B
P03865743A0859|51 54|apo B
P03865743A0859|56 68|apo A-I/B ratio
P03865743A0859|56 61|apo A-I
P03865743A0859|63 63|B
P03865743A0859|72 85|apo A-II/B ratio
P03865743A0859|72 78|apo A-II
P03865743A0859|80 80|B
P03865743A0859|115 134|coronary heart disease
P03866085A0795|26 47|suppository formulation
P03866085A0795|50 54|CZX-S
P03866085A0795|79 88|infections
P03866085A0795|91 98|children
P03866085A0795|108 133|psychophysiologic disorders
P03866085A0795|139 146|children
P03866085A0795|160 168|oral drugs
P03866085A0795|178 191|severe vomiting
P03869442A0223|17 28|hypertension
P03869442A0223|58 70|abnormalities
P03869442A0223|84 95|hypertension
P03869442A0223|108 148|1-desamino-8-D-arginine vasopressin therapy
P03869442A0223|108 141|1-desamino-8-D-arginine vasopressin
P03871298A0217|0 47|Single photon emission computerized tomography (SPECT
P03871298A0217|94 103|myocardial
P03871298A0217|149 151|CAD
P03871445T0000|25 44|quantitative analysis
P03871445T0000|47 79|cerebral positron emission tomograms
P03873141A0304|4 11|patients
P03873141A0304|65 71|therapy
P03873141A0304|73 82|Visick I-II
P03873141A0304|86 93|patients
P03874921A0862|0 12|Documentation
P03874921A0862|26 50|intrauterine fertilization
P03874921A0862|70 73|baby
P03874921A0862|112 113|EP
P03875231A0627|0 2|MRI
P03875231A0627|85 115|corticomedullary differentiation
P03875231A0627|138 156|subcapsular hematoma
P03875231A0627|176 184|renal cyst
P03875231A0627|203 215|abnormalities
P03877298A0718|59 78|Cremophor formulation
P03877298A0718|147 165|emulsion formulation
P03878585A0507|35 37|CPB
P03878585A0507|94 112|oxygen flow rate index
P03878585A0507|114 117|OFRI
P03878585A0507|124 131|flow/min
P03878585A0507|173 190|blood flow rate index
P03878585A0507|192 195|BFRI
P03878585A0507|217 227|blood pumped
P03878585A0507|238 261|heart-lung machine/min CPB
P03880838T0000|0 8|Diagnosis
P03880838T0000|11 38|unilateral renal artery lesions
P03880838T0000|44 66|captopril administration
P03881260A0000|1 5|yeast
P03881260A0000|6 16|DNA fragment
P03881260A0000|28 35|gene CP A1
P03881260A0000|32 35|CP A1
P03881260A0000|64 107|arginine pathway carbamoyl-phosphate synthetase
P03881260A0000|79 107|carbamoyl-phosphate synthetase
P03882029A0000|1 18|retrospective study
P03882029A0000|21 30|banked sera
P03882029A0000|37 40|cats
P03882029A0000|60 75|granuloma complex
P03882029A0000|93 104|affected cats
P03882029A0000|143 161|normal cat epithelium
P03883052T0001|2 7|memory
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|3 23|H2 receptor antagonists
P03883541A0200|3 12|H2 receptor
P03883541A0200|63 73|side effects
P03885983A0254|39 68|Class III antiarrhythmic activity
P03887085A0000|31 38|nontoxic
P03887085A0000|86 93|mexamine
P03887085A0000|142 148|hypoxia
P03887085A0000|168 171|CBA X
P03887085A0000|172 183|C57Bl)F1 mice
P03887769A0093|40 47|Median 61
P03887769A0584|54 70|iodine deficiency I
P03887769A0584|89 106|iodine deficiency II
P03888621A0185|3 16|structural gene
P03888621A0185|20 30|hydrogenase
P03890486A0000|0 38|Pancreaticoduodenal lymph node enlargement
P03890486A0000|74 80|imaging
P03890486A0000|119 138|pancreatic malignancy
P03890486A0000|150 167|biliary obstruction
P03891766A1473|16 31|rheumatoid factor
P03891766A1473|16 31|rheumatoid factor
P03891766A1473|52 65|ELISA enzygnost
P03891766A1473|68 71|sera
P03891766A1473|93 107|latex adsorbents
P03894482A0549|3 10|patients
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|53 71|crude soybean extract
P03896991T0000|37 51|natural products
P03898382A0000|16 33|subtraction imaging
P03898382A0000|39 44|spleen
P03898382A0000|64 68|99mTc
P03898382A0000|172 201|sulfur colloid liver-spleen image
P03904004A1577|203 206|124I
P03904952T0000|0 15|Nursing education
P03904952T0000|21 38|computer obligation
P03908196T0000|0 16|Shear bond strength
P03908196T0000|38 55|etched glass ionomer
P03908493A0246|53 68|immunoperoxidase
P03908493A0246|90 101|thin sections
P03910310A0666|44 52|pathology
P03911052A0909|14 19|DIL-CP
P03911052A0909|14 19|DIL-CP
P03911052A0909|39 40|CP
P03911052A0909|43 53|CABG surgery
P03911052A0909|78 79|CP
P03911052A0909|85 92|patients
P03911052A0909|102 112|CABG surgery
P03911702A0530|74 94|microembolism syndrome
P03911702A0530|124 145|musculo-skeletal trauma
P03911702A0530|148 151|pigs
P03911702A0530|165 183|long-term anesthesia
P03911965A0513|10 32|statistical significance
P03911965A0513|101 111|Galphimia D6
P03911965A0513|179 185|placebo
P03912247A0282|11 15|blood
P03912247A0282|126 139|capillary blood
P03913522A0000|4 8|aging
P03913522A0000|23 42|immune function change
P03914875T0001|4 14|candidiasis
P03915540A0863|14 29|gcd1-101 mutation
P03915540A0863|14 29|gcd1-101 mutation
P03915540A0863|43 68|low translational efficiency
P03915540A0863|71 83|GCN4-lacZ mRNA
P03915540A0863|71 74|GCN4
P03915540A0863|76 79|lacZ
P03915540A0863|94 111|gcn2- and gcn3- cells
P03915540A0863|94 97|gcn2
P03915540A0863|102 105|gcn3
P03920700A0491|62 105|postsynaptic muscarinic and alpha 1 adrenoceptors
P03920700A0491|74 105|muscarinic and alpha 1 adrenoceptors
P03921727A0523|19 24|apo A-I
P03921727A0523|19 24|apo A-I
P03921727A0523|28 34|apo A-II
P03921727A0523|28 34|apo A-II
P03921727A0523|106 113|controls
P03922116A0197|17 24|patients
P03922116A0197|46 65|complex gamma-therapy
P03922116A0197|84 103|complex gamma-therapy
P03922116A0197|108 127|iliac lymphadenectomy
P03922116A0197|140 145|group 3
P03922116A0197|177 202|megavolt bremsstrahlung beam
P03922116A0197|210 228|luc type installation
P03922116A0197|232 251|iliac lymphadenectomy
P03923828A1031|17 31|cryoprecipitate
P03923828A1031|35 39|DDAVP
P03923828A1031|105 110|uremic
P03923828A1031|121 128|patients
P03923828A1031|139 162|urgent invasive procedures
P03923976T0001|0 35|Thrombophlebitis and pulmonary embolism
P03923976T0001|38 66|congenital factor XII deficiency
P03923976T0001|48 56|factor XII
P03925712A0229|13 25|jejunal mucosa
P03925712A0229|35 56|abnormal enzyme activity
P03928357A0340|0 18|Laboratory pyrolyses
P03928357A0340|38 41|PCBs
P03928357A0340|65 69|PCDFs
P03928357A0340|96 100|PCDFs
P03928357A0340|104 108|PCDDs
P03928442A0463|61 69|Mtase gene
P03928442A0463|61 69|Mtase gene
P03928442A0463|79 86|phage SPR
P03928678T0000|0 27|Thyrotropin-releasing hormone
P03928678T0000|0 27|Thyrotropin-releasing hormone
P03928678T0000|49 72|urethral and vaginal muscle
P03929486A0309|26 33|patients
P03929486A0309|38 41|COCM
P03929486A0309|43 48|NYHA II
P03929486A0309|58 68|sinus rhythm
P03929486A0309|73 103|left ventricular ejection fraction
P03929486A0309|105 109|LV-EF
P03929486A0309|132 145|consecutively D
P03929486A0309|169 172|PLAC
P03929486A0309|175 175|P
P03929486A0309|190 191|SR
P03929486A0309|200 201|SR
P03929486A0309|200 201|SR
P03929610A0268|0 20|Mild orbital discomfort
P03929610A0268|35 42|patients
P03930549A0209|46 57|valproic acid
P03930549A0209|121 136|gas chromatograph
P03930894T0000|9 40|muscarinic acetylcholine receptors
P03930894T0000|9 40|muscarinic acetylcholine receptors
P03930894T0000|43 52|guinea-pig
P03930894T0000|53 56|lung
P03931293A0437|40 46|sucrose
P03931293A0437|98 104|albumin
P03931293A0437|98 104|albumin
P03931797A0134|22 30|psoriasis
P03931797A0134|41 43|men
P03931797A0134|54 58|women
P03933232T0000|0 14|Greek classicism
P03933232T0000|37 53|deductive pathways
P03933232T0000|56 71|animal morphology
P03933784A0420|3 16|possible origin
P03933784A0420|26 37|CSF prolactin
P03933784A0420|26 37|CSF prolactin
P03934667A0124|5 28|chromosomal crsA mutations
P03934667A0124|5 28|chromosomal crsA mutations
P03934667A0124|30 34|crsA1
P03934667A0124|30 34|crsA1
P03934667A0124|36 40|crsA4
P03934667A0124|36 40|crsA4
P03934667A0124|45 50|crsA47
P03934667A0124|45 50|crsA47
P03934667A0124|72 76|"gene
P03934667A0124|99 119|subtilis plasmid pRPD11
P03934667A0124|145 171|wild-type rpoD coding sequence
P03934667A0124|145 171|wild-type rpoD coding sequence
P03934667A0124|184 193|major sigma
P03934667A0124|189 226|sigma 43 factor of B. subtilis RNA polymerase
P03934667A0124|194 226|43 factor of B. subtilis RNA polymerase
P03934667A0124|231 236|pUB110
P03935117T0000|17 64|pulmonary oedema on prostaglandin E2 pharmacokinetics
P03935117T0000|67 73|rat lung
P03935375A0414|100 106|medulla
P03935375A0414|113 121|pathology
P03935375A0414|136 138|RPN
P03935375A0414|155 170|secondary changes
P03935375A0414|186 226|cortical degeneration or epithelial carcinoma
P03935797A0183|63 75|messenger RNAs
P03935797A0183|88 99|early embryos
P03935797A0183|170 190|protein-coding regions
P03935797A0183|170 190|protein-coding regions
P03935797A0183|217 220|beta
P03935797A0183|222 234|alpha and delta
P03936828T0000|0 17|Chronic thyroiditis
P03936828T0000|33 46|B-cell lymphoma
P03936828T0000|52 63|thyroid gland
P03937294A0404|0 19|Plasma secretin levels
P03937294A0404|0 13|Plasma secretin
P03937294A0404|57 72|ethanol solutions
P03937481T0001|0 30|Spectrophotometric microanalysis
P03937481T0001|33 61|ethylenediaminotetracetic acid
P03937481T0001|64 89|pharmaceutical preparations
P03939317A0352|19 35|5' flanking regions
P03939317A0352|62 71|HS promoter
P03939317A0352|62 71|HS promoter
P03939317A0352|77 98|soybean HS-protein genes
P03939317A0352|77 98|soybean HS-protein genes
P03940426A0618|30 32|GLC
P03940426A0618|35 44|short chain
P03940426A0618|45 54|fatty acids
P03940426A0618|116 119|Gram
P03940426A0618|130 147|colonial morphology
P03940733A0755|48 55|vitamin A
P03940733A0755|112 127|fat malabsorption
P03940818T0000|0 18|Fulminant hepatitis A
P03940818T0000|21 37|chronic HBV carrier
P03944212A0166|0 13|Tissue pressure
P03944212A0166|15 18|rCBF
P03944212A0166|23 34|water content
P03944212A0166|83 98|peripheral margin
P03944212A0166|104 115|MCA territory
P03944212A0166|127 130|MCAO
P03944239A0780|49 75|plasma thyroid hormone changes
P03944239A0780|90 106|amiodarone therapy
P03944239A0780|121 122|T4
P03944239A0780|124 129|free T4
P03944239A0780|134 136|rT3
P03944239A0780|149 150|T3
P03946125T0000|0 26|Drug and nutrient interactions
P03952387A0336|43 58|chemical reaction
P03952387A0336|81 93|oxyhemoglobin
P03952387A0336|81 93|oxyhemoglobin
P03952387A0336|95 98|HbO2
P03952387A0336|95 98|HbO2
P03953361A0000|22 32|propranolol
P03953361A0000|35 54|myocardial metabolism
P03953361A0000|60 78|coronary reperfusion
P03953361A0000|80 85|serial
P03953361A0000|100 126|myocardial creatine kinase (CK
P03953361A0000|100 123|myocardial creatine kinase
P03953361A0000|125 126|CK
P03953361A0000|131 137|calcium
P03953361A0000|139 140|Ca
P03953361A0000|153 154|CK
P03953361A0000|153 154|CK
P03953361A0000|158 167|lactic acid
P03953361A0000|169 170|LA
P03953361A0000|188 205|coronary sinus blood
P03953361A0000|224 237|open-chest dogs
P03956647A1063|0 10|Dissolution
P03956647A1063|62 79|electron microscopy
P03956647A1063|117 119|X ph
P03956647A1063|154 175|iridium microelectrodes
P03956647A1063|200 205|charge
P03956647A1063|240 242|X ph
P03956695A0617|0 16|Cortisol excretion
P03956695A0617|83 110|social and environmental stress
P03959045A0000|0 9|Two studies
P03959045A0000|112 115|MCAT
P03963860A0137|10 17|patients
P03963860A0137|49 59|MY-1 treated
P03963860A0137|49 52|MY-1
P03963860A0137|64 77|untreated group
P03964489A1195|18 21|PaO2
P03964489A1195|23 26|NADH
P03964855A0254|0 10|Angiography
P03964855A0254|58 66|vasospasm
P03965012A0163|43 46|1972
P03965012A0163|80 88|ischaemic
P03965012A0163|97 109|heart diseases
P03965012A0163|111 120|ICD A83-A84
P03965012A0163|171 177|workers
P03966687A0000|20 34|childhood asthma
P03966687A0000|58 62|Vance
P03966687A0000|99 107|Allergy 13
P03967144T0001|0 12|Hypersplenism
P03970191A0275|0 17|Electrical activity
P03970191A0275|52 69|electrocorticogram
P03970191A0275|71 74|ECoG
P03970191A0275|89 105|DC steady potential
P03972038A0000|3 12|topography
P03972038A0000|33 49|commissural fibers
P03972038A0000|78 80|STR
P03972038A0000|100 124|autoradiographic technique
P03972185A0137|3 15|diabetic state
P03972185A0137|38 54|insulin deficiency
P03972185A0137|38 44|insulin
P03972185A0137|56 67|plasma levels
P03972185A0137|78 85|controls
P03972185A0137|90 106|mild hyperglycemia
P03972185A0137|112 140|nonfasting plasma glucose levels
P03974790A0053|3 11|primary CT
P03974790A0053|41 52|brain infarct
P03974790A0053|64 69|tumour
P03976323A0821|30 48|blood pressure change
P03976323A0821|52 54|SCR
P03977577T0000|0 21|Shoulder forearm support
P03977577T0000|28 43|subluxed shoulder
P03977603A0326|0 8|Piroxicam
P03977603A0326|34 46|gastric ulcers
P03977603A0326|68 79|indomethacin
P03978045A0857|33 43|early stages
P03978045A0857|45 46|0T
P03978045A0857|48 49|0N
P03978045A0857|74 113|VWF (stages 1-2) cold induced hyperreactivity
P03978045A0857|119 132|digital vessels
P03978045A0857|136 152|Raynaud's syndrome
P03978045A0857|156 172|vascular disorders
P03978132A0108|2 14|MCCP functions
P03979084A1019|53 66|renal functions
P03979084A1019|85 88|IMPK
P03979084A1019|91 94|IBPK
P03980386A0000|28 34|hypoxia
P03980386A0000|38 58|angiotensin II infusion
P03980386A0000|38 50|angiotensin II
P03980386A0000|89 92|lung
P03980386A0000|104 121|perfusion lung scans
P03980386A0000|148 162|ventilated lambs
P03981421A0246|1 8|flow rate
P03981421A0246|43 57|receptor (volume
P03981640A0168|19 24|5' ends
P03981640A0168|46 50|mRNAs
P03981952T0000|28 55|qualitative chloride titrators
P03981952T0000|61 70|estimation
P03981952T0000|73 87|human salt intake
P03984683A0000|0 14|Acute appearance
P03984683A0000|57 66|spasticity
P03984683A0000|81 94|stroke patients
P03985849A0221|9 27|acute rhinosinusitis
P03985849A0221|51 58|patients
P03985849A0221|79 99|chronic rhinosinusitis
P03985849A0221|114 121|patients
P03985849A0221|126 129|CVID
P03985849A0221|196 208|IgA deficiency
P03985849A0221|196 198|IgA
P03987818A0440|20 23|AP-A
P03987818A0440|20 23|AP-A
P03987818A0440|63 74|heart failure
P03987857A0733|22 38|pelvic floor region
P03987857A0733|86 93|mass unit
P03988001A0227|21 44|rat blood chloroform levels
P03988001A0227|89 92|ClO2
P03989827T0000|14 30|lactase phenotypes
P03989827T0000|33 46|Aymara children
P03992022A0330|0 9|Activities
P03992022A0330|12 33|hepatic cytochrome P-450
P03992022A0330|12 33|hepatic cytochrome P-450
P03992022A0330|56 62|enzymes
P03992022A0330|69 99|aminopyrine- and TMO N-demethylase
P03992022A0330|69 99|aminopyrine- and TMO N-demethylase
P03992022A0330|103 128|aniline hydroxylase activity
P03992022A0330|103 120|aniline hydroxylase
P03992022A0330|158 161|rats
P03992022A0330|166 175|cimetidine
P03992022A0330|189 192|rats
P03992022A0330|207 216|ranitidine
P03995513T0000|0 10|Doxorubicin
P03995513T0000|12 22|dacarbazine
P03995513T0000|24 34|vincristine
P03995513T0000|39 54|cyclophosphamide
P03995513T0000|79 94|gastrointestinal
P03995513T0000|95 108|leiomyosarcoma
P03997467A0000|14 29|opiate antagonist
P03997467A0000|30 37|naloxone
P03997467A0000|54 71|unselected patients
P03997467A0000|76 91|cerebral ischemia
P03998071T0000|0 23|Electrochemical detection
P03998071T0000|54 62|vitamin K1
P03998071T0000|65 76|osteoporosis
P03998813A0406|72 85|neural activity
P03998813A0406|125 150|mouse central auditory system
P03999219A0463|0 13|Ultrastructure
P03999219A0463|19 23|tumor
P03999219A0463|85 98|alum irrigation
P03999219A0463|181 194|alum irrigation
P04000347A0442|112 114|BEN
P04000347A0442|140 142|BEN
P04000347A0442|176 187|renal disease
P04001413A0093|22 46|respiration-control device
P04001413A0093|123 127|scans
P04001490T0001|3 15|POEMS syndrome
P04001490T0001|17 30|Polyneuropathy
P04001490T0001|60 78|Monoclonal component
P04001490T0001|80 83|Skin
P04001490T0001|80 83|Skin
P04002131A0506|43 54|GAG secretion
P04002131A0506|59 63|urine
P04002131A0506|75 90|hyperheparinuria
P04002667A0181|2 24|metastasis-free patients
P04002667A0181|56 69|tumor diameters
P04002667A0181|107 118|in lung tissue
P04002667A0181|132 163|cm tumors embedded in lung parenchyma
P04004168A0000|3 10|siblings
P04004168A0000|15 29|hemolytic anemia
P04004168A0000|38 71|triosephosphate isomerase deficiency
P04004168A0000|38 61|triosephosphate isomerase
P04004168A0000|113 138|featuring dystonic movements
P04004168A0000|147 160|pyramidal tract
P04005190A1288|23 32|PCA content
P04011338A0620|7 14|patients
P04011338A0620|62 68|fat loss
P04011338A0620|154 166|fatty acid loss
P04011338A0620|169 175|placebo
P04011338A0620|196 199|loss
P04011338A0620|202 208|taurine
P04011466T0000|0 14|Aortic diameters
P04011466T0000|17 39|infants and young children
P04013576A0981|62 71|fatty acids
P04013576A0981|74 96|Leptospira phospholipids
P04013576A0981|137 143|neutral
P04013576A0981|168 187|unsaturated fatty acid
P04013576A0981|223 235|phospholipids
P04013604A0412|12 49|frequency of potassium-induced ulceration
P04013604A0412|77 89|patient-years
P04014833A0400|0 13|Hydrocortisone
P04014833A0400|20 30|lymphopenia
P04014833A0400|46 64|blastogenic response
P04014833A0400|67 92|peripheral blood lymphocytes
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|116 128|concanavalin A
P04014833A0400|116 128|concanavalin A
P04014833A0400|129 136|mitogens
P04014861A0000|27 35|liposomes
P04014861A0000|67 71|lungs
P04014861A0000|84 104|liposome-encapsulated
P04014861A0000|105 123|superoxide dismutase
P04014861A0000|105 123|superoxide dismutase
P04014861A0000|125 127|SOD
P04014861A0000|125 127|SOD
P04014861A0000|131 138|catalase
P04014861A0000|131 138|catalase
P04014861A0000|141 163|pulmonary oxygen toxicity
P04014861A0000|176 179|rats
P04015988T0000|0 17|Marrow cell necrosis
P04015988T0000|20 34|anorexia nervosa
P04015988T0000|38 58|involuntary starvation
P04017295A0139|25 31|heparin
P04017295A0139|64 71|patients
P04018444A0000|0 19|Chenodeoxycholic acid
P04018444A0000|21 25|cheno
P04018444A0000|30 48|ursodeoxycholic acid
P04018444A0000|50 53|urso
P04018444A0000|63 83|cholesterol gallstones
P04019066A0000|0 27|Sensory evoked field potentials
P04019066A0000|47 77|mesencephalic reticular formation
P04019066A0000|79 81|MRF
P04019066A0000|96 97|CG
P04019066A0000|102 120|somatosensory cortex
P04019066A0000|122 124|SCX
P04019066A0000|154 162|halothane
P04019066A0000|165 170|freely
P04021281T0001|0 13|Ultrastructure
P04021281T0001|19 23|heart
P04021281T0001|32 60|experimental myocardial infarct
P04021305A0530|0 30|Pharmacological desympathization
P04021305A0530|107 114|dopamine
P04021305A0530|156 171|electric activity
P04021305A0530|186 199|catecholamines
P04021431A0000|0 3|OODG
P04021431A0000|108 134|ophthalmic circulatory system
P04021431A0000|136 142|retinal
P04021431A0000|153 165|arterial blood
P04021431A0000|224 229|pupils
P04021437A0000|0 14|Viral infections
P04021437A0000|66 85|inner ear dysfunctions
P04024685A0650|55 56|RS
P04024685A0650|71 75|mVolt
P04024685A0650|87 91|mVolt
P04024685A0650|238 243|RBV 117
P04025178A0126|65 79|left ventricular
P04025178A0126|81 107|LV) end-diastolic volume index
P04025178A0126|109 112|EDVI
P04025179A0955|2 7|group I
P04026903A0512|11 12|80
P04026903A0512|63 71|guinea pig
P04026903A0512|72 76|ileum
P04026903A0512|79 87|rat uterus
P04026903A0512|113 124|contractions
P04026903A0512|134 146|acetylcholine
P04026903A0512|148 156|histamine
P04026903A0512|165 183|5-hydroxytryptamine
P04026903A0512|199 218|dose-dependent manner
P04026972T0000|10 32|alcohol reaction profiles
P04027182T0000|0 7|Vitiligo
P04027182T0000|10 25|diabetes mellitus
P04028871A0133|3 18|pharmacokinetics
P04028871A0133|25 36|tetracycline
P04028871A0133|39 43|serum
P04028871A0133|47 52|dermal
P04028871A0133|54 72|suction blister fluid
P04028871A0133|92 95|oral
P04028871A0133|126 136|doxycycline
P04028871A0133|142 147|3rd day
P04031488A1091|58 74|brain localization
P04031488A1091|77 103|neuropsychological syndromes
P04032268A0358|7 8|UV
P04032268A0358|47 48|EC
P04032268A0358|97 100|NaCl
P04032349A0000|2 9|patients
P04032349A0000|14 36|acute arterial occlusions
P04032349A0000|44 58|graft thromboses
P04032349A0000|92 99|ischemia
P04032349A0000|114 132|fibrinolytic therapy
P04032349A0000|134 142|Urokinase
P04032349A0000|165 178|Lys Plasminogen
P04032349A0000|168 178|Plasminogen
P04032716A0299|3 20|mean transfer ratios
P04032716A0299|37 50|genital tissues
P04032716A0299|74 80|uterine
P04032716A0299|81 93|arterial blood
P04032716A0299|129 143|portio vaginalis
P04032716A0299|171 183|uterine cervix
P04032716A0299|190 199|myometrium
P04032716A0299|257 271|portio vaginalis
P04033402A1112|14 31|androgenic hormones
P04033402A1112|38 52|HDL-cholesterol
P04033402A1112|38 52|HDL-cholesterol
P04033402A1112|73 88|HDL2-cholesterol
P04033402A1112|73 88|HDL2-cholesterol
P04033402A1112|120 152|hepatic triglyceride lipase activity
P04033402A1112|120 144|hepatic triglyceride lipase
P04034220A0205|53 62|ampicillin
P04034220A0205|154 179|respiratory tract infections
P04034220A0205|182 189|children
P04034666T0000|0 19|Lower extremity weight
P04034666T0000|82 89|patients
P04034666T0000|94 104|hemiparesis
P04036838A0918|0 10|Shape factor
P04036838A0918|29 43|hemodynamic data
P04036838A0918|47 73|RV/LV systolic pressure ratios
P04036838A0918|149 152|0.95
P04037809A0964|38 44|KW-2083
P04038454A0984|22 39|plasma retinol level
P04038454A0984|57 59|RBP
P04038454A0984|57 59|RBP
P04038454A0984|85 92|patients
P04038454A0984|108 111|dl-1
P04038454A0984|118 121|dl-1
P04038454A0984|193 198|cancer
P04038454A0984|214 217|dl-1
P04038454A0984|219 221|4.6
P04038454A0984|224 227|dl-1
P04038702A0768|89 96|handling
P04038702A0768|121 135|circadian rhythm
P04038702A0768|138 145|cortisol
P04038702A0768|179 184|estrus
P04038702A0768|226 232|penning
P04038702A0768|272 293|cortisol concentrations
P04039109A0139|4 8|laser
P04039109A0139|36 54|amniotic fluid medium
P04039109A0139|64 79|placental vessels
P04039307A0613|7 18|progesterone
P04039307A0613|44 65|hysterectomized heifers
P04039439A0000|4 16|Japanese quail
P04039439A0000|58 59|Mn
P04039439A0000|58 59|Mn
P04039439A0000|63 87|particulate manganese oxide
P04039439A0000|89 93|Mn3O4
P04039439A0000|102 105|diet
P04039439A0842|25 37|Japanese quail
P04039439A0842|67 79|Mn3O4 exposure
P04039439A0842|84 90|rodents
P04039525A0475|0 5|Plasma
P04039525A0475|9 23|bladder platinum
P04039525A0475|58 72|intravesical DDP
P04039525A0475|129 138|blood count
P04039525A0475|142 155|blood chemistry
P04039525A0475|195 209|intravesical DDP
P04039667T0000|0 25|Scintigraphic visualisation
P04039667T0000|28 46|Walker carcinoma-256
P04039667T0000|49 66|Sprague-Dawley rats
P04039667T0000|90 98|monocytes
P04039744A0141|45 51|mothers
P04039744A0141|83 96|oral supplement
P04039744A0141|102 102|u
P04039744A0141|104 112|vitamin D3
P04039744A0141|135 143|lactation
P04040083A0000|0 9|Rabbit eyes
P04040083A0000|75 80|saline
P04040307A0145|25 52|perivascular adrenergic nerves
P04040307A0145|71 80|low ovarian
P04040307A0145|81 82|NE
P04040339T0001|22 26|heart
P04040339T0001|45 49|fetus
P04040339T0001|72 101|beta-adrenomimetics partusisten
P04040858A0000|43 50|patients
P04040858A0000|55 67|ovarian cancer
P04041307A0614|24 40|calcium antagonist
P04041307A0614|42 50|diltiazem
P04041307A0614|73 82|isoflurane
P04041307A0614|85 102|myocardial function
P04041346T0000|0 26|Supraventricular arrhythmias
P04041346T0000|39 47|quinidine
P04043489A0648|0 7|Visidex I
P04043489A0648|33 42|re-reading
P04048245A0331|33 46|hydrocortisone
P04048245A0331|65 84|raised serum CPN levels
P04048245A0331|76 78|CPN
P04050771A0474|70 86|prognostic factors
P04050771A0474|90 106|long-term survival
P04050821A0531|56 77|myocardial oxygen demand
P04051521T0001|0 7|Duration
P04051521T0001|29 41|gastric cancer
P04051521T0001|42 49|patients
P04051521T0001|78 80|MTX
P04051521T0001|84 87|5-FU
P04052919A0205|20 40|progesterone secretion
P04052919A0205|65 80|human luteal phase
P04052919A0205|107 121|mid-luteal phase
P04052919A0205|136 150|mid-luteal phase
P04052919A0205|155 162|subjects
P04052919A0205|166 183|progesterone levels
P04052919A0205|266 277|progesterone
P04052919A0205|283 297|mid-luteal phase
P04052919A0205|329 337|ovulation
P04055593A0523|16 32|digital processing
P04055593A0523|38 39|N2
P04055593A0523|132 159|gas composition and temperature
P04056218A0463|4 8|slope
P04056218A0463|42 46|dB/dB
P04056218A0463|51 52|L1
P04056218A0463|54 55|L2
P04056218A0463|67 70|80 dB
P04056256A0416|0 8|Histamine
P04056256A0416|50 66|nifedipine aerosol
P04056256A0416|125 149|specific airway conductance
P04056256A0416|177 185|histamine
P04058985A0000|20 28|vitamin B6
P04058985A0000|43 56|lactating women
P04058985A0000|83 97|plasma prolactin
P04058985A0000|83 97|plasma prolactin
P04061342A0512|92 97|fasted
P04061342A0512|117 124|fed state
P04062128T0028|20 34|Health Consensus
P04063732A0509|54 66|type I activity
P04066194A0163|23 27|N1-P2
P04066194A0163|23 24|N1
P04066194A0163|26 27|P2
P04066194A0163|31 41|baseline-P2
P04066194A0163|61 63|EPs
P04066194A0163|112 119|right ear
P04066194A0163|154 157|left
P04066274A0265|11 18|patients
P04066274A0265|30 43|mixed neoplasms
P04066274A0265|65 89|conservative parotidectomy
P04066274A0265|99 103|3 (9,7
P04066274A0265|115 119|3 (9,7
P04066274A0265|124 125|En
P04067540A0413|26 59|female homicide-suicide perpetrators
P04067540A0413|78 99|female homicide-suicide
P04067540A0413|109 112|live
P04067540A0413|115 125|mobile homes
P04067540A0413|143 150|ex-lover
P04067540A0413|257 278|female homicide-suicide
P04067540A0413|288 291|live
P04067540A0413|297 302|spouse
P04068663A0452|0 3|Germ
P04068663A0452|148 154|rabbits
P04068774A1292|27 27|F
P04068774A1292|31 32|Zn
P04068774A1292|97 100|bone
P04068969A0300|0 19|L3-L4 compressive load
P04068969A0300|61 86|trunk musculoskeletal system
P04069756T0025|0 8|Diagnosis
P04069756T0025|21 49|multifocal leukoencephalopathy
P04070725A0442|0 12|Component P100
P04070725A0442|31 47|frontal negativity
P04070725A0442|88 112|dipolar occipital generator
P04071063A0863|45 58|platelet counts
P04071063A0863|79 94|fibrinogen levels
P04071063A0863|79 88|fibrinogen
P04071063A0863|98 121|alpha 2-antiplasmin levels
P04071063A0863|98 115|alpha 2-antiplasmin
P04071063A0863|150 174|antithrombin-treated group
P04071063A0863|150 161|antithrombin
P04073848T0000|0 6|Failure
P04073848T0000|46 61|myasthenia gravis
P04074214A0000|40 49|young boars
P04074214A0000|59 80|subtropical environment
P04075021T0000|0 24|[14C]-beta-phenethylamine
P04075021T0000|97 122|monoamine oxidase inhibitors
P04075021T0000|97 112|monoamine oxidase
P04075061A0355|29 33|water
P04081425T0016|0 24|Clinical aspects and therapy
P04082267A0720|59 70|Ae. vexans nip
P04082592T0000|0 15|Blood eosinophils
P04082592T0000|18 25|patients
P04082592T0000|30 52|Taenia saginata taeniasis
P04084607A0663|3 13|imino proton
P04084607A0663|23 35|O6meG.T 12-mer
P04084607A0663|29 35|T 12-mer
P04084607A0663|39 40|G3
P04084607A0663|39 40|G3
P04084607A0663|46 63|O6meG.N 12-mer helix
P04084607A0663|172 192|Watson-Crick base pairs
P04084607A0663|194 197|12.5
P04084896A0569|3 16|recommendation
P04085589A0264a|28 41|secretor status
P04085589A0264a|45 58|clinical status
P04085589A0264a|60 81|spirometry measurements
P04085589A0264a|94 106|serum lysozyme
P04085589A0264a|99 112|lysozyme levels
P04085589A0264a|122 149|respiratory tract colonization
P04085589A0264a|154 165|P. aeruginosa
P04085589A0264a|169 177|S. aureus.
P04085589A0264b|28 41|secretor status
P04085589A0264b|45 58|clinical status
P04085589A0264b|60 81|spirometry measurements
P04085589A0264b|94 106|serum lysozyme
P04085589A0264b|99 112|lysozyme levels
P04085589A0264b|122 149|respiratory tract colonization
P04085589A0264b|154 165|P. aeruginosa
P04085589A0264b|169 177|S. aureus.
P04086403A1016|0 4|Gains
P04086403A1016|77 85|steers fed
P04086403A1016|90 95|AS-VFA
P04086657T0000|0 29|Postnatal volumetric development
P04086657T0000|35 50|prefrontal cortex
P04086657T0000|56 58|rat
P04086993T0000|0 4|Daily
P04086993T0000|16 26|rhythmicity
P04086993T0000|32 42|methylation
P04086993T0000|45 66|pineal indolic compounds
P04086993T0000|69 91|adult male golden hamsters
P04086993T0000|102 118|natural conditions
P04088396A0145|8 26|patients grades 1-2-3
P04088396A0145|88 95|patients
P04088733T0001|10 23|acid hydrolases
P04088733T0001|26 50|peripheral blood leukocytes
P04088733T0001|53 78|focal and segmental pneumonia
P04088733T0001|81 88|children
P04088936T0001|23 42|antithrombin III level
P04088936T0001|23 37|antithrombin III
P04088936T0001|46 65|plasminogen activator
P04088936T0001|46 65|plasminogen activator
P04088936T0001|76 83|patients
P04088936T0001|88 103|thrombophlebitis
P04093211A0560|100 109|1975 to 1982
P04101003T0001|0 8|Relations
P04101003T0001|16 41|cellular electrical activity
P04101003T0001|45 69|cardiac mechanical activity
P04101003T0001|72 74|man
P04101003T0001|88 93|rabbit
P04103248T0000|16 25|CRT display
P04113011T0000|2 17|desensitization'
P04113011T0000|36 58|immunologically specific
P04114211T0000|0 4|Renal
P04114211T0000|32 55|normal and uraemic subjects
P04115870T0000|0 10|Experiences
P04115870T0000|46 63|Urat-I lithotriptor
P04123217T0000|36 56|Cryptococcus laurentii
P04123662T0000|12 26|thyroid function
P04138224T0095|27 34|vitamin A
P04138224T0095|38 62|nonspecific gamma-globulin
P04138224T0095|49 62|gamma-globulin
P04138224T0095|68 81|blood clearance
P04138224T0095|84 90|rabbits
P04139081T0001|0 13|HL-A antibodies
P04139081T0001|0 13|HL-A antibodies
P04139081T0001|16 37|polytransfused patients
P04139943T0001|15 27|fine structure
P04139943T0001|33 41|guinea pig
P04139943T0001|59 91|electron microscopic silver staining
P04140567T0001|0 8|Histamine
P04140567T0001|21 48|hemorrhagic-hypotensive shock
P04145244T0000|0 9|Relaxation
P04145244T0000|29 40|smooth muscle
P04152725T0001|9 28|alcoholic liver injury
P04160980T0000|0 18|Hypothalamic control
P04160980T0000|21 39|coronary circulation
P04160980T0000|45 47|dog
P04164595T0020|53 70|immunological types
P04164669T0000|0 37|Ultraviolet light-induced kinin formation
P04164669T0000|24 28|kinin
P04164669T0000|40 48|human skin
P04172166T0000|0 12|Poliomyelitis
P04172166T0000|18 24|vaccine
P04175007T0001|41 60|transplantable tumors
P04175007T0001|91 104|antineoplastic
P04175007T0001|105 115|antibiotics
P04176249T0001|0 9|Assessment
P04176249T0001|12 24|nutrient media
P04176249T0001|41 49|diptheria
P04176268T0000|0 13|Aluminium resin
P04176268T0000|48 59|renal failure
P04176625T0000|0 4|Value
P04176625T0000|10 12|EMG
P04176625T0000|59 74|myotonic myopathy
P04189158T0000|0 9|Prevention
P04189158T0000|20 34|Rh sensitization
P04189158T0000|36 56|anti-Rh immune globulin
P04189158T0000|41 56|Rh immune globulin
P04194466T0000|0 14|Serotonin levels
P04194466T0000|17 36|infant hypothyroidism
P04196986T0000|0 37|Cerebrospinal fluid transferrin II studies
P04196986T0000|18 30|transferrin II
P04196986T0000|40 56|ischemic disorders
P04196986T0000|62 81|central nervous system
P04213917T0001|13 27|D-penicillamine
P04213917T0001|30 46|pulmonary fibroses
P04214345T0000|22 42|serum IgG concentration
P04214345T0000|27 29|IgG
P04214345T0000|46 71|glucose and xylose absorption
P04214345T0000|74 93|Zambian African adults
P04226360T0001|0 8|Disorders
P04226360T0001|11 26|platelet function
P04226360T0001|29 51|chronic myeloid leukemias
P04239041T0045|11 25|anticonvulsants
P04239041T0045|28 59|sodium-potassium-activated ATPase
P04239041T0045|54 59|ATPase
P04239041T0045|81 86|cortex
P04246054T0028|8 24|immune lymphocytes
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|61 65|RAMLG
P04246054T0028|61 65|RAMLG
P04246054T0028|69 87|infected macrophages
P04246054T0028|106 126|incubation temperature
P04247472T0001|0 10|Estral cycle
P04247472T0001|13 21|white rats
P04247472T0001|48 56|Kirghizia
P04247966T0000|0 8|Lactation
P04247966T0000|11 17|baboons
P04247966T0000|22 46|low protein maintenance diet
P04262268T0001|12 24|organic matrix
P04262268T0001|27 42|human ear ossicles
P04281856T0001|42 66|Ornithodoros tatarovski Ol.
P04282315T0001|0 12|Sensitization
P04282315T0001|54 69|subtotal ablation
P04282315T0001|75 82|pancreas
P04284435T0000|0 8|Vitamin D3
P04284435T0000|12 28|calcium absorption
P04284435T0000|34 38|chick
P04289156T0000|14 20|tumours
P04289156T0000|28 35|chickens
P04291759T0048|0 16|Laboratory aspects
P04291759T0048|42 53|chemotherapy
P04295031T0062|16 35|guinea pig vas deferens
P04305850T0000|0 17|Androgens and growth
P04308979T0000|52 54|BCG
P04308979T0000|58 67|quartz dust
P04308979T0000|85 94|quartz dust
P04308979T0000|102 106|lungs
P04308979T0000|122 131|lymph nodes
P04311951T0001|20 42|new antibiotic-corticoid
P04315233T0128|0 30|Clinico-physiological experiment
P04316696T0001|0 26|Enzyme histochemical findings
P04316696T0001|32 50|ultimobranchial body
P04321861T0001|0 48|Familial glutathione reductase deficiency and disorder
P04321861T0001|8 27|glutathione reductase
P04321861T0001|51 70|glutathione synthesis
P04321861T0001|76 86|erythrocyte
P04323641T0000|9 26|swine enteroviruses
P04325736T0001|0 12|Serodiagnosis
P04328746T0073|0 15|Ultrasound effect
P04328746T0073|21 45|cytochrome oxidase activity
P04328746T0073|21 37|cytochrome oxidase
P04335965T0000|0 9|Metastasis
P04335965T0000|12 25|colon carcinoma
P04350410T0000|0 6|Genesis
P04350410T0000|9 17|foam cells
P04350410T0000|26 29|rats
P04350410T0000|51 58|Cloforex
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|54 73|coronary heart disease
P04369884T0000|36 63|colony-stimulating factor (CSF
P04369884T0000|36 59|colony-stimulating factor
P04369884T0000|61 63|CSF
P04371279T0000|35 55|muscle fibres paralysed
P04371279T0000|58 71|botulinum toxin
P04371279T0000|58 71|botulinum toxin
P04377003A0000|2 16|automated method
P04377003A0000|23 42|quantitative analysis
P04377003A0000|48 67|polyamines putrescine
P04377003A0000|69 89|spermidine and spermine
P04377003A0000|92 109|cerebrospinal fluid
P04377003A0000|111 113|CSF
P04377003A0000|147 154|patients
P04377003A0000|159 178|central nervous system
P04377003A0000|180 182|CNS
P04377003A0000|184 189|tumors
P04377003A0000|199 206|patients
P04377003A0000|214 219|tumors
P04377328T0027|0 0|I
P04385060T0000|0 9|Disulfiram
P04385060T0000|16 34|drug-induced effects
P04385060T0000|37 44|motility
P04387103T0000|51 64|perianal glands
P04387103T0000|67 70|dogs
P04392584T0000|27 50|western hemisphere monkeys
P04394290T0000|14 32|adrenergic receptors
P04394290T0000|77 79|cat
P04407649T0000|0 24|Intracranial arachnoid cyst
P04407649T0000|30 40|middle fossa
P04407649T0000|55 84|positive 99mTc brainscintigraphy
P04418687T0000|9 16|estrogen
P04418687T0000|20 34|glucocorticoids
P04418687T0000|63 67|fetus
P04423347T0001|0 28|Copper and ceruloplasmin content
P04423347T0001|9 21|ceruloplasmin
P04423347T0001|31 43|pregnant women
P04423347T0001|49 53|women
P04423347T0001|65 85|gynecological diseases
P04428800T0001|15 33|CO-induced increases
P04428800T0001|36 38|LAP
P04428800T0001|36 38|LAP
P04428800T0001|42 52|GPT activity
P04428800T0001|42 44|GPT
P04428800T0001|66 69|rats
P04428981T0000|0 7|Kinetics
P04428981T0000|10 26|calcium metabolism
P04429269T0000|16 20|mucus
P04429269T0000|47 61|ciliated systems
P04437406T0000|89 110|transcapillary exchange
P04445874T0001|0 8|Pathology
P04446923T0001|0 22|Abnormal characteristics
P04446923T0001|42 61|Platynothrus peltifer
P04460692T0000|8 13|topics
P04460692T0000|26 39|animal medicine
P04482661T0001|0 13|Clinical course
P04482661T0001|30 37|patients
P04482661T0001|42 55|decubitus ulcer
P04482661T0001|81 94|buckwheat chaff
P04487835T0001|2 8|parents
P04487920T0001|7 18|Icelandic Red
P04488271T0001|18 38|adult diabetes mellitus
P04495034T0000|26 32|toluene
P04495034T0000|49 67|Ancylostomum caninum
P04506738T0000|0 8|Junctions
P04506738T0000|26 41|human enamel organ
P04510102T0000|0 17|Electrocardiograms
P04511139T0001|0 9|Composites
P04512496T0000|0 15|Hodgkin's disease
P04515631T0000|0 4|Value
P04515631T0000|7 15|Normotest
P04515631T0000|19 31|antithrombin 3
P04515631T0000|19 31|antithrombin 3
P04515631T0000|49 61|liver function
P04518624T0000|0 20|Glutathione peroxidase
P04518624T0000|0 20|Glutathione peroxidase
P04518624T0000|23 35|human red cells
P04524081T0000|0 22|Histopathologic response
P04524081T0000|25 39|gingival tissues
P04524081T0000|53 77|aluminum chloride solutions
P04524081T0000|80 106|tissue displacement materials
P04533208T0083|16 33|periodontal surgery
P04536964T0000|0 14|Intracellular pH
P04536964T0000|16 23|H ion flux
P04536964T0000|27 53|H ion permeability coefficient
P04536964T0000|56 72|bullfrog toe muscle
P04539552T0001|0 19|Teratological studies
P04539552T0001|22 27|SF-837
P04544430T0001|0 10|Proceedings
P04544430T0001|49 55|surgery
P04544430T0001|58 79|congenital heart defects
P04544704T0001|0 5|Method
P04544704T0001|22 37|rheumatoid factor
P04544704T0001|22 31|rheumatoid
P04544704T0001|40 67|clinico-immunological studies
P04546974T0000|0 9|Variations
P04546974T0000|39 57|His bundle recordings
P04547933T0000|0 27|Extracellular fibril formation
P04547933T0000|30 44|neuroglial cells
P04547933T0000|76 83|human eye
P04548483T0001|0 13|Blood platelets
P04548483T0001|15 32|coagulation factors
P04548483T0001|47 58|organ changes
P04548483T0001|68 80|scalding shock
P04548483T0001|83 95|rhesus monkeys
P04551650T0001|0 12|Cell viability
P04551650T0001|16 31|lysosomal enzymes
P04552263T0000|0 13|State-approved
P04552263T0000|23 29|nursing
P04562038T0001|47 59|thymic hormone
P04562038T0001|47 59|thymic hormone
P04562038T0001|62 72|lymphocytes
P04563045T0000|0 35|1,3-bis(2-chloroethyl)-1-nitrosourea
P04563045T0000|0 8|1,3-bis(2
P04563045T0000|37 40|bcnu
P04563045T0000|64 78|cancer treatment
P04578686T0000|0 11|Pneumothorax
P04578686T0000|21 31|lung abscess
P04578686T0000|37 58|renal transplant patient
P04579436T0000|13 36|significant colour changes
P04579436T0000|82 103|carotenoid-like pigment
P04583791T0000|15 25|dermatology
P04598670T0000|5 20|graft irradiation
P04600603T0001|0 5|Letter
P04600603T0001|7 16|Salmonella
P04613073T0001|36 43|Shigella
P04615525T0001|11 28|antilymphocyte sera
P04615525T0001|25 28|sera
P04615525T0001|42 56|transplantation
P04615525T0001|60 81|anti-infection immunity
P04615525T0001|84 87|mice
P04615828T0001|0 11|60th birthday
P04615828T0001|14 24|colonel prof
P04621188T0000|0 9|Morphology
P04621188T0000|28 44|Klebsiella bacilli
P04622430T0000|0 16|Cortical afferents
P04622430T0000|22 37|entorhinal cortex
P04622430T0000|43 54|Rhesus monkey
P04624863T0001|26 36|vaccination
P04624863T0001|41 69|streptomycin-dependent mutants
P04624863T0001|72 82|salmonellae
P04624863T0001|86 94|shigellae
P04627477T0001|19 43|Mycobacterium tuberculosis
P04627477T0001|57 66|antibiotic
P04627477T0001|68 78|lividomycin
P04632967T0000|9 24|arterial pressure
P04632967T0000|42 52|patas monkey
P04632967T0000|83 98|aminorex fumarate
P04638365T0001|30 59|hippocampal bioelectric activity
P04640155T0045|0 7|Sex ratio
P04646045T0001|0 21|Benign intramural tumors
P04653144T0000|0 14|General formulae
P04653144T0000|64 70|parents
P04654249T0000|13 21|open-loop
P04654249T0000|33 53|electrical stimulation
P04654249T0000|56 64|olfactory
P04654249T0000|71 73|cat
P04656185T0000|36 50|plasma nutrients
P04656185T0000|76 82|glucose
P04656185T0000|85 98|normoglycaemic
P04656185T0000|126 133|newborns
P04661961T0001|18 32|peripheral blood
P04661961T0001|36 45|bone marrow
P04661961T0001|51 71|grey (Armenian) hamster
P04676734T0000|17 47|human umbilical arterial and venous
P04676734T0000|62 76|corticosteroids
P04679438T0001|0 15|Antibiotic effect
P04679807T0000|0 24|Sulfuric acid concentration
P04679807T0000|30 57|catalyzed breathalyzer ampules
P04704137T0001|44 63|spontaneous abortions
P04704186T0000|0 12|Range behavior
P04704186T0000|15 22|Hereford
P04704186T0000|44 71|Holstein non-lactating heifers
P04712626T0000|65 88|Swertia chirata Buch.-Ham.
P04718233T0000|27 36|rat kidneys
P04727344T0000|0 17|Microdetermination
P04727344T0000|20 33|adrenocortical
P04727344T0000|44 62|double isotope method
P04729063T0000|0 18|Compensative justice
P04729063T0000|42 49|Japanese
P04729063T0000|51 57|Chinese
P04729063T0000|62 68|Koreans
P04730467T0000|33 39|rickets
P04730467T0000|42 66|oxidative enzyme activities
P04730467T0000|92 95|rats
P04733391T0000|28 40|thiabendazole
P04746559T0053|0 9|Estimation
P04746559T0053|12 29|renin secretion rate
P04746559T0053|12 16|renin
P04746559T0053|33 47|renal plasma flow
P04746559T0053|52 73|peripheral and renal vein
P04746559T0053|65 78|renal vein renin
P04746559T0053|74 84|renin levels
P04752455T0000|0 18|Disability insurance
P04752455T0000|24 37|social security
P04753073T0000|0 5|Choice
P04753073T0000|8 13|vessel
P04753286T0000|28 30|rat
P04753286T0000|33 39|tung oil
P04757217T0000|9 26|lipoprotein-X (LP-X
P04757217T0000|9 21|lipoprotein-X
P04757217T0000|23 26|LP-X
P04757217T0000|31 39|bile acids
P04757217T0000|42 63|familial LCAT deficiency
P04757217T0000|50 53|LCAT
P04758799T0000|25 47|chronic steroid treatment
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|8 14|anxiety
P04760826T0000|17 49|Vietnam returnees and undergraduates
P04764049T0001|0 31|Familial juvenile nephronophthisis
P04766888T0000|5 11|heparin
P04766888T0000|23 30|children
P04766888T0000|35 54|acute meningococcemia
P04778129T0000|0 16|9,11-Seco steroids
P04778129T0000|0 3|9,11
P04778129T0000|28 36|estradiol
P04778129T0000|37 49|3-methyl ether
P04782788T0001|0 24|Psychological examinations
P04782788T0001|27 34|patients
P04782788T0001|39 64|chronic kidney insufficiency
P04784432T0001|0 12|Possibilities
P04784432T0001|15 38|needleless administration
P04784432T0001|41 57|various substances
P04787472T0001|0 5|Change
P04787472T0001|70 82|magnetic field
P04787472T0001|88 96|human body
P04787472T0001|88 96|human body
P04787716T0000|17 32|flight activities
P04787716T0000|35 52|Chrysops caecutiens
P04787716T0000|53 54|L.
P04788701T0001|0 10|Combination
P04788701T0001|22 37|primary malignant
P04788701T0001|41 52|benign tumors
P04788701T0001|58 73|breasts and uterus
P04789916T0001|30 37|bengal-I
P04791420T0000|0 10|Proceedings
P04791420T0000|34 44|S I neocortex
P04791420T0000|50 67|brush-tailed possum
P04794218T0001|11 17|K agents
P04796997T0000|0 17|Canine reproduction
P04796997T0000|46 71|medroxyprogesterone acetate
P04796997T0000|100 104|bitch
P04798293T0029|0 0|3
P04801663T0049|0 11|Hypoglycemic
P04801663T0049|15 26|antidiabetic
P04803629T0001|0 18|Hematopoietic system
P04803629T0001|34 40|allergy
P04810131T0000|0 5|Letter
P04810131T0000|7 42|Aryl hydrocarbon hydroxylase and smoking
P04810131T0000|7 32|Aryl hydrocarbon hydroxylase
P04813394T0000|12 30|1,10-phenanthroline
P04813394T0000|44 53|sialic acid
P04820791T0001|0 23|Delta-aminolevulinic acid
P04820791T0001|26 48|physiological conditions
P04820791T0001|66 73|children
P04824747T0000|0 16|Nonteratogenicity
P04824747T0000|19 22|rats
P04824747T0000|25 40|blighted potatoes
P04826272T0074|0 2|VII
P04828587T0000|14 50|avian reticuloendothelial virus (strain T
P04837183T0000|14 21|saccules
P04837183T0000|24 27|rats
P04837183T0000|37 57|long-term hypergravity
P04839176T0001|9 30|high-intensity SHF field
P04839176T0001|36 57|blood coagulation system
P04843031T0000|11 39|galactosyltransferase activity
P04843031T0000|11 31|galactosyltransferase
P04843031T0000|42 45|sera
P04843031T0000|50 74|normal children and patients
P04843031T0000|79 92|cystic fibrosis
P04852635T0000|17 42|appetite stimulant pizotifen
P04852635T0000|44 48|BC 105
P04852635T0000|67 87|isonicotinylhydrazine
P04863895T0000|34 48|Escherichia coli
P04863895T0000|60 84|chronic respiratory disease
P04863895T0000|86 88|CRD
P04863895T0000|92 98|poultry
P04871589T0001|0 35|Plastic solution of elbow joint ankylosis
P04878680T0000|9 25|ionizing radiation
P04878680T0000|36 45|oral cavity
P04878680T0000|49 58|oropharynx
P04884060T0000|28 51|Pomeranian Medical Academy
P04890336T0001|0 26|Immunelectrophoretic pattern
P04890336T0001|29 44|Wassermann reagin
P04890336T0001|84 87|RPCF
P04890336T0001|84 87|RPCF
P04890336T0001|91 103|FTA antibodies
P04890336T0001|91 103|FTA antibodies
P04909355T0000|0 29|Motile nocardoid Actinomycetales
P04911925T0001|20 31|QRS complexes
P04911925T0001|54 60|QRS loop
P04919613T0001|18 31|autoantibodies
P04919613T0001|34 58|immunofluorescence technic
P04921762T0000|0 18|Cardiac preservation
P04925617T0000|0 8|Labial bar
P04942414T0000|3 12|metabolism
P04942414T0000|30 43|5-fluorouracil
P04947347T0000|0 11|Spleen weight
P04947347T0000|14 17|rats
P04947347T0000|24 35|tumour growth
P04947347T0000|41 58|homograft rejection
P04948325T0000|11 25|Proteus vulgaris
P04948325T0000|26 30|MC-63
P04948325T0000|35 43|carcinoma
P04948325T0000|69 85|Crocker sarcoma 180
P04948325T0000|89 104|Ehrlich carcinoma
P04959816T0000|0 17|Human synovial fluid
P04967824T0000|38 53|melanin synthesis
P04967824T0000|64 80|Triturus cristatus
P04970131T0001|4 20|reflexions apropos
P04970918T0069|0 6|LA-3848
P04970918T0069|8 9|MS
P04973523T0000|25 40|filarial antigens
P04975676T0000|47 76|baboon renal allotransplantation
P04976988T0000|15 31|human serum albumin
P04976988T0000|20 31|serum albumin
P04989251T0000|10 24|corticosteroids
P04990556T0000|0 11|Reactivities
P04990556T0000|14 41|horse anti-lymphocyte globulin
P04990556T0000|24 41|lymphocyte globulin
P04992478T0000|0 16|Plasma histaminase
P04992478T0000|19 26|patients
P04992478T0000|29 43|bronchial asthma
P04992478T0000|58 83|prednisolone administration
P04999086T0001|60 79|postnatal ontogenesis
P04999086T0001|87 93|monkeys
P04999086T0001|97 99|man
P05000171T0000|41 61|horseradish peroxidase
P05000171T0000|41 61|horseradish peroxidase
P05000171T0000|71 89|intercellular spaces
P05000171T0000|96 112|bladder epithelium
P05005311T0000|0 13|Immunogenicity
P05005311T0000|23 34|mycobacteria
P05012220T0000|22 45|one-stage proctocolectomy
P05012220T0000|49 61|anal ileostomy
P05015678T0000|0 8|Nitrogen-
P05015678T0000|9 27|hydrogen tautomerism
P05015678T0000|30 50|porphyrins and chlorins
P05020660T0000|31 42|phagocytosis
P05021912T0000|0 26|Photopic spectral sensitivity
P05021912T0000|67 75|pigeon eye
P05025918T0000|0 10|Angiography
P05025918T0000|13 30|aneurysmal bone cyst
P05027295T0034|0 13|Cholinesterase
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05027799T0000|19 32|cardiac failure
P05028628T0001|0 52|Clinical and angiographic examinations in occlusion disease
P05028628T0001|58 62|great
P05028628T0001|63 80|intestinal arteries
P05031074T0001|5 16|lipid changes
P05031074T0001|37 61|oral calcium administration
P05031659T0000|0 18|Successful treatment
P05031659T0000|21 31|candidiasis
P05034373T0000|19 50|mixed function oxidase enzyme system
P05034373T0000|32 38|oxidase
P05034373T0000|70 77|selenium
P05034373T0000|83 85|rat
P05045351T0000|0 16|Periodic breathing
P05045351T0000|27 40|preterm infants
P05049711T0000|0 6|Working
P05049711T0000|21 43|in vivo-in vitro screening
P05060388T0000|0 23|Clinicopathologic studies
P05060388T0000|26 41|feminizing tumors
P05060388T0000|47 51|ovary
P05065548T0075|19 37|Dryopteris polylepis
P05066316T0001|0 7|Relation
P05066316T0001|28 39|raw materials
P05068271T0000|11 14|diet
P05068271T0000|17 35|urinary VMA excretion
P05075857T0000|0 21|Oscilloscope triggering
P05081814T0000|0 10|Derivatives
P05081814T0000|13 26|boswellic acids
P05083872T0000|23 38|training programs
P05083872T0000|41 55|speech pathology
P05083872T0000|59 67|audiology
P05087496T0000|0 15|Coronary arteries
P05091970T0000|0 14|Antiviral agents
P05093030T0001|68 119|medium-tension intophoresis and partition chromatography
P05095988T0001|0 20|Conservative treatment
P05095988T0001|23 42|central nervous system
P05095988T0001|43 50|injuries
P05101762T0000|0 12|Spasmus nutans
P05101762T0000|25 36|auto-arousal
P05101997T0040|0 0|6
P05110049T0001|0 6|1st data
P05110049T0001|12 35|immunosuppressive therapy
P05110049T0001|38 48|scleroderma
P05114515T0000|0 27|Slowed lysosomal enzyme release
P05114515T0000|6 20|lysosomal enzyme
P05114515T0000|56 84|adjuvant-induced polyarthritis
P05119546T0001|11 26|ovarian neoplasms
P05120197T0000|12 23|pancreatitis
P05120197T0000|26 29|pigs
P05123884T0000|0 18|Bacterial metabolism
P05123884T0000|21 42|4-chlorophenoxyacetate
P05124707T0001|0 7|Dynamics
P05124707T0001|24 42|peptic ulcer patients
P05124972T0042|0 0|I
P05128149T0001|0 16|Surgical treatment
P05128149T0001|19 33|pathologic scars
P05128149T0001|36 52|myocardial infarct
P05132558T0000|55 80|monoamine oxidase inhibitors
P05132558T0000|55 70|monoamine oxidase
P05133723T0000|45 52|rat liver
P05135168T0000|3 11|alkaloids
P05135168T0000|22 42|Erythrophleum ivorense
P05138738T0001|7 21|M hemoglobinosis
P05145925T0000|22 62|paravascular infiltrate-producing potential
P05145925T0000|65 83|parental spleen cells
P05152314T0001|0 21|Sinusoidal oscillations
P05152314T0001|25 35|gas dilution
P05154132T0000|28 35|nitrogen
P05154132T0000|49 64|early-weaned calf
P05161399T0025|0 0|1
P05162342T0001|0 14|Abdominal tumors
P05162342T0001|17 25|childhood
P05170106T0034|35 101|commercial anti-inflammatory enzyme preparations containing chymotrypsin
P05170106T0034|90 101|chymotrypsin
P05170106T0034|105 111|trypsin
P05170106T0034|105 111|trypsin
P05170106T0034|129 139|NF 13 methods
P05172320T0001|12 27|hereditary nature
P05172970T0001|28 48|pulmonary tuberculosis
P05172970T0001|86 93|395 cases
P05174753T0001|0 22|Cleidocranial dysostosis
P05177935T0001|0 8|Proposals
P05177935T0001|11 23|authorization
P05177935T0001|45 64|psychiatric hospitals
P05203499T0001|10 31|abdominal scintillation
P05203499T0001|36 50|131-I-tagged BSP
P05203499T0001|69 80|thyroid gland
P05203499T0001|82 87|kidney
P05203499T0001|91 96|spleen
P05203499T0001|112 120|131-I-RB)
P05210791T0001|0 8|Pneumonia
P05210791T0001|11 18|children
P05253274T0001|0 11|Osteosarcoma
P05253274T0001|20 34|3,4-benzopyrene
P05274128T0001|12 22|glucosamine
P05274526T0000|0 6|Relapse
P05274526T0000|9 16|leukemia
P05276380T0000|11 26|cigarette smoking
P05276380T0000|33 53|blood coagulation tests
P05284310T0000|13 20|fluoride
P05284310T0000|35 47|plasma calcium
P05284310T0000|53 75|parathyroidectomized rat
P05299993T0000|0 11|Modification
P05299993T0000|61 79|adrenergic mechanism
P05303700T0066|0 5|SAM-TR
P05308271T0000|0 5|BIM 130
P05309471T0000|31 46|antigenic content
P05309471T0000|49 65|influenza vaccines
P05316745T0000|0 14|Aedes aegypti (L.
P05316745T0000|19 33|Aedes albopictus
P05316745T0000|35 39|Skuse
P05316745T0000|43 55|Singapore City
P05322558T0000|0 16|Homograft response
P05322558T0000|20 42|hemagglutinin production
P05322558T0000|20 32|hemagglutinin
P05322558T0000|45 54|sensitized
P05322558T0000|55 86|thymectomized irradiated adult mice
P05322747T0034|18 34|acute oral overload
P05322747T0034|40 50|tolbutamide
P05322747T0034|66 90|normal and diabetic subjects
P05340801T0000|0 9|Mycotoxins
P05340801T0000|20 24|foods
P05344097T0000|18 56|in vitro skin permeability factor production
P05344097T0000|59 72|Vibrio cholerae
P05353667T0000|6 23|cord representation
P05353667T0000|40 45|reflex
P05356107T0001|0 15|Biological action
P05356107T0001|45 56|tritium oxide
P05357390T0001|0 14|Auto- and isotopy
P05357390T0001|20 30|conjunctiva
P05359130T0086|0 1|IX
P05359464T0000|0 7|Pitfalls
P05359464T0000|49 76|biological radiation dosimetry
P05362866T0000|0 13|Renin secretion
P05362866T0000|0 4|Renin
P05362866T0000|39 50|hypertension
P05363816T0001|54 87|urgent criminal investigative actions
P05364951T0001|0 13|Histopathology
P05364951T0001|31 50|exanthematous viroses
P05368978T0000|0 9|CNS effects
P05368978T0000|52 74|biogenic amine mechanisms
P05372511T0105|10 16|benzene
P05379901T0000|0 11|Midge control
P05388567T0000|12 21|taloximine
P05388567T0000|48 64|human smooth muscle
P05389125T0000|44 47|mice
P05394352T0000|0 11|Genitography
P05394352T0000|14 30|intersexual states
P05394461T0001|15 16|HB
P05394461T0001|22 38|animal experiments
P05410590T0000|9 20|ascorbic acid
P05410590T0000|38 44|bladder
P05410641T0000|27 50|obstructive airway disease
P05412122T0000|0 8|3'-Methyl
P05412122T0000|10 17|8-methyl
P05412122T0000|22 40|8-phenyl derivatives
P05412122T0000|43 72|5,9-dimethyl-6,7-benzomorphans
P05412687T0000|0 17|Antidromic invasion
P05412687T0000|20 27|impulses
P05412687T0000|31 49|recurrent collateral
P05412687T0000|62 83|pyramidal tract neurones
P05413428T0000|36 45|hemorrhage
P05414186T0001|16 24|influenza
P05414186T0001|30 40|Netherlands
P05417431T0001|0 14|Early disagnosis
P05417431T0001|39 46|patients
P05421537T0001|30 44|sputum viscosity
P05424220T0001|0 17|Lipid concentration
P05424220T0001|21 34|lipase activity
P05424220T0001|21 26|lipase
P05424220T0001|51 70|adrenalectomized rats
P05424220T0001|97 109|sodium content
P05425195T0001|0 34|Behavior of aspartate aminotransferase
P05425195T0001|10 34|aspartate aminotransferase
P05425195T0001|36 44|EC 2.6.1.1
P05425195T0001|36 37|EC
P05425195T0001|49 71|alanine aminotransferase
P05425195T0001|49 71|alanine aminotransferase
P05425195T0001|73 81|EC 2.6.1.2
P05425195T0001|73 74|EC
P05425195T0001|85 92|rat serum
P05425195T0001|110 131|acute radiation syndrome
P05425195T0001|141 162|whole body X-irradiation
P05437405T0000|10 41|forearm arteriolar dilator capacity
P05437405T0000|52 89|mineralocorticoid-induced salt retention
P05441564T0001|27 31|ECHO 9
P05441564T0001|33 42|HILL) virus
P05441564T0001|59 70|suckling mice
P05445187T0000|32 50|respiratory passages
P05445187T0000|60 78|water and heat balance
P05451324T0000|0 10|Calibration
P05451324T0000|51 53|Po2
P05451324T0000|57 58|CO
P05456002T0000|3 6|West
P05456002T0000|13 26|doctor shortage
P05460466T0001|0 10|Elimination
P05460466T0001|13 70|gamma-irradiation induced oxidation in aqueous drug preparations
P05463837T0023|26 28|C-2
P05463837T0023|26 28|C-2
P05463837T0023|31 46|monocrotalic acid
P05466177T0001|0 17|Teratogenic effects
P05466177T0001|20 31|actinomycin D
P05466177T0001|34 37|rats
P05471866T0000|3 34|plasma growth hormone concentration
P05471866T0000|3 21|plasma growth hormone
P05471866T0000|40 49|foetal lamb
P05472485T0000|31 37|rodents
P05474466T0001|45 60|rheumatoid factor
P05474466T0001|45 60|rheumatoid factor
P05488121T0000|0 14|CO2 assimilation
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|0 14|Foreign profiles
P05496619T0000|20 45|pollution control activities
P05497793T0000|9 35|chronic metaraminol treatment
P05497793T0000|100 103|warm
P05497793T0000|106 121|cold environments
P05500957T0001|16 24|clopamide
P05500957T0001|28 36|hydergine
P05500957T0001|38 46|Brinedine
P05500957T0001|67 88|vasculo-renal syndromes
P05500957T0001|91 99|pregnancy
P05501347T0001|11 28|low dosage radiation
P05501347T0001|31 40|metabolism
P05501347T0001|57 65|rat kidney
P05501347T0001|66 72|damaged
P05501347T0001|75 82|ischemia
P05502054T0000|0 7|Leukemia
P05502054T0000|10 14|twins
P05529283T0000|14 24|exocrine IgA
P05529283T0000|14 24|exocrine IgA
P05529283T0000|27 36|human serum
P05532854T0001|0 29|Gastrointestinal manifestations
P05532854T0001|32 48|systemic sclerosis
P05533214T0001|0 15|Iodine metabolism
P05533214T0001|18 35|chronic thyroiditis
P05536803T0001|5 13|body water
P05536803T0001|15 49|rhodanide space and I-131-albumin space
P05536803T0001|32 44|I-131-albumin
P05536803T0001|58 68|acute effect
P05536803T0001|71 80|furosemide
P05544291T0031|0 0|V
P05552149T0000|0 20|18F and 85Sr scintimetry
P05552149T0000|33 52|primary arthropathies
P05552642T0000|14 30|hormone production
P05552642T0000|33 66|human normal and malignant trophoblast
P05552642T0000|69 72|rats
P05553261T0000|0 5|Health
P05553261T0000|9 28|integrative reticulum
P05555149T0001|0 26|Sensitive fluorometric method
P05555149T0001|40 48|SH- and S-S
P05555149T0001|46 48|S-S
P05556977T0001|0 12|Morphogenesis
P05556977T0001|69 86|Carausius morosus Br
P05560428T0001|0 9|Behavioral
P05560428T0001|46 50|sleep
P05567721T0000|0 12|Sensitivities
P05567721T0000|15 29|thromboplastins
P05567721T0000|32 40|factor VII
P05567721T0000|38 50|VII deficiency
P05570175X0000|0 0|3
P05572662T0000|0 12|Central venous
P05572662T0000|28 65|recording intracardiac electrocardiogram
P05574818T0000|46 54|isometric
P05574818T0000|58 65|isotonic
P05574818T0000|94 107|skeletal muscle
P05593469T0001|4 21|head-brain injuries
P05594277T0051|17 25|P32 uptake
P05594277T0051|33 45|Jensen sarcoma
P05594277T0051|63 70|peroxide
P05594277T0051|76 90|nutritive medium
P05595036T0001|0 7|Students
P05595036T0001|28 43|hearing disorders
P05621339T0001|0 7|Changing
P05621339T0001|28 43|Cs137 irradiation
P05627251T0000|0 13|Positive shifts
P05627251T0000|16 34|basal skin potentials
P05627251T0000|41 50|human sleep
P05642051T0000|0 16|Evaluating dietary
P05671267T0000|0 70|5-(Dimethylaminopropyl)-19,11-dihydro-5H-benzo[2,3]pyrido[6,7-b]azepine
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|28 31|Ca45
P05683809T0000|8 17|thrombotic
P05683809T0000|21 39|antithrombotic drugs
P05683809T0000|45 72|surface charge characteristics
P05683809T0000|75 92|canine blood vessels
P05684081T0001|0 11|Measurements
P05684081T0001|29 58|radioprotective chamber VA-K-254
P05684081T0001|64 71|osimeter
P05684081T0001|72 77|VA-J18
P05689427T0052|0 82|3-(N-Alkyl-N-2-chloroethylaminomethyl)-5- or 7-halogenobenzo[b]thiophen hydrochlorides
P05693602T0001|12 37|automatic blood cell counters
P05693605T0001|0 12|Determination
P05715613T0000|0 6|Sterols
P05715613T0000|9 14|pollen
P05718386T0001|0 10|Dermoid cyst
P05718386T0001|18 25|skin flap
P05718500T0001|0 11|Histological
P05718500T0001|29 35|decidua
P05718994T0000|0 25|Endocardial fibro-elastosis
P05718994T0000|27 44|mitral incompetence
P05718994T0000|62 75|abdominal aorta
P05719031T0000|35 52|medicinal compounds
P05719746T0001|0 7|Children
P05722341T0000|17 26|estimation
P05722341T0000|29 43|monosaccharides
P05722341T0000|69 92|gas-liquid chromatography
P05725509T0000|0 7|Steroids
P05725509T0000|33 36|rats
P05727222T0000|22 37|respiratory pumps
P05727222T0000|43 59|oxygen consumption
P05727222T0000|62 76|Callionymus lyra
P05732641T0001|0 5|Trials
P05732641T0001|8 21|sevine activity
P05732641T0001|29 42|mosquito larvae
P05733952T0001|38 51|lymphoid tissue
P05733952T0001|55 72|antibody production
P05733953T0001|38 55|phagocytic activity
P05733953T0001|58 66|Paramecia
P05734847T0000|24 46|Glossina morsitans colony
P05734847T0000|49 54|Lisbon
P05740389T0001|0 8|Relations
P05740389T0001|16 35|adrenergic mechanisms
P05742879T0000|0 14|Transformations
P05749438T0001|0 49|Dissociative anesthetics 2-(o-chlorophenyl)-2-methyl
P05749438T0001|51 76|amino cyclohexane HCL (CI-581
P05750950T0001|0 5|Estrus
P05750950T0001|30 37|androgen
P05751819T0000|12 17|season
P05751819T0000|51 61|male, female
P05751819T0000|80 90|Hariana cows
P05758469T0001|0 18|Hemodynamics changes
P05758469T0001|21 23|man
P05758469T0001|30 35|flight
P05760665T0000|6 15|prevention
P05760665T0000|21 32|dental office
P05763287T0063|0 0|I
P05763347T0000|0 19|Clinical applications
P05763347T0000|34 57|beta-adrenergic receptors
P05763347T0000|34 57|beta-adrenergic receptors
P05763347T0000|62 72|propranolol
P05774062T0000|13 32|gastric acid secretion
P05779953T0000|20 38|pituitary and serum LH
P05779953T0000|37 38|LH
P05779953T0000|42 44|FSH
P05779953T0000|42 44|FSH
P05779953T0000|47 58|testosterone
P05781385T0000|20 44|phenolphthalein sulphatase
P05781385T0000|89 103|Nocardia species
P05782943T0001|14 22|mast cells
P05782943T0001|36 44|granuloma
P05782943T0001|50 53|skin
P05787318T0000|0 15|Long-term effects
P05787318T0000|18 27|clofibrate
P05787318T0000|29 38|Atromid-S)
P05787318T0000|41 51|serum lipids
P05789870T0001|0 28|Phosphate glucose dehydrogenase
P05789870T0001|9 38|glucose dehydrogenase deficiency
P05789870T0001|69 75|newborn
P05792868T0000|8 44|forthe electroosmosis theory of transport
P05792868T0000|50 55|phloem
P05792911T0000|9 31|beta-adrenergic receptor
P05792911T0000|9 31|beta-adrenergic receptor
P05792911T0000|42 58|airway conductance
P05792911T0000|62 71|lung volume
P05792911T0000|74 99|normal and asthmatic subjects
P05794247T0000|8 14|heparin
P05794247T0000|34 55|serum lipoprotein lipase
P05794247T0000|34 55|serum lipoprotein lipase
P05794247T0000|61 65|liver
P05794247T0000|68 85|unanesthetized dogs
P05796272T0000|12 34|chlorpromazine cataracts
P05797287T0069|0 0|I
P05798063T0000|0 9|Specialist
P05799686T0001|25 36|chemotherapy
P05799686T0001|59 74|ovarian carcinoma
P05799686T0001|87 102|cytodiagnosis and
P05799686T0001|118 134|tagged idoxuridine
P05805644T0001|44 48|228Ra
P05805644T0001|52 56|224Ra
P05805644T0001|62 86|RES and marrow-free skeleton
P05805644T0001|107 119|colloidal ThO2
P05806615T0001|0 19|Oxidative degradation
P05806615T0001|22 40|adrenaline solutions
P05806936T0000|0 9|Absorption
P05806936T0000|45 61|ulcerative colitis
P05806936T0000|67 81|control subjects
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05810259T0001|19 34|solution mediator
P05819249T0000|19 25|iron ore
P05826818T0098|0 0|I
P05833022T0001|28 41|enzyme activity
P05833022T0001|47 57|brain tissue
P05833022T0001|64 77|reflex epilepsy
P05836483T0000|1 21|malignant true teratoma
P05836483T0000|24 28|liver
P05836483T0000|31 39|childhood
P05837169T0001|0 29|Methoxyflurane and renal function
P05839844T0000|0 13|Histochemistry
P05839844T0000|17 34|electron microscopy
P05839844T0000|37 53|acute liver lesions
P05839844T0000|63 73|Aflatoxin B1
P05839844T0000|63 73|Aflatoxin B1
P05839844T0000|76 84|ducklings
P05847772T0001|10 18|disorders
P05847772T0001|39 56|gynecologic surgery
P05850652T0001|23 42|intestinal absorption
P05850652T0001|73 94|whole body irradiated rat
P05857301T0000|8 17|histologic
P05857301T0000|21 40|immunologic responses
P05857301T0000|43 46|rats
P05857301T0000|49 53|CC1-4
P05857301T0000|49 53|CC1-4
P05858571T0000|18 64|1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05859016T0000|30 58|water-miscible embedding medium
P05859016T0000|62 79|electron microscopy
P05879595T0094|0 9|Statistics
P05881833T0001|16 29|bovine leucosis
P05881833T0001|45 63|southern Lower Saxony
P05884183T0001|0 9|Experience
P05884183T0001|30 52|agglutination properties
P05884183T0001|55 90|non-agglutinating dysenterial cultures
P05884183T0001|103 119|Rzhaninov's method
P05890093T0000|7 17|micromelias
P05890093T0000|28 32|fetus
P05890093T0000|41 51|x-radiation
P05890093T0000|53 59|hypoxia
P05890093T0000|61 79|trypan blue injection
P05890093T0000|82 99|hypervitaminosis-A
P05890093T0000|104 116|mother animals
P05890093T0000|123 131|pregnancy
P05890351T0001|0 20|Human antitetanus serum
P05890351T0001|24 35|unused wealth
P05892712T0034|1 1|3
P05893495T0001|12 34|intracutaneous infection
P05893495T0001|46 66|Staphylococcus aureus.
P05896996T0001|2 11|catabolism
P05896996T0001|28 38|climacteric
P05901778T0000|11 25|feeding patterns
P05901778T0000|28 40|fat deposition
P05901778T0000|43 46|mice
P05902458T0001|0 10|Naphthalene
P05908762T0031|0 1|IV
P05909034T0000|9 28|powdered preparations
P05919308T0001|19 29|adrenergics
P05919308T0001|46 71|monoamine oxidase inhibitors
P05919308T0001|46 71|monoamine oxidase inhibitors
P05930797T0000|18 20|new
P05930797T0000|22 45|human isoprecipitin system
P05930797T0000|27 39|isoprecipitin
P05930797T0000|47 62|Australia antigen
P05933228T0000|0 16|Pigmentary rhythms
P05933228T0000|31 44|neurosecretion
P05938720T0000|0 4|Story
P05938720T0000|29 54|employee orientation program
P05939748T0000|7 14|cervical
P05942953T0049|0 0|I
P05947377T0001|13 24|iodine (I-132
P05947377T0001|37 43|thyroid
P05947377T0001|46 53|children
P05947377T0001|58 73|growth deficiency
P05949971T0000|0 10|Persistence
P05949971T0000|24 35|treated lakes
P05959588T0000|9 38|Coxsackie B Type 5 virus infections
P05960999T0001|0 4|Value
P05960999T0001|45 59|polysaccharide C
P05960999T0001|71 87|C-reactive protein
P05960999T0001|71 87|C-reactive protein
P05960999T0001|129 142|slide latex test
P05960999T0001|147 159|anti-CRP serum
P05960999T0001|147 154|anti-CRP
P05967610T0000|0 14|Adrenergic nerve
P05967610T0000|24 41|noradrenaline level
P05967610T0000|45 63|noradrenaline uptake
P05967610T0000|66 87|cat nictitating membrane
P05967610T0000|93 110|reserpine treatment
P05969185T0001|0 9|Concussion
P05969185T0001|15 24|spinal cord
P05982700T0000|23 43|Cysticercus pisiformis
P05985275T0000|0 21|Antimicrobial substance
P05985275T0000|36 47|acorn extract
P05992157T0001|18 38|Achromobacter puntatum
P05992157T0001|42 52|cold blooded
P05992157T0001|56 59|warm
P05992157T0001|60 73|blooded animals
P05994421T0045|0 24|Consanguinity and migration
P05994421T0045|52 56|Nunoa
P05995140T0001|31 51|effective glucose level
P05995140T0001|54 59|tumors
P05999607T0001|53 55|rat
P06012827T0000|27 46|cardiovascular system
P06012827T0000|62 77|hypertensive rats
P06027841T0000|0 10|Nuclear spin
P06027841T0000|13 17|249Bk
P06027841T0000|25 42|hyperfine structure
P06035001T0000|33 42|guinea pigs
P06035001T0000|64 73|trypan blue
P06048505T0000|0 10|Derivatives
P06048505T0000|13 20|fluorene
P06051644T0000|0 3|Note
P06051644T0000|6 17|Slot's method
P06054411T0000|19 26|steroids
P06054411T0000|29 45|gas chromatography
P06065507T0000|0 27|Compensatory renal hypertrophy
P06065507T0000|30 43|parabiotic rats
P06070072T0052|1 1|3
P06070204T0025|0 2|XXI
P06072512T0000|22 30|mucolytic
P06072512T0000|39 42|urea
P06073427T0001|0 30|Electrophoretic characteriaztion
P06073427T0001|33 55|virus-induced interferon
P06073427T0001|46 55|interferon
P06073427T0001|61 65|blood
P06073427T0001|69 73|urine
P06074093T0001|0 22|Iron and folate deficiency
P06074093T0001|25 33|pregnancy
P06074640T0001|0 8|Symposium
P06074640T0001|11 41|presenile spongy encephalopathies
P06084279A0218|17 24|patients
P06084279A0218|38 54|total serum amylase
P06084279A0218|43 54|serum amylase
P06084279A0218|64 67|ERCP
P06084810A0169|18 21|mRNA
P06084810A0169|27 41|polysome complex
P06084810A0169|93 106|genomic library
P06084864T0001|8 32|maternal alpha fetoproteins
P06084864T0001|8 32|maternal alpha fetoproteins
P06084864T0001|48 61|fetal prognosis
P06085839A0721|40 70|genetic and environmental etiology
P06088722A0171|0 6|Courses
P06088722A0171|40 55|myelosuppression
P06089575A0464|15 17|MCh
P06089575A0464|27 56|Ca-dependent transient elevation
P06089575A0464|59 62|cGMP
P06090369A0000|21 28|patients
P06090369A0000|41 47|WR-2721
P06090369A0000|55 65|I-II studies
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|86 91|TK gene
P06090458A0407|86 87|TK
P06091914A0000|4 16|mammary tumors
P06091914A0000|26 47|mouse mammary tumor virus
P06091914A0000|49 52|MMTV
P06091914A0000|62 69|provirus
P06091914A0000|90 104|host-cell genome
P06091914A0000|136 151|cellular oncogene
P06091914A0000|158 162|int-1
P06091914A0000|158 162|int-1
P06092048A1111|23 43|erionite-tissue burden
P06092048A1111|54 61|fibrosis
P06092588T0000|0 14|Hepatitis B virus
P06092588T0000|18 25|hepatoma
P06093354A0000|5 24|recombinant DNA clones
P06093354A0000|27 55|endogenous murine leukemia virus
P06093354A0000|57 60|MuLV
P06093354A0000|70 81|DNA sequences
P06093354A0000|103 127|lambdaphage genomic library
P06093354A0000|130 135|Balb/c
P06093354A0000|136 143|mouse DNA
P06093363A0612|54 70|amino acid sequence
P06093363A0612|76 84|alignment
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|26 46|Rous sarcoma virus (RSV)
P06094591A0000|26 41|Rous sarcoma virus
P06094591A0000|43 45|RSV
P06094591A0000|48 51|gp85
P06094591A0000|48 51|gp85
P06094591A0000|55 58|gp37
P06094591A0000|55 58|gp37
P06094591A0000|63 70|anchored
P06094591A0000|76 83|membrane
P06094591A0000|87 99|27-amino acid,
P06094591A0000|100 116|hydrophobic domain
P06094591A0000|139 165|amino acid, cytoplasmic domain
P06094591A0000|171 185|carboxy terminus
P06094591A0000|188 191|gp37
P06094591A0000|188 191|gp37
P06095372A0435|56 73|radiation treatment
P06095774T0001|21 39|mesoblastic nephroma
P06096246T0000|8 39|acute and chronic psychogenic stress
P06096246T0000|42 55|corticoadrenal
P06096246T0000|69 83|thyroid hormones
P06096246T0000|86 93|male rats
P06096380A0662|6 9|mRNA
P06096380A0662|13 53|cytosolic phosphoenolpyruvate carboxykinase
P06096380A0662|13 21|cytosolic
P06096380A0662|59 65|chicken
P06096380A0662|120 123|mRNA
P06096380A0662|140 145|enzyme
P06096380A0662|151 153|rat
P06096863T0000|0 17|Upstream activation
P06096863T0000|28 35|CYC1 gene
P06096863T0000|28 35|CYC1 gene
P06096863T0000|38 60|Saccharomyces cerevisiae
P06096863T0000|38 60|Saccharomyces cerevisiae
P06096863T0000|113 120|"TATA box
P06097027A0000|27 52|avian erythroblastosis virus
P06097027A0000|53 55|E26
P06097027A0000|98 121|avian myeloblastosis virus
P06097027A0000|123 125|AMV
P06097027A0000|135 151|avian tumor viruses
P06097285A1077|17 27|haloperidol
P06097285A1077|49 54|animal
P06097285A1077|77 88|non-stimulus
P06098828A0352|45 65|SV40 G-C-rich sequences
P06098828A0352|45 65|SV40 G-C-rich sequences
P06098828A0352|90 135|RNA polymerase II transcriptional-control elements
P06098828A0352|90 104|RNA polymerase II
P06099656T0000|14 27|human cell lines
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|109 119|HSV-1 tk gene
P06099656T0000|109 113|HSV-1
P06099656T0000|114 119|tk gene
P06101359T0000|0 8|Diagnosis
P06101359T0000|23 29|insulin
P06101359T0000|40 46|tumours
P06108610A0518|0 16|Theories proffered
P06109017A0000|12 49|cardioselective beta-1 adrenergic agonist
P06109017A0000|51 96|1-(4-hydroxyphenoxy)-isopropylamino-2-propanol
P06109017A0000|104 114|prenalterol
P06109017A0000|163 177|left ventricular
P06109017A0000|179 189|LV) pressure
P06109017A0000|200 204|dP/dt
P06109017A0000|227 253|arterial pressure, iliac blood
P06109017A0000|261 269|heart rate
P06109017A0000|274 286|conscious dogs
P06110026T0000|0 9|Endorphins
P06110026T0000|0 9|Endorphins
P06110026T0000|25 29|death
P06111283T0032|0 13|Trial treatment
P06111283T0032|16 28|schizophrenia
P06111283T0032|33 55|des-Tyr-gamma-endorphin
P06111283T0032|33 45|des-Tyr-gamma
P06113084T0000|0 19|Cardiac taurine levels
P06113084T0000|34 55|calcium binding activity
P06113084T0000|58 91|furazolidone-induced cardiomyopathy
P06113443T0000|12 18|malaria
P06113443T0000|28 39|erythrocytes
P06113443T0000|70 109|high-gradient magnetic separation technique
P06119262T0000|34 42|pregnancy
P06120429T0000|3 20|thyroglobulin assay
P06120429T0000|3 15|thyroglobulin
P06120429T0000|35 50|radioiodine scans
P06120429T0000|53 60|patients
P06120429T0000|65 91|differentiated thyroid cancer
P06121577A0280|41 53|blood pressure
P06121577A0280|107 109|800
P06121577A0280|174 192|plasma renin activity
P06121577A0280|174 184|plasma renin
P06131038A0000|0 5|Plasma
P06131038A0000|9 50|erthrocyte lipid profile and lipoprotein lipase
P06131038A0000|34 50|lipoprotein lipase
P06131038A0000|72 77|plasma
P06131038A0000|80 98|vasectomized rabbits
P06131038A0000|131 145|atherosclerosis
P06131038A0000|157 168|arterial beds
P06131378A0818|8 11|mRNA
P06131378A0818|28 41|polyadenylated
P06131378A0818|58 62|3' end
P06131378A0818|68 75|DHFR cDNA
P06131378A0818|68 75|DHFR cDNA
P06131378A0818|128 135|DHFR cDNA
P06131378A0818|128 135|DHFR cDNA
P06136374A0151|6 22|water temperatures
P06136374A0151|24 26|VO2
P06137028A0624|0 10|Propranolol
P06137028A0624|39 52|familial tremor
P06138313A0948|3 19|distribution phase
P06141764A0339|0 26|Hybrid-selection experiments
P06141764A0339|39 53|PB-inducible RNA
P06141764A0339|39 50|PB-inducible
P06141764A0339|51 53|RNA
P06141764A0339|71 80|plasmid DNA
P06141764A0339|108 119|PB-inducible
P06142279T0000|6 18|HTLV infection
P06142279T0000|21 28|patients
P06142279T0000|31 43|haemodialysis
P06143734T0000|2 16|vitro metabolism
P06143734T0000|19 30|progesterone
P06143734T0000|36 57|human undescended testis
P06147504A0086|3 10|patients
P06147504A0086|23 29|therapy
P06150069A0422|3 10|patients
P06150069A0422|19 21|VCR
P06150069A0422|49 64|dose modification
P06150069A0422|68 80|neurotoxicity
P06151518A0000|0 11|Glutamic acid
P06151518A0000|31 34|LD50
P06151518A0000|57 66|sodium salt
P06151518A0000|71 93|male and female Wistar rats
P06151518A0000|130 137|dexazone
P06151942A0235|5 16|ascorbic acid
P06151942A0235|59 79|systolic blood pressure
P06151942A0235|108 120|blood pressure
P06151942A0235|127 137|cholesterol
P06151942A0235|139 150|triglyceride
P06151942A0235|152 160|gamma-GTP
P06151942A0235|152 160|gamma-GTP
P06152670T0000|0 13|Plasma secretin
P06152670T0000|0 13|Plasma secretin
P06152670T0000|15 26|pancreozymin
P06152670T0000|31 54|somatostatin-like hormone
P06152670T0000|31 54|somatostatin-like hormone
P06152670T0000|57 75|chronic renal failure
P06152670T0000|76 83|patients
P06152844T0000|20 32|growth hormone
P06152844T0000|36 53|prolactin secretion
P06152844T0000|36 44|prolactin
P06152844T0000|56 69|normal subjects
P06153936A0784|24 26|SjS
P06153936A0784|28 46|labial salivary gland
P06155967A1132|3 14|radiologists
P06155967A1132|90 111|reporting abnormalities
P06158844A0000|0 16|Thalamotomy aiming
P06158844A0000|22 33|CM-Pf complex
P06158844A0000|22 23|CM
P06158844A0000|42 69|stereotactic gamma irradiation
P06158844A0000|97 106|52 patients
P06158844A0000|111 120|severe pain
P06161823A0129|1 16|Silastic capsules
P06161823A0129|41 56|ethinyl estradiol
P06161823A0129|87 89|men
P06161823A0129|94 119|benign prostatic hypertrophy
P06162419A0118|63 72|antibiotic
P06162419A0118|98 115|lymphadenosis NK/Li
P06163433T0000|8 41|2-(p-chlorophenyl)cyclopropylamine
P06163433T0000|75 98|monoamine oxidase activity
P06163433T0000|75 90|monoamine oxidase
P06163433T0000|101 108|rat brain
P06165068A0547|9 23|pancreatic juice
P06165068A0547|41 48|duodenum
P06165132A0000|85 94|spray lento
P06165132A0000|98 114|mesogenic vaccines
P06165132A0000|162 165|RIHA
P06165132A0000|169 189|provoking pseudoplague
P06165551A0793|1 1|2
P06165551A0793|62 67|spikes
P06165551A0793|71 80|sharp waves
P06165551A0793|232 252|segmentation algorithm
P06167806A0000|12 54|chronic UM-272 (dimethylpropranolol) treatment
P06167806A0000|78 113|reentrant ventricular tachyarrhythmias
P06167806A0000|130 141|conscious dog
P06167806A0000|153 158|serial
P06167806A0000|205 224|myocardial infarction
P06173032T0000|11 23|echothiophate
P06173032T0000|29 44|biphasic response
P06173032T0000|47 66|rabbit ocular pressure
P06173860A0000|13 37|acute transmural infarction
P06173860A0000|82 94|contralateral
P06175691T0000|0 28|Bacillus cereus cross-infection
P06175691T0000|32 45|maternity-unit
P06181216A0070|33 40|patients
P06181216A0070|52 73|serum IgA concentrations
P06181216A0070|57 59|IgA
P06182979A0807|55 76|anthracycline analogues
P06182979A0807|79 101|doxorubicin and analogues
P06182979A0807|104 132|cisplatinum diammine dichloride
P06184276T0001|15 27|plasmocytosis
P06184487A1485|19 22|cDNA
P06184487A1485|38 60|HindIII-P/EcoRI-B region
P06184487A1485|38 46|HindIII-P
P06184487A1485|48 60|EcoRI-B region
P06184487A1485|66 73|AcNPV map
P06184487A1485|96 98|31K
P06184487A1485|102 104|30K
P06184487A1485|135 137|31K
P06184487A1485|141 151|30K proteins
P06184487A1485|182 205|HindIII-A/EcoRI-C/SstI-G
P06184487A1485|182 190|HindIII-A
P06184487A1485|192 198|EcoRI-C
P06184487A1485|200 209|SstI-G cDNA
P06184487A1485|206 209|cDNA
P06185014A0642|19 37|complement factor C3c
P06185014A0642|19 34|complement factor
P06185014A0642|35 37|C3c
P06185014A0642|58 75|alpha 1-antitrypsin
P06185014A0642|58 75|alpha 1-antitrypsin
P06185493A0468|0 16|A polypeptide chain
P06185493A0468|100 113|ADP binding site
P06185493A0468|100 113|ADP binding site
P06185493A0468|116 141|bovine muscle pyruvate kinase
P06185493A0468|128 141|pyruvate kinase
P06189698A0246|3 15|P165 component
P06189698A0246|130 131|N2
P06189698A0246|135 146|P3 amplitudes
P06191243T0000|0 22|Differential drawing size
P06191243T0000|37 57|unilateral brain damage
P06193351A1010|3 29|intracoronary administration
P06193351A1010|70 71|VF
P06193351A1010|100 122|coronary artery occlusion
P06198241A0209|26 33|plasmids
P06198241A0209|47 71|yeast and E. coli replication
P06198241A0209|139 143|yeast
P06198241A0209|146 157|E. coli cells.
P06198532A0982|28 37|thrombotic
P06198532A0982|64 71|patients
P06198532A0982|76 77|MS
P06198532A0982|100 102|RHD
P06198532A0982|196 198|RHD
P06199132A0179|43 50|patients
P06199132A0179|60 68|WBC counts
P06199132A0179|115 120|sepsis
P06200300A0409|0 17|Subdural electrodes
P06200300A0409|32 44|VEP amplitudes
P06200300A0409|49 53|skull
P06200300A0409|56 70|scalp electrodes
P06203843A0757|0 7|Products
P06203843A0757|10 20|immune cells
P06203843A0757|44 54|lymphokines
P06203843A0757|98 121|immune-stimulating agents
P06204120T0001|8 31|immunofluorescence method
P06204120T0001|66 77|cell cultures
P06208024A0168|37 42|DNase I
P06208024A0168|37 42|DNase I
P06208024A0168|46 52|RNase T1
P06208024A0168|46 52|RNase T1
P06208024A0168|80 95|alkali hydrolysis
P06208477A0000|3 14|construction
P06208477A0000|32 49|mouse repetitive DNA
P06209403A0562|2 14|direct repeats
P06209403A0562|38 46|U2/4 locus
P06209403A0562|38 46|U2/4 locus
P06209499A0682|18 35|transmitter release
P06209499A0682|56 58|MAP
P06209499A0682|74 86|pressor effect
P06209499A0682|127 137|tachycardia
P06212776A0000|2 7|Cabras
P06212776A0000|9 16|Oristano
P06212776A0000|55 66|thalassaemia
P06212776A0000|70 73|G6PD
P06212776A0000|70 73|G6PD
P06212776A0000|99 104|people
P06212776A0000|139 153|genetic diseases
P06212776A0000|164 173|prevention
P06214605A0123|79 93|five experiments
P06216125A0470|51 52|ET
P06216125A0470|66 70|cycle
P06216125A0470|89 96|follicle
P06216125A0470|129 133|cycle
P06216125A0470|153 160|follicle
P06217859T0000|0 9|Experience
P06217859T0000|17 42|tensor fasciae latae free flap
P06218005A0948|9 16|patients
P06218005A0948|30 36|L-L size
P06223586A0000|0 17|Immunochemotherapy
P06223586A0000|22 34|schizophyllan
P06223586A0000|36 38|SPG
P06223586A0000|52 73|chemotherapeutic agents
P06223586A0000|91 123|syngeneic tumor-C3H/He mouse systems
P06223586A0460|24 33|mitomycin C
P06223586A0460|90 92|SPG
P06223586A0460|132 148|tumor-bearing mice
P06224974A0833|30 45|15 beta-hydroxy-,
P06224974A0833|58 60|CPA
P06225279A0498|3 18|abluminal surface
P06227570A0523|13 22|LL patients
P06227570A0523|29 31|ENL
P06227570A0523|35 38|ConA
P06227570A0523|35 38|ConA
P06227570A0523|47 64|suppressor response
P06230499A0128|36 46|irradiation
P06230499A0128|127 130|24 Gy
P06230499A0128|174 184|irradiation
P06230499A0128|316 332|dose fractionation
P06233924T0000|0 9|Fibrin gels
P06233924T0000|0 5|Fibrin
P06233924T0000|40 58|surface hemorheology
P06234369T0000|0 21|Hepatitis-B vaccination
P06234369T0000|27 33|elderly
P06234786A0606|0 18|Radiogallium imaging
P06234786A0606|60 74|giant cell tumors
P06234786A0606|77 80|bone
P06237518A0117|20 40|reagent sulfanilic acid
P06237518A0117|58 83|1,3-dimethylbarbituric acid
P06237518A0117|85 88|CNCl
P06237518A0117|104 107|flow
P06237518A0117|133 135|KCN
P06238540A0798|0 16|Ventricular volume
P06238540A0798|60 75|LVH shifted upward
P06238540A0798|87 106|normalized wall muscle
P06238540A0798|150 152|LVH
P06238704T0001|11 26|(+)-lysergic acid
P06238704T0001|39 46|tartrate
P06239545A0649|46 64|intravascular volume
P06239545A0649|102 120|sympathetic activity
P06240448A0652|11 19|treatment
P06240448A0652|85 90|LV mass
P06240448A0652|106 118|cardiac output
P06240448A0652|208 214|cardiac
P06241900A0000|42 52|hypothermia
P06241900A0000|114 133|non-failing rat hearts
P06241900A0000|163 177|global ischaemia
P06241980A0855|0 5|Oxygen
P06241980A0855|30 39|Krogh model
P06242113T0001|0 18|Cultivation technics
P06242113T0001|22 39|Codonopsis pilosula
P06244732T0000|0 15|Radioimmunoassay
P06244732T0000|18 37|serum creatine kinase B
P06244732T0000|23 46|creatine kinase B isoenzyme
P06244732T0000|63 87|acute myocardial infarction
P06245672T0000|9 28|macrophage inhibition
P06245672T0000|38 62|warfarin-induced reduction
P06245672T0000|65 74|metastasis
P06246254A0676|0 39|Restriction enzyme and heteroduplex analyses
P06246254A0676|70 73|FeSV
P06246254A0676|75 86|src sequences
P06246254A0676|75 86|src sequences
P06246254A0676|114 123|FeSV genome
P06246254A0676|146 158|kilobase pairs
P06251469A0830|48 59|7-kb IAP units
P06251469A0830|52 59|IAP units
P06251469A0830|65 80|restriction sites
P06252520T0000|0 32|Catecholamines and aversive learning
P06252883A0100|1 10|haemolytic
P06252883A0100|34 39|E. coli
P06252883A0100|41 53|O149:K88:H10)
P06252883A0100|90 92|PWD
P06254403A0000|3 15|antibody titer
P06254403A0000|21 28|chickens
P06254403A0000|31 44|SA-11 rotavirus
P06254403A0000|60 98|enzyme-linked immunosorbent blocking assay
P06254973A1757|0 6|Poly(dT
P06254973A1757|11 23|denatured calf
P06254973A1757|24 29|thymus
P06254973A1757|63 77|polynucleotides
P06254973A1757|111 114|HDP*
P06254973A1757|111 114|HDP*
P06254973A1757|117 120|dT)8
P06254973A1757|159 162|dT)n
P06254973A1757|168 177|dT)4 and (dT
P06254973A1757|219 229|binding site
P06254973A1757|242 257|HDP* accumulation
P06254973A1757|242 245|HDP*
P06254973A1757|288 291|dT)n
P06258699T0000|44 50|Soluble
P06258699T0000|51 52|GU
P06258699T0000|53 69|bladder irrigation
P06258699T0000|72 81|cystoscopy
P06258806A0963|29 47|transposable element
P06258806A0963|55 64|5' terminus
P06258806A0963|70 83|structural gene
P06258806A0963|127 133|glucose
P06259220A0000|37 53|opiate antagonists
P06259220A0000|63 89|short-term analgesic reaction
P06259220A0000|119 134|inescapable shock
P06259220A0000|141 166|long-term analgesic reaction
P06259220A0000|207 230|inescapable shock exposure
P06259220A0464|0 10|Experiment 3
P06259220A0464|24 49|long-term analgesic reaction
P06259220A0464|86 95|naltrexone
P06259220A0464|103 119|reexposure to shock
P06259389A0000|53 56|foot
P06259389A0000|60 71|mouth disease
P06259389A0000|73 76|HFMD
P06259389A0000|88 101|Gifu prefecture
P06270347A0740|1 14|22K polypeptide
P06270347A0740|76 86|DNA fragment
P06272844A0000|11 28|simian virus 40 (SV40
P06272844A0000|30 40|chromosomes
P06272844A0000|78 88|chromosomes
P06272844A0000|113 131|micrococcal nuclease
P06272844A0000|113 131|micrococcal nuclease
P06272844A0000|133 138|MNase)
P06272844A0000|133 137|MNase
P06272844A0000|202 214|SV40 chromatin
P06278424A0145|38 43|CH gene
P06278424A0145|38 43|CH gene
P06278424A0145|69 90|rearranged gamma 2b genes
P06278424A0145|69 90|rearranged gamma 2b genes
P06278424A0145|96 123|gamma 2b producing mouse myeloma
P06278424A0145|96 102|gamma 2b
P06278424A0145|125 130|MPC-11
P06278424A0145|125 130|MPC-11
P06278544T0027|0 9|Physiology
P06279309A0000|11 36|avian erythroblastosis virus
P06279309A0000|82 87|v-erbA
P06279309A0000|82 87|v-erbA
P06279309A0000|91 96|v-erbB
P06279309A0000|91 96|v-erbB
P06279309A0000|154 158|virus
P06281759A1086|7 25|RNase III host mutants
P06281759A1086|7 25|RNase III host mutants
P06281759A1086|40 52|sib regulation
P06281759A1086|40 42|sib
P06281759A1086|69 74|PL mRNA
P06281759A1086|69 70|PL
P06281759A1086|77 79|sib
P06281759A1086|77 79|sib
P06281759A1086|110 144|int mRNA decay and decrease int synthesis
P06281786A1222|10 14|clone
P06281786A1222|16 24|lambda HHG
P06281786A1222|52 63|histone genes
P06281786A1222|52 63|histone genes
P06281786A1222|118 131|330 nucleotides
P06281891A0399|4 9|neural
P06281891A0399|13 28|hormonal pathways
P06281891A0399|101 112|transmission
P06286191T0000|21 35|immune functions
P06286191T0000|38 49|aging animals
P06286443A0498|13 27|serum ACTH levels
P06286443A0498|18 21|ACTH
P06286549A0000|0 6|WR-2721
P06286549A0000|8 54|S-2-(3 aminopropylamino) ethylphosphorothioic acid
P06286549A0000|8 10|S-2
P06286549A0000|97 99|gut
P06286549A0000|101 104|lung
P06286549A0000|109 114|testis
P06286549A0000|124 135|fibrosarcoma
P06286549A0000|137 152|FSa) tumor nodules
P06286549A0000|159 163|lungs
P06286549A0000|166 169|mice
P06286549A0000|174 194|gamma-radiation injury
P06287212A1352|17 28|polypeptides
P06287212A1352|55 65|translation
P06287212A1352|68 76|AUG codons
P06287212A1352|101 103|VP1
P06287212A1352|101 103|VP1
P06287212A1352|107 107|T
P06287212A1352|172 177|5' ends
P06287212A1352|206 209|AUGs
P06287231A0914|11 25|TRP1 RI Circle DNA
P06287231A0914|11 14|TRP1
P06287737A0477|22 32|transfusion
P06287737A0477|35 60|chronic hepatitis, cirrhosis
P06287737A0477|64 86|hepatocellular carcinoma
P06287737A0477|89 96|type NANB
P06287737A0477|152 180|early posttransfusion hepatitis
P06287737A0477|214 233|chronic liver diseases
P06287737A0477|248 255|jaundice
P06287737A0477|262 270|hepatitis
P06287737A0477|327 330|NANB
P06287737A0477|343 350|B disease
P06290859A0426|2 14|115 hepatitis B
P06290859A0426|15 22|patients
P06290859A0426|43 72|chronic hepatitis Bs antigenaemia
P06290859A0426|89 106|anti-HBs antibodies
P06290859A0426|89 106|anti-HBs antibodies
P06290859A0426|123 143|abnormal liver function
P06290899T0000|0 5|Survey
P06290899T0000|53 59|chicken
P06291369A0000|4 11|patients
P06291369A0000|53 74|cardiac catheterization
P06291369A0000|136 141|global
P06291369A0000|153 168|right ventricular
P06291369A0000|186 189|RVEF
P06291369A0000|209 241|pulmonary arterial systolic pressure
P06294111A1141|0 9|74, 193-197
P06295429A0412|16 19|MISO
P06295429A0412|23 29|WR-2721
P06296833A0000|22 55|larval cuticle protein gene expression
P06296833A0000|22 45|larval cuticle protein gene
P06296833A0000|71 92|Drosophila melanogaster
P06298014A0647|3 11|ensembles
P06298720A0893|34 55|terminal repeat sequence
P06298720A0893|96 107|VL30 elements
P06298720A0893|96 107|VL30 elements
P06300662T0000|1 11|cDNA cloning
P06300662T0000|41 51|cDNA inserts
P06300662T0000|54 67|mammalian cells
P06300836A0285|0 12|Hybridization
P06300836A0285|49 59|RR1 colonies
P06300836A0285|64 74|32P-labeled
P06300836A0285|75 85|viral genome
P06300836A0285|149 150|10
P06300836A0285|151 162|reovirus RNAs
P06300836A0285|199 213|rotavirus genome
P06304771A1284|7 14|sequence
P06304771A1284|16 23|GGGXGGAG
P06304771A1284|75 86|adenoviruses
P06304771A1284|118 131|DNA replication
P06304771A1284|138 150|transcription
P06304771A1284|167 177|JCV sequence
P06306342A1156|37 40|LiCl
P06306342A1156|53 92|histamine-stimulated gastric acid secretion
P06306342A1156|110 131|bile-induced disruption
P06306342A1156|137 143|gastric
P06306342A1156|151 157|barrier
P06306342A1156|163 183|canine Heidenhain pouch
P06307099A1005|0 10|Lung density
P06307099A1005|22 35|quartz-exposed
P06307099A1005|45 71|volcanic-ash-exposed animals
P06308536T0001|3 25|hepatitis A virus antibody
P06308536T0001|3 17|hepatitis A virus
P06308536T0001|18 25|antibody
P06308536T0001|27 34|anti-HAV
P06308536T0001|27 34|anti-HAV
P06308536T0001|38 64|chronic diffuse liver diseases
P06308607A0375|19 43|viral and cellular sequences
P06308607A0375|60 78|DNA sequence analysis
P06308607A0375|83 96|517 nucleotides
P06308607A0375|104 114|p30 sequence
P06308607A0375|104 114|p30 sequence
P06308607A0375|118 133|1,920 nucleotides
P06308607A0375|141 158|polymerase sequence
P06309020A0473|0 7|Naloxone
P06309020A0473|27 32|-1 X h-1
P06309020A0473|29 32|X h-1
P06309020A0473|67 84|lipopolysaccharide
P06309855T0000|30 48|dental porcelain frit
P06309969T0055|0 0|I
P06310159A0000|0 4|Viral
P06310159A0000|26 36|proviral DNA
P06310159A0000|41 61|virus-specific protein
P06310159A0000|64 81|avian retrovirus MH2
P06310457A0000|0 22|Intracellular recordings
P06310553T0000|0 17|Molecular structure
P06310553T0000|41 67|human cardiac muscle actin gene
P06310553T0000|41 58|human cardiac muscle
P06310553T0000|59 67|actin gene
P06310608A0749|57 62|M-MuLV
P06310608A0749|105 123|Ableson MuLV (Ab-MuLV
P06310608A0749|128 152|Moloney murine sarcoma virus
P06310608A0749|156 158|MSV
P06314276T0000|36 66|full-length double-stranded cDNAs
P06314276T0000|47 66|double-stranded cDNAs
P06314276T0000|84 110|SV40 early or late gene promoter
P06314276T0000|84 102|SV40 early or late gene
P06314312A0359|14 27|soybean protein
P06314312A0359|31 47|sucrose-based diet
P06314312A0359|60 62|2.2
P06314312A0359|80 89|antibiotic
P06316347A0852|3 25|dnaQ-lacZ and the rnh-lacZ
P06316347A0852|3 6|dnaQ
P06316347A0852|8 11|lacZ
P06316347A0852|18 20|rnh
P06316347A0852|22 25|lacZ
P06316347A0852|54 67|hybrid proteins
P06316347A0852|72 97|beta-galactosidase activity
P06316347A0852|72 89|beta-galactosidase
P06316623A0188|7 17|prevalences
P06316623A0188|20 27|antibody
P06316623A0188|61 65|sheep
P06316623A0188|99 117|immunodiffusion test
P06318078T0000|12 41|herpes simplex virus beta and gamma
P06318078T0000|12 33|herpes simplex virus beta
P06318078T0000|37 41|gamma
P06318078T0000|59 72|mammalian cells
P06318078T0000|94 109|alpha gene product
P06318078T0000|94 102|alpha gene
P06318322A0350|39 41|SSV
P06318322A0350|76 86|proviral DNA
P06318322A0350|90 129|simian sarcoma associated virus and proto-sis
P06318322A0350|90 117|simian sarcoma associated virus
P06318322A0350|121 129|proto-sis
P06318322A0350|137 143|introns
P06318322A0350|180 188|viral-sis
P06319040A1627|19 40|autonomic nervous system
P06319040A1627|49 62|intact, carotid
P06319040A1627|76 91|reflex activation
P06319040A1627|138 154|coronary blood flow
P06319040A1627|167 178|conscious dog
P06319040A1627|199 214|arterial pressure
P06319071A0173|0 13|Female subjects
P06319071A0173|28 41|normal subjects
P06319071A0173|55 74|calcium stone-formers
P06319071A0173|93 101|cyclic AMP
P06319071A0173|117 132|male counterparts
P06319071A0173|168 174|urinary
P06319071A0173|175 183|cyclic AMP
P06319072A0711|18 27|morning dip
P06319072A0711|39 55|asthmatic patients
P06319072A0711|90 107|cell receptor number
P06319072A0711|162 178|beta-adrenoceptor
P06319072A0711|162 178|beta-adrenoceptor
P06319421A0937|52 65|neuronal uptake
P06319421A0937|110 123|neuronal uptake
P06319421A0937|127 161|prejunctional alpha 2-adrenoreceptors
P06319421A0937|140 161|alpha 2-adrenoreceptors
P06319740A1331|17 34|gp54 structural gene
P06319740A1331|17 34|gp54 structural gene
P06319740A1331|78 96|splenic erythroblast
P06319740A1331|129 144|preleukemic phase
P06319740A1331|147 161|Rauscher disease
P06320380T0001|0 16|Surgical treatment
P06320380T0001|28 37|metastases
P06321505A0401|1 16|promoter sequence
P06321505A0401|18 33|Goldberg-Hogness
P06321505A0401|36 42|TATA box
P06321505A0401|54 72|28 base pairs upstream
P06321505A0401|99 111|transcription
P06321505A0401|127 136|S1 nuclease
P06321505A0401|127 128|S1
P06321505A0401|129 143|nuclease mapping
P06321505A0401|149 163|oligonucleotide
P06321505A0401|171 190|reverse transcription
P06321505A0401|193 202|rat PTH mRNA
P06321505A0401|193 195|rat
P06321505A0401|196 202|PTH mRNA
P06321634A0123|18 22|mRNAs
P06321634A0123|56 63|249 bases
P06321634A0123|74 79|intron
P06321634A0123|134 149|TRs/IRs sequences
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06321770A1353|91 106|recombinant virus
P06321770A1353|137 145|promoters
P06322183A1070|0 13|NPT II synthesis
P06322183A1070|0 4|NPT II
P06322183A1070|25 39|agar plate assays
P06322183A1070|42 60|kanamycin resistance
P06322183A1070|66 84|immunoprecipitation
P06322183A1070|90 101|NPT II protein
P06322183A1070|90 101|NPT II protein
P06322183A1070|130 137|cysteine
P06323556A0126|37 42|EOE-13
P06323556A0126|91 107|implanted catheter
P06324089A0453|24 43|GAL7 5' flanking region
P06324089A0453|24 43|GAL7 5' flanking region
P06324089A0453|87 101|eukaryotic genes
P06324121A0256|3 28|12,000 MW (12K) IE polypeptide
P06324121A0256|3 10|12,000 MW
P06324121A0256|12 28|12K) IE polypeptide
P06324121A0256|38 45|IEmRNA-5
P06324121A0256|38 45|IEmRNA-5
P06324121A0256|66 86|codon open reading frame
P06324121A0256|96 105|1200 base 3'
P06325415A0757|31 43|Ad7 and Ad5 DBPs
P06325415A0757|31 33|Ad7
P06325415A0757|37 39|Ad5
P06325415A0757|40 43|DBPs
P06325415A0757|62 71|Ad7 protein
P06325415A0757|62 71|Ad7 protein
P06325415A0757|77 86|amino acids
P06325415A0757|129 138|Ad5 protein
P06325415A0757|129 138|Ad5 protein
P06325415A0757|150 156|151-162
P06327039A0743|39 56|LVM or wall thickness
P06327039A0743|60 74|body surface area
P06327039A0743|80 102|blood pressure, heart rate
P06327039A0743|146 149|left
P06327039A0743|150 178|ventricular systolic wall stress
P06327039A0743|187 190|CD25
P06327039A0743|187 190|CD25
P06327039A0743|208 214|urinary
P06327039A0743|215 228|catecholamines
P06327039A0743|235 254|hypertensive patients
P06327292A0846|14 36|Shine-Dalgarno sequences
P06327292A0846|81 91|start codons
P06327638A0155|3 12|gene cat-86
P06327638A0155|24 80|chloramphenicol-inducible chloramphenicol acetyltransferase
P06327638A0155|24 80|chloramphenicol-inducible chloramphenicol acetyltransferase
P06327638A0155|96 107|1.1-kilobase
P06328002A0000|3 37|myeloproliferative sarcoma virus (MPSV
P06328002A0000|60 86|Moloney sarcoma virus (Mo-MuSV
P06328002A0000|90 98|adult mice
P06328012A0549|13 23|EBNA protein
P06328012A0549|13 23|EBNA protein
P06328012A0549|73 79|BamHI-K
P06328012A0549|73 79|BamHI-K
P06328012A0549|81 96|5.2 kilobase pairs
P06328012A0549|108 121|I1f subfragment
P06328485A0277|23 40|nucleotide sequence
P06328485A0277|55 59|3' end
P06328485A0277|62 69|delta gag
P06328485A0277|62 69|delta gag
P06328485A0277|75 79|3' end
P06328485A0277|99 112|proviral MH2 DNA
P06328485A0277|156 160|virus
P06328485A0277|184 204|mht - and myc-containing
P06328485A0277|184 193|mht - and myc
P06328485A0277|205 220|oncogenic viruses
P06328485A0277|236 255|chicken proto-myc gene
P06328485A0277|236 255|chicken proto-myc gene
P06328504A0161|31 53|genomic clone lambda PGK-1
P06328504A0161|49 53|PGK-1
P06328504A0161|76 89|autosomal locus
P06328504A0161|93 118|phosphoglycerate kinase (PGK
P06328504A0161|93 114|phosphoglycerate kinase
P06328504A0161|116 118|PGK
P06330478A0304|0 10|188 patients
P06330478A0304|19 28|cimetidine
P06331684A0607|2 16|immunologic test
P06331684A0607|22 28|stomach
P06331684A0607|32 44|tumor antigens
P06331684A0607|77 89|stomach cancer
P06333433A0000|16 41|Haemophilus influenzae type b
P06333433A0000|82 103|influenzae type b disease
P06333433A0000|126 147|electrophoretic profile
P06333433A0000|155 172|lipopolysaccharide
P06333433A0000|174 176|LPS
P06333878T0000|0 22|Tiaprofenic acid overdose
P06336045A0261a|0 8|Frog type I
P06336045A0261a|10 31|Ft I) and frog type II (Ft II
P06336045A0261a|39 49|adapting (SA
P06336045A0261a|79 94|indentation phase
P06336045A0261a|125 127|TRP
P06336045A0261a|125 127|TRP
P06336045A0261a|164 166|ca.
P06336045A0261b|0 8|Frog type I
P06336045A0261b|10 31|Ft I) and frog type II (Ft II
P06336045A0261b|39 49|adapting (SA
P06336045A0261b|79 94|indentation phase
P06336045A0261b|125 127|TRP
P06336045A0261b|125 127|TRP
P06336045A0261b|164 166|ca.
P06340643A0598|0 3|DMCM
P06341139A0213|5 11|glucose
P06341139A0213|21 27|insulin
P06341139A0213|21 27|insulin
P06341139A0213|65 66|60
P06341139A0213|98 104|glucose
P06341139A0213|106 113|fructose
P06341139A0213|116 122|lactose
P06341139A0213|164 171|potatoes
P06341139A0213|185 195|260 g carrots
P06341661T0001|13 38|absorbable polyglycolic acid
P06341661T0001|47 72|Blalock-Taussig's operation
P06342141A0226|103 122|diagnostic techniques
P06342141A0226|284 286|met
P06345840A0348|2 9|patients
P06345840A0348|12 17|group A
P06345840A0348|19 28|"normal" CI
P06345840A0348|34 35|CI
P06345840A0348|37 45|heart rate
P06345840A0348|56 75|circumferential fiber
P06345840A0348|95 98|mVCF
P06345840A0348|117 119|TPR
P06346427A0000|15 35|reactive insulin levels
P06346427A0000|23 29|insulin
P06346427A0000|52 64|freely-moving
P06346427A0000|71 74|rats
P06346427A0000|96 105|test-meals
P06349364A1051|48 54|passive
P06349364A1051|70 82|serum globulin
P06349364A1051|75 93|globulin) antibodies
P06349364A1051|96 128|type III group B Streptococcus antigen
P06349364A1051|158 171|intra-amniotic
P06350092A0916|24 26|AMI
P06350092A0916|38 41|CCHD
P06350092A0916|58 71|high-grade VPBs
P06350092A0916|113 120|coronary
P06350092A0916|124 127|left
P06350092A0916|170 176|cardiac
P06354594A0114|0 11|Sweet oranges
P06355483A0134|14 18|locus
P06355483A0134|50 64|coding sequences
P06355483A0134|79 91|646 base-pairs
P06355483A0134|97 117|locus and 676 base-pairs
P06360426A0501|3 19|enzymic hydrolysis
P06360426A0501|22 25|urea
P06360426A0501|58 63|yellow
P06360426A0501|66 83|purple colour change
P06361318A0440|44 53|KS-R1 group
P06361318A0440|64 72|oral group
P06361318A0440|75 76|74
P06361318A0440|103 118|committee members
P06361318A0440|134 143|KS-R1 group
P06361318A0440|158 166|oral group
P06361318A1127|19 28|subjective
P06361318A1127|81 90|KS-R1 group
P06361318A1127|101 109|oral group
P06361318A1127|159 168|KS-R1 group
P06361318A1127|183 191|oral group
P06362143A0565|0 18|Plasma renin activity
P06362143A0565|0 10|Plasma renin
P06362143A0565|50 75|tilt or isoprenaline infusion
P06362143A0565|81 88|patients
P06362602T0001|16 29|immune response
P06362602T0001|32 40|aspecific
P06362602T0001|49 64|vaccine additives
P06362602T0001|105 115|swine plague
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|0 7|Bepridil
P06367414A0000|10 26|calcium antagonist
P06367414A0000|79 85|placebo
P06367414A0000|89 100|double-blind
P06367414A0000|102 126|randomized, crossover trial
P06369355A0834|66 75|trfA region
P06369355A0834|66 75|trfA region
P06369355A0834|92 100|A2 protein
P06369355A0834|92 100|A2 protein
P06369355A0834|115 144|trfA-encoded replication protein
P06369355A0834|115 144|trfA-encoded replication protein
P06369355A0834|147 156|plasmid RK2
P06369954T0000|9 31|negative pleural pressure
P06369954T0000|34 60|left ventricular hemodynamics
P06370553A0444|0 12|Resting plasma
P06370553A0444|13 26|norepinephrine
P06370553A0444|28 29|NE
P06370553A0444|34 44|epinephrine
P06370553A0444|46 53|E) levels
P06370553A0444|69 81|active therapy
P06370553A0444|126 133|plasma NE
P06370553A0444|164 170|plasma E
P06372563T0000|0 4|Renal
P06372563T0000|15 23|captopril
P06372563T0000|26 43|severe heart failure
P06372563T0000|87 98|hyponatremia
P06373409A1163|0 8|Lauciello
P06373409A1163|66 72|amalgam
P06373855A0000|6 11|biopsy
P06373855A0000|26 32|papules
P06373855A0000|39 43|dusky
P06373855A0000|46 59|crusted lesions
P06373855A0000|69 76|patients
P06373855A0000|104 121|varioliformis acuta
P06373855A0000|123 127|PLEVA
P06373855A0000|142 165|direct immunofluorescence
P06373855A0000|169 184|immunoperoxidase
P06374369A1112|46 55|food intake
P06374369A1112|58 72|hyperphagic rats
P06374369A1112|80 102|quinine-adulterated diet
P06374369A1112|110 130|postingestional events
P06374418A0877|16 30|parathyroid cyst
P06374418A0877|69 86|parathyroid hormone
P06376227A0217|0 2|EGV
P06376227A0217|26 36|PP secretion
P06376227A0217|26 27|PP
P06376227A0217|42 68|basal or stimulated conditions
P06379363A0415|34 39|HDL-2M
P06379363A0415|34 39|HDL-2M
P06379363A0415|87 119|insulin-dependent diabetes mellitus
P06379363A0415|87 93|insulin
P06381438A1280|0 25|Lung prostacyclin production
P06381438A1280|40 43|flow
P06382374A0206|25 45|insulin administration
P06382374A0206|25 31|insulin
P06382374A0206|64 76|glucose levels
P06382374A0206|105 112|patients
P06382374A0206|117 139|major depressive disorder
P06382374A0206|158 165|patients
P06382374A0206|170 186|dysthymic disorder
P06382374A0206|192 212|normal control subjects
P06384983T0000|0 9|Management
P06384983T0000|12 23|hypertension
P06384983T0000|29 35|elderly
P06385474T0001|0 16|Climatic treatment
P06385474T0001|19 26|children
P06385474T0001|31 41|respiratory
P06388189T0001|0 14|Transplantation
P06388189T0001|26 39|juvenile donors
P06388189T0001|42 56|adult recipients
P06388818A0000|3 10|patients
P06388818A0000|15 64|advanced, diffuse Hodgkin's and non-Hodgkin's lymphomas
P06388818A0000|104 130|primary chemotherapy regimens
P06388818A0000|156 171|chemotherapy (HDC
P06388818A0000|203 230|autologous bone marrow infusion
P06388818A0000|232 235|ABMT
P06391496T0000|29 40|polypeptides
P06391496T0000|63 70|almagate
P06391496T0000|79 86|antacids
P06394347A1024|0 11|Hydrallazine
P06394347A1024|39 57|plasma renin activity
P06394347A1024|39 49|plasma renin
P06394347A1024|61 76|urinary excretion
P06394347A1024|79 91|noradrenaline
P06395804A0382|0 13|Urease activity
P06395804A0382|0 5|Urease
P06401749T0000|11 17|lithium
P06401749T0000|39 66|arginine vasopressin secretion
P06401749T0000|39 57|arginine vasopressin
P06402480A0373|22 32|PPNG strains
P06402480A0373|53 63|antibiotics
P06402480A0373|77 83|plasmid
P06402480A0373|118 138|permanent surveillance
P06402480A0373|141 160|gonococcal infections
P06402480A0373|206 227|antimicrobial treatment
P06402859A0000|0 20|Antithrombin III (AT III
P06402859A0000|0 14|Antithrombin III
P06402859A0000|16 20|AT III
P06402859A0000|25 37|plasma protein
P06402859A0000|72 79|thrombin
P06402859A0000|72 79|thrombin
P06402859A0000|102 125|intravascular coagulation
P06404842A0127|8 15|patients
P06404842A0127|67 83|depot testosterone
P06406060A0000|0 22|195mPt-labeled cisplatin
P06406060A0000|47 57|control mice
P06407348A0516|3 15|beta-blocking
P06407348A0516|129 144|cardiac receptors
P06407348A0516|129 144|cardiac receptors
P06407348A0516|146 150|beta1
P06407348A0516|146 150|beta1
P06407348A0516|163 183|smooth muscle receptors
P06407348A0516|163 183|smooth muscle receptors
P06407348A0516|185 189|beta2
P06407348A0516|185 189|beta2
P06411659A0793|73 79|N intake
P06412385A0356|7 14|patients
P06412385A0356|22 32|lung disease
P06412385A0356|50 57|weakness
P06412385A0356|115 126|lung capacity
P06412385A0356|131 157|maximum voluntary ventilation
P06412385A0356|183 196|residual volume
P06412385A0356|214 227|dioxide tension
P06412385A0356|229 233|PaCO2
P06412385A0356|270 280|ventilators
P06413492A0990|0 5|Commun
P06414990A0057|3 21|statistical analysis
P06414990A0057|30 32|TRH
P06414990A0057|30 32|TRH
P06414990A0057|50 66|healthy volunteers
P06414990A0057|112 136|normal thyrotropin response
P06414990A0057|118 128|thyrotropin
P06415299A0233|22 32|doxorubicin
P06419251T0000|43 64|behavioral requirements
P06426493A0331|63 65|IOP
P06426493A0331|84 92|heart rate
P06426493A0331|94 97|FIO2
P06426493A0331|99 104|FE'CO2
P06426493A0331|108 110|CVP
P06426493A0331|134 141|patients
P06428116T0000|10 20|subclinical
P06428116T0000|33 46|hypothyroidism
P06428116T0000|60 78|subacute thyroiditis
P06429992T0000|0 11|Gonadotropin
P06429992T0000|0 11|Gonadotropin
P06429992T0000|20 26|mothers
P06429992T0000|48 52|twins
P06433442T0000|0 7|Freezing
P06433442T0000|37 46|factor VIII
P06434572A0157|5 12|children
P06434572A0157|65 76|GH deficiency
P06434572A0157|65 66|GH
P06434572A0157|84 107|2) organic hypopituitarism
P06434572A0157|116 144|intrauterine growth retardation
P06434572A0157|202 208|stature
P06434572A0157|245 280|physiological and pharmacological tests
P06434572A0157|283 284|GH
P06434572A0157|283 284|GH
P06434587A0551|4 10|patient
P06434587A0551|24 25|LH
P06434587A0551|24 25|LH
P06434587A0551|29 37|FSH levels
P06434587A0551|29 31|FSH
P06434587A0551|43 66|pulsed nocturnal secretion
P06434587A0551|71 80|pubertal LH
P06434587A0551|79 80|LH
P06434587A0551|84 95|FSH responses
P06434587A0551|84 86|FSH
P06434587A0551|98 100|LRH
P06434587A0551|98 100|LRH
P06435565A0648|48 69|mean aortic pressure fell
P06435565A0648|178 189|cm-5/sec/m-2
P06435565A0648|187 189|m-2
P06435565A0648|191 191|p
P06437579A0727|10 12|800
P06437579A0727|67 77|dose regimen
P06439114A0677|0 10|Ceftazidime
P06439114A0677|25 43|single-agent therapy
P06439114A0677|47 85|serious gram-negative bacillary infections
P06439135A0250|8 10|CBF
P06439135A0250|37 44|xenon 133
P06439135A0250|49 56|patients
P06439135A0250|67 74|coronary
P06439135A0250|81 98|grafting procedures
P06441624A0263|22 29|serum BGP
P06441624A0263|22 29|serum BGP
P06441624A0263|54 67|bone metabolism
P06443639T0001|7 23|bacterial motility
P06443639T0001|33 40|movement
P06443639T0001|47 69|closed circuit television
P06443714T0001|0 6|Finding
P06443714T0001|9 24|Rhodnius prolixus
P06444119A0340|68 78|temperature
P06444119A0340|113 125|growth factors
P06451557A0777|0 10|Deformities
P06451557A0777|24 32|olecranon
P06452461A0930|32 37|LVM/M2
P06452461A0930|41 44|PWVn
P06452461A0930|48 71|pre-AVR and post AVR studies
P06452827T0001|0 25|Statokinesimetric recording
P06452827T0001|28 44|Huntington choreas
P06453290A0000|46 57|intrahepatic
P06453290A0000|58 69|biliary ducts
P06453290A0000|84 108|human embryofetal material 6
P06454625A0000|18 33|animal experiment
P06454625A0000|54 82|renal vasculature and parenchyma
P06454625A0000|88 97|hemostasis
P06454625A0000|109 136|Infrared-Contact-Coagulation
P06454625A0000|151 184|intravital magnification angiography
P06459831T0001|0 51|Cardiovascular and adrenal medullo-sympathetic reactions
P06459831T0001|59 74|tobacco poisoning
P06460889A0111|23 27|SG-75
P06460889A0111|50 74|systemic blood pressure (SBP
P06460889A0111|72 74|SBP
P06460889A0111|88 106|peripheral (coronary
P06460889A0111|108 123|renal, mesenteric
P06460889A0111|127 139|femoral) blood
P06460889A0111|145 147|PBF
P06460889A0512|24 25|v.
P06460889A0512|27 31|SG-75
P06460889A0512|57 79|pulse pressure, heart rate
P06460889A0512|81 91|aortic blood
P06460889A0512|97 111|left ventricular
P06460889A0512|121 123|LVP
P06460889A0512|128 137|LVdP/dt max
P06463429A0414|7 8|VE
P06463429A0414|14 24|luteal phase
P06463429A0414|52 66|follicular phase
P06466804A0686|10 20|endothelium
P06466804A0686|32 44|shear stresses
P06466804A0686|73 98|physiological flow waveforms
P06466804A0686|100 123|electromagnetic flowmeter
P06466804A0686|171 175|shear
P06467241A0000|0 18|Modern cancer therapy
P06467241A0000|30 36|surgery
P06467241A0000|38 49|radiotherapy
P06467241A0000|51 62|chemotherapy
P06467241A0000|80 92|immunotherapy
P06467241A0000|96 107|hyperthermia
P06467797A0233|32 46|plasma clearance
P06467797A0233|49 50|NT
P06467797A0233|53 68|10-hydroxylation
P06467797A0233|76 89|metabolic ratio
P06467797A0233|93 98|4-OH-D
P06467797A0233|101 105|urine
P06467797A0233|112 120|Ghanaians
P06467797A0233|126 129|0.95
P06467797A0233|148 153|Swedes
P06468565A0000|23 49|cat horizontal canal afferents
P06468565A0000|75 89|three parameters
P06468565A0000|96 112|long time constants
P06468565A0000|114 116|tau
P06468565A0000|145 146|G1
P06468565A0000|152 179|middle frequency gain constants
P06468565A0000|181 182|Gm
P06468632A0135|0 10|Endothelium
P06468632A0135|16 25|central ear
P06468632A0135|48 53|rabbit
P06468632A0135|56 62|damaged
P06468632A0135|108 113|vessel
P06468673A0358|7 38|supraphysiologic E2 concentrations
P06468673A0358|48 66|cervical mucus scores
P06468673A0358|96 110|CC-treated group
P06468694A0441|16 54|caudate nucleus' dophamine-reactive system
P06468694A0441|86 94|dophamine
P06468694A0441|112 120|phenamine
P06468694A0441|141 151|conditioned
P06473219T0000|0 4|Value
P06473219T0000|12 23|glucose tests
P06473219T0000|41 62|type II diabetes mellitus
P06473252A1073|53 65|egg production
P06479362A0680|0 13|Hydrocortisone
P06479362A0680|67 72|muscle
P06479362A0680|136 149|muscle membrane
P06479976A0386|40 47|patients
P06479976A0386|69 71|AMB
P06479976A0386|158 162|nerve
P06479976A0386|180 187|patients
P06480542A0000|1 20|pharmacokinetic study
P06480542A0000|23 32|apalcillin
P06480542A0000|49 56|patients
P06482179A0497|0 13|Catch-up growth
P06482179A0497|50 57|children
P06482318A0117|0 18|Thrombocyte function
P06482318A0117|35 42|patients
P06482318A0117|70 88|platelet shape change
P06482665A0735|26 43|AMPH administration
P06482665A0735|112 125|caudate nucleus
P06482665A0735|128 141|pigtail monkeys
P06482665A0735|161 188|amphetamine-induced increases
P06482665A0735|233 246|emotional state
P06482665A0735|252 257|animal
P06483863A0000|31 40|BALB/cCrgl
P06483863A0000|43 60|BALB/cfC3HCrgl mice
P06483863A0000|105 120|17 beta-estradiol
P06483863A0000|230 235|I and II
P06483863A0000|239 244|silica
P06483863A0000|246 257|Experiment II
P06486932A0000|3 5|228
P06486932A0000|8 16|425 deaths
P06486932A0000|62 75|Malumfashi area
P06486932A0000|78 92|northern Nigeria
P06487290A0000|0 16|Salivary estradiol
P06487290A0000|17 25|17 beta (E2
P06487290A0000|24 32|E2-17 beta
P06487290A0000|27 32|17 beta
P06487290A0000|37 48|progesterone
P06487290A0000|50 51|P)
P06487290A0000|73 98|radioimmunoassay techniques
P06487290A0000|103 117|pregnant females
P06487290A0000|165 184|non-pregnant controls
P06487290A0000|194 204|luteal phase
P06487290A0000|210 223|menstrual cycle
P06492188A0615|52 59|implants
P06493655A0415|8 23|FHR decelerations
P06493655A0415|57 70|nonstress tests
P06493655A0415|89 104|postdate patients
P06494297A0939|19 26|kindling
P06494297A0939|77 81|HPC SS
P06494766A0241|3 27|persistent fetal dispersion
P06494766A0241|30 34|nodal
P06494766A0241|38 56|Hiss bundle fragments
P06494766A0241|66 82|ventricular septum
P06495195A0536|14 29|biochemical tests
P06495195A0536|57 75|alkaline phosphatase
P06495195A0536|57 75|alkaline phosphatase
P06495195A0536|100 107|patients
P06495195A0536|115 153|lymphogranulomatosis-induced liver damage
P06497671T0001|9 27|plasma cortisol level
P06497671T0001|30 51|late asthmatic responses
P06501086A0165|27 42|vasectomized rats
P06501086A0165|51 54|rats
P06501086A0165|77 97|epididymal hypertrophy
P06501086A0165|151 167|total serum protein
P06501086A0165|156 167|serum protein
P06501086A0165|169 189|lowered alpha-globulin
P06501086A0165|176 189|alpha-globulin
P06501086A0165|205 224|serum electrophoresis
P06501086A0165|238 266|sperm agglutinin antibody titers
P06501086A0165|243 252|agglutinin
P06503132A0784|0 2|SFP
P06503132A0784|29 30|Hn
P06503132A0784|29 30|Hn
P06503132A0784|32 32|s
P06503329A0588|26 33|newborns
P06503885A0342|49 71|water phantom temperature
P06503885A0342|106 119|estimated x-ray
P06503885A0342|178 190|cerebral blood
P06503885A0342|196 199|rCBF
P06503885A0342|205 212|xenon/CT
P06503885A0342|213 224|rCBF protocol
P06505014A1192|5 17|uncertainties
P06505014A1192|41 45|Vinca
P06506074A0456|0 1|E2
P06506074A0456|20 30|hen plasma TG
P06506074A0456|31 41|7.2X, PL 5.1X
P06506074A0456|46 49|C 7.2
P06506074A0456|55 68|pullet plasma TG
P06506074A0456|69 79|6.8X, PL 3.7X
P06507629A0717|22 25|rats
P06507629A0717|30 53|chronic metabolic acidosis
P06507629A0717|79 81|NH3
P06507629A0717|118 124|X min-1 X
P06507629A0717|119 127|min-1 X g-1
P06508393T0000|0 12|Serodiagnosis
P06508393T0000|32 46|dromedary camels
P06508393T0000|78 88|Testryp CATT
P06513456T0001|0 20|Adenyl cyclase activity
P06513456T0001|0 12|Adenyl cyclase
P06513456T0001|23 29|gastric
P06513456T0001|30 35|mucosa
P06513456T0001|38 45|patients
P06513456T0001|50 62|duodenal ulcer
P06516977T0000|0 7|Reaction
P06517816A0388|0 1|HA
P06517816A0388|55 56|HR
P06517816A0388|55 56|HR
P06517816A0388|58 66|17 b X min-1
P06517816A0388|103 110|X m-2 X h-1
P06517816A0388|103 110|X m-2 X h-1
P06517816A0388|121 137|saline experiments
P06520418A0325|46 56|orifice area
P06520418A0325|58 60|MVA
P06520418A0325|87 94|patients
P06520418A0325|99 105|type III
P06520418A0325|111 114|LVIT
P06520418A0325|140 147|patients
P06520418A0325|152 156|type I
P06521802A0251|23 32|CMEA member
P06521802A0251|92 114|Cancer Research Institute
P06521802A0251|131 138|Sciences
P06521802A0251|140 153|Czechoslovakia
P06521802A0251|175 178|CMEA
P06521999A0677|46 54|melanomas
P06521999A0677|64 74|enucleation
P06524202A0167|16 28|EMG-BFB method
P06524202A0167|30 41|multichannel
P06524727A0601|0 10|Lymphocytes
P06524727A0601|113 113|C
P06524727A0601|126 133|dilution
P06524761A0596|58 71|body weight loss
P06524761A0596|107 130|killed-toxoplasma vaccine
P06524761A0596|164 172|T-1 strain
P06524761A0596|164 166|T-1
P06524761A0596|209 216|hamsters
P06524761A0596|225 246|live-toxoplasma vaccine
P06524761A0596|274 281|RH strain
P06524761A0596|274 275|RH
P06527379T0044|11 33|proline/alanine sequence
P06527379T0044|36 48|beta B1 subunit
P06527379T0044|36 48|beta B1 subunit
P06527379T0044|64 84|repetitive DNA sequence
P06527872T0000|3 11|segmental
P06527872T0000|106 115|spinal cord
P06527872T0000|118 121|rats
P06527872T0000|152 168|an acid phosphatase
P06527872T0000|154 168|acid phosphatase
P06527872T0000|170 179|ACP) method
P06527872T0000|170 172|ACP
P06531286A0382|9 22|lipid fractions
P06531286A0382|25 40|plant extractions
P06531286A0382|45 50|hexane
P06531286A0382|82 91|HPLC column
P06539738T0000|28 53|chlorofluorocarbon 22 (CFC 22
P06541019A0555|3 10|patients
P06541932A0000|20 42|experimental algesimetry
P06541932A0000|90 101|peripherally
P06542918A1131|107 124|delayed P3 latencies
P06545651A0346|0 19|Ammonia concentration
P06545651A0346|96 121|protein nitrogen degradation
P06545651A0346|124 142|non-protein nitrogen
P06545651A0346|144 146|NH3
P06546392A0542|13 28|C reactive protein
P06546392A0542|22 42|protein concentrations
P06546392A0542|82 98|sedimentation rate
P06546392A0542|103 113|temperature
P06546392A0542|136 148|antiproteases
P06548953T0001|0 25|Human thyroid stimulator (HTS
P06548953T0001|23 25|HTS
P06548953T0001|29 43|thyroid diseases
P06555107A1227|33 49|calcium antagonist
P06555107A1227|50 58|Verapamil
P06555107A1227|104 116|beta-mimetics
P06568939A0000|0 31|Brainstem auditory evoked responses
P06568939A0000|33 37|BAERs
P06568939A0000|62 64|eye
P06568939A0000|135 143|brainstem
P06571587T0000|22 41|circulatory functions
P06571587T0000|45 65|body tissue oxygenation
P06571587T0000|86 106|hypovolemic conditions
P06579152A1061|30 32|NPF
P06579152A1061|62 83|velopharyngeal activity
P06582285A0222|32 40|U-P and D&E
P06582285A0222|32 34|U-P
P06582285A0222|63 79|9,572 D&E abortions
P06584416A0157|5 16|radiologists
P06584416A0157|89 100|examinations
P06584416A0157|108 110|PGF
P06585277A0000|3 5|man
P06585277A0000|10 31|myelomonocytic leukemia
P06585277A0000|58 89|prostatic acid phosphatase activity
P06585277A0000|58 81|prostatic acid phosphatase
P06585277A0000|120 130|bone lesions
P06585277A0000|171 200|disseminated prostatic carcinoma
P06588306A0076|17 37|prophylactic treatment
P06588306A0076|54 65|meningopathy
P06588306A0076|69 86|AIL- AIEOP protocols
P06588501T0059|2 27|experimental long-term study
P06591992A0569|2 13|anisotropism
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|113 130|submandibular gland
P06594105A0560|157 159|dog
P06594105A0560|181 188|lambda tp
P06594105A0560|203 213|temperature
P06597709A0596|2 18|pleural thickening
P06597709A0596|60 70|lung volumes
P06597709A0596|201 217|pleural thickening
P06599282T0001|20 40|squamous cell carcinoma
P06600533T0000|0 9|Azygos vein
P06600533T0000|21 33|posterior wall
P06600533T0000|39 43|right
P06600533T0000|51 66|upper lobe bronchi
P06600533T0000|69 83|normal CT variant
P06602580A0664|20 43|acute severe complications
P06602580A0664|48 58|otitis media
P06602580A0664|105 132|alpha 1-antitrypsin deficiency
P06602580A0664|105 122|alpha 1-antitrypsin
P06602580A0664|145 151|normals
P06602600A0582|3 27|Sarns 51F cavoatrial cannula
P06602600A0582|43 48|venous
P06602600A0582|73 91|double caval cannulas
P06606043A0598|20 39|3-, 5-, and 6-positions
P06606043A0598|68 78|phenyl group
P06606043A0598|81 89|position 2
P06607427A0000|38 54|6-hydroxydopamine
P06607427A0000|63 69|lesions
P06607427A0000|75 127|ventral noradrenergic and dorsal noradrenergic projections
P06607427A0000|144 164|hypothalamus and cortex
P06607427A0000|183 199|body weight changes
P06607427A0000|229 231|rat
P06607714T0000|4 13|allografts
P06607714T0000|16 19|rats
P06607714T0000|40 51|cyclosporin A
P06609166A0209|54 65|acetonitrile
P06609166A0209|133 152|reversed-phase column
P06610347A0581|22 31|AV junction
P06610347A0581|85 90|AV node
P06612373A0000|71 82|prescription
P06612373A0000|91 107|psychotropic drugs
P06612373A0000|117 134|1960s and early 1970s
P06615053A0202|7 14|patients
P06615053A0202|75 98|right ventricular ejection
P06615053A0202|100 103|RVEF
P06615053A0202|113 140|increased end-diastolic volume
P06615053A0202|142 147|RVEDVI
P06615403A0718|13 24|LAD occlusion
P06615403A0718|63 65|TMs
P06615403A0718|131 137|infused
P06625058A0666|77 80|0.95
P06627123A0000|0 15|Female Wistar rats
P06627123A0000|24 33|liquid diet
P06627123A0000|58 64|ethanol
P06627123A0000|71 78|calories
P06627569T0001|0 27|HL 02 type oculomotor stimulator
P06629370A0252|4 11|patients
P06629370A0252|36 54|membrane nephropathy
P06629370A0252|106 121|basement membrane
P06629370A0252|148 163|Alport's syndrome
P06630319A0244|0 6|Brain pH
P06630319A0244|20 40|cerebral focal ischemia
P06630319A0244|82 88|animals
P06630319A0244|115 133|halothane anesthesia
P06634712A0557|36 44|phosphate
P06634712A0557|48 54|calcium
P06634712A0557|82 84|PTH
P06634712A0557|82 84|PTH
P06634712A0557|88 89|CT
P06634712A0557|88 89|CT
P06634712A0557|92 97|uremia
P06643612A0000|0 9|Thin-layer
P06643612A0000|47 68|pharmacokinetic studies
P06643612A0000|83 88|plasma
P06643612A0000|92 96|urine
P06648156T0034|0 18|Introductory remarks
P06653755A0192|5 26|clofelin administration
P06653755A0192|63 67|right
P06653755A0192|85 92|AP levels
P06654047A0694|89 97|apoptosis
P06654047A0694|141 149|embryonal
P06654047A0694|150 165|rhabdomyosarcoma
P06654686T0001|0 10|Combination
P06654686T0001|14 30|Shwachman syndrome
P06654686T0001|42 68|granulocyte function disorder
P06655634A0195|17 24|patients
P06655634A0195|37 39|TOL
P06655634A0195|90 104|vaginal delivery
P06656249T0000|0 20|Nursing home discharges
P06657559A0489|13 20|chickens
P06657559A0489|167 180|ppm ochratoxin A
P06657559A0489|185 193|heart rate
P06657559A0489|197 209|blood pressure
P06658029A0086|69 86|toxicological tests
P06658445A0140|0 13|Harmful effects
P06658445A0140|16 22|animals
P06658445A0140|26 28|man
P06658445A0140|75 80|intake
P06658586T0001|0 22|Angionephroscintigraphy
P06658586T0001|52 57|kidney
P06659982A0231|30 40|sleep period
P06659982A0231|85 99|delta-wave stage
P06659982A0231|101 102|DS
P06659982A0231|109 110|QS
P06659982A0231|131 151|polygraphic parameters
P06659982A0231|189 193|sleep
P06662623A0124|1 9|82Br]MISO
P06662623A0124|43 49|Br-MISO
P06662623A0124|53 67|SLOWPOKE reactor
P06662623A0124|76 93|thermal neutron flux
P06662623A0124|103 109|cm-2 s-1
P06662623A0124|103 109|cm-2 s-1
P06667015A0832|50 63|myocardial wall
P06667015A0832|81 87|surgery
P06667015A0832|131 140|serum CK-MB
P06667015A0832|136 140|CK-MB
P06667868T0001|0 21|Morphofunctional status
P06667868T0001|46 50|blood
P06667868T0001|53 56|rats
P06667868T0001|116 119|BR-1
P06667868T0001|120 126|benzene
P06668316A0178|6 17|MOS-Hypersil
P06668316A0178|43 57|phosphate buffer
P06668316A0178|118 153|metabolites 3-hydroxymethylantipyrine
P06668316A0178|171 189|4-hydroxyantipyrine
P06669864T0001|3 7|liver
P06670732A0000|23 30|patients
P06670732A0000|32 34|ASA
P06670732A0000|58 68|anaesthesia
P06670732A0000|82 89|Fentanyl
P06670732A0000|114 121|Fentanyl
P06670732A0000|132 141|Droperidol
P06670732A0000|156 165|Thalamonal
P06670732A0000|170 177|Atropine
P06670732A0000|200 226|cardiocirculatory parameters
P06671047A1124|39 41|NOM
P06671047A1124|72 103|tumoural hyperprolactinemic states
P06671047A1124|135 139|CD/LD
P06671047A1124|135 136|CD
P06671047A1124|138 139|LD
P06671047A1124|141 142|LD
P06671047A1124|141 142|LD
P06671047A1124|146 148|DOM
P06671047A1124|187 199|Prolactinomas
P06671047A1124|215 226|maintained DA
P06671047A1124|274 298|etiopathogenetical factors
P06671047A1124|310 341|tumoural hyperprolactinemic states
P06671065A0000|0 10|Serum lipids
P06671065A0000|14 25|lipoproteins
P06671065A0000|30 53|insulin dependent diabetic
P06671065A0000|54 61|children
P06671065A0000|95 109|metabolic status
P06671065A0000|115 122|patients
P06671385A0856|3 4|NA
P06671385A0856|36 54|plasma renin activity
P06671385A0856|36 46|plasma renin
P06671385A0856|62 63|PA
P06671385A0856|115 131|body sodium content
P06671925T0000|0 21|Amikacin concentrations
P06671925T0000|32 43|blister fluid
P06671925T0000|46 62|healthy volunteers
P06671925T0000|68 75|patients
P06671925T0000|80 94|renal impairment
P06672094A0390|11 30|innervating the medial
P06672094A0390|60 65|medial
P06672094A0390|75 91|oculomotor nucleus
P06672094A0390|99 113|aberrant neurons
P06672094A0390|119 146|medial longitudinal fasciculus
P06672094A0390|170 176|mammals
P06674374T0000|0 20|Hepatitis B vaccination
P06674374T0000|62 93|intermediate hepatitis B endemicity
P06674516A0350|27 29|AMK
P06674516A0350|79 96|infectious diseases
P06674516A0350|99 123|otorhinolaryngologic field
P06674977A1181|34 42|pregnancy
P06674977A1181|44 50|table IX
P06674977A1181|70 86|prenatal diagnosis
P06674977A1181|88 94|table VI
P06675047A0000|40 49|hemoglobin
P06675047A0000|40 49|hemoglobin
P06675047A0000|70 85|Berthelot classic
P06675047A0000|128 140|plasmatic urea
P06683807A0160|0 19|Parkinsonian patients
P06684624A0298|0 5|Female
P06684624A0298|16 26|mortalities
P06684624A0298|53 64|cake-fed rats
P06684624A0298|77 86|fed diet 41B
P06684624A0736|0 37|Urinary N-acetylglucosaminidase activity
P06684624A0736|0 29|Urinary N-acetylglucosaminidase
P06685004A0000|22 48|sex-hormone-binding globulin
P06685004A0000|22 48|sex-hormone-binding globulin
P06685004A0000|58 61|SHBG
P06685004A0000|58 61|SHBG
P06685004A0000|68 80|body mass index
P06685004A0000|82 84|BMI
P06685004A0000|124 126|men
P06685004A0000|132 136|women
P06685177T0000|0 41|Dipetalonema (Alafilaria) hydrochoerus subgen
P06685177T0000|48 48|n
P06685536A0502|60 86|bilateral orbital enucleation
P06685643A0179|19 20|C4
P06685643A0179|19 20|C4
P06685643A0179|24 29|C1-INH
P06685643A0179|24 29|C1-INH
P06685643A0179|59 65|disease
P06686454A0585|0 24|Less antibacterial activity
P06686454A0585|42 61|Gram-negative bacilli
P06686454A0585|68 78|Pseudomonas
P06686454A0585|104 111|Shigella
P06686454A0585|113 127|Escherichia coli
P06686454A0585|129 146|Serratia marcescens
P06686454A0585|150 157|Proteus.
P06687953T0000|3 24|mucosal defence capacity
P06687953T0000|43 58|leukocyte enzymes
P06689413A0174|3 11|apparatus
P06689413A0174|55 68|pure Ge detector
P06689413A0174|92 97|K alpha
P06689413A0174|98 114|fluorescent x-rays
P06689413A0174|142 153|exited iodine
P06689513T0001|37 45|premature
P06689513T0001|46 52|infants
P06691304A0284|41 52|median values
P06691304A0284|103 107|males
P06691304A0284|111 117|females
P06691304A0284|145 149|45-59
P06691304A0284|151 155|60-70
P06692517T0000|12 30|antithrombotic drugs
P06692517T0000|33 40|patients
P06692517T0000|45 66|left ventricular thrombi
P06692517T0000|82 140|indium-111 platelet imaging and two-dimensional echocardiography
P06692631A0129|7 15|interface
P06692631A0129|32 37|stress
P06692631A0129|69 72|bone
P06692631A0129|86 99|trabecular bone
P06694380A1483|6 7|NE
P06694380A1483|23 35|anephric group
P06694778A0000|0 1|10
P06694778A0000|11 30|hemodialysis patients
P06694778A0000|72 88|myocardial imaging
P06694778A0000|112 123|hemodialysis
P06698047A0445|3 11|Prolactin
P06698047A0445|31 48|physiological norms
P06698047A0445|64 66|TRH
P06698047A0445|64 66|TRH
P06700231A0259|12 25|tumor resection
P06700231A0259|50 61|tumor nodules
P06702257T0001|0 26|Antithrombin III in hip surgery
P06702257T0001|0 14|Antithrombin III
P06702643A0000|8 19|infant hearts
P06702643A0000|29 34|aortic
P06702643A0000|61 77|left common carotid
P06702643A0000|81 102|left subclavian arteries
P06702643A0000|104 108|type B
P06702643A0000|111 117|Celoria
P06702643A0000|121 126|Patton
P06702643A0000|132 136|right
P06702643A0000|147 172|artery (SA) arose anomalously
P06704467A0539|39 48|pallid bats
P06704467A0539|66 72|mammals
P06704467A0539|89 99|pineal gland
P06705456A0346|0 9|Absorption
P06707357A0180|29 36|patients
P06707357A0180|41 58|mitral versus aortic
P06709700A0230|43 52|depression
P06709700A0230|67 111|Hamilton Depression Scale (or the Melancholia Scale
P06709700A0230|183 205|antidepressant treatment
P06711642A0093|61 68|azotemia
P06711642A0093|123 133|proteinuria
P06711642A0093|157 164|dipstick
P06711642A0093|219 226|oliguria
P06712314A0148|40 42|135
P06713200A0630|0 19|Epileptiform activity
P06713200A0630|32 63|superficial laminae bordering layer
P06713204A0867|3 4|AD
P06713204A0867|64 66|rat
P06713204A0867|77 87|V1 component
P06714298X0000|2 12|nisoldipine
P06714298X0000|30 44|left ventricular
P06714298X0000|58 73|anesthetized pigs
P06714298X0000|75 85|nisoldipine
P06714298X0000|100 105|X kg-1 X
P06714298X0000|114 134|calcium channel blocker
P06714298X0000|174 204|left ventricular systolic pressure
P06714298X0000|221 238|vascular resistance
P06714298X0000|252 261|maxLVdP/dt
P06714354A0194|0 6|Monkeys
P06714354A0194|34 43|unilateral
P06714354A0194|47 52|serial
P06714354A0194|79 92|temporal cortex
P06715792A0295|0 15|HBB concentration
P06716977A0136|29 35|ethanol
P06716977A0136|58 63|losses
P06718064T0001|0 16|Plasma lactoferrin
P06718064T0001|6 16|lactoferrin
P06718064T0001|23 32|blood count
P06718064T0001|35 56|polynuclear neutrophils
P06719057A0181|24 44|renal vein phlebography
P06719057A0181|103 118|excretory urogram
P06720371T0000|12 27|blood coagulation
P06720371T0000|30 41|gout patients
P06721188A0200|3 21|statistical analysis
P06723849A0197|3 16|pyramidal tract
P06723849A0197|52 54|MRF
P06726257A1179|22 46|5-hydroxytryptophan (5-HTP
P06726257A1179|62 64|LSD
P06726257A1179|104 115|methiothepin
P06726257A1179|140 145|cortex
P06726257A1179|184 213|autoreceptor antagonist activity
P06726257T0000|24 47|lysergic acid diethylamide
P06726257T0000|50 58|serotonin
P06726257T0000|76 84|serotonin
P06726257T0000|119 127|serotonin
P06728580A0291|33 34|TX
P06728580A0291|36 42|120,000
P06731302A0930|2 8|patient
P06731302A0930|36 38|SCD
P06732946A0281|26 31|fibrin
P06732946A0281|26 31|fibrin
P06732946A0281|44 55|fibrinolysis
P06732946A0281|107 119|magnification
P06732946A0281|129 141|image analyser
P06732946A0281|143 151|Videoplan
P06734713T0000|10 38|sodium-chlormezanone poisoning
P06735247A0803|12 44|plasma enteroglucagon concentration
P06735247A0803|12 31|plasma enteroglucagon
P06735247A0803|70 77|patients
P06735247A0803|103 120|faecal fat excretion
P06738410T0000|15 22|children
P06740373A0891|83 88|rhesus
P06740697A0318|45 53|guinea pig
P06740919A0162|0 28|Adult Amblyomma lepidum ticks fed
P06740919A0162|43 46|goat
P06740919A0162|71 93|Friesian (Bos taurus) calf
P06743061A0239|24 31|patients
P06743061A0239|35 51|neurologic disease
P06744024A0000|44 46|rat
P06744024A0000|55 73|unilateral analgesia
P06748227A0423|9 13|Case 2
P06748227A0423|9 13|Case 2
P06748227A0423|55 59|right
P06748227A0423|83 87|right
P06748227A0423|97 111|posterior thorax
P06749072A0116|0 20|Urinary urate excretion
P06749072A0116|97 110|water immersion
P06749072A0116|142 155|water immersion
P06750608A1442|0 8|Mutations
P06750608A1442|21 28|lts genes
P06750608A1442|45 57|mak- phenotype
P06751455A0117|67 74|patients
P06751455A0117|83 90|glucagon
P06751455A0117|83 90|glucagon
P06751455A0117|96 102|placebo
P06753902A0437|5 12|patients
P06753902A0437|33 41|captopril
P06753902A0437|99 106|class IIM
P06753902A0437|115 117|IIS
P06754662T0001|0 30|Bullous angiolymphoid hyperplasia
P06754662T0001|35 46|eosinophilia
P06755468A0180|22 38|open reading frames
P06755468A0180|41 61|cobA and the third intron
P06755468A0180|41 44|cobA
P06755468A0180|67 73|cob gene
P06755468A0180|67 73|cob gene
P06755468A0180|89 105|amino acid homology
P06755986A0382|33 38|humans
P06755986A0382|41 64|enteral toxico-infections
P06755986A0382|75 86|infected mice
P06760394T0001|0 21|Single tooth replacement
P06760394T0001|37 101|ITI (International Team fur Implantologie) type F hollow-cylinder implant
P06762025A0171|3 15|13,14-dihydro
P06762025A0171|17 35|15-keto-metabolites
P06762025A0171|38 41|PGE2
P06762025A0171|45 53|PGF2 alpha
P06762321T0000|0 17|Nucleotide sequence
P06762321T0000|82 104|Streptococcus pneumoniae
P06763897A0216|3 14|hypertension
P06763897A0216|27 29|PRA
P06763897A0216|56 79|angiotensin II (AII) analog
P06763897A0216|56 68|angiotensin II
P06763897A0216|70 72|AII
P06763897A0216|81 84|Sar1
P06763897A0216|86 89|Ile8
P06763897A0216|91 93|ALL
P06764669T0001|27 33|urinary
P06764669T0001|34 37|iron
P06764669T0001|51 63|deferoxamine B
P06767648A0734|0 11|Measurements
P06767648A0734|63 75|active therapy
P06772370A0342|0 5|Volume
P06772370A0342|27 30|DMDZ
P06772370A0342|65 68|DMDZ
P06772370A0342|87 100|protein binding
P06772370A0342|112 115|243 l
P06772370A0342|131 135|women
P06772370A0342|142 144|men
P06772370A0342|163 169|elderly
P06772612A0000|9 16|dopamine
P06772612A0000|43 53|haloperidol
P06772612A0000|71 95|carotid body chemoreceptors
P06772612A0000|98 104|hypoxia
P06772612A0000|108 118|hypercapnia
P06772612A0000|139 154|anesthetized cats
P06775834A0000|0 18|HLA-A and B phenotypes
P06775834A0000|0 4|HLA-A
P06775834A0000|8 8|B
P06775834A0000|24 31|patients
P06775834A0000|45 62|malignant melanomas
P06775834A0000|98 111|metastatic form
P06776918T0000|0 15|Trypanosoma cruzi
P06777229A0243|27 40|normal subjects
P06777229A0243|46 53|patients
P06777229A0243|58 78|gastroduodenal disease
P06778645A0000|0 0|1
P06781339A0501|84 91|patients
P06781728A0690|33 52|osteoprogenitor cells
P06781728A0690|78 91|mineralization
P06781728A0690|128 140|bone formation
P06781728A0690|154 173|fluorochrome labeling
P06781728A0690|180 202|magnesium-deficient rats
P06782612A0142|74 74|V
P06782612A0142|85 91|lithium
P06782612A0142|102 104|CLi
P06782869A0263|0 14|Nitrogen balance
P06782869A0263|30 51|metabolic complications
P06782869A0263|77 79|BUN
P06782869A0263|117 124|serum CO2
P06782869A0263|126 129|SGOT
P06782869A0263|126 129|SGOT
P06782869A0263|131 134|SGPT
P06782869A0263|131 134|SGPT
P06782869A0263|136 143|serum LDH
P06782869A0263|141 143|LDH
P06782869A0263|148 171|serum alkaline phosphatase
P06782869A0263|148 171|serum alkaline phosphatase
P06784123A0286|12 18|C mu RNAs
P06784123A0286|12 18|C mu RNAs
P06784123A0286|26 32|mu mRNAs
P06784123A0286|26 32|mu mRNAs
P06784123A0286|82 89|JH) locus
P06784123A0286|82 83|JH
P06784123A0771|6 14|-kb C mu RNA
P06784123A0771|9 14|C mu RNA
P06784123A0771|26 35|3' sequence
P06784123A0771|60 66|mu chain
P06784123A0771|60 66|mu chain
P06784123A0771|101 120|membrane-bound mu chin
P06784123A0771|115 120|mu chin
P06784123T0000|16 36|immunoglobulin C mu gene
P06784123T0000|16 36|immunoglobulin C mu gene
P06784123T0000|69 87|lymphoid development
P06785113A0337|24 49|sperm-immobilizing activity
P06785113A0337|70 77|cervical
P06785113A0337|92 99|patients
P06786756T0000|9 24|DNA rearrangement
P06786756T0000|39 51|RNA processing
P06786756T0000|69 92|immunoglobulin delta genes
P06786756T0000|69 92|immunoglobulin delta genes
P06788388A0000|30 37|ICRF-159
P06788388A0000|88 98|preclinical
P06790572A0330|0 4|All 62
P06790572A0330|28 37|lincomycin
P06790572A0330|57 89|amphotericin B, trimethoprim lactate
P06790572A0330|91 100|polymyxin B
P06790572A0330|105 114|anisomycin
P06791500A0622|28 37|delta OD450
P06793764T0001|4 9|lipids
P06794666A0208|55 58|ATCI
P06794666A0208|100 127|neurotransmitter biosynthesis
P06794666A0208|141 168|cardiomyocyte adrenoreceptors
P06795119T0000|0 18|Lens aldose reductase
P06795119T0000|0 18|Lens aldose reductase
P06795119T0000|21 52|diabetic and galactosemic cataracts
P06795654A0434|0 11|Fenfluramine
P06795654A0434|70 96|self-administration behavior
P06795654A0434|127 129|(FR
P06795832A0148|13 40|Hepatitis A HBs- and HBe-antigen
P06795832A0148|13 26|Hepatitis A HBs-
P06795832A0148|30 40|HBe-antigen
P06795832A0148|49 51|HBc
P06795832A0148|49 51|HBc
P06795832A0148|53 55|IgM
P06795832A0148|59 85|IgG)-, HBs- and HBe-antibodies
P06795832A0148|59 61|IgG
P06795832A0148|65 85|HBs- and HBe-antibodies
P06795900A0000|14 46|fatty acid cyclo-oxygenase inhibitor
P06795900A0000|14 37|fatty acid cyclo-oxygenase
P06795900A0000|47 58|indomethacin
P06795900A0000|61 77|cerebral blood flow
P06795900A0000|79 81|CBF
P06795900A0000|89 101|metabolic rate
P06795900A0000|105 110|oxygen
P06795900A0000|112 116|CMRO2
P06795900A0000|154 163|ventilated
P06795900A0000|164 167|rats
P06795971A0000|3 12|rat incisor
P06795971A0000|51 61|amelgenesis
P06796300A0759|18 32|prolactin levels
P06796300A0759|18 26|prolactin
P06796300A0759|35 46|nursing women
P06796300A0759|66 96|chronic oestradiol administration
P06797063A0000|0 9|Factor VIII
P06797063A0000|31 50|antigen concentration
P06797063A0000|54 74|von Willebrand activity
P06797063A0000|54 66|von Willebrand
P06797063A0000|77 94|ristocetin cofactor
P06797063A0000|125 132|patients
P06797063A0000|137 139|DIC
P06798609A0000|0 17|Morphine-dependent
P06798609A0000|21 31|control rats
P06798609A0000|36 58|oral free-choice protocol
P06798609A0000|74 88|gamma-vinyl GABA
P06798609A0000|90 92|GVG
P06798609A0000|95 100|60, 120
P06798609A0000|112 113|IP
P06801778T0001|26 44|gas exchange reaction
P06801778T0001|92 111|mitral commissurotomy
P06802500T0001|0 12|Thyreoliberin
P06802500T0001|13 16|VUFB
P06802500T0001|19 36|thyroid gammagraphy
P06803634A0810|2 10|silicosis
P06803634A0810|43 50|patients
P06803634A0810|54 57|sons
P06803634A0810|82 94|arterial blood
P06803634A0810|115 134|ventilatory responses
P06803634A0810|144 148|Paco2
P06803634A0810|151 158|patients
P06803634A0810|173 192|ventilatory responses
P06803634A0810|195 198|sons
P06805504A0629|12 25|urinary N values
P06805504A0629|30 38|403 and 295
P06805504A0629|44 45|W0
P06805504A0629|111 117|faecal N
P06805504A0629|127 129|320
P06805504A0629|135 139|W0.75
P06805537T0001|10 28|hemophilia treatment
P06805537T0001|31 54|hepatitis-safe factor VIII
P06805537T0001|45 54|factor VIII
P06807149A0222|71 73|DSG
P06807149A0222|81 83|EIB
P06807149T0000|40 59|disodium cromoglycate
P06807149T0000|93 104|bronchospasm
P06807149T0000|107 123|double-blind study
P06807192A0312|0 3|LCBF
P06807192A0312|15 28|hypoxic puppies
P06807192A0312|51 81|cerebral glucose utilization (LCGU
P06807192A0312|103 124|experimental conditions
P06807192A0312|126 130|Duffy
P06807659T0001|31 41|macrophages
P06808287T0001|11 29|hemophilia A carriers
P06808529A0167|14 31|isoniazid solutions
P06808529A0167|68 71|EDTA
P06809474A1156|0 12|Bile bilirubin
P06809586T0000|0 41|Autoimmune manipulation aids juvenile diabetes
P06810070A0502|17 31|Hg- and Cd-spores
P06810070A0502|52 64|control spores
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|42 59|VLDL-triglycerides
P06810694A0328|47 59|triglycerides
P06810694A0328|111 116|apo A-I
P06810694A0328|111 116|apo A-I
P06810694A1000|0 5|Apo A-I
P06810694A1000|0 5|Apo A-I
P06810694A1000|45 62|ethanol consumption
P06810694A1000|79 87|adiposity
P06812389A0658|0 4|TEMTU
P06812389A0658|8 11|DPTU
P06812389A0658|29 38|teratogens
P06815368A0203|3 25|osmotic diuretic mannitol
P06815368A0203|45 52|patients
P06816053A0849|5 12|patients
P06816053A0849|29 41|drug reactions
P06816053A0849|43 45|190
P06816053A0849|83 94|mast cell test
P06816123A0526|0 7|Selenium
P06816123A0526|25 45|glutathione peroxidase
P06816123A0526|25 45|glutathione peroxidase
P06816123A0526|122 129|selenium
P06816442T0001|0 14|Diagnostic value
P06816442T0001|22 30|myoglobin
P06816442T0001|40 59|neuromuscular disease
P06816609A0639|28 31|PCO2
P06816609A0639|42 44|kPa
P06816609A0639|86 88|CBF
P06817410A0982|69 78|hepatitis A
P06817410A0982|145 153|hepatitis
P06817410A0982|159 169|drug addicts
P06818113A0384|0 16|Asthmatic patients
P06818113A0384|102 124|corticosteroid treatment
P06818113A0384|136 149|acute responses
P06818113A0384|152 192|plasminogen activator and clotting factor VIII
P06818113A0384|152 171|plasminogen activator
P06818113A0384|175 192|clotting factor VIII
P06818113A0384|195 212|adrenaline infusion
P06821147A0468|0 16|Sulphur amino acids
P06821147A0468|57 62|flours
P06822645T0039|18 37|growth hormone release
P06823837A0562|16 41|right ventricular wavefronts
P06823837A0562|56 71|right ventricular
P06823837A0562|72 116|anterior atrioventricular groove and outflow tract
P06825641A0076|48 57|early 1950s
P06825641A0076|61 65|1960s
P06825641A0076|124 134|waste buried
P06826813A0264|0 7|Vesicles
P06826813A0264|49 51|UVA
P06828396A0095|10 22|contamination
P06828396A0095|28 32|wound
P06828396A0095|55 82|rapid biopsy fixation technique
P06829082A0187|17 31|deep hypothermia
P06829082A0187|76 87|brain tissues
P06829082A0187|176 186|control rats
P06829082A0187|190 193|rats
P06830033A0661|31 52|unilateral pneumothorax
P06830033A0661|55 61|15 cmH2O
P06830351A0397|50 55|Type Ia
P06830351A0397|62 67|Type Ib
P06830351A0397|74 79|Type II
P06830351A0397|89 95|Type III
P06833047A0000|48 68|respiratory inhibition
P06833047A0000|120 123|HFOV
P06833422T0000|0 12|Determination
P06833422T0000|15 65|20 alpha-hydroxy-9 beta,10 alpha-pregna-4,6-dien-3-one
P06833422T0000|15 35|20 alpha-hydroxy-9 beta
P06833422T0000|68 73|plasma
P06835516A0000|13 26|epidermoid cyst
P06835516A0000|32 49|suprasellar cistern
P06835914A0192|0 15|Copper treatments
P06835914A0192|149 166|commercial industry
P06837312A0000|90 98|vitamin D3
P06837312A0000|104 107|diet
P06837312A0000|148 166|vitamin D3 withdrawal
P06837312A0000|168 189|atherosclerotic lesions
P06838388A0896|85 108|glandular parenchyma areas
P06838388A0896|137 152|organ's structure
P06838388A0896|169 174|42d day
P06840803A0397|0 16|Histological signs
P06840803A0397|22 37|flare-up reaction
P06840803A0397|68 78|v. challenge
P06842629A0446|35 44|early shock
P06848729A0000|5 12|children
P06848729A0000|17 36|neuroblastoma treated
P06848729A0000|39 40|St
P06849842T0000|0 22|Penicillin-G degradation
P06849842T0000|38 58|in vitro granulopoiesis
P06851280A0144|6 15|fibrinogen
P06851280A0144|6 15|fibrinogen
P06851280A0144|32 50|turbidimetric method
P06851327A0000|4 11|patients
P06851327A0000|16 46|type III musculoskeletal infection
P06851327A0000|51 79|nongonococcal Neisseria species
P06853042A0282|0 25|Distal tubular acidification
P06853042A0282|44 81|proximal tubular bicarbonate reabsorption
P06854957T0066|37 58|M-mode echocardiography
P06856306T0000|20 30|fistula test
P06856669A1004|35 53|pulmonary metabolism
P06856669A1004|56 59|5-HT
P06856669A1004|78 83|5-HIAA
P06856669A1004|88 93|venous
P06856669A1004|112 133|single-pass circulation
P06858449A0335|0 11|Disturbances
P06858449A0335|14 34|placental maturation, 2
P06858640A0262|49 55|amyloid
P06858640A0262|87 97|fibroblasts
P06858805A0314|32 54|delayed hypersensitivity
P06858805A0314|59 66|Candidin
P06858805A0314|59 66|Candidin
P06858805A0314|68 78|Trycophytin
P06858805A0314|82 91|Tuberculin
P06858805A0314|82 91|Tuberculin
P06858967A0167|0 44|Serum lactate dehydrogenase and haptoglobin levels
P06858967A0167|5 24|lactate dehydrogenase
P06858967A0167|28 38|haptoglobin
P06858967A0167|59 72|total bilirubin
P06863087A0664|0 8|Low-dose D
P06863087A0664|23 24|DB
P06864837T0000|0 7|Efficacy
P06864837T0000|10 17|cervical
P06864955T0000|0 4|Leads
P06864955T0000|12 15|MMWR
P06868345A0000|13 23|visna-maedi
P06869215A0347|0 9|High levels
P06869215A0347|12 13|IC
P06869215A0347|35 52|hypocomplementemia
P06869986A0000|0 19|Circulating platelets
P06869986A0000|50 56|helical
P06869986A0000|57 64|collagen
P06869986A0000|57 64|collagen
P06869986A0000|67 88|atherosclerotic lesions
P06869986A0000|91 111|Mg-deficient ruminants
P06872800T0000|0 18|Acute type A hepatitis
P06872800T0000|26 33|patients
P06872800T0000|38 56|chronic HBV infection
P06873504T0000|32 51|renal tubular acidosis
P06873504T0000|55 60|sodium
P06873504T0000|84 97|liver cirrhosis
P06875478A0542|9 19|thyrotropin
P06875478A0542|9 19|thyrotropin
P06876317T0033|0 12|Relationships
P06876317T0033|20 51|acquired immune deficiency syndrome
P06880563A0516|15 18|CPAF
P06880563A0516|31 51|type 1 and type 2 diabetes
P06880563A0516|65 69|women
P06880563A0516|76 78|men
P06880563A0516|168 181|chlorpropamide
P06880604A0167|1 12|reassessment
P06880604A0167|50 74|southern province of Uusimaa
P06880604A0167|83 97|western province
P06880650A0316|45 55|researchers
P06882578A0464|5 23|ultramarathon runner
P06882578A0464|27 38|testosterone
P06882578A0464|75 89|training session
P06882578A0464|124 134|20' training
P06883385A0509|2 9|patients
P06883385A0509|14 39|complete or partial remission
P06883385A0509|45 49|tumor
P06883385A0509|54 72|neopterine excretion
P06883385A0509|82 93|normal values
P06884450A0234|9 15|tumours
P06884450A0234|46 47|FB
P06884450A0234|58 60|TBN
P06886031A0898|5 13|PGE levels
P06886031A0898|16 28|synovial fluid
P06886031A0898|110 117|tolmetin
P06886948A0750|13 22|weight gain
P06890622A0067|3 14|vasodilatory
P06890622A0067|16 31|anti-vasopressor
P06890622A0067|16 31|anti-vasopressor
P06890622A0067|92 108|placental ischemia
P06890622A0067|110 121|hypertension
P06890622A0067|134 144|coagulation
P06890622A0067|158 170|pre-eclampsia
P06890935T0001|0 15|Behcet's syndrome
P06891051A0587|0 7|Survival
P06891051A0587|28 46|autologous platelets
P06891051A0587|60 67|patients
P06891051A0587|85 97|platelet count
P06891270A0000|11 33|emotional-painful stress
P06891270A0000|35 37|EPS
P06891270A0000|41 63|myocardial extensibility
P06891270A0000|67 79|contractility
P06891270A0000|102 110|rat atrium
P06895559A0000|0 10|Terbutaline
P06895559A0000|13 35|beta2-adrenergic agonist
P06895559A0000|54 79|phosphodiesterase inhibitor
P06895559A0000|54 79|phosphodiesterase inhibitor
P06895559A0000|119 131|rabbit fetuses
P06895663A0810|51 53|RBT
P06895663A0810|57 59|RLF
P06895663A0810|73 95|statistical significance
P06897114A0240|4 17|two-helix motif
P06897114A0240|41 70|specific DNA sequence recognition
P06897114A0240|73 75|CAP
P06902722T0000|3 17|hyperacute phase
P06902722T0000|20 53|posterolateral myocardial infarction
P06911559T0000|0 9|Statistics
P06911559T0000|13 25|nurse managers
P06916588A0304|3 11|infection
P06916588A0304|37 44|patients
P06916588A0304|49 64|Hickman catheters
P06916588A0304|80 95|Broviac catheters
P06919347T0001|25 51|Laboratory Assistants' School
P06928974T0000|3 19|electrocardiogram
P06931124A0109|0 6|Setting
P06931124A0109|43 50|NH4Mg PO4
P06931124A0109|52 57|6H2O)n
P06931124A0109|78 82|water
P06938948T0001|0 11|Secretory IgA
P06938948T0001|0 11|Secretory IgA
P06938948T0001|15 34|serum immunoglobulins
P06938948T0001|49 61|local immunity
P06938948T0001|67 82|intestinal mucosa
P06938948T0001|85 98|acute leukemias
P06946314T0000|0 13|Serum IgE levels
P06946314T0000|5 7|IgE
P06946314T0000|16 31|Tauranga children
P06946693T0000|5 24|prostaglandin F2 alpha
P06946693T0000|26 34|PGF2 alpha
P06946693T0000|38 51|cattle breeding
P06948398A0523|32 36|blood
P06948493T0026|0 15|Range, variations
P06948493T0026|19 37|neoplastic potential
P06948868A0082|3 8|scores
P06948868A0082|45 62|faculty evaluations
P06950004T0047|21 25|metal
P06953957A0503|7 28|creatine kinase activity
P06953957A0503|7 20|creatine kinase
P06953957A0503|66 74|myoglobin
P06953957A0503|66 74|myoglobin
P06953957A0503|133 141|peak value
P06957125T0000|0 14|Utero-placental
P06957125T0000|38 71|beta 2-adrenoceptor stimulating drugs
P06957125T0000|38 55|beta 2-adrenoceptor
P06957633T0001|13 30|basophilic leukemia
P06957633T0001|35 42|trisomy 8
P06957633T0001|46 69|atypical erythroblastosis
P06957633T0001|73 79|patient
P06957633T0001|94 107|aplastic anemia
P06959130A0996|3 21|arginyl peptide bonds
P06959130A0996|53 73|human factor IX to factor
P06959130A0996|53 65|human factor IX
P06959130A0996|68 76|factor IXa
P06959130A0996|74 76|IXa
P06959130A0996|79 87|factor XIa
P06959130A0996|85 87|XIa
P06959130A0996|104 116|Arg145-Ala146
P06959130A0996|120 132|Arg180-Val181
P06962492A0612|8 13|growth
P06962492A0612|31 44|dental eruption
P06962492A0612|90 98|maxillary
P06962634A0190|0 18|Fluorometric methods
P06962634A0190|97 114|porphyrin transport
P06963337T0000|0 4|Renal
P06963337T0000|8 17|extrarenal
P06963337T0000|26 49|fibromuscular hyperplasia
P06963337T0000|54 65|hypertension
P06966678A0523|3 21|monoexponential rate
P06966678A0523|70 76|residue
P06966678A0523|114 122|fatty acid
P06966678A0523|139 151|neutral lipids
P06966678A0523|192 208|tension-time index
P06966678A0523|231 240|left atrium
P06966678A0523|255 265|right atrium
P06966678A0523|283 289|ear vein
P06969638A0180|4 15|examinations
P06969638A0180|40 55|CNS abnormalities
P06969638A0180|70 97|bacterial meningeal infections
P06969638A0180|130 136|therapy
P06969638A0180|163 175|complications
P06972179A0556|8 16|IgE levels
P06972179A0556|8 10|IgE
P06972443A0375|7 24|clinical evaluation
P06972443A0375|29 43|obligate carrier
P06972443A0375|54 72|ocular abnormalities
P06972501A0615|18 39|intraocular involvement
P06973664A0000|7 30|anterior cleavage syndrome
P06973664A0000|45 57|female patient
P06975206A0279|80 86|calcium
P06975206A0279|90 98|phosphate
P06975206A0279|110 119|growth rate
P06977605T0000|0 23|Endorphins and legal issues
P06977605T0000|0 9|Endorphins
P06978566A0197|33 40|F344 rats
P06978566A0197|51 61|lung lesions
P06978566A0197|102 120|colony-forming units
P06978566A0197|123 132|M. pulmonis
P06981991A0756|0 13|Aneurysmectomy
P06981991A0756|20 30|performance
P06981991A0756|33 36|CABG
P06981991A0756|84 93|ECG changes
P06981991A0756|108 113|grafts
P06981991A0756|166 175|ECG changes
P06981991A0756|191 211|coronary artery disease
P06984225A0367|0 3|REV I
P06984225A0367|41 45|graft
P06986168A0304|45 60|thrombic peptides
P06986168A0304|88 95|peptides
P06986168A0304|103 112|V8 protease
P06986168A0304|103 112|V8 protease
P06992600A0405|3 24|extraction measurements
P06992600A0405|42 67|extracerebral contamination
P06992600A0405|70 82|venous outflow
P06993660A0000|0 19|Contractile responses
P06993660A0000|22 35|norepinephrine
P06993660A0000|37 45|serotonin
P06993660A0000|49 57|potassium
P06993660A0000|65 81|relaxant responses
P06993660A0000|84 96|isoproterenol
P06993660A0000|143 162|thoracic aortic strips
P06993660A0000|167 172|aortic
P06993660A0000|181 196|hypertensive rats
P06993660A0000|198 204|AHR)2, 6
P06993660A0000|198 200|AHR
P06993660A0000|271 290|normotensive controls
P06994035T0001|19 39|steroid concentrations
P06994035T0001|42 57|radioimmunoassay
P06994049T0001|11 34|congenital hypothyroidism
P06994049T0001|43 56|newborn infants
P06997203A0325|2 16|rubella patients
P06997203A0325|21 41|serologic confirmation
P06997203A0325|44 45|HI
P06997203A0325|50 55|IF test
P06997203A0325|82 84|219
P06997203A0325|97 104|patients
P06997203A0325|111 117|PHA test
P06997203A0325|111 113|PHA
P06997203A0325|157 164|patients
P07004236A0741|45 63|formate accumulation
P07004236A0741|90 105|formate oxidation
P07004236A0741|181 202|human methanol poisoning
P07007181T0000|11 25|sodium saccharin
P07007181T0000|31 34|diet
P07007181T0000|37 52|caecal microflora
P07007591A0324|3 9|residue
P07007591A0324|20 20|R
P07007591A0324|22 22|t
P07007591A0324|28 34|C-11 CPZ
P07007591A0324|41 55|113m transferrin
P07007591A0324|45 55|transferrin
P07007591A0324|111 136|CPZ area-weighted extraction
P07007591A0324|138 140|E(t
P07007591A0324|138 138|E
P07007591A0324|140 140|t
P07007591A0324|197 201|E(t) =
P07007591A0324|197 197|E
P07007591A0324|199 199|t
P07007591A0324|203 204|RT
P07007591A0324|203 204|RT
P07007591A0324|206 224|t) - RR(t)]/[1 - RR(t)]
P07007591A0324|206 210|t) - RR
P07007591A0324|212 217|t)]/[1
P07007591A0324|219 220|RR
P07007591A0324|222 222|t
P07007591A0324|231 232|RT
P07007591A0324|231 232|RT
P07007591A0324|236 237|RR
P07007591A0324|236 237|RR
P07007591A0324|273 275|CPZ
P07007591A0324|279 289|transferrin
P07007591A0324|279 289|transferrin
P07015018A0395|0 18|Synchronous extracts
P07015018A0395|59 74|allogeneic assays
P07015262A0396|9 25|cefadroxil therapy
P07015262A0396|42 49|children
P07015262A0396|54 74|urinary tract infection
P07015262A0396|78 86|CRP values
P07015262A0396|78 80|CRP
P07015262A0396|122 138|CRP-positive group
P07015262A0396|122 124|CRP
P07016141A0238|4 19|resting blood flow
P07016141A0238|21 23|RBF
P07016141A0238|28 43|maximal blood flow
P07016141A0238|45 47|NBF
P07016141A0238|62 78|Xenon 133 clearance
P07018810A0002|0 23|Plasma renin concentration
P07018810A0002|0 10|Plasma renin
P07018810A0002|50 73|subcapsular venous outflow
P07018810A0002|89 105|superficial cortex
P07018810A0002|116 132|deep venous outflow
P07018810A0002|148 156|inner half
P07018810A0002|162 167|cortex
P07018810A0002|171 177|medulla
P07018810A0002|183 185|cat
P07018810A0002|186 191|kidney
P07021505A0510|5 15|acclimation
P07021505A0510|33 42|sitting DPB
P07026328A0369|15 27|Ca2+ infusions
P07026328A0369|48 51|Ca2+
P07026328A0369|81 99|circulating glucagon
P07026328A0369|92 99|glucagon
P07026328A0369|132 138|glucose
P07034479A1050|11 13|RMI
P07034479A1050|29 40|placebo group
P07034479A1050|68 74|AC group
P07037479T0000|4 25|cracked-tooth" syndrome
P07038189A2301|27 29|CXD
P07038684A1050|37 58|amino-terminal sequence
P07038684A1050|73 85|genetic origin
P07038684A1050|104 106|p60
P07038684A1050|104 106|p60
P07038684A1050|110 112|p62
P07038684A1050|110 112|p62
P07038684A1050|126 159|amino acid sequences carboxy-terminal
P07038684A1050|165 167|p60
P07038684A1050|165 167|p60
P07038684A1050|177 186|methionine
P07038684A1050|188 194|residue
P07038684A1050|199 201|p62
P07038684A1050|199 201|p62
P07040659A0212|3 10|patients
P07040659A0212|16 27|control group
P07040659A0212|64 67|PEFR
P07040659A0212|78 85|patients
P07040659A0212|91 102|treated group
P07044389T0000|0 4|Facts
P07044389T0000|10 31|Economic Recovery Tax Act
P07044389T0000|41 67|speech-language pathologists
P07044389T0000|71 82|audiologists
P07044562T0000|9 12|ApUp
P07044842A2062|79 95|Bartter's syndrome
P07045156A0204|7 36|opsonophagocytic bacterial assay
P07045156A0204|41 56|suckling rat model
P07045156A0204|59 67|GBS sepsis
P07045156A0204|80 106|modified human immunoglobulin
P07045156A0204|88 106|human immunoglobulin
P07045156A0204|110 116|opsonic
P07049690T0000|0 16|Glomerular lesions
P07049690T0000|24 33|allografts
P07053251A0666|37 46|bone marrow
P07053251A0666|48 68|gastrointestinal tract
P07059567T0055|0 0|2
P07061263A0293|4 19|vascular pressure
P07061263A0293|21 24|Pvas
P07061263A0293|47 58|-5 to +25 cmH2O
P07061263A0293|82 83|Px
P07061263A0293|85 86|f)
P07061263A0293|85 85|f
P07061350A0042|18 22|77-72
P07061350A0042|42 67|crossed olivocochlear bundle
P07061350A0042|69 72|COCB
P07061350A0042|100 116|distortion product
P07061350A0042|118 122|f2-f1
P07061350A0042|118 119|f2
P07061350A0042|121 122|f1
P07061350A0042|129 150|ear-canal sound pressure
P07062036A0072|26 28|JIB
P07062269A0798|9 42|methadone-sensitive, opioid receptor
P07062269A0798|29 42|opioid receptor
P07062269A0798|54 61|naloxone
P07062269A0798|131 148|nonopioid mechanism
P07063606T0000|9 20|hyperthermia
P07063606T0000|29 46|blood-brain barrier
P07064662A0222|8 28|small medullary lesions
P07064662A0222|123 133|dorsal roots
P07064923T0000|0 8|Diagnosis
P07064923T0000|11 44|phenylalanine hydroxylase deficiency
P07064923T0000|11 34|phenylalanine hydroxylase
P07064923T0000|46 60|phenylketonuria
P07065206A0398|0 10|In 10 control
P07065206A0398|20 42|plasma TXB2 concentration
P07065206A0398|26 29|TXB2
P07068493A0414|3 17|respiratory rate
P07068493A0414|54 74|respiratory cycle spent
P07068493A0414|77 108|inspiration; end-tidal CO2 pressure
P07068493A0414|145 147|SIP
P07068493A0636|27 32|oxygen
P07068493A0636|98 100|SIP
P07068496A0000|33 45|extravascular
P07068496A0000|47 69|extracellular water space
P07068496A0000|75 80|sodium
P07068496A0000|130 134|lungs
P07068496A0000|137 158|steady-state techniques
P07068887A0000|75 95|psychiatric inpatients
P07072635A0000|25 31|urinary
P07072635A0000|32 35|iron
P07072635A0000|64 78|desferrioxamine
P07072635A0000|80 81|DF
P07073520A0153|6 31|conventional hemofiltration
P07073520A0153|59 74|Na+ concentration
P07073520A0153|97 120|extracellular fluid volume
P07073520A0153|139 162|intracellular fluid volume
P07075024A0540|3 15|uncomplicated
P07075024A0540|58 61|CMIR
P07075438T0000|11 31|serial xeroradiography
P07076222A0543|0 14|Recommendations
P07076222A0543|40 45|issues
P07078263T0000|41 55|hemochromatosis
P07078263T0000|70 102|congenital dyserythropoietic anemia
P07079595A0848|56 58|spg
P07079595A0848|125 144|histological sections
P07079595A0848|165 179|sperm production
P07080496A0097|30 41|lipoproteins
P07080496A0097|64 86|high-density lipoprotein
P07080496A0097|64 86|high-density lipoprotein
P07080496A0097|88 90|HDL
P07080496A0097|88 90|HDL
P07080496A0097|148 175|low-density lipoproteins (LDL)
P07080496A0097|148 170|low-density lipoproteins
P07080496A0097|172 174|LDL
P07080496A0097|178 193|cerebral infarcts
P07081327A0546|8 25|noninhibitory fluid
P07081327A0546|55 64|phosphorus
P07081327A0546|68 71|zinc
P07081327A0546|104 126|meconium-stained samples
P07084198T0000|0 13|Selenium status
P07084198T0000|34 46|United Kingdom
P07084617A0204|22 40|parasites reappeared
P07084617A0204|45 52|patients
P07084617A0204|69 80|between 1 and 7
P07084814T0000|20 38|phospholipid reagent
P07084814T0000|42 58|coagulation assays
P07088195T0019|25 32|UV vision
P07088195T0019|35 39|birds
P07090151A0165|6 12|turnout
P07090151A0165|45 48|MSRB
P07094856A0115|0 19|In a longitudinal study
P07094856A0115|23 37|low-risk fetuses
P07094905A0644|43 44|KA
P07094905A0644|43 44|KA
P07094905A0644|75 88|pyramidal cells
P07094905A0644|112 122|hippocampus
P07096587A0267|14 15|35
P07096587A0267|16 23|patients
P07097182A0480|31 47|negative potential
P07097182A0480|157 175|nonregenerating ears
P07105635A0412|19 34|normal volunteers
P07105635A0412|45 49|great
P07105635A0412|63 70|patients
P07105635A0412|90 95|asthma
P07105635A0412|110 123|ciliary beating
P07106323A0560|42 46|fetus
P07106323A0560|78 84|E3-16-G
P07106323A0560|78 84|E3-16-G
P07106534A0160|91 93|man
P07106534A0160|125 127|rat
P07107287A1083|27 33|drivers
P07107287A1083|62 75|99Mo generators
P07107462A0202|3 11|steepness
P07107462A0202|67 80|training period
P07107773A0000|0 9|Conjugated
P07107773A0000|13 73|unconjugated phenylacetic acid and m- and p-hydroxyphenylacetic acid
P07107773A0000|112 126|healthy subjects
P07107773A0000|132 138|fasting
P07107773A0000|189 203|amine precursors
P07107773A0000|222 238|gas chromatography
P07107773A0000|303 348|trifluoroethyl-pentafluoropropionyl derivatives
P07109788A0333|13 20|patients
P07109788A0333|56 67|pyloroplasty
P07110999A0160|15 34|behavioural disorders
P07110999A0160|36 47|tetraparesis
P07112320A0086|0 20|CSF adenosine deaminase
P07112320A0086|3 20|adenosine deaminase
P07112320A0086|30 32|ADA
P07112320A0086|30 32|ADA
P07112471A0639|0 8|Histamine
P07112471A0639|47 53|workers
P07112471A0639|60 63|left
P07112471A0639|133 139|factory
P07112654A0388|70 74|nasal
P07112654A0388|85 92|S. aureus
P07112654A0388|122 129|patients
P07113365A0737|0 32|Ficat and Bizou's condylar depth index
P07113365A0737|39 52|condylar-joint
P07113897A0285|35 36|EF
P07113897A0285|98 99|NS
P07113897A0285|146 147|NS
P07114083A0153|5 15|MOPP therapy
P07114083A0153|36 51|Hodgkin's disease
P07114083A0153|86 108|glucocerebrosidase level
P07114083A0153|86 103|glucocerebrosidase
P07114083A0153|127 140|Gaucher's cells
P07116298A1079|24 38|adjuvant therapy
P07116298A1079|97 104|patients
P07116298A1079|114 134|Corynebacterium parvum
P07116298A1079|176 178|BCG
P07116298A1079|208 215|patients
P07116298A1079|225 232|BCG + DTIC
P07116298A1079|264 267|DTIC
P07116298A1079|275 282|patients
P07116962A0299|3 18|COP-PAWP gradient
P07116962A0299|45 49|shock
P07116962A0299|53 61|non-shock
P07116962A0299|62 69|patients
P07116962A0299|74 87|pulmonary edema
P07119890T0000|24 37|in vivo labeling
P07119890T0000|40 52|red blood cells
P07119890T0000|57 62|Tc-99m
P07124743A1223|16 31|glassware factory
P07124743A1223|33 37|As2O3
P07124743A1223|85 91|arsenic
P07124743A1223|111 117|urinary
P07124743A1223|118 124|arsenic
P07124743A1223|151 168|mouth contamination
P07124743A1223|171 177|arsenic
P07124743A1223|223 242|urinary arsenic levels
P07124743A1223|306 315|oral intake
P07124743A1223|371 375|lungs
P07125064T0000|0 14|Parasitological
P07125064T0000|40 54|capuchin monkeys
P07125064T0000|67 86|Schistosoma japonicum
P07125064T0000|89 106|Schistosoma mansoni
P07125238T0000|3 10|pia mater
P07125238T0000|32 43|blood vessels
P07125238T0000|51 70|central nervous system
P07126067T0000|12 23|reproduction
P07126067T0000|26 43|malignant catarrhal
P07126067T0000|51 60|Bali cattle
P07126413A0000|2 22|colonic delivery system
P07126413A0000|111 127|acrylic based resin
P07130335A1081|19 46|dopamine agonist bromocriptine
P07130335A1081|109 126|plasma 18-OHB levels
P07132408A0387|10 13|time
P07132408A0387|30 50|magnesium cardioplegia
P07134924A0640|20 32|malformations
P07134924A0640|50 60|open coeloms
P07135112T0000|0 5|Repair
P07135112T0000|41 60|myocutaneous free flap
P07136524A0180|31 56|malignant epithelial tumours
P07136524A0180|73 90|mesenchymal tumours
P07136524A0180|97 108|osteosarcoma
P07136524A0180|120 142|retinoblastoma survivors
P07136569A0000|27 34|children
P07137927A0000|10 19|immunology
P07137927A0000|50 57|serology
P07137927A0000|82 99|infectious diseases
P07140060T0000|0 25|Intra-articular dislocation
P07140060T0000|31 37|patella
P07140493A1045|48 59|human stomach
P07140493A1045|94 111|basal acid secretion
P07141130A0615|0 11|Histological
P07141130A0615|67 97|interepithelial mononuclear cells
P07141130A0615|131 145|epithelial cells
P07141130A0615|159 171|villous mucosa
P07141130A0615|182 187|height
P07141130A0615|193 207|epithelial cells
P07143347T0000|0 5|Cramps
P07143347T0000|8 30|extrapyramidal disorders
P07147622T0000|29 34|cattle
P07149047A0260|10 19|dog vessels
P07149047A0260|47 51|47 X 10
P07149303T0000|3 19|tetraphasic action
P07149303T0000|22 30|lidocaine
P07149303T0000|33 53|CNS electrical activity
P07154928T0001|0 11|Modification
P07154928T0001|33 49|cytostatic therapy
P07155579T0001|0 26|Asymptomatic bacteriospermia
P07158726T0001|0 6|Triumph
P07158726T0001|9 30|Leninist national policy
P07160491A0547|3 18|favourable effect
P07160491A0547|21 35|thymic shielding
P07160491A0547|76 82|LD50/30
P07162146A0000|16 30|ultrafiltration
P07162146A0000|83 96|ethylene glycol
P07162146A0000|99 104|plasma
P07162146A0000|107 123|gas chromatography
P07165767T0000|0 11|Mastocytosis
P07168531T0001|4 20|Onchocerca species
P07168531T0001|23 30|parasite
P07168531T0001|33 46|domestic cattle
P07172690A0547|60 98|creatine phosphate, creatine phosphokinase
P07172690A0547|60 76|creatine phosphate
P07172690A0547|108 118|calcium pump
P07172690A0547|120 130|Ca++-ATPase
P07172690A0547|120 130|Ca++-ATPase
P07172690A0547|136 156|sarcoplasmic reticulum
P07172690A0547|158 160|SPR
P07172690A0547|248 260|coronary blood
P07173729A0000|2 22|vitro penetration tests
P07173729A0000|25 34|human sperm
P07173729A0000|39 51|cervical mucus
P07173729A0000|101 105|sperm
P07173729A0000|109 121|cervical mucus
P07174046T0000|0 14|Vibrio fluvialis
P07174046T0000|16 27|group F vibrio
P07174122A0000|0 22|Serum creatine kinase (SCK
P07174122A0000|5 18|creatine kinase
P07174122A0000|20 22|SCK
P07174122A0000|40 47|subjects
P07174122A0000|80 90|performance
P07174122A0000|113 123|lifting task
P07174437A0181|0 8|Organisms
P07174437A0181|52 59|counties
P07175474A0102|10 14|death
P07175474A0102|57 77|toxicological findings
P07179412A1131|29 38|population
P07179412A1131|46 48|X 46
P07180901A0539|63 85|prostaglandin synthetase
P07180901A0539|105 113|ibuprofen
P07180901A0539|125 139|tubular necrosis
P07181985A0107|10 18|mitomycin
P07181985A0107|24 37|distilled water
P07181985A0107|49 62|distilled water
P07181985A0107|89 95|bladder
P07182523A0462|31 33|SOA
P07182523A0462|60 75|SOA concentration
P07183576A0157|94 106|synovial fluid
P07183576A0157|167 180|cancellous bone
P07183576A0157|209 220|cortical bone
P07184375T0001|31 42|methotrexate
P07184375T0001|47 58|prednisolone
P07184375T0001|60 87|VM*P) combination chemotherapy
P07184375T0001|91 124|advanced adult non-Hodgkin's lymphoma
P07184598T0001|0 16|Lacrimal secretion
P07184598T0001|19 33|hyperthyroidism
P07184774T0000|19 27|ED01 study
P07184795A0517|39 54|serum CPK activity
P07184795A0517|44 46|CPK
P07184795A0517|67 67|I
P07190627T0000|15 34|plasminogen activator
P07190627T0000|15 34|plasminogen activator
P07190627T0000|44 53|vasoactive
P07190627T0000|81 86|dog leg
P07190869A0316|0 3|CDDP
P07190869A0316|28 48|non-Hodgkin's lymphoma
P07191183A0505|21 24|800 V
P07191183A0505|88 93|lipids
P07191804A0000|3 18|hormonal response
P07191804A0000|67 76|male cadets
P07191804A0000|95 97|107
P07191972A0391|49 61|spinal cooling
P07191972A0391|81 89|dark phase
P07192369T0000|21 48|cumulative behavioral toxicity
P07192369T0000|54 78|chronic oral administration
P07192369T0000|81 87|l-alpha
P07192369T0000|105 114|female rats
P07192722A0682|63 77|serum iPTH levels
P07192722A0682|68 71|iPTH
P07192722A0682|86 87|CL
P07192722A0682|96 99|PMNs
P07192722A0682|142 143|CL
P07192722A0682|152 155|PMNs
P07194905A0332|0 2|TCZ
P07194905A0332|52 65|tissue necrosis
P07194905A0332|111 132|delayed brain maturation
P07195615A0087|11 23|muricidal rats
P07195615A0087|114 115|Cd
P07195615A0087|121 133|olfactory bulb
P07195615A0087|159 163|brain
P07195880A0621|49 55|leprosy
P07202224A0452|3 13|preferences
P07202224A0452|27 35|vis-a-vis
P07202224A0452|36 49|castrated males
P07202224A0452|69 70|TP
P07202224A0452|111 117|females
P07202525A0200|71 83|electric shock
P07202919A0142|0 4|Ulcer
P07202919A0142|30 36|stomach
P07203410T0000|0 11|Family visits
P07203410T0000|39 46|patients
P07205120T0000|1 18|transparent overlay
P07205120T0000|42 53|ECG wave forms
P07205967T0000|0 14|Adverse reaction
P07208984A0000|13 26|99mTc-labelled
P07208984A0000|27 48|macroaggregated albumin
P07208984A0000|42 48|albumin
P07208984A0000|66 90|computed tomography studies
P07208984A0000|92 93|CT
P07208984A0000|112 119|patients
P07208984A0000|124 143|intracranial diseases
P07214230T0000|12 46|Fusarium moniliforme var. subglutinans
P07214230T0000|64 78|pine pitch canker
P07214230T0000|89 97|bacterium
P07214230T0000|98 111|Arthrobacter sp
P07214665A0000|25 56|fluorouracil imidazole carboxamide
P07214665A0000|57 72|dimethyl triazeno
P07214665A0000|74 111|vincristine, bis-chloroethyl nitrosourea
P07214665A0000|116 130|prednisone (FIVB
P07214665A0000|132 133|P)
P07214665A0000|156 177|metastatic breast cancer
P07217329A0000|51 72|1, alpha-acetylmethadol
P07217329A0000|74 77|LAAM
P07217329A0000|86 102|active metabolites
P07217329A0000|167 179|dinormethadol
P07217329A0000|211 230|liquid chromatography
P07217329A0000|237 254|normal-phase column
P07217329A0000|259 268|UV detector
P07217329A0000|271 275|218 nm
P07217523A0364|55 70|consonant voicing
P07217523A0364|97 115|syllable recognition
P07218008T0000|0 23|Visual response properties
P07218008T0000|67 75|owl monkey
P07218008T0000|77 92|Aotus trivirgatus
P07218008T0000|120 125|medial
P07218008T0000|155 160|middle
P07219297T0000|1 7|unified
P07219297T0000|38 46|allergens
P07219821T0028|0 7|Clinical
P07221179A0156|21 31|GABA content
P07221354T0000|0 20|Theory and applications
P07221354T0000|23 33|pulse dosing
P07221354T0000|48 56|symposium
P07225300A0968|23 29|neonate
P07225540A0193|13 15|gas
P07225540A0193|80 92|plasma samples
P07226440T0000|3 14|hemodynamics
P07226440T0000|17 29|isoproterenol
P07226440T0000|38 51|cardiac failure
P07226440T0000|57 59|rat
P07228955A0000|48 67|theophylline analysis
P07228955A0000|70 102|paraxanthine (1,7-dimethylxanthine
P07228955A0000|128 135|caffeine
P07234308A0121|5 26|drug regimens like C-MOPP
P07234308A0121|28 31|CHOP
P07234308A0121|28 31|CHOP
P07234308A0121|35 39|BACOP
P07234755A0838|3 11|monocytes
P07234974T0000|23 34|Jat dentition
P07235317T0000|0 15|Clinical accuracy
P07235317T0000|18 31|updated version
P07235317T0000|37 52|Phadebas RAST test
P07235355A0462|4 18|control subjects
P07235355A0462|23 26|COPD
P07235355A0462|100 127|flow rates or density dependence
P07236351A0812|9 38|extended recovery hippocampal EEG
P07236351A0812|64 75|cellular loss
P07236351A0812|83 85|CA3
P07236351A0812|89 91|CA4
P07237123T0000|0 14|Evoked potential
P07237123T0000|18 36|single unit responses
P07237123T0000|39 59|olfactory nerve volleys
P07237123T0000|79 91|olfactory bulb
P07237560A1038|46 55|mature tRNA
P07237560A1038|76 87|mutated genes
P07237560A1038|76 87|mutated genes
P07237560A1038|106 119|central portion
P07237560A1038|122 140|concatenated Hind III
P07237560A1038|134 140|Hind III
P07237560A1038|173 185|transcription
P07237817T0000|0 14|Cross reactivity
P07237817T0000|29 34|RIA kit
P07240343A0000|0 11|Strontium-90
P07240343A0000|23 24|v.
P07240343A0000|29 40|pregnant rats
P07242929T0001|0 8|Recording
P07242929T0001|14 36|digital sphygmic activity
P07242929T0001|96 107|gauge methods
P07243380A0327|9 16|acidosis
P07243380A0327|60 62|P50
P07243380A0327|83 96|29.0 to 24.4 torr
P07247059A0775|0 14|Catheter transit
P07247059A0775|183 184|N2
P07249497A0688|5 9|women
P07249497A0688|44 46|PPI
P07249497A0688|66 74|warn women
P07249497A0688|109 111|PPI
P07249497A0688|142 149|patients
P07249544A0343|3 17|oral temperature
P07249544A0343|28 46|serum creatine kinase
P07249544A0343|28 46|serum creatine kinase
P07249544A0343|68 75|patients
P07249660T0000|0 12|Determination
P07249660T0000|15 34|aortic distensibility
P07249660T0000|61 72|hypertension
P07249895A0177|18 56|prostaglandins in acid-induced esophagitis
P07249895A0177|73 75|LES
P07249895A0177|76 86|hypotension
P07249895A0177|116 122|animals
P07249895A0177|127 138|indomethacin
P07249895A0177|189 201|prostaglandin
P07249895A0177|236 246|esophagitis
P07251564A0569|82 93|ASDC nosology
P07252346A0223|1 8|surgical
P07253335T0000|9 31|prostaglandin inhibitors
P07253335T0000|44 54|proteinuria
P07253335T0000|91 106|hypertensive rats
P07256543A0814|22 37|clinical criteria
P07256543A0814|69 74|facial
P07256543A0814|77 94|oropharyngeal burns
P07256543A0814|96 118|carboxyhemoglobin levels
P07256543A0814|96 112|carboxyhemoglobin
P07256543A0814|120 137|carbonaceous sputum
P07256543A0814|141 151|closed space
P07256543A0814|179 186|patients
P07256543A0814|191 202|airway injury
P07256543A0814|220 236|parenchymal injury
P07259325A0394|0 7|Survival
P07260389A0221|0 11|Methisergide
P07260389A0221|38 55|serotonin receptors
P07260389A0221|38 46|serotonin
P07260389A0221|108 116|serotonin
P07260987A0336|83 101|normal renal function
P07262239T0000|9 33|early monocular deprivation
P07262239T0000|49 77|cortico-geniculate projections
P07262239T0000|83 85|cat
P07262625A0000|0 20|Corticosteroid therapy
P07262625A0000|43 50|patients
P07262625A0000|55 69|occult infection
P07262625A0000|99 118|parasite relationship
P07262625A0000|130 137|steroids
P07262625A0000|161 170|intestinal
P07262625A0000|171 187|protozoal parasite
P07262625A0000|223 237|corticosteroids
P07262625A0000|251 259|parasites
P07263374T0000|0 17|Static lung function
P07263374T0000|32 44|pneumonectomy
P07263421A0351|11 13|So2
P07264787A0351|5 15|117 patients
P07264787A0351|25 27|136
P07264787A0351|52 69|chronic thyroiditis
P07264787A0351|100 114|hyperthyroidism
P07264787A0351|118 119|45
P07264787A0351|129 139|hypothyroid
P07266969A0246|22 41|estrogenic properties
P07266969A0246|44 52|Tamoxifen
P07267675A0000|6 9|semi
P07267675A0000|20 36|oral cephalosporin
P07267675A0000|38 45|CGP 9,000
P07267675A0000|79 98|hospitalized patients
P07267675A0000|103 119|urinary infections
P07268828A0000|60 70|propranolol
P07268828A0000|100 110|propranolol
P07268828A0000|132 184|solid-phase particles and fluorescein-labeled propranolol
P07270163A0684|3 34|syncytial microvillous projections
P07270163A0684|68 70|CNF
P07270163A0684|98 115|trophoblastic layer
P07270163A0684|121 125|villi
P07270163A0684|143 165|subtrophoblastic vessels
P07270163A0684|181 183|CNF
P07270163A0684|187 194|controls
P07270991A0149|27 38|grass species
P07270991A0149|51 59|RAST-test
P07274042A0249|0 27|DMI and 2-OH-DMI concentrations
P07274042A0249|61 79|DMI-treated patients
P07274428A0000|54 66|organic anions
P07274428A0000|97 99|RCA
P07274428A0000|135 144|Bengal pink
P07274428A0000|180 191|RCA triombrin
P07274428A0000|195 222|renotrophic dye indigo-carmine
P07274428A0000|230 247|plasmatic membranes
P07274428A0000|249 263|PM) of liver cells
P07274482A0000|21 23|cat
P07274482A0000|30 43|geniculate body
P07276210T0000|0 4|Assay
P07276210T0000|7 32|serum immunoreactive trypsin
P07276210T0000|26 32|trypsin
P07276210T0000|35 49|dried blood spots
P07276210T0000|72 85|cystic fibrosis
P07277222A1391|7 11|waves
P07277222A1391|40 48|motor unit
P07277222A1391|55 74|electronic oscillator
P07277222A1391|154 171|neural interactions
P07278104T0001|0 22|Leukocyte enzyme activity
P07278104T0001|26 45|blood lymphocyte blast
P07278104T0001|62 78|chronic bronchitis
P07278578T0001|0 12|Current status
P07278578T0001|15 26|chemotherapy
P07278578T0001|30 45|Hodgkin's disease
P07280654A0000|16 18|HBE
P07280654A0000|53 67|averaging method
P07282552A0990|12 25|salvaged tissue
P07282552A0990|79 92|salvaged tissue
P07282943A0097|19 35|stepwise decreases
P07282943A0097|38 69|superfusate oxygen partial pressure
P07282943A0097|105 111|620-650
P07282943A0097|152 166|isometric active
P07282943A0097|177 183|tension
P07283110A0000|8 20|B1 - deficiency
P07283110A0000|51 63|light exercise
P07286057A0159|10 25|infinity analyses
P07286057A0159|30 45|pharmacokinetics
P07286057A0159|118 128|v. injection
P07286057A0159|137 139|450
P07286057A0159|145 162|oral administration
P07293100T0001|0 15|Gastrin secretion
P07293100T0001|0 6|Gastrin
P07293100T0001|22 36|food stimulation
P07293327T0001|0 22|Fibrinogen determination
P07293327T0001|0 9|Fibrinogen
P07293327T0001|31 40|KZM-1 meter
P07295033A0513|58 63|faeces
P07295033A0513|76 80|urine
P07295417A0092|42 54|left ventricle
P07295417A0092|83 112|nuclear technique--phase imaging
P07296303A0418|11 19|brainstem
P07296303A0418|22 27|nuclei
P07296303A0418|45 62|lateralis posterior
P07296303A0418|87 93|latency
P07296997A0125|0 15|Nineteen patients
P07296997A0125|49 51|OCG
P07296997A0125|67 76|Tc-99m-PyG
P07297576A0454|18 39|drinking water ad libitum
P07297576A0454|76 88|drinking water
P07297978A0570|83 84|C.
P07298209A0291|26 44|performance capacity
P07298209A0291|55 58|W170
P07298209A0291|78 80|VO2
P07298259T0000|0 12|Determination
P07298259T0000|21 25|blood
P07298523T0000|8 19|indomethacin
P07298523T0000|23 42|prostaglandin F2 alpha
P07298523T0000|45 55|parturition
P07298523T0000|58 62|swine
P07299857A0294|0 9|LD50 values
P07299857A0294|19 20|KP
P07299857A0294|34 41|male rats
P07299857A0294|55 64|female rats
P07299857A0294|69 74|KP-CMC
P07299857A0294|117 120|male
P07299857A0294|133 138|female
P07299857A0294|143 148|KP-T10
P07299857A0294|184 204|peroral administration
P07299857A0294|207 212|KP-CMC
P07299857A0294|240 244|males
P07299857A0294|273 274|KP
P07304905A0336|0 14|Autotransfusion
P07304905A0336|37 78|Heparin-ACD-B- Heparin-DPD- Heparin-ACD-B etc
P07306839T0001|0 25|Electron microscopic picture
P07306839T0001|31 44|cerebral cortex
P07306839T0001|47 50|rats
P07308849A0817|35 37|gut
P07308849A0817|45 60|operation animals
P07308849A0817|100 112|mucosal weight
P07309562T0000|11 20|thin-layer
P07309562T0000|51 62|hippuric acid
P07309562T0000|66 84|methylhippuric acids
P07310206A0154|67 92|scanning electron microscopy
P07310206A0154|102 119|resin casting method
P07312707T0000|0 7|Chordoma
P07312707T0000|13 22|spinal cord
P07312707T0000|26 32|F344 rat
P07320153T0000|52 65|micro precolumn
P07320153T0000|69 95|dual electrochemical detector
P07320153T0000|124 137|catecholamines
P07323063A0000|32 60|virgin, male Sprague-Dawley rats
P07323063A0000|77 92|hypertensive rats
P07323063A0000|94 97|SHRs
P07323063A0000|162 174|isoproterenol
P07323063A0000|222 235|cardiac failure
P07323063A0000|239 256|functional recovery
P07323573A0644|13 37|myelin-axonal dissociation
P07326596A0061|3 15|IgA deficiency
P07326596A0061|3 5|IgA
P07326596A0061|33 35|IgE
P07326596A0061|33 35|IgE
P07327097A0647|2 7|PB mice
P07327097A0647|50 60|hippocampal
P07327097A0647|61 76|pyramidal neurons
P07327097A0647|87 94|controls
P07327097A0647|132 143|granule cells
P07328000T0000|0 19|Nutritional cataracts
P07328000T0000|22 33|timber wolves
P07330073T0000|0 9|Prevention
P07330073T0000|12 31|transfusion reactions
P07330073T0000|54 66|red blood cells
P07337609A0531|3 56|geometric mean hemagglutination-inhibition antibody titers
P07337609A0531|58 60|GMT
P07337609A0531|111 118|chickens
P07337609A0531|157 175|primary immunization
P07337609A0531|177 197|secondary immunization
P07340196T0001|30 34|HBSAG
P07340196T0001|30 34|HBSAG
P07340196T0001|80 102|hepatitis B virus carriers
P07341346A0174|0 0|2
P07341346A0174|16 27|shunt vessels
P07341346A0174|56 70|primary arteries
P07345217A0000|0 22|Urological complications
P07345217A0000|62 84|gynecological malignancy
P07347728T0000|0 12|Arachnoid cyst
P07349416A0337|16 25|summer coat
P07354367A0162|0 10|Hypotension
P07355527A0467|23 34|Lich-Gregoir
P07355527A0467|57 62|adults
P07356273T0022|0 13|Mucoepidermoid
P07356273T0022|17 37|acinous cell carcinomas
P07365183A0000|6 13|patients
P07365183A0000|22 26|older
P07365183A0000|55 64|depression
P07365183A0000|138 161|electroconvulsive therapy
P07365183A0000|181 204|electroconvulsive therapy
P07369183T0000|26 36|coagulation
P07369458A0606|58 67|deep muscle
P07369458A0606|117 131|amputation level
P07372433A0000|39 53|guinea pig ureter
P07372928A0105|0 4|Tests
P07372928A0105|30 44|Mossbauer source
P07372928A0105|61 75|basilar membrane
P07372928A0105|94 122|signal-transmission properties
P07372928A0105|163 177|basilar membrane
P07375836T0000|22 28|patient
P07375836T0000|37 53|vaginal metastasis
P07375836T0000|59 72|renal carcinoma
P07375864A0431|38 51|low platelet MAO
P07375864A0431|49 51|MAO
P07375864A0431|74 97|bipolar affective disorder
P07375864A0431|107 119|schizophrenia
P07375864A0431|171 184|low platelet MAO
P07375864A0431|171 184|low platelet MAO
P07375864A0431|200 206|primary
P07376165T0001|0 6|Ecthyma
P07376165T0001|14 20|disease
P07377378A0143|0 18|Estrogen replacement
P07377378A0143|28 43|17 beta-estradiol
P07377378A0143|46 59|beta-estradiol
P07377378A0143|86 101|Silastic capsules
P07377378A0143|135 148|heat production
P07377378A0143|173 203|untreated ovariectomized controls
P07377954A0117|49 68|cardiovascular system
P07377954A0117|103 111|pulse rate
P07377954A0117|116 132|oxygen consumption
P07377954A0117|134 136|VO2
P07377954A0117|155 170|health volunteers
P07377954A0117|199 206|anterior
P07377954A0117|254 263|volunteers
P07377954A0117|271 302|postexercise ankle pressure changes
P07377954A0117|307 314|subjects
P07379334A0503|9 29|immunologic reactivity
P07379334A0503|32 39|subjects
P07379334A0503|97 104|subjects
P07379334A0503|114 120|placebo
P07380615A0478|57 70|blue collar jobs
P07380615A0478|96 111|myocardial tissue
P07380615A0478|240 244|white
P07380615A0478|251 257|workers
P07385543T0001|0 9|Importance
P07385543T0001|31 46|sulfhydryl groups
P07385543T0001|63 73|long tubular
P07385920A0189|27 31|blood
P07385920A0189|69 79|haemoglobin
P07385920A0189|69 79|haemoglobin
P07385920A0189|92 107|urinary excretion
P07385920A0189|110 132|delta amino levulinic acid
P07385933A0085|40 49|body weight
P07385933A0085|63 67|2 mu Ci
P07385933A0085|77 97|14C-labelled galactose
P07385933A0085|99 103|14CO2
P07386500A0174|8 27|clotting factor assays
P07386500A0174|56 62|factor X
P07387242A0236|60 68|operation
P07387242A0236|83 101|seven plasma proteins
P07387242A0236|88 101|plasma proteins
P07387242A0236|107 116|hemoglobin
P07387242A0236|136 152|clotting functions
P07392519T0001|0 13|Retinal changes
P07392519T0001|16 36|pigmentary retinopathy
P07392519T0001|39 46|children
P07393856A0314|10 19|beta-apo-8
P07393856A0314|22 45|carotenoic acid ethyl ester
P07393856A0314|47 52|apo-EE
P07393856A0314|47 52|apo-EE
P07393976A0000|12 30|sodium phenobarbital
P07393976A0000|43 56|sodium barbital
P07393976A0000|100 111|deprived rats
P07393976A0000|148 170|bottle taste aversion task
P07393976A0000|178 192|sodium saccharin
P07393976A0000|203 207|water
P07394364A0738|25 35|gas exchange
P07394364A0738|36 45|parenchyma
P07394364A0738|61 67|mammals
P07394364A0738|150 163|metabolic rates
P07394364A0738|201 204|lung
P07394364A0738|213 215|VO2
P07395750A0294|0 15|Underestimations
P07396545A0217|0 11|Chemotherapy
P07397066T0000|0 13|Drug inhibition
P07397066T0000|33 40|esterase
P07405701T0000|0 28|Visual averaged evoked responses
P07405701T0000|32 55|platelet monoamine oxidase
P07405701T0000|32 55|platelet monoamine oxidase
P07405701T0000|58 65|patients
P07405701T0000|79 88|alcoholism
P07406527A0212|26 50|urinary porphyrin excretion
P07406527A0212|57 72|porphyrin content
P07406527A0212|75 87|lijver and skin
P07406527A0212|104 124|HCB-CQ-treated animals
P07406527A0212|148 158|HCB controls
P07408970A0706|35 40|uterus
P07408970A0706|43 53|Gf and Cv mice
P07410037A0752|8 20|stone-formers
P07410037A0752|55 73|magnesium metabolism
P07410037A0752|105 116|control group
P07410037A0752|128 143|urinary excretion
P07410037A0752|202 224|stone-forming propensity
P07413242A0000|60 64|T1-L3
P07413242A0000|60 61|T1
P07413242A0000|63 64|L3
P07413441T0070|58 63|kidney
P07413781A0169|0 21|Hippocampal stimulation
P07413781A0169|84 99|latent inhibition
P07413781A0169|132 143|conditioning
P07413781A0169|149 159|preexposure
P07413806T0000|3 22|centromedial amygdala
P07413806T0000|26 41|gastric pathology
P07413806T0000|44 47|rats
P07414817T0001|0 17|Cataract extraction
P07414817T0001|20 34|primary glaucoma
P07415340A0280|0 5|Number
P07415340A0280|18 33|myelin structures
P07415340A0280|39 54|pneumocytes typ II
P07416204A0437|80 81|t0
P07416204A0437|120 121|t0
P07416204A0437|201 202|t0
P07418498A0217|21 33|complications
P07418498A0217|36 50|corticosteroids
P07418498A0217|116 128|amphotericin B
P07418498A0217|132 139|surgical
P07418498A0217|153 163|lung abscess
P07419485A0158|34 59|short waves (deep-water waves
P07425838A0182|15 41|pheochromocytoma manifesting
P07425838A0182|67 75|pregnancy
P07426101A0124|7 45|plasma and lipoprotein lipid concentrations
P07426101A0124|47 76|adipose tissue lipoprotein lipase
P07426101A0124|54 76|tissue lipoprotein lipase
P07426101A0124|105 122|alcohol consumption
P07426101A0124|138 153|weekly mileage run
P07426101A0124|157 167|performance
P07426101A0124|216 229|training period
P07426604A0397|106 115|fatty acids
P07426745A0177|20 24|blood
P07426745A0177|25 43|erythrocyte membrane
P07426745A0177|91 106|gamma-irradiaton
P07428037A0989|9 31|3' terminal 50 nucleotides
P07428037A0989|36 49|mouse mt 12S rRNA
P07428037A0989|36 49|mouse mt 12S rRNA
P07428037A0989|68 87|10 bp hairpin structure
P07428037A0989|102 114|15 consecutive
P07428037A0989|145 165|small ribosomal subunit
P07428037A0989|145 158|small ribosomal
P07428037A0989|199 213|mRNA binding site
P07428037A0989|215 220|ACCUCC
P07428037A0989|229 234|E. coli
P07428037A0989|238 257|corn chloroplast rRNAs
P07429009T0121|21 42|cell population dynamics
P07431059A0000|6 18|cadaver brains
P07431059A0000|36 37|X 6
P07431059A0000|98 109|pineal region
P07431059A0000|143 152|pineal body
P07431059A0000|163 170|cerebral
P07431059A0000|171 176|artery
P07431059A0000|196 206|artery, vein
P07431059A0000|209 213|Galen
P07431059A0000|209 213|Galen
P07431059A0000|215 223|basal vein
P07431059A0000|226 234|Rosenthal
P07431059A0000|244 269|cerebral vein, straight sinus
P07431059A0000|296 304|tentorial
P07431059A0000|305 309|notch
P07431059A0000|334 346|cranial nerves
P07432288A0218|5 17|antibody titre
P07434431A0203|69 83|viral infections
P07434431A0203|106 111|famine
P07434456A0286|23 49|deglycerolized red blood cells
P07434456A0286|138 146|post-wash
P07434456A0286|165 179|refractive index
P07434456A0286|183 191|osmometry
P07435185A0074|44 60|malignant lymphoma
P07435185A0074|68 76|diagnosis
P07435185A0074|96 106|drill biopsy
P07436187A0147|56 71|diagnostic entity
P07436187A0147|111 116|social
P07436187A0147|120 138|work-related factors
P07436187A0147|141 150|disability
P07436459A0245|18 68|raised hydroxykynurenine/hydroxyanthranilic acid ratio
P07436459A0245|95 113|vitamin B6 deficiency
P07436459A0245|151 160|tryptophan
P07436702A0156|21 34|normal reaction
P07436702A0156|37 40|DNFB
P07436794A0148|25 39|carotid arteries
P07436794A0148|41 43|CCA
P07438346A0381|58 73|resting potential
P07438482A0145|12 16|right
P07438482A0145|20 30|left adrenal
P07438482A0145|34 55|peripheral blood samples
P07438482A0145|87 94|oestrone
P07438482A0145|96 97|E1
P07438482A0145|96 97|E1
P07438482A0145|102 111|oestradiol
P07438482A0145|113 114|E2
P07438482A0145|113 114|E2
P07440085T0061|0 15|Arm function tests
P07440430A1074|12 20|B breeding
P07440430A1074|43 44|Hb
P07440430A1074|43 44|Hb
P07440430A1074|81 87|NB lambs
P07440430A1074|93 100|S x B lambs
P07440430A1074|117 118|Hb
P07440430A1074|117 118|Hb
P07440430A1074|132 139|D x B lambs
P07440430A1074|144 149|B lambs
P07440430A1074|185 208|hemoglobin concentrations
P07440430A1074|185 194|hemoglobin
P07445971A0241|61 65|nerve
P07449221A0086|82 87|tendon
P07449253A0411|92 99|diuresis
P07449253A0411|119 129|blood volume
P07450031A0691|0 21|Marked sedative activity
P07450031A0691|37 99|9-methoxy-5-phenylpyrrolo[2,1-d][1,5]benzothiazepin-6,6-dioxide
P07450031A0691|101 177|NF19) and 9-chloro-5-p-nitrophenylpyrrolo[2,1-d][1,5]benzothiazepin-6,6-dioxide
P07450031A0691|179 182|NF20
P07450388A0406|2 9|patients
P07450388A0406|22 27|CCK-PZ
P07450388A0406|22 24|CCK
P07450388A0406|26 27|PZ
P07450388A0406|46 57|terminal part
P07450388A0406|63 70|bile duct
P07453919A0000|4 11|patients
P07453919A0000|16 31|Horton's headache
P07453919A0000|60 90|differential white blood cell count
P07453919A0000|121 146|alkaline and acid phosphatase
P07453919A0000|121 146|alkaline and acid phosphatase
P07453919A0000|148 167|non-specific esterase
P07453919A0000|160 167|esterase
P07453919A0000|172 193|cytoimmunological tests
P07453919A0000|195 197|IgM
P07453919A0000|201 203|IgG
P07453919A0000|201 203|IgG
P07453919A0000|228 252|capillary blood neutrophils
P07453919A0000|279 293|non-painful area
P07453919A0000|299 302|skin
P07453919A0000|308 311|head
P07453919A0000|317 333|contralateral side
P07455042A0457|2 11|high-speed
P07455042A0457|13 29|volumetric imaging
P07455042A0457|186 196|right atrium
P07455042A0457|204 217|peripheral vein
P07455521A0414|3 6|ESEG
P07455521A0414|30 38|NEXT study
P07456774A0448|14 30|SLE-inducing drugs
P07457931A0655|14 17|mice
P07457931A0655|45 51|5-OH-DA
P07457931A0655|78 97|ultrastructural study
P07461226A0958|19 26|hot flush
P07461226A0958|69 79|epinephrine
P07461226A0958|82 95|norepinephrine
P07461848A0230|52 63|tobacco smoke
P07461848A0230|78 79|NO
P07462481A0422|88 96|occlusion
P07462481A0422|144 152|occlusion
P07463294A1216|45 54|responders
P07463294A1216|64 72|group 5, 13
P07463294A1216|79 84|group 7
P07463294A1216|104 113|responders
P07463294A1216|142 142|5
P07463465A0297|0 13|Early infection
P07463465A0297|34 45|control women
P07463465A0297|68 73|infant
P07466831A0714|0 16|Pentachlorophenol
P07466831A0714|38 49|HCB porphyria
P07466831A0714|82 106|urinary porphyrin excretion
P07466831A0714|141 156|porphyrin pattern
P07467975A0316|0 22|Family planning continues
P07467975A0316|63 70|patients
P07467975A0316|85 102|oral contraceptives
P07469692A0000|38 58|sclerosing bone disease
P07469692A0000|63 81|dominant inheritance
P07471210A0384|3 12|87K protein
P07471210A0384|77 118|leftward transcribed (1-strand) messenger RNAs
P07471210A0384|144 154|viral genome
P07472582A0993|43 59|99mTc-tetrofosmin
P07472582A0993|63 67|201Tl
P07472736A0278|50 66|articular eminence
P07473169A0133|0 4|EUK-8
P07473169A0133|14 22|synthetic
P07473169A0133|24 65|low-molecular-weight salen-manganese complex
P07473169A0133|82 100|superoxide dismutase
P07473169A0133|82 100|superoxide dismutase
P07473169A0133|104 121|catalase activities
P07473169A0133|104 111|catalase
P07473742A0187|3 14|protein ELT-1
P07473742A0187|3 14|protein ELT-1
P07473742A0187|26 40|single-copy gene
P07473742A0187|56 65|GATA family
P07473742A0187|56 65|GATA family
P07473742A0187|68 97|vertebrate transcription factors
P07473742A0187|68 97|vertebrate transcription factors
P07474078A0838|30 63|in vitro cell-free integration studies
P07474078A0838|95 108|CA dinucleotide
P07474078A0838|149 176|wild-type integration activity
P07474085A0932|12 19|R protein
P07474085A0932|55 68|frameshift site
P07474085A0932|74 90|V protein stop codon
P07474124A1360|35 37|PI2
P07474124A1360|41 43|PI3
P07474124A1360|66 88|parainfluenza virus genus
P07474124A1360|164 178|cytoplasmic tail
P07474124A1360|184 196|F glycoprotein
P07474124A1360|184 196|F glycoprotein
P07474140A1036|2 25|site-specific mutagenesis
P07474140A1036|51 82|ICP27 C-terminal amino acid residues
P07474140A1036|51 56|ICP27 C
P07474140A1036|113 125|ICP27 homologs
P07474140A1036|113 125|ICP27 homologs
P07474140A1036|133 145|herpesviruses
P07474140A1036|147 151|D-357
P07474140A1036|153 157|E-358
P07474140A1036|180 184|C-488
P07474140A1036|200 223|trans-regulatory activity
P07474451A0000|0 27|Magnetic resonance imaging (MRI
P07474451A0000|49 77|spinal intramedullary pathology
P07474451A0000|93 107|signal intensity
P07474617A1035|0 7|Patients
P07474617A1035|12 28|psychotropic drugs
P07474617A1035|54 62|PRL levels
P07474617A1035|54 56|PRL
P07474772A0274|38 60|fundus-based examination
P07475733T0000|0 14|Malaria, anaemia
P07475733T0000|19 35|HIV-1 transmission
P07475793T0000|0 16|BSE and farmworkers
P07476164A1602|11 56|two-dimensional nuclear magnetic resonance studies
P07476164A1602|61 74|F17A, K13Q, F15Y
P07476164A1602|78 81|F27Y
P07476164A1602|136 155|wild-type CspB protein
P07476164A1602|136 155|wild-type CspB protein
P07476701A0654|24 36|IgE antibodies
P07476701A0654|24 36|IgE antibodies
P07476963A0000|0 40|Peroxisome proliferator-activated receptors
P07476963A0000|0 40|Peroxisome proliferator-activated receptors
P07476963A0000|42 46|PPARs
P07476963A0000|42 46|PPARs
P07476963A0000|51 68|retinoid X receptors
P07476963A0000|51 68|retinoid X receptors
P07476963A0000|70 73|RXRs
P07476963A0000|70 73|RXRs
P07476963A0000|78 100|nuclear hormone receptors
P07476963A0000|78 100|nuclear hormone receptors
P07476963A0000|119 128|fatty acids
P07476963A0000|132 149|9-cis-retinoic acid
P07476971A0381|35 41|SKUT-1B
P07476971A0381|57 75|transcription factor
P07476971A0381|76 80|Pit-1
P07476971A0381|76 80|Pit-1
P07476975A0492|11 62|lactotropes, somatotropes, thyrotropes, and gonadotropes
P07476975A0492|116 129|adult pituitary
P07476975A0492|131 142|POMC products
P07476975A0492|131 142|POMC products
P07477245A0625|13 13|A
P07477245A0625|41 58|aflatoxins B1 B2 G1 G2
P07477245A0625|41 56|aflatoxins B1 B2 G1
P07477245A0625|85 88|AF B1
P07477245A0625|117 126|aflatoxins
P07477245A0625|136 138|450
P07478514A0237|25 44|rat B-myc genomic clone
P07478514A0237|25 32|rat B-myc
P07478523A0551|24 45|terminal amino acid forms
P07478523A0551|81 100|43 terminal amino acids
P07478523A0551|124 140|RET protein isoform
P07478523A0551|124 140|RET protein isoform
P07478525A1177|13 25|MHBst proteins
P07478525A1177|13 25|MHBst proteins
P07478525A1177|79 90|dimerization
P07479004A0421|2 35|electrophoretic mobility shift assays
P07479004A0421|40 43|PERE
P07479004A0421|40 43|PERE
P07479004A0421|55 68|major complexes
P07479004A0421|60 68|complexes
P07479004A0421|70 74|P1, P2
P07479004A0421|70 71|P1
P07479004A0421|73 74|P2
P07479004A0421|78 79|P3
P07479004A0421|78 79|P3
P07479004A0421|95 109|nuclear extracts
P07479004A0421|114 127|HeLa or 293 cells
P07482069A0606|19 21|MTX
P07483276A0139|35 51|open reading frames
P07483276A0139|53 56|ORFs
P07483276A0139|76 78|UL1
P07483276A0139|76 78|UL1
P07483276A0139|80 82|UL2
P07483276A0139|80 82|UL2
P07483276A0139|84 86|UL3
P07483276A0139|84 86|UL3
P07483276A0139|91 95|UL3.5
P07483276A0139|91 95|UL3.5
P07483276A0139|130 149|herpes simplex virus-1
P07483276A0139|130 149|herpes simplex virus-1
P07483276A0139|151 155|HSV-1
P07483276A0139|151 155|HSV-1
P07483276A0139|158 174|pseudorabies virus
P07483276A0139|176 178|PRV
P07483276A0139|181 199|equine herpesvirus-1
P07483276A0139|204 224|varicella-zoster virus
P07483276A0139|204 224|varicella-zoster virus
P07483285A0322|5 11|HPV16 E6
P07483285A0322|10 11|E6
P07483285A0322|13 19|E7 cDNAs
P07483285A0322|13 14|E7
P07483285A0322|15 19|cDNAs
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|65 71|MMTV LTR
P07483285A0322|65 71|MMTV LTR
P07483285A0322|96 98|ras
P07483285A0322|141 160|cellular DNA synthesis
P07483285A0322|184 196|E7 gene product
P07483285A0322|184 196|E7 gene product
P07483857A0350|52 54|NIT
P07483857A0350|63 66|0.95
P07483857A0350|70 78|water, fat
P07483857A0350|80 91|crude protein
P07483857A0350|106 134|tissue-protein frei meat protein
P07487067A0592|55 58|APS1
P07487067A0592|55 58|APS1
P07487067A0592|122 143|amino terminal sequences
P07487067A0592|154 168|transit peptides
P07487067A0592|172 190|plastid localization
P07487363A0447|3 13|serum levels
P07487363A0447|16 18|IgE
P07487363A0447|16 18|IgE
P07487363A0447|23 27|asIgE
P07487363A0447|23 27|asIgE
P07487363A0447|31 33|IgG
P07487363A0447|51 63|food allergens
P07487811A0000|62 83|cancellous bone turnover
P07487811A0000|112 130|Systems Experiment-1
P07487811A0000|132 137|PSE-1)
P07487811A0000|132 136|PSE-1
P07487811A0000|165 169|PSE-2
P07487811A0000|165 169|PSE-2
P07487908A0230|49 100|promotorless chloramphenicol acetyltranferase (CAT) gene
P07487908A0230|61 91|chloramphenicol acetyltranferase
P07487908A0230|93 95|CAT
P07487908A0230|110 125|pancreatic origin
P07487908A0230|127 132|AR-42J
P07487908A0230|149 168|non-pancreatic origin
P07487908A0230|170 173|Rat 2
P07487908A0230|170 173|Rat 2
P07487908A0230|177 180|IEC 6
P07487908A0230|177 180|IEC 6
P07488247T0000|20 73|aryl hydrocarbon receptor nuclear translocator interactions
P07488247T0000|20 61|aryl hydrocarbon receptor nuclear translocator
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488247T0000|106 126|yeast two-hybrid system
P07488291A0934|41 52|somatostatin
P07488291A0934|56 77|triamcinolone acetonide
P07488291A0934|88 104|inflammatory signs
P07488291A0934|134 155|triamcinolone acetonide
P07488959T0000|35 51|lymphocytopoiesis
P07489502A0000|3 16|influenza virus
P07489502A0000|17 26|NS1 protein
P07489502A0000|17 26|NS1 protein
P07489502A0000|30 63|unique posttranscriptional regulator
P07489502A0000|100 112|nuclear export
P07489502A0000|115 135|poly A-containing mRNAs
P07489502A0000|115 135|poly A-containing mRNAs
P07489502A0000|151 166|pre-mRNA splicing
P07490079A0825|73 81|human STEP
P07490079A0825|73 81|human STEP
P07490079A0825|101 114|murine STEP gene
P07490079A0825|101 114|murine STEP gene
P07490079T0000|0 15|Molecular cloning
P07490079T0000|21 32|human homolog
P07490079T0000|36 63|striatum-enriched phosphatase
P07490079T0000|36 63|striatum-enriched phosphatase
P07490079T0000|65 73|STEP) gene
P07490079T0000|65 68|STEP
P07490079T0000|77 94|chromosomal mapping
P07490079T0000|100 117|human and murine loci
P07490079T0000|108 117|murine loci
P07490083A0000|0 17|Carbonic anhydrase V
P07490083A0000|8 21|anhydrase V (CA V
P07490083A0000|19 22|CA V)
P07490083A0000|36 54|mitochondrial matrix
P07490083A0000|57 61|liver
P07490156A0647|0 8|Vitamin D3
P07490156A0647|13 20|nicotine
P07490156A0647|57 67|cardiac mass
P07490156A0647|71 84|elastic modulus
P07490278A0799|45 49|Num1p
P07490278A0799|45 49|Num1p
P07490278A0799|55 64|mother cell
P07490278A0799|65 70|cortex
P07490742A0636|43 61|dsRNA binding domains
P07490742A0636|43 61|dsRNA binding domains
P07490742A0636|98 107|subdomains
P07490766T0000|64 66|Max
P07490766T0000|64 66|Max
P07490766T0000|70 88|c-Myc leucine zippers
P07490766T0000|70 74|c-Myc
P07490766T0000|75 88|leucine zippers
P07490766T0000|112 136|electrostatic interactions
P07490766T0000|167 184|heterodimerization
P07490770A0267|17 25|coxI genes
P07490770A0267|17 25|coxI genes
P07490770A0267|35 52|966-bp group I intron
P07490770A0267|89 106|yeast coxI intron aI4
P07490770A0267|89 93|yeast
P07490770A0267|94 106|coxI intron aI4
P07490770A0267|127 144|279-amino-acid site
P07490770A0267|157 168|endonuclease
P07491111A0221|12 13|GR
P07491111A0221|12 13|GR
P07491111A0221|16 18|DMS
P07491111A0221|39 43|human
P07491111A0221|44 47|ACTH
P07491111A0221|44 47|ACTH
P07491111A0221|58 76|small cell lung cancer
P07491305A0102|43 58|accessory pathway
P07491305A0102|98 107|QRS complex
P07491305A0102|114 124|sinus rhythm
P07491305A0102|137 139|ECG
P07491305A0102|153 169|delta wave polarity
P07491791A0263|3 18|promoter mutation
P07491791A0263|42 52|E1A products
P07491791A0263|42 44|E1A
P07491791A0263|58 75|heterologous helper
P07491791A0263|76 90|adenovirus type 5
P07491791A0263|92 94|Ad5
P07493327A0507|16 29|trans-splicing
P07493327A0507|53 54|U2
P07493327A0507|56 57|U4
P07493327A0507|56 57|U4
P07493327A0507|62 69|U6 snRNAs
P07493327A0507|62 63|U6
P07493327A0507|64 69|snRNAs
P07493627A0882|11 25|PCC4.aza1R cells
P07493627A0882|32 51|RAR-selective agonist
P07493627A0882|32 34|RAR
P07493627A0882|80 87|EC-1 mRNA
P07493627A0882|80 83|EC-1
P07493627A0882|108 127|RXR-selective agonist
P07493627A0882|108 110|RXR
P07493627A0882|135 148|EC-1 expression
P07493627A0882|135 138|EC-1
P07494244A0335|14 19|E1A243
P07494244A0335|14 19|E1A243
P07494244A0335|21 23|YY1
P07494244A0335|21 23|YY1
P07494244A0335|33 58|CRE-dependent transcription
P07494244A0335|61 65|c-fos
P07494244A0335|61 65|c-fos
P07494244A0335|93 108|ATF/CREB proteins
P07494244A0335|93 95|ATF
P07494244A0335|97 108|CREB proteins
P07494244A0335|119 124|-67 CRE
P07494274A1015|0 20|Shift-down experiments
P07494274A1015|81 104|nonpermissive temperature
P07494274A1015|129 136|alpha TIF
P07494274A1015|129 136|alpha TIF
P07494274A1015|143 151|infection
P07494293A0585|27 29|tip
P07494293A0585|53 83|T-cell signal transduction cascade
P07494293A0585|101 103|Lck
P07494293A0585|101 103|Lck
P07494293A0585|121 142|Lck-mediated activation
P07494303A0000|0 33|Human immunodeficiency virus type 1 Vpr
P07494303A0000|0 33|Human immunodeficiency virus type 1 Vpr
P07494303A0000|37 71|virion-associated, regulatory protein
P07494303A0000|98 113|viral replication
P07494303A0000|116 136|monocytes/macrophages
P07494306A0240|28 58|VP16 protein-protein interactions
P07494306A0240|28 46|VP16 protein-protein
P07494306A0240|69 87|virus-infected cells
P07494306A0240|99 102|VP16
P07494306A0240|99 102|VP16
P07494306A0240|185 214|virus-encoded structural protein
P07494306A0240|215 218|VP22
P07494306A0240|215 218|VP22
P07494314A1287|5 29|transcriptional regulation
P07494314A1287|40 61|kinase interaction sites
P07494314A1287|66 88|tyrosine phosphorylation
P07494314A1287|94 106|LMP2A homologs
P07494314A1287|94 106|LMP2A homologs
P07494314A1287|169 192|preterminal repeat regions
P07494314A1287|208 226|nonhuman primate EBVs
P07495059T0078|12 15|ECAT
P07495120A0260|79 89|cryosurgery
P07495120A0260|99 114|radiation therapy
P07495120A0260|117 119|men
P07495726A1189|19 26|Chi motif
P07495726A1189|31 45|Chi-like element
P07495726A1189|66 91|recombination hotspot region
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07495726A1189|150 159|T-ALL lines
P07496184T0001|27 34|surgical
P07496184T0001|50 56|Charite
P07496400A0525|35 43|HMGR1 mRNA
P07496400A0525|35 43|HMGR1 mRNA
P07496400A0525|45 54|HMGR1S mRNA
P07496400A0525|45 54|HMGR1S mRNA
P07496400A0525|107 116|HMGR1L mRNA
P07496400A0525|107 116|HMGR1L mRNA
P07496400A0525|201 214|inflorescences
P07498727A0724|24 27|rev3
P07498727A0724|24 27|rev3
P07498727A0724|52 52|T
P07498727A0724|73 84|rad18 mutator
P07498727A0724|73 84|rad18 mutator
P07498727A0724|140 153|rad6-mediated G
P07498727A0724|140 143|rad6
P07498727A0724|159 159|T
P07498727A0724|162 173|transversion
P07498791A0680|3 16|second mutation
P07498791A0680|37 42|mutant
P07498791A0680|74 77|PBS2
P07498791A0680|74 77|PBS2
P07498791A0680|92 112|putative protein kinase
P07498791A0680|100 112|protein kinase
P07498791A0680|131 157|high osmolarity stress pathway
P07499242A0898|2 13|adult tissues
P07499242A0898|49 63|RAFTK expression
P07499242A0898|49 53|RAFTK
P07499252A0150|2 21|hGM-CSF receptor (hGMR
P07499252A0150|2 16|hGM-CSF receptor
P07499252A0150|18 21|hGMR
P07499252A0150|67 76|PI 3-kinase
P07499252A0150|67 76|PI 3-kinase
P07499252A0150|78 81|hGMR
P07499252A0150|78 81|hGMR
P07499252A0150|143 152|PI 3-kinase
P07499252A0150|143 152|PI 3-kinase
P07499401A0444|18 29|hnRNPs H and H'
P07499401A0444|18 24|hnRNPs H
P07499401A0444|28 29|H'
P07499401A0444|43 43|H
P07499401A0444|62 63|H'
P07499409A0367|0 3|TPBF
P07499409A0367|0 3|TPBF
P07499409A0367|39 49|basic region
P07499409A0367|52 69|proline-rich region
P07499409A0367|72 94|histidine-rich N terminus
P07499409A0367|100 123|nuclear targeting sequence
P07499421A0237|59 72|rat hepatocytes
P07499421A0237|93 118|CYP3A1 5'-flanking sequences
P07499421A0237|93 118|CYP3A1 5'-flanking sequences
P07499421A0237|127 173|chloramphenicol acetyltransferase reporter plasmid
P07499421A0237|127 158|chloramphenicol acetyltransferase
P07499848A0409|23 42|resting splenic B cells
P07499848A0409|47 70|CD40L-expressing Sf9 cells
P07499848A0409|47 51|CD40L
P07499848A0409|78 113|germ-line gamma 1 and epsilon transcripts
P07499848A0409|78 92|germ-line gamma 1
P07499848A0409|129 137|cytokines
P07500386A0870|12 32|GapIII protein activity
P07500386A0870|12 24|GapIII protein
P07500386A0870|63 79|GapIII-GRD domains
P07500386A0870|63 68|GapIII
P07500386A0870|70 72|GRD
P07500386A0870|154 157|IRA1
P07500386A0870|154 157|IRA1
P07500597A0212|14 25|13 latest BPVs
P07500950A0000|1 16|tobacco homologue
P07500950A0000|1 7|tobacco
P07500950A0000|18 22|trolC
P07500950A0000|18 22|trolC
P07500950A0000|29 74|rolC gene of the Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|29 36|rolC gene
P07500950A0000|42 74|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|100 115|Nicotiana tabacum
P07500950A0000|116 119|L. cv
P07500953A0305|4 17|ADR1 gene dosage
P07500953A0305|4 11|ADR1 gene
P07500953A0305|58 76|peroxisomal proteins
P07500953A0305|101 108|ADR1 gene
P07500953A0305|101 108|ADR1 gene
P07501016T0000|1 22|water-vapour giga-maser
P07501016T0000|40 51|TXFS2226-184
P07501458A0578|15 25|C/EBP family
P07501458A0578|15 25|C/EBP family
P07501458A0578|37 46|Ig/EBP, LIP
P07501458A0578|37 42|Ig/EBP
P07501458A0578|44 46|LIP
P07501458A0578|50 56|CHOP-10
P07501458A0578|50 56|CHOP-10
P07501458A0578|62 67|Ig/EBP
P07501458A0578|62 67|Ig/EBP
P07501700A0000|47 66|monophosphoryl lipid A
P07501700A0000|68 70|MLA
P07501700A0000|89 90|v.
P07501700A0000|94 103|myocardial
P07501700A0000|122 149|repetitive coronary occlusions
P07501700A0000|163 187|barbital-anesthetized dogs
P07501992A0125|5 12|incisors
P07501992A0125|34 51|electron microscopy
P07501992A0125|59 88|dispersive spectroscopy analysis
P07501992A0125|101 115|light microscopy
P07501992A0125|164 173|rat incisor
P07501992A0125|174 185|labial dentin
P07504171A0715|1 58|platelet-derived growth factor receptor (PDGF-R) phosphopeptide
P07504171A0715|1 36|platelet-derived growth factor receptor
P07504171A0715|38 43|PDGF-R
P07504171A0715|69 75|Tyr-857
P07504171A0715|103 114|Src SH2 domain
P07504171A0715|103 114|Src SH2 domain
P07504171A0715|136 152|PDGF-R binding site
P07504171A0715|136 152|PDGF-R binding site
P07504171A0715|156 158|Src
P07504171A0715|156 158|Src
P07504171A1214|16 28|Src SH2 mutants
P07504171A1214|19 28|SH2 mutants
P07504171A1214|100 123|crystal structure solution
P07504171A1214|130 141|Src SH2 domain
P07504171A1214|130 141|Src SH2 domain
P07504712A0843|21 39|actin plaque assembly
P07504712A0843|21 25|actin
P07504712A0843|51 71|cell substrate adhesion
P07505349A0702|3 16|early lethality
P07505349A0702|22 39|left-sided resectio
P07505798A0000|11 26|immunogenic sites
P07505798A0000|32 74|type A influenza A/Japan/57 (H2N2) hemagglutinin
P07505798A0000|37 55|influenza A/Japan/57
P07505798A0000|57 74|H2N2) hemagglutinin
P07505798A0000|76 77|HA
P07505798A0000|76 77|HA
P07505798A0000|100 139|class I major histocompatibility complex (MHC
P07505798A0000|100 135|class I major histocompatibility complex
P07505798A0000|137 139|MHC
P07505798A0000|142 146|H-2Kd
P07505798A0000|158 178|cytolytic T lymphocytes
P07505798A0000|180 183|CTLs
P07506253A0742|28 49|K19 and TK basal promoters
P07506253A0742|28 30|K19
P07506253A0742|34 49|TK basal promoters
P07506253A0742|52 60|HeLa cells
P07507187T0000|24 36|DNA expression
P07507187T0000|69 99|replication-deficient adenovirus
P07507187T0000|103 112|unmodified
P07507187T0000|113 122|plasmid DNA
P07507207A0991|17 30|IRF binding site
P07507207A0991|17 30|IRF binding site
P07507207A0991|48 60|IRF-2 promoter
P07507207A0991|48 60|IRF-2 promoter
P07507207A0991|80 88|IRF-2 gene
P07507207A0991|80 88|IRF-2 gene
P07507207A0991|124 138|IRF-1 expression
P07507207A0991|124 128|IRF-1
P07507458A0250|38 45|patients
P07507458A0250|84 98|hepatitis C virus
P07507458A0250|100 102|HCV
P07507458A0250|122 126|ELISA
P07507458A0250|130 140|RIBA methods
P07508082A0821|20 36|mutagenic activity
P07508082A0821|89 96|chlorine
P07508140A0448|0 23|Hepatitis B surface antigen
P07508140A0448|38 45|patients
P07508140A0448|51 81|negative hepatitis C virus antibody
P07508250A0537|53 66|selenium intake
P07508250A0537|70 74|liver
P07508250A0537|75 82|selenium
P07508250A0537|147 154|selenium
P07508441A0487|35 45|bacterially
P07508441A0487|55 72|recombinant protein
P07508441A0487|55 72|recombinant protein
P07508441A0487|86 99|56K autoantigen
P07508441A0487|86 99|56K autoantigen
P07508441A0487|103 117|HeLa cell extract
P07508441A0487|148 154|56K cDNA
P07508441A0487|148 154|56K cDNA
P07508441A0487|188 197|nucleotide
P07508441A0487|206 222|amino acid sequence
P07508441A0487|234 248|bovine annexin XI
P07508441A0487|240 248|annexin XI
P07508441A0487|267 273|56K cDNA
P07508441A0487|267 273|56K cDNA
P07508441A0487|284 308|human homologue of annexin XI
P07508441A0487|284 297|human homologue
P07508441A0487|300 308|annexin XI
P07508441A0487|322 369|Ca(2+)-dependent phospholipid binding protein family
P07508441A0487|322 363|Ca(2+)-dependent phospholipid binding protein
P07508954A0000|3 32|avidin-biotin complex peroxidase
P07508954A0000|3 8|avidin
P07508954A0000|10 32|biotin complex peroxidase
P07508954A0000|34 45|ABC-P) method
P07508954A0000|34 38|ABC-P
P07508954A0000|61 78|Mycobacterium bovis
P07508954A0000|127 139|Ziehl-Neelsen
P07508954A0000|141 152|ZN) technique
P07509053A0139|48 52|c-Myb
P07509053A0139|48 52|c-Myb
P07509053A0139|95 114|hematopoietic lineage
P07509449A0000|3 18|transforming gene
P07509449A0000|24 44|avian sarcoma virus CT10
P07509449A0000|24 44|avian sarcoma virus CT10
P07509449A0000|53 65|fusion protein
P07509449A0000|67 76|p47gag-crk
P07509449A0000|67 72|p47gag
P07509449A0000|74 76|crk
P07509449A0000|79 83|v-Crk
P07509449A0000|79 83|v-Crk
P07509449A0000|95 111|viral Gag sequences
P07509449A0000|95 111|viral Gag sequences
P07509449A0000|157 198|Src homology regions 2 and 3 (SH2 and SH3 sequences
P07509449A0000|157 175|Src homology regions 2
P07509449A0000|179 179|3
P07509449A0000|181 183|SH2
P07509449A0000|187 198|SH3 sequences
P07509450A0705|4 29|specific methylation pattern
P07509450A0705|53 61|HSV tk gene
P07509450A0705|53 61|HSV tk gene
P07509450A0705|68 78|methylation
P07509450A0705|84 99|cytosine residues
P07509450A0705|109 126|nucleotide sequence
P07509450A0705|131 141|+811 to +1309
P07509450A0705|155 171|HSV tk gene activity
P07509450A0705|155 163|HSV tk gene
P07509472A1320|88 102|alpha interferon
P07509472A1320|88 102|alpha interferon
P07509624T0000|0 16|Long-range mapping
P07509624T0000|22 32|11q23 region
P07509624T0000|43 63|chromosome aberrations
P07509624T0000|66 76|human tumors
P07509624T0000|79 108|pulsed-field gel electrophoresis
P07509811A1357|0 3|GTRE
P07509811A1357|12 30|CRE oligonucleotides
P07509811A1357|142 157|oligonucleotides
P07509811A1357|176 179|GTRE
P07509811A1357|188 206|CRE oligonucleotides
P07509811A1357|225 228|GTRE
P07509811A1357|237 255|CRE oligonucleotides
P07509811A1357|278 291|common proteins
P07509811A1357|315 321|Jun/Fos
P07509811A1357|315 317|Jun
P07509811A1357|319 321|Fos
P07509811A1357|325 392|cAMP-responsive element-binding protein/activating transcription factors
P07509811A1357|325 392|cAMP-responsive element-binding protein/activating transcription factors
P07509811A1357|394 410|CREB/ATF) families
P07509811A1357|394 397|CREB
P07509811A1357|399 401|ATF
P07509811A1357|413 432|transcription factors
P07509811A1357|436 450|chromaffin cells
P07510635A0479|12 17|mAb1C2
P07510635A0479|12 17|mAb1C2
P07510635A0479|23 38|synthetic peptide
P07510635A0479|52 58|epitope
P07510635A0479|103 117|TATA-containing
P07510635A0479|129 146|TATA-less promoters
P07510635A0479|190 194|Pol II
P07510635A0479|190 194|Pol II
P07510635A0479|197 202|Pol III
P07510635A0479|197 202|Pol III
P07510724A1208|25 32|patients
P07510724A1208|37 55|rheumatoid arthritis
P07510724A1208|84 94|granulomata
P07510724A1208|140 150|sarcoidosis
P07510724A1208|154 172|rheumatoid arthritis
P07511444A0728|33 35|BMT
P07511444A0728|50 64|acute hepatitis C
P07511444A0728|83 99|chronic hepatitis C
P07511444A0728|105 111|patient
P07511444A0728|133 135|BMT
P07511444T0000|0 23|Hepatitis C virus infection
P07511444T0000|40 51|liver failure
P07511444T0000|56 76|veno-occlusive disease
P07511444T0000|82 106|bone marrow transplantation
P07511496A1511|4 23|plasma concentrations
P07511496A1511|33 42|E-selectin
P07511496A1511|33 42|E-selectin
P07511496A1511|68 92|multiple-organ dysfunction
P07511818A0485|10 44|IFN-beta-transformed cell populations
P07511818A0485|10 17|IFN-beta
P07511818A0485|86 93|human IFN
P07511818A0485|86 93|human IFN
P07511818A0485|133 150|untransformed cells
P07511818A0485|201 221|human IFN-beta sequence
P07511818A0485|206 221|IFN-beta sequence
P07511818A0485|241 254|mutated protein
P07512159A0992|16 34|polypyrimidine tract
P07512159A0992|117 135|branchpoint mutation
P07512258A0441|5 19|transplantation
P07512258A0441|40 61|metabolic complications
P07512258A0441|78 85|PMN count
P07512258A0441|91 106|infectious status
P07512258A0441|113 123|neutropenia
P07512258A0441|138 142|G-CSF
P07512258A0441|138 142|G-CSF
P07512552A0270|0 3|Joys
P07513703T0000|15 54|SH2-containing protein tyrosine phosphatase
P07513703T0000|15 54|SH2-containing protein tyrosine phosphatase
P07513703T0000|56 62|SH-PTP2
P07513703T0000|56 62|SH-PTP2
P07513703T0000|66 99|phosphotyrosine-containing peptides
P07513703T0000|111 136|insulin receptor substrate-1
P07513703T0000|111 136|insulin receptor substrate-1
P07514295A0000|0 22|Tyrosine phosphorylation
P07514295A0000|25 40|cellular proteins
P07514295A0000|25 40|cellular proteins
P07514295A0000|54 70|identifiable event
P07514295A0000|80 116|T-cell antigen receptor (TCR) stimulation
P07514295A0000|80 100|T-cell antigen receptor
P07514295A0000|102 104|TCR
P07514295A0000|144 171|downstream signaling machinery
P07514301A0000|3 46|interferon-induced RNA-dependent protein kinase
P07514301A0000|3 12|interferon
P07514301A0000|21 46|RNA-dependent protein kinase
P07514301A0000|48 50|PKR
P07514301A0000|48 50|PKR
P07514301A0000|112 125|viral infection
P07514301A0000|162 180|tumor suppressor gene
P07514301A0000|193 220|growth-suppressive properties
P07516337A1119|9 11|Lck
P07516337A1119|9 11|Lck
P07516337A1119|50 55|p95Vav
P07516337A1119|50 55|p95Vav
P07516337A1119|96 122|anti-CD3-treated Jurkat cells
P07516337A1119|96 103|anti-CD3
P07516466A1054|23 29|plasmid
P07516466A1054|38 63|simian virus 40 small t antigen
P07516466A1054|38 63|simian virus 40 small t antigen
P07516466A1054|83 86|PP2A
P07516466A1054|83 86|PP2A
P07516466A1054|121 134|phosphoprotein
P07516466A1054|184 187|CREB
P07516466A1054|184 187|CREB
P07516466A1054|214 224|NIH 3T3 cells
P07516469A1025|7 28|Src SH3-binding proteins
P07516469A1025|7 28|Src SH3-binding proteins
P07516469A1025|49 68|Src-transformed cells
P07516469A1025|49 51|Src
P07516597A1017|98 115|viral proteinase NS3
P07516597A1017|103 112|proteinase
P07516597A1017|113 115|NS3
P07516597A1017|118 134|antigen processing
P07516597A1017|155 189|MVE H-2Kk-restricted T cell determinant
P07516866A0000|1 44|full-length PRL receptor (PRLR) complementary DNA
P07516866A0000|1 22|full-length PRL receptor
P07516866A0000|24 27|PRLR
P07516866A0000|49 55|pigeons
P07516866A0000|78 99|pigeon crop sac libraries
P07516866A0000|105 124|reverse transcription
P07516866A0000|136 158|polymerase chain reaction
P07517544A0515|68 101|caerulein-induced acute pancreatitis
P07517544A0515|130 146|secretory function
P07517544A0515|152 159|pancreas
P07517544A0515|199 207|L-364,718
P07517869A0411|14 30|dephosphorylation
P07517869A0411|50 67|DNA-binding ability
P07517869A0411|70 80|C/EBP-delta
P07517869A0411|70 80|C/EBP-delta
P07517869A0411|135 163|cellular phosphatase inhibitors
P07517869A0411|135 153|cellular phosphatase
P07517869A0411|171 181|okadaic acid
P07517869A0411|185 203|sodium orthovanadate
P07518257A0351|3 11|promoters
P07518257A0351|28 37|S1 nuclease
P07518257A0351|30 44|nuclease mapping
P07518257A0351|46 47|P1
P07518257A0351|46 47|P1
P07518257A0351|82 95|structural gene
P07518257A0351|100 101|P2
P07518426A0000|0 12|Interleukin-8
P07518426A0000|0 12|Interleukin-8
P07518426A0000|14 17|IL-8
P07518426A0000|14 17|IL-8
P07518426A0000|28 47|inflammatory mediator
P07518426A0000|72 86|C-X-C chemokines
P07518426A0000|72 74|C-X
P07518460A0771|31 35|PTP1C
P07518460A0771|31 35|PTP1C
P07518460A0771|46 58|catalytic site
P07518460A0771|119 129|phosphatase
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518561A0496|78 91|TCR/CD3 complex
P07518561A0496|78 80|TCR
P07518561A0496|82 84|CD3
P07518561A0496|164 169|T cells
P07518561A0496|177 182|p56lck
P07518561A0496|177 182|p56lck
P07518578A0000|3 21|transforming protein
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|41 49|pp60v-src
P07518578A0000|41 49|pp60v-src
P07518578A0000|63 77|cellular homolog
P07518578A0000|79 87|pp60c-src
P07518578A0000|79 87|pp60c-src
P07518578A0000|104 121|oncogenic potential
P07518578A0000|136 158|subcellular localization
P07518578A0000|162 187|cytoskeletal binding ability
P07518578A0000|189 197|pp60v-src
P07518578A0000|189 197|pp60v-src
P07518578A0000|232 268|detergent-insoluble cytoskeletal matrix
P07518578A0000|277 285|pp60c-src
P07518578A0000|277 285|pp60c-src
P07519447T0000|0 11|Organization
P07519447T0000|17 26|bovine gene
P07519447T0000|38 67|endothelial nitric oxide synthase
P07519447T0000|38 67|endothelial nitric oxide synthase
P07519463A0000|27 36|myocardial
P07519463A0000|123 128|inflow
P07519481A1275|2 9|female Sl
P07519481A1275|11 17|pan)/Sl
P07519481A1275|11 14|pan)
P07519481A1275|16 17|Sl
P07519481A1275|19 21|pan
P07519481A1275|19 21|pan
P07519481A1275|23 26|mice
P07519481A1275|28 53|ovarian follicle development
P07519481A1275|110 121|KL expression
P07519481A1275|110 111|KL
P07519481A1275|124 136|follicle cells
P07519481A1275|156 160|c-kit
P07519481A1275|156 160|c-kit
P07519481A1275|163 174|oocyte growth
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|63 77|5-10-kDa proSP-C
P07519606A1269|71 77|proSP-C
P07519606A1269|85 98|lamellar bodies
P07519606A1269|102 112|homogenates
P07520098A0211|5 39|B6-derived Db mutant B6.CH-2bm13 (bm13)
P07520098A0211|5 24|B6-derived Db mutant B6
P07520098A0211|26 45|CH-2bm13 (bm13) strain
P07520098A0211|56 70|class I Db antigen
P07520098A0211|56 63|class I Db
P07520098A0211|64 87|antigen-presenting groove
P07520098A0211|99 122|class I Kb-encoded sequence
P07520098A0211|99 122|class I Kb-encoded sequence
P07521009A0377|13 16|pms1
P07521009A0377|13 16|pms1
P07521009A0377|18 21|pms2
P07521009A0377|18 21|pms2
P07521009A0377|25 28|pms3
P07521009A0377|25 28|pms3
P07521009A0377|49 56|MW104-1B
P07521009A0377|112 124|DNA mismatches
P07521009A0377|126 136|G/T, A/C, G/G
P07521009A0377|126 126|G
P07521009A0377|128 128|T
P07521009A0377|130 130|A
P07521009A0377|132 132|C
P07521009A0377|134 134|G
P07521009A0377|136 136|G
P07521009A0377|162 166|1989a
P07521285A1109|36 55|proximal nerve lesions
P07521285A1109|63 65|GBS
P07521285A1109|69 72|CIDP
P07521285A1109|115 137|conduction abnormalities
P07521285A1109|165 187|multiple F wave parameters
P07521285A1109|236 244|amplitude
P07521601A0000|0 25|Hematopoietic growth factors
P07521601A0000|0 25|Hematopoietic growth factors
P07521601A0000|63 74|myelopoiesis
P07521601A0000|84 104|high-dose chemotherapy
P07521601A0000|107 120|cancer patients
P07521916T0000|22 48|primer-binding site sequences
P07521916T0000|51 92|human immunodeficiency virus type 1 replication
P07521916T0000|51 81|human immunodeficiency virus type 1
P07522163T0000|15 37|horse cytochrome c peptide
P07522163T0000|15 30|horse cytochrome c
P07522163T0000|48 87|H-2b class I major histocompatibility complex
P07522163T0000|48 51|H-2b
P07522163T0000|52 101|class I major histocompatibility complex (MHC) molecules
P07522163T0000|89 91|MHC
P07522163T0000|104 109|C57BL/
P07522163T0000|115 146|bm1-derived cytotoxic T lymphocytes
P07522163T0000|159 167|single MHC
P07522163T0000|165 180|MHC anchor residue
P07522163T0000|168 180|anchor residue
P07522163T0000|199 228|peptide-specific CTL recognition
P07523363A0440|21 43|HpaII tiny fragment island
P07523363A0440|21 25|HpaII
P07523363A0440|69 77|base pairs
P07523363A0440|91 119|USF2 translation initiation site
P07523363A0440|91 94|USF2
P07523710T0000|0 8|Diagnosis
P07523710T0000|11 28|prostatic carcinoma
P07523710T0000|45 67|prostate specific antigen
P07523710T0000|45 67|prostate specific antigen
P07523710T0000|69 92|digital rectal examination
P07523710T0000|96 121|transrectal ultrasonography
P07524265T0000|9 43|granulocyte-colony stimulating factor
P07524265T0000|9 43|granulocyte-colony stimulating factor
P07524265T0000|45 49|G-CSF
P07524265T0000|45 49|G-CSF
P07524265T0000|59 66|neonates
P07524265T0000|71 92|perinatal complications
P07525548A1380|30 45|ligand affinities
P07525548A1380|63 78|adhesive activity
P07525548A1380|80 87|rsVCAM-1
P07525548A1380|80 87|rsVCAM-1
P07525548A1380|89 107|fibronectin variants
P07525548A1380|89 99|fibronectin
P07525548A1380|118 120|CS1
P07525548A1380|118 120|CS1
P07525548A1380|128 146|fibronectin variants
P07525548A1380|128 146|fibronectin variants
P07525596A0584|30 44|Escherichia coli
P07525596A0584|50 64|full-length Fpr3
P07525596A0584|61 64|Fpr3
P07525596A0584|79 97|COOH-terminal domain
P07525596A0584|122 135|PPIase activity
P07525596A0584|122 127|PPIase
P07525843A0859|0 8|Dilutions
P07525843A0859|11 14|H-2b
P07525843A0859|11 14|H-2b
P07525843A0859|17 30|H-2d NP peptides
P07525843A0859|17 20|H-2d
P07525843A0859|21 30|NP peptides
P07525843A0859|55 67|H-2b NP peptide
P07525843A0859|55 58|H-2b
P07525843A0859|59 67|NP peptide
P07525843A0859|90 98|syngeneic
P07525843A0859|113 129|CTL-specific lysis
P07525843A0859|169 179|H-2b and H-2d
P07525843A0859|169 172|H-2b
P07525843A0859|176 209|H-2d major histocompatibility complex
P07525843A0859|180 218|major histocompatibility complex molecules
P07525843A0859|268 269|NP
P07525843A0859|278 285|H-2b mice
P07525843A0859|278 281|H-2b
P07525843A0859|309 316|H-2d mice
P07525843A0859|336 337|NP
P07526609A0736|20 31|sigma 3 from S4
P07526609A0736|20 25|sigma 3
P07526609A0736|30 37|S4 (3'UTR
P07526609A0736|33 37|3'UTR
P07526609A0736|39 40|S1
P07526609A0736|39 40|S1
P07526609A0736|59 78|PKR activator sequence
P07526609A0736|59 78|PKR activator sequence
P07526609A0736|83 84|S1
P07526609A0736|94 99|3'-UTR
P07526609A0736|102 103|S4
P07526609A0736|102 103|S4
P07526609A0736|128 138|wild-type S4
P07526609A0736|128 138|wild-type S4
P07527168A0524|0 11|Microvessels
P07527168A0524|26 34|x200 field
P07527168A0524|63 74|angiogenesis
P07528028A1192|12 31|transfected cell lines
P07528028A1192|39 63|FGF-1 cell surface receptors
P07528028A1192|39 43|FGF-1
P07528028A1192|44 63|cell surface receptors
P07528028A1192|97 118|wild-type transfectants
P07528028A1192|143 147|FGF-1
P07528028A1192|143 147|FGF-1
P07528028A1192|159 177|mutant transfectants
P07528325A0165|45 54|GH receptor
P07528325A0165|45 54|GH receptor
P07528325A0165|67 71|Stat1
P07528325A0165|67 71|Stat1
P07528325A0165|74 103|cytoplasmic transcription factor
P07528325A0165|74 103|cytoplasmic transcription factor
P07528325A0165|115 122|tyrosine
P07528325A0165|157 163|nucleus
P07528325A0165|195 206|DNA sequences
P07528325A0165|217 230|gene expression
P07528531A0904|2 16|viral infections
P07528531A0904|18 22|G-CSF
P07528531A0904|18 22|G-CSF
P07528531A0904|40 55|mononuclear cells
P07528531A0904|73 92|white blood cell counts
P07528531A0904|110 120|neutrophils
P07528531A0904|140 142|CRP
P07528531A0904|140 142|CRP
P07528667A0834|0 19|Minor initiation sites
P07528667A0834|40 59|-128, -111, -91, and -74
P07528746A1049|0 23|Phosphoamino acid analysis
P07528746A1049|26 42|radiolabeled ASGPR
P07528746A1049|38 50|ASGPR subunits
P07528746A1049|61 63|Ser
P07528746A1049|65 66|P)
P07528746A1049|104 106|Thr
P07528746A1049|108 109|P)
P07528746A1049|193 195|Tyr
P07528746A1049|193 195|Tyr
P07528746A1049|197 198|P)
P07528746A1049|197 197|P
P07528746A1049|218 222|RHL1.
P07528746A1049|218 221|RHL1
P07528772A0616|43 48|ZAP-70
P07528772A0616|43 48|ZAP-70
P07528772A0616|67 69|TCR
P07528772A0616|67 69|TCR
P07528772A0616|83 94|binding assay
P07528772A0616|111 148|glutathione S-transferase fusion proteins
P07528772A0616|111 148|glutathione S-transferase fusion proteins
P07528772A0616|162 194|NH2- and/or COOH-terminal SH2 domains
P07528772A0616|185 187|SH2
P07528772A0616|197 202|ZAP-70
P07528772A0616|197 202|ZAP-70
P07528772A0616|207 230|soluble synthetic peptides
P07528772A0616|251 267|cytoplasmic region
P07528772A0616|273 284|TCR zeta chain
P07528772A0616|273 284|TCR zeta chain
P07528772A0616|286 295|TCR zeta cyt
P07528772A0616|286 295|TCR zeta cyt
P07528772A0616|309 315|TCR zeta
P07528772A0616|309 315|TCR zeta
P07528772A0616|319 337|CD3 epsilon TAM motifs
P07528772A0616|319 337|CD3 epsilon TAM motifs
P07528772A1539|35 45|TAM peptides
P07528772A1539|35 37|TAM
P07528772A1539|87 102|tandem SH2 domains
P07528772A1539|93 95|SH2
P07528772A1539|105 110|ZAP-70
P07528772A1539|105 110|ZAP-70
P07529124A0119|3 28|three-dimensional structure
P07529124A0119|31 32|RT
P07529124A0119|31 32|RT
P07529124A0119|57 66|asymmetric
P07529124A0119|67 77|heterodimer
P07529124A0119|162 207|amino-terminal amino acid sequences (residues 1-428
P07529504A0000|0 14|Pharmacological
P07529504A0000|18 47|pharmacokinetic characteristics
P07529504A0000|53 61|non-ionic
P07529504A0000|71 75|X-ray
P07529504A0000|89 97|iopromide
P07529504A0000|99 107|Ultravist
P07529504A0000|109 116|CAS 73334
P07529516A0474|3 12|subsequent
P07529516A0474|13 20|patients
P07529516A0474|59 62|EDXR
P07530128A0578|3 22|median post-treatment
P07530128A0578|42 44|PSA
P07530128A0578|42 44|PSA
P07530502A0974|17 35|recombinant human SLF
P07530502A0974|17 35|recombinant human SLF
P07530502A0974|38 53|SI4-h220 cultures
P07530502A0974|73 99|cell-surface c-kit expression
P07530502A0974|85 89|c-kit
P07530502A0974|106 123|protein degradation
P07530502T0000|0 13|Membrane-bound
P07530502T0000|14 24|Steel factor
P07530502T0000|14 24|Steel factor
P07530502T0000|46 69|tyrosine kinase activation
P07530502T0000|89 112|c-kit gene-encoded protein
P07530502T0000|89 112|c-kit gene-encoded protein
P07530502T0000|120 130|soluble form
P07530549A0956|29 33|BLAST
P07530549A0956|37 49|GRAIL programs
P07530549A0956|115 129|coding sequences
P07531321A0369|0 7|Patients
P07531321A0369|63 65|PVC
P07531321A0369|69 80|CI evaluation
P07532278A0833|0 6|Horvath
P07533527A0128|0 8|Cell lines
P07533527A0128|23 28|tumors
P07533527A0128|43 72|fluorescent in situ hybridization
P07533527A0128|101 115|human chromosome
P07533758A1038|3 20|amino acid sequences
P07533758A1038|35 38|RfbA
P07533758A1038|35 38|RfbA
P07533758A1038|42 53|RfbB homologs
P07533758A1038|42 53|RfbB homologs
P07533858A1503|8 22|multiple alanine
P07533858A1503|38 64|proline (helix-destabilizing
P07533858A1503|92 118|oligomerization and transport
P07533858A1503|121 127|GP64 EFP
P07533858A1503|121 127|GP64 EFP
P07533880T0000|3 13|FinO protein
P07533880T0000|3 6|FinO
P07533880T0000|16 27|IncF plasmids
P07533880T0000|33 48|FinP antisense RNA
P07533880T0000|33 48|FinP antisense RNA
P07533880T0000|62 69|traJ mRNA
P07533880T0000|62 69|traJ mRNA
P07533880T0000|82 96|duplex formation
P07534285A0155|23 65|ligand binding induced tyrosine phosphorylation
P07534285A0155|68 76|BaF3 cells
P07534285A0155|99 115|murine Mpl receptor
P07534285A0155|99 115|murine Mpl receptor
P07534285A0155|117 125|BaF3/mMpl
P07534285A0155|117 120|BaF3
P07534285A0155|122 125|mMpl
P07534286A0842|8 19|paxillin cDNA
P07534286A0842|8 15|paxillin
P07534286A0842|90 103|human paxil-lin
P07534286A0842|90 103|human paxil-lin
P07534297A0141|9 42|4.1-kilobase pair HindIII DNA fragment
P07534297A0141|25 42|HindIII DNA fragment
P07534297A0141|69 91|human AP endonuclease gene
P07534297A0141|69 91|human AP endonuclease gene
P07534297A0141|93 95|APE
P07534297A0141|93 95|APE
P07534297A0141|102 142|chloramphenicol acetyltransferase (CAT) gene
P07534297A0141|102 133|chloramphenicol acetyltransferase
P07534297A0141|135 137|CAT
P07534306A0444|16 41|His6-tagged GrsA derivatives
P07534306A0444|16 26|His6-tagged
P07534306A0444|27 41|GrsA derivatives
P07534306A0444|150 152|ATP
P07534306A0444|163 181|amino acid activation
P07534306A0444|183 208|carboxyl thioester formation
P07534306A0444|236 263|covalently bound phenylalanine
P07534306A0444|268 268|L
P07534306A0444|275 282|D-isomer
P07534306A0444|275 282|D-isomer
P07535593A0714|0 24|CD7+/CD3- T-cell precursors
P07535593A0714|0 3|CD7+
P07535593A0714|5 24|CD3- T-cell precursors
P07535593A0714|32 59|V delta 2D delta 3 rearrangements
P07535768A1076|0 7|HVH2 mRNA
P07535768A1076|0 7|HVH2 mRNA
P07535768A1076|45 49|CL100
P07535768A1076|45 49|CL100
P07535768A1076|51 64|human homologue
P07535768A1076|67 75|mouse MKP1
P07535768A1076|67 75|mouse MKP1
P07535768A1076|80 83|PAC1
P07535768A1076|80 83|PAC1
P07535768A1076|108 128|MAP kinase phosphatases
P07535768A1076|108 128|MAP kinase phosphatases
P07537267A2094|74 87|HPFH-3 deletion
P07537267A2094|74 79|HPFH-3
P07537267A2094|130 137|enhancer
P07537267A2094|154 177|developmental specificity
P07537267A2094|183 204|fetal gamma-globin genes
P07537267A2094|183 204|fetal gamma-globin genes
P07537267A2094|247 255|adult life
P07537362A1112|24 26|Shb
P07537362A1112|28 44|SH3 domain proteins
P07537362A1112|45 49|v-Src
P07537362A1112|45 49|v-Src
P07537362A1112|53 56|Eps8
P07537362A1112|53 56|Eps8
P07537362A1112|70 90|coimmunoprecipitation
P07537736A0453|40 43|Jak2
P07537736A0453|40 43|Jak2
P07537736A0453|47 50|PRLR
P07537736A0453|47 50|PRLR
P07537736A0453|60 79|proline-rich sequence
P07537736A0453|85 106|membrane proximal region
P07537736A0453|112 119|receptor
P07537736A0453|166 192|cytokine receptor superfamily
P07537736A0453|166 192|cytokine receptor superfamily
P07537851A0000|0 12|Transcription
P07537851A0000|18 46|vascular cell adhesion molecule 1
P07537851A0000|18 46|vascular cell adhesion molecule 1
P07537851A0000|48 58|VCAM-1) gene
P07537851A0000|48 53|VCAM-1
P07537851A0000|61 76|endothelial cells
P07537851A0000|88 105|lipopolysaccharide
P07537851A0000|112 132|inflammatory cytokines
P07537851A0000|133 149|interleukin-1 beta
P07537851A0000|133 149|interleukin-1 beta
P07537851A0000|153 176|tumor necrosis factor alpha
P07537851A0000|153 176|tumor necrosis factor alpha
P07537851A0000|178 186|TNF-alpha
P07537851A0000|178 186|TNF-alpha
P07537851A0891|15 33|recombinant proteins
P07537851A0891|15 33|recombinant proteins
P07537851A0891|44 50|p50/p65
P07537851A0891|44 46|p50
P07537851A0891|48 50|p65
P07537851A0891|54 83|high-mobility-group I(Y) protein
P07537851A0891|54 73|high-mobility-group I
P07537851A0891|75 83|Y) protein
P07537851A0891|120 124|IRF-1
P07537851A0891|120 124|IRF-1
P07537851A0891|130 148|VCAM1 IRF binding site
P07537851A0891|130 134|VCAM1
P07537851A0891|135 148|IRF binding site
P07537851A0891|156 160|IRF-1
P07537851A0891|156 160|IRF-1
P07537851A0891|185 187|p50
P07537851A0891|185 187|p50
P07537851A0891|195 224|high-mobility-group I(Y) protein
P07537851A0891|195 214|high-mobility-group I
P07537851A0891|216 216|Y
P07538068A1094|22 42|minimal control element
P07538068A1094|44 48|AX 470
P07538068A1094|63 70|anterior
P07538068A1094|81 93|Hox expression
P07538068A1094|81 83|Hox
P07538068A1094|109 122|Hoxa-7 enhancer
P07538068A1094|109 114|Hoxa-7
P07538122A0800|37 47|Fab fragment
P07538122A0800|49 53|Fab A8
P07538122A0800|52 53|A8
P07538173A0307|0 45|MBP-Rep68 delta-mediated DNA-RNA helicase activity
P07538173A0307|0 2|MBP
P07538173A0307|4 13|Rep68 delta
P07538173A0307|23 37|DNA-RNA helicase
P07538173A0307|83 90|Mg2+ ions
P07538173A0307|108 124|high ionic strength
P07538818A0197|34 57|growth signal transduction
P07538818A0197|60 66|hG-CSFR
P07538818A0197|60 66|hG-CSFR
P07538818A0197|79 113|site-directed amino acid substitutions
P07538818A0197|135 151|cytoplasmic domain
P07538818A0197|154 160|hG-CSFR
P07538818A0197|154 160|hG-CSFR
P07538818A0197|168 178|mutant cDNAs
P07538818A0197|168 178|mutant cDNAs
P07538818A0197|201 219|murine interleukin-3
P07538818A0197|201 219|murine interleukin-3
P07538818A0197|221 256|IL-3)-dependent Ba/F3 and FDCP cell lines
P07538818A0197|221 237|IL-3)-dependent Ba
P07538818A0197|239 240|F3
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|70 81|NH2-terminus
P07539119A0291|70 81|NH2-terminus
P07539119A0291|86 98|G128R mutation
P07539119A0291|86 90|G128R
P07539119A0291|125 136|double mutant
P07539119A0291|155 165|G128R mutant
P07539119A0291|155 165|G128R mutant
P07539119A0985|4 12|mutations
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|58 83|proline-rich target proteins
P07539119A0985|87 105|filter-binding assay
P07539314T0000|26 33|milkfish
P07539314T0000|35 54|Chanos chanos Forsskal
P07539314T0000|87 98|nifurpirinol
P07539314T0000|100 107|Furanace
P07540607A0709|0 10|Retreatment
P07540607A0709|63 81|human immunoglobulin
P07540607A0709|63 81|human immunoglobulin
P07540773A0576|11 13|NSE
P07540773A0576|11 13|NSE
P07540773A0576|17 19|MBP
P07540773A0576|17 19|MBP
P07540773A0576|25 28|IJVB
P07540773A0576|53 55|PVB
P07540866A1069|14 26|insulin effect
P07540866A1069|14 20|insulin
P07540866A1069|37 51|ras GTP formation
P07540866A1069|37 42|ras GTP
P07540866A1069|55 71|MAP kinase activity
P07540866A1069|55 63|MAP kinase
P07540866A1069|87 98|A/K1018 cells
P07540866A1069|111 121|supernormal
P07540866A1069|123 133|in Y/F2 cells
P07540866A1069|125 125|Y
P07540866A1069|127 128|F2
P07541589A0652|0 19|Morphologic variables
P07541589A0652|28 39|cancer volume
P07541589A0652|57 75|capsular penetration
P07541589A0652|77 98|seminal vesicle invasion
P07541589A0652|103 121|lymph node metastasis
P07541912A0485|0 15|Sequence analysis
P07541912A0485|37 43|CAAT box
P07541912A0485|54 59|exon 1a
P07541912A0485|54 59|exon 1a
P07541912A0485|63 69|high G-C
P07541912A0485|67 76|G-C content
P07541912A0485|94 95|P1
P07541912A0485|94 95|P1
P07541912A0485|99 100|P2
P07541912A0485|99 100|P2
P07542577A0438|3 16|fusion proteins
P07542577A0438|29 33|ELISA
P07542577A0438|59 74|human anti-La sera
P07542577A0438|59 74|human anti-La sera
P07542577A0438|104 111|epitopes
P07542616A0313|0 4|GCD10
P07542616A0313|0 4|GCD10
P07542616A0313|61 64|GCN4
P07542616A0313|61 64|GCN4
P07542616A0486|0 4|GCD10
P07542616A0486|0 4|GCD10
P07542616A0486|79 96|RNA-binding subunit
P07542616A0486|79 96|RNA-binding subunit
P07542616A0486|99 121|yeast initiation factor-3
P07542616A0486|99 121|yeast initiation factor-3
P07542616A0486|123 127|eIF-3
P07542616A0486|123 127|eIF-3
P07542616A0486|130 134|eIF-3
P07542616A0486|130 134|eIF-3
P07542616A0486|138 156|multisubunit complex
P07542616A0486|171 191|translation initiation
P07542698A0137|0 6|Sources
P07542698A0137|69 93|potentiometric probe RH-414
P07543592A0624|1 30|transformation-competent mutant
P07543592A0624|39 56|wild-type E5 protein
P07543592A0624|39 56|wild-type E5 protein
P07543592A0624|66 114|receptor and induced receptor tyrosine phosphorylation
P07543592A0624|118 132|down-regulation
P07543684A1027|14 17|cAMP
P07543684A1027|32 34|PKA
P07543684A1027|32 34|PKA
P07543684A1027|60 82|basal CFTR gene expression
P07543684A1027|65 72|CFTR gene
P07543684A1027|109 112|CFTR
P07543684A1027|109 112|CFTR
P07543684A1027|115 133|responsive cell types
P07543868A0414|0 21|Appropriate restriction
P07543868A0414|37 42|insert
P07543868A0414|62 73|cDNA fragment
P07543868A0414|125 128|long
P07543868A0414|129 139|poly(A) tail
P07544357A0808|4 8|PPC-1
P07544357A0808|12 15|ALVA
P07544357A0808|47 58|invasiveness
P07544357A0808|61 68|nude mice
P07544357A0808|77 86|LNCap cells
P07544357A0808|99 116|malignant phenotype
P07544357A0808|147 174|CD44 variant (CD44v) expression
P07544357A0808|147 157|CD44 variant
P07544357A0808|159 163|CD44v
P07544357A0808|188 208|prostate tumor behavior
P07545510A0735|16 19|cotS
P07545510A0735|16 19|cotS
P07545510A0735|47 53|Cot40-2
P07545510A0735|47 53|Cot40-2
P07545510A0735|56 63|SDS-PAGE
P07545510A0735|67 80|immunoblotting
P07545510A0735|85 99|Escherichia coli
P07545510A0735|136 145|cotS region
P07545510A0735|136 145|cotS region
P07545920A1336|23 32|hsiggll150
P07545920A1336|23 32|hsiggll150
P07545920A1336|36 45|hsiggll295
P07545920A1336|36 45|hsiggll295
P07545920A1336|73 82|genomic DNA
P07546256A0000|71 78|children
P07546293A0968|21 34|protein binding
P07546293A0968|40 56|E2F-like sequences
P07546293A0968|40 56|E2F-like sequences
P07546293A0968|71 80|expression
P07546294A0000|3 15|RAD6/UBC2 gene
P07546294A0000|3 6|RAD6
P07546294A0000|8 11|UBC2
P07546294A0000|20 42|Saccharomyces cerevisiae
P07546294A0000|20 42|Saccharomyces cerevisiae
P07546294A0000|51 77|ubiquitin-conjugating enzyme
P07546294A0000|51 71|ubiquitin-conjugating
P07546294A0000|88 96|DNA repair
P07546294A0000|105 115|mutagenesis
P07546794A0100|0 15|Echocardiography
P07546794A0100|24 61|right ventricular diastolic collapse (RVDC
P07546794A0100|85 100|cardiac tamponade
P07547220A0229|2 28|on-going screening programmes
P07547500A0066|22 35|a fusion protein
P07547500A0066|23 35|fusion protein
P07547500A0066|37 44|GAL4-p40
P07547500A0066|37 40|GAL4
P07547500A0066|42 44|p40
P07547500A0066|59 75|DNA-binding domain
P07547500A0066|59 75|DNA-binding domain
P07547500A0066|78 93|GAL4 and sequences
P07547500A0066|78 81|GAL4
P07547500A0066|96 115|chicken l kappa B-alpha
P07547500A0066|96 115|chicken l kappa B-alpha
P07547500A0066|117 119|p40
P07547500A0066|117 119|p40
P07547500A0066|140 144|yeast
P07547500A0066|145 167|Saccharomyces cerevisiae
P07547510A0261|35 46|binding sites
P07547510A0261|52 72|-184 HNF-3 beta promoter
P07547510A0261|52 72|-184 HNF-3 beta promoter
P07547510A0261|139 156|autoregulatory site
P07547510A0261|171 181|binding site
P07547510A0261|185 204|a cell-specific factor
P07547510A0261|186 204|cell-specific factor
P07547510A0261|206 214|LF-H3 beta
P07547510A0261|206 214|LF-H3 beta
P07547510A0261|244 256|HNF-3 beta gene
P07547510A0261|244 252|HNF-3 beta
P07547510A0261|269 279|hepatocytes
P07548425A0000|3 16|spinalized cats
P07548425A0000|30 43|afferent inputs
P07548425A0000|48 90|hindlimb cutaneous nerves (sural cutaneous nerve
P07548425A0000|92 94|Sur
P07548425A0000|106 118|poly-synaptic
P07548425A0000|137 157|tail muscle motoneurons
P07548425A0000|183 197|spinal lesioning
P07548425A0000|200 203|S2-3
P07548425A0000|200 201|S2
P07548425A0000|202 208|-3 level
P07548858A0000|3 10|flow rate
P07548858A0000|13 35|phosphate buffered saline
P07548858A0000|43 48|dermis
P07549005A0530|8 27|parallax measurements
P07549005A0530|40 52|150K, collapse
P07549005A0530|55 66|Epon sections
P07550216A0195|27 33|latency
P07551787A0917|112 116|ideal
P07551787A0917|127 147|radiotherapy technique
P07552974A0217|23 46|branched-chain amino acids
P07552974A0217|48 56|glutamine
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|31 37|introns
P07553942A0810|40 44|rrn26
P07553942A0810|40 44|rrn26
P07553942A0810|48 51|cox3
P07553942A0810|48 51|cox3
P07553942A0810|57 85|Marchantia mitochondrial genome
P07553942A0810|95 113|Marchantia rps10 gene
P07553942A0810|95 113|Marchantia rps10 gene
P07553942A0810|121 126|intron
P07554541A0587|16 25|CHF patient
P07554541A0587|68 90|electrolyte disturbances
P07555373A0000|0 13|Serum magnesium
P07555373A0000|28 47|gynecologic neoplasms
P07555373A0000|59 67|cisplatin
P07555373A0000|76 83|controls
P07557091A0314|8 13|rHb1.1
P07557091A0314|8 13|rHb1.1
P07557091A0314|16 32|human serum albumin
P07557091A0314|16 32|human serum albumin
P07557091A0314|63 83|fasting male volunteers
P07557276A0526|0 22|Alanine aminotransferase
P07557276A0526|7 33|aminotransferase (ALT) levels
P07557276A0526|24 26|ALT
P07557276A0526|66 73|patients
P07557276A0526|77 91|hepatitis B viral
P07557387A0241|38 46|C/EBP beta
P07557387A0241|38 46|C/EBP beta
P07557387A0241|62 78|adipogenic program
P07557387A0241|95 103|C/EBP beta
P07557387A0241|95 103|C/EBP beta
P07557387A0241|106 119|multipotential
P07557387A0241|120 137|NIH-3T3 fibroblasts
P07557424A0124|0 3|XYL1
P07557424A0124|0 3|XYL1
P07557424A0124|33 43|fusion clone
P07557424A0124|50 53|lacZ
P07557424A0124|50 53|lacZ
P07557424A0124|67 79|fusion library
P07557446T0000|37 45|VCSA1 gene
P07557446T0000|37 45|VCSA1 gene
P07557446T0000|48 66|alternative splicing
P07557446T0000|70 76|poly(A)
P07557446T0000|92 94|rat
P07557446T0000|95 112|submandibular gland
P07557717A0184|21 29|chest wall
P07557717A0184|49 57|diathermy
P07557717A0184|72 84|prolonged pain
P07558263T0000|0 6|Closure
P07558263T0000|60 80|skin-stretching device
P07558583A0562|84 100|peptide substrates
P07558583A0562|129 150|Src-like tyrosine kinase
P07558583A0562|129 150|Src-like tyrosine kinase
P07558583A0562|162 190|active site-directed inhibitors
P07558583A0562|213 219|enzymes
P07559233A0534|0 22|Citrate synthase activity
P07559233A0534|0 14|Citrate synthase
P07559233A0534|40 49|medial head
P07559233A0534|69 71|red
P07559233A0534|98 117|triceps brachii muscle
P07559233A0534|121 124|rats
P07559233A0534|141 148|long head
P07559347A0000|18 36|putative operon bglPH
P07559347A0000|32 36|bglPH
P07559347A0000|39 54|Bacillus subtilis
P07559347A0000|39 54|Bacillus subtilis
P07559347A0000|72 103|bglP'-lacZ transcriptional fusions
P07559347A0000|72 103|bglP'-lacZ transcriptional fusions
P07559355A0066|40 53|urease activity
P07559355A0066|40 45|urease
P07559355A0066|126 138|specific genes
P07559355A0066|148 165|Proteus gene cluster
P07559355A0066|148 165|Proteus gene cluster
P07559356T0000|3 16|hypBFCDE operon
P07559356T0000|3 16|hypBFCDE operon
P07559356T0000|21 54|Rhizobium leguminosarum biovar viciae
P07559356T0000|72 87|Fnr-type promoter
P07559356T0000|72 87|Fnr-type promoter
P07559356T0000|115 122|fnrN gene
P07559356T0000|115 122|fnrN gene
P07559402A0622|18 27|VT+ peptide
P07559402A0622|59 72|protein kinase C
P07559402A0622|59 72|protein kinase C
P07559402A0622|74 76|PKC
P07559402A0622|74 76|PKC
P07559402A0622|94 107|protein kinase A
P07559402A0622|94 107|protein kinase A
P07559402A0622|109 111|PKA
P07559402A0622|109 111|PKA
P07559430A0909|0 0|R
P07559488A0440|75 83|estradiol
P07559488A0440|85 90|17 beta
P07559488A0440|114 133|ERE-LacZ reporter gene
P07559488A0440|114 116|ERE
P07559488A0440|118 121|LacZ
P07559488A0440|153 162|wild type ER
P07559488A0440|153 162|wild type ER
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559510A0000|27 38|endonuclease
P07559510A0000|66 71|enzyme
P07559510A0000|97 115|16-kDa endonuclease V
P07559510A0000|103 115|endonuclease V
P07559510A0000|120 134|bacteriophage T4
P07559510A0000|136 141|Gordon
P07559524A0000|16 24|oncogenes
P07559524A0000|28 40|growth factors
P07559524A0000|48 65|G1 phase progression
P07559524A0741|0 15|Cyclin D1 promoter
P07559524A0741|0 7|Cyclin D1
P07559524A0741|8 23|promoter activity
P07559524A0741|55 84|mitogen-activated protein kinase
P07559524A0741|55 84|mitogen-activated protein kinase
P07559524A0741|86 92|p41MAPK
P07559524A0741|86 92|p41MAPK
P07559524A0741|96 102|c-Ets-2
P07559524A0741|96 102|c-Ets-2
P07559524A0741|113 131|proximal 22 base pairs
P07559555A0557|7 9|ERM
P07559555A0557|7 9|ERM
P07559555A0557|13 17|c-Jun
P07559555A0557|13 17|c-Jun
P07559555A0557|45 51|EBS-CRE
P07559555A0557|45 47|EBS
P07559555A0557|82 88|complex
P07559563A0282|1 6|mutant
P07559563A0282|36 61|Ca2+/CaM-dependent activity
P07559563A0282|36 39|Ca2+
P07559563A0282|41 43|CaM
P07559639A0996|14 21|R206S HSF
P07559639A0996|19 33|HSF substitution
P07559639A0996|54 78|transcriptional activation
P07559639A0996|84 100|consensus HSE (HSE2
P07559640A1230|33 49|5' end of the element
P07559640A1230|89 98|UAS element
P07559640A1230|133 145|bHLH core motif
P07559640A1230|133 145|bHLH core motif
P07559650A0558|27 34|PCNA gene
P07559650A0558|27 30|PCNA
P07559650A0558|56 58|E2F
P07559650A0558|56 58|E2F
P07560137T0000|0 22|Differential sensitivity
P07560137T0000|28 49|MMPI-2 depression scales
P07560137T0000|53 61|subscales
P07560662A0496|15 39|hypertonic saline challenge
P07562775A0596|10 20|eosinophils
P07562775A0596|43 67|peripheral white blood cells
P07563072A0773|0 10|Comparisons
P07563072A0773|13 23|rrnB P1-lacZ
P07563072A0773|13 16|rrnB
P07563072A0773|17 18|P1
P07563072A0773|20 23|lacZ
P07563072A0773|45 55|ppGpp levels
P07563072A0773|75 91|rpoD(P504L) mutant
P07563072A0773|75 78|rpoD
P07563072A0773|80 84|P504L
P07563072A0773|126 130|ppGpp
P07563076A0766|5 18|intron chimeras
P07563076A0766|73 83|splice sites
P07563076A0766|98 118|self-splicing activity
P07563076A0766|157 170|catalytic cores
P07563076A0766|173 175|ai4
P07563076A0766|173 175|ai4
P07563076A0766|179 181|bi4
P07563076A0766|179 181|bi4
P07563076A0766|200 204|cores
P07563090A0124|32 54|plus-strand DNA synthesis
P07563090A0124|60 74|yeast Ty1 element
P07563090A0124|60 74|yeast Ty1 element
P07563090A0124|123 142|3' long terminal repeat
P07563090A0124|123 142|3' long terminal repeat
P07563090A0124|144 147|PPT1
P07563090A0124|144 147|PPT1
P07563090A0124|159 164|middle
P07563090A0124|170 176|pol gene
P07563090A0124|170 176|pol gene
P07563090A0124|182 204|integrase coding sequence
P07563090A0124|182 204|integrase coding sequence
P07563090A0124|206 209|PPT2
P07563090A0124|206 209|PPT2
P07563090A0624|21 26|3' ends
P07563090A0624|43 54|DNA fragments
P07563090A0624|72 87|upstream fragment
P07563090A0624|105 108|PPT2
P07563090A0624|105 108|PPT2
P07563090A0624|176 180|-stop
P07563090A0624|207 211|minus
P07563090A0624|225 235|binding site
P07563090A0624|269 308|retroviral genomic RNA reverse transcription
P07563994A0488|3 10|patients
P07563994A0488|21 24|VTLB
P07563994A0488|63 66|VTLB
P07563994A0488|86 88|OLB
P07563994A0488|120 128|blood loss
P07563994A0488|130 133|VTLB
P07563994A0488|149 151|OLB
P07564004A0292|33 36|FEV1
P07564210A0557|100 112|clinical signs
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|97 107|cream cheese
P07565031A0454|109 128|apricot marmelade, hip
P07565031A0454|215 228|spinach ravioli
P07565031A0454|240 250|milk dessert
P07565031A0454|260 264|cocoa
P07565031A0454|266 278|milk confiture
P07565031A0454|289 297|additives
P07565031A0454|308 315|tuna fish
P07565031A0454|327 340|sterilized milk
P07565049A1032|55 65|symptomatic
P07565049A1032|69 90|asymptomatic infected NB
P07565104A0084|18 26|pilin gene
P07565104A0084|18 26|pilin gene
P07565104A0084|28 31|tcpA
P07565104A0084|28 31|tcpA
P07565104A0084|48 51|ToxR
P07565104A0084|48 51|ToxR
P07565104A0084|59 62|ToxT
P07565104A0084|59 62|ToxT
P07565113A0000|3 38|chloramphenicol-resistance transposon
P07565113A0000|3 28|chloramphenicol-resistance
P07565113A0000|39 44|Tn4451
P07565113A0000|39 44|Tn4451
P07565113A0000|87 105|parent plasmid plP401
P07565113A0000|108 129|Clostridium perfringens
P07565113A0000|163 179|multicopy plasmids
P07565113A0000|182 196|Escherichia coli
P07565669T0000|0 8|Ras p21Val
P07565669T0000|0 8|Ras p21Val
P07565669T0000|45 54|DNA binding
P07565669T0000|57 81|transcriptional activities
P07565669T0000|87 122|myogenic basic helix-loop-helix factors
P07565669T0000|87 122|myogenic basic helix-loop-helix factors
P07565672A0798|42 46|arg-2
P07565672A0798|42 46|arg-2
P07565672A0798|50 54|cpc-1
P07565672A0798|50 54|cpc-1
P07565672A0798|80 84|cox-5
P07565672A0798|80 84|cox-5
P07565672A0798|93 105|translational
P07565672A0798|109 133|transcriptional components
P07565685A0420|3 18|peptide sequences
P07565685A0420|48 68|GABP alpha and GABP beta 1
P07565685A0420|48 56|GABP alpha
P07565685A0420|60 68|GABP beta 1
P07565685A0420|73 89|Ets and Notch motifs
P07565685A0420|73 75|Ets
P07565685A0420|79 89|Notch motifs
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688A0797|31 55|cell fractionation analyses
P07565688A0797|69 82|110-kDa protein
P07565688A0797|69 82|110-kDa protein
P07565688A0797|115 128|150-kDa protein
P07565688A0797|115 128|150-kDa protein
P07565688A0797|148 156|cytoplasm
P07565688A0797|160 166|nucleus
P07565688A0797|169 178|human cells
P07565688T0000|25 34|interferon
P07565688T0000|25 34|interferon
P07565688T0000|38 83|double-stranded-RNA-specific adenosine deaminase
P07565688T0000|38 56|double-stranded-RNA
P07565688T0000|66 83|adenosine deaminase
P07565688T0000|88 97|human cells
P07565688T0000|123 131|deaminase
P07565709A0000|0 15|T-cell hybridomas
P07565709A0000|17 26|thymocytes
P07565709A0000|31 36|T cells
P07565709A0000|58 75|apoptotic cell death
P07565709A0000|98 111|T-cell receptor
P07565709A0000|98 111|T-cell receptor
P07565712A0286|26 33|LYS2 gene
P07565712A0286|26 33|LYS2 gene
P07565712A0286|109 126|secondary structure
P07565712A0286|138 153|quasipalindromes
P07565713A0634|16 19|SCS1
P07565713A0634|16 19|SCS1
P07565713A0634|40 55|HSP60-null allele
P07565713A0634|40 49|HSP60-null
P07565713A0634|107 119|Hsp60 activity
P07565713A0634|107 111|Hsp60
P07565720A0256|3 18|DNA binding domain
P07565720A0256|21 24|NirA
P07565720A0256|21 24|NirA
P07565720A0256|60 83|glutathione S-transferase
P07565720A0256|60 83|glutathione S-transferase
P07565720A0256|86 105|Schistosoma japonicum
P07565723A0200|3 8|kinase
P07565723A0200|29 49|normal phosphorylation
P07565723A0200|55 57|CTD
P07565723A0200|70 75|growth
P07565723A0200|79 93|differentiation
P07565731A1629|16 42|ARE-mediated mRNA degradation
P07565731A1629|76 113|heterogeneous nuclear ribonucleoproteins
P07565731A1629|96 135|ribonucleoproteins and ARE-binding proteins
P07565731A1629|117 135|ARE-binding proteins
P07565736A2134|25 34|C/EBP alpha
P07565736A2134|25 34|C/EBP alpha
P07565736A2134|51 77|GM-CSF receptor alpha promoter
P07565736A2134|51 77|GM-CSF receptor alpha promoter
P07565736A2134|80 94|nonmyeloid cells
P07565740T0000|0 10|Endocytosis
P07565740T0000|14 21|vacuolar
P07565740T0000|38 51|plasma membrane
P07565740T0000|62 104|Pdr5 ATP-binding cassette multidrug transporter
P07565740T0000|62 68|Pdr5 ATP
P07565740T0000|77 104|cassette multidrug transporter
P07565740T0000|107 129|Saccharomyces cerevisiae
P07565775A1265|10 18|mutations
P07565775A1265|21 37|motifs III, IV, and V
P07565775A1265|74 79|enzyme
P07565775A1265|83 85|GTP
P07565775A1265|114 125|EpG formation
P07565775A1265|143 145|GMP
P07565775T0000|0 17|Mutational analysis
P07565775T0000|20 23|mRNA
P07565775T0000|67 76|GTP binding
P07565775T0000|78 102|enzyme-guanylate formation
P07565775T0000|107 109|GMP
P07565776A0612|15 30|HOG1 and PBS2 genes
P07565776A0612|15 18|HOG1
P07565776A0612|22 30|PBS2 genes
P07565776A0612|60 76|HSP12 inducibility
P07565776A0612|60 64|HSP12
P07565776A0612|79 95|osmostressed cells
P07565776A0612|120 123|Hog1
P07565776A0612|120 123|Hog1
P07565776A0612|151 172|wild-type induced levels
P07565776A0612|186 206|high salt concentration
P07565797A0116|0 7|Deletion
P07565797A0116|24 27|CRY1
P07565797A0116|24 27|CRY1
P07565797A0116|64 71|CRY2 mRNA
P07565797A0116|64 71|CRY2 mRNA
P07567079A0014|26 51|Cryptosporidium spp. oocysts
P07567079A0014|162 169|C. parvum
P07567079A0014|176 193|fecal contamination
P07567300T0000|0 25|Staphylococcal enterotoxin A
P07567300T0000|0 13|Staphylococcal
P07567300T0000|14 25|enterotoxin A
P07567300T0000|64 74|burn patient
P07567830A0072|25 59|inspiratory and expiratory flow-volume
P07567830A0072|70 87|unselected patients
P07567830A0072|92 106|essential tremor
P07567830A0072|110 114|males
P07567830A0072|118 124|females
P07567979A1266|78 92|testis receptor 2
P07567979A1266|84 92|receptor 2
P07567979A1266|96 100|hERR1
P07567979A1266|96 100|hERR1
P07567980T0000|4 31|p53 DNA-binding domain peptides
P07567980T0000|4 23|p53 DNA-binding domain
P07567980T0000|24 31|peptides
P07567980T0000|43 62|p53-response elements
P07567980T0000|43 62|p53-response elements
P07568026A0622|3 12|Stat5b mRNA
P07568026A0622|3 8|Stat5b
P07568026A0622|23 27|5.6 kb
P07568026A0622|48 60|786 amino acids
P07568116A0902|3 16|hydropathy plot
P07568116A0902|26 58|rather hydrophilic N-terminal region
P07568116A0902|75 98|hydrophobic signal peptide
P07568118A1267|23 61|G beta gamma-stimulated Shc phosphorylation
P07568118A1267|23 32|G beta gamma
P07568118A1267|44 46|Shc
P07568118A1267|104 119|p21ras activation
P07568118A1267|104 109|p21ras
P07568118A1267|152 186|growth factor tyrosine kinase receptors
P07568118A1267|152 186|growth factor tyrosine kinase receptors
P07568576A0074|41 53|Type A behavior
P07568865A0305|3 11|carcasses
P07568865A0305|129 145|sporulate bacteria
P07568865A0305|172 174|CFU
P07568865A0305|179 185|Figure 1
P07569075A0585|7 33|stage I-II lung cancer patients
P07569075A0585|35 36|CR
P07569075A0585|35 36|CR
P07569075A0585|68 69|PR
P07569075A0585|110 125|chest radiography
P07569075A0585|127 128|CT
P07569075A0585|130 132|FBS
P07569075A0585|148 156|histology
P07569532T0001|58 63|locale
P07569640A0539|0 21|Protein electrophoresis
P07569640A0539|37 43|albumin
P07569640A0539|80 81|G2
P07569770A0298|60 66|vaccine
P07569770A0298|79 97|primary immunization
P07569770A0298|118 137|yeast-derived vaccine
P07571766A0122|28 47|hypertensive patients
P07571766A0122|76 97|cardiac catheterization
P07571766A0122|107 117|anginal pain
P07571766A0122|186 201|coronary arteries
P07571953T0000|0 16|Negative-staining
P07571953T0000|18 39|refractile mycobacteria
P07571953T0000|42 65|Romanowsky-stained smears
P07572582A0000|0 12|Mibefradil (Ro
P07572582A0000|29 45|calcium antagonist
P07572582A0000|110 123|calcium channel
P07574064A1416|84 85|VE
P07574064A1416|128 132|min-1
P07574064A1416|146 159|rightward shift
P07574682T0000|0 3|cDNA
P07574682T0000|29 69|liver/bone/kidney-type alkaline phosphatase
P07574682T0000|35 69|bone/kidney-type alkaline phosphatase
P07575416A0000|0 13|Protein kinase C
P07575416A0000|0 13|Protein kinase C
P07575416A0000|15 17|PKC
P07575416A0000|15 17|PKC
P07575416A0000|76 97|physiological processes
P07575416A0000|125 140|twelve isoenzymes
P07575416A0000|197 216|regulatory properties
P07575416A0000|218 220|etc
P07575416A1970|63 77|oligonucleotide
P07575416A1970|81 90|cDNA probes
P07575416A1970|98 108|PKC zeta mRNA
P07575416A1970|101 108|zeta mRNA
P07575438A1409|23 45|helix-loop-helix factors
P07575438A1409|23 45|helix-loop-helix factors
P07575438A1409|56 64|E1 element
P07575438A1409|56 64|E1 element
P07576178A0000|11 23|growth factors
P07576178A0000|27 35|cytokines
P07576178A0000|48 67|biochemical functions
P07576179A0781|37 52|CpG dinucleotides
P07576307A0144|27 54|5' proximal regulatory cassette
P07576307A0144|72 84|rat enkephalin
P07576307A0144|72 84|rat enkephalin
P07576307A0144|86 94|rENK) gene
P07576307A0144|86 89|rENK
P07576307A0144|128 146|enkephalin phenotype
P07576307A1654|16 33|ENK-specific motifs
P07576307A1654|16 33|ENK-specific motifs
P07576307A1654|65 84|protein-DNA complexes
P07576307A1654|89 103|nuclear extracts
P07576307A1654|111 128|human tumor cell line
P07576307A1654|130 134|HeLa)
P07576307A1654|155 157|ENK
P07576307A1654|155 157|ENK
P07577904A0141|39 60|primordial vitreous body
P07577904A0141|65 86|crystalline dislocation
P07577904A0141|92 126|camera aquosa and secondary buphthalmos
P07577904A0141|132 138|left eye
P07577904A0141|192 203|vitreous body
P07577904A0141|209 216|right eye
P07579023A0214|25 32|patients
P07579023A0214|120 131|liver enzymes
P07579164A0409|14 17|cDNA
P07579164A0409|21 36|genomic sequences
P07579164A0409|72 80|atp9 genes
P07579164A0409|72 80|atp9 genes
P07579328A0653|0 4|MZF-1
P07579328A0653|0 4|MZF-1
P07579328A0653|14 38|CAT reporter gene expression
P07579328A0653|14 28|CAT reporter gene
P07579328A0653|42 57|GAL4 binding sites
P07579328A0653|42 45|GAL4
P07579328A0653|63 87|nonhematopoietic cell lines
P07579328A0653|88 93|NIH 3T3
P07579328A0653|97 99|293
P07579328A1345|9 36|heterologous DNA binding domain
P07579328A1345|21 36|DNA binding domain
P07579328A1345|38 42|MZF-1
P07579328A1345|38 42|MZF-1
P07579328A1345|52 73|reporter gene expression
P07579328A1345|76 100|nonhematopoietic cell lines
P07579328A1345|125 146|hematopoietic cell lines
P07579683A0660|10 31|hGMR beta subunit mutants
P07579683A0660|10 24|hGMR beta subunit
P07579683A0660|43 60|cytoplasmic regions
P07579683A0660|86 98|c-myc promoter
P07579683A0660|86 98|c-myc promoter
P07579695A0336|57 84|MIF2 and trans-acting mutations
P07579695A0336|57 60|MIF2
P07579695A0336|64 84|trans-acting mutations
P07579695A0336|125 138|CEP1/CBF1/CPF1
P07579695A0336|125 128|CEP1
P07579695A0336|130 133|CBF1
P07579695A0336|135 138|CPF1
P07579695A0336|140 149|NDC10/CBF2
P07579695A0336|140 144|NDC10
P07579695A0336|146 149|CBF2
P07579695A0336|154 163|CEP3/CBF3B
P07579695A0336|154 157|CEP3
P07579695A0336|159 163|CBF3B
P07579695A0693|37 47|Mif2 protein
P07579695A0693|37 47|Mif2 protein
P07579695A0693|61 65|Cep1p
P07579695A0693|61 65|Cep1p
P07579695A0693|121 149|higher order protein-DNA complex
P07579704A0085|17 27|actin cables
P07579704A0085|17 21|actin
P07579704A0085|120 129|cell growth
P07580058A0000|12 44|Codonopsis pilosula oral liquor (CPOL
P07580058A0000|48 78|tissue-type plasminogen activator
P07580058A0000|59 78|plasminogen activator
P07580058A0000|80 83|t-PA
P07580058A0000|82 83|PA
P07580058A0000|88 116|plasminogen activator inhibitor
P07580058A0000|88 116|plasminogen activator inhibitor
P07580058A0000|118 120|PAI
P07580058A0000|118 120|PAI
P07580058A0000|137 144|patients
P07580058A0000|147 166|coronary heart disease
P07580058A0000|171 181|blood stasis
P07580330A0331|14 20|intakes
P07580330A0331|22 25|EDIs
P07580330A0331|61 63|HCH
P07580330A0331|81 89|gamma-HCH
P07580330A0331|107 114|dieldrin
P07580330A0331|138 140|DDT
P07580330A0331|161 163|HCB
P07580782T0000|0 14|Imaging features
P07580782T0000|24 37|epidermoid cyst
P07581364A0500|32 41|type III SMA
P07581364A0500|44 58|de novo deletions
P07581364A0500|74 79|Ag1-CA
P07581364A0500|74 79|Ag1-CA
P07581364A0500|83 86|C212
P07581364A0500|83 86|C212
P07582316A0696|66 86|IS6110 banding patterns
P07582316A0696|115 117|MTB
P07582592A0545|0 3|HRES
P07582592A0545|47 62|histologic damage
P07582592A0545|72 90|pneumatic dilatation
P07582592A0545|109 111|LES
P07582592A0545|137 164|intrasphincter botulinum toxin
P07582592A0545|151 164|botulinum toxin
P07582592A0545|190 198|achalasia
P07583190A0306|5 28|early structural processes
P07583190A0306|57 64|anterior
P07583190A0306|75 88|left hemisphere
P07583190A0306|105 119|brain potentials
P07583190A0306|200 219|circumscribed lesions
P07583190A0306|253 279|on-line structural assignment
P07583562A1826|2 4|men
P07583562A1826|9 11|BMI
P07583562A1826|19 20|OR
P07583562A1826|43 44|TG
P07583562A1826|75 76|RP
P07583562A1826|112 113|TG
P07583562A1826|115 119|LDL-C
P07583562A1826|115 119|LDL-C
P07583562A1826|124 135|hypertension
P07585246T0000|0 16|SL1 trans-splicing
P07585246T0000|0 2|SL1
P07585246T0000|28 34|AU-rich
P07585246T0000|60 64|5' end
P07585246T0000|67 95|Caenorhabditis elegans pre-mRNA
P07585246T0000|67 87|Caenorhabditis elegans
P07585246T0000|88 95|pre-mRNA
P07585559A0000|1 95|pyrazolo-quinoline compound, 6-methoxy-4-[2-[(2-hydroxyethoxyl)-ethyl]amino]-3-methyl-1M-pyrazo lo
P07585559A0000|97 111|3,4-b]quinoline
P07585559A0000|113 120|SCH 51344
P07585559A0000|169 199|smooth muscle alpha-actin promoter
P07585559A0000|169 191|smooth muscle alpha-actin
P07585559A0000|192 207|promoter activity
P07585559A0000|210 229|ras-transformed cells
P07585559A0000|210 212|ras
P07586403A0765|54 57|RFSS
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588240A0000|48 52|ced-3
P07588240A0000|48 52|ced-3
P07588240A0000|103 151|interleukin-1 beta (IL-1 beta)-converting enzyme (ICE)
P07588240A0000|103 119|interleukin-1 beta
P07588240A0000|121 146|IL-1 beta)-converting enzyme
P07588240A0000|148 150|ICE
P07588240A0000|153 161|Ich-1long
P07588240A0000|153 161|Ich-1long
P07588240A0000|166 170|CPP32
P07588240A0000|166 170|CPP32
P07588245T0000|12 67|glucocorticoid receptor-mediated transcriptional activation
P07588245T0000|12 33|glucocorticoid receptor
P07588245T0000|70 101|unliganded thyroid hormone receptor
P07588245T0000|80 101|thyroid hormone receptor
P07588245T0000|103 104|TR
P07588245T0000|103 104|TR
P07588245T0000|108 125|TR isoform-specific
P07588603A1054|60 76|DH regulatory sites
P07588603A1054|60 76|DH regulatory sites
P07588608A1687|0 10|Obstruction
P07588608A1687|16 35|ERF repressor function
P07588608A1687|16 27|ERF repressor
P07588608A1687|68 83|ets family of genes
P07588608A1687|68 83|ets family of genes
P07588608A1687|85 99|i.e.gag-myb-ets
P07588608A1687|89 99|gag-myb-ets
P07588608A1687|145 161|cell proliferation
P07588628A0318|16 27|wild-type p53
P07588628A0318|16 27|wild-type p53
P07588628A0318|39 47|apoptosis
P07588628A0318|52 54|LCL
P07588633A0362|10 14|c-Fos
P07588633A0362|10 14|c-Fos
P07588633A0362|19 43|c-fos protooncogene product
P07588633A0362|19 43|c-fos protooncogene product
P07588633A0362|76 89|nuclear protein
P07588633A0362|144 165|transforming efficiency
P07588633A0362|168 178|NIH 3T3 cells
P07588633A0362|182 184|Mos
P07588633A0362|182 184|Mos
P07588750T0061|8 17|sequencing
P07588750T0061|36 63|3-phosphoglycerate kinase gene
P07588750T0061|36 63|3-phosphoglycerate kinase gene
P07588750T0061|66 81|Pyrococcus woesei
P07588750T0061|84 98|Escherichia coli
P07588777A1524|41 49|RNAP II CTD
P07588777A1524|41 49|RNAP II CTD
P07588777A1524|86 92|p42mapk
P07588777A1524|86 92|p42mapk
P07588777A1524|96 112|p44mapk MAP kinases
P07588777A1524|96 102|p44mapk
P07588777A1524|103 112|MAP kinases
P07589069A1245|44 55|human CD6 cDNA
P07589069A1245|44 55|human CD6 cDNA
P07589069A1245|80 103|membrane-proximal regions
P07589069A1245|109 125|cytoplasmic domain
P07589069A1245|160 162|CD6
P07589069A1245|164 166|PB1
P07589069A1245|164 166|PB1
P07590264A0373|87 98|DHFR and mRNAs
P07590264A0373|87 98|DHFR and mRNAs
P07590264A0373|118 123|allele
P07590264A0373|178 190|RNA processing
P07590264A0373|216 222|poly(A)
P07590264A0373|250 263|gene expression
P07590268A0350|15 44|Drosophila melanogaster (Dm) cDNA
P07590268A0350|15 36|Drosophila melanogaster
P07590268A0350|38 44|Dm) cDNA
P07590268A0350|104 121|mammalian MAPKAPK-2
P07590268A0350|104 121|mammalian MAPKAPK-2
P07590268A0740|1 22|2.4-kb MAPKAPK-2 message
P07590268A0740|7 22|MAPKAPK-2 message
P07590268A0740|131 138|germline
P07590283A0820|17 27|chimeric TdT
P07590283A0820|17 27|chimeric TdT
P07590283A0820|30 43|Pol beta protein
P07590283A0820|30 36|Pol beta
P07590283A0820|82 99|polymerase activity
P07590283A0820|120 126|Pol beta
P07590283A0820|120 126|Pol beta
P07590283A0820|168 189|polymerization reaction
P07590283A0820|229 249|8-kDa N-terminal domain
P07590283A0820|234 249|N-terminal domain
P07590283A0820|252 258|Pol beta
P07590283A0820|252 258|Pol beta
P07590283A0820|268 288|ssDNA-binding activity
P07590525A0811|26 28|424
P07590525A0811|60 66|hot dogs
P07590657A0624|0 14|Cholangiography
P07590657A0624|99 106|patients
P07590744A0829|17 28|cDNA sequence
P07590744A0829|60 83|overlapping genomic clones
P07590744A0829|95 102|GAR1 gene
P07590744A0829|95 102|GAR1 gene
P07592072A0217|2 7|Trial 1
P07592072A0217|14 17|sows
P07592072A0217|37 45|naturally
P07592072A0217|52 57|NF sows
P07592072A0217|67 70|sows
P07592072A0217|91 96|IF sows
P07592072A0217|122 141|prostaglandin F2 alpha
P07592220A0846|0 11|End-tidal PO2
P07592220A0846|25 41|minute ventilation
P07592220A0846|44 60|oxygen consumption
P07592220A0846|62 67|VE/VO2
P07592220A0846|83 88|PETCO2
P07592220A0846|101 103|Hyp
P07592337A0891|25 28|NfxB
P07592337A0891|25 28|NfxB
P07592337A0891|67 70|nfxB
P07592337A0891|67 70|nfxB
P07592439A0000|0 3|A511
P07592439A0000|24 31|virulent
P07592439A0000|43 63|Listeria monocytogenes
P07592467A0000|24 36|proliferation
P07592485A0734|2 28|NCR-sensitive gene expression
P07592485A0734|95 108|NCR sensitivity
P07592485A0734|112 127|gene's expression
P07592485A0734|148 164|ure2 delta mutation
P07592485A0734|148 156|ure2 delta
P07592647A0797|3 46|single-stranded DNA Pur alpha recognition element
P07592647A0797|3 20|single-stranded DNA
P07592647A0797|24 46|alpha recognition element
P07592647T0000|13 25|human Pur alpha
P07592647T0000|13 25|human Pur alpha
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|55 56|Rb
P07592647T0000|55 56|Rb
P07592647T0000|79 122|single-stranded DNA Pur alpha recognition element
P07592647T0000|79 96|single-stranded DNA
P07592647T0000|100 122|alpha recognition element
P07592658A0309|3 35|insulin-induced DNA-binding complex
P07592658A0309|3 9|insulin
P07592658A0309|18 35|DNA-binding complex
P07592658A0309|54 71|p50/p65 heterodimer
P07592658A0309|54 56|p50
P07592658A0309|58 60|p65
P07592676A0466|83 91|NIP region
P07592676A0466|83 91|NIP region
P07592676A0466|122 138|repressor activity
P07592706A1465|0 7|Exchange
P07592706A1465|13 15|LPL
P07592706A1465|13 15|LPL
P07592706A1465|19 24|HL lids
P07592706A1465|19 20|HL
P07592706A1465|49 75|phospholipase/neutral lipase
P07592706A1465|49 75|phospholipase/neutral lipase
P07592706A1465|133 152|substrate specificity
P07592710T0000|3 35|interferon-inducible protein kinase
P07592710T0000|3 35|interferon-inducible protein kinase
P07592710T0000|36 38|PKR
P07592710T0000|36 38|PKR
P07592710T0000|51 75|transcriptional activation
P07592710T0000|78 100|immunoglobulin kappa gene
P07592710T0000|78 100|immunoglobulin kappa gene
P07592711T0000|0 8|Truncated
P07592711T0000|22 33|yeast protein
P07592711T0000|22 33|yeast protein
P07592711T0000|57 86|G protein alpha subunit deficiency
P07592711T0000|57 76|G protein alpha subunit
P07592711T0000|107 117|beta subunit
P07592711T0000|107 117|beta subunit
P07592721A0827|7 20|common mutation
P07592723A0814|0 12|Phorbol esters
P07592723A0814|23 37|phosphorylation
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|102 119|PKC binding activity
P07592723A0814|102 104|PKC
P07592723A0814|134 136|PKC
P07592723A0814|134 136|PKC
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|32 36|PTX-3
P07592730A0204|32 34|PTX
P07592730A0204|57 61|serum
P07592730A0204|64 67|mice
P07592730A0204|71 76|humans
P07592730A0204|95 121|bacterial lipopolysaccharide
P07592730A0204|150 167|acute phase proteins
P07592730A0204|178 192|TSG-14 synthesis
P07592730A0204|178 183|TSG-14
P07592730A0204|228 232|liver
P07592771A0258|3 27|mouse beta 2-syntrophin gene
P07592771A0258|3 27|mouse beta 2-syntrophin gene
P07592771A0258|55 59|exons
P07592771A0258|116 136|alpha 1-syntrophin gene
P07592771A0258|116 136|alpha 1-syntrophin gene
P07592790A1457|29 32|PEDF
P07592790A1457|29 32|PEDF
P07592790A1457|55 74|noninhibitory serpins
P07592790A1457|68 74|serpins
P07592790A1457|85 100|N-terminal region
P07592790A1457|85 100|N-terminal region
P07592790A1457|109 133|neurite-promoting activity
P07592946A0261|27 44|murine p44 MAP kinase
P07592946A0261|27 44|murine p44 MAP kinase
P07592946A0261|46 86|extracellular signal-regulated kinase 1) gene
P07592946A0261|46 81|extracellular signal-regulated kinase 1
P07592946A0997|23 31|TATA boxes
P07592946A0997|48 61|main start sites
P07592946A0997|72 78|AP-1 box
P07592946A0997|72 78|AP-1 box
P07592946A0997|83 89|AP-2 box
P07592946A0997|83 89|AP-2 box
P07592946A0997|94 100|Malt box
P07592946A0997|94 100|Malt box
P07592946A0997|105 111|GAGA box
P07592946A0997|120 142|serum-responsive element
P07592946A0997|147 166|putative binding sites
P07592946A0997|170 172|Sp1
P07592946A0997|170 172|Sp1
P07592946A0997|180 199|GC-rich binding factor
P07592946A0997|180 199|GC-rich binding factor
P07592946A0997|207 209|CTF
P07592946A0997|207 209|CTF
P07592946A0997|211 213|NF1
P07592946A0997|211 213|NF1
P07592946A0997|220 222|Myb
P07592946A0997|220 222|Myb
P07592946A0997|229 231|p53
P07592946A0997|229 231|p53
P07592946A0997|238 242|Ets-1
P07592946A0997|238 242|Ets-1
P07592946A0997|249 254|NF-IL6
P07592946A0997|249 254|NF-IL6
P07592946A0997|261 264|MyoD
P07592946A0997|261 264|MyoD
P07592946A0997|271 279|Zeste (one
P07592946A0997|271 275|Zeste
P07592946A0997|285 309|hepatocyte nuclear factor-5
P07592946A0997|285 309|hepatocyte nuclear factor-5
P07593266A1174|26 50|adenine-uridine rich region
P07593266A1174|64 74|11-base pair
P07593266A1174|75 87|stem structure
P07593896A1053|18 40|new measurement technique
P07593896A1053|66 67|P0
P07593896A1053|94 113|respiratory equipment
P07593896A1053|127 135|lung model
P07594047T0000|21 31|propranolol
P07594047T0000|34 58|early afterdepolarizations
P07594047T0000|62 83|ventricular arrhythmias
P07594047T0000|93 103|epinephrine
P07594047T0000|106 129|congenital long QT syndrome
P07594592A0755|0 7|Deletion
P07594592A0755|13 41|NF-IL6 beta leucine zipper domain
P07594592A0755|13 22|NF-IL6 beta
P07594592A0755|23 41|leucine zipper domain
P07595221A0733|35 39|CIITA
P07595221A0733|35 39|CIITA
P07595221A0733|51 65|MHC class II genes
P07595221A0733|51 65|MHC class II genes
P07595221A0733|97 115|MHC class II promoters
P07595221A0733|97 115|MHC class II promoters
P07595221A0733|166 186|CIITA-expressing cells
P07595221A0733|166 170|CIITA
P07595374A1215|12 16|EBNA2
P07595374A1215|12 16|EBNA2
P07595374A1215|36 52|amino acids 247-337
P07595374A1215|56 62|437-476
P07595374A1215|107 115|promoters
P07595374A1215|202 213|LMP1 promoter
P07595374A1215|202 205|LMP1
P07595857A0521|3 16|peak velocities
P07595857A0521|22 40|atrial systolic waves
P07595857A0521|46 56|transmitral
P07595857A0521|75 88|flow velocities
P07595857A0521|94 96|PVA
P07595857A0521|119 130|systolic wave
P07595857A0521|132 135|PVS1
P07595857A0521|174 192|atrial systolic waves
P07595857A0521|352 359|patients
P07595857A0521|370 377|patients
P07595857A0521|382 402|dilated cardiomyopathy
P07596283A0396|16 21|enzyme
P07596283A0396|42 54|triglycerides
P07596283A0396|61 68|olive oil
P07596283A0396|72 81|tributyrin
P07596283A0396|92 108|egg-yolk emulsions
P07596287A0183|3 20|nucleotide sequence
P07596287A0183|39 42|fimA
P07596287A0183|39 42|fimA
P07596287A0183|54 70|open reading frames
P07596287A0183|72 75|ORF5
P07596287A0183|79 82|ORF1
P07596287A0183|149 192|ATP-binding cassette membrane transport proteins
P07596287A0183|149 192|ATP-binding cassette membrane transport proteins
P07596287A0183|221 252|eukaryotic uptake and export systems
P07596287A1724|3 11|ORF3 probe
P07596287A1724|67 70|ORF3
P07596287A1724|94 108|mutagenesis data
P07596287A1724|111 121|non-linkage
P07596558A0824|42 49|IL-1 beta
P07596558A0824|42 49|IL-1 beta
P07596558A0824|86 108|human vitreous hemorrhage
P07596697A0971|38 53|motilin responses
P07596697A0971|38 44|motilin
P07596697A0971|85 92|children
P07596697A0971|99 106|children
P07596697A0971|112 123|control group
P07597030A0260|69 81|32-kDa subunit
P07597030A0260|84 96|human (h) TFIID
P07597030A0260|84 96|human (h) TFIID
P07597030A0260|104 111|hTAFII32
P07597030A0260|104 111|hTAFII32
P07597488T0000|0 16|Hemolytic jaundice
P07597488T0000|22 25|G6PD
P07597488T0000|22 25|G6PD
P07597488T0000|63 69|newborn
P07597804A1007|63 83|novel glycoprotein gene
P07597804A1007|68 87|glycoprotein gene EUS4
P07597804A1007|84 87|EUS4
P07598106A0709|4 16|growth changes
P07598106A0709|23 35|Class II sample
P07598106A0709|78 89|male subjects
P07598106A0709|94 112|Class I malocclusions
P07598106A0709|157 179|postpubertal development
P07598303A1728|58 82|bone marrow transplantation
P07599449A0445|3 10|fracture
P07599449A0445|75 87|control groups
P07599653A0898|43 56|nuclear factors
P07599653A0898|125 132|promoter
P07600111A0000|27 62|human immunodeficiency virus types 1 and 2
P07600111A0000|64 68|HIV-1
P07600111A0000|64 68|HIV-1
P07600111A0000|70 74|HIV-2
P07600111A0000|70 74|HIV-2
P07600111A0000|77 106|human T-lymphotropic virus types I
P07600111A0000|106 111|I and II
P07600111A0000|113 121|HTLV-I/II
P07600111A0000|113 121|HTLV-I/II
P07600111A0000|127 146|syphilitic infections
P07600111A0000|211 224|police officers
P07600111A0000|227 239|Guinea-Bissau
P07600986A0605|2 28|in vitro immunoprecipitations
P07600986A0605|32 45|gel shift assays
P07600986A0605|83 104|Engrailed-binding sites
P07600986A0605|83 91|Engrailed
P07601078A1003|0 7|Subjects
P07601078A1003|38 49|dioxin burden
P07601078A1003|100 116|unexposed subjects
P07601078A1003|118 129|hypoergy I: OR
P07601078A1003|153 165|hypoergy II: OR
P07601121A0153|62 78|5'-flanking region
P07601121A0153|107 119|transcription
P07601445A0207|16 37|BAT1 translation product
P07601445A0207|16 19|BAT1
P07601445A0207|20 37|translation product
P07601445A0207|55 74|rat p47 nuclear protein
P07601445A0207|55 57|rat
P07601445A0207|58 74|p47 nuclear protein
P07601445A0207|79 102|WM6 Drosophila gene product
P07601445A0207|79 102|WM6 Drosophila gene product
P07601445A0207|119 125|Ce08102
P07601445A0207|128 148|Caenorhabditis elegans
P07601445A0207|165 181|DEAD protein family
P07601445A0207|165 175|DEAD protein
P07601445A0207|184 208|ATP-dependent RNA helicases
P07601445A0207|184 208|ATP-dependent RNA helicases
P07601827A0778|7 17|lacZ fusions
P07601827A0778|7 17|lacZ fusions
P07601827A0778|45 56|DNA sequences
P07601827A0778|74 90|nitrate repression
P07601827A0778|96 123|pfl promoter-regulatory region
P07601827A0778|96 123|pfl promoter-regulatory region
P07601828A0095|47 72|early class II flagellar genes
P07601828A0095|47 72|early class II flagellar genes
P07601828A0095|87 100|orfX-fliP locus
P07601828A0095|92 95|fliP
P07603726T0000|0 19|Vestibular adaptation
P07603726T0000|41 50|acute stage
P07603726T0000|56 79|acoustic neuroma resection
P07603956A0115|3 20|experimental design
P07603956A0115|106 108|RSB
P07603956A0115|151 160|uninfected
P07604047A0704|1 9|cDNA clone
P07604047A0704|36 62|GA 20-oxidase genomic sequence
P07604047A0704|36 47|GA 20-oxidase
P07604047A0704|84 113|reverse transcription-PCR method
P07604047A0704|134 142|cDNA clone
P07604047A0704|184 196|fusion protein
P07604047A0704|208 222|Escherichia coli
P07604047A0704|232 235|GA53
P07604047A0704|232 235|GA53
P07604047A0704|238 241|GA44
P07604047A0704|238 241|GA44
P07604047A0704|245 248|GA19
P07604047A0704|245 248|GA19
P07604047A0704|251 254|GA20
P07604047A0704|251 254|GA20
P07604783A0952|40 76|fatty acid composition of biliary lecithin
P07604783A0952|105 108|bile
P07604794A0958|5 15|cholesterol
P07605990A1110|60 64|PEBP2
P07605990A1110|60 64|PEBP2
P07605990A1110|70 83|GM-CSF promoter
P07605990A1110|70 83|GM-CSF promoter
P07605990A1110|162 174|PEBP2 isoforms
P07605990A1110|162 174|PEBP2 isoforms
P07605990A1110|201 216|promoter activity
P07606548T0000|0 7|Benefits
P07606548T0000|39 53|pharmacotherapy
P07606587A0266|0 22|Piperacillin-tazobactam
P07606587A0266|49 58|infections
P07606587A0266|67 79|gram-negative
P07606587A0266|81 84|gram
P07606587A0266|106 122|anaerobic bacteria
P07607197A1048|5 23|plasma renin activity
P07607197A1048|11 15|renin
P07607197A1048|25 27|PRA
P07607197A1048|53 60|training
P07607197A1048|82 89|controls
P07607213A0140|23 52|structure/activity relationship
P07607233A0186|28 54|novel lantibiotic epilancin K7
P07607233A0186|44 54|epilancin K7
P07607233A0186|59 83|Staphylococcus epidermidis
P07607233A0186|84 85|K7
P07607233A0186|101 118|nucleotide sequence
P07607342A0703|70 94|aldose reductase inhibitors
P07607342A0703|70 84|aldose reductase
P07607342A0703|97 104|diabetic
P07607342A0703|105 112|patients
P07607342A0703|171 178|patients
P07607537A0954|13 22|phenotypes
P07607537A0954|36 44|mutations
P07607537A0954|98 117|VP16 activation domain
P07607537A0954|98 101|VP16
P07607607T0000|17 23|calcium
P07607607T0000|39 54|fructose infusion
P07607669A1112|3 18|5'flanking region
P07607669A1112|27 32|GC rich
P07607669A1112|46 56|CpG doublets
P07607669A1112|69 88|multiple binding sites
P07607669A1112|92 94|Sp1
P07607669A1112|92 94|Sp1
P07608268A0194|32 35|GnRH
P07608268A0194|32 35|GnRH
P07608268A0194|70 95|melatonin secretion profiles
P07608268A0194|116 128|young males IGD
P07608268A0194|137 138|DP
P07608268A0194|146 171|normal pubertal male controls
P07608649A1429|9 21|blood pressure
P07608649A1429|28 30|CyA
P07608649A1429|56 76|circulating ET-1 levels
P07608649A1429|67 70|ET-1
P07608968A0836|17 26|Tat mutants
P07608968A0836|17 26|Tat mutants
P07608968A0836|47 59|cysteine-rich
P07608968A0836|66 76|core domains
P07608968A0836|83 96|transactivator
P07608968A0836|149 151|TBP
P07608968A0836|149 151|TBP
P07609037A0775|22 26|Oct-1
P07609037A0775|22 26|Oct-1
P07609037A0775|34 47|nuclear extract
P07609037A0775|55 59|Oct-1
P07609037A0775|55 59|Oct-1
P07609037A0775|69 77|antiserum
P07609037A0775|81 113|sequence-specific DNA affinity resin
P07609037A0775|150 170|wild-type MMTV promoter
P07609037A0775|207 214|promoter
P07609037A0775|230 253|octamer-related sequences
P07609079A0387|0 14|Transactivation
P07609079A0387|20 27|HIV-1 LTR
P07609079A0387|20 27|HIV-1 LTR
P07609079A0387|30 37|T3R alpha
P07609079A0387|30 37|T3R alpha
P07609079A0387|48 62|receptor mutants
P07609079A0387|48 62|receptor mutants
P07609079A0387|78 109|50-amino-acid N-terminal A/B region
P07609079A0387|78 101|50-amino-acid N-terminal A
P07609079A0387|103 103|B
P07609079A0387|112 119|T3R alpha
P07609079A0387|112 119|T3R alpha
P07609079A0387|143 166|basal transcription factor
P07609079A0387|167 171|TFIIB
P07609079A0387|167 171|TFIIB
P07609079A0387|202 251|Tat-dependent and Tat-independent responsive sequences
P07609079A0387|202 204|Tat
P07609079A0387|218 220|Tat
P07609079A0387|257 259|LTR
P07609372A0261|0 0|M
P07609372A0261|38 47|HR patients
P07609372A0261|51 52|LR
P07609372A0261|53 60|patients
P07609372A0261|89 90|HR
P07609372A0261|91 98|patients
P07609372A0261|102 111|LR patients
P07610052A1064|39 45|C25, C30
P07610052A1064|39 41|C25
P07610052A1064|43 45|C30
P07610052A1064|49 60|C35 complexes
P07610052A1064|49 60|C35 complexes
P07610052A1064|72 80|rat cortex
P07610052A1064|81 95|nuclear extracts
P07610052A1064|102 111|SAA element
P07610052A1064|114 128|EMSA experiments
P07610052A1064|203 216|rat APP promoter
P07610052A1064|203 216|rat APP promoter
P07610324A0319|0 10|Oncological
P07610324A0319|23 42|psychological aspects
P07610324A0319|117 137|delayed reconstruction
P07610716A0117|51 56|global
P07610716A0117|109 126|geographic latitude
P07610735A1471|0 8|Diltiazem
P07610735A1471|39 57|ventricular response
P07610735A1471|77 87|sinus rhythm
P07612174A1064|0 15|Subhuman primates
P07612174A1064|77 80|PCBs
P07612174A1064|85 90|humans
P07612557A0635|13 20|children
P07612557A0635|25 30|ocular
P07612557A0635|34 50|cerebral pathology
P07612557A0635|68 76|premature
P07612557A0635|80 94|control children
P07614762A0224|3 25|cryptococcal antigen test
P07614762A0224|46 63|latex agglutination
P07615541T0000|20 45|DNase-I hypersensitive sites
P07615541T0000|20 45|DNase-I hypersensitive sites
P07615541T0000|51 83|mouse porphobilinogen deaminase gene
P07615541T0000|51 79|mouse porphobilinogen deaminase
P07615634A0535|27 46|5'untranslated region
P07615634A0535|50 69|NH2-terminal sequence
P07615634A0535|98 102|121 kD
P07616056A0278|4 30|mu and gamma 2b heavy chain genes
P07616056A0278|9 30|gamma 2b heavy chain genes
P07616056A0278|60 86|heavy chain gene rearrangement
P07616056A0278|60 73|heavy chain gene
P07616563A0532|8 11|CarP
P07616563A0532|8 11|CarP
P07616563A0532|29 46|carAB control region
P07616563A0532|29 46|carAB control region
P07616563A0532|65 70|DNase I
P07616563A0532|91 103|long stretches
P07616563A0532|143 154|GATC sequence
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|60 66|cox1 to 3
P07616569A0168|60 63|cox1
P07616569A0168|69 86|apocytochrome b (cob
P07616569A0168|69 82|apocytochrome b
P07616569A0168|84 86|cob
P07616569A0168|107 135|NADH dehydrogenase complex (nad1
P07616569A0168|107 123|NADH dehydrogenase
P07616569A0168|132 138|nad1 to 6
P07616569A0168|140 144|nad4L
P07616569A0168|140 144|nad4L
P07616569A0168|147 155|two ATPase
P07616569A0168|150 163|ATPase subunits
P07616569A0168|165 168|atp6
P07616569A0168|165 168|atp6
P07616569A0168|172 176|atp9)
P07616569A0168|172 175|atp9
P07616569A0168|183 195|ribosomal RNAs
P07616569A0168|183 195|ribosomal RNAs
P07616569A0168|197 200|rrn5
P07616569A0168|197 200|rrn5
P07616569A0168|202 204|srn
P07616569A0168|208 210|lrn
P07616569A0168|208 210|lrn
P07616569A0168|215 254|tRNAs and four ribosomal proteins (rps3, rps11
P07616569A0168|227 243|ribosomal proteins
P07616569A0168|245 248|rps3
P07616569A0168|250 254|rps11
P07616569A0168|256 260|rps12
P07616569A0168|256 260|rps12
P07616569A0168|264 268|rpl16
P07616569A0168|264 268|rpl16
P07616802A0315|32 44|platelet count
P07616802A0315|71 78|patients
P07616802A0315|90 96|heparin
P07616802A0315|138 144|heparin
P07616802A0315|164 173|responders
P07618280A0550|5 33|"nucleocapsid-like" structures
P07618548T0000|3 23|Babcock Surgical Clinic
P07620491T0000|0 8|Resources
P07620491T0000|12 26|helping patients
P07620491T0000|29 39|quit smoking
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|29 43|128-amino-acid (
P07622058A0411|74 115|Drosophila melanogaster segmentation gene runt
P07622058A0411|74 115|Drosophila melanogaster segmentation gene runt
P07622060A0967|2 24|human proliferative cells
P07622060A0967|29 52|NADP-dependent ME activity
P07622060A0967|29 44|NADP-dependent ME
P07622060A0967|90 104|thyroid hormones
P07622521A0418|27 49|G beta gamma binding region
P07622521A0418|27 36|G beta gamma
P07622521A0418|52 58|beta ARK
P07622521A0418|52 58|beta ARK
P07622521A0418|72 79|residues
P07622521A0418|89 96|PH domain
P07622521A0418|89 96|PH domain
P07622521A0418|136 151|carboxyl terminus
P07622521A0418|154 160|beta ARK
P07622521A0418|154 160|beta ARK
P07622521A0418|206 215|G beta gamma
P07622521A0418|206 215|G beta gamma
P07622521A0418|219 222|PIP2
P07622521A0418|219 222|PIP2
P07622932T0000|0 24|Histopathological features
P07622932T0000|27 41|relapsed leprosy
P07623807A0162|25 55|wild-type and mutant Raf-1 proteins
P07623807A0162|43 55|Raf-1 proteins
P07623807A0162|96 110|plasma membranes
P07623807A0162|115 128|v-Ras- and v-Src
P07623807A0162|115 119|v-Ras
P07623807A0162|124 128|v-Src
P07623807A0162|129 145|-transformed cells
P07623807A0162|147 157|transformed
P07623807A0162|158 166|membranes
P07623814A1040|2 10|CV-1 cells
P07623814A1040|31 58|retinoid and estrogen receptors
P07623814A1040|42 58|estrogen receptors
P07623814A1040|108 109|RA
P07623814A1040|132 141|ER activity
P07623814A1040|132 133|ER
P07623821A0649|18 22|HRF-1
P07623821A0649|18 22|HRF-1
P07623821A0649|35 44|cis element
P07623821A0649|67 82|palindromic motif
P07623821T0000|12 26|Gax homeobox gene
P07623821T0000|12 26|Gax homeobox gene
P07623821T0000|56 70|positive factors
P07623821T0000|80 110|myocyte-specific enhancer factor 2
P07623821T0000|80 110|myocyte-specific enhancer factor 2
P07623825T0000|3 40|carboxyl-terminal transactivation domain
P07623825T0000|43 58|heat shock factor 1
P07623825T0000|43 58|heat shock factor 1
P07623840A0352|20 46|synthetase-related sequences
P07623840A0352|49 52|GCN2
P07623840A0352|49 52|GCN2
P07623840A0352|109 121|uncharged tRNA
P07623844A0639|14 18|Bcl-2
P07623844A0639|14 18|Bcl-2
P07623844A0639|25 38|E1B 19K proteins
P07623844A0639|25 38|E1B 19K proteins
P07623844A0639|60 68|apoptosis
P07623844A0639|75 99|p53-dependent growth arrest
P07623844A0639|75 77|p53
P07623844A0639|101 105|H-ras
P07623844A0639|125 136|DNA synthesis
P07623844A0639|140 156|cell proliferation
P07623844A0639|184 195|wild-type p53
P07623844A0639|184 195|wild-type p53
P07624119A0528|12 15|PAX3
P07624119A0528|12 15|PAX3
P07624119A0528|19 57|putative PAX3-FKHR transactivation domains
P07624119A0528|27 30|PAX3
P07624119A0528|32 35|FKHR
P07624119A0528|106 126|GAL4 DNA-binding domain
P07624119A0528|106 126|GAL4 DNA-binding domain
P07624119A0528|148 160|a reporter gene
P07624581A0312|26 28|ECG
P07624581A0312|40 65|blood pressure determination
P07624581A0312|83 85|TSH
P07624581A0312|83 85|TSH
P07624581A0312|87 100|thyroid hormone
P07624581A0312|87 100|thyroid hormone
P07624581A0312|102 104|PRL
P07624581A0312|102 104|PRL
P07624581A0312|106 112|glucose
P07624581A0312|125 132|nitrogen
P07624581A0312|134 154|glutamine transaminase
P07624581A0312|134 154|glutamine transaminase
P07624581A0312|156 166|cholesterol
P07624581A0312|170 182|triglycerides
P07624581A0312|201 207|therapy
P07624581A0312|234 236|T30
P07624581A0312|261 263|T45
P07624615A0267|0 12|Acute decrease
P07624615A0267|15 29|body temperature
P07624615A0267|31 32|TB
P07624615A0267|41 45|PaCO2
P07624615A0267|107 109|pHa
P07624615A0267|140 145|[OH-]/
P07624615A0267|147 154|H+] ratio
P07624615A0267|183 186|[SID
P07624615A0267|214 223|phosphorus
P07624615A0267|231 248|inorganic phosphate
P07626378T0000|0 16|Hepatitis B vaccine
P07626469A1341|5 20|promoter activity
P07626469A1341|44 51|M1 domain
P07626469A1341|44 51|M1 domain
P07626469A1341|54 88|LHR-expressing mouse Leydig tumor cells
P07626469A1341|90 93|MLTC
P07626469A1341|103 124|non-expressing CHO cells
P07626806A1098|3 10|RAT3 gene
P07626806A1098|3 10|RAT3 gene
P07626806A1098|20 40|1157-amino acid protein
P07627317A1502|57 76|urinary concentration
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|26 33|TNF alpha
P07628389A0145|26 33|TNF alpha
P07628389A0145|37 59|proinflammatory cytokine
P07628389A0145|69 105|cAMP-stimulated testosterone production
P07628389A0145|108 123|mouse Leydig cells
P07628438T0000|3 34|Drosophila insulin receptor homolog
P07628438T0000|13 34|insulin receptor homolog
P07628438T0000|53 72|embryonic development
P07628438T0000|112 129|signaling potential
P07628451A0114|14 15|RA
P07628451A0114|14 15|RA
P07628451A0114|19 21|E1A
P07628451A0114|19 21|E1A
P07628451A0114|28 42|phosphorylation
P07628451A0114|48 74|E1A-associated 300 kDa protein
P07628451A0114|48 74|E1A-associated 300 kDa protein
P07628451A0114|76 79|p300
P07628451A0114|76 79|p300
P07628451A0114|107 113|F9 cells
P07628456A0000|3 20|double-stranded RNA
P07628456A0000|35 39|dsRBD
P07628456A0000|121 139|double-stranded (ds)
P07628456A0000|140 142|RNA
P07628456A0000|150 172|Escherichia coli RNase III
P07628456A0000|165 172|RNase III
P07628456A0000|179 199|dsRNA-dependent kinase
P07628456A0000|179 199|dsRNA-dependent kinase
P07628456A0000|201 203|PKR
P07628456A0000|201 203|PKR
P07629103T0000|0 48|CCAAT/enhancer-binding protein isoforms beta and delta
P07629103T0000|0 40|CCAAT/enhancer-binding protein isoforms beta
P07629103T0000|44 48|delta
P07629103T0000|63 84|mammary epithelial cells
P07629103T0000|94 106|multiple sites
P07629103T0000|112 134|beta-casein gene promoter
P07629103T0000|112 126|beta-casein gene
P07629113A0726|0 2|SCA
P07629113A0726|0 2|SCA
P07629113A0726|29 34|serine
P07629113A0726|36 43|aspartyl
P07629113A0726|48 63|metalloproteases
P07629113A0726|84 99|N-ethylmaleimide
P07629122A0323|0 17|Mutational analysis
P07629122A0323|39 58|phosphorylation sites
P07629122A0323|66 69|NIMA
P07629122A0323|66 69|NIMA
P07629122A0323|71 75|NIM-1
P07629122A0323|71 75|NIM-1
P07629122A0323|87 100|protein kinases
P07629122A0323|87 100|protein kinases
P07629122A0323|115 118|NIMA
P07629122A0323|115 118|NIMA
P07629123A0885|27 33|leucine
P07629123A0885|43 50|arginine
P07629123A0885|53 63|position 422
P07629123A0885|84 101|heterodimerization
P07629123A0885|103 112|DNA binding
P07629123A0885|116 140|transcriptional activation
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|39 46|hormones
P07629150A0155|54 72|adrenocorticotropin
P07629150A0155|76 93|luteinizing hormone
P07629150A0155|76 93|luteinizing hormone
P07629150A0155|114 126|growth factors
P07629150A0155|163 180|regulatory elements
P07629150A0155|194 227|multiple signal transduction pathways
P07629163A0770|0 19|NH2- and COOH-terminal
P07629163A0770|55 105|PH and putative guanine nucleotide exchange factor domains
P07629163A0770|55 56|PH
P07629163A0770|68 105|guanine nucleotide exchange factor domains
P07629163A0770|124 136|zinc butterfly
P07629196A0274|30 52|GTPase-deficient mutants
P07629196A0274|30 35|GTPase
P07629196A0274|55 61|alpha 12
P07629196A0274|55 61|alpha 12
P07629196A0274|63 74|alpha 12Q229L
P07629196A0274|63 74|alpha 12Q229L
P07629196A0274|78 97|alpha 13 (alpha 13Q226L
P07629196A0274|78 84|alpha 13
P07629196A0274|86 97|alpha 13Q226L
P07629196A0274|127 165|Jun kinase/stress-activated protein kinase
P07629196A0274|127 135|Jun kinase
P07629196A0274|137 165|stress-activated protein kinase
P07629196A0274|167 182|JNK/SAPK) pathway
P07629196A0274|167 169|JNK
P07629196A0274|171 174|SAPK
P07630687A0010|111 130|radiologic evaluation
P07630687A0010|145 164|pulmonary involvement
P07630687A0010|178 192|antithrombin III
P07630687A0010|178 192|antithrombin III
P07630687A0010|194 201|protein C
P07630687A0010|229 247|lupus anticoagulants
P07630687A0010|250 257|children
P07630687A0010|270 284|thrombotic event
P07630934A0343|0 4|Harel
P07631267T0001|0 11|Radiotherapy
P07631267T0001|33 37|stage
P07631267T0001|38 57|D1 prostatic carcinoma
P07633444T0000|0 21|Structural organization
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|108 129|myotonic dystrophy locus
P07633756A0690|78 88|EEG activity
P07633756A0690|132 141|white noise
P07635140A0172|33 38|enzyme
P07635140A0172|40 44|CYP19
P07635140A0172|40 44|CYP19
P07635140A0172|67 90|tissue-specific promoters
P07635140A0172|82 90|promoters
P07635140A0172|106 125|alternative-splicing
P07635312A0692|5 15|mutagenesis
P07635312A0692|50 74|second actin-binding domain
P07635312A0692|56 74|actin-binding domain
P07635312A0692|97 109|act1 mutations
P07635312A0692|97 100|act1
P07635572A1153|0 8|CIITA mRNA
P07635572A1153|0 8|CIITA mRNA
P07635572A1153|30 38|IFN-gamma
P07635572A1153|30 38|IFN-gamma
P07635572A1153|41 78|class II non-inducible, RB-defective lines
P07635572A1153|93 105|re-expression
P07635572A1153|108 109|RB
P07635572A1153|108 109|RB
P07635572A1153|123 146|CIITA mRNA induction levels
P07635572A1153|123 131|CIITA mRNA
P07636179A0000|3 17|normal cell cycle
P07636179A0000|57 82|tumor-suppressor protein pRb
P07636179A0000|57 79|tumor-suppressor protein
P07636179A0000|80 82|pRb
P07636179A0000|87 95|G1 cyclins
P07636179A0000|87 95|G1 cyclins
P07636179A0000|100 122|cyclin-dependent kinases
P07636179A0000|100 122|cyclin-dependent kinases
P07636179A0000|127 141|their inhibitors
P07636187A0585|39 61|V beta 8.3 gene transcripts
P07636187A0585|40 50|beta 8.3 gene
P07636187A0585|80 94|transgenic lines
P07636187A0585|102 118|wild-type promoter
P07636187A0585|102 118|wild-type promoter
P07636337A0687|48 55|hormones
P07636337A0687|70 83|serum estradiol
P07636337A0687|91 93|HRT
P07636337A0687|97 109|Japanese women
P07636408T0000|27 73|Tesla field strength magnetic resonance imaging scans
P07636408T0000|106 133|lumbar intervertebral foramina
P07636648A1229|16 37|DTaP booster vaccination
P07636648A1229|74 100|serum antibody concentrations
P07636648A1229|74 86|serum antibody
P07636648A1229|153 169|pertussis antigens
P07636648A1229|153 169|pertussis antigens
P07636648A1229|185 195|DTaP-primed
P07636648A1229|196 203|children
P07636962A1288|18 42|amino-terminal determinant
P07636962A1288|66 77|HSV-alpha TIF
P07636962A1288|66 77|HSV-alpha TIF
P07636962A1288|94 118|independent amino-terminal
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|48 51|GAL4
P07636962A1883b|48 51|GAL4
P07636962A1883b|82 93|BHV-alpha TIF
P07636962A1883b|82 93|BHV-alpha TIF
P07636962A1883b|107 129|amino and carboxyl termini
P07636984A1349|31 33|SP1
P07636984A1349|31 33|SP1
P07636984A1349|45 59|nuclear extracts
P07636984A1349|64 81|HCMV-infected cells
P07637718A0218|14 26|messenger RNAs
P07637718A0218|35 50|trans-sialidases
P07637718A0218|115 129|trypomastigotes
P07638517A0000|52 69|Sao Paulo City Morgue
P07638517A0000|93 103|AIDS victims
P07638517A0000|109 123|unnatural deaths
P07639106A0678|44 48|TBBMD
P07639106A0678|61 66|weight
P07639106A0678|104 112|body TBBMC
P07639703A1703|2 13|retinoic acid
P07639703A1703|17 30|thyroid hormone
P07639703A1703|17 30|thyroid hormone
P07639703A1703|54 85|developmental regulatory processes
P07639703A1703|142 150|islet cell
P07640309A0000|3 28|C-terminal peptide sequences
P07640309A0000|34 102|human lymphocyte-specific high mobility group (HMG)-box transcription factor
P07640309A0000|76 107|HMG)-box transcription factor TCF-1
P07640309A0000|103 107|TCF-1
P07640309A0000|134 149|splice mechanisms
P07640309A0000|162 170|exons VIII
P07640309A0000|173 173|X
P07640422A0649|0 12|Thromboxane B2
P07640422A0649|81 103|heparin free hemodialysis
P07640422A0649|130 136|heparin
P07642490A0318|11 17|pHBK280
P07642538A0138|23 35|RSK activation
P07642538A0138|23 25|RSK
P07642538A0138|49 55|RSK cDNA
P07642538A0138|49 55|RSK cDNA
P07642538A0138|57 60|RSK3
P07642538A0138|57 60|RSK3
P07642538A0138|101 123|site-directed RSK mutants
P07642538A0138|114 123|RSK mutants
P07642538A0138|130 134|N-Lys
P07642538A0138|136 164|NH2-terminal ATP-binding mutant
P07642538A0138|136 158|NH2-terminal ATP-binding
P07642538A0138|159 164|mutant
P07642538A0138|167 177|K444A (C-Lys
P07642538A0138|179 191|COOH-terminal
P07642538A0138|192 208|ATP-binding mutant
P07642538A0138|192 208|ATP-binding mutant
P07642538A0138|211 217|N/C-Lys
P07642538A0138|211 211|N
P07642538A0138|213 241|C-Lys (double ATP-binding mutant
P07642538A0138|225 253|ATP-binding mutant) T570A (C-Thr
P07642538A0138|266 296|putative MAPK phosphorylation site
P07642538A0138|274 277|MAPK
P07642538A0138|308 311|VIII
P07642538A0138|317 324|C-domain
P07642538A0138|317 324|C-domain
P07642538A0138|327 337|S218A (N-Ser
P07642538A0138|363 381|NH2-terminal residue
P07642538A0744|15 19|C-Lys
P07642538A0744|23 27|C-Thr
P07642538A0744|48 61|kinase activity
P07642544A0868|22 58|human protein-tyrosine phosphatase alpha
P07642544A0868|22 53|human protein-tyrosine phosphatase
P07642544A0868|59 78|-overexpressing cells
P07642544A0868|83 99|phenylarsine oxide
P07642544A0868|115 143|constitutive NF-kappa B activity
P07642544A0868|127 135|NF-kappa B
P07642633T0000|1 17|TATA-less promoter
P07642633T0000|28 39|binding sites
P07642633T0000|43 72|ubiquitous transcription factors
P07642633T0000|81 107|cell type-specific regulation
P07642633T0000|120 148|transcription enhancer factor-1
P07642633T0000|120 148|transcription enhancer factor-1
P07642633T0000|150 154|TEF-1
P07642633T0000|150 154|TEF-1
P07644127A0000|5 25|electrical stimulation
P07644127A0000|28 35|neurones
P07644127A0000|54 63|cell bodies
P07644127A0000|71 84|neuronal fibres
P07644127A0000|158 180|rat substantia innominata
P07644127A0000|182 183|SI
P07644127A0000|211 219|carbachol
P07644466A0578|16 27|in vitro assay
P07644466A0578|36 52|NS3-4A polyprotein
P07644466A0578|36 41|NS3-4A
P07644466A0578|54 56|NS3
P07644466A0578|54 56|NS3
P07644466A0578|61 82|serine proteinase domain
P07644466A0578|61 82|serine proteinase domain
P07644466A0578|87 107|N-terminal 181 residues
P07644466A0578|110 112|NS3
P07644466A0578|110 112|NS3
P07644466A0578|121 132|NS4A cofactor
P07644466A0578|121 132|NS4A cofactor
P07644466A0578|179 194|trans-processing
P07644466A0578|197 218|radiolabeled substrates
P07644503A0729|28 34|RAR beta
P07644503A0729|28 34|RAR beta
P07644503A0729|53 67|differentiation
P07644503A0729|91 98|RAR gamma
P07644503A0729|91 98|RAR gamma
P07644503A0729|117 127|target genes
P07646439A0535|31 47|platelet membranes
P07646439A0535|53 80|DEAE-Sepharose chromatography
P07646439A0535|91 96|mAb F11
P07646439A0535|94 118|F11 affinity chromatography
P07647303T0000|3 18|homeobox gene ATK1
P07647303T0000|3 14|homeobox gene
P07647303T0000|15 18|ATK1
P07647303T0000|21 39|Arabidopsis thaliana
P07647303T0000|70 110|seedling and in flowers and inflorescence stems
P07647303T0000|119 124|plants
P07647570A0713|37 40|gold
P07647570A0713|68 79|Kupffer cells
P07647570A0713|83 93|renal cortex
P07647570A0713|119 133|Type I deiodinase
P07647570A0713|119 133|Type I deiodinase
P07648338A0815|40 57|intestinal ischemia
P07648338A0815|71 86|cytokine profiles
P07648338A0815|97 112|early TNF response
P07648338A0815|102 104|TNF
P07648338A0815|127 143|SMA occlusion model
P07649098A0676|87 115|122 nucleotides (nt) of promoter 1
P07649098A0676|119 123|328 nt
P07649098A0676|129 134|5'-UTR
P07649098A0676|147 179|PGE2-stimulated reporter expression
P07649098A0676|190 218|PGE2-driven reporter expression
P07649098A0676|240 256|nt 196 to 328 of exon 1
P07649098A0676|285 298|IGF-I promoter 1
P07649098A0676|285 298|IGF-I promoter 1
P07649098A0676|318 360|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|318 330|IGF-I promoter
P07649098A0676|332 360|luciferase-reporter constructs
P07649098A0676|366 372|plasmid
P07649098A0676|384 396|alpha-isoform
P07649098A0676|384 396|alpha-isoform
P07649098A0676|402 417|catalytic subunit
P07649098A0676|420 452|murine cAMP-dependent protein kinase
P07649098A0676|420 452|murine cAMP-dependent protein kinase
P07649098A0676|454 456|PKA
P07649098A0676|454 456|PKA
P07649098A0676|498 501|PGE2
P07649098A0676|538 544|plasmid
P07649098A0676|554 576|mutant regulatory subunit
P07649098A0676|560 576|regulatory subunit
P07649098A0676|579 581|PKA
P07649098A0676|579 581|PKA
P07649098A0676|596 599|cAMP
P07649098A0676|607 636|PGE2-induced reporter expression
P07650958A0123|110 118|auxiliary
P07651131A1407|0 15|Band-shift assays
P07651131A1407|19 47|DNase I footprinting experiments
P07651131A1407|19 24|DNase I
P07651131A1407|53 60|purified
P07651131A1407|61 81|42 kDa repressor isoform
P07651131A1407|95 103|CIRs 5 and 6
P07651141A0265|3 13|5'-terminus
P07651141A0265|19 30|p-gvpF-M mRNA
P07651141A0265|19 24|p-gvpF
P07651141A0265|26 30|M mRNA
P07651141A0265|41 62|169 nucleotides upstream
P07651141A0265|65 70|p-gvpF
P07651141A0265|65 70|p-gvpF
P07651141A0265|77 82|p-gvpE
P07651141A0265|77 82|p-gvpE
P07651340A0286|0 15|Retransformation
P07651340A0286|18 30|uvsH77 mutants
P07651340A0286|18 23|uvsH77
P07651340A0286|45 51|cosmids
P07651340A0286|59 84|MMS-resistant transformants
P07651340A0286|112 113|UV
P07651340A0286|117 119|MMS
P07651340A0286|132 146|wild-type levels
P07651386A0925|16 22|element
P07651386A0925|30 41|p53 induction
P07651386A0925|30 32|p53
P07651386A0925|69 95|adenovirus major late promoter
P07651398A0257|11 21|dShc protein
P07651398A0257|11 21|dShc protein
P07651398A0257|58 67|Drosophila
P07651398A0257|68 103|epidermal growth factor receptor homolog
P07651398A0257|68 103|epidermal growth factor receptor homolog
P07651398A0257|105 107|DER
P07651398A0257|105 107|DER
P07651398A0257|139 146|tyrosine
P07651398A0257|149 151|DER
P07651398A0257|149 151|DER
P07651398A0803|27 39|dShc PTB domain
P07651398A0803|27 39|dShc PTB domain
P07651398A0803|51 53|Tyr
P07651398A0803|61 63|DER
P07651398A0803|61 63|DER
P07651398T0000|1 24|Drosophila shc gene product
P07651398T0000|1 24|Drosophila shc gene product
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651400A0335|46 51|exon's
P07651400A0335|52 55|5' or
P07651400A0335|56 67|3' splice site
P07651400A0335|110 126|consensus sequence
P07651424A0487|0 18|Biochemical analysis
P07651424A0487|28 32|Ssm1p
P07651424A0487|28 32|Ssm1p
P07651424A0487|78 96|60S ribosomal subunit
P07651424A0487|78 89|60S ribosomal
P07651424A0743|2 15|wild-type cells
P07651424A0743|17 32|SSM1b transcripts
P07651424A0743|17 32|SSM1b transcripts
P07651424A0743|60 75|SSM1a transcripts
P07651424A0743|60 75|SSM1a transcripts
P07651424A0743|91 95|SSM1b
P07651424A0743|91 95|SSM1b
P07651424A0743|128 136|Ssm1p pool
P07651424A0743|128 132|Ssm1p
P07651734A0961|0 19|Northern blot analysis
P07651734A0961|43 52|LIMK-1 mRNA
P07651734A0961|43 52|LIMK-1 mRNA
P07651734A0961|71 75|brain
P07651734A0961|94 103|LIMK-2 mRNA
P07651734A0961|94 103|LIMK-2 mRNA
P07651734A0961|125 127|rat
P07652066A0677|16 23|anatomic
P07652066A0677|35 56|brachioplasty procedure
P07652066A0677|109 122|axillary fascia
P07652066A0677|138 167|superficial fascial system repair
P07652066A0677|197 215|widening or migration
P07652066A0677|218 222|scars
P07652066A0677|226 242|unnatural contours
P07652575A0435|51 61|Rac and Cdc42
P07652575A0435|51 53|Rac
P07652575A0435|57 61|Cdc42
P07652575A0435|69 80|Rho inhibitor
P07652575A0435|69 71|Rho
P07652575A0435|81 93|C3 transferase
P07652575A0435|81 93|C3 transferase
P07652575A0435|101 125|serum-induced DNA synthesis
P07652582A0000|0 15|INF-alpha therapy
P07652582A0000|0 8|INF-alpha
P07652582A0000|56 58|CML
P07653094A0169|38 60|d10, d20, d27, d31, d40, d44
P07653094A0169|65 67|d73
P07653094A0169|95 115|cell surface expression
P07653094A0169|138 157|biological attributes
P07653094A0169|183 193|mutant genes
P07653094A0169|200 212|plasmid vector
P07653094A0169|214 225|pcDL-SR alpha
P07653094A0169|219 229|SR alpha-296
P07653094A0169|233 236|CV-1
P07653094A0169|233 236|CV-1
P07653094A0169|240 248|HeLa cells
P07653812T0000|0 40|Intrathecal acetyl cholinesterase inhibitors
P07653812T0000|11 30|acetyl cholinesterase
P07653812T0000|78 85|morphine
P07653812T0000|100 103|rats
P07653892A0306|16 28|isoflurane MAC
P07653892A0306|31 46|triplicate, birds
P07653892A0306|57 72|mu-opioid agonist
P07653892A0306|74 81|morphine
P07653892A0306|90 108|kappa-opioid agonist
P07653892A0306|110 116|U50488H
P07654239A0698|0 2|Max
P07654239A0698|0 2|Max
P07654239A0698|54 73|cell cycle progression
P07654712A0774|3 13|yeast enzyme
P07654712A0774|36 51|mammalian enzymes
P07654712A0774|36 51|mammalian enzymes
P07654712A0774|145 149|pH 6.0
P07654740A0563|0 7|Key areas
P07654740A0563|48 55|surgical
P07654740A0563|70 84|transplantation
P07654740A0563|164 182|psychosocial factors
P07655184A0852|79 94|ER leader sequence
P07655184A0852|147 156|ER sequence
P07655184A0852|147 156|ER sequence
P07655505A0527|15 19|roots
P07655505A0527|21 31|GT-2 protein
P07655505A0527|21 24|GT-2
P07655505A0527|48 65|meristematic tissue
P07655505A0527|100 118|cellular development
P07655505A0527|167 192|phytochrome A gene expression
P07655505A0527|167 182|phytochrome A gene
P07655509T0000|1 11|polymorphic
P07655509T0000|12 25|bipartite motif
P07655509T0000|33 48|nuclear targeting
P07655509T0000|56 78|auxin-inducible proteins
P07655509T0000|88 115|PS-IAA4 from pea (Pisum sativum)
P07655509T0000|88 94|PS-IAA4
P07655509T0000|99 101|pea
P07655509T0000|103 114|Pisum sativum
P07656588A0101|11 29|DNA sequence analysis
P07656588A0101|47 67|microsatellite D19S596
P07656588A0101|47 67|microsatellite D19S596
P07656588A0101|72 76|2.2 kb
P07656588A0101|92 103|coding region
P07656588A0101|106 109|FUT1
P07656588A0101|106 109|FUT1
P07656588A0101|148 176|closely linked FUT1 and FUT2 genes
P07656588A0101|161 164|FUT1
P07656588A0101|168 176|FUT2 genes
P07656588A0101|187 188|cM
P07656588A0101|197 203|D19S412
P07656588A0101|197 203|D19S412
P07656588A0101|221 221|9
P07656588A0101|222 223|cM
P07656588A0101|234 240|D19S571
P07656588A0101|234 240|D19S571
P07657162A1412|14 36|transcription activation
P07657162A1412|39 43|LEF-1
P07657162A1412|39 43|LEF-1
P07657162A1412|54 79|chromatin-dependent process
P07657162A1412|103 124|trans-activation domain
P07657162A1412|140 148|HMG domain
P07657162A1412|140 148|HMG domain
P07657668A0642|0 12|TH-SH3 binding
P07657668A0642|0 1|TH
P07657668A0642|3 5|SH3
P07657668A0642|48 69|amino acid substitutions
P07657668A0642|79 89|Btk TH domain
P07657668A0642|79 81|Btk
P07657668A0642|82 89|TH domain
P07657668A0642|95 106|Fyn SH3 domain
P07657668A0642|95 97|Fyn
P07657705A1181|24 33|K-glypican
P07657705A1181|24 33|K-glypican
P07657705A1181|37 57|novel GPI-anchored HSPG
P07657705A1181|42 57|GPI-anchored HSPG
P07657705A1181|68 87|embryonic development
P07658262A0944|0 13|Protein S levels
P07658262A0944|50 58|admission
P07658262A0944|101 106|plasma
P07658262A0944|147 166|anticoagulant factors
P07658471A0000|3 19|plant hormone auxin
P07658471A0000|46 55|early genes
P07658777A0400|28 35|patients
P07658777A0400|45 61|contraindications
P07659085A1520|3 31|ubiquitous transcription factor
P07659085A1520|32 36|Oct-1
P07659085A1520|32 36|Oct-1
P07659085A1520|57 68|octamer motif
P07659085A1520|82 85|FPIV
P07659085A1520|88 103|gel shift analysis
P07659085A1520|108 112|liver
P07659085A1520|116 121|kidney
P07659085A1520|137 141|Oct-1
P07659085A1520|137 141|Oct-1
P07659085A1520|179 196|androgen regulation
P07659515T0000|4 25|non-LTR retrotransposon
P07659515T0000|4 25|non-LTR retrotransposon
P07659515T0000|61 81|site-specific elements
P07659515T0000|84 117|Crithidia fasciculata miniexon arrays
P07659529A0135|6 21|deletion analysis
P07659529A0135|25 42|transfection assays
P07659529A0135|47 68|reporter gene constructs
P07659529A0135|81 108|transcription control elements
P07659529A0135|114 129|5' flanking region
P07659529A0135|135 147|human EpoR gene
P07659529A0135|135 147|human EpoR gene
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659746A1464|3 9|CVA16.4
P07659757A0191|15 36|purified fusion proteins
P07659757A0191|41 51|[gamma-32P]
P07659757A0191|52 54|ATP
P07659757A0191|59 70|in vitro assay
P07659757A0191|106 124|autophosphorylation
P07660712A0118|22 35|immune response
P07660712A0118|41 57|immunized children
P07660712A0118|65 70|adults
P07660712A0118|83 95|high risk group
P07660712A0118|109 111|VHB
P07663138A0835|5 11|nadolol
P07663138A0835|13 17|heart
P07663138A0835|50 52|PBV
P07663138A0835|56 58|PBF
P07663160A0287|12 22|DNA sequence
P07663160A0287|70 99|Escherichia coli 16S ribosomal RNA
P07663160A0287|85 99|16S ribosomal RNA
P07663160A0287|112 137|internal secondary structure
P07663160A0287|142 153|optimal codon
P07663160A0287|172 188|protein expression
P07663160A0287|209 219|preferences
P07663160A0287|222 227|E. coli
P07663963A1588|0 25|Adrenergic system activation
P07663963A1588|51 61|epinephrine
P07663963A1588|179 192|control animals
P07663998T0000|0 19|Transabdominal repair
P07663998T0000|22 27|type IV
P07663998T0000|45 59|aortic aneurysms
P07665172A0000|0 19|Transcription factors
P07665172A0000|31 62|basic helix-loop-helix (bHLH) motif
P07665172A0000|31 51|basic helix-loop-helix
P07665172A0000|53 62|bHLH) motif
P07665172A0000|86 105|tissue-specific genes
P07665172A0000|86 105|tissue-specific genes
P07665172A0000|117 125|mammalian
P07665172A0000|129 141|insect systems
P07665187A0208|0 14|Primer extension
P07665187A0208|18 28|cDNA cloning
P07665187A0208|57 61|5' end
P07665187A0208|67 76|Nramp1 mRNA
P07665187A0208|67 76|Nramp1 mRNA
P07665187A0824|0 14|Primer extension
P07665187A0824|18 27|S1 nuclease
P07665187A0824|18 19|S1
P07665187A0824|20 45|nuclease mapping experiments
P07665187A0824|65 91|transcription initiation site
P07665187A0824|94 99|Nramp1
P07665187A0824|94 99|Nramp1
P07665477A0901|0 3|EsaR
P07665477A0901|0 3|EsaR
P07665477A0901|66 69|esaI
P07665477A0901|66 69|esaI
P07665567A0495|0 15|Sequence analysis
P07665567A0495|21 37|5'-flanking region
P07665567A0495|43 50|CD69 gene
P07665567A0495|43 50|CD69 gene
P07665567A0495|82 92|TATA element
P07665567A0495|93 111|30 base pairs upstream
P07665567A0495|117 148|major transcription initiation site
P07665567A0495|195 214|transcription factors
P07665567A0495|195 214|transcription factors
P07665567A0495|216 224|NF-kappa B
P07665567A0495|216 224|NF-kappa B
P07665567A0495|226 230|Egr-1
P07665567A0495|226 230|Egr-1
P07665567A0495|232 235|AP-1
P07665567A0495|232 235|AP-1
P07665605A1127|3 47|plasmin-derived D (approximately 105-kDa) product
P07665605A1127|3 18|plasmin-derived D
P07665605A1127|33 47|105-kDa) product
P07665605A1127|80 81|DD
P07665633A0284|64 81|dilution procedures
P07665633A0284|125 143|Laboratory Standards
P07665948A0591|0 8|IgE levels
P07665948A0591|0 2|IgE
P07665948A0591|37 53|normal individuals
P07665948A0591|57 65|IgE levels
P07665948A0591|57 59|IgE
P07665948A0591|78 85|children
P07665948A0591|98 103|adults
P07666414A0614|0 24|Tissue-specific expression
P07666414A0614|30 38|tmy-1 gene
P07666414A0614|30 38|tmy-1 gene
P07666414A0614|70 78|a promoter
P07666414A0614|71 93|promoter/lacZ fusion gene
P07666414A0614|80 93|lacZ fusion gene
P07666414A0614|101 120|immunohistochemistry
P07666414A0614|145 176|tissue-specific anti-tropomyosins
P07666414A0614|160 176|anti-tropomyosins
P07666415A0000|3 20|nucleotide sequence
P07666415A0000|26 43|chloroplast (cp) DNA
P07666415A0000|38 39|cp
P07666415A0000|48 52|maize
P07666415A0000|54 60|Zea mays
P07666523T0000|27 64|coronavirus subgenomic mRNA transcription
P07666523T0000|84 111|negative-sense RNA transcripts
P07666538A0000|28 47|human hepatitis C virus
P07666538A0000|49 51|HCV
P07666538A0000|53 61|RNA genome
P07666538A0000|98 114|5' noncoding region
P07666538A0000|116 120|5'NCR
P07666538A0000|125 145|cap-independent manner
P07666966A0207|4 24|longitudinal extension
P07666966A0207|30 43|epidural lesion
P07666966A0207|50 66|vertebral segments
P07667097A0267|16 19|p255
P07667097A0267|16 19|p255
P07667097A0267|68 73|mAb CC3
P07667097A0267|68 73|mAb CC3
P07667097A0267|84 98|in vitro splicing
P07667097A0267|102 118|immunoprecipitate
P07667097A0267|119 134|pre-messenger RNA
P07667195A0146|0 29|L-735,524 free base or sulfate salt
P07667195A0146|45 50|orally
P07667195A0146|76 86|solid dosage
P07667195A0146|102 114|fed Beagle dogs
P07667621T0001|0 23|Doppler ultrasound studies
P07667621T0001|46 53|children
P07667621T0001|58 81|hemolytic-uremic syndrome
P07668009A0172|24 41|hepatitis A diseases
P07669351A1278|18 22|phi 29
P07669351A1278|21 31|29 SSB-ssDNA
P07669351A1278|23 31|SSB-ssDNA
P07670504A0834|34 54|diffuse banding pattern
P07670504A0834|95 99|G-box
P07670504A0834|95 99|G-box
P07670504A0834|117 128|binding assay
P07670504A0834|152 154|GBF
P07670943A0308|21 34|female patients
P07670943A0308|39 46|early CAD
P07670943A0308|115 121|sibling
P07670943A0308|130 132|CAD
P07672821A0763|23 44|FHR2 and the factor H genes
P07672821A0763|23 26|FHR2
P07672821A0763|33 44|factor H genes
P07672821A0763|93 109|complement factor H
P07672821A0763|93 108|complement factor
P07672821A0763|109 109|H
P07672821A0763|116 138|factor H-related proteins
P07672822T0000|0 15|Genomic structure
P07672822T0000|43 74|mouse pre-T-cell receptor alpha gene
P07672822T0000|48 74|pre-T-cell receptor alpha gene
P07673128A0989|3 13|third domain
P07673128A0989|28 46|cAMP response element
P07673128A0989|28 46|cAMP response element
P07673128A0989|48 50|CRE
P07673128A0989|48 50|CRE
P07673154A0688|3 10|tyrosine
P07673154A0688|33 39|CAK beta
P07673154A0688|33 39|CAK beta
P07673154A0688|55 68|trypsinization
P07673154A0688|93 107|plating 3Y1 cells
P07673154A0688|112 122|fibronectin
P07673154A0688|112 122|fibronectin
P07673178A0982|30 39|muscle gene
P07673178A0982|40 46|E-boxes
P07673178A0982|102 111|MDF/bH-L-H
P07673178A0982|102 111|MDF/bH-L-H
P07673178A0982|132 141|MCK-L type E
P07673178A0982|132 141|MCK-L type E
P07675445A0463|49 52|p(CA
P07675445A0463|49 49|p
P07675445A0463|51 52|CA
P07675445A0463|70 100|sequence length polymorphism (SSLP
P07675449A0848|5 24|glioblastoma cell line
P07675449A0848|27 44|Shc-associated p190
P07675449A0848|27 44|Shc-associated p190
P07675449A0848|72 76|PDGFR
P07675449A0848|72 76|PDGFR
P07676492A1000|65 89|renal transplant recipients
P07676492A1000|105 109|dying
P07676492A1000|112 114|IHD
P07676587T0000|0 22|Veterinary certification
P07676587T0000|26 40|livestock export
P07676655A0214|3 20|serum concentration
P07676655A0214|23 24|iP
P07676655A0214|31 38|dialysis
P07676655A0214|40 41|HD
P07677573A0000|61 76|gastric secretion
P07677573A0000|78 86|incretion
P07677573A0000|90 108|histological changes
P07677573A0000|111 123|gastric mucosa
P07677573A0000|134 141|patients
P07677573A0000|146 161|chronic gastritis
P07677715A1076|3 11|TAF factor
P07677715A1076|3 11|TAF factor
P07677715A1076|48 50|OCD
P07677836A1356|0 23|Diffuse white matter injury
P07677836A1356|41 49|radiation
P07677836A1356|67 86|neurological deficits
P07677836A1356|140 151|chemotherapy
P07678006A0472|0 22|RNase protection analyses
P07678006A0472|0 4|RNase
P07678006A0472|41 56|61-kDa CaM PDE mRNA
P07678006A0472|47 52|CaM PDE
P07678006A0472|78 88|transcripts
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0472|135 155|tissue-specific manner
P07678006A0901|36 48|adrenal cortex
P07678006A0901|50 56|adrenal
P07678006A0901|57 69|medulla, liver
P07678006A0901|71 82|kidney cortex
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|40 47|PLC gamma
P07678051A1303|40 47|PLC gamma
P07678051A1303|71 94|PDGF-dependent production
P07678051A1303|71 74|PDGF
P07678051A1303|97 114|inositol phosphates
P07678242A0473|61 68|acc genes
P07678242A0473|61 68|acc genes
P07678242A0473|81 94|cellular growth
P07678593A0708|21 21|V
P07678602A0153|23 42|lymphoblast cell lines
P07678602A0153|64 71|patients
P07678602A0153|76 120|p47-phox-deficient chronic granulomatous disease
P07678602A0153|76 83|p47-phox
P07678602A0153|134 140|parents
P07678695A0604|3 19|ectopic expression
P07678695A0604|22 28|Oct-3/4
P07678695A0604|22 28|Oct-3/4
P07678695A0604|31 41|hybrid cells
P07678695A0604|48 67|constitutive promoter
P07678695A0604|83 107|transcriptional activation
P07678695A0604|112 136|octamer-dependent promoter
P07679390A0721|0 14|RNase protection
P07679390A0721|0 4|RNase
P07679390A0721|18 38|primer extension assays
P07679390A0721|55 70|5' non-coding exon
P07679390A0721|86 97|DDT1 aFGF mRNA
P07679390A0721|90 97|aFGF mRNA
P07679390A0721|111 132|transcription start site
P07679390A0721|148 160|136 bp upstream
P07679390A0721|166 177|5' non-coding
P07679390A0721|198 201|exon
P07679836A0387|23 27|FK 506
P07679836A0387|37 58|immunosuppressive agent
P07679836A0387|61 81|kidney transplantation
P07680035A0221|10 22|phorbol esters
P07680035A0221|26 34|cyclic AMP
P07680035A0221|49 60|GnRH response
P07680035A0221|49 52|GnRH
P07680120A1008|0 5|RT-PCR
P07680120A1008|11 29|1.D-specific primers
P07680120A1008|40 45|kidney
P07680120A1008|47 51|brain
P07680120A1008|55 62|prostate
P07680120A1008|77 77|D
P07680120A1008|78 81|mRNA
P07680120A1008|92 105|kidney and brain
P07680120A1008|133 143|aFGF protein
P07680120A1008|133 143|aFGF protein
P07680629T0000|0 15|Molecular cloning
P07680629T0000|53 57|gp138
P07680629T0000|53 57|gp138
P07680629T0000|60 82|cell surface glycoprotein
P07680629T0000|96 111|sexual cell fusion
P07680629T0000|114 136|Dictyostelium discoideum
P07681147A1420|0 36|Two-dimensional phosphotryptic analyses
P07681147A1420|49 63|phosphorylation
P07681147A1420|66 68|Ser
P07681147A1420|75 77|Ser
P07681147A1420|83 99|unstimulated cells
P07681147A1420|141 149|pp60c-src
P07681147A1420|141 149|pp60c-src
P07681147A1420|162 186|beta-adrenergic signalling
P07681513A0000|0 9|Piroximone
P07681513A0000|16 44|phosphodiesterase III inhibitor
P07681513A0000|16 35|phosphodiesterase III
P07681513A0000|69 89|vasodilator properties
P07681539A0000|0 17|Cytogenetic studies
P07681539A0000|33 43|lymphocytes
P07681539A0000|56 62|workers
P07681539A0000|82 90|radiation
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0294|64 87|chemotactic receptor genes
P07682842A0294|107 126|fMLF-R gene expression
P07682842A0294|107 116|fMLF-R gene
P07682842A0294|143 152|copy number
P07682842A0294|200 218|5'-flanking sequence
P07682842A0294|224 238|human fMLF-R gene
P07682842A0294|224 238|human fMLF-R gene
P07682842A0771|3 11|first exon
P07682842A0771|28 50|5'-untranslated sequence
P07682842A0771|57 61|exon 2
P07682842A0771|72 104|coding and 3'-untranslated sequences
P07683131A0885|3 18|genomic structure
P07683131A0885|37 46|SRC-family
P07683131A0885|37 46|SRC-family
P07683131A0885|70 90|exon/intron boundaries
P07683131A0885|100 114|catalytic domain
P07683375A0000|28 40|growth factors
P07683375A0000|56 64|estradiol
P07683375A0000|66 67|E2
P07683375A0000|66 67|E2
P07683375A0000|119 134|estrogen receptor
P07683375A0000|119 134|estrogen receptor
P07683375A0000|136 137|ER
P07683375A0000|136 137|ER
P07683375A0000|187 212|activators of protein kinases
P07683375A0000|199 212|protein kinases
P07683375A0000|224 246|transcriptional activity
P07683375A0000|252 253|ER
P07685263A0503|8 30|polymerase chain reaction
P07685263A0503|92 107|Whipple bacterium
P07685263A0503|109 127|Tropheryma whippelii
P07685823A1234|0 12|RNA polymerase
P07685823A1234|0 12|RNA polymerase
P07685823A1234|23 34|+10A promoter
P07685823A1234|53 71|20 base-pair sequence
P07685823A1234|76 81|DNase I
P07685823A1234|76 81|DNase I
P07685823A1234|104 112|start site
P07685874A0258|0 13|Salivary sodium
P07685874A0258|15 21|calcium
P07685874A0258|26 48|magnesium concentrations
P07685874A0258|77 87|SLE patients
P07685874A0258|92 117|systemic lupus erythematosus
P07685874A0258|126 134|potassium
P07685874A0258|138 163|total protein concentrations
P07685874A0258|167 173|amylase
P07685874A0258|167 173|amylase
P07685874A0258|214 221|controls
P07687320A0526|11 23|plasmid pFV100
P07687320A0526|71 86|B-band expression
P07687320A0526|89 92|ge6.
P07687320A0526|89 91|ge6
P07687541A0200|22 42|temperature-sensitive
P07687541A0200|50 60|yeast mutant
P07687541A0200|81 94|homologous gene
P07687541A0200|120 134|mtr1/prp20/srm1
P07687541A0200|120 123|mtr1
P07687541A0200|125 129|prp20
P07687541A0200|131 134|srm1
P07687541A0200|160 170|poly(A)+ RNA
P07687541A0992|5 9|RCC1p
P07687541A0992|5 9|RCC1p
P07687541A0992|16 19|GNRP
P07687541A0992|23 25|Ran
P07687541A0992|23 25|Ran
P07687541A0992|28 45|small nuclear GTPase
P07687541A0992|33 45|nuclear GTPase
P07687541A0992|51 64|ras superfamily
P07687541A0992|51 64|ras superfamily
P07687541A0992|95 97|Ran
P07687541A0992|95 97|Ran
P07687541A0992|100 111|S.cerevisiae
P07687541A0992|100 111|S.cerevisiae
P07687541A0992|113 116|CNR1
P07687541A0992|113 116|CNR1
P07687541A0992|120 123|CNR2
P07687541A0992|120 123|CNR2
P07687745T0000|3 19|immunosuppressant
P07687745T0000|20 24|FK506
P07687745T0000|33 47|amino acid import
P07687745T0000|50 72|Saccharomyces cerevisiae
P07688112A0274|0 22|Prostate specific antigen
P07688112A0274|0 22|Prostate specific antigen
P07688112A0274|31 45|metastatic cases
P07688112A0274|75 98|prostatic acid phosphatase
P07688112A0274|75 98|prostatic acid phosphatase
P07689154A0168|0 21|Protein phosphorylation
P07689154A0168|50 66|uPA gene expression
P07689154A0168|50 56|uPA gene
P07689154A0168|80 117|protein kinase C-activating phorbol esters
P07689154A0168|80 93|protein kinase C
P07689154A0168|131 139|pp60v-src
P07689154A0168|131 139|pp60v-src
P07689154A0168|165 171|uPA mRNA
P07689154A0168|165 171|uPA mRNA
P07689154A0168|180 217|cyclic AMP (cAMP)-dependent protein kinase
P07689154A0168|180 188|cyclic AMP
P07689154A0168|190 234|cAMP)-dependent protein kinase-activating agents
P07689154A0168|241 251|8-bromo cAMP
P07689154A0168|260 272|uPA mRNA levels
P07689154A0168|260 266|uPA mRNA
P07691837A1359|9 27|5'-upstream sequence
P07691837A1359|30 42|K3 keratin gene
P07691837A1359|30 42|K3 keratin gene
P07691837A1359|70 98|keratinocyte-specific promoter
P07691837A1359|157 177|NFkB consensus sequence
P07691837A1359|157 160|NFkB
P07691837A1359|193 197|GC box
P07691885T0000|49 67|proto-oncogene c-kit
P07691885T0000|49 62|proto-oncogene
P07691885T0000|63 67|c-kit
P07691885T0000|71 99|human mast cell leukemia cell line
P07691885T0000|107 134|ligand-independent activation
P07691885T0000|137 148|c-kit product
P07691885T0000|137 148|c-kit product
P07692366A0000|47 76|age-related macular degeneration
P07692366A0000|78 81|ARMD
P07692366A0000|112 127|clinical features
P07692668A0326|28 44|polyadenylated RNA
P07692668A0326|71 88|polyadenylated RNAs
P07692668A0326|131 155|northern blot hybridization
P07692668A0326|229 232|ORFs
P07692754T0000|46 69|hepatitis C virus infection
P07692754T0000|72 90|Egyptian blood donors
P07693132A0100|39 47|Zm-ERabp1
P07693132A0100|39 47|Zm-ERabp1
P07693132A0100|49 57|Zm-ERabp4
P07693132A0100|49 57|Zm-ERabp4
P07693132A0100|62 75|Zm-ERabp5 genes
P07693132A0100|62 75|Zm-ERabp5 genes
P07693372A0115|31 54|Streptomyces tsukubaensis
P07693372A0115|92 103|cyclosporine
P07693672A0259|0 17|DNase I footprinting
P07693672A0259|0 5|DNase I
P07693672A0259|23 38|proximal promoter
P07693699A0831|25 49|nucleotide binding function
P07693699A0831|100 103|urea
P07693708A0000|0 40|Insulin-like growth factor-binding protein-2
P07693708A0000|7 40|-like growth factor-binding protein-2
P07693708A0000|42 49|IGF-BP-2
P07693708A0000|42 49|IGF-BP-2
P07693708A0000|66 73|rat liver
P07693708A0000|103 109|fasting
P07693967A0905|16 32|RV 5'(+)SL sequence
P07693967A0905|63 73|translation
P07693975A1418|36 45|methionine
P07693975A1418|82 90|N terminus
P07693975A1418|93 94|PR
P07693975A1418|93 94|PR
P07693975A1418|115 125|proteolysis
P07693975T0000|0 40|Reverse transcriptase and protease activities
P07693975T0000|0 19|Reverse transcriptase
P07693975T0000|23 30|protease
P07693975T0000|43 60|avian leukosis virus
P07693975T0000|61 63|Gag
P07693975T0000|61 63|Gag
P07693975T0000|65 81|Pol fusion proteins
P07693975T0000|65 81|Pol fusion proteins
P07693975T0000|93 103|insect cells
P07695629A0489|13 30|mck1 mds1 mrk1 triple
P07695629A0489|13 16|mck1
P07695629A0489|17 20|mds1
P07695629A0489|21 24|mrk1
P07696183A0567|33 35|Rak
P07696183A0567|55 69|Src-like kinases
P07696183A0567|55 69|Src-like kinases
P07696183A0567|86 88|Rak
P07696183A0567|86 88|Rak
P07696183A0567|107 133|epithelial-derived cell lines
P07696183A0567|137 143|tissues
P07696183A0567|161 165|liver
P07696183A0567|169 174|kidney
P07696183A0567|190 195|breast
P07696183A0567|199 209|colon origin
P07696183A0567|214 216|Rak
P07696183A0567|233 251|NH2-terminal glycine
P07696183A0567|264 276|myristylation
P07696183A0567|280 299|membrane localization
P07696183A0567|305 306|c)
P07696183A0567|307 309|Rak
P07696183A0567|328 361|bipartite nuclear localization signal
P07696183A0567|367 375|SH2 domain
P07696183A0567|367 375|SH2 domain
P07696183A0567|380 410|subcellular fractionation studies
P07696183A0567|423 428|p54rak
P07696183A0567|423 428|p54rak
P07696183A0567|454 460|nucleus
P07696450A0271|49 56|children
P07696450A0271|77 90|Crohn's disease
P07696450A0271|97 102|casein
P07696450A0271|129 137|TGF-beta 2
P07696450A0271|129 137|TGF-beta 2
P07696450A0271|182 192|Switzerland
P07696878A0222|30 38|cDNA clone
P07696878A0222|59 75|open reading frames
P07696878A0222|116 131|open reading frame
P07696878A0222|144 161|homeodomain protein
P07696878A0222|144 161|homeodomain protein
P07697294A0329|14 24|HSP81-1 mRNA
P07697294A0329|14 24|HSP81-1 mRNA
P07698219A0551|0 11|Cell adhesion
P07698219A0551|15 29|migration assays
P07698219A0551|45 55|alpha 6 beta 1
P07698219A0551|45 55|alpha 6 beta 1
P07698219A0551|66 80|laminin receptor
P07698219A0551|66 80|laminin receptor
P07698219A0551|83 105|undifferentiated F9 cells
P07698219A0551|114 130|F9-derived PE cells
P07698727A0386|20 35|tumor or infection
P07698727A0386|64 75|HIV infection
P07699632A0522|27 40|Chukcha-Eskimo
P07699632A0522|44 45|AS
P07699632A0522|67 84|psoriatic arthritis
P07699632A0522|86 88|PsA
P07699632A0715|31 52|circumpolar populations
P07699632A0715|93 95|SPA
P07699632A0715|93 95|SPA
P07699632A0715|99 105|HLA-B27
P07699632A0715|99 105|HLA-B27
P07699845A0537|0 20|Clinical studies SY5555
P07699845A0537|40 47|patients
P07699845A0537|59 76|infectious diseases
P07699845A0537|83 98|acute pharyngitis
P07699845A0537|105 120|acute tonsillitis
P07699845A0537|127 144|lacunar tonsillitis
P07699845A0537|155 169|acute bronchitis
P07699845A0537|183 193|pertussis, 7
P07699845A0537|216 233|impetigo contagiosa
P07699845A0537|240 266|acute urinary tract infections
P07699845A0537|300 320|cervical lymphadenitis
P07699845A0537|342 353|acute colitis
P07699845A0537|386 386|t
P07700361A0125|12 31|SH2-pTyr interactions
P07700361A0125|12 14|SH2
P07700361A0125|16 19|pTyr
P07700361A0125|103 115|molecular type
P07701266A0808|31 38|patients
P07701266A0808|48 63|TPN + somatostatin
P07701266A0808|52 63|somatostatin
P07701266A0808|142 144|TPN
P07702327T0000|12 19|adhesion
P07702327T0000|35 71|recombinant tissue plasminogen activator
P07702327T0000|35 51|recombinant tissue
P07702327T0000|52 71|plasminogen activator
P07702378A0668|0 9|Scratching
P07702378A0668|16 20|sleep
P07702378A0668|23 30|children
P07702378A0668|35 50|atopic dermatitis
P07702378A0668|76 78|VO2
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|75 106|cAMP-stimulated gene transcription
P07702752A0545|75 93|cAMP-stimulated gene
P07702752A0545|143 148|-1,560
P07702752A0545|166 179|5'-flanking DNA
P07702752A0545|187 200|rat P450c17 gene
P07702752A0545|187 200|rat P450c17 gene
P07702752A0545|214 221|plasmids
P07702752A0545|235 256|reporter gene luciferase
P07702752A0545|247 256|luciferase
P07702752A0545|278 291|mouse cell lines
P07702752A0545|293 307|adrenal Y-1 cells
P07702752A0545|328 337|MA-10 cells
P07702808A0427|14 15|BP
P07702808A0427|34 40|fish oil
P07702808A0427|44 50|corn oil
P07702808A0427|74 80|Dinamap
P07702808A0427|116 118|ABP
P07704040A0000|27 39|mouse NMO1 cDNA
P07704040A0000|27 39|mouse NMO1 cDNA
P07704040A0000|56 86|NAD(P)H:menadione oxidoreductase
P07704040A0000|56 62|NAD(P)H
P07704040A0000|64 87|menadione oxidoreductase [
P07704040A0000|98 136|NAD(P)H:(quinone acceptor) oxidoreductase
P07704040A0000|98 121|NAD(P)H:(quinone acceptor
P07704040A0000|123 153|oxidoreductase; quinone reductase
P07704040A0000|138 153|quinone reductase
P07704040A0000|155 169|azo dye reductase
P07704040A0000|161 193|reductase; DT diaphorase; EC 1.6.99.2
P07704040A0000|171 182|DT diaphorase
P07704040A0000|184 193|EC 1.6.99.2
P07704273A0000|0 14|Escherichia coli
P07704273A0000|15 20|JRG582
P07704273A0000|25 40|ampD ampE deletion
P07704273A0000|25 28|ampD
P07704273A0000|29 32|ampE
P07704273A0000|59 62|HfrH
P07704273A0000|116 142|inducible beta-lactamase gene
P07704273A0000|125 138|beta-lactamase
P07704273A0000|145 163|Citrobacter freundii
P07704273A0000|174 186|plasmid pNU305
P07704456A1014|126 136|HMS subjects
P07704689T0000|8 20|thyroid nodule
P07704730T0000|0 16|Male contraception
P07704730T0000|29 34|future
P07705476A0292|10 19|food intake
P07705476A0292|52 70|dietary protein level
P07705476A0292|72 82|water intake
P07705476A0292|86 90|urine
P07705476A0292|123 136|dietary protein
P07705627A1107|13 15|Mad
P07705627A1107|13 15|Mad
P07705627A1107|19 23|Medea
P07705627A1107|63 73|dpp pathways
P07705627A1107|63 65|dpp
P07706273T0000|0 24|Transcriptional regulation
P07706273T0000|30 61|vacuolar H(+)-ATPase B2 subunit gene
P07706273T0000|30 61|vacuolar H(+)-ATPase B2 subunit gene
P07706273T0000|64 88|differentiating THP-1 cells
P07706287A0698|38 44|nucleus
P07706287A0698|50 58|cytoplasm
P07706287A0698|95 111|cell division cycle
P07706291T0000|2 12|E box element
P07706291T0000|2 12|E box element
P07706291T0000|44 52|ad4bp gene
P07706291T0000|44 52|ad4bp gene
P07706291T0000|55 84|mammalian homologue of ftz-f1 gene
P07706291T0000|55 72|mammalian homologue
P07706291T0000|75 84|ftz-f1 gene
P07706291T0000|105 121|adrenal and gonadal
P07706299A0563|44 72|natural and synthetic sialylated
P07706299A0563|79 86|sulfated
P07706299A0563|166 195|oligosaccharide-protein binding
P07706307A0914|3 19|amino acid sequence
P07706307A0914|82 100|S. griseus proteases A
P07706307A0914|82 90|S. griseus
P07706307A0914|102 102|B
P07706307A0914|102 102|B
P07706307A0914|107 108|C.
P07706396T0000|0 8|Mutations
P07706396T0000|14 22|VPS45 gene
P07706396T0000|14 22|VPS45 gene
P07706396T0000|25 37|SEC1 homologue
P07706396T0000|25 28|SEC1
P07706396T0000|47 75|vacuolar protein sorting defects
P07706396T0000|93 108|membrane vesicles
P07707523A0704|2 9|293 cells
P07707523A0704|26 43|NF-kappa B inhibitor
P07707523A0704|26 34|NF-kappa B
P07707523A0704|45 57|I kappa B-alpha
P07707523A0704|45 57|I kappa B-alpha
P07707523A0704|69 87|stimulatory activity
P07707523A0704|90 92|LMP
P07707523A0704|90 92|LMP
P07707531A0550|4 21|experimental design
P07707531A0550|68 86|alpha 4-2 binding site
P07707531A0550|68 86|alpha 4-2 binding site
P07707531A0550|104 126|alpha 4 gene transcription
P07707531A0550|104 113|alpha 4 gene
P07707531A0550|129 132|ICP4
P07707531A0550|129 132|ICP4
P07707544T0000|0 27|Immediate-early transcription
P07707544T0000|35 59|channel catfish virus genome
P07707544T0000|82 107|immediate-early transcripts
P07707544T0000|82 107|immediate-early transcripts
P07708058A0178|3 5|GRE
P07708058A0178|8 21|nucleotide 7640
P07708058A0178|34 36|GRE
P07708058A0178|38 41|cGRE
P07708058A0178|66 89|activator protein-1 (AP-1)
P07708058A0178|66 83|activator protein-1
P07708058A0178|85 88|AP-1
P07708058A0178|101 139|c-jun homodimer and c-jun/c-fos heterodimer
P07708058A0178|101 114|c-jun homodimer
P07708058A0178|118 122|c-jun
P07708058A0178|124 128|c-fos
P07708497A0000|0 24|Transcriptional activation
P07708497A0000|27 40|thyroid hormone
P07708497A0000|27 40|thyroid hormone
P07708497A0000|42 43|T3
P07708497A0000|42 43|T3
P07708497A0000|75 87|T3 receptor (TR
P07708497A0000|75 84|T3 receptor
P07708497A0000|86 87|TR
P07708497A0000|92 109|T3 response elements
P07708497A0000|92 93|T3
P07708497A0000|111 114|TREs
P07708497A0000|111 114|TREs
P07708497A0000|155 160|AGGTCA
P07711667A0766|0 20|A multivariate analysis
P07711667A0766|56 58|WBC
P07711667A0766|71 80|blast count
P07711667A0766|105 116|marrow blasts
P07711667A0766|118 127|FAB subtype
P07711667A0766|118 120|FAB
P07711667A0766|175 183|remission
P07711667A0766|204 223|consolidation therapy
P07711667A0766|259 280|GVHD prophylaxis regimen
P07711730A0000|0 45|Carnitine palmitoyltransferase (CPT) II deficiency
P07711730A0000|0 35|Carnitine palmitoyltransferase (CPT) II
P07711730A0000|80 94|lipid metabolism
P07711730A0000|104 117|skeletal muscle
P07713421A1435a|86 107|sex determination signal
P07713421A1435a|113 117|SxlM4
P07713421A1435a|113 117|SxlM4
P07713421A1435a|138 142|SxlM1
P07713421A1435a|138 142|SxlM1
P07713421A1435b|86 107|sex determination signal
P07713421A1435b|113 117|SxlM4
P07713421A1435b|113 117|SxlM4
P07713421A1435b|138 142|SxlM1
P07713421A1435b|138 142|SxlM1
P07713936A0393|9 13|meAda
P07713936A0393|9 13|meAda
P07713936A0393|109 112|aidB
P07713936A0393|109 112|aidB
P07713936A0393|139 143|meAda
P07713936A0393|139 143|meAda
P07714608A1252|57 61|PaCO2
P07714608A1252|84 92|heart rate
P07714608A1252|94 109|brain temperature
P07714608A1252|113 125|glucose levels
P07714758A1193|31 39|lidocaine
P07715200A0000|0 16|Anesthesiologists
P07715200A0000|43 49|patient
P07715200A0000|82 101|desired blood pressure
P07715602A1088|46 77|multisubunit cytochrome c haem lyase
P07715602A1088|46 57|multisubunit
P07715602A1088|58 68|cytochrome c
P07715922A0188|49 71|corneal endothelial cells
P07715922A0188|92 99|patients
P07715922A0188|121 123|PRK
P07717823A0328|0 16|Standard reference
P07717823A0328|114 136|basal metabolic functions
P07719527T0000|0 16|Weak allergenicity
P07719527T0000|19 44|recombinant hirudin CGP 39393
P07719527T0000|30 36|hirudin
P07719527T0000|37 44|CGP 39393
P07719527T0000|46 51|REVASC
P07719527T0000|55 79|immunocompetent volunteers
P07720572A0701|15 26|myoD promoter
P07720572A0701|15 26|myoD promoter
P07720572A0701|31 42|myoD enhancer
P07720572A0701|31 42|myoD enhancer
P07720572A0701|75 80|humans
P07720572A0701|84 87|mice
P07720572A1584|37 59|myoblasts and 10T1/2 cells
P07720572A1584|69 87|non-muscle cell types
P07720572A1584|94 111|chromatin structure
P07720572A1584|117 143|chromosomal myoD core enhancer
P07720572A1584|128 143|myoD core enhancer
P07720572A1584|162 173|myoD enhancer
P07720572A1584|162 173|myoD enhancer
P07720572A1584|187 206|epigenetic mechanisms
P07720572A1584|209 219|10T1/2 cells
P07720709A0755|5 10|Ki-ras
P07720709A0755|5 10|Ki-ras
P07720709A0755|23 30|3T3 cells
P07720709A0755|60 61|RA
P07720709A0755|69 80|dissociating
P07720709A0755|82 90|retinoids
P07720709A0755|98 135|anchorage-independent cell proliferation
P07720709A0755|151 182|retinoid-induced growth inhibition
P07720709A0755|197 199|AP1
P07720709A0755|197 199|AP1
P07720710A0861|3 20|Oct and HMG2 proteins
P07720710A0861|3 5|Oct
P07720710A0861|9 20|HMG2 proteins
P07721074A0766|0 15|Atopic dermatitis
P07721422A0241|0 25|Primer extension experiments
P07721422A0241|47 74|transcription initiation sites
P07721422A0241|77 78|bp
P07721422A0241|89 110|mouse type 2 receptor gene
P07721422A0241|89 110|mouse type 2 receptor gene
P07721878A1163|3 13|beta subunit
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|33 60|33-kDa tyrosine phosphoprotein
P07721878A1163|39 60|tyrosine phosphoprotein
P07721878A1163|68 89|p33 Grb2-binding protein
P07721878A1163|68 70|p33
P07721878A1163|71 89|Grb2-binding protein
P07721878A1163|125 144|Fc epsilon R1 beta chain
P07721878A1163|125 144|Fc epsilon R1 beta chain
P07723247A0187|89 97|dialysate
P07723247A0187|111 122|computerized
P07723247A0187|190 235|arterial, venous, dialysate inflow and outflow ports
P07723247A1161|42 47|IL-1Ra
P07723247A1161|42 47|IL-1Ra
P07723247A1161|51 58|IL-1 beta
P07723247A1161|51 58|IL-1 beta
P07723247A1161|81 96|radioimmunoassay
P07724452A0344|4 19|dietary treatment
P07728201A0660|37 44|children
P07728201A0660|49 73|sickle-hemoglobin C disease
P07728201A0660|49 65|sickle-hemoglobin
P07728201A0660|86 103|functional asplenia
P07728201A0660|148 168|penicillin prophylaxis
P07729427A0942|0 15|Deletion analysis
P07729427A0942|29 31|TBP
P07729427A0942|29 31|TBP
P07729427A0942|35 42|hTAFII18
P07729427A0942|35 42|hTAFII18
P07729427A0942|66 73|hTAFII28
P07729427A0942|66 73|hTAFII28
P07729427A0942|75 82|hTAFII18
P07729427A0942|75 82|hTAFII18
P07729427A0942|100 102|TBP
P07729427A0942|100 102|TBP
P07729427A0942|134 141|hTAFII28
P07729427A0942|134 141|hTAFII28
P07729427A0942|145 152|hTAFII30
P07729427A0942|145 152|hTAFII30
P07730273A1309|3 6|NarX
P07730273A1309|3 6|NarX
P07730273A1309|10 21|NarQ proteins
P07730273A1309|10 21|NarQ proteins
P07730273A1309|26 47|amino acid substitutions
P07730273A1309|67 75|histidine
P07730273A1309|115 128|NarL-phosphate
P07730273A1309|115 118|NarL
P07730328A0000|0 23|Vascular endothelial cells
P07730328A0000|31 45|profound changes
P07730328A0000|50 67|cellular activation
P07730328A0000|100 129|cell activation-associated genes
P07730336A0606|7 11|ATF-1
P07730336A0606|7 11|ATF-1
P07730336A0606|15 18|CREM
P07730336A0606|15 18|CREM
P07730336A0606|35 54|cAMP response elements
P07730336A0606|35 54|cAMP response elements
P07730336A0606|56 58|CRE
P07730336A0606|56 58|CRE
P07730336A0606|65 82|functional sequence
P07730336A0606|94 105|kappa E3'-CRE
P07730336A0606|94 105|kappa E3'-CRE
P07730337A1439|3 8|Ng/RC3
P07730337A1439|3 4|Ng
P07730337A1439|6 8|RC3
P07730337A1439|12 25|PKC-gamma genes
P07730337A1439|12 20|PKC-gamma
P07730337A1439|60 64|brain
P07730337T0000|42 101|neuron-specific protein kinase C substrate neurogranin (RC3 protein
P07730337T0000|42 79|neuron-specific protein kinase C substrate
P07730337T0000|80 90|neurogranin
P07730337T0000|92 101|RC3 protein
P07730795A0104|3 20|amino acid sequences
P07730795A0104|48 52|DdRPs
P07730795A0104|48 52|DdRPs
P07731686A0000|3 11|TTG-2 gene
P07731686A0000|3 11|TTG-2 gene
P07731686A0000|40 64|chromosomal translocations
P07731686A0000|67 93|acute T-cell leukemia's (T-ALL
P07731898A0823|18 27|blood cells
P07731898A0823|50 64|bicarbonate ions
P07731898A0823|110 121|hemodialysis
P07731898A0823|170 185|superoxide anions
P07731898A0823|197 212|erythrocyte SOD-1
P07731898A0823|208 212|SOD-1
P07731898A0823|216 223|catalase
P07731898A0823|216 223|catalase
P07731898A0823|248 272|membrane lipid peroxidation
P07733075A1200|0 11|Short therapy
P07733075A1200|16 25|omeprazole
P07733075A1200|68 70|CBS
P07733075A1200|133 147|eradication rate
P07733075A1200|161 185|duodenal ulcer healing rates
P07735590A0990|59 72|Der p milligrams
P07735590A0990|79 87|house dust
P07735590A0990|103 105|cat
P07735590A0990|133 135|cat
P07735590A0990|151 164|Fel d milligrams
P07735590A0990|186 188|cat
P07735590A0990|203 216|Fel d milligrams
P07735833A1078|28 47|LysU crystal structure
P07735833A1078|28 31|LysU
P07735833A1078|67 99|seryl- and aspartyl-tRNA synthetases
P07735833A1078|76 88|aspartyl-tRNA
P07737024A1003|0 19|Whole bowel irrigation
P07737024A1003|91 97|pylorus
P07737118A0317|3 22|MPS1 open reading frame
P07737118A0317|55 65|LexA protein
P07737118A0317|55 65|LexA protein
P07737118A0317|71 80|GST protein
P07737118A0317|71 80|GST protein
P07737118A0317|115 119|yeast
P07737508A0649|4 5|Tb
P07737508A0649|7 8|U6
P07737508A0649|7 8|U6
P07737508A0649|12 26|single-copy gene
P07737508A0649|33 41|tRNA genes
P07737508A0649|33 41|tRNA genes
P07737508A0649|43 49|tRNAGln
P07737508A0649|43 49|tRNAGln
P07737508A0649|53 59|tRNAIle
P07737508A0649|53 59|tRNAIle
P07737944A0000|0 25|Hematopoietic growth factors
P07737944A0000|0 25|Hematopoietic growth factors
P07737944A0000|58 68|transfusion
P07737944A0000|79 89|eliminating
P07737944A0000|110 121|red blood cell
P07737944A0000|146 157|anemic states
P07737944A0000|203 216|erythropoietin
P07737944A0000|203 216|erythropoietin
P07738026A0216|63 65|ADH
P07738839A0173|6 14|IC breaths
P07738839A0173|27 40|EC and VC breaths
P07738839A0173|57 71|CO2 pressure (PET
P07738839A0173|73 75|CO2
P07738856A0174|0 0|2
P07739382A0457|0 19|Phylogenetic analyses
P07739382A0457|24 41|amino acid sequences
P07739382A0457|76 99|actin-associated proteins
P07739382A0457|76 80|actin
P07739382A0457|109 116|gelsolin
P07739382A0457|159 176|flightless proteins
P07739382A0457|159 176|flightless proteins
P07739520A1250|29 46|Surfeit gene cluster
P07739520A1250|29 46|Surfeit gene cluster
P07739520A1250|80 80|D
P07739520A1250|94 109|Surf-3/rpL7a gene
P07739520A1250|94 99|Surf-3
P07739520A1250|101 105|rpL7a
P07739542A1419|20 26|cyclin E
P07739542A1419|20 26|cyclin E
P07739542A1419|40 47|cyclin D1
P07739542A1419|40 47|cyclin D1
P07739542A1419|66 79|G1/S transition
P07739542A1419|98 118|retinoblastoma protein
P07739542A1419|98 118|retinoblastoma protein
P07739544A0364|3 28|predicted amino acid sequence
P07739544A0364|34 48|SGC1 gene product
P07739544A0364|34 48|SGC1 gene product
P07739544A0364|94 121|basic-helix-loop-helix domain
P07739544A0364|94 121|basic-helix-loop-helix domain
P07739544A0364|127 129|Myc
P07739544A0364|127 129|Myc
P07739544A0364|138 156|DNA-binding proteins
P07739544A0364|138 156|DNA-binding proteins
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07739566A1076|10 14|Pax-6
P07739566A1076|16 19|BSAP
P07739566A1076|61 76|amino acid stretch
P07739566A1076|82 95|N-terminal part
P07739566A1076|152 173|DNA-binding specificity
P07740487A0167|38 62|familial dysfibrinogenemia
P07740487A0167|66 78|thrombophilia
P07740487A0167|153 167|SSC Subcommittee
P07740487A0167|170 179|Fibrinogen
P07740487A0167|170 179|Fibrinogen
P07740487A0167|185 197|International
P07740487A0167|207 216|Thrombosis
P07740487A0167|220 230|Haemostasis
P07740490T0000|0 18|Conjugated estrogens
P07740490T0000|63 71|serotonin
P07741255A0194|8 16|districts
P07741255A0194|29 37|34,000 km2
P07742024A0121|26 40|imaging features
P07742024A0121|71 76|places
P07742024A0121|107 111|tumor
P07742363A0135|3 18|mammalian enzymes
P07742363A0135|23 50|haem-controlled repressor (HCR
P07742363A0135|23 46|haem-controlled repressor
P07742363A0135|48 50|HCR
P07742363A0135|58 94|double-stranded RNA-activated inhibitor
P07742363A0135|58 94|double-stranded RNA-activated inhibitor
P07742363A0135|96 98|dsI
P07742363A0135|96 98|dsI
P07742363A0135|114 116|Ser
P07742363A0135|125 136|alpha subunit
P07742363A0135|125 136|alpha subunit
P07742363A0135|173 183|nucleotides
P07742363A0135|197 205|recycling
P07742363A0135|209 213|eIF-2
P07742363A0135|209 213|eIF-2
P07742363A0941|7 9|Ser
P07742363A0941|13 15|Ala
P07742363A0941|28 42|yeast eIF-2 alpha
P07742363A0941|28 42|yeast eIF-2 alpha
P07742363A0941|90 94|yeast
P07742363A0941|98 129|mammalian) casein kinase activities
P07742363A0941|98 119|mammalian) casein kinase
P07742550A0407|31 49|aggressive lymphomas
P07742550A0407|51 53|DAL
P07742550A0407|57 78|large-cell, 4 mixed-cell
P07742550A0407|95 107|immunoblastic
P07742550A0407|123 141|aggressive lymphomas
P07742550A0407|153 171|follicular lymphomas
P07742550A0407|173 175|TFL
P07742550A0407|188 206|follicular lymphomas
P07742550A0407|208 209|FL
P07742550A0407|214 232|mantle cell lymphomas
P07742550A0407|234 236|MCL
P07742550A0407|249 271|noncleaved cell lymphomas
P07742550A0407|273 276|SNCL
P07742917T0001|0 6|Icterus
P07742917T0001|10 25|beta-thalassemia
P07742917T0001|28 44|Congolese children
P07743472A0181|0 13|Female patients
P07743472A0181|18 29|breast cancer
P07743472A0181|59 84|Roswell Park Cancer Institute
P07743472A0181|86 89|RPCI
P07743472A0181|101 107|New York
P07743472A0181|177 185|diagnosis
P07743515A0223|37 40|AAMP
P07743515A0223|75 90|endothelial cells
P07743515A0223|112 150|poorly differentiated colon adenocarcinoma
P07743697A0703|11 18|V-HeFT II
P07743697A0703|69 82|norepinephrine
P07743697A0703|173 209|angiotensin-converting enzyme inhibitor
P07743697A0703|173 200|angiotensin-converting enzyme
P07743697A0703|211 219|enalapril
P07743697A0703|223 240|vasodilator therapy
P07743697A0703|245 275|hydralazine/isosorbide dinitrate
P07744763A0514|0 14|Binding activity
P07744763A0514|17 24|rat liver
P07744763A0514|53 67|orphan receptors
P07744763A0514|53 67|orphan receptors
P07744763A0514|80 115|electromobility supershift experiments
P07744763A0514|181 187|CYP2C11
P07744763A0514|181 187|CYP2C11
P07744763A0514|198 202|HNF-4
P07744763A0514|198 202|HNF-4
P07744776A0617|0 17|Transcript analysis
P07744776A0617|29 35|lethal B
P07744776A0617|60 73|U6 RNA synthesis
P07744776A0617|60 64|U6 RNA
P07744846A1006|10 20|Bcl-2/Bcl-2
P07744846A1006|10 14|Bcl-2
P07744846A1006|16 20|Bcl-2
P07744846A1006|21 36|homodimerization
P07744846A1006|46 65|in vitro binding assays
P07744846A1006|75 95|yeast two-hybrid method
P07744846A1006|144 170|Bcl-2/Bcl-2 homodimerization
P07744846A1006|144 148|Bcl-2
P07744846A1006|150 154|Bcl-2
P07744846A1006|204 222|NH2-terminal A domain
P07744846A1006|204 222|NH2-terminal A domain
P07744846A1006|277 296|carboxyl B and C domains
P07744846A1006|277 285|carboxyl B
P07744846A1006|289 296|C domains
P07744954A0418|23 49|central alpha-helical portion
P07744954A0418|54 68|globular domains
P07744954A0418|75 91|NH2 and COOH termini
P07744954A0418|111 128|monoclonal antibody
P07744954A0418|141 165|central alpha-helical stalk
P07745008A0892|0 17|Radioligand binding
P07745311A0264|0 8|Diagnosis
P07745311A0264|11 14|FHCS
P07745311A0264|33 52|laparoscopic findings
P07745684T0000|0 33|Human papillomavirus type 31b late gene
P07745684T0000|0 25|Human papillomavirus type 31b
P07745684T0000|26 43|late gene expression
P07745684T0000|62 91|protein kinase C-mediated changes
P07745684T0000|62 75|protein kinase C
P07745684T0000|94 106|RNA processing
P07745685A1442|14 20|virions
P07745685A1442|64 73|antibodies
P07745685A1442|88 104|accessory proteins
P07745685A1442|113 114|SN
P07745685A1442|113 114|SN
P07745685A1442|118 134|CAT fusion partners
P07745685A1442|118 120|CAT
P07745693A0914|26 43|mutant Lb proteinase
P07745693A0914|34 43|proteinase
P07745693A0914|70 91|IRES-driven translation
P07745693A0914|105 115|proteolysis
P07745693A0914|122 138|cellular component
P07745696A0932|0 25|Restriction mapping analysis
P07745696A0932|39 42|cDNA
P07745696A0932|48 81|HHV-6A(U1102) genomic BamHI G fragment
P07745696A0932|48 53|HHV-6A
P07745696A0932|55 81|U1102) genomic BamHI G fragment
P07745696A0932|88 92|right
P07745696A0932|107 117|long segment
P07745696A0932|137 141|SalI L
P07745696A0932|137 141|SalI L
P07745696A0932|145 158|SalI O fragments
P07745696A0932|145 158|SalI O fragments
P07745696A0932|168 171|left
P07745696A0932|175 179|right
P07745726A0960|3 31|replication reporter constructs
P07745726A0960|37 38|E1
P07745726A0960|37 38|E1
P07745726A0960|42 43|E2
P07745726A0960|42 43|E2
P07745726A0960|77 93|expression vectors
P07745726A0960|113 121|half sites
P07745726A1496|36 50|18-bp palindrome
P07745726A1496|69 97|nucleotide sequence information
P07745726A1496|101 102|E1
P07745726A1496|101 102|E1
P07745726A1496|134 151|E1 recognition motif
P07745726A1496|134 151|E1 recognition motif
P07745726A1496|169 176|half site
P07746397A0233|16 23|patients
P07746397A0233|33 47|anticoagulation
P07746397A0233|81 88|patients
P07746397A0233|121 127|heparin
P07746397A0233|167 180|thromboplastin
P07746397A0233|186 189|aPTT
P07746794A0000|26 47|intravenous formulation
P07746794A0000|50 61|Cyclosporin A
P07746794A0000|63 71|Sandimmun
P07746794A0000|74 98|polyoxyethylated castor oil
P07746794A0000|100 110|Cremophor EL
P07746794A0000|121 137|solubilizing agent
P07746937A0100|0 20|Lung function tests (EFR
P07747462A0332|21 44|prokaryotic RCR initiators
P07747462A0332|21 44|prokaryotic RCR initiators
P07747462A0332|67 78|common motifs
P07747462A0332|125 158|downstream active-site tyrosine motif
P07747462A0332|190 217|parvoviral replicator proteins
P07748451A0343|28 50|provisional restorations
P07748451A0343|91 95|stone
P07748451A0343|110 127|poly(vinyl siloxane
P07748451A0343|149 166|poly(vinyl siloxane
P07748493A1045|16 29|Aplysia Afurin2
P07748493A1045|23 29|Afurin2
P07748493A1045|42 43|PC
P07748493A1045|87 103|egg-laying hormone
P07748493A1045|87 103|egg-laying hormone
P07748493A1045|105 126|ELH)-related precursors
P07748493A1045|105 107|ELH
P07748493A1045|132 145|secretory cells
P07748493A1045|151 161|atrial gland
P07748502A0794|0 3|Rats
P07748502A0794|15 23|8-OH-DPAT
P07748848A0263|7 38|endovascular papillary haemangioma
P07748952A0462|14 30|internal promoters
P07748952A0462|32 36|PmiaA
P07748952A0462|32 36|PmiaA
P07748952A0462|40 44|P1hfq
P07748952A0462|40 44|P1hfq
P07748952A0462|70 97|201 and 837 nucleotides upstream
P07748952A0462|115 135|translation start sites
P07748952A1329|24 27|mutL
P07748952A1329|24 27|mutL
P07748952A1329|29 32|miaA
P07748952A1329|29 32|miaA
P07748952A1329|37 49|hfq expression
P07748952A1329|37 39|hfq
P07748952A1329|68 85|multiple mechanisms
P07748952A1329|123 135|upstream genes
P07748952A1329|179 192|RNase E activity
P07748952A1329|179 184|RNase E
P07749088A0119|8 9|T1
P07749088A0119|13 14|T2
P07749461A0632|8 24|5'-flanking region
P07749461A0632|31 35|1.1 kb
P07749461A0632|47 74|sGTH alpha subunit coding region
P07749461A0632|47 62|sGTH alpha subunit
P07749461A0632|108 119|sGTH alpha-G1
P07749461A0632|108 116|sGTH alpha
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|82 110|sGTH alpha/CAT chimeric plasmids
P07749461A1022|82 90|sGTH alpha
P07749461A1022|92 94|CAT
P07749461A1022|115 140|rainbow trout pituitary cells
P07749461A1022|156 183|pituitary-specific expression
P07749461A1022|186 198|GSE-dependent
P07750217T0000|19 23|CR/OV
P07750217T0000|27 33|F-18 FDG
P07750217T0000|36 64|colorectal and ovarian carcinoma
P07751848A0222|0 31|His carnitine palmitoyltransferase
P07751848A0222|3 42|carnitine palmitoyltransferase (CPT) I and II
P07751848A0222|33 42|CPT) I and II
P07751848A0222|172 186|control subjects
P07752223A0960|3 7|Myc LZ
P07752223A0960|3 5|Myc
P07752223A0960|6 7|LZ
P07752223A0960|25 47|homodimeric interactions
P07752223A0960|63 65|Myc
P07752223A0960|63 65|Myc
P07752454A0341|0 19|Staphylococcus aureus
P07752454A0341|23 25|CNS
P07752454A0341|75 79|DMPPC
P07752644A1031|5 6|VF
P07752644A1031|18 31|defibrillation
P07752644A1031|66 85|toxic plasma drug level
P07752644A1031|108 117|conduction
P07752886A0595|11 30|active FecR derivative
P07752886A0595|11 30|active FecR derivative
P07752886A0595|40 58|59 amino acid residues
P07752886A0595|74 84|317 residues
P07752886A0595|87 99|wild-type FecR
P07752886A0595|96 99|FecR
P07753027A0240|12 20|psbB-psbT
P07753027A0240|12 20|psbB-psbT
P07753027A0240|24 32|psbH-psbN
P07753027A0240|24 32|psbH-psbN
P07753030A0173|0 19|Hybridization signals
P07753030A0173|40 48|total DNAs
P07753030A0173|51 83|Rhizobium leguminosarum bv. phaseoli
P07753030A0173|85 105|Rhodobacter capsulatus
P07753030A0173|109 123|Escherichia coli
P07753030A0173|138 171|Xanthomonas campestris pv. campestris
P07753030A0173|175 191|Pseudomonas putida
P07753796A0625|3 28|predicted amino acid sequence
P07753796A0625|69 76|peptides
P07753796A0625|88 116|bovine liver eIF-2B alpha subunit
P07753796A0625|88 98|bovine liver
P07753796A0625|99 104|eIF-2B
P07753796A0625|105 116|alpha subunit
P07753796A0743|16 19|cDNA
P07753796A0743|60 77|natural eIF-2B alpha
P07753796A0743|67 77|eIF-2B alpha
P07753796A0743|80 101|SDS/polyacrylamide gels
P07753837A0724|4 6|RNA
P07753837A0724|18 27|tail domain
P07753837A0724|30 39|desmoglein
P07753837A0724|57 70|plakoglobin RNA
P07753837A0724|79 95|dorsalizing effect
P07753837A0724|120 130|plakoglobin
P07754713A0227|10 13|NUC1
P07754713A0227|10 13|NUC1
P07754713A0227|15 19|PRP21
P07754713A0227|15 19|PRP21
P07754713A0227|31 35|SPP91
P07754713A0227|31 35|SPP91
P07754713A0227|38 41|CDC6
P07754713A0227|38 41|CDC6
P07754713A0227|43 46|CRY2
P07754713A0227|43 46|CRY2
P07754713A0227|66 84|ribosomal protein S24
P07754713A0227|66 84|ribosomal protein S24
P07754713A0227|126 138|599 amino acids
P07755884A0000|0 18|Intrastriatal grafts
P07755884A0000|21 36|nigral and adrenal
P07755884A0000|37 43|tissues
P07755884A0000|165 178|dopamine system
P07755914A0000|49 62|clarithromycin
P07755914A0000|105 112|patients
P07755914A0000|117 120|AIDS
P07755914A0000|136 165|Mycobacterium avium complex (DMAC
P07757315A1227|103 119|observation period
P07758167A1488|45 47|CA9
P07758167A1488|66 70|serum
P07758167A1488|98 102|clone
P07758167A1488|103 106|ME10
P07758246A0469|49 54|intron
P07758246A0469|62 66|exons
P07758459A1277|3 5|UAS
P07758459A1277|11 18|AAC2 gene
P07758459A1277|11 18|AAC2 gene
P07758459A1277|54 89|DNA-binding transcriptional activators
P07758459A1277|54 89|DNA-binding transcriptional activators
P07758459A1277|130 149|HAP2/3/4 binding motif
P07758459A1277|130 149|HAP2/3/4 binding motif
P07758459A1277|171 198|ABF1 consensus binding sequence
P07758459A1277|171 198|ABF1 consensus binding sequence
P07758837A1118|26 43|5' regulatory region
P07758837A1118|49 62|GH receptor gene
P07758837A1118|49 62|GH receptor gene
P07758837A1118|113 118|exon 1B
P07758837A1118|125 138|distal 3' intron
P07758837A1118|222 231|P1 promoter
P07758837A1118|222 231|P1 promoter
P07758837A1118|235 239|exon 2
P07759094A0634|1 23|polymorphic dinucleotide
P07759094A0634|25 37|GT/CA)n repeat
P07759094A0634|25 26|GT
P07759094A0634|28 29|CA
P07759094A0634|52 55|NHE5
P07759094A0634|56 61|cosmid
P07759094A0634|92 114|microsatellite PCR marker
P07759525A0417|54 72|protein kinase domain
P07759525A0417|54 72|protein kinase domain
P07759525A0417|102 122|casein kinase I isoforms
P07759525A0417|102 122|casein kinase I isoforms
P07759529A0288|37 39|CDP
P07759529A0288|41 43|cut
P07759529A0288|64 86|gp91-phox gene expression
P07759529A0288|64 67|gp91
P07759529A0288|69 76|phox gene
P07760790A0327|0 13|Serum induction
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|56 66|NIH 3T3 cells
P07760790A0327|82 104|MEF2 site binding activity
P07760790A0327|82 89|MEF2 site
P07760819A0731|27 57|intracellular signaling molecules
P07760819A0731|59 84|PDGF beta receptor activation
P07760819A0731|59 74|PDGF beta receptor
P07760819A0731|113 129|cell proliferation
P07760819A0731|132 146|differentiation
P07760841A0221|0 3|UAS1
P07760841A0221|26 49|transcriptional regulator
P07760841A0221|50 54|Adr1p
P07760841A0221|50 54|Adr1p
P07760841A0647|17 44|ADH2 upstream regulatory region
P07760841A0647|17 44|ADH2 upstream regulatory region
P07760841A0647|55 58|UAS1
P07760841A0647|83 107|ADH2 basal promoter elements
P07760841A0647|83 107|ADH2 basal promoter elements
P07760841A0647|109 126|UAS2-dependent gene
P07760841A0647|109 126|UAS2-dependent gene
P07760841A0647|151 172|orientation, copy number
P07760841A0647|177 186|helix phase
P07760844A0413|11 24|AP-1 DNA binding
P07760844A0413|11 14|AP-1
P07760844A0413|51 68|GH trans-activation
P07760844A0413|71 75|c-jun
P07760844A0413|71 75|c-jun
P07760844A0413|79 88|c-fos genes
P07760844A0413|79 88|c-fos genes
P07761091A0294|14 23|MAP kinases
P07761091A0294|14 23|MAP kinases
P07761091A0294|33 52|a specific phosphatase
P07761091A0294|42 52|phosphatase
P07761091A0294|54 58|MKP-1
P07761091A0294|54 58|MKP-1
P07761216T0000|0 31|Short-course amphotericin B therapy
P07761216T0000|56 63|patients
P07761420A0909|12 29|45Ca-binding assays
P07761420A0909|42 46|CCaMK
P07761420A0909|42 46|CCaMK
P07761420A0909|60 63|Ca2+
P07761434A1084|5 8|AP-1
P07761434A1084|5 8|AP-1
P07761434A1084|32 50|tumor promoter action
P07761434A1084|32 44|tumor promoter
P07761434A1084|78 105|anti-tumor-promoting activity
P07761434A1084|108 127|phenolic antioxidants
P07761467A0666|72 84|36-kDa protein
P07762431A0356|26 35|cloned cDNA
P07762431A0356|53 65|culture medium
P07762504A0648|40 53|oral amiodarone
P07763727A1035|8 13|pAMS12
P07763727A1035|15 20|pAMS13
P07763727A1035|24 29|pAMS14
P07763727A1035|68 90|Saccharomyces cerevisiae
P07763727A1035|99 104|pAMS15
P07763727A1035|145 156|yeast strains
P07765118A0967|3 18|maximum induction
P07765118A0967|21 42|ACC-oxidase transcripts
P07765118A0967|21 31|ACC-oxidase
P07765118A0967|89 102|enzyme activity
P07766885A0405|6 26|their polypeptide chain
P07766885A0405|75 83|plant CDPK
P07766885A0405|80 83|CDPK
P07766885A0405|121 151|calmodulin-like regulatory domain
P07766885A0405|121 151|calmodulin-like regulatory domain
P07766885A0405|160 173|junction region
P07767011A0689|0 5|Repair
P07767011A0689|70 78|hprt locus
P07767011A0689|70 78|hprt locus
P07767011A0689|103 110|mutation
P07768824A0167|3 8|timing
P07768824A0167|11 27|fla gene expression
P07768824A0167|11 17|fla gene
P07768824A0167|74 86|RNA polymerase
P07768824A0167|74 86|RNA polymerase
P07768824A0167|121 138|regulatory proteins
P07768836A1126|0 25|Primer extension experiments
P07768836A1126|41 80|transcription initiation site 102 bp upstream
P07768848A1880|0 11|Polypeptides
P07768848A1880|56 69|cotE null mutant
P07768848A1880|56 59|cotE
P07768848A1880|110 119|cotJ operon
P07768848A1880|110 119|cotJ operon
P07768848A1880|173 176|coat
P07768848A1880|217 220|coat
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|76 115|synonymous and non-synonymous suhstitutions
P07768898A0492|135 141|apobec1
P07768898A0492|135 141|apobec1
P07768898A0492|166 172|protein
P07768953T0039|0 3|EEA1
P07768953T0039|0 3|EEA1
P07768953T0039|16 28|alpha-helical
P07768953T0039|39 53|membrane protein
P07768953T0039|63 79|cysteine "fingers"
P07768953T0039|92 116|calmodulin-binding IQ motif
P07768953T0039|92 116|calmodulin-binding IQ motif
P07770033A0978|0 18|Nucleotide sequences
P07770033A0978|51 54|cap3
P07770033A0978|51 54|cap3
P07770033A0978|67 82|open reading frame
P07770033A0978|84 86|ORF
P07770033A0978|105 137|26-amino acid, cysteine-rich peptide
P07770033A0978|163 199|Neurospora crassa copper metallothionein
P07770033A0978|163 199|Neurospora crassa copper metallothionein
P07771671T0000|0 6|Sensing
P07771745A0442|72 85|temporal region
P07771745A0442|94 103|cheekbones
P07772036A1000|28 41|nuclear factors
P07772036A1000|43 50|USF/MLTF
P07772036A1000|43 45|USF
P07772036A1000|47 50|MLTF
P07772036A1000|57 102|CAAT-binding transcription factor/nuclear factor 1
P07772036A1000|57 87|CAAT-binding transcription factor
P07772036A1000|89 102|nuclear factor 1
P07772036A1000|104 110|CTF/NF1
P07772036A1000|104 106|CTF
P07772036A1000|108 110|NF1
P07774137A0000|26 44|rapid diagnostic test
P07774137A0000|46 54|Strep A OIA
P07774137A0000|81 113|group A beta-hemolytic streptococcal
P07774137A0000|115 119|GABHS
P07774807A0405|3 14|bHLH proteins
P07774807A0405|3 14|bHLH proteins
P07774807A0405|31 55|transcriptional activators
P07774807A0405|58 77|tissue-specific genes
P07774807A0405|58 77|tissue-specific genes
P07774807A0405|87 98|heterodimers
P07774807A0405|106 146|ubiquitous and cell-restricted family members
P07774925A0084|0 2|YAC
P07774925A0084|6 18|cosmid contigs
P07774925A0084|30 40|BRCA1 region
P07774925A0084|30 40|BRCA1 region
P07774925A0084|57 66|cDNA clones
P07774925A0084|78 82|cDNAs
P07774925A0084|108 116|HeLa cells
P07774925A0084|118 132|activated T cells
P07774925A0084|137 145|fetal head
P07775428A0172|18 27|Ash-m and -s
P07775428A0172|18 22|Ash-m
P07775428A0172|64 72|Ash-l cDNA
P07775428A0172|78 97|amino-terminal region
P07776685A0000|52 64|immunotherapy
P07776685A0000|69 96|tumor infiltrating lymphocytes
P07776685A0000|111 123|interleukin-2
P07776685A0000|111 123|interleukin-2
P07776685A0000|128 135|patients
P07776685A0000|168 191|non-small-cell lung cancer
P07776711A0295|26 28|men
P07776711A0295|34 38|women
P07776711A0295|69 83|hereditary motor
P07776711A0295|104 112|type I and 7
P07776711A0295|116 150|acquired demyelinating polyneuropathy
P07776882A0000|47 61|intact rat hearts
P07776882A0000|69 76|ischemia
P07776882A0000|85 95|reperfusion
P07776979A0702|11 17|COUP-TF
P07776979A0702|11 17|COUP-TF
P07776979A0702|36 72|repCRS2-dependent reporter gene activity
P07777518A0483|0 12|DNA sequencing
P07777518A0483|16 35|Southern blot analyses
P07777518A0483|54 63|cDNA clones
P07779558T0000|0 11|Muscle GSH-Px
P07779558T0000|6 19|GSH-Px activity
P07779558T0000|55 77|selenium supplementation
P07779811A0901|13 22|Sp1 element
P07779811A0901|13 22|Sp1 element
P07779811A0901|38 47|Sp1 binding
P07779811A0901|38 40|Sp1
P07779811A0901|79 94|reporter activity
P07779812A0000|3 11|c-myc gene
P07779812A0000|3 11|c-myc gene
P07779812A0000|39 48|tumor types
P07780148A1153|11 13|PML
P07780148A1153|11 13|PML
P07780148A1153|88 94|G1 phase
P07780525A0495|0 8|Schooling
P07780719A0477|36 47|abnormal echo
P07780738A0091|8 11|Cdks
P07780738A0091|17 28|G1 and S phases
P07780738A0091|17 18|G1
P07780738A0091|34 42|cell cycle
P07780738A0091|58 88|proliferating cell nuclear antigen
P07780738A0091|71 93|cell nuclear antigen (PCNA
P07780738A0091|90 93|PCNA
P07780738A0091|104 117|DNA replication
P07782087A0559|3 46|major and one minor transcription initiation sites
P07782087A0559|61 91|positions +1 and +24 and position +14
P07782087A0559|122 143|ribonuclease protection
P07782087A0559|145 159|primer extension
P07782087A0559|164 169|5' RACE
P07782113A0726|72 82|blood levels
P07782302A0479|24 38|-DEDDDL sequence
P07782302A0479|49 58|GDP binding
P07782302A0479|61 63|Ran
P07782302A0479|61 63|Ran
P07782302A0479|122 139|Ran-binding protein
P07782302A0479|122 139|Ran-binding protein
P07782302A0479|141 145|HTF9A
P07782302A0479|147 152|RanBP1
P07782302A0479|147 152|RanBP1
P07782775A0889|11 14|ORFs
P07782775A0889|83 97|BBTV coat protein
P07782775A0889|83 97|BBTV coat protein
P07783064A0452|30 37|patients
P07783064A0452|60 78|creatinine kinase (CK
P07783064A0452|60 75|creatinine kinase
P07783064A0452|77 78|CK
P07783641A0591|0 3|CodY
P07783641A0591|0 3|CodY
P07783822A0000|52 87|acute pernicious or fulminating beriberi
P07784061A0894|15 28|small G proteins
P07784061A0894|20 28|G proteins
P07784061A0894|59 61|TTF
P07784061A0894|59 61|TTF
P07784061A0894|82 97|hemopoietic cells
P07784078A1064|34 47|gene expression
P07784078A1064|72 79|RAR alpha
P07784078A1064|72 79|RAR alpha
P07784078A1064|82 84|PML
P07784078A1064|82 84|PML
P07784078A1064|98 100|APL
P07784079A1018|14 40|non-deleted expression vector
P07784079A1018|45 55|NIH3T3 cells
P07784079A1018|176 183|basic FGF
P07784079A1018|181 183|FGF
P07784197A0827|0 16|Cytosolic extracts
P07784197A0827|31 48|mammalian cell lines
P07784197A0827|50 59|monkey Cos7
P07784197A0827|68 72|mouse
P07784197A0827|73 85|fibrosarcomas
P07784197A0827|89 99|human HeLa S3
P07784197A0827|120 158|TGF-beta 1 dependent RNA-protein band shifts
P07784197A0827|120 148|TGF-beta 1 dependent RNA-protein
P07784197A0827|161 171|cell extract
P07784197A0827|176 200|BALB/c 3T3 mouse fibroblasts
P07784199A0000|3 35|ribosomal protein (rp) gene promoters
P07784199A0000|3 18|ribosomal protein
P07784199A0000|20 21|rp
P07784199A0000|40 62|Saccharomyces cerevisiae
P07784199A0000|118 136|global gene regulator
P07784199A0000|137 141|Rap1p
P07784199A0000|137 141|Rap1p
P07784199A0000|168 179|global factor
P07784199A0000|181 185|Abf1p
P07784199A0000|181 185|Abf1p
P07784870A0119|39 57|macroscopic findings
P07784870A0119|145 169|microscopy, histochemistry
P07784870A0119|181 198|electron microscopy
P07784870A0119|200 219|immunohistochemistry
P07784870A0119|226 237|microbiology
P07784942T0001|11 24|thrombomodulin
P07784942T0001|11 24|thrombomodulin
P07784942T0001|45 59|future prospects
P07786820A0284|0 5|CPT-11
P07786820A0284|35 44|v. infusion
P07786821A2292|20 37|CPT-11 administered
P07786821A2292|85 101|patient population
P07787179A0312|0 12|A 73 bp fragment
P07787179A0312|14 21|X1 region
P07787179A0312|14 21|X1 region
P07787179A0312|28 41|PRB-1b promoter
P07787179A0312|28 41|PRB-1b promoter
P07787179A0312|66 76|-213 and -141
P07787179A0312|126 137|reporter gene
P07789275A0325|24 26|E74
P07789275A0325|24 26|E74
P07789275A0325|86 110|loss-of-function mutations
P07789275A0325|125 141|transcription unit
P07789342A1352|11 29|extracellular domain
P07789342A1352|35 39|TSH-R
P07789342A1352|35 37|TSH
P07789342A1352|39 39|R
P07789342A1352|76 78|TSH
P07789342A1352|76 78|TSH
P07789342A1352|97 107|hyt mutation
P07789342A1352|119 137|transmembrane domain
P07789342A1352|148 157|TSH binding
P07789342A1352|148 150|TSH
P07789396A0504|0 7|Lipiodol
P07789396A0504|35 38|EDTB
P07789809A1246|9 20|Western blots
P07789809A1246|50 52|Ypt
P07789809A1246|50 52|Ypt
P07789809A1246|59 60|Cr
P07789809A1246|59 60|Cr
P07789809A1246|64 65|Vc
P07789809A1246|86 88|Ypt
P07789809A1246|160 182|cellular differentiation
P07789971A0758|26 38|hybridization
P07789971A0758|179 183|genes
P07789971A0758|208 212|GSTT2
P07789971A0758|208 212|GSTT2
P07790271A1185|20 36|3.6 Gy/25 fractions
P07790377A0561|15 24|human PTS1R
P07790377A0561|15 24|human PTS1R
P07790377A0561|47 78|human, monkey, rat, and hamster cells
P07790719A0098|37 50|female patients
P07791760A0424|0 12|GnRH treatment
P07791760A0424|0 3|GnRH
P07791760A0424|51 66|tyrosine residues
P07791760A0424|69 72|MAPK
P07791760A0424|69 72|MAPK
P07791760A0424|86 97|MAPK activity
P07791760A0424|86 89|MAPK
P07791760A0424|115 138|immune complex kinase assay
P07791760A0424|115 133|immune complex kinase
P07791763T0000|0 15|Molecular cloning
P07791763T0000|20 62|amphibian insulin receptor substrate 1-like cDNA
P07791763T0000|29 53|insulin receptor substrate 1
P07791763T0000|59 62|cDNA
P07791763T0000|79 106|phosphatidylinositol 3-kinase
P07791763T0000|79 106|phosphatidylinositol 3-kinase
P07791763T0000|109 146|insulin-induced Xenopus oocyte maturation
P07791763T0000|109 115|insulin
P07791764A0357|18 37|cultured Jurkat T cells
P07791764A0357|39 41|Cbl
P07791764A0357|39 41|Cbl
P07791764A0357|80 93|adapter protein
P07791764A0357|94 97|Grb2
P07791764A0357|94 97|Grb2
P07791768A0930|16 34|cell cycle regulators
P07791768A0930|53 57|rap1s
P07791768A0930|53 57|rap1s
P07791768A0930|60 76|hmr delta A mutation
P07791768A0930|60 68|hmr delta A
P07791768A0930|83 86|swi6
P07791768A0930|83 86|swi6
P07791768A0930|88 91|swi4
P07791768A0930|88 91|swi4
P07791768A0930|96 108|clb5 mutations
P07791768A0930|96 99|clb5
P07791768A0930|100 108|mutations
P07791768A0930|121 129|mutations
P07791768A0930|132 135|SIR1
P07791768A0930|132 135|SIR1
P07791769A0826|0 3|ICP4
P07791769A0826|0 3|ICP4
P07791769A0826|22 40|tripartite complexes
P07791769A0826|61 82|TATA box-binding protein
P07791769A0826|61 82|TATA box-binding protein
P07791769A0826|86 90|TFIIB
P07791769A0826|86 90|TFIIB
P07791769A0826|93 122|DNA containing an ICP4 binding site
P07791769A0826|108 122|ICP4 binding site
P07791769A0826|127 133|TATA box
P07791771A0183|0 3|Otte
P07791776T0000|18 21|fus1
P07791776T0000|18 21|fus1
P07791776T0000|24 47|Schizosaccharomyces pombe
P07791783A0000|0 30|SRY-related cDNA encoding a protein
P07791783A0000|0 14|SRY-related cDNA
P07791783A0000|36 62|high-mobility-group (HMG) box
P07791783A0000|36 54|high-mobility-group
P07791783A0000|56 62|HMG) box
P07791783A0000|66 84|a leucine zipper motif
P07791783A0000|67 84|leucine zipper motif
P07791783A0000|104 109|SOX-LZ
P07791783A0000|104 106|SOX
P07791783A0000|108 109|LZ
P07791783A0000|127 144|rainbow trout testis
P07791783A0000|145 155|cDNA library
P07793783A0189|0 9|Scalp flaps
P07793783A0189|80 101|scalp flap transposition
P07794556A0000|14 26|Human Genetics
P07794556A0000|60 78|Huntington's disease
P07794556A0000|137 147|DNA-linkage
P07794556A0000|156 158|mid
P07794556A0000|171 186|mutation analysis
P07795104T0000|0 4|Risks
P07795104T0000|31 45|hepatitis B virus
P07795104T0000|46 54|infection
P07795576A0126|13 31|neurohumoral factors
P07795576A0126|41 75|hyperactive sympathetic nervous system
P07795576A0126|91 109|plasma renin activity
P07795576A0126|91 101|plasma renin
P07796935A0284|55 62|hTR beta 1
P07796935A0284|55 62|hTR beta 1
P07796935A0284|83 98|hTR alpha 1 mutants
P07796935A0284|83 91|hTR alpha 1
P07796935A0284|100 111|c-erbA alpha 2
P07796935A0284|100 111|c-erbA alpha 2
P07796935A0284|118 162|human peroxisome proliferator-activated receptor
P07796935A0284|118 162|human peroxisome proliferator-activated receptor
P07796935A0284|164 168|hPPAR
P07796935A0284|164 168|hPPAR
P07796935A0284|187 205|T3-response elements
P07796935A0284|187 205|T3-response elements
P07796935A0284|207 210|TREs
P07796935A0284|207 210|TREs
P07796935A0284|213 234|TRE-PAL, DR + 4 and TRE-LAP
P07796935A0284|213 219|TRE-PAL
P07796935A0284|221 224|DR + 4
P07796935A0284|228 230|TRE
P07796935A0284|232 234|LAP
P07797077A0842|3 33|amino-terminal DNA-binding domain
P07797077A0842|17 33|DNA-binding domain
P07797077A0842|36 38|Pip
P07797077A0842|36 38|Pip
P07797077A0842|73 90|DNA-binding domains
P07797077A0842|73 90|DNA-binding domains
P07797077A0842|105 141|interferon regulatory factor (IRF) family
P07797077A0842|105 130|interferon regulatory factor
P07797077A0842|132 141|IRF) family
P07797077A0842|156 160|IRF-1
P07797077A0842|156 160|IRF-1
P07797077A0842|162 166|IRF-2
P07797077A0842|162 166|IRF-2
P07797077A0842|168 172|ICSBP
P07797077A0842|168 172|ICSBP
P07797077A0842|177 186|ISGF3 gamma
P07797077A0842|177 186|ISGF3 gamma
P07797346T0000|2 9|outbreak
P07797346T0000|12 21|hepatitis A
P07797346T0000|27 39|homosexual men
P07797476A1001|3 14|RAP74 subunit
P07797476A1001|3 14|RAP74 subunit
P07797476A1001|17 21|TFIIF
P07797476A1001|17 21|TFIIF
P07797476A1001|39 57|stimulatory activity
P07797476A1001|114 141|COOH-terminal residues 358-517
P07797583A0222|70 95|DRE (nucleotide positions -93
P07797583A0222|118 144|transcription initiation site
P07797583A0222|118 144|transcription initiation site
P07797583A0222|151 158|PCNA gene
P07797583A0222|151 154|PCNA
P07797583A0222|215 218|DREF
P07797583A0222|215 218|DREF
P07797583A0222|220 237|DRE-binding factor)
P07797583A0222|220 236|DRE-binding factor
P07797583A0222|241 248|PCNA gene
P07797583A0222|241 244|PCNA
P07797583A0222|266 290|cultured Drosophila Kc cells
P07798134T0000|3 11|hsp70 gene
P07798134T0000|3 7|hsp70
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|37 43|cloning
P07798134T0000|45 60|sequence analysis
P07798134T0000|95 121|major stress-inducible member
P07798207A0759|10 27|amino acid sequences
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|122 124|ETF
P07798207A0759|122 124|ETF
P07798207A0759|129 137|human, rat
P07798207A0759|142 164|Paracoccus denitrificans
P07798217T0000|1 24|secondary phosphorylation
P07798217T0000|27 33|CREB341
P07798217T0000|27 33|CREB341
P07798217T0000|36 41|Ser129
P07798217T0000|58 77|cAMP-mediated control
P07798217T0000|80 93|gene expression
P07798217T0095|8 31|glycogen synthase kinase-3
P07798217T0095|8 31|glycogen synthase kinase-3
P07798217T0095|46 59|gene expression
P07798271A0330|4 13|last region
P07798271A0330|38 56|Ets-related proteins
P07798271A0330|38 56|Ets-related proteins
P07798271A0330|66 70|liver
P07798271A0330|71 85|nuclear extracts
P07798271A0330|105 124|purified Ets-1 protein
P07798271A0330|113 124|Ets-1 protein
P07799437A0656|54 57|pNeo
P07799437A0656|59 61|Myc
P07799437A0656|59 61|Myc
P07799437A0656|73 90|dispersive labeling
P07799437A0656|100 107|plasmids
P07799925A0526|0 13|Reconstitution
P07799925A0526|35 37|p62
P07799925A0526|35 37|p62
P07799925A0526|44 58|src family kinase
P07799925A0526|44 58|src family kinase
P07799925A0526|59 64|p59fyn
P07799925A0526|59 64|p59fyn
P07799925A0526|67 75|HeLa cells
P07799925A0526|92 107|complex formation
P07799925A0526|118 140|tyrosine phosphorylation
P07799925A0526|143 145|p62
P07799925A0526|143 145|p62
P07799925A0526|169 184|SH3 and SH2 domains
P07799925A0526|169 171|SH3
P07799925A0526|175 177|SH2
P07799925A0526|187 192|p59fyn
P07799925A0526|187 192|p59fyn
P07799931A0287|63 68|L7 gene
P07799931A0287|63 68|L7 gene
P07799931A0287|105 133|functional fate and organization
P07799931A0287|139 151|nervous system
P07799931A1232|12 29|Maf-related protein
P07799931A1232|12 29|Maf-related protein
P07799931A1232|31 33|Nrl
P07799931A1232|31 33|Nrl
P07799931A1232|53 57|c-Maf
P07799931A1232|53 57|c-Maf
P07799939A0628|5 16|-base element
P07799939A0628|31 74|PDGF-activated serine/threonine phosphoprotein
P07799939A0628|31 34|PDGF
P07799939A0628|45 74|serine/threonine phosphoprotein
P07799939A0628|102 108|nucleus
P07799939A0628|111 130|PDGF-treated 3T3 cells
P07799939A0628|111 114|PDGF
P07799948A0777|25 39|Ras-binding site
P07799948A0777|25 39|Ras-binding site
P07799948A0777|66 76|Raf-1 kinase
P07799948A0777|66 76|Raf-1 kinase
P07799948A0777|79 81|Src
P07799948A0777|79 81|Src
P07799948A0777|95 97|Src
P07799948A0777|95 97|Src
P07799948A0777|101 103|Ras
P07799948A0777|101 103|Ras
P07799948A0777|115 119|Raf-1
P07799948A0777|115 119|Raf-1
P07799950A0282|55 57|CRE
P07799950A0282|63 86|somatostatin gene promoter
P07799950A0282|63 86|somatostatin gene promoter
P07799950A0282|90 98|prototype
P07799950A0282|108 129|cAMP-responsive element
P07799950A0282|141 144|CREB
P07799950A0282|141 144|CREB
P07800479A0201|3 11|first gene
P07800479A0201|13 16|NSR1
P07800479A0201|13 16|NSR1
P07800479A0201|19 42|previously identified gene
P07800479A0201|69 90|ribosomal RNA maturation
P07800479A0201|130 136|nucleus
P07800505T0000|21 28|promoter
P07800505T0000|35 72|human 85 kDa cytosolic phospholipase A2 gene
P07800505T0000|45 68|cytosolic phospholipase A2
P07802355T0000|21 51|differential white blood cell count
P07802355T0000|81 91|Coulter STKS
P07802355T0000|93 104|Sysmex NE 8000
P07802355T0000|108 119|Technicon H-1
P07802655T0000|18 25|FIII/YY1
P07802655T0000|18 21|FIII
P07802655T0000|23 25|YY1
P07802655T0000|28 67|Xenopus laevis conserved zinc-finger protein
P07802655T0000|28 40|Xenopus laevis
P07802655T0000|41 67|conserved zinc-finger protein
P07802655T0000|80 88|first exon
P07802655T0000|91 92|L1
P07802655T0000|91 92|L1
P07802655T0000|96 119|L14 ribosomal protein genes
P07802655T0000|96 119|L14 ribosomal protein genes
P07803809A1852|32 49|Ep-induced increase
P07803809A1852|32 33|Ep
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|88 110|tyrosine kinase inhibitor
P07803809A1852|88 101|tyrosine kinase
P07803809A1852|111 119|genistein
P07803809A1852|126 148|protein kinase C inhibitor
P07803809A1852|126 139|protein kinase C
P07803809A1852|149 157|Compound 3
P07806492A1162|15 23|cucumisin
P07806507A0121|34 47|CD3-TCR complex
P07806507A0121|34 36|CD3
P07806507A0121|80 91|polypeptides
P07806507A0121|93 99|CD3 zeta
P07806507A0121|93 99|CD3 zeta
P07806507A0121|103 112|CD3 epsilon
P07806507A0121|103 112|CD3 epsilon
P07806507A0121|132 151|antigenic recognition
P07806507A0121|182 214|intracytoplasmic activation cascade
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|33 42|AT-rich DNA
P07806651A0097|95 95|L
P07806651A0097|97 97|K
P07806651A0097|102 103|MF
P07806651A0097|115 120|MMPI-2
P07806820A0091|26 40|vascular pedicle
P07806820A0091|62 75|temporal artery
P07807002A0500|29 35|5' flank
P07807002A0500|41 55|initiation sites
P07807002A0500|59 76|germline epsilon RNA
P07807002A0500|91 112|luciferase reporter gene
P07807002A0500|91 112|luciferase reporter gene
P07807002A0500|134 148|mouse B cell lines
P07807002A0500|182 184|IgE
P07807002A0500|182 184|IgE
P07808210A1510|43 47|NCEP I
P07809128T0000|22 29|E2F1 gene
P07809128T0000|22 29|E2F1 gene
P07809410A0606|18 31|solitary lesion
P07809410A0606|33 46|serum TSH levels
P07809410A0606|38 40|TSH
P07809410A0606|53 65|thyroglobulin
P07809410A0606|53 65|thyroglobulin
P07809410A0606|76 86|131I protein
P07809410A0606|94 99|iodine
P07809410A0606|101 108|131I-PBI
P07809410A0606|179 197|unsuccessful therapy
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|43 54|vegetal plate
P07811639A0222|57 76|blastula stage embryos
P07811639A0222|125 135|archenteron
P07811639A0222|154 159|midgut
P07811964A1252|7 34|leucine-proline repeat element
P07811964A1252|55 71|DNA-binding domain
P07811964A1252|55 71|DNA-binding domain
P07811964A1252|74 79|EmBP-1
P07811964A1252|74 79|EmBP-1
P07811964A1252|106 130|DNA-binding or dimerization
P07812450A0849|11 13|ORF
P07812450A0849|58 65|nspC gene
P07812450A0849|58 65|nspC gene
P07813466A0074|3 10|U14 genes
P07813466A0074|3 10|U14 genes
P07813466A0074|26 36|rat, hamster
P07813466A0074|44 50|Xenopus
P07813466A0074|75 81|introns
P07813466A0074|110 145|70-kDa-cognate-heat-shock protein gene
P07813466A0074|110 116|70-kDa-
P07813466A0074|117 145|cognate-heat-shock protein gene
P07813466A0074|147 151|hsc70
P07813466A0074|147 151|hsc70
P07813786A0641|10 14|cDNAs
P07813786A0641|61 75|XMyoDa TATA motif
P07813786A0641|61 75|XMyoDa TATA motif
P07814321A0850|0 7|Deletion
P07814321A0850|14 17|prfA
P07814321A0850|14 17|prfA
P07814321A0850|21 24|ponA
P07814321A0850|21 24|ponA
P07814321A0850|69 89|sporulation efficiency
P07814323A0313|23 30|proteins
P07814323A0313|43 46|FliQ
P07814323A0313|43 46|FliQ
P07814323A0313|50 53|FliR
P07814323A0313|50 53|FliR
P07814323A0313|96 112|flagellum assembly
P07814388A0662|33 66|wild type or mutant M6P/IGF II receptors
P07814388A0662|33 48|wild type or mutant
P07814388A0662|49 51|M6P
P07814388A0662|53 66|IGF II receptors
P07814388A0662|72 76|IGF II
P07814388A0662|72 76|IGF II
P07814388A0662|98 128|pertussis toxin substrate activity
P07814388A0662|98 111|pertussis toxin
P07814405A1170|59 104|plasma membrane family of guanylyl cyclase receptors
P07814405A1170|59 72|plasma membrane
P07814405A1170|81 104|guanylyl cyclase receptors
P07814405A1170|140 163|dominant negative proteins
P07814717A0669|10 18|blood NEFA
P07814717A0669|40 42|fat
P07814717A0669|47 63|AA supplementation
P07814717A0669|95 97|Lys
P07814717A0669|100 102|Met
P07814717A0669|105 109|blood
P07815811A1487b|0 23|Coronary vasoconstriction
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|56 75|ischemia-reperfusion
P07815811A1487b|81 94|norepinephrine
P07816025A0196|22 38|amino acid sequence
P07816025A0196|41 53|gamma-kafirin
P07816025A0196|81 110|gamma-prolamins of maize, and Coix
P07816025A0196|98 102|maize
P07816049A0686|0 5|Atcys1
P07816049A0686|0 5|Atcys1
P07816049A0686|7 12|Athyp1
P07816049A0686|7 12|Athyp1
P07816049A0686|14 19|AKin10
P07816049A0686|14 19|AKin10
P07816049A0686|26 28|ORF
P07816049A0686|150 167|regulatory elements
P07816049A0686|211 223|transcription
P07816049A1157|0 24|Southern blot hybridization
P07816049A1157|65 70|Atcys1
P07816049A1157|65 70|Atcys1
P07816049A1157|72 77|Athyp1
P07816049A1157|72 77|Athyp1
P07816049A1157|81 86|AKin10
P07816049A1157|81 86|AKin10
P07816049A1157|107 126|Northern blot analysis
P07816617A0763|23 26|HAC1
P07816617A0763|23 26|HAC1
P07816617A0763|44 55|meiotic genes
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0000|67 73|sterile
P07816619A0000|88 121|Schizosaccharomyces pombe pde1 mutant
P07816619A0000|88 121|Schizosaccharomyces pombe pde1 mutant
P07816619A0000|141 161|cAMP phosphodiesterase
P07816619A0872|32 46|Dr1-like protein
P07816619A0872|32 46|Dr1-like protein
P07816619A0872|191 193|Dr1
P07816619A0872|191 193|Dr1
P07816630A1333|52 72|translation terminator
P07816630A1333|73 75|TGA
P07816630A1333|81 93|beta-tubulin 2
P07816630A1333|81 93|beta-tubulin 2
P07816630A1333|95 103|BTU2) gene
P07816630A1333|95 98|BTU2
P07816630A1333|125 132|3' region
P07816630A1333|138 145|H4-I gene
P07816630A1333|138 145|H4-I gene
P07816808A1102|27 42|STR family of genes
P07816808A1102|27 42|STR family of genes
P07816808A1102|140 147|Chordata
P07818416A0895|23 47|haemoglobin concentrations
P07818416A0895|23 33|haemoglobin
P07818416A0895|115 117|THR
P07818416A0895|156 158|THR
P07819225A1094|19 31|acidic residue
P07819225A1094|78 92|Asn-285 mutation
P07819225A1094|100 106|Lys-220
P07819225A1094|110 112|Gln
P07819225A1094|117 134|second-site mutants
P07819225A1094|140 146|Asn-285
P07819225A1094|166 187|tetracycline resistance
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|28 35|cytokine
P07820057A0000|57 78|autocrine growth control
P07820057A0000|81 97|hairy cell leukemia
P07820057A0000|107 130|bone resorptive properties
P07821790A1084|1 3|iv)
P07821790A1084|12 16|UCRBP
P07821790A1084|12 16|UCRBP
P07821790A1084|47 70|transcriptional repressor
P07821790A1084|86 90|UCRBP
P07821790A1084|86 90|UCRBP
P07821790A1084|104 125|positive transactivator
P07821790A1084|145 155|UCR elements
P07822161A1172|3 18|sequence of monkey
P07822161A1172|43 55|human sequence
P07822161A1172|43 55|human sequence
P07822161A1172|61 70|nucleotide
P07822161A1172|77 91|amino acid levels
P07822161A1172|133 143|348 residues
P07822329A0773|44 56|lymphoid cells
P07822329A0773|94 104|novel factor
P07822329A0773|147 151|50 kDa
P07823919A1422|23 37|Oct-3/4 promoter
P07823919A1422|23 29|Oct-3/4
P07823919A1422|40 42|RAR
P07823919A1422|40 42|RAR
P07823919A1422|44 58|RXR heterodimers
P07823919A1422|44 46|RXR
P07823919A1422|83 96|EAR-3/COUP-TFI
P07823919A1422|83 87|EAR-3
P07823919A1422|89 96|COUP-TFI
P07823919A1422|102 106|ARP-1
P07823919A1422|108 116|COUP-TFII
P07823919A1422|108 116|COUP-TFII
P07823951A1100|27 30|EKLF
P07823951A1100|27 30|EKLF
P07823951A1100|73 88|globin expression
P07823951A1100|73 78|globin
P07823951A1100|119 122|EKLF
P07823951A1100|119 122|EKLF
P07823951A1100|147 180|CACCC element-directed transcription
P07823951A1100|183 196|erythroid cells
P07823953A0777|15 33|I kappa B alpha mutants
P07823953A0777|15 26|I kappa B alpha
P07823953A0777|66 85|I kappa B alpha molecule
P07823953A0777|66 77|I kappa B alpha
P07823953A0777|94 115|acidic C-terminal region
P07823953A0777|118 129|I kappa B alpha
P07823953A0777|118 129|I kappa B alpha
P07823953A0777|146 167|protein-protein binding
P07823953A0777|146 160|protein-protein
P07823953A0777|185 209|nuclear localization signal
P07823953A0777|215 219|dimer
P07823953A0777|233 248|C-terminal region
P07823953A0777|233 248|C-terminal region
P07823953A0777|274 283|DNA binding
P07823953A0777|352 366|PEST-like region
P07823953A0777|352 366|PEST-like region
P07823953A0777|373 389|DNA-binding region
P07823953A0777|373 389|DNA-binding region
P07823953A0777|413 417|dimer
P07823964A0922|3 28|negative regulatory activity
P07823964A0922|34 49|N-terminal domain
P07823964A0922|34 49|N-terminal domain
P07823964A0922|67 83|C-terminal segment
P07823964A0922|67 83|C-terminal segment
P07823964A0922|86 91|Pho81p
P07823964A0922|86 91|Pho81p
P07824325A0714|21 38|surgical procedures
P07824325A0714|107 114|patients
P07824325A0714|126 149|vancomycin concentrations
P07824325A0714|177 181|MIC 90
P07824325A0714|185 204|Staphylococcus aureus
P07824325A0714|222 246|Staphylococcus epidermidis
P07824464A0169|26 44|tissue flaps floating
P07824464A0169|50 54|lumen
P07824464A0169|64 80|structured thrombi
P07824464A0169|82 102|artery wall dissections
P07824464A0169|104 117|plaque ruptures
P07824464A0169|119 134|deep fissurations
P07824464A0169|175 184|live colour
P07824464A0169|189 216|pathophysiological mechanisms
P07824464A0169|219 226|coronary
P07824464A0169|227 240|artery stenosis
P07824657A1456|3 27|enhanced cysteine formation
P07824657A1456|78 86|leaf discs
P07824726A0454|4 7|type
P07824726A0454|72 79|pancreas
P07824726A0454|93 108|fatty replacement
P07824726A0454|134 149|fatty replacement
P07824726A0454|175 190|fatty replacement
P07825888A0715|21 37|dementia disorders
P07825888A0715|73 91|basal cortisol levels
P07826412T0112|39 55|catalytic subunits
P07826412T0112|58 71|gamma-subunits
P07826412T0112|58 71|gamma-subunits
P07826412T0112|100 109|transducin
P07826625X0000|20 41|transcription apparatus
P07826625X0000|43 57|RNA polymerase II
P07826625X0000|43 57|RNA polymerase II
P07826625X0000|59 77|TATA-binding protein
P07826625X0000|59 77|TATA-binding protein
P07826625X0000|119 134|C-terminal domain
P07826625X0000|119 134|C-terminal domain
P07826625X0000|136 138|CTD
P07826625X0000|136 138|CTD
P07826625X0000|142 156|RNA polymerase II
P07826625X0000|142 156|RNA polymerase II
P07826625X0000|158 180|"portable enhancer domain
P07826625X0000|196 201|serine
P07826625X0000|203 211|threonine
P07826625X0000|216 230|proline residues
P07826625X0000|289 298|N-terminal
P07826625X0000|306 334|mammalian TATA-binding proteins
P07826625X0000|306 334|mammalian TATA-binding proteins
P07828584A0681|0 10|Mutagenesis
P07828584A0681|13 15|IM1
P07828584A0681|13 15|IM1
P07828584A0681|36 40|c-Fos
P07828584A0681|36 40|c-Fos
P07828584A0681|53 70|AP1 bearing promoter
P07828584A0681|53 55|AP1
P07828584A0681|63 70|promoter
P07828600A0095|9 11|SSP
P07828600A0095|9 11|SSP
P07828600A0095|17 36|stage selector element
P07828600A0095|17 36|stage selector element
P07828600A0095|38 40|SSE
P07828600A0095|38 40|SSE
P07828600A0095|47 74|proximal gamma-globin promoter
P07828600A0095|55 74|gamma-globin promoter
P07828600A0095|113 131|linked beta-promoter
P07828600A0095|119 131|beta-promoter
P07828600A0095|134 179|embryonic/fetal stage erythroleukemia (K562) cells
P07828811A0556|29 38|G1/S arrest
P07828811A0556|63 102|thermosensitivity of colony-forming ability
P07828824A0307|18 43|photoreceptor cell structure
P07828852A0153|36 41|nuclei
P07829057A1097|32 33|RH
P07829057A1097|32 33|RH
P07829057T0000|0 24|Integrated mapping analysis
P07829057T0000|30 43|Werner syndrome
P07829057T0000|52 62|chromosome 8
P07829097A0000|16 37|DXS52 and Factor VIII gene
P07829097A0000|16 20|DXS52
P07829097A0000|24 37|Factor VIII gene
P07829097A0000|43 66|human Xq28 chromosomal band
P07829097A0000|76 91|G+C-rich isochore
P07829097A0000|76 78|G+C
P07829102T0000|0 15|Haplotype mapping
P07829102T0000|19 34|sequence analysis
P07829102T0000|40 53|mouse Nramp gene
P07829102T0000|45 53|Nramp gene
P07829102T0000|90 102|intracellular
P07829102T0000|103 112|parasites.
P07829519A1251|19 26|intronic
P07829519A1251|27 45|polyadenylation site
P07829519A1251|53 63|alternative
P07829519A1251|64 72|exon usage
P07829519A1251|121 139|membrane-bound forms
P07829519A1251|145 170|immunoglobulin mu heavy chain
P07829519A1251|145 170|immunoglobulin mu heavy chain
P07829554A0257|29 63|systemic humoral immune system response
P07829554A0257|70 85|hapten-syngeneic
P07829554A0257|88 124|allogeneic protein conjugates (corrosion
P07829554A0257|142 166|metallic orthopedic devices
P07829554A0257|179 209|enzyme-linked immunosorbent assay
P07829554A0257|211 215|ELISA
P07829554A0257|236 243|antibody
P07829554A0257|245 259|humoral immunity
P07830112A0532|11 25|peak filling rate
P07830112A0532|27 29|PFR
P07830112A0532|47 61|diastolic volume
P07830112A0532|63 65|EDV
P07830112A0532|70 81|stroke volume
P07830112A0532|83 84|SV
P07830112A0532|110 119|PFR-to-PER
P07830112A0532|145 147|PFR
P07830112A0532|149 152|TPFR
P07830112A0532|195 218|left ventricular mass index
P07830112A0532|239 246|patients
P07830112A0532|251 260|acromegaly
P07830112A0532|271 277|normals
P07831310A0000|48 63|tobacco etch virus
P07831310A0000|65 78|TEV) polymerase
P07831310A0000|65 78|TEV) polymerase
P07831310A0000|80 82|NIb
P07831310A0000|80 82|NIb
P07831310A0000|105 110|plants
P07831310A0000|142 164|NIb-defective TEV mutants
P07831310A0000|142 144|NIb
P07831310A0000|155 164|TEV mutants
P07831799T0000|0 17|Nucleotide sequence
P07831799T0000|21 43|transcriptional analysis
P07831799T0000|49 101|DNA polymerase gene of Bombyx mori nuclear polyhedrosis virus
P07831799T0000|49 61|DNA polymerase
P07831799T0000|68 101|Bombyx mori nuclear polyhedrosis virus
P07831829A1324|15 21|genomes
P07831829A1324|24 27|PMTV
P07831829A1324|29 33|BNYVV
P07831829A1324|38 42|SBWMV
P07832086A1023|3 17|drug sensitivity
P07832086A1023|39 41|VCM
P07832086A1023|59 61|IMP
P07832086A1023|80 83|MINO
P07832086A1023|101 103|AMK
P07832086A1023|125 127|FOM
P07832779A0719|0 14|Deglycosylation
P07832779A0719|19 34|endoglycosidase H
P07832779A0719|19 34|endoglycosidase H
P07832779A0719|48 62|mutant receptors
P07832779A0719|48 62|mutant receptors
P07832779A0719|72 83|high-mannose
P07832779A0719|84 104|oligosaccharide chains
P07834582A0115|0 16|Dietary supplement
P07834582A0115|21 27|fish oil
P07834582A0115|38 44|n-3 EFAs
P07834582A0115|38 44|n-3 EFAs
P07834582A0115|68 91|antihypertensive property
P07834582A0115|94 100|animals
P07834582A0115|104 109|humans
P07834582A0115|114 123|borderline
P07834582A0115|127 147|essential hypertension
P07835088A0238|3 8|HSD3B1
P07835088A0238|3 8|HSD3B1
P07835088A0238|12 22|HSD3B2 genes
P07835088A0238|12 17|HSD3B2
P07835088A0238|34 63|types I and II 3 beta-HSD isoenzymes
P07835088A0238|39 63|I and II 3 beta-HSD isoenzymes
P07835088A0238|106 124|in situ hybridization
P07835088A0238|130 151|chromosome 1p13.1 region
P07835214A0603|41 43|GDM
P07835273A0000|0 6|Insulin
P07835273A0000|18 33|glucose transport
P07835273A0000|36 45|adipocytes
P07835273A0000|61 75|insulin receptor
P07835273A0000|61 75|insulin receptor
P07835273A0411|29 38|adipocytes
P07835273A0411|50 53|EGFR
P07835273A0411|50 53|EGFR
P07835273A0411|86 95|adipocytes
P07835273A0411|153 168|3T3-L1 adipocytes
P07835710T0000|25 56|porcine I kappa B alpha-encoding gene
P07835710T0000|25 56|porcine I kappa B alpha-encoding gene
P07835826A0195|0 8|Fraction 2
P07835826A0195|17 35|1,25(OH)2-vitamin D3
P07835826A0195|37 62|vitamin D3, 25(OH)-vitamin D3
P07835826A0195|66 87|1,24,25(OH)3-vitamin D3
P07835886A0894|3 17|kallistatin gene
P07835886A0894|3 17|kallistatin gene
P07835886A0894|32 50|in situ hybridization
P07835886A0894|53 78|human chromosome 14q31-q32.1
P07835886A0894|90 100|serpin genes
P07835886A0894|109 149|alpha 1-antichymotrypsin, protein C inhibitor
P07835886A0894|109 131|alpha 1-antichymotrypsin
P07835886A0894|133 140|protein C
P07835886A0894|151 168|alpha 1-antitrypsin
P07835886A0894|151 168|alpha 1-antitrypsin
P07835886A0894|173 202|corticosteroid-binding globulin
P07835886A0894|173 202|corticosteroid-binding globulin
P07835888A0402|19 24|XD gene
P07835888A0402|19 24|XD gene
P07835888A0402|36 37|Xd
P07835888A0402|36 37|Xd
P07835888A0402|53 62|distal part
P07835888A0402|65 81|mouse chromosome 17
P07835888A0402|84 100|haplotype analysis
P07835888A0402|106 131|interspecific backcross mice
P07836218A0128|35 48|beta-endorphin
P07836218A0128|69 82|exertion levels
P07836218A0128|112 119|acidosis
P07836218A0128|144 157|beta-endorphin
P07836218A0128|144 157|beta-endorphin
P07836228A1052|2 25|interatrial communication
P07836228A1052|50 59|LV function
P07836228A1052|90 110|intrathoracic pressure
P07836364A0000|6 28|foreign cellular proteins
P07836364A0000|61 110|major histocompatibility complex (MHC) class I molecules
P07836364A0000|61 90|major histocompatibility complex
P07836364A0000|92 110|MHC) class I molecules
P07836364A0000|125 146|antigen presenting cells
P07836364A0000|148 150|APC
P07836364A0000|148 150|APC
P07836390A1152|23 58|VirD1/VirD2-mediated cleavage reaction
P07836390A1152|23 27|VirD1
P07836390A1152|29 33|VirD2
P07836390A1152|105 116|IncP plasmids
P07836390A1152|147 160|DNA replication
P07836390A1152|167 186|bacterial conjugation
P07836406A0884|0 18|Isoelectric focusing
P07836406A0884|21 35|tryptic peptides
P07836406A0884|49 53|MHC-B
P07836406A0884|49 53|MHC-B
P07836406A0884|72 81|cdc2 kinase
P07836406A0884|72 81|cdc2 kinase
P07836406A0884|129 141|reverse-phase
P07836406A0884|157 176|liquid chromatography
P07836471A0375|10 24|protein sequence
P07836471A0375|49 53|hNUC I
P07836471A0375|49 53|hNUC I
P07836471A0375|67 88|human osteosarcoma cells
P07838156A0789|8 28|cotransfection studies
P07838156A0789|41 43|RVR
P07838156A0789|41 43|RVR
P07838156A0789|169 184|ROR alpha function
P07838156A0789|169 176|ROR alpha
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07840643A1006|30 49|glycosylasparaginase
P07840643A1006|55 83|mammalian glycosylasparaginase
P07840643A1006|64 83|glycosylasparaginase
P07840643A1006|160 169|eukaryotic
P07840643A1006|180 185|enzyme
P07841230T0000|32 60|fluoroquinolone antimicrobials
P07841663A0685|0 18|Superoxide dismutase
P07841663A0685|0 18|Superoxide dismutase
P07841663A0685|20 22|SOD
P07841663A0685|20 22|SOD
P07841663A0685|56 60|sperm
P07841663A0685|141 158|electrolyzed medium
P07841663A0845|69 89|reactive oxygen species
P07841663A0845|99 101|SOD
P07841663A0845|99 101|SOD
P07841663A0845|148 152|sperm
P07844142A0640|0 15|Molecular cloning
P07844142A0640|32 35|cDNA
P07844142A0640|44 49|SR beta
P07844142A0640|44 49|SR beta
P07844142A0640|62 67|SR beta
P07844142A0640|62 67|SR beta
P07844142A0640|71 90|transmembrane protein
P07844142A0640|99 105|SR alpha
P07844142A0640|99 105|SR alpha
P07844142A0640|109 113|SRP54
P07844142A0640|109 113|SRP54
P07844142A0640|129 145|GTPase superfamily
P07844142A0640|129 145|GTPase superfamily
P07844155A0327|25 59|receptor-linked tyrosine phosphatases
P07844155A0327|25 59|receptor-linked tyrosine phosphatases
P07844155A0327|62 78|neural development
P07844155A0327|98 108|LAR isoforms
P07844155A0327|98 108|LAR isoforms
P07844155A0327|137 149|nervous system
P07844155A0327|180 201|LAR alternative splicing
P07844201T0000|0 11|Sex selection
P07844201T0000|15 21|albumin
P07844201T0000|15 21|albumin
P07844425A0289|0 10|135 students
P07844425A0289|42 46|urine
P07844425A0289|50 51|56
P07844555A0406|20 27|E mu pim-1
P07844555A0406|20 27|E mu pim-1
P07844555A0406|28 41|transgenic mice
P07844555A0406|64 82|lymphoma development
P07844555A0406|99 108|wild-type M
P07844555A0406|99 107|wild-type
P07844555A0406|108 113|M-MuLV
P07845672A0368|12 37|human and murine blk sequences
P07845672A0368|20 37|murine blk sequences
P07845672A0368|63 79|amino acid identity
P07845672A0368|111 125|catalytic domain
P07846163A0422|3 7|mRNAs
P07846163A0422|13 20|GRF genes
P07846163A0422|13 20|GRF genes
P07846163A0422|36 40|exons
P07846163A0422|58 64|introns
P07846199A0000|11 17|ethanol
P07846199A0000|20 46|human sensorimotor reactivity
P07846199A0000|72 94|acoustic startle response
P07846942A0717|0 44|Digitalis glycosides or beta-receptor antagonists
P07846942A0717|21 33|beta-receptor
P07846942A0717|107 112|class I
P07846942T0001|0 17|Atrial fibrillation
P07846942T0001|24 45|autonomic nervous system
P07847036A0353|0 3|VIII
P07848358A0254|15 47|aspartate aminotransferase activity
P07848358A0254|15 39|aspartate aminotransferase
P07848358A0254|63 65|800
P07851643A1365|32 45|104-kDa isoform
P07851643A1365|32 45|104-kDa isoform
P07851643A1365|59 77|normal proliferation
P07851643A1365|112 132|oocyte differentiation
P07851758A0330|20 23|SAL6
P07851758A0330|20 23|SAL6
P07851758A0330|26 38|chromosome XVI
P07851758A0330|46 49|TPK2
P07851758A0330|46 49|TPK2
P07851758A0330|53 57|spt14
P07851758A0330|53 57|spt14
P07852037A0548|15 23|DCT method
P07852037A0548|53 55|TBF
P07852361A0868|9 12|PDMP
P07852361A0868|20 29|cell medium
P07852361A0868|53 68|cell cycle changes
P07852361A0868|93 98|S phase
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07852400A0519|28 33|Rho GDI
P07852400A0519|28 33|Rho GDI
P07852400A0519|49 52|Rac2
P07852400A0519|49 52|Rac2
P07852400A0519|56 59|RhoA
P07852400A0519|56 59|RhoA
P07852400A0519|67 70|Rac1
P07852400A0519|67 70|Rac1
P07853448A0601|13 28|sports scientists
P07853476A0159|0 6|Schnell
P07853488T0000|0 12|Encapsidation
P07853488T0000|53 90|human immunodeficiency virus type 1 gag gene
P07853488T0000|53 90|human immunodeficiency virus type 1 gag gene
P07853488T0000|99 119|complementation system
P07853488T0000|136 150|P1 capsid protein
P07853488T0000|136 150|P1 capsid protein
P07853524A1944|12 20|GST domain
P07853524A1944|12 14|GST
P07853524A1944|25 31|GST-Tax
P07853524A1944|25 27|GST
P07853524A1944|29 31|Tax
P07853524A1944|34 41|thrombin
P07853524A1944|34 41|thrombin
P07853524A1944|50 52|Tax
P07853524A1944|50 52|Tax
P07853524A1944|80 107|Tax-CREB-21-bp-repeat complex
P07853524A1944|80 82|Tax
P07853524A1944|84 100|CREB-21-bp-repeat
P07854130A1387|16 19|PilE
P07854130A1387|16 19|PilE
P07854130A1387|68 98|chromosomal pilE insertion mutants
P07854130A1387|68 82|chromosomal pilE
P07854130A1387|112 138|twitching-motility deficient
P07854130T0000|3 17|pilE gene product
P07854130T0000|3 10|pilE gene
P07854130T0000|20 40|Pseudomonas aeruginosa
P07854130T0000|75 91|amino acid sequence
P07854130T0000|107 115|N-termini
P07854130T0000|118 138|type 4 prepilin proteins
P07854130T0000|118 138|type 4 prepilin proteins
P07854324A0281|77 90|vertebrate wee1
P07854324A0281|87 90|wee1
P07854324A0281|93 103|mik1 homolog
P07854324A0281|93 103|mik1 homolog
P07854324A0281|148 152|yeast
P07854324A0742|19 23|clone
P07854324A0742|27 51|wee1/mik1-deficient mutant
P07854324A0742|27 51|wee1/mik1-deficient mutant
P07854324A0742|69 81|cell phenotype
P07854324A0742|87 116|non-permissive growth conditions
P07856102A1616|21 35|phosphorylation
P07856102A1616|38 45|M protein
P07856102A1616|38 45|M protein
P07856102A1616|84 96|virus assembly
P07857086A0949|19 25|Insulin
P07857086A0949|58 64|Insulin
P07857086A0949|80 80|D
P07857086A0949|80 80|D
P07857086A0949|82 82|F
P07857086A0949|85 96|White's Class
P07857163A0551|39 63|nonfluorinated derivatives
P07857344A0591|76 106|pidotimod administration schedule
P07857762A0611|3 18|MAP kinase cascade
P07857762A0611|3 11|MAP kinase
P07857762A0611|41 50|eukaryotes
P07857762A0611|72 88|cellular responses
P07858986A0310|49 74|porcine bioprosthetic valves
P07858986A0310|81 101|Carpentier-Edwards SAV
P07858986A0310|106 127|BioImplant and one Valcor
P07858986A0310|137 153|human aortic valves
P07858986A0310|168 190|glutaraldehyde treatment
P07859238A1150|2 19|serious side effects
P07859301A0325|24 40|DNA-binding domain
P07859301A0325|24 40|DNA-binding domain
P07859301A0325|45 89|basic-helix-loop-helix and leucine-zipper motifs
P07859301A0325|45 66|basic-helix-loop-helix
P07859301A0325|70 89|leucine-zipper motifs
P07859301A0325|110 145|myc-related transcription factor family
P07859301A0325|121 145|transcription factor family
P07859371A1246|42 71|orthologous rat or mouse fragments
P07859371A1246|77 97|human or rodent extracts
P07859665A0498|3 30|mean jitter and the fiber density
P07859739T0000|6 25|cyclin D-Cdk complexes
P07859739T0000|6 12|cyclin D
P07859739T0000|14 16|Cdk
P07859739T0000|28 43|Rb-negative cells
P07859739T0000|28 29|Rb
P07859739T0000|70 81|p16INK4/MTS1
P07859739T0000|70 76|p16INK4
P07859739T0000|78 101|MTS1 tumour suppressor gene
P07859739T0000|82 108|tumour suppressor gene product
P07859777A0000|11 27|human serum albumin
P07859777A0000|16 27|serum albumin
P07859777A0000|29 32|rHSA
P07859777A0000|29 32|rHSA
P07859777A0000|44 63|cultured fermentation
P07859777A0000|90 114|microcapsules nominally 3-5
P07859777A0000|152 165|technetium-99m
P07859777A0000|188 203|stannous chloride
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|44 47|IL-1
P07860208A0000|44 47|IL-1
P07860208A0000|52 77|tumour necrosis factor-alpha
P07860208A0000|52 77|tumour necrosis factor-alpha
P07860208A0000|79 81|TNF
P07860208A0000|79 81|TNF
P07860208A0000|85 105|unstimulated monocytes
P07860208A0000|109 117|monocytes
P07860208A0000|132 149|lipopolysaccharide
P07860208A0000|151 153|LPS
P07860208A0000|170 184|peripheral blood
P07860208A0000|190 197|patients
P07860208A0000|202 245|acute poststreptococcal glomerulonephritis (AGN
P07860208A0000|252 266|healthy controls
P07860646A1363|57 86|angiogenesis-dependent diseases
P07860646A1363|96 100|FGF-2
P07860646A1363|96 100|FGF-2
P07862092A0302|61 69|ts mutants
P07862092A0302|71 74|sdp1
P07862092A0302|71 74|sdp1
P07862092A0302|78 92|mutation pol3-14
P07862092A0302|86 92|pol3-14
P07862092A0302|96 101|sdp5-1
P07862092A0302|96 101|sdp5-1
P07862092A0302|105 119|mutation pol3-11
P07862092A0302|113 119|pol3-11
P07862092A0302|164 190|pol3-14 sdp1 and pol3-11 sdp5-1
P07862092A0302|164 174|pol3-14 sdp1
P07862092A0302|178 190|pol3-11 sdp5-1
P07862092A0302|195 219|wild-type genomic libraries
P07862092A0302|234 249|multicopy vectors
P07862108A0987|0 25|UV cross-linking experiments
P07862108A0987|34 36|TEP
P07862108A0987|34 36|TEP
P07862129A1391|2 18|acute-phase livers
P07862129A1391|50 59|HNF-3 alpha
P07862129A1391|50 59|HNF-3 alpha
P07862129A1391|132 138|TTR gene
P07862129A1391|132 138|TTR gene
P07862141A0317|14 36|loss-of-function alleles
P07862141A0317|55 58|cAPK
P07862141A0317|55 58|cAPK
P07862141A0317|86 106|sexual differentiation
P07862141A1412|22 25|RFX1
P07862141A1412|22 25|RFX1
P07862141A1412|30 48|transcription factor
P07862141A1412|62 82|viral and cellular genes
P07862150A0429|39 46|TGF-beta
P07862150A0429|39 46|TGF-beta
P07862150A0429|72 99|mink lung epithelial cell clones
P07862150A0429|114 136|TGF-beta binding activity
P07862150A0429|114 121|TGF-beta
P07862150A0429|148 191|antiproliferative and transcriptional responses
P07862150A0429|194 201|TGF-beta
P07862150A0429|194 201|TGF-beta
P07862154A0340|83 86|RAF1
P07862154A0340|83 86|RAF1
P07862162A0408|15 32|inositol and choline
P07862162A0408|61 68|OPI1 gene
P07862162A0408|61 68|OPI1 gene
P07862162A0408|104 116|UASINO element
P07862165A0184|16 23|COS cells
P07862165A0184|28 43|oligonucleotides
P07862165A0184|96 120|simian virus 40 (SV40) vector
P07862165A0184|147 179|intracellular triple helix formation
P07862168A0000|3 49|interleukin 2 receptor alpha-chain (IL-2R alpha) gene
P07862168A0000|3 33|interleukin 2 receptor alpha-chain
P07862168A0000|35 49|IL-2R alpha) gene
P07862168A0000|79 84|T cells
P07862168A0000|97 112|mitogenic stimuli
P07862533A0000|3 31|Wilms' tumour suppressor protein
P07862533A0000|3 7|Wilms
P07862533A0000|9 31|tumour suppressor protein
P07862533A0000|33 35|WT1
P07862533A0000|33 35|WT1
P07862533A0000|40 79|putative transcriptional regulatory protein
P07862533A0000|88 98|zinc fingers
P07862533A0000|153 173|early growth response-1
P07862533A0000|153 173|early growth response-1
P07862533A0000|175 187|EGR-1) protein
P07862533A0000|175 179|EGR-1
P07863047A0229|29 31|ACE
P07863047A0229|29 31|ACE
P07863047A0229|42 49|patients
P07863047A0229|54 57|COPD
P07863047A0229|89 111|ambulatory oxygen therapy
P07863047A0229|162 164|ACE
P07863047A0229|162 164|ACE
P07863047A0229|171 183|hematological
P07863992A0908|5 11|9 group I
P07863992A0908|12 19|patients
P07863992A0908|90 101|heart disease
P07864652A0753|34 43|E2L1(1-98)
P07864652A0753|34 42|E2L1(1-98
P07864652A0753|45 58|E2L1.H1(1-128)
P07864652A0753|45 57|E2L1.H1(1-128
P07864652A0753|60 63|E2L2
P07864652A0753|60 63|E2L2
P07864652A0753|65 72|120-233)
P07864652A0753|74 88|E2H1.L2(98-233)
P07864652A0753|74 77|E2H1
P07864652A0753|79 80|L2
P07864652A0753|93 109|E2L1.H1.L2(1-233)
P07864652A0753|93 99|E2L1.H1
P07864652A0753|101 102|L2
P07864652A0753|143 159|amino acid sequence
P07864652A0753|179 189|E2 component
P07864652A0753|207 215|construct
P07864652A1901|85 88|E2L1
P07864652A1901|85 88|E2L1
P07864652A1901|92 95|E2L2
P07864652A1901|92 95|E2L2
P07864652A1901|122 140|regulatory processes
P07864709A0324|11 33|influenza A (H3N2) viruses
P07864709A0324|87 96|amantadine
P07864709A0324|122 138|enzyme immunoassay
P07864709A0324|159 163|viral
P07864709A0324|164 174|nucleic acid
P07864709A0324|189 207|transmembrane domain
P07864709A0324|213 221|M2 protein
P07864709A0324|213 221|M2 protein
P07865129A0293|16 47|ATF/CRE and TBP/TATA sequence motifs
P07865129A0293|16 18|ATF
P07865129A0293|20 22|CRE
P07865129A0293|26 28|TBP
P07865129A0293|30 47|TATA sequence motifs
P07865129A0293|56 66|87-bp region
P07865786A0457|0 13|Gene expression
P07865786A0457|23 37|circadian rhythm
P07865786A0457|50 54|light
P07865786A0457|65 82|dark-adapted plants
P07865787A1086|39 51|octamer motifs
P07865787A1086|156 173|wheat histone H3 gene
P07865787A1086|156 173|wheat histone H3 gene
P07865876A1292|3 27|tissue-specific expression
P07865876A1292|30 44|DP family members
P07865876A1292|30 44|DP family members
P07865876A1292|73 74|DP
P07865876A1292|73 74|DP
P07865876A1292|76 90|E2F heterodimers
P07865876A1292|76 78|E2F
P07865876A1292|105 113|DRTF1/E2F
P07865876A1292|105 109|DRTF1
P07865876A1292|111 113|E2F
P07865888A1309|12 25|mammalian cells
P07865888A1309|26 30|PBP74
P07865888A1309|26 30|PBP74
P07865888A1309|47 57|pre-protein
P07865888A1309|70 102|membrane potential-dependent import
P07865888A1309|107 118|mitochondria
P07865888A1309|125 134|maturation
P07865895A0896|34 51|lung clearance assay
P07865895A0896|62 69|mAb 3.2.3
P07865895A0896|62 69|mAb 3.2.3
P07865895A0896|79 82|rats
P07865895A0896|85 95|LGL/NK cells
P07865895A0896|85 87|LGL
P07865895A0896|89 90|NK
P07865895A0896|124 134|LGL/NK cells
P07865917A0191|20 23|FSGS
P07865917A0191|44 51|steroids
P07865917A0191|62 73|cyclosporine
P07865917A0191|75 77|CSA
P07865917A0191|98 110|ACE inhibitors
P07865917A0191|98 100|ACE
P07867604A1777|31 63|inhibin/activin beta B-subunit mRNAs
P07867604A1777|46 63|beta B-subunit mRNAs
P07867604A1777|149 174|negative regulatory elements
P07867604A1777|195 203|promoters
P07867604A1777|218 221|cAMP
P07867604A1777|228 240|phorbol esters
P07867622X0000|0 13|Promoter region
P07867622X0000|19 37|transcriptional unit
P07867622X0000|41 61|human alpha 1-chimaerin
P07867622X0000|41 61|human alpha 1-chimaerin
P07867622X0000|64 102|neuron-specific GTPase-activating protein
P07867622X0000|64 102|neuron-specific GTPase-activating protein
P07867622X0000|106 111|p21rac
P07867622X0000|106 111|p21rac
P07867622X0000|113 128|alpha 1-chimaerin
P07867622X0000|113 128|alpha 1-chimaerin
P07867622X0000|132 170|neuron-specific GTPase-activating protein
P07867622X0000|132 170|neuron-specific GTPase-activating protein
P07867622X0000|174 179|p21rac
P07867622X0000|174 179|p21rac
P07867622X0000|199 217|morphological events
P07867944A0365|0 7|Upstream
P07867944A0365|15 37|transcription start point
P07867944A0365|39 41|tsp
P07867944A0365|45 62|nucleotide sequence
P07867944A0365|112 138|sigma 35-recognized promoters
P07867944A0365|112 116|sigma
P07867944A0365|130 138|promoters
P07869721A0000|40 51|closing phase
P07869721A0000|68 108|mechanical monoleaflet heart valve prosthesis
P07869913A1076|6 8|ISO
P07869913A1076|21 41|abdominal fat blood flow
P07869913A1076|101 104|lean
P07869913A1076|108 120|obese subjects
P07869937A1142|24 33|body weight
P07869937A1142|39 41|GIT
P07869937A1142|56 62|dF group
P07869937A1142|84 86|RMR
P07869937A1142|133 138|P group
P07870305A1015|2 40|nucleus ventralis anterior thalami-nucleus
P07870305A1015|98 104|nucleus
P07870305A1015|188 198|haloperidol
P07871718A1132|33 44|CGGAAR motifs
P07871718A1132|52 63|ICP4 promoter
P07871718A1132|52 63|ICP4 promoter
P07871718A1132|74 80|factors
P07871718A1132|81 96|GABP alpha and beta
P07871718A1132|81 96|GABP alpha and beta
P07871718A1132|114 134|synergistic activation
P07871721A0000|8 23|open reading frame
P07871721A0000|29 53|blueberry scorch carlavirus
P07871721A0000|55 66|BBScV) genome
P07871721A0000|75 111|putative replication-associated protein
P07871721A0000|114 124|223 kDa (p223
P07871721A0000|121 124|p223
P07871721A0392|49 55|viruses
P07871721A0392|66 76|tymoviruses
P07871721A0392|93 96|p223
P07871721A0392|93 96|p223
P07871721A0392|107 133|papain-like proteinase domain
P07871721A0392|107 133|papain-like proteinase domain
P07871721A0392|147 166|catalytic cysteine994
P07871721A0392|170 182|histidine1075
P07871754A0857|62 68|HPV gene
P07871754A0857|62 64|HPV
P07871754A0857|65 78|gene expression
P07871755A0521|16 19|VLPs
P07871757A0846|13 20|sequence
P07871757A0846|35 49|initiation codon
P07871757A0846|71 86|promotor sequence
P07871891A0227|0 4|SUP46
P07871891A0227|0 4|SUP46
P07871891A0227|19 37|translation fidelity
P07871891A0227|51 69|ribosomal protein S13
P07871891A0227|51 69|ribosomal protein S13
P07872673A0332|41 50|c-fos and Rb
P07872673A0332|41 45|c-fos
P07872673A0332|49 50|Rb
P07872673A0332|63 79|expression plasmid
P07872673A0332|107 115|c-fos gene
P07872673A0332|107 115|c-fos gene
P07872673A0332|133 144|SV40 promoter
P07872673A0332|133 144|SV40 promoter
P07872788A1717|15 30|sequence identity
P07872788A1717|43 52|hydrolase B
P07872788A1717|43 52|hydrolase B
P07872788A1717|56 56|C
P07872788A1717|56 56|C
P07872788A1717|75 94|3' untranslated region
P07872788A1717|132 148|carboxylesterases
P07872788A1717|191 203|ancestral gene
P07873831T0000|9 29|pancreatic involvement
P07873831T0000|69 80|palpable mass
P07873876A1035|3 11|NR2 hybrid
P07873876A1035|128 145|subtractive cloning
P07874060A0810|0 4|TDEYA
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|66 67|XO
P07874060A0810|66 67|XO
P07874060A0810|82 94|stomach tissue
P07874060A0810|107 124|oral administration
P07875595A0910|4 9|humans
P07875595A0910|14 27|PITSLRE PK genes
P07875595A0910|14 27|PITSLRE PK genes
P07875595A0910|30 37|chickens
P07875595A0910|65 94|fluorescent in situ hybridization
P07875595A0910|96 99|FISH
P07875595A0910|134 155|chicken microchromosome
P07876134A0348|64 71|AFAP-110
P07876134A0348|64 71|AFAP-110
P07876134A0348|98 108|base pair (bp
P07876134A0348|112 127|open reading frame
P07876191A0808|12 25|class IV ADH mRNA
P07876191A0808|12 18|class IV
P07876191A0808|19 25|ADH mRNA
P07876191A0808|39 61|human stomach but not liver
P07876192A0443|2 9|ICE gamma
P07876192A0443|2 9|ICE gamma
P07876192A0443|102 104|ICE
P07876192A0443|102 104|ICE
P07876194T0000|0 10|Endocytosis
P07876194T0000|14 31|lysosomal targeting
P07876194T0000|34 63|epidermal growth factor receptors
P07876194T0000|34 63|epidermal growth factor receptors
P07876194T0000|110 129|tyrosine kinase domain
P07876194T0000|110 129|tyrosine kinase domain
P07876210A0275|35 63|eukaryotic and prokaryotic genes
P07876210A0275|69 86|5'-flanking regions
P07876210A0275|108 136|barbiturate-inducible proteins
P07876210A0275|147 162|Barbie box element
P07876210A0751|13 29|P450BM-3 Barbie box
P07876210A0751|13 29|P450BM-3 Barbie box
P07876210A0751|71 78|P450BM-3
P07876210A0751|71 78|P450BM-3
P07876210A0751|82 86|Bm3P1
P07876210A0751|82 86|Bm3P1
P07876210A0751|95 103|small gene
P07876210A0751|95 103|small gene
P07876210A0751|124 135|P450BM-3 gene
P07876210A0751|124 135|P450BM-3 gene
P07876210A0751|192 213|pentobarbital induction
P07876210A0751|217 220|left
P07876300A0994|3 20|p97-depleted nuclei
P07876300A0994|3 5|p97
P07876300A0994|48 67|nuclear protein import
P07876562A1646|78 91|infected T cells
P07876562A1646|94 113|antigenic stimulation
P07876562A1646|128 141|HIV-1 infection
P07877308A1175|7 14|protocol
P07877308A1175|31 38|patients
P07877619A1284|22 45|cell-specific suppression
P07877619A1284|48 80|RA-stimulated zif268 gene expression
P07877619A1284|48 49|RA
P07877619A1284|61 70|zif268 gene
P07877619A1284|109 126|nucleotide sequence
P07877619A1284|150 168|RA-responsive region
P07877619A1284|150 168|RA-responsive region
P07877619A1284|174 183|zif268 gene
P07877619A1284|174 183|zif268 gene
P07878029A0721|10 14|CBF-A
P07878029A0721|10 14|CBF-A
P07878029A0721|18 22|CBF-C
P07878029A0721|18 22|CBF-C
P07878029A0721|51 68|CBF-A-CBF-C complex
P07878029A0721|51 55|CBF-A
P07878029A0721|57 68|CBF-C complex
P07878029A0721|76 80|CBF-B
P07878029A0721|76 80|CBF-B
P07878029A0721|100 104|CBF-A
P07878029A0721|100 104|CBF-A
P07878029A0721|107 111|CBF-C
P07878029A0721|107 111|CBF-C
P07878029A0721|150 167|CBF-A-CBF-C complex
P07878029A0721|150 154|CBF-A
P07878029A0721|156 160|CBF-C
P07878040A0505|5 29|first, homologous sequences
P07878040A0505|46 58|mouse enhancer
P07878040A0505|46 58|mouse enhancer
P07878040A0505|114 127|transgenic mice
P07879204T0000|0 14|OKT3 prophylaxis
P07879204T0000|0 3|OKT3
P07879204T0000|23 49|long-term renal graft survival
P07879204T0000|61 68|patients
P07879204T0000|81 92|cyclosporine
P07879204T0000|116 126|prospective
P07879204T0000|148 156|US studies
P07880442A0236|8 41|PKC beta transcription initiation site
P07880442A0236|8 14|PKC beta
P07880442A0236|15 41|transcription initiation site
P07880442A0236|57 71|primer extension
P07880442A0236|75 84|S1 nuclease
P07880442A0236|75 76|S1
P07880442A0236|77 94|nuclease protection
P07880449A0091|28 40|X-rays effects
P07880449A0091|57 59|ICR
P07880449A0091|60 73|white Swiss mice
P07880449A0091|103 118|mounting behavior
P07880449A0091|124 143|whole body irradiation
P07880449A0091|154 159|X-rays
P07880650A0493|1 20|quantitative analysis
P07880650A0493|172 193|crotoxin complex crystal
P07881077A0195|18 29|Contraste RSE
P07881077A0195|86 93|patients
P07883167A0157|2 6|yeast
P07883167A0157|24 39|UPF1 and UPF3 genes
P07883167A0157|24 27|UPF1
P07883167A0157|31 39|UPF3 genes
P07883167A0157|133 149|additional factors
P07883167A0157|173 191|nonsense-containing
P07883167A0157|192 196|mRNAs
P07883168A0090|0 8|Mutations
P07883168A0090|11 14|UPF1
P07883168A0090|48 52|mRNAs
P07883168A0090|68 84|nonsense mutations
P07883168A0090|125 129|mRNAs
P07883193A0000|1 11|DNA fragment
P07883193A0000|23 39|DNA-binding domain
P07883193A0000|23 39|DNA-binding domain
P07883193A0000|41 55|amino acids 1-60)
P07883193A0000|61 102|Escherichia coli fru transcriptional regulator
P07883193A0000|61 102|Escherichia coli fru transcriptional regulator
P07883193A0000|119 131|pGEX-KT vector
P07883193A0000|175 198|glutathione S-transferase
P07883193A0000|175 198|glutathione S-transferase
P07883754A0993|5 24|gel retardation assays
P07883754A0993|29 47|HepG2 nuclear extract
P07883754A0993|85 91|protein
P07883754A0993|107 117|NRE fragment
P07885999A0000|7 20|nuclear factors
P07885999A0000|51 66|5' flanking region
P07885999A0000|72 90|mouse tyrosinase gene
P07885999A0000|72 90|mouse tyrosinase gene
P07885999A0000|110 118|band shift
P07885999A0000|122 150|methylation interference assays
P07886610A0000|46 53|patients
P07886610A0000|58 68|hemophilia A
P07887226A0858|21 28|ferritin
P07887226A0858|21 28|ferritin
P07887226A0858|32 41|hemoglobin
P07887226A0858|60 88|serum transferrin receptor assay
P07887226A0858|65 83|transferrin receptor
P07887226A0858|169 192|functional iron deficiency
P07887226A0858|215 217|IDA
P07887226A0858|225 230|anemia
P07887226A0858|233 246|chronic disease
P07887859A0315|21 28|patients
P07887859A0315|33 47|ischaemic ulcers
P07887859A0315|70 83|ankle/brachial
P07887859A0315|85 87|ABI
P07887859A0315|92 103|toe/brachial
P07887859A0315|105 107|TBI
P07887859A0998|0 15|TcPO2 measurement
P07888156A0169|32 37|Tromso
P07888156A0169|65 72|northern
P07888156A0169|96 109|section service
P07888156A0169|155 173|microscopic findings
P07888156A0169|195 215|major diagnostic issues
P07888156T0000|0 12|Current status
P07888156T0000|15 27|telepathology
P07888306A1659|12 15|h6.1
P07888306A1659|12 15|h6.1
P07888306A1659|18 27|COS-1 cells
P07888306A1659|56 64|type IV PDE
P07888306A1659|56 64|type IV PDE
P07888306A1659|79 82|cAMP
P07888306A1659|90 94|cGMP,
P07888306A1659|148 155|Ca2+/CaM
P07888306A1659|148 151|Ca2+
P07888306A1659|153 155|CaM
P07888306A1659|158 161|cGMP
P07888306A1659|198 205|rolipram
P07888623A0721|0 4|PMEK1
P07888623A0721|0 4|PMEK1
P07888623A0721|48 58|tobacco NTF3
P07888623A0721|48 58|tobacco NTF3
P07888623A0721|62 85|Arabidopsis ATMPK1 kinases
P07888623A0721|62 85|Arabidopsis ATMPK1 kinases
P07888623A0721|127 141|MAP kinase MsERK1
P07888623A0721|127 135|MAP kinase
P07888623A0721|136 141|MsERK1
P07888629A0344|0 10|Translation
P07888629A0344|16 28|coding segment
P07888629A0344|48 53|MsPRP2
P07888629A0344|48 53|MsPRP2
P07888629A0344|74 87|chimeric 40,569
P07888629A0344|111 138|amino-terminal signal sequence
P07888629A0344|151 170|proline-rich sequence
P07888629A0344|176 213|cysteine-rich carboxyl-terminal sequence
P07888788A1010|13 33|type I hypersensitivity
P07888788A1010|70 92|immunoallergic component
P07888788A1010|129 155|chronic inflammatory response
P07888788A1010|158 168|Aspergillus
P07888788A1010|175 187|aspergillomas
P07888828A0765|43 54|RH-like genes
P07888828A0765|43 54|RH-like genes
P07888828A0765|57 72|non human primates
P07890485A0827|4 21|steady illumination
P07890485A0827|36 52|photoreceptor) QO2
P07890485A0827|92 106|inner retinal QO2
P07890599A0132|17 32|mouse cDNA library
P07890599A0132|37 48|MIN6 cell line
P07890599A0132|61 79|pancreatic beta cells
P07890599A0132|117 120|cDNA
P07890599A0132|130 149|593-amino acid protein
P07890599A0132|180 200|munc-18/n-Sec1/rbSec1
P07890599A0132|180 186|munc-18
P07890599A0132|188 200|n-Sec1/rbSec1
P07890599A0132|202 227|Caenorhabditis elegans unc18
P07890599A0132|202 227|Caenorhabditis elegans unc18
P07890599A0132|232 259|Saccharomyces cerevisiae Sec1p
P07890599A0132|232 254|Saccharomyces cerevisiae
P07890674A0916|3 10|catenins
P07890674A0916|17 19|APC
P07890674A0916|17 19|APC
P07890674A0916|23 32|E-cadherin
P07890674A0916|23 32|E-cadherin
P07890674A0916|54 56|APC
P07890674A0916|54 56|APC
P07890674A0916|60 69|E-cadherin
P07890674A0916|60 69|E-cadherin
P07890674A0916|127 134|catenins
P07890674A0916|127 134|catenins
P07890680A1193|18 37|core DNA polymerase III
P07890680A1193|22 37|DNA polymerase III
P07890680A1193|120 124|alpha
P07890680A1193|130 143|primer terminus
P07890740A0997|3 10|PSD2 gene
P07890740A0997|3 10|PSD2 gene
P07890740A0997|50 53|Sf-9
P07890740A0997|54 64|insect cells
P07890740A0997|69 90|recombinant baculovirus
P07890740A0997|121 131|PSD activity
P07890740A0997|121 123|PSD
P07891638T0000|0 20|Computerized detection
P07891638T0000|23 39|abnormal asymmetry
P07891638T0000|42 64|digital chest radiographs
P07891685A1051|68 72|Cat8p
P07891685A1051|68 72|Cat8p
P07891685A1051|109 113|Cat4p
P07891685A1051|109 113|Cat4p
P07891685A1051|115 119|Mig1p
P07891685A1051|115 119|Mig1p
P07891685A1051|128 139|CAT8 promoter
P07891685A1051|128 139|CAT8 promoter
P07891708A0690|4 6|Epo
P07891708A0690|4 6|Epo
P07891708A0690|8 12|HNF-4
P07891708A0690|8 12|HNF-4
P07891708A0690|26 31|kidney
P07891708A0690|33 37|liver
P07891708A0690|42 51|Hep3B cells
P07891708A0690|60 68|HeLa cells
P07891708A1192|12 36|hypoxia-induced expression
P07891708A1192|42 58|endogenous Epo gene
P07891708A1192|52 58|Epo gene
P07891708A1192|86 95|Hep3B cells
P07891708A1192|117 127|HNF-4 delta C
P07891708A1192|117 127|HNF-4 delta C
P07891709A1542|106 118|deadenylation
P07891713T0000|0 15|Small Maf proteins
P07891713T0000|0 7|Small Maf
P07891713T0000|34 36|Fos
P07891713T0000|34 36|Fos
P07891713T0000|74 97|NF-E2 transcription factor
P07891713T0000|74 78|NF-E2
P07891713T0000|79 97|transcription factor
P07891720A0818|26 28|C1F
P07891720A0818|26 28|C1F
P07891720A0818|67 77|calcium ions
P07892076A0578|0 7|Survival
P07892076A0578|26 45|symptomatic infection
P07892076A0578|47 49|P-2
P07892076A0578|65 80|transmission mode
P07892353A0667|50 53|rCBF
P07892353A0667|59 80|medial prefrontal cortex
P07892353A0667|84 101|frontal polar cortex
P07892353A0667|165 185|posterior brain regions
P07894021A1130|36 38|DS2
P07894021A1130|36 38|DS2
P07894021A1130|62 71|nuclear DNA
P07894021A1130|76 86|desiccation
P07894359T0000|0 21|Glomerular hemodynamics
P07894359T0000|28 35|abortion
P07894359T0000|45 49|RU 486
P07894359T0000|53 58|sepsis
P07894359T0000|61 64|rats
P07894761A0000|66 93|expulsive choroidal hemorrhage
P07894761A0000|95 97|ECH
P07894761A0000|156 175|vitreoretinal surgery
P07896088A0720|16 29|C-terminal tail
P07896088A0720|32 50|telomere maintenance
P07896088A0720|74 94|RAP1 interacting factor
P07896088A0720|74 94|RAP1 interacting factor
P07896088A0720|95 98|RIF1
P07896088A0720|95 98|RIF1
P07896088A0720|100 110|rap1 alleles
P07896088A0720|100 110|rap1 alleles
P07896088A0720|129 167|C-terminal tail and RIF1 interaction domains
P07896088A0720|146 149|RIF1
P07896088A0720|189 202|telomere length
P07896291A0693|42 55|cytogenetic map
P07896291A0693|127 138|WAGR syndrome
P07896615A0554|17 20|skin
P07896615A0554|39 45|760-800
P07896615A0554|46 57|nm absorption
P07896615A0554|100 103|skin
P07896615A0554|110 125|laser flow Doppler
P07896615A0554|129 141|NIR recordings
P07896615A0554|148 164|hot water immersion
P07896817A0204|39 68|control- and VEGF-stimulated BAEC
P07896817A0204|50 53|VEGF
P07896817A0204|73 80|antisera
P07896817A0204|83 102|phospholipase C-gamma
P07896817A0204|83 102|phospholipase C-gamma
P07896817A0204|104 112|PLC-gamma
P07896817A0204|104 112|PLC-gamma
P07896817A0204|132 167|SDS-polyacrylamide gel electrophoresis
P07896846T0000|32 65|cellular nucleic acid-binding protein
P07896846T0000|32 39|cellular
P07896846T0000|40 50|nucleic acid
P07896846T0000|51 65|-binding protein
P07896846T0000|100 129|human beta-myosin heavy chain gene
P07896846T0000|100 129|human beta-myosin heavy chain gene
P07896852T0000|13 42|early growth response factor Egr-1
P07896852T0000|13 37|early growth response factor
P07896852T0000|38 42|Egr-1
P07896852T0000|45 64|apolipoprotein AI gene
P07896852T0000|59 77|AI gene transcription
P07897359A0354|3 11|wild-type
P07897359A0354|32 39|F protein
P07897359A0354|32 39|F protein
P07897359A0354|55 60|BHK-21
P07897359A0354|85 135|recombinant vaccinia virus-encoding T7 polymerase system
P07897359A0354|85 129|recombinant vaccinia virus-encoding T7 polymerase
P07897696A0000|0 45|Erythrocyte delta-aminolevulinic acid dehydratase
P07897696A0000|11 45|delta-aminolevulinic acid dehydratase
P07897696A0000|47 59|ALAD) activity
P07897696A0000|47 50|ALAD
P07897696A0000|61 89|erythrocyte zinc protoporphyrin
P07897696A0000|91 93|ZPP
P07897696A0000|96 104|heme ratio
P07897696A0000|109 129|urinary coproporphyrin
P07897696A0000|236 246|blood levels
P07897696A0000|275 287|human subjects
P07898178A0849|17 25|graft loss
P07898178A0849|67 75|graft loss
P07898178A0849|117 138|cyclosporin maintenance
P07898178A0849|177 188|patient death
P07898275A0254|14 24|test objects
P07898275A0254|73 90|31P MRS measurements
P07898275A0254|104 127|slice-selective sequences
P07898275A0254|177 181|1H MRS
P07898275A0254|243 261|experimental systems
P07898275A0254|267 270|ISIS
P07898275A0254|301 306|31P MRS
P07898589T0000|4 10|tobacco
P07898840X0000|0 17|Pregnancy screening
P07898840X0000|20 26|uterine
P07898840X0000|33 50|Doppler velocimetry
P07898840X0000|209 237|pregnancy-induced hypertension
P07898840X0000|241 266|fetal growth restriction (FGR
P07898840X0000|264 266|FGR
P07898840X0000|308 319|quantitative
P07898840X0000|350 356|uterine
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899581A0000|55 73|superoxide dismutase
P07899581A0000|55 73|superoxide dismutase
P07899581A0000|75 77|SOD
P07899581A0000|75 77|SOD
P07899581A0000|97 108|nitrendipine
P07899581A0000|112 130|superoxide dismutase
P07899581A0000|112 130|superoxide dismutase
P07899581A0000|133 157|postischemic renal function
P07899581A0000|188 191|rats
P07899634A0000|68 86|orderly wired surface
P07899634A0000|102 107|Ti Al Va
P07899634A0000|125 129|488 mu
P07900915A0000|28 32|water
P07900915A0000|38 58|gastrointestinal tract
P07900915A0000|79 89|blood volume
P07900915A0000|93 105|plasma protein
P07900915A0000|144 147|rats
P07900915A0000|200 210|blood volume
P07900915A0000|224 235|Evans blue dye
P07900915A0000|239 246|dilution
P07900915A0000|249 258|hematocrit
P07901121T0000|0 22|Cooperative dimerization
P07901121T0000|25 47|paired class homeo domains
P07901125A0416|57 62|DAHPSs
P07901125A0416|57 62|DAHPSs
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|121 125|yeast
P07901125A0416|126 140|Candida albicans
P07902532A0312|29 31|BOX
P07902532A0312|43 55|transcription
P07902532A0312|63 89|thymidine kinase (TK) promoter
P07902532A0312|63 77|thymidine kinase
P07902532A0312|79 89|TK) promoter
P07902532A0312|99 105|EC cells
P07902532A1655|0 15|Deletion analyses
P07902532A1655|60 68|BOXF1 gene
P07902532A1655|60 68|BOXF1 gene
P07902532A1655|82 87|BOX DNA
P07902532A1655|121 127|EC cells
P07902532A1655|134 152|differentiated cells
P07902583A0545|45 65|Grf10-Swi5-DNA complex
P07902583A0545|45 49|Grf10
P07902583A0545|51 54|Swi5
P07902583A0545|56 65|DNA complex
P07902583A0545|89 108|protein-DNA complexes
P07902583A0545|124 127|Swi5
P07902583A0545|124 127|Swi5
P07902583A0545|130 134|Grf10
P07902583A0545|130 134|Grf10
P07903099A0918|42 51|IVS2C beta 1
P07903099A0918|42 51|IVS2C beta 1
P07903099A0918|57 66|5' terminus
P07903670A1202|3 14|mutant allele
P07903670A1202|20 37|alpha 1-tubulin gene
P07903670A1202|20 33|alpha 1-tubulin
P07903670A1202|51 56|tua1-1
P07903670A1202|51 56|tua1-1
P07905413A0585|6 21|chronic treatment
P07905413A0585|27 46|plasma concentrations
P07905413A0585|203 209|placebo
P07905453A0281|11 50|in vitro transcription-translation analysis
P07905453A0281|54 72|maxicell experiments
P07905453A0281|95 97|ORF
P07906265A0897|60 70|fasD mutants
P07906265A0897|60 70|fasD mutants
P07906265A0897|104 117|fimbrial export
P07906616A0191|0 30|Evoked electromyographic response
P07906616A0191|86 95|adult goats
P07906616A0191|101 132|thiopentone-halothane anaesthesia
P07907846A0623|14 26|physostigmine
P07907846A0623|38 39|v.
P07907846A0623|55 79|cholinesterase degradation
P07907846A0623|55 68|cholinesterase
P07907846A0623|91 115|bupivacaine administration
P07907846A0623|148 172|physostigmine pretreatment
P07907846A0623|176 201|electrical vagal stimulation
P07908012A0678|27 30|LNNB
P07908012A0678|31 41|performance
P07908012A0678|47 59|schizophrenic
P07908012A0678|86 115|neuroleptic medication, analyses
P07908012A0678|172 181|LNNB scores
P07908827A1200|8 25|specific antibodies
P07908827A1200|59 65|RAR beta
P07908827A1200|59 65|RAR beta
P07908827A1200|77 96|DNA-protein complexes
P07908827A1200|77 96|DNA-protein complexes
P07908827A1200|132 135|RARs
P07908827A1200|149 156|COS cells
P07908827A1200|203 231|canonical RAR responsive element
P07908827A1200|212 231|RAR responsive element
P07909936A0672|40 48|disorders
P07909936A0672|67 85|complementary effect
P07909936A0672|115 148|autologous stem-cell transplantation
P07909936A0672|168 176|cytokines
P07909936A0672|184 208|colony-stimulating factors
P07909936A0672|184 208|colony-stimulating factors
P07910716A0359|28 35|patients
P07910716A0359|47 48|SC
P07910716A0359|49 53|rIL-2
P07910716A0359|49 53|rIL-2
P07910716A0359|121 128|patients
P07910716A0359|140 151|rIFN-alpha 2b
P07910716A0359|140 151|rIFN-alpha 2b
P07910716A0359|211 218|patients
P07910716A0359|231 232|SC
P07910716A0359|233 244|rIFN-alpha 2b
P07910716A0359|233 244|rIFN-alpha 2b
P07910716A0359|281 282|SC
P07910716A0359|283 287|rIL-2
P07910716A0359|283 287|rIL-2
P07910946A0323|16 33|deletion constructs
P07910946A0323|72 95|heterologous reporter gene
P07910946A0323|97 115|luciferase) activity
P07910946A0323|97 106|luciferase
P07910946A0323|135 157|182-bp 5'-flanking region
P07910946A0323|170 185|promoter activity
P07910946A0323|188 209|IL-2-stimulated L2 cells
P07910946A0323|188 191|IL-2
P07911736A1715|5 7|MTD
P07912123A0711|0 37|Mitogen-induced lymphocyte proliferation
P07913080A0564|55 60|humans
P07913080A0564|64 67|mice
P07913080A0564|83 102|5' untranslated region
P07913080A0564|108 116|horse gene
P07913080A0564|108 116|horse gene
P07913891A0174|58 78|cell-cell interactions
P07913891A0174|130 137|Hox genes
P07913891A0174|130 137|Hox genes
P07913891A0174|146 165|transcription factors
P07913891A0174|204 220|tissue specificity
P07913926A0878|0 15|Northern analysis
P07913926A0878|40 61|ammonium-grown cultures
P07913926A0878|67 76|ntcA mutant
P07913926A0878|67 70|ntcA
P07913926A0878|99 109|glnA message
P07913926A0878|99 102|glnA
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0211|0 3|HER2
P07914192A0211|45 68|DNase I hypersensitive site
P07914192A0211|45 50|DNase I
P07914192A0211|106 123|ets response element
P07914192A0211|106 123|ets response element
P07914192A0211|125 130|GAGGAA
P07914192A0211|165 171|CAAT box
P07914192A0211|190 196|TATA box
P07914192A0211|202 218|human HER2 promoter
P07914192A0211|202 218|human HER2 promoter
P07914192A0844|0 14|Gel-shift assays
P07914192A0844|19 33|nuclear extracts
P07914192A0844|72 93|0.125-kb promoter region
P07914192A0844|104 128|ETS-immunoreactive complex
P07914192A0844|172 175|HER2
P07914192A0844|172 175|HER2
P07914192A0844|215 235|GAGGAA response element
P07914507A1029|12 24|cDNA sequences
P07914507A1029|43 53|mRNA species
P07914507A1029|84 91|poly(A)-
P07914700A0000|13 48|RNA-dependent eIF-2 alpha protein kinase
P07914700A0000|13 48|RNA-dependent eIF-2 alpha protein kinase
P07914700A0000|50 52|PKR
P07914700A0000|50 52|PKR
P07914700A0000|69 83|mouse genomic DNA
P07915144A0000|0 34|High-frequency electrical stimulation
P07915144A0000|40 50|hippocampus
P07915144A0000|70 77|synaptic
P07916003A0688|12 20|mouse gene
P07916003A0688|12 20|mouse gene
P07916003A0688|25 40|5' flanking region
P07916003A0688|43 56|human CD79 alpha
P07916003A0688|43 56|human CD79 alpha
P07916003A0688|63 69|TATA box
P07916003A0688|85 98|mouse CD79 alpha
P07916003A0688|85 98|mouse CD79 alpha
P07916003A0688|110 121|octamer motif
P07916003A0688|147 155|human gene
P07916003A0688|147 155|human gene
P07916326A0000|8 28|molecular organization
P07916326A0000|34 67|coding and upstream regulatory regions
P07916326A0000|73 104|murine homeodomain-containing gene
P07916326A0000|73 104|murine homeodomain-containing gene
P07916326A0000|106 110|Msx-1
P07916326A0000|106 110|Msx-1
P07916327A0250|27 44|human goosecoid gene
P07916327A0250|27 44|human goosecoid gene
P07916327A0250|46 48|GSC
P07916327A0250|46 48|GSC
P07916327A0250|55 68|genomic library
P07916577A0190|24 37|candidate genes
P07916577A0190|41 58|inherited disorders
P07916577A0190|74 95|aberrant gene expression
P07916577A0190|107 130|Kruppel-related sequences
P07916577A0190|107 130|Kruppel-related sequences
P07916577A0190|140 165|zinc finger-containing cDNAs
P07916577A0190|140 165|zinc finger-containing cDNAs
P07916588A0471|21 32|South African
P07916588A0471|41 66|passion fruit woodiness virus
P07916588A0471|68 70|PWV
P07916588A0471|83 92|CP sequence
P07916588A0471|83 92|CP sequence
P07916588A0471|117 119|CPs
P07916588A0471|145 147|PWV
P07916588A0471|206 208|PWV
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|120 131|purification
P07916689A0312|11 20|POT1 clones
P07916689A0312|11 14|POT1
P07916689A0312|34 41|1.4 kb RNA
P07916689A0312|89 94|oleate
P07916689A1407|5 29|lipolytica genomic POT1 gene
P07916689A1407|22 25|POT1
P07916689A1407|104 123|Y. lipolytica LEU2 gene
P07916689A1407|104 123|Y. lipolytica LEU2 gene
P07916729T0000|1 19|leucine zipper domain
P07916729T0000|25 53|suppressor of Hairy-wing protein
P07916729T0000|25 34|suppressor
P07916729T0000|37 53|Hairy-wing protein
P07916729T0000|83 98|enhancer function
P07916983A0623|17 18|CT
P07916983A0623|46 53|patients
P07916983A0623|58 73|N1-N3 neck disease
P07916983A0623|94 120|electron-energy prescription
P07917016A0581|12 39|DNA-binding, zinc finger domain
P07917016A0581|24 54|zinc finger domain protein sequence
P07917540A0000|2 9|patients
P07917540A0000|76 93|interferon-alpha 2b
P07917540A0000|76 93|interferon-alpha 2b
P07917540A0000|116 124|vindesine
P07917540A0000|134 143|interferon
P07917540A0000|134 143|interferon
P07917540A0000|166 192|metastatic malignant melanoma
P07918097T0000|8 21|Notch homologue
P07918097T0000|8 12|Notch
P07918097T0000|22 32|mouse Notch 3
P07918097T0000|27 32|Notch 3
P07918097T0000|46 74|epidermal growth factor-repeats
P07918097T0000|46 66|epidermal growth factor
P07918097T0000|91 118|proliferating neuroepithelium
P07918128A0000|38 48|MDL 73,147EF
P07918128A0000|54 97|5 hydroxytryptamine 3 (5-HT3) receptor antagonist
P07918128A0000|54 72|5 hydroxytryptamine 3
P07918128A0000|74 87|5-HT3) receptor
P07918128A0000|103 110|patients
P07918128A0000|120 141|emetogenic chemotherapy
P07918494A1163|18 37|in vivo reducing system
P07918494A1163|39 49|thioredoxin
P07918494A1163|39 49|thioredoxin
P07918494A1163|51 70|thioredoxin reductase
P07918494A1163|51 70|thioredoxin reductase
P07918494A1163|75 79|NADPH
P07918494A1163|156 161|enzyme
P07919540A0240|5 22|genetic alterations
P07919540A0240|53 64|c-myc protein
P07919540A0240|53 64|c-myc protein
P07919540A0240|66 68|p64
P07919540A0240|66 68|p64
P07919540A0240|98 105|AUG codon
P07919540A0240|108 112|exon 2
P07919540A1119|18 41|exon 1- and exon 2-initiated
P07919540A1119|52 63|c-Myc protein
P07919540A1119|52 63|c-Myc protein
P07919540A1119|90 96|Myc/Max
P07919540A1119|90 92|Myc
P07919540A1119|94 96|Max
P07919540A1119|97 124|-responsive reporter construct
P07922709T0000|0 19|Biological activities
P07922709T0000|22 47|hematopoietic growth factors
P07922709T0000|22 47|hematopoietic growth factors
P07925097A1205|14 22|AR content
P07925097A1205|14 15|AR
P07925097A1205|36 45|COS-1 cells
P07925097A1205|74 82|8-Br-cAMP
P07925282A0705|58 68|SRP proteins
P07925282A0705|58 68|SRP proteins
P07925282A0705|95 125|inefficient protein translocation
P07925282A0705|135 144|ER membrane
P07926729A0000|36 63|signal transduction mechanisms
P07926729A0000|76 90|oncogenic events
P07926729A0000|137 153|gene transcription
P07926739A0766|22 24|GL2
P07926739A0766|22 24|GL2
P07926739A0766|42 60|in situ hybridization
P07926739A0766|95 117|trichome progenitor cells
P07926739A0766|143 161|trichome development
P07926748A0383|0 3|NOT4
P07926748A0383|0 3|NOT4
P07926748A0383|17 20|NOT1
P07926748A0383|17 20|NOT1
P07926748A0383|24 27|NOT3
P07926748A0383|24 27|NOT3
P07926748A0383|33 47|two-hybrid assay
P07926748A0383|68 71|NOT3
P07926748A0383|68 71|NOT3
P07926748A0383|74 77|NOT4
P07926748A0383|74 77|NOT4
P07926748A0383|88 91|not1
P07926748A0383|88 91|not1
P07926748A0383|95 98|not2
P07926748A0383|95 98|not2
P07926748A0383|99 107|mutations
P07926749A0471|7 19|site selection
P07926749A0471|25 51|in vitro-synthesized proteins
P07926749A0471|66 74|ROR alpha 1
P07926749A0471|66 74|ROR alpha 1
P07926749A0471|78 94|ROR alpha 2 isoforms
P07926749A0471|78 86|ROR alpha 2
P07926749A0471|148 166|6-bp AT-rich sequence
P07926749A0471|177 194|half-site core motif
P07926749A0471|195 206|PuGGTCA (RORE
P07926749A0471|203 206|RORE
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926774A0652|3 9|p73pct1
P07926774A0652|11 18|p85cdc10
P07926774A0652|53 55|MCB
P07926774A0652|62 64|SCB
P07926774A0652|62 64|SCB
P07926774A0652|67 74|E2F sites
P07926774A0652|67 74|E2F sites
P07926775A0895|13 14|en
P07926775A0895|40 55|slp mutant embryos
P07926775A0895|40 42|slp
P07926775A0895|63 65|slp
P07926775A0895|113 124|wg expression
P07926775A0895|113 114|wg
P07926775A0895|142 156|wg transcription
P07926775A0895|142 143|wg
P07926775A0895|170 171|hh
P07926775A0895|170 171|hh
P07926789A0960|27 34|lacZ gene
P07926789A0960|27 34|lacZ gene
P07926789A0960|67 77|fusion genes
P07926789A0960|116 140|meiotically induced fusions
P07927130A0625|0 2|CMV
P07927130A0625|3 30|hyperimmunoglobulin treatment
P07927130A0625|3 21|hyperimmunoglobulin
P07927130A0625|41 47|Biotest
P07927130A0625|116 126|eradication
P07927130A0625|132 149|residual infiltrate
P07927130A0625|153 159|CMV-DNA
P07927130A0625|165 174|myocardium
P07927267T0000|8 22|biliary drainage
P07927267T0000|79 97|cholestatic rat liver
P07927711A0698|0 3|ORF 2
P07927711A0698|23 40|hydrophobic protein
P07927711A0698|67 90|membrane-spanning regions
P07927838A0000|15 22|subjects
P07927838A0000|65 68|aged
P07927838A0000|105 126|vibration-induced white
P07927838A0000|134 136|VWF
P07927838A0000|141 148|numbness
P07927838A0000|171 175|upper
P07928954A0545|0 18|DNA sequence analysis
P07928954A0545|59 79|175-amino-acid protein
P07928954A0545|147 171|signal peptide and consensus
P07929165T0000|0 10|DNA sequence
P07929165T0000|28 38|actVI region
P07929165T0000|28 38|actVI region
P07929165T0000|44 78|actinorhodin biosynthetic gene cluster
P07929165T0000|44 71|actinorhodin biosynthetic gene
P07929165T0000|81 104|Streptomyces coelicolor A3
P07929238A0734|6 15|Genomics 12
P07929411A0087|16 43|predicted polypeptide sequence
P07929411A0087|49 65|Drosophila protein
P07929411A0087|49 65|Drosophila protein
P07929411A0087|95 99|mouse
P07929411A0087|103 107|yeast
P07929411A0087|202 215|enzyme activity
P07929431A0949|30 48|mouse promoter region
P07929431A0949|30 42|mouse promoter
P07929431A0949|60 107|reporter gene chloramphenicol acetyltransferase (CAT
P07929431A0949|72 103|chloramphenicol acetyltransferase
P07929431A0949|105 107|CAT
P07929431A0949|149 158|INS-1 cells
P07929431A0949|149 153|INS-1
P07929559A0000|0 16|Cytoplasmic dynein
P07929559A0000|0 16|Cytoplasmic dynein
P07929559A0000|20 31|multisubunit
P07929559A0000|33 74|microtubule-dependent mechanochemical enzyme
P07929559A0000|116 137|intracellular movements
P07929559A0000|148 174|minus-end-directed transport
P07929559A0000|177 186|organelles
P07929560T0000|19 43|plakoglobin-binding domain
P07929560T0000|19 43|plakoglobin-binding domain
P07929560T0000|46 55|desmoglein
P07929560T0000|68 81|plaque assembly
P07929560T0000|85 113|intermediate filament anchorage
P07931490A0237|58 65|patients
P07931490A0237|75 92|high-dose cisplatin
P07931490A0237|94 95|81
P07931490A0237|156 159|5, 10
P07931490A0237|200 211|chemotherapy
P07932095A0000|35 48|I, IV, V, VII-XII
P07932095A0000|40 48|V, VII-XII
P07932095A0000|81 89|II, III, VI
P07932095A0000|91 94|XIII
P07932095A0000|125 144|Oroxylum indicum Vent.
P07933066T0000|33 55|adenovirus E4-6/7 protein
P07933066T0000|33 46|adenovirus E4-6
P07933066T0000|48 55|7 protein
P07933066T0000|62 86|retinoblastoma gene product
P07933066T0000|62 86|retinoblastoma gene product
P07933066T0000|91 105|internal domains
P07933066T0000|108 112|E2F-1
P07933066T0000|108 112|E2F-1
P07933066T0000|116 119|DP-1
P07933066T0000|116 119|DP-1
P07933076A0211|18 22|EBNA2
P07933076A0211|18 22|EBNA2
P07933076A0211|40 48|promoters
P07933076A0211|54 80|viral latent membrane proteins
P07933076A0211|54 80|viral latent membrane proteins
P07933095A0000|22 26|v-Rel
P07933095A0000|22 26|v-Rel
P07933095A0000|31 41|oncoprotein
P07933095A0000|47 64|avian retrovirus Rev
P07933095A0000|47 61|avian retrovirus
P07933095A0000|62 66|Rev-T
P07933095A0000|66 66|T
P07933095A0000|93 101|promoters
P07933095A0000|112 123|binding sites
P07933095A0000|130 156|cellular transcription factor
P07933095A0000|157 159|Sp1
P07933095A0000|157 159|Sp1
P07933095A0000|169 185|embryo fibroblasts
P07933101A0131|38 48|TATA element
P07933101A0131|38 48|TATA element
P07933101A0131|70 99|Tat-induced HIV-1 gene expression
P07933101A0131|70 72|Tat
P07933101A0131|81 89|HIV-1 gene
P07933107A0991|16 33|nucleotide sequence
P07933107A0991|39 45|p54 gene
P07933107A0991|39 41|p54
P07933107A0991|58 76|virulent ASFV strains
P07933107A0991|78 80|E70
P07933107A0991|78 80|E70
P07933107A0991|84 86|E75
P07933107A0991|84 86|E75
P07933107A0991|108 117|virus Ba71V
P07933116A0412|3 9|p55 mRNA
P07933116A0412|3 5|p55
P07933116A0412|6 9|mRNA
P07933116A0412|26 57|non-EBV-infected B- and T-cell lines
P07933116A0412|63 84|myelomonocytic cell line
P07933116A0412|86 89|U937
P07934666A0158|3 25|transverse magnetization
P07934666A0158|70 71|T2
P07934666A0158|77 79|T2f
P07934666A0158|85 86|T2
P07934666A0158|92 104|T2s) component
P07935094A0516|30 38|FDG images
P07935094A0516|95 109|liver background
P07935370A0000|3 23|coordinated expression
P07935370A0000|26 28|CD4
P07935370A0000|26 28|CD4
P07935370A0000|32 34|CD8
P07935370A0000|32 34|CD8
P07935370A0000|41 57|T-cell development
P07935370A0000|101 105|T cell
P07935375A1197|13 36|dominant-negative ras gene
P07935375A1197|30 36|ras gene
P07935375A1197|47 65|TIS10/PGS2 induction
P07935375A1197|47 51|TIS10
P07935375A1197|53 56|PGS2
P07935375A1197|68 72|v-src
P07935375A1197|68 72|v-src
P07935379A0347|3 10|dying tTG
P07935379A0347|98 106|apoptosis
P07935383A0108|7 37|RNase H-mediated mapping technique
P07935383A0108|7 12|RNase H
P07935383A0108|52 64|64-kDa subunit
P07935383A0108|52 64|64-kDa subunit
P07935383A0108|67 70|CstF
P07935383A0108|67 70|CstF
P07935383A0108|99 103|mRNAs
P07935383A0108|106 118|U-rich regions
P07935383A0108|141 152|cleavage site
P07935383A0108|158 174|simian virus 40 late
P07935383A0108|178 198|adenovirus L3 pre-mRNAs
P07935383A0108|178 187|adenovirus
P07935383A0108|188 198|L3 pre-mRNAs
P07935395A0094|41 56|zinc finger motifs
P07935415T0000|0 24|Tissue-specific expression
P07935415T0000|30 54|diazepam-binding inhibitor
P07935415T0000|30 54|diazepam-binding inhibitor
P07935415T0000|57 78|Drosophila melanogaster
P07935415T0000|80 86|cloning
P07935418A0447|6 16|v-erbA probe
P07935418A0447|6 11|v-erbA
P07935418A0447|29 32|cDNA
P07935418A0447|51 71|445-amino-acid protein
P07935418A0447|51 71|445-amino-acid protein
P07935418A0447|73 77|RLD-1
P07935418A0447|73 77|RLD-1
P07935418A0447|117 132|nuclear receptors
P07935418A0447|117 132|nuclear receptors
P07935426A0714|12 19|isoforms
P07935426A0714|30 55|N-terminal zinc finger domain
P07935426A0714|30 55|N-terminal zinc finger domain
P07935426A0714|87 104|TdT promoter binding
P07935426A0714|87 97|TdT promoter
P07935447A0972|35 37|USF
P07935447A0972|35 37|USF
P07935447A0972|51 90|basic helix-loop-helix leucine zipper family
P07935447A0972|51 90|basic helix-loop-helix leucine zipper family
P07935447A0972|99 102|MLE1
P07935447A0972|99 102|MLE1
P07935447A0972|104 108|HF-1a
P07935447A0972|104 108|HF-1a
P07935447A0972|113 121|PRE B sites
P07935447A0972|113 121|PRE B sites
P07935447A0972|153 168|protein complexes
P07935447A0972|210 215|MLC-2v
P07935447A0972|210 215|MLC-2v
P07935447A0972|219 246|alpha-myosin heavy-chain genes
P07935447A0972|219 246|alpha-myosin heavy-chain genes
P07935451T0000|0 31|Human T-cell leukemia virus type I Tax
P07935451T0000|0 28|Human T-cell leukemia virus type I
P07935451T0000|29 31|Tax
P07935451T0000|44 56|NF-kappa B/Rel
P07935451T0000|44 52|NF-kappa B
P07935451T0000|54 56|Rel
P07935451T0000|96 107|I kappa B alpha
P07935451T0000|96 107|I kappa B alpha
P07935451T0000|111 114|RelA
P07935451T0000|111 114|RelA
P07935451T0000|115 137|(p65)-mediated induction
P07935451T0000|116 118|p65
P07935451T0000|143 151|c-rel gene
P07935451T0000|143 151|c-rel gene
P07935468T0000|12 30|c-fos gene expression
P07935468T0000|12 20|c-fos gene
P07935468T0000|33 39|a kinase
P07935468T0000|50 78|epidermal growth factor receptor
P07935468T0000|50 78|epidermal growth factor receptor
P07935471A0613|17 38|HSF DNA-binding activity
P07935471A0613|17 19|HSF
P07935471A0613|47 64|anti-hHSF1 antibody
P07935471A0613|47 64|anti-hHSF1 antibody
P07935471A0613|81 90|Xenopus HSF
P07935471A0613|81 87|Xenopus
P07935471A0613|88 90|HSF
P07935471A0613|131 135|hHSF1
P07935471A0613|173 186|monomeric state
P07935472A0276|28 44|Ets-1 binding sites
P07935472A0276|28 44|Ets-1 binding sites
P07935472A0276|57 81|transient expression assays
P07935472A0276|87 105|murine T-cell line EL4
P07935472A0276|107 108|E1
P07935472A0276|126 135|LVb element
P07935472A0276|144 171|constitutive enhancer activity
P07935472A0276|197 211|LVb or LVc element
P07935472A0276|221 256|phorbol ester-induced enhancer activity
P07935472A0790|35 39|Ets-1
P07935472A0790|35 39|Ets-1
P07935472A0790|63 82|DNA-protein complexes
P07935472A0790|63 73|DNA-protein
P07935472A0790|99 117|mobility shift assays
P07935491A0495|5 15|RZR subtypes
P07935491A0495|5 7|RZR
P07935491A0495|46 67|orphan nuclear receptors
P07935491A0495|46 67|orphan nuclear receptors
P07935491A0495|90 111|specific gene expression
P07935491A1182|72 110|retinoic acid receptor-retinoid-X receptor
P07935491A1182|72 91|retinoic acid receptor
P07935491A1182|93 110|retinoid-X receptor
P07935577A0305|13 25|amphotericin B
P07935577A0305|29 39|flucytosine
P07935577A0305|112 129|cerebrospinal fluid
P07935577A0305|131 133|CSF
P07935626A1249|26 54|tRNA(trp)(CCA)-gene transcript
P07935626A1249|26 34|tRNA(trp)
P07935626A1249|36 54|CCA)-gene transcript
P07935626A1249|57 68|mitochondria
P07935997A0000|15 40|nonspecific humoral immunity
P07935997A0000|43 62|serum immunoglobulins
P07935997A0000|43 62|serum immunoglobulins
P07935997A0000|66 80|immune complexes
P07935997A0000|115 122|patients
P07935997A0000|127 148|uterine cervix carcinoma
P07935997A0000|150 165|Stages IIB and IIIB
P07936635A1134|10 13|KRKR
P07936635A1134|27 30|MO15
P07936635A1134|27 30|MO15
P07936635A1134|36 57|cytoplasmic compartment
P07936635A1134|68 83|wild-type protein
P07936635A1134|68 83|wild-type protein
P07936635A1134|110 116|nucleus
P07936640A0900|62 94|in vivo genomic footprinting analysis
P07936640A0900|113 128|TGF alpha promoter
P07936640A0900|113 128|TGF alpha promoter
P07936640A0900|131 177|normal and transformed rat liver epithelial cell lines
P07936640A0900|192 205|endogenous gene
P07936640A0900|192 205|endogenous gene
P07936650A0656|60 85|N-terminal activating region
P07936650A0656|88 97|p58c-ets-2
P07936650A0656|88 97|p58c-ets-2
P07936650A0656|113 115|BEC
P07936650A0656|113 115|BEC
P07936650A0656|119 134|Ets-1-beta/Ets-2
P07936650A0656|119 128|Ets-1-beta
P07936650A0656|130 152|Ets-2-Conserved sequence
P07936650A1752|31 45|ets-1/ets-2 gene
P07936650A1752|31 35|ets-1
P07936650A1752|37 45|ets-2 gene
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|21 35|avian retrovirus
P07937106A0100|36 38|E26
P07937106A0100|71 80|p68c-ets-1
P07937106A0100|71 80|p68c-ets-1
P07937106A0100|86 107|amino acid substitutions
P07937106A0100|109 115|alanine
P07937106A0100|122 131|isoleucine
P07937106A0100|137 143|c-ets-1
P07937106A0100|137 143|c-ets-1
P07937106A0100|161 166|valine
P07937106A0100|169 173|v-ets
P07937106A0100|169 173|v-ets
P07937106A0100|208 226|carboxy-terminal end
P07937108A0325|22 26|mRNAs
P07937108A0325|52 65|RNA polymerase I
P07937108A0325|52 65|RNA polymerase I
P07937112A0220|23 24|Ku
P07937112A0220|23 24|Ku
P07937112A0220|55 64|human cells
P07937112A0220|72 83|denaturation
P07937112A0220|114 126|recombinant Ku
P07937112A0220|125 126|Ku
P07937127A0645|34 69|strong enhancer-type activation domains
P07937127A0645|77 97|immediate early regions
P07937127A0645|103 115|herpesviruses
P07937127A0645|123 139|pseudorabies virus
P07937127A0645|143 160|bovine herpesvirus 1
P07937132A0819|11 13|U21
P07937132A0819|11 13|U21
P07937132A0819|61 83|highly conserved sequence
P07937132A0819|86 92|28S rRNA
P07937132A0819|86 92|28S rRNA
P07937147A0205|1 13|genetic system
P07937147A0205|35 50|pi protein mutants
P07937147A0205|35 50|pi protein mutants
P07937147A0205|75 76|IR
P07937147A0205|75 76|IR
P07937147A0205|80 81|DR
P07937147A0205|80 81|DR
P07937147A0205|98 102|Amst.
P07937656A0182|10 28|statistical analysis
P07937656A0182|36 68|Kaplan-Meier-estimates and Log-Rank
P07937656A0182|153 165|NSE serum level
P07937656A0182|198 221|serum alkaline phosphatase
P07937656A0182|198 221|serum alkaline phosphatase
P07937656A0182|252 263|serum albumin
P07937656A0182|252 263|serum albumin
P07937656A0182|300 301|70
P07937841A0790|38 57|p53-induced Waf1/Cip1
P07937841A0790|38 40|p53
P07937841A0790|49 52|Waf1
P07937841A0790|54 57|Cip1
P07937841A0790|67 93|cell cycle regulatory pathways
P07937841A0790|108 124|myb oncogene family
P07937841A0790|108 118|myb oncogene
P07937954A0612|0 2|HBx
P07937954A0612|0 2|HBx
P07937954A0612|27 38|GTP-bound Ras
P07937954A0612|36 38|Ras
P07937954A0612|66 68|Raf
P07937954A0612|66 68|Raf
P07937954A0612|73 80|tyrosine
P07937954A0612|99 116|activated MAP kinase
P07937954A0612|108 116|MAP kinase
P07937965T0000|6 10|c-myc
P07937965T0000|6 10|c-myc
P07937965T0000|13 62|simian virus 40 large tumor antigen-induced DNA synthesis
P07937965T0000|74 95|3T3-L1 mouse fibroblasts
P07938137A0384|39 46|naloxone
P07938137A0384|109 124|opiate withdrawal
P07941174T0001|0 11|Laser therapy
P07941174T0001|14 28|penile carcinoma
P07941739A0000|0 14|A 15.1 kb fragment
P07941739A0000|20 30|yeast genome
P07941739A0000|48 79|centromeric region of chromosome XIV
P07941739A0000|82 95|genetic mapping
P07941750A0344|43 69|prokaryotic hydantoinase HyuA
P07941750A0344|43 65|prokaryotic hydantoinase
P07941750A0344|66 69|HyuA
P07941750A0344|89 99|hydatoinase
P07941750A0344|100 103|HyuB
P07941750A0344|100 103|HyuB
P07942076A0497|14 22|estradiol
P07942076A0497|50 88|estradiol valerate and micronized estradiol
P07942448A1227|10 17|patients
P07942448A1227|20 35|NYHA class III and 8
P07942448A1227|38 44|class IV
P07942722T0000|0 11|Constipation
P07943556A0694|58 67|Og4C3 assay
P07943556A0694|58 62|Og4C3
P07944461A0321|0 1|TG
P07944461A0321|9 10|TG
P07944542T0000|0 17|Vibrio cholerae O139
P07945134A0079|3 12|volunteers
P07945134A0079|25 39|18,000 ft (5,486 m
P07945134A0079|68 86|5,000 ft (3,657, 2,438
P07945330A0103|4 18|differentiation
P07945330A0103|23 37|retinoic acid (RA
P07945330A0103|23 34|retinoic acid
P07945330A0103|36 37|RA
P07945330A0103|58 66|Rex-1 gene
P07945330A0103|58 62|Rex-1
P07945937A0358|0 15|Sequence analysis
P07945937A0358|21 45|zebrafish egr1 coding region
P07945937A0358|21 45|zebrafish egr1 coding region
P07945937A0358|85 87|rat
P07945937A0358|92 105|human Egr1 genes
P07945937A0358|92 105|human Egr1 genes
P07945937A0358|132 174|polymorphic, triplet nucleotide repeat sequence
P07945937A0358|198 210|amino terminus
P07945937A0358|216 226|Egr1 protein
P07945937A0358|216 226|Egr1 protein
P07947930A0499|3 12|fibrinogen
P07947930A0499|3 12|fibrinogen
P07947930A0499|14 26|serum proteins
P07947930A0499|14 26|serum proteins
P07947930A0499|34 40|heparin
P07948129A0297|17 42|chimeric long terminal repeat
P07948129A0297|25 42|long terminal repeat
P07948129A0297|44 48|chLTR
P07948129A0297|44 48|chLTR
P07948129A0297|74 122|chloramphenicol acetyl transferase (CAT) reporter gene
P07948129A0297|74 105|chloramphenicol acetyl transferase
P07948129A0297|107 109|CAT
P07948129A0297|149 176|SV40 virus early region promoter
P07948129A0297|188 224|neomycin phosphotransferase II (NEO) gene
P07948129A0297|188 215|neomycin phosphotransferase II
P07948129A0297|217 219|NEO
P07948921A0051|0 20|Optima) genomic library
P07948921A0051|38 73|elicitor-induced stilbene synthase cDNA
P07948921A0051|54 73|stilbene synthase cDNA
P07949137A0000|11 36|acute leukemia adult patients
P07949137A0000|56 65|bone marrow
P07949137A0000|67 68|BM
P07949137A0000|78 88|mafosfamide
P07949137A0000|90 94|ASTA Z
P07949137A0532|3 22|pretransplant regimen
P07949137A0532|34 49|cyclophosphamide
P07949137A0532|68 82|body irradiation
P07949164A0799|3 23|site-directed mutation
P07949164A0799|29 39|kappa B motif
P07949164A0799|29 39|kappa B motif
P07949164A0799|42 56|IL-6/CAT plasmid
P07949164A0799|42 45|IL-6
P07949164A0799|47 49|CAT
P07949164A0799|90 109|IL-6 promoter activity
P07949164A0799|90 101|IL-6 promoter
P07949205A0286|90 104|breast carcinoma
P07949551A0000|27 31|right
P07949551A0000|32 40|renal vein
P07949551A0000|44 65|cadaver transplantation
P07949770T0000|0 29|Enhanced hepatic portal blood flow
P07949770T0000|39 53|prostaglandin E1
P07949770T0000|63 82|liver transplantation
P07949770T0000|85 88|pigs
P07951235A0277|72 77|muscle
P07951410A0647|3 6|HeLa
P07951410A0647|8 10|293
P07951410A0647|12 15|U937
P07951410A0647|20 28|A549 cells
P07951410A0647|45 49|E2F-1
P07951410A0647|45 49|E2F-1
P07951410A0647|51 54|DP-1
P07951410A0647|51 54|DP-1
P07951410A0647|56 62|cyclin A
P07951410A0647|56 62|cyclin A
P07951410A0647|67 68|RB
P07951410A0647|67 68|RB
P07951410A0647|154 158|E2F-1
P07951410A0647|154 158|E2F-1
P07951410A0647|161 164|DP-1
P07951410A0647|161 164|DP-1
P07951410A1332|0 16|E1A autoactivation
P07951410A1332|0 2|E1A
P07951410A1332|65 82|ninefold activation
P07951410A1332|106 116|E1A promoter
P07951410A1332|106 108|E1A
P07951874A0320|0 14|Cestode invasion
P07951874A0320|67 83|ionizing radiation
P07951874A0320|96 107|immune system
P07953785A0648|6 17|heat exposure
P07953785A0648|70 95|non-metyrapone-treated food
P07953785A0648|136 163|marble spleen disease infection
P07954475A0714|46 62|reciprocal crosses
P07954475A0714|64 67|A/J x
P07954475A0714|68 77|C3H/HeJ F1 (
P07954475A0714|93 97|AC3F1
P07954475A0714|102 108|C3H/HeJ
P07954475A0714|112 114|J F1
P07954475A0714|131 135|C3AF1
P07954475A0714|131 135|C3AF1
P07954475A0714|177 182|allele
P07954475A0714|196 225|chromosome 4 tumor suppressor gene
P07954891T0000|0 3|ERV1
P07954891T0000|0 3|ERV1
P07954891T0000|19 36|cell-division cycle
P07954891T0000|56 75|mitochondrial genomes
P07954891T0000|78 100|Saccharomyces cerevisiae
P07956578A0851|0 14|Lesion diameters
P07956578A0851|43 68|sessile-type configurations
P07956869A0000|90 108|Pathology laboratory
P07956869A0000|161 173|flow cytometry
P07956869A0000|177 203|DNA ploidy and S-phase fraction
P07957085A0207|0 3|Cbf3
P07957085A0207|0 3|Cbf3
P07957085A0207|26 30|Cbf3a
P07957085A0207|26 30|Cbf3a
P07957085A0207|32 36|Cbf3b
P07957085A0207|32 36|Cbf3b
P07957085A0207|40 44|Cbf3c
P07957085A0207|40 44|Cbf3c
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0471|38 40|GST
P07957106A0471|42 57|POU fusion protein
P07957106A0471|65 88|glutathione-agarose beads
P07957106A0875|5 13|mutations
P07957106A0875|49 69|HSV transactivator VP16
P07957106A0875|49 69|HSV transactivator VP16
P07957106A0875|100 111|VP16 contacts
P07957106A0875|100 103|VP16
P07957158A1532|13 26|filtration rate
P07957158A1532|126 133|vascular
P07957158A1532|147 165|interstitial control
P07957158A1532|171 184|Starling forces
P07957243A1316|13 20|residues
P07957559A1557|8 16|rapamycin
P07957559A1557|26 38|proliferation
P07957559A1557|41 54|Ba/F3-EpoRgp55
P07957559A1557|41 42|Ba
P07957559A1557|44 45|F3
P07957559A1557|63 70|MEL cells
P07957559A1557|90 100|p70 S6 kinase
P07957559A1557|90 100|p70 S6 kinase
P07957632A0000|0 24|Intraventricular injection
P07957632A0000|28 29|2S
P07957632A0000|31 70|1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl
P07957632A0000|72 78|glycine
P07957632A0000|80 85|DCG-IV
P07957632A0000|105 134|metabotropic glutamate receptors
P07957632A0000|117 134|glutamate receptors
P07957632A0000|228 230|rat
P07958446A0000|3 27|hepatocyte nuclear factor-3
P07958446A0000|3 27|hepatocyte nuclear factor-3
P07958446A0000|29 34|HNF-3)
P07958446A0000|29 33|HNF-3
P07958446A0000|36 56|forkhead (fkh) proteins
P07958446A0000|36 43|forkhead
P07958446A0000|45 47|fkh
P07958446A0000|85 129|tissue-specific and developmental gene regulators
P07958446A0000|157 182|winged helix DNA binding motif
P07958446A0000|157 162|winged
P07958446A0000|163 182|helix DNA binding motif
P07958865A1152|0 20|Homozygous null embryos
P07958865A1152|34 46|abnormalities
P07958865A1152|49 64|heart development
P07958865A1152|97 99|Tek
P07958865A1152|97 99|Tek
P07958865A1152|114 147|endocardial/myocardial interactions
P07958898A1050|14 23|dTFIIA-L/S
P07958898A1050|14 21|dTFIIA-L
P07958898A1050|23 23|S
P07958898A1050|56 80|transcriptional activation
P07958898A1050|83 110|upstream transcription factors
P07958898A1050|120 122|Sp1
P07958898A1050|120 122|Sp1
P07958898A1050|124 127|VP16
P07958898A1050|124 127|VP16
P07958898A1050|132 136|NTF-1
P07958898A1050|132 136|NTF-1
P07958911A0500|7 26|trithorax binding site
P07958911A0500|7 26|trithorax binding site
P07958911A0500|64 75|fork head gene
P07958911A0500|64 75|fork head gene
P07958911A0500|93 104|homeotic gene
P07958911A0500|93 104|homeotic gene
P07958911A0500|122 136|homeotic complex
P07958911A0500|122 136|homeotic complex
P07958915A1507|22 38|intracellular Ca2+
P07958915A1507|91 94|cAMP
P07958915A1507|106 118|transcription
P07958915A1507|159 197|Ca2+/calmodulin-dependent protein kinases
P07958915A1507|159 162|Ca2+
P07958915A1507|164 197|calmodulin-dependent protein kinases
P07958920A1157|0 9|Antibodies
P07958920A1157|28 38|SNM1 protein
P07958920A1157|28 38|SNM1 protein
P07958920A1157|57 67|RNase MRP RNA
P07958920A1157|57 61|RNase
P07958920A1157|62 67|MRP RNA
P07958920A1157|72 89|whole-cell extracts
P07958920A1157|147 155|RNase P RNA
P07958920A1157|147 155|RNase P RNA
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379a|26 33|promoter
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379a|59 81|sequence-specific manner
P07959011A0379b|0 9|C/EBP alpha
P07959011A0379b|0 9|C/EBP alpha
P07959011A0379b|26 33|promoter
P07959011A0379b|39 55|rat class-I ADH gene
P07959011A0379b|39 55|rat class-I ADH gene
P07959011A0379b|59 81|sequence-specific manner
P07959015A0478|21 23|ORF
P07959015A0478|26 30|hAMPK
P07959015A0478|26 30|hAMPK
P07959015A0478|38 50|552 amino acids
P07959015A0478|90 94|rAMPK
P07959015A0478|90 94|rAMPK
P07959015A0478|126 127|aa
P07959015A0478|131 132|nt
P07959734A0194|2 11|human brain
P07959734A0194|13 21|contactin
P07959734A0194|13 21|contactin
P07959734A0194|58 74|peptide sequencing
P07959734A0194|80 117|lentil-lectin-binding glycoprotein Gp135
P07959734A0194|80 112|lentil-lectin-binding glycoprotein
P07959734A0194|113 117|Gp135
P07959760A0763|14 22|YAC contig
P07959760A0763|52 55|YACs
P07959760A0763|65 86|19 sequence-tagged sites
P07959760A0763|88 91|STSs
P07959760A0763|110 112|2.2
P07959760A0763|126 147|Ewing sarcoma breakpoint
P07959760A0763|149 154|c-ets 1
P07959760A0763|149 154|c-ets 1
P07959760A0763|158 162|Fli-1
P07959760A0763|158 162|Fli-1
P07959760A0763|179 187|ets family
P07959760A0763|179 187|ets family
P07959760A0763|209 213|400 kb
P07959760A0763|227 229|DNA
P07959760A0763|277 301|microsatellite, D11S912 (CA
P07959760A0763|292 298|D11S912
P07959760A0763|300 301|CA
P07959760A0763|334 342|Fli-1 gene
P07959760A0763|334 338|Fli-1
P07959952A1446|24 33|pseudogene
P07959952A1446|54 74|mouse mast cell chymases
P07959952A1446|59 74|mast cell chymases
P07959952A1446|88 123|polymerase chain reaction amplification
P07959952A1446|155 166|mast cell line
P07959953A0423|0 4|IFI16
P07959953A0423|0 4|IFI16
P07959953A0423|18 22|exons
P07959953A0423|41 47|introns
P07960608A0228|0 6|Courses
P07960796A0154|38 43|ruling
P07961545A1314|5 17|adverse events
P07961545A1314|59 65|placebo
P07961545A1314|117 135|abnormal ejaculation
P07961755A0474|33 62|putative transit peptide sequence
P07961755A0474|65 81|cysteine synthase C
P07961755A0474|65 81|cysteine synthase C
P07961957A1565|44 48|TEF-1
P07961957A1565|44 48|TEF-1
P07961957A1565|57 75|HF-1a-related factor
P07961957A1565|57 61|HF-1a
P07961957A1565|96 108|alpha-MHC gene
P07961957A1565|96 108|alpha-MHC gene
P07961957A1565|109 117|EM element
P07961958T0000|0 24|Rat kidney carboxylesterase
P07961958T0000|0 2|Rat
P07961958T0000|3 8|kidney
P07963540A0795|0 23|Recombinant I-kappa B alpha
P07963540A0795|0 23|Recombinant I-kappa B alpha
P07963540A0795|33 50|kappa B motif binding
P07963540A0795|33 43|kappa B motif
P07963540A0795|53 73|nuclear factor-kappa B1
P07963540A0795|53 73|nuclear factor-kappa B1
P07963540A0795|75 78|RelA
P07963540A0795|75 78|RelA
P07963540A0795|83 87|c-Rel
P07963540A0795|83 87|c-Rel
P07963540A0795|113 152|UV radiation-induced covalent cross-linking
P07963540A0795|156 205|bromodeoxyuridine-substituted kappa B oligonucleotide
P07963782A0000|79 104|epidural or intrathecal space
P07963782A0000|122 132|chronic pain
P07964162A0941|46 61|MAP kinase cascade
P07964162A0941|46 54|MAP kinase
P07964162A0941|116 132|cellular responses
P07964458A0179|17 19|Bcg
P07964458A0179|17 19|Bcg
P07964458A0179|31 75|natural resistance-associated macrophage protein
P07964458A0179|31 75|natural resistance-associated macrophage protein
P07964458A0179|77 81|Nramp
P07964458A0179|77 81|Nramp
P07964458A0179|121 154|macrophage-specific membrane protein
P07964458A0179|121 154|macrophage-specific membrane protein
P07964458A0179|183 189|animals
P07964459A0845|38 46|LIM domain
P07964459A0845|38 46|LIM domain
P07964459A0845|53 68|RING finger family
P07964459A0845|53 68|RING finger family
P07964459A0845|93 112|metal-binding regions
P07964624A0491|3 9|P131 ORF
P07964624A0491|3 6|P131
P07964624A0491|7 9|ORF
P07964624A0491|37 39|ORF
P07964624A0491|89 107|UGA termination codon
P07964624A0491|113 119|P131 ORF
P07964624A0491|113 116|P131
P07964624A0491|117 119|ORF
P07964624A0491|143 143|M
P07964624A0491|145 145|r
P07964624A0491|154 157|P191
P07964624A0491|154 157|P191
P07964770A0172|15 22|patients
P07964770A0172|47 58|arthroplasty
P07964814T0000|32 50|migraine and epilepsy
P07964918A0000|14 35|patient-related factors
P07965152A0764|0 7|Segments
P07965152A0764|23 33|BMIPP uptake
P07965152A0764|38 47|MIBI uptake
P07965152A0764|49 59|mismatching
P07965152A0764|73 82|normal wall
P07965152A0764|125 145|dobutamine stimulation
P07966565A0901|21 24|mRNA
P07966565A0901|26 41|1,838 nucleotides
P07966565A0901|68 73|1.9-kb
P07966565A0901|74 76|RNA
P07966565A0901|99 114|replication cycle
P07966565A0901|142 150|infection
P07966580A0518|0 5|Infect
P07966583A1268|0 21|Transient transfections
P07966583A1268|25 33|construct
P07966583A1268|47 59|RNA transcript
P07966583A1268|47 59|RNA transcript
P07966583A1268|69 77|clone B1.1
P07966583A1268|82 89|D17 cells
P07966583A1268|112 134|Env/Mlvi-4 fusion protein
P07966583A1268|112 114|Env
P07966583A1268|116 121|Mlvi-4
P07966602A0130|0 6|Roizman
P07966873A0693|0 37|Articles addressing valvular heart disease
P07966873A0693|40 51|heart failure
P07966873A0693|63 87|acute myocardial infarction
P07966873A0693|90 103|Chagas' disease
P07967360A1048|42 56|TGBM nephropathy
P07967360A1048|77 90|IgA nephropathy
P07967360A1048|77 79|IgA
P07967360A1048|94 133|mesangial proliferative glomerulonephritis
P07967725A0262|3 18|nuclear receptors
P07967725A0262|48 64|structural domains
P07967725A0262|85 101|DNA-binding domain
P07967725A0262|85 101|DNA-binding domain
P07967725A0262|107 125|ligand binding domain
P07967725A0262|131 146|carboxyl terminus
P07967725A0262|152 159|receptor
P07968409A0123|23 43|HIV-infected-patients
P07968409A0123|91 112|Infectious Diseases dept
P07968409A0123|116 149|Bologna's "Ospedale Maggiore" General
P07968409A0123|177 183|19-23rd
P07969115A0000|7 32|organello footprint analysis
P07969115A0000|57 70|human placental
P07969115A0000|71 82|mitochondria
P07969115A0000|102 119|protein-DNA binding
P07969115A0000|157 168|500-bp region
P07969115A0000|184 189|D-loop
P07969115A0000|206 220|promoter regions
P07969116A0196|3 14|Nur77 protein
P07969116A0196|3 14|Nur77 protein
P07969116A0196|30 51|transcription activator
P07969116A0196|91 105|downstream genes
P07969116A0196|118 137|extracellular stimuli
P07969132A0268|10 17|plasmids
P07969132A0268|27 40|tRNA(His) genes
P07969132A0268|100 108|histidine
P07969132A0268|115 122|plasmids
P07969132A0268|134 145|gcn2 deletion
P07969132A0268|134 137|gcn2
P07969132A0268|183 190|gcn2-507
P07969132A0268|183 190|gcn2-507
P07969135A0913|21 34|Cln2 PEST domain
P07969135A0913|21 34|Cln2 PEST domain
P07969135A0913|62 80|heterologous protein
P07969136A0273|0 33|Electrophoretic mobility shift assays
P07969136A0273|114 126|NF-kappa B site
P07969136A0273|114 126|NF-kappa B site
P07969136A0273|134 153|kappa light-chain gene
P07969136A0273|134 153|kappa light-chain gene
P07969152A0721|9 59|carboxyl-terminal HSF transcriptional activation domain
P07969152A0721|26 59|HSF transcriptional activation domain
P07969152A0721|88 104|CUP1 transcription
P07969152A0721|88 91|CUP1
P07969152A0721|121 135|heat shock stress
P07969152A0721|139 155|glucose starvation
P07969152A0721|192 210|heat shock activation
P07969152A0721|248 264|S. cerevisiae hsp70
P07969152A0721|248 259|S. cerevisiae
P07969152A0721|260 270|hsp70 family
P07969181A0313|34 40|CKB mRNA
P07969181A0313|34 40|CKB mRNA
P07969181A0313|43 51|HeLa cells
P07969181A0313|123 132|p53 protein
P07969181A0313|123 132|p53 protein
P07969181A0313|142 150|HeLa cells
P07969954T0000|44 69|serum IgM anti-GM1 antibodies
P07969954T0000|49 51|IgM
P07969954T0000|52 69|anti-GM1 antibodies
P07969954T0000|91 103|immunotherapy
P07969954T0000|108 128|monthly plasma exchange
P07969954T0000|143 158|cyclophosphamide
P07971282A0000|0 9|Regulators
P07971282A0000|37 78|nonsex-specific alternative pre-mRNA splicing
P07971709A0907|1 22|normal systemic response
P07971709A0907|39 40|IF
P07971709A0907|56 62|rhG-CSF
P07971709A0907|56 62|rhG-CSF
P07971709A0907|83 87|solid
P07972012A0956|1 20|full-length cDNA clone
P07972012A0956|34 40|rat lung
P07972012A0956|69 81|55-kDa protein
P07972012A0956|69 81|55-kDa protein
P07972012A0956|97 109|amino terminus
P07972012A0956|140 168|ANP-receptor kinase-like domain
P07972012A0956|140 168|ANP-receptor kinase-like domain
P07972012A0956|187 202|carboxyl terminus
P07972012A0956|212 236|protein-serine phosphatase
P07972012A0956|220 225|serine
P07972012A0956|226 242|phosphatase domain
P07972237A0665|1 26|high-resolution restriction
P07972237A0665|43 55|contiguous DNA
P07972237A0665|66 70|N-myc
P07972237A0665|66 70|N-myc
P07972237A0665|99 102|YACs
P07972237A0665|107 113|cosmids
P07972831A0563|0 10|PAI-1 levels
P07972831A0563|0 4|PAI-1
P07972831A0563|35 42|patients
P07973364A0325|31 35|death
P07973364A0325|109 134|OFA (Sprague-Dawley-derived
P07973364A0325|139 148|Wistar rats
P07973364A0325|168 170|OF1
P07973364A0325|174 181|NMRI mice
P07973397T0001|0 29|Determination of potassium iodide
P07973397T0001|32 47|Polish edible salt
P07973825A0445|18 33|systolic pressure
P07973825A0445|47 63|diastolic pressure
P07973825A0445|67 79|pulse pressure
P07975763A0000|15 43|hepatitis C virus (HCV) infection
P07975763A0000|54 72|chronic liver disease
P07975882T0000|0 14|Human adenovirus
P07975882T0000|32 37|fibers
P07977239A1283|0 17|Outflow obstruction
P07977239A1283|20 34|pancreatic juice
P07977239A1283|63 74|minor papilla
P07977239A1283|106 113|patients
P07977239A1283|118 130|type II papilla
P07977239A1283|149 156|patients
P07977239A1283|161 173|type II papilla
P07977239A1283|189 205|acute pancreatitis
P07977239A1283|233 247|pancreatic juice
P07977239A1283|273 282|dorsal duct
P07977648A0880|15 29|TP53 transcripts
P07977648A0880|15 29|TP53 transcripts
P07977648A0880|34 39|exons 2
P07977648A0880|88 93|allele
P07977648A0880|106 111|tumors
P07978229T0000|25 41|unsuitable patient
P07978406A0998|5 12|ISO group
P07978406A0998|16 22|pre-DEX
P07978406A0998|24 26|CBF
P07978406A0998|83 93|hypercapnia
P07978406A0998|95 98|PCO2
P07979810A0340|8 43|ejaculate parameters (density, motility
P07979810A0340|45 56|swelling test
P07979810A0340|58 72|penetration test
P07979810A0340|115 134|therapeutic pregnancy
P07979827A0722|0 6|KRN2391
P07979827A0722|10 19|cromakalim
P07979827A0722|53 58|aortic
P07979827A0722|62 78|coronary blood flow
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980440A0138|24 38|glucocorticoids
P07980440A0138|40 51|retinoic acid
P07980440A0138|55 63|cyclic AMP
P07980440A0138|65 68|cAMP
P07980440A0138|78 99|PEPCK gene transcription
P07980440A0138|78 86|PEPCK gene
P07980440A0138|107 113|insulin
P07980440A0138|107 113|insulin
P07980440A0138|117 129|phorbol esters
P07980468A0298|0 10|Acta 572, 113
P07980669A0373|11 13|AVP
P07980669A0373|23 25|AVP
P07980669A0373|23 25|AVP
P07980669A0373|38 51|postural change
P07980669A0373|68 82|plasma NPY levels
P07980669A0373|74 76|NPY
P07981143A0633|10 22|16 nucleotides
P07981143A0633|40 45|IL-4RE
P07981143A0633|40 45|IL-4RE
P07981143A0633|59 74|IL-4 inducibility
P07981143A0633|59 62|IL-4
P07981143A0633|84 105|nucleoprotein complexes
P07981143A0633|110 128|constitutive factors
P07981246A0112|29 42|pertussis toxin
P07981246A0112|29 42|pertussis toxin
P07981246A0112|44 75|IAP)-sensitive GTP-binding protein
P07981246A0112|44 75|IAP)-sensitive GTP-binding protein
P07981246A0112|77 77|s
P07981246A0112|80 88|G-protein
P07981246A0112|80 88|G-protein
P07981246A0112|114 128|differentiation
P07981246A0112|131 138|hormones
P07981246A0112|140 143|IBMX
P07981246A0112|158 171|c-fos induction
P07981246A0112|158 162|c-fos
P07982964A1017|0 2|ATX
P07982964A1017|0 2|ATX
P07982964A1017|8 11|PC-1
P07982964A1017|8 11|PC-1
P07982964A1017|35 104|type I phosphodiesterase substrate p-nitrophenyl thymidine-5'-monophosphate
P07982964A1017|35 56|type I phosphodiesterase
P07982995A0000|11 32|site-specific mutations
P07982995A0000|38 80|mouse platelet-derived growth factor (PDGF) beta
P07982995A0000|38 70|mouse platelet-derived growth factor
P07982995A0000|72 89|PDGF) beta-receptor
P07982995A0000|107 121|Na+/H+ exchanger
P07982995A0000|135 174|normal murine mammary gland epithelial (NMuMG
P07982995A0000|179 207|Chinese hamster ovary (CHO) cells
P07983011A0617|0 15|Sequence analysis
P07983011A0617|28 48|kinase catalytic domain
P07983011A0617|69 91|serine/threonine kinases
P07983011A0617|69 91|serine/threonine kinases
P07983011A0617|128 175|microtubule-associated protein kinase kinase kinases
P07983011A0617|128 175|microtubule-associated protein kinase kinase kinases
P07983011A0617|182 217|fibroblast growth factor receptor family
P07983011A0617|192 217|growth factor receptor family
P07983011A0617|224 263|putative alpha-helical leucine zipper motifs
P07983011A0617|326 348|NH2-terminal basic domain
P07983011A0617|355 401|COOH-terminal and NH2-terminal proline-rich domains
P07983011A0617|414 450|src homology 3 (SH3) domain binding regions
P07983011A0617|414 425|src homology 3
P07983011A0617|427 436|SH3) domain
P07983704A0330|0 11|Type 2 genomes
P07983704A0330|79 100|infectious, replication
P07983704A0330|135 140|HERV-K
P07983704A0330|153 164|type 1 genomes
P07983712A0914|12 29|domain I and domain II
P07983715A0996|0 13|Point mutations
P07983715A0996|47 50|NF-Y
P07983715A0996|47 50|NF-Y
P07983715A0996|56 77|internal palindromic arm
P07983715A0996|109 118|P4 promoter
P07983715A0996|109 118|P4 promoter
P07983715A0996|140 155|complex formation
P07983715A0996|160 162|USF
P07983715A0996|160 162|USF
P07983715A0996|184 208|transient expression assays
P07983715A0996|217 238|luciferase reporter gene
P07983715A0996|217 238|luciferase reporter gene
P07983716A1082|13 37|Northern (RNA) blot analysis
P07983716A1082|41 65|reverse transcriptase-PCRs
P07983716A1082|41 60|reverse transcriptase
P07983716A1082|94 98|COS-7
P07983716A1082|101 109|HeLa cells
P07983716A1082|119 127|viral RNAs
P07983716A1082|140 143|Y88S
P07983716A1082|140 143|Y88S
P07983716A1082|147 154|Y88L RNAs
P07983716A1082|147 154|Y88L RNAs
P07983744A0920|27 31|IE110
P07983744A0920|27 31|IE110
P07983744A0920|48 62|cytoplasmic form
P07983744A0920|65 69|IE175
P07983744A0920|65 69|IE175
P07983744A0920|74 98|nuclear punctate structures
P07983744A0920|104 118|cytoplasmic form
P07983744A0920|121 125|IE110
P07983744A0920|121 125|IE110
P07983744A0920|155 159|IE175
P07983744A0920|155 159|IE175
P07983744A0920|162 190|cytoplasmic punctate structures
P07984088A0592|0 12|Transcription
P07984088A0592|25 35|ivanolysin O
P07984088A0592|25 35|ivanolysin O
P07984088A0592|66 85|virulence gene cluster
P07984088A0592|88 97|L. ivanovii
P07984088A0592|88 97|L. ivanovii
P07984088A0592|113 116|PrfA
P07984088A0592|113 116|PrfA
P07984105A1509|31 42|WA fyuA mutant
P07984105A1509|31 42|WA fyuA mutant
P07984105A1509|54 61|fyuA gene
P07984105A1509|54 61|fyuA gene
P07984105A1509|86 99|mouse virulence
P07984261A0536|3 6|ICBF
P07984261A0536|12 26|ischaemic cortex
P07984261A0536|58 72|ischaemic centre
P07984261A0536|89 95|tissues
P07985305T0001|14 27|hydronephrosis
P07985305T0001|30 37|children
P07987924A0670|3 14|inflation hub
P07987924A0670|56 78|USCI Tuohy-Borst Y adaptor
P07987924A0670|100 114|transected probe
P07988559A0836|20 29|RBP-J kappa
P07988559A0836|20 22|RBP
P07988559A0836|24 29|J kappa
P07988730A0220|63 70|U5 region
P07988730A0220|76 78|LTR
P07988730A0220|92 134|chloramphenicol acetyltransferase (CAT) assays
P07988730A0220|92 123|chloramphenicol acetyltransferase
P07988730A0220|125 127|CAT
P07988730A0220|158 166|HeLa cells
P07988730A0220|169 181|Jurkat T-cells
P07988730A0220|206 234|viral transactivator tax protein
P07988730A0220|206 224|viral transactivator
P07988730A0220|225 234|tax protein
P07988731A0002|43 75|environmentally inducible promoters
P07988731A0002|110 127|cis-acting elements
P07988731A0002|142 157|promoter activity
P07988731A0002|174 178|G-box
P07988731A0002|174 178|G-box
P07988731A0002|180 187|CCACGTGG
P07988731A1301|10 16|protein
P07988731A1301|27 30|GF14
P07988731A1301|27 30|GF14
P07988731A1301|69 85|GBF protein complex
P07988731A1301|69 78|GBF protein
P07988945T0000|3 22|diagnostic strategies
P07988945T0000|26 44|lupus anticoagulants
P07988945T0000|48 73|antiphospholipid antibodies
P07990136A1124|50 55|polIII
P07990136A1124|50 55|polIII
P07990136A1124|83 107|tRNA gene transcription unit
P07990136A1124|83 90|tRNA gene
P07990136A1124|175 205|mammalian polIII ternary complexes
P07990136A1124|175 205|mammalian polIII ternary complexes
P07991437A1032|0 10|Propafenone
P07991437A1032|41 53|young patients
P07991582A1023b|0 17|Mutational analysis
P07991582A1023b|20 28|yeast CEG1
P07991582A1023b|20 28|yeast CEG1
P07991582A1023b|54 57|five
P07991582A1023b|58 72|conserved motifs
P07991582A1023b|88 108|capping enzyme function
P07992027A0485|1 8|patients
P07992027A0485|67 81|transplantation
P07993559A0233|13 30|Fluorosis Risk Index
P07993559A0233|43 49|Pendrys
P07994021A1223|24 38|cytoplasmic tail
P07994021A1223|64 78|PECAM-1 isoforms
P07994021A1223|64 70|PECAM-1
P07994021A1223|94 108|phosphorylation
P07994021A1223|110 132|cytoskeletal association
P07995173A0585|35 48|gastric juice pH
P07995910A0119|90 105|nodal involvement
P07995910A0119|116 125|laparotomy
P07997174A0936|27 41|phosphorylation
P07997174A0936|92 107|A. vinelandii NifL
P07997174A0936|92 107|A. vinelandii NifL
P07999066A0238|9 14|HIV tat
P07999066A0238|9 14|HIV tat
P07999066A0238|48 55|viral LTR
P07999066A0238|48 55|viral LTR
P07999066A0238|74 94|IL-2 gene transcription
P07999066A0238|74 81|IL-2 gene
P07999066A0238|142 148|tat gene
P07999066A0238|142 148|tat gene
P07999066A0238|151 162|phorbol ester
P07999066A0238|166 181|calcium ionophore
P07999066A0238|192 202|Jurkat cells
P07999066A0238|218 280|IL-2 promoter-chloramphenicol acetyltransferase reporter constructs
P07999066A0238|218 229|IL-2 promoter
P07999066A0238|231 280|chloramphenicol acetyltransferase reporter constructs
P07999363A0000|0 15|Splice variations
P07999363A0000|18 22|genes
P07999363A0000|35 58|transmembrane FGF receptor
P07999363A0000|48 58|FGF receptor
P07999363A0000|60 63|FGFR
P07999363A0000|60 63|FGFR
P07999363A0000|73 80|isoforms
P07999363A0000|105 136|intracellular juxtamembrane domain
P07999363A0000|144 168|intracellular kinase domain
P07999604A0139|59 81|atypical lesions biopsied
P07999982A0086|0 8|Cumulated
P07999982A0086|32 35|FRDA
P07999982A0086|32 35|FRDA
P07999982A0086|39 42|D9S5
P07999982A0086|39 42|D9S5
P07999982A0086|53 56|FRDA
P07999982A0086|53 56|FRDA
P07999982A0086|60 64|D9S15
P07999982A0086|60 64|D9S15
P07999982A0086|136 154|recombination events
P07999995A0000|0 26|A receptor-like protein kinase
P07999995A0000|1 26|receptor-like protein kinase
P07999995A0000|28 33|OsPK10
P07999995A0000|28 33|OsPK10
P07999995A0000|57 67|Oryza sativa
P08000074A0162|1 8|sequence
P08000074A0162|90 106|open reading frames
P08000074A0162|117 139|1.6 kb DNA genomic fragment
P08000112T0000|0 25|Goodpasture's-like syndrome
P08000112T0000|37 75|extracorporeal membrane oxygenator support
P08000427A0000|1 13|cDNA clone pCZ1
P08000427A0000|20 30|1.1 kb insert
P08000427A0000|48 59|NaCl-adapted
P08000427A0000|60 81|tobacco cell cDNA library
P08000427A0000|116 127|29 kDa protein
P08000427A0000|129 141|251 amino acids
P08000497A0179|39 65|methacholine provocation test
P08000497A0179|120 126|gas (VTG
P08001136T0000|14 33|CDK-activating kinase
P08001136T0000|14 33|CDK-activating kinase
P08001136T0000|37 51|RNA polymerase II
P08001136T0000|37 51|RNA polymerase II
P08001136T0000|52 60|CTD kinase
P08001136T0000|52 60|CTD kinase
P08001136T0000|61 71|TFIIH/TFIIK
P08001136T0000|61 65|TFIIH
P08001136T0000|67 71|TFIIK
P08001792A0284|3 26|git1, git3, git5, git7, git8
P08001792A0284|3 6|git1
P08001792A0284|8 11|git3
P08001792A0284|13 16|git5
P08001792A0284|18 21|git7
P08001792A0284|23 26|git8
P08001792A0284|30 39|git10 genes
P08001792A0284|30 39|git10 genes
P08001792A0284|53 68|adenylate cyclase
P08001792A0284|53 68|adenylate cyclase
P08001792A0284|90 122|adenylate cyclase activation pathway
P08001792A0284|90 105|adenylate cyclase
P08001966A0563|66 68|CNC
P08001966A0563|66 68|CNC
P08001966A0563|72 77|skin-1
P08001966A0563|72 77|skin-1
P08001966A0563|99 118|embryonic development
P08001966A0563|121 142|Drosophila melanogaster
P08001966A0563|146 166|Caenorhabditis elegans
P08002564A0249|0 18|DNA sequence analysis
P08002564A0249|57 72|C-terminal region
P08002564A0249|57 72|C-terminal region
P08002564A0249|78 89|alpha subunit
P08002564A0249|78 89|alpha subunit
P08002564A0249|100 113|leucine residue
P08002564A0249|116 126|position 290
P08002564A0249|130 138|histidine
P08002564A0249|140 148|rpoAL290H
P08002564A0249|140 148|rpoAL290H
P08002857A1070|51 71|oesophageal surfactant
P08002857A1070|116 139|gastro-oesophageal reflux
P08003700T0000|0 20|Differential screening
P08003700T0000|23 48|mitochondrial cDNA libraries
P08003700T0000|53 64|male-fertile
P08003700T0000|79 90|male-sterile
P08003700T0000|91 100|sugar-beet
P08003700T0000|130 133|atp6
P08003700T0000|130 133|atp6
P08003700T0000|137 144|atpA loci
P08003700T0000|137 144|atpA loci
P08004442A0265|29 61|morphine-induced locomotor activity
P08004442A0265|80 86|animals
P08004442A0265|99 136|hypothalamo-pituitary-adrenal (HPA) axis
P08004442A0265|156 192|stress-induced corticosterone secretion
P08004442A0265|205 217|adrenalectomy
P08005230A0222|9 26|reporter gene system
P08005230A0222|50 70|EPO-induced activation
P08005230A0222|50 52|EPO
P08005230A0222|76 88|c-fos promoter
P08005230A0222|76 88|c-fos promoter
P08005230A0222|138 163|cellular luciferase activity
P08005230A0222|146 155|luciferase
P08005412A0608|16 34|white gene expression
P08005412A0608|39 43|P[en]
P08005412A0608|72 85|protein complex
P08005412A0608|107 122|engrailed PS sites
P08005412A0608|162 171|genomic DNA
P08005438A1185|0 4|SPP41
P08005438A1185|0 4|SPP41
P08005438A1185|48 52|spp43
P08005438A1185|48 52|spp43
P08005438A1185|87 100|suppressor srn1
P08005438A1185|97 100|srn1
P08005438A1185|134 147|gene expression
P08006101A1142|0 35|Standard curve correlation coefficients
P08006101A1142|70 90|validation experiments
P08006772A0000|8 20|pulse oximeter
P08006772A0000|34 38|fetus
P08006772A0000|65 78|Caucasian women
P08006772A0000|87 105|uncomplicated labour
P08006773A0836|22 41|plasma concentrations
P08006773A0836|44 47|PGI2
P08006773A0836|60 63|TxA2
P08006773A0836|66 73|patients
P08006773A0836|78 96|normal blood pressure
P08006773A0836|102 113|preeclampsia
P08006773A0836|117 127|hypotension
P08006773A0836|138 155|severe preeclampsia
P08006773A0836|181 184|PGI2
P08006773A0836|220 223|TxA2
P08007835A0538|1 14|causal analysis
P08007835A0538|17 34|secondary variables
P08007835A0538|59 68|FB memories
P08007954A0374|0 14|Deletion studies
P08007954A0374|26 46|distal response element
P08007954A0374|70 85|cytokine response
P08007954A0374|115 137|transcriptional enhancer
P08007975A0000|3 10|IPL1 gene
P08007975A0000|3 10|IPL1 gene
P08007975A0000|70 74|yeast
P08007975A0000|75 97|Saccharomyces cerevisiae
P08011009T0057|0 0|2
P08011017A0169|25 28|SaO2
P08011017A0169|48 79|transient electroencephalographic
P08011017A0169|81 83|EEG
P08011166A0207|3 26|complete gene organization
P08011166A0207|116 138|polymerase chain reaction
P08011166A0207|149 163|genomic segments
P08012448T0000|0 3|INO2
P08012448T0000|0 3|INO2
P08012448T0000|5 19|a regulatory gene
P08012448T0000|6 19|regulatory gene
P08012448T0000|22 50|yeast phospholipid biosynthesis
P08012448T0000|80 98|bud pattern formation
P08012566A0254|3 29|pentafluorobenzyl derivative
P08012566A0254|32 40|clonidine
P08012566A0254|49 66|intense ion fragment
P08013348A0143|0 12|Mammalian ABPs
P08013348A0143|0 12|Mammalian ABPs
P08013348A0143|16 20|SHBGs
P08013348A0143|16 20|SHBGs
P08013348A0143|25 35|sex steroids
P08013457A0342|0 44|Src homology (SH) domain dependent protein-protein
P08013457A0342|0 44|Src homology (SH) domain dependent protein-protein
P08013457A0342|71 110|tyrosine kinase receptor signal transduction
P08013457A0342|71 92|tyrosine kinase receptor
P08014228A0278|0 14|Sample treatment
P08014228A0278|44 61|complete extraction
P08014228A0278|64 88|labetalol diastereoisomers
P08014228A0278|117 126|extraction
P08014377A1277|5 21|resting conditions
P08014377A1277|39 72|cardiac vagal and sympathetic outflows
P08014377A1277|92 117|young, healthy human subjects
P08014377A1277|165 182|autonomic divisions
P08014919A0530|4 17|proprioceptive
P08014919A0530|62 76|receptive fields
P08014919A0530|81 88|anterior
P08014919A0530|91 103|posterior body
P08014919A0530|149 151|DGR
P08015672A1282|2 16|control patients
P08015672A1282|51 56|Type II
P08015672A1282|59 59|7
P08015672A1282|67 73|Type III
P08015672A1282|87 90|Type
P08015672A1282|118 121|Type
P08015850A1076|49 64|Ga administration
P08015850A1076|66 74|preinjury
P08015850A1076|77 86|postinjury
P08015850A1076|106 107|Ga
P08015850A1076|117 134|blood-brain barrier
P08016102A1238|47 66|transcription factors
P08016102A1238|73 81|NF-kappa B
P08016102A1238|73 81|NF-kappa B
P08016102A1238|85 88|AP-2
P08016102A1238|85 88|AP-2
P08016102A1238|154 159|injury
P08016102A1238|201 204|HO-1
P08016102A1238|201 204|HO-1
P08016102A1238|238 249|tissue injury
P08016189A0741|0 10|Granisetron
P08016189A0741|34 50|vomiting and nausea
P08016189A0741|91 103|emetic regimen
P08017290A1347|17 29|coronary sinus
P08017290A1347|67 68|pH
P08017290A1347|70 73|PCO2
P08017290A1347|120 125|pacing
P08018361A0636|22 35|thermal neutron
P08020702A0000|0 10|Endotoxemia
P08020702A0000|20 40|gram-negative bacteria
P08020702A0000|48 61|endotoxic shock
P08020702A0000|115 127|bacterial wall
P08020702A0000|130 135|lipid A
P08020702A0137|32 36|lipid
P08020702A0137|38 57|monoclonal antibodies
P08020702A0137|67 77|hemodynamic
P08020702A0137|95 105|endotoxemia
P08020702A0137|144 153|antibodies
P08020806A0187|1 10|randomised
P08020806A0187|44 51|patients
P08020806A0187|62 75|Crohn's disease
P08020806A0187|97 107|nutritional
P08020806A0187|123 140|amino acid based diet
P08020806A0187|153 155|fat
P08020806A0187|191 206|peptide based diet
P08020806A0187|220 222|fat
P08020962A1226|24 33|V beta locus
P08020962A1226|24 33|V beta locus
P08020962A1226|59 79|repetitive DNA elements
P08020962A1226|83 85|Alu
P08020962A1226|92 93|L1
P08020962A1226|92 93|L1
P08020962A1226|100 102|MER
P08020962A1226|100 102|MER
P08020965A0465|66 80|known transcript
P08021175A0486|3 20|pexB upstream region
P08021175A0486|3 20|pexB upstream region
P08021175A0486|30 43|245 nucleotides
P08021175A0486|92 115|cyclic AMP receptor protein
P08021175A0486|92 115|cyclic AMP receptor protein
P08021175A0486|130 139|host factor
P08021177A0000|3 22|fepA-entD and fes-entF
P08021177A0000|3 6|fepA
P08021177A0000|8 11|entD
P08021177A0000|15 17|fes
P08021177A0000|19 22|entF
P08021177A0000|35 55|enterobactin synthesis
P08021177A0000|114 122|promoters
P08021177A0000|148 166|Fur repressor protein
P08021177A0000|148 166|Fur repressor protein
P08021177A0000|172 175|iron
P08021225A0000|0 15|Sequence analysis
P08021225A0000|19 46|6.3-kbp genomic EcoRI-fragment
P08021225A0000|33 46|EcoRI-fragment
P08021225A0000|49 68|Alcaligenes eutrophus
P08021225A0000|104 149|dihydrolipoamide dehydrogenase-specific DNA probe
P08021225A0000|104 132|dihydrolipoamide dehydrogenase
P08022212A0071|39 50|AC excitation
P08022212A0071|52 72|three-electrode method
P08022212A0071|77 99|admittance locus plot (ALP
P08022212A0071|97 99|ALP
P08022212A0071|173 184|straight line
P08022212A0071|206 236|frequency-independent parameters
P08022212A0071|248 256|alpha pi/2
P08022212A0071|307 326|ion relaxation time tau
P08023662T0000|43 56|thromboplastin
P08023662T0000|64 74|prothrombin
P08024139A0393|148 166|anesthetic solutions
P08025074A0000|62 66|laser
P08025074A0000|89 99|suture lysis
P08025669A0724|30 33|rpoN
P08025669A0724|30 33|rpoN
P08025669A0724|62 68|sigma 54
P08028671A0687|34 50|anti-CBP antiserum
P08028671A0687|39 41|CBP
P08028671A0687|55 65|fibroblasts
P08028671A0687|94 115|cAMP responsive promoter
P08028671A0687|94 115|cAMP responsive promoter
P08029001A1020|35 63|proline-rich activator proteins
P08029001A1020|35 63|proline-rich activator proteins
P08029001A1020|67 81|RNA polymerase II
P08029001A1020|67 81|RNA polymerase II
P08029001A1020|166 194|general transcription machinery
P08029334T0000|15 46|plant omega-3 fatty acid desaturases
P08029334T0000|20 46|omega-3 fatty acid desaturases
P08030239A0833|38 50|IE polypeptide
P08030239A0833|38 50|IE polypeptide
P08030239A0833|58 81|IE amino acid residues 1-322
P08030239A0833|58 77|IE amino acid residues 1
P08030239A0833|111 141|transcriptional activation domain
P08030239A0833|167 181|EHV-1 tk promoter
P08030239A0833|167 181|EHV-1 tk promoter
P08030239A0833|221 235|EHV-1 IE promoter
P08030239A0833|221 235|EHV-1 IE promoter
P08030243A1011|12 39|NS35-specific RNA capture assay
P08030243A1011|12 27|NS35-specific RNA
P08030243A1011|74 92|RNA-binding activity
P08030243A1011|118 121|NS35
P08030243A1011|118 121|NS35
P08030704A1503|75 90|17 beta-estradiol
P08030704A1503|108 112|women
P08030704A1503|124 128|labor
P08031424T0000|0 7|Ketamine
P08031424T0000|42 62|mechanical ventilation
P08033490A0875|29 64|venlafaxine and O-desmethylvenlafaxine
P08033490A0875|84 95|renal disease
P08033490A0875|136 143|patients
P08034318A0724|76 82|UBE site
P08034318A0724|129 160|NF-1 family of transcription factors
P08034318A0724|129 132|NF-1
P08034486A0579|14 18|HSV-2
P08034486A0579|14 18|HSV-2
P08034486A0579|36 40|HSV-2
P08034486A0579|36 40|HSV-2
P08034486A0579|42 59|HSV-1 antibody ratio
P08034486A0579|42 54|HSV-1 antibody
P08034486A0579|77 99|Jewish Israeli population
P08034486A0579|116 131|demographic areas
P08034680A0180|19 25|zeta PKC
P08034680A0180|23 25|PKC
P08034680A0180|35 43|NF-kappa B
P08034680A0180|35 43|NF-kappa B
P08034680A0180|80 100|putative I kappa B kinase
P08034680A0180|88 100|I kappa B kinase
P08034680A0180|129 133|50 kDa
P08034680A0180|168 174|I kappa B
P08034680A0180|168 174|I kappa B
P08034682T0000|27 53|inositol 1,4,5-trisphosphate
P08034682T0000|72 85|3T3 fibroblasts
P08034708A0000|48 64|eosinophil lineage
P08034708A0000|85 108|eosinophil-specific genes
P08034741A0000|46 49|myr 4
P08034741A0000|46 49|myr 4
P08034741A0000|51 56|myosin
P08034741A0000|51 56|myosin
P08034741A0000|61 63|rat
P08034741A0000|74 89|mammalian myosin I
P08034741A0000|83 89|myosin I
P08034741A0000|126 132|myosin I
P08034741A0000|126 132|myosin I
P08034742A0307|0 0|M
P08035498A0833|61 71|stem element
P08035498A0833|96 98|AAV
P08035499A0941|105 117|stem substrate
P08035499A0941|125 144|protein-DNA complexes
P08035499A0941|125 144|protein-DNA complexes
P08035499A0941|196 197|TR
P08035505A0586|15 32|NS3'-5B polyprotein
P08035505A0586|15 21|NS3'-5B
P08035517A0753|31 35|IEP86
P08035517A0753|31 35|IEP86
P08035517A0753|77 81|IEP72
P08035517A0753|77 81|IEP72
P08035796A0890|0 11|32Pi labeling
P08035796A0890|43 52|eIF-2 alpha
P08035796A0890|43 52|eIF-2 alpha
P08035796A0890|68 88|casein kinase II mutants
P08035796A0890|68 81|casein kinase II
P08035796A0890|102 116|phosphorylation
P08035796A0890|119 128|eIF-2 alpha
P08035796A0890|119 128|eIF-2 alpha
P08035796A0890|165 174|eIF-2 alpha
P08035796A0890|165 174|eIF-2 alpha
P08035796A0890|226 241|growth conditions
P08035833A1556|5 8|YMIP
P08035833A1556|5 8|YMIP
P08035833A1556|12 28|functional homolog
P08035833A1556|31 34|RMIP
P08035833A1556|31 34|RMIP
P08035833A1556|66 98|yeast mitochondrial import machinery
P08036004A0292|20 33|class I enhancer
P08036004A0292|20 33|class I enhancer
P08036004A0292|41 55|negative element
P08036004A0292|58 78|Ad12-transformed cells
P08036004A0292|130 163|nontumorigenic Ad5-transformed cells
P08036004A0292|185 200|class I expression
P08036004A0292|185 190|class I
P08037338A0000|31 44|erythropoietin
P08037338A0000|31 44|erythropoietin
P08037338A0000|46 48|EPO
P08037338A0000|46 48|EPO
P08037338A0000|87 92|anemia
P08037338A0000|117 119|EPO
P08037338A0000|117 119|EPO
P08037338A0000|128 134|infants
P08039422A0000|3 27|nerve growth factor beta gene
P08039422A0000|3 19|nerve growth factor
P08039422A0000|20 27|beta gene
P08039422A0000|29 32|NGFB
P08039422A0000|29 32|NGFB
P08039422A0000|44 65|conserved syntenic group
P08039422A0000|68 83|human chromosome 1
P08039422A0000|92 102|Chromosome 3
P08040336A0435|14 28|upstream element
P08040336A0435|30 56|collagen element I (-370/-344)
P08040336A0435|30 45|collagen element I
P08040336A0435|84 104|LAP binding cis-element
P08040336A0435|84 86|LAP
P08040336A0435|94 104|cis-element
P08040336A0435|110 124|albumin promoter
P08040336A0435|110 116|albumin
P08040391T0000|0 5|Number
P08040391T0000|15 36|silver-stained nucleoli
P08040391T0000|38 43|Ag-NOR
P08040391T0000|55 69|canine seminomas
P08040391T0000|86 105|histological features
P08040468A0303|15 22|mast cell
P08040468A0303|23 35|degranulation
P08040468A0303|68 78|necrobiosis
P08040468A0303|89 112|fibroblast enzyme activity
P08040468A0303|137 157|inflammatory reactions
P08041362T0000|0 15|Molecular cloning
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|43 59|Citrullus vulgaris
P08041362T0000|61 70|watermelon
P08041362T0000|100 114|Escherichia coli
P08041362T0000|115 127|Cys- auxotroph
P08041793A0242|35 52|regulatory elements
P08041793A0242|64 88|transcriptional activation
P08041793A0242|92 108|aerobic repression
P08041793A0242|127 131|COX5b
P08041793A0242|127 131|COX5b
P08043523A0000|16 26|serum levels
P08043523A0000|29 38|antibodies
P08043523A0000|44 73|nicotinic acetylcholine receptor
P08043523A0000|44 73|nicotinic acetylcholine receptor
P08043523A0000|75 79|nAChR
P08043523A0000|75 79|nAChR
P08043523A0000|99 124|neuroleptic treated patients
P08043523A0000|129 145|tardive dyskinesia
P08043523A0000|207 214|patients
P08044794A0000|3 17|tumor suppressor
P08044794A0000|21 41|transcriptional factor
P08044794A0000|42 44|p53
P08044794A0000|42 44|p53
P08044794A0000|48 68|phosphorylated protein
P08044800A0550|4 32|DNA containing promoter activity
P08044802A0462|23 39|karyotype analyses
P08044802A0462|75 84|copy number
P08044802A0462|111 117|p53 gene
P08044802A0462|111 117|p53 gene
P08044802A0462|128 140|p53- cell lines
P08044802A0462|128 130|p53
P08045431A0894|0 3|HupI
P08045431A0894|0 3|HupI
P08045431A0894|26 61|rubredoxin and rubredoxin-like proteins
P08045431A0894|26 35|rubredoxin
P08045431A0894|39 61|rubredoxin-like proteins
P08045431A0894|75 82|bacteria
P08045834A0783|3 5|PCr
P08045834A0783|57 81|mitochondrial ATP synthesis
P08046923A0000|29 36|patients
P08046923A0000|83 98|gastric resection
P08048582A0821|16 19|MVO2
P08048582A0821|54 56|CFX
P08048582A0821|111 119|LAD region
P08048916A0000|0 3|IGF I
P08048916A0000|0 3|IGF I
P08048916A0000|7 22|insulin receptors
P08048916A0000|7 22|insulin receptors
P08048916A0000|66 86|physiological pathways
P08049401A0428|0 15|Immunodepression
P08049401A0428|44 65|glucocorticoid activity
P08049401A0428|68 80|adrenal cortex
P08049401A0428|109 123|thyroid hormones
P08049444A0351|0 14|Tryptic cleavage
P08049444A0351|18 40|peptide sequence analysis
P08049444A0351|60 71|98-kD protein
P08049444A0351|60 71|98-kD protein
P08049444A0351|100 106|protein
P08049444A0351|115 143|A-T-rich binding protein 1 (SATB1
P08049444A0351|115 137|A-T-rich binding protein 1
P08049444A0351|139 143|SATB1
P08049444A0351|168 207|nuclear matrix/scaffold-associated regions
P08049444A0351|210 212|DNA
P08049444A0351|214 222|MARs/SARs
P08049444A0351|214 217|MARs
P08049444A0351|219 222|SARs
P08049521T0000|8 29|protein phosphorylation
P08049521T0000|32 39|tyrosine
P08049521T0000|84 92|pp60v-src
P08049521T0000|84 92|pp60v-src
P08049521T0000|107 111|yeast
P08049521T0000|112 134|Saccharomyces cerevisiae
P08049885T0000|0 16|Acute pancreatitis
P08049885T0000|19 36|multisystem disease
P08051019A0365|0 19|Alginate biosynthesis
P08051019A0365|42 60|regulatory mechanism
P08051059A1000|24 35|rhlA promoter
P08051059A1000|24 35|rhlA promoter
P08051059A1000|99 111|RhlR regulator
P08051059A1000|99 111|RhlR regulator
P08051074A0000|16 34|in vitro footprinting
P08051074A0000|64 95|human immunodeficiency virus, type 1
P08051074A0000|64 89|human immunodeficiency virus
P08051074A0000|91 95|type 1
P08051074A0000|97 101|HIV-1
P08051074A0000|97 101|HIV-1
P08051074A0000|136 150|DNase I digestion
P08051074A0000|136 141|DNase I
P08051102A0532|0 6|Heparin
P08051102A0532|20 52|rAC-st myosin light chain phosphatase
P08051102A0532|20 52|rAC-st myosin light chain phosphatase
P08051102A0532|70 93|B subunit-containing forms
P08051102A0532|70 93|B subunit-containing forms
P08051102A0532|108 110|2-3
P08051151A0347|46 49|mRNA
P08051151A0347|65 108|reverse transcription-polymerase chain reaction
P08051151A0347|65 100|reverse transcription-polymerase chain
P08051151A0347|118 129|human tissues
P08053697A0000|30 44|melanocytic nevi
P08053697A0000|49 61|eccentric foci
P08053697A0000|64 80|hyperpigmentation
P08053697A0000|88 95|dark dots
P08053697A0000|174 183|histologic
P08053697A0000|199 206|dark dots
P08054281A0731|19 28|201Tl SPECT
P08054281A0731|49 67|metastatic potential
P08054281A0731|157 180|201Tl uptake and malignancy
P08055939A0159|3 23|central globular domain
P08055939A0159|62 72|H1 molecules
P08055939A0159|62 72|H1 molecules
P08055939A0159|80 102|carboxyl-terminal domain
P08055939A0159|80 102|carboxyl-terminal domain
P08055939A0159|112 136|repeating hexapeptide motif
P08055939A0159|170 180|H1 molecules
P08055939A0707|36 41|intron
P08055939A0707|63 87|tomato and Arabidopsis genes
P08055939A0707|115 126|'nose' region
P08055939A0707|137 141|exon 1
P08055939A0707|150 170|central globular domain
P08055939A0707|172 176|exon 2
P08055941A1264|3 10|topology
P08055941A1264|31 42|beta subunits
P08055941A1264|31 42|beta subunits
P08055941A1264|48 70|artifactual beta 60 capsid
P08055941A1264|86 109|native alpha 3 beta 60 enzyme
P08055941A1264|92 109|alpha 3 beta 60 enzyme
P08056474A0438|1 10|single NMSC
P08057356A0531|34 50|substitution (V88A
P08057356A0531|57 95|amino-terminal (response regulator) region
P08057356A1824|0 10|Comparisons
P08057356A1824|20 39|operon control regions
P08057356A1824|62 74|NarL heptamers
P08057356A1824|62 74|NarL heptamers
P08057421A1583|6 12|binding
P08057421A1583|16 32|competition assays
P08057421A1583|38 64|30-mer oligonucleotide probes
P08057421A1583|90 105|CBF1 binding sites
P08057421A1583|90 105|CBF1 binding sites
P08057421A1583|119 122|CBF1
P08057421A1583|119 122|CBF1
P08057421A1583|148 159|CD23 promoter
P08057421A1583|148 159|CD23 promoter
P08057421A1583|166 173|EBV LMP-1
P08057421A1583|166 173|EBV LMP-1
P08057421A1583|196 201|Cp site
P08057421A1583|196 201|Cp site
P08057762A0878|55 56|T2
P08057762A0878|122 123|T2
P08057833A0573|6 17|ParA proteins
P08057833A0573|6 17|ParA proteins
P08057833A0573|44 75|independent translation initiation
P08057833A0573|90 100|start codons
P08057833A0573|114 129|open reading frame
P08057833A0573|149 163|Escherichia coli
P08058326A0463|27 45|molecular mechanisms
P08058326A0463|57 71|tal-1 expression
P08058326A0463|57 61|tal-1
P08058326A0463|87 97|5' sequences
P08058326A0463|103 112|murine gene
P08058326A0463|103 112|murine gene
P08058326A0463|135 151|human counterparts
P08058948A0810|22 32|angiography
P08058948A0810|79 86|patients
P08058948A0810|91 93|CRF
P08062824A0626|28 34|FKBP-33
P08062824A0626|28 31|FKBP
P08062824A0626|51 91|peptidyl-prolyl cis-trans isomerase activity
P08062824A0626|51 83|peptidyl-prolyl cis-trans isomerase
P08062824A0626|134 140|FKBP-12
P08062824A0626|134 140|FKBP-12
P08062833A0000|3 19|first 85 nt upstream
P08062833A0000|25 51|transcription initiation site
P08062833A0000|57 71|mouse desmin gene
P08062833A0000|57 71|mouse desmin gene
P08062833A0000|87 90|E box
P08062833A0000|87 90|E box
P08062833A0000|92 93|E1
P08062833A0000|92 93|E1
P08062833A0000|115 148|helix-loop-helix myogenic regulators
P08062833A0000|115 130|helix-loop-helix
P08062833A0000|131 148|myogenic regulators
P08062833A0000|179 203|muscle-specific expression
P08063108A0109|3 10|acfD gene
P08063108A0109|3 6|acfD
P08063108A0109|53 68|88-amino-acid (aa
P08063766A0595|10 18|beta II PKC
P08063766A0595|10 18|beta II PKC
P08063766A0595|33 53|nuclear envelope lamin B
P08063766A0595|33 53|nuclear envelope lamin B
P08063766A0595|75 82|alpha PKC
P08063766A0595|75 82|alpha PKC
P08063766A0595|115 127|soluble lamin B
P08063766A0595|122 127|lamin B
P08063775T0000|12 65|parathyroid hormone-related protein (PTHrP) gene expression
P08063775T0000|12 44|parathyroid hormone-related protein
P08063775T0000|46 55|PTHrP) gene
P08063791A1370|40 70|carboxyl-terminal sequence motifs
P08063791A1370|110 130|functional Ras proteins
P08063791A1370|120 130|Ras proteins
P08063791A1370|133 137|yeast
P08063836A0904|14 18|c-Abl
P08063836A0904|14 18|c-Abl
P08063836A0904|28 45|c-myc transcription
P08063836A0904|28 32|c-myc
P08063836A0904|76 85|DNA binding
P08063836A0904|88 92|c-Abl
P08063836A0904|88 92|c-Abl
P08064351A1020|0 11|Long-latency
P08064351A1020|13 23|locked units
P08064351A1020|60 70|long latency
P08064351A1020|72 77|4-11 ms
P08065310A1144|47 64|heterodimerization
P08065310A1144|91 119|receptor-inhibitor interaction
P08065310A1144|91 108|receptor-inhibitor
P08065310A1144|168 185|receptor gene family
P08065310A1144|168 179|receptor gene
P08065324A0458|29 38|snRNA genes
P08065324A0458|73 75|USE
P08065324A0458|79 90|TATA elements
P08065324A0458|124 136|transcription
P08065327A0000|9 24|DNA rearrangement
P08065327A0000|56 74|somatic macronucleus
P08065327A0000|104 121|ciliated protozoans
P08065331A0279|2 37|in vitro binding site selection procedure
P08065331A0279|89 100|wild-type HLF
P08065331A0279|89 100|wild-type HLF
P08065331A0279|104 126|chimeric E2A-HLF proteins
P08065331A0279|104 118|chimeric E2A-HLF
P08065331A0279|146 170|t(17;19)-bearing leukemias
P08065338T0000|3 53|Oct-2 glutamine-rich and proline-rich activation domains
P08065338T0000|3 21|Oct-2 glutamine-rich
P08065338T0000|113 125|transcription
P08065365A0000|9 45|U2 small nuclear ribonucleoprotein (snRNP
P08065365A0000|16 45|nuclear ribonucleoprotein (snRNP
P08065365A0000|52 59|pre-mRNA
P08065365A0000|52 59|pre-mRNA
P08065365A0000|87 105|spliceosome assembly
P08065366A0918|32 36|Dbf8p
P08065366A0918|32 36|Dbf8p
P08065368A0839|0 4|Ariga
P08065901A0997|25 34|KRAB domain
P08065901A0997|25 34|KRAB domain
P08065901A0997|47 62|non-finger region
P08065901A0997|47 62|non-finger region
P08065901A0997|69 76|ZFP genes
P08065901A0997|69 76|ZFP genes
P08065901A0997|119 145|protein-protein interactions
P08065901A0997|119 133|protein-protein
P08065901A0997|156 167|KRAB-A domain
P08065901A0997|156 167|KRAB-A domain
P08065901A0997|186 217|proximal transcriptional apparatus
P08066094T0000|0 9|Marine oils
P08066094T0000|13 36|cardiovascular reactivity
P08067013T0001|3 24|diagnostic significance
P08067013T0001|27 57|creatine phosphokinase antibodies
P08067013T0001|27 47|creatine phosphokinase
P08067013T0001|63 69|cardiac
P08067013T0001|78 112|non-coronarogenic myocardial diseases
P08067123A0248|66 70|ELISA
P08067123A0248|74 85|ABBOTT HCV EIA
P08067123A0248|87 89|USA
P08067123A0248|110 124|anti-HCV-C100-3
P08067123A0248|130 147|primary blood donors
P08067123A0248|150 155|Moscow
P08067123A0248|195 207|HBsAg carriers
P08067123A0248|195 199|HBsAg
P08067123A0248|222 227|donors
P08067123A0248|232 246|anti-HCV-C100-3
P08067123A0248|232 246|anti-HCV-C100-3
P08067123A0248|252 256|blood
P08067546A0000|30 55|coronary vasomotor responses
P08067546A0000|58 70|etomidate (ETO
P08067546A0000|68 70|ETO
P08067546A0000|73 80|propofol
P08067546A0000|82 84|PRO
P08067546A0000|90 105|sodium thiopental
P08067546A0000|107 109|STP
P08067546A0000|159 169|nitric oxide
P08067546A0000|171 172|NO
P08067546A0000|184 198|vasodilator tone
P08067546A0000|203 242|opposes adrenergic vasoconstrictor activity
P08067546A0000|254 256|dog
P08067607A0568|24 26|CBC
P08067607A0568|37 44|serum CRP
P08067607A0568|42 44|CRP
P08067607A0568|71 84|baseline values
P08067607A0568|108 119|control group
P08069298A0492|16 21|splice
P08069298A0492|83 109|primary leptomeningeal tissue
P08069298A0492|132 150|leptomeningeal cells
P08069298A0492|152 154|LMC
P08069427T0000|0 6|Roux-en
P08069427T0000|55 65|gallbladder
P08069481A0736|25 32|phantoms
P08069481A0736|38 46|human calf
P08070004A0782|5 25|interpatient variation
P08070004A0782|32 46|PCZ plasma levels
P08070004A0782|48 49|91
P08070004A0782|92 100|t1/2 alpha
P08070004A0782|127 134|patients
P08070004A0782|140 142|135
P08070004A0782|152 154|PCZ
P08070393A0631|33 35|EGF
P08070393A0631|33 35|EGF
P08070654A0000|0 3|KAR1
P08070654A0000|0 3|KAR1
P08070654A0000|36 59|yeast spindle pole body (SPB
P08070654A0000|78 86|karyogamy
P08070654A0000|90 103|SPB duplication
P08070654A0574|0 4|CDC31
P08070654A0574|0 4|CDC31
P08070654A0574|18 31|SPB duplication
P08070654A0574|43 64|calmodulin-like protein
P08070654A0574|43 64|calmodulin-like protein
P08070654A0574|91 108|caltractin/centrin
P08070654A0574|91 100|caltractin
P08070654A0574|102 108|centrin
P08070654A0574|135 156|Chlamydomonas basal body
P08071356A0232|6 25|transcript elongation
P08071356A0232|40 51|DNA footprint
P08071356A0232|58 85|single-stranded transcription
P08071356A0232|109 130|transcription complexes
P08071356A0232|156 164|positions
P08071982T0000|18 39|skeletogenital syndrome
P08072352A0567|6 13|patients
P08072352A0567|24 25|23
P08072352A0567|34 39|asthma
P08072352A0567|80 91|eosinophilia
P08072352A0567|96 96|9
P08072352A0567|119 127|IgE levels
P08072352A0567|119 121|IgE
P08072547A0690|0 43|Ras- and ultra-violet-responsive protein kinases
P08072547A0690|0 43|Ras- and ultra-violet-responsive protein kinases
P08072547A0690|61 65|c-Jun
P08072547A0690|61 65|c-Jun
P08072547A0690|68 81|serine residues
P08072547A0690|84 99|positions 63 and 73
P08072547A0690|115 137|transcriptional activity
P08072547A1009|6 13|sequence
P08072547A1009|33 54|JNK phosphorylation site
P08072547A1009|33 35|JNK
P08072547A1009|57 61|c-Jun
P08072547A1009|57 61|c-Jun
P08072547A1009|75 79|c-Fos
P08072547A1009|75 79|c-Fos
P08072547A1009|94 109|activation domain
P08072547A1009|125 129|c-Fos
P08072547A1009|125 129|c-Fos
P08072547T0000|0 4|c-Fos
P08072547T0000|0 4|c-Fos
P08072547T0000|40 67|H-Ras-activated protein kinase
P08072547T0000|40 61|H-Ras-activated protein
P08072547T0000|80 82|JNK
P08072547T0000|80 82|JNK
P08072547T0000|86 88|ERK
P08072547T0000|86 88|ERK
P08073505T0000|70 84|ExPASy WWW server
P08075070A1632|43 56|DNA double helix
P08075070A1632|134 160|helix-turn-helix (HTH) motifs
P08075070A1632|134 149|helix-turn-helix
P08075070A1632|151 153|HTH
P08075070A1632|168 186|DNA-binding proteins
P08075070A1632|168 186|DNA-binding proteins
P08075421A0621a|10 12|ORF
P08075421A0621a|39 47|C terminus
P08075421A0621a|50 54|HrpJ2
P08075421A0621a|50 54|HrpJ2
P08075421A0621b|10 12|ORF
P08075421A0621b|39 47|C terminus
P08075421A0621b|50 54|HrpJ2
P08075421A0621b|50 54|HrpJ2
P08076631A0000|12 30|transcription factor
P08076631A0000|31 34|AP-1
P08076631A0000|31 34|AP-1
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|55 57|VDR
P08076631A0000|55 57|VDR
P08076631A0000|64 76|composite AP-1
P08076631A0000|73 76|AP-1
P08076631A0000|81 114|vitamin-D-responsive promoter region
P08076631A0000|81 114|vitamin-D-responsive promoter region
P08076631A0000|116 124|AP-1 + VDRE
P08076631A0000|116 119|AP-1
P08076631A0000|121 124|VDRE
P08076631A0000|131 150|human osteocalcin gene
P08076631A0000|131 150|human osteocalcin gene
P08076631A0000|169 252|osteocalcin-producing (MG-63) and non-producing (U2-Os, SaOs-2) human osteosarcoma cell lines
P08076631A0000|169 179|osteocalcin
P08076631A0000|191 195|MG-63
P08076631A0000|214 218|U2-Os
P08076937A0851|0 13|Rapid detection
P08076937A0851|20 27|mutation
P08076937A0851|40 59|restriction digestion
P08076937A0851|62 65|PCR-
P08076937A0851|75 84|genomic DNA
P08076937A0851|137 156|Tru9I restriction site
P08076937A0851|137 156|Tru9I restriction site
P08077236A0243|0 16|Wild type and mutant
P08077236A0243|11 24|mutant Epo cDNAs
P08077236A0243|20 24|cDNAs
P08077236A0243|63 66|COS1
P08077236A0243|70 78|COS7 cells
P08078167A0000|28 37|hepatitis A
P08078167A0000|40 61|international travelers
P08078167A0000|76 93|preventive measures
P08078416A0581|3 14|bactericidal
P08078416A0581|43 54|biofilm cells
P08078416A0581|121 133|disinfectants
P08078473A1107|12 20|ME31B cDNA
P08078473A1107|12 20|ME31B cDNA
P08078473A1107|23 29|S. pombe
P08078473A1107|43 55|ste13 mutation
P08078473A1107|43 47|ste13
P08079268T0028|5 17|Medi-Jector EZ
P08079268T0028|46 52|surgery
P08081293A0078|0 0|2
P08082215A0230|3 16|immune response
P08082215A0230|35 49|cytomegalovirus
P08082215A0230|55 62|patients
P08082215A0230|65 68|RTID
P08082286A0748|0 16|Acupuncture effect
P08082286A0748|19 31|deep receptors
P08082292T0000|7 16|NK activity
P08082292T0000|31 43|active disease
P08082292T0000|46 57|HIV- patients
P08082292T0000|62 101|multidrug-resistant pulmonary tuberculosis
P08082360A0411|0 13|Smoking history
P08082360A0411|17 37|awake oxygen saturation
P08082360A0411|39 42|SaO2
P08082440A0339a|0 2|(LH
P08082440A0339a|1 2|LH
P08082440A0339a|10 15|LH/FSH
P08082440A0339a|10 11|LH
P08082440A0339a|13 15|FSH
P08083011A0584|3 29|relative R- and L-brain weights
P08083011A0584|64 85|relative R-L brain weight
P08083011A0584|95 106|RH female cats
P08083011A0584|111 113|R-L
P08083011A0584|114 118|brain
P08083011A0584|141 152|testosterone
P08083011A0584|161 168|estrogen
P08083220A0988|10 32|ternary complex formation
P08083220A0988|75 92|c-fos protooncogene
P08083220A0988|75 92|c-fos protooncogene
P08083220A0988|120 126|complex
P08083220A0988|161 196|serum response factor-DNA binary complex
P08083220A0988|161 179|serum response factor
P08083220A0988|190 196|complex
P08083963A0795|3 23|LTR-binding activities
P08083963A0795|26 28|VBP
P08083963A0795|26 28|VBP
P08083963A0795|30 35|a1/EBP
P08083963A0795|30 35|a1/EBP
P08083963A0795|40 66|B-cell nuclear extract protein
P08083963A0795|40 59|B-cell nuclear extract
P08083963A0795|90 97|gel shift
P08083963A0795|99 116|DNase I footprinting
P08083963A0795|99 104|DNase I
P08083963A0795|121 149|methylation interference assays
P08083998A1723a|23 39|leader-mRNA fusion
P08083998A1723a|42 65|coronavirus transcription
P08083998A1723a|80 85|direct
P08083998A1723a|86 92|RNA-RNA
P08083998A1723a|86 92|RNA-RNA
P08083998A1723a|111 132|complementary sequences
P08083998A1723b|23 39|leader-mRNA fusion
P08083998A1723b|42 65|coronavirus transcription
P08083998A1723b|80 85|direct
P08083998A1723b|86 92|RNA-RNA
P08083998A1723b|86 92|RNA-RNA
P08083998A1723b|111 132|complementary sequences
P08083999A0501|0 22|Vaccinia virus-expressed
P08083999A0501|32 48|full-length HPV-16
P08083999A0501|43 48|HPV-16
P08083999A0501|52 66|BPV-1 E2 proteins
P08083999A0501|52 56|BPV-1
P08083999A0501|57 58|E2
P08083999A0501|73 87|consensus E2 site
P08083999A0501|92 113|high specific affinities
P08084339A0907|4 33|alternatively spliced transcript
P08084339A0907|45 60|open reading frame
P08084339A0907|77 100|upstream J alpha 11-2 region
P08084339A0907|145 159|TCR C alpha region
P08084339A0907|145 159|TCR C alpha region
P08084592A0145|2 27|HeLa x fibroblast cell hybrids
P08084592A0145|55 68|tumorigenicity
P08085228A0000|0 25|Demographic characteristics
P08085228A0000|46 58|76,672 clients
P08085228A0000|114 144|human immunodeficiency virus (HIV)
P08085228A0000|114 139|human immunodeficiency virus
P08085228A0000|141 143|HIV
P08085609A0384|19 24|KNM-LU
P08085609A0384|43 63|human and chimpanzee M1s
P08085609A0384|122 135|fissure termini
P08086450A0467|17 26|bovine gene
P08086450A0467|40 56|5'-flanking region
P08086450A0467|62 70|hATP1 gene
P08086450A0467|62 70|hATP1 gene
P08086450A0467|87 94|guanine-
P08086450A0467|95 102|cytosine
P08086450A0467|104 116|GC) rich region
P08086450A0467|134 146|binding motifs
P08086450A0467|149 170|transcriptional factors
P08086450A0467|178 180|Sp1
P08086450A0467|178 180|Sp1
P08086450A0467|182 185|AP-2
P08086450A0467|182 185|AP-2
P08086450A0467|190 192|GCF
P08086453T0000|10 17|promoter
P08086453T0000|29 49|chromosomal assignment
P08086453T0000|55 67|human APEX gene
P08086453T0000|55 67|human APEX gene
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|76 85|1.6-kb mRNA
P08087887A1067|98 109|pre-cleavage
P08088022A1417|7 37|stress-induced arrhythmic disease
P08088022A1417|48 67|ischemic heart disease
P08088022A1417|106 110|heart
P08088022A1417|144 151|ischemia
P08088513A0419|31 53|Saccharomyces cerevisiae
P08088513A0419|89 99|DEAH protein
P08088513A0419|89 99|DEAH protein
P08088513A0419|100 104|Prp16
P08088513A0419|100 104|Prp16
P08088513A0419|112 113|U6
P08088513A0419|112 113|U6
P08088513A0419|117 136|U2 spliceosomal snRNAs
P08088513A0419|117 136|U2 spliceosomal snRNAs
P08088777A0754|3 15|consensus gene
P08088777A0754|60 65|D2Mit1
P08088777A0754|68 70|Dbh
P08088777A0754|72 86|Notch1)-(Col5a1
P08088777A0754|72 77|Notch1
P08088777A0754|81 86|Col5a1
P08088777A0754|88 101|Rxra)-Spna2-Ab
P08088777A0754|88 91|Rxra
P08088777A0754|94 98|Spna2
P08088777A0754|100 103|Ab l-
P08088777A0754|102 132|l-(Ak1,Fpgs)- (Grp78,Pbx3)-(Epb7
P08088777A0754|105 107|Ak1
P08088777A0754|109 112|Fpgs
P08088777A0754|116 120|Grp78
P08088777A0754|122 125|Pbx3
P08088777A0754|129 134|Epb7.2
P08088777A0754|136 141|Hc,Gsn
P08088777A0754|136 137|Hc
P08088777A0754|139 147|Gsn)-Acra
P08088777A0754|144 147|Acra
P08088818A1053|58 61|YACs
P08088818A1053|140 148|RAD52 gene
P08088818A1053|140 148|RAD52 gene
P08089184A0825|14 27|megabase region
P08089184A0825|42 50|dagA locus
P08089184A0825|42 50|dagA locus
P08089834A0561|29 57|extreme amino-terminal residues
P08089834A0561|65 80|amino acid residue
P08089887A0742|37 65|caffeine-withdrawal evaluation
P08090571T0001|0 10|Elimination
P08090571T0001|13 29|natural antibodies
P08090571T0001|32 51|discordant xenografts
P08090746A1288|2 13|8-bp sequence
P08090746A1288|15 22|ATTTCAAA
P08090746A1288|33 47|protected region
P08090746A1288|77 93|promoter sequences
P08090746A1288|105 126|ethylene responsiveness
P08090746A1288|134 153|tomato fruit-ripening
P08090746A1288|154 159|E4 gene
P08090746A1288|154 159|E4 gene
P08090767A0000|21 38|DNA polymerase delta
P08090767A0000|21 38|DNA polymerase delta
P08090767A0000|41 63|Saccharomyces cerevisiae
P08090767A0000|41 63|Saccharomyces cerevisiae
P08090767A0000|103 124|chromosomal replication
P08090767A0000|172 191|DNA methylation damage
P08091655A0000|19 32|Marek's Disease
P08091655A0000|33 37|Virus
P08091655A0000|39 47|MDV) genes
P08091655A0000|39 47|MDV) genes
P08091655A0000|57 71|EcoRI-B fragment
P08091655A0000|57 63|EcoRI-B
P08091655A0000|74 89|MDV-GA genomic DNA
P08091655A0000|74 79|MDV-GA
P08091665T0000|30 40|an early gene
P08091665T0000|32 40|early gene
P08091665T0000|50 56|soluble
P08091665T0000|74 90|type II TNF receptor
P08091665T0000|74 90|type II TNF receptor
P08091669A0828|18 20|P35
P08091669A0828|18 20|P35
P08091669A0828|37 47|39k promoter
P08091669A0828|62 64|IE1
P08091669A0828|62 64|IE1
P08091669A0828|69 71|p35
P08091669A0828|69 71|p35
P08091669A0828|72 87|open reading frame
P08091669A0828|117 127|ie1 promoter
P08091669A0828|117 127|ie1 promoter
P08093450A0688|0 10|Mutagenesis
P08093450A0688|17 26|NRF-1 motif
P08093450A0688|17 26|NRF-1 motif
P08093450A0688|32 43|ALAS promoter
P08093450A0688|32 43|ALAS promoter
P08093450A0688|76 117|chloramphenicol acetyltransferase expression
P08093450A0688|76 107|chloramphenicol acetyltransferase
P08093450A0688|143 153|NRF-1 motifs
P08093450A0688|143 153|NRF-1 motifs
P08093450A0688|187 196|expression
P08093616A1214|0 25|DNase I footprinting analysis
P08093616A1214|0 5|DNase I
P08093616A1214|39 42|DREF
P08093616A1214|39 42|DREF
P08093616A1214|58 66|DRE region
P08093616A1214|72 93|DNA polymerase alpha gene
P08093616A1214|72 89|DNA polymerase alpha
P08093616A1214|105 124|palindromic sequences
P08093616T0000|5 22|8-base pair sequence
P08093616T0000|24 62|Drosophila DNA replication-related element
P08093616T0000|24 62|Drosophila DNA replication-related element
P08093616T0000|67 87|specific binding factor
P08093616T0000|113 127|Drosophila genes
P08093616T0000|113 127|Drosophila genes
P08093616T0000|131 148|DNA polymerase alpha
P08093616T0000|131 148|DNA polymerase alpha
P08093616T0000|152 182|proliferating cell nuclear antigen
P08093642A0600|12 43|microsatellite repeat polymorphism
P08093642A0600|73 80|RET locus
P08093642A0600|73 80|RET locus
P08093642A0600|85 121|restriction fragment length polymorphism
P08093642A0600|157 167|lambda clone
P08093642A0600|175 185|D10S94 locus
P08093642A0600|175 185|D10S94 locus
P08094464A0869|8 11|tyrA
P08094464A0869|8 11|tyrA
P08094464A0869|43 58|internal promoter
P08094464A0869|85 93|3' portion
P08094464A0869|96 99|aroF
P08094464A0869|96 99|aroF
P08094464A2014|47 65|stem-loop structures
P08094464A2014|68 93|mRNA secondary configuration
P08094464A2014|95 102|hot spots
P08094464A2014|105 116|base-residue
P08094498A0614|25 30|spouse
P08094927A0311|39 47|6K protein
P08094927A0311|39 47|6K protein
P08094927A0311|78 105|multi-cored infectious virions
P08095698T0000|0 9|Metabolism
P08095698T0000|12 18|calcium
P08095698T0000|22 30|vitamin D3
P08095698T0000|33 40|patients
P08095698T0000|50 76|tubulointerstitial nephritis
P08095698T0000|88 95|patients
P08095698T0000|100 120|nephropathia epidemica
P08095872A1672|117 130|LONG/CIRC ratio
P08095875T0000|61 64|rats
P08096066A0623|3 6|RFLP
P08096066A0623|42 49|patients
P08096066A0623|108 112|band)
P08096066A0623|136 149|drug resistance
P08096944A0951|15 32|ovarian stimulation
P08096944A0951|109 113|women
P08096944A0951|124 141|ovarian stimulation
P08097666A1135|0 5|A23187
P08097666A1135|39 60|endolymphatic potential
P08097666A1135|91 124|frequency of the evoked afferent spikes
P08097732A0000|15 47|aboral ectoderm-specific Spec2a gene
P08097732A0000|21 47|ectoderm-specific Spec2a gene
P08097732A0000|50 79|blastula-stage sea urchin embryos
P08097732A0000|90 113|upstream regulatory region
P08097732A0000|127 151|repetitive sequence element
P08097732A0000|153 155|RSR
P08097732A0000|174 189|Spec1/Spec2 genes
P08097732A0000|174 189|Spec1/Spec2 genes
P08098228A0625|38 40|PPO
P08098842A0660|0 8|Mutations
P08098842A0660|29 42|30 bp downstream
P08098842A0660|50 76|major transcription start site
P08098842A0660|125 129|c-fos
P08098842A0660|125 129|c-fos
P08098842A0660|143 167|negative regulatory element
P08098842A0660|200 218|basal gene expression
P08098882T0001|0 26|Salazopyrine desensitization
P08098914A0400|18 24|Pes-Ves
P08098914A0400|52 55|left
P08098914A0400|67 88|[end-systolic elastance
P08098914A0400|90 94|Ees)]
P08099443A0359|10 12|HRI
P08099443A0359|10 12|HRI
P08099443A0359|16 23|dsRNA-PK
P08099443A0359|16 23|dsRNA-PK
P08099443A0359|37 51|yeast eIF-2 alpha
P08099443A0359|37 51|yeast eIF-2 alpha
P08099443A0359|96 106|GCN2 protein
P08099443A0359|96 99|GCN2
P08099443A0359|118 132|GCN4 translation
P08099443A0359|118 121|GCN4
P08099443A0359|135 139|yeast
P08100057A0577|58 81|CD68-positive macrophages
P08100057A0577|58 61|CD68
P08100057A0577|85 109|XIIIa-positive dendrocytes
P08100057A0577|85 89|XIIIa
P08100765A0361|19 23|adult
P08100765A0361|103 132|anterior-posterior compartments
P08100843A0134|0 15|Southern analysis
P08100843A0134|18 27|genomic DNA
P08100843A0134|40 46|tissues
P08100843A0134|70 81|mouse strains
P08100843A0134|87 95|mCD22 cDNA
P08100843A0134|87 91|mCD22
P08100843A0134|115 123|Cd22 locus
P08100843A0134|115 123|Cd22 locus
P08100843A0134|132 136|mCD22
P08100843A0134|132 136|mCD22
P08100843A0134|140 153|single copy gene
P08101134A0376|19 28|plasma ACTH
P08101134A0376|25 28|ACTH
P08101134A0376|32 39|cortisol
P08101134A0376|65 77|MPTP treatment
P08101171A0924|36 50|Pc group products
P08101171A0924|64 69|memory
P08101171A0924|122 146|gap and pair-rule regulators
P08101839A0000|43 55|human mdr1 gene
P08101839A0000|43 55|human mdr1 gene
P08101839A0000|73 84|mdr1 promoter
P08101839A0000|73 84|mdr1 promoter
P08101839A0000|104 120|cell proliferation
P08101843A0151|3 25|tyrosine hydroxylase gene
P08101843A0151|3 25|tyrosine hydroxylase gene
P08101843A0151|27 28|TH
P08101843A0151|27 28|TH
P08101843A0151|61 63|CRE
P08101843A0151|74 93|base pair (bp) upstream
P08101843A0151|99 125|transcription initiation site
P08102364A0000|0 6|Tobacco
P08102364A0000|7 12|mosaic
P08102364A0000|13 53|virus-infected tobacco (Nicotiana tabacum var
P08103379A0577|17 28|56 amino acids
P08103379A0577|45 54|MADS domain
P08103379A0577|45 54|MADS domain
P08103379A0577|94 127|conservative amino acid substitutions
P08103935T0000|30 49|SRF accessory proteins
P08103935T0000|30 49|SRF accessory proteins
P08104189A1168|24 30|proSRIF
P08104189A1168|24 30|proSRIF
P08104189A1168|55 57|TGN
P08104189A1168|116 150|Golgi-associated vacuolar-type ATPase
P08104189A1168|116 150|Golgi-associated vacuolar-type ATPase
P08105727A0099|0 9|Fenoldopam
P08105727A0099|12 34|dopamine receptor agonist
P08105727A0099|12 27|dopamine receptor
P08105727A0099|51 67|animal experiments
P08105727A0099|78 91|renal perfusion
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08105994T0000|64 81|cerebral infarction
P08106087A0139|5 20|3' flanking region
P08106087A0139|26 38|27 kDa zein gene
P08106087A0139|26 34|27 kDa zein
P08106087A0139|47 66|AATAAA-like sequences
P08106087A0139|92 115|mammalian GT-rich sequence
P08106087A0139|101 115|GT-rich sequence
P08106087A0139|135 154|polyadenylation sites
P08106245A0325|3 26|indoor radon concentration
P08106245A0325|69 73|Bq m-3
P08106245A0325|172 178|92 Bq m-3
P08106245A0325|212 224|12 and 119 Bq m-3
P08106313A1492|22 26|hrpRS
P08106313A1492|22 26|hrpRS
P08106313A1492|30 33|hrpL
P08106313A1492|30 33|hrpL
P08106313A1492|44 60|regulatory cascade
P08106313A1492|68 71|HrpR
P08106313A1492|68 71|HrpR
P08106313A1492|75 78|HrpS
P08106313A1492|75 78|HrpS
P08106313A1492|99 102|hrpL
P08106313A1492|99 102|hrpL
P08106313A1492|106 109|HrpL
P08106313A1492|106 109|HrpL
P08106313A1492|112 130|putative sigma factor
P08106313A1492|120 130|sigma factor
P08106313A1492|151 170|HrpL-responsive genes
P08106313A1492|151 170|HrpL-responsive genes
P08106325A0000|0 3|DtxR
P08106325A0000|0 3|DtxR
P08106325A0000|8 29|iron-dependent sequence
P08106325A0000|39 56|DNA-binding protein
P08106325A0000|39 56|DNA-binding protein
P08106325A0000|71 81|tox operator
P08106325A0000|71 81|tox operator
P08106325A0000|93 117|-repeat nucleotide sequence
P08106325A0000|140 158|diphtheria toxin gene
P08106325A0000|140 154|diphtheria toxin
P08106369A0000|0 10|Vasopressin
P08106369A0000|0 10|Vasopressin
P08106369A0000|12 14|AVP
P08106369A0000|12 14|AVP
P08106369A0000|20 38|antidiuretic hormone
P08106369A0000|43 59|cyclic nonapeptide
P08106369A0000|84 124|G protein-coupled specific membrane receptors
P08106369A0000|84 91|G protein
P08106369A0000|167 169|V1a
P08106369A0000|167 169|V1a
P08106369A0000|171 173|V1b
P08106369A0000|171 173|V1b
P08106369A0000|178 179|V2
P08106369A0000|178 179|V2
P08106369A0000|197 212|second messengers
P08106398A1003|44 50|peptide
P08106398A1003|66 80|nisin maturation
P08106398A1003|66 70|nisin
P08106398A1003|124 130|peptide
P08106512A0522|7 20|promoter region
P08106512A0522|35 58|heterologous reporter gene
P08106512A0522|74 87|promoter region
P08106512A0522|105 115|interferons
P08106512A0522|105 115|interferons
P08106512A0522|117 141|interferon-alpha and -gamma
P08106512A0522|117 141|interferon-alpha and -gamma
P08106512A0522|146 172|interferon regulatory factor 1
P08106512A0522|146 172|interferon regulatory factor 1
P08107167A0222|0 17|Anti-B. burgdorferi
P08107167A0222|0 17|Anti-B. burgdorferi
P08107167A0222|19 34|anti-B. turicatae
P08107167A0222|19 24|anti-B
P08107167A0222|38 61|anti-B. parkeri antibodies
P08107167A0222|38 43|anti-B
P08107167A0222|45 61|parkeri antibodies
P08107167A0222|99 103|assay
P08107167A0222|105 107|IFA
P08107167A0222|145 149|serum
P08107167A0222|178 184|IFA-ABS
P08107167A0222|187 193|1.3, 1.3
P08107208A0673|51 68|making recombinants
P08107208A0673|91 107|cosmid-cloned DNAs
P08108099T0000|46 53|patients
P08108099T0000|58 76|hemostatic disorders
P08108343A0000|25 44|antiandrogen niftolid
P08108343A0000|57 60|GnRH
P08108343A0000|57 60|GnRH
P08108343A0000|78 91|normal subjects
P08108343A0000|95 102|patients
P08108343A0000|127 147|secondary hypogonadism
P08108343A0000|155 162|patients
P08108343A0000|167 179|clinical signs
P08108343A0000|182 201|gonadal insufficiency
P08108343A0000|242 262|pituitary gonadotropin
P08108343A0000|242 250|pituitary
P08108343A0000|251 270|gonadotropin reserves
P08108413A0964|17 58|transformed lymphoid and nonlymphoid cell lines
P08108413A0964|62 74|normal tissues
P08108413A0964|90 103|PANG expression
P08108413A0964|90 93|PANG
P08108413A0964|116 120|brain
P08111035A0098|3 32|cis-acting regulatory properties
P08111035A0098|37 57|872 bp promoter fragment
P08111035A0098|63 78|napus oleosin gene
P08111035A0098|68 78|oleosin gene
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|122 135|GUS) expression
P08111035A0098|122 124|GUS
P08111035A0098|138 160|transgenic tobacco plants
P08111035A0098|173 212|oleosin promoter-GUS transcriptional fusion
P08111035A0098|173 187|oleosin promoter
P08111035A0098|189 191|GUS
P08111974A1034|36 37|CX
P08111974A1034|62 72|tubulin mRNA
P08111974A1034|62 72|tubulin mRNA
P08111974A1034|152 163|trans-factor
P08112526A0443|13 45|extracellular calcium concentration
P08112526A0443|54 74|detrusor contractility
P08112526A0443|78 97|dose-dependent manner
P08112526A0443|104 131|control and obstructed bladders
P08112601T0000|0 21|Structural organization
P08112601T0000|42 69|human lipocalin tear prealbumin
P08112601T0000|42 55|human lipocalin
P08112601T0000|87 104|recombinant protein
P08112601T0000|87 104|recombinant protein
P08112601T0000|107 121|Escherichia coli
P08112611A0404|15 37|1092-bp open reading frame
P08112611A0404|56 68|364 amino acids
P08112870A0484|0 14|Western blotting
P08112870A0484|16 29|immunoblotting
P08112870A0484|56 58|SOD
P08112870A0484|56 58|SOD
P08112870A0484|70 84|Escherichia coli
P08112870A0484|117 131|molecular masses
P08113736A0309|3 18|gene organization
P08113736A0309|21 29|CRSV RNA-1
P08113736A0309|21 29|CRSV RNA-1
P08113736A0309|48 76|red clover necrotic mosaic (RCNMV
P08113736A0309|81 111|sweet clover necrotic mosaic (SCNMV
P08113736A0309|147 155|CRSV RNA-1
P08113736A0309|147 155|CRSV RNA-1
P08113736A0309|188 190|ORF
P08114702A0000|12 62|myocyte-specific enhancer-binding factor 2 (MEF2) family
P08114702A0000|12 50|myocyte-specific enhancer-binding factor 2
P08114702A0000|52 55|MEF2
P08114702A0000|65 84|transcription factors
P08114702A0000|99 114|A/T-rich sequence
P08114702A0000|99 99|A
P08114702A0000|101 114|T-rich sequence
P08114702A0000|144 163|muscle-specific genes
P08114710A0137|25 29|LBP-1
P08114710A0137|25 29|LBP-1
P08114710A0137|39 56|HIV-1 transcription
P08114710A0137|39 43|HIV-1
P08114710A0137|81 85|TFIID
P08114710A0137|81 85|TFIID
P08114710A0137|91 97|TATA box
P08114745A0953|40 41|La
P08114745A0953|44 56|RNA production
P08114745A0953|110 117|class III
P08114745A0953|158 179|transcription complexes
P08114745A0953|182 187|pol III
P08114745A0953|182 187|pol III
P08115744A0462|3 7|films
P08115744A0462|34 61|helium-neon laser densitometer
P08115744A0846|3 18|GafChromic method
P08115744A0846|45 65|rapid method of analysis
P08115744A0846|106 121|assurance program
P08116245A0174|0 14|Viral genomic RNA
P08116245A0174|55 68|fecal specimens
P08116245A0174|79 88|infant rats
P08118044A0318|0 9|GATA-1 mRNA
P08118044A0318|0 9|GATA-1 mRNA
P08118044A0318|44 61|erythroid cell lines
P08118044A0318|79 89|FDC-P1 cells
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119149A0000|26 33|TNF alpha
P08119149A0000|26 33|TNF alpha
P08119149A0000|49 74|autocrine/paracrine factors
P08119149A0000|112 115|bone
P08119907A0000|27 47|cellular p21ras protein
P08119907A0000|35 40|p21ras
P08119907A0000|50 56|insulin
P08119907A0000|50 56|insulin
P08119907A0000|60 85|insulin-like growth factor-I
P08119907A0000|60 85|insulin-like growth factor-I
P08119907A0000|87 91|IGF-I
P08119907A0000|87 91|IGF-I
P08119958A0273|12 19|C2 domain
P08119958A0273|12 13|C2
P08119958A0273|25 44|Ca(2+)-dependent PKCs
P08119958A0273|25 44|Ca(2+)-dependent PKCs
P08119958A0273|68 87|NH2-terminal sequence
P08119958A0273|119 137|transmembrane domain
P08119958A0273|149 153|PKC mu
P08119958A0273|149 153|PKC mu
P08119958A0273|183 194|atypical PKCs
P08119958A0273|191 194|PKCs
P08119995A0814|36 54|T3R-RXR heterodimers
P08119995A0814|36 38|T3R
P08119995A0814|40 42|RXR
P08119995A0814|86 95|half-sites
P08119995A0814|134 145|4 nucleotides
P08119995A0814|175 193|5'-flanking sequence
P08119995A0814|207 215|half-site
P08120019A1500|13 22|Hm1 mutants
P08120019A1500|13 22|Hm1 mutants
P08120019A1500|63 72|PI turnover
P08120019A1500|82 100|normal sequestration
P08120029A0864|59 68|20-nt sense
P08120029A0864|69 81|RNA transcript
P08120029A0864|107 115|R2 message
P08120029A0864|107 108|R2
P08122364A0954|0 15|Deletion analyses
P08122364A0954|21 30|pCD41 ORF-A
P08122364A0954|21 25|pCD41
P08122364A0954|26 30|ORF-A
P08122364A0954|42 59|promoter constructs
P08122364A0954|110 122|pCD41 sequence
P08122364A0954|110 114|pCD41
P08122364A0954|153 175|trans-activating protein
P08122364A0954|153 175|trans-activating protein
P08122370A0331|32 33|US
P08122370A0331|36 53|herpes simplex type 1
P08122370A0331|36 53|herpes simplex type 1
P08122370A0331|55 59|HSV-1
P08122370A0331|55 59|HSV-1
P08122370A0331|62 78|pseudorabies virus
P08122370A0331|80 82|PRV
P08122370A0331|88 109|equine herpesvirus type 1
P08122370A0331|94 109|herpesvirus type 1
P08122370A0331|111 115|EHV-1
P08122370A0331|111 115|EHV-1
P08123787A0554|11 27|amino acid sequence
P08123787A0554|33 57|cyanobacterial HemB protein
P08123787A0554|33 50|cyanobacterial HemB
P08123787A0554|94 117|metal cofactor requirement
P08123787A0554|137 143|enzymes
P08123787A0554|164 177|overexpression
P08124785A0445|33 48|anesthetized dogs
P08124785A0445|77 84|stenosis
P08124785A0445|151 169|coronary flow reserve
P08124785A0445|208 215|Tmicro-1
P08124912A0456|38 45|SF levels
P08124912A0456|38 39|SF
P08124912A0456|48 51|IL-8
P08124912A0456|48 51|IL-8
P08124912A0456|63 69|lactate
P08124912A0456|71 73|LDH
P08124912A0456|71 73|LDH
P08124912A0456|75 93|beta 2-microglobulin
P08124912A0456|75 93|beta 2-microglobulin
P08124912A0456|97 103|glucose
P08124956T0000|0 54|Sodium-taurocholate-induced acute necrotizing pancreatitis
P08124956T0000|68 85|jejunal oxygenation
P08124956T0000|88 91|pigs
P08125258A0142|48 55|CHOP gene
P08125258A0142|48 55|CHOP gene
P08125258A0142|85 100|cellular stresses
P08125258A0142|111 129|nutrient deprivation
P08125258A0142|133 154|metabolic perturbations
P08125319A1085|3 11|ipiO genes
P08125319A1085|37 40|152-
P08125337A0940|0 13|Sterol analysis
P08125337A0940|91 104|Erg24p activity
P08125337A0940|91 96|Erg24p
P08125949A1162|30 40|translation
P08125949A1162|43 56|spinach L12 mRNA
P08125949A1162|73 81|AUG codons
P08125949A1162|101 110|rpl12 genes
P08125949A1162|101 110|rpl12 genes
P08125949A1162|180 182|L12
P08125949A1162|184 202|chloroplast ribosome
P08125949A1162|246 255|eubacteria
P08126096A0478|58 63|alpha 7
P08126096A0478|64 80|cytoplasmic domain
P08126096A0478|112 131|rat and human sequences
P08126096A0478|118 131|human sequences
P08126096A0478|135 152|immunologic studies
P08126096A0478|160 181|anti-cytoplasmic domain
P08126096A1071|3 9|alpha 7A
P08126096A1071|14 16|RNA
P08126096A1071|64 68|B form
P08126096A1071|80 91|coding region
P08126096A1071|97 109|A and B form RNAs
P08127950A0000|33 62|hypothalamic-pituitary-thyroid
P08127950A0000|64 72|HPT)-axis
P08127950A0000|75 92|unipolar depression
P08127950A0000|112 133|basal 0800h plasma levels
P08127950A0000|136 148|free thyroxine
P08127950A0000|150 152|FT4
P08127950A0000|159 174|triiodothyronine
P08127950A0000|176 178|FT3
P08127950A0000|184 208|thyroid stimulating hormone
P08127950A0000|184 208|thyroid stimulating hormone
P08127950A0000|210 212|TSH
P08127950A0000|210 212|TSH
P08127950A0000|230 249|ultrasensitive assays
P08127950A0000|251 258|TSH-IRMA
P08127950A0000|251 253|TSH
P08127950A0000|264 278|healthy controls
P08127950A0000|319 335|depressed subjects
P08128629A1164|0 10|CRS function
P08128629A1164|0 2|CRS
P08128629A1164|14 29|5' LTR-linked gene
P08128629A1164|16 44|LTR-linked gene expression assay
P08128629A1164|75 80|p60CRS
P08128629A1164|75 80|p60CRS
P08128629A1164|84 89|p40CRS
P08128629A1164|84 89|p40CRS
P08128629A1164|104 108|5' LTR
P08129955A0572|14 22|troponin T
P08129955A0572|14 22|troponin T
P08129955A0572|39 43|CK-MB
P08129955A0572|39 43|CK-MB
P08129955A0572|74 89|aortic unclamping
P08130942A0051|0 14|Regionalization
P08131545A0158|31 46|community members
P08131545A0158|50 52|men
P08131545A0158|57 61|women
P08131545A0158|121 154|acute and convalescent serologic tests
P08131545A0158|158 177|Mycoplasma pneumoniae
P08131545A0158|179 199|Legionella pneumophila
P08131545A0158|201 215|cytomegalovirus
P08131545A0158|217 226|adenovirus
P08131545A0158|248 266|Chlamydia pneumoniae
P08131746A0140|0 2|MEK
P08131746A0140|0 2|MEK
P08131746A0140|23 43|serine phosphorylation
P08131746A0140|46 69|upstream activator kinases
P08131746A0140|46 69|upstream activator kinases
P08131746A0140|80 84|c-raf
P08131746A0140|80 84|c-raf
P08131746A0140|86 88|mos
P08131746A0140|92 100|MEK kinase
P08131746A0140|92 94|MEK
P08132541A0000|29 55|T-cell-specific human MAL gene
P08132541A0000|29 55|T-cell-specific human MAL gene
P08132574A0831|9 11|SVA
P08132574A0831|9 11|SVA
P08132574A0831|31 46|complement C2 gene
P08132574A0831|31 42|complement C2
P08132574A0831|80 82|RP1
P08132574A0831|80 82|RP1
P08132574A0831|88 90|HLA
P08132574A0831|88 90|HLA
P08132574A0831|99 118|cytochrome CYP1A1 gene
P08132574A0831|99 118|cytochrome CYP1A1 gene
P08132667T0000|15 52|dibasic proprotein processing enzyme furin
P08132667T0000|48 52|furin
P08132667T0000|65 81|multiple promoters
P08133502T0105|8 35|Community Huntington's Disease
P08134108A0277|3 7|c-myc
P08134108A0277|3 7|c-myc
P08134108A0277|11 42|skeletal alpha-actin gene promoters
P08134108A0277|11 33|skeletal alpha-actin gene
P08134108A0277|50 64|YY1 binding sites
P08134108A0277|50 52|YY1
P08134108A0277|85 120|positive or negative cis-acting elements
P08134115A1161|0 5|MSSP-1
P08134115A1161|0 5|MSSP-1
P08134115A1161|16 21|E. coli
P08134115A1161|42 44|GST
P08134115A1161|42 44|GST
P08134115A1161|71 107|single-stranded TCTTAT (plus myc(H-P)21)
P08134115A1161|97 99|myc
P08134115A1161|101 103|H-P
P08134115A1161|111 117|ACT-ATT
P08134115A1161|121 128|minus myc
P08134115A1161|126 128|myc
P08134115A1161|130 136|H-P)21)
P08134115A1161|130 132|H-P
P08134115A1161|174 185|A/TCTA/TA/TT
P08134115A1161|174 174|A
P08134115A1161|176 179|TCTA
P08134115A1161|181 182|TA
P08134115A1161|184 185|TT
P08136383A0359|18 29|MR tomography
P08136383A0359|33 40|patients
P08138180A0593|7 29|spt10 spontaneous alleles
P08138180A0593|7 11|spt10
P08138180A0593|56 71|normal growth rate
P08138180A0593|90 101|SPT10 protein
P08138180A0593|90 101|SPT10 protein
P08138364T0000|0 8|Varieties
P08138364T0000|11 17|envious
P08139001A1235|25 46|amino and carboxy termini
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|87 103|residues 337 and 340
P08139001A1235|119 133|tubule formation
P08139004A0278|3 7|3' UTR
P08139004A0278|48 64|single-stranded (A
P08139004A0278|54 79|-stranded (A/U)UGC sequences
P08139004A0278|66 66|U
P08139017A1465|23 47|transcriptional initiation
P08139017A1465|101 105|5' end
P08139017A1465|111 119|Ets-1 cDNA
P08139017A1465|111 115|Ets-1
P08139017A1465|116 124|cDNA clone
P08139017A1465|149 159|normal cells
P08139017A1465|163 168|tumors
P08139017A1465|191 200|Tpl-1 locus
P08139017A1465|191 195|Tpl-1
P08139031A1168|15 62|oligonucleotide-directed site-specific mutagenesis
P08139031A1168|85 100|cysteine residues
P08139031A1168|106 120|ORF4 polypeptide
P08139031A1168|126 138|C-421 and C-426
P08139031A1168|195 210|cysteine residues
P08139031A1168|227 261|critical protein-protein interactions
P08139031A1168|272 302|protein-nucleic acid interactions
P08139031A1168|312 327|ORF4 inducibility
P08139539A0446|2 11|Rat 1a cells
P08139539A0446|13 15|m1R
P08139539A0446|13 15|m1R
P08139539A0446|29 46|phospholipase C beta
P08139539A0446|29 46|phospholipase C beta
P08139539A0446|65 84|intracellular calcium
P08139539A0446|95 109|cyclic AMP (cAMP)
P08139539A0446|95 103|cyclic AMP
P08139539A0446|105 108|cAMP
P08139539A0446|146 159|protein kinase A
P08139539A0446|146 159|protein kinase A
P08139542A1229|39 42|CPA1
P08139542A1229|39 42|CPA1
P08139542A1229|45 52|arginine
P08139542T0000|10 13|mRNA
P08139542T0000|43 50|CPA1 gene
P08139542T0000|43 50|CPA1 gene
P08139542T0000|70 77|arginine
P08139542T0000|81 101|heterologous yeast gene
P08139543A0427|35 50|SLK1-SLT2 pathway
P08139543A0427|35 38|SLK1
P08139543A0427|40 43|SLT2
P08139543A0427|62 84|lethal suppression screen
P08139543A1520|10 27|phenotypic analysis
P08139543A1520|41 45|NHP6A
P08139543A1520|41 45|NHP6A
P08139543A1520|49 53|NHP6B
P08139543A1520|49 53|NHP6B
P08139543A1520|74 77|SLT2
P08139543A1520|74 77|SLT2
P08139562A0404|71 74|GCN4
P08139562A0404|71 74|GCN4
P08139562A0404|99 103|uORF1
P08139562A0404|105 119|resumed scanning
P08139562A0404|140 152|GCN4 start site
P08139562A0404|140 143|GCN4
P08139577T0000|0 18|Identical components
P08139577T0000|21 48|yeast transcription factor IIIB
P08139577T0000|21 48|yeast transcription factor IIIB
P08139577T0000|91 108|TATA box-containing
P08139577T0000|112 125|TATA-less genes
P08139914A0554|0 11|Concordantly
P08139914A0554|30 44|dnHLH protein Id1
P08139914A0554|30 41|dnHLH protein
P08139914A0554|42 44|Id1
P08139914A0554|53 67|differentiation
P08139914A0554|70 75|muscle
P08139914A0554|79 90|myeloid cells
P08139928T0000|0 3|RNP1
P08139928T0000|0 3|RNP1
P08139928T0000|9 29|ribonucleoprotein gene
P08139928T0000|35 39|yeast
P08139928T0000|40 62|Saccharomyces cerevisiae
P08140847X0001|0 13|Crohn's disease
P08140847X0001|16 33|prolonged remission
P08140847X0001|51 71|protein-calorie intake
P08140847X0001|84 98|healthy subjects
P08140847X0001|155 181|adult Crohn's disease patients
P08140847X0001|184 201|prolonged remission
P08140847X0001|235 244|body weight
P08140847X0001|336 350|healthy controls
P08142875A0877|32 47|anterior vitreous
P08142875A0877|85 104|surgical intervention
P08143198T0001|13 28|opponens function
P08143198T0001|33 47|transplantation
P08143198T0001|64 82|dorsal pedal skin flap
P08143236A1055|7 20|ethanol regimen
P08143236A1055|29 50|spontaneous alternation
P08143236A1055|60 66|ethanol
P08143236A1055|104 118|completed trials
P08143667A0222|3 6|mean
P08143667A0222|14 40|intra-vesicular pressure (IVP
P08143667A0222|77 80|MUCP
P08143667A0222|115 119|cmH2O
P08143667A0222|152 155|MUCP
P08143667A0222|159 161|IVP
P08144035A0387|52 60|N terminus
P08144035A0387|62 67|middle
P08144035A0387|71 79|C terminus
P08144037A0000|0 13|Thioredoxin (TR
P08144037A0000|0 10|Thioredoxin
P08144037A0000|12 13|TR
P08144037A0000|23 55|ubiquitous dithiol-reductase enzyme
P08144037A0000|33 49|dithiol-reductase
P08144037A0000|84 89|plants
P08144470A0711|3 10|mutation
P08144470A0711|20 32|asgB480 allele
P08144470A0711|20 32|asgB480 allele
P08144470A0711|50 65|A-to-G transition
P08144470A0711|80 111|threonine-to-alanine substitution
P08144497T0000|3 21|cysteine-rich region
P08144497T0000|24 34|raf-1 kinase
P08144497T0000|24 34|raf-1 kinase
P08144497T0000|43 46|zinc
P08144497T0000|62 70|liposomes
P08144497T0000|104 110|GTP-ras
P08144497T0000|104 110|GTP-ras
P08144504T0064|0 44|Kinetic coupling and requirement for ATP hydrolysis
P08144572A0786|0 2|ATP
P08144572A0786|42 48|Ssb1/2p
P08144572A0786|42 48|Ssb1/2p
P08144572A0786|101 116|Ssa Hsp70 proteins
P08144572A0786|101 116|Ssa Hsp70 proteins
P08144572A0786|126 128|BiP
P08144572A0786|126 128|BiP
P08144572A0786|132 135|DnaK
P08144572A0786|132 135|DnaK
P08144615A0533|0 8|Digestion
P08144615A0533|11 16|NF-IL6
P08144615A0533|11 16|NF-IL6
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|67 69|TCD
P08144615A0533|67 69|TCD
P08144615A0533|71 87|NF-IL6 bZIP domains
P08144615A0533|71 76|NF-IL6
P08144615A0533|77 87|bZIP domains
P08144615A0533|89 92|NFBD
P08144615A0533|89 92|NFBD
P08144631A0000|0 8|Signaling
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|71 94|Src homology 2 (SH2) domains
P08144631A0000|71 82|Src homology 2
P08144631A0000|84 86|SH2
P08144631A0000|105 127|tyrosine phosphorylation
P08144668A0802|25 29|exon V
P08144668A0802|52 57|exon IV
P08144668A0802|60 65|exon VI
P08144668A0802|83 98|open reading frame
P08144668A0802|114 120|GPHe(P2
P08144668A0802|114 117|GPHe
P08144668A0802|119 120|P2
P08144668A0802|140 158|hydrophobic sequence
P08144668A0802|162 178|membrane anchoring
P08144852A0000|33 57|cortisol, 11-deoxycortisol
P08144852A0000|59 62|ACTH
P08144852A0000|59 62|ACTH
P08144852A0000|64 74|vasopressin
P08144852A0000|64 74|vasopressin
P08144852A0000|76 78|AVP
P08144852A0000|76 78|AVP
P08144852A0000|84 111|corticotropin releasing factor
P08144852A0000|84 105|corticotropin releasing
P08144852A0000|113 115|CRF
P08144852A0000|113 115|CRF
P08144852A0000|131 141|normal males
P08144852A0000|154 176|acute cortisol deficiency
P08144852A0000|189 227|11-beta-hydroxylase inhibitor, metyrapone
P08144852A0000|189 207|11-beta-hydroxylase
P08145646T0000|38 48|sigma factor
P08145646T0000|38 48|sigma factor
P08145646T0000|50 53|RpoN
P08145646T0000|50 53|RpoN
P08145646T0000|57 77|Rhodobacter capsulatus
P08145646T0000|105 138|autoactivated nifU2-rpoN superoperon
P08145646T0000|118 122|nifU2
P08145646T0000|124 127|rpoN
P08145770A1078|53 55|PKC
P08145770A1078|53 55|PKC
P08145770A1078|59 74|retinoid pathways
P08148463A0000|3 27|colony-stimulating factors
P08148463A0000|3 27|colony-stimulating factors
P08148463A0000|29 32|CSFs
P08148463A0000|29 32|CSFs
P08148463A0000|70 80|neutrophils
P08148463A0000|84 92|monocytes
P08148463A0000|96 109|granulocyte CSF
P08148463A0000|96 109|granulocyte CSF
P08148463A0000|111 135|granulocyte-macrophage CSF
P08148463A0000|111 135|granulocyte-macrophage CSF
P08148463A0000|137 149|macrophage CSF
P08148463A0000|137 149|macrophage CSF
P08148463A0000|154 165|interleukin 3
P08148463A0000|154 165|interleukin 3
P08148463A0000|182 190|multi-CSF
P08148463A0000|182 190|multi-CSF
P08148756A0358|11 25|lung destruction
P08148756A0358|38 59|interstitial hemorrhage
P08148756A0358|82 98|hemoglobin content
P08148756A0358|82 91|hemoglobin
P08148756A0358|114 125|lavaged lungs
P08149484A0151|0 17|Expression plasmids
P08149484A0151|40 51|kinase domain
P08149484A0151|54 61|PKC alpha
P08149484A0151|54 61|PKC alpha
P08149484A0151|65 72|PKC delta
P08149484A0151|65 72|PKC delta
P08149484A0151|74 82|PKC alpha K
P08149484A0151|74 82|PKC alpha K
P08149484A0151|86 94|PKC delta K
P08149484A0151|86 94|PKC delta K
P08149484A1551|28 35|PKC alpha
P08149484A1551|28 35|PKC alpha
P08149484A1551|37 52|calcium dependent
P08149484A1551|57 64|PKC delta
P08149484A1551|57 64|PKC delta
P08149484A1551|66 83|calcium independent
P08149484A1551|113 130|TPA-inducible genes
P08149484A1551|113 130|TPA-inducible genes
P08149484A1551|142 165|AP-1 and non-AP-1 sequences
P08149484A1551|142 145|AP-1
P08149484A1551|149 165|non-AP-1 sequences
P08150970A0434|5 15|cutoff level
P08150970A0434|19 24|TSST-1
P08150970A0434|19 24|TSST-1
P08150970A0434|67 74|patients
P08150970A0434|90 95|TSST-1
P08150970A0434|90 95|TSST-1
P08151787A0355|16 31|oligonucleotides
P08151787A0355|43 77|basic amino acid motifs 726-GRKRKSP-732
P08151787A0355|82 86|IE175
P08151787A0355|82 86|IE175
P08151787A0355|94 104|VRPRKRR-506
P08151787A0355|109 113|IE110
P08151787A0355|109 113|IE110
P08151787A0355|168 178|karyophilic
P08151787A0355|253 271|nuclear localization
P08151787T0000|9 40|intracellular localization domains
P08151787T0000|91 95|IE110
P08151787T0000|91 95|IE110
P08151787T0000|99 103|IE175
P08151787T0000|99 103|IE175
P08151787T0000|104 132|nuclear transactivator proteins
P08151787T0000|104 132|nuclear transactivator proteins
P08151787T0000|135 152|herpes simplex virus
P08151790A0354|12 20|TATA boxes
P08151790A0354|45 58|HIV replication
P08151790A0354|86 88|LTR
P08151790A0354|100 110|Sp1 mutation
P08151790A0354|100 102|Sp1
P08151790A0354|173 184|wild-type HIV
P08151980T0001|0 18|Panlobular emphysema
P08152800A0357|8 16|ETS domain
P08152800A0357|8 16|ETS domain
P08152800A0357|39 59|carboxy terminal region
P08152800A0357|108 111|PEA3
P08152800A0357|108 111|PEA3
P08152800A0357|115 118|ER81
P08152800A0357|115 118|ER81
P08152800A0357|154 185|Ets Related Molecule PEA3-like' (ERM
P08152800A0357|154 181|Ets Related Molecule PEA3-like'
P08152800A0357|183 185|ERM
P08152800A0709|0 15|Gel shift analysis
P08152800A0709|32 52|full-length ERM protein
P08152800A0709|32 52|full-length ERM protein
P08152800A0709|81 95|oligonucleotide
P08152800A0709|109 143|consensus nucleotide core sequence GGAA
P08152800A0709|159 169|Ets proteins
P08152800A0709|159 169|Ets proteins
P08153130T0000|9 17|estradiol
P08153130T0000|20 29|worm burden
P08153130T0000|33 52|peripheral leukocytes
P08153130T0000|55 93|Parastrongylus malaysiensis-infected rats
P08153146A0327|0 9|Dotarizine
P08153146A0327|40 70|systemic and pulmonary circulation
P08153146A0327|133 156|aortic and pulmonary artery
P08154171A0649|5 10|issues
P08154171A0649|26 30|LMWHs
P08154171A0649|33 40|patients
P08154171A0649|53 84|thrombosis or myocardial infarction
P08154171A0649|107 127|thrombolytic treatment
P08154171A0649|135 142|patients
P08154171A0649|147 163|pulmonary embolism
P08154182A0955|18 27|lambda PG15
P08154182A0955|34 56|lambda AD5 cloning vectors
P08154182A0955|107 119|cDNA libraries
P08156332T0000|0 35|Endoscopic transthoracic sympathectomy
P08156332T0000|58 84|critical upper-limb ischaemia
P08157009A0264|32 36|Aps1p
P08157009A0264|32 36|Aps1p
P08157009A0264|55 66|sigma subunit
P08157009A0264|72 76|Golgi
P08157009A0264|87 106|mammalian AP-1 complex
P08157009A0264|96 99|AP-1
P08157009A0264|111 115|Aps2p
P08157009A0264|111 115|Aps2p
P08157009A0264|140 169|plasma membrane AP-2 sigma subunit
P08157009A0264|140 153|plasma membrane
P08157009A0264|154 157|AP-2
P08157009A0264|158 169|sigma subunit
P08157009T0000|3 33|Saccharomyces cerevisiae APS1 gene
P08157009T0000|3 25|Saccharomyces cerevisiae
P08157009T0000|26 33|APS1 gene
P08157009T0000|71 98|mammalian clathrin AP-1 complex
P08157009T0000|71 87|mammalian clathrin
P08157009T0000|88 91|AP-1
P08157009T0000|136 143|clathrin
P08157009T0000|149 160|Golgi complex
P08157663A0882|64 77|vertebrate gene
P08157663A0882|88 110|integral membrane protein
P08157663A0882|116 130|nuclear envelope
P08157663A0882|158 169|polypeptides
P08157663A0882|181 189|evolution
P08157674T0000|29 53|valosin-containing protein
P08157674T0000|29 53|valosin-containing protein
P08157674T0000|56 85|protein tyrosine kinase substrate
P08157674T0000|56 76|protein tyrosine kinase
P08157674T0000|88 105|hematopoietic cells
P08159174A0581|16 22|foreign
P08159174A0581|41 56|Southern analysis
P08160054A0224|3 10|patients
P08160054A0224|15 28|deterioriation
P08160054A0224|31 42|mental status
P08160054A0224|66 87|liver enzymes (aspartate
P08160054A0224|79 115|aspartate and alanine aminotransaminases
P08160054A0224|91 115|alanine aminotransaminases
P08160054A0224|126 137|coagulopathy
P08160387T0000|10 29|postnatal development
P08160387T0000|35 44|rat primary
P08160387T0000|45 56|visual cortex
P08160387T0000|86 96|dark rearing
P08160387T0000|100 119|monocular deprivation
P08160905A0217|6 13|patients
P08160905A0217|34 57|hepatitis B surface antigen
P08160905A0217|34 43|hepatitis B
P08160905A0217|59 63|HBsAg
P08160905A0217|59 63|HBsAg
P08163183T0000|3 35|xylose isomerase-encoding gene (xylA
P08163183T0000|3 30|xylose isomerase-encoding gene
P08163183T0000|32 35|xylA
P08163183T0000|39 70|Clostridium thermosaccharolyticum
P08163183T0000|72 78|cloning
P08163183T0000|80 89|sequencing
P08163183T0000|104 114|XylA enzymes
P08163183T0000|104 114|XylA enzymes
P08163498A0789|31 52|RS-[32P]SGASGLLTSEHHSR
P08163498A0789|56 76|S-[32P]SGASGLLTSEHHSR
P08163498A0789|95 123|stoichiometric phosphorylation
P08163498A0789|146 152|peptide
P08163528T0000|0 38|Mitochondrial Mas70p signal anchor sequence
P08163528T0000|0 38|Mitochondrial Mas70p signal anchor sequence
P08163546A1230|31 36|Ypt51p
P08163546A1230|31 36|Ypt51p
P08163546A1230|38 43|Ypt52p
P08163546A1230|38 43|Ypt52p
P08163546A1230|48 53|Ypt53p
P08163546A1230|48 53|Ypt53p
P08163546A1230|82 97|endocytic pathway
P08163546A1230|120 137|vacuolar hydrolases
P08163546A1230|120 127|vacuolar
P08163546A1230|190 197|vacuolar
P08164302A0547|13 24|TPN solutions
P08164302A0547|133 139|glucose
P08164661A0414|13 23|TFIIIC alpha
P08164661A0414|13 23|TFIIIC alpha
P08164661A0414|47 65|yeast TFIIIC subunits
P08164661A0414|47 51|yeast
P08164661A0414|52 57|TFIIIC
P08164661A0414|135 157|RNA polymerase III factors
P08164661A0414|135 157|RNA polymerase III factors
P08164679A0809|45 76|128-amino-acid runt homology region
P08164679A0809|45 76|128-amino-acid runt homology region
P08164679A0809|93 102|Runt domain
P08164679A0809|93 102|Runt domain
P08164680A1086|17 32|protease activity
P08164680A1086|58 69|mature B cells
P08164680A1086|76 85|pre-B cells
P08164684A1266|12 14|RXR
P08164684A1266|12 14|RXR
P08164684A1266|16 32|9-cis retinoic acid
P08164684A1266|56 68|destabilizing
P08164684A1266|72 95|heterodimeric-DNA complex
P08164684A1266|72 95|heterodimeric-DNA complex
P08166402A0631|0 17|Cerebral125 albumin
P08166402A0631|0 17|Cerebral125 albumin
P08167396A0154|54 91|ipsilateral substantia nigra pars compacta
P08167555A0972|30 37|patients
P08167555A0972|88 94|heavily
P08169201A0291|13 34|amino-terminal sequence
P08169201A0291|40 58|purified carA product
P08169201A0291|48 58|carA product
P08169201A0291|90 107|nucleotide sequence
P08169709T0000|0 17|Aneurysmal bone cyst
P08170400T0000|0 7|Location
P08170400T0000|24 41|an activating region
P08170400T0000|26 41|activating region
P08170400T0000|47 80|Escherichia coli transcription factor
P08170400T0000|47 80|Escherichia coli transcription factor
P08170400T0000|82 84|FNR
P08170400T0000|82 84|FNR
P08172416A0860|0 9|Moxidectin
P08172416A0860|127 135|ovulation
P08172416A0860|143 174|early embryonic phase of development
P08172598A0237|0 20|Northern-blot analysis
P08172598A0237|23 26|mRNA
P08172598A0237|31 43|Avicel-grown N
P08172598A0237|66 69|xynB
P08172598A0237|66 69|xynB
P08172598A0237|88 98|mRNA species
P08172653A1589|3 17|variable regions
P08172653A1589|20 29|vertebrate
P08172653A1589|38 48|TnT isoforms
P08172653A1589|38 48|TnT isoforms
P08172653A1589|134 151|TnT multigene family
P08172653A1589|134 136|TnT
P08172905A0000|3 73|class II Escherichia coli alanine tRNA synthetase aminoacylates RNA miniduplexes
P08172905A0000|3 9|class II
P08172905A0000|10 24|Escherichia coli
P08172905A0000|25 45|alanine tRNA synthetase
P08172905A0000|59 73|RNA miniduplexes
P08172905A0000|107 117|alanine tRNA
P08172905A0000|133 134|G3
P08172905A0000|136 146|U70 base pair
P08173532A0000|19 20|RT
P08173532A0000|48 49|S2
P08173532A0000|48 49|S2
P08173532A0000|82 84|cue
P08173532A0000|86 87|S1
P08173532A0000|86 87|S1
P08173532A0000|103 104|S2
P08173693A0390|60 67|patients
P08173693A0390|92 102|class I to III
P08173814A0132|23 39|host cell machinery
P08173814A0132|128 141|host physiology
P08175188A0685|16 25|12.5 ppm SO2
P08175188A0685|84 86|MCA
P08175188A0685|108 110|CBF
P08176742A0190|58 77|transposition pathway
P08177143T0000|0 17|Renal cell carcinoma
P08177143T0000|20 27|children
P08177143T0000|36 48|institution's
P08178446A1160|18 22|ICP10
P08178446A1160|18 22|ICP10
P08178446A1160|46 56|ras activity
P08178446A1160|46 48|ras
P08178446A1160|64 72|TM segment
P08178446A1160|115 131|signaling pathways
P08178490A0879|23 36|signal function
P08178490A0879|44 49|anchor
P08178490A0879|66 74|K SA domain
P08178572A1118|4 12|concensus
P08178572A1118|13 17|poly A
P08178572A1118|46 57|350 base pairs
P08178572A1118|81 89|protein IX
P08178572A1118|81 89|protein IX
P08179827T0000|48 62|hepatitis B virus
P08179827T0000|63 71|infection
P08180129A1256|16 32|TPA concentrations
P08181755A0989|0 15|Northern analysis
P08181755A0989|29 43|pcbAB transcript
P08181755A0989|29 43|pcbAB transcript
P08181755A0989|99 102|mRNA
P08182041A1067|58 62|PEPCK
P08182041A1067|58 62|PEPCK
P08182041A1067|65 67|PKA
P08182041A1067|65 67|PKA
P08182041A1067|83 89|insulin
P08182041A1067|83 89|insulin
P08182041A1067|103 116|CREB activation
P08182041A1067|103 106|CREB
P08182041A1067|129 145|PEPCK TATA sequence
P08182041A1067|129 145|PEPCK TATA sequence
P08182041A1067|152 158|insulin
P08182041A1067|152 158|insulin
P08182041A1067|170 182|hepatoma cells
P08182056A0695|34 37|NQO2
P08182056A0695|34 37|NQO2
P08182056A0695|41 60|NQO1 gene organization
P08182056A0695|41 48|NQO1 gene
P08182056A0695|85 92|NQO2 gene
P08182056A0695|85 92|NQO2 gene
P08182056A0695|121 133|NQO gene family
P08182056A0695|121 133|NQO gene family
P08182171A0000|14 42|Propionibacterium acnes product
P08182171A0000|57 72|coliform mastitis
P08182171A0000|94 113|intramammary infusion
P08182171A0000|116 130|Escherichia coli
P08183552T0000|3 16|human eps15 gene
P08183552T0000|3 16|human eps15 gene
P08183552T0000|27 49|tyrosine kinase substrate
P08183552T0000|27 40|tyrosine kinase
P08183552T0000|64 72|evolution
P08183552T0000|82 89|1p31-p32
P08183915A0000|18 31|105-kDa protein
P08183915A0000|18 31|105-kDa protein
P08183915A0000|33 46|p105) precursor
P08183915A0000|33 36|p105
P08183915A0000|52 61|p50 subunit
P08183915A0000|52 54|p50
P08183915A0000|64 82|transcription factor
P08183915A0000|83 91|NF-kappa B
P08183915A0000|83 91|NF-kappa B
P08183915A0000|104 120|p70 I kappa B protein
P08183915A0000|104 106|p70
P08183915A0000|107 120|I kappa B protein
P08183915A0000|122 133|I kappa B gamma
P08183915A0000|122 133|I kappa B gamma
P08183915A0000|156 178|C-terminal 607 amino acids
P08183915A0000|181 184|p105
P08183915A0000|181 184|p105
P08183915T0000|21 34|RNA transcripts
P08183915T0000|21 34|RNA transcripts
P08183915T0000|47 69|murine p105 NF-kappa B gene
P08183915T0000|47 69|murine p105 NF-kappa B gene
P08183915T0000|79 98|I kappa B gamma isoforms
P08183915T0000|79 98|I kappa B gamma isoforms
P08183915T0000|112 131|inhibitory activities
P08184923A0829|0 11|Topical L-NNA
P08184923A0829|46 49|CoBF
P08184923A0829|62 65|CeBF
P08185288A0106|22 25|male
P08185288A0106|36 50|healthy subjects
P08185288A0106|78 96|respiration chambers
P08187085A0086|5 18|rearrangements
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|86 88|ret
P08187085A0086|86 88|ret
P08187085A0086|101 114|5' end sequences
P08187085A0086|126 130|genes
P08187088A0530|14 27|heterozygosity
P08187088A0530|29 31|LOH
P08187088A0530|73 85|chromosomes 3p
P08187088A0530|94 95|5q
P08187088A0530|104 105|6p
P08187088A0530|114 115|8p
P08187088A0530|124 125|9p
P08187088A0530|134 135|9q
P08187088A0530|144 146|11p
P08187088A0530|155 157|13q
P08187088A0530|166 168|17p
P08187088A0530|177 179|17q
P08187088A0530|188 190|18q
P08187088A0530|202 204|19q
P08187177A0405|1 21|single amino acid change
P08187177A0405|27 29|CPY
P08187177A0405|30 37|vacuolar
P08188258A0000|0 22|Glutamyl-tRNA synthetase
P08188258A0000|0 22|Glutamyl-tRNA synthetase
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188258A0000|73 97|aminoacyl-tRNA synthetases
P08188258A0000|73 86|aminoacyl-tRNA
P08188290A0544|35 56|human TCRAC/TCRDC region
P08188290A0544|40 44|TCRAC
P08188290A0544|46 50|TCRDC
P08188290A0544|73 106|polymerase chain reaction-based assay
P08188290A0544|144 160|TCRAJ gene segments
P08188290A0544|144 160|TCRAJ gene segments
P08188603A0230|22 31|intact gene
P08188603A0230|22 31|intact gene
P08188603A0230|33 36|arg4
P08188603A0230|33 36|arg4
P08188603A0230|73 103|Saccharomyces cerevisiae CPA2 gene
P08188603A0230|73 95|Saccharomyces cerevisiae
P08188603A0230|129 157|carbamoyl-phosphate synthetase
P08188603A0230|129 157|carbamoyl-phosphate synthetase
P08188603A0230|159 163|CPS-A
P08188603A0230|159 163|CPS-A
P08188606A1034|0 18|Restriction analysis
P08188606A1034|22 42|Southern hybridization
P08188606A1034|64 69|Tn5422
P08188606A1034|64 69|Tn5422
P08188606A1034|78 84|plasmid
P08188606A1034|94 110|cadmium-resistant
P08188606A1034|111 132|L. monocytogenes strains
P08188606A1034|162 178|cadmium resistance
P08188606A1034|184 193|chromosome
P08188978A0822|3 19|baroreflex latency
P08188978A0822|28 36|ECG R-wave
P08188978A0822|52 60|MSNA burst
P08188978A0822|103 107|sleep
P08188978A0822|123 141|pulse-synchronicity
P08189174A0148|41 45|women
P08189174A0148|78 98|breast cancer screening
P08189174A0148|113 125|city of Utrecht
P08189498T0000|18 36|immediate-early gene
P08189498T0000|18 36|immediate-early gene
P08189498T0000|42 60|Marek's disease virus
P08189498T0000|65 84|internal repeat region
P08189498T0000|98 127|unique 14-kilodalton polypeptide
P08189503A0000|11 30|full-length cDNA clone
P08189503A0000|11 25|full-length cDNA
P08189503A0000|34 58|mouse hepatitis virus strain
P08189503A0000|59 61|A59
P08189503A0000|83 88|DI) RNA
P08189503A0000|83 88|DI) RNA
P08189503A0000|90 96|pMIDI-C
P08189503A0000|90 96|pMIDI-C
P08189503A0000|101 119|cassette mutagenesis
P08189503A0000|141 174|coronavirus subgenomic mRNA synthesis
P08189533A0203|33 44|gene 5 product
P08189533A0203|46 63|wild-type and mutant
P08189533A0203|71 74|NS53
P08189533A0203|71 74|NS53
P08189533A0203|95 116|recombinant baculovirus
P08189533A0203|148 187|vaccinia virus/T7 (vTF7-3) expression system
P08189533A0919|0 17|Gel electrophoresis
P08189533A0919|21 45|Western immunoblot analyses
P08189533A0919|48 69|intracellular fractions
P08189533A0919|81 93|infected cells
P08189533A0919|120 123|NS53
P08189533A0919|120 123|NS53
P08189533A0919|140 146|cytosol
P08189533A0919|170 187|cytoskeletal matrix
P08190633A0000|3 21|transcription factor
P08190633A0000|22 25|AP-2
P08190633A0000|22 25|AP-2
P08190633A0000|51 61|chromosome 6
P08190633A0000|69 76|HLA locus
P08190633A0000|69 76|HLA locus
P08190633A0273|9 16|AP-2 mRNA
P08190633A0273|9 16|AP-2 mRNA
P08190633A0273|31 35|exons
P08191910A0228|113 126|political ruler
P08192140A0209|34 56|hepatitis B vaccine trials
P08192140A0209|71 72|74
P08192140A0209|75 85|New York City
P08192140A0209|97 108|San Francisco
P08192451A0885|38 56|mitochondrial uptake
P08192451A0885|59 63|Rh123
P08192451A0885|79 87|NAO uptake
P08192795T0000|0 32|Thrombotic thrombocytopenic purpura
P08192795T0000|35 60|systemic lupus erythematosus
P08193147A0831|17 32|crystal structure
P08193147A0831|35 52|Desulfovibrio gigas
P08193147A0831|57 58|Fd
P08193147A0831|182 185|Dg Fd
P08194139A0498|12 25|Serum prolactin
P08194139A0498|17 25|prolactin
P08194139A0498|76 85|fertile men
P08194549A0000|18 29|male kayakers
P08194549A0000|88 89|CP
P08194549A0000|104 127|blood lactate accumulation
P08194549A0000|129 132|OBLA
P08194753A0157|4 15|S. cerevisiae
P08194753A0157|30 35|rhp51+
P08194753A0157|30 35|rhp51+
P08194753A0157|45 63|MluI cell-cycle boxes
P08194753A0157|45 63|MluI cell-cycle boxes
P08194753A0157|76 102|DNA damage-responsive element
P08194753A0157|108 121|upstream region
P08194970A0000|0 19|Women's opportunities
P08194970A0000|72 83|primary carer
P08195186A0000|1 19|partial cDNA sequence
P08195186A0000|36 66|T lymphocyte early-activation gene
P08195186A0000|36 66|T lymphocyte early-activation gene
P08195186A0000|68 70|Tea
P08195186A0000|68 70|Tea
P08195186A0000|99 111|dual-function
P08195186A0000|112 147|ecotropic retrovirus receptor/cationic
P08195186A0000|112 138|ecotropic retrovirus receptor
P08195186A0000|140 167|cationic amino acid transporter
P08195186A0000|148 167|amino acid transporter
P08195186A0000|169 177|ecoR/CAT1
P08195186A0000|169 172|ecoR
P08195186A0000|174 177|CAT1
P08195186A0000|183 190|RNA blots
P08195186A0000|207 219|Tea expression
P08195186A0000|207 209|Tea
P08195186A0000|222 233|T lymphocytes
P08195186A0000|237 241|liver
P08195186A0000|243 249|MacLeod
P08195216A1022|28 31|HIS3
P08195216A1022|28 31|HIS3
P08195216A1022|57 74|TATA-like sequences
P08195216A1022|57 74|TATA-like sequences
P08195216A1022|116 120|GCN4p
P08195216A1022|116 120|GCN4p
P08195216A1022|135 152|TATA-like sequences
P08195216A1022|160 174|GCN4p activation
P08195216A1022|160 164|GCN4p
P08195216A1022|177 180|TRP3
P08195216A1022|177 180|TRP3
P08195217A0799|20 26|protein
P08195217A0799|108 120|37-kDa protein
P08195217A0799|123 161|sodium dodecyl sulfate-polyacrylamide gels
P08195233A0147|15 20|kinase
P08195233A0147|100 115|human chromosome 1
P08195233A0147|150 162|tumorigenesis
P08196607A0280|0 15|Deletion analysis
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|59 91|upstream activating sequence element
P08196607A0280|93 99|UASICL1
P08196607A0280|101 114|5' CATTCATCCG 3'
P08196607A0280|152 183|carbon source-dependent regulation
P08196607A0280|187 210|heterologous reporter gene
P08196616A1112|30 35|ZAP-70
P08196616A1112|30 35|ZAP-70
P08196616A1112|79 94|ZAP-70 SH2 domains
P08196616A1112|79 84|ZAP-70
P08196616A1112|85 94|SH2 domains
P08196616A1112|107 122|tyrosine residues
P08196616A1112|148 153|ZAP-70
P08196616A1112|148 153|ZAP-70
P08196616A1112|170 192|phosphotyrosine residues
P08196616A1112|215 227|two SH2 domains
P08196616A1112|218 227|SH2 domains
P08196618A0473|0 4|PRL-1
P08196618A0473|0 4|PRL-1
P08196618A0473|28 52|phosphotyrosine substrates
P08196618A0473|70 80|active-site
P08196618A0473|81 88|cysteine
P08196624A0593|2 25|Mv1Lu lung epithelial cells
P08196624A0593|27 33|ActR-IB
P08196624A0593|27 33|ActR-IB
P08196624A0593|37 44|T beta R-I
P08196624A0593|37 44|T beta R-I
P08196624A0593|83 106|transcriptional responses
P08196624A0593|152 166|type II receptors
P08196624A0593|152 166|type II receptors
P08198524A1134|0 10|50 kDa and 130
P08199204A0746|0 2|H-7
P08199204A0746|0 2|H-7
P08199204A0746|46 58|PKC activation
P08199204A0746|46 48|PKC
P08199204A0746|73 95|tyrosine phosphorylation
P08199204A0746|99 111|PtdIns(3,4)P2
P08199204A0746|99 104|PtdIns
P08199204A0746|106 108|3,4
P08199204A0746|110 111|P2
P08199878T0000|12 26|systemic glucose
P08199878T0000|42 56|brain metabolism
P08199878T0000|74 86|brain ischemia
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|101 117|PAL)-encoding gene
P08200528A0970|101 103|PAL
P08200528A0970|150 160|pPGK::REP2.
P08200528A0970|150 153|pPGK
P08201352A0239|11 38|congenital protein C deficiency
P08201352A0239|40 58|vitamin K antagonists
P08201352A0239|96 107|skin necrosis
P08201758A0125|13 19|patient
P08201932A0355|26 49|symmetrical polyarthritis
P08201932A0355|52 70|small and large joints
P08202546A1206|27 50|hUBF-promoter interaction
P08202546A1206|27 39|hUBF-promoter
P08202546A1206|94 102|cisplatin
P08203260A1204|17 20|SIMV
P08203260A1204|31 45|weaning neonates
P08203260A1204|53 62|ventilator
P08204348T0000|0 4|VP-16
P08204348T0000|0 4|VP-16
P08204348T0000|19 27|cisplatin
P08204348T0000|29 31|VIP
P08204348T0000|29 31|VIP
P08204348T0000|45 63|small cell lung cancer
P08204403A0000|11 15|males
P08204403A0000|20 35|females) patients
P08204403A0000|138 151|anti CEA/CA 19-9
P08204403A0000|138 144|anti CEA
P08204403A0000|146 171|CA 19-9 monoclonal antibodies
P08204426T0001|13 21|bilateral
P08204426T0001|67 75|childhood
P08204824A0000|19 27|cyc07 gene
P08204824A0000|19 27|cyc07 gene
P08204824A0000|62 67|S phase
P08204824A0000|77 85|cell cycle
P08204824A0000|109 143|periwinkle (Catharanthus roseus) cells
P08205827A0940|27 34|bacteria
P08205827A0940|53 73|gastrointestinal tract
P08205827A0940|81 91|bloodstream
P08205827A0940|106 122|animal experiments
P08205827A0940|176 191|hemorrhagic shock
P08206848A0296|3 6|pyrR
P08206848A0296|3 6|pyrR
P08206848A0296|10 37|pyrP genes encoded polypeptides
P08206848A0296|10 18|pyrP genes
P08206848A0296|52 66|molecular masses
P08206848A0296|69 82|19.9 and 45.2 kDa
P08206867A0874|0 23|Southern blotting analysis
P08206867A0874|54 63|COXVb genes
P08206867A0874|54 63|COXVb genes
P08206867A0874|69 77|rat genome
P08206991A0466|16 30|palmitate analog
P08206991A0466|47 51|Gly-2
P08206991A0466|64 70|alanine
P08206991A0466|84 98|N-myristylation
P08206991A0466|112 124|palmitylation
P08206991A0466|139 141|Cys
P08206991A0466|146 148|Cys
P08206991A0466|163 168|serine
P08207022T0000|0 6|Subunit
P08207022T0000|41 93|Spo0A sporulation transcription factor of Bacillus subtilis
P08207022T0000|41 85|Spo0A sporulation transcription factor of Bacillus
P08207232A0503|0 35|Electrophoretic mobility shift analysis
P08207232A0503|49 55|NF-IL-6
P08207232A0503|49 55|NF-IL-6
P08207232A0503|118 128|NF-IL-6 site
P08207232A0503|118 128|NF-IL-6 site
P08207232A0503|134 145|IL-8 promoter
P08207232A0503|134 145|IL-8 promoter
P08207405A0372|0 2|BYV
P08207405A0372|10 22|tristeza virus
P08207405A0372|24 26|CTV
P08207405A0372|33 48|yellow stunt virus
P08207405A0372|50 53|BYSV
P08207405A0372|58 93|carnation necrotic fleck virus templates
P08207405A0372|143 152|sequencing
P08207405A0372|188 197|HSP70 genes
P08207405A0372|188 197|HSP70 genes
P08207795A0409|33 51|phosphorylation site
P08207795A0409|57 69|64-kDa protein
P08207805A0000|3 31|p53 tumor suppressor gene product
P08207805A0000|3 24|p53 tumor suppressor gene
P08207805A0000|34 68|sequence-specific DNA-binding protein
P08207805A0000|51 68|DNA-binding protein
P08207805A0000|90 113|transcriptional activator
P08208247T0030|0 17|Mutational analysis
P08208247T0030|38 41|64AB
P08208247T0030|63 91|glutamic acid decarboxylase gene
P08208247T0030|63 87|glutamic acid decarboxylase
P08208540A0000|0 13|Rearrangements
P08208540A0000|19 27|NFKB2 gene
P08208540A0000|19 27|NFKB2 gene
P08208540A0000|45 64|lymphoid malignancies
P08208540A0417|38 42|cDNAs
P08208540A0417|60 78|alternative splicing
P08208540A0417|83 96|rearranged gene
P08208540A0417|83 96|rearranged gene
P08208540A0417|118 119|84
P08208540A0417|128 133|p84/85
P08208540A0417|128 133|p84/85
P08208540A0417|149 168|DNA-binding rel domain
P08208540A0417|149 168|DNA-binding rel domain
P08208540A0417|180 197|five ankyrin repeats
P08208540A0417|184 190|ankyrin
P08208540A0417|215 230|carboxy-terminus
P08208540A0417|243 262|seventh ankyrin repeat
P08208540A0417|250 256|ankyrin
P08208540A1114|9 29|co-transfection assays
P08208540A1114|39 43|NFKB2
P08208540A1114|39 43|NFKB2
P08208540A1114|64 92|kappa B-driven reporter plasmids
P08208540A1114|64 69|kappa B
P08208540A1114|105 112|NFKB2 p85
P08208540A1114|105 109|NFKB2
P08208540A1114|110 112|p85
P08208540A1114|171 178|NFKB2 p52
P08208540A1114|171 178|NFKB2 p52
P08208618A1334|5 10|HR21ap
P08208618A1334|5 10|HR21ap
P08208618A1334|19 25|HR21Xap
P08208618A1334|19 25|HR21Xap
P08208618A1334|56 65|Sp1 binding
P08208618A1334|56 58|Sp1
P08209051T0000|0 27|Intravenous antibiotic therapy
P08209051T0000|30 43|cystic fibrosis
P08209423T0000|0 16|Open reading frames
P08209423T0000|20 41|4556 nucleotide sequence
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|93 96|mRNA
P08209423T0000|105 125|viral glycoprotein gene
P08209423T0000|105 125|viral glycoprotein gene
P08209772A0167|3 9|ns2 gene
P08209772A0167|3 5|ns2
P08209772A0167|21 36|open reading frame
P08209772A0167|38 40|ORF
P08209772A0167|59 71|nonstructural
P08209772A0167|73 82|ns) protein
P08209772A0167|85 97|279 amino acids
P08212571A0597|0 14|Co-transfection
P08212571A0597|18 37|tat expressing plasmid
P08212571A0597|18 20|tat
P08212571A0597|67 72|tat ORF
P08212571A0597|67 69|tat
P08212571A0597|70 72|ORF
P08212571A0597|73 81|mutations
P08212571A0597|106 120|virus production
P08212571A0971|13 15|gag
P08212571A0971|13 15|gag
P08212571A0971|19 29|rev proteins
P08212571A0971|19 29|rev proteins
P08212571A0971|35 50|transfected cells
P08212571A0971|122 131|tat mutants
P08212571A0971|122 131|tat mutants
P08212571A0971|164 172|mutations
P08212571A0971|201 219|tat expression vector
P08212571A0971|201 203|tat
P08212897A0404|3 23|hydrophobicity profile
P08212897A0404|29 45|methyltransferase
P08212897A0404|86 105|transmembrane domains
P08213235A1024|13 16|SaO2
P08213235A1024|62 68|healthy
P08213235A1024|75 91|newborns or infants
P08213747A0000|39 69|human immunodeficiency virus type 1
P08213747A0000|39 69|human immunodeficiency virus type 1
P08213747A0000|71 75|HIV-1
P08213747A0000|71 75|HIV-1
P08213747A0000|88 89|US
P08213747A0000|90 118|black and Hispanic homosexual men
P08213747A0000|129 136|white men
P08213747A0000|166 188|sociodemographic factors
P08213747A0000|199 206|sexually
P08213747A0000|229 234|sexual
P08213747A0000|238 254|drug-use behaviors
P08213747A0000|309 313|HIV-1
P08213747A0000|331 346|HIV-1 risk factors
P08213747A0000|361 373|Hispanic white
P08213747A0000|375 390|234 Hispanic white
P08213747A0000|398 415|black homosexual men
P08213747A0000|436 447|United States
P08213747A0000|470 471|DC
P08216115A0158|3 10|patients
P08216115A0158|24 35|intrauterine
P08216115A0158|56 63|oxytocin
P08216115A0158|87 90|75th
P08216115A0158|103 117|uterine activity
P08217862A1336|0 19|Continued development
P08217862A1336|25 39|rat conditioning
P08217862A1336|107 119|nerve activity
P08217862A1336|207 224|pathological states
P08218056A0000|19 32|retinal vessels
P08218056A0000|59 66|diabetic
P08218056A0000|67 74|patients
P08218056A0000|89 103|control subjects
P08218230A1505|3 18|regulatory region
P08218230A1505|47 57|binding site
P08218230A1505|61 94|a liver-specific transcription factor
P08218230A1505|62 94|liver-specific transcription factor
P08218230A1505|96 119|hepatocyte nuclear factor 1
P08218230A1505|96 119|hepatocyte nuclear factor 1
P08218230A1505|121 125|HNF-1
P08218230A1505|121 125|HNF-1
P08218230A1505|145 148|-132
P08218230A1920|22 24|GRE
P08218230A1920|51 76|glucocorticoid inducibility
P08218230A1920|82 90|HNF-1 site
P08218230A1920|82 86|HNF-1
P08218230A1920|101 108|promoter
P08218230A1920|135 156|transcriptional control
P08218230A1920|162 194|Xenopus fibrinogen B beta subunit gene
P08218230A1920|162 168|Xenopus
P08218230A1920|179 190|B beta subunit
P08218230A1920|206 216|normal liver
P08219081A0000|3 12|PRB-1b gene
P08219081A0000|3 8|PRB-1b
P08219081A0000|24 42|basic-type component
P08219081A0000|68 84|PR-1 protein family
P08219081A0000|68 78|PR-1 protein
P08219227A0830|16 18|CRE
P08219227A0830|39 46|AP-1 site
P08219227A0830|39 46|AP-1 site
P08219227A0830|110 126|wild-type sequence
P08219227A0830|110 126|wild-type sequence
P08219227A0830|147 154|AP-1 site
P08219227A0830|147 154|AP-1 site
P08219227A0830|160 162|CRE
P08220494A0231|3 15|T-cyt promoter
P08220494A0231|3 15|T-cyt promoter
P08220494A0231|27 41|bacterial origin
P08220494A0231|64 79|30 bp cyt-1 element
P08220494A0231|64 79|30 bp cyt-1 element
P08220494A0231|120 140|T-cyt promotor activity
P08220494A0231|120 132|T-cyt promotor
P08220494A0231|143 163|leaf, stem and root cells
P08220494A0231|166 172|tobacco
P08220494A0231|173 178|plants
P08220621T0000|0 19|Reviewing manuscripts
P08221251A0239|13 14|CT
P08221251A0239|44 49|tumors
P08222384A0455|0 4|SIN-1
P08222384A0455|30 47|ischemic parameters
P08222384A0455|53 76|surface electrocardiogram
P08222384A0455|78 80|ECG
P08222384A0455|87 99|intracoronary
P08222384A0455|100 102|ECG
P08222556T0000|15 25|respiratory
P08222618A0000|3 7|BASIC
P08222618A0000|8 23|computer programs
P08222618A0000|29 47|logit transformation
P08223425T0000|3 15|yeast SSS1 gene
P08223425T0000|3 7|yeast
P08223425T0000|8 15|SSS1 gene
P08223425T0000|30 58|secretory protein translocation
P08223425T0000|91 110|endoplasmic reticulum
P08223554A0574|15 38|complete polypeptide chain
P08223554A0574|44 60|recombinant enzyme
P08223554A0574|44 60|recombinant enzyme
P08223554A0574|67 80|transit peptide
P08223576A1261|12 20|H4PteGlun
P08223576A1261|31 38|T protein
P08223576A1261|31 38|T protein
P08223576A1261|82 90|H4PteGlun
P08223576A1261|117 124|T protein
P08223576A1261|117 124|T protein
P08223592A0424|0 16|TATA and CCAAT boxes
P08223592A0424|67 88|transcription start site
P08223592A0424|93 113|5'-untranslated leader
P08223592A0424|118 153|nucleotides long, and the intronless gene
P08223592A0424|176 195|polyadenylation sites
P08223613A0105|0 3|GGS1
P08223613A0105|0 3|GGS1
P08223613A0105|19 22|TPS1
P08223613A0105|64 111|trehalose-6-phosphate synthase/phosphatase complex
P08223613A0105|64 104|trehalose-6-phosphate synthase/phosphatase
P08223613A0105|131 139|fdp1, byp1
P08223613A0105|131 134|fdp1
P08223613A0105|136 139|byp1
P08223613A0105|141 144|glc6
P08223613A0105|141 144|glc6
P08223613A0105|148 151|cif1
P08223613A0105|152 160|mutations
P08223613A0519|61 77|S. cerevisiae genes
P08223613A0519|61 72|S. cerevisiae
P08223613A0519|78 81|TPS2
P08223613A0519|78 81|TPS2
P08223613A0519|85 88|TSL1
P08223613A0519|85 88|TSL1
P08223613A0519|123 146|trehalose synthase complex
P08223613A0519|123 139|trehalose synthase
P08223613A0519|155 167|TSL1 homologue
P08223613A0519|155 167|TSL1 homologue
P08223613A0519|169 172|TPS3
P08223613A0519|169 172|TPS3
P08223823T0000|0 17|Stroop interference
P08223875A0711|13 16|[3H]
P08223875A0711|17 28|PA production
P08223875A0711|33 48|CD3 cross-linking
P08223875A0711|33 35|CD3
P08223875A0711|75 84|CD45- cells
P08223875A0711|75 78|CD45
P08223875A0711|91 100|CD45+ cells
P08223875A0711|91 95|CD45+
P08223875A0711|136 141|p59fyn
P08223875A0711|136 141|p59fyn
P08223875A0711|144 153|CD45- cells
P08223875A0711|144 147|CD45
P08224260A1248|35 61|transvaginal ultrasonography
P08224260A1248|84 111|differentiating endometriomas
P08224260A1248|121 133|ovarian masses
P08224907A0000|7 26|Southern blot analysis
P08224907A0000|29 72|rat EFIA (gene encoding enhancer factor I subunit A)
P08224907A0000|29 35|rat EFIA
P08224907A0000|37 71|gene encoding enhancer factor I subunit A
P08224907A0000|103 123|cDNA subfragment probes
P08225657A0000|11 19|ibopamine
P08225657A0000|38 45|patients
P08225657A0000|50 76|NYHA Class I and II heart failure
P08225657A0000|100 111|double-blind
P08225657A0000|113 157|randomized placebo-controlled multi-centre trial
P08226616A0000|3 11|nit-3 gene
P08226616A0000|3 11|nit-3 gene
P08226616A0000|17 49|filamentous fungus Neurospora crassa
P08226616A0000|57 72|nitrate reductase
P08226616A0000|57 72|nitrate reductase
P08226616A0000|111 129|nitrate assimilation
P08226776A0990|0 8|Unfolding
P08226776A0990|26 41|two-state process
P08226776A0990|75 83|delta Hvan
P08226777A0936|40 45|DdPTPa
P08226777A0936|40 45|DdPTPa
P08226780A0160|30 48|protein interactions
P08226780A0160|60 66|ankyrin
P08226780A0160|60 66|ankyrin
P08226794A0501|0 14|[Ala85]Dk(69-85
P08226794A0501|0 8|[Ala85]Dk
P08226794A0501|10 14|69-85
P08226794A0501|27 44|biological activity
P08226798A1124|15 17|CaM
P08226798A1124|15 17|CaM
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|61 84|diverse modulatory effects
P08226798A1124|104 126|HIV-induced cytotoxicity
P08226798A1124|157 159|CaM
P08226798A1124|157 159|CaM
P08226798A1124|170 186|cellular functions
P08226956A1397|68 75|fad7 mRNA
P08226956A1397|68 75|fad7 mRNA
P08226956A1397|86 91|plants
P08227129T0000|8 27|myosin-binding domain
P08227129T0000|8 27|myosin-binding domain
P08227129T0000|30 49|skeletal muscle MyBP-C
P08227129T0000|44 49|MyBP-C
P08227129T0000|51 58|C protein
P08227129T0000|51 58|C protein
P08227129T0000|72 84|COOH-terminal
P08227129T0000|86 106|immunoglobulin C2 motif
P08227129T0000|86 106|immunoglobulin C2 motif
P08228805A0540|26 46|TCR signal transduction
P08228805A0540|26 28|TCR
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|84 89|p21ras
P08228805A0540|84 89|p21ras
P08228805A0540|110 112|TCR
P08228805A0540|110 112|TCR
P08228805A0540|116 154|protein tyrosine kinase dependent mechanism
P08228805A0540|116 136|protein tyrosine kinase
P08228997A0866|33 49|lipid accumulation
P08228997A0866|61 79|cortical oxygenation
P08229102A0768|17 33|QLMI questionnaire
P08229102A0768|76 77|QL
P08229102A0768|85 87|AMI
P08229102A0768|88 95|patients
P08229330A0000|4 10|smokers
P08229826A1145|3 20|inhibitory response
P08229826A1145|23 26|taps
P08229826A1145|51 56|reflex
P08229826A1145|144 154|hard objects
P08230418A0812|11 13|nef
P08230418A0812|11 13|nef
P08230418A0812|30 32|LTR
P08230418A0812|48 50|nef
P08230418A0812|48 50|nef
P08230418A0812|80 98|simian virus 40, c-fms
P08230418A0812|80 92|simian virus 40
P08230418A0812|94 98|c-fms
P08230418A0812|100 128|urokinase plasminogen activator
P08230418A0812|109 151|plasminogen activator, or type 5 acid phosphatase
P08230418A0812|132 151|type 5 acid phosphatase
P08230418A0812|161 184|trans-activating activity
P08230418A0812|205 214|frameshift
P08230418A0812|243 254|35 amino acids
P08230445A0000|15 33|vpr open reading frame
P08230445A0000|15 33|vpr open reading frame
P08230445A0000|36 66|human immunodeficiency virus type 1
P08230445A0000|36 66|human immunodeficiency virus type 1
P08230445A0000|68 72|HIV-1
P08230445A0000|68 72|HIV-1
P08230445A0000|77 83|15-kDa,
P08230445A0000|84 103|arginine-rich protein
P08230445A0000|119 125|virions
P08230445A0000|161 163|Gag
P08230445A0000|161 163|Gag
P08230452A0551|14 42|vaccinia virus-expressed mutant
P08230452A0551|37 56|mutant P1 polyproteins
P08230452A0551|43 56|P1 polyproteins
P08230452A0551|122 145|recombinant vaccinia virus
P08230452A0551|147 150|VVP3
P08230452A0551|168 188|poliovirus 3CD protease
P08230452A0551|178 188|3CD protease
P08230452A0551|236 256|complementation system
P08230452A0551|264 265|P1
P08230452A0551|277 302|recombinant vaccinia viruses
P08230452A0551|328 352|defective poliovirus genome
P08230452A0551|371 394|functional capsid proteins
P08230452A0551|381 394|capsid proteins
P08230452A0551|396 396|D
P08230452A1489|11 24|capsid proteins
P08230452A1489|39 40|P1
P08230452A1489|55 60|valine
P08230452A1489|78 90|amino terminus
P08230452A1489|93 95|VP1
P08230452A1489|93 95|VP1
P08230452A1489|97 105|VP1-G001V
P08230452A1489|97 105|VP1-G001V
P08230452A1489|116 135|empty capsid particles
P08230452A1489|164 184|RNA-containing virions
P08231398A0802|14 23|moth period
P08231398A0802|114 127|M. tuberculosis
P08231398A0802|143 156|prison patients
P08231398A0802|172 197|human immunodeficiency virus
P08231398A0802|218 234|immunosuppression
P08231398A0802|242 244|CD4
P08231398A0802|242 244|CD4
P08231577A1027|0 12|Acid instilled
P08231577A1027|26 40|maturing rabbits
P08231577A1027|62 72|obstructive
P08231577A1027|74 80|central
P08231816A1473|7 27|total-protein extracts
P08231816A1473|32 43|mycelia grown
P08231816A1473|93 111|DNA-binding activity
P08231816A1473|135 142|promoter
P08231816A1473|165 175|-654 and -455
P08231816A1473|187 193|IPNS tsp
P08231816A1473|187 190|IPNS
P08232304A1166|9 20|5'-deletions
P08232304A1166|45 51|218 to +4
P08232304A1166|59 61|TSS
P08232304A1166|75 90|promoter activity
P08232304A1166|121 173|promoterless chloramphenicol acetyltransferase construct
P08232304A1166|133 164|chloramphenicol acetyltransferase
P08232412A1342|3 12|lemdr1 gene
P08232412A1342|3 12|lemdr1 gene
P08232412A1342|43 49|pALTNEO
P08232412A1342|68 76|wild-type
P08232412A1342|77 87|L. enriettii
P08232412A1342|103 118|transfected cells
P08232412A1342|178 188|mutant cells
P08234166A0425|32 39|capsules
P08234166A0425|91 96|humans
P08234166A0425|115 126|RT conditions
P08234276A0556|7 27|synergistic activation
P08234276A0556|44 55|IL-8 promoter
P08234276A0556|44 55|IL-8 promoter
P08234276A0556|78 83|NF-IL6
P08234276A0556|78 83|NF-IL6
P08234276A0556|87 107|NF-kappa B binding sites
P08234276A0556|87 95|NF-kappa B
P08234308T0000|0 5|Notice
P08234308T0000|8 17|retraction
P08237112A0553|28 37|36K protein
P08237171A0000|38 54|suprapineal recess
P08237171A0000|58 64|patient
P08237171A0000|69 95|triventricular hydrocephalus
P08237578A0253|2 23|regards lipid metabolism
P08237578A0253|46 58|triglycerides
P08237578A0253|60 70|cholesterol
P08237578A0253|72 86|LDL-cholesterol
P08237578A0253|72 86|LDL-cholesterol
P08237578A0253|90 104|HDL-cholesterol
P08237578A0253|90 104|HDL-cholesterol
P08237578A0253|130 139|Norplant-2
P08238626A0248|3 7|PaCO2
P08238626A0248|30 32|pHi
P08239164A0551|4 17|reduced isotime
P08239164A0551|58 60|VO2
P08239164A0551|100 110|lung disease
P08239164A0551|155 162|patients
P08239164A0551|175 185|lung disease
P08239586T0000|54 60|rabbits
P08240170A0000|11 23|salmonellosis
P08240170A0000|68 70|sea
P08240170A0000|87 100|acute, subacute
P08240170A0000|104 117|chronic enteric
P08241139A0378|61 66|MgdTDP
P08241139A0378|102 112|nucleotides
P08241656A0189|66 79|cholelithiasis
P08241656A0189|83 103|Wildervanck's syndrome
P08242861A0368|4 14|4,8-DiMeIQx
P08242861A0368|18 24|A alpha C
P08242861A0368|18 24|A alpha C
P08243476A1177|5 12|cysteine
P08243476A1177|20 37|tryptophan residues
P08243476A1177|77 99|nitrous-oxide reductases
P08243476A1177|77 99|nitrous-oxide reductases
P08244034T0000|11 20|Leishmania
P08244034T0000|28 43|glycoprotein GP63
P08244034T0000|28 43|glycoprotein GP63
P08244034T0000|95 111|metalloproteinase
P08244034T0000|95 111|metalloproteinase
P08245013A0000|46 60|destabilization
P08245013A0000|63 66|mRNA
P08245013A0000|69 93|G-protein-linked receptors
P08245013A0000|69 93|G-protein-linked receptors
P08245013A0000|111 133|receptor down-regulation
P08245013A0000|167 185|long-term regulation
P08245013A0000|188 196|receptors
P08245013A0000|199 205|agonist
P08245125A0822|31 37|F-actin
P08245125A0822|31 37|F-actin
P08245125A0822|47 56|phalloidin
P08245125A0822|65 74|L266D actin
P08245125A0822|70 75|actin'
P08245456A0501|28 31|IL-5
P08245456A0501|28 31|IL-5
P08245456A0501|50 52|PMA
P08245456A0501|67 68|N6
P08245456A0501|82 85|cAMP
P08245456A0501|87 93|Bt2cAMP
P08245456A0501|113 115|PMA
P08245456A0501|146 149|IL-5
P08245456A0501|146 149|IL-5
P08245456A0501|165 168|mRNA
P08245456A0501|175 187|protein levels
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245461A0700|0 11|Hu-Met-1 mRNA
P08245461A0700|38 57|human T cell tumor lines
P08245933A0617|7 17|engorgement
P08246984A0512|0 20|Northern (RNA) analysis
P08246984A0512|45 59|human PI 3-kinase
P08246984A0512|50 59|PI 3-kinase
P08246984A0923|46 63|PI 3-kinase isoforms
P08246984A0923|46 63|PI 3-kinase isoforms
P08246984A0923|103 112|PI 3-kinase
P08246984A0923|103 112|PI 3-kinase
P08246984A0923|150 152|p85
P08246984A0923|150 152|p85
P08246987A0260|15 42|protein-tyrosine kinase domain
P08246987A0260|23 30|tyrosine
P08246987A0260|44 49|p56lck
P08246987A0260|44 49|p56lck
P08246987A0260|59 92|Src homology 2 and 3 (SH2 and SH3) domains
P08246987A0260|59 70|Src homology 2
P08246987A0260|74 74|3
P08246987A0260|76 78|SH2
P08246987A0260|82 84|SH3
P08246987A0260|108 123|N-terminal region
P08247005A0584|17 28|drs2 mutation
P08247005A0584|17 28|drs2 mutation
P08247005A0584|39 50|20S precursor
P08247005A0584|39 50|20S precursor
P08247005A0584|56 68|mature 18S rRNA
P08247005A0584|56 68|mature 18S rRNA
P08247005A0584|92 111|40S ribosomal subunits
P08247005A0584|92 103|40S ribosomal
P08247043T0000|0 32|Hepatitis B and liver transplantation
P08248246A0838|29 31|Sp1
P08248246A0838|29 31|Sp1
P08248246A0838|56 78|S-phase-specific binding
P08248246A0838|106 141|cell-cycle-dependent R1 gene expression
P08248246A0838|126 131|R1 gene
P08248253A1785|32 39|promoter
P08248253A1785|59 74|chicken L-CAM gene
P08248253A1785|59 70|chicken L-CAM
P08248688A0726|9 26|enzymic stimulation
P08248688A0726|42 48|nitrate
P08248688A0726|106 120|nitrate molecule
P08249319A0578|0 7|Clipping
P08249319A0578|68 92|epicortical potential field
P08249390A0111|13 28|diabetes mellitus
P08249390A0111|36 43|patients
P08249390A0111|75 82|patients
P08249390A0111|98 117|myocardial infarction
P08251506A0503|44 63|protein-DNA complexes
P08251506A0503|79 87|232 and 256
P08251506A0503|146 163|DRE oligonucleotide
P08251506A0503|173 174|97
P08251506A0503|176 178|105
P08251506A0503|183 198|115-kDa complexes
P08251506A0503|222 224|DRE
P08251622A0000|3 10|promoter
P08251622A0000|14 27|upstream region
P08251622A0000|33 69|Brassica napus 2S storage protein napA gene
P08251622A0000|33 47|Brassica napus 2S
P08251622A0000|62 69|napA gene
P08251622A0000|91 109|cis-acting sequences
P08251622A0000|120 155|developmental seed-specific expression
P08252067A0917|44 60|NH2 and COOH termini
P08252976A0467|0 4|Rinit
P08252976A0467|16 35|Newtonian resistances
P08252976A0467|57 102|viscoelastic/inhomogeneous pressure dissipations
P08253386A0800|39 65|fibronectin splicing enhancer
P08253386A0800|39 49|fibronectin
P08253386A0800|81 89|SE element
P08253386A0800|81 82|SE
P08253386A0800|183 189|U2 snRNP
P08253386A0800|183 189|U2 snRNP
P08253386A0800|194 212|branch site sequences
P08253387A0801|0 9|Inspection
P08253387A0801|12 26|enhancer mutants
P08253387A0801|39 54|trans-activation
P08253387A0801|57 65|hLEF/GAL4
P08253387A0801|57 60|hLEF
P08253387A0801|62 65|GAL4
P08253387A0801|89 93|TCF-2
P08253387A0801|89 93|TCF-2
P08253387A0801|104 125|T-cell-enriched protein
P08253387A0801|157 172|hLEF-binding site
P08253387A0801|157 172|hLEF-binding site
P08253387A0801|178 185|enhancer
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|52 85|cell- and context-specific activation
P08253387A1291|91 106|TCR alpha enhancer
P08253387A1291|91 106|TCR alpha enhancer
P08253387A1291|142 145|hLEF
P08253387A1291|142 145|hLEF
P08253387A1291|154 175|T-cell-specific factors
P08253387A1291|190 197|enhancer
P08253777A0301|1 19|cAMP response element
P08253777A0301|21 23|CRE
P08253777A0301|58 75|5'-noncoding region
P08253777A0301|77 80|cAMP
P08253777A0301|105 113|Kv1.5 gene
P08253777A0301|105 109|Kv1.5
P08253777A0301|117 135|cell-specific manner
P08253958A0000|9 24|serological tests
P08253958A0000|47 97|Helicobacter pylori-specific serum immunoglobulin G (IgG
P08253958A0000|79 93|immunoglobulin G
P08253958A0000|95 97|IgG
P08254738A0428|14 28|mutant T antigens
P08254738A0428|14 28|mutant T antigens
P08254738A0428|40 63|recombinant baculoviruses
P08254738A0428|66 73|Sf9 cells
P08254738A0428|88 112|origin unwinding activities
P08254738A0428|119 127|TS677-->A
P08254738A0428|131 139|TS677,679
P08254738A0428|143 143|A
P08254738A0428|161 175|T-antigen kinase
P08254738A0428|161 175|T-antigen kinase
P08254738A0428|181 197|wild-type T antigen
P08254738A0428|190 197|T antigen
P08255022A0827|11 23|hypoperfusion
P08255022A0827|54 57|FEV1
P08255022A0827|62 64|V25
P08255022A0827|68 71|PaO2
P08255022A0827|85 106|circulating blood volume
P08255022A0827|120 137|red blood cell counts
P08255341A0554|3 10|patients
P08255341A0554|52 64|metronidazole
P08255341A0554|67 82|tissue amoebicide
P08255341A0554|87 96|diloxanide
P08255758A0000|21 40|5' untranslated region
P08255758A0000|46 75|Drosophila copia retrotransposon
P08255758A0000|46 75|Drosophila copia retrotransposon
P08255758A0000|84 87|left
P08255758A0000|88 90|LTR
P08255758A0000|104 128|transcriptional regulation
P08257666A0662|30 39|OPT complex
P08257666A0662|71 73|IHA
P08257666A0662|71 73|IHA
P08257666A0662|77 78|HD
P08257666A0662|77 78|HD
P08257754A0711|61 72|HB antibodies
P08257754A0711|125 136|HB antibodies
P08257754A0711|125 136|HB antibodies
P08258025A1131|74 87|Karnofsky index
P08258025A1131|92 115|graft-versus-host disease
P08259650A0640|0 17|Nucleotide sequence
P08259650A0640|31 36|HA gene
P08259650A0640|31 36|HA gene
P08259650A0640|66 77|HA- phenotype
P08259650A0640|66 67|HA
P08260635A0926|28 35|position
P08260635A0926|57 63|intron 1
P08260635A0926|69 88|transit peptide region
P08260635A0926|91 111|chloroplast GAPDH genes
P08260635A0926|102 111|GAPDH genes
P08260635A0926|113 116|GapA
P08260635A0926|113 116|GapA
P08260635A0926|120 123|GapB
P08260635A0926|120 123|GapB
P08260635A0926|133 138|plants
P08261398A0392|17 48|cell lines P388/ADR/3 and P388/ADR/7
P08261398A0392|66 90|topo II alpha mRNA transcript
P08261398A0392|66 80|topo II alpha mRNA
P08261398A0392|134 161|drug-sensitive P388/4 cell line
P08261398A0838|29 36|cDNA ends
P08261398A0838|58 62|cDNAs
P08261398A0838|78 87|3'-termini
P08261398A0838|97 111|native and mutant
P08261398A0838|131 158|P388/ADR/3 and P388/ADR/7 cells
P08262041A0727|3 14|phi AP3 factor
P08262041A0727|6 14|AP3 factor
P08262041A0727|18 38|nuclear phosphoprotein
P08262041A0727|54 68|phosphorylation
P08262041A0727|89 97|cell cycle
P08262054A0565|13 39|N-terminal cytoplasmic domain
P08262054A0565|13 39|N-terminal cytoplasmic domain
P08262054A0565|45 67|latent membrane protein 2A
P08262054A0565|45 67|latent membrane protein 2A
P08262054A0565|69 73|LMP2A
P08262054A0565|69 73|LMP2A
P08262054A0565|80 101|Epstein-Barr virus (EBV)
P08262054A0565|80 96|Epstein-Barr virus
P08262054A0565|98 100|EBV
P08262054A0565|126 156|Tyr-X-X-Leu/Ile-containing motif
P08262054A0565|126 132|Tyr-X-X
P08262054A0565|186 204|B cell transformation
P08262067A1608|3 20|functional homology
P08262067A1608|23 26|Cwg2
P08262067A1608|23 26|Cwg2
P08262067A1608|31 35|Cdc43
P08262067A1608|31 35|Cdc43
P08262067A1608|106 127|two morphogenetic events
P08262067A1608|164 183|cell wall biosynthesis
P08263933T0000|0 15|Molecular cloning
P08263933T0000|19 34|P-type ATPase gene
P08263933T0000|19 34|P-type ATPase gene
P08263933T0000|56 70|Synechocystis sp
P08264579A1209|12 15|PTR2
P08264579A1209|12 15|PTR2
P08264579A1209|81 97|eucaryotic peptide
P08264582A0750|10 37|full-length cytoplasmic domain
P08264582A0750|21 37|cytoplasmic domain
P08264582A0750|63 87|carboxy-terminal deletions
P08264582A0750|109 122|point mutations
P08264582A0750|147 163|amino acid residues
P08264582A0750|166 169|LIFR
P08264582A0750|166 169|LIFR
P08264582A0750|200 208|signaling
P08264583A0520|44 58|nuclear extracts
P08264583A0520|89 106|mammalian cell lines
P08264591A1190|40 54|RNA polymerase II
P08264591A1190|40 54|RNA polymerase II
P08264591A1190|58 62|TFIIB
P08264591A1190|58 62|TFIIB
P08264591A1190|122 133|S. cerevisiae
P08264617A0000|24 42|chimeric EGFR/ErbB-3
P08264617A0000|32 35|EGFR
P08264617A0000|37 50|ErbB-3 receptor
P08264617A0000|53 69|NIH 3T3 fibroblasts
P08264617A0000|123 128|ErbB-3
P08264617A0000|123 128|ErbB-3
P08264617A0000|151 166|ligand activation
P08264628A0418|0 14|Oligonucleotide
P08264628A0418|65 80|TATA-binding site
P08264628A0418|65 80|TATA-binding site
P08264628A0418|83 88|TIF-IB
P08264628A0418|83 88|TIF-IB
P08264628A0418|90 94|TFIID
P08264628A0418|90 94|TFIID
P08264628A0418|99 104|TFIIIB
P08264628A0418|99 104|TFIIIB
P08264631A0746|26 37|ADR1 activity
P08264631A0746|26 29|ADR1
P08264631A0746|56 58|TAD
P08264631A0746|56 58|TAD
P08264631A0746|68 86|ADR1, ADR1 DNA binding
P08264631A0746|68 71|ADR1
P08264631A0746|73 76|ADR1
P08264631A0746|99 119|ADH2 promoter sequences
P08264631A0746|99 119|ADH2 promoter sequences
P08264650A0925|28 43|mds1 null mutation
P08264650A0925|28 35|mds1 null
P08264650A0925|60 63|MDS1
P08264650A0925|60 63|MDS1
P08264650A0925|131 137|meiosis
P08264664A0128|0 17|TGF beta 1 expression
P08264664A0128|0 7|TGF beta 1
P08264664A0128|42 57|AP-1 binding sites
P08264664A0128|42 57|AP-1 binding sites
P08265602T0000|0 2|Val
P08265602T0000|6 8|Ala
P08265602T0000|34 51|helix-helix packing
P08265602T0000|57 76|transmembrane segment
P08265602T0000|79 97|phage M13 coat protein
P08265602T0000|79 97|phage M13 coat protein
P08265955T0000|0 14|Strategic change
P08265955T0000|20 22|NHS
P08267658A0391|30 31|UW
P08267658A0391|47 63|K(+)-lactobionate
P08267658A0391|65 70|KH2PO4
P08267658A0391|72 76|MgSO4
P08267658A0391|80 88|raffinose
P08267658A0391|128 141|rat hepatocytes
P08267658A0391|152 171|drug transport studies
P08267667A0748|24 27|GRg2
P08267667A0748|63 94|CYP-induced recognitional deficits
P08267667A0748|63 65|CYP
P08267667A0748|110 112|CYP
P08267667A0748|185 187|5.6
P08268718A0676|0 15|Human bcl3 protein
P08268718A0676|0 15|Human bcl3 protein
P08268718A0676|38 55|p50)2-DNA complexes
P08268718A0676|38 40|p50
P08268833T0000|3 19|therapeutic action
P08268833T0000|22 33|cyclosporin A
P08268833T0000|35 43|Sandimmun
P08268833T0000|62 80|rheumatoid arthritis
P08268912A0657|37 65|human cDNA derived RNA translates
P08268912A0657|37 55|human cDNA derived RNA
P08268912A0657|83 97|mobility of 44-46
P08268912A0657|102 122|SDS polyacrylamide gels
P08269424A0339|5 28|peripheral administration
P08269424A0339|35 37|CRF
P08269424A0339|35 37|CRF
P08269424A0339|41 43|TRH
P08269424A0339|41 43|TRH
P08269424A0339|45 54|ACTH levels
P08269424A0339|45 48|ACTH
P08269424A0339|83 91|tumor side
P08269424A0339|97 104|patients
P08269439X0000|0 19|Pentazocine analgesia
P08269439X0000|37 44|Talwin Nx
P08269439X0000|101 115|acute dental pain
P08270257A0551|1 24|sequence homology analysis
P08270257A0551|32 43|human nm23-H1
P08270257A0551|32 43|human nm23-H1
P08270257A0551|66 68|rat
P08270257A0551|70 78|NDP-K beta
P08270257A0551|70 78|NDP-K beta
P08270257A0551|89 99|exon-intron
P08270580A0155|1 18|favourable response
P08270580A0155|48 60|amphotericin B
P08270580A0155|64 76|cotrimoxazole
P08270985A0590|8 16|durations
P08273122A0708|27 38|QA/QI process
P08273122A0708|52 79|blood administration practices
P08273122A0708|105 122|institutional blood
P08273122A0708|168 196|blood and component transfusions
P08274774A0958|11 15|REP21
P08274774A0958|16 21|plants
P08274774A0958|82 98|tomato mosaic virus
P08274774A0958|100 106|tobacco
P08274774A0958|128 133|TMV-U5
P08274774A0958|128 133|TMV-U5
P08275618A0457|0 9|Drug effect
P08275618A0457|21 32|postural sway
P08275618A0457|53 60|patients
P08275618A0457|65 73|cirrhosis
P08275618A0457|77 91|control subjects
P08275618A0457|225 232|patients
P08275618A0457|237 245|cirrhosis
P08275618A0457|252 266|control subjects
P08276234A0119|21 23|YY1
P08276234A0119|21 23|YY1
P08276234A0119|26 64|ubiquitously expressed DNA-binding protein
P08276234A0119|47 64|DNA-binding protein
P08276234A0119|91 103|c-fos promoter
P08276234A0119|91 95|c-fos
P08276234A0119|130 141|DNA structure
P08276336A0371|56 66|685 patients
P08276336A0371|104 115|hyperplastic
P08276336A0371|119 135|adenomatous polyps
P08276732A0799|9 17|decrement
P08276732A0799|20 33|DPOAE amplitude
P08276732A0799|101 114|acoustic trauma
P08276762T0000|33 39|glycine
P08276762T0000|44 48|codon
P08276762T0000|51 76|gramicidin S synthetase 2 gene
P08276762T0000|51 72|gramicidin S synthetase 2
P08276762T0000|79 95|proline activation
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|36 61|putative ATP-binding domains
P08276851A0347|44 61|ATP-binding domains
P08276851A0347|109 127|ATP-binding proteins
P08276851A0347|109 127|ATP-binding proteins
P08276851A0347|138 156|biological processes
P08276851A0347|205 220|protein transport
P08276851A0347|222 237|cell cycle control
P08276851A0347|242 266|transcriptional regulation
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|180 196|gene transcription
P08276865A1188|3 17|kinase inhibitor
P08276865A1188|64 84|epidermal growth factor
P08276865A1188|64 84|epidermal growth factor
P08276865A1188|106 111|p21ras
P08276865A1188|106 111|p21ras
P08276865A1188|115 123|MAP kinase
P08276865A1188|115 123|MAP kinase
P08276865A1188|176 186|LPA receptor
P08276865A1188|176 186|LPA receptor
P08276865A1188|189 194|p21ras
P08276865A1188|189 194|p21ras
P08276871A1001|70 71|91
P08276871A1001|106 139|transmembrane and cytoplasmic domains
P08276900A0543|0 0|S
P08277632A0997|3 14|survival rate
P08277632A0997|32 39|patients
P08277632A0997|44 52|N2 disease
P08277632A0997|65 76|R2b operation
P08278423A0147|0 6|Mothers
P08278423A0147|11 39|severe anatomical abnormalities
P08278423A0147|47 57|HIV positive
P08278423A0147|69 70|TB
P08278423A0147|78 85|children
P08278423A0147|106 129|disaccharide intolerances
P08278480T0002|0 0|G
P08278548A0597|3 6|psaD
P08278548A0597|3 6|psaD
P08278548A0597|8 11|psaF
P08278548A0597|8 11|psaF
P08278548A0597|13 16|psaH
P08278548A0597|13 16|psaH
P08278548A0597|21 32|psaL products
P08278548A0597|21 24|psaL
P08278548A0597|134 144|psaE product
P08278548A0597|134 144|psaE product
P08278548A0597|152 159|isoforms
P08278929A0866|4 17|Hy-Vac SPF type V
P08278929A0866|18 24|embryos
P08278929A0866|62 64|CRS
P08278929A0866|75 77|CRS
P08278929A0866|89 95|ethanol
P08278929A0866|104 110|embryos
P08278929A0866|118 120|VSD
P08278929A0866|168 175|controls
P08279098T0001|0 39|Peripheral vitreochorioretinal dystrophies
P08279098T0001|42 55|myopia patients
P08280476A0602|23 56|HIV-1 HXB2 and HIV-1 Z2Z6 core enhancers
P08280476A0602|23 27|HIV-1
P08280476A0602|28 31|HXB2
P08280476A0602|35 39|HIV-1
P08280476A0602|40 56|Z2Z6 core enhancers
P08280476A0602|67 76|Z2Z6 strain
P08280476A0602|67 70|Z2Z6
P08280476A0602|111 130|right ETS-binding site
P08280476A0602|116 130|ETS-binding site
P08280925A0261|3 11|secondary
P08280925A0261|30 46|antibody responses
P08280925A0261|60 63|mice
P08280925A0261|79 82|mice
P08280925A0261|104 107|mice
P08280925A0261|153 155|IgM
P08280925A0261|153 155|IgM
P08280925A0261|159 179|IgG anti-KLH antibodies
P08280925A0261|159 179|IgG anti-KLH antibodies
P08281153A0543|47 61|intron sequences
P08281536A0626|0 12|Interleukin-6
P08281536A0626|0 12|Interleukin-6
P08281536A0626|34 43|metastasis
P08281536A0626|46 58|cardiac myxoma
P08281634A1801|17 20|iron
P08281634A1801|41 48|ferritin
P08281634A1801|41 48|ferritin
P08281740A0000|14 39|Plowright Rinderpest vaccine
P08281740A0000|103 115|IgG antibodies
P08281740A0000|103 115|IgG antibodies
P08281740A0000|147 156|ELISA assay
P08282501A0358|128 132|ionic
P08282576A0297|0 6|Tumours
P08282576A0297|12 20|cavum oris
P08282576A0297|24 33|oropharynx
P08282749A1474|0 5|Thomas
P08282749A1474|50 64|metabolic demand
P08282749A1474|70 88|ischaemic myocardium
P08282749A1474|121 133|cardiac arrest
P08283292A0779|0 9|Plasma, LDL
P08283292A0779|7 28|LDL and liver cholesterol
P08283292A0779|13 42|liver cholesterol concentrations
P08283292A0779|58 78|hyperlipidemic control
P08283292A0779|147 152|pectin
P08283292A0779|155 164|prune fiber
P08283292A0779|174 199|hyperlipidemic control group
P08283531A0700|47 49|HM3
P08283531A0700|121 135|ureteral calculi
P08283531A0700|157 162|gantry
P08284227A0336|0 23|Glomerular mesangial cells
P08284227A0336|43 61|1.1 kb mRNA transcript
P08284227A0336|65 67|Id1
P08284227A0336|98 104|Id1 mRNA
P08284227A0336|101 104|mRNA
P08284227A0336|131 142|cycling cells
P08284227A0336|148 161|serum-deprived
P08284227A0336|163 179|quiescent cultures
P08284337A0825|0 27|Routine psychometric screening
P08284337A0825|30 40|IHD patients
P08284337A0825|73 93|alerting cardiologists
P08284337A0825|134 141|distress
P08284337A0825|152 159|patients
P08285710A0634|7 26|1.8-kb transcript mRNA
P08285710A0634|40 64|Northern (RNA) blot analysis
P08285710A0634|72 76|5' end
P08285710A0634|92 103|51 bp upstream
P08285710A0634|129 144|protein synthesis
P08286035A0587|36 40|c11/1
P08286035A0587|36 40|c11/1
P08286035A0587|45 62|c11/1-specific cDNA
P08286035A0587|45 62|c11/1-specific cDNA
P08286035A0587|79 89|poly(A)+RNA
P08286035A0587|98 102|PMNLs
P08286035A0587|105 124|reverse transcription
P08286035A0587|142 164|polymerase chain reaction
P08286035A0587|166 176|PCR) methods
P08288240A0304|37 41|SCG10
P08288240A0304|37 41|SCG10
P08288240A0304|45 52|stathmin
P08288240A0304|108 112|genes
P08288240A1343|40 63|neuron-specific SCG10 gene
P08288240A1343|40 59|neuron-specific SCG10
P08288240A1343|124 131|stathmin
P08288240A1343|133 137|Lap18
P08288554A0295|10 26|amino acid sequence
P08288554A0295|32 44|mouse HO-1 gene
P08288554A0295|32 44|mouse HO-1 gene
P08288554A0295|64 66|p32
P08288554A0295|64 66|p32
P08288554A0295|90 110|stress-induced protein
P08288554A0295|113 131|mouse BALBc/3T3 cells
P08288596A0663|11 12|T3
P08288596A0663|11 12|T3
P08288596A0663|14 18|10(-8
P08288596A0663|60 76|rGH-TRE- and TREpal
P08288596A0663|60 62|rGH
P08288596A0663|85 121|ME-TRE- and F2-TRE-, containing templates
P08288596A0663|134 137|TREs
P08288596A0663|159 176|rGH minimal promoter
P08288596A0663|159 176|rGH minimal promoter
P08288596A0663|194 214|TATA box binding protein
P08288596A0663|194 214|TATA box binding protein
P08288596A0663|230 260|proximal binding protein, sequence
P08288606A0240|6 42|polymerase chain reaction-based approach
P08288606A0240|53 72|150-base pair fragment
P08288606A0240|93 109|human placenta mRNA
P08288606A0240|194 204|cDNA library
P08288622A0725|62 68|HDC mRNA
P08288622A0725|62 68|HDC mRNA
P08288622A0725|95 115|seventh intron sequence
P08288622A0725|163 170|12th exon
P08288633A0144|1 16|complementary DNA
P08288633A0144|32 52|Caenorhabditis elegans
P08288633A0144|78 81|1438
P08288633A0144|82 98|amino acid residues
P08288633A0144|100 104|CeGAP
P08288633A0144|100 104|CeGAP
P08288633A0144|153 172|COOH-terminal segment
P08288633A0144|153 172|COOH-terminal segment
P08288633A0144|174 203|GTPase-activating protein region
P08288633A0144|174 203|GTPase-activating protein region
P08288633A0144|207 209|Bcr
P08288633A0144|207 209|Bcr
P08288633A0144|223 247|GTPase-activating proteins
P08288633A0144|223 247|GTPase-activating proteins
P08288633A0144|253 264|Rho subfamily
P08288633A0144|253 264|Rho subfamily
P08289339A0527|10 33|exonuclease III protection
P08289339A0527|54 63|core region
P08289339A0527|73 84|5' and 3' sides
P08289339A0527|100 101|E1
P08289339A0527|100 101|E1
P08289339A0527|120 134|distal sequences
P08289341A1202|36 37|E2
P08289341A1202|36 37|E2
P08289341A1202|46 62|(for E2-C) promoter
P08289341A1202|50 53|E2-C
P08289341A1202|63 77|-proximal copies
P08289341A1202|80 84|E2-RS
P08289341A1202|80 84|E2-RS
P08289342A0931|12 14|AAV
P08289342A0931|38 40|trs
P08289342A0931|57 70|DNA replication
P08289342A0931|76 87|in vitro assay
P08289357A0724|22 24|rep
P08289357A0724|22 24|rep
P08289357A0724|54 79|negative regulatory elements
P08289357A0724|85 87|LTR
P08289593A1404|20 29|ventilated
P08289593A1404|30 33|rats
P08289593A1404|49 54|MK-801
P08289593A1404|133 136|rats
P08289593A1404|175 180|MK-801
P08289593A1404|199 209|respiratory
P08289593A1404|216 222|cardiac
P08289593A1404|242 265|urethane anesthetized rats
P08289783A0000|3 20|Oct-3/4 gene product
P08289783A0000|3 20|Oct-3/4 gene product
P08289783A0000|39 69|POU family of transcription factors
P08289783A0000|39 47|POU family
P08289783A0000|50 69|transcription factors
P08289783A0000|100 130|initial differentiation decisions
P08289783A1476|5 28|site-directed mutagenesis
P08289783A1476|43 49|RAREoct
P08289783A1476|43 49|RAREoct
P08289783A1476|93 107|Oct-3/4 promoter
P08289783A1476|93 99|Oct-3/4
P08289783A1476|110 117|P19 cells
P08289783A1476|151 170|RA-induced repression
P08289783A1476|173 196|RA-differentiated EC cells
P08289784A0381|0 2|176
P08289793A1226|23 43|transcriptional effect
P08289793A1226|46 53|COUP-TFs
P08289793A1226|46 53|COUP-TFs
P08289793A1226|92 129|Oct4 embryonic stem cell-specific enhancer
P08289793A1226|92 129|Oct4 embryonic stem cell-specific enhancer
P08289831A0290|10 16|mig/CAT
P08289831A0290|10 12|mig
P08289831A0290|14 16|CAT
P08289831A0290|17 34|chimeric constructs
P08289831A0290|64 93|RAW 264.7 mouse monocytic cell line
P08289831A0290|109 135|IFN-gamma-responsive element
P08289831A0290|109 135|IFN-gamma-responsive element
P08289831A0290|137 145|gamma RE-1
P08289831A0290|142 145|RE-1
P08289834A0341|30 34|Atr-I
P08289834A0341|30 34|Atr-I
P08289834A0341|49 56|TGF-beta
P08289834A0341|49 56|TGF-beta
P08289834A0341|58 64|activin
P08289834A0341|58 64|activin
P08289834A0341|68 92|bone morphogenetic protein 2
P08290278A0374|10 13|Mxi1
P08290278A0374|10 13|Mxi1
P08290278A0374|17 19|Mad
P08290278A0374|17 19|Mad
P08290278A0374|35 37|Myc
P08290278A0374|35 37|Myc
P08290278A0374|61 80|tumor suppressor genes
P08290421A0165|19 40|IV renal tubular acidosis
P08290421A0165|86 101|Alport's syndrome
P08290421A0165|106 117|adult patient
P08291233A0000|1 9|cDNA clone
P08291233A0000|26 38|chicken embryo
P08291233A0000|39 49|cDNA library
P08291233A0000|60 72|PCR-generated
P08291233A0000|73 89|radiolabeled probe
P08291233A0000|104 111|U3 region
P08291233A0000|104 111|U3 region
P08291233A0000|117 135|Rous sarcoma virus LTR
P08291233A0000|117 132|Rous sarcoma virus
P08291233A0000|133 135|LTR
P08291620A0372|3 15|basic patterns
P08291620A0372|18 34|locomotor behavior
P08291620A0372|51 65|torso morphology
P08291620A0372|76 92|extant anthropoids
P08291761A0416|6 8|age
P08291761A0416|40 53|CSF composition
P08291761A0416|58 65|serum IgG
P08291761A0416|63 65|IgG
P08293412T0000|1 10|randomized
P08293412T0000|65 75|tropisetron
P08293412T0000|81 103|5-HT3 receptor antagonist
P08293412T0000|81 93|5-HT3 receptor
P08293412T0000|110 144|metoclopramide-containing antiemetic
P08293412T0000|170 192|cisplatin-induced emesis
P08293992A0432|4 9|repeat
P08293992A0432|37 54|reiterated sequence
P08293992A0432|56 61|K/NPAG
P08293993A0948|0 2|ENV
P08293993A0948|0 2|ENV
P08293993A0948|22 31|P. pastoris
P08293993A0948|40 63|S. cerevisiae alpha-factor
P08293993A0948|40 51|S. cerevisiae
P08293993A0948|91 111|S. cerevisiae invertase
P08293993A0948|91 102|S. cerevisiae
P08294386A0000|59 68|depression
P08294386A0000|100 107|patients
P08294386A0000|112 126|major depression
P08294386A0000|205 214|blood level
P08294429A0153|19 25|hGH gene
P08294429A0153|19 25|hGH gene
P08294429A0153|28 44|hGH 5'-flanking DNA
P08294429A0153|28 30|hGH
P08294429A0153|31 44|5'-flanking DNA
P08294429A0153|46 50|5'-FR
P08294429A0153|46 50|5'-FR
P08294429A0153|64 121|hGh cDNA or chloramphenicol acetyltransferase or luciferase genes
P08294429A0153|64 70|hGh cDNA
P08294429A0153|73 104|chloramphenicol acetyltransferase
P08294429A0153|107 121|luciferase genes
P08294429A0153|136 139|cAMP
P08294429A0153|159 177|hGH promoter activity
P08294429A0153|159 169|hGH promoter
P08294459A0446|3 28|predicted amino acid sequence
P08294459A0446|34 42|SAP-1 cDNA
P08294459A0446|34 38|SAP-1
P08294459A0446|39 42|cDNA
P08294459A0446|59 63|SAP-1
P08294459A0446|59 63|SAP-1
P08294459A0446|93 113|transmembrane-type PTP
P08294459A0446|93 113|transmembrane-type PTP
P08294459A0446|136 154|PTP-conserved domain
P08294459A0446|136 154|PTP-conserved domain
P08294459A0446|160 176|cytoplasmic region
P08294511A0639|36 47|69-kD protein
P08294511A0639|36 47|69-kD protein
P08294511A0639|69 87|U1-specific, protein
P08294511A0639|69 87|U1-specific, protein
P08294511A0639|115 132|snRNP core particles
P08294511A0639|135 160|protein-protein interaction
P08294511A0639|135 149|protein-protein
P08294865A0236|89 107|peptide/DR complexes
P08294906A1315|34 71|neurotransmitters glutamate and aspartate
P08294906A1315|95 114|excitatory amino acids
P08296434A1141|3 18|Harleco apparatus
P08296434A1141|89 113|life-threatening condition
P08297376A0236|0 14|Co-transfection
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|66 76|C/EBP) alpha
P08297376A0236|66 76|C/EBP) alpha
P08297376A0236|80 88|C/EBP beta
P08297376A0236|80 88|C/EBP beta
P08297376A0236|107 138|rat uncoupling protein gene promoter
P08297376A0236|107 130|rat uncoupling protein gene
P08297376A0236|158 173|5' proximal region
P08298129A0274|80 96|beta 3 gene promoter
P08298129A0274|80 88|beta 3 gene
P08298129T0000|31 47|TATA-less promoter
P08298129T0000|54 75|human beta 3 integrin gene
P08298129T0000|54 75|human beta 3 integrin gene
P08299181A1148|0 14|Subretinal fluid
P08299181A1148|45 48|eyes
P08299181A1148|76 79|eyes
P08299568A1401|38 44|enzymes
P08299568A1401|66 81|acute stimulation
P08299568A1401|84 99|glucose transport
P08299725A0724|43 56|brain and muscle
P08299725A0724|74 87|tumor cell lines
P08299725A0724|144 148|5' end
P08299896A0626|0 10|Concordance
P08299896A0626|13 22|IBDQ scores
P08299896A0880|22 31|IBDQ scores
P08299896A0880|60 67|patients
P08299896A0880|110 112|[b]
P08300463A0581|0 11|Praziquantel
P08300463A0581|60 77|neurocysticercosis
P08300527T0000|12 32|erythromycin synthesis
P08300527T0000|47 84|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|47 80|malonyl-coenzyme A decarboxylase gene
P08300527T0000|81 84|eryM
P08300527T0000|87 112|Saccharopolyspora erythraea
P08300601A0745|47 50|MyoD
P08300601A0745|47 50|MyoD
P08300601A0745|54 66|E12 homodimers
P08300601A0745|54 56|E12
P08300601A0745|57 66|homodimers
P08300601A0745|70 89|E12/MyoD heterodimers
P08300601A0745|70 72|E12
P08300601A0745|74 77|MyoD
P08300605A0432|0 22|Transcriptional analysis
P08300605A0432|34 48|deletion mutants
P08300605A0432|63 77|nuclear extracts
P08300605A0432|93 98|middle
P08300605A0432|124 135|instar larvae
P08300605A0432|165 186|cis-regulatory elements
P08300605A0432|198 218|upstream and downstream
P08300605A0432|224 237|initiation site
P08300605A0671|22 47|homeodomain-binding element
P08300605A0671|22 47|homeodomain-binding element
P08300605A0671|71 88|negative regulation
P08300611A0341|0 23|Site-directed mutagenesis
P08300611A0341|29 46|traI structural gene
P08300611A0341|29 46|traI structural gene
P08300611A0341|71 80|mutant TraI
P08300611A0341|77 88|TraI proteins
P08300611A0341|92 104|in vitro assays
P08300611A0341|155 171|amino acid residues
P08300611T0000|0 14|Concerted action
P08300611T0000|42 77|DNA cleaving-joining reaction catalyzed
P08300611T0000|80 87|relaxase
P08300611T0000|80 87|relaxase
P08300611T0000|89 92|TraI
P08300611T0000|89 92|TraI
P08300611T0000|107 116|plasmid RP4
P08300625A1352|3 23|COOH-terminal 46 codons
P08300625A1352|26 29|slyD
P08300625A1352|26 29|slyD
P08300625A1352|37 75|remarkable histidine-rich peptide sequence
P08300625A1352|110 121|slyD function
P08300625A1352|110 113|slyD
P08300625A1352|124 138|E-mediated lysis
P08301702A1083|0 21|Monospecific antibodies
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301702A1083|79 95|hepatic microsomes
P08301702A1083|101 123|double-crested cormorant
P08301702A1083|144 157|great blue heron
P08301702A1083|159 171|Ardea herodias
P08301702A1083|179 192|immunoblotting
P08301841A0000|9 28|GSH-Px enzyme activity
P08301841A0000|9 20|GSH-Px enzyme
P08301841A0000|41 65|acute myocardial infarction
P08301841A0000|67 69|AMI
P08301841A0000|82 95|angina pectoris
P08301841A0000|97 99|UAP
P08302589A1132|3 25|HGF-induced cell motility
P08302589A1132|3 5|HGF
P08302589A1132|39 75|12-0-tetradecanoyl-phorbol-13-acetate
P08302589A1132|78 114|protein kinase C-activating phorbol ester
P08302589A1132|78 91|protein kinase C
P08302589A1132|124 136|Ca2+ ionophore
P08303233A0313|75 78|text
P08304301A0331|27 38|intrahepatic
P08304301A0331|56 58|HCC
P08304301A0331|106 109|HCCs
P08304342A0605|55 103|hemochromatosis chromosomes and 182 normal chromosomes
P08304342A0605|108 111|RFLP
P08304342A0605|151 180|newly derived polymorphic markers
P08304342A0605|194 202|HLA-F loci
P08304342A0605|194 202|HLA-F loci
P08304342A0605|210 212|150
P08304342A0605|232 236|HLA-A
P08304342A0605|232 236|HLA-A
P08305058T0000|0 11|Pneumothorax
P08305058T0000|45 63|diaphragmatic hiatus
P08306356A0000|9 29|cortical malformations
P08306356A0000|44 47|rats
P08306356A0000|63 68|X-rays
P08306834A0866|0 8|T2 cancers
P08306834A0866|44 66|preoperative irradiation
P08306959A0278|0 7|IFN alpha
P08306959A0278|0 7|IFN alpha
P08306959A0278|11 18|IFN gamma
P08306959A0278|11 18|IFN gamma
P08306959A0278|78 88|palindromic
P08306959A0278|101 122|IFN gamma activation site
P08306959A0278|101 122|IFN gamma activation site
P08306959A0278|124 126|GAS
P08306959A0278|124 126|GAS
P08307338A0227|0 8|Mutations
P08307338A0227|14 24|nuclear gene
P08307338A0227|14 24|nuclear gene
P08307338A0227|25 28|CBP1
P08307338A0227|25 28|CBP1
P08307338A0227|31 53|Saccharomyces cerevisiae
P08307338A0227|75 107|mitochondrially encoded cytochrome b
P08307338A0227|75 107|mitochondrially encoded cytochrome b
P08307338A0227|109 115|cob) RNA
P08307338A0227|109 111|cob
P08307564A0233|12 31|sequence-tagged sites
P08307564A0233|33 36|STSs
P08308008A0201|41 62|GA-binding protein (GABP
P08308008A0201|41 57|GA-binding protein
P08308008A0201|59 62|GABP
P08308008A0201|66 82|ets sequence motifs
P08308008A0201|66 82|ets sequence motifs
P08308008A0201|118 142|transcriptional activation
P08308008A0201|148 160|COXIV promoter
P08308008A0201|148 160|COXIV promoter
P08309726A0000|44 75|adult respiratory distress syndrome
P08309726A0000|77 80|ARDS
P08309726A0000|147 185|circulating polymorphonuclear neutrophils
P08309726A0000|187 189|PMN
P08309726A0000|192 205|cytokine levels
P08309726A0000|223 232|lung injury
P08309726A0000|237 244|patients
P08309726A0000|252 255|ARDS
P08309726A0000|277 289|uncomplicated
P08309726A0000|292 295|ARDS
P08309726A0000|301 330|mechanically ventilated patients
P08309726A0000|342 345|ARDS
P08309912A0306|0 9|Amiodarone
P08309953A0776|27 53|dopamine receptor stimulation
P08309953A0776|27 42|dopamine receptor
P08309953A0776|65 80|dopamine agonists
P08309957A0000|0 13|Two experiments
P08309957A0000|37 55|vacuous jaw movements
P08309957A0000|71 89|acute administration
P08309957A0000|95 118|monoamine-depleting agent
P08309957A0000|119 127|reserpine
P08309975A0662|11 18|dopamine
P08309975A0662|24 30|nucleus
P08309975A0662|106 118|lever pressing
P08309975A0662|157 163|lab chow
P08312243A0177|38 41|EDTA
P08312243A0177|73 79|Na2EDTA
P08312243A0177|83 84|Zn
P08312243A0177|86 87|Cu
P08312243A0177|91 102|Ca metabolism
P08312243A0177|105 108|rats
P08312243A0177|114 115|Zn
P08312243A0177|130 169|Zn-deficient soya-bean-isolate-based diets
P08314163T0000|0 7|Recovery
P08314163T0000|10 43|carbimazole-induced agranulocytosis
P08314163T0000|64 108|granulocyte-macrophage colony stimulating factor
P08314163T0000|64 108|granulocyte-macrophage colony stimulating factor
P08314163T0000|110 117|rhGM-CSF
P08314163T0000|110 117|rhGM-CSF
P08314922A0941|69 80|brain surface
P08314922A0941|85 103|minimal tissue damage
P08316100A0586|12 27|Richards's theory
P08316209A0000|3 46|positive-acting global sulfur regulatory protein
P08316209A0000|48 51|CYS3
P08316209A0000|48 51|CYS3
P08316209A0000|55 70|Neurospora crassa
P08316209A0000|135 141|enzymes
P08316209A0000|144 159|sulfur catabolism
P08316240A1068|13 38|upstream untranslated region
P08316240A1068|41 45|CHL15
P08316240A1068|41 45|CHL15
P08316240A1068|70 83|hexamer element
P08316240A1068|85 90|ACGCGT
P08316240A1068|94 112|MluI restriction site
P08316240A1068|94 112|MluI restriction site
P08316240A1068|132 149|periodic expression
P08316240A1068|204 208|yeast
P08317092A0304|3 18|C-terminal region
P08317092A0304|24 37|150-kDa protein
P08317092A0304|24 37|150-kDa protein
P08317092A0304|48 71|NTP-binding helicase motif
P08317092A0304|48 71|NTP-binding helicase motif
P08317092A0304|78 94|readthrough region
P08317092A0304|98 115|RNA polymerase motif
P08317092A0304|98 115|RNA polymerase motif
P08317092A0304|167 180|RNA replication
P08317092A0304|204 225|tobamo- and tobraviruses
P08317094A0778|3 8|5' ends
P08317094A0778|11 28|F3R late transcripts
P08317094A0778|11 13|F3R
P08317094A0778|44 44|A
P08317094A0778|62 69|5'-TAAAG
P08317094A0778|92 104|early promoter
P08317094A0778|108 119|17 nt upstream
P08317094A0778|127 141|initiation codon
P08319396A0448|2 3|T2
P08319396A0448|19 35|low intensity areas
P08319396A0448|65 76|anterior limb
P08319396A0448|90 96|capsule
P08319396A0448|112 119|midbrain
P08319396A0448|141 164|middle cerebellar peduncle
P08319396A0448|195 201|capsule
P08319396A0448|222 237|cerebral peduncle
P08319396A0448|245 252|cerebral
P08319907A0754|8 19|rap1t alleles
P08319907A0754|8 19|rap1t alleles
P08319907A0754|30 43|wild-type cells
P08319907A0754|59 78|telomere tract lengths
P08319907A0754|171 184|telomeric tract
P08320120A0361|0 24|Pronounced microangiopathy
P08320120A0361|40 54|avascular fields
P08320120A0361|56 85|enlarged and tortuous capillaries
P08320120A0361|123 139|sodium fluorescein
P08320120A0361|177 183|nodules
P08321199T0000|0 18|Epigenetic switching
P08321199T0000|21 41|transcriptional states
P08321199T0000|50 68|trans-acting factors
P08321199T0000|107 114|HMR locus
P08321199T0000|107 114|HMR locus
P08321199T0000|117 139|Saccharomyces cerevisiae
P08321203A0840|0 11|NF-kappa B p65
P08321203A0840|0 8|NF-kappa B
P08321203A0840|9 11|p65
P08321203A0840|13 15|p50
P08321203A0840|13 15|p50
P08321203A0840|20 22|Rel
P08321203A0840|48 57|C/EBP alpha
P08321203A0840|48 57|C/EBP alpha
P08321203A0840|59 67|C/EBP beta
P08321203A0840|59 67|C/EBP beta
P08321203A0840|72 81|C/EBP delta
P08321203A0840|72 81|C/EBP delta
P08321227A0854|33 45|culture medium
P08321227A0854|48 51|cDNA
P08321227A0854|64 71|COS cells
P08321741A0396|15 27|sequential BMB
P08321741A0396|56 68|myelofibrosis
P08321741A0396|88 123|Megakaryocytic-Granulocytic Myelosis"
P08321741A0396|150 180|Agnogenic Myeloid Metaplasia-AMM-
P08321741A0396|194 201|patients
P08321741A0396|214 216|CML
P08321741A0396|244 246|CML
P08322117A1019|28 35|patients
P08322117A1019|99 103|cmH2O
P08322117A1019|111 124|Sussett formula
P08322823A0839|36 38|MFA
P08322823A0839|58 69|UTS phenotype
P08323294T0000|7 48|sterol carrier protein 2/sterol carrier protein
P08323294T0000|7 27|sterol carrier protein 2
P08323294T0000|29 49|sterol carrier protein x
P08323294T0000|51 61|cDNA cloning
P08324107A0000|3 18|plasmatic albumin
P08324107A0000|73 85|plasma protein
P08324280A0098|5 11|lesions
P08324792T0000|54 64|infarct size
P08324792T0000|76 86|rabbit heart
P08325504A0226|7 10|RD19
P08325504A0226|7 10|RD19
P08325504A0226|14 30|RD21 mRNA synthesis
P08325504A0226|14 21|RD21 mRNA
P08325504A0226|54 63|heat stress
P08325639A0129|31 43|20S proteasome
P08325639A0129|31 43|20S proteasome
P08325639A0129|65 85|26S proteolytic complex
P08325639A0129|65 85|26S proteolytic complex
P08325639A0129|100 119|latent multicatalytic
P08325639A0129|120 129|proteinase
P08325639A0129|152 154|ATP
P08325639A0129|166 183|selective breakdown
P08325639A0129|203 211|ubiquitin
P08325720A0840|27 38|blood lactate
P08325720A0840|45 62|submaximal exercise
P08325720A0840|64 83|muscle enzyme activity
P08325720A0840|85 99|citrate synthase
P08325720A0840|85 99|citrate synthase
P08325720A0840|101 131|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|101 131|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|133 152|lactate dehydrogenase
P08325720A0840|133 152|lactate dehydrogenase
P08325720A0840|163 179|muscle capillaries
P08325720A0840|184 189|fibres
P08325883A0368|24 34|RBP1 protein
P08325883A0368|24 34|RBP1 protein
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|79 87|glutamine
P08325883A0368|100 120|asparagine-rich region
P08325883A0368|123 143|methionine-rich region
P08325883A0368|164 176|alpha-helixes
P08327488A0839|38 52|p70 coding region
P08327488A0839|38 40|p70
P08327488A0839|108 119|helper genome
P08327488A0839|186 197|wild-type p70
P08327488A0839|195 197|p70
P08331064A0440|0 6|Release
P08331064A0440|73 93|cointegrate structures
P08331067T0000|8 25|nucleotide sequence
P08331067T0000|31 54|bacteriophage K1F tail gene
P08331067T0000|31 50|bacteriophage K1F tail
P08331067T0000|63 93|endo-N-acylneuraminidase (endo-N
P08331067T0000|63 86|endo-N-acylneuraminidase
P08331067T0000|88 93|endo-N
P08331067T0000|112 124|endo-N homolog
P08331067T0000|112 124|endo-N homolog
P08331067T0000|127 143|bacteriophage PK1E
P08331728A0686|9 39|U2 small nuclear ribonucleoprotein
P08331728A0686|16 39|nuclear ribonucleoprotein
P08332033T0000|0 27|Morphometrical quantification
P08332033T0000|30 39|brain edema
P08332033T0000|85 88|mice
P08332033T0000|102 118|neurotropin effect
P08332033T0000|102 112|neurotropin
P08332492A0145|31 36|GATA-3
P08332492A0145|31 36|GATA-3
P08332492A0145|65 76|T lymphocytes
P08332492A0145|96 142|human immunodeficiency virus type 1 (HIV-1) infection
P08332492A0145|96 126|human immunodeficiency virus type 1
P08332492A0145|128 132|HIV-1
P08332492A0145|146 156|replication
P08332495A0408|25 35|CAT activity
P08332495A0408|25 27|CAT
P08332495A0408|49 71|human lung adenocarcinoma
P08332495A0408|73 84|A549-1) cells
P08332495A0408|120 134|T7 RNA polymerase
P08332495A0408|120 134|T7 RNA polymerase
P08332495A0408|136 149|pT7-EMC-CAT DNA
P08332495A0408|136 149|pT7-EMC-CAT DNA
P08332495A0408|153 154|DC
P08332495A0408|153 154|DC
P08332495A0408|160 176|cationic liposomes
P08333643A0000|0 12|Pneumoscrotum
P08333643A0000|67 71|texts
P08333643A0000|74 80|urology
P08334158A0660|40 54|cystein residues
P08334158A0660|80 91|Fe/S proteins
P08334158A0660|80 91|Fe/S proteins
P08334304A0473|68 87|peptide growth factors
P08334304A0473|103 112|GTP-loaded
P08334304A0473|113 123|p21 rasVal12
P08334304A0473|113 123|p21 rasVal12
P08334989A0070|68 77|cell-cycle
P08334989A0070|80 107|mouse B-myb 5' flanking sequence
P08334989A0070|80 107|mouse B-myb 5' flanking sequence
P08334989A0070|124 136|cosmid library
P08334989A0070|184 205|luciferase reporter gene
P08334989A0070|184 205|luciferase reporter gene
P08334989A0070|225 241|NIH3T3 fibroblasts
P08335710A0338|15 31|high ionic strength
P08336012A0632|11 18|bacteria
P08336012A0632|24 27|lung
P08336012A0632|29 52|peripheral white blood cell
P08336012A0632|56 67|BAL fluid cell
P08336012A0632|102 103|FN
P08336012A0632|102 103|FN
P08336543A0243|2 5|mice
P08336543A0243|27 36|L1 elements
P08336543A0243|27 36|L1 elements
P08336543A0243|44 45|"A
P08336543A0243|45 45|A
P08336543A0243|51 56|" and "V
P08336543A0243|107 116|5' terminus
P08336698T0000|0 3|TFEC
P08336698T0000|0 3|TFEC
P08336698T0000|6 33|basic helix-loop-helix protein
P08336698T0000|6 33|basic helix-loop-helix protein
P08336698T0000|40 51|heterodimers
P08336698T0000|56 59|TFE3
P08336698T0000|56 59|TFE3
P08336698T0000|71 107|TFE3-dependent transcription activation
P08336698T0000|71 74|TFE3
P08336738A1273|46 65|PSTAIRE sequence motif
P08337828A0895|24 35|Western blots
P08337828A0895|38 62|Autographa californica MNPV
P08337828A0895|64 69|AcMNPV
P08337828A0895|80 104|Spodoptera frugiperda cells
P08337841A0612|10 23|mammalian cells
P08337841A0612|28 42|ARV G and GNS genes
P08337841A0612|28 31|ARV G
P08337841A0612|35 42|GNS genes
P08337841A0612|113 129|consensus sequence
P08337841A0612|131 135|AACAG
P08337841A0612|152 156|G gene
P08337841A0612|152 156|G gene
P08337841A0612|198 203|CATG[A
P08337841A0612|243 268|GNS protein termination codon
P08337841A0612|243 252|GNS protein
P08340400T0000|0 15|Molecular cloning
P08340400T0000|31 35|RPE65
P08340400T0000|31 35|RPE65
P08340400T0000|38 66|novel retinal pigment epithelium
P08340400T0000|76 92|microsomal protein
P08342703A0966|15 17|mu W
P08342703A0966|47 54|flow rate
P08342703A0966|105 112|flow rate
P08342703A0966|136 144|lymphatic
P08342703A0966|145 150|vessel
P08343041A0000|8 26|antisperm antibodies
P08343041A0000|44 54|infertility
P08343041A0000|97 106|antibodies
P08343216A0883|0 31|PPD-specific IgG subclass responses
P08343216A0883|0 2|PPD
P08343216A0883|12 14|IgG
P08343216A0883|52 64|IgG subclasses
P08343216A0883|52 54|IgG
P08343961A0000|8 18|body pattern
P08343961A0000|70 82|bicoid protein
P08343961A0000|70 82|bicoid protein
P08343961A0000|84 87|bcd)
P08343961A0000|84 86|bcd
P08343961A0000|129 143|anterior domains
P08344248A0910|0 4|GAP-N
P08344248A0910|0 4|GAP-N
P08344248A0910|26 29|p190
P08344248A0910|26 29|p190
P08344248A0910|36 80|serum-deprived and growth factor-stimulated cells
P08345191A1140|3 17|peptide sequence
P08345191A1140|35 46|80 amino acids
P08345191A1140|68 72|bcl-2
P08345191A1140|68 72|bcl-2
P08345191A1140|98 114|bcl-2-related gene
P08345191A1140|98 114|bcl-2-related gene
P08345191A1140|116 119|MCL1
P08345191A1140|116 119|MCL1
P08347677A0308|3 27|phosphorylation efficiency
P08347677A0308|61 86|N-terminal arginine residues
P08347677A0308|165 167|Arg
P08347677A0308|171 189|Ala-Ala-Ser-Val-Ala
P08347677A0308|222 234|short peptides
P08348919T0000|0 13|Botulinum toxin
P08348919T0000|0 13|Botulinum toxin
P08348919T0000|36 50|hemifacial spasm
P08349104A0000|3 29|Saccharomyces cerevisiae GAL1
P08349104A0000|3 25|Saccharomyces cerevisiae
P08349104A0000|33 42|GAL10 genes
P08349104A0000|33 42|GAL10 genes
P08349104A0000|85 93|galactose
P08349104A0000|97 103|glucose
P08349104A0000|162 177|overlapping sites
P08349104A0000|180 183|UASG
P08349104A0450|57 64|TSF genes
P08349104A0450|57 64|TSF genes
P08349104A0450|71 93|global regulatory factors
P08349104A0450|95 98|tsf1
P08349104A0450|95 98|tsf1
P08349104A0450|101 104|tsf6
P08349104A0450|101 104|tsf6
P08349104A0450|105 113|mutations
P08349104A0450|139 165|yeast CYC-GAL hybrid promoters
P08349104A0450|139 143|yeast
P08349104A0450|144 150|CYC-GAL
P08349104A0450|151 165|hybrid promoters
P08349104A0450|174 177|lacZ
P08349104A0450|174 177|lacZ
P08349104A0450|226 243|pleiotropic defects
P08349104A0450|246 255|cell growth
P08349104A0450|257 262|mating
P08349499A1169|0 8|Sex of calf
P08349499A1169|10 17|variate 2
P08349499A1169|54 59|muzzle
P08349499A1169|63 66|head
P08349632A0679|31 39|exons 5'/L
P08349632A0679|39 39|L
P08349632A0679|43 45|L/N
P08349632A0679|43 43|L
P08349632A0679|45 45|N
P08349632A0679|48 63|PSG12 and PSG12 psi
P08349632A0679|48 52|PSG12
P08349632A0679|56 63|PSG12 psi
P08349632A0679|93 99|L/N exon
P08349632A0679|105 116|PSG12 psi gene
P08349632A0679|105 116|PSG12 psi gene
P08349632A0679|126 134|stop codon
P08350061A0209|54 60|CD8 gene
P08350061A0209|54 56|CD8
P08350061A0209|86 108|T cell development program
P08350398A1616|16 17|ER
P08350398A1616|25 38|variable domain
P08350398A1616|41 45|gp19K
P08350398A1616|41 45|gp19K
P08350398A1616|50 65|specific tertiary
P08350398A1616|105 137|polymorphic alpha 1 and alpha 2 domains
P08350398A1616|125 130|alpha 2
P08350398A1616|140 156|class I heavy (alpha
P08350398A1616|140 150|class I heavy
P08350398A1616|152 163|alpha) chains
P08352066A0000|19 34|17 beta-estradiol
P08352066A0000|36 37|E2
P08352066A0000|36 37|E2
P08352066A0000|87 99|bone formation
P08352066A0000|105 118|cancellous bone
P08352066A0000|127 130|rats
P08352268A0000|0 29|Recombinant human erythropoietin
P08352268A0000|11 37|human erythropoietin (epoetin
P08352268A0000|31 37|epoetin
P08352268A0000|70 80|intravenous
P08352268A0000|84 85|v.
P08352268A0000|89 100|subcutaneous
P08352268A0000|102 103|SC
P08355062A0000|0 44|Single-photon emission computed tomography (SPECT
P08355062A0000|50 84|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|86 90|HMPAO
P08355062A0000|121 137|cerebral blood flow
P08355062A0000|145 152|patients
P08355063A0456|3 11|rCBF ratio
P08355063A0456|30 41|frontal lobes
P08355539A0133|18 25|patients
P08355539A0133|53 60|etiology
P08355539A0133|78 98|antiadrenal antibodies
P08355539A0133|137 154|autoimmune etiology
P08355539A0133|157 159|EAA
P08355539A0133|198 200|EAT
P08355539A0133|263 265|EAI
P08355680A0824|0 3|2-AP
P08355680A0824|31 46|mRNA accumulation
P08355680A0824|92 106|HIV-1 constructs
P08355680A0824|127 159|endogenous gene encoding gamma-actin
P08355680A0824|127 140|endogenous gene
P08355680A0824|149 159|gamma-actin
P08355680A0824|162 192|glucose 6-phosphate dehydrogenase
P08355680A0824|162 192|glucose 6-phosphate dehydrogenase
P08355696A0236|3 13|UV induction
P08355696A0236|16 20|c-jun
P08355696A0236|16 20|c-jun
P08355696A0236|66 83|AP-1-like sequences
P08355696A0236|66 83|AP-1-like sequences
P08355696A0236|93 107|5' control region
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355697A0000|7 26|tyrosine phosphatases
P08355697A0000|28 31|PTPs
P08355697A0000|28 31|PTPs
P08355697A0000|46 67|protein tyrosine kinases
P08355697A0000|46 67|protein tyrosine kinases
P08355697A0000|69 72|PTKs
P08355697A0000|69 72|PTKs
P08355697A0000|103 116|cell activation
P08355697A0000|118 123|growth
P08355697A0000|128 142|differentiation
P08355857A1293|0 10|ST elevation
P08355857A1293|20 27|patients
P08355857A1293|37 45|subgroup A
P08355857A1293|65 73|subgroup B
P08356792A1275|13 23|p21X protein
P08356792A1275|34 43|N-terminus
P08356792A1275|34 43|N-terminus
P08356792A1275|46 49|Rex1
P08356792A1275|46 49|Rex1
P08356792A1275|94 97|p21X
P08356792A1275|94 97|p21X
P08356792A1275|117 126|1.6-kb mRNA
P08356792A1275|161 170|proviruses
P08356792T0000|0 19|HTLV-1 gene expression
P08356792T0000|0 9|HTLV-1 gene
P08356792T0000|31 40|proviruses
P08356792T0000|45 62|infected T-cell line
P08356944A0589|26 85|sodium lauryl sulfate method of estimating hemoglobin concentration
P08356944A0589|63 72|hemoglobin
P08356944A0589|117 139|cyanmethemoglobin method
P08356944A0589|117 133|cyanmethemoglobin
P08356944A0589|164 174|toxic wastes
P08357834A0285|16 42|predicted amino acid sequences
P08357834A0285|51 64|human PKC-delta
P08357834A0285|56 70|PKC-delta clones
P08357834A0285|78 80|rat
P08357834A0285|84 98|mouse homologues
P08357834A0285|220 240|human PKC family members
P08357834A0285|220 240|human PKC family members
P08357834A0285|249 269|mammalian counterparts
P08360112T0036|0 2|XII
P08360180A1041|16 26|barley PSI-K
P08360180A1041|16 21|barley
P08360180A1041|22 26|PSI-K
P08360180A1041|30 34|PSI-G
P08360180A1041|30 32|PSI
P08360180A1041|50 87|PSI-K sequence from Synechococcus vulcanus
P08360180A1041|50 62|PSI-K sequence
P08360180A1041|67 87|Synechococcus vulcanus
P08360180A1041|134 146|ancestral gene
P08360180A1041|167 187|chloroplast progenitor
P08361754A0733|33 43|b-Zip domain
P08361754A0733|33 43|b-Zip domain
P08361754A0733|70 88|Maf-related proteins
P08361754A0733|70 88|Maf-related proteins
P08361755A0734|38 42|cDNAs
P08361755A0734|48 59|NF-kappa B p50
P08361755A0734|48 59|NF-kappa B p50
P08361755A0734|63 85|serum response factor (SRF
P08361755A0734|63 81|serum response factor
P08361755A0734|83 85|SRF
P08361755A0734|96 103|factor(s
P08361755A0734|117 126|Tax binding
P08361755A0734|117 119|Tax
P08361755A0734|132 144|NF-kappa B site
P08361755A0734|132 144|NF-kappa B site
P08361755A0734|151 157|CArG box
P08361761A0174|14 18|v-Rel
P08361761A0174|14 18|v-Rel
P08361761A0174|55 69|reporter plasmid
P08361761A0174|88 102|Sp1 binding sites
P08361761A0174|88 90|Sp1
P08361761A0174|132 148|embryo fibroblasts
P08361761A0174|150 153|CEFs
P08361761A0174|166 170|v-Rel
P08361761A0174|166 170|v-Rel
P08361761A0174|202 206|v-Rel
P08361761A0174|202 206|v-Rel
P08361761A0174|235 249|reporter plasmid
P08361761A0174|261 291|human immunodeficiency virus type 1
P08361761A0174|261 291|human immunodeficiency virus type 1
P08361761A0174|293 297|HIV-1
P08361761A0174|293 297|HIV-1
P08361761A0174|299 316|long terminal repeat
P08361761A0174|318 320|LTR
P08361761A0174|332 349|kappa B binding sites
P08361761A0174|332 349|kappa B binding sites
P08361761A0174|389 403|Sp1 binding sites
P08361761A0174|389 403|Sp1 binding sites
P08363332A0365|3 23|simultaneous recording
P08363332A0365|26 43|electrical activity
P08363332A0365|51 74|surface electrocardiogram
P08363332A0365|76 95|right ventricular apex
P08363332A0365|97 105|His bundle
P08363332A0365|111 121|right atrium
P08363332A0365|123 135|coronary sinus
P08363332A0365|199 226|electrical activation sequence
P08363332A0365|232 236|heart
P08365944A1537|15 35|retrospective analysis
P08365944A1537|74 96|simultaneous Mitomycin-C
P08365944A1537|100 113|5-fluorouracil
P08365944A1537|148 159|radiotherapy
P08366034A0637|23 38|cysteine residues
P08366034A0637|93 106|disulfide bonds
P08367388T0035|0 34|Cerebro-oculo-facioskeletal syndrome
P08367388T0035|36 57|Pena-Shokeir syndrome II
P08367487A1014|37 47|17S U2 snRNPs
P08367487A1014|37 39|17S
P08367487A1014|40 47|U2 snRNPs
P08367487A1014|57 67|12S U2 snRNPs
P08367487A1014|57 59|12S
P08367487A1014|60 90|U2 snRNPs, to HeLa splicing extracts
P08367487A1014|101 119|endogeneous U2 snRNPs
P08367487A1014|112 119|U2 snRNPs
P08367487A1014|155 173|anti-PRP9 antibodies
P08367487A1014|155 163|anti-PRP9
P08367487A1014|190 210|mRNA-splicing activity
P08367487A1014|216 223|extracts
P08369887A0781|11 20|in profiles
P08369887A0781|59 61|EAD
P08369887A0781|64 65|RA
P08369887A0781|66 73|patients
P08370119A0642|19 29|1977-bp exon
P08370119A0642|51 78|5' and 3' untranslated sequences
P08370119A0642|92 114|1077-bp open reading frame
P08370119A0642|137 172|vascular smooth muscle cell AT1a receptor
P08370119A0642|137 160|vascular smooth muscle cell
P08370119A0642|161 177|AT1a receptor cDNAs
P08370119A1521|0 7|Deletion
P08370119A1521|11 34|53-bp early promoter region
P08370119A1521|48 69|transcription start site
P08370119A1521|82 88|TATA box
P08370119A1521|161 174|luciferase cDNA
P08370119A1521|161 174|luciferase cDNA
P08370275A0290|64 78|nonadjacent pair
P08371650T0000|0 10|Dissipation
P08371650T0000|13 28|claudication pain
P08371650T0000|57 73|endurance training
P08371713T0000|26 60|nonselective-type endothelin receptor
P08371713T0000|43 60|endothelin receptor
P08371713T0000|65 72|rat brain
P08371936T0000|52 60|clinician
P08371936T0000|64 74|self ratings
P08373274A0546|0 9|Polymyxin B
P08373274A0546|74 95|circulating endotoxemia
P08373972A0335|0 3|SvO2
P08374753A0335|3 26|transverse relaxation time
P08374753A0335|28 29|T2
P08374753A0335|64 68|water
P08375651T0000|3 34|Drosophila clathrin heavy chain gene
P08375651T0000|13 34|clathrin heavy chain gene
P08375651T0000|36 43|clathrin
P08376397A0788|3 20|binding specificity
P08376397A0788|58 60|E2F
P08376397A0788|58 60|E2F
P08376397A0788|75 88|mutant E2F sites
P08376397A0788|75 88|mutant E2F sites
P08376796A0172|12 20|VH regions
P08376796A0172|23 44|polyreactive antibodies
P08376796A0172|87 99|mutated status
P08376796A0172|116 118|IgG
P08376796A0172|116 118|IgG
P08376796A0172|125 128|IgG1
P08376796A0172|125 128|IgG1
P08376796A0172|135 142|IgG3) mAb
P08376796A0172|135 138|IgG3
P08376796A0172|149 154|B cells
P08376796A0172|187 219|insulin-dependent diabetes mellitus
P08376796A0172|187 193|insulin
P08376796A0172|224 230|patient
P08376796A0172|235 237|SLE
P08376796A0172|298 306|foreign Ag
P08377199A1432|19 23|patch
P08377199A1432|60 63|site
P08378082A1031|48 56|RB protein
P08378082A1031|48 56|RB protein
P08378082A1031|60 65|p21ras
P08378082A1031|60 65|p21ras
P08378082A1031|83 95|cell phenotype
P08378082A1031|103 128|normal and transformed states
P08380736A0895|20 38|alternative splicing
P08380736A0895|77 89|amino terminus
P08380896A0938|0 7|Kinetics
P08380896A0938|40 55|polymerase domain
P08380896A0938|66 81|viral replication
P08380896A0938|95 112|preinitiation stage
P08381121A0773|8 27|transmembrane regions
P08381121A0773|39 57|nucleoplasmic domain
P08382139A1111|0 0|3
P08382296A0766|0 8|McCann III
P08382300A0341|5 13|cell lines
P08382300A0341|62 91|temperature-sensitive VP5 mutant
P08382300A0341|83 91|VP5 mutant
P08382300A0341|110 112|VP5
P08382300A0341|110 112|VP5
P08382300A0341|116 130|VP23 null mutants
P08382300A0341|116 119|VP23
P08382303A0507|3 25|E1 nuclear transport motif
P08382303A0507|3 4|E1
P08382303A0507|48 53|animal
P08382303A0507|57 77|human papillomaviruses
P08382303A0507|118 124|E1 genes
P08382303A0507|118 124|E1 genes
P08382303T0000|3 22|E1 replication protein
P08382303T0000|25 49|bovine papillomavirus type 1
P08382303T0000|25 49|bovine papillomavirus type 1
P08382303T0000|106 131|p34cdc2 phosphorylation site
P08382303T0000|106 112|p34cdc2
P08382359A0469|64 77|tumor induction
P08382359A0469|140 166|putative pRb-binding sequence
P08382359A0469|148 166|pRb-binding sequence
P08382359A0469|169 181|large T antigen
P08382359A0469|174 181|T antigen
P08382359A0469|202 218|in vivo experiments
P08382359A0469|287 300|tumor induction
P08382769A0924|31 49|nucleotides 154 to 156
P08382769A0924|88 122|sequence-specific recognition element
P08382769A0924|129 140|SRP54 protein
P08382769A0924|129 133|SRP54
P08382778A0891|19 25|protein
P08382778A0891|54 68|catalytic region
P08382778A0891|71 80|Raf kinases
P08382778A0891|71 80|Raf kinases
P08382778A0891|104 108|TFIIE
P08382778A0891|104 108|TFIIE
P08382778A0891|114 133|transcription factors
P08383129A0776|60 78|antigen presentation
P08383129A0776|90 97|peptides
P08383129A0776|102 125|cytosolic protein antigens
P08383129A0776|102 125|cytosolic protein antigens
P08383129A0776|158 179|cytotoxic T-lymphocytes
P08383129A0776|185 195|cell surface
P08383214A0389|19 20|RT
P08383214A0389|23 30|Trp-595-
P08383214A0389|31 37|Tyr-596
P08383214A0389|40 42|Pol
P08383214A0389|40 42|Pol
P08383214A0389|73 94|C-terminal RNase H domain
P08383214A0389|73 94|C-terminal RNase H domain
P08383217A0357|40 44|Bel-1
P08383217A0357|40 44|Bel-1
P08383217A0357|69 81|Bel-1 activity
P08383217A0357|69 73|Bel-1
P08383217A0357|117 142|C-terminal activation domain
P08383217A0357|117 142|C-terminal activation domain
P08383217A0357|145 148|VP16
P08383217A0357|145 148|VP16
P08383287A0611|8 23|-172/-148 element
P08383287A0611|37 44|estrogen
P08383287A0611|48 75|thyroid hormone responsiveness
P08383287A0611|95 125|composite hormone response element
P08383323A0000|0 16|Optimal activation
P08383323A0000|19 24|T cells
P08383492A1205|37 47|interrupted
P08383492A1205|48 57|aromatic aa
P08383492A1205|136 167|cyanobacterial cytochrome oxidases
P08383492A1205|136 159|cyanobacterial cytochrome
P08383492A1205|171 193|acidic c-type cytochromes
P08383492A1205|177 193|c-type cytochromes
P08383526A0591|46 60|receptor protein
P08383526A0591|46 60|receptor protein
P08383526A0591|77 80|exon
P08383622T0000|0 7|Identity
P08383622T0000|10 13|GABP
P08383622T0000|10 13|GABP
P08383622T0000|18 22|NRF-2
P08383622T0000|18 22|NRF-2
P08383622T0000|25 45|multisubunit activator
P08383622T0000|48 74|cytochrome oxidase expression
P08383622T0000|48 64|cytochrome oxidase
P08383622T0000|101 118|ETS domain activator
P08383622T0000|101 109|ETS domain
P08383622T0000|121 134|viral promoters
P08383622T0000|121 134|viral promoters
P08383850A0206|18 45|beta-funaltrexamine (beta-FNA
P08383850A0206|38 45|beta-FNA
P08383850A0206|50 60|naltrindole
P08383850A0206|62 64|NTI
P08383850A0206|67 83|nonequilibrium mu-
P08383850A0206|87 102|delta-antagonist
P08383850A0206|127 147|precipitate withdrawal
P08383850A0206|150 174|butorphanol-dependent rats
P08384309A0000|3 15|intracellular
P08384309A0000|16 49|basic region/helix-loop-helix (bHLH)
P08384309A0000|16 26|basic region
P08384309A0000|28 43|helix-loop-helix
P08384309A0000|45 63|bHLH) dioxin receptor
P08384309A0000|50 63|dioxin receptor
P08384309A0000|92 97|dioxin
P08384309A0000|99 133|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|150 182|ligand-activated DNA binding protein
P08384309A0000|166 182|DNA binding protein
P08384309A0000|206 216|target genes
P08384309A0000|228 249|dioxin response elements
P08385131A0000|3 28|alpha 2A-adrenergic receptor
P08385131A0000|3 28|alpha 2A-adrenergic receptor
P08385131A0000|30 38|alpha 2AAR
P08385131A0000|30 38|alpha 2AAR
P08385131A0000|73 115|pertussis toxin-sensitive GTP-binding proteins
P08385131A0000|73 86|pertussis toxin
P08385131A0000|97 115|GTP-binding proteins
P08385337A0282|29 81|CCAAT/enhancer binding protein (C/EBP) consensus sequences
P08385337A0282|29 56|CCAAT/enhancer binding protein
P08385337A0282|58 81|C/EBP) consensus sequences
P08385337A0282|83 103|basic DNA binding region
P08385337A0282|83 103|basic DNA binding region
P08385337A0282|107 121|leucine zippers 1
P08385337A0282|127 131|bZIP1
P08385337A0282|135 139|bZIP2
P08385581A0126|16 21|REC114
P08385581A0126|16 21|REC114
P08385581A0126|60 65|REC114
P08385581A0126|60 65|REC114
P08385581A0126|85 101|recombination gene
P08385581A0126|128 134|mitosis
P08386279A1621|28 32|EBNA2
P08386279A1621|28 32|EBNA2
P08386279A1621|53 74|HeLa epithelial cell line
P08386279A1621|93 95|EBV
P08386279A1621|99 112|HIV-1 infection
P08386279A1621|115 124|non-B cells
P08386279A1621|136 158|HIV-1 promoter activation
P08386279A1621|136 148|HIV-1 promoter
P08386280T0000|13 29|C/EBP binding sites
P08386280T0000|13 29|C/EBP binding sites
P08386280T0000|35 68|Rous sarcoma virus long terminal repeat
P08386280T0000|35 50|Rous sarcoma virus
P08386280T0000|51 68|long terminal repeat
P08386280T0000|72 83|gag enhancers
P08386280T0000|72 74|gag
P08386280T0000|75 83|enhancers
P08386317T0000|0 75|Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB
P08386317T0000|0 26|Nuclear protein phosphatase 2A
P08386317T0000|43 56|protein kinase A
P08386317T0000|72 75|CREB
P08386317T0000|88 117|CREB transcriptional stimulation
P08386317T0000|88 91|CREB
P08386318A1102|10 13|IL-6
P08386318A1102|10 13|IL-6
P08386318A1102|23 29|JRE-IL6
P08386318A1102|23 29|JRE-IL6
P08386318A1102|39 57|H7-sensitive pathway
P08386318A1102|76 89|protein kinase C
P08386318A1102|76 89|protein kinase C
P08386318A1102|91 152|cyclic AMP-dependent kinase, Ca(2+)- or calmodulin-dependent kinases
P08386318A1102|91 115|cyclic AMP-dependent kinase
P08386318A1102|117 121|Ca(2+
P08386318A1102|126 152|calmodulin-dependent kinases
P08386318A1102|154 156|Ras
P08386318A1102|154 156|Ras
P08386318A1102|158 162|Raf-1
P08386318A1102|158 162|Raf-1
P08386318A1102|166 171|NF-IL6
P08386318A1102|166 171|NF-IL6
P08386318A1102|173 181|C/EBP beta
P08386318A1102|173 181|C/EBP beta
P08386319A1229|38 45|tyrosine
P08386319A1229|49 57|threonine
P08386319A1229|68 72|Mpk1p
P08386319A1229|68 72|Mpk1p
P08386319A1229|87 99|phenylalanine
P08386319A1229|103 109|alanine
P08386319A1229|140 152|Mpk1p function
P08386319A1229|140 144|Mpk1p
P08386592A0089|0 22|Growth factor stimulation
P08386592A0089|59 81|electrophoretic mobility
P08386592A0089|94 100|complex
P08386592A0089|144 164|Elk-1 C-terminal region
P08386592A0089|144 164|Elk-1 C-terminal region
P08386592A0089|198 208|Elk-1 kinase
P08386592A0089|198 208|Elk-1 kinase
P08386637A1220|26 39|mammalian cells
P08386637A1220|126 134|receptors
P08387155A1248|42 46|c-Jun
P08387155A1248|42 46|c-Jun
P08387155A1248|66 71|topo II
P08387155A1248|66 71|topo II
P08387155A1248|81 85|c-Fos
P08387155A1248|81 85|c-Fos
P08387155A1248|103 108|topo II
P08387155A1248|103 108|topo II
P08387155A1248|116 125|vitro assay
P08387507A1015|15 19|Myf-5
P08387507A1015|15 19|Myf-5
P08387507A1015|23 26|MyoD
P08387507A1015|23 26|MyoD
P08387507A1015|38 58|cAMP-dependent pathway
P08387507A1015|104 108|serum
P08387507A1015|119 138|peptide growth factors
P08387507A1015|159 165|nucleus
P08387507A1015|176 197|dominant-acting factors
P08387507A1015|176 197|dominant-acting factors
P08387507A1015|219 241|myoblast differentiation
P08387519A0000|37 57|human desmin expression
P08387519A0000|37 47|human desmin
P08387519A0000|68 79|280-base pair
P08387519A0000|80 102|muscle-specific enhancer
P08387519A0000|155 168|gene expression
P08387519A0000|171 179|myoblasts
P08387662A0302|5 11|surgery
P08387662A0302|92 98|placebo
P08387662A0302|115 123|ibuprofen
P08387662A0302|161 175|severe intensity
P08387743A0624|16 43|wild-type 5'-regulatory region
P08387743A0624|16 43|wild-type 5'-regulatory region
P08387743A0624|67 93|cis-acting regulatory element
P08387743A0624|134 155|Mn-superoxide dismutase
P08387743A0624|134 155|Mn-superoxide dismutase
P08387994A0980|3 18|orf61 gene product
P08387994A0980|3 18|orf61 gene product
P08387994A0980|39 55|exogenous promoter
P08387994A0980|39 55|exogenous promoter
P08387994A0980|66 88|int-mediated integration
P08387994A0980|66 68|int
P08387994A0980|94 112|chromosomal attB site
P08387994A0980|105 112|attB site
P08388496A1117|23 26|LCLs
P08388496A1117|51 55|virus
P08388496A1117|140 157|BamHI-A transcripts
P08388496A1117|140 157|BamHI-A transcripts
P08388496A1117|178 189|normal B cells
P08388496A1117|207 227|experimental infection
P08388496A1117|245 302|BamHI-C/W promoter-initiated but not BamHI-F promoter-initiated
P08388496A1117|245 251|BamHI-C
P08388496A1117|253 261|W promoter
P08388496A1117|278 292|BamHI-F promoter
P08388496A1117|303 307|mRNAs
P08388510A0891|10 38|cell surface immunofluorescence
P08388510A0891|52 59|UL28 gene
P08388510A0891|52 59|UL28 gene
P08388510A0891|88 105|viral glycoproteins
P08388510A0891|88 105|viral glycoproteins
P08388510A0891|120 132|infected cells
P08388543A1263|13 26|mutant receptor
P08388543A1263|13 26|mutant receptor
P08388543A1263|28 38|Y977F/Y989F
P08388543A1263|40 60|PLC gamma-binding sites
P08388543A1263|40 47|PLC gamma
P08388543A1263|81 83|Ras
P08388543A1263|81 83|Ras
P08388543A1263|109 122|protein kinase C
P08388543A1263|109 122|protein kinase C
P08388543A1263|126 144|calcium mobilization
P08388543A1263|167 178|GDP/GTP state
P08388543A1263|181 183|Ras
P08388543A1263|181 183|Ras
P08388543A1263|190 197|cell line
P08388600A0000|0 16|Estrogen treatment
P08388600A0000|49 60|adult stature
P08388600A0000|63 87|constitutionally tall girls
P08389074A1227|0 8|Mutations
P08389074A1227|14 30|extreme C-terminus
P08389074A1227|33 39|EIAV Tat
P08389074A1227|33 39|EIAV Tat
P08389074A1227|52 80|RNA binding and activation domain
P08389074A1227|52 80|RNA binding and activation domain
P08389074A1227|110 118|secondary
P08389074A1227|121 137|tertiary structure
P08389365A1344|4 22|observation suggests
P08389365A1344|30 35|methyl
P08389365A1344|68 90|proximal d(GATC) sequence
P08389453A0193|0 19|Uracil DNA glycosylase
P08389453A0193|6 19|DNA glycosylase
P08389453A0193|92 97|uracil
P08389453A0193|102 110|duplex DNA
P08390120A0785|7 20|clinical trials
P08390665A0000|0 20|Lithium phthalocyanine
P08390665A0000|22 25|LiPc
P08390665A0000|30 38|prototype
P08390665A0000|60 85|synthetic, metallic-organic
P08390665A0000|144 186|in vivo electron paramagnetic resonance oximetry
P08390747A0586|25 32|genetics
P08390747A0586|49 62|17 hep syn gB gene
P08390747A0586|57 58|gB
P08390747A0586|95 114|pathogenic phenotypes
P08390831A0143|0 9|Recipients
P08390831A0143|14 27|acute leukaemia
P08390831A0143|46 68|chronic myeloid leukaemia
P08390831A0143|76 87|chronic phase
P08390831A0143|147 154|patients
P08391534A0828|0 6|Elledge
P08391748A0452|52 63|contractions
P08391748A0452|69 76|patients
P08391748A0452|100 114|QRS prolongation
P08391748A0452|138 151|QT prolongation
P08391748A0452|160 167|patients
P08391748A0452|185 199|QRS prolongation
P08391748A0452|235 248|QT prolongation
P08391748A0452|287 301|QRS prolongation
P08391748A0452|325 338|QT prolongation
P08392221A0449|0 5|Losses
P08392221A0449|52 80|radioactive estrogen conjugates
P08392221A0449|166 177|matairesinol
P08392221A0449|204 233|daidzein, O-desmethylangolensin
P08392221A0449|244 252|genistein
P08392623A1374|0 6|IE2-IE2
P08392623A1374|0 2|IE2
P08392623A1374|4 6|IE2
P08392623A1374|57 77|helix-turn-helix motif
P08392623A1374|57 77|helix-turn-helix motif
P08392623A1374|92 100|C terminus
P08392623A1374|103 105|IE2
P08392623A1374|103 105|IE2
P08392623A1374|107 132|between amino acids 456 and 539
P08393143A1281|3 11|Sp1 region
P08393143A1281|3 11|Sp1 region
P08393143A1281|53 55|TRE
P08393143A1281|61 74|viral tat factor
P08393143A1281|61 74|viral tat factor
P08394019A0695|0 12|Precipitation
P08394019A0695|18 34|GST fusion proteins
P08394019A0695|18 20|GST
P08394019A0695|45 72|Fyn SH2, SH3, and SH2/SH3 domains
P08394019A0695|45 47|Fyn
P08394019A0695|48 50|SH2
P08394019A0695|52 54|SH3
P08394019A0695|59 61|SH2
P08394019A0695|63 72|SH3 domains
P08394019A0695|85 94|PI 3-kinase
P08394019A0695|85 94|PI 3-kinase
P08394019A0695|116 124|SH3 domain
P08394019A0695|116 124|SH3 domain
P08394019A0695|127 129|Fyn
P08394019A0695|127 129|Fyn
P08394255A0000|1 5|sheep
P08394255A0000|16 26|cDNA library
P08394255A0000|40 51|pcDNA1 vector
P08394255A0000|84 106|polymerase chain reaction
P08394255A0000|108 110|PCR
P08394255A0000|131 143|1.6 kb fragment
P08394255A0000|149 177|rat luteinizing hormone receptor
P08394255A0000|149 151|rat
P08394255A0000|152 177|luteinizing hormone receptor
P08394255A0000|178 181|cDNA
P08394464A1080|3 21|putative Rev proteins
P08394464A1080|11 21|Rev proteins
P08394464A1080|34 48|molecular masses
P08394464A1080|51 60|18 and 16 kDa
P08394464A1080|76 79|p2/2
P08394464A1080|76 79|p2/2
P08394464A1080|83 86|p176
P08394464A1080|83 86|p176
P08394464A1080|93 95|p20
P08394464A1080|93 95|p20
P08394862A0565|11 18|patients
P08394862A0565|28 37|CMV disease
P08394862A0565|46 52|patient
P08394862A0565|62 73|CMV hepatitis
P08395004A0141|12 24|spt2 mutations
P08395004A0141|12 24|spt2 mutations
P08395004A0141|76 111|delta promoter insertion his-4-912 delta
P08395004A0141|138 160|wild-type HIS4 mRNA levels
P08395004A0141|138 154|wild-type HIS4 mRNA
P08395004A0558|0 18|Nuclear localization
P08395004A0558|65 80|SPT2/SIN1 protein
P08395004A0558|65 68|SPT2
P08395004A0558|70 73|SIN1
P08395004A0558|98 129|nonhistone chromosomal protein HMG1
P08395004A0558|98 125|nonhistone chromosomal protein
P08395004A0558|126 129|HMG1
P08395010T0000|12 32|ninth C-terminal heptad
P08395010T0000|35 48|thyroid hormone
P08395010T0000|35 48|thyroid hormone
P08395010T0000|52 72|retinoic acid receptors
P08395010T0000|52 72|retinoic acid receptors
P08395010T0000|81 96|diverse responses
P08395010T0000|108 118|heterodimer
P08395010T0000|125 133|homodimer
P08395014A1364|26 29|BCK2
P08395014A1364|26 29|BCK2
P08395014A1364|68 80|BCK2 functions
P08395014A1364|68 71|BCK2
P08395014A1364|107 110|PPZ1
P08395014A1364|107 110|PPZ1
P08395014A1364|114 117|PPZ2
P08395014A1364|114 117|PPZ2
P08395654T0000|0 19|Steroidogenic factor 1
P08395654T0000|0 19|Steroidogenic factor 1
P08395654T0000|23 43|orphan nuclear receptor
P08395654T0000|23 43|orphan nuclear receptor
P08395654T0000|72 87|rat aromatase gene
P08395654T0000|72 87|rat aromatase gene
P08395654T0000|90 103|gonadal tissues
P08395681A0388|38 77|cutaneous HPV5 and HPV8 E7s and genital HPV16 E7
P08395681A0388|58 60|E7s
P08395681A0388|76 77|E7
P08395681A0388|96 97|E7
P08395681A0388|96 97|E7
P08395681A0388|98 114|open reading frames
P08395681A0388|145 166|transforming activities
P08395681A0388|204 224|retinoblastoma protein
P08395681A0388|204 224|retinoblastoma protein
P08395681A0388|226 227|RB
P08395681A0388|226 227|RB
P08395681A0388|237 259|complementation activity
P08395681A0388|263 294|RB-nonbinding adenovirus E1A mutant
P08395681A0388|263 275|RB-nonbinding
P08395681A0388|276 294|adenovirus E1A mutant
P08396120A0690|3 28|rhaB transcription start site
P08396120A0690|3 28|rhaB transcription start site
P08396120A0690|40 42|-24
P08396261A0388|71 81|PKA subunits
P08396261A0388|71 73|PKA
P08396261A0388|85 88|cAMP
P08396261A0388|155 177|adenylyl cyclase activity
P08396261A0388|155 169|adenylyl cyclase
P08396261A0388|202 214|transformants
P08396261A0388|236 239|cAMP
P08396261A0388|252 263|normal growth
P08396261A0388|274 288|wild-type RI cDNA
P08396261A0388|285 288|cDNA
P08396261A0388|302 331|mutant RI cDNA encoding a RI protein
P08396261A0388|302 313|mutant RI cDNA
P08396261A0388|323 331|RI protein
P08396261A0388|343 353|cAMP binding
P08396261A0388|396 420|transformed BL21(DE3) cells
P08396261A0388|443 455|C alpha protein
P08396261A0388|443 455|C alpha protein
P08396657A0452|0 2|Liu
P08396667T0000|0 6|BCR-ABL
P08396667T0000|0 2|BCR
P08396667T0000|4 6|ABL
P08396667T0000|10 23|v-abl oncogenes
P08396667T0000|10 23|v-abl oncogenes
P08396667T0000|48 61|thymic lymphoma
P08396667T0000|80 96|lymphocyte subsets
P08396713A0305|33 40|liganded
P08396713A0305|70 84|nuclear extracts
P08396713A0305|103 137|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|139 142|TCDD
P08396713A0305|155 171|Ah receptor protein
P08396713A0305|155 171|Ah receptor protein
P08396713A0305|175 178|ARNT
P08396713A0305|175 178|ARNT
P08396713A0305|188 209|90-kDa heat shock protein
P08396713A0305|188 209|90-kDa heat shock protein
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112a|0 2|LDL
P08396749A1112a|3 13|cholesterol
P08396749A1112a|70 80|simvastatin
P08396749A1112a|94 97|apo B
P08396749A1112a|94 97|apo B
P08396749A1112b|0 13|LDL cholesterol
P08396749A1112b|0 2|LDL
P08396749A1112b|3 13|cholesterol
P08396749A1112b|70 80|simvastatin
P08396749A1112b|94 97|apo B
P08396749A1112b|94 97|apo B
P08396913A1379|88 94|DGK gene
P08396913A1379|88 94|DGK gene
P08397123T0000|0 16|Regulated activity
P08397123T0000|22 47|distal promoter-like element
P08397123T0000|53 91|human corticotropin-releasing hormone gene
P08397123T0000|53 91|human corticotropin-releasing hormone gene
P08397123T0000|140 150|transcripts
P08399970T0000|33 51|microbial inoculants
P08400240A0166|8 32|hypersensitivity site 2 (HS2
P08400240A0166|41 58|locus control region
P08400240A0166|60 62|LCR
P08400240A0166|67 91|A gamma-globin gene (A gamma*
P08400240A0166|67 83|A gamma-globin gene
P08400240A0166|85 91|A gamma*
P08400240A0166|162 177|gamma-globin mRNA
P08400240A0166|162 177|gamma-globin mRNA
P08400928A0318|0 12|INTERVENTIONS
P08400928A0318|47 81|levodopa/dopa decarboxylase inhibitor
P08400928A0318|47 72|levodopa/dopa decarboxylase
P08400928A0318|94 135|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|94 115|levodopa/decarboxylase
P08400928A0318|158 170|bromocriptine
P08401570A0828|15 34|putative binding sites
P08401570A0828|38 56|transcription factor
P08401570A0828|57 59|Sp1
P08401570A0828|57 59|Sp1
P08401570A0828|110 128|cis-acting enhancers
P08401570A0828|146 165|transcription factors
P08401614A0187|0 9|French bean
P08401614A0187|45 47|PAL
P08401614A0187|45 47|PAL
P08401614A0187|67 70|PAL2
P08401614A0187|67 70|PAL2
P08401614A0187|74 77|PAL3
P08401614A0187|74 77|PAL3
P08401614A0187|124 132|mRNA level
P08401614A0187|135 145|bean tissues
P08403245A1234|6 24|thromboxane B2 levels
P08403245A1234|6 18|thromboxane B2
P08403245A1234|30 39|older group
P08403245A1234|62 75|younger piglets
P08403804A0754|24 41|regression analysis
P08403804A0754|50 58|magnesium
P08403804A0754|84 105|cyclosporin trough level
P08403804A0754|114 124|cholesterol
P08403804A0754|179 189|cyclosporin
P08405433A0000|8 33|insulin-like growth factor II
P08405433A0000|8 33|insulin-like growth factor II
P08405433A0000|35 45|IGF-II) gene
P08405433A0000|35 45|IGF-II) gene
P08405433A0000|58 66|promoters
P08405433A0000|68 75|P1, P2, P3
P08405433A0000|68 69|P1
P08405433A0000|71 72|P2
P08405433A0000|74 75|P3
P08405433A0000|79 80|P4
P08405433A0000|79 80|P4
P08406004A0691|11 37|transient transfection assays
P08406004A0691|39 42|PU.1
P08406004A0691|39 42|PU.1
P08406004A0691|88 100|JB cis-element
P08406004A0691|88 100|JB cis-element
P08406004A0691|142 163|glutamine-rich sequence
P08406004A0691|142 163|glutamine-rich sequence
P08406004A0691|169 189|amino-terminal portion
P08406004A0691|192 195|PU.1
P08406004A0691|192 195|PU.1
P08406352A0172|0 11|Army veterans
P08406352A0172|17 34|yellow fever vaccine
P08406352A0172|51 65|hepatitis B virus
P08406352A0172|75 82|controls
P08406352A0172|107 123|comparing veterans
P08406352A0172|128 150|hepatocellular carcinoma
P08406352A0172|153 176|Veterans Affairs hospitals
P08406352A0172|188 195|controls
P08406352A0172|230 236|vaccine
P08406352A0172|239 242|1942
P08406419A0155|32 41|antibodies
P08406419A0155|44 58|hepatitis C virus
P08406419A0155|61 66|second
P08406419A0155|86 90|RIBA 2
P08406419A0155|127 128|MA
P08406419A0155|127 128|MA
P08406497A0000|0 6|Defects
P08406497A0000|9 17|fibrillin
P08406497A0000|9 17|fibrillin
P08406497A0000|19 22|FBN1
P08406497A0000|19 22|FBN1
P08406497A0000|26 37|glycoprotein
P08406497A0000|52 75|extracellular microfibril
P08406497A0000|82 95|Marfan syndrome
P08407784A0850|18 29|recJ+ strains
P08407784A0850|18 22|recJ+
P08407784A0850|31 43|srjA mutations
P08407784A0850|31 34|srjA
P08407784A0850|53 72|hyperrecombinational
P08407784A0850|76 94|hyper-UVr phenotypes
P08407784A0850|76 84|hyper-UVr
P08408194T0000|24 44|membrane-cytoskeleton
P08408194T0000|48 80|cadherin mediated cell-cell adhesion
P08408194T0000|93 129|different Na+,K(+)-ATPase distributions
P08408194T0000|102 104|Na+
P08408194T0000|106 116|K(+)-ATPase
P08408194T0000|132 149|polarized epithelia
P08408825A0000|0 25|Neonatal lupus erythematosus
P08408825A0000|51 64|autoantibodies
P08408825A0000|72 73|Ro
P08408825A0000|77 86|La antigens
P08408841A0281|7 19|abnormalities
P08408841A0281|35 45|mutagenesis
P08408841A0281|53 76|chromosomal abnormalities
P08408841A0281|80 99|single-gene mutations
P08408841A0281|80 90|single-gene
P08408963A0048|0 3|Hops
P08408963A0048|8 9|L.
P08409284A0262|0 18|Continued absorption
P08409284A0262|21 30|amino acids
P08409284A0262|36 45|NBB carrier
P08409284A0262|50 66|neutral amino acids
P08409284A0262|72 79|Y+ system
P08409284A0262|84 100|dibasic amino acids
P08409284A0262|109 118|PHE carrier
P08409284A0262|145 164|actively purging stage
P08409284A0262|167 181|watery diarrhoea
P08409284A0262|187 193|cholera
P08409593A0357|0 0|1
P08409593A0357|2 5|CFDN
P08409593A0357|7 10|AMPC
P08409593A0357|14 16|MNZ
P08409593A0357|81 84|AMPC
P08409593A0357|98 117|bactericidal activity
P08410042T0000|0 23|Creutzfeldt-Jakob disease
P08410042T0000|27 52|lyophilised dura mater grafts
P08410097A0356|20 24|CLTPA
P08410097A0356|98 116|maximal oxygen uptake
P08410097A0356|118 127|beta -0.163
P08410097A0356|168 177|fibrinogen
P08410097A0356|168 177|fibrinogen
P08410097A0356|197 215|strongest covariates
P08411024T0000|4 14|young people
P08411024T0000|41 54|cystic fibrosis
P08411276A0302|1 7|patient
P08411276A0302|16 25|PIC patient
P08411276A0302|54 59|injury
P08411276A0302|76 102|Revised Trauma Score variables
P08411276A0302|104 124|Glascow Coma Scale score
P08411276A0302|126 146|systolic blood pressure
P08411276A0302|148 162|respiratory rate
P08411276A0302|210 222|Trauma) (ASCOT
P08411276A0302|258 258|A
P08411276A0302|260 260|B
P08411276A0302|265 265|C
P08411276A0302|270 274|ASCOT
P08411276A0302|288 302|serious injuries
P08412120A0839|0 3|Skin
P08412120A0839|12 15|TPO2
P08412120A0839|26 28|DO2
P08412620A0688|40 62|transcription start point
P08412620A0688|65 68|virB
P08412620A0688|65 68|virB
P08412620A0688|121 128|promoter
P08412620A0688|131 134|VirF
P08412620A0688|131 134|VirF
P08412662A0333|15 20|cosmid
P08412662A0333|60 78|transposon insertion
P08412662A0333|81 86|257DH4
P08412662A0333|103 105|Tn5
P08412662A0333|110 127|8.0 kb EcoRI fragment
P08412662A0333|110 127|8.0 kb EcoRI fragment
P08412665A0000|3 12|scr regulon
P08412665A0000|3 12|scr regulon
P08412665A0000|15 20|pUR400
P08412665A0000|27 85|chromosomally encoded scr regulon of Klebsiella pneumoniae KAY2026
P08412665A0000|47 56|scr regulon
P08412665A0000|59 78|Klebsiella pneumoniae
P08412665A0000|79 85|KAY2026
P08412665A0000|115 132|a specific repressor
P08412665A0000|124 132|repressor
P08412665A0000|134 137|ScrR
P08412665A0000|134 137|ScrR
P08413186A0077|107 125|trans-acting factors
P08413186A0077|150 180|nitrate and nitrite reductase genes
P08413186A0077|150 175|nitrate and nitrite reductase
P08413186A0077|201 207|enzymes
P08413186A1199|3 10|Ntl1 gene
P08413186A1199|3 10|Ntl1 gene
P08413186A1199|38 45|diploid N
P08413186A1199|47 68|plumbaginifolia species
P08413205A0733|0 31|Transient transfection experiments
P08413205A0733|44 48|Pax-8
P08413205A0733|44 48|Pax-8
P08413205A0733|69 73|c and d
P08413205A0733|140 171|paired-domain recognition sequence
P08413209A0159|43 66|high-mobility-group motif
P08413209A0159|83 101|DNA-binding proteins
P08413209A0159|83 101|DNA-binding proteins
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|91 102|IL-8 promoter
P08413215A0327|91 102|IL-8 promoter
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|70 90|simian virus 40 promoter
P08413223A0847|70 90|simian virus 40 promoter
P08413223A0847|119 175|phorbol ester- or lipopolysaccharide-inducible gene expression
P08413239A0490|14 20|3'-end-
P08413239A0490|21 38|adjacent sequence CA
P08413239A0490|40 52|N)3-10AGTNNAA
P08413239A0490|70 94|Pol II-specific U snRNA genes
P08413239A0490|70 74|Pol II
P08413239A0490|85 94|snRNA genes
P08413239A0490|113 118|3'-end
P08413239A0490|130 142|U2 transcripts
P08413239A0490|130 142|U2 transcripts
P08413239A0490|169 173|3' box
P08413239A0490|193 200|mutation
P08413260A1437|24 32|Rb protein
P08413260A1437|24 32|Rb protein
P08413260A1437|71 99|cell cycle-regulatory machinery
P08413260A1437|106 112|G2 phase
P08413274A0452|0 3|MDBP
P08413274A0452|0 3|MDBP
P08413274A0452|8 11|HeLa
P08413274A0452|15 23|Raji cells
P08413274A0452|30 49|DNA-protein complexes
P08413274A0452|54 74|X-box oligonucleotides
P08413274A0452|123 131|MDBP sites
P08413291A1473|0 13|Transgenic mice
P08413291A1473|26 45|rat TnI-CAT fusion gene
P08413291A1473|26 45|rat TnI-CAT fusion gene
P08413291A1473|83 96|skeletal muscle
P08414410A0270|17 53|healthy eyes, 169 ocular hypertensive eyes
P08414410A0270|200 209|optic nerve
P08414410A0270|213 227|nerve fiber layer
P08414502A0244|64 82|wild-type p53 protein
P08414502A0244|64 82|wild-type p53 protein
P08414502A0244|125 133|promoters
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|26 35|ARF) family
P08415637A0000|26 35|ARF) family
P08415637A0000|47 57|subfamilies
P08415637A0000|63 76|RAS superfamily
P08415637A0000|63 76|RAS superfamily
P08415637A0000|79 115|low molecular weight GTP-binding proteins
P08415637A0000|97 115|GTP-binding proteins
P08415637A0000|117 125|G proteins
P08415637A0000|117 125|G proteins
P08415643A0555|3 8|E1 gene
P08415643A0555|3 8|E1 gene
P08415643A0555|27 37|first intron
P08415643A0555|50 53|RCC1
P08415643A0555|50 53|RCC1
P08415643A0555|83 89|mitosis
P08415712A1153|7 26|Southern blot analysis
P08415712A1153|30 46|chromosome mapping
P08415712A1153|57 61|GPRK6
P08415712A1153|57 61|GPRK6
P08415712A1153|91 95|genes
P08415712A1153|105 116|chromosomes 5
P08415712A1153|154 157|GPRK
P08415712A1153|154 157|GPRK
P08415712A1153|172 188|Huntington disease
P08415712A1153|196 206|chromosome 4
P08416952A0956|26 37|S. cerevisiae
P08416952A0956|56 61|nmt72p
P08416952A0956|56 61|nmt72p
P08416952A0956|92 96|Nmt1p
P08416952A0956|92 96|Nmt1p
P08416952A0956|129 133|Leu99
P08416952A0956|137 139|Pro
P08416952A0956|140 151|substitution
P08416952A0956|197 213|protein substrates
P08416977A0892|5 14|CTD kinases
P08416977A0892|26 30|CTDK1
P08416977A0892|26 30|CTDK1
P08416977A0892|34 38|CTDK2
P08416977A0892|34 38|CTDK2
P08416977A0892|43 54|fractionated
P08416977A0892|57 70|chromatography
P08416977A0892|73 76|Mono
P08417330A0149|24 36|51-bp promoter
P08417330A0149|46 55|oligo31/32
P08417330A0149|71 91|heat shock inducibility
P08417330A0149|109 129|CYC1-lacZ reporter gene
P08417330A0149|109 129|CYC1-lacZ reporter gene
P08417330A0149|132 143|S. cerevisiae
P08417331A0745|16 23|HIR1 gene
P08417331A0745|16 23|HIR1 gene
P08417331A0745|81 111|G beta subunit of retinal transducin
P08417331A0745|81 92|G beta subunit
P08417331A0745|95 111|retinal transducin
P08417331A0745|118 146|yeast transcriptional repressor
P08417331A0745|118 146|yeast transcriptional repressor
P08417331A0745|148 151|Tup1
P08417331A0745|148 151|Tup1
P08417349A1633|38 56|UV-damaged templates
P08418183A0000|59 90|human T cell leukemia/lymphoma virus
P08418183A0000|91 95|type I
P08418183A0000|97 102|HTLV-I
P08418183A0000|97 102|HTLV-I
P08418183A0000|206 224|HTLV-I-seropositive
P08418183A0000|226 245|H+)/wife seropositive
P08418183A0000|247 278|W+), 33 H+/W-, 64 H-/W+, and 342 H-/W-.
P08419333A0126|33 47|DNA repair enzyme
P08419376A0357|3 20|nucleotide sequence
P08419376A0357|52 64|215 amino acids
P08419376A0357|81 112|putative membrane-spanning domains
P08420230A0544|0 4|SAECG
P08420230A0544|25 43|thallium-201 imaging
P08420230A0544|77 96|attempted angioplasty
P08420571A1880|14 18|PACE4
P08420571A1880|14 18|PACE4
P08420571A1880|22 24|PC4
P08420571A1880|22 24|PC4
P08421295A0365|4 17|fusion proteins
P08421295A0365|50 63|short DNA duplex
P08421295A0365|76 79|CTGT
P08421295A0365|81 105|at)4ACAG consensus sequence
P08421295A0365|111 123|LexA repressor
P08421295A0365|111 123|LexA repressor
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|12 33|Free protein S deficiency
P08421823A1041|16 23|protein S
P08421823A1041|47 66|hospitalized patients
P08421897A0000|46 64|retroviral sequences
P08421897A0000|85 95|human genome
P08421897A0000|105 130|low stringency hybridization
P08421897A0000|140 148|DNA probes
P08421910A0599|43 47|TRBPs
P08421910A0599|43 47|TRBPs
P08421910A0599|49 51|p30
P08421910A0599|49 51|p30
P08421910A0599|53 55|p37
P08421910A0599|53 55|p37
P08421910A0599|57 59|p46
P08421910A0599|57 59|p46
P08421910A0599|61 63|p50
P08421910A0599|61 63|p50
P08421910A0599|68 70|p56
P08421910A0599|68 70|p56
P08421910A0599|99 104|TAR RNA
P08421910A0599|99 101|TAR
P08421910A0599|102 104|RNA
P08421910A0599|122 141|uv cross-linking assay
P08421910A0599|122 123|uv
P08422975A1205|54 65|mitochondria
P08422975A1205|82 98|translatable mRNAs
P08423831A0523|72 90|denervating diseases
P08425050A0898|11 24|inverted repeat
P08425050A0898|38 41|rpeA
P08425050A0898|38 41|rpeA
P08425050A0898|81 82|PE
P08425221A0000|16 40|cytoplasmic tyrosine kinase
P08425221A0000|16 40|cytoplasmic tyrosine kinase
P08425221A0000|48 50|BPK
P08425221A0000|48 50|BPK
P08425221A0000|52 72|B cell progenitor kinase
P08425221A0000|57 72|progenitor kinase
P08425221A0000|107 114|B lineage
P08425221A0000|120 131|myeloid cells
P08427501A0221|49 69|HA-synthesizing enzyme
P08427501A0221|49 69|HA-synthesizing enzyme
P08427501A0221|82 106|degradative enzyme activity
P08427501A0221|122 128|aspirin
P08427501A0221|137 156|asthma-related polyps
P08427501A0221|175 185|nasal polyps
P08428722A1123|0 24|In the multivariate analysis
P08428722A1123|78 94|blood urea nitrogen
P08428722A1123|101 114|serum aspartate
P08428722A1123|106 130|aspartate aminotransferase
P08428722A1123|191 205|Child-Pugh score
P08428722A1123|209 213|ileus
P08428750T0000|0 11|Localization
P08428750T0000|17 30|intronless gene
P08428750T0000|40 64|calmodulin-like protein CLP
P08428750T0000|40 61|calmodulin-like protein
P08428750T0000|62 64|CLP
P08428750T0000|67 90|human chromosome 10p13-ter
P08428907A0653|2 21|wandering stage larvae
P08428907A0653|26 38|OBP transcript
P08428907A0653|26 38|OBP transcript
P08428907A0653|82 93|ribosomal RNA
P08428940A1763|27 40|overlapping -10
P08428940A1763|50 51|PR
P08428940A1763|50 51|PR
P08428940A1763|86 105|MerR and RNA polymerase
P08428940A1763|86 89|MerR
P08428940A1763|93 105|RNA polymerase
P08428940A1763|124 159|inefficient transcriptional initiation
P08428940A1763|162 169|merR mRNA
P08428940A1763|162 169|merR mRNA
P08428952A0399|8 16|L-plastin
P08428952A0399|8 16|L-plastin
P08428952A0399|42 60|malignant human cells
P08428952A0399|63 83|non-hemopoietic origin
P08428952A0399|132 144|tumorigenesis
P08428952A0399|147 158|solid tissues
P08428952A1957|29 35|fimbrin
P08428952A1957|52 65|plastin isoform
P08428952A1957|111 124|small intestine
P08428953A1718|4 11|promoter
P08428953A1718|53 78|reporter beta-galactosidase
P08428953A1718|61 78|beta-galactosidase
P08428953A1718|96 114|transfected colonies
P08428953A1718|117 132|transformed cells
P08428953A1718|144 152|L-plastin
P08428953A1718|144 152|L-plastin
P08428953A1718|183 190|promoter
P08428953A1718|213 231|transfected colonies
P08428953A1718|234 250|normal fibroblasts
P08428953A1718|304 322|transfected colonies
P08428953A1718|325 358|in vitro SV40-transformed fibroblasts
P08428953A1718|377 395|L-plastin expression
P08428953A1718|377 385|L-plastin
P08428965A1868|30 50|CBP/tk binding activity
P08428965A1868|30 32|CBP
P08428965A1868|34 35|tk
P08429019A0735|3 17|DNase I footprint
P08429019A0735|3 8|DNase I
P08429019A0735|33 46|silencer region
P08429019A0735|58 71|inverted repeat
P08429019A0735|75 93|six-nucleotide motif
P08429019A0735|95 113|epsilon -267 to -278 bp
P08429019A0735|142 164|GATA-1 consensus sequence
P08429019A0735|142 147|GATA-1
P08429019A2022|35 54|YY1 consensus sequence
P08429019A2022|35 54|YY1 consensus sequence
P08429019A2022|66 80|protein B binding
P08429019A2022|66 73|protein B
P08429019A2022|117 126|yeast ABF-1
P08429019A2022|122 143|ABF-1 consensus sequence
P08429019A2022|127 143|consensus sequence
P08429020A0495|31 37|introns
P08429020A0495|74 89|open reading frame
P08429020A0495|93 106|glycoprotein IX
P08429020A0495|93 106|glycoprotein IX
P08429020A0495|126 134|third exon
P08429568A0000|0 16|Rhizobium meliloti
P08429568A0000|17 21|large
P08429568A0000|22 36|plasmid pRmeGR4b
P08429568A0000|47 76|nodulation competitiveness locus
P08429568A0000|97 116|nodulation efficiency
P08429568A0000|146 148|GR4
P08429568A0000|151 162|alfalfa roots
P08430087A0467|20 51|recombinant beta and/or gamma chains
P08430087A0467|20 34|recombinant beta
P08430087A0467|41 51|gamma chains
P08430087A0467|71 87|biochemical assays
P08430087A0467|90 106|beta gamma activity
P08430087A0467|90 98|beta gamma
P08430087A0467|121 136|membrane extracts
P08430087A0467|172 179|Sf9 cells
P08430095A0161|61 64|SMD1
P08430095A0161|61 64|SMD1
P08430095A0161|88 92|PRP38
P08430095A0161|88 92|PRP38
P08430095A0913|18 22|Smd1p
P08430095A0913|18 22|Smd1p
P08430095A0913|48 72|cellular splicing apparatus
P08431100A0108|52 85|traumatically brain-injured children
P08431100A0108|149 167|normal children group
P08432137A0000|23 47|pleural adenosine deaminase
P08432137A0000|30 47|adenosine deaminase
P08432137A0000|49 52|PADA
P08432137A0000|49 52|PADA
P08432137A0000|69 76|patients
P08432137A0000|82 99|PADA/serum ADA ratio
P08432137A0000|82 85|PADA
P08432137A0000|87 94|serum ADA
P08432137A0000|101 106|P/SADA
P08432137A0000|101 101|P
P08432137A0000|103 106|SADA
P08432137A0000|118 132|pleural lysozyme
P08432137A0000|118 124|pleural
P08432137A0000|125 132|lysozyme
P08432137A0000|134 137|PLYS
P08432137A0000|134 137|PLYS
P08432137A0000|152 169|PLYS/serum LYS ratio
P08432137A0000|152 155|PLYS
P08432137A0000|157 164|serum LYS
P08432137A0000|171 176|P/SLYS
P08432137A0000|171 171|P
P08432137A0000|173 176|SLYS
P08432137A0000|191 216|pleural interferon gamma (IFN
P08432137A0000|191 212|pleural interferon gamma
P08432137A0000|214 216|IFN
P08432137A0000|274 289|pleural effusions
P08432526A0580|46 50|cDNAs
P08432526A0580|61 96|polymerase chain reaction amplification
P08432526A0580|100 120|fibroblast cDNA library
P08432696A1117|0 7|Deletion
P08432696A1117|13 20|apeA gene
P08432696A1117|13 20|apeA gene
P08432696A1117|56 66|proteinases
P08432696A1117|68 77|protease IV
P08432696A1117|68 77|protease IV
P08432696A1117|81 96|aminopeptidase N)
P08432696A1117|81 95|aminopeptidase N
P08432696A1117|119 128|cell growth
P08435755A0938|2 35|Experiment 2 scopolamine hydrobromide
P08435755A0938|113 115|rat
P08435755A1078|0 2|PNT
P08435755A1078|4 6|ADD
P08435755A1078|10 12|BSS
P08435755A1078|32 39|kindling
P08435755A1078|59 70|stage-3 and -5
P08435755A1078|80 96|seizure parameters
P08435755A1078|107 118|stage-3 and -5
P08435755A1078|155 181|saline-treated, control group
P08435885A0787|35 63|pyridinium cross-link excretion
P08435885A0787|67 94|thyroid hormone concentrations
P08435885A0787|67 80|thyroid hormone
P08437521A0000|9 18|truncating
P08437521A0000|27 47|143 C-terminal residues
P08437521A0000|55 78|transcriptional activator
P08437521A0000|91 98|areA gene
P08437521A0000|91 98|areA gene
P08437521A0000|109 116|nitrogen
P08437521A0000|139 157|Aspergillus nidulans
P08437521A0000|198 208|areA product
P08437521A0000|198 208|areA product
P08437521A0000|235 239|genes
P08437521A0000|245 255|areA control
P08437521A0000|245 248|areA
P08437737A0100|0 13|Naval personnel
P08437737A0100|36 37|BF
P08438584A0524|0 19|Weak promoter activity
P08438584A0524|50 51|C1
P08438584A0524|50 51|C1
P08438584A0524|55 60|C2 ORFs
P08438584A0524|55 56|C2
P08438584A0524|57 60|ORFs
P08438584A0524|62 70|C1-C2 gene
P08438584A0524|62 70|C1-C2 gene
P08438584A0524|94 95|V1
P08438584A0524|96 98|ORF
P08438584T0000|16 34|coat protein promoter
P08438584T0000|16 34|coat protein promoter
P08438584T0000|83 99|C1-C2 gene products
P08438584T0000|83 91|C1-C2 gene
P08439564A0883|3 19|amino acid sequence
P08439564A0883|20 34|alignment of TC II
P08439564A0883|31 34|TC II
P08439564A0883|50 67|Cbl binding proteins
P08439564A0883|50 67|Cbl binding proteins
P08439564A0883|69 86|rat intrinsic factor
P08439564A0883|69 86|rat intrinsic factor
P08439564A0883|88 107|human transcobalamin I
P08439564A0883|88 107|human transcobalamin I
P08439564A0883|111 128|porcine haptocorrin
P08439564A0883|111 128|porcine haptocorrin
P08439597A0000|36 74|fluorimetric microplate enzyme immunoassay
P08439597A0000|76 79|FEIA
P08439597A0000|147 157|thyrotropin
P08439597A0000|147 157|thyrotropin
P08439597A0000|160 174|dried blood spots
P08439597A0176|59 77|newborn blood samples
P08440238T0000|12 21|C-terminus
P08440238T0000|24 46|adenovirus 2/5 E1a protein
P08440238T0000|24 46|adenovirus 2/5 E1a protein
P08440238T0000|76 97|cellular phosphoprotein
P08440238T0000|136 142|T24-ras
P08440238T0000|136 142|T24-ras
P08440238T0000|182 191|metastasis
P08440688A1509|31 42|G alpha i genes
P08440688A1509|31 36|G alpha
P08440688A1509|68 79|LLC-PK1 cells
P08440688A1509|86 91|growth
P08440688A1509|93 107|differentiation
P08440688A1509|112 125|hormone signals
P08440720A1404|23 42|full-length PfCPK cDNA
P08440720A1404|34 42|PfCPK cDNA
P08440720A1404|62 76|Escherichia coli
P08440720A1404|100 123|60-kDa recombinant protein
P08441379A0912|16 33|proIL-1 beta cap site
P08441379A0912|16 33|proIL-1 beta cap site
P08441379A0912|34 48|-proximal region
P08441379A0912|82 127|proIL-1 beta and the simian virus 40 enhancer elements
P08441379A0912|82 92|proIL-1 beta
P08441379A0912|99 127|simian virus 40 enhancer elements
P08441379A0912|155 163|monocytes
P08441379A0912|170 178|HeLa cells
P08441379A0912|211 228|IL-1 beta expression
P08441379A0912|211 218|IL-1 beta
P08441394A1297|10 15|PC-PLC
P08441394A1297|10 15|PC-PLC
P08441394A1297|31 55|signal transduction pathway
P08441394A1297|65 77|transcription
P08441394A1297|80 84|c-fos
P08441394A1297|80 84|c-fos
P08441394A1297|88 91|junB
P08441394A1297|88 91|junB
P08441394A1297|112 116|c-myc
P08441394A1297|112 116|c-myc
P08441394A1297|135 143|PKC-delta
P08441394A1297|135 143|PKC-delta
P08441394A1297|147 159|Ras activation
P08441394A1297|147 149|Ras
P08441411A1260|2 30|mitogen-stimulated splenocytes
P08441411A1260|32 46|Gfi-1 expression
P08441411A1260|32 36|Gfi-1
P08441411A1260|192 195|IL-2
P08441411A1260|192 195|IL-2
P08441411A1260|245 257|G1 to the S phase
P08441411A1260|263 271|cell cycle
P08441423A0145|33 48|GCD6 and GCD7 genes
P08441423A0145|33 36|GCD6
P08441423A0145|40 48|GCD7 genes
P08441423A0145|94 108|GCN4 translation
P08441423A0145|94 97|GCN4
P08441423A0145|114 136|nonstarvation conditions
P08441869A0334|3 17|plateau MO2 value
P08442384A0430|38 50|824 amino acids
P08442384A0430|62 77|open reading frame
P08442384A0430|79 82|uORF
P08442384A0430|93 100|5' leader
P08442384A0430|126 141|amino acid peptide
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08442384T0000|33 44|long 5' leader
P08442384T0000|55 70|open reading frame
P08443122A0657|12 17|T cells
P08443122A0657|21 31|fibroblasts
P08443122A0657|32 40|PILOT gene
P08443122A0657|32 36|PILOT
P08443122A0657|73 75|PMA
P08443122A0657|95 97|CyA
P08443339A1374|0 24|Histochemical localization
P08443339A1374|27 29|GUS
P08443339A1374|27 29|GUS
P08443339A1374|56 68|leaf epidermis
P08443339A1374|70 78|mesophyll
P08443339A1374|82 96|vascular bundles
P08443339A1374|103 108|cortex
P08443339A1374|112 136|vascular cylinder of the root
P08443340A0522|87 92|acidic
P08443340A0522|97 110|basic glucanase
P08443340A0522|120 154|beta-glucuronidase (GUS) reporter gene
P08443340A0522|120 137|beta-glucuronidase
P08443340A0522|139 141|GUS
P08443340A0522|195 211|transgenic tobacco
P08443340A0522|212 217|plants
P08443341A0384|0 19|Southern blot analysis
P08443341A0384|53 63|genomic and B
P08443341A0384|63 71|B. napus MA
P08443341A0384|65 86|napus MA and MB cDNA clones
P08443341A0384|75 80|MB cDNA
P08443341A0384|97 113|MA type myrosinases
P08443341A0384|103 113|myrosinases
P08443341A0384|139 144|4 genes
P08443341A0384|151 167|MB type myrosinases
P08443341A0384|157 167|myrosinases
P08443341A0384|197 203|B. napus
P08444184A0245|0 8|Sudomoina
P08444344A0000|0 10|Zinc fingers
P08444344A0000|12 13|Zf
P08444344A0000|51 77|nucleic acid-binding proteins
P08444345A0403|10 42|bovine EFIA#1 amino acid (aa) sequence
P08444345A0403|16 42|EFIA#1 amino acid (aa) sequence
P08444345A0403|59 65|rat EFIA
P08444345A0403|62 65|EFIA
P08444345A0403|84 97|human EFIA/DbpB
P08444345A0403|89 92|EFIA
P08444345A0403|94 97|DbpB
P08444345A0403|99 133|YB-1 family member DNA-binding protein B
P08444345A0403|99 102|YB-1
P08444345A0403|115 133|DNA-binding protein B
P08444345A0403|135 138|DbpB
P08444345A0403|135 138|DbpB
P08445299T0000|44 61|acute ozone toxicity
P08445299T0000|64 67|rats
P08445655A1009|0 11|Localization
P08445655A1009|36 46|yeast genome
P08445655A1009|79 105|temperature-sensitive mutant
P08445655A1009|124 132|mutations
P08445729A0657|16 29|spacer sequence
P08445729A0657|43 46|ARMs
P08445729A0657|87 96|RNA binding
P08445792A0469|0 5|Type II
P08445792A0469|40 42|IIA
P08445792A0469|40 42|IIA
P08445792A0469|46 48|IIB
P08445792A0469|46 48|IIB
P08445792A0469|69 87|underscribed species
P08445792A0469|90 108|developmental stages
P08446579A0784|10 34|transcription factor Gal-ER
P08446579A0784|10 28|transcription factor
P08446579A0784|29 34|Gal-ER
P08446579A0784|76 101|cell type-specific variation
P08446579A0784|113 134|strong activating domain
P08446579A0784|140 161|herpesvirus protein VP16
P08446579A0784|140 161|herpesvirus protein VP16
P08446579A0784|169 177|C terminus
P08446579A1210|3 18|exogenous fos gene
P08446579A1210|12 18|fos gene
P08447005T0001|0 10|Elimination
P08447005T0001|13 38|Haemophilus influenzae type b
P08447005T0001|68 78|vaccination
P08449133A0578|32 45|tumor extension
P08449133A0578|51 58|T2 tumors
P08449133A0578|62 63|T3
P08449133A0578|64 69|tumors
P08449133A0578|79 86|T4 tumors
P08449943A0225|57 65|8-Cl-cAMP
P08449943A0225|88 101|kinase isozymes
P08449943A0225|104 139|HL-60 human promyelocytic leukemia cells
P08449978A0000|10 28|cell cycle regulation
P08449978A0000|41 45|yeast
P08449978A0000|46 68|Saccharomyces cerevisiae
P08449978A0000|82 111|central regulatory protein kinase
P08449978A0000|99 111|protein kinase
P08449978A0000|113 117|Cdc28
P08449978A0000|113 117|Cdc28
P08449978A0000|155 163|cell cycle
P08449978A0000|197 203|cyclins
P08449978A0000|197 203|cyclins
P08449986A0455|0 16|Overlapping clones
P08449986A0455|40 44|cDNAs
P08449986A0455|48 55|MMI alpha
P08449986A0455|48 55|MMI alpha
P08449986A0455|72 81|mouse brain
P08450015A0175|39 48|oxiracetam
P08450015A0175|80 100|solid-phase extraction
P08450015A0175|122 154|their n-propyl carbamate derivatives
P08451331T0000|18 26|olfactory
P08451331T0000|39 52|medial preoptic
P08451331T0000|53 60|anterior
P08451331T0000|88 106|intermale aggression
P08451331T0000|109 112|mice
P08453101A0128|0 14|Pokeweed mitogen
P08453101A0128|8 14|mitogen
P08453101A0128|16 18|PWM
P08453101A0128|16 18|PWM
P08453101A0128|22 29|anti-CD3
P08453101A0128|22 29|anti-CD3
P08453101A0128|52 73|c-jun messenger RNA (mRNA
P08453101A0128|52 68|c-jun messenger RNA
P08453101A0128|70 73|mRNA
P08453101A0128|83 88|T cells
P08453950A0498|9 24|seizure induction
P08453950A0498|26 29|MABP
P08453950A0498|46 58|Hg and brain pHi
P08454077A0956|11 14|rats
P08454077A0956|24 30|U74500A
P08454077A0956|40 49|v. infusion
P08454077A0956|99 110|enhanced GMBF
P08454077A0956|121 131|reperfusion
P08454077A0956|133 134|PI
P08454077A0956|223 229|normals
P08454077A0956|243 255|muscle salvage
P08454077A0956|257 259|GMV
P08454077A0956|320 321|NS
P08454591A0692|13 32|1.3-kilobase fragment
P08454591A0692|38 54|5'-flanking region
P08454591A0692|60 67|TSG6 gene
P08454591A0692|60 67|TSG6 gene
P08454591A0692|78 102|TATA-like and CAAT sequences
P08454591A0692|110 131|transcription start site
P08454591A1322|34 37|IL-1
P08454591A1322|34 37|IL-1
P08454591A1322|40 61|TNF (positions -165 to -58
P08454591A1322|40 42|TNF
P08454591A1322|95 104|IRF-1 and -2
P08454591A1322|95 104|IRF-1 and -2
P08454591A1322|106 109|AP-1
P08454591A1322|106 109|AP-1
P08454591A1322|114 120|NF-IL-6
P08454591A1322|114 120|NF-IL-6
P08454858A0285|0 7|Ig-alpha
P08454858A0285|0 7|Ig-alpha
P08454858A0285|11 17|Ig-beta
P08454858A0285|11 17|Ig-beta
P08454858A0285|33 52|cytoplasmic structure
P08454858A0285|101 120|cytoplasmic effectors
P08454858A0285|160 177|signal transduction
P08455598A0000|16 38|Saccharomyces cerevisiae
P08455598A0000|55 65|alpha * cells
P08455598A0000|75 95|a/alpha aar1-6 genotype
P08455598A0000|75 87|a/alpha aar1-6
P08455598A0000|107 117|alpha mating
P08455598A0000|166 184|a1-alpha 2 repression
P08455598A0000|166 174|a1-alpha 2
P08455611A0000|40 72|human embryonic zeta 2 globin promoter
P08455611A0000|40 72|human embryonic zeta 2 globin promoter
P08455611A0000|79 106|alpha globin regulatory element
P08455611A0000|79 106|alpha globin regulatory element
P08455611A0000|108 112|HS-40
P08455611A0000|108 112|HS-40
P08455611A0000|121 132|40 kb upstream
P08455611A0000|138 152|zeta 2 globin gene
P08455611A0000|138 152|zeta 2 globin gene
P08455611A0154|12 35|transient expression assay
P08455611A0154|40 44|HS-40
P08455611A0154|40 44|HS-40
P08455611A0154|65 72|enhancer
P08455611A0154|86 112|zeta 2 globin promoter activity
P08455611A0154|86 104|zeta 2 globin promoter
P08455611A0154|115 123|K562 cells
P08455611A0154|127 143|erythroid cell line
P08455623A0630|30 40|23S pre-rRNA
P08455623A0630|30 40|23S pre-rRNA
P08455623A0630|86 121|small nucleolar RNA-associated proteins
P08455623A0630|86 121|small nucleolar RNA-associated proteins
P08455623A0630|122 125|NOP1
P08455623A0630|122 125|NOP1
P08455623A0630|129 132|GAR1
P08455623A0630|129 132|GAR1
P08455623A0630|140 156|snr10 mutant strain
P08455623A0630|140 150|snr10 mutant
P08455629A0335|0 8|Breitbart
P08456378A0134|71 91|colonoscopic technique
P08456378A0134|95 105|canine model
P08456879A0000|65 77|serum cotinine
P08456879A0000|84 104|fetal and maternal blood
P08457205A0240|8 24|amino acid sequence
P08457205A0240|114 130|mammalian G alpha 11
P08457205A0240|114 130|mammalian G alpha 11
P08457205A0240|134 145|G alpha q cDNAs
P08457205A0240|134 139|G alpha
P08457205A0240|141 145|cDNAs
P08457291A0170|0 8|Estradiol
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|111 131|cellular c-fos oncogene
P08457291A0170|111 131|cellular c-fos oncogene
P08458849A0364|25 41|flaN transcription
P08458849A0364|25 28|flaN
P08458849A0364|58 72|sigma 54 promoter
P08458849A0364|79 89|ftr elements
P08458849A0364|112 133|transcription start site
P08458849A0364|140 143|ftr2
P08458849A0364|148 151|+120
P08458849A0364|153 156|ftr3
P08458906A0827|39 70|non-occupationally exposed persons
P08459012T0000|0 13|Fibular dimelia
P08459012T0000|18 27|deficiency
P08459012T0000|33 37|tibia
P08459465A0257|61 68|patients
P08459465A0257|147 169|Harris-Benedict equation
P08459465A0257|265 276|stress factor
P08460270A0205|32 47|hypobiotic larvae
P08460346A0350|19 31|double blinded
P08460346A0350|44 66|placebo-controlled study
P08460918A0252|5 5|I
P08460918A0252|20 41|noncholestatic patients
P08460918A0252|43 49|group II
P08460918A0252|65 89|mildly cholestatic patients
P08460918A0252|143 149|liter-1
P08460918A0252|151 169|alkaline phosphatase
P08460918A0252|151 169|alkaline phosphatase
P08460918A0252|176 211|liter-1; gamma-glutamyltranspeptidase
P08460918A0252|184 211|gamma-glutamyltranspeptidase
P08460918A0252|218 224|liter-1
P08460918A0252|227 234|group III
P08460918A0252|255 266|intrahepatic
P08460918A0252|278 285|patients
P08460918A0252|340 346|liter-1
P08461946A0386|39 57|renographic findings
P08461946A0386|91 98|patients
P08461981A0882|21 27|animals
P08461981A0882|58 62|adult
P08461981A0882|101 104|rats
P08463284A1531|0 15|Nuclear beta II PKC
P08463284A1531|0 15|Nuclear beta II PKC
P08463284A1531|21 33|p34cdc2 kinase
P08463284A1531|21 33|p34cdc2 kinase
P08463284A1531|94 102|cell cycle
P08463320A1219|2 38|situ copper-phenanthroline footprinting
P08463320A1219|51 79|gel shift assembly intermediates
P08463320A1219|94 113|302-nucleotide G4oric
P08463320A1219|126 145|SSB tetramers assemble
P08463320A1219|126 137|SSB tetramers
P08463320A1219|175 186|SSB tetramers
P08463320A1219|175 186|SSB tetramers
P08463485T0000|40 69|milking-induced oxytocin release
P08463485T0000|55 62|oxytocin
P08464056A0000|0 37|Finger associated box-zinc finger proteins
P08464056A0000|0 37|Finger associated box-zinc finger proteins
P08464056A0000|39 46|FAX-ZFPs
P08464056A0000|39 46|FAX-ZFPs
P08464056A0000|77 88|C2H2 type ZFPs
P08464056A0000|77 88|C2H2 type ZFPs
P08464056A0000|91 103|Xenopus laevis
P08464056A0510|42 48|FAX-ZFP
P08464056A0510|42 48|FAX-ZFP
P08464056A0510|49 66|transcription units
P08464056A0510|79 98|Southern blot analysis
P08464056A0510|106 132|genomic restriction fragments
P08464056A0510|144 176|transverse field gel electrophoresis
P08464056A0510|183 201|in situ hybridization
P08464056A0510|210 220|chromosomes
P08464924A0243|1 7|rat cDNA
P08464924A0243|19 23|eIF-5
P08464924A0243|19 23|eIF-5
P08464924A0243|53 67|Escherichia coli
P08464924A0243|76 106|catalytically active eIF-5 protein
P08464924A0243|95 106|eIF-5 protein
P08466864A0878|0 17|Mutational analyses
P08466864A0878|67 78|327 bp segment
P08466864A0878|99 138|cyclic AMP responsive element binding protein
P08466864A0878|99 138|cyclic AMP responsive element binding protein
P08466864A0878|140 143|CREB
P08466864A0878|140 143|CREB
P08466864A0878|159 167|TGF-beta 1
P08466864A0878|159 167|TGF-beta 1
P08466864A0878|171 187|PMA responsiveness
P08466864A0878|191 220|putative PU-1 and Sp1 binding sites
P08466864A0878|199 202|PU-1
P08466864A0878|206 208|Sp1
P08466864A0878|229 244|promoter activity
P08468475A1280|17 37|internalization assays
P08468475A1280|40 48|forskolin
P08468475A1280|57 65|YT-1 cells
P08468475A1280|57 60|YT-1
P08468475A1280|70 84|IL-2R alpha chain
P08468475A1280|70 84|IL-2R alpha chain
P08468475A1280|99 109|endocytosed
P08468475A1280|125 140|IL-2R beta subunit
P08468475A1280|125 140|IL-2R beta subunit
P08468475A1280|155 164|IL-2R alpha
P08468475A1280|155 164|IL-2R alpha
P08468475A1280|190 203|F42A-IL-2R beta
P08468475A1280|190 203|F42A-IL-2R beta
P08468475A1280|224 236|alpha-subunit
P08468475A1280|224 236|alpha-subunit
P08468475A1280|272 290|F42A binding reaction
P08469831T0001|3 26|microcirculatory dynamics
P08469831T0001|29 43|prostaglandin E1
P08469831T0001|92 116|hyper- and hypodynamic state
P08469831T0001|119 129|septic shock
P08469831T0001|133 140|rat model
P08470021A0195|25 37|IgG antibodies
P08470021A0195|25 27|IgG
P08470021A0195|70 80|blood donors
P08470021A0195|133 142|Mexico City
P08470895A1617|16 32|immediate sequence
P08470895A1617|33 34|5'
P08470895A1617|40 52|mRNA start site
P08470895A1617|62 68|TATA box
P08470895A1617|85 101|enhancer sequences
P08471241T0000|3 21|short-term synthesis
P08471241T0000|25 30|infant
P08471241T0000|56 69|lactating women
P08471629A0816|0 14|Pseudosubstrate
P08471629A0816|37 46|C-terminus
P08471629A0816|49 71|Ca-dependent PKC isotypes
P08471629A0816|49 71|Ca-dependent PKC isotypes
P08471629A0816|82 107|beta-PKC but not nPKC activity
P08471629A0816|82 89|beta-PKC
P08471629A0816|96 99|nPKC
P08471629A0816|119 129|Histone IIIS
P08471629A0816|119 129|Histone IIIS
P08471629A0816|132 144|peptide(19-31
P08471629A0816|132 138|peptide
P08471629A0816|140 144|19-31
P08471796A1654|47 67|nif/fix gene expression
P08471796A1654|47 49|nif
P08471796A1654|51 57|fix gene
P08471796A1654|70 82|A. caulinodans
P08472750A0999|0 10|Nitric oxide
P08472750A0999|39 59|pulmonary hypertension
P08472750A0999|62 68|porcine
P08472750A0999|69 82|endotoxin shock
P08472750A0999|94 112|arterial oxygenation
P08472750A0999|116 117|pH
P08472750A0999|142 162|sympathetic activation
P08473731A0149|0 28|B cell-specific mb-1 and B29 genes
P08473731A0149|0 17|B cell-specific mb-1
P08473731A0149|21 28|B29 genes
P08473731A0149|38 57|alpha/beta components
P08473731A0149|38 57|alpha/beta components
P08473731A0149|63 83|BCR-associated complex
P08473731A0149|63 83|BCR-associated complex
P08473731A0149|86 102|mature sIgM+ B cells
P08473731A0149|92 97|sIgM+ B
P08473967T0000|0 9|Bipolarity
P08473967T0000|35 59|Myers-Briggs Type Indicator
P08474438A0000|10 34|nuclear ribonucleoproteins
P08474438A0000|17 34|ribonucleoproteins
P08474438A0000|69 101|nascent RNA polymerase II transcripts
P08474438A0000|76 101|RNA polymerase II transcripts
P08474438A0000|137 165|nuclear RNA processing reactions
P08474438A0000|176 209|pre-mRNA polyadenylation and splicing
P08474438A0000|218 247|nucleocytoplasmic mRNA transport
P08474439A0877|0 8|Mutations
P08474439A0877|40 45|muscle
P08474439A0877|50 63|nonmuscle cells
P08474439A0877|67 86|A/T-rich site mutation
P08474439A0877|67 67|A
P08474439A0877|69 78|T-rich site
P08474439A0877|113 131|striated muscle types
P08474439A0877|147 166|MEF1 (Right E-box) site
P08474439A0877|147 166|MEF1 (Right E-box) site
P08474439A0877|202 215|skeletal muscle
P08474439A0877|234 241|CArG site
P08474439A0877|234 241|CArG site
P08474439A0877|277 289|cardiac muscle
P08474456A1041|0 28|Transient transfection analysis
P08474456A1041|38 46|mutations
P08474456A1041|64 74|10-bp region
P08474456A1041|98 128|Ets and proximal LyF-1 binding sites
P08474456A1041|98 100|Ets
P08474456A1041|112 128|LyF-1 binding sites
P08474464A0348|35 36|TR
P08474464A0348|35 36|TR
P08474464A0348|38 44|Rev-Erb
P08474464A0348|38 40|Rev
P08474464A0348|42 44|Erb
P08474464A0348|58 71|TR binding sites
P08474464A0348|58 71|TR binding sites
P08475104A0341|22 36|promoter element
P08475104A0341|71 84|G1-S activation
P08475104A0341|71 74|G1-S
P08475104A0341|90 122|human thymidine kinase (htk) promoter
P08475104A0341|90 109|human thymidine kinase
P08475104A0341|111 113|htk
P08475104A0341|125 146|growth-stimulated cells
P08475104A0341|166 172|cyclin A
P08475104A0341|166 172|cyclin A
P08475104A0341|179 194|p33cdk2 complexes
P08475104A0341|179 194|p33cdk2 complexes
P08476854A0097|0 17|DNase I footprinting
P08476854A0097|0 5|DNase I
P08476854A0097|22 44|rat liver nuclear extracts
P08476854A0097|56 82|major protein-binding domains
P08476854A0097|89 90|P1
P08476854A0097|89 90|P1
P08476854A0097|98 99|P7
P08476854A0097|98 99|P7
P08476854A0097|103 143|796 base pair DNA fragment (base pairs -763 to +33
P08479742A0985|52 54|p53
P08479742A0985|52 54|p53
P08479742A0985|64 80|cell proliferation
P08479742A0985|99 117|neoplastic processes
P08481004A0321|7 11|clone
P08481004A0321|29 40|endonuclease
P08482539A0913|0 19|Northern blot analysis
P08482539A0913|27 37|cellular RNA
P08482539A0913|51 54|xylP
P08482539A0913|51 54|xylP
P08482539A0913|63 78|1.3-kb transcript
P08482539A0913|95 99|xylan
P08483412A0000|3 6|nifJ
P08483412A0000|3 6|nifJ
P08483412A0000|10 22|nifH promoters
P08483412A0000|10 22|nifH promoters
P08483412A0000|25 44|Klebsiella pneumoniae
P08483412A0000|70 95|sigma 54-dependent promoters
P08483412A0000|127 137|NifA protein
P08483412A0000|127 137|NifA protein
P08483479A1056|17 19|PTH
P08483479A1056|17 19|PTH
P08483479A1056|23 26|cAMP
P08483479A1056|37 52|collagen promoter
P08483479A1056|45 60|promoter activity
P08483479A1056|76 89|transgenic mice
P08483479A1056|108 132|alpha 1(I) collagen promoter
P08483479A1056|108 113|alpha 1
P08483479A1056|115 132|I) collagen promoter
P08483479A1056|143 153|cis elements
P08483479A1056|191 210|PTH and cAMP repression
P08483479A1056|191 193|PTH
P08483479A1056|213 224|collagen gene
P08483479A1056|221 234|gene expression
P08483479A1056|237 240|bone
P08484689T0000|12 30|rheumatoid arthritis
P08484689T0000|34 49|rheumatoid factor
P08484689T0000|34 49|rheumatoid factor
P08484689T0000|52 56|women
P08484891A0000|8 39|olfactory associative conditioning
P08484891A0000|42 52|newborn rats
P08484891A0000|102 114|olfactory bulb
P08484891A0000|189 201|early memories
P08485317A0000|3 23|fission yeast dsk1+ gene
P08485317A0000|3 23|fission yeast dsk1+ gene
P08485317A0000|26 44|multicopy suppressor
P08485317A0000|48 72|cold-sensitive dis1 mutants
P08485317A0000|62 72|dis1 mutants
P08485317A0000|87 104|61-kd protein kinase
P08485317A0000|87 104|61-kd protein kinase
P08486035T0000|0 6|Closure
P08486035T0000|12 33|patent ductus arteriosus
P08486276A0419|38 40|ORF
P08486276A0419|45 59|protein database
P08486276A0419|105 138|bacterial transmembrane (TM) proteins
P08486276A0419|105 129|bacterial transmembrane (TM
P08486276A0419|162 179|chloramphenicol (Cm
P08486276A0419|162 176|chloramphenicol
P08486276A0419|178 179|Cm
P08486276A0419|184 195|tetracycline
P08486276A0419|197 209|Tc) resistance
P08486276A0419|215 244|arabinose-proton symport protein
P08486705A0181|3 11|yeast gene
P08486705A0181|3 11|yeast gene
P08486705A0181|23 27|eIF-5
P08486705A0181|23 27|eIF-5
P08486705A0181|39 42|TIF5
P08486705A0181|39 42|TIF5
P08486705A0181|73 87|Escherichia coli
P08486705A0181|96 126|catalytically active eIF-5 protein
P08486705A0181|115 126|eIF-5 protein
P08488700A0283|20 29|hepatitis B
P08488700A0283|33 42|hepatitis D
P08488700A0283|125 156|infective blood or blood derivatives
P08488700A0283|160 168|education
P08488700A0283|195 204|hepatitis B
P08488700A0283|195 204|hepatitis B
P08488700A0283|208 215|sexually
P08490002A0620|0 37|Xylose- and arabinose-containing polymers
P08490002A0620|79 84|breads
P08491124A0517|3 23|technical construction
P08491124A0517|29 43|mouth protectors
P08491124A0517|72 86|instrumentation
P08491124A0517|139 153|mouth protectors
P08491383A0154|3 15|alpha-subunit
P08491383A0154|3 15|alpha-subunit
P08491383A1291|17 29|alpha-subunit
P08491383A1291|17 29|alpha-subunit
P08491383A1291|35 57|telomere-binding protein
P08491383A1291|35 57|telomere-binding protein
P08491383A1291|67 86|transcription factors
P08491383A1291|100 146|DNA-binding and protein-protein interaction domains
P08491383A1291|114 128|protein-protein
P08491683A0651|5 12|patients
P08491683A0651|23 30|patients
P08491683A0651|50 57|patients
P08491683A0651|82 95|adenocarcinoma
P08491683A0651|101 108|prostate
P08492164T0000|11 21|burst firing
P08492164T0000|24 33|cat primary
P08492164T0000|34 47|auditory cortex
P08492164T0000|84 108|neural interaction measures
P08492290A0306|13 32|potentiometric method
P08492290A0306|34 63|in aqueous medium of ionic strength
P08492290A0306|64 65|mu
P08492290A0306|96 121|beta 1 = 4.42 and log beta 2 = 8.57
P08495786A0085|0 27|Cryopreservation straws filled
P08496157A0000|3 11|bcl-2 gene
P08496157A0000|3 11|bcl-2 gene
P08496157A0000|32 51|26- and 22-kDa proteins
P08496157A0000|38 51|22-kDa proteins
P08496157A0000|73 85|carboxyl tails
P08496157A0000|97 124|alternative splicing mechanism
P08496184A0772|9 24|open reading frame
P08496184A0772|51 66|E. coli chromosome
P08496185A0484|20 45|nucleotide sequence analysis
P08496185A0484|51 76|S. pombe adenylate kinase gene
P08496185A0484|51 57|S. pombe
P08496185A0484|58 72|adenylate kinase
P08496185A0484|78 81|adk1
P08496185A0484|78 81|adk1
P08496185A0484|92 103|coding region
P08496185A0484|106 119|660 nucleotides
P08496475T0000|0 12|Calcification
P08496475T0000|44 58|Corynebacterium
P08496475T0000|60 71|Bacterionema
P08496599A0310|11 29|alternative splicing
P08496599A0310|34 40|BGP gene
P08496599A0310|34 40|BGP gene
P08496599A0310|78 88|mRNA species
P08496601A1153|16 24|promoters
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|71 81|CK-1 element
P08496601A1153|71 81|CK-1 element
P08496601A1153|114 132|RAW 264.7 macrophages
P08496601A1153|137 153|proximal fragments
P08496601A1153|165 175|muMIP-1 beta
P08496601A1153|165 175|muMIP-1 beta
P08496601A1153|181 202|muMIP-1 alpha 5' promoter
P08496601A1153|181 202|muMIP-1 alpha 5' promoter
P08496601A1153|211 240|human growth hormone reporter gene
P08496601A1153|211 228|human growth hormone
P08496601A1153|245 260|LPS-inducibility
P08496601A1153|269 284|promoter segments
P08496601A1153|315 335|consensus CK-1 sequence
P08496601A1153|324 335|CK-1 sequence
P08496848A0692|54 65|FSE sequences
P08496848A0692|81 90|asymmetric
P08496848A0692|95 107|SE counterpart
P08497190T0079|0 15|Sequence analysis
P08497190T0079|38 57|hyp regulatory mutants
P08497190T0079|38 57|hyp regulatory mutants
P08497248A0000|29 63|macrophage colony-stimulating factor 1
P08497248A0000|29 63|macrophage colony-stimulating factor 1
P08497248A0000|65 69|CSF-1
P08497248A0000|65 69|CSF-1
P08497248A0000|75 92|c-fms protooncogene
P08497248A0000|75 92|c-fms protooncogene
P08497248A0000|118 170|immature and mature mononuclear phagocytes and trophoblasts
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|56 67|tap1-1 mutant
P08497259A0452|56 67|tap1-1 mutant
P08497269A0999|4 21|sequence similarity
P08497269A0999|46 49|GCN1
P08497269A0999|46 49|GCN1
P08497269A0999|63 86|ribosomes or tRNA molecules
P08497269A0999|116 119|GCN2
P08497269A0999|116 119|GCN2
P08497269A0999|132 150|uncharged tRNA levels
P08497269A0999|169 189|translation elongation
P08497273T0000|0 4|NF-HB
P08497273T0000|0 4|NF-HB
P08497273T0000|6 9|BSAP
P08497273T0000|6 9|BSAP
P08497273T0000|28 73|murine immunoglobulin heavy-chain 3' alpha enhancer
P08497273T0000|28 73|murine immunoglobulin heavy-chain 3' alpha enhancer
P08497273T0000|89 109|B-cell differentiation
P08497280A0266|20 23|SWI4
P08497280A0266|20 23|SWI4
P08497280A0266|43 62|cell cycle progression
P08497280A0266|90 111|trans-acting regulators
P08497280A0266|114 130|SWI4 transcription
P08497280A0266|114 117|SWI4
P08497280A1397|55 71|SWI4 transcription
P08497280A1397|55 58|SWI4
P08497280A1397|86 89|SWI6
P08497280A1397|86 89|SWI6
P08497280T0000|8 21|SWI6-dependent
P08497280T0000|8 11|SWI6
P08497280T0000|22 39|cis-acting elements
P08497280T0000|47 63|SWI4 transcription
P08497280T0000|47 50|SWI4
P08497280T0000|74 82|cell cycle
P08498570A1118|22 33|carotid sinus
P08498570A1118|93 97|Pcrit
P08498570A1118|101 102|Ra
P08499376A0000|9 11|PRK
P08499376A0000|57 79|higher myopic corrections
P08499903A0883|4 11|patients
P08499903A0883|16 24|deletions
P08499916A0000|3 12|COL7A1 gene
P08499916A0000|3 12|COL7A1 gene
P08499916A0000|26 40|type VII collagen
P08499916A0000|26 40|type VII collagen
P08499916A0000|118 147|dystrophic epidermolysis bullosa
P08500524A0424|28 36|gamma gene
P08500524A0424|81 101|normal splicing signals
P08500524A0424|120 125|intron
P08500938A0408|22 25|BGCT
P08500938A0408|48 68|intralesional excision
P08500938A0408|80 96|articular surfaces
P08501030A0456|25 38|aeg-46.5 operon
P08501030A0456|25 38|aeg-46.5 operon
P08501030A0456|74 88|narL null strains
P08501030A0456|74 77|narL
P08501678A0498|99 108|Hib disease
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08503348A0226|3 17|HMG CoA reductase
P08503348A0226|47 72|cholesterol-lowering agents
P08504707A0376|3 10|etiology
P08504707A0376|27 28|CT
P08504928T0000|0 27|Drosophila 230-kD TFIID subunit
P08504928T0000|0 27|Drosophila 230-kD TFIID subunit
P08504928T0000|30 46|functional homolog
P08504928T0000|52 76|human cell cycle gene product
P08504928T0000|52 76|human cell cycle gene product
P08504928T0000|112 133|TATA box-binding subunit
P08504928T0000|112 118|TATA box
P08504928T0000|136 140|TFIID
P08504928T0000|136 140|TFIID
P08504932A0123|20 39|GATA factor expression
P08504932A0123|20 29|GATA factor
P08504932A0123|53 64|GATA proteins
P08504932A0123|53 64|GATA proteins
P08504932A0123|93 118|DNA-binding site specificity
P08504932A0123|136 149|erythroid cells
P08504933A0000|0 4|Pit-1
P08504933A0000|0 4|Pit-1
P08504933A0000|8 37|tissue-specific POU domain factor
P08504933A0000|23 37|POU domain factor
P08504933A0000|90 111|anterior pituitary gland
P08505075A0236|44 53|S. bareilly
P08505075A0236|54 61|serotype
P08505075A0236|73 85|S. typhimurium
P08505075A0236|103 109|S. typhi
P08505340T0000|42 49|promoter
P08505340T0000|55 95|rat prostaglandin endoperoxide synthase 2 gene
P08505340T0000|55 57|rat
P08505340T0000|58 91|prostaglandin endoperoxide synthase 2
P08505340T0000|98 111|granulosa cells
P08505495A0253|14 21|75SeHCAT
P08505605A0461|0 21|Patient characteristics
P08505605A0461|36 45|deep wounds
P08505605A0461|54 60|patient
P08505605A0461|64 83|wound characteristics
P08506317A0000|12 22|C/EBP family
P08506317A0000|12 22|C/EBP family
P08506317A0000|25 69|basic-leucine zipper (bZip) transcription factors
P08506317A0000|25 69|basic-leucine zipper (bZip) transcription factors
P08506317A0000|74 85|heterodimers
P08506317A0000|98 104|CAAT box
P08506317A0000|113 142|sequence-related enhancer motifs
P08506384A0146|2 15|mammalian cells
P08506384A0146|34 43|eIF-2 alpha
P08506384A0146|34 43|eIF-2 alpha
P08506384A0146|65 70|eIF-2B
P08506384A0146|65 70|eIF-2B
P08506384A0146|75 95|GDP-GTP exchange factor
P08506384A0146|75 89|GDP-GTP exchange
P08506384A0146|99 103|eIF-2
P08506384A0146|99 103|eIF-2
P08507921A1021|62 76|acute MI patients
P08507921A1021|79 92|plasma ANF level
P08507921A1021|85 87|ANF
P08507921A1021|182 193|cardiac death
P08508774A0242|22 24|Lrp
P08508774A0242|22 24|Lrp
P08508774A0242|33 62|circularly permuted DNA fragments
P08508774A0242|90 92|Lrp
P08508774A0242|90 92|Lrp
P08508778A0112|0 11|Yeast mutants
P08508778A0112|0 11|Yeast mutants
P08508778A0112|30 37|NOP1 gene
P08508778A0112|30 37|NOP1 gene
P08508778A0112|57 72|human fibrillarin
P08508778A0112|62 72|fibrillarin
P08508778A0112|121 138|pre-rRNA processing
P08508861A0294|3 10|patients
P08508861A0294|38 56|non-ischaemia groups
P08508861A0294|80 101|lactate extraction ratio
P08508861A0294|108 123|balloon inflation
P08509333A0843|1 13|36-kDa protein
P08509333A0843|35 50|membrane fraction
P08509333A0843|98 105|ftsN gene
P08509333A0843|98 105|ftsN gene
P08509333A0843|121 124|FtsN
P08509333A0843|121 124|FtsN
P08509333A0843|129 143|membrane protein
P08509335T0000|0 3|SSG1
P08509335T0000|0 3|SSG1
P08509335T0000|19 56|sporulation-specific 1,3-beta-glucanase
P08509335T0000|39 56|1,3-beta-glucanase
P08509335T0000|59 81|Saccharomyces cerevisiae
P08509419A0785|25 30|E. coli
P08509419A0785|47 54|tyrosine
P08509419A0785|94 122|yeast cytoplasmic TyrRS activity
P08509419A0785|94 114|yeast cytoplasmic TyrRS
P08509430A0372|16 30|complementation
P08509430A0372|59 71|Chlamydomonas
P08509430A0372|81 90|ac-u-g-2.3
P08509430A0372|81 86|ac-u-g
P08509430A0372|102 119|frameshift mutation
P08509430A0372|125 132|psaB gene
P08509430A0372|125 132|psaB gene
P08509430A0372|162 174|transformants
P08509430A0372|177 189|minimal medium
P08510320A0000|19 39|methicillin-resistant
P08510320A0000|40 59|Staphylococcus aureus
P08510320A0000|61 64|MRSA
P08510320A0000|96 119|inhibitory concentrations
P08510320A0000|121 124|MICs
P08510320A0000|166 174|arbekacin
P08510320A0000|176 178|ABK
P08510320A1249|36 40|MRSAs
P08510320A1249|156 167|beta-lactams
P08510647A1347|0 3|Beg2
P08510647A1347|0 3|Beg2
P08510647A1347|7 10|Beg1
P08510647A1347|7 10|Beg1
P08510647A1347|99 113|barley globulins
P08510647A1347|99 113|barley globulins
P08510924A0490|54 71|human HSP70 promoter
P08510924A0490|59 71|HSP70 promoter
P08510924A0490|74 84|Myb proteins
P08510924A0490|74 84|Myb proteins
P08512728A0991|62 67|group I
P08512728A0991|94 101|patients
P08513025A0000|20 36|skinfold thickness
P08513025A0000|60 83|serum total bilirubin level
P08513025A0000|87 109|transcutaneous bilirubin
P08513025A0000|111 113|TcB
P08514757A1100|4 16|immunophilins
P08514757A1100|4 16|immunophilins
P08514757A1100|40 55|receptor assembly
P08514757A1100|124 138|protein function
P08514766A0732|3 8|GTPase
P08514766A0732|3 8|GTPase
P08514766A0732|19 25|CDC42Ce
P08514766A0732|19 25|CDC42Ce
P08514766A0732|50 65|human n-chimaerin
P08514766A0732|50 65|human n-chimaerin
P08514766A0732|68 91|GTPase-activating protein
P08514766A0732|68 91|GTPase-activating protein
P08514766A0732|105 111|p21 rac1
P08514766A0732|105 111|p21 rac1
P08515619A0184|22 35|right ventricle
P08515619A0184|62 72|total counts
P08515619A0184|78 99|right ventricle to counts
P08515619A0184|141 144|COPD
P08515619A0184|158 175|pulmonary emphysema
P08515619A0184|184 187|COPD
P08515619A0184|217 224|controls
P08515776A0971|7 23|hydrophobic domain
P08515776A0971|35 55|two hydrophilic regions
P08516301A0080|4 7|gene
P08516301A0080|36 54|exons and four introns
P08516308A0669|12 20|RAD+ cells
P08516308A0669|86 98|inviable cells
P08516324A0000|3 31|11;22 chromosomal translocation
P08516324A0000|52 63|Ewing sarcoma
P08516324A0000|76 95|neuroectodermal tumor
P08516324A0000|106 121|chimeric molecule
P08516324A0000|131 160|amino-terminal-encoding portion
P08516324A0000|166 172|EWS gene
P08516324A0000|166 168|EWS
P08516324A0000|178 211|carboxyl-terminal DNA-binding domain
P08516324A0000|178 211|carboxyl-terminal DNA-binding domain
P08516324A0000|224 231|FLI1 gene
P08516324A0000|224 231|FLI1 gene
P08517737A0889|32 59|microenvironmental conditions
P08517737A0889|79 90|water systems
P08517737A0889|122 129|bacteria
P08518797T0000|0 24|X-linked liver glycogenosis
P08519621A0150|43 60|immunologic changes
P08519621A0150|80 90|acute stages
P08519621A0150|178 198|gastrointestinal tract
P08519862T0001|13 33|anti-HCV IgM antibodies
P08519862T0001|13 33|anti-HCV IgM antibodies
P08519862T0001|40 54|experimental kit
P08520646A0000|6 20|coculture system
P08521414A1384|5 13|cell lines
P08521414A1384|23 33|methylation
P08521414A1384|39 47|CpG island
P08521414A1384|62 70|first exon
P08521414A1384|73 80|p16INK4A
P08521414A1384|73 80|p16INK4A
P08521414A1384|110 126|nontranslated mRNA
P08521414A1384|139 158|alternative first exon
P08521414A1384|160 165|E1 beta
P08521414A1384|160 165|E1 beta
P08521414A1384|200 212|p16INK4A locus
P08521414A1384|200 207|p16INK4A
P08521717A0126|2 25|immunoperoxidase reaction
P08521717A0126|2 17|immunoperoxidase
P08521717A0126|27 35|PAP method
P08521717A0126|55 64|Factor VIII
P08521717A0126|55 64|Factor VIII
P08521717A0126|70 84|primary antibody
P08521717A0126|104 114|endometrial
P08521717A0126|134 143|Factor VIII
P08521717A0126|134 143|Factor VIII
P08521717A0126|157 178|endometrial endothelium
P08521717A0126|204 213|LNG-IUD-20
P08521780A0485|0 9|Umweltchem
P08522175A0306|0 4|Egd1p
P08522175A0306|0 4|Egd1p
P08522175A0306|19 28|human BTF3b
P08522175A0306|19 28|human BTF3b
P08522175A0306|53 63|beta subunit
P08522175A0306|53 63|beta subunit
P08522175A0306|69 118|heterodimeric nascent-polypeptide-associated complex
P08522175A0306|69 118|heterodimeric nascent-polypeptide-associated complex
P08522175A0306|120 122|NAC
P08522175A0306|120 122|NAC
P08522175A0306|142 195|signal-sequence-specific protein sorting and translocation
P08522175A0306|221 233|1994) 434-440]
P08522511A1250|8 10|PLB
P08522511A1250|8 10|PLB
P08522511A1250|24 36|lyase activity
P08522511A1250|24 28|lyase
P08522511A1578|3 19|5' flanking regions
P08522511A1578|26 29|pelA
P08522511A1578|26 29|pelA
P08522511A1578|33 36|pelB
P08522511A1578|33 36|pelB
P08522511A1578|66 87|beta-glucuronidase gene
P08522511A1578|66 83|beta-glucuronidase
P08522511A1578|107 112|solani
P08522511A1578|113 121|f. sp. pisi
P08522511A1578|126 153|beta-glucuronidase activities
P08522511A1578|126 143|beta-glucuronidase
P08522511A1578|159 171|transformants
P08522530A1342|4 11|nifA mRNA
P08522530A1342|4 11|nifA mRNA
P08522530A1342|37 51|primer extension
P08522530A1342|63 80|upstream transcript
P08522530A1342|92 95|45 bp
P08522530A1342|153 156|10 bp
P08522530A1342|168 177|sigma 54 box
P08522530A1342|168 177|sigma 54 box
P08523031A0737|81 99|acute ischemic stroke
P08523545T0000|3 36|human papillomavirus type 16 E7 protein
P08523545T0000|3 21|human papillomavirus
P08523545T0000|22 27|type 16
P08523545T0000|28 36|E7 protein
P08523545T0000|48 79|adenovirus type 5 E1A amino-terminus
P08523545T0000|48 65|adenovirus type 5 E1A
P08523545T0000|66 79|amino-terminus
P08523545T0000|107 131|adenovirus type 5 early genes
P08523545T0000|107 131|adenovirus type 5 early genes
P08523545T0000|144 146|ATF
P08523545T0000|144 146|ATF
P08523545T0000|150 172|Oct-1 DNA binding activity
P08523545T0000|150 154|Oct-1
P08523566A1106|1 19|chaotropic detergent
P08523566A1106|25 35|Nonidet P-40
P08524036A0747|65 85|stripe 2 enhancer region
P08524036A0747|65 85|stripe 2 enhancer region
P08524036A0747|96 113|point substitutions
P08524036A0747|117 135|insertion/deletions
P08524229T0000|0 10|Degradation
P08524229T0000|16 75|soybean ribulose-1,5-bisphosphate carboxylase small-subunit mRNA
P08524229T0000|16 58|soybean ribulose-1,5-bisphosphate carboxylase
P08524229T0000|59 75|small-subunit mRNA
P08524229T0000|77 80|SRS4
P08524229T0000|77 80|SRS4
P08524235A0695|32 35|dMax
P08524235A0695|32 35|dMax
P08524235A0695|64 93|basic region and helix 1 and the loop
P08524235A0695|64 74|basic region
P08524235A0695|78 83|helix 1
P08524235A0695|99 120|helix-loop-helix region
P08524235A0695|99 120|helix-loop-helix region
P08524235A0695|143 161|alternative splicing
P08524235A0695|164 169|max RNA
P08524241A0212|26 30|HSP82
P08524241A0212|26 30|HSP82
P08524241A0212|47 89|early meiotic IME1-IME2 transcriptional cascade
P08524241A0212|59 62|IME1
P08524241A0212|64 67|IME2
P08524260A0835|20 31|bovine LTBP-2
P08524260A0835|26 31|LTBP-2
P08524260A0835|56 66|human LTBP-2
P08524260A0835|56 66|human LTBP-2
P08524260A0835|90 99|6-cysteine
P08524260A0835|100 132|epidermal growth factor-like repeats
P08524260A0835|100 120|epidermal growth factor
P08524260A0835|170 183|calcium binding
P08524260A0835|208 217|8-cysteine
P08524260A0835|240 249|fibrillins
P08524260A0835|240 249|fibrillins
P08524260A0835|253 258|LTBP-1
P08524260A0835|253 258|LTBP-1
P08524267A1022|45 73|wild-type prothymosin alpha gene
P08524267A1022|45 73|wild-type prothymosin alpha gene
P08524267A1022|104 131|repertoire of myc-derived genes
P08524267A1022|116 131|myc-derived genes
P08524267A1022|142 144|myc
P08524267A1022|154 190|dominant or recessive negative myc mutants
P08524267A1022|181 190|myc mutants
P08524272T0000|0 21|Differential regulation
P08524272T0000|27 46|alpha/beta interferon
P08524272T0000|58 72|Jak/Stat pathway
P08524272T0000|58 60|Jak
P08524272T0000|62 65|Stat
P08524272T0000|78 122|SH2 domain-containing tyrosine phosphatase SHPTP1
P08524272T0000|78 116|SH2 domain-containing tyrosine phosphatase
P08524272T0000|117 122|SHPTP1
P08524284A0309|38 42|cDNAs
P08524284A0309|51 58|PTF gamma
P08524284A0309|51 58|PTF gamma
P08524284A0309|62 69|PTF delta
P08524284A0309|62 69|PTF delta
P08524284A0309|100 116|cognate antibodies
P08524284A0309|139 148|PTF complex
P08524284A0309|139 148|PTF complex
P08524284A0309|151 162|HeLa extracts
P08524292A1022|44 46|YY1
P08524292A1022|44 46|YY1
P08524292A1022|93 95|AP1
P08524292A1022|93 95|AP1
P08524292A1022|101 118|Sp1-related protein
P08524292A1022|101 118|Sp1-related protein
P08524292A1022|123 144|YY1 suppressive activity
P08524292A1022|123 125|YY1
P08524294A0652|3 11|skp1+ gene
P08524294A0652|3 11|skp1+ gene
P08524314A0216|3 6|TEA1
P08524314A0216|3 6|TEA1
P08524314A0216|8 31|Ty enhancer activator) gene
P08524314A0216|8 26|Ty enhancer activator
P08524314A0216|58 64|86.9 kDa
P08524314A0216|70 78|N terminus
P08524314A0216|88 118|zinc cluster and dimerization motif
P08524314A0216|131 145|Gal4-type family
P08524314A0216|131 145|Gal4-type family
P08524314A0216|148 166|DNA-binding proteins
P08524314A0216|148 166|DNA-binding proteins
P08525186A0288|64 66|bad
P08525186A0288|95 113|Swedish counterparts
P08525186A0288|132 135|3.48
P08526620A1344|34 64|terminal SC5b-9 complement complex
P08526620A1344|42 64|SC5b-9 complement complex
P08528479A0000|0 17|Videonystagmoscopy
P08528479A0000|67 82|vestibular system
P08528479A0000|98 105|patients
P08528479A0000|110 127|vestibular deficits
P08528796A1470|3 5|MCA
P08528796A1470|9 18|UA PI values
P08529098A0549|29 30|57
P08529098A0549|54 79|yeast mitochondrial proteins
P08529098A0549|54 79|yeast mitochondrial proteins
P08529098A0549|81 84|SMF1
P08529098A0549|81 84|SMF1
P08529098A0549|88 91|SMF2
P08529098A0549|88 91|SMF2
P08529098A0549|135 139|exon 6
P08529098A0549|157 183|transmembrane spanning domain
P08529098A0549|185 188|site
P08529098A0549|194 221|murine susceptibility mutation
P08529098A0549|226 231|exon 11
P08529630A0840|0 4|Stems
P08529630A0840|26 37|P protein mRNA
P08529630A0840|26 33|P protein
P08529630A0840|59 63|roots
P08529654A0589|3 41|B. germanica cyclophilin amino acid sequence
P08529654A0589|14 24|cyclophilin
P08529654A0589|25 41|amino acid sequence
P08529654A0589|66 92|cytosolic cyclophilin isoform
P08529654A0589|75 92|cyclophilin isoform
P08529654A0589|97 118|Drosophila melanogaster
P08529654A0589|120 124|Cyp-1
P08529654A0589|120 124|Cyp-1
P08529662A0507|29 39|soluble form
P08529662A0507|42 52|ERp57/GRP58
P08529662A0507|42 46|ERp57
P08529662A0507|48 52|GRP58
P08529662A0507|55 92|Western blotting and biosynthetic labeling
P08530105A0308|27 57|Langer-Giedion syndrome deletions
P08530105A0308|93 100|patients
P08530105A0308|131 139|2 patients
P08530107A1003|17 35|hepatic and epidermal
P08530107A1003|48 56|histidase
P08530107A1003|81 102|histidase transcription
P08530107A1003|81 89|histidase
P08530149A0689|32 36|c-myc
P08530149A0689|32 36|c-myc
P08530149A0689|49 65|consensus sequence
P08530149A0689|71 91|initiator (Inr) element
P08530149A0689|93 104|TCA(+1)YYYNY
P08530342T0000|3 19|human gp39 promoter
P08530342T0000|3 19|human gp39 promoter
P08530345A0880|55 66|TGACCT motifs
P08530345A0880|90 95|HD PPRE
P08530345A0880|90 91|HD
P08530345A0880|109 111|DR1
P08530345A0880|115 124|DR2 element
P08530345A0880|148 170|transcriptional response
P08530345A0880|173 178|HD PPRE
P08530345A0880|173 174|HD
P08530345A0880|181 203|peroxisome proliferators
P08530369A0099|9 27|autophosphorylation
P08530369A0099|30 35|Tyr397
P08530369A0099|66 88|autophosphorylation site
P08530369A0099|96 119|Src family tyrosine kinases
P08530369A0099|96 119|Src family tyrosine kinases
P08530384A0559|4 29|protein-protein interaction
P08530384A0559|68 78|Oct proteins
P08530384A0559|68 78|Oct proteins
P08530384A0559|119 136|Oct-DNA interaction
P08530384A0559|119 125|Oct-DNA
P08530384A0559|157 167|BOB.1/OBF.1
P08530384A0559|157 161|BOB.1
P08530384A0559|163 167|OBF.1
P08530384A0559|170 173|Oct1
P08530384A0559|170 173|Oct1
P08530384A0559|176 179|Oct2
P08530384A0559|176 179|Oct2
P08530384A0559|210 212|DNA
P08530418A1182|30 46|TR2 orphan receptor
P08530418A1182|30 46|TR2 orphan receptor
P08530418A1182|101 104|HREs
P08530418A1182|106 123|RARE beta and CRBPIIp
P08530418A1182|138 174|retinoic acid signal transduction pathway
P08530432A0093|14 27|mutant proteins
P08530432A0093|14 27|mutant proteins
P08530432A0093|81 90|repression
P08530503A1004|6 8|ARF
P08530503A1004|6 8|ARF
P08530503A1004|13 15|ARP
P08530503A1004|13 15|ARP
P08530503A1004|45 59|plasma membranes
P08530503A1004|68 74|cytosol
P08530503A1004|77 99|fractionated 3T3-L1 cells
P08531373A0470|75 77|SjS
P08531373A0470|82 94|anti SS-A/SS-B
P08531373A0470|82 89|anti SS-A
P08531373A0470|91 104|SS-B antibodies
P08531373A0470|95 104|antibodies
P08531669A0950|0 10|Competition
P08531669A0950|41 54|Central America
P08531669A0950|120 135|planorbid species
P08532516A0000|36 43|cdc10-C4
P08532516A0000|36 40|cdc10
P08532516A0000|42 43|C4
P08532516A0000|62 66|yeast
P08532516A0000|67 90|Schizosaccharomyces pombe
P08532536A0925|0 13|TIEG expression
P08532536A0925|0 3|TIEG
P08532536A0925|16 24|hFOB cells
P08532536A0925|43 50|TGF-beta
P08532536A0925|43 50|TGF-beta
P08532536A0925|54 83|bone morphogenetic protein-2 (BMP
P08532536A0925|54 79|bone morphogenetic protein-2
P08532536A0925|81 85|BMP-2
P08532536A0925|112 136|epidermal growth factor (EGF
P08532536A0925|112 132|epidermal growth factor
P08532536A0925|134 136|EGF
P08532536A0925|160 182|growth factors/cytokines
P08532967A0364|2 17|infectious origin
P08532967A0364|53 68|etiologic therapy
P08533472A0777|29 37|ORFs N2417
P08533472A0777|29 32|ORFs
P08533472A0777|33 37|N2417
P08533472A0777|41 45|N2403
P08533472A0777|41 45|N2403
P08533472A0777|108 121|Candida maltosa
P08533472A0777|122 152|cycloheximide-resistance protein
P08533472A0777|122 134|cycloheximide
P08533472A0777|157 200|human interleukin enhancer-binding factor (ILF-2
P08533472A0777|157 194|human interleukin enhancer-binding factor
P08533472A0777|196 200|ILF-2
P08533473A0375|31 38|ADH1 gene
P08533473A0375|31 34|ADH1
P08533473A0375|58 65|database
P08533473A0375|80 91|EST sequences
P08533757A0204|14 28|Ashkenazi Jewish
P08533757A0204|46 61|185delAG mutation
P08533757A0204|78 86|haplotype
P08533757A0204|94 111|polymorphic markers
P08533757A0204|140 144|BRCA1
P08533757A0204|140 144|BRCA1
P08534217A0402|39 52|pollution level
P08534217A0402|61 63|FVC
P08534217A0402|67 76|FEV1 values
P08534217A0402|93 105|Viskovo region
P08534367A0984|0 5|PTP-S3
P08534367A0984|0 5|PTP-S3
P08534367A0984|17 22|PTP-S4
P08534367A0984|17 22|PTP-S4
P08534367A0984|44 53|amino acids
P08534367A0984|69 74|exon E1
P08534848A0188a|8 17|NR isoforms
P08534848A0188a|8 17|NR isoforms
P08534848A0188a|32 33|cv
P08534848A0188b|8 17|NR isoforms
P08534848A0188b|8 17|NR isoforms
P08534848A0188b|32 33|cv
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08534855A0000|14 21|FAD7 gene
P08534855A0000|30 66|chloroplast omega-3 fatty acid desaturase
P08534855A0000|30 66|chloroplast omega-3 fatty acid desaturase
P08534855A0000|109 125|dienoic fatty acids
P08535138A0857|57 68|cell division
P08535138A0857|84 96|plant hormones
P08535138A0857|98 116|cycMs4 transcription
P08535138A0857|98 103|cycMs4
P08535138A0857|143 154|DNA synthesis
P08535537A0000|19 44|pharmacological backgrounds
P08535537A0000|66 78|drug treatment
P08535537A0000|81 101|essential hypertension
P08535537A0000|107 113|elderly
P08536694A0000|0 13|Protein kinases
P08536694A0000|7 13|kinases
P08537388A0825|14 21|internal
P08537388A0825|25 35|5' deletions
P08537388A0825|50 63|distal promoter
P08537388A0825|85 107|transcriptional activity
P08537388A0825|137 142|WNT-5A
P08537388A0825|137 142|WNT-5A
P08537388A0825|154 178|strongest promoter activity
P08537403A0336|3 22|protein kinase domains
P08537403A0336|3 15|protein kinase
P08537403A0336|25 29|LIMK1
P08537403A0336|25 29|LIMK1
P08537403A0336|33 37|LIMK2
P08537403A0336|33 37|LIMK2
P08537403A0336|86 97|Asp-Leu-Asn-
P08537403A0336|98 108|Ser-His-Asn
P08537403A0336|120 122|VIB
P08537403A0336|127 143|highly basic insert
P08537403A0336|151 163|subdomains VII
P08537403A0336|167 170|VIII
P08538052A0000|1 25|human recombinant cDNA clone
P08538052A0000|6 20|recombinant cDNA
P08538052A0000|37 39|253
P08538052A0000|40 49|amino acids
P08538052A0000|61 78|zinc-finger protein
P08538052A0000|61 78|zinc-finger protein
P08538052A0000|80 86|THZif-1
P08538052A0000|80 86|THZif-1
P08538052A0000|109 119|cDNA library
P08538052A0000|132 166|human promyelocytic leukemia HL60 cells
P08538052A0000|171 205|synthetic oligodeoxynucleotide probes
P08538052A0000|227 244|amino acid sequences
P08538052A0000|247 261|tryptic peptides
P08538052A0000|276 293|DNA-binding protein
P08538052A0000|276 293|DNA-binding protein
P08538052A0000|308 337|nuclease-hypersensitive element
P08538052A0000|308 337|nuclease-hypersensitive element
P08538052A0000|339 341|NHE
P08538052A0000|339 341|NHE
P08538052A0000|348 361|human c-myc gene
P08538052A0000|348 361|human c-myc gene
P08538382A1012|11 12|AA
P08538382A1012|15 40|FO+EPO-supplemented infants
P08538382A1012|60 93|breast- and placebo formula-fed levels
P08538483A0207|49 56|bone mass
P08538483A0207|58 62|total
P08538483A0207|64 68|TBBMC
P08538483A0207|81 102|body bone mineral content
P08538483A0207|119 123|women
P08538483A0207|135 146|GnRH agonists
P08538483A0207|135 138|GnRH
P08538483A0207|160 172|endometriosis
P08538483A0207|175 185|leiomyomata
P08538702A0214|45 66|ABA-1 allergen of Ascaris
P08538702A0214|45 49|ABA-1
P08538702A0214|60 66|Ascaris
P08538702A0214|71 143|gp15/400 'ladder' protein of Brugia malayi, Brugia pahangi and Wuchereria bancrofti
P08538702A0214|71 75|gp15/
P08538702A0214|76 86|400 'ladder'
P08538702A0214|96 107|Brugia malayi
P08538702A0214|109 121|Brugia pahangi
P08538702A0214|125 143|Wuchereria bancrofti
P08538702A0214|149 161|15-kDa antigen
P08538702A0214|149 161|15-kDa antigen
P08538702A0214|164 181|Dirofilaria immitis
P08541499A0306|7 24|transcript patterns
P08541499A0306|27 42|Epifagus plastids
P08541499A0306|78 91|tobacco operons
P08542026A0792|0 2|DAF
P08542026A0792|0 2|DAF
P08542026A0792|6 21|70 kD glycoprotein
P08542026A0792|6 21|70 kD glycoprotein
P08542026A0792|57 72|consensus repeats
P08542026A0792|74 77|SCRs
P08542026A0792|134 148|RCA) gene cluster
P08542026A0792|151 161|chromosome 1
P08542026A0792|172 175|40 kb
P08542027A1471|3 9|XS2 gene
P08542027A1471|3 5|XS2
P08542027A1471|53 59|LU genes
P08542027A1471|53 59|LU genes
P08542027A1471|88 91|CD44
P08542027A1471|88 91|CD44
P08542746T0000|53 84|internationally endorsed standards
P08543173A0314|9 15|TATA box
P08543173A0314|52 54|tsp
P08543173A0314|71 93|primer extension analysis
P08543275A0130|111 118|sea lions
P08543275A0130|141 152|Arctic region
P08543275A0130|170 177|northern
P08543275A0130|207 214|host fish
P08543595A1093|25 43|adjuvant carboplatin
P08543595A1093|49 57|abdominal
P08543810A0000|35 59|LPS-activated coelomocytes
P08543810A0000|121 131|cDNA library
P08543810A0000|169 172|ESTs
P08544820T0000|20 37|EcR/USP heterodimer
P08544820T0000|20 22|EcR
P08544820T0000|24 26|USP
P08544820T0000|60 67|ecdysone
P08544820T0000|87 105|Drosophila Lsp-2 gene
P08544820T0000|87 105|Drosophila Lsp-2 gene
P08545502A0914|5 9|SPECT
P08545502A0914|29 31|PET
P08546707T0000|0 24|Transcriptional activation
P08546707T0000|30 48|chicken lysozyme gene
P08546707T0000|30 48|chicken lysozyme gene
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|64 67|RelA
P08546707T0000|64 67|RelA
P08546707T0000|72 76|c-Rel
P08546707T0000|72 76|c-Rel
P08546707T0000|86 97|NF-kappa Bp50
P08546707T0000|86 97|NF-kappa Bp50
P08547205A1060|25 41|bradycardic agents
P08547205A1060|42 50|alinidine
P08547205A1060|104 106|SVT
P08547205A1060|120 147|subacute myocardial infarction
P08547205A1060|150 162|conscious dogs
P08548291A1059|28 32|SAPKs
P08548291A1059|28 32|SAPKs
P08548291A1059|81 85|Elk-1
P08548291A1059|81 85|Elk-1
P08548291A1059|87 105|serum response factor
P08548291A1059|87 105|serum response factor
P08548291A1059|112 131|serum response element
P08548291A1059|112 131|serum response element
P08548291A1059|144 171|Elk-1-dependent transcription
P08548291A1059|144 148|Elk-1
P08549706T0000|12 26|hepatitis B virus
P08549706T0000|27 35|infection
P08549859A1604|33 37|1,000
P08549859A1604|42 53|chromosome 3p
P08549859A1604|56 98|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|42 51|dimeric POR
P08550425A1401|49 51|POR
P08550425A1401|57 74|mesophilic archaeon
P08550425A1401|76 96|Halobacterium halobium
P08550460A0374|40 43|pilP
P08550460A0374|40 43|pilP
P08550460A0374|77 91|19.1-kDa protein
P08550460A0374|121 139|membrane lipoprotein
P08550461A0284|0 5|Cheung
P08550462A0815|0 7|Upstream
P08550462A0815|13 19|dra gene
P08550462A0815|13 19|dra gene
P08550462A0815|22 37|open reading frame
P08550462A0815|40 52|313 amino acids
P08550467A0863|0 25|Sucrose-specific regulation
P08550467A0863|28 31|scrB
P08550467A0863|28 31|scrB
P08550467A0863|57 59|4 bp
P08550467A0863|63 81|palindromic sequence
P08550467A0863|83 84|OB
P08550467A0863|94 119|positions +6 to +21 downstream
P08550467A0863|125 152|scrB transcriptional start site
P08550467A0863|125 128|scrB
P08550470A1021|2 7|E. coli
P08550470A1021|9 12|CheW
P08550470A1021|9 12|CheW
P08550470A1021|59 64|kinase
P08550470A1021|65 68|CheA
P08550470A1021|65 68|CheA
P08550476A0610|16 24|first gene
P08550476A0610|26 29|epiF
P08550476A0610|26 29|epiF
P08550476A0610|45 64|activator protein EpiQ
P08550476A0610|45 64|activator protein EpiQ
P08550476A0610|78 96|palindromic sequence
P08550476A0610|109 123|EpiQ binding site
P08550476A0610|109 123|EpiQ binding site
P08550476A0610|129 140|epiA promoter
P08550476A0610|129 140|epiA promoter
P08550476A0610|164 167|EpiQ
P08550476A0610|164 167|EpiQ
P08550564T0000|0 12|CXC chemokines
P08550564T0000|125 151|human interleukin-8 receptor B
P08550564T0000|125 151|human interleukin-8 receptor B
P08551572A0155|44 71|translation initiation regions
P08551572A0155|74 77|ICP4
P08551572A0155|74 77|ICP4
P08551572A0155|81 89|pp38 mRNAs
P08551572A0155|81 89|pp38 mRNAs
P08551572A0155|99 111|proliferation
P08551572A0155|114 122|MSB1 cells
P08551572A0155|129 137|MDCC-CU91
P08551572A0155|139 186|CU91) reticuloendotheliosis virus-transformed cells
P08551577A0000|0 20|Retroviral replication
P08551577A0000|46 63|primary transcripts
P08551577A0000|77 87|proviral DNA
P08551577A0000|116 130|envelope protein
P08551577A0000|116 130|envelope protein
P08551577A0000|136 151|Rous sarcoma virus
P08551577A0000|154 160|src mRNA
P08551577A0000|154 156|src
P08551577A0000|157 160|mRNA
P08552042A1497|21 39|promoter methylation
P08552042A1497|125 136|poly(A)+ mRNA
P08552042A1497|130 136|A)+ mRNA
P08552045A0973|8 25|consensus sequences
P08552045A0973|29 49|phosphatase regulation
P08552045A0973|53 67|5'-GCACGTGGG-3'
P08552045A0973|71 85|5'-GCACGTTTT-3'
P08552045A0973|104 119|binding sequences
P08552045A0973|126 137|Cpflp protein
P08552045A0973|126 130|Cpflp
P08552045A0973|167 171|genes
P08552045A0973|174 195|methionine biosynthesis
P08552082A0480|19 36|proline-rich region
P08552082A0480|39 41|CAP
P08552082A0480|39 41|CAP
P08552082A0480|59 68|SH3 domains
P08552082A0480|59 68|SH3 domains
P08552082A0480|99 131|yeast actin-associated protein Abp1p
P08552082A0480|99 131|yeast actin-associated protein Abp1p
P08552086A0150|33 55|vitamin D response element
P08552086A0150|57 60|VDRE
P08552086A0150|77 81|c-fos
P08552086A0150|77 81|c-fos
P08552092A1678|12 25|protein binding
P08552092A1678|71 83|transcription
P08552092A1678|85 103|genomic footprinting
P08552092A1678|109 128|entire promoter region
P08552092A1678|144 156|protein factor
P08552092A1678|183 193|first intron
P08552092A1678|199 206|rep3 gene
P08552092A1678|199 206|rep3 gene
P08552093A0657|0 14|Differentiation
P08552093A0657|54 69|GTPase-deficient
P08552093A0657|54 59|GTPase
P08552093A0657|77 83|alpha i2
P08552093A0657|77 83|alpha i2
P08552093A0657|86 91|alpha 0
P08552093A0657|86 91|alpha 0
P08552093A0657|120 127|Gq family
P08552093A0657|120 121|Gq
P08552093A0657|130 138|G proteins
P08552093A0657|130 138|G proteins
P08552095A0686|29 41|transcription
P08552095A0686|43 47|Paf1p
P08552095A0686|43 47|Paf1p
P08552095A0686|64 70|nucleus
P08552095A0758|30 45|yeast transcripts
P08552095A0758|30 45|yeast transcripts
P08552095A0758|56 84|wild-type and paf1 mutant strains
P08552095A0758|56 64|wild-type
P08552095A0758|68 77|paf1 mutant
P08552095A0758|134 137|PAF1
P08552095A0758|134 137|PAF1
P08552095A1115|0 4|Paf1p
P08552095A1115|0 4|Paf1p
P08552095A1115|45 62|negative regulation
P08552095A1115|74 83|yeast genes
P08552095A1115|74 83|yeast genes
P08552096A0151|52 60|yeast gene
P08552096A0151|52 60|yeast gene
P08552096A0151|62 65|UBS1
P08552096A0151|62 65|UBS1
P08552096A0151|80 89|expression
P08552096A0151|114 129|cell cycle defects
P08552096A0151|144 157|cdc34 mutations
P08552096A0151|144 148|cdc34
P08552387A0000|27 43|malignant melanoma
P08552387A0000|50 82|parts or soft tissue clear cell sarcoma
P08552387A0000|94 124|t(12;22) chromosome translocation
P08552387A0000|141 143|EWS
P08552387A0000|141 143|EWS
P08552387A0000|149 178|transcriptional factor gene ATF-1
P08552387A0000|149 178|transcriptional factor gene ATF-1
P08552643A0261|19 21|DBD
P08552643A0261|32 56|dominant negative phenotype
P08552643A0261|72 88|antiviral activity
P08552643A0261|96 119|vesicular stomatitis virus
P08552643A0261|121 123|VSV
P08552643A0261|138 149|IFN treatment
P08552643A0261|138 140|IFN
P08552670A0665|0 3|Abp1
P08552670A0665|0 3|Abp1
P08552670A0665|25 37|multiple sites
P08552670A0665|40 46|ARS 3002
P08552670A0665|55 64|DNA polymer
P08552670A0665|65 72|poly[d(A
P08552670T0000|72 95|sequence-binding protein 1
P08552670T0000|107 111|yeast
P08552670T0000|112 135|Schizosaccharomyces pombe
P08553580A0102|6 21|open reading frame
P08553580A0102|23 26|ORF2
P08553580A0102|61 71|FIV isolates
P08554069A0743|39 46|mutation
P08554069A0743|71 82|transversion
P08554069A0743|127 131|exon 6
P08554069A0743|143 159|normal RNA splicing
P08554540A1480|26 52|HIT protein similarity regions
P08554723A0187|10 13|rats
P08554723A0187|18 45|electrophysiologically guided
P08554723A0187|47 65|ibotenic acid lesions
P08554723A0187|71 78|PBN (PBNx
P08554723A0187|115 129|LiCl-induced CTA
P08554723A0187|132 140|l-alanine
P08554723A0187|161 174|sodium appetite
P08554723A0187|184 202|furosemide treatment
P08554723A0187|206 214|overnight
P08554723A0187|223 241|sodium deficient chow
P08555076A0333|9 22|Amphotericin-B
P08555076A0333|34 41|patients
P08555076A0333|60 66|mycosis
P08555076A0333|91 101|Aspergillus
P08555076A0333|110 116|Candida
P08555168A0390|0 3|Mg2+
P08555168A0390|21 32|binding sites
P08555446A0000|0 16|Transgenic tobacco
P08555446A0000|17 22|plants
P08555446A0000|24 28|ppa-1
P08555446A0000|24 28|ppa-1
P08555446A0000|54 89|Escherichia coli pyrophosphatase behind
P08555446A0000|54 83|Escherichia coli pyrophosphatase
P08555446A0000|93 107|35S CaMV promoter
P08555446A0000|96 107|CaMV promoter
P08555498A0427|0 9|Human LAF-4
P08555498A0427|5 9|LAF-4
P08555498A0427|46 52|chicken
P08555498A0427|111 129|vertebrate evolution
P08555597A0808|0 7|Hb levels
P08555597A0808|0 1|Hb
P08555597A0808|25 26|Hb
P08555753A0591|0 2|CBT
P08555753A0591|122 133|frontal lobes
P08556707A1390|29 34|218leu
P08556707A1390|42 70|normal transactivation activity
P08556707A1390|74 84|p53 promoter
P08556707A1390|74 84|p53 promoter
P08556707A1390|142 152|p53 function
P08556707A1390|142 144|p53
P08556707A1390|169 180|248trp allele
P08556707A1390|169 180|248trp allele
P08556707A1390|183 193|SNU-C5 cells
P08561607A1443|7 28|class II nor IV infections
P08561607A1443|38 52|transplantation
P08561893A0100|38 48|bHLH factors
P08561893A0100|38 48|bHLH factors
P08561893A0100|57 73|gene transcription
P08561893A0100|77 102|E-box DNA consensus sequences
P08561893A0100|77 102|E-box DNA consensus sequences
P08561893A0100|113 130|bHLH factor function
P08561893A0100|113 122|bHLH factor
P08561893A0100|133 148|higher eukaryotes
P08561893A0100|185 205|multiple family members
P08561897A0604|0 26|Mobility and supershift assays
P08561897A0604|43 67|upstream stimulatory factor
P08561897A0604|43 67|upstream stimulatory factor
P08561897A0604|69 71|USF
P08561897A0604|69 71|USF
P08561897A0604|76 78|Sp1
P08561897A0604|76 78|Sp1
P08561897A0604|105 126|competition experiments
P08561897A0604|140 147|CREB/ATF
P08561897A0604|140 143|CREB
P08561897A0604|145 147|ATF
P08561897A0604|151 154|AP-1
P08561897A0604|151 154|AP-1
P08561897A0604|164 177|CRE/TRE element
P08562688A0968|0 7|Upstream
P08562688A0968|10 12|-37
P08562688A0968|17 39|5' untranslated sequences
P08562688A0968|74 81|sequence
P08563483A0094|29 54|human chorionic gonadotropin
P08563483A0094|43 54|gonadotropin
P08563483A0094|56 65|hCG) levels
P08563483A0094|56 58|hCG
P08563483A0094|79 87|TSH levels
P08563483A0094|79 81|TSH
P08563483A0094|99 101|hCG
P08563483A0094|99 101|hCG
P08564488A1359|4 19|fibrinogen levels
P08564488A1359|4 13|fibrinogen
P08564488A1359|52 61|thrombosis
P08564588A1318|0 16|Strontium chloride
P08564588A1318|17 20|Sr 89
P08565330A1783|33 54|tissue-specific control
P08565330A1783|72 88|allelic expression
P08565548A0196|22 43|arthritogenic potential
P08565548A0196|46 56|silicone gel
P08565548A0196|77 92|bovine collagen II
P08565548A0196|83 92|collagen II
P08565548A0196|94 96|BII
P08565548A0196|94 96|BII
P08565548A0196|102 121|injecting silicone gel
P08565548A0196|129 134|DA rats
P08566747A0756|0 2|SBF
P08566747A0756|13 20|promoter
P08566747A0756|62 63|G1
P08566747A0756|79 93|Cln/Cdc28 kinase
P08566747A0756|79 81|Cln
P08566747A0756|83 93|Cdc28 kinase
P08566747A0756|130 132|SBF
P08566747A0756|130 132|SBF
P08566747A0756|143 155|transcription
P08566751A0455|38 55|vertebrate Hox genes
P08566751A0455|38 55|vertebrate Hox genes
P08566751A0455|82 110|Drosophila regulatory sequences
P08566751A0455|82 110|Drosophila regulatory sequences
P08566751A0455|127 154|function of Drosophila Hox genes
P08566751A0455|137 154|Drosophila Hox genes
P08566751A0788|18 24|gHoxb-1
P08566751A0788|18 24|gHoxb-1
P08566751A0788|32 60|normal embryonic spatiotemporal
P08566754A0783|6 23|splice site sequence
P08566754A0783|83 121|U1 small nuclear ribonucleoproteins (snRNPs
P08566754A0783|83 121|U1 small nuclear ribonucleoproteins (snRNPs
P08566754A0783|126 174|alternative splicing factor/splicing factor 2 (ASF/SF2
P08566754A0783|126 166|alternative splicing factor/splicing factor 2
P08566754A0783|168 170|ASF
P08566754A0783|172 174|SF2
P08566756A0752|24 29|SAP 145
P08566756A0752|24 29|SAP 145
P08566756A0752|52 60|SF3a/SF3b
P08566756A0752|52 55|SF3a
P08566756A0752|57 60|SF3b
P08566756A0752|70 82|UV cross-links
P08566756A0752|85 92|pre-mRNA
P08566756A0752|85 92|pre-mRNA
P08566756A0752|96 114|20-nucleotide region
P08566756A0752|128 130|BPS
P08566773A1023|13 16|CTS1
P08566773A1023|13 16|CTS1
P08566773A1023|20 23|CTS2
P08566773A1023|20 23|CTS2
P08566773A1023|26 27|Ci
P08566773A1023|26 27|Ci
P08566773A1023|60 75|fungal chitinases
P08566773A1023|60 75|fungal chitinases
P08567556A0000|24 32|myoglobin
P08567556A0000|42 45|MbO2
P08567556A0000|127 132|diving
P08567556A0000|156 172|normal field diving
P08567556A0000|194 222|heart rate and lactate production
P08567556A0000|282 296|forced immersion
P08567683A0401|3 15|human purH cDNA
P08567683A0401|3 15|human purH cDNA
P08567683A0401|18 30|1776 base pairs
P08567683A0401|51 73|591-amino acid polypeptic
P08567717T0000|3 36|Saccharomyces cerevisiae spindle pole
P08567717T0000|37 55|body duplication gene
P08567717T0000|56 59|MPS1
P08567717T0000|69 85|mitotic checkpoint
P08567847A1005|16 21|SM-CMA
P08567847A1005|16 17|SM
P08567847A1005|59 72|user-interface
P08567847A1005|119 135|human semen samples
P08567847A1005|141 157|desirable features
P08569443A0123|73 74|T2
P08569443A0123|82 87|tumors
P08569443A0123|148 171|extracellular compartment
P08569680A0636|1 17|mutant areA product
P08569680A0636|7 17|areA product
P08569680A0636|77 99|GATA (DNA-binding) domain
P08569680A0636|77 99|GATA (DNA-binding) domain
P08569680A0636|107 121|partial function
P08569684A0000|37 78|conserved flanking amino acid sequence segments
P08569684A0000|88 102|catalytic domain
P08569684A0000|105 128|eukaryotic protein kinase C
P08569684A0000|105 128|eukaryotic protein kinase C
P08569684A0000|130 141|PKC) proteins
P08569684A0000|130 132|PKC
P08569684A0000|163 186|polymerase chain reactions
P08569684A0000|197 224|427-bp chromosomal DNA fragment
P08569684A0000|232 265|filamentous fungus Trichoderma reesei
P08570615T0000|12 13|RB
P08570615T0000|15 19|E2F-1
P08570615T0000|15 19|E2F-1
P08570615T0000|39 52|point mutations
P08570615T0000|55 59|E2F-1
P08570615T0000|55 59|E2F-1
P08570615T0000|68 79|S-phase entry
P08570615T0000|83 91|apoptosis
P08572616A0000|57 74|malignant neoplasms
P08573083A0645|67 95|ubiquitous transcription factor
P08573083A0645|96 120|upstream stimulatory factor
P08573083A0645|96 120|upstream stimulatory factor
P08573083A0645|122 124|USF
P08573083A0645|122 124|USF
P08573083A0645|142 161|human insulin promoter
P08573083A0645|147 161|insulin promoter
P08573637A0434|70 95|pharmaceutical formulations
P08574414A1037|20 29|PCR product
P08574414A1037|84 92|pathovars
P08574583A0658|3 12|Clb5 kinase
P08574583A0658|3 12|Clb5 kinase
P08574583A0658|27 32|S phase
P08574583A0658|56 69|G2-phase arrest
P08574583A0658|82 95|parental strain
P08574583A0658|128 137|sim mutants
P08574583A0658|128 137|sim mutants
P08575609A0526|3 10|C/D ratio
P08575609A0526|100 107|patients
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|29 48|pleiotropic phenotype
P08575614A0264|73 100|DNA damage-induced mutagenesis
P08575614A0264|136 153|retrotransposition
P08575618A1138|0 20|RNase protection assays
P08575618A1138|0 4|RNase
P08575618A1138|59 78|dorsal and ventral skin
P08575618A1138|93 127|pigmentation/phaeomelanin phenotypes
P08575754T0000|0 15|Molecular cloning
P08575754T0000|38 60|chromosomal localization
P08575754T0000|63 79|human CDKN2D/INK4d
P08575754T0000|68 73|CDKN2D
P08575754T0000|75 79|INK4d
P08575754T0000|94 117|cyclin D-dependent kinases
P08575754T0000|94 117|cyclin D-dependent kinases
P08576042A0765|16 26|HrcA protein
P08576042A0765|16 26|HrcA protein
P08576042A0765|44 47|hrcA
P08576042A0765|44 47|hrcA
P08576042A0765|60 66|plasmid
P08576042A0765|68 73|phrcA+
P08576042A0765|68 73|phrcA+
P08576042A0765|77 86|B. subtilis
P08576042A0765|87 103|wild-type and delta
P08576042A0765|104 107|hrcA
P08576042A0765|124 141|heat shock induction
P08576042A0765|147 157|dnaK and groE
P08576042A0765|147 150|dnaK
P08576042A0765|154 164|groE operons
P08576042A0765|236 239|mRNA
P08576131A0151|58 69|USF2 isoforms
P08576131A0151|58 61|USF2
P08576131A0151|87 99|44-kDa subunit
P08576131A0151|87 99|44-kDa subunit
P08576131A0151|101 105|USF2a
P08576131A0151|101 105|USF2a
P08576131A0151|114 126|38-kDa subunit
P08576131A0151|128 132|USF2b
P08576131A0151|128 132|USF2b
P08576131A0151|145 164|differential splicing
P08576131A0685|3 32|preferential heterodimerization
P08576131A0685|35 45|USF subunits
P08576131A0685|35 37|USF
P08576131A0685|128 138|USF proteins
P08576131A0685|128 138|USF proteins
P08576131A0685|152 157|random
P08576179A0126|9 11|PKR
P08576179A0126|9 11|PKR
P08576179A0126|48 97|eukaryotic translation initiation factor 2 alpha subunit
P08576179A0126|48 97|eukaryotic translation initiation factor 2 alpha subunit
P08576179A0126|99 108|cIF-2 alpha
P08576179A0126|99 108|cIF-2 alpha
P08576179A0126|119 144|polypeptide chain initiation
P08576245A0000|0 4|GRP78
P08576245A0000|0 4|GRP78
P08576245A0000|7 24|molecular chaperone
P08576245A0000|39 58|endoplasmic reticulum
P08576245A0000|64 88|glucose-regulated protein"
P08576245A0000|98 112|stress responses
P08576245A0000|117 130|deplete glucose
P08576245A0000|133 153|intracisternal calcium
P08576245A0000|172 194|glycoprotein trafficking
P08576262A0160|3 14|IL-8 receptor
P08576262A0160|3 14|IL-8 receptor
P08576262A0160|18 36|seven-transmembrane
P08576262A0160|70 92|heterotrimeric G proteins
P08576262A0160|70 92|heterotrimeric G proteins
P08576262A0160|102 103|Gi
P08576262A0160|102 103|Gi
P08576262A0160|107 109|G16
P08576262A0160|107 109|G16
P08576546A0975|42 50|PDC/HDC Ac
P08576546A0975|42 44|PDC
P08576546A0975|46 50|HDC Ac
P08576546A0975|86 98|dose regiments
P08580083A0259|38 40|Fyn
P08580083A0259|38 40|Fyn
P08580083A0259|58 71|viral promoters
P08580083A0259|58 71|viral promoters
P08580083A0259|87 106|Fyn-expression vector
P08580083A0259|87 89|Fyn
P08580083A0259|120 134|reporter plasmid
P08580083A0259|148 183|chloramphenicol acetyltransferase gene
P08580083A0259|148 183|chloramphenicol acetyltransferase gene
P08580083A0259|192 197|HIV LTR
P08580083A0259|192 197|HIV LTR
P08580083A0259|203 216|human T cell line
P08580083A0259|218 223|Jurkat
P08580671A0137|12 22|prospective
P08580671A0137|63 83|selective beta-blocker
P08580671A0137|99 114|gastrointestinal
P08580671A0137|133 144|hypertension
P08580671A0137|161 168|patients
P08580671A0137|173 184|liver disease
P08580671A0137|196 219|gastrointestinal bleeding
P08581174A0472|1 27|genetic and molecular analysis
P08581174A0472|30 53|non-inducible qutA mutants
P08581174A0472|43 53|qutA mutants
P08581174A0472|98 111|N-terminal half
P08581174A0472|124 134|QUTA protein
P08581174A0472|124 134|QUTA protein
P08582143A0614|27 41|acidimetric test
P08582143A0614|65 75|chromogenic
P08582143A0614|106 120|nitrocefin and S1
P08582143A0614|119 120|S1
P08582143A0614|143 166|beta-lactamase production
P08582143A0614|143 156|beta-lactamase
P08582633T0000|0 10|Suppressors
P08582633T0000|13 30|defective silencing
P08582633T0000|33 37|yeast
P08582633T0000|48 72|transcriptional repression
P08582633T0000|78 85|HMR locus
P08582633T0000|78 85|HMR locus
P08582633T0000|87 96|cell growth
P08582633T0000|100 116|telomere structure
P08583783A0870|8 44|ANP induced systemic capillary filtration
P08583783A0870|51 54|calf
P08583783A0870|80 82|ANP
P08583846A0121|32 48|beta-2 transferrin
P08583846A0121|32 37|beta-2
P08583846A0121|38 48|transferrin
P08583846A0121|82 90|perilymph
P08583846A0807|22 38|beta-2 transferrin
P08583846A0807|22 27|beta-2
P08583846A0807|28 38|transferrin
P08583846A0807|96 104|operative
P08584026A0115|3 12|hIGF-I gene
P08584026A0115|3 12|hIGF-I gene
P08584026A0115|19 27|promoters
P08584026A0115|29 30|P1
P08584026A0115|29 30|P1
P08584026A0115|34 35|P2
P08584026A0115|34 35|P2
P08584035A0740|0 21|Gel mobility shift assays
P08584035A0740|46 60|nuclear proteins
P08584035A0740|130 144|3 beta I-A element
P08584035A0740|130 144|3 beta I-A element
P08584035A0740|158 177|DNA-protein complexes
P08584035A0740|158 177|DNA-protein complexes
P08584035A0740|179 180|R1
P08584035A0740|179 180|R1
P08584035A0740|183 184|R4
P08584035A0740|183 184|R4
P08584074A0000|10 17|patients
P08584074A0000|67 84|medically resistant
P08584074A0000|85 104|temporal lobe epilepsy
P08584074A0000|106 108|TLE
P08584074A0000|147 166|Bethel Epilepsy Center
P08584530A0545|37 40|FEV1
P08584530A0545|68 70|Raw
P08584530A0545|72 76|MEF50
P08584530A0545|80 84|MEF25
P08585324A0467|28 35|SSC1 gene
P08585324A0467|28 35|SSC1 gene
P08585324A0823|38 54|Leu-tRNA precursor
P08585324A0823|38 54|Leu-tRNA precursor
P08585324A0823|69 78|tau element
P08585639T0000|22 36|hepatitis B virus
P08585639T0000|40 65|human immunodeficiency virus
P08585883A0381|0 15|Hybrid female mice
P08585883A0381|17 21|C57BL
P08585883A0381|23 25|CBA
P08585883A0381|41 52|breeder males
P08585883A0381|54 71|CD-1) and LNG pellets
P08585883A0381|54 57|CD-1
P08585883A0381|149 164|postcoital period
P08585957A0101|16 42|putative transcription factor
P08585957A0101|98 108|zinc fingers
P08585957A0101|129 158|Drosophila trithorax gene product
P08585957A0101|129 158|Drosophila trithorax gene product
P08585957A0101|166 190|"AT-hook" DNA-binding motif
P08585957A0101|193 217|high mobility group proteins
P08585994A0567|22 38|internal standards
P08585994A0567|53 72|ost transcription unit
P08585994A0567|53 72|ost transcription unit
P08585994A0567|114 119|89A1,2
P08585994A0567|125 152|right arm of the third chromosome
P08585994A0567|218 223|embryo
P08586643A0951|22 62|enzyme catalyzed specific phosphoryl transfer
P08586643A0951|67 69|ATP
P08586643A0951|72 74|UMP
P08586643A0951|78 80|CMP
P08586874T0000|23 39|Haplorchis pumilio
P08586874T0000|41 45|Looss
P08586874T0000|66 91|morphological redescription
P08586874T0000|94 113|larval and adult stages
P08587075T0000|0 23|Regressing microaneurysms
P08587075T0000|34 48|hepatitis B virus
P08588852A0236|59 63|fetus
P08588852A0236|96 113|severe micrognathia
P08588852A0236|137 143|big toes
P08588852A0236|148 158|bowed tibiae
P08589315A1029|102 119|tumor lysis syndrome
P08589315A1029|123 148|systemic lupus erythematosus
P08589315A1029|153 160|patients
P08589315A1029|181 194|uremic syndrome
P08589315A1029|199 206|patients
P08589358A0235|20 49|recombinant human erythropoietin
P08589358A0235|20 49|recombinant human erythropoietin
P08589358A0235|51 55|rhEPO
P08589358A0235|51 55|rhEPO
P08589358A0841|16 29|erythropoietin
P08589358A0841|16 29|erythropoietin
P08589358A0841|47 53|donor's
P08589358A0841|67 92|allogeneic blood transfusion
P08589358A0841|101 115|initial Hb levels
P08589358A0841|108 109|Hb
P08589358A0841|125 137|130 milligrams
P08589735A0577|18 30|GUS expression
P08589735A0577|18 20|GUS
P08589735A0577|42 56|promoter regions
P08589735A0577|71 101|Arabidopsis alcohol dehydrogenase
P08589735A0577|71 101|Arabidopsis alcohol dehydrogenase
P08589735A0577|103 106|Adh1
P08589735A0577|103 106|Adh1
P08589735A0577|114 122|ubiquitin
P08589735A0577|124 127|Ubi1
P08589735A0577|124 127|Ubi1
P08589735A0577|130 138|rice actin
P08589735A0577|134 143|actin (Act1
P08589735A0577|140 143|Act1
P08589735A0577|148 159|CaMV 35S genes
P08589735A0577|148 154|CaMV 35S
P08590465A0773|43 64|S. pombe URA1 gene product
P08590465A0773|43 49|S. pombe
P08590465A0773|50 64|URA1 gene product
P08590465A0773|88 107|S. cerevisiae URA2 gene
P08590465A0773|88 99|S. cerevisiae
P08590465A0773|100 114|URA2 gene product
P08591700A0972|3 19|mean body mass index
P08591700A0972|21 23|BMI
P08591700A0972|63 67|women
P08591700A0972|71 73|men
P08592590A0822|53 69|chronic hepatitis C
P08592590A0822|83 101|interferon treatment
P08592590A0822|83 92|interferon
P08592590A0822|110 126|long-term response
P08592590A0822|156 163|patients
P08592713T0001|0 8|Synthetic
P08593813A0967|0 15|Polysome analysis
P08593813A0967|41 65|germ cell-specific Sp1 mRNAs
P08593813A0967|58 65|Sp1 mRNAs
P08593813A0967|113 129|somatic transcript
P08595012A0817|27 31|tcPO2
P08595012A0817|40 42|LDF
P08595184A0407|35 60|global synchronizing effects
P08595184A0407|93 112|local field potentials
P08595184A0407|114 117|LFPs
P08595414A0000|27 53|high-resolution physical maps
P08595414A0000|117 128|model genomes
P08595414A0000|185 198|adjacent clones
P08595627A1513|13 16|KATP
P08595627A1513|85 101|coronary occlusion
P08595627A1513|111 114|KATP
P08595627A1513|122 152|attenuates reperfusion-induced VF
P08595627A1513|167 184|ischemia-induced VF
P08595658A0961|30 36|termini
P08595658A0961|59 87|mitochondrial-processing sites
P08595658A0961|101 114|proximal 5' ends
P08595658A0961|141 153|RNA processing
P08595836T0000|0 14|Curing shrinkage
P08595836T0000|18 34|volumetric changes
P08595836T0000|37 82|resin-modified glass ionomer restorative materials
P08595878A0201|42 45|PP2A
P08595878A0201|42 45|PP2A
P08595878A0201|67 70|Ras1
P08595878A0201|67 70|Ras1
P08595878A0201|76 136|Sevenless receptor tyrosine kinase (RTK) signal transduction pathway
P08595878A0201|76 84|Sevenless
P08595878A0201|85 106|receptor tyrosine kinase
P08595878A0201|108 110|RTK
P08595878A0201|150 151|R7
P08595878A0201|188 200|Drosophila eye
P08597108A0642|0 4|QBMDs
P08597108A0642|28 33|QBMD05
P08597108A0642|81 85|NOAEL
P08597177T0000|28 43|hydrogen sulphide
P08597177T0000|46 62|rat hippocampal EEG
P08597596A0135|16 34|ATP-binding cassette
P08597596A0135|16 34|ATP-binding cassette
P08597596A0135|36 49|ABC transporter
P08597596A0135|36 49|ABC transporter
P08597636A0000|3 12|T-box motif
P08597636A0000|3 12|T-box motif
P08597636A0000|33 37|genes
P08597636A0000|107 133|developmental gene regulation
P08598051T0000|0 16|Molecular analysis
P08598051T0000|20 52|novel schizosaccharomyces pombe gene
P08598051T0000|66 104|RNP consensus-sequence RNA-binding domains
P08598051T0000|66 104|RNP consensus-sequence RNA-binding domains
P08598359X0000|74 100|T1-T2 squamous cell carcinomas
P08598359X0000|106 118|glottic larynx
P08598359X0000|150 180|patient related prognostic factors
P08598359X0000|225 250|T1-T2 squamous cell carcinoma
P08598359X0000|256 268|glottic larynx
P08598449A0784|35 43|surface Ig
P08598449A0784|42 43|Ig
P08598449A0784|56 67|B lymphocytes
P08598449A0784|69 80|CD38 ligation
P08598449A0784|69 72|CD38
P08598449A0784|101 123|tyrosine phosphorylation
P08598449A0784|129 158|src-like protein tyrosine kinases
P08598449A0784|129 158|src-like protein tyrosine kinases
P08598449A0784|159 161|lyn
P08598449A0784|159 161|lyn
P08598449A0784|163 165|fyn
P08598449A0784|163 165|fyn
P08598449A0784|170 172|btk
P08598449A0784|178 212|vav- and ras-GTPase-activating protein
P08598449A0784|178 181|vav-
P08598449A0784|185 212|ras-GTPase-activating protein
P08598449A0784|247 259|cytosolic CA2+
P08599945T0000|0 8|Mutations
P08599945T0000|14 42|alpha-amanitin conserved domain
P08599945T0000|14 27|alpha-amanitin
P08599945T0000|64 84|yeast RNA polymerase III
P08599945T0000|64 84|yeast RNA polymerase III
P08599945T0000|91 97|pausing
P08599945T0000|99 109|RNA cleavage
P08599945T0000|113 138|transcriptional transitions
P08599946A0999|39 48|p40 complex
P08599946A0999|39 48|p40 complex
P08599946A0999|52 75|ribonucleoprotein complex
P08599946A0999|86 92|L1Hs RNA
P08599946A0999|86 92|L1Hs RNA
P08599946A0999|94 94|s
P08599946A0999|103 129|protein-protein interactions
P08599946A0999|103 117|protein-protein
P08599946A0999|137 157|alpha-helix structures
P08600028A1129|18 33|trans-activation
P08600028A1129|41 65|prothymosin intron enhancer
P08600028A1129|41 65|prothymosin intron enhancer
P08600028A1129|92 113|transforming properties
P08600028A1129|119 128|Myc protein
P08600028A1129|119 128|Myc protein
P08600048T0000|0 29|Pseudomembranous conjunctivitis
P08600048T0000|39 63|bone marrow transplantation
P08600048T0000|65 105|immunopathological and ultrastructural study
P08601283A0875|21 33|SECIS elements
P08601283A0875|39 55|open reading frames
P08601283A0875|57 60|ORFs
P08601283A0875|64 86|bacterial selenoproteins
P08601283A0875|64 86|bacterial selenoproteins
P08601283A0875|112 126|type 1 deiodinase
P08601283A0875|141 143|ORF
P08601283A0875|151 162|SECIS element
P08601283A0875|199 211|SECIS function
P08601284A0000|24 40|spacer (ETS) region
P08601284A0000|31 33|ETS
P08601284A0000|46 53|pre-rRNA
P08601284A0000|46 53|pre-rRNA
P08601284A0000|56 78|Saccharomyces cerevisiae
P08601284A0000|100 103|10 bp
P08601284A0000|133 140|U3 snoRNA
P08601284A0000|133 140|U3 snoRNA
P08601490A0659|5 11|animals
P08601490A0659|25 31|fertile
P08601616A0726|4 16|spindle defect
P08601616A0726|19 29|pds1 mutants
P08601616A0726|19 22|pds1
P08601616A0726|42 52|temperature
P08601616A0726|86 97|G1/S boundary
P08601616A0726|112 126|spindle assembly
P08601806A0875|20 24|RPF-1
P08601806A0875|20 24|RPF-1
P08601806A0875|79 102|amacrine and ganglion cells
P08602169A0484|40 58|endonuclease III site
P08602169A0484|40 58|endonuclease III site
P08602169A0484|66 74|wild type)
P08602169A0484|90 93|CPDs
P08602169A0484|99 121|MAT alpha and HML alpha loci
P08602169A0484|99 106|MAT alpha
P08602169A0484|110 121|HML alpha loci
P08602608A1056|49 54|CD3500
P08602608A1056|61 64|STKS
P08602608A1056|116 139|manual reference procedure
P08603921A1346|0 33|Carboxy-terminal Spc110p truncations
P08603921A1346|16 22|Spc110p
P08603921A1346|44 64|calmodulin binding site
P08603921A1346|44 64|calmodulin binding site
P08603921A1346|108 131|cell cycle-specific manner
P08604338A0198|4 28|EWS-FLI-1 and FLI-1 proteins
P08604338A0198|4 6|EWS
P08604338A0198|8 12|FLI-1
P08604338A0198|16 28|FLI-1 proteins
P08604338A0198|39 58|transcription factors
P08604338A0198|81 92|ets sequences
P08604338A0198|81 92|ets sequences
P08604338A0198|97 104|ets boxes
P08604338A0198|97 104|ets boxes
P08604338A0198|115 130|promoter elements
P08604338A0885|2 27|electromobility shift assays
P08604338A0885|29 37|EWS-FLI-1
P08604338A0885|29 31|EWS
P08604338A0885|33 37|FLI-1
P08604338A0885|50 52|SRE
P08604338A0885|50 52|SRE
P08604338A0885|79 81|SRF
P08604338A0885|79 81|SRF
P08604338A0885|101 105|FLI-1
P08604338A0885|101 105|FLI-1
P08604338A0885|174 180|complex
P08604338A0885|192 196|FLI-1
P08604338A0885|192 196|FLI-1
P08604708A1086|27 57|reprocessed regenerated cellulose
P08604708A1086|76 78|450
P08604708A1086|96 104|flow rates
P08604708A1086|132 134|BTG
P08605302A1770|0 13|DNA methylation
P08605302A1770|70 79|GATC motifs
P08605302A1770|114 124|first intron
P08605302A1770|130 141|rice CatA gene
P08605302A1770|134 141|CatA gene
P08605302A1770|173 184|CatA promoter
P08605302A1770|173 184|CatA promoter
P08605302A1770|208 221|transient assay
P08605324A0434|3 10|viral LTR
P08605324A0434|23 30|promoter
P08605326A0772|11 20|cDNA clones
P08605705A0676|13 23|IgM class CIC
P08605705A0676|13 15|IgM
P08605705A0676|40 42|CIC
P08605705A0676|50 59|hepatitis A
P08605705A0676|77 91|disease activity
P08605931A0777|0 13|Epitope mapping
P08605931A0777|70 82|epitope domain
P08605931A0777|95 112|C-terminal RNP motif
P08605931A0777|95 112|C-terminal RNP motif
P08605931A0777|118 127|U1A protein
P08605931A0777|118 127|U1A protein
P08606267A0740|30 48|weekly anginal events
P08606267A0740|132 157|semiquantitative evaluation
P08606267A0740|160 192|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|194 197|MIBI
P08608126A0811|16 24|fatty acid
P08608126A0811|64 75|myristic acid
P08608126A0811|92 92|K
P08608126A0811|92 92|K
P08608126A0811|94 94|d
P08608126A0811|127 138|decanoic acid
P08608126A0811|160 171|octanoic acid
P08608126A0811|177 182|lipids
P08608222T0000|3 34|membrane-distal cytoplasmic region
P08608222T0000|37 84|human granulocyte colony-stimulating factor receptor
P08608222T0000|37 84|human granulocyte colony-stimulating factor receptor
P08608222T0000|98 102|STAT3
P08608222T0000|98 102|STAT3
P08608222T0000|109 122|STAT1 homodimer
P08608222T0000|109 113|STAT1
P08608447A0806|20 43|nonsense codon recognition
P08608447A0806|50 63|TPI transcripts
P08608447A0806|50 52|TPI
P08608448A0353|12 19|residues
P08608448A0353|104 133|phylogenetic secondary structure
P08608448A0353|141 147|4.5S RNA
P08608448A0353|184 191|residues
P08608448A0353|202 206|loops
P08610272A0265|0 6|Ongoing
P08610272A0265|110 121|chemotherapy
P08610272A0265|171 183|growth factors
P08610272A0265|215 222|patients
P08610582A0150|10 17|patients
P08610582A0150|22 35|pleural lesions
P08610582A0150|48 49|CT
P08610582A0150|81 89|MR imaging
P08611280A0820|0 16|Left atrial volumes
P08611280A0820|45 57|young subjects
P08611280A0820|111 123|atrial systole
P08612852A0553|13 29|plasma IGF-I levels
P08612852A0553|13 23|plasma IGF-I
P08612852A0553|38 50|body mass index
P08612852A0553|52 54|BMI
P08612852A0553|67 85|amenorrheic patients
P08612852A0553|92 106|healthy controls
P08614403A0557|26 42|Rev-erbA alpha mRNA
P08614403A0557|26 38|Rev-erbA alpha
P08614403A0557|45 66|dividing C2C12 myoblasts
P08614403A0557|117 149|postmitotic multinucleated myotubes
P08614403A0989|24 49|GAL4-REV-erbA alpha chimeras
P08614403A0989|24 27|GAL4
P08614403A0989|29 31|REV
P08614403A0989|33 41|erbA alpha
P08614403A0989|64 73|'AB' region
P08614403A0989|85 92|E' region
P08614403A0989|117 136|GAL4 response elements
P08614403A0989|117 136|GAL4 response elements
P08614403A0989|152 164|8-Br-cAMP and 2
P08614403A0989|152 160|8-Br-cAMP
P08614403A0989|169 188|ligand-binding domain
P08614403A0989|190 192|LBD
P08614403A0989|210 232|transcriptional silencer
P08614410A0000|8 19|T3-1 cell line
P08614410A0000|22 55|GnRH-responsive gonadotroph cell line
P08614410A0000|22 25|GnRH
P08614410A0000|75 85|oncogenesis
P08614410A0000|88 101|transgenic mice
P08614410A0000|132 163|glycoprotein hormone alpha-subunit
P08614410A0000|132 155|glycoprotein hormone alpha
P08614410A0000|166 172|activin
P08614410A0000|166 172|activin
P08615012A0627|21 27|ie1 gene
P08615012A0627|21 27|ie1 gene
P08615012A0627|95 110|transfected cells
P08615025A1214|11 23|glycosylation
P08615025A1214|26 28|Env
P08615025A1214|26 28|Env
P08615025A1214|80 101|glycosylation phenotype
P08615025A1214|125 127|Env
P08615025A1214|125 127|Env
P08615025A1214|151 166|immunoreactivity
P08615025A1214|169 170|V3
P08615025A1214|169 170|V3
P08615025A1214|187 191|gp160
P08615025A1214|187 191|gp160
P08615025A1214|217 221|gp120
P08615025A1214|217 221|gp120
P08615025A1214|225 228|gp41
P08615025A1214|225 228|gp41
P08615025A1214|234 236|Env
P08615025A1214|234 236|Env
P08615025A1214|252 263|cell membrane
P08615025A1214|276 280|gp120
P08615025A1214|276 280|gp120
P08615025A1214|286 288|CD4
P08615025A1214|286 288|CD4
P08615025A1214|294 308|vi) membrane gp41
P08615025A1214|305 308|gp41
P08615025A1214|324 337|membrane fusion
P08615025A1214|342 350|CD4+ cells
P08615025A1214|342 345|CD4+
P08615183T0000|36 53|Parkinson's disease
P08616743T0000|12 14|Dr.
P08617216A0584|12 23|complete DnaJ
P08617216A0584|20 23|DnaJ
P08617216A0584|40 43|DnaK
P08617216A0584|40 43|DnaK
P08617216A0584|61 64|GrpE
P08617216A0584|61 64|GrpE
P08617216A0584|86 102|firefly luciferase
P08617216A0584|93 102|luciferase
P08617237A0489|29 33|STAT5
P08617237A0489|29 33|STAT5
P08617237A0489|47 74|in vitro DNA binding specificity
P08617237A0489|92 114|tyrosine phosphopeptides
P08617237A0489|132 151|cellular localization
P08617238A0334|0 2|TNF
P08617238A0334|30 41|p38 MAP kinase
P08617238A0334|88 99|p38 MAP kinase
P08617238A0334|88 99|p38 MAP kinase
P08617238A0334|138 151|MAPKAP kinase-2
P08617238A0334|138 151|MAPKAP kinase-2
P08617238A0334|192 215|heat shock protein 27 (hsp27
P08617238A0334|192 209|heat shock protein 27
P08617238A0334|211 215|hsp27
P08617243A0336|31 40|Drosophila
P08617243A0336|41 55|nuclear extracts
P08617243A0336|91 102|second region
P08617311A0979|59 67|avian mIgY
P08617311A0979|59 67|avian mIgY
P08617311A0979|71 83|mammalian mIgG
P08617311A0979|71 83|mammalian mIgG
P08617311A0979|87 89|IgE
P08617311A0979|87 89|IgE
P08617311A0979|125 135|Xenopus mIgY
P08617311A0979|125 135|Xenopus mIgY
P08617800A0150|27 36|erbB-2 gene
P08617800A0150|27 36|erbB-2 gene
P08617800A0150|63 80|receptor expression
P08617800A0675|0 17|DNase I footprinting
P08617800A0675|0 5|DNase I
P08617800A0675|21 54|electrophoretic mobility shift assays
P08617800A0675|67 69|PBP
P08617800A0675|67 69|PBP
P08617800A0675|95 104|palindrome
P08617800A0675|135 140|TGGGAG
P08617802A0993|41 57|SH2/SH3/SH2 region
P08617802A0993|41 43|SH2
P08617802A0993|45 47|SH3
P08617802A0993|49 51|SH2
P08617802A0993|60 66|p120 GAP
P08617802A0993|60 63|p120
P08617802A0993|64 66|GAP
P08617802A0993|85 101|catalytic activity
P08617802A0993|108 110|Ras
P08617802A0993|108 110|Ras
P08618433A0000|8 42|hematopoietic growth factor FLT3 ligand
P08618433A0000|8 32|hematopoietic growth factor
P08618433A0000|33 42|FLT3 ligand
P08618433A0000|44 45|FL
P08618433A0000|44 45|FL
P08618433A0000|71 97|FLT3, tyrosine kinase receptor
P08618433A0000|71 74|FLT3
P08618433A0000|76 97|tyrosine kinase receptor
P08618433A0000|99 99|R
P08618433A0000|99 99|R
P08618433A0000|118 122|FLK-2
P08618433A0000|118 122|FLK-2
P08618433A0000|126 130|STK-1
P08618433A0000|126 130|STK-1
P08618433A1720|39 46|receptor
P08618433A1720|48 59|FL expression
P08618433A1720|48 49|FL
P08618433A1720|103 119|leukemia cell lines
P08618433A1720|127 151|hematopoietic cell lineages
P08618864A0754|63 90|hydrophobic and acidic residues
P08618882A0343|10 24|RAR alpha mutants
P08618882A0343|10 17|RAR alpha
P08618882A0343|27 45|transfection studies
P08618882A0343|60 75|DNA binding domain
P08618882A0343|60 75|DNA binding domain
P08618882A0343|103 115|BZLF1 activity
P08618882A0343|103 107|BZLF1
P08619866A0000|15 36|hepatocyte growth factor
P08619866A0000|15 36|hepatocyte growth factor
P08619866A0000|38 40|HGF
P08619866A0000|38 40|HGF
P08619866A0000|44 51|patients
P08619866A0000|56 80|acute myocardial infarction
P08619866A0000|105 117|heart diseases
P08619910A0000|3 17|neural mechanism
P08619910A0000|20 44|parkinsonian motor symptoms
P08619910A0000|51 58|rigidity
P08619910A0000|69 76|akinesia
P08619910A0000|110 127|dopamine deficiency
P08619910A0000|180 187|surgical
P08619910A0000|191 214|pharmacological treatment
P08619910A0000|291 302|zona compacta
P08619910A0000|304 306|SNc
P08620003T0000|0 14|Protein splicing
P08620003T0000|29 48|N-O acyl rearrangement
P08620856A1172|25 46|western blot experiments
P08620856A1172|80 102|carboxy-terminal portion
P08620856A1172|108 124|mouse c-kit protein
P08620856A1172|113 117|c-kit
P08620856A1172|171 186|open reading frame
P08620856A1172|192 218|spermatid-specific c-kit cDNA
P08620856A1172|192 218|spermatid-specific c-kit cDNA
P08620856A1172|250 264|spermatogenesis
P08620856A1172|270 290|epididymal spermatozoa
P08620889A0771|16 32|(G+C)-rich element
P08620889A0771|17 19|G+C
P08620889A0771|38 54|aldolase C promoter
P08620889A0771|38 54|aldolase C promoter
P08620889A0771|62 74|transcription
P08620889A0771|95 110|nonneuronal cells
P08621017A1186|0 7|LY290181
P08621017A1186|24 44|uPA promoter activation
P08621017A1186|24 34|uPA promoter
P08621017A1186|55 84|phorbol ester-stimulated binding
P08621017A1186|87 101|nuclear proteins
P08621017A1186|87 101|nuclear proteins
P08621017A1186|107 149|uPA PEA3/12-0-tetradecanoylphorbol 13-acetate
P08621017A1186|107 116|uPA PEA3/12
P08621017A1186|168 170|TRE
P08621384A0935|11 23|keratinocytes
P08621384A0935|41 69|epidermal growth factor receptor
P08621384A0935|41 69|epidermal growth factor receptor
P08621384A0935|71 74|EGFR
P08621384A0935|71 74|EGFR
P08621384A0935|80 87|TGFalpha
P08621384A0935|80 87|TGFalpha
P08621384A0935|90 110|epidermal growth factor
P08621384A0935|90 110|epidermal growth factor
P08621384A0935|125 155|PKCdelta tyrosine phosphorylation
P08621384A0935|125 132|PKCdelta
P08621420A1166|46 48|p50
P08621420A1166|46 48|p50
P08621420A1166|69 71|p65
P08621420A1166|69 71|p65
P08621420A1166|79 95|NF-kappaB proteins
P08621420A1166|79 95|NF-kappaB proteins
P08621448A0862|11 26|complementary DNA
P08621448A0862|28 37|cDNA) clone
P08621448A0862|44 66|RL95-2 expression library
P08621448A0862|81 101|C1 site-binding protein
P08621448A0862|81 101|C1 site-binding protein
P08621453A0815|11 40|anti-phosphotyrosine antibodies
P08621453A0815|16 40|phosphotyrosine antibodies
P08621453A0815|59 63|80K-H
P08621453A0815|59 63|80K-H
P08621453A0815|68 78|cell lysates
P08621453A0815|81 94|FGF-stimulated
P08621453A0815|81 83|FGF
P08621453A0815|112 122|fibroblasts
P08621542A0535|3 21|novel protein kinases
P08621542A0535|8 21|protein kinases
P08621542A0535|23 46|c-Jun NH2-terminal kinases
P08621542A0535|23 46|c-Jun NH2-terminal kinases
P08621542A0535|48 83|JNKs)/stress-activated protein kinases
P08621542A0535|48 51|JNKs
P08621542A0535|54 83|stress-activated protein kinases
P08621542A0535|103 111|TNF-alpha
P08621542A0535|103 111|TNF-alpha
P08621542A0535|113 116|IL-1
P08621542A0535|113 116|IL-1
P08621542A0535|121 137|CD28 costimulation
P08621542A0535|121 124|CD28
P08621628A1233|5 11|hGRbeta
P08621628A1233|5 11|hGRbeta
P08621628A1233|35 59|dominant negative inhibitor
P08621628A1233|62 77|hGRalpha activity
P08621628A1233|62 69|hGRalpha
P08621659A0189|0 3|Gas6
P08621659A0189|0 3|Gas6
P08621659A0189|14 34|NH2-terminal Gla domain
P08621659A0189|14 34|NH2-terminal Gla domain
P08621659A0189|49 81|epidermal growth factor-like repeats
P08621659A0189|49 74|epidermal growth factor-like
P08621659A0189|85 108|tandem globular (G) domains
P08621661A1035|4 18|P5CDh cDNA clones
P08621661A1035|4 12|P5CDh cDNA
P08621661A1035|50 62|Northern blots
P08621661A1035|65 84|multiple human tissues
P08621661A1035|120 140|3'-untranslated intron
P08621664A1430|0 13|Polymerization
P08621664A1430|16 36|neurofilament L protein
P08621664A1430|29 36|L protein
P08621664A1430|58 72|phosphorylation
P08621664A1430|75 95|neurofilament L protein
P08621664A1430|88 95|L protein
P08621664A1430|98 100|PKN
P08621664A1430|98 100|PKN
P08621714A0361|31 44|disulfide bonds
P08621714A0361|53 62|thiol group
P08621714A0361|65 69|Cys25
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|87 109|tyrosine phosphorylation
P08621719A0000|114 137|T cell receptor stimulation
P08621719A0000|114 126|T cell receptor
P08621719A0568|22 24|Cbl
P08621719A0568|22 24|Cbl
P08621719A0568|56 59|Grb2
P08621719A0568|91 104|Grb2 SH3 domains
P08621719A0568|91 94|Grb2
P08621719A0568|95 104|SH3 domains
P08621730T0000|2 20|AP-1 binding sequence
P08621730T0000|2 20|AP-1 binding sequence
P08621730T0000|50 71|human alpha2(I) collagen
P08621730T0000|50 60|human alpha2
P08621730T0000|62 71|I) collagen
P08621730T0000|73 95|COL1A2) promoter activity
P08621730T0000|73 78|COL1A2
P08621730T0000|98 126|transforming growth factor-beta
P08621730T0000|98 126|transforming growth factor-beta
P08622030A0667|55 77|baseline characteristics
P08622030A0667|97 104|protocol
P08622030A0667|106 122|performance status
P08622030A0667|127 161|serum lactate dehydrogenase (LDH) level
P08622030A0667|132 151|lactate dehydrogenase
P08622030A0667|153 155|LDH
P08622070A0889|7 14|patients
P08622070A0889|25 37|CA 125 response
P08622596A0189|20 33|prescribed diet
P08622596A0189|51 62|saturated fat
P08622596A0189|75 77|fat
P08622645A1026|15 17|VDR
P08622645A1026|15 17|VDR
P08622645A1026|34 42|vitamin D3
P08622645A1026|53 59|9-cis RA
P08622645A1026|75 95|RXR-responsive element
P08622645A1026|75 95|RXR-responsive element
P08622668A1155|54 58|U6 RNA
P08622668A1155|54 58|U6 RNA
P08622668A1155|76 113|phosphorylation-dephosphorylation cycle
P08622668A1155|116 129|C1 hnRNP protein
P08622668A1155|116 129|C1 hnRNP protein
P08622668A1155|178 185|pre-mRNA
P08622668A1155|178 185|pre-mRNA
P08622675A0587|22 30|N terminus
P08622675A0587|56 62|protein
P08622675A0587|97 115|lymphoid factor Lef-1
P08622675A0587|97 110|lymphoid factor
P08622675A0587|111 115|Lef-1
P08622698T0000|9 23|mammalian Notch1
P08622698T0000|18 23|Notch1
P08622698T0000|33 42|CBF1/RBPJk
P08622698T0000|33 36|CBF1
P08622698T0000|38 42|RBPJk
P08622698T0000|86 107|Epstein-Barr virus EBNA2
P08622698T0000|86 102|Epstein-Barr virus
P08622698T0000|103 107|EBNA2
P08622887A1026|0 33|Electrophoretic mobility shift assays
P08622887A1026|35 39|EMSAs
P08622887A1026|54 91|glucocorticoid receptor DNA binding domain
P08622887A1026|54 91|glucocorticoid receptor DNA binding domain
P08622887A1026|93 95|DBD
P08622887A1026|93 95|DBD
P08622887A1026|117 132|GRE-2 and -3 motifs
P08622887A1026|117 132|GRE-2 and -3 motifs
P08622887A1026|145 147|DBD
P08622887A1026|234 236|DBD
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|43 46|RTKs
P08622893A0000|43 46|RTKs
P08622893A0000|56 58|EPH
P08622893A0000|56 58|EPH
P08622893A0000|64 72|prototype
P08622893A0000|90 115|intercellular communication
P08622893A0000|128 147|mammalian development
P08622893A0000|155 183|biochemical signalling pathways
P08623554A1058|3 15|17-kDa protein
P08623554A1058|3 15|17-kDa protein
P08623554A1058|32 48|systemic infection
P08623554A1058|51 56|plants
P08624445A0257|52 78|cytosine methylation patterns
P08624445A0257|84 106|transposase binding sites
P08624445A0257|84 94|transposase
P08624445A0257|117 118|Ac
P08624445A0257|117 118|Ac
P08624445A0257|128 132|wx-m9
P08624445A0257|135 142|Ac allele
P08624445A0257|135 136|Ac
P08624445A0257|149 150|Ac
P08624445A0257|149 150|Ac
P08624445A0257|182 189|Waxy gene
P08624445A0257|182 189|Waxy gene
P08625806A0263|0 6|Krox-20
P08625806A0263|9 22|zinc finger gene
P08625806A0263|9 22|zinc finger gene
P08625806A0263|64 65|r3
P08625806A0263|64 65|r3
P08625806A0263|69 70|r5
P08625806A0263|69 70|r5
P08625806A0263|117 128|mouse embryos
P08625900T0000|0 46|Pituitary adenylate cyclase-activating polypeptide
P08625900T0000|9 46|adenylate cyclase-activating polypeptide
P08625900T0000|56 80|prolactin promoter activity
P08625900T0000|56 64|prolactin
P08625900T0000|85 114|protein kinase A-mediated pathway
P08625900T0000|85 98|protein kinase A
P08625900T0000|137 158|transcriptional pathway
P08625900T0000|169 196|thyrotropin-releasing hormone
P08625900T0000|169 196|thyrotropin-releasing hormone
P08625924A0411|6 8|33F
P08625924A0411|12 14|34B
P08625924A0411|31 39|aromatase
P08625924A0411|50 62|503 amino acids
P08625924A0411|142 146|mRNAs
P08625987A1086|2 22|sorted bone marrow cells
P08625987A1086|39 48|VpreB genes
P08625987A1086|39 48|VpreB genes
P08625987A1086|62 73|pro-B/pre-BI
P08625987A1086|62 66|pro-B
P08625987A1086|68 73|pre-BI
P08625987A1086|77 93|large pre-BII cells
P08625987A1086|154 184|pre-BII and immature/mature B cells
P08626065A0000|25 62|3574-bp Bacillus subtilis (Bs) DNA fragment
P08626065A0000|32 50|Bacillus subtilis (Bs
P08626065A0000|80 95|nrdA and citB genes
P08626065A0000|80 83|nrdA
P08626065A0000|87 95|citB genes
P08626065A0000|118 127|chromosome
P08626290T0000|0 19|Aeromonas salmonicida
P08626290T0000|58 82|major outer membrane protein
P08626290T0000|68 82|membrane protein
P08626290T0000|84 87|OmpA
P08626290T0000|84 87|OmpA
P08626313A1037|12 14|Msp
P08626313A1037|12 14|Msp
P08626313A1037|25 30|E. coli
P08626313A1037|44 50|msp gene
P08626313A1037|44 50|msp gene
P08626325A0543|50 53|UmuD
P08626325A0543|50 53|UmuD
P08626325A0543|57 61|UmuD'
P08626325A0543|57 60|UmuD
P08626325A0543|79 88|homodimers
P08626325A0543|90 112|UmuD-UmuD and UmuD'-UmuD'
P08626325A0543|90 93|UmuD
P08626325A0543|95 98|UmuD
P08626325A0543|102 113|UmuD'-UmuD')
P08626325A0543|117 128|a heterodimer
P08626325A0543|118 128|heterodimer
P08626325A0543|130 139|UmuD-UmuD'
P08626325A0543|130 133|UmuD
P08626325A0543|135 139|UmuD'
P08626437A0332|0 8|Lyn kinase
P08626437A0332|0 8|Lyn kinase
P08626437A0332|40 52|irradiated BCP
P08626437A0332|73 100|glutathione S-transferase (GST
P08626437A0332|73 96|glutathione S-transferase
P08626437A0332|98 100|GST
P08626437A0332|103 156|Lyn fusion protein-phosphorylated recombinant human p34cdc2
P08626437A0332|103 118|Lyn fusion protein
P08626437A0332|134 156|recombinant human p34cdc2
P08626437A0332|159 168|tyrosine 15
P08626493A1468|0 8|Mutations
P08626493A1468|15 30|conserved region 2
P08626493A1468|32 34|CR2
P08626493A1468|32 34|CR2
P08626493A1468|38 40|E1A
P08626493A1468|38 40|E1A
P08626493A1468|64 66|E1A
P08626493A1468|64 66|E1A
P08626493A1468|72 96|retinoblastoma gene product
P08626493A1468|72 96|retinoblastoma gene product
P08626493A1468|98 100|pRb
P08626493A1468|98 100|pRb
P08626493A1468|153 165|PEPCK promoter
P08626493A1468|153 165|PEPCK promoter
P08626493A1468|187 197|wild type E1A
P08626493A1468|195 197|E1A
P08626529A0000|5 18|autoantibodies
P08626529A0000|24 47|Sjogren's syndrome patient
P08626529A0000|83 107|peripheral membrane protein
P08626529A0000|143 153|trans-Golgi
P08626529A0799|12 30|proline-rich regions
P08626529A0799|32 56|amino acids 1-117 and 239-270
P08626529A0799|59 62|p230
P08626529A0799|59 62|p230
P08626529A0799|121 133|alpha-helices
P08626529A0799|142 148|dimeric
P08626529A0799|171 174|p230
P08626529A0799|171 174|p230
P08626529A0799|198 225|ESLALEELEL (amino acids 538-546
P08626529A0799|244 255|granin family
P08626529A0799|258 271|acidic proteins
P08626529A0799|281 297|secretory granules
P08626529A0799|300 318|neuroendocrine cells
P08626539T0000|0 17|Binding specificity
P08626539T0000|36 49|ApoA-I promoter
P08626539T0000|36 49|ApoA-I promoter
P08626539T0000|60 79|homo- and heterodimers
P08626539T0000|82 97|nuclear receptors
P08626539T0000|82 97|nuclear receptors
P08626540A1007|62 92|biosynthetically labeled ceramide
P08626540A1007|114 129|lactosylceramide
P08626596A0000|26 60|mammalian AMP-activated protein kinase
P08626596A0000|26 60|mammalian AMP-activated protein kinase
P08626596A0000|62 65|AMPK
P08626596A0000|62 65|AMPK
P08626596A0000|115 126|ATP depletion
P08626596A0000|141 144|ATP-
P08626596A0000|145 173|consuming biosynthetic pathways
P08626610A0931|0 25|Sterol-mediated suppression
P08626610A0931|38 44|SREBP-1
P08626610A0931|38 44|SREBP-1
P08626610A0931|71 96|extreme COOH-terminal region
P08626610A0931|98 104|residue
P08626610A0931|114 125|COOH terminus
P08626610A0931|160 178|alternative splicing
P08626667A1372|0 25|EMSA competition experiments
P08626667A1372|54 66|direct repeats
P08626667A1372|97 111|nuclear proteins
P08626667A1372|97 111|nuclear proteins
P08626667A1372|121 143|wild type oligonucleotide
P08626667A1517|0 12|Transcription
P08626667A1517|20 27|promoter
P08626667A1517|48 60|direct repeats
P08626667A1517|147 163|GPT gene expression
P08626667A1517|147 153|GPT gene
P08626698A0989|27 38|ERK3 activity
P08626698A0989|27 30|ERK3
P08626698A0989|45 63|PKC beta transfectant
P08626698A0989|45 51|PKC beta
P08626698A0989|74 92|immunoprecipitation
P08626698A0989|97 123|anti-ERK3 monoclonal antibody
P08626698A0989|97 123|anti-ERK3 monoclonal antibody
P08626698A0989|140 163|immune complex kinase assay
P08626698A0989|170 183|gel kinase assay
P08626777A0537|0 15|Sequence analysis
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|57 70|sequence motifs
P08626777A0537|102 117|regulatory region
P08626777A0537|123 137|link protein gene
P08626777A0537|127 137|protein gene
P08626777A0537|146 158|cartilage gene
P08626785A0674|0 27|Retinoid-dependent activation
P08626785A0674|33 62|tissue transglutaminase promoter
P08626785A0674|33 62|tissue transglutaminase promoter
P08626785A0674|77 100|proximal regulatory region
P08626785A0674|145 191|human and the mouse tissue transglutaminase promoters
P08626785A0674|156 191|mouse tissue transglutaminase promoters
P08626785A0674|232 262|retinoid response element (mTGRRE1
P08626785A0674|265 271|mTGRRE1
P08626785A0674|285 308|hexanucleotide half-sites
P08626785A0674|345 356|DR7/DR5 motif
P08626785A0674|345 347|DR7
P08626785A0674|349 356|DR5 motif
P08626785A0674|369 387|RAR*RXR heterodimers
P08626785A0674|369 387|RAR*RXR heterodimers
P08626785A0674|391 403|RXR homodimers
P08626785A0674|391 393|RXR
P08626809A0729|14 17|pPKR
P08626809A0729|14 17|pPKR
P08626809A0729|56 60|Ser51
P08626809A0729|73 89|eIF-2alpha peptide
P08626809A0729|73 89|eIF-2alpha peptide
P08626809A0729|114 135|eIF-2alpha kinase family
P08626809A0729|114 129|eIF-2alpha kinase
P08627354A0000|0 18|Vertebrate synapsins
P08627354A0000|38 53|synaptic proteins
P08627354A0000|86 108|neurotransmitter release
P08627649A0734|0 33|Electrophoretic mobility shift assays
P08627649A0734|39 51|crude extracts
P08627649A0734|56 65|FREJ4 cells
P08627649A0734|101 131|Ets family of transcription factors
P08627649A0734|101 109|Ets family
P08627649A0734|112 131|transcription factors
P08627649A0734|137 141|P4 EBS
P08627649A0734|137 138|P4
P08627649A0734|139 141|EBS
P08627649A0734|182 190|Sp1 family
P08627649A0734|182 190|Sp1 family
P08627649A0734|192 194|Sp1
P08627649A0734|192 194|Sp1
P08627649A0734|198 200|Sp3
P08627649A0734|198 200|Sp3
P08627649A0734|217 221|GC box
P08627667A0132|0 4|ZEBRA
P08627667A0132|0 4|ZEBRA
P08627667A0132|8 33|cellular AP-1 bZip activators
P08627667A0132|8 33|cellular AP-1 bZip activators
P08627667A0132|41 45|c-Fos
P08627667A0132|41 45|c-Fos
P08627667A0132|61 78|DNA-binding domains
P08627688A1520|23 32|mutant I299
P08627688A1520|46 64|cap-binding activity
P08627719A0784|0 25|UV cross-linking experiments
P08627719A0784|42 53|HSV infection
P08627719A0784|77 90|protein factors
P08627719A0784|77 90|protein factors
P08627719A0784|104 118|64-kDa component
P08627719A0784|121 145|cleavage stimulation factor
P08627719A0784|147 150|CstF
P08627719A0784|147 150|CstF
P08627719A0784|155 169|poly(A) site RNAs
P08627719A0784|174 183|virus genes
P08627719A0784|250 253|IE63
P08627719A0784|250 253|IE63
P08628251A1455|0 6|CM-ACO3
P08628251A1455|0 6|CM-ACO3
P08628254A0665|19 33|Jun/eb1 chimeras
P08628254A0665|19 21|Jun
P08628254A0665|23 25|eb1
P08628254A0665|43 57|transactivators
P08628254A0665|60 67|AP1 sites
P08628254A0665|60 67|AP1 sites
P08628254A0665|95 102|c-Ha-Ras
P08628254A0665|95 102|c-Ha-Ras
P08628255A0932|14 22|HeLa cells
P08628255A0932|36 53|luciferase activity
P08628255A0932|36 45|luciferase
P08628255A0932|80 91|DNA synthesis
P08628255A0932|124 138|E2F-binding site
P08628255A0932|124 138|E2F-binding site
P08628255A0932|144 156|H2A.1 promoter
P08628255A0932|144 156|H2A.1 promoter
P08628260A0895|9 36|transient transfection studies
P08628260A0895|39 48|HepG2 cells
P08628260A0895|78 87|factor VIII
P08628260A0895|84 87|VIII
P08628260A0895|165 180|promoter activity
P08628284A0181|46 53|lacZ gene
P08628284A0181|46 53|lacZ gene
P08628284A0181|74 85|CYC1 promoter
P08628284A0181|74 77|CYC1
P08628284A0181|113 117|TRE-1
P08628284A0181|113 117|TRE-1
P08628302A0683|2 7|hnRNP K
P08628302A0683|2 7|hnRNP K
P08628302A0683|11 29|transcription factor
P08628302A0683|11 29|transcription factor
P08628302A0683|54 90|RNA polymerase II transcription apparatus
P08628302A0683|54 68|RNA polymerase II
P08628681A0364|25 33|4.6 kb mRNA
P08628681A0364|48 60|Northern blots
P08628681A0364|63 71|oocyte RNA
P08628681A0364|80 91|X.laevis cDNA
P08628681A0364|80 91|X.laevis cDNA
P08628681A0821|0 19|Sequence conservation
P08628681A0821|55 67|active centers
P08628681A0821|73 75|exo
P08628681A0821|73 75|exo
P08628681A0821|79 88|pol domains
P08628681A0821|79 88|pol domains
P08628681A0821|94 122|E.coli DNA polymerase I structure
P08628681A0821|94 113|E.coli DNA polymerase I
P08629348A0237|36 42|acute BI
P08629348A0237|106 145|cicatricial-adhesive and atrophic processes
P08629348A0237|192 212|posttraumatic epilepsy
P08629348A0237|228 230|etc
P08630548A0000|7 15|cytokines
P08630548A0000|62 78|somnogenic potency
P08630548A0000|85 97|interleukin-1
P08630548A0000|85 97|interleukin-1
P08630548A0000|99 103|IL-1]
P08630548A0000|99 102|IL-1
P08630548A0000|105 129|tumor necrosis factor-alpha
P08630548A0000|105 129|tumor necrosis factor-alpha
P08630548A0000|131 140|TNF-alpha]
P08630548A0000|131 139|TNF-alpha
P08630583A1056|2 3|pH
P08630583A1056|7 8|Hb
P08630583A1056|7 8|Hb
P08630583A1056|27 42|venous CO2 content
P08630599A0534|14 40|elastin peptide concentration
P08630599A0534|14 27|elastin peptide
P08630599A0534|59 79|emphysematous patients
P08630599A0534|83 97|control subjects
P08630599A0534|213 222|coal miners
P08631667A0851|31 43|E. coli tmk gene
P08631667A0851|31 43|E. coli tmk gene
P08631667A0851|86 100|yeast dTMP kinase
P08631667A0851|86 100|yeast dTMP kinase
P08631667A0851|101 127|temperature-sensitive mutant
P08631667A0851|101 127|temperature-sensitive mutant
P08631667A0851|133 150|in vitro enzyme assay
P08631667A0851|156 180|thymidylate kinase activity
P08631667A0851|156 172|thymidylate kinase
P08631667A0851|183 194|cell extracts
P08631667A0851|197 202|E. coli
P08631667A0851|210 234|tmk-overproducing plasmids
P08631667A0851|210 212|tmk
P08631685A0000|3 16|structural gene
P08631685A0000|20 67|copper- and topa quinone-containing monoamine oxidase
P08631685A0000|30 67|topa quinone-containing monoamine oxidase
P08631685A0000|69 72|maoA
P08631685A0000|69 72|maoA
P08631685A0000|79 101|unknown amine oxidase gene
P08631685A0000|86 101|amine oxidase gene
P08631685A0000|131 155|Escherichia coli chromosome
P08631760A0609|30 38|SH2 domain
P08631760A0609|30 38|SH2 domain
P08631760A0609|41 43|Crk
P08631760A0609|41 43|Crk
P08631760A0609|66 79|phosphopeptide
P08631760A0609|93 111|Crk-SH2 binding motif
P08631760A0609|93 95|Crk
P08631760A0609|97 111|SH2 binding motif
P08631797A0982|14 19|ErbB-2
P08631797A0982|14 19|ErbB-2
P08631797A0982|26 46|shared receptor subunit
P08631797A0982|51 73|tyrosine phosphorylation
P08631797A0982|149 151|NDF
P08631797A0982|149 151|NDF
P08631797A0982|154 163|EGF binding
P08631797A0982|154 156|EGF
P08631817T0000|26 47|cyclin-dependent kinase
P08631817T0000|26 47|cyclin-dependent kinase
P08631817T0000|91 138|human deoxyuridine triphosphate nucleotidohydrolase
P08631817T0000|91 138|human deoxyuridine triphosphate nucleotidohydrolase
P08631820A0755|3 6|cDNA
P08631820A0755|25 32|FPS1 gene
P08631820A0755|25 32|FPS1 gene
P08631820A0755|80 90|yeast strain
P08631820A0755|102 112|FPS activity
P08631820A0755|102 104|FPS
P08631822A0677|11 26|plasmin fragments
P08631822A0677|11 26|plasmin fragments
P08631822A0677|29 32|VEGF
P08631822A0677|29 32|VEGF
P08631822A0677|58 64|heparin
P08631822A0677|95 107|VEGF receptors
P08631822A0677|95 107|VEGF receptors
P08631822A0677|128 153|endothelial cell mitogenesis
P08631908A0224|0 6|VDR/RXR
P08631908A0224|0 2|VDR
P08631908A0224|4 6|RXR
P08631908A0224|21 25|VDREs
P08631908A0224|31 33|DR4
P08631908A0224|37 39|DR5
P08631908A0224|48 80|electrophoretic mobility shift assay
P08631934A0000|15 17|Myb
P08631934A0000|15 17|Myb
P08631934A0000|26 45|transcription factors
P08631934A0000|26 45|transcription factors
P08631934A0000|71 87|DNA-binding domain
P08631934A0000|71 87|DNA-binding domain
P08631934A0000|99 113|Myb-binding site
P08631934A0000|99 113|Myb-binding site
P08631934A0000|115 126|MBS) sequence
P08631934A0000|115 117|MBS
P08631934A0000|128 142|YG(A/G)C(A/C/G)
P08631934A0000|128 129|YG
P08631934A0000|131 131|A
P08631934A0000|133 135|G)C
P08631934A0000|137 137|A
P08631934A0000|139 139|C
P08631934A0000|141 141|G
P08631934A0000|143 150|GTT(G/A)
P08631934A0000|147 149|G/A
P08631944A0663|38 52|C epsilon4 domain
P08631944A0663|72 73|M2
P08631944A0663|74 77|exon
P08631944A0663|79 87|IgE grande
P08631944A0663|79 87|IgE grande
P08631944A0663|105 117|J558L cell line
P08631944A0663|158 196|cell line-dependent regulation of secretion
P08631958T0000|0 44|Human cytomegalovirus immediate-early protein IE2
P08631958T0000|0 19|Human cytomegalovirus
P08631958T0000|20 41|immediate-early protein
P08631958T0000|42 44|IE2
P08631958T0000|53 83|transcriptional repression domain
P08631958T0000|86 88|p53
P08631958T0000|86 88|p53
P08632009A1067|24 41|C/EBP family members
P08632009A1067|24 41|C/EBP family members
P08632009A1067|101 118|expression profiles
P08632009A1067|123 142|DNA binding affinities
P08632009A1067|180 202|DNA binding specificities
P08632015A0879|3 12|antibodies
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A1226|0 25|Immunocytochemical analysis
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|68 73|nuclei
P08632015A1226|82 107|eighth nuclear division cycle
P08632015A1226|144 147|DREF
P08632015A1226|144 147|DREF
P08632015A1226|194 207|DNA replication
P08632015A1226|229 240|DRE sequences
P08632018A0587|1 11|DNA fragment
P08632018A0587|20 35|1,100 nucleotides
P08632018A0587|50 66|5'-flanking region
P08632018A0587|72 81|UGT1A1 gene
P08632018A0587|72 81|UGT1A1 gene
P08632018A0587|94 104|MC induction
P08632463A1508|36 47|beta' subunit
P08632463A1508|36 47|beta' subunit
P08632463A1508|94 116|transcription elongation
P08632779A0351|3 12|XPG regions
P08632779A0351|25 27|NLS
P08632779A0351|29 40|amino acid (AA
P08632779A0351|54 58|NLS-B
P08632779A0351|75 79|NLS-C
P08632779A0351|133 140|beta-gal
P08632779A0351|163 169|nucleus
P08632779A0351|172 180|HeLa cells
P08633855A1064|3 10|lacS gene
P08633855A1064|3 10|lacS gene
P08633855A1064|24 56|E. coli-Streptococcus shuttle vector
P08633855A1064|79 82|lacS
P08633855A1064|103 116|S. thermophilus
P08633855A1064|123 139|pNZ63-cured strain
P08633855A1064|141 148|L. lactis
P08633855A1064|149 154|NZ6091
P08634290A0000|14 25|retroviruses
P08634290A0000|80 84|5' end
P08634357A0527|3 20|extraction recovery
P08634357A0527|23 35|Amphotericin B
P08634357A0527|43 60|cerebrospinal fluid
P08634420A1784|0 8|HuEpo-R Ab
P08634420A1784|0 8|HuEpo-R Ab
P08634420A1784|18 20|Epo
P08634420A1784|37 40|UT-7
P08634420A1784|71 77|clone 12
P08634420A1784|96 102|muEpo-R
P08634420A1784|96 102|muEpo-R
P08634420A1784|122 125|UT-7
P08634423A0498|53 60|lacZ gene
P08634423A0498|53 60|lacZ gene
P08634423A0498|145 152|32D cells
P08634423A0498|160 170|neutrophils
P08634697A1155|3 10|sequence
P08634697A1155|22 26|cDNAs
P08634697A1155|78 82|Brca1
P08634697A1155|78 82|Brca1
P08635771A0000|30 35|ONLINE
P08635771A0000|39 56|EMIT II immunoassays
P08635771A0000|61 96|gas chromatographic/mass spectrometric
P08635771A0000|98 99|GC
P08635771A0000|101 102|MS
P08635771A0000|114 136|methaqualone metabolites
P08636031A1413|16 27|Fur repressor
P08636031A1413|16 27|Fur repressor
P08636031A1413|33 46|150-bp fragment
P08636031A1413|62 73|pvdS promoter
P08636031A1413|62 73|pvdS promoter
P08636031A1413|100 116|Fur titration assay
P08636031A1413|100 102|Fur
P08636031A1413|138 162|gel retardation experiments
P08636031A1413|185 187|Fur
P08636124A0410|24 27|cDNA
P08636124A0410|46 52|p150TSP
P08636124A0410|46 52|p150TSP
P08636124A0410|57 96|TPR-containing, SH2-binding phosphoprotein
P08636124A0410|72 96|SH2-binding phosphoprotein
P08636124A0410|126 132|nucleus
P08636124A0410|155 163|evolution
P08636149A0220|4 18|mutant receptors
P08636149A0220|37 47|cell surface
P08636149A0220|56 62|insulin
P08636149A0220|56 62|insulin
P08636149A0220|97 115|autophosphorylation
P08636149A0220|128 134|insulin
P08636149A0220|128 134|insulin
P08636428A1363|36 74|thrombin-stimulated vascular smooth muscle
P08636428A1363|36 43|thrombin
P08636428A1363|75 87|proliferation
P08636428A1363|147 154|mitogens
P08637006A0000|0 12|Transcription
P08637006A0000|17 42|adenovirus E2-early promoter
P08637006A0000|17 42|adenovirus E2-early promoter
P08637006A0000|75 92|cis-acting elements
P08637006A0000|107 117|atypical TBP
P08637006A0000|115 121|TBP site
P08637006A0000|126 133|E2F sites
P08637006A0000|126 133|E2F sites
P08637006A0000|189 195|ATF site
P08637006A0000|189 195|ATF site
P08637711A1121|27 46|IL-6/interferon gamma
P08637711A1121|27 30|IL-6
P08637711A1121|32 46|interferon gamma
P08637711A1121|48 71|IFN gamma) response element
P08637711A1121|48 55|IFN gamma
P08637711A1121|77 89|IRF-1 promoter
P08637711A1121|77 89|IRF-1 promoter
P08637711A1121|91 98|IR/IRF-1
P08637711A1121|91 92|IR
P08637711A1121|94 98|IRF-1
P08637711A1121|115 130|Stat-binding site
P08637711A1121|115 130|Stat-binding site
P08637711A1121|136 155|adjacent CRE-like site
P08637711A1121|166 169|IL-6
P08637711A1121|166 169|IL-6
P08637711A1121|203 213|JRE-IL6-BCs
P08637711A1121|203 209|JRE-IL6
P08637717A0817|15 24|amino acids
P08637717A0817|46 57|p21-activity
P08637717A0817|46 48|p21
P08637717A0817|66 72|peptide
P08637717A0817|97 99|p21
P08637717A0817|97 99|p21
P08637717A0817|114 125|cyclin E/Cdk2
P08637717A0817|114 120|cyclin E
P08637717A0817|122 125|Cdk2
P08637717A1231|1 10|p21 peptide
P08637717A1231|1 3|p21
P08637717A1231|4 10|peptide
P08637717A1231|50 53|PCNA
P08637717A1231|50 53|PCNA
P08637717A1231|57 74|filter binding assay
P08637717A1231|110 117|p21-PCNA
P08637717A1231|110 112|p21
P08637717A1231|114 117|PCNA
P08638435A0522|103 114|A. hydrophila
P08639310A0548|39 50|prednisolone
P08639310A0548|74 76|MCP
P08639310A0548|105 106|v.
P08639310A0548|113 114|CT
P08639310A0548|118 120|MCP
P08639521A1032|73 101|isotropic and anisotropic models
P08639561T0000|0 8|Adduction
P08639561T0000|14 38|human N-ras codon 61 sequence
P08639561T0000|14 23|human N-ras
P08639561T0000|43 49|(-)-(7S
P08639561T0000|51 55|8R,9R
P08639561T0000|57 110|10S)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo
P08639561T0000|146 157|intercalated
P08639561T0000|158 174|SRSR(61,2) (-)-(7S
P08639561T0000|176 177|8R
P08639561T0000|179 184|9S,10R
P08639561T0000|191 218|10-(7,8,9,10- tetrahydrobenzo
P08639561T0000|222 253|pyrenyl)]-2'-deoxyadenosyl adduct
P08639561T0000|258 262|1H NMR
P08639742T0000|11 13|PCR
P08639742T0000|17 25|cDNA clone
P08639742T0000|30 38|pea petals
P08639742T0000|65 87|wheat zinc finger proteins
P08639742T0000|65 69|wheat
P08639742T0000|70 87|zinc finger proteins
P08639837A0268|26 44|trans-acting factors
P08639837A0268|62 67|GATA-1
P08639837A0268|62 67|GATA-1
P08639837A0268|83 91|Ets family
P08639837A0268|83 91|Ets family
P08640866A0473|10 30|peripheral blood T cells
P08640866A0473|35 47|young subjects
P08640866A0473|50 52|PHA
P08640866A0473|50 52|PHA
P08640866A0473|67 94|anti-CD3 monoclonal antibodies
P08640866A0473|67 94|anti-CD3 monoclonal antibodies
P08640866A0473|121 147|MAPK and MEK enzymatic activity
P08640866A0473|121 124|MAPK
P08640866A0473|128 130|MEK
P08641705A0986|53 53|A
P08641705A0986|57 57|G
P08641705A0986|68 76|codon beta
P08641705A0986|77 78|77
P08641705A0986|115 130|Hbs Lepore or Kenya
P08641705A0986|115 123|Hbs Lepore
P08641705A0986|126 130|Kenya
P08641705A0986|135 160|beta-globin gene duplication
P08641705A0986|135 145|beta-globin
P08641705A0986|200 210|Hb Costa Rica
P08641705A0986|200 210|Hb Costa Rica
P08642282A1009|43 60|regulatory elements
P08642282A1009|98 120|B7 costimulatory molecule
P08642282A1009|98 120|B7 costimulatory molecule
P08642285A1548|0 16|DNA-STAT complexes
P08642285A1548|0 16|DNA-STAT complexes
P08642285A1548|34 61|Bcr/Abl-transformed cell lines
P08642285A1548|34 36|Bcr
P08642285A1548|38 40|Abl
P08642285A1548|104 108|STAT1
P08642285A1548|104 108|STAT1
P08642285A1548|112 116|STAT5
P08642285A1548|112 116|STAT5
P08642313A0770|32 39|cell line
P08642313A0770|41 46|TAN-1C
P08642313A0770|41 46|TAN-1C
P08642313A0770|56 86|kappa B-dependent transactivation
P08642313A0770|56 61|kappa B
P08642313A0770|89 115|transient reporter gene assays
P08642313A0770|165 169|Bcl-3
P08642313A0770|165 169|Bcl-3
P08642313T0000|0 12|T cell leukemia
P08642313T0000|24 33|human Notch
P08642313T0000|29 63|Notch/translocation-associated Notch
P08642313T0000|59 63|Notch
P08642313T0000|76 95|I kappa B-like activity
P08642313T0000|76 87|I kappa B-like
P08642313T0000|122 149|nuclear factor-kappa B proteins
P08642313T0000|122 149|nuclear factor-kappa B proteins
P08642313T0000|152 157|T cells
P08642693T0000|0 20|Polyprotein processing
P08642693T0000|56 83|3C-like protease cleavage sites
P08642693T0000|56 70|3C-like protease
P08642693T0000|86 103|in vitro mutagenesis
P08643111A0855|3 14|humanized LL2
P08643111A0855|3 14|humanized LL2
P08643111A0855|16 19|hLL2
P08643111A0855|16 19|hLL2
P08643111A0855|29 52|light chain variable region
P08643111A0855|120 130|chimeric LL2
P08643111A0855|132 135|cLL2
P08643111A0855|132 135|cLL2
P08643111A0855|204 220|murine counterpart
P08643111A0855|239 265|VK-appended oligosaccharides
P08643111A0855|239 240|VK
P08643111A0855|273 276|mLL2
P08643111A0855|273 276|mLL2
P08643111A0855|295 308|antigen binding
P08643382A0752|10 33|N-terminal transit peptide
P08643382A0752|55 56|3'
P08643382A0752|57 63|poly(A)
P08643382A0752|78 86|cDNA clone
P08643382A0752|124 137|nuclear encoded
P08643513A0361|0 15|Deletion analysis
P08643513A0361|18 71|rOC promoter-chloramphenicol acetyltransferase constructs
P08643513A0361|18 28|rOC promoter
P08643513A0361|30 71|chloramphenicol acetyltransferase constructs
P08643513A0361|90 110|AML-1-binding sequence
P08643513A0361|90 94|AML-1
P08643513A0361|95 110|-binding sequence
P08643513A0361|120 135|proximal promoter
P08643513A0361|137 148|-138 to -130 nt
P08643513A0361|178 202|osteocalcin gene expression
P08643513A0361|178 192|osteocalcin gene
P08643557A0259|27 37|HOX proteins
P08643557A0259|27 37|HOX proteins
P08643557A0259|60 70|target genes
P08643578A0000|0 8|RAS2val19
P08643578A0000|0 8|RAS2val19
P08643578A0000|34 60|Saccharomyces cerevisiae Ras2
P08643578A0000|34 56|Saccharomyces cerevisiae
P08643578A0000|109 133|transcriptional reporter FG
P08643578A0000|132 133|FG
P08643578A0000|135 137|TyA
P08643578A0000|135 137|TyA
P08643578A0000|141 144|lacZ
P08643578A0000|141 144|lacZ
P08643578A0000|164 176|mating pathway
P08643578A0000|185 188|FUS1
P08643578A0000|191 194|lacZ
P08643578A0000|191 194|lacZ
P08643578A0532|12 27|Rho family protein
P08643578A0532|12 27|Rho family protein
P08643578A0532|28 32|Cdc42
P08643578A0532|28 32|Cdc42
P08643578A0532|35 64|conserved morphogenetic G protein
P08643578A0532|90 106|filamentous growth
P08643578A0532|110 111|FG
P08643578A0532|110 111|FG
P08643578A0532|113 115|TyA
P08643578A0532|113 115|TyA
P08643578A0532|119 122|lacZ
P08643578A0532|119 122|lacZ
P08643578A0532|135 146|S. cerevisiae
P08643633A1187|40 50|N1(deltaEC)
P08643633A1187|40 41|N1
P08643633A1187|43 49|deltaEC
P08643633A1187|54 57|CBF1
P08643633A1187|54 57|CBF1
P08643646A0479|18 21|verA
P08643646A0479|18 21|verA
P08643646A0479|24 37|structural gene
P08643646A0479|68 81|ST biosynthesis
P08643646A0479|144 148|7.2 kb
P08643646A0479|184 205|ST-producing conditions
P08643682A0268|29 44|wild-type CBFbeta
P08643682A0268|29 44|wild-type CBFbeta
P08643682A0268|51 76|CBFbeta-SMMHC fusion protein
P08643682A0268|51 57|CBFbeta
P08643682A0268|59 63|SMMHC
P08643682A0268|93 110|immunofluorescence
P08643682A0268|113 123|NIH 3T3 cells
P08643682A0268|139 162|wild-type or fusion protein
P08643682A0268|139 162|wild-type or fusion protein
P08643759A0338|0 19|Menstrual-cycle phase
P08644734A0404|22 31|human cDNAs
P08644734A0404|47 92|Drosophila dishevelled (dsh) segment-polarity gene
P08644734A0404|47 67|Drosophila dishevelled
P08644734A0404|69 71|dsh
P08645214A1052|0 14|Escherichia coli
P08645214A1052|15 18|BL21
P08645214A1052|20 28|DE3)plysS
P08645214A1052|41 58|recombinant plasmid
P08645214A1052|72 90|catalase-peroxidase
P08645214A1052|72 79|catalase
P08645214A1052|81 90|peroxidase
P08645214A1052|143 150|SDS/PAGE
P08645214A1052|158 169|native enzyme
P08645219A1377|0 3|Ca2+
P08645219A1377|13 16|Zn2+
P08645219A1377|26 33|S100 beta
P08645219A1377|26 33|S100 beta
P08645219A1377|63 67|MRP14
P08645219A1377|63 67|MRP14
P08645219A1377|86 89|Zn2+
P08645219A1377|138 155|Ca2+ binding domains
P08645219A1377|138 155|Ca2+ binding domains
P08647086A0622|0 3|Cdk2
P08647086A0622|22 29|cyclin D1
P08647086A0622|22 29|cyclin D1
P08647086A0720|3 6|Cdk2
P08647086A0720|8 23|cyclin-D1 complex
P08647086A0720|8 16|cyclin-D1
P08647086A0720|69 77|H1 histone
P08647086A0720|69 70|H1
P08647086A0720|71 77|histone
P08647086A0720|79 81|pRB
P08647086A0720|79 81|pRB
P08647086A0720|83 99|SV40 large T antigen
P08647086A0720|83 86|SV40
P08647086A0720|92 99|T antigen
P08647086A0720|101 103|p53
P08647086A0720|101 103|p53
P08647086A0720|105 109|E2F-1
P08647086A0720|105 109|E2F-1
P08647086A0720|126 140|nuclear proteins
P08647086A0720|126 140|nuclear proteins
P08647086A0720|145 153|HeLa cells
P08647086A0720|166 169|Cdk2
P08647086A0720|171 178|cyclin-E
P08647086A0720|171 178|cyclin-E
P08647086A0720|182 185|Cdk2
P08647086A0720|187 194|cyclin-A
P08647086A0720|187 194|cyclin-A
P08647086T0000|0 28|Cyclin-dependent kinase-2 (Cdk2
P08647086T0000|0 23|Cyclin-dependent kinase-2
P08647086T0000|25 28|Cdk2
P08647086T0000|37 51|inactive complex
P08647086T0000|56 63|cyclin D1
P08647086T0000|56 63|cyclin D1
P08647086T0000|69 72|Cdk2
P08647086T0000|87 94|cyclin D1
P08647086T0000|87 94|cyclin D1
P08647086T0000|116 128|Cdk7-cyclin-H
P08647086T0000|116 119|Cdk7
P08647086T0000|121 128|cyclin-H
P08647091A0592|40 48|Adh-2 gene
P08647091A0592|40 48|Adh-2 gene
P08647091A0592|63 67|exons
P08647091A0592|71 81|12-kb region
P08647091A0592|101 107|introns
P08647091A0592|135 151|mammalian ADH genes
P08647091A0592|135 151|mammalian ADH genes
P08647264T0000|10 13|CD40
P08647264T0000|10 13|CD40
P08647264T0000|21 47|Ramos-Burkitt lymphoma B cells
P08647264T0000|52 105|calcium ionophore- and antigen receptor-triggered apoptosis
P08647264T0000|72 86|antigen receptor
P08647264T0000|133 158|cysteine protease CPP32/Yama
P08647264T0000|133 148|cysteine protease
P08647264T0000|149 153|CPP32
P08647264T0000|155 158|Yama
P08647264T0000|184 187|PARP
P08647434A1124|5 12|T antigen
P08647434A1124|50 63|epitope-tagged
P08647434A1124|64 66|TBP
P08647434A1124|64 66|TBP
P08647434A1124|68 80|endogenous TBP
P08647434A1124|78 80|TBP
P08647434A1124|82 88|hTAF(II
P08647434A1124|82 88|hTAF(II
P08647434A1124|94 104|hTAF(II)130
P08647434A1124|94 100|hTAF(II
P08647434A1124|109 115|hTAF(II
P08647434A1124|109 115|hTAF(II
P08647434A1124|141 150|holo-TFIID
P08647434A1124|146 150|TFIID
P08647451A0663|0 24|Northern blot hybridization
P08647451A0663|41 47|HEP-COP
P08647451A0663|41 43|HEP
P08647451A0663|45 47|COP
P08647451A0663|74 83|human adult
P08647451A0663|87 98|fetal tissues
P08647802A0000|1 32|human cytoplasmic signaling protein
P08647802A0000|89 106|SH3-SH2-SH3 domains
P08647802A0000|89 91|SH3
P08647802A0000|93 95|SH2
P08647802A0000|97 99|SH3
P08647802A0000|109 112|Grb2
P08647802A0000|109 112|Grb2
P08647822T0000|14 50|sterol regulatory element binding protein
P08647822T0000|14 50|sterol regulatory element binding protein
P08647822T0000|65 108|3-hydroxy-3-methylglutaryl coenzyme A reductase
P08647822T0000|65 108|3-hydroxy-3-methylglutaryl coenzyme A reductase
P08647884A0547|0 5|E3/19K
P08647884A0547|0 5|E3/19K
P08647884A0547|18 37|endoplasmic reticulum
P08647884A0547|52 69|MHC class I molecules
P08647884A0547|52 69|MHC class I molecules
P08647884A0547|107 117|cell surface
P08648408A0792|7 9|PHT
P08648408A0792|13 15|CSA
P08648408A0792|72 83|PHT-GO+ group
P08648408A0792|93 104|CSA-GO+ group
P08648665A0956|8 19|LE6 deletions
P08648665A0956|8 10|LE6
P08648665A0956|74 89|transformed cells
P08648665A0956|112 123|wild-type LE6
P08648665A0956|121 123|LE6
P08648665A1320|0 4|ORF E8
P08648665A1320|0 4|ORF E8
P08648665A1320|17 21|ORF E6
P08648665A1320|17 21|ORF E6
P08648665A1320|42 61|50-amino-acid protein
P08648665A1320|67 84|hydrophobic segment
P08648665A1320|123 135|pZipNeo vector
P08648726A0713|19 27|ZI domains
P08648726A0713|39 53|minimal promoter
P08648726A0713|73 75|ZIA
P08648726A0713|77 79|ZIC
P08648726A0713|84 93|ZID domains
P08648726A0713|104 112|ZIB domain
P08648726A0713|117 129|TPA responsive
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0501|0 3|Clb2
P08649372A0501|5 15|Cdc28 kinase
P08649372A0501|47 63|MCB-binding factor
P08649372A0501|47 63|MCB-binding factor
P08649372A0501|89 99|G2 and M phase
P08649372A0755|3 17|carboxy terminus
P08649372A0755|20 23|Mbp1
P08649372A0755|20 23|Mbp1
P08649372A0755|54 57|Swi6
P08649372A0755|54 57|Swi6
P08649372A0755|65 79|carboxy terminus
P08649372A0755|82 85|Swi6
P08649372A0755|82 85|Swi6
P08649372A0755|114 117|Mbp1
P08649372A0755|114 117|Mbp1
P08649373T0000|8 33|single-stranded cis elements
P08649373T0000|74 87|human c-myc gene
P08649373T0000|74 87|human c-myc gene
P08649386A1032|4 24|UASH consensus sequence
P08649386A1032|82 96|Abf1 binding site
P08649386A1032|82 96|Abf1 binding site
P08649389A0000|30 33|CTCF
P08649389A0000|30 33|CTCF
P08649389A0000|62 84|ubiquitously expressed 11
P08649389A0000|83 106|11-zinc-finger factor CTCF
P08649389A0000|86 102|zinc-finger factor
P08649389A0000|103 106|CTCF
P08649389A0000|174 204|avian and human amino acid sequences
P08649389A0692|0 17|Mutational analysis
P08649389A0692|23 48|P2-proximal CTCF binding site
P08649389A0692|23 48|P2-proximal CTCF binding site
P08649389A0692|52 86|transient-cotransfection experiments
P08649389A0692|102 105|CTCF
P08649389A0692|102 105|CTCF
P08649389A0692|109 132|transcriptional repressor
P08649389A0692|138 151|human c-myc gene
P08649389A0692|138 151|human c-myc gene
P08649393A0000|1 30|chromosome transmission fidelity
P08649393A0000|32 34|ctf
P08649393A0000|32 34|ctf
P08649393A0000|43 46|s138
P08649393A0000|50 72|Saccharomyces cerevisiae
P08649393A0000|50 72|Saccharomyces cerevisiae
P08649393A0000|102 104|CEN
P08649403A0963|3 14|growth defect
P08649403A0963|18 37|reg1 reg2 double mutant
P08649403A0963|18 21|reg1
P08649403A0963|22 37|reg2 double mutant
P08649403A0963|53 76|loss-of-function mutation
P08649403A0963|82 106|SNF1-encoded protein kinase
P08649403A0963|82 106|SNF1-encoded protein kinase
P08649405T0000|0 2|Sp1
P08649405T0000|0 2|Sp1
P08649405T0000|21 33|CD11c promoter
P08649405T0000|21 33|CD11c promoter
P08649405T0000|54 65|myeloid cells
P08649405T0000|83 85|AP1
P08649405T0000|83 85|AP1
P08649405T0000|96 108|transcription
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649424A0000|45 50|livers
P08649424A0000|63 69|rodents
P08649424A0000|102 116|glucocorticoids
P08649424A0000|120 128|cyclic AMP
P08649424A0000|134 138|liver
P08649425A0373|21 28|enhancer
P08649425A0373|31 49|transcriptional core
P08649425A0373|57 76|DNase I hypersensitive
P08649425A0373|57 62|DNase I
P08649425A0373|84 100|B-cell development
P08649425T0000|48 81|mouse immunoglobulin kappa 3' enhancer
P08649425T0000|48 81|mouse immunoglobulin kappa 3' enhancer
P08649427A0689|32 35|cDNA
P08649427A0689|62 96|GTPase-activating protein (GAP) family
P08649427A0689|62 85|GTPase-activating protein
P08649427A0689|87 89|GAP
P08649427A0689|99 114|GTPase regulators
P08649427A0689|99 104|GTPase
P08649428A1227|65 84|c-mos oncogene product
P08649428A1227|65 84|c-mos oncogene product
P08649428A1227|120 123|Cdc2
P08649428A1227|120 123|Cdc2
P08649440T0000|18 33|bovine IgG2--VIII
P08649440T0000|24 33|IgG2--VIII
P08649773A1374|12 16|BCL-6
P08649773A1374|12 16|BCL-6
P08649773A1374|30 53|transcriptional repressor
P08649773A1374|91 101|lymphocytes
P08649773A1374|104 127|diffuse large cell lymphoma
P08649841A0956|15 18|uORF
P08649841A0956|47 60|Kozak sequences
P08649841A0956|70 89|heterologous promoter
P08649841A0956|94 97|SV40
P08649841A0956|102 116|CAT reporter gene
P08649841A0956|102 116|CAT reporter gene
P08649841A0956|145 164|CAT protein production
P08649841A0956|145 154|CAT protein
P08649841A0956|183 189|CAT mRNA
P08649841A0956|183 189|CAT mRNA
P08650818A0000|1 15|secondary spread
P08650818A0000|49 74|Staphylococcus aureus strain
P08650818A0000|76 79|MRSA
P08650818A0000|91 98|patients
P08650818A0000|114 131|Danish surgical ward
P08650818A0000|169 181|index-patient
P08650818A0000|223 235|Mediterranean
P08651853A0607|6 22|temporal sclerosis
P08651853A0607|47 58|neuronal loss
P08651853A0607|72 78|gliosis
P08651853A0607|93 108|CA1/prosubiculum
P08651853A0607|112 119|patients
P08651853A0607|139 150|dentate gyrus
P08651853A0607|154 161|patients
P08651853A0607|176 184|CA4 region
P08651853A0607|188 195|patients
P08651853T0000|6 22|temporal sclerosis
P08652081A1953|12 24|adverse events
P08652081A1953|83 93|hypotension
P08652081A1953|98 101|IL-1
P08652081A1953|98 101|IL-1
P08652081A1953|109 116|headache
P08652081A1953|119 126|skin rash
P08652081A1953|131 134|IL-3
P08652081A1953|131 134|IL-3
P08652081A1953|139 177|nasal congestion and gastroduodenal lesions
P08652081A1953|182 185|IL-4
P08652081A1953|182 185|IL-4
P08654200A0274|10 33|magnetic resonance imaging
P08654200A0274|52 62|liver volume
P08654200A0274|65 73|pediatric
P08654200A0274|77 94|adolescent patients
P08654200A0274|102 118|systemic clearance
P08654200A0274|163 172|antipyrine
P08654200A0274|186 201|indocyanine green
P08654200A0274|203 205|ICG
P08654375A0544|1 18|mutational analysis
P08654375A0544|44 66|amino acids (amino acids 26
P08654375A0544|76 85|N-terminus
P08654375A0544|76 85|N-terminus
P08654375A0544|88 91|Bob1
P08654375A0544|88 91|Bob1
P08654375A0544|124 142|DNA binding POU domain
P08654375A0544|124 136|DNA binding POU
P08654375A0544|145 149|Oct-1
P08654375A0544|145 149|Oct-1
P08654375A0544|152 156|Oct-2
P08654375A0544|152 156|Oct-2
P08654390A0000|0 13|Heme oxygenase 1
P08654390A0000|0 13|Heme oxygenase 1
P08654390A0000|27 32|enzyme
P08654390A0000|35 48|heme catabolism
P08654390A0000|60 63|heme
P08654390A0000|81 84|iron
P08654435A0540|18 27|wortmannin
P08654435A0540|29 32|WM12
P08654435A0540|46 74|TCR/CD3-induced Erk2 activation
P08654435A0540|46 48|TCR
P08654435A0540|50 52|CD3
P08654435A0540|61 64|Erk2
P08654435A0540|79 88|wortmannin
P08654435A0540|115 118|Erk2
P08654435A0540|115 118|Erk2
P08654435A0540|141 153|in vitro assays
P08654946A0475|0 2|155
P08654946A0475|47 63|Xenopus laevis FGF3
P08654946A0475|47 59|Xenopus laevis
P08654946A0475|60 63|FGF3
P08654946A0475|117 125|human gene
P08654946A0475|117 125|human gene
P08654946A0986|31 46|proximal promoter
P08654946A0986|61 75|mouse promoter P3
P08654946A0986|90 114|conserved region of sequence
P08654972A0000|0 6|Defects
P08654972A0000|12 35|Schizosaccharomyces pombe
P08654972A0000|12 35|Schizosaccharomyces pombe
P08654972A0000|37 65|Sp) cell cycle-controlling genes
P08654972A0000|37 38|Sp
P08654972A0000|76 95|cell cycle progression
P08654983A0000|14 38|signal recognition particle
P08654983A0000|40 66|SRP)-SRP receptor (Srb) system
P08654983A0000|40 55|SRP)-SRP receptor
P08654983A0000|57 59|Srb
P08654983A0000|69 87|Bacillus subtilis (Bs
P08654983A0000|69 87|Bacillus subtilis (Bs
P08654983A0000|101 109|Bs srb gene
P08654983A0000|101 109|Bs srb gene
P08654983A0000|138 170|mammalian SRP receptor alpha-subunit
P08654983A0000|138 170|mammalian SRP receptor alpha-subunit
P08655497A0000|20 22|cmr
P08655497A0000|20 22|cmr
P08655497A0000|49 64|Escherichia coli K
P08655497A0000|49 64|Escherichia coli K
P08655497A0000|65 73|-12 genome
P08655497A0000|104 118|chloramphenicol
P08655497A0000|142 156|multicopy vector
P08655555A0772|160 175|promoter activity
P08655555A1368|62 69|TGn motif
P08655555A1368|62 69|TGn motif
P08655555A1368|102 121|prokaryotic promoters
P08656672A0678|10 30|ufo mRNA overexpression
P08656672A0678|10 16|ufo mRNA
P08656672A0678|60 76|leukemia cell lines
P08656672A0678|127 149|cervix carcinoma cell line
P08656672A0678|150 153|HeLa
P08657135A1444|30 33|CKII
P08657135A1444|30 33|CKII
P08657135A1444|85 101|protein homodimers
P08657135A1444|115 142|muscle gene regulatory elements
P08657150A1049|9 26|negative regulators
P08657150A1049|33 36|NCE3
P08657150A1049|33 36|NCE3
P08657150A1049|68 75|SIN5 gene
P08657150A1049|68 75|SIN5 gene
P08657150A1049|93 111|promoter specificity
P08657150A1049|114 133|homologous activators
P08657157A0000|0 24|Transcriptional regulators
P08657157A0000|37 61|POU domain DNA-binding motif
P08657157A0000|37 61|POU domain DNA-binding motif
P08657157A0000|81 102|multi-protein complexes
P08657157A0000|117 125|POU domain
P08657157A0000|117 125|POU domain
P08657157A0000|138 156|flexible recognition
P08657157A0000|166 188|octamer sequence elements
P08657183A0145|13 27|selective repair
P08657183A0145|51 61|active genes
P08657183A0145|51 61|active genes
P08657183A0145|63 66|DHFR
P08657183A0145|63 66|DHFR
P08657183A0145|93 96|DHFR
P08657183A0145|93 96|DHFR
P08657918A0360|20 28|Coronal 3D
P08657918A0360|29 38|GRE imaging
P08657918A0360|62 67|middle
P08657918A0360|72 77|dorsal
P08657918A0360|91 93|SLL
P08657918A0360|98 105|patients
P08657918A0360|134 136|SLL
P08657918A0360|146 160|cadaveric wrists
P08657918A0360|169 177|normal SLL
P08659545A0000|42 58|human chromosome 21
P08659545A0000|100 108|trisomy 21
P08659545A0000|153 164|chromosome 21
P08660733X0000|0 21|Reproducing populations
P08660748X0000|28 48|predator-prey dynamics
P08660748X0000|81 98|population patterns
P08660866A0504|2 19|cuticular positions
P08660866A0504|33 55|Brd bristle loss phenotype
P08660866A0504|87 100|multiplied SOPs
P08660866A0504|135 142|thecogen
P08660866A0504|144 155|sheath) cells
P08660866A0504|168 176|trichogen
P08660866A0504|178 182|shaft
P08660866A0504|187 194|tormogen
P08660866A0504|196 201|socket
P08660892A1044|0 22|Transcriptional blockade
P08660892A1044|55 82|wild-type SRF expression vector
P08660892A1044|55 66|wild-type SRF
P08660892A1044|122 136|myogenic factors
P08660892A1044|144 147|MyoD
P08660892A1044|144 147|MyoD
P08660892A1044|151 156|Mef-2C
P08660892A1044|151 156|Mef-2C
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|42 71|TATA, CAAT, GATA, and AP-2 elements
P08660998A0851|60 71|AP-2 elements
P08660998A0851|73 87|primer extension
P08660998A0851|96 100|mMIWC
P08660998A0851|96 100|mMIWC
P08660998A0851|126 138|621 bp upstream
P08660998A0851|146 178|mMIWC1 translational initiation site
P08660998A0851|146 151|mMIWC1
P08661007T0000|0 14|Human MN/CA9 gene
P08661007T0000|0 14|Human MN/CA9 gene
P08661007T0000|33 55|carbonic anhydrase family
P08661007T0000|33 55|carbonic anhydrase family
P08661100A0285|3 13|exon-intron
P08661100A0285|28 32|Cdebp
P08661100A0285|28 32|Cdebp
P08661100A0285|68 74|App gene
P08661100A0285|68 74|App gene
P08661100A0285|98 113|conserved domains
P08661101A0396|0 18|DNA sequence analysis
P08661101A0396|70 76|rat CRP1
P08661101A0396|70 76|rat CRP1
P08661104A0687|52 80|nonlymphoid human cells/tissues
P08661104A0687|90 97|prostate
P08661104A0687|99 102|lung
P08661104A0687|104 108|liver
P08661104A0687|113 117|colon
P08661114A0564|50 57|human SIM
P08661114A0564|55 57|SIM
P08661114A0564|61 81|Drosophila SIM proteins
P08661114A0564|61 70|Drosophila
P08661114A0564|71 81|SIM proteins
P08661116A0963|0 15|Promoter activity
P08661116A0963|25 33|cell lines
P08661116A0963|59 74|endogenous D3 mRNA
P08661116A0963|59 74|endogenous D3 mRNA
P08661116A0963|89 108|Northern blot analyses
P08661116A0963|143 150|promoter
P08661116A0963|165 170|-122 bp
P08661119A0085|17 44|human EP4 receptor gene sequence
P08661119A0085|17 36|human EP4 receptor gene
P08661119A0085|80 87|EP4R cDNA
P08661119A0085|80 87|EP4R cDNA
P08661119A0085|103 128|peripheral blood lymphocytes
P08661613A0691|4 8|users
P08661613A0691|56 60|users
P08661613A0691|83 91|education
P08661613A0691|139 159|enforcement activities
P08662193A0404|40 60|negative-acting region
P08662193A0404|77 81|yeast
P08662193A0404|98 120|carboxyl-terminal region
P08662193A0404|123 126|NIT4
P08662193A0404|123 126|NIT4
P08662499A0484|9 9|F
P08662617A2051|34 36|HIP
P08662617A2051|34 36|HIP
P08662617A2051|40 75|membrane-associated HP-binding protein
P08662617A2051|59 75|HP-binding protein
P08662617A2051|110 125|uterine epithelia
P08662617A2051|129 135|uterine
P08662617A2051|136 154|epithelial cell lines
P08662789A0673|38 46|GenBankTM
P08662789A0673|57 73|sequence alignment
P08662789A0673|83 88|RPS30A
P08662789A0673|83 88|RPS30A
P08662852A1297|21 51|GRK2 and GRK5 phosphoacceptor sites
P08662852A1297|21 24|GRK2
P08662852A1297|28 51|GRK5 phosphoacceptor sites
P08662852A1297|57 79|extreme carboxyl terminus
P08662852A1297|85 91|beta2AR
P08662852A1297|85 91|beta2AR
P08662852A1297|113 140|GRK1-mediated phosphorylation
P08662852A1297|113 116|GRK1
P08662852A1297|143 151|rhodopsin
P08662852A1297|143 151|rhodopsin
P08662928A1153|65 76|STAT proteins
P08662928A1153|65 76|STAT proteins
P08662928T0000|12 29|interleukin (IL)-10
P08662928T0000|12 29|interleukin (IL)-10
P08662928T0000|33 36|IL-6
P08662928T0000|33 36|IL-6
P08662928T0000|42 50|cytokines
P08662928T0000|111 130|IL-6 response elements
P08662928T0000|111 114|IL-6
P08662936A0428|23 44|FR-19 amino acid sequence
P08662936A0428|23 44|FR-19 amino acid sequence
P08662936A0428|48 62|approximately89
P08662936A0428|64 65|77
P08662936A0428|90 102|chicken TEF-1A
P08662936A0428|90 96|chicken
P08662936A0428|97 113|TEF-1A, mouse TEF-1
P08662936A0428|104 113|mouse TEF-1
P08662936A0428|118 157|mouse embryonic TEA domain-containing factor
P08662936A0428|118 157|mouse embryonic TEA domain-containing factor
P08662980A0762|27 36|DNA binding
P08662980A0762|42 62|"interfering" receptor
P08662980A0762|80 92|hormone-bound
P08662980A0762|109 135|transcriptionally active form
P08662980A0762|152 159|receptor
P08663000A0000|14 60|hyaluronan mediated motility (RHAMM) gene expression
P08663000A0000|81 93|fibrosarcomas
P08663000A0000|103 132|transforming growth factor-beta1
P08663000A0000|103 132|transforming growth factor-beta1
P08663000A0000|134 142|TGF-beta1
P08663000A0000|134 142|TGF-beta1
P08663120T0000|0 13|Oncogenic Raf-1
P08663120T0000|9 13|Raf-1
P08663120T0000|23 33|p70 S6 kinase
P08663120T0000|23 33|p70 S6 kinase
P08663120T0000|38 86|mitogen-activated protein kinase-independent pathway
P08663120T0000|38 67|mitogen-activated protein kinase
P08663127A0697|0 17|Hydropathy analysis
P08663127A0697|20 23|KCC1
P08663127A0697|20 23|KCC1
P08663127A0697|53 56|NKCC
P08663127A0697|53 56|NKCC
P08663127A0697|67 88|12 transmembrane domains
P08663127A0697|96 112|extracellular loop
P08663127A0697|126 151|N-linked glycosylation sites
P08663127A0697|156 188|cytoplasmic N- and C-terminal regions
P08663141T0000|1 20|cis-acting DNA element
P08663141T0000|35 71|TATA box and transcription initiation site
P08663141T0000|35 41|TATA box
P08663141T0000|45 71|transcription initiation site
P08663141T0000|115 138|human angiotensinogen gene
P08663141T0000|120 138|angiotensinogen gene
P08663172A0311|16 39|hydrophobic amino terminus
P08663172A0311|60 66|protein
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|37 76|CAAT enhancer-binding protein consensus site
P08663219A0246|37 76|CAAT enhancer-binding protein consensus site
P08663219A0246|78 84|CAAT box
P08663219A0246|78 84|CAAT box
P08663219A0246|122 142|PGS-2.CAT reporter gene
P08663219A0246|122 126|PGS-2
P08663219A0246|128 142|CAT reporter gene
P08663219A0246|161 171|E-box region
P08663219A0246|161 171|E-box region
P08663310A0157|8 10|SRF
P08663310A0157|8 10|SRF
P08663310A0157|59 79|cellular response genes
P08663310A0157|86 105|immediate-early genes
P08663310A0157|86 105|immediate-early genes
P08663310A0157|107 110|IEGs
P08663310A0157|107 110|IEGs
P08663310A0157|159 168|cell growth
P08663310A0157|172 186|differentiation
P08663326A0000|8 37|sigma54-dependent DmpR activator
P08663326A0000|8 37|sigma54-dependent DmpR activator
P08663326A0000|65 73|dmp operon
P08663326A0000|65 73|dmp operon
P08663326A0000|88 94|enzymes
P08663326A0000|98 107|catabolism
P08663326A0000|111 124|methyl)phenols
P08663392A0215|27 39|human DSG3 gene
P08663392A0215|27 39|human DSG3 gene
P08664229T0000|23 54|Allergan Humphrey 500 autorefractor
P08664229T0000|61 67|Nidek AR
P08664347A0923|69 80|human pro-LPH
P08664347A0923|74 80|pro-LPH
P08664347A0923|143 148|enzyme
P08664462A1404|69 93|neuromuscular transmission
P08664462A1404|109 127|muscle contractility
P08664462A1404|166 180|plasma clearance
P08664462A1404|187 197|hypothermia
P08664667A0093|0 6|SETTING
P08665853A0228|7 34|interleukin-3-dependent cells
P08665853A0228|7 19|interleukin-3
P08665853A0228|65 76|ErbB proteins
P08665853A0228|65 76|ErbB proteins
P08665853A0228|108 113|ErbB-3
P08665853A0228|108 113|ErbB-3
P08665853A0228|152 157|ErbB-1
P08665853A0228|152 157|ErbB-1
P08665853A0228|161 166|ErbB-2
P08665853A0228|161 166|ErbB-2
P08665853A0228|200 216|mitogenic activity
P08666102A0820|0 3|ZIOS
P08666102A0820|61 63|Ptc
P08666102A0820|100 103|FEV1
P08666238T0000|9 29|translation initiation
P08666238T0000|32 46|ribosome jumping
P08666238T0000|49 67|adenovirus-infected
P08666238T0000|71 87|heat-shocked cells
P08666241A0930|29 39|43-bp region
P08666241A0930|45 56|24p3 promoter
P08666241A0930|45 56|24p3 promoter
P08666241A0930|71 87|Dex responsiveness
P08666383A1252|30 40|cDNA mapping
P08666383A1252|46 76|fluorescence in situ hybridization
P08666383A1252|148 158|human genome
P08666398T0000|0 2|YAC
P08666398T0000|6 18|cosmid contigs
P08666398T0000|30 47|Batten disease (CLN3
P08666398T0000|30 42|Batten disease
P08666398T0000|44 54|CLN3) region
P08666398T0000|57 69|16p12.1-p11.2
P08666404A0311|16 30|full-length cDNA
P08666404A0311|36 61|human fetal brain cDNA library
P08666404A0311|71 104|protein serine-threonine phosphatase
P08666404A0311|71 104|protein serine-threonine phosphatase
P08666404A0311|110 131|tetratricopeptide motif
P08666404A0311|150 159|human PPP5C
P08666404A0311|150 159|human PPP5C
P08666404A0311|161 163|PP5
P08666404A0311|161 163|PP5
P08666404A0311|186 191|rat PPT
P08666913A0000|0 4|Ly-49
P08666913A0000|0 4|Ly-49
P08666913A0000|8 40|family type II transmembrane proteins
P08666913A0000|18 40|II transmembrane proteins
P08666913A0000|51 61|gene cluster
P08666913A0000|64 80|murine chromosome 6
P08668124A0744|3 11|Dox-A2 ORF
P08668124A0744|3 8|Dox-A2
P08668124A0744|9 11|ORF
P08668124A0744|23 34|TDH3 promoter
P08668124A0744|23 34|TDH3 promoter
P08668124A0744|78 81|sun2
P08668124A0744|78 81|sun2
P08668142A1048|17 21|hARF4
P08668142A1048|17 21|hARF4
P08668142A1048|59 94|cytosolic and membrane-associated Sec7p
P08668142A1048|90 94|Sec7p
P08668158A0765|30 34|Rpm1r
P08668158A0765|30 34|Rpm1r
P08668158A0765|66 73|tRNA met f
P08668158A0765|66 73|tRNA met f
P08668158A0765|77 83|tRNAPro
P08668158A0765|77 83|tRNAPro
P08668158A0765|90 97|promoter
P08668158A0765|118 129|tRNA met f gene
P08668158A0765|118 125|tRNA met f
P08668158A0765|177 184|promoter
P08668158A0765|203 214|tRNA met f gene
P08668158A0765|203 214|tRNA met f gene
P08668158A0765|218 221|RPM1
P08668158A0765|218 221|RPM1
P08668158A1252|23 37|mutant RPM1 genes
P08668158A1252|23 37|mutant RPM1 genes
P08668158A1252|52 65|precursor Rpm1r
P08668158A1252|52 60|precursor
P08668158A1252|61 65|Rpm1r
P08668190A1364|0 23|Vacuolar membrane vesicles
P08668190A1364|28 38|hum1 mutants
P08668190A1364|28 31|hum1
P08668190A1364|46 60|Ca2+/H+ antiport
P08668190A1364|87 91|Hum1p
P08668190A1364|114 117|Ca2+
P08668190A1364|121 122|H+
P08668190A1364|132 152|yeast vacuolar membrane
P08668201A1059|8 18|mutagenesis
P08668201A1059|37 43|-codon/
P08668201A1059|44 45|AU
P08668201A1059|46 58|-rich sequence
P08668201A1059|82 102|destabilizing activity
P08668201A1059|108 118|MATalpha1 IE
P08668201A1059|108 118|MATalpha1 IE
P08668201A1059|136 148|terminal codon
P08668203A1230|0 2|FTF
P08668203A1230|0 2|FTF
P08668203A1230|33 40|pancreas
P08668203A1230|78 98|endodermal sublineages
P08668203A1230|109 112|SF-1
P08668203A1230|109 112|SF-1
P08668203A1230|115 134|steroidogenic tissues
P08668209A0406|0 5|Merlie
P08668210A0000|61 107|Raf-1/MEK/mitogen-activated protein kinase pathway
P08668210A0000|61 65|Raf-1
P08668210A0000|67 69|MEK
P08668210A0000|71 100|mitogen-activated protein kinase
P08668210A0000|110 144|oncogenic Ras-mediated transformation
P08668210A0000|119 121|Ras
P08669274T0000|0 26|Stylohyoid chain ossification
P08669274T0000|39 46|surgical
P08669676A1644|14 25|cardiac death
P08669676A1644|45 55|MI (propofol
P08669676A1644|85 94|non Q wave MI
P08669676A1644|96 103|propofol
P08670556A0425|91 102|9(0-infinity
P08670853A0000|0 15|Cluster formation
P08670853A0000|18 27|E-cadherin
P08670853A0000|18 27|E-cadherin
P08670853A0000|33 43|cell surface
P08670853A0000|78 94|cell-cell adhesion
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|15 26|DNA ligase III
P08670910A0156|15 26|DNA ligase III
P08670910A0156|31 63|DNA structure-specific endonuclease
P08672242A0517|7 28|reporter gene constructs
P08672242A0517|43 59|upstream sequences
P08672242A0517|65 74|P1 promoter
P08672242A0517|65 74|P1 promoter
P08675026A0420|67 69|EST
P08675026A0420|92 112|Caenorhabditis elegans
P08675026A0420|114 124|Oryza sativa
P08675026A0420|128 138|Homo sapiens
P08675608T0000|0 6|Outcome
P08675608T0000|9 38|severe congenital hypothyroidism
P08675763A0788|42 44|Met
P08675763A0788|49 51|Lys
P08675763A0788|74 87|protein content
P08675763A0788|100 103|milk
P08675769A0158|0 13|Nonreturn rates
P08675769A0158|45 62|biological measures
P08675769A0158|95 108|conception rate
P08675769A0158|112 122|calving rate
P08675769A0158|162 174|nonreturn rate
P08675769A0158|215 225|performance
P08675769A0158|230 241|AI technician
P08675821A0657|10 13|EMPD
P08675821A0657|25 48|glans penis or perianal area
P08676266A0838|15 30|protease activity
P08676383A0518|28 44|disulfide linkages
P08676383A0518|52 62|cis peptides
P08676454A0731|18 20|Pra
P08676454A0731|22 23|N0
P08676454A0731|22 23|N0
P08676454A0731|27 28|Nb
P08676454A0731|27 28|Nb
P08676454A0731|33 37|ICP35
P08676454A0731|33 37|ICP35
P08676454A0731|39 44|ICP35 e
P08676454A0731|46 46|f
P08676454A0731|46 46|f
P08676454A0731|60 67|B capsids
P08676454A0731|101 113|mature virions
P08676456A0879|1 25|chimeric VP16-Tat construct
P08676456A0879|9 12|VP16
P08676456A0879|14 16|Tat
P08676456A0879|39 54|leucine mutations
P08676456A0879|72 89|AP-1 responsiveness
P08676456A0879|72 75|AP-1
P08676456A0879|115 134|VP16 activation domain
P08676456A0879|115 118|VP16
P08676495A0129|13 22|splice site
P08676495A0129|33 50|nucleotide (nt) 3225
P08676495A0129|80 93|BPV-1 pre-mRNAs
P08676495A0129|80 84|BPV-1
P08676495A0129|89 93|mRNAs
P08676495A0129|96 121|BPV-1-transformed C127 cells
P08676495A0129|96 100|BPV-1
P08676858A0309|36 47|S-RNase genes
P08676858A0309|36 47|S-RNase genes
P08676858A0309|64 71|Rosaceae
P08676858A0309|73 77|apple
P08676858A0309|79 93|Malus x domestica
P08676858A0309|98 109|Japanese pear
P08676858A0309|111 123|Pyrus serotina
P08676858A0309|180 192|T2-type RNases
P08676858A0309|180 192|T2-type RNases
P08676858A1084|1 16|phylogenetic tree
P08676858A1084|31 40|T2/S-RNase
P08676858A1084|31 32|T2
P08676858A1084|34 51|S-RNase superfamily
P08676858A1084|54 59|plants
P08677443A0238|47 67|extensive-disease SCLC
P08677443A0238|68 75|patients
P08677443A0238|77 79|VIP
P08677443A0238|77 79|VIP
P08677443A0238|93 101|etoposide
P08677678A0258|30 55|immunomodulator neurotropin
P08677678A0258|45 55|neurotropin
P08677678A0258|57 59|NSP
P08677678A0258|57 59|NSP
P08677678A0258|117 133|avoidance behavior
P08678959A0640|0 20|Sestamibi scintigraphy
P08678959A0640|35 42|patients
P08678959A0640|64 78|ultrasonography
P08679131T0000|6 12|allergy
P08679131T0000|21 38|hypersensitivities
P08680702A0548|7 54|significant lethality and cardiovascular dysfunction
P08680702A0548|61 71|septic group
P08680702A0548|74 82|Days 1 and 2
P08680702A0548|84 89|septic
P08680702A0548|96 109|control animals
P08680702A0548|165 170|Vo2DIR
P08680702A0548|209 212|Day 2
P08680702A0548|252 264|intravascular
P08680702A0548|284 291|Vo2INDIR
P08680702A0548|330 333|Day 2
P08680706A0889|9 19|reperfusion
P08680706A0889|99 120|Recipient Instilled (117
P08680706A0889|185 200|Donor Aerosol dogs
P08682155A0902|3 21|euglobulin clot lysis
P08682155A0902|3 12|euglobulin
P08682155A0902|48 54|smokers
P08682155A0902|64 74|non-smokers
P08682317A0900|0 13|HS inducibility
P08682317A0900|25 27|HSE
P08682317A0900|43 65|HS transcription factor-1
P08682317A0900|43 65|HS transcription factor-1
P08682317A0900|67 71|HSF-1
P08682317A0900|67 71|HSF-1
P08682317A0900|116 117|HS
P08682868A0738|11 24|DSK2-1 mutation
P08682868A0738|11 16|DSK2-1
P08682868A0738|41 47|residue
P08682868A0738|53 77|Dsk2p ubiquitin-like domain
P08682868A0738|53 57|Dsk2p
P08682868A0738|58 77|ubiquitin-like domain
P08682868A0738|102 106|Dsk2p
P08682868A0738|102 106|Dsk2p
P08682868A0738|109 123|Cdc31p stability
P08682868A0738|109 114|Cdc31p
P08683106A0374|8 11|IL-2
P08683106A0374|8 11|IL-2
P08683106A0374|15 23|IFN-alpha
P08683106A0374|15 23|IFN-alpha
P08683106A0374|33 42|STAT1 alpha
P08683106A0374|33 42|STAT1 alpha
P08683106A0374|46 50|STAT5
P08683106A0374|46 50|STAT5
P08683106A0374|52 55|IL-2
P08683106A0374|52 55|IL-2
P08683106A0374|78 82|STAT5
P08683106A0374|78 82|STAT5
P08683106A0374|89 97|IFN-alpha
P08683106A0374|89 97|IFN-alpha
P08683106A0374|120 129|STAT1 alpha
P08683106A0374|120 129|STAT1 alpha
P08683108A0965|33 87|recombinant CREB and activating transcription factor proteins
P08683108A0965|44 47|CREB
P08683108A0965|51 87|activating transcription factor proteins
P08683108A0965|96 111|junB CRE-like site
P08683108A0965|96 99|junB
P08683108A0965|100 111|CRE-like site
P08683108A0965|135 152|mutant CRE-like site
P08683108A0965|135 152|mutant CRE-like site
P08683108A1501|51 80|protein kinase A signaling pathway
P08683108A1501|51 64|protein kinase A
P08683108A1501|95 97|mIg
P08683108A1501|95 97|mIg
P08683108A1501|106 122|junB transcription
P08683108A1501|106 109|junB
P08683983A0785|21 30|70 D protein
P08683983A0785|21 30|70 D protein
P08683983A0785|92 104|leukemia cells
P08683983A1163|35 41|intron 1
P08683983A1163|44 68|transcriptional regulation
P08683983A1163|74 82|c-myb gene
P08683983A1163|74 82|c-myb gene
P08683983A1163|94 98|human
P08683983A1163|130 149|regulatory mechanisms
P08683983A1163|168 196|myelomonocytic differentiation
P08683983A1163|200 224|leukemic cell growth control
P08684522A0415|0 27|Immunofluorescence microscopy
P08684522A0415|61 81|extracellular matrices
P08684522A0415|84 97|type IV collagen
P08684522A0415|84 97|type IV collagen
P08684522A0415|101 107|laminin
P08684522A0415|101 107|laminin
P08684522A0415|113 124|vascular wall
P08684742A0000|19 40|pregnancy complications
P08684742A0000|43 47|women
P08686381A0527|5 8|ORFs
P08686381A0527|10 20|9765orfR002
P08686381A0527|22 32|9765orfR011
P08686381A0527|36 46|9765orfR013
P08686381A0527|75 98|Schizosaccharomyces pombe
P08686381A0527|99 125|polyadenylate binding protein
P08686381A0527|154 168|38.1-kDa protein
P08686381A0527|174 184|BCR 5' region
P08686381A0527|174 176|BCR
P08686381A0527|177 184|5' region
P08686381A0527|189 218|transcription regulatory protein
P08686381A0527|189 218|transcription regulatory protein
P08686381A0527|219 222|Swi3
P08686381A0527|219 222|Swi3
P08688190A0000|24 53|nevadensin 5-O-beta-D-glucoside
P08688190A0000|36 43|O-beta-D
P08688190A0000|57 85|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|69 98|O-beta-D-glucosyl(1-->6)beta-D
P08688190A0000|93 108|beta-D-glucoside
P08688190A0000|146 166|Lysionotus pauciflorus
P08688556A0242|104 121|clathrin heavy chain
P08688556A0242|104 121|clathrin heavy chain
P08688556A0242|138 147|Chc - scd1-i
P08688556A0242|138 140|Chc
P08688556A0242|142 147|scd1-i
P08689520T0000|0 17|Reproductive period
P08689520T0000|25 35|water intake
P08689520T0000|51 65|dehydrated goats
P08690118A0845|34 45|manual method
P08690118A0845|57 72|normal morphology
P08690118A0845|77 80|IVOS
P08690118A0845|114 126|fertilization
P08690198A0346|52 64|elemental diet
P08690198A0346|88 94|oatbase
P08690198A0346|96 119|Lactobacillus reuteri R2LC
P08690198A0346|124 145|Lactobacillus plantarum
P08690198A0346|168 179|fermentation
P08691106A0733|8 9|D8
P08691106A0733|30 47|nuclease protection
P08691106A0733|71 104|somatotroph-like cell nuclear protein
P08691962T0000|14 31|PCR-based diagnosis
P08691962T0000|34 49|Whipple's disease
P08691962T0000|54 84|peripheral blood mononuclear cells
P08692885A0663|12 14|A20
P08692885A0663|12 14|A20
P08692885A0663|22 40|NF-kappaB activation
P08692885A0663|22 30|NF-kappaB
P08692885A0663|55 80|C-terminal zinc finger domain
P08692885A0663|55 80|C-terminal zinc finger domain
P08692892A0330|3 9|Pro-258
P08692892A0330|13 15|Leu
P08692892A0330|17 21|P258L
P08692892A0330|49 65|receptor signaling
P08692892A0330|120 133|wild-type cells
P08692892A0330|148 159|alpha-factor
P08692892A0330|148 159|alpha-factor
P08692924A0328|8 18|DNA sequence
P08692924A0328|46 61|recombinant BCL-6
P08692924A0328|57 61|BCL-6
P08692924A0328|84 88|BCL-6
P08692924A0328|84 88|BCL-6
P08692924A0328|100 119|DNA-binding complexes
P08692924A0328|100 119|DNA-binding complexes
P08692924A0328|122 136|nuclear extracts
P08692924A0328|148 158|B-cell lines
P08698756A1240|51 61|coenzyme Q10
P08698756A1240|90 114|routine vascular procedures
P08698756A1240|124 151|abdominal aortic cross clamping
P08698756A1240|176 193|peroxidative damage
P08700531A1420|7 17|chromosome X
P08700531A1420|73 90|Syrian hamster cells
P08700531A1420|104 122|chemical carcinogens
P08700531A1420|126 141|oncogenic viruses
P08700531A1420|163 170|cph locus
P08700531A1420|163 170|cph locus
P08700531A1420|177 186|chromosome
P08700531A1420|211 221|cph oncogene
P08700531A1420|211 221|cph oncogene
P08700531A1420|268 296|transformed hamster fibroblasts
P08702517A0000|21 38|oncogenic potential
P08702517A0000|53 90|murine B6SUtA1 myeloid progenitor cell line
P08702543A0000|0 10|Gap1(IP4BP)
P08702543A0000|0 3|Gap1
P08702543A0000|26 53|Ras GTPase-activating proteins
P08702543A0000|29 53|GTPase-activating proteins
P08702543A0000|83 135|inositol 1,3,4,5-tetrakisphosphate (IP4)-binding protein
P08702543A0000|83 115|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|117 135|IP4)-binding protein
P08702543A0000|137 142|Cullen
P08702556A0000|24 35|purification
P08702556A0000|40 72|83-kDa phosphatidic acid phosphatase
P08702556A0000|46 76|phosphatidic acid phosphatase (PAP
P08702556A0000|74 76|PAP
P08702556A0000|85 91|porcine
P08702556A0000|92 97|thymus
P08702556A0000|98 106|membranes
P08702633A0164|3 11|mechanism
P08702633A0164|20 54|Gbetagamma subunit-mediated increases
P08702633A0164|20 29|Gbetagamma
P08702633A0164|57 79|tyrosine phosphorylation
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|103 110|Shc*Grb2
P08702633A0164|103 110|Shc*Grb2
P08702633A0164|144 177|Ras guanine nucleotide exchange factor
P08702633A0164|147 177|guanine nucleotide exchange factor
P08702644A0499|1 4|cDNA
P08702644A0499|16 29|amino-terminal
P08702644A0499|35 38|apoB
P08702644A0499|35 38|apoB
P08702644A0499|40 45|apoB17
P08702644A0499|40 45|apoB17
P08702644A0499|58 61|cDNA
P08702644A0499|80 89|amino acids
P08702644A0499|92 115|decay-accelerating factor
P08702644A0499|117 119|DAF
P08702644A0499|117 119|DAF
P08702644A0499|147 190|glycosylphosphatidylinositol anchor attachment
P08702728A1325|26 37|wild-type Shc
P08702728A1325|26 37|wild-type Shc
P08702728A1325|40 53|Y317F mutant Shc
P08702728A1325|40 44|Y317F
P08702728A1325|51 53|Shc
P08702728A1325|58 66|HIRc cells
P08702756A0000|3 13|small GTPase
P08702756A0000|8 13|GTPase
P08702756A0000|14 16|Rho
P08702756A0000|14 16|Rho
P08702756A0000|31 52|physiological functions
P08702756A0000|67 87|actin-myosin filaments
P08702756A0000|67 87|actin-myosin filaments
P08702756A0000|94 104|cytokinesis
P08702756A0000|106 117|cell motility
P08702756A0000|122 144|smooth muscle contraction
P08702807A0964|78 87|MKK1 mutant
P08702807A0964|78 87|MKK1 mutant
P08702807A0964|109 124|cyclin D1 promoter
P08702807A0964|109 116|cyclin D1
P08702807A0964|117 132|promoter activity
P08702807A0964|136 150|cyclin D1 protein
P08702807A0964|136 143|cyclin D1
P08702807A0964|165 194|growth factor-independent manner
P08702826A0870|34 53|GSTP1 silencer element
P08702826A0870|34 53|GSTP1 silencer element
P08702826A0870|80 99|heterologous promoter
P08702826A0870|102 110|MCF7 cells
P08702845A0000|44 74|substrate affinity and recognition
P08702845A0000|81 104|human dopamine transporter
P08702845A0000|86 108|dopamine transporter (DAT
P08702845A0000|106 108|DAT
P08702845A0000|125 146|dopamine uptake kinetics
P08702845A0000|150 156|[3H]CFT
P08702845A0000|181 190|COS-7 cells
P08702845A0000|212 221|mutant DATs
P08702845A0000|212 221|mutant DATs
P08702845A0000|232 243|COOH terminus
P08702845A0000|258 268|substituted
P08702936A0168|2 18|expression library
P08702936A0168|35 52|inserting 5' portion
P08702936A0168|62 66|cDNAs
P08702936A0168|71 130|phytohemagglutinin-stimulated peripheral blood mononuclear cells
P08702936A0168|71 88|phytohemagglutinin
P08702936A0168|167 173|CD4 cDNA
P08702936A0168|167 173|CD4 cDNA
P08702936A0168|178 207|Epstein-Barr virus shuttle vector
P08702936A0984|0 26|Radiolabeled recombinant TARC
P08702936A0984|46 55|T cell lines
P08702936A0984|59 74|peripheral T cells
P08702936A0984|83 91|monocytes
P08702936A0984|94 105|granulocytes
P08703005A0645|3 20|cis-acting elements
P08703005A0645|32 47|promoter activity
P08703005A0645|55 66|binding sites
P08703005A0645|70 89|transcription factors
P08703005A0645|90 92|Sp1
P08703005A0645|90 92|Sp1
P08703005A0645|96 103|alphaCbf
P08703005A0645|96 103|alphaCbf
P08703005A0645|112 134|CCAAT box-binding protein
P08703005A0645|112 134|CCAAT box-binding protein
P08703010A0905|27 43|cis-acting element
P08703010A0905|48 54|E1 E-box
P08703010A0905|48 54|E1 E-box
P08703010A0905|68 87|GAP-43 promoter region
P08703010A0905|68 81|GAP-43 promoter
P08703010A0905|147 156|GAP-43 gene
P08703010A0905|147 149|GAP
P08703010A0905|173 193|E-box-binding proteins
P08703010A0905|173 193|E-box-binding proteins
P08703908A1814|39 42|SF-1
P08703908A1814|39 42|SF-1
P08703908A1814|80 104|cAMP-stimulated expression
P08703908A1814|110 117|StAR gene
P08703908A1814|110 117|StAR gene
P08703959A0659|28 43|proton resonances
P08703959A0659|53 70|-nucleotide segment
P08703959A0659|87 92|lesion
P08703959A0659|122 131|assignment
P08703959A0659|138 149|sugar protons
P08703959A0659|155 163|C7 residue
P08703959A0659|182 193|adduct duplex
P08704124A0420|13 24|six fragments
P08704124A0420|13 24|six fragments
P08704124A0420|26 31|CPK3-8
P08704124A0420|26 31|CPK3-8
P08704124A0420|45 63|2022 bp cDNA (VrCDPK-1
P08704124A0420|45 54|2022 bp cDNA
P08704124A0420|56 63|VrCDPK-1
P08704124A0420|70 98|Vigna radiata lambda gt11 library
P08704240A1111|10 18|TF-1 cells
P08704240A1111|10 13|TF-1
P08704240A1111|26 31|GM-CSF
P08704240A1111|26 31|GM-CSF
P08704240A1111|49 67|CREB phosphorylation
P08704240A1111|49 52|CREB
P08704240A1111|93 110|PIXY321 stimulation
P08704240A1111|93 99|PIXY321
P08705056T0000|0 16|Workplace violence
P08706368A1024|20 29|brightness
P08706368A1024|104 107|FIO2
P08706662A1125|35 52|perforin expression
P08706662A1125|35 42|perforin
P08706662A1125|55 72|non-cytotoxic cells
P08706662A1125|116 153|killer-cell-specific trans-acting factor
P08706662A1125|154 158|NF-P2
P08706662A1125|157 158|P2
P08706731A1303|84 93|Ypr10 genes
P08706731A1303|84 93|Ypr10 genes
P08706731A1303|97 113|ribonuclease genes
P08706731A1303|97 108|ribonuclease
P08706731A1303|170 188|ginseng ribonuclease
P08706731A1303|177 188|ribonuclease
P08706731A1303|213 232|ribonuclease function
P08706731A1303|236 248|PR-10 proteins
P08706731A1303|236 248|PR-10 proteins
P08707424A0709|15 25|ERV3 env mRNA
P08707424A0709|15 18|ERV3
P08707424A0709|19 25|env mRNA
P08707424A0709|108 127|monocytic development
P08707516A0194|28 39|27,193 people
P08707516A0194|70 91|mental handicap services
P08707825A0063|25 41|smooth muscle cells
P08707825A0063|44 59|Northern blotting
P08707825A0063|63 89|immunohistochemical analysis
P08707825A0063|112 124|"smoothelin."
P08707825A0063|112 122|"smoothelin
P08707825A0063|131 142|smooth muscle
P08707825A0063|143 153|cDNA library
P08707825A0063|172 192|monoclonal antibody R4A
P08707825A0063|172 192|monoclonal antibody R4A
P08707840A0753|5 32|immunogold electron microscopy
P08707840A0753|45 47|p58
P08707840A0753|49 57|p45 and p54
P08707840A0753|49 51|p45
P08707840A0753|55 57|p54
P08707840A0753|86 103|nuclear pore complex
P08707840A0753|86 103|nuclear pore complex
P08707840A0753|109 111|p62
P08707840A0753|109 111|p62
P08707846A2308|0 9|Concurrent
P08707846A2308|14 35|ligand-dependent uptake
P08707846A2308|84 97|ubiquitination
P08707846A2308|151 177|ligand-dependent endocytosis
P08707846A2308|183 198|a-factor receptor
P08707846A2308|212 234|constitutive endocytosis
P08707922A0334|33 50|rat II beta-, III beta
P08707922A0334|33 50|rat II beta-, III beta
P08707922A0334|55 71|O beta-globin genes
P08707922A0334|56 71|beta-globin genes
P08707922A0334|92 115|base pairs (bp) 5'-upstream
P08707922A0334|121 146|translation initiation codon
P08707922A0334|148 150|ATG
P08707922A0334|165 187|primer extension analysis
P08708984T0000|0 17|Aggravating process
P08708984T0000|27 38|indomethacin
P08708984T0000|48 60|gastric lesion
P08708984T0000|63 65|rat
P08709224T0000|0 31|Epstein-Barr virus nuclear protein 2
P08709224T0000|0 31|Epstein-Barr virus nuclear protein 2
P08709224T0000|33 37|EBNA2
P08709224T0000|33 37|EBNA2
P08709224T0000|61 79|human SNF-SWI complex
P08709224T0000|66 68|SNF
P08709224T0000|70 72|SWI
P08709224T0000|81 90|hSNF5/Ini1
P08709224T0000|81 85|hSNF5
P08709224T0000|87 90|Ini1
P08709245A1521|43 57|phosphorylation
P08709245A1521|60 64|Ser-2
P08709245A1521|60 62|Ser
P08709245A1521|66 72|Ser-123
P08709245A1521|76 78|Ser
P08709245A1521|97 121|trans-suppression activity
P08709245A1521|127 135|large HDAg
P08709245A1521|132 135|HDAg
P08709245A1521|152 178|empty virus-like HDAg particle
P08709245A1521|157 178|virus-like HDAg particle
P08709245A1521|188 203|nuclear transport
P08709245A1521|206 210|HDAgs
P08709245A1521|206 210|HDAgs
P08709251A0000|33 77|Autographa californica nuclear polyhedrosis virus
P08709251A0000|79 84|AcNPV)
P08709251A0000|95 117|0.6-kbp-long DNA fragment
P08709251A0000|132 142|putative DNA
P08709251A0000|140 190|DNA helicase gene of Bombyx mori nuclear polyhedrosis virus
P08709251A0000|157 173|Bombyx mori nuclear
P08709251A0000|174 190|polyhedrosis virus
P08709251A0000|200 208|eh2-AcNPV
P08709251A0000|231 241|AcNPV mutant
P08709637A1471|29 44|IL-7R alpha chains
P08709637A1471|29 44|IL-7R alpha chains
P08709637A1471|81 84|JAKs
P08709637A1471|81 84|JAKs
P08709637A1471|88 92|STATs
P08709637A1471|88 92|STATs
P08709637A1471|112 133|proliferative signaling
P08709637A1471|136 150|precursor B cells
P08709831A0599|51 65|carcinoid tumors
P08710151A0782|0 0|5
P08710151A0782|51 54|pnx s
P08710151A0782|58 63|class A
P08710151A0782|88 93|class B
P08710151A0782|107 113|patient
P08710151A0782|116 121|class A
P08710151A0782|143 148|class B
P08710371A0000|51 64|polyomavirus BK
P08710371A0000|51 62|polyomavirus
P08710371A0000|63 68|BK (BKV
P08710371A0000|66 69|BKV)
P08710371A0000|77 102|tumor-suppressor protein p53
P08710371A0000|77 99|tumor-suppressor protein
P08710371A0000|100 102|p53
P08710371A0000|176 193|p53 transactivation
P08710371A0000|176 178|p53
P08710371A0499|0 7|Site S-II
P08710371A0499|20 29|bp sequence
P08710371A0499|49 69|consensus binding sites
P08710377A0577|0 2|Cbl
P08710377A0577|0 2|Cbl
P08710377A0577|33 42|SH3 domains
P08710377A0577|33 42|SH3 domains
P08710377A0577|45 48|Grb2
P08710377A0577|45 48|Grb2
P08710377A0577|71 90|amino-terminal domain
P08710377A0577|117 119|Shc
P08710377A0577|117 119|Shc
P08710377A0577|124 137|BCR stimulation
P08710377A0577|124 126|BCR
P08710504A0995|20 24|Cat8p
P08710504A0995|20 24|Cat8p
P08710504A0995|49 58|cat1 mutant
P08710504A0995|49 58|cat1 mutant
P08711631A0989|25 34|prednisone
P08711631A0989|38 53|cyclophosphamide
P08713933A0606|0 19|Laboratory evaluation
P08713933A0606|73 78|venous
P08713933A0606|81 97|lymphatic drainage
P08716757T0001|25 66|chronic hepatitis B virus asymptomatic patients
P08717391A0466|16 25|N-terminus
P08717391A0466|82 91|N-terminus
P08717391A0466|82 91|N-terminus
P08717391A0466|100 109|C-terminus
P08717391A0466|100 109|C-terminus
P08717391A0466|195 199|HBcAg
P08717391A0466|195 199|HBcAg
P08717559A0223|3 16|standard dosage
P08717559A0223|19 24|anti-D
P08717559A0223|94 99|anti-D
P08717559A0223|94 99|anti-D
P08719155A0105|42 57|adhesive molecule
P08719155A0105|62 73|P. falciparum
P08719155A0105|155 164|Plasmodium
P08719155A0105|174 211|thrombospondin-related anonymous protein
P08719155A0105|174 211|thrombospondin-related anonymous protein
P08719155A0105|213 216|TRAP
P08719155A0105|213 216|TRAP
P08719155A0105|245 271|circumsporozoite (CS) protein
P08719155A0105|245 264|circumsporozoite (CS)
P08719156A0953|10 16|introns
P08719156A0953|45 67|9360-bp open reading frame
P08719156A0953|79 92|377-kDa protein
P08719697A0221|8 10|DSF
P08719697A0221|39 44|random
P08719697A0221|48 49|CF
P08719697A0221|68 81|normal subjects
P08719697A0221|89 96|patients
P08719697A0221|101 103|KCS
P08719832A0397|18 33|lateral rhinotomy
P08719832A0397|44 65|transsphenoidal surgery
P08719832A0397|68 77|acromegaly
P08720407A1386|47 66|lumbar disc herniation
P08720407A1386|68 88|inflammatory cytokines
P08720407A1386|95 112|interleukin-1 alpha
P08720407A1386|95 112|interleukin-1 alpha
P08720407A1386|139 153|prostaglandin E2
P08721526A0000|36 59|Swedish asthmatic children
P08721526A0000|63 78|furred pet animals
P08721989A1012|33 50|cytoplasmic domains
P08721989A1012|58 74|cytokine receptors
P08721989A1012|91 107|signaling pathways
P08721989A1012|130 134|beta c
P08721989A1012|130 134|beta c
P08721989A1012|138 146|IL-2R beta
P08721989A1012|138 146|IL-2R beta
P08721989A1012|166 181|signal transducer
P08721999A0432|67 75|snoRNA U14
P08721999A0432|67 75|snoRNA U14
P08721999A0727|0 2|U24
P08721999A0727|0 2|U24
P08721999A0727|60 64|tract
P08721999A0727|67 73|28S rRNA
P08721999A0727|67 73|28S rRNA
P08722011A0103|25 36|GTPase domain
P08722011A0103|25 36|GTPase domain
P08722011A0103|42 57|large subunit rRNA
P08722011A0103|54 57|rRNA
P08722011A0103|73 83|binding site
P08722011A0103|89 124|protein L11-like eukaryotic counterpart
P08722011A0103|89 98|protein L11
P08722011A0103|126 158|Saccharomyces cerevisiae protein L15
P08722011A0103|126 148|Saccharomyces cerevisiae
P08722011A0103|156 158|L15
P08722011A0103|162 180|mammalian protein L12
P08722011A0103|162 177|mammalian protein
P08722011A0103|178 180|L12
P08722568A1001|0 18|Chromatin repression
P08722568A1001|114 127|H3 histone genes
P08722568A1001|114 127|H3 histone genes
P08722568A1001|130 135|plants
P08723352A0084|37 38|G1
P08723352A0084|48 70|cyclin-dependent kinases
P08723352A0084|48 70|cyclin-dependent kinases
P08723352A0084|72 75|cdks
P08723352A0084|72 75|cdks
P08723352A0084|107 140|retinoblastoma tumour suppressor gene
P08723352A0084|107 120|retinoblastoma
P08723352A0084|121 140|tumour suppressor gene
P08723352A0084|142 144|pRb
P08723352A0084|142 144|pRb
P08723365T0000|27 55|hyperinsulinemia and glomerular
P08723365T0000|69 83|nephrosclerosis
P08723883A0823|5 18|GSH-Px activity
P08723883A0823|5 10|GSH-Px
P08723883A1684|19 26|vitamin A
P08723883A1684|40 47|vitamin E
P08723883A1684|85 97|dietary levels
P08723883A1684|101 106|llamas
P08723883A1684|111 120|alfalfa hay
P08723883A1684|157 165|vitamins A
P08723883A1684|169 169|E
P08726024A0532|22 24|PCR
P08726024A0532|29 35|primers
P08726024A0532|50 62|26-kDa product
P08726024A0532|50 62|26-kDa product
P08726024A0532|95 95|t
P08726024A0532|100 118|gastric fluid samples
P08726024A0532|176 176|t
P08727992A0570|23 39|PGF2 alpha, heifers
P08727992A0570|70 75|estrus
P08728040T0000|0 21|Differential activation
P08728040T0000|27 61|extracellular signal-regulated kinase
P08728040T0000|27 61|extracellular signal-regulated kinase
P08728040T0000|63 71|Jun kinase
P08728040T0000|63 71|Jun kinase
P08728040T0000|75 98|Janus kinase-Stat pathways
P08728040T0000|75 85|Janus kinase
P08728040T0000|87 90|Stat
P08728040T0000|101 111|oncostatin M
P08728040T0000|101 111|oncostatin M
P08728040T0000|115 141|basic fibroblast growth factor
P08728040T0000|115 141|basic fibroblast growth factor
P08728040T0000|144 155|AIDS-derived
P08728040T0000|156 170|Kaposi's sarcoma
P08730470A0000|30 44|hepatitis C virus
P08730470A0000|93 109|viral transmission
P08730470A0000|123 128|babies
P08730470A0000|133 138|sexual
P08731155A0499|13 26|reconstruction
P08731222A0000|3 14|distribution
P08731222A0000|50 63|spinal cervical
P08731222A0000|77 105|subnucleus reticularis dorsalis
P08731222A0000|107 109|SRD
P08731222A0000|117 142|neighbouring Cuneate nucleus
P08731222A0000|144 145|Cu
P08731222A0000|166 168|rat
P08731222A0000|193 224|Phaseolus vulgaris leucoagglutinin
P08731222A0000|193 224|Phaseolus vulgaris leucoagglutinin
P08731222A0000|226 228|PHA
P08731222A0000|226 228|PHA
P08731222A0000|230 230|L
P08731222A0000|261 267|C7 level
P08731511A0625|11 20|fibrinogen
P08731511A0625|11 20|fibrinogen
P08731511A0625|29 49|antithrombin III (ATIII
P08731511A0625|29 43|antithrombin III
P08731511A0625|45 49|ATIII
P08731511A0625|54 70|heparin cofactor II
P08731511A0625|54 70|heparin cofactor II
P08731511A0625|72 86|HCII) activities
P08731511A0625|72 75|HCII
P08731511A0625|110 128|loop-bearing animals
P08732665A0000|0 12|Amplification
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|49 88|21MT-2 and 21MT-1 human breast carcinoma cells
P08732665A0000|141 173|tyrosine-phosphorylated p185erbB-2
P08732665A0000|164 173|p185erbB-2
P08732665A0000|204 227|insulin-like growth factor
P08732665A0000|204 227|insulin-like growth factor
P08732665A0000|229 231|IGF
P08732665A0000|229 231|IGF
P08732665A0000|244 272|IGF/epidermal growth factor (EGF
P08732665A0000|244 246|IGF
P08732665A0000|248 268|epidermal growth factor
P08732665A0000|270 272|EGF
P08733123A0000|0 35|Facioscapulohumeral muscular dystrophy
P08733123A0000|37 40|FSHD
P08733123A0000|46 62|autosomal dominant
P08733123A0000|111 118|weakness
P08733123A0951|9 33|chromosome 4 FRG1 transcript
P08733123A0951|20 33|FRG1 transcript
P08733123A0951|65 69|exons
P08733123A0951|99 118|258 amino acid residues
P08733874A0000|0 7|Patients
P08733874A0000|24 36|thyroidectomy
P08733874A0000|40 55|thyroid carcinoma
P08733874A0000|96 115|severe hypothyroidism
P08733874A0000|132 135|131I
P08733874A0000|136 152|whole body scanning
P08733874A0000|174 175|TG
P08733881A0343|4 18|thyroid function
P08733881A0343|70 84|normal TSH values
P08733881A0343|76 78|TSH
P08733881A0343|106 122|abnormal TSH levels
P08733881A0343|114 116|TSH
P08734538A0613|19 29|crossover AM
P08734538A0613|120 121|AM
P08738510A0254|3 25|relative tumor FDG-uptake
P08738510A0254|27 33|Q-MRGlu
P08738510A0254|36 41|tumor/
P08738510A0254|42 60|contralateral cortex
P08738510A0254|67 77|meningiomas
P08739209A0700|111 135|two-stage coronary ligation
P08739209A0700|147 154|ligation
P08739209A0700|157 169|conscious dogs
P08739260T0000|0 10|Catha edulis
P08739260T0000|13 17|plant
P08740416A0239|20 24|Seb1p
P08740416A0239|20 24|Seb1p
P08740416A0239|36 47|82 amino acids
P08740416A0239|71 93|membrane-spanning region
P08740416A0239|99 108|C-terminus
P08740416A0239|99 108|C-terminus
P08740416A0239|114 137|N-terminal signal sequence
P08740416A0919|3 6|SEB1
P08740416A0919|3 6|SEB1
P08740416A0919|29 32|SEB2
P08740416A0919|29 32|SEB2
P08740416A0919|63 67|Seb1p
P08740416A0919|63 67|Seb1p
P08741206A1551|81 103|generalised vasodilation
P08741206A1551|107 117|hypotension
P08742135A0000|31 34|ACTH
P08742135A0000|31 34|ACTH
P08742135A0000|94 99|injury
P08742135A0000|122 135|corticosterone
P08742135A0000|137 138|CS
P08742385A0211|50 68|ventricular drainage
P08742385A0211|77 94|post-neurosurgical
P08742385A0211|104 107|head
P08745669A0000|9 16|patients
P08745669A0000|48 64|malignant lymphoma
P08745669A0000|68 88|non-Hodgkin's lymphoma
P08745669A0000|96 111|Hodgkin's disease
P08745669A0000|132 154|chemotherapeutic regimen
P08745669A0000|156 173|cisplatinum, methyl
P08745669A0000|174 176|GAG
P08745669A0000|189 205|methyl prednisolon
P08746605A0377|22 34|ACE inhibitors
P08746605A0377|22 24|ACE
P08746605A0377|85 102|lethal pancreatitis
P08746981A0154|0 19|In 3 treatments the diet
P08747078T0000|8 14|aspirin
P08747078T0000|18 37|recurrent miscarriage
P08747343A0790|0 11|Protein films
P08747343A0790|36 53|mechanical profiles
P08747343A0790|79 87|materials
P08748033A0874|12 25|cpxA* mutations
P08748033A0874|12 25|cpxA* mutations
P08748033A0874|59 80|LamB-LacZ hybrid protein
P08748033A0874|59 62|LamB
P08748033A0874|64 67|LacZ
P08748033A0874|108 116|cytoplasm
P08748033A0874|133 136|DegP
P08748033A0874|133 136|DegP
P08749393A0783|3 14|PI3K_68D cDNA
P08749393A0783|3 6|PI3K
P08749393A0783|8 14|68D cDNA
P08749393A0783|32 37|210 kDa
P08749393A0783|77 80|p110
P08749393A0783|77 80|p110
P08749393A0783|81 91|PI 3-kinases
P08749393A0783|81 91|PI 3-kinases
P08749393A0783|94 111|p85 adaptor proteins
P08749393A0783|94 111|p85 adaptor proteins
P08749393A0783|126 159|amino-terminal proline-rich sequence
P08749393A0783|177 186|SH3 domains
P08749393A0783|177 186|SH3 domains
P08749393A0783|192 215|carboxy-terminal C2 domain
P08749393A0783|192 209|carboxy-terminal C2
P08749394A0874|2 17|vitro interaction
P08749394A0874|46 70|glutathione-S-transferase
P08749394A0874|46 70|glutathione-S-transferase
P08749394A0874|82 91|RBP-J kappa
P08749394A0874|82 84|RBP
P08749394A0874|86 91|J kappa
P08749394A0874|95 96|Su
P08749394A0874|95 96|Su
P08749394A0874|98 98|H
P08749394A0874|98 98|H
P08749394A0874|117 128|RAM23 regions
P08749394A0874|117 128|RAM23 regions
P08749394A0874|131 141|mouse Notch1
P08749394A0874|136 141|Notch1
P08749394A0874|145 159|Drosophila Notch
P08749394A0874|145 159|Drosophila Notch
P08750173A0000|13 31|Reticuloendothelial
P08750173A0000|83 90|bacteria
P08750173A0000|111 121|liver injury
P08750173A0000|131 145|D-galactosamine
P08750173A0000|148 151|rats
P08750190A0000|31 49|alternative splicing
P08750190A0000|59 63|exons
P08750190A0000|75 91|extracellular site
P08750190A0000|134 144|CD44 variant
P08750190A0000|134 144|CD44 variant
P08750190A0000|146 159|CD44v) isoforms
P08750190A0000|146 150|CD44v
P08750702A0183|45 85|alpha1-adrenoceptor-subtype blockers WB4101
P08750702A0183|45 71|alpha1-adrenoceptor-subtype
P08750702A0183|97 98|v.
P08750702A0183|102 121|chloroethylclonidine
P08750702A0183|133 134|v.
P08751635A0135|33 44|neuronal loss
P08751635A0135|47 57|hippocampus
P08751635A0135|67 69|CA1
P08751635A0135|71 73|CA3
P08752714A0000|15 32|multiple malignancy
P08752714A0000|48 55|patients
P08752714A0000|60 82|hematologic malignancies
P08754777A1214|3 7|upTRE
P08754777A1214|17 29|T3R homodimers
P08754777A1214|17 19|T3R
P08754777A1214|20 29|homodimers
P08754777A1214|37 55|T3R-RXR heterodimers
P08754777A1214|37 39|T3R
P08754777A1214|41 43|RXR
P08754777A1214|63 67|dnTRE
P08754777A1214|72 73|T3
P08754777A1214|119 120|dn
P08754777A1214|131 135|upTRE
P08754802T0000|0 21|Transcriptional control
P08754802T0000|25 35|nuclear gene
P08754802T0000|25 35|nuclear gene
P08754802T0000|45 81|mitochondrial fatty acid oxidation enzyme
P08754802T0000|84 97|transgenic mice
P08754802T0000|106 121|nuclear receptors
P08754802T0000|106 121|nuclear receptors
P08754802T0000|124 130|cardiac
P08754802T0000|134 155|brown adipose expression
P08754827A0231|0 5|Hoeben
P08754834A1097|0 21|Twelve genomic fragments
P08754834A1097|32 52|novel response elements
P08754834A1097|72 88|transcription unit
P08754834A1097|113 119|NN-84AG
P08754834A1097|113 119|NN-84AG
P08754840A0793|9 30|glucan synthase activity
P08754840A0793|9 22|glucan synthase
P08754840A0793|50 54|Rho1p
P08754840A0793|50 54|Rho1p
P08754840A0793|84 98|deltabem4 mutant
P08754840A0793|84 98|deltabem4 mutant
P08754852A0960|2 21|gel retardation assays
P08754852A0960|25 47|RCS cell-specific protein
P08754852A0960|25 47|RCS cell-specific protein
P08754852A0960|94 101|RCS cells
P08754852A0960|105 123|primary chondrocytes
P08754852A0960|132 144|10-bp sequence
P08754852A0960|154 159|18-mer
P08755898A0339|12 38|Xanthomonas pathogens evading
P08755898A0339|39 41|Bs2
P08755898A0339|42 55|host resistance
P08755898A0339|117 123|avrBs2.
P08755898A0339|117 122|avrBs2
P08756332A0000|12 23|Ras subfamily
P08756332A0000|12 14|Ras
P08756332A0000|26 49|small GTP-binding proteins
P08756332A0000|26 49|small GTP-binding proteins
P08756332A0000|95 119|putative effector molecules
P08756332A0000|129 146|protein kinase c-Raf
P08756332A0000|129 141|protein kinase
P08756332A0000|142 146|c-Raf
P08756332A0000|153 195|Ral-specific guanine nucleotide exchange factor
P08756332A0000|165 195|guanine nucleotide exchange factor
P08756332A0000|197 203|Ral-GEF
P08756332A0000|197 203|Ral-GEF
P08756433A0282|29 42|promoter region
P08756433A0282|90 130|neuron-specific and developmental expression
P08756433A0282|136 144|MAP1B gene
P08756433A0282|136 144|MAP1B gene
P08756556A0406|3 6|cDNA
P08756556A0406|30 42|240 amino acids
P08756556A0406|54 79|29-amino acid signal sequence
P08756597A0854|17 18|3'
P08756597A0854|19 27|stem-loop
P08756597A0854|62 69|psaB mRNA
P08756597A0854|62 69|psaB mRNA
P08756609A0498|10 26|amino acid sequence
P08756609A0498|65 74|eukaryotes
P08756609A0498|76 86|vertebrates
P08756609A0498|88 100|invertebrates
P08756609A0498|108 113|plants
P08756609A0498|117 124|protozoa
P08756636T0000|0 20|Semidominant mutations
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|71 82|Srs2 helicase
P08756636T0000|71 74|Srs2
P08756642A0230|0 10|Alterations
P08756642A0230|16 23|5q23-q31
P08756642A0230|55 68|myelodysplasia
P08756642A0230|72 86|myeloid leukemia
P08756712A0227|48 60|70-kDa subunit
P08756712A0227|63 65|RPA
P08756712A0227|63 65|RPA
P08756712A0227|67 71|RPA 70
P08756712A0227|67 71|RPA 70
P08757265A0466|0 6|Neurons
P08757943A0876|50 72|thymidine kinase promoter
P08757943A0876|50 72|thymidine kinase promoter
P08759870A1128|14 33|fbpA operator sequence
P08759870A1128|14 33|fbpA operator sequence
P08759870A1128|35 38|42 bp
P08759870A1128|103 120|Fur repressor dimers
P08759870A1128|103 114|Fur repressor
P08760286A0696|30 32|Vav
P08760286A0696|30 32|Vav
P08760286A0696|41 72|guanine nucleotide exchange factors
P08760286A0696|41 72|guanine nucleotide exchange factors
P08760286A0696|76 99|small GTP-binding proteins
P08760286A0696|76 99|small GTP-binding proteins
P08760286A0696|178 180|Ras
P08760286A0696|178 180|Ras
P08760286A0696|184 186|Rho
P08760286A0696|184 186|Rho
P08760286A0696|195 201|GTPases
P08760286A0696|195 201|GTPases
P08760286A0696|229 232|MAPK
P08760286A0696|229 232|MAPK
P08760286A0696|235 237|JNK
P08760286A0696|235 237|JNK
P08760286A0696|266 268|Vav
P08760286A0696|266 268|Vav
P08760776A1559|122 133|theophylline
P08760776A1559|166 171|asthma
P08760872A0696|32 41|E2F- and CDE
P08760872A0696|39 60|CDE-mediated repression
P08760872A0696|90 98|cell cycle
P08760872A0696|114 141|promoter-specific CHR elements
P08760889A0170|3 11|cDNA clone
P08760889A0170|56 67|genomic clone
P08760889A0170|76 79|H2A1
P08760889A0170|76 79|H2A1
P08760889A0531|22 39|amino acid sequences
P08760889A0531|44 59|protein sequences
P08760889A0531|62 77|T. pyriformis H2As
P08760889A0531|74 77|H2As
P08760889A0531|149 152|H2A1
P08760889A0531|149 152|H2A1
P08760889A0531|173 176|H2A2
P08760889A0531|173 176|H2A2
P08761169T0000|9 25|visual dysfunction
P08761169T0000|38 51|cerebral damage
P08761480A0331|39 60|N-terminal splice region
P08761480A0331|63 68|RPDE-6
P08761480A0331|63 68|RPDE-6
P08761480A0331|75 92|PDE4A splice variant
P08761480A0331|75 79|PDE4A
P08761480A0331|93 99|RPDE-39
P08761480A0331|117 122|RPDE-6
P08761480A0331|117 122|RPDE-6
P08761480A0331|128 144|extreme N-terminus
P08761480A0331|167 175|v-Src-SH3
P08761480A0331|167 171|v-Src
P08761480A0331|173 175|SH3
P08761480A0331|177 184|met26RD1
P08761480A0331|191 193|RD1
P08761480A0331|191 193|RD1
P08761480A0331|196 212|rat 'dunc-like' PDE
P08761480A0331|196 212|rat 'dunc-like' PDE
P08761480A0331|226 247|N-terminal splice region
P08761480A0331|277 285|v-Src-SH3
P08761480A0331|277 281|v-Src
P08761480A0331|283 285|SH3
P08761480A0331|306 311|RPDE-6
P08761480A0331|306 311|RPDE-6
P08761480A0331|315 323|v-Src-SH3
P08761480A0331|315 319|v-Src
P08761480A0331|321 323|SH3
P08761480A0331|363 384|N-terminal splice region
P08762021A0156|0 34|Potentially load-insensitive measures
P08762021A0156|93 106|closed-chested
P08762021A0156|108 126|anesthetized rabbits
P08762172A0178|75 88|attacking males
P08762172A0178|107 120|brightly lit box
P08762172A0178|166 174|dark boxes
P08762472A0000|11 35|ligustrazine hydrochloride
P08762472A0000|37 39|LTH
P08762472A0000|43 67|depressing pulmonary artery
P08762472A0000|68 79|hypertension
P08763207A0402|43 53|acidic media
P08763207A0402|60 60|V
P08763207A0402|83 85|DPV
P08763207A0402|134 151|Nafion-modified CPE
P08763311A0189|0 12|Phenylephrine
P08763311A0189|16 26|pure alpha-1
P08763311A0189|20 40|alpha-1 adrenoreceptor
P08763311A0189|68 116|systemic vasoconstriction and associated hypertension
P08763311A0189|139 155|reflex bradycardia
P08763925A0588|49 54|c-gvpD
P08763925A0588|49 54|c-gvpD
P08763925A0588|58 63|c-gvpE
P08763925A0588|58 63|c-gvpE
P08763925A0588|83 113|Western blot (immunoblot) analyses
P08763925A0588|119 126|antisera
P08763925A0588|166 180|Escherichia coli
P08763953A0805|14 17|traA
P08763953A0805|14 17|traA
P08763953A0805|19 22|traF
P08763953A0805|19 22|traF
P08763953A0805|27 30|traB
P08763953A0805|27 30|traB
P08763953A0805|53 56|traC
P08763953A0805|53 56|traC
P08763953A0805|58 61|traD
P08763953A0805|58 61|traD
P08763953A0805|66 69|traG
P08763953A0805|66 69|traG
P08764136A0000|19 23|genes
P08764136A0000|57 65|mRNA level
P08764136A0000|72 94|oncogenic transformation
P08764136A0000|97 123|human mammary epithelial cells
P08764136A0000|125 128|MECs
P08764136A0000|142 165|subtractive hybridization
P08764136A0000|179 187|MEC strain
P08764136A0000|188 190|76N
P08764136A0000|239 244|76R-30
P08766049A0000|29 51|right corneal perforation
P08766049A0000|56 71|cellular reaction
P08766049A0000|74 88|anterior chamber
P08766781A0322|39 48|hematocrit
P08766781A0322|71 72|Hb
P08766781A0322|71 72|Hb
P08768374A0765|3 6|P-wr
P08768374A0765|3 6|P-wr
P08768374A0765|10 26|P-rr cDNA sequences
P08768374A0765|10 26|P-rr cDNA sequences
P08768374A0765|48 56|5' regions
P08768377A1387|10 20|hcf109 locus
P08768377A1387|10 20|hcf109 locus
P08768377A1387|64 79|phytochrome C gene
P08768377A1387|64 79|phytochrome C gene
P08769132A0000|3 23|human MSH-2 gene product
P08769132A0000|3 23|human MSH-2 gene product
P08769132A0000|85 114|post-replication mismatch repair
P08769132A0000|116 121|hMSH-2
P08769132A0000|116 121|hMSH-2
P08769132A0000|136 150|Escherichia coli
P08769132A0000|136 150|Escherichia coli
P08769132A0000|152 157|E. coli
P08769132A0000|152 157|E. coli
P08769132A0000|159 162|MutS
P08769132A0000|159 162|MutS
P08769132A0000|166 192|Sacchromyces cerevisiae MSH-1
P08769132A0000|166 187|Sacchromyces cerevisiae
P08769132A0000|188 192|MSH-1
P08769132A0000|196 208|MSH-2 proteins
P08769132A0000|196 208|MSH-2 proteins
P08769132A0000|260 285|base mismatches and deletions
P08769132A0000|313 318|hMSH-2
P08769132A0000|313 318|hMSH-2
P08769132A0000|329 394|hereditary non-polyposis colorectal cancer (HNPCC) tumor suppressor genes
P08769132A0000|329 338|hereditary
P08769132A0000|339 351|non-polyposis
P08769132A0000|352 367|colorectal cancer
P08769132A0000|369 394|HNPCC) tumor suppressor genes
P08769132A0000|405 423|human chromosome 2p16
P08769409A0114|26 50|tissue-specific expression
P08769409A0114|56 67|RAR beta 2 gene
P08769409A0114|56 67|RAR beta 2 gene
P08769409A0114|70 81|mouse embryos
P08769409A0114|98 115|translational level
P08769409A0114|131 147|open reading frames
P08769409A0114|149 153|uORFs
P08769409A0114|160 180|5'-untranslated region
P08769566A0000|25 28|cDNA
P08769566A0000|64 68|Zfhep
P08769566A0000|64 68|Zfhep
P08769566A0000|70 113|zinc finger homeodomain enhancer-binding protein
P08769566A0000|70 113|zinc finger homeodomain enhancer-binding protein
P08769566A0000|136 152|zinc finger domains
P08769566A0000|136 152|zinc finger domains
P08769566A0000|154 156|ZD1
P08769566A0000|154 156|ZD1
P08769566A0000|160 162|ZD2
P08769566A0000|160 162|ZD2
P08769566A0000|188 198|homeodomain
P08769568A0949|19 23|genes
P08769568A0949|53 68|viperid PLA2 genes
P08769568A0949|60 68|PLA2 genes
P08770021T0000|9 23|PTHRP production
P08770021T0000|9 13|PTHRP
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|50 56|Tpr-Met
P08770021T0000|67 85|Ras signaling pathway
P08770021T0000|67 69|Ras
P08770896A1121|30 35|IGF-II
P08770896A1121|30 35|IGF-II
P08770896A1121|38 52|xz97 and G11 cells
P08770896A1121|126 130|appMr
P08770896A1121|134 136|17K
P08770896A1121|140 142|14K
P08770920A1220|31 55|transcriptionally inactive
P08770920A1220|57 84|amino-terminally deleted IDX-1
P08770920A1220|80 98|IDX-1 mutant proteins
P08770920A1220|85 98|mutant proteins
P08770920A1220|113 126|wild-type IDX-1
P08770920A1220|113 126|wild-type IDX-1
P08770920A1220|173 187|transactivation
P08770920A1220|193 228|transcriptional TAAT-1 element reporter
P08770981A0328|3 10|patients
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|42 44|vWF
P08770981A0328|42 44|vWF
P08770981A0328|81 99|high molecular weight
P08770981A0328|112 129|low molecular weight
P08770981A0328|130 141|vWF multimers
P08771781A0103|60 66|oleosin
P08771781A0103|77 92|open reading frame
P08771781A0103|94 98|ORFII
P08771781A0103|102 118|Brassica napus (L.)
P08771781A0103|102 114|Brassica napus
P08771781A0103|131 138|promoter
P08771781A0103|164 168|ORFII
P08771781A0103|170 179|cDNA clones
P08771781A0103|192 196|ORFII
P08771781A0103|214 228|leaf cDNA library
P08771781A1103|3 18|ORFII gene product
P08771781A1103|3 18|ORFII gene product
P08771781A1103|102 105|PMSR
P08771781A1103|102 105|PMSR
P08771781A1103|119 129|chloroplast
P08771787T0000|18 20|LRP
P08771787T0000|18 20|LRP
P08771787T0000|22 40|a leucine-rich repeat
P08771787T0000|23 52|leucine-rich repeat (LRR) protein
P08771787T0000|42 52|LRR) protein
P08771787T0000|63 68|plants
P08771787T0000|90 101|pathogenesis
P08774732A0271|13 15|Sp1
P08774732A0271|13 15|Sp1
P08774732A0271|19 30|zif268/egr-1
P08774732A0271|19 24|zif268
P08774732A0271|26 30|egr-1
P08774732A0271|53 72|gel retardation assays
P08775674A0000|42 64|clinical characteristics
P08775674A0000|87 89|310
P08775674A0000|90 97|patients
P08775674A0000|102 117|hydatidiform mole
P08776735A0000|6 35|transfected human kidney 293 cells
P08776735A0000|57 77|rat LH/CG receptor (rLHR
P08776735A0000|60 61|LH
P08776735A0000|63 72|CG receptor
P08776735A0000|74 89|rLHR) or receptors
P08776735A0000|94 108|C-terminal tails
P08776735A0000|120 140|residues 653, 631, or 628
P08776735A0000|152 160|rLHR-t653
P08776735A0000|152 160|rLHR-t653
P08776735A0000|162 170|rLHR-t631
P08776735A0000|162 170|rLHR-t631
P08776735A0000|175 183|rLHR-t628
P08776735A0000|175 183|rLHR-t628
P08776735A0000|242 263|hormonal responsiveness
P08776748T0000|6 9|P300
P08776748T0000|30 42|schizophrenia
P08776792A0626|0 4|Sleep
P08776793A0811|3 10|patients
P08776793A0811|17 33|healthy adult males
P08776901A0000|0 17|Chloroplast mutator
P08776901A0000|0 17|Chloroplast mutator
P08776901A0000|19 35|chm) of Arabidopsis
P08776901A0000|19 21|chm
P08776901A0000|48 62|nuclear mutation
P08776901A0000|81 96|white variegation
P08776901A0000|122 141|non-Mendelian fashion
P08777374A1471|0 19|Indoor concentrations
P08777374A1471|48 68|outdoor concentrations
P08777374A1471|81 97|personal exposures
P08777374A1471|130 150|outdoor concentrations
P08778265A0422|1 29|neuropsychological test battery
P08778265A0422|53 76|Wisconsin card sorting test
P08778265A0422|99 108|Stroop test
P08778265A0422|111 137|dichotic memory listening test
P08778700A0476|37 51|left ventricular
P08778700A0476|77 80|ARVD
P08780339A0142|85 89|males
P08780339A0142|95 101|females
P08780339A0142|131 137|glucose
P08780339A0142|149 158|starch (RS)
P08780339A0142|166 187|high-amylose cornstarch
P08780339A0142|189 191|RS2
P08780339A0142|210 231|high-amylose cornstarch
P08780339A0142|233 235|RS3
P08780339A0142|233 235|RS3
P08781119A0723|3 18|5' flanking region
P08781119A0723|24 41|mouse Met-ase-1 gene
P08781119A0723|24 41|mouse Met-ase-1 gene
P08781119A0723|88 103|5' flanking region
P08781119A0723|109 124|rat Met-ase-1 gene
P08781119A0723|109 124|rat Met-ase-1 gene
P08781144A1520|3 7|[18F]
P08781144A1520|8 16|FMISO TMRR
P08781144A1520|62 74|tumour hypoxia
P08781144A1520|77 79|NPC
P08783180A0000|0 14|Improved methods
P08783180A0000|60 70|neotropical
P08783180A0000|71 90|short-tailed fruit bat
P08783180A0000|92 112|Carollia perspicillata
P08783666A0957|59 71|amifostine arm
P08784787A0383|11 26|thrombin receptor
P08784787A0383|11 26|thrombin receptor
P08784787A0383|28 31|PAR2
P08784787A0383|28 31|PAR2
P08784787A0383|115 130|receptor cleavage
P08787110A0981|14 17|CPET
P08787110A0981|57 64|patients
P08787110A0981|69 90|cardiopulmonary disease
P08787110A0981|144 160|pulmonary function
P08789441A0339|5 35|fluorescence in situ hybridization
P08789441A0339|48 70|chromosome-17 breakpoint
P08789441A0339|74 80|patient
P08789441A0339|85 99|acampomelic CMPD
P08789441A0339|103 113|sex reversal
P08789441A0339|146 166|t(12;17) translocation
P08789441A0339|183 188|cosmid
P08789441A0339|201 215|17q24-q25 region
P08790288A0068|33 37|cDNAs
P08790288A0068|42 48|spinach
P08790288A0068|50 65|Spinacia oleracea
P08790288A0068|70 75|barley
P08790288A0068|77 92|Hordeum vulgare cv
P08790291A1022|38 41|thi1
P08790291A1022|38 41|thi1
P08790291A1022|61 78|DNA damage tolerance
P08790291A1022|81 90|plant cells
P08790387A0299|5 16|rat rnu allele
P08790387A0299|5 16|rat rnu allele
P08790387A0299|32 47|nonsense mutation
P08790387A0299|50 54|exon 8
P08790387A0299|60 66|whn gene
P08790387A0299|60 66|whn gene
P08792217A1407|31 50|testicular TIMP-2 mRNA
P08792217A1407|41 46|TIMP-2
P08792217A1407|138 149|Sertoli cells
P08792217A1407|179 216|Sertoli cell steady-state TIMP-2 mRNA level
P08792217A1407|202 211|TIMP-2 mRNA
P08793029A0246|13 16|rats
P08793029A0246|46 58|treated groups
P08794254A2957|5 7|SPK
P08794254A2957|5 7|SPK
P08794254A2957|11 13|PTA
P08794254A2957|23 40|anti-T-cell therapy
P08794254A2957|23 28|anti-T
P08794254A2957|70 78|graft loss
P08794326A0405|23 43|Tas-responsive element
P08794326A0405|23 43|Tas-responsive element
P08794326A0405|55 57|TRE
P08794326A0405|55 57|TRE
P08794326A0405|59 60|GP
P08794326A0405|59 60|GP
P08794326A0405|70 74|3' end
P08794326A0405|80 86|gag gene
P08794326A0405|80 82|gag
P08794326A0405|102 115|pol gene of SFV-1
P08794326A0405|102 108|pol gene
P08794326A0405|111 115|SFV-1
P08794339A1162|20 24|IE2 86
P08794339A1162|20 22|IE2
P08794339A1162|44 58|full-length CREB
P08794339A1162|55 58|CREB
P08794339A1162|61 69|deltaCREB
P08794339A1162|61 69|deltaCREB
P08794339A1162|80 84|IE2 86
P08794339A1162|80 82|IE2
P08794339A1162|106 109|p300
P08794339A1162|106 109|p300
P08794339A1162|116 134|CREB-binding protein
P08794339A1162|116 134|CREB-binding protein
P08794339A1162|136 138|CBP
P08794339A1162|136 138|CBP
P08794339A1162|158 161|CREB
P08794339A1162|158 161|CREB
P08794339A1162|175 189|adaptor proteins
P08794339A1162|193 204|CREB function
P08794339A1162|193 196|CREB
P08794348A1067|11 30|complementation assay
P08794348A1067|51 53|NIa
P08794348A1067|103 114|viral genomes
P08794348A1067|130 140|NIa proteins
P08794348A1067|130 140|NIa proteins
P08794363A0259|15 18|bZIP
P08794363A0259|38 40|meq
P08794363A0259|68 84|jun-fos gene family
P08794363A0259|68 78|jun-fos gene
P08794547A0648|3 19|rCBF and vasomotion
P08794547A0648|34 55|laser-doppler fluxmetry
P08794547A1403|8 19|basal vessels
P08794547A1403|38 55|parenchymal vessels
P08794547A1403|73 75|SAH
P08794601A0000|22 31|nizatidine
P08794601A0000|51 67|bismuth subcitrate
P08794601A0000|80 95|ulcer healing rate
P08794601A0000|114 128|eradication rate
P08794869A0274|46 53|PKC-zeta
P08794869A0274|46 53|PKC-zeta
P08794869A0274|66 93|alpha 2 integrin gene expression
P08794869A0274|66 83|alpha 2 integrin gene
P08795304T0000|6 19|thrombomodulin
P08795304T0000|6 19|thrombomodulin
P08795304T0000|31 56|microvascular complications
P08795304T0000|59 74|diabetes mellitus
P08797362T0037|0 5|Update
P08797362T0037|63 66|USSR
P08798420A0207|24 37|promoter region
P08798420A0207|64 81|regulatory elements
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|117 119|TRE
P08798420A0207|123 140|PRDII/kappaB domain
P08798420A0207|123 140|PRDII/kappaB domain
P08798420A0207|146 152|CAAT box
P08798420A0207|181 184|pp60
P08798420A0207|181 184|pp60
P08798420A0207|186 191|v-)src
P08798420A0207|186 191|v-)src
P08798443A0660|0 8|Serine 528
P08798443A0660|40 48|cell lines
P08798443A0660|67 75|serine 528
P08798443A0660|78 84|alanine
P08798443A0660|86 90|S528A
P08798443A0660|122 124|Myb
P08798443A0660|122 124|Myb
P08798443A0660|141 157|synthetic promoter
P08798443A0660|183 209|mim-1A Myb-responsive element
P08798443A0660|183 209|mim-1A Myb-responsive element
P08798443A0660|214 236|minimal herpes tk promoter
P08798443A0660|221 236|herpes tk promoter
P08798443A1218|3 12|DNA binding
P08798443A1218|16 40|multimerization activities
P08798443A1218|43 47|c-Myb
P08798443A1218|43 47|c-Myb
P08798443A1218|73 89|S528A substitution
P08798443A1218|105 119|phosphorylation
P08798443A1218|122 130|serine 528
P08798443A1218|193 197|c-Myb
P08798443A1218|193 197|c-Myb
P08798512A1197|35 42|GEO cells
P08798512A1197|53 61|u-PAR gene
P08798512A1197|53 61|u-PAR gene
P08798610A0843|0 3|PIP2
P08798610A0843|25 43|phosphatidylcholine
P08798610A0843|44 58|carrier vesicles
P08798610A0843|109 115|Cdc42Hs
P08798610A0843|109 115|Cdc42Hs
P08798610A0843|130 142|GDP-bound form
P08798610A0843|148 165|GTP-binding protein
P08798610A0843|148 165|GTP-binding protein
P08798610A0843|182 197|GTP-bound Cdc42Hs
P08798610A0843|191 197|Cdc42Hs
P08798610A0843|229 242|Dbl oncoprotein
P08798610A0843|229 242|Dbl oncoprotein
P08798635A0870|8 37|spleen GAP accelerated hydrolysis
P08798635A0870|40 42|GTP
P08798635A0870|40 42|GTP
P08798635A0870|50 64|recombinant ARF1
P08798635A0870|50 64|recombinant ARF1
P08798635A0870|66 69|ARF3
P08798635A0870|66 69|ARF3
P08798635A0870|71 74|ARF5
P08798635A0870|71 74|ARF5
P08798635A0870|79 82|ARF6
P08798635A0870|79 82|ARF6
P08798635A0870|94 119|NH2-terminal myristoylation
P08798643T0000|1 34|novel phosphotyrosine-binding domain
P08798643T0000|40 67|N-terminal transforming region
P08798643T0000|70 72|Cbl
P08798643T0000|70 72|Cbl
P08798643T0000|108 113|ZAP-70
P08798643T0000|108 113|ZAP-70
P08798643T0000|116 121|T cells
P08798648A1816|0 6|Cys-757
P08798648A1816|17 45|Fe4S4)-siroheme-binding domain
P08798648A1816|67 80|enzyme activity
P08798700A0134|3 15|transcription
P08798700A0134|61 66|oxygen
P08798700A0134|69 82|heme deficiency
P08798700A0134|105 114|repression
P08798700A0134|124 128|Rox1p
P08798700A0134|124 128|Rox1p
P08798700A0134|162 187|upstream activation sequence
P08798700A0134|189 191|UAS
P08798762A1279|61 71|Cut proteins
P08798762A1279|61 71|Cut proteins
P08798762A1279|85 87|PKC
P08798762A1279|85 87|PKC
P08798782A0976|0 2|Lck
P08798782A0976|0 2|Lck
P08798782A0976|40 55|SH2 and SH3 domains
P08798782A0976|40 42|SH2
P08798782A0976|46 55|SH3 domains
P08798893A0611|35 51|bovine lactalbumin
P08798893A0611|35 51|bovine lactalbumin
P08798893A0611|108 124|CCCD heterogeneity
P08798893A0611|136 145|fresh cells
P08801403T0001|11 25|pleural effusion
P08801403T0001|46 60|multiple myeloma
P08803710A0701|66 73|I, II, III
P08803710A0701|75 77|IVA
P08803710A0701|81 83|IVB
P08803845A0665|25 48|macroscopic or microscopic
P08803845A0665|59 73|neoplastic cells
P08803845A0665|125 130|lesion
P08804012A0662|25 27|SIP
P08804012A0662|70 77|pastimes
P08804389A0893|0 19|Northern blot analysis
P08804389A0893|29 46|Ltp4-specific probe
P08804389A0893|29 32|Ltp4
P08804389A0893|61 83|Xanthomonas campestris pv
P08804389A0893|130 137|Ltp4 mRNA
P08804389A0893|130 137|Ltp4 mRNA
P08804389A0893|144 173|Pseudomonas syringae pv. japonica
P08805338A1061|0 17|Targeted disruption
P08805338A1061|23 30|OGG1 gene
P08805338A1061|23 30|OGG1 gene
P08805338A1061|53 78|OG glycosylase/lyase protein
P08805338A1061|53 78|OG glycosylase/lyase protein
P08805338A1061|96 99|Ogg2
P08805338A1061|96 99|Ogg2
P08805338A1061|117 120|Ogg1
P08805338A1061|117 120|Ogg1
P08805824A1155|59 81|wavefront reconstruction
P08805824A1155|149 167|inelastic scattering
P08805824A1155|190 204|lens aberrations
P08806491A0542|18 24|ODV-E18
P08806491A0542|18 24|ODV-E18
P08806491A0542|28 35|ODV-EC27
P08806491A0542|28 35|ODV-EC27
P08806491A0542|48 66|conserved TAAG motifs
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|79 94|ME26 viral protein
P08806693A0584|79 94|ME26 viral protein
P08806693A0584|116 123|promoter
P08806693A0584|140 165|luciferase expression vector
P08806693A0584|140 149|luciferase
P08806693A0584|190 205|mouse fibroblasts
P08806693A0584|224 229|GATA-1
P08806693A0584|224 229|GATA-1
P08806817A0244|0 15|Sequence analysis
P08806817A0244|21 40|isolated genomic clone
P08806817A0244|56 71|DNA binding domain
P08806817A0244|56 71|DNA binding domain
P08806817A0244|78 91|orphan receptor
P08806817A0244|78 91|orphan receptor
P08806817A0244|113 128|human TR2 receptor
P08806817A0244|113 128|human TR2 receptor
P08806817A0716|0 22|Genomic DNA hybridization
P08806817A0716|35 40|SpSHR2
P08806817A0716|35 40|SpSHR2
P08806817A0716|44 58|single-copy gene
P08807245A0843|53 62|undercalls
P08807288T0000|43 60|UAS2-dependent ADH2
P08807288T0000|43 46|UAS2
P08807288T0000|57 70|ADH2 expression
P08807288T0000|73 95|Saccharomyces cerevisiae
P08807408A0524|50 74|nodal reentrant tachycardia
P08807408A0524|108 121|AV modification
P08808120A0774|0 7|Patients
P08808120A0774|34 55|aluminum overload (serum
P08808120A0774|84 86|DAI
P08808120A0774|134 138|serum
P08808120A0774|139 142|iron
P08808120A0774|144 147|iron
P08808120A0774|148 158|transferrin
P08808120A0774|178 191|ferritin levels
P08808120A0774|178 185|ferritin
P08808120A0774|245 260|aluminum overload
P08808120A0774|262 280|serum aluminum levels
P08808120A0774|299 301|DAI
P08808275A1193|11 26|RAD23 equivalents
P08808275A1193|11 15|RAD23
P08808275A1193|62 75|mammalian genes
P08808275A1193|62 75|mammalian genes
P08808275A1193|92 112|UV-inducible phenotype
P08808707A0631|0 28|Ha-RasV12 and activated proteins
P08808707A0631|0 8|Ha-RasV12
P08808707A0631|38 66|extra-cellular regulated kinase
P08808707A0631|44 66|cellular regulated kinase
P08808707A0631|68 70|ERK
P08808707A0631|68 70|ERK
P08808707A0631|78 106|stress-activated protein kinase
P08808707A0631|78 106|stress-activated protein kinase
P08808707A0631|108 111|SAPK
P08808707A0631|108 111|SAPK
P08808707A0631|115 133|Jun N-terminal kinase
P08808707A0631|115 133|Jun N-terminal kinase
P08808707A0631|135 137|JNK
P08808707A0631|135 137|JNK
P08808707A0631|170 196|PEA3-mediated gene expression
P08808707A0631|170 186|PEA3-mediated gene
P08808756A0587|0 15|Sequence analysis
P08808756A0587|37 49|amplified cDNA
P08808756A0587|83 98|transfected cells
P08808756A0587|159 160|13
P08808756A0587|206 218|unspliced mRNA
P08808924A0326|3 19|hydropathy profile
P08808924A0326|28 45|seven transmembrane
P08808924A0326|55 78|hydrophilic amino terminus
P08808924A0326|134 155|amphiphilic alpha-helix
P08808924A0326|157 160|L-61
P08808924A0326|202 219|hydrophobic segment
P08808924A0326|222 225|ProW
P08808924A0326|222 225|ProW
P08808927A0417|7 28|HindIII genomic fragment
P08808927A0417|7 28|HindIII genomic fragment
P08808927A0417|40 47|vspA gene
P08808927A0417|40 47|vspA gene
P08808927A0417|52 58|M. bovis
P08808927A0417|59 62|PG45
P08808939A0000|0 25|Carbon catabolite repression
P08808939A0000|31 39|gnt operon
P08808939A0000|31 39|gnt operon
P08808939A0000|42 57|Bacillus subtilis
P08808939A0000|42 57|Bacillus subtilis
P08808939A0000|73 96|catabolite control protein
P08808939A0000|97 100|CcpA
P08808939A0000|97 100|CcpA
P08808939A0000|106 108|HPr
P08808939A0000|106 108|HPr
P08808939A0000|111 131|phosphocarrier protein
P08808939A0000|137 160|phosphotransferase system
P08809680T0000|0 8|Melatonin
P08810278A0682|28 42|cellular protein
P08810278A0682|51 57|BCR/ABL
P08810278A0682|51 53|BCR
P08810278A0682|55 57|ABL
P08810278A0682|68 81|CRKL-SH2 domain
P08810278A0682|68 71|CRKL
P08810278A0682|73 81|SH2 domain
P08810278A0682|84 87|p130
P08810278A0682|84 87|p130
P08810278A0682|89 91|CAS
P08810278A0682|89 91|CAS
P08810278A0682|94 97|p130
P08810278A0682|94 97|p130
P08810278A0682|99 101|CAS
P08810278A0682|99 101|CAS
P08810278A0682|115 136|tyrosine phosphorylated
P08810278A0682|154 157|CRKL
P08810278A0682|154 157|CRKL
P08810278A0682|160 166|BCR/ABL
P08810278A0682|160 162|BCR
P08810278A0682|164 166|ABL
P08810278A0682|189 197|in samples
P08810278A0682|210 226|CML and ALL patients
P08810278A0682|247 254|controls
P08810323A0735|12 30|polyglutamine motifs
P08810323A0735|47 67|histidine-rich regions
P08812012T0000|34 57|lateralized Stroop effects
P08812106T0000|0 7|PCNA mRNA
P08812106T0000|0 7|PCNA mRNA
P08812106T0000|12 16|3'UTR
P08812106T0000|28 33|yellow
P08812106T0000|61 82|ascidian eggs and embryos
P08812490A0000|1 15|1.8-kb cDNA clone
P08812490A0000|25 44|hKID, gene symbol AQP2L
P08812490A0000|25 28|hKID
P08812490A0000|30 44|gene symbol AQP2L
P08812490A0000|63 72|aquaporins
P08812490A0000|89 110|human kidney cDNA library
P08812490A0542|0 2|PCR
P08812490A0542|4 23|Southern blot analysis
P08812490A0542|26 40|human kidney cDNA
P08812490A0542|46 52|primers
P08812490A0542|64 81|hKID coding sequence
P08812490A0542|64 67|hKID
P08812490A0542|103 117|full-length mRNA
P08812490A0542|103 117|full-length mRNA
P08812490A0542|148 152|exon 1
P08812490A0542|163 176|exon 4 deletions
P08812490A1509|3 22|high sequence homology
P08812490A1509|51 74|identical chromosomal loci
P08812490A1509|77 80|hKID
P08812490A1509|77 80|hKID
P08812490A1509|82 84|MIP
P08812490A1509|82 84|MIP
P08812490A1509|89 93|AQP-2
P08812490A1509|89 93|AQP-2
P08812490A1509|102 121|MIP family gene cluster
P08812490A1509|102 121|MIP family gene cluster
P08812490A1509|124 143|chromosome locus 12q13
P08813766A0605|8 10|ORF
P08813766A0605|33 37|1.6 kb
P08813766A0605|58 68|382 residues
P08813766A0605|96 112|consensus sequence
P08813766A0605|116 135|C2H2 zinc finger domain
P08813766A0605|116 135|C2H2 zinc finger domain
P08813766A0605|164 173|yeast Mig1p
P08813766A0605|164 173|yeast Mig1p
P08813766A0605|177 181|Cre-A
P08813766A0605|177 181|Cre-A
P08813766A0605|198 216|Emericella and E. coli
P08813766A0605|211 216|E. coli
P08813900A1088|6 12|phytase
P08813900A1088|6 12|phytase
P08813900A1088|16 17|nP
P08813900A1088|54 67|mineralization
P08813900A1088|96 104|bone cells
P08813900A1088|131 141|P deficiency
P08813900A1088|131 131|P
P08813900A1088|147 158|histological
P08813900A1088|181 186|tibias
P08814651A0000|56 77|ethanol withdrawal signs
P08814651A0000|83 85|rat
P08814651A0000|104 114|rating scale
P08814651A0000|126 149|acoustic startle paradigms
P08816052A0238|28 35|WISC-III
P08816052A0238|85 90|K-FAST
P08816052A0238|85 85|K
P08816052A0238|87 90|FAST
P08816052A0238|97 145|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|147 152|K-SNAP
P08816052A0238|147 152|K-SNAP
P08816438A0316|0 19|Quantitative analysis
P08816438A0316|22 28|plasmid
P08816438A0316|40 54|cdc28-1N strains
P08816438A0316|40 47|cdc28-1N
P08816438A0316|132 145|DNA replication
P08816438A0316|164 183|plasmid loss phenotype
P08816443A1674|8 28|multidomained ROK alpha
P08816443A1674|21 28|ROK alpha
P08816443A1674|69 80|cytoskeleton
P08816443A1674|89 100|N and C termini
P08816443A1674|109 137|positive and negative regulators
P08816443A1674|157 168|kinase domain
P08816443A1674|205 224|stress fibers and focal
P08816452A0936|51 53|p54
P08816452A0936|51 53|p54
P08816452A0936|74 82|SR protein
P08816452A0936|74 82|SR protein
P08816452A0936|111 129|alternative splicing
P08816452A0936|133 167|tissue- and substrate-dependent manner
P08816453A0000|14 28|cyclic AMP (cAMP)
P08816453A0000|14 22|cyclic AMP
P08816453A0000|24 27|cAMP
P08816453A0000|73 83|Raf-1 kinase
P08816453A0000|73 83|Raf-1 kinase
P08816459A0090|26 41|repression domain
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|77 81|N-CoR
P08816459A0090|77 81|N-CoR
P08816459A0090|86 96|corepressor
P08816459A0090|100 124|thyroid hormone receptor (TR
P08816459A0090|100 121|thyroid hormone receptor
P08816459A0090|123 124|TR
P08816459A0090|129 148|retinoic acid receptor
P08816459A0090|129 148|retinoic acid receptor
P08816459A0090|150 152|RAR
P08816459A0090|150 152|RAR
P08816460A1769|36 54|Jun kinase activation
P08816460A1769|36 44|Jun kinase
P08816460A1769|77 93|Ras transformation
P08816460A1769|77 79|Ras
P08816460A1769|122 126|Erk-2
P08816460A1769|122 126|Erk-2
P08816461A0892|23 27|Upf1p
P08816461A0892|23 27|Upf1p
P08816461A0892|89 100|mRNA turnover
P08816461A0892|104 122|nonsense suppression
P08816472T0000|16 19|Ste4
P08816472T0000|16 19|Ste4
P08816472T0000|43 46|Byr2
P08816472T0000|43 46|Byr2
P08816472T0000|52 72|sexual response pathway
P08816472T0000|75 98|Schizosaccharomyces pombe
P08816482A0234|27 31|Stat5
P08816482A0234|27 31|Stat5
P08816482A0234|33 38|Stat5a
P08816482A0234|33 38|Stat5a
P08816482A0234|42 47|Stat5b
P08816482A0234|42 47|Stat5b
P08816483A0869|0 8|Mutations
P08816483A0869|16 19|loci
P08816483A0869|21 24|SIC1
P08816483A0869|21 24|SIC1
P08816483A0869|26 29|SWI5
P08816483A0869|26 29|SWI5
P08816483A0869|34 37|RIC3
P08816483A0869|34 37|RIC3
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816498A0000|3 24|serine/threonine kinase
P08816498A0000|25 29|Raf-1
P08816498A0000|51 54|Rats
P08816498A0000|58 82|signal transduction cascade
P08816498A0000|97 112|mitogenic stimuli
P08816498A0000|120 133|plasma membrane
P08816498A0000|139 145|nucleus
P08816504T0000|0 47|Platelet-derived growth factor-dependent activation
P08816504T0000|0 27|Platelet-derived growth factor
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|108 136|SH2-domain-containing proteins
P08816504T0000|108 136|SH2-domain-containing proteins
P08816504T0000|151 161|Ras activity
P08816504T0000|151 153|Ras
P08816507A1125|26 28|E1A
P08816507A1125|26 28|E1A
P08816507A1125|56 66|p53 promoter
P08816507A1125|56 66|p53 promoter
P08816507A1125|80 85|12S E1A
P08816507A1125|80 85|12S E1A
P08816507A1125|111 116|13S E1A
P08816507A1125|111 116|13S E1A
P08816507A1125|135 137|YY1
P08816507A1125|135 137|YY1
P08816507A1125|148 163|composite element
P08816759A0000|3 23|retinoid Z receptor beta
P08816759A0000|3 23|retinoid Z receptor beta
P08816759A0000|25 32|RZR beta)
P08816759A0000|25 31|RZR beta
P08816759A0000|36 49|orphan receptor
P08816759A0000|36 49|orphan receptor
P08816759A0000|65 84|retinoic acid receptor
P08816759A0000|65 84|retinoic acid receptor
P08816759A0000|86 89|RAR)
P08816759A0000|86 88|RAR
P08816759A0000|91 115|thyroid hormone receptor (TR
P08816759A0000|91 112|thyroid hormone receptor
P08816759A0000|114 115|TR
P08816759A0000|128 143|nuclear receptors
P08816759A0000|128 143|nuclear receptors
P08816792A0000|0 25|DNA-dependent protein kinase
P08816792A0000|0 25|DNA-dependent protein kinase
P08816792A0000|27 33|DNA-PK)
P08816792A0000|27 32|DNA-PK
P08816792A0000|45 64|heterodimeric protein
P08816792A0000|45 64|heterodimeric protein
P08816792A0000|66 67|Ku
P08816792A0000|66 67|Ku
P08816792A0000|78 93|catalytic subunit
P08816792A0000|95 102|DNA-PKcs
P08816792A0000|95 102|DNA-PKcs
P08817323A0714|48 52|3' end
P08817323A0714|58 69|DXS6673E gene
P08817323A0714|58 69|DXS6673E gene
P08817323A0714|73 96|two expressed sequence tags
P08817323A0714|98 101|ESTs
P08817323A0714|116 120|5' end
P08817323A0714|126 137|DXS6673E gene
P08817323A0714|126 137|DXS6673E gene
P08817323A0714|147 149|EST
P08817324A1070|15 48|16p 11.1/Xq28 duplication breakpoints
P08817324A1070|83 123|immunoglobulin-like CAGGG pentamer sequences
P08817324A1070|83 123|immunoglobulin-like CAGGG pentamer sequences
P08818436A0557|46 51|gender
P08818436A0557|74 95|cardiovascular diseases
P08818436A0557|103 108|gender
P08818436A0557|142 146|death
P08818718A1229|50 66|bicistronic vector
P08818718A1229|78 94|cationic liposomes
P08818718A1229|99 111|recipient mice
P08818718A1229|123 126|MDR1
P08818718A1229|123 126|MDR1
P08818718A1229|130 136|GC cDNAs
P08818718A1229|132 136|cDNAs
P08820324A1699|27 29|DBS
P08820324A1699|33 44|TOF responses
P08820642A0173|3 25|harpin-encoding hrpZ gene
P08820642A0173|3 8|harpin
P08820642A0173|18 25|hrpZ gene
P08820642A0173|39 44|operon
P08820642A0173|60 62|Hrp
P08820642A0173|60 62|Hrp
P08820642A0173|122 129|hrp genes
P08820642A0173|139 150|cosmid pHIR11
P08820642A0173|185 199|Escherichia coli
P08820642A0173|203 224|Pseudomonas fluorescens
P08820642A0173|236 237|HR
P08820642A0173|240 252|tobacco leaves
P08820648A0123|33 55|ribonucleotide reductase
P08820648A0123|33 55|ribonucleotide reductase
P08820648A0123|60 78|nrdAB-encoded enzyme
P08820648A0123|60 78|nrdAB-encoded enzyme
P08820648A0123|124 145|nrdAB-defective mutants
P08820648A0123|124 145|nrdAB-defective mutants
P08820648A0123|186 191|oxygen
P08822208A1364|42 49|isoforms
P08822399A0518|64 72|pregnancy
P08822399A0518|77 92|normative factors
P08823163T0000|0 23|High-resolution structure
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|93 111|SH3-like third domain
P08823163T0000|93 95|SH3
P08823163T0000|138 146|phosphate
P08823163T0000|152 162|corepressor
P08823187A1020|0 8|Titration
P08823187A1020|14 28|human and porcine
P08823187A1020|41 67|2-nitro-5-thiosulfabenzoate
P08823187A1020|81 99|membrane dipeptidase
P08823187A1020|124 147|intrachain disulfide bonds
P08823260A1161|0 3|FEV1
P08823260A1161|29 36|patients
P08823260A1161|44 61|acute or chronic GVHD
P08823260A1161|87 94|patients
P08823260A1161|102 133|posttransplant pulmonary infection
P08823646A1012|16 25|adrenaline
P08823646A1012|61 64|SaO2
P08823646A1012|73 85|7 measurements
P08823709A0220|11 57|dietary modification and triglyceride lowering drugs
P08823709A0220|111 117|patient
P08824201A0270|0 7|Chernoff
P08824585A0260|13 30|novel protein kinase
P08824585A0260|18 30|protein kinase
P08824585A0260|38 67|hematopoietic progenitor kinase 1
P08824585A0260|38 67|hematopoietic progenitor kinase 1
P08824585A0260|69 72|HPK1
P08824585A0260|69 72|HPK1
P08824585A0260|105 122|hematopoietic cells
P08824585A0260|133 152|early progenitor cells
P08824798A0761|0 20|Human ESP1/CRP2 protein
P08824798A0761|0 20|Human ESP1/CRP2 protein
P08824798A0761|27 36|LIM domains
P08824798A0761|27 36|LIM domains
P08824798A0761|59 60|77
P08824798A0761|87 111|human cysteine-rich protein
P08824798A0761|92 111|cysteine-rich protein
P08824798A0761|113 115|CRP
P08824798A0761|113 115|CRP
P08824798A0761|120 126|rat CRIP
P08824798A0761|120 126|rat CRIP
P08824800A0808|42 66|agarose gel electrophoresis
P08824805A0832|75 84|p55 protein
P08824805A0832|75 84|p55 protein
P08824881A0133|0 13|Linkage studies
P08824881A0133|48 54|TSC gene
P08824881A0133|48 54|TSC gene
P08824881A0133|63 76|chromosome 9q34
P08824881A0133|89 95|16p13.3
P08824884A0000|3 23|cytogenetic expression
P08824884A0000|29 54|folate sensitive fragile site
P08824884A0000|56 60|FRAXE
P08824884A0000|56 60|FRAXE
P08824884A0000|84 92|GCC repeat
P08824884A0000|103 106|Xq28
P08824884A0000|112 127|human X chromosome
P08824884A0000|158 171|mental handicap
P08825087A0213|0 18|DNA sequence analysis
P08825087A0213|22 45|3213 bp BamHI-ClaI fragment
P08825087A0213|28 45|BamHI-ClaI fragment
P08825087A0213|63 79|open reading frames
P08825087A0213|81 84|ORFs
P08825087A0213|106 116|orientation
P08825178A0071|10 18|inpatient
P08825178A0071|47 59|HIV-related TB
P08825178A0071|47 59|HIV-related TB
P08825554A0000|0 14|Tristetraprolin
P08825554A0000|0 14|Tristetraprolin
P08825554A0000|16 18|TTP
P08825554A0000|16 18|TTP
P08825554A0000|25 33|prototype
P08825554A0000|100 114|CCCH zinc fingers
P08825556A0522|18 24|CREsp-a
P08825556A0522|26 33|TGACCTCA
P08825556A0522|63 83|palindromic CRE (CREpal
P08825556A0522|85 92|TGACGTCA
P08825556A0522|113 116|CREB
P08825556A0522|113 116|CREB
P08825556A0522|120 128|homodimer
P08825633A0304|10 24|human genomic DNA
P08825633A0304|34 51|intronless sequence
P08825633A0304|72 87|human G alpha q cDNA
P08825633A0304|72 82|human G alpha
P08825633A0304|84 87|cDNA
P08825636T0000|11 30|exon-intron structure
P08825636T0000|36 50|156-kb human gene
P08825636T0000|42 55|human gene NFKB1
P08825636T0000|51 55|NFKB1
P08825636T0000|72 81|p105 and p50
P08825636T0000|72 75|p105
P08825636T0000|79 81|p50
P08825636T0000|92 111|transcription factors
P08825636T0000|112 120|NF-kappa B
P08825636T0000|112 120|NF-kappa B
P08825636T0000|124 136|I kappa B-gamma
P08825636T0000|124 136|I kappa B-gamma
P08825636T0000|153 188|NF-kappa B-mediated signal transduction
P08825636T0000|153 161|NF-kappa B
P08825639A0827|10 25|Alu repeat element
P08825639A0827|43 55|direct repeats
P08825639A0827|85 93|-913/-620
P08825639A0827|108 114|cap site
P08827783A0499|3 6|ewes
P08828142A0000|0 20|Feline leukemia viruses
P08828142A0000|22 26|FeLVs
P08828142A0000|79 86|domestic
P08828142A0000|87 96|cat species
P08828142A0000|133 144|environments
P08828152A1238|15 32|amino acid sequences
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|56 59|IIV6
P08828152A1238|61 64|LCDV
P08828152A1238|69 73|MCV-1
P08828152A1238|94 104|prokaryotic
P08828152A1238|106 115|eukaryotic
P08828152A1238|120 132|viral proteins
P08828152A1238|120 132|viral proteins
P08828152A1238|154 172|amino acid similarity
P08828152A1825|3 6|RPO1
P08828152A1825|3 6|RPO1
P08828152A1825|9 12|LCDV
P08828152A1825|43 46|RPO1
P08828152A1825|43 46|RPO1
P08828152A1825|49 52|IIV6
P08828152A1825|87 115|eukaryotic polymerases II and III
P08828152A1825|87 109|eukaryotic polymerases II
P08828152A1825|129 149|archaebacteral subunit
P08828857A2423|15 21|GE cells
P08828857A2423|78 86|endocrine
P08828857A2423|88 96|paracrine
P08828857A2423|101 116|autocrine factors
P08828857A2423|138 151|gene expression
P08828857A2423|158 166|pregnancy
P08829393A0083|11 26|dipole estimation
P08829393A0083|29 50|spikes and SEP components
P08829393A0083|62 69|patients
P08831364A1252|4 12|verapamil
P08831364A1252|16 26|propranolol
P08831364A1252|56 64|adenosine
P08831364A1252|79 83|nodal
P08831364A1252|164 165|AV
P08831364A1252|166 175|nodal block
P08832146A0959|8 10|CBD
P08832146A0959|37 59|bone alkaline phosphatase
P08832146A0959|41 59|alkaline phosphatase
P08832146A0959|85 87|PTH
P08832146A0959|85 87|PTH
P08832146A0959|92 95|0.59
P08833153A0628|27 44|hCHLR gene sequences
P08833153A0628|27 44|hCHLR gene sequences
P08833153A0628|115 119|exons
P08833153A0628|153 175|carboxyl-terminal region
P08833153A0628|224 251|human telomeric repeat sequence
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0304|17 40|LIM domain homeobox protein
P08833653A0304|41 45|isl-1
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|81 107|fibroblast and islet cell lines
P08833653A0783|8 12|isl-1
P08833653A0783|8 12|isl-1
P08833653A0783|27 62|insulin and amylin gene promoter elements
P08833653A0783|27 33|insulin
P08833653A0783|37 46|amylin gene
P08833653A0783|171 190|heterologous promoter
P08833653A0783|209 225|InR1 -G9 islet cells
P08835393A2829|43 66|signal transduction events
P08835393A2829|73 91|calcium mobilization
P08835393A2829|96 119|promoter response elements
P08835393A2829|126 128|SRE
P08835895A1292|3 10|CD4 count
P08835895A1292|3 5|CD4
P08835895A1292|18 26|remission
P08835895A1292|43 64|severe immunodeficiency
P08835895A1292|80 100|AIDS-related infection
P08835969A0000|8 28|diagnostic laparoscopy
P08835969A0000|82 97|ectopic pregnancy
P08835969A0000|99 100|EP
P08835969A0000|108 143|high-resolution endovaginal sonography
P08835969A0000|173 183|serum assays
P08835969A0000|189 199|beta subunit
P08835969A0000|189 199|beta subunit
P08835969A0000|202 227|human chorionic gonadotropin
P08835969A0000|216 227|gonadotropin
P08835969A0000|229 236|beta-hCG
P08835969A0000|229 236|beta-hCG
P08835969A0000|273 275|EPs
P08836032T0000|0 14|Bifunctionality
P08836032T0000|20 49|AcMNPV homologous region sequence
P08836032T0000|20 49|AcMNPV homologous region sequence
P08836032T0000|51 54|hr1)
P08836032T0000|51 53|hr1
P08836032T0000|67 69|ori
P08836032T0000|92 111|sequence requirements
P08836172A1382|0 3|RVR '
P08836172A1382|0 2|RVR
P08836172A1382|58 82|dominant negative RVR delta E
P08836172A1382|74 82|RVR delta E
P08836172A1382|110 137|p21Cip1/Waf1 and myogenin mRNAs
P08836172A1382|110 116|p21Cip1
P08836172A1382|118 121|Waf1
P08836172A1382|125 137|myogenin mRNAs
P08836172A1382|143 157|serum withdrawal
P08836740A1025|7 10|CES1
P08836740A1025|7 10|CES1
P08836740A1025|14 17|CES4
P08836740A1025|14 17|CES4
P08836740A1025|32 41|cell growth
P08836740A1025|47 66|double deletion mutant
P08837503A0392|8 19|repeat motifs
P08837503A0392|94 100|SbHRGP3
P08837503A0392|94 100|SbHRGP3
P08837503A0392|138 149|repeat motifs
P08837503A0392|171 184|dicot extensins
P08837503A0392|171 184|dicot extensins
P08837746A0951|26 47|BrAAP activity catalyzed
P08838144A0107|53 62|PRL binding
P08838144A0107|53 55|PRL
P08838144A0107|66 83|signal transduction
P08838144A0107|102 111|S1 or/and S2
P08838144A0107|102 103|S1
P08838148A1218|7 26|heterologous cell line
P08838148A1218|40 55|mouse TRH receptor
P08838148A1218|45 47|TRH
P08838148A1218|86 105|nonexcitable 293 cells
P08838148A1218|116 131|L channel activity
P08838314A0129|50 53|V1aR
P08838314A0129|50 53|V1aR
P08838314A0129|71 92|genomic characteristics
P08838314A0129|94 109|tissue expression
P08838314A0129|111 133|chromosomal localization
P08838314A0129|158 170|human V1aR gene
P08838314A0129|158 170|human V1aR gene
P08838314A0129|172 177|AVPR1A
P08838314A0129|172 177|AVPR1A
P08838585A0968|71 77|ras-p21
P08838585A0968|75 77|p21
P08838805T0000|0 18|Genomic organization
P08838805T0000|24 44|human beta-catenin gene
P08838805T0000|24 40|human beta-catenin
P08838805T0000|46 51|CTNNB1
P08838805T0000|46 51|CTNNB1
P08839498A0507|45 58|lean tissue mass
P08839498A0507|72 75|legs
P08839498A0507|149 151|fat
P08839832A0729|17 28|CD30v protein
P08839832A0729|17 28|CD30v protein
P08839832A0729|45 61|cytoplasmic region
P08839832A0729|74 109|extracellular and transmembrane domains
P08839832A1220|0 26|Constitutive phosphorylation
P08839832A1220|32 43|CD30v protein
P08839832A1220|32 43|CD30v protein
P08839832A1220|61 75|in vitro labeling
P08839832A1220|80 84|[32P]
P08840501A0345|30 46|actin-related gene
P08840501A0345|30 46|actin-related gene
P08840501A0345|78 81|ACT4
P08840501A0345|78 81|ACT4
P08840506A0544|8 11|ORFs
P08840506A0544|75 80|G2850.
P08840506A0544|75 79|G2850
P08840997A0765|0 8|MVR typing
P08840997A0765|22 28|alleles
P08840997A0765|127 139|common alleles
P08840997A0765|145 154|5'-most end
P08842143A0000|7 12|pAL618
P08842143A0000|46 53|H2 uptake
P08842143A0000|55 57|hup
P08842143A0000|55 57|hup
P08842143A0000|63 93|Rhizobium leguminosarum bv. viciae
P08842143A0000|126 149|hupSLCDEFGHIJK-hypABFCDE
P08842143A0000|126 149|hupSLCDEFGHIJK-hypABFCDE
P08843411A0801|12 28|inactive receptors
P08843411A0801|58 82|transcriptional activation
P08843411A0801|86 97|dimerization
P08843411A0801|134 158|transcriptional activation
P08843412A0543|15 44|transferable 40-amino acid region
P08843412A0543|54 57|LBDs
P08843412A0543|54 57|LBDs
P08843412A0543|60 62|RXR
P08843412A0543|60 62|RXR
P08843412A0543|64 66|RAR
P08843412A0543|64 66|RAR
P08843412A0543|68 69|TR
P08843412A0543|68 69|TR
P08843412A0543|74 105|chicken ovalbumin upstream promoter
P08843412A0543|74 105|chicken ovalbumin upstream promoter
P08843412A0543|196 218|high-affinity DNA binding
P08843419A1290|0 2|OKA
P08843419A1290|29 56|OCFRE DNA-protein interactions
P08843419A1290|29 33|OCFRE
P08843419A1290|34 44|DNA-protein
P08843419A1290|81 107|protein-protein interactions
P08844448A0000|13 41|placebo-controlled, randomized
P08844448A0000|43 63|two-way crossover study
P08844448A0000|80 96|healthy volunteers
P08844448A0000|142 149|orlistat
P08844448A0000|152 182|gastrointestinal lipase inhibitor
P08844448A0000|152 173|gastrointestinal lipase
P08844448A0000|194 213|dietary fat absorption
P08844448A0000|236 248|weight control
P08844448A0000|276 284|vitamins A
P08844448A0000|288 289|E.
P08844577A0000|0 9|Tilmicosin
P08844577A0000|18 36|macrolide antibiotic
P08844577A0000|63 80|veterinary medicine
P08844712A0000|8 19|nitrous oxide
P08844712A0000|21 23|N2O
P08844712A0000|30 61|somatosympathetic A- and C-reflexes
P08844712A0000|94 103|ventilated
P08844712A0000|104 107|rats
P08844712A0000|124 139|alpha-chloralose
P08844712A0000|143 150|urethane
P08845378A0368|0 23|Restriction enzyme mapping
P08845378A0368|27 42|Southern analysis
P08845378A0368|66 79|human MZF-1 gene
P08845378A0368|71 79|MZF-1 gene
P08845378A0368|83 97|single-copy gene
P08846775A0110|14 17|Swi4
P08846775A0110|14 17|Swi4
P08846775A0110|21 37|Swi6 cell viability
P08846775A0110|21 24|Swi6
P08846775A0110|85 105|G1 cyclin encoding genes
P08846775A0110|85 105|G1 cyclin encoding genes
P08846775A0110|107 116|CLN1 or CLN2
P08846775A0110|107 110|CLN1
P08846775A0110|113 116|CLN2
P08847403T0000|7 13|embryos
P08847403T0000|26 33|patients
P08847403T0000|44 46|IVF
P08847723A2351|0 11|IMPLICATIONS
P08847723A2351|100 112|ovarian cancer
P08848013A1469|3 21|nonconsensus TATA box
P08848013A1469|24 32|promoter B
P08848013A1469|58 73|promoter activity
P08848013A1469|81 87|TATA box
P08848052A0733|27 30|Gle1
P08848052A0733|27 30|Gle1
P08848052A0733|35 50|RNA-export factor
P08848052A0733|58 60|Rev
P08848052A0733|58 60|Rev
P08848052A0733|71 84|viral RNA export
P08848052A0733|109 112|Gle1
P08848052A0733|109 112|Gle1
P08849208A1022|0 7|Demispan
P08849208A1022|55 61|elderly
P08849569A0615|0 12|Two techniques
P08849569A0615|99 106|cortisol
P08849778A0226|15 33|toeprinting analyses
P08849778A0226|36 43|repA mRNA
P08849778A0226|36 43|repA mRNA
P08849778A0226|46 54|plasmid R1
P08849778A0226|82 93|antisense RNA
P08849778A0226|82 93|antisense RNA
P08849778A0226|95 98|CopA
P08849778A0226|95 98|CopA
P08849778A0598|22 42|repA (initiator protein
P08849778A0598|22 25|repA
P08849778A0598|36 53|protein) expression
P08849778A0598|62 64|tap
P08849778A0598|66 78|leader peptide
P08849834A0000|0 6|A system
P08849834A0000|44 48|blood
P08849834A0000|52 57|vessel
P08849834A0000|75 114|transverse colour Doppler ultrasound imaging
P08850585A0602|3 18|enzyme activities
P08850585A0602|68 79|dental caries
P08850585A0602|103 118|virulence factors
P08851337A1092|0 12|Tonsillectomy
P08851337A1092|52 71|respiratory infection
P08851337A1092|82 95|angina patients
P08851434A0383|2 5|lean
P08851434A0383|6 9|mice
P08851434A0383|14 36|fat/water intensity ratio
P08851434A0383|64 73|normal mice
P08853303A0431|0 24|Pharmacokinetic parameters
P08853303A0431|67 77|intravenous
P08853303A0431|84 99|intraarterial (IA
P08853303A0431|154 164|MMC infusion
P08853303A0431|179 180|C1
P08853893A0158|36 47|E2F complexes
P08853893A0158|36 47|E2F complexes
P08853893A0158|64 102|senescent normal, human diploid fibroblasts
P08854459A0000|29 41|global pattern
P08854459A0000|44 53|casualties
P08854844A0637|43 44|GB
P08854844A0637|93 94|AC
P08854844A0637|93 94|AC
P08854844A0637|99 116|diagnostic accuracy
P08855804A1528|55 68|hypogonadal men
P08855804A1528|89 91|SLT
P08856077T0000|26 56|tryptophanyl-tRNA synthetase mRNA
P08856077T0000|26 52|tryptophanyl-tRNA synthetase
P08856077T0000|61 88|interferon-treated human cells
P08856077T0000|61 70|interferon
P08856132T0000|32 49|intra-uterine kinin
P08856132T0000|32 36|intra
P08856132T0000|37 56|-uterine kinin release
P08856132T0000|79 110|hypertonic saline-induced abortion
P08858211A0694|4 14|GAP activity
P08858211A0694|4 6|GAP
P08858211A0694|28 33|3T3-L1
P08858211A0694|34 49|adipocyte lysates
P08858211A0694|91 101|[alpha-32P]
P08858211A0694|102 104|GTP
P08858211A0694|112 119|GST-Rab4
P08858211A0694|112 114|GST
P08858211A0694|116 119|Rab4
P08858211A0694|124 137|[alpha-32P]GDP
P08858268A1307|17 32|chronic treatment
P08858268A1307|59 72|oral cilazapril
P08858268A1307|131 138|patients
P08858268A1307|143 145|CHF
P08858268A1307|148 150|CLZ
P08858268A1307|171 194|acute haemodynamic effects
P08858463A0853|17 20|AIDS
P08858463A0853|21 28|patients
P08858463A0853|33 46|cryptococcosis
P08858463A0853|59 65|ILd-AmB
P08861955A0927|18 31|RCC1-like motif
P08861955A0927|18 31|RCC1-like motif
P08861955A0927|44 57|amino-terminus
P08861955A0927|60 63|p619
P08861955A0927|60 63|p619
P08861955A0927|101 104|ARF1
P08861955A0927|101 104|ARF1
P08861955A0927|129 139|Rab proteins
P08861955A0927|129 139|Rab proteins
P08861955A0927|154 176|small GTP binding proteins
P08861955A0927|154 176|small GTP binding proteins
P08861955A0927|183 185|Ran
P08861955A0927|183 185|Ran
P08861955A0927|188 198|R-Ras2/TC21
P08861955A0927|188 193|R-Ras2
P08861955A0927|195 198|TC21
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|43 61|mutant alpha subunits
P08861963A0375b|43 61|mutant alpha subunits
P08861963A0375b|92 114|transcription activation
P08861963A0375b|117 124|cAMP-CRP
P08861963A0375b|117 124|cAMP-CRP
P08861963A0375b|131 145|rrnBP1 UP element
P08861963A0375b|131 145|rrnBP1 UP element
P08861963T0000|0 36|Transcription factor recognition surface
P08861963T0000|42 66|RNA polymerase alpha subunit
P08861963T0000|42 54|RNA polymerase
P08861963T0000|55 66|alpha subunit
P08861963T0000|93 110|DNA enhancer element
P08862522A0690|32 45|cdc28-P8 mutant
P08862522A0690|32 36|cdc28
P08862522A0690|38 45|P8 mutant
P08862522A0690|57 65|unspliced
P08862522A0690|81 102|restrictive temperature
P08862743A0603|11 23|erythrocyte Mn
P08863824A0509|10 25|sequence analyses
P08863824A0509|41 44|cDNA
P08863824A0509|50 54|95-nt
P08863824A0509|100 116|intracellular loop
P08863824A0509|129 147|transmembrane domain
P08863824A0509|153 160|5-HT2C-R
P08863824A0509|153 160|5-HT2C-R
P08864061A0000|12 30|thymidine kinase gene
P08864061A0000|12 30|thymidine kinase gene
P08864061A0000|33 55|normal human diploid cells
P08864219A0178|10 33|inhibitory concentrations
P08864219A0178|35 38|MICs
P08864219A0178|42 53|ketoconazole
P08864219A0178|94 106|amphotericin B
P08866485A0125|5 12|bacteria
P08866485A0125|73 104|mammalian cell regulatory molecules
P08867519A0557|23 26|LDEE
P08868473A1287|13 15|p28
P08868473A1287|13 15|p28
P08868473A1287|48 70|early embryonic cleavages
P08868473A1287|128 136|cell cycle
P08868660A0087|63 73|Rivista dell
P08868660A0087|143 151|strengths
P08868660A0087|155 161|novelty
P08868954A0648|36 56|antihypertensive drugs
P08868954A0648|99 116|calcium antagonists
P08868954A0648|123 159|angiotensin converting enzyme inhibitors
P08868954A0648|123 149|angiotensin converting enzyme
P08868954A0648|163 184|intrarenal hemodynamics
P08869358A0121|4 15|human viruses
P08869358A0121|62 70|apoptosis
P08869358A0121|73 91|virus-infected cells
P08869358A0121|97 114|virus-primed T cells
P08869763A0378|57 64|morphine
P08869763A0378|124 137|opioid receptor
P08869763A0378|148 155|migraine
P08869825A0000|34 64|flavin-containing monooxygenases
P08869825A0000|34 64|flavin-containing monooxygenases
P08869825A0000|66 68|FMO
P08869825A0000|66 68|FMO
P08869825A0000|85 105|tissue-specific manner
P08870266A0651|46 67|C-terminal 24 amino acids
P08870266A0651|84 96|NodO secretion
P08870266A0651|84 87|NodO
P08871542A1352|27 52|common regulatory mechanisms
P08871542A1352|90 107|Mtx minimal promoter
P08871542A1352|90 107|Mtx minimal promoter
P08871542A1352|134 152|Thbs3 gene expression
P08871542A1352|134 142|Thbs3 gene
P08871567A0000|0 11|MSSP proteins
P08871567A0000|0 11|MSSP proteins
P08871567A0000|48 62|upstream element
P08871567A0000|65 69|c-myc
P08871567A0000|65 69|c-myc
P08871567A0629|0 4|Gene 1
P08871635A0000|0 41|B cell antigen receptor (BCR)-induced apoptosis
P08871635A0000|0 19|B cell antigen receptor
P08871635A0000|21 23|BCR
P08871635A0000|47 71|WEHI-231 B lymphoma cell line
P08871635A0000|96 99|CD40
P08871635A0000|96 99|CD40
P08872162A0884|4 10|alleles
P08872162A0884|58 78|CD4+/CD8+ T cell subsets
P08872162A0884|58 61|CD4+
P08872162A0884|63 66|CD8+
P08872671A0573|24 45|blood flow shunt fraction
P08872671A0573|47 51|Qs/QT
P08872671A0573|75 89|oxygen sine-wave
P08872671A0573|142 149|arterial
P08872671A0573|153 169|mixed-venous blood
P08872671A0573|180 194|simple equations
P08873063A0493|10 26|amino acid sequence
P08873063A0493|29 34|LvUSF2
P08873063A0493|29 34|LvUSF2
P08873063A0493|54 59|LvUSF1
P08873063A0493|54 59|LvUSF1
P08873063A0493|71 78|amino end
P08873063A0875|0 12|ECM disruption
P08873063A0875|15 31|Lytechinus embryos
P08873063A0875|53 76|USF RNA accumulation levels
P08873063A0875|53 58|USF RNA
P08873063A0875|97 110|control embryos
P08873063A0875|117 123|LpS1 RNA
P08873063A0875|117 123|LpS1 RNA
P08873159A0791|16 23|patients
P08873159A0791|26 32|group II
P08873159A0791|51 62|chemotherapy
P08874399A0277|39 53|tetanic tensions
P08874399A0277|78 107|extracellular Ca2+ concentration
P08874399A0277|110 113|Ca]o
P08874399A0277|131 131|B
P08874631A1133|0 13|Discrimination
P08874631A1133|21 25|HIV-1
P08874631A1133|21 25|HIV-1
P08874631A1133|29 33|HIV-2
P08874631A1133|29 33|HIV-2
P08874631A1133|64 68|HIV-1
P08874631A1133|64 68|HIV-1
P08876167A0322|19 36|DNA-binding subunit
P08876167A0322|19 36|DNA-binding subunit
P08876167A0322|40 45|HiNF-D
P08876167A0322|40 45|HiNF-D
P08876167A0717|3 16|HiNF-D (CDP/cut
P08876167A0717|3 8|HiNF-D
P08876167A0717|10 12|CDP
P08876167A0717|14 16|cut
P08876167A0717|32 41|H4 promoter
P08876167A0717|32 41|H4 promoter
P08876167A0717|79 81|CDP
P08876167A0717|83 85|cut
P08876167A0717|89 91|pRB
P08876167A0717|89 91|pRB
P08876167A0717|98 101|p107
P08876167A0717|98 101|p107
P08876167A0717|113 126|CDP/cut complex
P08876167A0717|113 115|CDP
P08876167A0717|117 119|cut
P08876167A0717|132 149|nonhistone promoter
P08876167A0717|132 149|nonhistone promoter
P08876167A0717|151 159|gp91-phox
P08876167A0717|151 154|gp91
P08876167A0717|156 159|phox
P08876167A0717|175 177|CDP
P08876167A0717|175 177|CDP
P08876167A0717|181 194|p107 antibodies
P08876167A0717|181 184|p107
P08876701A0177|26 37|UmuC-homolog
P08876701A0177|26 37|UmuC-homolog
P08876701A0177|39 42|DinB
P08876701A0177|39 42|DinB
P08876701A0177|67 72|E. coli
P08877103A0081|22 35|mdr2 expression
P08877103A0081|22 25|mdr2
P08877103A0081|53 60|mdr2 gene
P08877103A0081|53 60|mdr2 gene
P08877103A0081|81 115|murine vinblastine-resistant cell line
P08877103A0081|117 118|J7
P08877103A0081|120 123|V2-1
P08877103A0081|120 123|V2-1
P08877818A0184|59 79|TRH progenitor sequence
P08877818A0184|59 61|TRH
P08877818A0184|72 84|sequence (Lys/
P08877818A0184|81 83|Lys
P08877818A0184|85 88|Arg-
P08877818A0184|85 87|Arg
P08877818A0184|89 112|Arg-Gln-His-Pro-Gly-Lys/
P08877818A0184|89 91|Arg
P08877818A0184|93 103|Gln-His-Pro
P08877818A0184|113 116|Arg-
P08877818A0184|117 119|Arg
P08878019A0357|3 28|intranodal mesothelial cells
P08878019A0357|54 63|lymph nodes
P08878019A0357|113 124|ovarian tumor
P08878037A0000|3 10|gene ccpA
P08878037A0000|3 10|gene ccpA
P08878037A0000|22 49|catabolite control protein CcpA
P08878037A0000|46 49|CcpA
P08878037A0000|52 72|Staphylococcus xylosus
P08878044A1390|2 19|InlC deletion mutant
P08878044A1390|2 19|InlC deletion mutant
P08878044A1390|32 40|virulence
P08878044A1390|80 103|intracellular replication
P08878044A1390|109 114|mutant
P08878044A1390|117 134|Caco-2 and J774 cells
P08878044A1390|169 183|wild-type strain
P08878045A0606|8 19|N-Nus complex
P08878045A0606|8 12|N-Nus
P08878045A0606|55 57|CTD
P08878045A0606|63 74|alpha subunit
P08878045A0606|63 74|alpha subunit
P08878045A0606|77 89|RNA polymerase
P08878045A0606|77 89|RNA polymerase
P08878045A0606|103 120|regulatory proteins
P08878045A0606|147 159|transcription
P08878573A1370|16 19|RIFA
P08878573A1370|51 53|ATO
P08878573A1370|126 129|mice
P08878573A1370|142 144|ATO
P08878573A1370|147 150|RIFA
P08879080A0265|10 14|ACOAs
P08879080A0265|84 92|LISREL VII
P08879237A0744|5 24|seven initiation sites
P08879237A0744|62 83|consensus promoter motif
P08879237A0744|99 107|CRTA motif
P08879237A0744|114 114|R
P08879237A0744|114 114|R
P08879237A0744|120 120|G
P08879237A0744|127 143|rice mitochondrion
P08880405A1170|14 15|SC
P08880405A1170|16 18|EPD
P08880405A1170|39 57|phenotypic selection
P08880405A1170|68 70|age
P08880405A1170|82 90|daughters
P08881036A0351|5 15|anchored PCR
P08881036A0351|18 26|VL element
P08881036A0351|18 19|VL
P08881036A0351|39 41|CL2
P08881036A0351|39 41|CL2
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08881542T0000|38 44|lithium
P08881542T0000|63 90|serum potassium concentrations
P08882492A0000|3 30|mammalian homeodomain proteins
P08882492A0000|3 30|mammalian homeodomain proteins
P08882492A0000|40 47|Hox genes
P08882492A0000|40 47|Hox genes
P08882492A0000|69 88|embryonic development
P08882492A0000|158 176|anteroposterior axis
P08882710A0000|0 30|Interferon stimulated gene factor 3
P08882710A0000|0 30|Interferon stimulated gene factor 3
P08882710A0000|32 37|ISGF3)
P08882710A0000|32 36|ISGF3
P08882710A0000|41 67|trimeric transcription factor
P08882710A0000|41 67|trimeric transcription factor
P08882710A0000|99 114|interferon-alpha
P08882710A0000|99 114|interferon-alpha
P08882710A0000|118 131|beta (type I IFNs
P08882710A0000|118 121|beta
P08882710A0000|123 131|type I IFNs
P08884273A1413|3 17|TYAC/P1 resource
P08884273A1413|29 32|STSs
P08884273A1413|96 112|telomere structure
P08884273A1413|147 167|genetic map integration
P08884273A1413|171 177|closure
P08884757A0653|48 67|Global Impression (CGI
P08884757A0653|102 125|Assessment Geriatric (SCAG
P08884757A0653|162 174|nurse's rating
P08884757A0653|177 193|geriatric patients
P08884757A0653|237 239|BGP
P08884757A0653|262 290|Short Cognitive Performance Test
P08884757A0653|292 307|Syndrom-Kurztest
P08885270A0428|48 51|PAO1
P08886845A1274|28 43|myogenin promoter
P08886845A1274|28 35|myogenin
P08886845A1274|76 77|Me
P08886845A1274|184 192|myoblasts
P08887643A1167|52 54|Ras
P08887643A1167|52 54|Ras
P08887643A1167|58 61|TC21
P08887643A1167|58 61|TC21
P08887643A1167|75 78|TC21
P08887643A1167|75 78|TC21
P08887643A1167|87 96|cell growth
P08887643A1167|108 149|Raf-independent downstream signaling pathways
P08887643A1167|108 110|Raf
P08887647T0000|0 16|Fission yeast mal2+
P08887647T0000|7 11|yeast
P08887647T0000|12 16|mal2+
P08887652A0341|43 53|DNA fragment
P08887652A0341|67 97|con-10 promoter-regulatory region
P08887652A0341|67 80|con-10 promoter
P08887652A0341|130 151|con-10 open reading frame
P08887652A0341|171 222|bacterial hygromycin B phosphotransferase structural gene
P08887652A0341|180 222|hygromycin B phosphotransferase structural gene
P08887652A0341|224 234|con10'-'hph
P08887652A0341|224 234|con10'-'hph
P08887659A0753|0 8|Mutations
P08887659A0753|31 36|serine
P08887659A0753|43 51|threonine
P08887661A0138|0 4|IRF-1
P08887661A0138|0 4|IRF-1
P08887661A0138|12 35|transcriptional activator
P08887661A0138|42 46|IRF-2
P08887661A0138|42 46|IRF-2
P08887661A1061|27 31|TFIIB
P08887661A1061|27 31|TFIIB
P08887661A1061|35 39|IRF-1
P08887661A1061|35 39|IRF-1
P08887661A1061|44 54|NIH 3T3 cells
P08887661A1061|66 89|dose-dependent repression
P08887661A1061|92 109|promoter activation
P08887661A1061|126 129|TATA
P08887667A0992|16 18|Tyr
P08887667A0992|22 38|dephosphorylation
P08887667A0992|42 56|spindle assembly
P08887667A0992|93 108|spindle formation
P08887667A0992|124 130|mitosis
P08887667A0992|162 176|Cdc28/Clb kinase
P08887667A0992|162 166|Cdc28
P08887667A0992|168 170|Clb
P08887667A0992|179 191|SPB separation
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|49 68|GGA trinucleotide core
P08887674A0630|86 107|Ets-responsive elements
P08887674A0630|86 107|Ets-responsive elements
P08887674A0920|38 61|cyclin D-dependent kinases
P08887674A0920|38 61|cyclin D-dependent kinases
P08887674A0920|80 102|transcriptional activity
P08887678A0000|15 36|proapoptotic protein Bax
P08887678A0000|15 33|proapoptotic protein
P08887678A0000|34 36|Bax
P08887678A0000|55 67|GAL10 promoter
P08887678A0000|55 67|GAL10 promoter
P08887678A0000|70 92|Saccharomyces cerevisiae
P08887678A0000|103 130|galactose-inducible cell death
P08890537A0355|28 35|patients
P08890537A0355|41 58|unicameral bone cyst
P08891131A0000|0 25|Enterococcus faecium strains
P08891131A0000|30 64|vanA-mediated glycopeptide resistance
P08891131A0000|79 95|enrichment culture
P08891131A0000|103 112|intestines
P08891131A0000|150 155|horses
P08891131A0000|159 162|dogs
P08891131A0000|200 203|pigs
P08891337A0614|3 22|amino-terminal region
P08891337A0614|25 27|E1A
P08891337A0614|25 27|E1A
P08891337A0614|40 66|high molecular weight proteins
P08891337A0614|81 106|transcriptional coactivator
P08891337A0614|117 120|p300
P08891337A0614|117 120|p300
P08891337A0614|127 155|homologous cAMP response element
P08891337A0614|137 155|cAMP response element
P08891337A0614|157 175|CRE)-binding protein
P08891337A0614|157 175|CRE)-binding protein
P08891341A0724|0 26|Transient transfection assays
P08891341A0724|32 53|reporter gene constructs
P08891341A0724|83 98|5' mdr1b sequences
P08891341A0724|83 98|5' mdr1b sequences
P08891341A0724|136 147|-247 to -126 bp
P08891341A0724|181 192|reporter gene
P08891341A0724|208 216|cell lines
P08891345A0684|13 17|5'UTR
P08891345A0684|34 57|testis-specific c-mos mRNA
P08891345A0684|49 57|c-mos mRNA
P08891345A0684|75 85|translation
P08891345A0684|112 122|transcripts
P08891345A0684|135 139|5'UTR
P08891345A0684|151 165|beta-globin mRNA
P08891345A0684|151 165|beta-globin mRNA
P08891345A0684|194 198|uORFs
P08891346A1217|38 54|isoform expression
P08891346A1217|56 66|NIH3T3 cells
P08891346A1217|87 112|eukaryotic expression vector
P08891346A1217|123 126|cDNA
P08891346A1217|130 134|FGF8a
P08891346A1217|130 134|FGF8a
P08891346A1217|136 140|FGF8b
P08891346A1217|136 140|FGF8b
P08891346A1217|144 148|FGF8e
P08891346A1217|144 148|FGF8e
P08891474A0667|27 27|F
P08891474A0667|121 131|nerve fibers
P08892755A0186|11 18|carp JAK1
P08892755A0186|15 18|JAK1
P08892755A0186|48 60|mammalian JAK1
P08892755A0186|48 56|mammalian
P08892755A0186|57 60|JAK1
P08892755A0186|70 94|kinase-like (JH2) and kinase
P08892755A0186|70 84|kinase-like (JH2
P08892755A0186|89 94|kinase
P08892755A0186|96 106|JH1) domains
P08892755A0186|96 98|JH1
P08892755A0981|8 18|DNA fragment
P08892755A0981|41 89|chloramphenicol acetyltransferase (CAT) reporter gene
P08892755A0981|41 72|chloramphenicol acetyltransferase
P08892755A0981|74 89|CAT) reporter gene
P08892755A0981|115 122|cell line
P08892755A0981|150 160|CAT enzyme 16
P08892755A0981|150 152|CAT
P08892755A0981|188 199|promoterless
P08892755A0981|200 209|pCAT-Basic
P08892755A0981|200 209|pCAT-Basic
P08892757T0000|0 15|Molecular cloning
P08892757T0000|18 22|Elk-3
P08892757T0000|18 22|Elk-3
P08892757T0000|39 47|Ets family
P08892757T0000|39 47|Ets family
P08892757T0000|63 80|mouse embryogenesis
P08892859A0563|21 59|MDV-transformed T-lymphoblastoid cell line
P08892859A0563|61 62|T9
P08892859A0563|87 107|truncated C-MYB protein
P08892859A0563|87 107|truncated C-MYB protein
P08892859A0563|119 132|RAV integration
P08892859A0563|142 152|c-myb allele
P08892859A0563|142 152|c-myb allele
P08893779A0229|0 29|Frozen/thawed extensor digitorum
P08893779A0229|195 202|anatomic
P08893779A0229|232 253|fascia-muscle interface
P08893779A0229|285 308|musculotendinous junction
P08893822A0560|0 15|Northern analysis
P08893822A0560|21 35|3.1-kb PWP2H cDNA
P08893822A0560|21 35|3.1-kb PWP2H cDNA
P08893822A0560|55 69|major transcript
P08893822A0560|95 111|human adult tissues
P08894144A0330|25 46|male Sprague-Dawley rats
P08894144A0330|89 91|CsA
P08894144A0330|107 108|FB
P08894144A0330|122 124|CsA
P08894144A0330|142 143|FB
P08894144A0330|175 176|FB
P08894144A0330|196 198|CsA
P08894144A0330|216 217|FB
P08894144A1173|0 2|CsA
P08894144A1173|26 37|bone turnover
P08894826A0228|102 113|HIV infection
P08894826A0228|115 126|genital warts
P08894826A0228|128 140|genital herpes
P08894826A0228|142 169|non-specific genital infection
P08894826A0228|190 197|syphilis
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|49 70|human trk proto-oncogene
P08895522T0000|49 70|human trk proto-oncogene
P08895522T0000|82 101|cell adhesion molecule
P08895579A0583|0 15|Northern blotting
P08895579A0583|26 29|MDMX
P08895579A0583|26 29|MDMX
P08895579A0583|35 38|MDM2
P08895579A0583|35 38|MDM2
P08895579A0583|84 88|mRNAs
P08895579A0583|92 95|MDMX
P08895579A0583|92 95|MDMX
P08896272A0000|3 20|nucleotide sequence
P08896272A0000|23 30|22,846 bp
P08896272A0000|36 56|left arm of chromosome IV
P08896280A0860|44 58|IME1 and IME2 mRNA
P08896280A0860|44 47|IME1
P08896280A0860|51 58|IME2 mRNA
P08896280A0860|111 131|nucleic acid metabolism
P08896280A0860|143 156|yvh1 disruption
P08896280A0860|143 146|yvh1
P08896402A0587|7 15|FL protein
P08896402A0587|36 50|stromal cell line
P08896402A0587|64 109|65 kD nondisulfide-linked homodimeric glycoprotein
P08896402A0587|121 132|30 kD subunits
P08896402A0587|154 172|N- and O-linked sugars
P08896473A0282|49 52|HHCA
P08896473A0282|61 78|serological factors
P08896473A0282|99 101|VGS
P08896590T0000|7 11|exons
P08896590T0000|14 31|adenovirus late RNAs
P08896590T0000|14 31|adenovirus late RNAs
P08896590T0000|46 50|snRNP
P08896590T0000|62 74|nuclear domain
P08896795A0166|5 16|Spurr's resin
P08896795A0166|20 33|mounting medium
P08896795A0166|107 116|coverslips
P08896795A0166|144 151|specimen
P08896804A0000|66 83|benzodiazepine (BDZ
P08896804A0000|107 115|RO19-4603
P08896804A0000|162 193|BDZ receptor antagonists flumazenil
P08896804A0000|162 172|BDZ receptor
P08896804A0000|195 201|ZK 93426
P08896804A0000|206 212|CGS 8216
P08896804A0000|235 256|bred alcohol-preferring
P08896804A0000|258 259|P)
P08896804A0000|300 306|ethanol
P08896804A0000|308 312|EtOH)
P08896804A0000|326 343|palatable saccharin
P08897663T0000|16 20|Babel
P08897663T0000|38 48|suicidology
P08897721A0000|13 39|Neisseria meningitidis group B
P08897721A0000|82 95|bacterial group
P08897721A0000|98 111|polysaccharide
P08898336A0268|0 22|RNase protection analysis
P08898336A0268|0 4|RNase
P08898336A0268|28 40|rRNA fragments
P08898336A0268|82 104|polycistronic transcript
P08898336A0268|149 157|small RNAs
P08898365A0274|0 4|Rss1p
P08898365A0274|0 4|Rss1p
P08898365A0274|18 33|essential protein
P08898365A0274|36 48|538 amino acids
P08898365A0274|117 136|nuclear pore complexes
P08898365A0274|138 141|NPCs
P08898365A0274|151 159|cytoplasm
P08898866A0458|9 43|regulatory serine phosphorylation site
P08898866A0458|56 85|baculovirus-mediated expression
P08898866A0458|95 112|wild-type annexin II
P08898866A0458|104 112|annexin II
P08898866A0458|128 143|annexin II mutants
P08898866A0458|128 143|annexin II mutants
P08898866A0458|182 195|serine residues
P08898866A0458|208 223|N-terminal domain
P08898866A0458|208 223|N-terminal domain
P08898893A0202|3 11|PAI-2 gene
P08898893A0202|3 7|PAI-2
P08898893A0202|26 44|TNF-responsive genes
P08898893A0202|77 88|phorbol ester
P08898893A0202|89 117|phorbol 12-myristate 13-acetate
P08898893A0202|119 121|PMA
P08898893A0202|129 148|phosphatase inhibitor
P08898893A0202|150 160|okadaic acid
P08898893A0202|168 210|HT-1080 fibrosarcoma and U-937 histiocytic cells
P08898916A0791|0 10|220, 263-273
P08899719A0318|33 49|open reading frames
P08899719A0318|51 54|ORFs
P08899719A0318|71 77|operons
P08899719A0318|81 84|ORFs
P08899719A0318|106 124|reasonable certainty
P08900164A0188|0 0|T
P08900190A0430|0 12|Growth factors
P08900190A0430|37 62|immediate early gene products
P08900190A0430|37 62|immediate early gene products
P08900190A0430|63 84|MAP kinase phosphatase-1
P08900190A0430|63 84|MAP kinase phosphatase-1
P08900190A0430|86 90|MKP-1
P08900190A0430|86 90|MKP-1
P08900190A0430|93 97|c-Fos
P08900190A0430|93 97|c-Fos
P08900190A0430|101 105|c-Jun
P08900190A0430|101 105|c-Jun
P08900296A0000|18 27|E-selectin
P08900296A0000|18 27|E-selectin
P08900296A0000|37 53|adhesion molecules
P08900296A0000|108 127|inflammatory response
P08901135A1132|3 13|NIT2 protein
P08901135A1132|3 13|NIT2 protein
P08901135A1132|27 32|nuclei
P08901135A1132|59 77|cytoplasmic fraction
P08901135A1132|96 103|nitrogen
P08901135A1132|118 125|nitrogen
P08901135A1132|169 172|NIT2
P08901135A1132|169 172|NIT2
P08901635A0000|68 73|enzyme
P08901635A0000|102 110|cellulose
P08901635A0000|115 134|major cell wall polymer
P08901635A0000|137 142|plants
P08901658A0498|0 16|Vascular responses
P08901658A0498|19 35|reactive hyperemia
P08901658A0498|41 52|flow increase
P08901658A0498|62 90|endothelium-dependent dilation
P08901658A0498|107 124|glyceryl trinitrate
P08901658A0498|126 128|GTN
P08901658A0498|130 160|endothelium-independent dilation
P08902214A1486|52 54|PRL
P08902214A1486|52 54|PRL
P08902214A1486|101 111|Stat factors
P08902214A1486|101 111|Stat factors
P08902548A0144|0 28|Intraperitoneal administration
P08902548A0144|31 60|L-5-hydroxytryptophan (L-5-HTP)
P08902548A0144|31 59|L-5-hydroxytryptophan (L-5-HTP
P08902548A0144|102 111|defecation
P08902548A0144|114 117|mice
P08902641A0930|5 14|VA-SMV mode
P08902641A0930|61 66|LV apex
P08902641A0930|68 73|inflow
P08902641A0930|80 93|ascending aorta
P08902641A0930|95 101|outflow
P08902641A0930|116 118|DAo
P08902847A1946|147 159|hCG alpha 1 beta
P08902847A1946|147 159|hCG alpha 1 beta
P08902847A1946|242 246|rehCG
P08902847A1946|242 246|rehCG
P08902847A1946|251 253|4.6
P08902988A0258|0 12|Factor V Leiden
P08902988A0258|62 77|venous thrombosis
P08903339A0264|32 57|complete secondary structure
P08903339A0264|62 71|RNA spliced
P08905819A0531|52 57|cancer
P08906056A1290|39 55|pulmonary function
P08906056A1290|59 75|nutritional status
P08906139A2935|42 48|calcium
P08906139A2935|52 70|alkaline phosphatase
P08906139A2935|52 70|alkaline phosphatase
P08906139A2935|101 114|vitamin D intake
P08909546A0810|15 18|PEA2
P08909546A0810|15 18|PEA2
P08909546A0810|39 59|bipolar budding pattern
P08910292T0000|0 8|Signaling
P08910292T0000|16 39|small GTP-binding proteins
P08910292T0000|16 39|small GTP-binding proteins
P08910292T0000|40 43|Rac1
P08910292T0000|40 43|Rac1
P08910292T0000|47 51|Cdc42
P08910292T0000|47 51|Cdc42
P08910292T0000|57 114|c-Jun N-terminal kinase/stress-activated protein kinase pathway
P08910292T0000|57 77|c-Jun N-terminal kinase
P08910292T0000|79 107|stress-activated protein kinase
P08910373A0315|0 16|Percent identities
P08910373A0315|22 29|mouse PP2
P08910373A0315|22 29|mouse PP2
P08910373A0315|32 46|mouse Y1, mouse Y4
P08910373A0315|32 38|mouse Y1
P08910373A0315|45 46|Y4
P08910373A0315|48 50|PP1
P08910373A0315|48 50|PP1
P08910373A0315|54 69|human Y2 receptors
P08910373A0315|54 69|human Y2 receptors
P08910550A0501|0 10|Correlating
P08910550A0501|41 43|CBF
P08910550A0501|41 43|CBF
P08910550A0501|56 63|78C1 site
P08910550A0501|76 79|EGTA
P08910550A0501|83 86|EDTA
P08910550A0501|137 162|78C1-directed transcription
P08910567A2269|3 19|human gene fragment
P08910567A2269|39 57|rat liver glucokinase
P08910567A2269|39 46|rat liver
P08910567A2269|84 91|enhancer
P08910567A2269|97 124|hepatocyte transfection system
P08912232A0260|15 16|ML
P08912232A0260|15 16|ML
P08912232A0260|19 39|human reproductive axis
P08912232A0260|44 58|healthy children
P08912807A0411|11 31|truncated deer receptor
P08912807A0411|20 31|deer receptor
P08912807A0411|54 68|tyrosine residue
P08912807A0411|74 92|intracellular domain
P08912807A0411|139 157|beta-casein promoter
P08912807A0411|139 157|beta-casein promoter
P08913186A0431|39 43|riMLF
P08913186A0431|58 65|downgaze
P08913186A0431|126 144|retraction nystagmus
P08913387A1010|0 8|Rifabutin
P08913974A0533|23 25|EPs
P08913974A0533|30 34|tubal
P08913974A0533|47 51|tubes
P08913974A0533|65 81|pathologic changes
P08913974A0533|92 109|chronic salpingitis
P08913974A0533|120 140|follicular salpingitis
P08914388A1645|18 20|7 H 9
P08914388A1645|87 113|CS-940* and sparfloxacin (SPFX
P08914388A1645|126 133|AM-1155*
P08914388A1645|126 133|AM-1155*
P08914388A1645|135 147|ciprofloxacin
P08914388A1645|149 152|CPFX
P08914388A1645|155 166|levofloxacin
P08914388A1645|168 171|LVFX
P08914388A1645|174 183|OPC-17116*
P08914388A1645|185 190|NM-394
P08914522A0118|3 11|STE20 gene
P08914522A0118|3 11|STE20 gene
P08914522A0118|21 34|a protein kinase
P08914522A0118|22 34|protein kinase
P08914522A0118|55 72|signal transduction
P08914522A0118|118 126|high-gene
P08914522A0118|163 175|G beta mutation
P08914522A0118|163 175|G beta mutation
P08914532A0598|22 64|(1-->4)-beta-xylan endohydrolase isoenzyme X-I
P08914532A0598|22 23|(1
P08914532A0598|27 64|4)-beta-xylan endohydrolase isoenzyme X-I
P08915051T0000|0 23|Magnetic resonance imaging
P08915051T0000|26 46|coccidioidal arthritis
P08915508A0000|0 25|Moloney murine leukemia virus
P08915508A0000|27 30|MMLV
P08915508A0000|54 70|retroviral vectors
P08915508A0000|107 109|Tat
P08915508A0000|107 109|Tat
P08915508A0000|111 140|trans-activator of transcription
P08915508A0000|111 125|trans-activator
P08915508A0000|168 194|hammerhead ribozymes targeted
P08915508A0000|235 246|group antigen
P08915508A0000|235 246|group antigen
P08915508A0000|248 250|Gag
P08915508A0000|248 250|Gag
P08915508A0000|253 260|protease
P08915508A0000|262 264|Pro
P08915508A0000|262 264|Pro
P08915508A0000|267 289|reverse transcriptase (RT
P08915508A0000|267 286|reverse transcriptase
P08915508A0000|288 289|RT
P08915508A0000|292 306|tat, and envelope
P08915508A0000|292 294|tat
P08915508A0000|299 306|envelope
P08915508A0000|308 310|Env
P08915508A0000|308 310|Env
P08915508A0000|312 324|coding regions
P08915508A0000|327 358|human immunodeficiency virus type-1
P08915508A0000|327 358|human immunodeficiency virus type-1
P08915508A0000|360 364|HIV-1
P08915508A0000|360 364|HIV-1
P08915559A0366|0 18|REM sleep deprivation
P08915559A0366|39 55|platform technique
P08916928A0950|51 93|PDGF-BB-dependent [3H]thymidine incorporation
P08916928A0950|51 57|PDGF-BB
P08916928A0950|96 103|PAE cells
P08916928A0950|117 134|PDGF beta-receptors
P08916928A0950|117 124|PDGF beta
P08916960A0350|10 21|serial biopsy
P08916960A0350|40 47|patients
P08916960A0350|52 53|FL
P08916960A0350|57 76|secondary alterations
P08916960A0350|82 100|rearranged bcl-2 gene
P08916960A0350|92 100|bcl-2 gene
P08916960A0350|119 134|open reading frame
P08916960A0350|136 146|ORF) regions
P08916960A1331|23 24|FL
P08916960A1331|28 35|DLL cells
P08916960A1331|55 72|bcl-2 gene sequences
P08916960A1331|55 72|bcl-2 gene sequences
P08916960A1331|126 134|bcl-2 gene
P08916960A1331|126 134|bcl-2 gene
P08916960A1331|145 165|t(14; 18) translocation
P08916960A1331|145 148|t(14
P08916960A1331|199 205|FL cells
P08917270A0229|30 31|QT
P08917270A0229|33 35|QTc
P08917270A0229|82 96|ischemic disease
P08917270A0229|127 140|long QT syndrome
P08917435A0481|17 21|c-Jun
P08917435A0481|17 21|c-Jun
P08917435A0481|25 29|c-Fos
P08917435A0481|25 29|c-Fos
P08917435A0481|32 66|basal and PMA-stimulated transcription
P08917435A0481|72 80|PAI-1 gene
P08917435A0481|72 76|PAI-1
P08917435A0481|120 153|c-jun and c-fos oligodeoxynucleotides
P08917435A0481|120 124|c-jun
P08917435A0481|128 132|c-fos
P08917435A0481|181 183|PMA
P08917435A0481|195 208|PAI-1 synthesis
P08917435A0481|195 199|PAI-1
P08917449A0000|0 24|Leukemia-inhibitory factor
P08917449A0000|0 24|Leukemia-inhibitory factor
P08917449A0000|26 28|LIF
P08917449A0000|26 28|LIF
P08917449A0000|33 44|neuropoietin
P08917449A0000|123 141|neuronal populations
P08917696A0485|12 39|mechanism of fos/jun activation
P08917696A0485|23 29|fos/jun
P08917696A0485|42 45|TCDD
P08917696A0485|56 83|electrophoretic mobility shift
P08917696A0485|87 111|transient expression assays
P08917696A0485|114 135|reporter gene constructs
P08917696A0485|165 201|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|203 205|TRE
P08917696A0485|208 212|serum
P08917696A0485|214 216|SRE
P08917696A0485|219 226|cAMP (CRE
P08917696A0485|232 251|aromatic hydrocarbons
P08917696A0485|253 256|AhRE
P08917696A0485|265 278|fos and jun genes
P08917696A0485|265 278|fos and jun genes
P08917696A0485|289 309|firefly luciferase gene
P08917696A0485|289 309|firefly luciferase gene
P08917696A0485|330 348|SV40 minimal promoter
P08917696A0485|330 348|SV40 minimal promoter
P08918456A0455|3 17|optimal sequence
P08918456A0455|36 38|mu 2
P08918456A0455|36 38|mu 2
P08918456A0455|46 49|AP-2
P08918456A0455|46 49|AP-2
P08918456A0455|65 88|anchor and prefers arginine
P08918456A0455|91 101|position Y + 2
P08918456A0455|105 111|leucine
P08918456A0455|114 124|position Y + 3
P08918464A0225|0 32|STK/RON-expressing Ba/F3 pro-B cells
P08918464A0225|0 2|STK
P08918464A0225|4 6|RON
P08918464A0225|18 19|Ba
P08918464A0225|21 27|F3 pro-B
P08918464A0225|34 40|BaF/STK
P08918464A0225|34 36|BaF
P08918464A0225|38 40|STK
P08918464A0225|51 69|MSP-dependent growth
P08918464A0225|78 121|STK/ RON-expressing mouse erythroleukaemia cells
P08918464A0225|78 80|STK
P08918464A0225|82 84|RON
P08918464A0225|123 129|MEL/ STK
P08918464A0225|123 125|MEL
P08918464A0225|127 129|STK
P08918464A0225|140 159|MSP-induced apoptosis
P08918810A0967|7 24|DNase I footprinting
P08918810A0967|7 12|DNase I
P08918810A0967|35 44|OxyR-C199S
P08918810A0967|35 44|OxyR-C199S
P08918810A0967|54 57|Pmom
P08918810A0967|63 70|104 to -46
P08918810A0967|76 84|top strand
P08918810A0967|137 149|wild-type OxyR
P08918810A0967|146 149|OxyR
P08918885A0811|0 3|Kss1
P08918885A0811|0 3|Kss1
P08918885A0811|24 37|GST-Dig1 fusion
P08918885A0811|24 31|GST-Dig1
P08918885A0811|60 71|yeast protein
P08918885A1087|11 23|dig1 dig2 cells
P08918885A1087|11 14|dig1
P08918885A1087|15 18|dig2
P08918885A1087|63 87|dig1 dig2 ste12 triple mutant
P08918885A1087|63 66|dig1
P08918885A1087|67 70|dig2
P08918885A1087|71 75|ste12
P08918885A1087|110 113|Dig1
P08918885A1087|110 113|Dig1
P08918885A1087|117 120|Dig2
P08918885A1087|117 120|Dig2
P08918885A1087|164 176|growth pathway
P08918918T0000|0 18|Paracrine activation
P08918918T0000|24 39|HIV-1 LTR promoter
P08918918T0000|24 31|HIV-1 LTR
P08918918T0000|45 59|viral Tat protein
P08918918T0000|45 59|viral Tat protein
P08918934A0424|29 46|xFxFG repeat regions
P08918934A0424|49 51|p62
P08918934A0424|49 51|p62
P08918934A0424|55 59|Nsplp
P08918934A0424|73 76|NTF2
P08918934A0424|73 76|NTF2
P08918934A0424|106 129|phenylalanine-containing
P08918934A0424|168 185|hydrophilic linkers
P08919289A0402|47 49|MFH
P08919289A0402|66 84|renal capsular tissue
P08919289A0402|104 119|inferior vena cava
P08919907A0763|0 18|Transient expression
P08919907A0763|21 25|VSF-1
P08919907A0763|21 25|VSF-1
P08919907A0763|28 71|protoplasts stimulated vs-1 dependent activation
P08919907A0763|49 101|vs-1 dependent activation of the -76/grp1.8 minimal promoter
P08919907A0763|77 101|-76/grp1.8 minimal promoter
P08919986A1262|0 6|Keeping
P08921387A1182|13 16|cDNA
P08921387A1182|56 59|EZH1
P08921387A1182|56 59|EZH1
P08921387A1182|64 85|tandemly linked gene GPR2
P08921387A1182|82 85|GPR2
P08921387A1182|131 141|EZH1 protein
P08921387A1182|131 141|EZH1 protein
P08921387A1182|156 171|C-terminal domain
P08921387A1182|156 171|C-terminal domain
P08921667A0294|62 63|Vd
P08921667A0294|140 155|normal volunteers
P08921865A1293|32 50|(ss) DNA binding motif
P08921865A1293|33 50|ss) DNA binding motif
P08921865A1293|71 87|terminase proteins
P08921865A1293|92 95|gp17
P08921865A1293|92 95|gp17
P08921865A1293|134 145|ssDNA regions
P08922344A1539|22 41|normotensive subjects
P08922344A1539|43 50|uric acid
P08922344A1539|54 68|xanthine oxidase
P08922344A1539|54 68|xanthine oxidase
P08922344A1539|99 111|blood pressure
P08922344A1539|177 188|hypertension
P08922384A0466|25 43|recombinant proteins
P08922384A0466|25 43|recombinant proteins
P08922384A0466|51 71|monoclonal 08L antibody
P08922384A0466|51 71|monoclonal 08L antibody
P08922384A0466|84 93|08L epitope
P08922384A0466|84 86|08L
P08922384A0466|99 109|carboxyl end
P08922385A0622|77 102|beta-galactosidase tetramer
P08922385A0622|77 94|beta-galactosidase
P08922385A0622|108 120|fusion subunit
P08922390A0361|25 58|vinculin- and FAK-interaction domains
P08922390A0361|25 32|vinculin
P08922390A0361|37 58|FAK-interaction domains
P08922390A0361|61 68|paxillin
P08922390A0361|61 68|paxillin
P08922390A0361|94 101|paxillin
P08922390A0361|94 101|paxillin
P08922390A0793|34 50|single binding site
P08922390A0793|54 61|vinculin
P08922390A0793|76 87|binding sites
P08922390A0793|91 93|FAK
P08922390A0793|91 93|FAK
P08922390A2076|24 31|paxillin
P08922390A2076|24 31|paxillin
P08922390A2076|43 56|focal adhesions
P08922390A2076|86 93|vinculin
P08922390A2076|100 102|FAK
P08922390A2076|100 102|FAK
P08922390A2076|150 159|LIM domains
P08922390A2076|150 159|LIM domains
P08922390A2076|226 239|focal adhesions
P08922391A0304|1 33|single protease-resistant structure
P08922391A0304|59 73|PDZ repeats 1 and 2
P08922391A0304|59 69|PDZ repeats 1
P08922391A0304|73 73|2
P08922391A0304|75 80|PDZ1-2
P08922391A0304|75 80|PDZ1-2
P08922391A0304|93 114|protein 4.1-binding site
P08922391A0304|103 114|-binding site
P08922488A0187|53 68|toxic side effects
P08923258A0353|0 6|Jerseys
P08923258A0353|23 24|Cu
P08923258A0353|46 54|Holsteins
P08923258A0353|58 63|60 (346
P08923460A0565|0 9|RUSH-1 beta
P08923460A0565|0 9|RUSH-1 beta
P08923460A0565|37 47|RUSH-1 alpha
P08923460A0565|37 47|RUSH-1 alpha
P08923460A0565|90 93|exon
P08923460A0565|107 120|genomic cloning
P08923469A1391|57 77|RXR heterodimer binding
P08923469A1391|57 59|RXR
P08923469A1391|80 111|bipartite hormone response elements
P08923469A1391|120 122|VDR
P08923469A1391|120 122|VDR
P08923470A0458|0 12|PPAR gamma mRNA
P08923470A0458|0 12|PPAR gamma mRNA
P08923470A0458|42 58|TNF alpha treatment
P08923470A0458|42 49|TNF alpha
P08924211A0941|0 7|Exons III
P08924211A0941|10 13|VIII
P08924211A0941|46 65|3' untranslated region
P08924211A0941|97 99|PST
P08924211A0941|97 99|PST
P08924211A0941|102 109|AST cDNAs
P08924211A0941|102 104|AST
P08924381T0000|0 11|Growth factor
P08924381T0000|58 77|breast cancer patients
P08925545T0001|0 24|Recombinant erythropoietin
P08925545T0001|11 24|erythropoietin
P08925545T0001|26 32|r-HuEPO
P08925545T0001|26 32|r-HuEPO
P08925545T0001|50 55|anemia
P08925545T0001|58 72|multiple myeloma
P08927169A0178|29 36|body lice
P08927169A0178|61 68|patients
P08927169A0178|120 126|Utrecht
P08927612T0000|0 5|Ki-ras
P08927612T0000|0 5|Ki-ras
P08927612T0000|9 20|p53 mutations
P08927612T0000|9 11|p53
P08927612T0000|33 52|ductal adenocarcinoma
P08927841A0053|69 84|sporting activity
P08929089A0231|69 83|metabolic demand
P08929563T0000|0 15|Rat liver catalase
P08929563T0000|0 7|Rat liver
P08929563T0000|8 15|catalase
P08929563T0000|42 61|C-terminal tripeptide
P08929563T0000|62 72|Ala-Asn-Leu
P08929563T0000|82 100|internal Ser-Lys-Leu
P08931388A0806|3 20|mobility shift assay
P08931388A0806|26 27|65
P08931388A0806|53 66|nuclear extract
P08931388A0806|74 91|dark-adapted sample
P08931388A0806|110 113|band
P08931991A1026|34 36|E2F
P08931991A1026|34 36|E2F
P08931991A1026|41 70|E2F-related transcription factor
P08931991A1026|41 70|E2F-related transcription factor
P08931991A1026|98 122|nonmuscle myosin expression
P08931991A1026|98 112|nonmuscle myosin
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|41 61|squelshing experiments
P08932363A0807|73 93|CBP-induced activation
P08932363A0807|73 75|CBP
P08932363A0807|96 99|E2F1
P08932363A0807|96 99|E2F1
P08932363A0807|101 103|DP1
P08932363A0807|101 103|DP1
P08932363A0807|114 122|E1A mutant
P08932363A0807|114 122|E1A mutant
P08932363A0807|130 146|CBP binding ability
P08932363A0807|130 132|CBP
P08932385T0000|0 15|Small Maf proteins
P08932385T0000|0 7|Small Maf
P08932385T0000|31 54|human transcription factor
P08932385T0000|31 54|human transcription factor
P08932385T0000|55 71|TCF11/Nrf1/LCR-F1
P08932385T0000|55 59|TCF11
P08932385T0000|61 64|Nrf1
P08932385T0000|66 71|LCR-F1
P08933487A0325|18 22|water
P08933487A0325|50 52|run
P08933640A0000|46 64|sweetener erythritol
P08933640A0000|102 108|rabbits
P08934533A0784|44 60|junB 5' flanking DNA
P08934533A0784|44 47|junB
P08934533A0784|67 75|chromatin
P08934540A0673|3 21|nm23-H1/nm23-H2 gene
P08934540A0673|3 9|nm23-H1
P08934540A0673|11 21|nm23-H2 gene
P08934540A0673|70 77|cell line
P08935931A0787|11 43|Intravenous diazepam administration
P08935931A0787|50 52|EGD
P08935931A0787|79 82|SpO2
P08935931A0787|145 148|SpO2
P08935931A0787|167 169|EGD
P08935991A0844|3 29|nucleotide sequence alignment
P08935991A0844|37 41|mouse
P08935991A0844|45 53|human CA IV
P08935991A0844|45 53|human CA IV
P08935991A0844|98 108|exon-intron
P08935991A0844|150 156|introns
P08936128A0611|0 10|Discordance
P08936128A0611|16 28|cost dimension
P08936128A0611|53 55|G Hb
P08936128A0611|53 55|G Hb
P08936128A0611|73 87|glycemic control
P08936640A0105|110 119|lung cancer
P08937631A1223|0 18|Histological changes
P08937631A1223|37 50|cell involution
P08937631A1223|54 63|hemorrhage
P08937631A1223|82 95|neonatal period
P08937631A1223|155 165|vasculature
P08937981A0840|31 39|p46 and p54
P08937981A0840|31 33|p46
P08937981A0840|37 39|p54
P08937981A0840|91 93|p46
P08937981A0840|91 93|p46
P08937981A0840|107 109|p46
P08937981A0840|107 109|p46
P08937981A0840|131 137|nucleus
P08937981A0840|153 155|p54
P08937981A0840|153 155|p54
P08937989A1365|37 58|N- and C-terminal regions
P08937989A1365|37 58|N- and C-terminal regions
P08937989A1365|61 65|talin
P08937989A1365|70 74|actin
P08937989A1365|70 74|actin
P08938418A0099|0 3|Merr
P08938418A0099|6 18|embryo library
P08938420A0862|21 24|LHA4
P08938420A0862|21 24|LHA4
P08938420A0862|28 36|LHA2 mRNAs
P08938420A0862|28 36|LHA2 mRNAs
P08938420A0862|61 75|exogenous sugars
P08938420A0862|157 173|3-O-methylglucose
P08938420A0862|188 203|mRNA accumulation
P08939891A0285|8 28|yeast one-hybrid screen
P08939891A0285|43 59|NRE and flanking DNA
P08939891A0285|103 105|Nrl
P08939891A0285|103 105|Nrl
P08939966A0816|11 26|protein synthesis
P08939966A0816|46 58|embryogenesis
P08939966A0816|68 72|SEC-1
P08939966A0816|68 72|SEC-1
P08939966A0816|79 109|cognate mRNA decline precipitously
P08940132A1120|24 40|fodrin proteolysis
P08940132A1120|24 29|fodrin
P08940132A1120|78 95|ICE/Ced-3 proteases
P08940132A1120|78 95|ICE/Ced-3 proteases
P08940132A1120|121 128|DEVD-CHO
P08940132A1120|161 165|CPP32
P08940132A1120|161 165|CPP32
P08940132A1120|171 187|ICE/Ced-3 protease
P08940132A1120|171 187|ICE/Ced-3 protease
P08940132A1120|205 209|CPP32
P08940132A1120|205 209|CPP32
P08940132A1120|212 219|DEVD-CHO
P08940134A0705|2 4|3Y1
P08940134A0705|8 38|3Y1 v-crk-transformed fibroblasts
P08940134A0705|11 15|v-crk
P08940134A0705|59 63|PTP1B
P08940134A0705|59 63|PTP1B
P08940134A0705|82 85|p130
P08940134A0705|82 85|p130
P08940134A0705|87 89|Cas
P08940134A0705|87 89|Cas
P08940134A0705|106 114|membranes
P08940134A0705|134 153|endoplasmic reticulum
P08940298A0962|0 8|Replacing
P08940298A0962|26 33|delta419
P08940298A0962|50 59|AF-2 domain
P08940298A0962|50 59|AF-2 domain
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|89 104|estrogen receptor
P08940298A0962|89 104|estrogen receptor
P08940298A0962|141 163|transcriptional activity
P08942999T0000|9 26|G-to-A substitution
P08942999T0000|36 40|codon
P08942999T0000|43 73|SREBP cleavage-activating protein
P08942999T0000|43 73|SREBP cleavage-activating protein
P08942999T0000|80 95|sterol resistance
P08942999T0000|103 136|mutant Chinese hamster ovary cell lines
P08943032A0000|3 50|Escherichia coli tet-repressor (TetR) operator system
P08943032A0000|3 30|Escherichia coli tet-repressor
P08943032A0000|32 35|TetR
P08943032A0000|82 101|yeast two-hybrid assay
P08943032A0000|122 148|protein-protein interactions
P08943032A0000|122 136|protein-protein
P08943354A0295|30 34|SHP-1
P08943354A0295|30 34|SHP-1
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|124 133|Tyk2 kinase
P08943354A0295|124 133|Tyk2 kinase
P08943354A0295|140 159|hyperphosphorylation
P08943354A0295|162 171|Jak kinases
P08943354A0295|162 171|Jak kinases
P08943354A0295|177 190|motheaten cells
P08943354A0295|209 213|SHP-1
P08943354A0295|209 213|SHP-1
P08943928A1137|29 35|vaccine
P08943928A1137|45 52|outbreak
P08945479T0000|0 14|Structural basis
P08945479T0000|30 50|human lymphocyte kinase
P08945479T0000|30 50|human lymphocyte kinase
P08945479T0000|51 53|Lck
P08945479T0000|51 53|Lck
P08945479T0000|58 80|tyrosine phosphorylation
P08945810T0001|0 18|Evolutive morphology
P08945810T0001|24 36|olfactory bulb
P08945810T0001|39 41|man
P08945810T0001|52 67|non-human mammals
P08946166A0568|36 38|ORF
P08946166A0568|44 51|FRDS gene
P08946166A0568|44 51|FRDS gene
P08946668A0077|0 4|FK506
P08946668A0077|34 45|cyclosporin A
P08946668A0077|58 71|organ rejection
P08946668A0077|75 84|in toxicity
P08947028A0992|23 27|Rho1p
P08947028A0992|23 27|Rho1p
P08947028A0992|37 62|cytoskeletal reorganization
P08947028A0992|77 81|Bni1p
P08947028A0992|77 81|Bni1p
P08947028A0992|85 89|Pkc1p
P08947028A0992|85 89|Pkc1p
P08948440A0628|3 5|ERH
P08948440A0628|41 43|An3
P08948440A0628|41 43|An3
P08948440A0628|64 79|animal hemisphere
P08948440A0628|82 88|oocytes
P08948440A0628|118 123|embryo
P08950144A0172|0 6|Waves N1
P08950144A0172|8 9|P3
P08950144A0172|13 15|CNV
P08950144A0172|106 108|ISI
P08950352A0525|17 23|Chilean
P08950352A0525|30 37|Japanese
P08950352A0525|103 110|Japanese
P08950352A0525|136 158|statistical significance
P08950352A0525|169 182|chi-square test
P08951815A0465|12 15|ASN1
P08951815A0465|12 15|ASN1
P08951815A0465|19 22|ASN2
P08951815A0465|19 22|ASN2
P08951815A0465|48 58|lacZ fusions
P08951815A0465|48 58|lacZ fusions
P08951815A0465|126 152|transcription activator Gcn4p
P08951815A0465|148 152|Gcn4p
P08952483A0207|57 83|hamster lysyl-tRNA synthetase
P08952483A0207|64 83|lysyl-tRNA synthetase
P08952483A0207|143 164|multisynthetase complex
P08952796A0743|0 1|He
P08952965A1182|27 39|nonsynonymous
P08952965A1182|41 42|pN
P08952965A1182|47 56|synonymous
P08952965A1182|58 59|pS
P08952965A1182|96 121|tamarin variable region genes
P08952965A1182|96 116|tamarin variable region
P08952965A1182|146 147|pN
P08952965A1182|181 182|pN
P08952965A1182|196 212|MHC contact regions
P08952965A1182|196 212|MHC contact regions
P08952965A1182|214 224|CDR1 and CDR2
P08952965A1182|214 217|CDR1
P08952965A1182|221 224|CDR2
P08953340A0000|12 29|oral vanadyl sulfate
P08953340A0000|31 36|VOSO4)
P08953340A0000|53 65|anthropometry
P08953340A0000|67 81|body composition
P08953340A0000|86 96|performance
P08953340A0000|124 135|double-blind
P08953340A0000|137 159|placebo-controlled trial
P08954725A1175|5 17|in development
P08954725A1175|19 32|Tbx6 expression
P08954725A1175|19 22|Tbx6
P08954725A1175|58 73|paraxial mesoderm
P08954725A1175|106 111|streak
P08954725A1175|125 132|mesoderm
P08955071T0000|12 32|re-replication control
P08955071T0000|51 59|human ORC1
P08955071T0000|51 59|human ORC1
P08955071T0000|69 73|yeast
P08955111A0989|28 53|promoter and enhancer regions
P08955111A0989|106 121|promoter activity
P08955111A0989|127 154|human activin betaA subunit gene
P08955111A0989|127 154|human activin betaA subunit gene
P08955136A0606|12 22|bacterially
P08955136A0606|32 42|PIP5KIalpha
P08955136A0606|32 42|PIP5KIalpha
P08955136A0606|52 64|PIP5K activity
P08955136A0606|52 56|PIP5K
P08955136A0606|89 113|erythroid PIP5KI antibodies
P08955136A0606|89 113|erythroid PIP5KI antibodies
P08955159A0000|0 54|Human acid ceramidase ((AC) N-acylsphingosine amidohydrolase
P08955159A0000|0 18|Human acid ceramidase
P08955159A0000|20 54|(AC) N-acylsphingosine amidohydrolase
P08955159A0000|56 57|EC
P08955189A1198|3 14|0.22-kb NheI/
P08955189A1198|10 13|NheI
P08955189A1198|15 27|BglII promoter
P08955189A1198|15 19|BglII
P08955189A1198|37 39|PMA
P08955189A1198|54 65|myeloid cells
P08955189A1198|79 99|PMA-responsive element
P08955189A1198|112 114|Sp1
P08955189A1198|112 114|Sp1
P08955189A1198|118 122|EGR-1
P08955189A1198|118 122|EGR-1
P08955189A1198|123 142|transcription factors
P08955306A0224|0 24|Northern (RNA) blot analyses
P08955306A0224|41 48|cdh genes
P08955306A0224|77 92|open reading frame
P08955306A0224|94 97|ORF1
P08955402A0288|70 73|HOL1
P08955402A0288|70 73|HOL1
P08955402A0288|121 139|cis-acting mutations
P08955402A0288|158 173|HOL1-1 background
P08955402A0288|158 163|HOL1-1
P08955402A0288|203 213|Hol1 protein
P08955402A0288|203 213|Hol1 protein
P08955928A0390|11 13|BBB
P08955928A0390|40 55|Evans Blue (EB) dye
P08955928A0390|50 51|EB
P08955928A0390|106 109|MCAo
P08958137A0534|0 23|Lipid hydroperoxide levels
P08958137A0534|26 31|plasma
P08958137A0534|35 37|LDL
P08958137A0534|35 37|LDL
P08958720A1204|34 37|mPAP
P08958720A1204|52 54|SVI
P08958720A1204|65 66|HR
P08958720A1204|83 84|CO
P08958720A1204|88 90|VO2
P08959062A0372|15 24|vasculitis
P08959062A0372|26 34|cutaneous
P08959062A0372|38 47|neurologic
P08959062A0372|103 105|EBV
P08959062A0372|116 132|Purtilo's syndrome
P08959117A0708|27 42|endocrine changes
P08959117A0708|55 69|acute hypoxaemia
P08959117A0708|79 95|underlying disease
P08959117A0708|135 137|ICU
P08959117A0708|200 213|reference group
P08959117A0708|215 217|REF
P08959117A0708|238 259|experimental hypoxaemia
P08959778A0292|35 47|graft survival
P08959778A0292|70 82|graft function
P08959778A0292|84 86|EGF
P08959778A0292|84 86|EGF
P08959778A0292|91 93|DGF
P08959778A0292|91 93|DGF
P08959778A0292|108 143|transplantations or retransplantations
P08960827A1169|28 35|GG motifs
P08960827A1169|52 77|cell-specific transcription
P08960827A1169|83 98|human insulin gene
P08960827A1169|88 98|insulin gene
P08960827A1169|131 160|sequence-specific nuclear factor
P08961873T0000|0 34|Abnormal urinary coproporphyrin levels
P08961873T0000|37 44|patients
P08961873T0000|55 69|hepatitis C virus
P08961873T0000|83 108|human immunodeficiency virus
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|34 47|IgE) antibodies
P08962614A0000|34 36|IgE
P08962614A0000|80 94|skin-prick tests
P08962614A0000|153 169|atopic individuals
P08962614A0000|199 206|children
P08964067A0188|0 9|Thrombosis
P08964067A0188|15 23|renal vein
P08964067A0188|47 58|renal failure
P08964172A0221|0 34|Filter and cytocentrifuge preparations
P08964172A0221|40 44|urine
P08964172A0221|105 120|single tumor cells
P08964172A0221|125 146|inflammatory background
P08967870A0000|0 2|327
P08967870A0000|20 41|postmortem examinations
P08967870A0000|46 60|Moscow hospitals
P08967963A1735|50 70|rat glioma cell line C6B4
P08967963A1735|75 98|rat submandibular cell line
P08967963A1735|99 105|RSMT-A5
P08967963A1735|113 115|rat
P08967963A1735|130 137|cell line
P08967963A1735|138 144|RIN-5AH
P08967963A1735|171 194|endogenous alpha2c-AR gene
P08967963A1735|181 194|alpha2c-AR gene
P08969495A0256|3 12|sequencing
P08969495A0256|45 48|-A13
P08969495A0256|64 74|nrdE cistron
P08969495A0256|64 74|nrdE cistron
P08969495A0256|126 139|internal region
P08969495A0256|142 145|nrdE
P08969495A0256|142 145|nrdE
P08969495A0256|149 152|nrdF
P08969495A0256|149 152|nrdF
P08969777A0771|3 26|microdensitometric scores
P08969777A0771|35 57|side-to-side differences
P08969777A0771|60 67|patients
P08969777A0771|95 105|serum 25-OHD
P08970352A0880|29 31|LDD
P08970352A0880|59 62|MSOF
P08970352A0880|65 70|sepsis
P08970951A0823|33 40|secreted
P08970951A0823|41 58|hepatitis B e antigen
P08970951A0823|41 50|hepatitis B
P08970951A0823|92 95|core
P08970951A0823|99 109|Pol proteins
P08970951A0823|99 109|Pol proteins
P08970951A0823|113 126|replicative HBV
P08970951A0823|127 142|DNA intermediates
P08970979A1246|24 36|mutant virions
P08970979A1246|83 99|exogenous template
P08970979A1246|112 124|early promoter
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|73 75|SRF
P08970984A0765|73 75|SRF
P08970984A0765|77 88|Rel/NFkappaB
P08970984A0765|77 79|Rel
P08970984A0765|81 88|NFkappaB
P08970984A0765|90 92|ETS
P08970984A0765|90 92|ETS
P08970984A0765|97 124|YY1 class transcription factors
P08970984A0765|97 124|YY1 class transcription factors
P08970984A0765|149 179|serum or tumor necrosis factor alpha
P08970984A0765|156 179|tumor necrosis factor alpha
P08970991A0747|4 18|serum withdrawal
P08970991A0747|24 66|permissive temperature, p53-mediated apoptosis
P08970991A0747|46 48|p53
P08971009A0860|73 87|cis-acting sites
P08971009A0860|139 142|loci
P08971009A0860|150 164|viral DNA genomes
P08971721A1314|12 29|serological studies
P08971721A1314|34 55|highly conserved A domain
P08971721A1314|58 61|HspA
P08971721A1314|58 61|HspA
P08971721A1314|77 96|immunodominant domain
P08971835A1057|25 33|alpha-MSH
P08971835A1057|25 33|alpha-MSH
P08971835A1057|44 54|reperfusion
P08971835A1057|56 60|BAEPs
P08971835A1057|120 140|late reperfusion period
P08972182A0000|3 13|Fas receptor
P08972182A0000|3 13|Fas receptor
P08972182A0000|23 39|signalling cascade
P08972182A0000|51 69|programmed cell death
P08972182A0000|71 79|apoptosis
P08972182A0000|94 114|receptor cross-linking
P08972182A0527|0 2|Fas
P08972182A0527|24 26|ICE
P08972182A0527|24 26|ICE
P08972182A0527|28 61|interleukin-1 beta-converting enzyme
P08972182A0527|28 61|interleukin-1 beta-converting enzyme
P08972182A0527|86 94|apoptosis
P08972182A0527|124 142|ICE inhibitor protein
P08972182A0527|124 126|ICE
P08972182A0527|143 146|CrmA
P08972182A0527|143 146|CrmA
P08972182A0527|151 183|synthetic tetrapeptide ICE inhibitor
P08972182A0527|151 171|synthetic tetrapeptide
P08972182A0527|172 174|ICE
P08972182A0527|184 191|YVAD-CMK
P08972182A0527|184 191|YVAD-CMK
P08972182A0527|199 208|tripeptide
P08972182A0527|209 224|pan-ICE inhibitor
P08972182A0527|213 215|ICE
P08972182A0527|225 233|Z-VAD-FMK
P08972182A0527|225 233|Z-VAD-FMK
P08972211A0059|27 40|endogenous gene
P08972211A0059|27 40|endogenous gene
P08972211A0059|61 64|mice
P08972211A0059|99 122|4 kb of 5'-flanking sequence
P08972211A0059|129 147|3'-flanking sequence
P08972211A0059|168 193|endoderm-specific enhancers
P08972211A0059|217 230|structural gene
P08972232A0365|30 34|hGCN5
P08972232A0365|30 34|hGCN5
P08972232A0365|43 45|HAT
P08972232A0365|43 45|HAT
P08972232A0365|59 78|substrate specificity
P08972232A0365|81 85|yGCN5
P08972232A0365|81 85|yGCN5
P08973185T0061|14 30|arginine mutations
P08973185T0061|33 56|oxidative phosphorylation
P08973185T0061|60 72|AAC expression
P08973185T0061|60 62|AAC
P08973527A0000|0 16|Complementary DNAs
P08973527A0000|32 48|coat protein coding
P08973527A0000|32 42|coat protein
P08973527A0000|52 66|adjacent regions
P08973527A0000|69 93|Agropyron mosaic virus (AgMV
P08973527A0000|98 120|Hordeum mosaic virus (HoMV
P08973630A0923|26 38|Rac activation
P08973630A0923|26 28|Rac
P08973630A0923|48 60|Rho activation
P08973630A0923|48 50|Rho
P08973630A0923|79 93|Cdc42 activation
P08973630A0923|79 83|Cdc42
P08973630A0923|101 113|Rac activation
P08973630A0923|101 103|Rac
P08973630A0923|137 156|morphological changes
P08973917A0632|7 11|cDNAs
P08973917A0632|30 42|human PWP2 gene
P08973917A0632|30 42|human PWP2 gene
P08973917T0000|12 27|genomic structure
P08973917T0000|31 42|human homolog
P08973917T0000|48 78|yeast periodic tryptophan protein 2
P08973917T0000|48 52|yeast
P08973917T0000|53 60|periodic
P08973917T0000|61 70|tryptophan
P08973917T0000|71 95|protein 2 (PWP2) gene mapping
P08973917T0000|80 83|PWP2
P08973917T0000|98 104|21q22.3
P08974103A0451|92 94|PEM
P08974103A0451|108 112|all-0
P08974135A0052|16 23|thiamine
P08974135A0052|25 44|vitamin B1) deficiency
P08974135A0052|70 87|aphthous stomatitis
P08974135A0052|98 112|vitamin B1 levels
P08974135A0052|117 124|patients
P08974135A0052|138 155|aphthous stomatitis
P08974135A0052|173 184|control group
P08975532T0001|5 12|injuries
P08975713A0454|12 22|cDNA library
P08975713A0454|68 81|p53p2 start site
P08975713A0454|68 81|p53p2 start site
P08975713A0454|112 115|cDNA
P08975713A0454|172 184|p53p2 promoter
P08975713A0454|172 184|p53p2 promoter
P08976253A0637|42 46|serum
P08976253A0637|63 71|PSA levels
P08976253A0637|63 65|PSA
P08977013A0788|29 49|cortical magnification
P08977013A0788|94 99|foveal
P08977013A0788|103 118|peripheral vision
P08977235A0134|0 4|G-CSF
P08977235A0134|0 4|G-CSF
P08977235A0134|22 39|signaling molecules
P08977235A0134|53 56|JAK1
P08977235A0134|53 56|JAK1
P08977235A0134|60 70|JAK2 kinases
P08977235A0134|60 70|JAK2 kinases
P08977235A0134|77 100|STAT transcription factors
P08977235A0134|77 80|STAT
P08977235A0588|17 32|tyrosine residues
P08977235A0588|38 54|cytoplasmic domain
P08977235A0588|85 89|STAT5
P08977235A0588|85 89|STAT5
P08977235A0588|93 97|STAT1
P08977235A0588|93 97|STAT1
P08977235A0588|115 119|STAT3
P08977235A0588|115 119|STAT3
P08977235A0588|133 137|STAT5
P08977235A0588|133 137|STAT5
P08977235A0588|141 155|STAT1 activation
P08977235A0588|141 145|STAT1
P08977235A0588|170 200|receptor tyrosine phosphorylation
P08977401A0227|3 13|RI alpha gene
P08977401A0227|5 13|alpha gene
P08977401A0227|36 40|exons
P08977401A0227|69 75|introns
P08977401A0227|111 114|21 kb
P08977401A0227|144 160|RI alpha pseudogene
P08977401A0227|166 183|5'-noncoding region
P08977401A0227|220 240|alpha complementary RNA
P08977401A0227|257 267|RI alpha gene
P08977401A0227|259 267|alpha gene
P08977401A0227|324 336|messenger RNAs
P08977401A0227|338 342|mRNAs
P08978690A0262|15 23|Rad3/Mec1
P08978690A0262|15 18|Rad3
P08978690A0262|20 23|Mec1
P08978690A0262|73 84|DNA structure
P08978690A0262|102 118|yeast model systems
P08978817A0620|11 23|double mutants
P08978817A0620|34 51|dim1-delta or dim2-1
P08978817A0620|34 43|dim1-delta
P08978817A0620|46 51|dim2-1
P08978817A0620|58 75|endocytosis mutants
P08978817A0620|69 81|mutants end4-1
P08978817A0620|76 81|end4-1
P08978817A0620|84 89|act1-1
P08978817A0620|84 89|act1-1
P08978817A0620|108 120|growth defects
P08978817A0620|139 153|DIM gene products
P08978817A0620|139 153|DIM gene products
P08978817A0620|181 196|endocytic pathway
P08978996A0000|22 36|hepatitis C virus
P08978996A0000|54 65|liver disease
P08978996A0000|72 87|dialysis patients
P08978996A0000|93 110|transplant patients
P08978996A0000|187 193|patient
P08979089A1197|6 17|transfection
P08979089A1197|23 36|BL cell line Raji
P08979089A1197|61 72|core promoter
P08979089A1197|98 112|proximal Sp1 site
P08979089A1197|106 112|Sp1 site
P08979089A1197|119 125|TATA box
P08979089A1197|119 125|TATA box
P08979089A1197|156 165|promoter P1
P08979089A1197|171 186|Ig kappa enhancers
P08979089A1197|171 186|Ig kappa enhancers
P08979828A1561|4 27|multisensory interactions
P08980413A0500|3 5|P13
P08980413A0500|9 11|N22
P08980413A0500|14 19|ppSEPs
P08980413A0500|55 56|P2
P08980413A0500|55 56|P2
P08980413A0500|60 61|N2
P08980413A0500|77 79|PES
P08980522A0280|3 6|cDNA
P08980522A0280|9 12|cpm7
P08980522A0280|9 12|cpm7
P08980522A0280|44 50|36.8 kDa
P08980533A1160|11 26|C-terminal region
P08980533A1160|11 26|C-terminal region
P08980533A1160|29 33|ENBP1
P08980533A1160|29 33|ENBP1
P08980533A1160|67 69|rat
P08980533A1160|99 104|testis
P08980536A1196|24 28|G-box
P08980536A1196|24 28|G-box
P08980536A1196|32 36|H-box
P08980536A1196|32 36|H-box
P08980536A1196|48 59|CHS promoters
P08980536A1196|87 102|regulatory motifs
P08980819A0193|0 8|Mortality
P08980819A0193|74 80|turkeys
P08980819A0193|93 96|toms
P08980819A0193|98 109|heavier birds
P08981371A2049a|11 14|PIP2
P08981371A2049a|27 41|85-90 kDa protein
P08981371A2049a|64 77|CSF-1 treatment
P08981371A2049a|64 68|CSF-1
P08981371A2049b|11 14|PIP2
P08981371A2049b|27 41|85-90 kDa protein
P08981371A2049b|64 77|CSF-1 treatment
P08981371A2049b|64 68|CSF-1
P08985109A1285|0 3|Just
P08985109A1285|10 18|inserting
P08985109A1285|24 37|anterior margin
P08985115A1571|27 41|active 37LRP/p40
P08985115A1571|33 37|37LRP
P08985115A1571|39 41|p40
P08985115A1571|117 125|human gene
P08985115A1571|150 168|molecular mechanisms
P08985115A1571|216 228|tumor invasion
P08985115A1571|232 241|metastasis
P08985122A0501|3 16|promoter region
P08985122A0501|18 19|P1
P08985122A0501|18 19|P1
P08985122A0501|50 77|transcription initiation sites
P08985122A0501|88 91|TATA
P08985122A0501|95 103|CAAT boxes
P08985122A0501|136 157|transcription factor SP1
P08985122A0501|136 154|transcription factor
P08985122A0501|155 157|SP1
P08985122A0501|179 192|G + C-rich domain
P08985122A0501|196 204|CpG island
P08985122A0501|225 233|promoters
P08985122A0501|259 275|housekeeping genes
P08985415A1096|3 8|STAT-1
P08985415A1096|3 8|STAT-1
P08985415A1096|70 76|CAEV LTR
P08985415A1096|70 76|CAEV LTR
P08985415A1096|79 87|IFN-gamma
P08985415A1096|79 87|IFN-gamma
P08985415A1096|90 98|monocytes
P08986190A0927|0 10|Reperfusion
P08986190A0927|38 54|lactate production
P08986190A0927|80 89|LDH release
P08986190A0927|80 82|LDH
P08986214A0000|13 39|hepatic regenerative response
P08986214A0000|42 49|patients
P08986214A0000|54 74|alcoholic liver disease
P08986214A0000|76 79|sera
P08986214A0000|84 94|263 patients
P08986214A0000|99 137|severe alcoholic hepatitis and/or cirrhosis
P08986214A0000|153 174|hepatocyte growth factor
P08986214A0000|153 174|hepatocyte growth factor
P08986214A0000|176 178|HGF
P08986214A0000|176 178|HGF
P08986214A0000|183 199|alpha-fetoprotein
P08986214A0000|183 199|alpha-fetoprotein
P08986214A0000|201 203|AFP
P08986214A0000|201 203|AFP
P08986228A0000|16 31|chronic alcoholic
P08986228A0000|58 75|teratogenic effects
P08986228A0000|94 119|morphological malformations
P08986692A0306|0 11|INTERVENTION
P08986692A0306|26 45|hemostasis parameters
P08986692A0306|67 74|patients
P08986692A0306|85 90|IVF-ET
P08986770A0268|31 42|I-POU/tI-POU
P08986770A0268|31 35|I-POU
P08986770A0268|37 42|tI-POU
P08986770A0268|68 81|embryonic phase
P08986770A0268|84 93|Drosophila
P08986770A0268|109 113|I-POU
P08986770A0268|109 113|I-POU
P08986812A1214|6 17|wild-type p53
P08986812A1214|6 17|wild-type p53
P08986812A1214|22 41|delta proAE mutant cDNA
P08986812A1214|22 41|delta proAE mutant cDNA
P08986812A1214|64 84|tumor derived cell lines
P08987009A0400|46 62|expressive freedom
P08987225A0675|55 64|hepatitis C
P08987225A0675|157 158|NT
P08987225A0675|163 165|ACT
P08987225A0675|169 178|Queensland
P08988257A1256|56 72|reporter construct
P08988257A1256|96 100|yeast
P08988257A1256|141 161|chromosomal truncation
P08988913A0821|58 71|folate turnover
P08988913A0821|74 95|urinary folate excretion
P08988913A0821|117 151|fecal excretion and catabolic processes
P08989025A0359|4 31|voltage-operated Ca2+ channels
P08989025A0359|33 35|VOC
P08989025A0359|50 59|nifedipine
P08989025A0359|117 139|phasic and tonic responses
P08989763A0605|7 15|artifacts
P08989763A0605|60 68|diaphragm
P08990168A0688|8 14|p48 gene
P08990168A0688|8 10|p48
P08990168A0688|37 41|STAT1
P08990168A0688|37 41|STAT1
P08990168A0688|45 48|JAK1
P08990168A0688|45 48|JAK1
P08990168A0688|50 63|activated STAT1
P08990168A0688|59 63|STAT1
P08990168A0688|77 80|GATE
P08990168A0688|77 80|GATE
P08990194A0000|25 38|thyroid hormone
P08990194A0000|25 38|thyroid hormone
P08990194A0000|64 72|serum free
P08990194A0000|73 87|thyroid hormones
P08990194A0000|106 134|pituitary thyrotropin secretion
P08990194A0000|106 125|pituitary thyrotropin
P08990397A1437|45 74|tscA-lacking photosystem I mutant
P08990397A1437|45 48|tscA
P08990397A1437|57 74|photosystem I mutant
P08990397A1437|76 78|H13
P08990397A1437|76 78|H13
P08990397A1437|100 128|light-stimulated RNA processing
P08992115A0199|16 30|acute bronchitis
P08992115A0199|55 73|blood concentrations
P08992115A0199|96 108|KKS activation
P08992115A0199|96 98|KKS
P08992115A0199|114 118|blood
P08992115A0199|126 147|serotonin and lactic acid
P08992115A0199|183 192|exhaled air
P08993393A0498|50 64|human physiology
P08993393A0498|77 88|hPACAP-R gene
P08993393A0498|77 88|hPACAP-R gene
P08993393T0000|0 20|Differential signaling
P08993393T0000|24 52|immediate-early gene activation
P08993393T0000|24 42|immediate-early gene
P08993393T0000|78 91|human pituitary
P08993393T0000|83 137|pituitary adenylate cyclase-activating polypeptide receptor
P08993393T0000|92 137|adenylate cyclase-activating polypeptide receptor
P08993393T0000|139 146|hPACAP-R
P08993393T0000|139 146|hPACAP-R
P08993831A0000|48 59|muscle fibers
P08993831A0000|108 126|muscle-specific gene
P08993831A0000|108 126|muscle-specific gene
P08993836A0699|66 79|HNF-3 alpha gene
P08993836A0699|66 75|HNF-3 alpha
P08993836A0699|82 102|respiratory epithelium
P08993836A0699|109 121|embryogenesis
P08994825A0000|31 33|MPF
P08994825A0000|31 33|MPF
P08994825A0000|35 59|maturation promoting factor
P08994825A0000|77 100|Cdc2/28-cyclin B complexes
P08994825A0000|77 80|Cdc2
P08994825A0000|82 91|28-cyclin B
P08994832A0782|0 16|Ectopic expression
P08994832A0782|19 23|Apo-3
P08994832A0782|19 23|Apo-3
P08994832A0782|26 31|HEK293
P08994832A0782|34 42|HeLa cells
P08994832A0782|56 64|apoptosis
P08994968A0926|2 11|N-terminal
P08994968A0926|44 69|dinucleotide-binding domain
P08994968A0926|74 88|adjacent subunit
P08994968A0926|101 111|adenine ring
P08994968A0926|114 117|NADP
P08995054A0618|0 9|Similarity
P08995054A0618|29 45|zinc knuckle region
P08995054A0618|29 45|zinc knuckle region
P08995054A0618|70 77|gag genes
P08995054A0618|70 72|gag
P08995054A0618|84 117|replication-competent retroelements
P08995054A1368|0 13|D. melanogaster
P08995054A1368|14 33|HeT-A coding sequences
P08995054A1368|14 33|HeT-A coding sequences
P08995054A1368|39 55|polymorphic region
P08995054A1368|60 79|insertions/deletions
P08995054A1368|82 91|1-31 codons
P08995054A1368|99 115|nucleotide changes
P08995410A0000|0 26|Eukaryotic initiation factor 3
P08995410A0000|0 26|Eukaryotic initiation factor 3
P08995410A0000|28 31|eIF3
P08995410A0000|28 31|eIF3
P08995410A0000|41 59|multisubunit complex
P08995410A0000|84 90|complex
P08995410A0000|92 104|eIF2 x GTP x tRNA
P08995410A0000|92 95|eIF2
P08995410A0000|97 108|GTP x tRNA(Met
P08995410A0000|106 110|Met)i
P08995410A0000|122 132|mRNA binding
P08995410A0000|138 156|40 S ribosomal subunit
P08995410A0000|138 156|40 S ribosomal subunit
P08995410A0000|158 161|eIF3
P08995410A0000|158 161|eIF3
P08995410A1109|27 33|Hershey
P08995410A1109|59 71|mammalian eIF3
P08995410A1109|59 71|mammalian eIF3
P08995410A1109|102 105|p170
P08995410A1109|102 105|p170
P08995410A1109|107 110|p116
P08995410A1109|107 110|p116
P08995410A1109|112 116|hPrt1
P08995410A1109|112 116|hPrt1
P08995410A1109|119 122|p110
P08995410A1109|119 122|p110
P08995410A1109|124 126|p66
P08995410A1109|124 126|p66
P08995410A1109|128 130|p48
P08995410A1109|128 130|p48
P08995410A1109|132 138|p47, p44
P08995410A1109|132 134|p47
P08995410A1109|136 138|p44
P08995410A1109|140 153|p40, p36, and p35
P08995410A1109|140 142|p40
P08995410A1109|144 146|p36
P08995410A1109|151 153|p35
P08995614T0000|17 33|cis-acting element
P08995614T0000|39 78|class I major histocompatibility complex gene
P08995614T0000|39 78|class I major histocompatibility complex gene
P08995614T0000|79 86|promoter
P08995652A0812|36 42|capsids
P08995652A0812|97 123|C-terminal 65 amino acids) UL80
P08995652A0812|120 132|UL80.5 protein
P08995652A0812|125 132|5 protein
P08995652A0812|154 175|C-terminal 65 amino acids
P08995652A0812|181 193|UL80.5 protein
P08995652A0812|181 184|UL80
P08995652A0812|186 193|5 protein
P08995652A0812|213 234|C-terminal 25 amino acids
P08995652A0812|240 252|UL26.5 protein
P08995652A0812|240 243|UL26
P08995652A0812|245 252|5 protein
P08995652A0812|260 266|capsids
P08995652A0812|300 312|UL80.5 protein
P08995652A0812|300 303|UL80
P08995652A0812|305 312|5 protein
P08995652A0812|317 319|VP5
P08995652A0812|317 319|VP5
P08995652A0812|353 359|capsids
P08995652A0812|395 410|last 12 amino acids
P08995652A0812|416 428|UL80.5 protein
P08995652A0812|416 419|UL80
P08995652A0812|421 428|5 protein
P08995652A0812|457 468|RRIFVAAMMKLE
P08995652A0812|495 510|scaffold proteins
P08995652A0812|578 583|UL26.5
P08995652A0812|578 583|UL26.5
P08995652A0812|587 600|UL80.5 proteins
P08995652A0812|587 590|UL80
P08995652A0812|592 600|5 proteins
P08995659A0563|10 18|3'-region
P08995659A0563|39 42|MSRs
P08995659A0563|39 42|MSRs
P08995659A0563|49 76|latent and productive infection
P08995659A0563|93 117|sequencing RNA-PCR products
P08995659A0563|131 137|primers
P08995659A0563|150 157|3' splice
P08995681A0518|4 8|ICP27
P08995681A0518|4 8|ICP27
P08995681A0518|49 52|ICP4
P08995681A0518|49 52|ICP4
P08996730A1146|22 42|vibration measurements
P08996730A1146|116 128|grinder wheels
P08996730A1146|130 132|etc
P08997490A1127|0 11|C/EBP beta V > A
P08997490A1127|0 9|C/EBP beta V
P08997490A1127|43 52|C/EBP sites
P08997490A1127|43 52|C/EBP sites
P08997490A1127|64 71|DBP sites
P08997490A1127|79 94|oligonucleotides
P08997490A1127|127 133|albumin
P08997490A1127|127 133|albumin
P08997490A1127|137 167|cholesterol hydroxylase promoters
P08997490A1127|137 167|cholesterol hydroxylase promoters
P08997532A0116|8 10|IgG
P08997532A0116|8 10|IgG
P08997532A0116|20 22|IgE
P08997532A0116|20 22|IgE
P08997532A0116|31 48|IgE immunoglobulins
P08997532A0116|31 33|IgE
P08997532A0116|34 48|immunoglobulins
P08997532A0116|56 95|Toxocara canis excretory/secretory antigens
P08997532A0116|56 68|Toxocara canis
P08997532A0116|97 99|TES
P08997532A0116|97 99|TES
P08997532A0116|120 133|ELISA technique
P08998115A0114|104 123|lymph node dissections
P08999857A0801|11 15|E-box
P08999857A0801|11 15|E-box
P08999857A0801|33 49|3'-flanking region
P08999857A0801|94 116|transcriptional activity
P08999857A0801|122 150|alpha1(I) collagen gene promoter
P08999857A0801|122 142|alpha1(I) collagen gene
P08999882T0000|12 25|neuronal traits
P08999882T0000|28 46|pancreatic beta cells
P09000049A1341|13 15|Mnt
P09000049A1341|13 15|Mnt
P09000049A1341|17 19|Max
P09000049A1341|17 19|Max
P09000049A1341|21 24|Sin3
P09000049A1341|60 66|Myc:Max
P09000049A1341|60 62|Myc
P09000049A1341|64 66|Max
P09000049A1341|91 107|cell proliferation
P09000108A0330|3 22|transcription product
P09000108A0330|25 33|1.3 kb mRNA
P09000108A0330|77 108|eukaryotic polyadenylation signals
P09000108A0330|121 132|bp downstream
P09000108A0330|160 164|codon
P09000108A0330|168 171|CG30
P09000108A0330|168 171|CG30
P09000146T0000|0 16|Phenotypic changes
P09000146T0000|26 33|wild type
P09000146T0000|44 48|c-src
P09000146T0000|44 48|c-src
P09000146T0000|62 90|C-terminal sequence alterations
P09000589A0000|15 35|drug-resistant malaria
P09000589A0000|65 82|antimalarial agents
P09000632A2341|5 14|p51 subunit
P09000632A2341|5 14|p51 subunit
P09000632A2341|19 34|Cys181 side-chain
P09000632A2341|69 84|Tyr181 side-chain
P09000632A2341|90 105|wild-type complex
P09001213A1111|59 83|polymorphic chromosome ends
P09001213A1111|86 97|P. falciparum
P09001213A1111|177 184|var genes
P09001245A0187|0 5|NUP145
P09001245A0187|0 5|NUP145
P09001245A0187|53 64|lethal screen
P09001313A0000|12 36|sleep-disordered breathing
P09001313A0000|38 40|SDB
P09001313A0000|64 78|menopausal women
P09001667A0312|48 51|28th
P09001667A0312|55 70|post-vaccination
P09001828A0222|12 14|men
P09001828A0222|82 84|BPH
P09002648A0202|0 4|BCL-2
P09002648A0202|0 4|BCL-2
P09002648A0202|19 27|apoptosis
P09002648A0202|78 109|oxidative stress-induced cell death
P09002672A0439|23 31|mTRF1 cDNA
P09002672A0439|23 31|mTRF1 cDNA
P09002672A0439|43 54|56 kDa protein
P09002672A0439|66 77|TTAGGG repeat
P09002672A0439|85 89|mTRF1
P09002672A0439|85 89|mTRF1
P09002672A0439|106 124|sequence specificity
P09002672A0439|127 131|hTRF1
P09002672A0439|127 131|hTRF1
P09002672A0439|151 163|TTAGGG repeats
P09002672A0439|187 192|TTAGGC
P09002672A0439|196 208|TTGGGG repeats
P09003001A1593|24 37|E12 bHLH protein
P09003001A1593|24 30|E12 bHLH
P09003001A1593|59 82|cell-specific bHLH factors
P09003001A1593|72 82|bHLH factors
P09003001A1909|3 15|E-box sequence
P09003001A1909|3 15|E-box sequence
P09003001A1909|21 31|SE2 fragment
P09003001A1909|21 31|SE2 fragment
P09003001A1909|37 55|transferrin promoter
P09003001A1909|37 47|transferrin
P09003001A1909|94 122|consensus E-box elements (CANNTG
P09003001A1909|103 115|E-box elements
P09003311A0478|1 17|5.3-kb DNA fragment
P09003311A0478|41 59|structural porin gene
P09003311A0478|66 70|porCa
P09003311A0478|66 70|porCa
P09003311A0478|78 92|flanking regions
P09003312A0740|0 17|Full-length AT-PHH1
P09003312A0740|11 17|AT-PHH1
P09003312A0740|26 52|AT-PHH1 and AT-PHH1 delta C-513
P09003312A0740|26 32|AT-PHH1
P09003312A0740|36 52|AT-PHH1 delta C-513
P09003312A0740|54 62|truncated
P09003312A0740|89 112|microbial photolyase genes
P09003312A0740|89 112|microbial photolyase genes
P09003312A0740|114 118|cDNAs
P09003312A0740|153 157|yeast
P09003312A0740|161 182|Escherichia coli mutants
P09003312A0740|161 175|Escherichia coli
P09003312A0740|199 214|ultraviolet light
P09003410A0000|3 18|human p100 protein
P09003410A0000|3 18|human p100 protein
P09003410A0000|43 53|coactivator
P09003410A0000|59 90|Epstein-Barr virus nuclear antigen 2
P09003410A0000|59 90|Epstein-Barr virus nuclear antigen 2
P09003462A0792|15 27|mutation sites
P09003462A0792|15 27|mutation sites
P09003462A0792|29 50|S61, SL1, S29, SL11, SL196
P09003462A0792|29 31|S61
P09003462A0792|33 35|SL1
P09003462A0792|37 39|S29
P09003462A0792|41 44|SL11
P09003462A0792|46 50|SL196
P09003462A0792|54 58|SL126
P09003462A0792|54 58|SL126
P09003462A0792|74 83|nrdB intron
P09003462A0792|74 77|nrdB
P09003462A0792|94 106|self-splicing
P09003463A0198|54 70|5'-flanking region
P09003463A0198|81 85|exon 1
P09003463A0198|91 107|human RII alpha gene
P09003463A0198|91 103|human RII alpha
P09003617A0000|9 23|Swedish children
P09004304A0000|88 128|chromium-51 ethylenediamine tetraacetic acid
P09004304A0000|130 138|51Cr-EDTA
P09004504A0000|22 38|2671 bp DNA fragment
P09004504A0000|49 84|pla gene (encoding plasminogen activator
P09004504A0000|49 55|pla gene
P09004504A0000|65 84|plasminogen activator
P09004504A0000|116 151|wild-type Yersinia pestis plasmid pYP358
P09004987T0001|0 21|Serotonin concentration
P09004987T0001|27 31|blood
P09004987T0001|34 41|patients
P09004987T0001|46 56|hemorrhagic
P09004987T0001|66 78|renal syndrome
P09005273A0322|34 64|factor analysis-derived syndromes
P09005273A0322|83 102|chemical interactions
P09005273A0322|114 134|butyrylcholinesterase
P09005273A0322|114 134|butyrylcholinesterase
P09005273A0322|138 161|neuropathy target esterase
P09005273A1558|15 29|Gulf War veterans
P09005273A1558|45 70|chronic neurotoxic syndromes
P09005273A1558|106 114|chemicals
P09005273A1558|126 146|butyrylcholinesterase
P09005273A1558|126 146|butyrylcholinesterase
P09005273A1558|150 173|neuropathy target esterase
P09005836A0977|31 36|horses
P09005836A0977|43 55|antibody level
P09005979A0841|3 9|GHR mRNA
P09005979A0841|3 9|GHR mRNA
P09005979A0841|11 23|GHBP mRNA ratio
P09005979A0841|11 18|GHBP mRNA
P09005979A0841|63 77|differentiation
P09006007A0997|31 61|selenocysteine-specific UGA codon
P09006007A0997|104 124|homologous SelB protein
P09006007A0997|114 124|SelB protein
P09006007A0997|172 191|SelB-mRNA interaction
P09006007A0997|172 180|SelB-mRNA
P09006007A0997|222 238|quaternary complex
P09006007A0997|246 253|ribosome
P09006010A0527|3 25|linker-peptide insertion
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|45 56|amino acid 784
P09006010A0527|71 87|S-layer biogenesis
P09006010A0527|102 113|amino acid 907
P09006010A0527|160 163|RsaA
P09006010A0527|160 163|RsaA
P09006010A0527|194 216|C terminal to amino acid 784
P09006010A0527|233 244|amino acid 907
P09006022A0252|17 28|gene products
P09006022A0252|17 28|gene products
P09006022A0252|33 40|cvaA gene
P09006022A0252|33 40|cvaA gene
P09006022A0252|82 104|T7 RNA polymerase promoter
P09006022A0252|82 104|T7 RNA polymerase promoter
P09006051A1162|0 3|PrpB
P09006051A1162|0 3|PrpB
P09006051A1162|20 89|carboxyphosphonoenolpyruvate phosphonomutase of Streptomyces hygroscopicus
P09006051A1162|65 89|Streptomyces hygroscopicus
P09006051A1162|110 138|carnation Dianthus caryophyllus
P09006051A1162|140 143|PrpC
P09006051A1162|140 143|PrpC
P09006051A1162|163 198|archaeal and bacterial citrate synthases
P09006051A1162|174 198|bacterial citrate synthases
P09006051A1162|200 203|PrpD
P09006051A1162|200 203|PrpD
P09006051A1162|220 251|yeast and Bacillus subtilis proteins
P09006051A1162|228 251|Bacillus subtilis proteins
P09006051A1162|270 273|PrpE
P09006051A1162|270 273|PrpE
P09006051A1162|290 315|acetyl coenzyme A synthetases
P09006051A1162|290 315|acetyl coenzyme A synthetases
P09006555A0738|20 51|Systemic and pulmonary hemodynamics
P09006555A0738|53 65|arterial blood
P09006555A0738|66 81|gas determination
P09006555A0738|114 130|neutrophil content
P09006555A0738|132 153|neutrophil oxidant burst
P09006555A0738|155 180|lung myeloperoxidase content
P09006555A0738|155 173|lung myeloperoxidase
P09006555A0738|193 219|electron micrographic studies
P09006902A0370|15 18|cDNA
P09006902A0370|27 36|human MEKK3
P09006902A0370|27 36|human MEKK3
P09006910A0000|63 98|retinoid X receptor (RXR) gene expression
P09006910A0000|63 79|retinoid X receptor
P09006910A0000|81 88|RXR) gene
P09006910A0000|103 119|5'-flanking region
P09006910A0000|125 145|human RXRgamma2 isoform
P09006910A0000|125 145|human RXRgamma2 isoform
P09006914A0812|0 2|JNK
P09006914A0812|0 2|JNK
P09006914A0812|6 8|p38
P09006914A0812|6 8|p38
P09006914A0812|38 44|nucleus
P09006914A0812|58 62|c-JUN
P09006914A0812|58 62|c-JUN
P09006914A0812|66 70|ATF-2
P09006914A0812|66 70|ATF-2
P09006914A0812|91 93|JNK
P09006914A0812|91 93|JNK
P09006914A0812|97 99|p38
P09006914A0812|97 99|p38
P09006914A1127|41 63|JNK/p38 signaling pathway
P09006914A1127|41 43|JNK
P09006914A1127|45 47|p38
P09006914A1127|96 102|kinases
P09006914A1127|116 155|cytokine-induced E-selectin gene expression
P09006914A1127|132 145|E-selectin gene
P09006935A0590|0 2|Sp1
P09006935A0590|0 2|Sp1
P09006935A0590|11 19|CTC repeat
P09006935A0590|63 76|consensus GC box
P09006936T0000|27 46|actin-binding protein
P09006936T0000|27 46|actin-binding protein
P09006936T0000|61 77|cytoplasmic domain
P09006936T0000|80 98|glycoprotein IBalpha
P09006936T0000|80 98|glycoprotein IBalpha
P09008301A0193|0 16|Mutant enzyme forms
P09008301A0193|50 67|autoprocessing site
P09008301A0193|87 105|single-chain protein
P09008301A0193|87 105|single-chain protein
P09009208A0337|3 8|primer
P09009208A0337|65 71|Tf1 mRNA
P09009208A0337|65 71|Tf1 mRNA
P09010223A0667|30 33|ELK1
P09010223A0667|30 33|ELK1
P09010223A0667|35 39|SAP1a
P09010223A0667|35 39|SAP1a
P09010223A0667|41 44|FLI1
P09010223A0667|41 44|FLI1
P09010223A0667|46 53|EWS-FLI1
P09010223A0667|46 53|EWS-FLI1
P09010223A0667|55 58|ETS1
P09010223A0667|55 58|ETS1
P09010223A0667|60 63|ETS2
P09010223A0667|60 63|ETS2
P09010223A0667|65 68|PEA3
P09010223A0667|65 68|PEA3
P09010223A0667|72 83|PU.1 proteins
P09010223A0667|72 75|PU.1
P09010223A0667|111 113|SRF
P09010223A0667|111 113|SRF
P09010223A0667|119 131|Egr1 SREI and II
P09010223A0667|119 122|Egr1
P09010223A0667|123 131|SREI and II
P09010223A1850|4 11|R-domain
P09010223A1850|41 43|SRF
P09010223A1850|41 43|SRF
P09010223A1850|83 86|FLI1
P09010223A1850|83 86|FLI1
P09010223A1850|90 97|EWS-FLI1
P09010223A1850|90 97|EWS-FLI1
P09010223A1850|136 158|ETS transcription factors
P09010223A1850|136 158|ETS transcription factors
P09010223A1850|179 186|Egr1 gene
P09010223A1850|179 186|Egr1 gene
P09011591A0309|52 58|smokers
P09011744A0790|3 19|murine chromosomal
P09011744A0790|34 37|five
P09011744A0790|38 64|NMDA receptor channel subunits
P09011744A0790|38 49|NMDA receptor
P09011744A0790|69 83|epsilon 1 (Grin2a
P09011744A0790|69 76|epsilon 1
P09011744A0790|78 83|Grin2a
P09011744A0790|86 100|epsilon 2 (Grin2b
P09011744A0790|86 93|epsilon 2
P09011744A0790|95 100|Grin2b
P09011744A0790|103 110|epsilon 3
P09011744A0790|103 110|epsilon 3
P09011744A0790|112 117|Grin2c
P09011744A0790|112 117|Grin2c
P09011744A0790|120 127|epsilon 4
P09011744A0790|120 127|epsilon 4
P09011744A0790|129 143|Grin2d) and zeta 1
P09011744A0790|129 134|Grin2d
P09011744A0790|139 143|zeta 1
P09011744A0790|145 149|Grinl
P09011744A0790|145 149|Grinl
P09011744A0790|235 235|[
P09011744A0790|237 271|C57BL/6JxM. spretus) F1xC57BL/6J] mice
P09011745T0000|0 10|CDNA cloning
P09011745T0000|13 86|chick brain alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
P09011745T0000|23 77|alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
P09011745T0000|129 157|post-transcriptional processes
P09011745T0000|162 179|mammalian receptors
P09011745T0000|162 179|mammalian receptors
P09012405A0785|15 19|TTD-A
P09012405A0785|15 19|TTD-A
P09012405A0785|23 33|XP-D defects
P09012405A0785|23 26|XP-D
P09012405A0785|61 65|TFIIH
P09012405A0785|61 65|TFIIH
P09012405A0785|68 91|basal transcription factor
P09012405A0785|113 121|DNA repair
P09012636A0723|0 9|Adjustment
P09012636A0723|22 32|cholesterol
P09012636A0723|34 47|HDL cholesterol
P09012636A0723|34 47|HDL cholesterol
P09012636A0723|49 61|triglycerides
P09012636A0723|133 142|fibrinogen
P09012636A0723|133 142|fibrinogen
P09012636A0723|146 160|atherosclerosis
P09013499A0198|2 12|Experiment 1
P09013499A0198|49 62|noncompetitive
P09013499A0198|63 100|N-methyl-D-aspartate receptor antagonist
P09013499A0198|63 90|N-methyl-D-aspartate receptor
P09013499A0198|101 106|MK-801
P09013499A0198|208 229|saline-treated controls
P09013760A0000|0 42|Cholesterol side-chain cleavage cytochrome P450
P09013760A0000|0 20|Cholesterol side-chain
P09013760A0000|29 42|cytochrome P450
P09013760A0000|44 62|CYP11A; P450scc) gene
P09013760A0000|44 49|CYP11A
P09013760A0000|51 57|P450scc
P09013760A0000|86 98|gonadotropins
P09013760A0000|86 98|gonadotropins
P09013760A0000|102 105|cAMP
P09013760A0000|111 115|ovary
P09013760A0000|121 124|ACTH
P09013760A0000|121 124|ACTH
P09013760A0000|128 131|cAMP
P09013760A0000|141 153|cortical cells
P09015543A0210|22 46|thin radial forearm free flap
P09015757T0000|0 17|Structural analysis
P09015757T0000|48 75|hormonal responsive expression
P09015757T0000|81 101|avian bone sialoprotein
P09015757T0000|81 101|avian bone sialoprotein
P09015757T0000|103 110|BSP) gene
P09015757T0000|103 105|BSP
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|20 33|suicide victims
P09015799T0000|38 52|major depression
P09016566A0655|3 23|Y-type structural motif
P09016566A0655|3 23|Y-type structural motif
P09016566A0655|53 61|divergent
P09016566A0655|62 69|BiP mRNAs
P09016566A0655|62 69|BiP mRNAs
P09017443A0734|6 25|positive marker screen
P09017443A0734|58 74|hand-foot syndrome
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|30 40|human tumors
P09018122A1389|100 115|tumor development
P09018133A0244|0 19|Phylogenetic analysis
P09018133A0244|72 77|PhHV-1
P09018133A0244|93 111|Varicellovirus genus
P09018133A0244|117 154|alpha-Herpesvirinae and canid herpesvirus
P09019302A0600|13 15|PLP
P09019302A0600|13 15|PLP
P09019302A0600|18 23|plasma
P09019302A0600|43 57|high sensitivity
P09019302A0600|81 95|sodium bisulfite
P09019302A0600|101 111|mobile phase
P09020138A0833|4 7|HEF1
P09020138A0833|4 7|HEF1
P09020138A0833|11 13|Cas
P09020138A0833|11 13|Cas
P09020138A0833|46 72|adhesion focal tyrosine kinase
P09020138A0833|74 78|RAFTK
P09020138A0833|74 78|RAFTK
P09020138A0833|118 132|adapter molecule
P09020138A0833|133 136|CrkL
P09020138A0833|133 136|CrkL
P09020169A0552|0 3|SIM1
P09020169A0552|0 3|SIM1
P09020169A0552|7 10|SIM2
P09020169A0552|7 10|SIM2
P09020169A0552|20 29|homodimers
P09020169A0552|55 57|AHR
P09020172A0964|0 8|Complexes
P09020172A0964|11 16|qTBP42
P09020172A0964|11 16|qTBP42
P09020172A0964|85 96|guanine-rich
P09020172A0964|161 187|double-stranded telomeric DNA
P09020856A0560|27 30|TIS1
P09020856A0560|27 30|TIS1
P09020856A0560|58 68|MCK promoter
P09020856A0560|58 68|MCK promoter
P09021684A1418|31 46|abnormal proteins
P09021684A1418|78 84|nucleus
P09021684A1418|145 157|NF-kappa B2p52
P09021684A1418|145 157|NF-kappa B2p52
P09022040A0263|7 25|L-plastin expression
P09022040A0263|7 15|L-plastin
P09022040A0263|62 67|humans
P09022040A0263|71 77|rodents
P09022040A0263|118 140|L-plastin gene expression
P09022040A0263|118 130|L-plastin gene
P09022040A0263|143 161|human and rodent cells
P09022040A0263|239 274|human and murine L-plastin gene promoters
P09022040A0263|247 265|murine L-plastin gene
P09022632T0000|25 42|obstetrical surgery
P09023197T0000|3 12|dnaK operon
P09023197T0000|3 12|dnaK operon
P09023197T0000|15 30|Bacillus subtilis
P09023197T0000|15 30|Bacillus subtilis
P09023378A0959|21 24|CBF1
P09023378A0959|21 24|CBF1
P09023378A0959|27 31|yeast
P09023378A0959|65 77|reporter genes
P09023378A0959|91 102|C-repeat/DRE
P09023378A0959|91 98|C-repeat
P09023378A0959|100 102|DRE
P09023378A0959|107 131|upstream activator sequence
P09023378A0959|157 166|DNA element
P09024039A0247|9 11|ASA
P09024039A0247|26 30|I or II
P09024039A0247|36 43|patients
P09024039A0247|70 87|surgical procedures
P09024039A0247|118 120|CCA
P09024039A0247|125 134|desflurane
P09024039A0247|173 195|spontaneous or controlled
P09024097A0000|38 60|chlamydia-infected women
P09024097A0000|78 97|febrile complications
P09024097A0000|103 125|postpartum tubal ligation
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024793A1325|43 57|nuclear extracts
P09024793A1325|63 75|myogenic cells
P09024793A1325|77 80|MyoD
P09024793A1325|77 80|MyoD
P09024793A1325|84 91|myogenin
P09024793A1325|84 91|myogenin
P09024793A1325|102 106|right
P09024793A1325|107 111|E-box
P09024793A1325|117 130|enhancer region
P09024793A1325|136 142|MCK gene
P09024793A1325|136 142|MCK gene
P09024793A1325|162 166|BMP-2
P09024793A1325|162 166|BMP-2
P09024805A0905b|1 29|heterologous promoter construct
P09024805A0905b|55 70|consensus Sp1 site
P09024805A0905b|64 70|Sp1 site
P09024805A0905b|104 123|ZII (CREB/ AP1) element
P09024805A0905b|104 106|ZII
P09024805A0905b|108 111|CREB
P09024805A0905b|113 115|AP1
P09024805A0905b|131 143|BZLF1 promoter
P09024805A0905b|131 143|BZLF1 promoter
P09024805A0905b|155 172|beta-globin TATA box
P09024805A0905b|155 172|beta-globin TATA box
P09024805A0905b|183 206|phorbol ester inducibility
P09025122A0374|53 68|cognitive aspects
P09025122A0374|74 81|COWA task
P09025549A0000|41 50|competence
P09025549A0000|109 132|sex therapist Bianca Rucker
P09025549A0000|222 230|continent
P09027346A1957|25 32|site IIIa
P09027346A1957|38 58|hCG-ectodomain complex
P09027346A1957|38 58|hCG-ectodomain complex
P09027346A1957|78 92|anti-peptide mAb
P09027346A1957|78 92|anti-peptide mAb
P09027346A1957|109 115|peptide
P09027346A1957|128 137|eighth exon
P09027346A1957|139 142|pE x 8
P09027346A1957|149 151|LHR
P09027506T0000|0 10|cDNA cloning
P09027506T0000|34 56|chromosomal localization
P09027506T0000|82 86|wheat
P09027506T0000|87 97|eIF-(iso)4F
P09027506T0000|87 97|eIF-(iso)4F
P09027506T0000|101 115|mammalian eIF-4G
P09027506T0000|101 115|mammalian eIF-4G
P09028089A0183|32 43|hypertension
P09028089A0183|62 71|renal blood
P09028089A0183|88 114|renal transplantation surgery
P09028308A0590|3 9|initial
P09028308A0590|10 17|patients
P09028308A0590|29 31|AZQ
P09028308A0590|68 88|bone marrow suppression
P09028308A0590|135 139|G-CSF
P09028308A0590|135 139|G-CSF
P09028308A0590|203 214|chemotherapy
P09028942A0000|0 50|Human granulocyte-macrophage colony-stimulating factor
P09028942A0000|5 50|granulocyte-macrophage colony-stimulating factor
P09028942A0000|52 58|hGM-CSF
P09028942A0000|52 58|hGM-CSF
P09028942A0000|75 79|genes
P09028942A0000|86 90|c-fos
P09028942A0000|86 90|c-fos
P09028942A0000|92 126|jun, myc, and early growth response gene 1
P09028942A0000|92 94|jun
P09028942A0000|96 98|myc
P09028942A0000|103 126|early growth response gene 1
P09028942A0000|128 132|egr-1
P09028942A0000|128 132|egr-1
P09028998A0143|82 93|breast tissue
P09028998A0143|113 115|BCT
P09029091A0881|21 55|TCR-mediated tyrosine phosphorylation
P09029091A0881|21 23|TCR
P09029091A0881|58 77|phospholipase C gamma 1
P09029091A0881|58 77|phospholipase C gamma 1
P09029091A0881|96 106|Jurkat cells
P09029091A0881|120 132|A2/HCP chimera
P09029091A0881|120 121|A2
P09029091A0881|123 125|HCP
P09029104A0226|3 17|14.1(IGLL1) gene
P09029104A0226|8 17|IGLL1) gene
P09029104A0226|32 64|lineage- and stage-restricted manner
P09029159A0000|3 16|interferon (IFN
P09029159A0000|3 12|interferon
P09029159A0000|14 16|IFN
P09029159A0000|26 43|double-stranded RNA
P09029159A0000|26 43|double-stranded RNA
P09029159A0000|45 80|dsRNA)-activated Ser/Thr protein kinase
P09029159A0000|45 80|dsRNA)-activated Ser/Thr protein kinase
P09029159A0000|82 84|PKR
P09029159A0000|82 84|PKR
P09029159A0000|101 136|antiviral and antiproliferative effects
P09029159A0000|139 141|IFN
P09029713A1120|27 47|cAMP-dependent control
P09029713A1120|65 75|activator SF
P09029713A1120|74 77|SF-1
P09029713A1120|93 99|COUP-TF
P09029713A1120|93 99|COUP-TF
P09029713A1120|114 140|CRS2-dependent transcription
P09029956T0000|36 60|psychic structure formation
P09030581A0990|15 24|COS-7 cells
P09030581A0990|26 30|MKP-4
P09030581A0990|26 30|MKP-4
P09030581A0990|49 58|MAP kinases
P09030581A0990|49 58|MAP kinases
P09030581A0990|77 79|ERK
P09030581A0990|77 79|ERK
P09030581A0990|81 83|p38
P09030581A0990|85 92|JNK/SAPK
P09030581A0990|85 87|JNK
P09030581A0990|89 92|SAPK
P09030688A0435|2 12|rlf2 mutants
P09030688A0435|2 5|rlf2
P09030688A0435|23 31|chromatin
P09030688A0435|74 90|Rap1p localization
P09030688A0435|74 78|Rap1p
P09030781A0734|41 51|roscovitine
P09030781A0734|53 64|cdc2/cyclin B
P09030781A0734|53 56|cdc2
P09030781A0734|58 64|cyclin B
P09030781A0734|66 77|cdk2/cyclin A
P09030781A0734|66 69|cdk2
P09030781A0734|71 77|cyclin A
P09030781A0734|79 82|cdk2
P09030781A0734|79 82|cdk2
P09030781A0734|84 90|cyclin E
P09030781A0734|84 90|cyclin E
P09030781A0734|94 101|cdk5/p35
P09030781A0734|94 97|cdk5
P09030781A0734|99 101|p35
P09030781A0734|183 195|cdk4/cyclin D1
P09030781A0734|183 186|cdk4
P09030781A0734|188 195|cyclin D1
P09030781A0734|199 211|cdk6/cyclin D2
P09030781A0734|199 202|cdk6
P09030781A0734|204 211|cyclin D2
P09030781A0734|236 246|roscovitine
P09031639A0474|24 39|open reading frame
P09031639A0474|41 43|ORF
P09031639A0474|47 51|477 bp
P09031639A0474|74 86|159 amino acids
P09031639A0474|121 130|position 65
P09031639A0474|139 154|human U1-C protein
P09031639A0474|144 154|U1-C protein
P09032233T0000|13 17|Ets-1
P09032233T0000|13 17|Ets-1
P09032233T0000|24 50|POU-homeodomain protein GHF-1
P09032233T0000|24 45|POU-homeodomain protein
P09032233T0000|46 50|GHF-1
P09032233T0000|52 56|Pit-1
P09032233T0000|52 56|Pit-1
P09032233T0000|70 101|pituitary-specific gene expression
P09032248A0239|8 12|Pho85
P09032248A0239|8 12|Pho85
P09032248A0239|40 57|Pcl1,2-Pho85 kinase
P09032248A0239|40 57|Pcl1,2-Pho85 kinase
P09032248A0239|85 89|Start
P09032248A0239|104 122|Cln1,2-Cdc28 kinases
P09032248A0239|104 122|Cln1,2-Cdc28 kinases
P09032250A0257|8 28|yeast two-hybrid system
P09032250A0257|65 68|Tax1
P09032250A0257|65 68|Tax1
P09032250A0257|83 90|B subunit
P09032250A0257|96 118|CCAAT binding protein NF-Y
P09032250A0257|96 114|CCAAT binding protein
P09032250A0257|115 118|NF-Y
P09032250A0257|124 138|HeLa cDNA library
P09032254A0724|0 15|Enhancer activity
P09032254A0724|31 38|AP-1 site
P09032254A0724|31 38|AP-1 site
P09032258A0395|12 47|HLA-DR-B7-1-LFA-3 triple transfectants
P09032258A0395|12 22|HLA-DR-B7-1
P09032258A0395|24 28|LFA-3
P09032258A0395|61 65|LFA-3
P09032258A0395|61 65|LFA-3
P09032258A0395|74 96|NF-AT DNA binding activity
P09032258A0395|74 81|NF-AT DNA
P09032258A0395|121 124|B7-1
P09032258A0395|121 124|B7-1
P09032259A0150|0 21|Constitutive activation
P09032259A0150|24 27|Rac1
P09032259A0150|24 27|Rac1
P09032259A0150|31 34|RhoA
P09032259A0150|31 34|RhoA
P09032259A0150|68 78|NIH 3T3 cells
P09032259A0150|117 133|Ras transformation
P09032259A0150|117 119|Ras
P09032259A0972|12 15|Rac1
P09032259A0972|12 15|Rac1
P09032259A0972|28 30|JNK
P09032259A0972|28 30|JNK
P09032259A0972|33 35|SRF
P09032259A0972|33 35|SRF
P09032259A0972|50 61|lamellipodia
P09032259A0972|98 101|Rac1
P09032259A0972|98 101|Rac1
P09032267A0850|19 39|bZip interaction domain
P09032267A0850|42 44|CBP
P09032267A0850|42 44|CBP
P09032267A0850|93 94|TR
P09032267A0850|93 94|TR
P09032267A0850|98 106|p45/NF-E2
P09032267A0850|98 100|p45
P09032267A0850|102 106|NF-E2
P09032275A1133|4 19|inhibitory domain
P09032275A1133|57 74|AHC deletion mutants
P09032275A1133|57 74|AHC deletion mutants
P09032304T0000|17 54|promoter-specific transactivation domain
P09032304T0000|60 98|herpes simplex virus regulatory protein ICP4
P09032304T0000|60 94|herpes simplex virus regulatory protein
P09032304T0000|95 98|ICP4
P09032328A0650|0 12|DNA sequencing
P09032328A0650|16 27|17-kb segment
P09032328A0650|57 70|divergent locus
P09032328A0650|72 75|DL-B
P09032328A0650|72 75|DL-B
P09032328A0650|84 88|ORF11
P09032328A0650|92 96|ORF17
P09032328A0650|122 130|viral ORFs
P09032328A0650|165 180|cellular proteins
P09034337A0251|9 22|mammalian cells
P09034337A0251|48 67|inhibitory tyrosine 15
P09034337A0251|69 71|Y15
P09034337A0251|69 71|Y15
P09034337A0251|90 96|p34cdc2
P09034337A0251|90 96|p34cdc2
P09034337A0251|114 122|DNA damage
P09035307A0000|35 37|man
P09035307A0000|62 79|parathyroid adenoma
P09035307A0000|93 135|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|137 146|99mTc-MIBI
P09035612T0000|0 23|Cardiac endothelin release
P09035612T0000|39 57|myocardial blood flow
P09035612T0000|62 80|ventricular function
P09035612T0000|83 112|canine infarction and reperfusion
P09036529A0343|17 25|skin tests
P09036529A0343|45 53|Pharmacia
P09036529A0343|77 84|serum IgE
P09036529A0343|82 84|IgE
P09036529A0343|89 96|RAST-CAP
P09036529A0343|98 106|Pharmacia
P09036529A0343|112 115|CAST
P09036529A0343|141 143|bee
P09036529A0343|145 157|Apis mellifera
P09036529A0343|162 165|wasp
P09036529A0343|167 184|Vespula spec.) venom
P09036529A0343|186 195|Aquagen ALK
P09037032T0000|25 50|protein-related (P2P-R) gene
P09037032T0000|41 50|P2P-R) gene
P09037032T0000|70 106|heterogeneous nuclear ribonucleoprotein
P09037032T0000|121 123|Rb1
P09037032T0000|121 123|Rb1
P09037032T0000|145 154|expression
P09037032T0000|161 183|terminal differentiation
P09037064A0183|19 56|recombinant canarypox ALVAC/HIV-1 vectors
P09037064A0183|59 65|vaccine
P09037064A0183|78 105|HIV-1,-noninfected volunteers
P09037064A0183|78 82|HIV-1
P09037064A0183|117 128|CTL responses
P09037064A0183|151 159|vaccinees
P09037163A1652|59 76|gpc4 gene expression
P09037163A1652|59 66|gpc4 gene
P09038166A0818|0 7|Exons A1a
P09038166A0818|11 13|A1b
P09038166A0818|42 61|124-nucleotide intron
P09038192A0846|1 21|MEK-specific inhibitor
P09038192A0846|1 3|MEK
P09038192A0846|23 30|PD098059
P09038202A1951|50 58|NRSF/REST
P09038202A1951|50 53|NRSF
P09038202A1951|55 58|REST
P09038202A1951|82 89|promoter
P09039744T0000|0 26|Enhanced period-peak analysis
P09039744T0000|29 50|electro-encephalograms
P09040011A1316|10 17|p56(lck)
P09040011A1316|10 12|p56
P09040011A1316|14 16|lck
P09040011A1316|36 49|G1/S transition
P09040011A1316|52 70|immature thymoblasts
P09040011A1316|169 187|Ras/Raf/MAPK pathway
P09040011A1316|169 171|Ras
P09040011A1316|173 175|Raf
P09040011A1316|177 180|MAPK
P09041123A0195|23 35|cognate ligand
P09041123A0195|42 65|accessory cellular factors
P09041123A0195|98 121|transcriptional responses
P09041123A0195|125 146|heterodimer-DNA complex
P09042078A0202|17 19|MBF
P09042078A0202|22 29|incisors
P09042078A0202|90 97|subjects
P09042269A1007|24 59|intraarterial neoadjuvant chemotherapy
P09042269A1007|87 100|cervical cancer
P09042683A0492|3 18|FBF questionnaire
P09042683A0492|71 93|schizoaffective disorder
P09042683A0492|111 134|bipolar affective disorder
P09042683A0492|138 150|schizophrenia
P09042755T0000|14 30|sigma factor sigmaB
P09042755T0000|14 24|sigma factor
P09042755T0000|25 30|sigmaB
P09042755T0000|33 52|Staphylococcus aureus
P09042755T0000|69 78|sigB operon
P09042755T0000|69 78|sigB operon
P09042755T0000|91 101|growth phase
P09042755T0000|105 113|heat shock
P09042911A0626|0 22|Cognate promoter elements
P09042911A0626|35 75|glucocorticoid- and cAMP-mediated regulation
P09042911A0626|86 133|liver-, myeloid-, and lymphocyte-specific expression
P09042911A0626|153 170|5' flanking sequence
P09043534A1600|10 28|meaningful decreases
P09043768A0139|29 38|BLM labeled
P09043768A0139|43 52|indium-111
P09045636A0789|0 45|CD3 cross-linking induced tyrosine phosphorylation
P09045636A0789|0 2|CD3
P09045636A0789|48 52|Sam68
P09045636A0789|48 52|Sam68
P09045636A0789|55 70|uninfected T cells
P09045805A0945|0 26|Acetoin-dependent expression
P09045805A0945|32 44|acoABCD operon
P09045805A0945|32 44|acoABCD operon
P09045805A0945|65 81|E. coli acoK mutants
P09045805A0945|65 81|E. coli acoK mutants
P09045805A0945|94 100|plasmid
P09045805A0945|117 120|acoK
P09045805A0945|117 120|acoK
P09045842T0000|0 8|Mutations
P09045842T0000|14 29|alpha and sigma-70
P09045842T0000|14 29|alpha and sigma-70
P09045842T0000|40 52|RNA polymerase
P09045842T0000|40 52|RNA polymerase
P09045842T0000|74 82|mer operon
P09045842T0000|74 82|mer operon
P09045919A1250|48 58|an activator
P09045919A1250|60 62|NFE
P09045919A1250|60 62|NFE
P09045919A1250|89 91|p50
P09045919A1250|89 91|p50
P09045919A1250|95 107|c-Rel proteins
P09045919A1250|95 107|c-Rel proteins
P09045919A1250|121 139|transcription factor
P09045919A1250|162 179|3' enhancer activity
P09045919A1250|162 171|3' enhancer
P09045919A1250|203 210|IgH locus
P09045919A1250|203 210|IgH locus
P09045919A1250|213 238|late B lymphocyte development
P09046013A0000|63 83|calcium channel blocker
P09046013A0000|85 91|SNX-111
P09046013A0000|120 135|hypertensive rats
P09046013A0000|159 174|cerebral ischemia
P09046013A0000|199 203|right
P09046013A0000|204 222|common carotid artery
P09046013A0000|226 243|temporary occlusion
P09046013A0000|249 259|right middle
P09046013A0000|260 267|cerebral
P09046013A0000|268 273|artery
P09046090T0000|19 45|transcription factor yTAFII60
P09046090T0000|19 37|transcription factor
P09046090T0000|38 45|yTAFII60
P09046090T0000|50 60|G4p1 protein
P09046090T0000|50 60|G4p1 protein
P09046090T0000|73 90|glucose transporter
P09046090T0000|73 90|glucose transporter
P09046090T0000|106 122|12.3 kb DNA fragment
P09046090T0000|128 131|left
P09046090T0000|137 159|Saccharomyces cerevisiae
P09046090T0000|160 172|chromosome VII
P09046186A0189|59 68|trochanter
P09046384A0403|48 57|CD4+ counts
P09046384A0403|48 51|CD4+
P09046384A0403|69 75|amylase
P09046384A0403|69 75|amylase
P09046384A0403|91 101|DDI subgroup
P09047252A0209|19 26|patients
P09047252A0209|40 63|curative hepatic resection
P09047252A0209|67 69|HCC
P09047252A0209|90 98|AFP levels
P09047344A0000|0 24|Calmodulin-binding peptide
P09047344A0000|0 24|Calmodulin-binding peptide
P09047344A0000|26 28|CBP
P09047344A0000|26 28|CBP
P09047344A0000|32 38|peptide
P09047344A0000|43 52|amino acids
P09047344A0000|64 91|muscle myosin light chain kinase
P09047344A0000|64 91|muscle myosin light chain kinase
P09047344A0000|93 96|MLCK
P09047344A0000|93 96|MLCK
P09047344A0000|106 115|calmodulin
P09047344A0000|106 115|calmodulin
P09048617A0648|23 54|tyrosine kinase receptor stimulated
P09048617A0648|23 44|tyrosine kinase receptor
P09048617A0648|87 96|cAMP effect
P09049198A0289|41 43|p21
P09049198A0289|41 43|p21
P09049198A0289|46 60|liver cell growth
P09049198A0289|93 99|p21 gene
P09049198A0289|93 99|p21 gene
P09049198A0289|114 119|rodent
P09049198A0289|128 132|liver
P09049198A0289|159 168|human liver
P09049270A0488|0 19|Northern blot analysis
P09049270A0488|22 35|LeMT(A) and LeMT
P09049270A0488|22 27|LeMT(A
P09049270A0488|32 37|LeMT(B
P09049270A0488|66 77|MT-like genes
P09049270A0488|66 72|MT-like
P09049270A0488|119 124|plants
P09049270A0488|147 151|extra
P09049270A0488|152 160|metal ions
P09049270A0488|179 187|type II MTs
P09049270A0488|179 187|type II MTs
P09049304A1193|2 23|co-transfection studies
P09049304A1193|27 30|AP-2
P09049304A1193|27 30|AP-2
P09049304A1193|39 43|Egr-1
P09049304A1193|39 43|Egr-1
P09049304A1193|69 89|VPF/VEGF transcription
P09049304A1193|69 71|VPF
P09049304A1193|73 76|VEGF
P09049304A1193|109 119|AP-2 protein
P09049304A1193|109 119|AP-2 protein
P09049304A1193|145 182|TGF alpha-induced VPF/VEGF gene expression
P09049304A1193|145 152|TGF alpha
P09049304A1193|161 163|VPF
P09049304A1193|165 172|VEGF gene
P09049306A0830|3 9|HBP gene
P09049306A0830|3 9|HBP gene
P09049306A0830|51 58|short arm
P09049306A0830|61 71|chromosome 4
P09049313A0116|53 75|virally encoded proteases
P09049313A0116|116 120|eIF4G
P09049313A0116|116 120|eIF4G
P09050689A0685|7 25|endometrial ablation
P09050689A0685|37 41|SnET2
P09050689A0685|52 77|intrauterine administration
P09050689A0685|82 95|light treatment
P09050847A0180|6 19|class II- and III
P09050847A0180|6 19|class II- and III
P09050847A0180|29 44|TBP-TAF complexes
P09050847A0180|29 31|TBP
P09050847A0180|33 44|TAF complexes
P09050847A0180|62 129|murine and human class I-specific transcription initiation factor TIF-IB/SL1
P09050847A0180|71 125|human class I-specific transcription initiation factor TIF-IB
P09050847A0180|127 129|SL1
P09050849A0000|0 10|Cytohesin-1
P09050849A0000|0 10|Cytohesin-1
P09050849A0000|40 51|immune system
P09050849A0000|73 84|human homolog
P09050849A0000|90 127|Saccharomyces cerevisiae Sec7 gene product
P09050849A0000|90 112|Saccharomyces cerevisiae
P09050849A0000|113 127|Sec7 gene product
P09050849A0000|145 160|protein transport
P09050849A1459|43 62|BFA-sensitive ARF-GEP
P09050849A1459|56 58|ARF
P09050849A1459|60 62|GEP
P09050849A1459|76 85|Sec7 domain
P09050849A1459|76 85|Sec7 domain
P09050861A0903|32 34|DEK
P09050861A0903|32 34|DEK
P09050861A0903|41 56|43-kDa pets factor
P09050861A0903|47 56|pets factor
P09050867A0542|22 32|binding site
P09050867A0542|36 47|Krox proteins
P09050867A0542|36 47|Krox proteins
P09050867A0542|55 68|nuclear factor 1
P09050867A0542|55 68|nuclear factor 1
P09050867A0542|72 83|octamer motif
P09050867A0542|93 115|POU-homeodomain proteins
P09050867A0542|93 115|POU-homeodomain proteins
P09050867A0542|126 141|TN control element
P09050867A0542|126 141|TN control element
P09051656A0390|0 12|Tissue samples
P09051656A0390|35 38|rats
P09051656A0390|59 74|opiate withdrawal
P09051656A0390|122 136|control subjects
P09053309A1103|21 41|floor plate development
P09053309A1103|44 53|oep mutants
P09053309A1103|44 53|oep mutants
P09053309A1103|82 101|floor plate inducer shh
P09053309A1103|82 101|floor plate inducer shh
P09053494A0612|32 40|CD34+ cell
P09053494A0612|50 57|patients
P09053494A0612|69 78|paclitaxel
P09053494A0612|83 84|CY
P09053494A0612|83 84|CY
P09053494A0612|86 87|CE
P09053494A0612|86 87|CE
P09053494A0612|92 94|CEP
P09053494A0612|99 103|G-CSF
P09053494A0612|99 103|G-CSF
P09053494A0612|205 206|CY
P09053494A0612|211 215|G-CSF
P09053494A0612|211 215|G-CSF
P09053494A0612|235 236|09
P09053835A0865|9 19|p53 activity
P09053835A0865|9 11|p53
P09053835A0865|29 30|OP
P09053835A0865|29 30|OP
P09053835A0865|49 55|p53 mRNA
P09053835A0865|49 55|p53 mRNA
P09053835A0865|61 73|protein levels
P09053973A1252|11 31|Chronic administration
P09053973A1252|34 44|misoprostol
P09053973A1252|86 102|cirrhotic patients
P09053973A1252|107 113|ascites
P09055221A0288|17 21|SSTEs
P09055221A0288|61 64|MSEs
P09056761A0000|2 16|eukaryotic cells
P09056761A0000|18 37|premature termination
P09056761A0000|53 66|nonsense codons
P09056761A0000|106 130|posttranscriptional events
P09056761A0000|160 168|cytoplasm
P09056761A0000|189 207|splice site selection
P09057325A0177|11 21|plasmid pCM2
P09057325A0177|51 55|pat-1
P09057325A0177|51 55|pat-1
P09057325A0177|67 82|deletion analysis
P09057325A0177|86 107|complementation studies
P09057325A0177|117 137|Bg/II/SmaI DNA fragment
P09057325A0177|117 121|Bg/II
P09057325A0177|123 126|SmaI
P09057648A0422|0 22|Transient cotransfection
P09057648A0422|25 31|tat cDNA
P09057648A0422|25 31|tat cDNA
P09057648A0422|34 49|sense orientation
P09057648A0422|51 55|tat/S
P09057648A0422|51 53|tat
P09057648A0422|55 55|S
P09057648A0422|91 103|c-fos promoter
P09057648A0422|91 103|c-fos promoter
P09057648A0422|105 107|FC3
P09057648A0422|105 107|FC3
P09057648A0422|114 121|711 to +42
P09057648A0422|135 184|bacterial chloramphenicol acetyltransferase (CAT) gene
P09057648A0422|135 175|bacterial chloramphenicol acetyltransferase
P09057648A0422|177 179|CAT
P09057648A0422|206 216|CAT activity
P09057648A0422|206 208|CAT
P09057648A0422|219 229|Jurkat cells
P09057648A0422|257 270|fetal calf serum
P09057648A0422|272 274|FCS
P09057648A0422|292 309|phytohemagglutinin
P09057648A0422|292 309|phytohemagglutinin
P09057648A0422|325 347|phorbol myristate acetate
P09057648A0422|349 351|PMA
P09057648A0422|356 364|U937 cells
P09057648A0422|379 381|FCS
P09057648A0422|395 397|PMA
P09057703A1389|0 4|Snail
P09057840A0946|3 20|recombinant protein
P09057840A0946|3 20|recombinant protein
P09057840A0946|34 44|homogeneity
P09057840A0946|48 94|NH4)2SO4-precipitation and affinity chromatography
P09057840A0946|97 111|5' AMP-Sepharose
P09057841T0000|0 11|Derepression
P09057841T0000|14 27|gene expression
P09057841T0000|41 56|5' upstream region
P09057841T0000|62 80|isocitrate lyase gene
P09057841T0000|62 76|isocitrate lyase
P09057841T0000|83 99|Candida tropicalis
P09057841T0000|83 99|Candida tropicalis
P09057841T0000|125 142|regulatory pathways
P09057841T0000|145 167|Saccharomyces cerevisiae
P09058002T0000|0 20|Exploratory-motor task
P09058002T0000|36 52|frontal lobe damage
P09058250A0128|2 19|avoid complications
P09058250A0128|51 52|NO
P09058250A0128|51 52|NO
P09058250A0128|56 58|NO2
P09058250A0128|56 58|NO2
P09058323A1287|56 82|alpha 3 and beta 4 coding regions
P09058323A1287|56 61|alpha 3
P09058323A1287|65 82|beta 4 coding regions
P09058323A1287|129 139|CNS patterns
P09058323A1287|142 146|beta 4
P09058323A1287|142 146|beta 4
P09058323A1287|148 153|alpha 3
P09058323A1287|148 153|alpha 3
P09058323A1287|158 180|alpha 5 gene transcription
P09058323A1287|158 167|alpha 5 gene
P09058373A0670|0 25|RNase protection experiments
P09058373A0670|0 4|RNase
P09058373A0670|51 65|GHR1-279 variant
P09058373A0670|51 58|GHR1-279
P09058373A0670|68 76|IM-9 cells
P09058373A0670|80 89|human liver
P09058373A1620|20 32|a reporter gene
P09058373A1620|21 32|reporter gene
P09058373A1620|44 64|Stat5-binding elements
P09058373A1620|44 48|Stat5
P09058373A1620|148 166|full-length receptor
P09058373A1620|148 166|full-length receptor
P09058378A1134|20 42|glucocorticoid receptors
P09058378A1134|20 42|glucocorticoid receptors
P09058378A1134|81 83|p53
P09058378A1134|81 83|p53
P09058378A1134|107 109|p53
P09058378A1134|107 109|p53
P09059039A0850|0 10|99mTc-HMPAO
P09059039A0850|46 48|ACA
P09059039A0850|52 54|MCA
P09059039A0850|63 70|patients
P09059039A0850|89 109|intraarterial infusion
P09059039A0850|129 137|C4 segment
P09059039A0850|129 137|C4 segment
P09059039A0850|179 181|ACA
P09059039A0850|188 195|patients
P09059039A0850|214 234|intraarterial infusion
P09059039A0850|254 262|C1 segment
P09060045A0576|89 104|endotoxin release
P09060444A0557|42 63|luciferase reporter gene
P09060444A0557|42 63|luciferase reporter gene
P09060444A0557|83 107|transcriptional initiation
P09060444A0557|138 155|EGF-responsiveness
P09060444A0557|138 140|EGF
P09060444A0557|179 188|native gene
P09060622A1679|66 76|poly(A) tail
P09060622A1679|88 96|infection
P09060622A1679|109 133|polyadenylated viral genome
P09060623A0961|3 17|human coreceptor
P09060623A0961|3 17|human coreceptor
P09060623A0961|43 45|SIV
P09060676A1634|14 31|virus entry features
P09060676A1634|65 84|pathogenic properties
P09060971A0982|13 17|women
P09060971A0982|42 44|BMD
P09060971A0982|47 71|all non-spine skeletal sites
P09060971A0982|143 146|neck
P09060971A0982|159 160|/y
P09060971A0982|203 205|hip
P09060971A0982|218 219|/y
P09061697A0629|15 22|patients
P09061697A0629|42 44|MBq
P09061697A0629|98 102|21 mCi
P09061697A0629|124 131|protocol
P09061697A0629|148 155|patients
P09061697A0629|166 185|stress imaging studies
P09061697A0629|214 225|500 MBq (14 mCi
P09061697A0629|233 249|99Tcm-tetrofosmin
P09061697A0629|272 279|protocol
P09061697T0000|10 20|SPET imaging
P09061697T0000|25 41|99Tcm-tetrofosmin
P09061697T0000|86 100|imaging protocol
P09061698A0177|0 12|99Tcm-DMP-HSA
P09061698A0177|62 74|red blood cells
P09061698A0177|76 79|RBCs
P09061698A0177|132 146|blood pool agents
P09062130A0116|60 62|max
P09062130A0116|84 94|N-SH2 domain
P09062130A0116|84 94|N-SH2 domain
P09062130A0116|155 164|SH2 domains
P09062130A0116|155 164|SH2 domains
P09062130A0116|175 195|catalytic PTPase domain
P09062130A0116|184 195|PTPase domain
P09064659A1055|28 43|mammalian homolog
P09064659A1055|46 54|yeast UPF1
P09064659A1055|46 54|yeast UPF1
P09064659A1055|85 96|nonsense mRNA
P09064659A1055|129 138|human HUPF1
P09064659A1055|134 138|HUPF1
P09064659A1055|143 154|human homolog
P09064659A1055|157 160|UPF1
P09064659A1055|157 160|UPF1
P09064868T0001|1 11|miracle cure
P09065170A0853|13 22|zidovudine
P09065463A1012|0 25|DNA strand exchange catalyzed
P09065463A1012|28 39|Rad51 protein
P09065463A1012|28 39|Rad51 protein
P09065463A1012|65 67|RPA
P09065463A1012|65 67|RPA
P09065690A0463|0 4|Ume6p
P09065690A0463|0 4|Ume6p
P09065690A0463|38 54|early meiotic genes
P09065690A0463|65 78|CAR1 expression
P09065690A0463|65 68|CAR1
P09065690A0463|87 94|sequence
P09065690A0463|101 103|URS
P09065690A0463|118 125|nitrogen
P09065768A0862|9 13|class
P09065768A0862|16 19|cDNA
P09065768A0862|86 105|mammalian lactase mRNA
P09065768A0862|86 101|mammalian lactase
P09067577A0307|2 10|cell lines
P09067577A0307|24 30|BCR/ABL
P09067577A0307|24 26|BCR
P09067577A0307|28 30|ABL
P09067577A0307|32 35|CRKL
P09067577A0307|32 35|CRKL
P09067577A0307|67 69|CRK
P09067577A0307|67 69|CRK
P09067577A0721|2 19|untransformed cells
P09067577A0721|26 38|major proteins
P09067577A0721|26 38|major proteins
P09067577A0721|57 60|CRKL
P09067577A0721|57 60|CRKL
P09067577A0721|74 76|C3G
P09067577A0721|74 76|C3G
P09067577A0721|78 80|SOS
P09067577A0721|78 80|SOS
P09067577A0721|84 88|c-ABL
P09067577A0721|84 88|c-ABL
P09068989T0000|8 49|Azadirachta indica hydroalcoholic leaf extract
P09068989T0000|55 74|cardiovascular system
P09071308A0376|15 23|opacities
P09071308A0376|109 116|patients
P09071308A0376|121 123|MTB
P09071308A0376|127 130|NTMB
P09071407T0000|0 18|Circulating oxytocin
P09071407T0000|11 18|oxytocin
P09071407T0000|25 34|guinea pigs
P09071407T0000|48 65|female cohabitation
P09072361A0357|30 34|SHRSP
P09072361A0357|141 143|WKY
P09072361A0357|147 151|SHRSR
P09073074T0000|0 21|Antisense transcription
P09073074T0000|25 36|murine FGFR-3
P09073074T0000|31 46|FGFR-3 psuedogene
P09073074T0000|53 69|fetal developement
P09073582A0444|29 52|548-bp BglII-SmaI fragment
P09073582A0444|35 39|BglII
P09073582A0444|41 44|SmaI
P09073582A0444|58 68|SSO activity
P09074508A0397|3 15|human CD38 gene
P09074508A0397|8 11|CD38
P09074508A0397|50 53|77 kb
P09074508A0397|59 69|human genome
P09075739A0827|0 18|Type IV splice pattern
P09075739A0827|30 39|exon U3 and S
P09075739A0827|54 59|kidney
P09075739A0827|63 67|ovary
P09076336A0281|0 11|GH deficiency
P09076336A0281|0 1|GH
P09076336A0281|149 161|GH sufficiency
P09076336A0281|170 180|GH secretion
P09077076A0219|0 14|Positive CRP test
P09077108A0458|23 33|pleocytosis
P09077108A0458|63 65|IgG
P09077108A0458|63 65|IgG
P09077108A0458|67 70|IL-6
P09077108A0458|67 70|IL-6
P09077108A0458|72 80|TNF-alpha
P09077108A0458|72 80|TNF-alpha
P09077108A0458|85 88|PGE2
P09077108A0458|94 111|cerebrospinal fluid
P09077437T0000|11 43|mechanisms of the minus-strand origin
P09077437T0000|46 52|phage f1
P09077437T0000|55 82|Escherichia coli RNA polymerase
P09077437T0000|55 69|Escherichia coli
P09077437T0000|70 82|RNA polymerase
P09077438A0076|33 44|RNA synthesis
P09079625A0935|0 9|Syndecan-4
P09079625A0935|0 9|Syndecan-4
P09079625A0935|13 34|focal adhesion component
P09079625A0935|69 71|PKC
P09079625A0935|69 71|PKC
P09079638A0883|3 13|3ASubE cells
P09079638A0883|24 28|CXCR2
P09079638A0883|24 28|CXCR2
P09079638A0883|43 62|Ser-346, -347, and -348
P09079638A0883|65 71|alanine
P09079638A0883|153 158|ligand
P09079638A0883|202 216|ligand challenge
P09079650A0136|12 21|MAPK family
P09079650A0136|12 15|MAPK
P09079650A0136|32 59|extracellular response kinases
P09079650A0136|32 59|extracellular response kinases
P09079650A0136|61 64|ERKs
P09079650A0136|61 64|ERKs
P09079650A0136|67 78|p42/44(MAPK)
P09079650A0136|67 72|p42/44
P09079650A0136|74 77|MAPK
P09079650A0136|84 109|c-Jun amino-terminal kinases
P09079650A0136|84 109|c-Jun amino-terminal kinases
P09079650A0136|111 114|JNKs
P09079650A0136|111 114|JNKs
P09079650A0136|123 144|p38/Hog 1 protein kinases
P09079650A0136|123 125|p38
P09079650A0136|127 144|Hog 1 protein kinases
P09079689A0472|0 3|MOP5
P09079689A0472|0 3|MOP5
P09079689A0472|30 38|PAS domain
P09079689A0472|43 59|variable C terminus
P09079689A0472|93 102|bHLH domain
P09079689A0472|93 102|bHLH domain
P09079689A0472|116 131|open reading frame
P09079817A0928|62 65|mRNA
P09079817A0928|77 88|NO synthetase
P09079817A0928|77 88|NO synthetase
P09079878A0000|14 42|Lactobacillus sake plasmid pCIM1
P09079878A0000|86 102|open reading frames
P09079878A0000|104 107|ORFs
P09079878A0000|123 126|lasA
P09079878A0000|123 126|lasA
P09079878A0000|140 152|pre-lactocin S
P09079902A0713|8 10|Pra
P09079902A0713|8 10|Pra
P09079902A0713|47 63|pyruvate kinase (Pk
P09079902A0713|47 60|pyruvate kinase
P09079902A0713|62 63|Pk
P09079902A0713|66 67|Pk
P09079902A0713|71 73|Pra
P09079902A0713|71 73|Pra
P09079902A0713|100 108|12-kDa Ndk
P09079902A0713|110 111|Pk
P09079902A0713|116 118|Pra
P09079902A0713|133 134|Pk
P09079902A0713|157 159|Pra
P09079902A0713|185 193|12-kDa Ndk
P09079902A0713|191 193|Ndk
P09079904A0995|9 12|iron
P09079904A0995|24 37|sodA expression
P09079904A0995|24 27|sodA
P09079904A0995|60 70|DNA topology
P09079904A0995|80 91|coumermycin A
P09079904A0995|103 136|global virulence regulatory Bvg system
P09079915T0000|33 51|Borrelia burgdorferi
P09079915T0000|52 65|motility operon
P09079915T0000|94 108|sigma70 promoter
P09079915T0000|94 108|sigma70 promoter
P09079928A0525|0 11|M. leprae OxyR
P09079928A0525|0 7|M. leprae
P09079928A0525|8 11|OxyR
P09079928A0525|57 81|oxyR-ahpC intergenic region
P09079928A0525|57 65|oxyR-ahpC
P09079928A0525|66 81|intergenic region
P09079928A0525|84 91|M. leprae
P09079928A0525|84 91|M. leprae
P09079928A1319|17 36|OxyR overlapped P1oxyR
P09079928A1319|17 20|OxyR
P09079928A1319|31 36|P1oxyR
P09079928A1319|54 72|autoregulatory loops
P09079928A1319|96 99|oxyR
P09079928A1319|96 99|oxyR
P09079928A1319|102 116|enteric bacteria
P09079928A1319|139 153|LysR superfamily
P09079928A1319|139 153|LysR superfamily
P09080250A0212|51 71|p15E cDNA gene fragments
P09080250A0212|51 58|p15E cDNA
P09080250A0212|90 112|polymerase chain reaction
P09080250A0212|114 116|PCR
P09080250A0212|122 134|parental (P815
P09080250A0212|139 149|xenogenized
P09080250A0212|151 159|P815/DTIC
P09080250A0212|161 171|tumour cells
P09080517A0215|11 18|patients
P09081389A1088|0 16|Grade 3-4 mucositis
P09082335A0730|11 31|organic manifestations
P09082335A0730|47 64|scintigraphic means
P09083291A1378|5 13|TGF-beta1
P09083291A1378|5 13|TGF-beta1
P09083291A1378|29 53|mitogen-induced expression
P09083291A1378|68 82|G1 phase cyclin D1
P09083291A1378|68 74|G1 phase
P09083291A1378|75 82|cyclin D1
P09083291A1378|86 94|cdks 4 and 2
P09083291A1378|86 90|cdks 4
P09083291A1378|97 99|MCs
P09083291A1378|111 130|cyclin E-cdk 2 activity
P09083291A1378|111 117|cyclin E
P09083291A1378|119 122|cdk 2
P09083291A1378|194 196|pRb
P09083291A1378|194 196|pRb
P09083291A1378|199 205|G1 phase
P09083291A1378|221 226|S phase
P09083345A0851|98 102|SYPLR
P09083345A0851|145 175|sociodemographic characteristics
P09083563A0971|36 78|cerebral surface layer and leptomeningeal tissue
P09083563A0971|91 106|arachnoid vessels
P09083563A0971|131 148|cerebrospinal fluid
P09083563A0971|168 184|necrotizing toxins
P09083563A0971|217 224|B. cereus
P09084174A0667|24 33|C-terminal
P09084174A0667|49 52|leuB
P09084174A0667|49 52|leuB
P09084174A0667|62 91|3-isopropylmalate dehydrogenase
P09084174A0667|62 91|3-isopropylmalate dehydrogenase
P09084174A0667|93 144|asd, encoding aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|93 95|asd
P09084174A0667|105 144|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|146 148|Asd
P09084174A0667|146 148|Asd
P09084174A0667|154 157|orfA
P09084174A0667|192 202|Asd proteins
P09084174A0667|192 202|Asd proteins
P09084174A0667|207 215|Vibrio spp
P09084176A0601|0 22|Transcriptional activity
P09084176A0601|36 57|slot-blot hybridization
P09084176A0601|62 73|steady-state
P09084176A0601|89 110|lacZ+ M. smegmatis clones
P09084176A0601|89 104|lacZ+ M. smegmatis
P09084227A0833|0 26|Hovenitin I and (+)-ampelopsin
P09084227A0833|91 105|natural medicine
P09084227A0833|147 153|ethanol
P09084227A0833|162 177|muscle relaxation
P09084227A0833|180 183|rats
P09084621A0374|77 89|cerebral blood
P09084621A0374|111 123|brain activity
P09084621A0374|139 162|task and movement variables
P09084621A2567|0 4|Areas
P09084621A2567|52 66|left motor cortex
P09084621A2567|68 90|left intraparietal sulcus
P09084621A2567|95 105|left caudate
P09085842A0181|36 42|U1 snRNP
P09085842A0181|36 42|U1 snRNP
P09085842A0181|59 70|5' splice site
P09085842A0181|73 99|protein/protein interactions
P09085842A0181|73 87|protein/protein
P09085842A0181|112 120|SR domains
P09085842A0181|112 113|SR
P09085842A0181|126 138|U1-70K protein
P09085842A0181|126 131|U1-70K
P09085842A0181|142 148|SF2/ASF
P09085842A0181|142 144|SF2
P09085842A0181|146 148|ASF
P09085842A1559|8 28|tri-snRNP-specific 27K
P09085842A1559|8 16|tri-snRNP
P09085842A1559|26 35|27K protein
P09085842A1559|64 108|SR protein-mediated protein/protein interactions
P09085842A1559|64 96|SR protein-mediated protein/protein
P09085842A1559|162 177|pre-mRNA splicing
P09086268A0611|8 9|P7
P09086268A0611|8 9|P7
P09086268A0611|46 47|P7
P09086268A0611|46 47|P7
P09086268A0611|71 72|P2
P09086268A0611|71 72|P2
P09086268A0611|74 87|RNA polymerase)
P09086268A0611|74 86|RNA polymerase
P09086268A0611|91 92|P7
P09086268A0611|91 92|P7
P09087430A1046|15 24|U1A peptide
P09087430A1046|15 24|U1A peptide
P09087430A1046|42 44|BSA
P09087430A1046|42 44|BSA
P09087430A1046|54 66|vertebrate PAP
P09088371T0000|0 11|Plasma levels
P09088371T0000|14 21|protein C
P09088371T0000|14 21|protein C
P09088371T0000|23 30|protein S
P09088371T0000|23 30|protein S
P09088371T0000|35 49|antithrombin III
P09088371T0000|35 49|antithrombin III
P09088371T0000|52 59|patients
P09088371T0000|64 86|subarachnoid haemorrhage
P09088416A0000|10 18|bilateral
P09088416A0000|41 65|arterial occlusion (IBRBRAO
P09088416A0000|97 113|migraine headaches
P09088416A0000|132 142|hearing loss
P09088416A0000|169 183|artery occlusion
P09088416A0000|193 200|etiology
P09088737T0000|0 9|Epithelial
P09088737T0000|13 28|corneal thickness
P09088737T0000|43 66|in vivo confocal microscopy
P09088737T0000|83 86|CMTF
P09089093A0373|27 38|human CA genes
P09089093A0373|27 38|human CA genes
P09089093A0373|58 83|homologous enhancer elements
P09089653A0615|38 47|322 nt 5' UTR
P09089653A0615|50 54|exon 1
P09089653A0615|59 71|1630 nt segment
P09089653A0615|74 91|5' flanking sequence
P09089653A0615|102 119|luciferase activity
P09089653A0615|102 111|luciferase
P09089653A0615|144 169|promoterless control plasmid
P09089653A1112|11 33|DNA-protein interactions
P09089653A1112|11 21|DNA-protein
P09089653A1112|43 61|DNase-I footprinting
P09089653A1112|43 49|DNase-I
P09089653A1112|109 118|nt -12 to +38
P09090050A0419|42 52|human, mouse
P09090050A0419|56 70|Escherichia coli
P09090054A0186|20 23|loci
P09090054A0186|70 77|permease
P09090054A0186|81 97|alpha-glucosidase
P09090054A0186|81 97|alpha-glucosidase
P09090054A0186|104 113|fourth gene
P09090054A0186|127 152|extra alpha-glucosidase gene
P09090054A0186|132 152|alpha-glucosidase gene
P09090054A0186|164 167|MAL1
P09090592A0175|35 53|activation fMR images
P09090592A0175|143 160|spatial orientation
P09091010A1003|5 9|women
P09091010A1003|17 24|abnormal
P09091010A1003|65 79|residual disease
P09091125A0161|0 23|Autorosette-forming cells
P09091125A0161|57 83|alkaline and acid phosphatases
P09091125A0161|57 83|alkaline and acid phosphatases
P09091125A0161|87 103|low NBT-test values
P09091403T0001|10 31|homologous DNA sequences
P09091403T0001|41 51|first intron
P09091403T0001|57 78|mouse and human mts1 genes
P09091403T0001|65 78|human mts1 genes
P09091403T0001|80 90|kB-like site
P09091403T0001|80 90|kB-like site
P09091403T0001|94 110|microsatellite DNA
P09092493A0861|3 13|integration
P09092493A0861|19 25|VIP CyRE
P09092493A0861|19 21|VIP
P09092493A0861|22 25|CyRE
P09092493A0861|31 62|Jak-Stat and AP-1 signaling pathways
P09092493A0861|31 33|Jak
P09092493A0861|35 38|Stat
P09092493A0861|42 45|AP-1
P09092493A0861|121 154|cell- and cytokine-specific signaling
P09092580A1354|38 53|MAP kinase pathway
P09092580A1354|38 46|MAP kinase
P09092580A1354|71 84|monocytic cells
P09092580A1354|91 104|transmigration
P09092636A0802|21 54|temperature-sensitive rad54-3 allele
P09092636A0802|21 48|temperature-sensitive rad54-3
P09092636A0802|88 125|tandemly repeated DYZ3 satellite sequences
P09092636A0802|104 125|DYZ3 satellite sequences
P09092636A0802|153 189|human DYZ5 satellite-containing YAC clone
P09092636A0802|153 161|human DYZ5
P09092675A0283|1 16|P22 R17 derivative
P09092675A0283|23 31|OcRNA site
P09092675A0283|33 38|P22 R17
P09092675A0283|40 44|A(-10
P09092675A0283|57 65|lytically
P09093867T0000|0 27|Circularized Ac/Ds transposons
P09093867T0000|12 13|Ac
P09093867T0000|15 16|Ds
P09094093A0578|25 31|TATA box
P09094093A0578|38 49|somatic cells
P09094315A0541|41 45|B-Myb
P09094315A0541|41 45|B-Myb
P09094315A0541|56 66|cyclin-Cdks
P09094315A0541|56 66|cyclin-Cdks
P09094671A1192|9 28|tumor suppressor genes
P09094671A1192|30 33|Mts1
P09094671A1192|30 33|Mts1
P09094671A1192|35 42|p16INK4a
P09094671A1192|35 42|p16INK4a
P09094671A1192|47 50|Mts2
P09094671A1192|47 50|Mts2
P09094671A1192|52 59|p15INK4b
P09094671A1192|52 59|p15INK4b
P09094671A1192|94 113|Southern blot analysis
P09094671A1192|117 135|homozygous deletions
P09096229T0000|0 13|Excision repair
P09096229T0000|29 38|nucleotide
P09096229T0000|44 74|Saccharomyces cerevisiae MFA2 gene
P09096229T0000|44 66|Saccharomyces cerevisiae
P09096229T0000|67 74|MFA2 gene
P09096229T0000|90 103|enhanced repair
P09096229T0000|169 173|rad16
P09096229T0000|186 218|repairing upstream control sequences
P09096234T0000|2 17|aromatic stacking
P09096234T0000|56 77|DNA sequence specificity
P09096234T0000|107 128|phage lambda cI repressor
P09096234T0000|107 128|phage lambda cI repressor
P09096958A0000|28 47|monoclonal antibodies
P09096958A0000|61 78|human platelet talin
P09096958A0000|61 78|human platelet talin
P09096958A0000|81 95|Western blotting
P09096958A0000|97 137|immune precipitation, and immunofluorescence
P09096958A0000|151 165|antibodies TA205
P09096958A0000|151 160|antibodies
P09096958A0000|161 165|TA205
P09096958A0000|169 172|TD77
P09096958A0000|169 172|TD77
P09096958A0000|180 213|actin stress fibers and focal adhesions
P09096958A0000|225 236|cell motility
P09096958A0000|258 273|human fibroblasts
P09098066A0119|52 82|cytadherence-associated proteins
P09098066A0119|52 82|cytadherence-associated proteins
P09098066A0119|83 86|HMW1
P09098066A0119|83 86|HMW1
P09098066A0119|90 93|HMW3
P09098066A0119|90 93|HMW3
P09098066A0119|149 184|hemadsorption-negative (HA-) phenotype
P09098066A0119|209 236|cytadherence-regulatory locus
P09098066A0119|209 236|cytadherence-regulatory locus
P09098066A0119|238 240|crl
P09098066A0119|238 240|crl
P09098899A0000|0 12|Coliphage 186 B
P09098899A0000|0 12|Coliphage 186 B
P09098899A0000|16 34|72-amino acid protein
P09098899A0000|49 57|Ogr family
P09098899A0000|49 51|Ogr
P09098899A0000|69 88|transcription factors
P09098899A0000|98 109|P2-like phage
P09098899A0000|124 130|Cys-X2-
P09098899A0000|131 134|Cys-
P09098899A0000|135 175|X22-Cys-X4-Cys presumptive zinc-finger motif
P09098899A0000|160 175|zinc-finger motif
P09098899A0435|3 14|UV absorption
P09098899A0435|64 115|CysS-Cd(II) ligand-to-metal charge-transfer transitions
P09098899A0435|159 171|acidification
P09098899A0435|173 187|delta epsilon 248
P09098899A0435|223 238|Cd(Cys-S)4 center
P09098899A0435|223 230|Cd(Cys-S
P09099683A0000|0 24|Diacylglycerol kinase (DGK)
P09099683A0000|0 19|Diacylglycerol kinase
P09099683A0000|21 23|DGK
P09099683A0000|43 71|second messenger diacylglycerol
P09099683A0000|98 115|putative) messenger
P09099683A0000|117 132|phosphatidic acid
P09099702A0000|38 97|germ cell-specific, nuclear orphan receptor germ cell nuclear factor
P09099702A0000|38 55|germ cell-specific,
P09099702A0000|56 107|nuclear orphan receptor germ cell nuclear factor (GCNF)/RTR
P09099702A0000|99 102|GCNF
P09099702A0692|23 29|conRTRE
P09099702A0692|23 29|conRTRE
P09099702A0692|49 52|RTRE
P09099702A0692|49 52|RTRE
P09099702A0692|66 70|P2-RE
P09099702A0692|66 67|P2
P09099702A0692|69 70|RE
P09099702A0692|77 101|5' promoter-flanking region
P09099702A0692|77 86|5' promoter
P09099702A0692|107 125|mouse protamine 2 gene
P09099702A0692|107 125|mouse protamine 2 gene
P09099702A0692|161 175|spermatogenesis
P09099702A0692|178 180|RTR
P09099702A0692|178 180|RTR
P09099743A0585|60 62|320
P09099743A0585|87 93|mRNP3+4
P09099743A0585|87 93|mRNP3+4
P09099743A0585|111 122|polypeptides
P09099743A0585|133 156|mRNA-binding polypeptides
P09099743A0585|182 191|110/105 kDa
P09099743A0585|206 214|nucleolin
P09099745A1446|49 65|inactive complexes
P09099745A1446|96 104|p21 and p27
P09099745A1446|96 98|p21
P09099745A1446|102 104|p27
P09099745A1446|118 121|Cdk2
P09099745A1446|147 161|phosphorylation
P09099745A1446|201 212|cyclin E-Cdk2
P09099745A1446|201 207|cyclin E
P09099745A1446|209 212|Cdk2
P09099745A1446|233 255|CDK inhibitor association
P09099745A1446|233 235|CDK
P09099745A1446|259 302|CDK-activating kinase-mediated phosphorylation
P09099745A1446|259 278|CDK-activating kinase
P09099745A1446|305 308|Cdk2
P09099745A1446|305 308|Cdk2
P09100202A0000|6 31|Class I and Class II recessions
P09100202A0000|36 43|patients
P09100202A0000|97 110|graft procedure
P09101085A0686|28 36|cell lines
P09101085A0686|67 80|p27Kip1 protein
P09101085A0686|67 73|p27Kip1
P09101085A0686|96 105|cell growth
P09101910A0394|3 15|perioperative
P09101910A0394|30 37|patients
P09101910A0394|60 67|patients
P09102113A0739|0 18|Chronic renal failure
P09102113A0739|19 26|patients
P09102113A0739|45 58|cardiovascular
P09102113A0739|83 98|malignant disease
P09103382T0000|22 35|cervical cancer
P09104816A0610|11 13|Vpu
P09104816A0610|11 13|Vpu
P09104816A0610|16 31|class I biogenesis
P09104816A0610|61 85|Vpu-expressing recombinant
P09104816A0610|61 63|Vpu
P09104816A0610|86 98|vaccinia virus
P09104816A0610|100 101|VV
P09105042A1497|62 64|HCM
P09105042A1497|145 173|mutant myosin heavy chain protein
P09105042A1497|145 173|mutant myosin heavy chain protein
P09105042A1497|191 206|normal sarcomeres
P09105042A1497|223 237|secondary effect
P09105042A1497|262 274|chronic stress
P09105042A1497|286 300|beta MHC function
P09105042A1497|286 292|beta MHC
P09105363A0636|0 49|Inductively coupled plasma atomic emission spectroscopy
P09105363A0636|72 96|tissue silicon measurements
P09105530A0000|2 11|egg protein
P09105530A0000|13 20|lysozyme
P09105530A0000|13 20|lysozyme
P09105530A0000|62 78|cheese preparation
P09106057A0000|43 98|N-methyl)-N-ethyl-8,9 -anhydroerythromycin A 6,9-hemiacetal
P09106057A0000|100 106|EM523, I
P09106057A0000|119 129|metabolites
P09106057A0000|132 142|human plasma
P09106057A0000|146 150|urine
P09106057A0000|188 212|liquid chromatography (HPLC
P09106057A0000|218 247|chemiluminescence (CL) detection
P09108029A0399|13 31|DNA-binding activity
P09108029A0399|34 50|activator protein 1
P09108029A0399|34 50|activator protein 1
P09108029A0399|52 55|AP-1
P09108029A0399|52 55|AP-1
P09108029A0399|70 84|DNA repair enzyme
P09108029A0399|70 84|DNA repair enzyme
P09108029A0399|86 97|redox factor 1
P09108029A0399|86 97|redox factor 1
P09108029A0399|99 103|Ref-1
P09108029A0399|99 103|Ref-1
P09108029A0399|125 139|DNA repair enzyme
P09108029A0399|125 139|DNA repair enzyme
P09108029A0399|141 154|AP endonuclease
P09108029A0399|143 154|endonuclease
P09108038A1128|8 16|LRR domain
P09108038A1128|8 16|LRR domain
P09108038A1128|22 38|SH3-binding domain
P09108038A1128|22 38|SH3-binding domain
P09108038A1128|40 46|Acan125
P09108038A1128|40 46|Acan125
P09108038A1128|53 70|C. elegans homologue
P09108038A1128|53 61|C. elegans
P09108038A1128|91 117|bifunctional binding proteins
P09108207A0306|26 32|gagging
P09108207A0306|42 64|oropharyngeal irritation
P09108279A0431|19 24|8-OxoG
P09108279A0431|42 58|cell-free extracts
P09108279A0431|61 83|wild-type and ogg1 strains
P09108279A0431|61 69|wild-type
P09108279A0431|73 76|ogg1
P09108279A0431|90 105|34mer DNA fragment
P09108279A0431|147 154|cytosine
P09108279A0431|156 163|8-OxoG/C
P09108451A0160|51 56|UCN-01
P09108451A0160|51 56|UCN-01
P09108451A0160|64 95|preferential G1-phase accumulation
P09108451A0160|105 123|human tumor cell lines
P09110176A0890|0 7|Northern
P09110176A0890|14 24|PCR analysis
P09110176A0890|27 41|Ube3a expression
P09110176A0890|27 31|Ube3a
P09110176A0890|44 55|mouse tissues
P09110176A0890|60 66|animals
P09110176A0890|71 79|segmental
P09110176A0890|81 88|paternal
P09110176A0890|148 157|expression
P09110176A0890|213 239|maternal-specific expression
P09111004A0732|37 46|Xaa residue
P09111004A0732|56 83|phosphorylation motif Thr-Xaa-
P09111004A0732|84 86|Tyr
P09111004A0732|118 140|p38 substrate specificity
P09111004A0732|118 120|p38
P09111004A0732|160 162|L12
P09111004A0732|160 162|L12
P09111004A0732|191 209|autophosphorylation
P09111048X0000|7 25|testis-specific mRNA
P09111048X0000|22 35|mRNA transcript
P09111048X0000|44 91|an NH2-terminal truncated nitric-oxide synthase. mRNA
P09111048X0000|46 86|NH2-terminal truncated nitric-oxide synthase
P09111048X0000|124 151|neuronal nitric-oxide synthase
P09111048X0000|124 151|neuronal nitric-oxide synthase
P09111048X0000|153 156|nNOS
P09111048X0000|153 156|nNOS
P09111048X0000|158 171|gene expression
P09111048X0000|174 185|somatic cells
P09111059A0327|9 25|MAR-binding domain
P09111059A0327|9 25|MAR-binding domain
P09111059A0327|30 40|homeodomain
P09111059A0327|71 84|low specificity
P09111309A0674|0 13|Cotransfection
P09111309A0674|16 61|Ets-2 and p44 mitogen-activated protein (MAP) kinase
P09111309A0674|16 20|Ets-2
P09111309A0674|24 26|p44
P09111309A0674|27 50|mitogen-activated protein
P09111309A0674|52 61|MAP) kinase
P09111309A0674|98 121|HB-EGF promoter activation
P09111309A0674|98 111|HB-EGF promoter
P09111309A0674|134 143|deltaRaf-1
P09111309A0674|134 143|deltaRaf-1
P09111309A0674|145 146|ER
P09111309A0674|145 146|ER
P09111314A0970|0 7|Cyclin D1
P09111314A0970|0 7|Cyclin D1
P09111314A0970|31 34|cdk4
P09111314A0970|31 34|cdk4
P09111314A0970|49 60|184A1L5R cell
P09111314A1243|15 41|posttranslational regulation
P09111314A1243|44 51|p15INK4B
P09111314A1243|44 51|p15INK4B
P09111314A1243|54 61|TGF-beta
P09111314A1243|54 61|TGF-beta
P09111314A1243|96 121|TGF-beta-resistant 184A1L5R
P09111314A1243|96 103|TGF-beta
P09111314A1243|134 146|p15 transcript
P09111314A1243|134 136|p15
P09111314A1243|157 171|p15INK4B protein
P09111314A1243|157 171|p15INK4B protein
P09111314A1243|211 222|cyclin D1-cdk
P09111314A1243|211 218|cyclin D1
P09111314A1243|220 222|cdk
P09111314A1243|237 252|kinase activation
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|27 61|MADS box family of transcription factors
P09111331A0119|27 39|MADS box family
P09111331A0119|42 61|transcription factors
P09111331A0119|84 87|Mpk1
P09111331A0119|84 87|Mpk1
P09111340A0240|10 27|cis-acting elements
P09111340A0240|38 46|c-myc mRNA
P09111340A0240|38 46|c-myc mRNA
P09111340A0240|100 109|C2C12 cells
P09111340A0240|114 127|mutant myc genes
P09111340A0240|114 127|mutant myc genes
P09111340A0240|130 142|chimeric genes
P09111340A0240|130 142|chimeric genes
P09111340A0240|150 168|various myc sequences
P09111340A0240|157 168|myc sequences
P09111340A0240|183 202|human beta-globin gene
P09111340A0240|183 202|human beta-globin gene
P09111340A0240|210 259|bacterial chloramphenicol acetyltransferase (CAT) gene
P09111340A0240|210 250|bacterial chloramphenicol acetyltransferase
P09111340A0240|252 254|CAT
P09111367A1098|27 29|32D
P09111367A1098|30 53|temperature-sensitive p53
P09111367A1098|51 53|p53
P09111367A1098|79 93|tal-1 expression
P09111367A1098|79 83|tal-1
P09111367A1098|99 119|permissive temperature
P09111367A1098|133 151|proliferative effect
P09111367A1098|161 181|p53-mediated apoptosis
P09111367A1098|161 163|p53
P09111367A1098|191 214|tal-1 proliferative effect
P09111367A1098|241 260|cell cycle checkpoints
P09111367A1098|266 273|host cell
P09111367A1098|288 292|c-myc
P09111367A1098|288 292|c-myc
P09111367A1098|301 309|oncogenes
P09111367A1098|311 315|tal-1
P09111367A1098|311 315|tal-1
P09111367A1098|352 356|tal-1
P09111367A1098|384 425|DNA-binding and the heterodimerization domains
P09111367A1098|435 467|N-terminally truncated tal-1 variant
P09111367A1098|435 467|N-terminally truncated tal-1 variant
P09111367A1098|469 470|M3
P09111367A1098|469 470|M3
P09111367A1098|483 501|T-ALL malignant cells
P09111367A1098|523 538|wild-type protein
P09111367A1098|523 538|wild-type protein
P09111863A0743|54 68|tumor suppressor
P09111863A0743|117 134|chromosome fragment
P09111863A0743|146 159|tumorigenicity
P09111863A0743|178 187|tumor cells
P09112400A1155|0 18|DNA-binding activity
P09112400A1155|49 57|forskolin
P09112400A1155|68 73|luteal
P09114972A1366|15 17|SOS
P09114972A1366|15 17|SOS
P09115242A0934|13 19|Western
P09115242A0934|21 30|supershift
P09115242A0934|35 58|promoter deletion analyses
P09115242A0934|76 132|CCAAT/enhancer-binding protein-beta (C/EBP-beta) binding site
P09115242A0934|76 109|CCAAT/enhancer-binding protein-beta
P09115242A0934|111 120|C/EBP-beta
P09115242A0934|140 152|-2010 and -1954
P09115242A0934|180 192|collagenase-1
P09115242A0934|180 192|collagenase-1
P09115242A0934|195 208|monocytic cells
P09115247A2069|0 20|11-Aminoundecanoyl-SK
P09115247A2069|22 24|NH2
P09115247A2069|28 46|11-aminoundecanoyl-
P09115247A2069|47 52|SH-NH2
P09115247A2069|110 117|distance
P09115247A2069|165 176|fungal enzyme
P09115247A2069|179 197|peptide-binding site
P09115247A2069|179 197|peptide-binding site
P09115247A2069|206 229|omega-terminal amino group
P09115247A2069|232 244|beta-hydroxyl
P09115247A2069|251 268|epsilon-amino group
P09115247A2069|273 281|imidazole
P09115265A1160|3 29|carboxyl-terminal CCCC module
P09115265A1160|56 72|DNA-binding domain
P09115265A1160|56 72|DNA-binding domain
P09115265A1160|78 111|erythroid transcription factor GATA-1
P09115265A1160|78 105|erythroid transcription factor
P09115265A1160|106 111|GATA-1
P09115279A0345|0 3|Cdc2
P09115279A0345|0 3|Cdc2
P09115279A0345|23 26|Pch1
P09115279A0345|23 26|Pch1
P09115279A0345|29 39|S. pombe cell
P09115279A0345|56 59|Cdc2
P09115279A0345|56 59|Cdc2
P09115279A0345|95 104|Pch1 kinase
P09115279A0345|95 98|Pch1
P09115357A0073|51 67|rapid facile assays
P09115357A0073|81 107|immunoglobulin hypermutation
P09115357A0073|81 94|immunoglobulin
P09115357A0073|156 174|hypermutating B cells
P09115357A0073|198 208|individuals
P09115365A0000|15 41|human heat shock protein 70 gene
P09115365A0000|15 37|human heat shock protein 70
P09115365A0000|43 47|hsp70
P09115365A0000|43 47|hsp70
P09115365A0000|74 79|stress
P09115365A0000|85 93|oncogenes
P09115395A0478|67 73|mitosis
P09115395A0478|75 117|epithelial-microtubule associated protein-115
P09115395A0478|86 117|microtubule associated protein-115
P09115395A0478|119 123|Oct91
P09115395A0478|119 123|Oct91
P09115395A0478|125 146|Elongation factor 1gamma
P09115395A0478|125 146|Elongation factor 1gamma
P09115395A0478|148 151|BRG1
P09115395A0478|148 151|BRG1
P09115395A0478|155 174|Ribosomal protein L18A
P09115395A0478|155 174|Ribosomal protein L18A
P09115395A0478|224 230|mitosis
P09115395A0478|232 274|epithelial-microtubule associated protein-115
P09115395A0478|276 303|Schizosaccharomyces pombe Cdc5
P09115395A0478|300 303|Cdc5
P09115395A0478|305 326|innercentrosome protein
P09115395A0478|305 326|innercentrosome protein
P09115395A0478|328 331|BRG1
P09115395A0478|328 331|BRG1
P09115395A0478|338 351|RNA helicase WM6
P09115395A0478|349 351|WM6
P09115395A0478|373 392|transcription factors
P09115395A0478|373 392|transcription factors
P09115395A0478|394 397|BRG1
P09115395A0478|394 397|BRG1
P09115395A0478|407 421|co-factor 2alpha
P09115395A0478|407 415|co-factor
P09115395A0478|416 421|2alpha
P09115395A0478|423 427|Oct91
P09115395A0478|423 427|Oct91
P09115395A0478|429 439|S. pombe Cdc5
P09115395A0478|429 435|S. pombe
P09115395A0478|436 456|Cdc5, HoxD1, Sox3, Vent2
P09115395A0478|441 445|HoxD1
P09115395A0478|447 450|Sox3
P09115395A0478|452 456|Vent2
P09115395A0478|474 478|Xbr1b
P09115395A0478|474 478|Xbr1b
P09117345A0945|12 22|alpha 4 beta 1
P09117345A0945|12 22|alpha 4 beta 1
P09117345A0945|27 32|TS2/16
P09117345A0945|27 32|TS2/16
P09117345A0945|45 66|cytoplasmic protrusions
P09117345A0945|110 124|phosphorylation
P09118196A0281|0 10|Performance
P09118196A0281|34 46|National Adult
P09118196A0281|47 65|Reading Test-Revised
P09118196A0281|67 72|NART-R
P09118196A0281|112 141|Adult Intelligence Scale-Revised
P09118196A0281|143 148|WAIS-R
P09118196A0281|186 194|education
P09118664A1734|0 11|L-canavanine
P09118664A1734|46 64|nitric oxide synthase
P09118664A1734|46 64|nitric oxide synthase
P09118664A1734|82 104|systemic filling pressure
P09118704A0771|15 22|patients
P09118704A0771|44 55|chemotherapy
P09118704A0771|59 63|G-CSF
P09118704A0771|59 63|G-CSF
P09118704A0771|95 96|CI
P09118704A0771|150 166|bleomycin toxicity
P09119031A1036|22 35|RNA polymerases
P09119031A1036|92 124|core RNA polymerase (alpha2beta beta'
P09119031A1036|92 108|core RNA polymerase
P09119031A1036|110 124|alpha2beta beta'
P09119031A1036|142 164|transcriptional activity
P09119031A1036|182 187|enzyme
P09119031A1036|198 217|wild-type sigma factor
P09119031A1036|198 217|wild-type sigma factor
P09119112A1350|39 44|GATA-5
P09119112A1350|39 44|GATA-5
P09119112A1350|73 99|spatially restricted function
P09119112A1350|105 118|embryonic heart
P09119112A1350|122 125|lung
P09119391A0870|3 16|exonic sequence
P09119391A0870|34 46|495 amino acids
P09119391A0870|108 117|human GPT-1
P09119391A0870|108 117|human GPT-1
P09121424A0296|20 42|S. cerevisiae Swi3 homolog
P09121424A0296|20 31|S. cerevisiae
P09121424A0296|32 47|Swi3 homolog (Swh3
P09121424A0296|44 47|Swh3
P09121424A0296|98 108|Snf2 homolog
P09121424A0296|98 108|Snf2 homolog
P09121424A0296|110 113|Sthl
P09121430A0132|0 2|Shc
P09121430A0132|0 2|Shc
P09121430A0132|13 52|Ras/mitogen-activated protein kinase (MAPK)
P09121430A0132|13 15|Ras
P09121430A0132|17 46|mitogen-activated protein kinase
P09121430A0132|48 51|MAPK
P09121430A0132|79 82|Grb2
P09121430A0132|88 112|phosphorylated tyrosine (Y)
P09121430A0132|102 111|tyrosine (Y
P09121430A1075|11 22|Y239/240F Shc
P09121430A1075|11 19|Y239/240F
P09121430A1075|20 22|Shc
P09121430A1075|30 37|Y317F Shc
P09121430A1075|30 34|Y317F
P09121430A1075|35 37|Shc
P09121430A1075|49 71|EGF-induced c-myc message
P09121430A1075|49 51|EGF
P09121430A1075|60 64|c-myc
P09121432A0000|3 46|Ras guanine nucleotide-binding protein functions
P09121432A0000|3 37|Ras guanine nucleotide-binding protein
P09121432A0000|67 76|signalling
P09121432A0000|89 111|protein-tyrosine kinases
P09121432A0000|89 111|protein-tyrosine kinases
P09121433A0463|10 13|Rlm1
P09121433A0463|10 13|Rlm1
P09121433A0463|17 20|Smp1
P09121433A0463|17 20|Smp1
P09121433A0463|25 28|MEF2
P09121433A0463|37 60|DNA-binding specificities
P09121433A0463|62 65|Rlm1
P09121433A0463|62 65|Rlm1
P09121433A0463|95 98|MEF2
P09121433A0463|95 98|MEF2
P09121433A0463|100 102|CTA
P09121433A0463|100 102|CTA
P09121433A0463|104 111|T/A)4TAG
P09121433A0463|104 104|T
P09121433A0463|106 111|A)4TAG
P09121433A0463|118 121|SMP1
P09121433A0463|118 121|SMP1
P09121433A0463|140 156|consensus sequence
P09121433A0463|158 173|ACTACTA(T/A)4TAG
P09121433A0463|166 168|T/A
P09121435A1183|0 12|Domains I and II
P09121435A1183|15 15|B
P09121435A1183|43 59|TFIIIB-DNA complex
P09121435A1183|43 59|TFIIIB-DNA complex
P09121435A1183|75 93|protein footprinting
P09121452A0538|0 5|Domain
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|69 102|leucine zipper or the activation domain
P09121452A0538|105 114|C/EBP alpha
P09121452A0538|105 114|C/EBP alpha
P09121452A0538|138 148|2D5 promoter
P09121452A0538|138 148|2D5 promoter
P09121452A0538|186 203|artificial promoter
P09121452A0538|212 233|high-affinity C/EBP site
P09121452A0538|225 233|C/EBP site
P09121454A1328|22 25|bur6
P09121454A1328|22 25|bur6
P09121454A1328|29 32|bur3
P09121454A1328|29 32|bur3
P09121454A1328|34 37|mot1
P09121454A1328|34 37|mot1
P09121454A1328|59 63|Bur6p
P09121454A1328|59 63|Bur6p
P09121454A1328|67 71|Mot1p
P09121454A1328|67 71|Mot1p
P09121454A1328|137 165|general transcription machinery
P09121476T0000|0 4|PRH75
P09121476T0000|0 4|PRH75
P09121476T0000|38 58|DEAD-box protein family
P09121476T0000|38 58|DEAD-box protein family
P09121476T0000|69 74|plants
P09121774A0611|45 54|cell growth
P09121774A0611|57 64|middle-T
P09121774A0611|88 102|MAP kinase family
P09121774A0611|88 102|MAP kinase family
P09121774T0000|11 24|small GTPase Rac
P09121774T0000|11 24|small GTPase Rac
P09121774T0000|27 72|polyomavirus middle-T antigen-mediated activation
P09121774T0000|27 53|polyomavirus middle-T antigen
P09121774T0000|78 97|serum response element
P09121774T0000|78 97|serum response element
P09121774T0000|103 120|cell transformation
P09121998A0663|26 38|gastric region
P09121998A0663|86 105|corrective procedures
P09121998A0663|125 131|gastric
P09121998A0663|144 148|MTT 90
P09121998A0663|190 196|stomach
P09121998A0663|208 210|F90
P09122168A1427|47 56|G betagamma
P09122168A1427|71 101|agonist-stimulated translocation
P09122168A1427|104 107|GRK2
P09122168A1427|104 107|GRK2
P09122168A1427|111 114|GRK3
P09122168A1427|111 114|GRK3
P09122168A1427|125 138|cellular system
P09122176A0970|22 42|RA-mediated repression
P09122176A0970|48 55|hMGP gene
P09122176A0970|48 55|hMGP gene
P09122176A0970|72 86|liganded RAR/RXR
P09122176A0970|80 82|RAR
P09122176A0970|84 86|RXR
P09122176A0970|103 119|RA response element
P09122198A0478|0 13|Point mutations
P09122198A0478|44 60|cytoplasmic domain
P09122215A0335|27 49|Saccharomyces cerevisiae
P09122215A0335|62 88|protein-truncating mutations
P09123055T0000|0 19|Hepatocellular injury
P09123055T0000|40 50|human livers
P09123055T0000|55 56|UW
P09123055T0000|60 70|HTK solution
P09123787A0486|59 68|R1 response
P09123787A0486|74 95|orbicularis oculi muscle
P09123787A0486|131 151|bilateral late response
P09123787A0486|153 165|ipsilateral R2
P09123787A0486|195 204|R3 response
P09123787A0486|211 243|ipsilateral orbicularis oculi muscle
P09124054A1164|19 26|patients
P09124054A1164|38 42|ABSCT
P09124054A1164|77 84|patients
P09124054A1164|96 114|conventional therapy
P09126622A0466|25 41|melanized colonies
P09126622A0466|58 60|CAL
P09126622A0466|61 73|transformants
P09128730A0000|0 22|Malonate decarboxylation
P09128730A0000|25 40|Malonomonas rubra
P09128730A0000|63 92|malonyl-S-[acyl-carrier protein
P09128730A0000|63 92|malonyl-S-[acyl-carrier protein
P09128730A0000|98 126|acetyl-S-[acyl-carrier protein
P09128730A0000|98 105|acetyl-S
P09128730A0000|108 126|acyl-carrier protein
P09128730A0000|159 171|biotin protein
P09128730A0000|208 227|delta mu Na+ generation
P09129147A0644|3 20|Jem peptide sequence
P09129147A0644|3 20|Jem peptide sequence
P09129147A0644|28 41|leucine-zipper
P09129147A0644|43 59|dimerisation motif
P09129147A0644|81 87|Fos/Jun
P09129147A0644|81 83|Fos
P09129147A0644|85 87|Jun
P09129147A0644|91 106|ATF/CREB proteins
P09129147A0644|91 93|ATF
P09129147A0644|95 106|CREB proteins
P09129147A0644|125 144|phosphorylation sites
P09130595A0478|45 59|enhancer site III
P09130700A0676|37 41|Tub4p
P09130700A0676|37 41|Tub4p
P09130700A0676|43 48|Spc98p
P09130700A0676|43 48|Spc98p
P09130700A0676|52 57|Spc97p
P09130700A0676|52 57|Spc97p
P09130700A0676|86 90|SPC97
P09130700A0676|86 90|SPC97
P09130700A0676|143 146|TUB4
P09130700A0676|143 146|TUB4
P09130700A0676|149 153|SPC98
P09130700A0676|149 153|SPC98
P09130718A0497|18 21|iron
P09130718A0497|44 47|sid1
P09130718A0497|44 47|sid1
P09130718A0497|64 74|306 bp region
P09130718A0497|106 108|ATG
P09130720A0417|35 50|branch site region
P09130720A0417|86 100|TACTAAC sequence
P09131139T0000|13 15|PAF
P09131139T0000|13 15|PAF
P09131139T0000|19 40|acetylhydrolase (PAF-AH
P09131139T0000|19 33|acetylhydrolase
P09131139T0000|35 37|PAF
P09131139T0000|39 40|AH
P09131139T0000|52 69|periodontal disease
P09132011A0298|15 25|p50 sequence
P09132011A0298|15 25|p50 sequence
P09132011A0298|33 46|cloned proteins
P09132011A0298|71 102|glycosaminoglycan-binding protein
P09132011A0298|121 153|Drosophila cell cycle control protein
P09132011A0298|121 153|Drosophila cell cycle control protein
P09132011A0298|155 157|cdc
P09132057A0559|24 44|NTS 16 open reading frame
P09132057A0559|71 85|catalytic domain
P09132057A0559|95 116|receptor protein kinases
P09132057A0559|95 116|receptor protein kinases
P09132057A0559|121 126|plants
P09132057A0559|139 155|S-receptor kinases
P09132057A0559|139 155|S-receptor kinases
P09132057A0559|171 179|rejection
P09132057A0559|195 209|Brassica species
P09132057A0559|216 222|Pto gene
P09132057A0559|263 279|bacterial pathogen
P09132061A0828|3 18|atp 1 and atp 2 types
P09132061A0828|3 6|atp 1
P09132061A0828|10 13|atp 2
P09132061A0828|21 33|cDNA sequences
P09132061A0828|73 86|isoperoxidases
P09132061A0828|110 119|peroxidase
P09132061A0828|110 119|peroxidase
P09132061A0828|128 131|ESTs
P09133122A0656|30 55|echocardiographic sequences
P09133122A0656|57 97|perioperative video sequences, x-ray analysis
P09133122A0656|110 112|etc
P09135066A0653|36 39|Mek1
P09135066A0653|36 39|Mek1
P09135066A0653|53 59|p96h2bk
P09135066A0653|53 59|p96h2bk
P09135066A0653|74 85|oncogenic Ras
P09135066A0653|74 85|oncogenic Ras
P09135149A0000|2 25|Schizosaccharomyces pombe
P09135149A0000|43 90|M-phase-inducing Cdc2/Cdc13 cyclin-dependent kinase
P09135149A0000|59 62|Cdc2
P09135149A0000|64 68|Cdc13
P09135149A0000|69 90|cyclin-dependent kinase
P09135149A0000|104 107|Wee1
P09135149A0000|104 107|Wee1
P09135149A0000|111 114|Mik1
P09135149A0000|111 114|Mik1
P09135149A0000|115 129|tyrosine kinases
P09135149A0000|115 129|tyrosine kinases
P09135149A0000|145 149|Cdc25
P09135149A0000|145 149|Cdc25
P09135149A0000|153 156|Pyp3
P09135149A0000|153 156|Pyp3
P09135149A0000|157 176|tyrosine phosphatases
P09135149A0000|157 176|tyrosine phosphatases
P09135772T0000|0 15|Glycemic response
P09135772T0000|18 23|malted
P09135772T0000|34 66|roller dried wheat-legume based foods
P09135772T0000|69 82|normal subjects
P09135928A0912|29 38|systolic BP
P09135928A0912|50 60|intravenous
P09135928A0912|61 74|norepinephrine
P09135928A0912|78 90|angiotensin II
P09135928A0912|78 90|angiotensin II
P09135928A0912|135 143|metformin
P09136015A0529|3 12|sequencing
P09136015A0529|15 22|Stellate
P09136080A1469|22 35|DNA methylation
P09136080A1469|37 54|chromatin structure
P09136080A1469|78 84|Sp1 site
P09136080A1469|78 84|Sp1 site
P09136080A1469|132 164|myelomonocytic lineage specific gene
P09138076A1099|2 23|gel mobility shift assays
P09138076A1099|41 55|nuclear extracts
P09138076A1099|81 90|osteoblast
P09138076A1099|98 118|oligonucleotide probes
P09138076A1099|132 137|E-box 1
P09138076A1099|132 137|E-box 1
P09138076A1099|141 154|E-box 2 elements
P09138076A1099|141 154|E-box 2 elements
P09138492A0806|0 13|Laboratory exam
P09138492A0806|15 17|IDR
P09138492A0806|23 32|tuberculin
P09138492A0806|23 32|tuberculin
P09138492A0806|75 97|bilateral calcifications
P09138492A0806|99 105|ORL exam
P09138492A0806|131 140|epiglottis
P09138492A0806|144 166|anatomopathological exam
P09138492A0806|189 207|epidermoid carcinoma
P09139665A0784|18 30|PhLP complexes
P09139665A0784|18 21|PhLP
P09139665A0784|53 62|Gbetagamma
P09139694A0789|0 8|CTF1alpha
P09139694A0789|0 8|CTF1alpha
P09139694A0789|21 35|Escherichia coli
P09139694A0789|63 84|palindrome 2 DNA fragment
P09139694A0789|93 134|palindrome 1 or mutant palindrome 2 DNA fragments
P09139694A0789|163 171|CTF1alpha
P09139694A0789|163 171|CTF1alpha
P09139694A0789|174 184|palindrome 2
P09139721A0183|0 7|Cyclin G2
P09139721A0183|0 7|Cyclin G2
P09139721A0183|30 41|immune system
P09139721A0183|75 98|self-reactive lymphocytes
P09139721A0183|138 146|apoptosis
P09139737A0000|1 24|sterol-regulated protease
P09139737A0000|1 24|sterol-regulated protease
P09139737A0000|46 65|NH2-terminal segments
P09139737A0000|68 106|sterol regulatory element-binding proteins
P09139737A0000|68 106|sterol regulatory element-binding proteins
P09139737A0000|108 113|SREBPs
P09139737A0000|108 113|SREBPs
P09139737A0000|119 131|cell membranes
P09139737A0000|162 168|nucleus
P09139737A0000|250 259|fatty acids
P09139892A1150|8 19|P. aeruginosa
P09139892A1150|20 38|orfX and vfr promoters
P09139892A1150|27 38|vfr promoters
P09139892A1150|117 135|dorf and crp promoters
P09139892A1150|117 120|dorf
P09139892A1150|124 135|crp promoters
P09139910A0350|0 15|Sequence analysis
P09139910A0350|18 34|cloned PCR products
P09139910A0350|69 89|nifV-like DNA fragments
P09139910A0350|69 89|nifV-like DNA fragments
P09139910A0350|118 122|nifV-
P09139910A0350|118 121|nifV
P09139910A0350|126 144|leuA-specific probes
P09139910A0350|126 144|leuA-specific probes
P09139910A0350|166 178|XbaI fragments
P09139910A0350|166 178|XbaI fragments
P09139910A0350|188 192|pOST4
P09139910A0350|204 208|pOST2
P09139910A1572|14 27|Anabaena strain
P09139910A1572|28 39|7120 leuA gene
P09139910A1572|32 39|leuA gene
P09139910A1572|59 70|nifV mutation
P09139910A1572|59 62|nifV
P09139910A1572|73 77|R229I
P09140079A2528|1 1|3
P09140079A2528|34 36|TRs
P09140079A2528|44 46|TRE
P09140474T0000|2 21|leishmaniasis endemic
P09140474T0000|35 41|Minorca
P09140474T0000|43 47|Spain
P09142146A0887|21 23|PAF
P09142146A0887|21 23|PAF
P09142146A0887|55 60|trauma
P09142146A0887|67 74|WEB-2086
P09142146A0887|99 105|animals
P09142146A0887|126 137|cardiac index
P09143328A1002|43 70|noncomplementary dinucleotide
P09143328A1002|71 76|primer
P09143328A1002|81 93|RNA polymerase
P09143328A1002|81 93|RNA polymerase
P09143465A0838|4 5|T1
P09143465A0838|59 60|IQ
P09144165A0614|20 26|complex
P09144165A0614|40 50|NFAT nearest
P09144165A0614|40 43|NFAT
P09144165A0614|51 54|AP-1
P09144165A0614|51 54|AP-1
P09144165A0614|60 74|Rel insert region
P09144165A0614|60 74|Rel insert region
P09144165A0614|76 78|RIR
P09144165A0614|76 78|RIR
P09144165A0614|162 189|Rel transcription factor family
P09144165A0614|162 189|Rel transcription factor family
P09144165A1275|21 27|NFAT RIR
P09144165A1275|21 27|NFAT RIR
P09144165A1275|91 120|AP-1 family transcription factors
P09144165A1275|91 100|AP-1 family
P09144195A1051|21 32|PS1 fragments
P09144195A1051|21 32|PS1 fragments
P09144195A1051|62 94|phosphorylation/dephosphorylation
P09144195A1051|100 105|PS1 CTF
P09144195A1051|100 105|PS1 CTF
P09144770A0906|4 20|conformer features
P09144770A0906|22 30|Type I beta
P09144770A0906|22 26|Type I
P09144770A0906|77 82|FKBP12
P09144770A0906|77 82|FKBP12
P09144958A0047|4 10|protein
P09144958A0047|32 39|promoter
P09144958A0047|44 95|Arabidopsis light-harvesting chlorophyll a/b protein gene
P09144958A0047|44 82|Arabidopsis light-harvesting chlorophyll a
P09144958A0047|84 95|b protein gene
P09144958A0047|97 103|Lhcb1*3
P09144958A0047|97 103|Lhcb1*3
P09144958A0047|139 149|phytochrome
P09146027A0809|1 7|patient
P09146027A0809|33 34|CP
P09146027A0809|39 48|spasticity
P09146027A0809|63 75|right his trunk
P09146027A0809|79 82|neck
P09146071T0001|0 15|Dystonic movement
P09146071T0001|21 24|left
P09146071T0001|25 33|upper limb
P09146071T0001|46 67|right pontine hemorrhage
P09147420A0623|28 34|HCMV IE1
P09147420A0623|28 31|HCMV
P09147420A0623|32 38|IE1/IE2
P09147420A0623|36 38|IE2
P09147420A0623|68 75|HIV-1 LTR
P09147420A0623|68 75|HIV-1 LTR
P09147420T0000|0 2|TAR
P09147420T0000|0 2|TAR
P09147420T0000|6 35|Sp1-independent transactivation
P09147420T0000|6 8|Sp1
P09147420T0000|38 58|HIV long terminal repeat
P09147420T0000|64 73|Tat protein
P09147420T0000|64 73|Tat protein
P09147420T0000|89 111|human cytomegalovirus IE1
P09147420T0000|89 108|human cytomegalovirus
P09147420T0000|109 115|IE1/IE2
P09147420T0000|113 115|IE2
P09147788A0458|0 29|Respiratory chain enzyme activity
P09147832A0174|0 20|Children's temperament
P09147832A0174|24 44|maternal socialization
P09147832A0174|98 113|future conscience
P09147832A0174|147 163|narrative measures
P09148770A0977|0 10|Cellular Csk
P09148770A0977|8 10|Csk
P09148770A0977|35 49|phosphoproteins
P09148770A0977|84 95|Csk SH2 domain
P09148770A0977|84 86|Csk
P09148770A0977|87 95|SH2 domain
P09148903A1715|26 46|pV-mediated activation
P09148903A1715|49 56|HIV-1 LTR
P09148903A1715|49 53|HIV-1
P09148903A1715|54 64|LTR activity
P09148903A1715|82 101|nuclear translocation
P09148903A1715|107 134|NF-kappaB transcription factor
P09148903A1715|107 115|NF-kappaB
P09148903A1715|116 134|transcription factor
P09148903A1715|153 164|IkappaBalpha
P09148903A1715|153 164|IkappaBalpha
P09148903A1715|165 185|serine phosphorylation
P09148903A1715|189 199|degradation
P09148903A1715|225 252|NF-kappaB-independent pathway
P09148903A1715|225 233|NF-kappaB
P09148929A0372|3 4|P1
P09148929A0372|5 16|genomic clone
P09148929A0372|78 88|exon-intron
P09148929A0372|106 114|Ctpct gene
P09148929A0372|106 114|Ctpct gene
P09148935A0805|0 20|FN-stimulated c-Src PTK
P09148935A0805|0 1|FN
P09148935A0805|13 17|c-Src
P09148935A0805|18 20|PTK
P09148935A0805|50 52|FAK
P09148935A0805|50 52|FAK
P09148935A0805|71 93|FN-stimulated activation
P09148935A0805|71 72|FN
P09148935A0805|96 99|ERK2
P09148935A0805|96 99|ERK2
P09148935A0805|127 155|c-Src binding site Phe-397 mutant
P09148935A0805|127 142|c-Src binding site
P09148935A0805|158 160|FAK
P09148935A0805|158 160|FAK
P09149825A0151|20 44|4-META/MMA-TBB opaque resin
P09149825A0151|64 81|adhesive properties
P09149825A0151|85 94|bone cement
P09149929A0750|0 8|Congruent
P09149929A0750|13 32|empirical predictions
P09149929A0750|66 75|low control
P09149929A0750|116 135|relinquishing control
P09150334A0559|55 56|60
P09150566A0316|43 58|complex molecules
P09150566A0316|73 87|molecular clouds
P09150595A0225|44 45|HR
P09150595A0225|57 70|E. chrysanthemi
P09150595A0225|72 80|HarpinEch
P09150595A0225|85 104|E. amylovora (HarpinEa
P09150595A0225|117 129|36-kDa protein
P09150595A0225|181 211|putative membrane-spanning domain
P09150595T0000|0 24|Molecular characterization
P09150595T0000|43 70|Erwinia carotovora hrpNEcc gene
P09150595T0000|43 59|Erwinia carotovora
P09150595T0000|60 70|hrpNEcc gene
P09150595T0000|99 120|hypersensitive reaction
P09150728A0596|26 29|HES1
P09150728A0596|26 29|HES1
P09150728A0596|78 91|skeletal muscle
P09150774A0616|0 9|Anesthesia
P09150774A0616|27 36|isoflurane
P09150774A0616|38 40|ISO
P09151152A0174|21 36|protein C activity
P09151152A0174|21 28|protein C
P09151152A0174|120 138|factor X and factor VII
P09151152A0174|126 138|X and factor VII
P09151152A0174|204 219|serum lipoprotein
P09151152A0174|204 219|serum lipoprotein
P09151152A0174|221 221|a
P09151376A0000|16 45|type II hyperbetalipoproteinemia
P09151376A0000|139 157|rheumatoid arthritis
P09151806A1125|31 39|2.0-kb LAT
P09151806A1125|37 39|LAT
P09151806A1125|44 49|intron
P09151806A1125|55 66|mLAT pre-mRNA
P09151806A1125|55 66|mLAT pre-mRNA
P09151828A0919|3 26|altered amino acid residues
P09151828A0919|32 59|seven mutant 9ORF1 polypeptides
P09151828A0919|37 59|mutant 9ORF1 polypeptides
P09151828A0919|107 113|region I
P09151828A0919|127 128|41
P09151828A0919|131 138|region II
P09151828A0919|152 153|91
P09151828A0919|159 177|C-terminal region III
P09151828A0919|159 174|C-terminal region
P09151828A0919|179 194|residues 122 to 125
P09151837A0723|0 24|Rep-Rep protein interaction
P09151837A0723|0 13|Rep-Rep protein
P09151837A0723|51 82|coimmunoprecipitation experiments
P09151837A0723|88 98|bacterially
P09151837A0723|108 148|maltose-binding protein-Rep78 fusion protein
P09151837A0723|108 129|maltose-binding protein
P09151837A0723|131 135|Rep78
P09151837A0723|166 180|[35S]methionine
P09151837A0723|189 193|Rep78
P09151837A0723|189 193|Rep78
P09151837A0723|215 252|in vitro transcription-translation system
P09151925A0479|3 7|C-LIP
P09151925A0479|38 57|arterial embolization
P09151925A0479|59 61|TAE
P09151925A0479|63 67|C-LIP
P09151925A0479|78 90|gelatin sponge
P09151925A0479|95 129|percutaneous ethanol injection therapy
P09152656A0149|8 15|patients
P09152656A0149|20 31|New York Heart
P09152656A0149|87 98|double-blind
P09153010A0499|19 35|Multi-MUP analysis
P09153010A0499|65 68|MUPs
P09153010A0499|104 107|MUPs
P09153010A0499|113 125|recording site
P09153010A0499|201 204|MUPs
P09153010A0499|257 271|reference values
P09153319A0844|73 79|ethanol
P09153319A0844|96 100|water
P09153319A1332|51 65|reporter plasmid
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|132 144|transcription
P09153319A1332|162 184|control phosphorothioate
P09153319A1332|185 187|ODN
P09153348A0647|23 25|TBG
P09153348A0647|23 25|TBG
P09153348A0647|39 53|adrenal androgen
P09153348A0647|57 89|mineralocorticoid steroid secretion
P09153348A0647|97 113|cortisol secretion
P09153348A0647|163 170|patients
P09153348A0647|175 187|HIV-infection
P09153795A0298|19 22|RDFS
P09154283A0307|0 10|Latanoprost
P09154283A0307|42 64|intraocular pressure (IOP
P09154283A0307|91 97|timolol
P09154283A0307|127 136|dipivefrin
P09154621A1475|23 51|dietary safflower phospholipids
P09154621A1475|100 112|triglycerides
P09154621A1475|116 131|serum cholesterol
P09154795A0628|70 122|TATA-less human DNA polymerase beta (beta-pol) gene promoter
P09154795A0628|84 100|DNA polymerase beta
P09154795A0628|102 114|beta-pol) gene
P09154797A0777|0 27|Saturable spermidine transport
P09154797A0777|30 35|stk2::
P09154797A0777|30 33|stk2
P09154797A0777|36 46|lacZ mutants
P09154797A0777|36 46|lacZ mutants
P09154797A0777|116 129|parental strain
P09154819A0501|0 22|Transient overexpression
P09154819A0501|25 29|c-Jun
P09154819A0501|25 29|c-Jun
P09154819A0501|37 46|tenascin-C
P09154819A0501|37 46|tenascin-C
P09154819A0501|66 68|REF
P09154819A0501|74 78|FR3T3
P09154819A0501|93 110|fibroblast cell line
P09154822T0000|15 25|Raf-1 kinase
P09154822T0000|15 25|Raf-1 kinase
P09154822T0000|28 36|cyclic AMP
P09154822T0000|62 66|v-abl
P09154822T0000|62 66|v-abl
P09154822T0000|67 83|-transformed cells
P09154827A0158|40 47|cell line
P09154827A0158|49 52|ts13
P09154827A0158|77 86|TAF(II)250
P09154827A0158|77 82|TAF(II
P09154827A0158|88 91|CCG1
P09154827A0158|93 107|TAF(II)250) gene
P09154827A0158|93 98|TAF(II
P09154827A0158|155 159|genes
P09154827A0158|176 177|G1
P09155015A0140|17 29|protein kinase
P09155015A0140|17 29|protein kinase
P09155015A0140|30 34|MEKK1
P09155015A0140|30 34|MEKK1
P09155015A0140|44 65|reporter gene expression
P09155015A0140|73 108|atrial natriuretic factor (ANF) promoter
P09155015A0140|73 95|atrial natriuretic factor
P09155015A0140|97 99|ANF
P09155015A0140|145 161|in vivo hypertrophy
P09155024A0955|16 19|EFG1
P09155024A0955|16 19|EFG1
P09155024A0955|22 31|C. albicans
P09155024A0955|47 63|filamentous growth
P09155024A0955|97 102|liquid
P09155024A0955|108 112|solid
P09156883A0294|29 30|HR
P09156883A0294|41 57|blood pressure (ABP
P09156883A0294|55 57|ABP
P09156883A0294|83 86|SaO2
P09156883A0294|99 110|pulsoximetry
P09157100A0583|13 19|signing
P09157100A0583|53 55|SIB
P09157100A0583|79 88|extinction
P09157337A0545|3 9|husband
P09157337A0545|20 26|married
P09157337A0545|47 55|hepatitis
P09157337A0545|58 77|unidentified etiology
P09157760A0000|4 15|quantitative
P09157760A0000|82 97|Meynart's nucleus
P09157760A0000|172 188|normal individuals
P09159111A0437|55 56|CD
P09159111A0437|61 74|NMR experiments
P09159111A0437|80 88|Skn domain
P09159111A0437|80 88|Skn domain
P09159111A0437|96 112|truncated proteins
P09159160A0000|0 16|Positional cloning
P09159160A0000|59 68|human genes
P09159160A0000|83 98|specific diseases
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|33 36|OBFs
P09159183A0119|33 36|OBFs
P09159183A0119|66 116|basic-region leucine zipper (bZIP) transcription factors
P09159183A0119|66 116|basic-region leucine zipper (bZIP) transcription factors
P09159183A0119|145 150|plants
P09160361A0858|23 30|CPB group
P09160361A0858|37 48|non-CPB group
P09160361A0858|59 61|4.6
P09160881A0491|45 65|yeast two-hybrid screen
P09160881A0491|73 105|in vivo protein-protein interactions
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|57 63|PECAM-1
P09162084A0956|57 63|PECAM-1
P09162084A0956|84 108|GST-Src-SH2 affinity matrix
P09162084A0956|84 90|GST-Src
P09162084A0956|92 94|SH2
P09162092A0675|0 22|MKK3 autophosphorylation
P09162092A0675|0 3|MKK3
P09162092A0675|38 40|p38
P09162092A0675|38 40|p38
P09162092A0675|79 82|MKK3
P09162092A0675|79 82|MKK3
P09162092A0675|87 91|MEKK3
P09162092A0675|87 91|MEKK3
P09162092A0675|103 107|MEKK2
P09162092A0675|103 107|MEKK2
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|59 63|exon 4
P09162097A0776|75 85|mucin domain
P09162097A0776|75 85|mucin domain
P09162097A0776|100 116|leukocyte adhesion
P09162097A0776|119 124|LPAM-1
P09162097A0776|119 124|LPAM-1
P09162097A0776|132 139|adhesion
P09162097A0776|163 172|L-selectin
P09162097A0776|163 172|L-selectin
P09162097A1258|56 67|MAdCAM-1 cDNA
P09162097A1258|56 67|MAdCAM-1 cDNA
P09162097A1258|87 100|human homologue
P09162097A1258|103 115|mouse MAdCAM-1
P09162097A1258|103 115|mouse MAdCAM-1
P09162097A1258|149 176|MAdCAM-1 C-terminal structures
P09162097A1258|149 157|MAdCAM-1 C
P09163332A0275|58 78|Xaa and hydroxy (Ser/Thr
P09163332A0275|80 96|amino acid residues
P09163332A0275|120 142|glycosylation efficiency
P09164543A0219|39 45|persons
P09164543A0219|65 71|surgery
P09164543A0219|148 164|selective vagotomy
P09164543A0219|169 190|gastroduodenal drainage
P09164856A0980|26 48|identifiable TATA element
P09164856A0980|82 96|glutaminase gene
P09164856A0980|82 96|glutaminase gene
P09164856A0980|108 124|TATA-less promoter
P09165004A1700|0 2|SRE
P09165004A1700|0 2|SRE
P09165004A1700|41 55|phosphorylation
P09165004A1700|66 78|complex factor
P09165004A1700|96 116|ternary complex factors
P09165004A1700|119 123|Elk-1
P09165004A1700|119 123|Elk-1
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165035A0842|5 23|alkaline phosphatase
P09165035A0842|33 52|bone mass measurements
P09165035A0842|54 90|dual energy x-ray absortiometric analysis
P09165035A0842|93 106|mineral density
P09165035A0842|159 160|-D
P09165035A0842|164 170|animals
P09165035A0842|212 218|animals
P09165039A0728|3 15|monkey LHR cDNA
P09165039A0728|66 82|mammalian LHR cDNAs
P09165039A0728|66 82|mammalian LHR cDNAs
P09165039A1372|13 29|marmoset monkey LHR
P09165039A1372|13 26|marmoset monkey
P09165039A1372|27 29|LHR
P09165039A1372|44 51|sequence
P09165039A1372|67 72|exon 10
P09165039A1372|78 84|LHR gene
P09165039A1372|78 84|LHR gene
P09165039A1372|92 107|mammalian species
P09165118A0311|2 13|unc-4 mutants
P09165118A0311|2 13|unc-4 mutants
P09165118A0311|17 28|motor neurons
P09165118A0311|47 54|synaptic
P09165118A0311|105 106|VB
P09165118A0311|107 118|motor neurons
P09165118A0311|145 147|VAs
P09165118A0311|168 189|backward movement defect
P09167421A0234|0 23|Intracavitary irradiation
P09167421A0234|42 76|microSelectron HDR afterloading device
P09168083A0987|2 8|patient
P09168083A0987|26 28|HAT
P09168134A0858|23 44|0.38 kb promoter sequence
P09168134A0858|52 60|promoters
P09168134A0858|66 73|Sm-E gene
P09168134A0858|66 73|Sm-E gene
P09168134A0858|77 88|U1 snRNA genes
P09168134A0858|79 88|snRNA genes
P09168134A0858|104 119|homologous motifs
P09168134A0858|151 165|snRNP components
P09168218A0216|70 74|type I
P09168218A0216|76 101|reflex sympathetic dystrophy
P09168218A0216|106 117|thermal grill
P09168218A0216|145 165|stellate ganglion block
P09168511A0640|76 82|steroid
P09168511A0640|83 92|budesonide
P09168511A0640|96 112|oral dexamethasone
P09168511A0640|146 153|steroids
P09168623A0614|1 25|xylE transcriptional fusion
P09168623A0614|1 4|xylE
P09168623A0614|39 50|mxbD promoter
P09168623A0614|39 50|mxbD promoter
P09168623A0614|57 75|low-level expression
P09168623A0614|78 91|wild-type cells
P09168623A0614|110 111|C1
P09168623A0614|110 111|C1
P09168623A0614|161 169|succinate
P09168879A0219|2 24|AcMNPV-infected Sf9 cells
P09168879A0219|26 52|late transcription initiation
P09168879A0219|74 90|upstream TAAG sites
P09168879A0219|106 124|downstream TAAG sites
P09168892A1016|10 20|nucleotides
P09168892A1016|34 57|AP-1 cis-response elements
P09168892A1016|34 57|AP-1 cis-response elements
P09168892A1016|71 86|trans-activation
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|155 160|y1 gene
P09169127A0371|155 160|y1 gene
P09169127A0371|180 197|functional sequence
P09169127A0371|207 212|y5 gene
P09169127A0371|207 212|y5 gene
P09169127A0371|229 249|complementary sequence
P09169127A0371|285 290|5' exon
P09169127A0371|297 302|y1 gene
P09169127A0371|297 302|y1 gene
P09169420A0000|3 36|mammalian phosphoinositide 3-kinases
P09169420A0000|3 36|mammalian phosphoinositide 3-kinases
P09169420A0000|38 57|PI3Ks) p110alpha, beta
P09169420A0000|38 42|PI3Ks
P09169420A0000|44 57|p110alpha, beta
P09169420A0000|71 82|heterodimers
P09169420A0000|87 109|Src homology 2 (SH2) domain
P09169420A0000|87 98|Src homology 2
P09169420A0000|100 102|SH2
P09169420A0000|135 142|p85alpha
P09169420A0000|135 142|p85alpha
P09169420A0000|145 147|p55
P09169420A0000|145 147|p55
P09169420A0000|149 151|PIK
P09169420A0000|149 151|PIK
P09169475A0272|28 44|5'-flanking region
P09169475A0272|50 63|human gp130 gene
P09169475A0272|50 59|human gp130
P09169475A0272|81 108|transcription initiation sites
P09169475A0772|0 11|Localization
P09169475A0772|17 39|cytokine response element
P09169475A0772|42 60|5'-deletion analysis
P09169475A0772|64 87|site-directed mutagenesis
P09169475A0772|97 117|cis-acting binding site
P09169475A0772|130 142|STAT complexes
P09169475A0772|130 133|STAT
P09169593T0000|0 6|Insulin
P09169593T0000|19 54|mitogen-activated protein kinase kinase
P09169593T0000|19 54|mitogen-activated protein kinase kinase
P09169593T0000|56 58|MEK
P09169593T0000|56 58|MEK
P09169593T0000|61 90|mitogen-activated protein kinase
P09169593T0000|61 90|mitogen-activated protein kinase
P09169593T0000|94 105|casein kinase
P09169593T0000|94 105|casein kinase
P09169593T0000|111 121|cell nucleus
P09169593T0000|153 166|gene expression
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|71 86|nonsense mutation
P09169852A0235|96 106|zinc fingers
P09169852A0235|132 147|fourth zinc finger
P09169852A0235|172 180|histidine
P09169852A0235|184 191|tyrosine
P09169853A0000|0 4|Pax-3
P09169853A0000|0 4|Pax-3
P09169853A0000|8 30|paired-type homeobox gene
P09169853A0000|8 30|paired-type homeobox gene
P09169853A0000|63 68|dorsal
P09169853A0000|81 86|neural
P09170159A0348|21 34|dendritic cells
P09170159A0348|77 115|tyrosinase and tyrosinase-related protein 1
P09170159A0348|77 86|tyrosinase
P09170159A0348|90 115|tyrosinase-related protein 1
P09170159A0721|20 29|stop codons
P09170159A0721|32 36|exon 7
P09170159A0721|74 90|truncated proteins
P09170159A0721|98 104|HLH-Zip
P09170159A0721|98 104|HLH-Zip
P09171038A0219|12 28|Sjogren's syndrome
P09171038A0219|74 89|dental complaints
P09171038A0219|114 130|Sjogren's patients
P09171081T0000|29 32|cDNA
P09171081T0000|42 72|bacteriophage-type RNA polymerase
P09171081T0000|42 72|bacteriophage-type RNA polymerase
P09171081T0000|91 106|Chenopodium album
P09171235A0851|51 58|COUP-TFI
P09171235A0851|51 58|COUP-TFI
P09171235A0851|66 80|COUP-TFI delta35
P09171235A0851|66 80|COUP-TFI delta35
P09171235A0851|117 132|unliganded TRbeta
P09171235A0851|127 132|TRbeta
P09171239A1118|8 17|amino acids
P09171239A1118|29 44|amphipathic helix
P09171239A1118|71 93|nuclear hormone receptors
P09171239A1118|71 93|nuclear hormone receptors
P09171239A1118|108 117|core domain
P09171239A1118|123 161|ligand-dependent transactivation function
P09171239A1118|163 166|AF-2
P09171239A1118|163 166|AF-2
P09171239A2146|16 33|RXR-specific ligand
P09171239A2146|16 18|RXR
P09171239A2146|34 51|9-cis-retinoic acid
P09171239A2146|68 72|SRC-1
P09171239A2146|68 72|SRC-1
P09171239A2146|78 80|RXR
P09171239A2146|78 80|RXR
P09171239A2146|95 114|TRE-bound heterodimer
P09171363A0149|2 9|ciliates
P09171389A0549|29 48|transcription signals
P09171389A0549|54 77|Thermus pyr promoter region
P09171389A0549|54 71|Thermus pyr promoter
P09171389A0549|81 103|strong amino acid sequence
P09171389A0549|131 141|Thermus PyrR
P09171389A0549|131 141|Thermus PyrR
P09171389A0549|148 170|PyrR attenuation proteins
P09171389A0549|176 185|Bacillus sp
P09171389A0549|261 277|pyr gene expression
P09171389A0549|261 267|pyr gene
P09171389A0549|280 286|Thermus
P09171468T0000|5 24|respiratory responses
P09171468T0000|28 66|tunable closed-circuit breathing apparatus
P09171969A1165|30 32|VO2
P09171969A1165|36 46|oxygen pulse
P09171969A1165|132 139|patients
P09171969A1165|144 147|COPD
P09172312T0000|18 20|CR1
P09172312T0000|27 42|random PCR markers
P09172312T0000|56 68|chicken genome
P09172414A0000|1 14|reversed-phase
P09172414A0000|37 56|chromatographic (HPLC
P09172414A0000|85 102|cocaine metabolites
P09172414A0000|120 141|serum and liver esterases
P09172414A0000|120 124|serum
P09172414A0000|128 141|liver esterases
P09172641A0181|38 40|end
P09172641A0181|59 68|side chains
P09172812A0660|17 27|fludarabine
P09172812A0660|50 52|CLL
P09173733A0404|26 35|EA analysis
P09173733A0404|61 81|Fourier transformation
P09173733A0404|83 85|FFT
P09173733A0404|89 90|EA
P09173733A0404|138 158|non-harmonic expansion
P09173733A0404|164 166|EEG
P09173733A0404|222 223|EA
P09174049A1788|0 12|Concomitantly
P09174049A1788|14 29|p34CDC2 histone H1
P09174049A1788|14 20|p34CDC2
P09174049A1788|21 35|histone H1 kinase
P09174049A1788|128 153|radiation-induced cell death
P09175708A1526|5 15|PRL-R tagged
P09175708A1526|5 7|PRL
P09175708A1526|25 53|N-terminal or C-terminal regions
P09175708A1526|25 37|N-terminal or C
P09175708A1526|158 164|nucleus
P09175858A1449|8 16|B-S mutant
P09175858A1449|8 16|B-S mutant
P09175858A1449|43 61|chloroplastic GAPDHs
P09175858A1449|43 61|chloroplastic GAPDHs
P09175858A1449|66 75|long-range
P09175858A1449|82 100|second-layer effects
P09175858A1449|241 254|cytosolic GAPDH
P09175858A1449|241 254|cytosolic GAPDH
P09176340A1194|0 12|Transcription
P09176340A1194|42 44|gut
P09176340A1194|48 51|lung
P09176340A1194|58 65|freezing
P09176340A1194|70 79|mRNA levels
P09176340A1194|109 113|liver
P09176837A0211|8 31|software assisted ordering
P09176837A0211|33 36|CSAO
P09176837A0211|61 64|PN Ca
P09176837A0211|102 111|parenteral
P09176837A0211|112 113|Ca
P09176837A0211|117 131|P administration
P09177857A0000|81 86|oxygen
P09177857A0000|105 126|surgical stainless steel
P09177857A0000|132 139|type 316L
P09177857A0000|145 188|plasma assisted chemical vapour deposition method
P09178269A0107|6 10|genes
P09178491A0262|30 53|preS2/S gene transcription
P09178491A0262|30 34|preS2
P09178491A0262|36 40|S gene
P09178491A0262|59 71|HBV adw subtype
P09178491A0262|76 90|diverged TATA box
P09178491A0262|103 118|initiator element
P09178494A1123|30 56|5' and 3'-untranslated regions
P09178494A1123|75 95|stem and loop structures
P09178494A1123|108 132|all tick-borne flaviviruses
P09178494A1123|179 190|essential RNA
P09178494A1123|232 251|translational control
P09178752A0574|0 2|EGF
P09178752A0574|0 2|EGF
P09178752A0574|46 49|AF-1
P09178752A0574|58 61|cAMP
P09178752A0574|69 89|transactivation domain
P09178752A0574|90 93|AF-2
P09178752A0574|99 100|ER
P09180687A0096|24 27|SulA
P09180687A0096|24 27|SulA
P09180687A0096|57 68|cell division
P09180687A0096|92 123|N-terminal and C-terminal deletions
P09180687A0096|92 105|N-terminal and C
P09180687A0096|126 129|SulA
P09180687A0096|126 129|SulA
P09180687A0096|142 148|alanine
P09181130A1067|17 23|Krox-20
P09181130A1067|51 57|ES cells
P09181130A1067|80 87|mutation
P09181130A1067|108 109|r3
P09181130A1067|108 109|r3
P09181130A1067|113 114|r5
P09181130A1067|113 114|r5
P09181130A1587a|50 68|neuronal populations
P09181130A1587a|118 124|Krox-20
P09182281A0197|30 41|Cyclosporin A
P09182281A0197|60 80|immunosuppressive drug
P09182527A0443|23 39|p53 ubiquitination
P09182527A0443|23 25|p53
P09182527A0443|41 46|mE6-AP
P09182527A0443|41 46|mE6-AP
P09182527A0443|64 70|nucleus
P09182527A0443|74 80|cytosol
P09182527A0443|87 92|Nedd-4
P09182527A0443|87 92|Nedd-4
P09182527A0443|110 116|cytosol
P09182707A0254|0 2|SPP
P09182707A0254|0 2|SPP
P09182707A0254|23 45|tyrosine phosphorylation
P09182707A0254|48 66|focal adhesion kinase
P09182707A0254|48 66|focal adhesion kinase
P09182707A0254|68 71|p125
P09182707A0254|68 71|p125
P09182707A0254|73 76|FAK)
P09182707A0254|73 75|FAK
P09182707A0254|80 102|cytosolic tyrosine kinase
P09182707A0254|80 102|cytosolic tyrosine kinase
P09182707A0254|118 131|focal adhesions
P09182707A0254|141 170|cytoskeleton-associated protein
P09182707A0254|171 178|paxillin
P09182707A0254|171 178|paxillin
P09182990A0245|24 35|mutant allele
P09182990A0245|38 42|SUP45
P09182990A0245|38 42|SUP45
P09182990A0245|44 50|sup45-2
P09182990A0245|44 50|sup45-2
P09182990A0245|128 136|SUP45 gene
P09182990A0245|128 136|SUP45 gene
P09182990A0245|138 143|Sup45p
P09182990A0245|138 143|Sup45p
P09182990A0245|146 149|eRF1
P09182990A0245|146 149|eRF1
P09182990A0245|171 192|translation termination
P09182990A0245|195 199|yeast
P09183145T0001|12 30|myocardial perfusion
P09183145T0001|33 54|99mTc-tetrofosmin SPECT
P09183145T0001|77 119|percutaneous transluminal coronary angioplasty
P09183145T0001|123 147|acute myocardial infarction
P09183406A0637|9 34|alloimmune thrombocytopenia
P09183406A0637|41 67|HPA-3a (Baka) incompatibility
P09183406A0637|41 46|HPA-3a
P09183406A0637|48 51|Baka
P09185183T0000|0 41|Merosin positive congenital muscular dystrophy
P09185183T0000|0 6|Merosin
P09185183T0000|46 61|mental deficiency
P09185183T0000|74 83|MRI changes
P09185183T0000|89 96|cerebral
P09185586A0000|14 18|mRNAs
P09185586A0000|36 61|scanning ribosome" mechanism
P09185645T0000|12 42|Tc-99m sestamibi perfusion imaging
P09185645T0000|104 111|coronary
P09186056A0514|43 52|C2C12 cells
P09186056A0514|79 90|CAT-reporter
P09186056A0514|79 81|CAT
P09186056A0514|104 106|E12
P09186056A0514|104 106|E12
P09186056A0514|108 111|MyoD
P09186056A0514|108 111|MyoD
P09186056A0514|118 125|enhancer
P09186430A0341|23 44|oculocutaneous albinism
P09186507A0882|11 54|126-nucleotide 5' untranscribed genomic sequence
P09186507A0882|59 95|466-nucleotide 5' noncoding cDNA sequence
P09186507A0882|100 124|592-nucleotide 5' CpG island
P09186507A0882|131 134|TATA
P09186507A0882|138 146|CAAT boxes
P09186507A0882|164 173|G+C content
P09186507A0882|189 204|CpG dinucleotides
P09186507A0882|228 242|Sp1-binding site
P09186507A0882|228 242|Sp1-binding site
P09186507A0882|272 287|housekeeping gene
P09187136A0000|0 5|SSeCKS
P09187136A0000|0 5|SSeCKS
P09187136A0000|31 58|major protein kinase C substrate
P09187136A0000|31 49|major protein kinase C
P09187136A0000|98 107|src- and ras
P09187136A0000|98 101|src-
P09187136A0000|120 136|rodent fibroblasts
P09187136A0000|145 176|raf-transformed rodent fibroblasts
P09187277A0118|0 29|Type I position-vestibular-pause
P09187277A0118|31 34|PVP I
P09187277A0118|39 56|vestibular-only (V I
P09187277A0118|55 56|V I
P09187277A0118|95 111|type I and type II eye
P09187371A0450|16 26|mRNA species
P09187371A0450|45 49|heart
P09187371A0450|83 87|heart
P09187371A0450|89 102|kidney and brain
P09187371A0450|112 125|skeletal muscle
P09187371A0450|128 132|liver
P09187637A1199|0 16|Taurine deficiency
P09187637A1199|53 55|OP1
P09187637A1199|53 55|OP1
P09187637A1199|59 61|OP4
P09188094A0934|15 24|mcs4- cells
P09188094A0934|15 18|mcs4
P09188094A0934|51 54|Spc1
P09188094A0934|51 54|Spc1
P09188699A1388|11 13|rat
P09188699A1388|14 25|SP-A isoforms
P09188699A1388|14 17|SP-A
P09188699A1388|52 63|glycosylated
P09188699A1388|77 80|SP-A
P09188699A1388|77 80|SP-A
P09188699A1388|99 110|SDS-PAGE gels
P09188863A0954|21 26|CDC25B
P09188863A0954|21 26|CDC25B
P09188863A0954|63 79|cell proliferation
P09189783A0000|79 101|preexercise carbohydrate
P09189783A0000|142 153|blood glucose
P09189783A0000|157 172|insulin responses
P09189783A0000|157 163|insulin
P09189896A0611|22 24|ERP
P09189896A0611|34 56|distinct memory processes
P09190202A0166|4 14|coat protein
P09190202A0166|25 29|Sar1p
P09190202A0166|25 29|Sar1p
P09190202A0166|34 53|Sec23p protein complex
P09190202A0166|34 46|Sec23p protein
P09190202A0166|64 69|Sec23p
P09190202A0166|64 69|Sec23p
P09190202A0166|73 78|Sec24p
P09190202A0166|73 78|Sec24p
P09190202A0166|86 105|Sec13p protein complex
P09190202A0166|86 98|Sec13p protein
P09190202A0166|116 121|Sec13p
P09190202A0166|116 121|Sec13p
P09190202A0166|131 144|150-kDa protein
P09190202A0166|131 144|150-kDa protein
P09190202A0166|146 149|p150
P09190202A0166|146 149|p150
P09190821A0707|32 49|proline-to-leucine
P09190821A0707|58 74|position 243 (P243L
P09190940A0127|27 45|germline transcripts
P09190940A0127|81 93|recombination
P09191052A0850|8 10|PCE
P09191052A0850|8 10|PCE
P09191052A0850|17 24|Pbx dimer
P09191052A0850|17 19|Pbx
P09191052A0850|49 65|Class I Hox proteins
P09191052A0850|49 65|Class I Hox proteins
P09192732A1384|15 33|NH2-terminal portion
P09192732A1384|73 85|outer membrane
P09192732A1384|96 112|COOH-terminal part
P09192769T0000|0 15|Molecular cloning
P09192769T0000|38 41|cDNA
P09192769T0000|43 48|CHEMR1
P09192769T0000|43 48|CHEMR1
P09192769T0000|58 75|a chemokine receptor
P09192769T0000|59 75|chemokine receptor
P09192769T0000|94 118|human C-C chemokine receptor
P09192769T0000|94 118|human C-C chemokine receptor
P09192769T0000|120 124|CCR-4
P09192769T0000|120 124|CCR-4
P09192786T0000|0 11|Organization
P09192786T0000|17 27|human LU gene
P09192786T0000|17 27|human LU gene
P09192786T0000|50 82|Lu(a)/Lu(b) blood group polymorphism
P09192786T0000|50 54|Lu(a)
P09192786T0000|56 57|Lu
P09192786T0000|59 59|b
P09192842A0988|5 29|mouse-human somatic hybrids
P09192842A0988|33 44|FISH analysis
P09192842A0988|49 56|PE-2 gene
P09192842A0988|49 56|PE-2 gene
P09192842A0988|70 91|human chromosome 19q13.2
P09192842A0988|110 123|translocations
P09192842A0988|138 146|leukemias
P09192842A0988|157 167|solid tumors
P09192842A0988|192 200|ETS factor
P09192842A0988|192 200|ETS factor
P09192842A0988|215 228|carcinogenesis
P09192998A0356|61 65|T7 DNA
P09192998A0356|61 65|T7 DNA
P09192998A0356|67 72|T(phi)
P09192998A0356|67 67|T
P09192998A0356|69 73|phi))
P09192998A0356|77 80|rrnB
P09192998A0356|77 80|rrnB
P09192998A0356|81 82|T2
P09192998A0356|131 134|rrnB
P09192998A0356|131 134|rrnB
P09192998A0356|135 136|T1
P09192998A0356|135 136|T1
P09192998A0356|163 165|PTH
P09192998A0356|163 165|PTH
P09192998A0356|169 177|CJ signals
P09193072A0199|53 61|nucleolus
P09193077A0000|5 24|regulatory unit 1 (LRU1
P09193077A0000|21 24|LRU1
P09193077A0000|62 86|light-dependent activation
P09193077A0000|92 107|chalcone synthase
P09193077A0000|92 107|chalcone synthase
P09193077A0000|109 127|CHS) minimal promoter
P09193077A0000|109 111|CHS
P09193077A0000|113 127|minimal promoter
P09193077A0000|130 148|Petroselinum crispum
P09193080A0904|75 93|gene-specific probes
P09193671A0347|3 13|active state
P09193671A0347|45 47|GTP
P09193671A0347|66 72|ARF-GDP
P09193671A0347|66 68|ARF
P09194250A0708|39 46|Children
P09194250A0708|117 140|geographical inequalities
P09195923A0125|3 14|immunophilin
P09195923A0125|3 14|immunophilin
P09195923A0125|31 35|FK506
P09195923A0125|39 50|cyclosporin A
P09195923A0125|72 76|hsp90
P09195923A0125|72 76|hsp90
P09195923A0125|83 116|tetratricopeptide repeat (TPR) domain
P09195923A0125|138 152|heterocomplexes
P09195923A0125|176 187|immunophilin
P09195923A0125|176 187|immunophilin
P09195923A0125|199 215|TPR-binding region
P09195923A0125|199 215|TPR-binding region
P09195923A0125|218 222|hsp90
P09195923A0125|218 222|hsp90
P09197241A0770|2 20|adherent macrophages
P09197241A0770|31 34|CD45
P09197241A0770|31 34|CD45
P09197241A0770|43 80|hyperphosphorylation and hyperactivation
P09197241A0770|83 88|p56/59
P09197241A0770|83 88|p56/59
P09197241A0770|90 92|hck
P09197241A0770|90 92|hck
P09197241A0770|97 102|p53/56
P09197241A0770|97 99|p53
P09197241A0770|101 102|56
P09197241A0770|104 106|lyn
P09197241A0770|104 106|lyn
P09197241A0770|117 119|p58
P09197241A0770|117 119|p58
P09197241A0770|121 125|c-fgr
P09197241A0770|121 125|c-fgr
P09197342T0000|45 55|iodized oils
P09197342T0000|65 66|UF
P09197408A0126|15 22|facB gene
P09197408A0126|15 22|facB gene
P09197408A0126|66 75|N-terminal
P09197408A0126|76 89|GAL4-like Zn(II
P09197408A0126|85 95|Zn(II)2Cys6
P09197408A0126|99 121|C6 zinc) binuclear cluster
P09197408A0126|125 171|DNA binding, leucine zipper-like heptad repeat motifs
P09197408A0126|125 134|DNA binding
P09197408A0126|136 171|leucine zipper-like heptad repeat motifs
P09197408A0126|175 220|central and C-terminal acidic alpha-helical regions
P09197408A0126|185 205|C-terminal acidic alpha
P09197408A0126|248 282|DNA-binding transcriptional activator
P09197408A0126|248 282|DNA-binding transcriptional activator
P09199167A0942|16 20|Sed5p
P09199167A0942|16 20|Sed5p
P09199167A0942|48 52|Vti1p
P09199167A0942|48 52|Vti1p
P09199286A0086|17 20|mkh1
P09199286A0086|17 20|mkh1
P09199286A0086|58 80|1,116-amino-acid protein
P09199292A0536|38 41|p107
P09199292A0536|38 41|p107
P09199292A0536|44 47|p130
P09199292A0536|44 47|p130
P09199292A0536|58 69|cyclin E-cdk2
P09199292A0536|58 64|cyclin E
P09199292A0536|66 69|cdk2
P09199292A0536|72 83|cyclin A-cdk2
P09199292A0536|72 78|cyclin A
P09199292A0536|80 83|cdk2
P09199292A0536|111 117|kinases
P09199318A1147|12 15|p150
P09199318A1147|12 15|p150
P09199318A1147|26 38|actin gelation
P09199318A1147|26 30|actin
P09199318A1147|56 80|smooth muscle alpha-actinin
P09199318A1147|56 80|smooth muscle alpha-actinin
P09199322T0000|0 11|Denaturation
P09199322T0000|17 48|simian virus 40 origin of replication
P09199322T0000|59 82|human replication protein A
P09199322T0000|59 82|human replication protein A
P09199327A1250|29 35|EM motif
P09199327A1250|41 66|promoter-reporter construct
P09199327A1250|138 164|TEF-1-Max heterotypic complex
P09199327A1250|138 142|TEF-1
P09199327A1250|144 146|Max
P09199327A1250|206 212|EM motif
P09199328T0000|0 21|Interdigitated residues
P09199328T0000|42 45|VP16
P09199328T0000|42 45|VP16
P09199328T0000|58 62|Oct-1
P09199328T0000|58 62|Oct-1
P09199328T0000|64 66|HCF
P09199328T0000|64 66|HCF
P09199348A0156|36 50|U14 interactions
P09199348A0156|53 67|stem-loop domain
P09199348A0156|89 118|Saccharomyces cerevisiae U14 RNAs
P09199348A0156|89 111|Saccharomyces cerevisiae
P09199348A0156|112 118|U14 RNAs
P09199348A0156|123 129|Y domain
P09199348A0156|123 129|Y domain
P09199353A1924|29 33|Cdc68
P09199353A1924|29 33|Cdc68
P09199353A1924|65 82|chromatin structure
P09199353A1924|99 113|polymerase alpha
P09199353A1924|99 113|polymerase alpha
P09199413A0518|11 22|inoculum size
P09199413A0518|53 61|CFU/mouse
P09199413A0518|72 78|RB6-8C5
P09199413A0518|72 78|RB6-8C5
P09199413A0518|87 93|animals
P09199626A0613|25 29|stage
P09199932A1357|0 18|Promoter recognition
P09199932A1357|39 63|divergent promoter elements
P09199932A1357|73 81|CpG island
P09199932A1357|102 120|ATM and E14/NPAT genes
P09199932A1357|102 104|ATM
P09199932A1357|108 110|E14
P09199932A1357|112 115|NPAT
P09199932A1357|158 168|ATM promoter
P09199932A1357|158 168|ATM promoter
P09199932A1357|182 188|intron 3
P09199932A1357|214 228|first coding exon
P09199970A1101|0 21|Recombinant soluble pMCP
P09199970A1101|11 21|soluble pMCP
P09199970A1101|32 65|transmembrane and cytoplasmic domains
P09199970A1101|75 91|I cofactor activity
P09199970A1101|75 83|I cofactor
P09199970A1101|94 96|C3b
P09199970A1101|94 96|C3b
P09199970A1101|169 171|MCP
P09200029A0211|0 29|Clinical and haematological signs
P09200029A0211|81 100|histological features
P09200498T0000|0 11|Spatial zones
P09200498T0000|15 32|muscle coactivation
P09200498T0000|48 64|postural stability
P09200530A0411|6 30|chromatographic separation
P09200530A0411|45 70|Zorbax RX C8 analytical column
P09200811T0000|3 15|linear plasmid
P09200811T0000|16 20|pDHL1
P09200811T0000|25 44|Debaryomyces hansenii
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09201946A0000|3 41|RNA-binding and RNA-DNA helicase activities
P09201946A0000|3 31|RNA-binding and RNA-DNA helicase
P09201946A0000|47 94|Escherichia coli transcription termination factor rho
P09201946A0000|47 91|Escherichia coli transcription termination factor
P09201946A0000|120 138|natural RNA molecules
P09201946A0000|155 172|nucleotide residues
P09201946A0000|198 205|trp t' rho
P09201946A0000|201 234|t' rho-dependent termination sequence
P09201946A0000|237 242|E. coli
P09201980A0910|3 15|p20-CGGBP gene
P09201980A0910|3 15|p20-CGGBP gene
P09201980A0910|32 38|mammals
P09202147A0866|24 28|yeast
P09202147A0866|32 37|plants
P09202147A0866|57 59|UBC
P09202147A0866|57 59|UBC
P09202147A0866|111 126|abnormal proteins
P09202669A0614|3 8|pWP-19
P09202669A0614|3 8|pWP-19
P09202669A0614|23 48|AAV inverted terminal repeats
P09202669A0614|52 62|integration
P09202669A0614|66 76|replication
P09202669A0614|83 116|herpes virus thymidine kinase promoter
P09202669A0614|83 93|herpes virus
P09202669A0614|94 127|thymidine kinase promoter-driven gene
P09202669A0614|131 153|neomycin resistance (neoR
P09202669A0614|150 153|neoR
P09202669A1530|16 46|rAAV-mediated gene transfer system
P09202669A1530|53 74|rat preproinsulin II gene
P09202669A1530|53 74|rat preproinsulin II gene
P09202859A0091|3 13|serum levels
P09202859A0091|16 46|beta-human chorionic gonadotropin
P09202859A0091|21 34|human chorionic
P09202859A0091|35 46|gonadotropin
P09202859A0091|48 87|HCG) and placental alkaline phosphatase (PLAP
P09202859A0091|48 50|HCG
P09202859A0091|55 82|placental alkaline phosphatase
P09202859A0091|84 87|PLAP
P09203585A0660|21 40|recombinant H19 allele
P09203585A0660|32 40|H19 allele
P09203585A0660|82 103|neo replacement cassette
P09203586A1197|35 42|T antigen
P09203586A1197|48 59|rRNA promoter
P09203586A1197|62 64|SL1
P09203586A1197|62 64|SL1
P09203731A0497|9 31|International Commission
P09203731A0497|66 95|Poliomyelitis Eradication (ICCPE
P09203731A0497|168 179|transmission
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|65 92|Rhizobium leguminosarum strain
P09204566T0000|93 96|VF39
P09204570A0110|22 32|MADS box gene
P09204570A0110|22 32|MADS box gene
P09204570A0110|34 38|nmhC5
P09204570A0110|34 38|nmhC5
P09204570A0110|54 57|nmh7
P09204570A0110|54 57|nmh7
P09204570A0110|59 59|J
P09205113A0587|4 6|E14
P09205113A0587|8 13|1TG3B1
P09205113A0587|23 32|ES cell line
P09205113A0587|48 58|mouse genome
P09205113A0587|67 74|HPRT gene
P09205113A0587|67 74|HPRT gene
P09205113A0587|99 110|transmission
P09205677A0577|0 24|Lung and multi-system damage
P09205965A1249|46 57|reflex evoked
P09205965A1249|60 73|bladder filling
P09205965A1249|77 82|L-dopa
P09205965A1249|114 125|transmission
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09206230A0000|55 81|asthenopia, mixed astigmatism
P09206968A0000|78 90|tunica propria
P09208214A0572|0 18|Sternocleidomastoid
P09208214A0572|20 23|neck
P09208930T0000|48 84|interleukin-1beta converting enzyme gene
P09208930T0000|48 84|interleukin-1beta converting enzyme gene
P09208930T0000|101 119|functional proteases
P09209031A0350|3 24|C-terminal mature region
P09209031A0350|49 71|serine carboxypeptidases
P09209031A0350|49 71|serine carboxypeptidases
P09209312A0968|3 5|RNA
P09209312A0968|34 44|nucleotides
P09209312A0968|53 64|nt 639 to nt 750
P09209312A0968|72 91|heterodimeric complex
P09209312A0968|136 147|nt 551 to nt 750
P09209372A0345|21 25|AML1a
P09209372A0345|21 25|AML1a
P09209372A0345|53 76|transcriptional regulator
P09209372A0345|98 122|transcriptional activation
P09209372A0345|125 129|AML1b
P09209372A0345|125 129|AML1b
P09209372A0345|138 142|AML1a
P09209372A0345|138 142|AML1a
P09209372A0345|186 190|AML1b
P09209372A0345|186 190|AML1b
P09209406A1021|46 77|guanine nucleotide exchange factors
P09209406A1021|46 77|guanine nucleotide exchange factors
P09209406A1021|80 104|GTPase-activating proteins
P09209406A1021|80 104|GTPase-activating proteins
P09209406A1021|110 118|c-cbl gene
P09209406A1021|110 118|c-cbl gene
P09209438A0994|13 33|ATL-16T nuclear extract
P09209438A0994|53 58|GATA-4
P09209438A0994|53 58|GATA-4
P09209438A0994|68 86|GATA-binding protein
P09209438A0994|68 86|GATA-binding protein
P09209438A0994|104 121|DNA-protein complex
P09209438A0994|104 114|DNA-protein
P09209438A0994|129 139|-70 GATA site
P09210012A0000|11 23|social support
P09210012A0000|44 57|gay male couples
P09210478A0000|24 48|hypoxia-inducible factor-1
P09210478A0000|24 48|hypoxia-inducible factor-1
P09210478A0000|50 54|HIF-1
P09210478A0000|50 54|HIF-1
P09210478A0000|94 114|oxygen-regulated genes
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|14 38|matrix metalloproteinase-3
P09211354A0000|14 38|matrix metalloproteinase-3
P09211354A0000|40 44|MMP-3
P09211354A0000|40 44|MMP-3
P09211354A0000|95 106|somatic cells
P09211354A0000|109 120|organ tissues
P09211605A0478|0 5|Tendon
P09211605A0478|24 36|extensibility
P09211675A0392|0 11|Surveillance
P09211675A0392|15 26|preeclampsia
P09211675A0392|41 56|personnel unaware
P09211675A0392|117 155|blood pressure and urinary protein excretion
P09211675A0392|176 189|prenatal visits
P09211675A0392|257 264|delivery
P09211675A0392|327 342|hospitalizations
P09211913A0000|0 41|Aryl hydrocarbon receptor nuclear translocator
P09211913A0000|0 41|Aryl hydrocarbon receptor nuclear translocator
P09211913A0000|43 46|ARNT
P09211913A0000|43 46|ARNT
P09211913A0000|65 84|transcription factors
P09211913A0000|65 84|transcription factors
P09211913A0000|86 108|aryl hydrocarbon receptor
P09211913A0000|86 108|aryl hydrocarbon receptor
P09211913A0000|110 112|AhR
P09211913A0000|110 112|AhR
P09211913A0000|117 140|hypoxia-inducible factor 1
P09211913A0000|117 140|hypoxia-inducible factor 1
P09211913A0000|165 175|target genes
P09211913A0000|183 188|CYP1A1
P09211913A0000|183 188|CYP1A1
P09211913A0000|192 205|erythropoietin
P09211913A0000|192 205|erythropoietin
P09211913A0000|229 248|aromatic hydrocarbons
P09211934A0722|0 22|DNase I footprint analysis
P09211934A0722|0 5|DNase I
P09211934A0722|34 48|protected region
P09211934A0722|53 55|-37
P09211981A0526|25 28|gar2
P09211981A0526|25 28|gar2
P09211981A0526|55 85|p13(suc1)-Sepharose-bound kinase
P09211981A0526|55 57|p13
P09211981A0526|59 62|suc1
P09211981A0526|90 113|Schizosaccharomyces pombe
P09211981A0526|134 160|cell cycle-regulated activity
P09211981A0526|179 193|p34(cdc2(kinase
P09211981A0526|179 181|p34
P09211981A0526|183 193|cdc2(kinase
P09212059A1356|21 52|metal affinity chromatography assay
P09212059A1356|72 75|PR-A
P09212059A1356|72 75|PR-A
P09212059A1356|119 123|DhLBD
P09212059A1356|126 139|hLBD constructs
P09212059A1856|65 84|carboxyl-terminal LBD
P09212059A1856|112 125|PR dimerization
P09212059A1856|112 113|PR
P09212059A1856|161 191|hinge and amino-terminal sequences
P09212059A1856|249 250|PR
P09212063A0425|17 34|overlapping A-phage
P09212063A0425|38 49|cosmid clones
P09212063A0425|74 81|human DNA
P09212063A0425|103 109|VDR gene
P09212063A0425|103 105|VDR
P09214274T0001|0 18|Colorectal carcinoma
P09214274T0001|67 85|metastasis resection
P09215525A0581|50 64|E2F/DP complexes
P09215525A0581|50 52|E2F
P09215525A0581|54 64|DP complexes
P09215891A0000|16 42|Saccharomyces cerevisiae CIN1
P09215891A0000|16 38|Saccharomyces cerevisiae
P09215891A0000|44 47|CIN2
P09215891A0000|44 47|CIN2
P09215891A0000|51 59|CIN4 genes
P09215891A0000|51 59|CIN4 genes
P09215891A0000|74 92|nonessential pathway
P09215891A0000|110 128|microtubule function
P09216017A0621|0 9|Vitrectomy
P09216936T0000|19 40|Acute and chronic effects
P09216936T0000|53 64|leptin levels
P09216936T0000|53 58|leptin
P09216936T0000|67 72|humans
P09218436A0443|18 24|TATA box
P09218436A0443|29 32|Pint
P09218436A0443|29 32|Pint
P09218436A0443|45 49|MED-1
P09218436A0443|45 49|MED-1
P09218436A0443|57 65|promoters
P09218436A0443|80 92|transcription
P09218436A0443|95 107|multiple sites
P09218459A0000|0 18|Serum response factor
P09218459A0000|0 18|Serum response factor
P09218459A0000|20 22|SRF
P09218459A0000|20 22|SRF
P09218459A0000|36 48|ancient family
P09218459A0000|51 69|DNA-binding proteins
P09218459A0000|51 69|DNA-binding proteins
P09218459A0000|104 122|transcription factor
P09218459A0000|143 170|growth factor-responsive genes
P09218459A0000|143 170|growth factor-responsive genes
P09218520A0075|41 57|signal transducers
P09218520A0075|78 92|cytosolic domain
P09218520A0075|78 92|cytosolic domain
P09218520A0075|94 95|cd
P09218520A0075|94 95|cd
P09218520A0075|102 106|IL-1R
P09218520A0075|102 106|IL-1R
P09218599A0184|84 87|IL-4
P09218599A0184|84 87|IL-4
P09218775A0000|0 27|Pseudomonas aeruginosa strains
P09218775A0000|37 44|patients
P09218775A0000|49 62|cystic fibrosis
P09218775A0000|111 118|alginate
P09218775A1229|10 14|palgD
P09218775A1229|10 14|palgD
P09218775A1229|20 29|cysB mutant
P09218775A1229|20 29|cysB mutant
P09218775A1229|33 35|CHA
P09218775A1229|60 62|PAO
P09218775A1229|85 114|transcriptional algD-xylE fusion
P09218775A1229|100 103|algD
P09218775A1229|105 108|xylE
P09219526A0383|3 29|Man9-mannosidase specificity
P09219526A0383|3 18|Man9-mannosidase
P09219526A0383|35 47|cDNA construct
P09219526A0383|148 161|49-kDa fragment
P09219526A0383|180 191|coding region
P09220158A0537|1 20|soluble 62-kDa protein
P09220158A0537|8 20|62-kDa protein
P09220158A0537|65 73|inserting
P09220158A0537|93 105|amino acids 112
P09220158A0537|113 117|ORF-2
P09220158A0537|113 117|ORF-2
P09220158A0537|121 147|baculovirus expression vector
P09220158A0537|185 192|Sf9 cells
P09220177A0564|3 17|CPK-MB isoenzyme
P09220177A0564|3 5|CPK
P09220177A0564|7 17|MB isoenzyme
P09220177A0564|96 100|shock
P09220177A0564|136 148|cardioversion
P09222057A0176|0 34|Serum and peritoneal dialysis fluid (PDF
P09222057A0176|52 56|assay
P09222115A0545|31 69|endogenous corticotropin-releasing factor
P09222115A0545|31 40|endogenous
P09222115A0545|41 69|corticotropin-releasing factor
P09222115A0545|97 107|binding site
P09222115A0545|187 195|isolation
P09223042A0000|13 23|blood volume
P09223042A0000|25 28|LRBV
P09223042A0000|64 75|various drugs
P09223122A0774|13 18|NAA/mI
P09223229A0565|9 31|murine and human mb-1 genes
P09223229A0565|18 31|human mb-1 genes
P09223229A0565|36 43|5' region
P09223229A0565|49 62|bovine mb-1 gene
P09223229A0565|55 62|mb-1 gene
P09223229A0565|70 76|TATA box
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223475A0898|0 31|Chloramphenicol acetyltransferase
P09223475A0898|59 62|IE86
P09223475A0898|59 62|IE86
P09223475A0898|87 105|HCMV major IE promoter
P09223475A0898|87 105|HCMV major IE promoter
P09223475A0898|119 135|HCMV early promoter
P09223475A0898|119 135|HCMV early promoter
P09223475A0898|142 147|2.2-kb
P09223475A0898|155 158|RNAs
P09223475A0898|198 208|IE86 protein
P09223475A0898|198 201|IE86
P09223479A1193|0 4|ORF M1
P09223479A1193|0 4|ORF M1
P09223479A1193|26 40|poxvirus serpins
P09223479A1193|34 40|serpins
P09223479A1193|47 52|ORF M11
P09223479A1193|47 52|ORF M11
P09223479A1193|79 97|Bcl-2-like molecules
P09223479A1193|79 97|Bcl-2-like molecules
P09223479A1193|112 136|gammaherpesviruses (gene 16
P09223479A1193|139 141|HVS
P09223479A1193|145 148|KSHV
P09223479A1193|155 163|BHRF1 gene
P09223479A1193|155 159|BHRF1
P09223479A1193|166 168|EBV
P09223506T0000|0 30|Transcription factor binding sites
P09223506T0000|46 98|human immunodeficiency virus type 1 transcription start site
P09223506T0000|46 76|human immunodeficiency virus type 1
P09223506T0000|114 129|virus infectivity
P09223647T0000|0 15|Crystal structure
P09223647T0000|30 48|proteolytic zymogens
P09223647T0000|98 104|complex
P09223667A0139|7 27|transient transfection
P09223667A0139|30 50|NIH3T3 fibroblast cells
P09223667A0139|54 75|gel mobility shift assays
P09223667A0139|80 100|functional binding site
P09223667A0139|134 139|-303 bp
P09223667A0139|147 168|transcription start site
P09223667A0139|179 191|CTCCC sequence
P09223880A1147|42 44|s-1
P09223880A1147|59 74|spinal anesthesia
P09224655T0000|21 25|ClC-6
P09224655T0000|21 25|ClC-6
P09224655T0000|39 63|CIC chloride-channel family
P09224655T0000|39 63|CIC chloride-channel family
P09224655T0000|90 106|truncated isoforms
P09224655T0000|118 123|ClC-6c
P09224655T0000|118 123|ClC-6c
P09224811A0000|31 32|T3
P09224811A0000|61 94|NADPH:cytochrome P450 oxidoreductase
P09224811A0000|67 94|cytochrome P450 oxidoreductase
P09224811A0000|96 105|P450R) gene
P09224811A0000|96 105|P450R) gene
P09224811A0000|129 142|hormonal status
P09224811A0000|163 208|transcriptional and post-transcriptional pathways
P09224811A0000|238 259|cellular P450R mRNA level
P09224811A0000|246 254|P450R mRNA
P09225151T0000|29 56|polytetrafluoroethylene (PTFE
P09225151T0000|100 119|abdominal wall defects
P09225506A0462|3 14|control group
P09225506A0462|50 69|coagulation factors II
P09225506A0462|50 69|coagulation factors II
P09225506A0462|71 78|V and VIII
P09225506A0462|75 78|VIII
P09225506A0462|93 102|index group
P09225682A0579|14 43|positive anti-GM1 antibody titers
P09225682A0579|22 37|anti-GM1 antibody
P09225682A0579|49 78|Guillain-Barre syndrome patients
P09225682A0579|83 85|PEN
P09225682A0579|118 166|Guillain-Barre syndrome and Fisher's syndrome patients
P09225682A0579|174 176|PEN
P09225686A0683|0 34|Stereotactic radiofrequency lesioning
P09225686A0683|59 74|seizure remission
P09225686A0683|108 114|surgery
P09225998A0000|0 8|NF-kappa B
P09225998A0000|0 8|NF-kappa B
P09225998A0000|9 32|/Rel transcription factors
P09225998A0000|10 12|Rel
P09225998A0000|84 112|immune regulation/inflammation
P09225998A0000|122 130|cytokines
P09225998A0000|132 151|cell surface receptors
P09225998A0000|153 169|adhesion molecules
P09225998A0000|174 191|acute phase proteins
P09226113A0857|2 7|E. coli
P09226113A0857|74 81|borehole
P09226345A0436|51 58|ACT group
P09226345A0436|103 110|SEP group
P09227099A0106|90 100|convenience
P09227332A1798|45 53|cytokines
P09227332A1798|71 79|cytokines
P09227332A1798|94 95|DC
P09227799A0254|96 110|diagnostic tests
P09227799A0254|112 127|stool examination
P09227799A0254|129 133|ELISA
P09227799A0254|145 154|egg antigen
P09227799A0254|145 154|egg antigen
P09227799A0254|156 158|SEA
P09227799A0254|156 158|SEA
P09227799A0254|166 189|circumoval precipitin test
P09227799A0254|176 185|precipitin
P09227799A0254|191 194|COPT
P09228042A0109|16 30|dermatan sulfate
P09228042A0109|83 104|dissociative extraction
P09228042A0109|107 136|bovine fetal epiphyseal cartilage
P09228042A0109|158 169|ion-exchange
P09228042A0109|171 183|gel permeation
P09228042A0109|185 195|hydrophobic
P09228042A0109|200 203|Zn2+
P09228042A0109|211 230|chromatographic steps
P09228092A1779|31 37|dUTPase
P09228092A1779|31 37|dUTPase
P09228092A1779|122 139|alternative 5' exons
P09228202A0581|3 45|selective 5-HT3 receptor antagonists ramosetron
P09228202A0581|12 24|5-HT3 receptor
P09228202A0581|47 51|YM060
P09228202A0581|54 58|YM114
P09228202A0581|60 66|KAE-393
P09228202A0581|83 93|ondansetron
P09228202A0581|101 121|substituted benzamides
P09228202A0581|123 186|5-HT4 receptor agonist/5-HT3 receptor antagonists) cisapride mosapride
P09228202A0581|123 135|5-HT4 receptor
P09228202A0581|144 156|5-HT3 receptor
P09228202A0581|190 197|SC-53116
P09228202A0581|222 236|gastric emptying
P09228202A0581|239 248|normal rats
P09229420A0158|18 31|biopsy specimen
P09229420A0158|39 46|right hip
P09229420A0158|95 108|chondrosarcoma
P09229420A0158|133 154|synovial chondromatosis
P09229595A0618|3 16|corneal buttons
P09229595A0618|33 47|histopathologic
P09229595A0618|51 76|electron microscopic studies
P09230129A0039|19 29|homogeneity
P09230129A0039|45 66|affinity chromatography
P09230129A0039|76 88|DNA-cellulose
P09230129A0039|133 140|SDS/PAGE
P09230129A0039|148 160|contamination
P09230129A0039|168 176|nucleases
P09230129A0039|193 212|monospecific antibody
P09230129A0039|223 228|enzyme
P09230216T0000|0 26|Human thymine-DNA glycosylase
P09230216T0000|0 26|Human thymine-DNA glycosylase
P09230216T0000|33 53|chromosome 12q22-q24.1
P09230216T0000|74 87|heterozygosity
P09230216T0000|90 102|gastric cancer
P09230307A0329|0 2|FOG
P09230307A0329|0 2|FOG
P09230307A0329|20 25|GATA-1
P09230307A0329|20 25|GATA-1
P09230307A0329|32 51|embryonic development
P09230307A0329|57 87|erythroid and megakaryocytic cells
P09230384A0725|28 39|mycobacteria
P09230384A0725|44 55|BACTEC 9000 MB
P09230384A0725|68 69|TB
P09230384A1056|9 26|BACTEC 9000 MB system
P09230384A1056|43 62|respiratory specimens
P09230384A1056|122 133|mycobacteria
P09230384A1056|138 154|clinical specimens
P09230894A0422|18 24|KmMig1p
P09230894A0422|18 24|KmMig1p
P09230894A0422|57 68|S. cerevisiae
P09230945A0089|1 24|pre-boutonniere deformity
P09230945A0089|28 36|simulated
P09230945A0089|50 60|central slip
P09230986A0000|0 24|Autoimmune neutropenia (AIN
P09230986A0000|44 61|chronic neutropenia
P09230986A0000|74 89|youngest children
P09232593A0946|48 56|DJ protein
P09232593A0946|48 56|DJ protein
P09233487A1386|0 13|Future analysis
P09233487A1386|119 127|Prom-EABR
P09233772A0136|4 10|protein
P09233772A0136|22 25|p532
P09233772A0136|22 25|p532
P09233772A0136|45 59|molecular weight
P09233772A0136|96 112|structural domains
P09233772A0136|139 153|internal repeats
P09233772A0136|172 189|cell cycle regulator
P09233772A0136|190 193|RCC1
P09233772A0136|190 193|RCC1
P09233772A0136|196 226|guanine nucleotide exchange factor
P09233772A0136|196 226|guanine nucleotide exchange factor
P09233772A0136|233 258|small GTP-binding protein Ran
P09233772A0136|233 255|small GTP-binding protein
P09233772A0136|256 258|Ran
P09233772A0136|265 275|beta-repeat
P09233772A0136|265 275|beta-repeat
P09233772A0136|302 312|beta subunit
P09233772A0136|302 312|beta subunit
P09233772A0136|315 337|heterotrimeric G proteins
P09233772A0136|315 337|heterotrimeric G proteins
P09233772A0136|352 366|SH3 binding sites
P09233772A0136|352 366|SH3 binding sites
P09233772A0136|377 390|leucine-zipper
P09233772A0136|395 420|carboxy-terminal HECT domain
P09233772A0136|437 462|E3 ubiquitin-protein ligases
P09233772A0136|437 438|E3
P09233772A0136|439 462|ubiquitin-protein ligases
P09233801A1180|8 18|L45 sequence
P09233801A1180|47 47|V
P09233801A1180|57 64|TGF-beta
P09233801A1180|57 64|TGF-beta
P09233801A1180|84 96|type I receptor
P09233801A1180|84 96|type I receptor
P09233809A0381|6 15|mouse lines
P09233809A0381|27 48|unfragmented Hnf3g-lacZ
P09233809A0381|39 43|Hnf3g
P09233809A0381|45 48|lacZ
P09233809A0381|49 51|YAC
P09233809A0381|58 126|tissue-specific, copy number-dependent and position-independent expression
P09233809A0381|149 158|Hnf3g locus
P09233809A0381|149 153|Hnf3g
P09233809A0381|169 176|elements
P09233809A0381|203 207|Hnf3g
P09233809A0381|203 207|Hnf3g
P09233809A0815|7 31|plasmid-derived transgenes
P09233809A0815|35 47|gene targeting
P09233809A0815|53 76|endogenous Hnf3g gene locus
P09233809A0815|53 76|endogenous Hnf3g gene locus
P09233809A0815|105 121|3'-flanking region
P09233809A0815|163 184|reporter gene expression
P09233809A0815|187 191|liver
P09233809A0815|193 200|pancreas
P09233809A0815|202 208|stomach
P09233809A0815|212 225|small intestine
P09233811A0072|4 13|regulation
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|44 77|ubiquitous Ste11 transcription factor
P09233811A0072|54 77|Ste11 transcription factor
P09233811A0072|101 114|protein Mat1-Mc
P09233811A0072|108 114|Mat1-Mc
P09234677A0770|115 125|respiration
P09234690A0242|0 26|Upstream activating sequences
P09234690A0242|28 31|UASs
P09234690A0242|49 69|Ste12p-dependent genes
P09234690A0242|49 54|Ste12p
P09234690A0242|124 127|PREs
P09234690A0242|137 139|PRE
P09234690A0242|150 160|binding site
P09234696A0238|9 29|protein kinase cascades
P09234696A0238|50 85|mitogen-activated protein (MAP) kinases
P09234696A0238|50 73|mitogen-activated protein
P09234696A0238|75 85|MAP) kinases
P09234703A0192|0 2|JNK
P09234703A0192|0 2|JNK
P09234703A0192|31 50|Ras-related G proteins
P09234703A0192|31 50|Ras-related G proteins
P09234703A0192|51 61|Rac and Cdc42
P09234703A0192|51 53|Rac
P09234703A0192|57 61|Cdc42
P09234713A0754|37 56|ligation-mediated PCR
P09234713A0754|79 110|recombination-activating gene (RAG
P09234713A0754|79 106|recombination-activating gene
P09234713A0754|108 110|RAG
P09234713A0754|122 140|double-strand breaks
P09234713A0754|142 145|DSBs
P09234713A0754|157 163|Ddelta3
P09234713A0754|157 163|Ddelta3
P09234713A0754|171 177|Jdelta1
P09234713A0754|171 177|Jdelta1
P09234717A0000|33 35|Cbl
P09234717A0000|33 35|Cbl
P09234717A0000|40 60|120-kDa protein product
P09234717A0000|66 84|c-cbl proto-oncogene
P09234717A0000|66 84|c-cbl proto-oncogene
P09234717A0000|115 145|receptor-coupled tyrosine kinases
P09234717A0000|115 145|receptor-coupled tyrosine kinases
P09234717A0000|167 169|SH3
P09234717A0000|167 169|SH3
P09234717A0000|173 200|SH2 domain-containing proteins
P09234717A0000|173 200|SH2 domain-containing proteins
P09234717A0000|221 238|signal transduction
P09234720A1015|38 40|MEK
P09234720A1015|38 40|MEK
P09234720A1015|42 48|MEK-2E)
P09234720A1015|42 47|MEK-2E
P09234720A1015|52 56|v-Src
P09234720A1015|52 56|v-Src
P09234720A1015|100 109|H19-7 cells
P09234720A1015|100 102|H19
P09234720A1015|148 150|MEK
P09234720A1015|148 150|MEK
P09234720A1015|154 158|v-Src
P09234720A1015|154 158|v-Src
P09234720A1015|166 181|neurite outgrowth
P09234723A0846|59 61|PTB
P09234723A0846|59 61|PTB
P09234723A0846|73 79|protein
P09234725A1892|17 47|ligand-dependent transactivation
P09234725A1892|111 122|AP-1 activity
P09234725A1892|111 114|AP-1
P09234727A0770|0 20|Gal4-Eed fusion protein
P09234727A0770|0 20|Gal4-Eed fusion protein
P09234727A0770|46 57|reporter gene
P09234727A0770|67 74|promoter
P09234727A0770|87 109|Gal4-binding DNA elements
P09234727A0770|87 109|Gal4-binding DNA elements
P09234736A0999|2 26|situ hybridization analysis
P09234736A0999|29 42|adult rat tissue
P09234736A0999|96 102|drm mRNA
P09234736A0999|96 102|drm mRNA
P09234736A0999|126 136|nondividing
P09234736A0999|140 168|terminally differentiated cells
P09234736A0999|189 197|lung cells
P09234736A0999|202 212|goblet cells
P09234743A0475|55 71|alpha-globin 3'UTR
P09234743A0475|55 67|alpha-globin 3
P09234743A0475|114 120|poly(C)
P09234743A0475|119 135|C) binding proteins
P09234743A0475|141 153|alpha-complex
P09234743A0475|141 153|alpha-complex
P09235073A0000|20 32|female patient
P09235073A0000|52 65|Weaver syndrome
P09235424A1200|0 17|Confirming measures
P09235424A1200|24 29|nurses
P09235424A1200|53 57|women
P09235618A0000|11 18|patients
P09235618A0000|23 36|neuroinfection
P09235618A0000|38 48|Lyme disease
P09235618A0000|97 107|generalized
P09235618A0000|164 172|IgG and IgM
P09235618A0000|164 166|IgG
P09235618A0000|170 172|IgM
P09235618A0000|194 213|anticoagulant factors
P09235618A0000|236 252|sedimentation rate
P09235618A0000|255 266|erythrocytes
P09235995A0339|0 5|(1996a
P09235998A0788|30 49|alpha and beta subunits
P09235998A0788|30 49|alpha and beta subunits
P09235998A0788|63 73|cholesterol
P09235998A0788|77 94|17-ketocholesterol
P09235998A0788|114 129|HMG-CoA reductase
P09235998A0788|114 129|HMG-CoA reductase
P09236118A1455|21 23|Lrp
P09236118A1455|21 23|Lrp
P09236118A1455|37 51|palindromic site
P09236118A1455|84 94|major groove
P09236118A1455|139 151|flanking sites
P09236118A1455|159 171|nucleoprotein
P09236224A0939|21 33|p21 expression
P09236224A0939|21 23|p21
P09236224A0939|85 87|NGF
P09236224A0939|85 87|NGF
P09236224A0939|105 120|PC12 growth arrest
P09236441A0639|31 40|recordings
P09236441A0639|43 45|ECG
P09236441A0639|84 87|SaO2
P09236441A0639|93 103|respiration
P09236441A0639|114 146|spontaneous and controlled breathing
P09236656A0124|12 25|white cell count
P09236656A0124|86 88|4.6
P09237695A0000|1 11|prospective
P09237695A0000|69 93|acute dengue virus infection
P09237862A0782|5 20|experimental eyes
P09237862A0782|73 88|adrenergic nerves
P09237862A0782|94 97|iris
P09238467A0763|5 11|lesions
P09238467A0763|26 36|propranolol
P09238467A0763|39 50|phentolamine
P09238850A0785|12 15|ICER
P09238850A0785|12 15|ICER
P09238850A0785|42 60|alternative promoter
P09238850A2042|37 51|endogenous clock
P09238850A2042|65 79|suprachiasmatic
P09238850A2042|80 86|nucleus
P09238850A2042|88 90|SCN
P09238860A0175|16 22|nucleus
P09238860A0175|86 124|cyclic AMP response element binding proteins
P09238860A0175|86 124|cyclic AMP response element binding proteins
P09238860A0175|125 128|CREB
P09238860A0175|125 128|CREB
P09238860A0175|132 138|CREM tau
P09238860A0175|132 135|CREM
P09238860A0175|159 172|protein kinase A
P09238860A0175|159 172|protein kinase A
P09238860A1974|49 52|CREB
P09238860A1974|49 52|CREB
P09238860A1974|85 92|cytokine
P09238860A1974|93 105|Interleukin-2
P09238860A1974|93 105|Interleukin-2
P09238860A1974|107 110|IL-2
P09238860A1974|107 110|IL-2
P09238860A1974|148 164|intracellular Ca2+
P09238860A1974|179 192|protein kinase C
P09238860A1974|179 192|protein kinase C
P09239635A0477|26 28|IgG
P09239635A0477|26 28|IgG
P09239635A0477|80 87|serum IgA
P09239635A0477|85 87|IgA
P09241092A1108|57 86|carbamazepine-10,11-trans-diol
P09241092A1108|126 152|carbamazepine-10,11-epoxide
P09241092A1108|159 178|trans-diol derivative
P09241232A0653|3 6|Ogg1
P09241232A0653|33 41|DNA duplex
P09241232A0653|57 62|AP site
P09241232A0653|57 62|AP site
P09241232A0653|80 87|cytosine
P09241232A0653|89 92|AP/C
P09241232A0653|89 92|AP/C
P09241232A1154|43 55|lysine residue
P09241232A1154|63 77|endonuclease III
P09241232A1154|63 77|endonuclease III
P09241232A1154|80 83|K241
P09241232A1154|86 89|Ogg1
P09241232A1154|86 89|Ogg1
P09242375A1313|36 44|mutations
P09242375A1313|45 49|E768D
P09242375A1313|53 57|V804L
P09242375A1313|61 85|gain-of-function mutations
P09242375A1313|164 172|mutations
P09242375A1313|203 215|MEN2A and MEN2B
P09242375A1313|203 207|MEN2A
P09242375A1313|211 215|MEN2B
P09242375A1313|216 224|mutations
P09242499A0505|0 9|Volunteers
P09242499A0505|85 94|sunscreens
P09242506A1033|0 2|E2F
P09242506A1033|0 2|E2F
P09242506A1033|6 25|heterodimeric complex
P09242506A1033|38 53|E2F family members
P09242506A1033|38 53|E2F family members
P09242506A1033|55 58|1-5)
P09242506A1033|62 71|DP proteins
P09242506A1033|62 71|DP proteins
P09242506A1033|73 75|1-3
P09242551A0653|0 8|EBER1 mRNA
P09242551A0653|0 8|EBER1 mRNA
P09242551A0653|29 40|viral latency
P09242551A0653|58 60|PEL
P09242551A0653|97 103|non-PEL
P09242551A0653|117 131|EBER1 expression
P09242551A0653|117 121|EBER1
P09242551A0653|155 167|lymphoma cells
P09243267A0401|24 31|patients
P09243267A0401|50 70|squamous cell carcinoma
P09243267A0401|76 85|oral cavity
P09243267A0401|99 114|primary treatment
P09243267A0401|117 139|Roswell Park Cancer Center
P09243267A0401|141 144|RPCI
P09243385A1314|15 27|presaturation
P09243385A1314|44 53|myocardial
P09243385A1314|76 77|PC
P09243505A1194|14 35|DNA-binding experiments
P09243505A1194|61 71|MADS domains
P09243505A1194|61 71|MADS domains
P09243505A1194|75 79|dimer
P09243505A1194|114 135|DNA-binding specificity
P09243505A1194|174 198|amino-terminal basic region
P09243505A1194|204 213|MADS domain
P09243505A1194|204 213|MADS domain
P09243505A1194|245 266|DNA-binding specificity
P09243587A0000|69 77|pregnancy
P09243587A0000|79 82|FFTP
P09243587A0000|99 110|breast cancer
P09243587A0000|138 146|pregnancy
P09243587A0000|153 167|induced abortion
P09243587A0000|177 192|breast cancer risk
P09243840A0663|61 68|HLA-DQA1
P09243840A0663|61 68|HLA-DQA1
P09243840A0663|89 99|autopsy room
P09244100A0194|10 13|rats
P09244282A1371|0 10|Mutagenesis
P09244282A1371|16 35|pecT regulatory region
P09244282A1371|16 35|pecT regulatory region
P09244282A1371|95 108|pec-1 phenotype
P09244282A1371|95 99|pec-1
P09244350A0000|0 4|BRCA1
P09244350A0000|0 4|BRCA1
P09244350A0000|7 36|familial breast and ovarian cancer
P09244350A0000|37 54|susceptibility gene
P09244350A0000|62 83|nuclear phosphoproteins
P09244350A0000|116 137|human breast cancer cells
P09244430A0693|14 19|splice
P09244430A0693|39 45|adducin
P09244430A0693|54 59|beta-3
P09244430A0693|54 59|beta-3
P09246343T0000|0 10|Proteinuria
P09246343T0000|19 21|man
P09246585T0000|0 13|Neural blockade
P09246585T0000|16 35|chronic and cancer pain
P09247645A0000|3 33|new temperature-sensitive alleles
P09247645A0000|36 39|SEC3
P09247645A0000|36 39|SEC3
P09247645A0000|46 64|late-acting SEC genes
P09247645A0000|57 64|SEC genes
P09247645A0000|95 104|post-Golgi
P09247645A0000|105 121|secretory vesicles
P09247645A0000|127 140|plasma membrane
P09247645A0000|143 165|Saccharomyces cerevisiae
P09247645A0000|258 263|sec4-8
P09247645A0000|258 263|sec4-8
P09248639A0152|17 38|human dermal fibroblasts
P09248639A0152|72 87|burn blister fluid
P09248639A0152|165 180|collagen lattices
P09248639A0152|165 172|collagen
P09248639A0152|182 185|FPCL
P09249039A0124|16 25|key enzymes
P09249039A0124|39 70|triiodothyronine-mediated control
P09249039A0124|80 94|differentiation
P09249039A0124|98 112|basal metabolism
P09249039A0124|115 125|vertebrates
P09249710A0331|10 27|ELISA-positive sera
P09249710A0331|60 74|plaque reduction
P09250554A0402|0 7|Patients
P09250554A0402|80 97|antianginal therapy
P09251843A0189|0 26|Reactive lymphoid hyperplasia
P09251843A0189|69 87|lymphoid hyperplasia
P09251843A0189|90 107|Castleman's disease
P09251843A0189|109 135|atypical lymphoid hyperplasia
P09251843A0189|148 164|malignant lymphoma
P09251843A0189|188 204|malignant lymphoma
P09252397A0081|47 62|pyrimidine dimers
P09252397A0081|65 74|nucleotide
P09252397A0081|93 104|human JUN gene
P09252397A0081|93 100|human JUN
P09252397A0081|107 123|normal fibroblasts
P09252397A0081|169 195|transcription initiation site
P09252397A0081|217 224|promoter
P09252406A0511|18 42|multisubstrate binding site
P09252406A0511|49 52|Grb2
P09252406A0511|49 52|Grb2
P09252406A0511|56 73|Shc adaptor proteins
P09252406A0511|56 73|Shc adaptor proteins
P09252406A0511|78 87|p85 subunit
P09252406A0511|78 87|p85 subunit
P09252406A0511|90 118|phosphatidylinositol 3'-kinase
P09252406A0511|90 118|phosphatidylinositol 3'-kinase
P09252406A0511|120 138|phospholipase Cgamma
P09252406A0511|143 154|a phosphatase
P09252406A0511|144 154|phosphatase
P09252406A0511|156 159|SHP2
P09252406A0511|156 159|SHP2
P09252879A0470|35 50|clinical features
P09252879A0470|52 69|pulmonary functions
P09252879A0470|90 94|PC20M
P09254678A0106|0 6|Gtx mRNA
P09254678A0106|35 38|RNAs
P09254678A0106|50 72|major structural proteins
P09254678A0106|75 104|myelin, myelin basic protein (MBP)
P09254678A0106|82 99|myelin basic protein
P09254678A0106|101 103|MBP
P09254678A0106|109 126|proteolipid protein
P09254678A0106|109 126|proteolipid protein
P09254678A0106|128 130|PLP
P09254678A0106|128 130|PLP
P09254678A0106|138 162|postnatal brain development
P09254678A0106|164 179|Gtx mRNA decreases
P09254678A0106|164 170|Gtx mRNA
P09254678A0106|194 196|MBP
P09254678A0106|194 196|MBP
P09254678A0106|200 207|PLP mRNAs
P09254678A0106|200 207|PLP mRNAs
P09254678A0106|213 218|brains
P09254678A0106|221 240|myelin-deficient rats
P09254678A0106|270 276|PLP gene
P09254678A0106|270 276|PLP gene
P09254709T0000|0 7|Contacts
P09254709T0000|15 57|Bacillus subtilis catabolite regulatory protein
P09254709T0000|58 61|CcpA
P09254709T0000|58 61|CcpA
P09254709T0000|65 78|amyO target site
P09254709T0000|65 68|amyO
P09255349A0836|20 43|GTPase activating proteins
P09255349A0836|20 43|GTPase activating proteins
P09255349A0836|53 56|IRA1
P09255349A0836|53 56|IRA1
P09255349A0836|60 63|IRA2
P09255349A0836|60 63|IRA2
P09256973A0455|3 4|E2
P09256973A0455|10 12|cat
P09256973A0455|27 27|5
P09256973A0455|29 33|group
P09256973A0455|35 37|G] 1
P09256973A0455|67 74|capsules
P09256973A0673|11 12|E1
P09256973A0673|14 48|itraconazole plasma drug concentration
P09256973A0673|126 128|MRT
P09256973A0673|126 128|MRT
P09257651T0000|3 17|human U4/U6 snRNP
P09257651T0000|8 9|U4
P09257651T0000|11 17|U6 snRNP
P09257651T0000|31 34|90kD
P09257651T0000|97 101|Prp4p
P09257651T0000|97 101|Prp4p
P09257651T0000|105 109|Prp3p
P09257651T0000|105 109|Prp3p
P09257887A0457|0 4|G-CSF
P09257887A0457|0 4|G-CSF
P09257887A0457|103 117|neutrophil count
P09258439A1001|56 61|SsEF-2
P09258439A1001|56 61|SsEF-2
P09258606A0822|0 8|Crosstalk
P09258606A0822|49 54|stress
P09259052A0568|0 15|Supershift assays
P09259052A0568|22 61|Jun and Fos family member-specific antibodies
P09259052A0568|22 24|Jun
P09259052A0568|28 61|Fos family member-specific antibodies
P09259052A0568|97 102|AtT-20
P09259052A0568|103 121|cell nuclear extracts
P09259052A0568|132 144|c-jun AP-1 site
P09259052A0568|132 144|c-jun AP-1 site
P09259052A0568|160 175|Jun family members
P09259052A0568|160 175|Jun family members
P09259052A0568|177 180|JunD
P09259052A0568|177 180|JunD
P09259052A0568|182 185|JunB
P09259052A0568|182 185|JunB
P09259052A0568|190 193|cJun
P09259052A0568|190 193|cJun
P09259313A0950|13 28|PI kinase activity
P09259313A0950|13 20|PI kinase
P09259313A0950|41 43|cbl
P09259313A0950|60 73|PRL stimulation
P09259313A0950|60 62|PRL
P09259315A0809|10 13|Enh4
P09259315A0809|10 13|Enh4
P09259315A0809|26 44|GT-IIC-like enhanson
P09259315A0809|26 44|GT-IIC-like enhanson
P09259315A0809|62 75|intact enhancer
P09259315A0809|86 101|silencer activity
P09259315A0809|106 117|multimerized
P09259315A0809|118 132|GT-IIC enhansons
P09259315A0809|118 123|GT-IIC
P09259315A0809|147 167|CSEn enhancer/silencer
P09259315A0809|147 167|CSEn enhancer/silencer
P09259315A0809|180 183|BeWo
P09259315A0809|187 193|GC cells
P09259320A0830|5 33|lectin-affinity chromatography
P09259320A0830|65 79|O-glycosylation
P09259320A0830|82 85|SSBP
P09259320A0830|82 85|SSBP
P09259320A0830|89 92|DSBP
P09259320A0830|89 92|DSBP
P09259328A0440|0 25|Deletion mapping experiments
P09259328A0440|77 86|MSC-1 cells
P09259328A0440|105 109|619 bp
P09259328A0440|115 123|start site
P09259328A0440|176 193|luciferase activity
P09259328A0440|176 185|luciferase
P09259328A0440|198 248|-583 bp to -564 bp, -503 bp to -484 bp, and -114 bp to -65 regions
P09261155A0833|15 29|PH and PTB domains
P09261155A0833|15 16|PH
P09261155A0833|20 22|PTB
P09261155A0833|84 109|insulin receptor substrates 1
P09261155A0833|84 98|insulin receptor
P09261155A0833|111 116|2, and 3
P09261155A0833|118 122|IRS-1
P09261155A0833|118 122|IRS-1
P09261155A0833|124 128|IRS-2
P09261155A0833|124 128|IRS-2
P09261155A0833|133 137|IRS-3
P09261155A0833|133 137|IRS-3
P09261178T0000|3 43|mouse extracellular signal-regulated kinase 2
P09261178T0000|8 47|extracellular signal-regulated kinase 2 gene
P09261184A0170|16 39|gel mobility shift analysis
P09261184A0170|43 63|supershift experiments
P09261184A0170|65 69|FIRE1
P09261184A0170|65 69|FIRE1
P09261184A0170|85 95|-516 and -498
P09261184A0170|120 123|NF-Y
P09261184A0170|120 123|NF-Y
P09261200T0001|0 8|MR imaging
P09261200T0001|11 31|traumatic head injuries
P09261200T0001|37 50|FLAIR technique
P09261397A0509|0 2|Gag
P09261397A0509|0 2|Gag
P09261397A0509|29 36|NC domain
P09261397A0509|29 36|NC domain
P09261397A0509|39 57|primate foamy viruses
P09261397A0509|115 118|FeFV
P09263010T0000|11 24|B cell apoptosis
P09263010T0000|43 46|CD23
P09263010T0000|43 46|CD23
P09263010T0000|50 52|sIg
P09263010T0000|50 52|sIg
P09263010T0000|61 78|aberrant regulation
P09263010T0000|81 85|c-myc
P09263010T0000|81 85|c-myc
P09263010T0000|102 106|bcl-2
P09263010T0000|102 106|bcl-2
P09263094A0799|27 39|Lung elastance
P09263094A0799|41 42|EL
P09263094A0799|58 59|RL
P09263094A0799|93 106|airway pressure
P09263094A0799|108 125|esophageal pressure
P09263094A0799|130 139|airway flow
P09263094A0799|146 171|anesthetized, paralyzed dogs
P09263094A0799|178 194|sinusoidal forcing
P09263094A0799|210 223|airway pressure
P09263094A0799|247 266|breathing frequencies
P09263094A0799|273 277|1.0 Hz
P09263094A0799|298 309|tidal volumes
P09263856A0563|36 46|Gla and EGF-1
P09263856A0563|36 38|Gla
P09263856A0563|42 44|EGF
P09263856A0563|56 62|human PS
P09263856A0563|79 99|prothrombin and factor X
P09263856A0563|79 89|prothrombin
P09264466A0947|3 13|Cut9 subunit
P09264466A0947|3 13|Cut9 subunit
P09264466A0947|46 66|APC/ cyclosome function
P09264466A0947|46 58|APC/ cyclosome
P09264466A0947|74 100|protein-protein interactions
P09264466A0947|74 88|protein-protein
P09264466A0947|104 118|phosphorylation
P09265534A0455|3 6|dose
P09265534A0455|10 13|50 Gy
P09265642A0668|10 28|biosynthetic pathway
P09265642A0668|75 89|internalization
P09265642A0668|120 125|FM 4-64
P09265642A0668|141 150|sop mutants
P09265642A0668|141 150|sop mutants
P09265932A0575|6 10|women
P09265932A0575|70 83|L2-3 interspace
P09265932A0575|70 71|L2
P09267306A0381|0 2|Far
P09267306A0381|48 51|apo B
P09267306A0381|48 51|apo B
P09267431A0000|3 19|soybean cDNA clones
P09267431A0000|21 25|SPK-3
P09267431A0000|21 25|SPK-3
P09267431A0000|29 33|SPK-4
P09267431A0000|29 33|SPK-4
P09267431A0000|43 64|putative protein kinases
P09267431A0000|51 64|protein kinases
P09267439A0000|19 32|ras superfamily
P09267439A0000|39 81|low-molecular-weight GTP/GDP-binding proteins
P09267439A0000|63 81|GDP-binding proteins
P09267542A0126|0 9|Naltrexone
P09267542A0126|38 41|Food
P09267542A0126|80 96|alcohol dependence
P09268298T0000|0 44|Ent-kaurene synthase from the fungus Phaeosphaeria
P09268298T0000|0 18|Ent-kaurene synthase
P09268298T0000|32 46|Phaeosphaeria sp
P09268387A0293|52 54|ELL
P09268387A0293|100 114|RNA polymerase II
P09268387A0293|100 114|RNA polymerase II
P09268387A0293|128 144|elongation complex
P09268578A0225|12 24|cDNA sequences
P09268578A0225|77 81|death
P09268578A0225|83 90|mud)-1-8
P09268578A0225|83 90|mud)-1-8
P09268631A0316|3 10|position
P09268631A0316|84 88|Igf2r
P09268631A0316|84 88|Igf2r
P09268638A0332|62 67|D8S260
P09268638A0332|62 67|D8S260
P09268638A0332|76 81|D8S285
P09268638A0332|76 81|D8S285
P09268652A0116|16 32|zinc finger protein
P09268652A0116|16 32|zinc finger protein
P09268652A0116|34 42|dsRBP-ZFa
P09268652A0116|34 42|dsRBP-ZFa
P09268652A0116|86 90|dsRNA
P09268661A1405|25 56|retroplasmid reverse transcriptase
P09268661A1405|37 56|reverse transcriptase
P09268661A1405|84 96|cDNA synthesis
P09268661A1405|113 123|CCA sequence
P09269879A0266|0 4|Nasal
P09269900A1035|32 42|EGF/Ras/Raf
P09269900A1035|32 34|EGF
P09269900A1035|36 38|Ras
P09269900A1035|40 42|Raf
P09269900A1035|86 95|ATF3/c-Jun
P09269900A1035|86 89|ATF3
P09269900A1035|91 95|c-Jun
P09269900A1035|100 118|52-kDa nuclear factor
P09269900A1035|100 118|52-kDa nuclear factor
P09269900A1035|127 130|JunD
P09269900A1035|127 130|JunD
P09271393A1333|38 40|Tax
P09271393A1333|38 40|Tax
P09271393A1333|48 50|CBP
P09271393A1333|48 50|CBP
P09271393A1333|56 69|HTLV-1 promoter
P09271393A1333|56 69|HTLV-1 promoter
P09271393A1333|81 105|transcriptional activation
P09271393A1333|122 145|CBP-associated activities
P09271393A1333|122 124|CBP
P09271393A1333|148 167|nucleosome remodeling
P09271393A1333|187 215|general transcription machinery
P09271394A0558|0 5|DNase I
P09271394A0558|0 5|DNase I
P09271394A0558|9 34|1,10-phenanthroline-copper
P09271394A0558|49 68|MURA-Mu1 TIR complexes
P09271394A0558|49 52|MURA
P09271394A0558|54 56|Mu1
P09271394A0558|57 59|TIR
P09271394A0558|81 84|MURA
P09271394A0558|81 84|MURA
P09271394A0558|115 125|32-bp region
P09271394A0558|131 133|TIR
P09271394A0558|131 133|TIR
P09271394A0558|136 138|Mu1
P09271394A0558|136 138|Mu1
P09271397A1596|81 96|LDL receptor SREBP
P09271397A1596|81 91|LDL receptor
P09271397A1596|92 100|SREBP site
P09271397A1596|116 122|Sp1 site
P09271397A1596|116 122|Sp1 site
P09271397A1596|155 183|buttonhead-independent fashion
P09271397A1596|155 164|buttonhead
P09271400A0475|24 39|promoter activity
P09271400A0475|86 99|E2F2 expression
P09271400A0475|86 89|E2F2
P09271400A0475|107 123|growth stimulation
P09271417A0585|5 14|adult mouse
P09271417A0585|16 23|ERR alpha
P09271417A0585|16 23|ERR alpha
P09271417A0585|47 52|kidney
P09271417A0585|54 58|heart
P09271417A0585|68 77|adipocytes
P09271417A0585|115 124|fatty acids
P09271417A1011|3 37|MCAD nuclear receptor response element 1
P09271417A1011|3 37|MCAD nuclear receptor response element 1
P09271417A1011|39 44|NRRE-1
P09271417A1011|39 44|NRRE-1
P09271417A1011|66 73|ERR alpha
P09271417A1011|66 73|ERR alpha
P09271417A1011|85 94|COS-7 cells
P09271496T0000|17 30|HIV-1 integrase
P09271496T0000|17 21|HIV-1
P09271496T0000|64 75|DNA molecules
P09271496T0000|105 123|photo-cross-linking
P09272108A1295a|13 28|5' flanking region
P09272108A1295a|71 74|TATA
P09272108A1295a|78 90|CAAT sequences
P09272108A1295b|13 28|5' flanking region
P09272108A1295b|71 74|TATA
P09272108A1295b|78 90|CAAT sequences
P09272138A1153|3 18|complete response
P09272138A1153|20 21|CR
P09272138A1153|20 21|CR
P09272138A1153|38 41|CODE
P09272138A1153|46 52|rhG-CSF
P09272138A1153|46 52|rhG-CSF
P09272138A1153|69 72|CODE
P09275159T0000|0 38|Heterogeneous nuclear ribonucleoprotein A1
P09275159T0000|0 12|Heterogeneous
P09275159T0000|13 38|nuclear ribonucleoprotein A1
P09275159T0000|49 78|transcription-regulatory region
P09275159T0000|81 99|mouse hepatitis virus
P09275164A0000|3 21|m7GpppN cap structure
P09275164A0000|24 37|eukaryotic mRNA
P09275164A0000|24 37|eukaryotic mRNA
P09275164A0000|93 99|enzymes
P09275164A0000|101 117|RNA triphosphatase
P09275164A0000|101 117|RNA triphosphatase
P09275164A0000|119 140|RNA guanylyltransferase
P09275164A0000|119 140|RNA guanylyltransferase
P09275164A0000|145 176|RNA (guanine-7)-methyltransferase
P09275164A0000|145 147|RNA
P09275164A0000|149 176|guanine-7)-methyltransferase
P09275990A0938|35 46|mutagenicity
P09275990A0938|60 69|TA98 strain
P09275990A0938|77 95|enzymatic activation
P09275990A0938|145 150|diesel
P09276882A0479|25 26|CC
P09276882A0479|25 26|CC
P09276882A0479|30 31|CC
P09276882A0479|30 31|CC
P09276882A0479|33 34|SW
P09276882A0479|102 106|Day 21
P09276882A0479|171 182|carbohydrate
P09277472A1070|22 26|edema
P09277472A1070|60 79|diastolic dysfunction
P09277472A1070|85 92|DC shocks
P09277629A0268|0 13|Two experiments
P09277629A0268|58 60|ERP
P09277629A0268|76 97|visuospatial memory task
P09277629A0268|113 129|spatial memory task
P09278441A1160|21 38|CARP mRNA expression
P09278441A1160|21 28|CARP mRNA
P09278441A1160|49 67|transient expression
P09278441A1160|113 118|Nkx2.5
P09278441A1160|113 116|Nkx2
P09278441A1160|118 122|5/Csx
P09278441A1160|120 122|Csx
P09278441A1160|125 139|putative homolog
P09278441A1160|142 147|tinman
P09278441A1160|152 177|Drosophila melanogaster gene
P09278441A1160|152 177|Drosophila melanogaster gene
P09278441A1160|192 209|cardiac development
P09278441A1777|16 19|CARP
P09278441A1777|16 19|CARP
P09278441A1777|22 35|cardiomyocytes
P09278441A1777|46 100|cardiac troponin C and atrial natriuretic factor transcription
P09278441A1777|53 61|troponin C
P09278441A1777|65 87|atrial natriuretic factor
P09278445T0000|0 19|Substrate specificity
P09278445T0000|25 37|RNase activity
P09278445T0000|25 29|RNase
P09278445T0000|40 60|yeast RNA polymerase III
P09278445T0000|40 60|yeast RNA polymerase III
P09278450A1338|0 33|Electrophoretic mobility shift assays
P09278450A1338|37 58|competition experiments
P09278450A1338|90 99|NF1 protein
P09278450A1338|90 99|NF1 protein
P09278454A1261|16 31|MMP-2 RE1 sequence
P09278454A1261|16 20|MMP-2
P09278454A1261|21 31|RE1 sequence
P09278454A1261|52 64|Y-box sequence
P09278454A1261|66 77|CTGCTGGGCAAG
P09278454A1261|111 125|recombinant YB-1
P09278454A1261|122 125|YB-1
P09278454A1261|128 160|DMS protection footprinting analysis
P09278475A0465|6 10|scs32
P09278475A0465|6 10|scs32
P09278475A0465|37 47|ts phenotype
P09278475A0465|73 85|Ino-phenotype
P09278475A0465|88 95|rpo26-31
P09278475A0465|88 95|rpo26-31
P09278494A0762|15 17|Sp1
P09278494A0762|15 17|Sp1
P09278494A0762|21 31|ETS proteins
P09278494A0762|21 31|ETS proteins
P09278494A0762|59 74|promoter activity
P09278494A0762|80 94|Surf-1 direction
P09278494A0762|80 85|Surf-1
P09278758A1636|40 50|neck disease
P09278758A1636|52 55|N1-3
P09278758A1636|52 55|N1-3
P09278758A1636|90 101|nodal disease
P09278758A1636|103 121|extracapsular spread
P09278758A1636|137 154|positive lymph nodes
P09278758A1636|192 203|distant sites
P09279379A0310|19 48|pBR322 deoxyribonucleic acid (DNA
P09279379A0310|93 100|5' spacer
P09279379A0310|107 133|3' spacer of the H2B histone gene
P09279379A0310|120 133|H2B histone gene
P09279889A1124|0 3|Area
P09279889A1124|54 56|MTX
P09279889A1124|84 85|PG
P09279889A1124|99 100|PG
P09280747A0195|16 39|hydralazine hydrochloride
P09280747A0195|169 181|ACE inhibitors
P09280747A0195|169 171|ACE
P09282329A0527|43 65|Site II regulatory factors
P09282329A0527|43 65|Site II regulatory factors
P09282329A0527|74 96|cell cycle control element
P09282329A0527|135 159|transcriptional regulation
P09282329A0527|165 183|G1/S phase transition
P09282329A0527|186 219|FDC-P1 hematopoietic progenitor cells
P09282911A0277|31 50|neuronal cell cultures
P09282911A0277|62 76|RC3/neurogranin
P09282911A0277|62 64|RC3
P09282911A0277|66 76|neurogranin
P09282911A0277|110 111|T3
P09282985A0961|27 31|males
P09283828A0484|5 22|circadian responses
P09285715A1257|37 39|Rev
P09285715A1257|37 39|Rev
P09285715A1257|66 81|uracil-rich small
P09285715A1257|77 92|small nuclear RNAs
P09285715A1257|82 92|nuclear RNAs
P09285715A1257|96 109|5S ribosomal RNA
P09285715A1257|96 106|5S ribosomal
P09285715A1257|107 109|RNA
P09285715A1257|114 116|CTE
P09285715A1257|185 202|cellular mRNA export
P09285789A0712|0 7|Human Duo
P09285789A0712|17 47|guanine nucleotide exchange factor
P09285789A0712|17 47|guanine nucleotide exchange factor
P09285789A0712|49 58|GEF) domain
P09285789A0712|49 51|GEF
P09285789A0712|75 78|rac1
P09285789A0712|90 117|pleckstrin homology (PH) domain
P09285789A0712|90 107|pleckstrin homology
P09285789A0712|109 117|PH) domain
P09285789A0712|121 144|spectrin-like repeat units
P09285789A0712|121 144|spectrin-like repeat units
P09286115T0000|0 2|S2F
P09286115T0000|0 2|S2F
P09286115T0000|5 35|leaf-specific trans-acting factor
P09286115T0000|18 35|trans-acting factor
P09286115T0000|50 66|cis-acting element
P09286115T0000|96 104|RPL21 gene
P09286115T0000|96 104|RPL21 gene
P09286981A0147|0 3|ArgR
P09286981A0147|0 3|ArgR
P09287036A0457|0 25|Plasma leptin concentrations
P09287036A0457|6 11|leptin
P09287036A0457|38 42|women
P09287036A0457|47 49|men
P09287036A0457|89 95|fat mass
P09287036A0457|111 115|women
P09287352A0930|23 36|STAT activation
P09287352A0930|23 26|STAT
P09287352A0930|45 49|SHP-1
P09287352A0930|45 49|SHP-1
P09287352A0930|72 92|EGF-induced activation
P09287352A0930|72 74|EGF
P09287352A0930|98 134|mitogen-activated protein kinase pathway
P09287352A0930|98 127|mitogen-activated protein kinase
P09287352A0930|148 152|SHP-1
P09287352A0930|148 152|SHP-1
P09287352A0930|155 157|Cys
P09287352A0930|161 163|Ser
P09287352A0930|184 186|MEK
P09287352A0930|184 186|MEK
P09287352A0930|225 229|SHP-1
P09287352A0930|225 229|SHP-1
P09287362A0589|26 34|SH3 region
P09287362A0589|26 34|SH3 region
P09287362A0589|37 43|p50(csk
P09287362A0589|37 39|p50
P09287362A0589|41 43|csk
P09287362A0589|49 66|proline-rich region
P09287362A0589|68 84|PPPLPERTPESFVLADM
P09287362A0589|96 110|catalytic region
P09287362A0589|113 120|PTP-PEST
P09287362A0589|113 115|PTP
P09288848A0780|15 18|HbO2
P09288916T0000|0 18|Polarised expression
P09288916T0000|21 82|human intestinal N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase
P09288916T0000|21 35|human intestinal
P09288916T0000|36 82|N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase
P09288916T0000|84 115|human meprin) alpha and beta subunits
P09288916T0000|84 94|human meprin
P09288916T0000|104 115|beta subunits
P09288916T0000|118 145|Madin-Darby canine kidney cells
P09290207A0731|39 58|silent mating type loci
P09290207A0731|39 58|silent mating type loci
P09290571A0420|7 14|patients
P09290571A0420|19 39|inducible reentrant VTs
P09290571A0420|52 74|electrophysiologic study
P09290571A0420|76 78|EPS
P09290571A0420|83 85|VTs
P09290571A0420|91 98|patients
P09290571A0799|23 24|VT
P09291077T0000|0 23|Transient hyperammonaemia
P09291077T0000|28 49|adult German shepherd dog
P09291098A0452|29 31|V-1
P09291098A0452|43 58|GGT mRNA V-2 derive
P09291098A0452|85 101|primary transcript
P09291098A0452|114 127|distal promoter
P09291098A0452|133 142|rat GGT gene
P09291098A0452|133 142|rat GGT gene
P09291098T0000|9 22|distal promoter
P09291098T0000|31 72|gamma-glutamyl transpeptidase gene expression
P09291098T0000|31 62|gamma-glutamyl transpeptidase gene
P09291098T0000|75 114|undifferentiated rat transformed liver cells
P09292499A0887|22 35|pyrimidine rich
P09292499A0887|54 86|polypyrimidine tract binding protein
P09292499A0887|54 86|polypyrimidine tract binding protein
P09292499A0887|88 90|PTB
P09292499A0887|88 90|PTB
P09292499A0887|94 112|HeLa nuclear extracts
P09292499A0887|127 158|UV crosslinking/competition assays
P09293006A1412|21 24|lipA
P09293006A1412|21 24|lipA
P09293006A1412|27 36|S. lividans
P09293006A1412|69 81|aphII promoter
P09293006A1412|69 81|aphII promoter
P09294139A0729|7 30|135-bp core homology region
P09294139A0729|35 52|human HS12 enhancers
P09294139A0729|35 52|human HS12 enhancers
P09294139A0729|86 98|murine homolog
P09294139A0729|86 98|murine homolog
P09294139A0729|173 186|murine enhancer
P09294139A0729|173 186|murine enhancer
P09294139A0729|277 292|functional motifs
P09294161A0650|15 30|wild-type protein
P09294161A0650|15 30|wild-type protein
P09294161A0650|44 51|p45 NF-E2
P09294161A0650|44 46|p45
P09294161A0650|47 51|NF-E2
P09294161A0650|83 99|NF-E2 null cell line
P09294161A0650|83 87|NF-E2
P09294161A0650|114 144|enhancer-dependent transcription
P09294161A0650|147 161|transient assays
P09294161A1103|63 85|distal regulatory regions
P09294161A1103|91 100|globin loci
P09294161A1103|91 100|globin loci
P09294161A1103|116 124|promoters
P09294262A0885|34 40|TATA box
P09294262A0885|54 70|CCAAT and CreA boxes
P09294262A0885|94 99|stress
P09294262A0885|138 146|promoters
P09294422A1223|6 21|cysteine residues
P09294422A1223|81 95|disulfide bridge
P09294422A1223|135 151|catalytic activity
P09294422A1376|3 9|por gene
P09294422A1376|3 9|por gene
P09294422A1376|63 83|Escherichia coli behind
P09294422A1376|87 145|isopropyl-beta-D-thiogalactopyranoside-inducible tac promoter
P09294422A1376|135 145|tac promoter
P09294422A1376|173 175|POR
P09294422A1376|173 175|POR
P09294452A2107|7 24|downstream operator
P09294452A2107|64 83|reporter enzyme levels
P09294453A0949|3 12|ORF3 mutant
P09294453A0949|36 43|tabtoxin
P09294453A0949|36 43|tabtoxin
P09294453A0949|59 62|ORF3
P09294453A0949|77 94|T beta L biosynthesis
P09294471A1198|7 15|Cox models
P09294471A1198|22 29|CD4 count
P09294471A1198|22 24|CD4
P09294471A1198|32 41|150/microL
P09294471A1198|75 76|I0
P09294471A1198|80 81|I1
P09294471A1198|80 81|I1
P09296251A0163|50 57|patients
P09297698A0933|26 31|5' ends
P09297698A0933|34 50|mature UbCRBP mRNAs
P09297698A0933|40 50|UbCRBP mRNAs
P09297698A0933|65 70|UbCRBP
P09297698A0933|65 70|UbCRBP
P09297698A0933|130 140|enolase gene
P09297698A0933|130 140|enolase gene
P09299696A1074|73 83|ileal villus
P09299696A1074|95 97|DPI
P09299696A1074|147 155|infection
P09299696A1074|173 201|experimental cryptosporidiosis
P09300323A1182|46 54|flow ratio
P09300323A1182|56 63|ENDO/EPI
P09300323A1182|128 134|ITF 1129
P09300323A1182|157 158|v.
P09300323A1182|181 183|NTG
P09300697A0000|0 10|Proteasomes
P09300697A0000|17 36|multisubunit protease
P09300697A0000|17 36|multisubunit protease
P09300697A0000|62 69|peptides
P09300697A0000|81 98|MHC class I molecules
P09300697A0000|81 98|MHC class I molecules
P09300698A1219|46 49|MQ9b
P09300698A1219|46 49|MQ9b
P09300698A1219|83 115|pathogen-derived synthetic peptides
P09301350A0946|3 21|sputum interleukin-8
P09301350A0946|3 21|sputum interleukin-8
P09301350A0946|72 74|142
P09301350A0946|103 104|CI
P09301350A0946|129 135|placebo
P09301350A0946|145 165|maximal expiratory flow
P09301350A0946|259 261|pp)
P09301350A0946|259 260|pp
P09301350A0946|273 274|pp
P09301350A0946|309 315|placebo
P09303437A0875|26 28|Fp1
P09303437A0875|26 28|Fp1
P09303437A0875|34 43|hCRBP1 gene
P09303437A0875|34 43|hCRBP1 gene
P09303437A0875|60 70|CAT activity
P09303437A0875|60 62|CAT
P09303437A0875|87 112|negative regulatory function
P09303437A0875|159 174|p12 basal promoter
P09303437A0875|159 174|p12 basal promoter
P09303437A0875|186 214|impressive positive stimulation
P09303437A0875|217 233|CAT gene expression
P09303437A0875|217 223|CAT gene
P09303635A0000|0 15|Gaucher's disease
P09303635A0000|64 92|beta-glucocerebrosidase enzyme
P09303635A0000|64 92|beta-glucocerebrosidase enzyme
P09304123A0079|5 17|discoloration
P09304123A0079|147 165|restorative material
P09305592A0000|5 30|22 chromosomal translocation
P09305592A0000|47 49|CML
P09305592A0000|60 75|fused bcr/abl gene
P09305592A0000|65 67|bcr
P09305592A0000|69 71|abl
P09305592A0000|103 113|p210bcr/abl
P09305592A0000|103 109|p210bcr
P09305592A0000|111 113|abl
P09305631A0770|16 20|BAG-1
P09305631A0770|16 20|BAG-1
P09305631A0770|54 79|heat shock-induced cell death
P09305755A0540|3 18|5' flanking region
P09305755A0540|51 69|TATA-binding protein
P09305755A0540|51 69|TATA-binding protein
P09305755A0540|71 73|Sp1
P09305755A0540|71 73|Sp1
P09305755A0540|75 88|nuclear factor 1
P09305755A0540|75 88|nuclear factor 1
P09305755A0540|90 92|NF1
P09305755A0540|90 92|NF1
P09305755A0540|95 122|CAAT-box binding protein (C/EBP
P09305755A0540|95 116|CAAT-box binding protein
P09305755A0540|118 122|C/EBP
P09305755A0540|125 149|hepatocyte nuclear factors 1
P09305755A0540|125 149|hepatocyte nuclear factors 1
P09305755A0540|153 153|5
P09305755A0540|153 153|5
P09305755A0540|155 158|HNF1
P09305755A0540|155 158|HNF1
P09305755A0540|160 163|HNF5
P09305755A0540|160 163|HNF5
P09305755A0540|168 189|activator proteins 1 and 2
P09305755A0540|168 185|activator proteins 1
P09305755A0540|189 189|2
P09305755A0540|191 193|AP1
P09305755A0540|191 193|AP1
P09305755A0540|195 197|AP2
P09305755A0540|195 197|AP2
P09305870A0894|30 32|p55
P09305870A0894|30 32|p55
P09305870A0894|33 41|PDZ domain
P09305870A0894|33 41|PDZ domain
P09305870A0894|73 82|PDZ domains
P09305870A0894|73 82|PDZ domains
P09305870A0894|85 88|hDlg
P09305870A0894|85 88|hDlg
P09305870A0894|90 113|human lymphocyte homologue
P09305870A0894|90 113|human lymphocyte homologue
P09305870A0894|119 133|Drosophila discs
P09305870A0894|139 153|tumor suppressor
P09305870A0894|167 183|cytoplasmic domain
P09305870A0894|186 197|glycophorin C
P09305870A0894|186 197|glycophorin C
P09305944A0621|14 27|RanGAP activity
P09305944A0621|14 19|RanGAP
P09305944A0621|61 71|rna1p mutant
P09305944A0621|61 65|rna1p
P09305944A0621|97 116|highly acidic sequence
P09305944A0621|122 137|C-terminal domain
P09305944A0621|122 137|C-terminal domain
P09305944A0621|144 156|yeast proteins
P09305944A0621|144 156|yeast proteins
P09305944A0621|185 187|Ran
P09305944A0621|185 187|Ran
P09305944A0621|197 209|GTP hydrolysis
P09307065A0553|14 23|MHC class II
P09307065A0553|14 23|MHC class II
P09307065A0553|25 45|purified soluble D10 TCR
P09307065A0553|33 45|soluble D10 TCR
P09307065A0553|53 85|Staphylococcus aureus enterotoxin C2
P09307065A0553|126 129|M(-1
P09307065A0553|128 136|-1) sec(-1
P09307065A0553|131 136|sec(-1
P09307065A0553|177 182|sec(-1
P09307065A0553|177 182|sec(-1
P09307312A0172|53 71|auditory nerve fibers
P09307312A0172|173 201|membrane vibration measurements
P09308234A0225|0 15|Mnt:Max complexes
P09308234A0225|0 2|Mnt
P09308234A0225|4 6|Max
P09308234A0225|39 61|Myc-dependent activation
P09308234A0225|39 41|Myc
P09308234A0225|73 80|promoter
P09308738A1216|5 16|United States
P09308738A1216|17 23|high-MW
P09308738A1216|24 26|HES
P09308738A1216|96 101|vivo MW
P09308738A1216|125 134|factor VIII
P09308738A1216|136 160|von Willebrand factor levels
P09308738A1216|136 154|von Willebrand factor
P09309457A0680|13 23|cholesterol
P09309457A0680|35 46|HDL, HDL2, LDL
P09309457A0680|35 37|HDL
P09309457A0680|39 42|HDL2
P09309457A0680|44 46|LDL
P09309457A0680|48 85|triglycerides, endothelin-1, lipoprotein
P09309457A0680|62 73|endothelin-1
P09309457A0680|90 98|estradiol
P09309457A0680|102 104|FSH
P09309457A0680|102 104|FSH
P09309457A0680|146 148|ERT
P09309457A0680|166 168|ERT
P09310836A1019|21 28|P element
P09310836A1019|21 28|P element
P09310836A1019|40 51|SV40 promoter
P09310836A1019|40 51|SV40 promoter
P09310836A1019|63 91|phorbol 12-myristate 13-acetate
P09311164A0245|68 76|motor unit
P09311568A0595|23 38|C1YVV NIa protease
P09311568A0595|23 27|C1YVV
P09311568A0595|28 38|NIa protease
P09311568A0595|44 47|E)/S
P09311568A0595|44 45|E)
P09311568A0595|47 47|S
P09311568A0595|49 49|A
P09311568A0595|49 49|A
P09311568A0595|51 51|G
P09311796A0218|21 45|transcriptional activation
P09311796A0218|69 73|IEP86
P09311796A0218|90 111|TATA-box binding protein
P09311796A0218|90 111|TATA-box binding protein
P09311796A0218|113 115|TBP
P09311796A0218|113 115|TBP
P09311796A0218|123 141|transcription factor
P09311796A0218|123 141|transcription factor
P09311808A0341|31 40|p4 molecule
P09311808A0341|31 40|p4 molecule
P09311810A0814|1 2|iv
P09311810A0814|21 35|cyclin D3 protein
P09311810A0814|21 35|cyclin D3 protein
P09311810A0814|38 46|Vero cells
P09311810A0814|61 80|alpha0 deletion mutant
P09311810A0814|61 80|alpha0 deletion mutant
P09311810A0814|124 137|wild-type virus
P09311810A0814|141 156|recombinant virus
P09311810A0814|174 188|alpha0 sequences
P09311810A0814|174 188|alpha0 sequences
P09311835A0147|54 62|T antigens
P09311835A0147|54 62|T antigens
P09311835A0147|77 87|SV40 mutants
P09311835A0147|77 80|SV40
P09311835A0147|129 136|residues
P09311835A0147|152 154|ATP
P09311835A0147|162 167|pocket
P09312025A0373|58 64|PKC zeta
P09312025A0373|58 64|PKC zeta
P09312025A0373|80 120|phosphatidylinositol 3-kinase p85alpha-p110
P09312025A0373|80 107|phosphatidylinositol 3-kinase
P09312025A0373|108 115|p85alpha
P09312025A0373|117 120|p110
P09312025A0373|123 132|wortmannin
P09312025A0373|134 141|LY294002
P09312025A0373|171 178|p85alpha
P09312025A0373|171 178|p85alpha
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|42 59|protein kinase C zeta
P09312025T0000|42 59|protein kinase C zeta
P09312025T0000|79 88|SV40 small t
P09312025T0000|79 88|SV40 small t
P09312025T0000|98 107|cell growth
P09312025T0000|111 129|NF-kappaB activation
P09312025T0000|111 119|NF-kappaB
P09312028A0975|17 49|RXRalphaF318A constitutive activity
P09312028A0975|17 29|RXRalphaF318A
P09312028A0975|92 97|BMS614
P09312028A0975|124 126|RXR
P09312028A0975|124 126|RXR
P09312028A0975|130 143|RAR AF-2 domains
P09312028A0975|130 132|RAR
P09312028A0975|133 136|AF-2
P09312032A0165|5 11|introns
P09312032A0165|29 39|snoRNA genes
P09312032A0165|29 39|snoRNA genes
P09312032A0165|92 97|snoRNA
P09312087A0000|29 52|Src homology-2 (SH2) domain
P09312087A0000|29 41|Src homology-2
P09312087A0000|43 90|SH2) domain-containing protein-tyrosine phosphatase
P09312087A0000|64 90|protein-tyrosine phosphatase
P09312087A0000|92 96|SHP-2
P09312087A0000|92 96|SHP-2
P09312087A0000|115 131|cytoplasmic domain
P09312087A0000|134 140|PECAM-1
P09312087A0000|134 140|PECAM-1
P09312087A0000|152 159|tyrosine
P09312087A0000|181 199|platelet aggregation
P09312087A0000|239 262|synthetic phosphopeptides
P09312087A0000|281 297|cytoplasmic domain
P09312087A0000|300 306|PECAM-1
P09312087A0000|300 306|PECAM-1
P09312087A0000|319 334|tyrosine residues
P09312087A0000|335 341|Tyr-663
P09312087A0000|344 350|Tyr-686
P09313755A0816|52 58|factors
P09314306A0571|0 14|Supplementation
P09314306A0571|29 34|pl-ALB
P09314487T0000|19 43|Mycobacterium tuberculosis
P09314487T0000|62 84|polymerase chain reaction
P09314537A1600|21 25|EBP50
P09314537A1600|21 25|EBP50
P09314537A1600|52 70|ezrin binding protein
P09314537A1600|52 70|ezrin binding protein
P09314554A0149|66 68|AUG
P09314554A0149|72 94|primary open reading frame
P09314554A0149|147 161|cryptic epitopes
P09314554A0149|166 189|alternative reading frames
P09314554A0149|199 208|influenza A
P09314554A0149|209 232|PR/8/34 nucleoprotein gene
P09314554A0149|209 212|PR/8
P09314554A0149|213 232|/34 nucleoprotein gene
P09314570A0153|25 37|GC-rich motifs
P09314570A0153|102 111|repression
P09314570A0153|114 138|transcriptional activities
P09315631A1064|0 7|Deletion
P09315631A1064|13 20|POR2 gene
P09315631A1064|13 20|POR2 gene
P09315631A1064|84 99|POR1 and POR2 genes
P09315631A1064|84 87|POR1
P09315631A1064|91 99|POR2 genes
P09315631A1064|166 187|delta por1 single mutants
P09315631A1064|166 180|delta por1 single
P09315632A1137|63 79|FGFR3 kinase domain
P09315632A1137|63 79|FGFR3 kinase domain
P09315632A1137|112 122|fibroblasts
P09315632A1137|150 154|FGFR3
P09315632A1137|150 154|FGFR3
P09315632A1137|183 196|human neoplasia
P09315633A0333|10 26|amino acid sequence
P09315633A0333|63 89|interferon regulatory factors
P09315633A0333|63 89|interferon regulatory factors
P09315633A0333|91 94|IRFs
P09315633A0333|91 94|IRFs
P09315651T0000|13 16|AP-2
P09315651T0000|13 16|AP-2
P09315651T0000|34 43|R-FABP gene
P09315651T0000|34 43|R-FABP gene
P09315651T0000|59 69|chick retina
P09315678A0278|8 12|Cbf5p
P09315678A0278|8 12|Cbf5p
P09315678A0278|60 83|rat nucleolar protein NAP57
P09315678A0278|60 83|rat nucleolar protein NAP57
P09315678A0278|114 120|Nopp140
P09315678A0278|114 120|Nopp140
P09315678A0278|155 163|nucleolar
P09316937A0133|76 80|Vitek
P09316937A0133|84 89|API 20E
P09317131A0000|0 25|Ig heavy chain class switching
P09317131A0000|0 11|Ig heavy chain
P09317131A0000|38 46|cytokines
P09317131A0000|84 90|CH genes
P09317131A0000|84 90|CH genes
P09317131A1332|30 58|NF kappa B2 nucleoprotein complex
P09317131A1332|30 58|NF kappa B2 nucleoprotein complex
P09317131A1332|75 88|DNA-bound STAT6
P09317131A1332|84 88|STAT6
P09317131A1332|98 121|IL-4-dependent activation
P09317131A1332|98 101|IL-4
P09317131A1332|127 146|human IgE germline gene
P09317131A1332|127 146|human IgE germline gene
P09317757T0000|8 12|IN THE
P09317757T0000|13 86|TERRESTRIAL CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS - ENERGETICS OF LOCOMOTION
P09321406T0000|3 26|pheromone response pathway
P09321406T0000|51 69|Ty5 retrotransposons
P09321406T0000|51 53|Ty5
P09321406T0000|83 97|silent chromatin
P09321406T0000|100 122|Saccharomyces cerevisiae
P09321657A0439|69 81|cox3 promoters
P09321657A0439|69 81|cox3 promoters
P09321657A0439|101 111|core element
P09321657A0439|101 111|core element
P09321657A0439|126 145|cox3 promoter activity
P09321657A0439|126 137|cox3 promoter
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|40 47|e.g., p53
P09321930A0567|45 47|p53
P09321930A0567|49 51|DCC
P09321930A0567|49 51|DCC
P09321930A0567|53 55|APC
P09321930A0567|53 55|APC
P09321930A0567|57 59|MCC
P09321930A0567|57 59|MCC
P09321930A0567|61 79|BRCA1, and WAF1/CIP1)
P09321930A0567|61 65|BRCA1
P09321930A0567|70 73|WAF1
P09321930A0567|75 78|CIP1
P09321930A0567|149 162|heterozygosity
P09321930A0567|164 166|LOH
P09321930A0567|175 184|expression
P09321930A0567|217 238|cellular binding protein
P09321930A0567|217 238|cellular binding protein
P09322738A0510|3 22|histidine-tagged gene
P09322738A0510|24 30|rpoCHIS
P09322738A0510|24 30|rpoCHIS
P09322738A0510|51 65|wild-type allele
P09322738A0510|51 65|wild-type allele
P09322738A0510|83 94|S. coelicolor
P09322738A0510|98 107|S. lividans
P09322872A0745|29 44|TK gene, selection
P09322872A0745|29 34|TK gene
P09322872A0745|90 102|recombination
P09323366A0000|3 20|malate synthase gene
P09323366A0000|3 20|malate synthase gene
P09323366A0000|22 25|MLS1
P09323366A0000|22 25|MLS1
P09323366A0000|32 36|yeast
P09323366A0000|37 59|Saccharomyces cerevisiae
P09323366A0000|110 121|growth medium
P09323366A0299|2 17|deletion analysis
P09323366A0299|23 39|MLS1 control region
P09323366A0299|23 26|MLS1
P09323366A0299|62 65|UAS1
P09323366A0299|69 72|UAS2
P09323612A0374|36 61|sleep electroencephalograms
P09323612A0374|63 65|EEG
P09323612A0374|92 99|children
P09323612A0374|104 125|developmental dysphasia
P09323612A0374|166 173|children
P09323612A0374|178 222|severe developmental speech and language disorders
P09324720A0317|43 48|Alzoon
P09324878A0952|0 7|Widening
P09324878A0952|13 31|abdominal aortic wall
P09324878A0952|36 56|ultrasound examination
P09324878A0952|93 128|clinically unsuspected type B dissection
P09324922T0065|0 18|Fermentation process
P09324922T0065|41 47|nitrate
P09324922T0065|57 74|lactic acid bacteria
P09324922T0065|78 87|formic acid
P09324988X0000|0 9|Substrates
P09324988X0000|20 27|p21 (ras)
P09324988X0000|20 22|p21
P09324988X0000|24 35|ras) proteins
P09324988X0000|37 49|nuclear lamins
P09324988X0000|63 77|retinal proteins
P09325022A0192|0 6|Ovaries
P09325022A0192|11 17|animals
P09325022A0192|41 48|CD-1 mice
P09325022A0192|41 44|CD-1
P09325022A0192|64 66|C3H
P09325022A0192|70 75|C57BL/
P09325022A0192|77 80|mice
P09325135A0737|3 21|Trx-CT fusion protein
P09325135A0737|3 5|Trx
P09325135A0737|7 21|CT fusion protein
P09325135A0737|59 80|soluble cellular protein
P09325135A0737|66 80|cellular protein
P09325273A1240|23 27|UBP41
P09325273A1240|23 27|UBP41
P09325273A1240|55 63|recycling
P09325273A1240|66 74|ubiquitin
P09325273A1240|66 74|ubiquitin
P09325273A1240|89 116|branched poly-ubiquitin chains
P09325273A1240|89 116|branched poly-ubiquitin chains
P09325273A1240|139 151|26 S proteasome
P09325273A1240|154 157|poly
P09325273A1240|219 227|ubiquitin
P09325273A1240|219 227|ubiquitin
P09325273A1240|238 242|poly-
P09325273A1240|243 257|ubiquitin chains
P09325273A1240|291 313|ubiquitin fusion proteins
P09325273A1240|291 299|ubiquitin
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|104 106|rat
P09325278A0458|110 122|human proteins
P09325278A0458|110 122|human proteins
P09325278A0458|135 159|metastasis-associated gene
P09325278A0458|161 164|mta1
P09325278A0458|161 164|mta1
P09325278A0458|196 224|Caenorhabditis elegans sequence
P09325278A0458|240 243|mta1
P09325278A0458|240 243|mta1
P09325284A0469|25 44|704-amino acid protein
P09325284A0469|59 77|human progelatinase B
P09325284A0469|59 77|human progelatinase B
P09325322A1293|15 27|cytosolic Ca2+
P09325322A1293|76 79|EC50
P09325322A1293|92 110|InsP3 concentrations
P09326163A0942|38 40|SMR
P09326163A0942|48 65|malignant neoplasms
P09326163A0942|75 83|CI 74 to 118
P09326246A0567|0 15|Sequence analysis
P09326246A0567|94 108|wild-type levels
P09326246A0567|111 128|luciferase activity
P09326246A0567|111 120|luciferase
P09326246A0567|134 155|-916-bp reporter plasmid
P09326263A0410|5 10|5'RACE
P09326263A0410|14 37|reverse transcription-PCR
P09326263A0410|39 58|RT-PCR) methodologies
P09326263A0410|86 90|brain
P09326263A0410|94 101|placenta
P09326263A0410|194 200|exon (1A
P09326263A0410|213 231|-bp noncoding exon (1B
P09326317A0372|69 84|EXT1 and EXT2 genes
P09326317A0372|69 72|EXT1
P09326317A0372|76 84|EXT2 genes
P09326727T0000|3 15|regurgitation
P09327881T0000|0 37|Positron emission tomography radioligands
P09327881T0000|41 60|dopamine transporters
P09327881T0000|41 60|dopamine transporters
P09327881T0000|73 77|human
P09327881T0000|81 96|nonhuman primates
P09328341A1449|18 34|vit A2 consensus ERE
P09328341A1449|18 22|vit A2
P09328341A1449|32 34|ERE
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|121 146|E-dependent transactivation
P09328343A0181|39 63|heteromeric protein complex
P09328343A0181|74 83|ubiquitous
P09328343A0181|92 117|E2A- and HEB-encoded proteins
P09328343A0181|92 94|E2A
P09328343A0181|99 117|HEB-encoded proteins
P09328343A0181|122 142|islet-enriched members
P09328343A0181|148 157|bHLH family
P09328343A0181|148 157|bHLH family
P09328349A1679|8 15|CCAAT box
P09328349A1679|8 15|CCAAT box
P09328349A1679|89 105|alpha-subunit gene
P09328349A1679|89 105|alpha-subunit gene
P09328349A1679|108 119|trophoblasts
P09328476A0068|0 9|U4/U6 snRNP
P09328476A0068|0 1|U4
P09328476A0068|3 9|U6 snRNP
P09328476A0068|30 74|small nuclear ribonucleoprotein (snRNP) particles
P09328476A0068|35 58|nuclear ribonucleoprotein
P09328476A0068|60 74|snRNP) particles
P09328476A0068|76 77|U1
P09328476A0068|76 77|U1
P09328476A0068|79 83|U2, U5
P09328476A0068|79 80|U2
P09328476A0068|82 83|U5
P09328476A0068|87 91|U4/U6
P09328476A0068|87 88|U4
P09328476A0068|90 91|U6
P09328476A0068|105 115|spliceosome
P09328476A0374|0 5|Hprp3p
P09328476A0374|0 5|Hprp3p
P09328476A0374|44 85|Saccharomyces cerevisiae splicing factor Prp3p
P09328476A0374|44 66|Saccharomyces cerevisiae
P09328476A0374|81 85|Prp3p
P09328824A0000|3 28|growth-promoting properties
P09328824A0000|34 57|retroviral v-erbA oncogene
P09328824A0000|44 57|v-erbA oncogene
P09328824A0000|85 113|chicken thyroid hormone receptor
P09328824A0000|85 113|chicken thyroid hormone receptor
P09328824A0000|115 122|TR) alpha
P09328824A0000|115 122|TR) alpha
P09328824A0000|156 173|dominant repression
P09328824A0000|199 200|TR
P09328824A0000|199 200|TR
P09328824A0000|204 224|retinoic acid receptors
P09328824A0000|204 224|retinoic acid receptors
P09328833A0588|31 33|HET
P09328833A0588|31 33|HET
P09328833A0588|40 55|MCF-7 cDNA library
P09331119A0659|18 26|3 toxicity
P09331119A0659|42 57|thrombocytopenia
P09331119A0659|62 73|parasthesias
P09331864A0230|0 18|Serum concentrations
P09331864A0230|21 22|E2
P09331864A0230|21 22|E2
P09331864A0230|26 29|TBOH
P09331864A0230|47 56|1, 3, 5, 7, 13
P09331864A0230|67 68|56
P09331864A0230|148 150|MGA
P09331864A0230|173 181|Revalor-H
P09331864A0230|188 193|TBA + 14
P09331864A0230|196 197|E2
P09331864A0230|202 214|Revalor-H + MGA
P09331864A0230|218 227|Finaplix-H
P09331864A0230|234 236|TBA
P09331864A0230|244 257|Finaplix-H + MGA
P09331864A0848|0 6|Serum E2
P09331864A0848|5 6|E2
P09331864A0848|81 83|MGA
P09331864A0848|111 113|MGA
P09333018A0000|0 32|Interferon Regulatory Factor (IRF)-1
P09333018A0000|0 25|Interferon Regulatory Factor
P09333018A0000|27 32|IRF)-1
P09333018A0000|72 81|regulatory
P09333018A0000|101 119|transcription factor
P09333026A0397|3 18|genomic structure
P09333026A0397|21 23|brk
P09333026A0397|34 39|8 exons
P09333026A0397|76 87|non-receptor
P09333026A0397|76 87|non-receptor
P09333026A0397|88 103|PTK family members
P09333026A0397|88 90|PTK
P09333026A0851|41 60|tumour derived brk cDNA
P09333026A0851|54 60|brk cDNA
P09333026A0851|63 87|mouse embryonic fibroblasts
P09333026A0851|91 117|human mammary epithelial cells
P09333026A0851|126 151|anchorage independent growth
P09333026A0851|200 220|epidermal growth factor
P09333026A0851|200 220|epidermal growth factor
P09333168A0310|0 23|Anti-hepatitis A virus (HAV
P09333168A0310|61 92|HIV-positive and 39 HIV-negative men
P09333231T0018|3 7|skull
P09334264A0540|13 26|calf thymus CstF
P09334264A0540|13 26|calf thymus CstF
P09334264A0540|63 75|64-kDa subunit
P09334264A0540|63 75|64-kDa subunit
P09334264A0540|96 100|70 kDa
P09334330A0252|0 12|Null mutations
P09334330A0252|15 19|daf-3
P09334330A0252|15 19|daf-3
P09334330A0252|28 36|mutations
P09334330A0252|56 63|TGF-beta
P09334330A0252|56 63|TGF-beta
P09334330A0252|87 126|associated Smad signal transduction proteins
P09334330A0252|97 126|Smad signal transduction proteins
P09334330A0252|128 132|daf-3
P09334330A0252|128 132|daf-3
P09334330A0252|141 151|Smad protein
P09334330A0252|141 151|Smad protein
P09334330A0252|178 190|mammalian DPC4
P09334330A0252|178 190|mammalian DPC4
P09334330A0252|267 282|dauer development
P09334331A0910|36 64|Drosophila EGF receptor DER/Egfr
P09334331A0910|36 56|Drosophila EGF receptor
P09334331A0910|57 59|DER
P09334331A0910|61 64|Egfr
P09334331A0910|79 86|EMA cells
P09334331A0910|110 113|Vein
P09334331A0910|110 113|Vein
P09334475A0327|35 42|patients
P09334475A0327|125 133|chest pain
P09334475A0327|188 189|CK
P09334475A0327|235 237|EKG
P09334475A0327|265 276|thrombolysis
P09335267A0142|12 26|operon structure
P09335267A0142|42 59|traditional methods
P09335267A0142|125 139|downstream genes
P09335298A0529|24 35|parCBA operon
P09335298A0529|24 35|parCBA operon
P09335298A0529|51 68|partitioning system
P09335298A1227|29 40|ColE1 cer site
P09335298A1227|29 40|ColE1 cer site
P09335298A1227|48 64|RK2 plasmid deleted
P09335298A1227|48 50|RK2
P09335298A1227|71 79|par region
P09335298A1227|71 79|par region
P09335298A1227|100 106|plasmid
P09335298A1227|112 124|MC1061K strain
P09335298A1227|178 183|parCBA
P09335298A1227|178 183|parCBA
P09335298A1227|214 234|stabilization activity
P09335298A1227|250 255|operon
P09335298A2129|44 67|postsegregational killing
P09335298A2129|81 93|E. coli strains
P09335298A2129|95 114|transformation assays
P09335298A2129|181 196|ParE toxin protein
P09335298A2129|181 196|ParE toxin protein
P09335608T0000|0 22|Splice-junction elements
P09335608T0000|26 42|intronic sequences
P09335608T0000|51 69|alternative splicing
P09335608T0000|75 114|Drosophila myosin heavy chain gene transcript
P09335608T0000|75 104|Drosophila myosin heavy chain gene
P09335619A0583|0 17|Nucleotide sequence
P09335619A0583|28 28|R
P09335619A0583|28 28|R
P09335619A0583|57 65|R1 plasmid
P09335619A0583|77 99|South American maize races
P09335619A0583|104 105|RU
P09335619A0583|106 114|cytoplasm
P09335619A0583|121 129|M1 plasmid
P09335619A0583|148 167|Zea luxurians teosinte
P09335619A0583|174 194|atp9 mitochondrial gene
P09335619A0583|174 190|atp9 mitochondrial
P09335619A0583|201 218|3' flanking sequence
P09335619A0583|230 237|region 3'
P09335619A0583|243 252|orf221 gene
P09335619A0583|243 252|orf221 gene
P09336455A0000|40 52|mRNA synthesis
P09336455A0000|67 83|GAL10 and RNR3 genes
P09336455A0000|67 71|GAL10
P09336455A0000|75 83|RNR3 genes
P09336455A0000|99 108|yeast cells
P09336455A0000|111 121|ultraviolet
P09336455A0000|123 134|UV) radiation
P09337861T0000|10 38|human phosphoinositide 3-kinase
P09337861T0000|10 38|human phosphoinositide 3-kinase
P09337861T0000|44 51|C2 domain
P09337861T0000|44 45|C2
P09337861T0000|96 105|wortmannin
P09338414A0430|0 6|Ea value
P09338414A0430|35 77|steady-state end-systolic aortic pressure (ESAP
P09338414A0430|81 92|stroke volume
P09338414A0430|94 107|thermodilution
P09339900A0939|20 35|promoter activity
P09339900A0939|41 57|5'-flanking region
P09339900A0939|60 67|cyclin D2
P09339900A0939|60 67|cyclin D2
P09339900A0939|90 101|- 1,100 to - 805
P09339900A0939|111 115|C/EBP
P09339900A0939|111 115|C/EBP
P09339900A0939|117 120|PEA3
P09339900A0939|117 120|PEA3
P09339900A0939|122 124|AP2
P09339900A0939|122 124|AP2
P09339900A0939|126 129|NF-Y
P09339900A0939|126 129|NF-Y
P09339900A0939|131 135|c-Myc
P09339900A0939|131 135|c-Myc
P09339900A0939|140 142|Sp1
P09339900A0939|140 142|Sp1
P09339900A0939|156 181|positive regulatory activity
P09339900A0939|197 204|cyclin D2
P09339900A0939|197 204|cyclin D2
P09340641T0001|8 14|alcohol
P09340641T0001|33 45|nCPAP pressure
P09341139A0690|51 63|beta2AR mutant
P09341139A0690|51 57|beta2AR
P09341139A0690|121 124|GRK2
P09341139A0690|121 124|GRK2
P09341139A0690|127 140|beta-arrestin 1
P09341139A0690|127 140|beta-arrestin 1
P09341158A0167|32 34|mu1
P09341158A0167|32 34|mu1
P09341158A0167|38 40|mu2
P09341158A0167|38 40|mu2
P09341158A0167|99 117|beta1 and beta2 chains
P09341158A0167|99 111|beta1 and beta2
P09341158A0167|123 144|corresponding complexes
P09341158A0167|161 188|tyrosine-based sorting signals
P09341182A0605|61 73|BTB/POZ domain
P09341182A0605|61 63|BTB
P09341182A0605|65 73|POZ domain
P09341182A0605|78 81|PLZF
P09341182A0605|78 81|PLZF
P09341182A0605|83 94|PLZF-BTB/POZ
P09341182A0605|83 86|PLZF
P09341182A0605|88 90|BTB
P09341182A0605|92 94|POZ
P09341192T0000|0 11|Osmotic shock
P09341192T0000|22 26|GLUT4
P09341192T0000|22 26|GLUT4
P09341192T0000|42 56|3T3L1 adipocytes
P09341192T0000|65 85|tyrosine kinase pathway
P09341192T0000|65 78|tyrosine kinase
P09341193A0362|16 18|Sp1
P09341193A0362|16 18|Sp1
P09341193A0362|20 22|Sp3
P09341193A0362|20 22|Sp3
P09341193A0362|27 38|NGFI-A/Egr-1
P09341193A0362|27 32|NGFI-A
P09341193A0362|34 38|Egr-1
P09341193A0362|44 77|primary nuclear transcription factors
P09341193A0362|87 90|TRE1
P09341193A0362|87 90|TRE1
P09341193A0362|103 119|Tax responsiveness
P09341193A0362|103 105|Tax
P09343208A1405|66 70|genes
P09343208A1405|134 137|PDVs
P09343208A1405|227 240|parasitic wasps
P09343210A1112|44 57|VCAM-1 promoter
P09343210A1112|44 49|VCAM-1
P09343210A1112|71 112|chloramphenicol acetyltransferase constructs
P09343210A1112|71 112|chloramphenicol acetyltransferase constructs
P09343210A1112|125 127|Tax
P09343210A1112|125 127|Tax
P09343210A1112|149 162|VCAM-1 promoter
P09343210A1112|149 162|VCAM-1 promoter
P09343210A1112|169 182|NF-kappaB sites
P09343210A1112|169 182|NF-kappaB sites
P09343210A1112|208 225|VCAM-1 gene promoter
P09343210A1112|208 225|VCAM-1 gene promoter
P09343210A1112|260 280|Tax-induced expression
P09343210A1112|260 262|Tax
P09343210A1112|287 302|adhesion molecule
P09343222A0415|3 5|AGM
P09343222A0415|9 26|NIH/Swiss mouse CCR5
P09343222A0415|23 34|CCR5 proteins
P09343222A0415|71 82|human protein
P09343222A0415|71 82|human protein
P09343398A1193|0 11|Processivity
P09343398A1193|14 25|DNA synthesis
P09343398A1193|31 46|mutant holoenzyme
P09343398A1193|57 63|pcna-79
P09343398A1193|57 63|pcna-79
P09343398A1193|79 85|poly(dA
P09343398A1193|88 95|oligo(dT
P09343398A1193|144 161|secondary structure
P09343426A0456|7 27|substitution mutations
P09343426A0456|33 45|Zta activation
P09343426A0456|33 35|Zta
P09343426A0456|78 80|Zta
P09343426A0456|78 80|Zta
P09343426A0456|95 104|D-A complex
P09343426A0456|95 97|D-A
P09343432A0209|3 5|Scm
P09343432A0209|9 18|ph proteins
P09343432A0209|9 18|ph proteins
P09343432A0209|67 78|65 amino acids
P09343432A0209|89 97|SPM domain
P09343432A0209|129 136|C termini
P09343433A0000|46 60|RNA polymerase II
P09343433A0000|46 60|RNA polymerase II
P09343433A0000|62 67|RNAP II
P09343433A0000|62 67|RNAP II
P09343433A0000|121 134|yeast telomeres
P09343433A0360|9 18|rad6-delta
P09343433A0360|9 18|rad6-delta
P09343433A0360|40 82|telomere-located RNAP II-transcribed genes URA3
P09343433A0360|56 78|RNAP II-transcribed genes
P09343433A0360|79 82|URA3
P09343433A0360|86 89|ADE2
P09343433A0360|86 89|ADE2
P09343982A0890|3 11|amplitude
P09343982A0890|22 33|contractions
P09343982A0890|93 100|controls
P09344650A0967|14 32|transmembrane domain
P09344650A0967|34 41|Casr-rs2
P09344650A0967|34 41|Casr-rs2
P09344650A0967|45 52|Casr-rs3
P09344650A0967|45 52|Casr-rs3
P09344650A0967|70 77|Casr-rs1
P09344650A0967|70 77|Casr-rs1
P09345037A0886|41 65|nuclear trans-factor GATA-1
P09345037A0886|41 59|nuclear trans-factor
P09345037A0886|60 65|GATA-1
P09345037A0886|78 104|progenitor cell proliferation
P09345495A0000|0 12|PET activation
P09345495A0000|45 62|human brain function
P09346238T0000|0 12|F-box proteins
P09346238T0000|0 12|F-box proteins
P09346238T0000|36 59|phosphorylated substrates
P09346238T0000|65 83|SCF ubiquitin-ligase
P09346238T0000|65 67|SCF
P09346238T0000|68 90|ubiquitin-ligase complex
P09346621A1181|19 35|allograft shortage
P09346621A1181|60 62|ELT
P09346621A1181|85 92|patients
P09346621A1181|97 110|cardiac failure
P09346621A1181|123 125|OSF
P09346621A1181|131 143|APACHE II score
P09346925A0660|3 12|SH3 domains
P09346925A0660|3 5|SH3
P09346925A0660|15 18|Grb2
P09346925A0660|15 18|Grb2
P09346925A0660|41 58|proline-rich motifs
P09346925A0660|64 71|HPK1 tail
P09346925A0660|64 67|HPK1
P09346925A0660|126 129|Grb2
P09346925A0660|126 129|Grb2
P09346925A0660|132 135|HPK1
P09346925A0660|132 135|HPK1
P09346925A0660|149 157|Cos1 cells
P09346935A0459|2 20|far-Western analysis
P09346935A0459|24 51|coimmunoprecipitation studies
P09346935A0459|70 74|ZNF74
P09346935A0459|70 74|ZNF74
P09346935A0459|91 106|zinc finger domain
P09346935A0459|91 106|zinc finger domain
P09346935A0459|150 164|RNA polymerase II
P09346935A0459|150 164|RNA polymerase II
P09346935A0459|166 171|pol IIo
P09346935A0459|166 171|pol IIo
P09346935A0459|186 207|hypophosphorylated form
P09346935A0927|5 9|ZNF74
P09346935A0927|5 9|ZNF74
P09346935A0927|27 40|nuclear domains
P09346935A0927|51 58|pre-mRNA
P09346935A0927|80 97|RNA binding activity
P09346935A0927|145 150|pol IIo
P09346935A0927|145 150|pol IIo
P09346935A0927|162 174|RNA polymerase
P09346935A0927|162 174|RNA polymerase
P09346935A0927|201 218|pre- mRNA processing
P09346935A0927|201 208|pre- mRNA
P09346935A0927|250 277|KRAB multifinger protein family
P09346935A0927|250 277|KRAB multifinger protein family
P09346935A0927|280 292|RNA processing
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346938A1680|0 13|Ki-ras4BVal-12
P09346938A1680|54 66|protein levels
P09346938A1680|72 96|lysosomal cysteine protease
P09346938A1680|72 80|lysosomal
P09346938A1680|97 106|cathepsin B
P09346938A1680|97 106|cathepsin B
P09346938A1680|127 150|cathepsin B mRNA expression
P09346938A1680|127 140|cathepsin B mRNA
P09346953A0000|3 14|cellular rate
P09346953A0000|17 55|anticoagulant heparan sulfate proteoglycan
P09346953A0000|57 74|HSPGact) generation
P09346953A0000|57 63|HSPGact
P09346953A0000|119 136|microsomal activity
P09346953A0000|195 198|long
P09346953A0000|199 258|sought heparan sulfate D-glucosaminyl 3-O-sulfotransferase (3-OST
P09346953A0000|205 252|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09346953A0000|254 258|3-OST
P09348226A0852|14 16|EGF
P09348226A0852|14 16|EGF
P09348226A0852|24 30|insulin
P09348226A0852|24 30|insulin
P09348226A0852|42 64|tyrosine phosphorylation
P09348226A0852|67 71|c-cbl
P09348226A0852|67 71|c-cbl
P09348226A0852|93 98|Crk-II
P09348226A0852|93 98|Crk-II
P09349501A0196|25 41|N-terminal portion
P09349501A0196|57 75|chimeric MLL products
P09349501A0196|65 75|MLL products
P09349501A0196|87 106|MLL-LTG9 and MLL-LTG19
P09349501A0196|87 94|MLL-LTG9
P09349501A0196|98 106|MLL-LTG19
P09349501A0196|122 127|nuclei
P09349501A0196|182 195|leukemogenesis
P09349967A0653|33 43|blood supply
P09349967A0653|59 80|structural organisation
P09349967A0653|83 100|mature lamellar bone
P09351242A0719|11 33|AtP5CS1 mRNA accumulation
P09351242A0719|11 21|AtP5CS1 mRNA
P09351242A0719|115 117|ABA
P09351242A0719|148 160|cycloheximide
P09351242A0719|191 205|ABA biosynthesis
P09351242A0719|211 231|aba1 Arabidopsis mutant
P09351242A0719|211 214|aba1
P09351242A0719|215 231|Arabidopsis mutant
P09351823A0414|17 29|MAPK functions
P09351823A0414|17 20|MAPK
P09351823A0414|32 48|meiotic maturation
P09351823A0414|61 76|unfertilized eggs
P09351823A0414|95 120|parthenogenetic development
P09352016A1110|1 3|ii)
P09352016A1110|6 12|AF G-CSF
P09352016A1110|6 12|AF G-CSF
P09352016A1110|56 58|CAM
P09352127A0953|27 40|serum myoglobin
P09352127A0953|32 40|myoglobin
P09352127A0953|44 62|CA III concentrations
P09352127A0953|44 48|CA III
P09352127A0953|94 113|hemodialyzed patients
P09352127A0953|118 136|chronic renal failure
P09353247A0922|54 67|mutant p65cdc18
P09353247A0922|60 67|p65cdc18
P09353247A0922|90 114|mitotic cyclin/CDK activity
P09353247A0922|97 102|cyclin
P09353247A0922|104 106|CDK
P09353255A0159|0 4|Rip1p
P09353255A0159|0 4|Rip1p
P09353255A0159|33 52|nuclear pore complexes
P09353255A0159|33 52|nuclear pore complexes
P09353255A0159|81 100|FG-nucleoporin family
P09353255A0159|81 100|FG-nucleoporin family
P09353255A0159|103 114|pore proteins
P09353296A0510|3 12|CNXA domain
P09353296A0510|27 40|amino acid level
P09353296A0510|46 75|Escherichia coli moaA gene product
P09353296A0510|46 68|Escherichia coli moaA gene
P09353296A0510|82 85|CNXC
P09353296A0510|100 116|E. coli moaC product
P09353296A0510|100 109|E. coli moaC
P09353296A0510|126 139|E. coli products
P09353296A0510|126 139|E. coli products
P09353304A0732|36 55|membrane localization
P09353304A0732|58 62|Tiam1
P09353304A0732|58 62|Tiam1
P09353304A0732|66 81|membrane ruffling
P09353328A0736|18 38|kinase catalytic domain
P09353328A0736|48 72|leucine/isoleucine zippers
P09353343A0919|0 24|RNA polymerase II inhibition
P09353343A0919|0 14|RNA polymerase II
P09353343A0919|46 48|ARE
P09353343A0919|50 61|AUBP activity
P09353343A0919|66 69|poly
P09353343A0919|71 82|U)-Sepharose
P09353343A0919|85 102|cytoplasmic hnRNP A1
P09353343A0919|85 100|cytoplasmic hnRNP
P09353343A0919|101 102|A1
P09353343A0919|109 122|nuclear hnRNP A1
P09353343A0919|116 122|hnRNP A1
P09353343T0000|12 38|AUUUA response element binding
P09353343T0000|41 79|heterogeneous nuclear ribonucleoprotein A1
P09353343T0000|41 79|heterogeneous nuclear ribonucleoprotein A1
P09353343T0000|82 98|human T lymphocytes
P09354349A0338|0 11|Histological
P09354349A0338|35 41|patient
P09354349A0338|60 76|paraffin-embedded
P09354349A0338|94 110|Modified Giemsa (MG
P09354349A0338|116 129|Warthin-Starry
P09354349A0338|131 132|WS
P09354349A0338|140 164|immunohistochemical method
P09354349A0338|166 168|IMM
P09354349A0338|183 209|polyclonal H. pylori antiserum
P09354349A0338|211 218|DAKO B471
P09354644A0124|48 61|become branched
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354644A0124|91 102|IGnT6, GlcNAc
P09354644A0124|105 107|Gal
P09354676A1714|28 34|t(4; 14)
P09354676A1714|28 30|t(4
P09354676A1714|36 45|p16.3; q32)
P09354676A1714|36 40|p16.3
P09354676A1714|63 95|recurrent chromosomal translocation
P09354676A1714|98 99|MM
P09354676A1714|118 126|FGFR3 gene
P09354676A1714|118 126|FGFR3 gene
P09354676A1714|177 189|tumorigenesis
P09354676A1714|192 193|MM
P09354684A1158|24 30|Sp1 site
P09354684A1158|24 30|Sp1 site
P09354684A1158|55 70|promoter activity
P09354757A1444|5 16|acid residues
P09354757A1444|19 40|beta 1', alpha A', alpha B'
P09354757A1444|19 24|beta 1'
P09354757A1444|26 32|alpha A'
P09354757A1444|34 40|alpha B'
P09354757A1444|48 67|loop containing His539
P09354757A1444|73 84|RNase H domain
P09354757A1444|73 84|RNase H domain
P09354757A1444|100 111|primer strand
P09354757A1444|117 121|dsDNA
P09356645A0672|14 20|patient
P09356645A0672|26 32|sarcoma
P09356645A0672|46 65|leg-sparing procedure
P09356645A0672|76 91|nerve enlargement
P09358045A0000|3 24|full length cDNA sequence
P09358045A0000|28 32|Type I
P09358045A0000|33 61|transforming growth factor-beta
P09358045A0000|33 61|transforming growth factor-beta
P09358045A0000|63 79|TGF-beta) receptor
P09358045A0000|63 79|TGF-beta) receptor
P09358045A0000|102 139|filarial parasitic nematode Brugia pahangi
P09358055A0590|34 69|methylation-sensitive promoter element
P09358055A0590|71 74|Enh2
P09358055A0590|88 90|LTR
P09358055A0590|93 123|mouse intractisternal A-particles
P09358069T0000|20 39|high-level expression
P09358069T0000|42 60|human erythropoietin
P09358069T0000|47 60|erythropoietin
P09358069T0000|62 64|EPO
P09358069T0000|62 64|EPO
P09358069T0000|68 81|mammalian cells
P09358837T0000|0 14|Parodoxical rise
P09358837T0000|24 30|albumin
P09358837T0000|53 73|essential hypertension
P09359844A0674|10 23|HSL transcripts
P09359844A0674|10 23|HSL transcripts
P09359844A0674|26 52|human subcutaneous adipocytes
P09359887A1168|32 44|Rat7p/Nup159p
P09359887A1168|32 36|Rat7p
P09359887A1168|38 44|Nup159p
P09359887A1168|47 54|anchored
P09359887A1168|64 66|NPC
P09359887A1168|97 113|adjacent sequences
P09360422A0135|12 19|patients
P09360422A0135|24 49|obliterative arteriopathies
P09360422A0135|82 98|thrombomodulin (TM
P09360422A0135|82 95|thrombomodulin
P09360422A0135|97 98|TM
P09360422A0135|101 119|betathromboglobulin
P09360422A0135|101 119|betathromboglobulin
P09360422A0135|121 127|beta-TG
P09360422A0135|121 127|beta-TG
P09360422A0135|130 136|D-dimer
P09360422A0135|138 139|DD
P09360422A0135|138 139|DD
P09360422A0135|144 173|plasminogen activator-inhibitor
P09360422A0135|144 173|plasminogen activator-inhibitor
P09360422A0135|175 179|pAI-1
P09360422A0135|175 179|pAI-1
P09360422A0135|230 246|healthy volunteers
P09360953A1057|5 12|residues
P09360953A1057|25 40|extracellular end
P09360953A1057|43 61|transmembrane helix 3
P09360953A1057|66 71|Tyr318
P09360953A1057|77 96|COOH-terminal portion
P09360953A1057|99 116|extracellular loop 2
P09360953A1057|99 116|extracellular loop 2
P09360953A1057|131 133|Leu
P09360953A1057|137 139|Ile
P09360953A1057|145 157|PTH-1 receptor
P09360953A1057|145 157|PTH-1 receptor
P09360956A0840|41 50|14-3-3 zeta
P09360956A0840|41 50|14-3-3 zeta
P09360956A0840|56 67|CKIalpha site
P09360956A0840|56 67|CKIalpha site
P09360956A0840|69 76|Thr-233)
P09360956A0840|69 71|Thr
P09360956A0840|108 112|c-Raf
P09360956A0840|108 112|c-Raf
P09360956A0840|133 162|Raf-mediated signal transduction
P09360956A0840|133 135|Raf
P09360993T0000|0 21|Mouse mast cell protease 9
P09360993T0000|0 20|Mouse mast cell protease
P09360993T0000|40 51|chromosome 14
P09360993T0000|60 74|serine proteases
P09360993T0000|60 74|serine proteases
P09360993T0000|103 109|uterine
P09360993T0000|110 118|mast cells
P09361007A0922|1 25|DNase I-hypersensitive site
P09361007A0922|1 25|DNase I-hypersensitive site
P09361007A0922|48 73|258-base pair enhancer region
P09362105X0422|1 27|Pulmonary vascular resistance
P09362105X0422|29 31|PVR
P09362105X0422|90 121|hypoxic pulmonary vasoconstriction
P09362105X0422|123 125|HPV
P09362473A1540|27 32|tinman
P09362473A1540|64 79|enhancer elements
P09362473A1540|146 191|closely linked activator and repressor binding sites
P09362473A1540|200 219|early-acting enhancer
P09362473A1540|234 238|twist
P09362473A1540|271 291|twist expression domain
P09362473A1540|271 275|twist
P09362480A0452|9 23|cysteine triplet
P09362480A0452|49 57|TB domains
P09362480A0452|49 57|TB domains
P09362480A0452|74 84|hydrophobic
P09362480A0452|95 104|C-terminus
P09362480A0452|95 104|C-terminus
P09362480A0452|109 119|alpha-helix
P09362480A0452|109 119|alpha-helix
P09362499A0000|3 12|Fis protein
P09362499A0000|3 12|Fis protein
P09362499A0000|22 55|site-specific DNA inversion catalyzed
P09362499A0000|67 79|DNA invertases
P09362499A0000|92 124|cis-acting recombinational enhancer
P09363759A0000|0 18|Protein phosphatases
P09363759A0000|7 18|phosphatases
P09363759A0000|56 74|eukaryotic cell cycle
P09363759A0000|78 95|signal transduction
P09364211A0319|3 40|cell cycle-regulated transcription factor
P09364211A0319|41 43|E2F
P09364211A0319|41 43|E2F
P09364440A2206|43 57|FSH receptor gene
P09364440A2206|43 57|FSH receptor gene
P09364750T0000|0 24|Transcriptional regulation
P09364750T0000|27 31|SUP35
P09364750T0000|27 31|SUP35
P09364750T0000|35 39|SUP45
P09364750T0000|35 39|SUP45
P09364750T0000|42 64|Saccharomyces cerevisiae
P09365201A2018|61 79|regulatory mechanism
P09365201A2018|82 100|aromatase expression
P09365201A2018|82 90|aromatase
P09365201A2018|103 119|human breast cancer
P09365201A2018|123 126|ASCs
P09365272T0000|0 25|Xenopus Ran-binding protein 1
P09365272T0000|0 6|Xenopus
P09365272T0000|7 25|Ran-binding protein 1
P09365272T0000|27 47|molecular interactions
P09365272T0000|60 74|nuclear assembly
P09365272T0000|77 83|Xenopus
P09365272T0000|84 94|egg extracts
P09365431A0314|29 43|benzodiazepines
P09365431A0314|50 78|acetylcholinesterase inhibitor
P09365431A0314|50 69|acetylcholinesterase
P09365431A0314|79 91|physostigmine
P09366456A0234|70 81|obese persons
P09366456A0234|87 99|body mass index
P09366456A0234|127 141|nonobese persons
P09366456A0234|147 158|body mas index
P09366517A0835|0 19|PKA phosphorylated WT1
P09366517A0835|0 2|PKA
P09366517A0835|17 19|WT1
P09366517A0835|22 24|Ser
P09366517A0835|32 38|Ser-393
P09366517A0835|107 125|DNA-binding activity
P09366517A0835|128 130|WT1
P09366517A0835|128 130|WT1
P09366517A1828|51 53|WT1
P09366517A1828|51 53|WT1
P09366517A1828|73 87|phosphorylation
P09367288A0115|161 166|muscle
P09367288A0115|169 174|tendon
P09367392A0567|35 52|nucleotides 145-165
P09367392A0567|60 64|3' end
P09367392A0567|67 70|RNA3
P09367392A0567|67 70|RNA3
P09367392A0567|100 103|RdRp
P09367392A0567|100 103|RdRp
P09367392A0567|128 131|RNA3
P09367392A0567|128 131|RNA3
P09367392A0567|140 154|wild-type levels
P09367426A1354|27 28|hh
P09367426A1354|59 66|anterior
P09367426A1354|134 145|polarization
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A0275|39 51|DNA sequencing
P09367676A0275|62 94|recombinant phage lambda and P1 clones
P09367676A0275|62 83|recombinant phage lambda
P09367676A0275|87 88|P1
P09367676A0275|107 111|exons
P09367676A0275|123 133|1.9-kb mouse
P09367676A0275|129 139|mouse TS mRNA
P09367676A0275|134 139|TS mRNA
P09367676A1115|48 53|Tbxas1
P09367676A1115|48 53|Tbxas1
P09367676A1115|69 106|short (70-bp) positive regulatory sequence
P09367676A1115|117 142|upstream repressive elements
P09368006A1332|32 40|NF-kappaB
P09368006A1332|32 40|NF-kappaB
P09368006A1332|113 117|E2F-1
P09368006A1332|113 117|E2F-1
P09368014A0740|3 17|lysozyme FEF site
P09368014A0740|3 13|lysozyme FEF
P09368014A0740|36 38|PU.
P09368026A0000|0 13|Osteocalcin (OC
P09368026A0000|0 10|Osteocalcin
P09368026A0000|12 13|OC
P09368026A0000|18 45|matrix calcium-binding protein
P09368026A0000|57 82|osteoblasts and odontoblasts
P09368026A0000|93 106|mineralization
P09368026A0435|33 46|Msx2 expression
P09368026A0435|33 36|Msx2
P09368026A0435|49 68|OC promoter activation
P09368026A0435|49 58|OC promoter
P09368026A0435|70 87|luciferase reporter
P09368026A0435|70 87|luciferase reporter
P09368026A0435|91 98|FGF2/FSK
P09368026A0435|91 94|FGF2
P09368026A0435|96 98|FSK
P09368026A0435|102 111|calcitriol
P09368026A0435|114 121|MC3T3-E1
P09368026A0435|122 132|osteoblasts
P09368057A1083|41 43|SRF
P09368057A1083|41 43|SRF
P09368057A1083|56 72|repressor activity
P09368057A1083|90 103|GC-rich element
P09368057A1083|90 103|GC-rich element
P09368057A1083|152 154|SRF
P09368057A1083|152 154|SRF
P09368058A0969|11 42|CAK-phosphorylated phosphopeptide
P09368058A0969|11 13|CAK
P09368058A0969|58 90|Cdc2-phosphorylated phosphopeptide
P09368058A0969|58 61|Cdc2
P09368058A0969|150 152|CAK
P09368058A0969|150 152|CAK
P09368097T0000|3 5|pen
P09368100A1354|3 27|mHIF-1 alpha structural gene
P09368100A1354|3 27|mHIF-1 alpha structural gene
P09368100A1354|42 46|exons
P09368190A1053|20 43|upstream IRE-like sequence
P09368190A1053|28 43|IRE-like sequence
P09368190A1053|58 61|EMSA
P09368190A1053|120 128|IFN-gamma
P09368190A1053|120 128|IFN-gamma
P09368190A1053|178 186|IFN-alpha
P09368190A1053|178 186|IFN-alpha
P09368190A1053|190 198|IFN-gamma
P09368190A1053|190 198|IFN-gamma
P09368419A0000|28 54|a dehydration-responsive gene
P09368419A0000|29 54|dehydration-responsive gene
P09368419A0000|56 59|rd22
P09368419A0000|56 59|rd22
P09368419A0000|73 84|abscisic acid
P09368419A0000|86 88|ABA
P09368419A0000|101 119|protein biosynthesis
P09368419A0000|123 149|ABA-dependent gene expression
P09368419A0000|123 139|ABA-dependent gene
P09368419A0628|1 4|cDNA
P09368419A0628|14 41|MYC-related DNA binding protein
P09368419A0628|14 41|MYC-related DNA binding protein
P09368419A0628|55 80|DNA-ligand binding screening
P09368419A0628|90 100|67-bp region
P09368419A0628|123 129|rd22BP1
P09368419A0628|123 129|rd22BP1
P09368760A0665|0 8|Human PDK1
P09368760A0665|0 8|Human PDK1
P09368760A0665|26 55|Drosophila protein kinase DSTPK61
P09368760A0665|26 55|Drosophila protein kinase DSTPK61
P09368760A0665|96 113|sex differentiation
P09368760A0665|127 141|spermatogenesis
P09369450A1358|28 36|HNF-1beta
P09369450A1358|28 36|HNF-1beta
P09369450A1358|43 44|GR
P09369450A1358|43 44|GR
P09369450A1358|47 86|dexamethasone-stimulated promoter activity
P09369450A1358|115 123|HNF-1 site
P09369450A1358|115 119|HNF-1
P09369450A1358|130 132|GRE
P09369450A1358|160 186|protein-protein interactions
P09369450A1358|160 174|protein-protein
P09369450A1358|197 216|transcription factors
P09369450A1358|267 292|steroid receptor coactivator
P09369450A1358|267 292|steroid receptor coactivator
P09369451A0693|0 17|Mutational analysis
P09369451A0693|33 48|AP-1 like sequence
P09369451A0693|33 48|AP-1 like sequence
P09369451A0693|50 58|-294/-285
P09369451A0693|60 69|TGAATCATCA
P09369451A0693|76 123|A/T-rich myocyte enhancer factor (MEF)-2 like sequence
P09369451A0693|76 76|A
P09369451A0693|78 78|T
P09369451A0693|84 104|myocyte enhancer factor
P09369451A0693|106 123|MEF)-2 like sequence
P09369451A0693|125 133|-310/-298
P09369451A0693|135 147|TTAAAAATAAAAA
P09369451A0693|156 164|-bp region
P09369451A0693|183 186|OP-1
P09369451A0693|183 184|OP
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|39 41|BAD
P09369453A0273|39 41|BAD
P09369453A0273|43 77|Bcl-xL/Bcl-2 associated death promoter
P09369453A0273|43 48|Bcl-xL
P09369453A0273|50 77|Bcl-2 associated death promoter
P09369453A0273|81 93|death enhancer
P09369453A0273|100 128|C-terminal transmembrane domain
P09369453A0273|100 128|C-terminal transmembrane domain
P09369453A0273|146 189|outer mitochondrial membrane and nuclear envelope
P09369482A0690|0 19|Electromobility shift
P09369482A0690|23 42|cotransfection assays
P09369482A0690|59 67|HNF1alpha
P09369482A0690|59 67|HNF1alpha
P09369482A0690|75 78|HNF4
P09369482A0690|75 78|HNF4
P09369482A0690|118 127|G6Pase gene
P09369482A0690|118 123|G6Pase
P09369482A0690|124 137|gene expression
P09370276A0781|2 17|open reading frame
P09370276A0781|20 25|2862 bp
P09370276A0781|35 53|954 amino acid protein
P09370307A0093|13 21|AACA motif
P09370307A0093|59 73|non-seed tissues
P09370307A0093|96 129|barley gibberellin responsive element
P09370307A0093|142 167|MYB-like DNA binding proteins
P09370307A0093|142 167|MYB-like DNA binding proteins
P09371431A1172|6 11|CFN037
P09371431A1172|44 58|Tn5mob insertion
P09371431A1172|44 49|Tn5mob
P09371431A1172|64 77|promoter region
P09371431A1172|83 100|thiCOGE gene cluster
P09371431A1172|83 100|thiCOGE gene cluster
P09371431T0000|19 35|biosynthetic genes
P09371431T0000|37 43|thiCOGE
P09371431T0000|37 43|thiCOGE
P09371431T0000|60 87|symbiotic terminal oxidase cbb3
P09371431T0000|69 87|terminal oxidase cbb3
P09371431T0000|90 102|Rhizobium etli
P09371455A0000|40 51|lipase operon
P09371455A0000|40 51|lipase operon
P09371455A0000|90 104|metalloprotease
P09371455A0000|107 122|Vibrio cholerae O1
P09371564A0713|23 32|tRNA(3Lys)
P09371564A0713|23 26|tRNA
P09371564A0713|28 31|3Lys
P09371564A0713|50 57|viral RNA
P09371564A0713|60 73|mutated viruses
P09371564A0713|113 126|wild-type virus
P09371566A1384|26 44|HeLa nuclear extracts
P09371566A1384|48 59|S100 extracts
P09371566A1384|73 93|SR protein preparations
P09371566A1384|73 81|SR protein
P09371566A1384|126 134|SR protein
P09371596T0000|0 21|Differential regulation
P09371596T0000|27 53|pre-C and pregenomic promoters
P09371596T0000|27 31|pre-C
P09371596T0000|56 75|human hepatitis B virus
P09371596T0000|90 115|nuclear receptor superfamily
P09371596T0000|90 115|nuclear receptor superfamily
P09371622A0779|0 28|Chimeras containing IE1 peptides
P09371622A0779|18 28|IE1 peptides
P09371622A0779|68 80|basal promoter
P09371622A0779|89 108|lac operator sequences
P09371622A0779|89 108|lac operator sequences
P09371626A1345|12 26|replicase assays
P09371626A1345|12 20|replicase
P09371626A1345|40 48|mutant VP2
P09371626A1345|40 48|mutant VP2
P09371626A1345|73 89|RNA-binding domain
P09371626A1345|73 89|RNA-binding domain
P09371626A1345|121 123|VP2
P09371626A1345|121 123|VP2
P09371626A1345|126 136|replication
P09371626A1345|190 210|minus-strand synthesis
P09371657A0165|24 30|alanine
P09371657A0165|48 50|R77
P09371657A0165|53 53|A
P09371657A0165|55 64|R77A)-K79A
P09371657A0165|68 78|E192A-E194A
P09371657A0165|110 132|triphosphatase component
P09371698A1254|14 18|HepG2
P09371698A1254|22 33|SK-N-MC cells
P09371698A1254|67 86|5'-flanking fragments
P09371698A1254|112 139|minimal 200 bp promoter fragment
P09371698A1254|153 166|pseudo-TATA box
P09371698A1254|181 196|SP1-binding sites
P09371698A1254|181 196|SP1-binding sites
P09371731A0627|4 10|inserts
P09371731A0627|41 57|eIF-2alpha kinases
P09371731A0627|41 57|eIF-2alpha kinases
P09372287A0296|5 23|monopolar electrodes
P09372287A0296|43 81|left and right lateral vestibulospinal tract
P09372287A0296|83 86|LVST
P09372287A0296|91 116|medial vestibulospinal tract
P09372287A0296|118 121|MVST
P09372287A0296|128 136|C1 segment
P09372287A0296|128 136|C1 segment
P09372287A0296|161 165|axons
P09372451T0000|0 7|Epitopes
P09372451T0000|10 48|adhesion-perturbing monoclonal antibodies
P09372451T0000|68 86|alpha-helical domain
P09372451T0000|92 111|integrin beta 1 subunit
P09372451T0000|92 104|integrin beta 1
P09372908A1068|0 31|Polyhomeotic and Posterior Sex Combs
P09372908A1068|0 11|Polyhomeotic
P09372908A1068|60 83|transcriptional mechanism
P09372908A1068|103 116|gene repression
P09372908A1068|139 153|Polycomb protein
P09372908A1068|139 153|Polycomb protein
P09372908A1068|168 171|PREs
P09372924A0758|16 29|rhHR23 proteins
P09372924A0758|16 29|rhHR23 proteins
P09372924A0758|48 50|NER
P09372924A0758|74 89|purified proteins
P09372924A0758|120 132|hHR23 proteins
P09372924A0758|120 132|hHR23 proteins
P09372924A0758|138 154|DNA repair reaction
P09372924A0758|173 175|XPC
P09372924A0758|173 175|XPC
P09372937T0000|3 7|yeast
P09372937T0000|34 66|Sir4p anchors and partitions plasmids
P09372937T0000|34 38|Sir4p
P09372950A1283|31 59|-specific base-paired structure
P09372950A1283|131 140|human U2 RNA
P09372950A1283|136 140|U2 RNA
P09372960A0456|0 15|Polysome analyses
P09372960A0456|19 51|temperature-sensitive fal1-1 mutant
P09372960A0456|40 51|fal1-1 mutant
P09372960A0456|56 75|Fal1p-depleted strain
P09372960A0456|56 60|Fal1p
P09372960A0456|104 123|40S ribosomal subunits
P09372960A0456|104 115|40S ribosomal
P09372968A0532|0 15|Sequence analysis
P09372968A0532|37 46|cDNA clones
P09372968A0532|49 53|Dlc-1
P09372968A0532|49 53|Dlc-1
P09372968A0532|56 63|sequence
P09372968A0532|79 79|9
P09372968A0532|101 133|outer-arm dynein light-chain protein
P09372968A0532|101 126|outer-arm dynein light-chain
P09372968A0996|14 17|HeLa
P09372968A0996|21 28|293 cells
P09372968A0996|54 65|I kappaB alpha
P09372968A0996|54 65|I kappaB alpha
P09372968A0996|90 99|Myc-tagged
P09372968A0996|90 92|Myc
P09372968A0996|102 116|endogenous Dlc-1
P09372968A0996|112 116|Dlc-1
P09373140A0000|3 35|mouse M-lysozyme downstream enhancer
P09373140A0000|3 35|mouse M-lysozyme downstream enhancer
P09373140A0000|43 65|previously characterized
P09373140A0000|83 96|gene regulation
P09373155T0000|16 36|dynein heavy chain genes
P09373155T0000|16 36|dynein heavy chain genes
P09373155T0000|48 66|human and mouse testis
P09373155T0000|68 90|chromosomal localization
P09373155T0000|95 112|axonemal dynein gene
P09373155T0000|95 112|axonemal dynein gene
P09373651A0255|0 12|Bitter cassava
P09373651A0255|89 103|hydrogen cyanide
P09374082A0504|38 64|mono(2-ethylhexyl) phthalate
P09374082A0504|66 69|MEHP
P09374082A0504|101 104|DEHP
P09374082A0504|123 136|prostaglandins
P09374082A0504|138 143|PG) PGD
P09374082A0504|148 153|9alpha
P09374082A0504|155 164|11betaPGF2
P09374082A0504|169 177|PGF2alpha
P09374082A0504|199 203|lungs
P09374082A0504|239 250|inflammation
P09374082A0504|256 262|airways
P09374082A0504|288 293|asthma
P09374541T0000|0 21|Constitutive protection
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|52 79|human thymidine kinase promoter
P09374541T0000|52 79|human thymidine kinase promoter
P09374541T0000|86 105|cell cycle progression
P09376325A0167|39 45|ph locus
P09376325A0167|39 45|ph locus
P09376325A0167|81 115|proximal and distal transcription units
P09376626A0737|0 8|Radiation
P09376626A0737|29 30|T4
P09376626A0737|34 35|T3
P09376626A0737|46 51|group C
P09376626A0737|55 60|group A
P09376782A0328|57 85|hepatitis C virus (HCV) infection
P09377355A0362|69 91|cardiovascular disorders
P09377355A0362|94 116|chronic renal impairement
P09377355A0362|132 152|modern diagnostic tools
P09377374A0000|12 27|characterization
P09377374A0000|69 77|VH B course
P09379301A2036|13 27|A. microcephalum
P09379301A2036|44 50|A. wedli
P09380504A1255|3 11|ZnF20 cDNA
P09380504A1255|3 11|ZnF20 cDNA
P09380504A1255|46 66|thyroid cancer cell line
P09380504A1255|72 80|4.5 and 2 kb
P09380504A1255|100 112|cycloheximide
P09380504A1255|150 161|actinomycin D
P09380507A0514|0 27|Glutathione S-transferase (GST
P09380507A0514|0 23|Glutathione S-transferase
P09380507A0514|25 27|GST
P09380507A0514|30 32|E2F
P09380507A0514|30 32|E2F
P09380507A0514|36 55|GST-DP fusion proteins
P09380507A0514|36 38|GST
P09380507A0514|40 55|DP fusion proteins
P09380507A0514|95 102|E2F sites
P09380507A0514|95 102|E2F sites
P09380507A0514|108 137|DNA polymerase alpha gene promoter
P09380507A0514|108 137|DNA polymerase alpha gene promoter
P09380697T0000|3 39|sterol regulatory element-like sequences
P09380697T0000|62 86|caveolin gene transcription
P09380697T0000|62 73|caveolin gene
P09380697T0000|99 134|low density lipoprotein free cholesterol
P09380707A0714|21 29|LAZ3/BCL6
P09380707A0714|21 24|LAZ3
P09380707A0714|26 29|BCL6
P09380707A0714|38 41|SMRT
P09380707A0714|38 41|SMRT
P09380707A0714|99 109|nuclear dots
P09381261A0970|28 36|EPO levels
P09381261A0970|28 30|EPO
P09381261A0970|40 46|mothers
P09381261A0970|50 57|newborns
P09381950A0209|0 8|Ischaemia
P09381950A0209|71 90|40-minute reperfusion
P09382498A0618|9 12|MCTs
P09382498A0618|77 81|tumor
P09382498A0618|91 94|MCTs
P09382498A0618|103 111|electrode
P09382498A0618|136 163|peripheral and surrounding area
P09382498A0618|169 173|tumor
P09382850A0000|36 56|cell-cycle progression
P09382850A0000|69 78|DNA lesions
P09382886A1061|28 49|renal cellular apoptosis
P09382886A1061|52 54|PKD
P09382886A1061|76 78|p53
P09382886A1061|76 78|p53
P09382886A1061|116 118|SBM
P09382886A1061|122 133|p53(-/-) mice
P09382886A1061|122 129|p53(-/-)
P09382924A0131|52 67|interferon-gamma
P09382924A0131|52 67|interferon-gamma
P09382924A0131|69 77|IFN-gamma
P09382924A0131|69 77|IFN-gamma
P09382924A0131|85 101|beta-type subunits
P09382924A0131|85 101|beta-type subunits
P09382924A0131|113 116|LMP2
P09382924A0131|113 116|LMP2
P09382924A0131|118 121|LMP7
P09382924A0131|118 121|LMP7
P09382924A0131|126 131|PSMB10
P09382924A0131|126 131|PSMB10
P09382924A0131|155 167|20S proteasome
P09382924A0131|155 167|20S proteasome
P09382924A0131|183 203|housekeeping beta-type
P09382924A0131|222 226|PSMB6
P09382924A0131|222 226|PSMB6
P09382924A0131|228 232|PSMB5
P09382924A0131|228 232|PSMB5
P09382924A0131|237 241|PSMB7
P09382924A0131|237 241|PSMB7
P09383156A0691|8 28|RNase E cleavage product
P09383156A0691|8 13|RNase E
P09383156A0691|37 42|pSok-6
P09383156A0691|37 42|pSok-6
P09383156A0691|63 89|polynucleotide phosphorylase
P09383156A0691|63 89|polynucleotide phosphorylase
P09383156A0691|91 96|PNPase
P09383156A0691|91 96|PNPase
P09383188A0654|45 59|ARG box consensus
P09383188A0654|65 75|O(rocD) site
P09383188A0654|65 65|O
P09383188A0654|67 75|rocD) site
P09385169T0000|3 15|AONE's experts
P09386074A0694|0 6|All pigs
P09386074A0694|29 41|LV dysfunction
P09386074A0694|52 69|LV ejection fraction
P09387333T0001|13 33|morphological research
P09387333T0001|39 57|parabrachial nucleus
P09387999A1053|3 12|amplitudes
P09387999A1053|15 19|DPOAE
P09387999A1053|61 70|cell losses
P09387999A1053|90 106|R-PIA-treated ears
P09387999A1053|90 90|R
P09387999A1053|92 94|PIA
P09388198A1396|30 54|signal transduction pathway
P09388198A1396|68 70|JNK
P09388198A1396|68 70|JNK
P09388198A1396|72 74|ERK
P09388198A1396|72 74|ERK
P09388198A1396|79 90|p38 MAP kinase
P09388198A1396|79 90|p38 MAP kinase
P09388198A1396|119 122|rhoB
P09388198A1396|119 122|rhoB
P09388198A1396|125 139|genotoxic stress
P09388198A1396|180 183|rhoB
P09388198A1396|180 183|rhoB
P09388199A0948|29 32|FadR
P09388199A0948|29 32|FadR
P09388199A0948|44 53|DNA binding
P09388199A0948|55 66|dimerization
P09388199A0948|71 83|ligand binding
P09388199A0948|85 106|chimeric protein fusions
P09388199A0948|117 132|DNA binding domain
P09388199A0948|117 132|DNA binding domain
P09388199A0948|135 138|LexA
P09388199A0948|135 138|LexA
P09388199A0948|160 163|FadR
P09388199A0948|160 163|FadR
P09388200A0639|29 37|titration
P09388200A0639|47 66|transcription factors
P09388200A0639|74 77|MDM2
P09388200A0639|74 77|MDM2
P09388200A0639|100 104|c-fos
P09388200A0639|100 104|c-fos
P09388200A0639|118 126|promoters
P09388200A0639|136 153|basal transcription
P09388201A1027|0 3|4) PU
P09388201A1027|2 3|PU
P09388201A1027|7 8|PD
P09388201A1027|7 8|PD
P09388201A1027|18 42|canonical TATA or CAAT motifs
P09388201A1027|50 56|AT-rich
P09388246A0903|12 58|immunogold electron microscopy immunocytochemistry
P09388246A0903|63 74|amphiphysin I
P09388246A0903|74 74|I
P09388246A0903|91 113|nerve terminal cytomatrix
P09388246A0903|142 163|endocytic intermediates
P09388271A1243|3 15|mobility shift
P09388271A1243|75 77|PKC
P09388271A1243|75 77|PKC
P09388271A1243|80 149|mitogen-activated protein kinase/extracellular signal-related kinase kinase
P09388271A1243|80 109|mitogen-activated protein kinase
P09388271A1243|111 149|extracellular signal-related kinase kinase
P09389137A0763|3 14|prescription
P09389137A0763|18 25|apoplexy
P09389137A0763|34 37|C1-7
P09389137A0763|34 37|C1-7
P09389137A0763|39 42|T1-9
P09389137A0763|39 42|T1-9
P09389137A0763|46 49|L2-4
P09389137A0763|46 49|L2-4
P09389198A0363|35 38|skin
P09389198A0363|50 54|nerve
P09389198A0363|57 73|mental arithmetics
P09389198A0363|80 89|delta units
P09389198A0363|105 115|active state
P09389198A0363|129 147|mechanical threshold
P09389492A0520|26 37|stromal cells
P09389492A0520|68 80|dexamethasone
P09389492A0520|97 127|phorbol ester-stimulated activity
P09389666A0538|5 17|Hex expression
P09389666A0538|5 7|Hex
P09389666A0538|83 93|mouse embryo
P09389666A0538|113 131|anteroposterior axis
P09389666A0538|137 142|embryo
P09389666A0538|206 229|primitive endoderm lineage
P09389669A1009|5 7|dpp
P09389669A1009|11 13|omb
P09389669A1009|25 30|dorsal
P09389669A1009|78 89|leg disc cells
P09389982A1383|17 19|INR
P09389982A1383|88 90|INR
P09389982A1383|101 111|prothrombin
P09389982A1383|124 141|regression analysis
P09390125A0379|18 20|FNF
P09390183A1027|0 18|Western blot analysis
P09390183A1027|28 40|bovine tissues
P09390183A1027|45 67|human NMT peptide antibody
P09390183A1027|50 67|NMT peptide antibody
P09390183A1027|140 149|48.5-50 kDa
P09391173A0811|13 22|start sites
P09391173A0811|28 45|plastid ACCase genes
P09391173A0811|35 45|ACCase genes
P09391173A0811|93 99|5'-RACE
P09391173A0811|101 118|rapid amplification
P09391173A0811|121 128|cDNA ends
P09392979T0000|0 37|AIDS-related disseminated histoplasmosis
P09393706A1171|5 7|Fis
P09393706A1171|5 7|Fis
P09393706A1171|16 48|accessory transcriptional activator
P09393706A1171|54 64|mar promoter
P09393706A1171|54 64|mar promoter
P09393717A1517|63 72|mutant tRNA
P09393717A1517|112 136|UVM-constitutive phenotype
P09393717A1517|147 150|mutA
P09393717A1517|147 150|mutA
P09393717A1517|154 162|mutC cells
P09393717A1517|154 157|mutC
P09393771A1659|0 16|TNF-alpha exposure
P09393771A1659|0 8|TNF-alpha
P09393771A1659|44 69|several RNA-binding proteins
P09393771A1659|51 69|RNA-binding proteins
P09393771A1659|87 119|Mr 50,000-55,000 RNA-binding protein
P09393875A0873|18 45|human papillomavirus late mRNAs
P09393875A0873|18 40|human papillomavirus late
P09393875A0873|41 45|mRNAs
P09393875A0873|84 94|virus genome
P09393875A0873|104 116|infected cells
P09393875A0873|132 141|c-fos mRNAs
P09393875A0873|137 141|mRNAs
P09393875A0873|145 172|destabilizing cellular factors
P09393875A0873|193 216|elevated Fos protein levels
P09393875A0873|201 210|Fos protein
P09393875A0873|219 250|human papillomavirus infected cells
P09393966A0190|17 38|IgH constant region genes
P09393966A0190|17 19|IgH
P09393966A0190|20 38|constant region genes
P09393966A0190|40 42|CHA
P09393966A0190|40 42|CHA
P09393966A0190|46 48|CHB
P09393966A0190|46 48|CHB
P09394650A0121|57 72|normal lymph nodes
P09394650A0121|75 102|high-resolution mediastinal US
P09395456A0424|16 31|heavy chain motifs
P09395456A0424|34 53|substrate recognition
P09395456A0424|84 107|bovine proenteropeptidase
P09395456A0424|84 107|bovine proenteropeptidase
P09395456A0424|137 155|transmembrane domain
P09395456A0424|161 173|signal peptide
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|32 62|type II transmembrane glycoprotein
P09395470A0294|32 62|type II transmembrane glycoprotein
P09395470A0294|87 112|N-linked glycosylation sites
P09395525A0395|20 60|CCAAT/enhancer-binding protein (C/EBP) delta
P09395525A0395|20 48|CCAAT/enhancer-binding protein
P09395525A0395|50 60|C/EBP) delta
P09395525A0395|81 95|PGE2-stimulated
P09395525A0395|96 113|DNA-protein complex
P09395525A0395|96 106|DNA-protein
P09395525A0395|123 126|HS3D
P09395525A0395|123 126|HS3D
P09395525A0395|138 147|C/EBPdelta
P09395525A0395|138 147|C/EBPdelta
P09395525A0395|162 175|IGF-I promoter 1
P09395525A0395|162 175|IGF-I promoter 1
P09396402A0264|19 31|Semen analyses
P09396402A0264|49 56|patients
P09396402A0264|72 73|HD
P09396402A0264|96 107|chemotherapy
P09396402A0264|119 128|sperm count
P09396402A0264|163 174|radiotherapy
P09396402A0264|192 203|chemotherapy
P09396427A1488|59 66|patients
P09396427A1488|88 102|left ventricular
P09396427A1488|126 128|AMI
P09396427A1488|155 177|left ventricular geometry
P09396437A0878|5 13|BMI cutoff
P09396437A0878|30 31|NE
P09396437A0878|57 69|obese subjects
P09396437A0878|89 100|lean subjects
P09396722A0185|3 12|gene (ApxII
P09396722A0185|8 12|ApxII
P09396722A0185|26 67|chloroplastic ascorbate peroxidase isoenzymes
P09396722A0185|39 67|ascorbate peroxidase isoenzymes
P09396796A1173|31 35|CDF-1
P09396796A1173|31 35|CDF-1
P09396796A1173|43 57|E2F family member
P09396796A1173|43 57|E2F family member
P09396796A1173|114 118|CDF-1
P09396796A1173|114 118|CDF-1
P09396796A1173|122 124|E2F
P09396796A1173|122 124|E2F
P09396823T0000|3 20|proofreading domain
P09396823T0000|23 51|Escherichia coli DNA polymerase I
P09396823T0000|23 51|Escherichia coli DNA polymerase I
P09396823T0000|69 89|RNA exonuclease domains
P09397261A0940|0 18|Interleukin-1 levels
P09397261A0940|0 12|Interleukin-1
P09397723T0001|0 20|Responsibility matters
P09398267A0440|0 19|Southern blot analysis
P09398267A0440|22 52|endonuclease-digested genomic DNA
P09398267A0440|69 85|embryo fibroblasts
P09398267A0440|87 89|CEF
P09398267A0440|104 107|MEK2
P09398267A0440|104 107|MEK2
P09398267A0440|111 125|single-copy gene
P09398332A0732|33 35|mu2
P09398332A0732|33 35|mu2
P09398332A0732|39 44|CTLA-4
P09398332A0732|39 44|CTLA-4
P09398332A0732|69 76|161TTGVY
P09398332A0732|79 84|CTLA-4
P09398332A0732|79 84|CTLA-4
P09398332A0732|130 149|previously identified
P09398332A0732|150 164|SH2 binding motif
P09398332A0732|150 164|SH2 binding motif
P09398332A0732|166 172|165YVKM
P09398332A0732|184 198|CTLA-4 signaling
P09398332A0732|184 189|CTLA-4
P09398598A0256|18 60|transfected Chinese hamster ovary (CHO) cell line
P09398598A0256|72 88|murine CD4 fragment
P09398598A0256|72 88|murine CD4 fragment
P09398598A0256|110 126|N-terminal domains
P09398598A0256|139 156|monomeric molecules
P09398598A0256|160 175|disulfide-linked
P09398855A0438|0 21|SCID V(D)J recombination
P09398855A0438|4 4|V
P09398855A0438|6 6|D
P09398855A0438|42 54|T-lymphocytes
P09398855A0438|63 80|DNA-damaging agents
P09398855A0438|82 98|gamma-irradiation
P09398855A0438|102 110|bieomycin
P09398855A0438|132 138|p53 gene
P09398855A0438|132 138|p53 gene
P09398855A0438|176 192|DNA repair activity
P09398855A0438|205 213|DNA damage
P09398855A0438|225 233|apoptosis
P09398855A0438|248 250|p53
P09398855A0438|248 250|p53
P09400613A0594|19 30|PKR(1-515)WT
P09400613A0594|19 21|PKR
P09400613A0594|29 30|WT
P09400613A0594|34 54|Gal4 DNA-binding domain
P09400613A0594|34 37|Gal4
P09400613A0594|38 54|DNA-binding domain
P09400613A0594|98 118|PKR(1-551) K296R mutant
P09400613A0594|98 107|PKR(1-551)
P09400613A0594|123 168|RNA-binding-deficient human PKR(1-551)K64E/K296R
P09400613A0594|123 157|RNA-binding-deficient human PKR(1-551
P09400613A0594|159 180|K64E/K296R double mutant
P09400613A0594|184 197|wild-type mouse
P09400613A0594|198 209|PKR(1-515)WT
P09400613A0594|198 200|PKR
P09400613A0594|208 209|WT
P09400613A0594|223 225|PKR
P09400613A0594|223 225|PKR
P09400613A0594|227 230|Gal4
P09400613A0594|227 230|Gal4
P09400613A0594|279 298|HIS3 and lacZ reporters
P09400613A0594|279 282|HIS3
P09400613A0594|286 289|lacZ
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400613A1209|5 7|GST
P09400613A1209|9 11|PKR
P09400613A1209|68 72|mouse
P09400613A1209|76 80|human
P09400613A1209|81 91|PKR homologs
P09400613A1209|81 83|PKR
P09400738A1046|13 32|inflammatory response
P09400738A1046|76 79|ufCB
P09400738A1046|92 105|CB instillation
P09402029A1632|32 36|H37Ra
P09402029A1632|47 59|hybridization
P09402029A1632|98 102|genes
P09402029A1632|196 209|virulent strain
P09402029A1632|210 214|H37Rv
P09402088A2250|84 86|AVP
P09402139A1121|22 73|hIGFBP-1 and phosphoenolpyruvate kinase (PEPCK) promoters
P09402139A1121|22 29|hIGFBP-1
P09402139A1121|33 57|phosphoenolpyruvate kinase
P09402139A1121|59 63|PEPCK
P09402139A1121|101 107|insulin
P09402139A1121|101 107|insulin
P09402139A1121|109 122|glucocorticoid
P09402139A1121|127 155|cyclic adenosine-monophosphate
P09402139A1121|208 214|IGFBP-1
P09402139A1121|208 214|IGFBP-1
P09402139A1121|239 255|glucose metabolism
P09403059A0209|4 15|binary repeat
P09403059A0209|24 44|repetitive DNA elements
P09403059A0209|56 60|LINES
P09403059A0209|62 66|SINES
P09403059A0209|106 127|transposon-like element
P09404725A0644|19 30|gangliosides
P09404725A0644|50 56|females
P09404725A0644|63 67|males
P09405195A0320|5 21|genomic constructs
P09405195A0320|36 50|endogenous locus
P09405195A0320|36 50|endogenous locus
P09405195A0320|80 100|cDNA-derived sequences
P09405195A0320|133 142|genomic DNA
P09405195A0320|202 227|nonhomologous recombination
P09405380A0800|108 117|retrovirus
P09405536A0777|34 46|C-fiber reflex
P09405536A0777|107 125|anesthetized animals
P09405685A0113|3 48|sequence-specific DNA binding transcription factor
P09405685A0113|20 48|DNA binding transcription factor
P09405685A0113|50 52|p53
P09405685A0113|50 52|p53
P09405685A0113|73 91|20-bp consensus motif
P09405685A0113|92 145|5'-PuPuPuC(A/T) (T/A)GPyPyPyPuPuPuC(A/T)(T/A)GPyPyPy-3'
P09405685A0113|103 103|A
P09405685A0113|105 106|T)
P09405685A0113|108 108|T
P09405685A0113|110 110|A
P09405685A0113|127 127|A
P09405685A0113|129 130|T)
P09405685A0113|132 132|T
P09405685A0113|134 134|A
P09407026A0426|0 11|TSA treatment
P09407026A0426|42 62|enhancer factor binding
P09407026A0426|81 85|nuc-1
P09407026A0426|81 85|nuc-1
P09407026A0426|104 121|chromatin templates
P09407026A0426|136 153|protein acetylation
P09407026A0426|157 175|chromatin remodeling
P09407026A0426|263 267|nuc-1
P09407026A0426|263 267|nuc-1
P09407031A0557|4 11|UV damage
P09407031A0557|13 16|Crb2
P09407031A0557|13 16|Crb2
P09407031A0557|82 96|phosphorylation
P09407031A0557|99 108|Chk1 kinase
P09407031A0557|99 108|Chk1 kinase
P09407031A0557|135 148|Cdc2 activation
P09407031A0557|135 138|Cdc2
P09407031A0974|33 36|Chk1
P09407031A0974|33 36|Chk1
P09407031A0974|62 65|cut5
P09407031A0974|62 65|cut5
P09407031A0974|69 79|crb2 mutants
P09407031A0974|69 72|crb2
P09407036T0000|0 10|Tcn1p/Crz1p
P09407036T0000|0 4|Tcn1p
P09407036T0000|6 10|Crz1p
P09407036T0000|13 52|calcineurin-dependent transcription factor
P09407036T0000|13 46|calcineurin-dependent transcription
P09407036T0000|80 93|gene expression
P09407036T0000|96 118|Saccharomyces cerevisiae
P09407090T0000|29 37|human gene
P09407090T0000|29 37|human gene
P09407090T0000|46 56|SR-BI/CLA-1
P09407090T0000|46 50|SR-BI
P09407090T0000|52 56|CLA-1
P09407642A0305|15 26|gel technique
P09408516T0000|27 49|liquid dosage formulation
P09408796A0648|8 25|regression analyses
P09408796A0648|38 49|WAIS-R factor
P09408796A0648|56 74|Verbal Comprehension
P09408796A0648|138 142|WMS-R
P09408796A0648|146 149|CVLT
P09409416A0111|0 21|Bilateral basal arteries
P09409416A0111|66 68|MHz
P09409416A0111|82 102|instrument (TC-2 64B EME
P09409774A0214|5 16|genomic level
P09409774A0214|67 85|rat Rattus norvegicus
P09409774A0214|90 98|VCSA1 gene
P09409774A0214|90 98|VCSA1 gene
P09409774A0214|111 140|prohormone-like polypeptide SMR1
P09409774A0214|111 136|prohormone-like polypeptide
P09409774A0214|137 140|SMR1
P09409774A0214|148 156|VCSB1 gene
P09409774A0214|148 156|VCSB1 gene
P09409774A0214|175 193|Pro-rich polypeptide
P09409821T0000|3 34|Saccharomyces cerevisiae RAD30 gene
P09409821T0000|3 25|Saccharomyces cerevisiae
P09409821T0000|26 34|RAD30 gene
P09409821T0000|48 66|Escherichia coli dinB
P09409821T0000|48 62|Escherichia coli
P09409821T0000|63 73|dinB and umuC
P09409821T0000|70 73|umuC
P09409821T0000|77 94|DNA damage inducible
P09409821T0000|115 154|error-free postreplication repair mechanism
P09411459A0729|61 70|puppet game
P09411459A0729|79 89|pretraining
P09411459A0729|104 116|vowel deletion
P09411459A0729|168 182|children working
P09411459A0729|190 201|CVCC material
P09412079T0001|0 10|Diet therapy
P09412079T0001|15 25|soy proteins
P09412079T0001|29 48|chronic stomach ulcers
P09413375A1486|2 4|ICU
P09413375A1486|5 12|patients
P09413375A1486|51 59|IL-6 level
P09413375A1486|51 54|IL-6
P09413375A1486|84 103|plasma concentrations
P09413375A1486|106 114|cytokines
P09414074A0827|10 17|training
P09414074A0827|180 182|SSP
P09414287A0637|0 14|Gel-shift assays
P09414287A0637|28 42|Sp1 binding sites
P09414287A0637|28 42|Sp1 binding sites
P09414319A1442|0 12|Y15170 (Surf-2
P09414319A1442|0 5|Y15170
P09414319A1442|7 12|Surf-2
P09414319A1442|14 19|Surf-4
P09414319A1442|14 19|Surf-4
P09414319A1442|22 27|Y15171
P09414319A1442|22 27|Y15171
P09414319A1442|29 34|Surf-3
P09414319A1442|29 34|Surf-3
P09414319A1442|36 41|Surf-1
P09414319A1442|36 41|Surf-1
P09414319A1442|43 48|Surf-6
P09414319A1442|43 48|Surf-6
P09414319A1442|54 59|Y15172
P09414319A1442|54 59|Y15172
P09414319A1442|61 67|Surf-5.
P09414319A1442|61 66|Surf-5
P09415711A1348|0 35|Gel mobility shift and super-shift assays
P09415711A1348|46 60|nuclear extracts
P09415711A1348|71 78|rat liver
P09415711A1348|81 93|DDT1MF-2 cells
P09415711A1348|113 115|CRE
P09415711A1348|121 134|alpha 1B-AR gene
P09415711A1348|121 134|alpha 1B-AR gene
P09415711A1348|140 156|CRE binding protein
P09416467A0959|48 60|ACE inhibitors
P09416467A0959|48 50|ACE
P09416467A0959|89 108|ischemia-reperfusion
P09416898A1798|69 72|ARVD
P09416898A1798|73 80|patients
P09416898A1798|84 98|control subjects
P09417082A0127|40 56|urokinase receptor
P09417082A0127|40 56|urokinase receptor
P09417108A0000|3 12|murine Htf9
P09417108A0000|9 14|Htf9-a
P09417108A0000|16 21|RanBP1
P09417108A0000|16 21|RanBP1
P09417108A0000|25 35|Htf9-c genes
P09417108A0000|25 35|Htf9-c genes
P09417108A0000|72 88|TATA-less promoter
P09417493A0823|75 86|inflammation
P09417493A0823|88 104|C-reactive protein
P09417493A0823|88 104|C-reactive protein
P09417493A0823|106 121|alpha 2-globuline
P09417493A0823|106 121|alpha 2-globuline
P09417493A0823|123 137|prostaglandin E2
P09417870A0105|39 52|protein kinase C
P09417870A0105|39 52|protein kinase C
P09417870A0105|55 72|long-term treatment
P09417870A0105|75 95|B16 mouse melanoma cells
P09417870A0105|100 116|phorbol dibutyrate
P09417870A0105|118 121|PDBu
P09417870A0105|132 165|cell density-dependent melanogenesis
P09417928A0980|23 49|positions +3 (His128Asn) and +2
P09417928A0980|51 59|Gln155Lys
P09417928A0980|66 79|reading helices
P09417928A0980|82 93|fingers 2 and 3
P09417941A1287|3 19|disulphide bridges
P09417941A1287|43 63|spermadhesin molecules
P09417941A1287|71 80|CUB domains
P09417941A1287|82 94|crosslink loop
P09417941A1287|95 96|LA
P09417941A1287|106 110|beta 4
P09417941A1287|114 120|loops LE
P09417941A1287|124 125|LG
P09417941A1287|124 125|LG
P09417941A1287|173 178|domain
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|14 20|tobacco
P09418040T0000|39 54|Chl D cDNA sequence
P09418040T0000|39 54|Chl D cDNA sequence
P09418040T0000|126 146|yeast two-hybrid system
P09418040T0000|170 183|enzyme activity
P09418040T0000|201 215|recombinant CHL D
P09418040T0000|212 215|CHL D
P09418040T0000|217 220|CHL H
P09418040T0000|217 220|CHL H
P09418040T0000|224 227|CHL I
P09418040T0000|224 227|CHL I
P09418057A0684|3 7|R-EST
P09418057A0684|14 29|Pto-like sequence
P09418057A0684|14 29|Pto-like sequence
P09418861A0623|32 49|cysteine-rich motif
P09418861A0623|67 80|protein kinase C
P09418861A0623|67 80|protein kinase C
P09418861A0623|84 94|n-chimaerin
P09418861A0623|84 94|n-chimaerin
P09418861A0623|99 130|putative pleckstrin homology domain
P09418861A0623|107 130|pleckstrin homology domain
P09418871A0620|21 23|DDB
P09418871A0620|21 23|DDB
P09418871A0620|27 30|E2F1
P09418871A0620|27 30|E2F1
P09418871A0620|50 81|coimmunoprecipitation experiments
P09418882A0760|40 53|epitope-tagged
P09418882A0760|63 68|Prp42p
P09418882A0760|63 68|Prp42p
P09418882A0760|92 98|U1 snRNA
P09418882A0760|92 98|U1 snRNA
P09418882A0760|103 115|yeast extracts
P09418905A1396|36 39|Grb2
P09418905A1396|36 39|Grb2
P09418905A1396|61 63|Ras
P09418905A1396|61 63|Ras
P09418905A1396|65 74|PLC-gamma1
P09418905A1396|65 74|PLC-gamma1
P09418905A1396|84 96|DAG production
P09418905A1396|110 113|EGF-
P09418905A1396|110 112|EGF
P09418905A1396|117 140|PDGF-induced S-phase entry
P09418905A1396|117 120|PDGF
P09418905A1396|144 157|gene expression
P09418905A1396|186 188|PKC
P09418905A1396|186 188|PKC
P09419415A0236|26 39|STAT activation
P09419415A0236|50 74|rodent fibroblast cell lines
P09419415A0236|106 117|oncoproteins
P09419421A0385|2 22|serum-stimulated cells
P09419421A0385|36 43|NF-Y/CBF
P09419421A0385|36 39|NF-Y
P09419421A0385|41 43|CBF
P09419421A0385|46 49|TKC1
P09419421A0385|46 49|TKC1
P09419421A0385|90 95|S phase
P09419680A1112|28 45|blood-brain barrier
P09419680A1112|90 104|single-fraction
P09419680A1112|115 131|irradiation injury
P09420219A0284|50 64|selective export
P09420219A0284|67 90|adenovirus-infected cells
P09420219A0284|112 134|human beta-actin minigene
P09420219A0284|112 134|human beta-actin minigene
P09420219A0284|155 195|glucocorticoid-inducible enhancer-promoter
P09420219A0284|155 195|glucocorticoid-inducible enhancer-promoter
P09420219A0284|198 219|mouse mammary tumor virus
P09420219A0284|242 245|left
P09420219A0284|254 268|adenovirus type 5
P09420219A0284|254 268|adenovirus type 5
P09420219A0284|270 272|Ad5
P09420219A0284|270 272|Ad5
P09420220A0070|0 40|Cell factor-mediated regulatory interactions
P09420220A0070|92 123|HCMV major immediate-early (IE) gene
P09420220A0070|92 123|HCMV major immediate-early (IE) gene
P09420220A0070|125 125|J
P09420234A0654|0 7|MpB GroEL
P09420234A0654|0 7|MpB GroEL
P09420234A0654|20 37|sequence similarity
P09420234A0654|47 66|Escherichia coli GroEL
P09420234A0654|47 61|Escherichia coli
P09420234A0654|62 66|GroEL
P09420234A0654|87 105|chaperonin-60 family
P09420234A0654|87 105|chaperonin-60 family
P09420239A1937|3 19|critical mutations
P09420239A1937|70 79|elongation
P09420239A1937|85 86|TM
P09420239A1937|85 86|TM
P09420239A1937|90 92|Nef
P09420239A1937|90 92|Nef
P09420239A1937|93 107|coding sequences
P09420239A1937|118 126|RNA splice
P09420239A1937|149 160|TATA box sites
P09420239A1937|149 160|TATA box sites
P09420239A1937|165 172|Sp1 sites
P09420239A1937|165 172|Sp1 sites
P09420239A1937|194 201|V2 region
P09420239A1937|194 195|V2
P09420239A1937|204 205|SU
P09420239A1937|204 205|SU
P09420239A1937|217 246|consensus neutralization epitope
P09420239A1937|258 283|N-linked glycosylation sites
P09420239A1937|286 287|SU
P09420251A1363|0 0|C
P09420252A0092|11 28|long terminal repeat
P09420252A0092|30 41|LTR) promoter
P09420252A0092|72 94|viral structural proteins
P09420252A0092|72 94|viral structural proteins
P09420252A0092|106 121|internal promoter
P09420252A0092|140 144|3' end
P09420252A0092|150 156|env gene
P09420252A0092|150 156|env gene
P09420252A0092|184 205|viral auxiliary proteins
P09420269A0000|3 7|5' end
P09420269A0000|13 22|genomic RNA
P09420269A0000|25 36|rubella virus
P09420269A0000|38 40|RUB
P09420269A0000|51 63|14-nucleotide
P09420269A0000|74 98|-stranded leader (ss-leader
P09420269A0000|111 132|stem-and-loop structure
P09420269A0000|134 150|5'(+)SL] (nt 15 to 65
P09420269A0000|178 182|3' end
P09420269A0000|188 202|minus-strand RNA
P09420269A0000|204 210|3'(-)SL
P09420269A0000|273 279|strands
P09420275A0682|31 41|CBF2 binding
P09420275A0682|31 34|CBF2
P09420275A0682|65 80|oligonucleotides
P09420275A0682|89 115|double transversion mutations
P09420275A0682|140 151|core sequence
P09420275A0682|162 178|flanking sequences
P09420275A1111|26 29|CBF2
P09420275A1111|26 29|CBF2
P09420275A1111|45 49|LMP-1
P09420275A1111|45 49|LMP-1
P09420275A1111|51 55|LMP-2
P09420275A1111|51 55|LMP-2
P09420275A1111|60 72|CD23 promoters
P09420275A1111|60 63|CD23
P09420671A1190|15 30|myocardial uptake
P09420671A1190|33 37|99mTc
P09420671A1190|49 62|normal subjects
P09420671A1190|66 73|patients
P09420671A1190|78 98|coronary artery disease
P09420671A1190|141 155|adenosine stress
P09421507A0000|3 17|SR protein family
P09421507A0000|3 17|SR protein family
P09421507A0000|30 69|constitutive and regulated pre-mRNA splicing
P09421507A0000|114 130|metazoan organisms
P09421508A0696|26 30|TCF11
P09421508A0696|26 30|TCF11
P09421508A0696|82 85|MafG
P09421508A0696|82 85|MafG
P09421508A0696|98 123|transient transfection assay
P09421511A0827|59 83|RNA-polymerase specificity
P09421511A0827|59 72|RNA-polymerase
P09421511A0827|86 112|telomerase RNA-gene promoters
P09421511A0827|86 112|telomerase RNA-gene promoters
P09421511A0827|167 179|telomerase RNA
P09421516A1516|0 12|Deadenylation
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|40 48|K562 cells
P09421516A1516|82 92|NIH 3T3 cells
P09421516A1516|137 151|beta-globin mRNA
P09421516A1516|137 151|beta-globin mRNA
P09421516A1516|154 162|K562 cells
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|27 50|Schizosaccharomyces pombe
P09421521T0000|63 82|endonuclease activity
P09421521T0000|88 100|CCE1 homologue
P09421521T0000|88 100|CCE1 homologue
P09421521T0000|101 104|YDC2
P09421521T0000|101 104|YDC2
P09422351A0000|0 46|Ca2+/calmodulin-dependent protein kinase II (CaMK II
P09422351A0000|0 3|Ca2+
P09422351A0000|5 39|calmodulin-dependent protein kinase II
P09422351A0000|41 46|CaMK II
P09422351A0000|66 94|serine/threonine protein kinase
P09422351A0000|66 94|serine/threonine protein kinase
P09422351A0000|108 118|ion channels
P09422351A0000|137 156|cytoskeletal proteins
P09422351A0000|169 188|transcription factors
P09422727A0196|1 62|cAMP-responsive element-like (CRE-like, TGACGTGA) promoter sequence
P09422727A0196|1 27|cAMP-responsive element-like
P09422727A0196|29 36|CRE-like
P09422727A0196|67 96|protein kinase A signaling pathway
P09422727A0196|67 80|protein kinase A
P09422727A0196|143 159|CRE binding protein
P09422727A0196|143 159|CRE binding protein
P09422727A0196|161 164|CREB
P09422727A0196|161 164|CREB
P09422727A0196|169 199|activating transcription factor-2
P09422727A0196|169 199|activating transcription factor-2
P09422727A0196|201 205|ATF-2
P09422727A0196|201 205|ATF-2
P09423123A0000|0 3|IVOX
P09423123A0000|26 48|intravascular oxygenator
P09423310A0251|0 18|Histopathologically
P09423310A0251|21 38|cystic lymphangioma
P09423310A0251|63 83|morphological features
P09423310A0251|90 117|immunohistochemical stainings
P09423310A0251|120 136|CD34 and Factor VIII
P09423310A0251|120 123|CD34
P09423310A0251|127 150|Factor VIII related antigen
P09423310A0251|187 202|endothelial cells
P09423310A0251|208 212|cysts
P09423856A1098|33 52|streptococcal strains
P09423856A1098|89 103|molecular masses
P09423856A1098|205 223|proline peptide bonds
P09423856A1098|229 238|N-terminal
P09423968A0039|143 147|"pain
P09423968A0039|239 251|early ontogeny
P09423968A0039|254 257|rats
P09424012A1774|34 41|patients
P09424012A1774|86 103|simulated isocenter
P09424012A1774|183 195|smaller errors
P09425036A0649|12 39|catalytically inactive version
P09425036A0649|45 59|Src family member
P09425036A0649|45 59|Src family member
P09425036A0649|61 63|Lck
P09425036A0649|61 63|Lck
P09425036A0649|65 82|lymphoid cell kinase
P09425036A0649|65 82|lymphoid cell kinase
P09425036A0649|122 133|Csk substrate
P09425036A0649|122 124|Csk
P09425676A0000|0 7|Neuronal
P09425676A0000|28 48|stimulus-response (S-R
P09425676A0000|46 48|S-R
P09425676A0000|64 66|S-R
P09425676A0000|117 123|monkeys
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426068A0826|3 7|c-myc
P09426068A0826|9 17|TGF-alpha
P09426068A0826|76 84|TGF-alpha
P09426068A0826|76 84|TGF-alpha
P09426068A0826|95 108|apoptotic index
P09426068A0826|133 141|apoptosis
P09426068A0826|144 162|peritumorous tissues
P09426068A0826|166 170|c-myc
P09426068A0826|171 174|HCCs
P09426143A1358|56 58|CRP
P09426143A1358|56 58|CRP
P09426143A1358|62 65|KdgR
P09426143A1358|62 65|KdgR
P09426143A1358|86 102|pectinolysis genes
P09426143A1358|86 102|pectinolysis genes
P09426143A1358|169 178|regulators
P09426143A1358|191 199|repressor
P09426143A1358|203 215|RNA polymerase
P09426143A1358|241 249|DNA region
P09426143A1358|255 265|target genes
P09426183A0000|13 31|Rel/NF-kappaB family
P09426183A0000|13 15|Rel
P09426183A0000|17 25|NF-kappaB
P09426239A0386|3 11|cglIM gene
P09426239A0386|3 11|cglIM gene
P09426239A0386|97 114|restriction enzymes
P09426595T0000|0 28|Lysine-ketoglutarate reductase
P09426595T0000|0 28|Lysine-ketoglutarate reductase
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|61 79|Arabidopsis thaliana
P09426595T0000|81 98|nucleotide sequence
P09426907A0391|43 56|new formulation
P09426907A0391|59 76|silver sulfadiazine
P09426907A0391|80 94|water soluble gel
P09426907A0391|96 107|poloxamer 188
P09426958A0110|27 42|full-length clone
P09426958A0110|51 55|CO-Ag
P09426958A0110|51 55|CO-Ag
P09426958A0110|61 73|bovine corneal
P09426958A0110|74 84|cDNA library
P09426958A0110|108 122|Escherichia coli
P09426958A0110|108 122|Escherichia coli
P09426958A0110|124 129|E. coli
P09426958A0110|124 129|E. coli
P09427544A0000|3 9|pel gene
P09427544A0000|3 9|pel gene
P09427544A0000|16 26|Amycolata sp
P09427544A0000|37 48|pectate lyase
P09427544A0000|37 48|pectate lyase
P09427544A0000|50 58|EC 4.2.2.2
P09427544A0000|50 51|EC
P09427544A0000|91 107|genomic DNA library
P09427544A0000|110 134|Streptomyces lividans TK24.
P09427551A0501|18 22|exons
P09427551A0501|43 49|introns
P09427551A0501|74 90|murine chromosome 2
P09427627A0802|2 15|Xenopus embryos
P09427627A0802|20 48|engineered PDGF receptor protein
P09427627A0802|30 48|PDGF receptor protein
P09427627A0802|70 77|mesoderm
P09427627A0802|82 92|animal-pole
P09427627A0802|105 126|FK1012-dependent manner
P09427627A0802|105 110|FK1012
P09427627A0930|1 16|cytosolic variant
P09427627A0930|38 66|efficient transphosphorylation
P09427627A0930|104 110|p70(S6k
P09427627A0930|104 106|p70
P09427627A0930|108 110|S6k
P09427627A0930|114 122|MAP kinase
P09427627A0930|114 122|MAP kinase
P09427627A0930|145 150|FK1012
P09427627T0000|0 20|Small-molecule control
P09427627T0000|0 13|Small-molecule
P09427627T0000|23 29|insulin
P09427627T0000|23 29|insulin
P09427627T0000|33 53|PDGF receptor signaling
P09427627T0000|33 44|PDGF receptor
P09427627T0000|66 83|membrane attachment
P09427844A0739|14 24|inactive dAK
P09427844A0739|22 31|dAK subunit
P09427844A0739|76 78|dGK
P09427844A0739|76 78|dGK
P09427844A0739|81 94|dCK subunit and 2
P09427844A0739|81 90|dCK subunit
P09427844A0739|141 144|dGuo
P09427844A0739|141 144|dGuo
P09427844A0739|147 150|dCyd
P09427844A0739|147 150|dCyd
P09427844A0739|161 175|opposing subunit
P09428389A1805|29 40|bicalutamide
P09428389A1805|94 99|LHRH-A
P09428389A1805|94 97|LHRH
P09428389A1805|99 99|A
P09428389A1805|111 127|serum testosterone
P09428389A1805|145 156|bicalutamide
P09428787A0138|37 42|12.5 kb
P09428787A0138|48 64|5'-flanking region
P09428787A0138|85 108|p69/71 2-5A synthetase gene
P09428787A0138|85 104|p69/71 2-5A synthetase
P09428799A0897|44 53|human genes
P09428799A0897|44 53|human genes
P09428799A0897|62 81|mitochondrial enzymes
P09428799A0897|141 147|P450scc
P09428799A0897|141 147|P450scc
P09429913A0528|115 118|EMDR
P09429913A0528|121 135|eating disorders
P09429913A0528|150 168|psychiatric disorder
P09430461A0742|39 50|BMIPP imaging
P09430461A0742|63 70|anterior
P09430461A0742|77 92|inferior infarcts
P09430461A0742|247 254|patients
P09430461A0742|278 289|BMIPP imaging
P09430461A0742|377 389|subacute phase
P09430461A0742|445 469|acute myocardial infarction
P09430661A0796|0 22|Transient overexpression
P09430661A0796|25 50|mutant EphB1 receptors (Y594F
P09430661A0796|25 44|mutant EphB1 receptors
P09430661A0796|59 72|Nck recruitment
P09430661A0796|59 61|Nck
P09430661A0796|75 79|EphB1
P09430661A0796|75 79|EphB1
P09430661A0796|91 113|downstream JNK activation
P09430661A0796|101 103|JNK
P09430661A0796|125 147|cell attachment responses
P09430668A0172a|14 28|HMG-CoA synthase
P09430668A0172a|14 28|HMG-CoA synthase
P09430668A0172a|40 51|binding sites
P09430668A0172a|58 96|sterol regulatory element-binding proteins
P09430668A0172a|58 96|sterol regulatory element-binding proteins
P09430668A0172a|98 103|SREBPs
P09430668A0172a|98 103|SREBPs
P09430730A0374|0 0|S
P09431812A0576|21 22|Hh
P09431812A0576|21 22|Hh
P09431812A0576|26 32|Patched
P09431812A0576|26 32|Patched
P09431812A0576|34 36|Ptc
P09431812A0576|34 36|Ptc
P09431812A0576|53 54|Ci
P09431812A0576|87 123|Ci-dependent transcriptional activation
P09431812A0576|87 88|Ci
P09431812A0576|126 132|S2 cells
P09431828A1472|30 45|cyclosporine DR/C
P09431828A1472|62 64|h-1
P09431828A1472|77 79|h-1
P09432752A0109|0 7|Patients
P09432752A0109|98 102|right
P09434160A0767|7 13|PTPases
P09434160A0767|7 13|PTPases
P09434160A0767|42 72|5-FU-treated bone marrow stem cells
P09434160A2078|12 16|PTPRO
P09434160A2078|12 16|PTPRO
P09434160A2078|34 58|human CD34+ bone marrow cells
P09434160A2078|39 43|CD34+
P09434160A2078|74 97|murine primitive stem cells
P09434185A0902|17 25|SPP1 genes
P09434185A0902|17 25|SPP1 genes
P09434185A0902|66 70|phage
P09434185A0902|148 153|E. coli
P09434185A0902|154 177|double-stranded DNA phages
P09434979A0790|33 52|primary photon fluence
P09434979A0790|57 73|extra-focal photon
P09434979A0790|88 104|primary collimator
P09434979A0790|111 126|flattening filter
P09434979A0790|184 199|flattening filter
P09435056A0128|27 43|pediocin AcH (Lys+1
P09435056A0128|27 37|pediocin AcH
P09435056A0128|39 43|Lys+1
P09435056A0128|46 48|Cys
P09435056A0128|70 87|E. coli sec machinery
P09435056A0128|146 157|COOH terminus
P09435056A0128|163 200|secretory protein maltose-binding protein
P09435056A0128|179 200|maltose-binding protein
P09435056A0128|202 204|MBP
P09435056A0128|202 204|MBP
P09435116A0437|0 6|Isomers
P09435116A0437|49 85|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|8 12|RAD17
P09435789A0961a|8 12|RAD17
P09435789A0961a|14 18|RAD24
P09435789A0961a|14 18|RAD24
P09435789A0961a|22 25|MEC3
P09435789A0961a|22 25|MEC3
P09435789A0961a|43 57|cell cycle arrest
P09435789A0961a|62 67|S phase
P09435789A0961a|81 91|hydroxyurea
P09435789A0961a|93 94|HU
P09435789A0961a|129 133|yeast
P09435789A0961a|159 160|HU
P09435789A0961a|206 207|HU
P09435789A0961a|216 224|DNA damage
P09435806T0001|0 12|Clinical value
P09435806T0001|18 27|estimation
P09435806T0001|46 65|primary ovarian cancer
P09435806T0001|79 83|CA125
P09435806T0001|79 83|CA125
P09436657A0303|56 69|carcinogenesis
P09436657A0303|97 119|traditional" risk factors
P09436706A0168|38 57|sperm injection cycles
P09436706A0168|62 88|thawed epididymal spermatozoa
P09436706A0168|104 122|pharmacist's mistake
P09436706A0168|124 141|ovarian stimulation
P09436706A0168|182 218|gonadotrophin-releasing hormone agonist
P09436706A0168|182 211|gonadotrophin-releasing hormone
P09436706A0168|220 234|leuprolide depot
P09436706A0168|239 252|gonadotrophins
P09436795A0350|0 37|Protein C deficiency or protein S deficiency
P09436795A0350|0 7|Protein C
P09436795A0350|20 27|protein S
P09436795A0350|77 84|patients
P09436795A0350|96 103|patients
P09436795A0350|128 135|children
P09436989A1011|57 63|mitosis
P09436989A1011|65 68|MOB1
P09436989A1011|65 68|MOB1
P09436989A1011|135 160|spindle pole body duplication
P09437001A0769|27 31|Der3p
P09437001A0769|27 31|Der3p
P09437001A0769|43 55|sec61-2 strain
P09437001A0769|43 49|sec61-2
P09437001A0769|61 81|permissive temperature
P09438165A0405|6 13|baseline
P09438165A0405|21 28|PC levels
P09438165A0405|64 71|patients
P09438165A0405|109 110|40
P09438427A0727|22 31|CE2 element
P09438427A0727|44 58|Hoxa1 expression
P09438427A0727|44 48|Hoxa1
P09438427A0727|66 79|transgenic mice
P09438427A0727|106 140|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|106 140|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|167 176|CE2 element
P09438427T0000|23 29|element
P09438427T0000|44 49|somite
P09438427T0000|61 71|mesenchymal
P09438427T0000|87 95|Hoxa1 gene
P09438427T0000|87 95|Hoxa1 gene
P09440166A0857|17 34|cDNA insert sequence
P09440166A0857|72 75|mRNA
P09440166A0857|89 102|212 nucleotides
P09440166A0857|108 127|5' untranslated region
P09440166A0857|131 141|nucleotides
P09440166A0857|147 166|3' untranslated region
P09440166A0857|171 174|poly
P09440166A0857|176 181|A) tail
P09440616A0422|10 29|46 phase III activities
P09441664A0377|27 59|liver-enriched transcription factor
P09441664A0377|61 65|HNF-6
P09441664A0377|61 65|HNF-6
P09441664A0377|85 101|HNF-3 beta promoter
P09441664A0377|85 93|HNF-3 beta
P09441664A0377|130 145|regulatory region
P09441664A0377|156 179|hepatocyte-specific genes
P09441746A0546|1 9|cDNA clone
P09441746A0546|38 54|GHS-R-related gene
P09441746A0546|38 54|GHS-R-related gene
P09441746A0546|56 60|GPR39
P09441746A0546|56 60|GPR39
P09442024A0236|0 0|P
P09442024A0708|1 14|hybridoma clone
P09442024A0708|16 18|7H1
P09442024A0708|49 94|CEMLAI/NP and human embryonic fibroblasts MRC5 cells
P09442024A0708|121 123|P47
P09442024A0708|121 123|P47
P09442024A0708|144 156|Jacalin lectin
P09442024A0708|144 156|Jacalin lectin
P09442024A0708|169 177|O-glycans
P09442031A0586|28 37|estimation
P09442031A0586|52 73|deglycosylated A subunit
P09442031A0586|93 133|C-terminal truncated TSHR ectodomain variants
P09442031A0586|93 115|C-terminal truncated TSHR
P09442031A0586|149 153|Site 1
P09442072A0716|7 24|DNase I footprinting
P09442072A0716|7 12|DNase I
P09442072A0716|30 49|200-bp proximal region
P09442072A0716|55 62|promoter
P09442072A0716|68 84|murine Hepa 1-6 cell
P09442072A0716|68 80|murine Hepa 1-6
P09442072A0716|85 98|nuclear extract
P09442072A0716|161 174|murine fVII gene
P09442072A0716|161 174|murine fVII gene
P09442072A0716|190 201|liver factors
P09442080A0856|1 22|reciprocal binding assay
P09442080A0856|28 36|IM-9 cells
P09442080A0856|48 52|SHP-1
P09442080A0856|48 52|SHP-1
P09442080A0856|56 60|SHP-2
P09442080A0856|56 60|SHP-2
P09442080A0856|90 94|SHP-2
P09442080A0856|90 94|SHP-2
P09442080A0856|102 106|SHP-1
P09442080A0856|102 106|SHP-1
P09442080A0856|113 136|glutathione S-transferase
P09442080A0856|113 136|glutathione S-transferase
P09442080A0856|156 190|GHR cytoplasmic domain residues 485-620
P09442080A0856|226 248|tyrosine-phosphorylated
P09442172A0908|14 21|basal FSH
P09442172A0908|19 21|FSH
P09442172A0908|25 27|age
P09442172A0908|73 85|gonadotrophin
P09442172A0908|128 140|pregnancy rate
P09443948A0000|39 75|enzymatic immunohistochemical technique
P09443948A0000|77 79|EIT
P09443948A0000|107 125|human trichinellosis
P09443948A0000|132 161|indirect immunofluorescence test
P09443948A0000|163 165|IIF
P09443948A0000|177 180|sera
P09443948A0000|196 214|human trichinellosis
P09443972A1145|19 22|GKLF
P09443972A1145|19 22|GKLF
P09443972A1145|26 61|sequence-specific transcription factor
P09443972A1145|102 116|endogenous genes
P09443972A1145|102 116|endogenous genes
P09443973A1028|0 3|CES4
P09443973A1028|0 3|CES4
P09443973A1028|7 22|multicopy plasmid
P09443973A1028|42 50|tif1-A79V
P09443973A1028|42 50|tif1-A79V
P09443978A0262|18 30|cultured cells
P09443978A0262|35 64|Drosophila melanogaster human Sp1
P09443978A0262|62 64|Sp1
P09443978A0262|102 119|synthetic promoters
P09443978A0262|130 138|TATA boxes
P09443978A0262|172 180|initiator
P09443978A0262|191 197|TATA box
P09444316A0388|10 22|clinical signs
P09444316A0388|35 50|systemic toxicity
P09444316A0388|68 69|F0
P09444316A0388|68 69|F0
P09444316A0388|73 81|F1 animals
P09444316A0388|90 92|sex
P09445056A0215|10 47|mutation-directed chemical cross-linking
P09445056A0215|52 81|bis(sulfosuccinimidyl)suberate
P09445056A0215|83 85|BS3
P09445056A0215|120 131|gp41 oligomer
P09445056A0215|120 123|gp41
P09445488A0230|23 38|USH1C disease gene
P09445488A0230|98 108|chromosomes
P09445488A0230|110 113|YACs
P09445488A0230|134 136|STS
P09445488A0230|154 173|Alu-PCR hybridization
P09445488A0230|154 156|Alu
P09445488A1169|0 17|PowerBLAST analysis
P09445488A1169|63 66|ESTs
P09445488A1169|83 85|BIR
P09445488A1169|83 85|BIR
P09445488A1169|87 90|SUR1
P09445488A1169|87 90|SUR1
P09445488A1169|159 166|gene NEFA
P09445488A1169|168 207|DNA binding/EF hand/acidic amino-acid-rich)
P09445488A1169|168 180|DNA binding/EF
P09446600A0260|24 41|beta-galactosidase
P09446600A0260|24 41|beta-galactosidase
P09446600A0260|45 58|full-length Ahr
P09446600A0260|56 58|Ahr
P09446600A0260|78 86|cytoplasm
P09446600A0260|92 98|nucleus
P09446600A0260|102 123|ligand-dependent manner
P09446616A0780|0 13|Reconstitution
P09446616A0780|16 20|Raf-1
P09446616A0780|16 20|Raf-1
P09446616A0780|60 63|Jak1
P09446616A0780|60 63|Jak1
P09446616A0780|70 78|cell lines
P09446815A1021|49 62|-1782 to -1295 bp
P09447917A0000|15 21|Geisler
P09447962A0452|20 25|rhis4l
P09447962A0452|20 25|rhis4l
P09447962A1027|46 49|XRN1
P09447962A1027|46 49|XRN1
P09447962A1027|64 68|5'-3'
P09447962A1027|98 117|extragenic suppressor
P09447962A1027|145 153|rhis4 mRNA
P09447962A1027|145 153|rhis4 mRNA
P09447962A1027|182 203|steady-state mRNA levels
P09447962A1027|217 233|wild-type HIS4 mRNA
P09447962A1027|226 238|HIS4 mRNA level
P09447963A0223|0 3|Sip1
P09447963A0223|0 3|Sip1
P09447963A0223|54 57|SC35
P09447963A0223|54 57|SC35
P09447963A0223|79 86|SR family
P09447963A0223|79 86|SR family
P09447973A0168|63 67|mSos1
P09447973A0168|63 67|mSos1
P09447973A0168|69 75|MyrSos1
P09447973A0168|69 75|MyrSos1
P09447973A0168|102 112|NIH 3T3 cells
P09447973A0168|129 141|mSos C terminus
P09447973A0168|129 141|mSos C terminus
P09447973A0168|143 156|MyrSos1-deltaC
P09447973A0168|143 156|MyrSos1-deltaC
P09447979A1430|4 12|mutations
P09447979A1430|35 51|dominant phenotype
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447979A1430|104 107|GNEF
P09447979A1430|104 107|GNEF
P09447994A0000|34 57|upstream regulatory region
P09447994A0000|60 64|c-fos
P09447994A0000|60 64|c-fos
P09447994A0000|79 96|cis-acting elements
P09447994A0000|106 136|cyclic AMP (cAMP) response elements
P09447994A0000|106 114|cyclic AMP
P09447994A0000|116 119|cAMP
P09447994A0000|138 141|CREs
P09447994A0000|138 141|CREs
P09447994A0000|161 178|c-fos transcription
P09447994A0000|161 165|c-fos
P09447994A0000|201 220|extracellular stimuli
P09448268A0186|12 18|a kinase
P09448268A0186|13 18|kinase
P09448268A0186|20 22|Nlk
P09448268A0186|20 22|Nlk
P09448268A0186|31 43|murine homolog
P09448268A0186|49 71|Drosophila nemo (nmo) gene
P09448268A0186|49 62|Drosophila nemo
P09448268A0186|64 66|nmo
P09448574A0964|30 32|FDG
P09448574A0964|48 52|RACLO
P09448574A0964|87 102|striatal function
P09448574A0964|127 134|patients
P09448574A0964|139 159|multiple system atrophy
P09449018T0000|0 19|Childhood misbehavior
P09450932A0142|56 67|DNA structure
P09450932A0142|110 121|DNA synthesis
P09451003A0894|5 21|Esigma54 promoters
P09451003A0894|5 21|Esigma54 promoters
P09451003A0894|37 39|CRP
P09451003A0894|37 39|CRP
P09451003A0894|60 76|sigma54 activators
P09451003A0894|60 76|sigma54 activators
P09451003A0894|140 147|Esigma54
P09451003A0894|140 147|Esigma54
P09451003A0894|154 168|CRP-cAMP complex
P09451003A0894|154 156|CRP
P09451016A1037|0 40|GlcNAc- and GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|65 76|S.cerevisiae
P09451016A1037|107 124|recombinant plasmid
P09451016A1037|135 141|glucose
P09451016A1037|157 169|transcription
P09451016A1037|175 188|endogenous gene
P09451016A1037|175 188|endogenous gene
P09451857T0001|15 27|tissue lesions
P09451857T0001|72 85|creatine kinase
P09451857T0001|72 85|creatine kinase
P09451857T0001|88 92|blood
P09452421A1042|0 9|Antibodies
P09452421A1042|23 31|GST mSH2-B
P09452421A1042|23 31|GST mSH2-B
P09452421A1042|43 57|cellular protein
P09452421A1042|60 64|92 kDa
P09452421A1042|100 102|Tyr
P09452444A0000|0 12|Interleukin-6
P09452444A0000|0 12|Interleukin-6
P09452444A0000|14 17|IL-6
P09452444A0000|14 17|IL-6
P09452444A0000|22 40|pleiotropic cytokine
P09452444A0000|59 88|inflammatory and immune responses
P09452444A0000|90 108|acute phase reactions
P09452444A0000|113 125|hematopoiesis
P09452444A0450|58 78|human IL-6 gene promoter
P09452444A0450|58 78|human IL-6 gene promoter
P09452444A0450|88 100|a reporter gene
P09452444A0450|89 100|reporter gene
P09452444A0450|134 153|transcription factors
P09453537A0863|28 36|CCAATC box
P09453537A0863|69 75|GC boxes
P09453537A0863|102 104|SP1
P09453537A0863|102 104|SP1
P09453689A0000|32 39|perianal
P09453689A0000|41 44|S4-5
P09453689A0000|41 44|S4-5
P09453689A0000|59 61|PPS
P09453689A0000|66 80|bulbocavernosus
P09453689A0000|82 92|S2-4) reflex
P09453689A0000|82 85|S2-4
P09453689A0000|94 96|BCR
P09453689A0000|94 96|BCR
P09453689A0000|110 119|spinal cord
P09453689A0000|127 129|SCI
P09453689A0000|146 152|bladder
P09454719A0181|23 43|retroviral transcripts
P09454719A0181|49 65|3' LTR R/U5 junction
P09454719A0181|100 126|AAUAAA polyadenylation signal
P09454719A0181|181 195|signal sequences
P09454719A0181|230 245|retroviral vector
P09454735A1782|11 22|MEK inhibitor
P09454735A1782|11 13|MEK
P09454735A1782|23 29|PD98059
P09454735A1782|39 60|EGF-induced mitogenesis
P09454735A1782|39 41|EGF
P09454735A1782|64 87|MAP kinase phosphorylation
P09454735A1782|64 72|MAP kinase
P09454735A1782|100 134|EGF-induced focal adhesion disassembly
P09454735A1782|100 102|EGF
P09454735A1782|138 149|cell motility
P09455695A0762|0 8|ALT levels
P09455695A0762|0 2|ALT
P09455695A0762|11 20|responders
P09455695A0762|40 48|AST levels
P09455695A0762|40 42|AST
P09455695A0762|79 86|vitamin E
P09456312A1064|16 34|COOH-terminal domain
P09456312A1064|16 34|COOH-terminal domain
P09456312A1064|37 43|RanGAP1
P09456312A1064|37 43|RanGAP1
P09456312A1064|65 89|nuclear localization signal
P09458021A1373|20 22|MMF
P09458021A1373|32 40|AZA groups
P09458030A0192|43 45|MMF
P09458030A0192|48 74|in vivo bone mineral metabolism
P09459241A0707|0 3|Pao2
P09459241A0707|24 29|5.6 kPa
P09459241A0707|60 62|130
P09459685T0001|0 20|Typical configurations
P09459685T0001|23 47|psychosocial stress factors
P09459685T0001|76 83|children
P09459685T0001|87 97|adolescents
P09459835A0297|0 7|Nine cats
P09459835A0297|16 19|PMEA
P09459835A0297|38 47|body weight
P09459835A0297|53 56|cats
P09459835A0297|65 69|FPMPA
P09460171T0000|12 25|thyroid hormone
P09460171T0000|82 105|thyroid hormone disruptors
P09461594A0000|36 53|DT40 lymphoma B cells
P09461594A0000|65 88|electromagnetic field (EMF
P09461594A0000|100 133|tyrosine kinase-dependent activation
P09461594A0000|100 113|tyrosine kinase
P09461594A0000|136 155|phospholipase Cgamma2
P09461594A0000|136 155|phospholipase Cgamma2
P09461594A0000|157 166|PLC-gamma2
P09461594A0000|157 166|PLC-gamma2
P09461594A0000|186 213|inositol phospholipid turnover
P09463380A1050|9 15|xTAK1KN
P09463380A1050|9 15|xTAK1KN
P09463380A1050|41 55|ventral mesoderm
P09463380A1050|76 80|Smad1
P09463380A1050|76 80|Smad1
P09463560A0124|30 37|patients
P09463964A0243|3 7|assay
P09463964A0243|57 74|monoclonal antibody
P09463991T0000|0 7|Training
P09463991T0000|11 15|audit
P09464248A0289|1 16|canonical TATA box
P09464525T0000|31 55|recombinant single-chain Fv
P09464525T0000|42 55|single-chain Fv
P09464525T0000|59 69|Fv fragments
P09464525T0000|59 69|Fv fragments
P09464525T0000|87 105|catalytic antibodies
P09465035A1032|1 17|putative inhibitor
P09465035A1032|9 19|inhibitor(s
P09465035A1032|73 79|L(alpha
P09465035A1032|75 88|alpha) activity
P09465783A0449|0 18|Platelet aggregation
P09465783A0449|43 50|collagen
P09465783A0449|94 96|ASA
P09466267A1192|5 15|himA mutants
P09466267A1192|5 15|himA mutants
P09466267A1192|32 34|IHF
P09466267A1192|32 34|IHF
P09466267A1192|50 78|molybdate-dependent regulation
P09466267A1192|81 89|dmsA-lacZ
P09466267A1192|81 84|dmsA
P09466267A1192|86 89|lacZ
P09466931T0000|18 43|Drosophila nuclear receptors
P09466931T0000|18 27|Drosophila
P09466931T0000|28 43|nuclear receptors
P09466931T0000|49 74|promiscuous response element
P09466931T0000|80 83|ng-1
P09466931T0000|80 83|ng-1
P09466931T0000|87 104|ng-2 intermolt genes
P09467044A0973|3 24|ipsilateral breast tumor
P09467044A0973|56 59|PALP
P09467044A0973|63 67|MGDET
P09467707T0000|0 17|Sibling aggregation
P09467707T0000|27 60|high-density lipoprotein cholesterol
P09467707T0000|27 49|high-density lipoprotein
P09467707T0000|50 60|cholesterol
P09467707T0000|64 91|apolipoproteins B and A-I levels
P09467707T0000|64 79|apolipoproteins B
P09467707T0000|83 85|A-I
P09467707T0000|94 98|black
P09467707T0000|102 114|white children
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|75 79|18-19
P09467900A0701|80 96|amino acid residues
P09467900A0701|106 112|X domain
P09467900A0701|106 112|X domain
P09467900A0701|131 140|N-terminus
P09467900A0701|179 198|Ca(2+)-binding domain
P09467900A0701|179 198|Ca(2+)-binding domain
P09467955A0468|45 60|PEA3 binding sites
P09467955A0468|45 48|PEA3
P09467955A0468|66 77|PEA3 promoter
P09467955A0468|66 77|PEA3 promoter
P09467955A0468|97 100|PEA3
P09467955A0468|97 100|PEA3
P09467955A0468|120 127|promoter
P09468386A0594|0 4|Pet-1
P09468386A0594|0 4|Pet-1
P09468386A0594|27 49|PEA3 ETS DNA-binding motif
P09468386A0594|27 30|PEA3
P09468386A0594|31 49|ETS DNA-binding motif
P09468386A0594|64 76|transcription
P09468386A0594|79 105|synthetic promoter constructs
P09468386A0594|109 131|sequence-specific manner
P09468509A0463|21 29|F2771 cDNA
P09468509A0463|21 29|F2771 cDNA
P09468509A0463|43 50|COS cells
P09468509A0463|67 75|cytoplasm
P09468514A1065|0 15|Northern analysis
P09468514A1065|81 85|heart
P09468515A0621|27 40|promoter region
P09468515A0621|78 92|SF-1 binding site
P09468515A0621|80 92|-1 binding site
P09468515A0621|137 140|SF-1
P09468515A0621|137 140|SF-1
P09469415A1337|18 23|beta 2m
P09469415A1337|18 23|beta 2m
P09469415A1337|46 52|peptide
P09469415A1337|144 171|epitope-specific CTL responses
P09469415A1337|219 238|epitope-linked beta 2m
P09469415A1337|233 238|beta 2m
P09469820A0151|3 7|mRNAs
P09469820A0151|15 19|genes
P09469820A0151|43 50|YAP1 uORF
P09469820A0151|47 50|uORF
P09469820A0151|59 67|YAP2 uORF1
P09469820A0151|59 67|YAP2 uORF1
P09469820A0151|71 75|uORF2
P09469820A0151|85 101|open reading frames
P09469820A0151|103 125|uORF-mediated modulation
P09469820A0151|128 149|post-termination events
P09469820A0151|155 175|5'-untranslated region
P09469820A0151|177 182|5'-UTR
P09469820A0151|239 242|mRNA
P09469833A0533|55 69|deletion mutants
P09469833A0533|75 87|160 bp sequence
P09469933A1060|25 29|brain
P09469933A1060|44 51|CLIP-170
P09469933A1060|44 47|CLIP
P09469933A1060|78 83|Restin
P09469933A1060|78 83|Restin
P09471984A0000|11 19|Chemicals
P09471984A0000|66 90|allergic contact dermatitis
P09472038T0000|12 23|polarization
P09472038T0000|26 31|T cells
P09472038T0000|61 108|tyrosine-based activation motif-dependent mechanism
P09472608A0253|33 51|cellular protein YB-1
P09472608A0253|33 47|cellular protein
P09472608A0253|48 51|YB-1
P09472608A0253|62 74|transcription
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|96 118|human astrocytic cell line
P09472608A0253|120 125|U-87MG
P09472608A0253|137 144|cell line
P09472608A0253|146 152|SK-N-MC
P09472608A0253|146 152|SK-N-MC
P09472608A0253|157 169|lymphoid cells
P09472608A0253|171 176|Jurkat
P09472608A0253|180 196|transfection assay
P09472616A1004|48 48|B
P09472616A1004|52 52|C
P09472616A1004|55 57|VP7
P09472616A1004|55 57|VP7
P09472616A1004|86 105|phylogenetic lineages
P09473040A1303a|9 16|alcR gene
P09473040A1303a|9 16|alcR gene
P09473040A1303b|9 16|alcR gene
P09473040A1303b|9 16|alcR gene
P09473483A0953|60 82|trans-dominant Rev mutant
P09473483A0953|66 82|dominant Rev mutant
P09473483A0953|127 131|HIV-I
P09473483A0953|171 175|HIV-I
P09473483A0953|171 175|HIV-I
P09473483A0953|179 184|HTLV-1
P09473483A0953|179 184|HTLV-1
P09473755A0318|50 51|St
P09474001A0825|14 16|SPs
P09474001A0825|82 89|patients
P09474001A0825|128 138|normal MMFCV
P09474001A0825|144 144|9
P09474001A0825|154 155|SP
P09474648A0298|13 19|P-SAECG
P09474648A0298|51 58|patients
P09474648A0298|63 65|Paf
P09474648A0298|63 65|Paf
P09474648A0298|71 78|controls
P09475378A1449|11 54|reverse transcription-polymerase chain reaction
P09475378A1449|58 69|HPLC analysis
P09475378A1449|80 90|RUSH-1alpha
P09475378A1449|80 90|RUSH-1alpha
P09475378A1449|96 130|progesterone-dependent splice variant
P09475724T0000|0 3|TOR2
P09475724T0000|0 3|TOR2
P09475724T0000|63 85|Saccharomyces cerevisiae
P09475898T0000|0 25|Transcervical amnioinfusion
P09476399A0141|0 6|SETTING
P09476520A1326|14 35|bimolecular interaction
P09476520A1326|98 107|antibodies
P09476520A1326|114 120|hybrids
P09476520A1326|163 189|conformational heterogeneity
P09477316A0140|38 53|Hox gene induction
P09477316A0140|38 44|Hox gene
P09477316A0140|81 96|Hox gene regulator
P09477316A0140|81 96|Hox gene regulator
P09477316A0140|101 132|leucine zipper transcription factor
P09477316A0140|133 139|MafB/Kr
P09477316A0140|133 136|MafB
P09477316A0140|138 139|Kr
P09477316A0140|180 199|environmental signals
P09478921A0126|0 9|Substrates
P09478921A0126|13 24|p210(bcr-abl
P09478921A0126|13 16|p210
P09478921A0126|18 20|bcr
P09478921A0126|22 24|abl
P09478921A0126|66 68|CML
P09478971A1896|0 17|Reporter constructs
P09478971A1896|29 42|parallel manner
P09478971A1896|72 74|AhR
P09478971A1896|72 74|AhR
P09478971A1896|97 118|TCDD-induced expression
P09478971A1896|121 126|Cyp1B1
P09478971A1896|121 126|Cyp1B1
P09478971A1896|134 150|embryo fibroblasts
P09478976A0718|70 93|transcriptional start site
P09478976A0718|95 100|+1/+47
P09478976A0718|117 119|OSM
P09478976T0000|0 10|Oncostatin M
P09478976T0000|21 25|c-Fos
P09478976T0000|21 25|c-Fos
P09478976T0000|33 70|transcriptionally responsive AP-1 element
P09478976T0000|60 70|AP-1 element
P09478976T0000|80 123|tissue inhibitor of metalloproteinase-1 promoter
P09478976T0000|80 115|tissue inhibitor of metalloproteinase-1
P09479498A0000|18 37|human RING-finger gene
P09479498A0000|18 37|human RING-finger gene
P09479498A0000|39 42|RNF4
P09479498A0000|39 42|RNF4
P09479498A0000|56 76|190-amino-acid protein
P09480831A0272|35 55|human AM gene expression
P09480831A0272|35 45|human AM gene
P09480831A0272|77 93|5'-flanking region
P09480831A0272|96 101|AM gene
P09480831A0272|96 101|AM gene
P09480831A0272|115 141|human aortic endothelial cells
P09480831A0272|143 146|HAEC
P09480843A0848|3 21|COOH-terminal region
P09480843A0848|47 67|fifteen triplet repeats
P09480843A0848|69 71|GCT
P09480843A0848|73 79|alanine
P09480843A0848|83 100|nucleotide 465 to 509
P09480843A0848|143 150|rat RL14.
P09480843A0848|143 149|rat RL14
P09480929T0000|7 30|FasR ligand-binding domain
P09480929T0000|7 10|FasR
P09480929T0000|54 78|active fusion and non-fusion
P09480929T0000|79 97|recombinant proteins
P09480929T0000|106 133|baculovirus/insect cell system
P09481826T0000|9 26|fatty liver syndrome
P09481826T0000|30 39|Jersey herd
P09481826T0000|51 54|diet
P09481826T0000|66 76|recombinant
P09481826T0000|77 95|bovine somatotrophin
P09481826T0000|83 95|somatotrophin
P09482107A0551|3 28|inhibition of focus formation
P09482107A0551|52 54|C3G
P09482107A0551|52 54|C3G
P09482107A0551|110 117|C3G cells
P09482107A0551|110 112|C3G
P09482107A0551|158 181|untransfected NIH3T3 cells
P09482107A0551|204 216|plasmid vector
P09482902A0423|0 3|C.D2
P09482902A0423|0 0|C
P09482902A0423|2 8|D2-Chr 4
P09482902A0423|9 23|congenic strains
P09482902A0423|33 44|DBA/2 alleles
P09482902A0423|62 71|Pctr1 locus
P09482902A0423|62 71|Pctr1 locus
P09482902A0423|81 103|DBA/2 "resistant" alleles
P09482902A0423|109 117|CDK4/CDK6
P09482902A0423|109 112|CDK4
P09482902A0423|114 117|CDK6
P09482902A0423|128 130|p16
P09482902A0423|128 130|p16
P09482902A0423|134 136|p15
P09482902A0423|134 136|p15
P09482902A0942|14 22|wild-type
P09482902A0942|14 22|wild-type
P09482902A0942|24 28|DBA/2
P09482902A0942|24 28|DBA/2
P09482902A0942|30 32|p16
P09482902A0942|30 32|p16
P09482902A0942|38 42|A134C
P09482902A0942|46 50|G232A
P09482902A0942|51 56|BALB/c
P09482902A0942|56 73|c-specific variants
P09482902A0942|76 78|p16
P09482902A0942|76 78|p16
P09482902A0942|130 142|cyclin D2/CDK4
P09482902A0942|130 137|cyclin D2
P09482902A0942|139 142|CDK4
P09482902A0942|145 156|kinase assays
P09482902A0942|161 181|retinoblastoma protein
P09482902A0942|161 181|retinoblastoma protein
P09482902A0942|216 221|allele
P09482902A0942|270 279|BALB/c mice
P09482902A0942|283 303|plasmacytoma induction
P09482902A0942|311 319|p16(INK4a
P09482902A0942|311 313|p16
P09482902A0942|315 319|INK4a
P09482902A0942|345 354|Pctr1 locus
P09482902A0942|345 354|Pctr1 locus
P09483596A0626|36 55|intubating conditions
P09483596A0626|93 110|suxamethonium group
P09483596A0626|136 150|rocuronium group
P09484463T0000|38 58|auxin-binding proteins
P09484463T0000|38 58|auxin-binding proteins
P09484463T0000|63 69|tobacco
P09484781A1233|33 34|D3
P09484781A1233|90 96|PKB/Akt
P09484781A1233|90 92|PKB
P09484781A1233|94 96|Akt
P09485308A1165|3 11|FMN moiety
P09485308A1165|21 28|[3Fe-4S]
P09485790T0000|6 22|Bell Memorial Award
P09486035A0051|101 109|blindness
P09486531A0638|6 18|organogenesis
P09486531A0638|20 24|HFH-8
P09486531A0638|20 24|HFH-8
P09486531A0638|47 64|splanchnic mesoderm
P09486531A0638|87 97|gut endoderm
P09486531A0638|116 137|mesenchymal-epithelial
P09486531A0638|149 171|lung and gut morphogenesis
P09486890A0234|61 69|carcinoma
P09487130A0383|14 27|telomere length
P09487130A0383|69 72|Cdc2
P09487130A0383|69 72|Cdc2
P09487130A0383|90 105|DNA repair mutants
P09487841A0132|3 6|ESEM
P09487841A0132|67 95|eliminating artifactual changes
P09488441A0615|0 2|Sp1
P09488441A0615|0 2|Sp1
P09488441A0615|34 66|immunoglobulin kappa-chain enhancer
P09488441A0615|34 66|immunoglobulin kappa-chain enhancer
P09488441A0615|69 100|P-selectin promoter NF-kappaB sites
P09488441A0615|69 86|P-selectin promoter
P09488441A0615|87 100|NF-kappaB sites
P09488441A0615|102 114|p50 homodimers
P09488441A0615|102 104|p50
P09488441A0615|122 124|Sp1
P09488441A0615|122 124|Sp1
P09488441A0615|132 149|P-selectin promoter
P09488441A0615|132 149|P-selectin promoter
P09488441A0615|202 221|Sp1-driven expression
P09488441A0615|202 204|Sp1
P09488441A0615|238 242|Bcl-3
P09488441A0615|238 242|Bcl-3
P09488441A0615|253 262|expression
P09488466A0695|3 12|3' fragment
P09488466A0695|35 49|full-length mRNA
P09488466A0695|63 74|actinomycin D
P09488486A0000|3 24|TATA box-binding protein
P09488486A0000|3 24|TATA box-binding protein
P09488486A0000|26 28|TBP
P09488486A0000|26 28|TBP
P09488486A0000|52 64|transcription
P09488486A0000|75 117|eukaryotic nuclear RNA polymerases, polymerases
P09488486A0000|75 84|eukaryotic
P09488486A0000|85 117|nuclear RNA polymerases, polymerases
P09488486A0000|119 123|Pol) I
P09488486A0000|119 121|Pol
P09488486A0000|123 133|I, II, and III
P09488486A0906|14 16|TBP
P09488486A0906|14 16|TBP
P09488486A0906|18 34|R231E + R235E + R239S
P09488486A0906|64 92|yeast U6 snRNA gene transcription
P09488486A0906|64 79|yeast U6 snRNA gene
P09488486A0906|116 138|Pol II basal transcription
P09488486A0906|116 120|Pol II
P09488491A0000|0 10|E2F activity
P09488491A0000|0 2|E2F
P09488491A0000|33 52|retinoblastoma family
P09488491A0000|33 52|retinoblastoma family
P09488491A0000|55 77|tumor suppressor proteins
P09488491A0000|55 77|tumor suppressor proteins
P09488713A0886|35 48|Site-1 cleavage
P09488713A0886|35 40|Site-1
P09488713A0886|93 107|full-length SCAP
P09488725A0904|18 34|molecular identity
P09488725A0904|37 39|SFD
P09488725A0904|37 39|SFD
P09488725A0904|48 71|50- and 57-kDa polypeptides
P09488725T0000|30 49|50- and 57-kDa subunits
P09488725T0000|55 78|bovine vacuolar proton pump
P09489670A1157|2 11|C. albicans
P09489670A1157|13 16|HST6
P09489670A1157|13 16|HST6
P09489670A1157|86 90|yeast
P09489670A1157|92 97|hyphae
P09489670A1157|99 103|white
P09489670A1157|132 148|HST6 transcription
P09489670A1157|132 135|HST6
P09489670A1157|169 175|diploid
P09489670A1157|176 180|yeast
P09489670A1157|190 196|diploid
P09489670A1157|197 208|S. cerevisiae
P09489670A1157|253 268|Hst6p transporter
P09489670A1157|253 257|Hst6p
P09489670A1157|271 280|C. albicans
P09490676A0800|21 34|recombinant Myb
P09490676A0800|21 34|recombinant Myb
P09490676A0800|38 49|Ets-2 protein
P09490676A0800|38 49|Ets-2 protein
P09490676A0800|95 129|double stranded oligodeoxynucleotides
P09490676A0800|140 148|canonical
P09490676A0800|156 185|mutated, Myb- or Ets-binding sites
P09490676A0800|164 166|Myb
P09490676A0800|170 185|Ets-binding sites
P09490727A1041|4 41|structure interconnects specific triplets
P09490727A1041|47 57|basal bodies
P09490727A1041|65 83|microtubular bundles
P09490727A1041|101 114|basal apparatus
P09491074A0104|78 91|promoter region
P09492038A0352|39 56|cis-acting elements
P09492038A0352|66 79|-73 to +44 region
P09492038A0352|82 99|basal exon 2 promoter
P09492038A0352|126 136|mutagenesis
P09492038A0352|140 170|nuclear protein-DNA binding assays
P09492038A0352|140 157|nuclear protein-DNA
P09494078A1362|6 18|5HT5A receptor
P09494078A1362|6 18|5HT5A receptor
P09494078A1362|32 40|yohimbine
P09495283A0000|27 34|beta-gal
P09495283A0000|27 34|beta-gal
P09495283A0000|56 94|human heat shock transcription factors 1 and 2
P09495283A0000|56 90|human heat shock transcription factors 1
P09495283A0000|94 94|2
P09495283A0000|96 99|HSF1
P09495283A0000|96 99|HSF1
P09495283A0000|103 106|HSF2
P09495283A0000|103 106|HSF2
P09495283A0000|110 118|HeLa cells
P09495283A0000|130 152|Saccharomyces cerevisiae
P09495771A0379|0 20|Localized fluorescence
P09495771A0379|97 100|FtsK
P09495771A0379|97 100|FtsK
P09495771A0379|142 150|septation
P09498553A0702|2 8|TATA box
P09498553A0702|56 62|GC boxes
P09498553A0702|81 88|cap sites
P09498553A0702|121 132|housekeeping
P09498553A0702|141 149|CYP51 gene
P09498553A0702|141 149|CYP51 gene
P09498553A0702|170 205|multiple transcription initiation sites
P09498553T0000|0 9|Structural
P09498553T0000|34 57|sterol 14-demethylase P450
P09498553T0000|34 53|sterol 14-demethylase
P09498553T0000|54 57|P450
P09498553T0000|59 63|CYP51
P09498553T0000|59 63|CYP51
P09498553T0000|82 98|P450 monooxygenase
P09498553T0000|82 85|P450
P09498769A0095|42 63|B cell-specific proteins
P09498769A0095|42 63|B cell-specific proteins
P09498769A0095|85 100|B cell development
P09498769A0095|151 185|terminally differentiated plasma cells
P09499031A0000|32 55|vesicular stomatitis virus
P09499031A0000|57 59|VSV
P09499031A0000|68 92|conserved sequence elements
P09499031A0000|130 153|transcription termination
P09499031A0000|156 173|upstream transcript
P09499048A1003|0 27|Infectious mutant virus progeny
P09499048A1003|45 75|complementing gK-expressing cells
P09499048A1003|58 59|gK
P09499048A1003|91 92|gK
P09499048A1003|91 92|gK
P09499048A1003|120 135|replication cycle
P09499061A0000|11 29|DNA joining reactions
P09499061A0000|43 73|human immunodeficiency virus type 1
P09499061A0000|43 73|human immunodeficiency virus type 1
P09499061A0000|75 89|HIV-1) integrase
P09499061A0000|75 79|HIV-1
P09499061A0000|133 137|HIV-1
P09499061A0000|133 137|HIV-1
P09499061A0000|148 157|host genome
P09499254A1309|3 12|DSF regimen
P09499254A1309|47 54|patients
P09499254A1309|62 100|metastatic pancreatic islet-cell carcinoma
P09499254A1309|105 120|patient tolerance
P09501093A0071|15 48|mitogen activated protein (MAP) kinase
P09501093A0071|15 37|mitogen activated protein
P09501093A0071|39 48|MAP) kinase
P09501093A0071|72 84|Ras activation
P09501093A0071|72 74|Ras
P09501093A0071|112 132|Ras signal transduction
P09501093A0071|112 114|Ras
P09501169A0000|0 23|Histone acetylation levels
P09501169A0000|76 107|histone acetylases and deacetylases
P09501169A0000|76 107|histone acetylases and deacetylases
P09501982A1178|12 16|XCoe2
P09501982A1178|12 16|XCoe2
P09501982A1178|41 62|transcriptional cascade
P09501982A1178|76 89|primary neurons
P09501982A1178|92 105|Xenopus embryos
P09501982A1178|126 140|Notch signalling
P09501982A1178|126 130|Notch
P09501982A1178|142 146|XCoe2
P09501982A1178|142 146|XCoe2
P09501982A1178|166 180|neural potential
P09501982A1178|191 205|progenitor cells
P09501982A1178|217 224|X-ngnr-1
P09501982A1178|217 224|X-ngnr-1
P09501982A1178|254 259|neural
P09501982A1178|298 307|neural fate
P09501982A1178|322 344|neuronal differentiation
P09501982A1178|357 373|XNeuroD expression
P09501982A1178|357 363|XNeuroD
P09502627A0705|45 62|posterolateral wall
P09502627A0705|69 81|abnormalities
P09502627A0705|93 120|radionuclide ventriculography
P09502627A0705|129 139|infarct area
P09502627A0705|160 183|peak creatine kinase levels
P09502627A0705|164 177|creatine kinase
P09502627A0705|202 216|left ventricular
P09502627A0705|234 237|LVEF
P09502720A0214|0 17|CyIIa transcription
P09502720A0214|0 4|CyIIa
P09502720A0214|83 98|embryonic domains
P09502720T0000|0 2|Cis
P09502720T0000|55 68|compact element
P09502720T0000|102 110|CyIIa gene
P09502720T0000|102 110|CyIIa gene
P09502720T0000|113 128|sea urchin embryos
P09503017A1021|25 34|human HYAL1
P09503017A1021|25 34|human HYAL1
P09503017A1021|50 64|uncharacterized
P09503017A1021|99 114|chromosome 3p21.3
P09503017A1021|149 171|small-cell lung carcinoma
P09503526A0614|2 9|patients
P09503526A0614|14 20|myalgia
P09503526A0614|22 38|Raynaud's syndrome
P09503526A0614|40 53|skin vasculitis
P09503526A0614|57 90|vascular diseases WFAg concentrations
P09503526A0614|73 76|WFAg
P09503526A0614|107 114|patients
P09504423A0114|26 35|4E-BP1 gene
P09504423A0114|26 31|4E-BP1
P09504423A0114|88 102|Escherichia coli
P09504423A0114|104 107|BL21
P09504423A0114|109 112|DE3)
P09504423A0114|117 126|fusion gene
P09504423A0114|134 163|glutathione-S-transferase (GST)
P09504423A0114|134 158|glutathione-S-transferase
P09504423A0114|160 162|GST
P09504423A0114|174 200|prokaryotic gene fusion vector
P09504423A0114|174 188|prokaryotic gene
P09504423A0114|202 210|pGEX-4T-2
P09504423A0114|227 238|gene sequence
P09504423A0114|272 285|protease, alpha
P09504423A0114|281 294|alpha-thrombin
P09504423A0114|287 294|thrombin
P09504514T0000|32 67|autologous bone-marrow transplantation
P09504514T0000|79 90|chemotherapy
P09504514T0000|94 114|acute myeloid leukaemia
P09504514T0000|141 148|MRC AML 10
P09504553T0000|16 23|cannabis
P09504906A0099|63 71|amino acid
P09504906A0099|89 96|cysteine
P09504906A0099|109 125|DNA-binding domain
P09504906A0099|109 125|DNA-binding domain
P09504906A0099|128 132|Hap1p
P09504906A0099|128 132|Hap1p
P09505733A0246|64 76|common factors
P09505733A0246|89 109|psychological distress
P09505733A0246|113 118|social
P09505733A0246|154 161|patients
P09506439A2179|0 8|PKC-gamma
P09506439A2179|0 8|PKC-gamma
P09506439A2179|29 41|keratinocytes
P09506439A2179|54 77|involucrin gene expression
P09506439A2179|54 67|involucrin gene
P09506439A2179|81 101|TPA-independent manner
P09506439A2179|121 129|SVHK cells
P09506959T0000|43 62|DNA-binding complexes
P09506959T0000|43 62|DNA-binding complexes
P09506959T0000|85 91|Myc/Max
P09506959T0000|85 87|Myc
P09506959T0000|89 91|Max
P09506959T0000|92 102|/Mad network
P09506959T0000|93 95|Mad
P09506959T0000|105 129|transcriptional regulators
P09506962A1000|17 36|proteolytic targeting
P09506962A1000|39 47|calpain II
P09506962A1000|39 47|calpain II
P09506962A1000|54 63|proteasome
P09506962A1000|101 103|YY1
P09506962A1000|101 103|YY1
P09506983A0304|0 6|Primers
P09506983A0304|28 31|RACE
P09506983A0304|51 57|5'-ends
P09506983A0304|60 80|amplified RACE products
P09506990T0000|0 15|Human ZFM1 protein
P09506990T0000|5 15|ZFM1 protein
P09506990T0000|19 42|transcriptional repressor
P09506990T0000|63 91|transcription activation domain
P09506990T0000|94 123|stage-specific activator protein
P09507032A1144|16 31|CSF1R/IRDelta960
P09507032A1144|16 20|CSF1R
P09507032A1144|22 31|IRDelta960
P09507032A1144|51 58|CSF1R/IR
P09507032A1144|51 55|CSF1R
P09507032A1144|57 58|IR
P09507032A1144|61 84|mediating CSF-1 protection
P09507032A1144|70 74|CSF-1
P09507032A1144|96 125|staurosporine-induced apoptosis
P09508119A0498|61 77|Gardner's syndrome
P09508377A0863|33 45|UV sensitivity
P09508377A0863|81 98|low eumelanin levels
P09508377A0863|217 226|skin cancer
P09508377A0863|230 237|melanoma
P09508511A0588|100 114|bacterial urease
P09508775A0293|3 32|cAMP-dependent mitogenic pathway
P09508775A0293|60 99|mitogen-activated protein kinase activation
P09508775A0293|60 89|mitogen-activated protein kinase
P09508775A0293|114 143|growth factor-dependent pathways
P09508775A0293|178 212|protooncogenes/transcription factors
P09509226A1235|88 90|ICU
P09510189A0192|19 29|exon-intron
P09510189A0192|53 65|human CD58 gene
P09510189A0192|58 65|CD58 gene
P09510189A0192|89 120|2.5 kilobases (kb) of 5'-flanking DNA
P09510398A1138|28 35|patients
P09510398A1138|40 56|renal hypouricemia
P09510398A1138|74 98|urinary urate concentration
P09510582A0157|20 27|patients
P09510582A0157|40 43|DCBM
P09510582A0157|90 95|geG-25
P09510582A0157|100 102|geG
P09510582A0157|109 114|geG-50
P09510582A0157|119 121|HBB
P09510582A0157|128 141|hypotonic agent
P09510925A0389|5 28|haemoglobin concentration
P09510925A0389|5 15|haemoglobin
P09510925A0389|30 31|Hb
P09510925A0389|30 31|Hb
P09510925A0389|47 50|dL-1
P09510925A0389|81 95|ferrous sulphate
P09511724A0483|32 47|Dsg protein levels
P09511724A0483|32 41|Dsg protein
P09511724A0483|56 62|calcium
P09511760A0221|7 31|restriction enzyme analysis
P09511760A0221|33 45|Southern blots
P09511760A0221|47 77|polymerase chain reaction analysis
P09511760A0221|81 93|DNA sequencing
P09511760A0221|121 137|overlapping clones
P09511760A0221|160 168|cHO-1 gene
P09511760A0221|160 168|cHO-1 gene
P09511760A0221|191 194|10 kb
P09511760A0221|200 214|flanking regions
P09512416A0460|29 41|dbEST database
P09512416A0460|78 100|Arabidopsis thaliana gene
P09512416A0460|102 105|GCR1
P09512416A0460|102 105|GCR1
P09512416A0460|144 167|membrane-spanning domains
P09512416A0460|200 211|7TM receptors
P09512416A0460|200 211|7TM receptors
P09512550T0000|0 2|E1A
P09512550T0000|0 2|E1A
P09512550T0000|12 35|apolipoprotein AI enhancer
P09512550T0000|26 55|AI enhancer activity in liver cells
P09512550T0000|64 66|pRb
P09512550T0000|64 66|pRb
P09512550T0000|71 92|CBP-independent pathway
P09512550T0000|71 73|CBP
P09512559T0000|33 54|human nerve growth factor
P09512559T0000|38 54|nerve growth factor
P09512559T0000|56 77|luciferase reporter gene
P09513759A0716|0 9|Calcitriol
P09513759A0716|45 59|serum iPTH levels
P09513759A0716|50 53|iPTH
P09514156A1147|0 10|Alterations
P09514156A1147|13 28|DNase I reactivity
P09514156A1147|13 18|DNase I
P09514156A1147|34 57|GC-response element region
P09514156A1147|34 57|GC-response element region
P09514156A1147|69 90|GC receptor-GC complexes
P09514156A1147|69 70|GC
P09514156A1147|107 121|transient manner
P09514156A1147|130 137|promoter
P09514156A1147|143 162|actively transcribing
P09514159A0562|4 39|pituitary hormone-coding gene promoters
P09514159A0562|54 57|Ptx1
P09514159A0562|54 57|Ptx1
P09514260A1083|10 21|small inteins
P09514260A1083|15 21|inteins
P09514260A1083|41 52|pseudo intein
P09514260A1083|95 101|inteins
P09514260A1083|143 157|protein families
P09514260A1083|216 224|intein N, C
P09514260A1083|216 224|intein N, C
P09514260A1083|229 236|EN motifs
P09514272A0482|14 17|MvaT
P09514272A0482|14 17|MvaT
P09514272A0482|32 43|polypeptides
P09514272A0482|70 82|15 kDa and 16 kDa
P09514272A0482|94 96|P15
P09514272A0482|94 96|P15
P09514272A0482|100 102|P16
P09514962A0841|17 29|14-kDa protein
P09514962A0841|17 29|14-kDa protein
P09514962A0841|39 68|MMTV bearing T-cell lymphoma, EL-4
P09515031A1020|24 32|TGF-betaf
P09515031A1020|24 32|TGF-betaf
P09515031A1020|47 54|c-fos SRE
P09515031A1020|47 51|c-fos
P09515031A1020|66 68|PKC
P09515031A1020|66 68|PKC
P09515031A1020|79 92|SRF binding site
P09515031A1020|79 92|SRF binding site
P09515032A1230|0 5|RT-PCR
P09515032A1230|19 25|p21 mRNA
P09515032A1230|19 25|p21 mRNA
P09515032A1230|67 74|neonatal
P09515032A1230|81 88|neonatal
P09515032A1230|93 103|adult stages
P09515032A1230|137 146|fetal stage
P09515665T0000|0 10|Ganciclovir
P09515665T0000|33 64|AIDS-related CMV polyradiculopathy
P09515858A0000|11 19|Defensins
P09515858A0000|32 46|human neutrophil
P09515858A0000|92 108|azurophil granules
P09515858A0000|111 121|neutrophils
P09515921A1662|3 46|spontaneous mutation blocking pca gene expression
P09515921A1662|30 36|pca gene
P09515921A1662|76 84|pca operon
P09515921A1662|76 84|pca operon
P09515924A0104|31 40|PDH complex
P09515924A0104|31 40|PDH complex
P09515924A0104|74 80|protein
P09515924A0553|3 26|PDH complex-encoding genes
P09515924A0553|3 26|PDH complex-encoding genes
P09515924A0553|43 66|hybridization experiments
P09515924A0553|70 85|sequence analysis
P09515924A0553|123 123|Z
P09516472A0292|19 36|functional elements
P09516472A0292|66 74|TATA motif
P09516472A0292|66 74|TATA motif
P09516472A0292|87 105|Id4 promoter activity
P09516472A0292|87 97|Id4 promoter
P09517646A0149|0 11|Azithromycin
P09517646A0149|28 46|macrolide antibiotic
P09517646A0149|70 85|pharmacokinetics
P09517646A0149|121 136|innovative anti-H
P09517989A0476|40 42|CMV
P09517989A0476|46 48|HIV
P09517989A0476|64 66|CD4
P09517989A0476|64 66|CD4
P09518383A0000|27 34|sexually
P09518383A0000|55 57|STD
P09518383A0000|76 91|female sex workers
P09518383A0000|93 95|FSW
P09518383A0000|125 140|serological tests
P09518383A0000|144 151|syphilis
P09518383A0000|155 162|cervical
P09518383A0000|201 212|STD or condoms
P09518808T0000|0 20|National certification
P09518808T0000|46 54|assurance
P09519757A0482|12 20|mutations
P09519757A0482|22 26|D811N
P09519757A0482|29 42|exon 20 and R835C
P09519757A0482|45 50|exon 21
P09519757A0482|99 101|NBF
P09519757A0482|134 137|SUR1
P09519757A0482|134 137|SUR1
P09519757A0482|160 172|heterozygotes
P09519828A0809|9 15|VP16-E2
P09519828A0809|9 12|VP16
P09519828A0809|14 24|E2 molecules
P09519828A0809|39 81|epithelial specific transcriptional activation
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|118 119|E2
P09519828A0809|118 119|E2
P09519830A0282|34 57|transcriptional silencing
P09519830A0282|74 78|HSV-1
P09519830A0282|89 106|recombinant viruses
P09519830A0282|127 159|wild-type or mutant ICP34.5 promoters
P09519830A0282|127 148|wild-type or mutant ICP34
P09519830A0282|150 159|5 promoters
P09519830A0282|187 230|chloramphenicol acetyltransferase reporter gene
P09519830A0282|187 230|chloramphenicol acetyltransferase reporter gene
P09519830A0282|250 268|thymidine kinase gene
P09519830A0282|250 268|thymidine kinase gene
P09519830A0282|274 284|viral genome
P09520398A0124|74 85|core histones
P09521907A0190|0 22|Drosophila orthodenticle
P09521907A0190|0 22|Drosophila orthodenticle
P09521907A0190|24 26|otd
P09521907A0190|24 26|otd
P09521907A0190|31 44|murine Otx genes
P09521907A0190|72 89|expression patterns
P09521909A0081|0 18|APETALA3 transcripts
P09521909A0081|0 18|APETALA3 transcripts
P09521909A0081|77 99|petal and stamen primordia
P09521913A0400|29 35|60A gene
P09521913A0400|29 35|60A gene
P09521913A0400|55 76|TGF-beta-related factor
P09521913A0400|55 76|TGF-beta-related factor
P09521913A0400|79 88|Drosophila
P09522297A0744|0 8|Cell lines
P09522297A0744|46 51|tumors
P09522297A0744|54 61|nude mice
P09522297A0744|87 95|karyotype
P09522979T0000|0 30|Cervicovaginal foetal fibronectin
P09522979T0000|14 30|foetal fibronectin
P09522979T0000|48 54|preterm
P09522979T0000|64 81|low-risk population
P09523478A0572|11 13|IgM
P09523478A0572|11 13|IgM
P09523478A0572|27 34|children
P09523478A0572|39 61|congenital toxoplasmosis
P09523478A0572|76 96|secondary reactivation
P09523551A0367|22 48|seven-transmembrane topology
P09523551A0367|65 89|G protein-coupled receptors
P09523551A0367|65 89|G protein-coupled receptors
P09524122A0336|1 18|constitutive allele
P09524122A0336|21 24|GPA2
P09524122A0336|21 24|GPA2
P09524122A0336|65 72|RAS genes
P09524122A0336|65 72|RAS genes
P09524222A0769|3 15|COOH-terminus
P09524222A0769|49 53|beta 4
P09524222A0769|49 53|beta 4
P09524222A0769|63 90|amino acid lysine-rich sequence
P09524222A0769|106 146|human red cell alpha- and beta-adducin subunits
P09524222A0769|106 117|human red cell
P09524222A0769|118 146|alpha- and beta-adducin subunits
P09524222A0769|186 191|MARCKS
P09524222A0769|186 191|MARCKS
P09524222A0769|205 222|actin-cross linking
P09524222A0769|241 254|protein kinase C
P09524222A0769|241 254|protein kinase C
P09524222A0769|258 281|calcium/calmodulin. beta 4
P09524222A0769|266 289|calmodulin. beta 4-adducin
P09524222A0769|320 342|calmodulin binding domain
P09524222A0769|320 342|calmodulin binding domain
P09524222A1113|0 10|PCR analysis
P09524222A1113|31 49|beta-adducin isoform
P09524222A1113|31 49|beta-adducin isoform
P09524222A1113|63 80|fetal brain and liver
P09524222A1113|82 91|bone marrow
P09524222A1113|96 121|NT-2 (neuroepithelial) cells
P09524222A1113|96 99|NT-2
P09524229A0000|7 11|lac-1
P09524229A0000|7 11|lac-1
P09524229A0000|24 29|enzyme
P09524229A0000|30 36|laccase
P09524229A0000|81 100|chestnut blight fungus
P09524229A0000|102 124|Cryphonectria parasitica
P09524229A0000|197 201|lac-1
P09524229A0000|197 201|lac-1
P09524229A0000|272 293|translational inhibitor
P09524229A0000|294 306|cycloheximide
P09524229A0000|308 310|CHX
P09524229A0000|320 348|immunosuppressant cyclosporin A
P09524250A0767|4 19|TRE-like elements
P09524250A0767|40 42|AP1
P09524259A0301|3 18|hp55 gamma protein
P09524259A0301|3 11|hp55 gamma
P09524259A0301|52 56|IGFIR
P09524259A0301|52 56|IGFIR
P09524259A0301|70 98|kinase-negative mutant receptor
P09524259A0301|70 98|kinase-negative mutant receptor
P09524259A0301|100 108|hp55 gamma
P09524259A0301|100 108|hp55 gamma
P09524259A0301|129 143|insulin receptor
P09524259A0301|129 143|insulin receptor
P09524259A0301|145 146|IR
P09524259A0301|145 146|IR
P09524259A0301|153 173|yeast two-hybrid system
P09524267A1023|80 122|nuclear localization signal, DNA-binding domain
P09524267A1023|106 122|DNA-binding domain
P09524267A1023|126 139|helicase motifs
P09524267A1023|180 204|RNA transcription apparatus
P09524267A1023|214 237|nucleotide excision repair
P09524273A0205|42 46|mouse
P09524273A0205|47 52|gC1qBP
P09524273A0205|80 95|5' flanking region
P09524276A0939|0 11|LysR proteins
P09524276A0939|0 11|LysR proteins
P09524276A0939|35 61|urease in Klebsiella aerogenes
P09524276A0939|35 40|urease
P09524276A0939|43 61|Klebsiella aerogenes
P09524276A0939|63 65|NAC
P09524276A0939|63 65|NAC
P09524276A0939|71 78|catalase
P09524276A0939|71 78|catalase
P09524276A0939|81 100|Escherichia coli (OxyR
P09524276A0939|81 95|Escherichia coli
P09524276A0939|97 100|OxyR
P09524276A0939|117 138|intracellular bacterium
P09524276A0939|153 171|phagolysosome damage
P09525105A0298|8 34|anti-inflammatory activities
P09525105A0298|39 52|aqueous extract
P09525105A0298|55 69|Buddleia cordata
P09525598A0325|15 23|Raf kinase
P09525598A0325|15 23|Raf kinase
P09525598A0325|26 31|T cells
P09525598A0325|65 73|cell lines
P09525598A0325|81 95|catalytic domain
P09525598A0325|98 100|Raf
P09525598A0325|98 100|Raf
P09525598A0325|102 104|Raf
P09525598A0325|102 104|Raf
P09525598A0325|106 116|delta26-303
P09525888A1482|0 14|Full-length FLAP
P09525888A1482|11 20|FLAP clones
P09525888A1482|38 56|mouse skeletal muscle
P09525888A1482|57 67|cDNA library
P09525891T0000|12 48|meis1 and pbx homeodomain protein families
P09525891T0000|12 16|meis1
P09525891T0000|20 48|pbx homeodomain protein families
P09525891T0000|67 89|cAMP-responsive sequence
P09525891T0000|67 89|cAMP-responsive sequence
P09525891T0000|91 94|CRS1
P09525891T0000|91 94|CRS1
P09525891T0000|100 110|bovine CYP17
P09525891T0000|100 110|bovine CYP17
P09527921A1178|16 35|DNA-protein complexes
P09527921A1178|38 55|electron microscopy
P09527921A1178|60 83|high-affinity binding site
P09527921A1178|86 98|WDV Rep protein
P09527921A1178|86 98|WDV Rep protein
P09527921A1178|108 118|core element
P09527921A1178|108 118|core element
P09527921A1178|172 185|initiation site
P09527921A1178|197 205|start site
P09527921A1178|209 240|complementary-sense transcription
P09527921A1178|247 253|TATA box
P09528758T0000|0 4|Rex-1
P09528758T0000|0 4|Rex-1
P09528758T0000|20 38|transcription factor
P09528758T0000|53 63|early embryo
P09528758T0000|79 85|Oct-3/4
P09528758T0000|79 85|Oct-3/4
P09528758T0000|89 93|Oct-6
P09528758T0000|89 93|Oct-6
P09528758T0000|105 115|octamer site
P09528758T0000|133 137|Rox-1
P09528758T0000|133 137|Rox-1
P09528758T0000|150 161|adjacent site
P09528766A0915|27 33|ERK/RSK
P09528766A0915|27 29|ERK
P09528766A0915|31 33|RSK
P09528766A0915|40 64|p38/MAPKAP kinase 2 pathways
P09528766A0915|40 42|p38
P09528766A0915|44 56|MAPKAP kinase 2
P09528766A0915|84 98|NGF-induced CREB
P09528766A0915|84 86|NGF
P09528766A0915|95 105|CREB Ser-133
P09528766A0915|99 105|Ser-133
P09528768A0000|31 46|unfolded proteins
P09528768A0000|52 71|endoplasmic reticulum
P09528768A0000|73 74|ER
P09528768A0000|73 74|ER
P09528768A0000|122 149|ER-resident chaperone proteins
P09528768A0000|122 149|ER-resident chaperone proteins
P09528770A1379|3 42|RAS-cyclic AMP-dependent protein kinase cAPK
P09528770A1379|3 5|RAS
P09528770A1379|7 38|cyclic AMP-dependent protein kinase
P09528770A1379|39 42|cAPK
P09528770A1379|61 71|UAS activity
P09528770A1379|74 77|IREu
P09528770A1379|74 77|IREu
P09528770A1379|93 99|glucose
P09528770A1379|130 159|transcriptional activators Msn2p
P09528770A1379|155 159|Msn2p
P09528770A1379|163 167|Msn4p
P09528770A1379|163 167|Msn4p
P09528770A1379|178 188|UAS activity
P09528784A0000|3 11|mei4+ gene
P09528784A0000|3 7|mei4+
P09528784A0000|24 28|yeast
P09528784A0000|29 52|Schizosaccharomyces pombe
P09528792A0000|21 51|fibroblast growth factor receptor 2
P09528792A0000|21 51|fibroblast growth factor receptor 2
P09528792A0000|53 58|FGF-R2
P09528792A0000|53 58|FGF-R2
P09528792A0000|88 106|alternative splicing
P09528792A0000|114 129|exons IIIb and IIIc
P09528858A0205|15 33|aberrant methylation
P09528858A0205|36 39|CpGs
P09528858A0205|46 64|5' regulatory regions
P09528858A0205|86 97|gene activity
P09528950A0716|3 18|genomic fragments
P09528950A0716|41 62|luciferase reporter gene
P09528950A0716|41 62|luciferase reporter gene
P09528987A1348|0 21|Cotransfection analyses
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|64 84|T/EBP expression vector
P09528987A1348|64 68|T/EBP
P09528987A1348|89 103|human HepG2 cells
P09528987A1348|122 126|T/EBP
P09528987A1348|122 126|T/EBP
P09528987A1348|185 214|rat and human T/EBP gene expression
P09528987A1348|191 204|human T/EBP gene
P09529156A1238|0 7|Deletion
P09529156A1238|20 30|Ser residues
P09529156A1238|44 59|PKC consensus site
P09529156A1238|47 59|consensus site
P09529156A1238|65 76|receptor tail
P09529156A1238|91 142|phorbol 12-myristate 13-acetate-induced desensitization
P09529216A0644|0 11|Flap survival
P09529216A0644|51 69|vascular connections
P09529216A0644|77 83|vessels
P09529216A0644|98 131|pedicle and preexisting dermal vessels
P09529649A0307|41 65|respiratory tract infection
P09529649A0307|68 75|children
P09529721A0000|123 138|childhood illness
P09529721A0000|140 157|severe malnutrition
P09529721A0000|248 269|nutritional counselling
P09530251A0766|0 8|SNAC or PBS
P09530251A0766|47 54|ischemia
P09530251A0766|91 101|reperfusion
P09531538A0983|24 57|enhancer-dependent splicing activity
P09531538A0983|69 83|dU2AF38 RS domain
P09531538A0983|69 83|dU2AF38 RS domain
P09531549A0658|2 20|vitro binding studies
P09531549A0658|26 42|GST fusion proteins
P09531549A0658|26 28|GST
P09531549A0658|74 85|binding sites
P09531549A0658|88 94|yAP180A
P09531549A0658|88 94|yAP180A
P09531549A0658|98 102|Pan1p
P09531549A0658|98 102|Pan1p
P09531549A0658|106 113|clathrin
P09531549A0658|115 128|yAP180 proteins
P09531549A0658|115 128|yAP180 proteins
P09531549A0658|132 136|Pan1p
P09531549A0658|132 136|Pan1p
P09531549A0658|142 146|actin
P09531549A0658|142 146|actin
P09531549A0658|158 174|peripheral patches
P09531549A0658|183 196|plasma membrane
P09531559A1153|2 22|vitro affinity analyses
P09531559A1153|39 62|recombinant 130-kD protein
P09531559A1153|39 62|recombinant 130-kD protein
P09531559A1153|84 87|ZO-1
P09531559A1153|84 87|ZO-1
P09531559A1153|94 110|cytoplasmic domain
P09531559A1153|94 110|cytoplasmic domain
P09531559A1153|113 120|occludin
P09531559A1153|132 135|ZO-2
P09531559A1153|132 135|ZO-2
P09533030T0000|0 10|Cytochrome b
P09533030T0000|0 10|Cytochrome b
P09533030T0000|13 26|human complex II
P09533030T0000|13 26|human complex II
P09533030T0000|28 61|succinate-ubiquinone oxidoreductase
P09533030T0000|28 61|succinate-ubiquinone oxidoreductase
P09533030T0000|64 74|cDNA cloning
P09533030T0000|92 96|liver
P09533030T0000|97 108|mitochondria
P09533030T0000|112 131|chromosome assignment
P09533030T0000|154 157|SDHC
P09533030T0000|154 157|SDHC
P09533030T0000|162 171|small (SDHD
P09533030T0000|168 171|SDHD
P09533030T0000|183 186|1q21
P09533030T0000|190 194|11q23
P09533109A0449|19 38|theophylline's volume
P09533109A0449|100 110|chloroquine
P09533109A0449|155 177|statistical significance
P09535082A0537|14 34|Paf-containing extract
P09535082A0537|14 16|Paf
P09535082A0537|115 118|PrfA
P09535082A0537|115 118|PrfA
P09535082A0537|141 144|CIII
P09535082A0537|158 186|PrfA and the 109 bp hly DNA fragment
P09535082A0537|158 161|PrfA
P09535082A0537|190 204|slower migrating
P09535082A0537|205 223|PrfA-Paf-DNA complex
P09535082A0537|205 208|PrfA
P09535082A0537|210 212|Paf
P09535082A0537|214 223|DNA complex
P09535082A0537|225 226|CI
P09535082A0537|225 226|CI
P09535579A1105|113 116|EPOC
P09535579A1105|130 131|kJ
P09535833A0228|3 28|predicted amino acid sequence
P09535833A0228|31 36|m-Staf
P09535833A0228|63 66|Staf
P09535833A0228|63 66|Staf
P09535833A0228|75 125|selenocysteine tRNA gene transcription activating factor
P09535833A0228|75 109|selenocysteine tRNA gene transcription
P09535833A0228|128 140|Xenopus laevis
P09535835A0279|0 5|ROCK-I
P09535835A0279|0 5|ROCK-I
P09535835A0279|7 14|Kinectin
P09535835A0279|19 23|mDia2
P09535835A0279|19 23|mDia2
P09535835A0279|34 46|wild type forms
P09535835A0279|53 56|RhoA
P09535835A0279|53 56|RhoA
P09535835A0279|60 64|Cdc42
P09535835A0279|60 64|Cdc42
P09535835A0279|68 86|GTP-dependent manner
P09535851A0591|22 32|beta isoform
P09535851A0591|22 32|beta isoform
P09535851A0591|62 85|PtdIns(4)P kinase activity
P09535851A0591|62 77|PtdIns(4)P kinase
P09535851A0591|92 103|gamma isoform
P09535851A0591|92 103|gamma isoform
P09535851A0591|130 145|phosphatidic acid
P09535892A0000|3 13|beta subunit
P09535892A0000|19 41|heterotrimeric G proteins
P09535892A0000|19 41|heterotrimeric G proteins
P09535892A0000|71 84|plasma membrane
P09535892A0000|95 115|an amino-terminal alpha
P09535892A0000|97 130|amino-terminal alpha-helical segment
P09535892A0000|166 167|WD
P09535892A0000|166 167|WD
P09535892A0000|169 175|Trp-Asp
P09535892A0000|169 171|Trp
P09535908A0321|26 36|LNX messages
P09535908A0321|26 36|LNX messages
P09535908A0321|75 89|molecular masses
P09535908A0321|92 101|80 kDa (LNX)
P09535908A0321|98 100|LNX
P09535908A0321|105 115|70 kDa (LNX-b
P09535908A0321|111 115|LNX-b
P09536028A0945|33 47|arachidonic acid
P09536028A0945|61 81|cyclooxygenase product
P09536028A0945|61 81|cyclooxygenase product
P09536028A0945|97 108|contractions
P09536028A0945|121 122|TF
P09536028A0945|121 122|TF
P09536028A0945|126 128|EGF
P09536028A0945|126 128|EGF
P09536440A0000|25 38|unconventional
P09536440A0000|39 45|myosin V
P09536440A0000|39 45|myosin V
P09536440A0000|61 85|actin-based molecular motor
P09536440A0000|96 112|vesicular movement
P09536901A0362|22 23|T1
P09536901A0362|35 36|T2
P09536901A0362|56 79|T2 weighted axial sequences
P09537295A0951|57 65|major site
P09537295A0951|71 114|reverse transcriptase-polymerase chain reaction
P09537295A0951|71 106|reverse transcriptase-polymerase chain
P09537295A0951|126 134|P1 primers
P09537295A0951|136 148|primer walking
P09537295A0951|151 165|primer extension
P09537295A0951|170 180|cDNA cloning
P09537295T0000|10 17|promoter
P09537295T0000|21 47|androgen regulatory sequences
P09537295T0000|84 113|rat androgen-binding protein gene
P09537295T0000|87 113|androgen-binding protein gene
P09537361A0149|3 6|iron
P09537361A0149|19 31|transcription
P09537361A0149|47 50|cvaA
P09537361A0149|47 50|cvaA
P09537361A0149|65 91|transporter accessory protein
P09537361A0149|96 98|cvi
P09537361A0149|111 133|colicin V immunity protein
P09537361A0149|163 166|iron
P09537375A0198|3 20|gntR deletion mutant
P09537375A0198|3 20|gntR deletion mutant
P09537375A0198|38 64|chromosomal gntT::lacZ fusion
P09537375A0198|38 52|chromosomal gntT
P09537375A0198|55 64|lacZ fusion
P09537375A0198|105 108|GntR
P09537375A0198|105 108|GntR
P09537375A0198|133 136|gntT
P09537375A0198|133 136|gntT
P09537378A1227|25 27|bcp
P09537378A1227|35 44|chromosome
P09537378A1227|58 75|gcv-lacZ expression
P09537378A1227|58 60|gcv
P09537378A1227|62 65|lacZ
P09537651A0366|13 16|PEA3
P09537651A0366|13 16|PEA3
P09537651A0366|20 23|STAT
P09537651A0366|20 23|STAT
P09537651A0366|60 64|v-src
P09537651A0366|60 64|v-src
P09537651A0366|125 136|phorbol ester
P09537651A0366|137 159|phorbol myristate acetate
P09537651A0366|161 163|PMA
P09538156A0130|0 11|BRCA1 protein
P09538156A0130|0 4|BRCA1
P09538156A0130|22 50|amino-terminal zinc finger motif
P09538156A0130|22 50|amino-terminal zinc finger motif
P09538156A0130|55 82|carboxy-terminal acidic region
P09538220A0000|3 31|mitochondrial regulatory region
P09538220A0000|3 15|mitochondrial
P09538220A0000|16 31|regulatory region
P09538220A0000|33 35|mrr
P09538220A0000|54 75|tRNAPhe and tRNAPro genes
P09538220A0000|54 60|tRNAPhe
P09538220A0000|64 75|tRNAPro genes
P09538220A0000|78 93|mitochondrial DNA
P09538220A0000|95 99|mtDNA
P09538220A0000|159 177|mitochondrial genome
P09538258A0200|48 60|Ras activation
P09538258A0200|48 50|Ras
P09538258A0200|104 121|hematopoietic cells
P09539421A0970|5 15|Sir proteins
P09539421A0970|43 51|silencing
P09539721A0599|24 27|DnaA
P09539721A0599|24 27|DnaA
P09539721A0599|41 51|beta subunit
P09539721A0599|41 51|beta subunit
P09539721A0599|54 66|RNA polymerase
P09539721A0599|54 66|RNA polymerase
P09539721A0599|88 97|pR promoter
P09539721A0599|88 97|pR promoter
P09539746A0781|12 17|Bcl-XL
P09539746A0781|12 17|Bcl-XL
P09539746A0781|43 48|Apaf-1
P09539746A0781|43 48|Apaf-1
P09539746A0781|53 61|caspase-9
P09539746A0781|53 61|caspase-9
P09539746A0781|64 77|mammalian cells
P09539779A0621|11 29|in situ hybridization
P09539779A0621|37 48|mouse embryos
P09539779A0621|89 102|Arp1 expression
P09539779A0621|89 92|Arp1
P09539779A0621|142 145|All1
P09539779A0621|142 145|All1
P09540062A0755|47 67|Site II cognate proteins
P09540062A0755|47 50|Site
P09540062A0755|53 67|cognate proteins
P09540062A0755|111 135|H4 transcriptional activity
P09540062A0755|141 148|chimeric
P09540062A0755|149 178|H4 promoter/CAT fusion constructs
P09540062A0755|149 158|H4 promoter
P09540062A0755|160 162|CAT
P09541280A0404|9 17|plasma IgE
P09541280A0404|15 17|IgE
P09541280A0404|39 44|NC mice
P09541280A0404|62 66|FK506
P09541280A0404|85 98|plasma IgE level
P09541280A0404|91 93|IgE
P09541636T0000|0 20|Creatine kinase release
P09541636T0000|0 13|Creatine kinase
P09541636T0000|33 50|artery embolization
P09541636T0000|53 60|patients
P09541636T0000|65 79|carcinoid tumors
P09541721A0894|17 55|ischemia/angiotension II-induced AHF model
P09541721A0894|26 39|angiotension II
P09541721A0894|57 59|NIC
P09541721A0894|69 110|left ventricular end-diastolic pressure (LVEDP
P09543227A0815|34 41|patients
P09543227A0815|46 60|0 or 1 risk factors
P09543227A0815|62 62|B
P09543227A0815|89 100|2 risk factors
P09543227A0815|105 105|C
P09544987A1583|24 28|RU486
P09544987A1583|30 33|PR-B
P09544987A1583|30 33|PR-B
P09544987A1583|57 60|NCoR
P09544987A1583|57 60|NCoR
P09544991A0483|0 10|PRL receptor
P09544991A0483|0 10|PRL receptor
P09544991A0483|24 28|SHP-2
P09544991A0483|24 28|SHP-2
P09544991A0483|31 58|cytosolic tyrosine phosphatase
P09544991A0483|31 58|cytosolic tyrosine phosphatase
P09544991A0750|27 31|SHP-2
P09544991A0750|27 31|SHP-2
P09544991A0750|63 85|tyrosine phosphorylation
P09544991A0750|89 107|DNA-binding activity
P09544991A0750|110 117|m-Stat5a
P09544991A0750|112 117|Stat5a
P09544991A0750|119 126|m-Stat5b
P09544991A0750|121 126|Stat5b
P09544991A0750|134 150|carboxyl-terminal
P09544991A0750|159 181|variant m-Stat5adelta749
P09544991A0750|166 181|m-Stat5adelta749
P09544991A0750|194 217|transactivation potential
P09544991A0750|220 227|m-Stat5a
P09544991A0750|222 231|Stat5a and m
P09544991A0750|231 238|m-Stat5b
P09544991A0750|233 238|Stat5b
P09545146A0884|79 85|CBZ Cl/F
P09545146A0884|108 126|age-related decrease
P09545146A0884|129 132|Cl/F
P09545293A0590|0 9|Sites 1 and 4
P09545293A0590|12 18|lumican
P09545293A0590|12 18|lumican
P09545293A0590|22 30|keratocan
P09545312A1197|38 48|HMG-I family
P09545312A1197|38 48|HMG-I family
P09545312A1197|70 95|SRF-dependent transcription
P09545312A1197|70 72|SRF
P09545312A1197|136 161|protein-protein interaction
P09545312A1197|136 150|protein-protein
P09545323T0000|0 2|ATP
P09545323T0000|31 37|complex
P09545323T0000|68 81|yeast MSH2-MSH6
P09545323T0000|73 76|MSH2
P09545323T0000|78 81|MSH6
P09545323T0000|85 109|MLH1-PMS1 protein complexes
P09545323T0000|85 88|MLH1
P09545323T0000|90 93|PMS1
P09545332A0137|13 19|central
P09545332A0137|20 25|Tyr497
P09545332A0137|28 30|Phe
P09545332A0137|40 62|tyrosine phosphorylation
P09545332A0137|68 92|insulin receptor substrate 1
P09545332A0137|68 92|insulin receptor substrate 1
P09545332A0137|94 97|IRS1
P09545332A0137|94 97|IRS1
P09545332A0137|112 124|proliferation
P09545332A0137|137 140|IL-4
P09545332A0137|137 140|IL-4
P09545353A1071|28 41|kappaB elements
P09545353A1071|28 41|kappaB elements
P09545353A1071|45 81|a variant activating transcription factor
P09545353A1071|46 105|variant activating transcription factor/cAMP response element site
P09545353A1071|83 105|cAMP response element site
P09545353A1071|138 151|E-selectin gene
P09545353A1071|138 151|E-selectin gene
P09545353A1071|170 204|TNF-alpha- or LPS-inducible expression
P09545353A1071|170 178|TNF-alpha
P09545638A0330a|30 56|yeast hnRNP methyltransferase
P09545638A0330a|30 34|yeast
P09545638A0330a|35 56|hnRNP methyltransferase
P09545638A0330a|58 61|HMT1
P09545638A0330a|58 61|HMT1
P09545638A0330b|30 56|yeast hnRNP methyltransferase
P09545638A0330b|30 34|yeast
P09545638A0330b|35 56|hnRNP methyltransferase
P09545638A0330b|58 61|HMT1
P09545638A0330b|58 61|HMT1
P09545638A0836|0 24|Recombinant HRMT1L2 protein
P09545638A0836|0 17|Recombinant HRMT1L2
P09545638A0836|47 56|5'-variant
P09545638A0836|66 90|methyltransferase activity
P09545638A1181|18 24|HRMT1L1
P09545638A1181|18 24|HRMT1L1
P09545638A1181|28 34|HRMT1L2
P09545638A1181|28 34|HRMT1L2
P09545638A1181|37 48|human disease
P09545638T0000|46 76|human arginine methyltransferases
P09545638T0000|46 50|human
P09545638T0000|51 76|arginine methyltransferases
P09545638T0000|78 84|HRMT1L1
P09545638T0000|78 84|HRMT1L1
P09545638T0000|88 94|HRMT1L2
P09545638T0000|88 94|HRMT1L2
P09546424A1550|26 42|PDGF beta-receptor
P09546424A1550|26 42|PDGF beta-receptor
P09546424A1550|60 70|Crk proteins
P09546424A1550|60 62|Crk
P09547311A1394|45 64|endogenous E-cadherin
P09547311A1394|55 64|E-cadherin
P09547311A1394|71 77|chimera
P09547311A1394|91 100|E-cadherin
P09547311A1394|91 100|E-cadherin
P09547311A1394|101 119|extracellular domain
P09547311A1394|101 119|extracellular domain
P09547311A1394|126 155|desmoglein 1 intracellular domain
P09547311A1394|126 155|desmoglein 1 intracellular domain
P09547311A1394|222 231|E-cadherin
P09547311A1394|222 231|E-cadherin
P09547311A1394|232 251|extracellular domains
P09547311A1394|232 251|extracellular domains
P09547349A0000|3 19|ether phospholipid
P09547349A0000|20 72|1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|74 83|ET-18-OCH3
P09547349A0000|114 122|apoptosis
P09547349A0000|125 139|human tumor cells
P09548481A0000|36 43|promoter
P09548481A0000|45 46|P1
P09548481A0000|45 46|P1
P09548481A0000|73 86|second promoter
P09548481A0000|93 111|human IL-5Ralpha gene
P09548481A0000|93 111|human IL-5Ralpha gene
P09549179A0774|0 10|Serum levels
P09549179A0774|13 24|testosterone
P09549179A0774|67 74|p,p'-DDE
P09549398A1463|28 80|postnitroglycerin technetium-99m tetrofosmin SPET studies
P09549398A1463|133 143|SPET studies
P09549398A1463|167 185|myocardial viability
P09549632A1189|52 53|74
P09549632A1189|67 91|predictability of ALT levels
P09549632A1189|83 85|ALT
P09549660A0782|48 56|simulated
P09549783T0000|0 14|Spatial accuracy
P09549783T0000|17 56|primary and secondary memory-guided saccades
P09549783T0000|59 71|schizophrenic
P09549783T0000|72 79|patients
P09550591A0454|0 18|Successful treatment
P09550591A0454|38 59|positive airway pressure
P09550591A0454|112 128|mean blood pressure
P09550591A0454|131 134|OSAS
P09550919A0365|24 39|cumulative manner
P09550919A0365|54 64|intravenous
P09550919A0365|109 112|PSVT
P09551096A0108|0 3|RNAs
P09551096A0108|39 55|ribosomal subunits
P09551096A0108|39 47|ribosomal
P09551096A0108|74 91|interacting factors
P09551096A0108|98 114|particle formation
P09551182A0212|7 24|retinoid signalling
P09551182A0212|27 42|zebrafish embryos
P09551182A0212|56 66|novel method
P09551182A0212|85 93|retinoids
P09551182A0212|102 108|embryos
P09551182A0212|149 169|transactivation domain
P09551182A0212|173 192|retinoic acid receptor
P09551182A0212|173 192|retinoic acid receptor
P09551182A0212|197 224|heterologous DNA binding domain
P09551938A0318|10 33|nuclear regulatory factors
P09551938A0318|10 33|nuclear regulatory factors
P09551938A0318|79 94|CCR5 gene promoter
P09551938A0318|79 86|CCR5 gene
P09551972A1033|0 30|Fluorescence in situ hybridization
P09551972A1033|51 61|chromosome 8
P09551972A1033|73 97|hybrid cell line 706-B6 clone
P09551972A1033|101 105|CL-17
P09551972A1033|101 105|CL-17
P09551972A1033|111 116|cosmid
P09551972A1033|117 122|c101F1
P09551972A1033|133 140|9804 gene
P09551972A1033|133 140|9804 gene
P09551972A1033|161 166|8q24.3
P09552469A0225|21 41|piroxicam and poloxamer
P09552469A0225|54 72|x-ray diffractometry
P09552469A0225|74 76|XRD
P09552469A0225|79 86|infrared
P09552469A0225|88 102|IR) spectroscopy
P09552469A0225|88 89|IR
P09552469A0225|118 132|thermal analysis
P09552469A0225|134 136|DTA
P09552469A0225|143 157|solid dispersion
P09553040A0651|0 11|Cell survival
P09553040A0651|14 16|Epo
P09553040A0651|14 16|Epo
P09553040A0651|52 68|signaling pathways
P09553040A0651|78 87|PI-3 kinase
P09553040A0651|78 87|PI-3 kinase
P09553040A0651|89 97|PLC-gamma
P09553040A0651|89 97|PLC-gamma
P09553040A0651|99 108|Ras or Stats
P09553040A0651|99 101|Ras
P09553040A0651|104 108|Stats
P09553134A0596|3 38|N-syndecan-dependent neurite outgrowth
P09553134A0596|55 78|tyrosine kinase inhibitors
P09553134A0596|55 68|tyrosine kinase
P09553134A0596|79 89|herbimycin A
P09553134A0596|93 95|PP1
P09553134A0596|93 95|PP1
P09553143A0729|8 22|ZAP-70 substrate
P09553143A0729|8 13|ZAP-70
P09553143A0729|24 29|SLP-76
P09553143A0729|24 29|SLP-76
P09553143A0729|43 45|Erk
P09553143A0729|43 45|Erk
P09553143A0729|99 109|Jurkat cells
P09553143A0729|119 127|P116 cells
P09553143A0729|146 149|H2O2
P09553686A0000|3 25|pharmacokinetic patterns
P09553686A0000|28 36|estradiol
P09553686A0000|54 60|estrone
P09553686A0000|93 97|women
P09553686A0000|109 116|surgical
P09553686A0000|152 176|estradiol transdermal patch
P09553686A0000|181 192|active matrix
P09553686A0000|213 221|enhancers
P09553686A0000|233 256|epicutaneous applications
P09553686A0000|282 289|"patch 7D
P09555046A1617|28 31|base
P09555046A1617|43 70|branchpoint consensus sequence
P09555046A1617|75 80|intron
P09555046A1617|89 100|human disease
P09555046A1617|140 146|mammals
P09556557A1238|14 27|central regions
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|34 38|Gar1p
P09556561A0671|34 38|Gar1p
P09556561A0671|70 76|snoRNAs
P09556561A0671|98 102|yeast
P09556561A0671|151 166|pre-rRNA molecule
P09556561A0671|151 158|pre-rRNA
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|26 28|VDR
P09556566A0174|26 28|VDR
P09556566A0174|36 61|retinoic acid Xalpha receptor
P09556566A0174|36 47|retinoic acid
P09556566A0174|48 61|Xalpha receptor
P09556566A0174|63 70|RXRalpha
P09556566A0174|63 70|RXRalpha
P09556566A0174|77 98|human T cell line MT2 cells
P09556573A1062|33 48|PPARalpha ligand 8
P09556573A1062|33 41|PPARalpha
P09556573A1062|50 79|S)-hydroxyeicosatetraenoic acid
P09556573A1062|112 120|PPARalpha
P09556573A1062|112 120|PPARalpha
P09556573A1062|128 146|co-activator RIP-140
P09556573A1062|128 139|co-activator
P09556573A1062|140 142|RIP
P09556573A1062|175 183|PPARalpha
P09556573A1062|175 183|PPARalpha
P09556573A1062|191 202|co-repressor
P09556573A1062|191 202|co-repressor
P09556573A1062|203 206|SMRT
P09556573A1062|203 206|SMRT
P09556861A1018|64 65|OA
P09556861A1018|107 130|mitochondrial respiration
P09556861A1018|157 162|ATP; (2
P09556861A1018|157 159|ATP
P09556861A1018|176 190|tRNA-synthetase
P09556861A1018|176 190|tRNA-synthetase
P09556861A1018|212 227|protein synthesis
P09556861A1018|243 259|lipid peroxidation
P09557678A0140|28 42|acute expression
P09557678A0140|48 87|bovine papillomavirus type 1 (BPV1) E2 protein
P09557678A0140|48 72|bovine papillomavirus type 1
P09557678A0140|74 87|BPV1) E2 protein
P09557678A0140|90 93|HeLa
P09557678A0140|97 126|HT-3 cervical carcinoma cell lines
P09557678A0140|141 161|cellular proliferation
P09557678A0140|181 201|G1/S phase growth arrest
P09557682A0490|21 41|hGli2 alpha, beta, gamma
P09557682A0490|21 30|hGli2 alpha
P09557682A0490|32 41|beta, gamma
P09557682A0490|46 50|delta
P09557682A0490|121 128|isoforms
P09557682A0490|141 148|DNA motif
P09557682A0490|150 154|TRE2S
P09557682A0490|161 163|LTR
P09557708A1426|11 20|actin tails
P09557708A1426|11 15|actin
P09557708A1426|31 42|IEV particles
P09557708A1426|60 81|virus-tipped microvilli
P09557708A1426|95 117|wild-type-infected cells
P09557708A1426|148 156|vA33delta
P09557912A0699|5 11|mean IOP
P09557912A0699|48 57|anesthesia
P09557912A0699|92 97|reflex
P09557912A0699|118 130|methohexitone
P09557912A0699|163 182|muscle fasciculations
P09557912A0699|192 204|suxamethonium
P09557912A0699|213 215|5.6
P09557912A0699|237 246|convulsion
P09557912A0699|293 314|spontaneous respiration
P09560221A0282|1 4|cDNA
P09560221A0282|6 11|cak1At
P09560221A0282|6 11|cak1At
P09560221A0282|41 51|CAK mutation
P09560221A0282|41 43|CAK
P09560221A0282|101 109|CAK mutant
P09560221A0282|101 109|CAK mutant
P09560221A0282|111 116|cak1At
P09560221A0282|111 116|cak1At
P09560221A0282|141 150|animal CAKs
P09560325A1285|0 30|Post-translational modifications
P09560325A1285|37 67|glycosylation and phosphorylation
P09560325A1285|112 131|protein heterogeneity
P09560390A0771|12 37|restoring checkpoint control
P09560390A0771|55 59|sum1+
P09560390A0771|55 59|sum1+
P09560390A0771|96 108|osmotic stress
P09560430A0000|0 3|Ime1
P09560430A0000|0 3|Ime1
P09560430A0000|49 65|alpha diploid cells
P09560430A0000|68 90|Saccharomyces cerevisiae
P09561560A0579|0 13|Rhesus macaques
P09561560A0579|17 26|BALB/c mice
P09561560A0579|44 68|Mengo virus SIV recombinants
P09561560A0579|84 95|CTL responses
P09561560A0579|106 120|SIV gene products
P09561560A0579|106 112|SIV gene
P09561560A0579|135 153|HIV-Nef recombinants
P09561560A0579|135 153|HIV-Nef recombinants
P09561560A0579|166 176|CTL response
P09561560A0579|195 208|HIV1 Nef peptide
P09561560A0579|195 208|HIV1 Nef peptide
P09561560A0579|217 232|positions 182-198
P09561616A0142|0 11|Deltamethrin
P09561616A0142|33 47|thatched surface
P09562398A0848|0 16|Trichloroethylene
P09562398A0848|129 136|n-hexane
P09562398A0848|154 156|1.5
P09562398A0848|162 164|4.6
P09562398A0848|174 180|1.8-5.9
P09562558T0000|22 43|IRF-2 DNA-binding domain
P09562558T0000|22 43|IRF-2 DNA-binding domain
P09562558T0000|64 91|winged helix-turn-helix family
P09562558T0000|64 91|winged helix-turn-helix family
P09564860A2139|11 35|receptor/G protein coupling
P09564860A2139|11 27|receptor/G protein
P09564860A2139|72 80|3i domains
P09564860A2139|113 113|G
P09564860A2139|113 113|G
P09564860A2139|115 115|i
P09564860A2139|117 126|o) proteins
P09564860A2139|117 117|o
P09564860A2139|128 173|M2Ach-muscarinic and alpha2A-adrenergic receptors
P09564860A2139|128 173|M2Ach-muscarinic and alpha2A-adrenergic receptors
P09564860A2315|51 59|rat GnRH-R
P09564860A2315|51 59|rat GnRH-R
P09564860A2315|72 85|receptor G(q/11
P09564860A2315|82 85|q/11
P09564860A2315|87 101|protein coupling
P09564860A2315|128 143|GGH(3)1' cell line
P09564860A2315|128 130|GGH
P09564860A2315|132 132|3
P09564860A2315|169 186|signal transduction
P09564860A2315|205 213|Gs protein
P09564860A2315|205 213|Gs protein
P09564917A0900|17 34|alpha2-antiplasmin
P09564917A0900|17 34|alpha2-antiplasmin
P09565576T0000|1 15|catalytic domain
P09565576T0000|18 44|eukaryotic DNA topoisomerase I
P09565576T0000|28 44|DNA topoisomerase I
P09565584A0770|10 24|basic amino acids
P09565584A0770|26 29|KKKR
P09565584A0770|75 92|constitutive exon 13
P09565584A0770|99 115|alternative exon 16
P09565584A0770|134 149|nuclear targeting
P09565584A0770|155 155|H
P09565584A0770|173 204|site-directed mutagenesis analysis
P09565606A0520|7 30|stem-loop called structure
P09565606A0520|41 46|3'-end
P09565606A0520|49 52|repY
P09565606A0520|70 88|5'-rCGCC-3' sequence
P09565606A0520|95 118|repZ ribosome-binding site
P09565606A0520|95 118|repZ ribosome-binding site
P09566731A0458|57 79|chromosome 16p12.1-p11.2
P09566731A0458|93 108|mouse chromosome 7
P09566731A0458|116 133|somatic cell hybrids
P09566731A0458|137 148|cosmid clones
P09566871A0343|2 12|fus3 mutants
P09566871A0343|2 5|fus3
P09566871A0343|25 38|Ty1 RNA, protein
P09566871A0343|25 30|Ty1 RNA
P09566871A0343|32 47|protein synthesis
P09566871A0343|104 114|FUS3 strains
P09566871A0343|104 107|FUS3
P09566871A0343|138 140|TyA
P09566871A0343|138 140|TyA
P09566871A0343|142 150|integrase
P09566871A0343|155 182|reverse transcriptase proteins
P09566871A0343|155 182|reverse transcriptase proteins
P09566871A0343|186 192|Ty1 cDNA
P09566871A0343|186 192|Ty1 cDNA
P09566871T0000|0 26|Posttranslational regulation
P09566871T0000|29 31|Ty1
P09566871T0000|29 31|Ty1
P09566871T0000|52 85|mitogen-activated protein kinase Fus3
P09566871T0000|52 81|mitogen-activated protein kinase
P09566871T0000|82 85|Fus3
P09566876A0000|3 31|general transcription factor IIA
P09566876A0000|3 31|general transcription factor IIA
P09566876A0000|33 37|TFIIA
P09566876A0000|33 37|TFIIA
P09566876A0000|55 72|TATA binding protein
P09566876A0000|55 72|TATA binding protein
P09566876A0000|74 76|TBP
P09566876A0000|74 76|TBP
P09566876A0000|81 91|promoter DNA
P09566882A0693|31 34|Pho2
P09566882A0693|31 34|Pho2
P09566882A0693|40 47|promoter
P09566882A0693|78 81|Pho4
P09566882A0693|78 81|Pho4
P09566882A0693|94 97|Pho2
P09566882A0693|94 97|Pho2
P09566918A1115|17 20|Ser-
P09566918A1115|21 23|Thr
P09566918A1115|36 52|phosphomimetic Asp
P09566918A1115|89 93|IRF-3
P09566918A1115|89 93|IRF-3
P09566918A1115|132 140|promoters
P09566918A1115|151 161|PRDI-PRDIII
P09566918A1115|151 154|PRDI
P09566918A1115|156 161|PRDIII
P09566918A1115|164 185|ISRE regulatory elements
P09566918A1115|164 185|ISRE regulatory elements
P09568445T0000|0 14|New-onset angina
P09568445T0000|24 48|acute myocardial infarction
P09568445T0000|97 108|thrombolysis
P09568549A0188|23 41|acute administration
P09568549A0188|70 73|oral
P09568549A0188|77 82|dermal
P09568549A0188|91 94|mice
P09568549A0188|98 101|rats
P09568549A0188|104 114|serum levels
P09568549A0188|117 125|histamine
P09570030T0000|0 4|Fetal
P09570030T0000|32 57|impaired ovarian development
P09570107A0355|10 20|PCDFs/PCDDs
P09570107A0355|28 33|ESP ash
P09570107A0355|52 60|boiler ash
P09570133A0474|12 34|DNA-protein interactions
P09570133A0474|12 22|DNA-protein
P09570133A0474|36 62|protein-protein interactions
P09570133A0474|36 50|protein-protein
P09570133A0474|112 129|ETS-domain proteins
P09570133A0474|112 129|ETS-domain proteins
P09570133A0474|132 148|specific promoters
P09570944T0000|0 11|Localization
P09570944T0000|14 20|67 exons
P09570944T0000|24 32|YAC contig
P09570944T0000|86 106|human chromosome 7q21.1
P09570952A0000|11 21|exon-intron
P09570952A0000|39 48|murine gene
P09570952A0000|39 48|murine gene
P09570952A0000|57 65|M-protein
P09570952A0000|57 65|M-protein
P09570952A0000|68 84|structural protein
P09570952A0000|87 106|sarcomeric myofibrils
P09571563A0000|21 33|image analysis
P09571563A0000|47 72|photorefractive keratectomy
P09571563A0000|74 76|PRK
P09571563A0000|155 160|cornea
P09572428A0526|9 31|serum VEGF concentrations
P09572428A0526|14 17|VEGF
P09572428A0526|66 70|women
P09572428A0526|75 77|PCO
P09572428A0526|81 84|PCOS
P09572428A0526|138 142|women
P09572428A0526|147 159|normal ovaries
P09572491A1044|50 56|p53 gene
P09572491A1044|50 56|p53 gene
P09572491A1044|59 63|codon
P09572491A1044|68 74|p53(242
P09572491A1044|68 70|p53
P09572491A1044|94 100|alanine
P09572491A1044|104 110|glycine
P09572511A0148|3 14|new algorithm
P09572511A0148|22 28|RBI-MAP
P09572511A0148|22 28|RBI-MAP
P09572511A0148|64 65|EM
P09572511A0148|67 70|RBI-
P09572511A0148|71 82|EM) algorithm
P09572965A1235|6 8|ORF
P09572965A1235|10 13|ORF5
P09572965A1235|32 39|gene agrB
P09572965A1235|36 39|agrB
P09572965A1235|44 63|Staphylococcus aureus
P09572965A1235|111 128|virulence phenotype
P09572990A0630|20 23|hSIE
P09572990A0630|20 23|hSIE
P09572990A0630|27 32|Stat-3
P09572990A0630|27 30|Stat
P09572990A0630|38 42|MHC-I
P09572990A0630|38 42|MHC-I
P09572990A0630|89 94|Stat-3
P09572990A0630|89 94|Stat-3
P09572990A0630|99 113|nuclear extracts
P09572990A0630|130 138|hSIE probe
P09572990A0630|130 133|hSIE
P09572990A0630|142 162|avidin-coupled agarose
P09572990A0630|142 147|avidin
P09573187T0000|0 24|Transcriptional repression
P09573187T0000|35 56|LysR-type regulator CatR
P09573187T0000|35 52|LysR-type regulator
P09573187T0000|53 56|CatR
P09573187T0000|64 83|multiple binding sites
P09573202A0900|40 51|alpha subunit
P09573202A0900|40 51|alpha subunit
P09573202A0900|80 86|glycine
P09573202A0900|93 111|aspartic acid residue
P09573202A0900|114 124|position 171
P09573202A0900|131 146|N-terminal domain
P09573202A0900|131 146|N-terminal domain
P09573244A0523|8 18|mRNA species
P09573244A0523|44 62|polyadenylation site
P09573374A0687|5 24|Southern blot analysis
P09573374A0687|28 45|restriction mapping
P09573374A0687|48 84|genomic YAC (yeast artificial chromosome)
P09573374A0687|88 99|cosmid clones
P09573374A0687|113 131|human RIL gene 240-260
P09573374A0687|113 124|human RIL gene
P09573374A0687|148 155|IRF1 gene
P09573374A0687|148 155|IRF1 gene
P09573378A0761|0 2|U73
P09573378A0761|0 2|U73
P09573378A0761|11 23|C, D and D' boxes
P09573378A0761|70 84|28S ribosomal RNA
P09573378A0761|70 84|28S ribosomal RNA
P09573884A0392|27 41|S-N-B and S-N-Pog
P09573884A0392|27 31|S-N-B
P09573884A0392|35 41|S-N-Pog
P09573884A0392|83 89|Class II
P09573884A0392|106 119|Class I subjects
P09574799A1072|0 14|Echinostomiasis
P09574799A1072|29 48|socioeconomic factors
P09574799A1072|55 61|poverty
P09574799A1072|78 110|explosively growing free-food market
P09574799A1072|119 142|supervised food inspection
P09574799A1072|178 190|helminthiases
P09574799A1072|195 221|declining economic conditions
P09575143A1189|3 14|localization
P09575143A1189|17 22|ZAP-70
P09575143A1189|17 22|ZAP-70
P09575143A1189|28 37|cell cortex
P09575143A1189|75 91|SRC-family kinases
P09575143A1189|75 91|SRC-family kinases
P09575143A1189|149 178|tyrosine-based activation motifs
P09575143A1189|184 186|TCR
P09575143A1189|184 186|TCR
P09575187A1558|16 24|NF-kappaB
P09575187A1558|16 24|NF-kappaB
P09575187A1558|37 45|apoptosis
P09575187A1558|55 70|ER calcium release
P09575187A1558|103 111|sAPPalpha
P09575187A1558|103 111|sAPPalpha
P09575187A1558|120 148|thapsigargin-induced apoptosis
P09575187A1558|167 172|kappaB
P09575187A1558|173 180|decoy DNA
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|55 58|Jaks
P09575217A0000|55 58|Jaks
P09575217A0000|63 113|signal transducers and activators of transcription (Stats
P09575217A0000|109 113|Stats
P09575217A0000|118 133|nuclear signaling
P09575217A0971|1 26|site-directed R618K mutation
P09575217A0971|32 45|Stat5 SH2 domain
P09575217A0971|32 36|Stat5
P09575217A0971|37 39|SH2
P09575217A0971|58 72|phosphorylation
P09575217A0971|75 78|Jak2
P09575217A0971|75 78|Jak2
P09575217A0971|98 106|C terminus
P09575217A0971|98 106|C terminus
P09575217A0971|112 136|Stat5 hyperphosphorylation
P09575217A0971|112 116|Stat5
P09576230T0000|11 57|nitric oxide synthase inhibitor on reperfusion injury
P09576230T0000|11 29|nitric oxide synthase
P09576230T0000|63 67|brain
P09576230T0000|73 100|hypothermic circulatory arrest
P09576915A0269|13 25|recombination
P09576915A0269|28 30|HMR
P09576915A0269|65 78|E and I silencers
P09577365A0747|2 15|angiodysplasia
P09577365A0747|17 30|ectatic vessels
P09577365A0747|36 41|mucosa
P09577365A0747|63 76|collagen type IV
P09577365A0747|63 76|collagen type IV
P09577365A0747|81 101|similarly sized vessels
P09577365A0747|120 137|perforating vessels
P09577365A0747|186 202|muscularis mucosae
P09577395A0000|33 42|reflex (VOR
P09577395A0000|137 149|low-amplitude
P09578042A0363|16 37|seizure-offset patterns
P09578042A0363|85 93|SEEG/ECoG
P09578042A0363|111 118|patients
P09578042A0363|144 146|TLE
P09578570A0200|36 42|protein
P09578570A0200|43 43|Z
P09578570A0200|102 117|PCR amplification
P09578570A0200|120 131|leukocyte DNA
P09578570A0200|146 156|phage clones
P09578570A0200|162 180|human genomic library
P09579602A1720|63 80|CD34 determinations
P09579602A1720|63 66|CD34
P09579602A1720|100 113|sample handling
P09579789A0974|32 35|rats
P09579789A0974|68 80|olfactory bulb
P09579808A0000|0 33|UDP-GlcNAc:alpha-6-D-mannoside beta
P09579808A0000|0 9|UDP-GlcNAc
P09579808A0000|11 71|alpha-6-D-mannoside beta-1,2-N-acetylglucosaminyltransferase II
P09579808A0000|35 71|1,2-N-acetylglucosaminyltransferase II
P09579808A0000|73 80|GnT II; EC
P09579808A0000|73 77|GnT II
P09579808A0000|79 89|EC 2.4.1.143
P09579808A0000|131 147|Asn-linked glycans
P09580062A0100|30 40|intravenous
P09580062A0100|41 56|cyclophosphamide
P09580062A0100|60 67|steroids
P09580062A0100|99 111|cyclosporine A
P09580563A0331|3 28|predicted amino acid sequence
P09580563A0331|50 76|cytoplasmic dynein heavy chain
P09580563A0331|50 76|cytoplasmic dynein heavy chain
P09580563A0331|79 94|Neurospora crassa
P09580563A0331|79 94|Neurospora crassa
P09580563A0331|118 136|Aspergillus nidulans
P09580563A0331|162 184|Saccharomyces cerevisiae
P09580700A0841|3 22|DNA binding activities
P09580700A0841|33 53|repressor preparations
P09580700A0841|89 92|CIRs
P09580700A0841|94 102|CIR3-CIR6
P09580700A0841|111 130|essential early region
P09580700A0841|145 162|DNase I footprinting
P09580700A0841|145 150|DNase I
P09581552A1323|0 17|Molecular modelling
P09581552A1323|34 54|tetramerization domain
P09581552A1323|69 74|bundle
P09581552A1323|116 133|aromatic amino acids
P09581775A0185|58 66|NF-kappaB
P09581775A0185|58 66|NF-kappaB
P09581775A0185|77 117|chronically HIV-1-infected promonocytic U937
P09581775A0185|119 125|U9-IIIB
P09581775A0185|130 148|myeloblastic PLB-985
P09581775A0185|150 157|PLB-IIIB
P09581775A0185|150 157|PLB-IIIB
P09581775A0185|171 188|apoptotic signaling
P09581834A2578|90 92|PCA
P09581834A2578|139 172|erbB1-SHC-mediated signaling pathway
P09581834A2578|139 143|erbB1
P09581834A2578|145 147|SHC
P09581834A2578|185 189|CDKIs
P09581834A2578|185 189|CDKIs
P09581834A2578|204 211|G1 arrest
P09581872A0000|45 57|type I collagen
P09581872A0000|45 57|type I collagen
P09582267A0326|22 41|human SINA-homologous
P09582267A0326|27 55|SINA-homologous (Siah) proteins
P09582267A0326|43 55|Siah) proteins
P09582267A0326|57 74|expression plasmids
P09582267A0326|83 89|Siah-1A
P09582267A0326|83 89|Siah-1A
P09582267A0326|120 137|293 epithelial cells
P09582267A0326|141 160|GM701 fibroblast cells
P09582267A0326|173 184|growth arrest
P09582267A0326|203 211|apoptosis
P09582306T0000|1 13|point mutation
P09582306T0000|16 22|Galphao
P09582306T0000|26 33|Galphai1
P09582306T0000|26 33|Galphai1
P09582306T0000|66 90|G protein signaling proteins
P09582306T0000|66 73|G protein
P09582308A1165|44 69|disulfide-linked homodimers
P09582308A1165|91 110|homo- and heterodimers
P09582326A0151|0 0|N
P09582327A0295|25 27|GH3
P09582327A0295|51 69|rat GnRH receptor cDNA
P09582327A0295|51 53|rat
P09582327A0295|54 69|GnRH receptor cDNA
P09582327A0295|71 82|GGH3-1' cells
P09582327A0295|71 76|GGH3-1
P09582327A0295|120 129|fusion gene
P09582327A0295|154 185|rat LHbeta gene 5'-flanking sequence
P09582327A0295|154 185|rat LHbeta gene 5'-flanking sequence
P09582327A0295|197 206|5 base pairs
P09582327A0295|212 232|5'-untranslated region
P09582327A0295|241 276|luciferase reporter (-797/+5LHbetaLUC)
P09582327A0295|241 275|luciferase reporter (-797/+5LHbetaLUC
P09582327A0295|290 300|GnRH agonist
P09582327A0295|290 293|GnRH
P09582331A0506|3 19|5'-flanking region
P09582331A0506|25 44|nucleotide -837 to -336
P09582331A0506|54 57|TATA
P09582331A0506|69 77|CAAT boxes
P09582331A0506|86 141|GATA-1/SP1 erythroid-specific cis-acting regulatory elements
P09582331A0506|86 91|GATA-1
P09582331A0506|93 95|SP1
P09582331A0506|96 141|erythroid-specific cis-acting regulatory elements
P09582343A0000|16 40|radiosensitive cell line SX9
P09582343A0000|45 72|mammary carcinoma cell line FM3A
P09582350A0165|2 9|patients
P09582350A0165|18 19|IA
P09582350A0165|46 59|E1alpha subunit
P09582350A0165|46 59|E1alpha subunit
P09582350A0165|91 92|E1
P09582350A0165|91 92|E1
P09582350A0165|96 149|branched-chain ketoacid dehydrogenase catalytic activities
P09582350A0165|96 130|branched-chain ketoacid dehydrogenase
P09582635A0523|24 35|bond strength
P09582635A0523|92 103|bond strength
P09582953A0000|20 40|coagulation factor VIII
P09582953A0000|20 36|coagulation factor
P09582953A0000|37 40|VIII
P09582953A0000|52 57|F.VIII
P09582953A0000|59 59|C
P09582953A0000|64 83|C1-esterase inhibitor
P09582953A0000|64 74|C1-esterase
P09582953A0000|85 90|C1-INH
P09582953A0000|85 90|C1-INH
P09582953A0000|93 124|hemostasis-associated acute-phase
P09582953A0000|144 164|coagulation factors VII
P09582953A0000|144 164|coagulation factors VII
P09582953A0000|166 174|F.VII), IX
P09582953A0000|166 170|F.VII
P09582953A0000|173 174|IX
P09582953A0000|176 179|F.IX
P09582953A0000|176 179|F.IX
P09582953A0000|185 185|X
P09582953A0000|185 185|X
P09582953A0000|187 189|F.X
P09582953A0000|192 201|hemostasis
P09582953A0000|229 247|acute-phase response
P09582953A0000|280 284|colic
P09582953A0000|288 310|hemostasis abnormalities
P09582953A0000|329 346|acute-phase changes
P09582953A1097|45 67|fibrinogen concentration
P09582953A1097|45 54|fibrinogen
P09582953A1097|76 83|alpha 2AP
P09582953A1097|81 83|2AP
P09582953A1097|87 104|protein C activities
P09582953A1097|87 94|protein C
P09582953A1097|120 123|APTT
P09582953A1097|131 143|healthy horses
P09582953A1670|18 37|plasminogen, alpha 2AP
P09582953A1670|18 37|plasminogen, alpha 2AP
P09582953A1670|42 47|C1-INH
P09582953A1670|42 47|C1-INH
P09583201A0759|9 16|patients
P09583208A0171|0 14|Marked elevation
P09583208A0171|17 30|creatine kinase
P09583208A0171|17 30|creatine kinase
P09583208A0171|47 58|serum albumin
P09583208A0171|47 58|serum albumin
P09583208A0171|60 73|immunoglobulin
P09583208A0171|60 73|immunoglobulin
P09583208A0171|78 87|complement
P09583592A0263|17 25|Case study
P09583823A0238|18 21|pigs
P09583823A0238|48 67|left marginal arteries
P09583823A0238|92 95|TMLR
P09583823A0238|101 104|left
P09583823A0238|105 115|lateral wall
P09583823A0238|130 152|yttrium-aluminium garnet
P09583823A0238|154 155|Ho
P09583823A0238|157 176|YAG) laser (laser group
P09583823A0238|193 208|laser-infarction
P09584165T0000|0 4|RACK1
P09584165T0000|0 4|RACK1
P09584165T0000|27 33|C kinase
P09584165T0000|27 33|C kinase
P09584165T0000|50 60|beta subunit
P09584165T0000|50 60|beta subunit
P09584165T0000|63 71|G proteins
P09584165T0000|63 71|G proteins
P09584165T0000|91 108|src tyrosine kinases
P09584165T0000|91 108|src tyrosine kinases
P09584165T0000|120 130|NIH 3T3 cells
P09584179A0673|0 15|Peptide sequences
P09584179A0673|21 40|zinc finger protein Ttk
P09584179A0673|21 37|zinc finger protein
P09584179A0673|38 40|Ttk
P09584179A0673|47 70|transcription factor Adf-1
P09584179A0673|47 65|transcription factor
P09584179A0673|66 70|Adf-1
P09584180A0701|7 32|IL-4-inducible reporter gene
P09584180A0701|7 32|IL-4-inducible reporter gene
P09584180A0701|68 82|endogenous Stat6
P09584180A0701|78 82|Stat6
P09584180A0701|86 102|NF-kappaB proteins
P09584180A0701|86 94|NF-kappaB
P09584180A0701|105 120|IL-4-stimulated I
P09584180A0701|105 108|IL-4
P09584180A0701|122 139|29mu B lymphoma cells
P09584194A0000|0 3|HEF1
P09584194A0000|0 3|HEF1
P09584194A0000|5 8|p130
P09584194A0000|5 8|p130
P09584194A0000|10 12|Cas
P09584194A0000|10 12|Cas
P09584194A0000|18 24|Efs/Sin
P09584194A0000|18 20|Efs
P09584194A0000|22 24|Sin
P09584194A0000|44 69|multidomain docking proteins
P09584194A0000|121 132|cell adhesion
P09584194A1305|21 27|spindle
P09584194A1305|29 54|two-hybrid library screening
P09584194A1305|59 62|HEF1
P09584194A1305|59 62|HEF1
P09584194A1305|76 87|human homolog
P09584194A1305|93 96|G2/M
P09584194A1305|93 94|G2
P09584194A1305|96 126|M spindle-regulatory protein Dim1p
P09584194A1305|122 126|Dim1p
P09584194A1305|130 147|specific interactor
P09584194A1305|161 164|HEF1
P09584194A1305|161 164|HEF1
P09584194A1305|178 180|p55
P09584194A1305|178 180|p55
P09584194A1305|182 185|HEF1
P09584194A1305|182 185|HEF1
P09585253A1147|32 45|raf-ERK pathway
P09585253A1147|32 34|raf
P09585253A1147|36 38|ERK
P09585253A1147|63 74|TF expression
P09585253A1147|63 64|TF
P09585253A1147|77 96|breast carcinoma cells
P09585253A1147|155 170|high TF expression
P09585253A1147|159 160|TF
P09585253A1147|173 187|MDA-MB-231 cells
P09585253A1147|173 178|MDA-MB
P09585540A0440|71 111|specific chelating agent 1,10-phenanthroline
P09586285A0551|24 47|influenza type b meningitis
P09586832A0229|41 67|presynaptic, 5-HT1A receptors
P09586832A0229|53 67|5-HT1A receptors
P09587549T0001|0 16|Convulsive seizure
P09587549T0001|37 51|interferon alpha
P09587549T0001|37 51|interferon alpha
P09587549T0001|55 76|chronic viral hepatitis C
P09588228A0370|22 46|anticytokeratin 19 antibody
P09588228A0370|75 84|epithelial
P09588228A0370|88 108|sarcomatous MPM tissues
P09590294A0453|16 25|Drosophila
P09590294A0453|76 87|Notch pathway
P09590294A0453|76 80|Notch
P09590540A0513|3 21|bZP2 cDNA (115-1914 nt
P09590540A0513|3 10|bZP2 cDNA
P09590540A0513|12 21|115-1914 nt
P09590540A0513|57 116|N-terminal signal sequence and C-terminal transmembranelike domain
P09590540A0513|57 80|N-terminal signal sequence
P09590540A0513|84 84|C
P09590540A0513|136 162|Sac1-Sal1 restricted fragment
P09590540A0513|136 139|Sac1
P09590540A0513|141 144|Sal1
P09590540A0513|191 200|T5 promoter
P09590540A0513|191 200|T5 promoter
P09590540A0513|209 219|lac operator
P09590540A0513|230 241|pQE-30 vector
P09591221A0137|33 35|EPs
P09591221A0137|94 95|P1
P09591221A0137|94 95|P1
P09591221A0137|102 122|temporo-occipital site
P09592125A0000|0 26|Class I alpha1,2-mannosidases
P09592125A0000|0 4|Class
P09592125A0000|13 26|2-mannosidases
P09592125A0000|80 88|N -glycans
P09592125A0000|91 104|mammalian cells
P09592168T0000|0 17|Structural features
P09592168T0000|23 45|minimal DNA binding domain
P09592168T0000|47 54|M98-F219
P09592168T0000|58 96|human nucleotide excision repair protein XPA
P09592168T0000|94 96|XPA
P09592208A0470|168 194|19th-century moral statistics
P09592219A0652|38 60|educational intervention
P09593302A1165|28 35|aromatic
P09593302A1165|36 53|non-responsiveness
P09593302A1165|77 84|A-domain
P09593302A1165|77 84|A-domain
P09593302A1165|121 126|phenol
P09594299A0468|8 22|Acetabular index
P09594299A0468|111 134|developmental dislocation
P09594299A0468|140 142|hip
P09595496A0000|30 41|endothelin-1
P09595496A0000|30 41|endothelin-1
P09595496A0000|43 46|ET-1
P09595496A0000|43 46|ET-1
P09595496A0000|65 80|pericardial fluid
P09595496A0000|83 90|patients
P09595496A0000|101 114|cardiac surgery
P09596536A0219|28 45|knee loading changes
P09596536A0219|55 68|ACL transection
P09596536A0219|91 111|cartilage degeneration
P09596542A0542|23 45|tracheal cartilage matrix
P09596542A0542|49 61|collagen-rich
P09596542A0542|49 56|collagen
P09596542A0542|86 94|-rich core
P09596638T0000|23 42|Brassica S locus region
P09596638T0000|23 36|Brassica S locus
P09596738T0000|0 4|Roles
P09596738T0000|10 24|Candida albicans
P09596738T0000|25 61|mitogen-activated protein kinase homolog
P09596738T0000|42 61|protein kinase homolog
P09596738T0000|63 67|Cek1p
P09596738T0000|63 67|Cek1p
P09596738T0000|71 87|hyphal development
P09596738T0000|99 110|candidiasis.
P09598205A0430|20 34|monosaccharides
P09598205A0430|58 69|beta-alanine
P09598894A0732|6 13|subjects
P09598894A0732|24 36|bone formation
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|36 61|copper-dependent repression
P09599102A1191|67 70|Cu(I
P09599102A1191|67 68|Cu
P09599102A1191|112 125|CUP1 expression
P09599102A1191|112 115|CUP1
P09599102A1191|129 145|copper sensitivity
P09599664A0881|3 15|DNA sequencing
P09599664A0881|21 37|recombinant clones
P09599664A0881|61 68|RXR alpha
P09599664A0881|61 68|RXR alpha
P09599664A0881|72 78|RXR beta
P09599664A0881|72 78|RXR beta
P09599724A0193|71 77|workers
P09599724A0193|109 128|PCDD and PCDF congeners
P09599724A0193|131 141|blood lipids
P09599724A0193|165 183|PCDD and PCDF exposure
P09599724A0193|230 248|site-specific cancer
P09599897A0000|36 43|children
P09599897A0000|48 70|Henoch-Schonlein purpura
P09599897A0000|72 74|HSP
P09599897A0000|72 74|HSP
P09599897A0000|160 173|white blood cell
P09599897A0000|175 184|WBC) counts
P09599897A0000|186 207|serum C-reactive protein
P09599897A0000|191 207|C-reactive protein
P09599897A0000|209 211|CRP
P09599897A0000|209 211|CRP
P09599897A0000|220 238|platelet (PLT) counts
P09599897A0000|276 278|HSP
P09601007A0223|61 76|CO2 concentration
P09601007A0223|153 178|photosynthesis, respiration
P09601007A0223|197 201|CaCO3
P09601510A0215|22 33|retroviruses
P09601510A0215|38 47|FV pol genes
P09601510A0215|38 39|FV
P09601510A0215|40 47|pol genes
P09601510A0215|70 80|transcripts
P09601516A0695|19 37|hydrophobic residues
P09601516A0695|49 56|residues
P09601516A0695|63 66|PEP1
P09601516A0695|63 66|PEP1
P09601516A0695|96 103|S protein
P09601516A0695|96 103|S protein
P09601516A0695|133 149|surface expression
P09601921A0000|0 10|Tributyltin
P09601921A0000|43 53|di-butyltin
P09601921A0000|71 75|water
P09601921A0000|94 102|Lake Huron
P09601921A0000|107 116|Great Lakes
P09601921A0000|132 143|United States
P09601921A0000|162 176|British Columbia
P09601940A0280|3 18|5' flanking region
P09601940A0280|24 30|CD1 gene
P09601940A0280|24 30|CD1 gene
P09601940A0280|43 55|binding motifs
P09601940A0280|62 99|cytokine-inducible transcription factors
P09601940A0280|62 99|cytokine-inducible transcription factors
P09601940A0280|101 108|NF-IL2-A
P09601940A0280|101 108|NF-IL2-A
P09601940A0280|112 117|NF-IL6
P09601940A0280|112 117|NF-IL6
P09602124A0127|0 6|Fregnac
P09603345A1257|0 6|GLRaV-2
P09603345A1257|73 82|type member
P09603345A1257|94 96|BYV
P09603345A1257|157 174|genus Closterovirus
P09604052A0166|0 10|Demographic
P09604052A0166|57 59|339
P09604052A0166|60 82|healthy age-matched women
P09604052A0166|99 106|224 women
P09604052A0166|111 123|wrist fracture
P09605137A0677|20 24|c-Jun
P09605137A0677|20 24|c-Jun
P09605137A0677|28 30|p65
P09605137A0677|28 30|p65
P09605137A0677|61 107|IL-2 promoter- and CD28RE-driven reporter constructs
P09605137A0677|61 72|IL-2 promoter
P09605137A0677|77 107|CD28RE-driven reporter constructs
P09605137A0677|114 118|LFA-3
P09605137A0677|114 118|LFA-3
P09605137A0677|123 126|B7-1
P09605137A0677|123 126|B7-1
P09605137A0677|140 150|Jurkat cells
P09605930A1428|48 66|mobility shift assays
P09605930A1428|82 102|primary rat hepatocytes
P09605930A1428|113 129|endogenous ALS gene
P09605930A1428|123 129|ALS gene
P09605934A0801|4 15|E box sequence
P09605934A0801|17 22|CACGTG
P09605934A0801|40 53|binding element
P09605934A0801|57 59|USF
P09605934A0801|57 59|USF
P09605934A0801|61 85|upstream stimulatory factor
P09605934A0801|61 85|upstream stimulatory factor
P09605934A0801|100 121|helix-loop-helix family
P09605934A0801|100 121|helix-loop-helix family
P09605934A0801|124 143|transcription factors
P09606633A0523|0 13|Interferon beta
P09606633A0523|0 13|Interferon beta
P09606924T0000|6 26|chromatographic method
P09606924T0000|40 70|all-rac-alpha-tocopheryl acetate
P09606924T0000|40 52|all-rac-alpha
P09606924T0000|81 89|palmitate
P09606924T0000|92 114|milk-based infant formula
P09606924T0000|120 146|matrix solid-phase dispersion
P09609342A0000|26 35|turbo pumps
P09609342A0000|38 52|centrifugal pump
P09609342A0000|54 56|CFP
P09609342A0000|65 72|flow pump
P09609342A0000|74 76|MFP
P09609342A0000|84 96|axial flow pump
P09609342A0000|98 100|AFP
P09609342A0000|98 100|AFP
P09609705A0895|16 54|mitochondrial bc1 complex crystal structure
P09609705A0895|16 38|mitochondrial bc1 complex
P09609705A0895|62 62|Z
P09609720A0357|3 29|protease-resistant fragments
P09609720A0357|41 61|N- and C-terminal halves
P09609720A0357|41 46|N- and C
P09609720A0357|67 74|nuclease
P09609720A0357|103 111|proteases
P09610755A1731|3 24|side-to-side difference
P09611016A0652|13 17|women
P09611016A0652|34 45|conservative
P09611229A1664|32 35|FAS1
P09611229A1664|32 35|FAS1
P09611229A1664|38 55|nmt1-451Dino2 Delta
P09611229A1664|38 50|nmt1-451Dino2
P09611229A1664|90 108|transcription factor
P09611229A1664|90 108|transcription factor
P09611229A1664|194 210|N-myristoy-lation
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611234A0098|0 2|Rev
P09611234A0098|4 17|erbAalpha/beta
P09611234A0098|20 24|Mxi-1
P09611234A0098|20 24|Mxi-1
P09611234A0098|28 46|Mad bHLH-zip proteins
P09611234A0098|28 46|Mad bHLH-zip proteins
P09611234A0098|53 64|oncoproteins
P09611234A0098|65 68|PLZF
P09611234A0098|65 68|PLZF
P09611234A0098|72 80|LAZ3/BCL6
P09611234A0098|72 75|LAZ3
P09611234A0098|77 80|BCL6
P09611234A0098|96 112|corepressors N-CoR
P09611234A0098|108 112|N-CoR
P09611234A0098|116 119|SMRT
P09611234A0098|116 119|SMRT
P09611877A0455|23 25|CSF
P09611877A0455|39 42|ECHO
P09611877A0455|49 54|ECHO 11
P09611877A0455|59 63|ECHO 9
P09611877A0455|70 74|ECHO 7
P09612351A0386|33 43|oscillation
P09612351A0386|53 59|ULF band
P09612775A0726|3 17|ParaSight-F test
P09612775A0726|39 56|serum antigen levels
P09612775A0726|39 50|serum antigen
P09612775A0726|75 82|patients
P09613574A0905|3 28|purified recombinant protein
P09613574A0905|11 28|recombinant protein
P09613574A0905|45 58|enzyme activity
P09613574A0905|81 90|[3H]methyl
P09613574A0905|121 131|MGMT protein
P09613574A0905|121 131|MGMT protein
P09613946A0194|1 25|deproteinization procedure
P09613946A0194|41 68|reversed-phase HPLC separation
P09613946A0194|75 84|250x4.6 mm I
P09614065A0966|0 10|Elimination
P09614065A0966|16 32|inducible response
P09614065A0966|108 111|EpRE
P09614065A0966|115 130|upstream AP-1 site
P09614065A0966|123 130|AP-1 site
P09614106T0000|9 35|mobility group-like sequences
P09614106T0000|54 61|enhancer
P09614106T0000|67 76|Col2a1 gene
P09614106T0000|67 76|Col2a1 gene
P09614106T0000|91 118|cartilage-specific expression
P09617765A0174|21 36|open reading frame
P09617765A0174|39 44|1744 nt
P09617765A0174|69 88|3' untranslated region
P09617765A0174|91 96|1360 nt
P09617765A0174|101 102|3'
P09617765A0174|103 113|poly(A) tail
P09617807A0929|1 20|phylogenetic analysis
P09617807A0929|26 51|reverse transcriptase domain
P09617807A0929|26 45|reverse transcriptase
P09617807A0929|96 102|Cyclops
P09617807A0929|175 192|Gypsy-like elements
P09617807A0929|175 192|Gypsy-like elements
P09617807A0929|197 202|plants
P09618150A0127|2 19|physiological doses
P09618150A0127|27 51|insulin-like growth factor I
P09618150A0127|27 51|insulin-like growth factor I
P09618150A0127|53 57|IGF-I
P09618150A0127|53 57|IGF-I
P09618150A0127|61 67|insulin
P09618150A0127|61 67|insulin
P09618150A0127|100 103|cAMP
P09618150A0127|105 110|dbcAMP
P09618150A0127|124 144|UCP1 gene transcription
P09618150A0127|124 131|UCP1 gene
P09618150A0127|160 179|UCP1 mRNA accumulation
P09618150A0127|160 167|UCP1 mRNA
P09618150A1464|11 46|insulin induced AP-1 DNA binding activity
P09618150A1464|11 17|insulin
P09618150A1464|25 28|AP-1
P09618150A1464|94 107|MEK-1 inhibitor
P09618150A1464|94 98|MEK-1
P09618164A0709|0 10|Essentially
P09618164A0709|12 51|2'- O -methyl oligoribonucleotides (2'OMeRNA
P09618164A0709|71 76|nuclei
P09618164A0709|79 97|primary mdx myoblasts
P09618475A0747|19 34|CTD-binding motif
P09618475A0747|19 34|CTD-binding motif
P09618475A0747|94 97|Nrd1
P09618475A0747|94 97|Nrd1
P09618481T0000|15 22|human p21
P09618481T0000|20 32|p21/WAF1/Cip1
P09618481T0000|24 27|WAF1
P09618481T0000|29 32|Cip1
P09618481T0000|43 54|hepatic cells
P09618481T0000|86 108|Sp1 and Smad family members
P09618481T0000|86 88|Sp1
P09618481T0000|92 95|Smad
P09619631A0344|19 31|C. elegans cDNA
P09619631A0344|19 27|C. elegans
P09619631A0344|28 31|cDNA
P09619631A0344|96 111|mammalian p120 Ras
P09619631A0344|105 115|p120 Ras-GAP
P09619631A0344|113 115|GAP
P09619777A1583|11 22|ketoconazole
P09619777A1583|53 69|tablet formulation
P09619777A1583|72 92|Simulated Gastric Fluid
P09619777A1583|100 105|pepsin
P09619777A1583|100 105|pepsin
P09619777A1583|107 111|SGFsp
P09619777A1583|164 194|simulated upper jejunal conditions
P09619777A1583|228 248|fasted state conditions
P09620273A0189|2 8|mammals
P09620273A0189|13 21|Rb protein
P09620273A0189|13 21|Rb protein
P09620273A0189|47 59|D-type cyclins
P09620273A0189|47 59|D-type cyclins
P09620273A0189|72 88|cell proliferation
P09620273A0189|111 133|E2F transcription factors
P09620273A0189|111 133|E2F transcription factors
P09620606A0000|45 47|TCR
P09620606A0000|45 47|TCR
P09620606A0000|49 54|T cells
P09620606A0000|70 90|co-stimulatory signals
P09620873A1710|33 38|luteal
P09620873A1710|73 81|pregnancy
P09620873A1710|87 95|PKC-delta
P09620873A1710|87 95|PKC-delta
P09620873A1710|134 149|PKC family members
P09620873A1710|134 149|PKC family members
P09620873A1710|162 186|sHSP phosphorylation events
P09620873A1710|162 165|sHSP
P09620955A0370|39 42|mRNA
P09620955A0370|133 144|promoterless
P09620955A0370|145 153|lac operon
P09620955A0370|145 153|lac operon
P09621062A0810|28 52|transcriptional activation
P09621062A0810|65 88|site-directed mutagenesis
P09621062A0810|140 185|chloramphenicol acetyltransferase reporter system
P09621062A0810|140 171|chloramphenicol acetyltransferase
P09621372A0369|0 22|Routine blood examination
P09621372A0369|42 57|thrombocytopenia
P09621372A0369|59 69|positive CRP
P09621372A0369|67 69|CRP
P09621372A0369|82 98|myocardial enzymes
P09621893A0000|75 102|vascular alpha2-adrenoceptors
P09621893A0000|75 102|vascular alpha2-adrenoceptors
P09622055A0207|15 17|Cbl
P09622055A0207|15 17|Cbl
P09622055A0207|46 52|mammals
P09622055A0207|54 58|c-Cbl
P09622055A0207|54 58|c-Cbl
P09622055A0207|62 66|Cbl-b
P09622055A0207|62 66|Cbl-b
P09622055A0207|74 82|C. elegans
P09622055A0207|84 88|Sli-1
P09622055A0207|84 88|Sli-1
P09622055A0207|98 113|Drosophila (D-Cbl
P09622055A0207|98 113|Drosophila (D-Cbl
P09622121A0525|0 17|Anti-PTB antibodies
P09622121A0525|0 17|Anti-PTB antibodies
P09622121A0525|43 45|PTB
P09622121A0525|43 45|PTB
P09622121A0525|82 97|RNA-PTB complexes
P09622121T0000|23 55|polypyrimidine tract binding protein
P09622121T0000|23 55|polypyrimidine tract binding protein
P09622121T0000|57 59|PTB
P09622121T0000|57 59|PTB
P09622121T0000|124 132|pre-mRNAs
P09623830A0000|19 32|botulinum toxin
P09623830A0000|19 32|botulinum toxin
P09623830A0000|34 38|Botox
P09623830A0000|34 38|Botox
P09623830A0000|54 63|popularity
P09625762A0426|3 18|viral oncoprotein
P09625762A0426|19 21|E1A
P09625762A0426|19 21|E1A
P09625762A0426|30 58|NFAT-dependent transactivation
P09625762A0426|30 33|NFAT
P09625762A0426|62 81|p300-dependent manner
P09625762A0426|62 65|p300
P09625807A0000|16 44|mRNA differential display method
P09625807A0000|64 68|mRNAs
P09625807A0000|85 126|normal nasopharyngeal epithelial cell cultures
P09625807A0000|134 156|nasopharyngeal carcinoma
P09626662A1076|22 23|TR
P09626662A1076|48 53|RIP140
P09626662A1076|48 53|RIP140
P09626662A1076|59 68|RXR subunit
P09626662A1076|59 68|RXR subunit
P09626662A1076|105 121|TR/RXR heterodimer
P09626662A1076|105 106|TR
P09626662A1076|108 110|RXR
P09626662A1076|147 152|ligand
P09627285A0160|0 6|SETTING
P09627285A0160|18 40|hospital-based, tertiary
P09627285A0160|45 61|infertility center
P09627285A0554|0 5|RESULT
P09627285A0554|12 19|patients
P09627285A0554|32 40|FSH levels
P09627285A0554|32 34|FSH
P09627285A0554|57 62|oocyte
P09627285A0554|115 117|hMG
P09627285A0554|115 117|hMG
P09627285A0554|131 132|56
P09627598A0384|13 20|patients
P09627598A0384|25 26|IS
P09627598A0384|91 98|OVAR test
P09627598A0384|110 131|otolith system imbalance
P09627598A0384|145 159|control subjects
P09628375A0700|5 33|ePTFE specimens, tissue coverage
P09628419A0812|16 19|Wing
P09628419A0812|23 40|Kristofferson model
P09628419A0812|66 69|ISIs
P09628821A1194|18 31|KG1a EST dataset
P09628821A1194|51 60|human genes
P09628821A1194|51 60|human genes
P09628821A1194|92 117|differentiative progression
P09628821A1194|121 137|lineage commitment
P09628890A0455|91 98|HA trimer
P09628890A0455|91 98|HA trimer
P09629449A0540|18 20|ROS
P09629449A0540|18 20|ROS
P09629449A0540|90 100|PMN elastase
P09629449A0540|90 100|PMN elastase
P09629449A0540|119 137|peroxidase-positive
P09629449A0540|119 128|peroxidase
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0102|5 11|U1 snRNP
P09630245A0102|103 107|yeast
P09630245A0102|120 138|early splicing events
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|58 79|seven snRNP core proteins
P09630245A0903|101 132|metazoan U1 snRNP-specific proteins
P09630245A0903|111 132|snRNP-specific proteins
P09630245A0903|140 168|yeast-specific U1 snRNP proteins
P09630245A0903|140 144|yeast
P09630245A0903|156 168|snRNP proteins
P09632217A0477|3 18|opioid antagonist
P09632217A0477|19 28|naltrexone
P09632217A0477|89 94|heroin
P09632217A0477|174 180|cocaine
P09632637A0361|21 49|hepatic stellate cell regulation
P09632637A0361|52 71|M6P/IGFIIR expression
P09632637A0361|52 54|M6P
P09632637A0361|56 61|IGFIIR
P09632637A0361|84 113|M6P/IGFIIR mRNA transcript levels
P09632637A0361|84 86|M6P
P09632637A0361|88 93|IGFIIR
P09632637A0361|125 137|stellate cells
P09632637A0361|142 145|rats
P09632637A0361|155 173|carbon tetrachloride
P09632637A0361|175 178|CCl4
P09632709A0464|3 11|cDNA clone
P09632709A0464|22 28|NCoA-62
P09632709A0464|22 25|NCoA
P09632709A0464|75 78|BX42
P09632709A0464|75 78|BX42
P09632709A0464|81 116|Drosophila melanogaster nuclear protein
P09632709A0464|81 116|Drosophila melanogaster nuclear protein
P09632709A0464|127 159|ecdysone-stimulated gene expression
P09632734A0081|20 27|proteins
P09632734A0081|34 49|C-terminal region
P09632734A0081|34 49|C-terminal region
P09632734A0081|96 118|GDP/GTP exchange proteins
P09632734A0081|96 110|GDP/GTP exchange
P09632734A0081|125 134|Rab3 family
P09632734A0081|125 134|Rab3 family
P09632734A0081|137 159|small GTP binding proteins
P09632734A0081|137 159|small GTP binding proteins
P09632734A0943|7 19|p82 expression
P09632734A0943|7 9|p82
P09632734A0943|33 46|ERK2 activation
P09632734A0943|33 36|ERK2
P09632734A0943|49 52|p126
P09632734A0943|49 52|p126
P09632734A0943|54 56|p70
P09632734A0943|54 56|p70
P09632785A0000|3 18|pre-mRNA splicing
P09632785A0000|25 28|U2AF
P09632785A0000|25 28|U2AF
P09632785A0000|30 68|U2 small nuclear ribonucleoprotein particle
P09632785A0000|30 60|U2 small nuclear ribonucleoprotein
P09632785A0000|70 74|snRNP
P09632785A0000|76 90|auxiliary factor
P09632785A0000|112 123|3' splice site
P09633171A0321|3 10|brackets
P09633171A0321|42 55|bovine incisors
P09633171A0321|78 82|water
P09633171A0321|140 148|shear mode
P09633274A0000|0 15|Exercise training
P09633274A0000|62 73|heart failure
P09633274A0000|74 81|patients
P09633630A0740|3 8|growth
P09633630A0740|11 24|Aer. hydrophila
P09633630A0740|27 57|filter-sterilized lettuce extract
P09633630A0740|87 89|v/v
P09633630A0740|91 93|BMC
P09633630A0740|107 120|Ps. fluorescens
P09633630A0740|153 155|v/v
P09633630A0740|157 159|BMC
P09633879A0246|56 69|ferritin levels
P09633879A0246|56 63|ferritin
P09633879A0246|83 90|patients
P09633879A0246|97 109|veteran' group
P09633879A0246|125 126|L1
P09635149A1148|0 9|Hematocrit
P09635149A1148|13 16|PaO2
P09635276A1608|12 28|myosin phosphatase
P09635276A1608|12 28|myosin phosphatase
P09636119T0000|0 27|Commutative saccadic generator
P09636119T0000|50 58|3-D ocular
P09636119T0000|68 74|pulleys
P09636358A0000|3 24|virus-associated VAI RNA
P09636358A0000|27 36|adenovirus
P09636358A0000|106 126|cellular and viral mRNAs
P09636670T0000|29 64|human cyclin-dependent kinase inhibitor
P09636670T0000|34 55|cyclin-dependent kinase
P09636670T0000|65 67|p18
P09636670T0000|65 67|p18
P09636670T0000|91 102|breast cancer
P09636708A0460|3 13|YccA protein
P09636708A0460|3 13|YccA protein
P09636708A0460|38 57|FtsH-dependent manner
P09636708A0460|38 41|FtsH
P09636708A0460|85 103|YccA11 mutant protein
P09636708A0460|85 103|YccA11 mutant protein
P09636708A0460|117 133|amino acid residues
P09636708A0460|143 173|amino-terminal cytoplasmic domain
P09637689A0150|3 11|major type
P09637689A0150|20 36|activator proteins
P09637689A0150|68 85|RNA polymerase (RNAP
P09637689A0150|68 80|RNA polymerase
P09637689A0150|82 96|RNAP) holoenzyme
P09637689A0150|137 140|RNAP
P09637689A0150|137 140|RNAP
P09637689A0150|146 153|promoter
P09638342T0000|17 18|L1
P09638342T0000|17 18|L1
P09638342T0000|46 61|neuronal adhesion
P09638342T0000|65 84|membrane cytoskeleton
P09638485A0111|11 17|benzene
P09638485A0111|19 42|urinary muconic acid (tt-MA
P09638485A0111|38 42|tt-MA
P09638485A0111|47 74|leukocyte alkaline phosphatase
P09638485A0111|47 74|leukocyte alkaline phosphatase
P09638485A0111|84 87|LAPA
P09638485A0111|157 163|workers
P09638650A0169|11 28|5'-noncoding region
P09638650A0169|30 48|NCR) of 73 nucleotides
P09638650A0169|54 70|open reading frames
P09638650A0169|72 75|ORFs
P09638650A0169|104 139|M(r) 160 kDa RNA-dependent RNA polymerase
P09638650A0169|104 104|M
P09638650A0169|106 139|r) 160 kDa RNA-dependent RNA polymerase
P09638650A0169|141 144|ORF1
P09638650A0169|141 144|ORF1
P09638650A0169|147 167|26 kDa movement protein 1
P09638650A0169|147 167|26 kDa movement protein 1
P09638650A0169|169 172|ORF2
P09638650A0169|169 172|ORF2
P09638650A0169|175 195|13 kDa movement protein 2
P09638650A0169|197 200|ORF3
P09638650A0169|208 223|movement protein 3
P09638650A0169|225 228|ORF4
P09638650A0169|231 252|24 kDa coat protein (OFR5)
P09638650A0169|236 246|coat protein
P09638650A0169|248 251|OFR5
P09638650A0169|260 277|NCR of 76 nucleotides
P09638793A1446|5 36|profound normovolemic hemodilution
P09638793A1446|64 84|LV diastolic properties
P09638793A1446|98 118|myocardial oxygenation
P09638793A1446|135 146|v. perflubron
P09638793A1446|166 174|O2 carrier
P09639074A0707|0 2|Sp1
P09639074A0707|0 2|Sp1
P09639074A0707|9 19|Sp3 isoforms
P09639074A0707|9 11|Sp3
P09639074A0707|66 85|DNA-protein complexes
P09639074A0707|66 85|DNA-protein complexes
P09639074A0707|99 120|NF-kappaB-proximal site
P09639074A0707|99 120|NF-kappaB-proximal site
P09639410A3282|46 66|therapeutic strategies
P09639558A0957|18 40|C1q-dependent haemolysis
P09639558A0957|18 20|C1q
P09639558A0957|47 56|IgG- and IgM
P09639558A0957|47 49|IgG
P09639558A0957|54 56|IgM
P09639558A0957|58 79|sensitized erythrocytes
P09639565A0225|0 0|3
P09639565A0225|8 13|distal
P09639565A0225|39 54|enhancer activity
P09639565A0225|57 70|pituitary cells
P09639565A0225|94 105|SV40 promoter
P09639565A0225|94 105|SV40 promoter
P09640162A0242|9 15|patient
P09640162A0242|27 56|pituitary-derived growth hormone
P09640162A0242|27 56|pituitary-derived growth hormone
P09640162A0242|71 93|growth hormone deficiency
P09640162A0242|71 83|growth hormone
P09640802A0467|0 0|3
P09640802A0467|53 63|chinese flap
P09641167A1359|11 18|TNF alpha
P09641167A1359|11 18|TNF alpha
P09641167A1359|20 26|TGF beta
P09641167A1359|20 26|TGF beta
P09641167A1359|28 31|PDGF
P09641167A1359|28 31|PDGF
P09641167A1359|35 42|IL-1beta
P09641167A1359|35 42|IL-1beta
P09641167A1359|52 69|LDLr gene expression
P09641167A1359|52 59|LDLr gene
P09641167A1359|82 142|sterol-independent and mitogenesis-independent gene transcription
P09642042A0646|0 16|Binding affinities
P09642042A0646|28 43|nucleotide mono-,
P09642042A0646|44 62|di- and triphosphates
P09642042A0646|104 123|beta-phosphate moiety
P09642042A0646|137 152|substrate binding
P09642200A0956|64 84|M. thermoautotrophicum
P09642200A0956|88 99|M. jannaschii
P09642200A0956|114 117|ahaK
P09642200A0956|114 117|ahaK
P09642200A0956|131 145|Escherichia coli
P09642200A0956|173 191|cytoplasmic membrane
P09642200A0956|228 233|lipids
P09642200A0956|248 255|bacteria
P09642214A0244|30 56|protein-tyrosine phosphatase
P09642214A0244|30 56|protein-tyrosine phosphatase
P09642214A0244|57 61|SHP-2
P09642214A0244|57 61|SHP-2
P09642214A0244|64 86|ErbB-mediated activation
P09642214A0244|64 67|ErbB
P09642214A0244|89 118|mitogen-activated protein kinase
P09642214A0244|89 118|mitogen-activated protein kinase
P09642214A0244|120 123|MAPK
P09642214A0244|120 123|MAPK
P09642214A0244|141 152|SHP-2 mutants
P09642214A0244|141 145|SHP-2
P09642214A0244|155 164|COS-7 cells
P09642227A0000|0 11|Osteoadherin
P09642227A0000|0 11|Osteoadherin
P09642227A0000|58 71|keratan sulfate
P09642238A0532|22 55|erythroid-specific enhancer activity
P09642238A0532|22 47|erythroid-specific enhancer
P09642238A1285|3 23|intron 8 enhancer region
P09642238A1285|41 46|GATA-1
P09642238A1285|41 46|GATA-1
P09642238A1285|59 61|Sp1
P09642238A1285|59 61|Sp1
P09642238A1285|64 89|transactivation experiments
P09642238A1285|92 101|COS-1 cells
P09642238A1285|136 145|Sp1 protein
P09642238A1285|136 145|Sp1 protein
P09642238A1285|169 183|erythroid factor
P09642276A0881|13 15|Fak
P09642276A0881|13 15|Fak
P09642276A0881|18 25|caspases
P09642276A0881|18 25|caspases
P09642276A0881|71 84|suicide program
P09642276A0881|99 120|anti-apoptotic function
P09642276A0881|123 125|Fak
P09642276A0881|123 125|Fak
P09642764A0469|32 42|QCM response
P09642764A0469|53 69|Sauerbrey equation
P09642764A0469|143 156|enzymatic assay
P09642764A0469|174 186|deposited mass
P09642764A0469|216 218|QCM
P09643153T0000|24 39|T2N breast cancers
P09643546A0436|57 80|sigmaA-dependent promoter
P09643546A0436|57 80|sigmaA-dependent promoter
P09643546A0436|83 107|exponentially growing cells
P09643548A0000|16 44|(2Fe-2S) plant-like ferredoxins
P09643548A0000|17 22|2Fe-2S
P09643548A0000|34 44|ferredoxins
P09643548A0000|98 104|PCC6803
P09645576A0148|0 2|RNA
P09645576A0148|5 9|GBV-C
P09645576A0148|30 37|patients
P09645576A0148|44 46|BMT
P09645942A1164|1 9|major pool
P09645942A1164|12 35|Dsg-plakoglobin complexes
P09645942A1164|12 14|Dsg
P09645942A1164|16 26|plakoglobin
P09645942A1164|48 49|8S
P09645961A1158|34 41|CBF/NF-Y
P09645961A1158|34 36|CBF
P09645961A1158|38 41|NF-Y
P09645961A1158|55 62|CCAAT box
P09645961A1158|79 103|transcriptional activation
P09645961A1158|109 116|nTPH gene
P09645961A1158|109 116|nTPH gene
P09647233A0336|2 12|macrophages
P09647233A0336|14 45|LPS-inducible HIV-1 gene expression
P09647233A0336|27 35|HIV-1 gene
P09647233A0336|73 81|NF-kappa B
P09647233A0336|73 81|NF-kappa B
P09647233A0336|99 110|binding sites
P09647233A0336|127 148|long terminal repeat (LTR
P09647233A0336|127 144|long terminal repeat
P09647233A0336|146 148|LTR
P09647240A0000|14 16|p53
P09647240A0000|14 16|p53
P09647240A0000|19 61|cytokine-triggered Janus kinase-STAT signaling
P09647240A0000|37 47|Janus kinase
P09647240A0000|49 52|STAT
P09647240A0000|79 105|human hepatoma Hep3B cell lines
P09647240A0000|142 168|temperature-sensitive Val135
P09647240A0000|163 174|Val135 mutant
P09647240A0000|177 179|p53
P09647240A0000|177 179|p53
P09649069A0490|62 81|videotaped endoscopic
P09649069A0490|85 108|stroboscopic examinations
P09649265A1575|79 86|prostate
P09649265A1575|157 159|men
P09649265A1575|184 207|digital rectal examination
P09649265A1575|222 229|serum PSA
P09649265A1575|227 229|PSA
P09649315A0943|13 40|nuclear magnetic resonance (NMR
P09649315A0943|60 97|N-terminally truncated MIP-1 beta variants
P09649315A0943|60 89|N-terminally truncated MIP-1 beta
P09649426A0636|14 24|PKA activity
P09649426A0636|14 16|PKA
P09649426A0636|54 58|Msn2p
P09649426A0636|54 58|Msn2p
P09649426A0636|62 66|Msn4p
P09649426A0636|62 66|Msn4p
P09649437A1140|45 77|C/EBPs and specific Ets family members
P09649437A1140|45 50|C/EBPs
P09649437A1140|62 77|Ets family members
P09649437A1140|91 96|GATA-1
P09649437A1140|91 96|GATA-1
P09649437A1140|113 142|eosinophil lineage determination
P09649438A0182|10 49|human transcription elongation factor P-TEFb
P09649438A0182|10 43|human transcription elongation factor
P09649438A0182|44 49|P-TEFb
P09649438A0182|63 72|CDK9 kinase
P09649438A0182|63 72|CDK9 kinase
P09649438A0182|74 80|cyclin T
P09649438A0182|74 80|cyclin T
P09649438A0182|89 105|associated factors
P09649438A0182|133 135|Tat
P09649438A0182|133 135|Tat
P09649438A0182|145 157|Tat activation
P09649438A0182|145 147|Tat
P09649438A0182|160 177|HeLa nuclear extract
P09649438A0182|188 193|P-TEFb
P09649438A0182|188 193|P-TEFb
P09649501A0358|13 23|hydrophobic
P09649501A0358|36 58|HSF1 trimerization domain
P09649501A0358|36 39|HSF1
P09649501A0358|64 101|yeast two-hybrid protein interaction assay
P09649501A0358|112 141|heat shock factor binding protein 1
P09649501A0358|112 141|heat shock factor binding protein 1
P09649501A0358|143 147|HSBP1
P09649501A0358|143 147|HSBP1
P09649501A0358|170 186|amino-acid protein
P09649501A0358|218 235|hydrophobic repeats
P09649501A0358|255 271|HSF1 heptad repeats
P09649501A0358|255 258|HSF1
P09649537A0000|0 6|Genomic
P09649537A0000|10 19|cDNA clones
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09649537A0000|61 65|yGCN2
P09649537A0000|61 65|yGCN2
P09649537A0000|83 104|Drosophila melanogaster
P09650180A1130|3 22|general recombination
P09650180A1130|45 48|300 V
P09650275T0000|63 100|pharmaceutical and biotechnology industry
P09650299A0000|0 4|VirD2
P09650299A0000|0 4|VirD2
P09650299A0000|15 49|key Agrobacterium tumefaciens proteins
P09650299A0000|60 74|T-DNA processing
P09650299A1334|38 53|VirD2 omega domain
P09650299A1334|38 53|VirD2 omega domain
P09650299A1334|77 92|T-DNA integration
P09650403A0868|3 13|DHEAS levels
P09650403A0868|36 38|BMD
P09650403A0868|90 92|BMD
P09650789A0185|0 10|Orientation
P09650789A0185|16 32|nuclear spin system
P09650789A0185|35 48|optical pumping
P09650789A0185|57 71|Overhauser shift
P09650789A0185|123 140|nuclear orientation
P09651321A0000|0 8|Cystatin A
P09651321A0000|0 7|Cystatin
P09651321A0000|11 28|cysteine proteinase
P09651321A0000|19 37|proteinase inhibitor
P09651321A0000|49 65|precursor proteins
P09651321A0000|68 88|cornified cell envelope
P09651321A0000|91 103|keratinocytes
P09651321A0000|138 164|keratinocyte differentiation
P09651367T0000|8 13|RalGDS
P09651367T0000|8 13|RalGDS
P09651367T0000|23 33|Ras effector
P09651367T0000|23 25|Ras
P09651367T0000|39 60|Ras-mediated inhibition
P09651367T0000|39 41|Ras
P09651375T0000|0 5|GTPase
P09651375T0000|0 5|GTPase
P09651375T0000|29 33|RGS12
P09651375T0000|29 33|RGS12
P09651375T0000|79 81|PDZ
P09651375T0000|83 104|PSD-95/Dlg/ZO-1) domain
P09651375T0000|83 88|PSD-95
P09651375T0000|90 92|Dlg
P09651375T0000|94 97|ZO-1
P09651383A0967|22 37|HNF-4 binding site
P09651383A0967|22 26|HNF-4
P09651383A0967|66 70|HNF-4
P09651383A0967|66 70|HNF-4
P09651383A0967|82 91|HepG2 cells
P09651383A0967|103 117|HNF-4 constructs
P09651383A0967|103 107|HNF-4
P09651383A0967|130 151|apoCII promoter activity
P09651383A0967|130 143|apoCII promoter
P09651383A0967|187 191|HNF-4
P09651383A0967|187 191|HNF-4
P09651383A0967|217 226|apoCII gene
P09651383A0967|217 226|apoCII gene
P09651394A0440|0 14|272, 19107-19110
P09652736A1205|21 25|E2F-1
P09652736A1205|21 25|E2F-1
P09652736A1205|34 42|apoptosis
P09652736A1205|45 61|p53-/- tumour cells
P09652736A1205|45 47|p53
P09652736A1205|72 75|p300
P09652736A1205|72 75|p300
P09652736A1205|98 109|co-activator
P09652736A1205|98 109|co-activator
P09652736A1205|116 132|E2F/DP heterodimer
P09652736A1205|116 118|E2F
P09652736A1205|120 121|DP
P09652736A1205|145 161|apoptotic activity
P09652736A1205|164 168|E2F-1
P09652736A1205|164 168|E2F-1
P09652737A1244|0 30|Blocked shift/supershift analysis
P09652737A1244|44 66|Fos family member proteins
P09652737A1244|44 46|Fos
P09652737A1244|77 81|Fra-1
P09652737A1244|77 81|Fra-1
P09652737A1244|85 89|Fra-2
P09652737A1244|85 89|Fra-2
P09652737A1244|135 157|Jun family member proteins
P09652737A1244|135 137|Jun
P09652737A1244|185 206|AP-1/DNA binding complex
P09652737A1244|185 188|AP-1
P09652737A1244|190 206|DNA binding complex
P09652742A0455|33 35|p53
P09652742A0455|33 35|p53
P09652742A0455|57 81|premalignant mammary glands
P09652742A0455|87 99|mammary tumors
P09652742A0455|114 123|MMTV-c-myc
P09652742A0455|114 123|MMTV-c-myc
P09653182A1298|17 37|heterologous virus RNAs
P09653182A1298|39 42|BSMV
P09653182A1298|69 72|MStV
P09653182A1298|73 86|mRNA capped RNA-
P09653182A1298|87 105|primed transcription
P09653182A1298|122 127|plants
P09653641A0471|0 12|Human isoforms
P09653641A0471|0 12|Human isoforms
P09653641A0471|53 62|start codon
P09653648A0445|12 15|cDNA
P09653648A0445|19 34|genomic sequences
P09653648A0445|47 56|ZNF189 gene
P09653648A0445|47 56|ZNF189 gene
P09653648A0445|108 112|exons
P09653648A0445|122 131|3'-end exon
P09653648A0445|144 167|complete zinc finger domain
P09653648A0445|152 167|zinc finger domain
P09653648A0445|174 193|3' untranslated region
P09653745A0180|0 6|Malaria
P09653745A0180|38 47|early 1940s
P09653745A0180|148 155|projects
P09653745A0180|204 210|malaria
P09655248A0000|3 28|gp330/Megalin/LRP-2 protein
P09655248A0000|3 7|gp330
P09655248A0000|9 15|Megalin
P09655248A0000|17 28|LRP-2 protein
P09655248A0000|41 80|low-density lipoprotein receptor gene family
P09655248A0000|41 74|low-density lipoprotein receptor gene
P09655248A0000|139 150|lipoproteins
P09655916A0415|5 33|DNA recognition helix of finger II
P09655916A0415|5 23|DNA recognition helix
P09655916A0415|26 33|finger II
P09655916A0415|47 49|Arg
P09655916A0415|52 61|position 62
P09655916A0415|63 76|N-terminal side
P09655916A0415|87 112|zinc-coordinating histidine
P09655916A0415|127 129|Leu
P09655916A0415|132 134|Gln
P09656414A0220|0 5|Dosage
P09656485A0351|22 33|Lian elements
P09656485A0351|22 33|Lian elements
P09656485A0351|55 74|restriction digestion
P09657003T0000|38 64|RNA-dependent RNA polymerases
P09657003T0000|38 64|RNA-dependent RNA polymerases
P09657003T0000|75 100|mitochondrial virus-like RNA
P09657003T0000|75 100|mitochondrial virus-like RNA
P09657003T0000|106 126|Dutch elm disease fungus
P09657003T0000|128 146|Ophiostoma novo-ulmi
P09657003T0000|165 178|virus-like RNAs
P09657003T0000|165 178|virus-like RNAs
P09657003T0000|187 216|Arabidopsis mitochondrial genome
P09658104T0000|9 40|transcription start site core region
P09658104T0000|44 62|transcription factor
P09658104T0000|63 65|YY1
P09658104T0000|63 65|YY1
P09658104T0000|68 109|Rous sarcoma virus long terminal repeat promoter
P09658104T0000|68 83|Rous sarcoma virus
P09658104T0000|84 101|long terminal repeat
P09658104T0000|102 117|promoter activity
P09658122T0000|0 11|Fowlpox virus
P09658122T0000|41 58|cellular alpha-SNAP
P09658122T0000|41 58|cellular alpha-SNAP
P09658122T0000|60 63|PC-1
P09658122T0000|60 63|PC-1
P09658122T0000|70 87|orphan human homolog
P09658122T0000|99 113|nematode protein
P09658403A1207|10 12|Rap
P09658403A1207|15 18|KN62
P09658403A1207|41 52|progesterone
P09658403A1207|60 66|Org 2058
P09658403A1207|91 101|CAT activity
P09658403A1207|91 93|CAT
P09658405A0000|3 11|Dax-1 gene
P09658405A0000|3 11|Dax-1 gene
P09658405A0000|66 97|orphan nuclear receptor superfamily
P09658405A0000|66 97|orphan nuclear receptor superfamily
P09658769A0058|0 1|He
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|58 74|chronic hepatitis C
P09660823A0934|8 11|Ser/
P09660823A0934|12 14|Thr
P09660823A0934|32 50|downstream molecules
P09660823A0934|51 53|Akt
P09660823A0934|51 53|Akt
P09660823A0934|57 67|p70 S6 kinase
P09660823A0934|57 67|p70 S6 kinase
P09660836A0983|48 60|MEK inhibition
P09660836A0983|48 50|MEK
P09660836A0983|88 92|U0126
P09660836A0983|134 155|deltaN3-S218E/S222D MEK
P09660836A0983|134 155|deltaN3-S218E/S222D MEK
P09660836A0983|164 171|PD098059
P09660838A0920|57 77|protein kinase cascades
P09660838A0920|89 92|HSF1
P09660838A0920|89 92|HSF1
P09660838A0920|117 130|serine residues
P09660838A0920|131 144|303, 307, and 363
P09660838A0920|158 163|growth
P09660838A0920|180 196|heat shock response
P09661676T0000|36 39|IL-5
P09661676T0000|36 39|IL-5
P09661676T0000|42 54|induced sputum
P09661676T0000|57 73|asthmatic patients
P09662339A0744|13 33|ras-induced transition
P09662339A0744|13 15|ras
P09662339A0744|67 86|AP-1-binding activity
P09662339A0744|67 70|AP-1
P09662339A0744|117 124|CD44 mRNA
P09662339A0744|117 120|CD44
P09662339A0744|128 134|protein
P09662443A0402|83 100|caveolin gene family
P09662443A0402|83 94|caveolin gene
P09663062A0175|0 19|Tensile bond strengths
P09663062A0175|27 40|resin composite
P09663062A0175|44 55|bovine dentin
P09663062A0175|61 81|dentin adhesive systems
P09663062A0175|83 101|Clearfil Liner Bond II
P09663062A0175|103 106|LB II
P09663062A0175|132 133|MP
P09663062A0175|173 191|students and dentists
P09664033A1204|69 77|nucleolus
P09664033A1204|96 108|mature snoRNAs
P09664033A1204|102 108|snoRNAs
P09664033A1204|153 164|coiled bodies
P09665361T0000|11 17|therapy
P09665361T0000|21 34|thyroid nodules
P09665503A0526|8 28|healthy male volunteers
P09665720A0325|14 17|Mg2+
P09665720A0325|20 45|hydrophobic exonuclease site
P09665720A0325|94 107|primer terminus
P09665720A1145|18 21|Mg2+
P09665720A1145|47 60|primer terminus
P09665720A1145|76 90|exonuclease site
P09665720A1145|105 131|stacked polymerase active site
P09666103A0496|11 16|allele
P09666103A0496|18 22|P236S
P09666103A0496|77 83|alleles
P09666103A0496|85 89|L173F
P09666103A0496|91 95|E225K
P09666103A0496|97 101|S269L
P09666103A0496|105 109|E274K
P09666114A0389|0 17|Structural analysis
P09666114A0389|23 41|5'-regulatory region
P09666114A0389|23 41|5'-regulatory region
P09666114A0389|56 68|c-met promoter
P09666114A0389|56 68|c-met promoter
P09666114A0389|74 91|TATA or CAAT elements
P09666114A0389|113 122|G-C content
P09666114A0389|113 115|G-C
P09666114A0389|134 148|Sp1 binding sites
P09666114A0389|134 148|Sp1 binding sites
P09667482A0978|44 56|stress factors
P09667482A0978|71 104|therapy resistant periodontal disease
P09667482A0978|160 171|stress system
P09667795A0000|0 16|Acute pancreatitis
P09667795A0000|32 48|abdominal disorder
P09668063A0274|27 37|Ets proteins
P09668063A0274|27 37|Ets proteins
P09668063A0274|40 56|Ras transformation
P09668063A0274|40 42|Ras
P09668063A0274|113 126|Ets2 constructs
P09668063A0274|113 126|Ets2 constructs
P09668063A0274|129 158|Ras-transformed NIH3T3 (DT) cells
P09668063A0274|129 131|Ras
P09668096A0806|4 14|binding site
P09668098A0868|13 31|human FGF-BP promoter
P09668098A0868|18 23|FGF-BP
P09668098A0868|47 62|deletion analysis
P09668098A0868|67 87|TPA regulatory elements
P09668098A0868|109 133|first 118 base pairs upstream
P09668098A0868|139 160|transcription start site
P09668108A1017|0 11|Manipulation
P09668108A1017|17 36|checkpoint regulators
P09668108A1017|47 61|cell cycle arrest
P09668108A1017|65 73|apoptosis
P09668108A1017|104 116|cancer therapy
P09668119A0496|0 33|Electrophoretic mobility shift assays
P09668119A0496|54 83|nuclear protein binding to -85/-64
P09668119A0496|54 67|nuclear protein
P09668119A0496|94 107|point mutations
P09668119A0496|186 192|-74/-70
P09668119A0496|194 204|5'-CTCCT-3'
P09669641A0425|3 20|diagnostic accuracy
P09669641A0425|23 31|serum PE-1
P09669641A0425|28 31|PE-1
P09669641A0425|49 55|amylase
P09669641A0425|49 55|amylase
P09670034A0340|17 21|Ddc1p
P09670034A0340|17 21|Ddc1p
P09670034A0340|51 55|Mec3p
P09670034A0340|51 55|Mec3p
P09670034A0340|83 88|Rad17p
P09670034A0340|83 88|Rad17p
P09670943T0000|0 42|B cell antigen receptor (BCR)-mediated formation
P09670943T0000|0 19|B cell antigen receptor
P09670943T0000|21 23|BCR
P09670943T0000|46 56|SHP-2-pp120
P09670943T0000|46 50|SHP-2
P09670943T0000|52 56|pp120
P09670943T0000|82 107|Fc gamma RIIB1-BCR coligation
P09670943T0000|82 93|Fc gamma RIIB1
P09670943T0000|95 97|BCR
P09671313A0334|28 29|MT
P09671464A0316|0 11|Deleting SNF1
P09671464A0316|8 11|SNF1
P09671464A0316|66 72|glucose
P09671464A0316|88 94|glucose
P09671464A0316|120 123|Snf1
P09671464A0316|120 123|Snf1
P09671496A0557|26 30|c-Cbl
P09671496A0557|26 30|c-Cbl
P09671496A0557|33 57|development and homeostasis
P09671496A0557|60 63|mice
P09671496A0557|89 93|c-Cbl
P09671496A0557|89 93|c-Cbl
P09671496A0557|100 104|c-Cbl
P09671496A0557|100 104|c-Cbl
P09671496A0557|115 118|mice
P09671496A0557|130 136|fertile
P09671576A0900|50 68|streak morphogenesis
P09671579A1168|13 22|noi/pax2.1
P09671579A1168|13 15|noi
P09671579A1168|17 22|pax2.1
P09671579A1168|83 119|midbrain-hindbrain boundary development
P09671791T0000|0 27|Ligand-independent activation
P09671791T0000|30 65|platelet-derived growth factor receptor
P09671791T0000|30 65|platelet-derived growth factor receptor
P09671791T0000|92 112|lysophosphatidic, acid
P09671791T0000|124 140|mitogenic activity
P09671791T0000|143 148|L cells
P09673037A0358|8 22|Fibrotic changes
P09673037A0358|32 41|bone marrow
P09673037A0358|92 124|reticulin fiber impregnation (method
P09673037A0358|127 132|Gomori
P09673436A0898|2 23|canrenoate-treated rats
P09673436A0898|25 35|ANP infusion
P09673436A0898|25 27|ANP
P09673436A0898|60 74|sodium excretion
P09673436A0898|76 79|FENA
P09673436A0898|125 138|saline infusion
P09673436A0898|140 143|FENA
P09675154A0690|46 51|GSD-Ib
P09675154A0690|86 116|-base deletion/two-base insertion
P09675154A0690|139 164|consensus splicing donor site
P09675154A0690|187 191|W118R
P09675896A0959|12 25|carboxyl region
P09675896A0959|41 65|transcriptional activation
P09676349A0000|68 79|theophylline
P09676349A0000|104 116|Bronchoretard
P09676419A0158|20 27|children
P09676419A0158|106 130|patient and family histories
P09676419A0158|132 156|serological screening tests
P09676419A0158|166 186|inhalational allergens
P09676419A0158|188 193|CAP SX1
P09676419A0158|219 238|serum immunoglobulin E
P09676419A0158|224 238|immunoglobulin E
P09676419A0158|240 242|IgE
P09676419A0158|240 242|IgE
P09676419A0158|249 270|latex-specific serum IgE
P09676419A0158|268 270|IgE
P09676419A0158|273 295|solid-phase immunoassays
P09677330A0584|3 38|PDE4A-subfamily-specific linker region
P09677330A0584|27 38|linker region
P09677330A0584|39 41|LR1
P09677330A0584|53 56|UCR1
P09677330A0584|60 63|UCR2
P09677330A0584|79 83|exons
P09677330A0584|92 94|LR2
P09677330A0584|115 127|catalytic unit
P09677330A0584|147 150|exon
P09677405A0856|0 16|Pol32Delta strains
P09677405A0856|0 9|Pol32Delta
P09677405A0856|68 78|mutagenesis
P09677410A1059|36 38|p53
P09677410A1059|36 38|p53
P09677410A1059|65 67|HBV
P09677410A1059|100 114|HBV core promoter
P09677410A1059|100 102|HBV
P09677410A1059|103 114|core promoter
P09677410A1059|122 145|liver-specific enhancer II
P09677410A1059|122 145|liver-specific enhancer II
P09677410A1059|149 151|HBx
P09677410A1059|149 151|HBx
P09677410A1059|198 200|p53
P09677410A1059|198 200|p53
P09678579A0768|35 43|AtCP1 gene
P09678579A0768|35 43|AtCP1 gene
P09678579A0768|45 64|northern blot analysis
P09678837A0736|98 113|allergic rhinitis
P09678837A0736|147 159|total serum IgE
P09678837A0736|157 159|IgE
P09678837A0736|163 178|blood eosinophils
P09679066A1352|46 54|SR protein
P09679066A1352|46 54|SR protein
P09679066A1352|85 93|pre-mRNAs
P09679066A1352|85 93|pre-mRNAs
P09679750A0304|28 41|prostate cancer
P09679750A0304|62 95|nonsteroidal anti-inflammatory drugs
P09679750A0304|97 121|cyclo-oxygenase inhibitors
P09679750A0304|97 111|cyclo-oxygenase
P09679750A0304|123 128|NSAIDs
P09680994A0169|31 43|P. hybrida gene
P09680994A0169|45 49|jaf13
P09680994A0169|45 49|jaf13
P09680994A0169|60 87|basic helix-loop-helix protein
P09680994A0169|60 87|basic helix-loop-helix protein
P09680994A0169|158 166|P. hybrida
P09680994A0169|182 193|Z. mays r genes
P09680994A0169|182 182|Z
P09681822A0520|9 26|c-erbB3 transcripts
P09681822A0520|9 26|c-erbB3 transcripts
P09681822A0520|41 67|normal human placental tissues
P09682897A0218|89 98|QRS changes
P09682897A0218|116 133|acute injury pattern
P09683576A0542|18 29|cleavage site
P09683576A0542|37 65|N-terminal to the protease domain
P09683576A0542|52 65|protease domain
P09683576A0542|67 81|Gln2526-Asp2527
P09685021A0127|8 40|Millipore ultrafiltration membranes
P09685021A0127|103 121|nominal membrane pore
P09685021A0127|208 216|membranes
P09685021A0127|232 240|thin layer
P09685021A0127|243 263|collagen I and implanted
P09685021A0127|243 251|collagen I
P09685021A0127|286 299|anterior cornea
P09685021A0127|302 310|adult cats
P09685021A0127|352 368|epithelialization
P09685021A0127|388 407|epithelial attachment
P09685226A0000|9 18|calcitonin
P09685226A0000|9 18|calcitonin
P09685226A0000|52 62|cAMP pathway
P09685226A0000|94 131|human parathyroid hormone-related protein
P09685226A0000|99 142|parathyroid hormone-related protein (PTHrP) gene
P09685226A0000|133 142|PTHrP) gene
P09685226A0000|161 183|human lung cancer cell line
P09685226A0000|185 187|BEN
P09685346A0419|16 20|Pitx2
P09685346A0419|16 20|Pitx2
P09685346A0419|31 48|homeodomain protein
P09685346A0419|31 48|homeodomain protein
P09685346A0419|50 54|Pit-1
P09685346A0419|50 54|Pit-1
P09685346A0419|97 113|prolactin promoter
P09685346A0419|97 105|prolactin
P09685346A0419|116 133|transfection assays
P09686344T0000|3 13|biochemical
P09686344T0000|36 70|ornithine transcarbamylase deficiency
P09686344T0000|36 60|ornithine transcarbamylase
P09686603A0124|28 45|cis-acting elements
P09686603A0124|94 116|transcriptional promoter
P09686603A0124|127 144|germline expression
P09686603A0124|147 165|TCR beta gene segments
P09686603A0124|147 165|TCR beta gene segments
P09687498A1173|59 64|v-erbA
P09687498A1173|59 64|v-erbA
P09687498A1173|69 76|oncogene
P09687498A1173|89 102|c-ErbA/ TRalpha
P09687498A1173|89 94|c-ErbA
P09687498A1173|96 102|TRalpha
P09687498A1173|112 119|liganded
P09687498A1173|121 142|repressive conformation
P09687498A1173|161 174|overexpression
P09687511A1091|16 28|FUS expression
P09687511A1091|16 18|FUS
P09687511A1091|31 37|BCR/ABL
P09687511A1091|31 33|BCR
P09687511A1091|35 37|ABL
P09687511A1091|49 59|32Dcl3 cells
P09687511A1091|90 128|growth factor-independent colony formation
P09687511A1091|143 182|G-CSF-induced granulocytic differentiation
P09687511A1091|143 147|G-CSF
P09687514A0521|23 53|mammalian cell-free transcription
P09687514A0521|81 99|recombinant proteins
P09687514A0521|81 99|recombinant proteins
P09687514A0521|103 116|epitope-tagged
P09687514A0521|117 137|multiprotein complexes
P09688264A1029|4 12|repressor
P09688264A1029|39 41|spi
P09688264A1029|45 49|3' UTR
P09688264A1029|87 100|rat hepatocytes
P09689047A0253|30 54|sialylated glycoconjugates
P09689047A0253|93 108|5'-monophosphate
P09689047A0253|109 130|N-acetylneuraminic acid
P09689047A0253|132 141|CMP-Neu5Ac
P09689047A0253|170 192|Golgi sialyltransferases
P09689047A0253|170 192|Golgi sialyltransferases
P09689919A1192|8 21|bovine PEDF cDNA
P09689919A1192|14 21|PEDF cDNA
P09689919A1192|53 59|soluble
P09689919A1192|60 83|secreted PEDF glycoprotein
P09689919A1192|68 83|PEDF glycoprotein
P09691031A1050|22 25|Sro7
P09691031A1050|22 25|Sro7
P09691031A1050|63 76|myosin proteins
P09691031A1050|63 76|myosin proteins
P09691037A0355|40 55|wild-type strains
P09691037A0355|58 65|N. crassa
P09691037A0355|74 90|Neurospora species
P09692965A0904|4 11|cysteine
P09692965A0904|31 37|helices
P09692965A0904|72 86|solvent exposure
P09693035T0000|0 8|Human ULK1
P09693035T0000|0 8|Human ULK1
P09693035T0000|16 37|serine/threonine kinase
P09693035T0000|16 37|serine/threonine kinase
P09693035T0000|47 58|UNC-51 kinase
P09693035T0000|61 81|Caenorhabditis elegans
P09693035T0000|83 93|cDNA cloning
P09693035T0000|109 129|chromosomal assignment
P09693134A0782|17 32|molecular markers
P09693134A0782|55 76|neuroectodermal domains
P09693134A0782|104 114|neuroblasts
P09693134A0782|128 143|DER mutant embryos
P09693134A0782|189 200|medial column
P09693134A0782|272 289|lateral neuroblasts
P09693306T0000|0 28|Cochlear microphonic potentials
P09693306T0000|31 38|patients
P09693306T0000|43 63|vestibular schwannomas
P09694034A0713|39 40|LI
P09694034A0713|39 40|LI
P09694034A0713|131 132|LI
P09694034A0713|160 181|antipsychotic potential
P09694034A0713|184 193|novel drugs
P09694514A0000|13 36|C3a anaphylatoxin receptor
P09694514A0000|13 15|C3a
P09694514A0000|16 36|anaphylatoxin receptor
P09694514A0000|38 41|C3aR
P09694514A0000|38 41|C3aR
P09694514A0000|46 103|seven-transmembrane G-protein coupled chemoattractant receptor
P09694514A0000|46 103|seven-transmembrane G-protein coupled chemoattractant receptor
P09694514A0000|120 135|C3a peptide ligand
P09694514A0000|120 135|C3a peptide ligand
P09694514A0000|152 168|cellular responses
P09694514A0000|179 187|histamine
P09694514A0000|199 207|mast cells
P09694514A0000|209 220|smooth muscle
P09694514A0000|258 268|eosinophils
P09694599A1355|35 43|IL-1alpha
P09694599A1355|35 43|IL-1alpha
P09694599A1355|47 54|IL-1beta
P09694599A1355|47 54|IL-1beta
P09694599A1355|62 69|patients
P09694599A1355|74 90|bacterial cystitis
P09694599A1355|94 113|microscopic hematuria
P09694725A0500|0 15|Band-shift assays
P09694725A0500|37 65|LPS-and IL-1-responsive element
P09694725A0500|44 65|IL-1-responsive element
P09694725A0500|67 87|LILRE) oligonucleotide
P09694725A0500|67 71|LILRE
P09694725A0500|90 127|gamma interferon activation site-like site
P09694725A0500|90 127|gamma interferon activation site-like site
P09694725A0500|146 166|human IL-1beta promoter
P09694725A0500|146 158|human IL-1beta
P09694860A0498|3 18|C-terminal region
P09694860A0498|3 18|C-terminal region
P09694860A0498|30 43|PTP-like domain
P09694860A0498|30 43|PTP-like domain
P09694860A0498|55 70|N-terminal region
P09694860A0498|55 70|N-terminal region
P09694860A0498|96 111|mammalian protein
P09694860A0498|96 111|mammalian protein
P09694869A0932|41 45|STATs
P09694869A0932|41 45|STATs
P09694869A0932|66 76|p21 promoter
P09694869A0932|66 76|p21 promoter
P09694869A0932|94 98|Stat3
P09694869A0932|94 98|Stat3
P09694869A0932|132 142|p21 promoter
P09694869A0932|132 142|p21 promoter
P09694869A0932|168 172|Stat3
P09694869A0932|168 172|Stat3
P09694869A0932|190 208|STAT response element
P09694869A0932|190 208|STAT response element
P09694869A0932|214 221|promoter
P09694869A0932|246 259|cytokine effect
P09694897T0000|3 55|heterogeneous nuclear ribonucleoprotein C protein tetramer
P09694897T0000|3 47|heterogeneous nuclear ribonucleoprotein C protein
P09694897T0000|61 62|U1
P09694897T0000|61 62|U1
P09694897T0000|64 65|U2
P09694897T0000|64 65|U2
P09694897T0000|70 77|U6 snRNAs
P09694897T0000|70 71|U6
P09694897T0000|72 77|snRNAs
P09694897T0000|100 115|RNA binding domain
P09694897T0000|100 115|RNA binding domain
P09694897T0000|120 133|bZIP-like motif
P09694897T0000|120 133|bZIP-like motif
P09696164A0000|43 61|infant death syndrome
P09696164A0000|63 66|SIDS
P09696819A0450|38 39|gE
P09696819A0450|38 39|gE
P09696819A0450|45 75|vaccinia virus-based vTF7-3 system
P09696819A0450|95 114|endoplasmic reticulum
P09696819A0450|116 136|ER)-to-Golgi transport
P09696819A0450|116 117|ER
P09696819A0450|142 158|hetero-oligomeric
P09698457A0778|0 19|Homozygous mutant mice
P09698457A0778|31 45|Cux/CDPDeltaCR1
P09698457A0778|31 33|Cux
P09698457A0778|35 45|CDPDeltaCR1
P09698457A0778|79 92|curly vibrissae
P09698457A0778|100 103|hair
P09698457A0976|3 15|mutant protein
P09698457A0976|52 60|wild-type
P09698457A0976|80 97|tissue distribution
P09698457A0976|100 115|wild-type protein
P09698457A0976|100 115|wild-type protein
P09698457A0976|158 172|target sequences
P09698512A0296|36 40|adult
P09698512A0296|50 74|renal transplant recipients
P09698512A0296|82 93|between 11/91
P09700644T0000|13 44|age-associated brain abnormalities
P09701609A0116|37 64|phosducin-like orphan proteins
P09701609A0116|51 64|orphan proteins
P09701609A0116|66 71|PhLOP1
P09701609A0116|66 71|PhLOP1
P09701609A0116|75 80|PhLOP2
P09701609A0116|75 80|PhLOP2
P09701609A0116|114 123|Gbetagamma
P09701609A0116|114 123|Gbetagamma
P09701616A0108|0 43|Reverse transcriptase-polymerase chain reaction
P09701616A0108|0 35|Reverse transcriptase-polymerase chain
P09701616A0108|45 50|RT-PCR
P09701616A0108|69 76|eyestalk
P09701616A0108|98 123|sand shrimp Metapenaeus ensis
P09701821A1108|38 44|opuE P-1
P09701821A1108|38 44|opuE P-1
P09701821A1108|46 51|sigma A
P09701821A1108|46 51|sigma A
P09701895A0119|19 26|children
P09701895A0119|99 116|nutritional anaemia
P09703021A0000|2 8|insects
P09703021A0000|10 43|arylalkylamine N-acetyltransferases
P09703021A0000|10 43|arylalkylamine N-acetyltransferases
P09703021A0000|45 50|AANATs
P09703021A0000|45 50|AANATs
P09703021A0000|79 100|physiological processes
P09703021A0000|111 124|sclerotization
P09703021A0000|191 201|vertebrates
P09703021A0000|236 256|melatonin biosynthesis
P09703213A0280|0 12|In experiments
P09703213A0280|20 21|D1
P09703213A0280|20 21|D1
P09703213A0280|32 39|SCH 23390
P09703213A0280|62 71|depression
P09703276A2346|44 73|mutagenicity and carcinogenicity
P09703816A0139|0 4|IA-CT
P09703816A0139|25 35|doxorubicin
P09703816A0139|60 69|shot method
P09703816A0139|72 80|bilateral
P09703816A0139|89 101|iliac arteries
P09704006A0224|0 8|Arnt3 mRNA
P09704006A0224|0 8|Arnt3 mRNA
P09704006A0224|23 42|brain, skeletal muscle
P09704006A0224|52 58|embryos
P09704006A0224|63 70|P19 cells
P09704006A0224|82 93|retinoic acid
P09704296T0000|5 37|idiopathic thrombocytopenic purpura
P09704296T0000|53 94|serum level of immunoglobulin E and eosinophilia
P09704296T0000|65 79|immunoglobulin E
P09704296T0000|99 112|elderly patient
P09704569T0000|3 18|genomic structure
P09704569T0000|46 67|human TR2 orphan receptor
P09704569T0000|46 67|human TR2 orphan receptor
P09704569T0000|81 106|steroid receptor superfamily
P09704569T0000|81 106|steroid receptor superfamily
P09704857T0000|13 25|skin disorders
P09704857T0000|30 48|CD4 lymphocyte counts
P09704857T0000|30 32|CD4
P09704857T0000|51 58|patients
P09704857T0000|63 70|HIV/AIDS
P09704927A0479|0 4|E2F-6
P09704927A0479|0 4|E2F-6
P09704927A0479|34 40|E2Fs 1-5
P09704927A0479|34 40|E2Fs 1-5
P09704927A0479|61 70|DNA binding
P09704927A0479|72 89|heterodimerization
P09704927A0479|99 108|box domains
P09705258A0837|3 16|IE13.1 cell line
P09705258A0837|37 52|recombinant virus
P09705258A0837|75 80|IE gene
P09705258A0837|75 80|IE gene
P09705258A0837|109 131|Escherichia coli lacZ gene
P09705258A0837|109 131|Escherichia coli lacZ gene
P09705324A0213|0 17|DNase I footprinting
P09705324A0213|0 5|DNase I
P09705324A0213|21 56|electrophoretic mobility shift analyses
P09705324A0213|68 92|hepatocyte nuclear factor-1
P09705324A0213|68 92|hepatocyte nuclear factor-1
P09705324A0213|94 97|HNF1
P09705324A0213|94 97|HNF1
P09705324A0213|105 139|CCAAT/enhancer-binding protein (C/EBP
P09705324A0213|105 133|CCAAT/enhancer-binding protein
P09705324A0213|135 139|C/EBP
P09705324A0213|148 197|consensus palindromic thyroid hormone response elements
P09705324A0213|212 223|215 base pairs
P09705324A0213|225 226|bp
P09705324A0213|233 248|promoter sequence
P09705324A0213|251 256|rat Std
P09705324A0213|251 256|rat Std
P09705324A1602|19 40|rat Std promoter function
P09705324A1602|19 32|rat Std promoter
P09705324A1602|56 59|HNF1
P09705324A1602|56 59|HNF1
P09705324A1602|63 67|C/EBP
P09705324A1602|63 67|C/EBP
P09705324A1602|85 100|liver specificity
P09705324A1602|106 115|rat Std gene
P09705324A1602|106 115|rat Std gene
P09705324A1602|121 140|androgenic repression
P09705324A1602|146 149|gene
P09705324A1602|179 199|OCT-1 and C/EBP elements
P09705324A1602|179 183|OCT-1
P09705324A1602|187 199|C/EBP elements
P09705324A1602|216 226|-231 and -292
P09705324A1602|236 237|AR
P09705324A1602|249 272|negative regulatory effect
P09705324A1602|319 323|OCT-1
P09705324A1602|319 323|OCT-1
P09705324A1602|327 331|C/EBP
P09705324A1602|327 331|C/EBP
P09705324A1602|356 361|DNA-AR
P09705352A0879|0 11|Purified Hsk1
P09705352A0879|8 11|Hsk1
P09705352A0879|29 33|Cdc19
P09705352A0879|29 33|Cdc19
P09705352A0879|35 46|Mcm2) subunit
P09705352A0879|35 38|Mcm2
P09705352A0879|52 93|six-member minichromosome maintenance protein
P09705352A0879|52 61|six-member
P09705352A0879|120 124|yeast
P09705497A0227|3 15|yeast MMS2 gene
P09705497A0227|3 7|yeast
P09705497A0227|8 15|MMS2 gene
P09705497A0227|52 73|methyl methanesulfonate
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|132 156|DNA post-replication repair
P09705564T0000|15 49|human papillomavirus type 11 E5A protein
P09705564T0000|15 49|human papillomavirus type 11 E5A protein
P09705564T0000|57 73|E1E4,E5 transcript
P09705564T0000|57 73|E1E4,E5 transcript
P09706565A1072|0 9|Anesthesia
P09706565A1072|14 16|M/K
P09706565A1072|14 14|M
P09706565A1072|16 16|K
P09706565A1072|60 70|atipamezole
P09707498A0262|0 5|MK-801
P09707498A0262|31 46|biphasic response
P09707498A0262|49 62|seizure latency
P09707577A1047|28 43|endocytic markers
P09708450A0648|17 33|therapeutic period
P09708450A0648|81 97|historical control
P09708450A0648|131 135|G-CSF
P09708450A0648|131 135|G-CSF
P09708565A0000|128 149|radioimmunotherapy (RIT
P09708565A0000|154 174|non-Hodgkin's lymphoma
P09708565A0000|176 178|NHL
P09708565A0000|215 251|multicenter trials and commercialization
P09710131A0374|33 57|focal-film distances, image
P09710131A0374|81 99|laser printer formats
P09710582A0535|11 13|Rho
P09710582A0535|11 13|Rho
P09710582A0535|16 19|AP-1
P09710582A0535|16 19|AP-1
P09710582A0535|38 74|mitogen-activated protein kinase pathway
P09710582A0535|38 67|mitogen-activated protein kinase
P09710582A0535|79 98|dominant-negative MEK
P09710582A0535|96 98|MEK
P09710582A0535|103 114|MEK inhibitor
P09710582A0535|103 105|MEK
P09710582A0535|116 122|PD98059
P09710582A0535|136 158|Rho-induced AP-1 activity
P09710582A0535|136 138|Rho
P09710582A0535|147 150|AP-1
P09710589A1111|0 23|Site-directed mutagenesis
P09710589A1111|47 50|R82A
P09710589A1111|52 55|K85A
P09710589A1111|57 60|K88A
P09710589A1111|65 68|V89A
P09710589A1111|121 129|HTLV-1 LTR
P09710589A1111|121 129|HTLV-1 LTR
P09710591A0981|0 8|Mutations
P09710591A0981|18 26|C terminus
P09710591A0981|29 33|c-fos
P09710591A0981|29 33|c-fos
P09710591A0981|36 49|serine residues
P09710591A0981|82 94|growth factors
P09710591A0981|82 94|growth factors
P09710591A0981|98 106|MAP kinase
P09710591A0981|125 139|transactivation
P09710591A0981|162 170|MAP kinase
P09710591A0981|162 170|MAP kinase
P09710599A0310|17 21|ets-2
P09710599A0310|17 21|ets-2
P09710599A0310|26 57|CSF-1 immediate-early response gene
P09710599A0310|26 30|CSF-1
P09710599A0310|31 57|immediate-early response gene
P09710599A0310|76 80|ets-2
P09710599A0310|76 80|ets-2
P09710599A0310|129 140|ets-2 protein
P09710599A0310|129 140|ets-2 protein
P09710599T0000|22 52|mitogen-activated protein kinases
P09710599T0000|22 52|mitogen-activated protein kinases
P09710599T0000|53 61|p42 and p44
P09710599T0000|53 55|p42
P09710599T0000|59 61|p44
P09710599T0000|65 69|ets-2
P09710599T0000|65 69|ets-2
P09710599T0000|97 127|colony-stimulating factor 1/c-fms
P09710599T0000|97 121|colony-stimulating factor 1
P09710599T0000|123 127|c-fms
P09710614T0000|17 36|proline-rich sequence
P09710614T0000|42 61|CD2 cytoplasmic domain
P09710614T0000|42 61|CD2 cytoplasmic domain
P09710614T0000|85 109|integrin-mediated adhesion
P09710614T0000|85 92|integrin
P09710614T0000|125 148|phosphoinositide 3-kinase
P09710614T0000|125 148|phosphoinositide 3-kinase
P09710615T0000|0 4|Vam7p
P09710615T0000|0 4|Vam7p
P09710615T0000|7 26|SNAP-25-like molecule
P09710615T0000|7 26|SNAP-25-like molecule
P09710615T0000|31 35|Vam3p
P09710615T0000|31 35|Vam3p
P09710615T0000|38 52|syntaxin homolog
P09710615T0000|38 52|syntaxin homolog
P09710615T0000|72 84|yeast vacuolar
P09710621A0598|61 68|cysteine
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|149 166|interreceptor faces
P09710641A0000|35 39|Pax-6
P09710641A0000|35 39|Pax-6
P09710641A0000|42 69|paired domain (PD)/homeodomain
P09710641A0000|42 53|paired domain
P09710641A0000|55 56|PD
P09710641A0000|59 72|homeodomain (HD
P09710641A0000|71 72|HD
P09710641A0000|104 117|eye development
P09710641A0000|150 196|alphaB-, alphaA-, delta1-, and zeta-crystallin genes
P09710641A0000|150 196|alphaB-, alphaA-, delta1-, and zeta-crystallin genes
P09710641A0000|202 205|lens
P09712037A0470|0 13|Tctex-1 binding
P09712037A0470|0 6|Tctex-1
P09712037A0470|32 41|amino acids
P09712037A0470|44 46|Fyn
P09712037A0470|44 46|Fyn
P09712037A0470|64 77|lysine residues
P09712037A0470|135 137|Fyn
P09712037A0470|135 137|Fyn
P09712037A0470|157 200|immunoreceptor tyrosine-based activation motifs
P09712037A0470|202 206|ITAMs
P09712037A0470|210 230|lymphocyte Ag receptors
P09712037A0470|210 230|lymphocyte Ag receptors
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712297T0000|48 63|Japanese patients
P09712297T0000|68 85|deep vein thrombosis
P09712297T0000|89 106|healthy individuals
P09712644T0000|0 24|Transcriptional regulation
P09712644T0000|30 38|GluR2 gene
P09712644T0000|30 38|GluR2 gene
P09712644T0000|40 64|neural-specific expression
P09712644T0000|74 82|promoters
P09712644T0000|87 104|regulatory elements
P09712859A1110|12 17|NF-ATp
P09712859A1110|12 17|NF-ATp
P09712859A1110|30 35|NF-AT4
P09712859A1110|30 35|NF-AT4
P09712859A1110|70 93|HTLV-I-mediated infection
P09712859A1110|70 75|HTLV-I
P09712859A1110|96 122|human peripheral blood T-cells
P09712898A0911|5 9|TRAF2
P09712898A0911|5 9|TRAF2
P09712898A0911|19 38|SAPK and p38 activation
P09712898A0911|19 22|SAPK
P09712898A0911|26 28|p38
P09712898A0911|41 72|binding two proximal protein kinases
P09712898A0911|59 72|protein kinases
P09712898A0911|74 76|GCK
P09712898A0911|74 76|GCK
P09712898A0911|80 82|RIP
P09712898A0911|80 82|RIP
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712898T0000|0 18|Tumor necrosis factor
P09712898T0000|30 86|stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase
P09712898T0000|30 58|stress-activated protein kinase
P09712898T0000|60 63|SAPK
P09712898T0000|66 86|Jun NH2-terminal kinase
P09712898T0000|88 90|JNK
P09712898T0000|88 90|JNK
P09712898T0000|95 97|p38
P09712898T0000|95 97|p38
P09712915A0672|16 30|minimal promoter
P09712915A0672|87 106|transcription factors
P09712915A0672|107 109|Sp1
P09712915A0672|107 109|Sp1
P09712915A0672|111 113|Sp3
P09712915A0672|111 113|Sp3
P09712915A0672|118 121|NF-Y
P09712915A0672|118 121|NF-Y
P09712919A0307|55 70|signaling pathway
P09712919A0307|95 108|CREB activation
P09712919A0307|95 98|CREB
P09712919A0307|111 122|normal T cells
P09713584A1193|0 10|Respondents
P09713584A1193|24 29|spouse
P09713584A1193|64 83|unfavorable BMI status
P09713584A1193|88 93|people
P09713990T0000|17 30|TP53 target gene
P09713990T0000|17 30|TP53 target gene
P09713990T0000|36 54|colon cancer cell line
P09713990T0000|79 91|wild-type TP53
P09713990T0000|88 91|TP53
P09713996A0262|16 19|MDR1
P09713996A0262|16 19|MDR1
P09713996A0262|45 51|cancers
P09713996A0262|66 71|tumors
P09713996A0262|108 129|chemotherapeutic agents
P09713996T0000|0 10|Cytogenetic
P09713996T0000|85 102|drug resistance gene
P09713996T0000|104 122|MDR1/P-glycoprotein
P09713996T0000|104 107|MDR1
P09713996T0000|109 122|P-glycoprotein
P09713996T0000|126 147|drug-selected cell lines
P09713996T0000|151 158|patients
P09713996T0000|163 179|drug refractory ALL
P09714109A0000|52 64|blood pressure
P09714109A0000|76 105|muscle sympathetic nerve activity
P09714109A0000|107 109|SNA
P09714109A0785|59 79|nitroprusside infusion
P09714109A0785|108 116|muscle SNA
P09714835A0345|16 32|carboxypeptidase D
P09714835A0345|16 32|carboxypeptidase D
P09714835A0345|34 36|CPD
P09714835A0345|34 36|CPD
P09714835A0345|65 79|bovine pituitary
P09714835A0345|104 136|carboxypeptidase E (CPE)-like enzyme
P09714835A0345|104 120|carboxypeptidase E
P09714835A0345|122 136|CPE)-like enzyme
P09714835A0345|173 181|duck gp180
P09714835A0345|177 181|gp180
P09715278A1079|0 11|RA-treatment
P09715278A1079|19 31|transfectants
P09715278A1079|89 105|RA-regulated genes
P09715278A1079|89 105|RA-regulated genes
P09715278A1079|111 127|G1 cell cycle arrest
P09715278A1079|154 164|NT2/D1 cells
P09715278A1526|3 16|histopathology
P09715278A1526|20 37|neovascularization
P09715278A1526|68 82|xenograft tumors
P09715278A1526|94 97|FGF4
P09715278A1526|94 97|FGF4
P09715278A1526|126 138|transfectants
P09715384A0235|3 16|smaller vessels
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 8|RXR-gamma
P09716179A0974|0 8|RXR-gamma
P09716179A0974|57 74|RA-responsive genes
P09716179A0974|57 74|RA-responsive genes
P09716179A0974|87 130|cyclin-dependent kinase inhibitors p21Cip1/WAF1
P09716179A0974|87 108|cyclin-dependent kinase
P09716179A0974|119 125|p21Cip1
P09716179A0974|127 130|WAF1
P09716179A0974|134 140|p27Kip1
P09716179A0974|134 140|p27Kip1
P09716179A0974|162 165|cdc2
P09716179A0974|162 165|cdc2
P09716179A0974|169 178|cdk2 kinase
P09716179A0974|169 178|cdk2 kinase
P09716179A0974|190 206|RB phosphorylation
P09716179A0974|190 191|RB
P09716183A1036|0 2|TBP
P09716183A1036|0 2|TBP
P09716183A1036|41 49|U937 cells
P09716183A1036|54 64|bacterially
P09716183A1036|83 86|ERK2
P09716183A1036|83 86|ERK2
P09716183A1036|91 110|phosphorylation sites
P09716183A1036|123 145|ERK kinase consensus sites
P09716183A1036|123 131|ERK kinase
P09716183A1036|132 145|consensus sites
P09716183A1036|151 173|TBP amino-terminal domain
P09716183A1036|154 173|amino-terminal domain
P09716435A1004|9 17|CR/PP diet
P09716435A1004|25 34|HS subjects
P09716435A1004|48 65|stress-induced rise
P09716435A1004|88 93|vigour
P09716435A1004|97 113|cortisol elevation
P09716435A1004|136 137|PR
P09716435A1004|139 144|CP diet
P09717246A0526|9 11|ILC
P09717246A0526|15 24|ILVF values
P09717246A0526|110 120|lipid weight
P09717246A0526|125 127|ILC
P09717246A0526|149 152|ILVF
P09717835A0941|5 20|sequence analyses
P09717835A0941|32 37|xIRS-u
P09717835A0941|32 37|xIRS-u
P09717835A0941|57 65|IRS family
P09717835A0941|57 65|IRS family
P09717835A0941|77 83|Xenopus
P09717887A0239|50 56|VO2peak
P09717887A0239|59 76|peripheral arterial
P09717887A0239|94 97|PAOD
P09717887A0239|99 106|patients
P09717887A0239|111 134|intermittent claudication
P09717887A0239|172 178|VO2peak
P09718372T0000|17 41|MAPKKK-independent pathway
P09718372T0000|17 22|MAPKKK
P09718372T0000|71 88|Sty1/Spc1 MAP kinase
P09718372T0000|71 74|Sty1
P09718372T0000|76 79|Spc1
P09718372T0000|80 88|MAP kinase
P09718372T0000|91 102|fission yeast
P09718671A0000|3 28|Abbreviated Injury Scale (AIS
P09718671A0000|53 57|TRISS
P09718671A0000|119 144|injuries and injured patients
P09719636A1134|61 74|histidine pairs
P09719636A1134|79 94|H382-X2-H385 pair
P09719636A1134|99 114|H411-X2-H414 pair
P09719636A1134|99 102|H411
P09719636A1134|121 136|H430-X5-H436 pair
P09719636A1134|156 175|histidine-rich region
P09719636A1134|183 191|C terminus
P09719636A1134|194 197|gp17
P09719636A1134|194 197|gp17
P09721207A0637|5 21|backcross analysis
P09721207A0637|27 32|exons 1
P09721207A0637|46 59|proximal region
P09721207A0637|103 115|vacillans gene
P09721207A0637|103 115|vacillans gene
P09721798A1734|21 28|children
P09721798A1734|63 71|hepatitis
P09721798A1734|109 120|liver failure
P09722043A2070|12 14|TPN
P09722043A2070|56 76|liver lysosomal enzymes
P09722161A3065|30 47|lysosomal targeting
P09722161A3065|53 61|imprinted
P09722161A3065|62 73|Igf2/Mpr gene
P09722161A3065|62 65|Igf2
P09722161A3065|67 69|Mpr
P09722508A0953|30 42|Galpha11 Q209L
P09722508A0953|30 42|Galpha11 Q209L
P09722508A0953|53 67|Src family kinase
P09722508A0953|53 67|Src family kinase
P09722508A0953|86 108|tyrosine phosphorylation
P09722508A0953|111 125|several proteins
P09722508A0953|128 139|HEK-293 cells
P09722766A0706|3 21|micturition pressure
P09722766A0706|69 73|BUP-4
P09722766A0706|80 85|normal
P09722766A0706|89 102|obstructed rats
P09723896A0000|0 40|Peroxisome proliferator-activated receptors
P09723896A0000|0 40|Peroxisome proliferator-activated receptors
P09723896A0000|42 45|PPAR
P09723896A0000|42 45|PPAR
P09723896A0000|55 67|transcription
P09723896A0000|87 125|peroxisome proliferator-response elements
P09723896A0000|127 130|PPRE
P09723896A0000|127 130|PPRE
P09723896A0000|139 156|heterodimerization
P09723896A0000|164 188|9-cis retinoic acid receptor
P09723896A0000|164 180|9-cis retinoic acid
P09723896A0000|181 188|receptor
P09723896A0000|190 192|RXR
P09723896A0000|190 192|RXR
P09724654A0761|12 38|early- and late-firing origins
P09724654A0761|81 90|Mcm protein
P09724654A0761|81 90|Mcm protein
P09724654A0761|108 123|RPA's recruitment
P09724654A0761|108 112|RPA's
P09724654A1120|20 31|active S-CDKs
P09724654A1120|26 31|S-CDKs
P09724654A1120|35 43|Dbf4/Cdc7
P09724654A1120|35 38|Dbf4
P09724654A1120|40 43|Cdc7
P09724654A1120|45 48|Mcms
P09724654A1120|45 48|Mcms
P09724654A1120|95 97|RPA
P09724654A1120|95 97|RPA
P09724754A0173|0 7|Tyrosine
P09724754A0173|22 26|STATs
P09724754A0173|22 26|STATs
P09724754A0173|56 62|nucleus
P09724754A0173|73 85|specific genes
P09724763T0000|0 24|Nonsynonymous substitution
P09724763T0000|34 38|sperm
P09724763T0000|78 84|introns
P09724763T0000|88 100|mitochondrial
P09724772A0840|0 19|Gel retardation assays
P09724772A0840|28 31|ZiaR
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|88 102|ZiaR-DNA binding
P09724772A0840|88 91|ZiaR
P09724772A0840|130 143|metal-chelator
P09725292A1473|56 75|diagnosing fatty liver
P09725292A1473|78 84|helical
P09725292A1473|85 86|CT
P09725292A1473|110 126|protocol-specific
P09725651A0077|3 14|PC-based RTPS
P09725651A0077|35 65|Microsoft Windows 3.11 environment
P09725651A0077|114 130|Pentium processors
P09725854A1060|102 117|IS1112C Rf3 allele
P09725854A1060|102 108|IS1112C
P09725854A1060|109 117|Rf3 allele
P09725854A1060|140 154|maintainer lines
P09725854A1060|184 189|orf107
P09725854A1060|184 189|orf107
P09725854A1060|193 218|urf209 processing activities
P09725854A1060|193 198|urf209
P09726201T0000|0 11|JCAHO revised
P09726979T0000|0 15|Molecular cloning
P09726979T0000|47 69|murine sphingosine kinase
P09726979T0000|47 69|murine sphingosine kinase
P09726987T0000|1 24|human SPT3-TAFII31-GCN5-L
P09726987T0000|6 9|SPT3
P09726987T0000|11 17|TAFII31
P09726987T0000|19 22|GCN5
P09726987T0000|24 33|L acetylase
P09726987T0000|53 74|transcription factor IID
P09726987T0000|53 74|transcription factor IID
P09726988A0275|0 5|Oleate
P09726988A0275|33 42|M-CPT I mRNA
P09726988A0275|33 38|M-CPT I
P09726991T0000|12 27|DNA binding domain
P09726991T0000|12 27|DNA binding domain
P09726991T0000|33 72|copper-responsive transcription factor Mac1
P09726991T0000|33 68|copper-responsive transcription factor
P09726991T0000|69 72|Mac1
P09726991T0000|77 99|Saccharomyces cerevisiae
P09727045A0817|87 90|HREs
P09727045A0817|133 143|AR N terminus
P09727045A0817|133 134|AR
P09727045A0817|135 143|N terminus
P09727045A0817|147 165|ligand binding domain
P09727046A0000|27 44|DNA-binding protein
P09727046A0000|27 44|DNA-binding protein
P09727046A0000|46 51|HS2NF5
P09727046A0000|46 51|HS2NF5
P09727046A0000|93 115|hypersensitive site 2 (HS2
P09727046A0000|122 155|human beta-globin locus control region
P09727046A0000|122 155|human beta-globin locus control region
P09727046A0000|157 160|LCR)
P09727046A0000|157 159|LCR
P09727046A0000|162 164|Lam
P09727046A0784|3 10|CBF1 site
P09727046A0784|3 10|CBF1 site
P09727046A0784|17 19|HS2
P09727046A0784|39 61|hematopoietic regulators
P09727046A0784|68 73|GATA-1
P09727046A0784|68 73|GATA-1
P09727046A0784|75 79|NF-E2
P09727046A0784|75 79|NF-E2
P09727046A0784|84 87|TAL1
P09727046A0784|84 87|TAL1
P09729481A0000|3 59|rat branched-chain-2-oxo-acid dehydrogenase (BCOD) kinase mRNA
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|45 59|BCOD) kinase mRNA
P09729481A0000|78 94|TATA-less promoter
P09729481A0000|102 117|GC-rich sequences
P09729481A0000|132 146|Sp1 binding sites
P09729481A0000|132 146|Sp1 binding sites
P09729481A0000|154 175|transcription start site
P09729481A1177|0 14|Co-transfection
P09729481A1177|20 22|Sp1
P09729481A1177|20 22|Sp1
P09729481A1177|23 39|expression plasmid
P09729481A1177|46 56|-58 promoter
P09729481A1177|70 93|Drosophila Schneider cells
P09729481A1177|106 108|Sp1
P09729481A1177|106 108|Sp1
P09729481A1177|125 151|kinase basal promoter activity
P09729481A1177|166 182|non-consensus site
P09729481A1177|166 182|non-consensus site
P09729481A1177|188 196|-58 region
P09730413A0642|98 107|TME surgery
P09730413A0642|142 146|Stage
P09730413A0642|152 164|rectal cancers
P09731354A0963|50 52|NH2
P09731513A1090|53 72|transcription factors
P09731513A1090|73 81|NF-kappaB
P09731513A1090|73 81|NF-kappaB
P09731513A1090|85 88|AP-1
P09731513A1090|85 88|AP-1
P09731513A1090|120 127|IL-8 gene
P09731513A1090|120 127|IL-8 gene
P09731513A1090|130 138|HTLV-I Tax
P09731513A1090|130 135|HTLV-I
P09731513A1090|136 138|Tax
P09731704A0000|41 67|human estrogen receptor-alpha
P09731704A0000|46 67|estrogen receptor-alpha
P09731704A0000|69 83|ERalpha) isoform
P09731704A0000|69 75|ERalpha
P09731704A0000|86 110|estrogen (E2)-mediated gene
P09731704A0000|86 93|estrogen
P09731704A0000|95 96|E2
P09731704A0000|107 120|gene activation
P09731704A0000|123 144|U2-OS osteosarcoma cells
P09731704A0000|123 124|U2
P09731704A1472|33 61|delta5ERalpha expression vector
P09731704A1472|33 45|delta5ERalpha
P09731704A1472|67 74|ERalpha+
P09731704A1472|67 74|ERalpha+
P09731704A1472|107 108|E2
P09731704A1472|107 108|E2
P09731704A1472|120 133|ERELuc activity
P09731704A1472|120 125|ERELuc
P09731705A2126|15 35|yeast two-hybrid system
P09731705A2126|79 110|VDR-TR protein-protein interaction
P09731705A2126|79 81|VDR
P09731705A2126|83 99|TR protein-protein
P09733493A0493|24 58|thermodynamical standpoint, melatonin
P09733493A0493|78 93|hydroxyl radicals
P09733493A0493|100 105|vacuum
P09733493A0493|109 125|in aqueous solution
P09733647A1960|4 11|sequence
P09733647A1960|13 47|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|13 43|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile
P09733647A1960|63 68|B-loop
P09733647A1960|119 126|bacteria
P09733647A1960|136 149|archeabacteria
P09733794A1323|27 31|Bcl-2
P09733794A1323|27 31|Bcl-2
P09733794A1323|34 54|Bcl-2-related proteins
P09733794A1323|34 54|Bcl-2-related proteins
P09733794A1323|56 60|Bcl-x
P09733794A1323|56 60|Bcl-x
P09733794A1323|62 64|Bax
P09733794A1323|62 64|Bax
P09733794A1323|69 71|Bad
P09733794A1323|69 71|Bad
P09733794A1323|84 105|KCREB-transfected cells
P09733794A1323|84 88|KCREB
P09733794A1323|132 133|Tg
P09733815T0000|0 10|Tyrosine 112
P09733815T0000|13 35|latent membrane protein 2A
P09733815T0000|13 35|latent membrane protein 2A
P09733815T0000|50 77|protein tyrosine kinase loading
P09733815T0000|50 70|protein tyrosine kinase
P09733815T0000|93 109|Epstein-Barr virus
P09733854A0198|15 29|viral transcript
P09733854A0198|45 51|latency
P09733854A0198|57 78|latency-related (LR) RNA
P09733854A0198|73 74|LR
P09734808A0000|71 78|card test
P09735286A0599|68 77|Mu B protein
P09735286A0599|68 77|Mu B protein
P09735286A0599|93 95|ATP
P09735286A0599|99 107|target DNA
P09735366A1180|44 57|mouse homologue
P09735366A1180|44 57|mouse homologue
P09735366A1180|60 63|E(Pc
P09735366A1180|60 60|E
P09735366A1180|62 63|Pc
P09735366A1180|72 75|Epc1
P09735366A1180|72 75|Epc1
P09735366A1180|78 89|yeast protein
P09735366A1180|78 89|yeast protein
P09735366A1180|100 103|EPL1
P09735366A1180|100 103|EPL1
P09735366A1180|126 129|ESTs
P09735366A1180|134 154|Caenorhabditis elegans
P09735366A1180|156 159|mice
P09735366A1180|163 168|humans
P09735368A0636|10 25|wild-type m8 3' UTR
P09735368A0636|10 25|wild-type m8 3' UTR
P09735368A0636|55 77|heterologous transcripts
P09735368A0636|110 122|K box sequences
P09735371A0227|13 18|unc-86
P09735371A0227|27 52|POU-type homeodomain protein
P09735371A0227|27 52|POU-type homeodomain protein
P09735371A0227|80 89|touch cells
P09735371A0227|96 100|mec-3
P09735371A0227|96 100|mec-3
P09735371A0227|109 134|LIM-type homeodomain protein
P09735371A0227|109 134|LIM-type homeodomain protein
P09735371A0227|167 176|touch cells
P09736239A0436|31 52|extracellular aspartate
P09736239A0436|56 78|glutamate concentrations
P09736239A0436|84 99|cerebral striatum
P09736697A0783|32 35|MEK1
P09736697A0783|32 35|MEK1
P09736697A0783|40 45|kinase
P09736697A0783|59 62|ERKs
P09736697A0783|59 62|ERKs
P09736697A0783|82 85|ERK2
P09736697A0783|82 85|ERK2
P09736697A0783|93 96|JNK1
P09736697A0783|93 96|JNK1
P09736697A0783|107 121|Stat3 activation
P09736697A0783|107 111|Stat3
P09736697A1107|0 3|MEKs
P09736697A1107|0 3|MEKs
P09736697A1107|7 10|ERKs
P09736697A1107|7 10|ERKs
P09736697A1107|20 33|IL-6 activation
P09736697A1107|20 23|IL-6
P09736697A1107|36 40|Stat3
P09736697A1107|36 40|Stat3
P09736697A1107|61 70|serine-727
P09736697A1107|87 107|serine phosphorylation
P09736697A1107|130 143|wild-type Stat3
P09736697A1107|139 143|Stat3
P09736697A1107|157 168|Janus kinases
P09736697A1107|157 168|Janus kinases
P09736697A1107|169 172|Jak1
P09736697A1107|169 172|Jak1
P09736697A1107|176 179|Jak2
P09736697A1107|176 179|Jak2
P09736697A1107|190 194|Stat3
P09736697A1107|190 194|Stat3
P09736697A1107|200 224|Jak-STAT-signaling pathway
P09736697A1107|200 202|Jak
P09736697A1107|204 207|STAT
P09736715A0729|12 51|phosphatidylinositol(3,4,5)trisphosphate
P09736715A0729|87 89|ILK
P09736715A0729|87 89|ILK
P09736715A0729|112 119|membrane
P09736715A0729|149 154|Pi(3)K
P09736715A0729|149 150|Pi
P09736715A0729|154 154|K
P09736715A0729|164 166|ILK
P09736715A0729|164 166|ILK
P09736770A0351|52 65|HEFT1 a promoter
P09736770A0351|52 56|HEFT1
P09736770A0351|58 65|promoter
P09736770A0351|71 83|basal activity
P09736770A0351|93 97|GC box
P09736770A0351|109 111|Sp1
P09736770A0351|109 111|Sp1
P09736770A0351|114 116|Sp3
P09736770A0351|114 116|Sp3
P09737453A0557|0 5|Plasma
P09737453A0557|47 53|surgery
P09737453A0557|57 69|IgG antibodies
P09737453A0557|57 69|IgG antibodies
P09737453A0557|84 106|heparin/platelet factor 4
P09737453A0557|84 90|heparin
P09737453A0557|92 106|platelet factor 4
P09737453A0557|136 166|enzyme-linked immunosorbent assay
P09737453A0557|168 172|ELISA
P09737921T0000|0 15|Genome plasticity
P09737921T0000|31 40|fiber locus
P09737921T0000|52 64|bacteriophage
P09737921T0000|86 100|conserved motifs
P09738010A0305|3 13|FAS promoter
P09738010A0305|3 13|FAS promoter
P09738010A0305|31 37|insulin
P09738010A0305|31 37|insulin
P09738010A0305|56 78|insulin response sequence
P09738010A0305|56 78|insulin response sequence
P09738010A0305|91 100|E-box motif
P09738010A0305|91 100|E-box motif
P09738010A0305|106 125|-65-base pair position
P09738087A0583|59 73|regression model
P09738693T0000|9 15|rhG-CSF
P09738693T0000|9 15|rhG-CSF
P09738693T0000|18 36|neutrophil functions
P09738693T0000|50 55|sepsis
P09738693T0000|63 70|diabetic
P09738693T0000|71 74|rats
P09739401A0000|116 130|home environment
P09741391A0581|13 35|single-chambered body box
P09741391A0581|37 45|PenH units
P09741391A0581|55 59|Pause
P09741391A0581|77 85|breathing
P09741391A0581|133 142|expiration
P09741783A0000|0 10|Anastrozole
P09741783A0000|21 29|aromatase
P09741783A0000|78 93|megestrol acetate
P09741783A0000|101 115|menopausal women
P09741783A0000|128 139|breast cancer
P09743128A0969|0 6|Moritta
P09743128A0969|19 25|Bis-GMA
P09743233A0526|19 22|AP-1
P09743233A0526|19 22|AP-1
P09743233A0526|28 30|ets
P09743233A0526|28 30|ets
P09743233A0526|63 78|promoter activity
P09743233A0526|81 84|SMCs
P09743720A0268|0 6|ANIMALS
P09743720A0268|40 41|DM
P09744095A1016|31 43|shy2-1D mutant
P09744095A1016|31 37|shy2-1D
P09744095A1016|51 78|phytochrome-deficient mutants
P09744095A1016|51 78|phytochrome-deficient mutants
P09744095A1016|79 81|hy2
P09744095A1016|79 81|hy2
P09744095A1016|83 85|hy3
P09744095A1016|83 85|hy3
P09744095A1016|87 92|phyB-1
P09744095A1016|87 92|phyB-1
P09744095A1016|97 102|fre1-1
P09744095A1016|97 102|fre1-1
P09744095A1016|104 111|phyA-201
P09744095A1016|104 111|phyA-201
P09744095A1016|201 204|stem
P09744095A1016|235 241|CAB gene
P09744095A1016|235 241|CAB gene
P09744095A1016|249 267|shy2-1D single mutant
P09744095A1016|249 255|shy2-1D
P09747651A0000|0 12|Laser ablation
P09747651A0000|52 76|chronic pulmonary emphysema
P09747873T0000|3 35|SH2-containing adapter protein GRB10
P09747873T0000|3 30|SH2-containing adapter protein
P09747873T0000|31 35|GRB10
P09747873T0000|49 55|BCR-ABL
P09747873T0000|49 51|BCR
P09747873T0000|53 55|ABL
P09748261A0000|0 22|Saccharomyces cerevisiae
P09748261A0000|0 22|Saccharomyces cerevisiae
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|60 86|fatty acid activation proteins
P09748261A0000|60 68|fatty acid
P09748261A0000|88 92|Faaps
P09748261A0000|88 92|Faaps
P09748286A0000|27 43|-specific enhancer
P09748286A0000|49 85|human leukemia inhibitory factor receptor
P09748286A0000|49 85|human leukemia inhibitory factor receptor
P09748286A0000|87 95|LIFR) gene
P09748286A0000|87 90|LIFR
P09748286A0000|135 154|226-base pair enhancer
P09748286A0000|156 177|-4625/-4400 nucleotides
P09748669A0414|42 43|AD
P09748669A0414|47 49|VaD
P09749533A0764|0 4|Clone
P09749533A0764|20 27|CONSTANS
P09749533A0764|20 27|CONSTANS
P09749988A0000|0 6|Badcock
P09749988A0000|10 19|Westheimer
P09749988A0000|21 36|Spatial Vision 1 (1
P09749988A0000|60 75|thin vertical line
P09749988A0000|83 93|nearby zones
P09749988A0000|96 105|attraction
P09749988A0000|205 217|repulsion zone
P09749988A0000|253 261|repulsion
P09750325A0000|12 24|high intensity
P09750325A0000|67 87|energization technique
P09750325A0000|89 92|PPET
P09750325A0000|110 129|bacterial populations
P09750325A0000|132 176|verocytotoxigenic Escherichia coli (serotype 0157
P09750325A0000|178 179|H7
P09750325A0000|184 204|Listeria monocytogenes
P09750325A0000|206 215|serotype 4b
P09750540A0000|8 26|chemical sensitivity
P09750540A0000|28 30|MCS
P09750540A0000|94 109|chemical exposure
P09751061A0000|0 17|POU-domain proteins
P09751061A0000|0 17|POU-domain proteins
P09751061A0000|28 56|pituitary-specific factor Pit-1
P09751061A0000|28 51|pituitary-specific factor
P09751061A0000|52 56|Pit-1
P09751061A0000|73 99|homeodomain family of proteins
P09751061A0000|73 99|homeodomain family of proteins
P09751061A0000|119 143|development and homeostasis
P09751061A0000|179 205|signal-transduction pathways
P09751061A0000|246 258|specific genes
P09751114A0967|0 17|Wild-type and mutant
P09751114A0967|0 8|Wild-type
P09751114A0967|18 21|MyoD
P09751114A0967|18 21|MyoD
P09751114A0967|52 53|E1
P09751114A0967|52 53|E1
P09751114A0967|55 64|E3-deleted
P09751114A0967|55 56|E3
P09751114A0967|65 80|adenoviral vector
P09751114A1987|23 28|Thr115
P09751114A1987|68 71|MyoD
P09751114A1987|68 71|MyoD
P09751114A1987|97 111|high mitogenesis
P09751166A1460|36 48|CRE and Sp1 site
P09751166A1460|36 38|CRE
P09751166A1460|42 48|Sp1 site
P09751166A1460|75 89|TH transcription
P09751166A1460|75 76|TH
P09751166A1460|93 123|promoter context-dependent manner
P09751458A0845|0 19|desmethyltrimebutine
P09753241A0524|0 21|Endoscopic examinations
P09753241A0524|23 46|peripheral white blood cell
P09753241A0524|48 57|WBC) counts
P09753241A0524|70 92|myeloperoxidase activity
P09753241A0524|70 84|myeloperoxidase
P09753241A0524|94 96|MPO
P09753241A0524|94 96|MPO
P09753241A0524|118 123|mucosa
P09753241A0524|152 159|DSS model
P09753241A0524|177 184|DSS model
P09753730A0881|0 14|T7 transcription
P09753730A0881|59 80|constitutive expression
P09753730A0881|97 113|promoter mutations
P09753769A0362|30 45|oligonucleotides
P09753769A0362|62 79|amino acid sequences
P09753769A0362|85 97|PBAN precursor
P09753769A0362|85 97|PBAN precursor
P09753774A1642|24 32|35S-1-sst
P09753774A1642|24 28|35S-1
P09753774A1642|56 81|oligofructans 1-kestose (GF2
P09753774A1642|79 81|GF2
P09753774A1642|84 94|1,1-nystose
P09753774A1642|96 98|GF3
P09753774A1642|96 98|GF3
P09753774A1642|103 124|1,1,1-fructosylnystose
P09753774A1642|126 128|GF4
P09753774A1642|126 128|GF4
P09753774A2246|25 51|predicted amino acid sequences
P09753774A2246|54 58|1-sst
P09753774A2246|54 58|1-sst
P09753774A2246|62 66|1-fft
P09753774A2246|83 112|plant fructosyl transferase genes
P09753774A2246|88 112|fructosyl transferase genes
P09753774A2246|133 137|plant
P09753774A2246|138 149|fructan genes
P09753774A2246|170 183|invertase genes
P09753774A2246|170 178|invertase
P09753775A0734|8 11|ICK1
P09753775A0734|8 11|ICK1
P09753775A0734|24 26|ABA
P09753775A0734|40 52|ICK1 induction
P09753775A0734|40 43|ICK1
P09753775A0734|72 95|Cdc2-like histone H1 kinase
P09753775A0734|72 89|Cdc2-like histone H1
P09754571A0169|1 16|5.0-kb transcript
P09754571A0169|30 48|differential display
P09754571A0169|57 59|3G1
P09754571A0169|91 108|RAG1 mRNA expression
P09754571A0169|91 98|RAG1 mRNA
P09754571A0169|118 131|human cell lines
P09754571A1257|3 11|hBRAG gene
P09754571A1257|3 11|hBRAG gene
P09754571A1257|29 35|long arm
P09754571A1257|38 49|chromosome 10
P09755191A0553|17 22|swa5-1
P09755191A0553|17 22|swa5-1
P09755191A0553|29 49|temperature-sensitive
P09755191A0553|50 55|allele
P09755191A0553|61 82|clathrin heavy chain gene
P09755191A0553|61 82|clathrin heavy chain gene
P09755191A0553|84 89|chc1-5
P09755191A0553|84 89|chc1-5
P09755191A0553|105 122|frameshift mutation
P09755191A0553|130 134|3' end
P09755191A0553|140 159|CHC1 open reading frame
P09755191A0553|140 143|CHC1
P09755199A0373|19 34|molecular lesions
P09755199A0373|41 56|Scm mutant alleles
P09755199A0559|29 31|Scm
P09755199A0559|58 66|mbt repeat
P09755199A0559|58 66|mbt repeat
P09755199A0559|80 82|PcG
P09755199A0559|80 82|PcG
P09755199A0559|110 123|Scm null alleles
P09755199A0559|110 116|Scm null
P09755199A0559|117 123|alleles
P09755478A0366|0 15|Northern analysis
P09755478A0366|63 84|diapause- or nondiapause
P09755478A0366|136 153|nondiapausing pupae
P09756895A0322|0 11|Genomic locus
P09756895A0322|14 19|chCTCF
P09756895A0322|14 19|chCTCF
P09756895A0322|29 51|GC-rich untranslated exon
P09756895A0322|76 80|exons
P09756895A0322|84 93|long intron
P09757012A0942|13 15|PDZ
P09757012A0942|13 15|PDZ
P09757012A0942|19 28|SAM domains
P09757012A0942|19 28|SAM domains
P09757012A0942|34 43|KS5 protein
P09757012A0942|34 43|KS5 protein
P09757012A0942|118 142|signal transduction pathway
P09759180A0000|11 26|Fluoroquinolones
P09759180A0000|28 29|FQ
P09759180A0000|51 58|children
P09759180A0000|77 91|cartilage damage
P09759691A1051|0 9|In analyses
P09759691A1051|24 40|multiple variables
P09759691A1051|57 72|microalbuminuria
P09759691A1051|74 80|urinary
P09759691A1051|81 87|albumin
P09759691A1051|117 127|men and women
P09759691A1051|185 197|blood pressure
P09759691A1051|259 274|cholesterol level
P09759691A1051|304 310|smokers
P09759691A1051|368 380|body mass index
P09759865A0673|13 20|IL-1beta
P09759865A0673|13 20|IL-1beta
P09759865A0673|24 32|TNF-alpha
P09759865A0673|24 32|TNF-alpha
P09759865A0673|63 73|Rel proteins
P09759865A0673|63 73|Rel proteins
P09759865A0673|74 76|p50
P09759865A0673|74 76|p50
P09759865A0673|80 82|p65
P09759865A0673|80 82|p65
P09759865A0673|87 95|NF-kappaB
P09759865A0673|87 95|NF-kappaB
P09759865A0673|105 119|oligonucleotide
P09759865A0673|122 135|gel shift assays
P09759865A0673|145 164|transient degradation
P09759865A0673|178 192|NF-kappaB-alpha
P09759865A0673|178 192|NF-kappaB-alpha
P09759865A0673|194 206|IkappaB-alpha
P09759865A0673|194 206|IkappaB-alpha
P09759865A0673|213 221|cytoplasm
P09759865A0673|224 237|myofibroblasts
P09759865A0673|243 250|IL-1beta
P09759865A0673|243 250|IL-1beta
P09759865A0673|262 272|PDGF-Ralpha
P09759865A0673|262 272|PDGF-Ralpha
P09760243A0970|0 14|Cotransfections
P09760243A0970|19 23|ATF-2
P09760243A0970|19 23|ATF-2
P09760243A0970|27 31|HNF-4
P09760243A0970|27 31|HNF-4
P09760243A0970|88 102|apoCIII promoter
P09760243A0970|88 102|apoCIII promoter
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09760341T0000|31 48|submaximal exercise
P09760341T0000|61 64|FIO2
P09761711A0000|0 12|Pseudocontact
P09761711A0000|97 113|electron and nuclei
P09761711A0000|130 161|magnetic susceptibility anisotropy
P09761723A0226|0 5|GETS-1
P09761723A0226|0 5|GETS-1
P09761723A0226|46 59|retina and brain
P09761791A0489|16 21|U1-70K
P09761791A0489|16 21|U1-70K
P09761791A0489|29 39|SRZ proteins
P09761791A0489|29 39|SRZ proteins
P09761791A0489|75 86|overlay assay
P09763421A1199|3 17|major phenotypes
P09763421A1199|31 53|Fab1p kinase inactivation
P09763421A1199|31 41|Fab1p kinase
P09763421A1199|61 87|temperature-sensitive growth
P09763421A1199|89 116|vacuolar acidification defects
P09763421A1199|140 151|vacuolar size
P09763446A0000|0 11|Small GTPases
P09763446A0000|5 11|GTPases
P09763446A0000|17 29|Ypt/Rab family
P09763446A0000|17 19|Ypt
P09763446A0000|21 29|Rab family
P09763446A0000|58 75|vesicular transport
P09763446A1234|3 5|GEF
P09763446A1234|3 5|GEF
P09763446A1234|9 21|GAP activities
P09763446A1234|9 11|GAP
P09763446A1234|25 29|Ypt1p
P09763446A1234|25 29|Ypt1p
P09763446A1234|40 67|particulate cellular fractions
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|25 27|DBH
P09763470A0000|25 27|DBH
P09763470A0000|53 60|dopamine
P09763470A0000|103 135|noradrenergic and adrenergic neurons
P09763470A0000|139 157|neuroendocrine cells
P09763470A1756|47 52|Phox2a
P09763470A1756|47 52|Phox2a
P09763470A1756|92 111|transcription factors
P09763470A1756|118 121|CREB
P09763470A1756|118 121|CREB
P09763470A1756|123 125|AP2
P09763470A1756|123 125|AP2
P09763470A1756|130 132|Sp1
P09763470A1756|130 132|Sp1
P09763470A1756|136 160|transcriptional activation
P09763470A1756|166 172|DBH gene
P09763470A1756|166 172|DBH gene
P09763522A2545|31 37|N-SMase
P09763522A2545|31 37|N-SMase
P09763522A2545|49 54|Ox-LDL
P09763522A2545|49 54|Ox-LDL
P09763522A2545|59 84|TNF-alpha-induced apoptosis
P09763522A2545|59 67|TNF-alpha
P09763522A2545|126 134|apoptosis
P09763607A0521|11 28|virulent Ngo strains
P09763607A0521|35 49|phosphorylation
P09763607A0521|65 67|JNK
P09763607A0521|65 67|JNK
P09763607A0521|76 84|p38 kinase
P09763607A0521|76 84|p38 kinase
P09764741A0092|0 11|Focused beams
P09764741A0092|23 41|light ablate elements
P09764741A0092|47 67|cell division machinery
P09765261A0000|3 39|human T cell lymphotropic retrovirus type I
P09765261A0000|8 39|T cell lymphotropic retrovirus type I
P09765261A0000|41 62|HTLV-I) trans-activator
P09765261A0000|41 46|HTLV-I
P09765261A0000|64 66|Tax
P09765261A0000|64 66|Tax
P09765261A0000|96 135|basic-domain/leucine-zipper (bZip) protein
P09765261A0000|96 122|basic-domain/leucine-zipper
P09765261A0000|124 135|bZip) protein
P09765261A0000|137 169|cAMP response element binding protein
P09765261A0000|137 169|cAMP response element binding protein
P09765261A0000|171 174|CREB
P09765261A0000|171 174|CREB
P09765261A0000|187 212|viral Tax-responsive element
P09765261A0000|187 212|viral Tax-responsive element
P09765261A0000|239 256|21-base pair repeats
P09765261A0000|267 289|cAMP response element core
P09765261A0000|299 315|G/C-rich sequences
P09765261A0000|299 299|G
P09765261A0000|301 315|C-rich sequences
P09765271A1108|30 52|insulin response sequence
P09765271A1108|30 36|insulin
P09765271A1108|63 78|regulatory region
P09765271A1108|112 118|insulin
P09765271A1108|112 118|insulin
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|171 194|tyrosine aminotransferase
P09765271A1108|171 194|tyrosine aminotransferase
P09765271A1108|199 238|insulin-like growth factor-binding protein 1
P09765271A1108|199 238|insulin-like growth factor-binding protein 1
P09765277A0000|21 38|glucose transporter
P09765277A0000|48 52|Glut 3
P09765277A0000|48 52|Glut 3
P09765277A0000|109 130|neurons and trophoblasts
P09765285A0998|33 49|consensus sequence
P09765285A0998|50 55|AGGTCA
P09765285A0998|57 63|IRper-1
P09765285A0998|83 93|AaEcR.AaUSP
P09765285A0998|83 87|AaEcR
P09765285A0998|105 111|IRhsp-1
P09765285A0998|183 189|IRper-0
P09765285A0998|192 198|IRper-5
P09765285A1763|11 25|transactivation
P09765285A1763|78 93|response elements
P09765285A1763|95 101|IRper-1
P09765285A1763|103 106|DR-4
P09765285A1763|108 114|IRhsp-1
P09765372A0669|52 55|body
P09765372A0669|76 89|type II papillae
P09765372A0669|92 97|dorsal
P09765372A0669|138 146|C. armatus
P09765388T0000|14 16|p53
P09765388T0000|14 16|p53
P09765388T0000|23 25|p73
P09765388T0000|23 25|p73
P09765388T0000|28 88|adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins
P09765388T0000|28 45|adenovirus type 5 E1B
P09765388T0000|46 76|55-kilodalton and E4 34-kilodalton
P09765388T0000|77 88|oncoproteins
P09765394A0000|3 36|Epstein-Barr virus transactivator Zta
P09765394A0000|3 33|Epstein-Barr virus transactivator
P09765394A0000|34 36|Zta
P09765394A0000|45 63|lytic gene expression
P09765394A0000|97 107|lytic origin
P09765394A0000|109 114|oriLyt
P09765394A1590|0 13|Cotransfection
P09765394A1590|19 42|helicase-primase proteins
P09765394A1590|19 42|helicase-primase proteins
P09765394A1590|65 92|heterologous activation domain
P09765394A1590|99 126|Zta-dependent superactivation
P09765394A1590|99 101|Zta
P09765394A1590|129 141|CAT expression
P09765394A1590|129 131|CAT
P09765411A0991|41 74|S27a and the ubiquitin coding sequences
P09765411A0991|41 44|S27a
P09765411A0991|51 59|ubiquitin
P09765411A0991|93 97|CP Rit
P09765411A0991|118 127|bovine mRNA
P09765411A0991|118 123|bovine
P09765411A0991|124 127|mRNA
P09765411A0991|137 149|hybrid protein
P09765411A0991|166 188|NH2-ubiquitin-S27a-COOH
P09765411A0991|170 178|ubiquitin
P09765411A0991|180 183|S27a
P09765754A1727|35 37|PVI
P09767504A1371|7 12|rectal
P09767593A0130|8 11|YopH
P09767593A0130|8 11|YopH
P09767593A0130|27 29|PTP
P09767593A0130|27 29|PTP
P09767593A0130|63 93|tyrosine-phosphorylated proteins
P09767593A0130|63 93|tyrosine-phosphorylated proteins
P09767593A0130|96 104|host cells
P09767593A0130|115 121|p130Cas
P09767593A0130|115 121|p130Cas
P09767687T0000|25 35|Phacotaceae
P09767687T0000|45 61|Chlamydophyceaeas
P09767687T0000|82 88|18S rDNA
P09767687T0000|82 84|18S
P09767687T0000|85 88|rDNA
P09767687T0000|92 104|rbcL sequences
P09767687T0000|92 104|rbcL sequences
P09769209A0100|8 21|genetic studies
P09769209A0100|44 50|nitrate
P09769209A0100|72 81|nasF operon
P09769209A0100|72 81|nasF operon
P09769209A0100|107 145|transcriptional antitermination mechanism
P09769910A1700|3 12|activation
P09769910A1700|16 21|injury
P09769910A1700|24 39|endothelial cells
P09769910A1700|49 51|TNF
P09769910A1700|49 51|TNF
P09769910A1700|60 83|proinflammatory cytokines
P09769910A1700|117 125|mediators
P09770241A0000|13 26|thermal imaging
P09770241A0000|32 37|animal
P09770241A0000|41 56|human brain cortex
P09770241A0000|64 84|infrared optical system
P09770378A0641|0 3|EGFR
P09770378A0641|0 3|EGFR
P09770415A0139|21 26|THOV NP
P09770415A0139|21 24|THOV
P09770415A0139|25 26|NP
P09770415A0139|42 56|KRxxxxxxxxxKTKK
P09770415A0139|78 84|179-193
P09770415A0139|109 142|bipartite nuclear localization signal
P09770415A0139|144 146|NLS
P09770493A0499|2 5|PP2A
P09770493A0499|2 5|PP2A
P09770493A0499|20 36|cellular functions
P09770493A0499|46 64|cell cycle regulation
P09770493A0499|68 88|cell fate determination
P09770493A0499|120 126|embryos
P09770493A0499|170 181|embryonic day
P09770493A0499|182 188|5.5/6.0
P09770686A0484|28 36|ischaemic
P09771555A0499|22 44|anthraquinone sennoside B
P09771555A0499|62 70|genotoxic
P09771967A1052|12 18|LB1 gene
P09771967A1052|12 18|LB1 gene
P09771967A1052|27 41|chromosome 13q14
P09771967A1052|72 92|chromosomal breakpoint
P09771967A1052|95 98|DLBL
P09771985A0238|29 48|ethylmercury chloride
P09771985A0238|50 55|EtHgCl
P09771985A0238|62 86|solutions containing EtHgCl
P09771985A0238|96 105|L-cysteine
P09771985A0238|109 119|glutathione
P09773975A1873|0 21|Wild-type AT1A receptors
P09773975A1873|9 21|AT1A receptors
P09773975A1873|34 57|Chinese hamster ovary cells
P09773975A1873|83 98|Ang II stimulation
P09773975A1873|83 87|Ang II
P09773975A1873|125 139|internalization
P09773975A1873|141 144|Ymax
P09773975A1873|158 172|mutant receptors
P09773975A1873|187 205|acidic substitutions
P09773975A1873|207 211|T332E
P09773975A1873|234 238|S335D
P09773975A1873|261 265|T336E
P09773975A1873|288 292|S338D
P09773981A0415b|12 33|glucocorticoid receptor
P09773981A0415b|12 33|glucocorticoid receptor
P09773981A0415b|51 55|Stat5
P09773981A0415b|51 55|Stat5
P09773981A0415b|67 104|Stat5-mediated transcriptional induction
P09773981A0415b|67 71|Stat5
P09774403A0107|0 0|T
P09774444A0351|3 26|carboxyl-terminal portion
P09774444A0351|29 32|UKLF
P09774444A0351|29 32|UKLF
P09774444A0351|46 56|zinc fingers
P09774444A0351|62 74|Cys2-His2 type
P09774444A0351|95 104|CACCC motif
P09774444A0351|110 128|beta-globin promoter
P09774444A0351|110 128|beta-globin promoter
P09774444A0351|137 158|Sp1 recognition sequence
P09774444A0351|137 158|Sp1 recognition sequence
P09774450A0000|25 35|mouse enzyme
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|70 72|GGL
P09774450A0000|70 72|GGL
P09774450A0000|86 98|leukotriene C4
P09774450A0000|100 103|LTC4
P09774450A0000|107 119|leukotriene D4
P09774450A0000|121 124|LTD4
P09774484T0000|0 15|UGA codon position
P09774484T0000|38 64|selenocysteine incorporation
P09774484T0000|69 91|glutathione peroxidase-1
P09774484T0000|69 91|glutathione peroxidase-1
P09774641A0824|30 59|heregulin-stimulated expression
P09774641A0824|30 38|heregulin
P09774641A0824|62 86|cyclin D and phosphorylation
P09774641A0824|62 68|cyclin D
P09774641A0824|92 116|retinoblastoma gene product
P09774641A0824|92 116|retinoblastoma gene product
P09774662A0958|3 13|ARF promoter
P09774662A0958|3 13|ARF promoter
P09774662A0958|48 51|E2F1
P09774662A0958|48 51|E2F1
P09774662A0958|96 103|RNA level
P09776293A0777|20 24|99mTc
P09776293A0777|27 33|1-HMPAO
P09776360A0620|0 1|CM
P09776360A0620|36 54|transcription factor
P09776360A0620|55 58|AP-1
P09776360A0620|55 58|AP-1
P09776360A1781|0 8|NF-kappaB
P09776360A1781|0 8|NF-kappaB
P09776360A1781|37 49|basal activity
P09776360A1781|55 72|human NOS II promoter
P09776360A1781|55 72|human NOS II promoter
P09776360A1781|112 113|CM
P09776360A1781|116 125|DLD-1 cells
P09776360A1781|116 120|DLD-1
P09777477A0000|0 8|Observers
P09777477A0000|13 23|brain injury
P09777477A0000|92 105|periodic whiffs
P09777477A0000|108 131|unscented air or air scented
P09777477A0000|136 145|peppermint
P09777600A0000|53 72|liquid chromatography
P09777999A0796|54 64|PaCO2 levels
P09777999A0796|81 91|hypercapnia
P09778006A0718|61 73|arterial blood
P09778006A0718|75 79|PaCO2
P09778006A0718|169 185|dioxide reactivity
P09778006A0718|201 207|cm x s(-1
P09778006A0718|204 207|s(-1
P09778068A1129|12 30|Cox survival analysis
P09778068A1129|110 117|ablation
P09778068A1129|177 184|ablation
P09778068A1129|217 221|death
P09778191A0000|28 37|estimation
P09778191A0000|48 50|CBF
P09778191A0000|52 55|rCBF
P09778191A0000|60 89|cerebrovascular reserve capacity
P09778191A0000|93 111|pixel-by-pixel basis
P09778191A0000|128 155|magnetic resonance imaging (MRI
P09778197A0415|0 25|Cost-effectiveness analysis
P09778197A0415|121 141|lipid-lowering therapy
P09778197A0415|167 232|beta-hydroxy-beta-methylglutaryl-CoA (coenzyme A) reductase inhibitors
P09778197A0415|167 222|beta-hydroxy-beta-methylglutaryl-CoA (coenzyme A) reductase
P09778197A0415|234 240|statins
P09778197A0415|257 271|atherosclerosis
P09778197A0415|302 312|cholesterol
P09780002A0996|8 13|E2FBP1
P09780002A0996|8 13|E2FBP1
P09780002A0996|22 42|transactivation domain
P09780002A0996|56 85|E2F site-dependent transcription
P09780002A0996|56 62|E2F site
P09780002A0996|103 107|E2F-1
P09780002A0996|103 107|E2F-1
P09780228A0122|13 27|40-kb DNA segment
P09780228A0122|33 48|FK506 gene cluster
P09780228A0122|53 66|Streptomyces sp
P09780228A0613|30 33|FkbB
P09780228A0613|30 33|FkbB
P09780228A0613|37 40|FkbC
P09780228A0613|37 40|FkbC
P09780228A0613|61 64|FkbA
P09780228A0613|61 64|FkbA
P09780228A0613|78 97|fatty-acid-synthase(
P09780228A0613|78 96|fatty-acid-synthase
P09780228A0613|98 113|FAS)-like domains
P09780228A0613|98 100|FAS
P09780336A0771|10 27|Msy2 mRNA expression
P09780336A0771|10 17|Msy2 mRNA
P09780336A0771|30 40|prepubertal
P09780336A0771|44 59|adult mouse testes
P09780336A0771|66 84|isolated populations
P09780336A0771|87 95|germ cells
P09780336A0771|134 148|round spermatids
P09780336A0771|195 212|ribonucleoproteins
P09781761A0384|0 0|1
P09781761A0384|3 15|Ho Chi Minh City
P09781761A0384|38 55|latex agglutination
P09781761A0384|58 81|blood, cerebrospinal fluid
P09781761A0384|91 102|pleural fluid
P09781871A0404|0 29|Glycogen synthesis and catabolism
P09781871A0404|47 87|glycolysis, motility, cell surface properties
P09781871A0404|114 134|csrA in Escherichia coli
P09781871A0404|114 117|csrA
P09781871A0404|120 134|Escherichia coli
P09781871A0404|196 229|hypersensitive response elicitor HrpN
P09781871A0404|226 229|HrpN
P09781871A0404|231 233|Ecc
P09781871A0404|231 233|Ecc
P09781871A0404|256 275|secondary metabolites
P09781871A0404|290 312|rsmA in Erwinia carotovora
P09781871A0404|290 293|rsmA
P09781871A0404|296 312|Erwinia carotovora
P09781874A1061|3 16|cwg2-1 mutation
P09781874A1061|3 16|cwg2-1 mutation
P09781874A1061|33 39|guanine
P09781874A1061|42 48|adenine
P09781874A1061|63 75|nucleotide 604
P09781874A1061|81 92|coding region
P09781874A1061|114 118|A202T
P09781874A1061|124 129|cwg2p.
P09781874A1061|124 128|cwg2p
P09784063A0621|0 15|Deletion analysis
P09784063A0621|31 45|essential domain
P09784063A0621|52 59|promoter
P09784063A0621|70 98|ORF5/deltaX transcript promoter
P09784063A0621|70 90|ORF5/deltaX transcript
P09784063A0621|108 127|nucleotides 1525-1625
P09784192A1027|9 15|peptide
P09784192A1027|17 26|MBP fusions
P09784192A1027|17 26|MBP fusions
P09784192A1027|48 70|surface plasmon resonance
P09784245T0000|0 28|Cardiac myosin-binding protein C
P09784245T0000|0 6|Cardiac
P09784245T0000|7 28|myosin-binding protein C
P09784245T0000|30 35|MyBP-C
P09784245T0000|30 35|MyBP-C
P09784245T0000|54 67|protein kinase A
P09784245T0000|54 67|protein kinase A
P09784245T0000|71 104|protein kinase C phosphorylation sites
P09784245T0000|71 84|protein kinase C
P09785114A1026|0 7|Handling
P09785114A1026|10 13|PND 9
P09785114A1026|36 45|CORT levels
P09786197A0322|58 76|transposon insertion
P09786197A0322|90 106|open reading frames
P09786197A0322|118 121|csrR
P09786197A0322|118 121|csrR
P09786197A0322|125 128|csrS
P09786197A0322|125 128|csrS
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A0095|34 38|fatty
P09786926A0095|39 51|-acid synthase
P09786926A0095|52 59|promoter
P09786926A0095|117 134|fatty-acid synthase
P09786926A0095|117 134|fatty-acid synthase
P09786926A0095|136 143|FAS) gene
P09786926A0095|136 143|FAS) gene
P09786926A0095|183 200|downstream promoter
P09786926A0095|203 206|lean
P09786926A0095|218 228|rat fat cells
P09786926A1372|13 33|in vitro binding studies
P09786926A1372|47 52|SREBP2
P09786926A1372|47 52|SREBP2
P09786926A1372|70 80|ADD1/SREBP1
P09786926A1372|70 73|ADD1
P09786926A1372|75 80|SREBP1
P09786926A1372|95 117|sterol regulatory element
P09786926A1372|95 117|sterol regulatory element
P09786926A1372|119 126|SRE) site
P09786926A1372|119 121|SRE
P09786932A1042|5 9|IRF-7
P09786932A1042|5 9|IRF-7
P09786932A1042|40 44|IRF-3
P09786932A1042|40 44|IRF-3
P09786932A1042|81 85|IRF-7
P09786932A1042|81 85|IRF-7
P09786932A1042|88 100|lymphoid cells
P09786932A1042|126 129|IFNA
P09786932A1042|126 129|IFNA
P09786932A1042|143 147|IRF-7
P09786932A1042|143 147|IRF-7
P09786932A1042|183 200|IFNA gene expression
P09786932A1042|183 190|IFNA gene
P09787323A0000|15 27|interleukin-6
P09787323A0000|15 27|interleukin-6
P09787323A0000|29 32|IL-6
P09787323A0000|29 32|IL-6
P09787323A0000|50 76|congenital thrombocytopenias
P09788739A1096|0 3|CKII
P09788739A1096|0 3|CKII
P09788739A1096|7 33|CD44-associated serine kinase
P09788739A1096|7 33|CD44-associated serine kinase
P09788739A1096|75 90|signaling cascade
P09788739A1096|113 129|cellular responses
P09788739A1096|132 154|MDA231 breast cancer cells
P09789025A0149|0 6|Galphaq
P09789025A0149|0 6|Galphaq
P09789025A0149|8 15|Galpha12
P09789025A0149|8 15|Galpha12
P09789025A0149|20 27|Galpha13
P09789025A0149|20 27|Galpha13
P09789025A0149|35 41|Galphai
P09789025A0149|35 41|Galphai
P09789025A0149|51 53|SRF
P09789025A0149|51 53|SRF
P09789025A0149|61 64|RhoA
P09789025A0149|61 64|RhoA
P09789795A0607|19 36|subjects adrenaline
P09789795A0607|43 55|noradrenaline
P09789795A0607|57 73|NA) concentrations
P09790499A0545|0 19|Northern blot analyses
P09790499A0545|31 44|hBub1 mRNA level
P09790499A0545|31 39|hBub1 mRNA
P09790499A0545|87 102|high mitotic index
P09790767A0372|11 47|overlapping expressed sequence tag clones
P09790767A0372|55 67|genomic contig
P09790767A0372|70 85|human chromosome 5
P09790767A0372|87 93|band q31
P09790768A0621|0 10|Htra2-beta3
P09790768A0621|0 10|Htra2-beta3
P09790768A0621|64 68|brain
P09790768A0621|70 80|liver testis
P09790768A0621|93 98|kidney
P09790771A0956|0 16|Gng3lg transcripts
P09790771A0956|0 16|Gng3lg transcripts
P09790771A0956|41 47|tissues
P09790771A0956|61 74|brain and testes
P09790771A1032|50 53|Gng3
P09790771A1032|50 53|Gng3
P09790771A1032|57 62|Gng3lg
P09790771A1032|57 62|Gng3lg
P09790771A1032|79 90|chromosome 19
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09790986A0689|91 114|NH2-terminal 86 amino acids
P09790986A0689|117 127|human NRAMP2
P09790986A0689|117 127|human NRAMP2
P09792439T0000|15 33|apolipoprotein B mRNA
P09792439T0000|15 33|apolipoprotein B mRNA
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|74 90|40S hnRNP complexes
P09792439T0000|74 81|40S hnRNP
P09792627A0441|0 4|SRC-1
P09792627A0441|0 4|SRC-1
P09792627A0441|18 45|NF-kappaB-mediated repression
P09792627A0441|18 26|NF-kappaB
P09792627A0441|48 57|GR activity
P09792627A0441|48 49|GR
P09792630A1127|32 53|transcription start site
P09792630A1127|54 61|CTCA(+1)
P09792630A1127|62 65|TTCC
P09792630A1127|81 101|consensus CTCA(+1)NTCT
P09792630A1127|109 118|nucleoside
P09792630A1127|148 182|terminal deoxynucleotidyltransferase
P09792630A1127|156 182|deoxynucleotidyltransferase
P09792682A0713|50 51|F0
P09792682A0713|71 75|2 and 3
P09792702A0754|38 41|JNK1
P09792702A0754|38 41|JNK1
P09792702A0754|56 73|glucose deprivation
P09792702A0754|82 95|JNK1 activation
P09792702A0754|82 85|JNK1
P09792702A0754|104 112|HSP70 gene
P09792702A0754|104 108|HSP70
P09792702A0754|109 122|gene expression
P09792714A1408|16 19|AF-1
P09792714A1408|16 19|AF-1
P09792714A1408|59 71|transcription
P09792714A1408|118 131|gene expression
P09792714A1408|134 137|AF-1
P09792714A1408|134 137|AF-1
P09794414T0000|9 31|protein kinase C signaling
P09794414T0000|9 22|protein kinase C
P09794414T0000|43 58|DRA transcription
P09794414T0000|43 45|DRA
P09794795A0183|0 12|Ligand binding
P09794795A0183|18 32|receptor complex
P09794795A0183|18 32|receptor complex
P09794795A0183|40 62|tyrosine phosphorylation
P09794795A0183|78 89|Janus kinases
P09794795A0183|78 89|Janus kinases
P09794795A0183|91 93|Jak
P09794795A0183|91 93|Jak
P09794795A0183|116 144|signal transducing subunit gp130
P09794795A0183|116 139|signal transducing subunit
P09794795A0183|140 144|gp130
P09794795A0183|170 184|phosphorylation
P09794795A0183|190 239|signal transducer and activator of transcription factors
P09794795A0183|240 244|STAT3
P09794795A0183|240 244|STAT3
P09794795A0183|248 252|STAT1
P09794795A0183|248 252|STAT1
P09794795A0183|259 275|src homology domain
P09794795A0183|259 275|src homology domain
P09794795A0183|277 317|SH2)-containing protein tyrosine phosphatase
P09794795A0183|277 317|SH2)-containing protein tyrosine phosphatase
P09794795A0183|319 322|SHP2
P09794795A0183|319 322|SHP2
P09795130A0742|26 33|distance
P09795130A0742|69 89|translation efficiency
P09795170A0774|13 39|3'-polyadenylation site 504bp
P09795170A0774|55 66|TGA stop codon
P09795213A0129|0 11|RBP56 protein
P09795213A0129|0 11|RBP56 protein
P09795213A0129|25 32|hTAFII68
P09795213A0129|25 32|hTAFII68
P09795213A0129|52 86|TATA-binding protein associated factor
P09795213A0129|52 86|TATA-binding protein associated factor
P09795213A0129|88 90|TAF
P09795213A0129|88 90|TAF
P09795213A0129|113 126|TFIID complexes
P09795213A0129|113 117|TFIID
P09795213A0129|128 138|Bertolotti A
P09795213A0129|184 191|hTAFII68
P09795213A0129|184 191|hTAFII68
P09795213A0129|194 222|novel RNA/ssDNA-binding protein
P09795213A0129|199 201|RNA
P09795213A0129|203 222|ssDNA-binding protein
P09795213A0129|240 257|proto-oncoproteins
P09795213A0129|240 257|proto-oncoproteins
P09795213A0129|258 264|TLS/FUS
P09795213A0129|258 260|TLS
P09795213A0129|262 264|FUS
P09795213A0129|268 270|EWS
P09795213A0129|268 270|EWS
P09795213A0129|291 295|TFIID
P09795213A0129|291 295|TFIID
P09795213A0129|299 313|RNA polymerase II
P09795213A0129|299 313|RNA polymerase II
P09795341A0806|2 34|electrophoretic mobility shift assay
P09795341A0806|81 83|TR2
P09795341A0806|81 83|TR2
P09795341A0806|90 105|truncated isoform
P09797189A0559|0 24|Gel-mobility shift analysis
P09797189A0559|47 56|CCAAT motif
P09797189A0559|47 56|CCAAT motif
P09797456A0000|14 32|c-myc proto-oncogene
P09797456A0000|14 32|c-myc proto-oncogene
P09797456A0000|65 81|cell proliferation
P09797456A0000|83 97|differentiation
P09797456A0000|116 124|apoptosis
P09797456A0883|0 4|AMY-1
P09797456A0883|0 4|AMY-1
P09797456A0883|22 30|cytoplasm
P09797456A0883|48 52|c-myc
P09797456A0883|48 52|c-myc
P09797456A0883|73 79|nucleus
P09797456A0883|97 111|c-myc expression
P09797456A0883|97 101|c-myc
P09797456A0883|114 140|transiently transfected cells
P09798068A0290|21 35|full-length cDNA
P09798068A0290|21 35|full-length cDNA
P09798068A0290|42 57|open reading frame
P09798068A0290|60 65|2883 bp
P09798068A0290|100 112|961 amino acids
P09798068A0290|152 192|rat gamma-aminobutyric acid B (GABAB) receptor
P09798068A0290|152 177|rat gamma-aminobutyric acid B
P09798068A0290|179 192|GABAB) receptor
P09798100A0705|2 5|Day 8
P09798100A0705|10 15|CIDR-B
P09798100A0705|63 64|IM
P09798263T0000|0 28|Antidepressant-like properties
P09798263T0000|35 58|serotonin receptor ligands
P09798263T0000|62 86|calcium channel antagonists
P09798263T0000|102 119|forced swimming test
P09798263T0000|122 125|mice
P09799086A0725|50 59|frame shift
P09799086A0725|69 88|G nucleotide insertion
P09799086A0725|113 114|Gs
P09799086A0725|117 125|HPRT exon 3
P09799086A0725|117 125|HPRT exon 3
P09799086A0725|164 165|LN
P09799086A0725|166 173|patients
P09799237A0624|0 2|SRF
P09799237A0624|0 2|SRF
P09799237A0624|13 19|embryos
P09799237A0624|21 27|Srf -/-)
P09799237A0624|39 56|gastrulation defect
P09799362A0507|56 71|abbreviation AZF1
P09799362A0507|68 71|AZF1
P09799362A0507|73 104|Asparagine-rich Zinc Finger protein
P09799362A0507|73 104|Asparagine-rich Zinc Finger protein
P09799362A1463|17 21|Azf1p
P09799362A1463|17 21|Azf1p
P09799362A1463|27 35|yeast cell
P09799362A1463|75 111|mitochondrial transcription factor Mtf1p
P09799362A1463|75 106|mitochondrial transcription factor
P09799362A1463|107 111|Mtf1p
P09799362A1463|141 145|Azf1p
P09799362A1463|141 145|Azf1p
P09799362A1463|174 205|mitochondrial RNA polymerase mutant
P09799362A1463|174 205|mitochondrial RNA polymerase mutant
P09799634A0161|34 49|C-terminal domain
P09799634A0161|34 49|C-terminal domain
P09799634A0161|55 66|434 repressor
P09799634A0161|77 92|crystal structure
P09799634A0161|98 119|homologous UmuD' protein
P09799634A0161|108 119|UmuD' protein
P09799793T0000|40 53|chromosome 7q22
P09799793T0000|65 86|650 kb of genomic sequence
P09799793T0000|96 98|EPO
P09799793T0000|96 98|EPO
P09799793T0000|102 110|CUTL1 loci
P09799793T0000|102 110|CUTL1 loci
P09800187A0100|7 11|Trp53
P09800187A0100|7 11|Trp53
P09800187A0100|16 27|mouse homolog
P09800187A0100|30 38|human TP53
P09800187A0100|30 38|human TP53
P09800187A0100|53 55|Tk1
P09800187A0100|53 55|Tk1
P09800187A0100|58 69|chromosome 11
P09800187A0100|131 147|DNA damaging agents
P09800187A0100|175 192|mouse lymphoma cells
P09800187A0100|210 214|Trp53
P09800187A0100|210 214|Trp53
P09801156A0220|34 58|amino acid sequence homology
P09801156A0220|64 69|insect
P09801156A0220|70 93|ecdysone inducible gene E75
P09801333A0174|3 18|full-length N gene
P09801333A0174|3 18|full-length N gene
P09801333A0174|29 45|open reading frame 7
P09801333A0174|63 79|Canadian PRRS virus
P09801333A0174|81 82|PA
P09802206A1058|7 22|sequence homology
P09802206A1058|48 93|TEF, encoding translation elongation factor-1 alpha
P09802206A1058|48 50|TEF
P09802206A1058|71 93|elongation factor-1 alpha
P09802206A1058|97 100|RPS7
P09802206A1058|97 100|RPS7
P09802206A1058|110 127|ribosomal protein S7
P09802206A1058|110 127|ribosomal protein S7
P09802902A0225|25 28|ARNO
P09802902A0225|25 28|ARNO
P09802902A0225|43 56|plasma membrane
P09802902A0225|86 107|ARF6 nucleotide exchange
P09803081T0000|0 13|Renal pathology
P09803081T0000|35 46|childhood SLE
P09804779A0000|0 19|Transcription factors
P09804779A0000|25 34|Stat family
P09804779A0000|25 34|Stat family
P09804779A0000|50 63|protein kinases
P09804779A0000|50 63|protein kinases
P09804779A1163|32 57|Stat5 serine phosphorylation
P09804779A1163|32 36|Stat5
P09804779A1163|68 86|prolactin-activated
P09804779A1163|68 76|prolactin
P09804779A1163|90 96|PD98059
P09804779A1163|142 148|PD98059
P09804779A1163|183 188|Stat5a
P09804779A1163|183 188|Stat5a
P09804836A0000|21 38|cytoplasmic protein
P09804836A0000|86 109|mouse BAC1.2F5 macrophages
P09804836A0000|112 136|colony stimulating factor-1
P09804836A0000|112 136|colony stimulating factor-1
P09804836A0000|138 142|CSF-1
P09804836A0000|138 142|CSF-1
P09804836A0000|145 148|pp37
P09804836A0000|145 148|pp37
P09804836A0000|167 183|cytosolic fraction
P09804836A0000|186 193|anti-Tyr
P09804836A0000|191 193|Tyr
P09804836A0000|195 246|P) affinity chromatography, size exclusion chromatography
P09804836A0000|195 195|P
P09804836A0000|251 252|C4
P09804836A0000|277 296|liquid chromatography
P09805052A0119|8 9|ig
P09805977A0143|74 78|sperm
P09806516A1212|45 52|patients
P09806516A1689|37 41|Preop
P09806516A1689|44 51|patients
P09806516A1689|95 100|Postop
P09806516A1689|103 110|patients
P09806546A1270|18 21|RFX5
P09806546A1270|18 21|RFX5
P09806546A1270|25 29|RFXAP
P09806546A1270|25 29|RFXAP
P09806546A1270|56 65|RFX complex
P09806546A1270|56 58|RFX
P09806546A1270|68 82|MHC-II promoters
P09806546A1270|68 82|MHC-II promoters
P09806826A0244|33 39|RIIIS/J
P09806826A0244|48 57|mouse Chr 11
P09806826A0244|74 81|Vwf locus
P09806826A0244|74 81|Vwf locus
P09806826A0244|84 87|Chr 6
P09806826A1773|92 119|tricho-dento-osseous syndrome
P09806826A1773|124 134|murine locus
P09806826A1773|124 134|murine locus
P09806826A1773|154 181|ozone-induced acute lung injury
P09806857A0854|67 76|invertases
P09806857A0854|80 89|resolvases
P09806857A0854|80 89|resolvases
P09806857A0854|124 138|Pac25I R-M operon
P09806857A0854|124 129|Pac25I
P09806857A0854|130 138|R-M operon
P09806858T0000|20 23|gene
P09806858T0000|29 52|streptococcal plasmid pLS1
P09806858T0000|57 64|rnaI gene
P09806858T0000|57 64|rnaI gene
P09806919A0447|7 9|usp
P09806919A0447|57 96|developmental and transcriptional responses
P09806919A0447|102 109|ecdysone
P09806919A0447|127 143|puparium formation
P09807755A0146|8 26|neurovascular supply
P09807755A0146|56 65|muscle flap
P09808155A0813|13 39|DNA:protein binding complexes
P09808155A0813|17 39|protein binding complexes
P09808155A0813|42 58|gel-shift analysis
P09808155A0813|72 85|nuclear factors
P09808155A0813|159 169|-949- -722 bp
P09808216A0000|20 26|lean men
P09808216A0000|54 55|EB
P09808216A0000|54 55|EB
P09808216A0000|60 69|fat balance
P09808216A0000|71 72|FB
P09808216A0000|80 91|manipulation
P09808216A0000|94 106|dietary ratios
P09808216A0000|109 111|fat
P09808366A0828|0 12|Fatal apneusis
P09808366A0828|62 66|apnea
P09808366A0828|90 105|KA microinjection
P09808366A0828|120 126|VRG-Apa
P09808366A0828|129 135|animals
P09808441A0320|33 65|MOCT-associated malignant melanomas
P09808441A0320|128 135|melanoma
P09808441A0320|172 200|invasive squamous cell carcinoma
P09810087A0379|10 31|herpetic seroconversion
P09810087A0379|61 78|herpes simplex virus
P09810087A0379|80 84|HSV I)
P09810087A0379|80 83|HSV I
P09810087A0379|85 91|nucleic
P09810087A0379|102 124|recipient's aqueous humor
P09811695A1146|24 40|HIV-1 Gag sequences
P09811695A1146|24 28|HIV-1
P09811695A1146|29 40|Gag sequences
P09811695A1146|56 81|viral PR-mediated processing
P09811695A1146|87 105|MuLV TM Env protein p15
P09811695A1146|91 105|TM Env protein p15
P09811695A1146|107 107|E
P09811695A1146|107 107|E
P09811718A0979a|45 47|SIV
P09811718A0979a|51 58|HIV-2 nef
P09811718A0979a|51 55|HIV-2
P09811718A0979a|66 73|HIV-1 nef
P09811718A0979a|66 70|HIV-1
P09811718A0979a|71 73|nef
P09811718A0979a|79 85|TCRzeta
P09811718A0979a|79 85|TCRzeta
P09811730A1396|11 14|EMSA
P09811730A1396|30 67|constitutively expressed nuclear proteins
P09811730A1396|53 67|nuclear proteins
P09811730A1396|76 85|KCS element
P09811730A1396|76 85|KCS element
P09811730A1396|98 122|KCS protein binding activity
P09811730A1396|98 107|KCS protein
P09811730A1396|137 152|promoter activity
P09811730A1396|158 191|transient transfection reporter assay
P09811730T0000|11 26|interferon action
P09811730T0000|11 20|interferon
P09811730T0000|71 97|novel 15-base-pair KCS element
P09811730T0000|76 97|15-base-pair KCS element
P09811730T0000|109 133|transcriptional activation
P09811730T0000|139 171|RNA-dependent protein kinase pkr gene
P09811730T0000|139 171|RNA-dependent protein kinase pkr gene
P09813041A1122|0 1|GH
P09813041A1122|0 1|GH
P09813041A1122|19 33|phosphorylation
P09813041A1122|48 66|Jun N-terminal kinase
P09813041A1122|48 66|Jun N-terminal kinase
P09813063T0000|18 44|murine phospholipase D homolog
P09813063T0000|18 37|murine phospholipase D
P09813063T0000|62 80|neuronal development
P09813063T0000|86 94|forebrain
P09813093A0624|28 34|YCL024W
P09813093A0624|28 34|YCL024W
P09813093A0624|76 79|GIN4
P09813093A0624|76 79|GIN4
P09813098A0521|0 9|Paralemmin
P09813098A0521|0 9|Paralemmin
P09813098A0521|37 40|mRNA
P09813110A0982|10 26|amino acid sequence
P09813110A0982|29 33|CBP90
P09813110A0982|29 33|CBP90
P09813110A0982|87 104|proline-rich domain
P09813110A0982|110 125|C-terminal region
P09813110A0982|110 125|C-terminal region
P09813203T0000|11 40|low-profile serine substitutions
P09813203T0000|46 51|V3 loop
P09813203T0000|46 47|V3
P09813203T0000|54 68|HIV-1 gp120 IIIB/
P09813203T0000|54 67|HIV-1 gp120 IIIB
P09813203T0000|69 71|LAI
P09813203T0000|69 71|LAI
P09813203T0000|96 110|envelope protein
P09813203T0000|96 110|envelope protein
P09813207A0434|54 88|aphidicolin-sensitive late transcript
P09813207A0434|101 109|TAAG motif
P09813207A0434|119 133|-352 nucleotides
P09813207A0434|193 201|TTGT motif
P09813207A0434|209 221|35 nucleotides
P09813207A0434|235 241|TATA box
P09813207A0434|248 258|nucleotides
P09813207A0434|276 280|+1 ATG
P09813207A0434|283 286|lef2
P09813207A0434|283 286|lef2
P09813254A0000|3 44|human 2', 5'-oligoadenylate (2-5A) synthetases
P09813254A0000|3 44|human 2', 5'-oligoadenylate (2-5A) synthetases
P09813254A0000|57 73|a family interferon
P09813254A0000|75 106|IFN)-inducible anti-viral proteins
P09813254A0000|75 77|IFN
P09813254A0000|89 106|anti-viral proteins
P09813259A1097|50 70|mechanical sensitivity
P09813259A1097|84 96|thermal injury
P09813259A1097|103 105|GBP
P09813259A1097|109 111|IBG
P09813635A0678|5 14|striations
P09813635A0678|58 68|upper canine
P09813635A0678|75 76|P3
P09813635A0678|83 88|honing
P09813635A0678|90 111|canine/premolar complex
P09814637A1214|3 15|PbrO2 readings
P09814637A1214|40 60|local microhemorrhages
P09814637A1214|76 77|CT
P09814637A1214|80 82|MRI
P09814905A0598|26 40|swine production
P09815578A1245|37 41|CDKN2
P09815578A1245|37 41|CDKN2
P09815578A1245|64 83|genetic abnormalities
P09815578A1245|86 99|prostate cancer
P09815578A1245|118 139|prostate carcinogenesis
P09815948A1065|3 27|pharmacokinetic parameters
P09815948A1065|51 60|toxicities
P09815948A1065|89 103|peak plasma level
P09817131A0296|1 10|Chinese (HK
P09817190A0074|16 27|cyclosporin A
P09817190A0074|67 78|hypertension
P09817190A0074|81 106|kidney transplant recipients
P09817373A0000|31 50|hypercholesterolemia
P09817373A0000|54 114|atherosclerosis-induced chronic cavernosal arterial insufficiency
P09817373A0000|117 142|cavernosal smooth muscle tone
P09817373A0000|144 162|nitric oxide synthase
P09817373A0000|144 162|nitric oxide synthase
P09817373A0000|164 166|NOS
P09817373A0000|164 166|NOS
P09817373A0000|179 203|cavernosal tissue synthesis
P09817373A0000|217 227|eicosanoids
P09817601T0000|21 37|regulatory regions
P09817601T0000|43 70|human aromatase (P450arom) gene
P09817601T0000|48 56|aromatase
P09817601T0000|58 65|P450arom
P09817601T0000|81 107|placenta-specific expression
P09819038A0448|0 15|Recombinant FVIIa
P09819038A0448|11 15|FVIIa
P09819038A0448|58 72|room temperature
P09819038A0448|84 98|body temperature
P09819110A0703|0 30|CD4 lymphocyte and viral load levels
P09819110A0703|0 2|CD4
P09819110A0703|59 68|ARV therapy
P09819288A0578|8 15|serum IgE
P09819288A0578|13 15|IgE
P09819288A0578|44 46|IgE
P09819288A0578|44 46|IgE
P09819377A1209|1 8|mutation
P09819377A1209|14 25|5' C2U4 repeat
P09819377A1209|51 56|snR13F
P09819377A1209|51 56|snR13F
P09819377A1209|79 90|3' C2U4 repeat
P09819377A1209|121 124|RNAs
P09819377A1209|141 146|500-nt
P09819391A1123|29 32|Arfs
P09819391A1123|29 32|Arfs
P09819391A1123|36 50|tyrosine kinases
P09819391A1123|36 50|tyrosine kinases
P09819391A1123|71 80|cell growth
P09819391A1123|84 107|cytoskeletal organization
P09819391A1123|109 113|ASAP1
P09819391A1123|109 113|ASAP1
P09819391A1123|129 152|membrane remodeling events
P09819411A0897|2 24|DNase I footprint analysis
P09819411A0897|2 7|DNase I
P09819411A0897|30 39|PNR element
P09819411A0897|30 39|PNR element
P09819411A0897|42 51|palindrome
P09819411A0897|57 85|high-affinity Ets-binding sites
P09819411A0897|70 85|Ets-binding sites
P09819411A0897|87 98|CTTCCCTGGAAG
P09819414A1103|55 68|leptin receptor
P09819414A1103|55 68|leptin receptor
P09819421A0000|0 11|Cyclophilins
P09819421A0000|0 11|Cyclophilins
P09819421A0000|15 49|cis-trans-peptidyl-prolyl isomerases
P09819421A0000|19 49|trans-peptidyl-prolyl isomerases
P09819421A0000|80 108|immunosuppressant cyclosporin A
P09819421A0000|110 112|CsA
P09819422A0768|2 33|vitro protein retention experiments
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|104 107|Cns1
P09819422A0768|104 107|Cns1
P09819430A0000|3 20|Ras-related GTPases
P09819430A0000|3 20|Ras-related GTPases
P09819430A0000|76 88|GDP-bound form
P09819430A0000|100 113|GTP-bound state
P09819440A0000|2 22|modulate transcription
P09819440A0000|56 80|basal transcription factors
P09819440A0000|87 100|RNA polymerases
P09819440A0000|87 100|RNA polymerases
P09819440A0783|10 12|RMP
P09819440A0783|63 66|RPB5
P09819440A0783|63 66|RPB5
P09819440A0783|69 81|RNA polymerase
P09819440A0783|69 81|RNA polymerase
P09819440A0783|84 97|mammalian cells
P09819507A0000|64 68|Dexon
P09819507A0000|81 101|conjunctival flap 1, 4, 7
P09819507A0000|119 139|trabeculectomy surgery
P09819507A0000|161 171|mitomycin-C
P09820163A0565|26 41|Southern blotting
P09820163A0565|45 63|restriction analysis
P09820205A0000|3 15|zona pellucida
P09820205A0000|17 18|ZP
P09820205A0000|24 46|extracellular glycocalyx
P09820205A0000|63 68|oocyte
P09820205A0000|90 116|homologous gamete interaction
P09820611T0000|48 77|recombinant human erythropoietin
P09820611T0000|48 77|recombinant human erythropoietin
P09820611T0000|80 116|malnourished predialysis anemic patients
P09820611T0000|121 139|diabetic nephropathy
P09820621A0067|8 34|pathological thyroid function
P09820621A0067|75 89|body composition
P09820621A0067|113 124|leptin levels
P09820621A0067|113 118|leptin
P09821978A1255|5 21|cognitive deficits
P09821978A1255|37 43|animals
P09821978A1255|55 60|MK-801
P09821978A1255|67 68|SE
P09822602A0237|47 56|HIF-1alpha
P09822602A0237|47 56|HIF-1alpha
P09822602A0237|90 119|hypoxia-dependent nuclear import
P09822602A0237|152 172|transactivation domain
P09822602A0237|201 240|CREB-binding protein (CBP)/p300 coactivator
P09822602A0237|201 219|CREB-binding protein
P09822602A0237|221 223|CBP
P09822602A0237|226 240|p300 coactivator
P09822602A1172|5 34|hypoxia-inducible nuclear import
P09822602A1172|68 70|CBP
P09822602A1172|68 70|CBP
P09822602A1172|133 150|signal transduction
P09822602A1172|153 162|HIF-1alpha
P09822602A1172|153 162|HIF-1alpha
P09822647A0000|3 18|rat aldolase C gene
P09822647A0000|6 18|aldolase C gene
P09822647A0000|27 42|glycolytic enzyme
P09822647A0000|62 71|adult brain
P09822652A1118|20 38|HCK promoter activity
P09822652A1118|20 30|HCK promoter
P09822652A1118|72 74|Sp1
P09822652A1118|72 74|Sp1
P09822661T0073|0 20|Quinone-binding domain
P09822661T0073|24 40|amino acid residues
P09822661T0073|51 57|quinone
P09822685A0596|0 14|Western analyses
P09822685A0596|19 26|antisera
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|68 83|N-terminal region
P09822685A0596|68 83|N-terminal region
P09822685A0596|98 113|open reading frame
P09822690A0000|0 21|Mammalian sperm motility
P09822690A0000|45 86|cAMP-dependent protein phosphorylation events
P09822690A0000|45 65|cAMP-dependent protein
P09822690A0000|97 110|protein kinase A
P09822690A0000|97 110|protein kinase A
P09822825A0141|27 30|BAP2
P09822825A0141|27 30|BAP2
P09822825A0141|50 57|BAP3 gene
P09822825A0141|50 57|BAP3 gene
P09822825A0141|60 71|S. cerevisiae
P09822825A0141|96 119|branched-chain amino acids
P09823014T0000|15 25|nutritional
P09823014T0000|60 62|fat
P09823014T0000|74 103|carbohydrate and lipid metabolism
P09823014T0000|106 113|patients
P09823014T0000|118 122|NIDDM
P09823561T0001|0 52|Low-grade gastric MALT lymphoma and helicobacter heilmannii
P09823561T0001|54 75|Gastrospirillum hominis
P09823775A1122|30 33|HMG I
P09823775A1122|33 36|I(Y)
P09823775A1122|35 35|Y
P09823775A1122|61 81|HLA-DRA gene activation
P09823775A1122|61 71|HLA-DRA gene
P09823775A1122|84 89|Oct-2A
P09823775A1122|84 89|Oct-2A
P09824001A1665|12 22|hemodynamic
P09824001A1665|64 66|vWF
P09824001A1665|64 66|vWF
P09824001A1665|68 69|Ag
P09824001A1665|68 69|Ag
P09824021A1263|108 116|NO therapy
P09824158A1336|10 14|BCL-6
P09824158A1336|10 14|BCL-6
P09824158A1336|15 32|POZ domain mutations
P09824158A1336|62 66|N-CoR
P09824158A1336|62 66|N-CoR
P09824158A1336|70 73|SMRT
P09824158A1336|70 73|SMRT
P09826434T0000|28 37|active site
P09826434T0000|43 71|platelet cAMP phosphodiesterase
P09826434T0000|43 71|platelet cAMP phosphodiesterase
P09826434T0000|73 77|PDE3A
P09826434T0000|73 77|PDE3A
P09826434T0000|81 104|site-directed mutagenesis
P09826658A0691|4 15|core sequence
P09826658A0691|57 67|nucleotides
P09826658A0691|104 122|spliceosome assembly
P09826658A0691|136 149|BPV-1 pre-mRNAs
P09826658A0691|136 149|BPV-1 pre-mRNAs
P09826778A0943|28 31|p300
P09826778A0943|28 31|p300
P09826778A0943|50 60|coactivator
P09826778A0943|63 88|myoD-mediated transcription
P09826778A0943|63 66|myoD
P09826778A0943|90 109|alleviated repression
P09826778A0943|112 120|COUP-TF II
P09826778A0943|112 120|COUP-TF II
P09827446T0001|8 26|autoimmune hepatitis
P09827446T0001|30 41|C4 deficiency
P09827446T0001|30 31|C4
P09827724A1362|2 10|mutations
P09827724A1362|22 39|follicular adenomas
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|27 29|GPX
P09827878A0091|27 29|GPX
P09827878A0091|34 52|superoxide dismutase
P09827878A0091|34 52|superoxide dismutase
P09827878A0091|54 56|SOD
P09827878A0091|54 56|SOD
P09827878A0091|91 110|antioxidative defence
P09827878A0091|155 168|occupationally
P09827993A0000|0 29|Retroviral nucleocapsid proteins
P09827993A0000|10 29|nucleocapsid proteins
P09827993A0000|31 34|NCPs
P09827993A0000|31 34|NCPs
P09827993A0000|39 65|CCHC-type zinc finger proteins
P09827993A0000|39 65|CCHC-type zinc finger proteins
P09827993A0000|83 102|RNA binding activities
P09827993A0000|138 160|genomic RNA encapsidation
P09828137A0000|3 26|Schizosaccharomyces pombe
P09828137A0000|27 50|rad1+ cell cycle checkpoint
P09828137A0000|27 31|rad1+
P09828137A0000|75 94|S-phase and G2/M arrest
P09828137A0000|111 119|DNA damage
P09828137A0000|123 146|incomplete DNA replication
P09829836A0000|47 65|eukaryotic cell cycle
P09829836A0000|107 129|cyclin- dependent kinases
P09829836A0000|107 129|cyclin- dependent kinases
P09829836A0000|131 134|CDKs
P09829836A0000|131 134|CDKs
P09829836A0815|0 7|Positive
P09829836A0815|40 57|cyclin/CDK function
P09829836A0815|40 45|cyclin
P09829836A0815|47 49|CDK
P09829836A0815|83 91|E. coli neo
P09829836A0815|83 88|E. coli
P09829836A0815|89 108|neo and yeast LEU2 genes
P09829836A0815|95 108|yeast LEU2 genes
P09829843A0119|3 40|hematopoietic colony-stimulating factors
P09829843A0119|3 40|hematopoietic colony-stimulating factors
P09829843A0119|42 44|CSF
P09829843A0119|42 44|CSF
P09829843A0119|96 113|supportive measures
P09829843A0119|141 163|infectious complications
P09829843A0119|166 173|patients
P09829843A0119|178 197|cancer and neutropenia
P09829843A0819|15 17|CSF
P09829843A0819|15 17|CSF
P09829843A0819|47 57|neutropenia
P09829843A0819|100 117|neutrophil recovery
P09829843A0819|119 127|rHu GM-CSF
P09829843A0819|119 127|rHu GM-CSF
P09829843A0819|131 138|rHu G-CSF
P09829843A0819|131 138|rHu G-CSF
P09829843A0819|252 266|neutrophil count
P09829843A0819|270 287|neutrophil function
P09829843A0819|312 334|chemiluminescence system
P09829916T0000|12 15|lacZ
P09829916T0000|12 15|lacZ
P09829916T0000|23 30|promoter
P09829916T0000|36 59|Escherichia coli spc operon
P09829916T0000|36 59|Escherichia coli spc operon
P09829916T0000|88 104|W205 trp-lac fusion
P09829916T0000|88 104|W205 trp-lac fusion
P09832099A0000|19 38|right ventricular wall
P09832099A0000|51 57|systole
P09832099A0000|60 67|patients
P09832099A0000|101 110|Fallot (TOF
P09832099A0000|122 135|kinesis imaging
P09832436A0738|0 13|RT-PCR analysis
P09832436A0738|24 28|PLP-H
P09832436A0738|24 28|PLP-H
P09832436A0738|37 41|PLP-C
P09832436A0738|37 41|PLP-C
P09832436A0738|45 49|PLP-D
P09832436A0738|45 49|PLP-D
P09832436A0738|67 76|rat strains
P09832436A0738|100 102|PLP
P09832436T0000|0 15|Molecular cloning
P09832436T0000|52 72|rat placental prolactin
P09832436T0000|52 63|rat placental
P09832436T0000|64 72|prolactin
P09832436T0000|74 83|PRL) family
P09832436T0000|74 83|PRL) family
P09832436T0000|85 100|PRL-like protein H
P09832436T0000|85 87|PRL
P09832504A0596|45 47|Tat
P09832504A0596|45 47|Tat
P09832504A0596|51 56|hCycT1
P09832504A0596|51 56|hCycT1
P09832504A0596|86 101|cysteine residues
P09832505A0903|42 55|human activator
P09832505A0903|42 55|human activator
P09832505A0903|57 61|Oct-1
P09832505A0903|57 61|Oct-1
P09832505A0903|79 103|basal transcription complex
P09832511A0269|6 22|early neurogenesis
P09832511A0269|24 33|Vnd protein
P09832511A0269|48 73|ventral column neuroectoderm
P09832518A0615|3 18|repression domain
P09832518A0615|38 49|Cdc68 protein
P09832518A0615|38 49|Cdc68 protein
P09832518A0615|94 115|Cdc68 functional homolog
P09832518A0615|94 98|Cdc68
P09832518A0615|123 127|yeast
P09832518A0615|128 146|Kluyveromyces lactis
P09832518A0615|152 167|database searches
P09833610A0626|3 11|exodomain
P09833610A0626|80 93|hormonal signal
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09833740A1112|63 70|viral LTR
P09833740A1112|63 70|viral LTR
P09833740A1112|84 100|cytokine responses
P09833740A1112|107 108|U1
P09833740A1112|107 108|U1
P09833740A1112|112 121|ACH-2 cells
P09833740A1112|112 116|ACH-2
P09833740A1112|140 181|TNF-alpha-mediated transcriptional mechanism
P09833740A1112|140 148|TNF-alpha
P09833740A1112|226 240|provirus latency
P09834070A0793|35 38|ERK2
P09834070A0793|35 38|ERK2
P09834070A0793|70 86|intracellular Ca2+
P09834070A0793|118 139|protein kinase C activity
P09834070A0793|118 131|protein kinase C
P09834070A0793|176 179|CD19
P09834070A0793|176 179|CD19
P09834070A0793|189 201|B cell function
P09834521A0000|3 25|retrovesical hydatid cyst
P09835615A0574|0 18|Biochemical analysis
P09835615A0574|30 32|KS1
P09835615A0574|30 32|KS1
P09835615A0574|36 49|nuclear protein
P09835615A0574|36 49|nuclear protein
P09835615A0574|63 93|transcriptional repressor domains
P09835615A0574|95 101|R1 and R2
P09835615A0574|95 96|R1
P09835615A0574|100 101|R2
P09836881A0441|11 18|BCH group
P09836881A0441|84 99|Motor Proficiency
P09837714A1068|33 72|pH induced post-translational modifications
P09837714A1068|75 79|DdRPA
P09837714A1068|75 79|DdRPA
P09837714A1068|107 123|cell proliferation
P09837715A0581|48 50|DNA
P09837715A0581|62 98|chloramphenicol acetyltransferase (CAT)
P09837715A0581|62 93|chloramphenicol acetyltransferase
P09837715A0581|95 102|CAT) mRNA
P09837715A0581|99 102|mRNA
P09837715A0581|116 134|Vpr-expressing cells
P09837715A0581|146 150|HIV-1
P09837715A0581|146 150|HIV-1
P09837715A0581|154 185|murine leukemia virus (MLV) SL3-3 LTR
P09837715A0581|154 182|murine leukemia virus (MLV) SL3-3
P09837715A0581|183 206|LTR-CAT reporter construct
P09837715A0581|187 189|CAT
P09837824A0419|12 26|telSMN mutations
P09837824A0419|12 17|telSMN
P09837824A0419|87 92|telSMN
P09837824A0419|87 92|telSMN
P09837824A0419|109 127|frameshift mutations
P09837824A0419|129 136|800ins11
P09837824A0419|140 147|542delGT
P09837824A0419|165 173|mutations
P09837824A0419|175 177|A2G
P09837824A0419|179 183|S262I
P09837824A0419|188 192|T274I
P09837907A0857|13 24|TNF receptors
P09837907A0857|13 24|TNF receptors
P09837907A0857|27 30|IL-4
P09837907A0857|27 30|IL-4
P09837907A0857|64 84|TNF-induced activities
P09837907A0857|64 66|TNF
P09837907A0857|95 106|cytotoxicity
P09837907A0857|108 116|caspase-3
P09837907A0857|108 116|caspase-3
P09837907A0857|128 136|NF-kappaB
P09837907A0857|128 136|NF-kappaB
P09837907A0857|140 153|AP-1 activation
P09837907A0857|140 143|AP-1
P09837907A0857|158 178|c-Jun N-terminal kinase
P09837907A0857|158 178|c-Jun N-terminal kinase
P09837913A0000|0 14|Type 2 deiodinase
P09837913A0000|0 14|Type 2 deiodinase
P09837913A0000|16 17|D2
P09837913A0000|16 17|D2
P09837913A0000|31 56|5'-deiodination of thyroxine
P09837913A0000|63 85|3,5,3'-triiodothyronine
P09837913A0419|19 55|overlapping expressed sequence tag clones
P09837913A0419|82 90|-kb 3'-UTR
P09837913A0419|96 102|human D2
P09837913A0419|96 102|human D2
P09837913A0419|104 111|hD2) cDNA
P09837913A0419|104 106|hD2
P09837920A0222|64 88|regulatory phosphorylation
P09837920A0222|113 117|c-Jun
P09837920A0222|113 117|c-Jun
P09837920A0222|121 123|JNK
P09837920A0222|121 123|JNK
P09837933T0000|0 5|P-CIP1
P09837933T0000|0 5|P-CIP1
P09837933T0000|8 19|novel protein
P09837933T0000|40 54|cytosolic domain
P09837933T0000|57 99|peptidylglycine alpha-amidating monooxygenase
P09837933T0000|72 99|alpha-amidating monooxygenase
P09837933T0000|117 125|endosomes
P09837945A0820|0 17|Immunolocalization
P09837945A0820|20 24|Sop1p
P09837945A0820|20 24|Sop1p
P09837945A0820|60 83|cell fractionation studies
P09837945A0820|116 120|Sop1p
P09837945A0820|116 120|Sop1p
P09837945A0820|161 177|cytosolic material
P09837978T0093|0 18|Resultant activation
P09837978T0093|21 80|c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK
P09837978T0093|21 41|c-Jun N-terminal kinase
P09837978T0093|43 71|stress-activated protein kinase
P09837978T0093|73 75|JNK
P09837978T0093|77 80|SAPK
P09838122A0489|15 43|full-length coding cDNA sequence
P09838122A0489|26 43|coding cDNA sequence
P09838122A0489|49 68|mouse homologue of MPP3
P09838122A0489|49 62|mouse homologue
P09838122A0489|65 68|MPP3
P09840822A0462|32 42|venous spins
P09840822A0462|58 95|asymmetric magnetization transfer effects
P09840928A0884|27 55|Dlk phosphorylated core histones
P09840928A0884|27 29|Dlk
P09840928A0884|48 57|histones H3
P09840928A0884|56 66|H3, H2A and H4
P09840928A0884|59 61|H2A
P09840928A0884|65 66|H4
P09840928A0884|69 87|exogenous substrates
P09840928A0884|91 109|endogenous histone H3
P09840928A0884|101 109|histone H3
P09840928A0884|112 123|kinase assays
P09840928A0884|128 142|nuclear extracts
P09840932A0365|32 36|B-Myb
P09840932A0365|32 36|B-Myb
P09840932A0365|68 79|cyclin A/Cdk2
P09840932A0365|68 74|cyclin A
P09840932A0365|76 79|Cdk2
P09840934A0435|7 17|Ha-Ras (G12V
P09840934A0435|7 12|Ha-Ras
P09840934A0435|19 36|T35S) (Ha-RasV12S35
P09840934A0435|25 36|Ha-RasV12S35
P09840934A0435|56 75|Rafl signaling pathway
P09840934A0435|56 59|Rafl
P09840934A0435|80 96|Ha-Ras(G12V, E37G)
P09840934A0435|80 90|Ha-Ras(G12V
P09840934A0435|92 109|E37G) (Ha-RasV12G37
P09840934A0435|98 109|Ha-RasV12G37
P09840934A0435|130 135|RalGDS
P09840934A0435|130 135|RalGDS
P09840934A0435|174 199|factor-withdrawal apoptosis
P09840934A0435|202 213|myeloid cells
P09840943A0144|20 30|human cyclin
P09840943A0144|20 30|human cyclin
P09840943A0144|32 39|cyclin E2
P09840943A0144|32 39|cyclin E2
P09840943A0144|74 81|cyclin E.
P09840943A0144|74 80|cyclin E
P09842517A0497|50 57|SieScape
P09842517A0497|93 94|CT
P09842517A0497|98 100|MRI
P09843378A0187|3 20|dopamine D4 receptor
P09843378A0187|11 20|D4 receptor
P09843378A0187|38 63|catecholaminergic receptors
P09843378A0187|86 102|SH3 binding domains
P09843378A0187|86 102|SH3 binding domains
P09843412A0130|38 42|Abeta
P09843412A0130|38 42|Abeta
P09843412A0130|44 50|Abeta42
P09843412A0130|44 50|Abeta42
P09843412A0130|107 108|AD
P09843572A0944|44 47|Cdr2
P09843572A0944|44 47|Cdr2
P09843572A0944|65 90|N-terminal regulatory domain
P09843572A0944|65 90|N-terminal regulatory domain
P09843572A0944|93 96|Wee1
P09843572A0944|93 96|Wee1
P09843572A0944|99 109|cell lysates
P09843572A0944|127 130|Wee1
P09843572A0944|127 130|Wee1
P09843577A0000|0 28|Schizosaccharomyces pombe cells
P09843577A0000|0 23|Schizosaccharomyces pombe
P09843577A0000|38 56|nutrient deprivation
P09843577A0000|67 85|G2/M cell size control
P09843944A0976|0 7|A-tracts
P09843944A0976|69 75|helical
P09843944A0976|129 137|UP element
P09843944A0976|129 130|UP
P09844106A0835|0 18|Pyk2 phosphorylation
P09844106A0835|0 3|Pyk2
P09844106A0835|43 54|FLG 29.1 cells
P09844106A0835|57 67|fibronectin
P09844106A0835|57 67|fibronectin
P09844106A0835|73 87|ST2 stromal cells
P09844921A0000|0 2|Raf
P09844921A0000|0 2|Raf
P09844921A0000|9 37|serine-threonine protein kinase
P09844921A0000|9 37|serine-threonine protein kinase
P09844921A0000|81 120|anti-apoptotic and differentiation messages
P09845043A0000|3 21|US National Institute
P09845043A0000|24 35|Alcohol Abuse
P09845043A0000|39 48|Alcoholism
P09845043A0000|50 54|NIAAA
P09845043A0000|76 94|problematic drinking
P09845043A0000|97 116|willful alcohol abuse'
P09845043A0000|142 159|alcohol dependence'
P09845043A0000|249 264|medically treated
P09845662A0085|0 7|Collagen
P09845662A0085|0 7|Collagen
P09845662A0085|27 30|skin
P09845662A0085|44 58|type III collagen
P09845662A0085|44 58|type III collagen
P09845662A0085|81 133|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P09845662A0085|135 142|SDS-PAGE
P09845856A0560|30 67|10,331 symptomatic duodenal ulcer diseases
P09846482A0441|39 57|enzymatic activation
P09846482A0441|63 89|p21-activated protein kinase 1
P09846482A0441|63 89|p21-activated protein kinase 1
P09846482A0441|104 122|actin polymerization
P09846927A0227|11 16|button
P09846927A0227|40 59|posterior stomach wall
P09847371A0000|0 19|Jembrana disease virus
P09847371A0000|21 23|JDV
P09847371A0000|84 114|bovine immunodeficiency virus (BIV
P09847371A0000|84 110|bovine immunodeficiency virus
P09847371A0000|112 114|BIV
P09847397A0935|21 28|residues
P09847397A0935|113 127|glucocorticoids
P09847397A0935|153 162|CCAAT boxes
P09847397A0935|188 196|TATA boxes
P09848653A0597|0 4|Nhp2p
P09848653A0597|0 4|Nhp2p
P09848653A0597|19 25|protein
P09848653A0597|48 74|putative RNA-binding proteins
P09848653A0597|56 74|RNA-binding proteins
P09849421A0332|102 109|Research
P09849421A0332|130 133|Core
P09849421A0332|147 175|Questionnaire (EORTC QLQ-C30 (+3
P09849722A0797|20 41|happy facial expressions
P09849722A0797|86 89|left
P09849722A0797|90 111|anterior cingulate gyrus
P09849722A0797|113 143|bilateral posterior cingulate gyri
P09849722A0797|145 163|medial frontal cortex
P09849722A0797|167 189|right supramarginal gyrus
P09849722A0797|191 202|brain regions
P09849722A0797|225 236|visuospatial
P09849961A0387|0 14|Down-regulation
P09849961A0387|17 21|IRS-1
P09849961A0387|17 21|IRS-1
P09849961A0387|35 55|serine phosphorylation
P09849961A0387|67 84|PI 3-kinase activity
P09849961A0387|67 76|PI 3-kinase
P09849961A0387|131 135|IRS-1
P09849961A0387|131 135|IRS-1
P09849961A0387|176 209|nondifferentiating myoblast cell line
P09849965A0000|20 44|mammalian two-hybrid system
P09849965A0000|63 68|ligand
P09849965A0000|88 118|human progesterone receptor (hPR).
P09849965A0000|88 112|human progesterone receptor
P09849965A0000|114 116|hPR
P09851614A0109|50 71|5'-untranslated regions
P09851614A0109|73 91|UTR) (1-6 nucleotides
P09851614A0109|93 96|nts)
P09851614A0109|121 126|5'-cap
P09851614A0109|144 148|mRNAs
P09851700A0000|15 50|human tissue-type plasminogen activator
P09851700A0000|31 50|plasminogen activator
P09851700A0000|52 55|t-PA
P09851700A0000|54 55|PA
P09851700A0000|71 94|cell-type-specific manner
P09851988A0085|17 39|arginine and anaerobiosis
P09852005A1287|0 10|Competition
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|58 65|promoter
P09852005A1287|92 116|opaque-phase-specific gene
P09852005A1287|113 116|gene
P09852005A1287|117 120|PEP1
P09852005A1287|117 120|PEP1
P09852005A1287|122 125|SAP1
P09852005A1287|122 125|SAP1
P09852005A1287|133 164|human MADS box consensus binding site
P09852005A1287|138 164|MADS box consensus binding site
P09852005A1287|168 186|serum response factor
P09852005A1287|168 186|serum response factor
P09852005A1287|247 257|OP4 sequence
P09852005A1287|247 257|OP4 sequence
P09852068A0150b|3 27|human SHBG proximal promoter
P09852068A0150b|3 27|human SHBG proximal promoter
P09852068A0150b|41 58|DNase I footprinting
P09852068A0150b|41 46|DNase I
P09852068A0150b|91 108|footprinted regions
P09852068A0150b|110 116|FP1-FP6
P09852068A0150b|127 142|proximal promoter
P09852068A0150b|155 183|human HepG2 hepatoblastoma cells
P09852109A1475|21 49|in vivo polysome profile analysis
P09852109A1475|78 78|E
P09852109A1475|104 128|translational efficiencies
P09852109A1475|166 176|transcript D
P09852109A1475|192 213|5'-untranslated regions
P09852109A1475|225 244|translational control
P09852136A0174|26 36|Ser36 --> Asn
P09852136A0174|54 57|p190
P09852136A0174|54 57|p190
P09852136A0174|87 103|guanine nucleotide
P09852136A0174|120 150|hemagglutinin (HA)-tagged protein
P09852136A0174|120 132|hemagglutinin
P09852136A0174|134 135|HA
P09852136A0174|153 160|COS cells
P09852136A0507|0 9|Wild type HA
P09852136A0507|8 14|HA-p190
P09852136A0507|11 14|p190
P09852136A0507|34 45|rounded cells
P09852136A0507|50 53|long
P09852136A0507|92 94|Rho
P09852136A0507|92 94|Rho
P09852136A0507|116 131|ADP-ribosylation
P09852752A0950|15 39|ANCA-associated vasculitis
P09852752A0950|15 18|ANCA
P09852752A0950|72 73|RA
P09854034A0536|3 12|downstream
P09854034A0536|14 30|TATA-less promoter
P09854034A0536|38 47|G+C content
P09854034A0536|52 57|exon 1b
P09854034A0536|94 104|mRNA species
P09855111A0905|42 61|COOH-terminal domains
P09855111A0905|42 61|COOH-terminal domains
P09855111A0905|108 122|SREBP processing
P09855111A0905|108 112|SREBP
P09855111A0905|152 191|SREBP-dependent transcriptional regulation
P09855111A0905|152 156|SREBP
P09855111A0905|201 205|genes
P09855111A0905|210 219|mRNA levels
P09855111A0905|223 273|3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase
P09855111A0905|223 257|3-hydroxy-3-methylglutaryl coenzyme A
P09855111A0905|259 273|HMG CoA) synthase
P09855111A0905|284 292|cell lines
P09855111A0905|309 330|sterol-dependent manner
P09856397A0099|48 69|serum chemistry profiles
P09856397A0099|114 125|FB1 in tissues
P09856732A0114|86 94|lidocaine
P09857038A1374|0 0|E
P09857197A0289|0 4|Yap1p
P09857197A0289|0 4|Yap1p
P09857197A0289|31 40|crm1 mutant
P09857197A0289|31 40|crm1 mutant
P09857197A0289|45 49|Crm1p
P09857197A0289|45 49|Crm1p
P09857197A0289|58 78|nuclear export sequence
P09857197A0289|80 96|NES)-like sequence
P09857197A0289|99 103|Yap1p
P09857197A0289|99 103|Yap1p
P09857197A0289|119 124|RanGTP
P09857197A0289|119 124|RanGTP
P09857265A0669|4 9|intake
P09857265A0669|12 19|vitamin A
P09857265A0669|41 42|RE
P09857265A0669|50 60|men and women
P09857265A0669|93 119|meat, fats and oils, vegetables
P09858094A0583|33 42|potentials
P09858094A0583|44 54|O1+O2+O3+O4
P09858531A1017|12 16|RING1
P09858531A1017|12 16|RING1
P09858531A1017|63 77|proto-oncogenes
P09858531A1017|63 77|proto-oncogenes
P09858531A1017|78 82|c-jun
P09858531A1017|78 82|c-jun
P09858531A1017|86 90|c-fos
P09858531A1017|86 90|c-fos
P09858571T0000|3 15|yeast RER2 gene
P09858571T0000|3 7|yeast
P09858571T0000|8 15|RER2 gene
P09858571T0000|29 48|endoplasmic reticulum
P09858571T0000|85 105|cis-prenyltransferase
P09858571T0000|85 105|cis-prenyltransferase
P09858571T0000|119 135|dolichol synthesis
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858572A0000|63 77|silent chromatin
P09858577A1186|9 12|SKO1
P09858577A1186|9 12|SKO1
P09858577A1186|31 44|ENA1 expression
P09858577A1186|31 34|ENA1
P09858577A1186|48 57|hog1 mutant
P09858577A1186|48 57|hog1 mutant
P09858577A1186|83 106|osmotic stress sensitivity
P09858577A1186|118 122|Sko1p
P09858577A1186|118 122|Sko1p
P09858577A1186|149 151|HOG
P09858577A1186|149 151|HOG
P09858581A0183|31 49|uncharacterized gene
P09858581A0183|51 56|SPP381
P09858581A0183|51 56|SPP381
P09858581A0183|82 105|growth and splicing defects
P09858581A0183|109 146|temperature-sensitive (Ts) mutant prp38-1
P09858581A0183|131 146|Ts) mutant prp38-1
P09858588A1046|10 33|electrophoretic-mobility
P09858588A1046|40 42|p68
P09858588A1046|40 42|p68
P09858588A1046|54 63|human cells
P09858588A1046|66 69|G1/S
P09858588A1046|66 67|G1
P09858588A1046|69 69|S
P09858588A1046|98 101|G2/M
P09858593A0334|16 33|amino acid sequences
P09858593A0334|36 44|mammalian
P09858593A0334|48 54|Xenopus
P09858593A0334|55 61|NeuroD1
P09858593A0334|63 67|BETA2
P09858593A0334|87 107|insulin gene expression
P09858593A0334|87 97|insulin gene
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858599A0392|4 8|NUP98
P09858599A0392|10 14|HOXA9
P09858599A0392|34 50|NIH 3T3 fibroblasts
P09858599A0392|84 95|HOXA9 domains
P09858599A0392|84 95|HOXA9 domains
P09858599A0392|99 108|DNA binding
P09858599A0392|112 125|PBX interaction
P09858599A0392|112 114|PBX
P09858619A0356|30 33|Y319
P09858619A0356|56 69|ZAP-70 function
P09858619A0356|56 61|ZAP-70
P09858713A1174|35 46|wild-type Pan
P09858713A1174|44 52|Pan and CiD
P09858713A1174|50 52|CiD
P09858713A1174|72 74|Arm
P09858713A1174|114 121|Wg signal
P09858713A1174|114 115|Wg
P09858713A1174|124 147|heterozygous ciD/+ animals
P09858713A1174|136 140|ciD/+
P09858713A1174|178 201|gain-of-function activity
P09858713A1174|204 206|CiD
P09858713A1174|204 206|CiD
P09858714A1171|7 9|ORF
P09858714A1171|11 15|dda.2
P09858714A1171|30 33|modA
P09858714A1171|30 33|modA
P09858714A1171|37 39|dda
P09858714A1171|69 75|sigma70
P09858714A1171|69 75|sigma70
P09858714A1171|88 90|srd
P09858745A1350|16 18|IBS
P09858745A1350|28 45|catB structural gene
P09858745A1350|28 45|catB structural gene
P09858745A1350|73 91|footprinting studies
P09858745A1350|123 125|IBS
P09858745A1350|156 159|CatR
P09858745A1350|156 159|CatR
P09858745A1350|167 186|upstream binding sites
P09858745A2033|2 25|vitro transcription assays
P09858745A2033|44 64|TCA-cycle intermediate
P09858745A2033|123 136|clcA transcript
P09858745A2033|123 136|clcA transcript
P09858883A1106|0 14|BIAcore analysis
P09858883A1106|54 57|N-A3
P09858883A1106|54 57|N-A3
P09858883A1106|60 64|T84.1
P09858883A1106|60 64|T84.1
P09858883A1106|96 99|N-A3
P09858883A1106|96 99|N-A3
P09858883A1106|102 107|T84.66
P09858883A1106|102 107|T84.66
P09860979A0521|12 15|p130
P09860979A0521|12 15|p130
P09860979A0521|17 19|Cas
P09860979A0521|17 19|Cas
P09860979A0521|22 24|Cas
P09860979A0521|22 24|Cas
P09860979A0521|28 46|major binding protein
P09860979A0521|28 46|major binding protein
P09860979A0521|53 65|Crk SH2-domain
P09860979A0521|53 65|Crk SH2-domain
P09860979A0521|78 90|JNK activation
P09860979A0521|78 80|JNK
P09860979A0521|112 121|SH2-mutant
P09860979A0521|112 121|SH2-mutant
P09860979A0521|124 126|Crk
P09860979A0521|124 126|Crk
P09861099A1011|53 65|protein intake
P09861365A0000|3 38|Og4C3 enzyme-linked immunosorbent assay
P09861365A0000|3 7|Og4C3
P09861365A0000|40 44|ELISA
P09861365A0000|65 90|Wuchereria bancrofti antigen
P09861365A0000|65 90|Wuchereria bancrofti antigen
P09862343A0225|13 29|gp200-MR6 ligation
P09862343A0225|13 17|gp200
P09862343A0225|19 21|MR6
P09862343A0225|42 45|IL-4
P09862343A0225|42 45|IL-4
P09862343A0225|107 118|immune system
P09862343A0225|142 164|co-stimulatory molecules
P09862343A0225|142 164|co-stimulatory molecules
P09862343A0225|167 178|B lymphocytes
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|19 35|zinc finger protein
P09862481A0000|19 35|zinc finger protein
P09862481A0000|48 64|glucose repression
P09862481A0000|67 71|yeast
P09862496A0187|0 7|Ethylene
P09862496A0187|20 35|endosperm rupture
P09862496A0187|49 66|betaGLU I expression
P09862496A0187|49 56|betaGLU I
P09862496A0187|117 134|betaGLU I expression
P09862496A0187|117 124|betaGLU I
P09863624A0629|41 49|sheep CRF1
P09863624A0629|46 49|CRF1
P09863624A0629|61 74|mammalian CRF1s
P09863624A0629|61 74|mammalian CRF1s
P09863624A0629|100 131|extracellular amino terminal domain
P09863624A0629|137 144|receptor
P09863624A0629|177 185|human CRF1
P09863624A0629|182 185|CRF1
P09863624A2301|0 37|Agonist-induced receptor internalization
P09863624A2301|63 82|total [125I] Tyr0-oCRF
P09863624A2301|74 82|Tyr0-oCRF
P09863624A2301|124 143|transfected Cos 7 cells
P09863624A2301|190 213|wild-type and variant oCRF1
P09863624A2301|190 213|wild-type and variant oCRF1
P09863720T0000|17 33|thrombotic disease
P09863720T0000|36 45|young onset
P09863720T0000|49 66|protein S deficiency
P09864141A0528|12 16|Stat3
P09864141A0528|12 16|Stat3
P09864141A0528|20 28|Stat3beta
P09864141A0528|20 28|Stat3beta
P09864141A0528|79 82|Y704
P09864141A0528|86 89|Y744
P09864141A0528|98 121|nonphosphorylated peptide
P09864141A0528|160 163|Y729
P09864141A0528|167 170|Y764
P09864335A1226|39 46|FCR1 gene
P09864335A1226|39 46|FCR1 gene
P09864335A1226|76 89|drug resistance
P09864335A1226|92 101|C. albicans
P09864335A1226|135 147|FCZ resistance
P09864335A1226|179 194|regulatory factor
P09864335A1226|201 205|Fcr1p
P09864335A1226|201 205|Fcr1p
P09864689A1408|28 32|MYO/M
P09864689A1408|90 101|heart failure
P09864689A1408|107 109|DCM
P09865775A0162|35 42|couplers
P09865775A0162|69 96|ALGO2 click spectral properties
P09866068A1058|28 30|OCs
P09866068A1058|38 57|pituitary suppression
P09866068A1058|68 82|follicular phase
P09866068A1058|92 111|ovarian cyst formation
P09866068A1058|148 168|follicular recruitment
P09866068A1058|171 184|pregnancy rates
P09867159A1444|89 94|FDG PET
P09867159A1444|127 128|IS
P09867253A0229|4 16|c-Jun activity
P09867253A0229|4 8|c-Jun
P09867253A0229|30 34|c-Fos
P09867253A0229|30 34|c-Fos
P09867253A0229|78 82|c-Jun
P09867253A0229|78 82|c-Jun
P09867253A0229|92 110|transcription factor
P09867253A0229|111 114|AP-1
P09867253A0229|111 114|AP-1
P09867855T0000|0 47|Dorsal root ganglia neuron-specific promoter activity
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09868412A1628|36 42|body BMD
P09868412A1628|46 59|femoral neck BMD
P09868412A1628|140 154|control subjects
P09868412A1628|188 190|BMD
P09868412A1628|220 240|bone-building exercise
P09869297A1807|27 43|CE1 and CE2 elements
P09869297A1807|27 29|CE1
P09869297A1807|33 43|CE2 elements
P09869297A1807|56 74|Hoxb1 gene expression
P09869297A1807|56 64|Hoxb1 gene
P09869356A0926|0 6|CAL gain
P09869356A0926|51 57|CAL gain
P09869400A0203|0 10|Comparisons
P09869400A0203|25 31|germins
P09869400A0203|25 31|germins
P09869400A0203|35 53|germin-like proteins
P09869400A0203|35 53|germin-like proteins
P09869400A0203|71 95|Arabidopsis GLP subfamilies
P09869400A0203|109 119|wheat germin
P09869400A0203|114 119|germin
P09869528T0000|14 17|dogs
P09869528T0000|30 31|RF
P09871353A0174|36 58|A. salmonicida infections
P09872326A0566|35 42|CBF/cdc2
P09872326A0566|35 37|CBF
P09872326A0566|39 42|cdc2
P09872326A0566|57 59|CBF
P09872326A0566|86 103|heat shock protein 70
P09872326A0566|86 103|heat shock protein 70
P09872337A0000|3 24|percutaneous absorption
P09872337A0000|27 37|clindamycin
P09872337A0000|50 70|healthy male volunteers
P09872337A0000|84 107|investigative clindamycin
P09872337A0000|135 138|gels
P09872337A0000|150 160|clindamycin
P09872337A0000|161 174|phosphate ester
P09872337A0000|178 191|clindamycin HCl
P09872337A0000|217 242|clindamycin phosphate lotion
P09872832A1262|3 19|BAL concentrations
P09872832A1262|72 76|lungs
P09872832A1262|90 102|interleukin-6
P09872832A1262|90 102|interleukin-6
P09872832A1262|104 107|IL-6
P09872832A1262|104 107|IL-6
P09872832A1262|110 113|IL-8
P09872832A1262|110 113|IL-8
P09872832A1262|115 119|IL-12
P09872832A1262|115 119|IL-12
P09872832A1262|121 145|tumor necrosis factor-alpha
P09872832A1262|121 145|tumor necrosis factor-alpha
P09872832A1262|147 155|TNF-alpha
P09872832A1262|147 155|TNF-alpha
P09872832A1262|161 175|interferon gamma
P09872832A1262|161 175|interferon gamma
P09872832A1262|177 185|IFN-gamma
P09872832A1262|177 185|IFN-gamma
P09873060A0901|0 22|Phosphorylation analyses
P09873060A0901|48 54|ERK-1/2
P09873060A0901|48 54|ERK-1/2
P09873060A0901|64 74|okadaic acid
P09873060A0901|84 98|phosphorylation
P09873060A0901|101 104|JunD
P09873060A0901|101 104|JunD
P09873060A0901|108 111|FosB
P09873060A0901|108 111|FosB
P09873291A0620|0 14|Two-way analysis
P09873291A0620|86 92|patient
P09874803A0000|18 26|bacterium
P09874803A0000|27 32|group A
P09874803A0000|56 84|extracellular cysteine protease
P09874803A0000|86 116|streptococcal pyrogenic exotoxin B
P09874803A0000|86 116|streptococcal pyrogenic exotoxin B
P09874803A0000|118 121|SpeB
P09874803A0000|118 121|SpeB
P09874803A0000|139 171|virulence factor for invasive disease
P09875541A0210|3 15|orbitofrontal
P09875541A0210|51 69|dorsal premotor areas
P09875541A0210|133 136|SELF
P09876794T0000|27 37|anaesthesia
P09877417A0704|6 14|CCK levels
P09877417A0704|6 8|CCK
P09878256A0000|23 31|disorders
P09878256A0000|33 36|PBDs
P09878256A0000|83 93|peroxisomal
P09878256A0000|116 139|multisystem abnormalities
P09878256A0000|141 157|mental retardation
P09878256A0000|162 175|premature death
P09878437A0967|3 12|active site
P09878437A0967|24 39|acidic triad Asp53
P09878437A0967|67 71|Asp10
P09878437A0967|75 78|Glu9
P09878542A1151|42 65|transcriptional silencing
P09878542A1151|77 79|VDR
P09878542A1151|77 79|VDR
P09878542A1151|99 113|osteopontin VDRE
P09878542A1151|99 109|osteopontin
P09879766A0402|2 6|PAV-3
P09879766A0402|11 19|E1A region
P09879766A0402|11 19|E1A region
P09880029A0703|11 27|MDV genome products
P09880029A0703|41 43|Rep
P09880029A0703|51 65|non-Rep proteins
P09880029A0703|87 103|amino acid identity
P09880029A0703|125 137|FBNYV proteins
P09880029A0703|125 137|FBNYV proteins
P09880029A0703|154 164|Rep proteins
P09880029A0703|154 164|Rep proteins
P09880029A0703|174 179|MDV-C2
P09880029A0703|174 179|MDV-C2
P09880029A0703|183 184|C3
P09880029A0703|183 184|C3
P09880029A0703|226 232|SCSV-C2
P09880029A0703|226 232|SCSV-C2
P09880029A0703|236 237|C6
P09880029A0703|236 237|C6
P09880103A0387|0 2|MPO
P09880103A0387|0 2|MPO
P09880103A0387|17 24|1 mCi 125I
P09880103A0387|39 51|self-labeling
P09880103A0387|74 89|hydrogen peroxide
P09880327A0322|23 55|mammalian Golgi-associated proteins
P09880327A0322|64 73|yeast Uso1p
P09880327A0322|69 73|Uso1p
P09880327A0322|112 147|endoplasmic reticulum-derived vesicles
P09880327A0322|153 161|cis-Golgi
P09880512A1251|19 22|Bmp2
P09880512A1251|19 22|Bmp2
P09880512A1251|44 70|retinoic acid-bound receptors
P09880512A1251|44 70|retinoic acid-bound receptors
P09880512A1251|74 76|Sp1
P09880512A1251|74 76|Sp1
P09880513A1013|53 59|tubulin
P09880513A1013|53 59|tubulin
P09880543A0570|0 3|HEED
P09880543A0570|0 3|HEED
P09880543A0570|20 28|MA protein
P09880543A0570|20 28|MA protein
P09880543A0570|60 69|yeast cells
P09880544A0693|0 32|Fas-resistant DT-40 lymphoma B-cells
P09880544A0693|41 53|BTK-deficient
P09880544A0693|41 43|BTK
P09880544A0693|84 90|btk gene
P09880544A0693|84 90|btk gene
P09880544A0693|133 141|apoptosis
P09880544A0693|147 157|Fas ligation
P09880544A0693|147 149|Fas
P09880544A0693|162 180|wild-type DT-40 cells
P09880544A0693|183 200|BTK-deficient DT-40
P09880544A0693|183 185|BTK
P09880544A0693|223 243|wild-type human btk gene
P09880544A0693|232 243|human btk gene
P09881666A0535|0 5|A motif
P09881666A0535|7 14|TGATGTCA
P09881666A0535|29 36|CREB site
P09881666A0535|29 36|CREB site
P09881666A0535|53 60|AP-1 site
P09881666A0535|53 60|AP-1 site
P09881666A0535|77 79|ER2
P09881666A0535|77 79|ER2
P09881692A0094|0 13|Conventionally
P09881692A0094|44 45|b4
P09881692A0094|47 48|b5
P09881692A0094|50 51|b6
P09881692A0094|55 56|b9
P09881692A0094|101 116|Ckappa1 gene locus
P09881692A0094|101 111|Ckappa1 gene
P09881692A1109|31 41|latent genes
P09881692A1109|31 41|latent genes
P09881692A1109|49 81|allotype-specific oligonucleotides
P09881692A1109|85 86|b5
P09881692A1109|88 89|b6
P09881692A1109|93 105|b9 to probe DNAs
P09881692A1109|114 146|normal and T. brucei-infected rabbits
P09881692A1109|149 164|Southern blotting
P09882303A1413|0 4|TRAF2
P09882303A1413|0 4|TRAF2
P09882303A1413|27 31|TRADD
P09882303A1413|27 31|TRADD
P09882303A1413|49 83|dominant-negative N-terminal deletion
P09882303A1413|84 88|TRAF2
P09882303A1413|84 88|TRAF2
P09882303A1413|121 145|LMP1-induced JNK activation
P09882303A1413|121 124|LMP1
P09882303A1413|133 135|JNK
P09882303A1413|148 155|293 cells
P09882303A1984|30 34|TRADD
P09882303A1984|30 34|TRADD
P09882303A1984|38 42|TRAF2
P09882303A1984|38 42|TRAF2
P09882303A1984|45 57|JNK activation
P09882303A1984|45 47|JNK
P09882303A1984|72 75|LMP1
P09882303A1984|72 75|LMP1
P09882303A1984|84 103|signalling mechanisms
P09882303A1984|113 134|TNF receptor/CD40 family
P09882303A1984|113 123|TNF receptor
P09882303A1984|125 128|CD40
P09882303T0000|0 46|Epstein-Barr virus-encoded latent membrane protein 1
P09882303T0000|0 46|Epstein-Barr virus-encoded latent membrane protein 1
P09882303T0000|59 61|JNK
P09882303T0000|59 61|JNK
P09882303T0000|79 94|extreme C terminus
P09882303T0000|117 121|TRADD
P09882303T0000|117 121|TRADD
P09882303T0000|125 129|TRAF2
P09882303T0000|125 129|TRAF2
P09882321A0948|11 37|transiently transfected cells
P09882321A0948|48 53|EBNA-3
P09882321A0948|48 53|EBNA-3
P09882321A0948|80 92|EBNA-3 protein
P09882321A0948|80 85|EBNA-3
P09882321A0948|117 126|EBNA-3 gene
P09882321A0948|117 122|EBNA-3
P09882321A0948|137 146|EBNA-3 cDNA
P09882321A0948|137 146|EBNA-3 cDNA
P09882334A0822|8 13|serial
P09882334A0822|24 48|fetal lamb kidney (FLK) cells
P09882334A0822|82 84|BLV
P09882334A0822|91 111|transient transfection
P09882334A0822|141 155|tyrosine residue
P09882334A0822|161 175|N-terminal motif
P09882334A0822|161 175|N-terminal motif
P09882334A0822|214 218|virus
P09882337A0000|0 39|Varicella-zoster virus (VZV) glycoprotein gI
P09882337A0000|0 39|Varicella-zoster virus (VZV) glycoprotein gI
P09882337A0000|43 72|type 1 transmembrane glycoprotein
P09882337A0000|43 72|type 1 transmembrane glycoprotein
P09882337A0000|97 111|heterodimeric gE
P09882337A0000|97 109|heterodimeric
P09882337A0000|110 111|gE
P09882337A0000|113 131|gI Fc receptor complex
P09882337A0000|113 124|gI Fc receptor
P09882348A0611|56 78|tyrosine kinase substrate
P09882348A0611|56 69|tyrosine kinase
P09882348A0611|83 111|transforming Shc adapter protein
P09882348A0611|95 111|Shc adapter protein
P09882348A0611|115 125|fibroblasts
P09882348A0611|139 151|viral oncogene
P09882451A0195|26 54|Saccharomyces cerevisiae mutant
P09882451A0195|26 54|Saccharomyces cerevisiae mutant
P09882451A0195|65 92|endogenous ferrochelatase gene
P09882451A0195|65 92|endogenous ferrochelatase gene
P09882451A0195|94 98|HEM15
P09882451A0195|94 98|HEM15
P09882451A0195|136 148|transformants
P09882489A0451|65 78|mef2 expression
P09882489A0451|65 68|mef2
P09882489A0451|108 134|cis-acting regulatory modules
P09882489A0451|163 176|genetic signals
P09882499A0231|17 31|transgenic mouse
P09882499A0231|64 85|cis-regulatory elements
P09882499A0231|127 130|Pax6
P09882499A0231|127 130|Pax6
P09882593A0996|43 46|61Ni
P09882593A0996|92 96|women
P09882593A0996|162 174|pompholyx type
P09882638A0235|0 11|Folded tissue
P09882638A0235|15 35|crimped collagen fibers
P09882638A0235|22 29|collagen
P09882638A0235|80 87|erection
P09883639A0000|0 5|Number
P09883639A0000|8 15|patients
P09883639A0000|42 53|mycobacteria
P09883639A0000|55 57|NTM
P09884232A0286|26 29|attP
P09884232A0286|26 29|attP
P09884232A0286|31 34|attB
P09884232A0286|31 34|attB
P09884232A0286|38 54|bacteria-prophage
P09884232A0286|64 67|attL
P09884232A0286|64 67|attL
P09884232A0286|71 74|attR
P09884232A0286|71 74|attR
P09884232A0286|92 103|core sequence
P09884232A0286|110 122|recombination
P09884232A0286|141 145|5' end
P09884232A0286|151 163|integrase gene
P09884232A0286|151 163|integrase gene
P09884275T0000|0 24|Interferon-alpha treatment
P09884275T0000|0 15|Interferon-alpha
P09884275T0000|27 67|posttransplant lymphoproliferative disorder
P09884275T0000|82 102|solid organ transplants
P09884747A0477|0 12|Immunological
P09884747A0477|44 50|workers
P09884747A0477|58 74|control volunteers
P09884747A0477|80 88|skin prick
P09884747A0477|100 103|hops
P09884747A0477|115 127|yeast antigens
P09884747A0477|115 127|yeast antigens
P09884747A0477|141 164|nonoccupational allergens
P09884747A0477|187 200|serum IgE levels
P09884747A0477|192 194|IgE
P09885431A0000|48 61|crown and bridge
P09885431A0000|86 136|mix putty/wash silicone elastomeric impression materials
P09886602A0000|60 83|prostate-specific antigen
P09886602A0000|85 87|PSA
P09886602A0000|85 87|PSA
P09886602A0000|102 119|clinical tumor stage
P09886602A0000|121 130|tumor grade
P09886602A0000|192 205|prostate cancer
P09886602A0000|223 242|beam radiation therapy
P09886602A0000|270 272|PSA
P09886602A0000|270 272|PSA
P09886602A0000|276 286|tumor marker
P09886843A0339|20 28|human gene
P09886843A0339|20 28|human gene
P09886843A0339|44 57|thyroid hormone
P09886843A0339|75 95|T3-responsive elements
P09886843A0339|75 76|T3
P09886843A0339|98 101|NRGN
P09886843A0339|108 123|genomic fragments
P09886850A0145|3 25|transcriptional activity
P09886850A0145|28 36|PPARgamma
P09886850A0145|28 36|PPARgamma
P09886850A0145|60 72|ligand binding
P09886850A0145|97 111|phosphorylation
P09886850A0145|125 127|MEK
P09886850A0145|125 127|MEK
P09886850A0145|129 131|ERK
P09887544A0000|49 61|tranquilizers
P09887544A0000|112 118|anxiety
P09887544A0000|135 142|epilepsy
P09888711A0781|12 20|granuloma
P09888711A0781|33 61|irregularly shaped cystic spaces
P09888711A0781|119 131|foreign bodies
P09888711A0781|147 155|granuloma
P09888711A0781|169 173|round
P09888711A0781|220 224|round
P09888711A0781|276 288|foreign bodies
P09888994A0858|4 21|Tbx6-subfamily gene
P09888994A0858|4 21|Tbx6-subfamily gene
P09888994A0858|53 69|mesoderm formation
P09888994A0858|88 98|human embryo
P09889202T0000|31 55|Z-DNA-binding domain Zalpha
P09889202T0000|31 49|Z-DNA-binding domain
P09889202T0000|58 85|dsRNA adenosine deaminase type I
P09889202T0000|58 85|dsRNA adenosine deaminase type I
P09889202T0000|109 125|alpha + beta) family
P09889202T0000|109 118|alpha + beta
P09889202T0000|128 151|helix-turn-helix proteins
P09889202T0000|128 151|helix-turn-helix proteins
P09889306A0321|26 45|Glvr-1 gene expression
P09889306A0321|26 35|Glvr-1 gene
P09889306A0321|76 86|gene therapy
P09889306A0321|118 155|gibbon ape leukemia virus envelope proteins
P09889306A0321|127 155|leukemia virus envelope proteins
P09890778T0000|0 12|Carbohydrates
P09890778T0000|16 30|glycoconjugates
P09891009T0000|0 15|Molecular cloning
P09891009T0000|18 38|mouse glycolate oxidase
P09891009T0000|18 38|mouse glycolate oxidase
P09891046A0269|23 25|PKR
P09891046A0269|23 25|PKR
P09891046A0269|34 43|cell growth
P09891046A0269|54 62|apoptosis
P09891046A0269|83 100|normal PKR signaling
P09891046A0269|89 91|PKR
P09891046A0269|121 130|cell growth
P09891046A0554|11 29|ribosomal protein L18
P09891046A0554|11 29|ribosomal protein L18
P09891046A0554|47 49|PKR
P09891046A0554|47 49|PKR
P09891049A0761|15 36|polycistronic precursor
P09891049A0761|68 81|rRNA processing
P09891049A0761|88 92|Rnt1p
P09891049A0761|88 92|Rnt1p
P09891049A0761|96 100|Rat1p
P09891049A0761|96 100|Rat1p
P09891061A0373|11 35|transcriptional regulators
P09891061A0373|57 68|SpHE promoter
P09891061A0373|57 68|SpHE promoter
P09891061A0373|86 103|individual elements
P09891061A0373|145 166|multimerized cis element
P09891061A1240|14 49|positive SpHE transcriptional regulator
P09891061A1240|22 49|SpHE transcriptional regulator
P09891061A1240|62 81|SpEts4 gene expression
P09891061A1240|62 71|SpEts4 gene
P09891061A1240|114 117|SpHE
P09891061A1240|114 117|SpHE
P09891061A1240|132 148|sea urchin blastula
P09891065A1493|12 37|rhoA-mediated SRE activation
P09891065A1493|12 15|rhoA
P09891065A1493|75 83|PKC-alpha
P09891065A1493|75 83|PKC-alpha
P09891065A1493|86 96|PKC-epsilon
P09891065A1493|86 96|PKC-epsilon
P09891085A0815|0 18|Nip7p-depleted cells
P09891085A0815|0 4|Nip7p
P09891085A0815|44 62|Nop8p-depleted cells
P09891085A0815|44 48|Nop8p
P09891085A0815|89 91|27S
P09891092A1000|13 26|Sm-binding site
P09891092A1000|13 26|Sm-binding site
P09891092A1000|30 51|stem-loop III structures
P09891092A1000|74 79|3'-end
P09891707A0000|23 41|spondyloarthropathy
P09891707A0000|43 45|SpA
P09891707A0000|43 45|SpA
P09892017A2151|58 61|ELE1
P09892017A2151|58 61|ELE1
P09892017A2151|64 78|nuclear receptor
P09892021A0712|16 19|PTTG
P09892021A0712|16 19|PTTG
P09892021A0712|33 43|NIH 3T3 cells
P09892021A0712|82 108|basic fibroblast growth factor
P09892021A0712|82 108|basic fibroblast growth factor
P09892021A0712|111 152|human pituitary tumor growth-regulating factor
P09892021A0712|116 152|pituitary tumor growth-regulating factor
P09892422A1096|103 115|lateral spread
P09892422A1096|118 127|conduction
P09892422A1096|200 204|fibre
P09892642A0172|0 1|E1
P09892642A0172|0 1|E1
P09892642A0172|4 14|DNA helicase
P09892642A0172|4 6|DNA
P09892642A0172|35 46|HPV E2 protein
P09892642A0172|35 37|HPV
P09892642A0172|38 46|E2 protein
P09892642A0172|49 72|ori-dependent replication
P09892662A0334|15 32|mutant alpha subunit
P09892662A0334|67 84|hormonal activation
P09892662A0334|87 88|Gs
P09892662A0334|87 88|Gs
P09892662A0334|115 129|adenylyl cyclase
P09892662A0334|115 129|adenylyl cyclase
P09892736A0343|1 12|gapped search
P09892736A0343|20 35|C-terminal region
P09892736A0343|20 35|C-terminal region
P09892736A0343|38 46|CDED/LIOR
P09892736A0343|38 41|CDED
P09892736A0343|43 46|LIOR
P09892736A0343|98 115|signal transduction
P09892736A0343|119 133|cell replication
P09892736A0343|141 144|ORC1
P09892736A0343|141 144|ORC1
P09892736A0343|148 150|KSR
P09892736A0343|148 150|KSR
P09893060A0767|0 19|Northern blot analysis
P09893262A1272|64 81|spatial restriction
P09893262A1272|84 100|TGF-beta responses
P09893262A1272|84 91|TGF-beta
P09893913A0656|63 73|thiopentone
P09893913A0656|83 92|atracurium
P09894962T0000|16 30|clinical profile
P09894962T0000|33 54|cavernous malformations
P09894962T0000|79 97|venous malformations
P09895323T0000|0 8|Conserved
P09895323T0000|27 34|kreisler
P09895323T0000|52 79|paralogous Hoxa3 and Hoxb3 genes
P09895323T0000|62 66|Hoxa3
P09895323T0000|70 79|Hoxb3 genes
P09897032T0000|0 11|Magnetically
P09900679T0000|0 14|Wave cybernetics
P09903722T0000|0 18|Autoionization rates
P09903722T0000|36 44|triplet nf
P09903722T0000|49 61|Rydberg states
P09903722T0000|64 65|H2
P09904139T0000|0 20|Unitary-group approach
P09904139T0000|23 45|spin-dependent operators
P09911328T0000|0 15|Nonlocal approach
P09913308T0000|0 15|Soft-x-ray lasing
P09913308T0000|26 34|Ne-like Ti
P09913308T0000|33 38|Ti ions
P09913308T0000|65 81|650-ps laser pulses
P09914156A1496|27 34|promoter
P09914156A1496|63 90|tenascin-C promoter constructs
P09914156A1496|63 80|tenascin-C promoter
P09914156A1496|95 105|5' deletions
P09914156A1496|128 153|collagen-dependent promoter
P09914156A1496|146 161|promoter activity
P09914156A1496|176 194|122-base pair element
P09914156A1496|204 221|43 to -165 bp upstream
P09914156A1496|227 238|RNA start site
P09914500A0000|0 18|Nuclear factor kappa B
P09914500A0000|0 18|Nuclear factor kappa B
P09914500A0000|20 28|NF-kappaB
P09914500A0000|20 28|NF-kappaB
P09914500A0000|43 61|transcription factor
P09914500A0000|79 102|pro-inflammatory proteins
P09914500A0000|130 138|cytokines
P09914500A0000|139 151|interleukin-1
P09914500A0000|139 151|interleukin-1
P09914500A0000|155 183|tumor necrosis factor (TNF)alpha
P09914500A0000|155 173|tumor necrosis factor
P09914500A0000|175 183|TNF)alpha
P09914518A1217|26 50|transcriptional activation
P09914518A1217|53 60|COUP-TFI
P09914518A1217|53 60|COUP-TFI
P09914518A1217|84 87|AF-1
P09914518A1217|84 87|AF-1
P09914518A1217|113 114|ER
P09914518A1217|113 114|ER
P09914518A1217|146 147|E2
P09914518A1217|150 167|4-hydroxytamoxifen
P09914518A1217|174 182|ICI 164384
P09914525A0890|0 13|Recombinant Ffh
P09914525A0890|11 13|Ffh
P09914525A0890|37 44|degreesC
P09915118T0000|0 23|Unilateral naris occlusion
P09915118T0000|30 41|rat accessory
P09915118T0000|42 54|olfactory bulb
P09915798A1077|12 16|hsp90
P09915798A1077|12 16|hsp90
P09915798A1077|25 48|ATP-independent chaperone
P09915798A1077|69 91|hsp90 dimerization domain
P09915798A1077|69 73|hsp90
P09915798A1077|134 159|steroid receptor interaction
P09915798A1077|134 148|steroid receptor
P09915860A0000|16 32|rat pgp2/mdr1b gene
P09915860A0000|19 22|pgp2
P09915860A0000|24 32|mdr1b gene
P09915860A0000|37 49|GC-rich region
P09915860A0000|37 49|GC-rich region
P09915860A0000|51 56|pgp2GC
P09915860A0000|51 56|pgp2GC
P09915860A0000|81 88|mdr genes
P09915860A0000|102 117|consensus Sp1 site
P09915860A0000|111 117|Sp1 site
P09915860A0119|0 8|Sp1's role
P09915860A0119|0 2|Sp1
P09915860A0119|31 48|pgp2/mdr1b promoter
P09915860A0119|31 34|pgp2
P09915860A0119|36 40|mdr1b
P09915860A0119|60 83|Drosophila Schneider cells
P09916786A0811|20 37|bone mineral density
P09916786A0811|43 69|lumbar spine and proximal femur
P09916786A0811|84 102|X-ray absorptiometry
P09916786A0811|127 140|bone remodeling
P09916786A0811|142 191|serum bone-specific alkaline phosphatase by immunoassay
P09916786A0811|147 178|bone-specific alkaline phosphatase
P09916786A0811|195 199|urine
P09916786A0811|219 251|high-pressure liquid chromatography
P09916809A0405|0 7|Human MGP
P09916809A0405|0 7|Human MGP
P09916809A0405|24 54|extracellular matrix (ECM) protein
P09916809A0405|71 88|84-aa mature protein
P09916809A0405|96 123|aa transmembrane signal peptide
P09917064T0000|11 13|p82
P09917064T0000|11 13|p82
P09917064T0000|22 32|CPEB homolog
P09917064T0000|22 32|CPEB homolog
P09917064T0000|36 84|cytoplasmic polyadenylation and translational masking
P09917387T0000|3 41|RNA polymerase III-recruiting factor TFIIIB
P09917387T0000|3 18|RNA polymerase III
P09917387T0000|30 35|factor
P09917387T0000|36 41|TFIIIB
P09917387T0000|50 56|DNA bend
P09917387T0000|67 73|TATA box
P09917387T0000|80 103|transcriptional start site
P09917389A1239|12 26|RNase E digestion
P09917389A1239|12 17|RNase E
P09917389A1239|29 38|finP305 RNA
P09917389A1239|29 38|finP305 RNA
P09917389A1239|51 54|FinP
P09917389A1239|51 54|FinP
P09917389A1239|59 66|GST-FinO
P09917389A1239|59 61|GST
P09917389A1239|63 66|FinO
P09917389A1239|80 89|finP305 RNA
P09917389A1239|80 89|finP305 RNA
P09917391A0380|0 23|Transcription readthrough
P09917555T0001|10 34|hematopoietic growth factor
P09917555T0001|10 34|hematopoietic growth factor
P09917555T0001|52 70|french cancer centers
P09918096A0520|18 30|epidermal cyst
P09918715A0304|0 3|MotA
P09918715A0304|0 3|MotA
P09918715A0304|14 24|DNA sequence
P09918715A0304|27 33|MotA box
P09918715A0304|27 33|MotA box
P09918715A0304|54 56|-30
P09918715A1158|13 16|MotA
P09918715A1158|13 16|MotA
P09918715A1158|20 23|AsiA
P09918715A1158|20 23|AsiA
P09918715A1158|46 59|eukaryotic TAFs
P09918715A1158|46 59|eukaryotic TAFs
P09918715A1158|61 78|TATA binding protein
P09918715A1158|61 78|TATA binding protein
P09918715A1158|80 100|TBP) associated factors
P09918715A1158|80 82|TBP
P09918715A1158|116 118|TBP
P09918715A1158|116 118|TBP
P09918715A1158|148 168|core promoter sequences
P09918720A0998|3 14|S229A variant
P09918720A0998|98 103|pocket
P09918720A0998|119 124|Ser229
P09918720A0998|147 160|flipped adenine
P09918842A0184|24 33|3' terminus
P09918842A0184|110 123|RNA replication
P09920539A0272|37 42|GnRH-a
P09920539A0272|37 40|GnRH
P09920539A0272|62 73|long protocol
P09920539A0272|80 91|gonadotropin
P09920539A0272|80 91|gonadotropin
P09920775A0075|15 20|-267 bp
P09920775A0075|34 55|transcription start site
P09920775A0075|78 99|reporter gene expression
P09920775A0075|114 138|mesodermal differentiation
P09920775A0075|141 148|P19 cells
P09920896A1230|48 63|wild type peptides
P09920896A1230|48 63|wild type peptides
P09920896A1230|118 124|protein
P09920896A1230|145 150|global
P09920903A1045|26 34|c-met gene
P09920903A1045|26 34|c-met gene
P09920903A1045|50 66|p53 gene regulation
P09920903A1045|50 56|p53 gene
P09920930A0521|0 6|C3 toxin
P09920930A0521|0 6|C3 toxin
P09920930A0521|26 37|RhoA function
P09920930A0521|26 29|RhoA
P09920930A0521|57 59|SRE
P09920930A0521|57 59|SRE
P09920930A0521|61 71|Luc activity
P09920930A0521|61 63|Luc
P09920930A0521|89 117|LPA-stimulated c-Fos expression
P09920930A0521|103 107|c-Fos
P09920930A0959|8 14|C3 toxin
P09920930A0959|8 14|C3 toxin
P09920930A0959|39 51|growth factors
P09920930A0959|67 70|AP-1
P09920930A0959|67 70|AP-1
P09920930A0959|72 82|Luc activity
P09920930A0959|72 74|Luc
P09920930A0959|131 134|AP-1
P09920930A0959|131 134|AP-1
P09920930A0959|136 138|Luc
P09920930A0959|177 189|growth factors
P09920930A0959|193 202|Ro-31-8220
P09920982A0253|114 120|P. acnes
P09920982A0253|133 143|acne lesions
P09920982A0253|163 172|Rap ID ANA II
P09921179T0001|9 38|intraoperative echocardiography
P09921179T0001|41 47|surgery
P09921179T0001|53 72|heart and large vessels
P09922230A1482|39 42|CAP1
P09922230A1482|39 42|CAP1
P09922230A1482|77 99|oxidative stress response
P09922230A1482|102 111|C. albicans
P09922856A0459|0 9|Trinipatch
P09922856A0459|19 29|transparent
P09922856A0459|61 78|absorption promoter
P09922856A0459|129 150|Laboratoires Synthelabo
P09923245A0482|3 6|RMRI
P09923245A0482|50 58|simulated
P09923245A0482|70 77|patients
P09924675A0412|65 69|ICIDH
P09924675A0412|192 208|diagnostic process
P09924987A0000|0 23|Pokeweed antiviral protein
P09924987A0000|8 27|antiviral protein (PAP
P09924987A0000|25 27|PAP
P09924987A0000|33 51|Phytolacca americana
P09924987A0000|69 104|N-glycosidase removing adenine residues
P09924987A0000|69 81|N-glycosidase
P09924987A0000|106 110|A4324
P09924987A0000|113 119|28S rRNA
P09924987A0000|113 119|28S rRNA
P09924987A0000|123 127|A2660
P09924987A0000|130 136|23S rRNA
P09924987A0000|130 136|23S rRNA
P09924987A0000|163 186|eukaryotes and prokaryotes
P09925120A0074|72 97|cholesterol-lowering effect
P09925120A0074|100 104|major
P09925120A0074|105 117|dietary fibers
P09925372A0458|13 16|ZFPs
P09925372A0458|13 16|ZFPs
P09925372A0458|24 30|ZFP cDNA
P09925372A0458|24 30|ZFP cDNA
P09925372A0458|36 39|HFHZ
P09925372A0458|36 39|HFHZ
P09925372A0458|41 58|human fetal heart ZFP
P09925372A0458|41 58|human fetal heart ZFP
P09925372A0458|83 103|Kruppel-associated box
P09925372A0458|83 103|Kruppel-associated box
P09925372A0458|105 108|KRAB
P09925372A0458|105 108|KRAB
P09925372A1063|32 41|fetal heart
P09925372A1063|51 60|adult heart
P09925372A1063|73 80|HFHZ mRNA
P09925372A1063|73 80|HFHZ mRNA
P09925777A1195|7 25|high affinity hnRNP A1
P09925777A1195|19 36|hnRNP A1 binding site
P09925777A1195|55 73|beta-globin reporter
P09925777A1195|55 73|beta-globin reporter
P09925777A1195|75 77|Rev
P09925777A1195|75 77|Rev
P09925777A1195|117 130|unspliced mRNAs
P09927193A0107|23 26|PLZF
P09927193A0107|23 26|PLZF
P09927193A0107|30 40|LAZ-3/BCL-6
P09927193A0107|30 34|LAZ-3
P09927193A0107|36 40|BCL-6
P09927193A0107|62 72|oncogenesis
P09927449A0421|16 19|POG1
P09927449A0421|16 19|POG1
P09927449A0421|28 55|alpha-factor-induced G1 arrest
P09927449A0421|28 39|alpha-factor
P09927449A0421|59 83|transcriptional repression
P09927449A0421|89 104|CLN1 and CLN2 genes
P09927449A0421|89 92|CLN1
P09927449A0421|96 99|CLN2
P09927570A0507|13 16|RNU2
P09927570A0507|13 16|RNU2
P09927570A0507|58 73|expression vector
P09927570A0507|82 88|Ad12 E1B
P09927570A0507|82 88|Ad12 E1B
P09927570A0507|89 93|55 kDa
P09927570A0507|109 110|E1
P09927570A0507|128 137|E1 products
P09927570A0507|128 129|E1
P09927570A0507|139 150|3 E1A proteins
P09927570A0507|140 150|E1A proteins
P09927570A0507|163 186|E1B 19 kDa and 55 kDa proteins
P09927570A0507|163 170|E1B 19 kDa
P09927570A0507|174 186|55 kDa proteins
P09927585A0796|21 30|EMSA assays
P09927585A0796|43 58|multiple proteins
P09927585A0796|73 97|bandshift complex formation
P09927585A0796|102 104|KCS
P09927585A0796|102 104|KCS
P09927585A0796|137 139|Sp1
P09927585A0796|137 139|Sp1
P09927589T0000|0 9|Similarity
P09927589T0000|12 21|DNA binding
P09927589T0000|25 49|transcriptional regulation
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|81 105|Drosophila melanogaster DSX
P09927589T0000|81 105|Drosophila melanogaster DSX
P09927589T0000|128 141|sex determining
P09929088A0000|0 6|CONTEXT
P09929088A0000|8 15|ThinPrep
P09929088A0000|17 23|AutoPap
P09929088A0000|88 110|cervical cancer screening
P09929811A0000|13 26|narcotized cats
P09929811A0000|59 91|2-mercaptobenzimidazole possessing
P09929811A0000|115 131|bradycardic agents
P09929811A0000|142 150|CM-251, CM
P09929811A0000|159 160|CM
P09929811A0000|241 254|5-min occlusion
P09929811A0000|260 277|anterior descending
P09929811A0000|289 292|left
P09929811A0000|293 300|coronary
P09929811A0000|301 306|artery
P09931118A1072|10 15|p42/44
P09931118A1072|10 15|p42/44
P09931118A1072|22 24|JNK
P09931118A1072|22 24|JNK
P09931118A1072|56 63|IL-1beta
P09931118A1072|56 63|IL-1beta
P09931191A0434|2 10|protocol 2
P09931191A0434|62 68|fatigue
P09931191A0434|98 105|ischemia
P09931191A0434|135 143|protocol 1
P09931216A0566|0 6|Airflow
P09931216A0566|49 64|45-ft.-long cable
P09931252A1055|19 40|amino acid substitutions
P09931252A1055|46 61|viral coat protein
P09931252A1055|46 61|viral coat protein
P09931252A1055|107 131|foreign scaffolding protein
P09931391A0944|18 30|liver function
P09931435A0357|40 44|exons
P09931435A0357|54 58|ZIS-2
P09931435A0357|54 58|ZIS-2
P09931435A0357|70 74|ZIS-1
P09931435A0357|70 74|ZIS-1
P09931435A0357|87 101|exon 11 (10th exon
P09931435A0357|105 109|ZIS-1
P09931435A0357|105 109|ZIS-1
P09931435A0357|143 148|3'-UTR
P09932288A0378|15 24|second gene
P09932288A0378|26 28|XT3
P09932288A0378|26 28|XT3
P09932288A0378|53 63|human kidney
P09932288A0378|99 114|human cDNA library
P09933428A0351|0 8|IFN-gamma
P09933428A0351|0 8|IFN-gamma
P09933428A0351|26 33|active TB
P09933428A0351|50 64|healthy controls
P09933641A0241|10 20|5' sequences
P09933641A0241|58 65|cDNA ends
P09933641A0241|83 98|NHE5 genomic clone
P09933641A0241|161 168|cDNA ends
P09933848A1008|74 87|autoantibodies
P09934611A1054|72 89|mean aortic pressure
P09935377T0108|0 4|Genoa
P09936001T0000|0 18|Electronic structure
P09936001T0000|21 35|delta -plutonium
P09936001T0000|56 57|Sc
P09936001T0000|70 84|delta -plutonium
P09938097T0000|72 75|ZnTe
P09940132T0000|15 43|segregated-stack organic charge
P09940132T0000|60 77|Magnetic properties
P09944066T0073|0 1|II
P09945838T0000|0 16|Envelope-function
P09945838T0000|38 45|GaAs/(Al
P09945838T0000|44 45|Al
P09945838T0000|47 48|Ga
P09945838T0000|47 48|Ga
P09947191T0000|0 28|Neutron scattering measurements
P09947191T0000|50 56|CsMnBr3
P09947191T0000|59 63|Z2 &gt
P09949160A0600|1 1|2
P09949160A0600|3 14|Erythroid 32D
P09949160A0600|15 18|Epo1
P09949160A0600|47 66|PKC catalytic activity
P09949160A0600|47 49|PKC
P09949160A0600|89 112|epsilon and eta PKC isoforms
P09949160A0600|89 95|epsilon
P09949160A0600|102 112|PKC isoforms
P09949160A0600|177 181|betaI
P09949160A0600|199 201|Epo
P09949160A0600|199 201|Epo
P09949178A0264|33 45|interleukin-6
P09949178A0264|33 45|interleukin-6
P09949178A0264|47 50|IL-6
P09949178A0264|47 50|IL-6
P09949178A0264|86 106|pre-B-cell variant line
P09949178A0264|108 112|1A9-M
P09949312A0524|0 6|Airflow
P09949312A0524|17 24|dust trap
P09949312A0524|43 52|vacuum pump
P09950213A1660|13 43|intestinal epithelial goblet cells
P09950213A1660|45 51|TbetaRI
P09950213A1660|45 51|TbetaRI
P09950213A1660|55 62|TbetaRII
P09950213A1660|55 62|TbetaRII
P09950213A1660|75 83|autocrine
P09950213A1660|99 106|TGF-beta
P09950213A1660|99 106|TGF-beta
P09950213A1660|132 140|TbetaRIII
P09950213A1660|132 140|TbetaRIII
P09950394A0336|23 45|carboxyhemoglobin levels
P09950394A0336|23 39|carboxyhemoglobin
P09950394A0336|60 68|physician
P09952378A0529|15 17|CHD
P09952378A0529|92 104|IgG antibodies
P09952378A0529|92 94|IgG
P09952378A0529|123 132|covariates
P09952425A0893|14 40|HIPP- and HCX-lesioned animals
P09952425A0893|66 71|lesion
P09952425A0893|175 180|lesion
P09952425A0893|202 212|hippocampus
P09959737T0000|23 30|SN 1987A.
P09961326T0000|0 20|Scaling of fluctuations
P09961326T0000|38 62|interface and hopping models
P09961682T0000|0 4|Model
P09964171T0000|0 2|NMR
P09964171T0000|22 41|periodic porous medium
P09964171T0000|58 80|nonuniform magnetic field
P09964770T0000|0 13|Microstructure
P09964770T0000|31 60|hierarchical laminate composites
P09965234T0000|11 23|heat transport
P09965234T0000|29 51|octylcyanobiphenyl (8CB)
P09965234T0000|52 64|liquid crystal
P09965909T0000|26 45|soliton perturbations
P09971776A0838|22 34|CD4 regulation
P09971776A0838|22 24|CD4
P09971776A0838|87 89|Nef
P09971776A0838|87 89|Nef
P09971776A0838|111 113|W57
P09971776A0838|117 119|L58
P09971776A0838|133 159|AP-recruiting dileucine motif
P09971776A0838|133 159|AP-recruiting dileucine motif
P09971776A0838|167 181|acidic dipeptide
P09971776A0838|187 202|C-terminal region
P09971776A0838|187 202|C-terminal region
P09971790A0856|7 15|mutations
P09971790A0856|28 60|endonuclease and helicase activities
P09971790A0856|28 50|endonuclease and helicase
P09971790A0856|77 97|amino-terminal-charge
P09971790A0856|119 132|D40A-D42A-D44A
P09971790A0856|148 150|AAV
P09971790A0856|158 175|DNA binding activity
P09971806A1585|3 12|lytic cycle
P09971806A1585|15 18|KSHV
P09971806A1585|55 66|KSHV/Rta gene
P09971806A1585|55 58|KSHV
P09971806A1585|60 62|Rta
P09971806A1585|91 107|tumor pathogenesis
P09971815A2094|63 77|murine gammaHV68
P09971815A2094|106 112|latency
P09971815A2094|159 181|multiple latency programs
P09971815A2094|196 208|cellular sites
P09971815A2094|211 217|latency
P09971815A2094|239 249|viral genome
P09971815A2094|251 261|v-bcl-2 gene
P09971815A2094|251 261|v-bcl-2 gene
P09971815A2094|263 271|v-GCR gene
P09971815A2094|263 271|v-GCR gene
P09971815A2094|303 309|latency
P09971815A2094|318 326|gammaHV68
P09971815A2094|330 354|primate gammaherpesviruses
P09971822A1542|35 36|U1
P09971822A1542|35 36|U1
P09971822A1542|39 68|NRS-mediated splicing inhibition
P09973351A1522|19 33|DcuS-DcuR system
P09973351A1522|19 22|DcuS
P09973351A1522|24 27|DcuR
P09973607A0254|59 84|Sp100 splice variant proteins
P09973607A0254|59 84|Sp100 splice variant proteins
P09973607A0254|127 132|3'-end
P09973607A0254|138 146|Sp100 gene
P09973607A0254|138 142|Sp100
P09974642T0000|0 8|Crossover
P09974642T0000|28 40|dilute magnets
P09974642T0000|50 74|critical spin-wave dynamics
P09976626T0000|0 6|Erratum
P09976626T0000|41 65|martensitic transformation
P09976626T0000|69 81|virgin crystal
P09976626T0000|86 90|metal
P09980944T0000|0 17|Interplane coupling
P09980944T0000|23 36|superconductor
P09980944T0000|37 47|Y2Ba4Cu7O15
P09980944T0000|60 86|NQR spin-echo double resonance
P09982923T0000|0 18|Electronic structure
P09982923T0000|22 32|buried NiSi2
P09982923T0000|35 44|CoSi2 layer
P09983871T0000|20 41|YBa2-xLaxCu3O7 ceramics
P09984526T0000|9 20|point defects
P09984526T0000|23 39|lattice parameters
P09984526T0000|42 55|semiconductors
P09985302T0000|0 22|Chaotic electron dynamics
P09985302T0000|36 60|elliptically shaped antidot
P09986796A1761|22 32|C terminal 11
P09986796A1761|22 32|C terminal 11
P09986796A1761|35 46|14 amino acids
P09987176A0260|26 36|vaccination
P09987176A0260|41 49|vaccinees
P09987176A0260|102 109|anti-HAV
P09987176A0260|102 109|anti-HAV
P09987634A1265|13 15|PRK
P09987634A1265|82 90|PRK effect
P09987961A0093|3 14|early lesions
P09987961A0093|47 58|vasculopathy
P09987961A0093|78 103|synoviocytes and fibroblasts
P09988682T0033|0 15|Molecular cloning
P09988682T0033|18 26|human cDNA
P09988682T0033|18 26|human cDNA
P09988682T0033|36 45|novel beta1
P09988682T0033|41 79|beta1,6-N-acetylglucosaminyltransferase
P09988682T0033|87 91|core 2
P09988682T0033|95 99|core 4
P09988767A1496|13 35|mouse back-cross analysis
P09988767A1496|49 52|loci
P09988767A1496|56 80|mouse 3Ost genes and syntenic
P09988767A1496|56 69|mouse 3Ost genes
P09988767A1496|107 118|human isologs
P09988767A1496|159 177|sequence-tagged site
P09988850A0000|39 66|Institutional Records (SCIRFIR
P09988850A0000|96 120|dementia rating instruments
P09988850A0000|147 174|chronically institutionalized
P09988850A0000|176 203|elderly schizophrenia patients
P09988850A0000|265 279|cognitive change
P09988850A0000|282 294|schizophrenia
P09988850A0000|319 334|autopsy materials
P09989334A0964|87 105|polyadenylation site
P09989334A0964|118 123|muscle
P09989339A0968|33 43|brain weight
P09990057T0000|0 12|Recombination
P09990057T0000|34 60|endogenous Ig heavy chain locus
P09990057T0000|44 60|Ig heavy chain locus
P09990057T0000|76 113|Ig heavy chain intronic enhancer core region
P09990057T0000|76 113|Ig heavy chain intronic enhancer core region
P09990057T0000|131 153|matrix attachment regions
P09990060A0803|53 71|dyad symmetry element
P09990060A0803|103 114|IL-2 enhancer
P09990060A0803|103 114|IL-2 enhancer
P09990060A0803|121 132|CD18 promoter
P09990060A0803|121 132|CD18 promoter
P09990060A0937|16 44|coactivator CREB binding protein
P09990060A0937|27 44|CREB binding protein
P09990060A0937|45 49|/p300
P09990060A0937|46 49|p300
P09990060A0937|69 77|GABPalpha
P09990060A0937|69 77|GABPalpha
P09990060A0937|91 107|GABPalpha and -beta
P09990060A0937|91 99|GABPalpha
P09990060A0937|113 131|dyad symmetry element
P09990060A0937|154 166|IL-16 promoter
P09990060A0937|154 166|IL-16 promoter
P09990060A0937|169 174|T cells
P09990315A0205|0 2|TPO
P09990315A0205|0 2|TPO
P09990315A0205|25 28|ERK1
P09990315A0205|25 28|ERK1
P09990315A0205|30 33|ERK2
P09990315A0205|30 33|ERK2
P09990315A0205|37 50|protein kinase C
P09990315A0205|37 50|protein kinase C
P09990315A0205|52 54|PKC
P09990315A0205|52 54|PKC
P09990315A0205|64 66|TPO
P09990315A0205|64 66|TPO
P09990315A0205|86 108|PKC-dependent activation
P09990315A0205|86 88|PKC
P09990315A0205|111 114|ERKs
P09990315A0205|111 114|ERKs
P09990315A0205|146 153|thrombin
P09990315A0205|146 153|thrombin
P09990315A0205|157 169|phorbol esters
P09990315A0205|190 202|PKC activation
P09990315A0205|190 192|PKC
P09990507A0000|16 52|ubiquitin-dependent proteolysis pathway
P09990507A0000|16 24|ubiquitin
P09990507A0000|55 69|ubiquitin ligase
P09990507A0000|55 69|ubiquitin ligase
P09990507A0000|71 72|E3
P09990507A0000|71 72|E3
P09990507A0000|90 109|substrate selectivity
P09990507A0000|121 131|degradation
P09990507A0763|12 26|Fission yeast SCF
P09990507A0763|24 26|SCF
P09990507A0763|39 42|Pop1
P09990507A0763|39 42|Pop1
P09990507A0763|46 49|Pop2
P09990507A0763|46 49|Pop2
P09990507A0763|99 121|F-box/WD-repeat proteins
P09990507A0763|101 104|box/
P09990507A0763|105 113|WD-repeat
P09994942T0000|0 12|19F NMR studies
P09994942T0000|15 46|ABF4-type layered antiferromagnets
P09995847T0000|0 50|Optical-absorption spectra, crystal-field energy levels
P09995847T0000|89 99|trigonal Na3
P09995897T0000|0 10|Observation
P09995897T0000|39 48|Pb0 defects
P09995897T0000|55 57|111
P09995897T0000|62 74|SiO2 interface
P09999256T0000|27 45|high-field transport
P09999742T0000|0 2|NH3
P09999742T0000|6 7|NO
P09999742T0000|23 24|Si
P09999742T0000|23 24|Si
P09999742T0000|26 34|100)-(2 x 1
P10000253T0000|0 14|Chirality-glass
P10000253T0000|60 77|random-bond XY model
P10001333T0038|0 13|Echo modulation
P10001333T0038|16 26|Pr3+:YAlO3.
P10001541T0000|37 65|electro-oxidized porous silicon
P10002245T0000|0 30|Far-infrared hopping conductivity
P10002245T0000|36 44|CuO chains
P10002245T0000|48 82|single-domain YBa2Cu3O7- delta crystal
P10006319T0000|0 15|Surface spin waves
P10006319T0000|19 39|Heisenberg ferrimagnet
P10006319T0000|45 73|single-ion anisotropy (uniaxial
P10006319T0000|77 87|nonuniaxial
P10007469T0000|36 49|crystalline C60
P10007564T0000|0 28|Multilayer-relaxation geometry
P10007564T0000|32 50|electronic structure
P10007564T0000|54 58|W(111
P10008261T0000|36 59|spontaneous magnetization
P10008261T0000|62 70|YBa2Cu3O6
P10009565T0000|23 43|electron self-energies
P10009565T0000|46 72|semiconductors and insulators
P10013227T0000|25 45|pion mass difference m pi
P10013227T0000|49 51|pi 0
P10021333A0674|0 17|Genetic experiments
P10021333A0674|41 47|apontic
P10021333A0674|51 55|bruno
P10021350A0093|18 35|Wingless/Wnt signal
P10021350A0093|18 25|Wingless
P10021350A0093|27 29|Wnt
P10021350A0093|46 67|Armadillo/beta-catenin
P10021350A0093|46 54|Armadillo
P10021350A0093|56 67|beta-catenin
P10021350A0093|91 96|nuclei
P10021350A0093|105 125|TCF/LEF family proteins
P10021350A0093|105 107|TCF
P10021350A0093|109 125|LEF family proteins
P10021350A0093|143 162|transcription factors
P10021350A0093|191 202|Wingless/Wnt
P10021350A0093|191 198|Wingless
P10021350A0093|200 217|Wnt responsive genes
P10022032A0000|41 61|vasodilator nicorandil
P10022032A0000|63 65|NIC
P10022032A0000|85 107|beta-adrenergic receptor
P10022032A0000|85 107|beta-adrenergic receptor
P10022032A0000|119 129|propranolol
P10022032A0000|131 133|PRO
P10022032A0000|138 145|atenolol
P10022032A0000|147 149|ATN
P10022032A0000|161 190|calcium channel blocker diltiazem
P10022032A0000|192 194|DTZ
P10022032A0000|229 255|pharmacokinetic interactions
P10022210A0620|18 49|direct-immersion (DI)-SPME process
P10022850A0929|13 34|amino-terminal fragment
P10022850A0929|48 57|C/H1 domain
P10022850A0929|48 57|C/H1 domain
P10022850A0929|74 85|coactivation
P10022850A0929|88 103|Zta transcription
P10022850A0929|88 90|Zta
P10022850A0929|107 131|viral reactivation function
P10022858A0985|82 96|20-kDa SR protein
P10022858A0985|88 96|SR protein
P10022867A1069a|0 10|Elimination
P10022867A1069a|13 16|ETH1
P10022867A1069a|13 16|ETH1
P10022867A1069a|19 29|apn1 strains
P10022867A1069a|19 22|apn1
P10022867A1069a|67 72|9- or 31
P10022867A1069a|133 149|lysine prototrophy
P10022867A1069b|0 10|Elimination
P10022867A1069b|13 16|ETH1
P10022867A1069b|13 16|ETH1
P10022867A1069b|19 29|apn1 strains
P10022867A1069b|19 22|apn1
P10022867A1069b|67 72|9- or 31
P10022867A1069b|133 149|lysine prototrophy
P10022875A1265|25 36|Ras effectors
P10022875A1265|25 27|Ras
P10022875A1265|55 64|PI 3-kinase
P10022875A1265|55 64|PI 3-kinase
P10022875A1265|91 93|Pak
P10022875A1265|91 93|Pak
P10022880A0000|0 35|Mammalian Ras GTPase-activating protein
P10022880A0000|0 8|Mammalian
P10022880A0000|9 35|Ras GTPase-activating protein
P10022880A0000|37 39|GAP
P10022880A0000|37 39|GAP
P10022880A0000|42 52|p120 Ras-GAP
P10022880A0000|42 45|p120
P10022880A0000|46 48|Ras
P10022880A0000|50 52|GAP
P10022880A0000|104 114|Ras proteins
P10022880A0000|104 114|Ras proteins
P10022880A0000|135 172|Ras-mediated signal transduction pathways
P10022880A0000|135 137|Ras
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|24 42|premature stop codons
P10022905A0446|63 69|alleles
P10022905A0446|115 130|residual activity
P10022905A0446|132 140|mog-1 mRNA
P10022905A0446|132 140|mog-1 mRNA
P10022921A0608|17 24|SIN3 gene
P10022921A0608|17 24|SIN3 gene
P10022921A0608|27 49|Saccharomyces cerevisiae
P10022921A0608|27 49|Saccharomyces cerevisiae
P10022921A0608|51 56|pst1(+
P10022921A0608|51 54|pst1
P10022921A0608|72 84|cell viability
P10022925A0870|3 21|Nmd3 protein sequence
P10022925A0870|3 21|Nmd3 protein sequence
P10022978A1261|71 97|beta-heterochromatic regions
P10022978A1261|114 132|major chromosome arms
P10024383T0000|37 58|periosteal hyperostosis
P10024383T0000|62 81|trabecular osteopenia
P10024383T0000|87 109|spinal hyperostotic mouse
P10024383T0000|111 117|twy/twy
P10024383T0000|111 113|twy
P10024383T0000|115 117|twy
P10024498A0783|0 34|Electrophoretic mobility-shift assays
P10024498A0783|51 56|HNF-3 X
P10024498A0783|51 55|HNF-3
P10024498A0783|56 65|X and Y sites
P10024498A0783|110 119|HNF-3alpha
P10024498A0783|110 119|HNF-3alpha
P10024498A0783|123 131|HNF-3beta
P10024498A0783|123 131|HNF-3beta
P10024882A0541|25 28|cdk7
P10024882A0541|25 28|cdk7
P10024882A0541|48 69|carboxy-terminal domain
P10024882A0541|48 69|carboxy-terminal domain
P10024882A0541|71 73|CTD
P10024882A0541|71 73|CTD
P10024882A0541|77 84|RNA pol II
P10024882A0541|77 84|RNA pol II
P10025050A1052|3 9|therapy
P10025050A1052|15 35|H2-receptor antagonist
P10025050A1052|15 25|H2-receptor
P10025050A1052|77 100|omeprazole or lansoprazole
P10025506A0079|2 7|humans
P10025506A0079|14 43|tissue-specific plastin isoforms
P10025506A0079|14 43|tissue-specific plastin isoforms
P10025506A1078|2 18|TATA or Inr sequence
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|79 82|cAMP
P10026146A0680|114 117|PrKX
P10026146A0680|114 117|PrKX
P10026146A0680|127 158|type I cAMP-dependent protein kinase
P10026146A0680|127 158|type I cAMP-dependent protein kinase
P10026146A0680|181 184|cAMP
P10026146A0680|223 235|Calpha subunit
P10026146A0680|223 235|Calpha subunit
P10026146A0680|238 264|cAMP-dependent protein kinase
P10026146A0680|238 264|cAMP-dependent protein kinase
P10026211A0136|22 29|PEPCK CRE
P10026211A0136|22 29|PEPCK CRE
P10026211A0136|40 57|CRE-binding protein
P10026211A0136|40 57|CRE-binding protein
P10026211A0136|59 62|CREB
P10026211A0136|59 62|CREB
P10026211A0136|79 120|CCAAT/enhancer-binding protein (C/EBP) family
P10026211A0136|79 107|CCAAT/enhancer-binding protein
P10026211A0136|109 120|C/EBP) family
P10026211A0543|20 33|pDeltaCREC/EBP
P10026211A0543|20 29|pDeltaCREC
P10026211A0543|31 33|EBP
P10026211A0543|40 49|C/EBPalpha
P10026211A0543|40 49|C/EBPalpha
P10026211A0543|53 56|beta
P10026211A0543|53 56|beta
P10026211A0543|63 66|CREB
P10026211A0543|63 66|CREB
P10026211A0543|95 116|glucocorticoid response
P10026211A0543|147 167|H4IIE rat hepatoma cells
P10026229A0950|35 50|Engrailed and Pbx1
P10026229A0950|35 43|Engrailed
P10026229A0950|47 55|Pbx1 sites
P10026229A0950|111 136|transcriptional enhancement
P10026229A0950|152 167|intronic fragment
P10026275A0549|7 24|secondary structure
P10026784A0331|57 76|transcription factors
P10026784A0331|95 112|POU DNA binding motif
P10026784A0331|95 112|POU DNA binding motif
P10026784A0331|126 145|mammalian development
P10026784A0929|0 35|High-affinity site-specific DNA binding
P10026784A0929|38 66|POU domain transcription factors
P10026784A0929|38 66|POU domain transcription factors
P10026784A0929|82 114|POU-specific and the POU-homeodomain
P10026784A0929|82 84|POU
P10026784A0929|100 114|POU-homeodomain
P10026784A2166|5 16|Oct-1 crystal
P10026784A2166|5 9|Oct-1
P10026784A2166|21 38|POU-specific domain
P10026784A2166|21 38|POU-specific domain
P10026784A2166|50 62|GCAT half-site
P10026784A2166|85 92|sequence
P10026784A2166|108 130|Pit-1 POU-specific domain
P10026784A2166|108 112|Pit-1
P10026784A2166|113 130|POU-specific domain
P10026784A2166|132 135|GTAT
P10026784A2166|132 135|GTAT
P10026784A2166|144 157|opposing strand
P10026824A0309|30 41|V1a/V2 hybrid
P10026824A0309|30 32|V1a
P10026824A0309|34 35|V2
P10026824A0309|70 86|intracellular loop
P10026824A0309|92 102|V1a receptor
P10026824A0309|92 102|V1a receptor
P10026824A0309|148 152|Gq/11
P10026824A0309|148 152|Gq/11
P10026824A0309|191 200|V2 receptor
P10026824A0309|191 200|V2 receptor
P10026824A0309|237 238|Gs
P10029337A0406|3 17|fatigue exercise
P10029337A0406|38 62|blood lactate concentration
P10029337A0406|64 67|12.5
P10029337A0406|80 83|l(-1
P10029337A0406|101 122|serum creatine kinase (CK
P10029337A0406|101 119|serum creatine kinase
P10029337A0406|121 122|CK
P10029337A0406|157 162|U x l(-1
P10029860A0605|5 23|radiological aspects
P10029860A0605|57 97|type I-presenting variable sinusoidal filling
P10029917A0366|36 49|myofibroblasts
P10029917A0366|103 128|smooth muscle cell dispersion
P10029917A0366|149 160|medium-sized
P10029917A0366|161 167|damaged
P10029917A0366|168 185|portal vein branches
P10031854T0000|60 72|asymmetric top
P10032519T0000|0 19|Radiative corrections
P10032581T0000|0 22|Depth-controlled grazing
P10032581T0000|46 66|synchrotron x radiation
P10033973T0000|0 18|Oscillatory exchange
P10033973T0000|48 62|Bose condensates
P10034615T0000|26 66|adsorbate-induced multilayer reconstruction
P10034615T0000|69 74|1 x 2)-H
P10034615T0000|71 77|2)-H/Ni
P10034615T0000|76 81|Ni(110
P10034615T0000|79 81|110
P10035841T0000|38 45|hydrogen
P10036181A0603|0 11|Northern blot
P10036181A0603|15 41|in situ hybridization analyses
P10036181A0603|50 69|GPR34 mRNA transcripts
P10036181A0603|50 58|GPR34 mRNA
P10036181A0603|79 83|human
P10036181A0603|87 101|rat brain regions
P10036191A0000|3 20|microphthalmia-TFE
P10036191A0000|18 24|TFE (MiT
P10036191A0000|22 24|MiT
P10036191A0000|37 100|basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factors
P10036191A0000|37 100|basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factors
P10036191A0000|111 114|TFE3
P10036191A0000|111 114|TFE3
P10036191A0000|116 119|TFEB
P10036191A0000|116 119|TFEB
P10036191A0000|121 124|TFEC
P10036191A0000|121 124|TFEC
P10036191A0000|129 132|Mitf
P10036191A0000|168 196|tissue-specific gene expression
P10036191A0000|168 186|tissue-specific gene
P10037004A0000|11 18|patients
P10037004A0000|35 60|acute lymphoblastic leukemia
P10037004A0000|62 64|ALL
P10037004A0000|81 90|bone marrow
P10037004A0000|92 93|BM
P10037378A0176|3 8|dorsal
P10037378A0176|56 64|lidocaine
P10037460A0221|5 9|brain
P10037460A0221|11 29|muscarinic receptors
P10037460A0221|11 29|muscarinic receptors
P10037460A0221|81 99|ligand acetylcholine
P10037576T0000|0 25|Early-onset scleral necrosis
P10037576T0000|31 36|iodine
P10037576T0000|47 58|radiotherapy
P10037576T0000|62 83|ciliochoroidal melanoma
P10037681A0494|0 20|Successful interaction
P10037681A0494|23 25|ARF
P10037681A0494|23 25|ARF
P10037681A0494|29 37|PKC-alpha
P10037681A0494|29 37|PKC-alpha
P10037681A0494|42 45|PLD1
P10037681A0494|42 45|PLD1
P10037681A0494|65 82|C-terminal fragment
P10037681A0494|65 82|C-terminal fragment
P10037681A0494|85 93|human PLD1
P10037681A0494|85 93|human PLD1
P10037681A0494|103 106|D4")
P10037681A0494|138 141|RhoA
P10037681A0494|138 141|RhoA
P10037681A0494|143 152|RhoAVal-14
P10037681A0494|143 152|RhoAVal-14
P10037774A0366|29 54|signal transduction pathways
P10037774A0366|82 98|LDLR transcription
P10037774A0366|82 85|LDLR
P10041728T0000|31 47|linear-dispersion
P10043466T0000|0 19|High-pressure effects
P10043466T0000|22 59|ultrafast-relaxation kinetics of excitons
P10043466T0000|62 81|polydiacetylene 4BCMU
P10044519T0000|15 28|turbulent flows
P10046849T0000|5 40|scale electronic structure calculations
P10049357A0608|20 22|Ski
P10049357A0608|20 22|Ski
P10049357A0608|40 50|HDAC complex
P10049357A0608|40 50|HDAC complex
P10049357A0608|58 60|Ski
P10049357A0608|58 60|Ski
P10049357A0608|77 101|transcriptional repression
P10049359A1073|0 13|Recombinant unr
P10049359A1073|37 50|recombinant PTB
P10049359A1073|48 50|PTB
P10049359A1073|97 100|IRES
P10049742T0000|13 36|consensus binding sequence
P10049742T0000|43 59|DNA-binding domain
P10049742T0000|43 59|DNA-binding domain
P10049742T0000|62 64|ZF5
P10049742T0000|62 64|ZF5
P10049775T0000|12 54|human Voltage-Dependent Anion Channel isoforms 1
P10049775T0000|12 54|human Voltage-Dependent Anion Channel isoforms 1
P10049775T0000|59 70|reconsidered
P10049912T0000|16 21|RNase T
P10049912T0000|16 21|RNase T
P10049912T0000|49 61|UV sensitivity
P10049912T0000|76 112|single-strand DNA exonuclease deficiency
P10049912T0000|115 129|Escherichia coli
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|70 84|p53 conformation
P10050883A0967|70 72|p53
P10050883A0967|122 142|Tpo-enhanced viability
P10050883A0967|122 124|Tpo
P10051030A1080|26 30|males
P10051030A1080|71 72|CP
P10051030A1080|71 72|CP
P10051030A1080|82 96|feeding regimens
P10051400A0000|3 15|Lp mouse mutant
P10051400A0000|5 15|mouse mutant
P10051400A0000|47 52|neural
P10051400A0000|69 87|cranio-rachischisis
P10051488A1293|17 40|AP-1 DNA binding activities
P10051488A1293|17 20|AP-1
P10051488A1293|69 72|HSCs
P10051488A1293|92 116|high mobility AP-1 complexes
P10051488A1293|92 103|high mobility
P10051488A1293|104 116|AP-1 complexes
P10051488A1293|118 123|HMAP-1
P10051488A1293|118 123|HMAP-1
P10051488A1610|0 8|Mutations
P10051488A1610|14 21|AP-1 site
P10051488A1610|14 21|AP-1 site
P10051488A1610|27 40|TIMP-1 promoter
P10051488A1610|27 40|TIMP-1 promoter
P10051488A1610|65 70|HMAP-1
P10051488A1610|65 70|HMAP-1
P10051488A1610|97 107|transfected
P10051488A1610|117 120|HSCs
P10052371A0171|12 34|Salivary immunoglobulin A
P10052371A0171|51 58|subjects
P10052371A0171|151 157|smoking
P10052878A0135|20 27|accuracy
P10053852T0000|6 7|g2
P10053852T0000|6 7|g2
P10053852T0000|33 53|Gerasimov-Drell-Hearn
P10054976T0000|0 11|Spectroscopy
P10055173T0000|0 3|Band
P10055173T0000|43 66|icosahedral quasicrystals
P10059496T0000|0 19|Acoustic transmission
P10059496T0000|32 45|Penrose lattice
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063122T0000|26 40|Incoherent Metal
P10063739A0601|23 49|esophageal sphincter pressure
P10063739A0601|101 108|controls
P10063739A0601|157 159|EVS
P10063739A0601|162 164|EVL
P10064604A0824|0 3|CPDs
P10064604A0824|41 46|TFIIIA
P10064604A0824|41 46|TFIIIA
P10064604A0824|63 73|rapid repair
P10065176A0657|25 45|hormone receptor status
P10065176A0657|68 76|lymph node
P10065176A0657|77 86|metastases
P10065176A0657|94 102|lymph node
P10065176A0657|103 143|metastases, 'clandestine' or macrometastases
P10065684A0916|39 52|residual volume
P10065684A0916|54 78|RV)/total lung capacity (TLC
P10065684A0916|110 112|mit
P10065684A0916|146 154|microm(-2
P10065684A0916|174 190|sarcomeres (L(sar)
P10065684A0916|196 203|subjects
P10066790A0497|0 12|Gel filtration
P10066790A0497|14 26|sedimentation
P10066790A0497|39 68|immunoprecipitation experiments
P10066790A0497|81 85|beta4
P10066790A0497|101 119|multisubunit complex
P10066790A0497|101 119|multisubunit complex
P10066790A0497|121 124|AP-4
P10066790A0497|121 124|AP-4
P10066790A0497|145 161|sigma4 polypeptide
P10066790A0497|205 207|mu4
P10066790A0497|205 207|mu4
P10066790A0497|209 215|mu-ARP2
P10066790A0497|209 210|mu
P10066790A0497|212 215|ARP2
P10066798A0391|0 24|Cyclin D1-associated kinase
P10066798A0391|0 24|Cyclin D1-associated kinase
P10066798A0391|36 48|protein levels
P10066798A0391|64 76|mammary tumors
P10066798A0391|81 108|murine mammary tumor virus-pp60
P10066798A0391|105 108|pp60
P10066798A0391|110 118|c-src527F
P10066798A0391|110 118|c-src527F
P10066798A0391|120 133|transgenic mice
P10066815T0000|3 44|SH2 domain-containing inositol 5'-phosphatase
P10066815T0000|3 11|SH2 domain
P10066815T0000|23 44|inositol 5'-phosphatase
P10066815T0000|46 50|SHIP)
P10066815T0000|46 49|SHIP
P10066815T0000|62 71|p85 subunit
P10066815T0000|62 71|p85 subunit
P10066815T0000|74 97|phosphoinositide 3-kinase
P10066815T0000|74 97|phosphoinositide 3-kinase
P10066815T0000|104 134|FcgammaRIIb1-mediated inhibition
P10066815T0000|104 115|FcgammaRIIb1
P10066815T0000|137 158|B cell receptor signaling
P10066815T0000|137 149|B cell receptor
P10068040A0136|13 23|mouse genome
P10068040A0136|47 55|ubc-9 gene
P10068040A0136|47 55|ubc-9 gene
P10068418A1194|12 29|bone mineral density
P10068418A1194|41 48|total hip
P10068418A1194|53 57|total
P10068418A1194|58 61|body
P10068418A1194|123 150|estrogen or alendronate therapy
P10068446A0124|40 50|thiol agents
P10068446A0124|56 70|PKC preparations
P10068446A0124|56 58|PKC
P10068446A0124|94 96|BPO
P10068446A0124|113 128|cysteine residues
P10068446A0124|131 133|PKC
P10068446A0124|131 133|PKC
P10068637A1320|14 21|Csx/Nkx2
P10068637A1320|14 16|Csx
P10068637A1320|18 21|Nkx2
P10068674A0644|42 47|Lyp RNA
P10068674A0644|42 47|Lyp RNA
P10068674A0644|49 52|Lyp2
P10068674A0644|49 52|Lyp2
P10068834A0713|3 7|costs
P10068834A0713|24 25|PE
P10068834A0713|27 28|DM
P10068834A0713|39 40|VR
P10068834A0713|44 45|DM
P10068834A0713|55 56|MR
P10069815A0285|62 65|Doa4
P10069815A0285|62 65|Doa4
P10069815A0285|72 81|proteasome
P10070158A0573|0 18|Independent splicing
P10070158A0573|64 68|exons
P10070158A0573|110 128|transmembrane domain
P10071205A0833|41 43|ORF
P10071205A0833|50 53|STA2
P10071205A0833|50 53|STA2
P10071205A0833|78 88|AUG codons 5'
P10071205A0833|94 105|major cistron
P10071212A0399|0 9|Nipponbare
P10071761A2374|23 36|promoter region
P10071761A2374|59 93|putative promoter regulatory sequences
P10071761A2374|118 142|transcriptional regulation
P10071761A2374|145 158|UCP2 expression
P10071761A2374|145 148|UCP2
P10071806A0377|9 21|resectability
P10072205A0167|44 45|ML
P10072205A0167|44 45|ML
P10072774A0537|0 5|RT-PCR
P10072774A0537|41 72|degenerate oligonucleotide primers
P10072774A0537|78 96|ligand binding domain
P10072774A0537|98 100|LBD
P10072774A0537|109 128|beta integrin subunits
P10072774A0537|109 128|beta integrin subunits
P10072774A0537|132 138|Bge cDNA
P10072774A0537|132 138|Bge cDNA
P10073899A0740|52 54|EAF
P10073899A0740|82 84|CVS
P10073940A0335|0 16|Ectopic expression
P10073940A0335|19 24|d-axin
P10073940A0335|21 24|axin
P10073940A0335|34 50|Wingless signaling
P10073940A0335|34 41|Wingless
P10073947A1110|29 33|FVIIa
P10073947A1110|29 33|FVIIa
P10073947A1110|37 41|PAI-1
P10073947A1110|37 41|PAI-1
P10074135T0000|0 6|Primary
P10074135T0000|59 95|barley yellow dwarf virus subgenomic RNA1.
P10074282A0236|22 31|aortic ring
P10074282A0236|47 73|L-NNA (NO-synthesis inhibitor
P10074282A0236|47 51|L-NNA
P10074282A0236|53 54|NO
P10074282A0236|77 113|methylene blue (soluble cGMPase inhibitor
P10074282A0236|98 104|cGMPase
P10074425A0729|30 48|cyclin E-Cdk2 complex
P10074425A0729|30 36|cyclin E
P10074425A0729|38 41|Cdk2
P10074425A0729|61 67|mitogen
P10074425A0729|94 97|MEFs
P10074425A0729|130 132|p27
P10074425A0729|130 132|p27
P10074520T0000|35 40|IS2404
P10074520T0000|35 40|IS2404
P10074520T0000|44 49|IS2606
P10074520T0000|44 49|IS2606
P10074520T0000|93 113|Mycobacterium ulcerans
P10074520T0000|116 118|PCR
P10074903A0915|61 71|p202 protein
P10074903A0915|61 71|p202 protein
P10074903A0915|122 125|IFNs
P10074903A0915|122 125|IFNs
P10074903A0915|153 168|p21 protein levels
P10074903A0915|153 162|p21 protein
P10074921A1169|35 61|HepG2 hepatoblastoma cell line
P10074921A1169|72 74|p53
P10074921A1169|72 74|p53
P10075415A1178|7 16|sequencing
P10075415A1178|40 46|ORF-Pto
P10075415A1178|40 46|ORF-Pto
P10075415A1178|68 77|ru/AB genes
P10075415A1178|68 77|ru/AB genes
P10075415A1178|89 100|UV resistance
P10075415A1178|113 117|pPSR1
P10076007A0656|3 22|MSY2 associated kinase
P10076007A0656|3 6|MSY2
P10076007A0656|28 40|casein kinase 2
P10076007A0656|28 40|casein kinase 2
P10076007A0656|74 80|mRNP3+4
P10076007A0656|74 80|mRNP3+4
P10076007A0656|110 115|kinase
P10077188A1172|16 33|helicase-like genes
P10077188A1172|66 77|nucleic acids
P10077188A1172|138 146|heat shock
P10077188A1172|185 188|mRNA
P10077188A1172|192 198|protein
P10077533A0976|63 65|MKS
P10077533A0976|63 65|MKS
P10077533A0976|72 79|MUL genes
P10077533A0976|72 79|MUL genes
P10078734A0480|5 23|reflex recovery curve
P10078734A0480|62 66|nerve
P10078734A0480|72 88|elbow and recording
P10078734A0480|96 114|flexor carpi radialis
P10078876A0000|3 9|origins
P10078876A0000|47 62|neuronal activity
P10078876A0000|97 118|rat somatosensory cortex
P10078876A0000|123 136|optical imaging
P10078876A0000|164 185|laser-Doppler flowmetry
P10078876A0000|211 247|hemoglobin concentration and oxygenation
P10078876A0000|211 220|hemoglobin
P10079173A0000|0 29|Human neuronal Elav-like proteins
P10079173A0000|0 4|Human
P10079173A0000|13 29|Elav-like proteins
P10079173A0000|42 69|RNP-type RNA recognition motifs
P10079173A0000|42 49|RNP-type
P10079173A0000|50 52|RNA
P10079173A0000|53 69|recognition motifs
P10079173A0000|71 74|RRMs
P10080436T0000|25 42|atrial fibrillation
P10080436T0000|48 55|coronary
P10080875A0772|35 52|specific antibodies
P10080875A0772|60 79|transcription factors
P10080875A0772|125 143|NF-kappaB components
P10080875A0772|125 133|NF-kappaB
P10080875A0772|144 146|p50
P10080875A0772|144 146|p50
P10080875A0772|150 152|p65
P10080875A0772|150 152|p65
P10080875A0772|175 191|NF-kappaB proteins
P10080875A0772|175 191|NF-kappaB proteins
P10080875A0772|193 195|p52
P10080875A0772|193 195|p52
P10080875A0772|197 201|c-Rel
P10080875A0772|197 201|c-Rel
P10080875A0772|203 206|Rel B
P10080875A0772|203 206|Rel B
P10080875A0772|209 220|AP-1 proteins
P10080875A0772|209 220|AP-1 proteins
P10080875A0772|222 226|c-Fos
P10080875A0772|222 226|c-Fos
P10080875A0772|228 232|C-Jun
P10080875A0772|228 232|C-Jun
P10080875A0772|235 238|CREB
P10080875A0772|235 238|CREB
P10080875A0772|241 249|C/EBPbeta
P10080875A0772|241 249|C/EBPbeta
P10080875A0772|251 256|NF-IL6
P10080875A0772|251 256|NF-IL6
P10080901A0271|6 13|peptides
P10080901A0271|52 69|secondary structure
P10080901A0271|84 99|N-terminal domain
P10080901A0271|84 99|N-terminal domain
P10080901A0271|105 122|ribosomal protein L9
P10080901A0271|105 122|ribosomal protein L9
P10082137A0262|20 28|IFN-gamma
P10082137A0262|20 28|IFN-gamma
P10082137A0262|42 58|rapid accumulation
P10082137A0262|61 92|interferon regulated factor (IRF)-1
P10082137A0262|61 85|interferon regulated factor
P10082137A0262|87 96|IRF)-1 mRNA
P10082137A0262|109 178|delayed and dose-dependent inhibition of alpha1(I) procollagen mRNA expression
P10082137A0262|145 168|alpha1(I) procollagen mRNA
P10082137A0262|181 195|skin fibroblasts
P10082137A0262|216 221|donors
P10082554T0000|19 46|c-myc promoter binding protein 1
P10082554T0000|19 46|c-myc promoter binding protein 1
P10082554T0000|57 81|transcriptional repression
P10082554T0000|85 104|cell growth regulation
P10082570A0440|29 33|UBP43
P10082573A1015|46 59|HS2, HS3, and HS4
P10082573A1015|46 48|HS2
P10082573A1015|50 52|HS3
P10082573A1015|95 122|human globin gene transcription
P10082573A1015|95 109|human globin gene
P10082573A1015|126 136|holocomplex
P10082573A1015|186 216|DNase I hypersensitive holocomplex
P10082573A1015|186 191|DNase I
P10082573A1015|249 281|high-level globin gene transcription
P10082573A1015|259 268|globin gene
P10082585A0512|44 56|rDNA silencing
P10082585A0512|134 156|reporter genes integrated
P10082585A0512|166 169|rDNA
P10084294A0219|26 29|iron
P10084294A0219|35 68|EPO-stimulated erythroid progenitors
P10084294A0219|35 37|EPO
P10084294A0219|87 91|serum
P10084294A0219|92 113|ferritin and transferrin
P10084294A0219|92 99|ferritin
P10084294A0219|103 113|transferrin
P10085088A0918|27 36|p33 subunit
P10085088A0918|27 36|p33 subunit
P10085088A0918|39 42|eIF3
P10085088A0918|39 42|eIF3
P10085088A0918|85 100|protein synthesis
P10085088A0918|111 127|RNA-binding domain
P10085088A0918|111 127|RNA-binding domain
P10085088A0918|141 155|optimal activity
P10085120A0000|23 39|signaling pathways
P10085120A0000|49 67|photodynamic therapy
P10085120A0000|77 85|hypericin
P10085140A1004|24 28|ATF-2
P10085140A1004|24 28|ATF-2
P10085140A1004|48 64|TGF-beta signaling
P10085140A1004|48 55|TGF-beta
P10085140A1004|101 119|Smad and TAK1 pathways
P10085140A1004|101 104|Smad
P10085140A1004|108 111|TAK1
P10085383A1367|47 56|Water level
P10085605A0239|0 8|Specimens
P10085605A0239|23 39|alpha-fetoprotein
P10085605A0239|23 39|alpha-fetoprotein
P10085605A0239|53 59|estriol
P10085605A0239|61 72|free alpha hCG
P10085605A0239|65 72|alpha hCG
P10085605A0239|77 84|total hCG
P10085605A0239|82 84|hCG
P10085697T0000|28 39|Conference FY
P10086544A0504|99 107|heart rate
P10086544A0504|123 132|left atrial
P10086544A0504|182 203|arterial-central venous
P10086544A0504|204 209|oxygen
P10086544A0504|259 265|lactate
P10086544A0504|269 286|neutrophil elastase
P10086544A0504|269 286|neutrophil elastase
P10086544A0504|297 327|Doppler echocardiographic factors
P10086544A0504|367 390|left-ventricular ejection
P10086544A0504|416 429|catecholamines
P10086544A0504|431 441|epinephrine
P10086725A0000|0 8|MDS1/EVI1
P10086725A0000|0 3|MDS1
P10086725A0000|5 8|EVI1
P10086725A0000|19 36|chromosome 3 band q26
P10086725A0000|46 89|zinc-finger DNA-binding transcription activator
P10086725A0000|46 89|zinc-finger DNA-binding transcription activator
P10086725A0000|103 126|normal hematopoietic cells
P10086725A0000|148 160|normal tissues
P10087213A0878|13 28|protein sequences
P10087213A0878|39 48|replicases
P10087213A0878|93 110|plasmid replication
P10087549A0720|3 10|JTc delta
P10087549A0720|49 56|JTc delta
P10087549A0720|62 68|VT group
P10087549A0720|87 94|JTc delta
P10087549A0720|100 107|PVC group
P10087549A0720|133 140|JTc delta
P10087549A0720|146 157|control group
P10087993A0782|24 38|upstream portion
P10087993A0782|44 56|delta promoter
P10087993A0782|44 56|delta promoter
P10087993A0782|79 88|expression
P10087993A1352|0 23|Site-directed mutagenesis
P10087993A1352|44 69|repressor proteins BP1 and BP2
P10087993A1352|44 63|repressor proteins BP1
P10087993A1352|67 69|BP2
P10087993A1352|75 89|upstream portion
P10087993A1352|95 122|beta globin gene flanking region
P10087993A1352|95 122|beta globin gene flanking region
P10087993A1352|146 161|promoter activity
P10090125A0750|15 30|alpha1 antagonist
P10090125A0750|31 38|prazosin
P10090125A0750|62 71|relaxation
P10090146T0000|0 21|Differential expression
P10090146T0000|24 32|AP-2alpha
P10090146T0000|24 32|AP-2alpha
P10090146T0000|36 43|AP-2beta
P10090146T0000|36 43|AP-2beta
P10090146T0000|83 104|R-FABP promoter activity
P10090146T0000|83 96|R-FABP promoter
P10090146T0000|107 110|AP-2
P10090146T0000|107 110|AP-2
P10090535A1194|3 11|algorithm
P10090535A1194|23 24|TG
P10090535A1194|36 39|apoB
P10090535A1194|36 39|apoB
P10090535A1194|53 56|Lp(a
P10090535A1194|53 54|Lp
P10090943A1426|3 11|mean value
P10090943A1426|17 21|CD79b
P10090943A1426|17 21|CD79b
P10090943A1426|27 31|CD79b
P10090943A1426|27 31|CD79b
P10090943A1426|72 83|normal donors
P10090943A1426|102 106|B-CLL
P10090943A1976|2 13|normal B cells
P10090943A1976|51 84|CD79b posttranscriptional regulation
P10090943A1976|51 55|CD79b
P10090943A1976|120 130|normal B cell
P10090943A1976|140 151|B-CLL derives
P10091594A0284|0 20|Conformational studies
P10091594A0284|30 58|secondary structure predictions
P10091594A0284|60 61|CD
P10091594A0284|65 79|NMR spectroscopy
P10091594A0284|92 102|ELISA assays
P10091594A0284|195 203|anti-K159
P10091594A0284|195 203|anti-K159
P10091619A0104|0 24|Schwab and England ADL scores
P10091619A0104|31 39|off" state
P10092132A0285|0 14|High-level gains
P10092132A0285|16 19|HLGs
P10092132A0285|33 50|gene amplifications
P10092132A0285|67 71|11q13
P10092132A0285|101 107|2q33-34
P10092132A0285|109 115|3q25-29
P10092132A0285|117 127|5p15.1-15.2
P10092132A0285|129 149|7q21-22, 11p11.2, 12p11
P10092132A0285|159 163|13q34
P10092847A0455|30 39|active MREs
P10092847A0455|47 60|promoter region
P10092847A0455|65 75|hMT-IIA gene
P10092847A0455|65 71|hMT-IIA
P10092847A0455|101 126|mouse metallothionein-I gene
P10092847A0455|101 120|mouse metallothionein
P10092847A0455|122 126|I gene
P10092847A0455|142 155|MRE arrangement
P10092847A0455|181 195|metal regulation
P10092856A0798|3 6|cDNA
P10092856A0798|21 43|Saccharomyces cerevisiae
P10092856A0798|64 100|yeast triose phosphate isomerase promoter
P10092856A0798|64 92|yeast triose phosphate isomerase
P10094314A0935|17 28|RNA sequences
P10094314A0935|42 69|mutated zinc knuckle 9G8 variant
P10094314A0935|49 59|zinc knuckle
P10094314A0935|60 69|9G8 variant
P10094314A0935|96 100|SRp20
P10094314A0935|96 100|SRp20
P10094314A0935|131 133|RBD
P10094314A0935|136 138|9G8
P10094314A0935|136 138|9G8
P10094314A0935|142 146|SRp20
P10094314A0935|142 146|SRp20
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|34 65|protein kinase casein kinase 2 (PK CK2
P10094396A0000|34 59|protein kinase casein kinase 2
P10094396A0000|61 65|PK CK2
P10094701A0000|54 66|acetate kinase
P10094701A0000|61 66|kinase
P10094701A0000|68 71|ackA
P10094701A0000|68 71|ackA
P10094701A0000|75 95|Sinorhizobium meliloti
P10094701A0000|122 130|phosphate
P10095059A1003|41 64|wild-type HIV-1 transcript
P10095059A1003|41 54|wild-type HIV-1
P10095061A0592|0 15|Sequence analysis
P10095061A0592|31 41|MEMA protein
P10095061A0592|31 41|MEMA protein
P10095061A0592|58 77|160 kDa nuclear 'domain
P10095061A0592|84 90|serines
P10095061A0592|93 95|DRS
P10095061A0592|122 132|nucleoplasm
P10095061A0592|138 167|U2-ribonucleoprotein structures
P10095061A0592|141 167|ribonucleoprotein structures
P10095062A0558|38 66|human topoisomerase IIalpha gene
P10095062A0558|38 66|human topoisomerase IIalpha gene
P10095062A0558|83 84|35
P10095062A0558|85 89|exons
P10096469T0000|0 21|Dopaminergic modulation
P10096469T0000|24 44|transcallosal activity
P10096469T0000|47 49|cat
P10096469T0000|55 69|cortical neurons
P10096573A0207|58 97|nuclear factor (NF)-kappaB consensus element
P10096573A0207|58 70|nuclear factor
P10096573A0207|72 97|NF)-kappaB consensus element
P10096573A0207|103 129|immediate 5' regulatory region
P10096573A0207|112 129|5' regulatory region
P10096573A0207|135 152|MGSA/GRO-alpha gene
P10096573A0207|135 138|MGSA
P10096573A0207|140 152|GRO-alpha gene
P10097120T0000|30 39|mature mRNA
P10097932A0915|4 22|CsA-treated patients
P10097932A0915|52 55|UAER
P10097932A0915|73 88|microalbuminuria
P10097932A0915|106 128|placebo-treated patients
P10097932A0915|138 141|UAER
P10098601A1320|0 17|Mutational analysis
P10098601A1320|43 62|JEG-3 nuclear proteins
P10098601A1320|43 62|JEG-3 nuclear proteins
P10098601A1320|107 118|SF-1 sequence
P10098601A1320|109 118|-1 sequence
P10098744A0630|106 122|proliferation rate
P10098744A0630|178 191|tumorigenicity
P10098744A0630|193 210|cellular morphology
P10098744A0630|229 250|differentiation markers
P10099247A1051|1 13|high reactor pH
P10099247A1051|27 31|solid
P10099247A1051|166 168|SRB
P10099247A1051|171 182|outcompete MB
P10099576A0666|2 17|throttling valves
P10099576A0666|78 90|inner geometry
P10099576A0666|96 100|valve
P10100605A0392|3 25|induced respiratory burst
P10100605A0392|59 81|oxidative transformation
P10100605A0392|108 118|fluorescent
P10100605A0392|137 149|flow cytometry
P10101159A0742|1 8|mutation
P10101159A0742|20 27|SOC1 gene
P10101159A0742|20 27|SOC1 gene
P10101159A0742|78 90|cbp1 ts alleles
P10101159A0742|78 90|cbp1 ts alleles
P10101159A0742|107 119|mitochondrial
P10101159A0742|120 124|mRNAs
P10101198A0632|9 24|mutation analysis
P10101198A0632|30 47|recombinant protein
P10101198A0632|30 47|recombinant protein
P10101198A0632|63 78|N-terminal region
P10101198A0632|63 78|N-terminal region
P10101198A0632|88 101|leucine zippers
P10101198A0946|0 14|A database search
P10101198A0946|69 122|human mitochondrial transcription termination factor (mTERF
P10101198A0946|69 116|human mitochondrial transcription termination factor
P10101198A0946|118 122|mTERF
P10101198A0946|175 188|leucine zippers
P10101198A0946|196 221|intramolecular interactions
P10101744A0917|12 27|antigen challenge
P10102000A1206|10 17|patients
P10102000A1206|33 43|ERA-II group
P10102000A1206|53 65|ERA-III group)
P10102000A1206|53 59|ERA-III
P10102136A0220|16 18|PSA
P10102136A0220|16 18|PSA
P10102136A0220|34 46|all cyst fluids
P10102136A0220|62 71|female sera
P10102136A0646|0 9|Type I cysts
P10102136A0646|20 30|K+/ Na+ ratio
P10102136A0646|53 55|PSA
P10102136A0646|60 70|Type II cysts
P10102627A0217|11 28|DNA binding activity
P10102627A0217|30 49|AP-1 reporter activity
P10102627A0217|30 41|AP-1 reporter
P10103002A0705|7 25|N-glycosylation site
P10103002A0705|35 45|chicken gp42
P10103002A0705|42 45|gp42
P10103002A0705|107 110|gp42
P10103002A0705|107 110|gp42
P10103002A0705|144 154|glycan chain
P10103057A0251|51 69|140-residue fragment
P10103057A0251|84 93|Runt domain
P10103057A0251|84 93|Runt domain
P10103057A0251|96 99|AML1
P10103057A0251|96 99|AML1
P10119827T0000|5 11|OKs docs
P10120952T0000|0 26|HANYS criticizes laparoscopic
P10120952T0000|31 47|bladder guidelines
P10125354T0000|38 56|gas goes multi-source
P10132730T0000|8 26|CareNetwork gets pact
P10134977T0000|0 8|JCAHO asks
P10134977T0000|12 29|hospitals' patience
P10146207A0223|0 14|Ultrasonography
P10146207A0223|58 67|spinal cord
P10153759A0360|0 3|UPMC
P10153759A0360|46 65|NHBC organ procurement
P10171173A0955|26 68|blood transfusion-related communicable disease
P10171173A0955|73 104|acquired immune deficiency syndrome
P10171173A0955|108 112|non-A
P10171173A0955|114 127|non-B hepatitis
P10171173A0955|227 251|extracorporeal circulation
P10181397A0641|117 128|United States
P10184191T0045|0 7|Holger v.
P10187317T0000|20 34|AHERF physicians
P10187798A1098|22 26|DAP-1
P10187798A1098|22 26|DAP-1
P10187798A1098|29 35|sentrin
P10187798A1098|29 35|sentrin
P10187798A1098|53 55|TNF
P10187798A1098|66 87|L929 fibroblast cell line
P10187798A1098|97 129|TNF-resistant osteosarcoma cell line
P10187798A1098|97 99|TNF
P10187798A1098|131 134|U2OS
P10187842A1155|18 27|PPARgamma2
P10187842A1155|18 27|PPARgamma2
P10187842A1155|134 142|PPARalpha
P10187842A1155|134 142|PPARalpha
P10187864A1372|19 22|KCC3
P10187864A1372|40 48|KCC family
P10187864A1372|40 48|KCC family
P10187864A1372|82 85|KCC1
P10187864A1372|82 85|KCC1
P10190324A0000|17 27|elastin gene
P10190324A0000|17 27|elastin gene
P10190324A0000|54 80|supravalvular aortic stenosis
P10190324A0000|82 85|SVAS
P10190324A0000|92 96|large
P10190324A0000|132 139|isolated
P10190324A0000|141 157|nonsyndromic) SVAS
P10191090A0000|0 23|Spatiotemporal expression
P10191090A0000|29 36|PAX3 gene
P10191090A0000|29 36|PAX3 gene
P10192134A1088|0 7|25-OH-D3
P10192134A1088|96 104|vitamin D3
P10192134A1088|107 119|turkey rations
P10192432A0214|83 96|Italian experts
P10192638T0000|0 22|Methanesulfonyl fluoride
P10192638T0000|24 26|MSF
P10192638T0000|30 41|double-blind
P10192638T0000|43 65|placebo-controlled study
P10192638T0000|101 114|senile dementia
P10192638T0000|120 132|Alzheimer type
P10193950A0478|40 42|men
P10193950A0478|55 56|T2
P10193950A0478|59 60|T3
P10193950A0478|72 97|TNM) prostate carcinoma (bone
P10193950A0478|130 149|lymph node involvement
P10193950A0478|160 182|111In-capromab pendetide
P10194225A1132|0 20|Voluntary wheel running
P10194225A1132|57 63|alanine
P10194225A1132|66 77|pyruvate Gneo
P10194230A0817|33 36|PGE2
P10194230A0817|40 62|adenosine concentrations
P10194451A0000|45 98|constitutive p210(bcr/abl) protein tyrosine kinase activity
P10194451A0000|57 60|p210
P10194451A0000|62 64|bcr
P10194451A0000|66 68|abl
P10194451A0000|77 90|tyrosine kinase
P10194451A0000|118 156|chronic-phase chronic myelogenous leukemia
P10194451A0000|158 160|CML
P10194451A0000|200 221|relevant p210 substrates
P10194451A0000|208 211|p210
P10194451A0000|231 246|chronic-phase CML
P10194451A0000|247 274|hematopoietic progenitor cells
P10194762A0648|2 19|vitro precipitation
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|77 107|C-terminal transactivation domain
P10194762A0648|77 107|C-terminal transactivation domain
P10194762A0648|110 115|STAT5a
P10194762A0648|110 115|STAT5a
P10194762A0648|122 144|GH-regulated association
P10194762A0648|147 152|ERK1/2
P10194762A0648|147 152|ERK1/2
P10194762A0648|160 172|fusion protein
P10194762A0648|197 205|serine 780
P10194762A0648|208 213|STAT5a
P10194762A0648|208 213|STAT5a
P10194762A0648|226 232|alanine
P10194769A0146|15 16|1P
P10194769A0146|15 16|1P
P10194769A0146|41 52|rat pituitary
P10194769A0146|44 56|pituitary cDNA
P10194769A0146|53 73|cDNA expression library
P10194769A0146|80 101|417-amino acid WD protein
P10194769A0146|84 101|amino acid WD protein
P10194769A0146|113 116|PREB
P10194769A0146|113 116|PREB
P10194769A0146|118 152|PRL regulatory element binding) protein
P10194769A0146|118 152|PRL regulatory element binding) protein
P10195425T0000|21 44|transcription factor MTF-1
P10195425T0000|21 39|transcription factor
P10195425T0000|40 44|MTF-1
P10195425T0000|52 69|Japanese pufferfish
P10195425T0000|71 82|Fugu rubripes
P10195425T0000|122 140|metal stress response
P10195690A0000|3 43|peroxisome proliferator-activated receptors
P10195690A0000|3 43|peroxisome proliferator-activated receptors
P10195690A0000|45 49|PPARs
P10195690A0000|45 49|PPARs
P10195690A0000|66 98|nuclear hormone receptor superfamily
P10195690A0000|66 98|nuclear hormone receptor superfamily
P10195697A0456|8 20|F-SRC-1 mutant
P10195697A0456|10 20|SRC-1 mutant
P10195697A0456|28 48|CBP-interacting domain
P10195697A0456|28 30|CBP
P10195697A0456|63 79|enhancing activity
P10196127A1059|3 15|catalytic site
P10196127A1059|21 22|S1
P10196127A1059|47 65|hydrophobic residues
P10196127A1059|82 100|pyroglutamyl residue
P10196248A0482|19 27|TTV genome
P10196248A0482|56 70|nt (nt 3740 to 3852
P10196248A0482|93 104|3'- and 5'-end
P10196248A0482|118 123|117-nt
P10196248A0482|124 137|GC-rich stretch
P10196248A0482|139 140|GC
P10196248A0482|156 167|nt 3736 to 3852
P10196266A0000|8 24|mouse Mus castaneus
P10196266A0000|62 74|mink cell focus
P10196266A0000|85 87|MCF
P10196266A0000|99 119|murine leukemia viruses
P10196266A0000|121 125|MuLVs
P10196316A0715|24 28|VZV gK
P10196316A0715|24 28|VZV gK
P10196316A0715|31 41|virus growth
P10196316A0715|52 68|gK deletion mutants
P10196316A0715|52 68|gK deletion mutants
P10196316A0715|88 90|VZV
P10196316A0715|91 99|cosmid DNA
P10196316A0715|114 122|Oka strain
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|53 78|human papillomavirus type 6 E6
P10196318T0000|53 78|human papillomavirus type 6 E6
P10196318T0000|80 81|E7
P10196318T0000|80 81|E7
P10196318T0000|86 96|E1 promoters
P10196318T0000|86 96|E1 promoters
P10196597A0510|62 82|social characteristics
P10196597A0510|85 96|drink drivers
P10197763A0580|14 35|site-directed mutations
P10197763A0580|41 64|cyclic AMP response element
P10197763A0580|79 95|nerve growth factor
P10197763A0580|79 95|nerve growth factor
P10197985A0145|7 27|RNase H protection assay
P10197985A0145|7 12|RNase H
P10197985A0145|47 62|oligonucleotides
P10197985A0145|90 102|5' splice-site
P10197985A0145|90 102|5' splice-site
P10197985A0145|104 130|5'ss) and branchpoint sequence
P10197985A0145|104 107|5'ss
P10197985A0145|132 143|BPS) elements
P10197985A0145|146 148|U11
P10197985A0145|146 148|U11
P10197985A0145|152 160|U12 snRNPs
P10197985A0145|152 154|U12
P10197985A0145|155 160|snRNPs
P10197985A0145|226 233|pre-mRNA
P10197985A0145|255 270|complex formation
P10198003A1505|10 35|lacZ transcriptional fusions
P10198003A1505|10 35|lacZ transcriptional fusions
P10198003A1505|48 64|KdgR-binding sites
P10198003A1505|48 64|KdgR-binding sites
P10198003A1505|96 99|rsmB
P10198003A1505|96 99|rsmB
P10198056A0000|4 32|eukaryotic cell surface proteins
P10198056A0000|36 43|anchored
P10198056A0000|49 60|lipid bilayer
P10198056A0000|68 99|glycosylphosphatidylinositol (GPI
P10198061A0339|5 24|cell-free import assay
P10198061A0339|26 37|beta-catenin
P10198061A0339|26 37|beta-catenin
P10198061A0339|60 66|nucleus
P10198061A0339|77 85|exogenous
P10198061A0339|96 102|cytosol
P10198061A0339|104 106|Ran
P10198061A0339|104 106|Ran
P10198061A0339|110 113|ATP/
P10198061A0339|114 116|GTP
P10199539A1353|2 9|ischemic
P10199539A1353|13 26|hypoxic hypoxia
P10199539A1353|66 67|a3
P10199539A1353|85 87|VO2
P10199539A1353|105 118|hypoxic hypoxia
P10200473A0171|12 29|mammalian regulator
P10200473A0171|49 55|Usurpin
P10200473A0171|49 55|Usurpin
P10200473A0171|85 91|Usurpin
P10200473A0171|99 102|CASH
P10200473A0171|99 102|CASH
P10200473A0171|104 109|Casper
P10200473A0171|111 115|CLARP
P10200473A0171|111 115|CLARP
P10200473A0171|117 123|FLAME-1
P10200473A0171|117 123|FLAME-1
P10200473A0171|125 128|FLIP
P10200473A0171|125 128|FLIP
P10200473A0171|130 136|I-FLICE
P10200473A0171|132 136|FLICE
P10200473A0171|140 143|MRIT
P10200473A0171|140 143|MRIT
P10201468A0297|0 12|Plasma glucose
P10201468A0297|14 34|immunoreactive insulin
P10201468A0297|28 34|insulin
P10201468A0297|36 38|IRI
P10201468A0297|36 38|IRI
P10201468A0297|41 49|C-peptide
P10201468A0297|41 49|C-peptide
P10201468A0297|51 58|glucagon
P10201468A0297|51 58|glucagon
P10201468A0297|63 67|GLP-1
P10201468A0297|63 67|GLP-1
P10201468A0297|95 98|OGTT
P10202006A0546|4 21|recombinant product
P10202006A0546|44 50|B domain
P10202006A0546|53 74|Staphylococcal protein A
P10202006A0546|53 73|Staphylococcal protein
P10202006A0546|74 74|A
P10202006A0546|76 78|SPA
P10202006A0546|76 78|SPA
P10202006A1266|0 28|Polypyrimidine and ssDNA binding
P10202006A1266|42 49|VH domain
P10202006A1266|72 83|anti-Z-DNA Ab
P10202006A1266|72 83|anti-Z-DNA Ab
P10202006A1266|106 126|natural autoantibodies
P10202006A1266|142 160|VH-dependent binding
P10202006A1266|142 143|VH
P10202006A1266|209 222|B cell selection
P10202006A1266|245 249|Z-DNA
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|76 87|breast masses
P10205099A0377|0 12|INTERVENTIONS
P10205099A0377|19 26|patients
P10205099A0377|124 126|T12
P10205099A0377|130 132|T16
P10205099A0377|199 200|I3
P10205099A0377|204 205|I4
P10205099A0377|204 205|I4
P10205176A0000|0 15|Nuclear receptors
P10205176A0000|0 15|Nuclear receptors
P10205176A0000|17 19|NRs
P10205176A0000|17 19|NRs
P10205176A0000|70 78|mammalian
P10205176A0000|82 91|yeast cells
P10205176A0000|126 147|transcriptional control
P10205176A0000|175 183|evolution
P10205176A0704|15 43|heterologous DNA-binding domain
P10205176A0704|27 43|DNA-binding domain
P10205176A0704|45 48|PSU1
P10205176A0704|45 48|PSU1
P10205588A0000|34 41|patients
P10205588A0000|73 99|beta-haemolytic streptococci
P10205588A0000|102 117|Lancefield group A
P10205588A0000|119 125|beta HSA
P10205588A0000|119 125|beta HSA
P10205588A0000|142 164|clinical characteristics
P10205588A0000|168 186|serological features
P10205933A0699|0 7|Bacteria
P10205933A0699|53 60|inner ear
P10205933A0699|115 122|syphilis
P10205933A0699|126 133|Borrelia
P10205933A0699|168 178|Lyme Disease
P10206152A1024|67 68|G1
P10206152A1024|107 118|messenger RNA
P10206698A2041|28 43|signature-tagged
P10206698A2041|82 95|bacterial genes
P10206698A2041|131 142|urinary tract
P10206959A0368|0 5|Pathol
P10207041A0065|3 21|eukaryotic cell cycle
P10207041A0065|43 63|periodic transcription
P10207041A0065|66 76|cyclin genes
P10207041A0065|66 76|cyclin genes
P10207041A0065|83 97|protein products
P10207041A0065|135 157|cyclin-dependent kinases
P10207041A0065|135 157|cyclin-dependent kinases
P10207049A0693|3 10|GAC1 gene
P10207049A0693|3 10|GAC1 gene
P10207049A0693|21 37|regulatory subunit
P10207049A0693|42 87|type 1 serine/threonine phosphoprotein phosphatase
P10207049A0693|42 87|type 1 serine/threonine phosphoprotein phosphatase
P10207049A0693|89 92|Glc7
P10207049A0693|89 92|Glc7
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|49 69|Gac1 regulatory subunit
P10207049A1001|49 69|Gac1 regulatory subunit
P10207049A1001|89 101|HSF activation
P10207049A1001|89 91|HSF
P10207049A1001|104 120|CUP1 transcription
P10207049A1001|104 107|CUP1
P10207087A0956|0 2|MEF
P10207087A0956|0 2|MEF
P10207087A0956|6 10|AML1B
P10207087A0956|6 10|AML1B
P10207087A0956|42 82|interleukin 3 promoter reporter gene construct
P10207087A0956|42 73|interleukin 3 promoter reporter gene
P10207087A0956|90 107|activating activity
P10207087A0956|110 112|MEF
P10207087A0956|110 112|MEF
P10207087A0956|129 131|MEF
P10207087A0956|129 131|MEF
P10207087A0956|150 157|AML1/ETO
P10207087A0956|150 153|AML1
P10207087A0956|155 157|ETO
P10207090A0801|0 14|Mechanistically
P10207090A0801|32 34|GRR
P10207090A0801|68 70|p50
P10207090A0801|68 70|p50
P10207092A0924|4 18|phosphorylation
P10207092A0924|36 95|break-ended double-stranded DNA-activated protein kinase activity
P10207092A0924|47 87|double-stranded DNA-activated protein kinase
P10207092A0924|103 111|sea urchin
P10207092A0924|112 118|nucleus
P10207115A0389|0 12|Concomitantly
P10207115A0389|37 39|p21
P10207115A0389|37 39|p21
P10208865A1246|23 40|osteoclast cultures
P10208865A1246|42 48|mrIhh-N
P10208865A1246|42 48|mrIhh-N
P10208865A1246|97 109|dentine slices
P10208893A0839|38 46|genotypes
P10208893A0839|60 76|WAD goat population
P10209021A0212|3 20|molecular mechanism
P10209021A0212|28 32|Gle2p
P10209021A0212|28 32|Gle2p
P10209021A0212|39 62|Gle2p-Nup116p interaction
P10209021A0212|39 43|Gle2p
P10209021A0212|45 51|Nup116p
P10209021A0212|73 82|mRNA export
P10209031A0832|3 16|Fyn NH2 terminus
P10209031A0832|3 5|Fyn
P10209031A0832|6 16|NH2 terminus
P10209031A0832|63 66|zeta
P10209031A0832|74 82|Fyn kinase
P10209031A0832|74 82|Fyn kinase
P10209031A0832|86 95|SH2 domains
P10209031A0832|86 95|SH2 domains
P10209031A0832|118 132|phosphorylation
P10209031A0832|135 142|zeta ITAM
P10209031A0832|135 138|zeta
P10209031A0832|139 142|ITAM
P10209031A0832|143 151|tyrosines
P10209031A0832|164 171|zeta ITAM
P10209031A0832|164 167|zeta
P10209031A0832|168 171|ITAM
P10209031A0832|172 187|phosphotyrosines
P10209119A0076|2 8|budding
P10209119A0076|9 13|yeast
P10209119A0076|25 29|Skp1p
P10209119A0076|25 29|Skp1p
P10209119A0076|34 52|cullin-family member
P10209119A0076|34 52|cullin-family member
P10209119A0076|53 58|Cdc53p
P10209119A0076|53 58|Cdc53p
P10209119A0076|66 87|F-box/WD-repeat protein
P10209119A0076|66 71|F-box/
P10209119A0076|72 80|WD-repeat
P10209119A0076|88 92|Cdc4p
P10209119A0076|88 92|Cdc4p
P10209119A0076|100 107|SCFCdc4p
P10209119A0076|100 107|SCFCdc4p
P10209119A0076|108 129|ubiquitin ligase complex
P10209119A0076|108 129|ubiquitin ligase complex
P10209119A0076|146 167|cyclin-dependent kinase
P10209119A0076|146 167|cyclin-dependent kinase
P10209119A0076|169 181|Cdk) inhibitor
P10209119A0076|169 171|Cdk
P10209119A0076|182 186|Sic1p
P10209119A0076|182 186|Sic1p
P10209119A0076|190 200|proteolysis
P10209119A0594|66 81|pop1 and pop2 genes
P10209119A0594|66 69|pop1
P10209119A0594|73 81|pop2 genes
P10209119A0594|109 126|deletion phenotypes
P10209119A0594|207 217|proteolysis
P10209759T0000|0 14|Antithrombin III
P10209759T0000|0 14|Antithrombin III
P10209759T0000|32 66|intestinal ischemia reperfusion injury
P10209759T0000|69 72|rats
P10210952A0261|2 11|retrospect
P10211329A0457|27 37|serum lipase
P10211329A0457|27 37|serum lipase
P10211329A0457|41 51|serum CA 19-9
P10211329A0457|41 51|serum CA 19-9
P10211329A0457|54 70|Sjogren's syndrome
P10211329A0457|108 128|pancreatic involvement
P10211422T0000|0 16|Acute pancreatitis
P10211422T0000|34 52|polyarteritis nodosa
P10211919A0846|44 53|sertraline
P10211919A0846|98 103|Y-BOCS
P10211919A0846|172 175|NIMH
P10211919A0846|179 194|CGI Severity scale
P10212278A0387|0 29|Stress-inducible protein kinases
P10212278A0387|0 5|Stress
P10212278A0387|49 63|c-jun expression
P10212278A0387|49 53|c-jun
P10212278A0387|71 128|stress-activated protein kinase/c-Jun N-terminal protein kinase
P10212278A0387|71 99|stress-activated protein kinase
P10212278A0387|101 128|c-Jun N-terminal protein kinase
P10212278A0387|130 137|SAPK/JNK
P10212278A0387|130 133|SAPK
P10212278A0387|135 137|JNK
P10212278A0387|142 151|p38 members
P10212278A0387|142 144|p38
P10212278A0387|157 186|mitogen-activated protein kinase
P10212278A0387|157 186|mitogen-activated protein kinase
P10212278A0387|188 203|MAPK) superfamily
P10212278A0387|188 191|MAPK
P10212278A0387|206 223|signaling molecules
P10212284A0000|0 23|Transforming growth factor
P10212284A0000|0 23|Transforming growth factor
P10212284A0000|25 34|TGF)-beta1
P10212284A0000|25 34|TGF)-beta1
P10212284A0000|42 70|extracellular matrix deposition
P10212284A0000|74 86|proliferation
P10212284A0000|89 104|mesenchymal cells
P10212332T0000|0 17|Chronotherapeutics
P10212332T0000|20 40|cardiovascular disease
P10212426A1067|5 25|psychometric functions
P10212426A1067|42 52|hearing loss
P10212426A1067|73 83|performance
P10212426A1067|104 109|delta f
P10212969A0470|0 11|Uroflowmetry
P10214610A0900|0 20|Marked racial variation
P10214610A0900|23 44|birthweight percentiles
P10215485A0837|30 41|mental status
P10215485A0837|57 67|Mini-Mental
P10215485A0837|87 91|NA/mI
P10215485A0837|87 91|NA/mI
P10215485A0837|93 97|mI/Cr
P10215485A0837|93 94|mI
P10215485A0837|96 97|Cr
P10215485A0837|101 102|NA
P10215594A1728|0 7|Glucagon
P10215594A1728|0 7|Glucagon
P10215594A1728|19 29|LUC activity
P10215594A1728|19 21|LUC
P10215594A1728|49 64|CRE1 and CRE2 sites
P10215594A1728|93 123|CRE1)3(CRE2)2SV40-LUC constructs
P10215594A1728|105 123|2SV40-LUC constructs
P10215594A1728|151 153|pO2
P10215608A0161|62 69|rat GSTA3
P10215608A0161|62 69|rat GSTA3
P10215608A0161|71 89|rGST Yc1) subunit gene
P10215608A0161|71 77|rGST Yc1
P10215803T0000|0 14|Calcinosis cutis
P10215803T0000|45 60|calcium gluconate
P10215811A0635|37 47|eradication
P10215811A0635|77 79|EVL
P10215850A0754|47 60|human TrxR2 gene
P10215850A0754|47 60|human TrxR2 gene
P10215850A0754|79 83|exons
P10215850A0754|108 130|chromosomal localization
P10215850A0754|133 145|position 22q11
P10216052A0105|171 184|factor analysis
P10216052A1682|155 158|loss
P10216052A1682|165 173|mean score
P10216161A1530|20 32|cytochromes bd
P10216161A1530|115 128|two subfamilies
P10216161A1530|159 166|E. coli bd
P10216161A1530|159 166|E. coli bd
P10216161A1530|208 233|B. stearothermophilus enzyme
P10217683A0509|0 20|Canalith repositioning
P10218109T0000|8 16|structure
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218200A0534|49 85|recombinant tissue plasminogen activator
P10218200A0534|66 85|plasminogen activator
P10218357A0486|22 56|Brandt's double cuff-tubes (G2) succeed
P10218357A0486|67 86|uncontrolled increase
P10218357A0486|89 101|cuff-pressure
P10218357A0486|123 125|N2O
P10219091A0246|28 35|gene CTL1
P10219091A0246|37 72|capping enzyme RNAtriphosphatase-like 1
P10219091A0246|37 72|capping enzyme RNAtriphosphatase-like 1
P10220275A0694|12 20|PH domains
P10220275A0694|12 20|PH domains
P10220275A0694|23 32|Gbetagamma
P10220275A0694|62 71|Gbetagamma
P10220275A0694|79 87|GDP-bound
P10220275A0694|97 118|GTP-bound form of Gialpha
P10220275A0694|112 118|Gialpha
P10220364A0087|5 14|afterglows
P10220364A0087|61 70|hypernovae
P10221467T0000|0 23|Constrictive pericarditis
P10221467T0000|62 83|dopamine agonist therapy
P10221467T0000|100 117|Parkinson's disease
P10221820A0902|17 20|APBD
P10221820A0902|47 49|AMT
P10221820A0902|124 127|APBD
P10221820A0902|131 133|AMT
P10223338A1601|40 60|chimeric fusion protein
P10223338A1601|40 60|chimeric fusion protein
P10223338A1601|73 80|HIV-2 gag
P10223338A1601|73 80|HIV-2 gag
P10223338A1601|85 93|V3 domains
P10223338A1601|85 86|V3
P10223338A1601|96 104|HIV-1IIIB
P10223338A1601|96 104|HIV-1IIIB
P10223338A1601|106 112|HIV-1MN
P10223338A1601|114 121|HIV-1SF2
P10223338A1601|125 131|HIV-1RF
P10223338A1601|125 131|HIV-1RF
P10223338A2186|22 31|V3 peptides
P10223338A2186|22 31|V3 peptides
P10223338A2186|52 56|HIV-1
P10223338A2186|52 56|HIV-1
P10223338A2186|66 73|HIV-2 gag
P10223338A2186|66 73|HIV-2 gag
P10223338A2186|95 109|HIV/AIDS vaccine
P10223498A0479|0 7|Efficacy
P10223498A0479|34 42|question 3
P10223498A0479|74 82|question 4
P10223498A0479|124 141|International Index
P10223498A0479|161 164|IIEF
P10224244T0000|30 49|Glc7-Reg1 phosphatase
P10224244T0000|30 33|Glc7
P10224244T0000|35 49|Reg1 phosphatase
P10224244T0000|56 70|Snf1-Snf4 kinase
P10224244T0000|56 59|Snf1
P10224244T0000|61 64|Snf4
P10224244T0000|88 104|INO1 transcription
P10224244T0000|88 91|INO1
P10224244T0000|107 129|Saccharomyces cerevisiae
P10224257A0079|13 22|her-1 mRNAs
P10224257A0079|13 22|her-1 mRNAs
P10224257A0079|24 29|her-1a
P10224257A0079|24 29|her-1a
P10224257A0079|33 38|her-1b
P10224257A0079|36 38|-1b
P10224257A0079|69 77|promoters
P10224257A0079|79 80|P1
P10224257A0079|79 80|P1
P10224257A0079|94 110|5'-flanking region
P10224257A0079|94 110|5'-flanking region
P10224257A0079|115 116|P2
P10224257A0079|115 116|P2
P10224257A0079|130 134|large
P10224257A0079|135 146|second intron
P10224289T0000|11 29|Fas ligand expression
P10224289T0000|11 19|Fas ligand
P10224289T0000|32 34|HIV
P10224289T0000|59 61|Nef
P10224289T0000|59 61|Nef
P10224289T0000|69 90|T cell receptor zeta chain
P10224289T0000|69 90|T cell receptor zeta chain
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A0000|8 34|protein tyrosine phosphatases
P10224293A0000|36 40|RPTPs
P10224293A0000|36 40|RPTPs
P10224293A0000|91 108|phosphatase domains
P10224293A0000|128 155|putative ligand-binding motifs
P10224293A2021|23 34|brain regions
P10224293A2021|54 66|future studies
P10224293A2021|69 86|RPTP-kappa function
P10224293A2021|69 78|RPTP-kappa
P10224513A0240|24 40|mental arithmetics
P10224513A0240|57 66|Stroop test
P10224513A0240|92 101|videotapes
P10224513A0240|105 114|interviews
P10224758A0202|67 77|pregnancies
P10225279A0450|35 42|MDV2 UL54
P10225279A0450|35 42|MDV2 UL54
P10225279A0450|46 54|UL55 genes
P10225279A0450|46 49|UL55
P10225279A0450|77 79|ORF
P10225279A0450|81 85|ORF-1
P10225279A0450|81 85|ORF-1
P10225279A0450|89 110|equine herpesvirus type 1
P10225279A0450|143 159|pseudorabies virus
P10225945A0436|20 31|MAD2 staining
P10225945A0436|20 23|MAD2
P10225945A0436|34 40|meiosis
P10225945A0436|68 88|microtubule attachment
P10225945A0436|130 137|distance
P10225945A0436|178 190|meiosis I and II
P10226029A0905|2 16|epithelial cells
P10226029A0905|21 28|PH domain
P10226029A0905|21 22|PH
P10226029A0905|31 37|Akt/PKB
P10226029A0905|31 33|Akt
P10226029A0905|35 37|PKB
P10226029A0905|56 85|cell-cell and cell-matrix contact
P10226029A0905|99 111|focal contacts
P10226029A0905|131 135|serum
P10226074A0637|3 32|5' untranslated and coding regions
P10226074A0637|53 57|exons
P10226074A0637|66 85|translation start site
P10226074A0637|102 110|first exon
P10226838A1011|3 10|motility
P10226838A1011|13 17|sperm
P10226838A1011|89 91|60s
P10228009A0600|14 25|CINC promoter
P10228009A0600|14 17|CINC
P10228009A0600|28 32|IL-17
P10228009A0600|28 32|IL-17
P10228009A0600|35 44|IEC-6 cells
P10228009A0600|35 39|IEC-6
P10228009A0600|48 77|TNF receptor-associated factor-6
P10228009A0600|48 77|TNF receptor-associated factor-6
P10228009A0600|79 83|TRAF6
P10228009A0600|79 83|TRAF6
P10228009A0600|92 96|TRAF2
P10228009A0600|92 96|TRAF2
P10228155A1293|0 6|SCFFWD1
P10228155A1293|0 6|SCFFWD1
P10228155A1293|23 52|tumor development and suppression
P10228155A1293|72 83|beta-catenin
P10228155A1293|72 83|beta-catenin
P10228157T0000|1 39|Bub2p-dependent spindle checkpoint pathway
P10228157T0000|1 5|Bub2p
P10228157T0000|52 62|Dbf2p kinase
P10228157T0000|52 62|Dbf2p kinase
P10228157T0000|65 76|budding yeast
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|88 100|DNA phosphates
P10228795A0842|59 70|enteric nerve
P10228795A0842|82 84|EFS
P10228795A0842|96 98|IAS
P10229084A0000|0 32|Two-dimensional gel electrophoresis
P10229084A0000|35 45|anti-p59fyn
P10229084A0000|40 45|p59fyn
P10229084A0000|76 114|non-transformed resting human T lymphocytes
P10229084A0000|146 169|oligomeric protein complex
P10229084A0000|204 206|Fyn
P10229084A0000|204 206|Fyn
P10229084A0000|227 241|phosphoproteins
P10229084A0000|243 246|pp43
P10229084A0000|243 246|pp43
P10229084A0000|248 251|pp72
P10229084A0000|248 251|pp72
P10229084A0000|253 256|pp85
P10229084A0000|253 256|pp85
P10229084A0000|261 281|protein tyrosine kinase
P10229084A0000|261 281|protein tyrosine kinase
P10229084A0000|282 285|Pyk2
P10229084A0000|282 285|Pyk2
P10229084A0000|315 329|adaptor proteins
P10229084A0000|331 336|SKAP55
P10229084A0000|331 336|SKAP55
P10229084A0000|340 347|SLAP-130
P10229084A0000|340 347|SLAP-130
P10229668A0190|15 26|cdc33 mutants
P10229668A0190|15 26|cdc33 mutants
P10229668A0190|39 40|G1
P10229668A0560|1 13|cdc33-1 strain
P10229668A0560|1 7|cdc33-1
P10229668A0560|36 40|Cln3p
P10229668A0560|36 40|Cln3p
P10229668A0560|42 48|Cln3-1p
P10229668A0560|42 48|Cln3-1p
P10229668A0560|59 73|UBI4 5'-CLN3 mRNA
P10229668A0560|59 73|UBI4 5'-CLN3 mRNA
P10229668A0560|120 124|eIF4E
P10229668A0560|120 124|eIF4E
P10229668A0560|147 155|cell cycle
P10229682A1151|19 32|gene expression
P10229682A1151|39 85|nuclear-factor-kappaB-binding-site-like sequence
P10229682A1151|39 59|nuclear-factor-kappaB
P10229682A1151|60 85|-binding-site-like sequence
P10229682A1151|87 96|kappaB site
P10229682A1151|87 96|kappaB site
P10229682A1151|101 154|nuclear-factor-interleukin-6-binding-site-like sequence
P10229682A1151|101 114|nuclear-factor
P10229682A1151|116 154|interleukin-6-binding-site-like sequence
P10229682A1151|156 166|NF-IL-6 site
P10229682A1151|156 166|NF-IL-6 site
P10229682A1151|182 208|5'-upstream regulatory region
P10231026A0253|3 15|gene structure
P10231026A0253|18 21|Elk1
P10231026A0253|18 21|Elk1
P10231026A0253|46 68|seven exons and six introns
P10231454A0731|0 4|Total
P10231454A0731|5 16|serum calcium
P10231454A0731|49 55|calcium
P10231454A0731|102 120|alkaline phosphatase
P10231454A0731|102 120|alkaline phosphatase
P10231485A0342|0 15|Sequence analysis
P10231485A0342|28 31|TtrA
P10231485A0342|28 31|TtrA
P10231485A0342|54 72|guanine dinucleotide
P10231485A0342|85 92|[4Fe-4S]
P10231485A0342|105 108|TtrB
P10231485A0342|105 108|TtrB
P10231485A0342|118 125|[4Fe-4S]
P10231485A0342|142 145|TtrC
P10231485A0342|142 145|TtrC
P10231485A0342|150 172|integral membrane protein
P10231513T0000|26 51|granulation tissue formation
P10231513T0000|77 79|rat
P10231581A1125|0 23|Site-directed mutagenesis
P10231581A1125|45 67|SP1 sites proximal to exon 1
P10231581A1125|100 120|basal promoter activity
P10231862A1117|0 9|Breast-fed
P10231862A1117|10 23|newborn infants
P10231862A1117|47 71|polyunsaturated fatty acids
P10231862A1117|124 142|endogenous synthesis
P10231862A1117|153 187|plasma long-chain polyunsaturated pool
P10232078A0552|0 21|Ischemia and reperfusion
P10232078A0552|51 66|6-keto-PGF1 alpha
P10232078A0552|70 73|TXB2
P10232600T0000|0 23|Prostate-specific antigen
P10232600T0000|0 23|Prostate-specific antigen
P10232600T0000|25 27|PSA
P10232600T0000|25 27|PSA
P10232600T0000|44 71|androgen-inducible expression
P10232600T0000|74 94|sodium iodide symporter
P10232600T0000|97 119|prostate cancer cell lines
P10232872A0081|13 23|subclinical
P10232872A0081|33 34|CD
P10232872A0081|61 76|celiac population
P10233147A0218|0 4|Ras2p
P10233147A0218|0 4|Ras2p
P10233147A0218|44 70|downstream signaling pathways
P10233147A0218|75 118|filamentation MAPK (Cdc42p/Ste20p/MAPK) cascade
P10233147A0218|88 91|MAPK
P10233147A0218|93 98|Cdc42p
P10233147A0218|100 105|Ste20p
P10233147A0218|107 110|MAPK
P10233147A0218|124 173|cAMP-dependent protein kinase (Cyr1p/cAMP/PKA) pathway
P10233147A0218|124 150|cAMP-dependent protein kinase
P10233147A0218|152 156|Cyr1p
P10233147A0218|158 166|cAMP/PKA)
P10233885A0899|49 75|hematopoietic cell line Jurkat
P10233885A0899|113 125|mim-1 promoter
P10233885A0899|113 125|mim-1 promoter
P10233885A0899|131 133|p32
P10233885A0899|131 133|p32
P10233885A0899|137 147|p30 isoforms
P10233885A0899|137 139|p30
P10233946A0000|24 46|spleen necrosis virus (SNV
P10233946A0000|48 66|long terminal repeats
P10233946A0000|68 71|LTRs
P10233946A0000|90 92|Rex
P10233946A0000|90 92|Rex
P10233946A0000|94 136|Rex-responsive element-independent expression
P10233946A0000|94 114|Rex-responsive element
P10233946A0000|139 160|bovine leukemia virus RNA
P10233946A0000|139 160|bovine leukemia virus RNA
P10233946A0000|189 191|SNV
P10233946A0000|204 220|cis-acting element
P10233946A0000|238 261|cellular Rex-like proteins
P10233946A0000|246 261|Rex-like proteins
P10234698A0728|38 51|CNS development
P10234698A0728|62 74|animal studies
P10234698A0728|141 145|brain
P10234698A0728|150 171|hypoxia-ischemic injury
P10235265A0197|27 62|ubiquitin-dependent proteolytic system
P10235265A0197|73 105|APC-dependent proteolysis machinery
P10235265A0197|73 75|APC
P10235265A0197|118 142|mitotic (Clb) cyclin subunit
P10235265A0197|126 128|Clb
P10235265A0197|130 142|cyclin subunit
P10236651T0000|0 9|Predictors
P10236651T0000|21 34|pharmacy school
P10236651T0000|36 39|PCAT
P10240361T0000|51 60|physicians
P10243927A0000|51 70|IIT Research Institute
P10243927A0000|119 128|fire origin
P10243927A0000|162 171|toxic smoke
P10243927A0000|175 179|gases
P10271171A0458|6 10|LATCH
P10271171A0458|50 56|library
P10271171A0458|61 72|isolated unit
P10271171A0458|88 101|resource center
P10281637A0000|0 8|Reporting
P10281637A0000|11 23|adverse events
P10281637A0000|39 52|clinical trials
P10281637A0000|55 74|investigational drugs
P10304090T0000|8 25|SNF benefits revised
P10308312A0203|88 102|biological media
P10318806A0000|12 51|mitogen activated protein (MAP) kinase family
P10318806A0000|12 34|mitogen activated protein
P10318806A0000|36 51|MAP) kinase family
P10318806A0000|53 87|extracellular signal-regulated kinase
P10318806A0000|53 87|extracellular signal-regulated kinase
P10318806A0000|89 143|stress-activated protein kinase-1/c-Jun NH2-terminal kinase
P10318806A0000|89 119|stress-activated protein kinase-1
P10318806A0000|121 143|c-Jun NH2-terminal kinase
P10318806A0000|148 150|p38
P10318806A0000|148 150|p38
P10318806A0000|203 215|growth factors
P10318806A0000|217 225|cytokines
P10318806A0476|63 72|MAP kinases
P10318806A0476|63 72|MAP kinases
P10318806A0476|75 104|PDGF-mediated cellular responses
P10318806A0476|75 78|PDGF
P10318806A0918|10 24|tyrosine residue
P10318806A0918|33 45|PDGF receptors
P10318806A0918|33 36|PDGF
P10318806A0918|54 90|Src homology 2 domain-containing proteins
P10318806A0918|54 71|Src homology 2 domain
P10318806A0918|100 115|Src family kinases
P10318806A0918|100 115|Src family kinases
P10318806A0918|117 144|phosphatidylinositol 3-kinase
P10318806A0918|117 144|phosphatidylinositol 3-kinase
P10318806A0918|149 172|GTPase-activating protein
P10318806A0918|149 172|GTPase-activating protein
P10318806A0918|175 177|Ras
P10318806A0918|175 177|Ras
P10318806A0918|182 221|Src homology 2 domain-containing phosphatase
P10318806A0918|182 210|Src homology 2 domain-containing
P10318806A0918|222 226|SHP-2
P10318806A0918|222 226|SHP-2
P10318806A0918|228 247|phospholipase C-gamma
P10318806A0918|228 247|phospholipase C-gamma
P10318806A0918|252 254|Crk
P10318806A0918|288 309|PDGF-induced activation
P10318806A0918|288 291|PDGF
P10318806A0918|312 314|p38
P10318806A0918|312 314|p38
P10318859A0535|14 22|calpeptin
P10318859A0535|14 22|calpeptin
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|98 105|paxillin
P10318859A0535|98 105|paxillin
P10318900A0637|39 60|electron cryomicroscopy
P10318900A0637|86 88|Fab
P10318900A0637|90 96|8H2/G5)
P10318900A0637|90 92|8H2
P10318900A0637|94 95|G5
P10318900A0637|130 135|capsid
P10318900A0637|155 168|mRNA production
P10318918A0824|28 31|NS5A
P10318918A0824|43 59|SH3-binding region
P10318918A0824|43 59|SH3-binding region
P10318918A0824|63 79|proline-rich motif
P10318918A0824|109 117|genotypes
P10319320A1022|35 41|16K hPRL
P10319320A1022|35 41|16K hPRL
P10319320A1022|53 77|VEGF-induced Ras activation
P10319320A1022|53 56|VEGF
P10319320A1022|65 67|Ras
P10319320A1022|156 167|angiogenesis
P10319327A1237|13 49|oligonucleotide gel mobility shift assays
P10319327A1237|54 68|nuclear extracts
P10319327A1237|73 84|Sertoli cells
P10319327A1237|117 119|SRF
P10319327A1237|117 119|SRF
P10319327A1237|126 157|ubiquitously expressed bHLH protein
P10319327A1237|147 157|bHLH protein
P10319327A1237|158 160|E12
P10319327A1237|158 160|E12
P10319327A1237|162 164|E47
P10319327A1237|162 164|E47
P10319955A0941|25 42|late occlusion rates
P10319955A0941|53 67|chi-square) test
P10320177A0487|0 27|Baseline electrocorticography
P10320177A0487|47 58|temporal lobe
P10320177A0487|102 112|hippocampus
P10320177A0487|143 151|recording
P10320177A0487|171 186|v. administration
P10320480A0451|60 76|extreme C-terminus
P10320480A0451|82 92|beta subunit
P10320480A0451|82 92|beta subunit
P10320480A0451|95 113|E. coli RNA polymerase
P10320480A0451|95 100|E. coli
P10320480A0451|101 113|RNA polymerase
P10320579A1831|13 16|FlgN
P10320579A1831|13 16|FlgN
P10320579A1831|20 23|FliT
P10320579A1831|20 23|FliT
P10320579A1831|75 89|oligomerization
P10320579A1831|95 98|HAPs
P10320579A1831|95 98|HAPs
P10320579A1831|115 128|helical domains
P10321158T0000|7 21|core fabrication
P10321158T0000|25 39|divergent canals
P10321158T0000|64 81|prefabricated dowel
P10322022A0263|0 20|Rep63A (513 amino acids [
P10322022A0263|0 9|Rep63A (513
P10322022A0263|45 47|ORF
P10322022A0263|123 130|pAMbeta1
P10322022A0263|132 137|pIP501
P10322022A0263|142 149|pSM19035
P10322022A0263|168 180|pAW63 replicon
P10322022A0263|193 206|pAMbeta1 family
P10322022A0263|209 212|gram
P10322022A0263|239 246|plasmids
P10322629A0198|43 54|Xenopus Pax-5
P10322629A0198|43 49|Xenopus
P10322629A0198|50 54|Pax-5
P10322629A0198|58 62|Pax-8
P10322629A0198|58 62|Pax-8
P10322629A0198|83 101|Pax-2/5/8 gene family
P10322629A0198|83 87|Pax-2
P10322629A0198|89 95|5/8 gene
P10323225A0244|0 7|Km values
P10323225A0244|11 33|ammonium, 2-oxoglutarate
P10323225A0244|35 38|NADH
P10323225A0244|52 55|NAD+
P10323225A0244|64 66|3.5
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|29 74|cryoblobulinemia-related ischemic manifestations
P10323463T0000a|114 136|anti-angiogenic activity
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|29 74|cryoblobulinemia-related ischemic manifestations
P10323463T0000b|114 136|anti-angiogenic activity
P10323863A0852|49 69|recombinant telomerase
P10323863A0852|49 69|recombinant telomerase
P10323863A0852|87 110|rabbit reticulocyte lysate
P10323863A0852|123 147|ribonucleoprotein assembly
P10325413A1211|20 24|c-Abl
P10325413A1211|20 24|c-Abl
P10325413A1211|27 29|DNA
P10325413A1211|42 63|methylcytosine residues
P10325413A1211|103 113|double helix
P10325413A1211|143 166|protein-induced reduction
P10325413A1211|172 194|base stacking interaction
P10326221A0531|0 17|Homozygous mutation
P10326221A0531|48 51|legs
P10326221A0531|57 72|purpura fulminans
P10326654A0351|60 65|global
P10326654A0351|73 80|ischemia
P10326654A0351|172 194|ventricular fibrillation
P10326654A0351|196 197|VF
P10326654A0351|222 232|arrhythmias
P10326654A0351|277 278|VF
P10326654A0351|335 342|ischemia
P10326856T0000|40 67|mechanical purse-string device
P10327051A0688|27 63|Stress-Activated-Protein-Kinase (SAPK)
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10327051A0688|59 62|SAPK
P10327051A0688|77 80|ATF2
P10327051A0688|77 80|ATF2
P10327051A0688|82 86|Thr69
P10327051A0688|90 94|Thr71
P10327051A0688|129 141|p300/CBP-ATF2
P10327051A0688|129 132|p300
P10327051A0688|134 136|CBP
P10327051A0688|138 141|ATF2
P10327051A0688|142 160|multiprotein complex
P10328351A0443|0 11|Blood samples
P10329135A1326|23 35|mitochondrial
P10329135A1326|63 70|mt-hsp70
P10329135A1326|66 70|hsp70
P10329135A1326|84 109|mitochondrial protein import
P10329566A0610|3 12|3' terminus
P10329566A0610|40 66|tRNA-like secondary structure
P10329566A0610|75 80|valine
P10329566A0610|94 111|tRNA-like structure
P10329566A0610|94 111|tRNA-like structure
P10329566A0610|133 145|aminoacyl stem
P10329566A0610|175 186|tetraviruses
P10329574A1733|0 15|O. novo-ulmi RNA-7
P10329574A1733|0 0|O
P10329574A1733|11 15|RNA-7
P10329574A1733|40 56|satellite-like RNA
P10329574A1733|94 105|OnuMV4-Ld RNA
P10329586A0414|12 22|fibronectin
P10329586A0414|12 22|fibronectin
P10329586A0414|24 25|FN
P10329586A0414|24 25|FN
P10329586A0414|62 73|LNCaP-r cells
P10329586A0414|123 124|FN
P10329586A0414|123 124|FN
P10329586A0414|127 140|prostate cancer
P10329625A0715|18 51|cell surface CD4(-)CD8(-)CD3(-) cells
P10329625A0715|29 34|CD4(-)
P10329625A0715|35 43|CD8(-)CD3
P10329625A0715|56 73|rearranged TCR genes
P10329625A0715|66 68|TCR
P10329625A0715|87 100|Id3-transduced
P10329625A0715|87 89|Id3
P10329625A0715|111 138|control-transduced pre-T cells
P10329625A0715|143 146|FTOC
P10329736A0681|23 43|yeast two-hybrid system
P10329736A0681|45 49|mIRS3
P10329736A0681|45 49|mIRS3
P10329736A0681|68 77|p85 subunit
P10329736A0681|68 77|p85 subunit
P10329736A0681|80 107|phosphatidylinositol 3-kinase
P10329736A0681|80 107|phosphatidylinositol 3-kinase
P10329736A1106|0 6|Insulin
P10329736A1106|42 46|mIRS3
P10329736A1106|42 46|mIRS3
P10329736A1106|51 53|p85
P10329736A1106|51 53|p85
P10329736A1106|55 58|SHP2
P10329736A1106|55 58|SHP2
P10329736A1106|60 62|Nck
P10329736A1106|67 69|Shc
P10329736A1106|67 69|Shc
P10330134A0765|3 16|mRNA expression
P10330134A0765|19 22|RFX1
P10330134A0765|19 22|RFX1
P10330134A0765|24 27|RFX2
P10330134A0765|24 27|RFX2
P10330134A0765|32 35|RFX3
P10330134A0765|32 35|RFX3
P10330134A0765|65 92|transient-transfection assays
P10330134A0765|94 105|multimerized
P10330134A0765|106 120|RFX binding sites
P10330134A0765|106 120|RFX binding sites
P10330134A0765|131 143|basal promoter
P10330134A0765|168 199|tissue- and lineage-specific manner
P10330146A0730|14 31|unspliceable intron
P10330146A0730|45 64|luciferase expression
P10330146A0730|45 54|luciferase
P10330146A0730|82 102|AUF1-binding sequences
P10330146A0730|82 102|AUF1-binding sequences
P10330146A0730|109 128|luciferase expression
P10330146A0730|109 118|luciferase
P10330159A1258|5 7|VDR
P10330159A1258|5 7|VDR
P10330159A1258|68 84|promoter/enhancer
P10330159A1258|100 104|NFAT1
P10330159A1258|100 104|NFAT1
P10330159A1258|120 132|composite site
P10330159A1258|161 167|Jun-Fos
P10330159A1258|161 167|Jun-Fos
P10330168A0135|26 32|kinases
P10330168A0135|37 43|cyclin B
P10330168A0135|37 43|cyclin B
P10330168A0135|45 82|Clb)/cyclin-dependent kinase (Cdk/Cdc28p
P10330168A0135|45 47|Clb
P10330168A0135|50 71|cyclin-dependent kinase
P10330168A0135|73 75|Cdk
P10330168A0135|77 82|Cdc28p
P10330168A0135|87 91|Cdc7p
P10330168A0135|87 91|Cdc7p
P10330168A0135|104 120|interacting factor
P10330168A0135|121 125|Dbf4p
P10330168A0135|121 125|Dbf4p
P10330168A0135|144 145|G1
P10330168A0135|156 169|DNA replication
P10330396A0387|3 22|RanQ69L preincubation
P10330396A0387|3 9|RanQ69L
P10330396A0387|44 47|CRM1
P10330396A0387|44 47|CRM1
P10330396A0387|53 72|cytoplasmic periphery
P10330396A0387|78 95|nuclear pore complex
P10330396A0387|78 95|nuclear pore complex
P10330396A0387|97 99|NPC
P10330396A0387|97 99|NPC
P10330396A0387|121 130|p62 complex
P10330396A0387|121 123|p62
P10330396A0387|134 136|Can
P10330396A0387|138 143|Nup214
P10331276A0298|8 15|elements
P10331646A0595|21 37|amino acid sequence
P10331646A0595|54 57|ART5
P10331646A0595|54 57|ART5
P10331646A0595|84 102|murine lymphoma cells
P10331646A0595|132 137|testis
P10331646A0595|148 171|hydrophobic amino terminus
P10331646A0595|188 201|signal sequence
P10331646A0595|212 236|hydrophobic signal sequence
P10331646A0595|242 257|carboxyl terminus
P10331730A0504|62 64|646
P10331730A0504|75 78|1591
P10331730A0504|79 86|patients
P10331875A0523|4 17|dimer interface
P10331875A0523|51 72|DNA-binding specificity
P10331875A0523|103 105|HSF
P10331875A0523|103 105|HSF
P10332733A0000|3 21|paramyxovirus fusion
P10332733A0000|23 31|F) protein
P10332733A0000|40 53|membrane fusion
P10333481A1102|34 60|UCP2 promoter-PLAP constructs
P10333481A1102|34 45|UCP2 promoter
P10333481A1102|47 50|PLAP
P10333481A1102|103 118|promoter activity
P10333481A1102|136 140|nt -33
P10333481A1102|163 170|enhancer
P10333481A1102|197 213|5'-promoter region
P10333481A1102|197 207|5'-promoter
P10333526A0459|3 11|hTERT gene
P10333526A0459|3 7|hTERT
P10333526A0459|31 34|37kb
P10333526A0459|48 54|16 exons
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|18 28|Abeta levels
P10333529A0277|18 22|Abeta
P10334888A0960|0 13|In reperfusion B
P10334888A0960|22 34|diabetic group
P10334888A0960|69 86|IL-8 concentrations
P10334888A0960|69 72|IL-8
P10336495A0547|4 13|repression
P10336495A0547|91 94|NCoR
P10336495A0547|91 94|NCoR
P10336495A0547|98 106|PPARalpha
P10336495A0547|98 106|PPARalpha
P10336495A0547|108 137|RXRalpha heterodimeric complexes
P10336495A0547|108 115|RXRalpha
P10336495A0547|140 153|mammalian cells
P10339552A0361|28 37|SRm160/300
P10339552A0361|28 37|SRm160/300
P10339552A0361|52 65|purine-rich ESE
P10339552A0361|111 133|Drosophila doublesex gene
P10339552A0361|111 133|Drosophila doublesex gene
P10339566A0602|0 5|Spc42p
P10339566A0602|0 5|Spc42p
P10339566A0602|38 61|cytoplasmic SPB subcomplex
P10339566A0602|72 83|Spc94p/Nud1p
P10339566A0602|72 77|Spc94p
P10339566A0602|79 83|Nud1p
P10339566A0602|85 90|Cnm67p
P10339566A0602|85 90|Cnm67p
P10339566A0602|95 100|Spc42p
P10339566A0602|95 100|Spc42p
P10340447A0424|60 62|QMF
P10340447A0424|69 77|QIT system
P10340883A1266|14 22|stage IIIB
P10341219A0481|12 23|heparin lyase
P10341219A0481|12 23|heparin lyase
P10341219A0481|35 42|extracts
P10341219A0481|60 86|recombinant YD-repeat protein
P10341219A0481|60 70|recombinant
P10341219A0481|71 86|YD-repeat protein
P10342511A0909|30 31|r2
P10342511A0909|43 48|scores
P10342511A0909|59 68|0.56 to 0.61
P10342536A0954|73 81|RAST/EAST
P10342536A0954|105 113|cow's milk
P10342536A0954|147 157|whey formula
P10342536A0954|178 195|whey/casein formula
P10342536A0954|183 188|casein
P10342536A0954|197 219|soy/pork collagen formula
P10342536A0954|197 212|soy/pork collagen
P10342536A0954|227 242|amino acid formula
P10342829A0236|24 28|GnRHR
P10342829A0236|24 28|GnRHR
P10342829A0236|65 89|transcriptional regulation
P10342829A0236|95 116|human GnRHR (hGnRHR) gene
P10342829A0236|95 104|human GnRHR
P10342829A0236|106 111|hGnRHR
P10342829A0236|147 163|human reproduction
P10342829A1370|0 29|Competitive mobility shift assays
P10342829A1370|41 49|alphaT3-1
P10342829A1370|50 63|nuclear extract
P10342829A1370|66 87|recombinant SF-1 protein
P10342829A1370|77 80|SF-1
P10342829A1370|108 111|SF-1
P10342829A1370|108 111|SF-1
P10342829A1370|148 150|GSE
P10342829A1370|170 173|-134
P10343189A0911|0 14|Grade 3 mucositis
P10344736A0796|0 19|CDK4 kinase activities
P10344736A0796|0 9|CDK4 kinase
P10344736A0796|55 66|CDK inhibitor
P10344736A0796|55 57|CDK
P10344736A0796|67 73|p21Cip1
P10344736A0796|67 73|p21Cip1
P10344736A0796|83 104|cyclin E immunocomplexes
P10344736A0796|83 104|cyclin E immunocomplexes
P10347144A0516|14 28|purified protein
P10347144A0516|43 59|baculovirus system
P10347144A0516|98 119|amino-terminal sequence
P10347144A0516|122 126|AVQGP
P10347197A0502|14 30|urokinase promoter
P10347197A0502|14 30|urokinase promoter
P10347197A0502|33 38|HGF/SF
P10347197A0502|33 35|HGF
P10347197A0502|37 38|SF
P10347197A0502|45 55|Met receptor
P10347197A0502|45 55|Met receptor
P10347197A0502|101 104|Grb2
P10347197A0502|101 104|Grb2
P10347197A0502|108 130|Sos1 expression construct
P10347197A0502|108 111|Sos1
P10347203A0832|0 20|Serine phosphorylation
P10347203A0832|23 27|STAT3
P10347203A0832|23 27|STAT3
P10347203A0832|48 68|somatostatin treatment
P10347203A0832|48 59|somatostatin
P10347203A0832|86 99|pertussis toxin
P10347203A0832|86 99|pertussis toxin
P10347203A0832|102 108|PD 98059
P10347203A0832|146 158|proliferation
P10347220A1477|59 74|capping apparatus
P10347220A1477|88 113|RNA 5'-triphosphatase (Cet1p
P10347220A1477|88 107|RNA 5'-triphosphatase
P10347220A1477|109 113|Cet1p
P10347220A1477|116 143|RNA guanylyltransferase (Ceg1p
P10347220A1477|116 137|RNA guanylyltransferase
P10347220A1477|139 143|Ceg1p
P10347220A1477|149 153|Abd1p
P10347220A1477|149 153|Abd1p
P10347220A1477|193 210|mammalian apparatus
P10347220A1477|236 274|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|236 274|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|281 311|methyltransferase Hcm1(121-476)p
P10347220A1477|281 309|methyltransferase Hcm1(121-476
P10347839A0434|3 12|IC50 values
P10347839A0434|16 18|rat
P10347839A0434|32 38|bladder
P10348859A0292|25 36|binding sites
P10348859A0292|41 52|purified MerR
P10348859A0292|49 61|MerR homodimer
P10348859A0292|74 82|Hg(II) ion
P10348859A0292|93 97|Cys82
P10348859A0292|115 120|Cys117
P10348859A0292|124 129|Cys126
P10349084T0000|14 30|Epstein-Barr virus
P10349084T0000|71 84|immune globulin
P10349084T0000|71 84|immune globulin
P10349084T0000|87 94|children
P10349084T0000|99 127|immune thrombocytopenic purpura
P10349443A0358|15 30|lab and field tests
P10350027A0942|42 52|psychomotor
P10350454A0000|0 3|MutY
P10350454A0000|0 3|MutY
P10350454A0000|8 29|adenine-DNA glycosylase
P10350454A0000|8 29|adenine-DNA glycosylase
P10350454A0000|48 57|mismatches
P10350454A0000|67 78|8-oxoguanine
P10350454A0000|80 81|oG
P10350454A0000|87 97|guanine (G.A
P10350454A0000|87 95|guanine (G
P10350484A0346|3 26|kinetics of kinase activity
P10350484A0346|57 60|CheA
P10350484A0346|57 60|CheA
P10350484A0346|104 105|KM
P10350484A0346|109 111|ATP
P10350484A0346|137 140|Vmax
P10350638A0000|0 6|Latexin
P10350638A0000|0 6|Latexin
P10350638A0000|9 34|carboxypeptidase A inhibitor
P10350638A0000|9 25|carboxypeptidase A
P10350638A0000|50 72|cell type-specific manner
P10350638A0000|89 112|peripheral nervous systems
P10350638A0000|118 120|rat
P10353073A0118|58 71|minimal overlap
P10353880A0257|54 60|infants
P10353880A0257|96 98|HSV
P10355085A1119|0 6|Subsets
P10355085A1119|9 16|patients
P10355085A1119|54 59|trauma
P10355085A1119|67 67|9
P10355085A1119|93 114|different injury pattern
P10357751A0866|17 32|infected children
P10357751A0866|60 65|weight
P10357751A0866|72 74|FFM
P10357751A0866|122 126|death
P10357751A0866|128 139|relative risk
P10357751A0866|201 208|children
P10357751A0866|223 229|disease
P10357751A0866|309 309|[
P10357751A0866|310 312|4.6
P10358031A0303|48 53|nuclei
P10358031A0303|78 92|nuclear division
P10358031A0303|109 119|cytokinesis
P10358031A0303|126 139|cell separation
P10358075A0984|0 4|DAF16
P10358075A0984|0 4|DAF16
P10358075A0984|29 44|signaling pathway
P10358075A0984|111 131|insulin/IGF-1 receptor
P10358075A0984|111 117|insulin
P10358075A0984|119 131|IGF-1 receptor
P10358075A0984|133 146|PtdIns 3-kinase
P10358075A0984|133 146|PtdIns 3-kinase
P10358075A0984|150 152|PKB
P10358075A0984|150 152|PKB
P10358079A0391|8 10|neu
P10358079A0391|11 51|differentiation factor-induced heterodimers
P10358079A0391|54 58|ErbB2
P10358079A0391|54 58|ErbB2
P10358079A0391|62 66|ErbB4
P10358079A0391|62 66|ErbB4
P10358079A0391|76 80|Stat5
P10358079A0391|76 80|Stat5
P10358080A1114|61 81|DNA binding specificity
P10358080A1114|107 115|human HSF1
P10358080A1114|107 111|human
P10358080A1114|112 115|HSF1
P10358080A1114|146 167|HSF1 binding preferences
P10358080A1114|146 149|HSF1
P10358080A1114|214 224|HSF1 monomer
P10358080A1114|214 217|HSF1
P10358080T0000|12 31|human heat shock factor
P10358080T0000|12 31|human heat shock factor
P10358080T0000|50 61|linker domain
P10358083A0263|4 21|functional analyses
P10358083A0263|57 63|F9 cells
P10358083A0263|85 104|DNA-protein complexes
P10358083A0263|85 95|DNA-protein
P10358083A0263|129 142|sequence motifs
P10358083A0263|143 148|GTGACT
P10358083A0263|153 157|ATTGT
P10358083A0263|162 165|GATA
P10358083A0263|174 192|transcription factor
P10358083A0263|193 204|binding sites
P10358138A0672|37 39|XLP
P10358138A0672|85 88|SLAM
P10358138A0672|85 88|SLAM
P10358138A0672|133 135|SAP
P10358138A0672|133 135|SAP
P10358138A0672|139 161|signaling adaptor protein
P10359014A1077|18 22|Fra-2
P10359014A1077|18 22|Fra-2
P10359014A1077|23 42|phosphorylation sites
P10359014A1077|45 48|MAPK
P10359014A1077|45 48|MAPK
P10359014A1077|56 64|threonine
P10359014A1077|73 86|serine residues
P10359014A1077|92 110|COOH-terminal region
P10359014A1077|120 143|site-directed mutagenesis
P10359014A1077|160 176|threonine residues
P10359014A1077|198 201|MAPK
P10359014A1077|198 201|MAPK
P10359575A0317|46 54|FcalphaRI
P10359575A0317|46 54|FcalphaRI
P10359575A0317|65 72|IgA (hIgA
P10359575A0317|65 67|IgA
P10359575A0317|69 72|hIgA
P10359575A0317|80 89|bovine IgG2
P10359575A0317|80 89|bovine IgG2
P10359575A0317|91 95|bIgG2
P10359575A0317|91 95|bIgG2
P10359575A0317|105 114|bFcgamma2R
P10359575A0317|105 114|bFcgamma2R
P10359575A0317|120 124|bIgG2
P10359575A0317|120 124|bIgG2
P10359575A0317|131 134|hIgA
P10359575A0317|131 134|hIgA
P10359603A0430|0 4|Vac1p
P10359603A0430|0 4|Vac1p
P10359603A0430|22 35|Sec1p homologue
P10359603A0430|22 35|Sec1p homologue
P10359603A0430|36 41|Vps45p
P10359603A0430|36 41|Vps45p
P10359663A0425|15 35|transcriptional system
P10359663A0425|46 60|upstream regions
P10359663A0425|63 69|oIFNtau
P10359663A0425|63 69|oIFNtau
P10359663A0425|91 117|simian virus 40 (SV40) promoter
P10359663A0425|91 103|simian virus 40
P10359663A0425|105 117|SV40) promoter
P10359663A0425|141 151|-654 and -555
P10359663A0425|176 189|enhancer region
P10359663A0425|201 231|oIFNtau-SV40-CAT transactivation
P10359663A0425|201 207|oIFNtau
P10359663A0425|209 216|SV40-CAT
P10359663A1280|2 23|co-transfection studies
P10359663A1280|40 44|c-Jun
P10359663A1280|40 44|c-Jun
P10359663A1280|49 53|c-Fos
P10359663A1280|49 53|c-Fos
P10359663A1280|82 92|oIFNtau-CAT
P10359663A1280|82 88|oIFNtau
P10359663A1280|90 92|CAT
P10359663A1280|111 116|GATA-1
P10359663A1280|111 116|GATA-1
P10359663A1280|118 123|GATA-2
P10359663A1280|118 123|GATA-2
P10359663A1280|126 131|GATA-3
P10359663A1280|126 131|GATA-3
P10359664A0579|21 24|Cdk2
P10359664A0579|40 45|MARCKS
P10359664A0579|40 45|MARCKS
P10359664A0579|61 77|lysyl endoprotease
P10359664A0579|61 77|lysyl endoprotease
P10359664A0579|103 104|MS
P10359673A0000|3 15|yeast LPD1 gene
P10359673A0000|3 11|yeast LPD1
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|76 96|amino acid biosynthesis
P10359673A0000|110 113|GCN4
P10359673A0000|110 113|GCN4
P10359673A0000|114 132|transcription factor
P10359792A0610|34 44|Rpd3 mutants
P10359792A0610|34 37|Rpd3
P10359792A0610|77 83|Groucho
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|153 171|histone deacetylases
P10359792A0610|153 171|histone deacetylases
P10360454A0916|16 20|TNF-a
P10360454A0916|58 65|patients
P10360454A0916|75 88|pentoxifylline
P10360454A0916|152 163|control group
P10360839A1338|69 87|KRAB zinc finger genes
P10360839A1338|69 87|KRAB zinc finger genes
P10360839A1338|110 134|hematopoietic cell lineages
P10360947A1113|9 32|fluorescence spectroscopy
P10360947A1113|84 88|ALG-2
P10360947A1113|84 88|ALG-2
P10360947A1113|107 127|conformational changes
P10360947A1113|137 166|N-terminal and C-terminal domains
P10360947A1113|137 166|N-terminal and C-terminal domains
P10361038A0281|36 44|promoters
P10361038A0281|59 79|ribosomal protein genes
P10361038A0281|59 79|ribosomal protein genes
P10362652A0350|4 12|carbachol
P10362652A0350|27 29|EGF
P10362652A0350|27 29|EGF
P10362652A0350|43 55|Ras activation
P10362652A0350|43 45|Ras
P10362652A1456|16 18|Sos
P10362652A1456|31 50|carbachol stimulation
P10362652A1456|53 54|HA
P10362652A1456|53 54|HA
P10362652A1456|56 59|ERK2
P10362652A1456|56 59|ERK2
P10362652A1456|94 96|EGF
P10362652A1456|94 96|EGF
P10363517A0401|48 62|ultrasonography
P10364076A0429|27 42|E-box palindromic
P10364076A0429|45 62|direct repeat motifs
P10364076A0429|70 76|SREBP-1
P10364076A0429|70 76|SREBP-1
P10364159A0813|36 51|FRAP/mTOR protein
P10364159A0813|36 39|FRAP
P10364159A0813|41 44|mTOR
P10364159A0813|56 64|FRAP/mTOR
P10364159A0813|56 59|FRAP
P10364159A0813|61 64|mTOR
P10364159A0813|96 114|in vitro kinase assays
P10364159A0813|130 135|4E-BP1
P10364159A0813|130 135|4E-BP1
P10364163A0092|0 2|Hrs
P10364163A0092|0 2|Hrs
P10364163A0092|7 16|FYVE double
P10364163A0092|17 32|zinc finger domain
P10364163A0092|56 77|phosphatidylinositol(3
P10364163A0092|56 75|phosphatidylinositol
P10364163A0092|77 88|3)-phosphate
P10364202A0646|17 47|full-length expression constructs
P10364202A0646|55 57|DBP
P10364202A0646|55 57|DBP
P10364202A0646|61 81|hepatic leukemia factor
P10364202A0646|61 81|hepatic leukemia factor
P10364202A0646|134 155|GAL4-DBP fusion proteins
P10364202A0646|134 137|GAL4
P10364202A0646|139 155|DBP fusion proteins
P10364202A0646|184 203|regulated coactivator
P10364314A0919|5 14|subgenomes
P10364314A0919|59 64|5' part
P10364314A0919|70 76|NS2 gene
P10364314A0919|70 76|NS2 gene
P10364319A0109|0 1|Cp
P10364319A0109|0 1|Cp
P10364319A0109|15 26|main promoter
P10364319A0109|30 47|EBNA mRNA initiation
P10364319A0109|30 37|EBNA mRNA
P10364319A0109|64 69|EBNA3C
P10364319A0109|64 69|EBNA3C
P10364319A0109|84 116|negative autoregulatory control loop
P10364425A0610|53 63|tyrosine 118
P10364425A0610|104 108|STAT3
P10364425A0610|104 108|STAT3
P10364523A0826|44 48|exons
P10364523A0826|56 64|YAC 946E12
P10364523T0000|0 18|Campomelic dysplasia
P10364523T0000|72 75|SOX9
P10364523T0000|72 75|SOX9
P10365883A1355|33 40|patients
P10365883A1355|92 112|enterococcal infection
P10366446A0893|19 27|conserved
P10366446A0893|90 95|FLI LRR
P10366446A0893|90 95|FLI LRR
P10366503A0812|0 16|Binding affinities
P10366503A0812|24 40|recombinant phages
P10366503A0812|83 89|His-tag
P10366503A0812|101 110|gp17 column
P10366503A0812|101 104|gp17
P10366503A0812|151 159|terminase
P10366503A0812|191 231|portal protein and terminase interaction sites
P10366503A0812|191 203|portal protein
P10366503A0812|207 215|terminase
P10366503A1506|11 19|terminase
P10366503A1506|47 63|gp20 portal peptide
P10366503A1506|47 63|gp20 portal peptide
P10366503A1506|93 105|portal peptide
P10366503A1506|134 148|native structure
P10366503A1506|181 184|gp20
P10366503A1506|181 184|gp20
P10366503A1506|188 191|gp17
P10366503A1506|188 191|gp17
P10366503A1506|212 227|terminase regions
P10366503A1506|248 263|packasome complex
P10366559A0605|9 15|viruses
P10366559A0605|59 64|plants
P10366559A0605|78 84|virions
P10366722T0000|0 3|cDNA
P10366722T0000|34 42|gene Pole1
P10366722T0000|34 42|gene Pole1
P10366722T0000|49 73|mouse DNA polymerase epsilon
P10366722T0000|54 73|DNA polymerase epsilon
P10366722T0000|74 89|catalytic subunit
P10367240A1354|12 27|cryopreservation
P10367240A1354|67 68|SP
P10367240A1354|212 225|sperm injection
P10367385A0000|7 27|chromatographic method
P10367385A0000|52 64|beta-carotene
P10367460A0191|3 16|FCMS conditions
P10367460A0191|32 33|kW
P10367460A0191|68 71|800 V
P10367460A0191|99 120|microseconds pulsewidth
P10367646A0569|0 14|Severe hemolysis
P10367646A0569|123 145|alanine aminotransferase
P10367646A0569|123 145|alanine aminotransferase
P10367646A0569|147 153|calcium
P10367646A0569|158 171|serum globulins
P10367646A0569|158 171|serum globulins
P10367646A0569|184 190|albumin
P10367646A0569|184 190|albumin
P10369418A0644|0 3|EMSA
P10369418A0644|59 63|CD40L
P10369418A0644|59 63|CD40L
P10369418A0644|87 104|NF-kappaB complexes
P10369418A0644|87 95|NF-kappaB
P10369418A0644|129 142|NF-kappaB sites
P10369418A0644|129 142|NF-kappaB sites
P10369418A0644|165 167|p50
P10369418A0644|165 167|p50
P10369418A0644|171 174|RelB
P10369418A0644|171 174|RelB
P10369418A0644|190 194|c-Rel
P10369418A0644|190 194|c-Rel
P10369418A0644|198 200|p65
P10369418A0644|198 200|p65
P10369625A0942|19 21|ODA
P10369757A0000|39 56|arginine metabolism
P10369757A0000|59 92|Escherichia coli and Bacillus subtilis
P10369757A0000|59 73|Escherichia coli
P10369757A0000|77 92|Bacillus subtilis
P10369757A0000|94 97|ArgR
P10369757A0000|94 97|ArgR
P10369757A0000|101 104|AhrC
P10369757A0000|101 104|AhrC
P10369757A0000|160 167|arginine
P10369757A0000|235 251|biosynthetic genes
P10369757A0000|284 297|catabolic genes
P10369757A0000|299 302|AhrC
P10369757A0000|299 302|AhrC
P10369775A0178|10 25|protein fragments
P10369775A0178|35 55|residues Arg183-His267
P10369775A0178|61 67|human ER
P10369775A0178|61 67|human ER
P10369775A0178|71 91|residues Lys438-Gln520
P10369775A0178|97 101|rat GR
P10369926A0251|3 22|exon:intron structure
P10369926A0251|25 34|chicken IL8
P10369926A0251|25 34|chicken IL8
P10369926A0251|67 74|human IL8
P10369926A0251|67 74|human IL8
P10369926A0251|106 131|mammalian CXC chemokine genes
P10369926A0251|115 126|CXC chemokine
P10369965A0000|3 13|Aa-Pri2 gene
P10369965A0000|3 13|Aa-Pri2 gene
P10369965A0000|42 67|basidiocarp differentiation
P10369965A0000|81 96|Agrocybe aegerita
P10370675A0649|15 26|liver disease
P10370675A0649|32 39|patients
P10370675A0649|44 46|HCC
P10370675A0649|51 65|hepatitis C virus
P10370675A0649|67 69|HCV
P10370675A0649|77 88|alcohol abuse
P10370675A0649|114 131|HCV and alcohol abuse
P10370778A0000|8 26|aromatase inhibitors
P10370778A0000|8 16|aromatase
P10370778A0000|79 100|metastatic breast cancer
P10370778A0000|103 122|post-menopausal women
P10370778A0000|155 163|tamoxifen
P10370778A0000|184 191|ARIMIDEX
P10370778A0000|193 198|Zeneca
P10370778A0000|201 209|letrozole
P10370778A0000|211 216|FEMARA
P10370778A0000|218 225|Novartis
P10370778A0000|230 237|vorozole
P10370778A0000|239 245|RIVIZOR
P10370778A0000|247 253|Janssen
P10371097A0963|38 54|asthmatic patients
P10371097A0963|56 63|training
P10371097A0963|138 148|Turbuhaler.
P10373029A0204|3 20|femoral artery/vein
P10373029A0204|70 95|healthy human male volunteers
P10373507A0680|0 8|SRFDelta5
P10373507A0680|0 8|SRFDelta5
P10373507A0680|34 65|dominant negative regulatory mutant
P10373507A0680|76 107|SRF-dependent skeletal alpha-actin
P10373507A0680|76 78|SRF
P10373507A0680|97 126|alpha-actin, cardiac alpha-actin
P10373507A0680|109 126|cardiac alpha-actin
P10373507A0680|128 144|smooth alpha-actin
P10373507A0680|128 144|smooth alpha-actin
P10373507A0680|146 198|SM22alpha, and SRF promoter-luciferase reporter activities
P10373507A0680|146 154|SM22alpha
P10373507A0680|159 169|SRF promoter
P10373507A0680|171 188|luciferase reporter
P10373523A0924|2 16|serum-free media
P10373523A0924|18 23|p50E4F
P10373523A0924|35 54|E1A-induced apoptosis
P10373523A0924|35 37|E1A
P10374632A0818|23 25|Nim
P10374632A0818|60 62|NBP
P10374632A0818|60 62|NBP
P10374632A0897|11 26|NBP pre-treatment
P10374632A0897|62 65|rCBF
P10374632A0897|78 86|RMCAO rats
P10375107A1138|0 10|Progression
P10375107A1138|84 91|patients
P10375107A1138|96 105|metastasis
P10375638A0859|0 8|Mutations
P10375638A0859|15 23|human UTR1
P10375638A0859|32 46|NRF-1 expression
P10375638A0859|32 36|NRF-1
P10375638A0859|64 90|mRNA translational efficiency
P10375638A0859|93 108|transfected cells
P10375640A0153|18 35|nucleotide sequence
P10375640A0153|41 44|cDNA
P10375640A0153|46 50|CBS-1
P10375640A0153|46 50|CBS-1
P10375640A0153|61 76|open reading frame
P10375640A0153|89 101|182 amino acids
P10375640A0153|125 131|19.5kDa
P10375694T0000|0 14|Corticostriatal
P10375694T0000|36 45|input zones
P10375694T0000|83 95|macaque monkey
P10375694T0000|114 123|input zones
P10375718A0000|0 26|Basic fibroblast growth factor
P10375718A0000|0 26|Basic fibroblast growth factor
P10375718A0000|28 31|bFGF
P10375718A0000|28 31|bFGF
P10375718A0000|53 64|angiogenesis
P10376065A0881|47 60|venous pressure
P10376065A0881|69 71|9.3
P10376065A0881|94 105|spring filter
P10376065A0881|109 118|RF02 filter
P10376446A0000|2 13|healthy women
P10376446A0000|55 80|'s method of passive leg rising
P10376446A0000|82 84|PLR
P10376446A0000|88 97|follicular
P10376446A0000|99 100|FP
P10376446A0000|105 110|luteal
P10376446A0000|112 113|LP
P10376446A0000|123 142|normal ovulatory cycle
P10376873A0706|5 10|sgRNA2
P10376873A0706|5 10|sgRNA2
P10376873A0706|17 20|3'TE
P10376873A0706|26 30|5' UTR
P10376874A0759|33 41|eRF1-eRF3
P10376874A0759|33 36|eRF1
P10376874A0759|38 41|eRF3
P10376874A0759|76 91|truncated protein
P10376874A0759|92 96|eRF3C
P10376874A0759|92 96|eRF3C
P10376874A0759|99 110|C-terminally
P10376874A0759|99 99|C
P10376874A0759|118 129|eRF1 proteins
P10376874A0759|118 121|eRF1
P10376874A0759|201 221|C-terminal interaction
P10376877A0611|45 58|N-terminal half
P10376877A0611|93 101|5.8Ss rRNA
P10376877A0611|96 101|Ss rRNA
P10376877A0611|127 142|C-terminal region
P10376877A0611|127 142|C-terminal region
P10376877A0611|180 186|18S rRNA
P10376877A0611|180 182|18S
P10376877A0611|183 186|rRNA
P10376991A0977|0 2|Ras
P10376991A0977|0 2|Ras
P10376991A0977|25 32|tegument
P10377345A0740|0 36|Green fluorescent protein-tagged UNC-49B
P10377345A0740|30 36|UNC-49B
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|71 81|muscle cells
P10377345A0740|101 115|synaptic regions
P10377438A0647|10 17|a protein
P10377438A0647|19 22|UBC9
P10377438A0647|19 22|UBC9
P10377438A0647|49 51|TEL
P10377438A0647|49 51|TEL
P10378989A0000|65 84|adverse drug reactions
P10378989A0000|96 110|elderly patients
P10378989A0000|131 142|Sicily (Italy
P10379547A0000|0 8|Molecules
P10379547A0000|11 13|NH3
P10379547A0000|44 58|radiation (MASER
P10379899A0446|76 80|GDF-9
P10379899A0446|76 80|GDF-9
P10379942A0956|14 34|highly charged residues
P10379942A0956|63 82|carboxy-terminal part
P10379942A0956|88 102|MDV2 UL10 protein
P10379942A0956|88 102|MDV2 UL10 protein
P10379942T0000|31 75|Marek's disease virus serotype 2 glycoprotein M gene
P10379942T0000|31 49|Marek's disease virus
P10379942T0000|50 75|serotype 2 glycoprotein M gene
P10379942T0000|91 108|glycoprotein M genes
P10379942T0000|91 108|glycoprotein M genes
P10379942T0000|111 129|Herpesviridae family
P10380232A0000|47 49|CEA
P10380232A0000|47 49|CEA
P10380232A0000|67 122|antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)-
P10380232A0000|127 161|5-HT3 receptor antagonist-tropisetron
P10380232A0000|127 139|5-HT3 receptor
P10380232A0000|163 167|TROP)
P10380232A0000|184 194|acute emesis
P10380232A0000|220 231|chemotherapy
P10380232A0000|234 241|children
P10380232A0000|289 296|patients
P10380659A0545|30 35|adults
P10380800A0194|16 25|nucleotide
P10380800A0194|36 53|amino acid sequences
P10380800A0194|59 69|core regions
P10380800A0194|75 107|RNA-dependent RNA polymerase domains
P10380800A0194|75 100|RNA-dependent RNA polymerase
P10380800A0194|125 130|dsRNAs
P10380800A0194|149 154|dsRNAs
P10380800A0194|213 220|ancestor
P10380878A0542|31 43|non-MBD region
P10380878A0542|46 49|Bin1
P10380878A0542|46 49|Bin1
P10380878A0542|114 131|histone deacetylase
P10380878A0542|114 131|histone deacetylase
P10380890A0619|48 60|IR-responsive
P10380890A0619|90 91|IR
P10381257A0000|18 24|protein
P10381257A0000|26 33|metaxin 1
P10381257A0000|26 33|metaxin 1
P10381257A0000|84 96|outer membrane
P10381257A0000|102 123|mammalian mitochondrion
P10381377T0000|0 15|Molecular cloning
P10381377T0000|18 54|rat SH2-containing inositol phosphatase 2
P10381377T0000|18 20|rat
P10381377T0000|21 54|SH2-containing inositol phosphatase 2
P10381377T0000|56 60|SHIP2
P10381377T0000|56 60|SHIP2
P10381377T0000|89 104|insulin signaling
P10381377T0000|89 95|insulin
P10381570A1355|0 3|Slp1
P10381570A1355|0 3|Slp1
P10381570A1355|33 43|binding site
P10381570A1355|46 55|yeast cells
P10381570A1355|98 107|ftz stripes
P10381570A1355|98 100|ftz
P10381570A1355|110 127|interstripe regions
P10381570A1355|146 158|embryogenesis
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|118 137|transenvelope channel
P10383764A1809|150 173|bidirectional DNA transfer
P10383764A1809|184 186|ATP
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|29 32|PBPs
P10383966A0000|29 32|PBPs
P10383966A0000|54 66|peptidoglycan
P10383966A0000|95 111|bacterial cell wall
P10384129A0000|0 23|TCR alpha (TCRA) expression
P10384129A0000|0 7|TCR alpha
P10384129A0000|9 12|TCRA
P10384129A0000|51 54|PBMC
P10384129A0000|58 76|isolated populations
P10384129A0000|79 99|CD4+, CD8+, and DN T cells
P10384129A0000|79 82|CD4+
P10384129A0000|84 87|CD8+
P10384129A0000|106 123|healthy individuals
P10385384A0654|30 36|xylitol
P10385384A0654|54 76|pentose phosphate pathway
P10385395A0000|3 24|high density lipoprotein
P10385395A0000|3 24|high density lipoprotein
P10385395A0000|26 37|HDL) receptor
P10385395A0000|26 29|HDL)
P10385395A0000|57 67|cholesterol
P10385395A0000|71 87|cholesteryl esters
P10385395A0000|124 134|HDL particle
P10385395A0000|124 126|HDL
P10385915A1341|0 6|D3S1261
P10385915A1341|0 6|D3S1261
P10385915A1341|37 45|MITF locus
P10385915A1341|37 45|MITF locus
P10385915A1341|52 58|D3S2465
P10385915A1341|52 58|D3S2465
P10385915A1341|62 68|D3S1766
P10385915A1341|62 68|D3S1766
P10385915A1341|83 87|locus
P10385915A1341|99 100|cM
P10388670A1976|70 79|dispersant
P10388670A1976|81 92|Tris-Tween 80
P10388670A1976|133 140|adhesion
P10390158A1150|0 13|Point mutations
P10390158A1150|37 41|Pit-1
P10390158A1150|37 41|Pit-1
P10390158A1150|68 87|tiGH promoter activity
P10390158A1150|68 79|tiGH promoter
P10390538T0000|1 37|human Raf-responsive zinc-finger protein
P10390538T0000|6 37|Raf-responsive zinc-finger protein
P10390538T0000|49 66|divergent sequences
P10391075A0000|44 60|multiple sclerosis
P10391075A0000|98 107|brain tumor
P10391075A0000|110 120|MRI findings
P10391246A0756|12 16|MOM-4
P10391246A0756|12 16|MOM-4
P10391246A0756|20 23|TAK1
P10391246A0756|20 23|TAK1
P10391246A0756|59 74|kinase activities
P10391277A0000|14 21|MAZE-III
P10391277A0000|27 43|surgical treatment
P10391277A0000|64 91|refractory atrial fibrillation
P10391903T0000|0 3|Gab2
P10391903T0000|0 3|Gab2
P10391903T0000|9 57|pleckstrin homology domain-containing adapter protein
P10391903T0000|9 32|pleckstrin homology domain
P10391903T0000|44 57|adapter protein
P10391903T0000|86 94|ERK kinase
P10391903T0000|86 94|ERK kinase
P10391903T0000|97 101|Elk-1
P10391903T0000|97 101|Elk-1
P10392266A0111|13 30|cutaneous xanthomas
P10392266A0111|35 56|normal serum lipid levels
P10392266A0111|99 122|monoclonal immunoglobulin
P10392266A0111|99 122|monoclonal immunoglobulin
P10392669A0935|33 37|NSAID
P10392669A0935|46 68|gastrointestinal lesions
P10392669A0935|120 151|prostaglandin analogue misoprostol
P10392669A0935|225 229|NSAID
P10392669A0935|238 244|gastric
P10392669A0935|280 320|serious upper gastrointestinal complications
P10392669A0935|326 344|histamine H2 receptor
P10392669A0935|335 355|H2 receptor antagonists
P10392669A0935|357 369|H2 antagonists
P10392669A0935|357 358|H2
P10392669A0935|376 385|ranitidine
P10392669A0935|387 396|cimetidine
P10392669A0935|442 468|NSAID-induced duodenal ulcers
P10392669A0935|475 491|long term treatment
P10392669A0935|516 520|NSAID
P10392669A0935|529 541|gastric ulcers
P10392669A0935|548 557|proton pump
P10392669A0935|624 645|NSAID-associated ulcers
P10392669A0935|681 693|barrier agents
P10392669A0935|699 708|sucralfate
P10392669A0935|763 786|NSAID-induced gastropathy
P10392710A1000|0 13|Lung mesenchyme
P10392710A1000|42 58|lung morphogenesis
P10392710A1000|84 96|growth factors
P10392900A1020|18 28|HIV promoter
P10392900A1020|18 28|HIV promoter
P10392900A1020|61 65|c-Abl
P10392900A1020|61 65|c-Abl
P10392900A1020|99 121|tyrosine phosphorylation
P10392900A1020|124 138|RNA polymerase II
P10392900A1020|124 138|RNA polymerase II
P10392903A0000|3 31|bovine papillomavirus E2 protein
P10392903A0000|3 31|bovine papillomavirus E2 protein
P10392903A0000|60 68|HT-3 cells
P10392903A0000|71 107|p53-negative cervical carcinoma cell line
P10392903A0000|71 73|p53
P10392903A0000|128 150|human papillomavirus type
P10392903A0889|0 1|E2
P10392903A0889|29 38|cell growth
P10392903A0889|52 76|cdc25A and cdc25B expression
P10392903A0889|52 57|cdc25A
P10392903A0889|61 66|cdc25B
P10392903A0889|106 116|hydroxyurea
P10392903A0889|120 127|mimosine
P10392914A0000|44 65|pancreaticobiliary duct
P10392914A0000|67 71|AAPBD
P10392914A0000|91 117|congenital biliary dilatation
P10392914A0000|145 166|biliary tract malignancy
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|35 53|exonic trap and intron
P10393197A0543|0 3|DDP1
P10393197A0543|0 3|DDP1
P10393197A0543|36 51|interphase nuclei
P10393197A0543|54 70|larval neuroblasts
P10393201A0654|3 35|reconstituted human DNA repair system
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|66 83|DNA ligase III-XRCC1
P10393201A0654|66 77|DNA ligase III
P10393201A0654|79 83|XRCC1
P10393201A0654|121 127|residue
P10393201A0654|131 148|single-strand break
P10393201A0654|175 185|exonuclease
P10393251A0283|3 10|PAC clone
P10393251A0283|17 26|insert size
P10393251A0283|29 33|120kb
P10393251A0283|56 74|restriction analysis
P10393251T0000|0 7|Sequence
P10393251T0000|10 19|10q24 locus
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|58 61|gene
P10393251T0000|62 65|HUG1
P10393251T0000|62 65|HUG1
P10393251T0000|78 90|T-ALL cell line
P10393422A0476|19 23|LAMB2
P10393422A0476|70 89|LAMB2-like pseudogene
P10393422A0476|70 89|LAMB2-like pseudogene
P10393422A0476|91 96|LAMB2L
P10393422A0476|91 96|LAMB2L
P10393910A0705|0 23|Site-directed mutagenesis
P10393910A0705|29 37|R2 protein
P10393910A0705|90 99|active site
P10393910A0705|105 116|endonuclease
P10393969A0000|25 25|0
P10393969A0000|27 30|ICP0
P10393969A0000|27 30|ICP0
P10393969A0000|34 52|herpes simplex virus 1
P10393969A0000|34 52|herpes simplex virus 1
P10393969A0000|56 80|promiscuous transactivator
P10393969A0000|148 159|transfection
P10394116T0000|18 30|blood pressure
P10394900A1166|0 23|G-box-directed expression
P10394900A1166|0 4|G-box
P10394900A1166|55 68|enhancer region
P10394900A1166|76 102|cauliflower mosaic virus (CaMV
P10394900A1166|99 114|CaMV) 35S promoter
P10394900A1166|107 114|promoter
P10394919A1058|75 85|-178 and -264
P10395199A0792|4 7|scFv
P10395199A0792|33 45|in experiments
P10395199A0792|58 69|anti-Ras scFv
P10395199A0792|58 69|anti-Ras scFv
P10395199A0792|71 78|Y259 scFv
P10395199A0792|75 78|scFv
P10395199A0792|106 123|anti-Ras mAb Y13-259
P10395199A0792|106 119|anti-Ras mAb Y13
P10395199A0792|135 144|Ras pathway
P10395199A0792|135 137|Ras
P10395199A0792|178 181|nude
P10395199A0792|229 242|Virone-Oddos, A
P10395283A0960|28 35|activin A
P10395283A0960|28 35|activin A
P10395283A0960|39 42|OP-1
P10395283A0960|39 40|OP
P10395283A0960|60 64|Smad4
P10395283A0960|60 64|Smad4
P10395283A0960|102 123|common signal transducer
P10395283A0960|161 179|biological responses
P10395378A1198|53 74|HA envelope glycoprotein
P10395378A1198|53 74|HA envelope glycoprotein
P10395378A1198|95 111|amino-terminal end
P10395827A1297|19 40|parallel beta helix model
P10395827A1297|60 68|helically
P10395827A1297|106 119|beta sheet faces
P10395908A0236|24 41|315-residue protein
P10395908A0236|57 81|hydrophobic helical regions
P10395908A0236|86 101|17 amino acid motif
P10395908A0236|121 129|R7G family
P10395908A0236|121 129|R7G family
P10395908A0236|132 170|G-protein coupled membrane-bound receptors
P10395908A0236|132 170|G-protein coupled membrane-bound receptors
P10395911A0288|21 48|chicken apolipoprotein A-I gene
P10395911A0288|28 48|apolipoprotein A-I gene
P10395911A0288|49 65|5'-flanking region
P10395920A1424|35 43|ATF family
P10395920A1424|35 43|ATF family
P10395920A1424|69 93|transcriptional regulation
P10395920A1424|99 105|KGF gene
P10395920A1424|99 105|KGF gene
P10395920A1424|118 137|extracellular stimuli
P10395920A1424|147 166|CRE regulatory element
P10395920A1424|147 166|CRE regulatory element
P10396343A0754|26 37|blood samples
P10396343A0754|43 48|random
P10396343A0754|94 116|trypanosome-specific DNA
P10396343A0754|119 121|PCR
P10396343A0754|131 133|T. b
P10396343A0754|155 157|T. b
P10396343T0000|1 22|multi-centre evaluation
P10396343T0000|60 74|trypanosomiasis
P10396343T0000|76 88|TrypTect CIATT
P10396793A0815|10 12|men
P10396793A0815|133 149|alcohol dependence
P10397257A1142|0 10|Mutagenesis
P10397257A1142|16 41|CDE/CHR elements and Sp1 sites
P10397257A1142|16 18|CDE
P10397257A1142|20 30|CHR elements
P10397257A1142|34 41|Sp1 sites
P10397257A1142|83 105|transcriptional activity
P10397257A1142|116 141|asynchronously growing cells
P10397257A1142|154 173|cell cycle periodicity
P10397257A1142|181 197|synchronized cells
P10398286A0678|5 22|Scheffe's procedure
P10398286A0678|106 121|stochastic nature
P10398286A0678|124 126|S2p
P10398682A0365|3 18|crystal structure
P10398682A0365|24 31|VP16 core
P10398682A0365|24 27|VP16
P10399136A0389|0 6|Ozagrel
P10399136A0389|8 17|ifenprodil
P10399136A0389|61 74|pentoxifylline
P10399136A0389|87 90|rCBF
P10399136A0389|96 98|HPC
P10400032A0304|32 47|inferior vena cava
P10400032A0304|63 73|hypotension
P10400593A1084|11 39|PvirE or Plac promoter constructs
P10400593A1084|11 15|PvirE
P10400593A1084|18 29|Plac promoter
P10400593A1084|57 61|VirE2
P10400593A1084|68 72|virE1
P10400593A1084|68 72|virE1
P10400593A1084|91 95|virE2
P10400593A1084|91 95|virE2
P10400712A0000|0 28|Simian parainfluenza virus 5 (SV5
P10400712A0000|33 41|prototype
P10400712A0000|47 67|Paramyxoviridae family
P10400712A0000|70 98|nonsegmented negative-sense RNA
P10400712A0577|27 28|GE
P10400712A0577|27 28|GE
P10400712A0577|30 31|IG
P10400712A0577|30 31|IG
P10400712A0577|36 46|GS sequences
P10400712A0577|36 37|GS
P10400712A0577|76 83|plasmids
P10400712A0577|94 98|cDNAs
P10400712A0577|104 123|full-length SV5 genome
P10400712A0577|134 154|gene junction sequences
P10400712A0577|134 154|gene junction sequences
P10400712A0577|156 157|GE
P10400712A0577|156 157|GE
P10400712A0577|159 175|IG, and GS sequences
P10400712A0577|159 160|IG
P10400712A0577|165 175|GS sequences
P10400712A0577|194 240|hemagglutinin-neuraminidase (HN) and the polymerase
P10400712A0577|194 220|hemagglutinin-neuraminidase
P10400712A0577|222 223|HN
P10400712A0577|242 248|L) genes
P10400757A0000|0 4|CXCR4
P10400757A0000|0 4|CXCR4
P10400757A0000|8 24|chemokine receptor
P10400757A0000|42 59|T-cell-line-tropic
P10400757A0000|42 59|T-cell-line-tropic
P10400757A0000|61 62|X4
P10400757A0000|61 62|X4
P10400757A0000|67 77|dual-tropic
P10400757A0000|79 114|R5X4) human immunodeficiency virus type 1
P10400757A0000|84 114|human immunodeficiency virus type 1
P10400757A0000|116 129|HIV-1) isolates
P10400757A0000|116 120|HIV-1
P10400757A1498|36 40|CXCR4
P10400757A1498|36 40|CXCR4
P10400757A1498|83 94|HIV-1 strains
P10400757A1498|83 87|HIV-1
P10400757A1498|166 170|CXCR4
P10400757A1498|166 170|CXCR4
P10400757A1498|184 188|HIV-1
P10400757A1498|184 188|HIV-1
P10400757A1498|189 213|Env-mediated fusion process
P10400757A1498|189 191|Env
P10400760A0663|40 49|proteinase
P10400760A0663|59 123|amino acid residues E960-A961, E1071-S1072, E1345-T1346, and E1419-G1420
P10400774A0240|0 0|y
P10400785A0912|0 1|SM
P10400785A0912|0 1|SM
P10400785A0912|57 73|CRM 1 export pathway
P10400785A0912|57 60|CRM 1
P10400785A0912|87 100|small GTPase Ran
P10400785A0912|87 97|small GTPase
P10400785A0912|98 100|Ran
P10400785A0912|107 120|nucleoporin CAN
P10400785A0912|118 120|CAN
P10400785A0912|122 127|Nup214
P10400794T0000|32 68|Kaposi's sarcoma-associated herpesvirus
P10400794T0000|103 130|latent membrane proteins 1 and 2A
P10400794T0000|133 149|Epstein-Barr virus
P10400794T0000|133 149|Epstein-Barr virus
P10402022A0432|0 13|Auditory clicks
P10402022A0432|32 37|20 s(-1
P10402467T0000|0 21|Myosin light chain kinase
P10402467T0000|0 21|Myosin light chain kinase
P10402467T0000|43 45|Ras
P10402467T0000|47 49|ERK
P10402467T0000|59 67|migration
P10402467T0000|70 103|urokinase-type plasminogen activator
P10402467T0000|84 119|plasminogen activator-stimulated cells
P10402467T0000|124 147|integrin-selective manner
P10402467T0000|124 131|integrin
P10403575A1401|15 35|StAR gene transcription
P10403575A1401|15 22|StAR gene
P10403575A1401|38 42|DAX-1
P10403575A1401|38 42|DAX-1
P10403575A1401|46 80|dose-dependent reducing transcription
P10403690A0000|3 28|prospective randomized study
P10403690A0000|33 40|patients
P10403690A0000|53 75|non-small cell lung cancer
P10403690A0000|77 91|NSCLC) stage IIIb
P10403690A0000|100 103|ECOG
P10403690A0000|104 120|performance status
P10403690A0000|126 130|-1 or 2
P10403690A0000|185 187|BSC
P10403690A0000|191 204|supportive care
P10403690A0000|209 242|combination chemotherapy (IEP regimen
P10403690A0000|266 283|mesna uroprotection
P10403690A0000|340 349|MVP regimen
P10403690A0000|351 361|mitomycin-C
P10403690A0000|424 425|15
P10403839A0140|5 23|sequence information
P10403839A0140|28 37|human BMAL1
P10403839A0140|28 37|human BMAL1
P10403839A0140|39 50|hBMAL1) cDNAs
P10403839A0140|39 44|hBMAL1
P10403839A0140|115 119|cDNAs
P10403839A0140|133 138|splice
P10403839A0140|152 173|mouse BMAL1 (mBMAL1) gene
P10403839A0140|152 161|mouse BMAL1
P10403839A0140|163 168|mBMAL1
P10403839A1459|17 35|bHLH/PAS family genes
P10403839A1459|17 30|bHLH/PAS family
P10403839A1459|62 74|splice pattern
P10403839A1459|77 82|mBMAL1
P10403839A1459|77 82|mBMAL1
P10403839A1459|110 113|mAhr
P10403839A1459|110 113|mAhr
P10403839A1459|132 136|BMAL1
P10403839A1459|132 136|BMAL1
P10403839A1459|140 142|Ahr
P10403839A1459|192 205|primordial gene
P10405635A0374|3 27|transcriptional activities
P10405635A0374|33 51|full-length promoter
P10405635A0374|33 51|full-length promoter
P10405635A0374|53 61|-295 to +85
P10405635A0374|73 90|deletion constructs
P10405635A0374|92 111|-197, -154 and -74 to +85
P10406047A1244|42 67|functional residual capacity
P10406047A1244|112 128|respiratory system
P10406047A1244|140 157|weight or lung volume
P10406047A1244|163 172|ILD infants
P10406047A1244|186 200|healthy controls
P10406047A1244|203 209|infants
P10406047A1244|216 219|PPHN
P10406047A1244|240 243|PFTs
P10406047A1244|274 293|abnormal lung function
P10406122T0000|6 26|cis-regulatory element
P10406122T0000|32 42|LTR promoter
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|102 114|tissue culture
P10406122T0000|125 139|methyl jasmonate
P10406122T0000|143 157|fungal elicitors
P10406459A0000|25 57|platelet-derived growth factor (PDGF
P10406459A0000|25 52|platelet-derived growth factor
P10406459A0000|54 57|PDGF
P10406459A0000|60 93|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|95 97|TPA
P10406459A0000|103 111|forskolin
P10406459A0000|119 122|CREB
P10406459A0000|119 122|CREB
P10406459A0000|124 160|cAMP-responsive element-binding protein
P10406459A0000|124 160|cAMP-responsive element-binding protein
P10406459A0000|162 168|Ser-133
P10406459A0000|220 230|NIH 3T3 cells
P10406462A1127|40 44|SRC-1
P10406462A1127|40 44|SRC-1
P10406462A1127|47 76|dimerization-induced activation
P10406462A1127|79 90|OR1/RXRalpha
P10406462A1127|79 81|OR1
P10406462A1127|83 90|RXRalpha
P10406464A0687|11 18|mTRAP100
P10406464A0687|11 18|mTRAP100
P10406464A0687|64 74|TRAP complex
P10406464A0687|64 67|TRAP
P10406464A0687|76 82|TRAP220
P10406464A0687|76 82|TRAP220
P10406464A0687|106 107|TR
P10406464A0687|106 107|TR
P10406464A0687|114 129|vitamin D receptor
P10406464A0687|114 129|vitamin D receptor
P10406464A0687|133 154|ligand-dependent manner
P10406465A0589|23 25|VDR
P10406465A0589|23 25|VDR
P10406465A0589|29 36|vitamin D
P10406465A0589|54 73|heterologous promoter
P10406466A0000|25 40|nuclear receptors
P10406466A0000|25 40|nuclear receptors
P10406466A0000|42 67|e.g. thyroid hormone receptor
P10406466A0000|46 67|thyroid hormone receptor
P10406466A0000|69 88|retinoic acid receptor
P10406466A0000|69 88|retinoic acid receptor
P10406466A0000|91 112|orphan nuclear receptors
P10406466A0000|91 112|orphan nuclear receptors
P10406466A0000|114 116|e.g
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406843A1265|27 33|tobacco
P10406843A1265|56 61|RT-PCR
P10406954A0715|25 48|site-specific mutagenesis
P10406954A0715|59 72|amino acids H219
P10406954A0715|76 78|D63
P10406954A0715|81 84|RegS
P10406954A0715|81 84|RegS
P10406954A0715|88 91|RegR
P10406954A0715|88 91|RegR
P10406954A0715|111 132|phosphorylated residues
P10407184A0149|2 15|overexpression
P10407184A0149|21 31|betaAPP gene
P10407184A0149|21 31|betaAPP gene
P10407184A0149|51 57|AD brain
P10407184A0149|116 117|AD
P10407184A0520|3 19|functional studies
P10407184A0520|24 38|promoter regions
P10407184A0520|62 73|reporter gene
P10407184A0520|75 111|chloramphenicol acetyl transferase (CAT)
P10407184A0520|75 106|chloramphenicol acetyl transferase
P10407184A0520|108 110|CAT
P10407184A0520|116 124|phbetaE-B
P10407184A0520|129 135|plasmid
P10407184A0520|151 166|human (h) promoter
P10407184A0520|151 158|human (h)
P10407184A0520|174 184|-2832 to +101
P10407184A0520|195 197|URE
P10407184A0520|206 215|prhbetaE-B
P10407184A0520|220 226|plasmid
P10407184A0520|242 250|rhesus (rh
P10407184A0520|275 277|URE
P10407184A0520|288 298|270 bp region
P10407184A0520|304 319|hbetaAPP promoter
P10407184A0520|304 319|hbetaAPP promoter
P10407184A0520|321 332|-2435 to -2165
P10407269A0000a|2 4|393
P10407269A0000a|43 47|cdc18
P10407269A0000a|43 47|cdc18
P10407269A0000a|51 55|cdc14
P10407269A0000a|51 55|cdc14
P10407269A0000a|61 94|right arm of fission yeast chromosome II
P10407269A0000a|122 134|European Union
P10407269A0000a|135 158|Schizosaccharomyces pombe
P10407269A0000b|2 4|393
P10407269A0000b|43 47|cdc18
P10407269A0000b|43 47|cdc18
P10407269A0000b|51 55|cdc14
P10407269A0000b|51 55|cdc14
P10407269A0000b|61 94|right arm of fission yeast chromosome II
P10407269A0000b|122 134|European Union
P10407269A0000b|135 158|Schizosaccharomyces pombe
P10407985A0574|0 4|G-CSF
P10407985A0574|0 4|G-CSF
P10407985A0574|19 32|subcutaneously
P10407985A0574|36 38|c.)
P10407985A0574|55 60|GM-CSF
P10407985A0574|55 60|GM-CSF
P10407985A0574|77 79|c.)
P10407985A0574|84 105|chemotherapeutic cycles
P10409656A1016|16 23|H411 cDNA
P10409656A1016|16 23|H411 cDNA
P10409656A1016|29 54|RAW 264.7 macrophage cell line
P10409656A1016|111 114|H411
P10409656A1016|111 114|H411
P10409656A1016|126 150|proliferative cell response
P10409656A1016|153 155|LPS
P10409699A0292|0 24|Human expressed sequence tag
P10409699A0292|67 75|mammalian
P10409699A0292|79 121|yeast oligosaccharide-processing mannosidases
P10409699A0292|79 83|yeast
P10409699A0292|84 121|oligosaccharide-processing mannosidases
P10409699A0292|129 151|full-length coding region
P10409699A0292|140 151|coding region
P10409699A0292|157 182|putative mannosidase homolog
P10409699A0292|165 182|mannosidase homolog
P10409699A0292|233 240|cDNA ends
P10409699A0292|244 272|direct polymerase chain reaction
P10409699A0292|277 294|human placental cDNA
P10409724A1021|12 17|ERK1/2
P10409724A1021|12 17|ERK1/2
P10409724A1021|48 75|immediate-early response genes
P10409724A1021|48 75|immediate-early response genes
P10409730A0597|3 15|transcription
P10409730A0597|22 28|RP genes
P10409730A0597|22 28|RP genes
P10409730A0597|45 61|Rap1p binding sites
P10409730A0597|45 61|Rap1p binding sites
P10409730A0597|68 80|400 bp upstream
P10409730A0597|100 112|transcription
P10409741A0382|34 37|CDC4
P10409741A0382|34 37|CDC4
P10409741A0382|39 45|cdc4-10
P10409741A0382|39 45|cdc4-10
P10409741A0382|47 53|cdc4-11
P10409741A0382|47 53|cdc4-11
P10409741A0382|58 64|cdc4-16
P10409741A0382|58 64|cdc4-16
P10409741A0382|82 102|nuclear division defect
P10409741A0382|105 116|cdc20-1 cells
P10409741A0382|105 111|cdc20-1
P10409749T0000|6 23|secondary structure
P10409749T0000|47 80|constitutive and inducible activators
P10409755A1846|10 35|Ca(2+)-dependent activation
P10409755A1846|10 14|Ca(2+
P10409755A1846|38 39|NO
P10409755A1846|58 66|apoptosis
P10409755A1846|72 73|TG
P10409755A1846|84 94|JT/Neo cells
P10411139A0887|17 21|U4/U6
P10411139A0887|17 18|U4
P10411139A0887|20 21|U6
P10411139A0887|57 71|wild-type Prp44p
P10411139A0887|57 71|wild-type Prp44p
P10411139A1344|82 87|Prp44p
P10411139A1344|82 87|Prp44p
P10411139A1344|90 98|unwinding
P10411139A1344|104 113|U4/U6 helix
P10411139A1344|104 105|U4
P10411139A1344|107 113|U6 helix
P10411140A0499|17 22|125-nt
P10411140A0499|23 25|RNA
P10411140A0499|42 55|RNase E cleavage
P10411140A0499|42 47|RNase E
P10411140A0499|63 79|3'-terminal region
P10411140A0499|85 89|mRNAs
P10411160T0000|3 11|mysteries
P10411160T0000|37 57|nonmelanoma skin cancer
P10413604A0063|2 24|Saccharomyces cerevisiae
P10413604A0063|28 48|cAMP-dependent kinases
P10413604A0063|28 48|cAMP-dependent kinases
P10413604A0063|50 53|PKAs
P10413604A0063|50 53|PKAs
P10413604A0063|62 78|cytoplasmic growth
P10413604A0063|138 149|DNA synthesis
P10413607A0085|42 101|extracellular matrix molecules pepsin-solubilized collagen VI (CVI
P10413607A0085|70 75|pepsin
P10413607A0085|88 97|collagen VI
P10413607A0085|99 101|CVI
P10413607A0085|115 126|DNA synthesis
P10413607A0085|136 155|mesenchymal cell types
P10413607A0085|180 214|integrin-mediated signal transduction
P10413607A0085|180 187|integrin
P10413662A0193|1 21|recombinant derivative
P10413662A0193|34 56|pMJ101 replication region
P10413662A0193|81 84|pJM1
P10413662A0193|107 110|iron
P10413662A0193|142 150|virulence
P10413662A0193|204 212|vibriosis
P10413676A0000|0 2|FAK
P10413676A0000|0 2|FAK
P10413676A0000|21 59|transmembrane integrin receptor clustering
P10413676A0000|21 49|transmembrane integrin receptor
P10413676A0000|74 101|intracellular signaling events
P10413676A0595|19 28|FAK mutants
P10413676A0595|19 21|FAK
P10413676A0595|34 42|FAK- cells
P10413676A0595|34 36|FAK
P10413676A0595|53 61|FAK kinase
P10413676A0595|53 61|FAK kinase
P10413676A0595|74 101|Tyr-397/SH2 domain binding site
P10413676A0595|74 81|Tyr-397/
P10413676A0595|82 101|SH2 domain binding site
P10413676A0595|114 141|proline-rich SH3 binding region
P10413676A0595|126 141|SH3 binding region
P10413676A0595|147 165|FAK C-terminal domain
P10413676A0595|147 165|FAK C-terminal domain
P10413676A0595|201 203|FAK
P10413676A0595|201 203|FAK
P10413676A0595|213 229|FAK- cell migration
P10413676A0595|213 215|FAK
P10413676A0595|232 233|FN
P10413676A0595|247 254|paxillin
P10413676A0595|247 254|paxillin
P10413676A0595|264 266|FAK
P10413676A0595|264 266|FAK
P10413676A1193|4 26|dominant-negative effect
P10413676A1193|29 32|FRNK
P10413676A1193|29 32|FRNK
P10413676A1193|47 59|point mutation
P10413676A1193|71 73|Ser
P10413676A1193|89 104|FRNK localization
P10413676A1193|89 92|FRNK
P10413676A1193|107 111|focal
P10414451A0093|8 20|young patients
P10414451A0093|49 51|DVT
P10414451A0093|96 138|activated protein C (APC-R), lupus anticoagulant
P10414451A0093|105 112|protein C
P10414451A0093|114 116|APC
P10414451A0093|118 118|R
P10414451A0093|140 141|LA
P10414451A0093|140 141|LA
P10414451A0093|144 168|anticardiolipin antibodies
P10414451A0093|144 168|anticardiolipin antibodies
P10414451A0093|186 193|protein C
P10414451A0093|186 193|protein C
P10414451A0093|195 202|protein S
P10414451A0093|195 202|protein S
P10414451A0093|204 218|ATIII activities
P10414451A0093|204 208|ATIII
P10416429A0221|27 31|women
P10416429A0221|36 38|PKU
P10416429A0221|58 71|NSW PKU database
P10416558A0000|105 127|cardiopulmonary function
P10416558A0000|129 140|CD4 cell count
P10416558A0000|129 131|CD4
P10416558A0000|145 153|physician
P10416558A0000|180 198|symptomatic pre-AIDS
P10416558A0000|199 221|HIV-infected individuals
P10417331A1008|17 31|optimal activity
P10417331A1008|44 53|pantoate (k
P10417331A1008|55 57|cat
P10417331A1008|65 67|-1)
P10417703A1326|44 45|RP
P10417703A1326|44 45|RP
P10417703A1326|54 66|20S proteasome
P10417703A1326|54 66|20S proteasome
P10417703A1326|111 120|eukaryotes
P10417703A1326|144 154|RPT subunits
P10417703A1326|144 154|RPT subunits
P10417703A1326|165 181|yeast counterparts
P10419006A0378|34 59|estrogen replacement therapy
P10419006A0378|83 98|breast cancer risk
P10419521A0136|15 32|elongation activity
P10419521A0136|34 36|ELL
P10419521A0136|34 36|ELL
P10419521A0136|57 88|RNA polymerase II interaction domain
P10419521A0136|57 71|RNA polymerase II
P10419521A0136|114 131|polymerase activity
P10419521A0136|134 163|promoter-specific transcription
P10422291A0572|12 20|IgA lambda
P10422291A0572|12 20|IgA lambda
P10422291A0572|40 60|peritoneal involvement
P10422342A0535|3 17|radiation burden
P10422342A0535|45 56|examinations
P10422342A0535|120 134|radiation burden
P10422342A0535|137 163|radiodiagnostic examinations
P10422342A0535|206 209|131I
P10422342A0535|211 215|201Tl
P10422342A0535|217 220|67Ga
P10422342A0535|224 228|111In
P10422468A0524|31 38|children
P10422468A0524|48 51|ICSI
P10422468A0524|98 117|genetic abnormalities
P10422468A0524|126 128|NOA
P10422468A0524|145 157|sex chromosome
P10422468A0524|161 174|microdeletions
P10422468A0524|180 190|Y chromosome
P10422468A0524|203 224|congenital OA (mutations
P10422468A0524|230 247|cystic fibrosis gene
P10422468A0524|230 243|cystic fibrosis
P10423156A0265|0 11|TaV particles
P10423156A0265|45 48|CsCl
P10423156A0265|61 77|two capsid proteins
P10423156A0265|80 88|56 and 6 kDa
P10423193A1309|51 67|neural involvement
P10423193A1309|94 110|digital neuropathy
P10423193A1309|123 125|CTS
P10423292A0782|28 32|Spam1
P10423292A0782|28 32|Spam1
P10423292A0782|71 101|transcription factor binding sites
P10423292A0782|71 89|transcription factor
P10423292A0782|90 101|binding sites
P10423292A0782|112 137|CRE (cAMP-responsive element
P10423292A0782|112 114|CRE
P10423292A0782|116 137|cAMP-responsive element
P10425094A1006|3 19|in vitro relaxivity
P10425094A1006|25 31|complex
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|0 20|Bacterial recovery of SA
P10426450A1458|28 32|liver
P10426450A1458|46 56|cecal tonsil
P10426450A1458|75 76|SG
P10426450A1458|105 107|ILK
P10426450A1458|105 107|ILK
P10426450A1458|144 176|non-treated contact poults and chicks
P10426878A0367|15 20|ISIS-2
P10426878A0367|43 77|Antiplatelet Trialists' Collaboration
P10426878A0367|91 97|aspirin
P10426878A0367|111 118|patients
P10426878A0367|123 147|acute myocardial infarction
P10426878A0367|163 172|prevention
P10427654A0000|95 102|patients
P10427654A0000|107 120|adenocarcinoma
P10427654A0000|136 148|gastric cancer
P10427654A0000|152 167|pancreatic cancer
P10427654A0000|175 197|intended curative surgery
P10428091A0322|32 35|MMRs
P10428091A0322|59 79|persistent disparities
P10428091A0322|82 89|maternal
P10428091A0322|106 110|black
P10428091A0322|114 123|white women
P10428294A0227|10 21|LPL mass level
P10428294A0227|86 96|men and women
P10428759A0743|11 47|insulin-induced receptor kinase activity
P10428759A0743|11 17|insulin
P10428759A0743|26 39|receptor kinase
P10428759A0743|73 89|chimeric receptors
P10428759A0743|73 89|chimeric receptors
P10428811A0628|0 4|Cat-1
P10428811A0628|0 4|Cat-1
P10428811A0628|59 87|beta-adrenergic receptor kinase
P10428811A0628|59 87|beta-adrenergic receptor kinase
P10428811A0628|89 95|betaARK
P10428811A0628|89 95|betaARK
P10428811A0628|98 102|GRK-2
P10428811A0628|98 102|GRK-2
P10428811A0628|124 138|Arf-GAP activity
P10428811A0628|124 126|Arf
P10428811A0628|128 130|GAP
P10428811A1067|0 10|Cat proteins
P10428811A1067|0 10|Cat proteins
P10428811A1067|67 85|focal adhesion kinase
P10428811A1067|67 85|focal adhesion kinase
P10428811A1067|86 88|Fak
P10428811A1067|86 88|Fak
P10428811A1067|92 94|Src
P10428811A1067|92 94|Src
P10428862A0834|0 29|Immunoprecipitation experiments
P10428862A0834|35 57|DokR-specific antibodies
P10428862A0834|35 57|DokR-specific antibodies
P10428862A0834|86 99|endogenous DokR
P10428862A0834|96 99|DokR
P10428862A0834|104 117|150-kDa protein
P10428862A0834|104 117|150-kDa protein
P10428862A0834|149 172|EGF-stimulated BaF/3 cells
P10428862A0834|149 151|EGF
P10429184A0000|0 8|Expansins
P10429184A0000|0 8|Expansins
P10429184A0000|41 58|long-term extension
P10429184A0000|74 82|cell walls
P10429184A0000|102 121|biochemical mechanism
P10429740A0000|66 87|irritable bowel syndrome
P10429740A0000|89 91|IBS
P10429946A0473|24 40|alpha 2(V) collagen
P10429946A0473|24 29|alpha 2
P10429946A0473|31 44|V) collagen gene
P10429946A0473|84 120|basal promoter and 150 bp of exon 1 sequences
P10429946A0473|139 154|CRE-like elements
P10429946A0473|139 154|CRE-like elements
P10429946A0988|22 66|B-Myb-glutathionine S-transferase fusion protein
P10429946A0988|22 26|B-Myb
P10429946A0988|28 66|glutathionine S-transferase fusion protein
P10429946A0988|76 91|complex formation
P10430421T0000|0 17|APOE-epsilon4 count
P10430421T0000|0 3|APOE
P10430421T0000|45 46|AD
P10430580A0000|0 5|Repair
P10430580A0000|8 26|double-strand breaks
P10430580A0000|28 31|DSBs
P10430580A0000|35 48|chromosomal DNA
P10430580A0000|51 79|nonhomologous end-joining (NHEJ
P10430580A0000|108 112|yeast
P10430580A0000|113 135|Saccharomyces cerevisiae
P10430583A0000|4 16|DNA repair gene
P10430583A0000|21 44|Schizosaccharomyces pombe
P10430583A0000|59 62|RecA
P10430583A0000|59 62|RecA
P10430883A0000|5 24|mucus-secreting cells
P10430883A0000|29 51|gastric gland mucous cells
P10430883A0000|53 108|Brunner's glands, accessory glands of pancreaticobiliary tract
P10430883A0000|113 127|pancreatic ducts
P10430883A0000|138 154|gastric metaplasia
P10430883A0000|181 193|class III mucin
P10430883A0000|181 193|class III mucin
P10430883A0000|206 228|paradoxical Con A staining
P10430883A0000|217 220|Con A
P10430883A0000|285 288|Con A
P10430883A0000|285 288|Con A
P10430883A0000|293 321|horseradish peroxidase reaction
P10430883A0000|293 313|horseradish peroxidase
P10430886A0838|3 19|C-terminal mutants
P10430886A0838|3 12|C-terminal
P10430886A0838|44 47|TraR
P10430886A0838|44 47|TraR
P10430886A0838|96 113|wild-type activator
P10430886A0838|96 113|wild-type activator
P10430890A1059|5 12|elongin C
P10430890A1059|5 12|elongin C
P10430944A1298|16 32|JAK/STAT signaling
P10430944A1298|16 18|JAK
P10430944A1298|20 23|STAT
P10430944A1298|43 68|EBV-associated malignancies
P10430980A0465|11 13|men
P10430980A0465|20 24|women
P10433729A1559|10 12|K.E
P10433970A0279|0 5|Spfkh1
P10433970A0279|0 5|Spfkh1
P10433970A0279|24 39|open reading frame
P10433970A0279|55 70|DNA binding domain
P10433970A0279|55 70|DNA binding domain
P10433970A0279|72 96|nuclear localization signal
P10433970A0279|100 120|transactivation domain
P10435595A0203|3 20|molecular mechanism
P10435595A0203|23 50|Tax-mediated trans-activation
P10435595A0203|23 25|Tax
P10436016A0337|0 12|Gel filtration
P10436016A0337|16 45|co-immunoprecipitation analyses
P10436016A0337|56 60|Mad2p
P10436016A0337|56 60|Mad2p
P10436016A0337|89 114|spindle checkpoint component
P10436016A0337|116 120|Mad1p
P10436016A0337|116 120|Mad1p
P10437043A0164|29 30|SS
P10438540A1185|21 43|regulatory domain mutants
P10438540A1185|51 65|Cd(2+) tolerance
P10438540A1185|71 82|mutant strain
P10438593A0000|3 34|human immunodeficiency virus type-1
P10438593A0000|3 34|human immunodeficiency virus type-1
P10438593A0000|36 51|HIV-1) Tat protein
P10438593A0000|36 40|HIV-1
P10438593A0000|42 51|Tat protein
P10438593A0000|87 111|RNA polymerase processivity
P10438593A0000|87 99|RNA polymerase
P10438607A0330|10 14|SEBPs
P10438607A0330|10 14|SEBPs
P10438607A0330|16 20|SEBP2
P10438607A0330|16 20|SEBP2
P10438607A0330|49 68|homeotic gene fork head
P10438607A0330|49 60|homeotic gene
P10438627A0885|0 15|Identity elements
P10438627A0885|18 21|tRNA
P10438627A0885|25 54|mono- and dimethylation reactions
P10438627A0885|60 77|recombinant pfTrm1p
P10438627A0885|60 77|recombinant pfTrm1p
P10438627A0885|104 116|T7 transcripts
P10438627A0885|131 150|tRNA(Asp)and tRNA(Phe
P10438627A0885|131 139|tRNA(Asp)
P10438627A0885|143 146|tRNA
P10438627A0885|148 150|Phe
P10438627A0885|156 160|yeast
P10438924A1009|2 24|insulin-responsive cells
P10438924A1009|2 8|insulin
P10438924A1009|26 28|Akt
P10438924A1009|26 28|Akt
P10438924A1009|60 81|serine/threonine kinase
P10438924A1009|60 81|serine/threonine kinase
P10438924A1009|82 105|glycogen synthase kinase-3
P10438924A1009|82 105|glycogen synthase kinase-3
P10438924A1009|107 111|GSK-3
P10438924A1009|107 111|GSK-3
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|35 52|Akt (protein kinase B
P10438924T0000|35 37|Akt
P10438924T0000|39 53|protein kinase B)
P10438924T0000|55 78|glycogen synthase kinase-3
P10438924T0000|55 78|glycogen synthase kinase-3
P10438924T0000|98 125|phosphatidylinositol 3-kinase
P10438924T0000|98 125|phosphatidylinositol 3-kinase
P10438941A1197|5 23|recombination events
P10438941A1197|50 63|B and T cell lines
P10438941A1197|106 120|endogenous genes
P10438950A0580|0 3|IL-1
P10438950A0580|0 3|IL-1
P10438950A0580|7 9|TNF
P10438950A0580|18 33|AND-34 transcript
P10438950A0580|24 39|transcript levels
P10438950A0580|66 76|thymic nurse
P10439040A0658|19 23|eIF4E
P10439040A0658|19 23|eIF4E
P10439040A0658|35 49|c-myc expression
P10439040A0658|35 39|c-myc
P10439040A0658|54 78|c-myc 5' untranslated region
P10439040A0658|54 58|c-myc
P10439040A0658|80 82|UTR
P10439040A0658|102 113|CAT reporters
P10439040A0658|102 113|CAT reporters
P10439040A0658|129 148|derivative constructs
P10440923A0684|10 26|cell cycle proteins
P10440923A0684|42 60|lovastatin treatment
P10440923A0684|66 77|control cells
P10440923A0684|111 141|cyclin-dependent kinase inhibitor
P10440923A0684|111 132|cyclin-dependent kinase
P10440923A0684|142 149|p27(kip1
P10440923A0684|142 144|p27
P10440923A0684|146 149|kip1
P10440923A0684|168 209|cyclin E- and cyclin A-dependent kinase activity
P10440923A0684|168 174|cyclin E
P10440923A0684|179 201|cyclin A-dependent kinase
P10440923A0684|250 270|retinoblastoma protein
P10440923A0684|250 270|retinoblastoma protein
P10440923A0684|272 274|pRb
P10440923A0684|272 274|pRb
P10441243A0443|19 38|leptin concentrations
P10441243A0443|19 24|leptin
P10441243A0443|41 42|AN
P10441243A0443|78 92|control subjects
P10441483A0454|0 20|Oligonucleotide probes
P10441483A0454|36 66|wild-type and mutant EpRE sequences
P10441483A0454|77 85|gel-shift
P10441506A0098|0 6|PKNbeta
P10441506A0098|0 6|PKNbeta
P10441506A0098|34 41|PKNalpha
P10441506A0098|34 41|PKNalpha
P10441506A0098|61 63|PKN
P10441506A0098|61 63|PKN
P10441506A0098|96 115|amino acid-rich region
P10441506A0098|120 146|leucine-zipper like sequences
P10441506A0098|120 146|leucine-zipper like sequences
P10441506A0098|148 159|CZ region/HR1
P10441506A0098|148 155|CZ region
P10441506A0098|157 159|HR1
P10441506A0098|167 198|carboxyl-terminal catalytic domain
P10441506A0098|218 220|130
P10441506A0098|221 248|amino acid stretch (D region/HR2
P10441506A0098|238 244|D region
P10441506A0098|246 248|HR2
P10441506A0098|265 276|CZ region/HR1
P10441506A0098|283 297|catalytic domain
P10442493A0815|2 9|baseline
P10442493A0815|11 21|serum levels
P10442493A0815|24 31|lycopene
P10442493A0815|35 38|FLOP
P10442493A0815|60 68|serum FLOP
P10442493A0815|105 122|cyclosporine levels
P10443990A0000|11 35|Chronic alcohol consumption
P10444597A0586|42 50|heat shock
P10444597A0586|52 59|high salt
P10444597A0586|63 69|ethanol
P10444597A0586|95 104|mRNA export
P10444597A0586|115 119|Npl3p
P10444597A0586|115 119|Npl3p
P10444597A0586|142 148|nucleus
P10444813A0448|3 19|symptomatic relief
P10444813A0448|49 58|metastases
P10444813A0448|59 70|interferon-a
P10444813A0448|74 94|somatostatin analogues
P10444813A0448|74 85|somatostatin
P10445161A1565|80 98|decreased weight gain
P10445161A1565|101 110|female rats
P10445161A1565|123 140|organ weight changes
P10445506A0073|17 29|gigantic sperm
P10445506A0073|54 63|body length
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446131A0132|0 10|PDGF A-chain
P10446131A0132|35 59|vascular smooth muscle cells
P10446131A0132|61 64|SMCs
P10446131A0132|75 78|ATII
P10446131A0132|75 78|ATII
P10446149A0809|0 4|M-Ras
P10446149A0809|0 4|M-Ras
P10446149A0809|24 43|yeast two-hybrid assay
P10446149A0809|56 67|Ras effectors
P10446149A0809|56 58|Ras
P10446149A0809|78 84|c-Raf-1
P10446149A0809|78 84|c-Raf-1
P10446149A0809|86 96|A-Raf, B-Raf
P10446149A0809|86 90|A-Raf
P10446149A0809|92 96|B-Raf
P10446149A0809|98 125|phosphoinositol-3 kinase delta
P10446149A0809|98 125|phosphoinositol-3 kinase delta
P10446149A0809|127 132|RalGDS
P10446149A0809|127 132|RalGDS
P10446149A0809|137 140|Rin1
P10446149A0809|137 140|Rin1
P10446206A0000|0 14|Deletion mapping
P10446206A0000|20 49|human presenilin-1 (PS1) promoter
P10446206A0000|20 36|human presenilin-1
P10446206A0000|38 40|PS1
P10446206A0000|85 94|-118 to +178
P10446206A0000|110 131|transcription start site
P10446206A0000|156 173|human neuroblastoma
P10446206A0000|174 201|SK-N-SH and hepatoma HepG2 cells
P10446833T0000|0 26|Microcirculatory oxygenation
P10446833T0000|40 45|sepsis
P10446833T0000|49 53|shock
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|71 72|E2
P10446910A0147|90 116|transient transfection assays
P10446910A0147|131 155|deletion/mutation analysis
P10446910A0147|173 221|upstream GC-rich and two downstream CCAAT-binding sites
P10446910A0147|254 255|E2
P10446912A0883|46 48|OF5
P10446912A0883|46 48|OF5
P10446912A0883|52 54|OF3
P10446912A0883|52 54|OF3
P10446912A0883|64 83|CYP11A1 transcription
P10446912A0883|64 70|CYP11A1
P10446912A0883|96 98|OF5
P10446912A0883|96 98|OF5
P10446912A0883|102 104|OF3
P10446912A0883|102 104|OF3
P10446912A0883|110 112|Sp1
P10446912A0883|110 112|Sp1
P10446912A0883|116 118|Sp3
P10446912A0883|116 118|Sp3
P10446912A0883|121 130|JEG-3 cells
P10446998A0375|31 60|neoplastically transformed cells
P10446998A0375|75 97|mitogenic responsiveness
P10446998A0375|100 103|junB
P10446998A0375|100 103|junB
P10446998A0375|106 122|c-fos inducibility
P10446998A0375|106 110|c-fos
P10446998A0955|0 23|Adipocyte differentiation
P10446998A0955|26 44|nontransformed cells
P10446998A0955|78 80|SRF
P10446998A0955|78 80|SRF
P10446998A0955|92 98|junB SRE
P10446998A0955|92 95|junB
P10446998A0955|103 110|c-fos SRE
P10446998A0955|103 107|c-fos
P10446998A0955|120 123|SREs
P10446998A0955|139 151|mobility shift
P10446998A0955|155 173|gel supershift assays
P10446998A0955|194 218|DNA binding characteristics
P10446998A0955|224 241|nuclear protein SP-1
P10446998A0955|224 237|nuclear protein
P10446998A0955|238 241|SP-1
P10446998T0000|0 13|Transformation
P10446998T0000|55 73|serum response factor
P10446998T0000|55 73|serum response factor
P10446998T0000|90 110|serum response elements
P10446998T0000|90 110|serum response elements
P10447593A0144|34 49|bacteriophages T3
P10447593A0144|51 52|T7
P10447593A0144|56 58|SP6
P10447593A0144|107 127|bacterial sigma factors
P10447593A0144|116 127|sigma factors
P10447597A1004|3 14|Cr.psbA-4 ORF
P10447597A1004|3 4|Cr
P10447597A1004|6 11|psbA-4
P10447597A1004|12 14|ORF
P10447597A1004|25 34|H-N-H motif
P10447597A1004|25 34|H-N-H motif
P10447597A1004|48 59|GIY-YIG motif
P10448036A0748|16 20|zf4-6
P10448036A0748|16 20|zf4-6
P10448036A0748|25 40|full-length 5 S RNA
P10448036A0748|36 37|5 S
P10448036A0748|38 40|RNA
P10448036A0748|62 96|non-specific competitor concentration
P10448036A0748|107 111|zf4-7
P10448036A0748|107 111|zf4-7
P10448036A0748|113 117|5 S RNA
P10448036A0748|114 128|S RNA interaction
P10448036A0748|208 221|RNA interaction
P10448095A0865|3 25|STAT protein accumulation
P10448095A0865|3 13|STAT protein
P10448095A0865|39 53|C/EBP expression
P10448095A0865|39 43|C/EBP
P10448095A0865|101 111|fibroblasts
P10448095A0865|114 123|adipocytes
P10448095A0865|182 197|mature adipocytes
P10448285A1035|3 17|median durations
P10448440T0020|46 53|patients
P10448440T0020|65 77|schizophrenia
P10448902A0921|29 36|catalase
P10448902A0921|29 36|catalase
P10448902A0921|38 58|glutathione peroxidase
P10448902A0921|38 58|glutathione peroxidase
P10448902A0921|62 80|superoxide dismutase
P10448902A0921|62 80|superoxide dismutase
P10448902A0921|87 101|MCT-treated rats
P10448902A0921|128 138|control rats
P10449072A0560|57 59|GPi
P10449072A0560|62 63|PD
P10450815A0180|50 73|dentally aware individuals
P10450815A0180|143 156|tobacco smoking
P10450815A0180|160 180|supragingival calculus
P10450815A0180|235 240|gender
P10450815A0180|242 252|oral hygiene
P10450815A0180|256 275|gingival inflammation
P10451209A0000|44 54|misoprostol
P10451209A0000|63 79|gastric hemorrhage
P10451209A0000|82 92|healthy dogs
P10451209A0000|115 132|methylprednisolone
P10451209A0000|133 147|sodium succinate
P10451209A0000|149 152|MPSS
P10452306A0502|0 7|Patients
P10452306A0502|23 39|cardiac MIBG uptake
P10452306A0502|52 65|norepinephrine
P10452306A0502|80 83|LVEF
P10452306A0502|89 116|Vo2, x-ray cardiothoracic ratio
P10452306A0502|118 123|M-mode
P10452306A0502|159 199|right-sided heart catheterization parameters
P10452951A0000|0 22|Nuclear hormone receptors
P10452951A0000|0 22|Nuclear hormone receptors
P10452951A0000|24 26|NRs
P10452951A0000|24 26|NRs
P10452951A0000|31 66|ligand-inducible transcription factors
P10452991A0331|27 49|influenza virus particles
P10452991A0331|52 80|HLA-DR1-restricted T cell clones
P10452991A0331|52 58|HLA-DR1
P10453006A0000|12 20|zebrafish
P10453006A0000|22 31|Danio rerio
P10453006A0000|65 66|P1
P10453006A0000|67 107|artificial chromosome genomic clone fragments
P10453006A0000|113 122|cDNA clones
P10453006A0000|157 160|loci
P10453006A0000|170 194|beta subunits of proteasomes
P10453006A0000|170 181|beta subunits
P10453006A0000|184 194|proteasomes
P10453006A0000|196 199|PSMB
P10453006A0000|196 199|PSMB
P10453006A0478|27 41|human genes PSMB5
P10453006A0478|27 36|human genes
P10453006A0478|37 41|PSMB5
P10453006A0478|49 53|PSMB9
P10453006A0478|49 53|PSMB9
P10453006A0478|67 72|PSMB11
P10453006A0478|67 72|PSMB11
P10453006A0478|76 81|PSMB12
P10453006A0478|76 81|PSMB12
P10453006A0478|139 144|humans
P10453248A0094|2 23|applies Udry's biosocial
P10453248A0094|76 93|sociological models
P10453248A0094|106 111|sexual
P10453371A0640|0 5|Weight
P10453371A0640|54 64|BMD z-scores
P10453721A0445|39 74|bayesian parameter estimation algorithm
P10453721A0445|90 111|ADAPT II software package
P10454533A0859|13 15|HRI
P10454533A0859|13 15|HRI
P10454533A0859|20 24|Hsc70
P10454533A0859|20 24|Hsc70
P10454533A0859|58 60|HRI
P10454533A0859|58 60|HRI
P10454533A0859|67 81|Hsc70 antagonist
P10454533A0859|67 71|Hsc70
P10454533A0859|82 94|clofibric acid
P10454533A0859|116 118|HRI
P10454533A0859|116 118|HRI
P10454540A0392|3 23|amino acid changes D206A
P10454540A0392|27 31|D208A
P10454540A0392|63 81|exonuclease activity
P10454550A0960|44 47|Reg1
P10454550A0960|44 47|Reg1
P10454550A0960|59 62|Glc7
P10454550A0960|59 62|Glc7
P10454550A0960|65 81|nuclear substrates
P10454550A0960|91 107|Snf1 kinase complex
P10454550A0960|91 100|Snf1 kinase
P10454557A0000|12 16|yeast
P10454557A0000|18 40|Saccharomyces cerevisiae
P10454557A0000|109 129|sequence (ARS) elements
P10454557A0000|145 157|chromosome III
P10454557A0000|166 169|ARSs
P10454557A0000|200 207|HML locus
P10454557A0000|200 202|HML
P10454557A0975|30 42|HML ARS cluster
P10454557A0975|30 32|HML
P10454557A0975|44 49|ARS303
P10454557A0975|44 49|ARS303
P10454557A0975|51 56|ARS320
P10454557A0975|51 56|ARS320
P10454557A0975|61 66|ARS302
P10454557A0975|61 66|ARS302
P10454557A0975|103 131|local transcriptional silencing
P10454557A0975|153 161|silencers
P10454557A0975|170 198|cis- and trans-acting components
P10454561A0594|47 61|TD-IkappaBalpha
P10454561A0594|47 61|TD-IkappaBalpha
P10454561A0594|69 91|phorbol myristate acetate
P10454561A0594|93 110|phytohemagglutinin
P10454561A0594|93 110|phytohemagglutinin
P10454561A0594|113 173|tumor necrosis factor alpha-induced IkappaBalpha gene transcription
P10454561A0594|113 136|tumor necrosis factor alpha
P10454561A0594|145 160|IkappaBalpha gene
P10454561A0594|186 212|NF-kappaB DNA binding activity
P10454561A0594|186 194|NF-kappaB
P10454561A0594|231 254|cytoplasmic sequestration
P10454561A0594|257 260|RelA
P10454561A0594|257 260|RelA
P10454561A0594|262 264|p65
P10454561A0594|262 264|p65
P10454561A0594|268 282|TD-IkappaBalpha
P10454561A0594|268 282|TD-IkappaBalpha
P10454568A0815|1 1|i
P10454568A0815|11 25|Grb10 expression
P10454568A0815|11 15|Grb10
P10454568A0815|30 33|cDNA
P10454568A0815|40 47|ecdysone
P10454568A0815|93 106|PDGF-BB-, IGF-I
P10454568A0815|93 99|PDGF-BB
P10454568A0815|102 106|IGF-I
P10454568A0815|111 149|insulin- but not epidermal growth factor (EGF
P10454568A0815|111 117|insulin
P10454568A0815|125 145|epidermal growth factor
P10454568A0815|147 149|EGF
P10454568A0815|159 170|DNA synthesis
P10454568A0815|175 204|ecdysone dose-responsive fashion
P10454570A0846|24 61|mitogen-activated protein kinase pathways
P10454570A0846|24 53|mitogen-activated protein kinase
P10454570A0846|71 119|stress-activated protein kinase-Jun N-terminal kinase
P10454570A0846|71 119|stress-activated protein kinase-Jun N-terminal kinase
P10454570A0846|162 166|ATF-2
P10454570A0846|162 166|ATF-2
P10454570A0846|168 172|c-Jun
P10454570A0846|168 172|c-Jun
P10454570A0846|177 180|JunD
P10454570A0846|177 180|JunD
P10454570A0846|205 208|IL-1
P10454570A0846|205 208|IL-1
P10454570A0846|223 244|TPA-dependent induction
P10454570A0846|254 287|extracellular signal-related kinase 1
P10454570A0846|254 287|extracellular signal-related kinase 1
P10454570A0846|289 293|ERK-1
P10454570A0846|289 293|ERK-1
P10454570A0846|298 312|ERK-2 activation
P10454570A0846|298 302|ERK-2
P10454570A0846|328 337|TPA- but not
P10454570A0846|343 367|IL-1-dependent stimulation
P10454570A0846|343 346|IL-1
P10454570A0846|373 383|uPA enhancer
P10454570A0846|373 383|uPA enhancer
P10455087A1400|14 31|healthy individuals
P10455087A1400|42 59|insulin sensitivity
P10455087A1400|42 48|insulin
P10455087A1400|72 79|"coupled
P10455143T0000|0 19|Interdomain signaling
P10455143T0000|23 40|two-domain fragment
P10455143T0000|46 72|human glucocorticoid receptor
P10455143T0000|46 72|human glucocorticoid receptor
P10455183A0530|14 27|xtRNA(Sec) gene
P10455183A0530|14 27|xtRNA(Sec) gene
P10455183A0530|53 67|Staf zinc fingers
P10455183A0530|53 67|Staf zinc fingers
P10455183A0530|75 79|Oct-1
P10455183A0530|75 79|Oct-1
P10455183A0530|91 113|transcriptional capacity
P10455183A0930|61 75|Staf zinc finger 1
P10455183A0930|61 75|Staf zinc finger 1
P10455183A0930|155 170|Xenopus tRNA(Sec)
P10455183A0930|155 165|Xenopus tRNA
P10455183A0930|167 169|Sec
P10455183A0930|174 190|human U6 snRNA genes
P10455183A0930|179 190|U6 snRNA genes
P10455189A0104|2 7|B cells
P10455189A0104|9 12|HEF1
P10455189A0104|9 12|HEF1
P10455189A0104|32 62|cytoskeleton-dependent mechanism
P10455189A0104|80 95|integrin ligation
P10455189A0104|80 87|integrin
P10455189A0427|3 43|calcitonin-induced tyrosine phosphorylation
P10455189A0427|3 12|calcitonin
P10455189A0427|46 49|HEF1
P10455189A0427|46 49|HEF1
P10455189A0427|62 89|time- and dose-dependent manner
P10457075A1198|46 47|VI
P10457075A1198|49 51|max
P10457075A1198|107 108|Rn
P10458905A0000|60 77|YAC/BAC clone contig
P10458905A0000|85 87|p23
P10458907A0543|3 21|human RAD30B and mouse
P10458907A0543|3 13|human RAD30B
P10458907A0543|17 31|mouse Rad30b mRNA
P10458907A0543|22 42|Rad30b mRNA transcripts
P10458907A0543|52 65|repair proteins
P10458907A0543|90 95|testis
P10458914A0674|13 25|mouse STAP gene
P10458914A0674|13 25|mouse STAP gene
P10458914A0674|41 54|genomic library
P10458914A0674|70 77|STAP gene
P10458914A0674|70 77|STAP gene
P10458914A0674|117 121|exons
P10459809A1262|1 25|reduced matrix distribution
P10459809A1262|37 47|cell density
P10459809A1262|65 71|biofilm
P10460015A0465|41 48|estrogen
P10460015A0465|66 71|weight
P10460015A0465|98 115|bone mineral density
P10460171A0842|0 19|Viscosity experiments
P10460171A0842|25 55|catalytic fragment kinase reaction
P10460171A0842|84 101|phosphoryl transfer
P10460172A0823|8 20|sedimentation
P10460172A0823|39 65|immunoprecipitation analyses
P10460172A0823|68 88|detergent-solubilized
P10460172A0823|89 96|rat brain
P10460172A0823|112 121|32 and 34 kDa
P10463057A0534|2 22|vitro expression levels
P10463057A0534|37 44|plasmids
P10463242A0316|2 4|EEG
P10463242A0316|29 32|left
P10464185T0000|27 47|type-specific capsular
P10464185T0000|81 110|Streptococcus agalactiae type Ia.
P10464291A0597|0 7|IL-1beta
P10464291A0597|0 7|IL-1beta
P10464291A0597|41 50|PDGFalphaR
P10464291A0597|41 50|PDGFalphaR
P10464291A0597|54 87|CCAAT/enhancer-binding protein delta
P10464291A0597|54 82|CCAAT/enhancer-binding protein
P10464291A0597|83 98|delta (C/EBPdelta
P10464291A0597|89 98|C/EBPdelta
P10464291A0597|100 109|mRNA levels
P10464302A1109b|44 51|p185(neu
P10464302A1109b|44 47|p185
P10464302A1109b|49 51|neu
P10464302A1109b|68 91|mitogenic pathway proteins
P10464302A1109b|98 134|membrane-microfilament interaction site
P10464302A1109b|187 202|mitogenic pathway
P10464302A1109b|247 258|cytoskeleton
P10464310A0218|9 31|tyrosine phosphorylation
P10464310A0218|34 36|Crk
P10464310A0218|34 36|Crk
P10464310A0218|39 89|fibroblast growth factor-2-stimulated endothelial cells
P10464310A0218|39 62|fibroblast growth factor-2
P10464310A0218|107 127|juxtamembrane tyrosine
P10464310A0218|140 145|FGFR-1
P10464310A0218|140 145|FGFR-1
P10464310A0218|151 162|Crk SH2 domain
P10464310A0218|151 162|Crk SH2 domain
P10464310A0218|175 180|FGFR-1
P10464310A0218|175 180|FGFR-1
P10464310A0218|198 204|Tyr-463
P10464310A0218|245 247|Crk
P10464310A0218|251 256|FGFR-1
P10464310A0218|251 256|FGFR-1
P10466306A0000|9 46|myocardial Technetium-99m sestamibi SPECT
P10466306A0000|74 92|myocardial perfusion
P10466825T0000|9 28|3' untranslated region
P10466825T0000|31 48|baculovirus p10 mRNA
P10466825T0000|31 48|baculovirus p10 mRNA
P10466825T0000|73 84|foreign genes
P10467004A0116|3 11|intron RNA
P10467004A0116|22 36|2492 nucleotides
P10467004A0116|58 75|secondary structure
P10467004A0116|110 122|subgroup-IIA1
P10467004A0116|123 129|introns
P10467004A0683|3 8|intron
P10467004A0683|53 61|EBS1/IBS1
P10467004A0683|53 56|EBS1
P10467004A0683|58 61|IBS1
P10467004A0683|68 90|EBS2/IBS2 sequence motifs
P10467004A0683|68 71|EBS2
P10467004A0683|73 76|IBS2
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467403A0000|3 5|Trk
P10467403A0000|7 31|Nerve Growth Factor receptor
P10467403A0000|69 98|intracellular signaling proteins
P10467403A0000|109 136|phosphatidylinositol 3-kinase
P10467403A0000|109 136|phosphatidylinositol 3-kinase
P10467403A0000|138 147|PI 3-kinase
P10467403A0000|138 147|PI 3-kinase
P10467465T0000|36 64|misconceptions and alternatives
P10468033T0000|18 36|human stratum corneum
P10468033T0000|58 77|non-volatile solvents
P10468585A0980|4 13|DNA binding
P10468585A0980|15 40|transcriptional enhancement
P10468585A0980|49 64|amino-terminally
P10468585A0980|72 93|basic amino acid residues
P10468585A0980|103 126|carboxyl-terminal portion
P10468585A0980|129 133|Hap46
P10468585A0980|129 133|Hap46
P10468585A0980|154 169|hsp70 interaction
P10468585A0980|154 158|hsp70
P10469140A0336|37 55|NF-kappaB-like sites
P10469140A0336|37 55|NF-kappaB-like sites
P10469140A0336|68 88|PAI-2 proximal promoter
P10469140A0336|68 72|PAI-2
P10469140A0336|73 88|proximal promoter
P10469140A0336|108 115|TNFalpha
P10469140A0336|108 115|TNFalpha
P10469140A0336|121 172|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|121 164|chloramphenicol acetyl transferase reporter gene
P10469140A0336|176 191|mutation analyses
P10469174A0678|0 25|N-terminal sequence analysis
P10469174A0678|29 43|NMR measurements
P10469174A0678|85 104|C-terminal 80 residues
P10469174A0678|107 110|MBF1
P10469174A0678|107 110|MBF1
P10469174A0678|133 148|C-terminal domain
P10469174A0678|151 154|MBF1
P10469174A0678|151 154|MBF1
P10469174A0678|156 162|MBF1CTD
P10469174A0678|156 162|MBF1CTD
P10469656T0000|3 21|nucleosomal response
P10469656T0000|36 54|immediate-early gene
P10469656T0000|36 54|immediate-early gene
P10469656T0000|77 104|alternative MAP kinase cascades
P10469656T0000|88 96|MAP kinase
P10469656T0000|106 109|MSK1
P10469656T0000|106 109|MSK1
P10469656T0000|122 130|histone H3
P10469656T0000|129 130|H3
P10469656T0000|132 143|HMG-14 kinase
P10469656T0000|132 143|HMG-14 kinase
P10470220A1011|21 33|cutoff-levels
P10470220A1011|80 90|Protein S100
P10470220A1011|80 90|Protein S100
P10470220A1011|105 107|RIA
P10470220A1011|164 166|LIA
P10471383A0229|0 2|272
P10471587A0239|16 28|C. trachomatis
P10471587A0239|31 46|triplicate assays
P10471587A0239|58 69|RT-PCR method
P10471587A0239|102 122|conventional technique
P10471587A0239|184 189|RT-PCR
P10471587A0239|234 236|195
P10471696A0734|0 10|Null alleles
P10471696A0734|13 16|SAS4
P10471696A0734|13 16|SAS4
P10471696A0734|20 23|SAS5
P10471696A0734|20 23|SAS5
P10471696A0734|44 59|Abf1p binding site
P10471696A0734|44 59|Abf1p binding site
P10471696A0734|65 77|HMR-E silencer
P10471696A0734|65 77|HMR-E silencer
P10471696A0734|96 98|ACS
P10471696A0734|96 98|ACS
P10471696A0734|101 116|Rap1p binding site
P10471696A0734|101 116|Rap1p binding site
P10471721A0141|41 46|S locus
P10471721A0141|41 46|S locus
P10471721A0141|84 88|genes
P10471721A0141|95 97|SLG
P10471721A0141|95 97|SLG
P10471721A0141|99 101|SRK
P10471721A0141|99 101|SRK
P10471721A0141|125 135|pollen S gene
P10471721A0141|125 135|pollen S gene
P10471721A0141|137 137|s
P10471743A0000|1 4|cDNA
P10471743A0000|22 41|RNA and/or DNA helicase
P10471743A0000|22 24|RNA
P10471743A0000|31 41|DNA helicase
P10471743A0000|61 92|Arabidopsis thaliana cDNA libraries
P10471746A1102|7 10|MyoD
P10471746A1102|7 10|MyoD
P10471746A1102|23 37|tryptophan motif
P10471746A1102|45 63|chromatin remodeling
P10471746A1102|69 84|Myogenin promoter
P10471746A1102|69 84|Myogenin promoter
P10471746A1102|98 118|Myogenin transcription
P10471746A1102|98 105|Myogenin
P10472314A0717|20 22|TTP
P10472314A0717|25 28|PUNP
P10472314A0717|43 45|men
P10472314A0717|54 58|women
P10472836A0189|0 9|Feed intake
P10472836A0189|13 19|BW gains
P10473589A0189|3 11|N terminus
P10473589A0189|14 17|beta
P10473589A0189|19 24|95 kDa)
P10473589A0189|50 64|integrase domain
P10473589A0189|50 58|integrase
P10473589A0189|78 86|C terminus
P10473589A0189|88 93|32 kDa)
P10473598A0691|0 5|Skn-1a
P10473598A0691|0 5|Skn-1a
P10473598A0691|16 31|C-terminal region
P10473598A0691|16 31|C-terminal region
P10473598A0691|46 67|transactivation ability
P10473598A0691|118 132|transactivation
P10473598A0691|135 146|normal Skn-1a
P10473598A0691|141 146|Skn-1a
P10473598A0691|149 165|competition assays
P10473623A0081|7 20|Xenopus embryos
P10473623A0081|25 59|transforming growth factor-beta member
P10473623A0081|25 53|transforming growth factor-beta
P10473623A0081|60 66|activin
P10473623A0081|60 66|activin
P10473623A0081|77 85|gene Mix.2
P10473623A0081|114 132|multiprotein complex
P10473623A0081|134 161|activin-responsive factor (ARF
P10473623A0081|134 157|activin-responsive factor
P10473623A0081|159 161|ARF
P10474898A0629|62 76|CMT1A-REP repeat
P10474898A0629|78 107|fluorescent in situ hybridization
P10474898A0629|109 112|FISH
P10474898A0629|137 151|PCR-based assays
P10475972A0269|43 53|vaccination
P10475972A0269|63 72|stop deaths
P10476970A0542|29 56|Rapl GTPase-activating protein
P10476970A0542|29 56|Rapl GTPase-activating protein
P10476970A0542|64 72|rap1GAPII
P10476970A0542|64 72|rap1GAPII
P10476970A0542|96 109|alpha-subunits
P10476970A0542|96 109|alpha-subunits
P10476970A0542|115 118|G(i)
P10476970A0542|115 115|G
P10476970A0542|127 150|heterotrimeric G-proteins
P10476970A0542|127 150|heterotrimeric G-proteins
P10477545T0000|15 28|pertussis toxin
P10477545T0000|15 28|pertussis toxin
P10477545T0000|40 59|CC chemokine receptor 5
P10477545T0000|40 58|CC chemokine receptor
P10477545T0000|59 59|5
P10477545T0000|76 88|M-tropic HIV-1
P10477545T0000|84 95|HIV-1 strains
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000a|32 34|BCR
P10477583A0000a|32 34|BCR
P10477583A0000a|38 55|surface Fc receptors
P10477583A0000a|45 55|Fc receptors
P10477583A0000a|59 61|IgG
P10477583A0000a|59 61|IgG
P10477583A0000a|63 70|Fc gamma R
P10477583A0000a|63 70|Fc gamma R
P10477583A0000a|80 97|G1-to-S progression
P10477583A0000a|80 81|G1
P10477583A0000b|16 30|B cell Ag receptor
P10477583A0000b|16 30|B cell Ag receptor
P10477583A0000b|32 34|BCR
P10477583A0000b|32 34|BCR
P10477583A0000b|38 55|surface Fc receptors
P10477583A0000b|45 55|Fc receptors
P10477583A0000b|59 61|IgG
P10477583A0000b|59 61|IgG
P10477583A0000b|63 70|Fc gamma R
P10477583A0000b|63 70|Fc gamma R
P10477583A0000b|80 97|G1-to-S progression
P10477583A0000b|80 81|G1
P10477597A0126|0 4|TRAF2
P10477597A0126|0 4|TRAF2
P10477597A0126|26 53|95-kDa serine/threonine kinase
P10477597A0126|32 53|serine/threonine kinase
P10477597A0126|60 91|germinal center kinase related (GCKR
P10477597A0126|60 86|germinal center kinase related
P10477597A0126|88 91|GCKR
P10477597A0126|109 112|KHS1
P10477597A0126|109 112|KHS1
P10477597A0126|142 152|SAPK pathway
P10477597A0126|142 145|SAPK
P10477599T0000|2 29|activation-responsive element
P10477599T0000|38 66|C motif-1/lymphotactin promoter
P10477599T0000|38 45|C motif-1
P10477599T0000|47 58|lymphotactin
P10477599T0000|100 122|DNA-protein interactions
P10477599T0000|100 110|DNA-protein
P10477599T0000|132 160|nuclear factor of activated T cell
P10477599T0000|132 144|nuclear factor
P10477620A0580|0 42|Cytokine-induced NF-kappa B DNA binding activity
P10477620A0580|16 24|NF-kappa B
P10477620A0580|44 67|RelA nuclear translocation
P10477620A0580|44 47|RelA
P10477620A0580|48 67|nuclear translocation
P10477620A0580|69 80|I kappa B alpha
P10477620A0580|69 80|I kappa B alpha
P10477620A0580|93 107|I kappa B serine 32
P10477620A0580|93 99|I kappa B
P10477620A0580|100 107|serine 32
P10477620A0580|127 152|I kappa B kinase (IKK) activity
P10477620A0580|127 139|I kappa B kinase
P10477620A0580|141 143|IKK
P10477620A0580|166 173|curcumin
P10477748A1076|10 13|p193
P10477748A1076|10 13|p193
P10477748A1076|40 53|mitotic spindle
P10478275A1230|88 92|diet"
P10478275A1230|110 121|coronary risk
P10478275A1230|136 141|" foods
P10478275A1230|152 167|modern technology
P10478844A1604|0 13|Cotransfection
P10478844A1604|19 48|coactivator CREB-binding protein
P10478844A1604|30 48|CREB-binding protein
P10478844A1604|60 84|transcriptional repression
P10478844A1604|87 97|PPARalphawt
P10478844A1604|87 97|PPARalphawt
P10478844A1604|100 110|PPARalphatr
P10478844A1604|100 110|PPARalphatr
P10478844A1604|153 163|PPARalphatr
P10478844A1604|153 163|PPARalphatr
P10478844A1604|195 215|essential coactivators
P10478848A0331|0 3|SF-1
P10478848A0331|0 3|SF-1
P10478848A0331|17 35|N-terminal AF1 domain
P10478848A0331|17 35|N-terminal AF1 domain
P10479025A0528|38 54|TF-MUSIC algorithm
P10479025A0528|38 39|TF
P10479025A0528|69 80|target region
P10479025A0528|102 123|somatosensory responses
P10479382A1098|53 63|nutritional
P10479382A1098|81 106|odonate development patterns
P10479492A0000|54 57|SEER
P10479492A0000|99 134|corpus uteri adenocarcinoma FIGO stage II
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|37 69|Drosophila A kinase anchor protein 200
P10480937A0000|37 66|Drosophila A kinase anchor protein
P10480937A0000|71 78|DAKAP200
P10480937A0000|71 78|DAKAP200
P10480937A0000|106 112|routing
P10480937A0000|154 157|cAMP
P10480937A0000|159 182|Ca(2+), and diacylglycerol
P10480937A0000|159 163|Ca(2+
P10480937A0000|187 187|Z
P10482516A1158|2 19|vitro transcription
P10482516A1158|43 53|5' structure
P10482516A1158|107 115|stem-loop
P10482516A1158|134 157|transcription readthrough
P10482516T0000|1 2|5'
P10482516T0000|3 5|RNA
P10482516T0000|6 14|stem-loop
P10482516T0000|92 122|Bacillus subtilis trpEDCFBA operon
P10482516T0000|92 107|Bacillus subtilis
P10482516T0000|108 122|trpEDCFBA operon
P10482565A0469|0 35|Single-alanine-substitution mutations
P10482565A0469|62 88|S-induced cell-to-cell fusion
P10482620A1009|49 57|MMTV 5' LTR
P10482620A1009|49 57|MMTV 5' LTR
P10482620A1009|86 91|Stat5a
P10482620A1009|86 91|Stat5a
P10482620A1009|94 112|transcription factor
P10482620A1009|174 180|MMTV LTR
P10482620A1009|174 180|MMTV LTR
P10483124T0000|50 68|CIC5F11/CIC2B9 locus
P10483124T0000|50 56|CIC5F11
P10483124T0000|58 63|CIC2B9
P10483124T0000|109 123|Ac/Ds transposon
P10483124T0000|109 110|Ac
P10483124T0000|112 113|Ds
P10483124T0000|144 161|cDNA scanning method
P10483945A0641|8 12|CK-MB
P10483945A0641|8 12|CK-MB
P10483945A0641|38 45|patients
P10483945A0641|84 85|5x
P10483945A0641|100 107|patients
P10484695A0791|5 10|NART-R
P10484695A0791|59 66|patients
P10484695A0791|71 89|neurologic disorders
P10485353T0000|7 64|Haemophilus influenzae type b capsular polysaccharide antibodies
P10485353T0000|70 87|infants and children
P10485353T0000|103 114|Burkina-Faso
P10485353T0000|119 124|France
P10485353T0000|127 151|cross-sectional serosurvey
P10485470A0242|24 26|Sp1
P10485470A0242|24 26|Sp1
P10485470A0242|30 32|Sp3
P10485470A0242|30 32|Sp3
P10485470A0242|35 46|major factors
P10485470A0242|59 66|Sp1 sites
P10485470A0242|59 66|Sp1 sites
P10485470A0242|72 84|p21/WAF1/Cip1
P10485470A0242|72 74|p21
P10485470A0242|76 79|WAF1
P10485470A0242|81 84|Cip1
P10485470A0242|95 103|MG63 cells
P10485470A0242|111 144|electrophoretic mobility shift assays
P10485470A0242|158 169|TSA treatment
P10485470A0242|187 203|binding activities
P10485585A0175|0 6|Galoyan
P10485585A0175|46 70|cardioactive neurohormones
P10486210A0126|39 75|human aldehyde reductase gene and promoter
P10486210A0126|39 64|human aldehyde reductase gene
P10487040A0453|0 26|Immunohistochemical staining
P10487040A0453|31 35|MIB-1
P10487040A0453|31 35|MIB-1
P10487040A0453|39 51|p53 antibodies
P10487040A0453|39 41|p53
P10487217A0735|3 9|C2C-Prx
P10487217A0735|3 5|C2C
P10487217A0735|7 9|Prx
P10487217A0735|34 46|273 amino acids
P10487217A0735|58 92|putative chloroplast-targeting signal
P10487217A0735|95 96|65
P10487217A0735|97 106|amino acids
P10487217A0735|112 121|N-terminus
P10487307A0768|17 23|surgery
P10487307A0768|24 31|patients
P10487307A0768|46 56|intravenous
P10487307A0768|57 70|hydrocortisone
P10487307A0768|78 84|placebo
P10487307A0768|94 110|double-blind order
P10487744T0000|1 27|tyrosine-based sorting signal
P10487744T0000|33 62|beta2 integrin cytoplasmic domain
P10487744T0000|33 45|beta2 integrin
P10487744T0000|46 62|cytoplasmic domain
P10487744T0000|88 101|plasma membrane
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|40 46|Xenopus
P10487753A0788|58 78|embryonic cell division
P10487759A0630|15 28|Xenopus embryos
P10487759A0630|119 150|Xbra2 promoter-driven reporter gene
P10487759A0630|119 150|Xbra2 promoter-driven reporter gene
P10487760A0336|76 87|Xenopus MEF2D
P10487760A0336|76 82|Xenopus
P10487760A0336|91 111|yeast two-hybrid screen
P10487762A0252|0 3|NuA4
P10487762A0252|0 3|NuA4
P10487762A0252|32 37|1.3 MDa
P10487921A0132|0 16|ATF1 transcription
P10487921A0132|0 3|ATF1
P10487921A0132|40 60|unsaturated fatty acids
P10487921A0132|64 69|oxygen
P10487953A0765|3 10|patients
P10487953A0765|15 29|recurrent tumors
P10487953A0765|37 52|S-phase fractions
P10487953A0765|107 115|operation
P10488087A0340|10 27|TTF-1-binding sites
P10488087A0340|10 27|TTF-1-binding sites
P10488087A0340|29 40|TBE) 1, 3, and 4
P10488087A0340|29 33|TBE) 1
P10488087A0340|71 93|transcriptional activity
P10488087A0340|96 107|SP-A promoter
P10488087A0340|96 107|SP-A promoter
P10488087A0340|108 150|-chloramphenicol acetyltransferase constructs
P10488087A0340|109 140|chloramphenicol acetyltransferase
P10488087A0340|161 190|SP-A gene sequences from -256 to +45
P10488087A0340|161 177|SP-A gene sequences
P10488088T0000|0 25|Insulin-like growth factor-I
P10488088T0000|7 25|-like growth factor-I
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|56 109|transcription factor cAMP-response element-binding protein
P10488088T0000|56 74|transcription factor
P10488088T0000|75 109|cAMP-response element-binding protein
P10488129T0058|11 22|antisense RNA
P10488129T0058|26 48|S phase-dependent binding
P10488129T0058|51 62|E2F complexes
P10488129T0058|51 62|E2F complexes
P10488129T0058|65 71|intron 1
P10488147A1176|16 24|eotaxin-3
P10488147A1176|16 24|eotaxin-3
P10488147A1176|73 93|eosinophil trafficking
P10488147A1176|102 105|CCR3
P10488147A1176|102 105|CCR3
P10488148A0111|0 8|NF-kappaB
P10488148A0111|0 8|NF-kappaB
P10488148A0111|41 49|HIV-1 gene
P10488148A0111|41 45|HIV-1
P10488148A0111|46 59|gene expression
P10488148A0111|62 70|cytokines
P10488148A0111|93 118|signal transduction pathways
P10488148A1267|23 26|MAPK
P10488148A1267|23 26|MAPK
P10488148A1267|44 47|AP-1
P10488148A1267|44 47|AP-1
P10488148A1267|96 99|AP-1
P10488148A1267|96 99|AP-1
P10488148A1267|104 112|NF-kappaB
P10488148A1267|104 112|NF-kappaB
P10488148A1267|169 176|HIV-1 LTR
P10488148A1267|169 176|HIV-1 LTR
P10488148T0000|0 11|ERK MAP kinase
P10488148T0000|0 11|ERK MAP kinase
P10488148T0000|17 31|cytokine signals
P10488148T0000|52 56|HIV-1
P10488148T0000|104 107|AP-1
P10488148T0000|104 107|AP-1
P10488148T0000|111 119|NF-kappaB
P10488148T0000|111 119|NF-kappaB
P10488337T0000|1 31|human nuclear-localized chaperone
P10488337T0000|45 56|dimerization
P10488337T0000|58 67|DNA binding
P10488337T0000|72 94|transcriptional activity
P10488337T0000|97 108|bZIP proteins
P10488337T0000|97 108|bZIP proteins
P10488875A0000|0 22|Clinical differentiation
P10488875A0000|25 32|patients
P10488875A0000|49 61|cerebral palsy
P10488875A0000|63 64|CP
P10488875A0000|69 88|idiopathic toe walking
P10488875A0000|90 92|ITW
P10489680A0927|0 9|Sputum IL-8
P10489680A0927|6 9|IL-8
P10489680A0927|13 15|MPO
P10489680A0927|13 15|MPO
P10489680A0927|47 49|BPT
P10489680A0927|56 78|TDI- and grain dust-asthma
P10489822T0000|18 47|airway eosinophilic inflammation
P10489822T0000|50 55|asthma
P10490065T0000|19 24|angina
P10490065T0000|32 52|antithrombotic therapy
P10490604A0601|39 52|wild-type forms
P10490604A0601|39 47|wild-type
P10490604A0601|55 57|Fyn
P10490604A0601|55 57|Fyn
P10490604A0601|59 61|Lck
P10490604A0601|59 61|Lck
P10490604A0601|66 71|ZAP-70
P10490604A0601|66 71|ZAP-70
P10490604A0601|80 105|Cbl-mediated NFAT activation
P10490604A0601|80 82|Cbl
P10490604A0601|92 95|NFAT
P10490609A0413|0 12|Substitutions
P10490609A0413|15 21|region I
P10490609A0413|26 43|synthetic sequences
P10490609A0413|122 129|thymines
P10490609A0413|152 158|guanine
P10490609A0413|161 168|cytosine
P10490609A0413|187 197|ARS activity
P10490609A0413|187 189|ARS
P10490639A0000|2 24|Saccharomyces cerevisiae
P10490639A0000|26 30|PHO85
P10490639A0000|26 30|PHO85
P10490639A0000|39 67|cyclin-dependent protein kinase
P10490639A0000|39 67|cyclin-dependent protein kinase
P10490639A0000|69 88|Cdk) catalytic subunit
P10490639A0000|69 71|Cdk
P10490639A0000|162 175|cyclin partners
P10490639A0000|162 175|cyclin partners
P10490639A0000|177 180|Pcls
P10490639A0000|177 180|Pcls
P10490662A0431|92 102|compound eye
P10490662A0819|7 17|SPT activity
P10490662A0819|7 9|SPT
P10490662A0819|23 25|fly
P10490662A0819|36 53|epitope-tagged Lace
P10490662A0819|50 53|Lace
P10490662A0819|67 90|epitope-specific antibody
P10490816A0000|0 8|Mutations
P10490816A0000|14 20|RET gene
P10490816A0000|14 20|RET gene
P10490816A0000|30 52|a receptor tyrosine kinase
P10490816A0000|31 52|receptor tyrosine kinase
P10490816A0000|79 107|inherited cancer syndromes MEN 2A
P10490816A0000|111 115|MEN 2B
P10490816A0000|111 115|MEN 2B
P10490822A1167|31 37|Ras-GAP
P10490822A1167|31 33|Ras
P10490822A1167|35 37|GAP
P10490822A1167|58 75|anticancer approach
P10490826T0000|0 3|EB-1
P10490826T0000|0 3|EB-1
P10490826T0000|6 41|tyrosine kinase signal transduction gene
P10490826T0000|6 37|tyrosine kinase signal transduction
P10490826T0000|76 82|t(1;19)
P10490826T0000|76 78|t(1
P10490826T0000|91 98|pre-B ALL
P10490826T0000|112 122|oncoprotein
P10490826T0000|123 130|E2a-Pbx1
P10490826T0000|123 125|E2a
P10490826T0000|127 130|Pbx1
P10490835T0000|0 55|Protein kinase A-Ialpha subunit-directed antisense inhibition
P10490835T0000|0 27|Protein kinase A-Ialpha subunit
P10490835T0000|58 80|ovarian cancer cell growth
P10490835T0000|95 124|tyrosine kinase signaling pathway
P10490835T0000|95 108|tyrosine kinase
P10490843A0159|0 3|BCL6
P10490843A0159|0 3|BCL6
P10490843A0159|12 30|POZ/Zn finger protein
P10490843A0159|12 30|POZ/Zn finger protein
P10490843A0159|61 93|Drosophila developmental regulators
P10490843A0159|124 141|human hematopoietic
P10490843A0159|153 156|PLZF
P10490843A0159|153 156|PLZF
P10490955T0000|0 48|Beta 1 integrin- and proteoglycan-mediated stimulation
P10490955T0000|0 12|Beta 1 integrin
P10490955T0000|75 113|mitogen-activated protein kinase signaling
P10490955T0000|75 104|mitogen-activated protein kinase
P10490955T0000|116 131|thrombospondin-1
P10490955T0000|116 131|thrombospondin-1
P10490955T0000|135 158|thrombospondin-1 peptides
P10490955T0000|135 150|thrombospondin-1
P10491133A0365|7 8|CD
P10491133A0365|13 39|spectral and activity analyses
P10491133A0365|69 78|HO isozymes
P10491133A0365|69 78|HO isozymes
P10491133A0365|83 91|NO species
P10491133A0365|102 109|NO donors
P10491187T0000|3 26|phosphotransferase system
P10491187T0000|28 30|PTS
P10491187T0000|34 55|Streptomyces coelicolor
P10491187T0000|95 124|histidine phosphocarrier protein
P10491187T0000|95 103|histidine
P10491187T0000|125 127|HPr
P10491187T0000|125 127|HPr
P10491187T0000|144 147|ptsH
P10491213A0263|0 18|Serum concentrations
P10491213A0263|21 56|bone specific alkaline phosphatase (BALP
P10491213A0263|33 51|alkaline phosphatase
P10491213A0263|53 56|BALP
P10491213A0263|61 71|osteocalcin
P10491213A0263|61 71|osteocalcin
P10491213A0263|73 86|bone Gla protein
P10491213A0263|77 86|Gla protein
P10491213A0263|88 90|BGP
P10491213A0263|88 90|BGP
P10491213A0263|93 99|urinary
P10491213A0263|108 119|pyridinoline
P10491213A0263|121 123|Pyr
P10491213A0263|128 144|deoxypyridinoline
P10491213A0263|146 149|Dpyr
P10491213A0263|154 171|computed tomography
P10491213A0263|173 174|CT
P10491213A0263|218 226|vertebrae
P10491213A0263|270 273|bone
P10491213A0263|324 335|cortical bone
P10492127A0914|42 51|devazepide
P10492127A0914|62 96|cholecystokinin-A receptor antagonist
P10492127A0914|62 86|cholecystokinin-A receptor
P10492127A0914|137 160|postprandial saline intake
P10492169A0939|45 48|ESTs
P10492169A0939|81 95|plasma protein-A
P10492169A0939|81 95|plasma protein-A
P10492169A0939|97 102|PAPP-A
P10492169A0939|97 102|PAPP-A
P10492169A0939|108 116|novel gene
P10492169A0939|134 140|EST-YD1
P10492169A0939|134 140|EST-YD1
P10493203T0000|0 14|Prognostic value
P10493203T0000|18 39|treadmill exercise score
P10493203T0000|42 60|symptomatic patients
P10493203T0000|76 92|ST-T abnormalities
P10493203T0000|102 104|ECG
P10493575T0000|0 16|Structural changes
P10493575T0000|22 31|C-terminus
P10493575T0000|34 37|Ca2+
P10493575T0000|44 51|rat S100B
P10493575T0000|44 51|rat S100B
P10493575T0000|53 60|beta beta
P10493575T0000|53 60|beta beta
P10493575T0000|97 122|C-terminal regulatory domain
P10493575T0000|97 122|C-terminal regulatory domain
P10493575T0000|125 127|p53
P10493575T0000|125 127|p53
P10493580A1126|13 17|Gly84
P10493580A1126|118 138|esterase/lipase family
P10493580A1126|118 125|esterase
P10493580A1126|127 132|lipase
P10493876A0000|3 19|solution structure
P10493876A0000|65 75|fjord region
P10493876A0000|81 91|11S, 12R, 13R
P10493876A0000|93 95|14S
P10493876A0000|111 198|anti -11,12-dihydroxy-13,14-epoxy-11,12,13, 14-tetrahydrobenzo[g]chrysene, (+)- anti -B[g]CDE
P10493876A0000|205 213|exocyclic
P10493876A0000|214 214|N
P10493876A0000|233 249|adenine residue dA6
P10493876A0000|262 286|(+)- trans-anti -(B[g]C)dA6
P10493876A0000|262 282|(+)- trans-anti -(B[g]C
P10493876A0000|308 314|thymine
P10493876A0000|322 325|dT17
P10493876A0000|351 358|C1-T2-C3
P10493876A0000|351 358|C1-T2-C3
P10493876A0000|360 371|T4-C5-(B[g]C
P10493876A0000|360 361|T4
P10493876A0000|363 371|C5-(B[g]C
P10493876A0000|373 391|A6-C7-T8-T9-C10-C11
P10493876A0000|373 377|A6-C7
P10493876A0000|379 394|T8-T9-C10-C11). d
P10493876A0000|396 442|G12-G13-A14-A15-G16-T17-G18-A19-G20++ +-A21-G22)
P10493876A0000|396 398|G12
P10493876A0000|400 406|G13-A14
P10493876A0000|408 410|A15
P10493876A0000|412 414|G16
P10493876A0000|454 462|(B[g]C)dA
P10493876A0000|531 537|NMR data
P10493876A0000|555 587|molecular dynamics (MD) calculations
P10495573A0365|5 14|sildenafil
P10495573A0365|52 55|MUSE
P10495573A0365|110 119|sildenafil
P10495573A0365|124 127|MUSE
P10496161A0503|5 14|antibodies
P10496161A0503|52 61|guinea pigs
P10496161A0503|79 82|rats
P10496161A0503|90 96|3-16 WPI
P10496284A0115|33 42|CSF protein
P10496284A0115|33 42|CSF protein
P10496284A0115|46 64|immunoglobulin G (IgG
P10496284A0115|46 60|immunoglobulin G
P10496284A0115|62 64|IgG
P10496284A0115|102 109|IgG index
P10496284A0115|102 104|IgG
P10496284A0115|112 127|IgG synthesis rate
P10496284A0115|112 114|IgG
P10496303A1968|80 90|ganciclovir
P10496303A1968|92 96|AUC24
P10496303A1968|125 135|intravenous
P10496388A1956a|23 48|neurosensory retinal vessels
P10496388A1956b|23 48|neurosensory retinal vessels
P10496553A1004|16 35|HIV-positive patients
P10496553A1004|112 119|patients
P10496553A1004|124 155|acquired immunodeficiency syndrome
P10497117A0358|3 7|P mRNA
P10497117A0358|26 28|ORF
P10497117A0358|35 42|V protein
P10497117A0358|35 42|V protein
P10497117A0358|79 81|ORF
P10497199A0559|16 20|yeast
P10497199A0559|49 69|transcriptional factor
P10497199A0559|82 85|GlRE
P10497199A0559|94 147|chicken ovalbumin upstream promoter-transcription factor II
P10497199A0559|94 147|chicken ovalbumin upstream promoter-transcription factor II
P10497199A0559|149 157|COUP-TFII
P10497199A0559|149 157|COUP-TFII
P10497262A0000|15 29|single-copy gene
P10497262A0000|36 60|trans -spliceosomal U5 snRNA
P10497262A0000|36 60|trans -spliceosomal U5 snRNA
P10497262A0000|68 106|trypanosomatid species Leptomonas seymouri
P10497262A0000|113 134|U5 RNA affinity selection
P10497262A0000|138 148|cDNA cloning
P10497800A0000|3 8|MMPI-A
P10497800A0000|36 44|older MMPI
P10497800A0000|55 62|McKinley
P10497800A0000|90 107|anorexia and bulimia
P10497874A0925|15 34|phosphatidyl inositol
P10497874A0925|35 49|4,5 bisphosphate
P10497874A0925|51 54|PIP2
P10497874A0925|97 104|tyrosine
P10497874A0925|117 133|PLC-gamma1 isozyme
P10497874A0925|117 133|PLC-gamma1 isozyme
P10498616A0157|1 10|G22V mutant
P10498616A0157|1 4|G22V
P10498616A0157|13 17|M-Ras
P10498616A0157|13 13|M
P10498616A0157|15 17|Ras
P10498616A0157|61 119|interleukin-3 (IL-3)-dependent mast cell/megakaryocyte cell line
P10498616A0157|61 73|interleukin-3
P10498616A0157|75 78|IL-3
P10498616A0157|161 164|IL-3
P10498616A0157|161 164|IL-3
P10498616A0157|183 186|IL-4
P10498616A0157|183 186|IL-4
P10498616A0157|217 240|factor-independent growth
P10498616A1280|0 13|Mammalian M-Ras
P10498616A1280|0 8|Mammalian
P10498616A1280|9 13|M-Ras
P10498616A1280|18 48|Caenorhabditis elegans orthologue
P10498616A1280|188 193|p21 Ras
P10498616A1280|188 193|p21 Ras
P10498706A1219|32 35|PecS
P10498706A1219|32 35|PecS
P10498706A1219|46 66|pelD and pelE expression
P10498706A1219|46 49|pelD
P10498706A1219|53 56|pelE
P10498706A1219|90 106|repressor like KdgR
P10498706A1219|103 106|KdgR
P10498717A1048|30 33|RsmC
P10498717A1048|30 33|RsmC
P10498717A1048|53 69|rsmB transcription
P10498717A1048|53 56|rsmB
P10498717A1048|90 103|RsmA production
P10498717A1048|90 93|RsmA
P10499121A0542|28 32|users
P10499121A0542|46 62|Class D instruments
P10499357A0439|13 16|food
P10499357A0439|60 89|(FR)/fixed interval (FI) schedule
P10499357A0439|61 62|FR
P10499357A0439|91 100|FR20:FI120
P10499357A0439|147 161|operant behavior
P10499357A0439|174 182|Weeks -1, 4
P10499357A0439|217 229|neurotoxicity
P10501034A0839|0 27|Ribonuclease protection assays
P10501034A0839|40 43|hmg1
P10501034A0839|40 43|hmg1
P10501034A0839|47 50|hmg2
P10501034A0839|47 50|hmg2
P10501034A0839|99 123|spatially-modulated manner
P10501034A0839|156 188|terpenoid-containing pigment glands
P10501034A0839|191 197|embryos
P10501656A1415|0 21|Differential expression
P10501656A1415|36 55|Northern blot analysis
P10501656A1415|82 95|tumor cell lines
P10501936T0000|17 70|Neurospora crassa mitochondrial outer membrane protein TOM70
P10501936T0000|17 70|Neurospora crassa mitochondrial outer membrane protein TOM70
P10501936T0000|87 99|point mutation
P10501936T0000|101 103|RIP
P10501936T0000|101 103|RIP
P10501936T0000|120 145|mitochondrial protein import
P10501965A0879|14 33|transcriptional units
P10501965A0879|61 89|3' end of ribosomal s6 kinase (Rsk3
P10501965A0879|68 84|ribosomal s6 kinase
P10501965A0879|86 89|Rsk3
P10501965A0879|118 130|ORF-less genes
P10501965A0879|135 139|Gpr31
P10501965A0879|135 139|Gpr31
P10501965A0879|162 185|G-protein coupled receptor
P10501965A0879|162 185|G-protein coupled receptor
P10501969A1329|21 26|GATA-5
P10501969A1329|21 26|GATA-5
P10501969A1329|42 58|downstream targets
P10501969A1329|66 80|GATA-4, -5, and -6
P10501969A1329|66 71|GATA-4
P10502216A0289|42 50|efegatran
P10502216A0289|55 67|streptokinase
P10502216A0289|74 80|heparin
P10502216A0289|96 121|tissue plasminogen activator
P10502216A0289|102 121|plasminogen activator
P10502216A0289|123 125|TPA
P10502216A0289|123 125|TPA
P10502216A0289|129 147|coronary reperfusion
P10502216A0289|150 156|acute MI
P10502402A0129|21 25|TRAIL
P10502402A0129|21 25|TRAIL
P10502402A0129|53 86|activated human and mouse T lymphocytes
P10502402A0129|113 117|TRAIL
P10502402A0129|113 117|TRAIL
P10502402A0129|135 160|T cell-mediated cytotoxicity
P10502402A0129|167 182|immune regulation
P10502402A0533|54 79|signal transduction pathways
P10502402A0533|90 107|TRAIL gene induction
P10502402A0533|90 98|TRAIL gene
P10502402A0533|117 137|T lymphocyte activation
P10502434A0367|29 39|124 patients
P10502434A0367|44 63|endometrial carcinoma
P10502434A0604|6 13|patients
P10502434A0604|22 28|IBG3, 14
P10502434A0604|32 35|ICG1
P10502434A0604|37 37|9
P10502434A0604|41 49|ICG2, and 3
P10502434A0604|53 63|ICG3 disease
P10502522A0000|9 23|provirus genomes
P10502522A0000|26 54|human T-cell leukemia virus type I
P10502522A0000|26 54|human T-cell leukemia virus type I
P10502522A0000|78 88|lymphocytes
P10502522A0000|93 111|infected individuals
P10502522A0000|117 133|infected cell lines
P10503540A0602|26 53|interpretable banding patterns
P10503540A0602|88 94|alleles
P10503540A0602|97 120|native polyacrylamide gels
P10503812A1450|11 30|pharmacokinetic study
P10503812A1450|33 43|cyclosporin
P10503812A1450|46 60|organ transplant
P10503812A1450|61 68|patients
P10503812A1450|86 104|allograft recipients
P10503812A1450|163 189|cyclosporin pharmacokinetics
P10504332A0701|48 61|mutant receptor
P10504332A0701|48 61|mutant receptor
P10504332A0701|63 84|fluorescent-labeled RAP
P10504332A0701|82 84|RAP
P10504332A0701|113 128|endosomal pathway
P10504332A0701|158 174|wild-type receptor
P10504332A0701|158 174|wild-type receptor
P10504332A0701|207 222|lysosomal markers
P10505694A0000|0 13|Interleukin-12
P10505694A0000|0 13|Interleukin-12
P10505694A0000|15 19|IL-12
P10505694A0000|15 19|IL-12
P10505694A0000|24 31|cytokine
P10505694A0000|42 72|peripheral blood mononuclear cells
P10505694A0000|74 77|PBMC
P10505694A0000|89 104|interferon-gamma
P10505694A0000|89 104|interferon-gamma
P10505694A0000|106 114|IFN-gamma
P10505694A0000|106 114|IFN-gamma
P10505694A0000|142 166|cell-mediated cytotoxicity
P10505694A0739|0 14|IL-12 production
P10505694A0739|0 4|IL-12
P10505694A0739|32 34|C3a
P10505694A0739|32 34|C3a
P10505694A0739|93 100|dialysis
P10506143A0610|2 10|HeLa cells
P10506143A0610|15 19|JNKK2
P10506143A0610|21 37|JNK1 fusion protein
P10506143A0610|21 24|JNK1
P10506143A0610|55 65|JNK activity
P10506143A0610|55 57|JNK
P10506143A0610|95 98|JNK1
P10506143A0610|95 98|JNK1
P10506143A0610|144 146|EGF
P10506143A0610|144 146|EGF
P10506143A0610|148 156|TNF-alpha
P10506143A0610|148 156|TNF-alpha
P10506143A0610|158 167|anisomycin
P10506143A0610|169 181|UV irradiation
P10506143A0610|183 187|MEKK1
P10506143A0610|183 187|MEKK1
P10506143A0610|192 214|small GTP binding proteins
P10506143A0610|192 214|small GTP binding proteins
P10506143A0610|215 218|Rac1
P10506143A0610|215 218|Rac1
P10506143A0610|222 228|Cdc42Hs
P10506143A0610|222 228|Cdc42Hs
P10508522A1598|19 29|TGF-beta RII
P10508522A1598|19 29|TGF-beta RII
P10508522A1598|47 54|EWS-FLI1
P10508522A1598|47 54|EWS-FLI1
P10509768A1118|14 32|saturated fatty acids
P10509768A1118|106 126|serum cholesterol level
P10509768A1118|106 121|serum cholesterol
P10510295A0606|11 45|ethanol repression autoregulation (ERA
P10510295A0606|59 66|TA repeat
P10510295A0606|68 87|TAB) repressor element
P10510295A0606|110 123|promoter region
P10510295A0606|129 136|GLK1 gene
P10510295A0606|129 136|GLK1 gene
P10510379A0105|8 26|transcription factor
P10510379A0105|42 46|STAT6
P10510379A0105|42 46|STAT6
P10510379A0105|69 78|DNA element
P10510379A0105|83 100|cytokine activation
P10511216A0654|32 41|tarsal kink
P10511554T0000|1 5|local
P10511554T0000|7 18|high-density
P10511554T0000|63 88|Caenorhabditis elegans cdf-1
P10511554T0000|63 88|Caenorhabditis elegans cdf-1
P10512699A0364|22 39|secondary structure
P10512699A0364|41 52|SECIS element
P10512699A0364|59 84|selenoprotein-encoding mRNA
P10512699A0364|81 84|mRNA
P10512699A0364|135 148|opal (UGA) codon
P10512699T0000|0 19|High-level expression
P10512699T0000|39 66|selenocysteine-containing rat
P10512699T0000|64 86|rat thioredoxin reductase
P10512699T0000|67 86|thioredoxin reductase
P10512699T0000|121 147|bacterial-type SECIS elements
P10512699T0000|171 174|selA
P10512699T0000|171 174|selA
P10512699T0000|176 191|selB and selC genes
P10512699T0000|176 179|selB
P10512699T0000|183 191|selC genes
P10512857A0000|2 13|Wnt signaling
P10512857A0000|2 4|Wnt
P10512857A0000|15 26|beta-catenin
P10512857A0000|15 26|beta-catenin
P10512857A0000|30 40|plakoglobin
P10512857A0000|62 68|nucleus
P10512857A0000|92 119|TCF-type transcription factors
P10512857A0000|92 119|TCF-type transcription factors
P10512882A0137|25 27|FAK
P10512882A0137|25 27|FAK
P10512882A0137|31 40|Src kinases
P10512882A0137|31 40|Src kinases
P10512882A0137|91 107|enzymatic activity
P10512882A0137|122 139|Src family of kinases
P10512882A0137|122 139|Src family of kinases
P10513756A0584|3 9|EPV 3, 10
P10513756A0584|13 14|40
P10513756A0584|19 22|bias
P10513756A0584|84 104|conventional selection
P10513922A1237|63 78|myelinated fibers
P10513922A1237|119 126|neonatal
P10513922A1237|130 140|adult groups
P10514493A0199|0 1|Me
P10514493A0199|15 37|neuronal differentiation
P10514493A0199|40 64|N1E-115 neuroblastoma cells
P10514493A0199|96 130|endogenous Ntr-1 gene and reporter genes
P10514493A0199|96 114|endogenous Ntr-1 gene
P10514493A0199|139 160|NTR-1 promoter sequences
P10514493A0199|139 143|NTR-1
P10514808T0000|0 26|Cortical dysplasias, genetics
P10516011A0471|28 41|peptide mapping
P10516011A0471|63 86|site-directed mutagenesis
P10516011A0471|106 128|pAP phosphorylation sites
P10516011A0471|106 108|pAP
P10516026A0270|4 18|HERV-K type 1 and 2
P10516072A0146|0 3|Duch
P10516738A0925|21 28|patients
P10516738A0925|50 64|irbesartan/HCTZ
P10516878T0000|0 11|Modification
P10516878T0000|14 39|dopamine D2 receptor activity
P10516878T0000|14 31|dopamine D2 receptor
P10516878T0000|53 70|Parkinson's disease
P10516878T0000|74 84|in vivo study
P10516878T0000|87 89|PET
P10517666A1069|0 24|High-affinity binding sites
P10517666A1069|32 33|GR
P10517666A1069|32 33|GR
P10517666A1069|37 54|AP-1 nucleoproteins
P10517666A1069|37 40|AP-1
P10517666A1069|41 54|nucleoproteins
P10517666A1069|71 86|adjacent elements
P10517666A1069|96 99|nGRE
P10517672A1417|9 19|-bp fragment
P10517672A1417|32 65|alpha1-globin promoter-CAT construct
P10517672A1417|32 52|alpha1-globin promoter
P10517672A1417|54 56|CAT
P10517672A1417|86 110|CCAAT transcription factor 1
P10517672A1417|86 110|CCAAT transcription factor 1
P10517672A1417|112 115|CTF1
P10517672A1417|112 115|CTF1
P10517672A1417|118 120|NF1
P10517672A1417|118 120|NF1
P10517672A1417|125 157|Drosophila Schneider SL2 insect cells
P10517672A1417|168 183|NF1-like proteins
P10517672A1417|168 183|NF1-like proteins
P10517672A1417|203 213|CAT activity
P10517672A1417|203 205|CAT
P10517675A0809|0 18|Western blot analysis
P10517675A0809|54 72|p21WAF1/CIP1 protein
P10517675A0809|54 60|p21WAF1
P10517675A0809|62 65|CIP1
P10517675A0809|114 150|cyclin-dependent kinase inhibitor family
P10517675A0809|114 150|cyclin-dependent kinase inhibitor family
P10517675A0809|152 158|p27kip1
P10517675A0809|152 158|p27kip1
P10518496A0952|13 45|vHnf1-deficient embryonic stem cells
P10518496A0952|13 17|vHnf1
P10518496A0952|50 58|wild-type
P10518496A0952|69 75|embryos
P10518496A0952|105 125|extraembryonic tissues
P10518496A0952|134 158|periimplantation lethality
P10518496A0952|191 208|early organogenesis
P10518502T0000|0 4|nos-1
P10518502T0000|0 4|nos-1
P10518502T0000|8 12|nos-2
P10518502T0000|8 12|nos-2
P10518502T0000|31 45|Drosophila nanos
P10518502T0000|31 45|Drosophila nanos
P10518502T0000|65 83|germ cell development
P10518502T0000|97 117|Caenorhabditis elegans
P10518561A0261|8 43|upstream regulators of Tec family kinases
P10518561A0261|28 43|Tec family kinases
P10518561A0261|93 111|downstream effectors
P10518561A0261|119 125|enzymes
P10518561A0885|9 23|phosphorylation
P10518561A0885|26 30|BRDG1
P10518561A0885|26 30|BRDG1
P10518561A0885|33 35|Tec
P10518561A0885|33 35|Tec
P10518561A0885|47 61|PH and SH2 domains
P10518561A0885|47 48|PH
P10518561A0885|52 61|SH2 domains
P10518561A0885|73 84|kinase domain
P10518822A1037|33 39|eotaxin
P10518822A1037|73 83|acute asthma
P10518822A1037|120 131|CCR3 receptor
P10518822A1037|120 131|CCR3 receptor
P10518822A1037|172 177|asthma
P10518937A0572|26 35|KlHIS4 gene
P10518937A0572|26 35|KlHIS4 gene
P10518937A0572|41 59|phosphate starvation
P10518937A0572|62 78|high adenine supply
P10518937A0572|102 105|Bas1
P10518937A0572|102 105|Bas1
P10518937A0572|108 111|Bas2
P10518937A0572|108 111|Bas2
P10518937A0572|126 137|basal control
P10518956A0137|5 25|thyroid hormone changes
P10518956A0137|47 55|cytokines
P10518956A0137|63 83|inflammatory mediators
P10518956A0137|106 134|hypothalamus and pituitary gland
P10518956A0137|139 150|thyroid gland
P10518956A0137|158 180|hepatic deiodinase system
P10518956A0137|158 174|hepatic deiodinase
P10518956A1212|0 7|ESS type 1
P10518956A1212|22 24|FT4
P10518956A1212|28 30|TSH
P10520800A0307|19 37|symptomatic patients
P10520800A0307|42 45|HOCM
P10520800A0307|49 51|men
P10520800A0307|88 102|septal reduction
P10520800A0307|108 123|echocardiography
P10520800A0307|127 143|electrocardiogram
P10520800A0307|145 147|ECG
P10521345A0202|0 20|Paleoceanographic data
P10521345A0202|28 40|Laurentian Fan
P10521345A0202|57 59|sea
P10521345A0202|171 174|16th
P10521345A0202|177 180|19th
P10521345A0202|213 235|NAO-driven coupled system
P10521443A0486|21 32|IR activation
P10521443A0486|54 63|IR mutation
P10521443A0486|54 55|IR
P10521443A0486|66 74|tyrosines
P10521443A0486|93 111|NF-kappaB activation
P10521443A0486|93 101|NF-kappaB
P10521443A0486|149 178|dominant-negative IkappaB-alpha
P10521443A0486|149 178|dominant-negative IkappaB-alpha
P10521443A0486|180 185|A32/36
P10521443A0486|180 182|A32
P10521443A0486|184 185|36
P10521443A0486|219 239|NF-kappaB c-Rel subunit
P10521443A0486|219 232|NF-kappaB c-Rel
P10521447A0606|19 19|B
P10521447A0606|19 19|B
P10521447A0606|55 60|TGTGGT
P10521447A0606|63 71|core motif
P10521447A0606|96 132|AML/CBFalpha transcription factor family
P10521447A0606|96 132|AML/CBFalpha transcription factor family
P10521447A1190|28 41|AML3/CBFalpha1
P10521447A1190|28 31|AML3
P10521447A1190|33 41|CBFalpha1
P10521447A1190|56 63|AML1-ETO
P10521447A1190|56 59|AML1
P10521447A1190|61 63|ETO
P10521450A0437|2 22|examined Akt activation
P10521450A0437|10 12|Akt
P10521450A0437|25 58|Lyn-, Syk- and Btk-deficient DT40 cells
P10521450A0437|25 27|Lyn
P10521450A0437|30 32|Syk
P10521450A0437|37 39|Btk
P10521450A0437|62 67|B cells
P10521450A0437|72 83|Lyn(-/-) mice
P10521450A0437|72 79|Lyn(-/-)
P10521509A0000|0 9|Regulators
P10521509A0000|12 41|G protein signaling (RGS) proteins
P10521509A0000|12 19|G protein
P10521509A0000|30 32|RGS
P10521509A0000|53 66|DEP (disheveled
P10521509A0000|53 55|DEP
P10521509A0000|57 66|disheveled
P10521509A0000|68 73|EGL-10
P10521509A0000|68 73|EGL-10
P10521509A0000|75 84|pleckstrin
P10521509A0000|75 84|pleckstrin
P10521509A0000|89 125|GGL (G protein gamma subunit-like) domains
P10521509A0000|89 91|GGL
P10521509A0000|93 125|G protein gamma subunit-like) domains
P10521509A0000|155 174|mammalian RGS proteins
P10521509A0000|155 174|mammalian RGS proteins
P10521509A0000|175 178|RGS6
P10521509A0000|175 178|RGS6
P10521509A0000|180 183|RGS7
P10521509A0000|180 183|RGS7
P10521509A0000|185 188|RGS9
P10521509A0000|185 188|RGS9
P10521509A0000|193 197|RGS11
P10521509A0000|193 197|RGS11
P10521544T0000|31 55|human alpha 1,2-mannosidase
P10521544T0000|31 55|human alpha 1,2-mannosidase
P10521544T0000|65 75|Man9GlcNAc2
P10521544T0000|78 88|Man8GlcNAc2
P10521544T0000|95 95|B
P10521544T0000|102 121|N-glycan biosynthesis
P10521796A0872|3 5|ORs
P10521796A0872|8 9|GC
P10521796A0872|78 108|superficial intestinal metaplasia
P10521796A0872|110 111|IM
P10521796A0872|137 138|IM
P10521796A0872|141 153|mild dysplasia
P10521796A0872|155 157|DYS
P10521796A0872|161 162|IM
P10521796A0872|167 182|glandular atrophy
P10521796A0872|186 200|neck hyperplasia
P10521796A0872|232 240|severe DYS
P10521796A0872|256 263|subjects
P10521796A0872|268 287|superficial gastritis
P10521796A0872|289 290|SG
P10521796A0872|294 317|chronic atrophic gastritis
P10521796A0872|319 321|CAG
P10523319A0209|16 20|Dbp5p
P10523319A0209|16 20|Dbp5p
P10523319A0209|24 28|Rat7p
P10523319A0209|24 28|Rat7p
P10523319A0209|49 64|Nterminal domains
P10523520A0986|41 51|Hh molecules
P10523520A0986|41 51|Hh molecules
P10523520A0986|59 63|phyla
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|70 82|Cbf5p proteins
P10523634A1404|70 82|Cbf5p proteins
P10523634A1404|95 109|box H/ACA snoRNAs
P10523634A1404|98 109|H/ACA snoRNAs
P10523634A1404|128 152|functional catalytic domain
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|47 66|Stat3 phosphorylation
P10523640A0367|47 51|Stat3
P10523640A0367|69 76|tyrosine
P10523640A0367|90 117|Stat3-mediated gene regulation
P10523640A0367|90 94|Stat3
P10523640A0367|130 161|tyrosine and serine phosphorylation
P10523640A0367|164 168|Stat3
P10523640A0367|164 168|Stat3
P10523647A0000|3 21|transcription factor
P10523647A0000|22 25|CHOP
P10523647A0000|22 25|CHOP
P10523647A0000|27 50|C/EBP homologous protein 10
P10523647A0000|27 48|C/EBP homologous protein
P10523647A0000|55 65|bZIP protein
P10523647A0000|55 65|bZIP protein
P10523647A0000|101 123|cellular stress responses
P10523647A0000|169 187|programmed cell death
P10523647A1001|5 8|CHOP
P10523647A1001|49 64|C/EBP target genes
P10523647A1001|49 64|C/EBP target genes
P10523647A1001|87 97|AP-1 factors
P10523647A1001|87 97|AP-1 factors
P10523647A1001|110 124|AP-1 target genes
P10523647A1001|110 113|AP-1
P10523647A1001|114 124|target genes
P10523663A0404|30 62|Drosophila homeobox activator DEAF-1
P10523663A0404|30 62|Drosophila homeobox activator DEAF-1
P10523674A0000|0 7|RNase MRP
P10523674A0000|0 7|RNase MRP
P10523674A0000|11 43|ribonucleoprotein endoribonuclease
P10523674A0000|77 103|mitochondrial DNA replication
P10523674A0000|117 131|S rRNA processing
P10524258A0286|32 41|FGFR-1 gene
P10524258A0286|32 41|FGFR-1 gene
P10524258A0286|43 47|cek-1
P10524258A0286|43 47|cek-1
P10524258A0286|51 55|avian
P10524258A0286|74 92|immunocytochemistry
P10524258A0286|96 115|Northern blot analysis
P10524258T0000|12 47|avian fibroblast growth factor receptor 1
P10524258T0000|12 47|avian fibroblast growth factor receptor 1
P10524258T0000|49 69|FGFR-1) gene expression
P10524258T0000|49 59|FGFR-1) gene
P10525413A1408|21 28|residues
P10525413A1408|53 67|CRP2(LIM2)R122A
P10525413A1408|53 56|CRP2
P10525413A1408|58 61|LIM2
P10525413A1408|63 67|R122A
P10525413A1408|91 97|proton-
P10525413A1408|111 125|NMR spectroscopy
P10526670A0236|0 2|Rac
P10526670A0236|0 2|Rac
P10526670A0236|20 33|actin filaments
P10526670A0236|20 33|actin filaments
P10526670A0236|35 41|F-actin
P10526670A0236|35 41|F-actin
P10526670A0236|48 56|plus-ends
P10526670A0236|65 84|phosphatidylinositol
P10526670A0236|85 99|4,5 bisphosphate
P10526670A0236|101 104|PIP2
P10526670A0236|127 142|membrane ruffling
P10526670A1828|17 29|ICE/caspase-1
P10526670A1828|17 19|ICE
P10526670A1828|21 29|caspase-1
P10526670A1828|45 49|N1445
P10526670A1828|72 90|CK-induced apoptosis
P10526670A1828|72 73|CK
P10526670A1828|105 107|PKB
P10526670A1828|105 107|PKB
P10526670A1828|131 132|CK
P10526670A1828|131 132|CK
P10526670A1828|154 170|Ras transformation
P10526670A1828|154 156|Ras
P10527158T0000|3 7|AL-R8
P10527158T0000|65 80|USDOE Pantex Plant
P10527180A0869|83 105|Cox multivariate analysis
P10527180A0869|149 152|1.17
P10527180A0869|176 177|CI
P10527180A0869|236 237|CI
P10527180A0869|259 274|hormone receptors
P10527180A0869|284 285|CI
P10527180A0869|308 327|adjuvant chemotherapy
P10527180A0869|337 338|CI
P10527180A0869|351 377|initial disease-free survival
P10527180A0869|391 407|adjuvant treatment
P10527180A0869|437 438|CI
P10527180A0869|451 460|metastases
P10527180A0869|466 470|liver
P10527180A0869|480 481|CI
P10527180A0869|495 514|central nervous system
P10527180A0869|524 525|CI
P10527180A0869|563 572|soft tissue
P10527180A0869|574 584|bone, or lung
P10527180A0869|600 616|metastatic disease
P10527180A0869|626 627|CI
P10527180A0869|643 660|incomplete response
P10527180A0869|681 705|standard-dose chemotherapy
P10527180A0869|715 716|CI
P10527426A0521|12 29|SBEI gene transcript
P10527426A0521|12 29|SBEI gene transcript
P10527426A0521|60 71|exon I+II+III
P10527426A0521|88 92|5' end
P10527426A0521|132 138|intron 1
P10527426A0521|152 166|exon II sequences
P10527475A0643|2 3|PC
P10527475A0643|9 13|MNGCs
P10527475A0643|42 48|grooves
P10528035A1102|46 79|serum alanine aminotransferase levels
P10528035A1102|46 73|serum alanine aminotransferase
P10529198A0068|3 27|C-terminal catalytic domain
P10529198A0068|60 81|homologues p140(ras-GRF
P10529198A0068|70 73|p140
P10529198A0068|75 77|ras
P10529198A0068|79 81|GRF
P10529198A0068|86 88|Sos
P10529198A0068|86 88|Sos
P10529246A0362|4 8|93-98
P10529354A0375|3 12|proteasome
P10529354A0375|43 64|multisubunit structures
P10529354A0375|69 71|20S
P10529354A0375|69 71|20S
P10529354A0375|75 77|19S
P10529354A0375|75 77|19S
P10529354A0375|79 83|PA700
P10529354A0375|79 83|PA700
P10529354A0375|87 98|P28 complexes
P10529354A0375|87 98|P28 complexes
P10529354A0375|120 131|26S particles
P10529354A0375|120 122|26S
P10531334A0525|0 7|In assays
P10531334A0525|20 26|enzymes
P10531334A0525|28 36|wild-type
P10531334A0525|43 51|PTPS-S19A
P10531334A0525|43 46|PTPS
P10531334A0525|48 51|S19A
P10531334A0525|79 115|cGMP-dependent protein kinase (cGK) type I
P10531334A0525|79 105|cGMP-dependent protein kinase
P10531334A0525|107 120|cGK) type I and II
P10531340A1275|0 0|R
P10531342A0348|3 18|N-terminal domain
P10531342A0348|58 73|amino acid repeats
P10531342A0348|96 127|promastigote surface glycoproteins
P10531342A0348|133 148|psa2/gp46 complex
P10531342A0348|133 136|psa2
P10531342A0348|138 141|gp46
P10531342A1111|35 54|proteophosphoglycans
P10531342A1111|59 73|ppg1 gene product
P10531342A1111|59 62|ppg1
P10531342A1111|89 107|membrane-associated
P10531342A1111|129 151|promastigote cell surface
P10531360A0958|39 57|adenoviral construct
P10531360A0958|39 57|adenoviral construct
P10531360A0958|101 108|VEGF mRNA
P10531360A0958|101 108|VEGF mRNA
P10531360A0958|133 139|hypoxia
P10531446A0203|0 9|Neuregulin
P10531446A0203|20 24|ErbB2
P10531446A0203|20 24|ErbB2
P10531446A0203|26 30|ErbB3
P10531446A0203|26 30|ErbB3
P10531446A0203|35 39|ErbB4
P10531446A0203|35 39|ErbB4
P10531446A0203|53 87|ErbB family of receptor tyrosine kinases
P10531446A0203|53 56|ErbB
P10531446A0203|65 87|receptor tyrosine kinases
P10532354A1374|21 25|Anu2p
P10532354A1374|21 25|Anu2p
P10532354A1374|31 44|yeast homologue
P10532354A1374|31 44|yeast homologue
P10532354A1374|47 66|mammalian epsilon-COP
P10532354A1374|47 66|mammalian epsilon-COP
P10532354A1374|96 105|ER membrane
P10532354A1374|128 155|early protein transport pathway
P10532354A1374|175 191|nuclear morphology
P10532354A1374|204 213|yeast cells
P10532805A0792|2 10|PC12 cells
P10532805A0792|12 28|nerve growth factor
P10532805A0792|12 28|nerve growth factor
P10532805A0792|36 58|neuronal differentiation
P10532805A0792|83 87|nrg-1
P10532805A0792|83 87|nrg-1
P10532805A1084|3 16|PC12 cell mutant
P10532805A1084|34 55|protein kinase A activity
P10532805A1084|34 47|protein kinase A
P10532805A1084|57 61|AB.11
P10532805A1084|57 58|AB
P10532805A1084|60 61|11
P10532805A1084|72 92|differentiating agents
P10532805A1084|118 126|nrg-1 mRNA
P10532805A1084|118 126|nrg-1 mRNA
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|23 39|nonsense mutations
P10533066A0758|64 78|splice mutations
P10533066A1197|6 13|patients
P10533066A1197|21 33|abnormalities
P10533066A1197|39 41|PTT
P10533066A1197|39 41|PTT
P10533066A1197|88 91|TSC2
P10533066A1197|88 91|TSC2
P10534048A0297|8 16|algorithm
P10534048A0297|18 25|FOREPROJ
P10534048A0297|87 89|3-D
P10534048A0297|119 121|ACF
P10534048A0297|138 169|two-dimensional (2-D) transmission
P10534048A0297|236 255|3-D forward projection
P10534402A0126|19 28|genomic DNA
P10534402A0126|33 41|mouse gene
P10534402A0126|33 41|mouse gene
P10534402A0126|129 140|Spo11p family
P10534402A0126|129 140|Spo11p family
P10534402A0659|0 5|RT-PCR
P10534402A0659|9 35|in situ hybridization analyses
P10534402A0659|51 64|juvenile testis
P10534402A0659|88 102|Spo11 expression
P10534402A0659|88 92|Spo11
P10534402A0659|111 131|early meiotic Prophase I
P10534402A0659|143 156|pachytene stage
P10534402A0659|186 189|mRNA
P10534402A0659|200 213|pachytene stage
P10534691A0542|38 43|grafts
P10534691A0542|80 99|microbiologic culture
P10534691A0542|103 130|standard histologic procedures
P10534691A0542|144 152|infection
P10535715A0268|3 5|RMR
P10535715A0268|76 85|follicular
P10535715A0268|104 109|luteal
P10536125A0093|0 10|Oseltamivir
P10536125A0093|42 47|orally
P10536125A0093|63 68|GS4071
P10536125A0093|100 127|influenzavirus neuraminidases
P10536125A0093|100 127|influenzavirus neuraminidases
P10536369A0662|2 23|gel mobility shift assays
P10536369A0662|45 61|VDR-TR heterodimer
P10536369A0662|45 47|VDR
P10536369A0662|49 50|TR
P10536369A1280|60 81|element-specific manner
P10536788A0931|29 38|PL profiles
P10536788A0931|84 96|control livers
P10536788A0931|116 117|PL
P10536788A0931|140 141|PL
P10540015A0664|0 3|C-SP
P10540015A0664|37 47|ALS patients
P10540015A0664|108 110|MEP
P10540292A1179|20 36|spv virulence genes
P10540292A1179|20 36|spv virulence genes
P10540292A1179|109 121|spv expression
P10540292A1179|109 111|spv
P10540292A1179|149 175|multiple environmental inputs
P10540553A0980|0 17|Intensive synthesis
P10540553A0980|20 22|PNA
P10540553A0980|35 51|microvascular wall
P10540553A0980|72 89|functional activity
P10540915A0697|32 44|hilar ligation
P10540915A0697|46 47|TL
P10540915A0697|49 50|PL
P10541432A0185|0 27|Kinase-deficient erbB proteins
P10541432A0185|16 27|erbB proteins
P10541432A0185|35 59|epidermal growth factor (EGF
P10541432A0185|35 55|epidermal growth factor
P10541432A0185|57 59|EGF
P10541432A0185|69 91|tyrosine phosphorylation
P10541432A0185|94 114|endogenous Shc proteins
P10541432A0185|104 114|Shc proteins
P10541432A0185|150 177|EGF-induced ERK MAPK activities
P10541432A0185|150 152|EGF
P10541432A0185|161 167|ERK MAPK
P10541432A0185|180 201|human glioblastoma cells
P10541432A0185|211 232|basal ERK MAPK activities
P10541432A0185|216 222|ERK MAPK
P10541550A0487|5 22|immunolocalization
P10541550A0487|37 40|ACE3
P10541550A0487|37 40|ACE3
P10541550A0487|43 62|440-bp chorion element
P10541550A0487|43 62|440-bp chorion element
P10541550A0487|124 140|DmORC localization
P10541550A0487|124 128|DmORC
P10541550A0487|143 155|follicle cells
P10541865A1301|34 39|CDKN2A
P10541865A1301|34 39|CDKN2A
P10541865A1301|43 48|CDKN2B
P10541865A1301|43 48|CDKN2B
P10541865A1301|59 67|mutations
P10541865A1301|129 134|tumors
P10542237A0357|15 28|aortic explants
P10542237A0357|41 58|PPARalpha-null mice
P10542237A0357|41 49|PPARalpha
P10542237A0357|89 107|inflammatory stimuli
P10542237A0357|115 132|lipopolysaccharide
P10542237A0357|134 136|LPS
P10542237A0357|164 176|IL-6 secretion
P10542237A0357|164 167|IL-6
P10542249A0415|0 16|Albumin expression
P10542249A0415|0 6|Albumin
P10542249A0415|34 38|liver
P10542249A0415|55 88|liver-enriched transcription factors
P10542249A0415|95 121|CAAT enhancer-binding protein
P10542249A0415|95 121|CAAT enhancer-binding protein
P10542249A0415|123 133|C/EBP)alpha
P10542249A0415|123 133|C/EBP)alpha
P10542249A0415|137 145|C/EBPbeta
P10542249A0415|137 145|C/EBPbeta
P10542260A0832|17 35|proteolytic activity
P10542260A0832|42 46|FVIIa
P10542260A0832|42 46|FVIIa
P10542260A0832|50 52|FXa
P10542260A0832|50 52|FXa
P10542260A0832|65 91|protease-activated receptors
P10542260A0832|65 91|protease-activated receptors
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|20 24|Abeta
P10542269A0000|20 24|Abeta
P10542269A0000|48 61|amyloid fibrils
P10542269A0000|69 81|senile plaques
P10542269A0000|85 99|cerebral vessels
P10542269A0000|102 119|Alzheimer's disease
P10542269A0000|121 122|AD
P10542269A0000|156 183|beta-amyloid precursor protein
P10542269A0000|156 183|beta-amyloid precursor protein
P10542269A0000|185 187|APP
P10542269A0000|185 187|APP
P10542274A1376|26 39|protein kinase A
P10542274A1376|26 39|protein kinase A
P10542274A1376|41 43|PKA
P10542274A1376|41 43|PKA
P10542274A1376|81 107|caveolin-1 protein expression
P10542274A1376|81 97|caveolin-1 protein
P10542274A1376|111 126|promoter activity
P10542277A0000|3 31|importin alpha.beta heterodimer
P10542277A0000|3 15|importin alpha
P10542277A0000|17 31|beta heterodimer
P10542277A0000|40 52|nuclear import
P10542281A0382|12 16|G1-G2
P10542281A0382|28 37|hyaluronan
P10542281A0382|69 92|immunoglobulin-fold motif
P10542281A0382|69 82|immunoglobulin
P10542281A0382|108 119|tandem repeat
P10542281A0382|130 137|G1 domain
P10542281A0382|130 137|G1 domain
P10542281A2021|48 61|keratan sulfate
P10542281A2021|64 74|native G1-G2
P10542281A2021|70 74|G1-G2
P10542281A2021|101 110|atrolysin C
P10543270A1054|9 24|v. steroid therapy
P10543270A1054|27 31|NOexh
P10543727A0282|10 21|binding sites
P10543727A0282|32 51|transcription factors
P10543727A0282|100 132|rel/NF-kappaB transcription factors
P10543727A0282|100 102|rel
P10543727A0282|104 112|NF-kappaB
P10543727A0282|138 143|3'-end
P10543727A0282|148 168|H2TF1 or kappaB1 element
P10543727A0282|148 152|H2TF1
P10543727A0282|155 168|kappaB1 element
P10543727A0282|182 191|kappaB site
P10543727A0282|182 191|kappaB site
P10543727A0282|196 209|kappaB2 element
P10543727A0282|196 209|kappaB2 element
P10543727A0282|245 246|5'
P10543727A0282|252 263|H2TF1 element
P10543727A0282|252 263|H2TF1 element
P10543727A0282|286 289|p65/
P10543727A0282|286 288|p65
P10543727A0282|290 293|relA
P10543727A0282|290 293|relA
P10543727A0282|299 312|human HLA system
P10543727A0282|299 306|human HLA
P10543727A0282|324 331|AP-1/ATF
P10543727A0282|324 327|AP-1
P10543727A0282|329 350|ATF recognition sequence
P10543727A0282|356 368|5' end (EnA-TRE
P10543727A0282|362 368|EnA-TRE
P10543728A0358|14 24|E1A + cHa-ras
P10543728A0358|14 16|E1A
P10543728A0358|18 24|cHa-ras
P10543728A0358|67 86|DNA binding activities
P10543728A0358|89 92|AP-1
P10543728A0358|89 92|AP-1
P10543728A0358|106 124|nontransformed cells
P10543728A0358|131 138|E1A cells
P10543728A0358|131 133|E1A
P10543730A0000|3 31|yeast C-type cyclin Ume3p/Srb11p
P10543730A0000|3 19|yeast C-type cyclin
P10543730A0000|20 24|Ume3p
P10543730A0000|26 31|Srb11p
P10543730A0000|38 59|cyclin-dependent kinase
P10543730A0000|38 59|cyclin-dependent kinase
P10543730A0000|61 69|Cdk) Ume5p
P10543730A0000|61 63|Cdk
P10543730A0000|65 69|Ume5p
P10543730A0000|121 143|stress response or meiosis
P10543949A0686|16 33|S1' specificity site
P10543949A0686|16 18|S1'
P10543949A0686|50 66|hydrophobic cavity
P10544037A0617|0 3|FZD4
P10544037A0617|0 3|FZD4
P10544037A0617|18 21|FZD9
P10544037A0617|18 21|FZD9
P10544037A0617|25 29|FZD10
P10544037A0617|25 29|FZD10
P10544037A0617|41 57|amino acid identity
P10544037A0617|70 73|FZD4
P10544037A0617|76 79|FZD9
P10544037A0617|76 79|FZD9
P10544037A0617|87 90|FZD4
P10544037A0617|93 97|FZD10
P10544037A0617|93 97|FZD10
P10544037A0617|105 108|FZD9
P10544037A0617|111 115|FZD10
P10544037A0617|111 115|FZD10
P10544088A0308|3 38|NF-kappaB responsive reporter construct
P10544088A0308|3 38|NF-kappaB responsive reporter construct
P10544088A0308|41 49|PRDII)(4)
P10544088A0308|41 48|PRDII)(4
P10544088A0308|51 53|CAT
P10544088A0308|51 53|CAT
P10544088A0308|97 105|NF-kappaB
P10544088A0308|97 105|NF-kappaB
P10544088A0308|117 119|Tat
P10544088A0308|117 119|Tat
P10544089A1208|3 16|RNA transcripts
P10544089A1208|41 50|I(2) sgRNAs
P10544089A1208|41 50|I(2) sgRNAs
P10544089A1208|53 57|TMV U1
P10544089A1208|53 57|TMV U1
P10544089A1208|61 65|crTMV
P10544089A1208|81 96|hairpin structure
P10544089A1208|98 98|H
P10544089A1208|121 131|IRES(MP,75)
P10544089A1208|121 124|IRES
P10544089A1208|126 127|MP
P10544089A1208|129 131|75)
P10544089A1208|133 141|HIRES(MP)
P10544089A1208|133 137|HIRES
P10544089A1208|139 140|MP
P10544089A1208|143 162|(75)(CR)-MP-CP-3'UTR
P10544089A1208|148 162|CR)-MP-CP-3'UTR
P10544089A1208|164 175|HIRES(MP,75)
P10544089A1208|170 171|MP
P10544089A1208|173 175|75)
P10544089A1208|177 191|U1)-MP-CP-3'UTR
P10544089A1208|177 191|U1)-MP-CP-3'UTR
P10544089A1208|214 219|MP gene
P10544089A1208|214 215|MP
P10544113A0293|0 14|EIAV LTR sequence
P10544113A0293|0 6|EIAV LTR
P10544113A0293|45 56|small portion
P10544113A0293|62 69|enhancer
P10544113A0293|79 87|U3 segment
P10544113A0293|79 87|U3 segment
P10544113A0293|93 95|LTR
P10545192T0000|0 27|Phosphatidylinositol 3-kinase
P10545192T0000|0 27|Phosphatidylinositol 3-kinase
P10545192T0000|56 74|ras/C-raf-1/MEK/ERK
P10545192T0000|56 58|ras
P10545192T0000|60 66|C-raf-1
P10545192T0000|68 70|MEK
P10545192T0000|72 74|ERK
P10545192T0000|78 85|p70(s6k)
P10545192T0000|78 80|p70
P10545192T0000|82 84|s6k
P10545192T0000|107 126|insulinomimetic agent
P10545192T0000|127 140|vanadyl sulfate
P10545248A0567|13 20|enhancer
P10545248A0567|32 66|evolutionarily conserved binding sites
P10545248A0567|73 90|homeodomain protein
P10545248A0567|73 90|homeodomain protein
P10545248A0567|91 96|Tinman
P10545248A0567|91 96|Tinman
P10545248A0567|98 100|Tin
P10545248A0567|98 100|Tin
P10545248A0567|114 164|developing cardiac, somatic, and visceral muscle lineages
P10545281A0836|70 91|C-terminal coding region
P10545281A0836|70 79|C-terminal
P10545281A0836|114 146|bop gene mRNA and protein accumulation
P10545281A0836|114 124|bop gene mRNA
P10548434A1549|32 53|polyoma middle T antigens
P10548434A1549|32 38|polyoma
P10548434A1549|45 53|T antigens
P10548434A1549|63 97|retinoic acid-induced differentiation
P10548434A1549|114 116|ERK
P10548434A1549|114 116|ERK
P10548434A1549|124 144|JNK/SPK or p38 signaling
P10548434A1549|124 126|JNK
P10548434A1549|128 130|SPK
P10548434A1549|133 135|p38
P10548622A0906|36 45|lignocaine
P10548622A0906|77 96|v. sedation/analgesia
P10548622A0906|103 115|egg collection
P10548622A0906|157 174|ultrasound guidance
P10548622A0906|176 180|TUGOR
P10548722A0099|41 44|H1.8
P10548722A0099|41 42|H1
P10548722A0099|59 71|TcP2beta genes
P10548722A0099|59 71|TcP2beta genes
P10548722A0099|132 135|SIRE
P10548722A0099|137 170|short interspersed repetitive element
P10548722A0099|202 210|first gene
P10548722A0099|216 234|tandem and downstream
P10549354A1782|13 15|APC
P10549354A1782|25 51|colon carcinomas and melanomas
P10549354A1782|83 92|Tcf-4/beta
P10549354A1782|83 87|Tcf-4
P10549354A1782|89 100|beta-catenin
P10549354A1782|93 109|-catenin complexes
P10549354A1782|143 151|N terminus
P10549354A1782|154 165|beta-catenin
P10549354A1782|154 165|beta-catenin
P10549354A1782|207 209|APC
P10549354A1782|207 209|APC
P10549354A1782|211 218|GSK3 beta
P10549354A1782|211 218|GSK3 beta
P10549354A1782|223 236|Axin/Conductin
P10549354A1782|223 226|Axin
P10549354A1782|228 236|Conductin
P10549354A2371|40 52|Tcf target gene
P10549354A2371|40 42|Tcf
P10549354A2371|84 91|melanoma
P10549354A2371|107 112|cancer
P10549912A0136|48 72|acute myocardial infarction
P10549912A0136|85 100|right ventricular
P10549912A0136|126 133|anterior
P10549912A0136|157 161|V1-V4
P10549912A0136|157 158|V1
P10549912A0136|160 161|V4
P10549912A0136|188 211|right ventricular branches
P10549912A0136|219 237|coronary angioplasty
P10549912A0136|243 255|right coronary
P10549912A0136|256 261|artery
P10550139A0191|36 55|radical prostatectomy
P10550139A0191|57 75|bone marrow aspirates
P10550139A0191|94 103|iliac crest
P10550139A0191|120 127|patients
P10550571A0000|28 49|pharmacokinetic studies
P10550571A0000|77 84|patients
P10550571A0000|94 116|platinum-based compounds
P10550571A0000|145 151|WR-2721
P10550571A0000|154 169|endogenous thiols
P10550574A1038|12 35|nonhematologic toxicities
P10550574A1038|46 54|infection
P10550574A1038|66 89|serum alkaline phosphatase
P10550574A1038|66 89|serum alkaline phosphatase
P10551788A0229|0 5|LHbeta
P10551788A0229|0 5|LHbeta
P10551788A0229|19 43|pituitary gonadotrope cells
P10551788A0229|47 52|CGbeta
P10551788A0229|47 52|CGbeta
P10551788A0229|66 90|placental trophoblast cells
P10551796T0000|12 29|HIV-1 transcription
P10551796T0000|12 16|HIV-1
P10551816A0162|0 10|Human LTBP-1
P10551816A0162|0 10|Human LTBP-1
P10551848A0000|54 62|MacLennan
P10551867A0350|12 15|2185
P10551867A0350|16 32|amino acid residues
P10551867A0350|43 60|9-kilobase pair mRNA
P10551867A0350|69 82|splice variants
P10551867A0350|101 111|human and rat
P10551867A0350|112 124|cDNA libraries
P10551879T0000|0 38|Cyclic AMP-dependent protein kinase binding
P10551879T0000|0 31|Cyclic AMP-dependent protein kinase
P10551879T0000|41 48|A-kinase
P10551879T0000|42 65|-kinase anchoring proteins
P10551879T0000|81 101|fluorescence resonance
P10551879T0000|118 154|green fluorescent protein fusion proteins
P10551879T0000|118 140|green fluorescent protein
P10552357A1936|40 99|octafluoropropane-filled microspheres to air-filled microspheres
P10552357A1936|103 117|LV opacification
P10552357A1936|132 135|OCTA
P10552357A1936|168 177|LV function
P10552357A1936|232 234|AIR
P10553551A0000|0 17|Factor XI deficiency
P10553551A0000|0 7|Factor XI
P10553551A0000|25 34|hereditary
P10553551A0000|63 78|intrinsic pathway
P10554946A0082|7 22|traditional SERMS
P10554946A0082|24 40|clomiphene citrate
P10554946A0082|44 52|tamoxifen
P10554946A0082|107 114|faslodex
P10554946A0082|146 163|breast, uterus, bone
P10554946A0082|167 172|lipids
P10555079A0254|0 1|Ti
P10555079A0254|12 33|feather-like morphology
P10555285A1065|65 85|primate FUT3-FUT5-FUT6
P10555285A1065|72 75|FUT3
P10555285A1065|77 80|FUT5
P10555285A1065|82 85|FUT6
P10555285A1065|118 165|long-interspersed-nuclear-element-based mechanism
P10555285A1065|205 217|globin cluster
P10555285A1065|205 217|globin cluster
P10555964A0778|0 0|S
P10556028A0292|32 53|plasmid incompatibility
P10556028A0292|72 89|stem-loop structure
P10556028A0292|94 105|repA promoter
P10556028A0292|94 105|repA promoter
P10556028A0292|107 110|Prep
P10556028A0292|131 146|RepA binding sites
P10556028A0292|131 146|RepA binding sites
P10556028A0292|148 151|BD-1
P10556028A0292|148 151|BD-1
P10556028A0292|155 158|BD-2
P10556028A0292|155 158|BD-2
P10556029A0852|0 11|WA constructs
P10556029A0852|30 48|positive topoisomers
P10556033A0000|3 18|RFX protein family
P10556033A0000|3 18|RFX protein family
P10556033A0000|38 42|yeast
P10556033A0000|45 50|humans
P10556033A0000|101 117|DNA-binding domain
P10556033A0000|101 117|DNA-binding domain
P10556033A0000|131 146|C-terminal region
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556044A0913|88 96|LG modules
P10556046A0328|33 70|BMP/ALK2/Smad-mediated signaling pathway
P10556046A0328|33 35|BMP
P10556046A0328|37 40|ALK2
P10556046A0328|42 45|Smad
P10556046A0328|84 92|right side
P10556046A0328|98 110|Xenopus embryo
P10556063A0092|45 56|Trk subfamily
P10556063A0092|45 56|Trk subfamily
P10556089A0901|19 23|etr-1
P10556089A0901|19 23|etr-1
P10556089A0901|38 54|muscle development
P10556089A0901|57 65|C. elegans
P10556089A0901|90 119|post-transcriptional processing
P10556089A0901|182 193|gene function
P10556089A0901|198 209|human CUG-bp.
P10556089A0901|198 208|human CUG-bp
P10556145A1034|0 9|Gentamicin
P10556145A1034|17 19|DPI
P10556145A1034|23 25|SVN
P10556145A1034|51 66|sputum Psa density
P10556263A1035|32 41|joint space
P10556263A1035|65 86|rheumatoid AC joint space
P10556595A0391|25 38|mutant recN gene
P10556595A0391|25 38|mutant recN gene
P10556595A0391|56 67|transversion
P10556595A0391|75 79|3' end
P10556595A0391|85 96|coding region
P10556751A0758|52 54|HGV
P10556751A0758|89 91|HGV
P10556751A0758|151 161|dental staff
P10557008T0000|22 27|Impila
P10557008T0000|29 46|Callilepis laureola
P10557008T0000|51 64|mother and child
P10557072A0127|26 43|mouse and human cDNAs
P10557072A0127|34 43|human cDNAs
P10557072A0127|52 68|UNC-51-like kinase
P10557072A0127|52 54|UNC
P10557072A0127|63 68|kinase
P10557072A0127|70 73|ULK1
P10557072A0127|70 73|ULK1
P10557072A0418|0 3|ULKs
P10557072A0418|0 3|ULKs
P10557072A0418|7 12|UNC-51
P10557072A0418|43 70|an amino-terminal kinase domain
P10557072A0418|45 70|amino-terminal kinase domain
P10557072A0418|73 107|central proline/serine rich (PS) domain
P10557072A0418|99 107|PS) domain
P10557072A0418|113 137|carboxy-terminal (C) domain
P10557072A0418|113 130|carboxy-terminal (C
P10557072A1218|23 26|ULK2
P10557072A1218|23 26|ULK2
P10557072A1218|65 80|signaling pathway
P10557072A1218|83 96|mammalian cells
P10557308A0000|0 16|Connector enhancer
P10557308A0000|0 16|Connector enhancer
P10557308A0000|19 21|KSR
P10557308A0000|19 21|KSR
P10557308A0000|23 25|CNK
P10557308A0000|23 25|CNK
P10557308A0000|30 47|multidomain protein
P10557308A0000|59 70|RAS signaling
P10557308A0000|59 61|RAS
P10559207A0207|2 17|simpler organisms
P10559207A0207|22 35|ATP sulfurylase
P10559207A0207|22 35|ATP sulfurylase
P10559207A0207|39 56|APS kinase reactions
P10559207A0207|39 47|APS kinase
P10559207A0207|79 85|enzymes
P10559207A0207|164 172|evolution
P10559303A0000|0 43|Epstein-Barr virus (EBV) latent membrane protein 1
P10559303A0000|0 16|Epstein-Barr virus
P10559303A0000|18 20|EBV
P10559303A0000|22 43|latent membrane protein 1
P10559303A0000|45 48|LMP1
P10559303A0000|45 48|LMP1
P10559303A0000|64 89|EBV-mediated transformation
P10559303A0000|92 110|primary B lymphocytes
P10559320A0080|3 20|amino-terminal half
P10559320A0080|23 24|1a
P10559320A0080|28 41|distant homolog
P10559320A0080|35 77|homolog of alphavirus nonstructural protein nsP1
P10559320A0080|74 77|nsP1
P10559320A0080|103 118|capping viral RNAs
P10559324A0716|10 22|recombinant Ad
P10559324A0716|33 43|Ad5 E4orf6/7
P10559324A0716|33 35|Ad5
P10559324A0716|36 43|E4orf6/7
P10559324A0716|51 59|apoptosis
P10559324A0716|62 69|rat cells
P10559324A0716|74 83|coinfected
P10559324A0716|88 99|wild-type p53
P10559324A0716|88 99|wild-type p53
P10559324A0716|111 112|Ad
P10559364A0846|2 5|HCMV
P10559364A0846|7 11|Towne
P10559364A0846|22 28|HF cells
P10559364A0846|39 41|IE2
P10559364A0846|39 41|IE2
P10559364A0846|75 88|DNA replication
P10559364A0846|114 141|polymerase processivity factor
P10559364A0846|124 146|processivity factor (UL44
P10559364A0846|143 146|UL44
P10559364A0846|152 183|single-stranded DNA binding protein
P10559364A0846|177 187|protein (SSB
P10559364A0846|185 187|SSB
P10559364A0846|189 192|UL57
P10559364A0846|198 222|UL112-113 accessory protein
P10559364A0846|207 222|accessory protein
P10559364A0846|262 265|BrdU
P10560014A0000|0 20|Macroscopic researches
P10560014A0000|23 42|heart vascularization
P10560014A0000|85 100|conducting system
P10560014A0000|121 136|normal myocardium
P10560997A1072|14 37|Measuring urinary LH levels
P10560997A1072|30 31|LH
P10560997A1072|71 79|ovulation
P10561095A2141|27 41|cervical disease
P10561095A2141|71 86|calcitonin levels
P10561095A2141|71 80|calcitonin
P10561095A2141|122 148|permanent hypoparathyroidism
P10561153A0225|16 24|carcinoma
P10561153A0225|30 45|breast presenting
P10561153A0225|62 64|SSc
P10561153A0225|93 122|dialysis-dependent renal failure
P10561251A0000|21 40|disease-free survival
P10561251A0000|69 85|prognostic factors
P10561251A0000|118 122|women
P10561251A0000|127 159|stage IIIB inflammatory breast cancer
P10561251A0000|161 163|IBC
P10561251A0000|176 198|combined modality therapy
P10561251A0000|207 232|high-dose chemotherapy (HDCT
P10561251A0000|248 271|stem-cell transplantation
P10561460A0615|3 17|GPI anchor moiety
P10561460A0615|88 91|cDNA
P10561460A0615|112 145|signal peptide and GPI signal sequences
P10561546A0000|25 40|mammalian protein
P10561546A0000|64 83|anti-peptide antibody
P10561546A0000|64 75|anti-peptide
P10561546A0000|93 135|epitope-containing nuclear localization signal
P10561546A0000|138 156|NF-kappaB p65 subunit
P10561546A0000|138 156|NF-kappaB p65 subunit
P10562418A0238|0 6|Insulin
P10562456T0000|22 29|promoter
P10562456T0000|33 43|third intron
P10562456T0000|49 65|growth hormone gene
P10562456T0000|49 65|growth hormone gene
P10562456T0000|68 79|rainbow trout
P10562456T0000|81 105|Oncorhynchus mykiss walbaum
P10562495A0188|12 19|SFV genes
P10562495A0188|66 74|SFV genome
P10563212A0514|21 22|SF
P10563212A0514|47 49|QoL
P10563212A0514|96 113|historical controls
P10563605A0773|40 43|IENF
P10563605A0773|47 68|sural nerve unmyelinated
P10563789A1951|26 42|F beta alpha/CG beta
P10563789A1951|26 35|F beta alpha
P10563789A1951|37 42|CG beta
P10563789A1951|78 79|CG
P10563789A1951|78 79|CG
P10563789A1951|83 94|FSH receptors
P10563789A1951|83 94|FSH receptors
P10563836A1234|11 29|AP-2 binding activity
P10563836A1234|11 14|AP-2
P10563836A1234|55 63|T47D cells
P10563836A1234|68 79|Western blots
P10563836A1234|98 114|AP-2 protein levels
P10563836A1234|98 108|AP-2 protein
P10564231A0315|0 0|N
P10564280A0140|16 52|tyrosine-phosphorylated nuclear protein
P10564280A0140|16 52|tyrosine-phosphorylated nuclear protein
P10564280A0140|54 60|YT521-B
P10564280A0140|54 60|YT521-B
P10564280A0140|91 147|nuclear transcriptosomal component scaffold attachment factor B
P10564280A0140|91 147|nuclear transcriptosomal component scaffold attachment factor B
P10564280A0140|155 172|68-kDa Src substrate
P10564280A0140|155 163|68-kDa Src
P10564280A0140|189 195|mitosis
P10564280A0140|197 201|Sam68
P10564280A0140|197 201|Sam68
P10564472A0853|38 47|TraR fusion
P10564472A0853|38 41|TraR
P10564472A0853|53 68|two-hybrid system
P10564474T0000|0 8|PhoP-PhoQ
P10564474T0000|0 3|PhoP
P10564474T0000|5 8|PhoQ
P10564474T0000|21 41|Pseudomonas aeruginosa
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|93 102|polymyxin B
P10564479A0384|0 7|Deletion
P10564479A0384|10 13|fdsR
P10564479A0384|10 13|fdsR
P10564479A0384|45 48|FdsR
P10564479A0384|45 48|FdsR
P10564479A0384|54 62|fds operon
P10564479A0384|54 62|fds operon
P10564479A0384|73 96|transcriptional activator
P10564479A0384|112 118|formate
P10564479A0384|146 152|formate
P10564484A0859|27 37|binding site
P10564484A0859|57 64|promoter
P10564484A0859|136 154|specific binding site
P10564484A0859|162 169|promoter
P10564495A0444|19 29|Opa proteins
P10564495A0444|19 29|Opa proteins
P10564495A0444|32 35|C751
P10564495A0444|53 61|HeLa cells
P10564495A0444|77 80|cDNA
P10564495A0444|92 114|carcinoembryonic antigen
P10564495A0444|92 114|carcinoembryonic antigen
P10564495A0444|116 118|CEA
P10564495A0444|116 118|CEA
P10564495A0444|120 125|CD66e)
P10564495A0444|120 124|CD66e
P10564495A0444|140 149|CD66 family
P10564495A0444|140 149|CD66 family
P10564495A0444|176 186|CGM1- (CD66d
P10564495A0444|176 179|CGM1
P10564495A0444|182 186|CD66d
P10564495A0444|191 193|NCA
P10564495A0444|191 193|NCA
P10564495A0444|195 216|CD66c)-expressing cells
P10564495A0444|195 199|CD66c
P10564593A0428|0 3|FISH
P10564593A0428|10 30|whole chromosome 4 paint
P10564593A0428|43 64|multiple rearrangements
P10564593A0428|74 84|chromosome 4
P10564593A0428|87 109|MCF-7 AdVp3000 and MCF-7 MX
P10564593A0428|116 123|S1-M1-80
P10564593A0428|116 120|S1-M1
P10564593A0428|144 166|reciprocal translocation
P10564593A1618|3 9|MXR gene
P10564593A1618|3 9|MXR gene
P10564593A1618|154 172|MXR half-transporter
P10564593A1618|154 172|MXR half-transporter
P10564593A1618|195 207|drug transport
P10564939A0981|11 17|smoking
P10566630A0371|5 29|insulin-like growth factor I
P10566630A0371|5 29|insulin-like growth factor I
P10566630A0371|31 35|IGF-I
P10566630A0371|31 35|IGF-I
P10566630A0371|70 80|men and women
P10566862A0000|57 60|real
P10566862A0000|63 93|simulated depth stereoacuity tests
P10566862A0000|121 128|patients
P10566862A0000|133 162|binocular imbalance or strabismus
P10567430A0785|29 50|bovine brain Galpha(q/11
P10567430A0785|40 45|Galpha
P10567430A0785|47 50|q/11
P10567430A0785|69 87|N-terminal construct
P10567430A0785|69 78|N-terminal
P10567430A0785|90 93|GRK2
P10567430A0785|90 93|GRK2
P10567430A0785|111 121|Galpha(q/11
P10567430A0785|111 116|Galpha
P10567430A0785|118 121|q/11
P10567430A0785|124 129|Galpha
P10567430A0785|124 129|Galpha
P10567430A0785|131 131|s
P10567430A0785|134 139|Galpha
P10567430A0785|134 139|Galpha
P10567430A0785|141 141|i
P10567430A0785|146 151|Galpha
P10567430A0785|146 151|Galpha
P10567430A0785|153 157|12/13
P10567430A0785|183 186|GRK5
P10567430A0785|183 186|GRK5
P10567430A0785|189 192|GRK6
P10567430A0785|189 192|GRK6
P10567524T0000|3 21|elm1 kinase functions
P10567524T0000|3 12|elm1 kinase
P10567524T0000|25 47|mitotic signaling network
P10567524T0000|57 61|yeast
P10567533A0818|0 27|Reverse transcription (RT)-PCR
P10567533A0818|58 74|degenerate primers
P10567533A0818|89 103|conserved motifs
P10567533A0818|113 127|tyrosine kinases
P10567533A0818|113 127|tyrosine kinases
P10567538A1028|11 30|the acetyltransferase
P10567538A1028|41 44|p300
P10567538A1028|41 44|p300
P10567538A1028|114 140|CH3 domain/E1A-binding region
P10567538A1028|114 122|CH3 domain
P10567538A1028|124 140|E1A-binding region
P10567581A0119|25 29|HNF-3
P10567581A0119|25 29|HNF-3
P10567581A0119|31 56|fork head homolog-11B protein
P10567581A0119|31 56|fork head homolog-11B protein
P10567581A0119|58 64|HFH-11B
P10567581A0119|58 64|HFH-11B
P10567581A0119|77 83|Trident
P10567581A0119|77 83|Trident
P10567581A0119|87 89|Win
P10567581A0119|87 89|Win
P10567581A0119|111 150|winged helix/fork head transcription factors
P10567581A0119|111 150|winged helix/fork head transcription factors
P10567581A0119|156 172|regenerating liver
P10567581A0119|206 220|hepatocyte entry
P10567581A0119|225 238|DNA replication
P10567581A0119|240 245|S phase
P10567582A1334|5 15|mouse, CtBP1
P10567582A1334|11 15|CtBP1
P10567582A1334|31 36|embryo
P10567582A1334|48 52|CtBP2
P10567582A1334|48 52|CtBP2
P10567582A1334|76 88|embryogenesis
P10567589A1268|3 19|multiple functions
P10567589A1268|22 26|Pmt3p
P10567589A1268|22 26|Pmt3p
P10567589A1268|58 72|nuclear proteins
P10567589A1268|87 91|Pmt3p
P10567589A1268|87 91|Pmt3p
P10568275A0679|20 25|sea ice
P10568275A0679|33 39|Kara Sea
P10568275A0679|47 57|Arctic Ocean
P10568275A0679|87 92|GEOMAR
P10568455A0000|49 57|estradiol
P10568455A0000|59 64|17beta
P10568455A0000|66 70|SRE2)
P10568455A0000|82 96|pseudopregnancy
P10568455A0000|114 122|PGF2alpha
P10568455A0000|138 170|corpora lutea (CL) of pseudopregnancy
P10568728A1445|10 28|serum creatine kinase
P10568728A1445|10 28|serum creatine kinase
P10568728A1445|59 63|ESWIB
P10568744A0728|17 23|22 sites
P10568744A0728|36 44|promoters
P10568744A0728|52 70|alpha-specific genes
P10568744A0728|52 70|alpha-specific genes
P10568744A0728|93 117|alpha2-Mcm1-dependent role
P10568744A0728|93 98|alpha2
P10568744A0728|100 103|Mcm1
P10568744A0728|145 163|mating type switching
P10570262A0000|12 17|T cells
P10570262A0000|24 26|TCR
P10570262A0000|24 26|TCR
P10570262A0000|74 90|signaling cascades
P10570996A1213|1 20|phylogenetic analysis
P10570996A1213|28 36|TK domains
P10570996A1213|71 84|novel scavenger
P10570996A1213|76 87|scavenger RTK
P10570996A1213|85 87|RTK
P10570996A1213|125 142|TK class II receptors
P10570996A1213|127 142|class II receptors
P10570996A1213|183 189|insulin
P10570996A1213|183 189|insulin
P10570996A1213|193 213|insulin-like receptors
P10570996A1213|193 213|insulin-like receptors
P10571047A1009|7 30|7SL RNA-encoding sequences
P10571047A1009|7 30|7SL RNA-encoding sequences
P10571047A1009|88 103|HindIII fragments
P10571047A1009|88 103|HindIII fragments
P10571474A0571|34 52|CA3 dendritic atrophy
P10572087A0326|35 60|Fanconi anemia group C protein
P10572087A0326|35 53|Fanconi anemia group C
P10572087A0326|62 66|FANCC
P10572087A0326|62 66|FANCC
P10572087A0326|70 93|yeast two-hybrid screening
P10572130A1623|27 49|transcription activators
P10572130A1623|91 103|RNA polymerase
P10572130A1623|91 103|RNA polymerase
P10572130A1623|141 151|DNA geometry
P10572131A0000|0 16|Klebsiella oxytoca
P10572131A0000|54 60|enzymes
P10572131A0000|73 87|nasFEDCBA operon
P10572131A0000|73 87|nasFEDCBA operon
P10572866A0481|0 14|Marked hemolysis
P10572866A0481|37 48|plasma values
P10572866A0481|51 59|potassium
P10572866A0481|88 112|aspartate aminotransferase
P10572866A0481|88 112|aspartate aminotransferase
P10573781A0631|61 71|chromosomes
P10573781A0631|83 84|10
P10573781A0631|85 95|chromosomes
P10574913A1108|22 56|GRK-mediated receptor phosphorylation
P10574913A1108|22 41|GRK-mediated receptor
P10574913A1108|58 88|beta-arrestin-mediated processes
P10574913A1108|58 70|beta-arrestin
P10574913A1108|95 97|Src
P10574913A1108|95 97|Src
P10574913A1108|112 119|clathrin
P10574913A1108|129 143|internalization
P10574913A1108|164 189|GPCR-mediated ERK activation
P10574913A1108|164 167|GPCR
P10574913A1108|177 179|ERK
P10574913A1108|224 236|ERK activation
P10574913A1108|224 226|ERK
P10574929A0583|7 30|subcellular fractionation
P10574929A0583|35 53|47-kDa P-CIP2 protein
P10574929A0583|35 53|47-kDa P-CIP2 protein
P10574982A1075|10 14|EMSAs
P10574982A1075|29 60|upstream stimulatory factor-1 and -2
P10574982A1075|29 60|upstream stimulatory factor-1 and -2
P10574982A1075|62 71|USF-1 and -2
P10574982A1075|62 71|USF-1 and -2
P10574992A0901|11 13|E1A
P10574992A0901|11 13|E1A
P10574992A0901|27 34|p300/CBP
P10574992A0901|27 30|p300
P10574992A0901|32 34|CBP
P10574992A0901|56 73|PARP enzyme activity
P10574992A0901|56 65|PARP enzyme
P10574992A0901|116 126|irradiation
P10574992A0901|163 183|PARP chemical inhibitor
P10574992A0901|163 166|PARP
P10574992A0901|184 199|3-aminobenzamide
P10575231A0355|41 53|13-kb Cdc6 gene
P10575231A0355|46 53|Cdc6 gene
P10575231A0355|69 73|exons
P10575231A0355|78 84|introns
P10575545A0147|15 19|CACCC
P10575545A0147|23 32|CAAT motifs
P10575642T0000|0 12|Skin pH changes
P10575642T0000|27 39|iontophoresis
P10576177A0308|77 85|prognoses
P10576545A0926|23 44|regulatory DNA cassettes
P10576545A0926|57 77|murine D1A gene promoter
P10576545A0926|57 77|murine D1A gene promoter
P10576545A0926|96 122|neuronal-specific expression
P10578528A0730|46 48|EEG
P10578528A0730|105 134|neuropsychologic symptomatology
P10579331A1225|42 44|rat
P10579331A1225|45 68|HDL receptor SR-BI promoter
P10579331A1225|45 47|HDL
P10579331A1225|56 60|SR-BI
P10579331A1225|80 101|sterol response elements
P10579331A1225|80 101|sterol response elements
P10579331A1225|103 106|pSRE
P10579331A1225|103 106|pSRE
P10579331A1225|110 113|dSRE
P10579331A1225|110 113|dSRE
P10579331A1225|127 134|SREBP-1a
P10579331A1225|127 134|SREBP-1a
P10579722T0000|0 14|Phosphorylation
P10579722T0000|17 37|myosin-binding subunit
P10579722T0000|17 37|myosin-binding subunit
P10579722T0000|39 41|MBS
P10579722T0000|39 41|MBS
P10579722T0000|45 61|myosin phosphatase
P10579722T0000|45 61|myosin phosphatase
P10579722T0000|64 73|Rho-kinase
P10579722T0000|64 73|Rho-kinase
P10580071A0436|7 14|patients
P10580071A0436|49 63|transplantation
P10580438A0508|2 34|electrophoretic mobility shift assay
P10580438A0508|36 39|EMSA
P10580438A0508|46 66|GLUT4 repressor element
P10580438A0508|46 66|GLUT4 repressor element
P10580438A0508|68 71|G4RE
P10580438A0508|68 71|G4RE
P10580438A0508|82 94|specific bands
P10580438A0508|99 113|nuclear extracts
P10580438A0508|118 130|preadipocytes
P10580438A0508|142 151|adipocytes
P10582831T0000|0 35|Syndromes of abnormal fat redistribution
P10582831T0000|39 60|metabolic complications
P10582831T0000|63 82|HIV-infected patients
P10584138T0001|0 13|Cytoprotection
P10584138T0001|30 41|radiotherapy
P10584138T0001|44 61|radio-chemotherapy
P10584138T0001|64 67|head
P10584138T0001|71 74|neck
P10584138T0001|75 80|tumors
P10584704A0913|0 26|Immunohistochemical staining
P10584704A0913|76 81|HMB-45
P10584704A0913|76 81|HMB-45
P10584704A0913|84 84|9
P10584704A0913|109 119|cytokeratin
P10584704A0913|144 151|melanoma
P10585311A0494|0 7|Patients
P10585311A0494|24 27|MPGN
P10585311A0494|115 130|diagnosis (biopsy
P10585311A1542|8 27|urinary abnormalities
P10585311A1542|59 66|patients
P10585311A1542|71 77|type III
P10585311A1542|82 90|type I MPGN
P10585417A1412|27 35|signaling
P10585417A1412|39 54|tissue expression
P10585417A1412|69 89|human intermediate PRLr
P10585417A1412|74 89|intermediate PRLr
P10585417A1412|104 111|long PRLr
P10585417A1412|104 111|long PRLr
P10585417A1412|114 134|physiological function
P10585440A0204|15 48|Drosophila melanogaster FAK homologue
P10585440A0204|15 36|Drosophila melanogaster
P10585440A0204|37 39|FAK
P10585440A0204|50 55|DFak56
P10585440A0204|50 55|DFak56
P10585440A0204|68 74|band 56D
P10585440A0204|80 87|right arm
P10585440A0204|99 108|chromosome
P10585453A1029|10 19|Pit-1 sites
P10585453A1029|10 19|Pit-1 sites
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|64 77|gene activation
P10585453A1029|110 144|chromatin-mediated developmental role
P10585453A1029|148 152|Pit-1
P10585453A1029|148 152|Pit-1
P10585453A1029|158 163|hGH LCR
P10585453A1029|158 160|hGH
P10585453A1029|161 163|LCR
P10585463A0859|0 29|Recombinant prenylcysteine lyase
P10585463A0859|11 29|prenylcysteine lyase
P10585463A0859|44 74|baculovirus-Sf9 expression system
P10585480A0157|22 30|SH3 domain
P10585480A0157|38 40|Sos
P10585480A0157|43 73|guanine nucleotide exchange factor
P10585480A0157|43 73|guanine nucleotide exchange factor
P10585480A0157|77 79|Ras
P10585480A0157|77 79|Ras
P10585480A0157|83 85|Rac
P10585480A0157|83 85|Rac
P10585480A0265|0 13|Point mutations
P10585480A0265|24 32|SH3 domain
P10585480A0265|45 66|vinexin-Sos interaction
P10585480A0265|45 51|vinexin
P10585480A0265|53 55|Sos
P10585491A0945|2 23|gel mobility shift assays
P10585491A0945|45 47|CBF
P10585491A0945|45 47|CBF
P10585491A0945|53 81|wild-type AtpC promoter sequence
P10585491A0945|53 81|wild-type AtpC promoter sequence
P10585491A0945|97 111|nuclear extracts
P10585491A0945|116 121|tissue
P10585491A0945|129 148|AtpC expression levels
P10585491A0945|129 132|AtpC
P10585491A0945|166 199|etiolated and photobleached seedlings
P10585491A0945|212 226|binding activity
P10585491A0945|271 290|AtpC expression levels
P10585491A0945|271 274|AtpC
P10585491A0945|331 348|etiolated seedlings
P10585491A0945|360 368|cytokinin
P10585491A0945|360 368|cytokinin
P10585808A0000|0 9|Mycoplasma
P10585808A0000|71 88|bacterial detection
P10586074A0129|30 46|plasmid constructs
P10586074A0129|74 94|envelope glycoprotein E
P10586074A0129|74 93|envelope glycoprotein
P10586074A0129|94 94|E
P10586074A0129|100 137|flavivirus tick-borne encephalitis virus.
P10586107A0160|41 60|transduction pathways
P10586115A0477|29 53|pro-inflammatory cytokines
P10586115A0477|63 71|IL-1alpha
P10586115A0477|63 71|IL-1alpha
P10586115A0477|73 80|IL-1beta
P10586115A0477|73 80|IL-1beta
P10586115A0477|82 90|TNF-alpha
P10586115A0477|82 90|TNF-alpha
P10586115A0477|94 97|IL-6
P10586115A0477|94 97|IL-6
P10586115A0477|103 106|IL-6
P10586115A0477|103 106|IL-6
P10586115A0477|132 153|PKCeta -expressing cells
P10586115A0477|132 137|PKCeta
P10586115A0477|183 208|serum-supplemented cultures
P10586115A0477|213 215|FCS
P10586626A0607|0 20|Demyelinating diseases
P10586626A0607|86 115|symmetrical thalamic involvement
P10586626A0607|118 125|patients
P10586626A0607|130 133|ADEM
P10587460A0302|18 34|VDRE binding domain
P10587460A0302|43 45|VDR
P10587460A0302|43 45|VDR
P10587460A0302|47 50|hVDR
P10587460A0302|47 50|hVDR
P10587460A0302|62 86|C-terminally truncated hVDR
P10587460A0302|83 93|hVDR mutants
P10587460A0302|95 144|Delta134, Delta113, Delta102, Delta90, Delta84, Delta80
P10587460A0302|149 155|Delta60
P10587460A0302|183 190|bacteria
P10587461A0341|4 23|induced-fit mechanism
P10587461A0341|104 106|70 A
P10587576A0596|5 8|REPs
P10587576A0596|22 31|paralogous
P10587576A0596|51 56|harbor
P10587576A0596|68 71|ESTs
P10587576A0596|86 100|SH3GL pseudogene
P10587576A0596|86 90|SH3GL
P10588946A0432|30 49|OSBP-related proteins
P10588946A0432|30 49|OSBP-related proteins
P10588946A0432|61 65|ORP-1
P10588946A0432|61 65|ORP-1
P10588946A0432|68 72|ORP-6
P10588946A0432|68 72|ORP-6
P10589562A1208|38 51|radiative loses
P10589562A1208|56 66|BB resonator
P10589711A1228|11 24|narZ expression
P10589711A1228|11 14|narZ
P10589711A1228|72 109|Madin-Darby canine kidney epithelial cells
P10589711A1228|122 139|intracellular salts
P10589711A1228|172 190|intracellular milieu
P10590092A0124|28 46|HIV-1 gene expression
P10590092A0124|28 36|HIV-1 gene
P10590092A0124|52 54|CNS
P10590368X0000|62 69|patients
P10590368X0000|74 91|stage IA-B carcinoma
P10590368X0000|97 102|cervix
P10590368X0000|141 157|lymph node negative
P10590368X0000|159 177|early stage carcinoma
P10591633A0138|101 112|SNARE protein
P10591633A0138|101 105|SNARE
P10591633A0138|149 173|vesicle-target recognition
P10591633A0138|179 192|membrane fusion
P10591933A0798|0 7|Scapulae
P10591933A0798|13 30|Type I configuration
P10591933A0798|136 157|coraco-humeral distance
P10591976A0317|0 11|Measurements
P10591976A0317|25 30|LWS lat
P10591976A0317|43 50|triangle
P10591976A0317|72 79|patients
P10591990A0178|10 12|DSM
P10591990A0178|24 36|schizophrenic
P10591990A0178|78 81|SAPS
P10591990A0178|83 86|SANS
P10591990A0178|88 91|BPRS
P10591990A0178|95 97|PAS
P10592791A0370|16 23|TECRA kit
P10592791A0370|78 85|SET-RPLA
P10592791A0370|89 98|RIDASCREEN
P10592791A0370|186 188|SEE
P10592791A0370|220 230|SET-RPLA kit
P10592791A0370|234 247|high background
P10592791A0370|257 269|RIDASCREEN kit
P10592791A0370|361 363|SEE
P10592791A0370|382 391|SET-EIA kit
P10592791A0370|382 384|SET
P10592791A0370|386 391|EIA kit
P10592791T0001|41 66|staphylococcal enterotoxins
P10592791T0001|77 96|Staphylococcus aureus
P10592824A1157|25 40|natural infection
P10592824A1157|45 61|seropositive rates
P10592824A1157|64 74|JEV antibody
P10592824A1157|107 113|vaccine
P10592824A1157|169 174|(19/47
P10592824A1157|179 186|children
P10592824A1157|196 200|3, 2, 1
P10592824A1157|212 221|JE vaccines
P10593939A0747|21 53|in vitro protein-protein interaction
P10593939A0747|28 42|protein-protein
P10593939A0747|78 88|SR33 protein
P10593939A0747|78 81|SR33
P10593939A0747|115 125|SR45 protein
P10593939A0747|115 125|SR45 protein
P10593939A0747|152 156|SRZ21
P10593939A0747|152 156|SRZ21
P10593939A0747|160 164|SRZ22
P10593939A0747|160 164|SRZ22
P10593939A0747|171 178|SR family
P10593939A0747|171 178|SR family
P10593939A0747|230 234|U-70K
P10593939A0747|230 234|U-70K
P10593950A1113|10 12|WT1
P10593950A1113|10 12|WT1
P10593950A1113|25 47|oligo(dT) chromatography
P10593950A1113|54 59|U2AF65
P10593950A1113|54 59|U2AF65
P10593950A1113|64 102|U5 small nuclear RNP-associated protein p116
P10593950A1113|64 98|U5 small nuclear RNP-associated protein
P10593950A1113|99 102|p116
P10593950A1113|106 112|hnRNP A1
P10593950A1113|106 112|hnRNP A1
P10594130A0652|21 45|macerated stillborn infants
P10594239A0614|0 3|Tih1
P10594239A0614|0 3|Tih1
P10594239A0614|16 58|mouse Chr 1 and human Chr 1q31, chromosomal regions
P10594239A0614|112 114|Ipl
P10594239A0614|116 119|Tih1
P10594239A0614|116 119|Tih1
P10594239A0614|146 160|parental alleles
P10594239T0000|6 35|pleckstrin homology-related gene
P10594239T0000|6 31|pleckstrin homology-related
P10594239T0000|51 59|Ipl/Tssc3
P10594239T0000|51 53|Ipl
P10594239T0000|55 59|Tssc3
P10594239T0000|61 66|TDAG51
P10594239T0000|61 66|TDAG51
P10594239T0000|71 74|Tih1
P10594239T0000|71 74|Tih1
P10594239T0000|76 100|tissue-specific expression
P10594903A0000|15 41|highly reactive nanoparticles
P10594903A0000|43 45|RNP
P10594903A0000|91 105|toxic substances
P10594903A0000|128 129|GA
P10594903A0000|131 132|GB
P10594903A0000|131 132|GB
P10594903A0000|134 135|HD
P10594903A0000|134 135|HD
P10594903A0000|139 140|VX
P10594903A0000|139 140|VX
P10595315A0344|33 71|hematological parameters, acid-base status
P10595315A0344|76 85|blood gases
P10596955A1032|13 24|renal failure
P10596955A1032|25 32|patients
P10596955A1032|36 44|troponin I
P10596955A1032|66 76|Axsym method
P10596955A1032|114 120|Immuno 1
P10597222A1371|23 25|p27
P10597222A1371|23 25|p27
P10597222A1371|54 57|HMBA
P10597222A1371|89 91|p21
P10597222A1371|89 91|p21
P10597223A0339|0 8|Transient
P10597223A0339|20 33|Ras-expression
P10597223A0339|20 22|Ras
P10597223A0339|41 65|transcriptional activation
P10597223A0339|68 70|p21
P10597223A0339|68 70|p21
P10597223A0339|82 94|GC-rich region
P10597223A0339|97 115|p21 promoter -83-54 bp
P10597223A0339|97 107|p21 promoter
P10597223A0339|129 155|transcription initiation site
P10597223A0339|166 177|binding sites
P10597223A0339|181 210|Sp1-family transcription factors
P10597223A0339|181 190|Sp1-family
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597232A0000|3 5|RET
P10597232A0000|7 10|PTC3
P10597232A0000|45 59|ELE1 and RET genes
P10597232A0000|45 48|ELE1
P10597232A0000|52 59|RET genes
P10597232A0000|83 139|radiation-induced post-Chernobyl papillary thyroid carcinomas
P10597317A1156|0 8|Apoptosis
P10597317A1156|58 60|JBD
P10597317A1156|58 60|JBD
P10597317A1156|64 67|LMP1
P10597317A1156|64 67|LMP1
P10597317A1156|85 104|apoptotic HD-MyZ cells
P10597317A1156|119 131|nuclear masses
P10597317A1156|179 181|JNK
P10597317A1156|179 181|JNK
P10597317A1156|193 201|apoptosis
P10597317A1156|204 221|LMP1 induced RS cells
P10597317A1156|204 207|LMP1
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0000|15 25|bZIP protein
P10598101A0000|26 32|Opaque2
P10598101A0000|34 35|O2
P10598101A0000|96 100|O2 box
P10598101A0000|103 115|22 kDa zein gene
P10598101A0000|108 124|zein gene promoters
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|46 62|truncated promoter
P10598101A0754|87 92|O2 site
P10598101A0754|95 104|yeast cells
P10598101A0754|150 166|22 kDa zein promoter
P10598101A0754|150 158|22 kDa zein
P10598101A0754|170 193|transient expression assay
P10598101A0754|199 225|cultured maize endosperm cells
P10598316A1534|0 6|GHB, 2 CB
P10598316A1534|8 10|HMB
P10599727A1567|8 9|GH
P10599727A1567|8 9|GH
P10599727A1567|13 36|estrogen treatment regimen
P10599727A1567|51 52|TS
P10599727A1567|51 52|TS
P10599727A1567|99 110|healthy peers
P10600171A1066|16 36|reduced responsiveness
P10600171A1066|39 44|CYP3A2
P10600171A1066|39 44|CYP3A2
P10600171A1066|79 85|COUP-TF
P10600171A1066|79 85|COUP-TF
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1432|6 25|CYP3A23 basal activity
P10600171A1432|6 12|CYP3A23
P10600171A1432|44 48|E-box
P10600171A1432|44 48|E-box
P10600171A1432|51 59|3A23SiteA
P10600171A1432|51 59|3A23SiteA
P10600171A1432|77 80|USF1
P10600171A1432|77 80|USF1
P10600171A1432|83 129|ubiquitous bHLH/leucine zipper transcription factor
P10600171A1432|93 129|bHLH/leucine zipper transcription factor
P10601280A0674|14 34|TPA-responsive element
P10601280A0674|50 77|base-line ST3 promoter activity
P10601280A0674|59 69|ST3 promoter
P10601290A0742|67 82|wild-type peptide
P10601290A0742|114 129|T cell recognition
P10601290A0742|137 139|I1Y
P10601290A0742|137 139|I1Y
P10601290A0742|143 145|I1F
P10601290A0742|143 145|I1F
P10601290A0742|162 173|x-ray crystal
P10601290A0742|192 217|class I MHC-peptide complexes
P10601290A0742|192 208|class I MHC-peptide
P10601335A0892|0 13|Redistribution
P10601335A0892|16 27|mannosidase I
P10601335A0892|27 27|I
P10601344A1653|16 34|biochemical activity
P10601344A1653|44 58|Rho-like GTPases
P10601344A1653|44 58|Rho-like GTPases
P10601344A1653|85 90|beta1A
P10601344A1653|85 90|beta1A
P10601344A1653|92 97|beta1D
P10601344A1653|92 97|beta1D
P10601344A1653|101 111|IL2R-beta1A
P10601344A1653|101 104|IL2R
P10601344A1653|106 111|beta1A
P10601344A1653|114 117|GE11
P10601344A1653|120 128|GD25 cells
P10601344A1653|153 156|RhoA
P10601344A1653|153 156|RhoA
P10601344A1653|160 163|Rac1
P10601344A1653|160 163|Rac1
P10601344A1653|173 177|Cdc42
P10601344A1653|173 177|Cdc42
P10601410A0977|40 43|IVIg
P10601410A0977|40 43|IVIg
P10601410A0977|70 93|multiple sclerosis lesions
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601606A0152|34 43|right flank
P10601606A0152|46 60|male WAG/Rij rats
P10601747A0482|36 40|quick
P10602419A1253|5 22|synergistic effects
P10602502A0422|7 16|Tob protein
P10602502A0422|7 16|Tob protein
P10602502A0422|18 21|Tob2
P10602502A0422|18 21|Tob2
P10602502A0422|31 50|cell cycle progression
P10602502A0422|58 71|G0/G1 to S phases
P10602502A0422|58 59|G0
P10602502A0422|61 62|G1
P10602507A0652|23 30|cyclin D1
P10602507A0652|23 30|cyclin D1
P10602507A0652|34 36|p21
P10602507A0652|34 36|p21
P10602507A0652|96 108|cyclin D1/cdk4
P10602507A0652|96 103|cyclin D1
P10602507A0652|105 108|cdk4
P10602507A0652|110 112|p53
P10602507A0652|110 112|p53
P10602507A0652|132 136|CSF-1
P10602507A0652|132 136|CSF-1
P10602507A0652|148 150|p21
P10602507A0652|148 150|p21
P10602507A0652|166 195|dominant-negative p53 expression
P10602507A0652|166 185|dominant-negative p53
P10602516A0182|11 13|SLK
P10602516A0182|11 13|SLK
P10602516A0182|36 46|microtubule
P10602516A0182|50 73|nuclear associated protein
P10602516A0182|50 73|nuclear associated protein
P10602516A0182|75 79|M-NAP
P10602516A0182|75 79|M-NAP
P10602516A0182|84 89|AT1-46
P10602516A0182|84 89|AT1-46
P10602838A0127|24 30|females
P10602838A0127|35 39|males
P10603349A1667|22 25|Wnt1
P10603349A1667|29 41|Sonic hedgehog
P10603349A1667|29 41|Sonic hedgehog
P10603349A1667|70 73|Myf5
P10603349A1667|70 73|Myf5
P10603349A1667|84 98|progenitor cells
P10603349A1667|145 164|Myf5 expression domain
P10603349A1667|145 148|Myf5
P10603349A1667|170 182|mesencephalon
P10604246A0523|64 68|PBPCs
P10604246A0523|89 96|AutoPBSC
P10604246A0523|106 106|V
P10604246A0523|115 122|AutoPBSC
P10604246A0523|148 176|MNC (mononuclear cell) procedure
P10604246A0523|178 181|V4.7
P10604246A0523|186 194|white cell
P10604246A0523|209 216|patients
P10604246A0523|220 232|healthy donors
P10604583T0000|0 14|Albumin dialysis
P10604583T0000|0 6|Albumin
P10604583T0000|43 49|patient
P10604583T0000|54 75|fulminant Wilson disease
P10604583T0000|99 118|liver transplantation
P10604583T0000|154 172|protein-bound toxins
P10604945A0731|4 31|artificial promoter constructs
P10604945A0731|50 57|Sp1 sites
P10604945A0731|50 57|Sp1 sites
P10604945A0731|80 86|ethanol
P10604945A0731|139 160|proximal promoter region
P10604945A0731|197 211|ethanol response
P10606245A0906|16 18|CDP
P10606245A0906|20 22|cut
P10606245A0906|25 27|ROS
P10606245A0906|31 50|2.8 osteosarcoma cells
P10606245A0906|72 89|OC promoter activity
P10606245A0906|72 81|OC promoter
P10606245A0906|126 131|OC box I
P10606245A0906|126 131|OC box I
P10606272A1241|11 28|double-stranded RNA
P10606272A1241|33 41|C. elegans
P10606272A1241|51 68|embryonic lethality
P10606272A1241|78 84|SF1 gene
P10606272A1241|78 84|SF1 gene
P10606515A0389|26 43|specific DNA binding
P10606515A0389|49 80|beta-retinoic acid receptor element
P10606515A0389|49 80|beta-retinoic acid receptor element
P10606515A0389|92 106|DNase I footprint
P10606515A0389|92 97|DNase I
P10606664A0000|0 18|Snail family proteins
P10606664A0000|0 18|Snail family proteins
P10606664A0000|22 56|zinc finger transcriptional regulators
P10606664A0000|108 128|cell fate determination
P10607566A0880|26 37|beta-catenin
P10607566A0880|26 37|beta-catenin
P10607566A0880|63 72|RA receptor
P10607566A0880|63 72|RA receptor
P10607566A0880|74 76|RAR
P10607566A0880|74 76|RAR
P10607566A0880|81 104|retinoid-dependent manner
P10607566A0880|119 135|retinoid X receptor
P10607566A0880|119 135|retinoid X receptor
P10607566A0880|137 139|RXR
P10607566A0880|137 139|RXR
P10607566A0880|145 147|RAR
P10607566A0880|145 147|RAR
P10607566A0880|160 177|TCF for beta-catenin
P10607566A0880|160 162|TCF
P10607566A0880|166 177|beta-catenin
P10607899A0605|0 15|Sequence analysis
P10607899A0605|21 34|promoter region
P10607899A0605|43 49|TATA box
P10607899A0605|63 84|consensus binding motifs
P10607899A0605|88 90|Sp1
P10607899A0605|88 90|Sp1
P10607899A0605|92 95|CREB
P10607899A0605|92 95|CREB
P10607899A0605|114 140|estrogen receptor binding site
P10607899A0605|114 140|estrogen receptor binding site
P10607900T0000|0 21|Sak kinase gene structure
P10607900T0000|0 12|Sak kinase gene
P10607900T0000|25 49|transcriptional regulation
P10608053A0923|0 11|Thrombolysis
P10608053A0923|43 58|platelet activity
P10608053A0923|88 90|3rd
P10608053A0923|175 176|NS
P10608893A0727|9 13|Hp140
P10608893A0727|9 13|Hp140
P10608893A0727|23 26|Hp55
P10608893A0727|23 26|Hp55
P10608893A0727|76 90|double-stranded
P10608893A0727|91 108|primer-template DNA
P10610716A1127|34 38|E138V
P10610716A1127|40 44|R254G
P10610716A1127|49 53|P362R
P10610716A1127|74 84|human AC gene
P10610716A1127|79 84|AC gene
P10610716A1127|89 90|FD
P10610716A1127|91 98|patients
P10611225A1127|37 41|eIF4A
P10611225A1127|37 41|eIF4A
P10611225A1127|49 60|middle region
P10611225A1127|63 68|eIF4GI
P10611225A1127|63 68|eIF4GI
P10611225A1127|83 93|translation
P10611225A1127|118 122|eIF4A
P10611225A1127|118 122|eIF4A
P10611225A1127|130 145|C-terminal region
P10611225A1127|130 145|C-terminal region
P10611225A1127|152 165|modulatory role
P10611228A1388|3 23|DAP5/p86 apoptotic form
P10611228A1388|3 6|DAP5
P10611228A1388|8 10|p86
P10611228A1388|41 48|DAP5/p97
P10611228A1388|41 44|DAP5
P10611228A1388|46 48|p97
P10611228A1388|56 71|functional assays
P10611235A1927|0 1|12
P10611235A1927|58 66|MAPK Fus3p
P10611235A1927|58 66|MAPK Fus3p
P10611235A1927|77 112|G(betagamma)-dependent relocalization
P10611235A1927|77 77|G
P10611235A1927|79 87|betagamma
P10611235A1927|118 134|Ste5p-MAPK cascade
P10611235A1927|118 122|Ste5p
P10611235A1927|124 127|MAPK
P10611235A1927|140 153|plasma membrane
P10611242A0541|26 38|wild-type SAGA
P10611242A0541|35 38|SAGA
P10611242A0541|47 56|TBP binding
P10611242A0541|47 49|TBP
P10611242A0541|62 73|HIS3 promoter
P10611242A0541|62 73|HIS3 promoter
P10611242A0541|87 90|SAGA
P10611242A0541|87 90|SAGA
P10611242A0541|98 101|Spt3
P10611242A0541|98 101|Spt3
P10611242A0541|104 107|Spt8
P10611242A0541|104 107|Spt8
P10611320A0816|0 22|Saccharomyces cerevisiae
P10611320A0816|0 22|Saccharomyces cerevisiae
P10611320A0816|65 71|CAK gene
P10611320A0816|65 67|CAK
P10611320A0816|73 76|CAK1
P10611320A0816|73 76|CAK1
P10611320A0816|90 98|monomeric
P10611320A0816|99 116|44-kDa Cak1p protein
P10611320A0816|105 116|Cak1p protein
P10611320A0816|128 131|Cdk7
P10611320A0816|128 131|Cdk7
P10611353A0458|0 11|Northern blot
P10611353A0458|15 46|reverse transcription-PCR analyses
P10611353A0458|49 57|human mRNA
P10611353A0458|80 82|RNR
P10611353A0458|80 82|RNR
P10611353A0458|166 170|3.0 kb
P10611353A0458|195 214|Northern blot analysis
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|66 84|nucleotides upstream
P10612044A1180|90 116|transcription initiation site
P10612044A1180|123 131|Aal-rpL34
P10612044A1180|123 125|Aal
P10612044A1180|127 131|rpL34
P10612044A1180|135 147|Aal-rpL8 genes
P10612044A1180|135 137|Aal
P10612044A1180|139 142|rpL8
P10612773A1210|25 33|S-100beta
P10612773A1210|25 33|S-100beta
P10612773A1210|85 98|cardiac surgery
P10612805A0716|10 26|genetic alteration
P10612918A0318|44 49|screws
P10613816X0000|0 6|Statins
P10613816X0000|0 6|Statins
P10613816X0000|64 88|cholesterol-lowering drugs
P10613816X0000|132 146|anabolic effects
P10613816X0000|149 152|bone
P10613816X0000|192 218|common metabolic bone diseases
P10613816X0000|225 236|osteoporosis
P10613843A0107|89 111|voltage-dependent Ca(2+)
P10613843A0107|112 122|ion channels
P10613863T0000|3 23|VirR response regulator
P10613863T0000|3 23|VirR response regulator
P10613863T0000|28 49|Clostridium perfringens
P10613863T0000|82 94|direct repeats
P10613863T0000|115 126|pfoA promoter
P10613863T0000|115 126|pfoA promoter
P10613874A0663|25 38|upstream region
P10613874A0663|41 44|pepX
P10613874A0663|41 44|pepX
P10613874A0663|69 72|ORFs
P10613874A0663|81 87|1,338 bp
P10613874A0663|143 146|GlnR
P10613874A0663|143 146|GlnR
P10613874A0663|150 161|GlnA proteins
P10613874A0663|150 161|GlnA proteins
P10614676A0000|0 8|Objective
P10614676A0000|57 71|uterine bleeding
P10614676A0000|74 92|postmenopausal women
P10614676A0000|140 148|estradiol
P10614676A0000|155 175|norethisterone acetate
P10614676A0000|177 182|E+NETA
P10614676A0000|191 215|hormone replacement therapy
P10614857A0584|0 16|Leukocyte cultures
P10614857A0584|30 34|blood
P10614857A0584|51 58|children
P10614857A0584|95 97|IFN
P10614857A0584|123 130|children
P10614857A0584|150 159|adenovirus
P10614857A0584|170 180|coronavirus
P10614857A0584|192 201|rhinovirus
P10617126A1005|0 19|Histological analysis
P10617126A1005|33 44|neuronal loss
P10617126A1005|50 66|DHED-treated group
P10617126A1005|89 103|hippocampal area
P10617126A1005|105 107|CA1
P10617126A1005|105 107|CA1
P10617126A1005|111 122|ischemic rats
P10617126A1005|131 160|dentate gyrus and hippocampal area
P10617126A1005|162 164|CA1
P10617126A1005|162 164|CA1
P10617126A1005|168 170|CA3
P10617126A1005|168 170|CA3
P10617126A1005|174 175|EC
P10617126A1005|204 213|nontreated
P10617144A0386|12 26|phosphorylation
P10617144A0386|29 33|Ser44
P10617144A0386|37 41|Ser64
P10617232A0393|0 25|Serum HBV-DNA, viral serology
P10617232A0393|30 41|liver enzymes
P10617232A0393|117 124|patients
P10618645A0750|0 15|Maximum induction
P10618645A0750|18 21|AP-1
P10618645A0750|18 21|AP-1
P10618645A0750|61 64|CalC
P10619062T0000|0 20|Haycocknema perplexum n
P10619062T0000|27 28|sp
P10619169A0411|0 3|Rams
P10619169A0411|18 23|testis
P10619254A1055|60 71|fluoroscopic
P10619254A1055|75 91|angiographic image
P10619353T0000|6 27|estrogen receptor ligand
P10619353T0000|31 61|estrogen response element sequence
P10619353T0000|31 61|estrogen response element sequence
P10619353T0000|79 129|chicken ovalbumin upstream promoter transcription factor
P10619353T0000|79 94|chicken ovalbumin
P10619353T0000|111 129|transcription factor
P10619353T0000|131 137|COUP-TF
P10619353T0000|131 137|COUP-TF
P10620010A1155|13 27|Cdks functioning
P10620010A1155|13 16|Cdks
P10620010A1155|41 49|cell cycle
P10620010A1155|51 73|tyrosine phosphorylation
P10620010A1155|103 108|kinase
P10620010A1155|137 145|threonine
P10620010A1155|151 156|T-loop
P10620335A0749|16 18|AHR
P10620335A0749|16 18|AHR
P10620335A0749|32 38|COUP-TF
P10620335A0749|32 38|COUP-TF
P10620335A0749|52 60|CV-1 cells
P10620335A0749|52 55|CV-1
P10620777A1399|0 7|AB004534
P10620777A1399|0 7|AB004534
P10622574A0000|15 43|hepatitis C virus (HCV) infection
P10622574A0000|61 69|childhood
P10622576A0552|0 4|Clear
P10622576A0552|52 59|patients
P10622576A0552|74 83|prevention
P10622576A0552|134 144|drug abusers
P10623758A0947|6 12|latency
P10623758A0947|74 91|beta-galactosidase
P10623758A0947|74 91|beta-galactosidase
P10623804A0808|83 86|SHIP
P10623804A0808|83 86|SHIP
P10623804A0808|88 92|SHP-1
P10623804A0808|88 92|SHP-1
P10623804A0808|96 100|SHP-2
P10623804A0808|96 100|SHP-2
P10623804A0808|101 127|SH2-containing decoy proteins
P10623804A0808|101 103|SH2
P10623804A0808|130 150|Fc gamma RIIB1 signaling
P10623804A0808|130 141|Fc gamma RIIB1
P10624787A0432|19 38|normal renal functions
P10624787A0432|45 52|patients
P10624787A0432|145 151|Type 1 DM
P10624787A0432|164 176|body mass index
P10624787A0432|190 203|waist-hip ratio
P10625438A1429|2 11|all tissues
P10625438A1429|46 52|insert 3
P10625438A1429|56 68|18 bp insertion
P10625438A1429|131 155|insert 3 negative transcript
P10625494A1059|23 33|CAAT-region
P10625494A1059|23 33|CAAT-region
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|75 87|HL60/VCR cells
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|43 46|PTKs
P10625683A0091|43 46|PTKs
P10625683A0091|54 68|phosphorylation
P10625683A0091|78 95|signaling molecules
P10625721T0101|16 33|Cardiac Arrest (HACA
P10627518A0544|28 32|5'-3'
P10627518A0544|112 115|UTRs
P10627532A0739|21 25|R and Z
P10627532A0739|21 21|R
P10627532A0739|25 25|Z
P10627532A0739|37 86|cellular stress mitogen-activated protein (MAP) kinases
P10627532A0739|51 74|mitogen-activated protein
P10627532A0739|76 86|MAP) kinases
P10627532A0739|88 90|p38
P10627532A0739|88 90|p38
P10627532A0739|94 96|JNK
P10627532A0739|94 96|JNK
P10627532A0739|109 137|phosphorylation (and activation
P10627532A0739|144 174|cellular transcription factor ATF2
P10627532A0739|144 170|cellular transcription factor
P10627532A0739|171 174|ATF2
P10627834A0178|3 23|US commercial cultivars
P10627834A0178|25 30|Tehama
P10627834A0178|34 37|Vina
P10627834A0178|45 71|European commercial cultivars
P10627834A0178|73 81|Esterhazy
P10627834A0178|87 90|G120
P10627834A0178|99 118|New Zealand selections
P10627834A0178|120 122|Rex
P10627834A0178|120 122|Rex
P10627834A0178|124 136|Dublin's Glory
P10627834A0178|145 153|McKinster
P10628490T0000|0 6|Anatomy
P10628490T0000|12 18|uterine
P10628490T0000|19 24|artery
P10628748A0344|23 33|cAMP pathway
P10628748A0344|57 68|inhibin alpha
P10628748A0344|57 68|inhibin alpha
P10628748A0344|107 110|SF-1
P10628748A0344|107 110|SF-1
P10628748A0746|0 7|Deletion
P10628748A0746|11 34|site-directed mutagenesis
P10628748A0746|50 70|SF-1 regulatory element
P10628748A0746|50 70|SF-1 regulatory element
P10628748A0746|72 92|TCA GGGCCA; -137 to -129)
P10628748A0746|111 130|cAMP-response element
P10628748A0746|111 130|cAMP-response element
P10628748A0746|132 145|CRE; -120 to -114
P10628748A0746|132 134|CRE
P10628750A0298|26 29|APRE
P10628750A0298|33 40|cytokine
P10628750A0298|42 66|tumor necrosis factor-alpha
P10628750A0298|42 66|tumor necrosis factor-alpha
P10628750A0298|68 75|TNFalpha
P10628750A0298|68 75|TNFalpha
P10628750A0298|78 95|- inducible enhancer
P10628750A0298|108 140|heterodimeric nuclear factor-kappaB
P10628750A0298|108 140|heterodimeric nuclear factor-kappaB
P10628750A0298|142 162|NF-kappaB) complex Rel A
P10628750A0298|142 150|NF-kappaB
P10628750A0298|159 162|Rel A
P10628750A0298|164 173|NF-kappaB1
P10628750A0298|164 173|NF-kappaB1
P10628750T0000|0 12|Angiotensin II
P10628750T0000|0 12|Angiotensin II
P10628750T0000|20 44|nuclear factor (NF)-kappaB1
P10628750T0000|20 32|nuclear factor
P10628750T0000|34 52|NF)-kappaB1 isoforms
P10628750T0000|62 80|angiotensinogen gene
P10628750T0000|62 80|angiotensinogen gene
P10628750T0000|81 106|acute-phase response element
P10628750T0000|109 132|stimulus-specific pathway
P10628750T0000|136 154|NF-kappaB activation
P10628750T0000|136 144|NF-kappaB
P10628755A0000|72 82|GH secretion
P10628755A0000|72 73|GH
P10628755A0000|103 131|orphan GH-secretagogue receptor
P10628755A0000|103 108|orphan
P10628755A0000|109 131|GH-secretagogue receptor
P10628755A0000|133 137|GHS-R
P10628755A0000|133 137|GHS-R
P10628971A0824|32 48|TGN sorting defects
P10628971A0824|99 125|vacuolar protein sorting genes
P10628971A0824|99 106|vacuolar
P10628971A0824|127 129|VPS
P10628971A0824|127 129|VPS
P10628971A0824|144 162|dynamin family member
P10628971A0824|144 150|dynamin
P10628971A0824|163 166|VPS1
P10628971A0824|163 166|VPS1
P10628971A1165|30 46|TGN sorting defects
P10628971A1165|86 89|RIC1
P10628971A1165|159 162|LUV1
P10628971A1165|159 162|LUV1
P10628971A1165|201 207|vacuole
P10628971A1165|211 233|microtubule organization
P10628971A1165|238 242|INP53
P10628971A1165|238 242|INP53
P10628971A1165|253 303|synaptojanin-like inositol polyphosphate 5-phosphatase
P10628971A1165|270 303|inositol polyphosphate 5-phosphatase
P10629035A0827|3 20|single strandedness
P10629035A0827|36 52|terminal extension
P10629035A0827|58 71|G-rich strand (G
P10629035A0827|58 69|G-rich strand
P10629035A0827|71 76|G tails
P10629035A0827|105 114|telomerase
P10629035A0827|105 114|telomerase
P10629035A0827|130 139|cdc17/pol1
P10629035A0827|130 134|cdc17
P10629035A0827|136 146|pol1 mutants
P10629035A0827|172 194|lagging-strand synthesis
P10629176A0887|11 16|CaMig1
P10629176A0887|11 16|CaMig1
P10629176A0887|47 56|URS1 region
P10629176A0887|62 81|S. cerevisiae FBP1 gene
P10629176A0887|62 73|S. cerevisiae
P10629176A0887|74 81|FBP1 gene
P10629938A1352|36 50|GFP-POLO protein
P10629938A1352|36 38|GFP
P10629938A1352|40 43|POLO
P10629938A1352|73 88|mitotic apparatus
P10629938A1352|113 125|future studies
P10629938A1352|128 136|cell cycle
P10630471T0000|77 88|cell behavior
P10630630A0614|8 18|calphostin C
P10630630A0614|40 42|PKC
P10630630A0614|40 42|PKC
P10630630A0614|56 74|TPA-induced increase
P10630630A0614|77 89|CFI mRNA levels
P10630630A0614|77 83|CFI mRNA
P10633075A1111|0 11|Preimmune IgG
P10633075A1111|9 11|IgG
P10633075A1111|13 33|anti-GalT Fab fragments
P10633075A1111|13 21|anti-GalT
P10633075A1111|65 83|N-acetylglucosamine
P10633075A1111|65 83|N-acetylglucosamine
P10633499A1306|52 63|Heterosentis
P10633499A1306|163 176|subapical hooks
P10634007A0202|17 37|acetaminophen overdose
P10634007A0202|60 71|hemodialysis
P10634007A0202|73 74|HD
P10634007A0202|79 81|NAC
P10634007A0202|87 104|severe intoxication
P10634007A0202|112 124|drug clearance
P10635209A0419|9 20|conditioning
P10635209A0419|23 32|single coat
P10635209A0419|35 42|adhesive
P10635209A0419|56 66|light-cured
P10637149A0806|15 17|G-A
P10637149A0806|33 34|RD
P10637149A0806|33 34|RD
P10637149A0806|36 37|CC
P10637149A0806|36 37|CC
P10637149A0806|39 39|E
P10637149A0806|39 39|E
P10637149A0806|41 41|p
P10637149A0806|46 54|loop areas
P10637149A0806|85 87|REF
P10637149A0806|118 120|A-A
P10637149A0806|118 120|A-A
P10637230A0332|19 23|c-myc
P10637230A0332|19 23|c-myc
P10637230A0332|64 78|Stat1-null cells
P10637230A0332|64 68|Stat1
P10637230A0332|91 94|IFNs
P10637230A0332|91 94|IFNs
P10637238A0291|36 40|E3186
P10637337A0545|15 23|DNA repair
P10637337A0545|36 39|TFA1
P10637337A0545|36 39|TFA1
P10637337A0545|51 59|mutations
P10638607A0000|5 12|articles
P10638607A0000|35 53|multi-institutional
P10638607A0000|66 77|phase 3 trials
P10638607A0000|95 102|patients
P10638607A0000|107 115|localized
P10638607A0000|117 126|T1-3 N0-1 M0
P10638607A0000|121 126|N0-1 M0
P10638607A0000|128 158|esophageal squamous cell carcinoma
P10638607A0000|160 162|SCC
P10638607A0000|166 189|esophageal adenocarcinoma
P10639585A0157|9 15|MPO gene
P10639585A0157|9 11|MPO
P10639585A0157|12 25|gene regulation
P10639585A0157|67 96|abnormal myeloid differentiation
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0204|0 3|NDRF
P10640683A0204|5 11|NeuroD2
P10640683A0204|34 36|PKN
P10640683A0204|34 36|PKN
P10640683A0204|52 61|COS-7 cells
P10640683A0204|104 115|NDRF/NeuroD2
P10640683A0204|104 107|NDRF
P10640683A0204|109 115|NeuroD2
P10640683A0204|119 121|PKN
P10640683A0204|119 121|PKN
P10640683A0670|0 26|Transient transfection assays
P10640683A0670|32 39|P19 cells
P10640683A0670|64 75|NDRF/NeuroD2
P10640683A0670|64 67|NDRF
P10640683A0670|69 75|NeuroD2
P10640683A0670|108 133|rat insulin promoter element 3
P10640683A0670|108 110|rat
P10640683A0670|111 148|insulin promoter element 3 (RIPE3) enhancer
P10640683A0670|135 139|RIPE3
P10640683A0670|220 222|PKN
P10640683A0670|220 222|PKN
P10640683A0670|230 255|kinase-deficient derivative
P10640683A0670|294 327|NDRF/NeuroD2-mediated transcription
P10640683A0670|294 297|NDRF
P10640683A0670|299 305|NeuroD2
P10640701T0000|3 23|Pax2/5/8-binding sites
P10640701T0000|3 23|Pax2/5/8-binding sites
P10640701T0000|26 35|Engrailed2
P10640701T0000|26 35|Engrailed2
P10640701T0000|78 100|mid-hindbrain expression
P10640734A0190|4 26|tyrosine phosphorylation
P10640734A0190|32 36|ITIMs
P10640734A0190|59 90|SH2 domain-containing phosphatases
P10640734A0190|59 90|SH2 domain-containing phosphatases
P10640734A0190|97 131|SH2-containing tyrosine phosphatase-1
P10640734A0190|97 131|SH2-containing tyrosine phosphatase-1
P10640734A0190|153 164|cell activity
P10641037A1371|0 7|AF154055
P10641037A1371|0 7|AF154055
P10641688A0341|14 26|cervical spine
P10641688A0341|28 49|vertebral abnormalities
P10642524A0156|3 24|concomitant interaction
P10642524A0156|27 31|mSTI1
P10642524A0156|27 31|mSTI1
P10642524A0156|36 40|hsp70
P10642524A0156|36 40|hsp70
P10642524A0156|44 48|hsp90
P10642524A0156|44 48|hsp90
P10642524A0156|54 67|N- and C-termini
P10642524A0156|95 117|tetratricopeptide repeat
P10642524A0156|119 128|TPR) motifs
P10642531A2322|0 21|Competition experiments
P10642531A2322|42 63|allosteric relationship
P10642531A2322|76 78|RGD
P10642531A2322|79 94|recognition sites
P10642889A0393|0 15|Sequence analysis
P10642889A0393|29 45|5'-flanking region
P10642889A0393|59 66|ATG codon
P10642889A0393|93 99|TATA box
P10643313A0345|7 22|v. administration
P10643313A0345|63 73|conjunctiva
P10643313A0345|87 91|rt-PA
P10643313A0345|100 102|BSS
P10643313A0345|112 114|SF6
P10644357A0935|23 25|VP1
P10644357A0935|23 25|VP1
P10644357A0935|56 62|nucleus
P10644357A0935|88 104|subnuclear regions
P10644357A0935|118 120|VP2
P10644357A0935|118 120|VP2
P10644357A0935|124 126|VP3
P10644357A0935|124 126|VP3
P10644414T0000|0 21|Differential expression
P10644414T0000|37 54|20-hydroxyecdysone
P10644414T0000|57 85|mosquito ultraspiracle isoforms
P10644753A0725|28 44|anti-FLAG antibody
P10644753A0725|28 44|anti-FLAG antibody
P10644753A0725|59 76|transferred sulfate
P10644753A0725|79 92|heparan sulfate
P10644753A0725|96 102|heparin
P10644753A0725|116 133|glycosaminoglycans
P10644760A0000|3 17|differentiation
P10644760A0000|112 127|genetic machinery
P10644760A0956|29 32|Arix
P10644760A0956|29 32|Arix
P10644760A0956|42 67|N-terminal activation domain
P10644760A0956|42 67|N-terminal activation domain
P10644760A0956|72 97|C-terminal repression domain
P10645921A0000|11 36|Left ventricular hypertrophy
P10645921A0000|73 84|morphologies
P10645921A1320|72 86|left ventricular
P10645921A1320|132 165|single-vessel left circumflex disease
P10646820T0000|42 59|positive lymph nodes
P10646820T0000|74 92|radical hysterectomy
P10646820T0000|96 112|cervical carcinoma
P10646863A0838|16 21|ICBP90
P10646863A0838|16 21|ICBP90
P10646863A0838|24 45|COS-1-transfected cells
P10646863A0838|75 104|endogenous topoisomerase IIalpha
P10646863A0838|85 104|topoisomerase IIalpha
P10647177A0599|3 12|RNA aptamer
P10647177A0599|121 128|anchored
P10647177A0599|136 154|base triple formation
P10647633A1685|55 57|RSJ
P10647633A1685|103 114|sigmoid colon
P10647817T0000|11 15|cDNAs
P10647817T0000|24 72|gibbon and monkey platelet and T cell activation antigen 1
P10647817T0000|24 72|gibbon and monkey platelet and T cell activation antigen 1
P10647817T0000|74 77|PTA1
P10647817T0000|74 77|PTA1
P10647859A0000|41 45|nasal
P10647859A0000|58 84|positive pressure ventilation
P10647859A0000|86 89|IPPV
P10647859A0000|93 111|inspiratory activity
P10647859A0000|142 165|conscious relaxed subjects
P10647859A0000|182 197|respiratory rates
P10647859A0000|207 220|quiet breathing
P10647859A0000|222 223|QB
P10647859A0000|259 267|Pappl)--6
P10647859A0000|275 279|cmH2O
P10647859A0000|291 300|hypocapnia
P10647859A0000|304 306|CO2
P10647859A0000|329 336|eucapnia
P10647859A0000|356 358|gas
P10648020A0151|8 26|Von Willebrand factor
P10648020A0151|8 26|Von Willebrand factor
P10648020A0151|28 30|vWF
P10648020A0151|28 30|vWF
P10648020A0151|57 82|tissue plasminogen activator
P10648020A0151|63 86|plasminogen activator (tPA
P10648020A0151|84 86|tPA
P10648020A0151|99 109|tPA capacity
P10648020A0151|99 101|tPA
P10648020A0151|114 143|plasminogen activator inhibitor 1
P10648020A0151|114 143|plasminogen activator inhibitor 1
P10648020A0151|145 149|PAI-1
P10648020A0151|145 149|PAI-1
P10648020A0151|152 160|platelets
P10648020A0151|162 171|fibrinogen
P10648020A0151|162 171|fibrinogen
P10648020A0151|176 194|inflammatory markers
P10648020A0151|209 218|74 patients
P10648020A0151|223 242|active seropositive RA
P10648211A0000|0 7|Neuronal
P10648211A0000|76 86|ion channels
P10648489A1117|96 113|peak concentrations
P10648619A0000|43 61|TATA-binding protein
P10648619A0000|43 61|TATA-binding protein
P10648619A0000|63 71|TBP)-TATA
P10648619A0000|63 65|TBP
P10648619A0000|89 104|promoter activity
P10648619A0000|131 154|silkworm tRNA(C)(Ala) gene
P10648619A0000|131 145|silkworm tRNA(C)
P10648619A0000|147 149|Ala
P10648619A0000|220 238|low promoter activity
P10648619A0000|220 230|low promoter
P10648619A0000|242 263|silk gland-specific tRNA
P10648619A0000|242 263|silk gland-specific tRNA
P10648619A0000|265 276|SG)(Ala) gene
P10648619A0000|265 266|SG
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|65 71|enzymes
P10649449A0413|102 129|extreme amino acid conservation
P10649449A0413|139 164|binding and catalytic domains
P10649456A1061|49 55|EUROFAN
P10649456A1061|68 83|centre (EUROSCARF
P10649456A1061|85 93|Frankfurt
P10649738A0953|40 46|patient
P10649738A0953|55 58|CAPD
P10650104X0284|30 41|Radiologists
P10650938T0000|3 18|estrogen receptor
P10650938T0000|3 18|estrogen receptor
P10650938T0000|20 30|ER) isoforms
P10650938T0000|20 21|ER
P10650938T0000|44 63|estrogen dependencies
P10650938T0000|83 93|trout ER gene
P10650938T0000|83 93|trout ER gene
P10650939A0789|36 40|A-Fos
P10650939A0789|36 40|A-Fos
P10650939A0789|61 64|AP-1
P10650939A0789|61 64|AP-1
P10650939A1542|2 14|myometrial SMC
P10650939A1542|33 52|progesterone receptor
P10650939A1542|33 52|progesterone receptor
P10650939A1542|54 57|PR-B
P10650939A1542|54 57|PR-B
P10650939A1542|61 64|PR-A
P10650939A1542|61 64|PR-A
P10650939A1542|73 98|ligand-dependent activation
P10650939A1542|101 114|PGDH-2368/luc3
P10650939A1542|101 109|PGDH-2368
P10650939A1542|111 114|luc3
P10650958A1315|0 17|Element B (-249/-229
P10650958A1315|55 66|c-myb element
P10650958A1315|55 66|c-myb element
P10650958A1315|119 123|c-myb
P10650958A1315|119 123|c-myb
P10650958A1315|129 161|electrophoretic mobility shift assay
P10651076T0000|0 31|High resolution computed tomography
P10651076T0000|37 41|lungs
P10651076T0000|44 51|patients
P10651076T0000|56 74|rheumatoid arthritis
P10651805A1600|6 17|transfection
P10651805A1600|45 55|carrier cDNA
P10651805A1600|60 82|mouse L1210 leukemia cells
P10651805A1600|93 110|folate accumulation
P10651805A1600|139 165|folic acid growth requirements
P10651805A1600|197 208|methotrexate
P10651805T0000|60 72|folate carrier
P10651805T0000|83 100|folate accumulation
P10651805T0000|103 123|parental leukemia cells
P10652093A0139|0 18|Electron microscopic
P10652093A0139|22 38|enzymatic analyses
P10652093A0139|54 63|A118 genome
P10652102A0620|30 42|wild-type Fus3
P10652102A0620|30 42|wild-type Fus3
P10652102A0620|73 105|Ty1 transposition and invasive growth
P10652102A0620|73 75|Ty1
P10652228A0759|0 11|Consistently
P10652228A0759|25 45|c-Jun N-terminal kinase
P10652228A0759|25 45|c-Jun N-terminal kinase
P10652228A0759|58 85|Rho family GTP-binding proteins
P10652228A0759|58 85|Rho family GTP-binding proteins
P10652228A0759|105 107|Dbl
P10652324A0177|26 33|collagen
P10652324A0177|26 33|collagen
P10652362A0933|32 47|carboxyl terminus
P10652362A0933|50 53|CFTR
P10652362A0933|50 53|CFTR
P10652362A0933|63 97|tyrosine-based internalization signal
P10652362A0933|127 140|adaptor complex
P10652362A0933|141 144|AP-2
P10652362A0933|141 144|AP-2
P10652362A0933|173 176|CFTR
P10652362A0933|173 176|CFTR
P10652362A0933|181 188|clathrin
P10652800A0984|3 23|insulin therapy regimen
P10652800A0984|3 9|insulin
P10652800A0984|53 60|patients
P10652800A0984|131 138|diabetes
P10652800A0984|145 157|insulin dosage
P10652800A0984|145 151|insulin
P10652800A0984|160 175|metabolic control
P10652800A0984|187 189|BMI
P10653359A1297|0 4|Scmh1
P10653359A1297|0 4|Scmh1
P10653359A1297|11 18|4D1-D2.1
P10653359A1297|11 18|4D1-D2.1
P10653359A1297|21 24|mice
P10653400A0000|18 45|laparoscopic donor nephrectomy
P10653400A0000|47 49|LDN
P10653400A0000|74 83|obese donor
P10653550A1120|0 18|Hyaluronan treatment
P10653550A1120|29 36|collagen
P10653550A1120|52 67|peripheral region
P10653550A1120|114 124|inner region
P10653693A0429|62 65|KRAB
P10653693A0429|62 65|KRAB
P10653693A0429|67 87|KAP-1-RBCC interaction
P10653693A0429|67 71|KAP-1
P10653693A0429|73 76|RBCC
P10653693A0429|93 110|purified components
P10653693A0903|3 12|RING finger
P10653693A0903|14 18|B2 box
P10653693A0903|54 68|oligomerization
P10653693A0903|71 80|KAP-1-RBCC
P10653693A0903|71 75|KAP-1
P10653693A0903|77 80|RBCC
P10653693A0903|84 94|KRAB binding
P10653693A0903|84 87|KRAB
P10653697A0133|0 5|Actins
P10653697A0133|29 38|N-terminal
P10653697A0133|65 82|N-terminal sequence
P10653733A0596|27 48|proline-threonine-rich
P10653733A0596|49 56|peptides
P10654032A1133|0 5|JPEG 53
P10655164A0546|113 122|amp;parl0;
P10655164A0546|123 128|Li&amp
P10655164A0546|136 140|H&amp
P10655230A0685|29 45|mouse GCN2 isoforms
P10655230A0685|29 37|mouse GCN2
P10655230A0685|53 74|HisRS-related sequences
P10655230A0685|53 74|HisRS-related sequences
P10655230A0685|90 110|kinase catalytic domain
P10656154A0722|4 8|women
P10656154A0722|16 26|met criteria
P10656154A0722|30 32|PMS
P10656161A0316|0 9|MBI and MMBI
P10656161A0316|23 32|Cmax values
P10656161A0316|68 72|serum
P10656802A1724|7 19|long insertion
P10656802A1724|25 51|cathepsin X amino acid sequence
P10656802A1724|25 51|cathepsin X amino acid sequence
P10656802A1724|58 77|beta-hairpin pointing
P10656802A1724|89 98|active site
P10657238A0541|42 58|5'-flanking region
P10657238A0541|60 69|-1894 to +37
P10657238A0541|76 84|mStaf gene
P10657238A0541|76 84|mStaf gene
P10657238A0541|106 120|mouse NMuMG cells
P10657238A0541|161 169|-387 to +37
P10657238A0541|186 208|transcriptional activity
P10657658A0165|41 51|HA fragments
P10657658A0165|41 42|HA
P10657658A0165|63 89|I kappa B alpha phosphorylation
P10657658A0165|63 74|I kappa B alpha
P10657658A0165|93 103|degradation
P10657658A0165|105 139|kappa B-linked reporter gene expression
P10657658A0165|105 129|kappa B-linked reporter gene
P10657658A0165|144 157|ICAM-1 promoter
P10657658A0165|144 149|ICAM-1
P10657658A0165|150 165|promoter activity
P10657658A0165|170 194|NF-kappa B-dependent manner
P10657658A0165|170 178|NF-kappa B
P10657899A0685|21 29|mouse skin
P10657899A0685|34 58|antisense oligonucleotides
P10657899A0685|61 67|PKCzeta
P10657899A0685|61 67|PKCzeta
P10657899A0685|98 101|AP-1
P10657899A0685|98 101|AP-1
P10657899A0685|104 111|JB6 cells
P10657899A0685|122 136|AP-1-luciferase
P10657899A0685|122 125|AP-1
P10657899A0685|127 136|luciferase
P10657899A0685|137 150|transgenic mice
P10658425A1567|10 29|subclinical infection
P10658425A1567|41 56|seropositive dogs
P10658445A0208|30 37|patients
P10658445A0208|70 92|PGE1 alpha-ciclodestrina
P10658445A0208|182 195|prostaglandins
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10658588A0304|30 57|didesmethylferrochloroquine 2
P10658588A0304|100 101|CQ
P10658588A0304|127 129|HB3
P10658588A0304|127 129|HB3
P10658588A0304|133 135|Dd2
P10658588A0304|133 135|Dd2
P10658588A0304|139 158|Plasmodium falciparum
P10660069A0819|3 19|rrd1,2delta mutant
P10660069A0819|3 6|rrd1
P10660069A0819|8 19|2delta mutant
P10660069A0819|55 58|HOG1
P10660069A0819|55 58|HOG1
P10660069A0819|61 64|PBS2
P10660069A0819|61 64|PBS2
P10660069A0819|99 106|RRD genes
P10660069A0819|99 106|RRD genes
P10660069A0819|113 142|Hog1p signal transduction pathway
P10660069A0819|113 117|Hog1p
P10660304A0522|12 24|JAK/Tyk family
P10660304A0522|12 14|JAK
P10660304A0522|16 18|Tyk
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|49 63|phosphorylation
P10660304A0522|66 70|STAT3
P10660304A0522|66 70|STAT3
P10660304A0522|73 78|Tyr705
P10660304A0522|85 97|CNTF signaling
P10660304A0522|85 88|CNTF
P10660304A0522|110 115|kinase
P10660304A0522|130 144|phosphorylation
P10660304A0522|147 157|STAT3 Tyr727
P10660304A0522|147 151|STAT3
P10660304A0522|182 202|extracellular stimulus
P10660604A0748|7 22|CARbeta/RXRalpha
P10660604A0748|7 13|CARbeta
P10660604A0748|15 22|RXRalpha
P10660604A0748|51 84|HD-PPRE luciferase reporter construct
P10660604A0748|51 52|HD
P10660604A0748|58 84|luciferase reporter construct
P10660676A0000|0 15|Zebrafish cyclops
P10660676A0000|9 15|cyclops
P10660676A0000|17 19|cyc
P10660676A0000|17 19|cyc
P10660676A0000|29 56|Transforming Growth Factor beta
P10660676A0000|29 56|Transforming Growth Factor beta
P10660676A0000|58 64|TGFbeta
P10660676A0000|58 64|TGFbeta
P10660676A0000|97 106|mouse Nodal
P10662550A0679|5 8|SOX8
P10662550A0679|5 8|SOX8
P10662550A0679|46 71|mental retardation phenotype
P10662550A0679|84 91|patients
P10662614A0000|42 52|wheat streak
P10662614A0000|53 58|mosaic
P10662614A0000|59 63|virus
P10662614A0000|65 68|WSMV
P10662614A0000|120 137|monopartite genomes
P10662614A0000|161 184|amino acid dissimilarities
P10662614A0000|194 214|potyviral polyproteins
P10662614A0972|3 17|two-hybrid assay
P10662614A0972|39 54|full-length genes
P10662614A0972|39 54|full-length genes
P10662614A0972|57 58|CI
P10662614A0972|57 58|CI
P10662614A0972|60 65|HC-Pro
P10662614A0972|60 65|HC-Pro
P10662614A0972|67 71|P1, P3
P10662614A0972|67 68|P1
P10662614A0972|70 71|P3
P10662614A0972|76 77|CP
P10662614A0972|76 77|CP
P10663558T0000|7 27|endogenous light chains
P10663558T0000|48 65|membrane reactivity
P10663558T0000|68 84|nonautoimmune mice
P10663558T0000|100 111|anti-laminin
P10663558T0000|112 123|Ig heavy chain
P10663558T0000|112 123|Ig heavy chain
P10664876A0000|0 8|Patch test
P10664876A0000|28 49|corticosteroid allergic
P10664876A0000|50 57|patients
P10664876A0000|129 151|corticosteroid molecules
P10664876A0000|195 200|group A
P10664876A0000|202 219|hydrocortisone type
P10664876A0000|222 238|group B (acetonides
P10664876A0000|241 246|group C
P10664876A0000|269 295|esterified) and group D (esters
P10665798A0598|22 33|serum enzymes
P10665798A0598|22 33|serum enzymes
P10665798A0598|41 61|aspartate transaminase
P10665798A0598|41 61|aspartate transaminase
P10665798A0598|63 81|alkaline phosphatase
P10665798A0598|63 81|alkaline phosphatase
P10665798A0598|83 124|creatine phosphokinase, lactate dehydrogenase
P10665798A0598|83 103|creatine phosphokinase
P10665798A0598|105 124|lactate dehydrogenase
P10665798A0598|156 165|albino rats
P10665798A0598|180 197|cell or tissue damage
P10666222A0330|25 48|murine survivin cDNA clones
P10666222A0330|25 42|murine survivin cDNA
P10666222A0330|95 110|survivin proteins
P10666222A0330|95 110|survivin proteins
P10666238A1322|19 28|E2F binding
P10666238A1322|19 21|E2F
P10666238A1322|34 46|E2F-1 promoter
P10666238A1322|34 46|E2F-1 promoter
P10666238A1322|52 57|E4-6/7
P10666238A1322|52 57|E4-6/7
P10666238A1322|94 108|transactivation
P10666238A1322|111 131|E2F-1 promoter activity
P10666238A1322|111 123|E2F-1 promoter
P10666253A1291|53 62|tRNA primer
P10666253A1291|82 84|PBS
P10666509A0494|69 79|propranolol
P10667597A0668|0 2|ZK7
P10667597A0668|0 2|ZK7
P10667597A0668|6 15|HZF16 genes
P10667597A0668|6 10|HZF16
P10667597A0668|29 34|splice
P10668701A1311|21 34|APOE epsilon4/*
P10668701A1311|21 34|APOE epsilon4/*
P10668701A1311|60 67|dementia
P10668701A1311|71 72|AD
P10668701A1311|99 110|dyslipidemia
P10668701A1311|114 126|atherogenesis
P10669319A1722|57 64|patients
P10669594A0000|11 28|Salmonella fimbrins
P10669594A0000|11 28|Salmonella fimbrins
P10669594A0000|30 33|AgfA
P10669594A0000|30 33|AgfA
P10669594A0000|37 40|SefA
P10669594A0000|37 40|SefA
P10669594A0000|52 79|thin aggregative fimbriae SEF17
P10669594A0000|75 79|SEF17
P10669594A0000|83 87|SEF14
P10669594A0000|83 87|SEF14
P10669594A0000|138 140|PT3
P10669594A0000|138 140|PT3
P10669594A0000|144 191|alpha-helical 16-amino acid Leishmania T-cell epitope
P10669594A0000|206 224|metalloprotease gp63
P10669594A0000|206 220|metalloprotease
P10669594A0000|221 224|gp63
P10669594A0969|18 21|AgfA
P10669594A0969|18 21|AgfA
P10669594A0969|32 51|chimeric SefA proteins
P10669594A0969|32 51|chimeric SefA proteins
P10669594A0969|80 87|fimbriae
P10669596A0430|10 15|growth
P10669596A0430|18 25|phage P22
P10669596A0430|28 36|wild-type
P10669596A0430|37 57|Salmonella typhimurium
P10669596A0430|85 88|Abc2
P10669596A0430|85 88|Abc2
P10669596A0430|126 146|ATP-dependent nuclease
P10669596A0430|126 146|ATP-dependent nuclease
P10669596A0430|197 223|Abc2-modified RecBCD nuclease
P10669596A0430|197 200|Abc2
P10669596A0430|210 223|RecBCD nuclease
P10669596A0430|251 256|enzyme
P10669633A0391|85 93|flt-1 gene
P10669633A0391|85 89|flt-1
P10669633A0391|115 124|THP-1 cells
P10669633A0391|115 119|THP-1
P10669736A0903|29 31|CAT
P10669736A0903|29 31|CAT
P10669736A0903|62 70|HeLa cells
P10669736A0903|110 112|PTB
P10669736A0903|110 112|PTB
P10669751T0000|8 54|mitogen-activated protein kinase signaling pathways
P10669751T0000|8 37|mitogen-activated protein kinase
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|84 96|c-jun promoter
P10669751T0000|84 96|c-jun promoter
P10669751T0000|102 123|cellular transformation
P10670358A0143|0 10|Dermatology
P10671224A0254|60 74|CD95L expression
P10671224A0254|60 64|CD95L
P10671519A0641|0 22|Protein sequence analysis
P10671519A0641|34 37|MAN1
P10671519A0641|34 37|MAN1
P10671519A0641|54 67|globular domain
P10671519A0641|110 118|LEM module
P10671519A0641|110 118|LEM module
P10671519A0641|124 151|inner nuclear membrane proteins
P10671519A0641|152 180|lamina-associated polypeptide 2
P10671519A0641|152 180|lamina-associated polypeptide 2
P10671519A0641|184 189|emerin
P10671519A0641|184 189|emerin
P10671520T0000|0 15|Molecular cloning
P10671520T0000|24 57|human I-mfa domain-containing protein
P10671520T0000|24 57|human I-mfa domain-containing protein
P10671520T0000|82 110|human T-cell leukemia virus type I
P10671520T0000|82 110|human T-cell leukemia virus type I
P10671520T0000|114 118|HIV-1
P10671520T0000|114 118|HIV-1
P10671554A0492|44 49|bovine
P10671554A0492|60 64|cDNAs
P10671554A0492|94 110|amino acid residues
P10671606A0884|4 23|chemical shift imaging
P10671606A0884|92 99|patients
P10671606A0884|104 106|APA
P10671606A0884|128 135|patients
P10671606A0884|140 142|BAH
P10672433A0199|54 60|bedtime
P10672433A0199|81 83|TIB
P10672433A0199|86 100|sleep efficiency
P10672433A0199|119 122|wake
P10672433A0199|128 142|sleep onset (WASO
P10672433A0199|156 164|awakening
P10672433A0199|181 187|morning
P10672433A0199|197 201|alarm
P10673426A0168|3 18|central (R) domain
P10673426A0168|11 18|R) domain
P10673426A0168|35 58|receptor-binding activity
P10673426A0168|69 87|N-terminal (T) domain
P10673426A0168|69 87|N-terminal (T) domain
P10673426A0168|96 108|translocation
P10673426A0168|130 154|C-terminal cytotoxic domain
P10673426A0168|197 208|cytotoxicity
P10674395A0262|69 80|neuropeptide
P10674395A0262|82 85|GnRH
P10674395A0262|82 85|GnRH
P10674395A0262|103 114|glutamate/NO
P10674395A0262|116 124|cyclic GMP
P10674395A0262|126 129|cGMP
P10674395A0262|131 155|signal transduction pathway
P10674395A0262|163 189|cGMP-dependent protein kinase
P10674395A0262|163 189|cGMP-dependent protein kinase
P10674395A0262|207 210|GnRH
P10674395A0262|229 241|cell line GT1-7
P10674484A0633|20 34|combined lesions
P10674484A0633|37 69|cholinergic and serotonergic neurons
P10674484A0633|75 82|rat brain
P10674484A0633|93 101|olfactory
P10674484A0633|114 122|olfactory
P10674484A0633|123 138|short-term memory
P10675154T0000|0 13|Extreme potency
P10675154T0000|16 29|botulinum toxin
P10675154T0000|16 29|botulinum toxin
P10675331A0600|11 15|c-Src
P10675331A0600|11 15|c-Src
P10675331A0600|27 39|isoproterenol
P10675331A0600|45 67|tyrosine phosphorylation
P10675331A0600|70 72|Shc
P10675331A0600|70 72|Shc
P10675331A0600|76 98|subsequent Erk activation
P10675331A0600|86 88|Erk
P10675331A0600|106 128|tyrosine phosphorylation
P10675331A0600|131 139|cortactin
P10675331A0600|142 146|Stat3
P10675331A0600|142 146|Stat3
P10675610A0279|0 4|MSSPs
P10675610A0279|0 4|MSSPs
P10675610A0279|26 39|DNA replication
P10675610A0279|41 53|transcription
P10675610A0279|68 87|cell cycle progression
P10675610A0279|108 119|C-MYC protein
P10675610A0279|108 119|C-MYC protein
P10677214A1045|3 14|wild type MutT
P10677214A1045|11 14|MutT
P10677214A1045|21 24|E53D
P10677214A1045|21 24|E53D
P10677214A1045|28 38|E44D mutants
P10677214A1045|28 31|E44D
P10677214A1045|47 51|log(k
P10677214A1045|53 56|cat)
P10677214A1045|97 109|ascending limb
P10677214A1045|192 193|pK
P10677214A1045|248 263|nonessential acid
P10677214A1045|297 336|quaternary MutT-Mg(2+)-dGTP-Mg(2+) complex
P10677214A1045|307 328|MutT-Mg(2+)-dGTP-Mg(2+
P10677214A2842|0 16|Structural changes
P10677214A2842|44 47|E44D
P10677214A2842|64 77|(1)H-(15)N HSQC
P10677214A2842|108 124|loop I-helix I motif
P10677214A2842|140 142|Glu
P10677214A2842|159 174|active site region
P10677297A0933|2 16|vitro expression
P10677297A0933|50 57|nonsense
P10677297A0933|69 77|mutations
P10677297A0933|139 151|cultured cells
P10678144A0509|7 8|v.
P10678968A1096|8 15|acquired
P10678968A1096|18 21|mice
P10678968A1096|28 54|I. scapularis nymphal activity
P10678968A1096|99 113|mouse population
P10678968A1096|129 144|E. phagocytophila
P10679015A0216|31 35|yeast
P10679015A0216|53 59|snoRNPs
P10679065A0711|0 15|BCR cross-linking
P10679065A0711|0 2|BCR
P10679065A0711|34 70|MAPK-activated protein kinase-2 activity
P10679065A0711|34 62|MAPK-activated protein kinase-2
P10679065A0711|113 119|p38 MAPK
P10679065A0711|113 119|p38 MAPK
P10679065A0711|121 164|MAPK-activated protein kinase-2 immune complexes
P10679065A0711|121 149|MAPK-activated protein kinase-2
P10679065A0711|180 195|peptide substrate
P10679065A0711|209 241|CREB serine 133 phosphoacceptor motif
P10679065A0711|209 212|CREB
P10679065A0711|213 221|serine 133
P10679065A0711|222 241|phosphoacceptor motif
P10679065A1217|13 87|CRE-dependent junB promoter/chloramphenicol acetyltransferase (CAT) reporter gene
P10679065A1217|26 37|junB promoter
P10679065A1217|39 70|chloramphenicol acetyltransferase
P10679065A1217|72 87|CAT) reporter gene
P10679065A1217|93 95|BCR
P10679065A1217|93 95|BCR
P10679065A1217|112 119|SB203580
P10679190A0693|24 47|upstream open reading frame
P10679190A0693|49 52|uORF
P10679190A0693|92 112|major open reading frame
P10679190A0693|114 117|mORF
P10679649A0311|8 22|TBN measurements
P10679649A0311|40 56|female outpatients
P10679649A0311|61 75|breast carcinoma
P10679649A0311|101 116|cyclophosphamide
P10679649A0311|118 129|methotrexate
P10679649A0311|134 147|5-fluorouracil
P10679649A0311|149 158|CMF)-based
P10679649A0311|159 170|chemotherapy
P10679781A1183|28 35|Unit (GRU
P10679781A1183|55 77|glucocorticoid induction
P10679781A1183|91 104|dibutyryl-cAMP
P10679781A1183|117 129|phorbol esters
P10679922A1110|59 62|ING1
P10679922A1110|59 62|ING1
P10679922A1110|69 87|tumor suppressor gene
P10679922A1110|69 87|tumor suppressor gene
P10679922A1110|88 93|target
P10679922A1110|96 99|head
P10679922A1110|103 106|neck
P10681520A0525|0 7|Ras-GRF1
P10681520A0525|0 2|Ras
P10681520A0525|4 7|GRF1
P10681520A0525|32 36|v-Src
P10681520A0525|32 36|v-Src
P10681520A0525|83 93|GEF activity
P10681520A0525|83 85|GEF
P10681520A0525|100 102|Rac
P10681520A0525|100 102|Rac
P10681520A0525|110 112|Rho
P10681520A0525|110 112|Rho
P10681520A0525|116 120|Cdc42
P10681520A0525|116 120|Cdc42
P10681520A0525|157 166|Gbetagamma
P10681520A0525|157 166|Gbetagamma
P10681562A0263|12 31|PPARgamma antagonists
P10681562A0263|12 20|PPARgamma
P10681562A0263|76 106|dominant-negative mutant receptor
P10681562A0263|76 106|dominant-negative mutant receptor
P10681562A0263|116 124|wild-type
P10681562A0263|125 133|PPARgamma
P10681562A0263|125 133|PPARgamma
P10681588A0899a|0 3|EMSA
P10681588A0899a|14 28|nuclear proteins
P10681588A0899a|14 28|nuclear proteins
P10681588A0899a|33 36|PC12
P10681588A0899a|43 44|C6
P10681588A0899a|47 55|Rat2 cells
P10681588A0899a|63 65|CRE
P10681588A0899a|86 121|activating transcription factor (ATF)-4
P10681588A0899a|86 114|activating transcription factor
P10681588A0899a|116 121|ATF)-4
P10681588A0899a|125 156|CCAAT enhancer-binding protein beta
P10681588A0899a|125 156|CCAAT enhancer-binding protein beta
P10681588A0899a|167 170|PC12
P10681588A0899a|174 194|C6 cell nuclear extracts
P10681588A0899a|213 221|CCAAT-box
P10681588A0899a|213 221|CCAAT-box
P10681588A0899a|242 255|nuclear factor Y
P10681588A0899a|242 255|nuclear factor Y
P10681588A0899b|0 3|EMSA
P10681588A0899b|14 28|nuclear proteins
P10681588A0899b|14 28|nuclear proteins
P10681588A0899b|33 36|PC12
P10681588A0899b|43 44|C6
P10681588A0899b|47 55|Rat2 cells
P10681588A0899b|63 65|CRE
P10681588A0899b|86 121|activating transcription factor (ATF)-4
P10681588A0899b|86 114|activating transcription factor
P10681588A0899b|116 121|ATF)-4
P10681588A0899b|125 156|CCAAT enhancer-binding protein beta
P10681588A0899b|125 156|CCAAT enhancer-binding protein beta
P10681588A0899b|167 170|PC12
P10681588A0899b|174 194|C6 cell nuclear extracts
P10681588A0899b|213 221|CCAAT-box
P10681588A0899b|213 221|CCAAT-box
P10681588A0899b|242 255|nuclear factor Y
P10681588A0899b|242 255|nuclear factor Y
P10681679A0220|22 33|solid portion
P10681679A0220|39 43|tumor
P10681679A0220|45 50|serial
P10681679A0220|51 53|MRI
P10681679A0220|74 89|bilobar tumor cyst
P10681679A0220|112 120|diagnosis
P10682570A0453|0 14|LPO and SOD levels
P10682570A0453|6 8|SOD
P10682570A0453|57 65|operation
P10683072T0000|9 30|ventricular tachycardia
P10683072T0000|78 90|interleukin-2
P10683072T0000|78 90|interleukin-2
P10683072T0000|101 128|metastatic renal cell carcinoma
P10683244A0939|14 26|NBF1+R protein
P10683244A0939|14 26|NBF1+R protein
P10683244A0939|31 41|NBF2 protein
P10683244A0939|31 41|NBF2 protein
P10683244A0939|103 129|molecular sieve chomatography
P10683244A0939|169 174|NBF1+R
P10683244A0939|169 174|NBF1+R
P10683244A0939|177 180|NBF2
P10683244A0939|177 180|NBF2
P10683244A1860|44 47|CFTR
P10683244A1860|44 47|CFTR
P10683244A1860|50 61|NBF1+R region
P10683244A1860|50 61|NBF1+R region
P10683244A1860|68 77|NBF2 domain
P10683244A1860|68 77|NBF2 domain
P10683259A0774|0 18|Sulfhydryl titration
P10683259A0774|23 35|iodoacetamide
P10683259A0774|95 113|maleimide derivative
P10683259A0774|116 121|biotin
P10683259A0774|116 121|biotin
P10683259A0774|163 164|pK
P10683989A0251|5 15|nitric oxide
P10683989A0251|62 65|PaO2
P10683989A0251|69 72|SaO2
P10683989A0251|106 117|Qs/Q tau ratio
P10684069A0508|20 22|MIP
P10684069A0508|20 22|MIP
P10684069A0508|24 27|MMIF
P10684069A0508|29 31|FIC
P10684069A0508|39 42|P0.1
P10684069A0508|39 42|P0.1
P10684069A0508|46 62|minute ventilation
P10684069A0508|64 65|Vr
P10684069A0508|114 129|methylphenidatum
P10684069A0508|133 145|aminophylline
P10684097A0175|17 26|female rats
P10684097A0175|81 100|bilateral ovariectomy
P10684097A0175|102 112|ovariectomy
P10684097A0175|117 145|supplementary ethinyl estradiol
P10684111A1411|32 51|extracellular factors
P10684111A1411|68 74|MAPK p44
P10684111A1411|68 71|MAPK
P10684111A1411|72 74|p44
P10684111A1411|78 81|MAPK
P10684111A1411|78 81|MAPK
P10684111A1411|82 84|p42
P10684111A1411|87 103|MAPK family members
P10684111A1411|87 90|MAPK
P10684265T0000|0 19|Covalent modification
P10684265T0000|25 52|transactivator protein IE2-p86
P10684265T0000|25 45|transactivator protein
P10684265T0000|46 52|IE2-p86
P10684265T0000|55 74|human cytomegalovirus
P10684265T0000|93 120|ubiquitin-homologous proteins
P10684265T0000|93 120|ubiquitin-homologous proteins
P10684265T0000|121 126|SUMO-1
P10684265T0000|121 126|SUMO-1
P10684265T0000|130 135|hSMT3b
P10684265T0000|130 135|hSMT3b
P10684286A0386|0 1|73
P10684304A1242|21 21|U
P10684304A1242|23 25|L)3
P10684304A1242|23 23|L
P10684534A0634|0 8|Protamine
P10684534A0634|12 18|heparin
P10684534A0634|34 43|Sigma-dose
P10684534A0634|61 70|Delta-dose
P10684646A0224|70 81|FC-dependent
P10684646A0224|94 101|caveolin
P10684660A1266|20 42|nuclear tRNA 3' processing
P10684660A1266|61 73|mitochondrial
P10684660A1266|115 121|enzymes
P10684941A0722|102 113|3'- or 5'-side
P10684941A0722|119 122|nick
P10684967A0000|0 5|NKX2.1
P10684967A0000|0 5|NKX2.1
P10684967A0000|20 28|NK2 family
P10684967A0000|20 22|NK2
P10684967A0000|31 72|homeodomain-containing transcription factors
P10684967A0000|31 72|homeodomain-containing transcription factors
P10684967A0000|157 169|lung phenotype
P10687366A0000|0 19|National abortion laws
P10687855A1197|17 34|postnatal pituitary
P10687855A1197|40 61|pre-somatotrophic cells
P10687855A1197|74 78|Zn-16
P10687855A1197|74 78|Zn-16
P10687855A1197|95 114|pituitary development
P10687855A1197|122 147|somatotroph differentiation
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687855T0000|0 30|Mouse growth hormone transcription
P10687855T0000|37 41|Zn-16
P10687855T0000|93 109|zinc finger domains
P10687855T0000|123 125|rat
P10687855T0000|126 130|Zn-15
P10687862A1980|3 19|CCAAT core sequence
P10687862A1980|38 41|CIII
P10687862A1980|38 41|CIII
P10687862A1980|45 50|CI/CII
P10687862A1980|45 46|CI
P10687862A1980|48 50|CII
P10687862A1980|81 96|promoter activity
P10687945A0000|0 10|Deglutition
P10687945A0000|37 43|infants
P10688639A1310|4 13|repression
P10688639A1310|31 62|PU.1 transactivation or PEST domains
P10688639A1310|31 34|PU.1
P10688639A1310|84 87|p300
P10688639A1310|84 87|p300
P10688646A0535|6 28|human erythroid K562 cells
P10688646A0535|56 67|HS-40 mutants
P10688646A0535|56 60|HS-40
P10688646A0535|80 128|human alpha-globin promoter-growth hormone hybrid gene
P10688646A0535|80 118|human alpha-globin promoter-growth hormone
P10688646A0535|119 128|hybrid gene
P10688646A0535|143 161|genomic footprinting
P10688660A0992|32 34|CBP
P10688660A0992|32 34|CBP
P10688660A0992|40 54|nuclear extracts
P10688660A0992|57 65|T47D cells
P10688660A0992|84 124|progesterone- and PR-dependent transcription
P10688660A0992|146 172|progesterone response element
P10688660A0992|146 172|progesterone response element
P10688660A0992|174 203|PRE)-linked reporter DNA template
P10688660A0992|174 176|PRE
P10688661A0237|3 23|cognate binding protein
P10688661A0237|25 33|REST/NRSF
P10688661A0237|25 28|REST
P10688661A0237|30 33|NRSF
P10688661A0237|48 66|transcription factor
P10688661A0237|92 109|embryonic lethality
P10688661A0237|167 186|neuron-specific genes
P10688661A0237|167 186|neuron-specific genes
P10688663A0207|16 33|histone tail domains
P10688663A0207|16 26|histone tail
P10688663A0207|43 60|trypsin proteolysis
P10688663A0207|43 49|trypsin
P10688663A0207|79 89|core histone
P10688663A0207|83 94|histone tails
P10688663A0207|139 144|TFIIIA
P10688663A0207|139 144|TFIIIA
P10688663A0207|176 189|nucleosomal DNA
P10688666A1010|22 35|ASK1 activation
P10688666A1010|22 25|ASK1
P10690702A0065|0 6|OUTCOME
P10690702A0065|8 38|Acetylcholine receptor antibodies
P10690702A0065|8 38|Acetylcholine receptor antibodies
P10690702A0065|42 67|single-fibre electromyogram
P10690702A0065|94 109|myasthenia gravis
P10690725A1037|25 28|PRFR
P10690866A0783|41 64|TSH frequency distribution
P10690866A0783|67 84|mothers and neonates
P10691972T0000|21 37|5'-flanking region
P10691972T0000|43 74|human multidrug resistance protein 2
P10691972T0000|76 84|MRP2) gene
P10691972T0000|76 79|MRP2
P10691972T0000|120 146|multidrug resistance protein 3
P10691972T0000|139 146|protein 3
P10691972T0000|148 156|MRP3) gene
P10691972T0000|148 151|MRP3
P10692167A0364|63 72|M. synoviae
P10692374A1873|26 37|M. jannaschii
P10692374A1873|53 74|archaeal 20S proteasomes
P10692374A1873|61 74|20S proteasomes
P10692374A1873|83 101|nucleotidase complex
P10692374A1873|108 110|PAN
P10692374A1873|108 110|PAN
P10692374A1873|151 174|folded-substrate proteins
P10692374A1873|185 213|N-terminal 73 amino acid residues
P10692374A1873|216 218|PAN
P10692374A1873|216 218|PAN
P10692433A0000|3 21|transcription factor
P10692433A0000|22 24|E2F
P10692433A0000|22 24|E2F
P10692433A0000|47 68|G(1) to S phase transition
P10692433A0000|47 49|G(1
P10692433A0000|74 98|higher eukaryotic cell cycle
P10693246A0252|2 10|two-field
P10693246A0252|56 70|modern two-field
P10693246A0252|82 101|traditional two-field
P10693246A0252|103 107|nodal
P10693246A0252|146 150|nerve
P10693246A0252|162 177|upper mediastinum
P10693314A0521|8 15|patients
P10693314A0521|24 28|CK-MB
P10693314A0521|24 28|CK-MB
P10693314A0521|50 51|91
P10693314A0521|57 64|patients
P10693314A0521|66 68|ECG
P10693314A0521|77 79|AMI
P10693314A0521|89 96|patients
P10694189A0469|11 13|MIB
P10694210A0385|21 23|H1R
P10694210A0385|21 23|H1R
P10694210A0385|54 61|temporal
P10694210A0385|65 89|anterior cingulate cortices
P10694210A0385|181 183|H1R
P10694210A0385|181 183|H1R
P10694210A0385|189 203|frontal cortices
P10694511A0570|18 28|yam8(+) cDNA
P10694511A0570|18 28|yam8(+) cDNA
P10694511A0570|34 48|mid1 mutant cells
P10694511A0570|34 43|mid1 mutant
P10694511A0570|71 82|mid phenotype
P10694511A0570|113 132|Ca(2+) uptake activity
P10694511A0570|113 117|Ca(2+
P10694605A1327|71 80|heart-lung
P10694605A1327|97 107|double-lung
P10694605A1327|111 112|NS
P10694609A0309|0 5|Static
P10694609A0309|53 62|anesthesia
P10695685T0000|0 17|Antipyretic therapy
P10695685T0000|66 85|clinical consequences
P10696007A1325|27 45|C2-C3 disk morphology
P10696007A1325|27 28|C2
P10696007A1325|52 67|diskographically
P10698516T0000|0 2|KFC
P10698516T0000|0 2|KFC
P10698516T0000|5 20|Ste20-like kinase
P10698516T0000|5 20|Ste20-like kinase
P10698516T0000|25 42|mitogenic potential
P10698516T0000|69 83|SAPK/JNK pathway
P10698516T0000|69 72|SAPK
P10698516T0000|74 76|JNK
P10698937T0000|0 4|TIP30
P10698937T0000|0 4|TIP30
P10698937T0000|19 32|kinase activity
P10698937T0000|68 81|apoptotic genes
P10698974A0951|15 28|human STAG3 gene
P10698974A0951|15 28|human STAG3 gene
P10698974A0951|34 43|7q22 region
P10698974A0951|46 56|chromosome 7
P10698974A0951|61 83|human STAG3-related genes
P10698974A0951|61 83|human STAG3-related genes
P10698974A0951|108 111|7q22
P10698974A0951|119 132|functional gene
P10698974A0951|139 142|7q11
P10698974A0951|157 163|7q11.23
P10698974A0951|221 248|Williams-Beuren syndrome (WBS)
P10698974A0951|221 243|Williams-Beuren syndrome
P10698974A0951|245 247|WBS
P10699354A0557|8 14|time (RT
P10699354A0557|19 22|P300
P10699653A0967|16 19|rats
P10699653A0967|68 72|water
P10699653A0967|102 108|ethanol
P10699653A0967|116 122|sucrose
P10699684A0661|12 24|Zelen's method
P10699684A0661|51 58|patients
P10699896A0455|21 28|patients
P10699896A0455|34 39|gender
P10700262A0000|83 94|sensory brain
P10701534A0164|3 9|patient
P10701534A0164|22 31|left-sided
P10702241A0357|11 19|a1 isoform
P10702241A0357|11 19|a1 isoform
P10702241A0357|44 48|brain
P10702241A0357|58 59|a2
P10702241A0357|58 59|a2
P10702241A0357|62 66|liver
P10702241A0357|70 75|kidney
P10702241A0357|80 81|a3
P10702241A0357|80 81|a3
P10702241A0357|84 88|liver
P10702241A0357|90 93|lung
P10702241A0357|95 105|heart, brain
P10702241A0357|107 112|spleen
P10702241A0357|117 122|kidney
P10702253A0357|18 61|reverse transcriptase-polymerase chain reaction
P10702253A0357|18 53|reverse transcriptase-polymerase chain
P10702253A0357|67 88|human HIF-1alpha subunit
P10702253A0357|67 88|human HIF-1alpha subunit
P10702253A0357|103 112|cDNA clones
P10702253A0357|132 150|alternative splicing
P10702253A0357|156 169|HIF-1alpha gene
P10702253A0357|156 169|HIF-1alpha gene
P10702285A0855|30 33|G(q)
P10702285A0855|30 32|G(q
P10702285A0855|35 38|G(11
P10702285A0855|35 38|G(11
P10702285A0855|55 82|phosphatidylinositol 3-kinase
P10702285A0855|55 82|phosphatidylinositol 3-kinase
P10702285A0855|133 152|p85 regulatory subunit
P10702285A0855|133 152|p85 regulatory subunit
P10702285A0855|162 171|wortmannin
P10702285A0855|190 207|insulin-stimulated
P10702285A0855|190 196|insulin
P10702285A0855|214 223|G(q)/Q209L
P10702285A0855|214 216|G(q
P10702285A0855|235 257|GLUT4-EGFP translocation
P10702285A0855|235 239|GLUT4
P10702285A0855|241 244|EGFP
P10702389A1148|2 10|endemic BL
P10702389A1148|15 26|RB2/p130 gene
P10702389A1148|15 17|RB2
P10702389A1148|19 26|p130 gene
P10702389A1148|83 91|cytoplasm
P10702794A1495|26 29|ERK2
P10702794A1495|26 29|ERK2
P10702794A1495|58 62|HePTP
P10702794A1495|58 62|HePTP
P10702794A1495|96 100|HePTP
P10702794A1495|96 100|HePTP
P10702794A1495|120 123|ERK2
P10702794A1495|120 123|ERK2
P10702926T0089|0 13|Cross-reaction
P10702926T0089|22 39|monoclonal antibody
P10702926T0089|22 39|monoclonal antibody
P10702926T0089|46 68|alpha beta T cell receptors
P10702926T0089|46 68|alpha beta T cell receptors
P10703633A0747|25 36|glycolic acid
P10703633A0747|54 65|glycolic acid
P10704196A1051|17 32|sulfhydryl groups
P10704196A1051|60 72|exofacial half
P10704196A1051|78 91|plasma membrane
P10704196A1051|112 118|helical
P10704196A1051|145 151|helices
P10704283A0649a|65 87|human chromosome 5q31-q33
P10704283A0649a|98 103|45 gene
P10704283A0649a|145 172|human IL-4 cytokine gene cluster
P10704283A0649a|145 165|human IL-4 cytokine gene
P10704285A0536|0 11|Human AP-2rep
P10704285A0536|5 11|AP-2rep
P10704285A0536|25 42|reporter expression
P10704285A0536|70 86|AP-2alpha promoter
P10704285A0536|70 78|AP-2alpha
P10704285A0536|103 115|AP-2alpha gene
P10704285A0536|103 111|AP-2alpha
P10704285A0536|152 160|AP-2alpha
P10704285A0536|152 160|AP-2alpha
P10704338A0354|42 61|amino-terminal domain
P10704338A0354|67 72|p24(CA
P10704338A0354|67 69|p24
P10704338A0354|71 72|CA
P10704338A0354|87 102|viral replication
P10704338A0354|124 138|proline residues
P10704338A0354|172 184|alpha-helices
P10704338A0354|194 213|p24 tertiary structure
P10704338A0354|194 196|p24
P10704338A0354|229 242|leucine residue
P10704338A0354|254 255|-L
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704410T0000|0 2|Clb
P10704410T0000|4 15|Cdc28 kinases
P10704410T0000|23 35|nuclear export
P10704410T0000|69 74|Mcm2-7
P10704410T0000|69 72|Mcm2
P10704499A0682|14 25|PC12-E2 cells
P10704499A0682|54 63|antibodies
P10704499A0682|69 90|fibroblast growth factor
P10704499A0682|69 90|fibroblast growth factor
P10704499A0682|92 103|FGF) receptor
P10704499A0682|92 103|FGF) receptor
P10704499A0682|120 147|nonreceptor tyrosine kinase p59
P10704499A0682|120 144|nonreceptor tyrosine kinase
P10704499A0682|145 147|p59
P10704499A0682|149 151|fyn
P10704499A0682|149 151|fyn
P10704499A0682|154 156|PLC
P10704499A0682|154 156|PLC
P10704499A0682|158 160|PKC
P10704499A0682|158 160|PKC
P10704499A0682|164 166|MEK
P10704499A0682|164 166|MEK
P10704499A0682|170 180|an activator
P10704499A0682|183 185|PKC
P10704499A0682|183 185|PKC
P10704499A0682|187 217|phorbol-12-myristate-13-acetate
P10704499A0682|219 221|PMA
P10704853T0000|18 55|Bozozok/Dharma and Nodal-related proteins
P10704853T0000|18 24|Bozozok
P10704853T0000|26 31|Dharma
P10704853T0000|35 55|Nodal-related proteins
P10704853T0000|75 80|dorsal
P10704853T0000|92 100|zebrafish
P10704975A0479|0 16|Thiopentone sodium
P10704975A0479|76 80|NOC-5
P10704975A0479|122 144|NO-induced neurotoxicity
P10704975A0479|157 164|controls
P10705380A0629|34 51|Xretpos transcripts
P10705380A0629|110 123|UV-irradiation
P10705380A0629|127 145|BMP-4 overexpression
P10705380A0629|127 131|BMP-4
P10705380A0629|148 173|cycloheximide-dependent way
P10705783A0433|38 70|chemical vestibular labyrinthectomy
P10706475A0644|27 30|DSPP
P10706475A0644|27 30|DSPP
P10706475A0644|44 46|DSP
P10706475A0644|44 46|DSP
P10706475A0644|50 52|DPP
P10706475A0644|50 52|DPP
P10706513A0843|54 74|mechanical ventilation
P10706688A0376|11 22|TCR signaling
P10706688A0376|11 13|TCR
P10706688A0376|30 33|AP-1
P10706688A0376|30 33|AP-1
P10706688A0376|66 85|fasl promoter function
P10706688A0376|66 77|fasl promoter
P10706688A0376|107 115|NF-kappaB
P10706688A0376|107 115|NF-kappaB
P10706736A1091|5 12|patients
P10706736A1091|17 34|metastatic melanoma
P10706736A1091|51 57|gp100 Ag
P10706736A1091|51 57|gp100 Ag
P10706736A1091|79 88|CD8+ T cells
P10706736A1091|79 83|CD8+ T
P10706736A1091|100 117|multiple HLA-A*0201
P10706736A1091|108 117|HLA-A*0201
P10706736A1091|130 150|gp100-derived epitopes
P10706736A1091|130 150|gp100-derived epitopes
P10706887A0281|18 22|ALCLs
P10706887A0281|34 36|ALK
P10706887A0281|34 36|ALK
P10706887A0281|52 56|t(2;5
P10706887A0281|52 54|t(2
P10706887A0281|117 129|ALK expression
P10706887A0281|117 119|ALK
P10706887A1457|30 50|ATIC enzymatic function
P10706887A1457|30 33|ATIC
P10706887A1457|53 80|ATIC-ALK-containing lymphomas
P10706887A1457|53 56|ATIC
P10706887A1457|58 60|ALK
P10706887A1457|116 130|antifolate drugs
P10706887A1457|137 148|methotrexate
P10708243A0000|69 81|pregnancy loss
P10708243A0000|85 96|preeclampsia
P10708243A0000|107 130|organ-specific antibodies
P10708424A0800|0 12|Manganese ions
P10708424A0800|38 56|autophosphorylation
P10708424A0800|59 63|BGLF4
P10708424A0800|59 63|BGLF4
P10708769A0433|3 22|Mif1 5' flanking region
P10708769A0433|3 22|Mif1 5' flanking region
P10708769A0433|42 67|ER stress-responsive element
P10708769A0433|99 109|tunicamycin
P10709705T0000|34 50|mutual information
P10710499A0000|0 11|Methysergide
P10710499A0000|15 33|serotonin antagonist
P10710499A0000|64 77|wound blood flow
P10710499A0000|81 94|edema formation
P10710742T0000|0 24|Serum leptin concentrations
P10710742T0000|5 10|leptin
P10710742T0000|27 31|women
P10710742T0000|38 66|gonadotropin stimulation cycles
P10710742T0000|38 49|gonadotropin
P10711674A0000|37 51|Pakistani family
P10711674A0000|56 97|autosomal recessive Leber congenital amaurosis
P10711674A0000|99 101|LCA
P10711674A0000|103 112|MIM 204,000
P10711674A0000|117 127|keratoconus
P10712512A0506|0 5|Ste18p
P10712512A0506|0 5|Ste18p
P10712512A0506|22 35|plasma membrane
P10712512A0506|54 64|prenylation
P10712512A0506|67 79|thioacylation
P10712599A0349|15 19|IRF-1
P10712599A0349|15 19|IRF-1
P10712599A0349|36 62|ubiquitin-proteasome pathway
P10712599A0349|36 55|ubiquitin-proteasome
P10712618A0181|2 19|amino-acid sequence
P10712618A0181|42 64|Bacillus YM55-1 aspartase
P10712618A0181|42 55|Bacillus YM55-1
P10712618A0181|86 110|Bacillus subtilis aspartase
P10712618A0181|86 110|Bacillus subtilis aspartase
P10712618A0181|121 135|Escherichia coli
P10712618A0181|121 135|Escherichia coli
P10712618A0181|139 170|Pseudomonas fluorescens aspartases
P10712618A0181|139 170|Pseudomonas fluorescens aspartases
P10713083A0170|32 35|TraR
P10713083A0170|32 35|TraR
P10713083A0170|80 83|TraM
P10713083A0170|80 83|TraM
P10713083A0560|37 59|AAI-dependent DNA binding
P10713083A0560|61 64|TraM
P10713083A0560|61 64|TraM
P10713083A0560|74 85|TraR function
P10713083A0560|74 77|TraR
P10713083A0560|135 152|DNA recognition site
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713155A0151|63 77|nuclear extracts
P10713155A0151|94 117|adenovirus-infected cells
P10713155A0151|119 120|Ad
P10713155A0151|122 123|NE
P10713155A0151|145 167|HeLa cell nuclear extracts
P10713155A0151|169 175|HeLa-NE
P10713161A0985|14 17|Ulp2
P10713161A0985|14 17|Ulp2
P10713161A0985|39 45|ulp1(ts
P10713161A0985|39 42|ulp1
P10713161A0985|44 53|ts) defects
P10713161A0985|61 72|double mutant
P10713161A0985|92 113|Smt3-protein conjugates
P10713161A0985|92 103|Smt3-protein
P10713175A1399|34 36|ARF
P10713175A1399|34 36|ARF
P10713175A1399|46 49|Mdm2
P10713175A1399|46 49|Mdm2
P10713175A1399|58 77|conformational change
P10713175A1399|93 107|nucleolar import
P10713175A1399|113 127|ARF-Mdm2 complex
P10713175A1399|113 115|ARF
P10713175A1399|117 120|Mdm2
P10713175A1399|131 158|p53-dependent cell cycle arrest
P10713175A1399|131 133|p53
P10713176A0422|0 6|Cyclin A
P10713176A0422|0 5|Cyclin
P10713176A0422|30 43|quiescent cells
P10713176A0422|46 48|E2F
P10713176A0422|46 48|E2F
P10713176A0422|96 97|Rb
P10713176A0422|96 97|Rb
P10713176A0422|99 102|p107
P10713176A0422|99 102|p107
P10713176A0422|107 110|p130
P10713176A0422|107 110|p130
P10713176A0422|120 124|v-Jun
P10713176A0422|120 124|v-Jun
P10713176A0422|167 168|Rb
P10713176A0422|167 168|Rb
P10713176A0422|194 210|E2F-p107 complexes
P10713176A0422|194 196|E2F
P10713176A0422|198 201|p107
P10713176A0422|225 241|mitogen withdrawal
P10713176A0885|0 7|D-cyclin
P10713176A0885|0 1|D-
P10713176A0885|2 11|cyclin-cdk
P10713176A0885|9 11|cdk
P10713176A0885|33 49|Rb phosphorylation
P10713176A0885|33 34|Rb
P10713176A0885|52 56|v-Jun
P10713176A0885|52 56|v-Jun
P10713176A0885|102 113|cdk4- and cdk6
P10713176A0885|102 105|cdk4
P10713176A0885|110 113|cdk6
P10713176A0885|132 141|p16(INK4A)
P10713176A0885|132 134|p16
P10713176A0885|136 140|INK4A
P10713176A0885|154 165|DNA synthesis
P10713176A0885|169 185|cell proliferation
P10713239A0988|79 86|IOL optic
P10713453A0172|30 50|monoclonal antibody Q18
P10713453A0172|30 50|monoclonal antibody Q18
P10713453A0172|76 78|57A
P10713453A0172|81 99|polytene chromosomes
P10713453A0172|127 132|Hrb57A
P10713453A0172|127 132|Hrb57A
P10714985A1057|0 23|3' RNA boundary experiments
P10714985A1057|39 49|5' structure
P10714985A1057|69 74|G/U)AG
P10714985A1057|69 69|G
P10714985A1057|71 71|U
P10714985A1057|99 102|TRAP
P10714985A1057|99 102|TRAP
P10714985A1057|104 106|trp
P10714985A1057|113 126|RNA association
P10715322A0000|0 12|Gene silencing
P10715322A0000|35 46|DNA sequences
P10715322A0000|69 78|eukaryotes
P10715322A0000|89 94|plants
P10715325A0834|3 12|AtERF genes
P10715325A0834|3 12|AtERF genes
P10715325A0834|55 67|abiotic stress
P10715325A0834|85 92|wounding
P10715325A0834|94 97|cold
P10715325A0834|114 120|drought
P10715325A0834|125 145|ETHYLENE-INSENSITIVE2
P10715325A0834|125 145|ETHYLENE-INSENSITIVE2
P10715325A0834|147 183|EIN2)-dependent or -independent pathways
P10715325A0834|147 150|EIN2
P10715602A0149|22 34|dexamethasone
P10715602A0149|58 79|protein-free surfactant
P10715602A0149|91 97|Exosurf
P10715602A0149|99 115|pure phospholipids
P10715602A0149|126 135|surfactant
P10715602A0149|137 148|Wellcome GmbH
P10715602A0149|172 191|rSP-C based surfactant
P10717612A0000|92 137|granulocyte-macrophage-colony stimulating factor
P10717612A0000|92 137|granulocyte-macrophage-colony stimulating factor
P10717612A0000|139 144|GM-CSF
P10717612A0000|139 144|GM-CSF
P10717612A0000|163 175|interleukin-2
P10717612A0000|163 175|interleukin-2
P10717612A0000|177 180|IL-2
P10717612A0000|177 180|IL-2
P10717612A0000|198 205|patients
P10717612A0000|210 237|metastatic renal cell carcinoma
P10720434A0291|20 28|synthetic
P10720434A0291|29 33|mRNAs
P10720434A0291|42 60|cis-acting sequences
P10720434A0291|87 98|cyclin B1 mRNA
P10720434A0291|87 94|cyclin B1
P10720434A0291|114 118|3'UTR
P10721698A1195|35 49|dodecamer repeat
P10721698A1195|62 77|proximal promoter
P10721698A1195|80 83|CSTB
P10721698A1195|80 83|CSTB
P10721698A1195|116 123|promoter
P10721698A1195|156 159|CSTB
P10721698A1195|156 159|CSTB
P10721704A1155|34 37|mHuA
P10721704A1155|34 37|mHuA
P10721704A1155|52 75|neural-restricted members
P10721704A1155|81 90|Elav family
P10721704A1155|81 90|Elav family
P10721704A1155|95 109|promoter element
P10721704A1155|136 151|sequence analysis
P10721704A1155|155 177|transcriptional activity
P10721704A1155|184 198|neural cell types
P10721704X0000|13 17|5' end
P10721704X0000|23 43|mouse Elavl1 (mHuA) gene
P10721704X0000|23 33|mouse Elavl1
P10721704X0000|35 38|mHuA
P10721704X0000|52 83|transcriptional regulatory element
P10721704X0000|107 125|genomic organization
P10721704X0000|127 130|mHuA
P10721704X0000|127 130|mHuA
P10721704X0000|132 138|Elavl1)
P10721704X0000|132 137|Elavl1
P10721704X0000|185 203|RNA-binding proteins
P10721704X0000|185 203|RNA-binding proteins
P10721704X0000|222 231|cell growth
P10721704X0000|235 247|proliferation
P10721704X0000|270 282|mRNA stability
P10721714A1087|0 33|Electrophoretic mobility shift assays
P10721714A1087|46 48|Sp1
P10721714A1087|46 48|Sp1
P10721714A1087|80 95|proximal promoter
P10721714A1087|105 111|Sp1 site
P10721714A1087|105 111|Sp1 site
P10721714A1087|134 162|G/C-rich region between (-67; -62
P10721714A1087|134 136|G/C
P10721717A0676|0 3|Fgd3
P10721717A0676|0 3|Fgd3
P10721717A0676|7 10|FGD1
P10721717A0676|7 10|FGD1
P10721717A0676|29 44|sequence identity
P10721717A0676|55 84|560 contiguous amino acid residues
P10721726T0000|0 15|Molecular cloning
P10721726T0000|18 43|mouse thioredoxin reductases
P10721726T0000|18 33|mouse thioredoxin
P10722063A0328|3 12|HPLC method
P10722063A0328|23 43|octadecylsilane column
P10722063A0328|67 104|water-acetonitrile-orthophosphoric acid
P10722063A0328|116 118|v/v
P10722509A0392|5 12|patients
P10722509A0392|52 61|body weight
P10722509A0392|69 76|patients
P10722661A0146|0 3|CYC2
P10722661A0146|0 3|CYC2
P10722661A0146|12 24|24-kDa protein
P10722661A0146|12 24|24-kDa protein
P10722661A0146|53 73|Neurospora crassa PREG1
P10722661A0146|53 73|Neurospora crassa PREG1
P10722661A0146|80 102|S. cerevisiae PHO80 cyclin
P10722661A0146|80 91|S. cerevisiae
P10722661A0146|97 102|cyclin
P10722661A0406|13 16|CYC2
P10722661A0406|13 16|CYC2
P10722661A0406|58 87|trypanosome cdc2-related kinases
P10722661A0406|58 87|trypanosome cdc2-related kinases
P10722661A0406|89 92|CRKs
P10722661A0406|89 92|CRKs
P10722661A0406|98 105|CYC2 gene
P10722661A0406|98 105|CYC2 gene
P10722661A0406|119 130|TY epitope tag
P10722661A0406|149 165|trypanosome genome
P10722661A0406|184 199|inducible control
P10722737A1726|37 39|Sp1
P10722737A1726|37 39|Sp1
P10722737A1726|50 76|non-cell-specific regulation
P10722737A1726|81 111|Kruppel-like transcription factor
P10722737A1726|81 111|Kruppel-like transcription factor
P10722737A1726|115 117|Sp1
P10722737A1726|115 117|Sp1
P10722737A1726|123 145|cell-specific regulation
P10722737A1726|151 161|LTC(4)S gene
P10722737A1726|151 161|LTC(4)S gene
P10723723A0781|16 28|mouse promoter
P10723723A0781|16 28|mouse promoter
P10723723A0781|48 49|CT
P10723723A0781|101 109|5' to exon 1
P10723727A0713|31 36|intron
P10723727A0713|89 103|signal sequences
P10724436A0085|0 7|Depleted
P10724483A0540|37 47|hypoxic SRP1
P10724483A0540|44 47|SRP1
P10724483A0540|51 60|HEM13 genes
P10724483A0540|51 60|HEM13 genes
P10724483A0540|80 89|HOG pathway
P10724483A0540|80 82|HOG
P10724519A1185|28 74|regulatory RNAs or transcribed transposable elements
P10725017A0673|19 42|middleware-based approach
P10725017A0673|52 62|CEN ENV 12967
P10725017A0673|100 115|healthcare record
P10725017A0673|123 133|CEN ENV 12265
P10725017A0673|135 173|Electronic Healthcare Record Architecture'
P10725382A0398|0 15|Sequence analyses
P10725382A0398|18 34|sos2 mutant alleles
P10725382A0398|18 21|sos2
P10725382A0398|52 76|N-terminal catalytic domain
P10725382A0398|52 76|N-terminal catalytic domain
P10725382A0398|83 108|C-terminal regulatory domain
P10725382A0398|83 108|C-terminal regulatory domain
P10725382A0398|111 114|SOS2
P10725382A0398|111 114|SOS2
P10725433A0543|1 8|mutation
P10725433A0543|54 63|Wp reporter
P10725433A0543|86 95|B cell lines
P10725433A0543|136 164|consensus CREB-binding sequence
P10725433A0543|145 164|CREB-binding sequence
P10725433A0543|174 198|wild-type promoter function
P10727247A0461|25 49|tissue-specific expression
P10727247A0461|97 109|TEF-1 isoforms
P10727247A0461|97 101|TEF-1
P10727247A0461|111 119|TEF-1beta
P10727247A0461|111 119|TEF-1beta
P10727247A0461|123 132|TEF-1gamma
P10727247A0461|123 132|TEF-1gamma
P10727413A1244|27 47|liver-enriched factors
P10727413A1244|61 89|hamster CYP7A1 proximal promoter
P10727413A1244|68 89|CYP7A1 proximal promoter
P10727413A1244|143 156|regulatory unit
P10727413A1244|169 190|basal hepatic expression
P10727413A1244|194 210|tissue restriction
P10727413A1244|238 244|insulin
P10727413A1244|238 244|insulin
P10727426A1280|3 16|kinase activity
P10727426A1280|19 23|PfPK6
P10727426A1280|19 23|PfPK6
P10727426A1280|37 49|CDK inhibitors
P10727426A1280|37 39|CDK
P10727426A1280|56 79|olomoucine and roscovitine
P10727428A0000|8 10|MAP
P10727428A0000|8 10|MAP
P10727428A0000|12 43|mitogen-activated protein) kinases
P10727428A0000|12 43|mitogen-activated protein) kinases
P10727428A0000|59 75|cell proliferation
P10727428A0000|79 93|differentiation
P10727428A0000|119 128|MAP kinases
P10727428A0000|119 128|MAP kinases
P10727428A0000|131 148|cardiac hypertrophy
P10727433A0560|17 22|CSF-1R
P10727433A0560|17 22|CSF-1R
P10727433A0560|49 73|CSF-1-dependent activation
P10727433A0560|49 53|CSF-1
P10727433A0560|79 95|signalling pathway
P10727433A0560|107 139|Ets/AP1 (activator protein 1) element
P10727433A0560|107 109|Ets
P10727433A0560|111 113|AP1
P10727433A0560|115 131|activator protein 1
P10727433A0560|145 155|uPA promoter
P10727433A0560|145 155|uPA promoter
P10727433A0560|195 206|oncogenic ras
P10727433A0560|195 206|oncogenic ras
P10727433A0560|210 231|protein kinase C pathways
P10727433A0560|210 223|protein kinase C
P10727433T0000|12 44|urokinase plasminogen activator gene
P10727433T0000|21 40|plasminogen activator
P10727433T0000|41 57|gene transcription
P10727433T0000|63 92|RAW264 murine macrophage cell line
P10727433T0000|95 128|macrophage colony-stimulating factor
P10727433T0000|95 128|macrophage colony-stimulating factor
P10727433T0000|130 134|CSF-1
P10727433T0000|130 134|CSF-1
P10727433T0000|161 180|cell-surface receptor
P10727511A0294|0 7|Molecule
P10727511A0294|21 36|neuronal cultures
P10727511A0294|64 68|GLT-1
P10727511A0294|64 68|GLT-1
P10727515A1202|35 55|G(q)-coupled receptors
P10727515A1202|35 55|G(q)-coupled receptors
P10727515A1202|63 82|delta-opioid receptor
P10727515A1202|63 82|delta-opioid receptor
P10727515A1202|111 117|PLCbeta
P10727515A1202|111 117|PLCbeta
P10727515A1202|159 172|pertussis toxin
P10727515A1202|159 172|pertussis toxin
P10728945A0233|41 59|Platelet Aggregation
P10728945A0233|63 93|Coronary Thrombosis-II (IMPACT-II
P10728986A0000|3 21|Wnt signaling pathway
P10728986A0000|3 5|Wnt
P10728986A0000|50 66|animal development
P10728986A0000|76 92|cell fate decisions
P10729151A1160|32 61|HPV-11 upstream regulatory region
P10729151A1160|32 37|HPV-11
P10729151A1160|38 90|upstream regulatory region-controlled reporter expression
P10729155A0653|17 26|MVMi capsid
P10729155A0653|48 57|carboxy end
P10729155A0653|63 91|amphipathic beta-strand I (betaI
P10729155A0653|103 115|basic residues
P10729155A0653|193 199|solvent
P10729220A0000|16 19|IGF2
P10729220A0000|16 19|IGF2
P10729220A0000|21 51|human insulin-like growth factor II
P10729220A0000|26 51|insulin-like growth factor II
P10729220A0000|56 63|H19 genes
P10729220A0000|56 63|H19 genes
P10729220A0000|102 106|mouse
P10729220A1569|3 23|asymmetric methylation
P10729220A1569|41 65|tissue-specific disruption
P10729220A1569|68 70|H19
P10729220A1569|90 99|fetal brain
P10729221A0798|46 61|Kv4 family members
P10729221A0798|46 61|Kv4 family members
P10730292T0000|0 13|Early treatment
P10730292T0000|28 55|Class II division 2 malocclusion
P10730763A1491|19 47|Nottingham Eczema Severity Score
P10731411A0958|94 113|DEAD-box RNA helicases
P10731411A0958|94 113|DEAD-box RNA helicases
P10731411A0958|158 164|residue
P10731411A0958|174 184|"DEAD" motif
P10731926A0775|0 14|Advanced adenoma
P10731926A0775|74 89|villous component
P10731926A0775|91 128|high-grade dysplasia or invasive carcinoma
P10732669A0510|2 16|transient assays
P10732669A0510|23 50|rice suspension-cultured cells
P10732669A0510|106 111|Oshox1
P10732669A0510|106 111|Oshox1
P10732669A0510|152 173|reporter gene constructs
P10732669A0510|186 203|HD-Zip binding sites
P10732669A0510|186 203|HD-Zip binding sites
P10732669A1336|28 61|electrophoretic mobility shift assays
P10732669A1336|84 97|HD-Zip proteins
P10732669A1336|84 89|HD-Zip
P10732669A1336|100 113|families I and II
P10732669A1336|121 130|homodimers
P10732669A1336|157 170|HD-Zip proteins
P10732669A1336|157 162|HD-Zip
P10733569A0364|14 17|HSFs
P10733569A0364|14 17|HSFs
P10733569A0364|19 22|HSF1
P10733569A0364|19 22|HSF1
P10733569A0364|66 97|heat-induced stress gene expression
P10733569A0364|78 87|stress gene
P10733569A0364|119 122|HSF2
P10733569A0364|119 122|HSF2
P10733569A0364|125 138|stress response
P10733581A1391|56 58|Raf
P10733581A1391|56 58|Raf
P10733581A1391|62 70|V12N38 Ras
P10733581A1391|62 67|V12N38
P10733581A1391|68 70|Ras
P10733581A1391|100 112|TTF-1 activity
P10733581A1391|100 104|TTF-1
P10733591A0146|13 29|downstream targets
P10733591A0146|55 59|actin
P10733591A0146|60 71|cytoskeleton
P10733591A0146|85 97|p70(S6) kinase
P10733591A0146|85 97|p70(S6) kinase
P10733591A0146|101 121|c-jun N-terminal kinase
P10733591A0146|101 121|c-jun N-terminal kinase
P10733591A0146|123 125|JNK
P10733591A0146|123 125|JNK
P10733591A0146|143 155|transcription
P10733591A0146|159 175|cell proliferation
P10733591A0533|21 25|Cdc42
P10733591A0533|21 25|Cdc42
P10733591A0533|53 61|PKClambda
P10733591A0533|53 61|PKClambda
P10733591A0533|69 75|nucleus
P10733591A0533|83 89|cytosol
P10733591A0533|94 98|Cdc42
P10733591A0533|94 98|Cdc42
P10733591A0533|102 110|PKClambda
P10733591A0533|126 139|plasma membrane
P10733591A0533|148 156|cytoplasm
P10734312A0503|19 21|Shc
P10734312A0503|19 21|Shc
P10734312A0503|36 48|membrane rafts
P10734312A0503|71 73|Shc
P10734312A0503|71 73|Shc
P10734312A0503|97 106|Shc chimera
P10734312A0503|97 99|Shc
P10734312A0503|120 147|Ras membrane localization motif
P10734312A0503|123 147|membrane localization motif
P10734312A0503|153 162|C-terminus
P10734312A0503|153 162|C-terminus
P10735272A0649|0 15|Southern blotting
P10735272A0649|19 62|single strand conformation polymorphism analyses
P10735272A0649|123 132|PCR studies
P10735272A0649|151 165|glioma cell lines
P10735272A0649|181 185|ANOVA
P10735272A0649|181 185|ANOVA
P10735272A0649|194 231|chromosome 19q glioma tumor suppressor gene
P10735848A1440|0 3|RegA
P10735848A1440|0 3|RegA
P10735848A1440|41 58|tol-oprL expression
P10735848A1440|41 43|tol
P10735848A1440|45 48|oprL
P10736161T0000|12 54|phosphoenolpyruvate:sugar phosphotransferase
P10736161T0000|37 60|phosphotransferase system
P10736223A1227|46 49|prgX
P10736223A1227|46 49|prgX
P10736223A1227|68 77|Qa promoter
P10736223A1227|68 77|Qa promoter
P10736223A1227|80 83|prgQ
P10736223A1227|80 83|prgQ
P10736223A1227|88 91|PrgX
P10736223A1227|88 91|PrgX
P10736223A1227|138 163|transcriptional readthrough
P10737366A0280|48 51|PTFL
P10737366A0280|87 103|mechanical stimuli
P10737366A0280|123 126|rats
P10738139A0681|0 15|Molecular mimicry
P10738139A0681|18 30|human cytokine
P10738139A0681|34 56|cytokine response pathway
P10738139A0681|64 67|KSHV
P10739408A0896|0 16|Family environment
P10739408A0896|85 97|social support
P10739671A0136|2 35|electrophoresis mobility shift assays
P10739671A0136|84 132|putative human c-myb intron 1 transcription pause region
P10739671A0136|92 108|human c-myb intron 1
P10739671A0136|136 150|nuclear extracts
P10739671A0136|155 173|myeloid leukemia HL 60
P10739671A0136|177 195|fibroblast WI 38 cells
P10739671A0136|208 232|HL-60-specific DNA-protein
P10739671A0136|208 212|HL-60
P10739671A0136|222 239|DNA-protein complex
P10739671A0136|245 258|123-bp fragment
P10739671A0136|269 280|binding sites
P10739671A0136|287 313|interferon regulatory factors
P10739671A0136|287 313|interferon regulatory factors
P10739671A0136|315 334|IRFs) nuclear proteins
P10739671A0136|315 318|IRFs
P10740602A0141|16 46|needle aspiration cytologic smears
P10740602A0141|60 83|invasive lobular carcinoma
P10740602A0141|85 87|ILC
P10740602A0141|120 142|cytomorphologic analysis
P10741850A0452|29 33|EpREs
P10741850A0452|45 64|5'-flanking sequences
P10741850A0452|74 96|GCSh and GCSl subunit genes
P10741850A0452|74 77|GCSh
P10741850A0452|81 96|GCSl subunit genes
P10741850A0452|138 150|gene induction
P10741947T0000|1 12|new technique
P10741947T0000|52 54|LAD
P10742114A0486|0 3|Dll3
P10742114A0486|0 3|Dll3
P10742114A0486|18 46|X-ray-induced mouse mutant pudgy
P10742114A0486|31 46|mouse mutant pudgy
P10742114A0486|48 49|pu
P10742114A0486|48 49|pu
P10742216A0555|0 7|Schlegel
P10743608A1154|0 6|TbRAB31
P10743608A1154|39 47|cell cycle
P10743608A1154|49 55|TbRAB31
P10743608A1154|116 122|mitosis
P10743608A1154|176 198|basal body and kinetoplast
P10743608A1154|226 237|microtubules
P10743719A0223|3 9|early dg
P10743719A0223|35 48|acute rejection
P10743719A0223|92 124|future chronic rejection nephropathy
P10744026A0000|0 9|Invertases
P10744026A0000|0 9|Invertases
P10744026A0000|41 47|sucrose
P10744026A0000|50 67|fructose and glucose
P10744749A0315|41 62|Tax-mediated inhibition
P10744749A0315|41 43|Tax
P10744749A0315|116 123|myogenic
P10744749A0315|124 134|MyoD protein
P10744749A0315|124 127|MyoD
P10744749A0315|161 171|bHLH factors
P10744749A0315|161 171|bHLH factors
P10744749T0000|3 43|human T cell leukemia/lymphotropic virus type 1
P10744749T0000|8 53|T cell leukemia/lymphotropic virus type 1 Tax protein
P10744749T0000|44 53|Tax protein
P10744749T0000|63 89|MyoD-dependent transcription
P10744749T0000|63 66|MyoD
P10744749T0000|102 105|MyoD
P10744749T0000|102 105|MyoD
P10744749T0000|119 127|KIX domain
P10744749T0000|119 127|KIX domain
P10744749T0000|130 133|p300
P10744749T0000|130 133|p300
P10744974T0000|0 44|Phosphorylation and spindle pole body localization
P10744974T0000|50 85|Cdc15p mitotic regulatory protein kinase
P10744974T0000|50 85|Cdc15p mitotic regulatory protein kinase
P10744974T0000|88 99|budding yeast
P10745563A0409|12 22|hyperplasia
P10745563A0409|26 48|thrombotic complications
P10745563A0409|65 72|stenting
P10745563A0409|100 109|gold stents
P10745563A0409|168 182|neo-endothelium
P10747053A1102|3 11|cell cycle
P10747053A1102|15 36|transcriptional defects
P10747053A1102|45 49|taf17
P10747053A1102|45 49|taf17
P10747053A1102|51 56|slm7-1
P10747053A1102|51 56|slm7-1
P10747053A1102|84 89|TAF(II
P10747053A1102|84 89|TAF(II
P10747053A1102|106 130|transcriptional activation
P10747053A1102|152 156|TAF17
P10747053A1102|152 156|TAF17
P10747053A1102|181 183|SBF
P10747053A1102|181 183|SBF
P10747053A1102|187 189|MBF
P10747053A1102|187 189|MBF
P10747099A0507|0 43|Extracellular-regulated kinase (ERK) activation
P10747099A0507|0 28|Extracellular-regulated kinase
P10747099A0507|30 32|ERK
P10747099A0507|69 83|adaptor proteins
P10747099A0507|84 110|p130 Crk-associated substrate
P10747099A0507|84 110|p130 Crk-associated substrate
P10747099A0507|112 114|CAS
P10747099A0507|112 114|CAS
P10747099A0507|119 125|c-CrkII
P10747099A0507|119 125|c-CrkII
P10747099A0507|127 129|Crk
P10747099A0507|127 129|Crk
P10747099A0507|169 180|cell invasion
P10747099A0507|200 208|apoptosis
P10747099A0507|212 242|three-dimensional collagen matrix
P10747782A0390|13 16|Mbp1
P10747782A0390|13 16|Mbp1
P10747782A0390|20 43|Swi4 DNA-protein complexes
P10747782A0390|20 43|Swi4 DNA-protein complexes
P10747782A0390|84 95|C-terminally
P10747782A0390|138 155|DNA binding activity
P10747782A0390|169 179|core domains
P10747879A0607|3 11|evolution
P10747879A0607|17 40|CCR5 cis-regulatory region
P10747879A0607|17 40|CCR5 cis-regulatory region
P10747879A0607|50 65|open reading frame
P10747879A0607|100 115|open reading frame
P10747890A1096|43 56|"protein sensor
P10747890A1096|60 66|altered
P10747890A1096|67 77|minor groove
P10747987A0658|3 20|recombinant enzymes
P10748054T0048|0 7|A pathway
P10748054T0048|23 67|B lymphocyte antigen receptor-induced calcium flux
P10748054T0048|23 48|B lymphocyte antigen receptor
P10748113A0187|20 29|RIM protein
P10748113A0187|20 29|RIM protein
P10748113A0187|37 40|RIM2
P10748113A0187|37 40|RIM2
P10748113A0187|66 69|RIM1
P10748113A0187|66 69|RIM1
P10748113A0187|97 101|brain
P10748125A0000|0 10|Inhibitor-1
P10748125A0000|0 10|Inhibitor-1
P10748125A0000|12 14|I-1
P10748125A0000|12 14|I-1
P10748125A0000|19 29|inhibitor-2
P10748125A0000|19 29|inhibitor-2
P10748125A0000|31 33|I-2
P10748125A0000|31 33|I-2
P10748125A0000|53 92|type 1 protein serine/threonine phosphatases
P10748125A0000|53 92|type 1 protein serine/threonine phosphatases
P10748125A0000|94 96|PP1
P10748125A0000|94 96|PP1
P10748164A1284|0 16|Scanning mutations
P10748164A1284|30 38|AC element
P10748164A1284|86 101|overlapping sites
P10748164A1284|105 121|regulatory factors
P10748164A1284|124 125|AC
P10748175A0000|16 30|glycan synthesis
P10748175A0000|36 40|lumen
P10748175A0000|46 50|Golgi
P10748175A0000|98 104|cytosol
P10748175A0000|107 140|specific membrane-bound transporters
P10748194T0000|0 16|Synaptic targeting
P10748194T0000|22 53|postsynaptic density protein PSD-95
P10748194T0000|22 47|postsynaptic density protein
P10748194T0000|48 50|PSD
P10748194T0000|65 95|tyrosine-based trafficking signal
P10748672A0130|0 4|Bites
P10748672A0130|19 24|adders
P10748672A0130|26 36|Vipera aspis
P10748672A0130|40 50|Vipera berus
P10748672A0130|82 98|multiorgan failure
P10749145T0000|13 36|transforming PCPH proteins
P10749145T0000|25 36|PCPH proteins
P10749145T0000|41 62|guanosine diphosphatase
P10749145T0000|81 91|oncoprotein
P10749145T0000|106 108|Ras
P10749145T0000|106 108|Ras
P10749145T0000|121 155|extracellular signal-regulated kinase
P10749145T0000|121 155|extracellular signal-regulated kinase
P10749145T0000|156 159|ERK1
P10749145T0000|156 159|ERK1
P10749166A0991|24 48|virulence-associated genes
P10749166A0991|119 128|B. henselae
P10749166A0991|137 157|gram-negative bacteria
P10749166A0991|164 176|A. tumefaciens
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|83 97|cell cycle arrest
P10749849A0000|120 150|cyclin-dependent kinase inhibitor
P10749849A0000|120 141|cyclin-dependent kinase
P10749849A0000|151 163|p21(WAF1/Cip1
P10749849A0000|151 153|p21
P10749849A0000|155 158|WAF1
P10749849A0000|160 163|Cip1
P10749932A0000|0 7|Paxillin
P10749932A0000|0 7|Paxillin
P10749932A0000|16 30|adaptor molecule
P10749932A0000|33 49|integrin signaling
P10749932A0000|33 40|integrin
P10750020A0843|5 16|growth factor
P10750020A0843|29 30|ER
P10750020A0843|29 30|ER
P10750020A0843|58 84|ER/Sp1 binding to GC-rich sites
P10750020A0843|58 59|ER
P10750020A0843|61 63|Sp1
P10750020A0843|73 84|GC-rich sites
P10750020A0843|114 139|ligand-independent ER action
P10750021A0728|22 56|deletion promoter-reporter constructs
P10750021A0728|84 85|P2
P10750021A0728|98 111|proximal region
P10750021A0728|114 115|P2
P10750524A0724|41 56|audiometric tests
P10750524A0724|110 126|hypertensive group
P10751398A1135|29 42|c-IAP2 promoter
P10751398A1135|29 42|c-IAP2 promoter
P10751398A1135|70 73|CD40
P10751398A1135|70 73|CD40
P10751398A1135|76 114|Epstein-Barr virus latent membrane protein 1
P10751398A1135|76 92|Epstein-Barr virus
P10751398A1135|93 114|latent membrane protein 1
P10752450A0288|10 21|professional
P10752450A0288|37 52|fluoride products
P10752450A0288|71 93|fluoride delivery systems
P10752475A1376|32 56|signal-transduction events
P10752475A1376|70 78|apoptosis
P10752475A1376|81 95|malignant B cells
P10752475A1376|128 131|CD20
P10752475A1376|128 131|CD20
P10752475A1376|134 152|anti-CD20 antibodies
P10752475A1376|139 152|CD20 antibodies
P10752475A1376|168 194|Fc-receptor-expressing cells
P10752475A1376|168 178|Fc-receptor
P10752475A1376|206 233|goat anti-(mouse Ig) antibodies
P10752475A1376|210 233|anti-(mouse Ig) antibodies
P10752475A1376|260 275|tumor regressions
P10752475A1376|286 296|mouse models
P10752807A1598|35 69|platelet-activating factor antagonist
P10752807A1598|35 59|platelet-activating factor
P10752807A1598|70 75|BB-882
P10752807A1598|97 103|placebo
P10752807A1598|115 131|hemodynamic status
P10752807A1598|133 151|respiratory function
P10752807A1598|155 172|organ failure scores
P10753553T0000|0 8|Phenazone
P10753553T0000|47 55|lidocaine
P10753553T0000|58 61|mice
P10754312A0798|3 12|solubility
P10754312A0798|21 35|mutated proteins
P10756007A0575|18 29|RBE sequences
P10756007A0575|69 79|human genome
P10756007A1512|0 9|EM analysis
P10756007A1512|33 46|Rep-DNA complex
P10756007A1512|33 46|Rep-DNA complex
P10756007A1512|58 71|ch-19 target DNA
P10756020A0571|27 56|purified vaccinia virus particles
P10756020A0571|64 72|membranes
P10756020A0571|75 98|immature and mature virions
P10756020A0571|119 136|electron microscopy
P10756020A0571|139 151|infected cells
P10756032A0599|2 32|vivo dimethyl sulfate footprinting
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|90 105|hypersensitivity
P10756032A0599|122 134|infected cells
P10756094A0671|35 36|Mb
P10756094A0671|90 93|15 kb
P10756100A0457|23 36|amino-terminus
P10756100A0457|39 41|IB1
P10756100A0457|39 41|IB1
P10756100A0457|59 66|diabetes
P10756225A1464|24 31|patients
P10756225A1464|56 58|CRS
P10756225A1464|132 139|IL-5 mRNA
P10756225A1464|132 139|IL-5 mRNA
P10756225A1464|145 158|ethmoid sinuses
P10757983A0733|20 30|CRS sequence
P10757983A0733|78 94|zinc finger protein
P10757983A0733|78 94|zinc finger protein
P10757983A0733|96 104|Adx factor
P10757983A0733|96 104|Adx factor
P10757983A0733|125 153|Kruppel-like zinc finger protein
P10757983A0733|125 153|Kruppel-like zinc finger protein
P10757983A0733|156 175|mouse ZBP-89 homologue
P10757983A0733|156 166|mouse ZBP-89
P10758289A0141|40 70|deep and superficial finger flexors
P10758289A0141|96 107|pisiform bone
P10758489A0206|28 31|ICK2
P10758489A0206|28 31|ICK2
P10758489A0206|59 65|Cdc2aAt
P10758489A0206|59 65|Cdc2aAt
P10758489A0206|84 86|CDK
P10758489A0206|84 86|CDK
P10758489A0206|103 109|Cdc2bAt
P10758489A0206|103 109|Cdc2bAt
P10759693A0201|22 33|odds ratio (OR
P10759693A0201|121 141|H2-receptor antagonist
P10759693A0201|121 131|H2-receptor
P10759693A0201|143 152|cimetidine
P10759693A0201|167 186|noninteracting agents
P10759693A0201|187 196|ranitidine
P10759693A0201|241 273|warfarin, phenytoin and theophylline
P10760109A1050|15 26|malnutrition
P10760109A1050|40 47|patients
P10760109A1050|55 57|CVD
P10760109A1050|103 110|patients
P10760109A1050|115 117|CVD
P10760109A1050|134 137|tHcy
P10760109A1050|139 142|SAlb
P10760109A1050|144 154|plasma IGF-1
P10760109A1050|150 154|IGF-1
P10760109A1050|172 174|SCr
P10760109A1050|180 194|blood hemoglobin
P10760109A1050|185 194|hemoglobin
P10760132A1169|67 87|Ypt protein prenylation
P10760132A1169|67 76|Ypt protein
P10760132A1169|119 130|polarization
P10760169A1142|25 33|CreA sites
P10760169A1142|25 33|CreA sites
P10760169A1142|56 83|transcription initiation sites
P10760950A1133|30 39|N-utrophin
P10760950A1133|30 39|N-utrophin
P10760950A1133|93 109|actin stress fibers
P10760950A1133|93 97|actin
P10761263A1108|4 18|Newcastle' model
P10761263A1108|45 46|T2
P10761263A1108|123 130|prostate
P10761263A1108|131 138|patients
P10762254A0954|3 9|MMA, DMA
P10762254A0954|14 34|TMA methyltransferases
P10762254A0954|14 34|TMA methyltransferases
P10762254A0954|65 88|MMA methyltransferase gene
P10762254A0954|65 67|MMA
P10762254A0954|68 88|methyltransferase gene
P10762254A0954|109 135|DMA and TMA methyltransferases
P10762254A0954|109 111|DMA
P10762254A0954|115 117|TMA
P10762254A0954|162 171|amber codon
P10762348A0269|5 19|phosphorylation
P10762348A0269|21 32|STAT proteins
P10762348A0269|21 32|STAT proteins
P10762348A0269|54 60|nucleus
P10762348A0269|71 93|transcriptional activity
P10763823A0824|16 20|mcl-1
P10763823A0824|16 20|mcl-1
P10763823A0824|49 57|apoptosis
P10763823A0824|79 83|mcl-1
P10763823A0824|79 83|mcl-1
P10763823A0824|106 114|cell death
P10763827A1158|13 38|multiple senescence pathways
P10763827A1158|64 74|ras oncogene
P10763827A1158|64 74|ras oncogene
P10763827A1158|90 97|TGFbeta1
P10763827A1158|90 97|TGFbeta1
P10764150A0000|67 76|Raf kinases
P10764150A0000|67 76|Raf kinases
P10764150A0000|90 107|cytokine dependency
P10764150A0000|110 120|FDC-P1 cells
P10764574A0718|60 78|Arabidopsis thaliana
P10764574A0718|152 160|alignment
P10764729A1846|25 42|human betaV spectrin
P10764729A1846|25 42|human betaV spectrin
P10764729A1846|58 67|GenBank(TM
P10764760T0000|0 14|Transactivation
P10764760T0000|35 58|HIV-1 long terminal repeats
P10764760T0000|35 58|HIV-1 long terminal repeats
P10764760T0000|64 82|JNK signaling pathway
P10764760T0000|64 66|JNK
P10764802A1258|20 36|alpha-helix domain
P10764802A1258|20 36|alpha-helix domain
P10764802A1258|39 41|p57
P10764802A1258|39 41|p57
P10764802A1258|43 46|Kip2
P10764802A1258|43 46|Kip2
P10764802A1258|70 84|Cip/Kip proteins
P10764802A1258|70 72|Cip
P10764802A1258|74 76|Kip
P10764802A1258|100 125|protein-protein interaction
P10764802A1258|100 114|protein-protein
P10764802A1258|137 163|specific regulatory mechanism
P10764802A1258|179 200|Cdk-inhibitory activity
P10764802A1258|212 214|p57
P10764802A1258|212 214|p57
P10764802A1258|216 233|Kip2) family members
P10764802A1258|216 219|Kip2
P10764802A1258|257 271|differentiation
P10764970A1009|21 45|quinupristin/dalfopristin
P10764970A1009|60 63|sat A
P10764970A1009|75 77|PCR
P10764970A1009|175 192|antimicrobial class
P10765095A0308|31 42|PRL secretion
P10765095A0308|31 33|PRL
P10765095A0308|55 68|prostate cancer
P10765095A0308|83 97|basal conditions
P10765095A0308|113 118|L-Dopa
P10765095A0308|122 135|metoclopramide
P10765095A0308|200 211|PRL secretion
P10765095A0308|200 202|PRL
P10766246A0000|0 24|Integrin adhesion receptors
P10766246A0000|8 24|adhesion receptors
P10766246A0000|52 71|complex cell functions
P10766246A0000|99 112|gene expression
P10766246A0000|120 132|proliferation
P10766246A0000|134 148|differentiation
P10766493T0000|0 24|Recombination, replication
P10766556T0000|3 21|somatoform conundrum
P10766556T0000|34 50|nosological valves
P10767091A0133|26 29|IOUS
P10767091A0133|104 124|two-dimensional nature
P10767091A0133|172 202|ablative or resectional techniques
P10767251A1046|48 60|fibrin sealant
P10767251A1046|48 53|fibrin
P10767251A1046|120 123|pigs
P10767338T0000|0 19|Hailey-Hailey disease
P10767338T0000|41 46|ATP2C1
P10767338T0000|41 46|ATP2C1
P10767338T0000|61 70|Ca(2+) pump
P10767338T0000|61 65|Ca(2+
P10767553A0100|0 2|Hex
P10767553A0100|0 2|Hex
P10767553A0100|29 33|liver
P10767553A0100|51 89|forkhead/winged helix transcription factor
P10767553A0100|51 58|forkhead
P10767553A0100|60 89|winged helix transcription factor
P10767553A0100|91 118|Hepatocyte Nuclear Factor 3beta
P10767553A0100|91 100|Hepatocyte
P10767553A0100|101 118|Nuclear Factor 3beta
P10767553A0100|120 127|HNF3beta
P10767553A0100|120 127|HNF3beta
P10767560A0105|49 59|exon-intron
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|126 147|mouse Pkr promoter region
P10767560A0105|126 147|mouse Pkr promoter region
P10767560A0105|159 184|IFN-inducible transcription
P10767560A0105|159 161|IFN
P10769144A0000|3 5|CRE
P10769144A0000|7 20|5'-TGACGTCA-3'
P10769144A0000|43 59|consensus sequence
P10769144A0000|66 76|cis-element
P10769144A0000|66 76|cis-element
P10769144A0000|88 115|cAMP-regulated gene expression
P10769144A0000|88 105|cAMP-regulated gene
P10770041A0731|0 11|Kidney length
P10770041A0731|44 48|right
P10770041A0731|52 55|left
P10770041A0731|65 75|kidney width
P10770041A0731|77 93|cortical thickness
P10770065A0264|3 15|clinical stage
P10770065A0264|19 26|I (T1N0M0
P10770065A0264|32 33|S2
P10770065A0264|57 65|lymph node
P10770065A0264|77 79|R 2 b
P10770065A0264|77 79|R 2 b
P10770471T0000|0 10|Benztropine
P10771528T0036|18 36|alkaline phosphatase
P10771528T0036|18 36|alkaline phosphatase
P10771528T0036|39 46|children
P10771709A0291|3 20|physicians in charge
P10771709A0291|26 33|patients
P10771709A0291|48 73|acute Q fever (seroconversion
P10771709A0291|90 92|IgM
P10771709A0291|90 92|IgM
P10771709A0291|110 125|prolonged disease
P10771709A0291|132 155|IgG antibody titer to phase I
P10771709A0291|132 142|IgG antibody
P10771709A0291|158 173|Coxiella burnetii
P10771709A0291|178 180|800
P10771709A0291|224 235|computerized
P10772977A0222|0 24|Viral cell-to-cell movement
P10772977A0222|27 37|PVX CP mutant
P10772977A0222|27 29|PVX
P10772977A0222|30 37|CP mutant
P10772977A0222|55 72|Nicotiana tabacum cv
P10773351A0672|11 14|CD86
P10773351A0672|11 14|CD86
P10773351A0672|40 48|U937 cells
P10773351A0672|53 61|IFN-gamma
P10773351A0672|53 61|IFN-gamma
P10773351A0672|96 138|GAS (gamma-interferon activation site) elements
P10773351A0672|96 98|GAS
P10773351A0672|100 129|gamma-interferon activation site
P10773455A1268|17 43|proximal GATA-1-binding sites
P10773455A1268|25 43|GATA-1-binding sites
P10773455A1268|45 63|-118/-113 and -98/-93
P10773455A1268|88 99|-518 to -315bp
P10773455A1268|105 122|mouse ALAS2 promoter
P10773455A1268|105 122|mouse ALAS2 promoter
P10773455A1268|139 163|transcriptional activation
P10773455A1268|170 201|chemically induced differentiation
P10773455A1268|204 211|MEL cells
P10773455A1268|273 302|ALAS2 transcriptional activation
P10773455A1268|273 277|ALAS2
P10773458A0000|0 6|SNAP-23
P10773458A0000|0 6|SNAP-23
P10773458A0000|64 77|mammalian cells
P10773667A0351|3 11|HMG domain
P10773667A0351|3 11|HMG domain
P10773667A0351|18 30|HMG20 proteins
P10773667A0351|18 30|HMG20 proteins
P10773667A0351|52 61|yeast NHP6A
P10773667A0351|52 61|yeast NHP6A
P10773951A0000|0 2|IgM
P10773951A0000|0 2|IgM
P10773951A0000|6 13|IgG anti A
P10773951A0000|9 13|anti A
P10773951A0000|17 29|anti B antibody
P10773951A0000|17 29|anti B antibody
P10773951A0000|41 50|antenatal O
P10773951A0000|56 63|mothers (
P10773951A0000|70 86|non O group husbands
P10775038A0142|23 36|Wee1 regulation
P10775038A0142|23 26|Wee1
P10775038A0142|43 51|cell cycle
P10775038A0142|53 76|yeast two-hybrid screening
P10775038A0142|94 112|Wee1-binding protein
P10775038A0142|94 112|Wee1-binding protein
P10775038A0142|114 114|s
P10775267A0363|0 21|Retroviral transduction
P10775267A0363|24 29|T/T(L)
P10775267A0363|24 24|T
P10775267A0363|26 26|T
P10775267A0363|28 28|L
P10775267A0363|44 73|fatal myeloproliferative disease
P10775267A0363|77 102|murine bone marrow transplant
P10775267A0363|104 106|BMT
P10775267A0363|121 125|T/T(F
P10775267A0363|121 121|T
P10775267A0363|123 123|T
P10775267A0363|125 125|F
P10775267A0363|134 145|long-latency
P10775267A0363|147 177|pre-B-cell lymphoblastic lymphoma
P10775585A0754|0 5|Ab-MLV
P10775585A0754|23 28|P70/S2
P10775585A0754|23 25|P70
P10775585A0754|27 28|S2
P10775585A0754|46 56|NIH 3T3 cells
P10775585A0754|136 190|Ras-dependent mitogen-activated protein (MAP) kinase pathway
P10775585A0754|136 138|Ras
P10775585A0754|149 172|mitogen-activated protein
P10775585A0754|174 183|MAP) kinase
P10775623A0120|3 7|codon
P10775623A0120|39 45|gag, pol
P10775623A0120|39 41|gag
P10775623A0120|43 45|pol
P10775623A0120|50 57|env genes
P10775623A0120|50 57|env genes
P10777217A0536|3 20|p53-homolog p73beta
P10777217A0536|3 13|p53-homolog
P10777217A0536|14 20|p73beta
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|65 67|p53
P10777217A0536|65 67|p53
P10777217A0536|72 89|proline-rich domain
P10777217A0536|92 98|p73beta
P10777217A0536|92 98|p73beta
P10777217A0536|100 113|residues 81-113
P10777217A0536|140 151|PIG3 promoter
P10777217A0536|140 151|PIG3 promoter
P10777499A0883|11 25|transient assays
P10777499A0883|78 94|phytochromes A and B
P10777499A0883|78 90|phytochromes A
P10777499A0883|94 94|B
P10777499A0883|133 155|light-responsive element
P10777586A1022|0 21|Co-immunoprecipitation
P10777586A1022|25 49|DNA affinity chromatography
P10777586A1022|59 61|Sp1
P10777586A1022|59 61|Sp1
P10777586A1022|81 86|ZBP-89
P10777586A1022|81 86|ZBP-89
P10777586A1022|101 115|silencer element
P10777586A1022|124 141|DNA-protein complex
P10777586A1022|124 134|DNA-protein
P10777586A1022|193 210|HeLa nuclear extract
P10777586A1022|213 227|band shift assays
P10777669A0582|3 12|ZNF274 gene
P10777669A0582|3 12|ZNF274 gene
P10777669A0582|35 40|RP S28 1
P10777669A0582|46 72|human chromosome 19qter region
P10777669A0582|76 84|RH mapping
P10778740A1493|3 27|C-terminal Cdk2 truncations
P10778740A1493|3 16|C-terminal Cdk2
P10778740A1493|101 117|pho85 coding region
P10778740A1493|101 117|pho85 coding region
P10778740A1493|136 146|mutant pho85
P10778740A1493|142 146|pho85
P10778740A1493|149 168|HIS3 chromosomal locus
P10778740A1493|149 168|HIS3 chromosomal locus
P10778757A0000|36 52|EMS-induced mutant
P10778757A0000|54 59|mn1-89
P10778757A0000|54 59|mn1-89
P10778757A0000|62 84|leaky semidominant allele
P10778757A0000|90 113|Miniature1 (Mn1) seed locus
P10778757A0000|90 99|Miniature1
P10778757A0000|101 103|Mn1
P10778757A0000|126 155|seed-specific cell wall invertase
P10778757A0000|126 155|seed-specific cell wall invertase
P10778757A0000|157 161|INCW2
P10778757A0000|157 161|INCW2
P10779313A1842|40 53|Xenopus oocytes
P10779313A1842|55 80|beta-adrenergic stimulation
P10779313A1842|95 108|ACh-evoked GIRK
P10779313A1842|140 167|PKA-catalyzed phosphorylation
P10779313A1842|140 142|PKA
P10779313A1842|182 190|beta(2)AR
P10779313A1842|182 187|beta(2
P10779329T0000|0 3|Slap
P10779329T0000|23 25|Src
P10779329T0000|26 42|mitogenic function
P10779329T0000|59 90|Src-induced cell morphology changes
P10779329T0000|59 61|Src
P10779352T0000|22 32|E2F3 product
P10779352T0000|22 32|E2F3 product
P10779352T0000|78 87|repression
P10779352T0000|90 99|Rb proteins
P10779352T0000|90 99|Rb proteins
P10779508A0452|2 37|DNase I footprinting protection analysis
P10779508A0452|2 7|DNase I
P10779508A0452|43 46|SFRE
P10779508A0452|43 46|SFRE
P10779508A0452|50 59|ERE regions
P10779508A0452|75 121|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0452|75 98|glutathione S-transferase
P10779508A0452|100 108|ERRalpha1
P10779508A0897|29 33|SRC1a
P10779508A0897|29 33|SRC1a
P10779508A0897|36 40|GRIP1
P10779508A0897|36 40|GRIP1
P10779508A0897|57 96|ERRalpha1-induced transcriptional activity
P10779508A0897|57 65|ERRalpha1
P10779508T0000|0 37|Estrogen receptor-related receptor alpha 1
P10779508T0000|0 31|Estrogen receptor-related receptor
P10779508T0000|32 37|alpha 1
P10779508T0000|51 61|coactivator
P10779508T0000|91 114|estrogen response elements
P10779508T0000|120 139|human lactoferrin gene
P10779508T0000|120 139|human lactoferrin gene
P10780018A0539|36 40|aging
P10780518A1270|17 25|mutations
P10780518A1270|28 42|protein function
P10780764A0722|3 14|median levels
P10780764A0722|83 87|PM2.5
P10780764A0722|113 114|95
P10780764A0722|116 126|range 61-218
P10780764A0722|128 136|micro x m-3
P10780764A0722|134 136|m-3
P10780883T0000|0 36|Kaposi's sarcoma-associated herpesvirus
P10780883T0000|42 67|interferon regulatory factor
P10780883T0000|42 67|interferon regulatory factor
P10780883T0000|115 130|interferon-alpha
P10780883T0000|115 130|interferon-alpha
P10781109T0000|20 38|genetic interference
P10781109T0000|41 58|double-stranded RNA
P10781109T0000|61 79|Arabidopsis thaliana
P10781423A0993|25 34|-215 to +1 bp
P10781423A0993|45 65|consensus binding sites
P10781423A0993|72 129|homeodomain transcription factor thyroid transcription factor-1
P10781423A0993|72 101|homeodomain transcription factor
P10781423A0993|102 129|thyroid transcription factor-1
P10781423A0993|131 135|TTF-1
P10781423A0993|131 135|TTF-1
P10781541A1063|13 31|cis-acting sequences
P10781541A1063|51 70|region 1 and 3 promoters
P10781541A1063|168 176|promoters
P10781552A0000|0 27|Purple photosynthetic bacteria
P10781552A0000|92 117|photosynthesis, respiration
P10781552A0000|122 125|H(2)
P10781552A0000|122 124|H(2
P10781604A0827|12 28|synthetic peptides
P10781604A0827|45 55|CTD sequence
P10781604A0827|89 100|Rsp5 WW domain
P10781604A0827|89 100|Rsp5 WW domain
P10781604A0827|102 108|Rsp5 WW2
P10781604A0827|102 108|Rsp5 WW2
P10781604A0827|122 142|yeast two-hybrid assays
P10781611A1023|12 40|bone marrow-derived macrophages
P10781611A1023|45 61|LAT-deficient mice
P10781611A1023|78 97|phagocytic efficiency
P10781611A1023|115 125|macrophages
P10781611A1023|130 142|wild-type mice
P10781990A0455|0 13|T1-weighted MRI
P10781990A0455|51 59|bilateral
P10781990A0455|63 92|symmetrical hyperintense lesions
P10781990A0455|98 111|globus pallidus
P10782640A0444|51 61|CM300 FEG/UT
P10782989A0575|52 81|amino-terminal DNA binding domain
P10782989A0575|87 104|amino acid sequences
P10782989A0575|115 130|DNA binding domain
P10782989A0575|115 130|DNA binding domain
P10782989A0575|144 153|amino acids
P10784367A0133|18 25|subjects
P10784367A0133|41 72|Suffolk County Mental Health Project
P10784367A0133|137 154|psychotic disorders
P10784367A0133|192 213|schizophrenic disorders
P10784393A0000|0 14|Marrow dysplasia
P10784393A0000|39 46|patients
P10784393A0000|51 73|myelodysplastic syndrome
P10784393A0000|75 77|MDS
P10785294A0720|10 36|non-acceptable inlays/onlays
P10785294A0720|118 126|composite
P10785668A0000|3 8|plants
P10785668A0000|36 45|herbivores
P10785668A0000|146 155|ecologists
P10785880A0947|27 54|cardiopulmonary complications
P10785880A0947|81 88|patients
P10785880A0947|96 114|class 1 HELLP syndrome
P10786671A0182|23 32|telomerase
P10786671A0182|68 83|catalytic subunit
P10786671A0182|89 94|enzyme
P10786671A0182|108 142|human telomerase reverse transcriptase
P10786671A0182|113 142|telomerase reverse transcriptase
P10786671A0182|144 153|hTERT) gene
P10786671A0182|144 153|hTERT) gene
P10786742A0670|18 32|platelet markers
P10786742A0670|49 55|surgery
P10787437A1616|31 52|transcription start site
P10787437A1616|69 73|SRE-1
P10787437A1616|69 73|SRE-1
P10787804T0000|0 8|AMDA white
P10787804T0000|37 50|pharmaceutical
P10787804T0000|57 60|SNFs
P10788320A1034|23 33|TPR elements
P10788320A1034|56 90|multiple protein-protein interactions
P10788320A1034|64 78|protein-protein
P10788320A1034|108 119|102kD protein
P10788320A1034|138 146|tri-snRNP
P10788320A1034|138 146|tri-snRNP
P10788320A1034|158 173|U5 and U4/U6 snRNPs
P10788320A1034|158 159|U5
P10788320A1034|163 164|U4
P10788320A1034|166 173|U6 snRNPs
P10788476A0891|0 9|Antibodies
P10788476A0891|24 40|C-terminal portion
P10788476A0891|43 48|Sec31A
P10788476A0891|43 48|Sec31A
P10788476A0891|63 67|Sec13
P10788476A0891|63 67|Sec13
P10788476A0891|78 94|ER-Golgi transport
P10788476A0891|78 79|ER
P10788476A0891|136 143|G protein
P10788476A0891|147 166|semi-intact cell assay
P10788480T0000|12 61|mitochondrial single-stranded DNA-binding protein gene
P10788480T0000|12 57|mitochondrial single-stranded DNA-binding protein
P10788480T0000|77 113|nuclear and mitochondrial DNA replication
P10788480T0000|116 125|drosophila
P10790390X0000|48 69|variegation modifier mod
P10790390X0000|67 69|mod
P10790390X0000|71 74|mdg4
P10790390X0000|71 74|mdg4
P10790390X0000|78 91|Drosophila. mod
P10790390X0000|78 87|Drosophila
P10790390X0000|93 96|mdg4
P10790390X0000|93 96|mdg4
P10790390X0000|110 110|E
P10790390X0000|110 110|E
P10790390X0000|112 120|var)3-93D
P10790390X0000|112 120|var)3-93D
P10790390X0000|160 172|gene silencing
P10790390X0000|201 203|PEV
P10790390X0000|218 240|gypsy insulator sequences
P10790390X0000|218 240|gypsy insulator sequences
P10790390X0000|254 275|homeotic gene expression
P10790390X0000|254 265|homeotic gene
P10790390X0000|280 298|programmed cell death
P10791251A0110|75 80|humans
P10791819A0771|60 74|asparagus genome
P10791819A0771|116 129|specific codons
P10791901A0609|0 11|Transduction
P10791901A0609|17 41|human leukemic cell line K562
P10791901A0609|52 65|viral MRP1-PG13
P10791901A0609|52 60|viral MRP1
P10791901A0609|98 105|MRP1 gene
P10791901A0609|98 105|MRP1 gene
P10791901A0609|132 140|K562 cells
P10791901A0609|213 231|toxic concentrations
P10791901A0609|234 242|etoposide
P10792583A0000|12 31|pituitary vasopressin
P10792583A0000|32 43|V1b receptors
P10792583A0000|32 43|V1b receptors
P10792583A0000|74 123|pituitary adrenocorticotropic hormone (ACTH) secretion
P10792583A0000|74 108|pituitary adrenocorticotropic hormone
P10792583A0000|110 113|ACTH
P10792718T0000|18 30|AfsA homologue
P10792718T0000|18 30|AfsA homologue
P10792718T0000|32 35|BarX
P10792718T0000|32 35|BarX
P10792718T0000|41 61|Streptomyces virginiae
P10792718T0000|65 84|pleiotropic regulator
P10792718T0000|96 120|autoregulator biosynthesis
P10792718T0000|122 174|virginiamycin biosynthesis and virginiamycin M1 resistance
P10793143A1533|27 36|DNA binding
P10793143A1533|57 83|Abf1 ARS1 DNA-binding activity
P10793143A1533|57 60|Abf1
P10793143A1533|106 128|Cdc6 DNA-binding activity
P10793143A1533|106 109|Cdc6
P10793143A1533|165 178|DNA replication
P10793991A0569|90 101|telemedicine
P10794405A0000|42 56|terminal domains
P10794405A0000|59 67|histone H1
P10794405A0000|59 67|histone H1
P10794405A0000|127 128|H1
P10794405A0000|127 128|H1
P10794936A0241|22 28|MB/BacT
P10794936A0241|30 36|MGIT 960
P10794936A0241|41 50|solid media
P10794936A0241|93 104|mycobacteria
P10794936A0241|161 174|M. tuberculosis
P10794936A0241|243 254|mycobacteria
P10795098A0253|0 17|Cerebral vasculitis
P10795098A0253|29 42|Crohn's disease
P10796465A0373|18 27|Randomised
P10796465A0373|78 83|asthma
P10796465A0373|87 105|asthma-like symptoms
P10796486A0817|43 50|children
P10797125A0000|23 49|progestin-mediated increases
P10797125A0000|137 144|estrogen
P10797125A0000|160 164|women
P10797125A0000|205 218|passive heating
P10797586A0402|82 88|bladder
P10798607A1359|19 35|phagocytic killing
P10798607A1359|38 49|meningococci
P10798607A1359|84 102|antibody titer levels
P10798607A1359|106 130|antimeningococcal immunity
P10798607A1359|144 164|LCC-deficient patients
P10799501A1391|42 60|cellular environment
P10799501A1391|74 87|SPRK activation
P10799501A1391|74 77|SPRK
P10799501A1391|90 94|Cdc42
P10799501A1391|90 94|Cdc42
P10799576A0196|0 1|M.
P10799590A0431|0 21|Jkappa DNA-binding sites
P10799590A0431|0 21|Jkappa DNA-binding sites
P10799590A0431|59 71|mutant EBNA-3C
P10799590A0431|65 71|EBNA-3C
P10799590A0431|91 96|Jkappa
P10799590A0431|91 96|Jkappa
P10799590A0431|134 149|wild-type EBNA-3C
P10799590A0431|143 149|EBNA-3C
P10799590A0431|165 171|EBNA-3C
P10799590A0431|165 171|EBNA-3C
P10799590A0431|232 237|Jkappa
P10799590A0431|232 237|Jkappa
P10799595A1454|9 17|YY1 and CDP
P10799595A1454|9 11|YY1
P10799595A1454|15 17|CDP
P10799595A1454|74 88|HPV-6 E1 promoter
P10799595A1454|74 78|HPV-6
P10799595A1454|79 88|E1 promoter
P10799595A1454|102 104|HPV
P10799863T0000|20 36|metallopeptidases
P10799863T0000|40 50|proteasomes
P10799863T0000|73 80|HIV-1 ENV
P10799863T0000|101 128|MHC class I antigen presentation
P10799863T0000|101 116|MHC class I antigen
P10799879T0000|28 35|human Lnk
P10799879T0000|39 52|adaptor protein
P10799879T0000|57 96|pleckstrin homology and Src homology 2 domains
P10799879T0000|57 74|pleckstrin homology
P10799879T0000|78 96|Src homology 2 domains
P10799879T0000|111 125|T cell activation
P10801244A0578|71 76|NONMEM
P10801244A0578|87 109|pharmacokinetic software
P10801330A1714|26 32|cytosol
P10801330A1714|36 64|membrane cytoskeleton fractions
P10801330A1714|70 81|resting state
P10801330A1714|109 127|platelet aggregation
P10801330A1714|133 135|FAK
P10801330A1714|133 135|FAK
P10801330A1714|153 172|cytoskeletal fraction
P10801482A0968|14 16|p65
P10801482A0968|14 16|p65
P10801482A0968|118 130|kappaB targets
P10801482A0968|118 130|kappaB targets
P10801809T0000|0 24|Transcriptional regulation
P10801809T0000|30 46|yeast PHO8 promoter
P10801809T0000|35 46|PHO8 promoter
P10801809T0000|64 86|coregulated PHO5 promoter
P10801809T0000|75 86|PHO5 promoter
P10801860A0000|3 9|Siglecs
P10801860A0000|25 37|I-type lectins
P10801860A0000|31 71|lectins (immunoglobulin superfamily proteins
P10801860A0000|39 63|immunoglobulin superfamily
P10801860A0000|112 122|sialic acids
P10802669A1434|71 73|A-T
P10802669A1434|71 73|A-T
P10802669A1434|77 79|NBS
P10802909A0478|34 41|children
P10804379T0001|0 5|Update
P10804379T0001|8 31|maternal-fetal infections
P10804379T0001|34 43|hepatitis C
P10804379T0001|45 47|HIV
P10804379T0001|51 65|cytomegalovirus
P10805286A0233|33 44|cis-elements
P10805286A0233|50 61|human PCI gene
P10805286A0233|50 61|human PCI gene
P10805286A0233|88 111|hepatoma-derived cell line
P10805286A0233|113 122|HepG2 cells
P10805286A0233|140 159|rat PCI mRNA expression
P10805286A0233|143 149|PCI mRNA
P10805286A0233|186 193|androgen
P10805286A0233|196 198|rat
P10805286A0233|199 217|reproductive tissues
P10805286A0914|12 28|PCI mRNA expression
P10805286A0914|12 18|PCI mRNA
P10805286A0914|66 75|rat PCI cDNA
P10805286A0914|66 75|rat PCI cDNA
P10805286A0914|103 110|androgen
P10805286A0914|116 132|PCI mRNA expression
P10805286A0914|116 122|PCI mRNA
P10805390A0340|15 25|performance
P10805390A0340|60 86|GaAs/AlGaAs heterostructures
P10805729A0987|3 15|stoichiometry
P10805729A0987|43 59|dodeca-satellite C
P10805729A0987|81 84|DDP1
P10805729A0987|81 84|DDP1
P10805729A0987|89 103|15 consecutive KH
P10805729A0987|144 154|nucleic acid
P10805729A0987|155 169|binding surfaces
P10805737T0000|0 17|Mutational analysis
P10805737T0000|20 62|mammalian translation initiation factor 5 (eIF5)
P10805737T0000|20 56|mammalian translation initiation factor 5
P10805737T0000|58 61|eIF5
P10805737T0000|91 101|beta subunit
P10805737T0000|91 101|beta subunit
P10805737T0000|104 107|eIF2
P10805737T0000|104 107|eIF2
P10805737T0000|111 114|eIF5
P10805737T0000|111 114|eIF5
P10805737T0000|117 128|eIF5 function
P10805737T0000|117 120|eIF5
P10805738A0799|25 27|p38
P10805738A0799|25 27|p38
P10805738A0799|43 46|MyoD
P10805738A0799|43 46|MyoD
P10805738A0799|51 67|p38 kinase activity
P10805738A0799|51 59|p38 kinase
P10805738A0799|96 115|MyoD-responsive genes
P10805738A0799|96 115|MyoD-responsive genes
P10805738A0799|140 142|p38
P10805738A0799|140 142|p38
P10805738A0799|182 185|Gal4
P10805738A0799|182 185|Gal4
P10805738A0799|187 203|MyoD fusion protein
P10805738A0799|187 190|MyoD
P10805738A0799|234 262|chromatin-integrated reporters
P10805738A0799|265 268|MyoD
P10805738A0799|265 268|MyoD
P10805738A0799|278 281|MyoD
P10805738A0799|278 281|MyoD
P10805738A0799|321 345|mouse embryonic fibroblasts
P10805738A0799|357 376|p38alpha(-/-) embryos
P10805738A0799|357 369|p38alpha(-/-)
P10805739A0343|26 41|complex formation
P10805739A0343|54 66|eIF2B subunits
P10805739A0343|54 66|eIF2B subunits
P10805739A0640|13 29|nonsense mutations
P10805739A0640|46 54|C terminus
P10805739A0640|57 86|eIF2Bepsilon (residues 518 to 712)
P10805739A0640|57 68|eIF2Bepsilon
P10805739A0640|70 85|residues 518 to 712
P10805739A0640|104 120|catalytic activity
P10805739A0640|139 142|eIF2
P10805739A0640|139 142|eIF2
P10805747A0633|40 59|Nim1p-related kinases
P10805747A0633|40 59|Nim1p-related kinases
P10805747A0633|62 73|S. cerevisiae
P10805747A0633|62 73|S. cerevisiae
P10805747A0633|75 79|Hsl1p
P10805747A0633|75 79|Hsl1p
P10805747A0633|83 87|Kcc4p
P10805747A0633|83 87|Kcc4p
P10805747A0633|116 133|septin organization
P10805747A0633|116 121|septin
P10805823A1920|23 28|pacing
P10805823A1920|89 94|stroke
P10805823A1920|107 120|cardiovascular
P10807900A0933|5 18|non-cirrhotics
P10807900A0933|26 48|portal vein visualisation
P10807900A0933|155 186|pre-sinusoidal portal hypertension
P10807903A0362|0 4|D5/D1
P10807903A0362|0 2|D5/
P10807903A0362|3 7|D1(CT
P10807903A0362|6 7|CT
P10807903A0362|11 19|D5/D1D(CT
P10807903A0362|11 16|D5/D1D
P10807903A0362|18 24|CT) tail
P10807903A0362|110 133|wild-type (wt) D1 receptors
P10807903A0362|110 121|wild-type (wt
P10807903A0362|123 133|D1 receptors
P10807903A0362|150 162|ligand binding
P10807903A0362|166 206|dopamine-stimulated cAMP accumulation assays
P10807903A0362|221 233|wt D1 receptors
P10807903A0362|223 233|D1 receptors
P10809233A0606|0 7|Modeling
P10809233A0606|60 62|H12
P10809233A0606|60 62|H12
P10809233A0606|64 79|exposing residues
P10809233A0606|84 93|H3, loop 3-4
P10809233A0606|84 85|H3
P10809233A0606|91 103|3-4, H4, and H11
P10809233A0606|95 96|H4
P10810083A1283|3 28|serine-threonine kinase gene
P10810083A1283|3 24|serine-threonine kinase
P10810083A1283|58 72|zinc finger motif
P10810083A1283|58 72|zinc finger motif
P10810294A0730|0 13|Stat activation
P10810294A0730|0 3|Stat
P10810294A0730|26 27|GH
P10810294A0730|26 27|GH
P10810294A0730|31 34|IL-6
P10810294A0730|31 34|IL-6
P10810294A0730|50 70|reporter gene induction
P10810745A0677|0 6|HFA 134a
P10810745A0677|67 72|HFA 227
P10811079A0555|49 64|epilepsy patients
P10811079A0555|76 96|vigabatrin monotherapy
P10811079A0555|108 123|epilepsy patients
P10811079A0555|135 158|carbamazepine monotherapy
P10811079A1277|5 21|SPP2 screening test
P10811804A0000|0 23|Mitogen-activated protein
P10811804A0000|17 47|protein (MAP) kinase phosphatase-3
P10811804A0000|25 47|MAP) kinase phosphatase-3
P10811804A0000|49 53|MKP-3
P10811804A0000|49 53|MKP-3
P10811804A0000|62 83|specificity phosphatase
P10811804A0000|99 133|extracellular signal-regulated kinase
P10811804A0000|99 133|extracellular signal-regulated kinase
P10811804A0000|135 148|ERK) MAP kinases
P10811804A0000|135 137|ERK
P10811804A0000|139 148|MAP kinases
P10811804A0800|29 36|peptides
P10811804A0800|49 60|docking sites
P10811804A0800|86 90|Elk-1
P10811804A0800|86 90|Elk-1
P10811804A0800|94 101|p90(rsk)
P10811804A0800|94 96|p90
P10811804A0800|98 100|rsk
P10811804A0800|109 131|ERK-dependent activation
P10811804A0800|109 111|ERK
P10811804A0800|134 138|MKP-3
P10811804A0800|134 138|MKP-3
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10811908A0938|26 44|amino acid sequencing
P10811908A0938|49 72|site-directed mutagenesis
P10811908A0938|87 90|NCLK
P10811908A0938|87 90|NCLK
P10811908A0938|105 107|Ser
P10811908A0938|109 110|67
P10811908A0938|114 116|I-1
P10811908A0938|114 116|I-1
P10812294X0000|13 16|diet
P10812294X0000|28 30|SBF
P10812294X0000|28 30|SBF
P10812294X0000|32 50|voluntary feed intake
P10812294X0000|76 78|SBF
P10812294X0000|76 78|SBF
P10814989T0000|0 23|Hepatitis C virus infection
P10814989T0000|27 53|lymphoproliferative diseases
P10814989T0000|64 76|national study
P10815410A0000|3 14|immune system
P10815410A0000|41 60|neuroendocrine system
P10815410A0000|65 90|infection-induced increases
P10815410A0000|93 101|cytokines
P10815410A0000|108 111|IL-1
P10815410A0000|108 111|IL-1
P10815410A0000|113 116|IL-6
P10815410A0000|113 116|IL-6
P10815410A0000|120 122|TNF
P10815410A0000|120 122|TNF
P10815410A0000|147 166|central nervous system
P10815807A1271|54 66|c-Myb promoter
P10815807A1271|54 66|c-Myb promoter
P10815807A1271|87 114|HTLV-I transformed T-cell lines
P10817754T0000|0 9|H19 and Igf2
P10817754T0000|0 2|H19
P10817754T0000|6 9|Igf2
P10817754T0000|10 30|monoallelic expression
P10817754T0000|68 92|cis acting regulatory region
P10817754T0000|103 105|H19
P10817754T0000|103 105|H19
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|16 26|OSM-3/KAP-1
P10819327T0000|16 20|OSM-3
P10819327T0000|22 26|KAP-1
P10819327T0000|42 60|sea urchin kinesin-II
P10819327T0000|42 60|sea urchin kinesin-II
P10819327T0000|65 84|mouse KIF3A/KIFB/KAP3
P10819327T0000|70 74|KIF3A
P10819327T0000|76 79|KIFB
P10819327T0000|81 100|KAP3 kinesin complexes
P10820829T0000|0 9|Flavonoids
P10820829T0000|14 32|Brosimum acutifolium
P10820904A0000|11 31|Hepatic encephalopathy
P10820904A0000|35 58|neuropsychiatric syndrome
P10820904A0000|73 89|acute liver failure
P10820904A0000|91 120|chronic parenchymal liver disease
P10820904A0000|123 147|portal systemic anastomosis
P10823837A1213|35 41|YLL031c
P10823837A1213|35 41|YLL031c
P10823837A1213|80 99|inner alpha1-2-linked
P10823837A1213|100 106|mannose
P10823837A1213|132 155|GPI lipid anchor to proteins
P10823837A1213|164 168|Mcd4p
P10823837A1213|164 168|Mcd4p
P10823837A1213|172 176|Gpi7p
P10823837A1213|172 176|Gpi7p
P10823837A1213|213 247|alpha1-4- and alpha1-6-linked mannoses
P10823837A1213|213 220|alpha1-4
P10823837A1213|225 232|alpha1-6
P10823837A1213|253 261|GPI anchor
P10823961A0664|3 11|C terminus
P10823961A0664|14 17|TRBP
P10823961A0664|14 17|TRBP
P10823961A0664|25 32|CBP/p300
P10823961A0664|25 27|CBP
P10823961A0664|29 32|p300
P10823961A0664|36 42|DRIP130
P10823961A0664|36 42|DRIP130
P10823961A0664|59 78|DRIP/TRAP/ARC complex
P10823961A0664|59 62|DRIP
P10823961A0664|64 67|TRAP
P10823961A0664|69 71|ARC
P10823961A0664|97 100|TRBP
P10823961A0664|97 100|TRBP
P10824485A0393|3 10|patients
P10824485A0393|27 46|mucocutaneous disease
P10824485A0393|57 77|CD4+ T lymphocyte counts
P10824485A0393|57 60|CD4+
P10824485A0393|95 98|AIDS
P10824958A1109|31 33|PAB
P10824958A1109|57 58|CO
P10824958A1109|69 70|PF
P10824958A1109|80 83|PSHL
P10824958A1109|108 109|26
P10825000A1245|3 24|gene amplification model
P10825200T0000|0 8|Hierarchy
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|35 47|interleukin-2
P10825200T0000|35 47|interleukin-2
P10825200T0000|49 52|IL-2
P10825200T0000|49 52|IL-2
P10825200T0000|76 78|syk
P10825200T0000|76 78|syk
P10825200T0000|88 91|Jak3
P10825200T0000|88 91|Jak3
P10825200T0000|108 110|Syk
P10825200T0000|108 110|Syk
P10825200T0000|114 116|Lck
P10825200T0000|114 116|Lck
P10825200T0000|130 156|IL-2-mediated STAT activation
P10825200T0000|130 133|IL-2
P10825200T0000|143 146|STAT
P10825293T0000|19 38|N-cadherin-Fc chimera
P10825293T0000|19 28|N-cadherin
P10825293T0000|30 31|Fc
P10825293T0000|44 80|cadherin-mediated cell contact formation
P10825293T0000|44 51|cadherin
P10825293T0000|113 129|inside-out signals
P10825294A0473|11 20|OC promoter
P10825294A0473|11 20|OC promoter
P10825294A0473|35 43|C terminus
P10825294A0473|63 69|MDR, LTR
P10825294A0473|63 65|MDR
P10825294A0473|67 69|LTR
P10825294A0473|73 84|BSP promoters
P10825294A0473|73 84|BSP promoters
P10825294A0473|156 167|AML C terminus
P10825294A0473|159 167|C terminus
P10825294A0473|196 222|C-terminal pentapeptide VWRPY
P10826861A0000|3 34|monoclonal immunoglobulin products
P10826861A0000|3 34|monoclonal immunoglobulin products
P10826861A0000|37 54|plasma cell neoplasm
P10826861A0000|101 114|hyperviscosity
P10826861A0000|159 170|renal failure
P10826946A1198|56 63|human Igs
P10826946A1198|61 63|Igs
P10826946A1198|67 71|gp120
P10826946A1198|67 71|gp120
P10826946A1198|84 96|viral gp120 SAg
P10826946A1198|84 96|viral gp120 SAg
P10826946A1198|125 130|human V
P10826946A1198|132 138|H)3+ Igs
P10826946A1198|132 132|H
P10826946A1198|136 138|Igs
P10827885T0059|13 35|placebo-controlled trial
P10827952A0158|18 25|TAFII250
P10827952A0158|18 25|TAFII250
P10827952A0158|46 50|TFIID
P10827952A0158|46 50|TFIID
P10827952A0158|69 86|bromodomain modules
P10827952A0158|116 134|acetylated histone H4
P10827952A0158|126 142|histone H4 peptides
P10827952A0158|135 142|peptides
P10828022A0877|0 18|Endostatin treatment
P10828022A0877|47 69|tyrosine phosphorylation
P10828022A0877|72 74|Shb
P10828022A0877|72 74|Shb
P10828022A0877|89 109|multiprotein complexes
P10828319A0342|19 27|vitamin D3
P10828319A0342|85 93|psoriasis
P10828591A0080|38 56|partial cDNA sequence
P10828591A0080|83 95|transcript map
P10828591A0080|121 128|D11S1765
P10828591A0080|121 128|D11S1765
P10828591A0080|132 142|uteroglobin
P10828591A0080|173 183|Best disease
P10828751A2258|3 6|real
P10828751A2258|49 56|patients
P10829973T0000|0 24|Iodine deficiency disorders
P10831972A0744|15 24|CD23 levels
P10831972A0744|15 18|CD23
P10831972A0744|50 54|women
P10831972A0744|59 71|endometriosis
P10831972A0744|96 109|normal controls
P10831972A1091|33 45|endometriosis
P10831972A1091|62 65|CD23
P10831972A1091|62 65|CD23
P10831972A1091|103 109|danazol
P10831972A1091|112 128|leuprolide acetate
P10833461A0603|19 41|P-1 artificial chromosome
P10833461A0603|43 53|PAC) library
P10833461A0603|70 90|full length UGT2B7 probe
P10833461A0603|70 85|full length UGT2B7
P10833486A0598|23 25|[OR
P10833486A0598|34 36|BMI
P10833486A0598|45 48|m(2)
P10833486A0598|46 51|(2) (OR
P10833486A0598|50 51|OR
P10833486A0598|58 70|triglycerides
P10833486A0598|84 128|OR, 5), and alanine aminotransferase (ALT) >/= 2N (OR
P10833486A0598|93 115|alanine aminotransferase
P10833486A0598|117 119|ALT
P10833486A0598|130 132|4.6
P10833486A0598|165 178|septal fibrosis
P10834707A1533|32 55|platelet activating factor
P10834707A1533|32 55|platelet activating factor
P10834781A0693|11 22|elderly group
P10834781A0693|67 70|MRTs
P10834781A0693|80 94|plasma clearance
P10834781A0693|136 145|adult group
P10835355A0225|18 38|zinc finger protein Gis1
P10835355A0225|18 34|zinc finger protein
P10835355A0225|35 38|Gis1
P10835355A0225|46 71|dosage-dependent suppressor
P10835355A0225|77 92|rim15Delta defect
P10835355A0225|77 86|rim15Delta
P10835355A0225|150 153|SSA3
P10835355A0225|150 153|SSA3
P10835485A0941|13 23|SH3" segment
P10835485A0941|13 15|SH3
P10835485A0941|29 40|linker domain
P10835485A0941|101 117|amino acid residues
P10835485A0941|141 154|human, and mouse
P10835732A0911|20 36|cholesterol levels
P10835732A0911|56 63|mapuches
P10835732A0911|67 73|aymaras
P10836542A0363|17 18|UV
P10836542A0363|42 53|UV-A waveband
P10836542A0363|55 57|320
P10836542A0363|59 63|400 nm
P10836786A0516|33 43|RNA subunits
P10836786A0516|33 35|RNA
P10836786A0516|46 59|enzyme function
P10836786A0516|114 117|MRP3
P10836786A0516|114 117|MRP3
P10836786A0516|121 122|P3
P10836786A0516|121 122|P3
P10836786A0516|131 141|RNase MRP RNA
P10836786A0516|131 141|RNase MRP RNA
P10836786A0516|145 153|RNase P RNA
P10836786A0516|145 153|RNase P RNA
P10836786A0516|156 167|S. cerevisiae
P10837126A1004|24 34|pMesogenin1
P10837126A1004|24 34|pMesogenin1
P10837126A1004|37 42|Xwnt-8
P10837126A1004|45 59|signaling factor
P10837126A1004|113 129|cellular phenotype
P10838139A1447|14 35|Ha-ras codon 12 mutations
P10838139A1447|14 19|Ha-ras
P10838139A1447|49 60|EtNU-induced
P10838139A1447|61 73|mammary tumors
P10838399A0525|13 18|PET FDG
P10838399A0525|33 45|lung infection
P10838399A0525|59 69|bone disease
P10838531A0675|0 10|Tumor stages
P10838531A0675|15 22|IIB (T3 N0
P10838531A0675|43 46|IIIB
P10838531A0675|54 61|patients
P10839470A1148|44 52|heart rate
P10839470A1148|164 170|Chinese
P10839547A0978|23 33|CTCF binding
P10839547A0978|23 26|CTCF
P10839547A0978|47 60|DNA methylation
P10839593A0000|43 74|amphotericin B oral suspension (ABOS
P10839593A0000|93 103|fluconazole
P10839593A0000|118 128|candidiasis
P10839593A0000|131 137|persons
P10839593A0000|142 153|HIV infection
P10840001A0188|0 18|Mucin gene expression
P10840001A0188|0 8|Mucin gene
P10840001A0188|48 65|intestinal diseases
P10840001A0188|91 111|gastrointestinal tract
P10841537A0669|32 35|RPB5
P10841537A0669|32 35|RPB5
P10841537A0669|101 113|alpha-helical
P10841593A0780|39 58|cigarette consumption
P10841593A0780|92 106|nicotine patches
P10841601T0000|0 9|Paper alert
P10843716A0406|3 15|tryptase locus
P10843716A0406|3 15|tryptase locus
P10843716A0406|39 62|tryptase-like pseudogenes
P10843716A0406|39 62|tryptase-like pseudogenes
P10843716A0406|73 78|mastin
P10843716A0406|73 78|mastin
P10843716A0406|108 113|humans
P10843810A0802|25 37|chimeric clone
P10843810A0802|66 69|exon
P10843810A0802|75 103|human tyrosine phosphatase 1 gene
P10843810A0802|75 99|human tyrosine phosphatase 1
P10843810A0802|126 143|antisense direction
P10843810A0802|157 167|adjacent LTR
P10845522A0000|57 88|99mTc-sestamibi scintimammography
P10845522A0000|119 131|breast lesions
P10845522A0000|166 176|mammography
P10846054A0573|0 17|Mutational analyses
P10846054A0573|36 45|stop codons
P10846054A0573|71 78|RNA 2 ORFs
P10846054A0573|105 115|progeny LIYV
P10846054A0573|112 119|LIYV RNA 1
P10846054A0573|116 119|RNA 1
P10846054A0573|122 125|RNA 2
P10846054A0573|122 125|RNA 2
P10846054A0573|141 144|RNA 2
P10846054A0573|141 144|RNA 2
P10846054A0573|178 195|LIYV RNA replication
P10846069T0000|6 34|NH(2)- and COOH-terminal domains
P10846069T0000|6 9|NH(2
P10846069T0000|40 47|P protein
P10846069T0000|40 47|P protein
P10846069T0000|50 77|human parainfluenza virus type 3
P10846069T0000|80 92|transcription
P10846069T0000|96 106|replication
P10848605T0000|0 14|Phosphorylation
P10848605T0000|17 32|tyrosine residues
P10848605T0000|38 49|kinase domain
P10848605T0000|53 71|juxtamembrane region
P10848605T0000|84 115|biological and catalytic activities
P10848605T0000|118 129|Eph receptors
P10848605T0000|118 129|Eph receptors
P10848848A0413|8 25|Fournier's gangrene
P10848993A0000|0 19|Genomic DNA sequencing
P10848993A0000|35 67|methylmalonyl-CoA mutase gene (mutAB
P10848993A0000|35 61|methylmalonyl-CoA mutase gene
P10848993A0000|63 67|mutAB
P10848993A0000|74 122|rifamycin SV-producing Amycolatopsis mediterranei U32
P10848993A0000|179 211|serine/threonine protein kinase (amk
P10848993A0000|179 207|serine/threonine protein kinase
P10848993A0000|209 211|amk
P10850329A0248|0 3|IL-2
P10850329A0248|0 3|IL-2
P10850329A0248|63 74|chemotherapy
P10850329A0248|104 121|metastatic melanoma
P10850329A0248|125 152|metastatic renal cell carcinoma
P10850453A0713|30 35|Ha-Ras
P10850453A0713|30 35|Ha-Ras
P10850453A0713|38 58|dominant negative Raf-1
P10850453A0713|38 56|dominant negative Raf
P10850453A0713|71 85|mitogenic effect
P10850453A0713|88 96|TGF-beta1
P10850453A0713|88 96|TGF-beta1
P10850453A0713|99 105|TSU-Pr1
P10850453A0713|113 131|TGF-beta1 inhibition
P10850453A0713|113 121|TGF-beta1
P10850453A0713|134 138|DU145
P10850453A0713|165 173|V12Ha-Ras
P10850453A0713|165 173|V12Ha-Ras
P10850453A1292|32 49|prostate carcinomas
P10850453A1292|57 81|Ras/MAPK pathway activation
P10850453A1292|57 59|Ras
P10850453A1292|61 64|MAPK
P10850453A1292|127 145|TGF-beta1 production
P10850453A1292|127 135|TGF-beta1
P10850719A0680|0 12|Vbeta segments
P10850719A0680|26 45|DJbeta rearrangements
P10850719A0680|26 31|DJbeta
P10850719A0680|67 71|Vbeta
P10850719A0680|74 85|Jbeta joining
P10850719A0680|74 78|Jbeta
P10850719A0680|114 125|Vbeta 23-RSSs
P10850719A0680|114 125|Vbeta 23-RSSs
P10850719A0680|129 140|Jbeta12-RSSs
P10850719A0680|129 140|Jbeta12-RSSs
P10850849A0730|3 20|oral administration
P10850849A0730|22 34|AUC0-infinity
P10850849A0730|63 70|t1/2beta
P10850849A0730|63 70|t1/2beta
P10850849A0730|113 116|Cmax
P10850942A0989|28 42|gastric emptying
P10850942A0989|60 66|glucose
P10850942A0989|82 85|rats
P10850942A0989|95 97|TPN
P10850997A1016|11 14|H-NS
P10850997A1016|59 61|Fur
P10850997A1016|59 61|Fur
P10851089A1248|5 7|SAG
P10851089A1248|5 7|SAG
P10851089A1248|24 43|cell cycle progression
P10851089A1248|46 50|yeast
P10851089A1248|62 75|ubiquitination
P10851089A1248|92 118|cell cycle regulatory proteins
P10851267A0000|0 4|E2F -1
P10851267A0000|0 4|E2F -1
P10851267A0000|8 26|transcription factor
P10851267A0000|40 59|cell cycle progression
P10851267A0000|64 70|S-phase
P10851745A0624|13 19|fatigue
P10851745A0624|21 33|negative moods
P10851745A0624|69 83|working capacity
P10852221A0422|34 38|graft
P10852221A0422|128 153|grafted dopaminergic neurons
P10852460A0170|42 56|thyroid hormones
P10852460A0170|60 67|selenium
P10852460A0170|69 72|zinc
P10852460A0170|85 100|alpha-tocopherol
P10852460A0170|138 155|oldest-old subjects
P10852460A0170|168 171|-107
P10852460A0170|202 216|SENIEUR protocol
P10852485A0477|7 15|Spring (CS
P10852485A0477|28 32|Q gene
P10852485A0477|28 32|Q gene
P10852485A0477|43 60|chromosome deletion
P10852485A0477|67 68|CS
P10852485A0477|67 68|CS
P10852485A0477|77 78|q5
P10852485A0477|110 114|Q gene
P10852485A0477|110 114|Q gene
P10852953A0000|0 13|Investigations
P10852953A0000|176 180|beta 1
P10853059X0751|6 7|AG
P10853778A0316|6 21|surgery bone cysts
P10853778A0316|44 53|bone grafts
P10853850A1103|0 10|Urinary LTE4
P10853850A1103|66 69|oral
P10853850A1103|82 102|inhalation provocation
P10854004A0788|5 7|FVR
P10854004A0788|38 40|ERT
P10854004A0788|44 46|HRT
P10854004A0788|51 62|FVR responses
P10854004A0788|79 91|angiotensin II
P10854004A0788|79 91|angiotensin II
P10854699A0424|5 15|FGF-AS cDNAs
P10854699A0424|5 10|FGF-AS
P10854699A0424|11 15|cDNAs
P10854699A0424|32 52|full-length FGF-AS mRNA
P10854699A0424|43 48|FGF-AS
P10854699A0424|70 75|splice
P10854699A0424|91 107|exon 2 or exons 2 and 3
P10854699A0424|113 126|FGF-AS sequence
P10854699A0424|113 126|FGF-AS sequence
P10855690A0870|38 46|MAP kinase
P10855690A0870|38 46|MAP kinase
P10855690A0870|60 72|hPL-B enhancer
P10855690A0870|60 72|hPL-B enhancer
P10855690A0870|77 100|NF-IL-6-dependent pathway
P10855690A0870|77 83|NF-IL-6
P10855793A1418|18 32|polymorphic TNRs
P10855793A1418|73 82|spinal cord
P10855793A1418|149 174|neurodegenerative disorders
P10855796A1160|8 36|in situ RNA hybridization studies
P10855796A1160|67 85|EphA8 gene expression
P10855796A1160|67 75|EphA8 gene
P10855796A1160|101 113|rostral region
P10855796A1160|116 129|midbrain tectum
P10855796A1160|136 155|embryonic development
P10856298A0798|14 18|cDNAs
P10856298A0798|27 39|mutant enzymes
P10856298A0798|44 76|FPGS-null Chinese hamster ovary cells
P10856298A0798|44 47|FPGS
P10856298A0798|100 111|clonal growth
P10856298A0798|121 131|T339I mutant
P10856298A0798|176 190|wild-type enzyme
P10856298A0798|176 190|wild-type enzyme
P10856491A0178|0 6|SETTING
P10856491A0178|20 27|Paris VII
P10856491A0178|52 56|women
P10856491A0178|75 90|symptomatic myoma
P10856491A0178|96 108|12 pregnancies
P10856805T0000|0 15|Improving fissure
P10856805T0000|31 51|mechanical preparation
P10856805T0000|55 66|filling level
P10857215A0000|3 24|Menopause-Rating-Scale
P10857215A0000|26 29|MRS I
P10857215A0806|3 7|MRS II
P10857262A0186|22 35|fruA transcript
P10857262A0186|22 35|fruA transcript
P10857262A0186|58 83|D. melanogaster type A protein
P10857262A0186|60 83|melanogaster type A protein
P10857262A0186|100 131|BTB protein-protein-binding domain
P10857262A0186|100 131|BTB protein-protein-binding domain
P10857262A0186|149 159|exons I and II
P10857751A0304|14 26|mouse ortholog
P10857751A0304|28 41|Mharp/Smarcal1
P10857751A0304|28 32|Mharp
P10857751A0304|34 41|Smarcal1
P10857751A0304|59 87|Caenorhabditis elegans ortholog
P10857751A0304|89 94|CEHARP
P10857751A0304|89 94|CEHARP
P10857751A0304|114 128|GenBank database
P10858355A0920|0 11|Sparfloxacin
P10858355A0920|48 72|Enterococcus faecium SF2149
P10858355A0920|76 100|Enterococcus faecalis WH245
P10858988A0786|0 2|ECP
P10858988A0786|0 2|ECP
P10858988A0786|6 13|tryptase
P10858988A0786|22 26|serum
P10858988A0786|60 72|oral challenge
P10860131A0847|0 15|Tolterodine users
P10860131A0847|59 73|spasmolytic drug
P10860752A1601|26 42|RNA- binding domain
P10860752A1601|26 42|RNA- binding domain
P10860752A1601|91 127|bacteriophage T4 DNA polymerase synthesis
P10860752A1601|91 118|bacteriophage T4 DNA polymerase
P10860827A0399|0 7|Deletion
P10860827A0399|11 28|mutational analyses
P10860827A0399|40 69|positive cis-regulatory elements
P10860827A0399|101 114|CSX1 expression
P10860827A0399|101 104|CSX1
P10860827A0399|117 130|cardiomyocytes
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|74 98|cotransfection experiments
P10860846A0480|106 124|AP2 expression vector
P10860846A0480|106 108|AP2
P10860846A0480|137 139|AP2
P10860846A0480|137 139|AP2
P10860846A0480|166 180|HGF gene promoter
P10860846A0480|166 168|HGF
P10860846A0480|169 188|gene promoter activity
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|38 63|IkappaBalpha overexpression
P10861080A0433|38 49|IkappaBalpha
P10861080A0433|81 89|TNF-alpha
P10861080A0433|81 89|TNF-alpha
P10861080A0433|99 106|whole GBS
P10861086A0259|2 26|reconstitution experiments
P10861086A0259|60 75|RAW 264.7 cell line
P10861086A0259|78 96|C-terminal Src kinase
P10861086A0259|78 96|C-terminal Src kinase
P10861086A0259|98 100|Csk
P10861086A0259|98 100|Csk
P10861086A0259|121 137|membrane-anchored
P10861086A0259|139 154|gain-of-function
P10861086A0259|155 157|Csk
P10861086A0259|170 195|Fc gamma R-mediated signaling
P10861086A0259|170 177|Fc gamma R
P10861086A0259|207 218|phagocytosis
P10861086A0259|222 243|kinase-dependent manner
P10861086A0904|11 32|c-Src-derived construct
P10861086A0904|11 32|c-Src-derived construct
P10861086A0904|34 38|a-Src
P10861086A0904|60 87|detergent-resistant membranes
P10861086A0904|115 135|phagocytosis signaling
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|58 78|meiosis-inducing genes
P10861906A0999|85 88|IME1
P10861906A0999|85 88|IME1
P10861906A0999|92 95|IME2
P10861906A0999|92 95|IME2
P10861906A0999|136 139|IME1
P10861906A0999|136 139|IME1
P10861906A0999|156 159|IME2
P10861906A0999|156 159|IME2
P10861906A0999|188 209|premeiotic DNA synthesis
P10861906A1479|15 37|environmental conditions
P10861906A1479|48 53|finely
P10861906A1479|83 87|KIN28
P10861906A1479|83 87|KIN28
P10861906A1479|91 94|CCL1
P10861906A1479|91 94|CCL1
P10861906A1479|104 111|nitrogen
P10861906A1479|166 171|medium
P10861909A0502|3 12|pJR vectors
P10861909A0502|54 84|Saccharomyces cerevisiae LEU 2 gene
P10861909A0502|54 76|Saccharomyces cerevisiae
P10861909A0502|77 84|LEU 2 gene
P10861909A0502|102 117|S. pombe leu1- gene
P10861909A0502|102 108|S. pombe
P10861909A0502|109 117|leu1- gene
P10861909A0502|121 127|S. pombe
P10861909A0502|128 132|ura4+
P10861909A0502|128 132|ura4+
P10861909A0502|136 145|his3+ genes
P10861909A0502|136 140|his3+
P10861909A0502|154 173|thiamine-repressible
P10861909A0502|174 185|nmt1 promoter
P10861909A0502|174 185|nmt1 promoter
P10861909A0502|187 192|3X, 41X
P10861909A0502|196 198|81X
P10861909A0502|227 252|low transcription efficiency
P10861909A0502|327 342|restriction sites
P10862289A0289|1 3|GUT
P10862289A0289|1 3|GUT
P10862289A0289|13 55|montoux negative healthy adults (age/sex matched
P10862289A0289|86 98|IgG anti bodies
P10862289A0289|89 98|anti bodies
P10862289A0289|101 110|A60 antigen
P10862289A0289|101 110|A60 antigen
P10863048A0000|17 28|mid-cervical
P10863048A0000|29 38|spinal cord
P10863048A0000|48 55|neuronal
P10863048A0000|59 72|reflex activity
P10863048A0000|108 127|colorectal distension
P10863048A0000|129 131|CRD
P10863048A0000|160 185|halothane-anesthetized rats
P10863352T0001|23 38|music and diseases
P10864271A0504|30 42|S. argyrostoma
P10864271A0504|63 79|Trichinella larvae
P10864271A0504|126 132|mammals
P10864271A0504|137 145|scavenger
P10864271A0504|149 169|cannibalistic behavior
P10864496A0401|60 63|TnrA
P10864496A0401|60 63|TnrA
P10864496A0401|71 91|nrgAB promoter fragment
P10864496A0401|71 91|nrgAB promoter fragment
P10864641A1400|27 35|N-glycans
P10864641A1400|47 66|receptor-binding site
P10864641A1400|47 66|receptor-binding site
P10864641A1400|72 81|HA molecule
P10864641A1400|72 81|HA molecule
P10864641A1400|103 122|influenza virus growth
P10864641A1400|139 144|Asn149
P10864641A1400|167 172|Asn123
P10864989A0484|28 31|PAIP
P10864989A0484|74 90|contaminating WBCs
P10864989A0484|128 130|FIP
P10865422A0138|21 28|ferritin
P10865422A0138|21 28|ferritin
P10865422A0138|30 31|SF
P10865422A0138|30 31|SF
P10865422A0138|34 43|hemoglobin
P10865422A0138|34 43|hemoglobin
P10865422A0138|45 46|Hb
P10865422A0138|45 46|Hb
P10865422A0138|83 113|donations and iron supplementation
P10865838A0000|0 30|Vascular endothelial growth factor
P10865838A0000|8 35|endothelial growth factor (VEGF
P10865838A0000|32 35|VEGF
P10865838A0000|88 96|migration
P10865838A0000|110 133|vascular endothelial cells
P10865940A0000|3 18|antioxidant agent
P10865940A0000|19 44|pyrrolidine dithiocarbamate
P10865940A0000|46 49|PDTC
P10865940A0000|72 87|endothelial cells
P10865940A0000|89 90|EC
P10865940A0000|96 119|pro-inflammatory-induced
P10865940A0000|123 160|pro-oxidant-induced NF-kappaB activation
P10865940A0000|142 150|NF-kappaB
P10866323A0666|28 32|SIE-1
P10866323A0666|28 32|SIE-1
P10866323A0666|51 66|p21WAF1 induction
P10866323A0666|51 57|p21WAF1
P10866323A0666|69 82|STAT activation
P10866323A0666|69 72|STAT
P10866677A1839|0 2|Phd
P10866677A1839|26 33|peptides
P10866677A1839|68 94|cytosolic and nuclear extracts
P10866689A0295|5 10|pRb(-)
P10866689A0295|5 7|pRb
P10866689A0295|11 24|SAOS-2 cell line
P10866689A0295|52 66|reporter plasmid
P10866689A0295|80 95|tal-1 binding site
P10866689A0295|80 95|tal-1 binding site
P10866689A0295|97 99|pRb
P10866689A0295|97 99|pRb
P10866689A0295|136 149|tal-1-E12-Lmo2
P10866689A0295|136 140|tal-1
P10866689A0295|142 144|E12
P10866689A0295|146 149|Lmo2
P10866689A0295|153 162|tal-1-E12-
P10866689A0295|153 157|tal-1
P10866689A0295|159 161|E12
P10866689A0295|163 180|Lmo2-Ldb1 complexes
P10866689A0295|163 166|Lmo2
P10866689A0295|168 171|Ldb1
P10866689A0295|194 202|tal-1-E12
P10866689A0295|194 198|tal-1
P10866689A0295|200 202|E12
P10866689A0295|203 213|heterodimer
P10866886A1277|37 45|oxycodone
P10866886A1277|48 62|morphine-like mu
P10866886A1277|61 71|mu-receptor
P10866886A1277|63 78|-receptor agonist
P10867199A0230|107 110|EPVs
P10867199A0230|129 134|insect
P10867496T0001|0 16|Neurofibromatosis
P10867496T0001|22 27|breast
P10867496T0001|31 37|patient
P10867496T0001|48 64|von Recklinghausen
P10868488A0921|30 39|aggression
P10868488A0921|73 84|testosterone
P10869076A1384|51 60|tryptophan
P10869076A1384|64 86|ribosome translating tnaC
P10869076A1384|83 86|tnaC
P10869076A1384|93 95|Rho
P10869076A1384|93 95|Rho
P10869076A1384|109 123|boxA and rut sites
P10869076A1384|109 112|boxA
P10869076A1384|116 123|rut sites
P10869076A1384|142 165|transcription termination
P10869465A1054|2 18|situ hybridization
P10869465A1054|26 43|antisense RNA probes
P10869465A1054|128 141|germ cell stages
P10869465A1054|173 184|interstitial
P10869465A1054|188 203|peritubular cells
P10870043A0621|22 32|GnRH agonist
P10870043A0621|22 25|GnRH
P10870043A0621|43 60|bone mineral density
P10870043A0621|94 105|control group
P10870391T0034|0 9|Prevention
P10870391T0034|35 41|therapy
P10870391T0034|44 57|travel diarrhea
P10871045A1221|18 26|C/EBPbeta
P10871045A1221|18 26|C/EBPbeta
P10871045A1221|43 54|C/EBP isoform
P10871045A1221|43 54|C/EBP isoform
P10871045A1221|71 83|stellate cells
P10871045A1221|100 115|C/EBPbeta protein
P10871045A1221|100 108|C/EBPbeta
P10871045A1221|119 127|C/EBPbeta
P10871045A1221|119 127|C/EBPbeta
P10871045A1221|138 161|proximal C/EBP binding site
P10871045A1221|146 161|C/EBP binding site
P10871045A1221|186 201|activating effect
P10871045A1221|204 215|acetaldehyde
P10871347A0477|40 45|TCCCCT
P10871347A0477|59 74|PyRo1 interaction
P10871347A0477|59 63|PyRo1
P10871379A0261|6 9|VP16
P10871379A0261|6 9|VP16
P10871379A0261|39 43|Luman
P10871379A0261|39 43|Luman
P10871379A0261|61 63|HCF
P10871379A0261|61 63|HCF
P10871412A0369|58 77|transforming ribozyme
P10871412A0369|70 83|ribozyme (Rz007
P10871412A0369|79 83|Rz007
P10871615A0368|0 0|G
P10871842A0988|21 40|proteasome inhibition
P10871842A0988|79 105|transcription factor families
P10871842A0988|117 138|cellular stress response
P10871842A0988|142 154|proliferation
P10872473A2286|3 15|ATR-X syndrome
P10872473A2286|41 47|XH2 gene
P10872473A2286|41 47|XH2 gene
P10872473A2286|61 71|X chromosome
P10872473A2286|73 76|Xq13
P10872473A2286|93 109|transacting factor
P10872473A2286|124 137|gene expression
P10872535A0000|24 36|environmental
P10872535A0000|37 49|intra-uterine
P10872535A0000|87 91|twins
P10872535A0000|121 128|diabetes
P10872535A0000|145 161|abnormal responses
P10872535A0000|167 190|oral glucose tolerance test
P10872535A0000|192 195|OGTT
P10872535A0000|266 287|metabolic abnormalities
P10872535A0000|290 298|adult life
P10872756A1325|2 10|NASCIS III
P10872756A1325|13 34|randomization imbalance
P10872756A1325|81 88|patients
P10872827A0000|0 16|Penicillin acylase
P10872827A0000|0 16|Penicillin acylase
P10872827A0000|18 19|PA
P10872827A0000|18 19|PA
P10872827A0000|25 39|Escherichia coli
P10872827A0000|40 48|ATCC11105
P10872827A0000|52 73|periplasmic heterodimer
P10872831A0000|1 26|murine expressed sequence tag
P10872831A0000|28 30|EST
P10872831A0000|51 72|erythropoietin receptor
P10872831A0000|51 72|erythropoietin receptor
P10872831A0000|74 77|EPOR
P10872831A0000|74 77|EPOR
P10872831A0000|97 107|EST database
P10872851A0714|7 9|LCx
P10872851A0714|35 55|PM-induced tachycardia
P10872851A0714|75 77|AoP
P10872851A0714|106 107|SV
P10872851A0714|121 125|LVEDP
P10873158A0000|12 35|nuclear factor (NF)-kappaB
P10873158A0000|12 24|nuclear factor
P10873158A0000|26 35|NF)-kappaB
P10873158A0000|49 77|proinflammatory gene expression
P10873158A0000|85 105|airway epithelial cells
P10873158A0000|119 133|oxidative stress
P10873286X0000|23 29|PREFACE
P10873386A0000|45 53|mouse gene
P10873386A0000|45 53|mouse gene
P10873386A0000|60 68|C2 subunit
P10873386A0000|60 61|C2
P10873386A0000|74 86|20S proteasome
P10873386A0000|74 86|20S proteasome
P10873387A0816|19 27|human gene
P10873387A0816|19 27|human gene
P10873387A0816|32 36|3' end
P10873387A0816|42 52|Cacna1f gene
P10873387A0816|42 52|Cacna1f gene
P10873387A0816|71 75|5' end
P10873387A0816|81 102|mouse synaptophysin gene
P10873387A0816|81 102|mouse synaptophysin gene
P10873387A0816|125 131|Xp11.23
P10873388A0623|7 23|human Rhotekin cDNA
P10873388A0623|7 23|human Rhotekin cDNA
P10873388A0623|33 53|Northern hybridization
P10873388A0623|109 116|prostate
P10873388A0623|123 133|middle level
P10873388A0623|181 185|liver
P10873388A0623|189 192|lung
P10874044A0647|51 58|p38alpha
P10874044A0647|51 58|p38alpha
P10874044A0647|68 71|ERK1
P10874044A0647|68 71|ERK1
P10874044A0647|73 76|ERK2
P10874044A0647|73 76|ERK2
P10874044A0647|78 81|JNK1
P10874044A0647|78 81|JNK1
P10874044A0647|85 88|JNK2
P10874044A0647|85 88|JNK2
P10874044A0647|105 134|cadmium-induced pE1-luc activity
P10874044A0647|120 126|pE1-luc
P10874151A0000|11 32|Gamma knife radiosurgery
P10874151A0000|34 36|GKR
P10874151A0000|70 76|surgery
P10874151A0000|92 98|lesions
P10878398A0542|2 21|hemodialyzed patients
P10878398A0542|23 25|Epo
P10878398A0542|23 25|Epo
P10878398A0542|29 47|Non-Epo group) leptin
P10878398A0542|33 53|Epo group) leptin levels
P10878398A0542|91 102|CAPD patients
P10878398A0542|104 106|Epo
P10878398A0542|104 106|Epo
P10878398A0542|110 112|Non
P10878398A0542|114 116|Epo
P10878606A0876|23 28|neural
P10878606A0876|44 59|developing organs
P10878606A0876|75 108|epithelial-mesenchymal interactions
P10878675A1278|14 40|alpha2-adrenergic antagonist
P10878675A1278|41 48|idazoxan
P10878675A1278|58 91|glucose-induced sympathetic activity
P10878675A1278|117 129|obese subjects
P10878944A0000|0 37|ID-PaGIA diphtheria toxin polymer particle
P10878944A0000|8 22|diphtheria toxin
P10878944A0000|67 72|DiaMed
P10878944A0000|73 74|AG
P10878944A0000|136 158|Childhood Infections in St
P10880486A0790|18 37|EMS-induced mutations
P10880486A0790|86 88|Ebr
P10880486A0790|86 88|Ebr
P10880486A0790|101 109|RhoA locus
P10880486A0790|101 104|RhoA
P10880702A0966|50 60|amphetamine
P10880702A0966|63 73|apomorphine
P10880702A0966|114 126|sensitization
P10880702A0966|129 180|amphetamine- or apomorphine-induced stereotyped behavior
P10881275T0000|10 17|serum IgM
P10881275T0000|15 17|IgM
P10881275T0000|27 29|GM1
P10881275T0000|30 40|ganglioside
P10882163A1077|0 17|Objective responses
P10882163A1077|90 106|aminoglutethimide
P10882163A1077|142 172|nonsteroidal aromatase inhibitors
P10882163A1077|154 162|aromatase
P10882213A0163|68 73|cancer
P10882213A0163|118 132|myositis patient
P10882213A0163|161 168|patients
P10882213A0163|173 199|dermatomyositis sine myositis
P10882213A0163|219 237|clinicopathological
P10882213A0163|241 266|serological classifications
P10882213A0163|288 312|childhood and adult myositis
P10882213A0163|409 424|myositis patients
P10882462T0000|3 9|science
P10882850A0000|0 14|Endonuclease III
P10882850A0000|0 14|Endonuclease III
P10882850A0000|16 18|Nth
P10882850A0000|16 18|Nth
P10882850A0000|22 36|Escherichia coli
P10882850A0000|22 36|Escherichia coli
P10882850A0000|40 53|DNA glycosylase
P10882850A0000|40 53|DNA glycosylase
P10882850A0000|86 107|pyrimidine base residues
P10882850A0000|112 114|DNA
P10884978A0633|13 29|reactive hyperemia
P10884978A0633|72 76|males
P10884978A0633|80 86|females
P10885708T0000|0 11|Acquired bile
P10885708T0000|56 74|intrahepatic abscess
P10885731A0915|74 86|crystallinity
P10885731A0915|105 112|blocking
P10885731A0915|151 158|polymers
P10885750A0236|51 56|CREB-2
P10885750A0236|51 56|CREB-2
P10885750A0236|59 78|mammalian development
P10885750A0236|81 95|organ physiology
P10887912A0740|7 10|MVBF
P10887912A0740|24 34|EMG activity
P10887912A0740|40 52|right masseter
P10887912A0740|59 62|left
P10887912A0740|63 80|anterior temporalis
P10887912A0740|120 129|muscle pain
P10887912A0740|153 163|painful side
P10887921A0718|33 42|topography
P10887921A0718|75 78|SWAP
P10887921A0718|85 117|inferotemporal neuroretinal rim area
P10888570A0678|3 16|total alkaloids
P10888570A0678|31 43|peel of Atzimba
P10888570A0678|78 83|Puebla
P10889399A0243|64 66|MEK
P10889399A0243|64 66|MEK
P10890911A0470|17 21|Smad3
P10890911A0470|17 21|Smad3
P10890911A0470|48 59|HMG box domain
P10890911A0470|48 59|HMG box domain
P10890911A0470|62 65|LEF1
P10890911A0470|62 65|LEF1
P10890911A0470|73 79|TGFbeta
P10890911A0470|73 79|TGFbeta
P10890911A0470|83 93|Wnt pathways
P10890911A0470|83 85|Wnt
P10890911A0470|131 149|Xenopus homeobox gene
P10890911A0470|131 149|Xenopus homeobox gene
P10890911A0470|150 153|twin
P10890911A0470|155 158|Xtwn
P10890911A0470|155 158|Xtwn
P10891093A0000|3 23|transmembrane topology
P10891093A0000|26 48|Na(+)/H(+) exchanger NHE3
P10891093A0000|26 30|Na(+)
P10891093A0000|32 34|H(+
P10891093A0000|45 48|NHE3
P10891093A0000|68 99|in vitro transcription/translation
P10891093A0000|112 124|fusion vectors
P10891093A0000|168 180|cDNA sequences
P10891093A0000|189 223|putative NHE3 membrane spanning domains
P10891093A0000|225 228|msds
P10891266A0421|0 4|ACE-2
P10891266A0421|0 4|ACE-2
P10891266A0421|9 28|hydrophobic C terminus
P10891266A0421|31 35|H type
P10891286A0000|12 39|titin/myosin light chain kinase
P10891286A0000|12 16|titin
P10891286A0000|18 45|myosin light chain kinase family
P10891286A0000|87 110|actin/myosin cytoskeleton
P10891286A0000|87 91|actin
P10891286A0000|93 98|myosin
P10891286A0000|124 140|sarcomere assembly
P10891399A1185|27 33|c-fosER
P10891399A1185|27 33|c-fosER
P10891399A1185|69 81|p21(Cip1/WAF1
P10891399A1185|69 71|p21
P10891399A1185|73 76|Cip1
P10891399A1185|78 81|WAF1
P10891399A1185|116 123|AP-1 site
P10891399A1185|116 123|AP-1 site
P10891399A1185|152 156|c-fos
P10891399A1185|152 156|c-fos
P10891441A0871|13 36|pTyr317 Shc phosphopeptide
P10891441A0871|13 36|pTyr317 Shc phosphopeptide
P10891441A0871|58 61|Grb2
P10891441A0871|58 61|Grb2
P10891441A0871|63 66|Sos1
P10891441A0871|63 66|Sos1
P10891441A0871|68 71|SHIP
P10891441A0871|68 71|SHIP
P10891441A0871|79 88|p85 subunit
P10891441A0871|79 88|p85 subunit
P10891441A0871|91 118|phosphatidylinositol 3' kinase
P10891441A0871|91 118|phosphatidylinositol 3' kinase
P10891441A0871|123 131|mast cells
P10891489A0152|32 46|HMG-I/Y proteins
P10891489A0152|32 36|HMG-I
P10891489A0152|38 46|Y proteins
P10891489A0152|63 83|cellular proliferation
P10891489A0152|120 131|human cancers
P10891489A0152|174 183|malignancy
P10891632A0435|3 34|naltrexone/lofexidine combination
P10891632A0435|77 100|opiate withdrawal syndrome
P10891632A0435|204 215|side-effects
P10892300A0268|18 35|enzootic calcinosis
P10892300A0268|83 104|locomotor abnormalities
P10892823A1040|36 42|alcohol
P10893243T0000|0 24|Transcriptional regulation
P10893243T0000|30 68|mouse cytosolic chaperonin subunit gene Ccta
P10893243T0000|30 60|mouse cytosolic chaperonin subunit
P10893243T0000|70 90|t-complex polypeptide 1
P10893243T0000|93 167|selenocysteine tRNA gene transcription activating factor family zinc finger proteins
P10893243T0000|93 127|selenocysteine tRNA gene transcription
P10893243T0000|138 167|factor family zinc finger proteins
P10893258T0000|3 25|unfolded protein response
P10893258T0000|52 88|secretory and membrane protein biogenesis
P10893258T0000|92 111|endoplasmic reticulum
P10894149T0000|0 3|PNRC
P10894149T0000|0 3|PNRC
P10894149T0000|6 51|proline-rich nuclear receptor coregulatory protein
P10894149T0000|6 51|proline-rich nuclear receptor coregulatory protein
P10894149T0000|65 89|transcriptional activation
P10894149T0000|100 115|nuclear receptors
P10894149T0000|125 139|orphan receptors
P10894149T0000|125 139|orphan receptors
P10894149T0000|140 142|SF1
P10894149T0000|140 142|SF1
P10894149T0000|144 163|steroidogenic factor 1
P10894149T0000|144 163|steroidogenic factor 1
P10894149T0000|168 176|ERRalpha1
P10894149T0000|168 176|ERRalpha1
P10894149T0000|178 207|estrogen related receptor alpha-1
P10894149T0000|178 207|estrogen related receptor alpha-1
P10894816A0836|13 27|reporter plasmid
P10894816A0836|54 77|sterol-responsive element
P10894816A0836|54 77|sterol-responsive element
P10894816A0836|79 84|SRE)-1
P10894816A0836|79 81|SRE
P10894816A0836|122 125|IL-6
P10894816A0836|122 125|IL-6
P10894886A0375|29 34|tumors
P10895417A0000|27 29|EPI
P10895417A0000|41 60|morphine encapsulated
P10895417A0000|63 85|multivesicular liposomes
P10895417A0000|87 112|DepoFoam drug delivery system
P10895417A0000|143 150|morphine
P10895417A0669|9 17|EPI-C0401
P10895417A0669|33 40|DepoFoam
P10895417A0669|85 99|food consumption
P10895417A0669|117 126|muscle tone
P10895417A0669|131 145|body temperature
P10896008A0531|0 11|PARTICIPANTS
P10896008A0531|32 52|ambulatory outpatients
P10896008A0531|57 91|hereditary motor and sensory neuropathy
P10896008A0531|104 128|myotonic muscular dystrophy
P10896859A0000|11 26|water deprivation
P10896859A0000|35 50|renal Na excretion
P10896859A0000|53 77|conscious adrenalectomized
P10896859A0000|79 81|ADX
P10896859A0000|83 87|sheep
P10896859A0000|130 140|aldosterone
P10896859A0000|144 151|cortisol
P10896859A0000|172 176|sheep
P10896859A0838|24 58|rehydration-induced renal Na retention
P10897973T0001|0 24|Antithrombin III deficiency
P10897973T0001|0 14|Antithrombin III
P10897973T0001|45 51|heparin
P10897973T0001|63 65|ABC
P10897973T0001|78 92|antithrombin III
P10897973T0001|78 92|antithrombin III
P10898795A0527|8 37|class I and II histone deacetylases
P10898795A0527|8 18|class I and II
P10898795A0527|19 37|histone deacetylases
P10898795A0527|39 43|HDACs
P10898795A0527|39 43|HDACs
P10898795A0527|63 66|BCoR
P10898795A0527|63 66|BCoR
P10898795A0527|82 85|BCoR
P10898795A0527|82 85|BCoR
P10898795A0527|122 126|HDACs
P10898795A0527|122 126|HDACs
P10899128A0661|24 59|eukaryotic transcription factor complex
P10899128A0661|24 59|eukaryotic transcription factor complex
P10899128A0661|75 82|MADS-box
P10899128A0661|75 82|MADS-box
P10899128A0661|87 101|forkhead protein
P10899128A0661|87 101|forkhead protein
P10899128A0661|150 172|mammalian gene expression
P10899128A0661|150 162|mammalian gene
P10899142A0000|25 55|Drosophila Genome Project database
P10899142A0000|95 109|Leu-rich repeats
P10899142A0000|121 144|G protein-coupled receptor
P10899142A0000|121 144|G protein-coupled receptor
P10899142A0000|146 148|LGR
P10899142A0000|146 148|LGR
P10899142A0000|154 163|Drosophila
P10899142A0000|165 170|DLGR-1
P10899142A0000|165 170|DLGR-1
P10899142A0000|209 211|LGR
P10899142A0000|209 211|LGR
P10899142A0000|213 218|DLGR-2
P10899142A0000|213 218|DLGR-2
P10899142A0000|232 235|cDNA
P10900129A0138|10 16|primers
P10900129A0138|58 71|CYP3A sequences
P10900129A0138|58 71|CYP3A sequences
P10900129A0138|90 96|RT-PCRs
P10900269A0396|30 33|TFOs
P10900269A0396|56 69|polypurine site
P10900269A0396|91 97|TK genes
P10900269A0396|99 111|recombination
P10901133A0381|0 15|Methyllevamisole
P10902348A0566|66 73|R5 strain
P10902348A0566|135 148|glass jar method
P10903440A0515|26 31|TSGF-2
P10903440A0515|26 31|TSGF-2
P10903440A0515|45 49|ovary
P10903440A0515|53 65|testes tissues
P10903440A0515|68 73|adults
P10903440A0515|128 152|larval developmental stages
P10903495A0533|3 21|gel retardation assay
P10903495A0533|27 46|HepG2 nuclear extracts
P10903495A0533|51 68|5' flanking sequence
P10903495A0533|73 80|-74 to -46
P10903583T0000|0 10|Reliability
P10903583T0000|13 20|cervical
P10903583T0000|42 50|OSI CA 6000
P10903583T0000|72 105|asymptomatic and symptomatic subjects
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903733A0540|43 58|transfected cells
P10903733A0540|69 72|BCMA
P10903733A0540|69 72|BCMA
P10903733A0540|87 114|TNFR-associated factor (TRAF) 1
P10903733A0540|87 107|TNFR-associated factor
P10903733A0540|109 114|TRAF) 1
P10903733A0540|116 120|TRAF2
P10903733A0540|116 120|TRAF2
P10903733A0540|125 144|TRAF3 adaptor proteins
P10903733A0540|125 144|TRAF3 adaptor proteins
P10903837A1208|8 15|RINX gene
P10903837A1208|8 15|RINX gene
P10903837A1208|39 54|goldfish Vsx1 gene
P10903837A1208|39 54|goldfish Vsx1 gene
P10903837A1208|70 73|VSX1
P10903837A1208|70 73|VSX1
P10903843A0447|3 25|chromosomal localization
P10903843A0447|28 44|distal chromosome 7
P10903843A0447|65 78|imprinted genes
P10903843A0447|111 128|Tapa1 and Kcnq1 genes
P10903843A0447|111 115|Tapa1
P10903843A0447|119 128|Kcnq1 genes
P10903877A0879|12 14|PKA
P10903877A0879|12 14|PKA
P10903877A0879|17 24|8-bromo-
P10903877A0879|25 33|cyclic AMP
P10903877A0879|36 44|forskolin
P10903877A0879|61 63|PKC
P10903877A0879|61 63|PKC
P10903877A0879|66 76|calphostin C
P10903877A0879|110 120|3TP activity
P10903877A0879|129 152|in vitro ERK kinase activity
P10903877A0879|136 144|ERK kinase
P10903877A0879|155 158|CRAC
P10904191A0000|66 70|AMP CT
P10904191A0000|72 74|Gen
P10904191A0000|103 104|CA
P10904191A0000|106 108|USA
P10904191A0000|112 121|urogenital
P10904191A0000|140 158|symptomatic patients
P10904191A0000|173 177|urine
P10904191A0000|179 191|FVU) specimens
P10904191A0000|196 215|asymptomatic patients
P10905349A0329|0 5|Mus81p
P10905349A0329|0 5|Mus81p
P10905349A0329|44 69|XPF endonuclease superfamily
P10905349A0329|44 69|XPF endonuclease superfamily
P10905349A0609|32 37|Rad54p
P10905349A0609|32 37|Rad54p
P10905349A0609|41 46|Mus81p
P10905349A0609|41 46|Mus81p
P10905349A0609|91 109|UV-induced DNA damage
P10905352A0000|3 15|linear plasmid
P10905352A0000|16 20|pCLU1
P10905352A0000|28 32|yeast
P10905352A0000|33 51|Kluyveromyces lactis
P10905352A0000|75 83|cytoplasm
P10905352A0000|100 123|helper linear plasmid pGKL2
P10905352A0000|130 147|terminal protein (TP
P10905352A0000|152 157|primer
P10906176A0000|3 15|repetitive ETn
P10906176A0000|13 15|ETn
P10906176A0000|17 38|early transposon) family
P10906176A0000|17 31|early transposon
P10906176A0000|88 98|mouse genome
P10906317A0351|38 54|attended hemifield
P10906317A0351|56 59|left
P10906317A0351|62 66|right
P10906317A0351|117 125|hemifield
P10906999T0000|16 17|NO
P10906999T0000|42 58|chemiluminescence
P10907348A0508|0 22|Biochemical examinations
P10907348A0508|25 52|calcium-phosphorus metabolism
P10907348A0508|68 84|PTH concentrations
P10907348A0508|68 70|PTH
P10907348A0508|87 96|blood serum
P10907348A0508|114 126|bone isoenzyme
P10907348A0508|129 130|AP
P10907971A0806|0 11|Atorvastatin
P10907971A0806|36 60|HMG-CoA reductase inhibitor
P10907971A0806|36 51|HMG-CoA reductase
P10907971T0000|28 52|HMG-CoA reductase inhibitor
P10907971T0000|28 43|HMG-CoA reductase
P10907971T0000|81 91|CURVES study
P10908317A1459|95 98|rtER
P10908317A1459|95 98|rtER
P10908317A1459|136 155|estradiol sensitivity
P10908317A1459|185 199|transactivation
P10908364A0000|0 4|G-DNA
P10908364A0000|0 4|G-DNA
P10908462A3159|18 20|NRT
P10908478A0717|42 47|adults
P10908478A0717|52 64|schizophrenia
P10908478A0717|110 116|placebo
P10908478A0717|124 139|neuroleptic drugs
P10908822A0519|6 7|CI
P10909973A1508|22 26|GLP-1
P10909973A1508|22 26|GLP-1
P10909973A1508|32 34|CRE
P10909973A1508|68 74|M1-CREB
P10909973A1508|68 69|M1
P10909973A1508|71 74|CREB
P10909973A1508|104 116|serine residue
P10909973A1508|138 164|PKA-mediated phosphorylation
P10909973A1508|138 140|PKA
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|67 70|exon
P10910073A0876|116 123|cDNA ends
P10910439A1196|37 52|acute protein load
P10910439A1196|71 73|GFR
P10910439A1196|95 119|antihypertensive treatment
P10910908A0767|27 51|PI3K-Akt activation pathway
P10910908A0767|27 30|PI3K
P10910908A0767|32 34|Akt
P10910908A0767|70 88|antiapoptotic effect
P10910908A0767|91 93|EPO
P10910908A0767|91 93|EPO
P10913094A0424|0 15|Nine DNA fragments
P10913094A0424|56 64|histidine
P10913094A0424|65 75|-tagged AdpA
P10913094A0424|72 75|AdpA
P10913094A0424|99 124|gel mobility shift-PCR method
P10913172A0442|21 36|NTP-binding motif
P10913172A0442|21 36|NTP-binding motif
P10913172A0442|51 63|Rad24 function
P10913172A0442|51 55|Rad24
P10913172A0442|86 103|lysine(115) residue
P10913276A0510|3 37|carboxyl-terminal proline-rich domain
P10913276A0510|40 43|SOS1
P10913276A0510|40 43|SOS1
P10913276A0510|77 95|PLC-gamma1 SH3 domain
P10913276A0510|77 86|PLC-gamma1
P10913276A0684|4 29|transient expression studies
P10913276A0684|56 64|SH3 domain
P10913276A0684|56 58|SH3
P10913276A0684|67 76|PLC-gamma1
P10913276A0684|67 76|PLC-gamma1
P10913276A0684|109 112|SOS1
P10913276A0684|109 112|SOS1
P10913304A0894|11 18|Ets mRNAs
P10913304A0894|14 18|mRNAs
P10913304A0894|34 37|Ets2
P10913304A0894|34 37|Ets2
P10913304A0894|39 42|Fli1
P10913304A0894|39 42|Fli1
P10913304A0894|44 52|GABPalpha
P10913304A0894|44 52|GABPalpha
P10913304A0894|54 57|SAP1
P10913304A0894|54 57|SAP1
P10913304A0894|59 62|Elk1
P10913304A0894|59 62|Elk1
P10913304A0894|67 69|PE1
P10913304A0894|67 69|PE1
P10913304A1180|1 13|2 kb transcript
P10913304A1180|29 33|brain
P10913304A1180|107 125|N-terminal Ets domain
P10913304A1180|107 125|N-terminal Ets domain
P10913304A1180|128 130|PE1
P10913304A1180|128 130|PE1
P10913304A1180|140 155|C-terminal domain
P10913304A1180|140 155|C-terminal domain
P10913304A1180|180 188|murine ERF
P10915728A0216|6 21|eligible patients
P10915728A0216|26 34|cirrhosis
P10915728A0216|65 72|patients
P10915728A0216|106 113|IFN-beta
P10915728A0216|106 113|IFN-beta
P10915728A0216|140 147|patients
P10915728A0216|155 164|IFN therapy
P10915728A0216|155 157|IFN
P10915780A1063|0 18|Wnt-1 overexpression
P10915780A1063|0 4|Wnt-1
P10915780A1063|21 42|mammary epithelial cells
P10915780A1063|50 61|cyclin D1 mRNA
P10915780A1063|50 57|cyclin D1
P10915780A1063|89 93|Wnt-1
P10915780A1063|89 93|Wnt-1
P10915780A1063|99 110|mammary gland
P10915780A1063|113 126|transgenic mice
P10915780A1063|140 150|ILK activity
P10915780A1063|140 142|ILK
P10915780A1063|154 161|cyclin D1
P10915780A1063|154 161|cyclin D1
P10917402T0000|0 34|Intravenous versus oral administration
P10917402T0000|37 49|amitriptyline
P10917402T0000|52 59|patients
P10917402T0000|64 78|major depression
P10918059A0569|0 7|Deletion
P10918059A0569|13 21|RVH domain
P10918059A0569|13 21|RVH domain
P10918059A0569|38 63|Ca(2+)-dependent activation
P10918059A0569|38 42|Ca(2+
P10918164A0878|8 25|regression analysis
P10918164A0878|78 88|thin lesions
P10918164A0878|112 132|nonphysician detectors
P10918164A0878|159 160|CI
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918440T0000|38 72|granulocyte colony-stimulating factor
P10918440T0000|38 72|granulocyte colony-stimulating factor
P10918440T0000|87 109|peripheral blood stem cell
P10918572A0794|0 2|VaI
P10918572A0794|0 2|VaI
P10918572A0794|6 9|VaII
P10918572A0794|6 9|VaII
P10918572A0794|35 39|ErbB2
P10918572A0794|35 39|ErbB2
P10918572A0794|51 55|ErbB1
P10918572A0794|51 55|ErbB1
P10918572A0794|57 61|ErbB3
P10918572A0794|57 61|ErbB3
P10918572A0794|65 69|ErbB4
P10918572A0794|65 69|ErbB4
P10918572A1547|19 20|WT
P10918572A1547|19 20|WT
P10918572A1547|31 39|TGF-alpha
P10918572A1547|31 39|TGF-alpha
P10918572A1547|47 51|ErbBs
P10918572A1547|47 51|ErbBs
P10918572A1547|63 77|ErbB2 activation
P10918572A1547|63 67|ErbB2
P10918572A1547|146 164|TGF-alpha precursors
P10918572A1547|146 154|TGF-alpha
P10918572A1547|187 190|ErbB
P10918572A1547|187 190|ErbB
P10918596A0000|26 38|p53 C-terminus
P10918596A0000|26 28|p53
P10918596A0000|29 38|C-terminus
P10918596A0000|85 101|wild-type molecule
P10918596A0000|85 101|wild-type molecule
P10918599A0071|12 27|full-length E2F-3
P10918599A0071|23 27|E2F-3
P10918599A0071|54 65|G1/S boundary
P10918599A0071|67 72|E2F-3B
P10918599A0071|67 72|E2F-3B
P10918599A0071|121 122|GO
P10918599A0071|146 147|Rb
P10918599A0071|146 147|Rb
P10918612A0000|3 24|transcription factor Jun
P10918612A0000|3 21|transcription factor
P10918612A0000|22 24|Jun
P10918612A0000|26 30|c-Jun
P10918612A0000|26 30|c-Jun
P10918612A0000|55 80|extracellular growth signals
P10918612A0000|110 123|gene expression
P10918943T0000|0 20|Developmental toxicity
P10918943T0000|26 33|class III
P10918943T0000|65 68|mice
P10918948A0110|42 54|trimebutine II
P10918948A0110|65 72|CAS 39133
P10918948A0110|108 125|intestinal diseases
P10919971A0606|36 53|neutrophil response
P10919971A0606|56 72|eccentric exercise
P10919971A0606|74 81|vitamin E
P10919971A0606|106 138|circulating creatine kinase activity
P10919971A0606|117 130|creatine kinase
P10920186A0528|25 42|stem-loop templates
P10920186A0528|50 60|fusion point
P10920186A0528|66 83|chimeric transcript
P10920186A0528|66 83|chimeric transcript
P10920186A0528|89 92|loop
P10920186A0528|104 113|MLL primers
P10920186A0528|116 127|two-sided PCR
P10920906A0759|56 65|primary STS
P10921197A0179|0 11|Measurements
P10921197A0179|78 81|VO5B
P10921197A0179|85 102|ADAC Pinnacle3 V4.0b
P10924061A0588|0 9|Activation
P10925159A1353|7 12|MARTA1
P10925159A1353|7 12|MARTA1
P10925159A1353|34 45|crude lysates
P10925159A1353|47 85|cytosolic and ribosomal salt-wash fractions
P10925159A1353|92 106|nuclear extracts
P10925159A1353|108 113|MARTA2
P10925159A1353|108 113|MARTA2
P10925159A1353|140 168|ribosomal salt-wash preparation
P10925207A0634|12 16|exons
P10925207A0634|56 71|5'- and 3'- (1218bp
P10925207A0634|75 79|701bp
P10925207A0634|114 117|UTRs
P10926776A0731|9 20|PDP1 isoforms
P10926776A0731|9 12|PDP1
P10926776A0731|57 66|amino acids
P10926776A0731|78 87|N-terminal
P10928179A0101|50 67|sentinel lymph nodes
P10928179A0101|69 72|SLNs
P10928337A0590|19 24|anemia
P10928337A0590|29 58|recombinant human erythropoietin
P10928337A0590|29 58|recombinant human erythropoietin
P10928337A0590|72 75|left
P10928337A0590|76 90|ventricular mass
P10928477A0764|28 42|PFA-100 analyzer
P10928477A0764|62 90|vWF-dependent platelet function
P10928477A0764|62 64|vWF
P10928477A0764|129 139|shear stress
P10928477A0764|149 166|patient populations
P10930526A0174|21 36|molecular cloning
P10930526A0174|40 51|PL scramblase
P10930526A0174|40 41|PL
P10930526A0174|54 82|human (HuPLSCR1) and mouse origin
P10930526A0174|60 67|HuPLSCR1
P10931524A0313|12 29|regulatory activity
P10931524A0313|32 34|Gtx
P10931524A0313|32 34|Gtx
P10931524A0313|56 81|optimal Gtx-binding sequence
P10931524A0313|63 81|Gtx-binding sequence
P10931524A0313|89 111|in vitro DNA-binding assay
P10931927A0655|21 49|5'-A(GGGTTA)(5)-3'/5'-(TAACCC
P10931927A0655|52 57|5)T-3'
P10931927A0655|94 107|Klenow fragment
P10931927A0655|94 107|Klenow fragment
P10931927A0655|110 138|Escherichia coli DNA polymerase I
P10931927A0655|110 138|Escherichia coli DNA polymerase I
P10931927A0655|142 164|HIV reverse transcriptase
P10931927A0655|142 164|HIV reverse transcriptase
P10931927A0655|184 195|DNA sequences
P10931950A0869|0 3|Cdk2
P10931950A0869|0 3|Cdk2
P10931950A0869|7 10|MAPK
P10931950A0869|7 10|MAPK
P10931950A0869|36 40|tumor
P10931950A0869|73 84|wild-type p27
P10931950A0869|82 84|p27
P10931950A0869|94 104|T187A mutant
P10931960A0630|9 26|avirulence activity
P10931960A0630|50 86|acidic transcriptional activation domain
P10931960A0630|113 128|activation domain
P10931960A0630|136 164|herpes simplex viral protein VP16
P10931960A0630|136 160|herpes simplex viral protein
P10931960A0630|161 164|VP16
P10932196A0359|0 8|Mutations
P10932196A0359|14 21|RP2 locus
P10932196A0359|14 21|RP2 locus
P10932196A0359|24 29|Xp11.3
P10932196A0359|57 68|XLRP patients
P10932329A0597|29 42|ascending colon
P10932329A0597|67 91|sulcus cecocolicus dorsalis
P10932329A0597|95 103|ventralis
P10932527A0947|13 30|HD inhibited healing
P10932527A0947|86 107|protracted inflammation
P10932527T0000|48 75|second-intention wound healing
P10932527T0000|87 92|ponies
P10932679A0049|33 47|diet composition
P10932679A0049|139 148|food intake
P10933154A1118|64 79|donor transplants
P10933154A1118|87 100|acute rejection
P10933728A1398|44 47|CBF2
P10933728A1398|44 47|CBF2
P10933728A1398|59 78|EBNA2 transactivation
P10933728A1398|59 63|EBNA2
P10933728A1398|95 110|hnRNP protein AUF1
P10933728A1398|95 110|hnRNP protein AUF1
P10933728A1398|130 133|CBF2
P10933728A1398|130 133|CBF2
P10933728A1398|163 180|cis-acting sequence
P10933728A1398|191 208|CBF1 binding element
P10933728A1398|191 208|CBF1 binding element
P10933728A1398|243 247|EBNA2
P10933728A1398|243 247|EBNA2
P10933732A0000|14 30|human herpesvirus 8
P10933732A0000|19 30|herpesvirus 8
P10933732A0000|32 36|HHV-8
P10933732A0000|32 36|HHV-8
P10933732A0000|56 72|open reading frames
P10933732A0000|74 77|ORFs
P10933732A0000|112 139|cellular transcription factors
P10933732A0000|145 181|interferon regulatory factor (IRF) family
P10933732A0000|145 170|interferon regulatory factor
P10933732A0000|172 181|IRF) family
P10934073A1433|26 37|CHIME monitor
P10934073A1433|110 113|home
P10934310A0698|27 36|ultrasound
P10934310A0698|86 104|coronary angiography
P10934640A1114|2 9|bone area
P10934640A1114|20 25|height
P10934640A1114|67 72|menses
P10934640A1114|90 94|TB BMC
P10934751T0001|0 12|CREST syndrome
P10935488A1033|0 11|Troglitazone
P10935488A1033|35 43|PPARgamma
P10935488A1033|35 43|PPARgamma
P10935488A1033|56 63|T24 cells
P10935488A1033|65 101|adipocyte-type fatty acid binding protein
P10935488A1033|65 101|adipocyte-type fatty acid binding protein
P10935488A1033|103 108|A-FABP
P10935488A1033|103 108|A-FABP
P10935488A1033|145 172|bladder cancer differentiation
P10935880A1049|24 28|lungs
P10935880A1049|35 39|PI-3V
P10935880A1049|35 39|PI-3V
P10935880A1049|46 48|NCP
P10935880A1049|49 62|BVDV type 1, and 1
P10935880A1049|71 76|BVHV-1
P10935880A1049|80 83|BVDV
P10936051T0000|3 49|RS447 human megasatellite tandem repetitive sequence
P10936051T0000|3 7|RS447
P10936051T0000|8 49|human megasatellite tandem repetitive sequence
P10936051T0000|58 84|novel deubiquitinating enzyme
P10936051T0000|90 107|functional promoter
P10936920A0105|8 34|experience and contextual cues
P10938102A0265|45 68|NS1 influenza virus protein
P10938102A0265|45 47|NS1
P10938102A0265|48 68|influenza virus protein
P10938102A1359|62 64|NS1
P10938102A1359|62 64|NS1
P10938102A1359|73 78|eIF4GI
P10938102A1359|73 78|eIF4GI
P10938102A1359|96 115|5' untranslated region
P10938102A1359|117 121|5' UTR
P10938102A1359|128 136|viral mRNA
P10938102A1359|128 136|viral mRNA
P10938102A1359|180 203|influenza virus messengers
P10938102T0000|0 39|Eukaryotic translation initiation factor 4GI
P10938102T0000|10 30|translation initiation
P10938102T0000|37 39|4GI
P10938102T0000|60 69|NS1 protein
P10938102T0000|60 69|NS1 protein
P10938102T0000|96 109|influenza virus
P10938105A0000|0 7|Splicing
P10938105A0000|13 17|K-SAM
P10938105A0000|38 72|fibroblast growth factor receptor 2 gene
P10938105A0000|38 68|fibroblast growth factor receptor 2
P10938105A0000|96 109|U-rich sequence
P10938105A0000|96 96|U
P10938105A0000|97 113|-rich sequence IAS1
P10938105A0000|110 113|IAS1
P10938105A0000|147 158|5' splice site
P10938109A1361|18 24|PKCbeta
P10938109A1361|18 24|PKCbeta
P10938109A1361|37 39|Ras
P10938109A1361|37 39|Ras
P10938109A1361|67 82|insulin but not EGF
P10938109A1361|67 73|insulin
P10938109A1361|80 82|EGF
P10938109A1361|90 117|growth factor mitogenic signals
P10938113A0388|48 55|isoforms
P10938113A0388|56 59|Vav2
P10938113A0388|56 59|Vav2
P10938113A0388|63 66|Vav3
P10938113A0388|63 66|Vav3
P10938113A0388|122 130|receptors
P10938113A0388|154 164|Vav isoforms
P10938113A0388|154 156|Vav
P10938113A0388|181 200|functional activities
P10938120A1093|0 24|Transcriptional regulation
P10938120A1093|27 48|fbp1 promoter constructs
P10938120A1093|27 38|fbp1 promoter
P10938120A1093|63 66|UAS1
P10938120A1093|69 72|UAS2
P10938120A1093|88 107|PKA and MAPK regulation
P10938120A1093|88 90|PKA
P10938120A1093|94 97|MAPK
P10938130A0338|0 4|X-ray
P10938130A0338|36 52|PLZF BTB/POZ domain
P10938130A0338|36 39|PLZF
P10938130A0338|40 42|BTB
P10938130A0338|44 52|POZ domain
P10938130A0338|91 99|interface
P10938135A0259|12 15|SMRT
P10938135A0259|12 15|SMRT
P10938135A0259|36 55|transcription factors
P10938135A0259|75 84|repression
P10938135A0259|118 148|tyrosine kinase signaling pathways
P10938135A0259|118 131|tyrosine kinase
P10938135A0259|176 204|epidermal growth factor receptor
P10938135A0259|176 204|epidermal growth factor receptor
P10938556A0248|14 33|ketamine-treated rats
P10938556A0248|51 60|glial cells
P10939030A0986|134 151|febrile neutropenia
P10939785A0540|0 7|Patients
P10939785A0540|46 57|ACE inhibitor
P10939785A0540|46 48|ACE
P10939785A0540|58 68|perindopril
P10940413A1153|25 36|open-section
P10940413A1153|146 163|longitudinal defect
P10940553A0912|41 58|tissue-specificity
P10940553A0912|66 84|circadian regulation
P10940553A0912|91 104|human hPer1 gene
P10940553A0912|91 104|human hPer1 gene
P10940557A1687|21 27|CF1/USP
P10940557A1687|21 23|CF1
P10940557A1687|25 27|USP
P10940557A1687|31 71|Broad Complex Z2 transcription factor elements
P10940557A1687|43 71|Z2 transcription factor elements
P10940557A1687|86 100|upstream regions
P10940557A1687|103 118|MIH and MO-IH genes
P10940557A1687|103 105|MIH
P10940557A1687|109 113|MO-IH
P10940562A0379|0 15|Sequence analysis
P10940562A0379|45 53|oasA2 gene
P10940562A0379|45 53|oasA2 gene
P10940562T0000|0 6|Genomic
P10940562T0000|41 53|oas gene family
P10940562T0000|41 47|oas gene
P10940562T0000|62 88|O-acetylserine (thiol) lyases
P10940562T0000|64 75|acetylserine
P10940562T0000|77 88|thiol) lyases
P10940562T0000|90 96|enzymes
P10940562T0000|121 140|cysteine biosynthesis
P10940562T0000|143 161|Arabidopsis thaliana
P10940892A0573|20 37|susceptibility loci
P10940892A0573|41 50|vasculitis
P10940892A0573|63 78|chromosome (Chr) 4
P10940892A0573|81 87|D4Mit89
P10940892A0573|81 87|D4Mit89
P10940892A0573|91 98|D4Mit147
P10940892A0573|91 98|D4Mit147
P10942587A0981|41 42|Rb
P10942587A0981|53 74|hypophosphorylated form
P10942587A0981|76 79|mRNA
P10942587A0981|86 91|HPV E6/
P10942587A0981|86 90|HPV E6
P10942587A0981|92 93|E7
P10942587A0981|92 93|E7
P10942587A0981|140 148|E7 protein
P10942587A0981|140 148|E7 protein
P10942587A0981|187 188|Rb
P10942587A0981|187 188|Rb
P10942587A0981|211 227|anti-E7 antibodies
P10942587A0981|216 227|E7 antibodies
P10942599A1298|38 54|Hoxa-1 target genes
P10942599A1298|38 43|Hoxa-1
P10942599A1298|44 54|target genes
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|150 162|embryogenesis
P10943891A1062|12 17|U6-U57
P10943891A1062|12 13|U6
P10943891A1062|15 17|U57
P10943891A1062|53 62|branch site
P10943891A1062|66 77|3' splice site
P10943891A1062|148 157|active site
P10943891A1062|148 157|active site
P10943891A1062|159 159|s
P10943891A1062|166 176|spliceosome
P10944466A0451|33 42|WNT-2B gene
P10944466A0451|33 42|WNT-2B gene
P10945010T0001|42 66|adult acute myeloid leukemia
P10945781A0412|9 24|Aeromonas strains
P10945781A0412|33 47|V cholerae non-O1
P10945781A0412|33 47|V cholerae non-O1
P10946303A0000|0 8|TNF-alpha
P10946303A0000|0 8|TNF-alpha
P10946303A0000|49 64|cyclooxygenase-2
P10946303A0000|49 64|cyclooxygenase-2
P10946303A0000|66 81|COX-2) expression
P10946303A0000|66 70|COX-2
P10946303A0000|85 88|PGE2
P10946303A0000|100 127|human NCI-H292 epithelial cells
P10947274A0839|51 57|RBE-cGy
P10947274A0839|78 82|157Gd
P10947274A0839|98 100|10B
P10947840A0762|0 3|Mis3
P10947840A0762|0 3|Mis3
P10947840A0762|29 42|18S ribosome RNA
P10947840A0762|29 42|18S ribosome RNA
P10950415A0866|44 57|Terson syndrome
P10950924A0393|0 21|RNA in situ hybridization
P10950924A0393|24 36|brain sections
P10950924A0393|39 56|normal human embryos
P10950924A0393|102 115|cerebral cortex
P10950935A0111|31 46|genomic sequences
P10950935A0111|78 92|Escherichia coli
P10950935A0111|93 94|P1
P10950935A0111|95 115|artificial chromosomes
P10950935A0111|117 120|PACs
P10950935A0111|141 151|chromosomes
P10950935A0111|153 156|YACs
P10951579A1238|5 21|gamma-irradiation
P10951579A1238|36 42|F9 cells
P10951579A1238|50 58|apoptosis
P10951579A1238|71 76|wt-p53
P10951579A1238|74 76|p53
P10951579A1238|91 117|pro-apoptotic gene expression
P10951579A1238|120 134|DNA damaged cells
P10951848A0230|16 31|cyclophosphamide
P10951848A0230|35 69|granulocyte-colony stimulating factor
P10951848A0230|35 69|granulocyte-colony stimulating factor
P10951848A0230|91 104|CD34+ cell shift
P10951848A0230|91 95|CD34+
P10951848A0230|107 121|peripheral blood
P10951848A0230|187 202|megachemotherapy
P10952828A2638|30 46|magnetic resonance
P10952828A2638|82 107|ejection fraction estimation
P10952828A2638|110 121|heart failure
P10952828A2638|122 129|patients
P10952828A2638|143 144|3D
P10952828A2638|156 178|non-symmetric ventricles
P10954093A0000|1 23|degenerate DNA transposon
P10954093A0000|47 53|genomes
P10954093A0000|63 78|wild-type strains
P10954093A0000|84 117|filamentous fungus Podospora anserina
P10954525A1161|21 24|Tax I
P10954525A1161|21 24|Tax I
P10954525A1161|80 84|TRE-2
P10954564A1262|21 36|functional domain
P10954564A1262|42 53|ORF 50 protein
P10954564A1262|42 53|ORF 50 protein
P10954564A1262|57 82|immediate-early gene product
P10954564A1262|57 82|immediate-early gene product
P10954564A1262|104 108|ORF 50
P10954913A0152|7 26|full-length cDNA clone
P10954913A0152|7 21|full-length cDNA
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|68 83|liver cDNA library
P10955313A0000|0 5|PLUS-3
P10955313A0000|12 26|Swedish protocol
P10955313A0000|29 41|natural speech
P10955313A0000|54 61|children
P10955913A0827|4 8|HIT II
P10955913A0827|4 8|HIT II
P10955913A0827|21 27|heparin
P10955913A0827|32 59|low-molecular-weight heparins
P10955998A1124|3 19|reduced efficiency
P10955998A1124|25 43|glycosylase activity
P10955998A1124|25 35|glycosylase
P10955998A1124|78 86|S120K MutY
P10955998A1124|78 82|S120K
P10955998A1124|83 86|MutY
P10955998A1124|96 107|DNA mutations
P10958271A0365|67 81|left ventricular
P10958271A0365|99 102|LVEF
P10958271A0365|146 148|99m
P10958271A0365|150 154|Tc99m
P10958271A0365|165 169|SPECT
P10958271A0365|185 213|radionuclide angiocardiography
P10958271A0365|215 218|ERNA
P10958271A0365|224 231|patients
P10958271A0365|290 297|patients
P10958456A0529|4 8|cDNAs
P10958456A0529|45 65|3' untranslated regions
P10958456A0529|69 73|577 bp
P10958456A0529|76 80|Cp.F6
P10958456A0529|76 77|Cp
P10958456A0529|79 80|F6
P10958456A0529|84 87|72 bp
P10958456A0529|90 95|Cp.F10
P10958456A0529|90 91|Cp
P10958456A0529|93 95|F10
P10958673A0142|4 25|intracellular signaling
P10958673A0142|37 63|unfolded protein response (UPR
P10958673A0142|81 118|cis-acting ER stress response element (ERSE
P10958673A0142|122 128|mammals
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958688A0265|3 23|lipolytica Kar2p mutant
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|108 112|Sls1p
P10958688A0265|108 112|Sls1p
P10958698A0280|59 72|Cse4p N terminus
P10958698A0280|59 72|Cse4p N terminus
P10958698A0485|24 39|N-terminal domain
P10958698A0485|24 39|N-terminal domain
P10958698A0485|41 43|END
P10958698A0485|41 43|END
P10958698A0485|58 60|HFD
P10958698A0485|58 60|HFD
P10958698A0485|111 123|Cse4p function
P10958698A0485|111 115|Cse4p
P10959838A0153|2 14|invertebrates
P10959838A0153|16 19|Fhit
P10959838A0153|16 19|Fhit
P10959838A0153|49 51|Nit
P10959838A0153|65 84|nitrilase superfamily
P10959838A0153|65 84|nitrilase superfamily
P10961046A0342|0 13|Platelet counts
P10961046A0342|33 42|fibrinogen
P10961046A0342|33 42|fibrinogen
P10961046A0342|46 64|von Willebrand factor
P10961046A0342|46 64|von Willebrand factor
P10961046A0342|66 75|vWF) levels
P10961046A0342|66 68|vWF
P10961585A0273|38 53|thrombocytopenia
P10962564A0883|1 26|beta2 RARE reporter construct
P10962564A0883|1 5|beta2
P10962564A0883|6 26|RARE reporter construct
P10962564A0883|37 47|methylation
P10962564A0883|148 172|chromatin-dependent manner
P10962593A0580|17 23|AFP rate
P10962738A0000|0 12|Consciousness
P10962738A0000|45 63|memory and perception
P10962881A0900|0 10|Multiparity
P10963735A0193|39 53|oxidative stress
P10963735A0193|56 70|healthy controls
P10963735A0193|72 74|CTL
P10963735A0193|88 90|CRF
P10963735A0193|94 103|HD patients
P10963735A0193|111 116|pre-HD
P10963735A0193|127 133|post-HD
P10963735A0193|138 152|dialysis session
P10963735A0193|209 212|AN69
P10963735A0651|0 23|Indirect plasma parameters
P10963735A0651|30 37|vitamin E
P10963735A0651|39 60|thiol and uric acid levels
P10964833A1696|41 44|POAG
P10964995A2152|55 66|ER(+) cancers
P10964995A2152|55 58|ER(+
P10964995A2152|97 114|endocrine treatment
P10964995A2152|141 145|HER-2
P10964995A2152|141 145|HER-2
P10965135A0735|0 15|Promoter activity
P10965135A0735|70 72|ras
P10965135A0735|70 72|ras
P10965135A0735|75 86|mos oncogenes
P10965135A0735|75 86|mos oncogenes
P10965135A0735|177 191|MAP kinase kinase
P10965135A0735|177 191|MAP kinase kinase
P10965135A0735|193 205|MKK) inhibitor
P10965135A0735|193 195|MKK
P10965135A0735|206 212|PD98059
P10965135A1207|37 44|Cktsf1b1
P10965135A1207|37 44|Cktsf1b1
P10965135A1207|84 101|cell transformation
P10965135A1207|116 124|MKK levels
P10965135A1207|116 118|MKK
P10965135A1207|153 171|transcription factor
P10965830A0305|0 12|INTERVENTIONS
P10965830A0305|38 41|PCO2
P10965830A0305|72 79|patients
P10965830A0305|84 103|necrotising fasciitis
P10965830A0305|109 125|healthy volunteers
P10965830A0305|132 141|normobaric
P10965830A0305|145 164|hyperbaric conditions
P10965905A1618|7 29|GH-induced Akt activation
P10965905A1618|17 19|Akt
P10965905A1618|87 94|LY294002
P10965905A1618|124 133|wortmannin
P10965905A1618|154 158|IRS-1
P10965905A1618|154 158|IRS-1
P10965905A1618|184 212|GH-induced MAP kinase activation
P10965905A1618|184 185|GH
P10965905A1618|194 202|MAP kinase
P10965905A1618|243 252|wortmannin
P10965905A1618|284 287|PI3K
P10965905A1618|284 287|PI3K
P10965905A1618|301 302|GH
P10965905A1618|301 302|GH
P10965905A1618|311 329|MAP kinase activation
P10965905A1618|311 319|MAP kinase
P10965905T0000|0 25|Insulin receptor substrate-1
P10965905T0000|7 45|receptor substrate-1-mediated enhancement
P10965905T0000|48 108|growth hormone-induced mitogen-activated protein kinase activation
P10965905T0000|48 60|growth hormone
P10965905T0000|69 98|mitogen-activated protein kinase
P10967361A0000|10 33|magnetic resonance imaging
P10967361A0000|35 38|fMRI
P10967361A0000|73 82|human brain
P10967531A1025|5 14|declamping
P10967531A1025|45 49|edema
P10967531A1025|56 68|fibre necrosis
P10967531A1025|83 92|leucocytes
P10967531A1025|107 116|fibre areas
P10967531A1025|151 155|type I
P10967890A1120|44 69|comprehension and production
P10970048A0352|27 33|RH level
P10970048A0352|27 28|RH
P10970048A0352|142 143|RH
P10972688A1272|68 83|hospitalizations
P10972894A0488|0 15|Genomic libraries
P10972894A0488|117 128|small library
P10972894A0488|137 154|medium-size library
P10972894A0488|165 176|large library
P10972980A0295|9 17|cell lines
P10972980A0295|19 22|mTOR
P10972980A0295|19 22|mTOR
P10972980A0295|28 44|downstream targets
P10972980A0295|61 92|phosphatidylinositol (PI) 3-kinase
P10972980A0295|61 80|phosphatidylinositol
P10972980A0295|82 92|PI) 3-kinase
P10972980A0295|94 108|protein kinases A
P10972980A0295|94 107|protein kinases
P10972980A0295|108 108|A
P10972980A0295|110 110|B
P10972980A0295|110 110|B
P10972980A0295|115 115|C
P10972980A0295|117 140|heterotrimeric G-proteins
P10972980A0295|117 140|heterotrimeric G-proteins
P10972980A0295|143 165|PD98059-sensitive kinase
P10972980A0295|168 174|calcium
P10972980A0295|186 195|amino acids
P10972990A0196|3 28|tumor-suppressor protein p53
P10972990A0196|3 25|tumor-suppressor protein
P10972990A0196|26 28|p53
P10972990A0196|52 67|genomic stability
P10972990A0526|0 9|Abrogation
P10972990A0526|12 22|p53 function
P10972990A0526|12 14|p53
P10972990A0526|25 26|E6
P10972990A0526|25 26|E6
P10972990A0526|52 81|spontaneous mutation frequencies
P10972990A0526|99 122|thymidine kinase (TK) locus
P10972990A0526|99 113|thymidine kinase
P10972990A0526|115 122|TK) locus
P10972990A0526|144 191|hypoxanthine phosphoribosyl transferase (HPRT) locus
P10972990A0526|144 180|hypoxanthine phosphoribosyl transferase
P10972990A0526|182 191|HPRT) locus
P10972990A0966|0 18|Cytogenetic analysis
P10972990A0966|21 30|LOH mutants
P10972990A0966|33 50|chromosome painting
P10972990A0966|69 90|chromosomal aberrations
P10972990A0966|100 111|chromosome 17
P10972990A0966|120 160|partial chromosome deletions, amplifications
P10972990A0966|165 186|multiple translocations
P10972990A0966|219 224|mutant
P10972990A1518|32 41|p53 protein
P10972990A1518|32 41|p53 protein
P10972990A1518|71 86|genomic integrity
P10972990A1518|94 114|recombinational repair
P10973151A0883|73 82|Pernambuco
P10973151A0883|130 146|human interference
P10973385A1423|2 9|patients
P10973385A1423|14 25|type II tumors
P10973385A1423|39 47|lymphatic
P10973385A1423|114 117|left
P10973385A1423|118 130|gastric artery
P10973385A1423|204 211|patients
P10973400A0664|34 42|vertebral
P10973400A0664|66 90|flexion-distraction Stage I
P10973400A0664|126 140|cervical flexion
P10974541A0389|11 25|K562 cDNA library
P10974541A0389|56 60|MZF1B
P10974541A0389|56 60|MZF1B
P10974541A0389|64 68|MZF1C
P10974541A0389|64 68|MZF1C
P10975465A0134|3 21|human cDNA clone NFBD1
P10975465A0134|43 50|KIAA0170
P10975465A0134|60 71|novel protein
P10975465A0134|140 150|BRCT domains
P10975465A0134|140 150|BRCT domains
P10975465A0134|156 170|carboxy terminus
P10975465A0134|172 188|amino acid residues
P10976413A0514|15 27|basal FSH level
P10976413A0514|20 22|FSH
P10976413A0514|41 48|FSH level
P10976413A0514|41 43|FSH
P10976413A0514|131 138|FSH level
P10976413A0514|131 133|FSH
P10976413A0514|168 175|FSH level
P10976413A0514|168 170|FSH
P10976413A0514|207 215|pregnancy
P10980416T0000|0 27|Parathyroid hormone regulation
P10980416T0000|0 17|Parathyroid hormone
P10980416T0000|30 67|bone sialoprotein (BSP) gene transcription
P10980416T0000|30 45|bone sialoprotein
P10980416T0000|47 54|BSP) gene
P10980416T0000|86 130|pituitary-specific transcription factor-1 (Pit-1
P10980416T0000|86 124|pituitary-specific transcription factor-1
P10980416T0000|126 130|Pit-1
P10980416T0000|142 159|rat BSP gene promoter
P10980416T0000|142 151|rat BSP gene
P10981094A0779|12 13|BP
P10981094A0779|35 45|Sixth Report
P10981094A0779|53 74|Joint National Committee
P10981094A0779|76 80|JNC VI
P10982076A0000|52 76|influenza-like illness (ILI
P10982076A0000|171 187|influenza activity
P10982143A0346|3 8|muskox
P10982143A0346|28 35|T. gondii
P10982391A0425|12 21|NPF repeats
P10982391A0425|24 42|leucine heptad repeat
P10982391A0425|73 92|proline-rich SH3-like
P10982391A0425|85 118|SH3-like and/or WW domain-binding site
P10982391A0425|99 118|WW domain-binding site
P10982391A0425|124 139|N-terminal domain
P10982391A0425|124 139|N-terminal domain
P10982391A0425|159 166|membrane
P10982391A0425|167 170|core
P10982391A0425|193 210|transmembrane spans
P10982391A0425|219 237|amphiphilic segments
P10982825A0363|49 63|Mot3 binding site
P10982825A0363|49 63|Mot3 binding site
P10982825A0363|66 68|OpA
P10982825A0363|66 68|OpA
P10983344A0000|57 64|ischemia
P10983857A0923|20 27|NCX-4016
P10983857A0923|48 49|PD
P10983857A0923|62 70|luminal H+
P10983857A0923|128 134|stomach
P10983857A0923|141 146|normal
P10983857A0923|150 161|STZ-diabetic
P10983857A0923|162 165|rats
P10983979T0000|23 34|5' splice site
P10983979T0000|37 41|U4/U6
P10983979T0000|37 38|U4
P10983979T0000|40 41|U6
P10983979T0000|43 53|U5 tri-snRNP
P10983979T0000|43 53|U5 tri-snRNP
P10983979T0000|86 109|early spliceosome assembly
P10984122A0911|2 8|control
P10984122A0911|37 47|DNA mixtures
P10984122A0911|64 69|mU6-C1
P10984122A0911|72 77|mU6-C2
P10987280A0604|3 19|amino acid sequence
P10987280A0604|22 33|matrilysin-2
P10987280A0604|22 33|matrilysin-2
P10987280A0604|47 62|threonine residue
P10987280A0604|76 89|Zn-binding site
P10987280A0604|76 89|Zn-binding site
P10987280A0604|128 137|matrilysin
P10987280A0604|128 137|matrilysin
P10987301A0332|40 83|constitutively active G protein-coupled receptor
P10987301A0332|60 83|G protein-coupled receptor
P10987301A0332|85 88|GPCR
P10987301A0332|85 88|GPCR
P10987301A0332|102 127|Kaposi's sarcoma-associated
P10987301A0332|128 138|herpes virus
P10987301A0332|140 143|KSHV
P10987301A0332|151 162|herpes virus 8
P10987301A0332|151 162|herpes virus 8
P10987301A0332|187 198|angiogenesis
P10987301A0332|225 255|vascular endothelial growth factor
P10987301A0332|225 255|vascular endothelial growth factor
P10987301A0332|257 260|VEGF
P10987301A0332|257 260|VEGF
P10987301A0332|274 293|angiogenic stimulator
P10987301A0332|306 312|mitogen
P10987301A0332|332 346|Kaposi's sarcoma
P10989777A1286|44 46|URD
P10989777A1286|57 72|prospective study
P10989777A1286|82 97|random assignment
P10991383A0289|71 86|magnetic sublevel
P10991383A0289|108 125|3D vibrational state
P10991648T0000|0 17|Coexisting vertical
P10991648T0000|38 50|half syndromes
P10992299A0745|29 42|gene expression
P10992299A0745|58 70|tumorigenesis
P10992299A0745|72 85|PI12 expression
P10992299A0745|72 75|PI12
P10992299A0745|114 130|tumor brain tissues
P10992299A0745|139 158|brain cancer cell lines
P10992299A0745|164 165|MG
P10992299A0745|169 170|H4
P10992983T0000|28 44|sexual orientation
P10993773A0717|47 54|ischemia
P10993773A0717|149 156|ischemia
P10993787A0369|11 13|MAP
P10993787A0369|17 20|MSNA
P10993787A0369|35 37|SHG
P10993787A0369|56 58|SHG
P10993787A0369|61 63|PHI
P10993787A0369|102 104|MAP
P10993787A0369|128 131|MSNA
P10995121A0569|70 73|0.95
P10995121A0569|84 91|vitamin K
P10995121A0569|96 100|K or K1
P10995751A0093|28 62|CCAAAT/enhancer-binding protein-beta
P10995751A0093|28 62|CCAAAT/enhancer-binding protein-beta
P10995751A0093|64 74|C/EBP-beta)
P10995751A0093|64 73|C/EBP-beta
P10995751A0093|82 98|gene transcription
P10995751A0093|112 129|IFN response element
P10995751A0093|112 129|IFN response element
P10995751A0093|139 179|gamma-IFN-activated transcriptional element
P10995751A0093|139 179|gamma-IFN-activated transcriptional element
P10997330A0361|0 19|Northern blot analysis
P10997330A0361|39 47|STORP gene
P10997330A0361|39 47|STORP gene
P10997330A0361|99 105|PML gene
P10997330A0361|99 105|PML gene
P10997863A0753|5 7|TLE
P10997863A0753|8 15|patients
P10997863A0753|70 72|FLE
P10997863A0753|73 80|patients
P10997904A1258|3 15|Spo0F residues
P10997904A1258|3 7|Spo0F
P10997904A1258|27 42|hydrophobic patch
P10997904A1258|142 181|interacting response regulator-kinase pairs
P10998679A0500|3 20|psychologic factors
P10998679A0500|49 65|terminal prognoses
P10998679A0500|124 139|nonmalignant pain
P10999205A0607|13 29|spatial resolution
P10999205A0607|85 100|contralateral VOI
P10999301A0000|24 48|magneto-optical parameters
P10999301A0000|92 108|optical microscope
P10999301A0000|110 113|SNOM
P10999301A0000|151 165|mesoscopic scale
P10999369A0192|28 35|cortical
P10999369A0192|67 71|N2/P2
P10999369A0192|99 104|microV
P10999369A0192|122 127|microV
P11000203A0752|5 13|mutations
P11000203A0752|16 20|K-Rev
P11000203A0752|16 20|K-Rev
P11000203A0752|69 93|K-Rev-dependent nuclear RNA
P11000203A0752|69 73|K-Rev
P11000203A0752|84 99|nuclear RNA export
P11000203A0752|108 119|K-Rev mutants
P11000203A0752|108 119|K-Rev mutants
P11000203A0752|215 223|RNA export
P11000250A0200|0 4|LMP-1
P11000250A0200|0 4|LMP-1
P11000250A0200|20 33|plasma membrane
P11000250A0200|47 50|TRAF
P11000250A0200|47 50|TRAF
P11000250A0200|52 56|TRADD
P11000250A0200|52 56|TRADD
P11000250A0200|61 72|JAK molecules
P11000250A0200|61 72|JAK molecules
P11000250A0200|83 91|NF-kappaB
P11000250A0200|83 91|NF-kappaB
P11000250A0200|94 97|AP-1
P11000250A0200|94 97|AP-1
P11000250A0200|103 124|STAT-dependent pathways
P11000250A0200|103 106|STAT
P11000250A0200|131 134|CD40
P11000250A0200|131 134|CD40
P11000266T0000|18 25|enhancer
P11000266T0000|31 49|alternative promoter
P11000266T0000|55 65|first intron
P11000266T0000|71 91|alpha-fetoprotein gene
P11000266T0000|71 91|alpha-fetoprotein gene
P11000521A0588|8 37|intracellular signaling pathways
P11000521A0588|59 81|malignant transformation
P11000521A0588|84 111|Ret-9bp expressing NIH3T3 cells
P11000521A0588|84 90|Ret-9bp
P11000521A0588|131 161|Ret-9bp dependent phosphorylation
P11000521A0588|131 137|Ret-9bp
P11000521A0588|164 189|insulin receptor substrate-2
P11000521A0588|164 189|insulin receptor substrate-2
P11000521A0588|191 195|IRS-2
P11000521A0588|191 195|IRS-2
P11000521A0588|224 251|phosphatidylinositol 3-kinase
P11000521A0588|224 251|phosphatidylinositol 3-kinase
P11000521A0588|253 262|PI 3-kinase
P11000521A0588|253 262|PI 3-kinase
P11000521A0588|267 280|protein kinase B
P11000521A0588|267 280|protein kinase B
P11000521A0588|282 288|PKB/AKT
P11000521A0588|282 284|PKB
P11000521A0588|286 288|AKT
P11002236A0328|142 156|Oncology centers
P11003471A1149|0 19|Phylogenetic analysis
P11003471A1149|33 37|ToLCV
P11003471A1149|104 116|Northern India
P11003641A0811|11 28|Fcp1p-binding motif
P11003641A0811|11 15|Fcp1p
P11003641A0811|29 33|KEFGK
P11003641A0811|39 57|RAP74 (Tfg1p) subunit
P11003641A0811|39 43|RAP74
P11003641A0811|45 49|Tfg1p
P11003641A0811|60 64|TFIIF
P11003641A0811|60 64|TFIIF
P11003641A0811|67 71|EEFGE
P11003641A0811|109 129|fcp1 tfg1 double mutants
P11003641A0811|109 112|fcp1
P11003641A0811|113 116|tfg1
P11003641A0811|150 154|Fcp1p
P11003641A0811|150 154|Fcp1p
P11003641A0811|209 216|promoter
P11003652A0961|23 28|Cdc42p
P11003652A0961|23 28|Cdc42p
P11003652A0961|48 64|pheromone response
P11003652A0961|90 98|PAK Ste20p
P11003652A0961|90 92|PAK
P11003652A0961|93 98|Ste20p
P11003653A0198|0 7|Deletion
P11003653A0198|22 36|DNA-binding site
P11003653A0198|56 76|human beta-globin locus
P11003653A0198|56 76|human beta-globin locus
P11003653A0198|102 134|human gamma- to beta-globin switching
P11003653A0198|102 111|human gamma
P11003653A0198|115 125|beta-globin
P11003653A0198|137 150|transgenic mice
P11003653A0198|169 178|PYR complex
P11003653A0198|169 178|PYR complex
P11003669A0000|12 20|rat gene 33
P11003669A0000|12 20|rat gene 33
P11003669A0000|38 62|ErbB-2-interacting protein
P11003669A0000|38 62|ErbB-2-interacting protein
P11003669A0000|66 81|two-hybrid screen
P11003669A0000|94 128|ErbB-2 juxtamembrane and kinase domains
P11003669A0000|94 99|ErbB-2
P11003669A0000|116 128|kinase domains
P11003805A0443|21 41|DGOR without acid reflux
P11003805A0443|118 129|oesophagitis
P11003807A0303|0 7|Symptoms
P11003807A0303|44 55|oesophagitis
P11003807A0303|63 76|severe symptoms
P11003807A0303|104 120|oesophageal damage
P11004369A0000|42 50|blood flow
P11004369A0000|76 92|Doppler ultrasound
P11004369A0000|94 111|microvessel density
P11004369A0000|116 152|vascular endothelial growth factor levels
P11004369A0000|116 146|vascular endothelial growth factor
P11004369A0000|155 174|endometrial carcinoma
P11005808A1082|23 61|Ras- and Raf-independent ERK MAPK activation
P11005808A1082|30 32|Raf
P11005808A1082|45 51|ERK MAPK
P11005808A1082|93 101|heat shock
P11005831A0242|5 9|cDNAs
P11005831A0242|18 66|basic leucine zipper (bZIP)-type ABRE-binding proteins
P11005831A0242|18 66|basic leucine zipper (bZIP)-type ABRE-binding proteins
P11005831A0242|89 109|yeast one-hybrid system
P11005831A0242|127 131|AREB1
P11005831A0242|127 131|AREB1
P11005831A0242|133 137|AREB2
P11005831A0242|133 137|AREB2
P11005831A0242|142 146|AREB3
P11005831A0242|142 146|AREB3
P11005831A0242|148 182|ABA-responsive element binding protein
P11005831A0242|148 182|ABA-responsive element binding protein
P11006283A1180|11 18|AROM-p64
P11006283A1180|11 14|AROM
P11006283A1180|16 18|p64
P11006283A1180|62 80|poly(A) homopolymers
P11006283A1180|122 146|mRNA maturation/metabolism
P11006284T0000|3 27|protein-tyrosine kinase fer
P11006284T0000|3 24|protein-tyrosine kinase
P11006284T0000|25 27|fer
P11006284T0000|42 59|signaling complexes
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006331A0319|3 19|variable phenotype
P11006331A0319|25 39|allotetraploids
P11006331A0319|61 84|cytological abnormalities
P11007509A1271|5 17|PMR target area
P11007509A1271|29 38|nontreated
P11007509A1271|66 86|myocardial flow reserve
P11007509A1271|147 161|stress perfusion
P11007777A0813|36 51|genomic BAC clones
P11007777A0813|67 73|junctin
P11007777A0813|75 82|junctate
P11007777A0813|87 110|aspartyl beta-hydroxylase
P11007777A0813|87 110|aspartyl beta-hydroxylase
P11007949A1395|41 44|PTEN
P11007949A1395|41 44|PTEN
P11007949A1395|67 77|solid tumors
P11007949A1607|35 37|ILK
P11007949A1607|35 37|ILK
P11007949A1607|64 78|PTEN mutant cells
P11007949A1607|64 73|PTEN mutant
P11007954A0170|3 36|growth factor receptor-bound protein 2
P11007954A0170|3 22|growth factor receptor
P11007954A0170|29 36|protein 2
P11007954A0170|38 41|Grb2
P11007954A0170|38 41|Grb2
P11007954A0170|67 69|Sos
P11007954A0170|67 69|Sos
P11007954A0170|71 84|Son of sevenless
P11007954A0170|76 84|sevenless
P11007954A0170|106 108|Ras
P11007954A0170|106 108|Ras
P11007954A0170|135 166|tyrosine kinase-activated receptor
P11007954A0170|135 166|tyrosine kinase-activated receptor
P11007954A0170|169 171|Ras
P11007954A0170|169 171|Ras
P11007954A0170|184 186|Sos
P11007954A0170|192 199|membrane
P11007954A0170|221 223|Ras
P11007954A0170|221 223|Ras
P11007961A0930|0 8|Mutations
P11007961A0930|24 37|PR65/A subunits
P11007961A0930|24 29|PR65/A
P11007961A0930|74 85|human cancers
P11007961A0930|92 104|PP2A inhibitor
P11007961A0930|92 95|PP2A
P11007961A0930|112 121|fostriecin
P11007961A0930|140 153|anticancer drug
P11007968A0255|25 27|dxr
P11007968A0255|44 68|Synechococcus leopoliensis
P11007968A0255|85 87|PCR
P11007968A0255|93 108|oligonucleotides
P11007968A0255|112 127|conserved regions
P11008139T0000|0 17|Perceptual learning
P11008420A0580|3 10|detector
P11008420A0580|67 70|ST-T
P11008420A0580|67 70|ST-T
P11011139A0000|9 31|Saccharomyces cerevisiae
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|91 105|RNA polymerase II
P11011139A0000|91 105|RNA polymerase II
P11011139A0000|144 147|Sin4
P11011139A0000|144 147|Sin4
P11011139A0000|177 194|chromatin structure
P11012568A0192|0 29|Primary adrenal hypersensitivity
P11012568A0192|32 35|ACTH
P11012568A0192|32 35|ACTH
P11012671A0576|24 40|C/EBP-binding site
P11012671A0576|24 40|C/EBP-binding site
P11012671A0576|50 68|Gadd45gamma promoter
P11012671A0576|50 68|Gadd45gamma promoter
P11012671A0576|74 82|C/EBPbeta
P11012671A0576|74 82|C/EBPbeta
P11012671A0576|86 95|C/EBPdelta
P11012671A0576|86 95|C/EBPdelta
P11012671A0576|121 153|electrophoretic mobility shift assay
P11012671A0576|155 158|EMSA
P11012671A0576|163 182|reporter gene analysis
P11012680A0676|0 2|Src
P11012680A0676|0 2|Src
P11012680A0676|22 25|FGF1
P11012680A0676|22 25|FGF1
P11012680A0676|41 49|SH2 domain
P11012680A0676|41 49|SH2 domain
P11012680A0676|52 54|Src
P11012680A0676|52 54|Src
P11012680A0676|58 60|PP2
P11012680A0676|58 60|PP2
P11012680A0676|82 84|Src
P11012680A0676|82 84|Src
P11012680A1020|11 35|PLCgamma inhibitory peptide
P11012680A1020|11 35|PLCgamma inhibitory peptide
P11012680A1020|37 44|neomycin
P11012680A1020|51 65|calcium chelator
P11012680A1020|66 73|BAPTA-AM
P11012680A1020|93 97|FGFR1
P11012680A1020|93 97|FGFR1
P11012680A1020|116 122|PDGF-BB
P11012680A1020|116 122|PDGF-BB
P11012680A1020|142 152|PDGFR-FGFR1
P11012680A1020|142 146|PDGFR
P11012680A1020|148 152|FGFR1
P11012680A1020|165 183|PLCgamma binding site
P11012680A1020|165 183|PLCgamma binding site
P11012680A1020|194 197|GVBD
P11012680A1020|201 204|ERK2
P11012680A1020|201 204|ERK2
P11013079A0927|8 30|transcription start sites
P11013079A0927|45 67|primer extension analysis
P11013079A0927|73 81|mouse gene
P11013079A0927|73 81|mouse gene
P11013079A0927|121 171|prospective promoter generated transcriptional activity
P11013079A0927|193 204|SV40 promoter
P11013079A0927|193 204|SV40 promoter
P11014197A0339|4 15|two inhibitor
P11014197A0339|16 24|scaffolds
P11014197A0339|51 69|selective inhibitors
P11014197A0339|106 116|subfamilies
P11014213A1019|46 66|hormone-binding domain
P11014213A1019|76 93|receptor activation
P11014213A1019|95 104|COS-1 cells
P11014213A1019|140 156|chimeric receptors
P11014213A1019|140 156|chimeric receptors
P11014213A1019|157 162|GAL-ER
P11014213A1019|157 162|GAL-ER
P11014213A1019|180 200|hormone-binding domain
P11014213A1019|203 209|ERalpha
P11014213A1019|203 209|ERalpha
P11014213A1019|216 232|DNA-binding domain
P11014213A1019|216 232|DNA-binding domain
P11014213A1019|238 256|transcription factor
P11014213A1019|257 260|GAL4
P11014213A1019|257 260|GAL4
P11014213A1019|266 295|GAL4-responsive CAT reporter gene
P11014213A1019|266 295|GAL4-responsive CAT reporter gene
P11014215A1092|13 23|5'-deletion
P11014215A1092|49 77|248-bp DNA fragment (-1018 to -771
P11014215A1092|92 111|translation start site
P11014215A1092|118 134|5'-flanking region
P11014215A1092|140 153|human GnRHR gene
P11014215A1092|140 153|human GnRHR gene
P11014215A1092|177 205|GnRHa-mediated down-regulation
P11014215A1092|208 233|human GnRHR promoter activity
P11014215A1092|208 225|human GnRHR promoter
P11014465A0479|23 50|periventricular echodensities
P11014465A0479|84 94|cystic PVL 21
P11014821T0000|3 21|LAMMER protein kinase
P11014821T0000|3 8|LAMMER
P11014821T0000|9 21|protein kinase
P11014821T0000|34 41|Doa locus
P11014821T0000|34 41|Doa locus
P11014821T0000|44 53|Drosophila
P11014821T0000|70 76|somatic
P11014821T0000|123 141|cytoplasmic isoforms
P11015197A0310|15 22|cysteine
P11015197A0310|67 69|TMS
P11015197A0310|71 73|TM4
P11016014A0181|0 9|HYPOTHESIS
P11016014A0181|72 109|apolipoprotein B-containing lipoproteins
P11016014A0181|86 109|B-containing lipoproteins
P11016014A0181|113 129|antioxidant status
P11016014A0181|132 139|patients
P11016014A0181|144 165|acute coronary syndromes
P11016014A0181|182 195|angina pectoris
P11016724A0536|10 12|MBq
P11016724A0536|15 23|150 microL
P11016724A0536|26 45|99mTc-HSA nanocolloid
P11016724A0536|91 97|surgery
P11016737A0275|55 70|functional status
P11016850A0423|9 19|DNA fragment
P11016850A0423|31 44|N-terminal part
P11016850A0423|94 130|LysR family of transcriptional regulators
P11016850A0423|94 103|LysR family
P11016850A0423|106 130|transcriptional regulators
P11016850A0423|132 136|LTTRs
P11016850A0423|132 136|LTTRs
P11016954A0438|0 3|AGO1
P11016954A0438|0 3|AGO1
P11016954A0438|15 19|QDE-2
P11016954A0438|15 19|QDE-2
P11016954A0438|31 38|quelling
P11016954A0438|42 46|RDE-1
P11016954A0438|42 46|RDE-1
P11016954A0438|58 61|RNAi
P11017876A0787|0 24|Intracellular localization
P11017876A0787|40 63|mDAP-3/EGFP fusion protein
P11017876A0787|40 45|mDAP-3
P11017876A0787|47 50|EGFP
P11017876A0787|65 81|cell fractionation
P11017876A0787|85 113|protease protection experiments
P11017876A0787|123 128|mDAP-3
P11017876A0787|123 128|mDAP-3
P11017876A0787|134 152|mitochondrial matrix
P11018028A0263|34 60|cAMP-dependent protein kinase
P11018028A0263|34 60|cAMP-dependent protein kinase
P11018028A0263|62 64|PKA
P11018028A0263|62 64|PKA
P11018028A0263|88 94|CDC25Mm
P11018028A0263|88 94|CDC25Mm
P11018028A0263|97 107|fibroblasts
P11018028A0263|126 131|RasGEF
P11018028A0263|126 131|RasGEF
P11018028A0263|142 151|mouse brain
P11018028A0263|152 172|synaptosomal membranes
P11018264A0397|0 29|Reporter gene expression analyses
P11018264A0397|46 58|WASP promoters
P11018264A0397|46 58|WASP promoters
P11018264A0397|96 117|hematopoietic cell lines
P11019257A0159|10 16|3T1-3T2
P11019257A0159|95 102|3T2 state
P11019257A0159|160 184|nontetrahedral distortions
P11020375A0134|20 36|Ross broiler chicks
P11020375A0134|98 100|CLI
P11020375A0134|107 114|(-1)diet
P11020375A0134|135 137|ppb
P11020375A0134|139 140|AF
P11020375A0134|147 148|AF
P11020375A0134|147 148|AF
P11020375A0134|153 155|CLI
P11020375A0134|163 164|AF
P11020375A0134|163 164|AF
P11020375A0134|172 173|AF
P11020375A0134|172 173|AF
P11020375A0134|178 180|CLI
P11023074A1105|3 13|cost per test
P11023074A1105|32 33|CC
P11023074A1105|35 38|kEIA
P11023074A1105|42 46|PACE2
P11023832A1038|36 44|KG1a cells
P11023832A1038|46 53|TNFalpha
P11023832A1038|46 53|TNFalpha
P11023832A1038|76 81|PC-PLC
P11023832A1038|76 81|PC-PLC
P11023832A1038|85 87|PLD
P11023832A1038|85 87|PLD
P11023832A1038|121 160|mitogen-activated protein kinase (MAP kinase
P11023832A1038|121 150|mitogen-activated protein kinase
P11023832A1038|152 160|MAP kinase
P11023832A1038|165 173|NF-kappaB
P11023832A1038|165 173|NF-kappaB
P11023853A0188|0 11|Concurrently
P11023853A0188|24 40|weather conditions
P11023853A0188|48 70|time-activity budget data
P11023853A0188|163 165|TAL
P11023853A0188|201 203|DEE
P11023853A0188|274 288|basal components
P11023934A0855|0 2|L/H
P11023934A0855|9 11|chi
P11023934A0855|45 58|filling pattern
P11023934A0855|60 62|chi
P11024026A0133|3 17|high selectivity
P11024026A0133|20 28|arrestins
P11024036A0984|19 29|fibroblasts
P11024036A0984|35 60|C/EBP alpha expression vector
P11024036A0984|35 44|C/EBP alpha
P11024036A0984|62 83|reporter gene expression
P11024036A0984|108 126|wild-type constructs
P11024036A0984|108 126|wild-type constructs
P11024047A0626|13 33|dominant negative Smad2
P11024047A0626|29 33|Smad2
P11024047A0626|64 89|luciferase reporter activity
P11024047A0626|64 81|luciferase reporter
P11024047A0626|99 112|nodal treatment
P11024182A0781|13 26|I) collagen mRNA
P11024182A0781|13 22|I) collagen
P11024182A0781|59 60|AR
P11024182A0781|59 60|AR
P11024182A0781|63 64|IR
P11024182A0781|63 64|IR
P11024182A0781|84 104|pHbetaAPr-1-neo vector
P11024182A0781|182 184|pCI
P11024182A0781|186 194|neo vector
P11024300A1579|10 16|828-830
P11024300A1579|25 42|amino acid sequences
P11024300A1579|45 60|peptide fragments
P11024300A1579|120 141|chromatin structure (ARC
P11024300A1579|139 141|ARC
P11024300A1579|177 192|open reading frame
P11024300A1579|195 203|TIG-1 mRNA
P11024300A1579|195 203|TIG-1 mRNA
P11025367A1009|15 35|plasma cholecystokinin
P11025367A1009|21 35|cholecystokinin
P11025367A1009|54 61|patients
P11025367A1009|73 87|gastric emptying
P11027027A0061|0 16|5 (Sunset Yellow FCF
P11027027A0061|37 61|liquid chromatography/mass
P11027027A0061|78 79|MS
P11027027A0061|85 106|electrospray ionization
P11027267A0752|0 7|Polysome
P11027267A0752|11 21|40S ribosome
P11027267A0752|11 13|40S
P11027267A0752|57 88|krr1 mutant and Kri1p-depleted cells
P11027267A0752|57 66|krr1 mutant
P11027267A0752|70 74|Kri1p
P11027274A1682|29 55|PI 3-kinase catalytic activity
P11027274A1682|29 38|PI 3-kinase
P11027274A1682|98 107|N-terminal
P11027280A0536|0 10|Cam kinase II
P11027280A0536|0 10|Cam kinase II
P11027280A0536|41 45|Smad2
P11027280A0536|41 45|Smad2
P11027280A0536|49 53|Smad4
P11027280A0536|49 53|Smad4
P11027280A0536|74 78|Smad3
P11027280A0536|74 78|Smad3
P11027289A0000|3 45|Drosophila melanogaster suppressor of sable gene
P11027289A0000|3 34|Drosophila melanogaster suppressor
P11027289A0000|37 48|sable gene, su
P11027289A0000|47 50|su(s
P11027289A0000|67 97|150-kDa nuclear RNA binding protein
P11027289A0000|67 97|150-kDa nuclear RNA binding protein
P11027289A0000|99 103|SU(S)
P11027289A0000|99 100|SU
P11027289A0000|102 102|S
P11027289A0000|128 142|RNA accumulation
P11027289A0000|207 223|transcribed region
P11027289A0321|26 44|arginine-rich motifs
P11027289A0321|46 49|ARM1
P11027289A0321|53 56|ARM2
P11027289A0321|72 89|RNA binding activity
P11027289A0321|92 96|SU(S)
P11027289A0321|92 93|SU
P11027289A0321|95 95|S
P11027294A0483|26 49|histone acetyltransferase
P11027294A0483|26 49|histone acetyltransferase
P11027294A0483|60 63|p300
P11027294A0483|60 63|p300
P11027294A0483|94 104|nucleosomal
P11027294A0483|138 155|chromatin structure
P11027724A0335|0 17|Recombinant BRI1-KD
P11027724A0335|0 14|Recombinant BRI1
P11027724A0335|38 43|serine
P11027724A0335|45 47|Ser
P11027724A0335|52 60|threonine
P11027724A0335|62 73|Thr) residues
P11027724A0335|80 95|Ser predominating
P11027833A0362|0 11|Flow cytomery
P11027833A0362|22 38|cell cycle analysis
P11028131A1374|71 72|MS
P11028131A1374|109 118|IFN beta-1b
P11028131A1374|109 118|IFN beta-1b
P11028131A1374|121 124|RRMS
P11028131T0000|20 36|interferon beta-1b
P11028131T0000|20 36|interferon beta-1b
P11028131T0000|46 83|multiple sclerosis disability progression
P11029045A0000|0 14|Hyperactivation
P11029045A0000|17 20|Cdc2
P11029045A0000|17 20|Cdc2
P11029045A0000|30 34|yeast
P11029045A0000|84 101|mitotic catastrophe
P11029262T0000|0 4|Diary
P11029458A0000|37 56|extracellular stimuli
P11029459A0000|0 29|Transforming growth factor-beta1
P11029459A0000|0 29|Transforming growth factor-beta1
P11029459A0000|31 39|TGF-beta1
P11029459A0000|31 39|TGF-beta1
P11029459A0000|50 64|tumor suppressor
P11029459A0000|68 80|tumor promoter
P11029459A0000|115 127|malignant cell
P11029467T0000|0 26|Vasoactive intestinal peptide
P11029467T0000|10 38|intestinal peptide and pituitary
P11029467T0000|30 76|pituitary adenylate cyclase-activating polypeptide
P11029467T0000|39 76|adenylate cyclase-activating polypeptide
P11029467T0000|84 127|nuclear factor-kappa B-dependent gene activation
P11029467T0000|84 117|nuclear factor-kappa B-dependent gene
P11029467T0000|149 170|human monocytic cell line
P11029467T0000|171 175|THP-1
P11029656A0640|20 34|junction binding
P11029656A0640|38 55|cleaving activities
P11029656A0640|61 74|mutant proteins
P11029656A0640|61 74|mutant proteins
P11029700A0295|5 13|Pt;cycH;1
P11029700A0295|8 25|cycH;1 and Os;cycH;1
P11029700A0295|17 25|Os;cycH;1
P11029700A0295|41 50|all tissues
P11029700A0295|97 109|dividing cells
P11029700A0746|11 31|in vitro pull-down assay
P11029700A0746|42 50|Os;CycH;1
P11029700A0746|42 43|Os
P11029700A0746|85 92|rice CDKs
P11029700A0746|85 92|rice CDKs
P11029704A0378|2 18|transient analysis
P11029704A0378|45 63|tobacco leaf sections
P11029704A0378|79 87|distB ABRE
P11029704A0378|79 87|distB ABRE
P11029704A0378|89 142|abscisic acid-responsive element) mediated transactivation
P11029704A0378|89 118|abscisic acid-responsive element
P11029704A0378|145 148|ABI3
P11029704A0378|145 148|ABI3
P11029704A0378|152 173|ABI3-dependent response
P11029704A0378|152 155|ABI3
P11029704A0378|176 178|ABA
P11029704A0378|201 220|composite RY/G complex
P11029704A0378|232 240|RY repeats
P11029704A0378|245 249|G-box
P11029704A0378|245 249|G-box
P11029704A0378|263 292|ABA-independent transactivation
P11029704A0378|295 298|ABI3
P11029704A0378|295 298|ABI3
P11030066A0142|3 33|major neurological manifestations
P11030066A0142|36 46|brain injury
P11030066A0142|54 59|babies
P11030066A0142|63 82|spastic motor deficits
P11030476A0685|0 5|Spores
P11030476A0685|10 27|Rhizopus stolonifer
P11030476A0685|43 56|distilled water
P11030744A0763|16 21|Trdpm1
P11030744A0763|16 21|Trdpm1
P11030744A0763|25 31|dpm1(+)
P11030744A0763|25 30|dpm1(+
P11030744A0763|34 44|his7/dpm1(+
P11030744A0763|39 45|dpm1(+)
P11030744A0763|46 52|S.pombe
P11030744A0763|53 59|diploid
P11030744A0763|95 113|DPM synthase activity
P11030744A0763|95 105|DPM synthase
P11031252A0646|3 10|LMW FGF-2
P11031252A0646|3 5|LMW
P11031252A0646|6 10|FGF-2
P11031252A0646|26 41|PKC epsilon levels
P11031252A0646|26 35|PKC epsilon
P11031252A0646|66 75|HMW isoform
P11031252A0646|66 75|HMW isoform
P11031252A0646|104 113|PKC isotype
P11031252A0646|104 113|PKC isotype
P11031252A0646|150 157|PKC delta
P11031252A0646|150 157|PKC delta
P11031366T0001|0 17|Helicobacter pylori
P11031366T0001|21 35|stomach diseases
P11031773A0174|18 29|writhing test
P11031773A0174|31 39|capsaicin
P11031773A0174|43 62|formalin induced-pain
P11031773A0174|65 68|mice
P11032599T0000|4 9|update
P11032599T0000|38 75|hematopoietic colony-stimulating factors
P11032599T0000|38 75|hematopoietic colony-stimulating factors
P11032677A0230|21 39|chronic pancreatitis
P11032677A0230|44 49|acinar
P11032677A0230|53 63|ductal plugs
P11032677A0230|65 114|granulomatous and necrotizing peripancreatic steatitis
P11032677A0230|137 153|testicular atrophy
P11032677A0230|155 165|candidiasis
P11032677A0230|169 197|bacterial necrotizing glossitis
P11034392A1072|33 56|multiple survival pathways
P11034392A1072|92 104|NF-kappaB/Rel
P11034392A1072|92 100|NF-kappaB
P11034392A1072|102 104|Rel
P11034392A1072|108 112|PI-3K
P11034392A1072|108 112|PI-3K
P11034392A1072|126 150|CD40-induced proliferation
P11034392A1072|126 129|CD40
P11034547A0674|8 11|Arix
P11034547A0674|15 20|NBPhox
P11034547A0674|15 20|NBPhox
P11034547A0674|82 101|DB1 regulatory element
P11034547A0674|82 101|DB1 regulatory element
P11034547A0674|119 145|homeodomain recognition sites
P11034547A0674|119 145|homeodomain recognition sites
P11034547A1355|27 30|Arix
P11034547A1355|27 30|Arix
P11034547A1355|34 39|NBPhox
P11034547A1355|34 39|NBPhox
P11034547A1355|67 112|independent transcriptional regulatory properties
P11034547A1355|118 128|DBH promoter
P11034547A1355|118 128|DBH promoter
P11034933A0389|50 64|guinea pig hearts
P11034933A0389|149 159|domperidone
P11035037A0183|3 24|N-terminal small segment
P11035037A0183|27 37|yeast TAF145
P11035037A0183|27 37|yeast TAF145
P11035037A0183|39 45|yTAF145
P11035037A0183|39 45|yTAF145
P11035037A0183|54 56|TBP
P11035037A0183|54 56|TBP
P11035037A0183|75 85|TBP function
P11035037A0183|75 77|TBP
P11035867A0000|47 84|oscillometric wrist blood pressure monitor
P11035867A0000|86 105|Braun PrecisionSensor
P11035867A0000|107 115|Braun GmbH
P11035867A0000|148 160|ANSI/AAMI SP10
P11035867A0000|225 233|algorithm
P11036786A0628|21 44|toxicological experiments
P11036938A1162|12 33|hypothalamic expression
P11036938A1162|51 63|erbB receptors
P11036938A1162|51 63|erbB receptors
P11036938A1162|106 128|gonadal steroid secretion
P11036938A1162|180 192|gonadotropins
P11036938A1162|180 192|gonadotropins
P11036939A2149|0 2|Dsh
P11036939A2149|0 2|Dsh
P11036939A2149|40 49|Wnt pathway
P11036939A2149|40 42|Wnt
P11036939A2149|76 85|Drosophila
P11037759T0000|0 13|Catch-up growth
P11037759T0000|17 38|craniofacial dimensions
P11037759T0000|67 85|antineoplastic agent
P11037759T0000|86 96|vincristine
P11037759T0000|99 107|young rats
P11037823A1134|12 27|LSCC malformation
P11037823A1134|38 58|inner ear malformations
P11037823A1134|65 87|large vestibular aqueduct
P11037823A1134|91 111|X-linked mixed deafness
P11037823A1134|116 130|perilymph gusher
P11037823A1134|151 153|CHL
P11037823A1134|155 158|SNHL
P11037823A1134|162 174|normal hearing
P11038042A0948|0 9|Escalation
P11038042A0948|39 62|white blood cell nadir count
P11038118A0000|0 12|Methyl formate
P11038118A0000|105 126|bovine serum albumin (BSA
P11038118A0000|105 122|bovine serum albumin
P11038118A0000|124 126|BSA
P11038317A0000|3 35|small monomeric GTP-binding proteins
P11038317A0000|17 35|GTP-binding proteins
P11038317A0000|41 52|RAB subfamily
P11038317A0000|41 52|RAB subfamily
P11038317A0000|59 76|regulatory elements
P11038317A0000|120 134|eukaryotic cells
P11038366A1322|18 28|methylation
P11038366A1322|70 87|yeast B-type subunit
P11038366A1322|70 75|yeast B
P11038366A1322|89 93|Rts1p
P11038366A1322|89 93|Rts1p
P11038366A1417|5 15|methylation
P11038366A1417|18 23|Pph21p
P11038366A1417|18 23|Pph21p
P11038366A1417|49 60|PP2A trimeric
P11038366A1417|49 52|PP2A
P11038366A1417|64 79|dimeric complexes
P11038366A1417|100 103|PP2A
P11038366A1417|100 103|PP2A
P11039341A0180|65 78|spatial mapping
P11039341A0180|143 160|finger-tapping task
P11039780A0770|82 95|osteoarthritis
P11039780A0770|101 111|gene therapy
P11039780A0770|171 181|gene therapy
P11039780A0770|184 206|osteoarthritis treatment
P11039780A0770|212 217|future
P11040101A1180|33 40|IL-1 beta
P11040101A1180|33 40|IL-1 beta
P11040101A1180|48 65|VEGF gene expression
P11040101A1180|48 55|VEGF gene
P11040101A1180|72 115|transcriptional and post-transcriptional levels
P11040101A1180|120 127|IL-1 beta
P11040101A1180|120 127|IL-1 beta
P11040101A1180|134 140|p38 MAPK
P11040101A1180|134 136|p38
P11040101A1180|137 140|MAPK
P11040101A1180|144 156|JNK signalings
P11040101A1180|144 146|JNK
P11040101A1180|199 206|VEGF gene
P11040101A1180|199 206|VEGF gene
P11040101A1180|214 229|Sp1-binding sites
P11040101A1180|214 229|Sp1-binding sites
P11040219A0548|9 12|NusA
P11040219A0548|9 12|NusA
P11040219A0548|33 37|alpha
P11040219A0548|51 80|amino-terminal S1 homology region
P11040219A0548|106 120|full-length NusA
P11040219A0548|106 120|full-length NusA
P11041308A0156|36 38|DSM
P11041308A0156|101 128|South Oaks Gambling Screen (SOGS
P11042197A0386|0 6|Lys(193
P11042197A0386|11 13|Arg
P11042197A0386|32 47|COOH-terminal end
P11042197A0386|50 51|HD
P11042197A0386|50 51|HD
P11042199A0572|24 35|Ca(2+) levels
P11042199A0572|71 96|receptor-associated protein
P11042199A0572|71 96|receptor-associated protein
P11042199A0572|109 113|MK801
P11042199A0572|124 128|Ca(2+
P11042199A0572|124 128|Ca(2+
P11042199A0572|137 155|medium and dantrolene
P11042199A0572|174 189|calcium elevation
P11042199A0572|217 220|CREB
P11042199A0572|217 220|CREB
P11042204A0186|24 51|phosphatidylinositol 3-kinase
P11042204A0186|24 51|phosphatidylinositol 3-kinase
P11042204A0186|62 80|p38 kinase activation
P11042204A0186|62 70|p38 kinase
P11042204A0186|90 107|Akt phosphorylation
P11042204A0186|90 92|Akt
P11042204A0186|121 136|human neutrophils
P11042703A0875|4 7|BFDS
P11042703A0875|31 40|W/A Z scores
P11042703A0875|100 103|boys
P11043469A0440|64 72|T-regions
P11043469A0440|64 72|T-regions
P11043469A0440|89 96|T-region
P11043469A0440|99 106|pTiChry5
P11043469A0440|114 123|T-right (TR
P11043469A0440|114 114|T
P11043469A0440|122 123|TR
P11043469A0440|152 164|Amadoriopines
P11044097A0422|13 27|recombinant HMG I
P11044097A0422|24 27|HMG I
P11044097A0422|52 76|high-affinity binding sites
P11044097A0422|98 116|transcription factor
P11044097A0422|117 128|binding sites
P11044097T0000|0 25|High-mobility-group protein
P11044097T0000|26 26|I
P11044097T0000|47 66|transcription factors
P11044097T0000|72 79|U5 region
P11044097T0000|72 79|U5 region
P11044097T0000|85 131|human immunodeficiency virus type 1 proviral promoter
P11044097T0000|85 131|human immunodeficiency virus type 1 proviral promoter
P11044105A0616|7 23|cis-acting element
P11044105A0616|25 54|exonic splicing suppressor 1 (ESS1
P11044105A0616|74 79|nt 3225
P11044105A0616|80 91|3' splice site
P11045180A1892|0 10|Leptinaemia
P11045180A1892|80 91|hypertension
P11045607A0239|0 6|5'-RACE
P11045607A0239|31 70|transcription initiation site 187 bp upstream
P11046146A1202|5 11|diamide
P11046146A1202|23 37|nuclear extracts
P11046146A1202|65 75|NFI proteins
P11046146A1202|65 75|NFI proteins
P11046146A1202|115 128|dithiothreitol
P11046146A1202|131 145|nuclear extracts
P11046146A1202|150 164|TG-treated cells
P11046146A1202|173 186|NFI-DNA binding
P11046146A1202|173 179|NFI-DNA
P11046146A1202|209 222|untreated cells
P11046148A0716|0 4|LMP2A
P11046148A0716|0 4|LMP2A
P11046148A0716|13 15|Lyn
P11046148A0716|13 15|Lyn
P11046148A0716|19 21|Syk
P11046148A0716|19 21|Syk
P11046148A0716|78 95|Nedd4 family members
P11046148A0716|78 82|Nedd4
P11046148A0716|113 127|destabilization
P11046148A0716|133 149|Lyn tyrosine kinase
P11046148A0716|133 149|Lyn tyrosine kinase
P11046153A1052|8 28|Tax-mediated apoptosis
P11046153A1052|8 10|Tax
P11046153A1052|76 90|p300 coactivator
P11046153A1052|76 90|p300 coactivator
P11046517A0619|34 34|Z
P11046517A0619|34 34|Z
P11046517A0619|51 51|Z
P11048832A0271|0 5|Fisher
P11048832A0271|19 25|Pearson
P11048832A0271|47 65|statistical analysis
P11049241A0659|13 25|pregnant group
P11049241A0659|27 35|serum PP14
P11049241A0659|32 35|PP14
P11049241A0659|76 77|ET
P11049241A0659|114 126|pregnant group
P11049241A0659|133 148|nonpregnant group
P11049241A0659|174 175|ET
P11049889A1271|0 18|Thromboelastography
P11049889A1271|113 119|heparin
P11050084A0000|0 13|High expression
P11050084A0000|19 63|peroxisome proliferator-activated receptor alpha
P11050084A0000|19 63|peroxisome proliferator-activated receptor alpha
P11050084A0000|65 73|PPARalpha
P11050084A0000|65 73|PPARalpha
P11050084A0000|89 96|brown fat
P11050084A0000|101 105|white
P11050084A0000|138 151|lipid oxidation
P11050084A0888|27 35|PPARalpha
P11050084A0888|27 35|PPARalpha
P11050084A0888|39 47|PPARgamma
P11050084A0888|39 47|PPARgamma
P11050084A0888|52 59|brown fat
P11050084A0888|60 65|nuclei
P11050168A1185|64 93|endonuclease-mediated mRNA decay
P11050168A1185|133 150|RNA-binding protein
P11050168A1185|133 150|RNA-binding protein
P11050168A1185|154 184|cis-acting stability determinants
P11051364A0890|23 30|patients
P11051364A0890|34 36|PHG
P11051364A0890|44 49|group A
P11051364A0890|57 58|74
P11051364A0890|70 72|PHG
P11051364A0890|86 96|eradication
P11051364A0890|98 103|group B
P11051370A1906|26 41|African Americans
P11053009A0000|0 6|Aspirin
P11053009A0000|48 75|gastric mucosal cyclooxygenase
P11053009A0000|48 54|gastric
P11053009A0000|62 75|cyclooxygenase
P11053009A0000|77 88|COX) activity
P11053009A0000|77 79|COX
P11053009A0000|92 104|prostaglandin
P11053370A0708|13 25|hybrid protein
P11053370A0708|39 63|cytoplasmic C-terminal half
P11053370A0708|66 69|UhpB
P11053370A0708|66 69|UhpB
P11053370A0708|77 104|glutathione S-transferase (GST
P11053370A0708|77 100|glutathione S-transferase
P11053370A0708|102 104|GST
P11053370A0708|124 135|Uhp signaling
P11053370A0708|124 126|Uhp
P11054011A1685|15 22|surgical
P11054011A1685|25 37|multimodality
P11054011A1685|49 52|MSGT
P11054011A1685|125 132|patients
P11054011A1685|145 162|oncology department
P11054341A0599|16 23|suspects
P11054341A0599|64 67|SWAP
P11054341A0599|76 83|high risk
P11054341A0599|89 105|SWAP abnormalities
P11054341A0599|110 117|low risk (
P11054539A0114|26 30|exons
P11054539A0114|38 49|short introns
P11054539A0114|57 72|open reading frame
P11054539A0114|83 95|6660 base pairs
P11054539A0114|97 98|bp
P11054539A0114|131 134|2220
P11054539A0114|135 151|amino acid residues
P11054565A0654|7 16|p190-B exon
P11054565A0654|7 12|p190-B
P11054565A0654|32 37|p190-A
P11054565A0654|32 37|p190-A
P11054565A0654|85 90|GTPase
P11054565A0654|85 90|GTPase
P11054565A0654|94 106|middle domains
P11054565A0654|108 121|residues 1-1228
P11054565A0654|142 150|GAP domain
P11054565A0654|142 150|GAP domain
P11054565A0654|207 215|p190 genes
P11054565A0654|207 215|p190 genes
P11054571A0230|9 33|human teneurin-1 (TEN1) gene
P11054571A0230|9 23|human teneurin-1
P11054571A0230|25 28|TEN1
P11054571A0230|52 60|PAC clones
P11054571A0230|82 101|chromosomal locus Xq25
P11054970A0282|3 23|plexiform neurofibroma
P11054970A0282|76 78|NF1
P11054970A0282|76 78|NF1
P11055513A0564|2 16|general lookback
P11055513A0564|21 28|patients
P11055513A0564|40 44|blood
P11055513A0564|65 74|hepatitis C
P11056007A0224|16 30|extra amino acids
P11056007A0224|33 39|FVVLNLQ
P11056007A0224|59 63|extra
P11056007A0224|87 89|Gln
P11056007A0224|91 100|421) and Phe
P11056007A0224|115 117|SET
P11056007A0224|115 117|SET
P11056007A0224|119 126|Suvar3-9
P11056007A0224|119 126|Suvar3-9
P11056007A0224|128 144|Enhancer-of-zeste
P11056007A0224|128 144|Enhancer-of-zeste
P11056007A0224|146 176|Trithorax) interacting domain (SID
P11056007A0224|146 154|Trithorax
P11056007A0224|180 183|rMTM
P11056007A0224|180 183|rMTM
P11056019A0926|0 3|MED1
P11056019A0926|0 3|MED1
P11056019A0926|12 30|glycosylase activity
P11056019A0926|12 22|glycosylase
P11056019A0926|36 71|mutagenic adduct 3,N(4)-ethenocytosine
P11056019A0926|53 55|N(4
P11056019A0926|86 98|vinyl chloride
P11056019A0926|102 115|ethyl carbamate
P11058008A0159|22 38|major flap necrosis
P11058119A0957|23 26|XAB1
P11058119A0957|23 26|XAB1
P11058119A0957|35 51|cytoplasmic GTPase
P11058119A0957|35 51|cytoplasmic GTPase
P11058119A0957|62 80|nuclear localization
P11058119A0957|83 85|XPA
P11058119A0957|83 85|XPA
P11058120A0256|18 22|IRF-2
P11058120A0256|18 22|IRF-2
P11058120A0256|71 75|IRF-1
P11058120A0256|71 75|IRF-1
P11058120A0256|80 97|oncogenic potential
P11058132A0264|13 16|CDSs
P11058132A0264|57 72|Bacillus subtilis
P11058132A0264|154 154|B
P11058406A0447|0 19|Tobramycin-loaded SLN
P11058406A0447|34 35|v.
P11058406A0447|82 82|v
P11059492A0376|0 8|Bacteriol
P11059777A0813|0 34|Terminal deoxynucleotidyl transferase
P11059777A0813|8 64|deoxynucleotidyl transferase-mediated nick end labeling assays
P11059777A0813|77 94|hormonal activation
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|130 138|apoptosis
P11059777A0813|174 181|BCL-X(L)
P11059777A0813|174 178|BCL-X
P11059777A0813|180 180|L
P11059786A0682|0 19|VEGF promoter activity
P11059786A0682|0 11|VEGF promoter
P11059786A0682|22 43|transient transfections
P11059786A0682|100 103|EGFR
P11059786A0682|100 103|EGFR
P11059786A0682|105 107|Ras
P11059786A0682|105 107|Ras
P11059786A0682|111 139|phosphatidylinositol 3'-kinase
P11059786A0682|111 139|phosphatidylinositol 3'-kinase
P11059786A0682|141 151|PI(3) kinase
P11059786A0682|141 151|PI(3) kinase
P11059786T0000|0 28|Epidermal growth factor receptor
P11059786T0000|9 28|growth factor receptor
P11059786T0000|58 98|vascular endothelial growth factor expression
P11059786T0000|58 88|vascular endothelial growth factor
P11059786T0000|101 122|human glioblastoma cells
P11059786T0000|143 171|phosphatidylinositol 3'-kinase
P11059786T0000|143 171|phosphatidylinositol 3'-kinase
P11059786T0000|200 206|hypoxia
P11062047A1208|5 9|IHHNV
P11062047A1208|45 64|genus Brevidensovirus
P11062047A1208|157 162|PstDNV
P11062067A0000|0 35|Stress-activated protein kinase 1 (SAPK1
P11062067A0000|0 29|Stress-activated protein kinase 1
P11062067A0000|31 35|SAPK1
P11062067A0000|48 68|c-Jun N-terminal kinase
P11062067A0000|48 68|c-Jun N-terminal kinase
P11062067A0000|70 72|JNK
P11062067A0000|70 72|JNK
P11062067A0000|109 133|pro-inflammatory cytokines
P11062067A0000|136 151|cellular stresses
P11062068T0000|0 18|Catalytic activation
P11062068T0000|21 68|mitogen-activated protein (MAP) kinase phosphatase-1
P11062068T0000|21 44|mitogen-activated protein
P11062068T0000|46 68|MAP) kinase phosphatase-1
P11062068T0000|80 91|p38 MAP kinase
P11062068T0000|80 91|p38 MAP kinase
P11062068T0000|110 128|p38 C-terminal domain
P11062068T0000|110 112|p38
P11062068T0000|113 128|C-terminal domain
P11062068T0000|134 151|negative regulation
P11062257A0977|8 24|class C-Vps complex
P11062257A0977|8 13|class C
P11062257A0977|15 17|Vps
P11062257A0977|32 48|multiple reactions
P11062274T0000|8 18|intravenous
P11062274T0000|22 26|intra
P11062274T0000|47 72|tissue plasminogen activator
P11062274T0000|53 72|plasminogen activator
P11062274T0000|75 93|acute ischemic stroke
P11062705A0658|43 47|ATF-2
P11062705A0658|43 47|ATF-2
P11062705A0658|51 69|human cancer cell line
P11063127A0000|0 17|Signal transduction
P11063127A0000|33 47|phosphorylation
P11063127A0000|74 96|protein phosphatase (PP) 1
P11063127A0000|74 91|protein phosphatase
P11063127A0000|93 94|PP
P11063127A0000|103 106|PP2A
P11063127A0000|103 106|PP2A
P11063127A0000|127 157|okadaic acid (OA)-mediated effects
P11063169T0000|0 14|Botulinum toxin A
P11063169T0000|0 14|Botulinum toxin A
P11063169T0000|31 47|hemiplegic spastic
P11063252A0437|0 3|Exon
P11063252A0437|37 59|HSL translation start site
P11063252A0437|37 59|HSL translation start site
P11063742A0000|0 8|NF-kappaB
P11063742A0000|0 8|NF-kappaB
P11063742A0000|12 45|redox-sensitive transcription factor
P11063742A0000|12 45|redox-sensitive transcription factor
P11063742A0000|66 80|oxidative stress
P11063742A0000|89 119|chemical and biological reductants
P11064829T0058|0 24|Cardiovascular risk factors
P11064829T0058|28 52|antihypertensive treatment
P11066245T0000|59 62|SNFs
P11067797A1306|61 99|intramyocardial microcirculatory function
P11067797A1306|122 134|microvascular
P11067797A1306|135 148|BV distribution
P11067928A0532|25 26|H)
P11067928A0532|25 25|H
P11067928A0532|30 45|J(H) gene segments
P11067928A0532|30 30|J
P11067928A0532|32 32|H
P11067928A0532|59 59|D
P11067928A0532|61 66|Vkappa
P11067928A0532|71 81|Jkappa genes
P11067928A0532|71 76|Jkappa
P11069011A0224|0 13|SSF experiments
P11069011A0224|30 60|bench-scale bioreactors (equipped
P11069011A0224|65 67|CO2
P11069011A0224|71 90|volatile organic traps
P11069011A0224|112 135|lignocellulosic materials
P11069011A0224|140 160|radiolabeled pesticide
P11069075T0000|19 52|Xenopus laevis CXC chemokine receptor 4
P11069075T0000|19 31|Xenopus laevis
P11069075T0000|32 51|CXC chemokine receptor
P11069075T0000|69 96|hematopoietic cell development
P11069075T0000|112 117|embryo
P11069223A0593|0 7|Patients
P11069223A0593|25 29|liver
P11069223A0593|31 54|renal, and marrow functions
P11069307A0546|12 15|RNA2
P11069307A0546|12 15|RNA2
P11069307A0546|16 26|translation
P11069307A0546|95 128|BMV RNA1-encoded replication factor 1a
P11069307A0546|98 128|RNA1-encoded replication factor 1a
P11069307A0546|149 151|p20
P11069307A0546|149 151|p20
P11069307A0546|174 177|DED1
P11069307A0546|174 177|DED1
P11069756A2618|0 12|Abbreviations
P11069756A2618|14 16|CAS
P11069756A2618|14 16|CAS
P11069756A2618|18 40|CRK-associated substrate
P11069756A2618|18 40|CRK-associated substrate
P11069756A2618|42 43|CH
P11069756A2618|42 43|CH
P11069756A2618|45 67|calponin-homology domain
P11069756A2618|45 67|calponin-homology domain
P11069756A2618|69 71|CSK
P11069756A2618|73 91|C-terminal SRC kinase
P11069756A2618|73 91|C-terminal SRC kinase
P11069756A2618|93 94|E6
P11069756A2618|93 94|E6
P11069756A2618|96 118|Papillomavirus E6 protein
P11069756A2618|96 118|Papillomavirus E6 protein
P11069756A2618|120 122|FAK
P11069756A2618|120 122|FAK
P11069756A2618|124 142|focal adhesion kinase
P11069756A2618|124 142|focal adhesion kinase
P11069756A2618|144 146|GIT
P11069756A2618|148 160|GRK interacter
P11069756A2618|148 150|GRK
P11069756A2618|162 165|GPCR
P11069756A2618|167 206|heterotrimeric-G-protein-coupled receptor
P11069756A2618|167 206|heterotrimeric-G-protein-coupled receptor
P11069756A2618|208 210|GRK
P11069756A2618|208 210|GRK
P11069756A2618|212 243|G-protein-coupled-receptor kinase
P11069756A2618|212 243|G-protein-coupled-receptor kinase
P11069756A2618|245 248|MAPK
P11069756A2618|245 248|MAPK
P11069756A2618|250 279|mitogen-activated protein kinase
P11069756A2618|250 279|mitogen-activated protein kinase
P11069756A2618|281 283|ERK
P11069756A2618|281 283|ERK
P11069756A2618|285 287|p38
P11069756A2618|285 287|p38
P11069756A2618|289 291|JNK
P11069756A2618|289 291|JNK
P11069756A2618|294 296|PAK
P11069756A2618|294 296|PAK
P11069756A2618|298 316|p21-activated kinase
P11069756A2618|298 316|p21-activated kinase
P11069756A2618|318 320|PBS
P11069756A2618|322 346|paxillin-binding subdomain
P11069756A2618|322 346|paxillin-binding subdomain
P11069756A2618|348 350|PIX
P11069756A2618|352 380|PAK-interacting exchange factor
P11069756A2618|352 380|PAK-interacting exchange factor
P11069756A2618|382 384|PKL
P11069756A2618|386 405|paxillin kinase linker
P11069756A2618|386 399|paxillin kinase
P11069756A2618|407 410|POR1
P11069756A2618|407 410|POR1
P11069756A2618|421 423|Rac
P11069756A2618|421 423|Rac
P11069756A2618|425 426|PS
P11069756A2618|425 426|PS
P11069756A2618|428 440|phosphoserine
P11069756A2618|465 479|phosphotyrosine
P11069756A2618|481 483|RTK
P11069756A2618|485 518|growth factor receptor tyrosine kinase
P11069756A2618|485 518|growth factor receptor tyrosine kinase
P11069756A2618|520 521|SH
P11069756A2618|520 521|SH
P11069756A2618|523 540|SRC-homology domain
P11069756A2618|523 540|SRC-homology domain
P11069788A0531|25 26|SB
P11069788A0531|47 54|patients
P11069788A0531|126 132|cm H(2)O
P11069788A0531|151 154|PEEP
P11069788A0531|175 181|cm H(2)O
P11069791A0226|5 20|eligible subjects
P11069791A0226|32 44|supervised IPT
P11069791A0226|77 84|Regimen A
P11069791A0226|135 142|Regimen B
P11069791A0226|170 175|IPT 300
P11069791A0226|190 197|Regimen C
P11069825A0530|19 30|tuberculosis
P11069897A1112|25 30|BACH1t
P11069897A1112|25 30|BACH1t
P11069897A1112|39 43|BACH1
P11069897A1112|39 43|BACH1
P11069897A1112|49 55|nucleus
P11069897A1112|63 91|BTB domain-mediated interaction
P11069897A1112|63 65|BTB
P11069999A1602|3 9|U17/U16
P11069999A1602|3 5|U17
P11069999A1602|7 9|U16
P11069999A1602|16 31|U16+ gene products
P11069999A1602|16 23|U16+ gene
P11069999A1602|49 54|HIV LTR
P11069999A1602|49 54|HIV LTR
P11070007A0136|0 12|Transcription
P11070007A0136|21 29|EBNA genes
P11070007A0136|21 29|EBNA genes
P11070007A0136|50 78|EBV-immortalized primary B cells
P11070007A0136|98 106|promoters
P11070007A0136|108 109|Cp
P11070007A0136|108 109|Cp
P11070007A0136|113 114|Wp
P11070007A0136|113 114|Wp
P11070007A0136|130 133|left
P11070007A0136|142 152|viral genome
P11070056A0704|3 17|Cili-2 sequences
P11070056A0704|40 51|RNaseH domain
P11070056A0704|40 51|RNaseH domain
P11070056A0704|54 61|Lian-Aa1
P11070056A0704|54 57|Lian
P11070056A0704|59 61|Aa1
P11070056A0704|72 93|non-LTR retrotransposon
P11070078A1153|42 72|p53 and Rb tumor suppressor pathways
P11070078A1153|42 44|p53
P11070078A1153|48 49|Rb
P11070078A1153|84 92|HeLa cells
P11070078A1153|112 116|HPV E6
P11070078A1153|112 114|HPV
P11070078A1153|115 116|E6
P11070078A1153|120 121|E7
P11070078A1153|120 121|E7
P11070078A1153|171 193|growth inhibitory signals
P11071651A1308|16 39|RARalpha-specific pathway
P11071651A1308|16 23|RARalpha
P11071651A1308|42 72|retinoid-induced differentiation
P11071651A1308|92 108|retinoid induction
P11071651A1308|111 127|FR-beta expression
P11071651A1308|111 117|FR-beta
P11071789T0000|30 42|ACE inhibitors
P11071789T0000|30 32|ACE
P11071789T0000|45 63|chronic heart failure
P11071852A0297|18 23|SOCS-3
P11071852A0297|18 23|SOCS-3
P11071852A0297|38 42|IGFIR
P11071852A0297|38 42|IGFIR
P11071852A0297|57 62|SOCS-3
P11071852A0297|57 62|SOCS-3
P11071852A0297|65 108|reverse transcription-polymerase chain reaction
P11071852A0297|65 100|reverse transcription-polymerase chain
P11071852A0297|113 131|human skeletal muscle
P11071852A0297|132 135|mRNA
P11071924A0588|18 40|SH2 and RING finger domains
P11071924A0588|18 20|SH2
P11071924A0588|24 40|RING finger domains
P11071924A0588|59 73|chimeric protein
P11071924A0588|59 73|chimeric protein
P11071924A0588|81 83|SH2
P11071924A0588|81 83|SH2
P11071924A0588|87 103|RING finger domains
P11071924A0588|87 103|RING finger domains
P11071924A0588|106 110|SLI-1
P11071924A0588|106 110|SLI-1
P11071924A0588|143 147|c-Cbl
P11071924A0588|143 147|c-Cbl
P11071974A0155|22 24|HRT
P11071974A0155|50 61|renal disease
P11071974A0155|63 66|ESRD
P11071974A0155|68 75|patients
P11071974A0155|100 111|lipid profile
P11071974A0155|113 123|coagulation
P11071974A0155|127 145|fibrinolysis markers
P11071974A0155|156 167|homocysteine
P11072155A0764|42 55|TGF beta 1 levels
P11072155A0764|42 49|TGF beta 1
P11072155A0764|96 98|SF2
P11072388T0000|0 4|Acute
P11072388T0000|55 61|smokers
P11072388T0000|66 78|schizophrenia
P11073163A0131|14 35|proteasomal degradation
P11073163A0131|57 72|cell cycle control
P11073163A0131|90 99|proteasome
P11073163A0131|113 129|cell proliferation
P11073163A0131|133 144|cell survival
P11073218A0800|63 83|adjacent helical region
P11073539A0866|23 34|mutant desmin
P11073539A0866|23 34|mutant desmin
P11073539A0866|37 51|SW13 (vim-) cells
P11073539A0866|42 44|vim
P11073539A0866|71 90|abnormal coarse clumps
P11073539A0866|93 123|desmin positive material dispersed
P11073539A0866|93 98|desmin
P11073539A0866|137 145|cytoplasm
P11073870A0375|0 7|Patients
P11073870A0375|31 33|PRC
P11073870A0375|31 33|PRC
P11073870A0375|47 49|PHC
P11073870A0375|54 61|patients
P11073870A0375|86 88|PRC
P11073870A0375|86 88|PRC
P11073870A0375|92 94|PHC
P11073870A0375|92 94|PHC
P11073870A0375|140 152|unpredictably
P11073919A0631|13 29|amino acid residues
P11073919A0631|31 151|K69, D88, E94, D134, R154, K169, H197, D233, G235, G236, G237, F238, E274, G276, R277, Y278, K294, Y323, Y331, D332, C360, D361, D364, G387, Y389
P11073919A0631|156 159|F397
P11073919A0631|161 177|mouse ODC numbering
P11073919A0631|166 168|ODC
P11073919A0631|222 253|pyridoxal phosphate-binding domain
P11073919A0631|231 253|phosphate-binding domain
P11073919A0631|260 282|substrate-binding domain
P11073919A0631|313 326|eukaryotic ODCs
P11073919A0631|323 326|ODCs
P11073919A0631|347 359|S. ruminantium
P11073919A0631|360 363|LDC.
P11073919A0631|360 362|LDC
P11073954A0337|3 10|Psc2 cDNA
P11073954A0337|3 10|Psc2 cDNA
P11073954A0337|22 37|open reading frame
P11073954A0337|50 66|CP2 family proteins
P11073954A0337|50 66|CP2 family proteins
P11074003A0741|22 24|Shh
P11074003A0741|22 24|Shh
P11074003A0741|60 77|proliferating CGNPs
P11074210A0623|47 71|insulin resistance syndrome
P11074210A0623|47 53|insulin
P11074210A0623|82 83|BP
P11074210A0623|82 83|BP
P11074210A0623|87 104|insulin sensitivity
P11074210A0623|87 93|insulin
P11075678A0298|45 53|vibration
P11075678A0298|76 78|DFT
P11075678A0298|80 92|B3LYP/6-31G**
P11075929A1657|32 35|ThlA
P11075929A1657|32 35|ThlA
P11075929A1657|51 60|metabolism
P11075929A1657|74 89|solvent formation
P11075929A1657|124 127|ThlB
P11075929A1657|124 127|ThlB
P11075944A0691|11 14|npm3
P11075944A0691|11 14|npm3
P11075944A0691|45 48|fgf8
P11075944A0691|45 48|fgf8
P11075944A0691|51 63|MMTV insertion
P11075944A0691|85 93|androgens
P11075944A0691|96 104|SC-3 cells
P11076860A0872|15 28|epitope-tagged
P11076860A0872|45 49|UEV1A
P11076860A0872|45 49|UEV1A
P11076860A0872|53 66|nuclear protein
P11076860A0872|53 66|nuclear protein
P11076860A0872|79 81|Kua
P11076860A0872|79 81|Kua
P11076860A0872|85 91|Kua-UEV
P11076860A0872|85 87|Kua
P11076860A0872|89 91|UEV
P11076860A0872|102 122|cytoplasmic structures
P11076860A0872|141 149|Kua domain
P11076860A0872|141 149|Kua domain
P11076860A0872|163 185|cytoplasmic localization
P11076860A0872|188 194|Kua-UEV
P11076860A0872|188 190|Kua
P11076860A0872|192 194|UEV
P11078726X0000|0 28|Stoichiometric phosphorylation
P11078726X0000|31 38|human p53
P11078726X0000|31 38|human p53
P11078726X0000|41 46|Ser315
P11078726X0000|57 93|p53-dependent transcription. p53 protein
P11078726X0000|57 82|p53-dependent transcription
P11078726X0000|84 101|p53 protein activity
P11078726X0000|104 123|a transcription factor
P11078726X0000|105 123|transcription factor
P11078726X0000|169 202|C-terminal negative regulatory domain
P11078726X0000|217 231|cellular enzymes
P11078726X0000|277 303|p53-dependent gene expression
P11078726X0000|277 293|p53-dependent gene
P11080796A0883|52 71|IKK regulatory protein
P11080796A0883|52 71|IKK regulatory protein
P11080796A0883|73 80|IKKgamma
P11080796A0883|73 80|IKKgamma
P11080796A1277|3 25|Tax/IKKgamma interaction
P11080796A1277|3 5|Tax
P11080796A1277|7 14|IKKgamma
P11080796A1277|41 43|Tax
P11080796A1277|41 43|Tax
P11080796A1277|49 68|IKK catalytic subunits
P11080796A1277|49 51|IKK
P11080796A1277|52 68|catalytic subunits
P11080796A1277|70 77|IKKalpha
P11080796A1277|70 77|IKKalpha
P11080796A1277|81 87|IKKbeta
P11080796A1277|81 87|IKKbeta
P11080796A1277|145 147|Tax
P11080796A1277|145 147|Tax
P11080796A1277|171 173|IKK
P11080796A1277|171 173|IKK
P11081962T0000|2 41|anchored AFLP- and retrotransposon-based map
P11081962T0000|44 55|diploid Avena
P11082185A0415|35 50|inhibitory domain
P11082185A0415|56 77|N-terminal 60 amino acids
P11082185A0415|80 84|IRF-1
P11082185A0415|80 84|IRF-1
P11082185A0415|109 131|transcriptional activity
P11082587X0000|48 66|brillouin scattering
P11082587X0000|116 133|laser beam smoothing
P11082587X0000|146 168|Brillouin backscattering
P11082587X0000|170 173|SBBS
P11082715X0001|27 38|theophylline
P11082715X0001|45 55|metabolites
P11082715X0001|58 61|HPLC
P11082715X0001|79 110|liquid chromatography (HPLC) method
P11082715X0001|160 171|theophylline
P11082715X0001|178 188|metabolites
P11082715X0001|208 218|metabolites
P11083154A0881|38 62|oxygen uptake VO2, heart rate
P11083154A0881|81 82|VE
P11083154A0881|93 100|exertion
P11083154A0881|104 118|spinal shrinkage
P11083358A1071|11 13|SPT
P11083358A1071|11 13|SPT
P11083358A1071|30 32|WST
P11083358A1071|50 57|patients
P11083432A0332|0 6|Studied
P11083432A0332|29 35|control
P11083432A0332|45 48|FK-1
P11083432A0332|45 48|FK-1
P11083432A0332|57 60|FK-3
P11083432A0332|57 60|FK-3
P11083868A0386|0 51|DNA binding and glutathione S-transferase pull-down assays
P11083868A0386|13 36|glutathione S-transferase
P11083868A0386|67 73|binding
P11083868A0386|82 88|Elk-1(1
P11083868A0386|82 86|Elk-1
P11083868A0386|103 133|C-terminal transactivation domain
P11083868A0386|103 133|C-terminal transactivation domain
P11084022A1178|13 16|ALK7
P11084022A1178|13 16|ALK7
P11084022A1178|53 66|cell morphology
P11084022A1178|82 95|cell flattening
P11084022A1178|118 135|short cell processes
P11084334A0590|3 14|swa2-1 allele
P11084334A0590|3 8|swa2-1
P11084334A0590|71 93|tetratricopeptide repeat
P11084334A0590|95 104|TPR) domain
P11084334A0590|122 128|auxilin
P11084334A0590|176 193|heat-shock proteins
P11084334A0590|176 193|heat-shock proteins
P11084556T0000|55 68|nucleated cells
P11084556T0000|72 99|hematopoietic progenitor cells
P11084556T0000|102 119|umbilical cord blood
P11084649A0497|10 21|older embryos
P11084649A0497|59 64|embryo
P11084649A0497|70 73|E6.5
P11084649A0497|70 71|E6
P11084649A0497|87 98|gastrulation
P11084649A0497|148 162|nascent mesoderm
P11084649A0497|170 184|primitive streak
P11085267A0562|0 13|Transformation
P11085267A0562|19 30|sconC3 mutant
P11085267A0562|19 30|sconC3 mutant
P11085267A0562|35 40|sconB+
P11085267A0562|35 40|sconB+
P11085267A0562|52 69|wild-type phenotype
P11085267A0562|52 69|wild-type phenotype
P11085600A0123|52 67|entorhinal cortex
P11086872A0000|11 22|oil emulsions
P11086872A0000|36 72|post-harvest physiconutritional changes
P11086872A0000|75 84|Kagzi limes
P11086872A0000|86 103|Citrus aurantifolia
P11087141A0977|18 38|alpha1,3GT transcripts
P11087141A0977|25 38|3GT transcripts
P11087141A0977|55 81|alternative splicing patterns
P11087141A0977|87 107|5'-untranslated region
P11087141A0977|109 114|5'-UTR
P11087141A0977|164 184|tissue-specific manner
P11088635A0200|1 37|thermal Kubo-Martin-Schwinger condition
P11088635A0200|80 93|periodic source
P11089911A1267|3 25|non-homologous sequences
P11089911A1267|31 51|5' untranslated regions
P11089911A1267|76 88|transcription
P11089911A1267|95 112|retrotransposition
P11089911A1267|118 129|ATLN elements
P11090172A0612|15 29|RNA1 replication
P11090172A0612|33 45|RNA3 synthesis
P11090172A0612|33 36|RNA3
P11090172A0612|76 80|yeast
P11090172A0612|96 102|natural
P11090172A0612|103 105|FHV
P11090172A0612|106 114|virion RNA
P11090272A1240|3 15|transcription
P11090272A1240|19 37|alternative splicing
P11090272A1240|40 48|human ORL1
P11090272A1240|40 48|human ORL1
P11090272A1240|52 55|GAIP
P11090272A1240|52 55|GAIP
P11090762A0527|23 32|muscle pain
P11090762A0527|44 65|non-painful stimulation
P11090762A0527|107 117|delta (1-3 Hz
P11090762A0527|107 113|delta (1
P11090762A0527|129 135|alpha-1
P11090762A0527|129 135|alpha-1
P11090762A0527|137 142|9-11 Hz
P11090762A0527|164 189|contralateral parietal locus
P11092770A0238|3 12|extraction
P11092770A0238|73 78|class C
P11092770A0238|95 114|difficult' extraction
P11092809A0823|29 32|ERKs
P11092809A0823|29 32|ERKs
P11092809A0823|36 40|PI3Ks
P11092809A0823|36 40|PI3Ks
P11092809A0823|74 81|mesoderm
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092850A1023|7 13|16S rRNA
P11092850A1023|38 46|11 species
P11092850A1023|56 63|tuf genes
P11092850A1023|56 63|tuf genes
P11092850A1023|137 155|enterococcal lineage
P11092850A1023|172 179|ancestor
P11092886A0341|13 37|protein kinase A stimulation
P11092886A0341|13 26|protein kinase A
P11092886A0341|45 53|CREMalpha
P11092886A0341|45 53|CREMalpha
P11092886A0341|80 87|promoter
P11092886A0341|93 135|phosphoenolpyruvate carboxykinase (PEPCK) gene
P11092886A0341|93 124|phosphoenolpyruvate carboxykinase
P11092886A0341|126 130|PEPCK
P11093745A0563|15 22|HNF3 site
P11093745A0563|15 22|HNF3 site
P11093745A0563|43 53|NF1/CTF site
P11093745A0563|43 45|NF1
P11093745A0563|47 53|CTF site
P11093745A0563|79 98|silencer-like element
P11094066A0505|4 28|transcriptional regulation
P11094066A0505|57 83|forkhead transcription factor
P11094066A0505|57 83|forkhead transcription factor
P11094066A0505|84 90|FKHR-L1
P11094066A0505|84 87|FKHR
P11094066A0505|89 90|L1
P11094066A0505|95 98|IL-3
P11094066A0505|95 98|IL-3
P11094066A0505|108 114|FKHR-L1
P11094066A0505|108 114|FKHR-L1
P11094066A0505|126 145|PI3K-dependent manner
P11094066A0505|126 129|PI3K
P11094066A1194|55 63|p27(KIP1)
P11094066A1194|55 57|p27
P11094066A1194|59 62|KIP1
P11094066A1194|84 117|PI3K-induced FKHR-L1 phosphorylation
P11094066A1194|84 87|PI3K
P11094066A1194|96 102|FKHR-L1
P11094066A1194|153 177|cytokine-mediated survival
P11094066A1194|181 193|proliferation
P11094072A0842|0 24|DNase I genomic footprinting
P11094072A0842|0 5|DNase I
P11094072A0842|40 48|c-Myb site
P11094072A0842|40 48|c-Myb site
P11094072A0842|62 83|tissue-specific fashion
P11094072A1234|14 18|c-Myb
P11094072A1234|14 18|c-Myb
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|46 51|T cells
P11094072A1234|67 91|consensus c-Myb binding site
P11094072A1234|76 80|c-Myb
P11094073A0000|31 47|Vav family proteins
P11094073A0000|31 47|Vav family proteins
P11094073A0000|49 52|Vav3
P11094073A0000|49 52|Vav3
P11094073A0000|73 104|Ros receptor protein tyrosine kinase
P11094073A0000|73 104|Ros receptor protein tyrosine kinase
P11094073A0000|106 128|RPTK) interacting protein
P11094073A0000|106 109|RPTK
P11094073A0000|131 154|yeast two-hybrid screening
P11094075A0257|43 54|r-PTPeta gene
P11094075A0257|43 50|r-PTPeta
P11094075A0257|57 81|highly malignant rat thyroid
P11094075A0257|100 111|retroviruses
P11094075A0257|123 147|v-mos and v-ras-Ki oncogenes
P11094075A0257|123 127|v-mos
P11094075A0257|131 147|v-ras-Ki oncogenes
P11094075A0257|163 180|malignant phenotype
P11094087T0000|19 22|Rnd3
P11094087T0000|19 22|Rnd3
P11094087T0000|55 78|polarized epithelial cells
P11094087T0000|84 133|Raf-MEK-extracellular signal-regulated kinase pathway
P11094087T0000|84 86|Raf
P11094087T0000|88 90|MEK
P11094087T0000|92 126|extracellular signal-regulated kinase
P11094091A0000|16 34|transcription factor
P11094091A0000|35 38|CREB
P11094091A0000|35 38|CREB
P11094091A0000|52 71|extracellular stimuli
P11094091A0000|87 101|phosphorylation
P11094091A0000|113 125|serine residue
P11094091A0000|127 132|Ser133
P11094590A0617|72 79|bacteria
P11094590A0617|82 93|Gram staining
P11094590A0617|116 118|VAP
P11094590A0617|123 125|PSB
P11094590A0617|129 131|PTC
P11094590A0617|156 157|74
P11095248A0423|9 25|mammalian proteins
P11095248A0423|9 25|mammalian proteins
P11095248A0423|27 31|XFGF3
P11095248A0423|27 31|XFGF3
P11095248A0423|56 75|Mr 31,000 glycoprotein
P11095248A0423|77 80|gp31
P11095248A0423|77 80|gp31
P11095248A0423|96 114|proteolytic cleavage
P11095248A0423|126 155|NH2-terminally truncated product
P11095248A0423|126 155|NH2-terminally truncated product
P11095248A0423|157 160|gp27
P11095248A0423|157 160|gp27
P11095248A1523|0 19|NH2-terminal trimming
P11095248A1523|22 28|Xenopus
P11095248A1523|32 45|mammalian FGF3s
P11095248A1523|41 45|FGF3s
P11095248A1523|82 99|biological activity
P11095981A0254|22 33|cis-elements
P11095981A0254|65 77|200 bp promoter
P11095981A0254|84 95|autonomously
P11095981A0254|130 138|mutations
P11096662T0000|0 8|Tranilast
P11096662T0000|23 43|Coronary Artery Disease
P11097040A0000|70 82|TRIS-extender
P11097040A0000|100 110|in 1 or 2 steps
P11097040A0000|202 218|post-thaw survival
P11097079A0525|50 73|clinician rated NIMH-LCM-p
P11098217A0674|3 11|Aie1 locus
P11098217A0674|3 11|Aie1 locus
P11098217A0674|23 43|mouse chromosome 7A2-A3
P11098217A0674|46 75|fluorescent in situ hybridization
P11098420A0175|0 19|Psychiatric disorders
P11098420A0175|22 29|children
P11098420A0175|33 43|adolescents
P11098420A0175|120 126|suicide
P11099377T0000|0 15|Molecular cloning
P11099377T0000|31 96|human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|31 47|human UDP-d-Xylose
P11099377T0000|65 96|protein beta-d-xylosyltransferase
P11099377T0000|115 119|XT-II
P11100515A0282|0 13|Thyrotoxicosis
P11100515A0282|75 97|pro-arrhythmic potential
P11100515A0282|100 113|thyrotoxicosis
P11100515A0282|120 145|fading antiarrhythmic effect
P11100515A0282|151 170|amiodarone withdrawal
P11101008A0649|0 14|Chaperones/HSPs
P11101008A0649|43 60|cell cycle processes
P11101847A0159|9 18|signalling
P11101847A0159|21 24|E2F1
P11101847A0159|21 24|E2F1
P11101847A0159|79 97|tumour suppressor p53
P11101847A0159|79 97|tumour suppressor p53
P11102367A1170|90 102|nervous system
P11102367A1170|105 114|Drosophila
P11102367A1170|169 192|en masse transposon-tagged
P11102367A1170|214 227|genetic screens
P11102458A0000|55 66|neurobeachin
P11102458A0000|69 101|neuron-specific multidomain protein
P11102458A0000|104 109|327 kDa
P11102458A0000|115 138|high-affinity binding site
P11102458A0000|140 140|K
P11102458A0000|142 142|d
P11102458A0000|156 178|type II regulatory subunit
P11102458A0000|162 178|regulatory subunit
P11102458A0000|181 194|protein kinase A
P11102458A0000|181 194|protein kinase A
P11102458A0000|196 201|PKA RII
P11102458A0000|196 201|PKA RII
P11103472A0802|0 7|Children
P11103472A0802|12 14|ADD
P11103472A0802|33 53|frontal CNV-1 amplitude
P11103472A0802|79 83|CNV-1
P11103472A0802|87 91|CNV-2
P11103601T0025|5 9|UMDNJ
P11103792A0755|16 20|c-Myc
P11103792A0755|16 20|c-Myc
P11103792A0755|23 61|serum-starved human or mouse embryonic cells
P11103792A0755|69 77|apoptosis
P11103792A0755|120 147|growth factor-containing serum
P11103792A0755|120 131|growth factor
P11103792A0755|143 153|serum. c-Myc
P11103792A0755|149 170|c-Myc-induced apoptosis
P11103792A0755|193 200|bax-null
P11103792A0755|193 195|bax
P11103792A0755|215 217|bax
P11103792A0755|215 217|bax
P11103792A0755|219 252|wild-type mouse embryonic fibroblasts
P11105129T0000|29 48|Klebsiella pneumoniae
P11105129T0000|49 88|Producing Extended-Spectrum beta-lactamase
P11105129T0000|58 88|Extended-Spectrum beta-lactamase
P11105129T0000|90 93|ESBL
P11105129T0000|90 93|ESBL
P11105129T0000|116 121|Brazil
P11105716A0782|32 34|AIF
P11105716A0782|103 105|CBV
P11105716A0782|109 111|CBF
P11105716A0782|182 199|MR perfusion studies
P11105717A0123|8 19|T2*-weighted
P11105717A0123|21 56|three-dimensional gradient-echo images
P11105717A0123|84 115|magnetic susceptibility difference
P11105717A0123|148 157|hemoglobin
P11105717A0123|148 157|hemoglobin
P11105717A0123|163 192|vasculature and microvasculature
P11106216A0918|5 8|COPD
P11106216A0918|9 16|patients
P11106216A0918|34 46|Delta-inst Rrs
P11106216A0918|72 77|FOT Rrs
P11106428A0635|54 68|catalytic domain
P11106428A0635|71 75|FAP-1
P11106428A0635|71 75|FAP-1
P11106428A0635|77 100|C-terminal 399 amino acids)
P11106428A0635|77 99|C-terminal 399 amino acids
P11106428A0635|106 117|inactive form
P11106428A0635|119 125|Cys2408
P11106428A0635|129 131|Ser
P11106428A0635|140 168|glutathione-S-transferase (GST
P11106428A0635|140 164|glutathione-S-transferase
P11106428A0635|166 168|GST
P11106667A1061|5 11|Pet111p
P11106667A1061|5 11|Pet111p
P11106667A1061|36 55|membrane localization
P11106667A1061|71 84|Cox2p synthesis
P11106667A1061|71 75|Cox2p
P11106667A1061|91 102|mitochondria
P11106668A0875|38 54|spacer-RING domain
P11106668A0875|73 93|antiapoptotic function
P11106668A0875|99 117|N-terminal BIR domain
P11106668A0875|99 111|N-terminal BIR
P11106668A0875|120 125|c-IAP1
P11106668A0875|120 125|c-IAP1
P11106668A0875|136 144|apoptosis
P11107637X0001|21 32|double bounds
P11107637X0001|35 44|blood serum
P11107637X0001|53 61|titration
P11107637X0001|75 89|pathophysiology
P11107637X0001|175 184|blood serum
P11107637X0001|187 194|patients
P11107637X0001|225 239|atherosclerosis
P11107637X0001|243 262|ischemic heart disease
P11108151A0560|13 27|fibronectin mRNA
P11108151A0560|13 27|fibronectin mRNA
P11108151A0560|44 46|PKC
P11108151A0560|44 46|PKC
P11108151A0560|59 70|PKC depletion
P11108151A0560|59 61|PKC
P11108151A0560|99 111|EGF-R function
P11108151A0560|99 101|EGF
P11108151A0560|103 103|R
P11108151A0560|115 141|dominant negative EGF-R mutant
P11108151A0560|131 141|EGF-R mutant
P11108151A0560|145 160|tyrphostin AG1478
P11108151A0560|181 195|fibronectin mRNA
P11108151A0560|181 195|fibronectin mRNA
P11108374A1466|0 5|Acoust
P11108523A0326|0 10|Video images
P11108523A0326|78 90|principal axis
P11108523A0326|115 123|minor axes
P11108523A0326|125 127|I11
P11108523A0326|129 131|I22
P11108523A0326|155 167|lateral offset
P11108548A0710|0 16|MS characteristics
P11108548A0710|19 64|coumarins, psoralens and polymethoxylated flavones
P11108548A0710|78 97|substitution patterns
P11108548A0710|150 162|APcI interface
P11108616A0000|0 8|Young fish
P11108616A0000|10 31|Oreochromis mossambicus
P11108616A0000|46 57|microgravity
P11108616A0000|59 64|micro g
P11108616A0000|84 99|space missions STS
P11108616A0000|106 111|STS-84
P11108616A0000|117 128|hypergravity
P11108616A0000|130 131|hg
P11108720A0124|0 3|S6K2
P11108720A0124|0 3|S6K2
P11108720A0124|24 27|S6K1
P11108720A0124|24 27|S6K1
P11108720A0124|33 42|core kinase
P11108720A0124|46 51|linker
P11108720A0124|52 68|regulatory domains
P11108720A0124|83 86|S6K1
P11108720A0124|83 86|S6K1
P11108720A0124|92 113|N- and C-terminal regions
P11108720A0124|92 113|N- and C-terminal regions
P11108720A0124|153 159|nucleus
P11108720A0124|170 204|C-terminal nuclear localization signal
P11108720A0124|213 216|S6K2
P11108720A0124|213 216|S6K2
P11108720A1130|26 105|mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor
P11108720A1130|26 49|mitogen-activated protein
P11108720A1130|51 91|extracellular signal-regulated kinase kinase
P11108720A1130|93 95|MEK
P11108720A1130|106 110|U0126
P11108720A1130|120 133|S6K2 activation
P11108720A1130|120 123|S6K2
P11108720A1130|154 157|S6K1
P11108720A1130|154 157|S6K1
P11108839A0401|0 5|T cells
P11108839A0401|26 29|S6k1
P11108839A0401|26 29|S6k1
P11108839A0401|32 53|70 kDa cytoplasmic kinase
P11108839A0401|37 53|cytoplasmic kinase
P11108839A0401|59 70|85 kDa isoform
P11110040A0000|0 9|Ketanserin
P11110040A0000|12 26|hypotensive drug
P11110040A0000|31 43|5-HT2 receptor
P11110040A0000|31 35|5-HT2
P11110040A0000|109 115|corneal
P11110040A0000|119 137|scleral applications
P11110040A0000|154 172|intraocular pressure
P11110040A0000|216 227|ketanserinol
P11110528A0414|19 33|2D axial sequence
P11110528A0414|85 98|cervical region
P11111051A0051|26 30|Tip60
P11111051A0051|26 30|Tip60
P11111051A0051|34 70|histone acetyltransferase (HAT) activity
P11111051A0051|34 57|histone acetyltransferase
P11111051A0051|59 61|HAT
P11112417A1126|23 38|MLSN1 transcripts
P11112417A1126|23 38|MLSN1 transcripts
P11112417A1126|92 121|cultured pigmented melanoma cells
P11112417A1126|137 151|MLSN1 expression
P11112417A1126|137 141|MLSN1
P11112417A1126|182 194|transcription
P11112417A1126|198 211|mRNA processing
P11112700A1936|0 6|Plectin
P11112700A1936|0 6|Plectin
P11112700A1936|10 20|desmoplakin
P11112700A1936|25 45|GSR-containing domains
P11112700A1936|53 61|C-termini
P11112700A1936|92 111|GSR-containing domain
P11112700A1936|92 111|GSR-containing domain
P11112700A1936|114 120|plectin
P11112700A1936|128 138|desmoplakin
P11112700A1936|149 151|MTs
P11112700T0000|21 44|microtubule binding domain
P11112700T0000|21 31|microtubule
P11112700T0000|47 80|microtubule actin crosslinking factor
P11112700T0000|47 57|microtubule
P11112700T0000|58 85|actin crosslinking factor (MACF
P11112700T0000|82 85|MACF
P11112700T0000|117 145|microtubule associated proteins
P11112700T0000|117 127|microtubule
P11112790A0989|62 64|UPR
P11113179A0541|22 25|SRC1
P11113179A0541|22 25|SRC1
P11113179A0541|42 44|CBP
P11113179A0541|42 44|CBP
P11113179A0541|50 65|estrogen receptor
P11113179A0541|50 65|estrogen receptor
P11113179A0541|87 99|SRC1 functions
P11113179A0541|87 90|SRC1
P11113179A0541|129 131|CBP
P11113179A0541|129 131|CBP
P11113179A0541|135 138|p300
P11113179A0541|135 138|p300
P11113179A1020|36 51|residues 631 to 970
P11113179A1020|73 83|LXXLL motifs
P11113179A1020|90 98|AD1 region
P11113179A1020|90 92|AD1
P11113179A1020|101 104|SRC1
P11113179A1020|101 104|SRC1
P11113179A1020|114 138|strong coactivator activity
P11113199A0800|5 7|MEK
P11113199A0800|5 7|MEK
P11113199A0800|15 31|cytoplasmic anchor
P11113199A0800|38 41|ERKs
P11113199A0800|38 41|ERKs
P11113199A0800|53 66|MEK interaction
P11113199A0800|53 55|MEK
P11113199A0800|80 106|aberrant nuclear localization
P11113199A0800|109 112|ERK2
P11113199A0800|109 112|ERK2
P11113199A0800|114 130|Delta19-25 mutants
P11113199A0800|114 120|Delta19
P11113199A0800|133 150|serum-starved cells
P11113201A1114|0 3|Pmt2
P11113201A1114|0 3|Pmt2
P11113201A1114|16 32|six-protein family
P11113201A1114|16 32|six-protein family
P11113201A1114|35 39|yeast
P11113201A1114|83 96|target proteins
P11113546A0728|0 11|Fecal samples
P11113546A0728|80 107|gastrointestinal nematode eggs
P11113546A0728|111 121|Giardia cyst
P11113692A0169|58 76|diabetic retinopathy
P11113692A0169|78 80|BDR
P11113692A0169|85 87|PDR
P11113692A0169|102 117|Japanese patients
P11113692A0169|122 145|early-onset type 2 diabetes
P11113692A0169|188 200|blood pressure
P11113822A0999|16 23|positive
P11113822A0999|29 36|controls
P11113823A0197|11 32|synovial chondromatosis
P11114294A0075|31 55|pro-inflammatory cytokines
P11114294A0075|56 79|tumor necrosis factor alpha
P11114294A0075|56 79|tumor necrosis factor alpha
P11114294A0075|83 97|interferon gamma
P11114294A0075|83 97|interferon gamma
P11114294A0075|122 168|cystic fibrosis transmembrane conductance regulator
P11114294A0075|170 178|CFTR) gene
P11114294A0075|170 178|CFTR) gene
P11114294A0075|180 183|CFTR
P11114294A0075|180 183|CFTR
P11114294A0075|187 191|HT-29
P11114294A0075|195 202|T84 cells
P11114521A0282|12 15|RhoA
P11114521A0282|12 15|RhoA
P11114521A0282|36 43|adhesion
P11114521A0282|98 106|migration
P11114718A0349|12 27|mouse fibroblasts
P11114718A0349|47 51|v-Src
P11114718A0349|47 51|v-Src
P11114718A0349|56 75|mRNA and protein levels
P11114718A0349|78 91|p21 (WAF1/CIP1)
P11114718A0349|78 80|p21
P11114718A0349|82 85|WAF1
P11114718A0349|87 90|CIP1
P11114718A0349|93 100|cyclin D1
P11114718A0349|93 100|cyclin D1
P11114718A0349|105 111|cyclin E
P11114718A0349|105 111|cyclin E
P11114924A0808|0 3|ORFA
P11114924A0808|7 10|ccdA
P11114924A0808|7 10|ccdA
P11114924A0808|56 78|primer extension analysis
P11116084A0000|0 10|Mouse Impact
P11116084A0000|0 10|Mouse Impact
P11116131A0863|18 28|P2Y(11) mRNA
P11116131A0863|18 23|P2Y(11
P11116131A0863|35 41|culture
P11116148A0741|31 37|insulin
P11116148A0741|31 37|insulin
P11116148A0741|41 43|PKB
P11116148A0741|41 43|PKB
P11116148A0741|52 66|transactivation
P11116148A0741|69 77|C/EBPbeta
P11116148A0741|69 77|C/EBPbeta
P11116148A0741|85 94|C/EBPalpha
P11116148A0741|85 94|C/EBPalpha
P11116148A0741|103 134|N-terminal transactivation domains
P11116148A0741|103 134|N-terminal transactivation domains
P11116148A0741|137 145|C/EBPbeta
P11116148A0741|137 145|C/EBPbeta
P11117263A0570|10 28|graminaceous species
P11117263A0570|36 49|Ids3 expression
P11117263A0570|36 39|Ids3
P11117263A0570|67 83|Fe-deficient roots
P11117263A0570|98 110|Secale cereale
P11117263A0570|131 150|2'-deoxymugineic acid
P11117263A0570|152 154|DMA
P11117263A0570|177 178|MA
P11117263A0570|183 206|3-epihydroxymugineic acid
P11117263A0570|208 213|epiHMA
P11117263A0570|229 249|3-hydroxymugineic acid
P11117263A0570|251 253|HMA
P11117263A0570|255 263|S. cereale
P11117523A0650|15 22|COUP-TFI
P11117523A0650|15 22|COUP-TFI
P11117523A0650|43 65|neuronal differentiation
P11117523A0650|68 75|P19 cells
P11117523A0650|87 88|RA
P11117826A0788|7 9|PET
P11117826A0788|71 85|stereotactic PET
P11117826A0788|93 100|patients
P11117826A0788|132 153|PET-based metabolic data
P11117826A0788|158 179|MR-based anatomical data
P11118062A1691|48 55|mutation
P11118062A1691|61 69|K-ras gene
P11118062A1691|61 65|K-ras
P11118062A1691|119 139|transforming phenotype
P11118438A0411|29 34|MdPin1
P11118438A0411|29 34|MdPin1
P11118438A0411|37 49|Pin1 homologue
P11118438A0411|37 40|Pin1
P11118438A0411|75 88|Malus domestica
P11118438A0411|205 208|Pin1
P11118438A0411|205 208|Pin1
P11118440T0000|0 22|Differential association
P11118440T0000|62 89|candidate tumor suppressor ING1
P11118440T0000|71 89|tumor suppressor ING1
P11118440T0000|97 101|mSin3
P11118440T0000|97 101|mSin3
P11118440T0000|103 107|HDAC1
P11118440T0000|108 140|transcriptional corepressor complex
P11118619A0835|37 49|TAg 're-models
P11118619A0835|37 39|TAg
P11118619A0835|51 78|host cell transcription factors
P11118619A0835|97 110|viral infection
P11118619A0835|160 173|transformation
P11118712A1296|73 108|screening test jeopardize the estimation
P11119611A0428|0 7|ORFK10.5
P11119611A0428|0 5|ORFK10
P11119611A0428|7 7|5
P11119611A0428|24 56|latency-associated nuclear antigen 2
P11119611A0428|42 56|nuclear antigen 2
P11119611A0428|58 62|LANA2
P11119611A0428|58 62|LANA2
P11119611A0428|83 95|KSHV-infected
P11119611A0428|96 115|hematopoietic tissues
P11119611A0428|126 128|PEL
P11119611A0428|126 128|PEL
P11119611A0428|132 133|CD
P11119611A0428|132 133|CD
P11119611A0428|140 148|KS lesions
P11120441A1193|46 71|right hemispheric activation
P11120441A1193|82 101|hemispheric asymmetry
P11121043A0074|2 8|Xenopus
P11121043A0074|10 13|BMPs
P11121043A0074|10 13|BMPs
P11121043A0074|19 27|epidermal
P11121043A0074|65 76|neurogenesis
P11121118A0075|13 26|unique variants
P11121118A0075|43 54|GAF sequences
P11121118A0075|43 54|GAF sequences
P11121118A0075|60 75|N-terminal region
P11121118A0075|60 75|N-terminal region
P11121118T0000|0 18|Genomic organization
P11121118T0000|24 55|human phosphodiesterase PDE11A gene
P11121118T0000|29 55|phosphodiesterase PDE11A gene
P11121397A0587|33 44|rib-2 protein
P11121397A0587|33 44|rib-2 protein
P11121397A0587|62 94|4-N-acetylglucosaminyltransferase
P11121397A0587|62 94|4-N-acetylglucosaminyltransferase
P11121397A0587|108 142|biosynthetic initiation and elongation
P11121397A0587|145 158|heparan sulfate
P11121434A0915|15 28|Mek/Erk pathway
P11121434A0915|15 17|Mek
P11121434A0915|19 21|Erk
P11121434A0915|31 43|Rat1/ras cells
P11121434A0915|31 34|Rat1
P11121434A0915|36 38|ras
P11121434A0915|53 64|Mek inhibitor
P11121434A0915|53 55|Mek
P11121434A0915|66 72|PD98059
P11121434A0915|92 111|cytoskeletal recovery
P11121434A0915|147 150|HR12
P11121490A0000|3 21|transcription factor
P11121490A0000|22 37|CHOP/GADD153 gene
P11121490A0000|22 25|CHOP
P11121490A0000|27 33|GADD153
P11121490A0000|49 62|cellular stress
P11121490A0000|87 95|apoptosis
P11122381A0908|19 49|tyrosine-phosphorylated peptides
P11122381A0908|77 85|tyrosines
P11122381A0908|93 109|GM-CSF stimulation
P11122381A0908|93 98|GM-CSF
P11122381A0908|122 138|in vitro activation
P11122381A0908|141 145|STAT5
P11122381A0908|141 145|STAT5
P11122588A0549|41 59|apnea-hypopnea index
P11122588A0549|61 63|AHI
P11122588A0549|65 90|apnea events + hypopnea events
P11122588A0549|125 145|moderate-to-severe SDB
P11122588A0549|158 160|AHI
P11122588A0549|210 215|weight
P11123054T0000|14 31|rheumatic syndromes
P11123089A0362|77 96|pathogenic mechanisms
P11123089A0362|102 113|vasculitides
P11123089A0362|125 132|patients
P11123316T0000|0 17|Tec kinase signaling
P11123316T0000|0 8|Tec kinase
P11123316T0000|20 25|T cells
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|73 99|Tec pleckstrin homology domain
P11123316T0000|73 75|Tec
P11123316T0000|76 99|pleckstrin homology domain
P11123701A0442|28 75|DNA supercoiling-dependent transcriptional coupling
P11123701A0442|94 109|in vivo activities
P11123701A0442|112 120|promoters
P11123701A0442|142 154|DNA constructs
P11123701A0442|171 190|transcription complex
P11123701A0442|225 237|DNA supercoils
P11123701A0442|277 285|DNA duplex
P11123912A0306|21 29|SH2 domain
P11123912A0306|21 29|SH2 domain
P11123912A0306|56 58|SH2
P11123912A0306|56 58|SH2
P11123912A0306|73 99|doubly phosphorylated peptide
P11123912A0306|111 136|polyomavirus middle T antigen
P11123912A0306|111 136|polyomavirus middle T antigen
P11123912A0306|138 139|MT
P11123912A0306|138 139|MT
P11124024A1098|21 32|binding sites
P11124024A1098|36 51|protein complexes
P11124024A1098|54 63|palindrome
P11124024A1098|83 93|C+T sequence
P11124024A1098|116 125|GAGA motifs
P11125151T0000|0 17|Nucleotide sequence
P11125151T0000|62 100|pineapple mealybug wilt-associated virus-2
P11125363A0525|50 61|tumor mapping
P11125363A0525|109 110|gm
P11125363A0525|122 135|5-fluorouracil
P11125363A0525|159 170|radiotherapy
P11125411A0857|30 40|laparoscopy
P11125411A0857|58 72|intra-abdominal
P11125411A0857|75 99|vanished and 2 peeping testes
P11125411A0857|105 118|atrophic testis
P11125411A0857|124 136|inguinal canal
P11125872A0133|4 13|philosophy
P11125872A0133|41 47|RP 73401
P11125872A0133|50 85|specific phosphodiesterase IV inhibitor
P11125872A0133|58 76|phosphodiesterase IV
P11125872A0133|125 132|delivery
P11125872A0133|139 176|oral and pulmonary routes of administration
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126353A0582|28 30|BMI
P11126353A0582|31 33|SDS
P11126353A0582|76 77|3y
P11126806A0206|21 47|antiphospholipid-antibodies
P11126806A0206|60 84|uteroplacental circulation
P11127161T0000|0 8|Bupropion
P11127200A1024|32 58|AP-1 transcriptional activity
P11127200A1024|32 35|AP-1
P11127200A1024|92 95|AP-1
P11127200A1024|92 95|AP-1
P11127200A1024|96 115|transcription factors
P11127200A1024|124 161|TGF-beta1- and BMP-2-regulated expression
P11127200A1024|124 132|TGF-beta1
P11127200A1024|137 141|BMP-2
P11127200A1024|167 187|(alpha1) collagen I gene
P11127200A1024|168 187|alpha1) collagen I gene
P11127200A1024|196 204|TGF-beta1
P11127200A1024|196 204|TGF-beta1
P11127200A1024|230 247|parathyroid hormone
P11127200A1024|230 247|parathyroid hormone
P11127200A1024|249 271|PTH)/PTH-related peptide
P11127200A1024|249 251|PTH
P11127200A1024|254 271|PTH-related peptide
P11127200A1024|273 286|PTHrP) receptor
P11127200A1024|273 277|PTHrP
P11127250A1111|0 3|PM 12
P11127250A1111|37 38|SB
P11127250A1111|81 82|SB
P11127250A1111|107 114|patients
P11127250A1111|119 120|VL
P11127250A1111|119 120|VL
P11127955X0001|0 14|Adjuvant therapy
P11127955X0001|18 28|colon cancer
P11127955X0001|30 36|Surgery
P11127955X0001|96 102|cancers
P11128312A1238|60 76|nonfracture groups
P11128312A1238|92 94|BMD
P11128312A1238|111 113|BMD
P11128312A1238|119 130|distal radius
P11128312A1238|163 178|radiographs (FD2)
P11128925A0000|52 76|interleukin-6 (IL-6) levels
P11128925A0000|52 64|interleukin-6
P11128925A0000|66 69|IL-6
P11128925A0000|79 105|gingival crevicular fluid (GCF
P11128925A0000|103 105|GCF
P11128925A0000|139 146|patients
P11128925A0000|151 169|rheumatoid arthritis
P11128925A0000|171 172|RA
P11128925A0000|182 194|periodontitis
P11128925A0000|196 198|AP)
P11128925A0000|196 197|AP
P11129515A0000|3 13|prospective
P11129515A0000|46 69|Vitex agnus castus L extract
P11129515A0000|70 74|Ze 440
P11129515A0000|94 101|patients
P11129515A0000|106 126|pre-menstrual syndrome
P11129515A0000|128 130|PMS
P11129724A0904|38 50|contamination
P11129724A0904|69 89|MRSA-contaminated milk
P11129724A0904|109 112|MRSA
P11129724A0904|115 122|neonates
P11131321T0000|9 24|Trypanosoma vivax
P11131321T0000|27 35|pregnancy
P11131321T0000|45 49|sheep
P11131321T0000|65 91|homidum chloride chemotherapy
P11131634A0955|0 7|NF kappa B
P11131634A0955|0 7|NF kappa B
P11131634A0955|58 64|WT cells
P11131634A0955|71 77|Y8 cells
P11132063A0250|80 90|late effects
P11132063A0250|98 106|cirrhosis
P11132063A0250|118 127|hepatitis C
P11132063A0250|130 174|late-onset anthracycline-induced cardiomyopathy
P11132063A0250|191 201|late effects
P11132063A0250|209 228|cognitive dysfunction
P11132148A0162|13 34|locus-specific residues
P11132148A0162|54 67|promoter region
P11132148A0162|98 110|HLA class I loci
P11132148A0162|98 106|HLA class I
P11132195A0000|87 92|memory
P11132195A0000|235 242|memories
P11132790A0609|3 16|standard method
P11132790A0609|53 57|S-B IV
P11132790A0609|79 86|raw score
P11132790A0609|156 163|children
P11133741A0617|0 28|NiCl(2)-induced MCP-1 synthesis
P11133741A0617|15 19|MCP-1
P11133741A0617|49 57|NF-kappaB
P11133741A0617|49 57|NF-kappaB
P11133741A0617|73 94|NF-kappaB-binding sites
P11133741A0617|73 81|NF-kappaB
P11133741A0617|82 94|-binding sites
P11133741A0617|100 107|promoter
P11133741A0617|132 156|inducible promoter activity
P11133830A0174|12 19|human CD2
P11133830A0174|17 19|CD2
P11133830A0174|22 35|mitogenic pairs
P11133830A0174|38 48|anti-CD2 mAb
P11133830A0174|38 48|anti-CD2 mAb
P11133830A0174|56 78|tyrosine phosphorylation
P11133830A0174|90 110|intracellular proteins
P11133830A0174|121 140|120 kDa phosphoprotein
P11133830A0174|160 178|proto-oncogene c-Cbl
P11133830A0174|160 173|proto-oncogene
P11133830A0174|174 178|c-Cbl
P11133927T0000|0 7|Validity
P11133927T0000|10 24|NIR spectroscopy
P11133927T0000|51 78|muscle oxidative metabolic rate
P11133986A0350|52 71|transcription factors
P11133986A0350|81 84|PU.1
P11133986A0350|81 84|PU.1
P11133986A0350|88 109|PU.1 interaction partner
P11133986A0350|88 91|PU.1
P11133986A0350|111 113|PIP
P11133986A0350|111 113|PIP
P11133986A0350|142 146|c-Fos
P11133986A0350|142 146|c-Fos
P11133986A0350|151 155|c-Jun
P11133986A0350|151 155|c-Jun
P11133986A0350|170 186|kappaE3'-enhancer
P11133986A0350|170 186|kappaE3'-enhancer
P11133986A0350|189 196|3T3 cells
P11134033A0000|3 18|murine int-6 locus
P11134033A0000|3 18|murine int-6 locus
P11134033A0000|58 81|mouse mammary tumor viruses
P11134033A0000|93 143|48-kDa eIF3e subunit of translation initiation factor eIF3
P11134033A0000|113 133|translation initiation
P11134033A0000|140 143|eIF3
P11134033A0639|2 30|int6 deletion (int6Delta) mutant
P11134033A0639|2 13|int6 deletion
P11134033A0639|15 23|int6Delta
P11134033A0639|55 67|minimal medium
P11134351A1405|13 18|MIP-2A
P11134351A1405|13 18|MIP-2A
P11134351A1405|56 60|MBP-1
P11134351A1405|56 60|MBP-1
P11134508A0317|20 25|plants
P11134508A0317|39 60|antisense Arabidopsis HD
P11134508A0317|62 71|AtHD1) gene
P11134508A0317|62 66|AtHD1
P11137296A0923|4 31|transcription initiation sites
P11137296A0923|52 71|full-length RNA ligase
P11137296A0923|63 71|RNA ligase
P11137296A0923|81 98|rapid amplification
P11137296A0923|101 108|cDNA ends
P11137296A0923|110 117|RLM-RACE
P11137296A0923|126 136|-61 and -32 bp
P11137296A0923|144 169|translation initiation codon
P11137296A0923|171 202|Reverse transcription-PCR analysis
P11137296A0923|215 219|PFK-A
P11137296A0923|215 219|PFK-A
P11137296A0923|221 225|PFK-B
P11137296A0923|221 225|PFK-B
P11137296A0923|229 238|PFK-C genes
P11137296A0923|229 238|PFK-C genes
P11137296A0923|255 269|all mouse tissues
P11137296A1216|0 8|PFK-A mRNA
P11137296A1216|0 8|PFK-A mRNA
P11137296A1216|37 46|all tissues
P11137296A1216|58 62|PFK-B
P11137296A1216|58 62|PFK-B
P11137296A1216|66 75|PFK-C genes
P11137296A1216|66 75|PFK-C genes
P11137367A0297|9 25|Toshiba IIDR system
P11137367A0297|46 58|X-ray TV system
P11137367A0297|63 89|digital image managing circuit
P11137551A0437|2 13|whole sardine
P11137551A0437|15 24|domoic acid
P11137551A0437|65 79|regulatory limit
P11138009A1032|36 45|Delta M1281
P11138009A1032|49 60|IVS51+5G-->A
P11138009A1032|71 74|USH1
P11138231T0000|0 6|Closeup
P11138231T0000|20 25|nurses
P11138694A0000|0 32|[18F](+)-4-fluorobenzyltrozamicol
P11138694A0000|34 36|FBT
P11138694A0000|74 97|acetylcholine transporter
P11138694A0000|184 209|cholinergic terminal density
P11138694A0000|231 233|PET
P11139148A0421|30 51|murine homologue of SAF-A
P11139148A0421|47 51|SAF-A
P11139148A0421|88 91|MARs
P11139148A0421|114 134|satMa-binding activity
P11139148A0421|114 118|satMa
P11139148A0421|140 163|chromatographic fractions
P11139336A0257|33 46|INCENP behavior
P11139336A0257|33 38|INCENP
P11139469A0402|0 4|Ang II
P11139469A0402|25 32|Ang2 mRNA
P11139469A0402|25 32|Ang2 mRNA
P11139469A0402|62 65|Ang1
P11139469A0402|62 65|Ang1
P11139469A0402|68 81|Tie2 expression
P11139469A0402|68 71|Tie2
P11139469A0402|102 125|protein kinase C inhibitors
P11139469A0402|102 115|protein kinase C
P11139469A0402|131 164|intracellular Ca(2+) chelating agents
P11139473A0696|0 15|Promoter analysis
P11139473A0696|54 84|consensus cAMP-responsive element
P11139473A0696|63 84|cAMP-responsive element
P11139473A0696|86 88|CRE
P11139473A0696|86 88|CRE
P11139473A0696|99 102|-481
P11139473A0696|108 120|SMemb promoter
P11139473A0696|108 120|SMemb promoter
P11139473A0696|135 151|Hex responsiveness
P11139473A0696|135 137|Hex
P11139567A1440|0 22|LH/CG receptor activation
P11139567A1440|0 1|LH
P11139567A1440|3 12|CG receptor
P11139567A1440|25 28|ARNO
P11139567A1440|25 28|ARNO
P11139567A1440|56 83|phosphatidylinositol 3-kinase
P11139567A1440|56 83|phosphatidylinositol 3-kinase
P11139567A1440|85 94|PI 3-kinase
P11139567A1440|85 94|PI 3-kinase
P11139567A1440|100 124|G protein beta gamma subunits
P11139567A1440|100 116|G protein beta gamma
P11139605A0811|0 15|Deletion analysis
P11139605A0811|35 44|41 sequence
P11139605A0811|68 95|constitutive promoter activity
P11139605A0811|117 150|electrophoretic mobility shift assays
P11139605A0811|177 182|C/EBPs
P11139605A0811|177 182|C/EBPs
P11139605A0811|186 188|Sp1
P11139605A0811|186 188|Sp1
P11139974A0762|0 10|Termination
P11139974A0762|20 21|VT
P11139974A0762|56 63|BV pacing
P11139974A0762|77 84|RV pacing
P11140472A0497|68 77|algorithms
P11140472A0497|89 97|algorithm
P11140472A0497|144 152|algorithm
P11141003T0000|36 42|nucleus
P11141003T0000|45 64|cochlear implant users
P11142380A0389|0 46|Nuclease probing and structure-directed mutagenesis
P11142380A0389|66 75|nt TE (TE105
P11142380A0389|83 109|cruciform secondary structure
P11142380A0389|124 130|helices
P11142380A0389|142 163|single-stranded regions
P11143384A0267|0 8|Tele-Talk
P11143384A0267|43 46|live
P11145562A0000|20 48|type 1 insulin-like growth factor
P11145562A0000|25 48|insulin-like growth factor
P11145562A0000|50 61|IGF) receptor
P11145562A0000|50 61|IGF) receptor
P11145562A0000|63 68|IGF-IR
P11145562A0000|63 68|IGF-IR
P11145562A0000|78 100|prostate epithelial cells
P11145562A0000|128 133|benign
P11145562A0000|139 153|metastatic state
P11145562A0468|3 13|P69 cell line
P11145562A0468|43 77|human primary prostate epithelial cells
P11145562A0468|82 103|simian virus-40 T antigen
P11145562A0468|82 103|simian virus-40 T antigen
P11145563A0202|22 38|human StAR promoter
P11145563A0202|22 38|human StAR promoter
P11145563A0202|53 91|sterol regulatory element-binding proteins
P11145563A0202|53 91|sterol regulatory element-binding proteins
P11145563A0202|93 98|SREBPs
P11145563A0202|93 98|SREBPs
P11145563A0303|12 19|SREBP-1a
P11145563A0303|12 19|SREBP-1a
P11145563A0303|30 49|StAR promoter activity
P11145563A0303|30 41|StAR promoter
P11145563A0303|64 73|COS-1 cells
P11145563A0303|77 102|human granulosa-lutein cells
P11145566A0000|10 40|high-density lipoprotein receptor
P11145566A0000|10 40|high-density lipoprotein receptor
P11145566A0000|42 46|HDL-R
P11145566A0000|42 46|HDL-R
P11145566A0000|63 84|cholesterol homeostasis
P11145566A0000|89 114|potential therapeutic target
P11145566A0000|118 142|hypercholesterolemic drugs
P11145566A0000|161 175|HDL-R regulation
P11145566A0000|161 165|HDL-R
P11145571A0788|0 25|IFN-stimulated gene factor-3
P11145571A0788|0 25|IFN-stimulated gene factor-3
P11145571A0788|29 43|STAT1 homodimers
P11145571A0788|29 33|STAT1
P11145571A0788|60 88|IFN-stimulated response element
P11145571A0788|60 88|IFN-stimulated response element
P11145571A0788|90 120|ISRE) and gamma-activated sequence
P11145571A0788|90 93|ISRE
P11145571A0788|98 120|gamma-activated sequence
P11145571A0788|122 132|GAS) element
P11145571A0788|122 124|GAS
P11145590A0217|46 54|TGF-beta1
P11145590A0217|46 54|TGF-beta1
P11145590A0217|63 75|thyroglobulin
P11145590A0217|63 75|thyroglobulin
P11145590A0217|77 83|TG) gene
P11145590A0217|77 78|TG
P11145590A0217|80 93|gene expression
P11145590A0217|118 136|TGF-beta1 regulation
P11145590A0217|118 126|TGF-beta1
P11145590A0217|139 174|thyroid-specific transcription factors
P11145590A0217|139 174|thyroid-specific transcription factors
P11145717A0936|20 25|lysine
P11145717A0936|27 27|K
P11145717A0936|42 57|30-aa TPO fragment
P11145717A0936|47 49|TPO
P11145717A0936|65 84|N-terminal sequencing
P11145717A0936|98 101|K713
P11145743A0170|48 59|thyroid cells
P11145743A0170|72 98|thyroid transcription factor 1
P11145743A0170|72 98|thyroid transcription factor 1
P11145743A0170|100 104|TTF-1
P11145743A0170|100 104|TTF-1
P11145743A0170|112 142|paired domain-containing protein 8
P11145743A0170|112 142|paired domain-containing protein 8
P11145743A0170|144 148|Pax-8
P11145743A0170|144 148|Pax-8
P11145743A0170|183 201|deiodinase promoters
P11145743A0170|183 201|deiodinase promoters
P11145813A0668|0 16|Regional blood blow
P11145813A0668|51 67|predefined regions
P11145813A0668|73 78|C6, T11
P11145813A0668|73 74|C6
P11145813A0668|83 84|L6
P11145887A1393|35 42|AP-1 site
P11145887A1393|35 42|AP-1 site
P11145887A1393|45 55|Jurkat cells
P11145887A1393|58 61|JunD
P11145887A1393|58 61|JunD
P11145887A1393|68 72|Fra-2
P11145887A1393|68 72|Fra-2
P11145887A1393|81 85|c-Jun
P11145887A1393|81 85|c-Jun
P11145887A1393|87 90|JunB
P11145887A1393|87 90|JunB
P11145887A1393|95 99|c-Fos
P11145887A1393|95 99|c-Fos
P11145887A1393|161 163|Tax
P11145887A1393|161 163|Tax
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|52 58|ERalpha
P11145955A0189|52 58|ERalpha
P11145955A0189|82 95|gene expression
P11145955A0189|106 108|SRE
P11145955A0189|147 154|promoter
P11145955A0189|166 218|mitogen-activated protein kinase (MAPK) pathway activation
P11145955A0189|166 195|mitogen-activated protein kinase
P11145955A0189|197 200|MAPK
P11145955A0189|221 222|E2
P11145955A0189|221 222|E2
P11145955A0189|227 255|transforming growth factor alpha
P11145955A0189|227 255|transforming growth factor alpha
P11145955A0189|257 265|TGF-alpha
P11145955A0189|257 265|TGF-alpha
P11146961T0000|0 17|Perfusion technique
P11146961T0000|45 52|coronary
P11146961T0000|66 71|PADCAB
P11148042A1258|18 19|LA
P11148042A1258|43 45|PEs
P11148042A1258|97 116|peptide immiscibility
P11148042A1258|119 141|thicker gel state bilayers
P11148589A1124|80 110|Asian and Pacific Islander children
P11148589A1124|122 138|United States today
P11148589A1124|161 163|HBV
P11148589A1124|169 174|future
P11148589A1124|198 217|liver carcinoma deaths
P11149472A1257|10 20|NP/NMP4/CIZ
P11149472A1257|13 16|NMP4
P11149472A1257|18 20|CIZ
P11149472A1257|44 54|osteoblasts
P11149472A1257|73 79|rat bone
P11150114T0000|0 8|Chlamydia
P11150114T0000|12 25|cervical cancer
P11150315A0226|40 58|transcription factor
P11150315A0226|83 125|NGF-activated, but not EGF-activated, signaling
P11150315A0226|83 85|NGF
P11150315A0226|103 105|EGF
P11150315A0226|132 152|random oligonucleotide
P11150315A0226|164 184|DNA recognition library
P11150315A0226|202 219|DNA binding proteins
P11150315A0226|202 219|DNA binding proteins
P11150315A0226|224 227|PC12
P11150315A0226|228 242|nuclear extracts
P11150315A0844|0 2|NGF
P11150315A0844|0 2|NGF
P11150315A0844|34 51|ERK phosphorylation
P11150315A0844|34 36|ERK
P11150315A0844|56 58|EGF
P11150315A0844|56 58|EGF
P11150315A1126|0 2|NGF
P11150315A1126|0 2|NGF
P11150315A1126|10 12|EGF
P11150315A1126|10 12|EGF
P11150315A1126|65 69|Fra-2
P11150315A1126|65 69|Fra-2
P11150439A0701|6 16|expenditure
P11150439A0701|34 39|primed
P11150439A0701|57 59|NaH
P11150439A0701|71 76|breath
P11150439A0701|111 138|isotope ratio mass spectroscopy
P11150439A0701|168 185|regression equation
P11151826T0000|0 7|Workload
P11151826T0000|9 12|UAPs
P11152070A0573|3 10|actA gene
P11152070A0573|3 10|actA gene
P11152070A0573|46 58|A. chrysogenum
P11152070A0573|92 95|pcbC
P11152070A0573|92 95|pcbC
P11152070A0573|99 133|cefEF cephalosporin biosynthetic genes
P11152070A0573|99 133|cefEF cephalosporin biosynthetic genes
P11152070A0573|150 174|cephalosporin fermentation
P11152081A0413|12 14|SDS
P11152081A0413|22 55|transient inhibition of acidification
P11152081A0413|57 75|metal solubilization
P11152081A0413|79 93|sulfur oxidation
P11152283A0223|27 29|NGF
P11152283A0223|27 29|NGF
P11152283A0223|42 58|gene transcription
P11152283A0223|61 77|PC12 and INS-1 cells
P11152283A0223|68 72|INS-1
P11152283A0223|104 121|NGF-regulated genes
P11152283A0223|104 106|NGF
P11152344A0416|0 10|Nine animals
P11152344A0416|43 49|animals
P11152344A0416|59 76|focal arachnoid scar
P11152344A0416|79 83|C1-C2
P11152344A0416|79 83|C1-C2
P11152344A0416|115 139|kaolin-soaked fibrin sponge
P11152344A0416|128 133|fibrin
P11152344A0416|166 175|spinal cord
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A0529|31 37|SmSmad2
P11152451A0529|31 37|SmSmad2
P11152451A0529|68 88|Sj26-GST fusion protein
P11152451A0529|68 71|Sj26
P11152451A0529|73 75|GST
P11152451A0529|103 120|specific antibodies
P11152451A1580|24 30|SmSmad2
P11152451A1580|24 30|SmSmad2
P11152451A1580|44 58|TGF-beta signals
P11152451A1580|44 51|TGF-beta
P11152451A1580|76 84|receptor I
P11152451A1580|76 84|receptor I
P11152451A1580|138 144|nucleus
P11152451A1580|218 231|TGF-beta effect
P11152451A1580|218 225|TGF-beta
P11152521A0181|6 16|Flag-tagged
P11152521A0181|58 81|genomic expression vectors
P11152521A0181|121 145|primase-helicase component
P11152521A0181|121 136|primase-helicase
P11152521A0181|168 179|127-bp intron
P11152963A0000|15 30|src homology 3 (SH3
P11152963A0000|15 26|src homology 3
P11152963A0000|28 30|SH3
P11152963A0000|64 73|astrocytes
P11152963A0000|75 83|SETA) gene
P11152963A0000|75 83|SETA) gene
P11152963A0000|100 122|astrocyte transformation
P11152963A0000|135 140|tumors
P11152963A0000|146 155|adult brain
P11153302A0000|0 22|Naltrexone hydrochloride
P11153302A0000|35 58|opioid receptor antagonist
P11153302A0000|94 113|opioid detoxification
P11154491A0322|37 60|patients (mean age 61 years)
P11154491A0322|65 85|focal pancreatic masses
P11154491A0322|97 98|CT
P11154491A0322|109 115|EUS-FNA
P11154491A0322|155 166|gauge needles
P11155096A0222|8 14|Thyroid
P11155096A0222|43 49|1990-93
P11155096A0222|71 85|serum antibodies
P11155096A0222|71 85|serum antibodies
P11155096A0222|88 104|thyroid peroxidase
P11155096A0222|88 104|thyroid peroxidase
P11155096A0222|106 112|TPO-Abs
P11155096A0222|106 112|TPO-Abs
P11155096A0222|133 146|serum TSH levels
P11155096A0222|138 140|TSH
P11155096A0222|155 157|TSH
P11155096A0222|155 157|TSH
P11155096A0222|186 204|serum thyroxin levels
P11156303A1098|13 37|ventriculopleural shunting
P11156303A1098|83 100|peritoneal drainage
P11156303A1098|103 110|children
P11156303A1098|115 119|intra
P11156303A1098|161 179|peritoneal infection
P11156413T0000|0 9|Derivation
P11156413T0000|39 63|mouse mammary tumor cell line
P11156413T0000|75 100|polyomavirus middle T antigen
P11156413T0000|75 100|polyomavirus middle T antigen
P11156413T0000|132 149|cancer therapeutics
P11156484A0223|0 10|TBARS levels
P11156484A0223|12 47|oxygen-radical absorbing capacity assay
P11156484A0223|51 53|AFR
P11156484A0223|51 53|AFR
P11156484A0223|71 103|electron paramagnetic resonance (EPR
P11156484A0223|136 150|oxidative stress
P11156484A0223|153 160|diabetes
P11156618T0000|0 9|Long-range
P11156618T0000|22 41|human and mouse SCL loci
P11156618T0000|30 41|mouse SCL loci
P11156618T0000|74 97|restriction endonucleases
P11156618T0000|128 154|conserved noncoding sequences
P11156789A1669|54 74|increased CSF pulsation
P11156789A1669|77 84|children
P11156789A1669|227 236|CSF protein
P11156789A1669|227 229|CSF
P11156789A1669|290 292|CSF
P11157035A1405|83 96|clinical trials
P11157035A1405|107 117|IFN alpha-2b
P11157035A1405|107 117|IFN alpha-2b
P11157035A1405|142 148|therapy
P11157334A1107|0 7|Serum PTH
P11157334A1107|29 35|WL group
P11157334A1107|47 53|WM group
P11157763T0000|14 25|EMAPII domain
P11157763T0000|14 25|EMAPII domain
P11157763T0000|28 63|human aminoacyl-tRNA synthetase complex
P11157763T0000|28 56|human aminoacyl-tRNA synthetase
P11157763T0000|71 94|evolutionary dimer mimicry
P11157774A0789|11 47|dSLBP alleles support zygotic development
P11157774A0789|11 22|dSLBP alleles
P11157774A0789|56 70|female sterility
P11157784A0141|11 19|DGCR6 gene
P11157784A0141|11 19|DGCR6 gene
P11157784A0141|22 36|chromosome 22q11
P11157784A0141|44 56|low copy repeat
P11157784A0141|64 70|sc11.1a
P11157784A0141|106 111|DGCR6L
P11157784A0141|106 111|DGCR6L
P11157784A0141|122 135|duplicate locus
P11157784A0141|143 149|sc11.1b
P11157879A0192|38 48|fluorescein
P11157879A0192|59 61|BRB
P11157879A0192|59 61|BRB
P11157879A0192|78 96|vitreous fluorometry
P11158236A0000|0 16|Nerve growth factor
P11158236A0000|5 16|growth factor
P11158236A0000|18 20|NGF
P11158236A0000|18 20|NGF
P11158236A0000|25 39|retinoic acid (RA
P11158236A0000|25 36|retinoic acid
P11158236A0000|38 39|RA
P11158236A0000|64 72|PC12 cells
P11158288T0000|15 36|RNA polymerase II complex
P11158288T0000|15 36|RNA polymerase II complex
P11158288T0000|82 85|CREB
P11158288T0000|82 85|CREB
P11158288T0000|102 120|CREB phosphorylation
P11158288T0000|102 105|CREB
P11158290A0728|23 29|serines
P11158290A0728|47 70|N-terminal destruction box
P11158290A0728|73 90|IkappaBalpha, -beta
P11158290A0728|73 84|IkappaBalpha
P11158290A0728|86 102|-beta, and -epsilon
P11158295A0158|30 41|kinase domain
P11158295A0158|44 46|Csk
P11158295A0158|44 46|Csk
P11158295A0158|58 87|Src homology 3 (SH3) and SH2 regions
P11158295A0158|58 69|Src homology 3
P11158295A0158|71 73|SH3
P11158295A0158|78 87|SH2 regions
P11158310A0993|24 27|ERSF
P11158310A0993|24 27|ERSF
P11158310A0993|37 40|NF-Y
P11158310A0993|37 40|NF-Y
P11158310A0993|44 62|ATF6alpha and/or beta
P11158310A0993|44 52|ATF6alpha
P11158310A0993|59 62|beta
P11158310A0993|84 87|ERSE
P11158310A0993|109 119|cellular UPR
P11158324A1073|62 88|very-low-density lipoprotein
P11158324A1073|137 151|apolipoprotein B
P11158324A1073|137 151|apolipoprotein B
P11158324A1073|155 191|microsomal triglyceride transfer protein
P11158324A1073|155 164|microsomal
P11158324A1073|165 176|triglyceride
P11158324A1073|209 232|hepatic cholesterol uptake
P11158324A1073|267 297|high-density lipoprotein receptor
P11158324A1073|267 297|high-density lipoprotein receptor
P11158324A1073|299 317|scavenger receptor BI
P11158324A1073|316 317|BI
P11158324A1073|338 351|bile acid uptake
P11158324A1073|403 440|bile acid transporters sodium taurocholate
P11158324A1073|464 494|organic anion transporter protein 1
P11158326A1032|27 31|SHIP2
P11158326A1032|27 31|SHIP2
P11158326A1032|56 64|SH2 domain
P11158326A1032|56 64|SH2 domain
P11158326A1032|66 69|R47G
P11158326A1032|66 69|R47G
P11158337A0000|3 44|gonadotrope-specific and regulated expression
P11158337A0000|50 73|GnRH receptor (GnRH-R) gene
P11158337A0000|50 61|GnRH receptor
P11158337A0000|63 66|GnRH
P11158337A0000|68 73|R) gene
P11158337A0000|95 114|transcription factors
P11158337A0000|134 169|noncanonical GnRH-R activating sequence
P11158337A0000|146 169|GnRH-R activating sequence
P11158337A0000|171 174|GRAS
P11158337A0000|171 174|GRAS
P11158337A0000|180 210|activator protein-1 (AP-1) element
P11158337A0000|180 197|activator protein-1
P11158337A0000|199 202|AP-1
P11158337A0000|218 238|steroidogenic factor-1
P11158337A0000|218 238|steroidogenic factor-1
P11158337A0000|240 243|SF-1
P11158337A0000|240 243|SF-1
P11158456A0223|116 118|BHS
P11158456A0223|203 208|spells
P11159081A1155|13 16|21.4
P11159081A1155|23 31|MR imaging
P11159081A1155|60 75|microscopic tumor
P11159081A1155|98 107|reexcision
P11159363A1251|0 10|Methylation
P11159363A1251|17 32|cytosine residues
P11159363A1251|38 58|E2F element ((m)CG(m)CG
P11159363A1251|38 47|E2F element
P11159363A1251|50 53|m)CG
P11159363A1251|55 55|m
P11159363A1251|73 113|methylcytosine-specific DNA-protein complex
P11159363A1251|96 106|DNA-protein
P11160096A1067|5 13|mutations
P11160096A1067|28 40|wild-type fliF
P11160096A1067|37 50|fliF background
P11160280A1275|7 33|IFN-gamma-induced expression
P11160280A1275|7 15|IFN-gamma
P11160280A1275|36 40|IRF-1
P11160280A1275|36 40|IRF-1
P11160280A1275|59 68|IRF element
P11160280A1275|59 68|IRF element
P11160307A0394|13 21|wH22xeGFP
P11160307A0394|13 21|wH22xeGFP
P11160307A0394|42 67|humanized anti-FcgammaRI mAb
P11160307A0394|56 70|FcgammaRI mAb H22
P11160307A0394|68 70|H22
P11160307A0394|75 78|eGFP
P11160307A0394|75 78|eGFP
P11160307A0394|100 112|C-terminal end
P11160307A0394|119 127|CH3 domain
P11160307A0394|119 127|CH3 domain
P11160307A0394|129 137|wH22xeGFP
P11160307A0394|129 137|wH22xeGFP
P11160307A0394|152 171|ligand-binding region
P11160307A0394|177 181|Fc end
P11160307A0394|201 220|ligand-binding region
P11160307A0394|226 228|Fab
P11160307A0394|254 262|FcgammaRI
P11160307A0394|254 262|FcgammaRI
P11160656A0000|0 9|Inactivity
P11160656A0000|15 76|human cytomegalovirus (HCMV) major immediate-early regulatory region
P11160656A0000|15 34|human cytomegalovirus
P11160656A0000|36 39|HCMV
P11160656A0000|41 76|major immediate-early regulatory region
P11160656A0000|78 82|MIERR
P11160656A0000|78 82|MIERR
P11160656A0000|102 109|promoter
P11160656A0000|111 118|enhancer
P11160656A0000|162 176|HCMV replication
P11160656A0000|179 199|latently infected cells
P11160656A0000|242 280|human embryonal NTera2 carcinoma (NT2) cells
P11160683A1220|33 42|C/EBP dimer
P11160683A1220|59 67|C/EBP site
P11160683A1220|59 67|C/EBP site
P11160683A1220|83 88|CREB-1
P11160683A1220|83 88|CREB-1
P11160683A1220|102 114|ATF/CREB sites
P11160683A1220|102 104|ATF
P11160683A1220|106 114|CREB sites
P11160683A1220|135 138|CREB
P11160683A1220|135 138|CREB
P11160688A1726|3 17|metabolic events
P11160688A1726|60 67|cyclin D3
P11160688A1726|60 67|cyclin D3
P11160688A1726|91 94|ICP0
P11160688A1726|91 94|ICP0
P11160688A1726|100 108|cytoplasm
P11160721A0932|0 21|Transient transfections
P11160721A0932|33 51|single mutation (556M
P11160721A0932|62 81|TBLV enhancer activity
P11160721A0932|62 73|TBLV enhancer
P11160721A0932|110 120|T-cell lines
P11160732A0464|6 37|stocks containing envelope proteins
P11160732A0464|22 37|envelope proteins
P11160732A0464|56 67|SIVmac clones
P11160732A0464|76 84|SIVmac239
P11160732A0464|86 103|T-lymphocyte tropic
P11160732A0464|105 112|T-tropic
P11160732A0464|116 124|SIVmac316
P11160732A0464|126 141|macrophage tropic
P11160732A0464|143 150|M-tropic
P11160732A0464|157 166|SIVmac1A11
P11160732A0464|168 177|dualtropic
P11160732A1199|74 80|nucleus
P11160732A1199|95 105|macrophages
P11160732A1199|132 145|316 pseudotypes
P11160732A1199|164 174|restriction
P11160732A1199|178 186|SIVmac239
P11160732A1199|203 222|reverse transcription
P11160732A1199|226 238|nuclear import
P11160732A1199|241 248|viral DNA
P11160738A1414|8 22|anti-interferon
P11160738A1414|8 22|anti-interferon
P11160738A1414|34 39|vIRF-2
P11160738A1414|34 39|vIRF-2
P11160738A1414|74 97|chronic or latent infection
P11160742A0696|4 4|Z
P11160742A0696|4 4|Z
P11160742A0696|8 18|R expression
P11160742A0696|8 8|R
P11160742A0696|29 41|PML dispersion
P11160742A0696|44 60|EBV-positive cells
P11160860A0662|27 39|IkappaB kinase
P11160860A0662|27 39|IkappaB kinase
P11160860A0662|41 48|IKK-beta
P11160860A0662|41 48|IKK-beta
P11160860A0662|78 96|NF-kappaB activation
P11160860A0662|78 86|NF-kappaB
P11160860A0662|104 125|IkappaB phosphorylation
P11160860A0662|104 110|IkappaB
P11160860A0662|147 169|paclitaxel-treated cells
P11160860A0662|181 192|IkappaBalpha
P11160860A0662|181 192|IkappaBalpha
P11160896A0713|0 24|Immunofluorescence studies
P11160896A0713|27 39|C2C12 myotubes
P11160896A0713|48 52|Smad2
P11160896A0713|48 52|Smad2
P11160896A0713|56 60|MEF2A
P11160896A0713|56 60|MEF2A
P11160896A0713|77 83|nucleus
P11160896A0713|86 105|multinuclear myotubes
P11160902A0962|13 16|TFOs
P11160902A0962|84 109|c-sis/PDGF-B proto-oncogene
P11160902A0962|84 88|c-sis
P11160902A0962|90 109|PDGF-B proto-oncogene
P11160929T0000|0 13|Rapid evolution
P11160929T0000|19 33|DNA-binding site
P11160929T0000|19 33|DNA-binding site
P11160929T0000|36 63|LAGLIDADG homing endonucleases
P11160929T0000|36 44|LAGLIDADG
P11160929T0000|45 63|homing endonucleases
P11161455A1286|0 19|Southern blot analysis
P11161455A1286|22 31|genomic DNA
P11161455A1286|36 53|somatic cell hybrids
P11161455A1286|64 91|endothelial-TACC-related cDNA
P11161455A1286|64 79|endothelial-TACC
P11161455A1286|98 109|chromosome 10
P11161793A1033|13 37|truncated receptor isoforms
P11161793A1033|13 37|truncated receptor isoforms
P11161793A1033|122 133|EGFR activity
P11161793A1033|122 125|EGFR
P11161816A0851|36 53|endophilin proteins
P11161816A0851|62 75|entire sequence
P11161816A0851|81 92|SH3GLB family
P11161816A0851|81 92|SH3GLB family
P11162278A0629|0 13|Mental rotation
P11162278A0629|16 48|paired figures engendered activation
P11162278A0629|54 79|left superior parietal lobule
P11162278A0629|86 108|right frontal medial gyrus
P11162576A0213|67 71|exons
P11162576A0213|77 92|intronic promoter
P11162576A0213|98 111|human PDE5A gene
P11162576A0213|98 111|human PDE5A gene
P11162666A0442|3 28|glucose/insulin stimulation
P11162666A0442|11 17|insulin
P11162666A0442|56 80|polyunsaturated fatty acids
P11162936A2727|56 64|estrogens
P11162936A2727|67 79|antiestrogens
P11162936A2727|83 89|ERalpha
P11162936A2727|83 89|ERalpha
P11162936A2727|92 97|ERbeta
P11162936A2727|92 97|ERbeta
P11162936A2727|118 134|tissue selectivity
P11162936A2727|151 185|menopausal hormone replacement therapy
P11162936A2727|216 227|breast cancer
P11163932A0000|0 15|Behavioural tests
P11163932A0000|20 30|192 specimen
P11163932A0000|36 51|roman garden snail
P11163932A0000|52 63|Helix pomatia
P11163932A0000|196 209|air temperature
P11163968A0152|45 64|Pyrococcus horikoshii
P11163968A0152|68 83|Pyrococcus abyssi
P11163968A0152|105 129|hyperthermophilic archaeon
P11163968A0152|131 145|archaebacterium
P11163968A0152|168 191|large genome polymorphisms
P11164078A0833|4 14|animal model
P11164078A0833|17 24|dystonia
P11164078A0833|44 46|NAD
P11166478T0000|0 9|Peripheral
P11166863A0167|19 20|CI
P11166863A0167|29 36|patients
P11166863A0167|58 70|acute toxicity
P11166863A0167|72 75|RTOG
P11167019A1249|3 12|TATA' motif
P11167019A1249|39 47|GABPalpha
P11167019A1249|39 47|GABPalpha
P11167019A1249|50 81|ATPsynCF6 transcription start sites
P11167019A1249|50 58|ATPsynCF6
P11167111A0957|13 40|higher lung function parameters
P11167111A0957|55 73|extubated recipients
P11167111A0957|105 106|TX
P11167778T0000|0 29|Acquired antithrombin deficiency
P11167778T0000|8 19|antithrombin
P11167778T0000|32 37|sepsis
P11168366A0569|26 40|genomic fragment
P11168366A0569|64 74|5' sequences
P11168366A0569|80 91|major GGT mRNA
P11168366A0569|80 91|major GGT mRNA
P11168366A0569|94 103|HepG2 cells
P11168422A0248|12 22|387, 370-376
P11168422A0248|42 75|metal fluoride ions replaced phosphate
P11168422A0248|84 99|ATP-binding sites
P11168422A0248|84 86|ATP
P11168422A0248|105 115|iron protein
P11168422A0248|117 119|Kp2
P11168422A0248|117 119|Kp2
P11168446T0000|9 31|erythropoietin synthesis
P11168446T0000|9 22|erythropoietin
P11168446T0000|34 41|patients
P11168446T0000|46 49|COLD
P11168446T0000|52 67|left heart failure
P11168446T0000|92 109|renal haemodynamics
P11168588T0000|12 37|herpes simplex virus type 2 US3
P11168588T0000|12 37|herpes simplex virus type 2 US3
P11168588T0000|48 63|Cdc42/Rac pathway
P11168588T0000|48 52|Cdc42
P11168588T0000|54 56|Rac
P11168588T0000|77 107|c-Jun N-terminal kinase activation
P11168588T0000|77 97|c-Jun N-terminal kinase
P11169080T0000|46 53|Bok's Law
P11169113A0555|22 26|p16.7
P11169113A0555|22 24|p16
P11169113A0555|29 39|phi29 mutant
P11169113A0555|51 70|suppressible mutation
P11169149A0097|24 28|SNTCS
P11170476A1546|3 24|extraordinary stability
P11170476A1546|27 48|peptide--gp96 complexes
P11170476A1546|36 48|gp96 complexes
P11170476A1546|55 64|plasticity
P11170476A1546|70 76|peptide
P11170476A1546|85 90|pocket
P11170476A1546|133 135|MHC
P11170476A1546|133 135|MHC
P11170476A1546|159 178|molecular recognition
P11171118A0836|22 25|NF-1
P11171118A0836|22 25|NF-1
P11171118A0836|28 32|PSE-B
P11171118A0836|28 32|PSE-B
P11171118A0836|42 46|PSE-A
P11171118A0836|42 46|PSE-A
P11171118A0836|75 97|DNA-protein interactions
P11171118A0836|75 85|DNA-protein
P11171118A0836|105 119|NF-1 DNA elements
P11171118A0836|105 108|NF-1
P11171118A0836|123 132|antibodies
P11171320A0894|17 32|p120(ctn) protein
P11171320A0894|17 20|p120
P11171320A0894|22 24|ctn
P11171320A0894|39 56|N-terminal deletion
P11171320A0894|39 48|N-terminal
P11171320A0894|86 113|tyrosine phosphorylation sites
P11171320A0894|138 146|amino acid
P11171320A0894|160 167|tyrosine
P11171320A0894|170 187|217 to phenylalanine
P11171320A0894|227 231|v-Src
P11171320A0894|227 231|v-Src
P11171320A0894|244 261|EL and EalphaCL cells
P11172610A0508|10 12|p73
P11172610A0508|10 12|p73
P11172610A0508|49 73|cellular and viral promoters
P11172944A0548|15 22|patients
P11172944A0548|28 44|Grade 1 pneumonitis
P11172944A0548|54 70|Grade 2 pneumonitis
P11172944A0826|61 68|TNFalpha
P11172944A0826|61 68|TNFalpha
P11172944A0826|72 91|radiation pneumonitis
P11175333A0336|5 41|immunochemical co-precipitation methods
P11176098A0342|15 18|pigs
P11176098A0342|51 55|shock
P11176290T0000|42 63|radiofrequency ablation
P11176290T0000|67 84|atrial fibrillation
P11176290T0000|90 92|MRI
P11177538A0655|0 13|Tumor cell lines
P11177538A0655|28 30|MOI
P11177686A0243|31 38|surgical
P11177686A0243|105 121|pneumatic dilation
P11178248A1042|103 111|positives
P11178696A0301|6 13|US images
P11178696A0301|38 42|30, 40
P11178696A0301|47 55|60, 90, 120
P11178696A0301|57 67|150, 180, 240
P11178696A0301|125 136|conventional
P11178696A0301|140 147|harmonic
P11178696A0301|148 151|PD US
P11178765A0642|25 33|exogenous
P11178765A0642|34 47|hyaluronic acid
P11178765A0642|65 83|port-site metastasis
P11178765A0642|100 118|mouse adenocarcinoma
P11179272T0000|0 14|Cytomegalovirus
P11179272T0000|16 34|Chlamydia pneumoniae
P11179272T0000|39 69|Helicobacter pylori IgG antibodies
P11179272T0000|57 69|IgG antibodies
P11179272T0000|123 150|intravascular ultrasound study
P11179400T0000|11 46|single-unit carotid body chemoreceptors
P11179400T0000|49 57|adult rats
P11179664T0000|0 11|Architecture
P11179664T0000|27 38|genomic locus
P11179664T0000|50 92|human leukemia-associated transcription factor
P11179664T0000|50 92|human leukemia-associated transcription factor
P11179664T0000|93 102|RUNX1/AML1
P11179664T0000|93 97|RUNX1
P11179664T0000|99 102|AML1
P11179668A0869|53 62|PLTP family
P11179668A0869|53 62|PLTP family
P11179687A0280|14 45|tyrosine dephosphorylating enzymes
P11179687A0280|50 77|protein-tyrosine phosphatases
P11179687A0280|50 77|protein-tyrosine phosphatases
P11179687A0280|79 82|PTPs
P11179687A0280|79 82|PTPs
P11179687A0280|116 129|two subfamilies
P11179687A0280|141 144|PTPs
P11179687A0280|141 144|PTPs
P11179687A0280|151 162|receptor PTPs
P11179687A0280|151 162|receptor PTPs
P11179687A0280|164 168|RPTPs
P11179687A0280|164 168|RPTPs
P11179687A1118|3 12|Ig-related
P11179687A1118|3 4|Ig
P11179687A1118|21 28|metazoan
P11179687A1118|70 78|Ig members
P11179687A1118|70 78|Ig members
P11179689A0000|3 15|Sox gene family
P11179689A0000|3 5|Sox
P11179689A0000|17 33|Sry like HMG box gene
P11179689A0000|17 33|Sry like HMG box gene
P11179689A0000|62 72|DNA sequence
P11179689A0000|136 161|sequence specific DNA binding
P11179956A1818|64 79|C-terminal domain
P11179956A1818|64 79|C-terminal domain
P11179956A1818|82 98|nucleotide binding
P11179956A1818|142 158|N-terminal domains
P11179956A1818|142 158|N-terminal domains
P11179956A1818|180 194|proton transport
P11180027A1306|0 20|Respiratory parameters
P11180027A1306|34 36|M6G
P11180027A1306|49 69|respiratory depression
P11180027A1306|74 81|morphine
P11180255A0776|141 145|space
P11180688A0000|18 29|oxygen uptake
P11180688A0000|56 63|children
P11180688A0000|94 113|respiratory illnesses
P11180688A0000|151 153|MFT
P11180688A0000|157 160|20-m
P11180688A0000|168 174|run test
P11181516A0119|11 55|5'-deletion insulin promoter-reporter constructs
P11181516A0119|22 55|insulin promoter-reporter constructs
P11181516A0119|58 79|transient transfections
P11181516A0119|82 102|clonal INS-1 beta-cells
P11181516A0119|88 96|INS-1 beta
P11181516A0119|113 142|activating Hh-responsive regions
P11181516A0119|123 142|Hh-responsive regions
P11181516A0119|152 170|rat insulin I promoter
P11181516A0119|152 154|rat
P11181516A0119|155 170|insulin I promoter
P11181516A0119|185 191|glucose
P11181516A0119|213 214|E2
P11181516A0119|213 214|E2
P11181516A0119|219 228|Flat (A2/A3
P11181516A0119|219 222|Flat
P11181516A0119|224 225|A2
P11181516A0119|227 228|A3
P11181525T0000|3 18|androgen receptor
P11181525T0000|3 18|androgen receptor
P11181525T0000|20 21|AR
P11181525T0000|20 21|AR
P11181525T0000|44 70|androgen-specific regulation
P11181525T0000|73 88|AR gene expression
P11181525T0000|73 78|AR gene
P11181525T0000|94 107|exonic enhancer
P11181531A0464|22 30|estrogens
P11181531A0464|38 49|osteoporosis
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|116 145|osteoclast-activating cytokines
P11181531A0464|146 158|interleukin-6
P11181531A0464|146 158|interleukin-6
P11181531A0464|162 174|interleukin-1
P11181531A0464|162 174|interleukin-1
P11181548A0214|22 45|cis-DNA regulatory element
P11181548A0214|62 103|tissue-, region-, and cell-specific expression
P11181548A0214|109 119|mE-RABP gene
P11181548A0214|109 119|mE-RABP gene
P11181548A0214|124 138|5-kb DNA fragment
P11181548A0214|124 138|5-kb DNA fragment
P11181564A0733|15 19|genes
P11181564A0733|31 47|syntenic region 8E1
P11181564A0733|50 60|chromosome 8
P11181995A1093|57 67|transcripts
P11181995A1093|139 159|12,000 computationally
P11181995A1093|176 180|mouse
P11182520A0889|16 23|genotype
P11182520A0889|42 69|restriction enzyme-based assay
P11182746A0872|13 20|patients
P11182746A0872|55 65|drug therapy
P11185475T0034|2 8|Caveman
P11187016T0000|0 15|Multistage models
P11187016T0000|22 35|A-bomb survivor
P11187016T0000|56 77|carcinogenic mechanisms
P11188971A0000|3 16|revitalization
P11188971A0000|19 25|surgery
P11188971A0000|29 46|Parkinson's disease
P11188971A0000|48 50|PD)
P11188993A0298|0 15|Corneal scrapping
P11188993A0298|19 22|deep
P11188993A0298|61 81|microscopic evaluation
P11188993A0298|86 104|periodic acid-Schiff
P11188993A0298|116 134|Gomori's methenamine
P11189314A1000|24 27|BACM
P11189314A1000|78 81|GLCM
P11191208A0000|0 18|Multidrug resistance
P11191208A0000|21 43|Saccharomyces cerevisiae
P11191208A0000|80 84|genes
P11191208A0000|97 115|membrane efflux pumps
P11191208A0000|143 172|ABC binding cassette transporters
P11191208A0000|143 172|ABC binding cassette transporters
P11191208A0000|194 216|transcription regulators
P11191208A0000|229 244|PDR1 and PDR3 genes
P11191208A0000|229 232|PDR1
P11191208A0000|236 244|PDR3 genes
P11191365A0682|16 42|ischemia-induced arrhythmias
P11191365A0682|78 91|diabetic hearts
P11191365A0682|112 125|tachycardia (VT
P11191365A0682|151 173|ventricular fibrillation
P11191365A0682|175 176|VF
P11191365A0682|234 246|non-diabetics
P11193045A1193|0 7|A picture
P11193045A1193|49 51|p53
P11193045A1193|49 51|p53
P11193045A1193|53 55|p73
P11193045A1193|53 55|p73
P11193045A1193|57 59|p63
P11193045A1193|57 59|p63
P11193045A1193|71 86|tumor suppression
P11193666A1269|36 56|Babesia carrier animals
P11193666A1269|82 85|herd
P11193704A0000|0 30|Contagious bovine pleuropneumonia
P11194101A0532|8 16|BMD values
P11194101A0532|44 65|oligo-amenorrheic group
P11194101A0532|96 106|lumbar spine
P11194101A0532|143 159|oligo-amenorrheic
P11194101A0532|192 196|cm(-2
P11194101A0532|227 243|contraceptive user
P11194101A0532|286 289|bone
P11194101A0532|296 319|proximal and midshaft femur
P11194147A1496|17 34|red rice cultivation
P11194147A1496|37 44|Sri Lanka
P11194147A1496|64 75|HIDD villages
P11194183A0866|21 33|terminal hairs
P11194183A0866|133 159|procyanidin B-2 group subjects
P11194183A0866|216 242|placebo control group subjects
P11194183A0866|244 257|procyanidin B-2
P11194183A0866|299 302|0.82
P11195338A0494|0 16|Ectopic expression
P11195338A0494|22 44|dominant mutant Lg3 allele
P11195338A0494|22 44|dominant mutant Lg3 allele
P11195401A1030|10 12|AVP
P11195401A1030|51 55|SSRIs
P11195401A1030|65 76|AVP secretion
P11195401A1030|65 67|AVP
P11195401A1030|92 96|SIADH
P11196191A1789|7 30|T47D breast carcinoma cells
P11196191A1789|32 35|IL-6
P11196191A1789|32 35|IL-6
P11196191A1789|53 80|EGF receptor autocrine activity
P11196191A1789|53 63|EGF receptor
P11196191A1789|99 102|MAPK
P11196191A1789|99 102|MAPK
P11196191A1789|104 115|PI3K pathways
P11196191A1789|104 107|PI3K
P11196199T0000|0 13|Human homologue
P11196199T0000|16 33|yeast Rad23 protein A
P11196199T0000|16 33|yeast Rad23 protein A
P11196199T0000|47 51|p300/
P11196199T0000|47 50|p300
P11196199T0000|52 106|cyclic AMP-responsive element binding (CREB)-binding protein
P11196199T0000|52 78|cyclic AMP-responsive element
P11196199T0000|87 106|CREB)-binding protein
P11196199T0000|147 149|p53
P11196199T0000|147 149|p53
P11196340A1046|3 22|immunological methods
P11196340A1046|44 51|antigens
P11197288A0855|4 11|patients
P11197288A0855|21 68|metronidazole- and clarithromycin-resistant strains
P11197328T0000|9 40|cell type-specific nuclear proteins
P11197328T0000|46 62|5'-flanking region
P11197328T0000|65 105|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|65 71|maize C4
P11197328T0000|91 105|carboxylase gene
P11197328T0000|116 140|differential transcription
P11197328T0000|143 156|mesophyll cells
P11197549A0748|37 41|PaCO2
P11197926A0000|60 66|12-item
P11197926A0000|80 86|General
P11197926A0000|107 109|GHQ
P11198053T0000|0 11|Acute effects
P11198053T0000|14 26|LI 160 (extract
P11198053T0000|29 60|Hypericum perforatum, St John's wort
P11198053T0000|87 109|neuroendocrine responses
P11198053T0000|115 117|rat
P11198289T0000|9 26|serum ceruloplasmin
P11198289T0000|9 26|serum ceruloplasmin
P11198289T0000|30 41|copper levels
P11198289T0000|44 59|cervical dystonia
P11198385A0000|1 14|microsporidian
P11198385A0000|16 33|Nosema algerae Vavra
P11198385A0000|37 42|undeen
P11198385A0000|100 111|Culex pipiens
P11198385A0000|112 123|L. originated
P11198385A0000|128 145|Gharbia Governorate
P11198424T0000|0 15|Molecular cloning
P11198424T0000|37 41|OsPSK
P11198424T0000|37 41|OsPSK
P11198424T0000|69 88|phytosulfokine-alpha
P11198424T0000|69 88|phytosulfokine-alpha
P11198424T0000|101 121|rice cell proliferation
P11200568A0830|0 4|Blood
P11200568A0830|9 12|dams
P11200568A0830|78 80|IgM
P11200568A0830|78 80|IgM
P11200568A0830|84 96|IgG antibodies
P11200568A0830|84 96|IgG antibodies
P11200568A0830|99 108|M. pulmonis
P11201250A0849|0 8|Plasma DHE
P11201250A0849|69 71|PSA
P11201250A0849|83 106|damaged skin in hairless rat
P11202434T0000|6 27|amino acid substitutions
P11202434T0000|33 54|acyl-CoA-binding domain
P11202434T0000|33 41|acyl-CoA-
P11202434T0000|67 81|C]palmitoyl-CoA
P11202434T0000|91 95|ACBP2
P11202434T0000|91 95|ACBP2
P11202434T0000|99 132|Arabidopsis acyl-CoA-binding protein
P11202434T0000|99 132|Arabidopsis acyl-CoA-binding protein
P11202434T0000|137 150|ankyrin repeats
P11202434T0000|137 143|ankyrin
P11202705A1112|94 110|Posidonia oceanica
P11203702A1307|5 10|Xlim-1
P11203702A1307|5 10|Xlim-1
P11203702A1307|33 61|tyrosine-rich activation domain
P11203702A1307|78 101|negative regulatory domain
P11203702A1307|104 112|CT239-403
P11203702A1307|189 194|Xlim-1
P11203702A1307|189 194|Xlim-1
P11204897A0797|53 71|bridge simulator task
P11207216A0296|3 18|bovine PGHS-2 cDNA
P11207216A0296|9 18|PGHS-2 cDNA
P11207216A0296|44 87|reverse transcription-polymerase chain reaction
P11207216A0296|44 79|reverse transcription-polymerase chain
P11207216A0296|91 110|cDNA library screening
P11207216A0719|15 24|PGHS-2 mRNA
P11207216A0719|15 24|PGHS-2 mRNA
P11207216A0719|64 69|bovine
P11207216A0719|70 76|uterine
P11207216A0719|103 131|phorbol 12-myristate 13-acetate
P11207216A0719|133 135|PMA
P11207261A1421|27 53|PTP-deficient DT40 B cell lines
P11207261A1421|27 29|PTP
P11207261A1421|79 98|chimeric Fc gamma RIIB1
P11207261A1421|87 98|Fc gamma RIIB1
P11207261A1421|100 114|PECAM-1 receptor
P11207261A1421|100 114|PECAM-1 receptor
P11207261A1421|128 180|cytoplasmic Src homology 2-domain-containing phosphatases
P11207261A1421|128 168|cytoplasmic Src homology 2-domain-containing
P11207261A1421|182 186|SHP-1
P11207261A1421|182 186|SHP-1
P11207261A1421|190 194|SHP-2
P11207261A1421|190 194|SHP-2
P11207261A1421|279 288|BCR complex
P11207261A1421|279 281|BCR
P11207261A1421|293 310|inhibitory receptor
P11207269A0745|0 16|Anti-nucleolin mAb
P11207269A0745|0 16|Anti-nucleolin mAb
P11207269A0745|61 72|p95 component
P11207269A0745|61 63|p95
P11207282A0729|57 69|chicken Notch1
P11207282A0729|64 69|Notch1
P11207282A0729|72 77|Notch2
P11207282A0729|72 77|Notch2
P11207282A0729|81 89|B cell line
P11207282A0729|100 114|down-regulation
P11207282A0729|124 126|IgM
P11207282A0729|124 126|IgM
P11207282A0729|172 189|IgH gene transcripts
P11207282A0729|172 189|IgH gene transcripts
P11207288A0897|0 12|Substitutions
P11207288A0897|18 40|YFV Ag-binding region (ABR
P11207288A0897|18 36|YFV Ag-binding region
P11207288A0897|38 40|ABR
P11207288A0897|78 85|residues
P11207288A0897|114 123|peptide-Ag
P11207288A0897|114 123|peptide-Ag
P11207288A0897|129 144|class Ia molecules
P11207288A0897|129 144|class Ia molecules
P11207308A0999|10 17|curcumin
P11207308A0999|19 35|diferuloylmethane
P11207308A0999|40 61|anti-inflammatory agent
P11207308A0999|73 106|OSM-stimulated STAT1 phosphorylation
P11207308A0999|73 75|OSM
P11207308A0999|87 91|STAT1
P11207308A0999|108 126|DNA-binding activity
P11207308A0999|129 133|STAT1
P11207308A0999|129 133|STAT1
P11207308A0999|138 158|c-Jun N-terminal kinase
P11207308A0999|138 158|c-Jun N-terminal kinase
P11207308A0999|185 188|JAK1
P11207308A0999|185 188|JAK1
P11207308A0999|190 193|JAK2
P11207308A0999|190 193|JAK2
P11207308A0999|195 198|JAK3
P11207308A0999|195 198|JAK3
P11207308A0999|200 205|ERK1/2
P11207308A0999|200 205|ERK1/2
P11207308A0999|210 227|p38 phosphorylation
P11207308A0999|210 212|p38
P11207609A0994|26 34|QKTT motif
P11207609A0994|38 57|TGN46 cytoplasmic tail
P11207609A0994|66 91|steady-state ER localization
P11207609A0994|94 129|vesicular stomatitis virus glycoprotein
P11207609A0994|103 129|stomatitis virus glycoprotein
P11207609A0994|131 143|VSVG) chimeras
P11207609A0994|131 134|VSVG
P11207609A0994|146 149|HeLa
P11207609A0994|153 160|NRK cells
P11207609A0994|203 222|secretory trafficking
P11208017A0070|1 9|cDNA clone
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208017A0070|45 50|SCOF-1
P11208017A0070|45 50|SCOF-1
P11208017A0070|67 73|soybean
P11208814A0673|55 65|DmCKIIalpha
P11208814A0673|55 65|DmCKIIalpha
P11208814A0673|75 86|bHLH proteins
P11208814A0673|75 86|bHLH proteins
P11208814A0673|88 104|sequence alignment
P11208814A0673|121 122|m5
P11208814A0673|121 122|m5
P11208814A0673|124 125|m7
P11208814A0673|124 125|m7
P11208814A0673|130 131|m8
P11208814A0673|130 131|m8
P11208814A0673|140 152|consensus site
P11208814A0673|156 170|phosphorylation
P11208814A0673|173 176|CKII
P11208814A0673|173 176|CKII
P11209100A0069|55 57|PMN
P11209100A0069|67 90|anti-inflammatory effects
P11209100A0069|116 134|cytokine antagonists
P11209100A0069|141 171|interleukin-1 receptor antagonist
P11209100A0069|141 161|interleukin-1 receptor
P11209100A0069|173 178|IL-1ra
P11209100A0069|173 178|IL-1ra
P11209814A0243|42 69|morphological characteristics
P11209814A0243|75 94|fibrous tissue capsule
P11209814A0243|125 148|aluminum calcium phosphate
P11209814A0243|150 154|ALCAP
P11209814A0243|159 172|hydroxyapetite
P11209814A0243|174 187|HA) bioceramics
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0000|23 29|Renagel
P11210401A0000|45 76|phosphate-binding polymer marketed
P11210401A0000|94 110|hyperphosphatemia
P11210401A0000|113 125|adult patients
P11210401A0000|135 146|hemodialysis
P11210401A0544|3 25|pharmacokinetic profiles
P11210401A0544|28 45|digoxin and warfarin
P11210401A0544|105 113|sevelamer
P11210839A0282|6 22|PO3 administration
P11210839A0282|48 55|patients
P11210839A0282|71 91|2 antituberculous drugs
P11210839A0282|93 103|ethambutole
P11210839A0282|107 117|ethionamide
P11210839A0282|120 130|ethambutole
P11210839A0282|134 145|oprofloxacin
P11210988T0000|25 32|patients
P11210988T0000|54 67|prostate cancer
P11211759A0165|0 7|Patients
P11211759A0165|39 44|group A
P11211759A0165|53 61|hot-water
P11211759A0165|103 122|transtracheal heating
P11211759A0165|126 145|humidification system
P11211759A0165|176 197|gastric cancer operation
P11211936A1490|52 55|blr1
P11211936A1490|52 55|blr1
P11211936A1490|65 80|JNK/SAPK activity
P11211936A1490|65 67|JNK
P11211936A1490|69 72|SAPK
P11211936A1490|85 102|JNK/ SAPK activation
P11211936A1490|85 87|JNK
P11211936A1490|89 92|SAPK
P11211936A1490|129 153|RA-induced differentiation
P11211936A1490|157 168|growth arrest
P11212249A0993|53 62|antagonism
P11212249A0993|65 81|activator protein 1
P11212249A0993|65 81|activator protein 1
P11212249A0993|83 86|AP-1
P11212249A0993|83 86|AP-1
P11212327A1564|26 38|rat adipocytes
P11212327A1564|63 65|PIG
P11212327A1564|82 110|IRS1/3 tyrosine phosphorylation
P11212327A1564|82 87|IRS1/3
P11212327A1564|113 124|p59Lyn kinase
P11212327A1564|113 124|p59Lyn kinase
P11212327A1564|192 199|caveolin
P11212327A1564|223 225|PIG
P11213342A0492|21 23|SF2
P11213342A0492|27 43|plating efficiency
P11214177A1125|5 9|small
P11214177A1125|41 48|22 nt RNAs
P11214177A1125|64 69|satRNA
P11214354A1104|0 12|VE-DEF animals
P11214354A1104|51 77|myocardial lipid peroxidation
P11214354A1104|116 118|I-R
P11214354A1104|132 141|CON animals
P11215622A0949|0 7|Grippers
P11215622A0949|12 21|integrated
P11216247T0000|8 17|left behind
P11218739A0811|0 9|Transition
P11218739A0811|17 27|P- and H-BPPV
P11220166A0616|23 45|dopaminergic stimulation
P11220166A0616|85 103|cognitive processing
P11220166A0616|174 181|dopamine
P11220166A0616|221 249|basal ganglia-prefrontal cortex
P11220166A0616|257 261|motor
P11220306A0911|0 5|HexA71
P11220306A0911|0 5|HexA71
P11220306A0911|23 26|RpoS
P11220306A0911|23 26|RpoS
P11220306A0911|56 66|sigma factor
P11220306A0911|56 66|sigma factor
P11220306A0911|81 91|HexA- mutant
P11220306A0911|81 91|HexA- mutant
P11220306A0911|101 111|HexA+ strain
P11220306A0911|101 105|HexA+
P11220306A1753|16 23|rsmB+ DNA
P11220306A1753|16 23|rsmB+ DNA
P11220306A1753|49 67|exoenzyme production
P11220306A1753|117 121|hexA+
P11220306A1753|117 121|hexA+
P11220486A0686|6 10|IL-12
P11220486A0686|6 10|IL-12
P11220487T0000|18 32|diagnostic tests
P11220487T0000|36 56|vaginal trichomoniasis
P11220857T0000|0 3|CHAP
P11220857T0000|22 36|Veterans Affairs
P11221836A0981|49 55|vaccine
P11221836A0981|103 104|E7
P11221836A0981|116 131|metastatic tumors
P11221845A0295|23 39|methylation status
P11221845A0295|47 57|normal liver
P11221845A0295|61 65|liver
P11221845A0295|74 87|SV40 T/t antigen
P11221845A0295|74 80|SV40 T/t
P11221845A0295|81 87|antigen
P11221845A0295|88 101|transgenic mice
P11221845A0295|103 111|MT-D2 mice
P11221845A0295|155 165|Methylation
P11221845A0295|167 172|RLGS-M
P11221845A0295|242 252|liver tumors
P11221845A0800|29 44|open reading frame
P11221845A0800|54 68|intron-less gene
P11221845A0800|82 85|B236
P11221845A0800|110 129|493-amino acid protein
P11221845A0800|143 160|SNAG repressor motif
P11221845A0800|166 183|NH2-terminal region
P11221845A0800|166 183|NH2-terminal region
P11221845A0800|191 215|C2H2-type zinc finger motifs
P11221845A0800|191 215|C2H2-type zinc finger motifs
P11221845A0800|221 237|COOH-terminal half
P11221845A1370|0 19|Northern blot analysis
P11221845A1370|32 35|mlt 1
P11221845A1370|32 35|mlt 1
P11221845A1370|57 61|brain
P11221845A1370|63 68|spleen
P11221845A1370|81 85|liver
P11221845A1713|11 22|N18TG-2 cells
P11221845A1713|47 65|5-aza-deoxycytidine
P11221845A1713|91 94|mlt 1
P11221845A1713|91 94|mlt 1
P11221845A1713|125 128|mlt 1
P11221845A1713|125 128|mlt 1
P11221845A1713|145 155|methylation
P11221845A1713|161 164|mlt 1
P11221845A1713|161 164|mlt 1
P11221845A1713|199 209|methylation
P11221845A1713|216 233|liver tumorigenesis
P11221845A1713|245 256|SV40 T antigen
P11221845A1713|245 256|SV40 T antigen
P11222387A1497|4 7|oral
P11222387A1497|9 24|nontoxic compound
P11222387A1497|65 91|ABL tyrosine kinase inhibition
P11222387A1497|65 81|ABL tyrosine kinase
P11222387A1497|93 103|FTI SCH66336
P11222387A1497|133 155|BCR/ABL-induced leukemia
P11222387A1497|133 135|BCR
P11222387A1497|137 139|ABL
P11222639A1273|37 44|tyrosine
P11222639A1273|73 85|L1 endocytosis
P11222720A1699|14 17|RPMS
P11222720A1699|14 17|RPMS
P11222720A1699|44 48|EBNA2
P11222720A1699|44 48|EBNA2
P11222720A1699|52 64|Notch activity
P11222720A1699|52 56|Notch
P11222720A1699|94 126|CBF1-associated corepressor complex
P11222720A1699|94 108|CBF1-associated
P11222720A1699|109 126|corepressor complex
P11223131A0000|0 15|Folate metabolism
P11223131A0000|21 40|human malaria parasite
P11223131A0000|41 60|Plasmodium falciparum
P11223131A0000|85 94|cell growth
P11223131A0000|98 108|replication
P11223153A0533|3 11|BFA System
P11223153A0533|48 78|fluorescent microsphere technique
P11223153A0533|96 99|lung
P11223164A0000|32 46|differentiation
P11223164A0000|48 56|apoptosis
P11223164A0000|75 80|growth
P11223164A0000|106 119|cancerous cells
P11223186A1095|0 14|Transactivation
P11223186A1095|17 50|oIFNtau enhancer-reporter constructs
P11223186A1095|17 23|oIFNtau
P11223186A1095|96 103|AP-1 site
P11223186A1095|96 103|AP-1 site
P11223186A1095|105 127|GATA like sequence and site
P11223186A1095|105 120|GATA like sequence
P11223199A0751|46 54|S. neurona
P11223199A0751|57 66|WB analysis
P11223199A0751|91 101|young horses
P11223240A0655|0 19|Drosophila Menin1 gene
P11223240A0655|0 19|Drosophila Menin1 gene
P11223246A0359|0 15|Sequence analysis
P11223246A0359|29 33|RBP21
P11223246A0359|29 33|RBP21
P11223246A0359|57 86|retinoblastoma-binding proteins
P11223246A0359|57 86|retinoblastoma-binding proteins
P11223246A0359|92 112|pRb-binding motif LxCxE
P11223246A0359|92 107|pRb-binding motif
P11223246A0359|118 133|C-terminal region
P11223246A0359|118 133|C-terminal region
P11223255A1034|14 36|consensus amino acid motif
P11223255A1034|40 69|serine threonine receptor kinases
P11223255A1034|40 69|serine threonine receptor kinases
P11223256A1212|32 47|5' flanking region
P11223256A1212|53 64|pea 33RNP gene
P11223256A1212|56 64|33RNP gene
P11223257A0404|0 5|OsBBPI
P11223257A0404|0 5|OsBBPI
P11223257A0404|62 64|cut
P11223257A0404|66 86|exogenous jasmonic acid
P11223257A0404|88 89|JA
P11223257A0404|88 89|JA
P11223257A0404|104 123|protein phosphatase 2A
P11223257A0404|104 123|protein phosphatase 2A
P11223257A0404|125 128|PP2A
P11223257A0404|125 128|PP2A
P11223257A0404|141 151|cantharidin
P11223257A0404|153 154|CN
P11223257A0404|159 167|endothall
P11223257A0404|169 170|EN
P11223257A0404|176 215|light/dark-, time- and dose-dependent manner
P11223257A0404|254 266|cycloheximide
P11223257A0404|268 270|CHX
P11223257A0404|298 319|de novo protein synthesis
P11224226A0000|12 27|chlordiazepoxide
P11224226A0000|49 77|benzodiazepine receptor agonist
P11224226A0000|49 70|benzodiazepine receptor
P11224226A0000|82 91|bretazenil
P11224226A0000|116 137|benzodiazepine receptor
P11224226A0000|130 144|receptor agonist
P11226228A0899|27 40|yeast TyrRS gene
P11226228A0899|27 40|yeast TyrRS gene
P11226228A0899|69 74|E. coli
P11226752A0750|11 28|tissue culture cells
P11226752A0750|58 68|mouse deltex
P11226752A0750|90 112|transcriptional activity
P11226752A0750|115 117|E47
P11226752A0750|115 117|E47
P11226752A0750|120 153|basic helix-loop-helix (bHLH) protein
P11226752A0750|120 140|basic helix-loop-helix
P11226752A0750|142 153|bHLH) protein
P11226752A0750|203 213|human Notch1
P11226752A0750|208 213|Notch1
P11226752A0750|216 224|human DTX1
P11226752A0750|216 224|human DTX1
P11227039A0953|0 15|Multiparous women
P11227039A0953|31 33|BMI
P11227039A0953|45 47|PBF
P11227039A0953|68 93|primi- and nulliparous groups
P11227182A1475|78 87|bone marrow
P11227182A1475|91 102|leptin levels
P11227182A1475|91 96|leptin
P11227182A1475|105 109|serum
P11227182A1475|113 122|bone marrow
P11227484T0000|70 79|rhodamine B
P11227484T0000|95 100|iodide
P11228700T0000|44 48|today
P11230145A0732|40 60|Notch-CBF1/RBP-Jkappa
P11230145A0732|40 44|Notch
P11230145A0732|46 49|CBF1
P11230145A0732|51 53|RBP
P11230145A0732|55 60|Jkappa
P11230145A0732|79 95|cell fate decisions
P11230145A0732|128 143|viral replication
P11230169A0480|6 16|novel method
P11230169A0480|26 53|chromatin immunoprecipitation
P11230169A0480|69 81|hybridization
P11230169A0480|106 128|CENP-A-binding DNA domain
P11230169A0480|106 128|CENP-A-binding DNA domain
P11230169A0480|159 169|20p12 region
P11230169A0480|174 205|invdup (20p) human marker chromosome
P11230534A0688|20 32|DEAH helicases
P11230534A0688|20 32|DEAH helicases
P11230889A1151|124 127|HBO2
P11231287A0158|16 38|human neuroblastoma cells
P11231287A0158|39 45|SK-N-SH
P11231287A0158|55 63|apoptosis
P11231287A0158|73 84|thapsigargin
P11232947A1451|0 20|Prophylactic lymph node
P11232947A1451|33 48|radiation therapy
P11232947A1451|54 63|nodal chain
P11233643A0000|26 50|5-aminolaevulinic acid (ALA
P11233643A0000|48 50|ALA
P11233643A0000|59 74|protoporphyrin IX
P11233643A0000|59 74|protoporphyrin IX
P11233643A0000|76 79|PPIX
P11233643A0000|76 79|PPIX
P11233643A0000|84 102|photodynamic therapy
P11234223A1451|13 23|antibiotics
P11234223A1451|51 62|bactericidal
P11234223A1451|78 89|P. aeruginosa
P11234223A1451|101 111|antibiotics
P11234223A1451|143 145|AMK
P11234223A1451|147 149|IPM
P11234223A1451|153 156|PAPM
P11234223A1451|168 170|CAZ
P11234223A1451|172 175|MEPM
P11235335T0000|8 10|HIV
P11235777A0878|2 22|Klinefelter's syndrome
P11235777A0878|24 28|47XXY
P11235777A0878|31 53|serum testosterone levels
P11235777A0878|89 107|dihydrotestosterone
P11235817A0000|3 32|histamine H1 receptor antagonists
P11235817A0000|3 21|histamine H1 receptor
P11235817A0000|34 47|antihistamines
P11235817A0000|127 151|hyperhistaminic conditions
P11235817A0000|163 179|children and adults
P11236056A0374|0 9|Conclusion
P11236056A0374|14 24|Lp(a) levels
P11236056A0374|32 39|children
P11237038A0889|9 16|patients
P11237038A0889|32 62|multichannel pressure flow studies
P11237038A0889|85 99|transrectal HIFU
P11237038A0889|107 131|bladder outflow obstruction
P11237491A0000|73 85|CEA, CA 50 and CA
P11237491A0000|73 75|CEA
P11237491A0000|91 98|patients
P11237491A0000|108 123|colorectal cancer
P11237491A0000|151 169|serum concentrations
P11237491A0000|173 199|intraindividual fluctuations
P11237491A0000|234 244|cancer-free
P11237598A0962|3 32|homologous active-site framework
P11237598A0962|40 46|enzymes
P11237598A0962|105 122|catalytic mechanism
P11238105A0959|15 27|alpha subunits
P11238105A0959|15 27|alpha subunits
P11238105A0959|39 50|distal domain
P11238105A0959|87 105|alpha-2 distal domain
P11238105A0959|145 167|tyrosine phosphorylation
P11238105A0959|170 174|Jak-2
P11238105A0959|170 174|Jak-2
P11238105A0959|206 209|CD86
P11238105A0959|206 209|CD86
P11238375A0617|11 14|RhoA
P11238375A0617|11 14|RhoA
P11238375A0617|27 45|linear kinase cascade
P11238375A0617|70 73|ERK6
P11238375A0617|70 73|ERK6
P11238375A0617|75 82|p38 gamma
P11238375A0617|75 82|p38 gamma
P11238375A0617|115 130|p38 family of MAPKs
P11238375A0617|115 117|p38
P11238375A0617|126 130|MAPKs
P11238402A0191|17 41|heme-responsive mechanisms
P11238402A0191|59 79|DAN/TIR gene expression
P11238402A0191|59 61|DAN
P11238402A0191|63 69|TIR gene
P11238405A0817|16 20|tup11
P11238405A0817|16 20|tup11
P11238405A0817|24 28|tup12
P11238405A0817|24 28|tup12
P11238405A0817|33 41|atf1-pcr1
P11238405A0817|33 36|atf1
P11238405A0817|38 41|pcr1
P11238405A0817|95 113|fbp1-lacZ expression
P11238405A0817|95 98|fbp1
P11238405A0817|100 103|lacZ
P11238405A0817|123 145|spc1 MAPK phosphorylation
P11238405A0817|123 130|spc1 MAPK
P11238405A0817|148 151|atf1
P11238405A0817|148 151|atf1
P11238447A0524|36 41|eIF-5A
P11238447A0524|36 41|eIF-5A
P11238447A0524|77 83|Rev-NES
P11238447A0524|77 79|Rev
P11238447A0524|81 83|NES
P11238447A0524|88 101|CRM1/exportin1
P11238447A0524|88 91|CRM1
P11238447A0524|93 101|exportin1
P11238447A0524|109 114|eIF-5A
P11238447A0524|109 114|eIF-5A
P11238447A0524|131 142|nucleoporins
P11238447A0524|143 152|CAN/nup214
P11238447A0524|143 145|CAN
P11238447A0524|147 152|nup214
P11238447A0524|154 159|nup153
P11238447A0524|154 159|nup153
P11238447A0524|161 165|nup98
P11238447A0524|161 165|nup98
P11238447A0524|170 174|nup62
P11238447A0524|170 174|nup62
P11238586A0000|0 16|Structural studies
P11238586A0000|30 110|class I major histocompatibility complex (MHC)-restricted peptide-specific T cell receptor
P11238586A0000|30 65|class I major histocompatibility complex
P11238586A0000|67 69|MHC
P11238586A0000|98 110|T cell receptor
P11238586A0000|112 127|TCR)-alpha/betas
P11238586A0000|112 127|TCR)-alpha/betas
P11238586A0000|164 169|alpha2
P11238586A0000|170 176|helices
P11238586A0000|182 184|MHC
P11238586A0000|182 184|MHC
P11238586A0000|245 261|functional binding
P11238882A0157|2 24|Saccharomyces cerevisiae
P11238882A0157|26 29|eIF6
P11238882A0157|26 29|eIF6
P11238882A0157|42 52|single-copy
P11238882A0157|53 65|essential gene
P11238884A0892|20 22|dlg
P11238884A0892|82 102|premaxilla and mandible
P11238884A0892|114 128|secondary palate
P11238916A0838|27 32|PTP phi
P11238916A0838|27 32|PTP phi
P11238916A0838|34 41|paxillin
P11238916A0838|34 41|paxillin
P11238916A0838|47 79|paxillin-associated tyrosine kinase
P11238916A0838|47 79|paxillin-associated tyrosine kinase
P11238916A0838|81 84|Pyk2
P11238916A0838|81 84|Pyk2
P11238916A0838|113 129|macrophage lysates
P11238916A0838|137 151|catalytic domain
P11238916A0838|154 159|PTP phi
P11238916A0838|154 159|PTP phi
P11238916A0838|176 183|paxillin
P11238916A0838|176 183|paxillin
P11238916A0838|187 190|Pyk2
P11238916A0838|187 190|Pyk2
P11238947A0636|1 16|single base change
P11238947A0636|18 20|A8G
P11238947A0636|45 51|hnRNP A2
P11238947A0636|45 51|hnRNP A2
P11238947A0636|74 79|A2RE-2
P11238947A0636|74 79|A2RE-2
P11238947A0636|89 100|RNA transport
P11239184A1340|0 16|Baseline variables
P11239184A1340|31 32|CD
P11239184A1340|68 74|aspirin
P11239184A1340|96 102|early CT
P11239184A1340|112 128|edema or mass effect
P11239184A1340|136 141|middle
P11239184A1340|142 149|cerebral
P11239529A0981|0 7|IL-1beta
P11239529A0981|0 7|IL-1beta
P11239529A0981|32 43|endometrioma
P11239529A0981|50 56|lesions
P11240600A0523|1 19|complete drug history
P11240600A0523|64 76|VGB medication
P11241166A0677|0 13|TaqMan analysis
P11241166A0677|16 29|gene expression
P11241166A0677|39 56|chronic FA treatment
P11241166A0677|92 115|leptin receptor (Ob-R) mRNA
P11241166A0677|92 105|leptin receptor
P11241166A0677|107 115|Ob-R) mRNA
P11241166A0677|155 168|STAT signalling
P11241166A0677|155 158|STAT
P11241166A0677|170 174|SOCS3
P11241166A0677|170 174|SOCS3
P11241166A0677|189 206|cytokine signalling
P11241166A0677|210 234|cytokine inducible sequence
P11241166A0677|210 234|cytokine inducible sequence
P11241166A0677|236 238|CIS
P11241166A0677|236 238|CIS
P11241215A0566|3 17|mutant receptors
P11241215A0566|3 17|mutant receptors
P11241215A0566|27 34|sBMPR-IA
P11241215A0566|27 34|sBMPR-IA
P11241215A0566|51 64|fusion proteins
P11241215A0566|69 79|thioredoxin
P11241215A0566|69 79|thioredoxin
P11241215A0566|82 96|Escherichia coli
P11241215A0566|114 125|reverse phase
P11241215A0566|141 168|liquid chromatography (RP-HPLC
P11241215A0566|188 199|enterokinase
P11241215A0566|188 199|enterokinase
P11241243A0693|43 51|pathology
P11241243A0693|87 110|papillary serous component
P11241243A0693|113 115|PSC
P11241243A0693|120 132|p53 expression
P11241243A0693|120 122|p53
P11241332A0393|90 102|swellable bone
P11241332A0393|103 115|anchor designs
P11241332A0393|118 123|smooth
P11241332A0393|124 129|anchor
P11241332A0393|134 144|screw anchor
P11241332A0393|192 195|bone
P11241356T0000|0 26|Constitutive phosphorylation
P11241356T0000|30 48|nuclear localization
P11241356T0000|51 55|Smad3
P11241356T0000|51 55|Smad3
P11241356T0000|82 93|collagen gene
P11241356T0000|90 106|gene transcription
P11241356T0000|118 137|hepatic stellate cells
P11241672T0000|31 63|murine beta(3) integrin gene promoter
P11241672T0000|31 63|murine beta(3) integrin gene promoter
P11241672T0000|83 112|interleukin-4 responsive element
P11241672T0000|83 112|interleukin-4 responsive element
P11241672T0000|128 133|STAT-6
P11241672T0000|128 133|STAT-6
P11243306A0961|31 45|oxLDL antibodies
P11243306A0961|31 45|oxLDL antibodies
P11243306A0961|68 79|hypertension
P11243306A0961|93 113|coronary artery disease
P11243306A0961|164 173|anti-oxLDL
P11243306A0961|169 179|oxLDL levels
P11243336A0000|0 9|GafChromic
P11243336A0000|11 17|MD-55-2
P11243336A0000|110 131|brachytherapy dosimetry
P11243494A0833|64 66|CRF
P11243777A0000|0 22|Cis-acting CCAAT elements
P11243777A0000|10 22|CCAAT elements
P11243777A0000|43 67|eukaryotic promoter regions
P11243980A0510|11 18|patients
P11243980A0510|31 45|PET examinations
P11243980A0510|55 71|staging procedures
P11244568A0506|3 8|Gap69C
P11244568A0506|3 8|Gap69C
P11244568A0506|12 26|single-copy gene
P11244568A0506|37 51|major 2.1-kb mRNA
P11244568A0506|99 104|larvae
P11244733A0782|0 4|Cases
P11244733A0782|7 16|lung cancer
P11244733A0782|21 44|intramedullary metastasis
P11245986T0000|6 33|growth-related nuclear protein
P11245986T0000|6 33|growth-related nuclear protein
P11245986T0000|50 73|rat aldolase B gene promoter
P11245986T0000|50 65|rat aldolase B gene
P11246679A0000|52 76|congenital heart block (CCHB
P11246679A0000|83 87|fetus
P11246679A0000|91 102|adult disease
P11246887A0000|26 41|cholesteryl ester
P11246887A0000|51 53|CET
P11246887A0000|51 53|CET
P11246887A0000|56 86|cholesteryl ester transfer protein
P11246887A0000|56 71|cholesteryl ester
P11246887A0000|88 91|CETP
P11246887A0000|88 91|CETP
P11246887A0000|105 131|phospholipid transfer protein
P11246887A0000|105 116|phospholipid
P11246887A0000|133 136|PLTP
P11246887A0000|133 136|PLTP
P11246887A0000|172 179|coronary
P11246887A0000|180 198|artery calcification
P11246887A0000|200 202|CAC
P11246887A0000|206 213|diabetic
P11246887A0000|234 252|nondiabetic subjects
P11246887A0000|270 282|sex difference
P11246887A0000|285 287|CAC
P11246887A0000|290 297|diabetes
P11247663A1447|38 49|DNAH9 alleles
P11247663A1447|38 49|DNAH9 alleles
P11247663A1447|52 70|affected individuals
P11248463A0187|3 13|blood levels
P11248463A0187|16 22|lactate
P11248463A0187|24 31|pyruvate
P11248463A0187|35 44|amino acids
P11248626T0000|0 7|Efficacy
P11248626T0000|63 77|cavernous nerves
P11248626T0000|84 103|radical prostatectomy
P11250196A0455|7 19|-motif) domain
P11250196A0455|39 45|calcium
P11250196A0455|84 93|two-domain
P11250196A0455|94 140|prokaryotic betagamma-crystallin fold family member
P11250196A0455|142 150|Protein S.
P11250196A0455|142 149|Protein S
P11250942A0626|0 17|Deletional analyses
P11250942A0626|20 22|VDR
P11250942A0626|20 22|VDR
P11250942A0626|36 40|GRIP1
P11250942A0626|36 40|GRIP1
P11250942A0626|44 47|RAC3
P11250942A0626|44 47|RAC3
P11250942A0626|64 84|VDR activation function
P11250942A0626|64 66|VDR
P11250942A0626|86 89|AF-2
P11250942A0626|86 89|AF-2
P11250942A0626|161 163|VDR
P11250942A0626|161 163|VDR
P11251083T0000|33 60|cell morphology and S phase entry
P11251083T0000|63 83|epidermal growth factor
P11251083T0000|63 83|epidermal growth factor
P11251083T0000|100 117|MEK/ERK activations
P11251083T0000|100 102|MEK
P11251083T0000|104 106|ERK
P11251104A0526|15 27|alpha-amylase
P11251104A0526|15 27|alpha-amylase
P11251104A0526|52 70|transcription factor
P11251104A0526|71 75|GAMyb
P11251104A0526|71 75|GAMyb
P11251104A0526|99 100|GA
P11251252A0494|0 17|3D image-processing
P11251252A0494|68 83|orthogonal planes
P11251252A0494|85 95|section mode
P11251252A0494|110 116|3D views
P11251276A0793|8 15|patients
P11251697T0000|6 33|superoxide scavenging activity
P11251697T0000|36 69|nonsteroidal anti-inflammatory drugs
P11251697T0000|86 106|electron spin resonance
P11251697T0000|115 128|spin trap method
P11251951A0000|60 77|diagnostic accuracy
P11251951A0000|80 99|pigmented skin lesions
P11251951A0000|136 143|patients
P11251951A0000|148 175|cutaneous melanoma in situ (CMIS
P11251951A0000|180 200|early invasive melanoma
P11254134A0648|9 12|PTax
P11254134A0648|9 12|PTax
P11254134A0648|52 54|PTF
P11254134A0648|52 54|PTF
P11254134A0648|86 110|synthetic regulatory region
P11254504A0766|11 24|promoter region
P11254504A0766|49 70|cis-regulatory elements
P11254504A0766|77 101|Sp1, early growth response-1
P11254504A0766|77 79|Sp1
P11254504A0766|81 101|early growth response-1
P11254504A0766|103 120|activator protein-2
P11254504A0766|103 120|activator protein-2
P11254504A0766|122 125|MyoD
P11254504A0766|122 125|MyoD
P11254504A0766|127 130|p300
P11254504A0766|127 130|p300
P11254504A0766|132 151|nuclear factor-kappaB
P11254504A0766|132 151|nuclear factor-kappaB
P11254504A0766|153 239|myeloid zinc finger protein-1, caudal-related homeobox (Cdx) gene A, and Cdx protein-2 binding sites
P11254504A0766|153 178|myeloid zinc finger protein-1
P11254504A0766|180 211|caudal-related homeobox (Cdx) gene A
P11254504A0766|216 239|Cdx protein-2 binding sites
P11254713A1029|21 23|Tat
P11254713A1029|21 23|Tat
P11254713A1029|47 49|rel
P11254713A1029|47 49|rel
P11254713A1029|51 53|AP1
P11254713A1029|65 71|complex
P11254713A1029|85 96|quantitative
P11254713A1029|180 200|IL-2 gene transcription
P11254713A1029|180 187|IL-2 gene
P11254864T0000|0 30|Adjuvant and neoadjuvant treatment
P11254864T0000|33 44|breast cancer
P11255035A0331|11 25|progenitor cells
P11255035A0331|31 35|brain
P11255035A0331|37 55|SVZa progenitor cells
P11255035A0331|101 117|neuronal phenotype
P11255252A0961|1 10|minimal ER3
P11255252A0961|59 64|FXR HRE
P11255252A0961|59 64|FXR HRE
P11255252A0961|85 103|FXR-expressing yeast
P11255252A0961|85 87|FXR
P11255423A0211|59 61|HIV
P11255423A0211|91 109|CD4 lymphocyte counts
P11255423A0211|91 93|CD4
P11255423A0211|115 119|women
P11255423A0211|124 126|HIV
P11256845A0340|2 17|economic analysis
P11256845A0340|61 67|WOSCOPS
P11256845A0340|90 104|statin treatment
P11256845A0340|141 148|patients
P11256845A0340|177 183|WOSCOPS
P11256845A0340|266 277|20,375 pounds
P11256845A0340|279 285|$31,818
P11256944A1144|29 32|ATF6
P11256944A1144|29 32|ATF6
P11256944A1144|39 52|G13 gene product
P11256944A1144|39 52|G13 gene product
P11256944A1144|94 105|cis-acting ER
P11256944A1144|153 160|ER stress
P11256962A0233|0 15|Sequence analysis
P11256962A0233|56 63|5' region
P11256962A0233|69 83|beta subunit gene
P11256962A0233|69 83|beta subunit gene
P11256962A0233|115 145|homologous GlyR alpha subunit genes
P11256962A0233|125 140|GlyR alpha subunit
P11256962A0233|169 172|exon
P11256962A0233|174 178|exon 0
P11256962A0233|200 221|5'-untranslated portion
P11256962A0233|227 238|GlyR beta mRNA
P11256962A0233|227 238|GlyR beta mRNA
P11257870A0000|84 98|trickling filter
P11257870A0000|100 101|TF
P11257870A0000|100 101|TF
P11257870A0000|115 127|sludge process
P11257870A0000|129 131|ASP
P11257870A0000|141 177|wastewater containing trichloroethylene
P11257870A0000|179 181|TCE
P11257870A0000|237 239|HRT
P11258906A0743|2 27|DNA strand exchange reactions
P11258906A0743|33 48|oligonucleotides
P11258906A0743|61 64|Rec2
P11258906A0743|61 64|Rec2
P11258906A0743|106 109|RecA
P11258906A0743|106 109|RecA
P11259347A0000|99 104|humans
P11259347A0000|121 136|dietary chemicals
P11259503A0212|0 17|Forskolin treatment
P11259503A0212|33 48|transfected cells
P11259503A0212|73 82|luciferase
P11259593A1094|10 23|ace2Delta cells
P11259593A1094|35 39|Ace2p
P11259593A1094|35 39|Ace2p
P11259593A1094|53 66|cell separation
P11259593A1094|76 90|polarized growth
P11260468A1179|31 33|AR1
P11260468A1179|31 33|AR1
P11260468A1179|39 65|promoter-proximal CAP subunit
P11260468A1179|56 65|CAP subunit
P11260468A1179|80 97|papBA transcription
P11260468A1179|80 84|papBA
P11260468A1179|119 141|histone-like protein H-NS
P11260468A1179|119 141|histone-like protein H-NS
P11263622A0683|54 70|mean wall thickness
P11263622A0683|74 87|vessel wall area
P11263622A0683|95 114|MRI and histopathology
P11263664A1085|19 22|SIP1
P11263664A1085|19 22|SIP1
P11263664A1085|42 59|XBra gene expression
P11263664A1085|42 49|XBra gene
P11263664A1085|65 72|mesoderm
P11263664T0000|0 27|SIP1 (Smad interacting protein 1
P11263664T0000|0 3|SIP1
P11263664T0000|5 27|Smad interacting protein 1
P11263664T0000|32 39|deltaEF1
P11263664T0000|32 39|deltaEF1
P11263664T0000|41 77|delta-crystallin enhancer binding factor
P11263664T0000|41 77|delta-crystallin enhancer binding factor
P11263664T0000|101 125|transcriptional repressors
P11264176A0181|0 4|B-myb
P11264176A0181|0 4|B-myb
P11264176A0181|19 32|G1/S transition
P11264176A0181|71 78|cyclin A2
P11264176A0181|71 78|cyclin A2
P11264176A0181|80 83|cdk2
P11264176A0181|80 83|cdk2
P11264177T0000|0 17|Nucleotide sequence
P11264177T0000|39 54|mutation analysis
P11264177T0000|60 81|13q14 chromosomal region
P11264177T0000|91 122|B-cell chronic lymphocytic leukemia
P11264182A0000|0 28|Human T-cell leukemia virus type I
P11264182A0000|0 28|Human T-cell leukemia virus type I
P11264182A0000|30 35|HTLV-I
P11264182A0000|30 35|HTLV-I
P11264182A0000|37 39|Tax
P11264182A0000|37 39|Tax
P11264182A0000|43 72|potent transcriptional regulator
P11264182A0000|105 117|cellular genes
P11264182A0000|154 167|leukemogenesis
P11264182A0000|170 188|adult T-cell leukemia
P11264372T0000|18 49|nuclear-cytoplasmic translocation
P11264372T0000|75 93|herpes simplex virus 1
P11264372T0000|75 93|herpes simplex virus 1
P11264375A0000|3 22|human cytomegalovirus
P11264375A0000|24 27|HCMV
P11264375A0000|29 55|major immediate-early protein
P11264375A0000|34 58|immediate-early protein IE2
P11264375A0000|56 58|IE2
P11264375A0000|62 82|nuclear phosphoprotein
P11264375A0000|120 143|lytic and latent infections
P11264561A0167|28 31|RSTD
P11264561A0167|40 47|coronary
P11264561A0167|61 82|acute coronary occlusion
P11265853A0000|3 41|Novacor Left Ventricular Assist System (LVAS
P11265853A0000|64 65|CA
P11265853A0000|123 143|wearable configuration
P11266184A0000|0 7|Atheroma
P11266184A0000|46 104|2-dimensional time-of-flight (TOF) magnetic resonance (MR) images
P11266184A0000|152 160|spin-echo
P11266194A0743|0 18|Body fat distribution
P11266194A0743|34 60|abdominal computed tomography
P11266227A0295|3 11|flux rates
P11266227A0295|14 24|p-toluidine
P11266540A0328|23 51|mammalian Groucho family members
P11266540A0328|23 44|mammalian Groucho family
P11266540A0328|103 122|Tcf/Lef family members
P11266540A0328|103 105|Tcf
P11266540A0328|107 109|Lef
P11266558A1470|137 151|RNA polymerase II
P11266558A1470|137 151|RNA polymerase II
P11266558A1470|157 173|SL RNA gene promoter
P11266558A1470|157 165|SL RNA gene
P11266615A0258|25 36|major domains
P11266615A0258|49 71|hydrophobic linker region
P11266615A0258|74 92|20 amino acid residues
P11267679A0102|3 20|438 bp EcoRI fragment
P11267679A0102|8 20|EcoRI fragment
P11267679A0102|40 60|Southern hybridization
P11267679A0102|71 86|open reading frame
P11267679A0102|112 121|amino acids
P11268459A0167|60 76|DOX binding ability
P11268459A0167|79 80|DB
P11268459A0167|88 105|histologic response
P11268459A0167|123 133|tumor volume
P11268459A0167|136 160|malignant soft tissue tumors
P11268459A0167|166 189|preoperative chemotherapy
P11268887A1174|33 47|reference values
P11268887A1174|100 102|FVC
P11268887A1174|106 109|FEV1
P11271297T0000|0 13|Nephrotoxicity
P11271297T0000|19 48|orthotopic liver transplantation
P11271297T0000|51 62|cyclosporin A
P11271297T0000|66 70|FK 506
P11271297T0000|79 86|patients
P11273995A1148|12 32|normal control subjects
P11273995A1148|37 49|74 TOF patients
P11273995A1148|62 69|systolic
P11273995A1148|73 101|diastolic myocardial velocities
P11273995A1148|112 131|isovolumic relaxation
P11274109A0129|0 6|Acetoin
P11274149A0625|0 17|Mutational analysis
P11274149A0625|31 35|U-box
P11274149A0625|31 35|U-box
P11274149A0625|44 53|RING finger
P11274149A0625|112 113|E2
P11274149A0625|114 120|enzymes
P11274179A0610|21 33|Rac/Cdc42/Pak
P11274179A0610|21 23|Rac
P11274179A0610|25 29|Cdc42
P11274179A0610|31 33|Pak
P11274179A0610|53 57|Raf-1
P11274179A0610|53 57|Raf-1
P11274179A0610|79 99|microtubule disruption
P11274184A0000|0 3|Nrf2
P11274184A0000|0 3|Nrf2
P11274184A0000|38 44|enzymes
P11274184A0000|49 59|antioxidant
P11274184A0000|65 79|heme oxygenase-1
P11274184A0000|65 79|heme oxygenase-1
P11274184A0000|81 84|HO-1
P11274184A0000|81 84|HO-1
P11274184A1068|24 27|ATF4
P11274184A1068|24 27|ATF4
P11274184A1068|37 69|basal and CdCl(2)-induced expression
P11274184A1068|75 82|ho-1 gene
P11274184A1068|75 82|ho-1 gene
P11274184A1068|86 104|cell-specific manner
P11274184A1068|130 133|Nrf2
P11274184A1068|130 133|Nrf2
P11274357A0724|58 81|kinase-inactivated mutant
P11274357A0724|84 89|nm23H1
P11274357A0724|84 89|nm23H1
P11274357A0724|103 116|GDP-bound forms
P11274357A0724|119 122|Rac1
P11274357A0724|119 122|Rac1
P11274357A0724|124 128|Cdc42
P11274357A0724|124 128|Cdc42
P11274357A0724|133 136|RhoA
P11274357A0724|133 136|RhoA
P11274357A0724|144 157|GTP-bound forms
P11274357A0724|170 204|nucleoside diphosphate kinase activity
P11274357A0724|170 196|nucleoside diphosphate kinase
P11274357A0724|209 214|nm23H1
P11274357A0724|209 214|nm23H1
P11274357A0724|246 258|GTP-bound form
P11274357A0724|266 272|GTPases
P11274357A0724|266 272|GTPases
P11274368A0469|35 56|de novo protein synthesis
P11274368A0469|76 101|histone deacetylase activity
P11274368A0469|76 93|histone deacetylase
P11274368A0818|0 7|Deletion
P11274368A0818|51 60|repression
P11274368A0818|66 76|p21 promoter
P11274368A0818|66 76|p21 promoter
P11274368A0818|79 83|c-Myc
P11274368A0818|79 83|c-Myc
P11274563T0000|0 8|Fetal lung
P11274563T0000|16 25|estimation
P11274563T0000|28 36|MR imaging
P11275986A0091|5 16|gene products
P11275986A0091|18 19|E6
P11275986A0091|18 19|E6
P11275986A0091|41 65|p53 tumor suppressor protein
P11275986A0091|41 65|p53 tumor suppressor protein
P11275986A0091|68 108|ubiquitin/proteasome-dependent degradation
P11275986A0091|68 87|ubiquitin/proteasome
P11276426A0501|2 12|mouse, Mmip1
P11276426A0501|8 12|Mmip1
P11276426A0501|14 41|Mad member interacting protein 1
P11276426A0501|14 41|Mad member interacting protein 1
P11276426A0501|46 49|Smc3
P11276426A0501|46 49|Smc3
P11277913T0000|18 37|5' untranslated region
P11277913T0000|40 53|human Hsp70 mRNA
P11277913T0000|45 49|Hsp70
P11278286A0456|2 3|SN
P11278286A0456|7 19|neuronal cells
P11278286A0456|31 32|MR
P11278286A0456|31 32|MR
P11278286A0456|34 35|GR
P11278286A0456|34 35|GR
P11278286A0456|40 54|5-HT1A receptors
P11278286A0456|40 54|5-HT1A receptors
P11278286A0456|83 98|nGRE (negative GRE
P11278286A0456|133 141|rat 5-HT1A
P11278286A0456|133 141|rat 5-HT1A
P11278286A0456|144 164|heterologous promoters
P11278286A0456|167 181|corticosteroids
P11278286A0456|211 242|corticosteroid-induced inhibition
P11278286A0456|246 265|heterologous promoter
P11278286A1083|0 47|Corticosteroid-mediated transcriptional inhibition
P11278286A1083|61 65|MR/GR
P11278286A1083|61 62|MR
P11278286A1083|64 65|GR
P11278286A1083|86 87|MR
P11278286A1083|86 87|MR
P11278286A1083|90 91|GR
P11278286A1083|90 91|GR
P11278290A1220|7 11|Smad2
P11278290A1220|7 11|Smad2
P11278290A1220|38 45|TGF-beta
P11278290A1220|38 45|TGF-beta
P11278290A1220|81 93|Agc expression
P11278290A1220|81 83|Agc
P11278290A1220|96 109|confluent cells
P11278290A1220|111 125|Smad2 activation
P11278290A1220|111 115|Smad2
P11278290A1220|168 180|Agc expression
P11278290A1220|168 170|Agc
P11278310A1516|16 37|kinase-deficient mutant
P11278310A1516|63 71|caspase-3
P11278310A1516|63 71|caspase-3
P11278310A1516|109 118|cell number
P11278390A0632|0 49|Reverse transcriptase-polymerase chain reaction assays
P11278390A0632|0 35|Reverse transcriptase-polymerase chain
P11278390A0632|60 69|PKRDeltaE7
P11278390A0632|60 69|PKRDeltaE7
P11278390A0632|96 107|human tissues
P11278390A0632|110 123|variable levels
P11278400A0668|4 13|pancreatic
P11278400A0668|17 35|intestinal cell lines
P11278400A0668|63 96|POU (OCT binding) homeodomain proteins
P11278400A0668|63 65|POU
P11278400A0668|67 96|OCT binding) homeodomain proteins
P11278400A0668|107 139|electrophoretic mobility shift assay
P11278440A0095|0 2|SV1
P11278440A0095|0 2|SV1
P11278440A0095|10 24|amino acid insert
P11278440A0095|30 50|S1 transmembrane domain
P11278440A0095|30 50|S1 transmembrane domain
P11278440A0095|67 68|S1
P11278440A0095|76 89|hydrophobicity
P11278440A0095|102 106|S0-S1
P11278440A0095|102 106|S0-S1
P11278461A0637|0 9|Polyclonal
P11278461A0637|30 99|N-terminal part (amino acids 12-363) and the C-terminal part (amino acids 330-730
P11278461A0637|103 124|rainbow trout HIF-1alpha
P11278461A0637|103 124|rainbow trout HIF-1alpha
P11278461A0637|142 186|rainbow trout and chinook salmon HIF-1alpha protein
P11278461A0637|170 179|HIF-1alpha
P11278461A0637|189 207|Western blot analysis
P11278488T0000|3 16|v-Src SH3 domain
P11278488T0000|3 7|v-Src
P11278488T0000|29 63|cell adhesion-independent association
P11278488T0000|68 86|focal adhesion kinase
P11278488T0000|68 86|focal adhesion kinase
P11278521A0849|1 26|20-base pair oligonucleotide
P11278521A0849|70 76|hypoxia
P11278521A0849|92 112|unsaturated fatty acids
P11278521A0849|134 153|heterologous promoter
P11278521A0849|157 177|lacZ reporter construct
P11278521A0849|157 177|lacZ reporter construct
P11278563A0917|28 50|N-terminal 110 amino acids
P11278563A0917|53 57|Grb14
P11278563A0917|53 57|Grb14
P11278563A0917|61 67|ankyrin
P11278563A0917|82 91|tankyrase 2
P11278563A0917|82 91|tankyrase 2
P11278583A0873|0 10|Mutagenesis
P11278583A0873|13 16|SNT1
P11278583A0873|13 16|SNT1
P11278583A0873|18 23|IRS)CX
P11278583A0873|18 20|IRS
P11278583A0873|95 107|ERK activation
P11278583A0873|95 97|ERK
P11278583A0873|111 133|neuronal differentiation
P11278583A0873|141 155|phosphotyrosine
P11278583A0873|186 189|Grb2
P11278583A0873|186 189|Grb2
P11278583A0873|196 210|phosphotyrosine
P11278583A0873|241 244|Shp2
P11278583A0873|241 244|Shp2
P11278583A0873|252 266|C-terminal motif
P11278583A0873|252 266|C-terminal motif
P11278583A0873|298 300|Sos
P11278583A0873|298 300|Sos
P11278594A0618|13 27|human propeptide
P11278594A0618|54 64|murine MIC-1
P11278594A0618|54 64|murine MIC-1
P11278594A0618|67 85|TGF-beta1 propeptide
P11278594A0618|67 75|TGF-beta1
P11278594A0618|110 130|unprocessed, monomeric
P11278594A0618|131 137|chimera
P11278594A0618|179 214|human MIC-1 propeptide and mature peptide
P11278594A0618|179 198|human MIC-1 propeptide
P11278604A0300|0 31|Radiolabeled biantennary N-glycans
P11278604A0300|45 56|Pro(-)5Lec20
P11278604A0300|113 128|parental CHO cells
P11278604A0300|133 149|Lec20 cell extracts
P11278604A0300|186 188|Gal
P11278604A0300|191 196|GlcNAc
P11278604A0300|209 217|acceptors
P11278610A0902|14 20|SOCS box
P11278610A0902|14 20|SOCS box
P11278610A0902|35 42|Cullin-2
P11278610A0902|35 42|Cullin-2
P11278610A0902|70 72|TEL
P11278610A0902|70 72|TEL
P11278610A0902|74 77|JAK2
P11278610A0902|74 77|JAK2
P11278671T0000|15 34|Bcl-2 homology 3 domain
P11278671T0000|15 34|Bcl-2 homology 3 domain
P11278671T0000|55 57|Bak
P11278671T0000|55 57|Bak
P11278671T0000|65 82|apoptotic in neurons
P11278671T0000|102 118|non-neuronal cells
P11278713A1054|8 26|10-nucleotide region
P11278713A1054|38 61|exon 4 protein-binding site
P11278713A1054|38 61|exon 4 protein-binding site
P11278713A1054|76 94|instability elements
P11278819A0565|40 61|18-bp MOK2-binding sites
P11278819A0565|40 61|18-bp MOK2-binding sites
P11278819A0565|71 77|intron 2
P11278819A0565|96 109|mouse IRBP genes
P11278819A0565|96 100|mouse
P11278819A0565|101 109|IRBP genes
P11278819A0565|121 135|3'-half sequence
P11278819A0565|141 160|essential core element
P11278819A0565|164 174|MOK2 binding
P11278819A0565|164 167|MOK2
P11278848A1316|12 19|SB203580
P11278848A1316|29 49|LPS-induced activation
P11278848A1316|52 54|Sp1
P11278848A1316|52 54|Sp1
P11278848A1316|67 82|promoter activity
P11278848A1316|126 145|Sp1 consensus sequence
P11278848A1316|126 128|Sp1
P11278855A0205|32 34|TLS
P11278855A0205|32 34|TLS
P11278855A0205|38 40|p65
P11278855A0205|38 40|p65
P11278855A0205|46 59|pull-down assay
P11278855A0205|73 103|coimmunoprecipitation experiment
P11278855A0205|114 124|Western blot
P11278855A0205|130 141|cultured cell
P11278870A0123|45 72|ctr4(+) copper transporter gene
P11278870A0123|45 72|ctr4(+) copper transporter gene
P11278870A0123|82 86|yeast
P11278870A0123|87 110|Schizosaccharomyces pombe
P11278870A0123|132 163|conserved copper-signaling element
P11278870A0123|165 168|CuSE
P11278870A0123|193 215|transcription factor Cuf1
P11278870A0123|193 211|transcription factor
P11278870A0123|212 215|Cuf1
P11278928A1634|7 20|mutational data
P11278928A1634|32 44|mRNA structure
P11278928A1634|76 88|mRNA structure
P11278928A1634|91 101|translation
P11278928A1634|115 134|C/EBPepsilon isoforms
P11278928A1634|115 126|C/EBPepsilon
P11278928A1634|136 138|p32
P11278928A1634|136 138|p32
P11278928A1634|142 144|p30
P11278928A1634|142 144|p30
P11279038A0194|0 10|WRN helicase
P11279038A0194|0 10|WRN helicase
P11279038A0194|50 71|tetraplex and triplex DNA
P11279086A1350|20 28|ADAM-TS12
P11279086A1350|20 28|ADAM-TS12
P11279086A1350|83 96|tumor processes
P11279086A1350|172 183|cell adhesion
P11279108T0000|9 45|serum response factor to CArG box sequences
P11279108T0000|9 27|serum response factor
P11279108T0000|30 45|CArG box sequences
P11279108T0000|83 96|gene expression
P11279108T0000|99 123|arterial smooth muscle cells
P11279207A0904|29 32|HPK1
P11279207A0904|29 32|HPK1
P11279207A0904|50 61|TCR signaling
P11279207A0904|50 52|TCR
P11279324A0710|40 53|creatine kinase
P11279324A0710|40 53|creatine kinase
P11279385A3917|58 62|M mode
P11279385A3917|75 76|2D
P11279385A3917|153 170|electric conduction
P11279385A3917|177 194|non-invasive method
P11279720A0844|72 79|patients
P11279720A0844|104 131|idiopathic Parkinson's disease
P11279720A0844|135 156|long-term complications
P11279720A0844|159 173|levodopa therapy
P11280495A1330|42 56|glucose-based PD
P11280495A1330|93 106|Amadori albumin
P11280495A1330|100 106|albumin
P11280495A1330|110 113|AGEs
P11280799A1025|20 43|PTHrP1-34 and 1-86 peptides
P11280799A1025|20 28|PTHrP1-34
P11280799A1025|36 43|peptides
P11280799A1025|69 82|IL-8 production
P11280799A1025|69 72|IL-8
P11280799A1025|93 120|PTHrP-neutralizing antibodies
P11280799A1025|93 97|PTHrP
P11280799A1025|149 152|IL-8
P11280799A1025|149 152|IL-8
P11280799A1025|166 170|PTHrP
P11280799A1025|166 170|PTHrP
P11281201T0000|0 19|Deterministic effects
P11281268A0000|7 31|two-domain arginine kinases
P11281268A0000|17 31|arginine kinases
P11281268A0000|33 35|AKs
P11281268A0000|33 35|AKs
P11281268A0000|76 93|molecular evolution
P11281268A0000|96 112|phosphagen kinases
P11281268A0000|96 112|phosphagen kinases
P11281268A0000|114 116|AKs
P11281268A0000|114 116|AKs
P11281268A0000|124 132|primitive
P11281268A0000|133 164|sea anemone Anthopleurura japonicus
P11281268A0000|179 204|Pseudocardium sachalinensis
P11282029A0075|3 62|mouse platelet-derived growth factor (PDGF) beta-receptor promoter
P11282029A0075|8 35|platelet-derived growth factor
P11282029A0075|37 62|PDGF) beta-receptor promoter
P11282029A0075|72 81|CCAAT motif
P11282029A0075|72 81|CCAAT motif
P11282029A0075|86 89|NF-Y
P11282029A0075|86 89|NF-Y
P11282029A0075|115 127|transcription
P11282088A0837|8 10|MBF
P11282088A0837|13 19|females
P11282088A0837|57 61|males
P11282394A0841|14 25|VH/VL-chains
P11282394A0841|14 15|VH
P11282394A0841|17 18|VL
P11282394A0841|59 77|antigen reactivities
P11282394A0841|86 89|mAbs
P11282395A0530|31 44|RAG1/2 proteins
P11282395A0530|31 44|RAG1/2 proteins
P11282395A0530|54 64|DNA hairpins
P11282395A0530|130 146|DNA repair proteins
P11282395A0530|130 146|DNA repair proteins
P11282395A0530|147 162|Nbs1/Mre11/Rad50
P11282395A0530|147 150|Nbs1
P11282395A0530|152 156|Mre11
P11282395A0530|158 162|Rad50
P11282395A1073|49 61|CDR3 sequences
P11282395A1073|49 61|CDR3 sequences
P11282395A1073|64 104|endogenous Ig lambdaL and kappaL chain gene loci
P11282395A1073|74 82|Ig lambdaL
P11282395A1073|86 104|kappaL chain gene loci
P11282395A1073|115 140|peripheral blood lymphocytes
P11282395A1073|145 154|NBS patient
P11282395A1073|160 177|healthy individuals
P11282433T0000|14 23|paclitaxel
P11282433T0000|31 39|etoposide
P11282433T0000|42 49|patients
P11282433T0000|71 103|metastatic non-small cell lung cancer
P11282761A0531|21 30|L-arginine
P11282761A0531|53 70|plasma L-citrulline
P11282761A0531|99 100|NO
P11283010A0701|4 13|activation
P11283010A0701|30 38|CGS 12066A
P11283014A0921|21 24|WASP
P11283014A0921|21 24|WASP
P11283014A0921|56 69|TCR stimulation
P11283014A0921|56 58|TCR
P11283014A0921|107 112|Arp2/3
P11283014A0921|107 112|Arp2/3
P11283014A0921|122 140|actin polymerization
P11283014A0921|122 126|actin
P11283168A0738|14 28|transgenic lines
P11283168A0738|70 76|Gus gene
P11283168A0738|70 76|Gus gene
P11283168A0738|109 123|mid-development
P11283256A0258|21 30|native MRCK
P11283256A0258|21 26|native
P11283256A0258|27 30|MRCK
P11283256A0258|39 68|high-molecular-weight complexes
P11283354A0548|49 68|histone modifications
P11283354A0548|80 86|histone
P11283354A0548|130 152|heterochromatin assembly
P11285054A0781|0 17|Regression analyses
P11285054A0781|28 33|SOREMP
P11285054A0781|87 94|REM sleep
P11285054A0781|101 121|NREMP dream occurrences
P11285054A0781|147 155|NREM sleep
P11285235A0466|8 12|TRPS1
P11285235A0466|8 12|TRPS1
P11285235A0466|45 69|transcriptional activation
P11285235A0466|85 95|GATA factors
P11285235A0466|85 95|GATA factors
P11285329A0682|33 37|women
P11286833A0959|5 12|patients
P11286833A0959|39 52|5-fluorouracil
P11286833A0959|79 90|chemotherapy
P11286833A0959|116 122|females
P11287555A1057|3 16|Delta6CCI virus
P11287555A1057|88 94|CEMx174
P11287555A1057|98 105|MT4 cells
P11287578A1311|11 23|interleukin-8
P11287578A1311|11 23|interleukin-8
P11287578A1311|25 30|RANTES
P11287578A1311|25 30|RANTES
P11287578A1311|32 66|macrophage inflammatory protein 1alpha
P11287578A1311|32 66|macrophage inflammatory protein 1alpha
P11287578A1311|71 106|10-kappaDa IFN-gamma-inducible protein
P11287578A1311|81 106|IFN-gamma-inducible protein
P11287578A1311|137 149|keratinocytes
P11287578A1311|152 153|E6
P11287578A1311|152 153|E6
P11287579A1084|14 18|T255A
P11287579A1084|40 45|E4orf6
P11287579A1084|40 45|E4orf6
P11287579A1084|63 86|viral late-gene expression
P11287579A1084|63 76|viral late-gene
P11287611A0802|6 14|PPARgamma
P11287611A0802|6 14|PPARgamma
P11287611A0802|16 23|liganded
P11287611A0802|32 38|natural
P11287611A0802|40 49|15d-PGJ(2)
P11287611A0802|53 58|PGD(2)
P11287611A0802|62 77|synthetic ligands
P11287611A0802|79 86|BRL49653
P11287611A0802|90 101|troglitazone
P11287611A0802|139 150|cyclin D1 gene
P11287611A0802|139 146|cyclin D1
P11287623A0286|24 100|Ras-activated Raf-MEK-extracellular signal-regulated kinase (ERK) signaling pathway
P11287623A0286|24 39|Ras-activated Raf
P11287623A0286|41 43|MEK
P11287623A0286|45 79|extracellular signal-regulated kinase
P11287623A0286|81 83|ERK
P11287623A0286|148 163|integrin subunits
P11287623A0286|148 155|integrin
P11287623A0286|176 197|human and mouse cell lines
P11287654A0150|0 3|PABP
P11287654A0150|0 3|PABP
P11287654A0150|30 57|N-terminal RNA-binding domains
P11287654A0150|30 57|N-terminal RNA-binding domains
P11287654A0150|72 80|C terminus
P11288208A0712|0 7|Children
P11288208A0712|25 50|respiratory tract infections
P11288208A0712|53 55|PCP
P11288208A0712|84 96|CD4 cell counts
P11288208A0712|84 86|CD4
P11288208A0712|120 123|life
P11288930A0000|43 76|4-chloro-2-methylphenoxyacetic acid
P11288930A0000|43 52|4-chloro-2
P11288930A0000|78 81|MCPA
P11288930A0000|135 140|mating
P11288930A0000|152 157|mating
P11289135A0975|0 9|Coexposure
P11289135A0975|12 13|FP
P11289135A0975|70 155|mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase cascade
P11289135A0975|70 105|mitogen-activated protein kinase kinase
P11289135A0975|107 148|extracellular signal-regulated protein kinase
P11289135A0975|161 172|PMA treatment
P11289135A0975|210 255|mitogen-activated protein kinase kinase 1 inhibitor
P11289135A0975|210 246|mitogen-activated protein kinase kinase 1
P11289135A0975|256 260|U0126
P11289135A0975|288 296|apoptosis
P11289149A0658|8 17|EWS protein
P11289149A0658|8 17|EWS protein
P11289149A0658|54 87|COOH-terminal transactivation domain
P11289149A0658|93 119|cofactor CREB-binding protein
P11289149A0658|101 119|CREB-binding protein
P11289149A0658|121 123|CBP
P11289149A0658|121 123|CBP
P11290415A0288|37 55|ICBP90 gene structure
P11290415A0288|37 42|ICBP90
P11290415A0288|70 96|human placenta genomic library
P11290415A0288|100 110|PCR analysis
P11290906T0000|0 21|Tumor-like accumulation
P11290906T0000|24 34|Tl-201 SPECT
P11290906T0000|45 73|hemorrhagic cerebral infarction
P11291552A0156|11 18|patients
P11291552A0156|23 36|histologically
P11291552A0156|46 48|MFH
P11292335A0852|18 24|dnaE173
P11292335A0852|59 78|sequence substitution
P11292335A0852|87 107|single-base frameshift
P11292335A0852|139 141|hot
P11292335A0852|147 164|frameshift mutation
P11292839A0531|3 15|transcription
P11292839A0531|25 30|pol III
P11292839A0531|25 30|pol III
P11292839A0531|58 63|U6 gene
P11292839A0531|58 63|U6 gene
P11292839A0531|100 107|TATA-box
P11292839A0531|141 159|TATA-binding protein
P11292839A0531|141 159|TATA-binding protein
P11292839A0531|161 170|TBP) mutant
P11292839A0531|161 170|TBP) mutant
P11292839A0531|172 178|TBP-DR2
P11292839A0531|172 174|TBP
P11292839A0531|176 178|DR2
P11292839A0531|190 207|TBP wild-type (TBPwt
P11292839A0531|190 192|TBP
P11292839A0531|193 201|wild-type
P11292839A0531|203 207|TBPwt
P11292844A0081|0 2|HSF
P11294895A0292|24 42|spo20(+) gene product
P11294895A0292|24 42|spo20(+) gene product
P11294895A0292|69 96|Saccharomyces cerevisiae Sec14
P11294895A0292|69 91|Saccharomyces cerevisiae
P11294895A0292|106 140|phosphatidylinositol transfer protein
P11294895A0292|106 125|phosphatidylinositol
P11294895A0292|150 154|yeast
P11295470A0954|51 65|polymorphic site
P11295470A0954|71 91|B cell specific promoter
P11295470A0954|71 91|B cell specific promoter
P11295470A0954|105 109|3' UTR
P11295523A0218|42 50|mid-1970s
P11295760A1374|0 20|Specimen mass reduction
P11295760A1374|74 74|9
P11296288A1107|30 37|pCMVJS21
P11296288A1107|39 53|pCMVJS21DeltaGP
P11296288A1107|65 67|gag
P11296288A1107|65 67|gag
P11296288A1107|69 96|pol (and orf-x) coding sequences
P11296288A1107|69 71|pol
P11296288A1107|76 80|orf-x
P11296442A0565|32 44|Cole's formula
P11296442A0565|107 123|cardiac anesthesia
P11297419A0894|2 31|F222W:W21F rGST A1-1 double mutant
P11297419A0894|8 19|W21F rGST A1-1
P11297419A0894|20 31|double mutant
P11297419A0894|94 110|C-terminal residue
P11297514A0218|12 23|hos1 mutation
P11297514A0218|12 15|hos1
P11297514A0218|52 74|CBF transcription factors
P11297514A0218|52 54|CBF
P11297514A0218|55 74|transcription factors
P11297514A0218|116 135|cold-responsive genes
P11297545A0948|6 17|transfection
P11297545A0948|20 32|human CHOP cDNA
P11297545A0948|20 32|human CHOP cDNA
P11297545A0948|37 57|mammary carcinoma cells
P11297545A0948|74 77|CHOP
P11297545A0948|74 77|CHOP
P11297545A0948|104 128|hGH-stimulated mitogenesis
P11297545A0948|104 106|hGH
P11297545A0948|182 184|hGH
P11297545A0948|182 184|hGH
P11297545A0948|188 194|p38 MAPK
P11297545A0948|188 194|p38 MAPK
P11297866A0484|18 18|I
P11297866A0484|32 32|I
P11297866A0484|34 41|theezans
P11297866A0484|60 61|BF
P11297866A0484|64 83|intestinal propulsion
P11298326A0677|26 36|Vkappa genes
P11298326A0677|26 36|Vkappa genes
P11298326A0677|67 100|complementarity-determining regions
P11298326A0677|123 136|point mutations
P11301189A1396|36 38|p19
P11301189A1396|36 38|p19
P11301189A1396|40 44|INK4d
P11301189A1396|40 44|INK4d
P11301189A1396|77 103|human or murine B-lineage cells
P11302072A0508|46 56|performance
P11302072A0508|146 168|statistical significance
P11302566A1318|48 74|dopamine receptor sensitivity
P11302566A1318|48 63|dopamine receptor
P11302566A1318|78 95|psychomotor slowing
P11302704T0000|0 19|Homo-oligomerisation
P11302704T0000|44 67|mouse histone deacetylase 1
P11302704T0000|44 67|mouse histone deacetylase 1
P11303027A0954|51 57|GTPases
P11303027A0954|51 57|GTPases
P11303027A0954|63 71|ARF family
P11303027A0954|63 71|ARF family
P11303638A0559|4 20|NEU overexpression
P11303638A0559|22 33|nodal control
P11305129T0000|23 35|tetanus toxoid
P11305129T0000|66 76|vaccination
P11305129T0000|100 113|immune globulin
P11305129T0000|100 113|immune globulin
P11306101A0000|5 18|RACE techniques
P11306101A0000|51 98|hamster liver 3-hydroxy-hexobarbital dehydrogenases
P11306101A0000|51 57|hamster
P11306101A0000|63 98|3-hydroxy-hexobarbital dehydrogenases
P11306101A0000|119 132|cyclic alcohols
P11306101A0000|140 162|17beta-hydroxy-steroids
P11306101A0000|166 187|3alpha-hydroxysteroids
P11306463A0383|1 8|mutation
P11306463A0383|14 20|C domain
P11306463A0383|14 20|C domain
P11306463A0383|23 24|Rb
P11306463A0383|23 24|Rb
P11306463A0383|26 30|L901Q
P11306463A0383|72 78|cdk4/D1
P11306463A0383|72 75|cdk4
P11306463A0383|77 78|D1
P11306463A0383|107 113|C domain
P11306511A1476|86 94|mdm2 mRNAs
P11306511A1476|86 94|mdm2 mRNAs
P11306511A1476|105 124|progesterone receptor
P11306511A1476|105 124|progesterone receptor
P11306845A0168|0 22|Histological examination
P11306845A0168|46 73|acantholytic blister formation
P11306845A0168|77 98|apoptotic keratinocytes
P11308851A0333|52 55|GSER
P11308877A0213|20 27|periodic
P11308877A0213|167 175|circle map
P11309077A0953|0 10|Nine strains
P11309077A0953|25 40|Camp. jejuni subsp
P11309077A0953|42 56|jejuni biotype II
P11309077A0953|85 85|I
P11309373A0783|10 18|mCTR mRNAs
P11309373A0783|10 18|mCTR mRNAs
P11309373A0783|53 61|promoters
P11309373A0783|84 95|mCTR isoforms
P11309373A0783|84 95|mCTR isoforms
P11309373A0783|101 108|5' region
P11309373A0783|129 150|5'-untranslated regions
P11309389A0273|64 75|phorbol ester
P11309389A0273|76 104|phorbol 12-myristate 13-acetate
P11309389A0273|106 108|PMA
P11309389A0273|122 144|metalloprotease activity
P11309389A0273|122 136|metalloprotease
P11309389A0273|165 168|GHBP
P11309389A0273|165 168|GHBP
P11309389A0273|172 225|a membrane-associated GHR transmembrane/cytoplasmic domain
P11309389A0273|173 225|membrane-associated GHR transmembrane/cytoplasmic domain
P11309389A0273|265 267|GHR
P11309389A0273|280 290|GH signaling
P11309389A0273|280 281|GH
P11309400T0000|9 18|3' terminus
P11309400T0000|59 81|in vitro protein synthesis
P11309677A0000|70 87|Gulf War Illness (GWI
P11309677A0000|110 116|fatigue
P11309677A0000|118 121|GV-F
P11309677A0000|128 142|healthy veterans
P11309677A0000|144 147|GV-H
P11309677A0000|144 147|GV-H
P11309678A0489|0 31|Reverse transcription-PCR analysis
P11309678A0489|34 37|mRNA
P11310937A0548|100 102|CRP
P11310937A0548|100 102|CRP
P11310937A0548|106 109|IL-6
P11310937A0548|106 109|IL-6
P11310937A0548|149 158|fibrinogen
P11310937A0548|149 158|fibrinogen
P11310937A0548|162 170|TNF-alpha
P11310937A0548|162 170|TNF-alpha
P11311153T0000|20 74|factor V Leiden mutation or the deletion-deletion polymorphism
P11311153T0000|26 40|V Leiden mutation
P11311153T0000|80 106|angiotensin converting enzyme
P11311153T0000|80 106|angiotensin converting enzyme
P11311153T0000|122 141|thromboembolic events
P11311464A0362|5 13|disorders
P11311464A0362|21 32|low-back pain
P11311464A0362|51 67|bilateral sciatica
P11311464A0362|78 85|weakness
P11311464A0362|109 125|chronic paraplegia
P11311464A0362|130 136|bladder
P11311480A0079|0 15|Sural nerve biopsy
P11311480A0079|53 71|vascular alterations
P11311480A0079|76 103|inflammatory cell infiltration
P11311480A0079|153 168|myelinated fibers
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|62 83|rat eIF4E promoter region
P11311550A0253|62 83|rat eIF4E promoter region
P11311550A0253|113 128|specific elements
P11311550A0253|141 153|transcription
P11311550A0253|186 199|rat cardiocytes
P11311550A0253|206 220|murine C(2)C(12)
P11311550A0253|206 214|murine C(2
P11311563A0423|8 15|CCAAT box
P11311563A0423|32 60|heterologous promoter construct
P11311563A0423|62 72|OA induction
P11311563A0423|95 102|CCAAT box
P11311687A0231|3 8|JHRLSS
P11311687A0231|140 142|RLS
P11311909A0938|47 57|proximal end
P11311909A0938|63 86|associated A1 fenestration
P11311980A1049|0 9|GABA(B)R1g
P11311980A1049|0 9|GABA(B)R1g
P11311980A1049|28 52|brain and peripheral tissues
P11312108A2853|0 3|Raes
P11312120A1311|0 25|NF-kappaB pathway activation
P11312120A1311|0 8|NF-kappaB
P11312120A1311|38 51|transformation
P11312120A1311|79 87|oncogenes
P11312120A1311|98 104|Bcr/Abl
P11312120A1311|98 100|Bcr
P11312120A1311|102 104|Abl
P11312120A1311|106 108|Ras
P11312120A1311|106 108|Ras
P11312120A1311|112 114|Rac
P11312120A1311|112 114|Rac
P11312120A1311|137 157|transforming potential
P11312326A0169|7 34|rev- and RRE-defective HIV type 1
P11312326A0169|7 9|rev
P11312326A0169|14 16|RRE
P11312326A0169|27 34|HIV type 1
P11312326A0169|36 55|HIV-1) molecular clone
P11312326A0169|36 40|HIV-1
P11312326A0169|58 83|complementation experiments
P11312326A0169|143 160|regulatory elements
P11312326A0169|168 182|mammalian genome
P11312326A0169|205 220|virus replication
P11313249T0000|6 23|myeloid-restricted
P11313249T0000|33 61|CCAAT/enhancer-binding protein
P11313249T0000|33 61|CCAAT/enhancer-binding protein
P11313249T0000|73 103|transcriptional activation domain
P11313342A0224|25 31|alanine
P11313342A0224|50 74|active center cleft residues
P11313342A0224|140 142|PAP
P11313342A0224|140 142|PAP
P11313386A0704|0 18|SH2D1A protein levels
P11313386A0704|0 12|SH2D1A protein
P11313386A0704|36 52|CD40 cross-linking
P11313386A0704|36 39|CD40
P11313386A0704|72 92|B cell receptor ligation
P11313386A0704|72 84|B cell receptor
P11313398A0687|0 29|Cross-linking FcalphaR on wt-ITAM
P11313398A0687|13 20|FcalphaR
P11313398A0687|23 29|wt-ITAM
P11313398A0687|32 44|IIA-ITAM cells
P11313398A0687|32 39|IIA-ITAM
P11313398A0687|64 93|PI 3-kinase-dependent activation
P11313398A0687|64 73|PI 3-kinase
P11313398A0687|96 103|PKBalpha
P11313398A0687|96 103|PKBalpha
P11313946A0449|0 7|RPM/RGL3
P11313946A0449|0 2|RPM
P11313946A0449|4 7|RGL3
P11313946A0449|17 20|AF-6
P11313946A0449|17 20|AF-6
P11313946A0449|24 28|Nore1
P11313946A0449|24 28|Nore1
P11313946A0449|74 78|M-Ras
P11313946A0449|74 78|M-Ras
P11313946A0449|82 87|p21 Ras
P11313946A0449|82 87|p21 Ras
P11313946T0000|25 29|M-Ras
P11313946T0000|25 29|M-Ras
P11313946T0000|33 38|p21 Ras
P11313946T0000|33 38|p21 Ras
P11313946T0000|58 85|p21 Ras-mediated gene induction
P11313946T0000|58 76|p21 Ras-mediated gene
P11313946T0000|89 98|cell growth
P11313961A1323|45 61|spontaneous tumors
P11313961A1323|87 112|knock-out (p53(-/-)) strains
P11313961A1323|97 104|p53(-/-)
P11313961A1323|127 133|p53 gene
P11313961A1323|127 133|p53 gene
P11314030A1264|24 39|C-terminal region
P11314030A1264|24 39|C-terminal region
P11314030A1264|42 44|Crk
P11314030A1264|42 44|Crk
P11314030A1264|53 78|negative regulatory elements
P11314030A1264|95 97|Abl
P11314030A1264|95 97|Abl
P11314030A1264|101 103|FAK
P11314030A1264|101 103|FAK
P11314030A1264|113 126|signal pathways
P11314030A1264|151 170|autoinhibitory region
P11314030A1264|176 185|SH3 linker/
P11314030A1264|176 184|SH3 linker
P11314030A1264|186 204|C-terminal SH3 domain
P11314030A1264|186 204|C-terminal SH3 domain
P11314046A0000|0 6|Cyclins
P11314046A0000|0 6|Cyclins
P11314046A0000|47 66|cell cycle progression
P11314428A0651|131 142|canine region
P11314428A0651|152 154|LHS
P11314428A0651|167 169|RHS
P11315633A0920|22 52|VPg and RNA dependent RNA polymerase
P11315633A0920|22 24|VPg
P11315633A0920|28 52|RNA dependent RNA polymerase
P11315633A0920|69 77|E445-T446
P11315633A0920|88 112|amino acid sequence analysis
P11316127A0485|4 8|SVend
P11316127A0485|11 15|HCM-I
P11316127A0485|11 15|HCM-I
P11316127A0485|65 70|HCM-II
P11316127A0485|65 70|HCM-II
P11317256A0361|19 31|S. intermedius
P11317256A0361|49 62|S. constellatus
P11317256A0361|83 93|S. anginosus
P11317256A0361|113 119|abscess
P11318608A0669|0 29|Human brain cDNA library screening
P11318608A0669|55 62|cDNA ends
P11318608A0669|70 89|full-length DENTT cDNA
P11318608A0669|81 89|DENTT cDNA
P11318608A0669|102 124|1899-bp open reading frame
P11318608A0669|134 163|predicted 633-amino-acid protein
P11318608A0669|208 211|NLSs
P11318608A1155|14 24|EGFP-tagged
P11318608A1155|14 17|EGFP
P11318608A1155|25 29|DENTT
P11318608A1155|25 29|DENTT
P11318608A1155|30 32|NLS
P11318608A1155|33 50|deletion constructs
P11318608A1155|61 69|bipartite
P11318608A1155|70 74|NLS-1
P11318608A1155|94 102|nucleolus
P11319098A0164|17 32|tryptophanyl tRNA
P11319098A0164|17 32|tryptophanyl tRNA
P11319098A0164|37 67|protein translocase component SecE
P11319098A0164|37 54|protein translocase
P11319098A0164|64 67|SecE
P11319098A0164|72 96|antiterminator protein NusG
P11319098A0164|72 92|antiterminator protein
P11319098A0164|93 96|NusG
P11319098A0164|104 123|ribosomal proteins L11
P11319098A0164|104 120|ribosomal proteins
P11319098A0164|121 123|L11
P11319098A0164|127 128|L1
P11319098A0164|127 128|L1
P11319098A0164|141 144|PkwR
P11319098A0164|141 144|PkwR
P11319098A0164|177 191|LacI-GalR family
P11319098A0164|177 180|LacI
P11319098A0164|182 185|GalR
P11319880A1108|0 27|Rapamycin (FRAP/mTOR inhibitor
P11319880A1108|10 13|FRAP
P11319880A1108|15 18|mTOR
P11319880A1108|36 41|4E-BP1
P11319880A1108|36 41|4E-BP1
P11319880A1108|82 86|alpha
P11319880A1108|88 105|hypophosphorylated
P11321187A0355|12 25|52 seropositive
P11321187A0355|26 27|MS
P11321187A0355|28 35|patients
P11321187A0355|71 94|C. pneumoniae-specific IgG
P11321187A0355|71 94|C. pneumoniae-specific IgG
P11321187A0355|109 128|seropositive controls
P11323411A0505|3 21|Western blot analysis
P11323411A0505|38 53|tandem SH2 domains
P11323411A0505|44 53|SH2 domains
P11323411A0505|56 59|SHP2
P11323411A0505|56 59|SHP2
P11323411A0505|66 69|Gab1
P11323411A0505|66 69|Gab1
P11323411A0505|103 113|N-SH2 domain
P11323411A0505|103 113|N-SH2 domain
P11323411A0505|121 135|phosphotyrosine
P11323411A0505|137 139|Tyr
P11323411A0505|141 142|P)
P11323411A0505|154 164|C-SH2 domain
P11323411A0505|154 164|C-SH2 domain
P11323411A0505|172 174|Tyr
P11323411A0505|172 174|Tyr
P11323411A0505|176 181|P)-659
P11323411A0505|176 176|P
P11323419T0000|0 15|Molecular cloning
P11323419T0000|17 30|genomic mapping
P11323419T0000|50 72|secretor blood group alpha
P11323419T0000|74 100|1,2)fucosyltransferase genes
P11323419T0000|74 76|1,2
P11323419T0000|78 100|fucosyltransferase genes
P11323419T0000|131 147|uterine epithelium
P11323419T0000|151 171|gastrointestinal tract
P11323716A0413|3 12|UBA domains
P11323716A0413|3 12|UBA domains
P11323716A0413|15 19|RAD23
P11323716A0413|15 19|RAD23
P11323716A0413|23 26|DDI1
P11323716A0413|23 26|DDI1
P11324516A0159|14 38|intrathecal administration
P11324516A0159|47 71|D2 receptor agonist LY171555
P11324516A0159|47 56|D2 receptor
P11324516A0159|74 86|D1/D2 receptor
P11324516A0159|74 75|D1
P11324516A0159|77 86|D2 receptor
P11324516A0159|154 155|AA
P11325195A0661|12 14|MFI
P11325195A0661|17 21|fresh
P11325195A0661|31 36|muscle
P11325195A0661|54 57|lamb
P11325195A0661|61 75|pork longissimus
P11325391A0498|15 27|d-amphetamine
P11325685A1624|0 30|Intravenous L-carnitine treatment
P11325685A1624|40 68|plasma carnitine concentrations
P11325685A1624|94 100|fatigue
P11325685A1624|149 168|hemodialysis patients
P11325944A0511|20 34|full-length UhpB
P11325944A0511|20 34|full-length UhpB
P11325944A0511|40 59|soluble hybrid protein
P11325944A0511|61 66|GST-Bc
P11325944A0511|61 66|GST-Bc
P11325944A0511|75 103|glutathione S-transferase (GST)
P11325944A0511|75 98|glutathione S-transferase
P11325944A0511|100 102|GST
P11325944A0511|114 141|cytoplasmic C-terminal portion
P11325944A0511|144 147|UhpB
P11325944A0511|144 147|UhpB
P11325944A0511|176 189|uhpT expression
P11325944A0511|176 179|uhpT
P11325944A0511|193 204|uhp(+) strain
P11325944A0511|193 197|uhp(+
P11327292A0190|20 40|cavernous malformation
P11327292A0190|82 87|vision
P11327698A0191|14 30|PKC and p44/p42MAPK
P11327698A0191|14 16|PKC
P11327698A0191|20 22|p44
P11327698A0191|24 30|p42MAPK
P11327698A0191|58 60|HBx
P11327698A0191|58 60|HBx
P11327698A0191|69 86|Sp1-mediated IGF-II
P11327698A0191|69 71|Sp1
P11327698A0191|81 88|IGF-II P4
P11327698A0191|89 111|transcriptional activity
P11327698A0191|120 132|PKC activation
P11327698A0191|120 122|PKC
P11327698A0191|135 137|PMA
P11327698A0191|135 137|PMA
P11327698A0191|140 142|PKC
P11327698A0191|140 142|PKC
P11327698A0191|168 185|Sp1 phosphorylation
P11327698A0191|168 170|Sp1
P11327698A0191|189 190|P4
P11327698A0191|189 190|P4
P11327698A0191|201 225|HBx-transfected HepG2 cells
P11327698A0191|201 203|HBx
P11327698A0191|231 233|PKC
P11327698A0191|231 233|PKC
P11327698A0191|246 257|PKC inhibitor
P11327698A0191|246 248|PKC
P11327698A0191|258 263|Go6976
P11327698A0191|271 288|Sp1 phosphorylation
P11327698A0191|271 273|Sp1
P11327698A0191|290 291|P4
P11327698A0191|290 291|P4
P11327698A0191|304 313|IGF-II mRNA
P11327698A0191|304 313|IGF-II mRNA
P11327698A0191|316 340|HBx-transfected HepG2 cells
P11327698A0191|316 318|HBx
P11327698A0191|365 377|MEK activation
P11327698A0191|365 367|MEK
P11327698A0191|380 384|U0126
P11327698A0191|392 409|Sp1 phosphorylation
P11327698A0191|392 394|Sp1
P11327698A0191|411 412|P4
P11327698A0191|411 412|P4
P11327698A0191|424 433|IGF-II mRNA
P11327698A0191|424 433|IGF-II mRNA
P11327698A0191|436 460|HBx-transfected HepG2 cells
P11327698A0191|436 438|HBx
P11327858A0087|26 28|Arf
P11327858A0087|26 28|Arf
P11327858A0087|40 54|oncoprotein Hdm2
P11327858A0087|40 50|oncoprotein
P11327858A0087|51 54|Hdm2
P11327858A0087|76 78|p53
P11327858A0087|76 78|p53
P11328699A0000|5 25|free-swimming rotatory
P11328699A0000|112 132|aversive test situation
P11328853A0644|20 42|promoter deletion mutants
P11328853A0644|56 59|SF-1
P11328853A0644|56 59|SF-1
P11328853A0644|74 95|proximal promoter region
P11328853A0644|99 123|upstream promoter sequences
P11331589A0113|3 12|MSL complex
P11331589A0113|3 12|MSL complex
P11331589A0113|45 55|X chromosome
P11331596A0710|0 3|Prrp
P11331596A0710|0 3|Prrp
P11331596A0710|27 36|EVH1 domain
P11331596A0710|27 36|EVH1 domain
P11331596A0710|39 42|Mena
P11331596A0710|39 42|Mena
P11331596A0710|51 81|microfilament-associated protein
P11331604A0267|0 4|Srb10
P11331604A0267|0 4|Srb10
P11331604A0267|8 29|physiological regulator
P11331604A0267|32 44|Gcn4 stability
P11331604A0267|32 35|Gcn4
P11331604A0267|84 87|Gcn4
P11331604A0267|84 87|Gcn4
P11331604A0267|103 114|srb10 mutants
P11331604A0267|103 114|srb10 mutants
P11331613A0827|19 30|pVHL function
P11331613A0827|19 22|pVHL
P11333263A0240|4 9|intron
P11333263A0240|12 23|476 base pairs
P11333263A0240|37 42|middle
P11333263A0240|48 76|5'-untranslated leader sequence
P11333263A0240|108 123|promoter activity
P11333268A1521|50 52|Sos
P11333268A1521|60 83|switch 1 and switch 2 regions
P11333268A1521|86 88|Ras
P11333268A1521|86 88|Ras
P11333268A1521|142 148|switch 2
P11333268A1521|160 168|anchoring
P11333268A1521|171 173|Ras
P11333268A1521|171 173|Ras
P11333268A1521|176 178|Sos
P11333268A1521|205 211|switch 1
P11333268A1521|234 255|nucleotide-binding site
P11333268A1521|259 273|GDP dissociation
P11334124A0903|58 61|FEV1
P11334124A0903|80 87|peak FEV1
P11334124A0903|120 127|Respimat
P11335116A1099|0 19|Bandshift experiments
P11335116A1099|35 40|BmHR3A
P11335116A1099|35 40|BmHR3A
P11335116A1099|60 63|RORE
P11335116A1099|60 63|RORE
P11335116A1099|65 128|Retinoic acid-related Orphan receptor Response Element)-like sequences
P11335116A1099|65 76|Retinoic acid
P11335116A1099|85 128|Orphan receptor Response Element)-like sequences
P11335116A1099|134 142|promoters
P11335116A1099|183 188|BmHR3A
P11335116A1099|183 188|BmHR3A
P11335116A1099|216 225|BmGATAbeta
P11335116A1099|216 225|BmGATAbeta
P11335116A1099|229 236|ESP genes
P11335116A1099|229 236|ESP genes
P11335116A1099|243 256|vitellogenesis
P11335710A0320|44 56|Erk activation
P11335710A0320|44 46|Erk
P11336211A0132|3 17|iterative method
P11336211A0132|28 36|Bengtsson
P11336698A0075|15 18|Rsc3
P11336698A0075|15 18|Rsc3
P11336698A0075|22 26|Rsc30
P11336698A0075|22 26|Rsc30
P11336698A0075|58 81|yeast remodeler RSC complex
P11336698A0075|72 81|RSC complex
P11337859A0651|3 21|COD and color removals
P11337859A0651|45 49|FeCl3
P11337859A0651|62 72|coagulation
P11337859A0651|91 101|coagulation
P11337859A0651|143 149|ferrous
P11337859A0651|150 165|hydrogen peroxide
P11337859A0651|190 199|H2O2 dosage
P11340048A0432|39 45|sap flux
P11340048A0432|111 117|sap flux
P11340080A0096|28 46|checkpoint signaling
P11340080A0096|48 51|Rad1
P11340080A0096|48 51|Rad1
P11340080A0096|53 56|Hus1
P11340080A0096|53 56|Hus1
P11340080A0096|61 64|Rad9
P11340080A0096|61 64|Rad9
P11340080A0096|91 109|immunoprecipitation
P11340080A0096|113 134|yeast two-hybrid studies
P11340085A0211|127 143|amino acid sequence
P11340085A0211|146 155|C/EBPalpha
P11340085A0211|146 155|C/EBPalpha
P11340085A0211|183 188|human)
P11340085A0211|206 227|highly conserved regions
P11340085A0211|229 235|CR1-CR4
P11340085A0211|229 231|CR1
P11340085A0211|233 235|CR4
P11340085A0211|246 266|transactivation domain
P11340516A0509|11 16|ADAL-2
P11340516A0509|35 46|Vicryl suture
P11340516A0509|61 66|ADAL-2
P11340516A0509|86 94|Tisuacryl
P11340525A0737|5 12|patients
P11340525A0737|130 133|C met
P11341349T0000|29 49|breast cancer screening
P11341349T0000|60 74|low-income women
P11341405A0146|17 19|MCB
P11341405A0146|74 89|MCB abnormalities
P11341405A1154|82 85|left
P11341405A1154|86 96|MCB-IV and -V
P11341405A1154|99 108|Greyhounds
P11341405A1154|165 170|dorsal
P11341405A1154|182 185|left
P11341405A1154|186 188|MCB
P11341405A1154|206 222|adaptive responses
P11341405A1154|237 246|asymmetric
P11341828A0744|19 35|residue D-peptides
P11341828A0744|50 69|pocket-binding domain
P11341828A0744|75 89|cyclic molecules
P11341828A0744|75 89|cyclic molecules
P11342479A0430|18 36|Palmaz-Schatz stents
P11342479A0430|55 64|paclitaxel
P11342479A0430|72 73|15
P11342479A0430|109 127|ethanolic paclitaxel
P11342479A0430|147 153|solvent
P11344530A0320|0 10|Percentages
P11344530A0320|24 31|overload
P11344530A0320|35 47|dilution tests
P11345435A0199|8 16|conserved
P11345435A0199|17 19|RNA
P11345435A0199|20 29|subdomains
P11345435A0199|41 42|P3
P11345435A0199|41 42|P3
P11345435A0199|81 101|nucleolar localization
P11345445A0533|2 18|Cd-spiked OECD soil
P11345445A0533|28 35|Cd levels
P11345445A0533|134 135|Cu
P11345445A0533|139 140|Zn
P11345445A0533|153 172|spiked concentrations
P11347201X0001|0 16|Nutritional status
P11347201X0001|19 24|adults
P11347201X0001|42 56|traditional diet
P11347201X0001|83 101|vitamin B12, vitamin D
P11347201X0001|114 138|polyunsaturated fatty acids
P11348318A0940|105 118|palpable masses
P11349796A0950|0 11|Measurements
P11349796A0950|40 56|traumatic exposure
P11349796A0950|58 59|D0
P11349796A0950|97 98|D3
P11349796A0950|121 123|D30
P11350038A0459|34 37|half
P11350038A0459|39 43|Stem 2
P11350038A0459|70 82|stem structure
P11350038A0459|93 98|hY RNAs
P11350038A0459|93 98|hY RNAs
P11350165A1606|12 21|DB sequence
P11350165A1606|51 63|stem structure
P11350165A1606|84 104|translation efficiency
P11350175A0173|35 47|protein family
P11350175A0173|59 73|prolyl isomerase
P11350175A0173|59 73|prolyl isomerase
P11350175A0173|77 85|chaperone
P11350812A0829|15 34|Raf-1 target ERK kinase
P11350812A0829|15 19|Raf-1
P11350812A0829|26 34|ERK kinase
P11350812A0829|36 38|MEK
P11350812A0829|36 38|MEK
P11350812A0829|67 102|Rp-cAMPS- and PKI-induced ERK activation
P11350812A0829|79 81|PKI
P11350812A0829|90 92|ERK
P11350812A0829|104 127|caldesmon phosphorylation
P11350812A0829|104 112|caldesmon
P11350812A0829|132 151|stress fiber formation
P11350957A0457|0 8|PACAP mRNA
P11350957A0457|0 8|PACAP mRNA
P11350957A0457|33 44|human tissues
P11350957A0457|48 63|transfected cells
P11350957A0457|65 69|PACAP
P11350957A0457|65 69|PACAP
P11350957A0457|96 104|cytoplasm
P11350982A0560|48 67|GCN1-GCN2 interaction
P11350982A0560|48 51|GCN1
P11350982A0560|53 56|GCN2
P11350982A0560|82 85|GCN2
P11350982A0560|82 85|GCN2
P11352423A0084|3 19|radial forearm flap
P11352663A0138|38 53|class I expression
P11352663A0138|38 43|class I
P11352663A0138|84 90|COUP-TF
P11352663A0138|84 90|COUP-TF
P11352663A0138|109 117|NF-kappaB
P11352663A0138|109 117|NF-kappaB
P11352671A0492|17 31|reverse genetics
P11352671A0492|48 63|nucleotide change
P11352671A0492|65 67|UCU
P11352671A0492|70 72|ACU
P11352671A0492|100 114|RNA-editing site
P11352671A0492|120 124|V gene
P11352671A0492|120 124|V gene
P11352671A0492|141 149|hPIV2 cDNA
P11352671A0492|169 185|infectious viruses
P11352671A0492|187 195|rPIV2V(-)
P11352671A0492|204 207|cDNA
P11353392A1127|3 12|frameshift
P11353392A1127|24 28|ADEx2
P11353392A1127|80 107|loss-of-function ASIP mutation
P11353770A0085|47 48|S3
P11353770A0085|47 48|S3
P11353770A0085|65 77|N-glycosylase
P11353770A0085|65 77|N-glycosylase
P11353770A0085|101 120|8-oxoguanine residues
P11353770A0085|156 161|places
P11353774A0255|48 64|forkhead homologue
P11353774A0255|48 64|forkhead homologue
P11353774A0255|67 82|rhabdomyosarcoma
P11353774A0255|84 87|FKHR
P11353774A0255|84 87|FKHR
P11353774A0255|119 151|hepatocyte nuclear factor 3/forkhead
P11353774A0255|119 142|hepatocyte nuclear factor 3
P11353774A0255|144 169|forkhead homeotic gene family
P11353774A0255|152 169|homeotic gene family
P11353774A0255|174 195|nuclear hormone receptor
P11353774A0255|174 195|nuclear hormone receptor
P11353774A0255|197 198|NR
P11353774A0255|197 198|NR
P11353774A0255|200 218|intermediary protein
P11354406A1373|3 31|improved CSF outflow conductance
P11354406A1373|85 107|pathological ICP waveform
P11354975A0850|13 23|Euspondylus
P11354975A0850|43 48|female
P11354975A0850|76 86|Cerro El Humo
P11355576A1125|3 9|cyclins
P11355576A1125|3 9|cyclins
P11355576A1125|30 32|CDK
P11355576A1125|30 32|CDK
P11355576A1125|46 60|phosphorylation
P11355576A1125|85 106|tumor suppressor protein
P11355576A1125|85 106|tumor suppressor protein
P11355576A1125|108 110|pRb
P11355576A1125|108 110|pRb
P11355576A1125|112 114|pRb
P11355576A1125|112 114|pRb
P11355576A1125|150 159|G1 to S phase
P11355576A1125|202 224|E2F transcription factors
P11355576A1125|202 204|E2F
P11355576A1125|239 255|cell proliferation
P11355615A0766|10 18|education
P11355668T0000|13 24|vasculopathy
P11355668T0000|28 36|cutaneous
P11355668T0000|50 56|porcine
P11355668T0000|57 64|neonates
P11355668T0000|102 125|respiratory syndrome virus
P11356214A0794|67 79|Knoop hardness
P11356214A0794|102 121|top and bottom surfaces
P11356214A0794|145 150|Teflon
P11356214A0794|177 182|cavity
P11356214A0794|193 198|dentin
P11356716A0372|54 66|GHS-R variants
P11356716A0372|54 66|GHS-R variants
P11356835A0000|0 22|Saccharomyces cerevisiae
P11356835A0000|0 22|Saccharomyces cerevisiae
P11356835A0000|114 130|protein precursors
P11356835A0000|137 155|amino acid starvation
P11356853A0429|2 10|Ka13 cells
P11356853A0429|12 15|CoCl
P11356853A0429|42 63|luciferase reporter gene
P11356853A0429|42 63|luciferase reporter gene
P11356853A0429|82 113|15-kilobase pair mouse ho-1 promoter
P11356853A0429|102 113|ho-1 promoter
P11356853A0429|115 122|pHO15luc
P11356853A0429|115 122|pHO15luc
P11356853A0554|29 54|cobalt-responsive sequences
P11356853A0554|60 82|stress-response elements
P11356853A0554|60 82|stress-response elements
P11356853A0554|84 88|StREs
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|29 54|basic-leucine zipper factors
P11356853A0873|29 54|basic-leucine zipper factors
P11356853A0873|64 67|StRE
P11357063A0138|0 11|Descriptions
P11357063A0138|132 147|single-copy equid
P11357063A0138|148 160|LH/CGbeta gene
P11357063A0138|148 149|LH
P11357063A0138|151 156|CGbeta
P11357063A0138|167 202|primate LHbeta-CGbeta gene cluster locus
P11357063A0138|174 179|LHbeta
P11357063A0138|181 186|CGbeta
P11357063A1053|16 34|mammalian LHbeta gene
P11357063A1053|16 34|mammalian LHbeta gene
P11357063A1053|39 55|5'-flanking region
P11357063A1053|61 75|gpLH/CGbeta gene
P11357063A1053|61 64|gpLH
P11357063A1053|66 71|CGbeta
P11357063A1053|91 114|TATA sequence 37 bp upstream
P11357063A1053|120 140|translation start codon
P11358801A1046|43 56|NHEJ deficiency
P11358801A1046|64 84|genomic rearrangements
P11358801A1046|101 118|chromosomal studies
P11358958A0878|12 21|human RACK1
P11358958A0878|12 21|human RACK1
P11358958A0878|41 68|E1A-mediated growth inhibition
P11358958A0878|41 43|E1A
P11358958A0878|71 74|HF7c
P11358958A0878|86 100|human tumor cells
P11358958A0878|105 124|E1A-induced apoptosis
P11358958A0878|105 107|E1A
P11358962A0344|0 4|Foxp1
P11358962A0344|0 4|Foxp1
P11358962A0344|8 12|Foxp2
P11358962A0344|8 12|Foxp2
P11358962A0344|42 45|lung
P11358962A0344|55 57|E12
P11358962A0344|62 77|mouse development
P11358962A0344|82 86|Foxp2
P11358962A0344|82 86|Foxp2
P11358962A0344|112 127|airway epithelium
P11359568T0000|0 16|Molecular analysis
P11359568T0000|22 43|pRA2 partitioning region
P11359568T0000|45 79|ParB autoregulates parAB transcription
P11359568T0000|45 48|ParB
P11359568T0000|62 66|parAB
P11359568T0000|89 108|nucleoprotein complex
P11359568T0000|116 122|plasmid
P11359568T0000|137 140|parS
P11359568T0000|137 140|parS
P11359827T0000|0 12|Immunological
P11359827T0000|45 86|streptococcal pyrogenic exotoxins I and J (SPE-I
P11359827T0000|45 76|streptococcal pyrogenic exotoxins I
P11359827T0000|80 80|J
P11359827T0000|82 86|SPE-I
P11359827T0000|90 94|SPE-J
P11359827T0000|90 94|SPE-J
P11359827T0000|100 120|Streptococcus pyogenes
P11359907A0099|7 23|dozen HIF-1 targets
P11359907A0099|12 23|HIF-1 targets
P11359907A0099|57 87|vascular endothelial growth factor
P11359907A0099|57 87|vascular endothelial growth factor
P11359907A0099|89 92|VEGF
P11359907A0099|89 92|VEGF
P11360190A0178|24 26|Tax
P11360190A0178|24 26|Tax
P11360190A0178|58 67|G0/G1 phase
P11360190A0178|70 83|S and G2/M phases
P11360190A0178|86 100|human T-cell line
P11360190A0178|101 111|Kit 225 cells
P11361338A0093|4 19|yeast peroxisomal
P11361338A0093|42 82|type 1C-terminal peroxisomal targeting signal
P11361338A0093|84 87|PTS1
P11361338A0093|104 116|tripeptide SKL
P11361338A0093|120 131|conservative
P11361338A0447|8 22|PEX5-TPR domains
P11361338A0447|8 11|PEX5
P11361338A0447|33 39|tobacco
P11361338A0447|69 86|TPR-less yeast Pex5p
P11361338A0447|82 86|Pex5p
P11361338A0447|106 119|Pex5p chimaeras
P11361338A0447|106 110|Pex5p
P11361493T0000|0 4|HIV-1
P11361493T0000|0 4|HIV-1
P11361493T0000|8 22|hepatitis B virus
P11361493T0000|35 45|adolescents
P11361493T0000|74 84|Buenos Aires
P11367523A1684|0 24|Immunofixation experiments
P11367523A1684|27 35|C4A and C4B
P11367523A1684|27 29|C4A
P11367523A1684|33 35|C4B
P11367523A2624|8 18|C4B proteins
P11367523A2624|99 110|long C4A genes
P11367523A2624|99 110|long C4A genes
P11368363A0129|25 44|transcription factors
P11368363A0129|65 84|human myeloperoxidase
P11368363A0129|65 84|human myeloperoxidase
P11368363A0129|86 88|MPO
P11368363A0129|86 88|MPO
P11368363A0129|139 155|cDNA and genomic DNA
P11368363A0129|159 167|human HBP1
P11368363A0129|159 167|human HBP1
P11368363A0129|169 193|HMG-Box containing protein 1
P11368363A0129|169 193|HMG-Box containing protein 1
P11368363A0129|208 224|high mobility group
P11368363A0129|227 256|non-histone chromosomal proteins
P11368363A0129|227 230|non-
P11368363A0129|231 256|histone chromosomal proteins
P11368363A1103|3 22|human protein sequence
P11368363A1103|3 22|human protein sequence
P11368363A1103|40 56|DNA-binding domain
P11368363A1103|76 82|rat HBP1
P11368363A1103|76 82|rat HBP1
P11368363A1103|162 171|rat protein
P11368363A1103|162 171|rat protein
P11368787A0180|8 30|transcriptional activity
P11368787A0180|52 60|5' portion
P11368787A0180|66 83|human annexin A5 gene
P11368787A0180|66 83|human annexin A5 gene
P11368787A0180|91 100|-1275 to +79
P11368901A0327|13 37|human and mouse BCNT proteins
P11368901A0327|21 37|mouse BCNT proteins
P11368901A0327|45 57|one repeat unit
P11368901A0327|68 87|RTE-1-derived portion
P11368901A0327|68 72|RTE-1
P11368911T0000|25 29|smg-4
P11368911T0000|25 29|smg-4
P11368911T0000|42 57|mRNA surveillance
P11368911T0000|60 68|C. elegans
P11368914T0071|3 10|remotely
P11368914T0071|19 23|exons
P11368914T0071|33 53|complement C3 gene locus
P11368914T0071|33 53|complement C3 gene locus
P11368914T0071|71 75|5' end
P11368914T0071|87 89|ORF
P11368914T0071|108 128|bidirectional promoter
P11369066A1210|18 20|MMF
P11369066A1210|36 49|corticosteroid
P11369066A1210|55 68|emollient cream
P11369066A1210|114 127|emollient cream
P11369066A1210|143 166|acute radiation dermatitis
P11369106A0428|27 40|volatile sulfur
P11369106A0428|52 73|ecological interactions
P11369106A0428|107 124|planktonic food webs
P11369410A0949|109 127|attentive processing
P11369453A1083|20 33|protein binding
P11369453A1083|58 73|peptide treatment
P11369700A0074|0 2|CSR
P11369700A0074|23 40|heavy chain isotypes
P11369700A0074|43 51|cytokines
P11369700A0074|55 69|B cell activators
P11369700A0074|115 125|germline (GL
P11369700A0074|124 126|GL)
P11369700A0074|128 142|C(H) region genes
P11369700A0074|128 128|C
P11369700A0074|130 130|H
P11369700A0616|42 49|Ets sites
P11369700A0616|42 49|Ets sites
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|82 106|transcription factors Elf-1
P11369700A0616|82 101|transcription factors
P11369700A0616|102 106|Elf-1
P11369700A0616|110 113|PU.1
P11369700A0616|110 113|PU.1
P11369700A0616|125 130|3' site
P11369700A0616|125 130|3' site
P11369700A0616|158 179|luciferase reporter gene
P11369700A0616|158 179|luciferase reporter gene
P11369700A0616|191 205|GL alpha promoter
P11369700A0616|191 205|GL alpha promoter
P11369759A0605|0 3|Cell
P11370174A0447|77 79|MMF
P11371115A0962|50 59|HBs antigen
P11371115A0962|50 59|HBs antigen
P11371115A0962|89 91|MGN
P11371115A0962|94 104|MPGN pattern
P11371160A0193|48 76|C1-G72 and discriminator base A73
P11371160A0193|82 99|amino acid-acceptor
P11371160A0854|20 41|canonical anticodon loop
P11371160A0854|47 63|tyrosine anticodon
P11371160A0854|72 77|anchor
P11371160A0854|81 85|TyrRS
P11371160A0854|81 85|TyrRS
P11371343A0125|15 23|cell cycle
P11371343A0125|25 32|separase
P11371343A0125|60 76|inhibitory protein
P11371343A0125|83 89|securin
P11371343A0125|83 89|securin
P11371417A0744|30 34|lungs
P11371417A0744|57 71|chord compliance
P11371417A0744|103 132|tumor necrosis factor (TNF)-alpha
P11371417A0744|103 121|tumor necrosis factor
P11371417A0744|123 132|TNF)-alpha
P11371417A0744|150 170|interleukin (IL)-1beta
P11371417A0744|150 170|interleukin (IL)-1beta
P11371417A0744|172 174|902
P11371417A0744|191 221|macrophage inflammatory protein-2
P11371417A0744|191 221|macrophage inflammatory protein-2
P11371417A0744|223 227|MIP-2
P11371417A0744|223 227|MIP-2
P11371417A0744|270 278|cytokines
P11371417A0744|359 360|LA
P11372882A1143|0 8|Maternal p
P11372882A1143|12 31|DDE and beta-HCH levels
P11372882A1143|54 66|newborn levels
P11372882A1143|79 82|PCBs
P11372959A1447|8 17|regression
P11372959A1447|91 103|positive sites
P11373277A0812|27 50|adenoviral oncoprotein E1A
P11373277A0812|27 50|adenoviral oncoprotein E1A
P11373277A0812|90 102|AP-2alpha gene
P11373277A0812|90 98|AP-2alpha
P11373277A0812|156 172|AP-2alpha promoter
P11373277A0812|156 164|AP-2alpha
P11373277A0812|188 190|E1A
P11373277A0812|188 190|E1A
P11373277A0812|198 220|AP-2rep corepressor CtBP1
P11373277A0812|198 204|AP-2rep
P11373277A0812|216 220|CtBP1
P11374051A0437|51 65|corticosteroids
P11374051A0437|88 105|ulcer complications
P11374051A0437|109 125|co-morbid diseases
P11374559A0103|25 41|vacuum evaporation
P11374559A0103|54 58|p-NTP
P11374559A0103|92 115|colloidal silver solutions
P11375392T0000|3 14|core promoter
P11375392T0000|17 42|human thioredoxin reductase 1
P11375392T0000|22 42|thioredoxin reductase 1
P11375392T0000|44 50|cloning
P11375392T0000|52 74|transcriptional activity
P11375392T0000|79 83|Oct-1
P11375392T0000|79 83|Oct-1
P11375392T0000|85 87|Sp1
P11375392T0000|85 87|Sp1
P11375392T0000|92 94|Sp3
P11375392T0000|92 94|Sp3
P11375392T0000|109 133|housekeeping-type promoter
P11375392T0000|140 167|AU-rich element-regulated gene
P11375392T0000|140 167|AU-rich element-regulated gene
P11376007A0584|46 66|protein kinase activity
P11376007A0584|46 58|protein kinase
P11376007A0584|69 74|DNA-PK
P11376007A0584|69 74|DNA-PK
P11376007A0584|103 126|purified catalytic subunit
P11376007A0584|135 153|protein phosphatase 1
P11376007A0584|135 153|protein phosphatase 1
P11376007A0584|156 175|protein phosphatase 2A
P11376007A0584|156 175|protein phosphatase 2A
P11376007A0584|177 180|PP2A
P11376007A0584|177 180|PP2A
P11376007A0584|225 251|protein phosphatase inhibitor
P11376007A0584|225 242|protein phosphatase
P11376007A0584|253 263|microcystin
P11376119A0346|3 11|first exon
P11376119A0346|13 18|exon 1A
P11376119A0346|41 61|5'-untranslated region
P11376119A0346|67 75|GHR 1A mRNA
P11376119A0346|67 71|GHR 1A
P11376119A0346|72 75|mRNA
P11376119A0346|99 103|exon 2
P11376119A0346|109 115|GHR gene
P11376119A0346|109 115|GHR gene
P11376134A1506|58 88|transcription factor binding sites
P11376134A1506|58 76|transcription factor
P11376134A1506|77 88|binding sites
P11376165T0000|0 27|FLP and Cre recombinase function
P11376165T0000|0 2|FLP
P11376165T0000|6 19|Cre recombinase
P11376165T0000|30 43|Xenopus embryos
P11376279A0000|22 70|three-dimensional magnetic resonance (MR) angiography
P11376279A0000|96 110|segmented volume
P11376687A0344|36 40|exon 2
P11376687A0344|74 84|GTG83/ATG83
P11376687A0344|125 127|AUG
P11376687A0344|130 144|B-type MTH1 mRNAs
P11376687A0344|136 144|MTH1 mRNAs
P11376687A0344|162 176|MTH1 polypeptide
P11376687A0344|162 176|MTH1 polypeptide
P11376687A0344|178 180|p26
P11376687A0344|178 180|p26
P11376687A0344|206 233|mitochondrial targeting signal
P11376946A0000|31 35|SHP-1
P11376946A0000|31 35|SHP-1
P11376946A0000|38 84|SH2 domain-containing protein-tyrosine phosphatase
P11376946A0000|38 84|SH2 domain-containing protein-tyrosine phosphatase
P11376946A0000|113 133|hematopoietic lineages
P11376946A0000|148 169|non-hematopoietic cells
P11376946A0000|189 222|alternative tissue-specific promoter
P11376946A0000|200 222|tissue-specific promoter
P11376946A0000|224 225|P1
P11376946A0000|224 225|P1
P11377975A0898|13 36|Arg1-expressing COS1 cells
P11377975A0898|56 65|proteinase
P11377975A0898|109 115|neutral
P11377975A0898|118 133|acidic conditions
P11378898A0164|0 3|ORF1
P11380028A0000|54 63|estimation
P11380028A0000|66 118|Technetium Tc 99m (99mTc)-pentetate and orthoiodohippurate
P11380028A0000|124 147|131I-OIH) plasma clearance
P11380028A0000|150 160|dogs and cats
P11380028A0000|170 181|blood samples
P11380370A0000|1 7|patient
P11380370A0000|23 33|skin lesions
P11380370A0000|44 62|Kaposi's sarcoma (KS)
P11380837A1505|0 12|Interventions
P11380837A1505|25 41|specific mediators
P11380837A1505|120 144|vascular access dysfunction
P11381094A0797|11 17|stonin 2
P11381094A0797|11 17|stonin 2
P11381094A0797|28 37|C2B domains
P11381094A0797|28 30|C2B
P11381094A0797|40 59|synaptotagmins I and II
P11381094A0797|40 54|synaptotagmins I
P11382701A0688|4 21|partial transection
P11382701A0688|33 43|vasopressin
P11382701A0688|81 105|plasma sodium concentration
P11382948A0793|13 33|USPIO-enhanced MRI data
P11382948A0793|59 74|tumor microvessel
P11382948A0793|91 107|breast cancer model
P11382948A0793|109 133|microvascular permeability
P11382948A0793|150 154|USPIO
P11382948A0793|183 192|tumor grade
P11383860A0661|3 8|images
P11383860A0661|34 49|urinary excretion
P11383860A0661|52 56|99mTc
P11383860A0661|57 69|ciprofloxacin
P11383860A0661|86 90|brain
P11383860A0661|92 95|lung
P11383860A0661|99 114|bone marrow uptake
P11383860A0661|121 143|liver uptake and excretion
P11384225A0634|53 75|green fluorescent protein
P11384225A0634|58 79|fluorescent protein (GFP
P11384225A0634|77 79|GFP
P11384225A0634|93 97|3' end
P11384225A0634|100 144|EAV-specific transcription-regulating sequences
P11384225A0634|100 144|EAV-specific transcription-regulating sequences
P11384229A1669|11 22|N63S mutation
P11384229A1669|28 39|wild-type VP5
P11384229A1669|28 39|wild-type VP5
P11384229A1669|87 112|beta-galactosidase activity
P11384229A1669|87 104|beta-galactosidase
P11384229A1669|143 153|PR7 mutation
P11384576A1132|11 26|severe vision loss
P11384576A1132|40 78|interferon alfa-2b-associated retinopathy
P11384576A1132|40 56|interferon alfa-2b
P11384880A0719|28 55|3beta-HSD type 1 gene expression
P11384880A0719|28 45|3beta-HSD type 1 gene
P11384880A0719|81 109|ZR-75-1 human breast cancer cells
P11385840A1684|12 23|RTC algorithm
P11385840A1684|30 50|urban wastewater system
P11385840A1684|108 133|global optimization routines
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387208T0000|0 3|SKP1
P11387208T0000|5 8|SnRK
P11387208T0000|9 21|protein kinase
P11387208T0000|41 58|proteasomal binding
P11387208T0000|67 84|SCF ubiquitin ligase
P11387208T0000|67 69|SCF
P11387208T0000|70 84|ubiquitin ligase
P11387351A0092|67 110|nucleoside analog 2-chlorodeoxyadenosine (2-CDA
P11387351A0092|116 123|children
P11387351A0092|128 137|primary AML
P11387351A0092|143 150|children
P11387351A0092|164 191|AML or myelodysplastic syndrome
P11387351A0092|193 195|MDS
P11387940A0647|13 29|pathologic changes
P11387940A0647|57 66|percussion
P11387950X0001|19 41|ta chengchi tang decoction
P11387950X0001|54 63|lung injury
P11387950X0001|70 97|acute necrotizing pancreatitis
P11387950X0001|151 171|leukocyte adhesiveness
P11387950X0001|175 197|tumor necrosis factor (TNF
P11387950X0001|175 193|tumor necrosis factor
P11387950X0001|195 197|TNF
P11387950X0001|216 243|acute necrotizing pancreatitis
P11387950X0001|245 247|ANP
P11387950X0001|245 247|ANP
P11387950X0001|292 301|lung injury
P11387950X0001|304 306|ANP
P11387950X0001|304 306|ANP
P11387950X0001|343 365|ta chengchi tang Decoction
P11387950X0001|368 384|leukocyte adhesion
P11387950X0001|388 399|TNF secretion
P11387950X0001|388 390|TNF
P11389077A0000|10 43|receptor-mediated signaling pathways
P11389077A0000|63 104|positive and negative extracellular regulators
P11389085A0290|0 6|TT cells
P11389085A0290|9 24|human MTC cell line
P11389085A0290|35 46|MEN 2A type RET
P11389085A0290|35 46|MEN 2A type RET
P11389085A0290|78 86|RelA(p65)
P11389085A0290|78 81|RelA
P11389085A0290|83 85|p65
P11389085A0290|92 98|nucleus
P11389085A1032|24 40|NF-kappaB activity
P11389085A1032|24 32|NF-kappaB
P11389085A1032|50 58|cell death
P11389085A1032|61 67|TT cells
P11389085A1032|100 108|oncogenic
P11389085A1032|116 118|RET
P11389085A1032|116 118|RET
P11389085A1032|121 131|NIH 3T3 cells
P11390395A1018|13 18|HMGI-C
P11390395A1018|13 18|HMGI-C
P11390395A1018|53 76|PIAS3-mediated repression
P11390395A1018|53 57|PIAS3
P11390395A1018|79 108|STAT3-dependent transactivation
P11390395A1018|79 83|STAT3
P11390581A1203|37 51|GC-rich sequence
P11390581A1203|64 71|Cp region
P11390581A1203|64 71|Cp region
P11390581A1203|90 112|oriPI-EBNA1-independent
P11390581A1203|96 100|EBNA1
P11390581A1203|121 149|oriPI-EBNA1-dependent activity
P11390581A1203|127 131|EBNA1
P11390581A1203|155 162|promoter
P11390650A0562|10 26|deletion mutations
P11390650A0562|40 52|67-amino-acid
P11390650A0562|53 68|functional domain
P11390650A0562|78 95|proline-rich region
P11390650A0562|98 103|SLP-76
P11390650A0562|98 103|SLP-76
P11390650A0562|125 133|P-1 domain
P11390650A0562|125 133|P-1 domain
P11390663A1400|20 34|gcn4Delta mutant
P11390663A1400|20 28|gcn4Delta
P11390663A1400|46 72|alternative induction pathway
P11390663A1400|88 103|Gcn4p target genes
P11390663A1400|88 103|Gcn4p target genes
P11390663A1400|106 127|histidine-starved cells
P11390684A1170|13 33|Northern hybridization
P11390684A1170|47 60|jadM expression
P11390684A1170|47 50|jadM
P11390684A1170|77 95|jadomycin B synthesis
P11390684A1170|77 86|jadomycin B
P11391303A0807|5 7|LHR
P11391303A0807|9 13|R-LHR
P11391303A0807|9 9|R
P11391303A0807|11 13|LHR
P11391303A1023|28 41|LHR measurement
P11391303A1023|90 95|Tl-201
P11391531A1157|13 25|NF-kappaB site
P11391531A1157|13 21|NF-kappaB
P11391531A1157|31 43|Mdr1b promoter
P11391531A1157|31 43|Mdr1b promoter
P11391531A1157|66 74|TNF-alpha
P11391531A1157|66 74|TNF-alpha
P11391793A0856|60 65|tumors
P11391793A0856|95 101|I Mbp SRO
P11391793A0856|127 139|bacteriophage
P11391793A0856|140 169|P1-derived artificial chromosome
P11391793A0856|171 173|PAC
P11392306T0000|0 33|Online teaching: design and techniques
P11392772A0182|37 42|plants
P11392772A0182|112 121|city of Kyiv
P11392772A0182|155 159|water
P11393463A0274|84 103|NEO-PI-R self-ratings
P11393463A0274|202 208|friends
P11393791A1153|0 19|Northern blot analysis
P11393791A1153|22 25|RNAs
P11393791A1153|39 50|mouse tissues
P11393791A1153|62 66|Atp6i
P11393791A1153|62 66|Atp6i
P11393791A1153|93 103|osteoclasts
P11393791A1153|147 190|reverse-transcription polymerase chain reaction
P11393791A1153|147 182|reverse-transcription polymerase chain
P11393791A1153|192 203|RT-PCR) assay
P11393791A1153|207 233|immunohistochemical analysis
P11395469A1373|66 69|sid1
P11395469A1373|66 69|sid1
P11395469A1373|105 108|sid2
P11395469A1373|105 108|sid2
P11396685A0477|27 29|DTD
P11397652A0381|0 9|Guidelines
P11397652A0381|24 41|routine spiral assay
P11397652A0381|108 128|technical difficulties
P11397652A0381|193 195|etc
P11398134A1565|13 33|obesity, alcohol intake
P11398134A1565|38 60|multimetabolic disorders
P11398134A1565|119 131|hyperuricemia
P11398899A1183|0 3|Fans
P11398899A1183|87 107|high PH3 concentrations
P11398899A1183|110 122|enclosed areas
P11399064T0000|21 37|different pathways
P11399064T0000|47 78|CCAAT/enhancer binding protein beta
P11399064T0000|47 74|CCAAT/enhancer binding protein
P11399064T0000|75 78|beta
P11399064T0000|80 88|C/EBP beta
P11399064T0000|80 88|C/EBP beta
P11399834T0000|66 77|NAT screening
P11400644A0435|66 69|90th
P11400644A0435|83 88|PCDD/F
P11400644A0435|118 124|I-TEQ/y
P11401105T0000|0 9|Gabapentin
P11401105T0000|13 34|opiod-related myoclonus
P11401105T0000|37 50|cancer patients
P11401611A1703|102 122|nonvertebral fractures
P11402674T0000|0 28|Newcastle disease antibody titre
P11402674T0000|42 66|serum calcium concentration
P11403173A0192|10 17|patients
P11403173A0192|22 42|malignant brain tumours
P11403663A0359|0 6|Net lift
P11403663A0359|43 58|4-bladed impeller
P11403719A1257|22 25|Gab1
P11403719A1257|22 25|Gab1
P11403719A1257|50 64|egr-1 expression
P11403719A1257|50 54|egr-1
P11403719A1257|76 82|insulin
P11403719A1257|76 82|insulin
P11404010A0235|42 47|repeat
P11404016A1922|17 25|TE domains
P11404016A1922|17 25|TE domains
P11404016A1922|39 42|PKSs
P11404016A1922|39 42|PKSs
P11404016A1922|86 94|TEs (TE IIs
P11404016A1922|86 88|TEs
P11404016A1922|90 94|TE IIs
P11404016A1922|143 171|non-ribosomal peptide synthases
P11404016A1922|156 171|peptide synthases
P11404016A1922|173 176|NRPS
P11404016A1922|173 176|NRPS
P11404019A0532|26 41|mGSTM2 regulation
P11404019A0532|26 31|mGSTM2
P11404019A0532|73 86|promoter region
P11406007A0292|138 142|women
P11406025A0204|114 123|spermicide
P11406277A0598|28 35|elements
P11406277A0598|50 65|promoter activity
P11406277A0598|126 134|mutations
P11406277A0598|167 191|parent Hlx promoter sequence
P11406277A0598|167 191|parent Hlx promoter sequence
P11407289A1507|12 49|Ketamine-induced dissociative anesthesia
P11407289A1507|78 85|BIS index
P11407448A0815|49 56|patients
P11407448A0815|101 133|hypopharyngo-esophageal tract voice
P11407448A0815|195 229|secondary tracheo-esophageal puncture
P11407448A0815|251 264|speech training
P11407650A0661|0 12|Hypercalcemia
P11407650A0661|35 55|serum PTH concentration
P11407650A0661|40 42|PTH
P11407650A0661|66 91|primary hyperparathyroidism
P11407650A0661|103 112|BC patients
P11407650A0661|128 139|healthy women
P11407650A0661|142 149|patients
P11407650A0661|154 166|thyroid cancer
P11408099A0518|0 7|Positive
P11408099A0518|60 68|pregnancy
P11408099A0518|72 79|Se levels
P11408099A0518|72 73|Se
P11408099A0518|82 87|kidney
P11408338A1686|21 23|PSP
P11408338A1686|21 23|PSP
P11408575A0000|2 24|Saccharomyces cerevisiae
P11408575A0000|65 86|cyclin-dependent kinase
P11408575A0000|65 86|cyclin-dependent kinase
P11408575A0000|87 91|Cdc28
P11408575A0000|87 91|Cdc28
P11408575A0000|97 123|cyclin B (Clb)-associated form
P11408575A0000|97 103|cyclin B
P11408575A0000|105 107|Clb
P11408591A0000|29 38|hyaluronan
P11408591A0000|40 41|HA
P11408591A0000|57 68|cell motility
P11408591A0000|89 100|v-src mutants
P11408591A0000|89 93|v-src
P11408604A1440|22 24|D(4
P11408604A1440|22 22|D
P11408604A1440|29 42|D(2L) receptors
P11408604A1440|29 42|D(2L) receptors
P11408604A1440|54 69|ERK kinase cascade
P11408604A1440|54 62|ERK kinase
P11408604A1440|101 112|PDGF receptor
P11408604A1440|101 112|PDGF receptor
P11408604A1440|149 154|ERK1/2
P11408604A1440|149 154|ERK1/2
P11408604A1440|183 204|receptor tyrosine kinase
P11408604A1440|183 204|receptor tyrosine kinase
P11408774X0893|6 7|AG
P11409425A0000|12 24|plasma samples
P11409425A0000|32 39|patients
P11409425A0000|64 83|Neurological Diseases
P11409425A0000|87 92|Stroke
P11409425A0000|94 98|NINDS
P11409425A0000|100 125|tissue plasminogen activator
P11409425A0000|106 125|plasminogen activator
P11409425A0000|127 130|t-PA
P11409425A0000|129 130|PA
P11409425A0000|176 196|apolipoprotein (Apo) E2
P11409425A0000|191 196|Apo) E2
P11409425A0000|201 205|Apo E4
P11409425A0000|201 205|Apo E4
P11409425A0000|247 252|stroke
P11409425A0000|263 285|intracerebral hemorrhage
P11409425A0000|303 313|intravenous
P11409425A0000|314 317|t-PA
P11409425A0000|314 315|t-
P11409425A0000|316 324|PA therapy
P11410110A0190|0 3|NIRS
P11410110A0190|42 48|muscle O
P11410110A0190|64 70|mV.O(2)
P11410110A0190|67 69|O(2
P11410110A0190|87 90|flow
P11410110A0190|92 94|FBF
P11410110A0190|100 114|healthy subjects
P11410563A0363|2 29|dominant clinical factor of risk
P11410563A0363|50 67|regression analysis
P11410563A0363|108 128|shop order fracture rate
P11410563A0363|168 170|OSF
P11410664A0963|37 70|human breast carcinoma MDA-MB231 cells
P11410664A0963|85 92|human MPG
P11410664A0963|85 92|human MPG
P11410664A0963|146 148|BER
P11410664A0963|181 183|BER
P11410664A0963|181 183|BER
P11410664A0963|185 189|hOGG1
P11410664A0963|185 189|hOGG1
P11410664A0963|193 201|APE/ref-1
P11410664A0963|193 195|APE
P11410664A0963|197 201|ref-1
P11410664A0963|205 218|direct reversal
P11410664A0963|220 240|MGMT) repair activities
P11410664A0963|220 223|MGMT
P11410679A0000|38 51|Cre recombinase
P11410679A0000|38 51|Cre recombinase
P11410679A0000|63 75|rearrangement
P11410679A0000|78 82|genes
P11410679A0000|92 114|LOX recognition sequences
P11410679A0000|92 114|LOX recognition sequences
P11410679A0000|145 161|genetic constructs
P11410679A0000|183 185|cre
P11410679A0000|233 240|LOX sites
P11410679A0000|233 240|LOX sites
P11411198A0711|0 15|Colorectal cancer
P11411198A0711|44 66|overburden Ashkenazi Jews
P11411198A0711|98 104|ovarian
P11411198A0711|106 131|pancreatic and stomach cancer
P11411198A0711|136 156|non-Hodgkin's lymphoma
P11411623T0000|11 28|compression therapy
P11411623T0000|52 63|tissue injury
P11411623T0000|68 91|maximal eccentric exercise
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11411961A0735|43 60|ocular complication
P11411961A0735|67 74|children
P11411961A0735|79 81|JRA
P11413148A0573|0 5|STAT5A
P11413148A0573|0 5|STAT5A
P11413148A0573|20 49|Src homology 2 (SH2) and SH3 domains
P11413148A0573|20 31|Src homology 2
P11413148A0573|33 35|SH2
P11413148A0573|40 49|SH3 domains
P11413148A0573|64 98|BTK-mediated tyrosine phosphorylation
P11413148A0573|64 66|BTK
P11413277A1121|13 31|primary chemotherapy
P11413277A1121|47 49|MTX
P11413277A1121|53 57|ara-C
P11413277A1121|53 57|ara-C
P11413277A1121|77 81|PCNSL
P11413310A0148|0 29|RANTES (regulated upon activation
P11413310A0148|0 5|RANTES
P11413310A0148|79 89|CC chemokine
P11413310A0148|115 123|monocytes
P11413310A0148|125 135|lymphocytes
P11413310A0148|140 150|eosinophils
P11413310A0148|176 201|lung inflammatory infiltrate
P11413310A0148|211 222|RSV infection
P11413319A0000|8 12|mRNAs
P11413319A0000|71 72|3'
P11413319A0000|73 91|polyadenylated tails
P11413760A0000|0 15|Myasthenia gravis
P11413760A0000|20 36|autoimmune disease
P11413760A0000|65 74|antibodies
P11413760A0000|85 96|ACh receptors
P11413760A0000|85 96|ACh receptors
P11413760A0000|102 121|neuromuscular synapse
P11415633A1253|38 53|3-D biomechanical
P11415633A1253|63 90|lumbosacral spinal compression
P11415952A0369|0 19|Angina (Q) persistence
P11415952A0369|56 75|myocardial infarction
P11415952A0369|93 117|electrocardiogram ischemia
P11415952A0369|132 156|major ischemic heart disease
P11415958A0000|55 73|Bayesian methodology
P11415958A0000|147 162|Bayesian approach
P11416012A1982|20 59|PKA-dependent mediation of LH's contribution
P11416012A1982|20 22|PKA
P11416012A1982|44 47|LH's
P11416012A1982|87 97|LDL receptor
P11416012A1982|87 97|LDL receptor
P11416012A1982|99 126|-1076 to +11 bp) reporter plasmid
P11416012A1982|148 160|full-sequence
P11416012A1982|161 194|rabbit muscle protein kinase inhibitor
P11416012A1982|161 194|rabbit muscle protein kinase inhibitor
P11416012A1982|196 198|PKI
P11416012A1982|196 198|PKI
P11416012A1982|231 254|Rous sarcoma virus promoter
P11416012A1982|231 246|Rous sarcoma virus
P11416012A1982|247 254|promoter
P11416012A2511|35 47|insulin/IGF-I
P11416012A2511|35 41|insulin
P11416012A2511|43 47|IGF-I
P11416012A2511|72 92|bihormonal stimulation
P11416012A2511|95 123|LDL receptor promoter expression
P11416012A2511|95 113|LDL receptor promoter
P11416012A2511|136 151|granulosa-luteal
P11416012A2511|206 232|phophatidylinositol 3-kinase
P11416012A2511|206 232|phophatidylinositol 3-kinase
P11416012A2511|234 243|wortmannin
P11416012A2511|254 261|LY 294002
P11416012A2511|277 312|mitogen-activated protein kinase kinase
P11416012A2511|277 312|mitogen-activated protein kinase kinase
P11416012A2511|314 320|PD 98059
P11416012A2511|332 336|U0126
P11416012A2511|380 384|U0124
P11416012T0000|9 33|transcriptional activation
P11416012T0000|39 71|low density lipoprotein receptor gene
P11416012T0000|39 67|low density lipoprotein receptor
P11416012T0000|74 80|insulin
P11416012T0000|74 80|insulin
P11416012T0000|84 101|luteinizing hormone
P11416012T0000|84 101|luteinizing hormone
P11416012T0000|104 139|cultured porcine granulosa-luteal cells
P11416012T0000|162 175|protein kinase a
P11416012T0000|162 175|protein kinase a
P11416012T0000|177 204|phosphatidylinositol 3-kinase
P11416012T0000|177 204|phosphatidylinositol 3-kinase
P11416012T0000|209 255|mitogen-activated protein kinase signaling pathways
P11416012T0000|209 238|mitogen-activated protein kinase
P11416132A1351|27 50|site-specific recognition
P11416132A1351|56 61|bxd PRE
P11416132A1351|59 61|PRE
P11416132A1351|64 64|d
P11416132A1351|64 64|d
P11416132A1351|66 68|GA)
P11416132A1351|66 68|GA)
P11416132A1351|70 70|n
P11416132A1351|103 124|PcG-dependent silencing
P11416132A1351|103 105|PcG
P11416144A1324|39 44|ZBP-89
P11416144A1324|39 44|ZBP-89
P11416144A1324|54 70|cell proliferation
P11416144A1324|106 115|p53 protein
P11416144A1324|106 115|p53 protein
P11416260A0000|1 18|computerized method
P11416260A0000|35 44|focal point
P11416260A0000|47 64|electrical activity
P11416260A0000|70 77|pallidum
P11416260A0000|80 99|parkinsonian patients
P11416260A0000|136 160|physiological data analysis
P11416393A0000|4 13|modalities
P11416393A0000|109 130|blood pressure elevation
P11416393A0000|156 165|body weight
P11416393A0000|187 198|hypertension
P11416393A0000|252 275|dietary sodium restriction
P11416393A0000|367 372|dosage
P11416393A0000|395 415|antihypertensive drugs
P11416393A0000|431 448|alcohol consumption
P11416393A0000|480 487|isotonic
P11416393A0000|520 537|tobacco consumption
P11416650T0000|16 27|Hypertension
P11416737T0000|0 4|Ga-67
P11416737T0000|42 53|plasmacytoma
P11416879A1589|13 23|gas tensions
P11418130A0499|11 33|homologous loxP sequences
P11418130A0499|11 33|homologous loxP sequences
P11418130A0499|54 78|Cre-mediated recombination
P11418662A0917|3 19|N-terminal portion
P11418662A0917|22 26|Notch
P11418662A0917|28 29|IC
P11418662A0917|28 29|IC
P11418662A0917|40 55|p50 DNA binding and
P11418662A0917|40 42|p50
P11418662A0917|82 91|p50 subunit
P11418662A0917|82 91|p50 subunit
P11418662A0917|96 98|p65
P11418662A0917|96 98|p65
P11418662A0917|101 109|NF-kappaB
P11418662A0917|101 109|NF-kappaB
P11419938T0000|0 20|Conformational changes
P11419938T0000|26 47|ferric uptake regulation
P11419938T0000|59 73|metal activation
P11419938T0000|77 86|DNA binding
P11419938T0000|130 153|diphtheria toxin repressor
P11419938T0000|130 153|diphtheria toxin repressor
P11422200A0000|0 34|Granulocyte colony-stimulating factor
P11422200A0000|0 34|Granulocyte colony-stimulating factor
P11422200A0000|36 40|G-CSF
P11422200A0000|36 40|G-CSF
P11422757A0737|58 66|ACR levels
P11422757A0737|58 60|ACR
P11423991A1393|22 31|p53 mutants
P11423991A1393|22 31|p53 mutants
P11423991A1393|34 38|yeast
P11423991A1393|55 65|p53 variants
P11423991A1393|55 65|p53 variants
P11423991A1393|93 121|p53 regulated cellular responses
P11423991A1393|93 95|p53
P11423991A1393|137 160|p53-based cancer therapies
P11423991A1393|137 139|p53
P11424992A0712|17 36|psychiatric diagnoses
P11424992A0712|85 102|biological criteria
P11425076A0364|28 45|physiological flows
P11425877A1026|12 15|p116
P11425877A1026|12 15|p116
P11425877A1026|121 136|phase pinocytosis
P11425877A1026|175 196|chemotactic aggregation
P11425877A1026|212 226|cellular F-actin
P11425877A1026|220 226|F-actin
P11427329A1077|16 20|FPS-R
P11427329A1077|16 20|FPS-R
P11427329A1077|75 77|VAS
P11427329A1077|97 99|CAS
P11427611A0000|57 81|echinocandin-like compound
P11427611A0000|91 106|antifungal agents
P11427611A0000|151 187|Laboratory Standards (NCCLS) M38-P method
P11427611A0000|190 280|2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide
P11427611A0000|282 308|XTT)-based colorimetric assay
P11427611A0000|328 361|morphologic alterations by microscopy
P11428276A0352|3 30|Van der Hoeve's syndrome lesions
P11428276A0352|58 68|calcium salt
P11428276A0352|90 99|phosphates
P11428283A0228|12 17|infant
P11428283A0228|22 48|persistent congenital stridor
P11428283A0228|52 75|acute respiratory distress
P11428435A0446|34 38|9,322
P11428435A0446|39 46|patients
P11428435A0446|57 74|surgical procedures
P11428487T0000|0 17|Pulmonary vein varix
P11428487T0000|35 64|bilateral pulmonary vein stenosis
P11428897A0318|0 21|Biochemical experiments
P11428897A0318|35 38|CopG
P11428897A0318|35 38|CopG
P11428897A0318|68 76|target DNA
P11428897A0318|124 135|helical turns
P11428897A0318|154 164|double helix
P11428897A0318|188 201|inverted repeat
P11428897A0318|220 223|CopG
P11429702A0917|48 53|KMS-11
P11429702A0917|57 66|OPM-2 cells
P11429702A0917|107 118|FGFR3 mutants
P11429702A0917|107 111|FGFR3
P11429702A0917|157 178|Y373C and K650E receptors
P11429702A0917|157 178|Y373C and K650E receptors
P11429702A0917|196 205|aFGF ligand
P11429702A0917|196 205|aFGF ligand
P11429702A0917|232 254|receptor phosphorylation
P11430042A0000|19 40|Stille coupling reaction
P11430042A0000|59 102|1-butyl-3-methylimidazolium tetrafluoroborate
P11430042A0000|104 110|BMIM BF4
P11430042A0000|114 134|room-temperature ionic
P11430042A0000|135 140|liquid
P11430042A0000|142 145|RTIL
P11430976X0000|0 19|Special issues devoted
P11430976X0000|44 59|plant biopolymers
P11431348A0000|22 46|checkpoint abrogator UCN-01
P11431348A0000|41 46|UCN-01
P11431348A0000|87 145|mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathway
P11431348A0000|87 116|mitogen-activated protein kinase
P11431348A0000|118 128|MAPK) kinase
P11431348A0000|130 132|MEK
P11431348A0000|135 138|MAPK
P11431348A0000|174 195|human leukemia cell lines
P11431472A0540|20 28|Rab6A-GTP
P11431472A0540|20 28|Rab6A-GTP
P11431472A0540|45 45|K
P11431472A0540|47 47|d
P11431472A0540|67 80|Rab1B, -5, -7, -8
P11431472A0540|67 80|Rab1B, -5, -7, -8
P11431472A0540|82 87|or -11A
P11431472A0540|84 87|-11A
P11431857A0186|3 10|students
P11432112A0000|47 64|embryo cleavage (FEC
P11432112A0000|93 111|sperm injection (ICSI
P11432112A0000|131 152|embryo selection process
P11432748T0000|12 32|laminin beta2 chain gene
P11432748T0000|19 42|beta2 chain gene expression
P11432748T0000|45 64|human cancer cell lines
P11432776A0421|0 7|Northern
P11432776A0421|11 29|Western blot analyses
P11432776A0421|46 50|Graf2
P11432776A0421|46 50|Graf2
P11432776A0421|71 77|tissues
P11432776A0421|105 118|skeletal muscle
P11433014A0683|25 34|nucleosome
P11433014A0683|45 63|core histone H2A or H2B
P11433014A0683|45 58|core histone H2A
P11433014A0683|61 63|H2B
P11433014A0683|68 82|non-histone tail
P11433014A0683|68 78|non-histone
P11433014A0683|90 92|MCB
P11433014A0683|124 140|endogenous protein
P11433014A0683|124 140|endogenous protein
P11433018A0756|41 59|Nhp2p to H/ACA snoRNAs
P11433018A0756|41 45|Nhp2p
P11433018A0756|48 59|H/ACA snoRNAs
P11433018A0756|86 97|H/ACA snoRNPs
P11433018A0756|86 97|H/ACA snoRNPs
P11433024A0260|0 9|Telomerase
P11433024A0260|0 9|Telomerase
P11433024A0260|13 36|ribonucleoprotein complex
P11433024A0260|61 78|DNA onto chromosomes
P11433024A0260|87 89|RNA
P11433379A0000|0 46|SIT (SHP2-interacting transmembrane adaptor protein
P11433379A0000|0 2|SIT
P11433379A0000|4 46|SHP2-interacting transmembrane adaptor protein
P11433379A0000|69 95|transmembrane adaptor protein
P11433379A0000|115 125|lymphocytes
P11434084A0508|19 20|DD
P11434084A0508|40 54|microlatex tests
P11434084A0508|69 71|BC d
P11435428A0000|0 35|Cytosolic acetyl-CoA synthetase (AceCS1
P11435428A0000|0 28|Cytosolic acetyl-CoA synthetase
P11435428A0000|30 35|AceCS1
P11435428A0000|73 82|acetyl-CoA
P11435428A0000|86 99|lipid synthesis
P11435517A0396|0 19|Ileal digestibilities
P11435517A0396|22 23|DM
P11435517A0396|22 23|DM
P11435517A0396|25 26|OM
P11435517A0396|28 29|CP
P11435517A0396|28 29|CP
P11435517A0396|36 51|dietary fiber (TDF
P11435517A0396|54 56|fat
P11435517A0396|72 73|GE
P11435517A0396|99 133|fed diets containing supplemental fiber
P11435517A0396|156 166|control diet
P11435560A1322|29 38|HFV R region
P11435560A1322|29 38|HFV R region
P11435560A1322|48 54|nucleus
P11435560A1322|66 80|cytoplasmic fate
P11435560A1322|89 95|HFV mRNA
P11435578A0760|5 8|TxRE
P11435578A0760|5 8|TxRE
P11435578A0760|16 43|cyclic AMP-responsive elements
P11435578A0760|16 43|cyclic AMP-responsive elements
P11435578A0760|45 47|CRE
P11435578A0760|45 47|CRE
P11435578A0760|69 86|TGACGTCA" consensus
P11435578A0760|116 126|viral strain
P11435578A0760|133 140|AGACGTCA
P11435578A0760|142 149|TGACGGCA
P11435578A0760|151 158|TGACCTCA
P11435578A2231|46 48|CRE
P11435578A2231|59 72|21-bp enhancers
P11435578A2231|91 106|CREB/ATF proteins
P11435578A2231|91 94|CREB
P11435578A2231|96 106|ATF proteins
P11435578A2231|119 133|basal repression
P11435578A2231|136 160|LTR-directed transcription
P11435605A0587|0 23|Site-directed mutagenesis
P11435605A0587|26 28|CAR
P11435605A0587|26 28|CAR
P11435605A0587|41 56|CAR residues Leu73
P11435605A0587|60 65|Lys121
P11435605A0587|72 77|Lys123
P11435605A0587|109 113|Tyr80
P11435605A0587|117 121|Tyr83
P11435605A0587|177 207|Ad5, Ad9, Ad12, and Ad41L fiber knobs
P11435605A0587|177 179|Ad5
P11435605A0587|181 183|Ad9
P11435605A0587|185 188|Ad12
P11435605A0587|193 207|Ad41L fiber knobs
P11435688A0262|34 50|ATP-binding domain
P11435688A0262|34 50|ATP-binding domain
P11435688A0262|56 65|N-terminus
P11435688A0262|56 65|N-terminus
P11435688A0262|76 85|C-terminal
P11435688A0262|91 111|transmembrane segments
P11435983T0000|11 30|renal transplantation
P11435983T0000|36 70|allogeneic bone marrow transplantation
P11437439A0201|3 18|promoter activity
P11437439A0201|24 37|proximal region
P11437439A0201|71 83|prestalk cells
P11437660A1219|14 27|serine residues
P11437660A1219|33 42|C-terminus
P11437660A1219|33 42|C-terminus
P11437660A1219|62 81|phosphorylation sites
P11437660A1219|111 137|transcription and replication
P11438651A1365|16 19|fork
P11438651A1365|32 34|HML
P11438651A1365|32 34|HML
P11438651A1365|44 55|silent origin
P11438651A1365|116 120|Orc2p
P11438651A1365|116 120|Orc2p
P11438654A1237|27 33|adapter
P11438654A1237|34 37|Gab1
P11438654A1237|34 37|Gab1
P11438654A1237|49 62|c-Met signaling
P11438654A1237|49 53|c-Met
P11438654A1237|70 73|PI3K
P11438654A1237|70 73|PI3K
P11438654A1237|83 111|c-Akt/Pak1 cell survival pathway
P11438654A1237|83 87|c-Akt
P11438654A1237|89 92|Pak1
P11438666A0555|18 29|mouse protein
P11438666A0555|31 36|TAF(II
P11438666A0555|31 36|TAF(II
P11438666A0555|54 56|HFD
P11438666A0555|54 56|HFD
P11438666A0555|61 76|plant homeodomain
P11438666A0555|66 80|homeodomain (PHD
P11438666A0555|78 87|PHD) finger
P11438666A0555|110 128|immunoprecipitation
P11438666A0555|134 147|mammalian TFIID
P11438666A0555|143 156|TFIID component
P11438838A0788|27 29|TAR
P11438838A0788|27 29|TAR
P11438838A0788|30 34|decoy
P11438838A0788|47 71|U6 small nuclear RNA promoter
P11438838A0788|47 71|U6 small nuclear RNA promoter
P11438838A0788|73 77|U6-P)
P11438838A0788|73 76|U6-P
P11439343A0785|12 15|MPc3
P11439343A0785|12 15|MPc3
P11439343A0785|36 47|Pc protein M33
P11439343A0785|36 44|Pc protein
P11439343A0785|45 47|M33
P11439343A0785|67 69|AF9
P11439343A0785|67 69|AF9
P11441311X0001|0 15|Long-term results
P11441311X0001|20 26|MACOP-B
P11441311X0001|30 45|radiation therapy
P11441311X0001|59 67|lymphomas
P11441311X0001|138 154|prognostic factors
P11441311X0001|157 178|non-Hodgkin's lymphomas
P11441311X0001|180 182|NHL
P11441952A0414|28 30|TBI
P11441952A0414|42 45|rats
P11441952A0414|149 151|TBI
P11441952A0414|205 207|TBI
P11441974A0320|68 70|kPa
P11441974A0320|96 104|saturated
P11441974A0320|117 129|venous reserve
P11441974A0320|161 164|l(-1
P11443509A0293|96 102|NHANES 1
P11443509A0293|132 136|NHEFS
P11443999A0573|4 19|Hg concentrations
P11443999A0573|25 30|livers
P11443999A0573|33 36|mice
P11443999A0573|162 177|human consumption
P11444762A0373|36 54|statistical analysis
P11445008A0816|52 55|FGFR
P11445008A0816|113 126|RNA pool samples
P11447490A0598|11 25|drained effusion
P11448051A0093|48 61|small intestine
P11448051A0093|155 158|NaCl
P11448051A0093|172 176|Emdex
P11448051A0093|183 194|inert polymer
P11448051A0093|196 208|Eudragit RS100
P11449014A0000|115 118|CCTs
P11449014A0000|152 181|epidemiologist/biostatistician
P11449014A0000|183 185|E/B
P11449014A0000|183 185|E/B
P11450490A0565|3 20|median preoperative
P11450490A0565|154 157|0.25
P11450776T0000|11 23|primary group A
P11451447A0205|0 4|Gimpl
P11451682A0190|24 25|AE
P11451682A0190|24 25|AE
P11451682A0190|54 86|benzimidazole carbamate derivatives
P11451682A0190|94 118|mebendazole and albendazole
P11451995T0000|0 10|Topological
P11451995T0000|34 62|Saccharomyces cerevisiae Ste14p
P11451995T0000|34 56|Saccharomyces cerevisiae
P11451995T0000|83 130|isoprenylcysteine carboxyl methyltransferase family
P11451995T0000|83 124|isoprenylcysteine carboxyl methyltransferase
P11454004T0000|0 17|Hormonal regulation
P11454004T0000|28 36|promoters
P11454004T0000|42 94|rat mitochondrial glycerol-3-phosphate dehydrogenase gene
P11454004T0000|42 90|rat mitochondrial glycerol-3-phosphate dehydrogenase
P11454004T0000|113 142|complex hormone-response element
P11454004T0000|148 166|ubiquitous promoter B
P11454190A0000|16 25|Hepatitis C
P11454190A0000|41 57|fatty liver disease
P11454190A0000|59 62|NAFL
P11454190A0000|90 101|liver disease
P11454190A0000|107 118|United States
P11454239A0478|27 31|ANOVA
P11454239A0478|156 170|Cronbach's alpha
P11454239A0478|166 176|alpha (alpha
P11454239A0478|172 177|alpha)
P11454239A0478|234 249|Chronbach's alpha
P11454239A0478|276 279|0.95
P11454703A0000|3 30|telomerase RNA-protein complex
P11454703A0000|3 23|telomerase RNA-protein
P11454703A0000|72 81|chromosome
P11454703A0000|110 133|primary somatic human cells
P11454703A0000|165 186|in vitro immortalization
P11454703A0000|196 208|tumorigenesis
P11456259A0142|10 47|TSH binding inhibitor immunoglobulin (TBII
P11456259A0142|10 42|TSH binding inhibitor immunoglobulin
P11456259A0142|44 47|TBII
P11457139A0604|18 20|CVN
P11457139A0604|18 20|CVN
P11457139A0604|68 75|9)GlcNAc
P11457139A0604|85 94|D1D3 isomer
P11457139A0604|97 101|Man(8
P11457139A0604|97 99|Man
P11457139A0604|103 108|GlcNAc
P11459048A0485|27 39|uncertainties
P11459048A0485|93 97|Venus
P11459048A0485|132 145|rotation states
P11459304T0078|0 19|Enantiomer separation
P11459304T0078|22 57|venlafaxine and O-desmethylvenlafaxine
P11459304T0078|60 70|human plasma
P11459794A1172|0 1|TE
P11459794A1172|34 68|cAMP response element mutant constructs
P11459794A1172|34 58|cAMP response element mutant
P11459794A1172|92 104|basal activity
P11459794A1172|110 124|GnRH-II promoter
P11459794A1172|110 116|GnRH-II
P11459960A1109|67 76|heat labile
P11459962A0785|37 69|Rad52 recombinational repair pathway
P11459962A0785|37 41|Rad52
P11459962A0785|97 106|rad27 Delta
P11459962A0785|145 158|semipermissive
P11460035A0548|53 63|fluvoxamine
P11461595A0000|39 56|spherical particles
P11461595A0000|61 67|inertia
P11461595A0000|102 104|B+B
P11461595A0000|108 108|B
P11461595A0000|156 170|periodic forcing
P11462004A0886|12 17|Vp1 DBD
P11462004A0886|12 17|Vp1 DBD
P11462004A0886|24 32|infection
P11462004A0886|67 69|NLS
P11462004A1500|21 30|mutant Vp1s
P11462004A1500|21 30|mutant Vp1s
P11462004A1500|64 70|nucleus
P11462004A1500|77 79|Vp2
P11462004A1500|77 79|Vp2
P11462004A1500|83 85|Vp3
P11462004A1500|83 85|Vp3
P11462004A1500|107 117|mutated NLS1
P11462004A1500|107 117|mutated NLS1
P11462004A1500|146 168|cytoplasmic localization
P11462004A1500|171 173|Vp1
P11462004A1500|171 173|Vp1
P11462024A0306|0 2|Zhu
P11462952A1040|0 19|Fasting gastrin levels
P11462952A1040|7 13|gastrin
P11463359A0167|18 29|phorbol ester
P11463359A0167|30 32|PMA
P11463359A0167|54 89|dexamethasone/cAMP-induced expression
P11463359A0167|93 106|luciferase gene
P11463359A0167|93 106|luciferase gene
P11463359A0167|127 140|G6Pase promoter
P11463359A0167|127 140|G6Pase promoter
P11463359A0167|143 182|transiently transfected H4IIE hepatoma cells
P11463834A0606|7 25|deletion mutagenesis
P11463834A0606|47 56|2003 to 2212
P11463834A0606|59 61|CBP
P11463834A0606|59 61|CBP
P11463834A0606|74 96|carboxy-terminal region 2
P11463834A0606|74 95|carboxy-terminal region
P11463834A0606|98 100|CR2
P11463834A0606|98 100|CR2
P11463834A0606|124 137|Tax interaction
P11463834A0606|124 126|Tax
P11464997A0566|51 57|patient
P11464997A0566|76 89|affected family
P11465518A0000|47 59|investigators
P11465518A0000|152 159|exposing
P11465655A0439|17 31|beta-adrenergic
P11465655A0439|42 49|atenolol
P11465844T0000|24 39|Kawasaki syndrome
P11465844T0000|56 72|Rickettsia conorii
P11465844T0000|74 88|Rickettsia typhi
P11465844T0000|90 105|Coxiella burnetii
P11465844T0000|108 130|Ehrlichia phagocytophila
P11466227A1665|13 20|AS-oligo
P11466227A1665|44 65|FSH-mediated activation
P11466227A1665|44 46|FSH
P11466227A1665|71 90|EB*-mTf-CAT construct
P11466227A1665|71 81|EB*-mTf-CAT
P11466227A1665|101 123|cAMP-mediated activation
P11467349A0452|47 56|ISF glucose
P11468958A0122|53 72|CJD-related decisions
P11468958A0122|79 84|recall
P11468958A0122|87 91|blood
P11468958A0122|97 101|donor
P11468958A0122|106 115|classic CJD
P11468958A0122|195 196|UK
P11468958A0122|237 243|variant
P11468958A0122|244 246|CJD
P11469701A0377|18 38|insulin administration
P11469701A0377|18 24|insulin
P11469701A0377|46 64|chronic intermittent
P11469701A0377|76 89|insulin therapy
P11469701A0377|76 82|insulin
P11469701A0377|91 96|CIIIT)
P11469701A0377|105 111|insulin
P11469701A0377|105 111|insulin
P11469701A0377|155 174|insulin concentration
P11469701A0377|180 189|portal vein
P11469737A1791|12 25|isokinetic test
P11469737A1791|83 92|manual test
P11469853A0702|21 35|domain shuffling
P11469853A0702|60 68|C1 domains
P11469853A0702|60 68|C1 domains
P11469853A0702|78 86|Raf kinase
P11469853A0702|78 86|Raf kinase
P11469853A0702|90 98|rat PKC eta
P11469853A0702|90 98|rat PKC eta
P11469853A0702|101 105|yeast
P11469853A1053|57 67|small GTPase
P11469853A1053|62 67|GTPase
P11469853A1053|77 94|regulatory function
P11469853A1053|100 107|C1 domain
P11469853A1053|100 107|C1 domain
P11469853A1053|110 114|yeast
P11469926T0000|0 11|Breast cancer
P11469926T0000|38 53|magic crystal ball
P11469970A0873|0 7|Patients
P11469970A0873|12 21|type III SOD
P11469970A0873|12 18|type III
P11469970A0873|19 21|SOD
P11469970A0873|58 72|antidepressants
P11469970A0873|96 109|botulinum toxin
P11469970A0873|96 109|botulinum toxin
P11469970A0873|126 132|ampulla
P11469970A0873|170 186|endoscopic therapy
P11470914A0305|13 16|Rac1
P11470914A0305|13 16|Rac1
P11470914A0305|24 41|STAT3 translocation
P11470914A0305|24 28|STAT3
P11470914A0305|47 53|nucleus
P11470914A0305|68 96|STAT3-dependent gene expression
P11470914A0305|68 86|STAT3-dependent gene
P11471077A0382|64 67|TRA1
P11471077A0382|64 67|TRA1
P11471077A0382|71 74|TRA2
P11471077A0382|71 74|TRA2
P11471077A0382|101 103|TRA
P11471231A0964|86 100|microbiological
P11471231A0964|118 174|clean-contaminated, contaminated and dirty surgical procedures
P11472523A0535|11 26|Extrusion cooking
P11472523A0535|58 60|DON
P11472523A0535|83 86|AFB1
P11472523A0535|83 86|AFB1
P11472696A0387|19 23|CPIgG
P11472696A0387|19 23|CPIgG
P11472696A0387|25 27|CRP
P11472696A0387|25 27|CRP
P11472696A0387|32 47|fibrinogen levels
P11472696A0387|32 41|fibrinogen
P11472696A0387|50 57|patients
P11472696A0387|78 80|ACS
P11472696A0387|103 109|non-ACS
P11473254A0000|0 3|NaeI
P11473254A0000|0 3|NaeI
P11473254A0000|11 25|DNA endonuclease
P11473254A0000|14 25|endonuclease
P11473254A0000|32 68|topoisomerase and recombinase activities
P11473254A0000|32 58|topoisomerase and recombinase
P11473254A0000|74 76|Lys
P11473254A0000|100 102|Leu
P11473261A0587|0 3|Mss4
P11473261A0587|0 3|Mss4
P11473261A0587|36 66|guanine nucleotide exchange factor
P11473261A0587|36 66|guanine nucleotide exchange factor
P11473261A0587|68 70|GEF
P11473261A0587|68 70|GEF
P11474642A1451|3 12|decrements
P11474642A1451|15 39|cerebrovascular resistance
P11474642A1451|49 61|hexamethonium
P11474642A1451|76 81|min(-1
P11478627A0573|3 22|desirability function
P11478627A0573|45 50|global
P11478627A0573|58 59|[D
P11478627A0573|61 64|f (Y1
P11478627A0573|63 64|Y1
P11478627A0573|66 67|Y2
P11478627A0573|66 67|Y2
P11478627A0573|69 71|...
P11478627A0573|73 74|Yn
P11479104A0446|21 52|positive anti-cardiolipin antibody
P11479104A0446|29 52|anti-cardiolipin antibody
P11479104A0446|88 113|systemic lupus erythematosis
P11479104A0446|144 160|autoimmune disease
P11479104A0446|173 175|POF
P11479501A0744|129 146|St Jude Medical valve
P11479501A0744|167 181|Omnicarbon valve
P11480490A0443|68 71|I(Kr
P11480490A0443|68 68|I
P11480490A0443|70 71|Kr
P11480490A0443|109 118|arrhythmia
P11480497T0000|9 25|aerosol-vapor JP-8
P11480497T0000|94 96|rat
P11480555A0928|15 22|ceramide
P11480555A0928|45 63|programmed cell death
P11481625A0202|76 96|TIW) interferon alfa-2b
P11481625A0202|80 96|interferon alfa-2b
P11481625A0202|103 105|MIU
P11481625A0202|112 122|once-weekly
P11481625A0202|124 146|QW) peginterferon alfa-2b
P11481625A0202|127 146|peginterferon alfa-2b
P11484028T0000|2 14|cross purposes
P11484578A1132|121 153|computer-aided dental design program
P11486032A1261|8 27|transcription factors
P11486032A1261|47 68|Groucho-related protein
P11486032A1261|47 68|Groucho-related protein
P11486032A1261|74 78|RUNX1
P11486032A1261|74 78|RUNX1
P11486032A1261|108 114|E2A-HLF
P11486032A1261|108 110|E2A
P11486032A1261|112 114|HLF
P11486141A0424|45 52|students
P11486141A0424|84 95|meta analysis
P11486141A0424|136 140|error
P11486399A0000|16 25|ifosfamide
P11486399A0000|40 48|etoposide
P11486399A0000|50 52|IEV
P11486399A0000|84 109|lymphoproliferative disease
P11486476A0147|69 76|patients
P11486476A0147|81 89|chest pain
P11486476A0147|115 123|troponin T
P11486476A0147|125 133|myoglobin
P11486476A0147|137 141|CK-MB
P11486476A0147|137 138|CK
P11486476A0147|148 169|differentiating cardiac
P11486476A0147|173 191|noncardiac chest pain
P11486476A0147|211 218|patients
P11486476A0147|223 225|ACS
P11486476A0147|282 290|admission
P11486476A1512|0 13|Cardiac markers
P11486476A1512|14 22|troponin T
P11486476A1512|24 32|CK-MB mass
P11486476A1512|24 28|CK-MB
P11486476A1512|36 44|myoglobin
P11486476A1512|36 44|myoglobin
P11486476A1512|84 92|chest pain
P11486476A1512|105 107|ECG
P11486476A1512|125 135|nonspecific
P11489597A0379|14 15|gd
P11489597A0379|38 44|females
P11489597A0379|77 90|clinical status
P11489597A0379|160 180|skeletal malformations
P11489597A0561|3 15|maternal death
P11489597A0561|24 33|body weight
P11489597A0561|45 54|weight gain
P11489597A0561|87 100|pregnancy rates
P11490862A0141|25 31|bladder
P11490862A0141|32 35|neck
P11490862A0141|89 99|bone anchors
P11494391A0579|34 46|hepatic artery
P11494391A0579|56 60|graft
P11495833T0000|25 36|human jumping
P11495833T0000|76 99|time-dependent properties
P11495920A0504|0 18|A 1-base pair mismatch
P11495920A0504|52 61|CYP3A4 gene
P11495920A0504|52 61|CYP3A4 gene
P11495920A0504|79 106|differential enhancer activity
P11496495A0000|26 52|social-economical conditions
P11496495A0000|108 115|children
P11496617A0301|10 15|female
P11496617A0301|21 32|male patients
P11496617A0301|43 56|thyroid surgery
P11496617A0301|82 87|gender
P11496617A0301|135 151|antiemetic regimes
P11496617A0301|172 177|orally
P11496617A0301|205 215|anaesthesia
P11496617A0301|217 222|group I
P11496617A0301|225 228|12.5
P11496617A0301|276 294|anaesthesia (group II
P11496617A0301|303 305|DHB
P11496617A0301|341 351|anaesthesia
P11496617A0301|353 360|group III
P11498795A0716|29 41|early G1-phase
P11498795A0716|61 75|phosphorylation
P11498795A0716|81 89|RB protein
P11498795A0716|81 89|RB protein
P11498795A0716|115 130|S phase transition
P11500377A0518|2 8|mammals
P11500377A0518|13 37|transcriptional repressors
P11500377A0518|43 52|Wnt pathway
P11500377A0518|43 45|Wnt
P11500512A0000|3 16|human ABCG1 gene
P11500512A0000|3 16|human ABCG1 gene
P11500512A0000|36 54|ATP-binding cassette
P11500512A0000|36 54|ATP-binding cassette
P11500512A0000|56 70|ABC) superfamily
P11500512A0000|56 58|ABC
P11500512A0000|73 91|transporter proteins
P11500512A0000|114 124|macrophages
P11500512A0000|141 150|oxysterols
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|47 58|mature pollen
P11500571A0976|60 75|gPAL1 transcripts
P11500571A0976|60 75|gPAL1 transcripts
P11500571A0976|95 100|pollen
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|26 34|HC11 cells
P11500913A1238|48 62|beta-casein mRNA
P11500913A1238|48 58|beta-casein
P11500913A1238|64 84|mammary epithelial cell
P11500913A1238|119 136|lactogenic hormones
P11502738A1457|0 15|Identical effects
P11502738A1457|88 99|+139 bp region
P11502738A1457|105 120|cyclin D1 promoter
P11502738A1457|105 112|cyclin D1
P11502758A0869|26 32|ankyrin
P11502758A0869|26 32|ankyrin
P11502758A0869|52 56|LAD-1
P11502758A0869|52 56|LAD-1
P11502758A0869|66 78|FGFR signaling
P11502758A0869|66 69|FGFR
P11502778A0941|16 18|men
P11502778A0941|23 43|bioavailable estradiol
P11502778A0941|116 123|bone loss
P11502778A0941|160 162|men
P11502778A0941|167 193|bioavailable estradiol levels
P11504545A0393|11 38|electrophoretic mobility shift
P11504545A0393|42 58|immunoshift assays
P11504545A0393|72 81|NF1 factors
P11504545A0393|72 81|NF1 factors
P11504545A0393|91 105|nuclear extracts
P11504545A0393|108 111|HeLa
P11504545A0393|115 123|CV-1 cells
P11504545A0393|115 118|CV-1
P11504545A0393|133 139|BKV-MLP
P11504545A0393|133 139|BKV-MLP
P11504709A0981|25 43|inducible expression
P11504709A0981|62 64|PMA
P11504709A0981|67 69|TPO
P11504709A0981|67 69|TPO
P11504709A0981|90 96|Ets site
P11504709A0981|90 96|Ets site
P11504709A0981|102 117|proximal promoter
P11504709A0981|120 123|GPIX
P11504709A0981|120 123|GPIX
P11504709A0981|165 204|MAPK/extracellular signal-regulated kinase
P11504709A0981|165 168|MAPK
P11504709A0981|170 204|extracellular signal-regulated kinase
P11505407A0461|51 68|EpCAM positive cells
P11505407A0461|51 55|EpCAM
P11505407A0461|98 121|tumor necrosis factor alpha
P11505407A0461|98 121|tumor necrosis factor alpha
P11505407A0461|123 130|TNFalpha
P11505407A0461|123 130|TNFalpha
P11509266A0955|34 47|adenocarcinoma
P11509266A0955|74 76|BPF
P11509266A0955|112 128|pathological stage
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509615T0000|58 75|T cell proliferation
P11509615T0000|89 100|IL-2 receptor
P11509615T0000|89 100|IL-2 receptor
P11509673A0574|25 32|BM3 cells
P11509673A0574|51 76|bacterial P450 AA epoxygenase
P11509673A0574|60 84|P450 AA epoxygenase, F87V BM3
P11509673A0574|148 156|14,15-EET
P11509673A0574|158 159|AA
P11509673A0574|172 180|apoptosis
P11509673A0574|200 223|agonist-induced apoptosis
P11511544T0000|3 12|loop domain
P11511544T0000|15 43|heat shock transcription factor 1
P11511544T0000|15 43|heat shock transcription factor 1
P11511544T0000|52 73|DNA-binding specificity
P11511544T0000|88 97|heat stress
P11512925A0000|0 16|EXAFS measurements
P11512925A0000|26 29|Ge-K
P11512925A0000|124 129|Ge atom
P11513121T0000|19 32|robustness test
P11513121T0000|35 43|QSAR model
P11513121T0000|51 75|quantum chemical parameters
P11513121T0000|89 91|BCF
P11513121T0000|102 132|polychlorinated organic compounds
P11513121T0000|134 138|PCOCs
P11513180A1257|15 32|malignant polyposis
P11513180A1257|57 58|CT
P11513579A0372|48 51|Rac1
P11513579A0372|48 51|Rac1
P11513579A0372|75 81|Rho-GDI
P11513579A0372|75 81|Rho-GDI
P11513579A0372|113 139|protein-isoprene interaction
P11513579A0372|142 157|complex formation
P11516890A0236|24 38|cytochrome P-450
P11516890A0236|24 38|cytochrome P-450
P11516890A0236|40 49|CYP) system
P11516890A0236|40 42|CYP
P11516890A0236|51 61|venlafaxine
P11516890A0236|70 81|CYP 2D6 and 3A4
P11516890A0236|70 75|CYP 2D6
P11516890A0236|79 81|3A4
P11516890A0236|109 113|SSRIs
P11517190A0352|13 28|promoter sequence
P11517190A0352|51 79|major transcriptional start site
P11517190A0352|82 97|canonical TATA box
P11517190A0352|101 129|putative cis regulatory elements
P11517190A0352|133 159|pituitary specific expression
P11517190A0352|170 188|E-responsive element
P11517190A0352|170 188|E-responsive element
P11517190T0000|5 20|intronic promoter
P11517190T0000|26 39|rat ER alpha gene
P11517190T0000|26 39|rat ER alpha gene
P11517190T0000|57 78|transient transcription
P11517190T0000|82 96|variant receptor
P11517269A0472|0 4|Pitx2
P11517269A0472|0 4|Pitx2
P11517269A0472|15 38|GABAergic differentiation
P11517269A0472|67 78|axon guidance
P11517269A0472|104 116|unc-30 mutants
P11517269A0472|175 200|evolutionarily related genes
P11517399A0858|13 41|early mRNA and protein expression
P11517399A0858|104 122|T'(135) acceptor site
P11517399A0858|104 109|T'(135
P11517399A0858|156 166|splice sites
P11517399A0858|188 196|T' species
P11517445A0221|16 22|cholera
P11517445A0221|35 46|V. cholerae O1
P11517445A0221|35 46|V. cholerae O1
P11518505A0107|74 79|organs
P11518868A0559|34 54|nonsexual risk behavior
P11518868A0559|79 93|hepatitis C virus
P11518868A0559|98 128|healthcare provider communication
P11519466A0196|4 15|selenium diet
P11520436A0705|5 14|BALB/c mice
P11520436A0705|51 54|mice
P11520436A0705|114 120|T. canis
P11520436A0705|124 137|allergic asthma
P11521191A0000|28 50|adenoviral 12S E1A protein
P11521191A0000|28 40|adenoviral 12S
P11521191A0000|41 50|E1A protein
P11521191A0000|63 83|phosphorylation status
P11521191A0000|86 89|p130
P11521191A0000|86 89|p130
P11521191A0000|93 96|p107
P11521191A0000|93 96|p107
P11521191A0000|124 156|cell cycle dependent phosphorylation
P11521191A0000|162 182|retinoblastoma protein
P11521191A0000|162 182|retinoblastoma protein
P11522431A0673|15 31|tobacco dependence
P11522431A0673|55 68|ICD-10 criteria
P11522431A0673|80 107|alcohol-dependent individuals
P11522431A0673|121 131|nondrinkers
P11522431A0673|134 147|social drinkers
P11522584A0882|0 14|Diffuse myalgias
P11522584A0882|33 40|patients
P11522584A0882|58 66|MMF lesion
P11522584A0882|69 87|deltoid muscle biopsy
P11522626A1374|32 52|G(1) gene transcription
P11522626A1374|32 39|G(1) gene
P11522626A1374|97 106|Mek-Erk1/2
P11522626A1374|97 99|Mek
P11522626A1374|101 106|Erk1/2
P11522626A1374|116 132|estrogen receptors
P11522626A1374|116 132|estrogen receptors
P11522658A0086|25 35|ErbB1/ErbB2
P11522658A0086|25 29|ErbB1
P11522658A0086|31 35|ErbB2
P11522658A0086|79 97|ErbB kinase inhibitor
P11522658A0086|79 88|ErbB kinase
P11522658A0086|98 105|AG1478in
P11522658A0086|106 110|ErbB2
P11522658A0086|130 157|SKBR-3 human breast cancer cells
P11522658A0870|11 32|reduced phosphorylation
P11522658A0870|35 37|p27
P11522658A0870|35 37|p27
P11522658A0870|40 43|MAPK
P11522658A0870|40 43|MAPK
P11522658A0870|66 68|p27
P11522658A0870|66 68|p27
P11522658A0870|87 97|nuclear Cdk2
P11522658A0870|87 97|nuclear Cdk2
P11522658A0870|132 145|kinase activity
P11523446A0523|43 65|LC and time-of-flight (TOF
P11523446A0523|86 118|chemiluminescent nitrogen detection
P11523446A0523|120 126|LC-CLND
P11524015A0937|18 23|BZAP45
P11524015A0937|18 23|BZAP45
P11524015A0937|42 51|H4 promoter
P11524015A0937|42 51|H4 promoter
P11524015A0937|53 79|nt -215 to -1)/CAT reporter gene
P11524015A0937|53 63|nt -215 to -1)
P11524015A0937|65 79|CAT reporter gene
P11524815A0753|0 16|Local control rates
P11524815A0753|27 46|metastatic lung cancer
P11524815A0753|54 70|primary lung cancer
P11524815A0753|80 81|T1
P11524823X0001|0 6|Utility
P11524823X0001|9 19|OAE screener
P11524823X0001|21 25|GSI 70
P11524823X0001|45 81|distortion product otoacoustic emissions
P11524823X0001|135 145|OAE screener
P11524823X0001|146 150|GSI 70
P11524823X0001|163 177|cochlea function
P11524823X0001|180 204|neonates, infants and adults
P11525102A0970|40 53|ACP Journal Club
P11525102A0970|65 78|PubMed strategy
P11525102A0970|105 106|CI
P11525486A0350|14 25|CaCO3-CO2/N2
P11525640A0560|12 15|JNK1
P11525640A0560|12 15|JNK1
P11525640A0560|19 27|ERK kinase
P11525640A0560|19 27|ERK kinase
P11525640A0560|61 82|dominant negative mutant
P11525640A0560|61 82|dominant negative mutant
P11525640A0560|83 86|JNK1
P11525640A0560|83 86|JNK1
P11525640A0560|133 135|ERK
P11525640A0560|133 135|ERK
P11525640A0560|137 144|PD098059
P11525640A0560|171 181|UV induction
P11525640A0560|187 200|GADD45 promoter
P11525640A0560|187 200|GADD45 promoter
P11528127A1402|5 13|GC content
P11528127A1402|49 78|"isochore H1" and the other segment
P11528127A1402|58 60|H1"
P11528127A1402|83 84|GC
P11528127A1402|96 97|GC
P11528127A1402|108 122|"isochore L1/L2"
P11528127A1402|117 118|L1
P11528127A1402|120 121|L2
P11528500A0571|2 9|mutation
P11528500A0571|15 21|NRL gene
P11528500A0571|15 17|NRL
P11529914T0000|0 8|NF-kappaB
P11529914T0000|0 8|NF-kappaB
P11529914T0000|36 40|CD154
P11529914T0000|36 40|CD154
P11529914T0000|42 51|CD40 ligand
P11529914T0000|42 45|CD40
P11529914T0000|65 82|primary human T cells
P11530684A0667|5 15|nerve injury
P11530684A0667|20 39|nociceptive responses
P11530684A0667|47 58|type I neurons
P11530684A0667|68 84|polymodal C-fibers
P11530684A0667|93 114|NK1-receptor mechanisms
P11530684A0667|93 95|NK1
P11530684A0667|117 138|spinal pain transmission
P11530684A0667|197 213|polymodal C-fibers
P11530684A0667|222 244|NMDA receptor-mechanisms
P11530684A0667|222 233|NMDA receptor
P11530684A0667|301 308|A-fibers
P11530684A0667|318 340|NMDA-receptor mechanisms
P11530684A0667|318 330|NMDA-receptor
P11530829A0000|45 64|ECG simulator intended
P11530829A0000|111 139|electrocardiographic equipment
P11532556A0000|0 38|Subacute diencephalic angioencephalopathy
P11532556A0000|40 43|SDAE
P11532556A0000|55 66|fatal disease
P11532556A0000|76 83|etiology
P11532556A0000|99 116|thalami bilaterally
P11532856A1175|30 45|N-acetylcysteine
P11532856A1175|75 77|HGF
P11532856A1175|75 77|HGF
P11532856A1175|80 101|stress kinase activities
P11532856A1175|80 91|stress kinase
P11532856A1175|108 113|p42/44
P11532856A1175|108 113|p42/44
P11532856A1175|114 135|mitogen activated kinase
P11532856A1175|114 135|mitogen activated kinase
P11532856A1175|137 140|MAPK
P11532856A1175|137 140|MAPK
P11532856A1175|181 202|c-Jun-N-terminal kinase
P11532856A1175|181 202|c-Jun-N-terminal kinase
P11532856A1175|204 206|JNK
P11532856A1175|204 206|JNK
P11532856A1175|211 217|p38 MAPK
P11532856A1175|211 217|p38 MAPK
P11532856A1175|220 234|HIF-1 activation
P11532856A1175|220 224|HIF-1
P11533238A1137|13 26|octamer element
P11533238A1137|63 67|HDAC1
P11533238A1137|63 67|HDAC1
P11533238A1137|76 85|repression
P11533238A1137|97 121|HLA-DRA promoter activation
P11533238A1137|97 111|HLA-DRA promoter
P11533340A1285|33 51|developmental scores
P11533340A1285|74 83|PDF infants
P11533340A1285|117 138|Bayley motor score scales
P11533863A0125|85 100|cognitive therapy
P11534900A0000|3 8|binary
P11534900A0000|34 76|plant-derived molluscicides Azadirachta indica
P11534900A0000|80 92|Cedrus deodara
P11534900A0000|110 116|MGK-264
P11534900A0000|118 134|piperonyl butoxide
P11534900A0000|136 137|PB
P11534900A0000|155 166|Embelia ribes
P11534900A0000|185 200|Lymnaea acuminata
P11535014A1157|52 54|TLE
P11535014A1157|124 140|abnormal latencies
P11535014A1157|143 146|P300
P11535014A1157|152 168|epileptic patients
P11535140T0000|22 30|pregnancy
P11535532A0189|3 24|deubiquitinating enzyme
P11535532A0189|25 29|DUB-2
P11535532A0189|25 29|DUB-2
P11535532A0189|51 54|IL-2
P11535532A0189|51 54|IL-2
P11535832A0586|21 26|HDAC9a
P11535832A0586|21 26|HDAC9a
P11535832A0586|47 55|C terminus
P11535832A0586|60 64|HDAC9
P11535832A0586|60 64|HDAC9
P11536063A0178|0 19|Pulmonary embolectomy
P11536063A0178|23 41|lung transplantation
P11536063A0178|74 91|heart-lung-machine
P11538437A0568|61 68|N2(A) + N2
P11538437A0568|61 62|N2
P11538437A0568|64 64|A
P11538437A0568|70 71|A)
P11538437A0568|75 76|N2
P11538437A0568|78 80|C,B
P11538437A0568|82 87|V') + N2
P11538437A0568|92 99|N2(A) + N2
P11538437A0568|92 93|N2
P11538437A0568|95 95|A
P11538437A0568|101 101|X
P11538437A0568|105 106|5)
P11538437A0568|110 111|N2
P11538437A0568|116 119|N2(B
P11538437A0568|126 131|pure N2
P11538437A0568|150 155|N2(A) +
P11538437A0568|150 151|N2
P11538437A0568|153 153|A
P11538437A0568|156 158|CH4
P11538437A0568|162 176|products, C + N + M2
P11538437A0568|180 183|CN(B
P11538437A0568|185 190|V') + M2
P11538437A0568|192 193|N2
P11538437A0568|192 193|N2
P11538437A0568|195 195|X
P11538437A0568|195 195|X
P11538437A0568|197 199|V>4
P11538437A0568|202 203|CN
P11538437A0568|207 208|N2
P11538437A0568|213 218|CN(B,A
P11539522A0612|3 16|NAUSICAA system
P11539522A0612|63 78|in space dosimetry
P11540991A0127|91 100|NASA KC-135
P11540991A0127|103 128|parabolic flight, and in space
P11540991A0127|136 146|EASE program
P11540991A0127|156 181|Shuttle Atlantis mission 61-B
P11542677A0411|85 108|composting facility design
P11542780A0086|9 34|thermoluminescent detectors
P11542780A0086|36 38|TLD
P11542780A0086|167 170|PNTD
P11542780A0086|202 214|LET) component
P11543154T0000|11 20|TLD Mg2SiO4
P11543154T0000|79 92|space radiation
P11543317A0203|65 91|thermo- luminescent dosemeter
P11543317A0203|94 103|Mg2SiO4: Tb
P11543317A0203|105 108|TDMS
P11543317A0203|141 144|PNTD
P11543662A0562|8 19|gstC' mutants
P11543662A0562|8 19|gstC' mutants
P11543662A0562|35 48|C-terminal half
P11543662A0562|51 52|C'
P11543662A0562|88 95|L protein
P11543662A0562|88 95|L protein
P11545594A1556|23 32|Myb domains
P11545594A1556|23 32|Myb domains
P11545594A1556|75 83|Myb domain
P11545594A1556|75 83|Myb domain
P11545594A1556|96 112|amino acid residues
P11547819A0532|103 107|laser
P11547819A0532|186 193|ablation
P11547819A0532|196 216|atherosclerotic tissue
P11547819A0532|234 241|ablation
P11547819A0532|254 275|tissue penetration rates
P11547819A0532|308 342|laser-induced in vivo vessel wall injury
P11548027A0163|129 133|water
P11550795A2583|16 23|RORgamma
P11550795A2583|16 23|RORgamma
P11550795A2583|45 75|T cell receptor-mediated apoptosis
P11550795A2583|45 57|T cell receptor
P11550795A2583|78 92|T cell hybridomas
P11550795A2583|119 128|Fas-ligand
P11550795A2583|119 128|Fas-ligand
P11550795A2583|132 143|interleukin 2
P11550795A2583|132 143|interleukin 2
P11552058A0235|4 6|ICP
P11552058A0833|65 68|THAM
P11552058A0833|70 108|Tris-hydroxy-methyl-aminomethane) buffer
P11552058A0833|113 133|high-dose barbiturates
P11552724A0527|12 33|ChromaFlo-enhanced IVUS
P11552724A0527|73 78|vessel
P11552724A0527|79 83|lumen
P11552724A0527|115 131|echolucent disease
P11552724A0527|136 147|luminal blood
P11552724A0527|177 199|peripheral interventions
P11552724A0527|202 209|patients
P11552724A0527|214 225|renal failure
P11552724A0527|228 234|allergy
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|33 99|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|117 140|Class II molar relationship
P11553704A0674|53 62|EGFR-CD533
P11553704A0674|53 56|EGFR
P11553704A0674|58 62|CD533
P11553704A0674|65 86|dominant negative Ras N17
P11553704A0674|65 86|dominant negative Ras N17
P11553704A0674|102 115|MAPK activation
P11553704A0674|102 105|MAPK
P11554469A1386|44 52|CesA genes
P11554469A1386|44 52|CesA genes
P11554469A1386|59 76|cellulose synthases
P11554469A1386|59 76|cellulose synthases
P11554469A1386|95 110|sub-class members
P11554469A1386|125 165|non-cellulosic (1-->4)beta-glycan synthases
P11554469A1386|125 165|non-cellulosic (1-->4)beta-glycan synthases
P11554469A1386|168 173|plants
P11554566A0668|3 19|hatcher incubators
P11554566A0668|43 54|persistently
P11554566A0668|71 91|Salmonella livingstone
P11554566A0668|95 115|Salmonella thomasville
P11554566A0668|118 125|company A
P11554566A0668|133 153|Salmonella senftenberg
P11554566A0833|6 19|companies sites
P11554566A0833|20 40|Salmonella enteritidis
P11554566A0833|44 64|Salmonella typhimurium
P11554566A0833|65 69|Tr104
P11554727A0890|3 21|mutation experiments
P11554727A0890|73 75|PTH
P11554727A0890|73 75|PTH
P11554727A0890|79 96|5'-GGGGGAGGGGAG-3'
P11554727A0890|108 112|PTHSR
P11554727A0890|108 112|PTHSR
P11555516A0639|0 6|Cardiac
P11555516A0639|15 32|anaerobic threshold
P11555516A0639|34 37|COAT
P11555516A0639|86 117|multivessel coronary artery disease
P11555669A0464|0 9|Experience
P11555669A0464|14 32|xylene-free sections
P11555669A0983|1 13|randomized mix
P11556809A2085|17 38|CYP71D20-encoded enzyme
P11556809A2085|17 38|CYP71D20-encoded enzyme
P11556809A2085|73 91|5-epi-aristolochene
P11556809A2085|161 170|P450 enzyme
P11557127A0991|13 34|NF-Y and Sp1 binding sites
P11557127A0991|13 16|NF-Y
P11557127A0991|20 34|Sp1 binding sites
P11557127A0991|77 87|rat mrp2 gene
P11557127A0991|77 87|rat mrp2 gene
P11557127A0991|97 109|human MRP2 gene
P11557127A0991|97 109|human MRP2 gene
P11559366T0000|0 37|E2F1-mediated transcriptional inhibition
P11559366T0000|0 3|E2F1
P11559366T0000|43 80|plasminogen activator inhibitor type 1 gene
P11559366T0000|43 76|plasminogen activator inhibitor type 1
P11559547T0000|0 24|Transcriptional regulation
P11559547T0000|30 62|estrogen-inducible pS2 breast cancer
P11559547T0000|78 86|ERR family
P11559547T0000|78 86|ERR family
P11559547T0000|89 110|orphan nuclear receptors
P11559547T0000|89 110|orphan nuclear receptors
P11559564A0459|0 5|NB-506
P11559564A0459|37 50|topoisomerase I
P11559564A0459|37 50|topoisomerase I
P11559564A0459|78 97|human splicing factor 2
P11559564A0459|99 131|alternative splicing factor (SF2/ASF
P11559564A0459|99 123|alternative splicing factor
P11559564A0459|125 127|SF2
P11559564A0459|129 131|ASF
P11559789A0314|26 51|replication-deficient virus
P11559789A0314|65 71|ASF/SF2
P11559789A0314|65 67|ASF
P11559789A0314|69 85|SF2 splicing factor
P11559789A0314|91 134|progesterone antagonist-inducible gene cassette
P11559789A0314|152 158|ASF/SF2
P11559789A0314|152 154|ASF
P11559789A0314|156 158|SF2
P11559789A0314|195 213|293 producer cell line
P11559789A0314|233 239|inducer
P11559821A1315|0 15|DNA binding assays
P11559821A1315|42 47|p30(II
P11559821A1315|42 47|p30(II
P11559821A1315|66 82|CREB-Tax-p300/CBP
P11559821A1315|66 69|CREB
P11559821A1315|71 73|Tax
P11559821A1315|75 78|p300
P11559821A1315|80 82|CBP
P11559821A1315|83 103|multiprotein complexes
P11559821A1315|106 116|21-bp repeat
P11559821A1315|117 132|oligonucleotides
P11560292A0557|51 62|prototype DSS
P11560509T0000|0 13|DNA recognition
P11560509T0000|16 28|F factor TraI36
P11560509T0000|16 22|F factor
P11560509T0000|23 28|TraI36
P11560990A0272|0 15|E47 protein levels
P11560990A0272|0 9|E47 protein
P11560990A0272|34 65|double positive developmental stage
P11560990A0272|159 177|single positive stage
P11560992A0000|7 54|specificity kinases mitogen-activated protein kinase
P11560992A0000|25 54|mitogen-activated protein kinase
P11560992A0000|56 66|MAPK) kinase
P11560992A0000|56 66|MAPK) kinase
P11560992A0000|68 70|MKK
P11560992A0000|68 70|MKK
P11560992A0000|76 79|MKK4
P11560992A0000|76 79|MKK4
P11560992A0000|125 167|stress kinases stress-activated protein kinases
P11560992A0000|125 137|stress kinases
P11560992A0000|138 167|stress-activated protein kinases
P11560992A0000|169 197|SAPKs)/c-Jun N-terminal kinases
P11560992A0000|169 173|SAPKs
P11560992A0000|176 197|c-Jun N-terminal kinases
P11560992A0000|199 202|JNKs
P11560992A0000|199 202|JNKs
P11560992A0000|216 228|environmental
P11560992A0000|231 246|mitogenic stimuli
P11560992A0651|0 17|SAPK/JNK activation
P11560992A0651|0 3|SAPK
P11560992A0651|5 7|JNK
P11560992A0651|54 57|MKK7
P11560992A0651|54 57|MKK7
P11560992A0651|81 84|MKK4
P11560992A0651|81 84|MKK4
P11560992A0651|109 130|mkk7(-/-) mast cell lines
P11560992A0651|109 117|mkk7(-/-)
P11560992A0651|135 149|phosphorylation
P11560992A0651|152 155|MKK4
P11560992A0651|152 155|MKK4
P11560992A0651|184 204|multiple stress stimuli
P11560992A1184|5 8|MKK7
P11560992A1184|5 8|MKK7
P11560992A1184|44 75|stress-induced SAPK/JNK activation
P11560992A1184|58 61|SAPK
P11560992A1184|63 65|JNK
P11560992A1184|78 86|mast cells
P11560992A1184|90 93|MKK7
P11560992A1184|90 93|MKK7
P11560992A1184|113 142|growth factor and antigen receptor
P11560992A1184|113 124|growth factor
P11560992A1184|128 162|antigen receptor-driven proliferation
P11560992A1184|165 182|hematopoietic cells
P11561623A0897|84 94|sand filters
P11561623A0897|152 168|meiofaunal biomass
P11561626A0197|13 28|aqueous solutions
P11561626A0197|31 53|TMT-55, aqueous solutions
P11561626A0197|75 78|zinc
P11561626A0197|80 86|cadmium
P11561626A0197|90 98|lead salts
P11561626A0197|122 127|Zn-TMT
P11561626A0197|153 159|Cd-TMT"
P11561626A0197|172 181|Pb-TMT" (M3
P11561626A0197|183 190|S3C3N3]2
P11561626A0197|192 195|nH2O
P11561626A0197|204 212|Cd2+, Pb2+
P11561626A0197|217 220|Zn2+
P11562278A0169|37 48|G1 regulation
P11562278A0169|78 90|proliferation
P11562278A0169|92 106|differentiation
P11562278A0169|110 132|oncogenic transformation
P11562278A0169|136 154|programmed cell death
P11562278A0169|156 164|apoptosis
P11562870A0892|29 39|lamotrigine
P11564871A1184|33 36|TATA
P11564871A1184|45 64|transcription systems
P11564871A1184|67 88|contemporary eukaryotes
P11564871A1184|128 130|TBP
P11564871A1184|128 130|TBP
P11564871A1184|141 144|Pols
P11564871A1184|152 161|eukaryotes
P11564871A1184|176 187|TATA elements
P11564871A1184|195 203|promoters
P11564893A1068|48 56|6RG lesion
P11564893A1068|58 61|MGMT
P11564893A1068|58 61|MGMT
P11564893A1068|75 89|DNA repair factor
P11564893A1068|93 114|transcription regulator
P11564893A1068|93 114|transcription regulator
P11564893A1068|116 121|R-MGMT
P11564893A1068|116 116|R
P11564893A1068|118 121|MGMT
P11564893A1068|163 170|mutagens
P11565747A1020|8 28|in vitro splicing assays
P11565747A1020|30 43|UV crosslinking
P11565747A1020|136 138|PSI
P11565747A1020|136 138|PSI
P11565747A1020|145 158|SELEX sequences
P11565747A1020|194 205|P element IVS3
P11565747A1020|194 201|P element
P11565747A1020|202 205|IVS3
P11566874T0000|20 36|cytoplasmic dynein
P11566874T0000|20 36|cytoplasmic dynein
P11566948A1217|2 28|hypertensive nephrosclerosis
P11566948A1217|49 52|ACEI
P11566948A1217|107 117|renal events
P11566961A0472|0 18|Body weight reduction
P11566961A0472|28 45|insulin sensitivity
P11566961A0472|28 34|insulin
P11566961A0472|61 72|blood glucose
P11566961A0472|76 95|blood pressure control
P11566996A1391|17 20|uvrA
P11566996A1391|17 20|uvrA
P11566996A1391|27 57|nucleotide excision repair pathway
P11566996A1391|94 102|DNA damage
P11566996A1391|145 152|S. mutans
P11566996A1391|155 159|low pH
P11568988A0960|7 21|regression model
P11568988A0960|47 50|WCXR
P11568988A0960|88 100|antibody titer
P11568988A0960|104 113|Pa elastase
P11568988A0960|104 113|Pa elastase
P11569800T0000|24 42|microfluidic systems
P11569800T0000|49 59|temperature
P11569800T0000|70 83|fluorescent dye
P11569900A0660|0 13|APC-resistance
P11569900A0660|0 2|APC
P11569900A0660|52 66|high sensitivity
P11569900A0660|93 107|V Leiden mutation
P11569900A0660|94 107|Leiden mutation
P11570735A1097|71 96|peak vertical ground reaction
P11570735A1097|108 126|post-test conditions
P11570735A1097|136 153|post-test reduction
P11570735A1097|173 190|post-test reduction
P11570735A1097|227 234|control I
P11570820T0000|4 24|casein kinase I isoforms
P11570820T0000|4 24|casein kinase I isoforms
P11570820T0000|60 66|nucleus
P11570820T0000|70 78|cytoplasm
P11572388A0000|97 101|LSERs
P11572388A0000|167 204|chromatographic (RPLC) method development
P11572467A0658|7 15|blood clot
P11572467A0658|29 42|vitreous cavity
P11572467A0658|67 70|t-PA
P11572467A0658|67 68|t-
P11572467A0658|69 70|PA
P11572467A0658|81 91|plasminogen
P11572467A0658|81 91|plasminogen
P11572467A0658|94 100|plasmin
P11572467T0000|0 9|Management
P11572467T0000|26 51|diabetic vitreous hemorrhage
P11572467T0000|56 81|tissue plasminogen activator
P11572467T0000|62 81|plasminogen activator
P11572467T0000|83 86|t-PA
P11572467T0000|85 86|PA
P11572467T0000|97 127|homeostatic fluid-fluid exchanger
P11573771T0000|8 21|heat treatments
P11573771T0000|40 46|cheeses
P11573891A0525|22 44|African Americans exposed
P11573891A0525|49 66|community outbreaks
P11573891A0525|116 134|comparable exposures
P11574088A1687|30 47|pancreas transplant
P11574088A1687|61 63|SPK
P11574088A1687|61 63|SPK
P11574088A1687|77 89|PAK recipients
P11574105A0727|0 7|Patients
P11574105A0727|121 123|GBS
P11574105A0727|174 176|GBS
P11574105A0727|202 212|anti-GM1 IgG
P11574105A0727|202 212|anti-GM1 IgG
P11574105A0727|216 235|anti-GD1a IgM antibody
P11574105A0727|221 235|GD1a IgM antibody
P11574105A0727|245 256|axonal damage
P11574105A0727|258 277|anti-GD1a IgM antibody
P11574105A0727|258 277|anti-GD1a IgM antibody
P11574105A0727|295 302|patients
P11574105A0727|310 327|peak antibody titers
P11575109A0214|9 35|baseline clinical examination
P11575109A0214|46 63|periodontal therapy
P11575109A0214|67 74|patients
P11575109A0214|83 101|mucogingival surgery
P11575109A0214|110 123|gingival grafts
P11575109A0214|158 164|gingiva
P11575977A1133|8 15|patients
P11575977A1133|20 45|isolated office hypertension
P11575977A1133|62 88|cardiovascular complications
P11576158A1371|5 16|TVD-patients
P11576158A1371|28 36|skin blood
P11576158A1371|67 81|healthy controls
P11576776T0081|20 44|microcrystalline cellulose
P11577094A1226|26 48|intracellular WT-1/HSAL2
P11577094A1226|39 42|WT-1
P11577094A1226|44 48|HSAL2
P11577094A1226|84 96|hematopoiesis
P11578685A0077|0 5|ICAM-1
P11578685A0077|0 5|ICAM-1
P11578685A0077|44 45|GO
P11579100T0000|0 21|Phosphotyrosyl peptides
P11579100T0000|27 58|Stat3-mediated DNA binding activity
P11579100T0000|27 31|Stat3
P11579100T0000|60 73|gene regulation
P11579100T0000|78 95|cell transformation
P11580173A0181|0 16|Plane wave geometry
P11580173A0181|98 99|P3
P11580173A0181|117 133|spherical geometry
P11580301A1161|14 25|HCV arthritis
P11580301A1161|28 35|patients
P11580301A1161|40 98|positive rheumatoid factor and chronic inflammatory polyarthritis
P11580757A0304|35 46|TFCD patients
P11580757A0304|111 132|magnetic resonance (MR)-
P11580757A0304|143 148|lesion
P11580757A0304|184 222|stereoelectroencephalographic recordings
P11580941A0815|32 44|UPDRS II and III
P11580941A0815|85 91|therapy
P11583621A0301|15 30|apoptotic stimuli
P11583621A0301|53 59|caspase
P11583621A0301|80 94|hTAF(II)80 delta
P11583621A0301|80 86|hTAF(II
P11583621A0301|96 102|hTAF(II
P11583621A0301|96 102|hTAF(II
P11583621A0301|118 124|hTAF(II
P11583621A0301|118 124|hTAF(II
P11583621A0301|135 151|TFIID-like complex
P11583621A0301|135 151|TFIID-like complex
P11583621A0301|159 165|hTAF(II
P11583621A0301|159 165|hTAF(II
P11583880T0000|0 25|Endovascular aneurysm repair
P11583880T0000|33 49|AneuRx stent-graft
P11584107T0000|7 25|nutritional diseases
P11584107T0000|28 43|infectious origin
P11584328A0532|0 15|Drug interactions
P11584328A0532|59 74|CYP450 isoenzymes
P11584328A0532|59 74|CYP450 isoenzymes
P11585856A0285|52 53|RR
P11585856A0285|55 66|nonuniform AC
P11585856A0285|134 136|PER
P11585856A0285|151 172|filtered backprojection
P11586096A0699|22 43|patient characteristics
P11586096A0699|80 91|normal muscle
P11586096A0699|97 104|patients
P11587514A0758|11 27|abi1-1 gene product
P11587514A0758|11 27|abi1-1 gene product
P11587514A0758|44 57|ABA suppression
P11587514A0758|61 90|GA-responsive alpha-amylase gene
P11587514A0758|61 86|GA-responsive alpha-amylase
P11587980A1039|2 9|children
P11587980A1039|25 49|forced expiratory maneuvers
P11587980A1039|57 59|FOT
P11587980A1039|74 93|interrupter technique
P11587980A1039|123 135|young children
P11587980A1039|140 159|high resistance values
P11589568A0744|2 8|budding
P11589568A0744|9 13|yeast
P11589568A0744|62 74|Mad1, 2, 3, Bub1
P11589568A0744|62 65|Mad1
P11589568A0744|71 74|Bub1
P11589568A0744|78 81|Bub3
P11589568A0744|78 81|Bub3
P11589568A0744|120 141|unattached kinetochores
P11589779T0000|0 5|HTLV-1
P11589779T0000|0 5|HTLV-1
P11589779T0000|15 21|Th2 type
P11589779T0000|24 37|immune response
P11589779T0000|40 47|patients
P11589779T0000|52 67|strongyloidiasis
P11590364A1056|11 29|beta5L splice variant
P11590364A1056|47 52|retina
P11592315A0325|0 8|PROCEDURE
P11592315A0325|47 58|abomasal body
P11592315A0325|81 84|calf
P11592532A0188|38 41|HFA I
P11592532A0188|116 131|perimetric method
P11593394A0000|0 28|Transforming growth factor-beta
P11593394A0000|0 28|Transforming growth factor-beta
P11593394A0000|30 37|TGF-beta
P11593394A0000|30 37|TGF-beta
P11593394A0000|46 57|growth arrest
P11593394A0000|104 126|D- and E-type cyclin kinase
P11593394A0000|109 126|E-type cyclin kinase
P11593394A0000|181 183|p15
P11593394A0000|181 183|p15
P11593394A0000|185 189|Ink4b
P11593394A0000|185 189|Ink4b
P11593394A0000|194 224|p27(Kip1) cyclin kinase inhibitors
P11593394A0000|194 196|p27
P11593394A0000|198 201|Kip1
P11593394A0000|203 214|cyclin kinase
P11595170A0582|20 24|cDNAs
P11595170A0582|30 44|NR5A2 (hB1F) gene
P11595170A0582|30 34|NR5A2
P11595170A0582|36 39|hB1F
P11595170A0582|180 186|introns
P11595176T0000|3 18|genomic structure
P11595176T0000|24 37|human SPEC1 gene
P11595176T0000|24 37|human SPEC1 gene
P11595176T0000|90 110|AF1q translocation gene
P11595176T0000|90 110|AF1q translocation gene
P11595478A1014|0 18|Hp positive relatives
P11595478A1014|21 33|gastric cancer
P11595478A1014|64 70|atrophy
P11595478A1014|84 95|Hp negativity
P11595478A1014|103 117|cancer relatives
P11595813A0633|10 19|metabolism
P11595813A0633|22 30|androgens
P11595813A0633|64 80|pilosebaceous unit
P11595813A0633|128 136|aromatase
P11595813A0633|128 136|aromatase
P11595813A0633|138 153|5alpha-reductase
P11595813A0633|138 153|5alpha-reductase
P11595813A0633|180 196|androgen receptors
P11595840A0000|11 44|fluorine-18 fluorodeoxyglucose (F-18
P11595840A0000|45 47|FDG
P11595840A0000|52 65|malignant tumor
P11595840A0000|78 94|blood glucose level
P11596104A0614|0 19|Northern blot analysis
P11596104A0614|32 37|PARNAs
P11596104A0614|32 37|PARNAs
P11596104A0614|110 118|cell lines
P11596838A1357|28 48|fluticasone propionate
P11596838A1357|90 97|patients
P11596838A1357|102 117|persistent asthma
P11596838A1357|151 163|beta2-agonist
P11597185A0477|7 11|space
P11597185A0477|62 80|computer simulations
P11597185A0477|134 155|metapopulation dynamics
P11597936A0570|5 7|CAD
P11597936A0570|8 15|patients
P11597936A0570|42 49|patients
P11597936A0570|76 96|low density lipoprotein
P11597936A0570|112 124|triglycerides
P11597936A0570|166 184|lipid-lowering drugs
P11599079A1040|75 84|30/90/130 V
P11599840A0813|3 8|moduli
P11599840A0813|26 29|gray
P11599840A0813|57 59|kPa
P11599840A0813|106 117|axial section
P11599840A0813|126 128|kPa
P11599840A0813|149 162|frontal section
P11599840A0813|176 178|kPa
P11599840A0813|199 213|sagittal section
P11600252A0795|3 7|LA 50s
P11600252A0795|71 80|1965 to 1970
P11600314A0000|28 64|differential pulse polarographic methods
P11600314A0000|107 126|quantitative analysis
P11600314A0000|129 137|vitamin B1
P11600314A0000|129 137|vitamin B1
P11600314A0000|139 145|B2 and B6
P11600314A0000|139 140|B2
P11600365A0471|0 28|Against gram-positive organisms
P11600365A0471|30 44|E-4767 and E-5065
P11600467A1436|48 69|intestinal permeability
P11602353A0770|13 21|HNF-3 beta
P11602353A0770|13 21|HNF-3 beta
P11602353A0770|23 27|HFH-1
P11602353A0770|23 27|HFH-1
P11602353A0770|29 33|HFH-2
P11602353A0770|29 33|HFH-2
P11602353A0770|35 39|HFH-3
P11602353A0770|35 39|HFH-3
P11602353A0770|41 58|C/EBP, and C/EBP beta
P11602353A0770|41 45|C/EBP
P11602353A0770|50 58|C/EBP beta
P11602353A0770|90 114|tissue-specific expression
P11603271T0001|0 14|Managing vertigo
P11603271T0001|18 33|vertigo syndromes
P11603271T0001|39 45|elderly
P11604152A0526|3 6|MABP
P11604152A0526|10 21|MCBFV signals
P11604152A0526|70 72|VLF
P11604152A0526|107 108|LF
P11604152A0526|145 146|HF
P11604152A0526|174 176|CCF
P11604152A0526|248 251|CCFs
P11605207T0001|11 30|ischemic heart disease
P11605207T0001|36 42|elderly
P11605598A0785|0 13|Hepatitis B and C
P11605598A0785|47 57|adolescents
P11605598A0785|68 73|El Paso
P11605598A0785|92 104|US populations
P11605598A0785|133 150|prevention programs
P11606538A1002|34 36|Nrk
P11606538A1002|39 75|"neurospecific" receptor tyrosine kinase
P11606538A1002|39 75|"neurospecific" receptor tyrosine kinase
P11606538A1002|80 82|Tpp
P11614398T0000|1 14|peculiar people
P11626110T0000|3 11|Available
P11639485A0478|66 69|Urdu
P11639485A0478|126 133|scholars
P11642687T0000|39 44|QWB-SA
P11642687T0000|74 81|patients
P11642687T0000|86 100|prostate disease
P11653491T0000|0 17|Disciplinary action
P11653491T0000|21 32|DNA violation
P11669281A0653|0 21|Epithelial cytotoxicity
P11669281A0653|32 42|antibiotics
P11669281A0653|71 92|competition or synergism
P11669476A0346|0 23|Pro-inflammatory cytokine
P11669476A0346|25 49|tumor necrosis factor-alpha
P11669476A0346|25 49|tumor necrosis factor-alpha
P11669476A0346|51 59|TNF-alpha
P11669476A0346|51 59|TNF-alpha
P11669476A0346|74 87|adipose tissues
P11669476A0346|90 102|obese subjects
P11669476A0346|143 159|insulin resistance
P11669476A0346|143 149|insulin
P11675912A0131|3 18|drank alcohol once
P11675912A0131|80 86|aspirin
P11675912A0131|90 102|acetaminophen
P11675912A0131|120 128|headaches
P11676899A0704|43 83|Epstein-Barr virus (infectious mononucleosis
P11676899A0704|88 97|congenital
P11676899A0704|101 124|acquired immunodeficiency
P11676899A0704|152 155|wood
P11676899A0704|156 163|industry
P11677363A0775|39 47|IMT values
P11677363A0775|71 72|PP
P11677363A0775|117 119|SBP
P11677363A0775|122 123|PP
P11677839A0876|23 30|patients
P11677839A0876|37 44|controls
P11678437A0000|11 26|crude oil spillage
P11678437A0000|36 47|productivity
P11678437A0000|67 79|maize (Zea mays
P11678437A0000|97 109|pot experiment
P11679441A0429|2 12|metabolites
P11679441A0429|45 59|nitrate/nitrite
P11679441A0429|61 63|NOx
P11679441A0429|92 119|cyclic guanosine monophosphate
P11679441A0429|121 124|cGMP
P11679441A0429|148 153|plasma
P11679441A0429|157 161|urine
P11680835A0756|5 21|base-case analysis
P11680835A0756|60 73|zoledronic acid
P11680835A0756|84 94|pamidronate
P11683558A0446|3 6|diet
P11683558A0446|9 16|migrants
P11683558A0446|27 76|positive (macronutrients) and negative (micronutrients
P11683558A0446|103 111|Dutch diet
P11684665A0000|0 0|C
P11684665A0000|2 21|elegans embryogenesis
P11684665A0000|54 63|asymmetric
P11684665A0000|120 135|nematode body plan
P11685047A0301|9 25|chromogenic method
P11685047A0301|41 58|thrombin inhibition
P11685047A0301|41 48|thrombin
P11685284X0000|1 12|Diabetologia
P11685284X0000|30 37|B37-B44]
P11686239A0464|3 20|5' flanking sequence
P11686239A0464|26 31|3B gene
P11686239A0464|26 31|3B gene
P11686239A0464|65 80|G/C rich stretches
P11686239A0464|99 101|7bp
P11686239A0464|145 150|G boxes
P11686378A0326|104 123|E. coli concentrations
P11686378A0326|104 109|E. coli
P11686378A0326|147 151|E coli
P11686378A0326|222 227|E. coli
P11686378A0326|314 324|viable cells
P11686378A0326|330 332|EHD
P11687083A0218|58 82|prophylactic prostaglandin
P11687083A0218|103 108|labour
P11687180A3209|46 63|pre-dialysis rHu EPO
P11687180A3209|58 63|rHu EPO
P11687180A3209|96 103|dialysis
P11687517A1619|2 6|ISREs
P11687517A1619|29 41|mouse promoter
P11687517A1619|29 41|mouse promoter
P11687737A0000|11 30|Ischemic heart disease
P11687737A0000|116 123|young age
P11687869A0000|21 37|ulcerative colitis
P11687869A0000|59 69|sarcoidosis
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11689217T0000|0 15|Cholesteryl ester
P11689217T0000|34 48|atherosclerosis
P11689217T0000|51 66|Japanese subjects
P11689217T0000|81 99|coronary angiography
P11691585A1174|0 33|Electrophoretic mobility shift assays
P11691585A1174|37 57|coimmunoprecipitation
P11691585A1174|76 101|homo- and heterodimerization
P11691585A1174|115 132|cKrox family members
P11691585A1174|115 132|cKrox family members
P11691585T0000|3 18|hcKrox gene family
P11691585T0000|3 8|hcKrox
P11691585T0000|28 59|multiple extracellular matrix genes
P11692004A1200|110 112|NF1
P11692004A1200|110 112|NF1
P11693461A1649|53 61|US 480,000
P11693461A1649|65 75|US 3,600,000
P11693461A1649|79 92|TNF antagonists
P11693461A1649|79 81|TNF
P11693461A1649|96 97|RA
P11695481A0310|36 37|UV
P11697760A0000|57 72|17beta-estradiol
P11697760A0000|74 75|E2
P11697760A0000|74 75|E2
P11697760A0000|79 100|parathyroid hormone (PTH
P11697760A0000|79 96|parathyroid hormone
P11697760A0000|98 100|PTH
P11697760A0000|124 144|ovariectomized OVX rats
P11703464A0560|66 99|meso-striatal and meso-corticolimbic
P11703464A0560|124 137|monetary reward
P11703464A0560|141 164|nonmonetary reinforcement
P11703558A0000|0 10|Doxorubicin
P11703558A0000|12 14|DOX
P11703558A0000|47 73|hematological and solid tumors
P11704380A1608|14 21|patients
P11704380A1608|26 40|chronic Irr-rMFP
P11704380A1608|43 50|Un-nrMFP
P11704380A1608|88 95|Rev-rMFP
P11704380A1608|88 90|Rev
P11704380A1608|98 106|Sta-nrMFP
P11704829A0312|0 23|Subtraction hybridization
P11704829A0312|34 56|melanoma differentiation
P11704829A0312|67 72|gene-7
P11704829A0312|74 78|mda-7
P11704829A0312|74 78|mda-7
P11704829A0312|133 145|melanoma cells
P11705093A2016|10 18|vitamin D3
P11706668A0000|0 9|Hydrocoele
P11706668A0000|20 22|men
P11706668A0000|25 56|Wuchereria bancrofti-endemic areas
P11706668A0000|25 43|Wuchereria bancrofti
P11706668A0000|89 96|surgical
P11706949T0000|0 12|Growth hormone
P11706949T0000|16 49|insulin-like growth factor I receptors
P11706949T0000|16 49|insulin-like growth factor I receptors
P11706949T0000|55 76|temporomandibular joint
P11706949T0000|82 84|rat
P11707977A0750|15 29|hepatic arterial
P11707977A0750|66 75|H3 patients
P11708032A0183|35 56|intra-arterial infusion
P11708032A0183|59 75|levoforinate (l-LV
P11708032A0183|85 98|5-fluorouracil
P11708032A0183|100 103|5-FU
P11708032A0183|136 145|metastases
P11708032A0183|233 243|infuser pump
P11708431A0904|8 15|patients
P11708431A0904|120 126|patient
P11708761A1388|58 70|ACE inhibitors
P11708761A1388|58 60|ACE
P11708761A1388|82 89|patients
P11708761A1388|94 109|diabetes mellitus
P11709561T0000|17 47|anti-G(D2) monoclonal antibody 3F8
P11709561T0000|17 22|anti-G
P11709561T0000|24 47|D2) monoclonal antibody 3F8
P11709561T0000|51 96|granulocyte-macrophage colony-stimulating factor
P11709561T0000|51 96|granulocyte-macrophage colony-stimulating factor
P11709561T0000|100 112|neuroblastoma
P11709890T0000|0 8|Hepatitis
P11709890T0000|42 66|Alberta retail food facility
P11710233T0000|0 8|Hydrogels
P11710685A0994a|22 26|ASCUS
P11710685A0994a|37 45|ASCUS/SIL
P11710685A0994a|100 115|Papanicolaou test
P11710685A0994b|22 26|ASCUS
P11710685A0994b|37 45|ASCUS/SIL
P11710685A0994b|100 115|Papanicolaou test
P11711701A0602|3 34|nuclear medicine physicians blinded
P11711701A0602|40 47|surgical
P11711701A0602|95 121|Tc-99m MIBI image combinations
P11711701A0602|244 257|thyroid imaging
P11714429X0000|23 29|aspirin
P11714429X0000|53 67|vascular disease
P11714429X0000|124 138|thienopyridines
P11714429X0000|140 150|clopidogrel
P11714429X0000|152 162|ticlopidine
P11714429X0000|170 176|aspirin
P11714429X0000|203 217|vascular disease
P11714429X0000|240 246|Aspirin
P11714429X0000|249 256|Patients
P11715079A1016|149 170|eye movement information
P11715079A1016|185 199|efferent command
P11715079A1016|241 260|proprioceptive organs
P11716043A0380|49 58|primary PTC
P11716043A0380|76 82|Surgery
P11716441A0585|0 2|ISS
P11716441A0585|9 23|acute physiology
P11716441A0585|51 58|APACHE II
P11716441A0585|72 80|admission
P11718197A1282|42 51|sternotomy
P11722993A0276|37 54|neonatal thrombosis
P11722993A0276|67 86|central nervous system
P11722993A0276|93 118|arterial and venous locations
P11722993A0276|139 143|utero
P11723500X0000|44 64|squamous cell carcinoma
P11723500X0000|70 79|oral cavity
P11723500X0000|82 86|women
P11723500X0000|99 119|Squamous cell carcinoma
P11723500X0000|121 123|SCC
P11723500X0000|130 139|oral cavity
P11723500X0000|157 170|male population
P11723511A0780|0 23|Regarding gestational risk
P11723511A0780|25 34|3,243 drugs
P11723511A0780|114 118|C, 289
P11723511A0780|127 135|category D
P11723675A1022|48 56|SOFA score
P11723675A1022|58 63|group A
P11723675A1022|102 107|group C
P11723675A1022|128 140|APACHE II score
P11723675A1022|142 147|group A
P11723675A1022|155 163|-8.1 point
P11723675A1022|190 195|group C
P11723675A1022|206 209|14.3
P11724510T0000|8 17|principles
P11724510T0000|20 39|therapeutic apheresis
P11726022A0909|57 80|steady-state calculations
P11726164A0215|16 29|food processors
P11726164A0215|77 94|allergenic residues
P11726164A0215|125 149|life-threatening reactions
P11726164A0215|166 172|allergy
P11726262A0692|0 18|Lactate accumulation
P11726262A0692|54 60|HMB, 8.1
P11726413A1756|3 20|increased clearance
P11726413A1756|31 42|young infants
P11726413A1756|62 68|opioids
P11727073A0842|24 30|novices
P11727073A0842|36 42|MIST-VR
P11727209A0502|3 10|patients
P11727209A0502|91 101|orthostasia
P11728771A0187|48 48|v
P11730182A0984|90 101|Philadelphia
P11730182A0984|107 116|Cherry Hill
P11730182A0984|123 123|r
P11730182A0984|125 125|p
P11730182A0984|142 142|r
P11730182A0984|144 144|p
P11730182A0984|160 160|r
P11730182A0984|162 162|p
P11730182A0984|177 177|r
P11730182A0984|179 179|p
P11730182A0984|201 201|r
P11730182A0984|203 203|p
P11730182A0984|220 220|r
P11730182A0984|222 222|p
P11730182A0984|240 240|r
P11730182A0984|242 242|p
P11730182A0984|260 260|r
P11730182A0984|262 262|p
P11730262A0874|0 9|Encouraged
P11730262A0874|28 46|etidronate/fluoride
P11730262A0874|49 77|corticoid-induced osteoporosis
P11730262A0874|105 107|men
P11730262A0874|136 147|osteoporosis
P11730262A0874|193 200|fluoride
P11730262A0874|205 225|calcium/vitamin D for 76
P11730712A0416|0 16|Treadmill training
P11730712A0416|62 66|edema
P11730712A0416|75 86|MCA occlusion
P11732088A0471|25 40|positive readings
P11732088A0471|58 75|sphincter manometry
P11732088A0471|89 99|use secretin
P11732088A0471|110 129|endoscopic ultrasound
P11732088A0471|131 135|SSEUS
P11732088A0471|146 169|pancreatic ductal response
P11732417A0571|103 114|serum samples
P11732417A0571|169 176|ELISA kit
P11736792A0204|61 62|G1
P11737056A0680|20 29|leucocytes
P11737056A0680|35 47|ME and ET mucosa
P11737056A0680|35 36|ME
P11737056A0680|63 66|BrdU
P11737158A1517|0 21|Modality-specific areas
P11737158A1517|28 32|right
P11737158A1517|42 58|left fusiform gyrus
P11737158A1517|60 87|Broca BA44, supramarginal gyrus
P11737900A0700|27 35|plasma COP
P11737900A0700|39 48|body weight
P11738404A0120|5 22|chemical structures
P11738404A0120|39 135|1 alpha,2 alpha-diacetoxy-8 beta-isobutanoyloxy- 9 alpha-benzoyloxy-13-(alpha-methyl)butanoyloxy-4 beta
P11738404A0120|39 51|1 alpha,2 alpha
P11738404A0120|137 174|6 beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|179 273|1 alpha,2 alpha-diacetoxy-8 beta-(beta- furancarbonyloxy)-9 alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|179 191|1 alpha,2 alpha
P11738404A0120|275 315|6 beta-dihydroxy-beta-dihydroagarofuran (2)
P11738404A0120|319 324|1 alpha
P11738404A0120|319 324|1 alpha
P11738404A0120|326 337|6 beta, 8 alpha
P11738404A0120|326 330|6 beta
P11738404A0120|332 409|8 alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|374 391|alpha-hydroxy-beta
P11738404A0120|429 431|NMR
P11738404A0120|435 448|MS spectral data
P11740571A0114|44 67|permissible concentration
P11740571A0114|87 107|glutathione peroxidase
P11740571A0114|87 107|glutathione peroxidase
P11740571A0114|110 120|brain tissue
P11740571A0114|147 172|chemiluminescence intensity
P11740571A0114|205 220|radical processes
P11740806X0810|8 14|Company
P11741259A1233|3 13|performance
P11741259A1233|16 36|pH-sensitive particles
P11741259A1233|121 144|molecular or amorphous form
P11741554T0000|12 43|remnant-like lipoprotein particles
P11741554T0000|46 64|postmenopausal women
P11741554T0000|79 99|coronary artery disease
P11741554T0000|105 107|men
P11741554T0000|112 132|coronary artery disease
P11742432A0798|63 86|continuing MAC prophylaxis
P11742432A0798|89 96|patients
P11742432A0798|174 182|macrolide
P11742432A0798|219 234|respiratory tract
P11742432A0798|274 282|macrolide
P11742432A0798|283 293|prophylaxis
P11742432A0798|299 310|AIDS patients
P11742432A0798|316 324|CD4 counts
P11742432A0798|316 318|CD4
P11743360A2491|0 10|Acute stress
P11743360A2491|14 17|rats
P11743360A2491|46 49|IL-6
P11743360A2491|46 49|IL-6
P11743360A2491|63 67|urine
P11743612A1179|0 7|Patients
P11743612A1179|12 13|CF
P11743612A1179|17 29|meconium ileus
P11743612A1179|44 60|nutritional status
P11743612A1179|113 124|CF population
P11744953A0878|0 10|Skin cancers
P11744953A0878|22 42|gastrointestinal tract
P11744953A0878|50 62|genital system
P11744953A0878|77 92|older age patients
P11752821A1365|11 13|MMF
P11752821A1365|51 91|mucocutaneous Adamantiades-Behcet's disease
P11755894A0466|22 34|naive patients
P11755894A0466|65 71|opioids
P11755894A0466|75 83|acute pain
P11755894A0466|85 88|oral
P11755894A0466|89 91|ADL
P11755894A0466|92 97|8-2698
P11755894A0466|147 149|POI
P11755894A0466|179 197|normal bowel function
P11760398A0553|22 29|patients
P11760398A0553|34 35|BS
P11760398A0553|39 49|438 patients
P11760398A0553|134 135|BS
P11760398A0553|189 199|ISG criteria
P11760796A0698|20 33|PHACES syndrome
P11760796A0698|40 56|random association
P11760796A0698|65 76|phakomatosis
P11761601A0133|17 26|ACCESS-IAQ
P11763176A0918|26 37|antithrombin
P11764062A0000|33 40|Children
P11764062A0000|42 47|PSWQ-C
P11764062A0000|116 123|children
P11764062A0000|144 154|generalized
P11764062A0000|159 177|uncontrollable worry
P11764226A0798|28 39|ILAR criteria
P11764226A0798|56 63|patients
P11764226A0798|68 75|patients
P11764226A0798|137 149|EULAR criteria
P11765448A0588|9 23|X-ray projection
P11765448A0588|41 48|patients
P11766747A0000|45 52|patients
P11766747A0000|57 79|immature ovarian teratoma
P11768467A0000|0 21|Pyrethroid insecticides
P11768467A0000|51 67|private households
P11769229A0357|3 20|sorption mechanisms
P11769229A0357|67 85|repetitious sorption
P11771979A1141|42 44|LDF
P11771979A1141|60 83|cerebrocortical microflow
P11771979A1141|128 133|organs
P11771979A1141|135 159|LDF cerebrocortical mapping
P11771979A1141|233 243|vasculature
P11773168A0915|56 64|PFS) rates
P11773921A0397|8 17|P-selectin
P11773921A0397|8 17|P-selectin
P11773921A0397|30 42|nonstimulated
P11773921A0397|46 68|ADP-stimulated platelets
P11773921A0397|152 161|52 patients
P11773921A0397|166 173|coronary
P11773921A0397|190 197|patients
P11773921A0397|259 266|patients
P11773921A0397|286 294|higher 450
P11775180A0379|11 18|surgical
P11775180A0379|54 73|gamma-detecting probe
P11775301A0797|27 42|depression scores
P11776922A0830|0 1|IV
P11776922A0830|3 19|combined sclerosis
P11776922A0830|38 46|skull base
P11776922A0830|56 86|group I lesions and 4 group II lesions
P11777575A0363|28 39|L. bulgaricus
P11777575A0363|41 54|S. thermophilus
P11777575A0363|85 88|PyMS
P11777575A0363|124 137|neural networks
P11777575A0363|139 142|ANNs
P11777632A1678|0 1|AF
P11777632A1678|0 1|AF
P11777632A1678|14 32|nuclear/cytoplasmic
P11777632A1678|57 78|epithelial, endothelial
P11777632A1678|83 98|stromal component
P11777632A1678|104 115|normal breast
P11777632A1678|119 131|benign lesions
P11777632A1678|158 169|AF expression
P11777632A1678|158 159|AF
P11777632A1678|180 208|in situ and invasive breast cancer
P11777632A1678|212 224|tumoral stroma
P11778044A0000|79 91|climate system
P11778044A0000|100 120|optimal fingerprinting
P11778044A0000|138 148|simulations
P11778804A0179|0 8|Frequency
P11778804A0179|60 62|FDT
P11781615A0000|0 30|Chronic graft-versus-host disease
P11781615A0000|32 36|cGVHD
P11781615A0000|70 101|hematopoietic cell transplantation
P11782218A0349|10 23|white-on-white
P11782218A0349|25 42|W-W) perimetry, SWAP
P11782218A0349|100 109|estimation
P11782218A0349|122 142|ocular media absorption
P11783457A0000|0 12|Preservatives
P11783457A0000|38 59|ophthalmic preparations
P11783457A0000|115 127|decomposition
P11785085X0001|40 48|prostatic
P11785085X0001|59 66|patients
P11785085X0001|78 99|obstructive prostatitis
P11785085X0001|114 122|prostatic
P11785085X0001|136 164|transurethral vacuum aspiration
P11785085X0001|166 177|Introl-4 unit
P11785085X0001|182 210|transrectal pneumovibromassage
P11785085X0001|212 219|PVM-R-01
P11785085X0001|257 278|obstructive prostatitis
P11785827A0986|34 49|acoustical models
P11785827A0986|102 128|height-dependent degradation
P11785827A0986|136 141|forest
P11785827A0986|193 197|avian
P11786248A1162|0 10|Consumption
P11786248A1162|38 55|excitotoxic lesions
P11786248A1162|61 64|PPTg
P11786248A1162|69 72|PPTg
P11786945A0958|0 15|Actuarial freedom
P11787041A0167|0 16|Mental development
P11787322X0001|29 48|chemical disinfection
P11787322X0001|74 79|type IV
P11787322X0001|83 83|V
P11787322X0001|102 112|instruments
P11787322X0001|163 172|stone casts
P11787322X0001|174 190|dental impressions
P11787322X0001|192 211|interocclusal records
P11787322X0001|276 293|infectious diseases
P11787720A1313|41 52|linoleic acid
P11787720A1313|54 56|C18
P11787720A1313|87 101|arachidonic acid
P11787720A1313|103 105|C20
P11787746A0374|0 9|Vitrectomy
P11787746A0374|77 93|secondary glaucoma
P11787746A0374|109 116|patients
P11789206A1182|26 29|MIRI
P11789206A1182|32 43|Qi deficiency
P11789206A1182|47 57|blood stasis
P11789206A1182|60 62|TCM
P11789206A1182|75 84|principles
P11789206A1182|102 103|Qi
P11789206A1182|118 128|blood stasis
P11789216T0001|19 34|blood circulation
P11789216T0001|56 68|barrier action
P11789216T0001|71 81|gastric wall
P11789216T0001|84 107|chronic atrophic gastritis
P11790897T0000|0 16|Proteomic patterns
P11790897T0000|19 38|nipple aspirate fluids
P11790897T0000|74 83|biomarkers
P11790897T0000|105 116|breast cancer
P11791292A0193|48 60|neural network
P11791571T0000|1 15|high-efficiency
P11791571T0000|26 48|micronebulizer interface
P11791571T0000|52 75|capillary electrophoresis
P11791571T0000|79 106|inductively coupled plasma mass
P11791585A0287|111 127|insulating surface
P11791853A0532|35 69|coagulation-electrooxidation process
P11791853A0532|106 108|COD
P11791853A0532|116 137|simulated dye wastewater
P11792586A0290|0 12|Cyclic loading
P11792586A0290|15 18|bone
P11792586A0290|85 96|tissue matrix
P11792586A0290|106 109|bone
P11793172A0545|29 34|PE head
P11793172A0545|62 64|THA
P11793172A0545|72 90|friction coefficient
P11793172A0545|128 139|unused PE head
P11793614A0000|38 63|steady-state concentrations
P11793614A0000|66 75|cilomilast
P11793614A0000|81 111|oral phosphodiesterase 4 inhibitor
P11793614A0000|85 102|phosphodiesterase 4
P11793614A0000|136 162|obstructive pulmonary disease
P11793614A0000|166 196|warfarin-induced anticoagulation
P11800119A0814|33 45|vibration mode
P11800586A1090|10 17|DPPD gene
P11800586A1090|10 17|DPPD gene
P11800586A1090|47 53|bacilli
P11800586A1090|138 149|tuberculosis
P11800878T0000|0 13|Dynamic imaging
P11800878T0000|16 35|nuclear wave functions
P11800878T0000|50 62|UV laser pulses
P11801459T0000|0 7|Efficacy
P11801459T0000|19 25|aspirin
P11801459T0000|52 67|atherothrombosis
P11802580A0000|3 9|General
P11802580A0000|35 38|GPRD
P11802580A0000|59 78|computerized database
P11802580A0000|81 102|anonymized longitudinal
P11802601A0107|46 53|aldicarb
P11802601A0107|64 74|metabolites
P11802601A0107|76 90|aldicarb sulfone
P11802601A0107|94 110|aldicarb sulfoxide
P11803325A0868|7 8|DC
P11803325A0868|38 45|HBS group
P11803325A0868|55 56|DC
P11803325A0868|62 69|CBC group
P11803325A0868|78 80|7 DC
P11803325A0868|86 93|GIK group
P11804081A0552|19 22|ENRP
P11804081A0552|50 51|TP
P11804081A0552|84 93|Everglades
P11804100A0365a|32 35|BOD5
P11804100A0365a|39 43|NH3-N
P11804100A0365b|32 35|BOD5
P11804100A0365b|39 43|NH3-N
P11804510A0730|0 5|Losses
P11804510A0730|8 20|dichlofluanid
P11804510A0730|27 38|chlozolinate
P11804510A0730|48 58|etridiazole
P11804510A0730|187 205|cryogenic processing
P11806132A0253|3 4|TB
P11806132A0253|20 25|AIRIN"
P11806132A0253|46 53|patients
P11810685A0147|50 59|q-space MRI
P11810685A0147|105 119|long-wavelength
P11810685A0147|148 181|3D Gaussian displacement distribution
P11810685A0147|189 196|in DT-MRI
P11811743A0800|58 65|Class III
P11811825A0972|155 158|0.95
P11815644A0081|3 25|physical characteristics
P11815644A0081|106 122|respiratory muscle
P11815644A0081|140 151|echolocation
P11816458A0319|0 7|Clicking
P11816458A0319|36 42|APA Form
P11816779A0343|7 13|packets
P11816779A0343|23 28|acetyl
P11816779A0343|29 35|aspirin
P11816779A0343|37 49|acetaminophen
P11816779A0343|53 67|chloramphenicol
P11818675X0897|6 7|AG
P11819326A0000|0 2|AIM
P11819326A0000|25 41|nutritional status
P11819326A0000|44 60|cirrhotic patients
P11819326A0000|90 107|encephalopathy (PSE
P11819326A0000|127 147|non-alcoholic patients
P11819326A0000|152 160|cirrhosis
P11819326A0000|168 170|PSE
P11821098A0269|35 40|FSH, LH
P11821098A0269|35 37|FSH
P11821098A0269|39 40|LH
P11821098A0269|45 52|inhibin A
P11821098A0269|45 52|inhibin A
P11821098A0269|56 56|B
P11822790A0907|18 25|SIP score
P11822790A0907|87 95|mean score
P11822811A0319|5 5|I
P11822811A0319|16 27|adult Collies
P11822811A0319|109 120|intoxication
P11824701A0894|0 7|Patients
P11824701A0894|22 33|cardiac event
P11824701A0894|47 67|Type A behavior patterns
P11824701A0894|77 89|Bortner scores
P11824701A0894|94 101|patients
P11824701A0894|119 130|cardiac event
P11824801A0661|31 47|interferon therapy
P11824801A0661|31 40|interferon
P11824801A0661|94 104|sarcoidosis
P11824801A0661|127 134|patients
P11824801A0661|139 165|noncritical organ involvement
P11825801A1212|11 23|tumor-related
P11826141T0000|0 17|Dissociable effects
P11826141T0000|46 52|rostral
P11826141T0000|62 80|basolateral amygdala
P11826141T0000|140 143|rats
P11828186A0239|33 35|men
P11828186A0239|43 47|women
P11828186A0239|70 89|coronary heart disease
P11828186A0239|97 111|CRP measurements
P11828186A0239|117 135|Third National Health
P11828186A0239|159 175|Survey (NHANES III)
P11830544A0335|0 8|Herceptin
P11830544A0335|28 43|HER-2/neu antigen
P11830544A0335|28 32|HER-2
P11830544A0335|34 43|neu antigen
P11830544A0335|69 84|G6-(1B4M-Gd)(256
P11830544A0335|118 123|WIBC-9
P11830544A0335|189 200|angiogenesis
P11831512A0468|11 14|pigs
P11831512A0468|98 104|lactose
P11831512A0468|131 137|lactose
P11831512A0468|147 150|gram
P11831512A0468|154 157|gram
P11831512A0468|163 165|CSS
P11831512A0468|167 184|dextrose equivalent
P11831512A0468|186 187|DE
P11831512A0468|199 205|lactose
P11831512A0468|218 222|DE-42
P11832019A0668|12 15|AMVT
P11832019A0668|43 58|emergency disease
P11833863A0987|59 67|positions
P11834476A1187|31 52|permanent focal ischemia
P11834476A1187|60 70|transfusion
P11834476A1187|87 94|ischemia
P11834476A1187|96 105|tetrameric
P11834476A1187|118 138|hemoglobin transfusion
P11834476A1187|118 127|hemoglobin
P11834476A1187|149 163|oxygen transport
P11834476A1187|169 182|ischemic cortex
P11835109A0000|105 108|HRQL
P11835109A0000|112 119|patients
P11835109A0000|124 150|chronic respiratory disorders
P11835109A0000|161 174|clinical trials
P11836046A0549|47 62|calcium carbonate
P11836046A0549|71 86|elemental calcium
P11836046A0549|118 123|group A
P11836046A0549|132 147|calcium carbonate
P11836046A0549|196 203|estrogen
P11836046A0549|210 228|medrogestone acetate
P11836046A0549|250 255|group B
P11836303A0518|0 20|TNFalpha and IL-6 levels
P11836303A0518|0 7|TNFalpha
P11836303A0518|11 14|IL-6
P11836303A1191|38 56|prenatal disturbance
P11836303A1191|82 96|cytokine biology
P11836303A1191|124 142|fetal and infant stage
P11837409A0584|3 10|two-wave
P11837409A0584|48 63|Adolescent Health
P11838058A0084|16 54|conventional intermittent tissue expansion
P11838058A0084|56 59|CITE
P11838058A0084|72 115|continuous pressure-controlled tissue expansion
P11838058A0084|117 120|CPTE
P11838102T0001|0 22|Wegener's granulomatosis
P11840365A0949|28 37|hematocrit
P11840365A0949|43 60|General Health scale
P11840365A0949|66 67|SF
P11842037A0327|7 24|analytic precisions
P11842728X0001|0 32|Schistosoma mansoni schistosomiasis
P11842728X0001|51 67|parasitic diseases
P11842728X0001|76 86|blood flukes
P11842728X0001|92 107|Schistosoma genus
P11843252A0907|1 18|global response rate
P11844591A0329|37 53|maximal peak torque
P11844591A0329|55 57|APT
P11844812A0915|34 39|ANN ROC
P11844812A0915|74 77|AUCs
P11844812A0915|97 99|PSA
P11844812A0915|97 99|PSA
P11844812A0915|110 115|PSA-TZ
P11844812A0915|110 112|PSA
P11844812A0915|129 138|PSA density
P11844812A0915|147 160|prostate volume
P11845547A0449|37 57|KATP channel activators
P11845547A0449|62 77|21-aminosteroids
P11846167A0000|0 7|Selenium
P11846167A0000|12 27|essential element
P11846167A0000|31 36|humans
P11846187A0894|71 92|hedonic and permeability
P11847580T0000|0 25|Emphysematous cholecystitis
P11847580T0000|27 45|sonographic findings
P11849417A0900|32 48|20-44, 45-64, 65-74
P11849417A0900|53 55|75+
P11849417A0900|82 99|dialysis PD patients
P11849417A0900|144 153|HD patients
P11849796A0452|39 44|3D-CRT
P11849796A0452|48 56|IMRT plans
P11849796A0452|102 111|IMRT fields
P11851941A0372|32 49|serumalbumin method
P11851941A0372|32 43|serumalbumin
P11851941A0372|61 71|blood volume
P11851941A0372|117 127|haemoglobin
P11851941A0372|117 127|haemoglobin
P11851941A0372|165 182|hydroxyethyl starch
P11851941A0372|184 186|HES
P11852907A0871|14 30|phosphorus content
P11852907A0871|39 49|surface soil
P11852907A0871|75 77|SRP
P11852907A0871|75 77|SRP
P11852907A0871|87 99|drainage water
P11853943A0122|33 41|algorithm
P11853943A0122|45 65|R-R interval estimation
P11858548A0241|43 73|mono- and bidimensional NMR spectra
P11858635A0896|37 46|QSAR models
P11858635A0896|61 79|LOO cross-validation
P11859400A0229|55 69|HSV reactivation
P11859400A0229|75 89|HSV seropositive
P11859400A0229|100 128|progenitor cell transplantation
P11859400A0229|130 133|APCT
P11859400A0229|135 142|patients
P11859400A0229|147 164|historical controls
P11859400A0229|182 190|acyclovir
P11859400A0229|195 208|HSV prophylaxis
P11859943A0150|94 107|12-item General
P11860097A1695|101 115|prosthesis users
P11860097A1695|119 127|non-users
P11860723A0182|49 61|Obstetricians
P11860723A0182|65 77|Gynecologists
P11860876A0409|0 12|HIV-1 C subtype
P11860876A0409|0 12|HIV-1 C subtype
P11861092A0730|55 61|patient
P11861092A0730|134 136|FGS
P11861092A0730|156 166|Doppler (FCD
P11861092A0730|193 195|FPD
P11861092A0730|222 224|HGS
P11861092A0730|249 251|Pim
P11861092A0730|260 285|HDI5000 scanner and C5-2 probe
P11861092A0730|277 280|C5-2
P11861092A0730|287 289|ATL
P11861092A0730|299 300|WA
P11862350T0000|31 43|carbamazepine
P11862350T0000|50 71|NMDA receptor antagonist
P11862350T0000|50 61|NMDA receptor
P11862350T0000|72 81|remacemide
P11862350T0000|112 122|performance
P11864173T0000|0 4|Viral
P11864173T0000|8 15|atypical
P11864173T0000|35 57|type 1 acute exacerbations
P11864173T0000|60 76|chronic bronchitis
P11865218A0069|58 86|dispersing agent (cerumenolytic
P11866130A0419|11 20|benzocaine
P11866130A0419|70 81|phagocytosis
P11866130A0419|88 92|MS222
P11866130A0419|96 113|quinaldine sulphate
P11867388A0502|3 4|EC
P11867388A0502|25 39|long-term memory
P11867388A0502|67 72|memory
P11867388A0502|114 123|plus/minus
P11867388A0502|134 143|plus/minus
P11867388A0502|155 176|fear conditioning to tone
P11867388A0502|185 194|plus/minus
P11870646A0668|37 53|ceramic/substrate
P11870646A0668|90 115|lifetime-threatening damage
P11872359A0000|21 37|insulin resistance
P11872359A0000|21 27|insulin
P11872359A0000|39 40|IR
P11872359A0000|39 40|IR
P11872359A0000|61 81|cardiovascular disease
P11872359A0000|83 85|CVD
P11872359A0000|112 128|metabolic syndrome
P11872359A0000|130 133|" CVD
P11872359A0000|151 159|premature
P11872570T0000|0 7|Dementia
P11872570T0000|24 26|NHS
P11873003X0000|0 13|HIV-1 infection
P11873003X0000|60 63|AIDS
P11873003X0000|93 115|industrialized countries
P11873003X0000|159 172|HIV-1 infection
P11873003X0000|193 196|AIDS
P11873003X0000|234 244|AIDS to death
P11874637A0212|34 40|therapy
P11874637A0212|100 111|HIV infection
P11874637A0212|165 196|acquired immune deficiency syndrome
P11874637A0212|198 222|AIDS)-related malignancies
P11876937A0261|0 6|Heparin
P11876937A0261|24 26|-1)
P11876937A0261|58 61|rats
P11879108A0719|53 71|chlamydial infection
P11879108A0719|77 100|ligase chain reaction assay
P11879108A0719|150 179|human immunodeficiency virus (HIV
P11879108A0719|150 175|human immunodeficiency virus
P11879108A0719|177 179|HIV
P11881268A0000|102 126|older Mexican American women
P11881923A1256|0 25|Neutrophil:lymphocyte ratio
P11881923A1256|27 43|plasma haptoglobin
P11881923A1256|33 43|haptoglobin
P11881923A1256|48 56|CBG levels
P11881923A1256|48 50|CBG
P11881923A1256|85 97|INITIAL period
P11881923A1256|111 113|PRE
P11881923A1256|116 119|POST
P11882054A0568|0 7|Adjacent
P11882054A0568|62 71|FMZ binding
P11882054A0568|128 131|ROIs
P11882054A0568|141 150|transaxial
P11882054A0568|154 166|coronal slices
P11882054A0568|194 205|lesion volume
P11882054A1250|50 59|FMZ binding
P11882054A1250|63 77|spiking activity
P11882054A1250|103 123|neocortical epilepsies
P11882054A1250|133 155|peri-lesional FMZ binding
P11882054A1250|192 229|epileptogenesis in symptomatic epilepsies
P11882747A0354|0 1|CD
P11882747A0354|0 1|CD
P11882747A0354|23 42|Farnsworth D-15 method
P11883682A0162|72 82|heavy metals
P11883682A0162|88 105|estuarine sediments
P11883763A1062|3 13|large fluxes
P11883763A1062|20 24|240Pu
P11883763A1062|44 58|episodic lateral
P11883763A1062|117 130|nepheloid layer
P11883763A1062|211 222|East China Sea
P11884014A0665|0 25|Rigorous treatment protocols
P11884014A0665|29 40|diet delivery
P11884014A0665|44 56|EEN-related GI
P11885737A1713|23 40|spermatozoa/microl
P11886473A0796|0 13|Gastritis score
P11886473A0796|37 46|nod-/CagA-
P11886473A0796|42 45|CagA
P11886473A0796|47 54|children
P11886473A0796|66 69|CagA
P11886473A0796|80 88|nod-/CagA
P11886473A0796|85 89|CagA+
P11886473A0796|101 103|nod
P11886473A0796|106 110|CagA+
P11886473A0796|129 143|antrum and corpus
P11887803A1455|3 15|mean thickness
P11887803A1455|29 38|peritoneum
P11887803A1455|66 72|animals
P11887803A1455|104 111|fibrosis
P11887803A1455|125 134|peritoneum
P11887803A1455|137 140|rats
P11887803A1455|150 154|CAPD 3
P11887803A1455|169 175|animals
P11887803A1455|187 198|CAPD 3 Balance
P11888183A0541|110 115|maxima
P11888867A0000|45 54|serum level
P11888867A0000|57 63|TA90-IC
P11888867A0000|57 63|TA90-IC
P11888867A0000|67 79|immune complex
P11888867A0000|83 111|90-kDa tumor-associated antigen
P11888867A0000|89 111|tumor-associated antigen
P11888867A0000|186 193|patients
P11888867A0000|198 218|thick primary melanomas
P11890354A0000|8 16|Institute
P11890354A0000|32 49|launched oprelvekin
P11890354A0000|40 49|oprelvekin
P11890354A0000|51 57|rhIL-11
P11890354A0000|51 57|rhIL-11
P11890354A0000|69 83|recombinant form
P11890354A0000|86 95|human IL-11
P11890354A0000|86 95|human IL-11
P11890438A0838|0 7|Patients
P11890438A0838|58 70|wounds checked
P11893403A0252|111 126|pharmacokinetics
P11893403A0252|130 139|toxicology
P11893767A0356|16 39|resting minute ventilation
P11893767A0356|41 41|E
P11893767A0356|71 78|VE/(O(2)
P11893767A0356|75 77|O(2
P11894605A1429|0 13|INTERPRETATION
P11894605A1429|195 205|advertising
P11895024A1054|0 3|Nine
P11895024A1054|11 13|GBS
P11895024A1054|44 58|AFP surveillance
P11895184A0000|12 15|rats
P11895184A0000|29 46|hippocampal lesions
P11895184A0000|82 92|object-odor
P11895184A0000|127 150|cheeseboard maze apparatus
P11897449A0566|56 62|esmolol
P11897449A0566|91 93|RFA
P11897449A0566|106 114|heart rate
P11897449A0566|126 139|drug-free state
P11897449A0566|161 169|beats/min
P11897888A0590|0 4|Urine
P11897950A0617|35 57|cynomolgus monkey eyelids
P11897950A0617|65 97|discrete lymphatic drainage pathways
P11897950A0617|117 123|eyelids
P11897950A0617|128 138|dual pathway
P11897950A0617|152 162|upper eyelid
P11898018T0000|16 37|practice-based research
P11898797A0124|39 70|choline acetyltransferase activity
P11898797A0124|39 62|choline acetyltransferase
P11898797A0124|76 89|cerebral cortex
P11898797A0124|92 99|patients
P11898797A0124|117 122|injury
P11898797A0124|155 184|cortical cholinergic innervation
P11899479A0122|21 27|lesions
P11899479A0122|33 36|oral
P11899479A0122|37 49|mucosa (tongue
P11899479A0122|58 63|palate
P11899479A0122|97 111|cotton wool swabs
P11899479A0122|134 165|Sabouraud glucose agar and CHROMagar
P11899479A0122|166 172|Candida
P11899479A0122|184 195|yeast species
P11899479A0122|237 253|assimilation tests
P11899479A0122|266 287|commercial kit AuxaColor
P11899489A0119|12 35|pharmacological treatment
P11899489A0119|39 50|professional
P11899489A0119|79 86|dementia
P11900770T0000|0 28|Sexually conditioned incentives
P11900770T0000|67 74|dopamine
P11902068T0000|3 21|CKD patient's journey
P11902738A0185|60 67|children
P11902738A0185|72 77|cancer
P11902738A0185|110 128|fever and neutropenia
P11902738A0185|149 163|neutrophil count
P11902781A0550|0 13|Concentrations
P11902781A0550|16 16|N
P11902781A0550|16 16|N
P11902781A0550|18 27|O3-)-N and N
P11902781A0550|18 23|O3-)-N
P11902781A0550|27 27|N
P11902781A0550|29 34|H3-)-N
P11902781A0550|29 34|H3-)-N
P11902781A0550|108 113|season
P11904017A0000|0 4|Steal
P11904017A0000|8 32|pathophysiological process
P11904017A0000|49 57|blood flow
P11904017A0000|135 154|central nervous system
P11907691A0214|65 78|object's center
P11908529A0553|21 24|flux
P11908529A0553|34 51|stars per cm3, charge
P11908529A0553|81 89|detectors
P11908529A0553|91 98|plastics
P11908529A0553|100 111|AgCl crystals
P11908529A0553|113 115|LiF
P11908529A0553|143 159|biological objects
P11910310A0279|30 41|double-blind
P11910344A1119|29 40|uncontrolled
P11910344A1119|57 64|patients
P11910344A1119|69 73|type 1
P11910344A1119|74 76|HRS
P11910344A1119|106 118|renal function
P11911552A0776|2 9|patients
P11911552A0776|22 39|quetiapine, therapy
P11912261A0284|0 17|Calcimimetic agents
P11912261A0284|33 44|PTH secretion
P11912261A0284|33 35|PTH
P11912261A0284|60 82|calcium-sensing receptor
P11912261A0284|88 104|parathyroid glands
P11917061A0922|28 37|tacrolimus
P11917061A0922|60 70|cyclosporin
P11917061A0922|74 83|prednisone
P11917061A0922|104 119|partial remission
P11917061A0922|121 129|remission
P11917882A0326|31 52|resin-dentine interface
P11917882A0326|71 92|dentine adhesive systems
P11917882A0326|120 136|adhesion-strategy
P11920896A0298|30 31|DR
P11920896A0298|41 53|combined test'
P11920896A0298|93 105|pregnant women
P11920896A0298|128 130|FPR
P11921126A1196|15 17|PDQ
P11921126A1196|22 28|STN-DBS
P11921126A1196|68 70|QoL
P11921126A1196|73 80|patients
P11921126A1196|93 94|PD
